<SEC-DOCUMENT>0001828185-24-000011.txt : 20240320
<SEC-HEADER>0001828185-24-000011.hdr.sgml : 20240320
<ACCEPTANCE-DATETIME>20240320162531
ACCESSION NUMBER:		0001828185-24-000011
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		121
CONFORMED PERIOD OF REPORT:	20231231
FILED AS OF DATE:		20240320
DATE AS OF CHANGE:		20240320

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Barinthus Biotherapeutics plc.
		CENTRAL INDEX KEY:			0001828185
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40367
		FILM NUMBER:		24768109

	BUSINESS ADDRESS:	
		STREET 1:		UNIT 6-10, ZEUS BUILDING
		STREET 2:		RUTHERFORD AVENUE, HARWELL
		CITY:			DIDCOT
		STATE:			X0
		ZIP:			OX11 0DF
		BUSINESS PHONE:		44 (0) 1865 818808

	MAIL ADDRESS:	
		STREET 1:		UNIT 6-10, ZEUS BUILDING
		STREET 2:		RUTHERFORD AVENUE, HARWELL
		CITY:			DIDCOT
		STATE:			X0
		ZIP:			OX11 0DF

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Vaccitech plc
		DATE OF NAME CHANGE:	20210407

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Vaccitech Ltd
		DATE OF NAME CHANGE:	20201014
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>brns-20231231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:568bf53a-35e8-4830-ae45-40f379b83a88,g:160c7384-88e8-453d-8496-8cc857f3b5f9,d:417e39f5b7bb45b295bb09394310bc8c-->
<html xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:brns="http://www.barinthusbio.com/20231231" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>brns-20231231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-34">0001828185</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-35">2023</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-36">FY</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-37">false</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-38">00-0000000</ix:nonNumeric><ix:nonNumeric contextRef="c-23" name="us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList" id="f-192">http://fasb.org/us-gaap/2023#LicenseMember</ix:nonNumeric><ix:nonNumeric contextRef="c-24" name="us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList" id="f-193">http://fasb.org/us-gaap/2023#LicenseMember</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="brns-20231231.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">brns:AmericanDepositarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="gbpPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:GBP</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">brns:DeferredShares.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">brns:DeferredShares.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">brns:DeferredBSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">brns:DeferredBSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">brns:DeferredCSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">brns:DeferredCSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">brns:ResearchGrantsAndContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">brns:ResearchGrantsAndContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">brns:DeferredShares.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">brns:DeferredSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">brns:DeferredBSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">brns:DeferredSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">brns:DeferredCSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">brns:DeferredSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">brns:DeferredBSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">brns:DeferredSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">brns:DeferredCSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">brns:DeferredSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">brns:DeferredShares.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">brns:DeferredSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">brns:DeferredBSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">brns:DeferredSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">brns:DeferredCSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">brns:DeferredSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">brns:DeferredShares.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">brns:DeferredSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">brns:DeferredBSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">brns:DeferredSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">brns:DeferredCSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">brns:DeferredSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>brns:segment</xbrli:measure></xbrli:unit><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">brns:SubsidiariesVOLTMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">brns:VOLTMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">brns:VOLTMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">brns:SubsidiariesVOLTMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">brns:SubsidiariesVOLTMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">brns:OxfordUniversityInnovationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">brns:OxfordUniversityInnovationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">brns:OxfordUniversityInnovationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">brns:OxfordUniversityInnovationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">brns:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">brns:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">brns:OuiLicenseAgreementAmendmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-28</xbrli:startDate><xbrli:endDate>2022-03-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">brns:AgreementWithOxfordUniversityInnovationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">brns:AgreementWithOxfordUniversityInnovationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">brns:AgreementWithOxfordUniversityInnovationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">brns:AgreementWithOxfordUniversityInnovationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">brns:AgreementWithScancellToGrantResearchAndDevelopmentLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">brns:AgreementWithScancellToGrantResearchAndDevelopmentLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">brns:AgreementWithScancellToGrantResearchAndDevelopmentLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">brns:AgreementWithScancellToGrantResearchAndDevelopmentLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">brns:CoalitionForEpidemicPreparednessInnovationsFundingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">brns:CoalitionForEpidemicPreparednessInnovationsFundingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-20</xbrli:startDate><xbrli:endDate>2023-12-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">brns:CoalitionForEpidemicPreparednessInnovationsFundingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-04</xbrli:startDate><xbrli:endDate>2021-05-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="vote"><xbrli:measure>brns:vote</xbrli:measure></xbrli:unit><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-21</xbrli:startDate><xbrli:endDate>2021-04-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-11-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="gbp"><xbrli:measure>iso4217:GBP</xbrli:measure></xbrli:unit><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">brns:DeferredBSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">brns:DeferredCSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">brns:AvideaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">brns:ContingentConsiderationLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">brns:ContingentConsiderationLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">brns:ContingentConsiderationLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">brns:ContingentConsiderationLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">brns:ContingentConsiderationLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">brns:RestrictedShareUnitsStockOptionsShareAppreciationRightsAndRestrictedSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">brns:BarinthusBiotherapeuticsPlcShareAwardPlan2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-08</xbrli:startDate><xbrli:endDate>2021-04-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">brns:RestrictedShareUnitsStockOptionsShareAppreciationRightsAndRestrictedSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">brns:BarinthusBiotherapeuticsPlcShareAwardPlan2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">brns:RestrictedShareUnitsStockOptionsShareAppreciationRightsAndRestrictedSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">brns:BarinthusBiotherapeuticsPlcShareAwardPlan2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">brns:RestrictedShareUnitsStockOptionsShareAppreciationRightsAndRestrictedSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">brns:BarinthusBiotherapeuticsPlcShareAwardPlan2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">brns:EnterpriseManagementIncentiveShareOptionSchemeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">brns:EnterpriseManagementIncentiveShareOptionSchemeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">brns:EnterpriseManagementIncentiveShareOptionSchemeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">brns:EnterpriseManagementIncentiveShareOptionSchemeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">brns:InLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">brns:InLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">brns:OxfordshireMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-03</xbrli:startDate><xbrli:endDate>2021-09-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">brns:OxfordshireMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-14</xbrli:startDate><xbrli:endDate>2022-06-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">brns:ShareholderTheUniversityOfOxfordMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">brns:ExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">brns:ShareholderTheUniversityOfOxfordMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">brns:ExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">brns:ShareholderTheUniversityOfOxfordMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">brns:ShareholderTheUniversityOfOxfordMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">brns:OxfordUniversityInnovationLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">brns:ExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">brns:OxfordUniversityInnovationLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">brns:ExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">brns:OxfordUniversityInnovationLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">brns:OxfordUniversityInnovationLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">brns:OxfordUniversityInnovationLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">brns:OxfordUniversityInnovationLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">brns:BarinthusBiotherapeuticsPlcShareAwardPlan2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-01-31</xbrli:endDate></xbrli:period></xbrli:context><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-125" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-1" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-140 f-141" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-2" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-239 f-253 f-264 f-286 f-203 f-214" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-3" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-354 f-335 f-336 f-356" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-4" order="1"/></ix:resources></ix:header></div><div id="i417e39f5b7bb45b295bb09394310bc8c_1"></div><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Washington, D.C. 20549</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-K</ix:nonNumeric></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">(Mark One)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.810%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="f-2">x</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">For the fiscal year ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-4"><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="f-3">December 31</ix:nonNumeric>, 2023</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">or</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"/><td style="width:2.845%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.955%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-5">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Commission file number: <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-6">001-40367</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"> <ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-7">BARINTHUS BIOTHERAPEUTICS PLC</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.596%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1.01pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:edgarprovcountryen" id="f-8">England and Wales</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.01pt;padding-right:0.01pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">Not Applicable</span></div></td></tr><tr><td colspan="3" style="padding:2px 1.01pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">(State or other jurisdiction of incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1.01pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">(I.R.S. Employer Identification No.)</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-9">Unit 6-10, Zeus Building</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine2" id="f-10">Rutherford Avenue</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-11" continuedAt="f-11-1">Harwell,</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%"><ix:continuation id="f-11-1">Didcot</ix:continuation>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-12">OX11 0DF</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCountry" format="ixt-sec:countrynameen" id="f-13">United Kingdom</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">(Address of principle executive offices) (Zip Code)</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Registrant&#8217;s telephone number, including area code: <ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-14">+44 (0)</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-15">1865 818 808</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.778%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.780%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-2" name="dei:Security12bTitle" id="f-16">American Depositary Shares</ix:nonNumeric>*</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-2" name="dei:TradingSymbol" id="f-17">BRNS</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-2" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-18">The Nasdaq Global Market</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-3" name="dei:Security12bTitle" id="f-19">Ordinary shares, nominal value &#163;0.000025 per share</ix:nonNumeric>**</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:6pt;padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%;padding-left:1pt">American Depositary Shares may be evidenced by American Depositary Receipts. Each American Depositary Share represents one (1) ordinary share.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">**</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%;padding-left:2pt">Not for trading, but only in connection with the listing of American Depositary Shares on The Nasdaq Global Market.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Securities registered pursuant to Section 12(g) of the Act: None</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:115%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%"> <ix:nonNumeric contextRef="c-1" name="dei:EntityWellKnownSeasonedIssuer" id="f-20">No</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:115%">x</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:115%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%"> <ix:nonNumeric contextRef="c-1" name="dei:EntityVoluntaryFilers" id="f-21">No</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:115%">x</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-22">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:115%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:115%">o</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-23">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:115%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:115%">o</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:16.172%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.172%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.172%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.172%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.172%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.532%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:114%">o</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:114%">o</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-24">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:114%">x</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">Smaller reporting company </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="f-25">x</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-true" id="f-26">x</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntityExTransitionPeriod" format="ixt:fixed-false" id="f-27">o</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-false" id="f-28">o</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt:fixed-false" id="f-29">o</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:115%">o</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:115%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-30">x</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">As of the last business day of the registrant&#8217;s most recently completed second fiscal quarter, the aggregate market value of the registrant&#8217;s ordinary shares, nominal value &#163;0.000025 per share, in the form of American Depositary Shares, held by non-affiliates was approximately $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="6" id="f-31">79.4</ix:nonFraction> million.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">The number of shares outstanding of the registrant&#8217;s ordinary shares, nominal value &#163;0.000025 per share, as of March&#160;14, 2024: <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-32">38,921,212</ix:nonFraction> shares.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><ix:nonNumeric contextRef="c-1" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="f-33" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Portions of the registrant&#8217;s definitive proxy statement to be filed with the Securities and Exchange Commission relative to the registrant&#8217;s 2024 Annual Meeting of Shareholders are incorporated by reference into Items 10, 11, 12, 13 and 14 of Part III of this Annual Report on Form 10-K.</span></div></ix:nonNumeric><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i417e39f5b7bb45b295bb09394310bc8c_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">BARINTHUS BIOTHERAPEUTICS PLC</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">ANNUAL REPORT ON FORM 10-K</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">FOR THE FISCAL YEAR ENDED DECEMBER 31, 2023</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">TABLE OF CONTENTS</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:78.748%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.992%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_16">PART I</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_19">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_19">Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i417e39f5b7bb45b295bb09394310bc8c_19">8</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_22">Item 1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_22">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i417e39f5b7bb45b295bb09394310bc8c_22">54</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_25">Item 1B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_25">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i417e39f5b7bb45b295bb09394310bc8c_25">111</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_657">Item 1C.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_657">Cybersecurity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i417e39f5b7bb45b295bb09394310bc8c_657">112</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_28">Item </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_28">2</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_28">.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_28">P</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_28">roperties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i417e39f5b7bb45b295bb09394310bc8c_28">112</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_31">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_31">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i417e39f5b7bb45b295bb09394310bc8c_31">112</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_34">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_34">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i417e39f5b7bb45b295bb09394310bc8c_34">112</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_37">PART II</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_40">Item 5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_40">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i417e39f5b7bb45b295bb09394310bc8c_40">113</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_43">Item 6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_43">[Reserved]</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i417e39f5b7bb45b295bb09394310bc8c_43">116</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_46">Item 7.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_46">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i417e39f5b7bb45b295bb09394310bc8c_46">116</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_82">Item 7A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_82">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i417e39f5b7bb45b295bb09394310bc8c_82">128</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_85">Item 8.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_85">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i417e39f5b7bb45b295bb09394310bc8c_85">129</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_88">Item 9.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_88">Changes in and Disagreements </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_88">w</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_88">ith Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i417e39f5b7bb45b295bb09394310bc8c_88">130</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_91">Item 9A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_91">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i417e39f5b7bb45b295bb09394310bc8c_91">130</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_94">Item 9B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_94">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i417e39f5b7bb45b295bb09394310bc8c_94">132</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_97">Item 9C.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_97">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i417e39f5b7bb45b295bb09394310bc8c_97">132</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_100">PART III</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_103">Item 10.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_103">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i417e39f5b7bb45b295bb09394310bc8c_103">133</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_106">Item 11.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_106">Executive Compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i417e39f5b7bb45b295bb09394310bc8c_106">133</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_109">Item 12.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_109">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i417e39f5b7bb45b295bb09394310bc8c_109">133</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_112">Item 13.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_112">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i417e39f5b7bb45b295bb09394310bc8c_112">133</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_115">Item 14.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_115">Principal Accounting Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i417e39f5b7bb45b295bb09394310bc8c_115">133</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_118">PART IV</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_121">Item 15.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_121">Exhibits, Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i417e39f5b7bb45b295bb09394310bc8c_121">134</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_124">Item 16.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_124">Form 10-K Summary</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i417e39f5b7bb45b295bb09394310bc8c_124">137</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_127">SIGNATURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i417e39f5b7bb45b295bb09394310bc8c_127">138</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">W</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">e </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">own the registered trademark BARINTHUS in the United Kingdom, and we </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">have filed applications at the UK Intellectual Property Office </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">and other intellectual properties </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">to register trademarks for BARINTHUS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, SNAP-TI, SNAP-CI</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> and a design logo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> globally</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We also own various trademark registrations and applications, and unregistered trademarks, including the registered trademark VACCITECH, and trademarks relating to the technologies acquired as part of our acquisition of Avidea Technologies, Inc. in December 2021 including the registered trademarks TRAPD, SNAPVAX and SYNTHOLYTIC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> All other trade names, trademarks and service marks of other companies appearing in this Annual Report on Form 10-K ("Annual Report") are the property of their respective holders. Solely for convenience, the trademarks and trade names in this Annual Report may be referred to without the &#174; and &#8482; symbols, but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. We do not intend to use or display other companies&#8217; trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">From time to time, we may use our website, our X (formerly known as Twitter) account at @Barinthusbio and our LinkedIn account at linkedin.com/company/barinthus-bio to distribute material information. Our financial and other material information is routinely posted to and accessible on the Investors section of our website, available at www.barinthusbio.com. Investors are encouraged to review the Investors section of our website because we may post material information on that site that is not otherwise disseminated by us. Information that is contained in and can be accessed through our website, our X (formerly known as Twitter) posts and our LinkedIn posts are not incorporated into, and does not form a part of, this </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Annual Report.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i417e39f5b7bb45b295bb09394310bc8c_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">This Annual Report contains express or implied forward-looking statements that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by the words &#8220;may,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;objective,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; &#8220;ongoing,&#8221; or the negative of these terms, or other comparable terminology intended to identify statements about the future. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. The forward-looking statements and opinions contained in this Annual Report are based upon information available to our management as of the date of this Annual Report and, while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. Forward-looking statements contained in this Annual Report include, but are not limited to, statements about:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the success, cost and timing of our product development activities and clinical trials;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the timing, scope or likelihood of regulatory filings and approvals, including timing of Investigational New Drug Application ("IND") and Biological License Application filings for our current and future product candidates, and final U.S. Food and Drug Administration ("FDA"), European Medicines Agency ("EMA"), United Kingdom Medicines and Healthcare products Regulatory Agency ("MHRA") or other foreign regulatory authority approvals relating to our current and future product candidates;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our ability to develop and advance our current and future product candidates and programs into, and successfully complete, clinical trials;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our ability to establish future or maintain current collaborations or strategic relationships;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the rate and degree of market acceptance and clinical utility of our current and future product candidates;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">any expectations surrounding the payments we could potentially receive pursuant to our collaborations and license agreements;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the ability and willingness of our third-party collaborators to continue research and development activities relating to our product candidates;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our ability to obtain, maintain, defend and enforce our intellectual property protection for our product candidates, and the scope of such protection;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our manufacturing, commercialization and marketing capabilities and strategy;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">future agreements with third parties in connection with the commercialization of our product candidates, if approved, and any other approved products;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">regulatory developments in the United States and foreign countries;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">competitive companies, technologies and our industry and the success of competing therapies that are or may become available;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our ability to attract and retain key scientific or management personnel;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our ability to obtain funding for our operations, including funding necessary to complete further development and commercialization of our product candidates;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the accuracy of our estimates of our annual total addressable markets, future revenue, expenses, capital requirements and needs for additional financing;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our expectations about market trends;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our ability to anticipate and overcome challenges posed to the conduct of our business in the event of a global pandemic, such as COVID-19, or similar event;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the impact of global economic and political developments on our business, including rising or sustained high inflation and capital market disruptions, the conflict in Ukraine, the conflict in Israel and Gaza, disruptions in the banking industry, economic sanctions and economic slowdowns or recessions that may result from such developments; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our expectations regarding the period during which we qualify as an emerging growth company under the Jumpstart Our Business Startups Act of 2012, as amended ("JOBS Act").</span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">You should refer to the section titled &#8220;Risk Factors&#8221; for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. As a result of these factors, we cannot assure you that the forward-looking statements in this Annual Report will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You should read this Annual Report and the documents that we reference in this Annual Report with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements in this Annual Report by these cautionary statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This Annual Report contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Unless the context otherwise requires, reference in this Annual Report to the terms &#8220;Barinthus Bio,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; and similar designations refer to Barinthus Biotherapeutics plc and, where appropriate, our wholly-owned subsidiaries. As used herein, all references before November 7, 2023 to (i) Barinthus Biotherapeutics plc shall refer to Vaccitech plc, (ii) Barinthus Biotherapeutics (UK) Limited shall refer to Vaccitech (UK) Limited, (iii) Barinthus Biotherapeutics North America, Inc. ("Barinthus Bio NA") shall refer to Vaccitech North America, Inc., (iv) Barinthus Biotherapeutics Switzerland GmbH shall refer to Vaccitech Switzerland GmbH, (v) Barinthus Biotherapeutics S.R.L. shall refer to Vaccitech Italia S.R.L. and (vi) Barinthus Biotherapeutics Pty Limited shall refer to Vaccitech Australia Pty Limited, after which the name change described herein shall have taken effect.</span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i417e39f5b7bb45b295bb09394310bc8c_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">SUMMARY OF THE MATERIAL RISKS ASSOCIATED WITH OUR BUSINESS</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We are a clinical-stage biopharmaceutical company with a limited operating history. We have incurred significant losses since inception. We expect to incur losses for at least the next several years and may never achieve or maintain profitability.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We have not yet generated any material revenue from our product candidates.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">If we engage in further acquisitions or future strategic partnerships, this may increase our capital requirements, dilute our shareholders, cause us to incur debt or assume contingent liabilities, and subject us to other risks.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Our limited operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Raising additional capital may cause dilution to our shareholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We will need to raise additional funding, which may not be available on acceptable terms, or at all. Failure to obtain this necessary capital when needed may force us to delay, limit or terminate our product development efforts or other operations.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We may require substantial additional funding in the future. If we are unable to raise capital when needed, we would be compelled to delay, reduce or eliminate our product development programs or commercialization efforts.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Actual payments we may receive in connection with certain milestones or net sales under the AstraZeneca License Agreement may differ from those described in this Annual Report, and there can be no assurance that we will receive any such payments at all.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">If we are unable to advance our current or future product candidates into and through clinical trials, obtain marketing approval or reimbursement and ultimately commercialize any product candidates we develop, or experience significant delays in doing so, our business will be materially harmed.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Clinical development involves a lengthy and expensive process with uncertain outcomes, and results of earlier preclinical studies and clinical trials may not be predictive of future clinical trial results. We may encounter substantial delays in clinical trials, or may not be able to conduct or complete clinical trials on the expected timelines, if at all. If our preclinical studies and clinical trials are not sufficient to support marketing authorization of any of our product candidates, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development of such product candidate.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Interim, &#8220;topline,&#8221; and preliminary data from our clinical trials that we announce or publish from time to time may change as more participant data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Our product candidates are based on a novel approach to the treatment of cancer, which makes it difficult to predict the time and cost of product candidate development.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Our product candidates may cause serious adverse events, serious side effects or have other properties that could halt their clinical development, prevent their marketing authorization, require expansion of the trial size, limit their commercial potential or result in significant negative consequences.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">If we are unable to advance our current or future product candidates into and through clinical trials, obtain marketing approval and ultimately commercialize any product candidates we develop, or experience significant delays in doing so, our business will be materially harmed.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The market opportunities for certain of our oncology product candidates may be relatively small as it may be limited to those patients who are ineligible for or have failed prior treatments and our estimates of the prevalence of our target patient populations may be inaccurate.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We may form or seek additional collaborations or strategic alliances or enter into additional licensing arrangements in the future, and we may not realize the benefits of such collaborations, alliances or licensing arrangements.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The marketing authorization processes of the FDA, the EMA, MHRA and other comparable foreign regulatory authorities are lengthy, time-consuming and inherently unpredictable, and if we are ultimately unable to obtain marketing authorizations for our product candidates, or the marketing authorization is for a narrower indication than we seek, our business will be substantially harmed.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Even if we receive marketing authorization for our product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">If we are unable to obtain and maintain patent protection for any products we develop and for our technology, or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize products and technology similar or identical to ours, and our ability to successfully commercialize any product candidates we may develop and our technology may be adversely affected.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Our rights to develop and commercialize our technology and product candidates are subject, in part, to the terms and conditions of licenses granted to us by others and if we fail to comply with our current or future obligations in any agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We are highly dependent on our key personnel, and if we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We will need to grow the size of our organization and we may experience difficulties in managing this growth.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">We previously identified material weaknesses in connection with our internal control over financial reporting. Although we have taken steps to remediate these material weaknesses, we may identify other material weaknesses in the future, which could have a significant adverse effect on our business and the trading price of our ADSs.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">If we were classified as a passive foreign investment company, it would result in adverse U.S. federal income tax consequences to U.S. Holders (as defined below).</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">A variety of risks associated with operating our business internationally could materially adversely affect our business.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The United Kingdom&#8217;s withdrawal from the EU could increase the regulatory burden of product development and authorization in the United Kingdom and European Union.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="i417e39f5b7bb45b295bb09394310bc8c_16"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">PART I</span></div><div id="i417e39f5b7bb45b295bb09394310bc8c_19"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 1. Business</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Overview</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity and cancer. Helping patients and their families is the guiding principle at the heart of Barinthus Bio. We stand apart through our broad pipeline, built around four proprietary platform technologies; two viral vector platforms, ChAdOx and MVA; and two versions of the synthetic SNAP platform, SNAP-TI (SNAP-Tolerance Immunotherapy) and SNAP-CI (SNAP-Cancer Immunotherapy), previously referred to collectively as SNAPvax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. These platforms are enabling us to develop antigen-specific immunotherapeutic candidates designed to optimize the disease-fighting capabilities of T cells and guide them towards a healthy balance. Our immunotherapeutic candidates are designed to work by increasing disease-specific CD8+ T cell activity in the case of chronic infectious diseases and cancers, or by dampening autoreactive CD4+ and CD8+ T cells, and increasing regulatory T cells in autoimmunity.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Harnessing our range of proprietary platform technologies, we are advancing a pipeline of four product candidates across a diverse range of therapeutic areas, including: VTP-300, a Phase 2 immunotherapeutic candidate designed as a potential component of a functional cure for chronic hepatitis B viral ("HBV") infection; VTP-200, a Phase 2 non-surgical product candidate for persistent high-risk human papillomavirus ("HPV") with near term clinical read-outs; VTP-1000, our first preclinical autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease; and VTP-850, a second-generation Phase 2 immunotherapeutic candidate designed to treat recurrent prostate cancer.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Alongside these proprietary programs, we have partnerships in place to advance three additional prophylactic and therapeutic product candidates in Middle East Respiratory Syndrome ("MERS"), Zoster and Non-Small Cell Lung Cancer (NSCLC). We also co-invented Vaxzevria, a COVID-19 vaccine with the University of Oxford, which has been exclusively licensed worldwide to AstraZeneca UK Limited ("AstraZeneca"). The co-invention of the COVID-19 vaccine demonstrated our ability to navigate a changing environment with speed and efficiency and lead the way in responding to urgent medical needs, as well as providing a strong proof-of-concept for the ChAdOx platform.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our proven scientific expertise, diverse portfolio and focus on product candidate development uniquely positions us to navigate towards delivering treatments for patients with infectious diseases, autoimmune disorders and cancers that have a significant impact on their everyday lives.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Scientists have successfully harnessed the strengths of the immune system to prevent and treat diseases using a wide range of approaches over hundreds of years. The most widely known application of such approaches is prophylactic vaccines, which aim to create long-lasting immunity largely via the generation of protective antibodies. More recently, approaches targeting the immune system to treat diseases have emerged with many immunotherapeutics aiming to balance the body&#8217;s immune response. These immunotherapeutic approaches can broadly fit into two categories: those that are designed to strengthen the immune system to enable clearance of pathogens and infected or cancerous cells, or those that are designed to dampen the immune system to limit inflammation and tissue damage due to autoimmune hyperactivity or uncontrolled inflammation. A key element of the immune system is specialized white blood cells, also called lymphocytes. B cells and T cells are the two main types of lymphocytes. B cells are responsible for generating antibodies while T cells assist in the clearance of acute and chronic infections, such as HBV and HPV, and are involved in killing cells that become cancerous. Although designed to be protective, these immune cells can also be hyperactive and, when targeted against self, they are responsible for tissue-specific damage in many autoimmune conditions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Over the past three decades, hundreds of trials have examined a wide variety of approaches that induce the production of cytotoxic CD8+ T cells against infected and cancerous cells. These trials have demonstrated that different approaches induce different breadths and magnitudes of immune response. While there have been many successes, certain diseases requiring a robust CD8+ T cell response have remained resistant to existing approaches. Infected or cancerous cells are recognized as a &#8220;danger&#8221; by the immune system through their expression of specific antigens, which elicit a targeted immune response, largely led by T cells, to eliminate the &#8220;danger.&#8221; Our platforms are designed to stimulate the production of very high levels of functional T cells, in addition to antibodies, against such antigens. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our approach for the treatment of a disease with known target antigens is to attempt to elicit a strong and specific immune response against these antigens using a combination of two proprietary platforms encoded with the target antigens, each administered one month apart. We employ unique antigen design strategies designed to optimize antigen presentation to the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">immune system and maximize the desired type of immune response we are seeking to induce. This specific combination approach has been shown to provide a very high magnitude and durable CD8+ T cell response induced in humans to date. Our platforms are further differentiated by their flexibility, applicability across diseases, favorable tolerability profile and proven rapid production on a large scale.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Autoimmunity develops when the tolerance checkpoints meant to maintain a state of unresponsiveness of our immune system towards self-antigens are lost. It results in abnormal immune reaction against our own tissues, causing tissue damage and disease. Although the past two decades have seen incredible progress in the treatment of chronic inflammatory and autoimmune diseases, current therapies still rely heavily on the use of non-specific immunosuppressive agents and supportive therapies. These may efficiently dampen inflammation and compensate organ dysfunction to some degree, but they require lifelong treatment and their lack of specificity for the pathogenic mechanism only can lead to several, sometimes life-threatening, side effects. A far less aggressive approach is to restore immune tolerance to self-antigens, in an antigen-specific manner, enabling to selectively blunt autoinflammation and control the disease without impairing protective immunity to pathogens and cancer. Our SNAP-TI platform is designed to exactly do that: restore immune tolerance to self. The platform is comprised of several self-antigens involved in the target disease associated with a tolerizing immunomodulator, enabling presentation of the disease antigens in a tolerizing context, which will potentially lead to dampening T cell hyperactivity and/or inducing self-antigen-specific regulatory T cells, whose main function is to control immune responses. We believe SNAP-TI is further differentiated from its competitors by its high antigen loading capacity, controlled size, and self-assembling nature for ease of manufacturing. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2023, we achieved a number of strategic, operational, and financial objectives, which we believe positions us to deliver on our long-term plans:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">In January, we announced the appointment of Nad&#232;ge Pelletier, Ph.D., as Chief Scientific Officer.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">In March, we announced favorable topline interim data from the HPV001 Phase 1b/2 clinical trial of VTP-200 in high risk HPV ("hrHPV") infection, and positive topline final data from the HBV002 Phase 1b/2 clinical trial for VTP-300 in chronic HBV. </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">In April, we presented interim data from the VTP-200 APOLLO (HPV001) Phase 1b/2 clinical trial in hrHPV infection at the 35</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Annual International Papillomavirus Conference ("IPVC"). The interim data showed VTP-200 induced high T cell responses to HPV antigens. VTP-200 was generally well-tolerated with no product-related grade 3 unsolicited events and no product-related SAE</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">s.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">In June, we announced the dosing of the first patient in the Phase 1/2 PCA001 clinical trial for VTP-850 in prostate cancer. </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">In June, we presented positive final data from the Phase 1b/2a HBV002 clinical trial for VTP-300 in chronic Hepatitis B (CHB) at the European Association for the Study of the Liver ("EASL") Congress 2023 &#8211; The International Liver Congress</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. The data showed meaningful, durable reductions of Hepatitis B Surface Antigen (HBsAg) in all participants with a &gt;0.5 log10 reduction in HBsAg who received VTP-300 alone (Group 2) or in combination with a single administration of low-dose PD-1 inhibitor, nivolumab (Group 3). Two of five patients with baseline HBsAg below 100 IU/mL in Group 3, developed a non-detectable HBsAg level, which continued eight months after last dose. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In June, we completed the move of our U.S. facility to Germantown, Maryland, which houses a state-of-the art wet laboratory and office space.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">In November, we announced our renaming as Barinthus Biotherapeutics plc to represent the evolution and expansion of its focus beyond vaccines. As part of the renaming, we announced the ticker on Nasdaq was changed to "BRNS," which became effective on November 7, 2023.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">In November, we conducted an oral presentation of interim data from the Phase 2b HBV003 clinical trial for VTP-300 in CHB at the American Association for the Study of Liver Diseases ("AASLD") &#8211; The Liver Meeting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> 2023, which indicated that VTP-300 in combination with nivolumab continued to show sustained HBsAg reductions, particularly in patients with HBsAg levels below or equal to 200 IU/mL at screening.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">In November, interim data from the Phase 2a AB-729-202 clinical trial in collaboration with Arbutus Biopharma Corporation in CHB patients were presented via poster presentation at AASLD, showing that imdusiran in combination with VTP-300 demonstrated meaningful and sustained declines in HBsAg levels. </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">In December, we announced we signed an agreement with the Coalition for Epidemic Preparedness Innovations ("CEPI") and the University of Oxford, aiming to fast-track the development of a vaccine candidate known as </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VTP-500 for the prevention of MERS. This agreement includes CEPI investing funding of up to $34.8 million with Barinthus Biotherapeutics (UK) Limited in addition to funds previously committed to the University of Oxford to develop and stockpile a ready reserve of emergency MERS vaccine candidate, VTP-500.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In December 2023, we submitted an Australian ethics submission and regulatory notification to the Alfred Research Review Committee for the Phase 1 GLU001 study in Celiac disease. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">The Key Elements of Our Antigen-Delivery Platforms</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our proprietary platforms are comprised of several components that are designed to be either immunostimulatory or tolerizing. When combined, our immunomodulatory platforms (ChAdOx, MVA and SNAP-CI) allow us to develop product candidates designed to induce high and durable levels of antigen-specific polyfunctional T cells and B cells to prevent and treat infectious diseases and cancer. Our tolerizing platform (SNAP-TI) is designed to restore immune tolerance by a mechanism of action that includes the induction of regulatory T cells and/or decrease of T cell activation to specifically restore a beneficial T regulatory to T effector ratio and control autoreactive immune cell hyperactivity, while maintaining the desired tolerability profile. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The key elements of our viral vector platforms, which include ChAdOx and MVA, are:</span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:14.5pt">Proprietary simian vectors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">: ChAdOx1 and ChAdOx2 are modified simian adenoviral vectors which deliver target antigens into cells to generate a specific immune response. These viruses were originally isolated from chimpanzees to avoid pre-existing immunity issues affecting the use of human adenovirus vectors. Researchers at the Jenner Institute modified the ChAdOx viruses to be non-replicating and to have an increased antigen-carrying capacity. To date, we have developed several candidates with the ChAdOx vectors, each carrying antigens that are specific to the targeted pathogens and diseases. Adenoviral vectors have demonstrable safety profiles and have induced the desired immune responses in all age groups evaluated to date.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Well-validated follow-up vector</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: MVA is a highly attenuated vaccinia virus used to deliver target antigens into cells to generate de novo or amplify an existing immune response. MVA has a large antigen-carrying capacity and generates a particularly strong immune response when used secondarily, in sequential combination, to an alternative viral vector carrying the same antigen load (ChAdOx in this case). MVA is replication-deficient and has a well-documented safety profile in hundreds of thousands of people, and is licensed as a smallpox vaccine in both Europe and the US.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Proprietary promoters and enhancers:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Promoters and molecular enhancers are genetic codes that influence antigen expression. For our adenoviral vectors, we use a proprietary promoter that is modified from cytomegalovirus. The use of this modified promoter has been shown to increase both antigen expression and the associated immune response. For our MVA vector, we use a proprietary promoter to control expression of recombinant antigens and thereby further enhance T cell induction levels. We may use molecular adjuvants to enhance the CD8+ T cell response.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Rapid vector generation and manufacturing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: We employ manipulation of adenovirus genomes to enable rapid generation of recombinant adenoviral vectors to meet GMP standards. We believe our sequencing techniques have the potential to result in safer, more stable, product candidates. We believe that our adenovirus product candidates can be manufactured quickly and to significant scale, as demonstrated by Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. Vaxzevria, which is based on the ChAdOx1 vector, was designed, constructed and manufactured for human use within three months. Normal GMP production processes typically take six to ten months each for adenovirus and for MVA.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The key elements of our synthetic platforms, which include SNAP-TI and SNAP-CI, are:</span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Synthetic nanoparticle technology:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> SNAP is a modular immunotherapy platform that is designed to co-deliver multiple targeted peptide antigens and immunomodulators in self-assembling nanoparticles to key immune cell populations for promoting the appropriate T cell immunity. SNAP&#8217;s unique design allows for trafficking to lymphoid organs and local tissues to engage with local immunity. The large antigen loading capacity is designed to allow for subcutaneous or intramuscular administration. It can be administered as a monotherapy or in combination with the viral vectors. Its synthetic nature allows for repeated administration. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;text-decoration:underline">SNAP-TI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: has shown promising data on protection from disease in a mouse model of autoimmunity. We are advancing assets based on the SNAP-TI platform designed to treat autoimmune diseases with known autoantigens. SNAP-TI contains autoantigens and immunomodulators (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">e.g.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, mTOR inhibitors). Its putative mechanism of action includes both dampening of pathogenic T effector activity and induction of regulatory T cells, crucial to restore immune tolerance to self-antigens and maximize therapeutic benefit. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:4.5pt"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;text-decoration:underline">SNAP-CI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: An article in Nature Biotechnology described SNAP as among the most efficient immunotherapy platforms for inducing T cell immunity reported to date. Another article in Nature Biotechnology reported that SNAP enabled repeated intravenous ("IV") administration to maximize clinical effect. SNAP-CI has been observed to induce high magnitude, functional CD8+ T cells, especially when given sequentially with ChAdOx1 in preclinical studies in mice and non-human primates. It contains cancer-specific antigens and immunomodulator (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">e.g</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">., Toll-like receptor agonists).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Antigen selection and design across all platforms</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: We select full-length and/or subunit antigen sequences involved in or associated with targeted infectious diseases, autoimmune diseases, or cancer. We employ unique antigen design strategies to optimize</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> antigen presentation and maximize the desired type of immune responses while maintaining the desired tolerability profile. For example, some targeted diseases may require a greater CD8+ T cell-mediated response, whereas others may require a more balanced T and B cell response, and others require the induction of regulatory T cells. We use cutting-edge bioinformatics methods to design and optimize our antigen load. For example, to select antigen targets for pathogens, we use databases to rank options based on factors including global distribution of genetic strains, evolutionary competitive advantage, known pathogenicity and sequence upload bias; and design our final antigens to achieve maximal antigen presenting cell processing to elicit CD8+ T cells.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have several product candidates in our pipeline focusing on infectious diseases, oncology and immune tolerance.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Proprietary Pipeline:</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The chart below provides key information about our programs.</span></div><div><span><br/></span></div><div><img src="brns-20231231_g1.jpg" alt="Image_No. 1.jpg" style="height:227px;margin-bottom:5pt;vertical-align:text-bottom;width:660px"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have worldwide rights for all product candidates.</span></div><div style="margin-bottom:12pt;text-align:center"><span style="background-color:#e6e6e6;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">These are estimated timelines only and are subject to change.</span></div><div><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Our Partnered Pipeline:</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="text-align:justify"><img src="brns-20231231_g2.jpg" alt="Image_2.jpg" style="height:246px;margin-bottom:5pt;vertical-align:text-bottom;width:660px"/></div><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">VTP-300: An Immunotherapeutic Targeting Chronic HBV Infection</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VTP-300 is composed of two viral vectors (ChAdOx and MVA), both encoding the same antigen sequence based on HBV genotype C antigen sequences that are administered intramuscularly one month apart, with the potential for additional administrations subsequently, depending upon outcome.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">HBV002 &#8211; Completed Phase 1b/2a</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023, we announced topline results from the Phase 1b/2a clinical trial, HBV002, to evaluate the safety and reactogenicity of VTP-300 with or without a low-dose (0.3 mg/kg) anti-PD-1 (nivolumab) in CHB patients whose infection has been suppressed with oral antiviral medication. In the HBV002 trial, we enrolled CHB patients in four treatment groups as described in the table below.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><img src="brns-20231231_g3.jpg" alt="Image_3.jpg" style="height:130px;margin-bottom:5pt;vertical-align:text-bottom;width:660px"/><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the participants were already infected with HBV, we thought it was possible that natural exposure could eliminate the need for the an initial ChAdOx1 dose. Hence, Group 1 of the HBV002 trial was designed to compare MVA-HBV given twice with the ChAdOx1-HBV plus MVA-HBV combination approach used in Group 2. We expected that the regimen given to Group 2 would be more potent and planned to further explore this specific regimen in Groups 3 and 4 with the addition of PD1 blockade.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the cancer field, the timing of PD-1 blockade has been reported to be critical as its administration prior to immune stimulation has been observed to result in diminished T cell responses as compared to later administration. Hence, Groups 3 and 4 evaluated the impact of the timing of PD1 blockade, administered either with the MVA dose (Group 3) or with both the ChAdOx1 and the MVA doses (Group 4). Nivolumab has been used in earlier immunotherapy trials at 1/10 the licensed dose for oncology indications and has been shown to give full peripheral blood T cell receptor occupancy for up to over one month.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The secondary objectives of this study were to evaluate the HBV-specific T cell response and the effect on the levels of hepatitis B markers, including HBsAg, hepatitis B surface antibody seroconversion, HBV DNA and HBeAg. The majority </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the patients were recruited in Taiwan and South Korea and these territories were selected due to the high prevalence of HBV genotype C virus in Asia. Patients were also enrolled in the United Kingdom.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An interim analysis of HBV002 was conducted in November 2021, after which the protocol was amended to stop enrollment in cohorts 1 and 4 as no meaningful T cell responses nor meaningful reduction of HBsAg were observed with these regimen. Enrollment continued in the cohort receiving VTP-300 as a monotherapy (Group 2) and the cohort receiving VTP-300 with a single low dose of nivolumab administered with the MVA dose (Group 3).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">EASL Poster to Present Final Analysis of Safety and Efficacy Data from the HBV002 Study</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2023, we announced final safety and efficacy data from the HBV002 study (NCT04778904), which was presented as a poster at the EASL Congress 2023 &#8211; The International Liver Congress</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In the HBV002 study, 55 participants were randomized into four groups to receive combinations of VTP-300 and low-dose nivolumab, with follow-up for eight months post-final dose.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><img src="brns-20231231_g4.jpg" alt="HBV002.jpg" style="height:170px;margin-bottom:5pt;vertical-align:text-bottom;width:660px"/></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VTP-300 as monotherapy and in combination with low-dose nivolumab was administered with no treatment-related serious adverse events. As reported previously, two out of 55 participants experienced transient transaminase flares. Both incidents occurred in participants with HBsAg declines, but not in any of the participants who cleared HBsAg (&lt;0.05 IU/mL).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Group 2</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Meaningful, durable reductions of HBsAg were seen in Group 2 (receiving VTP-300 monotherapy, N=18). Three participants had 0.7, 0.7, and 1.4 log10 declines two months post-final dose, with durable responses continuing eight months post-final dose. These participants all had baseline HBsAg &lt;50 IU/mL. A robust T cell response was generated and was highest in this group and there was a relation demonstrated between ELISpot response and HBsAg decline.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Group 3</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Those in Group 3 received VTP-300 followed by a single low dose of nivolumab together with Modified Vaccinia Ankara (MVA)-HBV (N=18). Two months post-final dose, the mean reduction in HBsAg was 0.76 log10 (p&lt;0.001). This effect persisted with a mean decline of 0.98 log10 at eight months (p&lt;0.001) after the last dose and was most prominent with starting values HBsAg &lt;1,000 IU/mL. Two participants developed non-detectable HBsAg levels, which continued eight months after last dose. Pre-genomic RNA levels were observed to decrease significantly in the majority of participants in this group only, consistent with the decline in HBsAg levels.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Groups 1 and 4</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No meaningful reductions in HBsAg were observed in Group 1, in which participants received two doses of MVA-HBV without ChAdOx1-HBV, or in Group 4, in which participants received low-dose nivolumab with both doses of VTP-300. These groups were discontinued following interim analysis, as previously announced in June 2022. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Importantly, VTP-300, based on HBV genotype C sequences, was observed to lead to a decline in HBsAg in both genotype B- and C-infected CHB patients. Additionally, T cell responses to HBV core protein induced by VTP-300 in healthy subjects were shown to cross-react with other prevalent genotypes (A to E). Together, these results highlighted that T cell responses induced by VTP-300, based on genotype C, were cross-reactive to other common HBV genotypes.</span></div><div><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">HBV003 &#8211; Ongoing Phase 2b</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HBV003 is designed to obtain critical information on treatment dosing regimen with patients receiving VTP-300 and low-dose nivolumab. Our first patient was dosed in October 2022. In the HBV003 trial, we are enrolling CHB patients in three treatment groups as described in the table below. The study design directly builds from HBV002 to evaluate PD-1 inhibition timing, and includes criteria for discontinuation of standard-of-care nucleos(t)ide reverse transcriptase inhibitor (NUC) to obtain information on the durability of the response in the absence of treatment.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><img src="brns-20231231_g5.jpg" alt="HBV003.jpg" style="height:161px;margin-bottom:5pt;vertical-align:text-bottom;width:660px"/></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AASLD Oral Presentation on Interim Data from the HBV003 Study </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, we announced interim data from HBV003 (NCT05343481) as of October 10, 2023, which was presented as an oral presentation at The AASLD &#8211; The Liver Meeting&#174; 2023. Seventy-four out of a planned 120 virally suppressed CHB patients on stable NUC therapy had been enrolled in the trial and 57 had reached Day 113. VTP-300 in combination with nivolumab led to HBsAg declines in all treatment groups, particularly in participants with screening HBsAg levels &#8804;200 IU/mL.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&gt;0.5 and &gt;1 log drops were observed in all groups at Day 113 in 23% and 9% of participants, respectively. Participants with an HBsAg level of &#8804;200 IU/mL at screening were more likely to have &gt;1 log HBsAg reductions (31%) compared to those with HBsAg levels &gt;200 IU/mL at Day 1 (2%). Greater mean HBsAg log reductions were observed in Group 2 (ChAdOx-HBV Day 1; MVA-HBV and nivolumab Day 29 and Day 85) but insufficient data were available for a definitive conclusion. Seven participants had met the criteria for NUC discontinuation; three had discontinued and two had restarted NUC therapy. One remained off NUC therapy at the time of analysis, retaining undetectable HBsAg 16 weeks post-NUC discontinuation. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><img src="brns-20231231_g6.jpg" alt="Image_6.jpg" style="height:207px;margin-bottom:5pt;vertical-align:text-bottom;width:660px"/></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preliminary safety data suggested that VTP-300 in combination with nivolumab was generally well tolerated, with no treatment-related SAEs observed or reported. Thyroid dysfunction was reported in seven participants attributed to nivolumab administration which had returned to normal in four patients.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We observed the highest rate of response in participants with screening HBsAg &#8804;200 IU/mL in the preliminary data. The HBV003 trial protocol has since been amended to include only participants with screening HBsAg &#8804;200 IU/mL and people with thyroid autoantibodies, family history of autoimmune thyroiditis, or abnormal thyroid levels have been excluded from trial eligibility to minimize the risk of thyroiditis and improve the overall risk/benefit ratio.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AB-729-202 &#8211; Ongoing Phase 2a in collaboration with Arbutus Biopharma Corporation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AB-729-202 is an ongoing Phase 2a clinical trial in collaboration with Arbutus Biopharma Corporation (NASDAQ: ABUS) to evaluate Arbutus&#8217; RNAi therapeutic candidate, imdusiran or AB-729, in combination with VTP-300 for the treatment of patients with chronic HBV infection. The clinical trial is designed to evaluate whether decreasing HBsAg levels with imdusiran prior to VTP-300 treatment, leads to a more sustained HBsAg reduction over treatment with imdusiran alone for CHB patients. Primary endpoints are evaluating the safety, antiviral activity and immunogenicity of VTP-300 administered after AB-729. The trial is designed to enroll 60 CHB patients as shown in the table below. All patients receive imdusiran (60mg every 8 weeks) plus NUC therapy for 24 weeks. At week 24, treatment with AB-729 stops and patients are randomized to receive either placebo (Group B) or VTP-300 (Groups A &amp; C) at week 26 and 30 (and conditionally at week 38 if they experienced a &gt;0.5log10 decline in HBsAg between week 26 and 34). Group C receives in addition low dose nivolumab together with their MVA dose. At week 48 all participants are evaluated for eligibility to either discontinue or remain on NUC therapy.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><img src="brns-20231231_g7.jpg" alt="Image_7.jpg" style="height:140px;margin-bottom:5pt;vertical-align:text-bottom;width:660px"/></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AASLD Poster Presentation on Interim Data from the AB-729-202 Study </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 9, 2023, we announced interim data from the AB-729-202 trial (ACTRN12622000317796) as of October 13, 2023, which was presented as a late-breaking poster presentation at AASLD. The preliminary data included a subset of patients from groups A and B (28/40 patients) and available follow-up data to week 48 (12/40 patients) and showed that robust reductions of HBsAg were observed during the imdusiran treatment period (-1.86 log10 mean reduction from baseline after 24 weeks of treatment). This decline in HBsAg was comparable to the declines seen with imdusiran in other clinical trials conducted to date. 97% of the imdusiran treated patients (33/34) had HBsAg &lt;100 IU/mL at the time of the first VTP-300/placebo dose. VTP-300 treatment appeared to contribute to the maintenance of low HBsAg levels in the early post-treatment period, as the mean HBsAg levels in the placebo group began to increase starting approximately 12 weeks after the last dose of imdusiran.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All VTP-300 treated patients, with available follow-up data to week 48, maintained HBsAg &lt;100 IU/mL through week 48, 60% have maintained HBsAg &lt;10 IU/mL, and all qualified to stop NUC therapy. Preliminary immunology data for those patients through to week 48 for which samples met the quality threshold and were available to be analyzed, suggested HBV-specific T cell IFN-&#947; production was enhanced in patients receiving imdusiran plus VTP-300 compared to placebo. The preliminary safety data from this trial demonstrated that imdusiran and VTP-300 were both generally well-tolerated. As of October 12, 2023, there were no serious adverse events, Grade 3 or 4 adverse events or treatment discontinuations.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="text-align:justify"><img src="brns-20231231_g8.gif" alt="AB-729 chart.gif" style="height:282px;margin-bottom:5pt;vertical-align:text-bottom;width:326px"/></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the interim analysis from the HBV003 Phase 2b and the AB-729-202 Phase 2a studies suggest that VTP-300 could become part of a regimen that can attain a functional cure. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Future Development</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to announce interim efficacy data from both the HBV003 study and the AB-729-202 combination study with Arbutus in the second quarter of 2024.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">VTP-200: Developing a Potential Non-Invasive Treatment for Persistent High-Risk HPV</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are developing VTP-200 as a potential curative treatment for persistent hrHPV infection and associated pre-cancerous lesions. An estimated 291 million women worldwide are carriers of HPV DNA, which can progress to pre-cancerous cervical lesions if untreated. Enrollment in our Phase 1b/2 APOLLO (HPV001) clinical trial of VTP-200, (NCT04607850), was completed in December 2022 and the last visit of the final patient to the clinic was in January 2024. VTP-200 is composed of two viral vectors (ChAdOx1 and MVA), both encoding the same HPV antigens (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">i.e.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,: E1, E2, E4, E5, E6, E7), designed to elicit an antigen-specific T cell immune response to HPV. Both vectors are administered intramuscularly and sequentially, one month apart.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical Development</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Phase 1b/2 APOLLO trial is designed to assess the safety and efficacy of VTP-200 and determine the optimal dosing regimen. We have enrolled a total of 108 healthy women with low grade lesions who had persistent hrHPV for at least six months. Patients with high-grade squamous intraepithelial lesions ("HSIL") or early cancer were excluded. The trial was run in the United Kingdom and the European Union. The diagram below provides an overview of the Phase 1b/2 clinical trial design.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><img src="brns-20231231_g9.gif" alt="vtp-200 trial design.gif" style="height:175px;margin-bottom:5pt;vertical-align:text-bottom;width:660px"/></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary objective of the trial is to evaluate the safety and tolerability of VTP-200. The secondary objectives of the trial are to determine the optimal dose and to evaluate the efficacy of HPV001 on the clearance of hrHPV infection and on the cervical intraepithelial neoplasia ("CIN").</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We announced the topline initial interim safety and immunogenicity data of 58 patients in the main phase of the trial that reached their six-month evaluation timepoint in April 2023, and presented a poster at the 35th IPVC.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IPVC Poster Presentation on Interim Data from the APOLLO (HPV001) Trial</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The poster presentation in April 2023 showed interim data for 42 women at Day 35, 7 days after the MVA dose of VTP-200, split by active treatment versus placebo. VTP-200 was generally well-tolerated and was administered with no product-related grade 3 unsolicited adverse events and no product-related SAEs. While the placebo group showed no antigen-specific T cell responses as measured by IFNg ELISpot, 26 of 29 women receiving varying doses of VTP-200 showed a response. The pooled active groups showed meaningful responses, with the average being greater than 1,000 spot-forming units per million peripheral blood mononuclear cells. Responses were strongest to the E1, E2 and E6 antigens. In addition, intracellular cytokine staining data from the active groups showed both CD4+ and CD8+ responses.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><img src="brns-20231231_g10.jpg" alt="image 9.jpg" style="height:257px;margin-bottom:5pt;vertical-align:text-bottom;width:566px"/></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Future Development</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to announce full data from the APOLLO trial at the beginning of the second quarter of 2024. Following the HPV001 Phase 1b/2 clinical trial, if successful, we intend to review options to initiate further clinical trials of VTP-200, whether that is directly funded by the company or through external parties via partnerships, collaborations or grant funding. Our next trials would potentially be a Phase 2/3 trial in healthy women with early grade CIN (squamous intraepithelial lesions ("LSIL")) and additional trials in patients with more advanced CIN, vulval intraepithelial neoplasia, or VIN, and anal intraepithelial neoplasia ("AIN"). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">VTP-850: Our Next-Generation Immunotherapeutic Candidate for Prostate Cancer</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are developing VTP-850, our next-generation prostate cancer product candidate, to improve upon VTP-800. Both VTP-800 and VTP-850 are composed of two viral vectors (ChAdOx1 and MVA, both encoding the same antigen sequences); however, VTP-800 encodes only one antigen, 5T4, while VTP-850 encodes four antigens, PSA, PAP, STEAP1 and 5T4. We designed VTP-850 to induce a broader immune response by encoding multiple antigens to reduce the ability of cancer cells to evade the immune response by mutating or losing expression of any one antigen. The antigens we encode in VTP-850 are expressed in most prostate cancers but have little or no expression on healthy tissues other than prostate.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical Development</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase 1 (VANCE) and Phase 2 (ADVANCE) clinical trials of VTP-800 were sponsored and conducted by the University of Oxford in the United Kingdom. VTP-800 was generally well tolerated in both studies, with no treatment-related serious adverse events reported in VANCE or ADVANCE. One grade 3 adverse event was reported in ADVANCE (chest infection), which was deemed not related to study drug. There were no grade 4 or 5 treatment-related adverse events.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VANCE was a first-in-human, open label, randomized, Phase 1 clinical trial designed to evaluate the safety and immunological response of VTP-800 with and without low dose cyclophosphamide in localized prostate cancer. Thirty-nine patients with early stage localized, castration-sensitive prostate cancer were treated. Thirty-three patients received sequential administration of ChAdOx1-5T4 and MVA-5T4, one month apart, while six patients received MVA-5T4 alone. Patients received both regimens alone or with cyclophosphamide preconditioning. VTP-800 was generally well tolerated, with side effects of local injection site pain, fatigue, feverishness, and myalgia, which are consistent with those observed for these vectors in other clinical trials. There were no reported treatment-related serious adverse events. Data showed that 59% of participants had no detectable T cell response at baseline and developed a 5T4-specific T cell response de novo. Two patients had a baseline response, and the frequency of 5T4-specific T cells was observed to increase following administration. T cell infiltration into the resected prostate was also observed.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ADVANCE was an open-label, non-randomized Phase 2 clinical trial of VTP-800 in combination with anti-PD-1 checkpoint inhibitor, nivolumab, in 23 patients with metastatic prostate cancer. The primary objectives of the ADVANCE trial were to assess the safety and response rate of VTP-800 when administered in combination with nivolumab. The secondary objectives were to assess the immune responses in peripheral blood and to evaluate radiographic progression-free survival and overall survival. Patients received sequential administration of ChAdOx1-5T4 followed by MVA-5T4 one month later. Nivolumab was administered at months one, two and three. In most patients, VTP-800 was also given at months three and four. All patients received 2.5 x 10&#708;10 vp of ChAdOx1-5T4, 2.0 x 10&#708;10 pfu of MVA-5T4 and 480mg of nivolumab. VTP-800 was generally well tolerated. The most common treatment emergent adverse events were bone pain, injection site pain, muscle pain, stomatitis, and constipation, and most were mild and grade 1 or 2. The only grade 3 adverse event was a chest infection, which was not related to study drug. There were no grade 4 or 5 treatment-related adverse events. Data showed that three of eight patients with measurable disease had partial tumor responses. Five of 23, or 22%, of enrolled patients had greater than 50% reduction of prostate specific antigen ("PSA") at any timepoint.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PSA Reduction in Patients from ADVANCE Phase 2 Clinical Trial</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><img src="brns-20231231_g11.jpg" alt="image.1b resize.jpg" style="height:192px;margin-bottom:5pt;vertical-align:text-bottom;width:351px"/></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2023, we dosed our first patient with VTP-850 in PCA001, an ongoing Phase 1/2 clinical trial designed to determine the recommended Phase 2 regimen and evaluate the safety, efficacy, as measured by prostate-specific antigen (PSA) response, and induced T cell response of VTP-850 monotherapy in men with rising PSA after definitive local therapy for their disease (i.e., biochemical recurrence). PCA001 builds on the previous promising data from the University of Oxford Phase 1 VANCE and Phase 1/2 ADVANCE clinical trials of VTP-800. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trial involves a Phase 1 lead-in dose finding stage testing 2 doses of ChAdOx-PCA with follow-up MVA-PCA dose administered either intramuscularly or intravenously to determine the Phase 2 recommended dose and route of administration, followed by a two-stage expansion Phase 2 to evaluate immunogenicity and anti-tumor activity of VTP-850. The diagram below provides an overview of the Phase 1/2 clinical trial design for PCA001.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="text-align:justify"><img src="brns-20231231_g12.gif" alt="vtp-850 trial design.gif" style="height:140px;margin-bottom:5pt;vertical-align:text-bottom;width:660px"/></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The first phase of the trial is enrolling participants in the US.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Future Development</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to announce futility data from the lead-in phase of PCA001 in 2025, which will allow us to determine how we will progress with the PCA001 trial. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">VTP-1000: Antigen-specific Tolerizing Immunotherapy Candidate for Celiac Disease</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patients with celiac disease have an unwanted immune response against gluten proteins and can become severely ill following exposure to gluten found in various cereal grains, especially wheat.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VTP-1000 is a tolerizing immunotherapy candidate that is designed to restore tolerance and suppress the unwanted immune response to gluten by restoring a beneficial T regulatory to T effector ratio. It is based on SNAP-TI and comprises multiple gluten antigens (representing the key antigens linked to celiac disease) and an immunomodulator co-delivered in nanoparticles of precise size and composition that are optimized to target the appropriate immune cells. The immunomodulator is a key component of VTP-1000 and is intended to drive Treg expansion and prevent proinflammatory responses.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Status and Future Development</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VTP-1000 is currently in preclinical development. We submitted a filing to an Australian Research Ethics Committee and received approval for the study to proceed in the first quarter of 2024. This application process will now be completed with a Clinical Trial Notification to the Australian Regulatory Authorities. We also intend to file an IND with the FDA, and initiate the Phase 1 clinical trial in the second quarter of 2024. We intend for the trials to be run in Australia and/or the U.S.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to include pharmacodynamic analysis as part of the Phase 1 study to provide an indication that the immunotherapy is inducing Tregs and/or decreasing Teffectors. Importantly, we also intend to include a controlled gluten challenge in the Phase 1 study to assess as an early signal whether VTP-1000 suppresses pathological response to gluten ingestion.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As VTP-1000 is our first product candidate directed towards the treatment of an inflammatory disease, we believe demonstration of Treg induction and/or suppression of unwanted immune responses to gluten would pave the way for other therapeutic candidates based on SNAP-TI, including those for alternative autoimmune indications.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">VTP-600: Our Immunotherapeutic Candidate Targeting MAGE-A3 and NY-ESO1 Antigens</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are developing VTP-600, our immunotherapy candidate encoding the tumor-associated antigens MAGE-A3 and NY-ESO1, initially as a potential first line treatment of NSCLC in combination with standard of care treatment, chemotherapy and pembrolizumab. Lung cancer is the most common cancer diagnosis and cause of cancer death worldwide, with 85% of cases classified as NSCLC. About 25% to 30% of NSCLC patients have squamous histology and the remainder have non-squamous histology. MAGE-A3 is expressed in 48% of squamous NSCLC and 24% of non- squamous NSCLC. NY-ESO1 has been shown to have an expression rate of 27% across all NSCLC types. We initiated a first-in-human Phase 1/2a trial in the first quarter of 2022, in collaboration with Cancer Research UK ("CRUK"), which is sponsoring and funding this study.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">VTP-500: A Prophylactic Vaccine Candidate to Prevent MERS</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are developing VTP-500 as a vaccine product candidate to prevent infection and subsequent disease caused by the MERS coronavirus. Although human-to-human transmission appears to be rare, MERS coronavirus has the potential to cause epidemics, infecting hundreds of thousands of people and causing significant morbidity and mortality in 34% of infected individuals. Clinical efficacy trials to prevent MERS are challenging to execute due to the sporadic nature of infection, however studies have demonstrated positive Phase 1 safety and immunogenicity data. In November 2021, VTP-500 results from the Saudi Arabia Phase 1 study were published in The Lancet Microbe. The Phase 1 data showed that VTP-500 was generally well tolerated in patients, and further development of the product candidate is planned by our non-exclusive licensee, the University of Oxford.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 21, 2023, we announced a project with the CEPI and the University of Oxford, aiming to fast-track the development of VTP-500 for the prevention of MERS. The project includes CEPI contributing funding of up to $34.8 million to Barinthus Bio, in addition to funds previously committed to the University of Oxford to develop and stockpile a ready reserve of emergency MERS vaccine candidate, VTP-500.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to VTP-500&#8217;s potential in significantly addressing the unmet need for MERS, the EMA confirmed support for the program through PRIME designation in December 2023. The EMA&#8217;s PRIME designation enhances support for the development of medicines that target an unmet medical need, offering early and proactive support to medicine developers to optimize the generation of robust data on a medicine's benefits and risks and enable accelerated assessment of medicines applications.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">VTP-400: A Prophylactic Vaccine Candidate for Shingles</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VTP-400 is our vaccine candidate in development to prevent shingles in adults aged 50&#160;years and older. There are an estimated 140 million cases globally of shingles each&#160;year, which can result in significant post-infection pain, known as post-herpetic neuralgia, or even death. Our regional partner in China and Southeast Asia, CanSino, initiated a Phase 1 clinical trial of VTP-400 in Canada in November 2023 to evaluate both T cell-mediated and B cell-mediated immune responses resulting from VTP-400.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Vaxzevria: A Prophylactic Vaccine for the Prevention of COVID-19 Infection </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The speed of the development of Vaxzevria (formerly VTP-900 and AZD1222) for the prevention of COVID-19, which entered the clinic within three months from initial antigen design, demonstrated that our ChAdOx platform positions us well to develop future products, if approved, rapidly. We co-invented VTP-900 in partnership with the University of Oxford&#8217;s Jenner Institute, which we assigned to Oxford University Innovation (OUI) to facilitate the licensing of those rights by OUI to AstraZeneca. As of November 2022, more than 3 billion doses of Vaxzevria have been supplied across 180 countries globally. It has been estimated that over 6 million lives have been saved worldwide, and between 37.7 and 122.4 million hospitalizations were prevented. We are eligible to receive a share of royalties and other revenue received by OUI pursuant to its agreement with AstraZeneca for Vaxzevria. There is no guarantee that further payments will be received pursuant to the agreement in the future and, if such payments are made, that we will be notified of such payments in a timely manner.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our History and Team</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were founded in May 2016 as a spin-out from a leading institution in the United Kingdom, the Jenner Institute at the University of Oxford, with the aim of developing and commercializing innovative immunotherapeutics and vaccines to treat and prevent infectious diseases and cancer. The ChAdOx1 and MVA platforms use technologies that were developed at the Jenner Institute over 15 years and through clinical trials involving thousands of participants. Our scientific founders, Professor Adrian Hill KBE, FRCP, FRS and Professor Dame Sarah Gilbert DBE, are leaders in the fields of infectious diseases, immunology, vaccine development and viral vectors. Professor Hill is the founding Director of the Jenner Institute at the University of Oxford and is also the Lakshmi Mittal and Family Professor of Vaccinology at the University of Oxford. Professor Gilbert is Professor of Vaccinology at the University of Oxford and leads programs on the development of vaccines against multiple emerging viral pathogens as well as research into vaccine manufacturing. She was the Oxford Project Lead for the Oxford/AstraZeneca COVID-19 vaccine project. Our strategic trajectory has grown with the acquisition of Avidea Technologies, Inc. ("Avidea") and the SNAP platform in 2021, expanding our product candidate pipeline and strengthening our scientific leadership in immunotherapies and the autoimmune space. </span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have assembled a management team with extensive expertise in building and operating biopharmaceutical organizations that have discovered, developed and delivered innovative medicines to patients. Our management team has broad experience and successful track records in biopharmaceutical drug discovery, clinical development, regulatory affairs, manufacturing and commercialization, as well as in business, operations, and finance. Our management team&#8217;s experience was gained at leading institutions that include Agalimmune, Altimmune, Ernst &amp; Young, GenVec, Merck-Serono, Novartis and Roche.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our board of directors has extensive expertise in the fields of science, business, and finance. Our scientific advisory board ("SAB") works with our management team in the planning and development of scientific, clinical, and research and development initiatives and strategies. The SAB is composed of scientific and clinical thought leaders in the fields of immunotherapy, vaccine development, immunology, infectious diseases, immunotolerance and oncology.</span></div><div><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Our Collaboration and License Agreements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">2016 License Agreement with OUI</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March 2016, we entered into a license agreement ("the 2016 OUI License Agreement") (as amended in January 2019 and April 2020), with OUI (previously known as Isis Innovation Limited) for the development and commercialization of vaccines for influenza, cancer (including therapeutic and prophylactic vaccines and including cancer associated with viral infections), varicella zoster and MERS. We refer to these areas together as the &#8220;Field.&#8221;</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to the 2016 OUI License Agreement, OUI granted us a worldwide license under certain patent rights of OUI, including rights related to the use of ChAdOx1, ChAdOx2, adenoviral and MVA promoters and influenza product candidates, among other rights (the "2016 Licensed Technology") to develop, manufacture, use and commercialize licensed products. The rights are exclusive in certain fields and non-exclusive in others. Our license to certain patents and applications relating to certain adenoviral vectors encoding a pathogen or tumor antigen and certain pox virus expression systems is exclusive within the Field, non- exclusive in all other fields, and excludes veterinary applications. Our license to certain patents and applications relating to certain compositions and methods is exclusive in all fields and excludes veterinary applications. Our license for the use of the ChAdOx1 vector under certain patents and applications relating to certain simian adenovirus and hybrid adenoviral vectors is exclusive in the Field, non-exclusive in all other fields, and excludes veterinary applications (apart from MERS) and certain specified indications. Furthermore, our license with respect to the use of the ChAdOx2 vector under certain patents and applications relating to certain adenoviral vectors is exclusive in certain vaccine-related fields, non- exclusive in all other fields, and excludes all veterinary applications (apart from MERS) and certain other specified indications. In addition, we also obtained a license to certain clinical data generated from OUI projects and related confidential know-how to develop, manufacture, use and commercialize licensed products, and such license is exclusive in the Field, other than with respect to know-how related to ChAdOx2, which is licensed non-exclusively. The 2016 Licensed Technology is sublicensable subject to obtaining OUI&#8217;s prior written consent (such consent not to be unreasonably withheld, conditioned or delayed) and inclusion in any sublicense agreement of restrictions on further sub-licensing, among other terms and conditions.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to the 2016 OUI License Agreement, all intellectual property rights resulting from improvements made prior to the second anniversary of the agreement (i) to the licensed patent rights by the inventor belong to OUI, and (ii) to the 2016 Licensed Technology by us belong to us. OUI retains the right for the University of Oxford and any person who works or has worked on the 2016 Licensed Technology to use the 2016 Licensed Technology, as well as any improvements that we made to that technology during the first two years of the license, for education, research and limited clinical patient care. Furthermore, the University of Oxford may publish the 2016 Licensed Technology and those improvements without our consent provided that they have first given us advance notice and delayed the publication if necessary for us to obtain patent protection. In addition, OUI retains the right to grant academic and research licenses to any third parties under the 2016 Licensed Technology to encourage basic research for education and limited clinical patient care but may not grant licenses for commercialization of the 2016 Licensed Technology that is exclusively licensed to us, nor for development or marketing or products or services that are produced or supplied using the 2016 Licensed Technology.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Upon execution of the 2016 OUI License Agreement, we paid OUI a one-time upfront fee of &#163;100,000. We are obligated to pay OUI a low single-digit royalty (that varies based on the indication) on net sales of any product or process produced by or using the 2016 Licensed Technology. If we sublicense the 2016 Licensed Technology, we will be required to pay OUI a mid-single-digit royalty on any royalties paid to us by the sublicensee and a high single-digit royalty on non-royalty sublicensing income (excluding milestone payment income overlapping with milestone payments paid to OUI and income used to fund research and development). In the event that the royalties (excluding the royalty on sublicensing income) owed to OUI do not amount to a specified minimum ranging from the mid five figures to low six figures based on the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">license year in each year following March 2020, we must also pay OUI the difference between the royalty paid and the applicable minimum sum payable. In addition, we are required to pay OUI milestone payments of up to an aggregate of &#163;14.8 million upon the achievement of specified development, regulatory and commercial milestones.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Unless earlier terminated, the 2016 OUI License Agreement will continue until the later of the expiration of the last claim of a licensed patent or 20 years from the date of the agreement. The last patent under the 2016 OUI License Agreement, if granted, is expected to expire in November 2039, without giving effect to any potential patent term extensions or patent term adjustments. Either party may terminate for the uncured breach of the other party. We may terminate the agreement at any time upon three months&#8217; prior written notice. OUI may terminate the agreement upon us filing for bankruptcy or in the event of liquidation or receivership proceedings, or upon 30 days&#8217; prior written notice upon the occurrence of certain other events. Upon termination of the 2016 OUI License Agreement, we are required to, among other things, grant to OUI an irrevocable, transferable, non-exclusive license to develop, make and use any improvements to the 2016 Licensed Technology which we made prior to the second anniversary of the date of the agreement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">2017 License Agreement with OUI (Barinthus Biotherapeutics (UK) Limited) </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In September 2017, we entered into a further license agreement with OUI (the "2017 OUI License Agreement") for the development and commercialization of immunotherapies for HBV and HPV.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to the 2017 OUI License Agreement, we acquired a worldwide license under certain additional patent rights of OUI, including rights related to the use of HBV immunotherapy product candidates, HPV immunotherapy product candidates and shark invariant chain polypeptides, among other rights (the "2017 Licensed Technology"), to develop, manufacture, use and commercialize licensed products. The rights are exclusive in some fields and non-exclusive in others. Our license to certain patents and applications relating to certain HBV and HPV vaccines is exclusive in all fields. Our license to certain patents and applications relating to molecular adjuvants is non-exclusive in the field of HBV. Our license to certain patents and applications relating to certain simian and hybrid adenoviral vectors is exclusive in the fields of HPV associated diseases and HBV. Further, our license to certain patents and applications relating to certain other vectors is exclusive in the field of HBV.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the 2017 OUI License Agreement, we also obtained a non-exclusive license under related know- how to develop, manufacture, use and commercialize licensed products in all fields. The 2017 Licensed Technology is sublicensable subject to obtaining OUI&#8217;s prior written consent (such consent not to be unreasonably withheld, conditioned or delayed) and inclusion in any sublicense agreement of restrictions on further sub-licensing, among other terms.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the 2017 OUI License Agreement, all intellectual property rights resulting from improvements made prior to the second anniversary of the agreement (i) to the licensed patent rights by the inventor belong to OUI, and (ii) to the 2017 Licensed Technology by us belong to us. OUI retains the right for the University of Oxford and any person who works or has worked on the 2017 Licensed Technology to use the 2017 Licensed Technology, as well as any improvements that we made to that technology during the first two years of the license, for education, research and limited clinical patient care. Furthermore, the University of Oxford may publish the 2017 Licensed Technology and those improvements without our consent provided that they have first given us advance notice and delayed the publication if necessary for us to obtain patent protection. In addition, OUI retains the right to grant academic and research licenses to any third parties under the 2017 Licensed Technology to encourage basic research for education and limited clinical patient care but may not grant licenses for commercialization of the 2017 Licensed Technology that is exclusively licensed to us, nor for development or marketing or products or services that are produced or supplied using the 2017 Licensed Technology.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon execution of the 2017 OUI License Agreement, we paid OUI a one-time upfront fee of &#163;50,000. We are obligated to pay OUI a low single-digit royalty (that varies based on the indication) on net sales made by us or our sublicensees of any product or process produced by or using the 2017 Licensed Technology. In the event that such sales royalties owed to OUI do not amount to a specified minimum ranging from the mid five figures to low six figures based on the license year in each year following September 2020, we must also pay OUI the difference between the royalty paid and the applicable minimum sum payable. If we sublicense the 2017 Licensed Technology, we will be required to pay OUI a mid-single-digit royalty on non- royalty sublicensing income (excluding milestone payment income overlapping with milestone payments paid to OUI and income used to fund research and development). In addition, we are required to pay OUI milestone payments of up to an aggregate of &#163;9.85 million upon the achievement of specified development, regulatory and commercial milestones.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the 2017 OUI License Agreement will continue until the later of the expiration of the last claim of a licensed patent or 20 years from the date of the agreement. The last patent under the 2017 OUI License Agreement, if </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">granted, is expected to expire in August 2038, without giving effect to any potential patent term extensions or patent term adjustments. Either party may terminate for the uncured breach of the other party. We may terminate the agreement at any time upon three months&#8217; prior written notice. OUI may terminate the agreement upon us filing for bankruptcy or in the event of liquidation or receivership proceedings, or upon 30 days&#8217; prior written notice upon the occurrence of certain other events. Upon termination of the 2017 OUI License Agreement, we are required to, among other things, grant to OUI an irrevocable, transferable, non-exclusive license to develop, make and use any improvements to the 2017 Licensed Technology which we made prior to the second anniversary of the date of the agreement.</span></div><div><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">2017 License Agreement with OUI (Barinthus Biotherapeutics North America, Inc.)</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March 2017, Avidea entered into a license agreement with OUI (the "March 2017 OUI License Agreement") for the development and commercialization of products comprising thermo-responsive adjuvant scaffolds for use in all indications. All of Avidea&#8217;s rights, duties and obligations under this March 2017 OUI License Agreement were assumed by Barinthus Bio NA following the acquisition of Avidea by Barinthus Biotherapeutics plc on December 10, 2021. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to the March 2017 OUI License Agreement, OUI granted us a worldwide license under certain patent rights of OUI related to the use of thermo-responsive adjuvant scaffolds, among other rights (the "March 2017 Licensed Technology"), to develop, manufacture, use and commercialize licensed products. The license to patent rights are exclusive in all fields, and the license to know how is non-exclusive. The March 2017 Licensed Technology is sublicensable subject to obtaining OUI&#8217;s prior written consent (such consent not to be unreasonably withheld, conditioned or delayed) and inclusion in any sublicense agreement of restrictions on further sub-licensing, among other terms and conditions.  </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to the March 2017 OUI License Agreement, all intellectual property rights resulting from improvements made by us belong to us. OUI retains the right for the University of Oxford, the U.S. National Institutes of Allergy and Infectious Diseases (&#8220;NIAID&#8221;), the Institute of Macromolecular Chemistry of the Czech Republic (&#8220;IMC&#8221;) and any person who works or has worked on the March 2017 Licensed Technology to use the March 2017 Licensed Technology and any licensee improvements for non-commercial use. Furthermore, the University of Oxford, NIAID or IMC may publish the March 2017 Licensed Technology and those improvements without our consent provided that they have first given us advance notice and delayed the publication if necessary for us to obtain patent protection. In addition, OUI retains the right to grant academic and research licenses to any third parties under the March 2017 Licensed Technology to encourage basic research for education and limited clinical patient care but may not grant licenses for commercialization of the March 2017 Licensed Technology that is exclusively licensed to us, nor for development or marketing or products or services that are produced or supplied using the March 2017 Licensed Technology.  </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Upon execution of the March 2017 OUI License Agreement, we paid OUI a one-time upfront fee of &#163;3,000. We are obligated to pay OUI a low single-digit royalty on net sales of any product or process produced by or using the March 2017 Licensed Technology. If we sublicense the March 2017 Licensed Technology, we will be required to pay OUI a mid-single-digit royalty on any non-royalty sublicensing income. As of March 14, 2024, OUI has not been paid any royalties under the 2017 OUI License Agreement. In the event that the royalties (excluding the royalty on sublicensing income) owed to OUI do not amount to a specified minimum ranging from the low to mid five figures based on the license year in each year following March 2020, the licensee must also pay OUI the difference between the royalty paid and the applicable minimum sum payable. For 2023, &#163;55 thousand was paid to OUI, being the difference between royalties paid and the minimum sum payable. In addition, we are required to pay OUI milestone payments of up to an aggregate of &#163;2.43 million upon the achievement of specified development, regulatory and commercial milestones. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Unless earlier terminated, the 2017 OUI License Agreement will continue for as long as anything within the definition of the licensed patent remains in effect or 20 years from the date of the agreement. The patent licensed under the March 2017 OUI License Agreement, if granted, is expected to expire in October 2035, without giving effect to any potential patent term extensions or patent term adjustments. Either party may terminate for the uncured breach of the other party. We may terminate the agreement at any time upon six months&#8217; prior written notice. OUI may terminate the agreement upon us filing for bankruptcy or in the event of liquidation or receivership proceedings, or upon 30 days&#8217; prior written notice upon the occurrence of certain other events. Upon termination of the March 2017 OUI License Agreement, we are required to, among other things, grant to OUI an irrevocable, transferable, non-exclusive license to develop, make and use any improvements to the March 2017 Licensed Technology which we made prior to the second anniversary of the date of the agreement. </span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">2017 Cooperative Research and Development Agreement with NIH (Barinthus Biotherapeutics NA)</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In February 2017, Avidea entered into a Cooperative Research and Development Agreement (&#8220;CRADA&#8221;) with the U.S. National Institutes of Health (&#8220;NIH&#8221;) to carry out collaborative research for the evaluation of Avidea&#8217;s synthetic, polymer-based vaccine technology, &#8220;Immunotherapeutic Nanoscaffolds&#8221; (IMNs) for infectious disease prevention and cancer treatment in animal models. Under this CRADA Avidea committed to providing scientific staff together with materials for use in experiments to evaluate their performance in various animal models of infectious disease and cancer. Under this CRADA NIH committed to evaluating Avidea materials in animal models and to perform comprehensive immune analysis. No funding was exchanged under this CRADA.  </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2019, the CRADA was amended (&#8220;1st CRADA Amendment&#8221;) to expand the scope of the collaborative research to evaluate the therapeutic potential of Avidea&#8217;s polymer-based vaccine technology, &#8220;Immunotherapeutic Nanoscaffolds&#8221; (IMNs), including Star polymers and self-assembling nanoparticles based on amphiphilic polymers (SNAP), in preclinical animal models for cancer, infectious and inflammatory diseases. Under this 1st CRADA Amendment Avidea committed to increase its scientific staffing contribution and to provide funding of $22,500 by October 15, 2019 and a further $62,500 by October 15, 2020. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2020, the CRADA was further amended (&#8220;2nd CRADA Amendment&#8221;) to defer payment of Avidea&#8217;s October 2020 funding contribution of the 1st CRADA Amendment to April 15, 2021. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the CRADA was further amended (&#8220;3rd CRADA Amendment&#8221;) to extend the term of the CRADA by 2 additional years and to defer payment of Avidea&#8217;s April 2021 funding contribution of the 2nd CRADA Amendment to October 31, 2021. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, the CRADA was further amended (&#8220;4th CRADA Amendment&#8221;) to expand the scope of the collaborative research to evaluate the therapeutic potential of Avidea&#8217;s polymer-based vaccine technology, &#8220;Immunotherapeutic Nanoscaffolds&#8221; (IMNs), including Star polymers and self-assembling nanoparticles based on amphiphilic polymers (SNAP), in preclinical animal models for cancer, infectious and inflammatory diseases (e.g., induction of suppression and/or tolerance for treating or preventing allergies, autoimmunity, and transplant rejection). </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022, the CRADA was further amended (&#8220;5th CRADA Amendment&#8221;) to acknowledge that all of Avidea&#8217;s rights, duties and obligations under the CRADA were assumed by Barinthus Bio NA following the acquisition of Avidea by Barinthus Biotherapeutics plc on December 10, 2021. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the CRADA as amended we own inventions made solely by our staff, and we have an option to enter an exclusive or nonexclusive license to any inventions made solely by NIH staff or made jointly by our staff and NIH under the CRADA (the "CRADA Licensed Technology"). NIH retains rights on behalf of the U.S. Government in the CRADA Licensed Technology as required by statute and NIH policy. We have an option to exclusively license any further inventions made under the CRADA. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the CRADA will expire on February 23, 2025. The parties may terminate the CRADA by mutual consent, or either party may unilaterally terminate the CRADA at any time upon 60 days&#8217; prior written notice. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2019 License Agreement with NIH (Barinthus Bio NA)</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In September 2019, Avidea entered into a license agreement with the NIH for the commercial development of products and processes for the prevention and/or treatment of cancer and infectious diseases within the scope of Licensed Patent rights that had been developed under a CRADA entered into by NIH and Avidea in February 2017 and amended in March 2019, December 2020, May 2021, November 2021 and October 2022. We are co-owners of all the Licensed Patents under this agreement, and we have an option to exclusively license NIH rights in all inventions made under this CRADA.</span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of Avidea&#8217;s rights, duties and obligations under the 2019 License Agreement with NIH were assumed by Barinthus Bio NA following the acquisition of Avidea by Barinthus Biotherapeutics plc on December 10, 2021. The 2019 License Agreement with NIH was amended in September 2022 to note Barinthus Bio NA&#8217;s rights, duties and obligations and also to include newly filed patents developed under the 2017 CRADA as amended.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the 2019 License Agreement with NIH, NIH granted us a worldwide exclusive license under certain patent rights co-owned by us and NIH related to the use of the SNAP platform, among other rights (the "2019 Licensed Technology"), to develop, manufacture, use and commercialize licensed products. The license to patent rights are exclusive in all fields. The 2019 Licensed Technology is sublicensable subject to obtaining NIH&#8217;s prior written consent (such consent not to be unreasonably withheld) and inclusion of other customary provisions. NIH retains rights on behalf of the U.S. Government in the 2019 Licensed Technology as required by statute and NIH policy.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon execution of the 2019 License Agreement with NIH, we paid NIH a one-time upfront fee of $20,000. We are obligated to pay NIH a low single-digit royalty on net sales of any product or process produced by or using the 2019 Licensed Technology. If we sublicense the 2019 Licensed Technology, we will be required to pay NIH a low-single-digit royalty on any non-royalty sublicensing income. As of March 23, 2023, NIH has not been paid any royalties under the 2019 License Agreement with NIH. In the event that the royalties (excluding the royalty on sublicensing income) owed to NIH do not amount to a specified minimum ranging from the low to mid five figures based on the license year in each year following September 2019, the licensee must also pay NIH the difference between the royalty paid and the applicable minimum royalty payment. For 2023, $10 thousand was paid to NIH, being the difference between royalties paid and the minimum sum payable. In addition, we are required to pay NIH milestone payments of up to an aggregate of $3.24 million upon the achievement of specified development, regulatory and commercial milestones for each Licensed Product. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the 2019 License Agreement with NIH will continue until expiry of the last to expire Licensed Patent. 5 patent families licensed under the 2019 License Agreement with NIH that cover the SNAP platform, if granted, are expected to expire in April 2038, in May 2039, in October 2039, in February 2042 and in June 2042, without giving effect to any potential patent term extensions or patent term adjustments. Two patent families licensed under the 2019 License Agreement with NIH that cover the syntholytic platform, if granted, are expected to expire in April 2040 and in October 2041, without giving effect to any potential patent term extensions or patent term adjustments. Either party may terminate for the uncured breach of the other party. We may terminate the agreement at any time upon 60 days&#8217; prior written notice. NIH may terminate the agreement upon the occurrence of certain events. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">2017 Research Collaboration Agreement (&#8220;RCA&#8221;) with Institute of Macromolecular Chemistry, Prague (Barinthus Biotherapeutics NA)</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In September 2017, Avidea entered into a RCA with the IMC to carry out collaborative research for the development of polymer-based immunotherapies for cancer treatment, HIV prevention and recombinant protein delivery. Under this RCA Avidea committed to providing bioactive molecules and to developing and deploying animal models for evaluating immunotherapies. Under this RCA IMC committed to synthesizing various polymers and bioactive molecules and to linking such polymers and bioactive molecules for use in experiments to characterize their physicochemical properties. No funding was exchanged under this RCA. All of Avidea&#8217;s rights, duties and obligations under the 2017 RCA with IMC were assumed by Barinthus Bio NA following the acquisition of Avidea by Barinthus Biotherapeutics plc on December 10, 2021. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under the RCA we own inventions made solely by our staff, and we have an exclusive option to enter an exclusive or nonexclusive license to any inventions made solely by IMC staff or made jointly by our staff and IMC under the RCA. We have secured exclusive rights in two patent families that we co-own with IMC under the 2022 License Agreement with IMC as described below. We have an exclusive option to exclusively license any further inventions made under the RCA. The RCA expired on September 18, 2022. Our rights in inventions made under the RCA survive expiry of the RCA.</span></div><div><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">2022 License Agreement with IMC (Barinthus Bio NA)</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In April 2022, we entered into an exclusive license agreement with the IMC for the exploitation, development and commercialization of technologies and products within the scope of Licensed Patent rights that had been developed under a RCA entered into by IMC and Avidea in September 2017. We are co-owners of all the Licensed Patents under this agreement, and we have an option to exclusively license IMC rights in all inventions made under this RCA.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to the 2022 License Agreement with IMC, IMC granted us a worldwide, exclusive license under certain patent rights co-owned by us and IMC related to the use of polymer-based immunotherapies, among other rights (the "2022 Licensed Technology"), to develop, manufacture, use and commercialize licensed products. The license to patent rights is exclusive in all fields. The 2022 Licensed Technology is sublicensable. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are obligated to pay IMC a low single-digit royalty on net sales of any product or process produced by or using the 2022 Licensed Technology. If we sublicense the 2022 Licensed Technology, we will be required to pay IMC a low-single-digit royalty on any non-royalty sublicensing income. As of March 14, 2024, IMC has not been paid any royalties under the 2022 License Agreement with IMC. In addition, we are required to pay IMC milestone payments of up to an aggregate of $820,000 upon the achievement of specified development, regulatory and commercial milestones for each Licensed Product.  </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Unless earlier terminated, the 2022 License Agreement with IMC will continue until expiry of the last valid claim of the Licensed Patents. One patent family licensed under the 2022 License Agreement with IMC that covers the SNAP platform, if granted, is expected to expire in September 2041, without giving effect to any potential patent term extensions or patent term adjustments. One patent family licensed under the 2022 License Agreement with IMC that covers the syntholytic platform, if granted, is expected to expire in April 2040, without giving effect to any potential patent term extensions or patent term adjustments. Either party may terminate for the uncured breach or insolvency of the other party. We may terminate the agreement at any time upon 3 months&#8217; prior written notice.</span></div><div><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">2019 License Agreement with OUI</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2019, we entered into an additional license agreement with OUI (the "2019 OUI License Agreement"). Pursuant to the 2019 OUI License Agreement, OUI granted us a worldwide, license under an additional patent application of OUI related to the rapid production of recombinant adenovirus constructs, to be used as personalized cancer vaccines or emerging pathogen vaccines, and related confidential know-how (the "2019 OUI Licensed Technology") to develop, manufacture, use and commercialize licensed products. The license is exclusive in the field of personalized cancer vaccines for therapeutic use in humans, non- exclusive in in all other fields and excludes veterinary applications (apart from MERS) and certain other specified indications. The license is sublicensable subject to obtaining OUI&#8217;s prior written consent (such consent not to be unreasonably withheld, conditioned or delayed) and inclusion in any sublicense agreement of restrictions on further sub-licensing, among other terms.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to the 2019 OUI License Agreement, all intellectual property rights resulting from improvements made prior to the second anniversary of the agreement (i) to the licensed patent rights by the inventor belong to OUI, and (ii) to the 2019 OUI Licensed Technology by us belong to us. OUI retains the right for the University of Oxford and any person who works or has worked on the 2019 OUI Licensed Technology to use the 2019 OUI Licensed Technology, as well as any improvements that we make to that technology during the first two years of the license, for education, research and limited clinical patient care. Furthermore, the University of Oxford may publish the 2019 OUI Licensed Technology and those improvements without our consent provided that they have first given us advance notice and delayed the publication if necessary for us to obtain patent protection. In addition, OUI retains the right to grant academic and research licenses to any third parties under the 2019 OUI Licensed Technology to encourage basic research for education and limited clinical patient care but may not grant licenses for commercialization of the 2019 OUI Licensed Technology that is exclusively licensed to us, nor for development or marketing or products or services that are produced or supplied using the 2019 OUI Licensed Technology.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Upon execution of the 2019 OUI License Agreement, we paid OUI a nominal upfront fee. We are required to pay OUI a variable low single-digit royalty on net sales of products we develop using the 2019 OUI Licensed Technology, which varies depending on whether the sales are within or outside of the field of personalized cancer vaccines for therapeutic use in humans. While we are continuing to develop the 2019 OUI Licensed Technology, no product candidate that we are currently developing incorporates this technology. If we sublicense the 2019 OUI Licensed Technology, we will be required to pay OUI a 15% or 7% royalty (for licensed products within the field and outside the field respectively) on any royalties paid to us by the sublicensee and 15% or 7.5% of non-royalty sublicensing income (for sublicenses granted before or after three years after the date of the agreement respectively). In the event that the aforementioned royalties (excluding the royalty on non-royalty sublicensing income) owed to OUI do not amount to a specified minimum ranging from the mid five figures to low six figures based on the license year in each year following January 2022, we must also pay to OUI the difference between the royalty paid and the applicable minimum sum payable. In addition, if we develop at least two products in the Field, we are required to pay OUI milestone payments of up to an aggregate of &#163;1.9 million upon the achievement of specified development, regulatory and commercial milestones.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Subject to earlier termination, the 2019 OUI License Agreement will continue until the later of the expiration of the last claim of a licensed patent or 20 years from the date of the agreement. The last patent under the 2019 OUI License Agreement, if granted, is expected to expire in August 2039, without giving effect to any potential patent term extensions or patent term adjustments. Either party may terminate for the uncured breach of the other party. At any time after the third anniversary of the agreement, we may terminate the agreement at any time upon three months&#8217; prior written notice. OUI </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">may terminate the agreement upon us filing for bankruptcy or in the event of liquidation or receivership proceedings, or upon 30 days&#8217; prior written notice upon the occurrence of certain other events. Upon termination of the 2019 OUI License Agreement, we are required to, among other things, grant to OUI an irrevocable, transferable, non- exclusive license to develop, make and use any improvements (to the technology embodied by the relevant licensed patent and know-how) which we made prior to the second anniversary of the date of the agreement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">2018 License Agreement with OUI and Oxford</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In September 2018, we entered into a license agreement (the "2018 License Agreement") with The Chancellor, Masters and Scholars of the University of Oxford, or Oxford, and OUI. Pursuant to the 2016 OUI License Agreement, OUI had granted us certain exclusive rights related to the Licensed Technology, as defined in the 2016 OUI License Agreement, in the field of diagnosis, prevention and treatment of MERS. The 2018 License Agreement enables Oxford to grant a further sublicense to CEPI in the field of MERS (the "Field") and to enable Oxford to conduct related activities.</span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the 2018 License Agreement, we agreed to grant to Oxford a fully-paid-up, worldwide, non- exclusive license under the Licensed Technology, as defined in the 2016 OUI License Agreement, and developments and improvements to such technology controlled by us during the term of the 2016 OUI License Agreement (the "MERS Technology") in the Field solely for the purpose of enabling Oxford to develop any product or process which uses or is within the scope of the MERS Technology ("Licensed Product"). This license includes the right to generate investigational stockpiles, but excludes any commercial use or sale of Licensed Products and is sublicensable by Oxford solely to its collaborators under the framework agreement entered into on or about the same date as the 2018 License Agreement between Oxford, CEPI and Janssen Vaccines &amp; Prevention B.V. Furthermore, we agreed that the rights retained by OUI under the 2016 OUI License Agreement include the right to allow Oxford to use the MERS Technology to carry out research activities (including in collaboration with other parties) up to and including the performance of Phase 1/2 clinical trials and related activities, and the generation of Licensed Product for research use (but excluding any commercial use or sale of such Licensed Product). We have been informed by Oxford that Janssen Vaccines &amp; Prevention B.V. is no longer a party to that framework agreement.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we agreed to grant to Oxford a fully-paid-up, worldwide, non-exclusive license under the MERS Technology in the Field solely for the purpose of enabling Oxford to grant a sublicense to CEPI in order to address (i) circumstances in which CEPI determines there to be a heightened need for the Licensed Product and that steps should be taken to prepare for such need; and/or (ii) material increases in the number of cases of people infected with MERS in particular geographical areas that are declared a public health emergency. Oxford is permitted to grant CEPI a fully-paid-up, worldwide, non-exclusive sublicense under the MERS Technology to develop, manufacture and commercialize the Licensed Product in the Field anywhere in the world, provided that all end users (i) are in a relevant affected territory, or (ii) are healthcare workers going to an affected territory under the direction of one or more governments or recognized not-for-profit organizations, or Public Sector Agencies, in order to help address a public healthcare issue. However, the sublicense must exclude the right for CEPI to (i) apply for or obtain any marketing approval or conduct any post-marketing activities, (ii) sell Licensed Product other than to Public Sector Agencies on a &#8220;cost plus&#8221; basis, where &#8220;cost plus&#8221; means the cost of manufacturing and supply plus a margin of 10% percent on such cost, or (iii) further sublicense its rights other than to its affiliates and/or to Public Sector Agencies and their appointees for the sole purpose of accelerating epidemic preparedness for public health applications.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the 2018 License Agreement, OUI agreed that, notwithstanding our payment obligations under the 2016 OUI License Agreement, we are not obligated to make any payment to OUI in connection with the 2018 License Agreement.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 2, 2024, following the entry by Barinthus Biotherapeutics (UK) Limited and Oxford into a funding agreement with CEPI (described below), Oxford, OUI and Barinthus Biotherapeutics (UK) Limited entered into a termination agreement, pursuant to which the 2018 License Agreement was terminated other than obligations that have accrued prior to the termination or were expressly intended to survive, including certain confidentiality obligations.</span></div><div><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">OUI License Agreement Amendment</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In April 2020, we entered into an amendment, assignment and revenue share agreement (the "OUI License Agreement Amendment") with OUI to amend the 2016 OUI License Agreement. Pursuant to the 2016 OUI License Agreement and among other rights and obligations, OUI granted to us a non-exclusive license to certain patent applications relating to its ChAdOx1 and ChAdOx2 vaccine vectors and the adenovirus long promoter for use in certain fields, or the Field, including </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">SARS-CoV2, which is the virus known to cause COVID 19. The OUI License Agreement Amendment was entered into to enable a single exclusive license agreement for a COVID 19 vaccine co-developed by us and the University of Oxford&#8217;s Jenner Institute to be negotiated with a suitable pharmaceutical partner.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under the OUI License Agreement Amendment, we agreed to exclude SARS-CoV2 from the Field and to cease use of the ChAdOx1 vector, ChAdOx2 vector and the adenovirus long promoter in SARS-CoV2. In addition, we assigned to OUI our rights to a jointly owned U.K. patent application relating to the composition of matter related to a ChAdOx1 vector-based or a ChAdOx2 vector-based vaccine to prevent COVID 19 (the "Assigned Patent Application"), as well as certain other intellectual property rights related to any ChAdOx1 vector-based or ChAdOx2 vector-based COVID 19 vaccine covered by the Assigned Patent Application and its manufacture, including rights to the variations, improvements and modifications thereof, whether existing at or arising after the date of the OUI License Agreement Amendment. In consideration of the rights granted by us, OUI agreed to pay us approximately 24% of payments, including royalties and milestones, received by OUI in connection with the commercialization of any ChAdOx1 vector-based or ChAdOx2 vector-based vaccine in the field of SARS-CoV2 covered by or disclosed in the Assigned Patent Application. The last patent under the OUI License Agreement Amendment, which is owned by OUI, if granted, is expected to expire in March 2041, without giving effect to any potential patent term extensions or patent term adjustments.</span></div><div><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Impact of OUI&#8217;s Agreement with AstraZeneca</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">OUI has entered into an exclusive research collaboration and worldwide license agreement (the "AstraZeneca License Agreement") with AstraZeneca. The following description of the impact of AstraZeneca License Agreement with respect to our rights under the OUI License Agreement Amendment is based solely on an extract of the AstraZeneca License Agreement provided by the parties to that agreement. We are not a party to the AstraZeneca License Agreement and do not have access to a copy of that agreement to verify the accuracy of such extract. In addition, no party to the AstraZeneca License Agreement has confirmed that there are no material terms in that agreement that are not included in the description below that could adversely impact the economic and other terms of the AstraZeneca License Agreement described below. Moreover, there can be no assurance that the AstraZeneca License Agreement is an enforceable agreement, that the parties thereto will comply with their obligations under that agreement (including any obligations of AstraZeneca to make milestone or royalty payments to OUI), or that the terms of that agreement (including royalty rates and other economic terms) will not be modified by the parties in the future. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The AstraZeneca License Agreement allows AstraZeneca to pursue, among other things, the commercialization of a vaccine product candidate for the prevention of COVID 19 containing one or more of the ChAdOx1 or ChAdOx2 vectors or their derivatives. AstraZeneca announced that as of January 13, 2022, the vaccine had been granted a conditional marketing authorization or emergency use in more than 90 countries. It also has Emergency Use Listing from the World Health Organization, which accelerates the pathway to access in up to 144 countries through the COVAX Facility.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to the OUI License Agreement Amendment, we received $2.4 million in July 2020 as our share of the upfront fee paid by AstraZeneca. We are also entitled to receive a share of certain regulatory and sales milestones and royalties on net sales of Vaxzevria, as well as a portion of any sublicensing income payable by AstraZeneca. Our share of the royalties on net sales of Vaxzevria is approximately 1.4%.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our understanding is that we were not entitled to receive any royalties or payments from sub-licensees from the commercialization of Vaxzevria until after the pandemic period, which was defined as a period that would end on July 1, 2021 (or such later date when AstraZeneca, in good faith, determines that the COVID-19 pandemic is over). However, our understanding is that we would be entitled to receive our share of any regulatory milestone payments during the pandemic period.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The royalty term for net sales of Vaxzevria commenced in 2022 and will continue, on a country-by-country basis, until the later of (i) the date upon which the vaccine is no longer subject to patent protection in such country, (ii) expiration of regulatory exclusivity for the vaccine in such country or (iii) ten years from the first commercial sale of the vaccine in such country.</span></div><div><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Master Collaboration Agreement with CanSino Biologics Inc.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In September 2018, we entered into a master collaboration agreement (the "CanSino Agreement") with CanSino Biologics Inc. ("CanSino"). The CanSino Agreement provides a framework under which we can agree with CanSino (in separate project agreements) the details of one or more collaborative projects for the development and commercialization of certain </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">products, and carry out those projects under the terms of the CanSino Agreement and the respective project agreements in our respective territories. Under the CanSino Agreement, the CanSino Territory includes China (including Taiwan, Hong Kong and Macao), Malaysia, Thailand, Myanmar, Indonesia, Laos, Vietnam, and the Philippines, while our territory (the "Barinthus Bio Territory") includes the rest of the world.</span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the CanSino Agreement, each party grants to the other party a royalty-free, non-exclusive license to use its relevant background intellectual property rights ("Background IPR") solely to perform the project in the other party&#8217;s territory, together with a right to sub-license to any agreed-upon subcontractor performing services for and on behalf of the other party. For any collaborative project, each party is obliged to provide to the other party all applicable materials specified in that project agreement and to grant to the other party a non-exclusive license to use such materials solely for the purpose of that project. In addition, each party grants to the other party a non-exclusive license to use its Background IPR and an exclusive license to any new intellectual property created in the course of activities performed by such party in relation to a project or otherwise under the CanSino Agreement ("New IPR") to the extent necessary to commercialize and exploit collaboration products in the other party&#8217;s territory. Such commercialization licenses are sublicensable (without further right to sub-license) and subject to the payment of royalties and milestones as set out in the relevant project agreement. CanSino is permitted to commercialize such products only in the CanSino Territory and we are entitled to commercialize such products in the Barinthus Bio Territory. Both parties are under obligations to use commercially reasonable efforts to maximize sales of products that are the subject of collaboration.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the term of any project agreement entered into as contemplated by the CanSino Agreement and for three months thereafter, neither party is permitted to enter into discussions, collaborations or similar arrangements with any third parties regarding matters or products which are materially the same as set forth in the project agreement or related to the project that is the subject of the project agreement, unless such party reasonably believes such an arrangement with such third party would not be detrimental to the relevant project or project arrangement. Furthermore, unless agreed otherwise in a project agreement, for any product which we collaboratively develop, CanSino has the exclusive and sub-licensable right to manufacture and supply all master virus seed and clinical adenoviral material necessary for the development and sale of any products by either party in their respective territories. CanSino will supply any such material to be used by us for the manufacture of products to be sold by us (or our sub-licensees) at the price of 15% to 30% over cost of goods sold ("COGS"). COGS is equal to the reasonable COGS for equivalent material manufactured by CanSino or its subcontractors for sale by CanSino or its sub-licensees.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless agreed otherwise in a project agreement: (i) any improvements of a party&#8217;s Background IPR will be owned by the party with rights to such Background IPR, and will be treated as Background IPR; and (ii) New IPR will be owned by one or both parties in accordance with the respective inventive contribution of each party as determined by the principles of United Kingdom patent law. Where any New IPR is wholly owned by a party, that party is obliged to endeavor to file patent applications to the extent required to provide reasonable protection for the relevant product. Where any New IPR is jointly owned by the parties, we are obliged to endeavor to file patent applications to the extent required to provide reasonable protection for the relevant product, in consultation with CanSino, with costs shared between the parties. Before we abandon a jointly-owned patent claiming any New IPR, we must give CanSino at least three months&#8217; notice, and CanSino can request assignment of our rights on terms to be agreed. We are obliged to discuss with CanSino the enforcement of jointly owned patent rights but are entitled to enforce such patent rights outside the CanSino Territory.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the CanSino Agreement will continue for ten years from the date of the agreement. Either party can terminate by written notice for the uncured material breach or persistent breaches of the other party. Either party may terminate by written notice if the other party cannot pay its debts, takes any step in connection with entering administration, liquidation, or other arrangement with creditors (other than a solvent arrangement), or suspends all or part of its business; or suffers a force majeure event that continues for 60 days. Furthermore, a project agreement entered into pursuant to the CanSino Agreement shall automatically terminate if the 2016 OUI License Agreement or the 2017 OUI License Agreement terminates or expires, Background IPR licensed from OUI is necessary under such project agreement and the parties are unable to agree to a modification of the project or relevant collaboration product that would not require use of such Background IPR.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2018 ChAdOx Zoster Project Agreement (under the CanSino Agreement)</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the CanSino Agreement, we entered into a project agreement in September 2018 with CanSino (the "ChAdOx Zoster Project Agreement") with the goal of developing a Zoster vaccine to become a competitor to Shingrix. Under the ChAdOx Zoster Project Agreement, we are responsible for funding and undertaking various development tasks, including </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(subject to availability of funding) conducting a Phase 1 clinical trial in the UK. CanSino was responsible for funding and undertaking various development tasks, including conducting a Phase 1 clinical trial in China. The ChAdOx Zoster Project Agreement was amended on August 31, 2023 following the parties&#8217; agreement that the Phase 1 clinical trial to be conducted by CanSino as Sponsor should be carried out in Canada (rather than China). It was also agreed that the parties would each be responsible for 50% of the budgeted cost of the Phase 1 clinical trial (rather than each being responsible for funding or securing funding for any Phase 1 clinical trial in its respective country). The amendment further expanded the scope of the ChAdOx Zoster Project Agreement to cover potential administration of the product by inhalation.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The parties&#8217; rights and responsibilities in relation to Phase 2 and 3 clinical trials are pending, subject to further negotiation. In addition, the parties agreed to use all reasonable efforts to enter into a separate supply agreement pursuant to which CanSino will manufacture all product necessary for clinical trials and commercialization under the project agreement. If the parties cannot agree upon such supply agreement, they must follow a specified dispute resolution process set forth in the CanSino Agreement. For all products manufactured by CanSino under a supply agreement that we wish to sell in the Barinthus Bio Territory, we have agreed to pay the costs incurred by CanSino to manufacture the products plus 20% of such costs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received an upfront payment of &#163;50,000 under this project agreement. We will also receive milestone payments of up to an aggregate of &#163;1.125 million based on successful conduct of clinical trials and commercialization of the product. We will receive mid-single-digit royalties on the net sales of the product by or on behalf of CanSino or its sub-licensees in the CanSino Territory. If CanSino sublicense their rights in the product to a non-affiliate third party, we are also entitled to receive a mid-teens royalty on the transaction value (excluding royalties). We must pay to CanSino mid-single-digit royalties on the net sales of the product by or on behalf of us or our sub-licensees in the Barinthus Bio Territory. A party will benefit from a reduction of its royalties (in the low single digits) where it requires a license from a third party to sell the product in its territory.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the term of the ChAdOx Zoster Project Agreement will expire upon the later of expiry of all registered patents in the New IP developed under the project, or ten years from first commercial sale of the product. The last patent under the ChAdOx Zoster Project Agreement, if granted, is expected to expire in November 2039, without giving effect to any potential patent term extensions or patent term adjustments. A party may terminate the ChAdOx Zoster Project Agreement by written notice if the other party unreasonably delays the performance of its obligations. Upon the expiration of the term, we agreed to grant CanSino a royalty-free, perpetual, sub-licensable, non-exclusive license to use our Background IPR and our New IPR used to develop, incorporated in, or referenced in any products that are the subject of the project agreement to the extent necessary for CanSino to undertake research, develop, manufacture and commercialize such products in the CanSino Territory. Pursuant to the CanSino Agreement, upon the expiration or earlier termination of the project agreement, except for termination by CanSino for our breach, CanSino agreed to grant us a royalty-free, perpetual, sub-licensable, non-exclusive license to use their Background IPR and New IPR used to develop, incorporated in, or referenced in any products that are the subject of the project agreement to the extent necessary for us to undertake research, develop, manufacture and commercialize such products in the Barinthus Bio Territory. Unless we terminate the project agreement early for CanSino&#8217;s breach, upon early termination after completion of a Phase 1 trial, we will continue to pay CanSino a low single-digit royalty on net sales of the product by us or our sub-licensees in the Barinthus Bio Territory, for the remainder of the Term. If such early termination is after completion of a Phase 2 trial, the royalty we must pay rises to mid-single digit.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical Trial and Option Agreement with CRUK</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, Vaccitech Oncology Limited ("VOLT"), entered into a clinical trial and option agreement (the "Clinical Trial Agreement") with CRUK and CRUK&#8217;s subsidiary, Cancer Research Technology Limited ("CRT"), relating to the conduct of a Phase 1/2a clinical trial of VOLT&#8217;s VTP 600 immunotherapy product in patients with non-small cell lung cancer, or the Clinical Trial. The trial opened in the first quarter of 2022 across multiple clinical sites in the UK.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VOLT is our oncology focused strategic collaboration with the Ludwig Institute for Cancer Research, an international non-profit organization that conducts innovative cancer research and is looking to enable the clinical development of new treatments that induce and harness CD8+ T cells of the immune system to fight cancer. VOLT has a license to our proprietary CD8+ T cell induction platform and research by Benoit Van den Eynde&#8217;s group at the Ludwig Oxford Branch.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Clinical Trial Agreement, CRUK is responsible for, among other things, designing, preparing, carrying out and sponsoring the Clinical Trial, at its cost, and VOLT has granted to CRUK a license under its intellectual property to enable CRUK to perform such activities. VOLT is responsible for supplying agreed quantities of its VTP 600 </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">immunotherapy product. VOLT retains the right to continue the development of the product during the Clinical Trial, provided that the parties have first agreed appropriate terms for sharing of safety data. CRUK owns all results, including all intellectual property therein, generated in the performance of the Clinical Trial. Upon the completion of the Clinical Trial, VOLT has the option to obtain a license to use such results (the "VTP 600 License"). The terms of the VTP 600 License have been pre-agreed and are set out in the Clinical Trial Agreement.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If VOLT exercises the option to take the VTP 600 License, CRT agrees to grant VOLT an exclusive license under the results of the Clinical Trial that exclusively relate to the VTP 600 immunotherapy product (the "Exclusive Results") and a non-exclusive license under any results that are not Exclusive Results, in each case, to develop and commercialize any product which makes use of the results of the Clinical Trial in an application for regulatory authorization, contains the relevant active ingredients, or is covered by the patent application PCT/EP2019/070555 (the "Product"). The rights under the VTP 600 License are sublicensable (except to a tobacco company). The exclusive rights granted under the VTP 600 License are subject to the right of certain third-party contributors associated with the Clinical Trial, CRUK and scientists funded or employed by CRUK to use the Exclusive Results for non-commercial scientific or clinical research purposes and to publish the Exclusive Results and the results of non-commercial research performed using the Exclusive Results (subject to the publication process set out in the Clinical Trial Agreement). Upon exercise of the option, VOLT is required to pay a one-time upfront fee of an amount in pounds Sterling in the high six-digits. VOLT is also obligated to make future milestone payments upon the achievement of development, regulatory and commercial milestones, with an aggregate total value of &#163;40.8 million. VOLT is required to pay to CRT a low single-digit royalty on net sales of Products sold by VOLT or its sublicensees. If VOLT sublicenses the right to sell Products, VOLT will also be required to pay to CRT a royalty of between 5% and 20% on non-royalty amounts due to VOLT from a sublicensee, with the precise rate depending on the stage in development at which such sublicense was granted. VOLT is obligated to use commercially reasonable efforts to meet certain development, regulatory and commercialization obligations, including commencement of a Phase 2 clinical trial of a Product in an oncology indication before the second anniversary of the date of the VTP 600 License. CRT may terminate the VTP 600 License in respect of any given Product if VOLT is not actively developing it or fails to launch it after receiving marketing authorization. CRT may also terminate the VTP 600 License as a whole if no Product is being actively developed or commercialized.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If VOLT does not exercise the option to take the VTP 600 License, or if the VTP 600 License or Clinical Trial Agreement is subsequently terminated by CRUK (as described below) VOLT will enter into a step-in agreement with CRT (the "Step-In Agreement"). Pursuant to the Step-In Agreement, the terms of which have been pre-agreed and are set out in the Clinical Trial Agreement, VOLT will assign to CRT certain know- how and materials owned or controlled by VOLT. In addition, we agreed to grant to CRT an exclusive sub-license to a third-party patent family relating to viral vectors and methods for the prevention or treatment of cancer and non-exclusive sub-licenses to the HEK293 TetR Cell Line as well as certain third party patents and patent applications relating to certain adenovirus vectors and poxvirus expression systems, in each case, to develop and commercialize the Products on a revenue sharing basis. VOLT will receive a share of between 55% and 80% of the net revenue received by CRT for commercialization of the Product, with the precise share depending on the stage in development at which such Step-In Agreement is entered into.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The term of the Clinical Trial Agreement continues until it is otherwise terminated by the parties or, if the option is not exercised, upon the execution of the Step-In Agreement. The Clinical Trial Agreement can be terminated by either party upon an insolvency event in respect of the other party, for material breach of the other party, or upon a change of control of the other party (if the new controlling entity generates its revenue from the sale of tobacco products). If the Clinical Trial Agreement is terminated by CRUK for such causes prior to VOLT&#8217;s exercise of its option, VOLT will reimburse CRUK for all costs incurred or committed in connection with the Clinical Trial. In addition, CRUK may terminate the Clinical Trial Agreement at any time before the last cycle of treatment under the Clinical Trial is complete, in which case, upon VOLT&#8217;s request, CRT will grant the VTP 600 License to VOLT with appropriately reduced payments, to reflect the stage of the Clinical Trial at the date of termination. If the Clinical Trial Agreement is terminated for any reason after VOLT&#8217;s exercise of its option, VOLT may for three months following such termination continue to manufacture Products to the extent necessary to satisfy orders for Products accepted before such termination, and sell, use or otherwise dispose of Product inventory.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">VOLT License Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, we entered into a license agreement (the "VOLT License Agreement") with VOLT. Pursuant to the VOLT License Agreement, we granted to VOLT a non-exclusive worldwide license under certain patent rights, know-how and materials related to the use of ChAdOx1, ChAdOx2, adenoviral and MVA promoters, and the TR293 Tet-Repressed Cell Line (the "VOLT Licensed Technology"), to manufacture, use and commercialize any product which uses or is within </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the scope of the VOLT Licensed Technology (the "VOLT Licensed Product"). In part, the rights granted are a sublicense of rights granted to us by OUI under the 2016 OUI License Agreement. The license is sublicensable subject to obtaining OUI&#8217;s prior consent with respect to sublicensing of any of the VOLT Licensed Technology licensed to us by OUI (with such consent not to be unreasonably withheld).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the VOLT License Agreement, we are required to make available to VOLT such further know- how relating to the manufacture of VOLT Licensed Products as we consider to be reasonably necessary or useful. We are also required to notify VOLT on a confidential basis of any improvements to the VOLT Licensed Technology that we develop or acquire rights in, and such improvements will be included within the scope of the license.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the VOLT License Agreement will continue until the later of the expiration of all patents included in the VOLT Licensed Technology or the know-how included in the VOLT Licensed Technology ceasing to be secret and substantial. The last patent under the VOLT License Agreement, if granted, is expected to expire in July 2039, without giving effect to any potential patent term extensions or patent term adjustments. Either party may terminate for the uncured material breach or insolvency of the other party. In the event of termination of the 2016 OUI License Agreement, we may terminate the VOLT License Agreement in respect of any of the VOLT Licensed Technology that is licensed to us by OUI, and VOLT and OUI shall enter into a direct license containing the same obligations and liabilities as set forth in the VOLT License Agreement.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The VOLT License Agreement was subsequently amended in July 2019 by two separate agreements for the research, development, and commercialization of cancer immunotherapy targeting MAGE-A3 and NY-ESO-1 for the treatment of various forms of cancer under the VOLT Licensed Technology. Such amendments further elaborated on the parties&#8217; respective rights and obligations, including with respect to VOLT&#8217;s payment obligations to us.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2023 CEPI Funding Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On December 20, 2023, we, the Chancellors, Masters and Scholars of the University of Oxford (&#8220;Oxford,&#8221; together with us, the &#8220;Partners&#8221;) and the CEPI entered into a Funding Agreement (the &#8220;Funding Agreement&#8221;) pursuant to which CEPI will provide funding of up to $34.8 million to us to advance the development of VTP-500, our vaccine candidate against MERS (such development activities, the &#8220;Project&#8221;). In December 2023, VTP-500 received PRIority MEdicines (&#8220;PRIME&#8221;) designation by the EMA. Under the Funding Agreement, the Partners have agreed to use reasonable endeavors to achieve the deliverables, milestones and timelines for the vaccine development activities under discrete &#8220;Work Packages&#8221; mutually agreed to by the parties from time to time.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the initial Work Package, we have agreed, subject to the achievement of certain milestones, including a successful Phase 2 clinical trial of VTP-500, that it will manufacture or have manufactured an investigational ready reserve of 100,000 doses of VTP-500 to be rapidly deployed for a clinical trial in the event of a substantial outbreak of MERS. During the Term (as defined below), we have also agreed to certain collaboration obligations in the event of a regional or national public health emergency or preparation need for an impending outbreak of MERS.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Funding Agreement, we will retain ownership of its intellectual property owned or controlled throughout the term of the Funding Agreement, subject to the rights of CEPI under the Funding Agreement. We will also own any intellectual property invented by or on behalf of us in connection with the activities contemplated by the Funding Agreement, as well as all tangible materials and results made or developed by or on behalf of us in connection with the Funding Agreement.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any amounts funded by CEPI to the Partners under the Funding Agreement in accordance with each Work Package will be paid in tranches covering six-month periods based on mutually agreed project-based budgets and subject to certain conditions as set forth in the Funding Agreement including the achievement of identified milestones.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Funding Agreement, we have agreed to pay CEPI on a country-by-country basis increasing mid-single digit percentage royalties of net sales and net income with respect to future cash sales of VTP-500, less certain deductions, for a period starting on December 20, 2023 (&#8220;Effective Date&#8221;) and ending the later of: (i) the expiration of the last valid patent claim included in intellectual property developed under the Project covering VTP-500 in such country, (ii) the expiration of Regulatory Exclusivity (as defined in the Funding Agreement) for VTP-500 in such country, and (iii) the tenth (10th) anniversary of the first commercial sale of VTP-500 (the &#8220;Royalty Term&#8221;). The Company shall also pay CEPI a mid-double digit percentage of net revenue earned on VTP-500 until CEPI has received payments from us under the Funding Agreement equaling the total amount of funding paid by CEPI to us and a low double-digit percentage of such net revenue thereafter. Sales for the benefit of end users in specified low and middle income countries (&#8220;LMICs&#8221;) and upper and middle </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">income countries (&#8220;UMICs&#8221;) are excluded from the calculations of net sales and net revenue. Sales of product for the benefit of end users in LMICs and UMICs are subject to tiered discounted pricing requirements under the Funding Agreement. The Company is further required to pay a mid-double digit percentage of any proceeds earned on any priority review voucher related to VTP-500 during the Royalty Period.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Funding Agreement will commence on the Effective Date and will continue until the fifth (5th) anniversary of the Effective Date, unless the parties agree to extend the Funding Agreement for a period of up to twenty-four (24) months unless all activities under the Funding Agreement have been completed (&#8220;Term&#8221;). Either Partner or CEPI can terminate the Funding Agreement following an insolvency event or material breach by the other party that is not cured within forty-five (45) business days, in the event of termination by a Partner, or thirty (30) business days, in the event of termination by CEPI. Pursuant to the Funding Agreement, CEPI also has certain discretionary termination rights, including if CEPI determines that we are involved in material safety, regulatory, scientific misconduct, or ethical issues or is no longer able to fulfill its obligations under the Funding Agreement.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Neither CEPI, us nor Oxford may assign its rights or obligations under the Funding Agreement without the other parties&#8217; consent; provided that CEPI may do so to an organization of equivalent charitable mission and technical capabilities. </span></div><div><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Intellectual Property</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our success depends, in part, on our ability to obtain and maintain intellectual property protection for our product candidates, technology and know-how, to defend and enforce our intellectual property rights, in particular, our patent rights, to preserve the confidentiality of our know-how and trade secrets, and to operate without infringing the proprietary rights of others. We seek to protect our product candidates and technologies by, among other methods, filing U.S. and foreign patent applications related to our proprietary technology, inventions and improvements that are important to the development of our business. We also rely on trade secrets, know-how, continuing technological innovation and in-licensing of third-party intellectual property to develop and maintain our proprietary position. We, or our licensors, file patent applications directed to our key product candidates in an effort to establish intellectual property positions to protect our product candidates as well as uses of our product candidates for the prevention and/or treatment of diseases.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 14, 2024, we own a patent family relating to our novel regimens that includes one pending U.S. patent application, two pending foreign patent applications and one pending Patent Cooperation Treaty ("PCT") patent application together with one pending U.S. provisional patent application relating to our novel products. In addition, we have in-licensed certain patent families relating to our key technology platforms and product candidates, including ten issued U.S. patents, nine pending U.S. patent applications, at least 20 issued foreign patents and at least 70 pending foreign patent applications. Following the acquisition of Avidea in December 2021 we control a further patent portfolio comprising in-licensed and co-owned patent families, including 10 pending U.S. patent applications, six issued foreign patents, 48 pending foreign patent applications and two pending PCT patent applications.</span></div><div><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Universal Vector Technology Platforms</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">ChAdOx 1 Expression Vector</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of March 14, 2024, with regard to our ChAdOx1 expression vector, we in-license from OUI a patent family that includes three issued U.S. patents with claims directed to the composition of matter of the ChAdOx1 adenovirus vector and methods of using such a vector, and 9 issued foreign patents granted in such jurisdictions as Australia, Canada, China, Europe (validated in 12 countries including Denmark, France, Germany, Italy, Spain, and Great Britain), India, Japan, Singapore and South Africa. A second granted European patent with further claims directed to the composition of matter of ChAdOx adenovirus vector is validated in France, Germany and Great Britain. This patent family also includes a pending U.S. patent application. The granted patents and pending applications, if issued, are expected to expire in 2032, without giving effect to any potential patent term extensions and patent term adjustments and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees. Patent term extensions have been granted in Australia until February 16, 2036 and in Japan for an additional 1 year, 1 month and 24 days, based on marketing authorisations received by AstraZeneca for Vaxzevria.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Adenoviral Promoter</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Certain of our ChAdOx1 vectors incorporate a proprietary adenoviral promoter, which is covered by a patent family that we in-license from OUI. As of March 14, 2024, the patent family includes two issued U.S. patents and one granted patent in Europe (validated in 7 countries including France, Germany, Italy, Spain, and Great Britain). The patents in this family are expected to expire in 2028, without giving effect to any potential patent term extensions and patent term adjustments and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">MVA-poxvirus Promoter</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our MVA vector incorporates a proprietary poxvirus promoter ("MVA-poxvirus promoter") which is covered by a patent family that we in-license from OUI. As of March 14, 2024, the patent family includes two issued U.S. patents and one granted European patent (validated in 9 countries including Denmark, France, Germany, Italy, Spain, and Great Britain) that are expected to expire in 2031, without giving effect to any potential patent term extensions and patent term adjustments and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Synthetic SNAP platform (SNAP-TI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">TM </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">and SNAP-CI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">)</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our proprietary synthetic SNAP platform is covered by a patent portfolio that includes one patent family we own, seven patent families that we co-own and one patent family that we in-license from OUI. As of March 14, 2024, we in-license a patent family from OUI that includes one pending U.S. patent application and one pending European patent application that are expected to expire in 2035, without giving effect to any potential patent term extensions and patent term adjustments and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees. As of March 14, 2024, we own a patent family that includes four issued foreign patents that are expected to expire in 2030, without giving effect to any potential patent term extensions and patent term adjustments and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees. As of March 14, 2024, we co-own a patent family that includes two issued foreign patents, one pending U.S. patent application, one pending European patent application and a at least 10 pending foreign patent applications that are expected to expire in 2038, without giving effect to any potential patent term extensions and patent term adjustments and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees. We have exclusively licensed rights in this patent family, which resulted from work carried out under a CRADA with the NIH. As of March 14, 2024, we co-own a patent family that includes one pending U.S. patent application, one pending European patent application and a further 5 pending foreign patent applications that are expected to expire in 2039, without giving effect to any potential patent term extensions and patent term adjustments and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees. We have exclusively licensed rights in this patent family, which resulted from work carried out under a CRADA with the NIH. As of March 14, 2024, we co-own a patent family that includes one pending U.S. patent application, one pending European patent application and a further 2 pending foreign patent applications that are expected to expire in 2039, without giving effect to any potential patent term extensions and patent term adjustments and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees. We have exclusive rights in this patent family, which resulted from work carried out under a CRADA with the NIH. As of March 14, 2024, we co-own a patent family that includes one pending U.S. patent application, one pending European patent application and a further nine pending foreign patent applications that are expected to expire in 2042, without giving effect to any potential patent term extensions and patent term adjustments and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees. We have exclusive rights in this patent family, which resulted from work carried out under a CRADA with the NIH. As of March 14, 2024, we co-own a patent family that includes one pending U.S. patent application, one pending European patent application and a further three pending foreign patent applications that are expected to expire in 2042, without giving effect to any potential patent term extensions and patent term adjustments and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees. We have exclusive rights in this patent family, which resulted from work carried out under a CRADA with the NIH. As of March 14, 2024, we co-own a patent family that includes one pending U.S. patent application, one pending foreign patent application and a further two pending foreign patent applications that are expected to expire in 2041, without giving effect to any potential patent term extensions and patent term adjustments and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees. We have licensed exclusive rights in this patent family, which resulted from work carried out under a RCA with the IMC. As of March 14, 2024, we co-own a patent family that includes one pending U.S. patent application and one pending international PCT patent application that are expected to expire in 2043, without giving effect to any potential patent term extensions and patent term adjustments and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees. We have exclusive rights in this patent family, which resulted from work carried out under a CRADA with the NIH. As of March 14, 2024, we co-own a patent family that includes one pending international PCT patent application that is expected to expire in 2043, without giving effect to any potential patent term extensions and patent term adjustments and assuming payment of all appropriate maintenance, renewal, annuity </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">or other governmental fees. We have exclusive rights in this patent family, which resulted from work carried out under a CRADA with the NIH.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Syntholytic</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our proprietary Syntholytic technology is covered by a patent portfolio that includes one patent family we own, 2 patent families that we co-own and one patent family that we in-license from OUI. As of March 14, 2024, we in-license a patent family from OUI that includes one pending U.S. patent application and one pending European patent application that are expected to expire in 2035, without giving effect to any potential patent term extensions and patent term adjustments and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees. As of March 14, 2024, we own a patent family that includes four issued foreign patents that are expected to expire in 2030, without giving effect to any potential patent term extensions and patent term adjustments and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees. As of March 14, 2024, we co-own a patent family that includes one pending U.S. patent application, one pending European patent application and a further 6 pending foreign patent applications that are expected to expire in 2040, without giving effect to any potential patent term extensions and patent term adjustments and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees. We have exclusive rights in this patent family, which resulted from work carried out under a CRADA with the NIH, and we have licensed exclusive rights in this patent family, which resulted from work carried out under a RCA with the IMC, Prague. As of March 14, 2024, we co-own a patent family that includes one pending U.S. patent application, one pending European patent application and a further two pending foreign patent applications that are expected to expire in 2041, without giving effect to any potential patent term extensions and patent term adjustments and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees. We have exclusive rights in this patent family, which resulted from work carried out under a CRADA with the NIH.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Product Candidates</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our VTP-200 product candidate comprises a ChAdOx1HPV vector and a MVA-HPV vector, where each vector incorporates an engineered HPV antigen. We in-license from OUI a patent family directed to the HPV antigen with claims directed to a nucleic acid encoding a polypeptide comprising certain peptide sequences based on certain HPV proteins. As of March 14, 2024, the patent family includes one issued U.S. patent, two issued foreign patents, one pending U.S. patent application and eight foreign patent applications pending in jurisdictions including Europe, Australia, Canada, and Japan. If patents were to issue from such patent applications, they would be expected to expire in 2038, without giving effect to any potential patent term extensions or patent term adjustments and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees. In addition, we also rely on patent protection afforded by the patent family directed to the ChAdOx1 expression vector, which is expected to expire in 2032, and the patent family directed to our MVA-poxvirus promoter, which is expected to expire in 2031, as discussed above.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our VTP-300 product candidate comprises a ChAdOx1HBV vector and a MVA-HBV vector, where each vector incorporates an engineered HBV antigen. As of March 14, 2024, we in-license from OUI a patent family with claims directed to a multi-HBV immunogen viral vector vaccine that includes two issued foreign patents, one pending U.S. patent application and 15 foreign patent applications pending in jurisdictions including Europe, Australia, Canada and China. If patents were to issue from such patent applications, they would be expected to expire in 2038, without giving effect to any potential patent term extensions or patent term adjustments and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees. In addition, we also rely on patent protection afforded by the patent family directed to the ChAdOx1 expression vector, which is expected to expire in 2032, and the patent family directed to our MVA-poxvirus promoter, which is expected to expire in 2031, as discussed above.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our VTP-600 product candidate comprises a ChAdOx1MAGE-NYESO vector, a MVA-MAGE vector, and a MVA-NYESO vector. We in-license from Ludwig Institute a patent family with claims directed to a chimpanzee adenovirus vector encapsulating a nucleic acid molecule encoding a MAGE antigen, a NY- ESO1 antigen or both a MAGE antigen and a NY-ESO1 antigen. As of March 14, 2024, the patent family includes one pending U.S. patent application and at least 8 foreign patent applications pending in jurisdictions including Europe, Australia, Canada, China, and Japan. If a patent were to issue from a patent application claiming the benefit of this PCT application, such a patent would be expected to expire in 2039, without giving effect to any potential patent term extensions or patent term adjustments and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees. In addition, we also rely on patent protection afforded by the patent family directed to the ChAdOx1 expression vector, which is expected to expire in 2032, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">the patent family directed to our adenoviral promotor, which is expected to expire in 2028, and the patent family directed to our MVA-poxvirus promoter, which is expected to expire in 2031, as discussed above.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our VTP-800 and VTP-850 product candidates comprise a ChAdOx15T4 vector and a MVA5T4 vector, where each vector incorporates an engineered 5T4 antigen and in VTP-850 the 5T4 antigen is also in combination with additional antigens. We in-license from OUI a patent family with claims directed to a composition for inducing a T Cell response comprising a MVA vector expressing the 5T4 antigen polypeptide. As of March 14, 2024, the patent family includes one pending U.S. patent application and 11 foreign patent applications pending in jurisdictions including Europe, Australia, Canada, China, and Japan. If a patent were to issue from a patent application claiming the benefit of this PCT application, such a patent would be expected to expire in 2039, without giving effect to any potential patent term extensions or patent term adjustments and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees. In addition, we also rely on patent protection afforded by the patent family directed to the ChAdOx1 expression vector, which is expected to expire in 2032, the patent family directed to our adenoviral promotor, which is expected to expire in 2028, and the patent family directed to our MVA-poxvirus promoter, which is expected to expire in 2031, as discussed above.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our VTP-500 product candidate comprises a ChAdOx1MERS vector that incorporates an engineered MERS antigen. We rely on patent protection afforded by the patent family directed to the ChAdOx1 expression vector, which is expected to expire in 2032 and the patent family directed to our adenoviral promotor, which is expected to expire in 2028, as discussed above.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our VTP-400 product candidate comprises a ChAdOx1VZVgE vector that incorporates an engineered VZVgE antigen. We in-license from OUI a patent family with claims directed to an adenoviral vector comprising a nucleic acid encoding the varicella-zoster virus antigen. As of March 14, 2024, the patent family includes one pending U.S. patent application and 13 foreign patent applications pending in jurisdictions including Europe, Australia, Canada, China, and Japan. If a patent were to issue from a patent application claiming the benefit of this PCT application, such a patent would be expected to expire in 2039, without giving effect to any potential patent term extensions or patent term adjustments and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees. We also rely on patent protection afforded by the patent family directed to the ChAdOx1 expression vector, which is expected to expire in 2032 and the patent family directed to our adenoviral promotor, which is expected to expire in 2028, as discussed above.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our VTP-1100 product candidate includes SNAP-CI platform technology to target HPV16+ cancers. We co-own a patent family with claims directed to methods of treating cancers using SNAP-CI compositions. As of March 14, 2024, the patent family includes one pending international PCT patent application. If a patent were to issue from a patent application claiming the benefit of this PCT application, such a patent would be expected to expire in 2043, without giving effect to any potential patent term extensions or patent term adjustments and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees. We have exclusive rights in this patent family, which resulted from work carried out under a CRADA between Barinthus Bio and the NIH. In addition, we rely on patent protection afforded by the patent families directed to the SNAP technology platforms, which are expected to expire between 2030 and 2042, as discussed above.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our VTP-1000 product candidate includes SNAP-TI platform technology to provide tolerizing immunotherapy for celiac disease. We co-own a patent family with claims directed to compositions and methods for treating celiac disease. As of March 14, 2024, the patent family includes one pending U.S. patent application and one pending international PCT patent application. If a patent were to issue from either of these pending applications or from a patent application claiming the benefit of either of these applications, such a patent would be expected to expire in 2043, without giving effect to any potential patent term extensions or patent term adjustments and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees. In addition, we rely on patent protection afforded by the patent families directed to the SNAP technology platforms, which are expected to expire between 2030 and 2042, as discussed above.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Individual patents have terms for varying periods depending on the date of filing of the patent application or the date of patent issuance and the legal term of patents in the countries in which they are obtained. Generally, utility patents issued for applications filed in the United States are granted a term of 20 years from the earliest effective filing date of a non-provisional patent application. The duration of foreign patents varies in accordance with provisions of applicable local law, but typically is also 20 years from the earliest effective filing date. All taxes, annuities or maintenance fees for a patent, as required by the USPTO and certain foreign jurisdictions, must be timely paid in order for the patent to remain in force during this period of time.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The actual protection afforded by a patent may vary on a product by product basis, from country to country and can depend upon many factors, including the type of patent, the scope of its coverage, the availability of regulatory-related extensions and the availability of legal remedies in a particular country and the validity and enforceability of the patent. Our patents </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">and patent applications may be subject to procedural or legal challenges by others. We may be unable to obtain, maintain and protect the intellectual property rights necessary to conduct our business, and we may be subject to claims that we infringe or otherwise violate the intellectual property rights of others, which could materially harm our business. For more information about the risks associated with our efforts to obtain adequate intellectual property protection for our product candidates, and the enforcement of such intellectual property rights, as well as the risks associated with third party intellectual property rights, see the section titled &#8220;Risk Factors &#8212; Risks Related to Our Intellectual Property.&#8221; With regard to our VTP-300 and VTP-850 product candidates, we are aware of third-party patents in the United States with claims which may be relevant to these product candidates. See &#8220;Risk Factors &#8212; Risks Related to Intellectual Property &#8212; The intellectual property landscape around immunotherapeutics and viral-vector based vaccines is crowded and dynamic, and third parties may initiate legal proceedings alleging that we are infringing, misappropriating or otherwise violating their intellectual property rights and such claims may be costly and time-consuming and may prevent or delay our product discovery and development efforts.&#8221;</span></div><div><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Government Regulation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the United States, biological products are subject to regulation under the Federal Food, Drug, and Cosmetic Act (the &#8220;FD&amp;C Act&#8221;), the Public Health Service Act (the &#8220;PHS Act&#8221;), and other federal, state, and local statutes and regulations. Both the FD&amp;C Act and the PHS Act and their corresponding regulations govern, among other things, the research, development, testing, manufacturing, quality control, approval, safety, efficacy, labeling, packaging, storage, record keeping, distribution, reporting, marketing, promotion, export and import, advertising, post-approval monitoring, and post-approval reporting involving biological products. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations, and international guidelines require the expenditure of substantial time and financial resources and we may not be able to obtain the required regulatory approvals.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Further, even if we obtain the required regulatory approvals for our products, pharmaceutical companies are subject to myriad federal, state, and foreign healthcare laws, rules, and regulations governing all aspects of our operations, including, but not limited to, our relationships with healthcare professionals, healthcare institutions, distributors of our products, and sales and marketing personnel; governmental and other third-party payor coverage and reimbursement of our products; and data privacy and security. Such laws, rules, and regulations are complex, continuously evolving, and, in many cases, have not been subject to extensive interpretation by applicable regulatory agencies or the courts. We are required to invest significant time and financial resources in policies, procedures, processes, and systems to ensure compliance with these laws, rules, and regulations, and our failure to do so may result in the imposition of substantial monetary or other penalties by federal or state regulatory agencies, give rise to reputational harm, or otherwise have a material adverse effect on our results of operations and financial condition.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">U.S. Biological Products Development Process</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the United States, the FDA is responsible for enforcing the laws in place to protect public health by ensuring the safety, efficacy, and security of biological products. The process required by the FDA before a biological product may be marketed in the United States generally involves the following:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">completion of extensive preclinical laboratory tests and animal studies performed in accordance with applicable regulations, including the FDA&#8217;s Good Laboratory Practices (GLPs), regulations and standards; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">submission to the FDA of an IND, which must become effective before clinical trials may begin; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">approval by an independent institutional review board ("IRB") or ethics committee representing each clinical site before the trial is commenced; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">performance of adequate and well-controlled human clinical trials in accordance with applicable IND regulations, Good Clinical Practices ("GCPs"), and other clinical trial-related regulations to establish the safety, purity and potency of the proposed biological product candidate for its intended purpose; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">preparation of and submission to the FDA of a BLA, which includes not only the results of the clinical trials, but also, detailed information on the chemistry, manufacture and quality controls for the product candidate and proposed labeling; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">payment of user fees for FDA review of the BLA (unless a fee waiver applies);</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">a determination by the FDA within 60 days of its receipt of a BLA to file the application for review; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">satisfactory completion of an FDA pre-approval inspection of the manufacturing facility or facilities at which the proposed product is produced to assess compliance with current Good Manufacturing Practice requirements ("cGMPs") and to assure that the facilities, methods and controls are adequate to preserve the biological product&#8217;s </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">identity, strength, quality and purity, and of selected clinical trial sites that generated the data in support of the BLA to assess compliance with the FDA&#8217;s GCPs; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">satisfactory completion of an FDA Advisory Committee review, if applicable; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">FDA review and approval, or licensure, of a BLA to permit commercial marketing of the product for particular indications for use in the United States.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Before testing any biological product candidate in humans, the product candidate enters the preclinical development stage. The preclinical development stage generally involves laboratory evaluations of drug chemistry, formulation and stability, as well as studies to evaluate toxicity in animals, which support subsequent clinical testing. The conduct of the preclinical studies must comply with federal regulations, including GLPs. The sponsor must submit the results of the preclinical studies, together with manufacturing information, analytical data, any available clinical data or literature and a proposed clinical protocol, as well as other information, to the FDA as part of the IND. An IND is a request for authorization from the FDA to administer an investigational drug product to humans. The central focus of an IND submission is on the general investigational plan and the protocol(s) for human trials. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA raises concerns or questions regarding the proposed clinical trials and places the IND on clinical hold within that 30-day time period. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. The FDA may also impose clinical holds on a drug product candidate at any time before or during clinical trials due to safety concerns, non-compliance, or other issues affecting the integrity of the trial. Accordingly, we cannot be sure that submission of an IND will result in the FDA allowing clinical trials to begin, or that, once begun, issues will not arise that could cause the trial to be suspended or terminated. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Clinical trials involve the administration of the biological product candidate to healthy volunteers or patients under the supervision of qualified investigators which generally are physicians not employed by, or under the control of, the trial sponsor. Clinical trials are conducted under written trial protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, subject selection (inclusion and exclusion criteria) and the parameters and criteria to be used to monitor subject safety, including stopping rules that assure a clinical trial will be stopped if certain adverse events should occur. Each protocol, and any subsequent amendments to the protocol, must be submitted to the FDA as part of the IND.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">An IRB representing each institution participating in the clinical trial must review and approve the plan for any clinical trial before it commences at that institution, and the IRB must conduct continuing review and reapprove the trial at least annually. The IRB must review and approve, among other things, the trial protocol and informed consent information to be provided to trial subjects. An IRB must operate in compliance with FDA regulations. An IRB can suspend or terminate approval of a clinical trial at its institution, or an institution it represents, if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the product candidate has been associated with unexpected serious harm to patients.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Some trials are overseen by an independent group of qualified experts organized by the trial sponsor, known as a data safety monitoring board or committee. This group provides authorization as to whether or not a trial may move forward at designated check points based on access that only the group maintains to available data (if blinded) or to data available also to the sponsor (unblinded) from the trial and may recommend halting the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Certain information about certain clinical trials must also be submitted within specific timeframes to the NIH for public dissemination on its ClinicalTrials.gov website. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Human clinical trials are typically conducted in three sequential phases that may overlap or be combined:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Phase 1. The investigational product is initially introduced into healthy human volunteers or patients with the target disease or condition. Phase 1 clinical trials are typically designed to test the safety, dosage tolerance, absorption, metabolism and distribution of the investigational product in humans, including any side effects associated with increasing doses, and, if possible, to gain early evidence of effectiveness.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Phase 2. The investigational product is evaluated in a limited patient population to identify possible adverse side effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance, optimal dosage and dosing schedule. Multiple Phase 2 clinical trials may be conducted to obtain information prior to beginning larger and more expensive Phase 3 clinical trials.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Phase 3. The investigational product is administered to an expanded patient population to further evaluate dosage, to provide substantial evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall benefit:risk </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ratio of the investigational product and to provide an adequate basis for physician labeling. Generally, two adequate and well-controlled Phase 3 clinical trials are required by the FDA for approval of a BLA.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In some cases, the FDA may require, or companies may voluntarily pursue, post-approval clinical trials, sometimes referred to as Phase 4 clinical trials, after initial marketing approval. These clinical trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication, particularly for long-term safety follow-up. During all phases of clinical development, regulatory agencies require extensive monitoring and auditing of all clinical trial activities, clinical data, and clinical trial investigators. Annual progress reports detailing the results of the clinical trials must be submitted to the FDA. Written IND safety reports must be submitted to the FDA and the investigators fifteen days after the trial sponsor determines the information qualifies for reporting for serious and unexpected suspected adverse events, findings from other studies or animal or in vitro testing that suggest a significant risk for human volunteers and any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. The sponsor must submit an IND safety report within seven days of the sponsor&#8217;s initial receipt of the information of any unexpected fatal or life-threatening suspected adverse reaction. Phase 1, Phase 2 and Phase 3 clinical trials may not be completed successfully within any specified period, if at all. The FDA or the sponsor, acting on its own or based on a recommendation from the sponsor&#8217;s data safety monitoring board may suspend a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the biological product has been associated with unexpected serious harm to patients.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Concurrent with clinical trials, companies usually complete additional animal studies and also must develop additional information about the chemistry and physical characteristics of the biological product and finalize a process for manufacturing the product in commercial quantities in accordance with cGMP. To help reduce the risk of the introduction of adventitious agents with use of biological products, the PHS Act emphasizes the importance of manufacturing control for products whose attributes cannot be precisely defined. The manufacturing process must be capable of consistently producing high quality batches of the product candidate and, among other things, the sponsor must develop methods for testing the identity, strength, quality, potency, stability, and purity of the final biological product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the biological product candidate does not undergo unacceptable deterioration over its shelf life.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">U.S. Review and Approval Processes</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product development, nonclinical studies and clinical trials are submitted to the FDA as part of a BLA requesting approval to market the product for one or more indications. The BLA must include results of product development, laboratory and animal studies, human trials, information on the manufacture and composition of the product, proposed labeling and other relevant information.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Within 60 days following submission of the application, the FDA reviews a BLA submitted to determine if it is substantially complete before the FDA accepts it for filing. The FDA may refuse to file any BLA that it deems incomplete or not properly reviewable at the time of submission and may request additional information. In this event, the BLA must be resubmitted with the required additional information. The resubmitted application also is subject to review to determine if it is substantially complete before the FDA accepts it for filing. In most cases, the submission of a BLA is subject to a substantial application user fee, although the fee may be waived under certain circumstances. Under the performance goals and policies implemented by the FDA under the Prescription Drug User Fee Act ("PDUFA") for original BLAs, the FDA targets ten months from the filing date in which to complete its initial review of a standard application and respond to the applicant, and six months from the filing date for an application with priority review. The FDA does not always meet its PDUFA goal dates, and the review process can be significantly extended by FDA requests for additional information or clarification.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Once the submission is accepted for filing, the FDA begins an in-depth substantive review of the BLA. The FDA reviews the BLA to determine, among other things, whether the proposed product is safe and effective for its intended use, conducting a benefit-risk assessment based on the information provided as to whether the benefits (with their uncertainties) of the biological product outweigh the risks (with their uncertainties and approaches to managing risks) under the conditions of use described in the proposed product labeling, and whether the product is being manufactured in accordance with cGMP to ensure its continued safety, purity and potency. The FDA may refer applications for novel biological products or biological products that present difficult or novel questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians, patient representatives, and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. During the biological product approval process, the FDA also will determine whether a Risk Evaluation and Mitigation </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Strategy ("REMS") is necessary to assure the safe use of the biological product. If the FDA concludes a REMS is needed, the sponsor of the BLA must submit a proposed REMS; the FDA will not approve the BLA without a REMS, if required.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Before approving a BLA, the FDA typically will inspect the facilities at which the product is manufactured. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. To assure cGMP and GCP compliance, an applicant must incur significant expenditure of time, money and effort in the areas of training, record keeping, production and quality control. Additionally, before approving a BLA, the FDA will typically inspect one or more clinical sites to assure that the clinical trials were conducted in compliance with the protocol and following GCP. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Under the Pediatric Research Equity Act ("PREA") a BLA or supplement to a BLA for a novel product (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">e.g.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, new active ingredient, new indication, etc.) must contain data to assess the safety and effectiveness of the biological product for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA may grant deferrals for submission of data or full or partial waivers. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">After the FDA evaluates a BLA and conducts inspections of manufacturing facilities where the drug substance and/or drug product for commercial supply will be produced, the FDA may issue an approval letter or a Complete Response Letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A Complete Response Letter will describe all of the deficiencies that the FDA has identified in the BLA, except that where the FDA determines that the data supporting the application are inadequate to support approval, the FDA may issue the Complete Response Letter without first conducting required inspections, testing submitted product lots, and/or reviewing proposed labeling. In issuing the Complete Response Letter, the FDA may recommend actions that the applicant might take to place the BLA in condition for approval, including requests for additional information or clarification. The FDA may delay or refuse approval of a BLA if applicable regulatory criteria are not satisfied, require additional testing or information and/or require post-marketing testing and surveillance to monitor safety or efficacy of a product.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If a product receives regulatory approval, the approval may be significantly limited to specific diseases and dosages or the indications for use may otherwise be limited, including to subpopulations of patients, which could restrict the commercial value of the product. Further, the FDA may require that certain contraindications, warnings, precautions or interactions be included in the product labeling. The FDA may impose restrictions and conditions on product distribution, prescribing, or dispensing in the form of a REMS, or otherwise limit the scope of any approval. The FDA also may condition approval on, among other things, changes to proposed labeling or the development of adequate controls and specifications. Once approved, the FDA may withdraw the product approval if compliance with pre- and post-marketing requirements is not maintained or if problems occur after the product reaches the marketplace. The FDA may require one or more Phase 4 post-market trials and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization, and may limit further marketing of the product based on the results of these post-marketing trials. In addition, new government requirements, including those resulting from new legislation, may be established, or the FDA&#8217;s policies may change, which could impact the timeline for regulatory approval or otherwise impact ongoing development programs.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Orphan Drug Designation</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Under section 526 of the FD&amp;C Act, the FDA may grant orphan designation to a drug or biological product intended to treat a rare disease or condition, which is defined as a disease or condition that affects fewer than 200,000 individuals in the United States, or 200,000 or more individuals in the United States and for which there is no reasonable expectation that the cost of developing and making available in the United States a drug or biological product for such disease or condition will be recovered from sales of the product in the United States of such drug. Orphan product designation must be requested before submitting a BLA for the orphan indication. After the FDA grants orphan product designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan product designation does not convey any advantage in or shorten the duration of the regulatory review and approval process.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If a product that has orphan drug designation subsequently receives the first FDA approval for a particular active ingredient for the disease for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications to market the same biologic for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity or if the FDA finds that the holder of the orphan drug exclusivity has not shown that it can assure the availability of sufficient quantities of the orphan drug to meet the needs of patients with the disease or condition for which the drug was designated. Orphan drug exclusivity does not prevent the FDA from approving a different drug or biologic for the same disease or condition, or the same drug or biologic for a different disease or condition. Among the other benefits of orphan drug designation are tax credits for qualified clinical testing expenses and a waiver of the BLA application user fee.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A designated orphan drug may not receive orphan drug exclusivity if the approved indication for a use is broader than the indication for which it received orphan designation. In addition, orphan drug exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or, as noted above, if the second applicant demonstrates that its product is clinically superior to the approved product with orphan exclusivity or the manufacturer of the approved product is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Orphan drug designation may also entitle a party to additional financial incentives such as opportunities for grant funding towards clinical trial costs.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Expedited Development and Review Programs</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The FDA has various programs, including fast track designation, breakthrough therapy designation, accelerated approval and priority review, that are intended to expedite or simplify the process for the development and FDA review of drugs and biologics that are intended for the treatment of serious or life-threatening diseases or conditions or fulfill an unmet medical need. To be eligible for fast track designation, new drugs and biological product candidates must be intended to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for that disease or condition. Fast track designation applies to the combination of the product and the specific indication for which it is being studied. The sponsor of a new drug or biologic may request the FDA to designate the drug or biologic as a fast track product at any time during the clinical development of the product. One benefit of fast track designation, for example, is that the FDA may consider for review sections of the marketing application on a rolling basis before the complete application is submitted if certain conditions are satisfied, including an agreement with the FDA on the proposed schedule for submission of portions of the application and the payment of applicable user fees before the FDA may initiate a review. However, the review of the BLA does not formally start until the full application has been received by the FDA.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Under the FDA&#8217;s breakthrough therapy program, a sponsor may seek FDA designation of its product candidate as a breakthrough therapy if the product candidate is intended, alone or in combination with one or more other drugs or biologics, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that it may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, defined as those that measure an effect on irreversible morbidity or mortality or on symptoms that represent serious consequences of the disease. Breakthrough therapy designation comes with all of the benefits of fast track designation. The FDA may take other actions appropriate to expedite the development and review of the product candidate, including holding meetings with the sponsor and providing timely advice to, and interactive communication with, the sponsor regarding the development program.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A product candidate is eligible for priority review if when approved, it would provide a significant improvement in the safety or effectiveness of the treatment, diagnosis or prevention of a serious disease or condition. The FDA will attempt to direct additional resources to the evaluation of an application for a new drug or biological product designated for priority review in an effort to facilitate the review. Under priority review, the FDA&#8217;s goal is to review an application in six months once it is filed, compared to ten months for a standard review. Priority review designation does not change the scientific/medical standard for approval or the quality of evidence necessary to support approval.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Additionally, drug or biological products studied for their safety and effectiveness in treating serious or life-threatening illnesses and that provide meaningful therapeutic benefit over existing treatments may be eligible for accelerated approval, which means that they may be approved on the basis of adequate and well-controlled clinical trials establishing that the product has an effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit, or on the basis of an effect on an intermediate clinical endpoint other than survival or irreversible morbidity or mortality, that is reasonably likely to predict irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA generally requires that a sponsor of a drug or biological product receiving accelerated approval perform adequate and well-controlled post-marketing clinical trials to verify the clinical benefit in relationship to the surrogate endpoint or ultimate outcome in relationship to the clinical benefit. Under the Food and Drug Omnibus Reform Act of 2022 ("FDORA") the FDA is now permitted to require, as appropriate, that such trials be underway prior to approval or within a specific time period after the date of approval for a product granted accelerated approval. Sponsors are also required to send updates to the FDA every 180 days on the status of such studies, including progress toward enrollment targets, and the FDA must promptly post this information publicly. Under FDORA, the FDA has increased authority for expedited procedures to withdraw approval of a drug or indication approved under accelerated approval if, for example, the sponsor fails to conduct such studies in a timely manner and send the necessary updates to the FDA, or if a confirmatory trial fails to verify the predicted clinical benefit of the product. In addition, the FDA currently requires sponsors, unless otherwise informed by the agency, to request pre-approval of promotional materials for products receiving accelerated approval, which could adversely impact the timing of the commercial launch of the product. The FDA may withdraw approval of a drug or </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">indication approved under accelerated approval if, for example, the confirmatory trial fails to verify the predicted clinical benefit of the product.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Post-approval Requirements </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Rigorous and extensive FDA regulation of biological products continues after approval, particularly with respect to cGMP requirements, as well as requirements relating to record-keeping, reporting of adverse experiences, periodic reporting, product sampling and distribution, and advertising and promotion of the product. We currently rely, and may continue to rely, on third parties for the production of clinical and commercial quantities of any products that we may commercialize. Manufacturers of our products are required to comply with applicable requirements in the cGMP regulations, including quality control and quality assurance and maintenance of records and documentation. Other post-approval requirements applicable to biological products include reporting of cGMP deviations that may affect the identity, potency, purity and overall safety of a distributed product, record-keeping requirements, reporting of adverse effects, reporting updated safety and efficacy information, and complying with electronic record and signature requirements. As part of the manufacturing process, the manufacturer is required to perform certain tests on each lot of the product before it is released for distribution. After a BLA is approved for a biological product, the product also may be subject to official lot release. If the product is subject to official release by the FDA, the manufacturer submits samples of each lot of product to the FDA together with a release protocol showing a summary of the history of manufacture of the lot and the results of all of the manufacturer&#8217;s tests performed on the lot. The FDA also may perform certain confirmatory tests on lots of some products before releasing the lots for distribution by the manufacturer. In addition, the FDA conducts laboratory research related to the regulatory standards on the safety, purity, potency, and effectiveness of biological products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Manufacturers also must comply with the FDA&#8217;s advertising and promotion requirements, such as those related to direct-to-consumer advertising, the prohibition on promoting products for uses or in patient populations that are not described in the product&#8217;s approved labeling (known as &#8220;off-label use&#8221;), industry-sponsored scientific and educational activities, and promotional activities involving the internet. Discovery of previously unknown problems or the failure to comply with the applicable regulatory requirements may result in restrictions on the marketing of a product or withdrawal of the product from the market as well as possible civil or criminal sanctions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Failure to comply with the applicable United States requirements at any time during the product development process, approval process, or after approval, may subject an applicant or manufacturer to administrative or judicial civil or criminal sanctions and adverse publicity. FDA sanctions could include refusal to approve pending applications, withdrawal of an approval, clinical holds, warning or untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, product detentions or refusal to permit the import or export of the product, restrictions on the marketing or manufacturing of the product, injunctions, fines, refusals of government contracts, mandated corrective advertising or communications with physicians or other stakeholders, debarment, restitution, disgorgement of profits, or civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Biological product manufacturers and other entities involved in the manufacture and distribution of approved biological products are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP and other laws, including applicable tracking and tracing requirements. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance. Discovery of problems with a product after approval may result in restrictions on a product, manufacturer, or holder of an approved BLA, including withdrawal of the product from the market. In addition, changes to the manufacturing process or facility generally require prior FDA approval before being implemented and other types of changes to the approved product, such as adding new indications and additional labeling claims, are also subject to further FDA review and approval.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Marketing Exclusivity</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Depending upon the timing, duration and specifics of the FDA approval of the use of our product candidates, some of our United States patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984 (the "Hatch-Waxman Amendments"). The Hatch-Waxman Amendments permit a patent restoration term of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. However, patent term restoration cannot extend the remaining term of a patent beyond a total of 14 years from the product&#8217;s approval date. The patent term restoration period is generally one-half the time between the effective date of an IND and the submission date of a BLA plus the time between the submission date of a BLA and the approval of that application. Only one patent applicable to an approved biological product is eligible for the extension and the application for the extension must be submitted prior to the expiration of the patent. In addition, a patent can only be extended once and only for a single product. The United States Patent and Trademark Office (the "USPTO") in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. In the future, we may intend to apply for restoration of patent term for one of our patents, if and as applicable, to add patent life beyond </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">its current expiration date, depending on the expected length of the clinical trials and other factors involved in the filing of the relevant BLA. The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (collectively, the "ACA") includes a subtitle called the Biologics Price Competition and Innovation Act of 2009 ("BPCIA"), which created an abbreviated approval pathway for biological products shown to be biosimilar to, or interchangeable with, an FDA-licensed reference biological product. This amendment to the PHS Act attempts to minimize duplicative testing. Biosimilarity, which requires that there be no clinically meaningful differences between the biological product and the reference product in terms of safety, purity, and potency, can be shown through analytical studies, animal studies, and a clinical trial or trials. Interchangeability requires that a product is biosimilar to the reference product and the product must demonstrate that it can be expected to produce the same clinical results as the reference product and, for products administered multiple times, the biologic and the reference biologic may be switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The FDA will not accept an application for a biosimilar or interchangeable product based on the reference biological product until four years after the date of first licensure of the reference product, and the FDA will not approve an application for a biosimilar or interchangeable product based on the reference biological product until twelve years after the date of first licensure of the reference product. &#8220;First licensure&#8221; typically means the initial date the particular product at issue was licensed in the United States. Date of first licensure does not include the date of licensure of (and a new period of exclusivity is not available for) a biological product if the licensure is for a supplement for the biological product or for a subsequent application by the same sponsor or manufacturer of the biological product (or licensor, predecessor in interest, or other related entity) for a change (not including a modification to the structure of the biological product) that results in a new indication, route of administration, dosing schedule, dosage form, delivery system, delivery device or strength, or for a modification to the structure of the biological product that does not result in a change in safety, purity, or potency.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The BPCIA is complex and continues to be interpreted and implemented by the FDA. In addition, government proposals have sought to reduce the 12 year reference product exclusivity period. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of litigation. As a result, the ultimate implementation and impact of the BPCIA is subject to significant uncertainty.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition to exclusivity under the BPCIA, a biological product can obtain pediatric market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to existing exclusivity for all formulations, dosage forms, and indications of the biologic. This six-month exclusivity, which runs from the end of other exclusivity protection, may be granted based on the voluntary completion of a pediatric trial in accordance with an FDA-issued &#8220;Written Request&#8221; for such a trial, provided that at the time pediatric exclusivity is granted there is not less than nine months of term remaining.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Additional Regulation</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition to the foregoing, state and federal laws regarding environmental protection and hazardous substances, including the Occupational Safety and Health Act, the Resource Conservancy and Recovery Act and the Toxic Substances Control Act, affect our business. These and other laws govern our use, handling and disposal of various biological, chemical and radioactive substances used in, and wastes generated by, our operations. If our operations result in contamination of the environment or expose individuals to hazardous substances, we could be liable for damages and governmental fines. We believe that we are in material compliance with applicable environmental laws and that continued compliance therewith will not have a material adverse effect on our business. We cannot predict, however, how changes in these laws may affect our future operations.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Government Regulation Outside of the United States</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition to regulations in the United States, we are subject to a variety of regulations in other jurisdictions governing, among other things, research and development, clinical trials, testing, manufacturing, safety, efficacy, labeling, packaging, storage, record keeping, distribution, reporting, advertising and other promotional practices involving biological products as well as authorization and approval of our products. Because biologically sourced raw materials are subject to unique contamination risks, their use may be restricted in some countries.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Whether or not we obtain FDA approval for a product, we must obtain the requisite approvals from regulatory authorities in foreign countries prior to the commencement of clinical trials or marketing of the product in those countries. Certain countries outside of the United States have a similar process that requires the submission of a clinical trial application much like the IND prior to the commencement of human clinical trials.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In April 2014, the EU adopted the new Clinical Trials Regulation (EU) No 536/2014, which replaced the current Clinical Trials Directive 2001/20/EC on January 31, 2022. The transitory provisions of the new Regulation offer sponsors the possibility to choose between the requirements of the previous Directive and the new Regulation if the request for </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">authorization of a clinical trial is submitted in the year after the new Regulation became applicable. If the sponsor chooses to submit under the previous Directive, the clinical trial continues to be governed by the Directive until three years after the new Regulation became applicable. If a clinical trial continues for more than three years after the Regulation became applicable, the new Regulation will at that time begin to apply to the clinical trial. The new Regulation, which is directly applicable in all EU Member States and those within the European Economic Area ("EEA") (meaning that no national implementing legislation in each EU Member State is required), aims at simplifying and streamlining the approval of clinical trials in the EU. The main characteristics of the new Regulation include: a streamlined application procedure via a single-entry point through the Clinical Trials Information System ("CTIS"); a single set of documents to be prepared and submitted for the application as well as simplified reporting procedures for clinical trial sponsors; and a harmonized procedure for the assessment of applications for clinical trials, which is divided in two parts (Part I contains scientific and medicinal product documentation and Part II contains the national and patient-level documentation). Part I is assessed by a coordinated review by the competent authorities of all European Union Member States in which an application for authorization of a clinical trial has been submitted (Concerned Member States) of a draft report prepared by a Reference Member State. Part II is assessed separately by each Concerned Member State. Strict deadlines have also been established for the assessment of clinical trial applications.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The requirements and process governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. In all cases, the clinical trials must be conducted in accordance with GCP and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension of clinical trials, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">European Union Drug Review and Approval</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the European Union, medicinal products, including biological medicinal products, are subject to extensive pre- and post-market regulation by regulatory authorities at both the European Union and national levels.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">To obtain regulatory approval of a biological medicinal product under the European Union regulatory system, we must submit a marketing authorization application ("MAA") either under a centralized procedure administered by the EMA or one of the procedures administered by competent authorities in the European Union: the decentralized procedure, national procedure, or mutual recognition procedure. A marketing authorization may be granted only to an applicant established in the EEA.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The centralized procedure provides for the grant of a single marketing authorization by the European Commission that is valid throughout the entire territory of the EU and the additional Member States of the EEA. Pursuant to Regulation (EC) No. 726/2004, the centralized procedure is compulsory for specific products, including for medicines produced by certain biotechnological processes, products designated as orphan medicinal products, advanced-therapy medicinal products (gene-therapy, somatic-cell therapy and tissue-engineered medicines) and products with a new active substance indicated for the treatment of certain diseases, including products for the treatment of viral diseases, autoimmune and other immune dysfunctions and cancer. For those products for which the use of the centralized procedure is not mandatory, applicants may elect to use the centralized procedure where the product contains a new active substance not yet authorized in the European Union, and where the applicant can show that the product constitutes a significant therapeutic, scientific or technical innovation or for which a centralized process is in the interest of public health at a European Union level.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Under the centralized procedure, the Committee for Medicinal Products for Human Use (the "CHMP"), established at the EMA is responsible for conducting an initial assessment of whether a product meets the required quality, safety and efficacy requirements, and whether a product has a positive benefit-risk profile. Under the centralized procedure in the European Union, the maximum timeframe for the evaluation of an MAA is 210 days from receipt of a valid MAA, excluding clock stops when additional information or written or oral explanation is to be provided by the applicant in response to questions asked by the CHMP. Clock stops may extend the timeframe of evaluation of an MAA considerably beyond 210 days. Where the CHMP gives a positive opinion, it provides the opinion together with supporting documentation to the European Commission, who make the final decision to grant a marketing authorization, which is issued within 67 days of receipt of the EMA&#8217;s recommendation. Accelerated evaluation may be granted by the CHMP in exceptional cases, when a medicinal product is of major interest from the point of view of public health and, in particular, from the viewpoint of therapeutic innovation. If the CHMP accepts such a request, the timeframe of 210 days for assessment will be reduced to 150 days (excluding clock stops), but it is possible that the CHMP may revert to the standard time limit for the centralized procedure if it determines that the application is no longer appropriate to conduct an accelerated assessment.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For products not falling within the mandatory scope of the centralized procedure, national marketing authorizations may be obtained, which are issued by the competent authorities of the European Union Member States and only cover their </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">respective territory. Where a product has already been authorized for marketing in an European Union Member State, this national marketing authorization can be recognized in another European Union Member State through the mutual recognition procedure. If the product has not received a national marketing authorization in any Member State at the time of application, it can be approved simultaneously in various European Union Member States through the decentralized procedure. As with the centralized procedure, the competent authorities of the European Union Member States assess the risk-benefit balance of the product on the basis of scientific criteria concerning its quality, safety and efficacy before granting the marketing authorization.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The application used to submit the BLA in the United States is similar to that required in the European Union, with certain exceptions. Directive 2001/83/EC and the laws in the Member States transposing this Directive into national law set out the requirements for an MAA. An MAA for a biological medicinal product must contain certain additional requirements to applications for other medicinal products, such as a description of the origin and history of the starting materials used for the product.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Data and Marketing Exclusivity</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The European Union also provides opportunities for market exclusivity. Upon receiving marketing authorization in the European Union, innovative medicinal products, approved on the basis of a complete independent package, generally receive eight years of data exclusivity and an additional two years of market exclusivity. Data exclusivity, if granted, prevents generic or biosimilar applicants from referencing the innovator&#8217;s preclinical/nonclinical and clinical trial data contained in the dossier of the reference product when applying for a generic or biosimilar marketing authorization in the European Union for a period of eight years from the date on which the reference product was first authorized in the European Union. During the additional two-year period of market exclusivity, a generic or biosimilar marketing authorization can be submitted, and the innovator&#8217;s data may be referenced, but no generic or biosimilar product can be marketed in the European Union until the expiration of the market exclusivity period. The overall ten-year period will be extended to a maximum of eleven years if, during the first eight years of those ten years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with currently approved therapies. Even if an innovative medicinal product gains the prescribed period of data exclusivity, another company could nevertheless also market another version of the product if such company obtained a marketing authorization based on an MAA with a complete and independent data package of pharmaceutical tests, nonclinical tests and clinical trials.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Orphan Designation and Exclusivity</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Products with an orphan designation in the European Union can receive ten years of market exclusivity, during which time &#8220;no similar medicinal product&#8221; for the same indication may be placed on the market. A &#8220;similar medicinal product&#8221; is defined as a medicinal product containing a similar active substance or substances as contained in an authorized orphan medicinal product, and which is intended for the same therapeutic indication. An orphan medicinal product can also obtain an additional two years of market exclusivity where an agreed pediatric investigation plan for pediatric trials has been complied with. No extension to any supplementary protection certificate ("SPC") can be granted on the basis of pediatric trials for orphan indications. The ten-year market exclusivity may be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan designation, for example, if the product is sufficiently profitable not to justify maintenance of market exclusivity.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The criteria for designating an &#8220;orphan medicinal product&#8221; in the European Union are similar in principle to those in the United States. Under Article 3 of Regulation (EC) 141/2000, a medicinal product may be designated as an orphan medicinal product if it meets the following criteria: (i) it is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition; (ii) either (a) the prevalence of such condition must not be more than five in 10,000 persons in the European Union when the application is made, or (b) without the benefits derived from orphan status, it must be unlikely that the marketing of the medicine would generate sufficient return in the European Union to justify the investment needed for its development; and (iii) there exists no satisfactory method of diagnosis, prevention or treatment of such condition, or if such a method exists, the product would be of significant benefit to those affected by the condition, as defined in Regulation (EC) 847/2000. Orphan medicinal products are eligible for financial incentives such as reduction of fees or fee waivers made available by the European Union and its Member States to support research into, and the development and availability of, orphan medicinal products. The application for orphan designation must be submitted before the application for marketing authorization. The applicant will receive a fee reduction for the MAA if the orphan drug designation has been granted, but not if the designation is still pending at the time the marketing authorization is submitted. Orphan designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Orphan medicine marketing exclusivity may be revoked only in very select cases, specifically:</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">if it is established that a similar medicinal product is safer, more effective or otherwise clinically superior;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">with consent from the marketing authorization holder for the authorized orphan product; or</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the marketing authorization holder for the authorized orphan product cannot supply enough orphan medicinal product.</span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Pediatric Development</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the European Union, companies developing a new medicinal product must agree upon a pediatric investigation plan, or PIP, with the EMA&#8217;s Pediatric Committee ("PDCO") and must conduct pediatric clinical trials in accordance with that PIP, unless a waiver applies, (e.g., because the relevant disease or condition occurs only in adults). The PIP sets out the timing and measures proposed to generate data to support a pediatric indication of the product for which marketing authorization is being sought. The PDCO can grant a deferral of the obligation to implement some or all of the measures of the PIP until there are sufficient data to demonstrate the efficacy and safety of the product in adults, in which case the pediatric clinical trials must be completed at a later date. Further, the obligation to provide pediatric clinical trial data can be waived by the PDCO when this data are not needed or appropriate because the product is likely to be ineffective or unsafe in children, the disease or condition for which the product is intended occurs only in adult populations, or when the product does not represent a significant therapeutic benefit over existing treatments for pediatric patients. Products that are granted a marketing authorization with the results of pediatric clinical trials conducted in accordance with the PIP are eligible for a six-month extension of the protection under a SPC, provided an application for such extension is made at the same time as filing the SPC application for the product or at any point up to 2 years before the SPC expires, even where the trial results are negative. In the case of orphan medicinal products, a two-year extension of the orphan market exclusivity may be available. This pediatric reward is subject to specific conditions and is not automatically available when data in compliance with the PIP are developed and submitted.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">PRIME Designation</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In March 2016, the EMA, launched an initiative to facilitate development of product candidates in indications, often rare, for which few or no therapies currently exist. The PRIME scheme is intended to encourage product development in areas of unmet medical need (where there is no satisfactory method of diagnosis, prevention or treatment in the European Union or, if there is, the new medicine will bring a major therapeutic advantage) and provides accelerated assessment of products representing substantial innovation. The PRIME scheme is open to medicines under development and for which the applicant intends to apply for an initial MAA through under the centralized procedure. Applicants will typically be at the exploratory clinical trial phase of development, and will have preliminary clinical evidence in patients to demonstrate the promising activity of the medicine and its potential to address to a significant extent an unmet medical need. In exceptional cases, products from small- and medium-sized enterprises may qualify for earlier entry into the PRIME scheme than larger companies, if compelling non-clinical data in a relevant model provide early evidence of promising activity, and first in human trials indicate adequate exposure for the desired pharmacotherapeutic effects and tolerability. Many benefits accrue to sponsors of product candidates with PRIME designation, including but not limited to, early and proactive regulatory dialogue with the EMA, frequent discussions on clinical trial designs and other development program elements, and accelerated MAA assessment once a dossier has been submitted. Importantly, a dedicated EMA contact and rapporteur from the CHMP or Committee for Advanced Therapies are appointed early in the PRIME scheme facilitating increased understanding of the product at EMA&#8217;s Committee level. A kick-off meeting initiates these relationships and includes a team of multidisciplinary experts at the EMA to provide guidance on the overall development and regulatory strategies. Where, during the course of development, a medicine no longer meets the eligibility criteria, support under the PRIME scheme may be withdrawn. VTP&#8209;500, under development for the prevention of MERS caused by the MERS coronavirus, was awarded PRIME designation in December 2023 by the EMA.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Post-Approval Controls</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Following approval, the holder of the marketing authorization is required to comply with a range of requirements applicable to the manufacturing, marketing, promotion and sale of the medicinal product. These include the following:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">The holder of a marketing authorization must establish and maintain a pharmacovigilance system and appoint an individual qualified person for pharmacovigilance, who is responsible for oversight of that system. Key obligations include expedited reporting of suspected serious adverse reactions and submission of periodic safety update reports ("PSURs").</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">All new MAAs must include a risk management plan ("RMP") describing the risk management system that the company will put in place and documenting measures to prevent or minimize the risks associated with the product. The regulatory authorities may also impose specific obligations as a condition of the marketing authorization. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Such risk-minimization measures or post- authorization obligations may include additional safety monitoring, more frequent submission of PSURs, or the conduct of additional clinical trials or post-authorization safety trials. RMPs and PSURs are routinely available to third parties requesting access, subject to limited redactions.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">All advertising and promotional activities for the product must be consistent with the approved SmPC and therefore all off-label promotion is prohibited. Direct-to-consumer advertising of prescription medicines is also prohibited in the European Union. Although general requirements for advertising and promotion of medicinal products are established under European Union directives, the details are governed by regulations in each European Union Member State and can differ from one country to another.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The aforementioned EU rules are generally applicable in the EEA.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Brexit and the Regulatory Framework in the United Kingdom</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In June 2016, the electorate in the United Kingdom voted in favor of leaving the European Union (commonly referred to as &#8220;Brexit&#8221;), and the United Kingdom officially withdrew from the European Union on January 31, 2020. Pursuant to the formal withdrawal arrangements agreed between the United Kingdom and the European Union, the United Kingdom was subject to a transition period until December 31, 2020 ("Transition Period"), during which European Union rules continued to apply. However, the European Union and the United Kingdom have concluded a trade and cooperation agreement ("TCA"), which was provisionally applicable since January 1, 2021 and has been formally applicable since May 1, 2021. The TCA includes specific provisions concerning pharmaceuticals, which include the mutual recognition of GMP inspections of manufacturing facilities for medicinal products and GMP documents issued, but does not foresee wholesale mutual recognition of United Kingdom and European Union pharmaceutical regulations. At present, Great Britain has implemented European Union legislation on the marketing, promotion and sale of medicinal products through the Human Medicines Regulations 2012 (as amended) (under the Northern Ireland Protocol, the European Union regulatory framework will continue to apply in Northern Ireland). The regulatory regime in Great Britain therefore largely aligns with current European Union regulations, however it is possible that these regimes will diverge in future now that Great Britain&#8217;s regulatory system is independent from the European Union and the TCA does not provide for mutual recognition of United Kingdom and European Union pharmaceutical legislation. For example, the United Kingdom has implemented the now repealed Clinical Trials Directive 2001/20/EC into national law through the Medicines for Human Use (Clinical Trials) Regulations 2004 (as amended). The extent to which the regulation of clinical trials in the United Kingdom will mirror the new Clinical Trials Regulation now that has come into effect is not yet known, however the MHRA has conducted a consultation on a set of proposals designed to improve and strengthen the United Kingdom clinical trials legislation.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Great Britain is no longer covered by the European Union&#8217;s procedures for the grant of centralized marketing authorizations, however as a result of the Northern Ireland Protocol, Northern Ireland will be covered by the centralized authorization procedure and can be covered as a Center for Medicare and Medicaid Services ("CMS") under the decentralized or mutual recognition procedures. A separate marketing authorization will therefore be required to market drugs in Great Britain. All medicinal products with a valid centralized marketing authorization on January 1, 2021 were automatically converted into Great Britain marketing authorizations (unless the marketing authorization holder opted out of such a conversion). For two years from 1 January 2021, the United Kingdom&#8217;s regulator, MHRA may rely on a decision taking by the European Commission on the approval of a new marketing authorization in the centralized procedure, in order to more quickly grant a new Great Britain marketing authorization. This is known as the EC Decision Reliance Procedure. The MHRA also offers a 150 day assessment timeline for all high quality applications for a UK, Great Britain or Northern Ireland marketing authorization. The 150 day timeline does not, however, include a &#8220;clock-off&#8221; period which may occur if issues arise or points require clarification following an initial assessment of the application. Such issues should be addressed within a 60 day period, although extensions may be granted in exceptional cases.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Since January 1, 2021, a separate process for orphan designation has applied in Great Britain. There is now no pre-marketing authorization orphan designation (as there is in the European Union) in Great Britain and the application for orphan designation will be reviewed by the MHRA at the time of a MAA application for a United Kingdom or Great Britain marketing authorization. The criteria for orphan designation are the same as in the European Union, save that they apply to Great Britain only (e.g., there must be no satisfactory method of diagnosis, prevention or treatment of the condition concerned in Great Britain, as opposed to the European Union, and the prevalence of the condition must be no more than 5 in 10,000 person in Great Britain).</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Coverage and Reimbursement</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Significant uncertainty exists as to the coverage and reimbursement status of any pharmaceutical or biological product for which we may seek regulatory approval. Sales of any product, if approved, depend, in part, on the extent to which such product will be covered by third-party payors, such as federal, state, and foreign government healthcare programs, commercial insurers, and managed healthcare organizations. Decisions regarding whether to cover any of our product candidates, if approved, the extent of coverage, and amount of reimbursement to be provided are made on a plan-by-plan </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">basis. Further, no uniform policy for coverage and reimbursement exists in the United States, and coverage and reimbursement can differ significantly from payor to payor.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Moreover, product candidates may not be considered medically necessary or cost-effective. A decision by a third-party payor not to cover any product candidates we may develop could reduce physician utilization of such product candidates once approved and have a material adverse effect on our sales, results of operations, and financial condition. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement rates, but also have their own methods and approval process apart from Medicare determinations. As a result, the coverage determination process is often a time- consuming and costly process that will require us to provide scientific and clinical support for the use of our product candidates to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. For products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs. Additionally, separate reimbursement for the product itself or the treatment or procedure in which the product is used may not be available, which may impact physician utilization of the product.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, the United States government and state legislatures have continued implementing cost-containment programs, including price controls, restrictions on coverage and reimbursement, and requirements for substitution of generic products. Third-party payors are increasingly challenging the prices charged for medical products and services; examining the medical necessity of pharmaceutical or biological products; reviewing the cost-effectiveness of such products; and questioning the safety and efficacy of such products. Adoption of new price controls and cost-containment measures, or adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit sales of any product that receives approval. Furthermore, there is no assurance that a product will be considered medically reasonable and necessary for a specific indication, that it will be considered cost-effective by third-party payors, that an adequate level of reimbursement will be established even if coverage is available, or that the third-party payors&#8217; reimbursement policies will not adversely affect the ability of manufacturers to sell products profitably. Decreases in third-party reimbursement for any product or a decision by a third party not to cover a product could reduce physician usage and patient demand for such product.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In international markets, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies. For example, the European Union provides options for its Member States to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. A Member State may approve a specific price for the medicinal product, or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. Pharmaceutical products may face competition from lower-priced products in foreign countries that have placed price controls on pharmaceutical products and may also compete with imported foreign products.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Other Healthcare Laws and Compliance Requirements</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pharmaceutical companies are subject to additional healthcare regulation and enforcement by the federal government and by authorities in the states and foreign jurisdictions in which they conduct their business. Such laws include, without limitation: the United States federal Anti-Kickback Statute ("AKS"); the civil False Claims Act ("FCA"); the federal Health Insurance Portability and Accountability Act of 1996 ("HIPAA"); and similar foreign, federal, and state fraud and abuse, transparency, and privacy laws.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The AKS prohibits, among other things, persons and entities from knowingly and willfully soliciting, receiving, offering, or paying remuneration to induce, or in return for, either the referral of an individual, or the purchase, lease, ordering, or arranging for or recommending the purchase, lease, or ordering, of any item or service for which payment may be made under any federal healthcare program. The term remuneration has been interpreted broadly to include anything of value, whether given directly or indirectly, in cash or in kind. The AKS has been interpreted to apply to arrangements between pharmaceutical manufacturers on one hand and prescribers, third-party payors, patients, and others on the other hand. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution, but they are drawn narrowly, and practices that involve remuneration, such as consulting agreements, that may be alleged to be intended to induce prescribing, purchasing, or recommending may be subject to scrutiny if they do not qualify for an exception or safe harbor. Failure to meet all of the requirements of an applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the AKS. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative review of all of its facts and circumstances. Our practices may not in all cases meet all of the criteria for protection under a statutory exception or regulatory safe harbor. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. In addition, a claim submitted to a federal healthcare program that includes items or services resulting from a violation of the AKS constitutes a false or fraudulent claim that may result in civil liability under the FCA.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Civil and criminal false claims laws, and civil monetary penalty laws, including the FCA, which can be enforced through civil whistleblower or qui tam actions, prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment to the federal government, including federal healthcare programs, that are false or fraudulent. For example, the FCA prohibits any person or entity from knowingly presenting, or causing to be presented, a false claim for payment to the federal government or knowingly making, using, or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal government. A claim includes &#8220;any request or demand&#8221; for money or property presented to the United States government. Several pharmaceutical companies have been prosecuted under these laws for allegedly providing free product to customers with the expectation that the customers would bill federal healthcare programs for the product, or for subsidizing copays for patients, including indirectly through charitable patient assistance programs, as an inducement for patients to utilize their products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">HIPAA created additional federal civil and criminal liability for, among other things, knowingly and willfully executing a scheme to defraud any healthcare benefit program, or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private) and knowingly and willfully falsifying, concealing, or covering up by any trick or device a material fact or making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items, or services relating to healthcare matters. Similar to the AKS, a person or entity can be found guilty of violating HIPAA&#8217;s fraud and abuse provisions without actual knowledge of the statute or specific intent to violate it.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 ("HITECH") and their respective implementing regulations, impose certain requirements on HIPAA covered entities, which include certain healthcare providers, healthcare clearinghouses, and health plans, and individuals and entities that provide services on their behalf that involve individually identifiable health information, known as business associates, relating to the privacy, security, and transmission of individually identifiable health information. In particular, regulations promulgated pursuant to HIPAA establish privacy and security standards that limit the use and disclosure of protected health information and require the implementation of administrative, physical and technological safeguards to protect the privacy of protected health information and ensure the confidentiality, integrity and availability of electronic protected health information. Determining whether protected health information has been handled in compliance with applicable privacy standards and our contractual obligations can require complex factual and statistical analyses, and may be complicated by the fact that the applicable rules are subject to changing interpretation. HIPAA mandates the reporting of certain breaches of health information to the United States Department of Health and Human Services ("HHS") affected individuals, and if the breach is large enough, the media. In addition to reputational harm, entities that are found to be in violation of HIPAA as the result of a breach of unsecured protected health information, a complaint about privacy practices, or an audit by HHS, may be subject to significant civil, criminal, and administrative fines and penalties and/or additional reporting and oversight obligations if required to enter into a resolution agreement and corrective action plan with HHS to settle allegations of HIPAA non-compliance. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#8217; fees and costs associated with pursuing civil actions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The U.S. federal Physician Payments Sunshine Act ("Sunshine Act") requires certain manufacturers of drugs, devices, biologics, and medical supplies for which payment is available under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program, with specific exceptions, to annually report to the CMSs, information related to payments or other transfers of value made to physicians (currently defined to include doctors of medicine or osteopathy, dentists, optometrists, podiatrists, and chiropractors), other licensed non-physician health care practitioners, and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. Additionally, we may be subject to federal government price reporting laws, which require us to calculate and report complex pricing metrics in an accurate and timely manner to government programs and federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are also subject to additional similar U.S. state and foreign equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers, or that apply regardless of payor; state laws which require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government; state and local laws which require pharmaceutical companies to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; state laws which require the reporting of information related to drug pricing; state and local laws requiring the registration of pharmaceutical sales representatives; and state and foreign laws governing the privacy and security of health information which, in some cases, differ from each other in significant ways, and may not have the same effect, thus complicating compliance efforts. If our operations are found to be in violation of any of such laws or any other governmental regulations that apply, we or our officers, directors, employees, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">contractors, or agents may be subject to penalties, including, without limitation, significant civil, criminal, and administrative penalties; damages; fines; exclusion from government-funded healthcare programs, such as Medicare and Medicaid or similar programs in other countries or jurisdictions; entry into a corporate integrity agreement or similar reporting obligations to resolve allegations of non-compliance; disgorgement; imprisonment; contractual damages; reputational harm; diminished profits; and the curtailment or restructuring of our operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Data Privacy and Security Laws</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We may also be subject to data privacy and security laws in the United States and various jurisdictions around the world in which we operate or process personally identifiable information (&#8220;personal information&#8221; or &#8220;personal data&#8221;). In the United States, even when HIPAA does not apply, according to the Federal Trade Commission (the "FTC") failing to take appropriate steps to keep consumers&#8217; personal information secure constitutes unfair acts or practices in or affecting commerce in violation of Section 5(a) of the Federal Trade Commission Act (the "FTCA") 15 U.S.C. &#167; 45(a). The FTC&#8217;s guidance for appropriately securing consumers&#8217; personal information is similar to what is required by the HIPAA security regulations. In addition, certain states have enacted laws that govern the privacy and security of health information and other personal information in certain circumstances, some of which are more stringent than HIPAA and many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. Failure to comply with these laws, where applicable, can result in the imposition of significant civil and/or criminal penalties and private litigation as well as reputational harm. For example, the California Consumer Privacy Act (the "CCPA") as amended by the California Privacy Rights Act (the "CPRA") went into effect on January 1, 2023. Also, on January 1, 2023, the Virginia Consumer Data Protection Act ("CDPA") became effective. Further, many additional United States state privacy laws will go into effect throughout 2023: the Colorado Privacy Act ("the CPA") (July 1, 2023); the Connecticut Data Privacy Act (the "CTDPA") (July 1, 2023); and the Utah Consumer Privacy Act (the "UCPA") (December 31, 2023). The CDPA, CPA, CTDPA, and UCPA are substantially similar in scope and contain many of the same requirements and exceptions as the CCPA, including a general exemption for clinical trial data and information governed by HIPAA. Any of these laws may broaden their scope in the future, and similar laws have been proposed on both a federal level and in more than half of the states in the United States. In addition, a number of other states have proposed new privacy laws, some of which are similar to the above discussed recently passed laws. Such proposed legislation, if enacted, may add additional complexity, variation in requirements, restrictions and potential legal risk, require additional investment of resources in compliance programs, impact strategies and the availability of previously useful data and could result in increased compliance costs and/or changes in business practices and policies.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Outside of the United States, we also face stringent privacy and data protection requirements. For example, in Europe, the collection, use, storage, disclosure, transfer, or other processing of personal data, including personal health data in the EEA and the UK is subject to the EU General Data Protection Regulation ("EU GDPR") (with regards to the EEA) and the UK General Data Protection Regulation ("UK GDPR") (with regards to the UK), as well as applicable data protection laws in effect in the Member States of the EEA and in the UK (including the UK Data Protection Act 2018). In this Annual Report, &#8220;GDPR&#8221; refers to both the EU GDPR and the UK GDPR, unless specified otherwise. The GDPR is wide-ranging in scope and imposes numerous requirements on companies that process personal data, including requirements relating to processing health and other sensitive data, obtaining consent of the individuals to whom the personal data relates, providing information to individuals regarding data processing activities, implementing safeguards to protect the security and confidentiality of personal data, providing notification of data breaches, and taking certain measures when engaging third-party processors. The GDPR also imposes strict rules on the transfer of personal data to countries outside the European Union, including the United States, and permits data protection authorities to impose large penalties for violations of the GDPR, including potential fines of up to &#8364;20 million (&#163;17.5 million for the UK GDPR) or 4% of annual global revenues, whichever is greater. The GDPR also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the GDPR. Compliance with the GDPR will be a rigorous and time-intensive process that may increase our cost of doing business or require us to change our business practices, and despite those efforts, there is a risk that we may be subject to fines and penalties, litigation, and reputational harm in connection with our European activities. Data protection authorities from the different EU member states may interpret the GDPR and national laws differently and impose additional requirements, which add to the complexity of processing personal data in the EU.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, various jurisdictions around the world continue to propose new laws that regulate the privacy and/or security of certain types of personal data. Complying with these laws, if enacted, would require significant resources and leave us vulnerable to possible fines, penalties, litigation, and reputational harm if we are unable to comply.</span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Healthcare Reform and Legislative Changes</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The United States and some foreign jurisdictions are considering or have enacted a number of reform proposals to change the healthcare system. There is significant interest in promoting changes in healthcare systems with the stated goals of </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">containing healthcare costs, improving quality, or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by federal and state legislative initiatives, including those designed to limit the pricing, coverage, and reimbursement of pharmaceutical and biological products, especially under government-funded healthcare programs, and increased governmental control of drug pricing.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The ACA, which was enacted in March 2010, substantially changed the way healthcare is financed by both governmental and private insurers in the United States, and significantly affected the pharmaceutical industry. The ACA contains a number of provisions of particular import to the pharmaceutical and biotechnology industries, including, but not limited to, those governing enrollment in federal healthcare programs and expanding enrollment in commercial health plans through new Health Insurance Marketplaces operated by the federal and state governments; a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted, or injected; and annual fees based on pharmaceutical companies&#8217; share of sales to federal healthcare programs. Since its enactment, there have been judicial, Congressional, and executive branch challenges to certain aspects of the ACA, and we expect there will be additional challenges and amendments to the ACA in the future. For example, Congress has considered legislation that would repeal, or repeal and replace, all or part of the ACA. While Congress has not passed comprehensive repeal legislation, it has enacted laws that modify certain provisions of the ACA such as removing penalties, which started on January 1, 2019, for not complying with the ACA&#8217;s individual mandate to carry health insurance, delaying the implementation of certain ACA-mandated fees, and increasing the point-of-sale discount that is owed by pharmaceutical manufacturers who participate in Medicare Part D.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On June 17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA. In addition, President Biden has issued multiple executive orders that have sought to reduce prescription drug costs. It is unclear how other healthcare reform measures of the Biden administration or other efforts, if any, to challenge, repeal or replace the ACA will impact our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, other legislative and regulatory changes have been proposed and adopted in the United States since the ACA was enacted.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For example:</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">The U.S. Budget Control Act of 2011, among other things, included aggregate reductions of Medicare payments to providers of 2% per fiscal year. These reductions went into effect on April 1, 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2031, absent further legislative action.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">The U.S. American Taxpayer Relief Act of 2012 further reduced Medicare payments to several types of providers.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">The Inflation Reduction Act of 2022, or IRA, includes several provisions that will impact our business to varying degrees, including provisions that require Medicare Part D plans to cover with $0 in cost sharing the cost of adult vaccines recommended by the U.S. Advisory Committee on Immunization Practices, or ACIP. The IRA also includes provisions that reduce the out-of-pocket cap for Medicare Part D beneficiaries to $2,000 starting in 2025; impose new manufacturer financial liability on certain drugs in Medicare Part D, allow the U.S. government to negotiate Medicare Part B and Part D price caps for certain high-cost drugs and biologics without generic or biosimilar competition, require companies to pay rebates to Medicare for certain drug prices that increase faster than inflation, and delay the rebate rule that would limit the fees that pharmacy benefit managers can charge. Further, under the IRA, orphan drugs are exempted from the Medicare drug price negotiation program, but only if they have one rare disease designation and for which the only approved indication is for that disease or condition. If a product receives multiple rare disease designations or has multiple approved indications, it will not qualify for the orphan drug exemption. The effects of the IRA on our business and the healthcare industry in general are not yet known.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, there have been several judicial challenges to the 340B drug pricing program, which imposes ceilings on prices that drug manufacturers can charge for medications sold to certain health care facilities. These include challenges to the government&#8217;s reimbursement formula on specified covered outpatient drugs and disputes over potential product diversion through the use of &#8220;contract pharmacies,&#8221; among other issues. It is unclear how these challenges could affect covered hospitals who might purchase our future products and affect the rates we may charge such facilities for our approved products in the future, if any.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Additionally, there has been increasing legislative and enforcement interest in the United States with respect to drug pricing practices. Specifically, there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several U.S. Congressional inquiries and proposed and enacted federal </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, and review the relationship between pricing and manufacturer patient programs. For example, FDA released regulations implementing the section 804 Importation Programs in accordance with the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, which went into effect on November 30, 2020 and which provide guidance for states to build and submit importation plans for drugs from Canada. In January 2024, FDA issued its first approval to Florida for a state plan on importation of certain drugs. CMS has stated drugs imported by states under this rule will not be eligible for federal rebates under Section 1927 of the Social Security Act and manufacturers would not report these drugs for &#8220;best price&#8221; or Average Manufacturer Price purposes. Since these drugs are not considered covered outpatient drugs, CMS further stated it will not publish a National Average Drug Acquisition Cost for these drugs. If implemented, importation of drugs from Canada may materially and adversely affect the price we receive for any of our product candidates. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On November 30, 2020, HHS published a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers. Pursuant to court order, the removal and addition of the aforementioned safe harbors were delayed, and the IRA extended the moratorium on implementation until January 1, 2032. Although a number of these and other proposed measures may require authorization through additional legislation to become effective, and the Biden administration may reverse or otherwise change these measures, both the Biden administration and Congress have indicated that they will continue to seek new legislative measures to control drug costs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Although a number of these and other proposed measures may require additional authorization to become effective, Congress and President Biden have each indicated that they will continue to seek new legislative and/or administrative measures to control drug costs. Additional state and federal healthcare reform measures may be adopted in the future. Further, it is possible that additional governmental action is taken in response to COVID-19. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Employees and Human Capital Resources</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2023, we had 130 full-time and part-time employees, of which 95 were located in the United Kingdom, 34 located in the United States and 1 located in Switzerland. As of December&#160;31, 2023, 62% of our workforce and 54% of our leadership (at Director level and above) were female. In addition, 20% of our workforce were racially or ethnically diverse. Of our full and part-time employees, 31 have Ph.D. or M.D. degrees, and 88 are engaged in research and clinical development activities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A breakdown of the employment statistics as of December&#160;31, 2023 is as follows:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.696%"><tr><td style="width:1.0%"/><td style="width:46.998%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.560%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.439%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.560%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.439%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.560%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.444%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Position</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Male</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Female</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Executives</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Director/Vice President</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">14</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">18</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">32</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Managers</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">15</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">24</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:7.2pt;text-indent:-7.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Scientists and Support Functions</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">24</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">45</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">69</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">50</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">80</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">130</span></td></tr></table></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.696%"><tr><td style="width:1.0%"/><td style="width:46.998%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.560%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.439%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.560%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.439%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.560%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.444%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Demographic</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Male</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Female</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Asian</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">15</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Black, Caribbean, or African</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Mixed, other or multiple ethnic groups</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">White</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">40</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">64</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">104</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">50</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">80</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">130</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing and new employees, advisors and consultants. We engage with our employees in multiple ways </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">including through company-wide events, social events and team events. We also have a bonus scheme and equity incentive plan in which all employees are entitled to participate. The principal purposes of our equity incentive plans are to attract, retain and reward personnel through the grant of equity-based compensation awards. We believe that attracting and retaining talent increases shareholder value and furthers the success of our company by motivating our employees to perform to the best of their abilities and achieve our objectives.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We employ individuals based on their experience and ability, and we are committed to promoting diversity and inclusion in our work environment. We focus on hiring and retaining qualified candidates by promoting a supportive and inclusive working environment for all. We believe that fostering diversity, equity, and inclusion is a key element to discovering, developing, and bringing transformative therapies to patients.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The safety of our workforce, including consultants and visitors to our office/laboratory, has and remained of paramount importance to us. We have a Health and Safety Committee that focuses on implementing policies and training programs to enhance workplace safety. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As we continue to grow, we also intend to expand our overall environmental, social, and governance, or ESG, efforts. In 2022, we assigned oversight for ESG to the Nominating and Governance Committee who were tasked with performing an assessment of our ESG impacts and establishing initiatives. Following this assessment, we have created specific goals and objectives to monitor and improve specific metrics. These include:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.5pt">Environmental &#8211; the impact we have on the environment, including its assessment of carbon footprint and the reporting thereof for new facilities.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.5pt">Social &#8211; the impact we have on society, including the impact on external groups through the development of life-saving products, the impact in low- and middle-income countries and clinical trial diversity. For internal groups the focus is on employees and how Barinthus Bio monitors and maintains gender pay parity, expands employee diversity, enhances engagement and morale, and minimizes staff turnover.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.5pt">Corporate Governance &#8211; how is the company run, to include diversity and inclusion within the company and the board of directors, board independence and the ratio of executive compensation to employee compensation.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Carbon emissions</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The group has calculated the emissions for the year ended December&#160;31, 2023 and 2022 in tons of carbon dioxide equivalent (&#8220;tCO2e&#8221;). The carbon footprint for the group for the years ended December&#160;31, 2023 and 2022 are as follows:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.333%"><tr><td style="width:1.0%"/><td style="width:27.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Scope</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">tCO2e</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">% Total emissions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">tCO2e</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">% Total emissions </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Scope 1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6.54</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5.59</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Scope 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">360.00</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">98%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">107.63</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">95%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">366.54</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">100%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">113.22</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">100%</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For clarity, scope 1 emissions are direct emissions produced from activities owned or controlled by us. Scope 2 emissions are indirect emissions related to the generation of the electricity consumed and purchased by us. We have used the most recent evidence or estimates provided by our energy supply partners to generate our disclosure of emissions for the period. Standard emissions factors from the &#8220;UK Government GHG Conversion Factors for Company Reporting (2023)&#8221; guidance were applied to estimate emissions. Electricity, heating and cooling usage at our leased facilities in the United States and the United Kingdom are responsible for a significant amount of our greenhouse gas emissions, with the remainder due to operations conducted within our laboratory. The increase in emissions is primarily attributable to the relocation of our U.S laboratory and office facilities which completed in June 2023. The relocation provides approximately 19,700 square foot of state-of-the-art wet laboratory and office facilities in Germantown, Maryland. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The group has elected not to include the voluntary disclosure for Scope 3 emissions.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For the year ended December&#160;31, 2023, the split of emissions by geography is as follows:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.212%"><tr><td style="width:1.0%"/><td style="width:57.537%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.464%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.351%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.464%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.351%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.464%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.371%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.798%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Scope</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Location</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">tCO2e</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">% Total emissions </span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Scope 1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">U.K.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.56</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">1</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">U.S.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4.98</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1%</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Scope 2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">U.K.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">94.21</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">26%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">U.S.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">265.79</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">73%</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">366.54</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">100%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="margin-top:12pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:5.75pt">Indicates amount less than one percent</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The group considers that the intensity ratio of tons of carbon dioxide per full-time employee, as a suitable metric for its operations for the years ended December&#160;31, 2023, and 2022 are as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.869%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.054%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Ratio</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">tCO2e /employee</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Average employees</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">tCO2e /employee</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Average employees</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Intensity ratio</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.98</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">123</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.26</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">90</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tons of carbon dioxide per employee has increased year on year, primarily as a result of an increase in the size of our leased facilities in the United States. Additionally, as we have expanded our facilities and increased headcount, more employees have been able to work from the office and therefore consumed more greenhouse gas emissions than in 2022, when many non-laboratory based employees were still working from home due to space limitations at the prior facilities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The directors have established that the Nominations and Corporate Governance Committee are to have oversight of the assessment and strategy on how to reduce our energy consumption and thereby reducing our carbon footprint.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Available Information</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We maintain an internet website at https://www.Barinthusbio.com/ and make available free of charge through our website our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, including exhibits and amendments to those reports filed or furnished pursuant to Sections 13(a) and 15(d) of the Exchange Act of 1934, or the Exchange Act. We make these reports available through our website as soon as reasonably practicable after we electronically file such reports with, or furnish such reports to, the SEC. You can review our electronically filed reports and other information that we file with the SEC on the SEC&#8217;s web site at http://www.sec.gov. We also make available, free of charge on our website, the reports filed with the SEC by our executive officers, directors and 10% stockholders pursuant to Section 16 under the Exchange Act as soon as reasonably practicable after copies of those filings are provided to us by those persons. In addition, we regularly use our website to post information regarding our business, product development programs and governance, and we encourage investors to use our website, particularly the information in the section entitled &#8220;Investors,&#8221; as a source of information about us.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The information on our website is not incorporated by reference into this Annual Report and should not be considered to be a part of this Annual Report. Our website address is included in this Annual Report as an inactive technical reference only.</span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div id="i417e39f5b7bb45b295bb09394310bc8c_22"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;1A. Risk Factors</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Investing in our American Depositary Shares ("ADSs") involves a high degree of risk. You should carefully consider the following risks and uncertainties, together with all other information in this report, including our consolidated financial statements and related notes and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; as well as our other filings with the Securities and Exchange Commission. Our business, results of operations, financial condition, and prospects could also be harmed by risks and uncertainties not currently known to us or that we currently do not believe to be material. If any of the risks actually occur, our business, results of operations, financial condition, and prospects could be harmed. In that event, the market price of our ADSs could decline, and you could lose part or all of your investment.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Risks Related to Our Financial Position and Capital Needs</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">We are a clinical-stage biopharmaceutical company with a limited operating history. We have incurred significant losses since inception. We expect to incur losses for at least the next several&#160;years and may never achieve or maintain profitability.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are a clinical-stage biopharmaceutical company with a limited operating history, and we are in the early stages of our development efforts. Investment in biopharmaceutical product development is highly speculative because it entails substantial upfront capital expenditures and significant risk that any potential product candidate will fail to demonstrate adequate efficacy or an acceptable safety profile, obtain marketing authorization and become commercially viable. We have no products approved for commercial sale and have not generated any revenue from product sales. To date, we have devoted substantially all of our resources to organizing and staffing our company, business planning, raising capital, undertaking preclinical studies and clinical trials of our product candidates, securing related intellectual property rights and conducting discovery, research and development activities for our programs. We have incurred net losses each year since inception through to December&#160;31, 2021. For the year ended December 31, 2022, we generated net income of $5.3 million, primarily as a result of revenues arising from AstraZeneca sales of Vaxzevria and our agreement with OUI. For the year ended December 31, 2023, we incurred net losses of $73.4 million. As of December 31, 2023 and 2022, we had an accumulated deficit of $176.6&#160;million and $103.2 million, respectively, and we do not currently expect profits or positive cash flows from operations in the foreseeable future. We anticipate that our expenses will increase substantially if, and as we:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">seek marketing authorizations for product candidates that successfully complete clinical trials, if any;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">conduct preclinical studies and clinical trials for our current and future product candidates based on our proprietary biologic and synthetic platforms, including the Chimpanzee Adenovirus Oxford ("ChAdOx") and Modified vaccinia Ankara ("MVA"), vectors, SNAP-TI, SNAP-CI and our other technologies;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">expand our operational, financial and management systems and increase personnel, including personnel to support our clinical development, manufacturing and commercialization efforts and our operations as a public company;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">establish our manufacturing capabilities through third parties or by ourselves and scale-up manufacturing to provide adequate supply for clinical trials and commercialization;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">expand, maintain, protect and enforce our intellectual property portfolio;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">establish a sales, marketing, medical affairs and distribution infrastructure to commercialize any products for which we may obtain marketing approval and intend to commercialize on our own or jointly;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">acquire or in-license other product candidates and technologies; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">incur additional legal, accounting and other expenses in operating our business, including the additional costs associated with operating as a public company.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Even if we succeed in commercializing one or more of our product candidates, we will continue to incur substantial research and development costs and other expenditures to develop and market additional product candidates and we may never generate revenue that is significant or large enough to achieve profitability. We may also encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue. Our prior losses and expected future losses have had and will continue to have an adverse effect on our stockholders&#8217; equity and working capital.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Accordingly, our failure to become and remain profitable would decrease the value of our company and could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations. A decline in the value of our company also could cause you to lose all or part of your investment.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">We have not yet generated any material revenue from our product candidates.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Our ability to become profitable depends upon our ability to generate revenue. We do not expect to generate significant revenue from our current or future product candidates unless or until we successfully complete clinical development and obtain marketing authorization for, and then successfully commercialize, at least one of our product candidates.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certain of our product candidates are in the preclinical stages of development and will require additional preclinical studies, and all of our product candidates will require additional clinical development, regulatory review and approval, substantial investment, access to sufficient commercial manufacturing capacity and significant marketing efforts before we can generate any revenue from product sales. We have not yet administered certain of our product candidates to humans </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">and, as such, we face significant translational risk as our product candidates advance into and through the clinical stage, as promising results in preclinical studies may not be replicated in subsequent clinical trials, and testing on animals may not accurately predict human experience. Our ability to generate revenue depends on a number of factors, including, but not limited to:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">timely completion of our manufacturing, preclinical studies and clinical trials, which may be significantly slower or cost more than we currently anticipate and will depend substantially upon the performance of third-party contractors;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">delays out of our control, such as participant willingness to enroll;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">our ability to complete IND, enabling trials and successfully submit INDs or comparable applications, for our product candidates;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">whether we are required by the FDA, the EMA, or the MHRA or similar foreign regulatory authorities, to conduct additional clinical trials or other studies beyond those planned to support the approval and commercialization of our product candidates or any future product candidates;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">our ability to demonstrate to the satisfaction of the FDA and similar foreign regulatory authorities the safety, potency, purity, efficacy and acceptable risk to benefit profile of our product candidates or any future product candidates and such regulatory authorities&#8217; acceptance of our development strategy;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the prevalence, duration and severity of potential side effects or other safety issues experienced with our product candidates or future product candidates, if any;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the timely receipt of necessary marketing approvals from the FDA and similar foreign regulatory authorities;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the willingness of physicians, operators of clinics and patients to utilize or adopt any of our product candidates or future product candidates over alternative or more conventional approaches, including antivirals, immune modulators, siRNA, CRISPR editing, capsid inhibitors, novel entry inhibitors, or other small molecules, RNA, DNA, nanoparticle, VLP, peptide, protein, whole-killed or other vaccine technologies;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the actual and perceived availability, cost, risk profile and side effects and efficacy of our product candidates, if approved, relative to existing and future alternative immunotherapies, therapeutic and prophylactic vaccines and competitive product candidates and technologies; our ability and the ability of third parties with whom we contract to manufacture adequate clinical and commercial supplies of our product candidates or any future product candidates, remain in good standing with regulatory authorities and develop, validate and maintain commercially viable manufacturing processes that are compliant with cGMP;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">our ability to successfully develop a commercial strategy and thereafter commercialize our product candidates or any future product candidates in the United States and internationally, if approved for marketing, reimbursement, sale and distribution in such countries and territories, whether alone or in collaboration with others;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">patient demand for our product candidates and any future product candidates, if approved;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">our ability to establish, maintain, protect and enforce intellectual property rights in and to our product candidates or any future product candidates;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the ability of our licensees and collaborators to develop and commercialize our products effectively;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the risk that some or all of the patients that receive Vaxzevria develop neutralizing antibodies against ChAdOx, which could limit the immunological response from subsequent dosing with one of our product candidates;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the possibility that immunogenicity may not translate into clinical benefit; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the increased costs and complexities associated with manufacturing and</span></div><div><span><br/></span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">funding for the development of product candidates contributed by third parties, such as CRUK, CEPI and CanSino, whether spent directly by them or by grant or other funding into our company.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Many of the factors listed above are beyond our control and could cause us to experience significant delays or prevent us from obtaining marketing authorizations for, or commercializing, our product candidates. Even if we are able to commercialize our product candidates, we may not achieve profitability soon after generating product sales, if ever. If we are unable to generate sufficient revenue through the sale of our product candidates or any future product candidates, we may be unable to continue operations without continued funding.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">If we engage in acquisitions or future strategic partnerships, this may increase our capital requirements, dilute our shareholders, cause us to incur debt or assume contingent liabilities, and subject us to other risks.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We may evaluate acquisitions and strategic partnerships in the future, including licensing or acquiring complementary product candidates, intellectual property rights, technologies or businesses. Any acquisition or strategic partnership may entail numerous risks, including:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">increased operating expenses and cash requirements;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the assumption of indebtedness or contingent liabilities;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the issuance of our equity securities which would result in dilution to our shareholders;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">assimilation of operations, intellectual property, products and product candidates of an acquired company, including difficulties associated with integrating new personnel;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the diversion of our management&#8217;s attention from our existing product programs and initiatives in pursuing such an acquisition or strategic partnership;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">retention of key employees, the loss of key personnel, and uncertainties in our ability to maintain key business relationships;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">risks and uncertainties associated with the other party to such a transaction, including the prospects of that party and their existing products or product candidates to achieve marketing authorizations; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">our inability to generate revenue from acquired intellectual property, technology and/or products sufficient to meet our objectives or even to offset the associated transaction and maintenance costs.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In addition, we may assume or incur debt obligations, incur large one-time expenses and/or acquire intangible assets that could result in significant future amortization expense.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Our limited operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We are a clinical-stage biopharmaceutical company with no approved products and a limited operating history. Our operations to date have been limited to organizing and staffing our company, business planning, raising capital, filing patent applications, identifying potential product candidates, undertaking preclinical studies, in-licensing product candidates for development, and establishing arrangements with third parties for the manufacture of initial quantities of our product candidates and component materials, as well as sponsoring and conducting clinical trials up to Phase 2b. We have not yet demonstrated our ability to successfully complete clinical trials beyond Phase 2b, obtain marketing approvals, manufacture a commercial-scale product or arrange for a third party to do so on our behalf, or conduct sales, marketing and distribution activities necessary for successful product commercialization. Consequently, any predictions you make about our future success or viability may not be as accurate as they could be if we had a longer operating history.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In addition, as a young business, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors. We will need to transition at some point from a company with a research and development focus to a company capable of supporting additional commercial activities. We may not be successful in such a transition.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">We will need to raise additional funding, which may not be available on acceptable terms, or at all. Failure to obtain this necessary capital when needed may force us to delay, limit or terminate our product development efforts or other operations.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We are currently advancing current and future product candidates based on our proprietary biologic and synthetic platforms, including the ChAdOx and MVA vectors, SNAP-TI, SNAP-CI and our other technologies through clinical development. Developing and commercializing products for therapeutic indications is expensive, and we do not expect to generate meaningful product revenues in the foreseeable future.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of December&#160;31, 2023, our cash and cash equivalents were $142.1 million. Based on our current business plan, our management believes that we have sufficient cash to support our operations into the fourth quarter of 2025, without additional financing. Our fundraising efforts to raise additional capital may divert our management from their day-to-day activities, which may adversely affect our ability to develop our platforms. In addition, we cannot guarantee that financing will be available in sufficient amounts or on terms acceptable to us, if at all. Moreover, the terms of any financing may adversely affect the holdings or the rights of our shareholders and the issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market price of our shares to decline. The sale of additional equity or convertible securities would dilute our stockholders. The incurrence of indebtedness would result in increased fixed payment obligations and we may be required to agree to certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">operating restrictions that could adversely impact our ability to conduct our business. We could also be required to seek funds through arrangements with collaborative partners or otherwise at an earlier stage than otherwise would be desirable and we may be required to relinquish rights to some of our technologies or product candidates or otherwise agree to terms unfavorable to us, any of which may have a material adverse effect on our business, operating results and prospects.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If we are unable to obtain funding on a timely basis, we may be required to revise our business plan and strategy, which may result in us significantly curtailing, delaying or discontinuing one or more of our clinical trials, decreasing headcount or may result in our being unable to expand our operations or otherwise capitalize on our business opportunities. As a result, our business, financial condition and results of operations could be materially affected.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Raising additional capital may cause dilution to our shareholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We expect our expenses to increase in connection with our planned operations. Unless and until we can generate a substantial amount of revenue from our product candidates, we expect to finance our future cash needs through public or private equity offerings, debt financings, collaborations, licensing arrangements or other sources, or any combination of the foregoing. In addition, we may seek additional capital due to favorable market conditions or strategic considerations, even if we believe that we have sufficient funds for our current or future operating plans.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">To the extent that we raise additional capital through the sale of ordinary shares, convertible securities or other equity securities, your ownership interest may be diluted, and the terms of these securities could include liquidation or other preferences and anti-dilution protections that could adversely affect your rights as a common shareholder. In addition, debt financing, if available, may result in fixed payment obligations and may involve agreements that include restrictive covenants that limit our ability to take specific actions, such as incurring additional debt, making capital expenditures, creating liens, redeeming shares or declaring dividends, that could adversely impact our ability to conduct our business. In addition, securing financing could require a substantial amount of time and attention from our management and may divert a disproportionate amount of their attention away from day-to-day activities, which may adversely affect our management&#8217;s ability to oversee the development of our product candidates.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If we raise additional funds through collaborations, strategic alliances, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds when needed, we would be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">We may require substantial additional funding in the future. If we are unable to raise capital when needed, we would be compelled to delay, reduce or eliminate our product development programs or commercialization efforts.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Since our inception, we have invested a significant portion of our efforts and financial resources in research and development activities for our platform and our product candidates developed using our platform. Preclinical studies, clinical trials and additional research and development activities will require substantial funds to complete. We expect our expenses to increase in parallel with our ongoing activities, particularly as we continue our preclinical and clinical development activities to identify new product candidates and conduct clinical trials of, and seek marketing approval for, our product candidates. In addition, if we obtain marketing approval for any of our product candidates, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution. Furthermore, we expect to incur significant additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">However, we have estimated our current additional funding needs based on assumptions that may prove to be wrong. Additionally, changing circumstances may cause us to consume capital significantly faster than we currently anticipate, and we may need to spend more money than currently expected because of circumstances beyond our control. We cannot be certain that additional funding will be available on acceptable terms, or at all. Until such time, if ever, as we can generate substantial product revenue, we expect to finance our operations through a combination of public or private equity offerings, debt financings, governmental funding, collaborations, strategic partnerships and alliances or marketing, distribution or licensing arrangements with third parties. If we are unable to raise capital or generate revenue when needed or on attractive terms, we would be forced to delay, reduce or eliminate our discovery and preclinical development programs or any future commercialization efforts.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We had cash and cash equivalents of $142.1 million as of December&#160;31, 2023. Our future capital requirements will depend on many factors, including:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the scope, progress, results and costs of preclinical development and clinical trials for our product candidates;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the extent to which we enter into additional collaboration arrangements with regard to product candidate development or acquire or in-license products or technologies;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the costs, timing and outcome of regulatory review of our product candidates;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the costs of future commercialization activities, including product sales, marketing, manufacturing and distribution, for any of our product candidates for which we receive marketing approval;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">revenue, if any, received from commercial sales of our product candidates, should any of our product candidates receive marketing approval; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the costs of preparing, filing and prosecuting patent applications, obtaining, maintaining, enforcing and protecting our intellectual property rights and defending intellectual property-related claims including litigation costs and any damages awarded in such litigation.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identifying potential product candidates, manufacturing them and conducting preclinical testing and clinical trials is a time-consuming, expensive and uncertain process that takes&#160;years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve product sales. In addition, our product candidates, if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of products that we do not expect to be commercially available for many&#160;years, if at all. Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms, or at all.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Recent volatility in capital markets and lower market prices for many securities may affect our ability to access new capital through sales of shares of our ordinary shares or issuance of indebtedness, which may harm our liquidity, limit our ability to grow our business, pursue acquisitions or improve our operating infrastructure and restrict our ability to compete in our markets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Our operations consume substantial amounts of cash, and we intend to continue to make significant investments to support our business growth, respond to business challenges or opportunities, develop new product candidates, retain or expand our current levels of personnel, enhance our operating infrastructure, and potentially acquire complementary businesses and technologies. Our future capital requirements may be significantly different from our current estimates and will depend on many factors, including the need to:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9679;&#160;&#160;&#160;&#160;finance unanticipated working capital requirements;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9679;&#160;&#160;&#160;&#160;develop or enhance our technological infrastructure and our existing solutions;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9679;&#160;&#160;&#160;&#160;pursue acquisitions or other strategic relationships; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9679;&#160;&#160;&#160;&#160;respond to competitive pressures.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accordingly, we may need to pursue equity or debt financings to meet our capital needs. With uncertainty in the capital markets and other factors, such financing may not be available on terms favorable to us or at all. If we raise additional funds through further issuances of equity or convertible debt securities, our existing stockholders could suffer significant dilution, and any new equity securities we issue could have rights, preferences, and privileges superior to those of holders of our ordinary shares. Any debt financing secured by us in the future could involve additional restrictive covenants relating to our capital-raising activities and other financial and operational matters, which may make it more difficult for us to obtain additional capital and to pursue business opportunities, including potential acquisitions. If we are unable to obtain adequate financing or financing on terms satisfactory to us, we could face significant limitations on our ability to invest in our operations and otherwise suffer harm to our business.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Adverse developments affecting the financial services industry, such as actual events or concerns involving liquidity, defaults, or non-performance by financial institutions or transactional counterparties, could adversely affect our current and projected business operations and its financial condition and results of operations.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actual events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions, transactional counterparties or other companies in the financial services industry or the financial services industry generally, or concerns or rumors about any events of these kinds or other similar risks, have in the past and may in the future lead to market-wide liquidity problems. For example, on March 10, 2023, Silicon Valley Bank was closed by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation ("FDIC") as receiver. Similarly, on March 12, 2023, Signature Bank was swept into receivership.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Although we assess our banking relationships as we believe necessary or appropriate, our access to funding sources and other credit arrangements in amounts adequate to finance or capitalize our current and projected future business operations could be significantly impaired by factors that affect us, the financial institutions with which we have financial arrangements directly, or the financial services industry or economy in general. These factors could include, among others, events such as liquidity constraints or failures, the ability to perform obligations under various types of financial, credit or liquidity agreements or arrangements, disruptions or instability in the financial services industry or financial markets, or concerns or negative expectations about the prospects for companies in the financial services industry. These factors could </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">involve financial institutions or financial services industry companies with which we have financial or business relationships, but could also include factors involving financial markets or the financial services industry generally. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The results of events or concerns that involve one or more of these factors could include a variety of material and adverse impacts on our current and projected business operations and our financial condition and results of operations. These could include, but may not be limited to, the following:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">Delayed access to deposits or other financial assets or the uninsured loss of deposits or other financial assets;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">Delays, inability or reductions in our ability to refund, roll over or extend the maturity of, or enter into new credit facilities or other working capital resources;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">Potential or actual breach of contractual obligations that require us to maintain letters of credit or other credit support arrangements; or</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">Termination of cash management arrangements and/or delays in accessing or actual loss of funds subject to cash management arrangements.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In addition, investor concerns regarding the U.S. or international financial systems could result in less favorable commercial financing terms, including higher interest rates or costs and tighter financial and operating covenants, or systemic limitations on access to credit and liquidity sources, thereby making it more difficult for us to acquire financing on acceptable terms or at all. Any decline in available funding or access to our cash and liquidity resources could, among other risks, adversely impact our ability to meet our operating expenses, financial obligations or fulfill our other obligations, result in breaches of our financial and/or contractual obligations or result in violations of federal or state wage and hour laws. Any of these impacts, or any other impacts resulting from the factors described above or other related or similar factors not described above, could have material adverse impacts on our liquidity and our current and/or projected business operations and financial condition and results of operations. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In addition, any further deterioration in the macroeconomic economy or financial services industry could lead to losses or defaults by our third-party manufacturers or suppliers, which in turn, could have a material adverse effect on our current and/or projected business operations and results of operations and financial condition. For example, a third-party manufacturer or supplier may default under their agreements with us, become insolvent or declare bankruptcy, or determine that they will no longer deal with us as a customer. In addition, a third-party manufacturer or supplier could be adversely affected by any of the liquidity or other risks that are described above as factors that could result in material adverse impacts on us, including but not limited to delayed access or loss of access to uninsured deposits or loss of the ability to draw on existing credit facilities involving a troubled or failed financial institution. Any third-party manufacturer or supplier bankruptcy or insolvency, or any breach or default by a third-party manufacturer or supplier, or the loss of any significant third-party manufacturer or supplier relationships, could result in material losses to us and may have a material adverse impact on our business. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Actual payments we may receive in connection with certain milestones or net sales under the AstraZeneca License Agreement may differ from those described in this Annual Report, and there can be no assurance that we will receive any such payments at all.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We received a share of certain milestones and royalties on net sales of certain vaccines under the research collaboration and exclusive worldwide license agreement (the "AstraZeneca License Agreement"), between Oxford University Innovation Limited ("OUI") and AstraZeneca UK Limited ("AstraZeneca"), through to the second quarter of 2023, however there can be no assurance as to the timing or amount of any such milestones or royalties on future net sales.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In particular, we are not party to the AstraZeneca License Agreement, and we do not have any direct claim against AstraZeneca to receive a share of any milestones or net sales, or any other payments under the AstraZeneca License Agreement. Instead, we are party to the amendment, assignment and revenue share agreement, or the OUI License Agreement Amendment, with OUI, to the license agreement we entered into with OUI in March&#160;2016, pursuant to which OUI agreed to pay us approximately 24% of payments, including royalties and milestones, received by OUI in connection with the commercialization of any ChAdOx1 vector-based or ChAdOx2 vector-based vaccine in the field of SARS-CoV2 covered by or disclosed in the assigned patent application. As a result, we will only receive a share of any milestones or royalties paid on net sales of any such vaccine under the AstraZeneca License Agreement if, and to the extent that, OUI receives a share of any such milestones or royalties pursuant to that agreement.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Our understanding of the terms of the AstraZeneca License Agreement is based solely on an extract of the agreement provided by the parties to that agreement. We are not a party to the AstraZeneca License Agreement and do not have access to a copy of that agreement to verify such extract. In addition, no party to the AstraZeneca License Agreement has confirmed that there are no material terms in that agreement that could adversely impact the economic and other terms of the AstraZeneca License Agreement. Moreover, there can be no assurance that the AstraZeneca License Agreement is an enforceable agreement, that the parties thereto will comply with their obligations under the agreement (including any obligations of AstraZeneca to make milestone or royalty payments to OUI), that the agreement will not be terminated pursuant to its terms or otherwise, or that the terms of the agreement (including royalty rates and other economic terms) will not be modified by the parties in the future. Accordingly, these and other factors could cause amounts received by OUI pursuant to the AstraZeneca License Agreement, and accordingly any share of the revenue under that agreement that we may receive, to fluctuate. Any such fluctuations could be material. Additionally, our understanding of the terms of the AstraZeneca License Agreement is that AstraZeneca is required to notify OUI of OUI&#8217;s shares of milestone and royalty payments within 30 days following the close of a fiscal quarter. OUI is then required to notify us of our share of the payments within 30 days after the end of a quarter when OUI received such milestone or royalty payments from AstraZeneca. If the required notifications are not made in accordance with the terms of the agreements, we may not be able to recognize revenue in the period in which it is earned.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In addition, the announcement of adverse events observed in individuals who receive Vaxzevria and any negative impact on the perceptions of Vaxzevria safety may reduce sales of the vaccine and AstraZeneca may decide not to market Vaxzevria, and therefore reduce the potential payments that we would receive from royalties paid on net sales of Vaxzevria. Any association of Vaxzevria with adverse events, or the perception of such association, may otherwise adversely impact the development of, and our ability to commercialize, any of our product candidates.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Risks Related to Our Business and Industry and Risks Related to Clinical Development</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">If we are unable to advance our current or future product candidates into and through clinical trials, obtain marketing approval or reimbursement and ultimately commercialize any product candidates we develop, or experience significant delays in doing so, our business will be materially harmed.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All of our product candidates are in early stages of development, including our lead product candidates VTP-300 and VTP-200, and as such will require extensive preclinical and clinical testing, as applicable. Product candidates may not meet targeted clinical or safety endpoints during clinical trials such as the MVA-based influenza vaccine candidate, VTP-100, which did not meet defined primary clinical endpoints in two concurrent Phase 2b trials and we subsequently discontinued further development of this program. Our product candidate VTP-1100 in HPV cancer was paused in January 2024 to prioritize the other pipeline candidates already in the clinic, and the advancement of VTP-1100 may depend on our ability to fund or how we prioritize our pipeline. Our ability to generate product revenues, which we do not expect to occur for several years, if ever, will depend heavily on the successful development and eventual commercialization or out-license of the product candidates we develop, which may never occur. Before we are able to generate any revenues from product sales, our current product candidates, and any future product candidates we develop, will require additional preclinical and clinical development, management of preclinical, clinical, and manufacturing activities, marketing approval in the United States and other markets, demonstrating effectiveness to pricing and reimbursement authorities, obtaining sufficient manufacturing supply for both clinical development and commercial production, building of a commercial organization, and substantial investment and significant marketing efforts. The success of our current and future product candidates will depend on several factors, including the following:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">successful completion, with sufficient safety and efficacy profiles, of preclinical studies and clinical trials;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">sufficiency of our financial and other resources to complete the necessary preclinical studies and clinical trials;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">acceptance of INDs or equivalent clinical trial authorizations in other regions for our planned clinical trials or future clinical trials;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">successful enrollment and completion of our ongoing and future clinical trials;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">sufficient data from our clinical program that support an acceptable risk-benefit profile of our product candidates in the intended populations;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">receipt and maintenance of marketing authorizations from applicable regulatory authorities;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">scale-up of our manufacturing processes and formulation of our product candidates for later stages of development and commercialization;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">establishing our own manufacturing capabilities or agreements with third-party manufacturers for clinical supply for our clinical trials and commercial manufacturing, if our product candidate is approved;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">ability to develop product candidate designs and formulations that provide sufficient genetic and thermal stability for long term storage and shipment to meet market requirements;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">entry into collaborations, where needed, to further the development of our product candidates;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">obtaining and maintaining patent and trade secret protection or regulatory exclusivity for our product candidates;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">successfully launching commercial sales of our product candidates, if and when approved;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">acceptance of the product candidate&#8217;s benefits and uses, if and when approved, by patients, the medical community and third- party payors;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the prevalence and severity of adverse events experienced with our product candidates;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">maintaining a continued acceptable benefit/risk profile of the product candidates following authorization;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">effectively competing with other therapies, including new therapies that may be developed and approved;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">obtaining and maintaining healthcare coverage and adequate reimbursement from third-party payors;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">qualifying for, maintaining, enforcing, and defending intellectual property rights and claims; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the risk that foreign regulatory authorities may not authorize our clinical trial protocols and other clinical trial documentation, including manufacturing documentation, even when previously authorized by the FDA, EMA or MHRA, which could lead to a delay in starting such clinical trials. For example, our HBV002 clinical trial conducted in South Korea experienced delays due to additional regulatory review of our clinical protocol. We have limited experience obtaining such approvals in foreign jurisdictions and therefore may need more time to navigate the regulatory process as a result.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We do not have complete control over many of these factors, including certain aspects of clinical development and the regulatory submission process, potential threats to our intellectual property rights and the manufacturing, marketing, distribution and sales efforts of any future collaborator. If we are not successful with respect to one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize the product candidates we develop, which would materially harm our business. We have no control over third-party use of ChAdOx and MVA technologies outside of our exclusively licensed field under license from OUI, and such third-party use could have a negative impact on our ability to develop current and future product candidates, which would materially harm our business.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Clinical development involves a lengthy and expensive process with uncertain outcomes, and results of earlier preclinical studies and clinical trials may not be predictive of future clinical trial results. We may encounter substantial delays in clinical trials, or may not be able to conduct or complete clinical trials on the expected timelines, if at all. If our preclinical studies and clinical trials are not sufficient to support marketing authorization of any of our product candidates, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development of such product candidate.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We may experience delays in obtaining the FDA&#8217;s or other regulatory agencies authorization to initiate clinical trials under future INDs, completing ongoing preclinical studies of our other product candidates, and initiating our planned preclinical studies and clinical trials. Additionally, we cannot be certain that preclinical studies or clinical trials for our product candidates will begin on time, not require redesign, enroll an adequate number of participants on time, or be completed on schedule, if at all. We may experience numerous adverse or unforeseen events during, or as a result of, preclinical studies and clinical trials that could delay or prevent our ability to receive marketing authorization or commercialize our product candidates, including:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">we may receive feedback from regulatory authorities that requires us to modify the design of our clinical trials;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">new treatments may become standard of care during the process of completing a clinical trial, which may impact the initial clinical trial design or future patient care pathways;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">significant changes in relevant regulatory requirements may cause a delay in the start of a clinical trial, due to additional requirements needing to be met;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">clinical trials of our product candidates may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon our research efforts for our other product candidates;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">clinical trials of our product candidates may not produce differentiated or clinically significant results across infectious diseases, cancers and autoimmune diseases;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the number of participants required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate or participants may drop out of our clinical trials at a higher rate than we anticipate;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">our third-party contractors may fail to comply with regulatory requirements, fail to maintain adequate quality controls or be unable to provide us with sufficient or timely product supply to conduct and complete preclinical studies or clinical trials of our product candidates in a timely manner, or at all;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">we or our investigators might have to suspend or terminate clinical trials of our product candidates for various reasons, including non-compliance with regulatory requirements, a finding that our product candidates have undesirable side effects or other unexpected characteristics or a finding that the participants are being exposed to unacceptable health risks;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the cost of clinical trials of our product candidates may be greater than we anticipate, for example, if we experience delays or challenges in identifying participants with the eligibility criteria required for our clinical trials, we may have to reimburse sites for the cost of testing of additional participants in order to encourage enrollment of additional participants;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the quality of our product candidates or other materials necessary to conduct preclinical studies or clinical trials of our product candidates may be insufficient or inadequate, and any transfer of manufacturing activities may require unforeseen manufacturing or formulation changes;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">regulators may revise the requirements for approving our product candidates, or such requirements may not be as we anticipate; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">future collaborators may conduct clinical trials in ways they view as advantageous to them but that are suboptimal for us.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In addition, the ChAdOx vectors are currently being evaluated in clinical trials outside of our licensed fields conducted by Oxford and other third parties to which OUI has granted licenses. We have no control over these other clinical trials and any adverse results in these clinical trials could impact public perception and regulatory approval of our product candidates. Even after any of our product candidates obtain regulatory marketing authorization, the announcement of adverse events observed in individuals who receive these products may impact public perception and may result in increased regulatory scrutiny across our platform. For example, in March 2021, several countries announced plans to either temporarily suspend the use of a particular batch of Vaxzevria or the use of Vaxzevria altogether following reports of very rare thromboembolic events in people following vaccination. While the EMA subsequently issued an update confirming the overall risk-benefit profile of Vaxzevria remains positive, and Vaxzevria later received full marketing authorization in the EU in November 2022, the applicable regulatory authorities continue to assess available safety data as Vaxzevria continues to be administered and have made recommendations regarding updates to the vaccine&#8217;s labeling and use in certain populations. These recommendations may continue to evolve, and these types of announcements may affect public perception of the safety of Vaxzevria, which may extend to product candidates we are developing. Other very rare events have been reported in people who have received Vaxzevria, including thrombocytopenia (low platelet numbers in the blood), capillary leak syndrome, and neurological syndromes such as Guillain Barre Syndrome and transverse myelitis. Perception about the efficacy of Vaxzevria, such as its effectiveness against emerging COVID-19 variants, may also impact perception of our product candidates. Additionally, these announcements may lead to additional inquiries or scrutiny from regulators on whether similar safety or efficacy signals have been observed with our other candidates. If we are required to conduct additional clinical trials or other testing of our product candidates beyond those that we currently contemplate, if we are unable to successfully complete clinical trials of our product candidates or other testing, if the results of these trials or tests are not positive or are only moderately positive or if there are safety concerns, our business and results of operations may be adversely affected and we may incur significant additional costs.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We could also encounter delays if a clinical trial is suspended or terminated by us, by the IRBs, or ethics committees of the institutions in which such clinical trials are being conducted, or by the FDA or other regulatory authorities, or suspended or terminated based on recommendations by the Data Safety Monitoring Board or equivalent for such clinical trial.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Such authorities may suspend or terminate a clinical trial due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical trial protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from the product candidates, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. In addition, any disclosure of negative data of clinical trials being conducted by our collaborators could have an adverse impact on our business.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Moreover, principal investigators for our future clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA or comparable foreign regulatory authorities. The FDA or comparable foreign regulatory authority may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of the clinical trial. The FDA or comparable foreign regulatory authority may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA or comparable foreign regulatory authority, as the case may be, and may ultimately lead to the denial of marketing approval of one or more of our product candidates.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If we experience delays in the completion of any preclinical study or clinical trial of our product candidates, or our preclinical studies or clinical trials are terminated, the commercial prospects of our product candidates may be harmed, and our ability to generate revenues from any of these product candidates will be delayed or not realized at all. In addition, any delays in completing our preclinical studies or clinical trials may increase our costs, slow down our product candidate development and authorization procedure and jeopardize our ability to commence product sales and generate revenues. Any of these occurrences may significantly harm our business, financial condition and prospects. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of marketing authorization for our product candidates. If one or more of our product candidates generally prove to be ineffective, unsafe or commercially unviable, our entire pipeline may have little, if any, value, which would have a material and adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Interim, &#8220;topline,&#8221; and preliminary data from our clinical trials that we announce or publish from time to time may change as more participant data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">From time to time, we may publicly disclose preliminary or topline data from our preclinical studies and clinical trials, which is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the more complete data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the topline or preliminary results that we report may differ from future results of the same studies or clinical trials, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Topline data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, topline data should be viewed with caution until the final data are available. From time to time, we may also disclose interim data from our clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as participant enrollment continues and more participant data become available or as participants from our clinical trials continue other treatments for their disease. Adverse differences between preliminary or interim data and final data could significantly harm our business prospects. Further, disclosure of interim data by us or by our competitors could result in volatility in the price of our ADSs.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In addition, the ChAdOx vectors are currently being evaluated in clinical trials conducted by Oxford and other third parties to which Oxford has granted licenses. We have no control over these other clinical trials and any adverse results in these clinical trials could impact public perception and regulatory approval of our product candidates. The information these third parties choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and shareholders may not agree with what these third parties determine is material or otherwise appropriate information to include in their disclosure. Further, others, including regulatory authorities, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and shareholders may not agree with what we determine is material or otherwise appropriate information to include in our disclosure.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If the interim, topline, or preliminary data that we report differ from more complete results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain marketing authorization for, and commercialize, our product candidates may be harmed, which could harm our business, operating results, prospects or financial condition.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Our product candidates are based on a novel approach to the treatment of infectious disease, autoimmunity and cancer, which makes it difficult to predict the time and cost of product candidate development.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We have concentrated our research and development efforts on components of our proprietary platforms to develop product candidates that stimulate powerful, targeted immune responses against pathogens and tumor cells, which is a novel approach. Our future success depends on the successful development of these platforms. There can be no assurance that any development problems we experience in the future will not cause significant delays or unanticipated costs, or that such development problems can be solved. Should we encounter development problems, including unfavorable preclinical or clinical trial results, the FDA or foreign regulatory authorities may refuse to approve our product candidates, or may require additional information, tests, or trials, which could significantly delay product development and significantly increase our development costs. Moreover, even if we are able to provide the requested information or trials to the FDA, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">there would be no guarantee that the FDA would accept them or approve our product candidates. We may also experience delays in developing a sustainable, reproducible and scalable manufacturing process, or developing other testing and manufacturing methods, which may prevent us from completing our clinical trials or commercializing our product candidates on a timely or profitable basis, if at all.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In addition, the clinical trial requirements of the FDA and comparable foreign regulatory authorities and the criteria these regulators use to determine the safety and efficacy of a product candidate vary substantially according to the type, complexity, novelty and intended use and market of the potential products. The FDA and comparable foreign regulatory authorities have limited experience with the approval of novel immunotherapies. Any novel immunotherapies that are approved may be subject to extensive post- approval regulatory requirements, including requirements pertaining to manufacturing, distribution and promotion. We may need to devote significant time and resources to compliance with these requirements.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Difficulty in enrolling participants could delay or prevent clinical trials of our product candidates and prevent us from realizing the full commercial potential of any products we may develop.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identifying and qualifying participants to participate in clinical trials of our product candidates is critical to our success. The timing of completion of our clinical trials depends in part on the speed at which we can recruit participants to participate in testing our product candidates, and we may experience delays in our clinical trials if we encounter difficulties in enrollment. We may not be able to initiate or continue clinical trials for our product candidates if we are unable to locate and enroll a sufficient number of eligible participants to participate in these trials as required by the FDA, the EMA or other foreign regulatory authorities. For example, randomized clinical controlled trials for MERS are difficult due to the sporadic and low incidence of cases. Our ability to enroll participants may be significantly delayed when potential participants for our clinical trials have had previous exposure to the ChAdOx1 vector, as we may not be able to enroll these individuals in a clinical trial or their enrollment may be delayed due to the concern that neutralizing antibodies might be present for some time after ChAdOx exposure. For example, we may not be able to enroll or may need to delay the enrollment of potential subjects who received the Vaxzevria vaccine. Although we believe the presence and impact of such neutralizing antibodies is transient, we do not have full data on this yet and our assessment may change. The initiation of our Phase 1/2a clinical trial for VTP-200, our Phase 1b/2a clinical trial for VTP-300 and our Phase 1/2a clinical trial for VTP-600, were delayed due to COVID-19. We cannot anticipate the next pandemic or how that may or may not impact future clinical trial enrollment. In addition, some of our competitors have ongoing clinical trials for product candidates that treat the same indications as our product candidates, and participants who would otherwise be eligible for our clinical trials may instead enroll in clinical trials of our competitors&#8217; product candidates.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The enrollment of patients and participants further depends on many factors, including:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the phase of clinical testing;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the proximity of participants to clinical trial sites;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the increased inconvenience to patients by participating in a clinical trial, such as increased doctor visits, missed work, travel costs and time;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the design of the clinical trial, including the number of site visits, whether the clinical trial includes a placebo arm and invasive assessments required;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">our ability to recruit clinical trial investigators with the appropriate competencies and experience;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">our ability to obtain and maintain participant consents;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">reporting of the preliminary results of any of our clinical trials;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the risk that some or all of the patients that receive Vaxzevria develop neutralizing antibodies against ChAdOx, which could limit the immunogenicity from subsequent dosing with one of our product candidates;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the risk that participants enrolled in clinical trials will drop out of the clinical trials before clinical trial completion; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">factors we may not be able to control, such as potential pandemics that may limit participants, principal investigators or staff or clinical site availability (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">e.g.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, the COVID-19 pandemic).</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Since the number of qualified clinical investigators is limited, we expect to conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of participants who are available for our clinical trials at such clinical trial sites. Moreover, because certain of our product candidates represent a departure from more commonly used methods for treatment of disease, particularly in cancer, and because certain of our product candidates have not been tested in humans before, potential participants and their doctors may be inclined to use conventional therapies, rather than enroll participants in a future clinical trial.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="margin-bottom:12pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If we experience delays in the completion or termination of any clinical trial of our product candidates, the commercial prospects of our product candidates will be harmed, and our ability to generate product revenue from any of these product candidates could be delayed or prevented.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Our product candidates may cause serious adverse events, serious side effects or have other properties that could halt their clinical development, prevent their marketing authorization, require expansion of the trial size, limit their commercial potential or result in significant negative consequences.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Serious side effects caused by our product candidates could cause us or regulatory authorities, including IRBs and ethics committees, to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of marketing authorization by the FDA, the EMA or other comparable foreign regulatory authorities. Further, clinical trials by their nature utilize a sample of the potential patient population. Because of our dose escalation design for our clinical trials, undesirable side effects in initial cohorts could also result in the need to expand the size of our clinical trials, increasing the expected costs and timeline of our clinical trials. Additionally, because certain of our product candidates, including Vaxzevria, have been administered to substantial numbers of participants on a more rapid basis than is standard in clinical trials, undesirable side effects could result in a negative impact across a larger participant population. Results of our trials could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics. If we do observe serious side effects in our clinical trials, our ongoing clinical trials may be halted or put on clinical hold prior to completion if there is an unacceptable safety risk for participants.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If unacceptable toxicities arise in the development of our product candidates, we could suspend or terminate our trials or the FDA, the EMA or other comparable foreign regulatory authorities, or local regulatory authorities such as IRBs or ethics committees, could order us to cease clinical trials. Competent national health authorities, such as the FDA, could also deny approval of our product candidates for any or all targeted indications. Even if the side effects presented do not preclude the product from obtaining or maintaining marketing authorization, treatment-related side effects could also affect participant recruitment or the ability of enrolled participants to complete the trial or result in potential product liability claims. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">We intend to develop certain of our product candidates in combination with other therapies, which exposes us to additional risks.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We intend to develop certain of our product candidates in combination with one or more other approved therapies, such as anti-PD-1 antibodies and other checkpoint inhibitors to treat certain cancers and chronic infections. Even if any product candidate we develop were to receive marketing authorization or be commercialized for use in combination with other existing therapies, we would continue to be subject to the risks that the FDA, the EMA or comparable foreign regulatory authorities outside of the United States could revoke approval of the therapy used in combination with our product or that safety, efficacy, manufacturing or supply issues could arise with any of those existing therapies. If the therapies we use in combination with our product candidates are replaced as the standard of care for the indications we choose for any of our product candidates, the FDA, the EMA or comparable foreign regulatory authorities may require us to conduct additional clinical trials. The occurrence of any of these risks could result in our own products, if approved, being removed from the market or being less successful commercially.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We also may choose to evaluate our current product candidates and any other future product candidates in combination with one or more therapies that have not yet been approved for marketing by the FDA, the EMA or comparable foreign regulatory authorities. We will not be able to market and sell our current product candidates or any product candidate we develop in combination with any unapproved therapies for a combination indication if that unapproved therapy does not ultimately obtain marketing approval either alone or in combination with our product. In addition, unapproved therapies face the same risks described with respect to our product candidates currently in development and clinical trials, including the potential for serious adverse effects, delay in their clinical trials and lack of FDA approval.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If the FDA, the EMA or comparable foreign regulatory authorities do not approve these other products or revoke their approval of, or if safety, efficacy, quality, manufacturing or supply issues arise with, the products we choose to evaluate in combination with our product candidate we develop, we may be unable to obtain approval of or market such combination therapy.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Risks Related to Our Approach</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">The market opportunities for certain of our oncology product candidates may be relatively small as it may be limited to those patients who are ineligible for or have failed prior treatments and our estimates of the prevalence of our target patient populations may be inaccurate.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer therapies are sometimes characterized by line of therapy (first line, second line, third line, fourth line, etc.), and the regulatory authorities, including the FDA, often approve new therapies initially only for a particular line or lines of use. When cancer is detected early enough, first line therapy is sometimes adequate to cure the cancer or prolong life without a cure. Whenever first line therapy, usually chemotherapy, antibody drugs, tumor-targeted small molecules, hormone </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">therapy, radiation therapy, surgery, or a combination of these, proves unsuccessful, second line therapy may be administered. Second line therapies often consist of more chemotherapy, radiation, antibody drugs, tumor-targeted small molecules, or a combination of these. Third line therapies can include chemotherapy, antibody drugs and small molecule tumor-targeted therapies, more invasive forms of surgery and new technologies. We expect to seek approval of VTP-600 as a component of first line therapy but we expect to seek approval of our other oncology product candidates initially as second or third line therapy, for use in patients with relapsed or refractory metastatic cancer. Subsequently, for those product candidates that prove to be sufficiently safe and beneficial as third line or second line therapies, if any, we would expect to seek approval as earlier line therapies, but there is no guarantee that our product candidates, even if approved as a second or third line of therapy, would be approved for an earlier line of therapy, and, prior to any such approvals, we may have to conduct additional clinical trials.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Our projections of both the number of people who have the infectious diseases and cancers we are targeting, as well as the subset of people with these infectious diseases and cancers in a position to receive a particular line of therapy and who have the potential to benefit from treatment with our product candidates, are based on our beliefs and estimates. These estimates have been derived from a variety of sources, including scientific literature, commissioned reports, surveys of clinics, patient foundations or market research, and may prove to be incorrect. Further, new therapies may change the estimated incidence or prevalence of these cancers and chronic infections. The number of patients may turn out to be lower than expected. Additionally, the potentially addressable patient population for our product candidates may be limited or may not be amenable to treatment with our product candidates. Even if we obtain significant market share for our product candidates within our addressable patient population, because the potential target populations are small, we may never achieve profitability without obtaining marketing authorization for additional indications, including use as first or second line therapy.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Negative developments in the fields of infectious disease and immuno-oncology could damage public perception of any of our product candidates and negatively affect our business.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The commercial success of our product candidates will depend in part on public acceptance of the use of immunotherapies and viral vector-based antigen-delivery platforms. Adverse events in clinical trials of VTP-300 and VTP-200, or in clinical trials of similar products developed by others and the resulting publicity, as well as any other negative developments in the field of infectious disease and immuno-oncology that may occur in the future, including in connection with competitor therapies, could result in a decrease in demand for any product candidates that we may develop. These events could also result in the suspension, discontinuation, or clinical hold of or modification to our clinical trials. If public perception is influenced by claims that the use of cancer immunotherapies is unsafe, whether related to our therapies or those of our competitors, our product candidates may not be accepted by the general public or the medical community and potential clinical trial participants may be discouraged from enrolling in our clinical trials. In addition, responses by national or state governments to negative public perception may result in new legislation or regulations that could limit our ability to develop or commercialize any product candidates, obtain or maintain marketing authorization or otherwise achieve profitability. More restrictive statutory regimes, government regulations or negative public opinion would have an adverse effect on our business, financial condition, prospects and results of operations and may delay or impair the development and commercialization of our product candidates or demand for any products we may develop. As a result, we may not be able to continue or may be delayed in conducting our development programs.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Our present product candidates consist of modified viruses. Adverse developments in clinical trials of other immunotherapy products based on viruses, such as oncolytic viruses, may result in a disproportionately negative effect for our platform as compared to other products in the field of infectious disease and immuno-oncology that are not based on viruses. Future negative developments in the biopharmaceutical industry could also result in greater governmental regulation, stricter labeling requirements and potential regulatory delays in the testing or approvals of our products. Any increased scrutiny could delay or increase the costs of obtaining marketing approval for our product candidates.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">We may not be successful in our efforts to identify and successfully commercialize additional product candidates.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Part&#160;of our strategy involves researching and developing novel product candidates. We have developed a pipeline of product candidates and intend to pursue clinical development of additional product candidates. The process by which we identify product candidates may fail to yield product candidates for clinical development for a number of reasons, including those discussed in these risk factors and also:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">we may not be able to assemble sufficient resources to acquire or discover additional product candidates;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">competitors may develop alternatives that render our potential product candidates obsolete or less attractive;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">potential product candidates we develop may nevertheless be covered by third parties&#8217; patents or other exclusive rights;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">potential product candidates may, on further study, be shown to have harmful side effects, toxicities or other characteristics that indicate that they are unlikely to be products that will receive marketing approval and achieve market acceptance;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">potential product candidates may not be effective in treating their targeted diseases or symptoms;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the market for a potential product candidate may change so that the continued development of that product candidate is no longer reasonable;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">a potential product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all; or</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the regulatory pathway for a potential product candidate is highly complex and difficult to navigate successfully or economically.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developing, obtaining marketing authorization for and commercializing additional product candidates will require substantial additional funding and is prone to the risks of failure inherent in medical product development. We cannot provide you any assurance that we will be able to successfully advance any of these additional product candidates through the development process.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We may choose to focus our efforts on and allocate resources to a potential product candidate that ultimately proves to be unsuccessful, or to license or purchase a marketed product that does not meet our financial expectations. As a result, we may fail to capitalize on viable commercial products or profitable market opportunities, be required to forego or delay pursuit of opportunities with other product candidates or other diseases that may later prove to have greater commercial potential, or relinquish valuable rights to such product candidates through collaboration, licensing or other royalty arrangements in cases in which it would have been advantageous for us to retain sole development and commercialization rights. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products. If we are unable to evaluate the commercial potential or target market for a particular product candidate, identify and successfully commercialize additional suitable product candidates, this would adversely impact our business strategy and our financial position.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Risks Related to Sales, Marketing and Competition</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">We face substantial competition in an environment of rapid technological change, which may result in others discovering, developing, obtaining marketing authorization approval or commercializing products before or more successfully than we do, which may adversely affect our financial condition and our ability to successfully market or commercialize our product candidates.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The biotechnology and pharmaceutical industries utilize rapidly advancing technologies and are characterized by intense competition. While we believe that our scientific knowledge, platform technology and development expertise provide us with competitive advantages, we face potential competition from many different sources, including major pharmaceuticals, specialty pharmaceuticals and biotechnology companies, academic institutions and government agencies, as well as public and private research institutes that conduct research, development, manufacturing and commercialization. Many of our competitors have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, marketing authorizations and product marketing than we do. In addition, many of these competitors are active in seeking patent protection and licensing arrangements in anticipation of collecting royalties for use of technology that they have developed. Our competitors may compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and participant registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. As a result, our competitors may discover, develop, license or commercialize products before or more successfully than we do.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future. Specifically, we expect that our product candidates will compete against alternative or more conventional approaches, including antivirals, immune modulators, antisense oligonucleotides, siRNA, CRISPR editing, capsid inhibitors, novel entry inhibitors, or other small molecules, RNA, DNA, nanoparticle, VLP, peptide, protein, whole-killed vaccines or other technologies.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If our product candidates are approved for the indications for which we are currently conducting or planning clinical trials, they will likely compete with the competitor products mentioned above and with other products that are currently in development. Key product features that would affect our ability to effectively compete with other therapeutics include the safety, efficacy, formulation, stability, and convenience of our products. Our competitors may obtain patent protection or other intellectual property rights that limit our ability to develop or commercialize our product candidates. The availability of reimbursement from government and other third-party payors will also significantly affect the pricing and competitiveness of our products. Our competitors may also obtain marketing authorizations from the FDA or other regulatory authorities for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Risks Related to the Development of Our Product Candidates</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Our preclinical studies and clinical trials may fail to demonstrate adequately the safety, potency, purity, and efficacy of any of our product candidates, which would prevent or delay development, marketing authorization and commercialization. Furthermore, success in preclinical studies or clinical trials may not be indicative of results in future clinical trials for the same or other product candidates.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Before obtaining marketing authorization for the commercial sale of our product candidates, we must demonstrate the safety, purity and potency of our investigational biologics for use in each target indication through lengthy, complex and expensive preclinical studies and clinical trials. Preclinical and clinical testing is expensive and can take many&#160;years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the preclinical study and clinical trial processes, and, because our product candidates are in an early stage of development, there is a high risk of failure and we may never succeed in developing marketable products.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The results of preclinical studies and early clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials. Although product candidates may demonstrate promising results in preclinical studies and early clinical trials, they may not prove to be effective in subsequent clinical trials. For example, testing on animals occurs under different conditions than testing in humans and therefore, the results of animal studies may not accurately predict human experience. There is typically an extremely high rate of attrition from the failure of product candidates proceeding through preclinical studies and clinical trials.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product candidates in later stages of clinical trials may fail to show the desired risk-benefit profile despite having progressed through preclinical studies and initial clinical trials. Likewise, early, smaller-scale clinical trials may not be predictive of eventual safety or effectiveness in large-scale pivotal clinical trials. VTP-100 demonstrated tolerability and immunogenicity during small Phase 1 clinical trials but did not demonstrate sufficient clinical activity during adequately powered Phase 2b clinical trials to warrant continued development of this product candidate. A number of companies in the biopharmaceutical industry have suffered significant setbacks in later phase clinical trials due to lack of potency or efficacy, insufficient durability of potency or efficacy or unacceptable safety issues, notwithstanding promising results in earlier trials. The vast majority of product candidates that commence preclinical studies and early phase clinical trials are never approved as products.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Any preclinical studies or clinical trials that we may conduct may not demonstrate the safety, potency, purity and efficacy necessary to obtain regulatory authorization to market our product candidates. If the results of our ongoing or future preclinical studies and clinical trials are inconclusive with respect to the safety, potency, purity, and efficacy of our product candidates, if we do not meet the clinical endpoints with statistical and clinically meaningful significance, or if there are safety concerns associated with our product candidates, we may be prevented or delayed in obtaining marketing authorization for certain of our product candidates. In some instances, there can be significant variability in safety, potency, purity, or efficacy results between different preclinical studies and clinical trials of the same product candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, changes in and adherence to the clinical trial protocols and the rate of dropout among clinical trial participants. While we have not yet initiated clinical trials for certain of our product candidates, such as VTP-1000, and are in early stages of clinical trials for certain of our product candidates, VTP-300, VTP-500, VTP-200, VTP-400, VTP-850 and VTP-600, as is the case with all novel immunotherapeutics and viral-vector based antigen-delivery platforms, it is likely that there may be side effects associated with their use. Results of our trials could reveal a high and unacceptable severity and prevalence of these side effects. In such an event, our trials could be suspended or terminated and the FDA or comparable foreign regulatory authorities could order us to cease further development of or deny authorization of certain of our product candidates for any or all targeted indications. Treatment-related side effects could also affect participant recruitment or the ability of enrolled participants to complete the trial or result in potential product liability claims. Any of these occurrences may harm our business, financial condition and prospects significantly.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additionally, some of the clinical trials we conduct may be open-label in trial design and may be conducted at a limited number of clinical sites on a limited number of patients. An &#8220;open-label&#8221; clinical trial is one where both the patient and investigator know whether the patient is receiving the investigational product candidate or either an existing approved drug or placebo. Most typically, open-label clinical trials test only the investigational product candidate and sometimes may do so at different dose levels. Open-label clinical trials are subject to various limitations that may exaggerate any therapeutic effect as patients in open-label clinical trials are aware when they are receiving treatment. Open-label clinical trials may be subject to a &#8220;patient bias&#8221; where patients perceive their symptoms to have improved merely due to their awareness of receiving an experimental treatment. In addition, open-label clinical trials may be subject to an &#8220;investigator bias&#8221; where those assessing and reviewing the physiological outcomes of the clinical trials are aware of which patients have received treatment and may interpret the information of the treated group more favorably given this knowledge. The results from an open-label trial may not be predictive of future clinical trial results with any of our product candidates for which we include an open-label clinical trial when studied in a controlled environment with a placebo or active control.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Even if we obtain marketing authorization for our product candidates, the products may not gain market acceptance among physicians, patients, hospitals, cancer treatment centers and others in the medical community.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The use of novel immunotherapeutics, nanoparticle and viral-vector based product candidates to target the treatment and prevention of infectious diseases, and cancer and autoimmune diseases is a recent development and may not become </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">broadly accepted by physicians, patients, hospitals, cancer treatment centers and others in the medical community. Various factors will influence whether our product candidates are accepted in the market, including:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the clinical indications for which our product candidates are licensed;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">physicians, hospitals, cancer treatment centers and patients considering our product candidates as a safe and effective treatment;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the potential and perceived advantages of our product candidates over alternative treatments, including the adoption of our treatment as the standard of care;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">our ability to demonstrate the advantages of our product candidates over other vaccines and cancer, or chronic infectious disease or immune tolerance disease medicines;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the prevalence and severity of any side effects;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the prevalence and severity of any side effects for other immunotherapeutics and public perception of other immunotherapeutics;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the prevalence and severity of any side effects for other viral-vector based antigen-delivery platforms and public perception of other viral-vector based antigen-delivery platforms;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">The prevalence and severity of any side effects for other nanoparticle-based therapeutics and public perception of other nanoparticle-based therapeutics</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">product labeling or product insert requirements of the FDA or other regulatory authorities;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">limitations or warnings contained in the approved labeling;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the timing of market introduction of our product candidates as well as competitive products;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the cost of treatment in relation to alternative treatments;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the availability of adequate coverage, reimbursement and pricing by third-party payors and government authorities;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the willingness of patients to pay out-of-pocket in the absence of coverage by third-party payors and government authorities;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">relative convenience and ease of administration, including as compared to alternative treatments and competitive therapies; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the effectiveness of our sales and marketing efforts.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If our product candidates are licensed but fail to achieve market acceptance among physicians, patients, hospitals, cancer treatment centers or others in the medical community, we will not be able to generate significant revenue.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In addition, although our product candidates differ in certain ways from other immunotherapeutic and viral-vector based approaches, serious adverse events or deaths in other clinical trials involving immunotherapeutic and viral-vector based product candidates, even if not ultimately attributable to our product or product candidates, could result in increased government regulation, unfavorable public perception and publicity, potential regulatory delays in the testing or licensing of our product candidates, stricter labeling requirements for those product candidates that are licensed, and a decrease in demand for any such product candidates.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Even if our products achieve market acceptance, we may not be able to maintain that market acceptance over time if new products or technologies are introduced that are more favorably received than our products, are more cost effective or render our products obsolete.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">We currently have no marketing and sales organization and have no experience in marketing products. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our product candidates, if approved, we may not be able to generate product revenue.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We currently have no sales, marketing or distribution capabilities and have no experience in marketing products. We intend to develop an in-house marketing organization and sales force, which will require significant capital expenditures, management resources and time. We will have to compete with other pharmaceutical and biotechnology companies to recruit, hire, train and retain marketing and sales personnel. There are risks involved with both establishing our own sales </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">and marketing capabilities and entering into arrangements with third parties to perform these services. For example, recruiting and training a sales force is expensive and time-consuming and could delay any product launch.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If we are unable or decide not to establish internal sales, marketing and distribution capabilities, we will pursue arrangements with third-party sales, marketing, and distribution collaborators regarding the sales and marketing of our products, if approved. However, there can be no assurance that we will be able to establish or maintain such arrangements on favorable terms or if at all, or if we are able to do so, that these third-party arrangements will provide effective sales forces or marketing and distribution capabilities. Any revenue we receive will depend upon the efforts of such third parties, which may not be successful. We may have little or no control over the marketing and sales efforts of such third parties and our revenue from product sales may be lower than if we had commercialized our product candidates ourselves. We also face competition in our search for third parties to assist us with the sales and marketing efforts of our product candidates.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">There can be no assurance that we will be able to develop in-house sales and distribution capabilities or establish or maintain relationships with third-party collaborators to commercialize any product in the United States or overseas.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Insurance policies are expensive and protect us only from some business risks, which leaves us exposed to significant uninsured liabilities.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We do not carry insurance for all categories of risk that our business may encounter. Some of the policies we currently maintain include general liability, employment practices liability, property, umbrella, and directors&#8217; and officers&#8217; insurance.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance coverage is becoming increasingly expensive and in the future we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. We do not carry specific biological or hazardous waste insurance coverage, and our property, casualty and general liability insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination. Accordingly, in the event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources, and our clinical trials or marketing authorizations could be suspended.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We also expect that operating as a public company will make it more difficult and more expensive for us to obtain director and officer liability insurance, and we may be required to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. As a result, it may be more difficult for us to attract and retain qualified people to serve on our board of directors, our board committees or as executive officers. We do not know, however, if we will be able to maintain existing insurance with adequate levels of coverage. Any significant uninsured liability may require us to pay substantial amounts, which would adversely affect our cash position and results of operations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Risks Related to Our Reliance on Third Parties</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">We rely, and expect to continue to rely, on third parties to conduct certain of our preclinical studies and clinical trials. If these third parties do not properly and successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain marketing authorizations for, or commercialize, our product candidates and our business could be substantially harmed.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We utilize and depend, and expect to continue to utilize and depend, upon independent investigators and collaborators, such as medical institutions, contract research organizations ("CROs"), contract manufacturing organizations ("CMOs"), and strategic partners to conduct and support certain of our preclinical studies and clinical trials under agreements with us. For example, we are dependent on our regional partner, CanSino Biologics, to conduct a Phase 1 clinical trial of VTP-400 for herpes zoster prevention.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We expect to have to continue to negotiate budgets and contracts with CROs, trial sites and CMOs and we may not be able to do so on favorable terms, which may result in delays to our development timelines and increased costs. We will rely heavily on these third parties over the course of our preclinical studies and clinical trials, and we control only certain aspects of their activities. As a result, we will have less direct control over the conduct, timing and completion of these preclinical studies and clinical trials and the management of data developed through preclinical studies and clinical trials than would be the case if we were relying entirely upon our own staff. Nevertheless, we are responsible for ensuring that each of our preclinical studies and clinical trials is conducted in accordance with applicable protocol, legal and regulatory requirements and scientific standards, and our reliance on third parties does not relieve us of our regulatory responsibilities. We and these third parties are required to comply with GCP, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for product candidates in clinical development.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regulatory authorities enforce GCP through periodic inspections of trial sponsors, principal investigators and trial sites. If we, or any of these third parties fail to comply with applicable GCP regulations, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our MMAs. We cannot assure you that, upon inspection, such regulatory authorities will determine that any of our clinical trials comply with the GCP regulations. In addition, our clinical trials must be conducted with pharmaceutical product produced under cGMP regulations and will require a large number of test participants. Our failure or any failure by these third parties to comply with these regulations or to recruit a sufficient number of participants may require us to repeat clinical trials, which would delay the marketing authorization process. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Moreover, our business may be implicated if any of these third parties performing services or otherwise acting on our behalf violates federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Any third parties conducting our clinical trials are not and will not be our employees and, except for remedies available to us under our agreements with such third parties, we cannot control whether or not they devote sufficient time and resources to our ongoing clinical and preclinical product candidates. These third parties may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other product development activities, which could affect their performance on our behalf. If these third parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to complete development of, obtain marketing authorization for, or successfully commercialize, our product candidates. As a result, our financial results and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenue could be delayed.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switching or adding third parties to conduct our preclinical studies and clinical trials involves substantial cost and requires extensive management time and focus. In addition, there is a natural transition period when a new third party commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">We may form or seek additional collaborations or strategic alliances or enter into additional licensing arrangements in the future, and we may not realize the benefits of such collaborations, alliances or licensing arrangements.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We may form or seek additional strategic alliances, create joint ventures or collaborations, or enter into additional licensing arrangements with third parties that we believe will complement or augment our development and commercialization efforts with respect to our product candidates and any future product candidates that we may develop. Any of these relationships may require us to incur non-recurring and other charges, increase our near and long-term expenditures, issue securities that dilute our existing shareholders or disrupt our management and business.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In addition, we face significant competition in seeking appropriate strategic partners and the negotiation process is time-consuming and complex. Moreover, we may not be successful in our efforts to establish a strategic partnership or other alternative arrangements for our product candidates because they may be deemed to be at too early of a stage of development for collaborative effort and third parties may not view our product candidates as having the requisite potential to demonstrate safety, potency, purity, and efficacy and obtain marketing approval.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Further, collaborations involving our product candidates are subject to numerous risks, which may include the following:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">collaborators have significant discretion in determining the efforts and resources that they will apply to a collaboration;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">collaborators may not pursue development and commercialization of our product candidates or may elect not to continue or renew development or commercialization of our product candidates based on clinical trial results, changes in their strategic focus due to the acquisition of competitive products, availability of funding or other external factors, such as a business combination that diverts resources or creates competing priorities;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">collaborators may delay clinical trials, provide insufficient funding for a clinical trial, stop a clinical trial, abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">despite agreements, collaborators may develop our product candidates to standards that only meet their local regulatory requirements and therefore clinical data cannot be applied in support regulatory submissions in other jurisdictions;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">collaborators in certain countries may require joint ventures to manufactures and commercialize products in their territory, which may increase costs, increase dilution to shareholders, and offer lack of clarity on revenue and intellectual property sharing;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our product candidates;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">a collaborator with marketing and distribution rights to one or more products may not commit sufficient resources to their marketing and distribution;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">collaborators may not properly maintain or defend our intellectual property rights or may use our intellectual property or proprietary information in a way that gives rise to actual or threatened litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential liability;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">disputes may arise between us and a collaborator that cause the delay or termination of the research, development or commercialization of our product candidates, or that result in costly litigation or arbitration that diverts management attention and resources;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">collaboration and grant funding agreements may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">collaborators may own or co-own intellectual property covering our products that results from our collaborating with them, and in such cases, we would not have the exclusive right to commercialize such intellectual property.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As a result, if we enter into additional collaboration agreements and strategic partnerships or license our product candidates, we may not be able to realize the benefit of such transactions if we are unable to successfully integrate them with our existing operations and company culture, which could delay our timelines or otherwise adversely affect our business. We also cannot be certain that, following a strategic transaction or license, we will achieve the revenue or specific net income that justifies such transaction. Any delays in entering into new collaborations or strategic partnership agreements related to our product candidates could delay the development and commercialization of our product candidates in certain geographies for certain indications, which would harm our business prospects, financial condition and results of operations.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">We currently rely and expect to rely in the future on the use of manufacturing suites in third-party facilities or third parties to manufacture our product candidates, if approved. Our business could be harmed if we are unable to use third-party manufacturing suites or if the third party manufacturers fail to provide us with sufficient quantities of our product candidates or fail to do so at acceptable quality levels or prices.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We do not currently own any facility that may be used as our clinical-scale manufacturing and processing facility and must currently rely on outside vendors to manufacture our product candidates. We will need to negotiate and maintain contractual arrangements with these outside vendors for the supply of our product candidates and we may not be able to do so on favorable terms. We have not yet manufactured our product candidates on a commercial scale and may not be able to do so for any of our product candidates.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing of biologic and synthetic products is complex and requires significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls. Manufacturers of biologic products often encounter difficulties in production, particularly in scaling up, validating the production process and assuring high reliability of the manufacturing process, including the absence of contamination. These problems include logistics and shipping, difficulties with production costs and yields, quality control, including lot consistency, stability of the product, product testing, operator error and availability of qualified personnel, as well as compliance with strictly enforced federal, state and foreign regulations. Furthermore, if contaminants are discovered in our supply of our product candidates or in the manufacturing facilities, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination. We cannot assure you that any stability failures or other issues relating to the manufacture of our product candidates will not occur in the future.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Our anticipated reliance on a limited number of third-party manufacturers exposes us to a number of risks, including the following:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the production process for our product candidates is complex and requires specific know-how that only a limited number of CMOs can provide, as a result, we compete with other companies in the field for the scarce capacities of these organizations and may not be able to secure sufficient manufacturing capacity when needed;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">we may be unable to identify manufacturers on acceptable terms, or at all because the number of potential manufacturers is limited and the FDA or other regulatory authorities may inspect any manufacturers for current cGMP compliance as part of our marketing application;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">a new manufacturer would have to be educated in, or develop substantially equivalent processes for, the production of our product candidates;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">our third-party manufacturers might be unable to timely manufacture our product candidates or produce the quantity and quality required to meet our clinical and commercial needs, if any;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">contract manufacturers may not be able to execute our manufacturing procedures and other logistical support requirements appropriately;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">our future contract manufacturers may not perform as agreed, may not devote sufficient resources to our product candidates or may not remain in the contract manufacturing business for the time required to supply our clinical trials or to successfully produce, store, and distribute our products, if any;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">manufacturers are subject to ongoing periodic unannounced inspection by the FDA and corresponding state agencies to ensure strict compliance with cGMP and other government regulations and corresponding foreign </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">standards and we have no control over third-party manufacturers&#8217; compliance with these regulations and standards;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">we may not own, or may have to share, the intellectual property rights to any improvements made by our third-party manufacturers in the manufacturing process for our product candidates;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">our third-party manufacturers could breach or terminate their agreements with us;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">our third-party manufacturers may prioritize another customer&#8217;s needs in front of ours, especially in the event of a global pandemic;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">raw materials and components used in the manufacturing process, particularly those for which we have no other source or supplier, may not be available or may not be suitable or acceptable for use due to material or component defects, may be in short supply, and may significantly increase in price;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">our contract manufacturers and critical suppliers may be subject to inclement weather, pandemics, as well as natural or man- made disasters; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">our contract manufacturers may have unacceptable or inconsistent product quality success rates and yields, and we have no direct control over our contract manufacturers&#8217; ability to maintain adequate quality control, quality assurance and qualified personnel.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additionally, if any CMO with whom we contract fails to perform its obligations, we may be forced to manufacture the materials ourselves, for which we may not have the capabilities or resources, or enter into an agreement with a different CMO, which we may not be able to do on reasonable terms, if at all. In either scenario, our clinical trials or commercial distribution could be delayed significantly as we establish alternative supply sources. In some cases, the technical skills required to manufacture our products or product candidates may be unique or proprietary to the original CMO and we may have difficulty, or there may be contractual restrictions prohibiting us from, transferring such skills to a back-up or alternate supplier, or we may be unable to transfer such skills at all. In addition, if we are required to change CMOs for any reason, we will be required to verify that the new CMO maintains facilities and procedures that comply with quality standards and with all applicable regulations. We will also need to verify, such as through a manufacturing comparability study, that any new manufacturing process will produce our product candidate according to the specifications previously submitted to the FDA or another regulatory authority. The delays associated with the verification of a new CMO could negatively affect our ability to develop product candidates or commercialize our products in a timely manner or within budget. Furthermore, a CMO may possess technology related to the manufacture of our product candidate that such CMO owns independently. This would increase our reliance on such CMO or require us to obtain a license from such CMO in order to have another CMO manufacture our product candidates. In addition, in the case of the CMOs that supply our product candidates, changes in manufacturers often involve changes in manufacturing procedures and processes, which could require that we conduct bridging or comparability studies between our prior clinical supply used in our clinical trials and that of any new manufacturer. We may be unsuccessful in demonstrating the comparability of clinical supplies which could require the conduct of additional clinical trials.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Each of these risks could delay or prevent the completion of our clinical trials or the approval of any of our product candidates by the FDA, EMA or other appropriate regulatory authorities and result in higher costs or adversely impact commercialization of our product candidates. In addition, we will rely on third parties to perform certain specification tests on our product candidates prior to delivery to patients. If these tests are not appropriately done and test data are not reliable, patients could be put at risk of serious harm and the FDA, or other regulatory authorities could place significant restrictions on our company until deficiencies are remedied.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Our manufacturing process needs to comply with FDA and comparable foreign regulatory authority regulations relating to the quality and reliability of such processes. Any failure to comply with relevant regulations could result in delays in or termination of our clinical programs and suspension or withdrawal of any marketing authorizations.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In order to commercially produce our products either at our own facility or at a third party&#8217;s facility, we will need to comply with the FDA&#8217;s cGMP regulations and guidelines and similar requirements from comparable foreign regulatory authorities. We may encounter difficulties in achieving quality control and quality assurance and may experience shortages in qualified personnel. We are subject to inspections by the FDA and comparable foreign regulatory authorities to confirm compliance with applicable regulatory requirements. Any failure to follow cGMP or other regulatory requirements or delay, interruption or other issues that arise in the manufacture, fill-finish, packaging, or storage of our biologic products as a result of a failure of our facilities or the facilities or operations of third parties to comply with regulatory requirements or pass any regulatory authority inspection could significantly impair our ability to develop and commercialize our product candidates, including leading to significant delays in the availability of our biological products for our clinical trials or the termination of or suspension of a clinical trial, or the delay or prevention of a filing or approval of marketing applications for our product candidates. Significant non-compliance could also result in the imposition of sanctions, including warning or untitled letters, fines, injunctions, civil penalties, failure of regulatory authorities to grant marketing approvals for our product candidates, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of products, operating restrictions and criminal prosecutions, any of which could damage our reputation and our business.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">If our third-party manufacturers use hazardous and biological materials in a manner that causes injury or violates applicable law, we may be liable for damages.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Our research and development activities involve the controlled use of potentially hazardous substances, including biological materials, by our third-party manufacturers. Our manufacturers are subject to national, state, and local laws and regulations governing the use, manufacture, storage, handling, and disposal of medical and hazardous materials. Although we believe that our manufacturers&#8217; procedures for using, handling, storing, and disposing of these materials comply with legally prescribed standards, we cannot completely eliminate the risk of contamination or injury resulting from medical or hazardous materials. As a result of any such contamination or injury, we may incur liability or local, city, state or national authorities may curtail the use of these materials and interrupt our business operations. In the event of an accident, we could be held liable for damages or penalized with fines, and the liability could exceed our resources. Compliance with applicable environmental laws and regulations is expensive, and current or future environmental regulations may impair our research, development and production efforts, which could harm our business, prospects, financial condition or results of operations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Risks Related to Government Regulation</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">The marketing authorization processes of the FDA, the EMA, MHRA and other comparable foreign regulatory authorities are lengthy, time-consuming, and inherently unpredictable, and if we are ultimately unable to obtain marketing authorizations for our product candidates, or the marketing authorization is for a narrower indication than we seek, our business will be substantially harmed.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The time required to obtain marketing approval from the FDA, the EMA, MHRA and other comparable foreign regulatory authorities is unpredictable but typically takes many&#160;years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions. We have not yet obtained a marketing authorization for any product candidate and it is possible that none of our current or future product candidates will ever obtain marketing authorizations.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Our current and future product candidates could fail to receive marketing authorizations for many reasons, including the following:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the availability of financial resources to commence and complete planned clinical trials;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the FDA, the EMA, MHRA or other comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the data collected from clinical trials of our product candidates may not be sufficient to support the submission of a Biologics Licensing Application ("BLA") to the FDA, or an MAA to the EMA or other comparable submission to regulatory authorities in other regions, to obtain authorization in the United States, the European Union, or elsewhere;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">we may be unable to demonstrate to the satisfaction of the FDA, the EMA, MHRA or regulatory authorities in other regions that a product candidate has an overall suitable benefit/risk profile for its proposed indication;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the FDA, the EMA, MHRA or other comparable foreign regulatory authorities may find deficiencies with or fail to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the approval policies or regulations of the FDA, the EMA, MHRA or other comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the risk that foreign regulatory authorities may not authorize our clinical trial protocols and other clinical trial documentation, including manufacturing documentation, even when previously authorized by the FDA, EMA or MHRA, which could lead to a delay in starting such clinical trials. For example, the conduct of our HBV002 clinical trial in South Korea experienced delays due to additional regulatory review of our clinical protocol. We have limited experience obtaining such approvals in foreign jurisdictions and therefore may need more time to navigate the regulatory process as a result.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The unpredictability of clinical trial results may result in our failing to obtain marketing authorizations for any product candidate we develop, which would significantly harm our business, results of operations and prospects. The lengthy approval process in many regions may cause delays in market access, particularly if regulatory authorities have a large number of objections to the initial applications for marketing authorization which need to be addressed.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We have conducted, and intend to conduct, clinical trials of certain of our product candidates outside the United States. Although the FDA may accept data from clinical trials conducted outside the United States, acceptance of these data are </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">subject to certain conditions imposed by the FDA, including compliance with all applicable U.S. laws and regulations. For example, the clinical trial must be well designed and conducted and performed by qualified investigators in accordance with GCP, including review and approval by an independent ethics committee and informed consent from participants. The trial population must also adequately represent the U.S. population, and the data must be applicable to the U.S. population and U.S. medical practice in ways that the FDA deems clinically meaningful. In general, the participant population for any clinical trials conducted outside of the United States must be representative of the population for whom we intend to label the product in the United States. There can be no assurance the FDA will accept data from trials conducted outside of the United States.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The FDA, the EMA and other comparable foreign regulatory authorities have substantial discretion in the approval process, and determining when or whether marketing authorization will be obtained for any product candidate that we develop. Even if we believe the data collected from future clinical trials of our product candidates are promising, such data may not be sufficient to support approval by the FDA, the EMA, MHRA or any other comparable foreign regulatory authorities.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Even if we were to obtain marketing authorization, regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request, may not approve the price we intend to charge for our products, may grant approval conditional on the performance of costly post-marketing clinical trials, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">We may seek Orphan Drug Designation for drug candidates we develop, and we may be unsuccessful or may be unable to maintain the benefits associated with Orphan Drug Designation, including the potential for market exclusivity. In addition, even if we obtain orphan drug exclusivity for any of our product candidates, such exclusivity may not protect us from competition.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As part of our business strategy, we may seek Orphan Drug Designation for any drug candidates we develop, and we may be unsuccessful in obtaining such designation. Regulatory authorities in some jurisdictions, including the United States and the EU, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a drug as an orphan drug if it is a drug intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals annually in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States. In the United States, Orphan Drug Designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Similarly, in the EU, the European Commission grants designation after receiving the opinion of the Committee for Orphan Medicinal Products on a designation application. Orphan Drug Designation is intended to promote the development of drugs that are intended for the diagnosis, prevention or treatment of life-threatening or chronically debilitating conditions affecting not more than five in 10,000 persons in Europe and for which no satisfactory method of diagnosis, prevention, or treatment has been authorized (or the product would be a significant benefit to those affected). Additionally, designation is granted for drugs intended for the diagnosis, prevention, or treatment of a life-threatening, seriously debilitating, or serious and chronic condition and when, without incentives, it is unlikely that sales of the drug in Europe would be sufficient to justify the necessary investment in developing the drug. In Europe, Orphan Drug Designation entitles a party to a number of incentives, such as protocol assistance and scientific advice specifically for designated orphan medicines, and potential fee reductions depending on the status of the sponsor.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Generally, if a drug with an Orphan Drug Designation subsequently receives the first marketing approval for the indication for which it has such designation, the drug is entitled to a period of marketing exclusivity, which precludes the EMA or the FDA from approving another marketing application for the same drug and indication for that time period, except in limited circumstances. The applicable period is seven&#160;years in the United States and ten&#160;years in the EU. The EU exclusivity period can be reduced to six&#160;years if a drug no longer meets the criteria for Orphan Drug Designation or if the drug is sufficiently profitable such that market exclusivity is no longer justified.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Even if we obtain orphan drug exclusivity for a drug candidate, that exclusivity may not effectively protect the drug candidate from competition because different therapies can be approved for the same condition. Even after an orphan drug is approved, the FDA can subsequently approve the same drug for the same condition if the FDA concludes that the later drug is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care. In addition, a designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received orphan designation. Moreover, orphan drug exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the drug to meet the needs of patients with the rare disease or condition. Orphan Drug Designation neither shortens the development time or regulatory review time of a drug candidate nor gives the drug candidate any advantage in the regulatory review or approval process. The FDA may further reevaluate the Orphan Drug Act and its regulations and policies. We do not know if, when, or how the FDA may change the orphan drug regulations and policies in the future, and it is uncertain how any changes might affect our business. Depending on what changes the FDA may make to its orphan drug regulations and policies, our business could be adversely impacted. While we may seek Orphan Drug Designation for applicable indications for our current and any future drug candidates, we </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">may never receive such designations. Even if we do receive such designations, there is no guarantee that we will enjoy the benefits of those designations.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">A Breakthrough Therapy designation by the FDA, even if granted for any of our product candidates, may not lead to a faster development or regulatory review or approval process and it does not increase the likelihood that our product candidates will receive marketing approval.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We may seek Breakthrough Therapy designation for certain of our current and future product candidates. A breakthrough therapy is defined as a drug or biologic that is intended, alone or in combination with one or more other drugs or biologics, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the drug or biologic may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, defined as those that measure an effect on irreversible morbidity or mortality or on symptoms that represent serious consequences of the disease. For product candidates that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Drugs and biologics designated as breakthrough therapies by the FDA may also be eligible for other expedited approval programs, including accelerated approval.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Designation as a breakthrough therapy is within the discretion of the FDA. Accordingly, even if we believe one of our product candidates meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of a Breakthrough Therapy designation for a product candidate may not result in a faster development process, review or approval compared to candidate products considered for approval under non-expedited FDA review procedures and does not assure ultimate approval by the FDA. In addition, even if one or more of our product candidates qualify as breakthrough therapies, the FDA may later decide that the product no longer meets the conditions for qualification. Thus, even though we intend to seek Breakthrough Therapy designation for certain of our current and future product candidates for the treatment and prevention of infectious diseases and cancer, there can be no assurance that we will receive breakthrough therapy designation.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">A Fast Track designation by the FDA, even if granted for certain of our current or future product candidates, may not lead to a faster development or regulatory review or approval process, and does not increase the likelihood that our product candidates will receive marketing approval.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If a drug or biologic is intended for the treatment of a serious or life-threatening condition and the product demonstrates the potential to address unmet medical needs for this condition, the product sponsor may apply for FDA Fast Track designation for a particular indication. We may seek Fast Track designation for certain of our current or future product candidates, but there is no assurance that the FDA will grant this status to any of our proposed product candidates. Marketing applications filed by sponsors of products in Fast Track development may qualify for priority review under the policies and procedures offered by the FDA, but the Fast Track designation does not assure any such qualification or ultimate marketing approval by the FDA. The FDA has broad discretion whether or not to grant Fast Track designation, so even if we believe a particular product candidate is eligible for this designation, there can be no assurance that the FDA would decide to grant it. Even if we do receive Fast Track designation, we may not experience a faster development process, review or approval compared to conventional FDA procedures, and receiving a Fast Track designation does not provide assurance of ultimate FDA approval. In addition, the FDA may withdraw Fast Track designation if it believes that the designation is no longer supported by data from our clinical development program. In addition, the FDA may withdraw any Fast Track designation at any time.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Accelerated approval by the FDA, even if granted for certain of our current or future product candidates, may not lead to a faster development or regulatory review or approval process and it does not increase the likelihood that our product candidates will receive marketing approval.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We may seek approval of certain of our current or future product candidates using the FDA&#8217;s accelerated approval pathway. A product may be eligible for accelerated approval if it treats a serious or life-threatening condition, generally provides a meaningful advantage over available therapies, and demonstrates an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit. As a condition of approval, the FDA may require that a sponsor of a product receiving accelerated approval perform adequate and well-controlled post-marketing clinical trials. These confirmatory trials must be completed with due diligence and the FDA is permitted to require, as appropriate, that such studies be underway prior to approval or within a specified period after the date of approval. Sponsors must also update FDA on the status of these studies, and under FDORA, the FDA has increased authority to withdraw approval of a drug granted accelerated approval on an expedited basis if the sponsor fails to conduct such studies in a timely manner, send the necessary updates to the FDA, or if such post-approval studies fail to verify the drug&#8217;s predicted clinical benefit. In addition, the FDA currently requires sponsors, unless otherwise informed by the agency, to request pre-approval of promotional materials for products receiving Accelerated Approval, which could adversely impact the timing of the commercial launch of the product. Even if we do receive accelerated approval, we may not experience a faster development or regulatory review or approval process, and receiving accelerated approval does not provide assurance of ultimate full FDA approval.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">If approved, our investigational products regulated as biologics may face competition from biosimilars approved through an abbreviated regulatory pathway.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Patient Protection and Affordable Care Act, as amended by the ACA, includes a subtitle called the BPCIA which created an abbreviated approval pathway for biologic products that are biosimilar to or interchangeable with an FDA-licensed reference biologic product. Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four&#160;years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12&#160;years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a BLA for the competing product containing the sponsor&#8217;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity, and potency of the other company&#8217;s product. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We believe that any of our product candidates approved as a biologic product under a BLA should qualify for the 12 year period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider our investigational medicines to be reference products for competing products, potentially creating the opportunity for biosimilar competition sooner than anticipated. Moreover, the extent to which a biosimilar, once licensed, will be substituted for any one of our reference products in a way that is similar to traditional generic substitution for non-biologic products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If competitors are able to obtain marketing approval for biosimilars referencing our products, our products may become subject to competition from such biosimilars, with the attendant competitive pressure and consequences.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Even if we obtain FDA, EMA or MHRA approval for our current or future product candidates that we may identify and pursue in the United States, Europe or the United Kingdom, we may never obtain approval to commercialize any such product candidates outside of those jurisdictions, including in Asian markets wherein we intend to commercialize VTP-300, which would limit our ability to realize their full market potential.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Obtaining and maintaining marketing authorization for our product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain marketing authorizations in any other jurisdiction, while a failure or delay in obtaining marketing authorization in one jurisdiction may have a negative effect on the approval process in others. In order to market any products outside of the United States, we must establish and comply with numerous and varying regulatory requirements of other countries regarding safety and effectiveness. Approval processes vary among countries and can involve additional product testing and validation and additional or different administrative review periods from those in the United States, including additional preclinical studies or clinical trials, as clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to approval.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Seeking foreign marketing authorization could result in difficulties and costs and require additional preclinical studies or clinical trials which could be costly and time-consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our current or future product candidates in those countries. The foreign marketing authorization process may include all of the risks associated with obtaining FDA, EMA or MHRA approval, in addition to country-specific risks and challenges. For example, we are developing VTP-300 for chronic hepatitis B, which is most prevalent in China and other countries in Asia. We have limited development experience in this market and we may need to rely on a local, third-party partner to help us navigate the applicable regulatory requirements. Additionally, governments in this target market may deem the eradication of HBV infections to be a national priority which could impact the framework for available reimbursement or our ability to achieve a standard commercial return based on the value of our product, if approved. We do not have any product candidates approved for sale in any jurisdiction, including international markets, and we do not have experience in obtaining marketing authorizations in international markets for our current or future product candidates. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, or if marketing authorization in international markets is delayed, our target market will be reduced and our ability to realize the full market potential of our current or future product candidates will be harmed.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Future changes to tax laws could materially adversely affect our financial condition and results of operations, and reduce net returns to our shareholders.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We conduct business globally and file tax returns in multiple jurisdictions. The tax treatment of the Company or any of the group companies could be materially adversely affected by several factors, including: changing tax laws, regulations and treaties, or the interpretation thereof; tax policy initiatives and reforms under consideration (such as those related to the Organization for Economic Co-Operation and Development&#8217;s Base Erosion and Profit Shifting Project, the European Commission&#8217;s state aid investigations and other initiatives); the practices of tax authorities in jurisdictions in which we operate; the resolution of issues arising from tax audits or examinations and any related interest or penalties. Such changes (which may be retroactive) may include (but are not limited to) the taxation of operating income, investment income, dividends received or (in the specific context of withholding tax) dividends paid.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We are unable to predict what tax reform may be proposed or enacted in the future or what effect such changes would have on our business, but such changes, to the extent they are brought into tax legislation, regulations, policies or practices in jurisdictions in which we operate, could affect our financial position, future results of operations, cash flows in a particular period and overall or effective tax rates in the future in countries where we have operations, reduce post-tax returns to our shareholders and increase the complexity, burden and cost of tax compliance.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Tax authorities may disagree with our positions and conclusions regarding certain tax positions, or may apply existing rules&#160;in an unforeseen manner, resulting in unanticipated costs, taxes or non-realization of expected benefits.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We operate in a number of countries throughout the world. Consequently, we are subject to tax laws, treaties, and regulations in the countries in which we operate, and these laws and treaties are subject to interpretation. We have taken, and will continue to take, tax positions based on our interpretation of such tax laws. A tax authority may disagree with tax positions that we have taken, which could result in increased tax liabilities. For example HMRC, the IRS or another tax authority could challenge our allocation of income by tax jurisdiction and the amounts paid between our affiliated companies pursuant to our intercompany arrangements and transfer pricing policies, including amounts paid with respect to our intellectual property development. There can be no assurance that a taxing authority will not have a different interpretation of applicable law and assess us with additional taxes. Similarly, a tax authority could assert that we are subject to tax in a jurisdiction where we believe we have not established a taxable connection, often referred to as a &#8220;permanent establishment&#8221; under international tax treaties, and such an assertion, if successful, could increase our expected tax liability in one or more jurisdictions. A tax authority may take the position that material tax liabilities, interest and penalties are payable by us, for example where there has been a technical violation of contradictory laws and regulations that are relatively new and have not been subject to extensive review or interpretation, in which case we expect that we might contest such assessment. Contesting such an assessment may be lengthy and costly and if we were unsuccessful in disputing the assessment, the implications could increase our anticipated effective tax rate, where applicable, or result in other liabilities. If we are assessed with additional taxes, this may result in a material adverse effect on our results of operations and/or financial condition.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">We may be unable to use net operating loss and tax credit carryforwards and certain built-in losses or tax credits to reduce future tax payments or to benefit from favorable U.K. tax legislation.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As a U.K. incorporated and tax resident entity, we are subject to U.K. corporate taxation. Due to the nature of our business, we have generated losses since inception and therefore have not paid any U.K. corporation tax. As of December 31, 2023, we had cumulative carryforward tax losses of approximately $92.7 million (December 31, 2022: $39.6 million). Subject to any relevant criteria and restrictions (including those that limit the percentage of profits that can be reduced by carried forward losses and those that can restrict the use of carried forward losses where there is a change of ownership of more than half of our ordinary shares and a major change in the nature, conduct or scale of the trade), we expect these to be eligible for carry forward and utilization against future operating profits, if any. The use of loss carryforwards in relation to U.K. profits incurred on or after April 1, 2017 is generally limited each year to &#163;5.0 million plus an incremental 50% of U.K. taxable profits.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As a company that carries out extensive research and development activities, we seek to benefit from the U.K. research and development tax relief programs, being the Small and Medium-sized Enterprises R&amp;D tax relief program, or SME Program, and, to the extent that our projects are grant funded or relate to work subcontracted to us by third parties, the Research and Development Expenditure Credit program. Under the SME Program, where available, we may be able to surrender some of our trading losses that arise from our qualifying research and development activities for cash or carry forward such losses for potential offset against future profits (subject to relevant restrictions). The majority of our research, clinical trials management and manufacturing development activities are eligible for inclusion within these tax credit cash rebate claims. Our eligibility to claim payable research and development tax credits may be limited or eliminated because we may no longer qualify as a small or medium-sized company. In addition, the SME Program has been amended by the Finance Act 2021 which came into force in April&#160;2021. This legislation introduced a cap on claims under the SME Program to a multiple of payroll taxes (broadly, to a maximum payable credit equal to &#163;20,000 plus three times the total PAYE and NICs liability of the company) subject to an exception which prevents the cap from applying. That exception requires the company to be creating, taking steps to create or managing intellectual property, as well as having qualifying research and development expenditure in respect of connected parties which does not exceed 15% of the total claimed. If such exception does not apply, this could restrict the amount of payable credit that we claim.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Changes to the U.K. R&amp;D tax relief legislation that have been recently enacted or proposed, and which took effect from April 2023, reduce the R&amp;D cash rebate rate under the SME Program, and may introduce restrictions on relief that may be claimed for expenditure on sub-contracted R&amp;D activity, broadly requiring either that workers carrying on such activity are subject to U.K. PAYE or, where work is undertaken outside the U.K., that this must be due to geographical, environmental, social or other conditions that: (i) are not present in the U.K.; and (ii) it would be wholly unreasonable to replicate in the U.K. This rate reduction and any proposed restrictions may impact the quantum of R&amp;D relief that we are able to claim in the future. In addition, the U.K. government is currently consulting on the potential replacement of the SME Program and RDEC Program with a single program, operating similarly to the RDEC Program, which may, inter alia, change the present treatment of sub-contracted R&amp;D work and introduce different thresholds and caps on expenditure and relief. If enacted, the new program would be expected to have effect for expenditure incurred from April 2024 onwards, and could have a material impact on the quantum of R&amp;D relief that we are eligible to claim. This announcement also saw the introduction of a higher rate of relief for loss-making R&amp;D-intensive small and medium enterprises, the SME Intensive Scheme. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Companies claiming under the existing SME Intensive Scheme tax relief will be eligible for a higher payable credit rate if they meet the definition for R&amp;D intensity. We will assess if we can claim under the new loss-making R&amp;D-intensive SME Intensive Scheme for the accounting period ending December 31, 2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">and future periods, which will provide benefits consistent with those claimed under the current SME Programs.</span></div><div><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We may benefit in the future from the U.K.&#8217;s &#8220;patent box&#8221; regime, which allows certain profits attributable to revenue from patented products (and other qualifying income) to be taxed at an effective rate of 10% by giving an additional tax deduction. When taken in combination with the enhanced relief available on our research and development expenditures, we expect a long-term effective rate of corporation tax lower than the statutory rate to apply to us. If, however, there are unexpected adverse changes to the U.K. R&amp;D tax credit regime or the &#8220;patent box&#8221; regime, or for any reason we are unable to qualify for such advantageous tax legislation, or we are unable to use net operating loss and tax credit carryforwards and certain built-in losses to reduce future tax payments then our business, results of operations and financial condition may be adversely affected. This may impact our ongoing requirement for investment and the timeframes within which additional investment is required.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For completeness, it should be noted that the UK tax authority, HMRC, currently has an increased focus on claims for R&amp;D tax credits and so the Company may be subject to increased scrutiny in respect of any claims it makes. In addition, the legislation on the UK R&amp;D tax credits regime is updated and changed frequently, so there can be no guarantee of our ability of to make use of such credits as we might currently expect to in future.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Risks Related to Ongoing Regulatory Obligations</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Even if we receive marketing authorization for our product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Any marketing authorizations that we receive for our product candidates will require surveillance to monitor the safety and efficacy of the product candidate. The FDA may also require a REMS and the EMA may also require additional rapid microbiological method approvals or educational materials in order to approve our product candidates, which could entail requirements for a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA or a comparable foreign regulatory authority approves our product candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, import, export and recordkeeping for our product candidates will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMPs, good laboratory practice regulations and GCPs, for any clinical trials that we conduct post-approval, and compliance with applicable product tracking and tracing requirements. Later discovery of previously unknown problems with our product candidates, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">restrictions on the marketing or manufacturing of our product candidates, withdrawal of the product from the market or voluntary or mandatory product recalls;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">manufacturing delays and supply disruptions where regulatory inspections identify observations of noncompliance requiring remediation;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">revisions to the labeling, including limitation on approved uses or the addition of additional warnings, contraindications or other safety information, including boxed warnings;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">imposition of a REMS, which may include distribution or use restrictions;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">requirements to conduct additional post-market clinical trials to assess the safety of the product;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">fines, warning letters or holds on clinical trials;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">refusal by the FDA to approve pending applications or supplements to approved applications filed by us or suspension or revocation of approvals;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">product seizure or detention, or refusal to permit the import or export of our product candidates; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">injunctions or the imposition of civil, criminal, or administrative penalties.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additionally, under FDORA, sponsors of approved drugs and biologics must provide 6 months&#8217; notice to the FDA of any changes in marketing status, such as the withdrawal of a drug, and failure to do so could result in the FDA placing the product on a list of discontinued products, which would revoke the product&#8217;s ability to be marketed. The FDA&#8217;s and other regulatory authorities&#8217; policies may change and additional government regulations may be enacted that could prevent, limit </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">or delay marketing authorization of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">The FDA and other regulatory authorities actively enforce the laws and regulations prohibiting the promotion of off-label uses.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If any of our product candidates are approved and we are found to have improperly promoted off-label uses of those products, we may become subject to significant liability. The FDA and other regulatory authorities strictly regulate the promotional claims that may be made about prescription products, if approved. In particular, while the FDA permits the dissemination of truthful and non- misleading information about an approved product, a manufacturer may not promote a product for uses that are not approved by the FDA or such other regulatory authorities as reflected in the product&#8217;s approved labeling. If we are found to have promoted such off-label uses, we may become subject to significant liability. The federal government has levied large civil and criminal fines against companies for alleged improper promotion of off-label use and has enjoined several companies from engaging in off-label promotion. The FDA has also requested that companies enter into consent decrees, corporate integrity agreements or permanent injunctions under which specified promotional conduct must be changed or curtailed. If we cannot successfully manage the promotion of our product candidates, if approved, we could become subject to significant liability, which would materially adversely affect our business and financial condition.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">The insurance coverage and reimbursement status of newly-approved products are uncertain. Failure to obtain or maintain adequate coverage and reimbursement for any of our product candidates, if approved, could limit our ability to market those products and decrease our ability to generate revenue.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The regulations that govern marketing approvals, pricing and reimbursement for new drugs vary widely from country to country. In the United States, no uniform policy of coverage and reimbursement for products exists among third-party payors and, recently enacted legislation may significantly change the approval requirements in ways that could involve additional costs and cause delays in obtaining approvals. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain marketing approval for a product in a particular country, but then be subject to price regulations that delay our or their commercial launch of the product, possibly for lengthy time periods, and negatively impact the revenue we are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates, even if any product candidates we may develop obtain marketing approval. See section entitled &#8220;Business&#160;&#8211; Government Regulation&#160;&#8211; Coverage and Reimbursement.&#8221;</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Our ability to successfully commercialize our product candidates or any other products that we or they may develop also will depend in part on the extent to which reimbursement for these products and related treatments will be available from government health administration authorities, private health insurers, and other organizations. Government authorities and other third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. The availability and extent of reimbursement by governmental and private payors is essential for most patients to be able to afford treatments. Sales of our product candidates will depend substantially, both domestically and abroad, on the extent to which the costs of our product candidates will be paid by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or reimbursed by government health administration authorities, private health coverage insurers and other third-party payors. We may not be able to provide data sufficient to gain acceptance with respect to coverage and reimbursement. If reimbursement is not available, or is available only at limited levels, we may not be able to successfully commercialize our product candidates, if approved. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize a sufficient return on our investment.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. In the United States, the principal decisions about reimbursement for new medicines are typically made by CMS, an agency within the HHS, as CMS decides whether and to what extent a new medicine will be covered and reimbursed under Medicare. Private payors tend to follow CMS to a substantial degree. It is difficult to predict what CMS will decide with respect to reimbursement for fundamentally novel products such as ours. Patients who are provided medical treatment for their conditions generally rely on third-party payors to reimburse all or part of the costs associated with their treatment. Adequate coverage and reimbursement from governmental healthcare programs and commercial payors are critical to new product acceptance. Government authorities and other third-party payors, such as private health insurers and health maintenance organizations, decide which drugs and treatments they will cover and the amount of reimbursement. Coverage and reimbursement by a third-party payor may depend upon a number of factors, including the third-party payor&#8217;s determination that use of a product is:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">a covered benefit under its health plan;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">safe, effective and medically necessary;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">appropriate for the specific patient;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">cost-effective; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">neither experimental nor investigational.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and other third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Outside the United States, international operations are generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost-containment initiatives in Europe and certain other major markets where we plan to commercialize may put pressure on the pricing and usage of our product candidates. In many countries, the prices of medical products are subject to varying price control mechanisms as part of national health systems, and pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost effectiveness of our product candidates to other available therapies. In general, the prices of medicines under such systems are substantially lower than in the United States. Other countries allow companies to fix their own prices for medicines, but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our product candidates. Accordingly, in markets outside the United States, the reimbursement for our products may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenues and profits.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Moreover, efforts by governmental and other third-party payors, in the United States and abroad, to cap or reduce healthcare costs may cause such organizations to limit both coverage and level of reimbursement for new products approved and, as a result, they may not cover or provide adequate payment for our product candidates. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. We cannot be sure that reimbursement will be available for any product candidate that we commercialize and, if reimbursement is available, the level of reimbursement. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. We expect to experience pricing pressures in connection with the sale of any of our product candidates, due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs and surgical procedures and other treatments, has become very intense. Many pharmaceutical manufacturers must calculate and report certain price reporting metrics to the government, such as average sales price and best price. Penalties may apply in some cases when such metrics are not submitted accurately and timely. Further, these prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs. As a result, increasingly high barriers are being erected to the entry of new products.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Healthcare legislative or regulatory reform measures may have a material adverse effect on our business and results of operations.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The United States and many foreign jurisdictions have enacted or proposed legislative and regulatory changes affecting the healthcare system that could prevent or delay marketing approval of our product candidates or any future product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell a product for which we obtain marketing approval. Changes in applicable laws, rules, and regulations or the interpretation of existing laws, rules, and regulations could impact our business in the future by requiring, for example: (i)&#160;changes to our manufacturing arrangements; (ii)&#160;additions or modifications to product labeling; (iii)&#160;the recall or discontinuation of our products; or (iv)&#160;additional record-keeping requirements. If any such changes were to be imposed, they could adversely affect the operation of our business. See the section entitled &#8220;Business&#160;&#8211; Government Regulation&#160;&#8211; Healthcare Reform and Legislative Changes.&#8221;</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We expect that these and other healthcare reform measures that may be adopted in the future may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved product candidate. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. We cannot predict the reform initiatives that may be adopted in the future or whether initiatives that have been adopted will be modified or invalidated. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our drugs, and could have a material adverse effect on our business, financial condition, and results of operations.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Our business activities will be subject to the Foreign Corrupt Practices Act ("FCPA"), and similar anti-bribery and anti- corruption laws in other jurisdictions.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As we engage in and expand our business activities outside of the United States, including our clinical trial efforts, we will be subject to the FCPA and similar anti-bribery or anti-corruption laws, regulations or rules&#160;of other countries in which we operate. The FCPA generally prohibits offering, promising, giving, or authorizing others to give anything of value, either directly or indirectly, to a non- United States government official in order to influence official action, or otherwise obtain or retain business. The FCPA also requires public companies to make and keep books and records that accurately and fairly reflect the transactions of the corporation and to devise and maintain an adequate system of internal accounting controls. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Our business is heavily regulated and therefore involves significant interaction with public officials, including officials of non-United States governments. Additionally, in many other countries, the healthcare providers who prescribe pharmaceuticals are employed by their government, and the purchasers of pharmaceuticals are government entities; therefore, our dealings with these prescribers and purchasers will be subject to regulation under the FCPA. Recently the Securities and Exchange Commission, or the SEC, and Department of Justice have increased their FCPA enforcement activities with respect to biotechnology and pharmaceutical companies. There is no certainty that all of our employees, agents, suppliers, manufacturers, contractors, or collaborators, or those of our affiliates, will comply with all applicable laws and regulations, particularly given the high level of complexity of these laws. Violations of these laws and regulations could result in fines, criminal sanctions against us, our officers, or our employees, the closing down of facilities, including those of our suppliers and manufacturers, requirements to obtain export licenses, cessation of business activities in sanctioned countries, implementation of compliance programs, and prohibitions on the conduct of our business. Any such violations could include prohibitions on our ability to offer our products in one or more countries as well as difficulties in manufacturing or continuing to develop our products, and could materially damage our reputation, our brand, our international expansion efforts, our ability to attract and retain employees, and our business, prospects, operating results, and financial condition.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Inadequate funding for the FDA, the SEC and other government agencies, including from government shutdowns, or other disruptions to these agencies&#8217; operations, could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory and policy changes. Average review times at the agency have fluctuated in recent&#160;years as a result. Disruptions at the FDA and other agencies may also slow the time necessary for new product candidates to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For example, over the last several&#160;years the U.S. government has shut down several times and certain regulatory authorities, such as the FDA and the SEC, have had to furlough critical FDA, SEC and other government employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Our business operations and current and future relationships with principal investigators, healthcare providers, including physicians, consultants, third-party payors and customers may be subject, directly or indirectly, to U.S. federal and state, as well as foreign, healthcare fraud and abuse laws, false claims laws, health information privacy and security laws, and other healthcare laws and regulations. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Healthcare providers, including physicians and third-party payors in the United States and elsewhere will play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing approval. Our current and future arrangements with healthcare professionals, principal investigators, consultants, customers and third-party payors subject us to various U.S. federal and state fraud and abuse laws and other healthcare laws, including, without limitation, the AKS, the federal civil and criminal false claims laws, and the law commonly referred to as the Sunshine Act, along with regulations promulgated under such laws. These laws impact, among other things, our clinical research activities, proposed sales, marketing and educational programs, and other arrangements and relationships with third-party payors, healthcare professionals, and other parties through which we market, sell and distribute our product candidates for which we obtain marketing approval. In addition, we may be subject to patient data privacy and security regulation by both the U.S. federal government and the states in which we conduct our business, along with foreign regulators (including European data protection authorities). See section entitled &#8220;Business&#160;&#8211; Government Regulation&#160;&#8211; Other Healthcare Laws and Compliance Requirements.&#8221;</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Because of the breadth of these laws and the narrowness of the statutory exceptions and regulatory safe harbors available, it is possible that some of our business activities could be subject to challenge under one or more of such laws. Even if precautions are taken, it is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant penalties, including without limitation, civil, criminal and administrative penalties, damages, fines, disgorgement, individual imprisonment, exclusion from participating in federal and state funded healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, contractual damages, diminished profits and future earnings, reputational harm and the curtailment or restructuring of our operations. If any of the physicians or other healthcare providers or entities with whom we expect to do business is found not to be in compliance with applicable laws, that person may be subject to significant criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs. Prohibitions or restrictions on sales or withdrawal of future marketed products could materially affect business in an adverse way.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The risk of our being found in violation of these laws is increased by the fact that many of them have not been fully interpreted by applicable regulatory authorities or the courts, and their provisions are open to a variety of interpretations. Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business. The shifting compliance environment and the need to build and maintain robust and expandable systems to comply with multiple jurisdictions with different compliance and/or reporting requirements increases the possibility that a healthcare company may run afoul of one or more of the requirements.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Our employees, independent contractors, consultants, commercial partners and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We are exposed to the risk that our employees, independent contractors, consultants, collaborators, CROs or CMOs, principal investigators, suppliers and vendors may engage in fraudulent conduct or other illegal activity. Misconduct by these parties could include intentional, reckless and negligent conduct that fails to: comply with the regulations of the FDA and other comparable foreign regulatory bodies, provide true, complete and accurate information to the FDA and other comparable foreign regulatory bodies, comply with manufacturing standards we have established, comply with healthcare fraud and abuse laws in the United States and similar foreign fraudulent misconduct laws or report financial information or data accurately or to disclose unauthorized activities to us. If we obtain FDA approval of any of our product candidates and begin commercializing those products in the United States, our potential exposure under such laws and regulations will increase significantly, and our costs associated with compliance with such laws and regulations are also likely to increase. In particular, the promotion, sales and marketing of healthcare items and services, as well as certain business arrangements in the healthcare industry, are subject to extensive laws designed to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, structuring and commission(s), certain customer incentive programs and other business arrangements generally. Misconduct by persons acting on our behalf could also involve the improper use of individually identifiable information, including, without limitation, information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We have adopted a code of business conduct and ethics, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent inappropriate conduct may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant civil, criminal and administrative penalties, including, without limitation, damages, fines, disgorgement, imprisonment, exclusion from participation in government healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, and the curtailment or restructuring of our operations.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We and our collaborators and third-party providers are subject to national, supranational, federal or state laws and regulations, regulatory guidance and industry standards relating to data protection, privacy and information security. With respect to Europe, the collection and processing of personal data regarding (i) individuals in the EEA and UK, and/or (ii) carried out in the context of the activities of our establishments in the EEA or UK,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">is subject to the GDPR, as well as other national data protection legislation in force in relevant EEA member states and the UK, (including the UK Data Protection Act 2018).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The GDPR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">is wide-ranging in scope and impose numerous obligations on companies that process personal data, including imposing special requirements in respect of the processing of health and other sensitive data, requiring that consent of individuals to whom the personal data relates is obtained in certain circumstances, requiring additional disclosures to individuals regarding data processing activities, requiring that safeguards are implemented to protect the security and confidentiality of personal data, creating mandatory data breach notification requirements in certain circumstances, requiring data protection impact assessments for high risk processing and requiring that certain measures (including contractual requirements) are put in place when engaging third-party processors. The GDPR also provides individuals with various rights in respect of their personal data, including rights of access, erasure, portability, rectification, restriction and objection. The GDPR defines personal data to include pseudonymized or coded data and require different informed consent practices and more detailed notices for clinical trial participants and investigators than applies to clinical trials conducted in the United States. We are required to apply GDPR standards to any clinical trials that our EEA and UK established businesses carry out anywhere in the world.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The GDPR impose strict rules on the transfer of personal data to countries outside the EEA and UK, including the United States in certain circumstances, unless a derogation exists or we incorporate a GDPR transfer mechanism (such as the European Commission approved standard contractual clauses (&#8220;SCCs&#8221;) or the UK International Data Transfer Addendum </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(&#8220;IDTA&#8221;)) into our agreements with third parties to govern such transfers of personal data and carry out transfer impact assessments to assess whether the data importer can ensure sufficient guarantees for safeguarding the personal information under the GDPR, including an analysis of the laws in the recipient&#8217;s country. Carrying out such restricted transfers, therefore, comes with a significant compliance burden, requiring significant effort and expense to overcome. Failure to implement valid mechanisms for personal data transfers from Europe may result in increased exposure to regulatory actions, substantial fines, and injunctions against processing personal data from Europe. If we are unable to export personal data, this may also restrict our activities outside of Europe and require us to increase processing capabilities within Europe at significant expense or otherwise segregate our systems and operations. Switzerland has adopted similar transfer restrictions as under the GDPR. Although the UK is regarded as a third country under the EU GDPR, the European Commission issued a decision recognizing the UK as providing adequate protection under the EU GDPR and, therefore, transfers of personal data originating in the EEA to the UK remain unrestricted. Personal data transfers from the UK to the EEA remain free flowing by virtue of a UK government adequacy decision.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The GDPR may increase our responsibility and liability in relation to personal data that we process where such processing is subject to the GDPR. While we have taken steps to comply with the GDPR, and implementing legislation in applicable EEA member states and the UK, including by seeking to establish appropriate lawful bases for the various processing activities we carry out as a controller or joint controller, reviewing our security procedures and those of our vendors and collaborators, and entering into data processing agreements with relevant vendors and collaborators, we cannot be certain that our efforts to achieve and remain in compliance have been, and/or will continue to be, fully successful. Given the breadth and depth of the applicable obligations, complying with the GDPR and similar data protection laws&#8217; requirements are rigorous and time intensive and require significant resources and a review of our technologies, systems and practices, as well as those of any third-party collaborators, service providers, contractors or consultants that process or transfer personal data.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The UK&#8217;s data protection regime is independent from but aligned to the EU&#8217;s data protection regime. However following the Brexit, there will be increasing scope for divergence in application, interpretation and enforcement of the data protection laws between these territories. For example, the UK has recently introduced a new Data Protection &amp; Digital Information (No. 2) Bill, or the Data Reform Bill into the UK legislative process with the intention for this bill to reform the UK&#8217;s data protection regime following Brexit. if passed, the Data Reform Bill could reshape the UK's data protection regime, distancing it from the EU&#8217;s data protection regime and threaten the UK&#8217;s adequacy decision from the EC. This lack of clarity on future UK laws and regulations and their interaction with those of the EU could add legal risk, uncertainty, complexity, and cost to our handling of European personal data and our privacy and security compliance programs; and any resulting divergence in laws could increase our risk profile and may require us to implement different compliance measures for the UK and EEA.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In the United States, numerous federal and state laws and regulations, including federal health information privacy laws, state data breach notification laws, state health information privacy laws and federal and state consumer protection laws (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">e.g.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, Section&#160;5 of the FTCA), that govern the collection, use, disclosure and protection of health-related and other personal information could apply to our operations or the operations of our collaborators and third-party providers. For example, California recently enacted the CCPA which became effective on January&#160;1, 2020. The CCPA gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing and receive detailed information about how their personal information is used. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. US states are constantly amending existing laws, requiring attention to frequently changing regulatory requirements. At this time, we do not collect personal data on residents of California but should we begin to do so, and in the context of doing so, become subject to the CCPA, the CCPA will impose new and burdensome privacy compliance obligations on our business and will raise new risks for potential fines and class actions.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In addition to the CCPA, a California ballot initiative, the CPRA, was passed in November 2020. Effective as of January 1, 2023, the CPRA imposes additional obligations on companies covered by the legislation and will significantly modify the CCPA, including by expanding consumers&#8217; rights with respect to certain sensitive personal information. The CPRA also created a new state agency vested with authority to implement and enforce the CCPA and the CPRA. The effects of the CCPA and the CPRA are potentially significant and may require us to modify our data collection or processing practices and policies and to incur substantial costs and expenses in an effort to comply and increase our potential exposure to regulatory enforcement and/or litigation.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Some observers have noted that the CCPA and CPRA could mark the beginning of a trend toward more stringent privacy legislation in the United States, which could increase our potential liability and adversely affect our business. For example, on January 1, 2023, the CDPA became effective. Further, many additional United States state privacy laws will go into effect throughout 2023: the CPA (July 1, 2023); the CTDPA (July 1, 2023); and the UCPA (December 31, 2023). The CDPA, CPA, CTDPA, and UCPA are substantially similar in scope and contain many of the same requirements and exceptions as the CCPA, including a general exemption for clinical trial data and information governed by HIPAA. Any of these laws may broaden their scope in the future, and similar laws have been proposed on both a federal level and in more than half of the states in the United States. While the CDPA, CPA, CTDPA, and UCPA incorporate many similar concepts of the CCPA and CPRA, there are also several key differences in the scope, application, and enforcement of the laws that will change the operational practices of regulated businesses. The new laws will, among other things, impact how regulated </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">businesses collect and process personal sensitive data, conduct data protection assessments, transfer personal data to affiliates, and respond to consumer rights requests.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A number of other states have proposed new privacy laws, some of which are similar to the above discussed recently passed laws. Such proposed legislation, if enacted, may add additional complexity, variation in requirements, restrictions and potential legal risk, require additional investment of resources in compliance programs, impact strategies and the availability of previously useful data and could result in increased compliance costs and/or changes in business practices and policies. The existence of comprehensive privacy laws in different states in the country would make our compliance obligations more complex and costly and may increase the likelihood that we may be subject to enforcement actions or otherwise incur liability for noncompliance.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In addition to general privacy and data protection requirements, many jurisdictions around the world have adopted legislation that regulates how businesses operate online and enforces information security, including measures relating to privacy, data security and data breaches. Many of these laws require businesses to notify data breaches to the regulators and/or data subjects. These laws are not consistent, and compliance in the event of a widespread data breach is costly and burdensome.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In many jurisdictions, enforcement actions and consequences for non-compliance with protection, privacy and information security laws and regulations are rising. In the EU and the UK, data protection authorities may impose large penalties for violations of the data protection laws, including potential fines of up to &#8364;20 million (&#163;17.5 million in the UK) or 4% of annual global revenue, whichever is greater. The authorities have shown a willingness to impose significant fines and issue orders preventing the processing of personal data on non-compliant businesses. Data subjects also have a private right of action, as do consumer associations, to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of applicable data protection laws. In the United States, possible consequences for non-compliance include enforcement actions in response to rules&#160;and regulations promulgated under the authority of federal agencies and state attorneys general and legislatures and consumer protection agencies.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In addition, privacy advocates and industry groups have regularly proposed, and may propose in the future, self-regulatory standards that may legally or contractually apply to us. If we fail to follow these security standards, even if no customer information is compromised, we may incur significant fines or experience a significant increase in costs.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The risk of our being found in violation of these laws is increased by the fact that the interpretation and enforcement of them is not entirely clear. Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business. The shifting compliance environment and the need to build and maintain robust and expandable systems to comply with multiple jurisdictions with different compliance and/or reporting requirements increases the possibility that a healthcare company may run afoul of one or more of the requirements.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compliance with data protection laws and regulations could require us to take on more onerous obligations in our contracts, restrict our ability to collect, use and disclose data, or in some cases, impact our ability to operate in certain jurisdictions. It could also require us to change our business practices and put in place additional compliance mechanisms, may interrupt or delay our development, regulatory and commercialization activities and increase our cost of doing business. Failure by us or our collaborators and third-party providers to comply with data protection laws and regulations could result in government enforcement actions (which could include civil or criminal penalties and orders preventing us from processing personal data), private litigation and result in significant fines and penalties against us. Moreover, clinical trial participants about whom we or our potential collaborators obtain information, as well as the providers who share this information with us, may contractually limit our ability to use and disclose the information. Claims that we have violated individuals&#8217; privacy rights, failed to comply with data protection laws or breached our contractual obligations, even if we are not found liable, could be expensive and time-consuming to defend, could result in adverse publicity and could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Risks Related to Our Intellectual Property</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">If we are unable to obtain and maintain patent protection for any products we develop and for our technology, or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize products and technology similar or identical to ours, and our ability to successfully commercialize any product candidates we may develop and our technology may be adversely affected.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Our success depends in large part on our ability to obtain and maintain patent protection in the United States and other countries with respect to our product candidates. We seek to protect our proprietary position by in-licensing intellectual property relating to our platform technology and filing patent applications relating to our technologies that are important to our business. If we or our licensors are unable to obtain or maintain patent protection with respect to our product candidates, our competitive position, business, financial conditions, results of operations, and prospects could be materially harmed. We do not own any issued patents with respect to our product candidates and rely primarily on in-licensed patents and patent applications. We can provide no assurance that any of our current or future patent applications will result in issued patents or that any issued patents will provide us with any competitive advantage. Failure to obtain issued patents could have a material adverse effect on our ability to develop and commercialize our product candidates.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in either the patent laws or their interpretation in the United States and other countries may diminish our ability to protect our inventions, obtain, maintain, and enforce our intellectual property rights and, more generally, could affect the value of our intellectual property or narrow the scope of our patents. In addition, it is uncertain whether the World Trade Organization ("WTO") will waive certain intellectual property protections now or in the future on certain technologies. It is unknown if such a waiver would be limited to patents, or would include other forms of intellectual property including trade secrets and confidential know-how. We cannot be certain that any of our current or future product candidates or technologies would not be subject to an intellectual property waiver by the WTO. We also cannot be certain that any of our current or future intellectual property rights, whether patents, trade secrets, or confidential know-how would be eliminated, narrowed, or weakened by such a waiver. Given the uncertain future actions by the WTO and other countries and jurisdictions around the world, including the United States, it is unpredictable how our current or future intellectual property rights or how our current or future business would be impacted. With respect to both our in-licensed and owned intellectual property, we cannot predict whether the patent applications that we and our licensors are currently pursuing or that we may pursue in the future will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient protection from competitors.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The patent prosecution process is expensive, time-consuming, and complex, and we and our licensors may not be able to file, prosecute, maintain, enforce, or license all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output in time to obtain patent protection. Although we enter into non-disclosure and confidentiality agreements with parties who have access to confidential or patentable aspects of our research and development output, such as our employees, corporate collaborators, outside scientific collaborators, CROs, contract manufacturers, consultants, advisors, and other third parties, any of these parties may breach the agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection. In addition, publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18&#160;months after filing, or in some cases not at all. Therefore, we cannot be certain that we were the first to make the inventions claimed in our owned or any licensed patents or pending patent applications, or that we were the first to file for patent protection of such inventions.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions, and has been the subject of much litigation in recent&#160;years. As a result, the issuance, scope, validity, enforceability, and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued which protect our technology or product candidates or which effectively prevent others from commercializing competitive technologies and product candidates.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The issuance of a patent is not conclusive as to its inventorship, scope, validity, or enforceability, and our patents may be challenged in the courts or patent offices in the United States and abroad. We or our licensors may become subject to a third party pre-issuance submission of prior art to the USPTO, or opposition, derivation, revocation, reexamination, post-grant and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">inter partes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">review, or interference proceedings and other similar proceedings challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or products and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. Moreover, we, or one of our licensors, may have to participate in interference proceedings declared by the USPTO to determine priority of invention or in post-grant challenge proceedings, such as oppositions in a foreign patent office, that challenge priority of invention or other features of patentability. Such challenges may result in loss of patent rights, loss of exclusivity, or in patent claims being narrowed, invalidated, or held unenforceable, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and product candidates. Such proceedings also may result in substantial cost and require significant time from our scientists and management, even if the eventual outcome is favorable to us.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In addition, given the amount of time required for the development, testing, and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our intellectual property may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Our rights to develop and commercialize our technology and product candidates are subject, in part, to the terms and conditions of licenses granted to us by others and if we fail to comply with our current or future obligations in any agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We are heavily reliant upon licenses to certain patent rights and proprietary technology from third parties that are important or necessary to the development of our product candidates. These and other future agreements impose, and may continue to impose, numerous obligations, such as development, diligence, payment, commercialization, funding, milestone, royalty, sublicensing, insurance, patent prosecution and enforcement obligations on us and may require us to meet development timelines, or to exercise commercially reasonable efforts to develop and commercialize licensed products, in order to maintain the licenses. In spite of our best efforts, our current and future licensors might conclude that we have materially breached our license agreements and might therefore terminate the license agreements, thereby removing or limiting our ability to develop and commercialize products and technologies covered by these license agreements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In addition, we may not have the right to control the preparation, filing, prosecution, maintenance, enforcement, and defense of patents and patent applications covering the technology that we license from third parties. For example, we do not control the preparation, filing, prosecution or maintenance of patents in-licensed from OUI. Therefore, we cannot be certain that these patents and patent applications will be prepared, filed, prosecuted, maintained, enforced, and defended in a manner consistent with the best interests of our business. If our licensors fail to prosecute, maintain, enforce, and defend such patents, or lose rights to those patents or patent applications, the rights we have licensed may be reduced or eliminated, and our right to develop and commercialize any of our products that are the subject of such licensed rights could be adversely affected.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Any termination of these licenses, or any failure of the underlying patents to provide the intended exclusivity, could result in the loss of significant rights and could harm our ability to commercialize our product candidates, and competitors or other third parties would have the freedom to seek marketing authorization for, and to market, products identical to ours and we may be required to cease our development and commercialization of certain of our product candidates. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disputes may arise between us and our current and future licensors regarding intellectual property subject to a license agreement, including:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the scope of rights granted under the license agreement and other interpretation-related issues;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">whether and the extent to which our technology and processes infringe, misappropriate or otherwise violate intellectual property rights of the licensor that are not subject to the licensing agreement;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">our right to sublicense patent and other rights to third parties under collaborative development relationships and the amount of fees payable as a result of sublicensing arrangements;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">our diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization of our product candidates, and what activities satisfy those diligence obligations;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the priority of invention of any patented technology; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our current or future licensors and/or us and/or our partners.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In addition, the agreements under which we license intellectual property or technology from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations and prospects. Moreover, if disputes over intellectual property that we license prevent or impair our ability to maintain our licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates, which could have a material adverse effect on our business, financial conditions, results of operations and prospects.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In addition to the protection afforded by patents, we seek to rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable, processes for which patents are difficult to enforce and other elements of our product discovery and development processes. Although we require all of our employees, consultants, advisors and any third parties who have access to our proprietary know-how, information, or technology to enter into confidentiality agreements, trade secrets can be difficult to protect and we have limited control over the protection of trade secrets used by our collaborators and suppliers. We cannot be certain that we have or will obtain these agreements in all circumstances and we cannot guarantee that we have entered into such agreements with each party that may have or has had access to our trade secrets or proprietary information.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Moreover, any of these parties might breach the agreements and intentionally or inadvertently disclose our trade secret information and we may not be able to obtain adequate remedies for such breaches. In addition, competitors and other third parties may otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them from using that technology or information to compete with us and our competitive position would be materially and adversely harmed. Furthermore, the laws of some foreign countries do not protect proprietary rights and trade secrets to the same extent or in the same manner as the laws of the United States. As a result, we may encounter significant problems in protecting and defending our intellectual property both in the United States and abroad. If we are unable to prevent unauthorized material disclosure of our intellectual property to third parties, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">we will not be able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. If we choose to go to court to stop a third party from using any of our trade secrets, we may incur substantial costs. These lawsuits may consume our time and other resources even if we are successful and could have a material adverse effect on our business, financial conditions, results of operations and prospects.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">The intellectual property landscape around immunotherapeutic, nanoparticle and viral vector-based products is crowded and dynamic, and third parties may initiate legal proceedings alleging that we are infringing, misappropriating or otherwise violating their intellectual property rights and such claims may be costly and time-consuming and may prevent or delay our product discovery and development efforts.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The intellectual property landscape around immunotherapeutic, nanoparticle and viral vector-based products is crowded and dynamic, and third parties may initiate legal proceedings alleging that we are infringing, misappropriating, or otherwise violating their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business. Our commercial success depends upon our ability to develop, manufacture, market and sell our current and future product candidates and use our proprietary technologies without infringing, misappropriating or otherwise violating the intellectual property rights of third parties. There is a substantial amount of litigation involving patents and other intellectual property rights in the biotechnology and pharmaceutical industries, as well as administrative proceedings for challenging patents, including derivation, interference, reexamination, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">inter partes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">review, and post-grant review proceedings before the USPTO or oppositions and other comparable proceedings in foreign jurisdictions. We or any of our licensors or strategic partners may be party to, exposed to, or threatened with, adversarial proceedings or litigation by third parties having patent or other intellectual property rights alleging that our current or future product candidates and/or proprietary technologies infringe, misappropriate or otherwise violate their intellectual property rights. We cannot assure you that our product candidates and other technologies that we have developed, are developing or may develop in the future do not or will not infringe, misappropriate or otherwise violate existing or future patents or other intellectual property rights owned by third parties. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, including our competitors, exist in the fields in which we are developing our product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may give rise to claims of infringement of the patent rights of others. Moreover, it is not always clear to industry participants, including us, which patents cover various types of viral vectors and vaccines or their methods of use or manufacture. Thus, because of the large number of patents issued and patent applications filed in our fields, there may be a risk that third parties may allege they have patent rights encompassing our product candidates, technologies or methods. For example, we are aware of third-party patents in the United States and Europe with claims which may be relevant to our VTP-300 and VTP-850 product candidates. In the event that these patents were asserted against us in an infringement action, we may have to argue that the manufacture, use, sale or importation of our VTP-300 or VTP-850 product candidates in the United States and Europe do not infringe any valid claim of the asserted patents. There is no assurance that a court would find in our favor on questions of infringement or validity.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If a third party (including any third party that controls the above referenced patents) claims that we infringe, misappropriate or otherwise violate its intellectual property rights (including the above referenced patents), we may face a number of risks, including, but not limited to:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">infringement, misappropriation and other intellectual property claims which, regardless of merit, may be expensive and time- consuming to litigate and may divert our management&#8217;s attention from our core business and may impact our reputation;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">substantial damages for infringement, misappropriation or other violations, which we may have to pay if a court decides that the product candidate or technology at issue infringes, misappropriates or violates the third party&#8217;s rights, and, if the court finds that the infringement was willful, we could be ordered to pay treble damages and the patent owner&#8217;s attorneys&#8217; fees;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">a court prohibiting us from developing, manufacturing, marketing or selling our product candidates, or from using our proprietary technologies, unless the third party licenses its product rights to us, which it is not required to do, on commercially reasonable terms, or at all;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">if a license is available from a third party, we may have to pay substantial royalties, upfront fees and other amounts, and/or grant cross-licenses to intellectual property rights for our products, or the license to us may be non-exclusive, which would permit third parties to use the same intellectual property to compete with us;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">redesigning our product candidates or processes so they do not infringe, misappropriate or violate third party intellectual property rights, which may not be possible or may require substantial monetary expenditures and time; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">there could be public announcements of the results of hearings, motions or other interim proceedings or developments, and, if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on our share price.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise the funds necessary to continue our operations or could otherwise have a material adverse effect on our business, results of operations, financial condition and prospects. The occurrence of any of the foregoing could have a material adverse effect on our business, financial condition, results of operations or prospects.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We may choose to challenge the patentability of claims in a third party&#8217;s U.S. patent by requesting that the USPTO review the patent claims in an </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">ex-parte </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">reexamination, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">inter partes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">review or post-grant review proceedings. These proceedings are expensive and may consume our time or other resources. We may choose to challenge a third party&#8217;s patent in patent opposition proceedings in the European Patent Office ("EPO") or other foreign patent office. The costs of these opposition proceedings could be substantial, and may consume our time or other resources. If we fail to obtain a favorable result at the USPTO, EPO or other patent office then we may be exposed to litigation by a third party alleging that the patent may be infringed by our product candidates or proprietary technologies.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Third parties may assert that we are employing their proprietary technology without authorization. Patents issued in the United States by law enjoy a presumption of validity that can be rebutted only with evidence that is &#8220;clear and convincing,&#8221; a heightened standard of proof. There may be issued third-party patents of which we are currently unaware with claims to compositions of matter, methods of manufacture or methods for treatment related to our product candidates, their manufacture or use. Patent applications can take many&#160;years to issue. In addition, because some patent applications in the United States may be maintained in secrecy until the patents are issued, patent applications in the United States and many foreign jurisdictions are typically not published until 18&#160;months after filing, and publications in the scientific literature often lag behind actual discoveries, we cannot be certain that others have not filed patent applications covering our product candidates or technology. If any such patent applications issue as patents, and if such patents have priority over our patent applications or patents we may own or in-license, we may be required to obtain rights to such patents owned by third parties which may not be available on commercially reasonable terms, or at all, or may only be available on a non- exclusive basis. There may be currently pending patent applications which may later result in issued patents that our product candidates may infringe. It is also possible that patents owned by third parties of which we are aware, but which we do not believe are relevant to our product candidates or other technologies, could be found to be infringed by our product candidates or other technologies. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. Moreover, we may fail to identify relevant patents or incorrectly conclude that a patent is invalid, not enforceable, exhausted, or not infringed by our activities. If any third-party patents were held by a court of competent jurisdiction to cover the manufacturing process of our product candidates, molecules used in or formed during the manufacturing process, or any final product itself, the holders of any such patents may be able to block our ability to commercialize the product candidate unless we obtained a license under the applicable patents, or until such patents expire or they are finally determined to be held invalid or unenforceable. Similarly, if any third-party patent were held by a court of competent jurisdiction to cover aspects of our product candidates, process for their manufacture or methods of use, including combination therapies or participant selection methods, the holders of any such patent may be able to block our ability to develop and commercialize the product candidate unless we obtained a license or until such patent expires or is finally determined to be held invalid or unenforceable. In either case, such a license may not be available on commercially reasonable terms, or at all. If we are unable to obtain a necessary license to a third-party patent on commercially reasonable terms, or at all, our ability to commercialize our product candidates may be impaired or delayed, which could in turn significantly harm our business. Even if we obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In addition, if the breadth or strength of protection provided by our patent applications or any patents we in-license or may own in the future is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Parties making claims against us may seek and obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize our product candidates. Defense of these claims, regardless of their merit, could involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement, misappropriation or other violation against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, obtain one or more licenses from third parties, pay royalties or redesign our infringing products, which may be impossible or require substantial time and monetary expenditure. We cannot predict whether any such license would be available at all or whether it would be available on commercially reasonable terms. Furthermore, even in the absence of litigation, we may need or may choose to obtain licenses from third parties to advance our research or allow commercialization of our product candidates. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors and other third parties access to the same technologies licensed to us, and it could require us to make substantial licensing and royalty payments. We also could be forced, including by court order, to cease developing, manufacturing, and commercializing the infringing technology or product candidates. In that event, we would be unable to further develop and commercialize our product candidates, which could harm our business significantly.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">We may not be successful in obtaining or maintaining necessary rights to product components and processes for our development pipeline through acquisitions and in-licenses.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We currently have rights to intellectual property, through licenses from third parties, to develop and commercialize our product candidates. Many pharmaceutical companies, biotechnology companies, and academic institutions are competing with us in the field of infectious disease, immune tolerance and oncology and filing patent applications potentially relevant </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">to our business. Because our current and future product candidates may require the use of proprietary rights held by third parties, the growth of our business will likely depend in part on our ability to acquire, in-license or use these proprietary rights.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Our product candidates may also require particular vector components or gene sequences encoding antigenic peptides to work effectively and efficiently and these rights may be held by others. Similarly, efficient production, delivery or use of our product candidates may also require specific compositions or methods, and the rights to these may be owned by third parties. We may be unable to acquire or in-license any compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify as necessary or important to our business operations. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all, which would harm our business. We may need to cease use of the compositions or methods covered by such third-party intellectual property rights, and may need to seek to develop alternative approaches that do not infringe on such intellectual property rights which may entail additional costs and development delays, even if we were able to develop such alternatives, which may not be feasible. Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. We may be required to expend significant time and resources to develop or license replacement technology. Moreover, the molecules that will be used with our product candidates may be covered by the intellectual property rights of others.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additionally, we sometimes collaborate with academic institutions to accelerate our preclinical research or development under written agreements with these institutions. In certain cases, these institutions provide us with an option to negotiate a license to any of the institution&#8217;s rights in technology resulting from the collaboration. Regardless of such option, we may be unable to negotiate a license within the specified timeframe or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to others, potentially blocking our ability to pursue our program and allowing third parties to compete with us. If we are unable to successfully obtain rights to required third-party intellectual property or to maintain the existing intellectual property rights we have, we may have to abandon development of such program and our business and financial condition could suffer.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The licensing and acquisition of third-party intellectual property rights is a competitive area, and companies, which may be more established, or have greater resources than we do, may also be pursuing strategies to license or acquire third-party intellectual property rights that we may consider necessary or attractive in order to commercialize our product candidates. More established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would enable us to make an appropriate return on our investment or at all. There can be no assurance that we will be able to successfully complete such negotiations and ultimately acquire the rights to the intellectual property surrounding the additional product candidates that we may seek to acquire. If we are unable to successfully obtain rights to required third-party intellectual property or to maintain the existing intellectual property rights we have, we may have to abandon development of such program and our business, results of operations, financial condition and prospects could suffer.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">We may be involved in lawsuits to protect or enforce our intellectual property rights, including any patents we may own or in- license in the future, which could be expensive, time-consuming and unsuccessful.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Competitors may infringe any patents we in-license or may own in the future. In addition, any patents we may in-license or own also may become involved in inventorship, priority, validity or unenforceability disputes. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. In addition, in an infringement proceeding, a court may decide that one or more of any patents we may in-license or own in the future is not valid or is unenforceable or that the other party&#8217;s use of our technology falls under the safe harbor to patent infringement under 35 U.S.C. &#167;271 (e)(1). There is also the risk that, even if the validity of these patents is upheld, the court may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question or that such third party&#8217;s activities do not infringe our patents. An adverse result in any litigation or defense proceedings could put one or more of any patents we in-license or may own in the future at risk of being invalidated, held unenforceable, or interpreted narrowly and could put our patent applications at risk of not issuing. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, obtain one or more licenses from third parties, pay royalties or redesign our infringing products, which may be impossible or require substantial time and monetary expenditure. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing, or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Post-grant proceedings provoked by third parties or brought by the USPTO may be necessary to determine the validity or priority of inventions with respect to our patent applications or any patents we may in-license or own in the future. These proceedings are expensive and an unfavorable outcome could result in a loss of our current patent rights and could require </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. In addition to potential USPTO review proceedings, we may become a party to patent opposition proceedings in the EPO, or similar proceedings in other foreign patent offices, where our foreign patents are challenged. For example, one of our in-licensed European patents relating to our now discontinued MVA influenza product candidate has been revoked in a European opposition proceeding. This decision is currently on appeal, although there can be no assurance that any such appeal will be successful. The costs of opposition or similar proceedings could be substantial, and may result in a loss of scope of some claims or a loss of the entire patent. An unfavorable result at the USPTO, EPO or other patent office may result in the loss of our right to exclude others from practicing one or more of our inventions in the relevant country or jurisdiction, which could have a material adverse effect on our business.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Litigation or post-grant proceedings may result in a decision adverse to our interests and, even if we are successful, may result in substantial costs and distract our management and other employees. We may not be able to prevent, misappropriation of our trade secrets or confidential information, particularly in countries where the laws may not protect those rights as fully as in the United States.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our ADSs.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We may not be able to detect infringement of any patents we may in-license or own. Even if we detect infringement by a third party of any such patents, we may choose not to pursue litigation against or settlement with the third party. If we later sue such third party for patent infringement, the third party may have certain legal defenses available to it, which otherwise would not be available except for the delay between when the infringement was first detected and when the suit was brought. Such legal defenses may make it impossible for us to enforce any patents we may own or in-license against such third party.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and patent protection could be reduced or eliminated for non- compliance with these requirements.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Periodic maintenance fees, renewal fees, annuity fees and various other government fees on any issued patents and patent applications are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patent. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process and following the issuance of a patent. While an inadvertent lapse can in some cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. In such an event, our competitors and other third parties might be able to enter the market with similar or identical products or platforms, which could have a material adverse effect on our business prospects and financial condition.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Any issued patents we in-license or may own now or in the future covering our product candidates could be narrowed or found invalid or unenforceable if challenged in court or before administrative bodies in the United States or abroad, including the USPTO.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If we or our licensors or strategic partners initiate legal proceedings against a third party to enforce a patent covering one of our product candidates, the defendant could counterclaim that the patent covering our product candidate, as applicable, is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace, and there are numerous grounds upon which a third party can assert invalidity or unenforceability of a patent. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of patentable subject matter, lack of written description, lack of novelty, obviousness, or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. Third parties may also raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include reexamination, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">inter partes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">review, post-grant review, interference proceedings, derivation proceedings and equivalent proceedings in foreign jurisdictions (such as opposition proceedings). Such proceedings could result in revocation or amendment to our in-licensed patent applications or patents or any patent applications or patents we may own in the future in such a way that they no longer cover our product candidates. The outcome following legal assertions of invalidity and unenforceability is unpredictable. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate or render unenforceable, any rights we may have from our patent applications or any patents we in-license or may own in the future, allow third parties to commercialize our product candidates or other technologies and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Such proceedings also may result in substantial cost and require significant time from our scientists and management, even if the eventual outcome is favorable to us. If we are unsuccessful in any such proceeding or other priority or inventorship dispute, we may be required to obtain and maintain licenses from third parties, including parties involved in any such interference proceedings or other priority or inventorship disputes. Such licenses may not be available on commercially reasonable terms, or at all, or may be non-exclusive. If we are unable to obtain and maintain such licenses, we may need to cease the development, manufacture, and commercialization of one or more of the product candidates we may develop. The loss of exclusivity or the narrowing of our patent application claims could limit our ability to stop others from using or commercializing similar or identical technology and products. Any of the foregoing could have a material adverse effect on our business, results of operations, financial condition and prospects.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">We may be subject to claims challenging the inventorship or ownership of any intellectual property, including any patents we may in-license or own in the future.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We may be subject to claims that former employees, collaborators or other third parties have an interest in any patents we in-license or may own in the future, trade secrets, or other intellectual property as an inventor or co-inventor. For example, we may have inventorship disputes arise from conflicting obligations of employees, consultants or others who are involved in developing our product candidates or other technologies. We generally enter into confidentiality and intellectual property assignment agreements with our employees, consultants, and contractors. These agreements generally provide that inventions conceived by the party in the course of rendering services to us will be our exclusive property. However, those agreements may not be honored and may not effectively assign intellectual property rights to us. Moreover, there may be some circumstances, where we are unable to negotiate for such ownership rights. Disputes regarding ownership or inventorship of intellectual property can also arise in other contexts, such as collaborations and sponsored research. If we are subject to a dispute challenging our rights in or to patents or other intellectual property, such a dispute could be expensive and time-consuming. Litigation may be necessary to defend against these and other claims challenging inventorship of any patents we in-license or may own in the future, trade secrets or other intellectual property. If we were unsuccessful, in addition to paying monetary damages, we could lose valuable rights in intellectual property that we regard as our own, such as exclusive ownership of, or right to use, intellectual property that is important to our product candidates and other technologies. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information or alleged trade secrets of third parties or competitors or are in breach of non-competition or non- solicitation agreements with our competitors or other third parties.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We have received confidential and proprietary information from third parties. In addition, as is common in the biotechnology and pharmaceutical industries, we employ individuals who were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. We may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed confidential information or trade secrets of these third parties. In addition, we may in the future be subject to claims that we caused an employee to breach the terms of his or her non-competition or non-solicitation agreement. Litigation or arbitration may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation or other legal proceedings relating to intellectual property claims and possible aftermath could result in substantial cost and be a distraction to our management and employees. Any litigation or the threat thereof may adversely affect our ability to hire employees. A loss of key personnel or their work product could hamper or prevent our ability to commercialize product candidates, which could have an adverse effect on our business, results of operations and financial condition. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments, and, if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on our share price. This type of litigation or proceeding could substantially increase our operating losses and reduce our resources available for development activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their substantially greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other intellectual property related proceedings could adversely affect our ability to compete in the marketplace.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In addition, while it is our policy to require our employees and contractors who may be involved in the development of intellectual property to execute agreements that provide that all inventions conceived by the individual, and which are related to our current or planned business or research and development or made during normal working hours, on our premises or using our equipment or proprietary information, are our exclusive property, we may be unsuccessful in executing such an agreement with each party who, in fact, develops intellectual property that we regard as our own. The assignment of intellectual property rights may not be self- executing, or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. Such claims could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">If we do not obtain patent term extension and data exclusivity for any of our current or future product candidates we may develop, our business may be materially harmed.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depending upon the timing, duration and specifics of any FDA marketing approval of any of our current or future product candidates we may develop, one or more U.S. patents we in-license or may own in the future may be eligible for limited patent term extension under the Hatch-Waxman Amendments. The Hatch- Waxman Amendments permit a patent term extension of up to five&#160;years as compensation for patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14&#160;years from the date of product approval, only one patent may be extended and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. However, we may not be granted an extension because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents, or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or the term of any such extension is shorter than what we request, our competitors or other third parties may obtain approval of competing products following expiration of any patents that issue from our patent applications, and our business, financial condition, results of operations, and prospects could be materially harmed.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Changes to patent law in the United States and in foreign jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As is the case with other biotechnology and pharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involve both technological and legal complexity, and is therefore costly, time-consuming and inherently uncertain. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce patents that we might obtain in the future. For example, in the case </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Assoc. for Molecular Pathology v. Myriad Genetics,&#160;Inc., </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the U.S. Supreme Court held that certain claims to DNA molecules are not patentable. Any adverse changes in the patent laws of other jurisdictions could have a material adverse effect on our business and financial condition. Changes in the laws and regulations governing patents in other jurisdictions could similarly have an adverse effect on our ability to obtain and effectively enforce any rights we may have in our patent applications or any patents we may own or in-license in the future.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recent or future patent reform legislation could also increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of any patents we in-license or may own in the future. The United States has enacted and implemented wide-ranging patent reform legislation. On September&#160;16, 2011, the Leahy-Smith America Invents Act ("America Invents Act"), was signed into law, which includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted, redefine prior art, may affect patent litigation, establish a new post-grant review system and switch the U.S. patent system from a &#8220;first-to-invent&#8221; system to a &#8220;first-to-file&#8221; system. Under a &#8220;first-to-file&#8221; system, assuming the other requirements for patentability are met, the first inventor to file a patent application generally will be entitled to a patent on the invention regardless of whether another inventor had made the invention earlier. Since patent applications in the United States and most other countries are confidential for a period of time after filing or until issuance, we cannot be certain that we or our licensors were the first to either (i)&#160;file any patent application related to our product candidates or other technologies or (ii)&#160;invent any of the inventions claimed in our patent applications or any patents we may own or in-license. These changes also allow third party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO administered post-grant proceedings, including post-grant review, inter partes review, and derivation proceedings. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in United States federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. An adverse determination in any such proceeding could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or products and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. Accordingly, the America Invents Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of any issued patents we in-license or may own in the future, all of which could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Our European patents and patent applications could be challenged in the recently created Unified Patent Court (UPC) for the European Union, that is expected to be fully ratified in 2023. We may decide to opt out our European patents and patent applications from the UPC. However, if certain formalities and requirements are not met, our European patents and patent applications could be challenged for non-compliance and brought under the jurisdiction of the UPC. We cannot be certain that our European patents and patent applications will avoid falling under the jurisdiction of the UPC, if we decide to opt out of the UPC. Under the UPC, a granted European patent would be valid and enforceable in numerous European countries. A successful invalidity challenge to a European patent under the UPC would result in loss of patent protection in those European countries. Accordingly, a single proceeding under the UPC could result in the partial or complete loss of </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">patent protection in numerous European countries, rather than in each validated European country separately as such patents always have been adjudicated. Such a loss of patent protection could have a material adverse impact on our business and our ability to commercialize our technology and product candidates and, resultantly, on our business, financial condition, prospects and results of operations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">We may not be able to protect our intellectual property and proprietary rights throughout the world.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filing, prosecuting, and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and the laws of foreign countries may not protect our rights to the same extent as the laws of the United States. In addition, our intellectual property license agreements may not always include worldwide rights. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection or licenses but enforcement is not as strong as that in the United States. These products may compete with our products, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets, and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our intellectual property and proprietary rights generally. Proceedings to enforce our intellectual property and proprietary rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, could put our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property and proprietary rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. As a result, in response to the COVID-19 pandemic, it is possible that certain countries may take steps to facilitate compulsory licenses that permit the distribution of a COVID-19 vaccine in those countries. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of the relevant patent rights. If we or any of our licensors is forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations, and prospects may be adversely affected.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our marks of interest and our business may be adversely affected.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Our trademarks or trade names may be challenged, infringed or diluted, lapsed, abandoned, circumvented or declared generic or determined to be infringing on or become dilutive of other marks, or otherwise invalidated through administrative process or litigation. We intend to rely on both registration and common law protection for our trademarks. We may not be able to protect our rights to these trademarks and trade names or may be forced to stop using these names, which we need for name recognition by potential partners or customers in our markets of interest. Third parties may use trademarks similar to our trademarks and any potential confusion as to the source of goods or services could have an adverse effect on our business. For example, in April 2022, we received a letter asserting that our use of our &#8220;Vaccitech&#8221; trademark infringes a United Kingdom trademark held by a third party. We timely responded rejecting the claims and we believe that such claims are without merit. However, if such third party continues to assert its claims, we cannot provide any assurance whether we could reach a settlement relating to such claims or whether we would prevail in any litigation or action related to such claims.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Moreover, during the trademark registration process, we may receive Office Actions from the USPTO objecting to the registration of our trademarks. Although we would be given an opportunity to respond to those objections, we may be unable to overcome such rejections. In addition, at the USPTO and at comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and/or to seek the cancellation of registered trademarks through opposition or cancellation proceedings against our trademarks, and if such third parties are successful, our trademarks may not survive such proceedings. In some cases, there may be third-party trademark owners who have prior rights to our trademarks or third parties who have prior rights to similar trademarks, and we may not be able to prevent such third parties from using and marketing any such trademarks. Litigation brought to protect and enforce our intellectual property rights could be costly, unpredictable, time-consuming and distracting to management, regardless of whether we are successful in such litigation. If we are unable to obtain a registered trademark or establish name recognition based on our trademarks and trade names, we may not be able to compete effectively and our business, results of operations and financial condition may be adversely affected.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Numerous factors may limit any potential competitive advantage provided by the relevant patent rights.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The degree of future protection afforded by our intellectual property rights, whether owned or in-licensed, is uncertain because intellectual property rights have limitations, and may not adequately protect our business, provide a barrier to entry against our competitors or potential competitors, or permit us to maintain our competitive advantage. Moreover, if a third party has intellectual property rights that cover the practice of our technology, we may not be able to fully exercise or extract value from our intellectual property rights. The following examples are illustrative:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">patent applications that we own or in-license may not lead to issued patents;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">patents, that we in-license or may own in the future, may not provide us with any competitive advantages, may be narrowed in scope, or may be challenged and held invalid or unenforceable;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">others may be able to develop and/or practice technology, including compounds that are similar to the chemical compositions of our product candidates, that is similar to our technology or aspects of our technology but that is not covered by the claims of any patents we in-license or may own in the future;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">third parties may compete with us in jurisdictions where we do not pursue and obtain patent protection;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">we, or our licensors or collaborators, might not have been the first to make the inventions covered by a patent application that we own or in-license;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">we, or our licensors or collaborators, might not have been the first to file patent applications covering a particular invention;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">others may independently develop similar or alternative technologies without infringing, misappropriating or otherwise violating our intellectual property rights;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">our competitors or other third parties might conduct research and development activities in the United States and other countries that provide a safe harbor from patent infringement claims for certain research and development activities, as well as in countries where we do not have patent rights, and may then use the information learned from such activities to develop competitive products for sale in our major commercial markets;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">we may not be able to obtain and/or maintain necessary licenses on reasonable terms, or at all;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">third parties may assert an ownership interest in our intellectual property and, if successful, such disputes may preclude us from exercising exclusive rights, or any rights at all, over that intellectual property;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">we may choose not to file a patent in order to maintain certain trade secrets or know-how, and a third party may subsequently file a patent covering such trade secrets or know-how;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">we may not be able to maintain the confidentiality of our trade secrets or other proprietary information;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">we may not develop or in-license additional proprietary technologies that are patentable; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the patents of others may have an adverse effect on our business.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Should any of these events occur, they could significantly harm our business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Risks Related to Employee Matters, Managing Our Growth and Other Risks Related to Our Employee Matters</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">We are highly dependent on our key personnel, and if we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Our ability to compete in the highly competitive biotechnology and pharmaceutical industries depends upon our ability to attract and retain highly qualified managerial, scientific and medical personnel. We are highly dependent on our management, scientific and medical personnel, including Bill Enright, our Chief Executive Officer. The loss of the services of any of our executive officers, other key employees and other scientific and medical advisors, and an inability to find suitable replacements could result in delays in product development and harm our business.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We conduct our operations at our facilities in Harwell, United Kingdom and Germantown, Maryland. These regions are headquarters to many other biopharmaceutical companies and many academic and research institutions. Competition for skilled personnel in these markets is intense and may limit our ability to hire and retain highly qualified personnel on acceptable terms, or at all. Changes to U.K., U.S. or similar foreign immigration and work authorization laws and regulations, including those that restrain the flow of scientific and professional talent, can be significantly affected by </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">political forces and levels of economic activity. Our business may be materially adversely affected if legislative or administrative changes to the U.K. (including, but not limited to, those that result as a direct or indirect consequence of Brexit), U.S. or similar foreign immigration or visa laws and regulations impair our hiring processes and goals or projects involving personnel who are not U.S. citizens.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">To encourage valuable employees to remain at our company, in addition to salary and cash incentives, we have provided stock options that vest over time. The value to employees of stock options that vest over time may be significantly affected by movements in our share price that are beyond our control, and may at any time be insufficient to counteract more lucrative offers from other companies. Despite our efforts to retain valuable employees, members of our management, scientific and development teams may terminate their employment with us on short notice. Although we have employment agreements with all our employees, these employment agreements with U.S. employees provide for at-will employment, which means that any of our U.S. employees could leave our employment at any time, by providing the required contractual notification of their intent to leave. The standard notice period for U.K. employed personnel is three calendar&#160;months or six calendar&#160;months for the senior executive team. Our success also depends on our ability to continue to attract, retain and motivate highly skilled junior, mid-level and senior managers as well as junior, mid-level and senior scientific and medical personnel.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Risks Related to Our Business Operations and Growth</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">We will need to grow the size of our organization, and we may experience difficulties in managing this growth.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of December 31, 2023, we had 130 full-time and part-time employees. As our development and commercialization plans and strategies develop, and as we continue to transition into operating as a public company, we expect to need additional managerial, operational, technical, sales, marketing, financial and other personnel, as well as additional facilities to expand our operations. Future growth would impose significant added responsibilities on members of management, including:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">identifying, recruiting, integrating, maintaining and motivating additional and existing employees;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">managing clinical trial sites in multiple countries;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">managing our internal development efforts effectively, including the clinical and regulatory review process for our product candidates, while complying with our contractual obligations to contractors and other third parties; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">improving our operational, financial and management controls, reporting systems and procedures.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Our future financial performance and our ability to commercialize our product candidates will depend, in part, on our ability to effectively manage any future growth, and our management may also have to divert a disproportionate amount of its attention away from day-to-day activities in order to devote a substantial amount of time to managing these growth activities.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">There can be no assurance that the services of independent organizations, advisors and consultants will continue to be available to us on a timely basis when needed, or that we can find qualified replacements. In addition, if we are unable to effectively manage our outsourced activities or if the quality or accuracy of the services provided by consultants is compromised for any reason, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain marketing authorization for our product candidates or otherwise advance our business. There can be no assurance that we will be able to manage our existing consultants or find other competent outside contractors and consultants on economically reasonable terms, or at all.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If we are not able to effectively expand our organization by hiring new employees and expanding our groups of consultants and contractors, or we are not able to effectively build out new facilities to accommodate this expansion, we may not be able to successfully implement the tasks necessary to further develop and commercialize our product candidates and, accordingly, may not achieve our research, development and commercialization goals.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Our internal computer systems, or those used by our third-party CROs or other contractors or consultants, may fail or suffer security breaches, which could result in the disclosure of confidential or proprietary information, including personal data, damage to our reputation, and subject us to significant financial and legal exposure and cause a material disruption of the development programs of our product candidates.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We and our third-party CROs and other contractors and consultants rely extensively on information technology systems to conduct and manage our business. Despite the implementation of security measures, our internal computer systems and those of our current and future third-party providers are vulnerable to damage from computer viruses and unauthorized access. The risk of a security breach or disruption, particularly through cyberattacks or cyber intrusion, including by computer hackers, foreign governments, and cyber terrorists, has generally increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased. Cyberattacks could include wrongful conduct by hostile foreign governments, industrial espionage, wire fraud and other forms of cyber fraud, the deployment of harmful malware, denial-of-service, social engineering fraud or other means to threaten data security, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">confidentiality, integrity and availability. If such an event were to occur, it could result in the theft or destruction of intellectual property, data or other misappropriation of assets, or otherwise compromise our confidential or proprietary information and result in a material disruption of our development programs and our business operations, such as the loss of clinical trial data from completed or future clinical trials. Such loss could result in delays in our marketing authorization efforts and significantly increase our costs to recover or reproduce the data.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Although we devote resources to protect our information systems, including organization-wide prevention software, we realize that cyberattacks are a threat, and there can be no assurance that our efforts will prevent information security breaches that would result in business, legal, financial or reputational harm to us, or would have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Likewise, we rely on third parties for the manufacture of our product candidates and to conduct clinical trials, and similar events relating to their computer systems could also have a material adverse effect on our business. We rely on our third-party providers to implement effective security measures and identify and correct for any such failures, deficiencies or breaches.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Any breach in our or our third-party providers&#8217; information technology systems could lead to the unauthorized access, disclosure and use of non-public information, including information from our participant registry or other participant information, which is protected by HIPAA, and other laws. Any such access, disclosure, or other loss of information could result in legal claims or proceedings, liability under laws that protect the privacy of personal information, damage to our reputation and the further development and commercialization of our product candidates could be delayed. If we or our third-party providers fail to maintain or protect our information technology systems and data integrity effectively or fail to anticipate, plan for or manage significant disruptions to our information technology systems, we or our third-party providers could have difficulty preventing, detecting and controlling such cyberattacks and any such attacks could result in losses described above as well as disputes with physicians, participants and our partners, regulatory sanctions or penalties, increases in operating expenses, expenses or lost revenues or other adverse consequences, any of which could have a material adverse effect on our business, results of operations, financial condition, prospects and cash flows. If we are unable to prevent or mitigate the impact of such security or data privacy breaches, we could be exposed to litigation and governmental investigations, which could lead to a potential disruption to our business.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Our operations, and those of our CROs, CMOs and other contractors and consultants, could be subject to earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, medical epidemics, pandemics and other natural or man-made disasters or business interruptions, for which we are predominantly self-insured. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses. We rely on third-party manufacturers to produce our product candidates. Our ability to obtain clinical supplies of our product candidates could be disrupted if the operations of these suppliers are affected by a man-made or natural disaster or other business interruption.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product candidates.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We face an inherent risk of product liability as a result of the clinical testing of our product candidates and will face an even greater risk if we commercialize any product candidate for which we receive marketing authorization. For example, we may be sued if our product candidates cause or are perceived to cause injury or are found to be otherwise unsuitable during clinical testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability or a breach of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our product candidates. Even successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">decreased demand for our product candidates or products that we may develop;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">injury to our reputation;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">withdrawal of clinical trial participants;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">initiation of investigations by regulators;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">costs to defend the related litigation;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">a diversion of management&#8217;s time and our resources;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">substantial monetary awards to trial participants or participants;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">product recalls, withdrawals or labeling, marketing or promotional restrictions;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">loss of revenue;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">exhaustion of any available insurance and our capital resources;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the inability to commercialize any product candidate; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">a decline in our share price.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Failure to obtain or retain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of products we develop, alone or with corporate collaborators. Although we have clinical trial insurance, our insurance policies also have various exclusions, and we may be subject to a product liability claim for which we have no coverage. In the future, we may be unable to maintain this insurance coverage, or we may not be able to obtain additional or replacement coverage at a reasonable cost, if at all. We may have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. Even if our agreements with any future corporate collaborators entitle us to indemnification against losses, such indemnification may not be available or adequate should any claim arise.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Unfavorable global economic conditions could adversely affect our business, financial condition or results of operations.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets. The most recent global financial crisis caused extreme volatility and disruptions in the capital and credit markets. A severe or prolonged economic downturn could result in a variety of risks to our business, including a reduced ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy or international trade disputes could also strain our third-party suppliers, possibly resulting in supply disruption. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact our business.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Risks Related to Our International Operations</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">A variety of risks associated with operating our business internationally could materially adversely affect our business.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We plan to seek marketing authorization for our product candidates outside of the United States and, accordingly, we expect that we, and any potential collaborators in those jurisdictions, will be subject to additional risks related to operating in foreign countries, including:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">differing regulatory requirements in foreign countries;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">unexpected changes in tariffs, trade barriers, price and exchange controls, and other regulatory requirements;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">economic weakness, including inflation, or political instability in particular foreign economies and markets;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">compliance with tax, employment, immigration, and labor laws for employees living or traveling abroad;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">foreign taxes, including withholding of payroll taxes;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">difficulties staffing and managing foreign operations;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">workforce uncertainty in countries where labor unrest is more common than in the United States;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">potential liability under the FCPA Office of Foreign Assets Control Anti-Money Laundering Program as required by the Bank Secrecy Act and its implementing regulations, or comparable foreign laws, including the UK Bribery Act 2010 ("Bribery Act");</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">challenges enforcing our contractual and intellectual property rights, especially in those foreign countries that do not respect and protect intellectual property rights to the same extent as the United States;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">business interruptions resulting from geo-political actions, including war and terrorism.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">These and other risks associated with our planned international operations may materially adversely affect our ability to attain or maintain profitable operations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Our business is subject to economic, political, regulatory and other risks associated with international operations.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Our business is subject to risks associated with conducting business internationally. Accordingly, our future results could be harmed by a variety of factors, including the following:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">economic weakness, including inflation, political instability in particular in foreign economies and markets;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">differing regulatory requirements for drug approvals;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">differing jurisdictions potentially presenting different issues for securing, maintaining or obtaining freedom to operate in such jurisdictions;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">potentially reduced protection for intellectual property rights;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">difficulties in compliance with different, complex and changing laws, regulations and court systems of multiple jurisdictions and compliance with a wide variety of foreign laws, treaties and regulations;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">changes in regulations and customs, tariffs and trade barriers;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">changes in currency exchange rates of the euro, U.S. dollar, pound sterling and currency controls;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">changes in a specific country&#8217;s or region&#8217;s political or economic environment;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">trade protection measures, import or export licensing requirements or other restrictive actions by governments;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">differing reimbursement regimes and price controls in certain international markets;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">negative consequences from changes in tax laws or practice;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">workforce uncertainty in countries where labor unrest is more common than in the United States and EU;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">difficulties associated with staffing and managing international operations, including differing labor relations;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">business interruptions resulting from geo-political actions, including war, terrorism, pandemics, or natural disasters including earthquakes, typhoons, floods and fires.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Claims of U.S. civil liabilities may not be enforceable against us.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We are incorporated under English law and have our registered office in England. Many of the members of our senior management and certain members of our board of directors are non-residents of the United States, and all or a substantial portion of our assets and the assets of such persons are held outside the United States. As a result, it may not be possible to serve process on such persons or us in the United States or to enforce judgments obtained in U.S. courts against them or us based on civil liability provisions of the U.S. federal securities laws.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The United States and the UK do not currently have a treaty providing for recognition and enforcement of judgments (other than arbitration awards) in civil and commercial matters. Consequently, a final judgment for payment given by a court in the United States, whether or not predicated solely upon U.S. securities laws, would not automatically be recognized or enforceable in the UK. In addition, uncertainty exists as to whether the courts of England and Wales would entertain original actions brought in the UK against us or our directors or senior management predicated upon securities laws of the U.S. or any state in the United States. Any final and conclusive monetary judgment for a definite sum obtained against us in U.S. courts would be treated by the courts of England and Wales as a cause of action in itself and sued upon as a debt at common law so that no retrial of the issues would be necessary, provided that certain requirements are met. Whether these requirements are met in respect of a judgment based upon the civil liability provisions of the U.S. securities laws, including whether the award of monetary damages under such laws would constitute a penalty, is an issue for the court making such decision. If the courts of England and Wales give a judgment for the sum payable under a U.S. judgment, the English </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">judgment will be enforceable by methods generally available for this purpose. These methods generally permit the courts of England and Wales discretion to prescribe the manner of enforcement.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As a result, U.S. investors may not be able to enforce against us or certain of our senior management, board of directors or certain experts named herein who are residents of the UK or countries other than the United States any judgments obtained in U.S. courts in civil and commercial matters, including judgments under the U.S. federal securities laws.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Fluctuations in the exchange rate between the U.S. dollar and the pound sterling may increase the risk of holding our ADSs and may materially affect our results of operations and financial condition.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Our ADSs trade on Nasdaq in U.S. dollars. Due to the international scope of our operations, our assets, earnings and cash flows are influenced by movements in exchange rates of several currencies, particularly the U.S. dollar, the pound sterling and the euro. Our reporting currency is denominated in U.S. dollars and our functional currency is the pound sterling (except that the functional currency of our U.S. subsidiaries is the U.S. dollar) and the majority of our operating expenses are paid in pound sterling. We also regularly acquire services, consumables and materials in U.S. dollars, pound sterling, AUS dollars and the euro. Further potential future revenue may be derived from abroad, particularly from the United States. As a result, our business and the price of our ADSs may be affected by fluctuations in foreign exchange rates between the pound sterling and these other currencies, which may also have a significant impact on our results of operations and cash flows from period to period. Currently, we do not have any exchange rate hedging arrangements in place. See Note&#160;3 in the notes to our annual financial statements appearing elsewhere in this Annual Report for a description of foreign exchange risks.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The possible abandonment of the euro by one or more members of the European Union could materially affect our business in the future. Despite measures taken by the EU to provide funding to certain EU member states in financial difficulties and by a number of European countries to stabilize their economies and reduce their debt burdens, it is possible that the euro could be abandoned in the future as a currency by countries that have adopted its use. This could lead to the re-introduction of individual currencies in one or more EU member states, or in more extreme circumstances, the dissolution of the EU. The effects on our business of a potential dissolution of the EU, the exit of one or more EU member states from the EU or the abandonment of the euro as a currency, are impossible to predict with certainty, and any such events could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In addition, as a result of fluctuations in the exchange rate between the U.S. dollar and the pound sterling, the U.S. dollar equivalent of the proceeds that a holder of ADSs would receive upon the sale in the U.K. of any ordinary shares withdrawn from the depositary and the U.S. dollar equivalent of any cash dividends paid in euros on our ordinary shares represented by ADSs could also decline.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Risks Related to Ownership of Our ADSs</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">An active trading market for our ADSs may not be sustained.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior to our IPO in May&#160;2021, there had been no public trading market for our ADSs. Although our ADSs are listed on The Nasdaq Global Market, an active trading market for our shares may not be sustained. If an active market for our ADSs is not sustained, it may be difficult for holders of our ADSs to sell ADSs without depressing the market price for the shares, or at all. Further, an inactive market may also impair our ability to raise capital by selling our ADSs and may impair our ability to enter into strategic partnerships or acquire companies or products by using our ADSs as consideration.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Our principal shareholders and management own a significant&#160;percentage of our stock and exert significant influence over matters subject to shareholder approval.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of March 14, 2024, our executive officers, directors, and 5% shareholders beneficially owned approximately 42% of our voting stock. Depending on the level of attendance at our meetings of shareholders, these shareholders either alone or voting together as a group may be in a position to determine or significantly influence the outcome of decisions taken at any such meeting. Any shareholder or group of shareholders controlling more than 50% of the share capital present and voting at our meetings of shareholders may control any shareholder resolution requiring a simple majority, including the appointment of board members, certain decisions relating to our capital structure and the approval of certain significant corporate transactions. This may prevent or discourage unsolicited acquisition proposals or offers for our ADSs that holders of our ADSs may feel are in their best interest as shareholders.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">The price of our ADSs is volatile and holders of our ADSs could lose all or part of their investment.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The trading price of our ADSs is highly volatile and subject to wide fluctuations in response to various factors, some of which are beyond our control, including limited trading volume. In addition to the factors discussed in this &#8220;Risk Factors&#8221; section and elsewhere in this Annual Report, these factors include:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the commencement, enrollment, or results of clinical trials of our product candidates or any future clinical trials we may conduct, or changes in the development status of our product candidates;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">adverse results or delays in preclinical studies and clinical trials;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">our decision to initiate a clinical trial, not to initiate a clinical trial, or to terminate an existing clinical trial;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">any delay in our regulatory filings or any adverse regulatory decisions, including failure to receive marketing authorization for our product candidates;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">changes in laws or regulations applicable to our products, including but not limited to clinical trial requirements for approvals;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">adverse developments concerning our manufacturers or our manufacturing plans;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">our inability to obtain adequate product supply for any licensed product or inability to do so at acceptable prices;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">our inability to establish collaborations if needed;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">our failure to commercialize our product candidates;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">additions or departures of key scientific or management personnel;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">unanticipated serious safety concerns related to the use of our product candidates;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">introduction of new products or services offered by us or our competitors;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us or our competitors;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">our ability to effectively manage our growth;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the size and growth of our initial cancer target markets;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">our ability to successfully treat additional types of cancers or at different stages;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">actual or anticipated variations in quarterly operating results;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">our cash position;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">our failure to meet the estimates and projections of the investment community or that we may otherwise provide to the public;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">publication of research reports about us or our industry, or immunotherapy in particular, or positive or negative recommendations or withdrawal of research coverage by securities analysts;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">changes in the market valuations of similar companies;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">overall performance of the equity markets;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">sales of our ADSs by us or our shareholders in the future;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">trading volume of our ADSs;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">changes in accounting practices;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">ineffectiveness of our internal controls;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">disputes or other developments relating to intellectual property or proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">significant lawsuits, including intellectual property or shareholder litigation;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">general political and economic conditions; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">other events or factors, many of which are beyond our control.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In addition, the stock market in general, and the market for biopharmaceutical companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our ADSs, regardless of our actual operating performance.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Holders of our ADSs are not treated as holders of our ordinary shares.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Holders of ADSs are not treated as holders of our ordinary shares, unless they withdraw the ordinary shares underlying their ADSs in accordance with the deposit agreement and applicable laws and regulations. The depositary is the holder of the ordinary shares underlying our ADSs. Holders of ADSs therefore do not have any rights as holders of our ordinary shares, other than the rights that they have pursuant to the deposit agreement.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Holders of our ADSs will not have the same voting rights as the holders of our ordinary shares, and may not receive voting materials or any other documents that would need to be provided to our shareholders pursuant to English corporate law, including the Companies Act 2006, in time to be able to exercise their right to vote.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Except as described elsewhere in this Annual Report and the deposit agreement, holders of the ADSs will not be able to exercise voting rights attaching to the ordinary shares represented by the ADSs. The deposit agreement provides that, upon receipt of notice of any meeting of holders of our ordinary shares, the depositary will fix a record date for the determination of ADS holders who shall be entitled to give instructions for the exercise of voting rights. Upon our request, the depositary shall distribute to the holders as of the record date (i)&#160;the notice of the meeting or solicitation of consent or proxy sent by us and (ii)&#160;a statement as to the manner in which instructions may be given by the holders. We cannot guarantee that ADS holders will receive the voting materials in time to ensure that they can instruct the depositary to vote the ordinary shares underlying their ADSs.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Otherwise, ADS holders will not be able to exercise their right to vote, unless they withdraw the ordinary shares underlying the ADSs they hold to vote them in person or by proxy in accordance with applicable laws and regulations and our articles of association. However, ADS holders may not know about the meeting far enough in advance to withdraw those ordinary shares. A shareholder is only entitled to participate in, and vote at, the meeting of shareholders, provided that it holds our ordinary shares as of the record date set for such meeting and otherwise complies with our Articles. In addition, the depositary&#8217;s liability to ADS holders for failing to execute voting instructions or for the manner of executing voting instructions is limited by the deposit agreement. As a result, ADS holders may not be able to exercise their right to vote, and there may be nothing they can do if the ordinary shares underlying their ADSs are not voted as they requested or if their shares cannot be voted.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Holders of ADSs may be subject to limitations on the transfer of their ADSs and the withdrawal of the underlying ordinary shares.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ADSs are transferable on the books of the depositary. However, the depositary may close its books at any time or from time to time when it deems expedient in connection with the performance of its duties. The depositary may refuse to deliver, transfer or register transfers of ADSs generally when our books or the books of the depositary are closed, or at any time if we or the depositary think it is advisable to do so because of any requirement of law, government or governmental body, or under any provision of the deposit agreement, or for any other reason, subject to the right of ADS holders to cancel their ADSs and withdraw the underlying ordinary shares. Temporary delays in the cancellation of ADSs and withdrawal of the underlying ordinary shares may arise because the depositary has closed its transfer books or we have closed our transfer books, the transfer of ordinary shares is blocked to permit voting at a shareholders meeting or we are paying a dividend on our ordinary shares. In addition, ADS holders may not be able to cancel their ADSs and withdraw the underlying ordinary shares when they owe money for fees, taxes and similar charges and when it is necessary to prohibit withdrawals in order to comply with any laws or governmental regulations that apply to ADSs or to the withdrawal of ordinary shares or other deposited securities.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">ADS holders may not be entitled to a jury trial with respect to claims arising under the deposit agreement, which could result in less favorable outcomes to the plaintiff(s)&#160;in any such action.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The deposit agreement governing our ADSs representing our ordinary shares provides that, to the fullest extent permitted by law, holders and beneficial owners of ADSs irrevocably waive the right to a jury trial of any claim they may have against us or the depositary arising out of or relating to our ADSs or the deposit agreement.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If this jury trial waiver provision is not permitted by applicable law, an action could proceed under the terms of the deposit agreement with a jury trial. If we or the depositary opposed a jury trial demand based on the waiver, the court would determine whether the waiver was enforceable based on the facts and circumstances of that case in accordance with the applicable state and federal law. To our knowledge, the enforceability of a contractual pre-dispute jury trial waiver in connection with claims arising under the federal securities laws has not been finally adjudicated by the United States Supreme Court. However, we believe that a contractual pre-dispute jury trial waiver provision is generally enforceable, including under the laws of the State of New York, which govern the deposit agreement, by a federal or state court in the City of New York, which has non-exclusive jurisdiction over matters arising under the deposit agreement. In determining whether to enforce a contractual pre-dispute jury trial waiver provision, courts will generally consider whether a party knowingly, intelligently and voluntarily waived the right to a jury trial. We believe that this is the case with respect to the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">deposit agreement and our ADSs. It is advisable that you consult legal counsel regarding the jury waiver provision before entering into the deposit agreement.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If you or any other holders or beneficial owners of ADSs bring a claim against us or the depositary in connection with matters arising under the deposit agreement or our ADSs, including claims under federal securities laws, you or such other holder or beneficial owner may not be entitled to a jury trial with respect to such claims, which may have the effect of limiting and discouraging lawsuits against us and/or the depositary. If a lawsuit is brought against us and/or the depositary under the deposit agreement, it may be heard only by a judge or justice of the applicable trial court, which would be conducted according to different civil procedures and may result in different outcomes than a trial by jury would have had, including results that could be less favorable to the plaintiff(s)&#160;in any such action, depending on, among other things, the nature of the claims, the judge or justice hearing such claims, and the venue of the hearing.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">No condition, stipulation or provision of the deposit agreement or ADSs serves as a waiver by any holder or beneficial owner of ADSs or by us or the depositary of compliance with U.S. federal securities laws and the rules&#160;and regulations promulgated thereunder.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The trading market for our ADSs depends in part on the research and reports that securities or industry analysts publish about us or our business. Although we have obtained research coverage from certain analysts, there can be no assurance that analysts will continue to cover us, or provide favorable coverage. If one or more of the analysts who cover us downgrades our stock or publishes inaccurate or unfavorable research about our business, our stock price may decline. If one or more of these analysts ceases coverage of our company or fails to publish reports on us regularly, demand for our stock could decrease, which might cause our stock price and trading volume to decline.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">We are an emerging growth company and a smaller reporting company, and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies and smaller reporting companies will make our ADSs less attractive to investors.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We are an emerging growth company, as defined in the JOBS Act enacted in April&#160;2012. For as long as we continue to be an emerging growth company, we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding nonbinding advisory votes on executive compensation and shareholder approval of any golden parachute payments not previously approved. We could be an emerging growth company for up to five&#160;years following the&#160;year in which we became a public company, although circumstances could cause us to lose that status earlier. We will remain an emerging growth company until the earlier of (1)&#160;the last day of the fiscal&#160;year (a)&#160;following the fifth anniversary of the date we became a public company, (b)&#160;in which we have total annual gross revenue of at least $1.24 billion or (c)&#160;in which we are deemed to be a large accelerated filer, which requires the market value of our ADSs that are held by non-affiliates to exceed $700 million as of the prior June&#160;30th, and (2)&#160;the date on which we have issued more than $1 billion in non-convertible debt during the prior three-year period.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Under the JOBS Act, emerging growth companies can also delay adopting new or revised accounting standards until such time as those standards apply to private companies. We have elected to avail ourselves of this exemption and, therefore, we will not be subject to the same timing of adoption of new or revised accounting standards as other public companies that are not emerging growth companies.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Even after we no longer qualify as an emerging growth company, we may still qualify as a &#8220;smaller reporting company,&#8221; which may allow us to continue to take advantage of many of the same exemptions from disclosure requirements, including not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act and reduced disclosure obligations regarding executive compensation in this Annual Report and our periodic reports and proxy statements. We cannot predict if investors will find our ADSs less attractive because we may rely on these exemptions. If some investors find our ADSs less attractive as a result, there may be a less active trading market for our ADSs and our stock price may be more volatile.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">We will incur increased costs as a result of operating as an English public company listed in the U.S., and our board of directors will be required to devote substantial time to new compliance initiatives and corporate governance practices.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As an English public company listed in the U.S., and particularly after we no longer qualify as an emerging growth company, we will incur significant legal, accounting and other expenses that we did not incur as a private company. In addition, the Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of Nasdaq, and other applicable securities rules&#160;and regulations impose various requirements on foreign reporting public companies, including the establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our board of directors, management and other personnel will need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules&#160;and regulations will increase our legal and financial compliance costs and will make some activities more time-consuming and costly. For example, we expect that these </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">rules&#160;and regulations may make it more difficult and more expensive for us to obtain director and officer liability insurance, which in turn could make it more difficult for us to attract and retain qualified members of our board of directors.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">However, these rules&#160;and regulations are often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We are subject to the reporting requirements of the Securities Exchange Act of 1934, the Sarbanes-Oxley Act and the rules and regulations of The Nasdaq Global Market. Pursuant to Section 404 of the Sarbanes-Oxley Act, we are required to perform system and process evaluation and testing of our internal control over financial reporting to allow our management to report on the effectiveness of our internal control over financial reporting. See section entitled &#8220;Controls and Procedures &#8211; Management&#8217;s Annual Report on Internal Controls Over Financial Reporting.&#8221; However, while we remain an emerging growth company, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. We will incur substantial additional professional fees and internal costs to expand our accounting and finance functions and expend significant management efforts.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">General Risk Factors</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or our guidance.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Our quarterly and annual operating results may fluctuate significantly in the future, which makes it difficult for us to predict our future operating results. From time to time, we may enter into license or collaboration agreements with other companies that include development funding and significant upfront and milestone payments and/or royalties, which may become an important source of our revenue. Accordingly, our revenue may depend on development funding and the achievement of development and clinical milestones under current and any potential future license and collaboration agreements and, if approved, sales of our product candidates. These upfront and milestone payments may vary significantly from period to period and any variance could cause a significant fluctuation in our operating results from one period to the next.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Further, our operating results may fluctuate due to a variety of other factors, many of which are outside of our control and may be difficult to predict, including the following:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the timing and cost of, and level of investment in, research and development activities relating to our current and any future product candidates, which will change from time to time;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the timing and outcomes of clinical trials for our current and any other future product candidates;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the cost of manufacturing our current and any future product candidates, which may vary depending on regulatory guidelines and requirements, the quantity of production and the terms of our agreements with manufacturers;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">our ability to adequately support our future growth;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">potential unforeseen business disruptions that increase our costs or expenses;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">future accounting pronouncements or changes in our accounting policies; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the changing and volatile global economic environment.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The cumulative effect of these factors could result in large fluctuations and unpredictability in our quarterly and annual operating results. As a result, comparing our operating results on a period-to-period basis may not be meaningful. Investors should not rely on our past results as an indication of our future performance. This variability and unpredictability could also result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our revenue or operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, or if the forecasts we provide to the market are below the expectations of analysts or investors, the price of our ADSs could decline substantially. The price of our ADSs could decline even when we have met any previously publicly stated revenue and/or earnings guidance we may provide.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Holders of our ADSs may not receive distributions on our ordinary shares represented by the ADSs or any value for them if it is illegal or impractical to make them available to holders of ADSs.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The depositary for the ADSs has agreed to pay to holders of our ADSs the cash dividends or other distributions it or the custodian receives on our ordinary shares or other deposited securities after deducting its fees and expenses. Shareholders will receive these distributions in proportion to the number of our ordinary shares our ADSs represent. However, in accordance with the limitations set forth in the deposit agreement, it may be unlawful or impractical to make a distribution available to holders of ADSs. We have no obligation to take any other action to permit distribution on the ADSs, ordinary </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">shares, rights or anything else to holders of the ADSs. This means that holders of our ADSs may not receive the distributions we make on our ordinary shares or any value from them if it is unlawful or impractical to make them available to holders of our ADSs. These restrictions may have an adverse effect on the value of our ADSs.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">We do not intend to pay dividends on our ADSs, so any returns will be limited to the value of our ordinary shares.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Under current English law, a company&#8217;s accumulated realized profits must exceed its accumulated realized losses (on a non-consolidated basis) before dividends can be declared and paid. Therefore, we must have distributable profits before declaring and paying a dividend. In addition, as a public limited company incorporated in England&#160;&amp; Wales, we will only be able to make a distribution if the amount of our net assets is not less than the aggregate of our called-up share capital and undistributable reserves and if, and to the extent that, the distribution does not reduce the amount of those assets to less than that aggregate.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We have not paid dividends in the past on our ordinary shares. We currently anticipate that we will retain future earnings for the development, operation, and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. In addition, we may enter into agreements that prohibit us from paying cash dividends without prior written consent from our contracting parties, or which other terms prohibiting or limiting the amount of dividends that may be declared or paid on our ADSs. Any return to shareholders and holders of our ADSs will therefore be limited to the appreciation of their stock, which may never occur.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">As an English public limited company, certain capital structure decisions require shareholder approval, which limits our flexibility to manage our capital structure.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">English law provides that a board of directors may only allot shares (or grant rights to subscribe for or to convert any security into shares) with the prior authorization of shareholders, such authorization stating the aggregate nominal amount of shares that it covers and being valid for a maximum period of five&#160;years, each as specified in our Articles or relevant ordinary resolution passed by shareholders at a general meeting. Such authority from our shareholders to allot shares (or grant rights to subscribe for or to convert any security into shares) for a period of five&#160;years from April&#160;21, 2021 was included in the ordinary resolution passed by our shareholders on April&#160;21, 2021, which authorization will need to be renewed upon expiration (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">i.e.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, at least every five&#160;years) but may be sought more frequently for additional five-year terms (or any shorter period).</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">English law also generally provides shareholders with preemptive rights when new shares are issued for cash. However, it is possible for the Articles, or for shareholders to pass a special resolution at a general meeting, being a resolution passed by at least 75% of the votes cast, to disapply preemptive rights. Such a disapplication of preemptive rights may be for a maximum period of up to five&#160;years from the date of adoption of the Articles, if the disapplication is contained in the Articles, but not longer than the duration of the authority to allot shares to which this disapplication relates or from the date of the shareholder special resolution, if the disapplication is by shareholder special resolution. In either case, this disapplication would need to be renewed by our shareholders upon its expiration (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">i.e.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, at least every five&#160;years). Such authority from our shareholders to disapply preemptive rights for a period of five&#160;years was included in the special resolution passed by our shareholders on April&#160;21, 2021, which disapplication will need to be renewed upon expiration (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">i.e.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, at least every five&#160;years) to remain effective, but may be sought more frequently for additional five-&#160;year terms (or any shorter period).</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">English law also generally prohibits a public company from repurchasing its own shares without the prior approval of shareholders by ordinary resolution, being a resolution passed by a simple majority of votes cast, and other formalities. Such approval may be for a maximum period of up to five&#160;years.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Shareholder protections found in provisions under the UK City Code on Takeovers and Mergers (the "Takeover Code"), will not apply if our place of central management and control is considered to be outside of the UK (or the Channel Islands or the Isle of Man).</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We believe that our place of central management and control is not in the United Kingdom (or the Channel Islands or the Isle of Man) for the purposes of the jurisdictional criteria of the Takeover Code. Accordingly, we believe that we are not currently subject to the Takeover Code and, as a result, our shareholders are not currently entitled to the benefit of certain takeover offer protections provided under the Takeover Code, including the rules&#160;regarding mandatory takeover bids.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In the event that this changes, or if the interpretation and application of the Takeover Code by the Panel on Takeovers and Mergers, (the "Takeover Panel"), changes (including changes to the way in which the Takeover Panel assesses the application of the Takeover Code to English companies whose shares are listed outside of the United Kingdom), the Takeover Code may apply to us in the future.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Takeover Code provides a framework within which takeovers of companies which are subject to the Takeover Code are regulated and conducted. The following is a brief summary of some of the most important rules&#160;of the Takeover Code:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">in connection with a potential offer, if following an approach by or on behalf of a potential bidder, the company is &#8220;the subject of rumor or speculation&#8221; or there is an &#8220;untoward movement&#8221; in the company&#8217;s share price, there is a </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">106</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">requirement for the potential bidder to make a public announcement about a potential offer for the company, or for the company to make a public announcement about its review of a potential offer;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">when any person acquires, whether by a series of transactions over a period of time or not, an interest in shares which (taken together with shares already held by that person and an interest in shares held or acquired by persons acting in concert with him or her) carry 30% or more of the voting rights of a company that is subject to the Takeover Code, that person is generally required to make a mandatory offer to all the holders of any class of equity share capital or other class of transferable securities carrying voting rights in that company to acquire the balance of their interests in the company;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">when any person who, together with persons acting in concert with him or her, is interested in shares representing not less than 30% but does not hold more than 50% of the voting rights of a company that is subject to the Takeover Code, and such person, or any person acting in concert with him or her, acquires an additional interest in shares which increases the&#160;percentage of shares carrying voting rights in which he or she is interested, then such person is generally required to make a mandatory offer to all the holders of any class of equity share capital or other class of transferable securities carrying voting rights of that company to acquire the balance of their interests in the company;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">a mandatory offer triggered in the circumstances described in the two paragraphs above must be in cash (or be accompanied by a cash alternative) and at not less than the highest price paid within the preceding 12&#160;months to acquire any interest in shares in the company by the person required to make the offer or any person acting in concert with him or her;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">in relation to a voluntary offer (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">i.e.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, any offer which is not a mandatory offer), when interests in shares representing 10% or more of the voting rights of a class have been acquired for cash by an offeror (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">i.e.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, a bidder) and any person acting in concert with it in the offer period and the previous 12&#160;months, the offer must be in cash or include a cash alternative for all shareholders of that class at not less than the highest price paid for any interest in shares of that class by the offeror and by any person acting in concert with it in that period. Further, if an offeror acquires for cash any interest in shares during the offer period, a cash alternative must be made available at not less than the highest price paid for any interest in the shares of that class;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">if, after making an offer for a company, the offeror or any person acting in concert with them acquires an interest in shares in an offeree company (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">i.e.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, a target) at a price higher than the value of the offer, the offer must be increased to not less than the highest price paid for the interest in shares so acquired;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">an offeree company must appoint a competent independent adviser whose advice on the financial terms of the offer must be made known to all the shareholders, together with the opinion of the board of directors of the offeree company;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">special or favorable deals for selected shareholders are not permitted, except in certain circumstances where independent shareholder approval is given and the arrangements are regarded as fair and reasonable in the opinion of the financial adviser to the offeree;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">all shareholders must be given the same information;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">each document published in connection with an offer by or on behalf of the offeror or offeree must state that the directors of the offeror or the offeree, as the case may be, accept responsibility for the information contained therein;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">profit forecasts, quantified financial benefits statements and asset valuations must be made to specified standards and must be reported on by professional advisers;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">misleading, inaccurate or unsubstantiated statements made in documents or to the media must be publicly corrected immediately;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">actions during the course of an offer by the offeree company, which might frustrate the offer are generally prohibited unless shareholders approve these plans. Frustrating actions would include, for example, lengthening the notice period for directors under their service contract or agreeing to sell off material parts of the target group;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">stringent and detailed requirements are laid down for the disclosure of dealings in relevant securities during an offer, including the prompt disclosure of positions and dealing in relevant securities by the parties to an offer and any person who is interested (directly or indirectly) in 1% or more of any class of relevant securities; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">employees of both the offeror and the offeree company and the trustees of the offeree company&#8217;s pension scheme must be informed about an offer. In addition, the offeree company&#8217;s employee representatives and pension scheme trustees have the right to have a separate opinion on the effects of the offer on employment appended to the offeree board of directors&#8217; circular or published on a website.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">107</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">The rights of our shareholders may differ from the rights typically offered to shareholders of a U.S. corporation.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We are incorporated under the laws of England and Wales. The rights of holders of ordinary shares and, therefore, certain of the rights of holders of ADSs, are governed by the laws of England and Wales, including the provisions of the Companies Act 2006, and by our Articles. These rights differ in certain respects from the rights of shareholders in typical U.S. corporations.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The principal differences include the following:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">under English law and our Articles, each shareholder present at a meeting has only one vote unless demand is made for a vote on a poll, in which case each holder gets one vote per share owned. Under U.S. law, each shareholder typically is entitled to one vote per share at all meetings;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">under English law, it is only on a poll that the number of shares determines the number of votes a holder may cast. You should be aware, however, that the voting rights of ADSs are also governed by the provisions of a deposit agreement with our depositary bank;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">under English law, subject to certain exceptions and disapplications, each shareholder generally has preemptive rights to subscribe on a proportionate basis to any issuance of ordinary shares or rights to subscribe for, or to convert securities into, ordinary shares for cash. Under U.S. law, shareholders generally do not have preemptive rights unless specifically granted in the certificate of incorporation or otherwise;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">under English law and our Articles, certain matters require the approval of 75% of the shareholders who vote (in person or by proxy) on the relevant resolution (or on a poll of shareholders representing 75% of the ordinary shares voting (in person or by proxy)), including amendments to the Articles. This may make it more difficult for us to complete corporate transactions deemed advisable by our board of directors. Under U.S. law, generally only majority shareholder approval is required to amend the certificate of incorporation or to approve certain significant transactions;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">in the UK, takeovers may be structured as takeover offers or as schemes of arrangement. Under English law, a bidder seeking to acquire us by means of a takeover offer would need to make an offer for all of our outstanding ordinary shares/ADSs. If acceptances are not received for 90% or more of the ordinary shares/ADSs under the offer, under English law, the bidder cannot complete a &#8220;squeeze out&#8221; to obtain 100% control of us. Accordingly, acceptances of 90% of our outstanding ordinary shares (including those represented by ADSs) will likely be a condition in any takeover offer to acquire us, not 50% as is more common in tender offers for corporations organized under Delaware law. By contrast, a scheme of arrangement, the successful completion of which would result in a bidder obtaining 100% control of us, requires the approval of a majority of shareholders voting at the meeting and representing 75% of the ordinary shares (including those represented by ADSs) voting for approval;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">under English law and our Articles, shareholders and other persons whom we know or have reasonable cause to believe are, or have been, interested in our shares may be required to disclose information regarding their interests in our shares upon our request, and the failure to provide the required information could result in the loss or restriction of rights attaching to the shares, including prohibitions on certain transfers of the shares, withholding of dividends and loss of voting rights. Comparable provisions generally do not exist under U.S. law; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the quorum requirement for a shareholders&#8217; meeting is one or more qualifying persons present at a meeting and between them holding (or being the proxy or corporate representative of the holders of) at least thirty-three and one-third&#160;percent (33 1/3%) in number of the issued shares (excluding any shares held as treasury shares) entitled to attend and vote on the business to be transacted. Under U.S. law, a majority of the shares eligible to vote must generally be present (in person or by proxy) at a shareholders&#8217; meeting in order to constitute a quorum. The minimum number of shares required for a quorum can be reduced pursuant to a provision in a company&#8217;s certificate of incorporation or bylaws, but typically not below one-third of the shares entitled to vote at the meeting.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Our Articles provide that the courts of England and Wales are the exclusive forum for the resolution of all shareholder complaints other than complaints asserting a cause of action arising under the Securities Act or the Exchange Act, and that the United States District Court for the Southern District of New York will be the exclusive forum for the resolution of any shareholder complaint asserting a cause of action arising under the Securities Act or the Exchange Act.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Our Articles provide that, unless we consent by ordinary resolution to the selection of an alternative forum, the courts of England and Wales shall, to the fullest extent permitted by law, be the exclusive forum for: (a)&#160;any derivative action or proceeding brought on our behalf; (b)&#160;any action or proceeding asserting a claim of breach of fiduciary duty owed by any of our directors, officers or other employees to us; (c)&#160;any action or proceeding asserting a claim arising out of any provision of the Companies Act 2006 or our Articles (as may be amended from time to time); or (d)&#160;any action or proceeding asserting a claim or otherwise related to our affairs (the &#8220;England and Wales Forum Provision&#8221;.) The England and Wales Forum Provision will not apply to any causes of action arising under the Securities Act or the Exchange Act. Our Articles further provide that unless we consent by ordinary resolution to the selection of an alternative forum, the United States District Court for the Southern District of New York shall be the exclusive forum for resolving any complaint </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">108</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">asserting a cause of action arising under the Securities Act or the Exchange Act (the &#8220;U.S. Federal Forum Provision.&#8221;) In addition, our Articles provide that any person or entity purchasing or otherwise acquiring any interest in our shares is deemed to have notice of and consented to the England and Wales Forum Provision and the U.S. Federal Forum Provision; provided, however, that our shareholders cannot and will not be deemed to have waived our compliance with the U.S. federal securities laws and the rules&#160;and regulations thereunder.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The England and Wales Forum Provision and the U.S. Federal Forum Provision in our Articles may impose additional litigation costs on our shareholders in pursuing any such claims. Additionally, the forum selection clauses in our Articles may limit the ability of our shareholders to bring a claim in a judicial forum that they find favorable for disputes with us or our directors, officers or employees, which may discourage the filing of lawsuits against us and our directors, officers and employees, even though an action, if successful, might benefit our shareholders. In addition, while the Delaware Supreme Court ruled in March&#160;2020 that federal forum selection provisions purporting to require claims under the Securities Act be brought in federal court are &#8220;facially valid&#8221; under Delaware law, there is uncertainty as to whether other courts, including the courts of England and Wales and other courts within the U.S., will enforce our U.S. Federal Forum Provision. If the U.S. Federal Forum Provision is found to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our results of operations and financial condition. The U.S. Federal Forum Provision may also impose additional litigation costs on our shareholders who assert that the provision is not enforceable or invalid. The courts of England and Wales and the United States District Court for the Southern District of New York may also reach different judgments or results than would other courts, including courts where a shareholder considering an action may be located or would otherwise choose to bring the action, and such judgments may be more or less favorable to us than our shareholders.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Changes in U.S. tax law could adversely affect our financial condition and results of operations.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The rules&#160;dealing with U.S. federal, state, and local income taxation are constantly under review by persons involved in the legislative process and by the Internal Revenue Service and the U.S. Treasury Department. Changes to tax laws (which changes may have retroactive application) could adversely affect us or holders of our ordinary shares or ADSs. In recent&#160;years, many such changes have been made and changes are likely to continue to occur in the future. Future changes in U.S. tax laws could have a material adverse effect on our business, cash flow, financial condition or results of operations. We urge investors to consult with their legal and tax advisors regarding the implications of potential changes in U.S. tax laws on an investment in our ordinary shares or ADSs.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">If we were classified as a passive foreign investment company, it would result in adverse U.S. federal income tax consequences to U.S. Holders.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Under the Internal Revenue Code (the "Code"), we will be a passive foreign investment company, or PFIC, for any taxable&#160;year in which (i)&#160;75% or more of our gross income consists of passive income or (ii)&#160;50% or more of the average quarterly value of our assets consists of assets that produce, or are held for the production of, passive income. For purposes of these tests, passive income includes dividends, interest, gains from the sale or exchange of investment property and certain rents and royalties. In addition, for purposes of the above calculations, a non-U.S. corporation that directly or indirectly owns at least 25% by value of the shares of another corporation is treated as holding and receiving directly its proportionate share of assets and income of such corporation. If we are a PFIC for any taxable&#160;year during which a U.S. Holder holds our ordinary shares or ADSs, the U.S. Holder may be subject to adverse tax consequences regardless of whether we continue to qualify as a PFIC, including ineligibility for any preferred tax rates on capital gains or on actual or deemed dividends, interest charges on certain taxes treated as deferred and additional reporting requirements. A &#8220;U.S. Holder&#8221; is a holder who, for U.S. federal income tax purposes, is a beneficial owner of ordinary shares or ADSs and is: (i)&#160;an individual who is a citizen or individual resident of the United States; (ii)&#160;a corporation, or other entity taxable as a corporation for U.S. federal income tax purposes, created or organized in or under the laws of the United States, any state therein or the District of Columbia; (iii)&#160;an estate the income of which is subject to U.S. federal income taxation regardless of its source; or (iv)&#160;a trust if (1)&#160;a U.S. court is able to exercise primary supervision over the administration of the trust and one or more U.S. persons have authority to control all substantial decisions of the trust or (2)&#160;the trust has a valid election to be treated as a U.S. person under applicable U.S. Treasury Regulations.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Based on the current and expected composition of our income and the value of our assets, we were a PFIC for the year ended December 31, 2023 and expect to remain a PFIC for our current taxable year. No assurances regarding our PFIC status can be provided for the current taxable year or any future taxable years. The determination of whether we are a PFIC is a fact-intensive determination made on an annual basis applying principles and methodologies that in some circumstances are unclear and subject to varying interpretation. Under the income test, our status as a PFIC depends on the composition of our income which will depend on the transactions we enter into in the future and our corporate structure. The composition of our income and assets is also affected by the spending of the cash we raise in any offering.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Each U.S. Holder should consult its own tax advisors with respect to the potential adverse U.S. tax consequences to it if we are or were to become a PFIC. If we were a PFIC for any taxable year during which a U.S. investor owns ADSs, certain adverse U.S. federal income tax consequences could apply to such U.S. investor. We will provide the information necessary for a U.S. investor to make a qualified electing fund election with respect to us.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">109</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">If we are a controlled foreign corporation, there could be adverse U.S. federal income tax consequences to certain U.S. Holders.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Each &#8220;Ten&#160;Percent Shareholder&#8221; (as defined below) in a non-U.S. corporation that is classified as a &#8220;controlled foreign corporation,&#8221; or a CFC, for U.S. federal income tax purposes generally is required to include in income for U.S. federal tax purposes such Ten&#160;Percent Shareholder&#8217;s pro rata share of the CFC&#8217;s &#8220;Subpart F income,&#8221; &#8220;global intangible low-taxed income&#8221; and investment of earnings in U.S. property, even if the CFC has made no distributions to its shareholders. In addition, if a non-U.S. corporation owns at least one U.S. subsidiary, under current law, any current non-U.S. subsidiaries and any future newly formed or acquired non-U.S. subsidiaries of the non-U.S. corporation will be treated as CFCs, regardless of whether the non-U.S. corporation is treated as a CFC. Subpart F income generally includes dividends, interest, rents, royalties, gains from the sale of securities and income from certain transactions with related parties. In addition, a Ten&#160;Percent Shareholder that realizes gain from the sale or exchange of shares in a CFC may be required to classify a portion of such gain as dividend income rather than capital gain. A non-U.S. corporation generally will be classified as a CFC for U.S. federal income tax purposes if Ten&#160;Percent Shareholders own, directly or indirectly, more than 50% of either the total combined voting power of all classes of stock of such corporation entitled to vote or of the total value of the stock of such corporation. A &#8220;Ten&#160;Percent Shareholder&#8221; is a United States person (as defined by the Code) who owns or is considered to own 10% or more of the value or total combined voting power of all classes of stock entitled to vote of such corporation.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We do not believe that we were a CFC in 2023, and we do not expect to be a CFC in 2024. The determination of CFC status is complex and includes attribution rules, the application of which is not entirely certain. An individual that is a Ten&#160;Percent Shareholder with respect to a CFC generally would not be allowed certain tax deductions or foreign tax credits that would be allowed to a Ten&#160;Percent Shareholder that is a U.S. corporation. Failure to comply with CFC reporting obligations may subject a United States shareholder to significant monetary penalties. We cannot provide any assurances that we will furnish to any Ten&#160;Percent Shareholder information that may be necessary to comply with the reporting and tax paying obligations applicable under the CFC rules&#160;of the Code. U.S. Holders should consult their own tax advisors with respect to the potential adverse U.S. tax consequences of becoming a Ten&#160;Percent Shareholder in a CFC.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective internal controls over financial reporting are necessary for us to provide reliable financial reports and, together with adequate disclosure controls and procedures, are designed to prevent fraud. Any failure to implement required new or improved controls, or difficulties encountered in their implementation could cause us to fail to meet our reporting obligations.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In addition, testing required to be conducted by us in connection with Section 404 of the Sarbanes-Oxley Act, and any subsequent testing by our independent registered public accounting firm, may reveal deficiencies in our internal controls over financial reporting that are deemed to be material weaknesses or that may require prospective or retroactive changes to our financial statements or identify other areas for further attention or improvement. Deficient internal controls could also cause investors to lose confidence in our reported financial information, which could have a negative effect on the trading price of our ADSs.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">If we fail to establish and maintain proper internal controls, our ability to produce accurate financial statements or comply with applicable regulations could be impaired. As a result, shareholders could lose confidence in our financial and other public reporting, which would harm our business and the trading price of our ADSs.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Implementing any appropriate changes to our internal controls, including changes relating to our application of the requirements of Section&#160;404 of the Sarbanes-Oxley Act, may distract our officers and employees, entail substantial costs to modify our existing processes, and take significant time to complete. These changes may not, however, be effective in maintaining the adequacy of our internal controls, and any failure to maintain that adequacy, or consequent inability to produce accurate financial statements on a timely basis, could increase our operating costs and harm our business. In addition, investors&#8217; perceptions that our internal controls are inadequate or that we are unable to produce accurate financial statements on a timely basis may harm our stock price and make it more difficult for us to continue to discover and develop novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases, immunetolerance and cancer.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">We previously identified material weaknesses in connection with our internal control over financial reporting. Although we have taken steps to remediate these material weaknesses, we may identify other material weaknesses in the future, which could have a significant adverse effect on our business and the trading price of our ADSs.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For the year ended December&#160;31, 2023, pursuant to Section 404 of the Sarbanes-Oxley Act, we are required to furnish a report by our senior management on our internal control over financial reporting. This report is required to include disclosure of any material weaknesses identified by our management in our internal control over financial reporting. However, while we remain an non-accelerated filer, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To achieve compliance with Section 404 of the Sarbanes-Oxley Act, we have been engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, potentially continue to engage outside consultants and adopt a detailed work plan to assess and document the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Management previously reported, in our Annual Report for the year ended December 31, 2022, material weaknesses in our internal control over financial reporting related to: (i) our IT general control environment has not been sufficiently designed to include appropriate controls over program development, program changes, computer operations and user access rights and (ii) policies and procedures with respect to the review, supervision and monitoring of our accounting and reporting functions were either not designed and in place or not operating effectively. During fiscal years 2022 and 2023, we undertook efforts to remediate previously disclosed material weaknesses, implement a company-wide formal control program, and strengthen our internal controls. Implementing Section 404 of the Sarbanes-Oxley Act within our environment has been a significant undertaking. Although management has concluded that the actions taken to strengthen our internal control over financial reporting, as well as the results of our testing over the design and operating effectiveness of these controls, remediated the previously identified material weaknesses as of December 31, 2023, there is no guarantee that our internal control over financial reporting will be effective in the future periods and the effectiveness of our internal controls are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with applicable policies, processes and documentation requirements may deteriorate. Ineffective disclosure controls and procedures and internal control over financial reporting could also cause investors to lose confidence in our reported financial and other information, which would likely have a negative effect on the trading price of our ADSs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">We could be subject to securities class action litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Historically, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for us because biotechnology and pharmaceutical companies have experienced significant stock price volatility in recent&#160;years. If we were to be sued, it could result in substantial costs and a diversion of management&#8217;s attention and resources, which could harm our business.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">The United Kingdom&#8217;s withdrawal from the EU could increase the regulatory burden of product development and authorization in the United Kingdom and European Union.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">On June&#160;23, 2016, a majority of voters in the United Kingdom voted in favor of the United Kingdom withdrawing from the European Union in a national referendum, commonly referred to as Brexit, and the United Kingdom formally left the European Union on January&#160;31, 2020. There was a transition period during which EU pharmaceutical laws continued to apply to the United Kingdom, which expired on December&#160;31, 2020. However, the EU and the United Kingdom have concluded a TCA which was provisionally applicable since January&#160;1, 2021 and has been formally applicable since May&#160;1, 2021. The TCA includes specific provisions concerning pharmaceuticals, which include the mutual recognition of GMP, inspections of manufacturing facilities for medicinal products and GMP documents issued, but does not foresee wholesale mutual recognition of the United Kingdom and European Union pharmaceutical regulations. At present, Great Britain has implemented EU legislation on the marketing, promotion, and sale of medicinal products through the Human Medicines Regulations 2012 (as amended) (under the Northern Ireland Protocol, the EU regulatory framework will continue to apply in Northern Ireland). The regulatory regime in Great Britain therefore currently aligns in the most part with EU regulations, however it is possible that these regimes will diverge in future now that Great Britain&#8217;s regulatory system is independent from the EU and the TCA does not provide for mutual recognition of United Kingdom and European Union pharmaceutical legislation. For example, the new Clinical Trials Regulation which became effective in the EU on January&#160;31, 2022 and provides for a streamlined clinical trial application and assessment procedure covering multiple European Union Member States has not been implemented into the United Kingdom law, and a separate application will need to be submitted for clinical trial authorization in the United Kingdom.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The cumulative effects of the disruption to the regulatory framework may add to the development lead time to marketing authorization and commercialization of products in the European Union and/or the United Kingdom. It is possible that there will be increased regulatory complexities which can disrupt the timing of our clinical trials and regulatory approvals. In addition, changes in, and legal uncertainty with regard to, national and international laws and regulations may present difficulties for our clinical and regulatory strategy.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In addition, as a result of Brexit, other European Union Member States may seek to conduct referenda with respect to their continuing membership with the European Union. Given these possibilities and others we may not anticipate, as well as the absence of comparable precedent, it is unclear what financial, regulatory and legal implications the withdrawal of the United Kingdom from the European Union will have in the long-term and the full extent to which our business could be adversely affected.</span></div><div id="i417e39f5b7bb45b295bb09394310bc8c_25"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 1B. Unresolved Staff Comments</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Not Applicable.</span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">111</span></div></div></div><div id="i417e39f5b7bb45b295bb09394310bc8c_657"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 1C. Cybersecurit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">y</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In the normal course of business, we may collect and store personal information and other sensitive information, including proprietary and confidential business information, financial information, trade secrets, intellectual property, information regarding trial participants in connection with clinical trials, sensitive third-party information and employee information. In an effort to protect this information from cybersecurity risks, we have developed a cybersecurity program which incorporates policies and practices designed to protect the confidentiality, integrity and security of our sensitive information. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As part of our cybersecurity risk management procedures, we perform system monitoring and scanning and utilize security tools supported by a third-party managed services provider. We also conduct penetration testing performed by a third-party provider. Employees are enrolled in cybersecurity awareness training courses designed to help them identify cybersecurity concerns and take appropriate actions, and we conduct periodic simulated phishing tests in an effort to further raise cybersecurity awareness and reduce the risk of a successful cyberattack. We have established an incident response plan to guide us in responding to cybersecurity incidents. We also take steps to protect against business interruption and conduct annual restoration testing for major systems. In addition, we are developing a cybersecurity risk management program for our third-party vendors. This program aims to assess the cybersecurity maturity of vendors who have access to our data or systems through an evaluation of the vendor&#8217;s cybersecurity practices.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our cybersecurity program is managed by our IT Director, who reports directly to senior management on matters regarding cybersecurity, as appropriate. Our IT Director has over twenty years of experience in IT, including cybersecurity, and previously served as the IT Director at another biopharmaceutical company. Together, our senior management and IT Director are responsible for leading company-wide cybersecurity strategy, policies, standards, and processes. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Audit Committee, pursuant to its charter, has oversight over management of cybersecurity risks. Senior management and our IT Director provide the Audit Committee with periodic updates on data management and cybersecurity initiatives, as well as on significant existing and emerging cybersecurity risks, including cybersecurity incidents, as applicable. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have a process to record identified risks from cybersecurity threats in our risk register, along with an assessment of the severity of the potential impact and the likelihood of occurrence. This process is designed to facilitate a unified and integrated assessment of corporate risk and governance. The risk register is reviewed periodically by senior management and at least annually by the Board of Directors. Our cybersecurity program is also periodically evaluated by external security consultants, with the results of those reviews reported to senior management and the Audit Committee, as appropriate. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have not identified any cybersecurity incidents or threats that have materially affected us or are reasonably likely to materially affect us, including our business strategy, results of operations, or financial condition; however, like other companies in our industry, we and our third-party vendors may experience threats and security incidents that could affect our information or systems. For more information about the cybersecurity risks we face, please see Section 1A. Risk Factors.</span></div><div><span><br/></span></div><div id="i417e39f5b7bb45b295bb09394310bc8c_28"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 2. Properties</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our principal executive offices are located on the Harwell Science and Innovation Campus, Harwell, Oxfordshire, United Kingdom, where we lease and occupy approximately 31,000 square feet of office and laboratory space. We also have 19,700 square feet of state-of-the-art wet laboratory and office space in Germantown, Maryland, United States.</span></div><div id="i417e39f5b7bb45b295bb09394310bc8c_31"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 3. Legal Proceedings</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are not currently a party to any material legal proceedings. From time to time, we may become involved in other litigation or legal proceedings relating to claims arising from the ordinary course of business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have no penalties to report in accordance with The Revenue Procedure 2005-51 and Section 6707A(e) of the Internal Revenue Code, which requires the Company to disclose any IRS demand for payment of certain penalties related to tax-avoidance transactions under I.R.C. Sections 6662(h), 6662A, or 6707A.</span></div><div id="i417e39f5b7bb45b295bb09394310bc8c_34"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 4. Mine Safety Disclosures</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Not applicable.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112</span></div></div></div><div id="i417e39f5b7bb45b295bb09394310bc8c_37"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">PART II</span></div><div id="i417e39f5b7bb45b295bb09394310bc8c_40"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 5. Market For Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Market Information</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our ordinary shares, nominal value &#163;0.000025 per share, in the form of ADSs trade under the symbol &#8220;BRNS&#8221; on the Nasdaq Global Market.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Holders of Our ADSs</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our ADSs each represent one ordinary share, nominal value &#163;0.000025 per share, of Barinthus Biotherapeutics plc. An ADS may be evidenced by an American Depositary Receipt issued by the Bank of New York Mellon as depositary bank. As of March 14, 2024, there was one holder of record of our ordinary shares, nominal value &#163;0.000025 per share, and 70 holders of record of our ADSs. The closing sale price per ADS on the Nasdaq Global Market on March 14, 2024 was $2.51.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Dividends</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have never paid or declared any cash dividends on shares of our ordinary shares, ADSs or other securities and do not anticipate paying or declaring any cash dividends in the foreseeable future. We currently intend to retain all future earnings, if any, for use in the operation of our business.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Securities Authorized for Issuance Under Equity Compensation Plans</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The information required by Item 5 of Form 10-K regarding equity compensation plans is incorporated herein by reference to Item 12 of Part III of this Annual Report.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Recent Sales of Unregistered Equity Securities</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">None.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Certain Material UK Tax Considerations</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following discussion is limited to an overview of the tax consequences of ownership and disposition of ordinary shares, or such shares represented by ADSs (those ordinary shares or ADSs deriving over 75% of their value otherwise than from United Kingdom land). Each shareholder should however seek individual tax advice as specific rules may apply in certain circumstances. The United Kingdom tax consequences discussed below do not reflect a complete analysis or listing of all the possible United Kingdom tax consequences that may be relevant to holders of our ordinary shares or ADSs.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Chargeable Gains </span></div><div style="margin-top:12pt"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A disposal or deemed disposal of ordinary shares or ADSs by a holder resident in the United Kingdom for tax purposes or subject to UK taxation (a &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">UK Holder</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221;) may, depending on such holder&#8217;s circumstances and subject to any available exemptions or reliefs (such as the annual exemption), give rise to a chargeable gain or an allowable loss for the purposes of UK capital gains tax (for individuals) and corporation tax on chargeable gains (for corporation tax payers).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If an individual UK Holder who is subject to UK income tax at either the higher or the additional rate is liable to UK capital gains tax on the disposal of ordinary shares or ADSs, the current applicable rate will be 20% (for the tax years 2023/2024 and 2024/2025). For an individual UK Holder who is subject to UK income tax at the basic rate and liable to UK capital gains tax on such disposal, the current applicable rate would be 10% (for the tax years 2023/2024 and 2024/2025), save to the extent that any capital gains when aggregated with the UK Holder&#8217;s other taxable income and gains in the relevant tax year exceed the unused basic rate tax band. In that case, the capital gains tax rate currently applicable to the excess would be 20% (for the tax years 2023/2024 and 2024/2025).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If a corporate UK Holder is or becomes liable to UK corporation tax on the disposal (or deemed disposal) of ordinary shares or ADSs, the main rate of UK corporation tax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">would apply (currently at 25% for companies with profits of more </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">113</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">than &#163;250,000 or 19% for companies with profits not exceeding &#163;50,000 with a marginal relief applying to profits between &#163;50,000 and &#163;250,000, in each case, for the 2023/2024 and 2024/2025 tax years).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Any chargeable gain (or allowable loss) will generally be calculated by reference to the consideration received for the disposal of the ADSs less the allowable cost to the UK Holder of acquiring such ADSs.</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If you are not resident in the UK for UK tax purposes (or, in the case of an individual, not temporarily non-resident), you should not normally be liable for UK tax on capital gains realized or accrued on the sale or other disposition of ordinary shares or ADSs unless the ordinary shares or ADSs are held in connection with your trade carried on in the UK through a branch or agency (or, in the case of a corporate holder, a permanent establishment) and the ordinary shares or ADSs are or have been used, held or acquired for the purposes of such trade or such branch or agency. </span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">An individual holder of ordinary shares or ADSs who ceases to be resident in the UK for UK tax purposes for a period of less than five years and who disposes of ordinary shares or ADSs during that period may also be liable on returning to the UK (or upon ceasing to be regarded as resident outside the UK for the purposes of any relevant double taxation treaty) for UK capital gains tax despite the fact that the individual may not be resident in the UK at the time of the disposal. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Stamp Duty and Stamp Duty Reserve Tax </span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Stamp duty and/or stamp duty reserve tax (&#8220;SDRT&#8221;) are imposed in the United Kingdom on certain transfers of securities (including shares in companies which, like us, are incorporated in the United Kingdom) at a rate of 0.5% of the consideration paid for the transfer. Certain transfers of shares to depositaries or into clearance systems are charged a higher rate of 1.5%. Transfers of interests in shares within a depositary or clearance system, and from a depositary to a clearance system, are generally exempt from stamp duty and SDRT.</span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under current UK tax law, no UK SDRT (or, where</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">effected by a written instrument, UK stamp duty) should generally be payable in respect of an issue or transfer of ordinary shares, including an unconditional agreement to transfer ordinary shares to a clearance service or a depositary receipt system (including to a nominee or agent for a person whose business is or includes the issue of depositary receipts or the provision of clearance services) where the transfer is carried out for the purpose of raising new capital, unless the clearance service has made and maintained an election under section 97A of the UK Finance Act 1986, or a section 97A election. It is understood that HMRC regards the facilities of DTC as a clearance service for these purposes and we are not aware of any section 97A election having been made by DTC. Any stamp duty or SDRT payable on a transfer of ordinary shares to a depositary receipt system or clearance service or in respect of a transfer within a depositary receipt system or clearance service, will strictly be accountable by the clearance service or depositary receipt system operator or their nominee, as the case may be, but will in practice generally be paid by the transferors or participants in the clearance service or depositary receipt system. Specific professional advice should be sought before incurring or reimbursing the costs of a UK stamp duty or UK SDRT charge in any circumstances.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Any transfer of, or unconditional agreement to transfer, our ordinary shares that occurs outside the DTC system, including repurchases by us, will ordinarily attract stamp duty or SDRT at a rate of 0.5% of the amount or value of the consideration payable for the transfer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(and in the case of stamp duty, rounded up to the next multiple of &#163;5), unless the transfer is to a connected company and in which case a market value may apply. This duty must be paid (and where applicable the transfer document stamped by HMRC) before the transfer can be registered in our books. Typically stamp duty would be paid by the purchaser of the ordinary shares.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Any transfer of, or unconditional agreement to transfer, our ordinary shares that occurs outside the DTC system, including repurchases by us, will ordinarily attract stamp duty or SDRT at a rate of 0.5% of the amount or value of the consideration payable for the transfer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(and in the case of stamp duty, rounded up to the next multiple of &#163;5), unless the transfer is to a connected company and in which case a market value may apply. This duty must be paid (and where applicable the transfer document stamped by HMRC) before the transfer can be registered in our books. Typically stamp duty would be paid by the purchaser of the ordinary shares.</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A transfer of title in our ordinary shares from within the DTC system out of the DTC system will not attract stamp duty or SDRT if undertaken for no consideration. If that ordinary shares is redeposited into DTC (which may only be done via a deposit of the ordinary shares first with an appropriate offshore depositary followed by a transfer of the ordinary shares from the offshore depositary into DTC), however, the redeposit will attract stamp duty or SDRT at a rate of 1.5%.</span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">No UK stamp duty or SDRT should be payable on the issue of ADSs in the Company.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">No UK stamp duty or SDRT should be required to be paid in respect of a paperless transfer of ADSs through the facilities of DTC, provided that no section 97A election has been made and maintained by DTC, and such ADSs are held through DTC at the time of any agreement for their transfer. We are not aware of any section 97A election having been made by the DTC.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On the basis of current published HMRC guidance, an ADR is not regarded as stock or a marketable security for the purposes of UK stamp duty or a chargeable security for the purposes of UK SDRT and, as such, no UK stamp duty or SDRT should be required to be paid on the issue or transfer of (including an agreement to transfer) ADSs in the Company.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">   </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Taxation of Dividends </span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under UK law, there is no withholding tax on dividends paid on the ordinary shares or ADSs.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">An individual UK Holder may, depending on his or her particular circumstances, be subject to UK tax on dividends received from us. An individual holder of ADSs who is not resident for tax purposes in the UK should not be chargeable to UK income tax on dividends received from us unless he or she carries on (whether solely or in partnership) a trade, profession or vocation in the UK through a branch or agency to which the ADSs are attributable. There are certain exceptions for trading in the UK through independent agents, such as some brokers and investment managers.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Dividend income is treated as the top slice of the total income chargeable to UK income tax for an individual UK Holder. An individual UK Holder who receives a dividend in the 2023/2024 tax year will be entitled to a dividend tax-free allowance of &#163;1,000. However, the UK government has legislated to reduce the dividend tax-free allowance to &#163;500 with effect from April 2024 (i.e. for the 2024/2025 tax year). Income within the dividend tax-free allowance counts towards an individual&#8217;s basic, higher or additional rate limits and may, therefore, affect the level of income tax personal allowance to which they are entitled. Dividend income received in excess of the dividend tax-free allowance will (subject to the availability of any income tax personal allowance) be charged at 8.75% to the extent the excess amount falls within the basic rate band, 33.75% to the extent the excess amount falls within the higher rate band and 39.35% to the extent the excess amount falls within the additional rate band. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A corporate holder of ADSs who is not resident for tax purposes in the UK should not be chargeable to UK corporation tax on dividends received from us unless it carries on (whether solely or in partnership) a trade in the UK through a permanent establishment to which the ADSs are attributable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Corporate UK Holders should not be subject to UK corporation tax on any dividend received from us so long as the dividends qualify for exemption, which should be the case, although certain conditions must be met. It should be noted that the exemptions, whilst of wide application, are not comprehensive and are subject to anti-avoidance rules. If the conditions for the exemption are not satisfied, such anti-avoidance provisions apply, or such UK Holder elects for an otherwise exempt dividend to be taxable, UK corporation tax will be chargeable on the amount of any dividends (at the current rate of 25% for companies with profits of more than &#163;250,000 or 19% for companies with profits not exceeding &#163;50,000, with a marginal relief applying to profits between &#163;50,000 and &#163;250,000, in each case for the 2023/2024 and 2024/2025 tax years).</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Use of Proceeds from Initial Public Offering</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On May 4, 2021, we completed our initial public offering (&#8220;IPO&#8221;) of 6,500,000 ADSs at a price of $17.00 per ADS for an aggregate offering price of approximately $110.5 million. Morgan Stanley &amp; Co., Jefferies LLC, Barclays Capital Inc., William Blair &amp; Company, L.L.C. and H.C. Wainwright &amp; Co., LLC served as the underwriters of the IPO. The offer and sale of all of the ADSs in the offering were registered under the Securities Act pursuant to a registration statement on Form S-1 (File No. 333-255158), which became effective on April 29, 2021.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We received aggregate net proceeds from the offering of approximately $102.8 million, after deducting underwriting discounts and commissions, as well as other offering expenses. No offering expenses were paid directly or indirectly to any of our directors or officers (or their associates) or persons owning ten percent or more of any class of our equity securities or to any other affiliates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There has been no material change in our planned use of the net proceeds from the IPO as described in the final prospectus filed with the SEC pursuant to Rule 424(b) under the Securities Act.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">115</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Purchase of Equity Securities by the Issuer and Affiliated Purchases</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">None.</span></div><div id="i417e39f5b7bb45b295bb09394310bc8c_43"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 6. [Reserved]</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Not applicable.</span></div><div id="i417e39f5b7bb45b295bb09394310bc8c_46"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">You should read the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and the related notes appearing elsewhere in this Annual Report. Some of the information contained in this discussion and analysis or set forth elsewhere in this report, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks, uncertainties and assumptions. As a result of many factors, including those factors set forth in the &#8220;Risk Factors&#8221; section of this Annual Report, our actual results could differ materially from the results described in, or implied by, the forward-looking statements contained in the following discussion and analysis. You should carefully read the &#8220;Cautionary Note Regarding Forward Looking Statements&#8221; and &#8220;Risk Factors&#8221; sections of this Annual Report to gain an understanding of the important factors that could cause actual results to differ materially from our forward-looking statements contained in the following discussion and analysis.</span></div><div id="i417e39f5b7bb45b295bb09394310bc8c_49"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Overview</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity and cancer. Helping patients and their families is the guiding principle at the heart of Barinthus Bio. The Company stands apart through its broad pipeline, built around four proprietary platform technologies; two viral vector platforms, ChAdOx and MVA; and two synthetic SNAP platforms, SNAP-Tolerance Immunotherapy ("SNAP-TI") and SNAP-Cancer Immunotherapy ("SNAP-CI").These platforms are enabling us to develop antigen-specific immunotherapeutic candidates designed to optimize the disease-fighting capabilities of T cells and guide them towards a healthy balance. Our immunotherapeutic candidates are designed to work by increasing disease-specific CD8+ T cell activity in the case of chronic infectious diseases and cancers, or by dampening CD4+ and CD8+ T cells, and increasing regulatory T cells in autoimmunity.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Harnessing our range of proprietary viral vector and synthetic platform technologies, we are advancing a pipeline of four product candidates across a diverse range of therapeutic areas, including: VTP-300, a Phase 2 immunotherapeutic candidate designed as a potential component of a functional cure for chronic HBV infection; VTP-200, a Phase 2 non-surgical product candidate for persistent high-risk HPV with near term clinical read-outs; VTP-1000, our first preclinical autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease; and VTP-850, a second-generation Phase 2 immunotherapeutic candidate designed to treat recurrent prostate cancer.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Alongside these proprietary programs, we have partnerships in place to advance three additional prophylactic and therapeutic product candidates in MERS, Zoster and Non-Small Cell Lung Cancer ("NSCLC"). The Company also co-invented a COVID-19 vaccine with the University of Oxford, which has been exclusively licensed worldwide to AstraZeneca. The co-invention of the COVID-19 vaccine demonstrated our ability to navigate a changing environment with speed and efficiency and lead the way in responding to urgent medical needs, as well as providing a strong proof-of-concept for the ChAdOx platform.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe our proven scientific expertise, diverse portfolio and focus on product candidate development uniquely positions us to navigate towards delivering treatments for patients with infectious diseases, autoimmune disorders and cancers that have a significant impact on their every day lives.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On May 4, 2021, we completed our IPO pursuant to which we issued and sold 6,500,000 American Depository Shares, or ADSs, at a public offering price of $17.00 per ADS, resulting in net proceeds of $102.8 million, after deducting underwriting discounts and commissions and offering expenses. Prior to our IPO, we funded our operations primarily from private placements of our ordinary and preferred shares, private placements of loan notes convertible into ordinary shares, as well as from grants and licensing agreements, research tax credit payments, investments from non-controlling interest, and a $2.4 million upfront payment from OUI in July 2020 in connection with the Amendment, Assignment and Revenue Share Agreement, or the OUI License Agreement Amendment, related to the licensing of the COVID-19 vaccine, Vaxzevria. We do not expect to generate revenue from any of our own product candidates, excluding Vaxzevria, until we </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">116</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">obtain regulatory authorization for one or more of such product candidates, if at all, and commercialize our products, or we enter into out-licensing agreements with third parties.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On August 9, 2022, we filed a Registration Statement on Form S-3, as amended (the "Shelf"), with the Securities and Exchange Commission in relation to the registration and potential future issuance of ordinary shares, including ordinary shares represented by ADSs, debt securities, warrants and/or units of any combination thereof in the aggregate amount of up to $200.0 million. The Shelf was declared effective on August 17, 2022. We also simultaneously entered into a sales agreement with Jefferies LLC, as sales agent, providing for the offering, issuance and sale by us of up to an aggregate of $75.0 million of our ordinary shares represented by ADSs from time to time in &#8220;at-the-market&#8221; offerings under the Shelf. As of December&#160;31, 2023, we sold 1,139,444 ordinary shares represented by ADSs under the sales agreement, amounting to gross proceeds of $3.1 million. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have incurred net losses each year since inception through to December 31, 2021. For the year ended December 31, 2022, we generated net income of $5.3 million, primarily as a result of revenues arising from AstraZeneca sales of Vaxzevria and our agreement with OUI. For the year ended December&#160;31, 2023, we incurred net losses of $73.4 million. As of December&#160;31, 2023 and 2022, we had an accumulated deficit of $176.6 million and $103.2 million, respectively, and we do not currently expect profits or positive cash flows from operations in the foreseeable future. We expect to incur net operating losses for at least the next several years as we advance our product candidates through clinical development, seek regulatory approval, prepare for approval, and in some cases proceed to commercialization of our product candidates, as well as continue our research and development efforts and invest to establish a commercial manufacturing facility, as and when appropriate.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">At this time, we cannot reasonably estimate, or know the nature, timing and estimated costs of all of the efforts that will be necessary to complete the development of any of our product candidates that we develop through our programs. We are also unable to predict when, if ever, material net cash inflows will commence from sales of product candidates we develop, if at all. This is due to the numerous risks and uncertainties associated with developing product candidates to approval and commercialization, including the uncertainty of:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">successful completion of preclinical studies and clinical trials;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">sufficiency of our financial and other resources to complete the necessary preclinical studies and clinical trials;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">acceptance of INDs for our planned clinical trials or future clinical trials;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">successful and timely enrollment and completion of clinical trials;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">data from our clinical program supporting approvable and commercially acceptable risk/benefit profiles for our product candidates in the intended populations;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">receipt and maintenance of necessary regulatory and marketing approvals from applicable regulatory authorities, in the light of the commercial environment then existent;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">availability and successful procurement of raw materials required to manufacture our products for clinical trials, scale-up of our manufacturing processes and formulation of our product candidates for later stages of development and commercial production;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">establishing either our own manufacturing capabilities or satisfactory agreements with third-party manufacturers for clinical supply for later stages of development and commercial manufacturing;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">entry into collaborations where appropriate to further the development of our product candidates;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">obtaining and maintaining intellectual property and trade secret protection or regulatory exclusivity for our product candidates as well as qualifying for, maintaining, enforcing and defending such intellectual property rights and claims;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">successfully launching or assisting with the launch of commercial sales of our product candidates following approval;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">acceptance of each product&#8217;s benefits and uses by patients, the medical community and third-party payors following approval;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">117</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the prevalence and severity of any adverse events experienced with our product candidates in development;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">establishing and maintaining a continued acceptable safety profile of the&#8201;product candidates following approval;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">obtaining and maintaining healthcare coverage and adequate reimbursement from third-party payors if necessary or desirable; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">effectively competing with other therapies.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A change in the outcome of any of these or other variables with respect to the development of any of our current and future product candidates could significantly change the costs and timing associated with the development of that product candidate, in either direction. Furthermore, our operating plans may change in the future owing to research outcomes or other opportunities, and we may need additional funds to meet operational needs and capital requirements associated with such altered operating plans. Unless and until we can generate a substantial amount of revenue from our product candidates, if approved, we expect to finance our future cash needs through public or private equity offerings, debt financings, collaborations, licensing arrangements or other sources, or any combination of the foregoing. Based on our research and development plans, we expect that our existing cash and cash equivalents and other financial resources, will enable us to fund our operating expenses and capital expenditure requirements into the fourth quarter of 2025. These estimates are based on assumptions that may prove to be wrong, and we could use our available capital resources more quickly than we expect. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we raise additional funds through collaborations, strategic alliances, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds when needed, we would be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span></div><div id="i417e39f5b7bb45b295bb09394310bc8c_52"></div><div style="margin-top:12pt"><span><br/></span></div><div id="i417e39f5b7bb45b295bb09394310bc8c_55"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Impact of Israel and Gaza Conflict</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In respect of the international conflict in Israel and Gaza, we have no operations or suppliers based in Israel or Gaza, and as a result, as of the date of this Annual Report, we believe the impact on our business, operations and financial condition will be minimal.</span></div><div id="i417e39f5b7bb45b295bb09394310bc8c_58"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Impact of the Ukraine Crisis</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In respect of the international situation in Ukraine, we have assessed the impact on us as minimal. We have no operations or suppliers based in Ukraine, Belarus, or Russia, and there is consequently no additional risk or negative impact on the consolidated financial statements.</span></div><div id="i417e39f5b7bb45b295bb09394310bc8c_61"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Impact of Global Economic Conditions and Inflationary Pressures</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Instability in global economic conditions and geopolitical matters, as well as volatility in financial markets, could have a material adverse effect on our results of operations and financial condition. These inflationary pressures and rising interest rates in the United States, the United Kingdom and elsewhere have given rise to increasing concerns that the U.S., U.K. and other economies are now in, or may soon enter, economic recession. Sustained inflationary pressures, increased interest rates, an economic recession or continued or intensified disruptions in the global financial markets could adversely affect our future financing capability or ability to access the capital markets. Additionally, we may incur future increases in operating costs due to additional inflationary increases.</span></div><div id="i417e39f5b7bb45b295bb09394310bc8c_64"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Components of Our Operating Results</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Revenue</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To date, we have not generated any revenue from direct product sales and do not expect to do so in the near future, if at all. Most of our revenue to date has been derived from the OUI License Agreement Amendment with OUI relating to Vaxzevria.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">118</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In April 2020, we entered into the OUI License Agreement Amendment with OUI in respect of our rights to use the ChAdOx1 technology in COVID-19 vaccines to facilitate the license of those rights by OUI to AstraZeneca. Under this agreement, we are entitled to receive from OUI a share of payments, including royalties and milestones, received by OUI from AstraZeneca in respect of this vaccine. On March 28, 2022, pursuant to the OUI License Agreement Amendment, we were notified of the commencement of payments, arising from AstraZeneca&#8217;s commercial sales of Vaxzevria. Under the terms of an exclusive worldwide license agreement between OUI and AstraZeneca, OUI is entitled to milestone payments and royalties on commercial sales of Vaxzevria that began after the pandemic period. As part of the assignment from us to OUI, we are entitled to receive approximately 24% of payments received by OUI from AstraZeneca. Our revenue for the year ending December&#160;31, 2023 was $0.8 million (year ended December&#160;31, 2022 $43.7 million), representing the amounts we have been notified of as due by OUI to date and an estimate of future receipts, constrained to the extent that it is probable that a significant reversal of revenue would not occur. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We determined that we have no further performance obligations under the terms of the OUI License Agreement Amendment, which comprised the transfer of intellectual property rights only. Accordingly, we plan to recognize these and any future amounts as revenue when earned, and it is probable that a significant reversal of revenue will not occur. There is, however, no guarantee or expectation that such payments will continue in the future and, if they do, that we will be notified of such payments in a timely manner.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Operating Expenses</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our operating expenses since inception have consisted of research and development costs and general administrative costs.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Research and Development Expenses</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Since our inception, we have focused significant resources on our research and development activities, including establishing and building on our adenovirus platform, further enhancing our in-licensed ChAdOx1, ChAdOx2 and MVA vectors, developing new next generation adenoviral vector, acquiring new technology platforms including SNAP (SNAP-TI and SNAP-CI), conducting preclinical studies, developing various manufacturing processes, and advancing clinical development of our programs including Phase 2 clinical trials for VTP-100, which we subsequently discontinued development of, as well as initiating the clinical trials for VTP-200, VTP-300, VTP-600 and VTP-850 and readying, VTP-500 and VTP-1000 for clinical trials. Research and development activities account for a large portion of our operating expenses, and we expect research and development expenses to increase in the future. Research and development costs are expensed as incurred. These costs include:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">salaries, benefits and other related costs, including share-based compensation, for personnel engaged in research and development functions;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">expenses incurred in connection with the development of our programs including preclinical studies and clinical trials of our product candidates, under agreements with third parties, such as consultants, contractors, academic institutions and ("CROs"); </span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the cost of manufacturing drug products for use in preclinical development and clinical trials, including under agreements with third parties, such as contract manufacturing organizations, consultants and contractors;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">laboratory costs; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">leased facility costs, equipment depreciation and other expenses, which include direct and allocated expenses.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">General and Administrative Expenses</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our general and administrative expenses consist primarily of personnel-related expenses, including share-based compensation, in our executive, finance, business development and other administrative functions. Other general and administrative expenses include consulting fees and professional service fees for auditing, tax and legal services, rent expenses related to our offices, depreciation, foreign exchange gains and losses on our cash balances, other central non-research costs and changes in fair value of contingent consideration. Significant judgment is used to determine the probability of success of achievement of the technology and clinical milestones and the date of the expected milestone used in the valuation model of the contingent consideration. We expect our general and administrative expenses to continue to increase in the future as we expand our operating activities in both the United Kingdom and United States and potentially prepare for manufacturing and/or commercialization of our current and future product candidates. These costs will increase as our headcount rises to allow full support for our operations as a public company, including increased expenses related to legal, accounting, regulatory and tax-related services associated with maintaining compliance with requirements of the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">119</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Nasdaq Global Market and the Securities and Exchange Commission, directors&#8217; and officers&#8217; liability insurance premiums and investor relations activities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Other Income/ (Expense)</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Interest Income</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Interest income results primarily from the interest earned on our short-term cash deposits and cash balances held by Barinthus Biotherapeutics (UK) Limited in United States dollars and pounds sterling.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Interest Expense</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Interest expense results primarily from the asset retirement obligation provision discounted over the length of the lease in respect of our headquarters.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Research and Development Incentives</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Research and development incentives contain payments receivable from the United Kingdom government related to corporation tax relief on research and development projects in the United Kingdom. We account for such relief received as other income.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company benefits from the United Kingdom research and development tax credit regime, being the Small and Medium-sized Enterprises R&amp;D tax relief program ("SME Program"), and, to the extent that our projects are grant funded or relate to work subcontracted to us by third parties, the Research and Development Expenditure Credit program ("RDEC Program").</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Until March 2023, under the SME Program, we were able to surrender some of its trading losses that arise from qualifying research and development activities for a cash rebate of (after taking into account the enhanced rate of deduction) up to 33.35% of such qualifying research and development expenditure. Qualifying expenditures largely comprise employment costs for research staff, consumables, outsourced contract research organization costs and utilities costs incurred as part of research projects. Certain staff, consumables (including utilities), subcontractors and externally provided workers qualifying research and development expenditures are eligible for a cash rebate of up to 21.67%. A large portion of costs relating to research and development, clinical trials and manufacturing activities are eligible for inclusion within these tax credit cash rebate claims. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">From April 2023, under the SME Program the enhanced rate of deduction has decreased from 230% to 186%, the SME credit rate has was or has been reduced from 14.5% to 10% (except for R&amp;D intensive SMEs, which are expected to benefit form a credit rate of 14.5%), and the SME cash rebate for us was or has been reduced from an effective rate of 33.35% to 18.6% (or 26.97% for R&amp;D intensive SMEs) and from 21.67% to 12.1% for subcontractors. Furthermore, the SME credit rate will decrease to 10% for expenditure incurred on or after April 1, 2023 unless the SME qualifies as an R&amp;D intensive business, i.e., R&amp;D expenditure constitutes at least 40% (from April 1, 2023) or 30% (from accounting periods starting on or after April 1, 2024) of total expenditure.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company may not be able to continue to claim research and development tax credits under the SME program in the future because it may no longer qualify as a small or medium-sized company. In addition, the EU State Aid cap limits the total aid claimable in respect of a given project to &#8364;7.5 million which may impact our ability to claim R&amp;D tax credits in future. Further, the U.K. Finance Act of 2021 introduced a cap on payable credit claims under the SME Program in excess of &#163;20,000 with effect from April 2021 by reference to, broadly, three times the total Pay As You Earn ("PAYE"), and National Insurance Contributions ("NICs"), liability of the company, subject to an exception which prevents the cap from applying. That exception requires the company to be creating, taking steps to create or managing intellectual property, as well as having qualifying research and development expenditure in respect of connected parties, which does not exceed 15% of the total claimed. If such an exception does not apply, this could restrict the amount of payable credit that we claim. For the year ended December 31, 2022, the R&amp;D tax credits were further restricted by the available tax losses in the UK for the period. There was no tax loss restriction applied to the R&amp;D tax credits in the UK for the year ended December 31, 2023. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Unsurrendered UK losses may be carried forward indefinitely to be offset against future taxable profits, subject to numerous utilization criteria and restrictions. The amount that can be offset each year is limited to &#163;5.0 million plus an incremental 50% of UK taxable profits.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">120</span></div></div></div><div id="i417e39f5b7bb45b295bb09394310bc8c_67"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Critical Accounting Policies and Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">This discussion and analysis of financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States ("GAAP"). The preparation of financial statements requires management to make estimates and judgments that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue, income and expenses during the reporting period. On an ongoing basis, management evaluates its estimates, including those related to fair value of contingent consideration and impairment of goodwill and intangible assets. Management bases its estimates on historical experience and on various other market specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe that the following accounting policies are critical to the process of making significant judgments and estimates in the preparation of our financial statements and understanding and evaluating our reported financial results.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Goodwill and Purchased Intangible Assets</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">We assess goodwill and intangible assets for impairment at least annually, or more frequently if events or changes in circumstances indicate that the carrying amounts may not be recoverable. We have elected to assess goodwill for impairment by first performing a qualitative assessment to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount as a basis of determining whether it is necessary to perform the quantitative goodwill impairment test. We have one reporting unit. Accordingly, our review of goodwill impairment indicators is performed at the entity-wide level. This requires us to assess and make judgments regarding a variety of factors, including clinical data results, business plans, anticipated future cash flows, economic projections and other market data. Because there are inherent uncertainties involved in these factors, significant differences between these estimates and actual results could result in future impairment charges and could materially impact our future financial results. The goodwill of $12.2 million and the intangible asset of $25.1 million recognized as at December&#160;31, 2023 wholly relate to the acquisition of Avidea on December 10, 2021. The Company performed the annual impairment assessment as of December&#160;31, 2023, to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount. Based on this assessment, the Company has not recognized any impairment losses related to goodwill or intangible assets for the year ended December&#160;31, 2023.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Contingent consideration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company recognizes a contingent consideration liability related to the acquisition of Avidea. The liability is remeasured to fair value at each reporting date until the contingency is resolved. The fair value of the contingent consideration is a Level 3 valuation determined using significant unobservable inputs being the probability of success of achievement of the milestones and the expected date of the milestone achievement. Changes in fair value are recognized in general and administrative expenses in the consolidated statement of operations and comprehensive loss. Avidea&#8217;s stockholders may be entitled to receive an aggregate of up to $40.0 million in additional payments, payable in a combination of cash and ADSs, upon the achievement of certain milestones. This contingent consideration is included within the purchase price and is recognized at its fair value on the acquisition date, and subsequently remeasured to fair value at each reporting date until the contingency is resolved. Changes in fair value are recognized in general and administrative expenses in the consolidated statements of operations and comprehensive loss. The fair value of contingent consideration is based on the probability of pursuit of the activity associated with the milestone, the probability of success of the achievement of the milestone, the expected date of milestone achievement and applying the relevant discount rate.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">121</span></div></div></div><div id="i417e39f5b7bb45b295bb09394310bc8c_70"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Results of Operations</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Comparison of the Years Ended December&#160;31, 2023 and 2022</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table sets forth the significant components of our results of operations (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">ended December</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">31, 2023</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">ended December</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">31, 2022</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Revenue from Licenses, Grants and Services </span></div></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">802&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">44,703&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(43,901)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating expenses:</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Research and development</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">44,874&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">42,350&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,524&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">39,842&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,394&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">33,448&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">84,716&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">48,744&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">35,972&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Loss from operations</span></td><td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(83,914)</span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(4,041)</span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(79,873)</span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other income/(expense):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Interest income</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,877&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,103&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(226)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(28)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Research and development incentives</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,461&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,240&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,221&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,082&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">567&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">515&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total other income</span></div></td><td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,392&#160;</span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,891&#160;</span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,501&#160;</span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(Loss)/profit before income tax</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(76,522)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">850&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(77,372)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Tax benefit</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,075&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,471&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1,396)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net (loss)/income</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(73,447)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,321&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(78,768)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Revenue</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For the year ended December&#160;31, 2023, our revenue consisted of $0.8 million from the OUI License Agreement Amendment with respect to amounts owed to us by OUI for the commercial sales of Vaxzevria. The decrease in revenue from the OUI License Agreement Amendment, compared to the prior period, resulted from substantially declined sales of Vaxzevria in 2023. There is no guarantee that further payments will be received pursuant to the agreement in the future and, if such payments are made, that we will be notified of such payments in a timely manner.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For the year ended December&#160;31, 2022, our revenue primarily consisted of $43.7 million from the OUI License Agreement Amendment with respect to amounts owed to us by OUI for the commercial sales of Vaxzevria, and $0.8 million attributable to upfront fees associated with a research and license agreement with Scancell.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">122</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes our research and development expenses for the years ended December&#160;31, 2023 and 2022:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">ended December</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">31, 2023</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">ended December</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">31, 2022</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Direct research and development expenses by program:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">VTP-200 HPV</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,950&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,050&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">900&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">VTP-300 HBV</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">11,276&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">13,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(2,424)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">VTP-600 NSCLC</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">597&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">532&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">65&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">VTP-850 Prostate cancer</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,726&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,011&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(2,285)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">VTP-1000/VTP-1100 Celiac/HPV Cancer</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,420&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,118&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,302&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other and earlier stage programs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,787&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,916&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(129)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total direct research and development expenses</span></td><td style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">29,756&#160;</span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">30,327&#160;</span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(571)</span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Indirect research and development expenses:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Personnel-related (including share-based compensation)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12,702&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,424&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,278&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Facility related</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,339&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,308&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other indirect costs</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,077&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">291&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">786&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total indirect research and development expenses </span></div></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">15,118&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12,023&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,095&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total research and development expenses</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">44,874&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">42,350&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,524&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our research and development expenses for the years ended December&#160;31, 2023 and 2022 were $44.9 million and $42.4 million, respectively, and consisted of direct and indirect research and development expenses. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Direct expenses for the years ended December&#160;31, 2023 and 2022 were $29.8 million and $30.3 million, respectively, and consisted of outside services, consultants, laboratory materials, clinical trials, manufacturing of clinical trial materials, as well as costs for external preclinical services and sample testing. Of the $0.6 million decrease, a $2.4 million decrease pertains to VTP-300 as a result of completing the HBV002 Phase 2 clinical trial with final data that was presented at the EASL Congress in June 2023, and continuing enrollment in the HBV003 Phase 2b clinical trial and the AB-729-202 Phase 2a clinical collaboration with Arbutus. A $2.3 million decrease pertains to VTP-850 which is currently enrolling PCA001, a Phase 1/2 open-label clinical trial, compared to the prior year which was a result of manufacturing spend. These decreases were partially offset by a $3.3 million increase in SNAP candidates, namely in VTP-1000 Celiac disease program costs which increased as the program progresses to regulatory submissions and towards the clinic.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Indirect research and development expenses for the years ended December&#160;31, 2023 and 2022 were $15.1 million and $12.0 million, respectively. Of the $3.1 million increase, $2.3 million pertains to personnel-related expenses as a result of an increase in headcount across locations in the United Kingdom and United States and $0.8 million increase relates to other indirect cost mainly due to overhead allocations from the new U.S. laboratory and office facility that we relocated to in June 2023.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">General and Administrative Expenses</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">General and administrative expenses for the years ended December&#160;31, 2023 and 2022 were $39.8 million and $6.4 million, respectively. The increase of $33.4 million relates primarily to a change in foreign exchange gains and losses of $33.8 million from a gain of $26.0 million for the year ended December&#160;31, 2022 to a loss of $7.8 million for the year ended December&#160;31, 2023.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Interest Income</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For the years ended December&#160;31, 2023 and 2022, interest income was $2.9 million and $3.1 million respectively, which primarily resulted from the interest earned on our short-term cash deposits and cash balances held by Barinthus Biotherapeutics (UK) Limited in United States dollars and pound sterling.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">123</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Interest Expense</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For the year ended December&#160;31, 2023, interest expense was $0.03 million which related to an asset retirement obligation provision discounted over the length of the lease term in respect of the laboratory and office facilities in the United Kingdom and the United States. For the year ended December&#160;31, 2022 interest expense was $0.02 million which related to an asset retirement obligation provision discounted over the length of the lease in respect of our headquarters in the United Kingdom, and $0.003 million interest paid on the debt recognized on the acquisition of Avidea, which was repaid in full in the first quarter of 2022.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Research and Development Incentives</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For the years ended December&#160;31, 2023 and 2022, we accrued research and development incentives of $3.5 million and $1.2 million respectively, with the increase mainly attributable to an increase in losses available to surrender for the receipt of research and development incentives in Barinthus Biotherapeutics (UK) Limited due to a reduction in revenue received from commercial sales of Vaxzevria. Such research and development incentives relate to corporation tax relief on research and development project incentive programs in the United Kingdom. We account for such relief received as other income.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Tax benefit</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For the years ended December&#160;31, 2023 and 2022, the tax benefit was $3.1 million and $4.5 million respectively, which primarily relates to movements in deferred tax resulting from the deferred tax liability recognized in respect of the acquired intangible asset.</span></div><div id="i417e39f5b7bb45b295bb09394310bc8c_73"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Liquidity and Capital Resources</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Sources of Liquidity</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Since our inception, we have funded our operations primarily through private and public placements of our ordinary and preferred shares as well as from grants and research incentives, various agreements with public funding agencies, the issuance of convertible loan notes and most recently from royalty and milestone payments from OUI in connection with the OUI License Agreement Amendment. Through December&#160;31, 2023, we had received gross proceeds of approximately $327.9 million from the issuance of our ordinary and preferred shares and convertible loan notes. As of December&#160;31, 2023, we had cash and cash equivalents of $142.1 million. Key financing and corporate milestones include the following:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Between July 2020 and November 2020, we raised gross proceeds of $41.2 million from the issuance of convertible loan notes.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">In March 2021, we raised gross proceeds of $125.2 million from the issuance of our Series B shares.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">In May 2021, we raised gross proceeds of $110.5 million from the IPO of our ordinary shares on NASDAQ.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Between April 2022 and December 2023, we received $44.5 million of cash from OUI for the commercial sales of Vaxzevria.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Between December 2022 and December 2023, we raised net proceeds of $3.0 million from the issuance of shares represented by ADSs through &#8220;at-the-market&#8221; offerings under the sales agreement with Jefferies LLC. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On August 9, 2022, we filed the Shelf with the Securities and Exchange Commission in relation to the registration and potential future issuance of ordinary shares, including ordinary shares represented by ADSs, debt securities, warrants and/or units of any combination thereof in the aggregate amount of up to $200.0 million. The Shelf was declared effective on August 17, 2022. We also simultaneously entered into a sales agreement with Jefferies LLC, as sales agent, providing for the offering, issuance and sale by us of up to an aggregate of $75.0 million of our ordinary shares represented by ADSs from time to time in &#8220;at-the-market&#8221; offerings under the Shelf. As of December&#160;31, 2023, we have sold 1,139,444 ordinary shares represented by ADSs under the sales agreement, amounting to net proceeds of $3.0 million.</span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">We do not currently expect positive cash flows from operations in the foreseeable future, if at all. In most periods, we have incurred operating losses as a result of ongoing efforts to develop our novel T cell immunotherapeutic candidates, including conducting ongoing research and development, preclinical studies, clinical trials, providing general and administrative support for these operations and developing our intellectual property portfolio. We expect to continue to </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">124</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">incur net negative cash flows from operations for at least the next few years as we progress clinical development, seek regulatory approval, prepare for and, if approved, proceed to manufacture and commercialization of our most advanced product candidates. Operating profits may arise earlier if programs are licensed or sold to third parties before final approval, but this cannot be guaranteed.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Cash Flows</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table sets forth a summary of the primary sources and uses of cash (in thousands) for each period presented:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">ended December</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">31, 2023</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">ended December</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">31, 2022</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net cash used in operating activities</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(50,925)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(14,431)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net cash used in investing activities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(5,413)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(5,750)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,872&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">325&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Effect of exchange rates on cash and cash equivalents</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,171&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">187&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net decrease in cash and cash equivalents</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(52,295)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(19,669)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Cash Used in Operating Activities</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the year ended December&#160;31, 2023, net cash used in operating activities was $50.9 million, primarily resulting from our net loss of $73.4 million, adjusted by foreign exchange loss on translation of $7.5 million, share based compensation of $5.1 million, depreciation and amortization of $5.4 million, deferred tax benefit of $3.1 million and changes in our operating assets and liabilities, net decrease of $6.2 million primarily related to a $5.8 million decrease in accounts receivable, a $2.2 million decrease in prepaid expenses and other current assets, a $3.4 million decrease in accounts payable and a $2.0 million increase in accrued expenses.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the year ended December&#160;31, 2022, net cash used in operating activities was $14.4 million, primarily resulting from our net income of $5.3 million, adjusted by foreign exchange gain on translation of $24.8 million, share-based compensation of $9.9 million, depreciation and amortization of $4.3 million, and changes in our operating assets and liabilities, net of $5.5 million primarily resulting from the OUI receivable, and an increase in prepaid expense due to the payment of annual insurance premiums that occurred in the second quarter of 2022.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Net Cash Used in Investing Activities</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the year ended December&#160;31, 2023, cash used in investing activities was $5.4 million primarily resulted from capital expenditures related to leasehold improvements on our new office in Germantown, Maryland, United States. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the year ended December&#160;31, 2022, cash used in investing activities was $5.8 million, primarily resulted from capital expenditures related to our new headquarters in Harwell, United Kingdom.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Net Cash Provided by Financing Activities</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the year ended December&#160;31, 2023, cash provided by financing activities was $1.9 million primarily resulting from the issuance of ordinary shares in the form of ADSs through the &#8220;at-the-market&#8221; sales agreement with Jefferies LLC.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the year ended December&#160;31, 2022, cash provided by financing activities was $0.3 million resulting from $0.5 million from the issuance ordinary shares through the &#8220;at-the-market&#8221; sales agreement with Jefferies LLC, offset by $0.2 million repayment of debt incurred previously by the acquired company Avidea (acquired on December 10, 2021, that subsequently became Barinthus North America, Inc.).</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Effect of exchange rates on cash and cash equivalents</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the years ended December&#160;31, 2023 and 2022, the effect of foreign exchange on cash and cash equivalents was a $2.2 million gain and $0.2 million gain respectively, primarily as a result of fluctuations between the United States dollar and pound sterling exchange rates.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">125</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Future Funding Requirements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To date, we have devoted substantially all of our resources to organizing and staffing our company, business planning, raising capital, undertaking preclinical studies and conducting clinical trials of our product candidates. As a result, we have incurred losses in each year since our inception in 2016, through to December 31, 2021. We were profitable in 2022, however we have negative operating cash flows for the period ending December 31, 2023. As of December&#160;31, 2023, we had an accumulated deficit of $176.6 million. We expect to continue to incur significant losses and negative cash flows from operations for the foreseeable future. We anticipate that our expenses will increase substantially as we:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">pursue the clinical and preclinical development of our current product candidates;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">use our technologies to advance additional product candidates into preclinical and clinical development;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">seek marketing authorizations for product candidates that successfully complete clinical trials, if any;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">attract, hire and retain additional clinical, regulatory, quality control and other scientific personnel;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">establish our manufacturing capabilities through third parties or by ourselves and scale-up manufacturing to provide adequate supply for clinical trials and commercialization, including any manufacturing finishing and logistics personnel;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">expand our operational, financial and management systems and increase personnel appropriately, including personnel to support our manufacturing and commercialization efforts and our operations as a public company;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">maintain, expand, enforce, and protect our intellectual property portfolio as appropriate;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">establish sales, marketing, medical affairs and distribution teams and infrastructure to commercialize any products for which we may obtain marketing approval and intend to commercialize on our own or jointly;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">acquire or in-license other companies, product candidates and technologies; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">incur additional legal, accounting and other expenses in operating our business, including office expansion and the additional costs associated with operating as a public company.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Even if we succeed in commercializing one or more of our product candidates, we will continue to incur substantial research and development and other expenditure to develop and market additional product candidates. We may encounter unforeseen expenses, difficulties, complications, delays and other factors that may adversely affect our business. The size of our future net losses will depend on the rate of future growth of our expenses combined with our ability to generate revenue. Our prior losses and expected future losses have had and will continue to have an adverse effect on our stockholders&#8217; equity and working capital unless and until eliminated by revenue growth.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We may require substantial additional financing in the future to meet any such unanticipated factors and a failure to obtain this necessary capital could force us to delay, limit, reduce or terminate our product development programs, commercialization efforts or other operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Since our foundation, we have invested a significant portion of our efforts and financial resources in research and development activities for our ChAdOx1, ChAdOx2 and MVA technologies, acquisition of additional complementary platforms such as SNAP-TI and SNAP-CI, development of new technologies in house, and our product candidates derived from these technologies. Preclinical studies and especially clinical trials and additional research and development activities will require substantial funds to complete. We believe that we will continue to expend substantial resources for the foreseeable future in connection with the development of our current product candidates and programs as well as any future product candidates we may elect to pursue, as well as the gradual gaining of control over our required manufacturing capabilities and other corporate functions. These expenditures will include costs associated with conducting preclinical studies and clinical trials, obtaining regulatory approvals, and potentially in-house manufacturing and supply, as well as marketing and selling any products approved for sale. In addition, other unanticipated costs may arise as outlined above. Because the outcome of any preclinical study or clinical trial is uncertain and the rate of change of third-party costs is also unpredictable, we cannot reasonably estimate now the actual amounts which will be necessary to complete the development and commercialization of our current or future product candidates successfully.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">126</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our future capital requirements may depend on many factors, including:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the scope, progress, results and costs of researching and developing our current and future product candidates and programs, and of conducting preclinical studies and clinical trials;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the number and development requirements of other product candidates that we may pursue, and of other indications for our current product candidates that we may pursue;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the stability, scale and yield of future manufacturing processes as we scale-up production and formulation of our product candidates either internally or externally for later stages of development and commercialization;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the timing of, success achieved and the costs involved in obtaining regulatory and marketing approvals and developing our ability to establish license or sale transactions and/or sales and marketing capabilities, if any, for our current and future product candidates if clinical trials and approval processes are successful;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the success of our collaborations with CEPI, CanSino, CRUK and the Ludwig Institute and any future collaboration partners;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our ability to establish and maintain collaborations, strategic licensing or other arrangements and the financial terms of such agreements;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the cost to the company of commercialization activities for our current and future product candidates that we may take on, whether alone or with a collaborator;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the costs involved in preparing, filing, prosecuting, maintaining, expanding, defending and enforcing patent and other intellectual property claims, including litigation costs and the outcome of such litigation;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the timing, receipt and amount of sales of, or royalties or other income from, our future products, if any; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the emergence and success or otherwise of competing oncology and infectious disease therapies and other market developments.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A change in the outcome of any of these or other variables with respect to the development of any of our current and future product candidates could significantly change the costs and timing associated with the development of that product candidate, in either direction. Furthermore, our operating plans may change in the future owing to research outcomes or other opportunities, and we may need additional funds to meet operational needs and capital requirements associated with such altered operating plans. Unless and until we can generate a substantial amount of revenue from our product candidates, we expect to finance our future cash needs through public or private equity offerings, debt financings, collaborations, licensing arrangements or other sources, or any combination of the foregoing.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Based on our research and development plans, we expect that our existing cash and cash equivalents and other financial resources, will enable us to fund our operating expenses and capital expenditure requirements into the fourth quarter of 2025. These estimates are based on assumptions that may prove to be wrong, and we could use our available capital resources more quickly than we expect.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we raise additional funds through collaborations, strategic alliances, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds when needed, we would be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Lease, Purchase, and Other Obligations</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have operating lease obligations related to our property and equipment. The details of these leases are disclosed in Item 2. &#8220;Properties.&#8221;. The obligations related to both short- and long-term lease arrangements are set forth in Note 16 &#8220;Commitment and Contingencies&#8221; to our consolidated financial statements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We enter into contracts in the normal course of business with CROs and other third parties for clinical trials and preclinical research studies and testing. These contracts are generally cancellable by us upon prior notice. Payments due upon </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">127</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">cancellation consist only of payments for services provided or expenses incurred, including noncancellable obligations of our service providers, up to the date of cancellation.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have contingent payment obligations that we may incur upon achievement of clinical, regulatory and commercial milestones, as applicable, or royalty payments that we may be required to make under our licenses; however, the amount, timing and likelihood of such payments are not known as of December&#160;31, 2023. See section entitled &#8220;Business - Our Collaboration and License Agreements.</span></div><div id="i417e39f5b7bb45b295bb09394310bc8c_76"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Emerging Growth Company Status</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are an emerging growth company under the JOBS Act. As an emerging growth company, we may delay the adoption of certain accounting standards until those standards would otherwise apply to private companies.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We will remain an emerging growth company until the earliest of (1) the last day of the fiscal year (a) following the fifth anniversary of the date of the closing of our IPO, (b) in which we have total annual gross revenue of at least $1.235 billion, or (c) in which we are deemed to be a &#8220;large accelerated filer&#8221; as defined in Rule 12b-2 under the Exchange Act, which would occur if the market value of our ADSs held by non-affiliates exceeded $700.0 million as of the prior June 30th, and (2) the date on which we have issued more than $1.0 billion in non-convertible debt securities during the prior three-year period.</span></div><div id="i417e39f5b7bb45b295bb09394310bc8c_79"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Recent Accounting Pronouncements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A description of recently issued accounting pronouncement that may potentially impact our financial position and results of operations is disclosed in Note 2 to our consolidated financial statements.</span></div><div id="i417e39f5b7bb45b295bb09394310bc8c_82"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 7A. Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Foreign Currency and Currency Translation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">We are subject to the risk of fluctuations in foreign currency exchange rates, specifically with respect to the euro, pound sterling, Swiss franc and Australian dollar. Our reporting currency is the United States dollar, and the functional currency of Barinthus Biotherapeutics plc and its consolidated subsidiaries, Barinthus Biotherapeutics (UK) Limited and VOLT, is the pound sterling. The functional currency of our wholly owned foreign subsidiary, Barinthus Bio NA is the United States dollar. The functional currency of our wholly owned foreign subsidiary, Barinthus Biotherapeutics Australia Pty, is the Australian dollar. The functional currency of our wholly owned foreign subsidiary, Barinthus Biotherapeutics S.R.L, is the euro. The functional currency of our wholly owned foreign subsidiary, Barinthus Biotherapeutics Switzerland GmbH, is the Swiss franc. Our cash and cash equivalents as of December&#160;31, 2023 consisted primarily of cash balances held by Barinthus Biotherapeutics (UK) Limited in United States dollars.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Assets and liabilities are translated into United States dollars at the exchange rate in effect on the balance sheet date. Revenue and expenses are translated at the average exchange rate in effect during the period. Translation adjustments are included in the consolidated Balance Sheets as a component of accumulated other comprehensive loss. Adjustments that arise from exchange rate changes on transactions denominated in a currency other than the local currency are included in operating expenses, net in the consolidated Statements of Operations and Comprehensive Loss as incurred.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We incur significant operating costs in the UK and face exposure to changes in the exchange ratio of the United States dollar and the pound sterling arising from expenses and payables at our UK operations that are settled in pound sterling. For the year ended December&#160;31, 2023, an average 10% weakening in the United States dollar relative to the pound sterling would have resulted in an immaterial change to our expenses denominated in pound sterling for the year ended December 31, 2023.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Interest Rate Sensitivity</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are not currently exposed significantly to market risk related to changes in interest rates, as we have no significant interest-bearing liabilities. We had cash and cash equivalents of $142.1 million as of December&#160;31, 2023, which were primarily held as account balances with banks in the United Kingdom, United States and Australia. A hypothetical 10% relative change in interest rates during any of the periods presented would not have had a material impact on our financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">128</span></div></div></div><div id="i417e39f5b7bb45b295bb09394310bc8c_85"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Financial Statements and Supplementary Data</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Consolidated Financial Statements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our audited consolidated financial statements are included at the end of this Annual Report, starting at page F-1.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">129</span></div></div></div><div id="i417e39f5b7bb45b295bb09394310bc8c_88"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">None.</span></div><div id="i417e39f5b7bb45b295bb09394310bc8c_91"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 9A. Controls and Procedures </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Evaluation of Disclosure Controls and Procedures </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rule&#8239;13a-15(e) and 15d-15(e) under the Exchange Act) as of December&#8239;31, 2023. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The term &#8220;disclosure controls and procedures&#8221;, means controls and other procedures of a company that are designed to provide reasonable assurance that the information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to provide reasonable assurance that the information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&#8217;s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Based on our evaluation, our management, with the participation of our principal executive officer and principal financial officer, has concluded that, as of such date, that the previously reported material weaknesses have been remediated and our disclosure controls and procedures were effective at the reasonable assurance level. </span></div><div><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Management&#8217;s Annual Report on Internal Control Over Financial Reporting</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company&#8217;s management is responsible for establishing and maintaining adequate internal control over financial reporting, as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act, and for the assessment of the effectiveness of internal control over financial reporting. The Company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. GAAP.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A company&#8217;s internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit the preparation of financial statements in accordance with U.S. GAAP, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of the effectiveness of our internal controls in future periods are subject to the risk that such controls may become inadequate because of changes in conditions, or that the degree of compliance with applicable policies, processes and documentation requirements may deteriorate.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In making its assessment of the Company&#8217;s internal control over financial reporting as of December 31, 2023, management used the criteria set forth in Internal Control&#8212;Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (&#8220;COSO&#8221;) and evaluated the internal control over financial reporting. Based on our assessment, management concluded that our internal control over financial reporting was effective as of December 31, 2023, based on criteria in Internal Control-Integrated Framework (2013) issued by the COSO.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Remediation of Previously Reported Material Weaknesses</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As previously reported in our Form 10-K for the fiscal year ended December 31, 2022, and in our subsequent Form 10-Q reports for the periods ending March 31, June 30 and September 30, 2023, management identified material weaknesses in our internal control over financial reporting related to the following: (i) our IT general control environment had not been </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">130</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">sufficiently designed to include appropriate user access rights, nor were controls over program development, program changes and computer operations designed, implemented and operating effectively, and (ii) policies and procedures with respect to the review, supervision and monitoring of our accounting and reporting functions were either not designed and in place or not operating effectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During fiscal years 2022 and 2023, we undertook efforts to remediate the previously disclosed material weaknesses. Our internal control remediation efforts focused on the areas detailed below.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;IT general controls environment </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We took measures to address the IT environment and have implemented a new enterprise resource planning ("ERP") system, and completed the controls design and operation over program development, program changes, computer operations and access rights.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the new ERP system and all other IT systems where material risks to financial reporting were identified, we implemented and tested the operating effectiveness of: (i) program change management controls to ensure that IT program and data changes affecting financial applications and underlying accounting records are identified, tested, authorized, and implemented appropriately; (ii) user access controls to ensure appropriate segregation of duties exist, to adequately restrict user and privileged access to certain financial applications, programs and data to appropriate company personnel; (iii) computer operations controls to ensure that critical batch jobs are monitored and data backups are authorized and monitored; (iv) testing and approval controls for program development to ensure that changes are aligned with business and IT requirements; and (v) identification and testing of system-generated information and calculations used in the execution of manual controls. In addition, we further developed and executed a testing protocol that allows us to validate the operating effectiveness of certain IT general controls to gain assurance that such controls are operating as designed.</span></div><div><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;policies and procedures with respect to the review, supervision and monitoring of our accounting and reporting functions</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We took measures to address this material weakness, which included hiring appropriate personnel whose roles are to enhance policies and procedures with respect to the review, supervision, formalization and monitoring of our accounting and reporting functions. Additionally, we enhanced our business process controls through the following activities:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">evaluated and refined the design, implementation, and documentation of the internal controls to ensure controls address the relevant risks, are properly designed, and provide appropriate evidence of performance;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">enhanced the design of controls that address the completeness and accuracy of reports being utilized in the execution of internal controls;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">evaluated the assignment of responsibilities associated with the performance of control activities and hired additional resources, obtained third party assistance, and provided additional training to existing resources; and</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">further developed and executed a testing protocol that allows us to validate the operating effectiveness of certain key controls over financial reporting and gain assurance that such controls are operating as designed.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Management has concluded that the actions taken to strengthen our internal control over financial reporting, as well as the results of our testing over the design and operating effectiveness of these controls, remediated the previously identified material weaknesses as of December 31, 2023. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Attestation Report of the Registered Public Accounting Firm</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report does not include an attestation report of our registered public accounting firm due to an exemption provided by the JOBS Act for &#8220;emerging growth companies.&#8221;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than the remediation activities related to the previously reported material weaknesses noted above, no other changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) occurred during the year ended December 31, 2023 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">131</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div><span><br/></span></div><div id="i417e39f5b7bb45b295bb09394310bc8c_94"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 9B. Other Information</span></div><div style="margin-top:12pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(a)</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">None</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(b)</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">None</span></div><div><span><br/></span></div><div id="i417e39f5b7bb45b295bb09394310bc8c_97"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Not Applicable.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">132</span></div></div></div><div id="i417e39f5b7bb45b295bb09394310bc8c_100"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">PART III</span></div><div id="i417e39f5b7bb45b295bb09394310bc8c_103"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 10. Directors, Executive Officers and Corporate Governance</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The information required under this item is incorporated herein by reference and will be included in our definitive proxy statement for our 2024 Annual General Meeting to be filed with the U.S. Securities and Exchange Commission within 120 days of the end of our fiscal year.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have adopted a Code of Conduct that applies to all officers, directors and employees in connection with their work for us. The full text of our Code of Conduct is posted on the investor relations page of our website at investors.barinthusbio.com/corporate-governance.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We intend to satisfy any disclosure requirements under Item 5.05 of Form 8-K regarding an amendment to, or waiver from, a provision of this Code of Conduct by posting such information on our website, at the Internet address and location specified above.</span></div><div><span><br/></span></div><div id="i417e39f5b7bb45b295bb09394310bc8c_106"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 11. Executive Compensation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The information required under this item is incorporated herein by reference and will be included in our definitive proxy statement for our 2024 Annual General Meeting to be filed with the United States Securities and Exchange Commission within 120 days of our fiscal year.</span></div><div id="i417e39f5b7bb45b295bb09394310bc8c_109"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The information required under this item is incorporated herein by reference and will be included in our definitive proxy statement for our 2024 Annual General Meeting to be filed with the U.S. Securities and Exchange Commission within 120 days of the end of our fiscal year.</span></div><div id="i417e39f5b7bb45b295bb09394310bc8c_112"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 13. Certain Relationships and Related Transactions, and Director Independence</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The information required under this item is incorporated herein by reference and will be included in our definitive proxy statement for our 2024 Annual General Meeting to be filed with the United States Securities and Exchange Commission within 120 days of the end of our fiscal year.</span></div><div id="i417e39f5b7bb45b295bb09394310bc8c_115"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 14. Principal Accounting Fees and Services</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The information required under this item is incorporated herein by reference and will be included in our definitive proxy statement for our 2024 Annual General Meeting to be filed with the United States. Securities and Exchange Commission within 120 days of the end of our fiscal year.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">133</span></div></div></div><div id="i417e39f5b7bb45b295bb09394310bc8c_118"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">PART IV</span></div><div id="i417e39f5b7bb45b295bb09394310bc8c_121"></div><div style="-sec-extract:summary;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 15. Exhibits, Financial Statement Schedules</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">The following documents are filed as part of this report:</span></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Financial Statements.</span></div><div style="margin-top:12pt;padding-left:90pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The financial statements filed as part of this report are listed on the Index to Consolidated Financial Statements in Item 8.</span></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Financial Statement Schedules.</span></div><div style="margin-top:12pt;padding-left:90pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">No schedules are submitted because they are not applicable, not required, or because the information is included in the consolidated financial statements or the notes thereto.</span></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Exhibits. </span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">EXHIBIT INDEX</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:85.113%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Exhibits number</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Description of exhibit</span></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.1&#8224;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1828185/000110465921149607/tm2135290d1_ex2-1.htm">Agreement and Plan of Merger and Reorganization, dated December 9, 2021, by and among </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1828185/000110465921149607/tm2135290d1_ex2-1.htm">Barinthus Biotherapeutics plc</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1828185/000110465921149607/tm2135290d1_ex2-1.htm">, VA Merger Sub 1 Inc., VA Merger Sub 2 Inc., Avidea Technologies Inc., and Benjamin Eisler, as the Securityholder Agent (Incorporated by reference to Exhibit 2.1 to our Periodic Report on Form 8-K (File No. 001-40367) filed on December 14, 2021).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.2*&#8224;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1828185/000110465922037794/vacc-20211231xex2d2.htm">Amendment No. 1 to Agreement and Plan of Merger and Reorganization, dated March 11, 2022, by and between </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1828185/000110465922037794/vacc-20211231xex2d2.htm">Barinthus Biotherapeutics plc</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1828185/000110465922037794/vacc-20211231xex2d2.htm"> and Benjamin Eisler, as Securityholder Agent (Incorporated by reference to Exhibit 2.2 to our Annual Report on Form 10-K (File No. 001-40367) filed on March 25, 2022).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1828185/000110465922087945/vacc-20220630xex2d1.htm">Amendment No. 2 to Agreement and Plan of Merger and Reorganization, dated May 9, 2022, by and between </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1828185/000110465922087945/vacc-20220630xex2d1.htm">Barinthus Biotherapeutics plc</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1828185/000110465922087945/vacc-20220630xex2d1.htm"> and Benjamin Eisler, as the Securityholder Agent (Incorporated herein by reference to Exhibit 2.1 to the Registrant&#8217;s Quarterly Report on Form 10-Q (File No. 001-40367), filed with the Securities and Exchange Commission on August 9, 2022).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1828185/000110465921063872/tm2115595d1_ex3-1.htm">Articles of Association of the Registrant (Incorporated by reference to Exhibit 3.1 to our Form 8-K (File No. 001-40367) filed on May 10, 2021)).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1828185/000110465921054698/tm2035121d14_ex4-1.htm">Form of Deposit Agreement (Incorporated by reference to Exhibit 4.1 to our Registration Statement on Form S-1/A (File No. 333-255158) filed on April 27, 2021).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1828185/000110465921054698/tm2035121d14_ex4-1.htm">Form of American Depositary Receipt (included in Exhibit 4.1).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1828185/000110465922037794/vacc-20211231xex4d3.htm">Description of Registrant&#8217;s Securities (Incorporated by reference to Exhibit 4.3 to our Annual Report on Form 10-K (File No. 001-40367) filed on March 25, 2022).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.1#</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1828185/000110465921048698/tm2035121d10_ex10-1.htm">EMI Option Scheme and form of award agreement thereunder (Incorporated by reference to Exhibit 10.1 to our Registration Statement on Form S-1/A (File No. 333-255158) filed on April 27, 2021).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.2#</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1828185/000110465921054698/tm2035121d14_ex10-2.htm">2021 Stock Option and Incentive Plan and forms of award agreements thereunder (Incorporated by reference to Exhibit 10.2 to our Registration Statement on Form S-1/A (File No. 333-255158) filed on April 27, 2021).</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">134</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:85.113%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.3#</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1828185/000110465921054698/tm2035121d14_ex10-17.htm">2021 Employee Share Purchase Plan (Incorporated by reference to Exhibit 10.17 to our Registration Statement on Form S-1/A (File No. 333-255158) filed on April 27, 2021).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.4&#8224;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1828185/000110465921048698/tm2035121d10_ex10-3.htm">License of Technology by and between the Registrant and Oxford University Innovation Limited, dated as of March 4, 2016, as amended on January 14, 2019 and as further amended April 29, 2020 (Incorporated by reference to Exhibit 10.3 to our Registration Statement on Form S-1/A (File No. 333-255158) filed on April 27, 2021).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.5&#8224;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1828185/000110465921048698/tm2035121d10_ex10-4.htm">License Agreement by and between the Registrant and Oxford University Innovation Limited, dated as of September 8, 2017 (Incorporated by reference to Exhibit 10.4 to our Registration Statement on Form S-1/A (File No. 333-255158) filed on April 27, 2021).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.6&#8224;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1828185/000110465921048698/tm2035121d10_ex10-5.htm">Master Collaboration Agreement by and between the Registrant and CanSino Biologics, Inc., dated as of September 4, 2018 (Incorporated by reference to Exhibit 10.5 to our Registration Statement on Form S-1/A (File No. 333-255158) filed on April 27, 2021).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.9&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1828185/000110465921048698/tm2035121d10_ex10-8.htm">Clinical Trial and Option Agreement by and among Vaccitech Oncology Limited, Cancer Research Technology Limited, and Cancer Research UK, dated as of December 16, 2019 (Incorporated by reference to Exhibit 10.8 to our Registration Statement on Form S-1/A (File No. 333-255158) filed on April 27, 2021).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.10#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1828185/000110465921048698/tm2035121d10_ex10-9.htm">Form of Deed of Indemnity between the Registrant and each of its directors and officers (Incorporated by reference to Exhibit 10.9 to our Registration Statement on Form S-1/A (File No. 333-255158) filed on April 27, 2021).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.11#**</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1828185/000110465921048698/tm2035121d10_ex10-10.htm">Form of Employment Agreement between the Registrant and William Enright (Incorporated by reference to Exhibit 10.10 to our Registration Statement on Form S-1/A (File No. 333-255158) filed on April 27, 2021).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.12#**</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1828185/000110465921054698/tm2035121d14_ex10-15.htm">Form of Employment Agreement between the Registrant and Graham Griffiths (Incorporated by reference to Exhibit 10.1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1828185/000110465921054698/tm2035121d14_ex10-15.htm">1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1828185/000110465921054698/tm2035121d14_ex10-15.htm"> to our Registration Statement on Form S-1/A (File No. 333-255158) filed on April 27, 2021).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.13</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1828185/000110465922058820/vacc-20220331xex10d1.htm">Registration Rights Agreement, dated March 28, 2022, by and among the Registrant and Benjamin Eisler, as the Securityholder Agent (Incorporated by reference to Exhibit 10.1 to our Quarterly Report on Form 10-Q (File No. 001-40367) filed on May 11, 2022).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.14</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1828185/000110465922117255/vacc-20220930xex10d1.htm">Service Agreement with Gemma Brown, effective September 15, 2022 (Incorporated by reference to Exhibit 10.1 to our Quarterly Report on Form 10-Q (File No. 001-40367) filed on November 10, 2022).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.15</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1828185/000110465923059430/vacc-20230331xex10d1.htm">Employment Agreement by and between Vaccitech Switzerland GmbH and Nad&#232;ge Pelletier, effective February 1, 2023</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1828185/000110465923059430/vacc-20230331xex10d1.htm"> (Incorporated by reference to Exhibit 10</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1828185/000110465923059430/vacc-20230331xex10d1.htm">.1 to our Q</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1828185/000110465923059430/vacc-20230331xex10d1.htm">uarte</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1828185/000110465923059430/vacc-20230331xex10d1.htm">rl</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1828185/000110465923059430/vacc-20230331xex10d1.htm">y Report on From 10-Q (File No. 001-40367) filed on </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1828185/000110465923059430/vacc-20230331xex10d1.htm">May 12, 2023).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.16</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1828185/000110465922117255/vacc-20220930xex10d2.htm">Form of Indemnification Agreement between the Registrant and each of its directors and officers (Incorporated by reference to Exhibit 10.2 to our Quarterly Report on Form 10-Q (File No. 001-40367) filed on November 10, 2022).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">135</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:85.113%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.17</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1828185/000110465921137646/vacc-20210930xex10d1.htm">Lease Agreement dated September 3, 2021 by and among The Harwell Science and Innovation Campus General Partner Limited, The Harwell Science and Innovation Campus Nominee Limited, The Harwell Science and Innovation Campus Limited Partnership and </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1828185/000110465921137646/vacc-20210930xex10d1.htm">Barinthus</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1828185/000110465921137646/vacc-20210930xex10d1.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1828185/000110465921137646/vacc-20210930xex10d1.htm">Biother</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1828185/000110465921137646/vacc-20210930xex10d1.htm">ap</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1828185/000110465921137646/vacc-20210930xex10d1.htm">eutics </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1828185/000110465921137646/vacc-20210930xex10d1.htm">(UK) Limited (Incorporated by reference to Exhibit 10.1 to our Quarterly Report on Form 10-Q (File No. 001-40367) filed on November 12, 2021).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.18*&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="brns-20231231xex1018.htm">Funding</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="brns-20231231xex1018.htm"> Agreement by and between the Registrant</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="brns-20231231xex1018.htm">,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="brns-20231231xex1018.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="brns-20231231xex1018.htm">Coalition for Epidemic Preparedness Innovations</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="brns-20231231xex1018.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="brns-20231231xex1018.htm">and the University of Oxford</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="brns-20231231xex1018.htm">, dated as of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="brns-20231231xex1018.htm">December 20</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="brns-20231231xex1018.htm">, 2023</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">21.1*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="brns-20231231xex211.htm">Subsidiaries of the Registrant.</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">23.1*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="brns-20231231xex231.htm">Consent of PricewaterhouseCoopers LLP, independent registered public accounting firm.</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">24.1*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Power of Attorney (included on signature page to this Annual Report).</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">31.1*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="brns-20231231xex311.htm">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">31.2*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="brns-20231231xex312.htm">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">32.1*+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="brns-20231231xex321.htm">Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97.0</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1828185/000141057823002303/tmb-20230930xex10d1.htm">Compensation Recovery Policy (Incorporated by reference to Exhibit 10.1 to our Quarterly Report on Form 10-Q (File No. 001-40367) filed on November 9, 2023).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">101.INS*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XBRL Instance Document</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">101.SCH*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XBRL Taxonomy Extension Schema Document</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">101.CAL*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">101.DEF*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">101.LAB*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">101.PRE*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">104*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cover Page Interactive Data File (the cover page XBRL tags are embedded within the iXBRL document).</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">___________________________</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13pt">Filed or furnished herewith.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8224;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">Certain portions of this exhibit have been omitted because they are not material and the Registrant customarily and actually treats that information as private or confidential.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">#&#160;&#160;&#160;&#160;Indicates a management contract or any compensatory plan, contract or arrangement.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">136</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">**</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt">Certain exhibits and schedules to these agreements have been omitted pursuant to Item 601(b)(2) of Regulation S-K. The Registrant will furnish copies of any of the exhibits and schedules to the Securities and Exchange Commission upon request. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">+ The certifications furnished in Exhibits 32.1 and 32.2 hereto are deemed to be furnished with this Annual Report and will not be deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, except to the extent that the Registrant specifically incorporates it by reference.</span></div><div id="i417e39f5b7bb45b295bb09394310bc8c_124"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 16. Form 10-K Summary</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Not Applicable.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">137</span></div></div></div><div id="i417e39f5b7bb45b295bb09394310bc8c_127"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">SIGNATURES</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"/><td style="width:46.851%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.997%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:46.852%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">March 20, 2024</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Barinthus Biotherapeutics plc</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">/s/ William Enright</span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">William Enright</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Chief Executive Officer</span></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">POWER OF ATTORNEY</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Each person whose signature appears below constitutes and appoints William Enright and Gemma Brown, and each of them, as his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his or her substitutes, may lawfully do or cause to be done by virtue thereof.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.174%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Signature</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Title</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Date</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:7.2pt;text-indent:-7.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">/s/&#160;&#160;William Enright</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Chief Executive Officer and Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">March 20, 2024</span></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">William Enright</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(Principal Executive Officer)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:7.2pt;text-indent:-7.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">/s/&#160;&#160;Gemma Brown</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Chief Financial Officer</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">March 20, 2024</span></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Gemma Brown</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(Principal Financial and Accounting Officer)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:7.2pt;text-indent:-7.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">/s/&#160;&#160;Robin Wright</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Chairman and Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">March 20, 2024</span></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Robin Wright</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:7.2pt;text-indent:-7.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">/s/&#160;&#160;Alex Hammacher</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">March 20, 2024</span></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alex Hammacher</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:7.2pt;text-indent:-7.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">/s/&#160;&#160;Pierre A. Morgon</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">March 20, 2024</span></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Pierre A. Morgon</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:7.2pt;text-indent:-7.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">/s/&#160;&#160;Anne M. Phillips</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">March 20, 2024</span></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Anne M. Phillips</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:7.2pt;text-indent:-7.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">/s/&#160;&#160;Karen T. Dawes</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">March 20, 2024</span></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Karen T. Dawes</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:7.2pt;text-indent:-7.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">/s/&#160;&#160;Joseph C. F. Scheeren</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">March 20, 2024</span></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Joseph C. F. Scheeren</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">138</span></div></div></div><div id="i417e39f5b7bb45b295bb09394310bc8c_130"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:90.263%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.931%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:127%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_1">Report of Independent Registered Public Accounting Firm PricewaterhouseCoopers LLP </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(PCAOB ID <ix:nonNumeric contextRef="c-1" name="dei:AuditorFirmId" id="f-39">876</ix:nonNumeric>)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_139">Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">F-1</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_145">Consolidated Statements of Operations and Comprehensive Loss</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">F-<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%;text-decoration:none" href="#i417e39f5b7bb45b295bb09394310bc8c_145">2</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_148">Consolidated Statements of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_148"> S</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_148">tock</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_148">holders&#8217; Equity</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">F-<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%;text-decoration:none" href="#i417e39f5b7bb45b295bb09394310bc8c_148">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_151">Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">F-<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%;text-decoration:none" href="#i417e39f5b7bb45b295bb09394310bc8c_151">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_154">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">F-<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%;text-decoration:none" href="#i417e39f5b7bb45b295bb09394310bc8c_154">6</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i417e39f5b7bb45b295bb09394310bc8c_133"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Georgia',serif;font-size:10pt;font-weight:400;line-height:100%">T</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">o</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Board of Directors and Shareholders of Barinthus Biotherapeutics plc</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Opinion on the Financial Statements</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We have audited the accompanying consolidated</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">balance sheets of Barinthus Biotherapeutics plc and its subsidiaries (the &#8220;Company&#8221;) as of December 31, 2023 and 2022, and the related consolidated statements of operations and comprehensive loss, consolidated statements of stockholders' equity, and consolidated statements of cash flows for the years then ended, including the related notes (collectively referred to as the &#8220;consolidated</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">as of</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2023</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">and 2022, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Basis for Opinion</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">These consolidated</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We conducted our audits of these consolidated</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">financial statements in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud.</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Our audits included performing procedures to assess the risks of material misstatement of the consolidated</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">/s/<ix:nonNumeric contextRef="c-1" name="dei:AuditorName" id="f-40">PricewaterhouseCoopers LLP</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Reading, <ix:nonNumeric contextRef="c-1" name="dei:AuditorLocation" id="f-41">United Kingdom</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">March&#160;20, 2024</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have served as the Company&#8217;s auditor since 2022.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i417e39f5b7bb45b295bb09394310bc8c_139"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">BARINTHUS BIOTHERAPEUTICS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(IN THOUSANDS, EXCEPT NUMBER OF SHARES AND PER SHARE AMOUNTS)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.203%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.469%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">As of<br/>December 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">As of<br/>December 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Cash and cash equivalents</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-42">142,090</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-43">194,385</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:fixed-zero" scale="3" id="f-44">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="f-45">323</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Accounts receivable &#8211; related parties</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:fixed-zero" scale="3" id="f-46">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-47">5,524</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Research and development incentives receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="brns:ResearchAndDevelopmentIncentivesReceivable" format="ixt:num-dot-decimal" scale="3" id="f-48">4,908</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="brns:ResearchAndDevelopmentIncentivesReceivable" format="ixt:num-dot-decimal" scale="3" id="f-49">4,541</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Prepaid expenses and other current assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-50">9,907</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-51">8,268</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-52">156,905</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-53">213,041</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Goodwill</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-54">12,209</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-55">12,209</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-56">11,821</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-57">7,957</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Intangible assets, net</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-58">25,108</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-59">28,269</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Right of use assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-60">7,581</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-61">7,753</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Other assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherAssets" scale="3" id="f-62">882</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OtherAssets" scale="3" id="f-63">976</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total assets</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-64">214,506</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-65">270,205</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Accounts payable</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-66">1,601</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-67">3,748</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="brns:AccruedLiabilitiesAndOtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-68">9,212</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="brns:AccruedLiabilitiesAndOtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-69">8,061</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Operating lease liability - current</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-70">1,785</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-71">433</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-72">12,598</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-73">12,242</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Non-Current liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Operating lease liability - non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-74">11,191</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-75">8,340</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Contingent consideration</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-76">1,823</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-77">1,711</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Other non-current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-78">1,325</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="f-79">965</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Deferred tax liability, net</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="brns:DeferredTaxLiabilityNet" scale="3" id="f-80">574</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="brns:DeferredTaxLiabilityNet" format="ixt:num-dot-decimal" scale="3" id="f-81">3,746</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total liabilities</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-82">27,511</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-83">27,004</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Commitments and contingencies (Note 16)</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-6" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-84"></ix:nonFraction></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-7" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-85"></ix:nonFraction></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.05pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Ordinary shares, &#163;<ix:nonFraction unitRef="gbpPerShare" contextRef="c-7" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-86"><ix:nonFraction unitRef="gbpPerShare" contextRef="c-6" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-87">0.000025</ix:nonFraction></ix:nonFraction> nominal value; <ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-88"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-89"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-90">38,643,540</ix:nonFraction></ix:nonFraction></ix:nonFraction> shares authorized, issued and outstanding (December&#160;31, 2022: authorized, issued and outstanding: <ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-91"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-92"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-93">37,683,531</ix:nonFraction></ix:nonFraction></ix:nonFraction>)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-94">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-95">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.05pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Deferred A shares, &#163;<ix:nonFraction unitRef="gbpPerShare" contextRef="c-12" decimals="INF" name="brns:DeferredStockParOrStatedValuePerShare" scale="0" id="f-96"><ix:nonFraction unitRef="gbpPerShare" contextRef="c-13" decimals="INF" name="brns:DeferredStockParOrStatedValuePerShare" scale="0" id="f-97">1</ix:nonFraction></ix:nonFraction> nominal value; <ix:nonFraction unitRef="shares" contextRef="c-13" decimals="INF" name="brns:DeferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-98"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="INF" name="brns:DeferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-99"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="INF" name="brns:DeferredStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-100">63,443</ix:nonFraction></ix:nonFraction></ix:nonFraction> shares authorized, issued and outstanding (December&#160;31, 2022: authorized, issued and outstanding: <ix:nonFraction unitRef="shares" contextRef="c-12" decimals="INF" name="brns:DeferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-101"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="INF" name="brns:DeferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-102"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="INF" name="brns:DeferredStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-103">63,443</ix:nonFraction></ix:nonFraction></ix:nonFraction>)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="brns:DeferredStockValueIssued" scale="3" id="f-104">86</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="brns:DeferredStockValueIssued" scale="3" id="f-105">86</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.05pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Deferred B shares, &#163;<ix:nonFraction unitRef="gbpPerShare" contextRef="c-14" decimals="INF" name="brns:DeferredStockParOrStatedValuePerShare" scale="0" id="f-106"><ix:nonFraction unitRef="gbpPerShare" contextRef="c-15" decimals="INF" name="brns:DeferredStockParOrStatedValuePerShare" scale="0" id="f-107">0.01</ix:nonFraction></ix:nonFraction> nominal value; <ix:nonFraction unitRef="shares" contextRef="c-15" decimals="INF" name="brns:DeferredStockSharesOutstanding" scale="0" id="f-108"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="INF" name="brns:DeferredStockSharesAuthorized" scale="0" id="f-109"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="INF" name="brns:DeferredStockSharesIssued" scale="0" id="f-110">0</ix:nonFraction></ix:nonFraction></ix:nonFraction> shares authorized, issued and outstanding (December&#160;31, 2022: authorized, issued and outstanding: <ix:nonFraction unitRef="shares" contextRef="c-14" decimals="INF" name="brns:DeferredStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-111"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="INF" name="brns:DeferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-112"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="INF" name="brns:DeferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-113">570,987</ix:nonFraction></ix:nonFraction></ix:nonFraction>)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="brns:DeferredStockValueIssued" format="ixt:fixed-zero" scale="3" id="f-114">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="brns:DeferredStockValueIssued" scale="3" id="f-115">8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.05pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Deferred C shares, &#163;<ix:nonFraction unitRef="gbpPerShare" contextRef="c-16" decimals="INF" name="brns:DeferredStockParOrStatedValuePerShare" scale="0" id="f-116"><ix:nonFraction unitRef="gbpPerShare" contextRef="c-17" decimals="INF" name="brns:DeferredStockParOrStatedValuePerShare" scale="0" id="f-117">0.000007</ix:nonFraction></ix:nonFraction> nominal value, <ix:nonFraction unitRef="shares" contextRef="c-17" decimals="INF" name="brns:DeferredStockSharesAuthorized" scale="0" id="f-118"><ix:nonFraction unitRef="shares" contextRef="c-17" decimals="INF" name="brns:DeferredStockSharesIssued" scale="0" id="f-119"><ix:nonFraction unitRef="shares" contextRef="c-17" decimals="INF" name="brns:DeferredStockSharesOutstanding" scale="0" id="f-120">0</ix:nonFraction></ix:nonFraction></ix:nonFraction> shares authorized, issued and outstanding (December&#160;31, 2022: authorized, issued and outstanding: <ix:nonFraction unitRef="shares" contextRef="c-16" decimals="INF" name="brns:DeferredStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-121"><ix:nonFraction unitRef="shares" contextRef="c-16" decimals="INF" name="brns:DeferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-122"><ix:nonFraction unitRef="shares" contextRef="c-16" decimals="INF" name="brns:DeferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-123">27,828,231</ix:nonFraction></ix:nonFraction></ix:nonFraction>)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="brns:DeferredStockValueIssued" format="ixt:fixed-zero" scale="3" id="f-124">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="brns:DeferredStockValueIssued" scale="3" id="f-125">0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:114%;position:relative;top:-3.15pt;vertical-align:baseline">1</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Additional paid-in capital</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-126">386,602</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-127">379,504</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-128">176,590</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-129">103,243</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Accumulated other comprehensive loss &#8211; foreign currency translation adjustments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-130">23,315</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-131">33,460</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total stockholders&#8217; equity attributable to Barinthus Biotherapeutics plc shareholders</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-132">186,784</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-133">242,896</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Noncontrolling interest</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:MinorityInterest" scale="3" id="f-134">211</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:MinorityInterest" scale="3" id="f-135">305</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total stockholders&#8217; equity</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-136">186,995</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-137">243,201</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total liabilities and stockholders&#8217; equity</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-138">214,506</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-139">270,205</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">___________________________</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">1</span><ix:footnote id="fn-1" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:5.75pt">Indicates amount less than one thousand</span></ix:footnote></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-1</span></div></div></div><div id="i417e39f5b7bb45b295bb09394310bc8c_145"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">BARINTHUS BIOTHERAPEUTICS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(IN THOUSANDS, EXCEPT NUMBER OF SHARES AND PER SHARE AMOUNTS)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year Ended</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31, 2023</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:7.2pt;text-indent:-7.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">License revenue </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="f-140">802</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-141">44,694</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Research grants and contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="f-142">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="f-143">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="f-144">802</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-145">44,703</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating expenses</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-146">44,874</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-147">42,350</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-148">39,842</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-149">6,394</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-150">84,716</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-151">48,744</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-152">83,914</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-153">4,041</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other income /(expense):</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="3" id="f-154">2,877</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="3" id="f-155">3,103</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="f-156">28</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="f-157">19</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Research and development incentives</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="brns:ResearchAndDevelopmentIncentiveIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-158">3,461</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="brns:ResearchAndDevelopmentIncentiveIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-159">1,240</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-160">1,082</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-161">567</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 20.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total other income, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-162">7,392</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-163">4,891</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(Loss)/profit before income tax</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-164">76,522</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="f-165">850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-166">3,075</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-167">4,471</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net (loss)/income </span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-168">73,447</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-169">5,321</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net loss attributable to noncontrolling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="f-170">100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="f-171">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net (loss)/income attributable to Barinthus Biotherapeutics plc shareholders</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-172">73,347</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-173">5,342</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 8.2pt;text-indent:-7.2pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Weighted-average ordinary shares outstanding, basic </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-174">38,386,491</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-22" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-175">37,248,126</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Weighted-average ordinary shares outstanding, diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-176">38,386,491</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-22" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-177">38,169,307</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net (loss)/income per share attributable to ordinary shareholders, basic</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-178">1.91</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-22" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-179">0.14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net (loss)/income per share attributable to ordinary shareholders, diluted</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-180">1.91</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-22" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-181">0.14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 8.2pt;text-indent:-7.2pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net (loss)/income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-182">73,447</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-183">5,321</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other comprehensive gain/(loss) &#8211; foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-184">10,151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-185">25,083</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-186">63,296</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-187">19,762</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Comprehensive loss attributable to noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="3" id="f-188">94</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="3" id="f-189">132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Comprehensive loss attributable to Barinthus Biotherapeutics plc shareholders</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-190">63,202</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-191">19,630</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">___________________________</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">1</span><ix:footnote id="fn-2" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:5.75pt">Includes <span style="-sec-ix-hidden:f-192"><span style="-sec-ix-hidden:f-193">license revenue</span></span> from related parties for the year ended December&#160;31, 2023 totaling $<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-194">0.8</ix:nonFraction>&#160;million (December&#160;31, 2022: $<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-195">43.7</ix:nonFraction>&#160;million). License revenue is generated in the United Kingdom. </span></ix:footnote></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-2</span></div></div></div><div id="i417e39f5b7bb45b295bb09394310bc8c_148"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">BARINTHUS BIOTHERAPEUTICS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(IN THOUSANDS, EXCEPT NUMBER OF SHARES)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:12.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.022%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.677%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.122%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.022%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.677%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.261%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="84" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">Year ended December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:20pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">Ordinary&#160;Shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">Deferred A Shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">Deferred B Shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">Deferred C Shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%">Additional Paid-in-Capital</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%">Accumulated Deficit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%">Accumulated Other Comprehensive Loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">Total stockholders&#8217; equity attributable to Barinthus Biotherapeutics plc stockholders</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%">Non-Controlling Interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%">Total Stockholders' Equity</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:33pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%">Balance, January 1,2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-25" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-196">37,683,531</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-197">1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-26" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-198">63,443</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-199">86</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-27" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-200">570,987</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-201">8</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-28" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-202">27,828,231</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-203">0</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#CCEEFF;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:700;line-height:120%">1</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-204">379,504</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-205">103,243</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-206">33,460</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-207">242,896</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-208">305</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-209">243,201</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">Share based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-210">5,055</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-211">5,055</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-212">5,055</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">Issue of ordinary shares, net of issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-36" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesOther" format="ixt:num-dot-decimal" scale="0" id="f-213">960,009</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="3" id="f-214">0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#CCEEFF;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:120%">1</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueOther" format="ixt:num-dot-decimal" scale="3" id="f-215">2,035</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueOther" format="ixt:num-dot-decimal" scale="3" id="f-216">2,035</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueOther" format="ixt:num-dot-decimal" scale="3" id="f-217">2,035</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">Foreign currency translation adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-218">10,145</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-219">10,145</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-220">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-221">10,151</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Cancellation of deferred shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="shares" contextRef="c-39" decimals="INF" name="brns:SharesCancelledDuringPeriodSharesDeferredShares" format="ixt:num-dot-decimal" scale="0" id="f-222">570,987</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" name="brns:SharesCancelledDuringPeriodValueDeferredShares" scale="3" id="f-223">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="shares" contextRef="c-40" decimals="INF" name="brns:SharesCancelledDuringPeriodSharesDeferredShares" format="ixt:num-dot-decimal" scale="0" id="f-224">27,828,231</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" sign="-" name="brns:SharesCancelledDuringPeriodValueDeferredShares" scale="3" id="f-225">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="brns:SharesCancelledDuringPeriodValueDeferredShares" format="ixt:fixed-zero" scale="3" id="f-226">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="brns:SharesCancelledDuringPeriodValueDeferredShares" format="ixt:fixed-zero" scale="3" id="f-227">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-228">73,347</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-229">73,347</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" sign="-" name="us-gaap:ProfitLoss" scale="3" id="f-230">100</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-231">73,447</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%">Balance, December 31,2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-42" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-232">38,643,540</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-233">1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-43" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-234">63,443</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-235">86</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-44" decimals="INF" name="us-gaap:SharesIssued" format="ixt:fixed-zero" scale="0" id="f-236">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="f-237">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-45" decimals="INF" name="us-gaap:SharesIssued" format="ixt:fixed-zero" scale="0" id="f-238">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-239">0</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#CCEEFF;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:700;line-height:120%">1</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-240">386,602</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-241">176,590</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-242">23,315</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-243">186,784</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-244">211</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-245">186,995</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">___________________________</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">1</span><ix:footnote id="fn-3" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:5.75pt">Indicates amount less than one thousand</span></ix:footnote></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">BARINTHUS BIOTHERAPEUTICS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(IN THOUSANDS, EXCEPT NUMBER OF SHARES)</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.666%"><tr><td style="width:1.0%"/><td style="width:12.438%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.905%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.255%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.905%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.710%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.905%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.255%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.905%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.255%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.905%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.255%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.905%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.255%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.905%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.255%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.905%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.710%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.474%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.255%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.368%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.929%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.255%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.839%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.255%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.255%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.929%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.255%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.940%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="87" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">Year ended December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">Ordinary&#160;Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">Deferred A Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">Deferred B Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">Deferred C Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">Additional Paid-in-Capital</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">Accumulated Deficit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">Accumulated Other Comprehensive Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">Total stockholders&#8217; equity attributable to Barinthus Biotherapeutics plc stockholders</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">Non-Controlling Interest</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">Total Stockholders' Equity</span></td></tr><tr><td colspan="3" style="background-color:#CCEEFF;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">Balance, January 1,2022</span></td><td colspan="3" style="background-color:#CCEEFF;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-51" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-246">37,188,730</ix:nonFraction></span></td><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"/><td style="background-color:#CCEEFF;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#CCEEFF;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-247">1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#CCEEFF;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"/><td colspan="3" style="background-color:#CCEEFF;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-52" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-248">63,443</ix:nonFraction></span></td><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"/><td style="background-color:#CCEEFF;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#CCEEFF;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-249">86</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#CCEEFF;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"/><td colspan="3" style="background-color:#CCEEFF;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-53" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-250">570,987</ix:nonFraction></span></td><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"/><td style="background-color:#CCEEFF;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#CCEEFF;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-251">8</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#CCEEFF;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"/><td colspan="3" style="background-color:#CCEEFF;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-54" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-252">27,828,231</ix:nonFraction></span></td><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"/><td colspan="3" style="background-color:#CCEEFF;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-253">0</ix:nonFraction></span></td><td colspan="3" style="background-color:#CCEEFF;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:700;line-height:120%">1</span></td><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"/><td style="background-color:#CCEEFF;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#CCEEFF;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-254">369,103</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#CCEEFF;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"/><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"/><td style="background-color:#CCEEFF;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#CCEEFF;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-255">108,585</ix:nonFraction>)</span></td><td style="background-color:#CCEEFF;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"/><td style="background-color:#CCEEFF;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#CCEEFF;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-256">8,488</ix:nonFraction>)</span></td><td style="background-color:#CCEEFF;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"/><td style="background-color:#CCEEFF;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#CCEEFF;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-257">252,125</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#CCEEFF;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#CCEEFF;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#CCEEFF;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#CCEEFF;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-258">437</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#CCEEFF;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#CCEEFF;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#CCEEFF;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#CCEEFF;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-259">252,562</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#CCEEFF;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Share based compensation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-260">9,877</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-261">9,877</ix:nonFraction></span></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-262">9,877</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#CCEEFF;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Issue of ordinary shares, net of issuance costs</span></td><td colspan="3" style="background-color:#CCEEFF;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-63" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesOther" format="ixt:num-dot-decimal" scale="0" id="f-263">494,801</ix:nonFraction></span></td><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"/><td colspan="2" style="background-color:#CCEEFF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="3" id="f-264">0</ix:nonFraction>&#160;</span></td><td style="background-color:#CCEEFF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#CCEEFF;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:120%">1</span></td><td colspan="2" style="background-color:#CCEEFF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#CCEEFF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"/><td colspan="2" style="background-color:#CCEEFF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#CCEEFF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"/><td colspan="2" style="background-color:#CCEEFF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#CCEEFF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"/><td colspan="2" style="background-color:#CCEEFF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#CCEEFF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"/><td colspan="2" style="background-color:#CCEEFF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#CCEEFF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"/><td colspan="2" style="background-color:#CCEEFF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#CCEEFF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"/><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"/><td colspan="3" style="background-color:#CCEEFF;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="3" id="f-265">484</ix:nonFraction></span></td><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"/><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"/><td colspan="2" style="background-color:#CCEEFF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#CCEEFF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"/><td colspan="2" style="background-color:#CCEEFF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#CCEEFF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"/><td colspan="3" style="background-color:#CCEEFF;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="3" id="f-266">484</ix:nonFraction></span></td><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"/><td colspan="2" style="background-color:#CCEEFF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#CCEEFF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"/><td colspan="3" style="background-color:#CCEEFF;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="3" id="f-267">484</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Foreign currency translation adjustments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-268">24,972</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-269">24,972</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-270">111</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-271">25,083</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#CCEEFF;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Measurement period and contingent consideration adjustments</span></td><td colspan="2" style="background-color:#CCEEFF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#CCEEFF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"/><td colspan="2" style="background-color:#CCEEFF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#CCEEFF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"/><td colspan="2" style="background-color:#CCEEFF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#CCEEFF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"/><td colspan="2" style="background-color:#CCEEFF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#CCEEFF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"/><td colspan="2" style="background-color:#CCEEFF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#CCEEFF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"/><td colspan="2" style="background-color:#CCEEFF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#CCEEFF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"/><td colspan="2" style="background-color:#CCEEFF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#CCEEFF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"/><td colspan="2" style="background-color:#CCEEFF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#CCEEFF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"/><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"/><td colspan="2" style="background-color:#CCEEFF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" name="brns:AdjustmentsToAdditionalPaidInCapitalMeasurementPeriodAdjustmentsInBusinessCombination" scale="3" id="f-272">40</ix:nonFraction>&#160;</span></td><td style="background-color:#CCEEFF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"/><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"/><td colspan="2" style="background-color:#CCEEFF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#CCEEFF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"/><td colspan="2" style="background-color:#CCEEFF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#CCEEFF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"/><td colspan="2" style="background-color:#CCEEFF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" name="brns:AdjustmentsToAdditionalPaidInCapitalMeasurementPeriodAdjustmentsInBusinessCombination" scale="3" id="f-273">40</ix:nonFraction>&#160;</span></td><td style="background-color:#CCEEFF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"/><td colspan="2" style="background-color:#CCEEFF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#CCEEFF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"/><td colspan="2" style="background-color:#CCEEFF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="brns:AdjustmentsToAdditionalPaidInCapitalMeasurementPeriodAdjustmentsInBusinessCombination" scale="3" id="f-274">40</ix:nonFraction>&#160;</span></td><td style="background-color:#CCEEFF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-275">5,342</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-276">5,342</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-3" sign="-" name="us-gaap:ProfitLoss" scale="3" id="f-277">21</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-278">5,321</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#CCEEFF;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">Balance, December 31,2022</span></td><td colspan="3" style="background-color:#CCEEFF;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-25" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-279">37,683,531</ix:nonFraction></span></td><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"/><td style="background-color:#CCEEFF;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#CCEEFF;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-280">1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#CCEEFF;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"/><td colspan="3" style="background-color:#CCEEFF;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-26" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-281">63,443</ix:nonFraction></span></td><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"/><td style="background-color:#CCEEFF;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#CCEEFF;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-282">86</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#CCEEFF;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"/><td colspan="3" style="background-color:#CCEEFF;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-27" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-283">570,987</ix:nonFraction></span></td><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"/><td style="background-color:#CCEEFF;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#CCEEFF;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-284">8</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#CCEEFF;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"/><td colspan="3" style="background-color:#CCEEFF;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-28" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-285">27,828,231</ix:nonFraction></span></td><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-286">0</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CCEEFF;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:700;line-height:120%">1</span></td><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"/><td style="background-color:#CCEEFF;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#CCEEFF;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-287">379,504</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#CCEEFF;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"/><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"/><td style="background-color:#CCEEFF;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#CCEEFF;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-288">103,243</ix:nonFraction>)</span></td><td style="background-color:#CCEEFF;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"/><td style="background-color:#CCEEFF;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#CCEEFF;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-289">33,460</ix:nonFraction>)</span></td><td style="background-color:#CCEEFF;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"/><td style="background-color:#CCEEFF;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#CCEEFF;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-290">242,896</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#CCEEFF;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#CCEEFF;border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#CCEEFF;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#CCEEFF;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-291">305</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#CCEEFF;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#CCEEFF;border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#CCEEFF;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#CCEEFF;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-292">243,201</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#CCEEFF;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:12pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">___________________________</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:5.75pt">Indicates amount less than one thousand</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-4</span></div></div></div><div id="i417e39f5b7bb45b295bb09394310bc8c_151"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">BARINTHUS BIOTHERAPEUTICS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">CONSOLIDATED STATEMENTS OF CASH FLOWS (IN THOUSANDS)</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.203%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.469%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">December 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">December 31,<br/>2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">CASH FLOWS FROM OPERATING ACTIVITIES:</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">Net (loss)/income</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-293">73,447</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-294">5,321</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">Adjustments to reconcile net (loss)/income to net cash used in operating activities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">Share based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-295">5,055</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-296">9,877</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">Depreciation and amortization</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-297">5,429</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-298">4,323</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">Non-cash lease expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="brns:NonCashLeaseExpenses" format="ixt:num-dot-decimal" scale="3" id="f-299">1,328</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="brns:NonCashLeaseExpenses" format="ixt:num-dot-decimal" scale="3" id="f-300">1,216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">Unrealized foreign exchange loss/(gain)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" format="ixt:num-dot-decimal" scale="3" id="f-301">7,531</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" format="ixt:num-dot-decimal" scale="3" id="f-302">24,905</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">Change in contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" id="f-303">55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" id="f-304">73</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">Non cash interest expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="brns:NonCashInterestExpenseOnConvertibleLoanNotes" scale="3" id="f-305">28</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="brns:NonCashInterestExpenseOnConvertibleLoanNotes" scale="3" id="f-306">19</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">Deferred tax expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-307">3,075</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-308">4,337</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">Profit on sale of property and equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" format="ixt:fixed-zero" scale="3" id="f-309">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="f-310">348</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">Accounts receivable (including related parties)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-311">5,800</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-312">5,833</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-313">2,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-314">2,170</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">Research and development incentives receivable</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="brns:IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable" scale="3" id="f-315">127</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" sign="-" name="brns:IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable" format="ixt:num-dot-decimal" scale="3" id="f-316">1,158</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-317">3,378</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-318">1,140</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-319">1,993</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" id="f-320">751</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:fixed-zero" scale="3" id="f-321">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="f-322">183</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">Operating lease liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="f-323">445</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="f-324">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="f-325">128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="f-326">387</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">Net cash used in operating activities</span></td><td style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">$</span></td><td style="border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-327">50,925</ix:nonFraction>)</span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">$</span></td><td style="border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-328">14,431</ix:nonFraction>)</span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">CASH FLOWS FROM INVESTING ACTIVITIES:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">Proceeds from sale of property and equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-329">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="f-330">388</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-331">5,413</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-332">6,138</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">Net cash used in investing activities</span></td><td style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">$</span></td><td style="border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-333">5,413</ix:nonFraction>)</span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">$</span></td><td style="border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-334">5,750</ix:nonFraction>)</span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">CASH FLOWS FROM FINANCING ACTIVITIES:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">Issue of shares from the exercise of stock options</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="f-335">0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:114%;position:relative;top:-2.44pt;vertical-align:baseline">1</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="f-336">0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">1</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">Proceeds from issue of ordinary shares, net of issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-337">2,035</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="f-338">484</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">Payment of contingent consideration</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" scale="3" id="f-339">163</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-340">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">Repayment of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RepaymentsOfShortTermDebt" format="ixt:fixed-zero" scale="3" id="f-341">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:RepaymentsOfShortTermDebt" scale="3" id="f-342">159</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">Net cash provided by financing activities</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-343">1,872</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="f-344">325</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">Effect of exchange rates on cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="f-345">2,171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" id="f-346">187</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">Net decrease in cash and cash equivalents</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-347">52,295</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-348">19,669</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">Cash and cash equivalents, beginning of the year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-349">194,385</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-350">214,054</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">Cash and cash equivalents, end of the year</span></td><td style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">$</span></td><td style="border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-351">142,090</ix:nonFraction>&#160;</span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">$</span></td><td style="border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-352">194,385</ix:nonFraction>&#160;</span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">Supplemental cash flow disclosures:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">Cash paid for interest</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:fixed-zero" scale="3" id="f-353">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="f-354">0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:114%;position:relative;top:-2.44pt;vertical-align:baseline">1</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">Cash paid for income taxes</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" format="ixt:fixed-zero" scale="3" id="f-355">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="f-356">0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:114%;position:relative;top:-2.44pt;vertical-align:baseline">1</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">Non-Cash investing and financing activities</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">Purchases of property and equipment included in accounts payable and accrued liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="f-357">87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="f-358">559</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">ROU assets obtained in exchange for operating lease liabilities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="f-359">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-360">2,400</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">Asset retirement obligation</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="brns:AssetRetirementObligations" scale="3" id="f-361">287</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="brns:AssetRetirementObligations" scale="3" id="f-362">999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">Changes to right-of-use asset resulting from lease reassessment event</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="brns:ChangesToRightOfUseAssetResultingFromLeaseReassessmentEvent" scale="3" id="f-363">88</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" sign="-" name="brns:ChangesToRightOfUseAssetResultingFromLeaseReassessmentEvent" scale="3" id="f-364">207</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">Measurement period adjustments</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="brns:NonCashInvestingAndFinancingActivityOfMeasurementPeriodAdjustments" format="ixt:fixed-zero" scale="3" id="f-365">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" sign="-" name="brns:NonCashInvestingAndFinancingActivityOfMeasurementPeriodAdjustments" scale="3" id="f-366">38</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">Contingent Consideration settled in equity</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="brns:ContingentConsiderationSettledInEquity" format="ixt:fixed-zero" scale="3" id="f-367">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="brns:ContingentConsiderationSettledInEquity" scale="3" id="f-368">78</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">___________________________</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">1</span><ix:footnote id="fn-4" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:5.75pt">Indicates amount less than one thousand</span></ix:footnote></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-5</span></div></div></div><div id="i417e39f5b7bb45b295bb09394310bc8c_154"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of Contents</a></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">BARINTHUS BIOTHERAPEUTICS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:115%"> </span></div><div id="i417e39f5b7bb45b295bb09394310bc8c_157"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">1. <ix:nonNumeric contextRef="c-1" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="f-369" continuedAt="f-369-1" escape="true">Nature of Business and Basis of Presentation</ix:nonNumeric></span></div><ix:continuation id="f-369-1" continuedAt="f-369-2"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Nature of business</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Barinthus Biotherapeutics plc (formerly Vaccitech plc) is a public limited company incorporated pursuant to the laws of England and Wales in March 2021. Barinthus Biotherapeutics plc and its direct and indirect subsidiaries, Barinthus Biotherapeutics (UK) Limited (formerly Vaccitech (UK) Limited), Barinthus Biotherapeutics Australia Pty Limited (formerly Vaccitech Australia Pty Limited), Vaccitech Oncology Limited (&#8220;VOLT&#8221;), Barinthus Biotherapeutics North America, Inc. (formerly Vaccitech North America, Inc.), Barinthus Biotherapeutics Switzerland GmbH (formerly Vaccitech Switzerland GmbH) and Barinthus Biotherapeutics S.R.L. (formerly Vaccitech Italia S.R.L.), are collectively referred to as the &#8220;Company&#8221; or &#8220;Barinthus Bio&#8221;. The Company is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity and cancer. The Company is headquartered in Harwell, Oxfordshire, United Kingdom. On November 6, 2023, the Company announced its renaming as Barinthus Bio to represent the evolution and expansion of its focus beyond vaccines.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In connection with the initial public offering of American Depositary Shares (&#8220;ADSs&#8221;), in March 2021, the Company completed a corporate reorganization wherein the shareholders of Barinthus Biotherapeutics (UK) Limited exchanged each of their ordinary shares, series A shares and series B shares of Barinthus Biotherapeutics (UK) Limited for the same quantity of ordinary shares, series A shares and series B shares in Barinthus Biotherapeutics plc (resulting in the shareholders of the Company holding the same percentage and class of shares in Barinthus Biotherapeutics plc as they had in Barinthus Biotherapeutics (UK) Limited). The group reorganization under common control constituted a change in reporting entity and has been given retrospective effect reflecting the net assets of Barinthus Biotherapeutics (UK) Limited and its subsidiaries and Barinthus Biotherapeutics plc at their historical carrying amounts. On April 4, 2022, a merger was effected between subsidiaries Vaccitech USA, Inc. and Barinthus Biotherapeutics North America, Inc., with Barinthus Biotherapeutics North America, Inc. being the surviving entity.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company operates in an environment of rapid technological change and substantial competition from pharmaceutical and biotechnology companies. The Company is subject to risks common to companies in the biopharmaceutical industry in a similar stage of its life cycle including, but not limited to, the need to obtain adequate additional funding, possible failure of preclinical testing or clinical trials, the need to obtain marketing approval for its vaccine product candidates, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of any of its products that are approved, and protection of proprietary technology. There can be no assurance that the Company&#8217;s research and development will be successfully completed, that adequate protection for the Company&#8217;s intellectual property will be obtained, that any products developed will obtain required regulatory approval or that any approved products will be commercially viable. Even if the Company&#8217;s development efforts are successful, it is uncertain when, if ever, the Company will generate significant product sales. If the Company does not successfully commercialize any of its products or mitigate any of these other risks, it will be unable to generate revenue or achieve profitability.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Basis of presentation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and pursuant to the rules and regulations of the Securities and Exchange Commission for annual financial reporting. The Company&#8217;s reporting currency is the U.S. dollar. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2023, the Company had cash and cash equivalents of $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-370">142.1</ix:nonFraction> million and an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="f-371">176.6</ix:nonFraction> million and the Company expects to incur losses for the foreseeable future. The Company expects that its cash and cash equivalents will be sufficient to fund current operations into the fourth quarter of 2025, without additional financing. The Company expects to seek additional funding through equity financing, government or private-party grants, debt financings or other capital sources, including collaborations with other companies or other strategic transactions. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into collaborations or other arrangements. The terms of any financing may adversely affect the holdings or rights of the Company&#8217;s stockholders. If the Company is unable to obtain sufficient capital, the Company will be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or future commercialization efforts, which could adversely affect its business prospects, or the Company may be unable to continue operations. Although management continues to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations, if at all.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of Contents</a></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">BARINTHUS BIOTHERAPEUTICS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><ix:continuation id="f-369-2"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates, among other things, the realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:GuaranteesIndemnificationsAndWarrantiesPolicies" id="f-372" continuedAt="f-372-1" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Guarantees and indemnifications</span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="f-372-1">As permitted under the laws of England and Wales, the Company indemnifies its officers, directors, consultants and employees for certain events or occurrences that happen by reason of the relationship with, or position held at, the Company.</ix:continuation> Through the years ended December&#160;31, 2023 and 2022, the Company had not experienced any losses related to these indemnification obligations, and no claims were outstanding. The Company does not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and no related reserves were established.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-373" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Use of estimates</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue, income and expenses during the reporting period. The Company bases estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions on an ongoing basis, including those related to fair value of contingent consideration and impairment of goodwill and intangible assets. The Company&#8217;s actual results may differ from these estimates under different assumptions or conditions.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of the date of issuance of these consolidated financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update its estimates, assumptions and judgments or revise the carrying value of its assets or liabilities. These estimates may change as new events occur and additional information is obtained and are recognized in the consolidated financial statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to the Company&#8217;s financial statements.</span></div></ix:nonNumeric></ix:continuation><div id="i417e39f5b7bb45b295bb09394310bc8c_160"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2. <ix:nonNumeric contextRef="c-1" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="f-374" continuedAt="f-374-1" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="f-374-1" continuedAt="f-374-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ConsolidationPolicyTextBlock" id="f-375" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Principles of consolidation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The accompanying consolidated financial statements include the accounts of Barinthus Biotherapeutics plc and those entities in which it has a controlling interest. Intercompany amounts are eliminated on consolidation. Amounts attributable to the noncontrolling interest are presented as a separate element of equity in the accompanying consolidated financial statements.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="f-376" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Comprehensive loss</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Comprehensive loss for all periods presented is comprised primarily of net (loss)/income and other comprehensive loss, which solely relates to foreign currency translation adjustments.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="f-377" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Foreign currency translation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company&#8217;s reporting currency is the United States dollar. The functional currency of the parent and each subsidiary is the currency of the country and economic environment in which it is located. Assets and liabilities of each legal entity denominated or measured in a currency other than British Pounds are first translated into British pounds and consolidated. The consolidated balances are then converted into United States dollars at period-end exchange rates. Revenues and expenses are translated into British pounds, then into U.S. dollars at average exchange rates for each reporting period. Translation adjustments are reflected as accumulated other comprehensive loss within stockholders&#8217; equity. Gains and losses on foreign currency transactions are included in the consolidated statements of operations and comprehensive loss in the general and administrative expenses. The aggregate net foreign exchange gain or loss included in determining net loss was a loss of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" format="ixt:num-dot-decimal" scale="6" id="f-378">7.6</ix:nonFraction> million and gain of $<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" format="ixt:num-dot-decimal" scale="6" id="f-379">26.4</ix:nonFraction> million for the years ended December&#160;31, 2023 and 2022, respectively.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of Contents</a></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">BARINTHUS BIOTHERAPEUTICS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><ix:continuation id="f-374-2" continuedAt="f-374-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="f-380" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Segment information</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, the Company&#8217;s Chief Executive Officer, in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="f-381">one</ix:nonFraction> operating segment, the research and development of immunotherapies and vaccines.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="brns:MinorityInterestPolicyTextBlock" id="f-382" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Noncontrolling interest</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In 2018, Barinthus Biotherapeutics plc established VOLT with a related party. As of December&#160;31, 2021, Barinthus Biotherapeutics plc had contributed cash and intellectual property with an aggregate value of $<ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-5" name="brns:SubsidiaryCumulativeContributionsParent" format="ixt:num-dot-decimal" scale="6" id="f-383">11.9</ix:nonFraction> million for a <ix:nonFraction unitRef="number" contextRef="c-68" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="f-384">76</ix:nonFraction>% controlling interest. The related party had contributed cash and intellectual property with an aggregate value of $<ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-5" name="brns:SubsidiaryCumulativeContributionsNoncontrollingOwner" format="ixt:num-dot-decimal" scale="6" id="f-385">3.8</ix:nonFraction> million for a <ix:nonFraction unitRef="number" contextRef="c-70" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" id="f-386">24</ix:nonFraction>% noncontrolling interest. There were <ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-5" name="us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries" format="ixt:fixed-zero" scale="6" id="f-387"><ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-5" name="us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries" format="ixt:fixed-zero" scale="6" id="f-388">no</ix:nonFraction></ix:nonFraction> further contributions in the years ended December&#160;31, 2023 and 2022. The contributed intellectual properties were initially recorded at investment date fair value by VOLT and immediately expensed as research and development costs. The Company accounts for the noncontrolling interest in the accompanying consolidated financial statements initially at fair value with the subsequent carrying value adjusted for the noncontrolling share of VOLT&#8217;s comprehensive loss.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:BusinessCombinationsPolicy" id="f-389" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Business Combinations</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company accounts for business combinations using the acquisition method of accounting, which requires the recognition of tangible and identifiable intangible assets acquired and liabilities assumed at their estimated fair values as of the business combination date. The Company allocates any excess purchase price over the estimated fair value assigned to the net tangible and identifiable intangible assets acquired and liabilities assumed to goodwill. Contingent consideration is included within the acquisition cost and is recognized at its fair value on the acquisition date. A liability resulting from contingent consideration is remeasured to fair value at each reporting date until the contingency is resolved and changes in fair value are recognized in general and administrative expenses in the consolidated statements of operations and comprehensive loss. Transaction costs are expensed as incurred in general and administrative expenses. Results of operations and cash flows of acquired companies are included in the Company&#8217;s operating results from the date of acquisition.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="f-390" continuedAt="f-390-1" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Cash and cash equivalents</span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="f-390-1">The Company considers all highly liquid investments purchased with remaining maturities of three months or less on the purchase date to be cash and cash equivalents. Cash and cash equivalents include bank demand deposits and money market funds that are actively traded (a Level 1 input).</ix:continuation> As of December&#160;31, 2023, and 2022 there were <ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" format="ixt:fixed-zero" scale="0" id="f-391"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" format="ixt:fixed-zero" scale="0" id="f-392">no</ix:nonFraction></ix:nonFraction> cash equivalents.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="f-393" continuedAt="f-393-1" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Revenue</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has entered into collaboration and license agreements, which are within the scope of Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, to discover, develop, manufacture and commercialize product candidates. The terms of these agreements typically contain multiple promises or obligations, which may include licenses, or options to obtain licenses, to product candidates or future product candidates. The Company also derives revenue from government grants.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Amounts received prior to revenue recognition are recorded as deferred revenue. Amounts expected to be recognized as revenue within the 12 months following the balance sheet date are classified as current portion of deferred revenue in the accompanying consolidated balance sheets. Amounts recognized as revenue, but not yet received or invoiced are generally recognized as accounts receivable.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">License revenue</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company&#8217;s arrangements may provide the collaboration partner with the right to select a target for licensing either at the inception of the arrangement or in the future. Under these arrangements, fees may be due to the Company (i) at the inception of the arrangement as an upfront fee or payment, (ii) upon the exercise of an option to acquire a license or (iii) </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of Contents</a></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">BARINTHUS BIOTHERAPEUTICS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><ix:continuation id="f-374-3" continuedAt="f-374-4"><ix:continuation id="f-393-1"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">upon extending the selection period as an extension fee or payment. If an arrangement is determined to contain customer options that allow the customer to acquire additional goods or services, the goods and services underlying the customer options are not considered to be performance obligations at the outset of the arrangement, as they are contingent upon option exercise. The Company evaluates the customer options for material rights, or options to acquire additional goods or services for fee or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the inception of the arrangement. The Company allocates the transaction price to material rights based on the relative standalone selling price, which is determined based on the identified discount and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised or expires.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For arrangements that include sales-based milestones and royalties, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). This could require management to estimate the amount of revenue to recognize in the period if the actual data for the period has not been provided.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="brns:ResearchAndDevelopmentServicesPolicyPolicyTextBlock" id="f-394" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Research and development services</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The promises under the Company&#8217;s collaboration and license agreements generally include research and development services to be performed by the Company on behalf of the collaboration partner. For performance obligations that include research and development services, the Company recognizes revenue allocated to such performance obligations based on an appropriate measure of progress. The Company utilizes judgment to determine the appropriate method of measuring progress for the purposes of recognizing revenue, which may include an input measure such as costs incurred during the reporting period or ratably over the service period. Reimbursements from the partner are evaluated as to whether the Company acts as a principal or an agent in such relationships. The Company evaluates whether control over the underlying goods or services were obtained prior to transferring these goods or services to the collaboration partner. Where the Company does not control the goods or services prior to transferring these goods or services to the collaboration partner, such reimbursements are presented net of costs. At the inception of each arrangement that includes development milestone payments in respect of development efforts, the Company evaluates whether the development milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated development milestone value is included in the transaction price. Development milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular development milestone in making this assessment. There is judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each reporting period, the Company reevaluates the probability of achievement of all development milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. If a milestone or other variable consideration relates specifically to the Company&#8217;s efforts to satisfy a single performance obligation or to a specific outcome from satisfying the performance obligation, the Company generally allocates the milestone amount entirely to that performance obligation once it is probable that a significant revenue reversal would not occur. To date, the Company has not recognized any development milestone revenue resulting from any of its arrangements.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="brns:GrantIncomePolicyPolicyTextBlock" id="f-395" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Grant income</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company receives certain grant income which support its research efforts in defined projects and include contributions towards the research and development costs. When there is reasonable assurance that the Company will comply with the conditions attached to a received grant, and when there is reasonable assurance that the grant will be received, grant income is recognized as other operating income on a gross basis in the consolidated statements of operations and comprehensive loss on a systematic basis over the periods in which the Company recognizes expenses for the related costs for which the grants are intended to compensate. Grant income may be subject to review by the grantor in periods subsequent to its recognition and may result in the reversal of grant income previously recognized. Payments received in advance of incurring reimbursable expenses are recorded as deferred income.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of Contents</a></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">BARINTHUS BIOTHERAPEUTICS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><ix:continuation id="f-374-4" continuedAt="f-374-5"><ix:nonNumeric contextRef="c-1" name="us-gaap:ConcentrationRiskCreditRisk" id="f-396" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Concentrations of credit risk</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash and cash equivalents and accounts receivable. Periodically, the Company maintains deposits in financial institutions in excess of government insured limits. Management believes that the Company is not exposed to significant credit risk as the Company&#8217;s deposits are held at financial institutions that management believes to be of high credit quality and the Company has not experienced any losses in these deposits. The Company&#8217;s standard payment terms are <ix:nonNumeric contextRef="c-1" name="brns:AccountsReceivableStandardPaymentTermsPeriod" format="ixt-sec:durday" id="f-397">30</ix:nonNumeric> days&#8217;.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company recognizes revenue earned in connection with the license and services provided to customers and grantors. The Company provides credit to the grantors in the normal course of providing such services based on evaluations of their financial condition and generally does not require collateral. To manage accounts receivable credit risk, the Company monitors the creditworthiness of its grantors. Historically, the Company has not experienced any credit losses related to accounts receivable and does not maintain allowances for uncollectible amounts.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="f-398" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Licensees and grantors that represented 10% of more of the Company&#8217;s revenue and accounted for 10% or more of accounts receivable are presented below:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.606%"><tr><td style="width:1.0%"/><td style="width:53.767%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.820%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.507%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.298%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.507%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.301%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Revenue</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Country</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year ended<br/>December 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year ended<br/>December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Oxford University Innovation</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">U.K.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-73" decimals="2" name="brns:ConcentrationRiskThresholdPercentage" scale="-2" id="f-399">100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-74" decimals="2" name="brns:ConcentrationRiskThresholdPercentage" scale="-2" id="f-400">98</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.000%"><tr><td style="width:1.0%"/><td style="width:53.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.912%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.513%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.408%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.513%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.409%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Accounts Receivable</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Country</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">As of<br/>December 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">As of<br/>December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Oxford University Innovation</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">U.K.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-75" decimals="2" name="brns:ConcentrationRiskThresholdPercentage" format="ixt:fixed-zero" scale="-2" id="f-401">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-76" decimals="2" name="brns:ConcentrationRiskThresholdPercentage" scale="-2" id="f-402">94</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:CreditLossFinancialInstrumentPolicyTextBlock" id="f-403" continuedAt="f-403-1" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Allowance for credit losses</span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="f-403-1">The Company evaluates its cash equivalents and accounts receivable for expected credit losses. Expected credit losses represent the portion of the amortized cost basis of a financial asset that an entity does not expect to collect. An allowance for expected credit losses is meant to reflect a risk of loss even if remote, irrespective of the expectation of collection from a particular issuer or debt security. The Company has not historically experienced any credit losses on any of its financial assets.</ix:continuation> With respect to cash equivalents and accounts receivable, given consideration of their short maturity, historical losses and the current market environment, the Company concluded there are <ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:ProvisionForDoubtfulAccounts" format="ixt:fixed-zero" scale="0" id="f-404"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ProvisionForDoubtfulAccounts" format="ixt:fixed-zero" scale="0" id="f-405">no</ix:nonFraction></ix:nonFraction> expected credit losses for these financial assets.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="f-406" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Property and equipment</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Property and equipment are stated at cost, net of accumulated depreciation. Expenditures for maintenance and repairs are charged to operating expenses as incurred, whereas major betterments are capitalized as additions to property and equipment. <ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="f-407" continuedAt="f-407-1" escape="true">Depreciation is recorded using the straight-line method over the estimated useful lives of the assets as follows:</ix:nonNumeric></span></div><ix:continuation id="f-407-1" continuedAt="f-407-2"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.787%"><tr><td style="width:1.0%"/><td style="width:73.323%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.477%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Asset Category</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Estimated Useful Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Office furniture and equipment</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-77" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-408">3</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Laboratory equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-78" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-409">4</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Lesser of lease term or estimated useful lives</span></td></tr></table></div></ix:continuation></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:IntangibleAssetsFiniteLivedPolicy" id="f-410" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Intangible assets acquired through business combinations</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Intangible assets consist of acquired developed technology. Intangible assets are stated at cost less accumulated amortization and impairment losses. Amortization is computed using the straight-line method over the estimated useful lives of the respective assets, which is <ix:nonNumeric contextRef="c-79" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-411">10</ix:nonNumeric> years.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of Contents</a></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">BARINTHUS BIOTHERAPEUTICS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><ix:continuation id="f-374-5" continuedAt="f-374-6"><ix:nonNumeric contextRef="c-1" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="f-412" continuedAt="f-412-1" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Impairment of long-lived assets</span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="f-412-1">The Company reviews long-lived assets to be held and used, including property and equipment, intangible assets and operating lease right-of-use assets, for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets or asset group may not be recoverable. Evaluation of recoverability is first based on an estimate of undiscounted future cash flows resulting from the use of the asset or asset group and its eventual disposition. In the event such cash flows are not expected to be sufficient to recover the carrying amount of the asset or asset group, the assets are written down to their estimated fair values.</ix:continuation> <ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:fixed-zero" scale="3" id="f-413"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:fixed-zero" scale="3" id="f-414">No</ix:nonFraction></ix:nonFraction> such impairments were recorded during the years ended December&#160;31, 2023 and 2022.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="f-415" continuedAt="f-415-1" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Goodwill</span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="f-415-1">Goodwill represents the excess of cost over the fair value of the net tangible and intangible assets of businesses acquired in a business combination. Goodwill is not amortized but rather is tested for impairment at least annually, or more frequently if events or changes in circumstances indicate that the carrying amount of goodwill may not be recoverable. The Company has elected to first assess the qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount as a basis of determining whether it is necessary to perform the quantitative goodwill impairment test. If the Company determines that it is more likely than not that its fair value is less than its carrying amount, then the quantitative goodwill impairment test will be performed. The quantitative goodwill impairment test identifies goodwill impairment and measures the amount of goodwill impairment loss to be recognized by comparing the fair value of a reporting unit with its carrying amount. If the fair value exceeds the carrying amount, no further analysis is required; otherwise, any excess of the goodwill carrying amount over the implied fair value is recognized as an impairment loss, and the carrying value of goodwill is written down to fair value.</ix:continuation> For the years ended December&#160;31, 2023 and 2022, goodwill has been tested, and <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="3" id="f-416"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="3" id="f-417">no</ix:nonFraction></ix:nonFraction> impairments have been recorded.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="f-418" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Financial instruments</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company&#8217;s financial instruments consist of cash and cash equivalents, accounts receivable, accounts payable, certain accrued expenses, contingent consideration and short-term debt. The carrying amounts of cash, cash equivalents, accounts receivable, security deposits, accounts payable, accrued expenses and short-term debt approximate their fair value due to the short-term nature of those financial instruments.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="f-419" continuedAt="f-419-1" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Fair value measurements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company follows the guidance in ASC 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Fair Value Measurements and Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, which defines fair value and establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are described below:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.67pt">Level 1 &#8211; Inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.67pt">Level 2 &#8211; Valuations based on quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.67pt">Level 3 &#8211; Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Fair value is a market-based measure considered from the perspective of a market participant rather than an entity-specific measure. Therefore, even when market assumptions are not readily available, the Company&#8217;s own assumptions are set to reflect those that market participants would use in pricing the asset or liability at the measurement date. The Company uses prices and inputs that are current as of the measurement date, including during periods of market dislocation. In periods of market dislocation, the observability of prices and inputs may change for many instruments. This condition could cause an </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of Contents</a></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">BARINTHUS BIOTHERAPEUTICS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><ix:continuation id="f-374-6" continuedAt="f-374-7"><ix:continuation id="f-419-1"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">instrument to be reclassified within levels in the fair value hierarchy. There were no transfers within the fair value hierarchy during the years ended December&#160;31, 2023 and 2022.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company recognizes a contingent consideration liability related to the acquisition of Avidea Technologies, Inc. The liability is remeasured to fair value at each reporting date until the contingency is resolved. The fair value of the contingent consideration is a Level 3 valuation determined using significant unobservable inputs being the probability of success of achievement of the milestones and the expected date of the milestone achievement. Changes in fair value are recognized in general and administrative expenses in the consolidated statements of operations and comprehensive loss.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeLeasesPolicyTextBlock" id="f-420" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Leases</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Leases are accounted for under ASC 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(&#8220;ASC 842&#8221;) resulting in the recognition of lease liabilities and right-of-use assets. The Company only has operating leases. The Company has elected the practical expedient allowed under ASC 842 to account for each lease component (e.g., the right to use office space) and the associated non-lease components (e.g., maintenance services) as a single lease component. The Company also elected the short-term lease accounting policy for all asset classes; therefore, the Company is not recognizing a lease liability or right-of-use asset for any lease that, at the commencement date, has a lease term of 12 months or less and does not include an option to purchase the underlying asset that the Company is reasonably certain to exercise.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Variable lease payments such as the Company&#8217;s share of real estate taxes, utilities, and common area maintenance, are reported as non-lease operating expenses.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Right-of-use assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Right-of-use assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. As the Company&#8217;s leases typically do not provide an implicit rate, the Company uses an estimate of its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Right-of-use assets also include the effect of any lease payments made and exclude lease incentives. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized as part of total operating expenses on a straight-line basis over the lease term. The difference between the value of the right of use asset and lease liability is due to the reclassification of prepaid rent and unamortized lease incentives.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="f-421" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Research and development</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Research and development costs are expensed as incurred on an accruals basis. Research and development costs include payroll and personnel expense (including share-based compensation), consulting costs, external contract research and development expenses, raw materials, drug product manufacturing costs, and allocated overheads including depreciation and amortization, facility costs, and utilities. Research and development costs that are paid in advance of performance are capitalized as a prepaid expense and amortized over the service period as the services are provided.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="brns:ClinicalTrialCostsPolicyTextBlock" id="f-422" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Clinical trial costs</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Clinical trial costs are a component of research and development expenses. The Company accrues and expenses clinical trial activities performed by third parties based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activation, and other information provided to the Company by its vendors.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend" id="f-423" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Patent and licensing costs</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Patent and licensing costs are expensed as incurred because their realization is uncertain.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityPolicyTextBlock" id="f-424" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Ordinary shares</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Ordinary shares are classified in stockholders&#8217; equity and represent issued share capital.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of Contents</a></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">BARINTHUS BIOTHERAPEUTICS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><ix:continuation id="f-374-7" continuedAt="f-374-8"><ix:nonNumeric contextRef="c-1" name="brns:AdditionalPaidInCapitalPolicyTextBlock" id="f-425" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Additional paid-in capital</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additional paid-in capital is classified in stockholders&#8217; equity and represents the share premium account, where the difference between the price paid per share and the nominal value is recognized. The equity element of share based compensation is also recognized in additional paid in capital.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="f-426" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Share based compensation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company grants options over ordinary shares and restricted shares units to employees or Non-Executive Directors and accounts for share based compensation using the grant date fair value. Share based compensation awards are classified in the accompanying statements of operations based on the function to which the related services are provided. For service-based awards, compensation expense is generally recognized over the requisite service period of the awards, usually the vesting period. The Company applies the &#8220;multiple option&#8221; method of allocating expense. In applying this method, each vesting tranche of an award is treated as a separate grant and recognized on a straight-line basis over that tranche&#8217;s vesting period. For performance-based awards where the vesting of the awards may be accelerated upon the achievement of certain milestones, vesting and the related share-based compensation is recognized as an expense when it is probable the milestone will be met. Assumptions used in the option pricing model include the following:</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Expected volatility.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Previously there was insufficient trading history for the Company&#8217;s ordinary shares, therefore the expected price volatility for our ordinary shares was estimated using the average historical volatility of industry peers&#8217; shares as of the grant date of our options over a period of history commensurate with the expected life of the options. When selecting industry peers used in measuring implied volatility, the Company considered the similarity of their products and business lines, as well as their stage of development, size and financial leverage. The Company applied this process consistently using the same or similar public companies until 2023. During 2023, the Company determined that there is sufficient historical information on volatility of its share price available and the expected volatility used in the fair value calculation of new option grants is calculated based on a blended volatility of both historical volatility of the Company's share price and the expected volatility of the average historical volatility of industry peers&#8217; shares.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Expected term</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. The expected term of the Company&#8217;s share options has been determined utilizing the &#8220;simplified&#8221; method for awards that qualify as &#8220;plain-vanilla&#8221; options. The &#8220;simplified&#8221; method was determined to be appropriate as the Company does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term due to the limited period of time its equity shares have been publicly traded.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Risk-free interest rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods that are approximately equal to the expected term of the award.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Expected dividend.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Expected dividend yield of <ix:nonFraction unitRef="number" contextRef="c-22" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="f-427"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="f-428">zero</ix:nonFraction></ix:nonFraction> is based on the fact that the Company has never paid cash dividends on ordinary shares and does not expect to pay any cash dividends in the foreseeable future.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has elected to recognize the effect of forfeitures on share-based compensation when they occur. Any differences in compensation recognized at the time of forfeiture are recorded as a cumulative adjustment in the period where the forfeiture occurs.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">When awards are modified, the Company compares the fair value of the affected award measured immediately prior to modification to its value after modification. To the extent that the fair value of the modified award exceeds the original award, the incremental fair value of the modified award is recognized as compensation on the date of modification for vested awards, and over the remaining vesting period for unvested awards.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:RegulatoryIncomeTaxesPolicy" id="f-429" continuedAt="f-429-1" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Income taxes</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The financial statements reflect provisions for income taxes in the United Kingdom and foreign jurisdictions. Deferred tax assets and liabilities represent future tax consequences of temporary differences between the financial statement carrying amounts and the tax basis of assets and liabilities and for loss carryforwards using enacted tax rates expected to be in effect in the years in which the differences reverse. A valuation allowance is recorded when it is more likely than not that some or all of the deferred tax assets will not be realized.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company determines whether it is more likely than not that a tax position will be sustained upon examination. If it is not more likely than not that a position will be sustained, none of the benefit attributable to the position is recognized. The </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of Contents</a></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">BARINTHUS BIOTHERAPEUTICS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><ix:continuation id="f-374-8" continuedAt="f-374-9"><ix:continuation id="f-429-1"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">tax benefit to be recognized for any tax position that meets the more-likely-than-not recognition threshold is calculated as the largest amount that is more than 50% likely of being realized upon resolution of the contingency. The Company accounts for interest and penalties related to uncertain tax positions as part of its provision for income taxes. To date, the Company has not incurred interest and penalties related to uncertain tax positions nor has it recorded any unrecognized tax benefits.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="brns:ResearchAndDevelopmentIncentivesPolicyTextBlock" id="f-430" continuedAt="f-430-1" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Research and development incentives</span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><ix:continuation id="f-430-1" continuedAt="f-430-2"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the United Kingdom, the Company had previously been entitled to a research and development tax credit regime, being the Small and Medium-sized Enterprises R&amp;D tax relief program, or SME Program, and, to the extent that our projects are grant funded or relate to work subcontracted to us by third parties, the Research and Development Expenditure Credit program, or RDEC Program. Until March 2023, under the SME program, the Company was able to surrender some of its trading losses that arise from qualifying research and development activities for a cash rebate of up to 33.35% of such qualifying research and development expenditure. Qualifying expenditures largely comprise employment costs for research staff, consumables, outsourced contract research organization costs and utilities costs incurred as part of research projects. Certain staff, consumables (including utilities), subcontractors and externally provided workers qualifying research and development expenditures are eligible for a cash rebate of up to 21.67%. A large portion of costs relating to research and development, clinical trials and manufacturing activities are eligible for inclusion within these tax credit cash rebate claims. From April 2023, under the SME program the additional deduction has decreased from 130% to 86%, the SME credit rate has reduced from 14.5% to 10% and the SME cash rebate for the Company has reduced from 33.35% to 18.6% and from 21.67% to 12.1% for subcontractors. Furthermore, the SME credit rate will decrease to 10% for expenditure incurred on or after April 1, 2023 unless the SME qualifies as an R&amp;D intensive business i.e., R&amp;D expenditure constitutes at least 40% (from April 1, 2023) or 30% (from accounting periods starting on or after April 1, 2024) of total expenditure. If the Company incurs tax losses, the Company is entitled to surrender the lesser of unrelieved tax loss sustained and the tax relief. As the realization of the tax relief does not depend on our generation of future taxable income or the Company&#8217;s ongoing tax status or tax position, the Company does not consider the tax relief as an element of income tax accounting under ASC 740, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Income taxes </span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="f-430-2">and records the tax relief as a form of government grant or assistance. For the years ended December&#160;31, 2023 and 2022, the Company recognized research and development incentives of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="brns:ResearchAndDevelopmentIncentiveIncomeExpense" format="ixt:num-dot-decimal" scale="6" id="f-431">3.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="brns:ResearchAndDevelopmentIncentiveIncomeExpense" format="ixt:num-dot-decimal" scale="6" id="f-432">1.2</ix:nonFraction> million respectively.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerSharePolicyTextBlock" id="f-433" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Net (loss)/income per share</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Basic net (loss)/income per share is computed by dividing the net (loss)/income attributable to ordinary shareholders by the weighted-average number of ordinary shares outstanding for the reporting period without consideration for potentially dilutive securities. Net (loss)/income attributable to ordinary shareholders is computed as if all net (loss)/income for the period had been distributed. During periods in which the Company incurred a net loss, the Company allocates no net loss to participating securities because they do not have a contractual obligation to share in the net loss of the Company.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company computes diluted net (loss)/income per ordinary share after giving consideration to all potentially dilutive ordinary equivalents, including stock options outstanding during the period, except where the effect of such non-participating securities would be antidilutive.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Diluted net (loss)/income per share is computed by dividing the net (loss)/income attributable to ordinary shareholders by the weighted-average number of ordinary shares and dilutive ordinary share equivalents outstanding for the period, determined using the treasury-stock and if-converted methods.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ContingentLiabilityReserveEstimatePolicy" id="f-434" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Contingent liabilities</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A provision for contingent liabilities is recorded when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. With respect to legal matters, provisions are reviewed and adjusted to reflect the impact of negotiations, estimated settlements, legal rulings, advice of legal counsel and other information and events pertaining to a particular matter. The Company is a party to certain litigation and disputes arising in the normal course of business. As of December&#160;31, 2023, the Company does not expect that such matters will have a material adverse effect on the Company&#8217;s business, financial position, results of operations, or cash flows.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of Contents</a></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">BARINTHUS BIOTHERAPEUTICS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-435" escape="true"><ix:continuation id="f-374-9"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Recent Accounting Pronouncements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">From time to time, new accounting pronouncements are issued by FASB or other standard setting bodies that the Company adopts as of the specified effective date. The Company qualifies as an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups Act of 2012 and has elected not to &#8220;opt out&#8221; of the extended transition related to complying with new or revised accounting standards, which means that when a standard is issued or revised and it has different applications dates for public and nonpublic companies, the Company can adopt the new or revised standard at the time nonpublic companies adopt the new or revised standard and can do so until such time the Company either (i) irrevocably elects to &#8220;opt out&#8221; of such extended transition period or (ii) no longer qualifies as an emerging growth company.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Recently Issued Accounting Pronouncements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have reviewed all recently issued standards and have determined that such standards will not have a material impact on our consolidated financial statements or do not otherwise apply to our current operations.</span></div></ix:continuation></ix:nonNumeric><div id="i417e39f5b7bb45b295bb09394310bc8c_166"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">3. <ix:nonNumeric contextRef="c-1" name="us-gaap:ForeignCurrencyDisclosureTextBlock" id="f-436" continuedAt="f-436-1" escape="true">Foreign Currency Translation in General and Administrative Expenses</ix:nonNumeric></span></div><ix:continuation id="f-436-1"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The aggregate, net foreign exchange gain or loss included in determining net (loss)/income recognized in general and administrative expenses for the year ended December&#160;31, 2023, and 2022, was a loss of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" format="ixt:num-dot-decimal" scale="6" id="f-437">7.6</ix:nonFraction>&#160;million and a gain of $<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" format="ixt:num-dot-decimal" scale="6" id="f-438">26.4</ix:nonFraction>&#160;million, respectively.</span></div></ix:continuation><div id="i417e39f5b7bb45b295bb09394310bc8c_169"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">4. <ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerShareTextBlock" id="f-439" continuedAt="f-439-1" escape="true">Net (Loss)/Income Per Share</ix:nonNumeric></span></div><ix:continuation id="f-439-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="f-440" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table sets forth the computation of basic and diluted net (loss)/income per share for the years ended December&#160;31, 2023 and 2022 (in thousands, except number of shares and per share amounts):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Numerator:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net (loss)/income </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-441">73,447</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-442">5,321</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net loss attributable to noncontrolling interest</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="f-443">100</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="f-444">21</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net (loss)/income attributable to Barinthus Biotherapeutics plc shareholders</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-445">73,347</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-446">5,342</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Denominator:</span></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Weighted-average ordinary shares outstanding, basic</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-447">38,386,491</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-22" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-448">37,248,126</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Effect of dilutive stock options</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="0" id="f-449">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-22" decimals="0" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:num-dot-decimal" scale="0" id="f-450">921,181</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Weighted-average ordinary shares outstanding, diluted</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-451">38,386,491</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-22" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-452">38,169,307</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net (loss)/income per share attributable to ordinary shareholders, basic</span></td><td style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-453">1.91</ix:nonFraction>)</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-22" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-454">0.14</ix:nonFraction>&#160;</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net (loss)/income per share attributable to ordinary shareholders, diluted</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-455">1.91</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-22" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-456">0.14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Since the Company was in a loss position for 2023, basic net loss per share is the same as diluted net loss per share, as the inclusion of all potential ordinary share equivalents outstanding would have been anti-dilutive. For the year ended December&#160;31, 2023, <ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-457">6,207,664</ix:nonFraction> potential ordinary shares issuable for stock options were excluded from the computation of diluted weighted-average shares outstanding because including them would have had an anti-dilutive effect. For the year ended December 31, 2022, <ix:nonFraction unitRef="shares" contextRef="c-22" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-458">2,912,756</ix:nonFraction> potential ordinary shares issuable for stock options, respectively, were excluded from the computation of diluted weighted-average shares outstanding because including them would have had an anti-dilutive effect.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-15</span></div></div></div><div id="i417e39f5b7bb45b295bb09394310bc8c_172"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of Contents</a></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">BARINTHUS BIOTHERAPEUTICS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">5. <ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="f-459" continuedAt="f-459-1" escape="true">Property and Equipment, Net</ix:nonNumeric></span></div><ix:continuation id="f-459-1"><ix:continuation id="f-407-2"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Property and equipment, net consists of the following (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Office furniture and equipment</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-460">1,108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-461">1,041</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Laboratory equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-462">5,728</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-463">4,312</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-464">8,673</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-465">3,926</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Property and equipment, at cost</span></td><td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-466">15,509</ix:nonFraction>&#160;</span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-467">9,279</ix:nonFraction>&#160;</span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-468">3,688</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-469">1,322</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Property and equipment, net</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-470">11,821</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-471">7,957</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Depreciation expense for the year ended December&#160;31, 2023 was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="f-472">2.3</ix:nonFraction> million (December&#160;31, 2022: $<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="f-473">1.1</ix:nonFraction> million).</span></div></ix:continuation><div id="i417e39f5b7bb45b295bb09394310bc8c_175"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">6. <ix:nonNumeric contextRef="c-1" name="us-gaap:IntangibleAssetsDisclosureTextBlock" id="f-474" continuedAt="f-474-1" escape="true">Intangible assets, net</ix:nonNumeric></span></div><ix:continuation id="f-474-1"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The gross amount of amortizable intangible assets, consisting of acquired developed technology, was $<ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="f-475"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="f-476">31.6</ix:nonFraction></ix:nonFraction> million at both December&#160;31, 2023 and 2022 and accumulated amortization was $<ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="f-477">6.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="f-478">3.3</ix:nonFraction> million as of December&#160;31, 2023 and 2022, respectively. The amortization expense for the year ended December&#160;31, 2023 was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-479">3.2</ix:nonFraction> million (December&#160;31, 2022: $<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-480">3.2</ix:nonFraction> million). The estimated annual amortization expense is $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="brns:FiniteLivedIntangibleAssetExpectedAmortizationYearEight" format="ixt:num-dot-decimal" scale="6" id="f-481"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:num-dot-decimal" scale="6" id="f-482"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="6" id="f-483"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" format="ixt:num-dot-decimal" scale="6" id="f-484"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="6" id="f-485"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="brns:FiniteLivedIntangibleAssetExpectedAmortizationYearSeven" format="ixt:num-dot-decimal" scale="6" id="f-486"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="6" id="f-487"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="brns:FiniteLivedIntangibleAssetExpectedAmortizationYearSix" format="ixt:num-dot-decimal" scale="6" id="f-488">3.2</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> million for the years 2024 through to 2031.</span></div></ix:continuation><div id="i417e39f5b7bb45b295bb09394310bc8c_178"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">7. <ix:nonNumeric contextRef="c-1" name="brns:PrepaidExpenseAndOtherAssetsCurrentTextBlock" id="f-489" continuedAt="f-489-1" escape="true">Prepaid and other current assets</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" id="f-490" escape="true"><ix:continuation id="f-489-1"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Prepaid and other current assets consist of the following (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Prepayments and accrued income</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="f-491">5,402</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="f-492">5,887</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Value Added Tax receivable</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ValueAddedTaxReceivableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-493">3,031</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ValueAddedTaxReceivableCurrent" format="ixt:fixed-zero" scale="3" id="f-494">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Lease incentives receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="brns:LeaseIncentiveReceivablesCurrent" format="ixt:fixed-zero" scale="3" id="f-495">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="brns:LeaseIncentiveReceivablesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-496">1,770</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-497">1,474</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OtherAssetsCurrent" scale="3" id="f-498">611</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-499">9,907</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-500">8,268</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div id="i417e39f5b7bb45b295bb09394310bc8c_181"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">8. <ix:nonNumeric contextRef="c-1" name="brns:AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock" id="f-501" continuedAt="f-501-1" escape="true">Accrued Expenses and Other Current Liabilities</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="brns:AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" id="f-502" escape="true"><ix:continuation id="f-501-1"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Accrued expenses and other current liabilities consist of the following (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued manufacturing and clinical expenses</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="brns:AccruedManufacturingAndClinicalExpensesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-503">4,003</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="brns:AccruedManufacturingAndClinicalExpensesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-504">2,997</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued bonus</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AccruedBonusesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-505">2,412</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AccruedBonusesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-506">1,925</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued payroll and employee benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AccruedEmployeeBenefitsCurrent" scale="3" id="f-507">789</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AccruedEmployeeBenefitsCurrent" scale="3" id="f-508">928</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued professional fees</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="f-509">942</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-510">1,270</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-511">1,066</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="f-512">941</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="brns:AccruedLiabilitiesAndOtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-513">9,212</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="brns:AccruedLiabilitiesAndOtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-514">8,061</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-16</span></div></div></div><div id="i417e39f5b7bb45b295bb09394310bc8c_184"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of Contents</a></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">BARINTHUS BIOTHERAPEUTICS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">9. <ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="f-515" continuedAt="f-515-1" escape="true">Out-licenses and Grants</ix:nonNumeric></span></div><ix:continuation id="f-515-1" continuedAt="f-515-2"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">OUI license</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In April 2020, the Company entered into an Amendment, Assignment and Revenue Sharing Agreement (&#8220;License Agreement Amendment&#8221;) with Oxford University Innovation, or OUI, which vested and assigned all intellectual property rights in relation to any ChAdOx1 or ChAdOx2 vector-based vaccine jointly owned by the Company and OUI in order to facilitate the license of vaccines based on the ChAdOx1 by OUI to AstraZeneca plc (&#8220;AstraZeneca&#8221;). Under this agreement, the Company is entitled to receive from OUI a share of all payments received by OUI from AstraZeneca in respect of the vaccine based on the ChAdOx1. On December 30, 2020, AstraZeneca announced that vaccine based on the ChAdOx1 which we refer to as Vaxzevria had been approved for emergency supply in the United Kingdom by the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA).</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company determined that the intellectual property vested and assigned under the License Agreement Amendment is a functional intellectual property (that is, it has significant standalone functionality in the form of its ability to treat a disease or condition) and there is no expectation under the License Agreement Amendment that the Company will undertake activities to change the functionality. Consequently, the Company concluded that the nature of the Company&#8217;s promise in transferring the intellectual property is to provide a right to use the Company&#8217;s functional intellectual property. Accordingly, the Company recognizes revenue in manner that depicts the Company&#8217;s progress toward satisfying its performance obligation of providing access to its intellectual property throughout the license period based on the terms of OUI&#8217;s agreement with AstraZeneca.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On March&#160;28, 2022, pursuant to the OUI License Agreement Amendment, we were notified of the commencement of payments, arising from AstraZeneca&#8217;s commercial sales of Vaxzevria. Under the terms of an exclusive worldwide license agreement between OUI and AstraZeneca, OUI is entitled to milestone payments and royalties on commercial sales of Vaxzevria that began after the pandemic period. As part of the assignment from us to OUI, we are entitled to receive approximately <ix:nonFraction unitRef="number" contextRef="c-85" decimals="2" name="brns:PercentageOfRoyaltiesOnNetSales" scale="-2" id="f-516">24</ix:nonFraction>% of payments received by OUI from AstraZeneca. For the year ended December&#160;31, 2023, the Company recognized approximately $<ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-517">0.8</ix:nonFraction> million as revenue (year ended December&#160;31, 2022: $<ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-518">43.7</ix:nonFraction> million) and had an outstanding receivable of <ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:fixed-zero" scale="3" id="f-519">nil</ix:nonFraction> as of December&#160;31, 2023 (2022: $<ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="f-520">5.5</ix:nonFraction> million). There is no guarantee that further payments will be received pursuant to the agreement in the future and, if such payments are made, that we will be notified of such payments in a timely manner.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Scancell contract</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On November 2, 2022, the Company entered into an agreement with Scancell to grant a research and development license, consisting of upfront and development milestone and royalty payments, for the development and commercialization of the SNAPvax functional intellectual property. The Company recognized non-refundable upfront revenue, amounting to <ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-5" name="brns:ContractWithCustomerLiabilityRevenueRecognized1" format="ixt:fixed-zero" scale="6" id="f-521">nil</ix:nonFraction> for the year ended December 31, 2023 (December 31, 2022: $<ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-5" name="brns:ContractWithCustomerLiabilityRevenueRecognized1" format="ixt:num-dot-decimal" scale="6" id="f-522">0.7</ix:nonFraction> million). As of December&#160;31, 2023, <ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:fixed-zero" scale="3" id="f-523">nil</ix:nonFraction> was recorded as a receivable (December 31, 2022: $<ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="f-524">0.3</ix:nonFraction>&#160;million). </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Coalition for Epidemic Preparedness Innovations (&#8220;CEPI&#8221;) Funding Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 20, 2023, Barinthus Biotherapeutics (UK) Limited (the &#8220;Company&#8221;), the Chancellors, Masters and Scholars of the University of Oxford (&#8220;Oxford,&#8221; together with the Company, the &#8220;Partners&#8221;) and the Coalition for Epidemic Preparedness Innovations (&#8220;CEPI&#8221;) entered into a Funding Agreement (the &#8220;Funding Agreement&#8221;) pursuant to which CEPI will provide funding of up to $<ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-5" name="brns:FundingAmountMaximum" format="ixt:num-dot-decimal" scale="6" id="f-525">34.8</ix:nonFraction> million to the Company to advance the development of VTP-500, the Company&#8217;s vaccine candidate against Middle East Respiratory Syndrome (&#8220;MERS,&#8221; and such development activities, the &#8220;Project&#8221;). In December 2023, VTP-500 received PRIME (PRIority MEdicines) designation by the European Medicines Agency. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Funding Agreement, the Company has agreed to pay CEPI on a country-by-country basis increasing mid-single digit percentage royalties of net sales and net income with respect to future cash sales of VTP-500, less certain deductions, for a period starting on December 20, 2023 (&#8220;Effective Date&#8221;) and ending the later of: (i) the expiration of the last valid patent claim included in intellectual property developed under the Project covering VTP-500 in such country, (ii) the expiration of Regulatory Exclusivity (as defined in the Funding Agreement) for VTP-500 in such country, and (iii) the tenth (<ix:nonNumeric contextRef="c-95" name="brns:RoyaltyPaymentTermMaximum" format="ixt-sec:duryear" id="f-526">10</ix:nonNumeric>th) anniversary of the first commercial sale of VTP-500 (the &#8220;Royalty Term&#8221;). The Company shall also pay CEPI a mid-double digit percentage of net revenue earned on VTP-500 until CEPI has received payments from the Company under the Funding Agreement equaling the total amount of funding paid by CEPI to the Company and a low double-digit percentage of such net revenue thereafter. Sales for the benefit of end users in specified low and middle income countries </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of Contents</a></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">BARINTHUS BIOTHERAPEUTICS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><ix:continuation id="f-515-2"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;LMICs&#8221;) and upper and middle income countries (&#8220;UMICs&#8221;) are excluded from the calculations of net sales and net revenue. Sales of product for the benefit of end users in LMICs and UMICs are subject to tiered discounted pricing requirements under the Funding Agreement. The Company is further required to pay a mid-double digit percentage of any proceeds earned on any priority review voucher related to VTP-500 during the Royalty Period.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For the year ended December&#160;31, 2023, <ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-5" name="brns:ProceedsFromGrantsReceived" format="ixt:fixed-zero" scale="0" id="f-527">no</ix:nonFraction> proceeds have been received and <ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-5" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt-sec:numwordsen" scale="0" id="f-528">no</ix:nonFraction> income has been recognized in relation to this contract as no activities eligible for the funding were undertaken during the period. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Contract assets and liabilities</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company discloses accounts receivable separately in the consolidated balance sheets at the net amount expected to be collected. Contract assets primarily relate to the Company&#8217;s conditional right to consideration for work completed but not billed at the reporting date. As of December&#160;31, 2023 and 2022 the Company did not have any contract assets.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Contract liabilities primarily relate to payments received from customers in advance of performance under the contract and are disclosed as deferred revenue separately in the consolidated balance sheets. The Company&#8217;s contract liabilities arise when payment is received upfront for various multi-period extended license and service arrangements.</span></div><ix:nonNumeric contextRef="c-1" name="brns:ContractWithCustomerLiabilitiesTableTextBlock" id="f-529" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Changes in the contract liabilities during the years ended December&#160;31, 2023 and 2022, are as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.112%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.620%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:fixed-zero" scale="3" id="f-530">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" name="us-gaap:ContractWithCustomerLiability" scale="3" id="f-531">182</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Revenue recognized related to contract liability balance</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="brns:ContractWithCustomerLiabilityRevenueRecognized1" format="ixt:fixed-zero" scale="3" id="f-532">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="brns:ContractWithCustomerLiabilityRevenueRecognized1" scale="3" id="f-533">158</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Foreign exchange translation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="brns:ContractWithCustomerLiabilityForeignExchangeTranslation" format="ixt:fixed-zero" scale="3" id="f-534">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" sign="-" name="brns:ContractWithCustomerLiabilityForeignExchangeTranslation" scale="3" id="f-535">24</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Ending balance</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:fixed-zero" scale="3" id="f-536">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:fixed-zero" scale="3" id="f-537">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i417e39f5b7bb45b295bb09394310bc8c_193"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">10. <ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-538" continuedAt="f-538-1" escape="true">Ordinary Shares</ix:nonNumeric></span></div><ix:continuation id="f-538-1" continuedAt="f-538-2"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On May&#160;4, 2021, the Company closed its initial public offering (&#8220;IPO&#8221;) of <ix:nonFraction unitRef="shares" contextRef="c-97" decimals="INF" name="brns:NumberOfAmericanDepositarySharesAdsIssued" format="ixt:num-dot-decimal" scale="0" id="f-539">6,500,000</ix:nonFraction> ADS representing <ix:nonFraction unitRef="shares" contextRef="c-98" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-540">6,500,000</ix:nonFraction> ordinary shares having a nominal value of &#163;<ix:nonFraction unitRef="gbpPerShare" contextRef="c-98" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-541">0.000025</ix:nonFraction> per share, at a public offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-98" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-542">17.00</ix:nonFraction> per share, for aggregate net proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="f-543">102.8</ix:nonFraction> million after deducting underwriting commissions of $<ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-5" name="brns:IssuanceOfCommonStockUnderwritingCommissions" format="ixt:num-dot-decimal" scale="6" id="f-544">7.7</ix:nonFraction> million and incurred offering costs of $<ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-5" name="brns:IssuanceOfCommonStockOfferingCosts" format="ixt:num-dot-decimal" scale="6" id="f-545">2.2</ix:nonFraction> million.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">All ordinary shares rank pari passu as a single class. The following is a summary of the rights and privileges of the holders of ordinary shares as of December&#160;31, 2023:</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Liquidation preference:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> In the event of the liquidation, dissolution or winding up of the Company, the assets of the Company available for distribution to holders of the ordinary shares shall be distributed amongst all holders of the ordinary shares in proportion to the number of shares held irrespective of the amount paid or credited as paid on any share.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Dividends:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Holders of the ordinary shares are entitled to dividends, as may be recommended from time to time by the Board and declared by the ordinary shareholders out of legally available funds.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Voting Rights:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Each holder of ordinary shares is entitled to <ix:nonFraction unitRef="vote" contextRef="c-6" decimals="INF" name="brns:CommonStockNumberOfVotesPerShare" format="ixt-sec:numwordsen" scale="0" id="f-546">one</ix:nonFraction> vote for each share on all matters to be voted on by ordinary shareholders.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Preemption rights:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Pursuant to section 561 of the Companies Act 2006, shareholders are granted preemptive rights when new shares are issued for cash. However, it is possible for our Articles, or shareholders at a general meeting representing at least <ix:nonFraction unitRef="number" contextRef="c-6" decimals="2" name="brns:PercentageOfSharesNecessaryToExercisePreemptiveRights" scale="-2" id="f-547">75</ix:nonFraction>% of our ordinary shares present (in person or by proxy) and eligible to vote at that general meeting, to disapply these preemptive rights. Such a disapplication of preemption rights may be for a maximum period of up to <ix:nonNumeric contextRef="c-1" name="brns:PeriodOfPreemptiveRightsToBeExercised" format="ixt-sec:durwordsen" id="f-548">five years</ix:nonNumeric> from the date of the shareholder special resolution. In either case, this disapplication would need to be renewed by our shareholders upon its expiration (i.e., at least every <ix:nonNumeric contextRef="c-99" name="brns:PeriodOfPreemptiveRightsToBeExercised" format="ixt-sec:durwordsen" id="f-549">five years</ix:nonNumeric>) to remain effective.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of Contents</a></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">BARINTHUS BIOTHERAPEUTICS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><ix:continuation id="f-538-2"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On April&#160;21, 2021, our shareholders approved the disapplication of preemptive rights for a period of <ix:nonNumeric contextRef="c-100" name="brns:PeriodOfPreemptiveRightsToBeExercised" format="ixt-sec:durwordsen" id="f-550">five years</ix:nonNumeric> from the date of approval by way of a special resolution of our shareholders. This included the disapplication of preemption rights in relation to the allotment of our ordinary shares in connection with the IPO. This disapplication will need to be renewed upon expiration (i.e., at least every <ix:nonNumeric contextRef="c-100" name="brns:PeriodOfPreemptiveRightsToBeExercised" format="ixt-sec:durwordsen" id="f-551">five years</ix:nonNumeric>) to remain effective, but may be sought more frequently for additional <ix:nonNumeric contextRef="c-100" name="brns:PeriodOfPreemptiveRightsToBeExercised" format="ixt-sec:durwordsen" id="f-552">five-year</ix:nonNumeric> terms (or any shorter period).</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On November 6, 2023, we held a general meeting where our shareholders approved resolutions granting our board of directors or any duly authorized committee of the board of directors the authority to allot shares in the Company or grant rights to subscribe for or to convert any security into shares in the Company free from preemption rights. Pursuant to such approval, our board of directors was authorized to allot shares up to an aggregate nominal amount of &#163;<ix:nonFraction unitRef="gbp" contextRef="c-101" decimals="0" name="brns:MaximumAggregateNominalAmountOfSharesAuthorizedToBeAllottedFreeFromStatutoryPreEmptionRights" format="ixt:num-dot-decimal" scale="0" id="f-553">1,928</ix:nonFraction> free from statutory preemption rights.</span></div><ix:nonNumeric contextRef="c-1" name="brns:ScheduleOfOrdinarySharesReservedForFutureIssuanceTableTextBlock" id="f-554" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2023, the Company has reserved the following ordinary shares for future issuance:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Exercise of stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-555">6,207,664</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Shares available for future stock incentive plan awards</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="f-556">1,623,840</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-557">7,831,504</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i417e39f5b7bb45b295bb09394310bc8c_196"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">11. <ix:nonNumeric contextRef="c-1" name="brns:StockholdersEquityDeferredSharesDisclosureTextBlock" id="f-558" continuedAt="f-558-1" escape="true">Deferred shares</ix:nonNumeric></span></div><ix:continuation id="f-558-1"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">All deferred shares rank pari passu as a single class. The deferred shares do not have rights to dividends or to participate in profits on a return of assets on liquidation, the deferred shares confer on the holders thereof an entitlement to receive out of the assets of the Company available for distribution amongst the shareholders (subject to the rights of any new class of shares with preferred rights) the amount credited as paid up on the deferred shares held by them respectively after (but only after) payment shall have been made to the holders of the ordinary shares of the amounts paid up or credited as paid up on such shares and the sum of &#163;<ix:nonFraction unitRef="gbp" contextRef="c-13" decimals="-5" name="brns:OrdinarySharesLiquidationPreference" format="ixt:num-dot-decimal" scale="6" id="f-559">1.0</ix:nonFraction> million ($<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="brns:OrdinarySharesLiquidationPreference" format="ixt:num-dot-decimal" scale="6" id="f-560">1.4</ix:nonFraction> million) in respect of each ordinary share held by them respectively. The deferred shares shall confer on the holders thereof no further right to participate in the assets of the Company.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On March 29, 2023, all deferred B shares (nominal value of &#163;<ix:nonFraction unitRef="gbpPerShare" contextRef="c-102" decimals="INF" name="brns:DeferredStockParOrStatedValuePerShare" scale="0" id="f-561">0.01</ix:nonFraction> each) and deferred C shares (nominal value of &#163;<ix:nonFraction unitRef="gbpPerShare" contextRef="c-103" decimals="INF" name="brns:DeferredStockParOrStatedValuePerShare" scale="0" id="f-562">0.00000736245954692556</ix:nonFraction> each) previously in issue were transferred back to the Company and subsequently cancelled. These deferred shares had previously been issued to certain pre-IPO shareholders in connection with the implementation of certain stages of the Company&#8217;s pre-IPO share capital reorganization. The Company received shareholder pre-approval on April 21, 2021 (pursuant to the shareholder resolutions passed on that date) in order to effect the transfer back and cancellation of the deferred shares for nil consideration in accordance with sections 659 and 662 of the Companies Act 2006.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s deferred A shares with a nominal value of &#163;<ix:nonFraction unitRef="gbpPerShare" contextRef="c-13" decimals="INF" name="brns:DeferredStockParOrStatedValuePerShare" scale="0" id="f-563">1.00</ix:nonFraction> each remain in issue for the purposes of satisfying the minimum share capital requirements for a public limited company as prescribed by the Companies Act 2006.</span></div></ix:continuation><div id="i417e39f5b7bb45b295bb09394310bc8c_163"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">12. <ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueDisclosuresTextBlock" id="f-564" continuedAt="f-564-1" escape="true">Fair Value</ix:nonNumeric></span></div><ix:continuation id="f-564-1" continuedAt="f-564-2"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company&#8217;s financial instruments consist of cash and cash equivalents, accounts receivable, accounts payable, certain accrued expenses, contingent consideration and short-term debt. The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable, certain accrued expenses, contingent consideration and short-term debt approximated their respective fair value due to the short-term nature and maturity of these instruments.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2023, the Company had a contingent consideration liability of $<ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="6" id="f-565">1.8</ix:nonFraction> million related to the acquisition of Avidea Technologies, Inc. The fair value of the contingent consideration is a Level 3 valuation with the significant </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of Contents</a></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">BARINTHUS BIOTHERAPEUTICS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><ix:continuation id="f-564-2"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">unobservable inputs being the probability of success of achievement of the milestones and the expected date of the milestone achievement. Significant judgment is employed in determining the appropriateness of certain of these inputs.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="f-566" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes changes in the fair value of Contingent Consideration (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year ended December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year ended December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="f-567">1,711</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="f-568">2,371</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Change in fair value recognized in net loss</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="f-569">55</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="f-570">73</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Settlement of contingency</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="3" id="f-571">163</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="3" id="f-572">325</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Foreign exchange translation recognized in other comprehensive loss</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" name="brns:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeTranslation" scale="3" id="f-573">219</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" sign="-" name="brns:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeTranslation" scale="3" id="f-574">262</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="f-575">1,823</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="f-576">1,711</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div id="i417e39f5b7bb45b295bb09394310bc8c_595"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">13. <ix:nonNumeric contextRef="c-1" name="us-gaap:GoodwillDisclosureTextBlock" id="f-577" continuedAt="f-577-1" escape="true">Goodwill</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfGoodwillTextBlock" id="f-578" escape="true"><ix:continuation id="f-577-1"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes changes in goodwill (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year ended<br/>December 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year ended<br/>December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-579">12,209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-580">12,630</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Measurement period adjustments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GoodwillPurchaseAccountingAdjustments" format="ixt:fixed-zero" scale="3" id="f-581">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" sign="-" name="us-gaap:GoodwillPurchaseAccountingAdjustments" scale="3" id="f-582">421</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-583">12,209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-584">12,209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div><span><br/></span></div><div id="i417e39f5b7bb45b295bb09394310bc8c_199"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">14. <ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-585" continuedAt="f-585-1" escape="true">Share-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="f-585-1" continuedAt="f-585-2"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On April&#160;8, 2021, the Board of the Company adopted the Barinthus Biotherapeutics plc Share Award Plan 2021 (&#8220;the Plan&#8221;) and the Barinthus Biotherapeutics plc Non-Employee Sub-Plan which is a sub-plan of the Plan. Under the terms of the Plan, the Board is permitted to grant awards to employees as restricted share units, options, share appreciation rights and restricted shares. The aggregate number of shares initially available for issuance under the Plan and the Barinthus Biotherapeutics plc Non-Employee Sub-Plan cannot exceed <ix:nonFraction unitRef="shares" contextRef="c-110" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-586">3,675,680</ix:nonFraction> ordinary shares (the &#8220;Initial Limit&#8221;). Beginning calendar year 2023, the total number of ordinary shares available for issuance under the Plan shall be increased on January 1 of each year in an amount equal to the lesser of (i) <ix:nonFraction unitRef="number" contextRef="c-110" decimals="2" name="brns:ShareBasedCompensationPercentageOfSharesAvailableForIssuanceAsPercentageOfIssuedAndOutstandingShares" scale="-2" id="f-587">4</ix:nonFraction>% of the Company&#8217;s issued and outstanding ordinary shares (which <ix:nonFraction unitRef="number" contextRef="c-110" decimals="2" name="brns:ShareBasedCompensationPercentageOfSharesAvailableForIssuanceAsPercentageOfIssuedAndOutstandingShares" scale="-2" id="f-588">4</ix:nonFraction>% limit shall be measured as of January 1 of such year) and (ii) such number of ordinary shares as determined by the Compensation Committee of the Board in its discretion (the &#8220;Annual Increase&#8221;). In accordance with the terms of the Annual Increase, the total number of ordinary shares available for issuance under the Plan increased by <ix:nonFraction unitRef="shares" contextRef="c-111" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-589">1,507,341</ix:nonFraction> of January 1, 2023. The awards generally vest based on the grantee&#8217;s continued service with the Company during a specified period following grant as determined by the Board and generally expire <ix:nonNumeric contextRef="c-110" name="brns:ExpirationOfShareBasedCompensationPlanFromDateOfInitialIssuance" format="ixt-sec:durwordsen" id="f-590">ten years</ix:nonNumeric> from the grant date. Option awards generally vest over <ix:nonNumeric contextRef="c-110" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-591">three years</ix:nonNumeric>, but vesting conditions can vary at the discretion of the Company&#8217;s Board. As of December&#160;31, 2023 and 2022, <ix:nonFraction unitRef="shares" contextRef="c-112" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-592">1,623,840</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-113" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-593">1,670,268</ix:nonFraction> ordinary shares are available for future grants, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In 2018, the Company&#8217;s board of directors adopted the Enterprise Management Incentive Share Option Scheme (the &#8220;EMI Plan&#8221;) which provided for the grant of incentive stock options and nonqualified stock options to non-director employees of the Company. The Company also has a nonqualified stock option plan for officers and directors. The awards generally vest based on the grantee&#8217;s continued service with the Company during a specified period following grant as determined by the board of directors and generally expire <ix:nonNumeric contextRef="c-114" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="f-594">ten years</ix:nonNumeric> from the grant date. Option awards generally vest over <ix:nonNumeric contextRef="c-114" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-595">three years</ix:nonNumeric>, but vesting conditions can vary at the discretion of the Company&#8217;s board of directors. A total of <ix:nonFraction unitRef="shares" contextRef="c-115" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-596">3,530,634</ix:nonFraction> ordinary shares were reserved for issuance in accordance with the provisions of the EMI Plan and restricted stock unit (&#8220;RSUs&#8221;) plan. Upon adoption of the Plan, no further awards are to be made under the EMI Plan.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of Contents</a></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">BARINTHUS BIOTHERAPEUTICS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><ix:continuation id="f-585-2" continuedAt="f-585-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="f-597" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The fair value of each stock option issued to employees was estimated at the date of grant using Black-Scholes with the following weighted-average assumptions:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.454%"><tr><td style="width:1.0%"/><td style="width:65.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.284%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.285%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year Ended, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-116" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-598">97.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-117" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-599">94.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Expected term (years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-116" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-600">6</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-117" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-601">6</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-116" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-602">3.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-117" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-603">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Expected dividend yield</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-116" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-604">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-117" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-605">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Prior to the IPO, the Company applied a discount for lack of marketability calculated using the Finnerty model</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Expected volatility: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Previously there was insufficient trading history for the Company&#8217;s ordinary shares, therefore the expected price volatility for our ordinary shares was estimated using the average historical volatility of industry peers&#8217; shares as of the grant date of our options over a period of history commensurate with the expected life of the options. When selecting industry peers used in measuring implied volatility, the Company considered the similarity of their products and business lines, as well as their stage of development, size and financial leverage. The Company applied this process consistently using the same or similar public companies until 2023. During 2023, the Company determined that there is sufficient historical information on volatility of its share price available and the expected volatility used in the fair value calculation of new option grants is calculated based on a blended volatility of both historical volatility of the Company's share price and the expected volatility of the average historical volatility of industry peers&#8217; shares. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Expected term (years): </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expected term represents the period that the Company&#8217;s option grants are expected to be outstanding. There is not sufficient historical share exercise data to calculate the expected term of the stock options. Therefore, the Company elected to utilize the simplified method to value option grants. Under this approach, the weighted-average expected life is presumed to be the average of the vesting term and the contractual term of the option.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Risk-free interest rate: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company determined the risk-free interest rate by using a weighted-average equivalent to the expected term based on the daily U.S. Treasury yield curve rate in effect as of the date of grant.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Expected dividend yield:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> The Company does not anticipate paying any dividends in the foreseeable future.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="f-606" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A summary of stock option activity is presented below:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Number of<br/>Stock Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Weighted-<br/>average<br/>Exercise<br/>Price Per<br/>Option</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Weighted-<br/>average <br/>Remaining <br/>Contractual <br/>Term (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Aggregate <br/>Intrinsic Value <br/>(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Outstanding, January 1, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-607">4,884,720</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-608">9.04</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-22" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-609">7.36</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-610">2,619</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Granted</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-611">2,288,236</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-612">2.51</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-613">72,386</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="5" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-614">0.00026</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Forfeited/expired</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-615">892,906</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="f-616">7.30</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Outstanding, December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-617">6,207,664</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-618">6.91</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-619">7.95</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-620">6,044</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Exercisable, December 31, 2023</span></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-621">2,839,791</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-622">8.91</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-623">7.33</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="3" id="f-624">2,883</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The weighted-average grant date per-share fair value of stock options granted during the year ended December&#160;31, 2023 was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-625">1.99</ix:nonFraction> per share (December&#160;31, 2022: $<ix:nonFraction unitRef="usdPerShare" contextRef="c-22" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-626">3.51</ix:nonFraction> per share). The aggregate intrinsic value of stock options exercised during the year ended December&#160;31, 2023 was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="f-627">0.2</ix:nonFraction> million (December&#160;31, 2022: $<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="f-628">0.8</ix:nonFraction> million). As of December&#160;31, 2023, there was $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="f-629">3.0</ix:nonFraction> million (2022: $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="f-630">7.1</ix:nonFraction> million) of unrecognized compensation cost related to stock options, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="c-1" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-631">1.60</ix:nonNumeric> years.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of Contents</a></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">BARINTHUS BIOTHERAPEUTICS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="f-632" escape="true"><ix:continuation id="f-585-3"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Share based compensation expense is classified in the consolidated statements of operations and comprehensive loss as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year ended December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year ended December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Research and development</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-633">2,011</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-634">2,668</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-635">3,044</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-636">7,209</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-637">5,055</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-638">9,877</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div id="i417e39f5b7bb45b295bb09394310bc8c_202"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">15. <ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxDisclosureTextBlock" id="f-639" continuedAt="f-639-1" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="f-639-1" continuedAt="f-639-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="f-640" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Loss) income before income taxes are as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.778%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year ended<br/>December 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year ended<br/>December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">United Kingdom</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="f-641">50,534</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="f-642">15,511</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="f-643">24,507</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="f-644">14,648</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="f-645">1,481</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="3" id="f-646">13</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(Loss)/income before income taxes</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-647">76,522</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="f-648">850</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="f-649" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The components of income tax benefit are as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year ended<br/>December 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year ended<br/>December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Current income tax benefit/(expense):</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">United States</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="f-650">28</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-3" sign="-" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="f-651">133</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="f-652">45</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-653">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Deferred income tax benefit:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">United States</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-3" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-654">3,148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-3" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-655">4,338</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total income tax benefit</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-656">3,075</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-657">4,471</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="f-658" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A reconciliation of the UK statutory income tax rate to the Company's effective tax rate as reflected in the consolidated financial statements is as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year ended<br/>December 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year ended<br/>December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Statutory tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-659">23.52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-22" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-660">19.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Increase (decreases) resulting from:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Permanent differences</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" id="f-661">1.03</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="number" contextRef="c-22" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" id="f-662">103.46</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Provision to return adjustments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="4" sign="-" name="brns:EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustments" scale="-2" id="f-663">4.09</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="number" contextRef="c-22" decimals="4" sign="-" name="brns:EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustments" scale="-2" id="f-664">105.66</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Research and development credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="4" name="brns:EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment" scale="-2" id="f-665">4.94</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="number" contextRef="c-22" decimals="4" name="brns:EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment" scale="-2" id="f-666">307.09</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Foreign rate differential</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="f-667">1.23</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="number" contextRef="c-22" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="f-668">149.82</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="f-669">11.84</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-22" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="f-670">146.55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Share based compensation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" scale="-2" id="f-671">0.84</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="number" contextRef="c-22" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" scale="-2" id="f-672">10.21</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Effective tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="4" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-673">4.07</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="number" contextRef="c-22" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-674">510.69</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of Contents</a></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">BARINTHUS BIOTHERAPEUTICS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><ix:continuation id="f-639-2" continuedAt="f-639-3"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income and for tax carryforwards. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="f-675" continuedAt="f-675-1" escape="true">Significant components of the Company&#8217;s deferred tax assets and liabilities are as follows (in thousands):</ix:nonNumeric></span></div><ix:continuation id="f-675-1"><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net operating loss carryforwards</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-676">23,589</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-677">9,940</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Research and development credit carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" id="f-678">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="3" id="f-679">3,146</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Deferred revenue</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsDeferredIncome" format="ixt:fixed-zero" scale="3" id="f-680">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsDeferredIncome" scale="3" id="f-681">54</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Share based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="f-682">4,226</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="f-683">3,956</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Lease liability</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="brns:DeferredTaxAssetsLeasingArrangements" format="ixt:num-dot-decimal" scale="3" id="f-684">3,404</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="brns:DeferredTaxAssetsLeasingArrangements" format="ixt:num-dot-decimal" scale="3" id="f-685">2,257</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accruals and intangibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="brns:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsIntangibles" scale="3" id="f-686">745</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="brns:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsIntangibles" scale="3" id="f-687">765</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Capitalized Research and Development expenditure</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="f-688">4,228</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="f-689">2,522</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="f-690">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="f-691">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Gross deferred tax asset</span></td><td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-692">36,233</ix:nonFraction>&#160;</span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-693">22,641</ix:nonFraction>&#160;</span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-694">25,057</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-695">13,707</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net deferred tax assets</span></td><td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-696">11,176</ix:nonFraction>&#160;</span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-697">8,934</ix:nonFraction>&#160;</span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Depreciation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-698">1,652</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-699">1,704</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Right-of-use lease asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" format="ixt:num-dot-decimal" scale="3" id="f-700">1,922</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" format="ixt:num-dot-decimal" scale="3" id="f-701">1,993</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Unrealized gain on investment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities" format="ixt:num-dot-decimal" scale="3" id="f-702">1,267</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities" format="ixt:num-dot-decimal" scale="3" id="f-703">1,204</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-704">6,909</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-705">7,779</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net deferred tax liabilities</span></td><td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="f-706">11,750</ix:nonFraction>)</span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="f-707">12,680</ix:nonFraction>)</span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total deferred tax, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxLiabilities" scale="3" id="f-708">574</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-709">3,746</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Specified research and experimentation costs under Section 174 of the Internal Revenue Code are required to be capitalized and amortized ratably over five years for domestic expenditures and over 15 years for foreign expenditures. This provision of Section 174 became effective for tax years beginning after December 31, 2021. As a result of the capitalization of these costs in the current year, the Company has recorded a $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="6" id="f-710">4.2</ix:nonFraction> million deferred tax asset (2022: $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="6" id="f-711">2.5</ix:nonFraction> million). </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2023, the Company had a valuation allowance of $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="f-712">25.1</ix:nonFraction> million (2022: $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="f-713">13.7</ix:nonFraction> million) against its deferred tax assets, which consisted principally of net operating loss and research and development credit carryforwards. The Company considered the positive and negative evidence bearing upon its ability to realize the deferred tax assets. In addition to the Company&#8217;s history of cumulative losses, the Company cannot be certain that future taxable income will be sufficient to realize its deferred tax assets. Accordingly, a valuation allowance has been provided against its deferred tax assets. When the Company changes its determination as to the amount of its deferred tax assets that can be realized, the valuation allowance is adjusted with a corresponding impact to the provision for income taxes in the period in which such determination is made.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:SummaryOfValuationAllowanceTextBlock" id="f-714" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Changes in the valuation allowance for deferred tax assets during the years ended December 31, 2023 and 2022 related primarily to the increase in net operating loss and credit carryforwards, and were as follows:</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.901%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year ended<br/>December 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year ended<br/>December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Valuations allowance at beginning of year</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-715">13,707</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-716">13,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Changes in valuation allowance arising from in-year additions</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="brns:ValuationAllowanceDeferredTaxAssetIncreaseResultingFromCurrentPeriodAdditions" format="ixt:num-dot-decimal" scale="3" id="f-717">1,052</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="brns:ValuationAllowanceDeferredTaxAssetIncreaseResultingFromCurrentPeriodAdditions" format="ixt:fixed-zero" scale="3" id="f-718">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Increases recorded to income tax provision</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="brns:ValuationAllowanceDeferredTaxAssetIncreaseResultingFromIncomeTaxProvision" format="ixt:num-dot-decimal" scale="3" id="f-719">9,605</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="brns:ValuationAllowanceDeferredTaxAssetIncreaseResultingFromIncomeTaxProvision" format="ixt:num-dot-decimal" scale="3" id="f-720">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Foreign exchange translation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="brns:ValuationAllowanceDeferredTaxAssetIncreaseDecreaseResultingFromForeignCurrencyTranslation" scale="3" id="f-721">693</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" sign="-" name="brns:ValuationAllowanceDeferredTaxAssetIncreaseDecreaseResultingFromForeignCurrencyTranslation" format="ixt:num-dot-decimal" scale="3" id="f-722">1,293</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Valuation allowance at end of year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-723">25,057</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-724">13,707</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of Contents</a></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">BARINTHUS BIOTHERAPEUTICS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><ix:continuation id="f-639-3"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2023, the Company had net operating loss ("NOL") carryforwards totaling approximately $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-725">92.7</ix:nonFraction> million which have an unlimited carryforward period, of which $<ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-726">74.2</ix:nonFraction> million originate in the United Kingdom. As of December&#160;31, 2023, the Company had $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-4" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="f-727">0.04</ix:nonFraction> million of research and development tax credit carryforwards which also have an unlimited carryforward period.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2022, the Company had NOL carryforwards totaling approximately $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-728">39.6</ix:nonFraction> million which have an unlimited carryforward period, of which $<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:IncomeTaxCreditsAndAdjustments" format="ixt:num-dot-decimal" scale="6" id="f-729">35.1</ix:nonFraction> million originate in the United Kingdom. As of December&#160;31, 2022, the Company had $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="f-730">3.1</ix:nonFraction> million of research and development tax credit carryforwards which also have an unlimited carryforward period.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2023 and 2022, the Company does not have any material unrecognized tax benefit liabilities. The Company files corporation/income tax returns in the United Kingdom, Australia, and the United States. The associated tax filings remain subject to examination by applicable tax authorities for a certain length of time following the tax year to which those filings relate. In the United Kingdom, tax years from 2020 remain subject to examination by HMRC. In all other jurisdictions, the tax years since inception remain subject to examination by the applicable taxing authorities as of December&#160;31, 2023 and 2022.</span></div></ix:continuation><div id="i417e39f5b7bb45b295bb09394310bc8c_205"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">16. <ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-731" continuedAt="f-731-1" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="f-731-1" continuedAt="f-731-2"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">In-License Agreements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company is party to a number of licensing agreements, these agreements serve to provide the Company with the right to develop and exploit the counterparties&#8217; intellectual property for certain medical indications. As part of execution of these arrangements, the Company paid certain upfront fees, which have been expensed as incurred because the developing technology has not yet reached technical feasibility, the lack of alternative use, and the lack of proof of potential value. The agreements cover a variety of fields, including influenza, cancer, HPV, HBV and MERS. The Company&#8217;s obligations for future payments under these arrangements are dependent on its ability to develop promising drug candidates, the potential market for these candidates and potential competing products, and the payment mechanisms in place in countries where the Company retains the right to sell. Each agreement provides for specific milestone payments, typically triggered by achievement of certain testing phases in human candidates, and future royalties ranging from <ix:nonFraction unitRef="number" contextRef="c-127" decimals="2" name="brns:PercentageOfFutureRoyaltiesForDirectSalesOfCoveredProductLicenseAgreement" scale="-2" id="f-732">1</ix:nonFraction> to <ix:nonFraction unitRef="number" contextRef="c-128" decimals="2" name="brns:PercentageOfFutureRoyaltiesForDirectSalesOfCoveredProductLicenseAgreement" scale="-2" id="f-733">5</ix:nonFraction>% for direct sales of a covered product to <ix:nonFraction unitRef="number" contextRef="c-127" decimals="2" name="brns:PercentageOfNetPaymentsReceivedForAllowableSublicensesOfTechnologyDevelopedLicenseAgreement" scale="-2" id="f-734">3</ix:nonFraction> to <ix:nonFraction unitRef="number" contextRef="c-128" decimals="2" name="brns:PercentageOfNetPaymentsReceivedForAllowableSublicensesOfTechnologyDevelopedLicenseAgreement" scale="-2" id="f-735">7</ix:nonFraction>% of net payments received for allowable sublicenses of technology developed by the Company. The obligation to make these payments is contingent upon the Company&#8217;s ability to develop candidates for submission for phased testing and approvals, and for the development of markets for the products developed by the Company. The Company has not made any material payments under these license agreements during the years ended December&#160;31, 2023, and 2022.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Leases</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company leases certain laboratory and office space under operating leases, which are described below.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">The Oxford Science Park, Oxford</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company leased an office and laboratory space from a related party in Oxford, England under an operating lease with a contractual term expiring in 2028. The lease was terminated on July 31, 2022, and the Company relocated its corporate headquarters to The Harwell Science and Innovation Campus, Oxfordshire, in the third quarter of 2022.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">The Harwell Science and Innovation Campus, Oxfordshire</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On September&#160;3, 2021, the Company entered into a lease agreement for the lease of approximately <ix:nonFraction unitRef="sqft" contextRef="c-129" decimals="-3" name="brns:NumberOfSquareFeetUnderLeaseAgreement" format="ixt:num-dot-decimal" scale="0" id="f-736">31,000</ix:nonFraction> square feet in Harwell, Oxfordshire which expires in September 2031. The property is the Company&#8217;s corporate headquarters. As the Company&#8217;s leases typically do not provide an implicit rate, the Company uses an estimate of its incremental borrowing rate based on the information available at the lease commencement date, being the rate incurred to borrow on a collateralized basis over a similar term at an amount equal to the lease payments in a similar economic environment. The Company has provided the lessor with a refundable security deposit of $<ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-5" name="us-gaap:SecurityDeposit" format="ixt:num-dot-decimal" scale="6" id="f-737">0.7</ix:nonFraction> million which is included in Other assets.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of Contents</a></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">BARINTHUS BIOTHERAPEUTICS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><ix:continuation id="f-731-2"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Germantown, Maryland</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On June&#160;14, 2022, the Company entered into a lease agreement for the lease of approximately <ix:nonFraction unitRef="sqft" contextRef="c-131" decimals="-2" name="brns:NumberOfSquareFeetUnderLeaseAgreement" format="ixt:num-dot-decimal" scale="0" id="f-738">19,700</ix:nonFraction> square feet in Germantown, Maryland. The site will house the Company&#8217;s state-of-the-art wet laboratory in the United States of America. The lease expires on February 28, 2034, with the Company having a single right to extend for an additional <ix:nonNumeric contextRef="c-131" name="brns:LesseeOperatingLeaseExtendedTerm" format="ixt-sec:durwordsen" id="f-739">five years</ix:nonNumeric> on the same terms and conditions other than for the base rent. The Company has a rent-free period up to February 29, 2024 and is entitled to up to $<ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-5" name="us-gaap:LeaseholdImprovementsGross" format="ixt:num-dot-decimal" scale="6" id="f-740">3.5</ix:nonFraction> million for leasehold improvements to the premises desired by the Company. The Company has provided the lessor with a refundable security deposit of $<ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-5" name="us-gaap:SecurityDeposit" format="ixt:num-dot-decimal" scale="6" id="f-741">0.2</ix:nonFraction> million which is included in Other assets.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company recorded a right-of-use asset and a lease liability on the effective date of the lease term. <ix:nonNumeric contextRef="c-1" name="brns:LesseeOperatingLeaseRightOfUseAssetAndOtherInformationTableTextBlock" id="f-742" continuedAt="f-742-1" escape="true">The Company&#8217;s right-of-use assets and lease liabilities are as follows (in thousands):</ix:nonNumeric></span></div><ix:continuation id="f-742-1"><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Right-of-use asset</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-743">7,581</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-744">7,753</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Lease liability, current</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-745">1,785</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-746">433</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Lease liability, noncurrent</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-747">11,191</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-748">8,340</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 13pt 0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 13pt 0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Other information</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating cash flows from operating leases</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeasePayments" scale="3" id="f-749">639</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="f-750">1,081</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Weighted average remaining lease term (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-6" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-751">8.93</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-7" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-752">9.44</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Weighted average discount rate</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-6" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-753">7.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-7" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-754">7.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Lease Costs</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Short-term lease costs</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShortTermLeaseCost" scale="3" id="f-755">189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:ShortTermLeaseCost" scale="3" id="f-756">529</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Fixed Lease Costs</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="f-757">883</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-758">1,216</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease cost</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-759">1,072</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-760">1,745</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="f-761" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Maturities of the Company&#8217;s minimum lease liabilities as of December&#160;31, 2023 were as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Maturity of lease liabilities:</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2024</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-762">1,785</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-763">1,936</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="f-764">1,960</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2027</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="f-765">1,985</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" format="ixt:num-dot-decimal" scale="3" id="f-766">2,010</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="f-767">7,999</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total minimum lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="f-768">17,675</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: imputed interest</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="f-769">4,699</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total lease liability</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-770">12,976</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Non-lease and other costs paid to the lessors are primarily related to services provided by the lessors in operating the premises that includes fees, operating costs, taxes, and insurance related to the leased premises.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Other contingencies</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company is a party in various contractual disputes, litigation, and potential claims arising in the ordinary course of business. The Company does not believe that the resolution of these matters will have a material adverse effect on its financial position or results of operations.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-25</span></div></div></div><div id="i417e39f5b7bb45b295bb09394310bc8c_208"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i417e39f5b7bb45b295bb09394310bc8c_7">Table of Contents</a></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">BARINTHUS BIOTHERAPEUTICS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">17. <ix:nonNumeric contextRef="c-1" name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" id="f-771" continuedAt="f-771-1" escape="true">Employee Benefit Plans</ix:nonNumeric></span></div><ix:continuation id="f-771-1"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the United Kingdom, the Company has adopted a defined contribution plan (the U.K. Plan) which qualifies under the rules established by HM Revenue &amp; Customs. Contributions to the U.K. Plan are charged to the consolidated statements of operations and comprehensive loss in the year to which they relate.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has 401(k) defined contribution retirement plans in which all its employees located in the United States are eligible to participate. Eligible employees may elect to contribute up to the maximum limits, as set by the Internal Revenue Service, of their eligible compensation. Contributions to the plans are charged to the consolidated statements of operations and comprehensive loss in the year to which they relate.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the year ended December&#160;31, 2023, the Company provided a total of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" format="ixt:num-dot-decimal" scale="6" id="f-772">0.7</ix:nonFraction> million (December&#160;31, 2022: $<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" format="ixt:num-dot-decimal" scale="6" id="f-773">0.5</ix:nonFraction> million) in contributions under both the U.K. Plan and the 401(k) plans.</span></div></ix:continuation><div id="i417e39f5b7bb45b295bb09394310bc8c_211"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">18. <ix:nonNumeric contextRef="c-1" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="f-774" continuedAt="f-774-1" escape="true">Related Party Transactions</ix:nonNumeric></span></div><ix:continuation id="f-774-1"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the year ended December&#160;31, 2023, the Company incurred expenses of $<ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-5" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" format="ixt:num-dot-decimal" scale="6" id="f-775">0.4</ix:nonFraction> million (December&#160;31, 2022: $<ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-5" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" format="ixt:num-dot-decimal" scale="6" id="f-776">0.4</ix:nonFraction> million) from its shareholder, the University of Oxford, related to clinical study costs. As of December&#160;31, 2023, the Company owed <ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-5" name="us-gaap:AccountsPayableCurrent" format="ixt:fixed-zero" scale="3" id="f-777">nil</ix:nonFraction> (2022: $<ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-5" name="us-gaap:AccountsPayableCurrent" format="ixt:fixed-zero" scale="3" id="f-778">nil</ix:nonFraction>).</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the year ended December&#160;31, 2023, the Company incurred expenses of $<ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-5" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" format="ixt:num-dot-decimal" scale="6" id="f-779">0.6</ix:nonFraction> million (December&#160;31, 2022: $<ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-5" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" format="ixt:num-dot-decimal" scale="6" id="f-780">0.4</ix:nonFraction> million) from Oxford University Innovation Limited which is a wholly owned subsidiary of the Company&#8217;s shareholder, the University of Oxford. As of December&#160;31, 2023, the Company owed $<ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-781">2</ix:nonFraction>&#160;thousand (December 31, 2022: <ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:fixed-zero" scale="6" id="f-782">nil</ix:nonFraction>) to Oxford University Innovation Limited.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the year ended December&#160;31, 2023, the Company recognized license revenue of $<ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-783">0.8</ix:nonFraction> million (December&#160;31, 2022: $<ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-784">43.7</ix:nonFraction> million) from Oxford University Innovation Limited which is a wholly owned subsidiary of the Company&#8217;s shareholder, the University of Oxford. As of December&#160;31, 2023, the Company was owed <ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:fixed-zero" scale="3" id="f-785">nil</ix:nonFraction> (2022: $<ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="f-786">5.5</ix:nonFraction> million) from Oxford University Innovation Limited.</span></div></ix:continuation><div id="i417e39f5b7bb45b295bb09394310bc8c_214"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">19. <ix:nonNumeric contextRef="c-1" name="us-gaap:SubsequentEventsTextBlock" id="f-787" continuedAt="f-787-1" escape="true">Subsequent Events  </ix:nonNumeric></span></div><ix:continuation id="f-787-1"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In accordance with the terms of the Annual Increase of the Barinthus Biotherapeutics plc Share Award Plan 2021, the total number of ordinary shares available for issuance under the Plan increased by <ix:nonFraction unitRef="number" contextRef="c-143" decimals="2" name="brns:ShareBasedCompensationPercentageOfSharesAvailableForIssuanceAsPercentageOfIssuedAndOutstandingShares" scale="-2" id="f-788">4</ix:nonFraction>% of the Company&#8217;s issued and outstanding ordinary shares as of January&#160;1, 2024.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2024, the Company granted a total of <ix:nonFraction unitRef="shares" contextRef="c-144" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-789">1,592,423</ix:nonFraction> share options to employees and directors with a weighted average exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-144" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-790">3.70</ix:nonFraction>.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-26</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.18
<SEQUENCE>2
<FILENAME>brns-20231231xex1018.htm
<DESCRIPTION>EX-10.18
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i4cb52855f4374a6ca077b349c7ceffd4_1"></div><div style="min-height:35.28pt;width:100%"><div><font><br></font></div></div><div style="padding-left:21.9pt"><img alt="image_0a.jpg" src="image_0a.jpg" style="height:36px;margin-bottom:5pt;vertical-align:text-bottom;width:29px"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><img alt="image_1a.jpg" src="image_1a.jpg" style="height:36px;margin-bottom:5pt;vertical-align:text-bottom;width:20px"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><img alt="image_2a.jpg" src="image_2a.jpg" style="height:36px;margin-bottom:5pt;vertical-align:text-bottom;width:22px"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">   </font><img alt="image_3a.jpg" src="image_3a.jpg" style="height:35px;margin-bottom:5pt;vertical-align:text-bottom;width:4px"></div><div style="padding-left:21.9pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CERTAIN INFORMATION IDENTIFIED WITH &#91;***&#93; HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.</font></div><div style="margin-top:4.95pt;padding-right:7.05pt;text-align:right"><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19 December 2023</font></div><div><font><br></font></div><div style="margin-top:5pt"><font><br></font></div><div style="padding-left:20pt;padding-right:342.85pt;text-indent:-0.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:172%">Funding Agreement Agreement Summary</font></div><div style="margin-top:7.05pt"><font><br></font></div><div style="padding-left:26.6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.805%"><tr><td style="width:1.0%"></td><td style="width:24.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:73.304%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="background-color:#c0c0c0;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">PARTNER INFORMATION</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.6pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Names&#58;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:114%">The Chancellors, Masters and Scholars of the University of Oxford</font></div><div style="margin-top:0.2pt;padding-left:5.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Oxford</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)&#59; and</font></div><div style="margin-top:5.8pt;padding-left:5.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Barinthus Biotherapeutics (UK) Limited</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, a private limited company incorporated in England and Wales with company number 09973585 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Barinthus Bio</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;),</font></div><div style="margin-top:6.1pt;padding-left:5.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(each of Oxford and Barinthus Bio a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Partner</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; and together the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Partners</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Mailing Address&#58;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">For Oxford&#58; University Offices, Wellington Square, Oxford, OX1 2JD</font></div><div style="margin-top:5.8pt;padding-left:5.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">For Barinthus Bio&#58; Barinthus Biotherapeutics (UK) Limited, Units 6 to 10 Zeus Building, Rutherford Avenue, Harwell, Oxfordshire, Didcot OX11 0DF</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Project Lead&#58;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">For Oxford&#58; &#91;***&#93;</font></div><div style="margin-top:6.05pt;padding-left:5.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">For Barinthus Bio&#58; &#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Management Contact&#58;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">For Oxford&#58; &#91;***&#93;</font></div><div style="margin-top:6.05pt;padding-left:5.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">For Barinthus Bio&#58; &#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Bank Account Details&#58;</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">For Oxford</font></div><div style="margin-top:6.05pt;padding-left:5.45pt;padding-right:175.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:170%;text-decoration:underline">Account Name&#58; University of Oxford Account Number&#58; &#91;***&#93;</font></div><div style="margin-top:3.15pt;padding-left:5.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">IBAN Number&#58; &#91;***&#93;</font></div><div style="margin-top:8.95pt;padding-left:5.45pt;padding-right:175.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:198%;text-decoration:underline">Bank Sort Code Number&#58; &#91;***&#93; Swift Code&#58; &#91;***&#93;</font></div><div style="padding-left:5.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%;text-decoration:underline">Bank&#58; &#91;***&#93;</font></div><div style="margin-top:6.2pt;padding-left:5.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Bank Address&#58; &#91;***&#93;</font></div><div style="margin-top:11.85pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">For Barinthus Bio</font></div><div style="margin-top:6.05pt;padding-left:5.45pt;padding-right:60.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:170%;text-decoration:underline">Account Name&#58; Barinthus Biotherapeutics (UK) Limited Account Number&#58; &#91;***&#93;</font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:50.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.706%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sensitivity&#58; Official Use</font></div></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">           1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:35.28pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:0.05pt;margin-top:7pt"><font><br></font></div><div style="padding-left:26.6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.805%"><tr><td style="width:1.0%"></td><td style="width:24.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:73.304%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">IBAN Number&#58; &#91;***&#93;</font></div><div style="margin-top:8.95pt;padding-left:5.5pt;padding-right:175.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:199%">Bank Sort Code Number&#58; &#91;***&#93; Swift Code&#58; &#91;***&#93;</font></div><div style="padding-left:5.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:111%">Bank&#58; &#91;***&#93;</font></div><div style="margin-top:6.15pt;padding-left:5.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Bank Address&#58; &#91;***&#93;.</font></div></td></tr></table></div><div style="margin-top:7.2pt"><font><br></font></div><div style="padding-left:26.6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.805%"><tr><td style="width:1.0%"></td><td style="width:23.701%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:74.099%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="background-color:#c0c0c0;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CEPI INFORMATION</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Mailing Address&#58;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.75pt;padding-left:5.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Coalition for Epidemic Preparedness Innovations </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CEPI</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)</font></div><div style="margin-top:7.15pt;padding-left:5.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Postbox 1030 Hoff, 0218 Oslo, Norway</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt;padding-left:5.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Project Lead&#58;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt;padding-left:0.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt;padding-left:5.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Management Contact&#58;</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt;padding-left:0.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td></tr></table></div><div style="margin-top:7.35pt"><font><br></font></div><div style="padding-left:26.6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.805%"><tr><td style="width:1.0%"></td><td style="width:23.701%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:74.099%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="background-color:#c0c0c0;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">AGREEMENT INFORMATION</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Project Name</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.5pt"><font style="color:#0d0d0d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CEPI &#8211; Oxford &#8211; Barinthus Bio ChAdOx1 MERS vaccine development</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Effective Date</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date of last signature below</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Expiry Date</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">As described in Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">19.1</a> of the Terms and Conditions in <a href="#i4cb52855f4374a6ca077b349c7ceffd4_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">Annex A.</a></font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Agreement includes and</font></div><div style="margin-top:5.95pt;padding-left:5.6pt;padding-right:2.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">incorporates by reference&#58;</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) means this Agreement Summary together with the following&#58;</font></div><div style="margin-top:5.1pt;padding-left:15.4pt;text-indent:-5.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-&#160;&#160;&#160;&#160;Terms and Conditions (<a href="#i4cb52855f4374a6ca077b349c7ceffd4_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">Annex A</a>)</font></div><div style="margin-top:5.7pt;padding-left:15.5pt;text-indent:-6.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-&#160;&#160;&#160;&#160;Team Charter (Annex B)</font></div><div style="margin-top:6.05pt;padding-left:15.25pt;text-indent:-5.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-&#160;&#160;&#160;&#160;Integrated Product Development Plan and Work Package(s) (Annex C)</font></div><div style="margin-top:6pt;padding-left:15.75pt;text-indent:-6.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-&#160;&#160;&#160;&#160;Budget for Work Packages (Annex D)</font></div><div style="margin-top:5.95pt;padding-left:15.75pt;text-indent:-6.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-&#160;&#160;&#160;&#160;Equitable Access Plan (Annex E)</font></div><div style="margin-top:6.05pt;padding-left:15.75pt;text-indent:-6.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-&#160;&#160;&#160;&#160;List of UMICs, HICs and LMICs as at the Effective Date (Annex F)</font></div><div style="margin-top:6.2pt;padding-left:15.75pt;text-indent:-6.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-&#160;&#160;&#160;&#160;List of Sub-Contractors (Annex G)</font></div><div style="margin-top:6.05pt;padding-left:15.75pt;text-indent:-6.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-&#160;&#160;&#160;&#160;COGs (Annex H)</font></div><div style="margin-top:5.85pt;padding-left:3.9pt;padding-right:17.9pt;text-indent:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-&#160;&#160;&#160;&#160;CEPI&#8217;s Policies&#58; Third Party Code, Cost Guidance and Transparency and Confidentiality Policy (Annex I)</font></div><div style="margin-top:6.15pt;padding-left:15.75pt;text-indent:-6.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-&#160;&#160;&#160;&#160;Stage Gate(s) (Annex J)</font></div><div style="margin-top:5.95pt;padding-left:15.75pt;text-indent:-6.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-&#160;&#160;&#160;&#160;Template Technical Report (Annex K)</font></div><div style="margin-top:6.05pt;padding-left:15.75pt;text-indent:-6.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-&#160;&#160;&#160;&#160;List of CEPI Affiliates as at the Effective Date (Annex L)</font></div><div style="margin-top:5.95pt;padding-left:15.75pt;text-indent:-6.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-&#160;&#160;&#160;&#160;Clinical Trial Policy (Annex M)</font></div></td></tr></table></div><div><font><br></font></div><div style="height:50.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.706%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sensitivity&#58; Official Use</font></div></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">           2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:35.28pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:3.5pt"><font><br></font></div><div style="padding-left:19.95pt;padding-right:6.95pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">THIS AGREEMENT is between The Chancellor, Masters and Scholars of the University of Oxford, Barinthus Biotherapeutics (UK) Limited and the Coalition for Epidemic Preparedness Innovations and is effective as of the date of the last signature, below (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). Each party to this Agreement may be referred to individually as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; and together as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.&#8221;</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:5.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:20pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Signed for and on behalf of&#58;</font></div><div style="margin-top:12pt"><font><br></font></div><div style="padding-left:20pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">COALITION FOR EPIDEMIC PREPAREDNESS INNOVATIONS</font></div><div style="margin-top:12.05pt"><font><br></font></div><div style="padding-left:20pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Signature&#58; &#47;s&#47; In-Kyu Yoon&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#160;&#160;&#160;&#160;Name&#58; In-Kyu Yoon</font></div><div style="margin-top:5.6pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:49.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:93%">Acting Executive Director, R&#38;D&#160;&#160;&#160;&#160;December 19, 2023</font></div><div style="padding-left:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:111%">Title&#58; &#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;..&#160;&#160;&#160;&#160;Date.&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:9.8pt"><font><br></font></div><div style="padding-left:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD</font></div><div style="margin-top:4.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:298.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:92%">Carly Banner</font></div><div style="padding-left:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:109%">Signature&#58; &#8230;&#47;s&#47; Carly Banner&#8230;&#8230;&#8230;&#8230;                          Name&#58; &#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;..</font></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:45.711%"><div style="margin-top:9.5pt;padding-left:49.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:99%">Assistant Director (Research Contracts)</font></div><div style="margin-top:2.55pt"><font><br></font></div></div><div style="display:inline-block;max-width:8.577%;min-width:7.577%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:45.712%"><div><font><br></font></div><div style="padding-left:49.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:80%">December 20, 2023</font></div></div></div><div style="padding-left:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%">Title&#58;  &#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;..          &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Date&#58;  &#8230;&#8230;&#8230;&#8230;.&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:10.55pt"><font><br></font></div><div style="padding-left:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">BARINTHUS BIOTHERAPEUTICS (UK) LIMITED</font></div><div style="margin-top:12pt"><font><br></font></div><div style="padding-left:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Signature&#58;&#47;s&#47; William Enright&#160;&#160;&#160;&#160;Name&#58; William Enright</font></div><div style="margin-top:3.1pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:294.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:96%">December 20, 2023</font></div><div style="padding-left:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:111%">Title&#58; CEO&#160;&#160;&#160;&#160;Date&#58; &#8230;&#8230;&#8230;&#8230;.&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;.</font></div><div style="height:50.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.706%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sensitivity&#58; Official Use</font></div></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">           3</font></div></div></div><div id="i4cb52855f4374a6ca077b349c7ceffd4_4"></div><hr style="page-break-after:always"><div style="min-height:35.28pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:11.25pt"><font><br></font></div><div style="padding-left:25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Annex A&#58; Terms and Conditions</font></div><div style="margin-top:5.95pt;padding-left:96.95pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.&#160;&#160;&#160;&#160;DEFINITIONS&#58;</font></div><div style="margin-top:5.95pt;padding-left:97.1pt;padding-right:19.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any business entity controlled by, controlling or under common control with, a Party. For clarity, for the purpose of this Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">1.1</a> only, &#8220;control&#8221;, &#8220;controlling&#8221; or &#8220;controlled&#8221; shall mean the ability to directly or indirectly control the management and&#47;or business of the other entity, whether through ownership of voting stock or the power to appoint a majority of the Party&#8217;s governing board, including, (a) direct or indirect, ownership of more than fifty percent (50%) of the shares of stock entitled to vote for the election of directors in the case of a corporation or more than fifty percent (50%) of the equity interest in the case of any other type of legal entity&#59; or (b) any other arrangement whereby the entity or person appoints or has the right to appoint (other than through the ownership of voting securities) a majority of the members of the board of directors or equivalent governing body of a corporation or other entity or has the ability to cause the direction of the management or policies of a corporation or other entity&#59; provided, however, in the case of this clause (b), no person or entity will be deemed to be an Affiliate of such business entity solely by virtue of such person&#8217;s or entity&#8217;s direct or indirect ownership of any securities of such business entity. CEPI&#8217;s &#8220;Affiliates&#8221; as of the Effective Date are listed in Annex L.</font></div><div style="margin-top:5.95pt;padding-left:97.15pt;padding-right:19.95pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">1.2&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:118%">Agreement Summary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">&#8221; means the signature page that identifies the Parties and to which this <a href="#i4cb52855f4374a6ca077b349c7ceffd4_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%;text-decoration:none">Annex A</a> and other annexes are attached.</font></div><div style="margin-top:5.5pt;padding-left:97.15pt;padding-right:19.85pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">1.3&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:118%">Annual Net Income</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">&#8221; means the total Net Income received by the Partners in a particular Calendar Year.</font></div><div style="margin-top:5.5pt;padding-left:97.15pt;padding-right:20pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.4&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Annual Net Sales</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the total Net Sales received by the Partners in a particular Calendar Year.</font></div><div style="margin-top:6.15pt;padding-left:96.95pt;text-align:justify;text-indent:-35.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.5&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Assessors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning described in Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">11.1</a>.</font></div><div style="margin-top:5.85pt;padding-left:97.15pt;padding-right:19.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.6&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Background Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; (or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Background IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) means any and all Intellectual Property&#58; (a) necessary for completion of the Project, or (b) for the purposes of the Public Health Licence only, that has been used or incorporated, or is used or incorporated by Barinthus Bio or its Affiliates at the time that the Public Health Licence is triggered pursuant to Clause 14.6, in the development or commercialisation of the Project Vaccine, in each case ((a) and (b)) that is owned or controlled by either Partner during the Term of this Agreement that is&#58; (i) in existence as of the Effective Date, or (ii) later developed, acquired or in-licensed independently of the Project. For clarity, Background IP includes commercial freedom-to-operate licenses obtained by either Partner.</font></div><div style="margin-top:6.1pt;padding-left:96.95pt;text-align:justify;text-indent:-35.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.7&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Barinthus Bio Licence Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set out in Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">14.9</a>.</font></div><div style="margin-top:5.95pt;padding-left:97.15pt;padding-right:19.85pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.8&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Budget</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the schedule of funds identified in Annex D to be paid by CEPI to each of the Partners for the Project activities in the Work Package(s), as may be amended from time to time by the written agreement of the Parties.</font></div><div style="margin-top:5.95pt;padding-left:97.15pt;padding-right:19.85pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">1.9&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:117%">Business Days</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">&#8221; means any day, other than (a) a Saturday or Sunday&#59; and (b) any public holiday in London, England, Washington DC in the United States of America, or Oslo, Norway.</font></div><div style="margin-top:5.6pt;padding-left:96.95pt;text-align:justify;text-indent:-35.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.10&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Calendar Year</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means each respective period of twelve (12) consecutive months</font></div><div style="margin-top:4pt"><font><br></font></div><div style="padding-left:6.85pt;padding-right:6.85pt;text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:41.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.706%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sensitivity&#58; Official Use</font></div></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">           4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:35.28pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="margin-top:11.1pt"><font><br></font></div><div style="padding-left:97.15pt;padding-right:19.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">ending on December 31. For the avoidance of doubt, the first Calendar Year shall commence on the Effective Date, and the final Calendar Year shall end on the effective date of the expiration or termination of this Agreement.</font></div><div style="margin-top:5.75pt;padding-left:96.95pt;text-align:justify;text-indent:-35.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.11&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CEPI Indemnitees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning described in Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">17.2.1.</a></font></div><div style="margin-top:5.95pt;padding-left:97.15pt;padding-right:19.8pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.12&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CEPI Service Provider</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a third party contracted and funded directly by CEPI, which CEPI, at its discretion, may make available to one or more of the Partners to support its activities under the Project.</font></div><div style="margin-top:5.95pt;padding-left:97.2pt;padding-right:19.8pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">1.13&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:117%">Commercial Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">&#8221; means any economically quantifiable benefits that arise from&#58; (i) the exploitation of the Project Vaccine, or (ii) the exploitation of the Project Intellectual Property or Project Results.</font></div><div style="margin-top:5.7pt;padding-left:96.95pt;text-align:justify;text-indent:-35.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.14&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning described in Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">18.1.</a></font></div><div style="margin-top:5.85pt;padding-left:97.15pt;padding-right:19.85pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.15&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Cost Guidance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means CEPI&#8217;s explanatory document regarding eligible direct and indirect costs, non-eligible costs, and valuation of in-kind contributions, as further described in Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">12.2</a> and attached hereto as Annex I.</font></div><div style="margin-top:6.2pt;padding-left:96.95pt;text-align:justify;text-indent:-35.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.16&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Cost of Goods</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; (or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">COGs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) has the meaning set forth on Annex H.</font></div><div style="margin-top:5.85pt;padding-left:97.15pt;padding-right:19.8pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.17&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Cover</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to a product, process, method, or service, that a Valid Claim would, absent a license thereunder, be infringed by the research, development, making, using, sale, offering for sale, importation, or other exploitation of such product, process, method, or service.</font></div><div style="margin-top:6.15pt;padding-left:96.95pt;text-align:justify;text-indent:-35.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.18&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">DSMB</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning described in Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">7.5.2.</a></font></div><div style="margin-top:5.85pt;padding-left:97.15pt;padding-right:19.8pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.19&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Enabling Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to a Partner, such Partner&#8217;s Background IP and improvements thereto, Project IP and Project Results that could be asserted by the applicable Partner to block CEPI from exercising its rights under Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">14.6</a> of this Agreement. For the purposes of this Agreement, &#8216;Enabling Rights&#8217; also includes the contractual rights under contracts executed for the Project that control the use of such items, for example, in material transfer agreements.</font></div><div style="margin-top:6.05pt;padding-left:97.15pt;padding-right:19.85pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.20&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Equitable Access</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the principle that appropriate vaccines are first available to populations when and where they are needed to end an Outbreak or curtail an epidemic or pandemic, regardless of ability to pay, in accordance with CEPI&#8217;s Equitable Access Policy, the terms of Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">14</a> and the Equitable Access Plan.</font></div><div style="margin-top:6.05pt;padding-left:97pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.21&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Equitable Access Group</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the group established in accordance with Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">14.3.</a></font></div><div style="margin-top:6.05pt;padding-left:97pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.22&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Equitable Access Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning described in Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">14.2.</a></font></div><div style="margin-top:5.95pt;padding-left:97pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.23&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Financial Irregularity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning described in Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">19.4.6.</a></font></div><div style="margin-top:5.95pt;padding-left:97pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.24&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Financial Report</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning described in Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">3.11.</a></font></div><div style="margin-top:6pt;padding-left:97.15pt;padding-right:19.85pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.25&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">First Commercial Sale</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the first sale or supply of a Project Vaccine by either Partner or any of its Affiliates or its or their licensees or sublicensees for monetary value.</font></div><div style="margin-top:6.1pt;padding-left:97pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.26&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Force Majeure Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning described in Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">21.8.</a></font></div><div style="margin-top:5.85pt;padding-left:97.15pt;padding-right:19.85pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.27&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">GMP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means Good Manufacturing Practice as set forth in the ICH Good Manufacturing Guide for Active Pharmaceutical Ingredients Guideline Q7, as adopted by CPMP November 2000 as CPMP&#47;ICH&#47;4106&#47;00, as amended, or analogous standards utilised by</font></div><div style="margin-top:5.9pt"><font><br></font></div><div style="padding-left:6.85pt;padding-right:6.85pt;text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:41.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.706%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sensitivity&#58; Official Use</font></div></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">           5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:35.28pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="margin-top:11.1pt"><font><br></font></div><div style="padding-left:97.15pt;padding-right:19.9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">the relevant Regulatory Authority, or the equivalent applicable laws and regulations as required for the manufacturing of the Project Vaccine in the country of manufacture.</font></div><div style="margin-top:6.05pt;padding-left:97.15pt;padding-right:19.85pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.28&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">HICs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Higher Income Countries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the countries identified as such in Part 2 of Annex F.</font></div><div style="margin-top:6pt;padding-left:97.15pt;padding-right:19.8pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.29&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Increased Outbreak Preparation Need</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means when, having considered the reasonably accessible and relevant information including epidemiological data, travel and migration patterns and the likely availability of other products or product candidates, CEPI determines, acting reasonably following consultation with experts (for example a sub-group or subcommittee of CEPI&#8217;s Scientific Advisory Committee that CEPI determines has appropriate expertise), that, as evidenced by an increase in the number of actual cases of MERS being reported, there is a heightened need for the Project Vaccine to address potential Outbreaks.</font></div><div style="margin-top:6.1pt;padding-left:96.95pt;text-align:justify;text-indent:-35.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.30&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Initial Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning described in Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">19.1.</a></font></div><div style="margin-top:5.85pt;padding-left:97.15pt;padding-right:19.8pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">1.31&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:117%">Integrated Product Development Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">&#8221; (or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:117%">iPDP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">&#8221;) means the planning document setting out details of the various activities associated with the Project Vaccine described in the Work Package(s). The initial iPDP and Work Packages in support of such iPDP to which the Parties have mutually agreed are set forth in Annex C.</font></div><div style="margin-top:5.5pt;padding-left:97.15pt;padding-right:19.8pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.32&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means&#58; (a) inventions, patents, utility models, and rights in the foregoing&#59; (b) trade marks, trade names, geographical indications and appellations of origin, rights under the law of passing off, unfair competition and equivalents&#59; (c) copyright, rights in software, rights in performances and in recordings, moral rights, and database rights&#59; (d) designs, design patents, registered and unregistered designs and design rights&#59; (e) confidential information, trade secrets and rights under the law of breach of confidence and equivalents&#59; and all other intellectual property rights of any kind however designated that may subsist anywhere in the world whether arising by operation of law, treaty, contract, conduct or otherwise, together with all registrations, applications, rights to priority, renewals, extensions, continuations, divisions or reissues thereof and all rights to bring action for infringement past, present and future.</font></div><div style="margin-top:5.95pt;padding-left:97.15pt;padding-right:19.85pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">1.33&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:118%">Joint Monitoring and Advisory Group</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:118%">JMAG</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">&#8221; has the meaning described in Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%;text-decoration:none">2.4.</a></font></div><div style="margin-top:5.55pt;padding-left:97.15pt;padding-right:19.9pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.34&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">LMIC or UMIC Recipients</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any purchasers procuring in, or on behalf of, LMICs and&#47;or UMICs (whether Gavi, UNICEF, CEPI, the World Health Organisation, their respective designees, funding or procurement mechanisms, governments, non-public purchasers, non-governmental organisations or any other third party for the purpose of supply only within LMICs and UMICs).</font></div><div style="margin-top:5.95pt;padding-left:97.15pt;padding-right:19.9pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">1.35&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:118%">LMICs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:118%">Low and Middle Income Countries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">&#8221; means the countries identified as such in Part 3 of Annex F.</font></div><div style="margin-top:5.55pt;padding-left:97.15pt;padding-right:19.9pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.36&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Net Income</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means &#91;***&#93;.</font></div><div style="margin-top:6.05pt;padding-left:97.15pt;padding-right:19.85pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.37&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Net Revenue</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means &#91;***&#93;</font></div><div style="margin-top:5.95pt;padding-left:97.1pt;padding-right:19.9pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">1.38&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:117%">Net Sales</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">&#8221; means &#91;***&#93;.</font></div><div style="margin-top:5.95pt;padding-left:97.15pt;padding-right:19.9pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">1.39&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:117%">Outbreak</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">&#8221; means a Public Health Emergency of International Concern declared by WHO, or a public health emergency on a national or regional scale declared by one or more public health agencies, with respect to Middle East respiratory syndrome (MERS) including any regional outbreak, an epidemic or a pandemic.</font></div><div style="margin-top:5.55pt;padding-left:97.15pt;padding-right:19.9pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.40&#160;&#160;&#160;&#160;&#91;***</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#93;</font></div><div style="margin-top:6.05pt;padding-left:97.15pt;padding-right:19.85pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">1.41&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:117%">Project</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">&#8221; means the activities under the Work Package(s), as described therein and in the Budget, to be performed under this Agreement by or on behalf of the Partners and&#47;or any Subawardee.</font></div><div style="margin-top:5.7pt;padding-left:96.95pt;text-align:justify;text-indent:-35.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.42&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Project Clinical Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning described in Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">7.1</a></font></div><div style="height:41.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.706%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sensitivity&#58; Official Use</font></div></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">           6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:35.28pt;width:100%"><div><font><br></font></div></div><div style="margin-top:5.85pt;padding-left:97.15pt;padding-right:19.85pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.43&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Project Clinical Trial Material</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the clinical trial material consisting of quantities of Project Vaccine described in a Work Package(s) and manufactured by or on behalf a Partner using the funding to be provided by CEPI under any Work Package.</font></div><div style="margin-top:6.2pt;padding-left:96.95pt;text-align:justify;text-indent:-35.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.44&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Project Continuity Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning described in Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">2.3.1.</a></font></div><div style="margin-top:6pt;padding-left:97.15pt;padding-right:19.8pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.45&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Project Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means pre-clinical or clinical trial data generated by or on behalf of a Partner under any Work Package, including any such data with respect to negative results, model animal deaths and any toxicology study results. For clarity, Project Data shall not include any Chemistry, Manufacturing and Controls (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CMC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) or other manufacturing- related information or data.</font></div><div style="margin-top:6pt;padding-left:97.15pt;padding-right:19.85pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">1.46&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:117%">Project Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">&#8221; (or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:117%">Project IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">&#8221;) means the Intellectual Property conceived, invented or made by or on behalf of any Partner (whether solely or jointly) and&#47;or any Subawardee in the performance of the Project.</font></div><div style="margin-top:5.6pt;padding-left:97.15pt;padding-right:19.8pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.47&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Project Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means biological samples or, if applicable, animal models that are controlled by a Partner and are generated by or on behalf of Partner under any Work Package.</font></div><div style="margin-top:6pt;padding-left:97.15pt;padding-right:19.7pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.48&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Project Results</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the Project Materials, Project Data and Technical Reports that are generated by or on behalf of a Partner and&#47;or any Subawardee under the Project, including with respect to results of assays necessary for Project Clinical Trial Material manufacturing in support of such manufacturing by or on behalf of a Partner and&#47;or any Subawardee under the Project, whether in whole or in components or serum samples collected. For clarity, Project Results does not include Project Clinical Trial Materials.</font></div><div style="margin-top:6.05pt;padding-left:97.15pt;padding-right:19.9pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">1.49&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:117%">Project Vaccine</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">&#8221; means the ChAdOx1 MERS (Middle Eastern Respiratory Syndrome) vaccine candidate, which induces a specific immune response against at least one MERS- CoV antigen for prophylactic use against MERS.</font></div><div style="margin-top:5.6pt;padding-left:97.15pt;padding-right:20.05pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">1.50&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:118%">PRV Proceeds</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">&#8221; means amounts received by Barinthus Bio or any of its Affiliates from the sale of any priority review voucher relating to the Project Vaccine.</font></div><div style="margin-top:5.65pt;padding-left:96.95pt;text-align:justify;text-indent:-35.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.51&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Public Health License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning described in Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">14.6</a>.</font></div><div style="margin-top:5.8pt;padding-left:97.15pt;padding-right:20pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">1.52&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:118%">Ready Reserve of Project Clinical Trial Material</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">&#8221; has the meaning described in Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%;text-decoration:none">13.1.2</a>.</font></div><div style="margin-top:5.5pt;padding-left:97.15pt;padding-right:19.8pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.53&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Regulatory Approval</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, on an indication-by-indication and country-by-country basis, all approvals, licenses and authorizations of the applicable Regulatory Authority necessary for the marketing and sale of a pharmaceutical or biological product for a particular indication and a particular country, and, as applicable, including the approvals by the applicable Regulatory Authority of any expansion or modification of the label for such indication. For clarity&#58; (a) Regulatory Approval shall not be deemed to occur with respect to an indication and a country until all approvals, licenses and authorizations of the applicable Regulatory Authority necessary to lawfully market and sell a pharmaceutical or biological product for such indication in such country have been obtained, and (b) any emergency use authorization issued by a Regulatory Authority shall be deemed a Regulatory Approval if sufficient to lawfully market and sell a pharmaceutical or biological product for the applicable country and indication. WHO Emergency Use Listing or Prequalification is considered a Regulatory Approval, if it is required to allow product distribution in the country(ies) of interest.</font></div><div style="margin-top:6.05pt;padding-left:97.15pt;padding-right:19.85pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.54&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Regulatory Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any national or supranational governmental authority, including, as applicable, the FDA, the EMA, the MHRA or any health regulatory authority in any country or region that is a counterpart to the foregoing agencies, in each case, that holds the right to grant Regulatory Approval for a pharmaceutical or biological product in such country or region.</font></div><div style="margin-top:3.3pt"><font><br></font></div><div style="height:41.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.706%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sensitivity&#58; Official Use</font></div></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">           7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:35.28pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="margin-top:11.1pt"><font><br></font></div><div style="padding-left:97.15pt;padding-right:19.75pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.55&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Regulatory Exclusivity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to any country or multi-country jurisdiction, an additional market protection, other than patent protection, granted by a Regulatory Authority in such country which confers on Barinthus Bio, its Affiliates or sublicensees the exclusive right, either through data exclusivity or market exclusivity, to market and sell a Project Vaccine in such country or multi-country jurisdiction and which prevents the Regulatory Approval of any Third Party pharmaceutical or biologic product containing the same or similar active pharmaceutical ingredient as contained in such Project Vaccine (e.g., new biologic entity exclusivity, new chemical entity exclusivity, new use or indication exclusivity, new formulation exclusivity, orphan drug exclusivity, new patient population exclusivity, pediatric exclusivity, or any applicable data or marketing exclusivity).</font></div><div style="margin-top:6.1pt;padding-left:96.95pt;text-align:justify;text-indent:-35.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.56&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Restricted Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a person that is&#58;</font></div><div style="margin-top:5.95pt;padding-left:133pt;padding-right:19.75pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.56.1&#160;&#160;&#160;&#160;listed on any Sanctions List or targeted by Sanctions (whether designated by name or by reason of being included in a class of persons)&#59;</font></div><div style="margin-top:6pt;padding-left:133pt;padding-right:19.9pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.56.2&#160;&#160;&#160;&#160;located in or incorporated under the laws of any country or territory that is the target of country- or territory-wide Sanctions&#59; or</font></div><div style="margin-top:6pt;padding-left:133pt;padding-right:19.75pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.56.3&#160;&#160;&#160;&#160;directly or indirectly owned or controlled by, or acting on behalf, at the direction, or for the benefit of, a person referred to in (a) and&#47;or (to the extent relevant under Sanctions) (b) above.</font></div><div style="margin-top:6pt;padding-left:97.15pt;padding-right:19.95pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.57&#160;&#160;&#160;&#160;&#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Royalty Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, on a Project Vaccine-by-Project Vaccine and country-by- country basis, the period starting on the Effective Date and ending on the later of&#58;</font></div><div style="margin-top:6pt;padding-left:133.05pt;padding-right:19.9pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.57.1&#160;&#160;&#160;&#160;the expiration of the last Valid Claim of a patent included in the Project Intellectual Property which Covers such Project Vaccine in such country of sale&#59;</font></div><div style="margin-top:5.9pt;padding-left:133pt;padding-right:19.95pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">1.57.2&#160;&#160;&#160;&#160;expiry of Regulatory Exclusivity for such Project Vaccine in such country of sale&#59; and</font></div><div style="margin-top:5.65pt;padding-left:132.9pt;text-indent:-35.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.57.3&#160;&#160;&#160;&#160;the tenth (10th) anniversary of the First Commercial Sale.</font></div><div style="margin-top:5.95pt;padding-left:97.15pt;padding-right:19.8pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.58&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Sanctions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any applicable (to any Party) laws, regulations or orders concerning any trade, economic or financial sanctions or embargoes.</font></div><div style="margin-top:5.9pt;padding-left:97.15pt;padding-right:19.8pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.59&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Sanctions Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the Norwegian State, the United Nations, the European Union, the Member States of the European Union, the United Kingdom, the United States of America, Canada, Australia, and any authority acting on behalf of any of them or their respective legislative, executive, enforcement and&#47;or regulatory authorities or bodies acting in connection with Sanctions.</font></div><div style="margin-top:6.15pt;padding-left:96.95pt;text-align:justify;text-indent:-35.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.60&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Sanctions List</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means&#58;</font></div><div style="margin-top:5.95pt;padding-left:133pt;padding-right:19.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.60.1&#160;&#160;&#160;&#160;the lists of Sanctions designations and&#47;or targets maintained by any Sanctions Authority&#59; and&#47;or</font></div><div style="margin-top:6pt;padding-left:133pt;padding-right:19.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.60.2&#160;&#160;&#160;&#160;any other Sanctions designation or target listed and&#47;or adopted by a Sanctions Authority,</font></div><div style="margin-top:6pt;padding-left:97.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">in all cases, as amended, supplemented or replaced from time to time.</font></div><div style="margin-top:5.95pt;padding-left:97.15pt;padding-right:19.85pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.61&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Selected Manufacturer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means an LMIC-based manufacturer within CEPI&#8217;s list of preferred manufacturers and which is either (i) agreed with the Partners under the iPDP</font></div><div style="margin-top:5.25pt"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:41.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.706%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sensitivity&#58; Official Use</font></div></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">           8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:35.28pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="margin-top:11.25pt"><font><br></font></div><div style="padding-left:97.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">or (ii) otherwise agreed between CEPI and the relevant Partner(s).</font></div><div style="margin-top:5.95pt;padding-left:97pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.62&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Selling Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set out in Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">15.1.4.</a></font></div><div style="margin-top:5.95pt;padding-left:97.15pt;padding-right:19.8pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.63&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Stage Gate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a mutually agreed &#8220;go&#47;no go&#8221; decision point to continue a given Work Package or to commence activities in another Work Package.</font></div><div style="margin-top:6.15pt;padding-left:97pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.64&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Stage Gate Deadline</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set out in Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">2.2</a>.</font></div><div style="margin-top:5.95pt;padding-left:97pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.65&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Stage Gate Review Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning described in Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">2.6.</a></font></div><div style="margin-top:5.8pt;padding-left:97.15pt;padding-right:19.85pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.66&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Subawardee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a third party that is contracted by a Partner and receives CEPI funds from such Partner to perform activities or provide support under the Project. For clarity, Subawardees includes &#8220;Sub-Contractors&#8221;.</font></div><div style="margin-top:6.25pt;padding-left:96.95pt;text-align:justify;text-indent:-35.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.67&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Sub-Contractors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set out in Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">3.2.</a></font></div><div style="margin-top:5.95pt;padding-left:96.95pt;text-align:justify;text-indent:-35.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.68&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Team Charter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the team charter set out in Annex B.</font></div><div style="margin-top:5.95pt;padding-left:96.95pt;text-align:justify;text-indent:-35.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.69&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Technical Report(s)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning described in Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">2.5.</a></font></div><div style="margin-top:6.05pt;padding-left:96.95pt;text-align:justify;text-indent:-35.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.70&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning described in Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">19.1.</a></font></div><div style="margin-top:5.85pt;padding-left:97.15pt;padding-right:19.75pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.71&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Third Party Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; (or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) means the consolidated statement of CEPI&#8217;s values and of the policies, practices and principles described in Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">12.2</a> and attached hereto in Annex I.</font></div><div style="margin-top:6.05pt;padding-left:97.15pt;padding-right:19.85pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.72&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Third Party Code Declaration Letter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the declaration letter dated 19th February 2021 and attached hereto in Annex I.</font></div><div style="margin-top:5.95pt;padding-left:97.15pt;padding-right:19.85pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.73&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Transparency and Confidentiality Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the statement of CEPI&#8217;s standards regarding transparency with the public, Regulatory Authorities, CEPI&#8217;s funders and others as attached hereto as Annex I, part 4.</font></div><div style="margin-top:6.2pt;padding-left:96.95pt;text-align:justify;text-indent:-35.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.74&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Trial Steering Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">TSC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning described in Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">7.5.2.</a></font></div><div style="margin-top:5.95pt;padding-left:96.95pt;text-align:justify;text-indent:-35.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.75&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Trusted Collaborator</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning defined in Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">4.3.1</a>.</font></div><div style="margin-top:5.8pt;padding-left:97.15pt;padding-right:19.9pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">1.76&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:118%">UMICs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:118%">Upper- and Middle-Income Countries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">&#8221; means the countries identified in Part 1 of Annex F.</font></div><div style="margin-top:5.55pt;padding-left:97.15pt;padding-right:19.85pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.77&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Valid Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a claim of an issued and unexpired patent which has not lapsed or been revoked, abandoned or held unenforceable or invalid by a final decision of a court or governmental or supra-governmental agency of competent jurisdiction, unappealable or unappealed within the time allowed for appeal, and which has not been disclaimed, denied or admitted to be invalid or unenforceable through reissue, reexamination or disclaimer or otherwise.</font></div><div style="margin-top:6.05pt;padding-left:97.15pt;padding-right:19.85pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.78&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Work Package(s)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a discrete set of Project activities agreed by the Parties from time to time.</font></div><div><font><br></font></div><div style="margin-top:8.8pt"><font><br></font></div><div style="padding-left:96.95pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.&#160;&#160;&#160;&#160;PROJECT ORGANISATION AND MANAGEMENT</font></div><div style="margin-top:5.85pt;padding-left:97.15pt;padding-right:19.9pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Team Charter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Project shall be managed by the Parties under the oversight of the Parties&#8217; designated representatives as described in the Team Charter in Annex B.</font></div><div><font><br></font></div><div style="margin-top:3.85pt"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:41.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.706%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sensitivity&#58; Official Use</font></div></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">           9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:35.28pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="margin-top:11.1pt"><font><br></font></div><div style="padding-left:97.15pt;padding-right:19.7pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Work Packages</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Each Partner shall undertake its obligations under the Project, including using reasonable endeavours to achieve the deliverables, milestones and timelines of each Work Package and to achieve each Stage Gate by the agreed deadline (each a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Stage Gate Deadline</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), it being understood that a Party cannot assure a positive technical outcome or timeline for any Work Package. The Project is organised into one or more Work Packages and each Work Package has an associated budget as set out in the Budget. Each Partner shall use all reasonable endeavours to pursue and perform its obligations under each Work Package in accordance with the Budget. CEPI will pay each Partner in accordance with the Budget and, where applicable, upon completion of a Stage Gate (as determined pursuant to Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">2.6</a>). Additional Work Package(s) may be agreed in writing by the Parties after the Effective Date, which, upon execution by all Parties, shall be annexed to and become a part of this Agreement. Work Packages may be modified or extended with the mutual written consent of all Parties in accordance with Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">21.6.</a></font></div><div style="margin-top:6.1pt;padding-left:96.95pt;text-align:justify;text-indent:-35.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Project Continuity Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:5.95pt;padding-left:133pt;padding-right:19.9pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.3.1&#160;&#160;&#160;&#160;The iPDP shall include the following in order to address continuity of the Project in the event either or both Partners becomes unable to continue its activities under this Agreement and must delegate certain activities to another Party or third party (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Project Continuity Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)&#58;</font></div><div style="margin-top:5.95pt;padding-left:169pt;padding-right:19.8pt;text-align:justify;text-indent:-35.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">(i)&#160;&#160;&#160;&#160;responsibilities and level of access on the part of other collaborators, Sub- Contractors and consortium members, if any, to Project Results&#59;</font></div><div style="margin-top:5.5pt;padding-left:169pt;padding-right:19.9pt;text-align:justify;text-indent:-35.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">(ii)&#160;&#160;&#160;&#160;management of key Project Materials through participants in the Project and other entities&#59;</font></div><div style="margin-top:5.5pt;padding-left:169pt;padding-right:19.75pt;text-align:justify;text-indent:-35.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;the identification of a proposed third party for each Partner, for example, a Sub-Contractor, that will, with the prior written approval of CEPI, be contracted by such Partner and will be capable of performing such Partner&#8217;s material or critical activities in the agreed Work Packages in geographically diverse locations, in the event that such Partner is unable to continue its activities under this Agreement or declines CEPI&#8217;s request to undertake additional Work Packages&#59; and</font></div><div style="margin-top:6.05pt;padding-left:169pt;padding-right:19.7pt;text-align:justify;text-indent:-35.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">(iv)&#160;&#160;&#160;&#160;a preliminary identification of one or more Selected Manufacturers for technology transfer in the event of an Outbreak or Increased Outbreak Preparation Need in accordance with Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%;text-decoration:none">4.2</a>.</font></div><div style="margin-top:5.55pt;padding-left:132.9pt;text-align:justify;text-indent:-35.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">2.3.2&#160;&#160;&#160;&#160;Such Project Continuity Plan shall be agreed between the Parties within &#91;***&#93; of the Effective Date and, once agreed, shall be incorporated into the iPDP by reference.</font></div><div style="margin-top:5.5pt;padding-left:97pt;padding-right:19.85pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Joint Monitoring and Advisory Group</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Promptly following the Effective Date, the Parties will establish a joint monitoring and advisory group (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">JMAG</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) that shall meet regularly as specified in the applicable Team Charter to monitor progress of and advance the Project. The JMAG shall coordinate the efforts of CEPI and the Partners, with respect to the following activities for each Work Package (in addition to the responsibilities set out in the applicable Team Charter)&#58;</font></div><div style="margin-top:6.2pt;padding-left:132.95pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.4.1&#160;&#160;&#160;&#160;facilitate communications between the Parties&#59;</font></div><div style="margin-top:5.85pt;padding-left:133.05pt;text-align:justify;text-indent:-35.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.4.2&#160;&#160;&#160;&#160;monitor the performance and technical content of each Work Package against the</font></div><div style="margin-top:9.95pt"><font><br></font></div><div style="padding-left:6.85pt;padding-right:6.85pt;text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:41.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.706%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sensitivity&#58; Official Use</font></div></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">           10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:35.28pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="margin-top:11.1pt"><font><br></font></div><div style="padding-left:133.15pt;padding-right:19.9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">milestones and their dates, and critically assess the results on an on-going basis to identify and address any weaknesses or delays in any Work Package&#59;</font></div><div style="margin-top:6.05pt;padding-left:133.15pt;padding-right:19.85pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">2.4.3&#160;&#160;&#160;&#160;approve the achievement of milestones (but the JMAG shall not have the right to approve final Project completion or confirm completion of Stage Gates, which shall be subject to the provisions of Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%;text-decoration:none">2.6</a>)&#59;</font></div><div style="margin-top:5.6pt;padding-left:133.15pt;padding-right:19.9pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.4.4&#160;&#160;&#160;&#160;provide a forum for discussion as to whether the activities currently agreed to are sufficient to satisfy CEPI&#8217;s mission&#59;</font></div><div style="margin-top:6pt;padding-left:133.15pt;padding-right:19.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.4.5&#160;&#160;&#160;&#160;have the authority to approve extensions to Work Package timelines up to ten (10) percent of the originally planned timeframe as set out in the relevant Work Package, provided that each such extension is at no cost to CEPI and does not impact the overall completion date of the Project&#59;</font></div><div style="margin-top:5.95pt;padding-left:133.15pt;padding-right:19.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">2.4.6&#160;&#160;&#160;&#160;have the authority to approve transfer of funds between cost categories within a Budget, to the extent that any such changes are cost neutral&#59;</font></div><div style="margin-top:5.5pt;padding-left:133.15pt;padding-right:19.95pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">2.4.7&#160;&#160;&#160;&#160;review and approve proposed changes and updates to the iPDP including, but not limited to, the Project Continuity Plan&#59;</font></div><div style="margin-top:5.5pt;padding-left:133.15pt;padding-right:19.8pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">2.4.8&#160;&#160;&#160;&#160;review and discuss pre-clinical and clinical trial protocols, including CMC development study protocols, and any substantial changes&#59;</font></div><div style="margin-top:5.55pt;padding-left:133.15pt;padding-right:19.9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.4.9&#160;&#160;&#160;&#160;review and approve the regulatory strategy for the use of the Project Vaccine and receive regular updates on regulatory filings and submissions&#59;</font></div><div style="margin-top:6pt;padding-left:133.15pt;padding-right:19.9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.4.10&#160;&#160;&#160;&#160;review the contractual and operational status and capabilities of Trusted Collaborator(s)&#59;</font></div><div style="margin-top:6.15pt;padding-left:133.05pt;text-indent:-35.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.4.11&#160;&#160;&#160;&#160;review and discuss publications&#59;</font></div><div style="margin-top:5.8pt;padding-left:133.15pt;padding-right:19.9pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">2.4.12&#160;&#160;&#160;&#160;discuss each Partner&#8217;s willingness to share any Project Results with any other CEPI awardees, such sharing of Project Results not to occur without the agreement of the Parties, unless otherwise agreed in a Work Package&#59;</font></div><div style="margin-top:5.6pt;padding-left:133.15pt;padding-right:19.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.4.13&#160;&#160;&#160;&#160;review and update the Equitable Access Plan (until the Equitable Access Group is established in accordance with Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">14.3</a> in which case this will become a function of the Equitable Access Group)&#59;</font></div><div style="margin-top:6pt;padding-left:133.15pt;padding-right:19.85pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">2.4.14&#160;&#160;&#160;&#160;discuss plans, as appropriate, for the development and manufacturing of the Project Vaccine and their scale-up and scale-out&#59;</font></div><div style="margin-top:5.5pt;padding-left:133.15pt;padding-right:19.9pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">2.4.15&#160;&#160;&#160;&#160;approve the Technical Reports and Project Results made available by a Partner pursuant to Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%;text-decoration:none">2.5</a>&#59;</font></div><div style="margin-top:5.65pt;padding-left:133.05pt;text-align:justify;text-indent:-35.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.4.16&#160;&#160;&#160;&#160;review any reports and updates provided by any site visit groups&#59;</font></div><div style="margin-top:5.8pt;padding-left:133.15pt;padding-right:19.85pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.4.17&#160;&#160;&#160;&#160;keep CEPI updated on any progress with regard to the SPV, including plans for it to be established, funded, its proposed remit, any funding sources it may benefit from, the associated business case and any other relevant details&#59;</font></div><div style="margin-top:6.1pt;padding-left:133.15pt;padding-right:19.85pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.4.18&#160;&#160;&#160;&#160;provide a forum for coordinating the Parties&#8217; responses to issues with respect to the Project Vaccine, to the extent relating to CEPI&#8217;s use, including unexpected disruptions to the supply of the Project Vaccine, recalls, safety issues or withdrawals of the Project Vaccine&#59;</font></div><div style="margin-top:11.9pt"><font><br></font></div><div style="padding-left:6.85pt;padding-right:6.85pt;text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:41.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.706%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sensitivity&#58; Official Use</font></div></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">           11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:35.28pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="margin-top:11.25pt"><font><br></font></div><div style="padding-left:133.05pt;text-align:justify;text-indent:-35.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.4.19&#160;&#160;&#160;&#160;receive written notification of all Project Results&#59;</font></div><div style="margin-top:5.8pt;padding-left:133.15pt;padding-right:19.85pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.4.20&#160;&#160;&#160;&#160;discuss (i) any further cooperation of the Parties as further set forth in Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">4.1</a> and Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">4.3</a>, and (ii) any collaboration in the event of an Outbreak as further set forth in Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">4.2</a>&#59; and</font></div><div style="margin-top:6.1pt;padding-left:133pt;padding-right:19.95pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.4.21&#160;&#160;&#160;&#160;discuss plans, as appropriate, for the development of manufacturing for the Project Vaccine, and its scale-up and scale-out.</font></div><div style="margin-top:6.05pt;padding-left:97pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The JMAG shall disband on completion of the Project.</font></div><div style="margin-top:5.95pt;padding-left:97.15pt;padding-right:19.75pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Technical Reports and Access to Project Results</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Each Partner shall disclose to CEPI&#8217;s Project Lead at JMAG meetings the Project Data that such Partner has been responsible for generating under the Project, and details of progress made under the Work Package(s) for such Project, in a form (including level of abstraction) reasonably acceptable to CEPI and the applicable Partner and consistent with applicable laws and regulations. Each Partner shall provide written reports of progress made under the Work Package(s) for such Project using the template provided by CEPI and attached hereto as Annex K (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Technical Reports</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) every &#91;***&#93; during the Term in which activities under such Project are occurring. In addition, each Partner shall make Project Data available to CEPI as designated in and required by the applicable Work Package or otherwise as may reasonably be requested by CEPI from time to time, in a form (including level of abstraction) reasonably acceptable to CEPI and the applicable Partner, and consistent with applicable laws and regulations. Technical Reports and such Project Data and Project Results disclosed or provided by a Partner under this Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">2.5</a> shall be such Partner&#8217;s Confidential Information.</font></div><div style="margin-top:5.95pt;padding-left:97.1pt;padding-right:19.75pt;text-align:justify;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Stage Gate Review</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Unless otherwise addressed in a Work Package for a given Stage Gate, when a Partner believes that a Stage Gate in a Work Package will be achieved in the near term, such Partner shall notify the JMAG promptly and provide relevant information (including the completion of a form provided by CEPI) and request a meeting of CEPI&#8217;s committee authorised to assess whether Stage Gates have been completed (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Stage Gate Review Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). Each Partner&#8217;s Project Lead shall coordinate with CEPI&#8217;s Project Lead to schedule a Stage Gate Review Committee meeting as early as possible, but generally no later than &#91;***&#93; before the planned meeting date. CEPI shall notify each Partner of the Stage Gate Review Committee&#8217;s decision as to whether such Stage Gate was completed as soon as possible, but generally no later than &#91;***&#93; after the meeting date. If the Stage Gate Review Committee, acting reasonably, determines that the Stage Gate was not completed by the Stage Gate Deadline, the relevant Partner shall have the right either to (i) &#91;***&#93; or (ii) &#91;***&#93;. If following &#91;***&#93;, CEPI reasonably determines that the Stage Gate has not been completed, then, without prejudice to the relevant Partner&#8217;s rights and remedies under this Agreement, including Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">20,</a> CEPI shall have the right to terminate this Agreement pursuant to Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">19.4.2.</a></font></div><div><font><br></font></div><div style="margin-top:2.05pt"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:41.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.706%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sensitivity&#58; Official Use</font></div></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">           12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:35.28pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:4.55pt"><font><br></font></div><div style="padding-left:97pt;text-indent:-36.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.&#160;&#160;&#160;&#160;USE OF FUNDS&#59; PROCUREMENT&#59; PROJECT RECORDS</font></div><div style="margin-top:5.95pt;padding-left:97.1pt;padding-right:19.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Use and Management of Funds</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Budget sets out the total funding to be provided by CEPI to each Partner for each Work Package. Each Partner shall use this funding only in accordance with the applicable Work Package and this Agreement unless otherwise agreed in writing by CEPI in advance, subject to any transfer of funds between cost categories as approved by the JMAG under Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">2.4.6.</a> Each Partner shall manage all funds provided to it hereunder for the Project (whether CEPI funds or funds provided by a third party) with financial controls and practices consistent with U.S. GAAP, IFRS or local GAAP, as applicable, and further in compliance with applicable laws and CEPI policies and procedures as described in Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">12</a> of this Agreement.</font></div><div style="margin-top:5.9pt;padding-left:97.15pt;padding-right:19.9pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Use of Sub-Contractors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Each Partner may use third party service providers and&#47;or Subawardees (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Sub-Contractors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) to undertake work pursuant to the Work Packages on its behalf, provided that any such Sub-Contractors are listed in Annex G or the applicable Work Package, and are listed in the iPDP and Budget. The use of any Sub-Contractors that are not included in Annex G or the applicable Work Package and the iPDP and Budget are subject to the applicable Partner providing notice in advance in writing to CEPI and CEPI&#8217;s prior written approval (such approval not to be unreasonably withheld, conditioned or delayed). The following terms shall apply to the engagement of any Sub-Contractors&#58;</font></div><div style="margin-top:6.1pt;padding-left:133pt;padding-right:19.85pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.2.1&#160;&#160;&#160;&#160;The applicable Partner shall select and oversee each Sub-Contractor in accordance with the terms of this Agreement.</font></div><div style="margin-top:6pt;padding-left:133pt;padding-right:19.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.2.2&#160;&#160;&#160;&#160;Each Partner shall notify CEPI promptly in writing if, to its knowledge, any Sub- Contractor is not in compliance with the warranties related to Sanctions as shall be included in the sub-contract or sub-grant pursuant to Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">3.2.3(vi).</a></font></div><div style="margin-top:6pt;padding-left:133pt;padding-right:19.7pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.2.3&#160;&#160;&#160;&#160;A Sub-Contractor must agree to comply with all of the relevant obligations applicable to the relevant Partner, whether explicitly defined as such or as is reasonable from the nature of the obligation. Each sub-agreement with a Sub- Contractor must&#58;</font></div><div style="margin-top:5.9pt;padding-left:169pt;padding-right:19.85pt;text-align:justify;text-indent:-35.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">(i)&#160;&#160;&#160;&#160;be consistent with the Work Package structure as well as the associated milestones and budgets&#59;</font></div><div style="margin-top:5.55pt;padding-left:169pt;padding-right:19.85pt;text-align:justify;text-indent:-35.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;require the same record keeping obligations and provide CEPI the same access (either directly or indirectly through the relevant Partner) to iPDP and Financial Reports (as are applicable to such Partner)&#59;</font></div><div style="margin-top:5.95pt;padding-left:169pt;padding-right:19.75pt;text-align:justify;text-indent:-35.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">(iii)&#160;&#160;&#160;&#160;require compliance with Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%;text-decoration:none">12.3</a> as if such Sub-Contractor were the applicable Partner for such purposes&#59;</font></div><div style="margin-top:5.5pt;padding-left:169pt;padding-right:19.75pt;text-align:justify;text-indent:-35.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iv)&#160;&#160;&#160;&#160;be consistent with the applicable Partner&#8217;s obligations under this Agreement including in relation to Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">4.2.2</a> (Technology Transfer in Event of Outbreak), Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">5</a> (Ownership of Project Results&#59; Intellectual Property), Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">10</a> (Dissemination of Project Results&#59; Publication) Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">14</a> (Equitable Access), Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">15</a> (Commercial Benefits), and Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">19</a> (Term and Termination)&#59;</font></div><div style="margin-top:6.1pt;padding-left:169pt;padding-right:19.9pt;text-align:justify;text-indent:-35.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(v)&#160;&#160;&#160;&#160;prohibit the Sub-Contractor from subcontracting its obligations, except to the extent that such subcontracted obligations have a corresponding cost</font></div><div style="margin-top:3.9pt"><font style="background-color:#e6e6e6;color:#2b569a;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15</font></div><div style="text-align:center"><font><br></font></div><div style="height:41.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.706%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sensitivity&#58; Official Use</font></div></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">           13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:35.28pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="margin-top:11.1pt"><font><br></font></div><div style="padding-left:168.95pt;padding-right:19.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">of &#91;***&#93; in any &#91;***&#93; period, when such subcontracting may be permitted provided that the applicable Partner notifies CEPI in writing in advance of such Sub- Contractor subcontracting its obligations and the contact details of the entity performing such obligations. In each case that the Sub-Contractor subcontracts any obligations under this Agreement it will use all reasonable endeavours to ensure that such subcontracted work is performed subject to the same obligations as those imposed on the Sub-</font></div><div style="margin-top:0.1pt;padding-left:169pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Contractor pursuant to this Agreement&#59; and</font></div><div style="margin-top:5.95pt;padding-left:169pt;padding-right:19.85pt;text-align:justify;text-indent:-35.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(vi)&#160;&#160;&#160;&#160;ensure that equivalent warranties related to Sanctions as contained in Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">16.1.9</a> and <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">16.1.10</a> of this Agreement, and the corresponding definitions, are incorporated into all sub-contracts and sub-grants entered into in connection with the performance of this Agreement.</font></div><div style="margin-top:5.95pt;padding-left:133pt;padding-right:19.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.2.4&#160;&#160;&#160;&#160;On request from CEPI, each Partner shall disclose to CEPI a copy of any applicable agreement executed with any Sub-Contractor, which agreement shall be Confidential Information of the disclosing Partner and shall not be disclosed to any person other than a CEPI employee, contractor, consultant or outside professional advisor, including legal counsel, with a need to know the contents of such disclosed agreement for the purposes of confirming compliance with this Agreement. The Partners shall have the right to reasonably redact any such agreements provided to CEPI, and may redact any terms or content that relates to any product or activities that are not the subject of the Project, it being understood that the Partners will not redact terms or content that CEPI reasonably requires to assess activities being performed under the subcontract with respect to the Project.</font></div><div style="margin-top:6pt;padding-left:133pt;padding-right:19.7pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.2.5&#160;&#160;&#160;&#160;If a Partner is using a Sub-Contractor to undertake work pursuant to a Work Package, the funding allocated for the Sub-Contractor will be consistent with the Budget, except to the extent such Partner elects to fund work by a Sub-Contractor other than through the use of funding under this Agreement. Each Partner shall be responsible for the acts and omissions of its Sub-Contractors that participate in the Project, as if such acts or omissions were the acts or omissions of such Partner under this Agreement.</font></div><div style="margin-top:6pt;padding-left:133pt;padding-right:19.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.2.6&#160;&#160;&#160;&#160;Each Partner shall notify CEPI promptly in writing if it determines that any Sub- Contractor is not in material compliance with such Sub-Contractor&#8217;s obligations under the applicable Sub-Contractor agreement in relation to work delegated to such Sub-Contractor under any Work Packages.</font></div><div style="margin-top:6.05pt;padding-left:97.15pt;padding-right:19.8pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CEPI Service Providers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. CEPI has entered into certain service agreements with CEPI Service Providers that have agreed to provide preferential charging to CEPI awardees. CEPI may make available various laboratory services or other support to one or more of the Partners provided by a CEPI Service Provider, for example, &#91;***&#93;. Each Partner agrees to utilise any CEPI Service Provider for the provision of services as may be, and solely if and to the extent, specified in a Work Package and agreed in writing between the Parties. Each Partner and the CEPI Service Provider may, at their own discretion, enter directly into an appropriate agreement between themselves setting out the terms on which the services will be provided. CEPI</font></div><div style="margin-top:2pt"><font><br></font></div><div style="height:41.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.706%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sensitivity&#58; Official Use</font></div></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">           14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:35.28pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="margin-top:11.1pt"><font><br></font></div><div style="padding-left:97.1pt;padding-right:19.95pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">shall, through the JMAG or otherwise, discuss with the applicable Partner protocols and data management related to any services provided by any CEPI Service Provider.</font></div><div style="margin-top:6.05pt;padding-left:97.15pt;padding-right:19.55pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Third Party Licences</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. It will be each Partner&#8217;s responsibility to ensure that it has obtained all necessary licences and consents to perform the Project. CEPI shall be entitled to retain funding or to condition any funding unless and until each Partner has reasonably satisfied CEPI that it has obtained all of the third party licences reasonably required to perform the Project and to supply the Project Vaccine. In the event that a Partner is bound by, or is to be bound by, certain obligations to any third party that holds IP rights necessary to develop and commercialize the Project Vaccine (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Third Party Collaborators</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), such Partner shall (i) notify CEPI in writing of the identity of such Third Party Collaborators as well as such Partner&#8217;s obligations in relation to them, (ii) use reasonable endeavours to facilitate the necessary arrangements between CEPI and Third Party Collaborators in the event the Public Health License is triggered under Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">14.7</a>, and (iii) use reasonable endeavours to secure all IP rights from Third Party Collaborators as required for a technology transfer under Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">4.2</a>.</font></div><div style="margin-top:5.95pt;padding-left:97.15pt;padding-right:19.65pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Payment to each Partner under this Agreement shall be made in U.S. dollars (US$) to each Partner&#8217;s bank account identified on the Agreement Summary or such other bank account as may otherwise be designated by such Partner in writing and agreed with CEPI, from time to time. CEPI shall make payments in tranches covering &#91;***&#93; periods as set out in the Budget, with each such payment intended to be made in advance of such &#91;***&#93; period. Each Partner shall be entitled to submit a payment request form to CEPI upon execution of this Agreement and thereafter at the same time as any relevant financial reporting. Tranches of funding for each payment request submitted under this Agreement in accordance with the Budget shall be paid by CEPI within &#91;***&#93; after receipt and approval by CEPI of all of the following&#58; (i) the payment request from the applicable Partner, (ii) any Technical Report due from such Partner at the time of the payment request&#59; and (iii) any Financial Report due from such Partner at the time of the payment request&#59; each to be submitted and duly completed using templates provided by CEPI. Payments may be adjusted by CEPI to reflect any underspend as well as any interest earned on unutilized funds as noted in the Financial Report. In the event that money is not required by a Partner for the next &#91;***&#93; period, such Partner shall provide the reconciliation showing that &#91;***&#93;.</font></div><div style="margin-top:6.1pt;padding-left:96.95pt;text-align:justify;text-indent:-35.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Delayed Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. CEPI may delay or condition a payment to a Partner if such Partner&#58;</font></div><div style="margin-top:5.95pt;padding-left:132.95pt;padding-right:19.85pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.6.1&#160;&#160;&#160;&#160;has not achieved a material milestone that it is required to achieve in accordance with the Work Package by the agreed time, unless such delay has been approved in writing by the JMAG in accordance with the Team Charter or otherwise by CEPI&#59;</font></div><div style="margin-top:5.9pt;padding-left:133pt;padding-right:19.9pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.6.2&#160;&#160;&#160;&#160;or any Sub-Contractors of such Partner are no longer in compliance with the representations and warranties in Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">16</a> at the time the payment tranche is requested&#59;</font></div><div style="margin-top:6.1pt;padding-left:133pt;padding-right:19.85pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.6.3&#160;&#160;&#160;&#160;has not reasonably completed the payment request form or submitted reasonably satisfactory Technical Reports and Financial Reports&#59;</font></div><div style="margin-top:6pt;padding-left:133pt;padding-right:19.85pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.6.4&#160;&#160;&#160;&#160;in CEPI&#8217;s reasonable belief, is unable to meet its financial commitments when due or is otherwise not in reasonable financial standing&#59; or</font></div><div style="margin-top:2.65pt"><font><br></font></div><div style="padding-left:6.85pt;padding-right:6.85pt;text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:41.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.706%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sensitivity&#58; Official Use</font></div></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">           15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:35.28pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="margin-top:11.1pt"><font><br></font></div><div style="padding-left:133pt;padding-right:19.85pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.6.5&#160;&#160;&#160;&#160;is subject to any Sanctions, or any payment under this Agreement would be in breach of any Sanctions.</font></div><div style="margin-top:6.05pt;padding-left:97.15pt;padding-right:19.7pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.7&#160;&#160;&#160;&#160;Subject to Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">19.4.5,</a> in the event that CEPI delays or conditions a payment in accordance with Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">3.6,</a> CEPI and the affected Partner shall work together in good faith to resolve any such impediments to payment and discuss any concerns raised by CEPI.</font></div><div style="margin-top:5.9pt;padding-left:97.2pt;padding-right:19.7pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">3.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:117%">Hold on Payment During a Material Breach</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">. CEPI is not obliged to pay any tranches of funding to a Partner for any Work Package for so long as that Partner is in material breach of this Agreement, unless such breach is cured within the cure period set forth in Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%;text-decoration:none">19.3.</a></font></div><div style="margin-top:5.55pt;padding-left:97.1pt;padding-right:19.85pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.9&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Retained Final Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. CEPI shall retain &#91;***&#93; of the payment tranche due to a Partner in respect of the final &#91;***&#93; of each Work Package and release it &#91;***&#93; after approving such Partner&#8217;s final Technical Report and Financial Report for the final Work Package in a particular Project. CEPI shall act reasonably and in good faith in approving each such final Technical Report and Financial Report and shall provide its approval, or raise any queries regarding, such reports within &#91;***&#93; after receiving them.</font></div><div style="margin-top:6pt;padding-left:97.15pt;padding-right:19.85pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.10&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Foreign Exchange</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Each Partner shall abide by the CEPI Foreign Exchange Policy, or a substantially similar policy with CEPI&#8217;s prior approval, for financial reporting and for budgeting purposes, including in relation to any Net Income, Net Sales or Net Revenue. Implementation of this policy shall remain consistent throughout the Project&#8217;s life cycle and shall not be changed to ensure consistency.</font></div><div style="margin-top:6pt;padding-left:97.15pt;padding-right:19.85pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.11&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Financial Reports</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Each Partner shall provide reports of its expenditure under the Budget for the Project with supporting documentation and using a template provided by CEPI (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Financial Reports</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). In addition to the completed Financial Report template (the financial summary, a narrative explanation of the expenses&#47;variances, assets register, and payment request), each Partner will provide the following additional supporting documentation&#58; (i) general ledger report of all direct cost transactions during the reporting period&#59; (ii) labour report that lists time charged by individual staff for the reporting period&#59;</font></div><div style="padding-left:97.15pt;padding-right:19.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii) sub-award invoices paid during the reporting period&#59; and (iv) invoices&#47;receipts&#47;timesheets as requested by CEPI following receipt of general ledger report and based on a random sampling methodology. In addition, Barinthus Bio shall provide a copy of the published quarterly financial statements of Barinthus Biotherapeutics plc and the published annual statutory financial statements of Barinthus Bio.</font></div><div style="margin-top:6pt;padding-left:97.15pt;padding-right:19.8pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">3.12&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:118%">Frequency of Financial Reporting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">. Each Partner shall submit financial reports within &#91;***&#93; of the end of its quarterly reporting period.</font></div><div style="margin-top:5.5pt;padding-left:97.15pt;padding-right:19.85pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">3.13&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:117%">Project Records</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">. Each Partner shall keep accurate records of its Project activities and expenditure under each Work Package and retain them for a period of &#91;***&#93; from the date of expiry or termination of this Agreement.</font></div><div style="margin-top:5.6pt;padding-left:97.15pt;padding-right:19.85pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.14&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Access to Financial Records</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. During the Term and for a period of &#91;***&#93; after expiration or termination of this Agreement, CEPI&#8217;s designee (which shall be an internationally recognised certified public accounting firm, not engaged on a contingent basis), and at CEPI&#8217;s reasonable cost, shall have on-site access to inspect each Partner&#8217;s</font></div><div style="margin-top:9.35pt"><font><br></font></div><div style="padding-left:6.85pt;padding-right:6.85pt;text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:41.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.706%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sensitivity&#58; Official Use</font></div></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">           16</font></div></div></div><hr style="page-break-after:always"><div style="min-height:35.28pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="margin-top:11.1pt"><font><br></font></div><div style="padding-left:97.15pt;padding-right:19.7pt;text-align:justify;text-indent:-0.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">financial records with respect to the funding provided by CEPI pursuant to this Agreement once annually upon at least &#91;***&#93; advance written notice. Such inspections shall be conducted during normal operating hours in a manner to minimise disruption to such Partner&#8217;s business. For clarity, access to such records also shall be provided to records related to Cost of Goods for the Project Vaccine, as described in Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">14.4.</a> CEPI&#8217;s designee carrying out such inspection shall treat all financial records and other information subject to review under this Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">3.14</a> in accordance with the confidentiality provisions of Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">18.</a> CEPI shall cause such designee to enter into a reasonably acceptable confidentiality agreement with the relevant Partner obligating such firm to retain all such financial records and other information in confidence pursuant to such confidentiality agreement.</font></div><div style="margin-top:5.95pt;padding-left:97.1pt;padding-right:19.85pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.15&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Project Financial Audits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. During the Term and for a period of &#91;***&#93; after expiration or termination of this Agreement, if requested by CEPI, and at CEPI&#8217;s reasonable cost, once annually upon reasonable prior notice, each Partner agrees to an external audit firm appointed by CEPI, reasonably acceptable to such Partner, conducting an audit or agreed-upon procedures with respect to the funding provided by CEPI pursuant to this Agreement in accordance with ISA800 and&#47;or ISA805 and like standards and provide CEPI with an audit report. Such inspections shall be conducted during normal operating hours, on advance notice of at least &#91;***&#93; on dates and at such times as reasonably agreed by CEPI and the applicable Partner, in a reasonable manner and in a manner to minimise disruption to such Partner&#8217;s activities. The receiving Party shall treat all information subject to review under this Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">3.15</a> in accordance with the confidentiality provisions of Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">18.</a> CEPI shall cause any auditor pursuant to this Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">3.15</a> to enter into a reasonably acceptable confidentiality agreement with the relevant Partner obligating such firm to retain all such financial information in confidence pursuant to such confidentiality agreement.</font></div><div style="margin-top:6.1pt;padding-left:90.9pt;padding-right:19.75pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.16&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Funding provided to Oxford in relation to MERS vaccine development prior to signature of this Agreement. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Parties acknowledge that CEPI continues to provide funding to Oxford for the development of the ChAdOx1 MERS vaccine candidate separately, under the PADOVAX project, now governed by the terms of the &#91;***&#93;. For the avoidance of doubt, Oxford led Work Packages listed within Annex C that were initiated prior to the signature of this Agreement, specifically WP MERS 2.1.2 (MERS003), MERS 2.1.3 (Subcontracting of OXB for manufacture of GMP doses for Phase 2 Clinical Trial) are governed by the PADOVAX project under the &#91;***&#93; and do not fall under the terms of this Agreement. For the avoidance of doubt, where Oxford undertakes new Project activity, not previously initiated at the point of signature of this Agreement, the funding provided by CEPI for such activity will be reflected in Annex D to this Agreement.</font></div><div style="margin-top:5.95pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:97pt;padding-right:19.85pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.&#160;&#160;&#160;&#160;FUNDING FOR FUTURE PROJECTS&#59; TECHNOLOGY TRANSFER TO A SELECTED MANUFACTURER</font></div><div style="margin-top:6.1pt;padding-left:96.95pt;text-align:justify;text-indent:-35.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#93;</font></div><div style="margin-top:6.05pt;padding-left:133.05pt;padding-right:19.9pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.1.1 &#91;***&#93;</font></div><div style="padding-left:72pt;padding-right:19.9pt;text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> 4.1.2 &#91;***&#93;</font></div><div style="padding-left:94.5pt;padding-right:19.9pt;text-align:justify;text-indent:-0.01pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.1.3&#160;&#160;&#160;&#160;In the case of Oxford only, the provisions of Clauses <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">4.1.1</a> and <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">4.1.2</a> shall not apply where Oxford &#91;***&#93;.</font></div><div style="margin-top:6.15pt;padding-left:96.95pt;text-align:justify;text-indent:-35.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Collaboration in Event of Outbreak.</font></div><div style="margin-top:5.85pt;padding-left:97pt;padding-right:19.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">Should there be an Outbreak or Increased Outbreak Preparation Need at any time during the Term&#58;</font></div><div style="margin-top:5.5pt;padding-left:133pt;padding-right:19.75pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.2.1&#160;&#160;&#160;&#160;if CEPI believes, in its reasonable discretion, that the Project Vaccine can be used to help address the relevant Outbreak or Increased Outbreak Preparation Need, each Partner shall, subject to receipt of sufficient funding, continue to develop, and, if relevant, manufacture or have manufactured (to GMP, or another clinical standard if agreed between the Parties), and distribute such Project Vaccine, as agreed with CEPI&#59;</font></div><div style="height:41.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.706%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sensitivity&#58; Official Use</font></div></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">           17</font></div></div></div><hr style="page-break-after:always"><div style="min-height:35.28pt;width:100%"><div><font><br></font></div></div><div style="margin-top:5.95pt;padding-left:133pt;padding-right:19.75pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.2.2&#160;&#160;&#160;&#160;to the extent such technology transfer has not already occurred, at such time as is mutually agreed between the Parties, and on such terms as agreed between the Partner and the relevant third party, acting in good faith, each Partner shall use all reasonable endeavours to transfer or grant licenses or sublicenses to its Background IP, Project Data and Project IP (including, for the avoidance of doubt, all product data, product dossiers, and regulatory submissions submitted to a Regulatory Authority in relation to the Project Vaccine) necessary for the manufacture of the Project Vaccine to a Selected Manufacturer to manufacture such vaccines to address an Outbreak or Increased Outbreak Preparation Need, provided that the foregoing obligations shall apply only if&#58;</font></div><div style="margin-top:6.1pt;padding-left:169pt;padding-right:19.9pt;text-align:justify;text-indent:-35.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;CEPI reasonably anticipates that the Partners cannot meet CEPI&#8217;s good faith and reasonable estimate of the anticipated demand of public-sector customers in, or purchasing on behalf of, LMICs, in the timeframe required to address an Outbreak or Increased Outbreak Preparation Need and at a price consistent with the pricing provisions contained in Clause</font></div><div style="margin-top:0.1pt;padding-left:169.05pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">14.5</a>&#59; and</font></div><div style="margin-top:5.95pt;padding-left:169pt;padding-right:19.9pt;text-align:justify;text-indent:-35.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;the Partners have the right to grant necessary licenses or sublicenses to a third party under agreements with Third Party Collaborators, after using reasonable endeavours to secure such rights.</font></div><div style="margin-top:6pt;padding-left:133pt;padding-right:19.75pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.2.3&#160;&#160;&#160;&#160;CEPI shall be responsible for the reasonable evidenced cost related to the technology transfer (including, without limitation, capacity reservation fees and process validation engineering runs), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, prior to commencing the technology transfer, each Partner has provided a good faith estimate of the costs that it will incur in carrying out such technology transfer and CEPI has provided written confirmation of its acceptance of such estimate. Should CEPI not provide such written confirmation then the relevant Partner shall have no obligation under Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">4.2.2</a> to undertake such technology transfer. If CEPI accepts a Partner&#8217;s costs estimate, the Parties shall negotiate and enter into a Work Package setting out which activities will be performed by such Partner and the associated Budget.</font></div><div style="margin-top:6.1pt;padding-left:96.95pt;text-align:justify;text-indent:-35.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Further Co-Operation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:5.85pt;padding-left:133pt;padding-right:19.75pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.3.1&#160;&#160;&#160;&#160;Each Partner shall, if notified by CEPI, promptly discuss in good faith a potential collaboration with a third party collaborator approved by such Partner and CEPI (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Trusted Collaborator</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). Any such collaboration agreement that a Partner may enter into with a Trusted Collaborator will be consistent with the terms of this Agreement and shall permit CEPI, the other Partner and specified third parties of the Trusted Collaborators, to access any vaccine materials and candidates that may be developed on terms substantially similar to the Project Results under this Agreement. For the avoidance of doubt, nothing in this Agreement shall impose an obligation on a Partner to enter into any collaboration agreement with a Trusted Collaborator in relation to the Project or otherwise.</font></div><div style="margin-top:5.95pt;padding-left:133pt;padding-right:19.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.3.2&#160;&#160;&#160;&#160;The Partners acknowledge that CEPI is seeking third party collaborators developing innovative technologies, including but not limited to partners improving vaccine thermostability (each an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Innovation Partner</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). If CEPI deems that the Project Vaccine may be suitable for collaboration with an Innovation Partner, CEPI shall notify the Partners, and the Partners shall promptly discuss in good faith a potential collaboration with the relevant Innovation Partner. For the avoidance of doubt, nothing in this Agreement shall impose an obligation on the Partners to enter into any collaboration agreement with the Innovation Partner in relation to the Project Vaccine or otherwise.</font></div><div style="margin-top:6.2pt;padding-left:96.95pt;text-align:justify;text-indent:-35.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Technology Transfer</font></div><div style="margin-top:5.8pt;padding-left:133pt;padding-right:19.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.4.1&#160;&#160;&#160;&#160;If agreed in any Work Package, or otherwise agreed between CEPI and the relevant Partner(s), each such Partner shall use all reasonable endeavours to transfer or grant licenses or sublicenses to its Background IP, Project Results and Project IP (including, for the avoidance of doubt, all product data, product dossiers, and regulatory submissions submitted to a Regulatory Authority in relation to the Project Vaccine) which are necessary for the manufacture and release of the Project Vaccine to a Selected Manufacturer to manufacture and</font></div><div style="height:41.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.706%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sensitivity&#58; Official Use</font></div></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">           18</font></div></div></div><hr style="page-break-after:always"><div style="min-height:35.28pt;width:100%"><div><font><br></font></div></div><div style="margin-top:2.75pt"><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:11.1pt"><font><br></font></div><div style="padding-left:133pt;padding-right:19.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">release such vaccines, subject to the relevant Partner having the right to grant necessary licenses or sublicenses to a third party under agreements with Third Party Collaborators, after using reasonable endeavours to secure such rights.</font></div><div style="margin-top:5.6pt;padding-left:133pt;padding-right:19.7pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.4.2&#160;&#160;&#160;&#160;CEPI shall be responsible for the reasonable evidenced cost related to the technology transfer referenced in Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">4.4.1</a> (including, without limitation, capacity reservation fees and process validation engineering runs), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, such cost has been agreed in a Work Package Budget or otherwise agreed between CEPI and the relevant Partner(s) and in no circumstance shall CEPI, the relevant Selected Manufacturer, or any third party, be required to pay any consideration for the transfer, or grant or exercise of the licences or sublicences referred to in Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">4.4.1.</a></font></div><div style="margin-top:6pt;padding-left:133pt;padding-right:19.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.4.3&#160;&#160;&#160;&#160;If any Selected Manufacturer ceases to meet the necessary requirements, to manufacture the Project Vaccine to GMP at a reasonable cost and within a reasonable timeframe, at any time, then CEPI and the Partners shall negotiate in good faith and agree on a replacement, either from other Selected Manufacturers or such other manufacturer as the Partners and CEPI may identify. The Partners may not unreasonably withhold agreement to a replacement manufacturer, and CEPI and the Partners shall use all reasonable endeavours to ensure that any replacement Selected Manufacturer shall have comparable rights to the original Selected Manufacturer considering all relevant circumstances including then- current demands for the Project Vaccine, manufacturing capacity or level of experience.</font></div><div style="margin-top:6.05pt;padding-left:133pt;padding-right:19.85pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.4.4&#160;&#160;&#160;&#160;If a Partner wishes to manufacture or have manufactured Project Vaccine for sale or supply to one or more LMICs or UMICs, then prior to any manufacturer being granted the relevant rights or any orders for any such Project Vaccine doses being placed, the relevant Partner shall first notify CEPI of such intent and the identity of the Partner&#8217;s proposed manufacturer, in writing, promptly after first forming such intent, and identifying such proposed manufacturer. The Parties shall discuss such proposal in good faith.</font></div><div style="margin-top:12.05pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:97pt;text-indent:-36.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">5.&#160;&#160;&#160;&#160;OWNERSHIP OF PROJECT RESULTS&#59; INTELLECTUAL PROPERTY</font></div><div style="margin-top:5.95pt;padding-left:97.1pt;padding-right:19.9pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Partners&#8217; Background IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Each Partner shall retain ownership of its Background IP. Other than pursuant to Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">14.6</a>, nothing in this Agreement shall be deemed to assign any ownership interest in or grant any license or other right to or under such Background IP to CEPI or any other person.</font></div><div style="margin-top:5.9pt;padding-left:97.15pt;padding-right:19.85pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Partners&#8217; IP Responsibilities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. As between CEPI and the Partners, the Partners are solely responsible for having access to the Intellectual Property (via ownership or license) necessary to develop and commercialise the Project Vaccine and to comply with the Partners&#8217; obligations and CEPI&#8217;s rights pursuant to this Agreement.</font></div><div style="margin-top:6.05pt;padding-left:97.15pt;padding-right:19.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Ownership of Project Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Each Partner shall own all right, title and interest in and to the Project Intellectual Property created by or on behalf of such Partner. Each Partner shall have the right, but not the obligation, to seek patent or other intellectual property protection in respect of any Project Intellectual Property at its own cost. Upon reasonable written request, each Partner shall provide a written update to CEPI regarding</font></div><div style="margin-top:9.3pt"><font><br></font></div><div style="height:41.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.706%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sensitivity&#58; Official Use</font></div></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">           19</font></div></div></div><hr style="page-break-after:always"><div style="min-height:35.28pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="margin-top:11.1pt"><font><br></font></div><div style="padding-left:97.15pt;padding-right:19.9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">the status of any patent within the Project Intellectual Property that is filed by or on behalf of a Partner.</font></div><div style="margin-top:6.05pt;padding-left:97.2pt;padding-right:19.65pt;text-align:justify;text-indent:-36.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">5.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:117%">Ownership of Project Results</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">. Each Partner shall own all right, title and interest in and to the Project Results created by or on behalf of such Partner. For clarity CEPI shall have the right to use Project Results solely as expressly set out in this Agreement.</font></div><div style="margin-top:5.6pt;padding-left:97.15pt;padding-right:19.7pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Third Party IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Each Party shall notify the other promptly regarding any published third party patent application it becomes aware of (whether or not yet granted) that such Party believes in good faith is likely to have a material adverse impact on any Partner&#8217;s ability to perform its obligations under this Agreement. The Parties shall discuss in good faith the implications for the Project.</font></div><div style="margin-top:12.05pt"><font><br></font></div><div style="padding-left:97pt;text-indent:-36.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">6.&#160;&#160;&#160;&#160;MANUFACTURE</font></div><div style="margin-top:5.95pt;padding-left:97.15pt;padding-right:19.9pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">6.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:117%">Manufacturing Standards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">. Unless otherwise agreed by the Parties in writing, each Partner shall ensure that all components of the Project Vaccine are manufactured to GMP and any other applicable standards (including ISO9001).</font></div><div style="margin-top:5.6pt;padding-left:97.15pt;padding-right:19.75pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Raw Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Partners shall use reasonable endeavours to ensure that all manufacturing, whether performed by a Partner or by any third party acting on a Partner&#8217;s behalf, and any raw materials, components and intermediates used in the production of the Project Vaccine, are available, in stock or for purchase, initially in sufficient quantities for research and development purposes, and subsequently in quantities sufficient to meet supply needs under the Equitable Access Plan and in the event of an Outbreak or Increased Outbreak Preparation Need.</font></div><div style="margin-top:6pt;padding-left:97.15pt;padding-right:19.8pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Excipients</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Each Partner shall ensure that the vaccine formulation excipients that it uses or procures are on the FDA&#8217;s Generally Recognised as Safe (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">GRAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) excipient list. Each Partner shall promptly inform CEPI if a novel excipient, which is not on the FDA&#8217;s GRAS excipient list, is being considered by such Partner (or a third party acting on such Partner&#8217;s behalf) for use in connection with a Project Vaccine and if so, such Partner shall (or shall cause such third party to), undertake a detailed risk assessment and seek advice from the relevant Regulatory Authorities regarding such novel excipient including the extent of data required to demonstrate the safety of such novel excipient, which may include preclinical toxicology study design and data generation during clinical development. Before use of such novel excipient in connection with a Project Vaccine, the relevant Partner shall notify CEPI and provide such information regarding such excipient to CEPI as CEPI may reasonably request.</font></div><div style="margin-top:6.05pt;padding-left:97.15pt;padding-right:19.9pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Manufacturing Process</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. When developing the process for manufacturing the Project Vaccine, the Partners shall endeavour to make such process as suitable as possible for technology transfer to geographically diverse locations (including LMICs) at an affordable price, consistent with Equitable Access and the Partners&#8217; obligations under Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">14.</a></font></div><div style="margin-top:5.95pt;padding-left:97.15pt;padding-right:19.8pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Records and Reporting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Each Partner shall use all reasonable endeavours to ensure that all data in relation to the manufacture of the Project Vaccine is appropriately recorded and that all such records are kept up to date and maintained in accordance with applicable laws and regulations. Upon CEPI&#8217;s reasonable request, each Partner will allow CEPI or its representative to review the data such Partner holds or controls from time to time in</font></div><div style="margin-top:3.3pt"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:41.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.706%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sensitivity&#58; Official Use</font></div></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">           20</font></div></div></div><hr style="page-break-after:always"><div style="min-height:35.28pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="margin-top:11.25pt"><font><br></font></div><div style="padding-left:3.42pt;padding-right:3.42pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">respect of the progress of the development of the manufacturing process.</font></div><div style="margin-top:12pt"><font><br></font></div><div style="padding-left:96.95pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">7.&#160;&#160;&#160;&#160;CLINICAL TRIALS</font></div><div style="margin-top:5.85pt;padding-left:97.15pt;padding-right:19.8pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Clinical Trials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Each Partner shall undertake the clinical trial(s) listed as its responsibility in any Work Package (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Project Clinical Trials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) in compliance with all applicable laws and regulations, including applicable requirements related to the Partners&#8217; use of clinical data outside of the country in which a given Project Clinical Trial is conducted. Each Partner shall ensure that all Project Clinical Trials undertaken by it comply with CEPI&#8217;s Clinical Trial Policy attached hereto as Annex M.</font></div><div style="margin-top:6.05pt;padding-left:97.15pt;padding-right:19.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Clinical Trial Protocols</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Preparation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Each Partner undertaking a Project Clinical Trial shall be responsible for the preparation of any clinical trial protocol(s) for such Project Clinical Trial. Each Partner shall provide CEPI and&#47;or CEPI&#8217;s designee with a draft of each clinical trial protocol for each Project Clinical Trial to be undertaken by such Partner, and shall consider any reasonable suggestions made by CEPI and&#47;or its designee regarding the clinical trial protocols reasonably in advance of finalizing the relevant clinical trial protocol and submitting it to the institutional review boards, ethics committees, and&#47;or Regulatory Authorities. Notification of any reasonable suggestions from CEPI and&#47;or its designee must be received by the relevant Partner within &#91;***&#93; after the receipt of the draft by CEPI, failing which such Partner shall be free to assume that CEPI and&#47;or its designee has no objection to the proposed protocol.</font></div><div style="margin-top:5.95pt;padding-left:97.15pt;padding-right:19.85pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Clinical Trial Protocols</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Reporting of Submitted Versions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Each Partner shall provide to CEPI a copy of all clinical trial protocols as approved by institutional review boards, ethics committees and Regulatory Authorities in respect of each Project Clinical Trial to be undertaken by such Partner. For clarity, all such information is the Confidential Information of the Partner who has submitted such information to CEPI hereunder.</font></div><div style="margin-top:6pt;padding-left:97.15pt;padding-right:19.8pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Clinical Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Each Partner shall include in the informed consent obtained from each clinical trial subject in any Project Clinical Trial to be undertaken by such Partner, terms to allow, to the extent permitted by and consistent with applicable laws and regulations&#58;</font></div><div style="margin-top:5.95pt;padding-left:133pt;padding-right:19.75pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.4.1&#160;&#160;&#160;&#160;the transfer of anonymised data to CEPI and&#47;or CEPI&#8217;s designee. CEPI shall treat such data confidentially and not disclose to third parties in accordance with all applicable data protection legislation. For the avoidance of doubt, where any personal data is to be transferred to CEPI, the Parties will enter into appropriate data protection agreements to enable compliance with applicable data protection legislation&#59; and</font></div><div style="margin-top:6.1pt;padding-left:133pt;padding-right:19.75pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.4.2&#160;&#160;&#160;&#160;the collection and use of Project Materials and the use of data (duly anonymised and, as the Parties may agree, blinded) derived from such Project Materials by CEPI or its designated Assessors, solely for the purpose of research under a study protocol which has received the appropriate ethical approval.</font></div><div style="margin-top:6.05pt;padding-left:96.95pt;text-align:justify;text-indent:-35.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Sponsorship and Management of Project Clinical Trials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:5.95pt;padding-left:133pt;padding-right:19.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.5.1&#160;&#160;&#160;&#160;As between the Parties, Barinthus Bio shall be the sponsor of any Project Clinical Trial (unless the Parties otherwise agree in writing), subject to all necessary approvals being obtained (including relevant internal approvals). Where a Partner is the sponsor of a Project Clinical Trial, such Partner shall be responsible for</font></div><div style="margin-top:9.95pt"><font style="background-color:#e6e6e6;color:#2b569a;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">24</font></div><div style="text-align:center"><font><br></font></div><div style="height:41.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.706%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sensitivity&#58; Official Use</font></div></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">           21</font></div></div></div><hr style="page-break-after:always"><div style="min-height:35.28pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="margin-top:11.1pt"><font><br></font></div><div style="padding-left:133pt;padding-right:19.9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">obtaining and maintaining all regulatory and ethical committee approvals necessary for the conduct of such Project Clinical Trial.</font></div><div style="margin-top:6.05pt;padding-left:133pt;padding-right:19.7pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.5.2&#160;&#160;&#160;&#160;In respect of each Project Clinical Trial, upon discussion with CEPI, the sponsoring Partner shall establish either an internal Trial Steering Committee (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">TSC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) or a Safety Monitoring Committee or Data Safety Monitoring Board (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">DSMB</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), as applicable. CEPI shall be entitled to appoint, and the sponsoring Partner shall permit, a CEPI representative or designee to attend all meetings of each Project Clinical Trial&#8217;s TSC and&#47;or DSMB as an observer (either in person or by telephone, video or other electronic means), to the extent permitted by applicable laws and regulations and agreed by the TSC or DSMB, as applicable. Subject to Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">7.5.3</a> below, the sponsoring Partner shall provide a copy to CEPI of all documents, correspondence and records that a member of the TSC and&#47;or DSMB would be entitled to receive at the same time as any such documents, correspondence and records are provided to the members of the TSC and&#47;or DSMB (as applicable), subject to compliance with applicable laws and regulations.</font></div><div style="margin-top:6pt;padding-left:133pt;padding-right:19.75pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.5.3&#160;&#160;&#160;&#160;In the event that CEPI&#8217;s attendance at a meeting of the TSC and&#47;or DSMB or receipt of documents, correspondence and records would, in the sponsoring Partner&#8217;s reasonable discretion acting in good faith, jeopardise the integrity&#47;blinded nature of an ongoing Project Clinical Trial, the sponsoring Partner shall promptly notify CEPI of such fact and CEPI shall not be entitled to, and the sponsoring Partner shall not be required to permit CEPI to, attend such meeting or receive such documents, correspondence and records at that time. During an ongoing Project Clinical Trial, the sponsoring Partner will continue to provide CEPI with all open session DSMB documents, DSMB recommendation forms and other &#8220;open&#8221; documents identified by the Parties in the Work Package and&#47;or protocol for such Project Clinical Trial. After the Project Clinical Trial is unblinded, and upon reasonable written request from CEPI, the Partners shall provide a copy of all documents, correspondence and records that were provided to the members of the TSC and&#47;or DSMB and&#47;or that a member of the TSC and&#47;or DSMB would be entitled to receive.</font></div><div style="margin-top:6pt;padding-left:97.15pt;padding-right:19.85pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Safety Notifications</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Each Partner shall notify the JMAG in writing promptly following any single safety event of concern or a series of safety events which in each case is or are considered by the DSMB as relevant enough to recommend modification of study design, dosing regimen, or discontinuation of vaccination, in relation to any Project Vaccine or any Project Clinical Trial and within five (5) days from the time when the DSMB&#8217;s recommendation in relation to such event or series of events becomes known to such Partner.</font></div><div style="margin-top:5.9pt;padding-left:97.15pt;padding-right:19.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Records and Reporting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Each Partner shall use all reasonable endeavours to ensure that all clinical data in relation to any Project Clinical Trials and any other clinical trials that utilise Project Clinical Trial Materials are appropriately recorded and that all such records are kept up to date and maintained in accordance with applicable laws, regulations, and study site policies. The Partners will use all reasonable endeavours to ensure that CEPI is able to review and verify all anonymised data at the end of the relevant Project Clinical Trial or other clinical trial that utilises any Project Clinical Trial Materials and will promptly following the end of such Project Clinical Trial or other clinical trial that utilises</font></div><div style="text-align:center"><font><br></font></div><div style="height:41.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.706%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sensitivity&#58; Official Use</font></div></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">           22</font></div></div></div><hr style="page-break-after:always"><div style="min-height:35.28pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="margin-top:11.1pt"><font><br></font></div><div style="padding-left:97.15pt;padding-right:19.8pt;text-align:justify;text-indent:-0.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">any Project Clinical Trial Materials provide a copy of such anonymised data to CEPI in such form as CEPI may reasonably require, in each case to the extent required by and consistent with applicable laws and regulations.</font></div><div style="margin-top:5.6pt;padding-left:97.15pt;padding-right:19.7pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Priority for Clinical Trials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Partners acknowledge that the pool of subjects available in areas of Outbreak to participate in a clinical trial to test the Project Vaccine may be limited. Accordingly, if WHO, CEPI or a Regulatory Authority in the area where the Project Clinical Trial is to be conducted determines that a product other than the Project Vaccine has substantially greater potential and should be prioritised instead for a particular clinical trial, the Partners shall consider in good faith any written request of CEPI not to proceed with the Project Clinical Trial of such Project Vaccine, it being understood and agreed that the determination of whether to proceed or not proceed with any such Project Clinical Trial shall be made by the Partner who was to act as the sponsor of such Project Clinical Trial, in its sole discretion. Each Partner shall be reimbursed for its reasonable, non-cancellable costs incurred (whether before or after the determination) resulting from any determination to not proceed as a result of CEPI&#8217;s request.</font></div><div style="margin-top:6pt;padding-left:97.1pt;padding-right:19.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.9&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Potential WHO Clinical Trials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. In the event a Partner, pursuant to a subsequent written agreement with CEPI, participates in a Phase IIb or III clinical trial as requested by WHO to compare the Project Vaccine with any other vaccine candidates indicated for use against the same pathogen, each Partner will, promptly following the end of such clinical trial, meet and confer with CEPI regarding the results of such clinical trial and shall provide access to any data and final study reports relating to such clinical trial as may be set out in such subsequent written agreement, to the extent that WHO has given their prior written consent to such access.</font></div><div style="margin-top:12.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:97pt;text-indent:-36.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">8.&#160;&#160;&#160;&#160;REGULATORY ACTIVITIES</font></div><div style="margin-top:5.8pt;padding-left:97.15pt;padding-right:19.85pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Regulatory Strategy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Upon completion of the development of the Project Vaccine, Barinthus Bio shall use &#91;***&#93; to obtain Regulatory Approval for such product in jurisdictions that would enable Equitable Access to such Project Vaccine. Barinthus Bio shall be responsible for developing the regulatory strategy for the Project Vaccine. Barinthus Bio shall use &#91;***&#93; to file for, obtain and maintain the appropriate licenses for the Project Vaccine with the relevant Regulatory Authorities.</font></div><div style="margin-top:6.05pt;padding-left:97.15pt;padding-right:19.7pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Meetings with Regulatory Authorities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Each Partner shall notify CEPI in writing of any material meetings with Regulatory Authorities with respect to the Project Vaccine, or any Project Clinical Trial or other clinical trial that utilises any Project Clinical Trial Materials at least &#91;***&#93; in advance of such meetings, or if a Partner itself receives less than &#91;***&#93; notice of such a meeting, as soon as practicable. At CEPI&#8217;s option, the Partners shall consult with CEPI or its designee regarding any material interactions between a Partner and Regulatory Authorities relating to the Project Vaccine, or any Project Clinical Trial or other clinical trial that utilises any Project Clinical Trial Materials. At CEPI&#8217;s reasonable request, a Partner shall request a meeting with Regulatory Authorities to address any significant unresolved issues with respect to any Project Clinical Trial or other clinical trial that utilises any Project Clinical Trial Materials.</font></div><div style="margin-top:6.05pt;padding-left:97.1pt;padding-right:20pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Regulatory Strategy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Partners shall consult regularly with CEPI regarding the regulatory strategy for the Project Vaccine and each Project Clinical Trial or other clinical</font></div><div style="margin-top:2.6pt"><font><br></font></div><div style="padding-left:6.85pt;padding-right:6.85pt;text-align:center"><font style="background-color:#e6e6e6;color:#2b569a;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">26</font></div><div style="text-align:center"><font><br></font></div><div style="height:41.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.706%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sensitivity&#58; Official Use</font></div></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">           23</font></div></div></div><hr style="page-break-after:always"><div style="min-height:35.28pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="margin-top:11.1pt"><font><br></font></div><div style="padding-left:97.1pt;padding-right:19.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">trial that utilises any Project Clinical Trial Materials and shall provide copies of the clinical trial authorisation and all material regulatory submissions with respect to such trial(s) to CEPI no later than &#91;***&#93; prior to their contemplated submission to a Regulatory Authority. For the avoidance of doubt the Partners shall have final editorial control of such submissions. If a final version is not available by &#91;***&#93; prior to submission, then a mature draft version may be electronically delivered to CEPI for review at that time. Additionally, the Partners shall promptly make available for review by CEPI or its designated Assessors at one of the Partner&#8217;s premises copies of the following to the extent reasonably required for CEPI to evaluate the progress of the conduct and completion of each Project Clinical Trial or other clinical trial that utilises any Project Clinical Trial Materials&#58;</font></div><div style="margin-top:5.95pt;padding-left:133pt;padding-right:19.85pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">8.3.1&#160;&#160;&#160;&#160;all submissions to Regulatory Authorities and regulatory filings for the Project Clinical Trial or other clinical trial that utilises any Project Clinical Trial Materials together with all data included or referenced therein (other than ministerial submissions that do not involve safety or efficacy issues)&#59; and</font></div><div style="margin-top:5.55pt;padding-left:133pt;padding-right:19.85pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.3.2&#160;&#160;&#160;&#160;material documents and information exchanged between any Regulatory Authority and a Partner, including relating to the Project Clinical Trial or other clinical trial that utilises any Project Clinical Trial Materials including official meeting minutes.</font></div><div style="margin-top:6.05pt;padding-left:97.15pt;padding-right:19.85pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Referencing Market Authorisation package</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. At the reasonable request of CEPI, each Partner agrees to co-operate with CEPI to allow CEPI or its nominee to cross-reference the market authorization package, the drug master file and all existing data of the Project Vaccine only for the purpose of supporting regulatory filings and submissions for any vaccines that may be used in the event of a potential public health emergency utilizing the same, or a similar, platform technology, if applicable. For clarity, (i) no Partner shall be required to disclose any non-public information that is proprietary to a third party other than to the Regulatory Agency with which the applicable market authorization package is filed, and (ii) a Partner&#8217;s market authorization package or data may not be disclosed to or cross-referenced by a third party without prior approval of the applicable Partner, which shall not be unreasonably withheld or delayed.</font></div><div style="margin-top:5.95pt;padding-left:97.15pt;padding-right:19.75pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Redactions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Notwithstanding any other provision of this Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">8</a> or other terms or conditions of this Agreement, a Partner shall have the right to redact any documentation made available pursuant to this Agreement to the extent reasonably necessary to protect its trade secrets or other non-public sensitive information or financially sensitive information or data that is proprietary to a third party that Partner is prohibited from disclosing.</font></div><div style="margin-top:12.1pt"><font><br></font></div><div style="padding-left:97pt;text-indent:-36.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">9.&#160;&#160;&#160;&#160;ANIMAL STUDIES</font></div><div style="margin-top:5.85pt;padding-left:97.15pt;padding-right:19.85pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Animal Studies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Each Partner shall pursue any studies involving animals as described in any Work Package, in compliance with all applicable laws and regulations and further in compliance with Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">12.</a></font></div><div style="margin-top:6.1pt;padding-left:97.15pt;padding-right:19.75pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Animal Study Protocols</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Each Partner shall be responsible for the preparation of any animal study protocol(s) for any studies involving animals. Each Partner shall, through the regular JMAG meetings, share the details of its protocols with CEPI and, upon CEPI&#8217;s</font></div><div style="margin-top:9.25pt"><font><br></font></div><div style="height:41.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.706%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sensitivity&#58; Official Use</font></div></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">           24</font></div></div></div><hr style="page-break-after:always"><div style="min-height:35.28pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="margin-top:11.1pt"><font><br></font></div><div style="padding-left:97.1pt;padding-right:19.9pt;text-align:justify;text-indent:0.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">reasonable request, provide CEPI and&#47;or CEPI&#8217;s designee with a draft of each animal trial protocol for any animal studies it has conducted or intends to conduct and shall consult with and consider any reasonable suggestions made by CEPI and&#47;or its designee regarding the animal trial protocols. Each Partner represents and warrants that it will comply with principles of NC3Rs (Replacement, Refinement, and Reduction) in conducting animal studies hereunder.</font></div><div style="margin-top:12.15pt"><font><br></font></div><div style="padding-left:96.95pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">10.&#160;&#160;&#160;&#160;DISSEMINATION OF PROJECT RESULTS&#59; PUBLICATION</font></div><div style="margin-top:5.85pt;padding-left:97.15pt;padding-right:19.85pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Dissemination of Project Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. CEPI encourages the timely publication and other dissemination of Project Results. The Partners shall make the Project Data available to specified third parties if and to the extent described in a Work Package, as agreed by the JMAG, or as otherwise may be agreed between the Parties, always in compliance with applicable data protection legislation.</font></div><div style="margin-top:6pt;padding-left:97.15pt;padding-right:19.75pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Dissemination of Project Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Partners shall make the Project Materials available to specified third parties if and to the extent described in a Work Package, as agreed by the Parties at the JMAG, or as otherwise may be agreed between the Parties, and in each case subject to each Partner&#8217;s biobank standard operating procedures and policies and where there is appropriate ethical approval and informed consent. Such Project Materials shall be made available solely to the extent the applicable laws permit, as reasonably required by CEPI to inform the public health response and help save lives, and to the extent reasonably available after the Partners, their Affiliates and their (sub)licensees with respect to such materials have completed all research or development activities involving the use of such materials and applied for any desired patent protection, provided that, the dissemination of the Project Materials shall be delayed by no more than &#91;***&#93; to secure any such patent protection. Notwithstanding the foregoing, (i) the Partners shall be notified in advance of the purpose of use of Project Materials and the identity of recipient third parties, and (ii) any results of such use shall be promptly disclosed to the Partners. Any publication of the Project Material shall be subject to Clauses <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">10.3</a> and <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">10.5</a>.</font></div><div style="margin-top:6.05pt;padding-left:97.15pt;padding-right:19.75pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Publication of Project Data for the Outbreak Research Community</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Each Partner shall promptly publish or cause to be published Project Data consisting of reasonably relevant and appropriate pre-clinical and clinical trial data (for clarity, excluding raw data) in a peer-reviewed scientific journal to inform the public health response and help save lives. Key principles of this sharing of data have been agreed to by funders, research organisations, government agencies, civil society organisations and for-profit life science enterprises, as described and provided in (i) WHO&#8217;s 2016 Guidance for Managing Ethical Issues in Infectious Disease Outbreaks&#59; and (ii) WHO&#8217;s 2016 Guidance on Good Participatory Practices in Trials of Interventions Against Emerging Pathogens.</font></div><div style="margin-top:6.05pt;padding-left:96.95pt;text-align:justify;text-indent:-35.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Clinical Trial Registration and Results</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:5.95pt;padding-left:133pt;padding-right:19.85pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.4.1&#160;&#160;&#160;&#160;Project Clinical Trials and any other clinical trials that utilise any Project Clinical Trial Materials must be registered through an easily discoverable existing public route such as clinicaltrials.gov, The EU Clinical Trials Register, or the International Clinical Trials Registry Platform, in accordance with all applicable laws and regulations. The information provided shall follow the current WHO Trial Registration Data Set. The clinical trial ID or registry identifier code&#47;number</font></div><div style="text-align:center"><font><br></font></div><div style="height:41.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.706%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sensitivity&#58; Official Use</font></div></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">           25</font></div></div></div><hr style="page-break-after:always"><div style="min-height:35.28pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="margin-top:11.25pt"><font><br></font></div><div style="padding-left:133pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">shall be included in all publications of clinical trials.</font></div><div style="margin-top:5.8pt;padding-left:133pt;padding-right:19.7pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.4.2&#160;&#160;&#160;&#160;Publication of clinical trial results (including negative results) from Project Clinical Trials and any other clinical trials that utilise any Project Clinical Trial Materials shall be made by the Partner who has been responsible for the applicable Project Clinical Trial Materials or other clinical trial promptly through an easily discoverable existing public route (website or system). Such Partner shall submit clinical trial data from Project Clinical Trials and any other clinical trials that utilise any Project Clinical Trial Materials for publication as soon as reasonably possible but, in any event, within &#91;***&#93; after study completion. During the same time period, such Partner shall make the results available to the national Ministry of Health or equivalent in the countries where Project Clinical Trials are held. Such Partner shall deposit Clinical Trial data in an open sharing platform such as ClinicalStudyDataRequest.com, Vivli Center for Global Clinical Research Data, or an equivalent service.</font></div><div style="margin-top:6.1pt;padding-left:97.15pt;padding-right:19.8pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Open Access</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Prior to publishing any manuscripts of any research publications, journal articles, scholarly monologues and book chapters with respect to any Project Clinical Trial published under this Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">10,</a> the applicable Partner shall submit a copy to CEPI. Each Partner must ensure that a copy of the final manuscript of all research publications, journal articles, scholarly monologues and book chapters with respect to any Project Clinical Trial published under this Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">10</a> is deposited into PubMed Central (or Europe PubMed Central) or otherwise made freely available upon acceptance for publication or promptly after the publisher&#8217;s official date of final publication. Moreover, each Partner shall ensure that all peer-reviewed published research that is funded, in whole or in part, by CEPI shall be published in accordance with the principles of Plan S (&#8220;Accelerating the transition to full and immediate Open Access to scientific publications&#8221;), a UK and European data sharing initiative for research funded by public grants. Each Partner shall comply with CEPI&#8217;s reasonable requests to share information in a preprint service such as bioRxiv.</font></div><div style="margin-top:5.95pt;padding-left:97.1pt;padding-right:19.75pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Statement of Support in Publications</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. All such publications with respect to any Project Clinical Trial shall include a statement that the work was </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">&#8220;supported, in whole or in part, by funding from CEPI&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(or such other words to the same effect regarding other sources of (direct or indirect) funding for the Project as reasonably requested by CEPI, as applicable) and shall credit, where appropriate, the country in which any such clinical trials were performed.</font></div><div style="margin-top:12.15pt"><font><br></font></div><div style="padding-left:97pt;text-indent:-36.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">11.&#160;&#160;&#160;&#160;INDEPENDENT ASSESSORS</font></div><div style="margin-top:5.85pt;padding-left:97.1pt;padding-right:19.85pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Independent Assessors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. During the Term, as required in a Work Package or as otherwise reasonably requested by CEPI, subject to Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">11.2,</a> each Partner shall cooperate with and provide reasonable assistance to consultants reasonably acceptable to such Partner (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Assessors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) (which may include but is not limited to the Task Force for Global Health and its Safety Platform for Emergency vACcines (SPEAC) Project), retained in confidence and at CEPI&#8217;s expense, to consult on development of clinical trial protocols, explore development strategies, and evaluate Project Data and review Project Results, including to use such Project Data to evaluate any Project Vaccine. Each Partner acknowledges that such Assessors may provide CEPI with directly comparable evaluations of similar materials developed under CEPI&#8217;s portfolio of awarded projects. The results of the analysis, meta-</font></div><div style="margin-top:8.7pt"><font><br></font></div><div style="padding-left:6.85pt;padding-right:6.85pt;text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:41.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.706%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sensitivity&#58; Official Use</font></div></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">           26</font></div></div></div><hr style="page-break-after:always"><div style="min-height:35.28pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="margin-top:11.1pt"><font><br></font></div><div style="padding-left:97.1pt;padding-right:19.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">analysis or other assessments by such Assessor(s) shall be subject to the confidentiality obligations of this Agreement and all non-disclosure agreements or material transfer agreements entered into pursuant to Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">11.2.</a> CEPI shall promptly provide the Partners with access to the results of any evaluation by an Assessor solely to the extent such assessment directly relates to the Project Results or Project Vaccine. For clarity, CEPI shall not be required to grant access to any information regarding CEPI&#8217;s portfolio of other awarded projects and shall be entitled to redact such information to the extent it is not obliged to grant access to such information to the Partners in accordance with this Clause.</font></div><div style="margin-top:6pt;padding-left:97.1pt;padding-right:19.7pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Conditions for Assessor(s) Access. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Prior to any Partner or CEPI disclosing to any Assessor any Project Results or other relevant information or materials with respect to any Project Vaccine under the Work Package(s), such Partner and the Assessor(s) shall, at their own discretion, enter directly into an appropriate agreement between themselves to the extent necessary to facilitate any Assessor&#8217;s activities under Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">11.1,</a> such as a non-disclosure agreement or material transfer agreement, and pursuant to such agreement the Assessor(s) shall covenant to comply with the confidentiality terms thereof and use such Project Results and other relevant information or materials solely for the purpose(s) of the applicable assessment(s) and not for any other purpose. CEPI shall, through the JMAG or otherwise, discuss with the Partners protocols and data management related to any Assessor&#8217;s activities under Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">11.1.</a></font></div><div style="margin-top:6.05pt;padding-left:97.15pt;padding-right:19.8pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Partner Cooperation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Partners shall provide reasonable assistance to CEPI and any designated Assessors to facilitate any Assessor&#8217;s activities under Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">11.1</a> at such times and locations as are reasonably agreeable to by the applicable Partner and CEPI and, to the extent reasonably required for CEPI or the designated Assessor, to evaluate the progress of the funded activities, including&#58;</font></div><div style="margin-top:6pt;padding-left:133.05pt;padding-right:19.75pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.3.1&#160;&#160;&#160;&#160;ensuring that any samples to be transferred or exported by or on behalf of a Partner from a clinical trial site or sample storage site are transferred and&#47;or exported pursuant to the terms and conditions of a material transfer agreement to be entered into between such Partner and the Assessor in a form reasonably acceptable to CEPI, the applicable Partner and the Assessor, in addition to any other applicable laws and regulations&#59; and</font></div><div style="margin-top:5.95pt;padding-left:133pt;padding-right:19.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.3.2&#160;&#160;&#160;&#160;cooperating with regard to any data analysis, to the extent relevant under a given Work Package and permitted under applicable laws, regulations, and study site policies, and as reasonably requested by CEPI by&#58;</font></div><div style="margin-top:5.95pt;padding-left:169pt;padding-right:19.75pt;text-align:justify;text-indent:-35.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;providing appropriate data or other information generated under any Work Package to CEPI&#8217;s designated Assessor as CEPI may instruct, including data regarding the results of any of its pre-clinical or clinical trials under any Work Package (duly anonymised and, upon CEPI&#8217;s request, blinded), and other documents and information from activities under any Work Package such as study protocols, case report forms needed to develop standardised approaches and tools for safety data management&#59;</font></div><div style="margin-top:6.05pt;padding-left:169pt;padding-right:19.7pt;text-align:justify;text-indent:-35.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">(ii)&#160;&#160;&#160;&#160;considering in good faith whether to provide CEPI&#8217;s designated Assessor with other data not generated under any Work Package (duly anonymised and, upon CEPI&#8217;s or the applicable Partner&#8217;s request, blinded) as CEPI may reasonably request in order to conduct comparative assessments&#59;</font></div><div style="margin-top:5.5pt;padding-left:168.9pt;text-align:justify;text-indent:-35.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;providing CEPI&#8217;s designated Assessor with clinical trial data generated</font></div><div style="margin-top:2.65pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:6.85pt;padding-right:6.85pt;text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:41.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.706%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sensitivity&#58; Official Use</font></div></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">           27</font></div></div></div><hr style="page-break-after:always"><div style="min-height:35.28pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="margin-top:11.1pt"><font><br></font></div><div style="padding-left:169pt;padding-right:19.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">under any Work Package (duly anonymised and, at CEPI&#8217;s request, blinded) for the purposes of signal detection or meta-analyses of safety data (including across product candidates)&#59; and</font></div><div style="margin-top:5.6pt;padding-left:169pt;padding-right:19.8pt;text-align:justify;text-indent:-52pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iv)&#160;&#160;&#160;&#160;providing CEPI&#8217;s designated Assessor a reasonable opportunity to inspect appropriate CMC data generated by or on behalf of a Partner under any Work Package at the applicable facility(ies) designated by such Partner on reasonable notice during ordinary business hours.</font></div><div style="margin-top:6.05pt;padding-left:97pt;padding-right:19.9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Any disclosures by or on behalf of a Partner pursuant to this Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">11.3</a> shall be made in the form maintained by or on behalf of such Partner and shall be subject to reasonable redactions to the extent reasonably necessary to protect such Partner&#8217;s trade secrets or other non-public financially sensitive information (including CMC data). Each Partner may require written obligations of confidentiality, non-disclosure and non-use between CEPI and its designated Assessor in accordance with Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">18.3.5</a></font><font style="background-color:#e6e6e6;color:#2b569a;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">,</font><font style="color:#2b569a;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">such obligations to include that Assessor will not disclose such information, without the applicable Partner&#8217;s prior written consent.</font></div><div style="margin-top:12.15pt"><font><br></font></div><div style="padding-left:96.95pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">12.&#160;&#160;&#160;&#160;COMPLIANCE</font></div><div style="margin-top:5.85pt;padding-left:97.15pt;padding-right:19.9pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">12.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:117%">Compliance with applicable laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">. Each Partner shall comply, and shall ensure that all of its Sub-contractors comply, with all laws and regulations that are applicable to its activities, operations and use of CEPI funds under the Project.</font></div><div style="margin-top:5.6pt;padding-left:97.1pt;padding-right:19.8pt;text-align:justify;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CEPI&#8217;s Third Party Code and Cost Guidance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Third Party Code is a statement of CEPI&#8217;s values and of the policies, practices and principles applicable to recipients of CEPI funding. CEPI shall notify each Partner of material changes to the Code without undue delay. Neither Partner shall be subject to any changes to the Code or any other applicable policy of CEPI without such Partner&#8217;s prior written consent&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">that&#58; (i) each Partner shall consider in good faith any changes to the Code or other applicable policy that are provided to such Partner in writing and shall not unreasonably withhold, condition or delay its agreement to be bound by any changes to the Code or other applicable policy, and (ii) in the event such Partner withholds, conditions or delays (for more than thirty (30) Business Days after receipt of CEPI&#8217;s notice) any such consent, CEPI shall have the right to terminate such Partner&#8217;s involvement in this Agreement pursuant to Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">19.4.3.</a> CEPI&#8217;s Cost Guidance provides additional information regarding the treatment of costs.</font></div><div style="margin-top:6.1pt;padding-left:96.95pt;text-align:justify;text-indent:-35.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Partner Responsibilities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Each Partner&#58;</font></div><div style="margin-top:5.95pt;padding-left:132.9pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.3.1&#160;&#160;&#160;&#160;acknowledges the statement of CEPI&#8217;s values in Section 1 of the Code&#59;</font></div><div style="margin-top:6pt;padding-left:133.05pt;padding-right:19.9pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.3.2&#160;&#160;&#160;&#160;shall adhere to business practices, ethical principles and legal requirements that are at least substantially similar to those described in Sections 2 to 10 of the Code&#59;</font></div><div style="margin-top:6pt;padding-left:133pt;padding-right:19.95pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.3.3&#160;&#160;&#160;&#160;confirms that it has understood and will comply with the provisions of the &#8216;Accurate Records and Documentation&#8217; paragraph in Section 10 of the Code&#59;</font></div><div style="margin-top:5.9pt;padding-left:133pt;padding-right:19.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">12.3.4&#160;&#160;&#160;&#160;shall comply with the requirements for reporting compliance concerns and misconduct to CEPI (Sections 4 and 11 of the Code)&#59;</font></div><div style="margin-top:5.5pt;padding-left:133pt;padding-right:19.8pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.3.5&#160;&#160;&#160;&#160;shall cooperate as may be reasonably requested by CEPI in the submission of information related to Project activities and expenditures in accordance with the</font></div><div style="margin-top:10.65pt"><font><br></font></div><div style="padding-left:6.85pt;padding-right:6.85pt;text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:41.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.706%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sensitivity&#58; Official Use</font></div></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">           28</font></div></div></div><hr style="page-break-after:always"><div style="min-height:35.28pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="margin-top:11.25pt"><font><br></font></div><div style="padding-left:133pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">International Aid Transparency Initiative (Section 12 of the Code)&#59;</font></div><div style="margin-top:5.8pt;padding-left:133pt;padding-right:19.85pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.3.6&#160;&#160;&#160;&#160;shall comply with the terms and conditions of this Agreement that are being adopted in furtherance of CEPI&#8217;s Equitable Access Policy, which is further described in Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">14</a> of this Agreement&#59; provided that the Parties acknowledge that the Partner&#8217;s obligations set forth Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">14</a> herein shall be deemed to comply with, and to satisfy any specific performance obligations under, CEPI&#8217;s Equitable Access Policy&#59;</font></div><div style="margin-top:6.1pt;padding-left:133pt;padding-right:19.85pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.3.7&#160;&#160;&#160;&#160;to the extent applicable to the Project, comply with CEPI&#8217;s Animals in Research Policy&#59;</font></div><div style="margin-top:6pt;padding-left:133pt;padding-right:19.85pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.3.8&#160;&#160;&#160;&#160;to the extent applicable to the Project, rely upon its own reasonable and customary policies and principles so as to comply with, and&#47;or enable CEPI to comply with&#58;</font></div><div style="padding-left:133pt;padding-right:19.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">(i) CEPI&#8217;s Clinical Trials Policy&#59; (ii) CEPI&#8217;s Managing Conflicts of Interest Policy&#59; (iii) CEPI&#8217;s Scientific Integrity Policy&#59; (iv) CEPI&#8217;s Transparency and Confidentiality Policy&#59; and (v) CEPI&#8217;s Travel and Expenses Policy&#59; and</font></div><div style="margin-top:5.6pt;padding-left:133pt;padding-right:19.85pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.3.9&#160;&#160;&#160;&#160;shall, for any Sub-Contractor not listed in Annex G, comply with the provisions of the Third Party Code related to Sub-Contractors (Section 14 of the Code) and for any Subawardee not listed in the iPDP, comply with the provisions of the Third Party Code related to Sub-Grantees (Section 15 of the Code).</font></div><div style="margin-top:5.95pt;padding-left:97.05pt;padding-right:19.9pt;text-align:justify;text-indent:-35.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Compliance Audit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. During the Term and for a period of &#91;***&#93; after expiration or termination of this Agreement, CEPI, or an auditor appointed by CEPI, shall be entitled not more than once annually to audit each Partner&#8217;s performance of its compliance obligations under this Agreement, upon reasonable advance notice of at least &#91;***&#93;. Such audits will be conducted during normal operating hours, on a date and at such time as reasonably agreed by CEPI and the audited Partner, in a reasonable manner and in a manner so as to minimise disruption to such Partner&#8217;s business. Such audits may include requests for documentation concerning such Partner&#8217;s own costs as well as Subawardees&#8217; costs in connection with the Project, and such Partner shall use all reasonable endeavours to provide such documentation to CEPI without undue delay. CEPI shall cause any auditor pursuant to this Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">12.4</a> to enter into a reasonably acceptable confidentiality agreement with the audited Partner obligating such auditor to retain all such information in confidence pursuant to such confidentiality agreement.</font></div><div style="margin-top:6.1pt;padding-left:97.15pt;padding-right:19.85pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Compliance by Sub-Contractors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Each Partner shall use all reasonable endeavours to ensure that any Sub-Contractors engaged for the Project conduct any activities pursuant to this Agreement in accordance with the compliance obligations in this Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">12</a> in all material respects. If any Partner becomes aware that a Sub-Contractor does not comply with the compliance obligations in this Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">12</a> in all material respects, such Partner shall promptly notify CEPI and the Parties will discuss in good faith whether such Sub- Contractor can be brought into compliance within a reasonable time or whether any other actions are necessary to achieve compliance.</font></div><div style="margin-top:12pt"><font><br></font></div><div style="padding-left:97pt;text-indent:-36.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">13.&#160;&#160;&#160;&#160;READY RESERVE OF PROJECT CLINICAL TRIAL MATERIAL</font></div><div style="margin-top:6.1pt;padding-left:97pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Ready Reserve.</font></div><div style="margin-top:5.8pt;padding-left:132.9pt;text-indent:-35.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13.1.1&#160;&#160;&#160;&#160;CEPI and a Partner may mutually agree in writing that such Partner shall</font></div><div style="margin-top:10pt"><font><br></font></div><div style="padding-left:6.85pt;padding-right:6.85pt;text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:41.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.706%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sensitivity&#58; Official Use</font></div></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">           29</font></div></div></div><hr style="page-break-after:always"><div style="min-height:35.28pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="margin-top:11.1pt"><font><br></font></div><div style="padding-left:132.95pt;padding-right:19.75pt;text-align:justify;text-indent:0.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">undertake the manufacturing, or having manufactured, and maintenance of a Ready Reserve of Project Clinical Trial Material through a Work Package. If at any time a Partner wishes to dispose of the Ready Reserve of Product Clinical Trial Material it is storing, such Partner shall discuss the same with CEPI (including taking into consideration, without limitation, the shelf-life of such materials) and may only dispose of such materials after it has received CEPI&#8217;s prior written consent (which shall not be unreasonably withheld, conditioned or delayed). Such Ready Reserve of Project Clinical Trial Material may be used&#58; (a) for further clinical trials pursuant to a mutually agreed Work Package, (b) to otherwise advance development of the Project Vaccine, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">such Research Reserve of Project Clinical Trial Material is not necessary for activities pursuant to clause (a) at such time, or (c) for emergency use (subject to obtaining all necessary regulatory approvals and consents) in emergency situations based on national or international guidance (such as from WHO) or in such other manner, in each case as may be agreed in the relevant Work Package or otherwise by the Parties in writing.</font></div><div style="margin-top:6.05pt;padding-left:132.95pt;padding-right:19.75pt;text-align:justify;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13.1.2&#160;&#160;&#160;&#160;For the purposes of this Agreement, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Ready Reserve of Project Clinical Trial Material</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means an agreed quantity of doses of the Project Vaccine for potential use in a clinical trial. At the Effective Date, Barinthus Bio has agreed that it will, subject to achievement of the relevant Stage Gate, manufacture or have manufactured and store as a Ready Reserve of Project Clinical Trial Material &#91;***&#93; in accordance with GMP and all other requirements and specifications agreed with CEPI. Promptly following achievement of the relevant Stage Gate, Barinthus Bio will submit to CEPI a reasonable budget detailing the reasonable costs of storage and stability testing of the Ready Reserve of Project Clinical Trial Material for approval by CEPI, such approval not to be unreasonably withheld, conditioned or delayed. From time to time, Barinthus Bio shall submit to CEPI revised budgets detailing such costs for approval by CEPI, such approval not to be unreasonably withheld, conditioned or delayed. CEPI shall bear Barinthus Bio&#8217;s out-of-pocket costs incurred in performing such storage and stability testing, provided that CEPI shall not be required to pay any mark-up or handling charges.</font></div><div style="margin-top:12.1pt"><font><br></font></div><div style="padding-left:96.95pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">14.&#160;&#160;&#160;&#160;EQUITABLE ACCESS.</font></div><div style="margin-top:5.85pt;padding-left:97.15pt;padding-right:19.85pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Commitment to Equitable Access</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Each Partner and CEPI confirm their commitment to achieving Equitable Access to the results of all CEPI-supported programmes, whether in an Outbreak, Increased Outbreak Preparation Need, epidemic or pandemic situation, as provided herein with respect to any Project Vaccine in accordance with CEPI&#8217;s &#8220;Equitable Access Policy&#8221;.</font></div><div style="margin-top:6.1pt;padding-left:96.95pt;text-align:justify;text-indent:-35.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Equitable Access Plan.</font></div><div style="margin-top:5.95pt;padding-left:133pt;padding-right:19.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.2.1&#160;&#160;&#160;&#160;The initial plan to support such Equitable Access commitment is set out in Annex E (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Equitable Access Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)&#59; and the Equitable Access Plan shall be reviewed by the JMAG and&#47;or the Equitable Access Group after it is established in accordance with Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">14.3</a> no less than every &#91;***&#93; and shall take</font></div><div style="margin-top:8.65pt"><font><br></font></div><div style="padding-left:6.85pt;padding-right:6.85pt;text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:41.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.706%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sensitivity&#58; Official Use</font></div></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">           30</font></div></div></div><hr style="page-break-after:always"><div style="min-height:35.28pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="margin-top:11.1pt"><font><br></font></div><div style="padding-left:133pt;padding-right:19.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">into account, as applicable, changes in COGs over time, production yield and volume and production economics. The Equitable Access Plan shall be updated throughout the Term to reflect such reviews or as otherwise agreed between the Parties. A significantly more detailed Equitable Access Plan shall be agreed promptly after the Equitable Access Group is established. Each Partner will keep CEPI fully and regularly informed of its adherence to the Equitable Access Plan and its progress, or lack thereof, in meeting its objectives.</font></div><div style="margin-top:6.05pt;padding-left:133pt;padding-right:19.7pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.2.2&#160;&#160;&#160;&#160;The Equitable Access Plan shall include a commitment from the Partners to negotiate future purchase, allocation and supply commitments in respect of the Project Vaccine(s), with purchasers in LMICs and UMICs, including with relevant international public health stakeholders such as Gavi, UNICEF and the Pan American Health Organisation.</font></div><div style="margin-top:6pt;padding-left:97pt;padding-right:19.7pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Equitable Access Group</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Parties will establish an Equitable Access Group that shall meet regularly to monitor the progress of and advance the Partners commitment to Equitable Access. The Equitable Access Group shall coordinate the efforts of the Parties to update the Equitable Access Plan and set out how the Project Vaccine will be used to enable Equitable Access. The rules and frequency of meeting of the Equitable Access Group shall be the same as for the JMAG, unless otherwise agreed by the Parties in writing.</font></div><div style="margin-top:6pt;padding-left:97.15pt;padding-right:19.7pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Information about Production, Supply, Pricing and Sales</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Upon written request by CEPI, each Partner shall provide reasonable information about its COGs, production, supply, pricing and sales of the Project Vaccine, sufficient to enable CEPI to evaluate whether such activities are consistent with the Partners&#8217; obligations under this Agreement.</font></div><div style="margin-top:5.9pt;padding-left:97.15pt;padding-right:19.8pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Pricing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Parties acknowledge that the price of the Project Vaccine is critical to achieving Equitable Access. Accordingly, the Partners each agree, and shall each procure that its licensees (and any sublicensees) agree, that the pricing of, and any other payments received with respect to, the Project Vaccine shall be as reasonably required to achieve Equitable Access for populations in need of such products, recognising that on-going supply should be commercially sustainable and, in any event, shall reflect the terms agreed in the Equitable Access Plan. Each Partner shall ensure that, and shall procure that its Affiliates, licensees and sublicensees ensure that&#58;</font></div><div style="margin-top:6.1pt;padding-left:133pt;padding-right:19.85pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.5.1&#160;&#160;&#160;&#160;when sold in an LMIC, the price of any Project Vaccine does not exceed &#91;***&#93;&#59; and</font></div><div style="margin-top:5.95pt;padding-left:133pt;padding-right:19.85pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.5.2&#160;&#160;&#160;&#160;when sold in a UMIC, the price of any Project Vaccine does not exceed &#91;***&#93;.</font></div><div style="margin-top:6.05pt;padding-left:97.15pt;padding-right:19.85pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Public Health Licence</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Subject to the terms of this Agreement, each Partner hereby grants (and shall ensure that each Subawardee grants) to CEPI a non-exclusive, worldwide, irrevocable, fully paid up, royalty free license under such Partner&#8217;s Enabling Rights that is necessary or reasonably useful to develop, manufacture, and commercialise the Project Vaccine in order to achieve Equitable Access during the Term and for &#91;***&#93; thereafter (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Public Health License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), on the condition that CEPI may only</font></div><div style="margin-top:2.65pt"><font><br></font></div><div style="padding-left:3.42pt;padding-right:3.42pt;text-align:center"><font><br></font></div><div style="height:41.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.706%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sensitivity&#58; Official Use</font></div></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">           31</font></div></div></div><hr style="page-break-after:always"><div style="min-height:35.28pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="margin-top:11.25pt"><font><br></font></div><div style="padding-left:97.15pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">exercise the Public Health License in the event that&#58;</font></div><div style="margin-top:5.95pt;padding-left:132.9pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.6.1&#160;&#160;&#160;&#160;CEPI is not in material breach of its obligations under this Agreement&#59; and</font></div><div style="margin-top:5.95pt;padding-left:133pt;padding-right:19.85pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.6.2&#160;&#160;&#160;&#160;one or more of the triggers set out in Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">14.7</a> has occurred with respect to such Partner.</font></div><div style="margin-top:6pt;padding-left:95.8pt;padding-right:19.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Public Health License shall be sub-licensable to one or more third parties. Notwithstanding the foregoing, CEPI acknowledges and agrees that each Partner&#8217;s obligations to any Third Party Collaborators may limit the availability or the scope of a Partner&#8217;s sublicensees, and as such, if required by CEPI, such Partner shall use reasonable efforts to facilitate the necessary arrangements between CEPI and any Third Party Collaborators, as contemplated in Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">3.4.</a> Any sublicence of the Public Health License shall be in writing and CEPI shall require that each sublicensee complies with the terms of the Public Health Licence.</font></div><div style="margin-top:6pt;padding-left:97.15pt;padding-right:19.8pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">14.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:117%">Public Health Licence Triggers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">. Consistent with Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%;text-decoration:none">14.6,</a> CEPI shall have the right to exercise the Public Health Licence with respect to a Partner, in the event that any one or more of the following events occurs with respect to such Partner&#58;</font></div><div style="padding-right:19.8pt;text-align:justify"><font><br></font></div><div style="padding-left:94.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.7.1&#160;&#160;&#160;&#160;&#91;***&#93;</font></div><div style="padding-left:72pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.7.2&#160;&#160;&#160;&#160;&#91;***&#93;</font></div><div style="padding-left:130.5pt;padding-right:19.8pt;text-align:justify;text-indent:-36.01pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.7.3&#160;&#160;&#160;&#160;Such Partner is in material breach of this Agreement or the Equitable Access Plan and has not cured such breach &#91;***&#93;&#59; or</font></div><div style="margin-top:6pt;padding-left:133pt;padding-right:19.75pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.7.4&#160;&#160;&#160;&#160;The Agreement is terminated by CEPI pursuant to Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">19.3</a> (Termination by CEPI for Default or Insolvency) or Clauses <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">19.4.5</a> (failure to satisfy payment criteria), <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">19.4.6</a> (Financial Irregularity) or <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">19.4.7</a> (reputation impact).</font></div><div style="margin-top:6pt;padding-left:97.15pt;padding-right:19.9pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Effects of Exercise of the Public Health Licence</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Upon exercise of the Public Health Licence by CEPI and provision of written notice to the Partners, the Partner in respect of which the Public Health Licence has been exercised shall promptly&#58;</font></div><div style="margin-top:6.2pt;padding-left:132.9pt;text-align:justify;text-indent:-35.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.8.1&#160;&#160;&#160;&#160;provide CEPI with an up-to-date written list of all its Enabling Rights&#59; and</font></div><div style="margin-top:5.85pt;padding-left:133pt;padding-right:19.7pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.8.2&#160;&#160;&#160;&#160;promptly and diligently make available to CEPI all guidance, information, materials and assistance reasonably required to accomplish any Project activities that were to be performed by such Partner, and which guidance, information, materials and assistance are identified by CEPI. Such transfer shall be&#58; (i) in the event the Public Health Licence is exercised by CEPI pursuant to Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">14.7.1</a> or Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">14.7.2</a> at CEPI&#8217;s reasonable cost&#59; or (ii) in the event the Public Health Licence is exercised by CEPI pursuant to Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">14.7.3</a> or Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">14.7.4</a> at such Partner&#8217;s cost.</font></div><div style="margin-top:6.05pt;padding-left:97.1pt;padding-right:19.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.9&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Effects of Termination of Barinthus Bio Licence Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. In addition to the foregoing, in the event that the licence agreement between Oxford University Innovation Limited, a private limited company registered in England and Wales with company number 02199542 and with its registered office address at University Offices, Wellington Square, Oxford, OX1 2JD (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">OUI</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and Barinthus Bio dated 4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> March 2016 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Barinthus Bio Licence Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) is terminated, then Oxford shall, and shall procure that OUI shall, immediately upon such termination, grant to CEPI a non-exclusive, worldwide, irrevocable, fully paid up, royalty free license under all rights previously licensed to Barinthus Bio pursuant to the Barinthus Bio Licence Agreement that are necessary or reasonably useful to develop, manufacture, and commercialise the Project Vaccine in order to achieve Equitable Access during the Term and for twenty (20) years thereafter.</font></div><div style="margin-top:12.05pt"><font><br></font></div><div style="padding-left:96.95pt;text-align:justify;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">15.&#160;&#160;&#160;&#160;COMMERCIAL BENEFITS</font></div><div style="margin-top:12.1pt;padding-left:96.95pt;text-align:justify;text-indent:-35.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Barinthus Bio</font></div><div style="margin-top:5.85pt;padding-left:133pt;padding-right:20.15pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.1.1&#160;&#160;&#160;&#160;Barinthus Bio shall pay to CEPI the following percentage of each of Net Sales and Net Income received during the Royalty Term&#58; &#91;***&#93;</font></div><div style="height:41.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.706%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sensitivity&#58; Official Use</font></div></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">           32</font></div></div></div><hr style="page-break-after:always"><div style="min-height:35.28pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6.2pt;padding-left:132.9pt;text-align:justify;text-indent:-35.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.1.2&#160;&#160;&#160;&#160;Barinthus Bio shall pay CEPI the following percentages of Net Revenue&#58;</font></div><div style="margin-top:5.85pt;padding-left:169pt;padding-right:19.85pt;text-align:justify;text-indent:-46.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">&#91;***&#93;.</font></div><div style="margin-top:5.95pt;padding-left:133pt;padding-right:19.9pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.1.3&#160;&#160;&#160;&#160;Barinthus Bio shall pay to CEPI &#91;***&#93; of any PRV Proceeds received during the Royalty Term.</font></div><div style="margin-top:5.9pt;padding-left:133pt;padding-right:19.85pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.1.4&#160;&#160;&#160;&#160;Barinthus Bio shall promptly notify CEPI, in writing, of any Commercial Benefits arising from the Project Vaccine, including details of all Net Income, Net Sales and Net Revenue received, on which payments are due hereunder. Once the foregoing notification has been provided, Barinthus Bio shall, from then on, submit to CEPI within &#91;***&#93;, a written report setting out the details of (i) the price at which Barinthus Bio and its Affiliates sell Project Vaccines in LMICs or UMICs, including COGs for such Project Vaccines (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Selling Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), and (ii) all Net Income, Net Sales and Net Revenue received by Barinthus Bio &#91;***&#93; and the associated payment due to CEPI under Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">15.1.1.</a> CEPI will invoice Barinthus Bio for the payments due to CEPI under Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">15.1.1</a> on the Net Income, Net Sales and Net Revenue reported by Barinthus Bio and Barinthus Bio will pay such amounts to CEPI within &#91;***&#93; following receipt of such invoice.</font></div><div style="margin-top:5.95pt;padding-left:133pt;padding-right:19.9pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.1.5&#160;&#160;&#160;&#160;All payments made under this Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">15</a> shall be payable in US dollars and be made by wire transfer in immediately available funds to a bank and account designated in writing by CEPI, unless otherwise specified in writing by CEPI.</font></div><div style="margin-top:6.1pt;padding-left:133pt;padding-right:19.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.1.6&#160;&#160;&#160;&#160;If any Net Income or Net Revenue is received as non-cash consideration, Barinthus Bio shall, at Barinthus Bio&#8217;s discretion, either&#58; (i) transfer a percentage of such non-cash consideration into the name of CEPI to satisfy Barinthus Bio&#8217;s obligation under Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">15.1.1</a>&#59; or (ii) transfer cash to CEPI calculated based on applying the applicable percentage set out in Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">15.1</a> to the cash value of such Net Income or Net Revenue at the time such non-cash consideration was received by Barinthus Bio, with either Party having the right to refer the determination of the cash value of such non-cash consideration to a mutually agreed independent expert for determination if the Parties do not agree on such cash value.</font></div><div style="margin-top:5.9pt;padding-left:133pt;padding-right:19.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.1.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Financial Records and Audits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Barinthus Bio shall keep, and shall require its Affiliates to keep, accurate records pertaining to all Net Income, Net Sales and Net Revenue received by Barinthus Bio and its Affiliates. If requested by CEPI, and at CEPI&#8217;s reasonable cost, once annually upon reasonable prior notice, Barinthus Bio agrees to an external audit firm appointed by CEPI, reasonably acceptable to Barinthus Bio, conducting an audit with respect to all amounts owed to CEPI pursuant to this Agreement, including in respect of the calculation of Net Income, Net Sales and Net Revenue and associated payments to CEPI, in accordance with ISA800 and&#47;or ISA805 and like standards and provide CEPI with an audit report. Such inspections shall be conducted during normal operating hours, on advance notice of at least &#91;***&#93; on dates and at such times as reasonably agreed by CEPI and Barinthus Bio, in a reasonable manner and in a manner to minimise disruption to Barinthus Bio&#8217;s activities. The receiving Party shall treat all information subject to review under this Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">15.1.7</a> in accordance with the confidentiality provisions of Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">18</a>. CEPI shall cause any auditor pursuant to this Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">15.1.7</a> to enter into a reasonably acceptable confidentiality agreement with Barinthus Bio obligating such firm to retain all such financial information in confidence pursuant to such confidentiality agreement. CEPI shall disclose to Barinthus Bio the audit report, and, to the extent that it is in CEPI&#8217;s possession, any calculations and workings underlying it, and shall give Barinthus Bio an opportunity to discuss the report with CEPI and the audit firm. Absent manifest error or fraud, the audit report shall be binding on both Parties. Barinthus Bio promptly pay any shortfall to CEPI, and CEPI shall promptly repay any overpayment, and if the report finds an underpayment by</font></div><div style="margin-top:1.45pt"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:41.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.706%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sensitivity&#58; Official Use</font></div></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">           33</font></div></div></div><hr style="page-break-after:always"><div style="min-height:35.28pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="margin-top:11.1pt"><font><br></font></div><div style="padding-left:133pt;padding-right:19.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Barinthus Bio of more than &#91;***&#93; Barinthus Bio shall pay the reasonable fees and expenses charged by the audit firm. Otherwise the costs of the audit firm shall be payable by CEPI. If either Party challenges the audit report on the basis of manifest error or fraud, the matter shall be dealt with under Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">20</a> (Resolving Differences).</font></div><div style="margin-top:6pt;padding-left:133pt;padding-right:19.75pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.1.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Selling Price and COGs Audit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Barinthus Bio shall keep, and shall require its Affiliates and manufacturers (as applicable) to keep, accurate records pertaining to the Selling Price and the calculation of COGs in respect of the Project Vaccine in order to demonstrate Barinthus Bio&#8217;s compliance with its obligations under Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">14.5</a>. If requested by CEPI, and at CEPI&#8217;s reasonable cost, Barinthus Bio shall provide to CEPI all such records and any supporting documentation reasonably requested by CEPI for review by CEPI or an external audit firm appointed by CEPI, reasonably acceptable to Barinthus Bio. If requested by CEPI or Barinthus Bio, Barinthus Bio and CEPI and any such audit firm shall meet to discuss the Selling Price and such calculation. Such review shall take place no more than once annually. CEPI shall treat all information subject to review under this Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">15.1.8</a> in accordance with the confidentiality provisions of Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">18.</a> CEPI shall cause any audit firm receiving information pursuant to this Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">15.1.8</a> to enter into a reasonably acceptable confidentiality agreement with Barinthus Bio obligating such firm to retain all such information in confidence pursuant to such confidentiality agreement. CEPI shall disclose to Barinthus Bio the results of any such review, and, to the extent it is in CEPI&#8217;s possession, any calculations and workings underlying those results, and shall give Barinthus Bio an opportunity to discuss the results of the review with CEPI and the audit firm. Absent manifest error or fraud, if the audit report concludes that there has been an error in the calculation of the Selling Price, this shall be binding on both Parties and &#91;***&#93;. For the avoidance of doubt, any remedies set out in this Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">15.1.8</a> are in addition to all other remedies available to CEPI, whether under this Agreement, at law or in equity.. If either Party challenges the audit report, on the basis of manifest error or fraud, the matter shall be dealt with under Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">20</a> (Resolving Differences).</font></div><div style="margin-top:6.2pt;padding-left:96.95pt;text-align:justify;text-indent:-35.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Oxford</font></div><div style="margin-top:5.8pt;padding-left:133pt;padding-right:19.85pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.2.1&#160;&#160;&#160;&#160;Oxford will promptly notify CEPI of any Commercial Benefits it receives. Promptly after receipt of such notification, Oxford and CEPI shall enter into a revenue share agreement detailing the share of Commercial Benefits that will be allocated to CEPI.</font></div><div style="margin-top:6.05pt;padding-left:133pt;padding-right:19.9pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.2.2&#160;&#160;&#160;&#160;The share of Commercial Benefits received by CEPI shall be proportionate to the added value of CEPI&#8217;s funding under this Agreement, taking into account all relevant factors, including the amount of funding by CEPI and the results of such funding. Without prejudice to the foregoing, CEPI does not require a share of Commercial Benefits received from the exploitation of the Project Results for the</font></div><div style="margin-top:8pt"><font><br></font></div><div style="padding-left:6.85pt;padding-right:6.85pt;text-align:center"><font><br></font></div><div style="height:41.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.706%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sensitivity&#58; Official Use</font></div></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">           34</font></div></div></div><hr style="page-break-after:always"><div style="min-height:35.28pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="margin-top:11.1pt"><font><br></font></div><div style="padding-left:133pt;padding-right:19.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">benefit of LMICs, including technology transfer to manufacturers or service providers who are engaged specifically to assist in making vaccines available to LMICs.</font></div><div style="margin-top:5.75pt;padding-left:97pt;text-indent:-35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Tax</font></div><div style="margin-top:5.95pt;padding-left:133pt;padding-right:19.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.3.1&#160;&#160;&#160;&#160;Payments under this Agreement are to be made without withholding for or on account of any tax unless required by law, in which case, any such tax withheld shall be treated as having been paid by the paying Party to the recipient Party for all purposes under this Agreement, and the paying Party shall duly account for such tax withheld to the relevant tax authority and provide reasonable evidence of this to the recipient Party. The paying Party will notify the recipient Party in writing as soon as reasonably practicable once it becomes aware it has an obligation to so withhold, and the Parties will cooperate with respect to reasonable requests by that recipient Party to secure a reduction in the rate of, or eliminate, applicable withholding tax or to permit that recipient Party to obtain a repayment of, or credit for, tax withheld. &#91;***&#93;.</font></div><div style="margin-top:12.1pt"><font><br></font></div><div style="padding-left:97pt;text-indent:-36.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">16.&#160;&#160;&#160;&#160;REPRESENTATIONS AND WARRANTIES</font></div><div style="margin-top:5.8pt;padding-left:97.15pt;padding-right:19.85pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">16.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:118%">Partner Warranties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">. Each Partner warrants that the following statements are true and correct as of the Effective Date&#58;</font></div><div style="margin-top:5.55pt;padding-left:133pt;padding-right:19.85pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16.1.1&#160;&#160;&#160;&#160;it has the full power and authority to enter into and assume its obligations under this Agreement&#59;</font></div><div style="margin-top:6pt;padding-left:133pt;padding-right:19.85pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16.1.2&#160;&#160;&#160;&#160;this Agreement has been duly executed by it and is legally binding and enforceable on it in accordance with its terms, except to the extent that enforcement of the rights and remedies created hereby is subject to&#58; (i) bankruptcy, insolvency, reorganization, moratorium and other similar laws of general application affecting the rights and remedies of creditors&#59; or (ii) laws governing specific performance, injunctive relief and other equitable remedies&#59;</font></div><div style="margin-top:5.95pt;padding-left:133pt;padding-right:19.85pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16.1.3&#160;&#160;&#160;&#160;it is in material compliance with all statutes, regulations, directives and requirements of any governmental entity related to the conduct of the Project hereunder&#59;</font></div><div style="margin-top:6pt;padding-left:133pt;padding-right:19.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">16.1.4&#160;&#160;&#160;&#160;it has disclosed in writing to CEPI any actual commitments or obligations to provide to third parties Project Vaccine doses&#59;</font></div><div style="margin-top:5.5pt;padding-left:133pt;padding-right:19.85pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16.1.5&#160;&#160;&#160;&#160;its actions or obligations under any Work Package will not infringe, misappropriate or violate any Third Party Intellectual Property, privacy or publicity rights&#59;</font></div><div style="margin-top:5.95pt;padding-left:133pt;padding-right:19.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">16.1.6&#160;&#160;&#160;&#160;the execution of this Agreement does not conflict with the terms or conditions of any written agreement, instrument or understanding to which it is a party&#59; or violate any applicable law or regulation of any court, governmental body or administrative agency having jurisdiction over such Partner&#59;</font></div><div><font><br></font></div><div style="margin-top:3.55pt"><font><br></font></div><div style="padding-left:6.85pt;padding-right:6.85pt;text-align:center"><font><br></font></div><div style="height:41.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.706%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sensitivity&#58; Official Use</font></div></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">           35</font></div></div></div><hr style="page-break-after:always"><div style="min-height:35.28pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="margin-top:11.1pt"><font><br></font></div><div style="padding-left:133pt;padding-right:19.9pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16.1.7&#160;&#160;&#160;&#160;neither such Partner nor any agreed Subawardees, if any, nor any officer or employee of the foregoing has been debarred or is subject to debarment under 21</font></div><div style="margin-top:0.05pt;padding-left:133pt;padding-right:19.9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">U.S.C. 335(a) or under similar provision by a Regulatory Authority or funding agency anywhere in the world&#59;</font></div><div style="margin-top:6pt;padding-left:133pt;padding-right:19.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16.1.8&#160;&#160;&#160;&#160;all financial and other information with respect to the Project Vaccine submitted to CEPI by such Partner in relation to this Agreement is true, complete and accurate in all material respects&#59;</font></div><div style="margin-top:6.1pt;padding-left:132.9pt;text-align:justify;text-indent:-35.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16.1.9&#160;&#160;&#160;&#160;it is not&#58;</font></div><div style="margin-top:12.3pt;padding-left:161.7pt;text-align:justify;text-indent:-39.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;a Restricted Party&#59;</font></div><div style="margin-top:5.95pt;padding-left:161.6pt;text-align:justify;text-indent:-39pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;in breach of Sanctions from a Sanctions Authority&#59; or</font></div><div style="margin-top:5.95pt;padding-left:161.7pt;padding-right:19.85pt;text-align:justify;text-indent:-39.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">(iii)&#160;&#160;&#160;&#160;subject to or involved in any complaint, claim, proceeding, formal notice, investigation or other action by any regulatory or enforcement authority or third party concerning any Sanctions from a Sanctions Authority&#59;</font></div><div style="margin-top:5.6pt;padding-left:133pt;padding-right:19.85pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16.1.10&#160;&#160;&#160;&#160;none of the funds provided under this Agreement (whether via a sub-contract or otherwise) are used in any way directly or indirectly to provide support, resources or assets to a Restricted Party, provided, however, that it shall not be a breach of this Agreement to supply vaccines, including the Project Vaccine, to a Restricted Party, provided that such supply of vaccines is exempt from any applicable Sanctions&#59; and</font></div><div style="margin-top:5.95pt;padding-left:133pt;padding-right:19.75pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16.1.11&#160;&#160;&#160;&#160;the Barinthus Bio Licence Agreement is in full force and effect&#59; the version of the Barinthus Bio Licence Agreement provided to CEPI is complete and accurate in all respects and has not been amended, varied, or terminated (whether in whole or in part)&#59; no party has received a notice from any other party seeking to terminate the Barinthus Bio Licence Agreement&#59; and Barinthus Bio is not aware of any material breach of the Barinthus Bio Licence Agreement by any other party to it, nor is Oxford aware of any material breach of the Barinthus Bio Licence by Barinthus Bio.</font></div><div style="margin-top:6.2pt;padding-left:96.95pt;text-align:justify;text-indent:-35.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Partner Representations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. During the Term of this Agreement, each Partner shall&#58;</font></div><div style="margin-top:5.85pt;padding-left:133pt;padding-right:19.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16.2.1&#160;&#160;&#160;&#160;notify CEPI promptly in writing in the event that any of the warranties it has given under Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">16.1</a> would no longer be true and correct were they repeated at the time that such Partner requests any disbursement of Project funds in accordance with Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">3.5</a>&#59; and</font></div><div style="margin-top:6.05pt;padding-left:133.05pt;padding-right:19.8pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16.2.2&#160;&#160;&#160;&#160;notify CEPI promptly if it becomes aware that any actions are reasonably likely to be taken or have already been taken by the government of any country in which such Partner conducts Project activities that may adversely affect such Partner&#8217;s commitments in this Agreement, including Equitable Access. For clarity, such government actions may relate, for example, to the exercise of eminent domain or sovereign rights over Project Vaccine doses.</font></div><div style="margin-top:5.95pt;padding-left:97.1pt;padding-right:19.95pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CEPI Warranties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. CEPI warrants that the following statements are true and correct to its reasonable knowledge and belief, in so far as they relate to the Project, as of the Effective Date&#58;</font></div><div style="margin-top:5.95pt;padding-left:132.9pt;text-align:justify;text-indent:-35.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16.3.1&#160;&#160;&#160;&#160;it has the full power and authority to enter into and assume its obligations under</font></div><div style="margin-top:4.35pt"><font><br></font></div><div style="padding-left:6.85pt;padding-right:6.85pt;text-align:center"><font><br></font></div><div style="height:41.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.706%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sensitivity&#58; Official Use</font></div></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">           36</font></div></div></div><hr style="page-break-after:always"><div style="min-height:35.28pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="margin-top:11.25pt"><font><br></font></div><div style="padding-left:133pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">this Agreement&#59;</font></div><div style="margin-top:5.8pt;padding-left:133pt;padding-right:19.85pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16.3.2&#160;&#160;&#160;&#160;it is in material compliance with all statutes, regulations, directives and requirements of any governmental entity related to the conduct of such Project and the funding of same hereunder&#59;</font></div><div style="margin-top:6.1pt;padding-left:133pt;padding-right:19.85pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16.3.3&#160;&#160;&#160;&#160;it has disclosed in writing to the Partners any actual commitments or obligations to provide to third parties Project Vaccine doses&#59;</font></div><div style="margin-top:5.9pt;padding-left:133pt;padding-right:19.85pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16.3.4&#160;&#160;&#160;&#160;so far as it is aware, its actions or obligations under this Agreement will not infringe, misappropriate or violate any Third Party Intellectual Property, privacy or publicity rights&#59;</font></div><div style="margin-top:6.25pt;padding-left:132.9pt;text-align:justify;text-indent:-35.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16.3.5&#160;&#160;&#160;&#160;it is not&#58;</font></div><div style="margin-top:5.95pt;padding-left:169pt;text-align:justify;text-indent:-46.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;a Restricted Party&#59;</font></div><div style="margin-top:5.95pt;padding-left:169pt;text-align:justify;text-indent:-46.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;in breach of Sanctions from a Sanctions Authority&#59; or</font></div><div style="margin-top:5.95pt;padding-left:169pt;padding-right:19.85pt;text-align:justify;text-indent:-46.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">(iii)&#160;&#160;&#160;&#160;subject to or involved in any complaint, claim, proceeding, formal notice, investigation or other action by any regulatory or enforcement authority or third party concerning any Sanctions from a Sanctions Authority&#59; and</font></div><div style="margin-top:5.55pt;padding-left:132.95pt;padding-right:19.9pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">16.3.6&#160;&#160;&#160;&#160;it has not granted rights to any third party in respect of Project Results (other than in accordance with the terms of this Agreement).</font></div><div style="margin-top:5.55pt;padding-left:97.15pt;padding-right:19.9pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">No Other Warranties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, NO PARTY MAKES, AND EACH PARTY EXPRESSLY DISCLAIMS, ANY AND ALL WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING THE WARRANTIES OF DESIGN, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, VALIDITY OF PATENTS, NON-INFRINGEMENT OF THE INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES, OR ARISING FROM A COURSE OF DEALING, USAGE OR TRADE PRACTICES.</font></div><div style="margin-top:12.05pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:96.95pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">17.&#160;&#160;&#160;&#160;INSURANCE, LIABILITY AND INDEMNIFICATION</font></div><div style="margin-top:5.95pt;padding-left:97.1pt;padding-right:19.3pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Insurance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Each Partner shall maintain insurance that is reasonable and customary with respect to the activities, risks, and potential omissions relevant to the Project, including clinical trial liability insurance coverage, in accordance with generally accepted industry standards and as required by law during the Term and for &#91;***&#93; thereafter. Each Partner shall provide CEPI with a certificate confirming such insurance upon request. In the event that the Public Health License becomes exercisable and CEPI exercises such rights, CEPI shall maintain comparable insurance protection.</font></div><div style="margin-top:6pt;padding-left:96.95pt;text-align:justify;text-indent:-35.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Indemnification for Third Party Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:5.95pt;padding-left:133pt;padding-right:19.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17.2.1&#160;&#160;&#160;&#160;Each Partner shall indemnify CEPI and its Affiliates and its and their respective officers, directors, employees and third party consultants, auditors and Assessors engaged by CEPI for the purposes of this Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CEPI Indemnitees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), from and against any and all claims, damages, and liabilities asserted against such persons by third parties (including claims for negligence) to the extent resulting from (i) such Partner&#8217;s, or its Affiliate&#8217;s or Subawardee&#8217;s activities under this Agreement,  (ii)  the  research,  development,  manufacture,  supply,</font></div><div style="margin-top:11.25pt"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:41.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.706%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sensitivity&#58; Official Use</font></div></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">           37</font></div></div></div><hr style="page-break-after:always"><div style="min-height:35.28pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="margin-top:11.1pt"><font><br></font></div><div style="padding-left:133pt;padding-right:19.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">commercialisation, disposal or use by or on behalf of such Partner, its third party licensees, Subawardees and its Affiliates, including all customers and end users thereof, of the Project Vaccine, Project Intellectual Property or any Project Results&#59; or (iii) any claim that the use of such Partner&#8217;s Intellectual Property in relation to the Project Vaccine infringes the intellectual property rights of any third party, except to the extent such claim, damage or liability is caused by breach of any term or condition of this Agreement by, or the negligence or intentional misconduct of, any CEPI Indemnitees.</font></div><div style="margin-top:6pt;padding-left:133pt;padding-right:19.65pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17.2.2&#160;&#160;&#160;&#160;In the event that the Public Health License becomes exercisable and CEPI exercises such rights, CEPI shall grant an indemnity to the Partner(s) in respect of which the Public Health Licence has been granted on the same terms as the indemnity set out in this Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">17.2</a>, which shall apply to CEPI </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">mutatis mutandis.</font></div><div style="margin-top:6.05pt;padding-left:132.95pt;padding-right:19.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17.2.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Conduct of Responses to Third Party Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The indemnified party shall use all reasonable endeavours to inform the indemnifying Party promptly of any circumstances that are likely to give rise to a third party claim which may be covered by Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">17.2.1</a> together with copies of all relevant documents, correspondence and records. The indemnified party shall not take any material action in respect of any third party claim which is covered by Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">17.2.1</a> without the consent of the indemnifying party, including any settlement of any such third party claim, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">such consent is not unreasonably conditioned, withheld or delayed. The indemnifying party shall have the right to assume control of defence of the claim and shall keep the indemnified party reasonably informed of the progress of all relevant third party claims which are covered by Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">17.2.1</a> and shall consult with the indemnified party on the nature of any defence to be advanced in advance. The indemnified party may have its counsel participate in (but not control) the defence of a claim, at the indemnified party&#8217;s own expense.</font></div><div style="margin-top:6pt;padding-left:133pt;padding-right:19.85pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17.2.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exclusions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. No Party shall be liable to any other Party for any loss of profits, loss of opportunity, loss of contract or bargain (in each case, whether direct or indirect damages)&#59; or indirect, incidental, consequential, special, punitive or exemplary losses or damages, whether in contract, warranty, negligence, tort, strict liability, indemnity, contribution or otherwise, arising out of or in connection with this Agreement.</font></div><div style="margin-top:5.95pt;padding-left:97.15pt;padding-right:19.75pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Liability Cap</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Subject to Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">17.4,</a> CEPI&#8217;s maximum liability in aggregate arising out of, or in connection with, this Agreement shall not exceed &#91;***&#93;. Notwithstanding the foregoing, if CEPI has exercised the Public Health License, or if CEPI is in breach of the confidentiality obligations in Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">18,</a> CEPI&#8217;s maximum liability in aggregate to Partner shall not exceed &#91;***&#93;. Subject to Clause 17.4, the maximum liability of each Partner to any other Party in aggregate arising out of, or in connection with, this Agreement shall not exceed &#91;***&#93;</font></div><div style="margin-top:8.05pt"><font><br></font></div><div style="height:41.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.706%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sensitivity&#58; Official Use</font></div></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">           38</font></div></div></div><hr style="page-break-after:always"><div style="min-height:35.28pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="margin-top:11.1pt"><font><br></font></div><div style="margin-top:5.6pt;padding-left:97.15pt;padding-right:19.8pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exclusions from Liability Cap</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Notwithstanding the foregoing, nothing in this Agreement shall limit the liability of any Party in respect of&#58; (i) personal injury or death arising out of that Party&#8217;s negligence or intentional misconduct&#59; (ii) fraud or fraudulent misrepresentation or intentional misconduct, (iii) any Party&#8217;s obligations under Clause</font></div><div style="margin-top:0.05pt;padding-left:97.15pt;padding-right:19.9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%"><a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%;text-decoration:none">17.2</a> or, (iv) any Party&#8217;s obligation to make payments to any other Party, subject to any applicable rights to withhold, condition, delay or otherwise not pay as permitted under this Agreement.</font></div><div style="margin-top:11.65pt"><font><br></font></div><div style="padding-left:96.95pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">18.&#160;&#160;&#160;&#160;CONFIDENTIALITY</font></div><div style="margin-top:6.1pt;padding-left:96.95pt;text-align:justify;text-indent:-35.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:5.8pt;padding-left:133pt;padding-right:19.85pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18.1.1&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means information disclosed by one Party to another Party or its Affiliates or designees (including, for clarity, any information disclosed by or on behalf of a Partner (i) to CEPI pursuant to Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">3</a>, (ii) to any Assessor pursuant to Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">11</a> and any information disclosed by or on behalf of a Partner to any auditor pursuant to this Agreement) under or in connection with this Agreement, whether prior to, on, or after the Effective Date. For avoidance of doubt, the Project Results and Project Intellectual Property shall be deemed the Confidential Information of the Partner that first created, invented or generated such Project Results or Project Intellectual Property.</font></div><div style="margin-top:6.05pt;padding-left:133pt;padding-right:19.45pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18.1.2&#160;&#160;&#160;&#160;Each Party undertakes that it shall keep confidential and not disclose another Party&#8217;s Confidential Information to any person other than&#58; (i) to a Party, (ii) any Affiliate of a Party or such Party&#8217;s or its Affiliates&#8217; employees, officers, agents, contractors, consultants and legal and accounting advisers, who have a need to know such Confidential Information to achieve the specific purpose under this Agreement for which such Confidential Information was disclosed (or for which such Confidential Information was permitted to be created by the person or entity deemed to be the recipient of the same) and are subject to customary confidentiality terms, or (iii) as permitted in Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">18.3.</a> The obligations of confidentiality, non-use and non-disclosure under this Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">18.1</a> shall be in full force and effect during the Term of this Agreement and until &#91;***&#93; after its expiry or termination. In the event that at any time a Partner wishes to disclose to CEPI any Confidential Information that is subject to obligations to a third party under any agreement between such Partner or any of its Affiliates and a third party (or to which such Partner or any of its Affiliates is otherwise subject), it shall have the right to condition such disclosure on CEPI&#8217;s agreement to comply with any additional confidentiality or non-use obligations owed to such third party(ies). In such event, the relevant Partner shall notify CEPI that such Confidential Information would be subject to such additional confidentiality or non-use obligations, and CEPI and such Partner shall discuss and agree whether such Confidential Information will be disclosed by such Partner. In the event that CEPI elects to receive such Confidential Information, CEPI and the relevant Partner shall work together to enter into a written agreement setting out such additional</font></div><div style="height:41.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.706%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sensitivity&#58; Official Use</font></div></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">           39</font></div></div></div><hr style="page-break-after:always"><div style="min-height:35.28pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:11.1pt"><font><br></font></div><div style="padding-left:133pt;padding-right:19.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">confidentiality and non-use obligations hereunder. Each Party shall take commercially reasonable precautions to protect against unauthorised use or unauthorised disclosure of another Party&#8217;s Confidential Information. For clarity, Project Results may be disclosed and utilised by the Parties as expressly set out in this Agreement.</font></div><div style="margin-top:6pt;padding-left:133pt;padding-right:19.85pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18.1.3&#160;&#160;&#160;&#160;Notwithstanding Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">18.1.2</a> or any term or condition of this Agreement to the contrary, any information produced by Assessors pursuant to Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">11</a> using any Confidential Information of a Partner shall be deemed Confidential Information of such Partner.</font></div><div style="margin-top:6.2pt;padding-left:96.95pt;text-align:justify;text-indent:-35.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Confidentiality Limitations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Confidential Information shall not include&#58;</font></div><div style="margin-top:5.8pt;padding-left:133pt;padding-right:19.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18.2.1&#160;&#160;&#160;&#160;information already known to the receiving Party and which is not subject to pre- existing obligations of confidentiality&#59;</font></div><div style="margin-top:6.05pt;padding-left:133pt;padding-right:19.9pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18.2.2&#160;&#160;&#160;&#160;information that is independently developed by the receiving Party without access to or the use of or access to another Party&#8217;s Confidential Information&#59;</font></div><div style="margin-top:6pt;padding-left:133.05pt;padding-right:19.7pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">18.2.3&#160;&#160;&#160;&#160;information that is or becomes part of the public domain other than by unauthorised disclosure by receiving Party or any of its Affiliates or any designee or other person to which the receiving Party has disclosed such information&#59; and</font></div><div style="margin-top:5.6pt;padding-left:133pt;padding-right:19.9pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18.2.4&#160;&#160;&#160;&#160;information properly obtained by the receiving Party from a source that is not bound by a confidentiality obligation to the disclosing Party.</font></div><div style="margin-top:6pt;padding-left:97.15pt;padding-right:19.75pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Permitted Disclosures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Notwithstanding Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">18.1,</a> the receiving Party may disclose Confidential Information of a disclosing Party&#58;</font></div><div style="margin-top:6.05pt;padding-left:133pt;padding-right:19.85pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18.3.1&#160;&#160;&#160;&#160;as permitted by and in accordance with Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">18.6,</a> to the U.S. Securities and Exchange Commission or any national securities exchange in any relevant jurisdiction (each a &#8220;securities regulator&#8221; for purposes of Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">18.6</a>)&#59;</font></div><div style="margin-top:5.95pt;padding-left:133pt;padding-right:19.7pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18.3.2&#160;&#160;&#160;&#160;in response to a valid order of a court of competent jurisdiction or other governmental authority or, if in the reasonable opinion of the receiving Party&#8217;s legal counsel, such disclosure is otherwise required by applicable law (other than to a securities regulator)&#59; provided that to the extent legally permissible the receiving Party will first give written notice to the disclosing Party and give the disclosing Party a reasonable opportunity to (i) quash any such order&#59; (ii) obtain a protective order or confidential treatment requiring that the Confidential Information that is the subject of such order or applicable law (A) be held in confidence by the recipient and (B) be used only for the purposes for which the order was issued or as required by applicable law&#59; and (iii) propose redactions to such Confidential Information&#59; and provided, further, that any Confidential Information disclosed in response to any such order or applicable law will be limited to that information which is required or reasonably deemed to be required to be disclosed in response thereto&#59;</font></div><div style="margin-top:5.95pt;padding-left:133pt;padding-right:19.9pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18.3.3&#160;&#160;&#160;&#160;by a Partner, as the receiving Party, to a Regulatory Authority, as reasonably required or useful in connection with any filing, submission or communication with respect to the Project Vaccine&#59;</font></div><div style="margin-top:6.05pt;padding-left:133pt;padding-right:19.85pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18.3.4&#160;&#160;&#160;&#160;to the limited extent that is required to be disclosed by a competent legal authority or which is required to be disclosed pursuant to a request under the Freedom of</font></div><div style="margin-top:3.95pt"><font><br></font></div><div style="padding-left:6.85pt;padding-right:6.85pt;text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:41.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.706%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sensitivity&#58; Official Use</font></div></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">           40</font></div></div></div><hr style="page-break-after:always"><div style="min-height:35.28pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="margin-top:11.1pt"><font><br></font></div><div style="padding-left:133pt;padding-right:19.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">information Act 2000, the Freedom of Information (Scotland) Act 2002, Environmental Information Regulations 2004 or Environmental Information (Scotland) Regulations 2004&#59; provided that, where it is free to do so, the receiving Party shall give notice of such disclosure to the disclosing Party as soon as reasonably practicable&#59; and</font></div><div style="margin-top:6pt;padding-left:133pt;padding-right:19.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18.3.5&#160;&#160;&#160;&#160;(i) in the case of CEPI, to a Regulatory Authority and to CEPI&#8217;s funders and Assessors, and (ii) in the case of a Partner as the receiving Party, (1) to any actual or potential collaborators, partners, investors, funders, lawyers, bankers, advisors, (sub)licensees, (sub)contractors or Subawardees in connection with the development, manufacture or commercialization of the Project Vaccine, or (2) otherwise to the extent necessary or useful for such Partner to exercise its rights or perform its obligations hereunder&#59; provided that, in each case ((i) and (ii)), prior to any such disclosure, each disclosee will be bound by written obligations of confidentiality, non- disclosure and non-use no less restrictive than the obligations set forth in this Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">18</a>&#59; and provided, further, that the receiving Party will remain responsible for any failure by any such disclosee to treat such Confidential Information as required under this Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">18.</a></font></div><div style="margin-top:6.05pt;padding-left:97.15pt;padding-right:19.75pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Permitted Uses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Notwithstanding Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">18.1</a> or any other term or condition of this Agreement, Confidential Information of a Partner shall be used by CEPI or any third party to which CEPI discloses any such Confidential Information (for clarity, which third party disclosure shall be made in accordance with Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">18.3</a>) solely to fulfil CEPI&#8217;s obligations and exercise CEPI&#8217;s rights in accordance with this Agreement in connection with the Project, and shall not be disclosed to any third party who engages in the same or similar business, including development of same or similar products except as agreed otherwise by the Parties in writing.</font></div><div style="margin-top:5.95pt;padding-left:97.15pt;padding-right:19.85pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Notice of Breach</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Each Party shall promptly notify the other Parties of any breach or unauthorized disclosure with respect to another Party&#8217;s Confidential Information of which it becomes aware.</font></div><div style="margin-top:5.95pt;padding-left:97.1pt;padding-right:19.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Securities Filings&#59; Disclosure under Applicable Law. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Each Party acknowledges and agrees that each other Party shall have the right to submit this Agreement to, or file this Agreement with, the securities regulators or to other governmental persons or entities, if required by applicable law, and if a Party submits this Agreement to, or files this Agreement with, any securities regulator or other person or entity as required by applicable law, to the extent practicable in a given timeline and as permitted under applicable law, such Party shall consult with the other Parties with respect to the preparation and submission of a confidential treatment request for this Agreement. Notwithstanding the foregoing, if a Party seeks to make a disclosure as required by a securities regulator or other person or entity as required by applicable law as set forth in this Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">18.6</a> and any other Party provides comments in accordance with this Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">18.6,</a> the Party seeking to make such disclosure or its counsel, as the case may be, will reasonably consider such comments, to the extent permitted under and consistent with applicable law.</font></div><div style="margin-top:12.15pt"><font><br></font></div><div style="padding-left:97pt;text-indent:-36.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">19.&#160;&#160;&#160;&#160;TERM AND TERMINATION</font></div><div style="margin-top:5.95pt;padding-left:97.15pt;padding-right:19.75pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. This Agreement shall commence on the Effective Date identified in the Agreement Summary and, unless earlier terminated pursuant to this Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">19</a>, shall continue in full</font></div><div style="margin-top:2.65pt"><font><br></font></div><div style="padding-left:6.85pt;padding-right:6.85pt;text-align:center"><font><br></font></div><div style="height:41.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.706%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sensitivity&#58; Official Use</font></div></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">           41</font></div></div></div><hr style="page-break-after:always"><div style="min-height:35.28pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="margin-top:11.1pt"><font><br></font></div><div style="padding-left:97.15pt;padding-right:19.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">force and effect until the fifth (5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">) anniversary of the Effective Date (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Initial Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). Following expiry of the Initial Term, the Parties may agree to extend this Agreement for a period of up to twenty four (24) months unless all activities set out in all Work Packages, including any additional Work Packages, have been completed (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-top:6.05pt;padding-left:97.15pt;padding-right:19.85pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Termination by Either Partner for Default or Insolvency</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. A Partner (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Terminating Partner</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) shall be entitled, in its sole discretion, to terminate its involvement in this Agreement by giving written notice of termination to the other Partner and to CEPI, effective immediately, if any other Party&#58;</font></div><div style="margin-top:5.95pt;padding-left:133pt;padding-right:19.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19.2.1&#160;&#160;&#160;&#160;materially breaches this Agreement, where such breach is material in respect of the Terminating Partner&#8217;s rights under this Agreement, and either fails to cure such material breach within a cure period of &#91;***&#93; after notice from the Terminating Partner or such longer time if agreed in writing or if prompt and reasonable steps to cure such material breach are undertaken when the breach is not reasonably capable of cure with &#91;***&#93; and such diligent efforts are maintained until cure is achieved, provided cure is achieved within &#91;***&#93; after the notification of breach&#59;</font></div><div style="margin-top:6.05pt;padding-left:133pt;padding-right:19.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19.2.2&#160;&#160;&#160;&#160;(a) makes an assignment for the benefit of its creditors, (b) files or resolves to file for protection under bankruptcy, insolvency, reorganisation, restructuring or business rescue laws anywhere in the world (except for the purpose of solvent amalgamation, reorganisation or restructuring), (c) appoints or suffers the appointment of a receiver, administrative receiver, bailiff or trustee or analogous appointment over substantially all of its property, (d) proposes or implements a scheme of arrangement, company voluntary arrangement or other agreement of composition, compromise or extension of its debts, (e) proposes or is a party to any dissolution or liquidation or ceases continuation of substantially all of its business, (f) is subject to any filing of an application or a petition under any bankruptcy, insolvency, reorganisation, restructuring or business rescue laws anywhere in the world (except for the purpose of solvent amalgamation, reorganisation or restructuring), or has any such application or petition filed against it that, in any such case, is not discharged, within fourteen (14) days of the filing thereof&#59; or (g) admits in writing its inability generally to meet its obligations as they fall due in the general course&#59; or</font></div><div style="margin-top:5.95pt;padding-left:133pt;padding-right:19.9pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19.2.3&#160;&#160;&#160;&#160;violates any applicable Sanctions, anti-bribery, anti-corruption or anti- competitive laws and regulations or commits any illegal business practices.</font></div><div style="margin-top:6.05pt;padding-left:97.15pt;padding-right:19.85pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Termination by CEPI for Default or Insolvency</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. CEPI shall be entitled, in its sole discretion, to terminate either Partner&#8217;s involvement in this Agreement, or this Agreement in its entirety, by giving written notice of termination to the other Parties, effective immediately, if a Partner&#58;</font></div><div style="margin-top:5.9pt;padding-left:132.95pt;padding-right:19.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19.3.1&#160;&#160;&#160;&#160;materially breaches this Agreement and either fails to cure such material breach within a cure period of thirty (30) Business Days after notice from CEPI or such longer time if agreed in writing&#59; or</font></div><div style="margin-top:6.1pt;padding-left:133pt;padding-right:19.9pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19.3.2&#160;&#160;&#160;&#160;(a) makes an assignment for the benefit of its creditors, (b) files or resolves to file for protection under bankruptcy, insolvency, reorganisation, restructuring or business rescue laws anywhere in the world (except for the purpose of solvent amalgamation, reorganisation or restructuring), (c) appoints or suffers the</font></div><div style="margin-top:2.65pt"><font><br></font></div><div style="padding-left:6.85pt;padding-right:6.85pt;text-align:center"><font><br></font></div><div style="height:41.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.706%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sensitivity&#58; Official Use</font></div></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">           42</font></div></div></div><hr style="page-break-after:always"><div style="min-height:35.28pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="margin-top:11.1pt"><font><br></font></div><div style="padding-left:133pt;padding-right:19.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">appointment of a receiver, administrative receiver, bailiff or trustee or analogous appointment over substantially all of its property, (d) proposes or implements a scheme of arrangement, company voluntary arrangement or other agreement of composition, compromise or extension of its debts, (e) proposes or is a party to any dissolution or liquidation or ceases continuation of substantially all of its business, (f) is subject to any filing of an application or a petition under any bankruptcy, insolvency, reorganisation, restructuring or business rescue laws anywhere in the world (except for the purpose of solvent amalgamation, reorganisation or restructuring), or has any such application or petition filed against it that, in any such case, is not discharged, within fourteen (14) days of the filing thereof&#59; or (g) admits in writing its inability generally to meet its obligations as they fall due in the general course&#59; or</font></div><div style="margin-top:6.05pt;padding-left:133pt;padding-right:19.9pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19.3.3&#160;&#160;&#160;&#160;violates any applicable Sanctions, anti-bribery, anti-corruption or anti- competitive laws and regulations or commits any illegal business practices.</font></div><div style="margin-top:6pt;padding-left:97.15pt;padding-right:19.85pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">19.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:117%">Other Termination by CEPI</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">. CEPI shall be entitled, in its sole discretion, to terminate either Partner&#8217;s involvement in this Agreement, this Agreement in its entirety, or any Work Package, by providing written notice of termination to the other Parties, if&#58;</font></div><div style="margin-top:5.6pt;padding-left:133pt;padding-right:19.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19.4.1&#160;&#160;&#160;&#160;CEPI notifies a Partner that there are material safety, regulatory, scientific misconduct or ethical issues associated with continuing the Project, as reasonably determined by CEPI and the Partner either fails to end or cure such issue within a period of &#91;***&#93; after notice from CEPI or such longer time if agreed in writing&#59;</font></div><div style="margin-top:6pt;padding-left:133pt;padding-right:19.9pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">19.4.2&#160;&#160;&#160;&#160;the Stage Gate Review Committee determines that a Stage Gate was not completed by the Stage Gate Deadline pursuant to Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%;text-decoration:none">2.6</a> &#91;***&#93;&#59;</font></div><div style="margin-top:5.6pt;padding-left:133pt;padding-right:19.9pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">19.4.3&#160;&#160;&#160;&#160;a Partner withholds, conditions or delays its consent to the material changes to the Code or other applicable policy pursuant to Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%;text-decoration:none">12.2</a>&#59;</font></div><div style="margin-top:5.5pt;padding-left:133pt;padding-right:19.75pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19.4.4&#160;&#160;&#160;&#160;CEPI reasonably determines that a Partner is unable to discharge its obligations under this Agreement, for example if key personnel or technology resources which are essential for the successful completion of all Projects become unavailable to Partner, and Partner does not reasonably alleviate CEPI&#8217;s concerns within a cure period of &#91;***&#93; or such longer time as may be agreed by the Parties in writing&#59;</font></div><div style="margin-top:5.95pt;padding-left:133.05pt;padding-right:19.85pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19.4.5&#160;&#160;&#160;&#160;CEPI delays or conditions a payment in accordance with Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">3.6,</a> or a Partner has failed to satisfy the payment requirements set out in Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">3.5</a>, and a Partner fails to resolve any such impediments to payment or address CEPI&#8217;s concerns to CEPI&#8217;s  reasonable  satisfaction,  within  a  cure  period  of &#91;***&#93; or such longer time as may be agreed by the Parties in writing or &#91;***&#93;&#59;</font></div><div style="margin-top:6pt;padding-left:133pt;padding-right:19.85pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19.4.6&#160;&#160;&#160;&#160;a Partner has committed fraud or a Financial Irregularity. For purposes of this Agreement, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Financial Irregularity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; includes any and all kinds of corruption,</font></div><div style="margin-top:9.3pt"><font><br></font></div><div style="height:41.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.706%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sensitivity&#58; Official Use</font></div></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">           43</font></div></div></div><hr style="page-break-after:always"><div style="min-height:35.28pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="margin-top:11.1pt"><font><br></font></div><div style="padding-left:133pt;padding-right:19.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">including bribery, nepotism and illegal gratuities&#59; misappropriation of cash, inventory and all other kinds of assets&#59; and making fraudulent financial and non- financial statements to CEPI&#59; or</font></div><div style="margin-top:5.6pt;padding-left:133pt;padding-right:19.7pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">19.4.7&#160;&#160;&#160;&#160;upon notice in writing if CEPI reasonably believes that a Partner&#8217;s or its Affiliate&#8217;s tax affairs would have a material adverse impact on CEPI&#8217;s reputation.</font></div><div style="margin-top:5.55pt;padding-left:97.15pt;padding-right:19.9pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Other Termination by mutual agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Partners and CEPI may terminate this Agreement by mutual written agreement.</font></div><div style="margin-top:6pt;padding-left:97.15pt;padding-right:19.8pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Payments After Certain Terminations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. If this Agreement as a whole, or the involvement of any Partner, is terminated by a Partner pursuant to Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">19.2.1</a> to <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">19.2.3</a> (material breach, insolvency or breach of sanctions), as a result of the breach or insolvency of CEPI&#59; terminated by the Parties pursuant to Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">19.5</a> (mutual termination)&#59; or is terminated by CEPI pursuant to Clause 19.4.1 to <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">19.4.3</a> (issues precluding continuation of the Project, required termination by CEPI, or non-acceptance of material changes to the Code), then CEPI shall reimburse such Partner(s) for all reasonably incurred out-of-pocket expenses through termination and any non-cancellable out-of-pocket expenses relating to Project activities that were included in the terminated Work Package(s) and&#47;or authorised in writing by CEPI, and that arise through termination and after the termination date, solely to the extent they are not otherwise covered by CEPI funding provided prior to the date of termination and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">always that the relevant Partner uses all reasonable endeavours to minimise and mitigate any such expenses.</font></div><div style="margin-top:5.95pt;padding-left:97.15pt;padding-right:19.8pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Additional Effects of Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Irrespective of the grounds for termination of the Agreement (if this Agreement is terminated as a whole, then the following shall apply to all Work Packages and Partners, and if this Agreement is terminated only with respect to a particular Partner or a particular Work Package, then the following shall apply solely to such terminated Partner or Work Package)&#58;</font></div><div style="margin-top:6pt;padding-left:133pt;padding-right:19.85pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19.7.1&#160;&#160;&#160;&#160;CEPI shall not be required to make any further payments to the terminated Partner(s) and&#47;or in respect of the terminated Work Package(s), other than as specified in this Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">19</a>&#59;</font></div><div style="margin-top:6pt;padding-left:133pt;padding-right:19.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19.7.2&#160;&#160;&#160;&#160;each terminated Partner shall return any CEPI funds relating to the Project, or terminated Work Packages, as the case may be, within &#91;***&#93; from the date of termination that are unspent, if any, after deducting reimbursement to such terminated Partner for all reasonably incurred out-of- pocket expenses incurred prior to the termination date and any non-cancellable out-of-pocket expenses relating to the Project activities that were included in any terminated Work Package(s) and&#47;or authorised in writing by CEPI and that arise before or after the date of termination, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">always that such Partner uses all reasonable endeavours to minimise and mitigate any such expenses&#59;</font></div><div style="margin-top:6pt;padding-left:133pt;padding-right:19.85pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19.7.3&#160;&#160;&#160;&#160;each Party shall return or destroy (and certify the destruction of), as requested by any other Party, the Confidential Information of such requesting Party relating to the terminated elements of this Agreement, except that&#58; (i) CEPI may retain the Project Results subject to the limitations on use thereof provided in this Agreement and obligations of confidentiality set out in Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">18,</a> and (ii) each Party may keep one (1) copy of such Confidential Information for monitoring compliance with this Agreement. Neither Party shall be required to delete copies of Confidential Information stored on automatic electronic backup systems&#59; and</font></div><div style="margin-top:2.7pt"><font><br></font></div><div style="padding-left:6.85pt;padding-right:6.85pt;text-align:center"><font><br></font></div><div style="height:41.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.706%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sensitivity&#58; Official Use</font></div></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">           44</font></div></div></div><hr style="page-break-after:always"><div style="min-height:35.28pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="margin-top:11.1pt"><font><br></font></div><div style="padding-left:133pt;padding-right:19.75pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19.7.4&#160;&#160;&#160;&#160;if there is an on-going clinical trial which is to be terminated, unless agreed otherwise by the Parties in writing or otherwise required by institutional review boards, ethics committee, or relevant regulatory authorities under applicable laws, CEPI shall not be required to make any further payments to a Partner under this Agreement or any Work Package other than as specified in this Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">19</a>&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">that in the event that the Partner responsible for such clinical trial elects (in its sole discretion) to wind-down the clinical trial as a result of such termination, such Partner shall do so in an orderly fashion, with due regard for patient safety and the rights of any participating subjects&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided, further, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">that the expenses of winding down or (to the extent required by applicable law or patient safety and rights) completing such clinical trial shall be reimbursed by CEPI subject to Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">19.6</a> or Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">19.7,</a> as applicable.</font></div><div style="margin-top:6.05pt;padding-left:97.1pt;padding-right:19.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Repayment of Funds for Financial Irregularity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Notwithstanding Clauses <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">19.6</a> and <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">19.7,</a> where termination is due to any Financial Irregularity, the relevant Partner shall repay to CEPI the amount of funds related to such Financial Irregularity activity within &#91;***&#93; of the notice of termination and CEPI shall not be required to make any payments to such Partner pursuant to Clauses <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">19.6</a> and <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">19.7</a> unless and until such repayment has occurred in full.</font></div><div style="margin-top:5.95pt;padding-left:97.15pt;padding-right:19.8pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19.9&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Survival of Rights and Identified Clauses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Termination of this Agreement shall be without prejudice to the rights and duties of the Parties accrued prior to termination or expiry of the Agreement. The following Clauses shall continue to be enforceable notwit standing termination or expiry&#58; <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">1</a>, <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">3.4</a>, <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">3.13,</a> <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">3.14,</a> <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">3.15,</a> <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">4.1,</a> <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">4.3,</a> <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">4.4,</a> <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">6,</a> <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">8,</a> <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">10,</a> <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">12.4,</a> <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">14,</a> <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">15,</a> <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">16.4,</a> <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">17,</a> <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">18,</a> <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">19.6,</a> <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">19.7,</a> <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">19.8,</a> <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">19.9,</a> <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">20</a> and <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">21.</a></font></div><div style="margin-top:12pt"><font><br></font></div><div style="padding-left:97pt;text-indent:-36.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">20.&#160;&#160;&#160;&#160;RESOLVING DIFFERENCES</font></div><div style="margin-top:5.85pt;padding-left:97.15pt;padding-right:19.75pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">20.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:118%">Resolution by the Joint Oversight Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">. The Partners and CEPI shall cooperate in good faith to attempt to resolve differences and disputes at the JMAG.</font></div><div style="margin-top:5.5pt;padding-left:97pt;padding-right:19.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">20.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Escalation to Senior Management of the Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Any difference or dispute that cannot be resolved by the JMAG shall be submitted to the Parties&#8217; respective Chief Executive Officers or designees for resolution. If the Parties remain unable to resolve such dispute within &#91;***&#93; (or such additional time as mutually agreed in writing), then the Parties irrevocably submit to arbitration for its resolution upon referral of such dispute by a Party pursuant to Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">20.3.</a></font></div><div style="margin-top:6.05pt;padding-left:96.95pt;padding-right:19.85pt;text-align:justify;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">20.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Arbitration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Any controversy, dispute, or claim arising out of or relating to this Agreement, or the breach thereof, shall be determined by binding arbitration (including any question regarding its existence, validity or termination or this Agreement), and be referred to and finally resolved under the Rules of the London Court of International Arbitration, which Rules are incorporated by reference into this Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">20.3.</a> The number of arbitrators shall be three (3). The seat, or legal place, of arbitration shall be London, England. The language to be used in the arbitral proceedings shall be English. Notwithstanding the foregoing, any Party may seek specific performance, interim or final injunctive relief or any other relief of similar nature or effect in any court of competent jurisdiction. This Clause shall be governed by and construed in accordance with the law of England and Wales without giving effect to any choice of law or conflict of law provisions</font></div><div style="margin-top:2.6pt"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:41.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.706%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sensitivity&#58; Official Use</font></div></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">           45</font></div></div></div><hr style="page-break-after:always"><div style="min-height:35.28pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="margin-top:11.25pt"><font><br></font></div><div style="padding-left:97pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">or rules that would cause the application of the laws of any other jurisdiction.</font></div><div style="margin-top:12pt"><font><br></font></div><div style="padding-left:96.95pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">21.&#160;&#160;&#160;&#160;MISCELLANEOUS</font></div><div style="margin-top:5.85pt;padding-left:97.05pt;padding-right:19.8pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">21.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Relationship of the Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Nothing in this Agreement is intended to, or shall be deemed to, establish any partnership or joint venture between the Parties, constitute any Party the agent of any other Party, or authorise any Party to make or enter into any commitments for or on behalf of another Party. No Party shall be held liable for or incur liability in respect of the acts or defaults of any other Party.</font></div><div style="margin-top:6pt;padding-left:97pt;padding-right:19.85pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">21.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Announcements and Use of Names</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. No Party shall issue any press release, public statement or public announcement with respect to this Agreement without the prior written consent of the other Parties. Subject to Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">18.6,</a> no Party shall use the name or trademarks of another Party or its Affiliates in any press release, public statement or publication in connection with this Agreement without the named Party&#8217;s prior express written consent. After the initial announcement, or as required by law, either Party may disclose a description of the Project, the names of each Party and its Project Lead, and the amount of the CEPI funding without the prior consent of the other Parties.</font></div><div style="margin-top:6.2pt;padding-left:96.9pt;text-align:justify;text-indent:-35.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">21.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Assignment.</font></div><div style="margin-top:5.85pt;padding-left:133.05pt;padding-right:19.85pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">21.3.1&#160;&#160;&#160;&#160;No Party shall, without the prior written consent of the other Parties, such consent not to be unreasonably withheld or delayed, assign its rights or obligations under this Agreement to any third party, except that CEPI may do so to an organisation of equivalent charitable mission and technical capabilities.</font></div><div style="margin-top:6pt;padding-left:133pt;padding-right:19.65pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">21.3.2&#160;&#160;&#160;&#160;Save as otherwise permitted under this Agreement, neither Partner shall assign, license or encumber its rights in the Project Intellectual Property, Project Results or any Intellectual Property controlled by such Partner, in each case to the extent that they relate to the Project Vaccine, including all Enabling Rights, without the consent of CEPI, such consent not to be unreasonably withheld or delayed, and as a condition of giving such consent CEPI may require that such assignment, or license is made subject to the terms of this Agreement, and that any encumbrance is subject and subordinate to CEPI&#8217;s rights under this Agreement. In the event of a change of control of a Partner, or any Partner is otherwise acquired, then such Partner shall ensure that any such acquirer is made aware of the terms of this Agreement and shall remain bound by and subject to the terms of this Agreement in all respects.</font></div><div style="padding-left:133pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">21.3.3&#160;&#160;&#160;&#160;Notwithstanding the restriction set out in Clause <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:none">21.3.2,</a> CEPI understands that Barinthus Bio is considering &#91;***&#93;. Barinthus Bio shall keep CEPI updated with regards to any plans it may have &#91;***<a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:none">&#93;.</a> In the event that Barinthus Bio does &#91;***&#93; it will notify CEPI in writing &#91;***&#93; and CEPI and Barinthus Bio shall discuss, in good faith, the appropriate terms pursuant to which CEPI may give its consent pursuant to Clauses <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:none">21.3.1</a> and <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:none">21.3.2</a> &#91;***&#93;.</font></div><div style="margin-top:5.6pt;padding-left:133pt;padding-right:19.75pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">21.3.4&#160;&#160;&#160;&#160;This Agreement will be binding upon, inure solely to the benefit of, and be enforceable by each Party and their respective permitted successors and assigns.</font></div><div style="margin-top:5.55pt;padding-left:97pt;padding-right:19.85pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">21.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Any notice to be given pursuant to this Agreement shall be in writing in the English language and shall be delivered by overnight courier, by registered, recorded delivery or certified mail (postage prepaid) or email to the address (or email address) of the recipient Party provided in the Agreement Summary or such other address (or email address) as a Party may from time to time designate by notice in writing. Any notice given pursuant to this Clause shall be deemed to have been received on the day of receipt, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">receipt occurs on a Business Day of the recipient Party or otherwise on the next following Business Day of the recipient.</font></div><div style="margin-top:5.95pt;padding-left:97pt;padding-right:19.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">21.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. This Agreement (including the Agreement Summary and its Annexes) constitutes the entire agreement and understanding between the Parties relating to its subject matter and together they supersede and replace all prior arrangements, whether written or oral, between the Parties relating to the subject matter of this Agreement.</font></div><div style="height:41.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.706%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sensitivity&#58; Official Use</font></div></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">           46</font></div></div></div><hr style="page-break-after:always"><div style="min-height:35.28pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;padding-left:97pt;padding-right:19.85pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">21.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amendments to this Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. No variation, amendment, modification or supplement to this Agreement, including its Annexes, shall be valid unless and until it is made in writing and signed by a duly authorised representative of each Party.</font></div><div style="margin-top:6.1pt;padding-left:97pt;padding-right:19.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">21.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Order of Precedence</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. If there is any conflict between the provisions of this Agreement, and the Third Party Code or any Work Package, then the provisions of this Agreement shall prevail. Subject to the foregoing sentence, if there is any conflict between the provisions of a Work Package and the Third Party Code, the provisions of the Third Party Code to the extent described in the Third Party Code Declaration Letter shall prevail. If there is an inconsistency between any provision in this Agreement and the corresponding provision in the &#91;***&#93; then, as between &#91;***&#93; the terms of the &#91;***&#93; shall prevail.</font></div><div style="margin-top:5.95pt;padding-left:97pt;padding-right:19.75pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">21.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Force Majeure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. A Party shall not be deemed to have defaulted under or to be in breach of this Agreement for failure or delay in fulfilling material obligations when such failure or delay is directly caused by an event outside of their reasonable control, including acts of war, insurrections, acts of terrorism, acts of God, epidemics, pandemics, quarantines or delays in acting or failure to act by any of CEPI&#8217;s funders, in each case other than in respect of an Outbreak (collectively a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Force Majeure Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). Each Party shall inform the other Parties promptly and in writing of any Force Majeure Event and the Parties shall seek to agree on the appropriate course of action under the circumstances. In the event that any delay or failure to fulfil material obligations occurs or is likely to occur due to the Outbreak, the affected Party shall promptly notify the other Parties and the Parties shall discuss in good faith any reasonable and appropriate actions in order to minimize and mitigate the effects of such delay or failure.</font></div><div style="margin-top:6pt;padding-left:97pt;padding-right:19.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">21.9&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:117%">No Rights for Third Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">. A person who is not a Party to this Agreement has no right under the Contracts (Rights of Third Parties) Act of 1999 or otherwise to enforce or to enjoy the benefit of any term of this Agreement.</font></div><div style="margin-top:3pt;padding-left:97pt;padding-right:19.55pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">21.10&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Equitable Relief. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Each Party acknowledges and agrees that the restrictions set forth in Clauses <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">5</a> (IP), <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">14</a> (Equitable Access) and <a href="#i4cb52855f4374a6ca077b349c7ceffd4_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">18</a> (Confidentiality) are reasonable and necessary to protect the legitimate interests of the other Parties and that such other Parties would not have entered into this Agreement in the absence of such restrictions and that any breach or threatened breach of any provision of such Clauses may result in irreparable injury to one or more such other Parties for which there will be no adequate remedy at law. In the event of a breach or threatened breach of any provision of such Clauses, the non-breaching Party(ies) shall be authorized and entitled to seek from any court of competent jurisdiction injunctive relief, whether preliminary or permanent, or specific performance, which rights shall be cumulative and in addition to any other rights or remedies to which such non- breaching Party(ies) may be entitled in law or equity.</font></div><div style="margin-top:5.95pt;padding-left:97pt;padding-right:19.9pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">21.11&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">No Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. A Party shall not be deemed to have waived any of its rights or remedies under this Agreement unless the waiver is expressly made in writing and signed by a duly authorised representative of that Party.</font></div><div style="margin-top:6.1pt;padding-left:97pt;padding-right:19.85pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">21.12&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Waiver of Rule of Construction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Each Party has had the opportunity to consult with counsel in connection with the review, drafting and negotiation of this Agreement. Accordingly, the rule of construction that any ambiguity in this Agreement shall be construed against the drafting Party, including the doctrine commonly known as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">contra proferentem, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">shall not apply.</font></div><div style="margin-top:6pt;padding-left:97pt;padding-right:19.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">21.13&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Business Day Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. In the event that any notice or other action or omission is required to be taken by a Party under this Agreement on a day that is not a Business Day then such notice or other action or omission shall be deemed to be required to be taken on the next occurring Business Day.</font></div><div style="margin-top:5.9pt;padding-left:97pt;padding-right:19.85pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">21.14&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Further Assurances</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Each Party shall duly execute and deliver, or cause to be duly executed and delivered, such further instruments and do and cause to be done such further acts and things, including the filing of such assignments, agreements, documents and instruments, as may be necessary to carry out more effectively the provisions and purposes hereof or to better assure and confirm unto such other Party its rights and remedies under this Agreement.</font></div><div style="margin-top:6.1pt;padding-left:97pt;padding-right:19.9pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">21.15&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Counterparts and Electronic Signing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. No counterpart shall be effective until each </font></div><div style="height:41.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.706%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sensitivity&#58; Official Use</font></div></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">           47</font></div></div></div><hr style="page-break-after:always"><div style="min-height:35.28pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6.1pt;padding-left:97pt;padding-right:19.9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Party has executed at least one counterpart. Additionally, this Agreement may be signed electronically by exchanging signed PDF versions or by using an electronic signature platform which meets the European Union requirements for valid electronic signatures (such as DocuSign</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">).</font></div><div style="margin-top:6pt;padding-left:97pt;padding-right:19.7pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">21.16&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Choice of Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. This Agreement shall be governed by and construed in accordance with, and any dispute or claim arising out of or in connection with it or its subject matter (including non-contractual disputes or claims) shall be governed by, the laws of England and Wales without giving effect to any choice of law or conflict of law provisions or rules that would cause the application of the laws of any other jurisdiction.</font></div><div style="margin-top:6pt;padding-left:97pt;padding-right:19.75pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">21.17&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. If any provision or part-provision of this Agreement is or becomes invalid, illegal or unenforceable, it shall be deemed modified to the minimum extent necessary to make it valid, legal and enforceable. If such modification is not possible, the relevant provision or part-provision shall be deemed deleted. Any modification to or deletion of a provision or part-provision under this clause shall not affect the validity and enforceability of the rest of this Agreement.</font></div><div style="margin-top:6.15pt;padding-left:96.95pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">21.18&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Interpretation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. In this Agreement&#58;</font></div><div style="margin-top:5.85pt;padding-left:133pt;padding-right:19.9pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">21.18.1&#160;&#160;&#160;&#160;any headings in this Agreement shall not affect the interpretation of this Agreement&#59;</font></div><div style="margin-top:5.5pt;padding-left:133pt;padding-right:19.95pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">21.18.2&#160;&#160;&#160;&#160;unless the context otherwise requires, reference to the singular includes the plural and vice versa, any reference to a person includes a body corporate and words importing one gender include both genders&#59;</font></div><div style="margin-top:5.6pt;padding-left:132.95pt;padding-right:19.9pt;text-align:justify;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">21.18.3&#160;&#160;&#160;&#160;a reference to a statute or statutory provision is (unless otherwise stated) a reference to the applicable UK or other country&#8217;s statute as it is in force for the time being, taking account of any amendment, extension, or re-enactment and includes any subordinate legislation for the time being in force made under it&#59;</font></div><div style="margin-top:6.05pt;padding-left:133pt;padding-right:19.85pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">21.18.4&#160;&#160;&#160;&#160;where the words &#8220;include(s)&#8221; or &#8220;including&#8221; are used in this Agreement, they are deemed to have the words &#8220;without limitation&#8221; following them, and are illustrative and shall not limit the sense of the words preceding them&#59;</font></div><div style="margin-top:5.6pt;padding-left:133pt;padding-right:19.85pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">21.18.5&#160;&#160;&#160;&#160;the word &#8220;or&#8221; shall have its inclusive sense (and&#47;or), and no contrary inference shall be drawn from the use of &#8220;or&#8221; in certain phrases and the use of &#8220;and&#47;or&#8221; in other phrases&#59; and</font></div><div style="margin-top:6.1pt;padding-left:132.9pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">21.18.6&#160;&#160;&#160;&#160;&#8220;third party(ies)&#8221; shall not be construed to include Affiliate(s) of either Party.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:11.25pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:41.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.706%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sensitivity&#58; Official Use</font></div></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">           48</font></div></div></div><hr style="page-break-after:always"><div style="min-height:35.28pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="padding-left:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Annex B&#58; Team Charter</font></div><div style="margin-top:5.8pt;padding-left:20.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:6.85pt;padding-right:6.85pt;text-align:center"><font><br></font></div><div style="height:41.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.706%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sensitivity&#58; Official Use</font></div></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">           49</font></div></div></div><div id="i4cb52855f4374a6ca077b349c7ceffd4_19"></div><hr style="page-break-after:always"><div style="min-height:54.72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.9pt;padding-left:5pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:4.3pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:39pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Annex C&#58; Integrated Product Development Plan and Work Package(s)</font></div><div style="margin-top:5.95pt;padding-left:39pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:7.95pt"><font><br></font></div><div style="padding-left:39pt"><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.205%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sensitivity&#58; Official Use</font></div></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">           50</font></div></div></div><div id="i4cb52855f4374a6ca077b349c7ceffd4_52"></div><hr style="page-break-after:always"><div style="min-height:54.72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.9pt;padding-left:5pt"><font><br></font></div><div><font><br></font></div><div style="margin-top:11pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:39pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Annex D&#58; Budget for Work Packages</font></div><div style="margin-top:5.8pt;padding-left:39.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:2.55pt"><font><br></font></div><div style="padding-left:39pt"><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.205%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sensitivity&#58; Official Use</font></div></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">           51</font></div></div></div><div id="i4cb52855f4374a6ca077b349c7ceffd4_61"></div><hr style="page-break-after:always"><div style="min-height:54.72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:8.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:103%">ANNEX E&#58; Equitable Access Plan</font></div><div><font><br></font></div><div><img alt="annexev6a.jpg" src="annexev6a.jpg" style="height:539px;margin-bottom:5pt;vertical-align:text-bottom;width:660px"></div><div style="height:23.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:45.875%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sensitivity&#58; Official Use</font></div></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">           52</font></div></div></div><div id="i4cb52855f4374a6ca077b349c7ceffd4_76"></div><hr style="page-break-after:always"><div style="min-height:54.72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.35pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Annex F&#58; List of UMICs, HICs and LMICs as at the Effective Date</font></div><div style="margin-top:5.8pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#93;</font></div><div><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.205%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sensitivity&#58; Official Use</font></div></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">           53</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54.72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:4.05pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Annex G&#58; Sub-Contractors</font></div><div style="margin-top:12.6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.205%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sensitivity&#58; Official Use</font></div></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">           54</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54.72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:4.15pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Annex H&#58; COGs</font></div><div style="margin-top:5.85pt;padding-left:36pt;padding-right:5.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.205%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sensitivity&#58; Official Use</font></div></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">           55</font></div></div></div><div id="i4cb52855f4374a6ca077b349c7ceffd4_79"></div><hr style="page-break-after:always"><div style="min-height:54.72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:4.05pt;padding-left:5.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Annex I&#58; Third Party Code, Cost Guidance and Transparency and Confidentiality Policy</font></div><div style="margin-top:4.45pt"><font><br></font></div><div style="padding-left:5.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">&#91;***&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:5.55pt"><font><br></font></div><div style="padding-left:5.95pt"><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:50.419%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sensitivity&#58; Official Use</font></div></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">           56</font></div></div></div><div id="i4cb52855f4374a6ca077b349c7ceffd4_118"></div><hr style="page-break-after:always"><div style="min-height:40.32pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:2.85pt"><font><br></font></div><div style="padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Annex J &#8211; Stage Gates</font></div><div style="padding-left:7.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#91;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:115%">***</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#93;</font></div><div style="margin-top:1.25pt"><font><br></font></div><div style="padding-left:26.75pt"><font><br></font></div><div style="height:36.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:46.279%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sensitivity&#58; Official Use</font></div></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">           57</font></div></div></div><hr style="page-break-after:always"><div style="min-height:40.32pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:3.4pt"><font><br></font></div><div style="padding-left:11.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Annex K &#8211; Template Technical Report</font></div><div style="padding-left:12.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">&#91;***&#93;</font></div><div style="height:36.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:46.279%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sensitivity&#58; Official Use</font></div></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">           58</font></div></div></div><div id="i4cb52855f4374a6ca077b349c7ceffd4_139"></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div><font><br></font></div></div><div style="margin-top:4.05pt;padding-left:5.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Annex L &#8211; List of CEPI Affiliates as at the Effective Date</font></div><div style="padding-right:5.9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="height:36.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:45.544%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sensitivity&#58; Official Use</font></div></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">           59</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:4.05pt;padding-left:5.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Annex M &#8211; CEPI&#8217;s Clinical Trial Policy</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:6.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font></div><div style="height:36.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:45.544%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sensitivity&#58; Official Use</font></div></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">           60</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>3
<FILENAME>brns-20231231xex211.htm
<DESCRIPTION>EX-21.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i7db6944a6e7d4ae59fc164388129ad2f_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 21.1</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SUBSIDIARIES</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.198%"><tr><td style="width:1.0%"></td><td style="width:49.950%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.266%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subsidiary</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jurisdiction of Incorporation</font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Barinthus Biotherapeutics Pty Limited (formerly Vaccitech Australia Pty Limited)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vaccitech Oncology Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">England and Wales</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Barinthus Biotherapeutics (UK) Limited (formerly Vaccitech (UK) Limited)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">England and Wales</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Barinthus Biotherapeutics North America, Inc. (formerly Vaccitech North America, Inc.)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Barinthus Biotherapeutics Italia S.R.L. (formerly Vaccitech Italia S.R.L.)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Italy</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Barinthus Biotherapeutics Switzerland GmbH (formerly Vaccitech Switzerland GmbH)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></td></tr></table></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>brns-20231231xex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i57cf602593484ec8b1d0f3355e794538_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:24pt;margin-top:24pt;padding-right:14.1pt;text-align:right"><font style="color:#000000;font-family:'Georgia',serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 23.1</font></div><div style="padding-left:7.05pt;padding-right:7.05pt;text-align:center"><font><br></font></div><div style="padding-left:7.05pt;padding-right:7.05pt;text-align:center"><font style="color:#000000;font-family:'Georgia',serif;font-size:10pt;font-weight:700;line-height:100%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div style="padding-left:7.05pt;padding-right:7.05pt;text-align:center"><font><br></font></div><div style="padding-left:7.05pt;padding-right:7.05pt;text-align:center"><font><br></font></div><div style="margin-bottom:6pt;padding-right:14.1pt"><font style="color:#000000;font-family:'Georgia',serif;font-size:10pt;font-weight:400;line-height:115%">We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 333-255664, 333-263844 and 333-270815) and Form S-3 (Nos. 333-265763 and 333-266724) of Barinthus Biotherapeutics plc of our report dated March&#160;20, 2024 relating to the financial statements, which appears in this Form 10-K.</font></div><div style="margin-bottom:6pt;padding-right:14.1pt"><font><br></font></div><div style="margin-bottom:6pt;padding-right:14.1pt"><font><br></font></div><div style="margin-top:12pt;padding-right:14.1pt"><font style="color:#000000;font-family:'Georgia',serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; PricewaterhouseCoopers LLP </font></div><div style="margin-top:12pt;padding-right:14.1pt"><font style="color:#000000;font-family:'Georgia',serif;font-size:10pt;font-weight:400;line-height:100%">Reading, United Kingdom</font></div><div style="margin-top:12pt;padding-right:14.1pt"><font style="color:#000000;font-family:'Georgia',serif;font-size:10pt;font-weight:400;line-height:100%">March&#160;20, 2024<br></font></div><div style="padding-right:21.2pt"><font><br></font></div><div style="height:0pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Georgia',serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">PricewaterhouseCoopers LLP, 3 Forbury Place, 23 Forbury Road, Reading, Berkshire, RG1 3JH</font></div><div><font style="color:#000000;font-family:'Georgia',serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">T&#58; +44 (0) 118 959 7111, F&#58; +44 (0) 1189 383 020, www.pwc.co.uk</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:6pt;font-weight:400;line-height:100%">PricewaterhouseCoopers LLP is a limited liability partnership registered in England with registered number OC303525.  The registered office of </font></div><div><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:6pt;font-weight:400;line-height:100%">PricewaterhouseCoopers LLP is 1 Embankment Place, London WC2N 6RH.  PricewaterhouseCoopers LLP is authorised and regulated by the Financial Conduct Authority for designated investment business.</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>brns-20231231xex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i98cfa97330254ea0b8ace2a72c01fa09_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Exhibit 31.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">RULES 13a-14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">a</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">AND 15d-14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">a</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">UNDER THE SECURITIES EXCHANGE ACT OF 1934</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">I, William Enright, certify that&#58;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.5pt">I have reviewed this Annual Report on Form 10-K for the year ended December&#160;31, 2023 of Barinthus Biotherapeutics plc&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:6.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:6.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:6.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:6.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:6.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:6.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"></td><td style="width:46.851%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.997%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.852%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Date&#58; March&#160;20, 2024</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#47;s&#47; William Enright</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">William Enright</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Chief Executive Officer</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>brns-20231231xex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i33c57a6830ff43278c6f7856e051ee75_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Exhibit 31</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">RULES 13a-14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">a</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">AND 15d-14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">a</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">UNDER THE SECURITIES EXCHANGE ACT OF 1934</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">I, Gemma Brown, certify that&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.5pt">I have reviewed this Annual Report on Form 10-K for the year ended December&#160;31, 2023 of Barinthus Biotherapeutics plc&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:6.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:6.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:6.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:6.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:6.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:4.02pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"></td><td style="width:46.851%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.997%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.852%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Date&#58; March&#160;20, 2024</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#47;s&#47; Gemma Brown</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Gemma Brown</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Chief Financial Officer</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>brns-20231231xex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i112a9fb264a8460b957c5539092628ab_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Exhibit 32</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">CERTIFICATIONS PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">18 U</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">S</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">SECTION 1350</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In connection with the Annual Report of Barinthus Biotherapeutics plc (the &#8220;Company&#8221;) on Form 10-K for the fiscal year ending December&#160;31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), each of the undersigned officers of the Company certifies, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, to the best of his or her knowledge that&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:6.34pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:6.34pt">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"></td><td style="width:46.851%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.997%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.852%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Date&#58; March&#160;20, 2024</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#47;s&#47; William Enright</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">William Enright</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Chief Executive Officer</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Date&#58; March&#160;20, 2024</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">By&#58;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#47;s&#47; Gemma Brown</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Gemma Brown</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Chief Financial Officer</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>brns-20231231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:568bf53a-35e8-4830-ae45-40f379b83a88,g:160c7384-88e8-453d-8496-8cc857f3b5f9-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:brns="http://www.barinthusbio.com/20231231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.barinthusbio.com/20231231">
  <xs:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/stpr/2023" schemaLocation="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="brns-20231231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="brns-20231231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="brns-20231231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="brns-20231231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.barinthusbio.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.barinthusbio.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETS" roleURI="http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS">
        <link:definition>0000003 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" roleURI="http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS">
        <link:definition>0000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical" roleURI="http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical">
        <link:definition>0000006 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" roleURI="http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
        <link:definition>0000007 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>0000008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureofBusinessandBasisofPresentation" roleURI="http://www.barinthusbio.com/role/NatureofBusinessandBasisofPresentation">
        <link:definition>0000009 - Disclosure - Nature of Business and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>0000010 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ForeignCurrencyTranslationinGeneralandAdministrativeExpenses" roleURI="http://www.barinthusbio.com/role/ForeignCurrencyTranslationinGeneralandAdministrativeExpenses">
        <link:definition>0000011 - Disclosure - Foreign Currency Translation in General and Administrative Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossIncomePerShare" roleURI="http://www.barinthusbio.com/role/NetLossIncomePerShare">
        <link:definition>0000012 - Disclosure - Net (Loss)/Income Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNet" roleURI="http://www.barinthusbio.com/role/PropertyandEquipmentNet">
        <link:definition>0000013 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Intangibleassetsnet" roleURI="http://www.barinthusbio.com/role/Intangibleassetsnet">
        <link:definition>0000014 - Disclosure - Intangible assets, net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Prepaidandothercurrentassets" roleURI="http://www.barinthusbio.com/role/Prepaidandothercurrentassets">
        <link:definition>0000015 - Disclosure - Prepaid and other current assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesandOtherCurrentLiabilities" roleURI="http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilities">
        <link:definition>0000016 - Disclosure - Accrued Expenses and Other Current Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OutlicensesandGrants" roleURI="http://www.barinthusbio.com/role/OutlicensesandGrants">
        <link:definition>0000017 - Disclosure - Out-licenses and Grants</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrdinaryShares" roleURI="http://www.barinthusbio.com/role/OrdinaryShares">
        <link:definition>0000018 - Disclosure - Ordinary Shares</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Deferredshares" roleURI="http://www.barinthusbio.com/role/Deferredshares">
        <link:definition>0000019 - Disclosure - Deferred shares</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValue" roleURI="http://www.barinthusbio.com/role/FairValue">
        <link:definition>0000020 - Disclosure - Fair Value</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Goodwill" roleURI="http://www.barinthusbio.com/role/Goodwill">
        <link:definition>0000021 - Disclosure - Goodwill</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensation" roleURI="http://www.barinthusbio.com/role/ShareBasedCompensation">
        <link:definition>0000022 - Disclosure - Share-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.barinthusbio.com/role/IncomeTaxes">
        <link:definition>0000023 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.barinthusbio.com/role/CommitmentsandContingencies">
        <link:definition>0000024 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlans" roleURI="http://www.barinthusbio.com/role/EmployeeBenefitPlans">
        <link:definition>0000025 - Disclosure - Employee Benefit Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://www.barinthusbio.com/role/RelatedPartyTransactions">
        <link:definition>0000026 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.barinthusbio.com/role/SubsequentEvents">
        <link:definition>0000027 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>9954472 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossIncomePerShareTables" roleURI="http://www.barinthusbio.com/role/NetLossIncomePerShareTables">
        <link:definition>9954473 - Disclosure - Net (Loss)/Income Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNetTables" roleURI="http://www.barinthusbio.com/role/PropertyandEquipmentNetTables">
        <link:definition>9954474 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PrepaidandothercurrentassetsTables" roleURI="http://www.barinthusbio.com/role/PrepaidandothercurrentassetsTables">
        <link:definition>9954475 - Disclosure - Prepaid and other current assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesandOtherCurrentLiabilitiesTables" roleURI="http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables">
        <link:definition>9954476 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OutlicensesandGrantsTables" roleURI="http://www.barinthusbio.com/role/OutlicensesandGrantsTables">
        <link:definition>9954477 - Disclosure - Out-licenses and Grants (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrdinarySharesTables" roleURI="http://www.barinthusbio.com/role/OrdinarySharesTables">
        <link:definition>9954478 - Disclosure - Ordinary Shares (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueTables" roleURI="http://www.barinthusbio.com/role/FairValueTables">
        <link:definition>9954479 - Disclosure - Fair Value (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillTables" roleURI="http://www.barinthusbio.com/role/GoodwillTables">
        <link:definition>9954480 - Disclosure - Goodwill (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationTables" roleURI="http://www.barinthusbio.com/role/ShareBasedCompensationTables">
        <link:definition>9954481 - Disclosure - Share-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.barinthusbio.com/role/IncomeTaxesTables">
        <link:definition>9954482 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesTables" roleURI="http://www.barinthusbio.com/role/CommitmentsandContingenciesTables">
        <link:definition>9954483 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureofBusinessandBasisofPresentationDetails" roleURI="http://www.barinthusbio.com/role/NatureofBusinessandBasisofPresentationDetails">
        <link:definition>9954484 - Disclosure - Nature of Business and Basis of Presentation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesForeigncurrencytranslationDetails" roleURI="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesForeigncurrencytranslationDetails">
        <link:definition>9954485 - Disclosure - Summary of Significant Accounting Policies - Foreign currency translation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesSegmentinformationDetails" roleURI="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesSegmentinformationDetails">
        <link:definition>9954486 - Disclosure - Summary of Significant Accounting Policies - Segment information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesNoncontrollinginterestDetails" roleURI="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesNoncontrollinginterestDetails">
        <link:definition>9954487 - Disclosure - Summary of Significant Accounting Policies - Noncontrolling interest (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesCashandcashequivalentsDetails" roleURI="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesCashandcashequivalentsDetails">
        <link:definition>9954488 - Disclosure - Summary of Significant Accounting Policies - Cash and cash equivalents (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesConcentrationsofcreditriskDetails" roleURI="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesConcentrationsofcreditriskDetails">
        <link:definition>9954489 - Disclosure - Summary of Significant Accounting Policies - Concentrations of credit risk (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesAllowanceforcreditlossesDetails" roleURI="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesAllowanceforcreditlossesDetails">
        <link:definition>9954490 - Disclosure - Summary of Significant Accounting Policies - Allowance for credit losses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPropertyandequipmentDetails" roleURI="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPropertyandequipmentDetails">
        <link:definition>9954491 - Disclosure - Summary of Significant Accounting Policies - Property and equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesIntangibleAssetsDetails" roleURI="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsDetails">
        <link:definition>9954492 - Disclosure - Summary of Significant Accounting Policies - Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesImpairmentoflonglivedassetsandGoodwillDetails" roleURI="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesImpairmentoflonglivedassetsandGoodwillDetails">
        <link:definition>9954493 - Disclosure - Summary of Significant Accounting Policies - Impairment of long-lived assets and Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesSharebasedcompensationDetails" roleURI="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesSharebasedcompensationDetails">
        <link:definition>9954494 - Disclosure - Summary of Significant Accounting Policies - Share based compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesResearchandDevelopmentIncentivesDetails" roleURI="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesResearchandDevelopmentIncentivesDetails">
        <link:definition>9954495 - Disclosure - Summary of Significant Accounting Policies - Research and Development Incentives (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ForeignCurrencyTranslationinGeneralandAdministrativeExpensesDetails" roleURI="http://www.barinthusbio.com/role/ForeignCurrencyTranslationinGeneralandAdministrativeExpensesDetails">
        <link:definition>9954496 - Disclosure - Foreign Currency Translation in General and Administrative Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossIncomePerShareComputationDetails" roleURI="http://www.barinthusbio.com/role/NetLossIncomePerShareComputationDetails">
        <link:definition>9954497 - Disclosure - Net (Loss)/Income Per Share - Computation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossIncomePerShareAdditionalInformationDetails" roleURI="http://www.barinthusbio.com/role/NetLossIncomePerShareAdditionalInformationDetails">
        <link:definition>9954498 - Disclosure - Net (Loss)/Income Per Share - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNetComponentsDetails" roleURI="http://www.barinthusbio.com/role/PropertyandEquipmentNetComponentsDetails">
        <link:definition>9954499 - Disclosure - Property and Equipment, Net - Components (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNetAdditionalInformationDetails" roleURI="http://www.barinthusbio.com/role/PropertyandEquipmentNetAdditionalInformationDetails">
        <link:definition>9954500 - Disclosure - Property and Equipment, Net - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleassetsnetDetails" roleURI="http://www.barinthusbio.com/role/IntangibleassetsnetDetails">
        <link:definition>9954501 - Disclosure - Intangible assets, net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PrepaidandothercurrentassetsDetails" roleURI="http://www.barinthusbio.com/role/PrepaidandothercurrentassetsDetails">
        <link:definition>9954502 - Disclosure - Prepaid and other current assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesandOtherCurrentLiabilitiesDetails" roleURI="http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails">
        <link:definition>9954503 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OutlicensesandGrantsAdditionalInformationDetails" roleURI="http://www.barinthusbio.com/role/OutlicensesandGrantsAdditionalInformationDetails">
        <link:definition>9954504 - Disclosure - Out-licenses and Grants - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OutlicensesandGrantsChangesinthecontractliabilitiesDetails" roleURI="http://www.barinthusbio.com/role/OutlicensesandGrantsChangesinthecontractliabilitiesDetails">
        <link:definition>9954505 - Disclosure - Out-licenses and Grants - Changes in the contract liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrdinarySharesAdditionalInformationDetails" roleURI="http://www.barinthusbio.com/role/OrdinarySharesAdditionalInformationDetails">
        <link:definition>9954506 - Disclosure - Ordinary Shares - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrdinarySharesOrdinarysharesforfutureissuanceDetails" roleURI="http://www.barinthusbio.com/role/OrdinarySharesOrdinarysharesforfutureissuanceDetails">
        <link:definition>9954507 - Disclosure - Ordinary Shares - Ordinary shares for future issuance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DeferredsharesDetails" roleURI="http://www.barinthusbio.com/role/DeferredsharesDetails">
        <link:definition>9954508 - Disclosure - Deferred shares (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueAdditionalinformationDetails" roleURI="http://www.barinthusbio.com/role/FairValueAdditionalinformationDetails">
        <link:definition>9954509 - Disclosure - Fair Value - Additional information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueChangeinfairvalueofcontingentconsiderationDetails" roleURI="http://www.barinthusbio.com/role/FairValueChangeinfairvalueofcontingentconsiderationDetails">
        <link:definition>9954510 - Disclosure - Fair Value - Change in fair value of contingent consideration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillDetails" roleURI="http://www.barinthusbio.com/role/GoodwillDetails">
        <link:definition>9954511 - Disclosure - Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationAdditionalInformationDetails" roleURI="http://www.barinthusbio.com/role/ShareBasedCompensationAdditionalInformationDetails">
        <link:definition>9954512 - Disclosure - Share-Based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationWeightedaverageassumptionsDetails" roleURI="http://www.barinthusbio.com/role/ShareBasedCompensationWeightedaverageassumptionsDetails">
        <link:definition>9954513 - Disclosure - Share-Based Compensation - Weighted-average assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationSummaryofstockoptionactivityDetails" roleURI="http://www.barinthusbio.com/role/ShareBasedCompensationSummaryofstockoptionactivityDetails">
        <link:definition>9954514 - Disclosure - Share-Based Compensation - Summary of stock option activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationSharebasedcompensationexpenseDetails" roleURI="http://www.barinthusbio.com/role/ShareBasedCompensationSharebasedcompensationexpenseDetails">
        <link:definition>9954515 - Disclosure - Share-Based Compensation - Share based compensation expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesLossincomebeforeincometaxesDetails" roleURI="http://www.barinthusbio.com/role/IncomeTaxesLossincomebeforeincometaxesDetails">
        <link:definition>9954516 - Disclosure - Income Taxes - (Loss) income before income taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesComponentsofincometaxbenefitexpenseDetails" roleURI="http://www.barinthusbio.com/role/IncomeTaxesComponentsofincometaxbenefitexpenseDetails">
        <link:definition>9954517 - Disclosure - Income Taxes - Components of income tax benefit (expense) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesReconciliationtotheeffectivetaxrateDetails" roleURI="http://www.barinthusbio.com/role/IncomeTaxesReconciliationtotheeffectivetaxrateDetails">
        <link:definition>9954518 - Disclosure - Income Taxes - Reconciliation to the effective tax rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDeferredtaxassetsandliabilitiesDetails" roleURI="http://www.barinthusbio.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails">
        <link:definition>9954519 - Disclosure - Income Taxes - Deferred tax assets and liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesAdditionalInformationDetails" roleURI="http://www.barinthusbio.com/role/IncomeTaxesAdditionalInformationDetails">
        <link:definition>9954520 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesChangesinthevaluationallowancefordeferredtaxassetsDetails" roleURI="http://www.barinthusbio.com/role/IncomeTaxesChangesinthevaluationallowancefordeferredtaxassetsDetails">
        <link:definition>9954521 - Disclosure - Income Taxes - Changes in the valuation allowance for deferred tax assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesAdditionalinformationDetails" roleURI="http://www.barinthusbio.com/role/CommitmentsandContingenciesAdditionalinformationDetails">
        <link:definition>9954522 - Disclosure - Commitments and Contingencies - Additional information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesRightofuseassetsleaseliabilitiesandotherinformationDetails" roleURI="http://www.barinthusbio.com/role/CommitmentsandContingenciesRightofuseassetsleaseliabilitiesandotherinformationDetails">
        <link:definition>9954523 - Disclosure - Commitments and Contingencies - Right-of-use assets, lease liabilities and other information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails" roleURI="http://www.barinthusbio.com/role/CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails">
        <link:definition>9954524 - Disclosure - Commitments and Contingencies - Maturities of minimum lease liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails_1" roleURI="http://www.barinthusbio.com/role/CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails_1">
        <link:definition>9954524 - Disclosure - Commitments and Contingencies - Maturities of minimum lease liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlansDetails" roleURI="http://www.barinthusbio.com/role/EmployeeBenefitPlansDetails">
        <link:definition>9954525 - Disclosure - Employee Benefit Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsDetails" roleURI="http://www.barinthusbio.com/role/RelatedPartyTransactionsDetails">
        <link:definition>9954526 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://www.barinthusbio.com/role/SubsequentEventsDetails">
        <link:definition>9954527 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="brns_DeferredCSharesMember" abstract="true" name="DeferredCSharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="brns_MinorityInterestPolicyTextBlock" abstract="false" name="MinorityInterestPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="brns_ScheduleOfOrdinarySharesReservedForFutureIssuanceTableTextBlock" abstract="false" name="ScheduleOfOrdinarySharesReservedForFutureIssuanceTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="brns_PercentageOfSharesNecessaryToExercisePreemptiveRights" abstract="false" name="PercentageOfSharesNecessaryToExercisePreemptiveRights" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="brns_ValuationAllowanceDeferredTaxAssetIncreaseResultingFromCurrentPeriodAdditions" abstract="false" name="ValuationAllowanceDeferredTaxAssetIncreaseResultingFromCurrentPeriodAdditions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="brns_PercentageOfNetPaymentsReceivedForAllowableSublicensesOfTechnologyDevelopedLicenseAgreement" abstract="false" name="PercentageOfNetPaymentsReceivedForAllowableSublicensesOfTechnologyDevelopedLicenseAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="brns_IncomeTaxesTable" abstract="true" name="IncomeTaxesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="brns_NumberOfAmericanDepositarySharesAdsIssued" abstract="false" name="NumberOfAmericanDepositarySharesAdsIssued" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="brns_NonCashInvestingAndFinancingActivityOfMeasurementPeriodAdjustments" abstract="false" name="NonCashInvestingAndFinancingActivityOfMeasurementPeriodAdjustments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent" abstract="false" name="AccruedLiabilitiesAndOtherLiabilitiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="brns_ExpensesMember" abstract="true" name="ExpensesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="brns_IssuanceOfCommonStockUnderwritingCommissions" abstract="false" name="IssuanceOfCommonStockUnderwritingCommissions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="brns_ShareBasedCompensationPercentageOfSharesAvailableForIssuanceAsPercentageOfIssuedAndOutstandingShares" abstract="false" name="ShareBasedCompensationPercentageOfSharesAvailableForIssuanceAsPercentageOfIssuedAndOutstandingShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="brns_CoalitionForEpidemicPreparednessInnovationsFundingAgreementMember" abstract="true" name="CoalitionForEpidemicPreparednessInnovationsFundingAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="brns_RestrictedShareUnitsStockOptionsShareAppreciationRightsAndRestrictedSharesMember" abstract="true" name="RestrictedShareUnitsStockOptionsShareAppreciationRightsAndRestrictedSharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="brns_DeferredTaxLiabilityNet" abstract="false" name="DeferredTaxLiabilityNet" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="brns_ProceedsFromGrantsReceived" abstract="false" name="ProceedsFromGrantsReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="brns_ResearchAndDevelopmentIncentivesReceivable" abstract="false" name="ResearchAndDevelopmentIncentivesReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="brns_ChangesToRightOfUseAssetResultingFromLeaseReassessmentEvent" abstract="false" name="ChangesToRightOfUseAssetResultingFromLeaseReassessmentEvent" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="brns_SharesCancelledDuringPeriodValueDeferredShares" abstract="false" name="SharesCancelledDuringPeriodValueDeferredShares" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="brns_OuiLicenseAgreementAmendmentMember" abstract="true" name="OuiLicenseAgreementAmendmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="brns_ValuationAllowanceDeferredTaxAssetIncreaseResultingFromIncomeTaxProvision" abstract="false" name="ValuationAllowanceDeferredTaxAssetIncreaseResultingFromIncomeTaxProvision" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="brns_OrdinarySharesLiquidationPreference" abstract="false" name="OrdinarySharesLiquidationPreference" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock" abstract="false" name="AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" abstract="false" name="AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="brns_ClinicalTrialCostsPolicyTextBlock" abstract="false" name="ClinicalTrialCostsPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="brns_PrepaidExpenseAndOtherAssetsCurrentTextBlock" abstract="false" name="PrepaidExpenseAndOtherAssetsCurrentTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="brns_VOLTMember" abstract="true" name="VOLTMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="brns_ConcentrationRiskThresholdPercentage" abstract="false" name="ConcentrationRiskThresholdPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="brns_DeferredStockSharesAuthorized" abstract="false" name="DeferredStockSharesAuthorized" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="brns_LesseeOperatingLeaseRightOfUseAssetAndOtherInformationTableTextBlock" abstract="false" name="LesseeOperatingLeaseRightOfUseAssetAndOtherInformationTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="brns_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsIntangibles" abstract="false" name="DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsIntangibles" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="brns_LesseeOperatingLeaseExtendedTerm" abstract="false" name="LesseeOperatingLeaseExtendedTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="brns_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment" abstract="false" name="EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="brns_ResearchGrantsAndContractsMember" abstract="true" name="ResearchGrantsAndContractsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="brns_ResearchAndDevelopmentIncentiveIncomeExpense" abstract="false" name="ResearchAndDevelopmentIncentiveIncomeExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="brns_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseResultingFromForeignCurrencyTranslation" abstract="false" name="ValuationAllowanceDeferredTaxAssetIncreaseDecreaseResultingFromForeignCurrencyTranslation" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="brns_OtherInformationLesseeAbstract" abstract="true" name="OtherInformationLesseeAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="brns_AmericanDepositarySharesMember" abstract="true" name="AmericanDepositarySharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="brns_ContingentConsiderationLiabilityMember" abstract="true" name="ContingentConsiderationLiabilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="brns_OxfordshireMember" abstract="true" name="OxfordshireMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="brns_BarinthusBiotherapeuticsPlcShareAwardPlan2021Member" abstract="true" name="BarinthusBiotherapeuticsPlcShareAwardPlan2021Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="brns_CommonStockNumberOfVotesPerShare" abstract="false" name="CommonStockNumberOfVotesPerShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="brns_AgreementWithOxfordUniversityInnovationMember" abstract="true" name="AgreementWithOxfordUniversityInnovationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="brns_ContractWithCustomerLiabilityRevenueRecognized1" abstract="false" name="ContractWithCustomerLiabilityRevenueRecognized1" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="brns_FundingAmountMaximum" abstract="false" name="FundingAmountMaximum" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="brns_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustments" abstract="false" name="EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="brns_IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable" abstract="false" name="IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="brns_EnterpriseManagementIncentiveShareOptionSchemeMember" abstract="true" name="EnterpriseManagementIncentiveShareOptionSchemeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="brns_SubsidiariesVOLTMember" abstract="true" name="SubsidiariesVOLTMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="brns_AgreementWithScancellToGrantResearchAndDevelopmentLicenseMember" abstract="true" name="AgreementWithScancellToGrantResearchAndDevelopmentLicenseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="brns_DeferredTaxAssetsLeasingArrangements" abstract="false" name="DeferredTaxAssetsLeasingArrangements" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="brns_GrantIncomePolicyPolicyTextBlock" abstract="false" name="GrantIncomePolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="brns_AccruedManufacturingAndClinicalExpensesCurrent" abstract="false" name="AccruedManufacturingAndClinicalExpensesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="brns_DeferredBSharesMember" abstract="true" name="DeferredBSharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="brns_AccountsReceivableStandardPaymentTermsPeriod" abstract="false" name="AccountsReceivableStandardPaymentTermsPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="brns_NumberOfSquareFeetUnderLeaseAgreement" abstract="false" name="NumberOfSquareFeetUnderLeaseAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="brns_DeferredStockSharesIssued" abstract="false" name="DeferredStockSharesIssued" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="brns_AdditionalPaidInCapitalPolicyTextBlock" abstract="false" name="AdditionalPaidInCapitalPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="brns_PercentageOfRoyaltiesOnNetSales" abstract="false" name="PercentageOfRoyaltiesOnNetSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="brns_ContractWithCustomerLiabilityForeignExchangeTranslation" abstract="false" name="ContractWithCustomerLiabilityForeignExchangeTranslation" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="brns_SharesCancelledDuringPeriodSharesDeferredShares" abstract="false" name="SharesCancelledDuringPeriodSharesDeferredShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="brns_EffectiveIncomeTaxRateReconciliationPercentIncreaseDecreaseAbstract" abstract="true" name="EffectiveIncomeTaxRateReconciliationPercentIncreaseDecreaseAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="brns_DeferredStockParOrStatedValuePerShare" abstract="false" name="DeferredStockParOrStatedValuePerShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="brns_PercentageOfFutureRoyaltiesForDirectSalesOfCoveredProductLicenseAgreement" abstract="false" name="PercentageOfFutureRoyaltiesForDirectSalesOfCoveredProductLicenseAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="brns_ContractWithCustomerLiabilitiesTableTextBlock" abstract="false" name="ContractWithCustomerLiabilitiesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="brns_PeriodOfPreemptiveRightsToBeExercised" abstract="false" name="PeriodOfPreemptiveRightsToBeExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="brns_InLicenseAgreementsMember" abstract="true" name="InLicenseAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="brns_SubsidiaryCumulativeContributionsParent" abstract="false" name="SubsidiaryCumulativeContributionsParent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="brns_MaximumAggregateNominalAmountOfSharesAuthorizedToBeAllottedFreeFromStatutoryPreEmptionRights" abstract="false" name="MaximumAggregateNominalAmountOfSharesAuthorizedToBeAllottedFreeFromStatutoryPreEmptionRights" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="brns_ExpirationOfShareBasedCompensationPlanFromDateOfInitialIssuance" abstract="false" name="ExpirationOfShareBasedCompensationPlanFromDateOfInitialIssuance" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="brns_ValuationAllowanceRollForward" abstract="true" name="ValuationAllowanceRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="brns_IssuanceOfCommonStockOfferingCosts" abstract="false" name="IssuanceOfCommonStockOfferingCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSeven" abstract="false" name="FiniteLivedIntangibleAssetExpectedAmortizationYearSeven" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="brns_IncomeTaxesLineItems" abstract="true" name="IncomeTaxesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="brns_AvideaMember" abstract="true" name="AvideaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="brns_DeferredSharesMember" abstract="true" name="DeferredSharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="brns_AssetRetirementObligations" abstract="false" name="AssetRetirementObligations" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="brns_OxfordUniversityInnovationMember" abstract="true" name="OxfordUniversityInnovationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSix" abstract="false" name="FiniteLivedIntangibleAssetExpectedAmortizationYearSix" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="brns_AdjustmentsToAdditionalPaidInCapitalMeasurementPeriodAdjustmentsInBusinessCombination" abstract="false" name="AdjustmentsToAdditionalPaidInCapitalMeasurementPeriodAdjustmentsInBusinessCombination" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="brns_ResearchAndDevelopmentServicesPolicyPolicyTextBlock" abstract="false" name="ResearchAndDevelopmentServicesPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="brns_NonCashLeaseExpenses" abstract="false" name="NonCashLeaseExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="brns_SubsidiaryCumulativeContributionsNoncontrollingOwner" abstract="false" name="SubsidiaryCumulativeContributionsNoncontrollingOwner" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="brns_StockholdersEquityDeferredSharesDisclosureTextBlock" abstract="false" name="StockholdersEquityDeferredSharesDisclosureTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="brns_RoyaltyPaymentTermMaximum" abstract="false" name="RoyaltyPaymentTermMaximum" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="brns_FiniteLivedIntangibleAssetExpectedAmortizationYearEight" abstract="false" name="FiniteLivedIntangibleAssetExpectedAmortizationYearEight" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="brns_NonCashInterestExpenseOnConvertibleLoanNotes" abstract="false" name="NonCashInterestExpenseOnConvertibleLoanNotes" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="brns_ContingentConsiderationSettledInEquity" abstract="false" name="ContingentConsiderationSettledInEquity" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="brns_LaboratoryEquipmentMember" abstract="true" name="LaboratoryEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="brns_ContractWithCustomerLiabilityRollForward" abstract="true" name="ContractWithCustomerLiabilityRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="brns_DeferredStockSharesOutstanding" abstract="false" name="DeferredStockSharesOutstanding" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="brns_LeaseIncentiveReceivablesCurrent" abstract="false" name="LeaseIncentiveReceivablesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="brns_ResearchAndDevelopmentIncentivesPolicyTextBlock" abstract="false" name="ResearchAndDevelopmentIncentivesPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="brns_DeferredShares.Member" abstract="true" name="DeferredShares.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="brns_OxfordUniversityInnovationLimitedMember" abstract="true" name="OxfordUniversityInnovationLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="brns_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="brns_ShareholderTheUniversityOfOxfordMember" abstract="true" name="ShareholderTheUniversityOfOxfordMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="brns_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeTranslation" abstract="false" name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeTranslation" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="brns_DeferredStockValueIssued" abstract="false" name="DeferredStockValueIssued" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>brns-20231231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:568bf53a-35e8-4830-ae45-40f379b83a88,g:160c7384-88e8-453d-8496-8cc857f3b5f9-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="brns-20231231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_fae171af-aaa3-4f27-8171-9f923f17a727" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_997cb97f-9e80-4666-b591-4956de8287f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_fae171af-aaa3-4f27-8171-9f923f17a727" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_997cb97f-9e80-4666-b591-4956de8287f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_9962153a-1a23-4691-b0ea-1aa4e19ec093" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_fae171af-aaa3-4f27-8171-9f923f17a727" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_9962153a-1a23-4691-b0ea-1aa4e19ec093" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ResearchAndDevelopmentIncentivesReceivable_6582bdbf-a1e6-4e6e-a508-c82e9bdf3854" xlink:href="brns-20231231.xsd#brns_ResearchAndDevelopmentIncentivesReceivable"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_fae171af-aaa3-4f27-8171-9f923f17a727" xlink:to="loc_brns_ResearchAndDevelopmentIncentivesReceivable_6582bdbf-a1e6-4e6e-a508-c82e9bdf3854" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1d645205-bc85-424e-8129-1ac6611fc0b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_fae171af-aaa3-4f27-8171-9f923f17a727" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1d645205-bc85-424e-8129-1ac6611fc0b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_91d7d6e9-73a2-45f0-bbf6-4289f26abf4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_29705979-0603-4675-b5b3-1bdcd80db102" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_91d7d6e9-73a2-45f0-bbf6-4289f26abf4c" xlink:to="loc_us-gaap_AccountsPayableCurrent_29705979-0603-4675-b5b3-1bdcd80db102" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent_88d8d79a-5ba0-4b03-a2c5-64ec25ec03ad" xlink:href="brns-20231231.xsd#brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_91d7d6e9-73a2-45f0-bbf6-4289f26abf4c" xlink:to="loc_brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent_88d8d79a-5ba0-4b03-a2c5-64ec25ec03ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_33262908-0d84-4012-a9b4-8f983653cefc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_91d7d6e9-73a2-45f0-bbf6-4289f26abf4c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_33262908-0d84-4012-a9b4-8f983653cefc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_7b2f9c1f-6397-465b-b195-4ca081d7795f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_522ab28e-c6d4-49cc-baba-aceb7837a7f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7b2f9c1f-6397-465b-b195-4ca081d7795f" xlink:to="loc_us-gaap_Goodwill_522ab28e-c6d4-49cc-baba-aceb7837a7f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_23da46d6-488c-4652-a88c-ed9c3b1c8367" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7b2f9c1f-6397-465b-b195-4ca081d7795f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_23da46d6-488c-4652-a88c-ed9c3b1c8367" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_76b96243-87c1-4065-8708-7ef2d0f6d8f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7b2f9c1f-6397-465b-b195-4ca081d7795f" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_76b96243-87c1-4065-8708-7ef2d0f6d8f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_a2aa8f51-2837-4a79-9252-6e9d83edcadd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7b2f9c1f-6397-465b-b195-4ca081d7795f" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_a2aa8f51-2837-4a79-9252-6e9d83edcadd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssets_5e7209e8-0640-4b31-b101-4626aaf96881" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssets"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7b2f9c1f-6397-465b-b195-4ca081d7795f" xlink:to="loc_us-gaap_OtherAssets_5e7209e8-0640-4b31-b101-4626aaf96881" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_783c4856-26a5-45f1-a55b-ac1a3be72261" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7b2f9c1f-6397-465b-b195-4ca081d7795f" xlink:to="loc_us-gaap_AssetsCurrent_783c4856-26a5-45f1-a55b-ac1a3be72261" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_536b9942-1fb9-43b6-ac80-6fa2fde2a493" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredStockValueIssued_be9d4dcd-dbd2-4fdd-8b98-37a45217f862" xlink:href="brns-20231231.xsd#brns_DeferredStockValueIssued"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_536b9942-1fb9-43b6-ac80-6fa2fde2a493" xlink:to="loc_brns_DeferredStockValueIssued_be9d4dcd-dbd2-4fdd-8b98-37a45217f862" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5adc1558-b467-4e2c-a7a6-603f3e46a786" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_536b9942-1fb9-43b6-ac80-6fa2fde2a493" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5adc1558-b467-4e2c-a7a6-603f3e46a786" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_0f244d21-6133-4f8b-aae4-26569ceb0de7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_536b9942-1fb9-43b6-ac80-6fa2fde2a493" xlink:to="loc_us-gaap_CommonStockValue_0f244d21-6133-4f8b-aae4-26569ceb0de7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_6bef5619-ceec-42f6-9bee-8f74abf65b5d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_536b9942-1fb9-43b6-ac80-6fa2fde2a493" xlink:to="loc_us-gaap_AdditionalPaidInCapital_6bef5619-ceec-42f6-9bee-8f74abf65b5d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_726e4a6a-fac5-40e2-9762-f8da63302bda" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_536b9942-1fb9-43b6-ac80-6fa2fde2a493" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_726e4a6a-fac5-40e2-9762-f8da63302bda" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_fe08d56c-6b03-4890-8832-2945bbcc2ca4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_220b332f-1c0f-401a-922f-547180692f56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_fe08d56c-6b03-4890-8832-2945bbcc2ca4" xlink:to="loc_us-gaap_Liabilities_220b332f-1c0f-401a-922f-547180692f56" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_4314b482-e68b-4c70-8443-bb5d40d60fd7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_fe08d56c-6b03-4890-8832-2945bbcc2ca4" xlink:to="loc_us-gaap_CommitmentsAndContingencies_4314b482-e68b-4c70-8443-bb5d40d60fd7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5795df03-b575-4d3a-98c9-d52b672fd6a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_fe08d56c-6b03-4890-8832-2945bbcc2ca4" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5795df03-b575-4d3a-98c9-d52b672fd6a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_063cae18-b85c-422d-9af0-f5d8c3a97b7f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_e82f069c-0f98-408f-b3b2-c1e0170008f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_063cae18-b85c-422d-9af0-f5d8c3a97b7f" xlink:to="loc_us-gaap_MinorityInterest_e82f069c-0f98-408f-b3b2-c1e0170008f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e7fd028a-3e6c-4d31-b822-f76f56f05cf9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_063cae18-b85c-422d-9af0-f5d8c3a97b7f" xlink:to="loc_us-gaap_StockholdersEquity_e7fd028a-3e6c-4d31-b822-f76f56f05cf9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_48c65e96-072f-4436-a1e6-61d4797fdaf2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_ff3430c7-a181-4fce-8d69-7eb36b1a18a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_48c65e96-072f-4436-a1e6-61d4797fdaf2" xlink:to="loc_us-gaap_LiabilitiesCurrent_ff3430c7-a181-4fce-8d69-7eb36b1a18a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a63aa1ee-5776-44bc-a24a-a24e9ba538b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_48c65e96-072f-4436-a1e6-61d4797fdaf2" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a63aa1ee-5776-44bc-a24a-a24e9ba538b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_41c6c9f4-2d85-43bd-9bef-0ae815c6170a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_48c65e96-072f-4436-a1e6-61d4797fdaf2" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_41c6c9f4-2d85-43bd-9bef-0ae815c6170a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredTaxLiabilityNet_0d7511be-7189-45b6-b44e-26366f6749e1" xlink:href="brns-20231231.xsd#brns_DeferredTaxLiabilityNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_48c65e96-072f-4436-a1e6-61d4797fdaf2" xlink:to="loc_brns_DeferredTaxLiabilityNet_0d7511be-7189-45b6-b44e-26366f6749e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_25e95df1-694a-4baa-8c95-50c72872024e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_48c65e96-072f-4436-a1e6-61d4797fdaf2" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_25e95df1-694a-4baa-8c95-50c72872024e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="brns-20231231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:calculationLink xlink:role="http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_2d27efb1-4b6a-4a3b-808a-46fef9082635" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_02796025-d9e1-4a4a-ab2b-aaa206fa8379" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_2d27efb1-4b6a-4a3b-808a-46fef9082635" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_02796025-d9e1-4a4a-ab2b-aaa206fa8379" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_f4955a5f-8566-402d-aab6-c8bbdbc452b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_2d27efb1-4b6a-4a3b-808a-46fef9082635" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_f4955a5f-8566-402d-aab6-c8bbdbc452b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b1affcf6-7d6a-41d7-ba19-454248057fed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_83ee23c0-7ea9-4f7c-ba0a-2d50c39fd7dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b1affcf6-7d6a-41d7-ba19-454248057fed" xlink:to="loc_us-gaap_OperatingIncomeLoss_83ee23c0-7ea9-4f7c-ba0a-2d50c39fd7dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_ed138dff-3bd3-4475-a8b8-b19f0b4f324b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b1affcf6-7d6a-41d7-ba19-454248057fed" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_ed138dff-3bd3-4475-a8b8-b19f0b4f324b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_a94055f0-63ce-48c6-9cae-552198ee893c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c6e0b812-cc53-4306-9529-9debb1381556" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_a94055f0-63ce-48c6-9cae-552198ee893c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c6e0b812-cc53-4306-9529-9debb1381556" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_8f65fccb-09f8-45d9-a32f-ee45a57898b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_a94055f0-63ce-48c6-9cae-552198ee893c" xlink:to="loc_us-gaap_OperatingExpenses_8f65fccb-09f8-45d9-a32f-ee45a57898b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_274da278-6a4f-4bb5-a953-e83fb1ff6346" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_e950c502-a0ad-4998-a2ba-ec3d99bff9e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_274da278-6a4f-4bb5-a953-e83fb1ff6346" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_e950c502-a0ad-4998-a2ba-ec3d99bff9e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_7be67ea1-a273-41e3-81df-c94e9efa5eb5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_274da278-6a4f-4bb5-a953-e83fb1ff6346" xlink:to="loc_us-gaap_ProfitLoss_7be67ea1-a273-41e3-81df-c94e9efa5eb5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_bffcbc2d-1c2a-432d-8cff-fa39cbce6391" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_94c04dc6-30bc-470f-970c-f318928b7550" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_bffcbc2d-1c2a-432d-8cff-fa39cbce6391" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_94c04dc6-30bc-470f-970c-f318928b7550" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_bb9fefed-ee20-4f07-ba82-6f317cf53fb5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_bffcbc2d-1c2a-432d-8cff-fa39cbce6391" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_bb9fefed-ee20-4f07-ba82-6f317cf53fb5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_ccc5b503-de80-477b-94be-3dcd6e03e014" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_066b1ed1-cd3c-4fa7-855f-1745c2ac1fb1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_ccc5b503-de80-477b-94be-3dcd6e03e014" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_066b1ed1-cd3c-4fa7-855f-1745c2ac1fb1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_acd73593-cbd0-4ea7-8d95-d7f16a0168ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_ccc5b503-de80-477b-94be-3dcd6e03e014" xlink:to="loc_us-gaap_ProfitLoss_acd73593-cbd0-4ea7-8d95-d7f16a0168ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_808eebb8-602a-457a-b951-8a3ecc7cc815" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_03257fc5-3668-40e1-a1ad-cdea4af53b71" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_808eebb8-602a-457a-b951-8a3ecc7cc815" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_03257fc5-3668-40e1-a1ad-cdea4af53b71" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8c44d6eb-bcfc-483b-bb80-da263fa91553" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_808eebb8-602a-457a-b951-8a3ecc7cc815" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8c44d6eb-bcfc-483b-bb80-da263fa91553" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_b0495062-3bda-4892-879b-472ca58ca18f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_940a7cd8-e198-4cdf-93d8-47ca1e605a42" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_b0495062-3bda-4892-879b-472ca58ca18f" xlink:to="loc_us-gaap_InvestmentIncomeInterest_940a7cd8-e198-4cdf-93d8-47ca1e605a42" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_742299d9-b80b-48ab-8a73-39a57b6faa2e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_b0495062-3bda-4892-879b-472ca58ca18f" xlink:to="loc_us-gaap_InterestExpense_742299d9-b80b-48ab-8a73-39a57b6faa2e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ResearchAndDevelopmentIncentiveIncomeExpense_b3f29aed-0524-4163-8b7f-78ab192349ad" xlink:href="brns-20231231.xsd#brns_ResearchAndDevelopmentIncentiveIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_b0495062-3bda-4892-879b-472ca58ca18f" xlink:to="loc_brns_ResearchAndDevelopmentIncentiveIncomeExpense_b3f29aed-0524-4163-8b7f-78ab192349ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_8b222e22-ca67-472c-a138-13fb1c28f7ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_b0495062-3bda-4892-879b-472ca58ca18f" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_8b222e22-ca67-472c-a138-13fb1c28f7ea" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="brns-20231231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_30eb1f5a-2148-4c67-aba9-980b895a1245" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_b954cbfe-3f9c-4cad-9187-3685c48deda2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_30eb1f5a-2148-4c67-aba9-980b895a1245" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_b954cbfe-3f9c-4cad-9187-3685c48deda2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ac556914-46fa-406e-a30d-6bb04732b817" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_30eb1f5a-2148-4c67-aba9-980b895a1245" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ac556914-46fa-406e-a30d-6bb04732b817" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f25ffd2e-9ace-49f8-9f50-d1b42a5d4e8d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_c389f671-82ac-4aa3-b582-e5085fcda372" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f25ffd2e-9ace-49f8-9f50-d1b42a5d4e8d" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_c389f671-82ac-4aa3-b582-e5085fcda372" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_f32aa463-44e2-47ca-806e-0e47739cf911" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f25ffd2e-9ace-49f8-9f50-d1b42a5d4e8d" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_f32aa463-44e2-47ca-806e-0e47739cf911" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_73103ec1-7aa0-4d69-b6d1-133170b5006f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f25ffd2e-9ace-49f8-9f50-d1b42a5d4e8d" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_73103ec1-7aa0-4d69-b6d1-133170b5006f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_742b3ab8-6001-4cd8-9c6c-3952757e1dfb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f25ffd2e-9ace-49f8-9f50-d1b42a5d4e8d" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_742b3ab8-6001-4cd8-9c6c-3952757e1dfb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_df5f22a9-5cc6-4df1-8f0e-8085135c12d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_c68dcd90-0a38-441d-ba46-49401052e441" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_df5f22a9-5cc6-4df1-8f0e-8085135c12d3" xlink:to="loc_us-gaap_ProfitLoss_c68dcd90-0a38-441d-ba46-49401052e441" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_1a4d6bca-1ce2-4cfa-87e1-0d149d9b8e77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_df5f22a9-5cc6-4df1-8f0e-8085135c12d3" xlink:to="loc_us-gaap_ShareBasedCompensation_1a4d6bca-1ce2-4cfa-87e1-0d149d9b8e77" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_2f1d5b62-a474-4d83-a2c3-823caf9f8254" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_df5f22a9-5cc6-4df1-8f0e-8085135c12d3" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_2f1d5b62-a474-4d83-a2c3-823caf9f8254" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_NonCashLeaseExpenses_4e4a0ef7-4dc9-446c-a850-f298e43aed89" xlink:href="brns-20231231.xsd#brns_NonCashLeaseExpenses"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_df5f22a9-5cc6-4df1-8f0e-8085135c12d3" xlink:to="loc_brns_NonCashLeaseExpenses_4e4a0ef7-4dc9-446c-a850-f298e43aed89" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_49e36c3f-2515-4697-9140-a5c194cd90be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_df5f22a9-5cc6-4df1-8f0e-8085135c12d3" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_49e36c3f-2515-4697-9140-a5c194cd90be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_398580ee-91d5-41ec-9182-8a2edc01a58f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_df5f22a9-5cc6-4df1-8f0e-8085135c12d3" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_398580ee-91d5-41ec-9182-8a2edc01a58f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_f35372f4-2367-4a6e-9d0f-6f5e6014f3b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_df5f22a9-5cc6-4df1-8f0e-8085135c12d3" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_f35372f4-2367-4a6e-9d0f-6f5e6014f3b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_NonCashInterestExpenseOnConvertibleLoanNotes_ced9c14b-7e9c-4aeb-bcb0-511a451c42d7" xlink:href="brns-20231231.xsd#brns_NonCashInterestExpenseOnConvertibleLoanNotes"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_df5f22a9-5cc6-4df1-8f0e-8085135c12d3" xlink:to="loc_brns_NonCashInterestExpenseOnConvertibleLoanNotes_ced9c14b-7e9c-4aeb-bcb0-511a451c42d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_10d6cf6b-5970-4889-86d2-063c4a566b56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_df5f22a9-5cc6-4df1-8f0e-8085135c12d3" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_10d6cf6b-5970-4889-86d2-063c4a566b56" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_70a7c51e-6bda-4774-bf5a-c6be2d476eaf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_df5f22a9-5cc6-4df1-8f0e-8085135c12d3" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_70a7c51e-6bda-4774-bf5a-c6be2d476eaf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_3f4fb604-c269-43e7-bf6a-4b7fb3dbb03c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_df5f22a9-5cc6-4df1-8f0e-8085135c12d3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_3f4fb604-c269-43e7-bf6a-4b7fb3dbb03c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_b72db626-b23f-42a3-8329-1bc560a79161" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_df5f22a9-5cc6-4df1-8f0e-8085135c12d3" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_b72db626-b23f-42a3-8329-1bc560a79161" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable_a2b2b87d-00ca-4bb9-a68a-a820e2f29807" xlink:href="brns-20231231.xsd#brns_IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_df5f22a9-5cc6-4df1-8f0e-8085135c12d3" xlink:to="loc_brns_IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable_a2b2b87d-00ca-4bb9-a68a-a820e2f29807" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_79c733a8-b4f8-4c2c-818a-208825f56ff8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_df5f22a9-5cc6-4df1-8f0e-8085135c12d3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_79c733a8-b4f8-4c2c-818a-208825f56ff8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_99262222-0bc6-4611-b462-49ac284885b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_df5f22a9-5cc6-4df1-8f0e-8085135c12d3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_99262222-0bc6-4611-b462-49ac284885b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_0b980e6f-52a0-4eaf-91fb-af4f4365b51e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_df5f22a9-5cc6-4df1-8f0e-8085135c12d3" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_0b980e6f-52a0-4eaf-91fb-af4f4365b51e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_66032625-584a-45b6-abf4-fb8e2efab308" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="17" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_df5f22a9-5cc6-4df1-8f0e-8085135c12d3" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_66032625-584a-45b6-abf4-fb8e2efab308" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_145e8f12-d683-4f06-8ae2-2f016dff0850" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d90d7eeb-6fff-487f-845e-19efdcaec8c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_145e8f12-d683-4f06-8ae2-2f016dff0850" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d90d7eeb-6fff-487f-845e-19efdcaec8c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8765d828-94b0-47da-ac09-1449d0e38713" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_145e8f12-d683-4f06-8ae2-2f016dff0850" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8765d828-94b0-47da-ac09-1449d0e38713" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_30bd1e52-9c45-4f48-a1b2-33208f8496d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_145e8f12-d683-4f06-8ae2-2f016dff0850" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_30bd1e52-9c45-4f48-a1b2-33208f8496d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_eab3bf47-8ff7-4d2c-b427-a55e266ef49e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_145e8f12-d683-4f06-8ae2-2f016dff0850" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_eab3bf47-8ff7-4d2c-b427-a55e266ef49e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/NetLossIncomePerShareComputationDetails" xlink:type="simple" xlink:href="brns-20231231.xsd#NetLossIncomePerShareComputationDetails"/>
  <link:calculationLink xlink:role="http://www.barinthusbio.com/role/NetLossIncomePerShareComputationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8d3a5162-0fee-450c-994f-7fca083666bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9716a217-080a-49d0-8c10-d250bc128bc0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8d3a5162-0fee-450c-994f-7fca083666bf" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9716a217-080a-49d0-8c10-d250bc128bc0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_35d6fb12-3855-468c-a6d5-7feb887c7895" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8d3a5162-0fee-450c-994f-7fca083666bf" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_35d6fb12-3855-468c-a6d5-7feb887c7895" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/PropertyandEquipmentNetComponentsDetails" xlink:type="simple" xlink:href="brns-20231231.xsd#PropertyandEquipmentNetComponentsDetails"/>
  <link:calculationLink xlink:role="http://www.barinthusbio.com/role/PropertyandEquipmentNetComponentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_efd7cb04-c731-42c3-81eb-7a9599aee5d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_16c77223-1fb7-403b-8950-aa98d78e6c77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_efd7cb04-c731-42c3-81eb-7a9599aee5d1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_16c77223-1fb7-403b-8950-aa98d78e6c77" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_538c1000-f4c4-4159-a67e-5ffd6d6192e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_efd7cb04-c731-42c3-81eb-7a9599aee5d1" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_538c1000-f4c4-4159-a67e-5ffd6d6192e1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/PrepaidandothercurrentassetsDetails" xlink:type="simple" xlink:href="brns-20231231.xsd#PrepaidandothercurrentassetsDetails"/>
  <link:calculationLink xlink:role="http://www.barinthusbio.com/role/PrepaidandothercurrentassetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5bc8b652-c9b0-4d6a-8697-20c09adb7b2d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_8fc1e4a3-30b5-4ca9-bba3-5aa5f2e8cbc7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5bc8b652-c9b0-4d6a-8697-20c09adb7b2d" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_8fc1e4a3-30b5-4ca9-bba3-5aa5f2e8cbc7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValueAddedTaxReceivableCurrent_9c2cd934-eedd-47c7-8013-0dc735aa7cf4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValueAddedTaxReceivableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5bc8b652-c9b0-4d6a-8697-20c09adb7b2d" xlink:to="loc_us-gaap_ValueAddedTaxReceivableCurrent_9c2cd934-eedd-47c7-8013-0dc735aa7cf4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_LeaseIncentiveReceivablesCurrent_94dd3117-94d4-4e9b-b868-71f767ab1ee2" xlink:href="brns-20231231.xsd#brns_LeaseIncentiveReceivablesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5bc8b652-c9b0-4d6a-8697-20c09adb7b2d" xlink:to="loc_brns_LeaseIncentiveReceivablesCurrent_94dd3117-94d4-4e9b-b868-71f767ab1ee2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_45cc042c-c048-4f36-8fc4-a38e79ac6b2d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5bc8b652-c9b0-4d6a-8697-20c09adb7b2d" xlink:to="loc_us-gaap_OtherAssetsCurrent_45cc042c-c048-4f36-8fc4-a38e79ac6b2d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="brns-20231231.xsd#AccruedExpensesandOtherCurrentLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent_277845c5-5b8c-476a-8876-3435542dc428" xlink:href="brns-20231231.xsd#brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_AccruedManufacturingAndClinicalExpensesCurrent_d6f48844-e371-4106-947c-302e1681bc96" xlink:href="brns-20231231.xsd#brns_AccruedManufacturingAndClinicalExpensesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent_277845c5-5b8c-476a-8876-3435542dc428" xlink:to="loc_brns_AccruedManufacturingAndClinicalExpensesCurrent_d6f48844-e371-4106-947c-302e1681bc96" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedBonusesCurrent_aa55479d-0609-410d-a1fd-08c2cb2eea8a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedBonusesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent_277845c5-5b8c-476a-8876-3435542dc428" xlink:to="loc_us-gaap_AccruedBonusesCurrent_aa55479d-0609-410d-a1fd-08c2cb2eea8a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_8babbcb2-e138-449d-b8b8-1c8b9f76b398" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent_277845c5-5b8c-476a-8876-3435542dc428" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_8babbcb2-e138-449d-b8b8-1c8b9f76b398" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_cd97c198-359d-4b9d-a6fb-f49b70091f6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent_277845c5-5b8c-476a-8876-3435542dc428" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_cd97c198-359d-4b9d-a6fb-f49b70091f6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_313b1d64-d71b-46b5-9da5-b3fd34c63d45" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent_277845c5-5b8c-476a-8876-3435542dc428" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_313b1d64-d71b-46b5-9da5-b3fd34c63d45" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/OrdinarySharesOrdinarysharesforfutureissuanceDetails" xlink:type="simple" xlink:href="brns-20231231.xsd#OrdinarySharesOrdinarysharesforfutureissuanceDetails"/>
  <link:calculationLink xlink:role="http://www.barinthusbio.com/role/OrdinarySharesOrdinarysharesforfutureissuanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_19d50f79-6e26-457e-956a-6111c0d3fe76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1bbc0798-87d2-4033-badd-e3eaee34c9a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_19d50f79-6e26-457e-956a-6111c0d3fe76" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1bbc0798-87d2-4033-badd-e3eaee34c9a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1b4a321f-5b3d-413e-9651-fefed81c2b76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_19d50f79-6e26-457e-956a-6111c0d3fe76" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1b4a321f-5b3d-413e-9651-fefed81c2b76" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/IncomeTaxesLossincomebeforeincometaxesDetails" xlink:type="simple" xlink:href="brns-20231231.xsd#IncomeTaxesLossincomebeforeincometaxesDetails"/>
  <link:calculationLink xlink:role="http://www.barinthusbio.com/role/IncomeTaxesLossincomebeforeincometaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a007a062-e7bf-457b-b239-7add44293e8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_3f4db575-15ec-40c0-ba9b-281b648e5fca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a007a062-e7bf-457b-b239-7add44293e8f" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_3f4db575-15ec-40c0-ba9b-281b648e5fca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_6eaafa14-d565-4104-ba59-f2f9538a1893" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a007a062-e7bf-457b-b239-7add44293e8f" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_6eaafa14-d565-4104-ba59-f2f9538a1893" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/IncomeTaxesComponentsofincometaxbenefitexpenseDetails" xlink:type="simple" xlink:href="brns-20231231.xsd#IncomeTaxesComponentsofincometaxbenefitexpenseDetails"/>
  <link:calculationLink xlink:role="http://www.barinthusbio.com/role/IncomeTaxesComponentsofincometaxbenefitexpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_208d5c77-6e33-4b22-8e71-cdfe955746d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_448c60fe-0da3-4389-ad62-de90e0b7f322" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_208d5c77-6e33-4b22-8e71-cdfe955746d7" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_448c60fe-0da3-4389-ad62-de90e0b7f322" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_0cfe5828-9dbc-4407-a8c2-4fdad5eed4d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_208d5c77-6e33-4b22-8e71-cdfe955746d7" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_0cfe5828-9dbc-4407-a8c2-4fdad5eed4d8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/IncomeTaxesReconciliationtotheeffectivetaxrateDetails" xlink:type="simple" xlink:href="brns-20231231.xsd#IncomeTaxesReconciliationtotheeffectivetaxrateDetails"/>
  <link:calculationLink xlink:role="http://www.barinthusbio.com/role/IncomeTaxesReconciliationtotheeffectivetaxrateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8c6b5283-6463-4d5e-ab58-36d1a8bcb825" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_a0bfe3e5-0545-4cd1-aed8-9d591c1d1487" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8c6b5283-6463-4d5e-ab58-36d1a8bcb825" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_a0bfe3e5-0545-4cd1-aed8-9d591c1d1487" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_a2e0c2f6-2231-4299-a123-808083095d8c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8c6b5283-6463-4d5e-ab58-36d1a8bcb825" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_a2e0c2f6-2231-4299-a123-808083095d8c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustments_3fc722f9-f673-4a6a-b52e-65d44d4dd669" xlink:href="brns-20231231.xsd#brns_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8c6b5283-6463-4d5e-ab58-36d1a8bcb825" xlink:to="loc_brns_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustments_3fc722f9-f673-4a6a-b52e-65d44d4dd669" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment_cc5171c4-aa55-4f23-bcc1-beda83d47353" xlink:href="brns-20231231.xsd#brns_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8c6b5283-6463-4d5e-ab58-36d1a8bcb825" xlink:to="loc_brns_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment_cc5171c4-aa55-4f23-bcc1-beda83d47353" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_d79c9f03-5106-4e18-9b44-53efdcfa7353" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8c6b5283-6463-4d5e-ab58-36d1a8bcb825" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_d79c9f03-5106-4e18-9b44-53efdcfa7353" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_25809e13-7aaa-426c-884f-20dadb5ffc72" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8c6b5283-6463-4d5e-ab58-36d1a8bcb825" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_25809e13-7aaa-426c-884f-20dadb5ffc72" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_cb1cd1aa-fe7f-459a-8c66-f73dd08c0328" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8c6b5283-6463-4d5e-ab58-36d1a8bcb825" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_cb1cd1aa-fe7f-459a-8c66-f73dd08c0328" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails" xlink:type="simple" xlink:href="brns-20231231.xsd#IncomeTaxesDeferredtaxassetsandliabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.barinthusbio.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_ed1a51f4-5267-4996-ab20-4f388e874b95" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_9e7d9dde-3165-43b3-ade2-b1c8a5282e1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_ed1a51f4-5267-4996-ab20-4f388e874b95" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_9e7d9dde-3165-43b3-ade2-b1c8a5282e1b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_c5db89d9-18d4-4046-ac96-e310d08537e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_ed1a51f4-5267-4996-ab20-4f388e874b95" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_c5db89d9-18d4-4046-ac96-e310d08537e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_6c95e616-7f1d-4cdf-9483-4e3cfcd4636a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_ed1a51f4-5267-4996-ab20-4f388e874b95" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_6c95e616-7f1d-4cdf-9483-4e3cfcd4636a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_1571c3e9-b3b3-4eff-8ba0-af520f35d50d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_ed1a51f4-5267-4996-ab20-4f388e874b95" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_1571c3e9-b3b3-4eff-8ba0-af520f35d50d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredTaxAssetsLeasingArrangements_9b6dc79e-4004-4ffd-b3cc-b5b391c07cb7" xlink:href="brns-20231231.xsd#brns_DeferredTaxAssetsLeasingArrangements"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_ed1a51f4-5267-4996-ab20-4f388e874b95" xlink:to="loc_brns_DeferredTaxAssetsLeasingArrangements_9b6dc79e-4004-4ffd-b3cc-b5b391c07cb7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsIntangibles_7720e772-4707-44d8-b2fd-7d2927d92347" xlink:href="brns-20231231.xsd#brns_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsIntangibles"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_ed1a51f4-5267-4996-ab20-4f388e874b95" xlink:to="loc_brns_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsIntangibles_7720e772-4707-44d8-b2fd-7d2927d92347" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_db514ef5-d9de-46f1-bc0d-b8ab7913ed28" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_ed1a51f4-5267-4996-ab20-4f388e874b95" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_db514ef5-d9de-46f1-bc0d-b8ab7913ed28" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_d3248955-435c-445c-a146-6b12a2c49fab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_ed1a51f4-5267-4996-ab20-4f388e874b95" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_d3248955-435c-445c-a146-6b12a2c49fab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_ef8a8413-a99f-4334-8197-e66353b109fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_32d57733-0162-494f-8884-61304a7c923e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_ef8a8413-a99f-4334-8197-e66353b109fd" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_32d57733-0162-494f-8884-61304a7c923e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_15c88d40-4a5f-4b52-989b-766b6d1caccb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_ef8a8413-a99f-4334-8197-e66353b109fd" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_15c88d40-4a5f-4b52-989b-766b6d1caccb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_68d33969-6662-490e-a5fc-7d8ef4ee8e04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_fb70dc60-6a37-4e43-8594-13c6582c9225" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_68d33969-6662-490e-a5fc-7d8ef4ee8e04" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_fb70dc60-6a37-4e43-8594-13c6582c9225" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_f1f805f9-40d8-4876-b043-e087e8075d43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_68d33969-6662-490e-a5fc-7d8ef4ee8e04" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_f1f805f9-40d8-4876-b043-e087e8075d43" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_0a8d820e-b8af-4e0c-84b7-caaed970254b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_498699e2-98ca-4630-ac12-7e066dd81bd7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_0a8d820e-b8af-4e0c-84b7-caaed970254b" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_498699e2-98ca-4630-ac12-7e066dd81bd7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_876a9c2a-48e4-4ad6-9f89-7136cadc0d16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_0a8d820e-b8af-4e0c-84b7-caaed970254b" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_876a9c2a-48e4-4ad6-9f89-7136cadc0d16" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities_f503d27d-fcb3-49f1-885f-779d9a8681ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_0a8d820e-b8af-4e0c-84b7-caaed970254b" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities_f503d27d-fcb3-49f1-885f-779d9a8681ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_eff7a6e6-0830-4b3e-8258-9e9bec049a74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_0a8d820e-b8af-4e0c-84b7-caaed970254b" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_eff7a6e6-0830-4b3e-8258-9e9bec049a74" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/CommitmentsandContingenciesRightofuseassetsleaseliabilitiesandotherinformationDetails" xlink:type="simple" xlink:href="brns-20231231.xsd#CommitmentsandContingenciesRightofuseassetsleaseliabilitiesandotherinformationDetails"/>
  <link:calculationLink xlink:role="http://www.barinthusbio.com/role/CommitmentsandContingenciesRightofuseassetsleaseliabilitiesandotherinformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_6d851410-8b9e-40f7-b7b5-47828b36b16d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_43bab1ea-d997-40df-82d4-bfbc6db659ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_6d851410-8b9e-40f7-b7b5-47828b36b16d" xlink:to="loc_us-gaap_OperatingLeaseCost_43bab1ea-d997-40df-82d4-bfbc6db659ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_c1b5f3ce-8c6d-4279-88fe-bd76c549940f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_6d851410-8b9e-40f7-b7b5-47828b36b16d" xlink:to="loc_us-gaap_ShortTermLeaseCost_c1b5f3ce-8c6d-4279-88fe-bd76c549940f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails" xlink:type="simple" xlink:href="brns-20231231.xsd#CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.barinthusbio.com/role/CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c0946d76-8785-4dee-9dce-709c5a4b99b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_51d21bf4-1918-494f-b42f-9d58f225aa72" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c0946d76-8785-4dee-9dce-709c5a4b99b2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_51d21bf4-1918-494f-b42f-9d58f225aa72" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_42ce2718-8ad9-4b4d-a396-a61f86564bea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c0946d76-8785-4dee-9dce-709c5a4b99b2" xlink:to="loc_us-gaap_OperatingLeaseLiability_42ce2718-8ad9-4b4d-a396-a61f86564bea" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails_1" xlink:type="simple" xlink:href="brns-20231231.xsd#CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails_1"/>
  <link:calculationLink xlink:role="http://www.barinthusbio.com/role/CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7e8b2fc8-5df1-4a15-86c7-8509d7b41deb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_4a084b1e-f04c-4eb1-928a-e2e34ca5f8f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7e8b2fc8-5df1-4a15-86c7-8509d7b41deb" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_4a084b1e-f04c-4eb1-928a-e2e34ca5f8f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_a354960a-33f2-49f5-a250-3f06ba60442b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7e8b2fc8-5df1-4a15-86c7-8509d7b41deb" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_a354960a-33f2-49f5-a250-3f06ba60442b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_6744a2e7-7ebf-4c87-9f5a-29972a209daf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7e8b2fc8-5df1-4a15-86c7-8509d7b41deb" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_6744a2e7-7ebf-4c87-9f5a-29972a209daf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_fad6ab34-5380-4f7f-9337-0103afd8da8c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7e8b2fc8-5df1-4a15-86c7-8509d7b41deb" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_fad6ab34-5380-4f7f-9337-0103afd8da8c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_5af59fbe-7876-455c-9d9a-5620542185a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7e8b2fc8-5df1-4a15-86c7-8509d7b41deb" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_5af59fbe-7876-455c-9d9a-5620542185a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_f21eac10-fcbe-489e-8d54-94b72e8261f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7e8b2fc8-5df1-4a15-86c7-8509d7b41deb" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_f21eac10-fcbe-489e-8d54-94b72e8261f0" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>brns-20231231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:568bf53a-35e8-4830-ae45-40f379b83a88,g:160c7384-88e8-453d-8496-8cc857f3b5f9-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/Cover" xlink:type="simple" xlink:href="brns-20231231.xsd#Cover"/>
  <link:definitionLink xlink:role="http://www.barinthusbio.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_cf15fe6d-ef71-4b43-9c7e-a47bb857b51e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_789cdf02-1d99-41af-a2dc-dbb0ceac7457" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_cf15fe6d-ef71-4b43-9c7e-a47bb857b51e" xlink:to="loc_dei_DocumentInformationTable_789cdf02-1d99-41af-a2dc-dbb0ceac7457" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_cdcb25bf-5b66-45db-a441-538a7cbaa217" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_789cdf02-1d99-41af-a2dc-dbb0ceac7457" xlink:to="loc_us-gaap_StatementClassOfStockAxis_cdcb25bf-5b66-45db-a441-538a7cbaa217" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_cdcb25bf-5b66-45db-a441-538a7cbaa217_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_cdcb25bf-5b66-45db-a441-538a7cbaa217" xlink:to="loc_us-gaap_ClassOfStockDomain_cdcb25bf-5b66-45db-a441-538a7cbaa217_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_5dd47c46-baa8-46f0-9a00-0d75534852ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_cdcb25bf-5b66-45db-a441-538a7cbaa217" xlink:to="loc_us-gaap_ClassOfStockDomain_5dd47c46-baa8-46f0-9a00-0d75534852ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_de03bfca-98e2-4b31-bff3-2c580b37e2a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_5dd47c46-baa8-46f0-9a00-0d75534852ec" xlink:to="loc_us-gaap_CommonStockMember_de03bfca-98e2-4b31-bff3-2c580b37e2a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_AmericanDepositarySharesMember_31402981-6e59-4f1e-9128-3c58a8e07f45" xlink:href="brns-20231231.xsd#brns_AmericanDepositarySharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_5dd47c46-baa8-46f0-9a00-0d75534852ec" xlink:to="loc_brns_AmericanDepositarySharesMember_31402981-6e59-4f1e-9128-3c58a8e07f45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_280c48ea-c226-44e2-bc5a-f369cf1a0313" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_cf15fe6d-ef71-4b43-9c7e-a47bb857b51e" xlink:to="loc_dei_DocumentType_280c48ea-c226-44e2-bc5a-f369cf1a0313" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_04a091e7-a49c-41d5-aa3a-d48a7ad6c881" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_cf15fe6d-ef71-4b43-9c7e-a47bb857b51e" xlink:to="loc_dei_DocumentAnnualReport_04a091e7-a49c-41d5-aa3a-d48a7ad6c881" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_7c4462c3-66bb-4da1-b080-598ffd343506" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_cf15fe6d-ef71-4b43-9c7e-a47bb857b51e" xlink:to="loc_dei_DocumentPeriodEndDate_7c4462c3-66bb-4da1-b080-598ffd343506" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_28397e28-c5e8-47aa-9d00-be45d8654f39" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_cf15fe6d-ef71-4b43-9c7e-a47bb857b51e" xlink:to="loc_dei_CurrentFiscalYearEndDate_28397e28-c5e8-47aa-9d00-be45d8654f39" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_1045e961-6002-49d2-b6e7-ec0ce936984b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_cf15fe6d-ef71-4b43-9c7e-a47bb857b51e" xlink:to="loc_dei_DocumentTransitionReport_1045e961-6002-49d2-b6e7-ec0ce936984b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_af7b94f9-748d-4476-ad4b-b70afedc1dc0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_cf15fe6d-ef71-4b43-9c7e-a47bb857b51e" xlink:to="loc_dei_EntityFileNumber_af7b94f9-748d-4476-ad4b-b70afedc1dc0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_7a74c40b-6db6-43b8-a8b5-de175b2c4717" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_cf15fe6d-ef71-4b43-9c7e-a47bb857b51e" xlink:to="loc_dei_EntityRegistrantName_7a74c40b-6db6-43b8-a8b5-de175b2c4717" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_5b66d3a5-d7a5-4ee8-9f5f-53690f5a684a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_cf15fe6d-ef71-4b43-9c7e-a47bb857b51e" xlink:to="loc_dei_EntityIncorporationStateCountryCode_5b66d3a5-d7a5-4ee8-9f5f-53690f5a684a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_28a3cce2-05b4-4395-ba31-c7fbaef2ec16" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_cf15fe6d-ef71-4b43-9c7e-a47bb857b51e" xlink:to="loc_dei_EntityTaxIdentificationNumber_28a3cce2-05b4-4395-ba31-c7fbaef2ec16" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_008328d9-b461-4245-ab3c-9320761babbf" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_cf15fe6d-ef71-4b43-9c7e-a47bb857b51e" xlink:to="loc_dei_EntityAddressAddressLine1_008328d9-b461-4245-ab3c-9320761babbf" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_dd8861d3-9669-40bb-af31-984ef0cf319d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_cf15fe6d-ef71-4b43-9c7e-a47bb857b51e" xlink:to="loc_dei_EntityAddressAddressLine2_dd8861d3-9669-40bb-af31-984ef0cf319d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_50ecd367-83b1-4774-b7f8-bc3cc77e7f9f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_cf15fe6d-ef71-4b43-9c7e-a47bb857b51e" xlink:to="loc_dei_EntityAddressCityOrTown_50ecd367-83b1-4774-b7f8-bc3cc77e7f9f" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_5b9c42cc-b3bd-4ee0-b8cf-25cf86cbc954" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_cf15fe6d-ef71-4b43-9c7e-a47bb857b51e" xlink:to="loc_dei_EntityAddressPostalZipCode_5b9c42cc-b3bd-4ee0-b8cf-25cf86cbc954" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry_7f02ac64-3649-4793-b01c-9ac6bf9d7215" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_cf15fe6d-ef71-4b43-9c7e-a47bb857b51e" xlink:to="loc_dei_EntityAddressCountry_7f02ac64-3649-4793-b01c-9ac6bf9d7215" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_3d5197e7-3038-49f4-a737-d37f12aa3ab1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_cf15fe6d-ef71-4b43-9c7e-a47bb857b51e" xlink:to="loc_dei_CityAreaCode_3d5197e7-3038-49f4-a737-d37f12aa3ab1" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_db93448b-850e-4bfb-a197-8f4c20c46c98" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_cf15fe6d-ef71-4b43-9c7e-a47bb857b51e" xlink:to="loc_dei_LocalPhoneNumber_db93448b-850e-4bfb-a197-8f4c20c46c98" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_ea5a0bdf-d481-4c0e-a740-0744028559ec" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_cf15fe6d-ef71-4b43-9c7e-a47bb857b51e" xlink:to="loc_dei_Security12bTitle_ea5a0bdf-d481-4c0e-a740-0744028559ec" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_fad4b185-1e02-4fb5-9133-c948f0b28f40" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_cf15fe6d-ef71-4b43-9c7e-a47bb857b51e" xlink:to="loc_dei_TradingSymbol_fad4b185-1e02-4fb5-9133-c948f0b28f40" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_c9b65939-1566-4321-925f-960a014cce57" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_cf15fe6d-ef71-4b43-9c7e-a47bb857b51e" xlink:to="loc_dei_SecurityExchangeName_c9b65939-1566-4321-925f-960a014cce57" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_51cafe5f-2193-46d2-87d0-04b731853818" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_cf15fe6d-ef71-4b43-9c7e-a47bb857b51e" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_51cafe5f-2193-46d2-87d0-04b731853818" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_b6c5417d-7a72-4f7f-b01b-7d8c7124e7e6" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_cf15fe6d-ef71-4b43-9c7e-a47bb857b51e" xlink:to="loc_dei_EntityVoluntaryFilers_b6c5417d-7a72-4f7f-b01b-7d8c7124e7e6" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_f95db436-4ab4-4964-85f8-1e26bec28c23" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_cf15fe6d-ef71-4b43-9c7e-a47bb857b51e" xlink:to="loc_dei_EntityCurrentReportingStatus_f95db436-4ab4-4964-85f8-1e26bec28c23" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_f3dd1577-bfee-4478-ba31-69362052b2d2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_cf15fe6d-ef71-4b43-9c7e-a47bb857b51e" xlink:to="loc_dei_EntityInteractiveDataCurrent_f3dd1577-bfee-4478-ba31-69362052b2d2" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_259e5a26-af80-495d-918b-c4e0dca004d7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_cf15fe6d-ef71-4b43-9c7e-a47bb857b51e" xlink:to="loc_dei_EntityFilerCategory_259e5a26-af80-495d-918b-c4e0dca004d7" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_2ed61f7d-e57e-4c09-8de1-91bbc5907e18" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_cf15fe6d-ef71-4b43-9c7e-a47bb857b51e" xlink:to="loc_dei_EntitySmallBusiness_2ed61f7d-e57e-4c09-8de1-91bbc5907e18" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_df8ac37d-d295-4a8a-80dd-a5db18b183ba" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_cf15fe6d-ef71-4b43-9c7e-a47bb857b51e" xlink:to="loc_dei_EntityEmergingGrowthCompany_df8ac37d-d295-4a8a-80dd-a5db18b183ba" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_9a57dcf8-4c9c-40ef-8d2a-a988ebf994c9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_cf15fe6d-ef71-4b43-9c7e-a47bb857b51e" xlink:to="loc_dei_EntityExTransitionPeriod_9a57dcf8-4c9c-40ef-8d2a-a988ebf994c9" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_a00efc24-f6b8-42f9-84e7-d12c113374d3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_cf15fe6d-ef71-4b43-9c7e-a47bb857b51e" xlink:to="loc_dei_IcfrAuditorAttestationFlag_a00efc24-f6b8-42f9-84e7-d12c113374d3" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_c20fa2f4-2e37-4b92-a419-77e0e1393f4c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_cf15fe6d-ef71-4b43-9c7e-a47bb857b51e" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_c20fa2f4-2e37-4b92-a419-77e0e1393f4c" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_074eb22c-1fa4-426b-8151-2f69bc8c8d6c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_cf15fe6d-ef71-4b43-9c7e-a47bb857b51e" xlink:to="loc_dei_EntityShellCompany_074eb22c-1fa4-426b-8151-2f69bc8c8d6c" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_d9fce211-138f-482f-9c45-75feb58e051f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_cf15fe6d-ef71-4b43-9c7e-a47bb857b51e" xlink:to="loc_dei_EntityPublicFloat_d9fce211-138f-482f-9c45-75feb58e051f" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_74904a83-67c3-4edc-a2eb-c2b78ec7d024" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_cf15fe6d-ef71-4b43-9c7e-a47bb857b51e" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_74904a83-67c3-4edc-a2eb-c2b78ec7d024" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_fd4c492e-845e-4511-988e-48d72d64481d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_cf15fe6d-ef71-4b43-9c7e-a47bb857b51e" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_fd4c492e-845e-4511-988e-48d72d64481d" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_c818d7dd-10b7-46a3-bf21-72e551832537" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_cf15fe6d-ef71-4b43-9c7e-a47bb857b51e" xlink:to="loc_dei_EntityCentralIndexKey_c818d7dd-10b7-46a3-bf21-72e551832537" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_6a674b4a-4404-4af3-a098-ee43c2583426" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_cf15fe6d-ef71-4b43-9c7e-a47bb857b51e" xlink:to="loc_dei_DocumentFiscalYearFocus_6a674b4a-4404-4af3-a098-ee43c2583426" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_ef2667fb-dd24-4b8d-ba4c-71951cde4b2e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_cf15fe6d-ef71-4b43-9c7e-a47bb857b51e" xlink:to="loc_dei_DocumentFiscalPeriodFocus_ef2667fb-dd24-4b8d-ba4c-71951cde4b2e" xlink:type="arc" order="35"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_a857f186-9d71-42e3-ad87-e440ce94521a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_cf15fe6d-ef71-4b43-9c7e-a47bb857b51e" xlink:to="loc_dei_AmendmentFlag_a857f186-9d71-42e3-ad87-e440ce94521a" xlink:type="arc" order="36"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="brns-20231231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:definitionLink xlink:role="http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_ac1ec670-23e4-495b-9879-f541a800fa5d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_2f71b51b-3403-419a-85c3-d5890df13195" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_ac1ec670-23e4-495b-9879-f541a800fa5d" xlink:to="loc_us-gaap_StatementTable_2f71b51b-3403-419a-85c3-d5890df13195" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2e43085c-f627-4fd4-8d6f-d528aee52a45" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2f71b51b-3403-419a-85c3-d5890df13195" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2e43085c-f627-4fd4-8d6f-d528aee52a45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_2e43085c-f627-4fd4-8d6f-d528aee52a45_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2e43085c-f627-4fd4-8d6f-d528aee52a45" xlink:to="loc_us-gaap_RelatedPartyDomain_2e43085c-f627-4fd4-8d6f-d528aee52a45_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_61cacd9e-1acc-48e7-8c35-fa6fcd9867e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2e43085c-f627-4fd4-8d6f-d528aee52a45" xlink:to="loc_us-gaap_RelatedPartyDomain_61cacd9e-1acc-48e7-8c35-fa6fcd9867e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember_45d2b802-5332-4ac9-bfc1-a8f16b365481" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_61cacd9e-1acc-48e7-8c35-fa6fcd9867e5" xlink:to="loc_us-gaap_NonrelatedPartyMember_45d2b802-5332-4ac9-bfc1-a8f16b365481" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_3e17b4a5-7a9d-4879-b744-d1b07738305e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_61cacd9e-1acc-48e7-8c35-fa6fcd9867e5" xlink:to="loc_us-gaap_RelatedPartyMember_3e17b4a5-7a9d-4879-b744-d1b07738305e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_ba2beab3-330c-4b0d-8d92-ef484e2c35f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2f71b51b-3403-419a-85c3-d5890df13195" xlink:to="loc_us-gaap_StatementClassOfStockAxis_ba2beab3-330c-4b0d-8d92-ef484e2c35f2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ba2beab3-330c-4b0d-8d92-ef484e2c35f2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ba2beab3-330c-4b0d-8d92-ef484e2c35f2" xlink:to="loc_us-gaap_ClassOfStockDomain_ba2beab3-330c-4b0d-8d92-ef484e2c35f2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_0cd623b8-6e44-4ed4-bd1c-4bb44d02b3ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ba2beab3-330c-4b0d-8d92-ef484e2c35f2" xlink:to="loc_us-gaap_ClassOfStockDomain_0cd623b8-6e44-4ed4-bd1c-4bb44d02b3ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredShares.Member_345aa8cc-1d14-43ea-a346-b7e4d9889346" xlink:href="brns-20231231.xsd#brns_DeferredShares.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_0cd623b8-6e44-4ed4-bd1c-4bb44d02b3ba" xlink:to="loc_brns_DeferredShares.Member_345aa8cc-1d14-43ea-a346-b7e4d9889346" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredBSharesMember_e9518342-d055-48a9-8ed6-f239ecf0f8b7" xlink:href="brns-20231231.xsd#brns_DeferredBSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_0cd623b8-6e44-4ed4-bd1c-4bb44d02b3ba" xlink:to="loc_brns_DeferredBSharesMember_e9518342-d055-48a9-8ed6-f239ecf0f8b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredCSharesMember_bc477291-c0c1-43c6-a4a2-00502001f048" xlink:href="brns-20231231.xsd#brns_DeferredCSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_0cd623b8-6e44-4ed4-bd1c-4bb44d02b3ba" xlink:to="loc_brns_DeferredCSharesMember_bc477291-c0c1-43c6-a4a2-00502001f048" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_95811e89-826b-4ddb-8321-00d5ec9df4f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ac1ec670-23e4-495b-9879-f541a800fa5d" xlink:to="loc_us-gaap_AssetsAbstract_95811e89-826b-4ddb-8321-00d5ec9df4f4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_24dee1b9-4dd8-4c36-8902-ab95333e90ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_95811e89-826b-4ddb-8321-00d5ec9df4f4" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_24dee1b9-4dd8-4c36-8902-ab95333e90ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_c8d67a2a-000e-4889-977f-03b2ddf4a670" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_95811e89-826b-4ddb-8321-00d5ec9df4f4" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_c8d67a2a-000e-4889-977f-03b2ddf4a670" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ResearchAndDevelopmentIncentivesReceivable_5c386d21-f710-4827-9a20-64101af16cdd" xlink:href="brns-20231231.xsd#brns_ResearchAndDevelopmentIncentivesReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_95811e89-826b-4ddb-8321-00d5ec9df4f4" xlink:to="loc_brns_ResearchAndDevelopmentIncentivesReceivable_5c386d21-f710-4827-9a20-64101af16cdd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8bbb12db-d6f0-489d-9166-ceebacd8daf8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_95811e89-826b-4ddb-8321-00d5ec9df4f4" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8bbb12db-d6f0-489d-9166-ceebacd8daf8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_0fe3daee-cc3a-407f-8509-7e79cdc4cb34" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_95811e89-826b-4ddb-8321-00d5ec9df4f4" xlink:to="loc_us-gaap_AssetsCurrent_0fe3daee-cc3a-407f-8509-7e79cdc4cb34" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_f7bcd639-6870-4047-bb31-10c18c3fa026" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_95811e89-826b-4ddb-8321-00d5ec9df4f4" xlink:to="loc_us-gaap_Goodwill_f7bcd639-6870-4047-bb31-10c18c3fa026" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_e13bae08-e041-4e95-9c20-8472e58a6369" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_95811e89-826b-4ddb-8321-00d5ec9df4f4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_e13bae08-e041-4e95-9c20-8472e58a6369" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_5fb61395-2cac-42cd-9c31-02be0a142f94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_95811e89-826b-4ddb-8321-00d5ec9df4f4" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_5fb61395-2cac-42cd-9c31-02be0a142f94" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_176d066f-94a6-4db8-8c42-7b0199adccb6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_95811e89-826b-4ddb-8321-00d5ec9df4f4" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_176d066f-94a6-4db8-8c42-7b0199adccb6" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssets_b132612f-c64a-4af7-9823-73063f1c4e8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_95811e89-826b-4ddb-8321-00d5ec9df4f4" xlink:to="loc_us-gaap_OtherAssets_b132612f-c64a-4af7-9823-73063f1c4e8b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_b5f38b81-03e5-4f42-904f-3067332334de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_95811e89-826b-4ddb-8321-00d5ec9df4f4" xlink:to="loc_us-gaap_Assets_b5f38b81-03e5-4f42-904f-3067332334de" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_99e75fe2-c4b2-4451-abe0-6dab1ef197a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ac1ec670-23e4-495b-9879-f541a800fa5d" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_99e75fe2-c4b2-4451-abe0-6dab1ef197a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_a75a2ebe-5767-47c3-9d3b-d07920fb349c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_99e75fe2-c4b2-4451-abe0-6dab1ef197a2" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_a75a2ebe-5767-47c3-9d3b-d07920fb349c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_58ff531d-25e3-42ca-b96c-0923e0d66506" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a75a2ebe-5767-47c3-9d3b-d07920fb349c" xlink:to="loc_us-gaap_AccountsPayableCurrent_58ff531d-25e3-42ca-b96c-0923e0d66506" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent_900c903b-034a-4e53-a9f6-fbb5876cd661" xlink:href="brns-20231231.xsd#brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a75a2ebe-5767-47c3-9d3b-d07920fb349c" xlink:to="loc_brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent_900c903b-034a-4e53-a9f6-fbb5876cd661" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_b5d23ff8-38c0-48cc-b47f-4f27a378eb5d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a75a2ebe-5767-47c3-9d3b-d07920fb349c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_b5d23ff8-38c0-48cc-b47f-4f27a378eb5d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_e3d03726-4318-4f27-909d-bdb329a3d73c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a75a2ebe-5767-47c3-9d3b-d07920fb349c" xlink:to="loc_us-gaap_LiabilitiesCurrent_e3d03726-4318-4f27-909d-bdb329a3d73c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_f5359bfd-45f8-4f2f-8d57-16e975b6ea71" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_99e75fe2-c4b2-4451-abe0-6dab1ef197a2" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_f5359bfd-45f8-4f2f-8d57-16e975b6ea71" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_8e0e5046-7134-47eb-a15c-fa029aa69c1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_f5359bfd-45f8-4f2f-8d57-16e975b6ea71" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_8e0e5046-7134-47eb-a15c-fa029aa69c1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_fdbe6dc3-6862-4961-8b89-81bb39cd6fe2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_f5359bfd-45f8-4f2f-8d57-16e975b6ea71" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_fdbe6dc3-6862-4961-8b89-81bb39cd6fe2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_502d0e84-5f5d-44be-900c-53878ab687c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_f5359bfd-45f8-4f2f-8d57-16e975b6ea71" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_502d0e84-5f5d-44be-900c-53878ab687c9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredTaxLiabilityNet_710ca327-3fc0-45ed-871d-ba20af9cae0d" xlink:href="brns-20231231.xsd#brns_DeferredTaxLiabilityNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_f5359bfd-45f8-4f2f-8d57-16e975b6ea71" xlink:to="loc_brns_DeferredTaxLiabilityNet_710ca327-3fc0-45ed-871d-ba20af9cae0d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_db368fb6-1a2e-430c-95ea-01a82b5132ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_99e75fe2-c4b2-4451-abe0-6dab1ef197a2" xlink:to="loc_us-gaap_Liabilities_db368fb6-1a2e-430c-95ea-01a82b5132ff" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_67bd7c12-07df-403d-9a6f-fcf940774cf5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_99e75fe2-c4b2-4451-abe0-6dab1ef197a2" xlink:to="loc_us-gaap_CommitmentsAndContingencies_67bd7c12-07df-403d-9a6f-fcf940774cf5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_24be7ee1-28a6-4092-857d-ea5b8477c9d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_99e75fe2-c4b2-4451-abe0-6dab1ef197a2" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_24be7ee1-28a6-4092-857d-ea5b8477c9d2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_2779cf99-48f6-4a69-856c-e784fcbc2de0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_24be7ee1-28a6-4092-857d-ea5b8477c9d2" xlink:to="loc_us-gaap_CommonStockValue_2779cf99-48f6-4a69-856c-e784fcbc2de0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredStockValueIssued_4e15935e-d690-42d8-9dce-218dc05541d1" xlink:href="brns-20231231.xsd#brns_DeferredStockValueIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_24be7ee1-28a6-4092-857d-ea5b8477c9d2" xlink:to="loc_brns_DeferredStockValueIssued_4e15935e-d690-42d8-9dce-218dc05541d1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_3b6c936b-d7a2-4332-92c9-e8d3d1b82496" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_24be7ee1-28a6-4092-857d-ea5b8477c9d2" xlink:to="loc_us-gaap_AdditionalPaidInCapital_3b6c936b-d7a2-4332-92c9-e8d3d1b82496" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5676f05c-0763-4cc3-a42a-dfad6fa53f1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_24be7ee1-28a6-4092-857d-ea5b8477c9d2" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5676f05c-0763-4cc3-a42a-dfad6fa53f1b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_2013b70d-fc80-4bfe-9f9a-fba1075dcb93" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_24be7ee1-28a6-4092-857d-ea5b8477c9d2" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_2013b70d-fc80-4bfe-9f9a-fba1075dcb93" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_07a26318-d98c-4fca-bb3d-277d105112eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_24be7ee1-28a6-4092-857d-ea5b8477c9d2" xlink:to="loc_us-gaap_StockholdersEquity_07a26318-d98c-4fca-bb3d-277d105112eb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_174840f9-8430-42b6-9a8a-029209251ad1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_24be7ee1-28a6-4092-857d-ea5b8477c9d2" xlink:to="loc_us-gaap_MinorityInterest_174840f9-8430-42b6-9a8a-029209251ad1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_becfc47b-5b38-4a35-bda4-d5c89c7fe7d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_24be7ee1-28a6-4092-857d-ea5b8477c9d2" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_becfc47b-5b38-4a35-bda4-d5c89c7fe7d3" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_233af636-7a7c-454b-88d1-f4ac496162ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_99e75fe2-c4b2-4451-abe0-6dab1ef197a2" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_233af636-7a7c-454b-88d1-f4ac496162ea" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="brns-20231231.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:definitionLink xlink:role="http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_c662cd4f-4dc3-4261-b0d6-f4d2f2ffdd64" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_891f302f-4d0d-455f-8e0c-3ca96bd71edf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_c662cd4f-4dc3-4261-b0d6-f4d2f2ffdd64" xlink:to="loc_us-gaap_StatementTable_891f302f-4d0d-455f-8e0c-3ca96bd71edf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_9bd5aab0-aafa-470a-8b9e-15c7fc1912ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_891f302f-4d0d-455f-8e0c-3ca96bd71edf" xlink:to="loc_us-gaap_StatementClassOfStockAxis_9bd5aab0-aafa-470a-8b9e-15c7fc1912ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_9bd5aab0-aafa-470a-8b9e-15c7fc1912ff_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9bd5aab0-aafa-470a-8b9e-15c7fc1912ff" xlink:to="loc_us-gaap_ClassOfStockDomain_9bd5aab0-aafa-470a-8b9e-15c7fc1912ff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_e94e9556-8904-4e2f-827d-bdcc85caae91" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9bd5aab0-aafa-470a-8b9e-15c7fc1912ff" xlink:to="loc_us-gaap_ClassOfStockDomain_e94e9556-8904-4e2f-827d-bdcc85caae91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredShares.Member_0c8ae606-d8b0-40d6-9fe5-0d49c218b3bb" xlink:href="brns-20231231.xsd#brns_DeferredShares.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_e94e9556-8904-4e2f-827d-bdcc85caae91" xlink:to="loc_brns_DeferredShares.Member_0c8ae606-d8b0-40d6-9fe5-0d49c218b3bb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredBSharesMember_dd268da3-abb9-4fe9-b6c6-1f86049330bc" xlink:href="brns-20231231.xsd#brns_DeferredBSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_e94e9556-8904-4e2f-827d-bdcc85caae91" xlink:to="loc_brns_DeferredBSharesMember_dd268da3-abb9-4fe9-b6c6-1f86049330bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredCSharesMember_208b0ee1-30e6-4717-a597-883f35b54ffa" xlink:href="brns-20231231.xsd#brns_DeferredCSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_e94e9556-8904-4e2f-827d-bdcc85caae91" xlink:to="loc_brns_DeferredCSharesMember_208b0ee1-30e6-4717-a597-883f35b54ffa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_4e3ed841-4b00-4ec2-96d4-97977c7ea1d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c662cd4f-4dc3-4261-b0d6-f4d2f2ffdd64" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_4e3ed841-4b00-4ec2-96d4-97977c7ea1d5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_6e689c06-4259-419a-bc38-16265e98d115" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c662cd4f-4dc3-4261-b0d6-f4d2f2ffdd64" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_6e689c06-4259-419a-bc38-16265e98d115" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_2a7807bb-9063-49a6-98c0-2bb16d61d308" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c662cd4f-4dc3-4261-b0d6-f4d2f2ffdd64" xlink:to="loc_us-gaap_CommonStockSharesIssued_2a7807bb-9063-49a6-98c0-2bb16d61d308" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_05b6c1fe-c04c-44bc-ada2-8f91be9d528c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c662cd4f-4dc3-4261-b0d6-f4d2f2ffdd64" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_05b6c1fe-c04c-44bc-ada2-8f91be9d528c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredStockParOrStatedValuePerShare_81057e77-ea85-4820-879a-41a788dc0e16" xlink:href="brns-20231231.xsd#brns_DeferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c662cd4f-4dc3-4261-b0d6-f4d2f2ffdd64" xlink:to="loc_brns_DeferredStockParOrStatedValuePerShare_81057e77-ea85-4820-879a-41a788dc0e16" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredStockSharesAuthorized_8d94748f-06bf-4db5-a952-f484f19f83c8" xlink:href="brns-20231231.xsd#brns_DeferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c662cd4f-4dc3-4261-b0d6-f4d2f2ffdd64" xlink:to="loc_brns_DeferredStockSharesAuthorized_8d94748f-06bf-4db5-a952-f484f19f83c8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredStockSharesIssued_1a74292a-8cdb-4453-a635-f56a52a30f36" xlink:href="brns-20231231.xsd#brns_DeferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c662cd4f-4dc3-4261-b0d6-f4d2f2ffdd64" xlink:to="loc_brns_DeferredStockSharesIssued_1a74292a-8cdb-4453-a635-f56a52a30f36" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredStockSharesOutstanding_a38156e5-ca61-4cfb-a8ed-82b134c2882c" xlink:href="brns-20231231.xsd#brns_DeferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c662cd4f-4dc3-4261-b0d6-f4d2f2ffdd64" xlink:to="loc_brns_DeferredStockSharesOutstanding_a38156e5-ca61-4cfb-a8ed-82b134c2882c" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="brns-20231231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:definitionLink xlink:role="http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_e36caab5-e3b5-4229-8553-44c5bcf32d04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_8b3aec4d-2e13-4f10-a2fc-4664215b63e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_e36caab5-e3b5-4229-8553-44c5bcf32d04" xlink:to="loc_us-gaap_StatementTable_8b3aec4d-2e13-4f10-a2fc-4664215b63e6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_286b9161-0bb3-4d3b-8b33-cf7ee47c92ac" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_8b3aec4d-2e13-4f10-a2fc-4664215b63e6" xlink:to="loc_srt_ProductOrServiceAxis_286b9161-0bb3-4d3b-8b33-cf7ee47c92ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_286b9161-0bb3-4d3b-8b33-cf7ee47c92ac_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_286b9161-0bb3-4d3b-8b33-cf7ee47c92ac" xlink:to="loc_srt_ProductsAndServicesDomain_286b9161-0bb3-4d3b-8b33-cf7ee47c92ac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6d9fbfa6-a1d3-482c-b9d8-1f112569b72c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_286b9161-0bb3-4d3b-8b33-cf7ee47c92ac" xlink:to="loc_srt_ProductsAndServicesDomain_6d9fbfa6-a1d3-482c-b9d8-1f112569b72c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_940d105b-9f08-4375-909f-1966e56d7124" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6d9fbfa6-a1d3-482c-b9d8-1f112569b72c" xlink:to="loc_us-gaap_LicenseMember_940d105b-9f08-4375-909f-1966e56d7124" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ResearchGrantsAndContractsMember_4149f947-ca82-4017-a564-2e486ced684f" xlink:href="brns-20231231.xsd#brns_ResearchGrantsAndContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6d9fbfa6-a1d3-482c-b9d8-1f112569b72c" xlink:to="loc_brns_ResearchGrantsAndContractsMember_4149f947-ca82-4017-a564-2e486ced684f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c0fe8f4b-1990-4651-91e9-d4217ba2aece" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e36caab5-e3b5-4229-8553-44c5bcf32d04" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c0fe8f4b-1990-4651-91e9-d4217ba2aece" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_bb3f14ca-0b46-4f27-9c92-01d8c201ef39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e36caab5-e3b5-4229-8553-44c5bcf32d04" xlink:to="loc_us-gaap_OperatingExpensesAbstract_bb3f14ca-0b46-4f27-9c92-01d8c201ef39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_f28ee5b8-47f1-41d9-981e-72b8200bb1fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_bb3f14ca-0b46-4f27-9c92-01d8c201ef39" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_f28ee5b8-47f1-41d9-981e-72b8200bb1fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_ddf94da3-2f9d-421e-a6d2-ab6d280942f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_bb3f14ca-0b46-4f27-9c92-01d8c201ef39" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_ddf94da3-2f9d-421e-a6d2-ab6d280942f3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_8a0079ff-421b-4374-a2e5-26c0ef96fee0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_bb3f14ca-0b46-4f27-9c92-01d8c201ef39" xlink:to="loc_us-gaap_OperatingExpenses_8a0079ff-421b-4374-a2e5-26c0ef96fee0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_bca0a8dd-9df8-41bb-a804-309d1d151601" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_bb3f14ca-0b46-4f27-9c92-01d8c201ef39" xlink:to="loc_us-gaap_OperatingIncomeLoss_bca0a8dd-9df8-41bb-a804-309d1d151601" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_c504a54a-8f87-40b1-be73-d177c818b8b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e36caab5-e3b5-4229-8553-44c5bcf32d04" xlink:to="loc_us-gaap_OtherIncomeAndExpensesAbstract_c504a54a-8f87-40b1-be73-d177c818b8b0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_f6480bcd-a16d-4771-a300-f7d62254b958" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_c504a54a-8f87-40b1-be73-d177c818b8b0" xlink:to="loc_us-gaap_InvestmentIncomeInterest_f6480bcd-a16d-4771-a300-f7d62254b958" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_faf146dc-d94b-4c82-b4d3-e7d826365c36" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_c504a54a-8f87-40b1-be73-d177c818b8b0" xlink:to="loc_us-gaap_InterestExpense_faf146dc-d94b-4c82-b4d3-e7d826365c36" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ResearchAndDevelopmentIncentiveIncomeExpense_f3faadba-5dfd-466b-b267-ddf6bce63f8c" xlink:href="brns-20231231.xsd#brns_ResearchAndDevelopmentIncentiveIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_c504a54a-8f87-40b1-be73-d177c818b8b0" xlink:to="loc_brns_ResearchAndDevelopmentIncentiveIncomeExpense_f3faadba-5dfd-466b-b267-ddf6bce63f8c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_cd7a3c5f-5f19-4838-86e1-bc573948abe7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_c504a54a-8f87-40b1-be73-d177c818b8b0" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_cd7a3c5f-5f19-4838-86e1-bc573948abe7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_cf2caf89-92a8-4931-be0d-dc8b853fb3ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_c504a54a-8f87-40b1-be73-d177c818b8b0" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_cf2caf89-92a8-4931-be0d-dc8b853fb3ad" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8ec294b3-eba9-4e96-925d-3aec3a2fc992" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e36caab5-e3b5-4229-8553-44c5bcf32d04" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8ec294b3-eba9-4e96-925d-3aec3a2fc992" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_58958240-2c82-446f-969d-35e54b84bd42" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e36caab5-e3b5-4229-8553-44c5bcf32d04" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_58958240-2c82-446f-969d-35e54b84bd42" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_4916065a-a0e9-49ea-a889-861a4737963b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e36caab5-e3b5-4229-8553-44c5bcf32d04" xlink:to="loc_us-gaap_ProfitLoss_4916065a-a0e9-49ea-a889-861a4737963b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_db865df8-04f0-4db5-93ed-194142d59992" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e36caab5-e3b5-4229-8553-44c5bcf32d04" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_db865df8-04f0-4db5-93ed-194142d59992" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b42b8f81-ee66-43a9-958a-c02685facd33" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e36caab5-e3b5-4229-8553-44c5bcf32d04" xlink:to="loc_us-gaap_NetIncomeLoss_b42b8f81-ee66-43a9-958a-c02685facd33" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6a5f6ec4-8b48-4d45-b70b-735b72d53e04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e36caab5-e3b5-4229-8553-44c5bcf32d04" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6a5f6ec4-8b48-4d45-b70b-735b72d53e04" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4a6d33f2-57d3-40ab-905f-29ed1575a03c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e36caab5-e3b5-4229-8553-44c5bcf32d04" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4a6d33f2-57d3-40ab-905f-29ed1575a03c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_bee1ff85-3472-4958-84ea-1b612f09f5ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e36caab5-e3b5-4229-8553-44c5bcf32d04" xlink:to="loc_us-gaap_EarningsPerShareBasic_bee1ff85-3472-4958-84ea-1b612f09f5ff" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_992e9778-d141-4613-8acd-fa2b594cfefe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e36caab5-e3b5-4229-8553-44c5bcf32d04" xlink:to="loc_us-gaap_EarningsPerShareDiluted_992e9778-d141-4613-8acd-fa2b594cfefe" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_1011101f-a228-4da2-8773-e736e0600fe9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_7019d32a-04fc-4a6f-9698-38c1656e2002" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e36caab5-e3b5-4229-8553-44c5bcf32d04" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_7019d32a-04fc-4a6f-9698-38c1656e2002" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_a4d2a1c3-3f07-44e4-85a8-b68bad2a99db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e36caab5-e3b5-4229-8553-44c5bcf32d04" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_a4d2a1c3-3f07-44e4-85a8-b68bad2a99db" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_c4ce9e4b-fa1d-4854-8182-6ec27ab24b21" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e36caab5-e3b5-4229-8553-44c5bcf32d04" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_c4ce9e4b-fa1d-4854-8182-6ec27ab24b21" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_d4fcc948-4070-47b7-a0de-fea753e025dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e36caab5-e3b5-4229-8553-44c5bcf32d04" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_d4fcc948-4070-47b7-a0de-fea753e025dd" xlink:type="arc" order="16"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical" xlink:type="simple" xlink:href="brns-20231231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical"/>
  <link:definitionLink xlink:role="http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_672a7392-4f39-42fd-8c56-f7cdf155924b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_16227075-fa4e-438a-b4be-cfc065749daa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_672a7392-4f39-42fd-8c56-f7cdf155924b" xlink:to="loc_us-gaap_StatementTable_16227075-fa4e-438a-b4be-cfc065749daa" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_96d8bc05-5db8-4a19-854e-45424d5edfab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_16227075-fa4e-438a-b4be-cfc065749daa" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_96d8bc05-5db8-4a19-854e-45424d5edfab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_96d8bc05-5db8-4a19-854e-45424d5edfab_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_96d8bc05-5db8-4a19-854e-45424d5edfab" xlink:to="loc_us-gaap_RelatedPartyDomain_96d8bc05-5db8-4a19-854e-45424d5edfab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_e93e78f4-c60b-422a-ad88-baaef5beff27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_96d8bc05-5db8-4a19-854e-45424d5edfab" xlink:to="loc_us-gaap_RelatedPartyDomain_e93e78f4-c60b-422a-ad88-baaef5beff27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_f116b763-2124-4d7c-9eeb-57c92f070797" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_e93e78f4-c60b-422a-ad88-baaef5beff27" xlink:to="loc_us-gaap_RelatedPartyMember_f116b763-2124-4d7c-9eeb-57c92f070797" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a97e2c95-f386-42a1-a77d-746aed7079d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_672a7392-4f39-42fd-8c56-f7cdf155924b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a97e2c95-f386-42a1-a77d-746aed7079d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_6fda9a0d-5c21-4f9d-8e5c-8e5d7826d3f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_672a7392-4f39-42fd-8c56-f7cdf155924b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_6fda9a0d-5c21-4f9d-8e5c-8e5d7826d3f2" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="brns-20231231.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_672ff6a0-7632-43ee-8216-bf4f621ddb85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f59ed825-44f0-4d8e-8287-eac9ac6eafc9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_672ff6a0-7632-43ee-8216-bf4f621ddb85" xlink:to="loc_us-gaap_StatementTable_f59ed825-44f0-4d8e-8287-eac9ac6eafc9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2f4abd6a-c6b6-4c86-84be-e593b490a74d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_f59ed825-44f0-4d8e-8287-eac9ac6eafc9" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2f4abd6a-c6b6-4c86-84be-e593b490a74d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2f4abd6a-c6b6-4c86-84be-e593b490a74d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2f4abd6a-c6b6-4c86-84be-e593b490a74d" xlink:to="loc_us-gaap_EquityComponentDomain_2f4abd6a-c6b6-4c86-84be-e593b490a74d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c3cb3297-fb57-4947-9c20-36feaf9f73da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2f4abd6a-c6b6-4c86-84be-e593b490a74d" xlink:to="loc_us-gaap_EquityComponentDomain_c3cb3297-fb57-4947-9c20-36feaf9f73da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_549e21f7-5473-49b4-a6c4-0c07fd7a7650" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c3cb3297-fb57-4947-9c20-36feaf9f73da" xlink:to="loc_us-gaap_ParentMember_549e21f7-5473-49b4-a6c4-0c07fd7a7650" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_2314574e-b551-440e-a687-b92451af5f34" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_549e21f7-5473-49b4-a6c4-0c07fd7a7650" xlink:to="loc_us-gaap_CommonStockMember_2314574e-b551-440e-a687-b92451af5f34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredSharesMember_b91da951-f7ba-4876-bd84-b112556ba6de" xlink:href="brns-20231231.xsd#brns_DeferredSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_549e21f7-5473-49b4-a6c4-0c07fd7a7650" xlink:to="loc_brns_DeferredSharesMember_b91da951-f7ba-4876-bd84-b112556ba6de" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_12f90fc1-c14b-45ad-9684-a99648aecb1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_549e21f7-5473-49b4-a6c4-0c07fd7a7650" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_12f90fc1-c14b-45ad-9684-a99648aecb1c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_874e18d4-a531-41aa-be8a-5ba2ab858bf5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_549e21f7-5473-49b4-a6c4-0c07fd7a7650" xlink:to="loc_us-gaap_RetainedEarningsMember_874e18d4-a531-41aa-be8a-5ba2ab858bf5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_96d33fa1-8e32-4450-a565-642ab507a9ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_549e21f7-5473-49b4-a6c4-0c07fd7a7650" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_96d33fa1-8e32-4450-a565-642ab507a9ab" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_c18bdd42-0d65-40c4-bacf-04ccbd9cf528" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c3cb3297-fb57-4947-9c20-36feaf9f73da" xlink:to="loc_us-gaap_NoncontrollingInterestMember_c18bdd42-0d65-40c4-bacf-04ccbd9cf528" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4c66d9a8-cb8f-44de-8667-5dd572a88ada" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_f59ed825-44f0-4d8e-8287-eac9ac6eafc9" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4c66d9a8-cb8f-44de-8667-5dd572a88ada" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_4c66d9a8-cb8f-44de-8667-5dd572a88ada_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4c66d9a8-cb8f-44de-8667-5dd572a88ada" xlink:to="loc_us-gaap_ClassOfStockDomain_4c66d9a8-cb8f-44de-8667-5dd572a88ada_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_a44b1b2d-e39d-49e0-acf6-8d0a2d028c4f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4c66d9a8-cb8f-44de-8667-5dd572a88ada" xlink:to="loc_us-gaap_ClassOfStockDomain_a44b1b2d-e39d-49e0-acf6-8d0a2d028c4f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredShares.Member_a295b0db-d74b-435e-96e3-ae42a38c3404" xlink:href="brns-20231231.xsd#brns_DeferredShares.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_a44b1b2d-e39d-49e0-acf6-8d0a2d028c4f" xlink:to="loc_brns_DeferredShares.Member_a295b0db-d74b-435e-96e3-ae42a38c3404" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredBSharesMember_1b62437d-46a4-4fd5-bcbe-1bb2ed631293" xlink:href="brns-20231231.xsd#brns_DeferredBSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_a44b1b2d-e39d-49e0-acf6-8d0a2d028c4f" xlink:to="loc_brns_DeferredBSharesMember_1b62437d-46a4-4fd5-bcbe-1bb2ed631293" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredCSharesMember_ebc244a7-09d7-47e2-8f56-3f0998fec444" xlink:href="brns-20231231.xsd#brns_DeferredCSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_a44b1b2d-e39d-49e0-acf6-8d0a2d028c4f" xlink:to="loc_brns_DeferredCSharesMember_ebc244a7-09d7-47e2-8f56-3f0998fec444" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b36c89f3-4d74-41b7-aa80-7d657efdd30a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_672ff6a0-7632-43ee-8216-bf4f621ddb85" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b36c89f3-4d74-41b7-aa80-7d657efdd30a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_d79e4711-0647-44e7-ba76-3ca760bb5bab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b36c89f3-4d74-41b7-aa80-7d657efdd30a" xlink:to="loc_us-gaap_SharesIssued_d79e4711-0647-44e7-ba76-3ca760bb5bab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1d1513f4-3cce-4520-ac50-706b704ee7c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b36c89f3-4d74-41b7-aa80-7d657efdd30a" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1d1513f4-3cce-4520-ac50-706b704ee7c9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_48e3fb01-42e2-49f7-a072-0bbd0236d6fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b36c89f3-4d74-41b7-aa80-7d657efdd30a" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_48e3fb01-42e2-49f7-a072-0bbd0236d6fd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_81e172d6-38cc-4a68-bb1d-d8d883f6e26a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b36c89f3-4d74-41b7-aa80-7d657efdd30a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesOther_81e172d6-38cc-4a68-bb1d-d8d883f6e26a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther_2f19abbf-312a-47d3-8e9a-7ce311aabd4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b36c89f3-4d74-41b7-aa80-7d657efdd30a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueOther_2f19abbf-312a-47d3-8e9a-7ce311aabd4c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_c2478f95-3d7d-450d-a508-7071a59fedc7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b36c89f3-4d74-41b7-aa80-7d657efdd30a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_c2478f95-3d7d-450d-a508-7071a59fedc7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_AdjustmentsToAdditionalPaidInCapitalMeasurementPeriodAdjustmentsInBusinessCombination_686c160f-2f38-42dc-9ab8-f26485eceb11" xlink:href="brns-20231231.xsd#brns_AdjustmentsToAdditionalPaidInCapitalMeasurementPeriodAdjustmentsInBusinessCombination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b36c89f3-4d74-41b7-aa80-7d657efdd30a" xlink:to="loc_brns_AdjustmentsToAdditionalPaidInCapitalMeasurementPeriodAdjustmentsInBusinessCombination_686c160f-2f38-42dc-9ab8-f26485eceb11" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_SharesCancelledDuringPeriodSharesDeferredShares_f5aba600-0d10-4a1e-80b4-d406d071b9b9" xlink:href="brns-20231231.xsd#brns_SharesCancelledDuringPeriodSharesDeferredShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b36c89f3-4d74-41b7-aa80-7d657efdd30a" xlink:to="loc_brns_SharesCancelledDuringPeriodSharesDeferredShares_f5aba600-0d10-4a1e-80b4-d406d071b9b9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_SharesCancelledDuringPeriodValueDeferredShares_514635d6-727e-43bf-b61c-5d523e41e441" xlink:href="brns-20231231.xsd#brns_SharesCancelledDuringPeriodValueDeferredShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b36c89f3-4d74-41b7-aa80-7d657efdd30a" xlink:to="loc_brns_SharesCancelledDuringPeriodValueDeferredShares_514635d6-727e-43bf-b61c-5d523e41e441" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_0acd13bf-e29c-4396-80c3-12bdb7ae2250" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b36c89f3-4d74-41b7-aa80-7d657efdd30a" xlink:to="loc_us-gaap_ProfitLoss_0acd13bf-e29c-4396-80c3-12bdb7ae2250" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_89522946-e59c-4826-addf-e10cf90af75b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7ed8fd21-3bc9-43b9-a2bf-9d593e1e12eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesNoncontrollinginterestDetails" xlink:type="simple" xlink:href="brns-20231231.xsd#SummaryofSignificantAccountingPoliciesNoncontrollinginterestDetails"/>
  <link:definitionLink xlink:role="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesNoncontrollinginterestDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_a7f99af0-24f5-47fc-8437-30d0b4cb2bd0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_f1250b03-1721-4c50-81de-3cf66be9a344" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_MinorityInterestLineItems_a7f99af0-24f5-47fc-8437-30d0b4cb2bd0" xlink:to="loc_us-gaap_MinorityInterestTable_f1250b03-1721-4c50-81de-3cf66be9a344" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_32095641-d6ab-4037-9b86-897b26102807" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_f1250b03-1721-4c50-81de-3cf66be9a344" xlink:to="loc_srt_OwnershipAxis_32095641-d6ab-4037-9b86-897b26102807" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_32095641-d6ab-4037-9b86-897b26102807_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_32095641-d6ab-4037-9b86-897b26102807" xlink:to="loc_srt_OwnershipDomain_32095641-d6ab-4037-9b86-897b26102807_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_37e428b5-a139-49c7-8d0c-5708bf559c8f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_32095641-d6ab-4037-9b86-897b26102807" xlink:to="loc_srt_OwnershipDomain_37e428b5-a139-49c7-8d0c-5708bf559c8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_VOLTMember_b3b23d26-9992-454e-8a34-2e00aeb5e144" xlink:href="brns-20231231.xsd#brns_VOLTMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_37e428b5-a139-49c7-8d0c-5708bf559c8f" xlink:to="loc_brns_VOLTMember_b3b23d26-9992-454e-8a34-2e00aeb5e144" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_fe47ac28-0f02-4998-8554-877c8f92c8b5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_f1250b03-1721-4c50-81de-3cf66be9a344" xlink:to="loc_srt_ConsolidatedEntitiesAxis_fe47ac28-0f02-4998-8554-877c8f92c8b5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_fe47ac28-0f02-4998-8554-877c8f92c8b5_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_fe47ac28-0f02-4998-8554-877c8f92c8b5" xlink:to="loc_srt_ConsolidatedEntitiesDomain_fe47ac28-0f02-4998-8554-877c8f92c8b5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_372249da-3930-42fb-8088-bdd30fade9ec" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_fe47ac28-0f02-4998-8554-877c8f92c8b5" xlink:to="loc_srt_ConsolidatedEntitiesDomain_372249da-3930-42fb-8088-bdd30fade9ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_SubsidiariesVOLTMember_6efb0118-1216-4c57-8406-ac3fb28c0d19" xlink:href="brns-20231231.xsd#brns_SubsidiariesVOLTMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_372249da-3930-42fb-8088-bdd30fade9ec" xlink:to="loc_brns_SubsidiariesVOLTMember_6efb0118-1216-4c57-8406-ac3fb28c0d19" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_817f1e63-4109-48ed-a23f-7b7945e06931" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_f1250b03-1721-4c50-81de-3cf66be9a344" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_817f1e63-4109-48ed-a23f-7b7945e06931" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_817f1e63-4109-48ed-a23f-7b7945e06931_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_817f1e63-4109-48ed-a23f-7b7945e06931" xlink:to="loc_us-gaap_RelatedPartyDomain_817f1e63-4109-48ed-a23f-7b7945e06931_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_c73c52b7-e476-4a86-a476-f4b34dbd451b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_817f1e63-4109-48ed-a23f-7b7945e06931" xlink:to="loc_us-gaap_RelatedPartyDomain_c73c52b7-e476-4a86-a476-f4b34dbd451b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_5127ef74-bc11-4ccf-b258-9fcc21df2ff0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_c73c52b7-e476-4a86-a476-f4b34dbd451b" xlink:to="loc_us-gaap_RelatedPartyMember_5127ef74-bc11-4ccf-b258-9fcc21df2ff0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_SubsidiaryCumulativeContributionsParent_1ca97047-f381-4d59-8468-2b851983f0ef" xlink:href="brns-20231231.xsd#brns_SubsidiaryCumulativeContributionsParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_a7f99af0-24f5-47fc-8437-30d0b4cb2bd0" xlink:to="loc_brns_SubsidiaryCumulativeContributionsParent_1ca97047-f381-4d59-8468-2b851983f0ef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_3d9d64ba-f5cd-4b68-a88f-816f26f49b77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_a7f99af0-24f5-47fc-8437-30d0b4cb2bd0" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_3d9d64ba-f5cd-4b68-a88f-816f26f49b77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_SubsidiaryCumulativeContributionsNoncontrollingOwner_e7798bd5-9ceb-4228-a1f8-252f81656a6f" xlink:href="brns-20231231.xsd#brns_SubsidiaryCumulativeContributionsNoncontrollingOwner"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_a7f99af0-24f5-47fc-8437-30d0b4cb2bd0" xlink:to="loc_brns_SubsidiaryCumulativeContributionsNoncontrollingOwner_e7798bd5-9ceb-4228-a1f8-252f81656a6f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_89bcf7b0-85c9-4dfa-b4de-97207ede63b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_a7f99af0-24f5-47fc-8437-30d0b4cb2bd0" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_89bcf7b0-85c9-4dfa-b4de-97207ede63b2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_67506fcf-617b-4c12-ae8c-e791b4d2f2da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_a7f99af0-24f5-47fc-8437-30d0b4cb2bd0" xlink:to="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_67506fcf-617b-4c12-ae8c-e791b4d2f2da" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesConcentrationsofcreditriskDetails" xlink:type="simple" xlink:href="brns-20231231.xsd#SummaryofSignificantAccountingPoliciesConcentrationsofcreditriskDetails"/>
  <link:definitionLink xlink:role="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesConcentrationsofcreditriskDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_8c0a1396-f896-4c7b-980e-8f69ac824945" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_238b6b86-38c6-4fe3-8d3c-315af91d4b3e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_8c0a1396-f896-4c7b-980e-8f69ac824945" xlink:to="loc_us-gaap_ConcentrationRiskTable_238b6b86-38c6-4fe3-8d3c-315af91d4b3e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_ca0437cd-690c-44ea-84db-6274716830ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_238b6b86-38c6-4fe3-8d3c-315af91d4b3e" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_ca0437cd-690c-44ea-84db-6274716830ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ca0437cd-690c-44ea-84db-6274716830ce_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_ca0437cd-690c-44ea-84db-6274716830ce" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ca0437cd-690c-44ea-84db-6274716830ce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_52ff5fee-d240-45df-99ec-8f7a4bcf5ec2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_ca0437cd-690c-44ea-84db-6274716830ce" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_52ff5fee-d240-45df-99ec-8f7a4bcf5ec2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_7bfc9d41-a266-4868-ade7-c5b8c478c6b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_52ff5fee-d240-45df-99ec-8f7a4bcf5ec2" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_7bfc9d41-a266-4868-ade7-c5b8c478c6b9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_0ef4f734-d62e-4c4d-aef6-70fca19a9110" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_52ff5fee-d240-45df-99ec-8f7a4bcf5ec2" xlink:to="loc_us-gaap_AccountsReceivableMember_0ef4f734-d62e-4c4d-aef6-70fca19a9110" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_185151b7-cd2e-4306-8a8f-8157407c3de8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_238b6b86-38c6-4fe3-8d3c-315af91d4b3e" xlink:to="loc_srt_StatementGeographicalAxis_185151b7-cd2e-4306-8a8f-8157407c3de8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_185151b7-cd2e-4306-8a8f-8157407c3de8_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_185151b7-cd2e-4306-8a8f-8157407c3de8" xlink:to="loc_srt_SegmentGeographicalDomain_185151b7-cd2e-4306-8a8f-8157407c3de8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_2c948fb9-754e-4ec3-bee9-bfb60ef8a420" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_185151b7-cd2e-4306-8a8f-8157407c3de8" xlink:to="loc_srt_SegmentGeographicalDomain_2c948fb9-754e-4ec3-bee9-bfb60ef8a420" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_GB_cd27c62d-74a4-4c8b-9b01-e89ec92d597a" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_GB"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_2c948fb9-754e-4ec3-bee9-bfb60ef8a420" xlink:to="loc_country_GB_cd27c62d-74a4-4c8b-9b01-e89ec92d597a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_03e4f733-456f-4a8f-8aad-31fa50c43de0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_238b6b86-38c6-4fe3-8d3c-315af91d4b3e" xlink:to="loc_srt_MajorCustomersAxis_03e4f733-456f-4a8f-8aad-31fa50c43de0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_03e4f733-456f-4a8f-8aad-31fa50c43de0_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_03e4f733-456f-4a8f-8aad-31fa50c43de0" xlink:to="loc_srt_NameOfMajorCustomerDomain_03e4f733-456f-4a8f-8aad-31fa50c43de0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_4dcbf0b0-11e7-42e5-820e-7973afd5b837" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_03e4f733-456f-4a8f-8aad-31fa50c43de0" xlink:to="loc_srt_NameOfMajorCustomerDomain_4dcbf0b0-11e7-42e5-820e-7973afd5b837" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_OxfordUniversityInnovationMember_7e0a055c-c768-4d9b-9691-0fc731878640" xlink:href="brns-20231231.xsd#brns_OxfordUniversityInnovationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_4dcbf0b0-11e7-42e5-820e-7973afd5b837" xlink:to="loc_brns_OxfordUniversityInnovationMember_7e0a055c-c768-4d9b-9691-0fc731878640" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_AccountsReceivableStandardPaymentTermsPeriod_a7b2b8e6-a96f-4635-b99c-468caad789b4" xlink:href="brns-20231231.xsd#brns_AccountsReceivableStandardPaymentTermsPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_8c0a1396-f896-4c7b-980e-8f69ac824945" xlink:to="loc_brns_AccountsReceivableStandardPaymentTermsPeriod_a7b2b8e6-a96f-4635-b99c-468caad789b4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ConcentrationRiskThresholdPercentage_2ad4d581-cfe3-4ddb-8350-6c028b7b5605" xlink:href="brns-20231231.xsd#brns_ConcentrationRiskThresholdPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_8c0a1396-f896-4c7b-980e-8f69ac824945" xlink:to="loc_brns_ConcentrationRiskThresholdPercentage_2ad4d581-cfe3-4ddb-8350-6c028b7b5605" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPropertyandequipmentDetails" xlink:type="simple" xlink:href="brns-20231231.xsd#SummaryofSignificantAccountingPoliciesPropertyandequipmentDetails"/>
  <link:definitionLink xlink:role="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPropertyandequipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_51677e04-0dfe-4f56-9619-561d5b3c6c89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7d4d83a6-2764-4afb-8cfb-cfe4b4153218" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_51677e04-0dfe-4f56-9619-561d5b3c6c89" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7d4d83a6-2764-4afb-8cfb-cfe4b4153218" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c9f5718d-c6d8-46a6-8ac6-9b594b328b34" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7d4d83a6-2764-4afb-8cfb-cfe4b4153218" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c9f5718d-c6d8-46a6-8ac6-9b594b328b34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c9f5718d-c6d8-46a6-8ac6-9b594b328b34_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c9f5718d-c6d8-46a6-8ac6-9b594b328b34" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c9f5718d-c6d8-46a6-8ac6-9b594b328b34_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ddec4c35-144b-4a7a-b759-7263bf77709c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c9f5718d-c6d8-46a6-8ac6-9b594b328b34" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ddec4c35-144b-4a7a-b759-7263bf77709c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_93388294-ea47-41da-923a-ef26dd398c69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ddec4c35-144b-4a7a-b759-7263bf77709c" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_93388294-ea47-41da-923a-ef26dd398c69" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_LaboratoryEquipmentMember_fb8e7c03-2ac3-4864-a4b9-290226a48763" xlink:href="brns-20231231.xsd#brns_LaboratoryEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ddec4c35-144b-4a7a-b759-7263bf77709c" xlink:to="loc_brns_LaboratoryEquipmentMember_fb8e7c03-2ac3-4864-a4b9-290226a48763" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_25dbe837-435d-4045-b732-e06594f6c8cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_51677e04-0dfe-4f56-9619-561d5b3c6c89" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_25dbe837-435d-4045-b732-e06594f6c8cf" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsDetails" xlink:type="simple" xlink:href="brns-20231231.xsd#SummaryofSignificantAccountingPoliciesIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d5fadd5c-15f2-4215-badd-67614170af74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_160ab386-2032-4278-b568-60db204de83a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d5fadd5c-15f2-4215-badd-67614170af74" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_160ab386-2032-4278-b568-60db204de83a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_87a53409-e4d8-4971-9b47-b568406992d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_160ab386-2032-4278-b568-60db204de83a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_87a53409-e4d8-4971-9b47-b568406992d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_87a53409-e4d8-4971-9b47-b568406992d2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_87a53409-e4d8-4971-9b47-b568406992d2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_87a53409-e4d8-4971-9b47-b568406992d2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b5cfe03f-3350-4e3e-83b9-692d326b36db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_87a53409-e4d8-4971-9b47-b568406992d2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b5cfe03f-3350-4e3e-83b9-692d326b36db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_a561570e-d75a-42dd-9560-3e0e37d9cf4e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b5cfe03f-3350-4e3e-83b9-692d326b36db" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_a561570e-d75a-42dd-9560-3e0e37d9cf4e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_07d61dec-101c-4e8f-b3bd-3508fe270513" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d5fadd5c-15f2-4215-badd-67614170af74" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_07d61dec-101c-4e8f-b3bd-3508fe270513" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/PropertyandEquipmentNetComponentsDetails" xlink:type="simple" xlink:href="brns-20231231.xsd#PropertyandEquipmentNetComponentsDetails"/>
  <link:definitionLink xlink:role="http://www.barinthusbio.com/role/PropertyandEquipmentNetComponentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fe1deb2e-4653-4a6a-9880-933480a323b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_39a0c5f2-2ccc-4d9d-b67f-6871bda81fb5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fe1deb2e-4653-4a6a-9880-933480a323b3" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_39a0c5f2-2ccc-4d9d-b67f-6871bda81fb5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_25f79467-c701-45ad-91b0-be0c03589d60" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_39a0c5f2-2ccc-4d9d-b67f-6871bda81fb5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_25f79467-c701-45ad-91b0-be0c03589d60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_25f79467-c701-45ad-91b0-be0c03589d60_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_25f79467-c701-45ad-91b0-be0c03589d60" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_25f79467-c701-45ad-91b0-be0c03589d60_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bee3553b-857e-4bdc-b59e-16b8993194cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_25f79467-c701-45ad-91b0-be0c03589d60" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bee3553b-857e-4bdc-b59e-16b8993194cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_016e3761-136f-42dc-baf7-8a91c2ab6db7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bee3553b-857e-4bdc-b59e-16b8993194cd" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_016e3761-136f-42dc-baf7-8a91c2ab6db7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_LaboratoryEquipmentMember_de44db86-6470-4ab6-afff-c3d69f73c2ac" xlink:href="brns-20231231.xsd#brns_LaboratoryEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bee3553b-857e-4bdc-b59e-16b8993194cd" xlink:to="loc_brns_LaboratoryEquipmentMember_de44db86-6470-4ab6-afff-c3d69f73c2ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_6cddb621-0f0e-4be5-af35-8017c135cd6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bee3553b-857e-4bdc-b59e-16b8993194cd" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_6cddb621-0f0e-4be5-af35-8017c135cd6f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_e9107697-89ad-4d10-9190-982eea531cb0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fe1deb2e-4653-4a6a-9880-933480a323b3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_e9107697-89ad-4d10-9190-982eea531cb0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_4bc0af35-f771-4912-8c34-adcfb6b030e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fe1deb2e-4653-4a6a-9880-933480a323b3" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_4bc0af35-f771-4912-8c34-adcfb6b030e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_667420e7-8fbd-4dbe-8479-2824b6ebb679" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fe1deb2e-4653-4a6a-9880-933480a323b3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_667420e7-8fbd-4dbe-8479-2824b6ebb679" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/IntangibleassetsnetDetails" xlink:type="simple" xlink:href="brns-20231231.xsd#IntangibleassetsnetDetails"/>
  <link:definitionLink xlink:role="http://www.barinthusbio.com/role/IntangibleassetsnetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b6b25b6b-a0b6-41a6-9761-7712920e338f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_6d721e16-720b-4934-ae0d-d8584798797a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b6b25b6b-a0b6-41a6-9761-7712920e338f" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_6d721e16-720b-4934-ae0d-d8584798797a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_51a45792-0ec3-4556-8db7-a674eb193fd3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_6d721e16-720b-4934-ae0d-d8584798797a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_51a45792-0ec3-4556-8db7-a674eb193fd3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_51a45792-0ec3-4556-8db7-a674eb193fd3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_51a45792-0ec3-4556-8db7-a674eb193fd3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_51a45792-0ec3-4556-8db7-a674eb193fd3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_54b7287f-26b3-4371-a889-21f660a81668" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_51a45792-0ec3-4556-8db7-a674eb193fd3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_54b7287f-26b3-4371-a889-21f660a81668" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_9992b619-075c-48d9-897c-4cc208906bf4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_54b7287f-26b3-4371-a889-21f660a81668" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_9992b619-075c-48d9-897c-4cc208906bf4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_64e4c485-227f-4864-99d0-a182d417c62a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b6b25b6b-a0b6-41a6-9761-7712920e338f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_64e4c485-227f-4864-99d0-a182d417c62a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_03b73a78-0e09-4413-9dfd-113fa9da2566" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b6b25b6b-a0b6-41a6-9761-7712920e338f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_03b73a78-0e09-4413-9dfd-113fa9da2566" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_a60987c2-070f-4e8c-96f3-2ecafecef037" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b6b25b6b-a0b6-41a6-9761-7712920e338f" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_a60987c2-070f-4e8c-96f3-2ecafecef037" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_05c7ca79-bbff-40b2-b804-8164226ede91" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b6b25b6b-a0b6-41a6-9761-7712920e338f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_05c7ca79-bbff-40b2-b804-8164226ede91" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_deaccbfd-5b76-4fb5-83a9-c059e264b38e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b6b25b6b-a0b6-41a6-9761-7712920e338f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_deaccbfd-5b76-4fb5-83a9-c059e264b38e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_d250d81d-5a3c-49c3-8f56-cf57a62dacd4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b6b25b6b-a0b6-41a6-9761-7712920e338f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_d250d81d-5a3c-49c3-8f56-cf57a62dacd4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_90f0f813-a2a8-443a-a11a-e56fa6d2e84c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b6b25b6b-a0b6-41a6-9761-7712920e338f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_90f0f813-a2a8-443a-a11a-e56fa6d2e84c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_0c1c46c7-e7a5-4f6d-b25d-f197b22a4e3e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b6b25b6b-a0b6-41a6-9761-7712920e338f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_0c1c46c7-e7a5-4f6d-b25d-f197b22a4e3e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSix_93776fab-95ac-415e-a178-3f0b43ee2e38" xlink:href="brns-20231231.xsd#brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSix"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b6b25b6b-a0b6-41a6-9761-7712920e338f" xlink:to="loc_brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSix_93776fab-95ac-415e-a178-3f0b43ee2e38" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSeven_322e70a9-1ac9-4207-af31-d0bb04e0ebad" xlink:href="brns-20231231.xsd#brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSeven"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b6b25b6b-a0b6-41a6-9761-7712920e338f" xlink:to="loc_brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSeven_322e70a9-1ac9-4207-af31-d0bb04e0ebad" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_FiniteLivedIntangibleAssetExpectedAmortizationYearEight_fdff1557-1c54-48ed-8e06-f7439506dd2a" xlink:href="brns-20231231.xsd#brns_FiniteLivedIntangibleAssetExpectedAmortizationYearEight"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b6b25b6b-a0b6-41a6-9761-7712920e338f" xlink:to="loc_brns_FiniteLivedIntangibleAssetExpectedAmortizationYearEight_fdff1557-1c54-48ed-8e06-f7439506dd2a" xlink:type="arc" order="10"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/OutlicensesandGrantsAdditionalInformationDetails" xlink:type="simple" xlink:href="brns-20231231.xsd#OutlicensesandGrantsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.barinthusbio.com/role/OutlicensesandGrantsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dd9b6185-5c42-4052-8cab-f51bb692cf31" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_951d5434-b3d5-470e-a630-e7d980ac3980" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dd9b6185-5c42-4052-8cab-f51bb692cf31" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_951d5434-b3d5-470e-a630-e7d980ac3980" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_f572256d-4300-41a4-a594-7941d4b4bd8e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_951d5434-b3d5-470e-a630-e7d980ac3980" xlink:to="loc_us-gaap_TypeOfArrangementAxis_f572256d-4300-41a4-a594-7941d4b4bd8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f572256d-4300-41a4-a594-7941d4b4bd8e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_f572256d-4300-41a4-a594-7941d4b4bd8e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f572256d-4300-41a4-a594-7941d4b4bd8e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_88770ec0-564d-48e1-9707-280c70dbaaee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_f572256d-4300-41a4-a594-7941d4b4bd8e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_88770ec0-564d-48e1-9707-280c70dbaaee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_OuiLicenseAgreementAmendmentMember_9a2495f7-18a9-4541-ae63-d55748a425cf" xlink:href="brns-20231231.xsd#brns_OuiLicenseAgreementAmendmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_88770ec0-564d-48e1-9707-280c70dbaaee" xlink:to="loc_brns_OuiLicenseAgreementAmendmentMember_9a2495f7-18a9-4541-ae63-d55748a425cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_AgreementWithOxfordUniversityInnovationMember_4ec58669-497e-4dfe-9fed-1ab66d35267c" xlink:href="brns-20231231.xsd#brns_AgreementWithOxfordUniversityInnovationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_88770ec0-564d-48e1-9707-280c70dbaaee" xlink:to="loc_brns_AgreementWithOxfordUniversityInnovationMember_4ec58669-497e-4dfe-9fed-1ab66d35267c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_AgreementWithScancellToGrantResearchAndDevelopmentLicenseMember_ecccb39c-fc3f-49a7-8c13-503f89ffbe50" xlink:href="brns-20231231.xsd#brns_AgreementWithScancellToGrantResearchAndDevelopmentLicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_88770ec0-564d-48e1-9707-280c70dbaaee" xlink:to="loc_brns_AgreementWithScancellToGrantResearchAndDevelopmentLicenseMember_ecccb39c-fc3f-49a7-8c13-503f89ffbe50" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_CoalitionForEpidemicPreparednessInnovationsFundingAgreementMember_76b7eefc-b97c-4595-8bb8-59794b40accd" xlink:href="brns-20231231.xsd#brns_CoalitionForEpidemicPreparednessInnovationsFundingAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_88770ec0-564d-48e1-9707-280c70dbaaee" xlink:to="loc_brns_CoalitionForEpidemicPreparednessInnovationsFundingAgreementMember_76b7eefc-b97c-4595-8bb8-59794b40accd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_02197810-107a-4ca0-aabd-03e072dfb45f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_951d5434-b3d5-470e-a630-e7d980ac3980" xlink:to="loc_srt_ProductOrServiceAxis_02197810-107a-4ca0-aabd-03e072dfb45f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_02197810-107a-4ca0-aabd-03e072dfb45f_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_02197810-107a-4ca0-aabd-03e072dfb45f" xlink:to="loc_srt_ProductsAndServicesDomain_02197810-107a-4ca0-aabd-03e072dfb45f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_bcd29b67-30b7-4555-bcfe-17e0e7b96787" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_02197810-107a-4ca0-aabd-03e072dfb45f" xlink:to="loc_srt_ProductsAndServicesDomain_bcd29b67-30b7-4555-bcfe-17e0e7b96787" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_3db17900-3815-493f-9d8c-09bdbb9f2c38" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_bcd29b67-30b7-4555-bcfe-17e0e7b96787" xlink:to="loc_us-gaap_LicenseMember_3db17900-3815-493f-9d8c-09bdbb9f2c38" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_PercentageOfRoyaltiesOnNetSales_7ab57d09-dc15-4b5c-9313-e47a258ce1bc" xlink:href="brns-20231231.xsd#brns_PercentageOfRoyaltiesOnNetSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dd9b6185-5c42-4052-8cab-f51bb692cf31" xlink:to="loc_brns_PercentageOfRoyaltiesOnNetSales_7ab57d09-dc15-4b5c-9313-e47a258ce1bc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_040cc8f0-5341-4534-b26d-6e504b33d962" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dd9b6185-5c42-4052-8cab-f51bb692cf31" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_040cc8f0-5341-4534-b26d-6e504b33d962" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_f98742b2-4fc2-48d0-b91a-018fafc8c382" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dd9b6185-5c42-4052-8cab-f51bb692cf31" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_f98742b2-4fc2-48d0-b91a-018fafc8c382" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ContractWithCustomerLiabilityRevenueRecognized1_8034d038-dcaa-4e57-9293-3d426c629dc9" xlink:href="brns-20231231.xsd#brns_ContractWithCustomerLiabilityRevenueRecognized1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dd9b6185-5c42-4052-8cab-f51bb692cf31" xlink:to="loc_brns_ContractWithCustomerLiabilityRevenueRecognized1_8034d038-dcaa-4e57-9293-3d426c629dc9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_FundingAmountMaximum_1b16635a-24f8-42f4-8af2-a0bba587913d" xlink:href="brns-20231231.xsd#brns_FundingAmountMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dd9b6185-5c42-4052-8cab-f51bb692cf31" xlink:to="loc_brns_FundingAmountMaximum_1b16635a-24f8-42f4-8af2-a0bba587913d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_RoyaltyPaymentTermMaximum_6b8ab09d-d1e9-4e67-a84f-629f821df49a" xlink:href="brns-20231231.xsd#brns_RoyaltyPaymentTermMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dd9b6185-5c42-4052-8cab-f51bb692cf31" xlink:to="loc_brns_RoyaltyPaymentTermMaximum_6b8ab09d-d1e9-4e67-a84f-629f821df49a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ProceedsFromGrantsReceived_8e758b79-5798-4a46-ae20-299972719745" xlink:href="brns-20231231.xsd#brns_ProceedsFromGrantsReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dd9b6185-5c42-4052-8cab-f51bb692cf31" xlink:to="loc_brns_ProceedsFromGrantsReceived_8e758b79-5798-4a46-ae20-299972719745" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_ebf05dfc-a2a6-4481-885a-2f3920436142" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dd9b6185-5c42-4052-8cab-f51bb692cf31" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_ebf05dfc-a2a6-4481-885a-2f3920436142" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/OrdinarySharesAdditionalInformationDetails" xlink:type="simple" xlink:href="brns-20231231.xsd#OrdinarySharesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.barinthusbio.com/role/OrdinarySharesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_7b97fa67-e718-4685-af32-db4edf8085ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_eeb58bc8-226a-42ee-9dc3-a57e430fcddc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_7b97fa67-e718-4685-af32-db4edf8085ad" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_eeb58bc8-226a-42ee-9dc3-a57e430fcddc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_f67fb9e5-bd67-4a98-b8d1-294160e46b6e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_eeb58bc8-226a-42ee-9dc3-a57e430fcddc" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_f67fb9e5-bd67-4a98-b8d1-294160e46b6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f67fb9e5-bd67-4a98-b8d1-294160e46b6e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_f67fb9e5-bd67-4a98-b8d1-294160e46b6e" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f67fb9e5-bd67-4a98-b8d1-294160e46b6e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4650cc10-ea65-4e28-9a48-012c6b080677" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_f67fb9e5-bd67-4a98-b8d1-294160e46b6e" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4650cc10-ea65-4e28-9a48-012c6b080677" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_b5e2bb5e-aae7-41a1-8164-03bc0e073a74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4650cc10-ea65-4e28-9a48-012c6b080677" xlink:to="loc_us-gaap_IPOMember_b5e2bb5e-aae7-41a1-8164-03bc0e073a74" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_NumberOfAmericanDepositarySharesAdsIssued_532d2e42-a5e4-46bb-8da0-49e859cc28fc" xlink:href="brns-20231231.xsd#brns_NumberOfAmericanDepositarySharesAdsIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_7b97fa67-e718-4685-af32-db4edf8085ad" xlink:to="loc_brns_NumberOfAmericanDepositarySharesAdsIssued_532d2e42-a5e4-46bb-8da0-49e859cc28fc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_5ab107f5-09a8-455f-81d0-a85d1b0c65bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_7b97fa67-e718-4685-af32-db4edf8085ad" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_5ab107f5-09a8-455f-81d0-a85d1b0c65bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_eef91d6c-5c39-4f26-87a6-441d4f79e6a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_7b97fa67-e718-4685-af32-db4edf8085ad" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_eef91d6c-5c39-4f26-87a6-441d4f79e6a5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_f7e90877-c216-4a97-ada0-1fbb649281bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_7b97fa67-e718-4685-af32-db4edf8085ad" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_f7e90877-c216-4a97-ada0-1fbb649281bc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_5acd90f8-6b1b-466f-9901-d685aac120e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_7b97fa67-e718-4685-af32-db4edf8085ad" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_5acd90f8-6b1b-466f-9901-d685aac120e5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_IssuanceOfCommonStockUnderwritingCommissions_4213d5d3-cf02-4a56-af24-e0aa0e22dadb" xlink:href="brns-20231231.xsd#brns_IssuanceOfCommonStockUnderwritingCommissions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_7b97fa67-e718-4685-af32-db4edf8085ad" xlink:to="loc_brns_IssuanceOfCommonStockUnderwritingCommissions_4213d5d3-cf02-4a56-af24-e0aa0e22dadb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_IssuanceOfCommonStockOfferingCosts_e8355dbe-22ad-4a28-b605-c3c7ff49788b" xlink:href="brns-20231231.xsd#brns_IssuanceOfCommonStockOfferingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_7b97fa67-e718-4685-af32-db4edf8085ad" xlink:to="loc_brns_IssuanceOfCommonStockOfferingCosts_e8355dbe-22ad-4a28-b605-c3c7ff49788b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_CommonStockNumberOfVotesPerShare_f9f5cab0-b48d-44f8-a660-ef55699272a1" xlink:href="brns-20231231.xsd#brns_CommonStockNumberOfVotesPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_7b97fa67-e718-4685-af32-db4edf8085ad" xlink:to="loc_brns_CommonStockNumberOfVotesPerShare_f9f5cab0-b48d-44f8-a660-ef55699272a1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_PercentageOfSharesNecessaryToExercisePreemptiveRights_9e8156b2-ef39-421e-9597-7a3c63ff4aa4" xlink:href="brns-20231231.xsd#brns_PercentageOfSharesNecessaryToExercisePreemptiveRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_7b97fa67-e718-4685-af32-db4edf8085ad" xlink:to="loc_brns_PercentageOfSharesNecessaryToExercisePreemptiveRights_9e8156b2-ef39-421e-9597-7a3c63ff4aa4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_PeriodOfPreemptiveRightsToBeExercised_815eff91-65e0-4226-8abf-b1f93fe82e02" xlink:href="brns-20231231.xsd#brns_PeriodOfPreemptiveRightsToBeExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_7b97fa67-e718-4685-af32-db4edf8085ad" xlink:to="loc_brns_PeriodOfPreemptiveRightsToBeExercised_815eff91-65e0-4226-8abf-b1f93fe82e02" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_MaximumAggregateNominalAmountOfSharesAuthorizedToBeAllottedFreeFromStatutoryPreEmptionRights_84c6fa6a-afb3-4d2d-b039-e0d0cf04720d" xlink:href="brns-20231231.xsd#brns_MaximumAggregateNominalAmountOfSharesAuthorizedToBeAllottedFreeFromStatutoryPreEmptionRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_7b97fa67-e718-4685-af32-db4edf8085ad" xlink:to="loc_brns_MaximumAggregateNominalAmountOfSharesAuthorizedToBeAllottedFreeFromStatutoryPreEmptionRights_84c6fa6a-afb3-4d2d-b039-e0d0cf04720d" xlink:type="arc" order="10"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/DeferredsharesDetails" xlink:type="simple" xlink:href="brns-20231231.xsd#DeferredsharesDetails"/>
  <link:definitionLink xlink:role="http://www.barinthusbio.com/role/DeferredsharesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_5d52d994-6de1-4f7f-ad97-b487e1f7a75e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_78bf326e-85c2-489b-af27-99fe7d9c6909" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_5d52d994-6de1-4f7f-ad97-b487e1f7a75e" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_78bf326e-85c2-489b-af27-99fe7d9c6909" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_31bbf2b4-423e-45b5-88b1-d321d2963d2b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_78bf326e-85c2-489b-af27-99fe7d9c6909" xlink:to="loc_us-gaap_StatementClassOfStockAxis_31bbf2b4-423e-45b5-88b1-d321d2963d2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_31bbf2b4-423e-45b5-88b1-d321d2963d2b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_31bbf2b4-423e-45b5-88b1-d321d2963d2b" xlink:to="loc_us-gaap_ClassOfStockDomain_31bbf2b4-423e-45b5-88b1-d321d2963d2b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_a2cbd46d-f5b4-4585-b852-280582110e1f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_31bbf2b4-423e-45b5-88b1-d321d2963d2b" xlink:to="loc_us-gaap_ClassOfStockDomain_a2cbd46d-f5b4-4585-b852-280582110e1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredShares.Member_ecb049a6-7572-499f-96d1-bce792b9d821" xlink:href="brns-20231231.xsd#brns_DeferredShares.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_a2cbd46d-f5b4-4585-b852-280582110e1f" xlink:to="loc_brns_DeferredShares.Member_ecb049a6-7572-499f-96d1-bce792b9d821" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredBSharesMember_fadefac6-59d2-4327-84aa-d17c981ceb2a" xlink:href="brns-20231231.xsd#brns_DeferredBSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_a2cbd46d-f5b4-4585-b852-280582110e1f" xlink:to="loc_brns_DeferredBSharesMember_fadefac6-59d2-4327-84aa-d17c981ceb2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredCSharesMember_8252a54d-8a08-41d0-94d9-37354a9789f3" xlink:href="brns-20231231.xsd#brns_DeferredCSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_a2cbd46d-f5b4-4585-b852-280582110e1f" xlink:to="loc_brns_DeferredCSharesMember_8252a54d-8a08-41d0-94d9-37354a9789f3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_OrdinarySharesLiquidationPreference_73204195-653b-4f1a-9d8c-fe0bf3d469ec" xlink:href="brns-20231231.xsd#brns_OrdinarySharesLiquidationPreference"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5d52d994-6de1-4f7f-ad97-b487e1f7a75e" xlink:to="loc_brns_OrdinarySharesLiquidationPreference_73204195-653b-4f1a-9d8c-fe0bf3d469ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredStockParOrStatedValuePerShare_c1a896e1-54f1-409e-b026-38e1e7eeeb8b" xlink:href="brns-20231231.xsd#brns_DeferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5d52d994-6de1-4f7f-ad97-b487e1f7a75e" xlink:to="loc_brns_DeferredStockParOrStatedValuePerShare_c1a896e1-54f1-409e-b026-38e1e7eeeb8b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/FairValueAdditionalinformationDetails" xlink:type="simple" xlink:href="brns-20231231.xsd#FairValueAdditionalinformationDetails"/>
  <link:definitionLink xlink:role="http://www.barinthusbio.com/role/FairValueAdditionalinformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_6bbba7c2-7b04-4fc7-a959-64c420bf2149" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_3bba5b1f-a961-4ece-889f-2b6201a85ec0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_6bbba7c2-7b04-4fc7-a959-64c420bf2149" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_3bba5b1f-a961-4ece-889f-2b6201a85ec0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_19924d61-2b9c-4407-9d0f-fa1b5f75a956" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_3bba5b1f-a961-4ece-889f-2b6201a85ec0" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_19924d61-2b9c-4407-9d0f-fa1b5f75a956" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_19924d61-2b9c-4407-9d0f-fa1b5f75a956_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_19924d61-2b9c-4407-9d0f-fa1b5f75a956" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_19924d61-2b9c-4407-9d0f-fa1b5f75a956_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a4f0fe8c-abef-405e-b47d-4fa8d42127c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_19924d61-2b9c-4407-9d0f-fa1b5f75a956" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a4f0fe8c-abef-405e-b47d-4fa8d42127c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_AvideaMember_bd2814df-967a-457a-b4ad-6c2d96fd7f54" xlink:href="brns-20231231.xsd#brns_AvideaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a4f0fe8c-abef-405e-b47d-4fa8d42127c5" xlink:to="loc_brns_AvideaMember_bd2814df-967a-457a-b4ad-6c2d96fd7f54" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_c21ed3a2-ee0b-445d-823d-6b85bebf80ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_6bbba7c2-7b04-4fc7-a959-64c420bf2149" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_c21ed3a2-ee0b-445d-823d-6b85bebf80ab" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/FairValueChangeinfairvalueofcontingentconsiderationDetails" xlink:type="simple" xlink:href="brns-20231231.xsd#FairValueChangeinfairvalueofcontingentconsiderationDetails"/>
  <link:definitionLink xlink:role="http://www.barinthusbio.com/role/FairValueChangeinfairvalueofcontingentconsiderationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_24aff454-7238-4a88-96fa-dc069a9f6a25" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_1cb65ea3-052d-4e61-8a28-03259e083918" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_24aff454-7238-4a88-96fa-dc069a9f6a25" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_1cb65ea3-052d-4e61-8a28-03259e083918" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_d8ad4f18-c57e-4a94-8f16-329920f2b83f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_1cb65ea3-052d-4e61-8a28-03259e083918" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_d8ad4f18-c57e-4a94-8f16-329920f2b83f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_d8ad4f18-c57e-4a94-8f16-329920f2b83f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_d8ad4f18-c57e-4a94-8f16-329920f2b83f" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_d8ad4f18-c57e-4a94-8f16-329920f2b83f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_88b3c79d-5c88-48af-91dc-c615b7258f96" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_d8ad4f18-c57e-4a94-8f16-329920f2b83f" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_88b3c79d-5c88-48af-91dc-c615b7258f96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ContingentConsiderationLiabilityMember_9adffb29-c779-423a-89c9-c311e80853dd" xlink:href="brns-20231231.xsd#brns_ContingentConsiderationLiabilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_88b3c79d-5c88-48af-91dc-c615b7258f96" xlink:to="loc_brns_ContingentConsiderationLiabilityMember_9adffb29-c779-423a-89c9-c311e80853dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_b8f2f6cd-4d37-411d-9e94-5ce038e676ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_24aff454-7238-4a88-96fa-dc069a9f6a25" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_b8f2f6cd-4d37-411d-9e94-5ce038e676ee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_21d2a20d-612a-4120-986a-5b950bd9bc50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_b8f2f6cd-4d37-411d-9e94-5ce038e676ee" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_21d2a20d-612a-4120-986a-5b950bd9bc50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_73e41ff0-1542-40c8-86d9-117f6330c2ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_b8f2f6cd-4d37-411d-9e94-5ce038e676ee" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_73e41ff0-1542-40c8-86d9-117f6330c2ff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_a83ea3d4-d124-4ec2-9cdc-a0c543d7ee24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_b8f2f6cd-4d37-411d-9e94-5ce038e676ee" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_a83ea3d4-d124-4ec2-9cdc-a0c543d7ee24" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeTranslation_36e241ee-929c-4cbe-8f66-531097fc5334" xlink:href="brns-20231231.xsd#brns_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeTranslation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_b8f2f6cd-4d37-411d-9e94-5ce038e676ee" xlink:to="loc_brns_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeTranslation_36e241ee-929c-4cbe-8f66-531097fc5334" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_fea8bf67-ae3a-43b2-bf14-1a35544010db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/ShareBasedCompensationAdditionalInformationDetails" xlink:type="simple" xlink:href="brns-20231231.xsd#ShareBasedCompensationAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.barinthusbio.com/role/ShareBasedCompensationAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_080f6118-c645-4be7-a5a8-2e23206ad56c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_16dfa84b-5d69-4a03-ad8f-a271307cbe0e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_080f6118-c645-4be7-a5a8-2e23206ad56c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_16dfa84b-5d69-4a03-ad8f-a271307cbe0e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_9f2f1fa1-dd7c-450c-9cfb-3a567fccfa52" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_16dfa84b-5d69-4a03-ad8f-a271307cbe0e" xlink:to="loc_us-gaap_PlanNameAxis_9f2f1fa1-dd7c-450c-9cfb-3a567fccfa52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_9f2f1fa1-dd7c-450c-9cfb-3a567fccfa52_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_9f2f1fa1-dd7c-450c-9cfb-3a567fccfa52" xlink:to="loc_us-gaap_PlanNameDomain_9f2f1fa1-dd7c-450c-9cfb-3a567fccfa52_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_76379b6c-a5b0-422a-8d31-d91fae538a6c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_9f2f1fa1-dd7c-450c-9cfb-3a567fccfa52" xlink:to="loc_us-gaap_PlanNameDomain_76379b6c-a5b0-422a-8d31-d91fae538a6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_BarinthusBiotherapeuticsPlcShareAwardPlan2021Member_18108dbf-0ecc-45c7-aaf5-db201d91f87a" xlink:href="brns-20231231.xsd#brns_BarinthusBiotherapeuticsPlcShareAwardPlan2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_76379b6c-a5b0-422a-8d31-d91fae538a6c" xlink:to="loc_brns_BarinthusBiotherapeuticsPlcShareAwardPlan2021Member_18108dbf-0ecc-45c7-aaf5-db201d91f87a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_EnterpriseManagementIncentiveShareOptionSchemeMember_bfe57e64-2f5b-4f44-a2c9-db31b0812a49" xlink:href="brns-20231231.xsd#brns_EnterpriseManagementIncentiveShareOptionSchemeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_76379b6c-a5b0-422a-8d31-d91fae538a6c" xlink:to="loc_brns_EnterpriseManagementIncentiveShareOptionSchemeMember_bfe57e64-2f5b-4f44-a2c9-db31b0812a49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_3aaba6f8-0e44-4f30-913b-77ab9b8d60aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_16dfa84b-5d69-4a03-ad8f-a271307cbe0e" xlink:to="loc_us-gaap_AwardTypeAxis_3aaba6f8-0e44-4f30-913b-77ab9b8d60aa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3aaba6f8-0e44-4f30-913b-77ab9b8d60aa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_3aaba6f8-0e44-4f30-913b-77ab9b8d60aa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3aaba6f8-0e44-4f30-913b-77ab9b8d60aa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c4c7dc0e-0c1e-41a7-b49f-6c801cea8b85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_3aaba6f8-0e44-4f30-913b-77ab9b8d60aa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c4c7dc0e-0c1e-41a7-b49f-6c801cea8b85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_RestrictedShareUnitsStockOptionsShareAppreciationRightsAndRestrictedSharesMember_3b35dd35-fc67-462b-b318-894154b74399" xlink:href="brns-20231231.xsd#brns_RestrictedShareUnitsStockOptionsShareAppreciationRightsAndRestrictedSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c4c7dc0e-0c1e-41a7-b49f-6c801cea8b85" xlink:to="loc_brns_RestrictedShareUnitsStockOptionsShareAppreciationRightsAndRestrictedSharesMember_3b35dd35-fc67-462b-b318-894154b74399" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_e0143781-5818-45f8-8c45-34419c5380c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c4c7dc0e-0c1e-41a7-b49f-6c801cea8b85" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_e0143781-5818-45f8-8c45-34419c5380c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_cc82007b-bb62-43f9-9e8f-8cc74487518f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_080f6118-c645-4be7-a5a8-2e23206ad56c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_cc82007b-bb62-43f9-9e8f-8cc74487518f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ShareBasedCompensationPercentageOfSharesAvailableForIssuanceAsPercentageOfIssuedAndOutstandingShares_f9f6cc4f-1b50-4a0c-80c4-8b6473d2928e" xlink:href="brns-20231231.xsd#brns_ShareBasedCompensationPercentageOfSharesAvailableForIssuanceAsPercentageOfIssuedAndOutstandingShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_080f6118-c645-4be7-a5a8-2e23206ad56c" xlink:to="loc_brns_ShareBasedCompensationPercentageOfSharesAvailableForIssuanceAsPercentageOfIssuedAndOutstandingShares_f9f6cc4f-1b50-4a0c-80c4-8b6473d2928e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_754efb26-738e-43f8-9e28-c5e25057eaea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_080f6118-c645-4be7-a5a8-2e23206ad56c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_754efb26-738e-43f8-9e28-c5e25057eaea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ExpirationOfShareBasedCompensationPlanFromDateOfInitialIssuance_80d109fe-bac6-4fbf-a079-7c4a106443cc" xlink:href="brns-20231231.xsd#brns_ExpirationOfShareBasedCompensationPlanFromDateOfInitialIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_080f6118-c645-4be7-a5a8-2e23206ad56c" xlink:to="loc_brns_ExpirationOfShareBasedCompensationPlanFromDateOfInitialIssuance_80d109fe-bac6-4fbf-a079-7c4a106443cc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3d0e79a7-b90d-43a8-82b5-78ce869f5508" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_080f6118-c645-4be7-a5a8-2e23206ad56c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3d0e79a7-b90d-43a8-82b5-78ce869f5508" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8c9ccda5-d8de-4dfb-af2b-d11f98aabb18" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_080f6118-c645-4be7-a5a8-2e23206ad56c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8c9ccda5-d8de-4dfb-af2b-d11f98aabb18" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_c0acb406-ea6d-459a-82e0-e56abe64536f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_080f6118-c645-4be7-a5a8-2e23206ad56c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_c0acb406-ea6d-459a-82e0-e56abe64536f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_312987e2-e485-48dd-80dd-2bda26c0161a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_080f6118-c645-4be7-a5a8-2e23206ad56c" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_312987e2-e485-48dd-80dd-2bda26c0161a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_805b4273-853e-4216-8969-116646e1ea3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_080f6118-c645-4be7-a5a8-2e23206ad56c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_805b4273-853e-4216-8969-116646e1ea3f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_572b3a7e-d9cd-467b-a7af-1b9b45316f5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_080f6118-c645-4be7-a5a8-2e23206ad56c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_572b3a7e-d9cd-467b-a7af-1b9b45316f5a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_93197e8a-d063-4500-a2a4-a091c411aa4f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_080f6118-c645-4be7-a5a8-2e23206ad56c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_93197e8a-d063-4500-a2a4-a091c411aa4f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_68db7182-5ad8-457d-9600-4443c66cdad4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_080f6118-c645-4be7-a5a8-2e23206ad56c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_68db7182-5ad8-457d-9600-4443c66cdad4" xlink:type="arc" order="11"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/ShareBasedCompensationWeightedaverageassumptionsDetails" xlink:type="simple" xlink:href="brns-20231231.xsd#ShareBasedCompensationWeightedaverageassumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.barinthusbio.com/role/ShareBasedCompensationWeightedaverageassumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_71f94d33-bce6-445e-854c-1d78c695fb34" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_682b6322-f00f-41de-965d-eeba88116c7a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_71f94d33-bce6-445e-854c-1d78c695fb34" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_682b6322-f00f-41de-965d-eeba88116c7a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_d8f23b34-4b7f-4ef3-9aa7-adb80c8a5b64" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_682b6322-f00f-41de-965d-eeba88116c7a" xlink:to="loc_us-gaap_PlanNameAxis_d8f23b34-4b7f-4ef3-9aa7-adb80c8a5b64" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_d8f23b34-4b7f-4ef3-9aa7-adb80c8a5b64_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_d8f23b34-4b7f-4ef3-9aa7-adb80c8a5b64" xlink:to="loc_us-gaap_PlanNameDomain_d8f23b34-4b7f-4ef3-9aa7-adb80c8a5b64_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_3e84d2ef-e7df-4b0c-a540-db97af314ff4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_d8f23b34-4b7f-4ef3-9aa7-adb80c8a5b64" xlink:to="loc_us-gaap_PlanNameDomain_3e84d2ef-e7df-4b0c-a540-db97af314ff4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_EnterpriseManagementIncentiveShareOptionSchemeMember_f67bc167-38dd-4ff9-afa8-09da126b9b34" xlink:href="brns-20231231.xsd#brns_EnterpriseManagementIncentiveShareOptionSchemeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_3e84d2ef-e7df-4b0c-a540-db97af314ff4" xlink:to="loc_brns_EnterpriseManagementIncentiveShareOptionSchemeMember_f67bc167-38dd-4ff9-afa8-09da126b9b34" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_432c6d00-f8ec-41e0-a079-cf575d6a04bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_71f94d33-bce6-445e-854c-1d78c695fb34" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_432c6d00-f8ec-41e0-a079-cf575d6a04bc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_b39add07-c542-42ca-85d8-72f4fa150ac3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_71f94d33-bce6-445e-854c-1d78c695fb34" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_b39add07-c542-42ca-85d8-72f4fa150ac3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_41efb29d-e3ee-4d58-89a6-8962b33ecffb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_71f94d33-bce6-445e-854c-1d78c695fb34" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_41efb29d-e3ee-4d58-89a6-8962b33ecffb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_332df4c3-4f4d-448f-ab2b-d0577765deda" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_71f94d33-bce6-445e-854c-1d78c695fb34" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_332df4c3-4f4d-448f-ab2b-d0577765deda" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/ShareBasedCompensationSharebasedcompensationexpenseDetails" xlink:type="simple" xlink:href="brns-20231231.xsd#ShareBasedCompensationSharebasedcompensationexpenseDetails"/>
  <link:definitionLink xlink:role="http://www.barinthusbio.com/role/ShareBasedCompensationSharebasedcompensationexpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_38b21bd9-0850-46d6-a4b1-37f911bce99a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a06793ea-335c-4665-b695-17590d0c27ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_38b21bd9-0850-46d6-a4b1-37f911bce99a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a06793ea-335c-4665-b695-17590d0c27ef" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_5703ff84-a370-4af4-ab00-4e877882bde7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a06793ea-335c-4665-b695-17590d0c27ef" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_5703ff84-a370-4af4-ab00-4e877882bde7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_5703ff84-a370-4af4-ab00-4e877882bde7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_5703ff84-a370-4af4-ab00-4e877882bde7" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_5703ff84-a370-4af4-ab00-4e877882bde7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_7c61f446-5bba-4def-8d32-3ac245f32695" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_5703ff84-a370-4af4-ab00-4e877882bde7" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_7c61f446-5bba-4def-8d32-3ac245f32695" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4664e33e-ffdc-4180-885d-77f8ed9f3d29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7c61f446-5bba-4def-8d32-3ac245f32695" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4664e33e-ffdc-4180-885d-77f8ed9f3d29" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_c0d7fad7-2f52-4dc5-89a3-1fe829327ad1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7c61f446-5bba-4def-8d32-3ac245f32695" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_c0d7fad7-2f52-4dc5-89a3-1fe829327ad1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_0bb4be20-41be-4aa0-855a-4ad2769ff41b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_38b21bd9-0850-46d6-a4b1-37f911bce99a" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_0bb4be20-41be-4aa0-855a-4ad2769ff41b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/IncomeTaxesLossincomebeforeincometaxesDetails" xlink:type="simple" xlink:href="brns-20231231.xsd#IncomeTaxesLossincomebeforeincometaxesDetails"/>
  <link:definitionLink xlink:role="http://www.barinthusbio.com/role/IncomeTaxesLossincomebeforeincometaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_brns_IncomeTaxesLineItems_4ca37c1d-17b0-49c3-9d1d-ea1d0000437a" xlink:href="brns-20231231.xsd#brns_IncomeTaxesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_IncomeTaxesTable_48b6c035-b5bb-43b1-9bf0-2b34511e623f" xlink:href="brns-20231231.xsd#brns_IncomeTaxesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_brns_IncomeTaxesLineItems_4ca37c1d-17b0-49c3-9d1d-ea1d0000437a" xlink:to="loc_brns_IncomeTaxesTable_48b6c035-b5bb-43b1-9bf0-2b34511e623f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_b1b281e8-5808-4d2a-99e7-cdf9c2ddccb2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_brns_IncomeTaxesTable_48b6c035-b5bb-43b1-9bf0-2b34511e623f" xlink:to="loc_srt_StatementGeographicalAxis_b1b281e8-5808-4d2a-99e7-cdf9c2ddccb2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_b1b281e8-5808-4d2a-99e7-cdf9c2ddccb2_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_b1b281e8-5808-4d2a-99e7-cdf9c2ddccb2" xlink:to="loc_srt_SegmentGeographicalDomain_b1b281e8-5808-4d2a-99e7-cdf9c2ddccb2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_8e3bebe8-c1bc-4dea-9ab7-9f2f73abea2c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_b1b281e8-5808-4d2a-99e7-cdf9c2ddccb2" xlink:to="loc_srt_SegmentGeographicalDomain_8e3bebe8-c1bc-4dea-9ab7-9f2f73abea2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_b06ef201-cca0-4b87-8b16-91c8388085c2" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_8e3bebe8-c1bc-4dea-9ab7-9f2f73abea2c" xlink:to="loc_country_US_b06ef201-cca0-4b87-8b16-91c8388085c2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_6cbbecc1-b486-4fa0-8ea6-20157fb6fe4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_8e3bebe8-c1bc-4dea-9ab7-9f2f73abea2c" xlink:to="loc_us-gaap_NonUsMember_6cbbecc1-b486-4fa0-8ea6-20157fb6fe4d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_3d581d38-c530-43b1-ac84-587d6fe28d25" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_brns_IncomeTaxesLineItems_4ca37c1d-17b0-49c3-9d1d-ea1d0000437a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_3d581d38-c530-43b1-ac84-587d6fe28d25" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_64647bc7-9ed2-448a-b589-814e514f3025" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_brns_IncomeTaxesLineItems_4ca37c1d-17b0-49c3-9d1d-ea1d0000437a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_64647bc7-9ed2-448a-b589-814e514f3025" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4b247996-27ca-4c2a-aee6-d6b4f90cc201" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_brns_IncomeTaxesLineItems_4ca37c1d-17b0-49c3-9d1d-ea1d0000437a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4b247996-27ca-4c2a-aee6-d6b4f90cc201" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/IncomeTaxesComponentsofincometaxbenefitexpenseDetails" xlink:type="simple" xlink:href="brns-20231231.xsd#IncomeTaxesComponentsofincometaxbenefitexpenseDetails"/>
  <link:definitionLink xlink:role="http://www.barinthusbio.com/role/IncomeTaxesComponentsofincometaxbenefitexpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_brns_IncomeTaxesLineItems_92c8284d-1ca2-4cf2-a4f4-1c8a44308eca" xlink:href="brns-20231231.xsd#brns_IncomeTaxesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_IncomeTaxesTable_65794393-54da-4f82-987e-236d919e8e7a" xlink:href="brns-20231231.xsd#brns_IncomeTaxesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_brns_IncomeTaxesLineItems_92c8284d-1ca2-4cf2-a4f4-1c8a44308eca" xlink:to="loc_brns_IncomeTaxesTable_65794393-54da-4f82-987e-236d919e8e7a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_ca749c0f-7815-4063-8085-5f8ffeddb13e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_brns_IncomeTaxesTable_65794393-54da-4f82-987e-236d919e8e7a" xlink:to="loc_srt_StatementGeographicalAxis_ca749c0f-7815-4063-8085-5f8ffeddb13e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_ca749c0f-7815-4063-8085-5f8ffeddb13e_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_ca749c0f-7815-4063-8085-5f8ffeddb13e" xlink:to="loc_srt_SegmentGeographicalDomain_ca749c0f-7815-4063-8085-5f8ffeddb13e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_4881bc6b-480a-4875-8c21-b226701c6832" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_ca749c0f-7815-4063-8085-5f8ffeddb13e" xlink:to="loc_srt_SegmentGeographicalDomain_4881bc6b-480a-4875-8c21-b226701c6832" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_100c855d-bba4-4f52-8659-fcee89ca106c" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_4881bc6b-480a-4875-8c21-b226701c6832" xlink:to="loc_country_US_100c855d-bba4-4f52-8659-fcee89ca106c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_7c769795-f11c-4476-bd02-eb4c4c6dfd41" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_4881bc6b-480a-4875-8c21-b226701c6832" xlink:to="loc_us-gaap_NonUsMember_7c769795-f11c-4476-bd02-eb4c4c6dfd41" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_4e1ee0aa-2be5-426c-ba3b-7e15dc7b6638" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_brns_IncomeTaxesLineItems_92c8284d-1ca2-4cf2-a4f4-1c8a44308eca" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_4e1ee0aa-2be5-426c-ba3b-7e15dc7b6638" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_844da483-c75a-449c-b502-4450e21d9ff8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_4e1ee0aa-2be5-426c-ba3b-7e15dc7b6638" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_844da483-c75a-449c-b502-4450e21d9ff8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_3addce26-69be-4a25-826a-332c50cd40a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_brns_IncomeTaxesLineItems_92c8284d-1ca2-4cf2-a4f4-1c8a44308eca" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_3addce26-69be-4a25-826a-332c50cd40a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_b2a152c0-5982-40d5-961a-f6f0f8640489" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_3addce26-69be-4a25-826a-332c50cd40a8" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_b2a152c0-5982-40d5-961a-f6f0f8640489" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_db567d4f-ffa5-4334-99c1-f605514b43cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_brns_IncomeTaxesLineItems_92c8284d-1ca2-4cf2-a4f4-1c8a44308eca" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_db567d4f-ffa5-4334-99c1-f605514b43cf" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="simple" xlink:href="brns-20231231.xsd#IncomeTaxesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.barinthusbio.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_b6178768-e3b0-4616-be36-fd2e5a80f1e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_0d06fc61-48f1-49a9-a434-f41bf9a854e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_b6178768-e3b0-4616-be36-fd2e5a80f1e1" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_0d06fc61-48f1-49a9-a434-f41bf9a854e7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_57ca848d-68e4-426c-8207-60702787a995" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_0d06fc61-48f1-49a9-a434-f41bf9a854e7" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_57ca848d-68e4-426c-8207-60702787a995" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_57ca848d-68e4-426c-8207-60702787a995_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_57ca848d-68e4-426c-8207-60702787a995" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_57ca848d-68e4-426c-8207-60702787a995_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_6daa6636-c445-4cb6-a525-c52e9789d9a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_57ca848d-68e4-426c-8207-60702787a995" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_6daa6636-c445-4cb6-a525-c52e9789d9a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_f428e4d3-da56-467d-89cb-e88f7ab995db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_6daa6636-c445-4cb6-a525-c52e9789d9a3" xlink:to="loc_us-gaap_DomesticCountryMember_f428e4d3-da56-467d-89cb-e88f7ab995db" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_c5e30e06-5cac-4106-9219-d71c58963746" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_b6178768-e3b0-4616-be36-fd2e5a80f1e1" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_c5e30e06-5cac-4106-9219-d71c58963746" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_4c432268-c0ad-4476-a7be-8910854ad4e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_b6178768-e3b0-4616-be36-fd2e5a80f1e1" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_4c432268-c0ad-4476-a7be-8910854ad4e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_c97cfdb2-c823-471a-8942-8f21bc9dc976" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_b6178768-e3b0-4616-be36-fd2e5a80f1e1" xlink:to="loc_us-gaap_OperatingLossCarryforwards_c97cfdb2-c823-471a-8942-8f21bc9dc976" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_2f58bf56-cfe9-409c-89b4-701b189a157c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_b6178768-e3b0-4616-be36-fd2e5a80f1e1" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_2f58bf56-cfe9-409c-89b4-701b189a157c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxCreditsAndAdjustments_3740506c-33c5-41b6-9c8d-3a67d7eb3cc6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxCreditsAndAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_b6178768-e3b0-4616-be36-fd2e5a80f1e1" xlink:to="loc_us-gaap_IncomeTaxCreditsAndAdjustments_3740506c-33c5-41b6-9c8d-3a67d7eb3cc6" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/CommitmentsandContingenciesAdditionalinformationDetails" xlink:type="simple" xlink:href="brns-20231231.xsd#CommitmentsandContingenciesAdditionalinformationDetails"/>
  <link:definitionLink xlink:role="http://www.barinthusbio.com/role/CommitmentsandContingenciesAdditionalinformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_e977c277-3ff1-4fa1-a22c-0b878e8c62ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_71d323ad-4f8e-4e50-988b-2b400dcde99b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_e977c277-3ff1-4fa1-a22c-0b878e8c62ca" xlink:to="loc_us-gaap_OtherCommitmentsTable_71d323ad-4f8e-4e50-988b-2b400dcde99b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_f6e57ca0-8efe-4908-82fc-269f602a17e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_71d323ad-4f8e-4e50-988b-2b400dcde99b" xlink:to="loc_us-gaap_TypeOfArrangementAxis_f6e57ca0-8efe-4908-82fc-269f602a17e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f6e57ca0-8efe-4908-82fc-269f602a17e0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_f6e57ca0-8efe-4908-82fc-269f602a17e0" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f6e57ca0-8efe-4908-82fc-269f602a17e0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_dd5d91f8-ec32-43ce-9411-de16cf653b5b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_f6e57ca0-8efe-4908-82fc-269f602a17e0" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_dd5d91f8-ec32-43ce-9411-de16cf653b5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_InLicenseAgreementsMember_66349bc0-b9ca-4793-907b-397c09ea413c" xlink:href="brns-20231231.xsd#brns_InLicenseAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_dd5d91f8-ec32-43ce-9411-de16cf653b5b" xlink:to="loc_brns_InLicenseAgreementsMember_66349bc0-b9ca-4793-907b-397c09ea413c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4643d1bf-f9b2-44f7-abd7-e80c14b4480a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_71d323ad-4f8e-4e50-988b-2b400dcde99b" xlink:to="loc_srt_RangeAxis_4643d1bf-f9b2-44f7-abd7-e80c14b4480a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4643d1bf-f9b2-44f7-abd7-e80c14b4480a_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_4643d1bf-f9b2-44f7-abd7-e80c14b4480a" xlink:to="loc_srt_RangeMember_4643d1bf-f9b2-44f7-abd7-e80c14b4480a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_680391cd-ce6e-43af-81ad-410b11429acf" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_4643d1bf-f9b2-44f7-abd7-e80c14b4480a" xlink:to="loc_srt_RangeMember_680391cd-ce6e-43af-81ad-410b11429acf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7e5edd88-0103-492f-809b-0310a3e6f870" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_680391cd-ce6e-43af-81ad-410b11429acf" xlink:to="loc_srt_MinimumMember_7e5edd88-0103-492f-809b-0310a3e6f870" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_3f7fff07-0f42-466a-8765-b381d95d532c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_680391cd-ce6e-43af-81ad-410b11429acf" xlink:to="loc_srt_MaximumMember_3f7fff07-0f42-466a-8765-b381d95d532c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_f2ecc03d-58ac-4062-a7ba-de50c8855ce4" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_71d323ad-4f8e-4e50-988b-2b400dcde99b" xlink:to="loc_srt_StatementGeographicalAxis_f2ecc03d-58ac-4062-a7ba-de50c8855ce4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_f2ecc03d-58ac-4062-a7ba-de50c8855ce4_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_f2ecc03d-58ac-4062-a7ba-de50c8855ce4" xlink:to="loc_srt_SegmentGeographicalDomain_f2ecc03d-58ac-4062-a7ba-de50c8855ce4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_3728b4e3-2c4c-4165-b2ef-2ff04eb0076d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_f2ecc03d-58ac-4062-a7ba-de50c8855ce4" xlink:to="loc_srt_SegmentGeographicalDomain_3728b4e3-2c4c-4165-b2ef-2ff04eb0076d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_OxfordshireMember_855ce156-1bfc-4e01-bb4e-71970e50fe2c" xlink:href="brns-20231231.xsd#brns_OxfordshireMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_3728b4e3-2c4c-4165-b2ef-2ff04eb0076d" xlink:to="loc_brns_OxfordshireMember_855ce156-1bfc-4e01-bb4e-71970e50fe2c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MD_8b77a9ea-de76-4c2e-ac0d-fec5e30e8a9a" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_MD"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_3728b4e3-2c4c-4165-b2ef-2ff04eb0076d" xlink:to="loc_stpr_MD_8b77a9ea-de76-4c2e-ac0d-fec5e30e8a9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_PercentageOfFutureRoyaltiesForDirectSalesOfCoveredProductLicenseAgreement_bec7434c-0134-4f17-9f8c-79f98b2911db" xlink:href="brns-20231231.xsd#brns_PercentageOfFutureRoyaltiesForDirectSalesOfCoveredProductLicenseAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_e977c277-3ff1-4fa1-a22c-0b878e8c62ca" xlink:to="loc_brns_PercentageOfFutureRoyaltiesForDirectSalesOfCoveredProductLicenseAgreement_bec7434c-0134-4f17-9f8c-79f98b2911db" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_PercentageOfNetPaymentsReceivedForAllowableSublicensesOfTechnologyDevelopedLicenseAgreement_f07e882d-8939-4f5f-ba24-3306eb7fe9cb" xlink:href="brns-20231231.xsd#brns_PercentageOfNetPaymentsReceivedForAllowableSublicensesOfTechnologyDevelopedLicenseAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_e977c277-3ff1-4fa1-a22c-0b878e8c62ca" xlink:to="loc_brns_PercentageOfNetPaymentsReceivedForAllowableSublicensesOfTechnologyDevelopedLicenseAgreement_f07e882d-8939-4f5f-ba24-3306eb7fe9cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_NumberOfSquareFeetUnderLeaseAgreement_cf90bce5-01fd-43f4-b9c9-3c2c3032864f" xlink:href="brns-20231231.xsd#brns_NumberOfSquareFeetUnderLeaseAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_e977c277-3ff1-4fa1-a22c-0b878e8c62ca" xlink:to="loc_brns_NumberOfSquareFeetUnderLeaseAgreement_cf90bce5-01fd-43f4-b9c9-3c2c3032864f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecurityDeposit_bff1a6ec-f879-4064-8dc1-e0111e8ccb25" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecurityDeposit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_e977c277-3ff1-4fa1-a22c-0b878e8c62ca" xlink:to="loc_us-gaap_SecurityDeposit_bff1a6ec-f879-4064-8dc1-e0111e8ccb25" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_LesseeOperatingLeaseExtendedTerm_01ffcdb0-9298-4558-abcb-9d1245487689" xlink:href="brns-20231231.xsd#brns_LesseeOperatingLeaseExtendedTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_e977c277-3ff1-4fa1-a22c-0b878e8c62ca" xlink:to="loc_brns_LesseeOperatingLeaseExtendedTerm_01ffcdb0-9298-4558-abcb-9d1245487689" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsGross_d69aa4ec-1838-4bab-8345-93794e373db8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_e977c277-3ff1-4fa1-a22c-0b878e8c62ca" xlink:to="loc_us-gaap_LeaseholdImprovementsGross_d69aa4ec-1838-4bab-8345-93794e373db8" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="brns-20231231.xsd#RelatedPartyTransactionsDetails"/>
  <link:definitionLink xlink:role="http://www.barinthusbio.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_2b7ee07a-7d6c-4efd-9e20-291adf67aa1f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b340b48d-458b-461d-883b-5cea10d240bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2b7ee07a-7d6c-4efd-9e20-291adf67aa1f" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b340b48d-458b-461d-883b-5cea10d240bd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_f69d0520-1a20-4f86-9fa8-3f55bd3795cf" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b340b48d-458b-461d-883b-5cea10d240bd" xlink:to="loc_srt_CounterpartyNameAxis_f69d0520-1a20-4f86-9fa8-3f55bd3795cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f69d0520-1a20-4f86-9fa8-3f55bd3795cf_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_f69d0520-1a20-4f86-9fa8-3f55bd3795cf" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f69d0520-1a20-4f86-9fa8-3f55bd3795cf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ea1dea92-dafd-4ca3-b4b4-a0b19a99c7ec" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_f69d0520-1a20-4f86-9fa8-3f55bd3795cf" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ea1dea92-dafd-4ca3-b4b4-a0b19a99c7ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ShareholderTheUniversityOfOxfordMember_c87ee020-57ed-4b10-9a4e-1f2ba5d94036" xlink:href="brns-20231231.xsd#brns_ShareholderTheUniversityOfOxfordMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ea1dea92-dafd-4ca3-b4b4-a0b19a99c7ec" xlink:to="loc_brns_ShareholderTheUniversityOfOxfordMember_c87ee020-57ed-4b10-9a4e-1f2ba5d94036" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_OxfordUniversityInnovationLimitedMember_a88390f7-d181-4b1e-a185-79483855fe11" xlink:href="brns-20231231.xsd#brns_OxfordUniversityInnovationLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ea1dea92-dafd-4ca3-b4b4-a0b19a99c7ec" xlink:to="loc_brns_OxfordUniversityInnovationLimitedMember_a88390f7-d181-4b1e-a185-79483855fe11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_ed46f8f6-09d8-4106-896d-9a8110398327" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b340b48d-458b-461d-883b-5cea10d240bd" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_ed46f8f6-09d8-4106-896d-9a8110398327" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_ed46f8f6-09d8-4106-896d-9a8110398327_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_ed46f8f6-09d8-4106-896d-9a8110398327" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_ed46f8f6-09d8-4106-896d-9a8110398327_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_06e0e32c-5b11-4506-91f6-3fdecb5efef1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_ed46f8f6-09d8-4106-896d-9a8110398327" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_06e0e32c-5b11-4506-91f6-3fdecb5efef1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ExpensesMember_da35e23b-c9e6-4dc2-a9d3-8a0bf6d2ce06" xlink:href="brns-20231231.xsd#brns_ExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_06e0e32c-5b11-4506-91f6-3fdecb5efef1" xlink:to="loc_brns_ExpensesMember_da35e23b-c9e6-4dc2-a9d3-8a0bf6d2ce06" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4d8c19a2-fc41-4326-b1d7-b34de2bc966f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b340b48d-458b-461d-883b-5cea10d240bd" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4d8c19a2-fc41-4326-b1d7-b34de2bc966f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_4d8c19a2-fc41-4326-b1d7-b34de2bc966f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4d8c19a2-fc41-4326-b1d7-b34de2bc966f" xlink:to="loc_us-gaap_RelatedPartyDomain_4d8c19a2-fc41-4326-b1d7-b34de2bc966f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_4da0247f-441f-4551-b641-faf4a16cd093" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4d8c19a2-fc41-4326-b1d7-b34de2bc966f" xlink:to="loc_us-gaap_RelatedPartyDomain_4da0247f-441f-4551-b641-faf4a16cd093" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_c1fbd36f-5cc9-48f3-983c-89d4cf2b1ba8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_4da0247f-441f-4551-b641-faf4a16cd093" xlink:to="loc_us-gaap_RelatedPartyMember_c1fbd36f-5cc9-48f3-983c-89d4cf2b1ba8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_4386b4b6-91d4-49b4-8f73-d8f52821ab0e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b340b48d-458b-461d-883b-5cea10d240bd" xlink:to="loc_srt_ProductOrServiceAxis_4386b4b6-91d4-49b4-8f73-d8f52821ab0e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4386b4b6-91d4-49b4-8f73-d8f52821ab0e_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_4386b4b6-91d4-49b4-8f73-d8f52821ab0e" xlink:to="loc_srt_ProductsAndServicesDomain_4386b4b6-91d4-49b4-8f73-d8f52821ab0e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f877bdbc-9187-4e3e-975a-66b5c4b2b840" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_4386b4b6-91d4-49b4-8f73-d8f52821ab0e" xlink:to="loc_srt_ProductsAndServicesDomain_f877bdbc-9187-4e3e-975a-66b5c4b2b840" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_efc13a14-4191-42d3-ab4e-b1683ed28f3a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f877bdbc-9187-4e3e-975a-66b5c4b2b840" xlink:to="loc_us-gaap_LicenseMember_efc13a14-4191-42d3-ab4e-b1683ed28f3a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_34537c48-0242-42f5-939a-6aa1a7ce1c02" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2b7ee07a-7d6c-4efd-9e20-291adf67aa1f" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_34537c48-0242-42f5-939a-6aa1a7ce1c02" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_6f4d0d82-4732-4089-8ac1-ed534a2b8a43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2b7ee07a-7d6c-4efd-9e20-291adf67aa1f" xlink:to="loc_us-gaap_AccountsPayableCurrent_6f4d0d82-4732-4089-8ac1-ed534a2b8a43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0f358f28-aa9e-4496-b534-d5d63d6309c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2b7ee07a-7d6c-4efd-9e20-291adf67aa1f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0f358f28-aa9e-4496-b534-d5d63d6309c0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_d79f0b22-d214-46eb-8a91-a31075feff45" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2b7ee07a-7d6c-4efd-9e20-291adf67aa1f" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_d79f0b22-d214-46eb-8a91-a31075feff45" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="brns-20231231.xsd#SubsequentEventsDetails"/>
  <link:definitionLink xlink:role="http://www.barinthusbio.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_061d444f-cfdb-4112-9809-037c12fb0fd9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_aa97b2a7-b7e5-4d5c-be53-8500e78ed389" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_061d444f-cfdb-4112-9809-037c12fb0fd9" xlink:to="loc_us-gaap_SubsequentEventTable_aa97b2a7-b7e5-4d5c-be53-8500e78ed389" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_f5f6dbb8-9dde-408b-aec2-0c2b88139f67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_aa97b2a7-b7e5-4d5c-be53-8500e78ed389" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_f5f6dbb8-9dde-408b-aec2-0c2b88139f67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_f5f6dbb8-9dde-408b-aec2-0c2b88139f67_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_f5f6dbb8-9dde-408b-aec2-0c2b88139f67" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_f5f6dbb8-9dde-408b-aec2-0c2b88139f67_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_b92fe56c-23ac-43db-b14a-765b78447f89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_f5f6dbb8-9dde-408b-aec2-0c2b88139f67" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_b92fe56c-23ac-43db-b14a-765b78447f89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_b744b23f-2660-413a-9063-923359d4a374" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_b92fe56c-23ac-43db-b14a-765b78447f89" xlink:to="loc_us-gaap_SubsequentEventMember_b744b23f-2660-413a-9063-923359d4a374" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_fa5d8b47-ea50-4918-bbae-e49afa1d385a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_aa97b2a7-b7e5-4d5c-be53-8500e78ed389" xlink:to="loc_us-gaap_PlanNameAxis_fa5d8b47-ea50-4918-bbae-e49afa1d385a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_fa5d8b47-ea50-4918-bbae-e49afa1d385a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_fa5d8b47-ea50-4918-bbae-e49afa1d385a" xlink:to="loc_us-gaap_PlanNameDomain_fa5d8b47-ea50-4918-bbae-e49afa1d385a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_1eef5f8d-bb6b-4697-b795-6695f0fd34de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_fa5d8b47-ea50-4918-bbae-e49afa1d385a" xlink:to="loc_us-gaap_PlanNameDomain_1eef5f8d-bb6b-4697-b795-6695f0fd34de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_BarinthusBiotherapeuticsPlcShareAwardPlan2021Member_def9e8f2-6e57-40b9-a2f3-ea291cef83bf" xlink:href="brns-20231231.xsd#brns_BarinthusBiotherapeuticsPlcShareAwardPlan2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1eef5f8d-bb6b-4697-b795-6695f0fd34de" xlink:to="loc_brns_BarinthusBiotherapeuticsPlcShareAwardPlan2021Member_def9e8f2-6e57-40b9-a2f3-ea291cef83bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2a956518-2827-429a-844b-d076fab71389" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_aa97b2a7-b7e5-4d5c-be53-8500e78ed389" xlink:to="loc_us-gaap_AwardTypeAxis_2a956518-2827-429a-844b-d076fab71389" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2a956518-2827-429a-844b-d076fab71389_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2a956518-2827-429a-844b-d076fab71389" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2a956518-2827-429a-844b-d076fab71389_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9e61b444-410f-494c-8180-916fd49f377c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2a956518-2827-429a-844b-d076fab71389" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9e61b444-410f-494c-8180-916fd49f377c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_f096983d-31f0-4886-8446-4f8c3e6c6911" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9e61b444-410f-494c-8180-916fd49f377c" xlink:to="loc_us-gaap_EmployeeStockOptionMember_f096983d-31f0-4886-8446-4f8c3e6c6911" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ShareBasedCompensationPercentageOfSharesAvailableForIssuanceAsPercentageOfIssuedAndOutstandingShares_74ea45a1-b616-4d77-b699-e120baee87cf" xlink:href="brns-20231231.xsd#brns_ShareBasedCompensationPercentageOfSharesAvailableForIssuanceAsPercentageOfIssuedAndOutstandingShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_061d444f-cfdb-4112-9809-037c12fb0fd9" xlink:to="loc_brns_ShareBasedCompensationPercentageOfSharesAvailableForIssuanceAsPercentageOfIssuedAndOutstandingShares_74ea45a1-b616-4d77-b699-e120baee87cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ba8a25c9-6ad8-4ab3-8a0d-3645f42213a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_061d444f-cfdb-4112-9809-037c12fb0fd9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ba8a25c9-6ad8-4ab3-8a0d-3645f42213a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_4e6e72c6-74ec-46dd-8b56-67b977126038" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_061d444f-cfdb-4112-9809-037c12fb0fd9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_4e6e72c6-74ec-46dd-8b56-67b977126038" xlink:type="arc" order="2"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>brns-20231231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:568bf53a-35e8-4830-ae45-40f379b83a88,g:160c7384-88e8-453d-8496-8cc857f3b5f9-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_60c61d99-7a37-4c43-ae71-b699aa876c89_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesAxis" xlink:to="lab_srt_ConsolidatedEntitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_3e4ea680-819e-4bcf-8572-f7b8e65cad4d_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Change in fair value recognized in net loss</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_43f59425-9a88-4a73-bfc4-5fe04b9d64a3_negatedLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Net loss attributable to noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_c9244a08-5115-486a-b6ef-02c4e33b8835_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_DeferredSharesMember_cf67bfda-f9dc-416c-886a-48a8cf14d936_verboseLabel_en-US" xlink:label="lab_brns_DeferredSharesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred Shares</link:label>
    <link:label id="lab_brns_DeferredSharesMember_label_en-US" xlink:label="lab_brns_DeferredSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Shares [Member]</link:label>
    <link:label id="lab_brns_DeferredSharesMember_documentation_en-US" xlink:label="lab_brns_DeferredSharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information pertaining to deferred shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredSharesMember" xlink:href="brns-20231231.xsd#brns_DeferredSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_DeferredSharesMember" xlink:to="lab_brns_DeferredSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_f37b9dbe-ec59-4c87-9b05-e623d82f5129_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_d1a9053d-3d1b-4e5c-bcb9-83d4658b0e1a_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5ece271b-4c9f-4c25-bdd9-2511fcaec037_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_9345a355-6477-4400-801d-57df9d545d66_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_11e0c806-11a8-44f4-868b-8b0628a17af1_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_ResearchGrantsAndContractsMember_5dd2e84f-98fb-4d20-840d-5799b01f42a0_terseLabel_en-US" xlink:label="lab_brns_ResearchGrantsAndContractsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research grants and contracts</link:label>
    <link:label id="lab_brns_ResearchGrantsAndContractsMember_label_en-US" xlink:label="lab_brns_ResearchGrantsAndContractsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research Grants And Contracts [Member]</link:label>
    <link:label id="lab_brns_ResearchGrantsAndContractsMember_documentation_en-US" xlink:label="lab_brns_ResearchGrantsAndContractsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to research grants and contracts.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ResearchGrantsAndContractsMember" xlink:href="brns-20231231.xsd#brns_ResearchGrantsAndContractsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_ResearchGrantsAndContractsMember" xlink:to="lab_brns_ResearchGrantsAndContractsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_919ce47f-0a3f-4ae0-af54-49aec971cb40_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfShortTermDebt_81cfd9e2-4674-4fd4-9d37-d134a4e76b0a_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Repayment of debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfShortTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Short-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfShortTermDebt" xlink:to="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_ContractWithCustomerLiabilitiesTableTextBlock_efd08a2f-6981-4345-ac7d-c3c1c2f489be_terseLabel_en-US" xlink:label="lab_brns_ContractWithCustomerLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of changes in contract liabilities</link:label>
    <link:label id="lab_brns_ContractWithCustomerLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_brns_ContractWithCustomerLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract With Customer Liabilities [Table Text Block]</link:label>
    <link:label id="lab_brns_ContractWithCustomerLiabilitiesTableTextBlock_documentation_en-US" xlink:label="lab_brns_ContractWithCustomerLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The tabular disclosure of contract with customer liability.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ContractWithCustomerLiabilitiesTableTextBlock" xlink:href="brns-20231231.xsd#brns_ContractWithCustomerLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_ContractWithCustomerLiabilitiesTableTextBlock" xlink:to="lab_brns_ContractWithCustomerLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_8d83e09a-5a9d-4ad0-ab5c-afb8d4139f4e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_ecfe8f06-cf4f-4cee-a615-49221ddecaf3_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_69f49d84-958c-43b6-b316-44d66f69ef86_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employer contribution</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueOther_e91216ae-4a97-4d9b-8e9e-697cf08d940d_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issue of ordinary shares, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueOther_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueOther" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_ScheduleOfOrdinarySharesReservedForFutureIssuanceTableTextBlock_ce769dfd-94cb-48e7-b305-d9e85b07c3d0_terseLabel_en-US" xlink:label="lab_brns_ScheduleOfOrdinarySharesReservedForFutureIssuanceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of ordinary shares reserved for future issuance</link:label>
    <link:label id="lab_brns_ScheduleOfOrdinarySharesReservedForFutureIssuanceTableTextBlock_label_en-US" xlink:label="lab_brns_ScheduleOfOrdinarySharesReservedForFutureIssuanceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Ordinary Shares Reserved For Future Issuance [Table Text Block]</link:label>
    <link:label id="lab_brns_ScheduleOfOrdinarySharesReservedForFutureIssuanceTableTextBlock_documentation_en-US" xlink:label="lab_brns_ScheduleOfOrdinarySharesReservedForFutureIssuanceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The tabular disclosure of ordinary shares reserved for future issuance.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ScheduleOfOrdinarySharesReservedForFutureIssuanceTableTextBlock" xlink:href="brns-20231231.xsd#brns_ScheduleOfOrdinarySharesReservedForFutureIssuanceTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_ScheduleOfOrdinarySharesReservedForFutureIssuanceTableTextBlock" xlink:to="lab_brns_ScheduleOfOrdinarySharesReservedForFutureIssuanceTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_eacf74a9-6c7f-46cb-87dd-a2020d728164_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyDisclosureTextBlock_8a607ac4-6736-4cca-be4e-27764a150e08_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Currency Translation in General and Administrative Expenses</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyDisclosureTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_fa7dc667-a664-432b-84fd-8634bc90fa69_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_23b4ead1-14ee-467f-b3e1-0f7aa3914368_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Amounts owed to other party</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_5887b117-d8ed-4957-8baf-0d0bc5605df6_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable, Weighted-average remaining contractual term (Years) (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_20326062-abfa-41c4-a087-59f099b704e5_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other income, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_ce0f9765-9c75-4640-b47f-3caffe779af6_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statutory tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_6e95bbb7-2793-4b2e-bc18-d73396dfef2d_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies (Note 16)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_e1c4cf66-39ce-42c8-be46-cbeb9d616239_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable at the end of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_e3f2d1f4-661c-49ff-ba43-7167b9c43488_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_c6d19a01-1a00-437c-9733-b60ae9005ec3_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ordinary Shares</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_020f2b44-7fb6-453c-94e0-59c410c7971c_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issue of ordinary shares, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_9dba263e-1d86-4c4f-8a56-1c2fb5675ab6_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_fb21f2fb-9185-4450-8b44-29b8c2de1ed1_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_2d34d4e0-f3aa-4b80-8812-6b1e5d98bf6e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_949aa015-4843-417d-8028-684aac99c5aa_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_LaboratoryEquipmentMember_cf969ff8-5eb6-4b6f-9d9d-b11c9b95fed5_terseLabel_en-US" xlink:label="lab_brns_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Laboratory equipment</link:label>
    <link:label id="lab_brns_LaboratoryEquipmentMember_label_en-US" xlink:label="lab_brns_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
    <link:label id="lab_brns_LaboratoryEquipmentMember_documentation_en-US" xlink:label="lab_brns_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This member stands for laboratory equipment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_LaboratoryEquipmentMember" xlink:href="brns-20231231.xsd#brns_LaboratoryEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_LaboratoryEquipmentMember" xlink:to="lab_brns_LaboratoryEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_882e77a2-213f-45c3-bba3-3c22e526895b_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_b5a87289-7569-42d0-8029-1b96d6612c18_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_fd0a6da9-eaa0-4fa6-a8c6-85379176ffb6_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_b8f1bbb1-e738-4861-aa9a-727f3f9d05c3_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_d1b3b9ac-0c42-4016-8d23-1f3d58c11d4d_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_5bca0085-ef23-494a-9b08-81b3efffcefd_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_393a4b15-3998-47c6-9a84-3ef81349faba_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_CoalitionForEpidemicPreparednessInnovationsFundingAgreementMember_3c78e45a-bc10-43f7-bab5-3b2a7233309b_terseLabel_en-US" xlink:label="lab_brns_CoalitionForEpidemicPreparednessInnovationsFundingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CEPI Funding Agreement</link:label>
    <link:label id="lab_brns_CoalitionForEpidemicPreparednessInnovationsFundingAgreementMember_label_en-US" xlink:label="lab_brns_CoalitionForEpidemicPreparednessInnovationsFundingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Coalition for Epidemic Preparedness Innovations Funding Agreement [Member]</link:label>
    <link:label id="lab_brns_CoalitionForEpidemicPreparednessInnovationsFundingAgreementMember_documentation_en-US" xlink:label="lab_brns_CoalitionForEpidemicPreparednessInnovationsFundingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Coalition for Epidemic Preparedness Innovations Funding Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_CoalitionForEpidemicPreparednessInnovationsFundingAgreementMember" xlink:href="brns-20231231.xsd#brns_CoalitionForEpidemicPreparednessInnovationsFundingAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_CoalitionForEpidemicPreparednessInnovationsFundingAgreementMember" xlink:to="lab_brns_CoalitionForEpidemicPreparednessInnovationsFundingAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestTable_21ccce46-d3a2-4f15-b882-bdbe79ea9e37_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest [Table]</link:label>
    <link:label id="lab_us-gaap_MinorityInterestTable_label_en-US" xlink:label="lab_us-gaap_MinorityInterestTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestTable" xlink:to="lab_us-gaap_MinorityInterestTable" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_SubsidiariesVOLTMember_9cb392ef-2eaf-4112-b6eb-e9b0913d946a_terseLabel_en-US" xlink:label="lab_brns_SubsidiariesVOLTMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">VOLT</link:label>
    <link:label id="lab_brns_SubsidiariesVOLTMember_label_en-US" xlink:label="lab_brns_SubsidiariesVOLTMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiaries, VOLT [Member]</link:label>
    <link:label id="lab_brns_SubsidiariesVOLTMember_documentation_en-US" xlink:label="lab_brns_SubsidiariesVOLTMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Subsidiaries, VOLT</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_SubsidiariesVOLTMember" xlink:href="brns-20231231.xsd#brns_SubsidiariesVOLTMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_SubsidiariesVOLTMember" xlink:to="lab_brns_SubsidiariesVOLTMember" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_PercentageOfSharesNecessaryToExercisePreemptiveRights_c1198ca6-25c0-46b7-baac-0b476dd05759_terseLabel_en-US" xlink:label="lab_brns_PercentageOfSharesNecessaryToExercisePreemptiveRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of ordinary shares present to exercise preemptive rights</link:label>
    <link:label id="lab_brns_PercentageOfSharesNecessaryToExercisePreemptiveRights_label_en-US" xlink:label="lab_brns_PercentageOfSharesNecessaryToExercisePreemptiveRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Shares Necessary To Exercise Preemptive Rights</link:label>
    <link:label id="lab_brns_PercentageOfSharesNecessaryToExercisePreemptiveRights_documentation_en-US" xlink:label="lab_brns_PercentageOfSharesNecessaryToExercisePreemptiveRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The minimum percentage of shares required to exercise preemptive rights.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_PercentageOfSharesNecessaryToExercisePreemptiveRights" xlink:href="brns-20231231.xsd#brns_PercentageOfSharesNecessaryToExercisePreemptiveRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_PercentageOfSharesNecessaryToExercisePreemptiveRights" xlink:to="lab_brns_PercentageOfSharesNecessaryToExercisePreemptiveRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_8e65202d-4aa3-46c3-913a-e0f2201e9ebc_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_b2865963-d937-4ccc-9cc6-cf0d8ed8f418_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payment of contingent consideration</link:label>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment for Contingent Consideration Liability, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:to="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_a4db9b1f-0754-4725-8f72-9aa20f026a67_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeited/expired (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_37d06993-e0c5-494a-b5f9-d3046958778d_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net (loss)/income per share attributable to ordinary shareholders, diluted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2a6f8b6c-77df-43a5-9100-79fa8994084b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_7488d465-2e0e-45f0-a971-1dd18c1b7f1b_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_4d374d4b-7574-4a54-9063-2e518e4a65fb_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Amounts owned from other party</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_0c4b3ca6-7ae0-4796-9843-ac1ee2f9e9d3_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyAbstract_4a376749-8094-4354-9b78-d3d102597709_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Currency [Abstract]</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyAbstract_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyAbstract" xlink:to="lab_us-gaap_ForeignCurrencyAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_SubsidiaryCumulativeContributionsNoncontrollingOwner_71cdf095-6717-4852-9656-98617a15d9d8_terseLabel_en-US" xlink:label="lab_brns_SubsidiaryCumulativeContributionsNoncontrollingOwner" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cumulative contributions from noncontrolling interest owner</link:label>
    <link:label id="lab_brns_SubsidiaryCumulativeContributionsNoncontrollingOwner_label_en-US" xlink:label="lab_brns_SubsidiaryCumulativeContributionsNoncontrollingOwner" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiary, Cumulative Contributions, Noncontrolling Owner</link:label>
    <link:label id="lab_brns_SubsidiaryCumulativeContributionsNoncontrollingOwner_documentation_en-US" xlink:label="lab_brns_SubsidiaryCumulativeContributionsNoncontrollingOwner" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Subsidiary, Cumulative Contributions, Noncontrolling Owner</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_SubsidiaryCumulativeContributionsNoncontrollingOwner" xlink:href="brns-20231231.xsd#brns_SubsidiaryCumulativeContributionsNoncontrollingOwner"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_SubsidiaryCumulativeContributionsNoncontrollingOwner" xlink:to="lab_brns_SubsidiaryCumulativeContributionsNoncontrollingOwner" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ddb93a0f-e0a3-4b36-a697-733ffaa7f26a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_70fd21bc-5885-4c9c-bd67-36bdd1c712a3_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Shares available for future grants (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c39e336f-e8cd-4ef9-97c3-44d7af94e11a_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding at the beginning of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f9180423-b220-4bdf-bffb-ac3877a996fc_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding at the end of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_9a26af5d-18d0-412a-a633-04e3222296af_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued payroll and employee benefits</link:label>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Employee Benefits, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_ExpensesMember_223ebd5f-64f4-4939-b9e5-e4663dcde68e_terseLabel_en-US" xlink:label="lab_brns_ExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expenses</link:label>
    <link:label id="lab_brns_ExpensesMember_label_en-US" xlink:label="lab_brns_ExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expenses [Member]</link:label>
    <link:label id="lab_brns_ExpensesMember_documentation_en-US" xlink:label="lab_brns_ExpensesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ExpensesMember" xlink:href="brns-20231231.xsd#brns_ExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_ExpensesMember" xlink:to="lab_brns_ExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_86ac942f-e4e0-4e15-8031-0a8126d11e3c_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_439a2417-147b-452a-b090-875b273cf03c_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_666bb38e-c58c-444c-b247-4783c09932b6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of options granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f9879160-989e-40ce-b33c-a6b4fa08b4aa_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average grant date fair value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_53c131b9-63e0-41a6-a32d-8aa9e2f26803_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_DeferredStockSharesOutstanding_652b94f2-18f0-41dc-9b81-faf10a918866_terseLabel_en-US" xlink:label="lab_brns_DeferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred shares, outstanding (in shares)</link:label>
    <link:label id="lab_brns_DeferredStockSharesOutstanding_label_en-US" xlink:label="lab_brns_DeferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Stock, Shares Outstanding</link:label>
    <link:label id="lab_brns_DeferredStockSharesOutstanding_documentation_en-US" xlink:label="lab_brns_DeferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of shares of deferred stock outstanding.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredStockSharesOutstanding" xlink:href="brns-20231231.xsd#brns_DeferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_DeferredStockSharesOutstanding" xlink:to="lab_brns_DeferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_961ae109-bfd8-40db-a912-3bf4a8f6c6dc_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net (loss)/income attributable to Barinthus Biotherapeutics plc shareholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_230c3e11-5762-49a3-9e9d-ee2a242ed9c7_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_eedfc9dc-5881-45dd-a538-7542ffce7997_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_9f167dcc-a09c-4899-a893-a3a447d88426_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssued_0337c03e-d9b6-497c-81f2-9c836b3d24e9_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_d4f32a40-bf52-4468-a9b1-d9e822573b9a_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_label_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_48462ba1-bf7c-48cc-a331-e27aa66fa64e_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_ed54765d-2426-43c9-bde4-87243cff8142_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_ae6874c0-5051-4ffc-af96-9a364b134180_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_a6a8500f-e308-4a94-99b9-95283e3dabe7_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b7b09f93-4f30-4cad-a651-4265624e0188_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_7ad945bb-1dd3-4acd-96c3-04756de5583c_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_d7f56e99-cc2d-4b4b-b612-b33d958d9e02_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_4ccc8d05-cfac-4008-89b9-a8030dedd672_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">United Kingdom</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_OrdinarySharesLiquidationPreference_5bb29779-9639-44a0-84e0-57478aea55f9_terseLabel_en-US" xlink:label="lab_brns_OrdinarySharesLiquidationPreference" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ordinary shares, liquidation preference</link:label>
    <link:label id="lab_brns_OrdinarySharesLiquidationPreference_label_en-US" xlink:label="lab_brns_OrdinarySharesLiquidationPreference" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ordinary Shares, Liquidation Preference</link:label>
    <link:label id="lab_brns_OrdinarySharesLiquidationPreference_documentation_en-US" xlink:label="lab_brns_OrdinarySharesLiquidationPreference" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of liquidation preference on ordinary shares to be paid after which the deferred shares have the entitlement to receive out of the assets of the Company.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_OrdinarySharesLiquidationPreference" xlink:href="brns-20231231.xsd#brns_OrdinarySharesLiquidationPreference"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_OrdinarySharesLiquidationPreference" xlink:to="lab_brns_OrdinarySharesLiquidationPreference" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_e666d935-3e1e-4de7-8037-a11b9a0c00cb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of computation of basic and diluted net (loss)/income per share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_ea2cd79f-28df-43b7-9293-22a508d8eca5_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amounts of related party transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Amounts of Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_0f949aae-7624-4855-abca-d5233d94db76_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_83c1bb63-8d5c-46ce-b21f-32e165ed33be_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_26eb5036-4f59-4ee6-981a-50b774c8fc2c_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of exchange rates on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_83a8cd75-feef-47f4-85bd-c810177aea43_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsTable" xlink:to="lab_us-gaap_OtherCommitmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_f7c91ac9-2e6a-462d-a045-182548cac77d_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1bad873a-1871-489d-92c0-1821736fb846_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_79e13bb6-56f0-4602-9965-85bcf5da4ede_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_93d97e0b-5e2c-41ae-829b-1a71a01ed8d1_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_80dc4cfd-4b44-43e8-82cc-6bfc28f075e9_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_d76b5340-aac3-4b46-bce4-3f65eca0cfb7_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_512907c8-ffb0-42c1-8073-1944b30842e6_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_747a15d6-bf12-4e51-b3aa-4107cc664f22_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_ContingentConsiderationSettledInEquity_bc7353c4-4685-42db-9059-1f5b09bfcdb6_terseLabel_en-US" xlink:label="lab_brns_ContingentConsiderationSettledInEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent Consideration settled in equity</link:label>
    <link:label id="lab_brns_ContingentConsiderationSettledInEquity_label_en-US" xlink:label="lab_brns_ContingentConsiderationSettledInEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Consideration Settled in Equity</link:label>
    <link:label id="lab_brns_ContingentConsiderationSettledInEquity_documentation_en-US" xlink:label="lab_brns_ContingentConsiderationSettledInEquity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of contingent consideration settled in equity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ContingentConsiderationSettledInEquity" xlink:href="brns-20231231.xsd#brns_ContingentConsiderationSettledInEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_ContingentConsiderationSettledInEquity" xlink:to="lab_brns_ContingentConsiderationSettledInEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_06f4214c-9609-4c1c-a128-4acc88dbf17e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock_4aeefe5b-d17f-46cc-8dd9-185eae90777f_terseLabel_en-US" xlink:label="lab_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allowance for credit losses</link:label>
    <link:label id="lab_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Loss, Financial Instrument [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditLossFinancialInstrumentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock" xlink:to="lab_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2a3218a6-5995-4e49-8379-9c56957102a1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares available for future stock incentive plan awards</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_EnterpriseManagementIncentiveShareOptionSchemeMember_e3a1df17-19d9-4d38-8c50-91db64b5e674_terseLabel_en-US" xlink:label="lab_brns_EnterpriseManagementIncentiveShareOptionSchemeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Enterprise Management Incentive Share Option Scheme</link:label>
    <link:label id="lab_brns_EnterpriseManagementIncentiveShareOptionSchemeMember_label_en-US" xlink:label="lab_brns_EnterpriseManagementIncentiveShareOptionSchemeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Enterprise Management Incentive Share Option Scheme [Member]</link:label>
    <link:label id="lab_brns_EnterpriseManagementIncentiveShareOptionSchemeMember_documentation_en-US" xlink:label="lab_brns_EnterpriseManagementIncentiveShareOptionSchemeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to the Enterprise Management Incentive Share Option Scheme.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_EnterpriseManagementIncentiveShareOptionSchemeMember" xlink:href="brns-20231231.xsd#brns_EnterpriseManagementIncentiveShareOptionSchemeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_EnterpriseManagementIncentiveShareOptionSchemeMember" xlink:to="lab_brns_EnterpriseManagementIncentiveShareOptionSchemeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock_1cbeecd9-162a-4f3b-9a79-e5ed70283119_terseLabel_en-US" xlink:label="lab_brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of accrued expenses and other current liabilities</link:label>
    <link:label id="lab_brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities And Other Current Liabilities [Table Text Block]</link:label>
    <link:label id="lab_brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock_documentation_en-US" xlink:label="lab_brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure of the components of accrued liabilities and other current liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" xlink:href="brns-20231231.xsd#brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" xlink:to="lab_brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_efadae32-a7ef-4f57-b045-fbbded43970b_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1043885a-d32a-4aa9-a837-f1c9cd3bdbcf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of options granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_b7097b5f-9403-416b-a2c5-8b38c4581c9d_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_f60740c2-3d86-411e-a94a-346386932690_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated annual amortization expense for 2027</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_3588249b-7207-4469-8ac4-e476babc00b2_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_a8b20cd9-6dd4-4c32-be30-8f232cb01389_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable (including related parties)</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_111822d2-e99f-4c99-8149-e3ac46df7f71_negatedLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Unrealized foreign exchange loss/(gain)</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized Gain (Loss), Foreign Currency Transaction, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_2eb1ebfb-2e7d-404c-abda-fa8677cd6639_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_b5166e3f-8fcc-4c3c-b13f-f561ac2d0a04_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share based compensation</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_523b7714-795a-4900-8202-466f8fd192cc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Settlement of contingency</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_711ec784-1419-485a-9d24-fab5289f6156_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liability - non-current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_8eee2517-94ea-4590-b7d3-f17273f40151_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Lease liability, noncurrent</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_PeriodOfPreemptiveRightsToBeExercised_ed1fd542-3f1c-417f-adbb-1bc9c4711063_terseLabel_en-US" xlink:label="lab_brns_PeriodOfPreemptiveRightsToBeExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum period to exercise preemptive rights</link:label>
    <link:label id="lab_brns_PeriodOfPreemptiveRightsToBeExercised_label_en-US" xlink:label="lab_brns_PeriodOfPreemptiveRightsToBeExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Period Of Preemptive Rights To Be Exercised</link:label>
    <link:label id="lab_brns_PeriodOfPreemptiveRightsToBeExercised_documentation_en-US" xlink:label="lab_brns_PeriodOfPreemptiveRightsToBeExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The period allowed to exercise preemptive rights.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_PeriodOfPreemptiveRightsToBeExercised" xlink:href="brns-20231231.xsd#brns_PeriodOfPreemptiveRightsToBeExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_PeriodOfPreemptiveRightsToBeExercised" xlink:to="lab_brns_PeriodOfPreemptiveRightsToBeExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_f6af1aef-4513-4fab-9fec-123904dc0a9e_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RSU's</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_eba8927e-d7e2-4c2f-ba49-178396d845e1_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_99b8b56d-69fc-40ee-82ac-09db7d4550c6_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_9145e248-9190-4220-94e2-71e47cff9ea4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_c033a3b0-fb16-4645-9ddc-c191d9194005_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_DeferredStockSharesAuthorized_face521e-c964-4ec1-8633-d93bbebea9e1_terseLabel_en-US" xlink:label="lab_brns_DeferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred shares, authorized (in shares)</link:label>
    <link:label id="lab_brns_DeferredStockSharesAuthorized_label_en-US" xlink:label="lab_brns_DeferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Stock, Shares Authorized</link:label>
    <link:label id="lab_brns_DeferredStockSharesAuthorized_documentation_en-US" xlink:label="lab_brns_DeferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The maximum number of deferred shares permitted to be issued by an entity's charter and bylaws.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredStockSharesAuthorized" xlink:href="brns-20231231.xsd#brns_DeferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_DeferredStockSharesAuthorized" xlink:to="lab_brns_DeferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_DeferredTaxLiabilityNet_ee688679-9011-4576-9ede-76c2e1456e2b_terseLabel_en-US" xlink:label="lab_brns_DeferredTaxLiabilityNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liability, net</link:label>
    <link:label id="lab_brns_DeferredTaxLiabilityNet_label_en-US" xlink:label="lab_brns_DeferredTaxLiabilityNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liability, Net</link:label>
    <link:label id="lab_brns_DeferredTaxLiabilityNet_documentation_en-US" xlink:label="lab_brns_DeferredTaxLiabilityNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of classified as non-current liabilities, net value of deferred tax liability.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredTaxLiabilityNet" xlink:href="brns-20231231.xsd#brns_DeferredTaxLiabilityNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_DeferredTaxLiabilityNet" xlink:to="lab_brns_DeferredTaxLiabilityNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ba0de88e-be57-4601-88bb-7fcf7fe4392b_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1dedf298-21e3-46e7-9260-84b32ca73193_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of maturities of minimum lease liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_NonCashLeaseExpenses_e9617f89-e658-407f-85f9-c618c6a499ad_terseLabel_en-US" xlink:label="lab_brns_NonCashLeaseExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash lease expenses</link:label>
    <link:label id="lab_brns_NonCashLeaseExpenses_label_en-US" xlink:label="lab_brns_NonCashLeaseExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Cash Lease Expenses</link:label>
    <link:label id="lab_brns_NonCashLeaseExpenses_documentation_en-US" xlink:label="lab_brns_NonCashLeaseExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of non-cash lease expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_NonCashLeaseExpenses" xlink:href="brns-20231231.xsd#brns_NonCashLeaseExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_NonCashLeaseExpenses" xlink:to="lab_brns_NonCashLeaseExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_OxfordUniversityInnovationMember_33c7fb01-8224-43cd-9fb1-862bba58535e_terseLabel_en-US" xlink:label="lab_brns_OxfordUniversityInnovationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Oxford University Innovation</link:label>
    <link:label id="lab_brns_OxfordUniversityInnovationMember_label_en-US" xlink:label="lab_brns_OxfordUniversityInnovationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Oxford University Innovation [Member]</link:label>
    <link:label id="lab_brns_OxfordUniversityInnovationMember_documentation_en-US" xlink:label="lab_brns_OxfordUniversityInnovationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represent information related to Oxford University Innovation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_OxfordUniversityInnovationMember" xlink:href="brns-20231231.xsd#brns_OxfordUniversityInnovationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_OxfordUniversityInnovationMember" xlink:to="lab_brns_OxfordUniversityInnovationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_ad050ff3-39c0-4339-84da-a57330d03592_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock_2424735b-6662-4b68-b649-321b64157ff4_terseLabel_en-US" xlink:label="lab_brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued Expenses and Other Current Liabilities</link:label>
    <link:label id="lab_brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock_label_en-US" xlink:label="lab_brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities And Other Current Liabilities [Text Block]</link:label>
    <link:label id="lab_brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock_documentation_en-US" xlink:label="lab_brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The entire disclosure of the components of accrued liabilities and other current liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock" xlink:href="brns-20231231.xsd#brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock" xlink:to="lab_brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_ff456c90-14d1-43f1-b3b9-a26fb610e4d7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesOther_34d6d3a5-4cf6-4e97-9398-d1bf8213d26a_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issue of ordinary shares, net of issuance costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesOther_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_64e24866-411a-48a1-9adc-06afd0f880c3_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_897c0939-14e7-448e-a12a-b4b5e83748b2_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d15ed097-b6d7-4f42-9291-ffd0d9358d4e_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_5e46f028-265a-4839-b308-ea3d24fc11db_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_583d85b9-778f-432c-a9fb-0f6f2f3868bb_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issuable for stock options that were excluded from the computation of diluted weighted-average shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_1e7f4432-25ba-4bf2-a389-fb49e9ecfec5_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_d35e672f-b612-4203-8a61-c5f8e35a6195_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income recognized</link:label>
    <link:label id="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_label_en-US" xlink:label="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:to="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_ce614ba5-03d7-4dcc-85b6-ed3b6a2a6e0f_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Cash investing and financing activities</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_7380d92f-360d-4b03-82e0-4c2e7ffd0526_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_ba409ac0-78ad-4b66-bc4f-8b65a2074bb4_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment included in accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_fdef4c84-5694-4b9f-a6fa-512afdf92d78_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_8e482e48-cabb-4549-9724-23da1d1d6639_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_cb4f186e-5561-4cb1-977f-09fc559be78c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, at cost</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_4a83ef54-5748-4faa-aaeb-851f0af970bb_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding, Weighted-average remaining contractual term (Years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_9c243502-7501-48dd-9bee-008f3801b3bd_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ROU assets obtained in exchange for operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_679f22e4-ebc7-4ddb-ae75-ab71735dc5f8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_104ee9f1-faad-49bf-acf8-c4639d6424ff_verboseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_cf33ae01-4bfc-410f-a5c2-5745d15c5bca_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_LeaseIncentiveReceivablesCurrent_26d77cae-bb49-4174-b464-3f5cff5f49ea_terseLabel_en-US" xlink:label="lab_brns_LeaseIncentiveReceivablesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease incentives receivable</link:label>
    <link:label id="lab_brns_LeaseIncentiveReceivablesCurrent_label_en-US" xlink:label="lab_brns_LeaseIncentiveReceivablesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Incentive Receivables, Current</link:label>
    <link:label id="lab_brns_LeaseIncentiveReceivablesCurrent_documentation_en-US" xlink:label="lab_brns_LeaseIncentiveReceivablesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This item represents the current receivable for an incentive or inducement contractually stipulated between parties to a lease whereby the lessor has committed to provide the entity (lessee) with a cash payment as inducement to enter the lease. The receivable is due within one year. For classified balance sheets, this element represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_LeaseIncentiveReceivablesCurrent" xlink:href="brns-20231231.xsd#brns_LeaseIncentiveReceivablesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_LeaseIncentiveReceivablesCurrent" xlink:to="lab_brns_LeaseIncentiveReceivablesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_6500af2c-a5d7-4f27-a7ca-74501af2e91e_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_670cea30-1b38-41fe-9691-c10eee98a7fb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of components of income tax benefit (expense)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_514fb602-f995-44b2-adb9-5e631681c2ba_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_GrantIncomePolicyPolicyTextBlock_3b5eb23a-716d-40d9-9aaf-ac60847cd189_terseLabel_en-US" xlink:label="lab_brns_GrantIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grant Income</link:label>
    <link:label id="lab_brns_GrantIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_brns_GrantIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Grant Income, Policy [Policy Text Block]</link:label>
    <link:label id="lab_brns_GrantIncomePolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_brns_GrantIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Grant Income, Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_GrantIncomePolicyPolicyTextBlock" xlink:href="brns-20231231.xsd#brns_GrantIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_GrantIncomePolicyPolicyTextBlock" xlink:to="lab_brns_GrantIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_0782abe8-4f58-4f11-ad08-3d61de1eea0b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_7975397c-101f-420d-880a-3933d2235016_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_892f7ce9-156c-48c7-ba2b-bee1eec2da8f_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepayments and accrued income</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_f06236cd-7c65-42a4-9ca8-ca8c9e6d00b9_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liability - current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_2ca18a4b-325c-43d1-bcc4-f9f388c7aa99_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Lease liability, current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseMember_4be913b4-cf6a-434f-ad17-9d6bbdabf742_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License revenue</link:label>
    <link:label id="lab_us-gaap_LicenseMember_label_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember" xlink:to="lab_us-gaap_LicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_DeferredStockParOrStatedValuePerShare_89ed12f5-a4b1-4bd1-9e78-d353219edc0f_terseLabel_en-US" xlink:label="lab_brns_DeferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred shares, nominal value (in gbp per share)</link:label>
    <link:label id="lab_brns_DeferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_brns_DeferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Stock, Par Or Stated Value Per Share</link:label>
    <link:label id="lab_brns_DeferredStockParOrStatedValuePerShare_documentation_en-US" xlink:label="lab_brns_DeferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Face amount or stated value per share of deferred stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredStockParOrStatedValuePerShare" xlink:href="brns-20231231.xsd#brns_DeferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_DeferredStockParOrStatedValuePerShare" xlink:to="lab_brns_DeferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_379f8b44-4040-4c9f-ac61-4dbe80a86482_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_ContingentConsiderationLiabilityMember_16b30472-50be-422b-93e8-e89099b3271c_terseLabel_en-US" xlink:label="lab_brns_ContingentConsiderationLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration liability</link:label>
    <link:label id="lab_brns_ContingentConsiderationLiabilityMember_label_en-US" xlink:label="lab_brns_ContingentConsiderationLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Consideration Liability [Member]</link:label>
    <link:label id="lab_brns_ContingentConsiderationLiabilityMember_documentation_en-US" xlink:label="lab_brns_ContingentConsiderationLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the information pertaining to contingent consideration liability.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ContingentConsiderationLiabilityMember" xlink:href="brns-20231231.xsd#brns_ContingentConsiderationLiabilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_ContingentConsiderationLiabilityMember" xlink:to="lab_brns_ContingentConsiderationLiabilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_b4558726-abac-4ad9-988f-c1c41acaa36d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_09807b1b-224c-4c6e-924d-64c528fcbe75_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization expense for intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_13563e69-f59e-45b1-a8fb-f96374b35721_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_f0371b61-2a73-4bb4-ad73-722cd05a14de_verboseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_RestrictedShareUnitsStockOptionsShareAppreciationRightsAndRestrictedSharesMember_ab65fcd0-64ad-41b9-a9bd-0802a0530250_terseLabel_en-US" xlink:label="lab_brns_RestrictedShareUnitsStockOptionsShareAppreciationRightsAndRestrictedSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted share units, options, share appreciation rights and restricted shares</link:label>
    <link:label id="lab_brns_RestrictedShareUnitsStockOptionsShareAppreciationRightsAndRestrictedSharesMember_label_en-US" xlink:label="lab_brns_RestrictedShareUnitsStockOptionsShareAppreciationRightsAndRestrictedSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Share Units, Stock Options, Share Appreciation Rights And Restricted Shares [Member]</link:label>
    <link:label id="lab_brns_RestrictedShareUnitsStockOptionsShareAppreciationRightsAndRestrictedSharesMember_documentation_en-US" xlink:label="lab_brns_RestrictedShareUnitsStockOptionsShareAppreciationRightsAndRestrictedSharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to aggregate awards under a specific share-based compensation plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_RestrictedShareUnitsStockOptionsShareAppreciationRightsAndRestrictedSharesMember" xlink:href="brns-20231231.xsd#brns_RestrictedShareUnitsStockOptionsShareAppreciationRightsAndRestrictedSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_RestrictedShareUnitsStockOptionsShareAppreciationRightsAndRestrictedSharesMember" xlink:to="lab_brns_RestrictedShareUnitsStockOptionsShareAppreciationRightsAndRestrictedSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_c45c626b-3969-40a1-a50f-a009dc00bf8b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_1b727047-0ddb-4667-8f00-d67477bf37dc_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_97d003e3-beea-45cc-a5bc-c4b493cf45b5_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_cad63cc0-c1e7-4f0a-a139-e36a469dfb2b_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_ResearchAndDevelopmentServicesPolicyPolicyTextBlock_3ba26a50-8312-4af0-8c9e-32d2994c9c65_terseLabel_en-US" xlink:label="lab_brns_ResearchAndDevelopmentServicesPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development services</link:label>
    <link:label id="lab_brns_ResearchAndDevelopmentServicesPolicyPolicyTextBlock_label_en-US" xlink:label="lab_brns_ResearchAndDevelopmentServicesPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Services, Policy [Policy Text Block]</link:label>
    <link:label id="lab_brns_ResearchAndDevelopmentServicesPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_brns_ResearchAndDevelopmentServicesPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of accounting policy for research and development services.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ResearchAndDevelopmentServicesPolicyPolicyTextBlock" xlink:href="brns-20231231.xsd#brns_ResearchAndDevelopmentServicesPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_ResearchAndDevelopmentServicesPolicyPolicyTextBlock" xlink:to="lab_brns_ResearchAndDevelopmentServicesPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_d41fdb44-974b-4512-b99b-3620777ec368_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_008794bb-a973-4ee8-b79e-31e73ae55e08_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, beginning of the year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3b5d2f06-b357-4c95-88bb-6f0a5f55d341_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, end of the year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_c47cf42c-2645-4338-a31c-c30a229cb03b_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated amortization for amortizable intangible assets</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_3e48271d-4d36-4bad-97ed-ca9ed178b714_verboseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_3288b9bd-1892-44a4-b964-d00d5169922a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of (loss) income before income taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_3da93ec3-a698-491f-a94e-8ef465245f1c_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ordinary shares, public offering price (in usd per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_03d51f34-a149-450f-b28f-fb8e579a2c9f_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_dddbc9ac-4645-45be-b521-b065f8be61fd_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_8a26689d-c394-4cc6-9c38-489440029481_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fixed Lease Costs</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_148a65a5-167c-43d1-afc0-0215fa7d1ce9_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_a6ee87bc-8343-4bd8-a420-1e01537f19ad_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of long-lived assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_c7f48e8c-4ec9-4ace-9e8f-74fe04e60bde_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ordinary shares, issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_ab2a67d5-4197-476e-89b1-51209e5ac42b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of weighted-average assumptions of fair value stock option issued to employees</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_c52aa5d3-ad1e-488a-a9c8-12de45d0faf0_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_dbf596a4-fa35-4dda-a573-c3864c6e81d8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_LesseeOperatingLeaseExtendedTerm_8b941920-cd10-4e91-a169-c0407b37e3a1_terseLabel_en-US" xlink:label="lab_brns_LesseeOperatingLeaseExtendedTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional lease term</link:label>
    <link:label id="lab_brns_LesseeOperatingLeaseExtendedTerm_label_en-US" xlink:label="lab_brns_LesseeOperatingLeaseExtendedTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee Operating Lease, Extended Term</link:label>
    <link:label id="lab_brns_LesseeOperatingLeaseExtendedTerm_documentation_en-US" xlink:label="lab_brns_LesseeOperatingLeaseExtendedTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Term of lessee's operating lease extended, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_LesseeOperatingLeaseExtendedTerm" xlink:href="brns-20231231.xsd#brns_LesseeOperatingLeaseExtendedTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_LesseeOperatingLeaseExtendedTerm" xlink:to="lab_brns_LesseeOperatingLeaseExtendedTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_BarinthusBiotherapeuticsPlcShareAwardPlan2021Member_f6503834-2cfc-4f70-93a2-93d3f23acb02_terseLabel_en-US" xlink:label="lab_brns_BarinthusBiotherapeuticsPlcShareAwardPlan2021Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Barinthus Biotherapeutics plc Share Award Plan 2021</link:label>
    <link:label id="lab_brns_BarinthusBiotherapeuticsPlcShareAwardPlan2021Member_label_en-US" xlink:label="lab_brns_BarinthusBiotherapeuticsPlcShareAwardPlan2021Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Barinthus Biotherapeutics plc Share Award Plan 2021 [Member]</link:label>
    <link:label id="lab_brns_BarinthusBiotherapeuticsPlcShareAwardPlan2021Member_documentation_en-US" xlink:label="lab_brns_BarinthusBiotherapeuticsPlcShareAwardPlan2021Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Barinthus Biotherapeutics plc Share Award Plan 2021</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_BarinthusBiotherapeuticsPlcShareAwardPlan2021Member" xlink:href="brns-20231231.xsd#brns_BarinthusBiotherapeuticsPlcShareAwardPlan2021Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_BarinthusBiotherapeuticsPlcShareAwardPlan2021Member" xlink:to="lab_brns_BarinthusBiotherapeuticsPlcShareAwardPlan2021Member" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_AmericanDepositarySharesMember_e78705b8-b178-4e1c-9055-7f3da7265b59_terseLabel_en-US" xlink:label="lab_brns_AmericanDepositarySharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">American Depositary Shares</link:label>
    <link:label id="lab_brns_AmericanDepositarySharesMember_label_en-US" xlink:label="lab_brns_AmericanDepositarySharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">American Depositary Shares [Member]</link:label>
    <link:label id="lab_brns_AmericanDepositarySharesMember_documentation_en-US" xlink:label="lab_brns_AmericanDepositarySharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the information pertaining to american depositary shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_AmericanDepositarySharesMember" xlink:href="brns-20231231.xsd#brns_AmericanDepositarySharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_AmericanDepositarySharesMember" xlink:to="lab_brns_AmericanDepositarySharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_4f199041-b411-4c9f-9acd-364cd6135ca7_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_9523a15c-7a0f-48ce-9472-b34e2dcc33bb_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average period over which unrecognized compensation cost is expected to be recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_5d7713fa-e236-4da4-a742-19ceb5c170b5_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_d4942343-bb10-4e85-b182-2c6ee453e6e6_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss attributable to Barinthus Biotherapeutics plc shareholders</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_ec6d222d-0225-4f83-b736-ad286355692b_terseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_e4f3f725-2b5e-4056-afd8-f817d33f3814_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_d37ebd26-f35f-4992-a0ba-50fb6d9ba0cb_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term lease costs</link:label>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_label_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-Term Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermLeaseCost" xlink:to="lab_us-gaap_ShortTermLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_924a4809-3d68-42f2-9574-720654f9c12e_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Domestic Tax Authority</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_DeferredTaxAssetsLeasingArrangements_a5a50fe2-bdac-4102-9852-8e79d8bc3311_terseLabel_en-US" xlink:label="lab_brns_DeferredTaxAssetsLeasingArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liability</link:label>
    <link:label id="lab_brns_DeferredTaxAssetsLeasingArrangements_label_en-US" xlink:label="lab_brns_DeferredTaxAssetsLeasingArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Leasing Arrangements</link:label>
    <link:label id="lab_brns_DeferredTaxAssetsLeasingArrangements_documentation_en-US" xlink:label="lab_brns_DeferredTaxAssetsLeasingArrangements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to lease liability.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredTaxAssetsLeasingArrangements" xlink:href="brns-20231231.xsd#brns_DeferredTaxAssetsLeasingArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_DeferredTaxAssetsLeasingArrangements" xlink:to="lab_brns_DeferredTaxAssetsLeasingArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_a11bd824-fe17-4518-b349-4e20edc48da6_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_1e78577a-fc59-44a9-a64d-2e59225a9214_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_3fe9de9b-a165-4dde-9892-930dfab4f379_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_AdjustmentsToAdditionalPaidInCapitalMeasurementPeriodAdjustmentsInBusinessCombination_360c345c-bb47-443d-9201-d4159a69da75_terseLabel_en-US" xlink:label="lab_brns_AdjustmentsToAdditionalPaidInCapitalMeasurementPeriodAdjustmentsInBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement period and contingent consideration adjustments</link:label>
    <link:label id="lab_brns_AdjustmentsToAdditionalPaidInCapitalMeasurementPeriodAdjustmentsInBusinessCombination_label_en-US" xlink:label="lab_brns_AdjustmentsToAdditionalPaidInCapitalMeasurementPeriodAdjustmentsInBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Measurement Period Adjustments in Business Combination,</link:label>
    <link:label id="lab_brns_AdjustmentsToAdditionalPaidInCapitalMeasurementPeriodAdjustmentsInBusinessCombination_documentation_en-US" xlink:label="lab_brns_AdjustmentsToAdditionalPaidInCapitalMeasurementPeriodAdjustmentsInBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of increase (decrease) to additional paid in capital (APIC) resulting from measurement period adjustment in business combination.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_AdjustmentsToAdditionalPaidInCapitalMeasurementPeriodAdjustmentsInBusinessCombination" xlink:href="brns-20231231.xsd#brns_AdjustmentsToAdditionalPaidInCapitalMeasurementPeriodAdjustmentsInBusinessCombination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_AdjustmentsToAdditionalPaidInCapitalMeasurementPeriodAdjustmentsInBusinessCombination" xlink:to="lab_brns_AdjustmentsToAdditionalPaidInCapitalMeasurementPeriodAdjustmentsInBusinessCombination" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_e066697f-2b9d-474a-bebf-c94de9745644_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_bb2ca0d0-0e4a-4a30-9aca-004800e179e3_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Controlling interest (as a percent)</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiary, Ownership Percentage, Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_57357659-52de-4343-8b6c-d27214bb2fdf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted- average Exercise Price Per Option</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_70225fde-fc5f-4dc5-b9e4-14af78678ff8_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_VOLTMember_4d32ac4f-be8e-4aa3-aa0d-3ce44347670c_terseLabel_en-US" xlink:label="lab_brns_VOLTMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">VOLT</link:label>
    <link:label id="lab_brns_VOLTMember_label_en-US" xlink:label="lab_brns_VOLTMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">VOLT [Member]</link:label>
    <link:label id="lab_brns_VOLTMember_documentation_en-US" xlink:label="lab_brns_VOLTMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represent of VOLT Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_VOLTMember" xlink:href="brns-20231231.xsd#brns_VOLTMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_VOLTMember" xlink:to="lab_brns_VOLTMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_ea0222f3-2fa6-49c1-85f6-edd95451565e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_0d079157-5516-4b85-8217-1af0065b29e3_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_3b42838b-c331-411c-9f38-32f06b383b9b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_7aefd332-6d32-4eb3-b171-c49e26ea40de_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Deferred Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable_620822ae-5855-4216-ac72-e85df0390c2d_negatedLabel_en-US" xlink:label="lab_brns_IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Research and development incentives receivable</link:label>
    <link:label id="lab_brns_IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable_label_en-US" xlink:label="lab_brns_IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Research and Development Incentives Receivable</link:label>
    <link:label id="lab_brns_IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable_documentation_en-US" xlink:label="lab_brns_IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of increase (decrease) in research and development incentives receivable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable" xlink:href="brns-20231231.xsd#brns_IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable" xlink:to="lab_brns_IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_1a3ed57c-5151-4a61-a9a4-ed1228a38577_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_IncomeTaxesLineItems_4beae884-0b06-4b18-bcf7-0ea7306543f0_terseLabel_en-US" xlink:label="lab_brns_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes [Line Items]</link:label>
    <link:label id="lab_brns_IncomeTaxesLineItems_label_en-US" xlink:label="lab_brns_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes [Line Items]</link:label>
    <link:label id="lab_brns_IncomeTaxesLineItems_documentation_en-US" xlink:label="lab_brns_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income Taxes [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_IncomeTaxesLineItems" xlink:href="brns-20231231.xsd#brns_IncomeTaxesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_IncomeTaxesLineItems" xlink:to="lab_brns_IncomeTaxesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsGross_695a18f8-f13b-4f91-9040-fcb1c2761676_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold improvement expense</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsGross_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsGross" xlink:to="lab_us-gaap_LeaseholdImprovementsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValueAddedTaxReceivableCurrent_eaedabb8-e866-4f85-af29-039b9fb2be14_terseLabel_en-US" xlink:label="lab_us-gaap_ValueAddedTaxReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Value Added Tax receivable</link:label>
    <link:label id="lab_us-gaap_ValueAddedTaxReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_ValueAddedTaxReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Value Added Tax Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValueAddedTaxReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValueAddedTaxReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValueAddedTaxReceivableCurrent" xlink:to="lab_us-gaap_ValueAddedTaxReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_DeferredStockValueIssued_06cd4bf3-1b11-4f18-a770-2bc82b039ca8_terseLabel_en-US" xlink:label="lab_brns_DeferredStockValueIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred shares</link:label>
    <link:label id="lab_brns_DeferredStockValueIssued_label_en-US" xlink:label="lab_brns_DeferredStockValueIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Stock, Value Issued</link:label>
    <link:label id="lab_brns_DeferredStockValueIssued_documentation_en-US" xlink:label="lab_brns_DeferredStockValueIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Aggregate par or stated value of issued deferred stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredStockValueIssued" xlink:href="brns-20231231.xsd#brns_DeferredStockValueIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_DeferredStockValueIssued" xlink:to="lab_brns_DeferredStockValueIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_03d09e66-2698-4034-915a-8b6f5a00850e_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_MaximumAggregateNominalAmountOfSharesAuthorizedToBeAllottedFreeFromStatutoryPreEmptionRights_6591bcb7-f04d-40bb-8610-ae7f39e198c5_terseLabel_en-US" xlink:label="lab_brns_MaximumAggregateNominalAmountOfSharesAuthorizedToBeAllottedFreeFromStatutoryPreEmptionRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum aggregate nominal amount of shares authorized to be allotted free from pre-emption rights</link:label>
    <link:label id="lab_brns_MaximumAggregateNominalAmountOfSharesAuthorizedToBeAllottedFreeFromStatutoryPreEmptionRights_label_en-US" xlink:label="lab_brns_MaximumAggregateNominalAmountOfSharesAuthorizedToBeAllottedFreeFromStatutoryPreEmptionRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum Aggregate Nominal Amount Of Shares Authorized To Be Allotted Free From Statutory Pre-emption Rights</link:label>
    <link:label id="lab_brns_MaximumAggregateNominalAmountOfSharesAuthorizedToBeAllottedFreeFromStatutoryPreEmptionRights_documentation_en-US" xlink:label="lab_brns_MaximumAggregateNominalAmountOfSharesAuthorizedToBeAllottedFreeFromStatutoryPreEmptionRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of maximum aggregate nominal amount of shares that the board of directors are authorized to allot free from statutory Pre-emption rights.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_MaximumAggregateNominalAmountOfSharesAuthorizedToBeAllottedFreeFromStatutoryPreEmptionRights" xlink:href="brns-20231231.xsd#brns_MaximumAggregateNominalAmountOfSharesAuthorizedToBeAllottedFreeFromStatutoryPreEmptionRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_MaximumAggregateNominalAmountOfSharesAuthorizedToBeAllottedFreeFromStatutoryPreEmptionRights" xlink:to="lab_brns_MaximumAggregateNominalAmountOfSharesAuthorizedToBeAllottedFreeFromStatutoryPreEmptionRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_7be0de4d-2f1b-4ad2-9843-797bef34bbf5_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityPolicyTextBlock_dd26124b-f95b-4c00-ae19-3c1eac9fa7aa_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ordinary shares</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityPolicyTextBlock" xlink:to="lab_us-gaap_StockholdersEquityPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_NumberOfAmericanDepositarySharesAdsIssued_33273cf1-243c-4b32-955b-4c85cb6ade64_terseLabel_en-US" xlink:label="lab_brns_NumberOfAmericanDepositarySharesAdsIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of ADS shares closed (in shares)</link:label>
    <link:label id="lab_brns_NumberOfAmericanDepositarySharesAdsIssued_label_en-US" xlink:label="lab_brns_NumberOfAmericanDepositarySharesAdsIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of American Depositary Shares (ADS) Issued</link:label>
    <link:label id="lab_brns_NumberOfAmericanDepositarySharesAdsIssued_documentation_en-US" xlink:label="lab_brns_NumberOfAmericanDepositarySharesAdsIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the number of ADS shares issued during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_NumberOfAmericanDepositarySharesAdsIssued" xlink:href="brns-20231231.xsd#brns_NumberOfAmericanDepositarySharesAdsIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_NumberOfAmericanDepositarySharesAdsIssued" xlink:to="lab_brns_NumberOfAmericanDepositarySharesAdsIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_OuiLicenseAgreementAmendmentMember_23a13658-adbd-4edd-8b04-268c13516600_terseLabel_en-US" xlink:label="lab_brns_OuiLicenseAgreementAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">OUI</link:label>
    <link:label id="lab_brns_OuiLicenseAgreementAmendmentMember_label_en-US" xlink:label="lab_brns_OuiLicenseAgreementAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OUI License Agreement Amendment [Member]</link:label>
    <link:label id="lab_brns_OuiLicenseAgreementAmendmentMember_documentation_en-US" xlink:label="lab_brns_OuiLicenseAgreementAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The member stands for OUI license agreement amendment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_OuiLicenseAgreementAmendmentMember" xlink:href="brns-20231231.xsd#brns_OuiLicenseAgreementAmendmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_OuiLicenseAgreementAmendmentMember" xlink:to="lab_brns_OuiLicenseAgreementAmendmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_87112091-0524-418e-ad62-cfb3bae51408_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling interest (as a percent)</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiary, Ownership Percentage, Noncontrolling Owner</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_30c2a100-8262-4042-8e14-2668fef30010_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAbstract" xlink:to="lab_us-gaap_NetIncomeLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_5e4e6627-a288-4a13-a85a-2a176efbfc20_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_ContractWithCustomerLiabilityRollForward_b7105424-e138-480b-8b66-b47c630ae32a_terseLabel_en-US" xlink:label="lab_brns_ContractWithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability [Roll Forward]</link:label>
    <link:label id="lab_brns_ContractWithCustomerLiabilityRollForward_label_en-US" xlink:label="lab_brns_ContractWithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability [Roll Forward]</link:label>
    <link:label id="lab_brns_ContractWithCustomerLiabilityRollForward_documentation_en-US" xlink:label="lab_brns_ContractWithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ContractWithCustomerLiabilityRollForward" xlink:href="brns-20231231.xsd#brns_ContractWithCustomerLiabilityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_ContractWithCustomerLiabilityRollForward" xlink:to="lab_brns_ContractWithCustomerLiabilityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_3fe7ec6a-9e0f-493b-a700-8b283e07908b_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_30bf687b-f1a1-4251-af3e-a9754be13a0b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_a47dc8b9-c6b7-433d-88eb-6f3c8627a8d3_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_label_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_ChangesToRightOfUseAssetResultingFromLeaseReassessmentEvent_c52e1dca-234c-4262-b08d-4043bd687628_terseLabel_en-US" xlink:label="lab_brns_ChangesToRightOfUseAssetResultingFromLeaseReassessmentEvent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes to right-of-use asset resulting from lease reassessment event</link:label>
    <link:label id="lab_brns_ChangesToRightOfUseAssetResultingFromLeaseReassessmentEvent_label_en-US" xlink:label="lab_brns_ChangesToRightOfUseAssetResultingFromLeaseReassessmentEvent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changes to right-of-use asset resulting from lease reassessment event</link:label>
    <link:label id="lab_brns_ChangesToRightOfUseAssetResultingFromLeaseReassessmentEvent_documentation_en-US" xlink:label="lab_brns_ChangesToRightOfUseAssetResultingFromLeaseReassessmentEvent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of changes to right-of-use asset resulting from lease reassessment event.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ChangesToRightOfUseAssetResultingFromLeaseReassessmentEvent" xlink:href="brns-20231231.xsd#brns_ChangesToRightOfUseAssetResultingFromLeaseReassessmentEvent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_ChangesToRightOfUseAssetResultingFromLeaseReassessmentEvent" xlink:to="lab_brns_ChangesToRightOfUseAssetResultingFromLeaseReassessmentEvent" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustments_6b74ea91-d307-4363-9d8d-a1dafda33a3f_terseLabel_en-US" xlink:label="lab_brns_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provision to return adjustments</link:label>
    <link:label id="lab_brns_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustments_label_en-US" xlink:label="lab_brns_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Provision to Return Adjustments</link:label>
    <link:label id="lab_brns_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustments_documentation_en-US" xlink:label="lab_brns_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to provision to return adjustments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustments" xlink:href="brns-20231231.xsd#brns_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustments" xlink:to="lab_brns_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e0d1c2aa-40d0-4c2b-8ad6-a1ae1a57197c_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_295bdfdf-fd4e-49b5-8364-4515d00a4b6b_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_cbe64c2e-9513-4480-a995-91ae0fd52c18_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_f7cdb10c-21db-4891-8f0d-1ea8e3a389fa_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_084a7cff-c62f-41d2-b1b6-4d0d4647856f_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_ShareBasedCompensationPercentageOfSharesAvailableForIssuanceAsPercentageOfIssuedAndOutstandingShares_c14ecd57-9f05-4585-9790-d2a69a327923_terseLabel_en-US" xlink:label="lab_brns_ShareBasedCompensationPercentageOfSharesAvailableForIssuanceAsPercentageOfIssuedAndOutstandingShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of issued and outstanding ordinary shares available for issuance</link:label>
    <link:label id="lab_brns_ShareBasedCompensationPercentageOfSharesAvailableForIssuanceAsPercentageOfIssuedAndOutstandingShares_label_en-US" xlink:label="lab_brns_ShareBasedCompensationPercentageOfSharesAvailableForIssuanceAsPercentageOfIssuedAndOutstandingShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation, Percentage Of Shares Available For Issuance As A Percentage Of Issued And Outstanding Shares</link:label>
    <link:label id="lab_brns_ShareBasedCompensationPercentageOfSharesAvailableForIssuanceAsPercentageOfIssuedAndOutstandingShares_documentation_en-US" xlink:label="lab_brns_ShareBasedCompensationPercentageOfSharesAvailableForIssuanceAsPercentageOfIssuedAndOutstandingShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total number of shares available for issuance under the Plan as a percentage of the Company's issued and outstanding shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ShareBasedCompensationPercentageOfSharesAvailableForIssuanceAsPercentageOfIssuedAndOutstandingShares" xlink:href="brns-20231231.xsd#brns_ShareBasedCompensationPercentageOfSharesAvailableForIssuanceAsPercentageOfIssuedAndOutstandingShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_ShareBasedCompensationPercentageOfSharesAvailableForIssuanceAsPercentageOfIssuedAndOutstandingShares" xlink:to="lab_brns_ShareBasedCompensationPercentageOfSharesAvailableForIssuanceAsPercentageOfIssuedAndOutstandingShares" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_c4a4253d-b9b6-47ea-aab0-23a800de9b78_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend_68fd25a8-4d19-41e0-9498-7257a68155f2_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Patent and licensing costs</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Costs Incurred to Renew or Extend, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend" xlink:to="lab_us-gaap_IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_45f799b4-ff97-4344-9186-fe1732c54dec_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_7090382d-af19-4d93-87a8-95a8a62244a1_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ParentMember_f1212037-24f4-4418-96ab-2b20208337ea_terseLabel_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity attributable to Barinthus Biotherapeutics plc stockholders</link:label>
    <link:label id="lab_us-gaap_ParentMember_label_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ParentMember" xlink:to="lab_us-gaap_ParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b181a2fb-98c3-4741-b515-3042a6c63695_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_NonCashInvestingAndFinancingActivityOfMeasurementPeriodAdjustments_fc229f2c-54d0-453d-a70d-b7987065a836_terseLabel_en-US" xlink:label="lab_brns_NonCashInvestingAndFinancingActivityOfMeasurementPeriodAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement period adjustments</link:label>
    <link:label id="lab_brns_NonCashInvestingAndFinancingActivityOfMeasurementPeriodAdjustments_label_en-US" xlink:label="lab_brns_NonCashInvestingAndFinancingActivityOfMeasurementPeriodAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non Cash Investing And Financing Activity Of Measurement Period Adjustments</link:label>
    <link:label id="lab_brns_NonCashInvestingAndFinancingActivityOfMeasurementPeriodAdjustments_documentation_en-US" xlink:label="lab_brns_NonCashInvestingAndFinancingActivityOfMeasurementPeriodAdjustments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of on cash investing and financing activity of measurement period adjustments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_NonCashInvestingAndFinancingActivityOfMeasurementPeriodAdjustments" xlink:href="brns-20231231.xsd#brns_NonCashInvestingAndFinancingActivityOfMeasurementPeriodAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_NonCashInvestingAndFinancingActivityOfMeasurementPeriodAdjustments" xlink:to="lab_brns_NonCashInvestingAndFinancingActivityOfMeasurementPeriodAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_c426c615-c09a-4b8d-ac54-fd6d97eeb8bf_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_09ada785-01db-40fe-86ad-a7083b04e455_negatedLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_47e92a87-5e04-4b05-91da-8774f43bec85_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_43f566ef-caab-46da-8a6d-0088f0ce80d2_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_2189b73b-f14c-4cd0-9656-d0c78097a03d_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecurityDeposit_fb7cf903-ef30-450f-861d-f1a956aca905_terseLabel_en-US" xlink:label="lab_us-gaap_SecurityDeposit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Refundable security deposit</link:label>
    <link:label id="lab_us-gaap_SecurityDeposit_label_en-US" xlink:label="lab_us-gaap_SecurityDeposit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Deposit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecurityDeposit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecurityDeposit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecurityDeposit" xlink:to="lab_us-gaap_SecurityDeposit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_6958593e-1bae-46ab-b8ed-98476993e1f2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsLineItems" xlink:to="lab_us-gaap_OtherCommitmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_9e0a0085-6b44-4f5f-988e-0f820e0ab0b4_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Components of Deferred Tax Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_16ac486e-fe21-47eb-bc0e-ad55d7405fa6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of significant components of deferred tax assets and liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_0194171e-26d3-43fe-863b-e3ecf69c8a0d_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b4a8a8be-0e30-4dd5-b783-67f26e5ee973_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IPOMember_8fa4b6f3-9e9d-4aa1-b476-80b8be41af04_terseLabel_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">IPO</link:label>
    <link:label id="lab_us-gaap_IPOMember_label_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">IPO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember" xlink:to="lab_us-gaap_IPOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_494629d9-7bc9-4c40-b404-42982c1d8fc6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_e6d06bac-32e8-4cfb-ab2b-d9b81d8736c1_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated annual amortization expense for 2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_269ed220-c700-48ae-bfce-11d4da05b087_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating cash flows from operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_fef41044-973d-4ce9-b136-4d8489d1046e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of share based compensation expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_892cbef0-1482-4097-92c2-ce26235414c7_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ordinary shares, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_SharesCancelledDuringPeriodSharesDeferredShares_56016312-09ce-49f9-b5af-8e97d44289c9_negatedTerseLabel_en-US" xlink:label="lab_brns_SharesCancelledDuringPeriodSharesDeferredShares" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cancellation of deferred shares (in shares)</link:label>
    <link:label id="lab_brns_SharesCancelledDuringPeriodSharesDeferredShares_label_en-US" xlink:label="lab_brns_SharesCancelledDuringPeriodSharesDeferredShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Cancelled During Period, Shares, Deferred Shares</link:label>
    <link:label id="lab_brns_SharesCancelledDuringPeriodSharesDeferredShares_documentation_en-US" xlink:label="lab_brns_SharesCancelledDuringPeriodSharesDeferredShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shares Cancelled During Period, Shares, Deferred Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_SharesCancelledDuringPeriodSharesDeferredShares" xlink:href="brns-20231231.xsd#brns_SharesCancelledDuringPeriodSharesDeferredShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_SharesCancelledDuringPeriodSharesDeferredShares" xlink:to="lab_brns_SharesCancelledDuringPeriodSharesDeferredShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_30d45618-f28f-48d8-8317-45643014dbd0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income /(expense):</link:label>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Income and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RegulatoryIncomeTaxesPolicy_836a99bc-e992-4071-9c56-f6e3fd8356f9_terseLabel_en-US" xlink:label="lab_us-gaap_RegulatoryIncomeTaxesPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_RegulatoryIncomeTaxesPolicy_label_en-US" xlink:label="lab_us-gaap_RegulatoryIncomeTaxesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Regulatory Income Taxes, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RegulatoryIncomeTaxesPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RegulatoryIncomeTaxesPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RegulatoryIncomeTaxesPolicy" xlink:to="lab_us-gaap_RegulatoryIncomeTaxesPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_680af202-aca9-415a-808d-c9852a27ff88_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentrations of credit risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_7390fd6e-c206-4285-b5bf-f7f5ff603315_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_8bc60f26-9c00-413f-9e43-00da14cc8c5a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ordinary shares, nominal value (in gbp per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_68837971-49ff-446e-b479-7b8afdce07ce_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Ordinary shares, nominal value (in gbp per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_4ad2a7c7-3aef-4156-ad10-263fbcf6e017_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_d657742b-8808-4199-a2f9-9636c66433e9_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_46a211fd-d31d-447c-87dd-f4b612123986_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_a7fdef3c-cf9d-43af-b2bc-e4f739f9b867_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_MinorityInterestPolicyTextBlock_d8a6ea0a-7544-439e-983b-94fa689a7da0_terseLabel_en-US" xlink:label="lab_brns_MinorityInterestPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling interest</link:label>
    <link:label id="lab_brns_MinorityInterestPolicyTextBlock_label_en-US" xlink:label="lab_brns_MinorityInterestPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minority Interest [Policy Text Block]</link:label>
    <link:label id="lab_brns_MinorityInterestPolicyTextBlock_documentation_en-US" xlink:label="lab_brns_MinorityInterestPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of accounting policy for Minority (Non Controlling) interest.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_MinorityInterestPolicyTextBlock" xlink:href="brns-20231231.xsd#brns_MinorityInterestPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_MinorityInterestPolicyTextBlock" xlink:to="lab_brns_MinorityInterestPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_ExpirationOfShareBasedCompensationPlanFromDateOfInitialIssuance_666abef4-66e0-4d84-90aa-7d284fcf3c4c_terseLabel_en-US" xlink:label="lab_brns_ExpirationOfShareBasedCompensationPlanFromDateOfInitialIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration period</link:label>
    <link:label id="lab_brns_ExpirationOfShareBasedCompensationPlanFromDateOfInitialIssuance_label_en-US" xlink:label="lab_brns_ExpirationOfShareBasedCompensationPlanFromDateOfInitialIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expiration Of Share Based Compensation Plan From Date Of Initial Issuance</link:label>
    <link:label id="lab_brns_ExpirationOfShareBasedCompensationPlanFromDateOfInitialIssuance_documentation_en-US" xlink:label="lab_brns_ExpirationOfShareBasedCompensationPlanFromDateOfInitialIssuance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The duration of grants awarded under a share-based compensation plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ExpirationOfShareBasedCompensationPlanFromDateOfInitialIssuance" xlink:href="brns-20231231.xsd#brns_ExpirationOfShareBasedCompensationPlanFromDateOfInitialIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_ExpirationOfShareBasedCompensationPlanFromDateOfInitialIssuance" xlink:to="lab_brns_ExpirationOfShareBasedCompensationPlanFromDateOfInitialIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_efc484ce-4e97-4575-b88f-a6b307ec190d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Stock Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_91e58788-db42-42cb-bf9d-478098b73be5_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_e55baa73-3d0a-426c-adad-4ffb315a7848_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_f5c3a9d6-0d9a-4da5-8304-c7c83193a9cb_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_eccee1c4-7714-4aef-ae32-1e9e89359916_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_LesseeOperatingLeaseRightOfUseAssetAndOtherInformationTableTextBlock_1c884b1b-fd8f-4938-970d-cd92f05e8a27_terseLabel_en-US" xlink:label="lab_brns_LesseeOperatingLeaseRightOfUseAssetAndOtherInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of right-of-use, lease liabilities and other information</link:label>
    <link:label id="lab_brns_LesseeOperatingLeaseRightOfUseAssetAndOtherInformationTableTextBlock_label_en-US" xlink:label="lab_brns_LesseeOperatingLeaseRightOfUseAssetAndOtherInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee Operating Lease Right of Use asset and Other Information [Table Text Block]</link:label>
    <link:label id="lab_brns_LesseeOperatingLeaseRightOfUseAssetAndOtherInformationTableTextBlock_documentation_en-US" xlink:label="lab_brns_LesseeOperatingLeaseRightOfUseAssetAndOtherInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure for Company's right-of-use asset and lease liability and other information.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_LesseeOperatingLeaseRightOfUseAssetAndOtherInformationTableTextBlock" xlink:href="brns-20231231.xsd#brns_LesseeOperatingLeaseRightOfUseAssetAndOtherInformationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_LesseeOperatingLeaseRightOfUseAssetAndOtherInformationTableTextBlock" xlink:to="lab_brns_LesseeOperatingLeaseRightOfUseAssetAndOtherInformationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_5522d609-0492-4f76-9d1f-005c9b776689_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nature of Business and Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_678ebec8-023d-44d1-833b-cac27e5bdcfb_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_fcb419fa-b711-44d6-9940-dc78077f89f2_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_9ad8f20e-48c4-4a92-9583-0106f9498b9c_totalLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_2ff4c3af-4625-4c07-a016-b548c79286d8_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares reserved for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_e6cddd91-2a60-4f02-b642-8d13083542fd_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_StockholdersEquityDeferredSharesDisclosureTextBlock_d9a4ab5d-ffa5-4343-b92c-f7e13b1dffb7_terseLabel_en-US" xlink:label="lab_brns_StockholdersEquityDeferredSharesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred shares</link:label>
    <link:label id="lab_brns_StockholdersEquityDeferredSharesDisclosureTextBlock_label_en-US" xlink:label="lab_brns_StockholdersEquityDeferredSharesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders Equity Deferred Shares Disclosure [Text Block]</link:label>
    <link:label id="lab_brns_StockholdersEquityDeferredSharesDisclosureTextBlock_documentation_en-US" xlink:label="lab_brns_StockholdersEquityDeferredSharesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The entire disclosure for Deferred Shares as disclosed by the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_StockholdersEquityDeferredSharesDisclosureTextBlock" xlink:href="brns-20231231.xsd#brns_StockholdersEquityDeferredSharesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_StockholdersEquityDeferredSharesDisclosureTextBlock" xlink:to="lab_brns_StockholdersEquityDeferredSharesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_8b03ea81-29bf-444b-93ad-1808da5e7167_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_InLicenseAgreementsMember_93114602-37ba-4106-b627-91814486dce4_terseLabel_en-US" xlink:label="lab_brns_InLicenseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">In-License Agreements</link:label>
    <link:label id="lab_brns_InLicenseAgreementsMember_label_en-US" xlink:label="lab_brns_InLicenseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">In-License Agreements [Member]</link:label>
    <link:label id="lab_brns_InLicenseAgreementsMember_documentation_en-US" xlink:label="lab_brns_InLicenseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the information pertaining to In-License Agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_InLicenseAgreementsMember" xlink:href="brns-20231231.xsd#brns_InLicenseAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_InLicenseAgreementsMember" xlink:to="lab_brns_InLicenseAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseResultingFromForeignCurrencyTranslation_5d086a26-287d-4424-836e-b3fe98d8bbac_terseLabel_en-US" xlink:label="lab_brns_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseResultingFromForeignCurrencyTranslation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign exchange translation</link:label>
    <link:label id="lab_brns_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseResultingFromForeignCurrencyTranslation_label_en-US" xlink:label="lab_brns_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseResultingFromForeignCurrencyTranslation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease) Resulting From Foreign Currency Translation</link:label>
    <link:label id="lab_brns_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseResultingFromForeignCurrencyTranslation_documentation_en-US" xlink:label="lab_brns_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseResultingFromForeignCurrencyTranslation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease) Resulting From Foreign Currency Translation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseResultingFromForeignCurrencyTranslation" xlink:href="brns-20231231.xsd#brns_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseResultingFromForeignCurrencyTranslation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseResultingFromForeignCurrencyTranslation" xlink:to="lab_brns_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseResultingFromForeignCurrencyTranslation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedBonusesCurrent_467628f2-e6bc-4bd0-9322-a7ef1867cf5f_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedBonusesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued bonus</link:label>
    <link:label id="lab_us-gaap_AccruedBonusesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedBonusesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Bonuses, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedBonusesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedBonusesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedBonusesCurrent" xlink:to="lab_us-gaap_AccruedBonusesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_56766aac-a9dc-47b1-bac6-19a3b2187533_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capitalized Research and Development expenditure</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_49c9c75b-da44-429a-b863-c3a826babebe_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets for capitalized research and development expenditure</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, in Process Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_a3f4517d-b8c7-4390-ba85-2432d50472f5_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_e2042e66-8dae-4b91-9b1f-391b93676f0d_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_ContractWithCustomerLiabilityForeignExchangeTranslation_2e05980c-8170-46a5-a139-507f69ea759a_terseLabel_en-US" xlink:label="lab_brns_ContractWithCustomerLiabilityForeignExchangeTranslation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign exchange translation</link:label>
    <link:label id="lab_brns_ContractWithCustomerLiabilityForeignExchangeTranslation_label_en-US" xlink:label="lab_brns_ContractWithCustomerLiabilityForeignExchangeTranslation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract With Customer Liability, Foreign Exchange Translation</link:label>
    <link:label id="lab_brns_ContractWithCustomerLiabilityForeignExchangeTranslation_documentation_en-US" xlink:label="lab_brns_ContractWithCustomerLiabilityForeignExchangeTranslation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of increase (decrease) in contract liabilities due to foreign exchange translations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ContractWithCustomerLiabilityForeignExchangeTranslation" xlink:href="brns-20231231.xsd#brns_ContractWithCustomerLiabilityForeignExchangeTranslation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_ContractWithCustomerLiabilityForeignExchangeTranslation" xlink:to="lab_brns_ContractWithCustomerLiabilityForeignExchangeTranslation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_f097b420-0435-4f47-bcb8-e7be6c6a94c1_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_ae4993b6-c4df-4168-8e9b-41518078cbf3_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_5cc38490-7a95-4deb-ba25-762a80364076_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_AuditInformationAbstract_label_en-US" xlink:label="lab_brns_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_brns_AuditInformationAbstract_documentation_en-US" xlink:label="lab_brns_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_AuditInformationAbstract" xlink:href="brns-20231231.xsd#brns_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_AuditInformationAbstract" xlink:to="lab_brns_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_155ef648-c3fc-4655-92e4-578a24cf5331_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ordinary shares, &#163;0.000025 nominal value; 38,643,540 shares authorized, issued and outstanding (December&#160;31, 2022: authorized, issued and outstanding: 37,683,531)</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_ee0c0e2f-3246-463a-bd5b-18397ace85a5_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2e7d14cd-f177-42f4-8488-22278b7d3a2f_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_4887d416-4760-4117-933c-65b7332b83b8_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_DeferredBSharesMember_4a687680-cdad-4d82-af92-1a62bc08c5fa_terseLabel_en-US" xlink:label="lab_brns_DeferredBSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred B shares</link:label>
    <link:label id="lab_brns_DeferredBSharesMember_3e2fd90f-afbc-42d5-9162-4526a61bd9e9_verboseLabel_en-US" xlink:label="lab_brns_DeferredBSharesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred B Shares</link:label>
    <link:label id="lab_brns_DeferredBSharesMember_label_en-US" xlink:label="lab_brns_DeferredBSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred B Shares [Member]</link:label>
    <link:label id="lab_brns_DeferredBSharesMember_documentation_en-US" xlink:label="lab_brns_DeferredBSharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information pertaining to deferred B shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredBSharesMember" xlink:href="brns-20231231.xsd#brns_DeferredBSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_DeferredBSharesMember" xlink:to="lab_brns_DeferredBSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_a4fd7193-ef11-4b44-a87b-82a31ad39eba_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_e670a4f1-5c0e-4108-8bf2-6ceb4b6eed9e_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_2ddacf6b-ccd4-4150-a45c-e86eacf239be_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred income tax benefit:</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_DeferredCSharesMember_3d7322fa-89a4-4814-8991-88212341c600_terseLabel_en-US" xlink:label="lab_brns_DeferredCSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred C shares</link:label>
    <link:label id="lab_brns_DeferredCSharesMember_38dce13e-f60a-406a-874c-e9dfb73d53ca_verboseLabel_en-US" xlink:label="lab_brns_DeferredCSharesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred C Shares</link:label>
    <link:label id="lab_brns_DeferredCSharesMember_label_en-US" xlink:label="lab_brns_DeferredCSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred C Shares [Member]</link:label>
    <link:label id="lab_brns_DeferredCSharesMember_documentation_en-US" xlink:label="lab_brns_DeferredCSharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information pertaining to deferred C shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredCSharesMember" xlink:href="brns-20231231.xsd#brns_DeferredCSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_DeferredCSharesMember" xlink:to="lab_brns_DeferredCSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_29bb8af2-a679-469e-b311-332c5e2bb3cc_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of long-lived assets</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_2e3e06f7-dd4a-42ca-8e62-1a2c99bedd49_terseLabel_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of concentration of credit risk</link:label>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_label_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_53d31519-b6cd-4360-9806-958acb7cdfef_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_0e17b912-42ab-4838-8fb0-61e4a216d14f_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental cash flow disclosures:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_f3177f16-cf43-4104-aaff-c454fee6b445_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_90eecd84-f9f7-4bf9-913f-ae0da78a29cb_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_d3ebb45f-6c1c-40be-834a-f524acaedee0_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_89ca9db6-9dea-4b29-93cc-1f6189990fa5_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_85e07f9e-89d7-4e03-b9ea-93df2e459a64_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_c0a728ba-6d52-4fd0-aebf-82b82b9c3111_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net (loss)/income per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_11f40e3c-edd9-49cc-bfd9-404c613854fa_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation to the effective tax rate</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_c6692d04-b782-492f-bcaf-ec94e0e1db34_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_98abbe26-ec52-43ba-a57b-aac156fc85bf_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration liability</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_ea75f49a-93ac-4496-8271-bf94087a350f_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_4bc6c0e6-8d0e-4074-8563-c70e08c7fac3_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_dd871ef8-4cfd-426b-a982-840e873196fb_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current income tax benefit/(expense):</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_IssuanceOfCommonStockUnderwritingCommissions_8040379e-1cf5-49b0-af94-bb2707157916_terseLabel_en-US" xlink:label="lab_brns_IssuanceOfCommonStockUnderwritingCommissions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underwriting commissions</link:label>
    <link:label id="lab_brns_IssuanceOfCommonStockUnderwritingCommissions_label_en-US" xlink:label="lab_brns_IssuanceOfCommonStockUnderwritingCommissions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance Of Common Stock, Underwriting Commissions</link:label>
    <link:label id="lab_brns_IssuanceOfCommonStockUnderwritingCommissions_documentation_en-US" xlink:label="lab_brns_IssuanceOfCommonStockUnderwritingCommissions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Underwriting commissions for issuance of common stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_IssuanceOfCommonStockUnderwritingCommissions" xlink:href="brns-20231231.xsd#brns_IssuanceOfCommonStockUnderwritingCommissions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_IssuanceOfCommonStockUnderwritingCommissions" xlink:to="lab_brns_IssuanceOfCommonStockUnderwritingCommissions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_c2169110-b58e-458f-a5bb-9c2679951444_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated annual amortization expense for 2028</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_008202d2-9538-4735-be8b-e73b2ce323fd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_24f6c172-7aca-4206-9464-36ea58f0e914_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of prepaid and other current assets</link:label>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_9d7dff8a-43c1-4cf0-a561-46eeaff21b8e_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share based compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_dee1b6e7-8565-4158-82a4-c063d3154b42_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_ea441966-1438-4bbb-9737-aa18b1a75ccf_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_3f9bc69e-a476-4d26-b3dd-f985d4833479_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_DeferredShares.Member_df8578ee-fda9-4f62-afda-0c1727b73a8b_terseLabel_en-US" xlink:label="lab_brns_DeferredShares.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred A shares</link:label>
    <link:label id="lab_brns_DeferredShares.Member_0253eb6c-0785-44cd-94f3-5918129b4e04_verboseLabel_en-US" xlink:label="lab_brns_DeferredShares.Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred A Shares</link:label>
    <link:label id="lab_brns_DeferredShares.Member_label_en-US" xlink:label="lab_brns_DeferredShares.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred A Shares. [Member]</link:label>
    <link:label id="lab_brns_DeferredShares.Member_documentation_en-US" xlink:label="lab_brns_DeferredShares.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This member stands for deferred A shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredShares.Member" xlink:href="brns-20231231.xsd#brns_DeferredShares.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_DeferredShares.Member" xlink:to="lab_brns_DeferredShares.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_7dff3fe6-27ca-45d7-bfb9-7fb87517627e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_fbad215d-e3db-4303-9391-b546b6a3f92e_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contributions to acquire additional interest in subsidiaries</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Additional Interest in Subsidiaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:to="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_4e1ecbe8-a7ab-4bff-a52b-5ab3ef95a8b9_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_35dfa95e-4a48-49a2-89cc-16c1696499b4_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Office furniture and equipment</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_74175740-9388-49c1-823c-ca11f16a959d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_0bfb190d-f1b8-4bdd-adf6-826ad60f0bba_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity attributable to Barinthus Biotherapeutics plc shareholders</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_3f85783a-dcff-40d9-b6ac-71dbf8ac6410_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_AccruedManufacturingAndClinicalExpensesCurrent_acce4770-1f7d-4b13-a20e-bb423ea5d1b4_terseLabel_en-US" xlink:label="lab_brns_AccruedManufacturingAndClinicalExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued manufacturing and clinical expenses</link:label>
    <link:label id="lab_brns_AccruedManufacturingAndClinicalExpensesCurrent_label_en-US" xlink:label="lab_brns_AccruedManufacturingAndClinicalExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Manufacturing and Clinical Expenses, Current</link:label>
    <link:label id="lab_brns_AccruedManufacturingAndClinicalExpensesCurrent_documentation_en-US" xlink:label="lab_brns_AccruedManufacturingAndClinicalExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred through that date and payable for manufacturing and clinical expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_AccruedManufacturingAndClinicalExpensesCurrent" xlink:href="brns-20231231.xsd#brns_AccruedManufacturingAndClinicalExpensesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_AccruedManufacturingAndClinicalExpensesCurrent" xlink:to="lab_brns_AccruedManufacturingAndClinicalExpensesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_e9456908-e43e-495a-9951-7729f573b4f5_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_50dd83dc-f507-45b8-be16-46f6b098646f_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_976d8945-f066-46cc-a839-d32101130cec_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_2e497308-9b85-452d-9609-f9a576b14142_periodStartLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Valuations allowance at beginning of year</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_ad6090c8-026c-4dc4-a568-dc824ed43e4d_periodEndLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance at end of year</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_PercentageOfRoyaltiesOnNetSales_e21f5001-ad7f-44d8-aea9-a677a62f77d6_terseLabel_en-US" xlink:label="lab_brns_PercentageOfRoyaltiesOnNetSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of royalties on commercial sales</link:label>
    <link:label id="lab_brns_PercentageOfRoyaltiesOnNetSales_label_en-US" xlink:label="lab_brns_PercentageOfRoyaltiesOnNetSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Royalties On Net Sales</link:label>
    <link:label id="lab_brns_PercentageOfRoyaltiesOnNetSales_documentation_en-US" xlink:label="lab_brns_PercentageOfRoyaltiesOnNetSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The percentage of royalties on the net sales.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_PercentageOfRoyaltiesOnNetSales" xlink:href="brns-20231231.xsd#brns_PercentageOfRoyaltiesOnNetSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_PercentageOfRoyaltiesOnNetSales" xlink:to="lab_brns_PercentageOfRoyaltiesOnNetSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c12de984-1fa7-42b9-b447-68e3fe210db6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_DeferredStockSharesIssued_7b635389-fc21-4067-9fcf-451962019e6e_terseLabel_en-US" xlink:label="lab_brns_DeferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred shares, issued (in shares)</link:label>
    <link:label id="lab_brns_DeferredStockSharesIssued_label_en-US" xlink:label="lab_brns_DeferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Stock, Shares Issued</link:label>
    <link:label id="lab_brns_DeferredStockSharesIssued_documentation_en-US" xlink:label="lab_brns_DeferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total number of deferred shares of an entity that have been sold or granted to shareholders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredStockSharesIssued" xlink:href="brns-20231231.xsd#brns_DeferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_DeferredStockSharesIssued" xlink:to="lab_brns_DeferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_OxfordshireMember_3c0bea23-242b-441c-bc28-69033f74ba03_terseLabel_en-US" xlink:label="lab_brns_OxfordshireMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Oxfordshire</link:label>
    <link:label id="lab_brns_OxfordshireMember_label_en-US" xlink:label="lab_brns_OxfordshireMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Oxfordshire [Member]</link:label>
    <link:label id="lab_brns_OxfordshireMember_documentation_en-US" xlink:label="lab_brns_OxfordshireMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Oxfordshire</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_OxfordshireMember" xlink:href="brns-20231231.xsd#brns_OxfordshireMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_OxfordshireMember" xlink:to="lab_brns_OxfordshireMember" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_ShareholderTheUniversityOfOxfordMember_5e77bad5-5346-4ba4-9541-fa0c69172a1e_terseLabel_en-US" xlink:label="lab_brns_ShareholderTheUniversityOfOxfordMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shareholder, The University of Oxford</link:label>
    <link:label id="lab_brns_ShareholderTheUniversityOfOxfordMember_label_en-US" xlink:label="lab_brns_ShareholderTheUniversityOfOxfordMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shareholder, The University Of Oxford [Member]</link:label>
    <link:label id="lab_brns_ShareholderTheUniversityOfOxfordMember_documentation_en-US" xlink:label="lab_brns_ShareholderTheUniversityOfOxfordMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the information pertaining to Shareholder, the University of Oxford.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ShareholderTheUniversityOfOxfordMember" xlink:href="brns-20231231.xsd#brns_ShareholderTheUniversityOfOxfordMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_ShareholderTheUniversityOfOxfordMember" xlink:to="lab_brns_ShareholderTheUniversityOfOxfordMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c567086b-58b6-4c51-83e8-ff3a96b16ea8_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_a798b217-b3e6-48be-9c1e-fd37afdd937d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive gain/(loss) &#8211; foreign currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_6b22c05f-0f5e-4da2-b9e2-f654438f59ab_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_245b2b2a-5f37-42ec-8bd2-aa5b272f8b1a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_ValuationAllowanceDeferredTaxAssetIncreaseResultingFromIncomeTaxProvision_21cc77b5-295e-4252-848b-e960d172e26b_terseLabel_en-US" xlink:label="lab_brns_ValuationAllowanceDeferredTaxAssetIncreaseResultingFromIncomeTaxProvision" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increases recorded to income tax provision</link:label>
    <link:label id="lab_brns_ValuationAllowanceDeferredTaxAssetIncreaseResultingFromIncomeTaxProvision_label_en-US" xlink:label="lab_brns_ValuationAllowanceDeferredTaxAssetIncreaseResultingFromIncomeTaxProvision" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase Resulting From Income Tax Provision</link:label>
    <link:label id="lab_brns_ValuationAllowanceDeferredTaxAssetIncreaseResultingFromIncomeTaxProvision_documentation_en-US" xlink:label="lab_brns_ValuationAllowanceDeferredTaxAssetIncreaseResultingFromIncomeTaxProvision" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase Resulting From Income Tax Provision</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ValuationAllowanceDeferredTaxAssetIncreaseResultingFromIncomeTaxProvision" xlink:href="brns-20231231.xsd#brns_ValuationAllowanceDeferredTaxAssetIncreaseResultingFromIncomeTaxProvision"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_ValuationAllowanceDeferredTaxAssetIncreaseResultingFromIncomeTaxProvision" xlink:to="lab_brns_ValuationAllowanceDeferredTaxAssetIncreaseResultingFromIncomeTaxProvision" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxCreditsAndAdjustments_ee9a840a-a560-46ff-85b3-eca562af5164_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxCreditsAndAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unlimited carryforward amount</link:label>
    <link:label id="lab_us-gaap_IncomeTaxCreditsAndAdjustments_label_en-US" xlink:label="lab_us-gaap_IncomeTaxCreditsAndAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Credits and Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxCreditsAndAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxCreditsAndAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxCreditsAndAdjustments" xlink:to="lab_us-gaap_IncomeTaxCreditsAndAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0be78147-a54a-4ae4-a929-36f9b3e9cc7e_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected term (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_db97c08a-1f94-45cd-9d52-d1cc21b66103_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_43fd4ac7-078f-4d94-9416-4c8ddaa05af1_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">(Loss)/profit before income tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_ResearchAndDevelopmentIncentiveIncomeExpense_2a68c424-cd9e-4221-bad8-2f29da9b8f5b_terseLabel_en-US" xlink:label="lab_brns_ResearchAndDevelopmentIncentiveIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development incentives</link:label>
    <link:label id="lab_brns_ResearchAndDevelopmentIncentiveIncomeExpense_label_en-US" xlink:label="lab_brns_ResearchAndDevelopmentIncentiveIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Incentive Income (Expense)</link:label>
    <link:label id="lab_brns_ResearchAndDevelopmentIncentiveIncomeExpense_documentation_en-US" xlink:label="lab_brns_ResearchAndDevelopmentIncentiveIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the research and development incentives (expenses) for the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ResearchAndDevelopmentIncentiveIncomeExpense" xlink:href="brns-20231231.xsd#brns_ResearchAndDevelopmentIncentiveIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_ResearchAndDevelopmentIncentiveIncomeExpense" xlink:to="lab_brns_ResearchAndDevelopmentIncentiveIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_NonCashInterestExpenseOnConvertibleLoanNotes_8b4db3ae-3369-4d3c-90c5-d2c807b8587e_verboseLabel_en-US" xlink:label="lab_brns_NonCashInterestExpenseOnConvertibleLoanNotes" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Non cash interest expense</link:label>
    <link:label id="lab_brns_NonCashInterestExpenseOnConvertibleLoanNotes_label_en-US" xlink:label="lab_brns_NonCashInterestExpenseOnConvertibleLoanNotes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Cash Interest Expense On Convertible Loan Notes</link:label>
    <link:label id="lab_brns_NonCashInterestExpenseOnConvertibleLoanNotes_documentation_en-US" xlink:label="lab_brns_NonCashInterestExpenseOnConvertibleLoanNotes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of non-cash interest expense on convertible loan notes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_NonCashInterestExpenseOnConvertibleLoanNotes" xlink:href="brns-20231231.xsd#brns_NonCashInterestExpenseOnConvertibleLoanNotes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_NonCashInterestExpenseOnConvertibleLoanNotes" xlink:to="lab_brns_NonCashInterestExpenseOnConvertibleLoanNotes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_6a9f9885-beae-4ad6-a1e3-86c1b86919a7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_dd62ddab-ab75-46b5-b229-7f331d33a139_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_118198fa-b2d8-4cf6-a73d-b12618870948_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_country_GB_029414a2-c1ad-4b23-a33c-5b7bb30aa505_terseLabel_en-US" xlink:label="lab_country_GB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.K.</link:label>
    <link:label id="lab_country_GB_label_en-US" xlink:label="lab_country_GB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UNITED KINGDOM</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_GB" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_GB"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_GB" xlink:to="lab_country_GB" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_f1ed5b31-e192-4450-91c5-16b946e70764_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_PercentageOfFutureRoyaltiesForDirectSalesOfCoveredProductLicenseAgreement_3fc48982-53f9-49dd-8e0c-f811f1a99301_terseLabel_en-US" xlink:label="lab_brns_PercentageOfFutureRoyaltiesForDirectSalesOfCoveredProductLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of future royalties for direct sales of a covered product</link:label>
    <link:label id="lab_brns_PercentageOfFutureRoyaltiesForDirectSalesOfCoveredProductLicenseAgreement_label_en-US" xlink:label="lab_brns_PercentageOfFutureRoyaltiesForDirectSalesOfCoveredProductLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage of Future Royalties for Direct Sales of Covered Product , License Agreement</link:label>
    <link:label id="lab_brns_PercentageOfFutureRoyaltiesForDirectSalesOfCoveredProductLicenseAgreement_documentation_en-US" xlink:label="lab_brns_PercentageOfFutureRoyaltiesForDirectSalesOfCoveredProductLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of future royalties for direct sales of a covered product under the In-License Agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_PercentageOfFutureRoyaltiesForDirectSalesOfCoveredProductLicenseAgreement" xlink:href="brns-20231231.xsd#brns_PercentageOfFutureRoyaltiesForDirectSalesOfCoveredProductLicenseAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_PercentageOfFutureRoyaltiesForDirectSalesOfCoveredProductLicenseAgreement" xlink:to="lab_brns_PercentageOfFutureRoyaltiesForDirectSalesOfCoveredProductLicenseAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_e0b139ce-75cf-4f6c-a834-3e933aa2887e_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Gross deferred tax asset</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_CommonStockNumberOfVotesPerShare_a6ba4948-7e9d-4a8b-9fbe-1f1dbc63f5a1_terseLabel_en-US" xlink:label="lab_brns_CommonStockNumberOfVotesPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of votes per common share (in votes)</link:label>
    <link:label id="lab_brns_CommonStockNumberOfVotesPerShare_label_en-US" xlink:label="lab_brns_CommonStockNumberOfVotesPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock Number of Votes Per Share</link:label>
    <link:label id="lab_brns_CommonStockNumberOfVotesPerShare_documentation_en-US" xlink:label="lab_brns_CommonStockNumberOfVotesPerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of votes that each common share is entitled.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_CommonStockNumberOfVotesPerShare" xlink:href="brns-20231231.xsd#brns_CommonStockNumberOfVotesPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_CommonStockNumberOfVotesPerShare" xlink:to="lab_brns_CommonStockNumberOfVotesPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6c4524f1-b0df-438e-b766-49d102219404_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_fa92f6ba-831a-4384-b1cc-3fcb7095f148_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_ee4448b3-3182-4120-8d9c-6376b32fdb40_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_b588155b-13be-402d-a273-bc4756054b6b_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Estimated useful life of intangible assets</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_c0bbb43b-58a6-450c-b493-2e352f79560b_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_8df21759-c0e0-478b-8a5f-a9594a2dc361_verboseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_da13aa07-1438-4a4c-94f3-71418f043d60_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding at the beginning of the period (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3d75fee8-fb94-4c74-ba95-6a55f35eabea_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding at the end of the period (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_69540536-05e5-4bef-9baf-64e3f6678460_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_PrepaidExpenseAndOtherAssetsCurrentTextBlock_c30cca22-b39f-4b8a-8566-ca6f119109ef_terseLabel_en-US" xlink:label="lab_brns_PrepaidExpenseAndOtherAssetsCurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid and other current assets</link:label>
    <link:label id="lab_brns_PrepaidExpenseAndOtherAssetsCurrentTextBlock_label_en-US" xlink:label="lab_brns_PrepaidExpenseAndOtherAssetsCurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current [Text Block]</link:label>
    <link:label id="lab_brns_PrepaidExpenseAndOtherAssetsCurrentTextBlock_documentation_en-US" xlink:label="lab_brns_PrepaidExpenseAndOtherAssetsCurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The entire disclosure on prepaid expense and other current assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_PrepaidExpenseAndOtherAssetsCurrentTextBlock" xlink:href="brns-20231231.xsd#brns_PrepaidExpenseAndOtherAssetsCurrentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_PrepaidExpenseAndOtherAssetsCurrentTextBlock" xlink:to="lab_brns_PrepaidExpenseAndOtherAssetsCurrentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_248193aa-ddaf-4070-97d8-dc885f701b74_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ordinary shares</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_75116189-6935-4420-ab2e-40aafe3bba22_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Ordinary Shares</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_2675bff3-074b-4ff2-bd68-cf0f8ef96e76_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares available for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_SubsidiaryCumulativeContributionsParent_2263fb68-4162-420d-8650-4cd42606c90c_terseLabel_en-US" xlink:label="lab_brns_SubsidiaryCumulativeContributionsParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cumulative contributions from controlling interest owner</link:label>
    <link:label id="lab_brns_SubsidiaryCumulativeContributionsParent_label_en-US" xlink:label="lab_brns_SubsidiaryCumulativeContributionsParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiary, Cumulative Contributions, Parent</link:label>
    <link:label id="lab_brns_SubsidiaryCumulativeContributionsParent_documentation_en-US" xlink:label="lab_brns_SubsidiaryCumulativeContributionsParent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Subsidiary, Cumulative Contributions, Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_SubsidiaryCumulativeContributionsParent" xlink:href="brns-20231231.xsd#brns_SubsidiaryCumulativeContributionsParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_SubsidiaryCumulativeContributionsParent" xlink:to="lab_brns_SubsidiaryCumulativeContributionsParent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_2badbe3e-28a5-4f74-9bd5-8cd6efdc6174_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_5c2c4bfb-ca03-41bd-9f71-5ab07ff77035_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_SharesCancelledDuringPeriodValueDeferredShares_8d1fead6-ef78-496b-8776-48030aa1d936_negatedTerseLabel_en-US" xlink:label="lab_brns_SharesCancelledDuringPeriodValueDeferredShares" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cancellation of deferred shares</link:label>
    <link:label id="lab_brns_SharesCancelledDuringPeriodValueDeferredShares_label_en-US" xlink:label="lab_brns_SharesCancelledDuringPeriodValueDeferredShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Cancelled During Period, Value, Deferred Shares</link:label>
    <link:label id="lab_brns_SharesCancelledDuringPeriodValueDeferredShares_documentation_en-US" xlink:label="lab_brns_SharesCancelledDuringPeriodValueDeferredShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shares Cancelled During Period, Value, Deferred Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_SharesCancelledDuringPeriodValueDeferredShares" xlink:href="brns-20231231.xsd#brns_SharesCancelledDuringPeriodValueDeferredShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_SharesCancelledDuringPeriodValueDeferredShares" xlink:to="lab_brns_SharesCancelledDuringPeriodValueDeferredShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_5b4d52cb-62a0-4fc5-8222-14837c2aa68e_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net (Loss)/Income Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_1b9157de-24c2-423c-855b-7a33010d32a8_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_580b4e55-5997-42bf-a30c-59904d92f454_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_d5aebf41-9e66-47bf-904f-08490f128896_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of financial instruments carried at fair value and classified within Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_0af095e7-8ad3-4684-967b-3bfc51183338_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_26a1d85b-eb6d-4425-b71c-6186e27c723d_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0865b55b-a016-44b1-883f-f0775bbe9cd9_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f55e9b80-3374-4d91-b71f-5265a861b433_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f811fdce-bba9-4b29-aa28-53288a329120_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_AgreementWithScancellToGrantResearchAndDevelopmentLicenseMember_58bcab64-ff3f-4844-b88f-d71ae0cbe27e_terseLabel_en-US" xlink:label="lab_brns_AgreementWithScancellToGrantResearchAndDevelopmentLicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Agreement with Scancell</link:label>
    <link:label id="lab_brns_AgreementWithScancellToGrantResearchAndDevelopmentLicenseMember_label_en-US" xlink:label="lab_brns_AgreementWithScancellToGrantResearchAndDevelopmentLicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Agreement with Scancell to Grant Research and Development License [Member]</link:label>
    <link:label id="lab_brns_AgreementWithScancellToGrantResearchAndDevelopmentLicenseMember_documentation_en-US" xlink:label="lab_brns_AgreementWithScancellToGrantResearchAndDevelopmentLicenseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This member stands for the information pertaining to Scancell contract.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_AgreementWithScancellToGrantResearchAndDevelopmentLicenseMember" xlink:href="brns-20231231.xsd#brns_AgreementWithScancellToGrantResearchAndDevelopmentLicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_AgreementWithScancellToGrantResearchAndDevelopmentLicenseMember" xlink:to="lab_brns_AgreementWithScancellToGrantResearchAndDevelopmentLicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_ResearchAndDevelopmentIncentivesPolicyTextBlock_d5316de4-9793-455e-80dd-6b40a3e34501_terseLabel_en-US" xlink:label="lab_brns_ResearchAndDevelopmentIncentivesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development incentives</link:label>
    <link:label id="lab_brns_ResearchAndDevelopmentIncentivesPolicyTextBlock_label_en-US" xlink:label="lab_brns_ResearchAndDevelopmentIncentivesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development, Incentives [Policy Text Block]</link:label>
    <link:label id="lab_brns_ResearchAndDevelopmentIncentivesPolicyTextBlock_documentation_en-US" xlink:label="lab_brns_ResearchAndDevelopmentIncentivesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of accounting policy for Incentives received o to be received from Research and Development.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ResearchAndDevelopmentIncentivesPolicyTextBlock" xlink:href="brns-20231231.xsd#brns_ResearchAndDevelopmentIncentivesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_ResearchAndDevelopmentIncentivesPolicyTextBlock" xlink:to="lab_brns_ResearchAndDevelopmentIncentivesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_de9c3a61-fe74-45f9-82c1-d14d0c9214d2_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_06d63d0d-50ac-4585-b1d0-82cd2aa4d807_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_ec7aad37-99e4-447a-b5fd-9a2720cda1c9_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_9793f338-a5b0-4f89-8cff-2bac0fcca427_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of stock option activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c5262aba-288a-4eb9-a0ec-4ca0c08a75ca_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_be66fd60-c45d-4f93-9fe7-cf8967964a07_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_7267d978-3342-4e11-937b-c293a1d7822f_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a8140ccc-37db-4dcd-97f0-36991a5db11b_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_89d42f1b-d172-404d-9bf9-0f5c45780a85_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net foreign exchange gain (loss)</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss), Foreign Currency Transaction, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_2822cd2b-c5fb-48d3-9a7d-974441cecef3_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonrelatedPartyMember_e13c3ac1-cc57-4a80-9809-0206c9692501_terseLabel_en-US" xlink:label="lab_us-gaap_NonrelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nonrelated parties</link:label>
    <link:label id="lab_us-gaap_NonrelatedPartyMember_label_en-US" xlink:label="lab_us-gaap_NonrelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonrelated Party [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonrelatedPartyMember" xlink:to="lab_us-gaap_NonrelatedPartyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_5560cc1d-d35f-4c04-8598-b068ed01383d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_6ea18d49-0bef-4434-b430-2e22bbb09d5b_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net (loss)/income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_cda3bd0d-5029-459b-8a8a-2fc21f7adbff_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net (loss)/income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_2cfa8147-2f46-4641-9017-f4b57de454e6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_d4f873f0-8cd9-4ff4-9f5d-9fb952d4d340_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1c06554a-249d-405f-8742-0c393baaf0d3_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_2d13de74-5dff-4012-8a0c-ff618b5f290a_terseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Developed technology</link:label>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_label_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:to="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_643625af-2f31-4d88-80ad-b7caf969d06a_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies_27e73768-5daa-4642-abab-48aaaf5c1d49_terseLabel_en-US" xlink:label="lab_us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Guarantees and indemnifications</link:label>
    <link:label id="lab_us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies_label_en-US" xlink:label="lab_us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Guarantees, Indemnifications and Warranties Policies [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies" xlink:to="lab_us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_d6d3a52d-4149-4293-839a-0ede6d76e0c4_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_00758859-f005-4a60-9c3e-2f0217e68e62_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2238a0e7-bfd6-4f1b-970e-ccab19dbe869_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_87098a11-c79d-4e25-b5ca-6f393ab9b2c7_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net (loss)/income per share attributable to ordinary shareholders, basic (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_dce87831-e303-4b2f-b17d-544ec4378427_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right of use assets, net</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_b29bd209-deb5-4d1d-a5ee-6177ee71575f_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use asset</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_3e46c877-5bdc-401b-8fff-0d6727f96add_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation cost related to options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_453140c7-b03d-4d7f-8fb5-e93761ae775a_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_ProceedsFromGrantsReceived_b2f8915c-05a7-49ea-8b6e-f81ed6d0ee66_terseLabel_en-US" xlink:label="lab_brns_ProceedsFromGrantsReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from grants received</link:label>
    <link:label id="lab_brns_ProceedsFromGrantsReceived_label_en-US" xlink:label="lab_brns_ProceedsFromGrantsReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Grants Received</link:label>
    <link:label id="lab_brns_ProceedsFromGrantsReceived_documentation_en-US" xlink:label="lab_brns_ProceedsFromGrantsReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds From Grants Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ProceedsFromGrantsReceived" xlink:href="brns-20231231.xsd#brns_ProceedsFromGrantsReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_ProceedsFromGrantsReceived" xlink:to="lab_brns_ProceedsFromGrantsReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment_1cc7d54a-13e0-4a8f-9a3c-059cf74c3c8b_negatedTerseLabel_en-US" xlink:label="lab_brns_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Research and development credits</link:label>
    <link:label id="lab_brns_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment_label_en-US" xlink:label="lab_brns_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credits, Research And Development</link:label>
    <link:label id="lab_brns_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment_documentation_en-US" xlink:label="lab_brns_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development tax credit.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment" xlink:href="brns-20231231.xsd#brns_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment" xlink:to="lab_brns_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_56cd37b6-6a8f-41f9-b3df-2826b1da2728_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_1f091453-ed41-4940-973f-9ce50925a1f5_negatedLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_d72704c8-c1da-45eb-a306-34cf59682274_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate intrinsic value of stock options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentLiabilityReserveEstimatePolicy_70aafa87-239f-4e50-b790-5f742d9a761d_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentLiabilityReserveEstimatePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent liabilities</link:label>
    <link:label id="lab_us-gaap_ContingentLiabilityReserveEstimatePolicy_label_en-US" xlink:label="lab_us-gaap_ContingentLiabilityReserveEstimatePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Liability Reserve Estimate, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentLiabilityReserveEstimatePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentLiabilityReserveEstimatePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentLiabilityReserveEstimatePolicy" xlink:to="lab_us-gaap_ContingentLiabilityReserveEstimatePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_994fff38-55f3-44ad-82dd-ad53d5df1fb3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyMember_6949ef1d-cebf-4c8e-ba1c-d1187158a700_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related parties</link:label>
    <link:label id="lab_us-gaap_RelatedPartyMember_label_en-US" xlink:label="lab_us-gaap_RelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyMember" xlink:to="lab_us-gaap_RelatedPartyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_c6dffe7e-fad7-4d46-bd3e-946e2a259acb_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Product and Service [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Product and Service [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_4eadca61-e59d-4107-a335-a6b2e1ec9e8c_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principles of consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeTranslation_974590b8-005b-4b45-a3db-1ebb5244fea0_verboseLabel_en-US" xlink:label="lab_brns_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeTranslation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign exchange translation recognized in other comprehensive loss</link:label>
    <link:label id="lab_brns_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeTranslation_label_en-US" xlink:label="lab_brns_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeTranslation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Foreign Exchange Translation</link:label>
    <link:label id="lab_brns_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeTranslation_documentation_en-US" xlink:label="lab_brns_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeTranslation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of foreign exchange translation of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeTranslation" xlink:href="brns-20231231.xsd#brns_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeTranslation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeTranslation" xlink:to="lab_brns_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeTranslation" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_AvideaMember_e7875796-5a37-457b-b688-2c624cc253a9_terseLabel_en-US" xlink:label="lab_brns_AvideaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Avidea</link:label>
    <link:label id="lab_brns_AvideaMember_label_en-US" xlink:label="lab_brns_AvideaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Avidea [Member]</link:label>
    <link:label id="lab_brns_AvideaMember_documentation_en-US" xlink:label="lab_brns_AvideaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This member stands for Avidea.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_AvideaMember" xlink:href="brns-20231231.xsd#brns_AvideaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_AvideaMember" xlink:to="lab_brns_AvideaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_52f9ba76-68a8-421f-80d5-064cfe9ad9a2_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillPurchaseAccountingAdjustments_1c83a6fa-0255-4474-9130-7ce22ad5d376_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement period adjustments</link:label>
    <link:label id="lab_us-gaap_GoodwillPurchaseAccountingAdjustments_label_en-US" xlink:label="lab_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Purchase Accounting Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:to="lab_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_AssetRetirementObligations_76afc746-50ea-4b99-9f53-a546e35a7ef6_terseLabel_en-US" xlink:label="lab_brns_AssetRetirementObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset retirement obligation</link:label>
    <link:label id="lab_brns_AssetRetirementObligations_label_en-US" xlink:label="lab_brns_AssetRetirementObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Retirement Obligations</link:label>
    <link:label id="lab_brns_AssetRetirementObligations_documentation_en-US" xlink:label="lab_brns_AssetRetirementObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of asset retirement obligations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_AssetRetirementObligations" xlink:href="brns-20231231.xsd#brns_AssetRetirementObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_AssetRetirementObligations" xlink:to="lab_brns_AssetRetirementObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_9d2cfd65-96bc-42a4-a392-5a7296419840_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_ResearchAndDevelopmentIncentivesReceivable_ec61ed3a-b5a9-49d3-9053-f2d04fc2fbcc_terseLabel_en-US" xlink:label="lab_brns_ResearchAndDevelopmentIncentivesReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development incentives receivable</link:label>
    <link:label id="lab_brns_ResearchAndDevelopmentIncentivesReceivable_label_en-US" xlink:label="lab_brns_ResearchAndDevelopmentIncentivesReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Incentives Receivable</link:label>
    <link:label id="lab_brns_ResearchAndDevelopmentIncentivesReceivable_documentation_en-US" xlink:label="lab_brns_ResearchAndDevelopmentIncentivesReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of research and development incentives receivable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ResearchAndDevelopmentIncentivesReceivable" xlink:href="brns-20231231.xsd#brns_ResearchAndDevelopmentIncentivesReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_ResearchAndDevelopmentIncentivesReceivable" xlink:to="lab_brns_ResearchAndDevelopmentIncentivesReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_fd648bbc-17b7-492b-94f3-f2d96d47e14d_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss &#8211; foreign currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSeven_f96ab92d-2201-4f08-9503-1243e8a8c923_terseLabel_en-US" xlink:label="lab_brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSeven" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated annual amortization expense for 2030</link:label>
    <link:label id="lab_brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSeven_label_en-US" xlink:label="lab_brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSeven" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Seven</link:label>
    <link:label id="lab_brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSeven_documentation_en-US" xlink:label="lab_brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSeven" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Seven</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSeven" xlink:href="brns-20231231.xsd#brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSeven"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSeven" xlink:to="lab_brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSeven" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_62fe5149-e8d8-438d-91f5-503880c4d1d0_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_10ee5691-895b-4449-8b1f-f5d4e2156797_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ordinary shares, authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationTable_98e73adc-1c3a-4ef8-9339-fd32d02eed55_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
    <link:label id="lab_dei_DocumentInformationTable_label_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_085c04c8-5338-4f25-b90e-3d8f5896b0a7_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_eab719d0-fca3-4488-bfe0-cb6651bfc1d8_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCountry_c8af0115-738c-4c3a-8f85-6f2892282f0d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Country</link:label>
    <link:label id="lab_dei_EntityAddressCountry_label_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Country</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCountry" xlink:to="lab_dei_EntityAddressCountry" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestLineItems_f82e1f96-c693-4c0c-8334-d56e56d8d016_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest [Line Items]</link:label>
    <link:label id="lab_us-gaap_MinorityInterestLineItems_label_en-US" xlink:label="lab_us-gaap_MinorityInterestLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestLineItems" xlink:to="lab_us-gaap_MinorityInterestLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_65e0c4f3-5d9e-4c83-b943-954f3d357d20_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net (loss)/income to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_PercentageOfNetPaymentsReceivedForAllowableSublicensesOfTechnologyDevelopedLicenseAgreement_8ff6aef3-af0e-4fb5-a2eb-0e37efbe3afb_terseLabel_en-US" xlink:label="lab_brns_PercentageOfNetPaymentsReceivedForAllowableSublicensesOfTechnologyDevelopedLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net payments received for allowable sublicenses of technology developed</link:label>
    <link:label id="lab_brns_PercentageOfNetPaymentsReceivedForAllowableSublicensesOfTechnologyDevelopedLicenseAgreement_label_en-US" xlink:label="lab_brns_PercentageOfNetPaymentsReceivedForAllowableSublicensesOfTechnologyDevelopedLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Net Payments Received For Allowable Sublicenses Of Technology Developed License Agreement</link:label>
    <link:label id="lab_brns_PercentageOfNetPaymentsReceivedForAllowableSublicensesOfTechnologyDevelopedLicenseAgreement_documentation_en-US" xlink:label="lab_brns_PercentageOfNetPaymentsReceivedForAllowableSublicensesOfTechnologyDevelopedLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of net payments received for allowable sublicenses of technology developed under the In-License Agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_PercentageOfNetPaymentsReceivedForAllowableSublicensesOfTechnologyDevelopedLicenseAgreement" xlink:href="brns-20231231.xsd#brns_PercentageOfNetPaymentsReceivedForAllowableSublicensesOfTechnologyDevelopedLicenseAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_PercentageOfNetPaymentsReceivedForAllowableSublicensesOfTechnologyDevelopedLicenseAgreement" xlink:to="lab_brns_PercentageOfNetPaymentsReceivedForAllowableSublicensesOfTechnologyDevelopedLicenseAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_1cbe3483-2b83-4b90-8f41-334f50de17df_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_ContractWithCustomerLiabilityRevenueRecognized1_0cbdf705-4b36-46f5-82af-422979ad4694_terseLabel_en-US" xlink:label="lab_brns_ContractWithCustomerLiabilityRevenueRecognized1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-refundable upfront revenue recognized</link:label>
    <link:label id="lab_brns_ContractWithCustomerLiabilityRevenueRecognized1_bb06ab80-eddc-4f9a-9266-fdeacecfeada_negatedTerseLabel_en-US" xlink:label="lab_brns_ContractWithCustomerLiabilityRevenueRecognized1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Revenue recognized related to contract liability balance</link:label>
    <link:label id="lab_brns_ContractWithCustomerLiabilityRevenueRecognized1_label_en-US" xlink:label="lab_brns_ContractWithCustomerLiabilityRevenueRecognized1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized1</link:label>
    <link:label id="lab_brns_ContractWithCustomerLiabilityRevenueRecognized1_documentation_en-US" xlink:label="lab_brns_ContractWithCustomerLiabilityRevenueRecognized1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ContractWithCustomerLiabilityRevenueRecognized1" xlink:href="brns-20231231.xsd#brns_ContractWithCustomerLiabilityRevenueRecognized1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_ContractWithCustomerLiabilityRevenueRecognized1" xlink:to="lab_brns_ContractWithCustomerLiabilityRevenueRecognized1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_0d323387-462b-40f7-8286-90c18df27378_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_ValuationAllowanceRollForward_a56175ce-9633-4ee3-bc2b-a327d5cc5cca_terseLabel_en-US" xlink:label="lab_brns_ValuationAllowanceRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation Allowance [Roll Forward]</link:label>
    <link:label id="lab_brns_ValuationAllowanceRollForward_label_en-US" xlink:label="lab_brns_ValuationAllowanceRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowance [Roll Forward]</link:label>
    <link:label id="lab_brns_ValuationAllowanceRollForward_documentation_en-US" xlink:label="lab_brns_ValuationAllowanceRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ValuationAllowanceRollForward" xlink:href="brns-20231231.xsd#brns_ValuationAllowanceRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_ValuationAllowanceRollForward" xlink:to="lab_brns_ValuationAllowanceRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_OxfordUniversityInnovationLimitedMember_dc533aca-e79d-4f88-9857-a185dd7b39d1_terseLabel_en-US" xlink:label="lab_brns_OxfordUniversityInnovationLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Oxford University Innovation Limited</link:label>
    <link:label id="lab_brns_OxfordUniversityInnovationLimitedMember_label_en-US" xlink:label="lab_brns_OxfordUniversityInnovationLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Oxford University Innovation Limited [Member]</link:label>
    <link:label id="lab_brns_OxfordUniversityInnovationLimitedMember_documentation_en-US" xlink:label="lab_brns_OxfordUniversityInnovationLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the information pertaining to Oxford University Innovation Limited.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_OxfordUniversityInnovationLimitedMember" xlink:href="brns-20231231.xsd#brns_OxfordUniversityInnovationLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_OxfordUniversityInnovationLimitedMember" xlink:to="lab_brns_OxfordUniversityInnovationLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_9e67290a-40cf-4a2e-bedb-dd23bd83868d_negatedLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss attributable to noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_ca1fe5ec-0478-481d-aabd-45ab18b99afd_terseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected credit losses for financial assets</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_74892108-cd7a-444e-b25d-d08b52882a72_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_IssuanceOfCommonStockOfferingCosts_fd50c9ee-c8bd-488a-a474-dc1ab1bd521a_terseLabel_en-US" xlink:label="lab_brns_IssuanceOfCommonStockOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Offering costs</link:label>
    <link:label id="lab_brns_IssuanceOfCommonStockOfferingCosts_label_en-US" xlink:label="lab_brns_IssuanceOfCommonStockOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance Of Common Stock, Offering Costs</link:label>
    <link:label id="lab_brns_IssuanceOfCommonStockOfferingCosts_documentation_en-US" xlink:label="lab_brns_IssuanceOfCommonStockOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Offering costs related to the issuance of common stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_IssuanceOfCommonStockOfferingCosts" xlink:href="brns-20231231.xsd#brns_IssuanceOfCommonStockOfferingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_IssuanceOfCommonStockOfferingCosts" xlink:to="lab_brns_IssuanceOfCommonStockOfferingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_3b3a906a-9f7a-4051-9fa0-b0a9dd879d0f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use lease asset</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Leasing Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_4cafc2db-ad7b-41be-84d8-ae76dd5ee58e_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax expense</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationLineItems_e5901a61-cdd0-4b1a-9817-dd478122f049_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:label id="lab_dei_DocumentInformationLineItems_label_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_bdc03149-8086-4a33-8fcf-2d44adb85889_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_FiniteLivedIntangibleAssetExpectedAmortizationYearEight_d7658cc0-783c-4b64-9c9c-79c14f065de2_terseLabel_en-US" xlink:label="lab_brns_FiniteLivedIntangibleAssetExpectedAmortizationYearEight" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated annual amortization expense for 2031</link:label>
    <link:label id="lab_brns_FiniteLivedIntangibleAssetExpectedAmortizationYearEight_label_en-US" xlink:label="lab_brns_FiniteLivedIntangibleAssetExpectedAmortizationYearEight" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Eight</link:label>
    <link:label id="lab_brns_FiniteLivedIntangibleAssetExpectedAmortizationYearEight_documentation_en-US" xlink:label="lab_brns_FiniteLivedIntangibleAssetExpectedAmortizationYearEight" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Eight</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_FiniteLivedIntangibleAssetExpectedAmortizationYearEight" xlink:href="brns-20231231.xsd#brns_FiniteLivedIntangibleAssetExpectedAmortizationYearEight"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_FiniteLivedIntangibleAssetExpectedAmortizationYearEight" xlink:to="lab_brns_FiniteLivedIntangibleAssetExpectedAmortizationYearEight" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a3756d45-144a-4b43-bfa4-549cf29ec266_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_b0cdb951-e57b-4f02-8002-bfebdb253ba8_totalLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_3f236aa5-8133-4c4f-a215-73994459ce06_terseLabel_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_label_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_ad83849e-94b7-42e8-b630-1ae233449b7b_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated annual amortization expense for 2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_fb3d510f-3e23-4af8-810a-f1dbc1d78028_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_fea14b2b-81a5-444e-97c0-a403ba15d4f3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_ClinicalTrialCostsPolicyTextBlock_f3e7a8ef-74c2-43d5-a6c8-6310bfdba3d6_terseLabel_en-US" xlink:label="lab_brns_ClinicalTrialCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Clinical trial costs</link:label>
    <link:label id="lab_brns_ClinicalTrialCostsPolicyTextBlock_label_en-US" xlink:label="lab_brns_ClinicalTrialCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Clinical Trial Costs [Policy Text Block]</link:label>
    <link:label id="lab_brns_ClinicalTrialCostsPolicyTextBlock_documentation_en-US" xlink:label="lab_brns_ClinicalTrialCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of accounting policy for Clinical Trial costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ClinicalTrialCostsPolicyTextBlock" xlink:href="brns-20231231.xsd#brns_ClinicalTrialCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_ClinicalTrialCostsPolicyTextBlock" xlink:to="lab_brns_ClinicalTrialCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssets_a572d064-fdf0-4374-ab69-4c9db16798de_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssets_label_en-US" xlink:label="lab_us-gaap_OtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssets" xlink:to="lab_us-gaap_OtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_RoyaltyPaymentTermMaximum_eade6230-de8b-4402-9a34-19de665dd6ff_terseLabel_en-US" xlink:label="lab_brns_RoyaltyPaymentTermMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum royalty payment period</link:label>
    <link:label id="lab_brns_RoyaltyPaymentTermMaximum_label_en-US" xlink:label="lab_brns_RoyaltyPaymentTermMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Payment, Term, Maximum</link:label>
    <link:label id="lab_brns_RoyaltyPaymentTermMaximum_documentation_en-US" xlink:label="lab_brns_RoyaltyPaymentTermMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty Payment, Term, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_RoyaltyPaymentTermMaximum" xlink:href="brns-20231231.xsd#brns_RoyaltyPaymentTermMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_RoyaltyPaymentTermMaximum" xlink:to="lab_brns_RoyaltyPaymentTermMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_4fa2b8f2-d5f0-4cc1-a5c2-b628a6679fa7_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_4781db14-2e00-4144-8a1e-7c7de3b04253_verboseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Effect of dilutive stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_25543216-b190-471d-b68a-5cf4db05463f_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_54ae24ae-2917-4a2a-a285-c8f809ddfbfd_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign rate differential</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_b2f05a8b-6d39-493e-9ee4-dffc19113ce5_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated annual amortization expense for 2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_MD_4a10de6b-b81f-4cc7-8040-023b49b4694c_terseLabel_en-US" xlink:label="lab_stpr_MD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maryland</link:label>
    <link:label id="lab_stpr_MD_label_en-US" xlink:label="lab_stpr_MD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MARYLAND</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MD" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_MD"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_MD" xlink:to="lab_stpr_MD" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_AccountsReceivableStandardPaymentTermsPeriod_ce15bbf7-7886-4c7d-89a7-4d098d9fdd66_terseLabel_en-US" xlink:label="lab_brns_AccountsReceivableStandardPaymentTermsPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Standard payment terms</link:label>
    <link:label id="lab_brns_AccountsReceivableStandardPaymentTermsPeriod_label_en-US" xlink:label="lab_brns_AccountsReceivableStandardPaymentTermsPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Standard Payment Terms, Period</link:label>
    <link:label id="lab_brns_AccountsReceivableStandardPaymentTermsPeriod_documentation_en-US" xlink:label="lab_brns_AccountsReceivableStandardPaymentTermsPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Standard Payment Terms, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_AccountsReceivableStandardPaymentTermsPeriod" xlink:href="brns-20231231.xsd#brns_AccountsReceivableStandardPaymentTermsPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_AccountsReceivableStandardPaymentTermsPeriod" xlink:to="lab_brns_AccountsReceivableStandardPaymentTermsPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_239b3037-bd9d-4b6b-94c3-27b5e60ef43b_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of property and equipment</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_e80ea866-74f5-4053-b2cd-0012736874f8_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_7cbc539f-fabf-4820-a234-cfd6325b0099_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_18c1dc82-106d-411e-926c-958c96c7b9f8_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Components of Deferred Tax Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_a722dde9-fe91-4f39-a047-8228856216e5_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_81a5ed6c-b0c3-47aa-b1d8-5da096f98079_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_acf698da-b0e4-4768-b6c2-8d24a887bc27_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_9b8cbbd3-129e-40d3-a4f8-5a4add3b6c68_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_1eafca12-2093-4508-9f02-bd4f1bbee66b_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_6bea142b-ae89-4c84-9ffe-ede0d5cd44a2_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Exercisable at the end of the period (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_FundingAmountMaximum_8e6ced00-ad3e-4fa8-ae32-e1507a66dd06_terseLabel_en-US" xlink:label="lab_brns_FundingAmountMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum funding amount</link:label>
    <link:label id="lab_brns_FundingAmountMaximum_label_en-US" xlink:label="lab_brns_FundingAmountMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Funding Amount, Maximum</link:label>
    <link:label id="lab_brns_FundingAmountMaximum_documentation_en-US" xlink:label="lab_brns_FundingAmountMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Funding Amount, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_FundingAmountMaximum" xlink:href="brns-20231231.xsd#brns_FundingAmountMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_FundingAmountMaximum" xlink:to="lab_brns_FundingAmountMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_69b71629-90db-4295-8342-5cf97751dc90_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsIntangibles_b70d4f5d-3625-49a0-bffd-5912438fd4cb_terseLabel_en-US" xlink:label="lab_brns_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsIntangibles" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accruals and intangibles</link:label>
    <link:label id="lab_brns_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsIntangibles_label_en-US" xlink:label="lab_brns_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsIntangibles" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Intangibles</link:label>
    <link:label id="lab_brns_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsIntangibles_documentation_en-US" xlink:label="lab_brns_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsIntangibles" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals and intangibles.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsIntangibles" xlink:href="brns-20231231.xsd#brns_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsIntangibles"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsIntangibles" xlink:to="lab_brns_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsIntangibles" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_e0ee9ee8-97a0-4287-97bf-51fa248e988e_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Profit on sale of property and equipment</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_6d0a13be-edb1-4bcd-a4bb-e591da711df0_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_1da9f5b5-88b4-4c23-80a1-aa763b7178ba_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross amount of amortizable intangible assets</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_c77a7d68-54a3-47ba-a654-8b22ecca19bc_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Tax benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_985eba32-3000-4c6d-a74e-90b04b7a8ded_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total income tax benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_96efaf6b-6329-41d1-9499-6c5b6ee084d2_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other foreign</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_ffca65fd-018a-4cd6-ab87-92ed96891963_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Permanent differences</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_01899000-9dbc-4838-9d6a-d1f29af390fe_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_b232e295-8149-49db-8611-a3f84aad2b1a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_5cf755b3-ca80-4d99-bc93-d6b1d3595252_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_201579f0-614b-4a09-a1a2-77825809da95_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_ef2ba4c7-34dc-4629-921b-568a5f88361e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average remaining lease term (years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ff013ea4-66b1-4208-8f51-bce35abd2c52_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_72a8db42-0a61-4207-badd-36ff5a1efcc6_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenue recognized</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_e4ccf0a7-3e69-45f1-a0c3-f930776b698e_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_ebc31cfd-c773-42a9-bca3-4cf429a4366e_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_AdditionalPaidInCapitalPolicyTextBlock_8fd0e6e2-0fb3-4e84-b433-007afa93da5b_terseLabel_en-US" xlink:label="lab_brns_AdditionalPaidInCapitalPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_brns_AdditionalPaidInCapitalPolicyTextBlock_label_en-US" xlink:label="lab_brns_AdditionalPaidInCapitalPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid In Capital [Policy Text Block]</link:label>
    <link:label id="lab_brns_AdditionalPaidInCapitalPolicyTextBlock_documentation_en-US" xlink:label="lab_brns_AdditionalPaidInCapitalPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of accounting policy for Additional paid in capital.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_AdditionalPaidInCapitalPolicyTextBlock" xlink:href="brns-20231231.xsd#brns_AdditionalPaidInCapitalPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_AdditionalPaidInCapitalPolicyTextBlock" xlink:to="lab_brns_AdditionalPaidInCapitalPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_910050a1-efb2-40c6-bffd-f99ee8f291b9_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development tax credit carryforwards</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities_17dc0382-8634-475e-8ab3-cac4dd934eb3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gain on investment</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Unrealized Gains on Trading Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_047093d6-b22d-4aee-bd7c-2efc458c7b13_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_AgreementWithOxfordUniversityInnovationMember_c45135cd-ec21-4f60-bd28-875994499815_terseLabel_en-US" xlink:label="lab_brns_AgreementWithOxfordUniversityInnovationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Agreement with OUI</link:label>
    <link:label id="lab_brns_AgreementWithOxfordUniversityInnovationMember_label_en-US" xlink:label="lab_brns_AgreementWithOxfordUniversityInnovationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Agreement With Oxford University Innovation [Member]</link:label>
    <link:label id="lab_brns_AgreementWithOxfordUniversityInnovationMember_documentation_en-US" xlink:label="lab_brns_AgreementWithOxfordUniversityInnovationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This member stands for Oxford University Innovation Agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_AgreementWithOxfordUniversityInnovationMember" xlink:href="brns-20231231.xsd#brns_AgreementWithOxfordUniversityInnovationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_AgreementWithOxfordUniversityInnovationMember" xlink:to="lab_brns_AgreementWithOxfordUniversityInnovationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_83ffba67-5ba7-4236-b1ac-e853e37f4451_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSix_d50f5e74-8423-4fd2-87e8-c06599018467_terseLabel_en-US" xlink:label="lab_brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSix" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated annual amortization expense for 2029</link:label>
    <link:label id="lab_brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSix_label_en-US" xlink:label="lab_brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSix" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Six</link:label>
    <link:label id="lab_brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSix_documentation_en-US" xlink:label="lab_brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSix" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Six</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSix" xlink:href="brns-20231231.xsd#brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSix"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSix" xlink:to="lab_brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSix" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_cf82b7ae-c345-46f3-aa10-8f2d3e790d5f_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_e9507e76-1670-4d0d-97be-dfba84503366_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_OtherInformationLesseeAbstract_7a53bab5-e5f2-44b0-b927-684a2489b22d_terseLabel_en-US" xlink:label="lab_brns_OtherInformationLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other information</link:label>
    <link:label id="lab_brns_OtherInformationLesseeAbstract_label_en-US" xlink:label="lab_brns_OtherInformationLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Information, Lessee [Abstract]</link:label>
    <link:label id="lab_brns_OtherInformationLesseeAbstract_documentation_en-US" xlink:label="lab_brns_OtherInformationLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Information, Lessee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_OtherInformationLesseeAbstract" xlink:href="brns-20231231.xsd#brns_OtherInformationLesseeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_OtherInformationLesseeAbstract" xlink:to="lab_brns_OtherInformationLesseeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_EffectiveIncomeTaxRateReconciliationPercentIncreaseDecreaseAbstract_5df5b338-8cdd-468d-a7ad-ce4c465d7580_terseLabel_en-US" xlink:label="lab_brns_EffectiveIncomeTaxRateReconciliationPercentIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (decreases) resulting from:</link:label>
    <link:label id="lab_brns_EffectiveIncomeTaxRateReconciliationPercentIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_brns_EffectiveIncomeTaxRateReconciliationPercentIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent, Increase (Decrease) [Abstract]</link:label>
    <link:label id="lab_brns_EffectiveIncomeTaxRateReconciliationPercentIncreaseDecreaseAbstract_documentation_en-US" xlink:label="lab_brns_EffectiveIncomeTaxRateReconciliationPercentIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent, Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_EffectiveIncomeTaxRateReconciliationPercentIncreaseDecreaseAbstract" xlink:href="brns-20231231.xsd#brns_EffectiveIncomeTaxRateReconciliationPercentIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_EffectiveIncomeTaxRateReconciliationPercentIncreaseDecreaseAbstract" xlink:to="lab_brns_EffectiveIncomeTaxRateReconciliationPercentIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy_5a375e15-5796-4343-b24e-d401edf016f7_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets acquired through business combinations</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_7bc9233d-2cfa-4635-bd6f-a5aeb0fe9949_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business combinations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_6545f9a2-60d5-45f5-800e-71392585c1f0_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated Useful Life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillDisclosureTextBlock_56887569-8fa4-4c3e-b54b-4e3f6881be6c_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_ffc6945f-61b8-451e-a831-9967f44070f1_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_e97c9b2f-a7f6-4728-ac38-9491fb5166cb_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_f55684d4-60e7-43dc-8272-932a5da8040c_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total deferred tax, net</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3ac1aeaa-7849-4c2f-934f-805591793202_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average ordinary shares outstanding, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d64f68f7-92d0-46e7-b5a7-ad8c128fb6eb_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Weighted-average ordinary shares outstanding, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SummaryOfValuationAllowanceTextBlock_bc2d4cc8-a311-49b5-a9a2-1abc8013e9a3_terseLabel_en-US" xlink:label="lab_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of changes in the valuation allowance for deferred tax assets</link:label>
    <link:label id="lab_us-gaap_SummaryOfValuationAllowanceTextBlock_label_en-US" xlink:label="lab_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary of Valuation Allowance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:to="lab_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_ValuationAllowanceDeferredTaxAssetIncreaseResultingFromCurrentPeriodAdditions_e5fc0b1c-c1f9-4ed8-8160-ece8c034a820_terseLabel_en-US" xlink:label="lab_brns_ValuationAllowanceDeferredTaxAssetIncreaseResultingFromCurrentPeriodAdditions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in valuation allowance arising from in-year additions</link:label>
    <link:label id="lab_brns_ValuationAllowanceDeferredTaxAssetIncreaseResultingFromCurrentPeriodAdditions_label_en-US" xlink:label="lab_brns_ValuationAllowanceDeferredTaxAssetIncreaseResultingFromCurrentPeriodAdditions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase Resulting From Current Period Additions</link:label>
    <link:label id="lab_brns_ValuationAllowanceDeferredTaxAssetIncreaseResultingFromCurrentPeriodAdditions_documentation_en-US" xlink:label="lab_brns_ValuationAllowanceDeferredTaxAssetIncreaseResultingFromCurrentPeriodAdditions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase Resulting From Current Period Additions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ValuationAllowanceDeferredTaxAssetIncreaseResultingFromCurrentPeriodAdditions" xlink:href="brns-20231231.xsd#brns_ValuationAllowanceDeferredTaxAssetIncreaseResultingFromCurrentPeriodAdditions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_ValuationAllowanceDeferredTaxAssetIncreaseResultingFromCurrentPeriodAdditions" xlink:to="lab_brns_ValuationAllowanceDeferredTaxAssetIncreaseResultingFromCurrentPeriodAdditions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_2792ef78-4702-4883-9ce0-b0e86bb88b5e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional number of shares available for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_55d6dbea-c45a-49a0-898a-210ab5fe7fe9_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_d84c3636-5fe0-4277-8a60-4eb28f986811_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Out-licenses and Grants</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_df11cae1-e724-48fa-9bf7-614ae57cd206_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_71ddd0e0-a953-4c5d-8ceb-f3500c376949_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-in-capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_0fd918de-831e-4a64-9aca-d5bcda971f7c_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_NumberOfSquareFeetUnderLeaseAgreement_ed559b59-4575-4d83-9a7a-3e65c98ca89c_terseLabel_en-US" xlink:label="lab_brns_NumberOfSquareFeetUnderLeaseAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Size of space under lease agreement (in square feet)</link:label>
    <link:label id="lab_brns_NumberOfSquareFeetUnderLeaseAgreement_label_en-US" xlink:label="lab_brns_NumberOfSquareFeetUnderLeaseAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Square Feet Under Lease Agreement</link:label>
    <link:label id="lab_brns_NumberOfSquareFeetUnderLeaseAgreement_documentation_en-US" xlink:label="lab_brns_NumberOfSquareFeetUnderLeaseAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the information pertaining to number of Square Feet Under Lease Agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_NumberOfSquareFeetUnderLeaseAgreement" xlink:href="brns-20231231.xsd#brns_NumberOfSquareFeetUnderLeaseAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_NumberOfSquareFeetUnderLeaseAgreement" xlink:to="lab_brns_NumberOfSquareFeetUnderLeaseAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostAbstract_9ab38a70-3c7a-46ba-93c3-2b0b810a335a_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease Costs</link:label>
    <link:label id="lab_us-gaap_LeaseCostAbstract_label_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostAbstract" xlink:to="lab_us-gaap_LeaseCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_ae13e4f9-1d10-41dc-99c9-4050d681bda1_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_IncomeTaxesTable_27504df2-7993-4ae4-9296-4928428f3fb3_terseLabel_en-US" xlink:label="lab_brns_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:label id="lab_brns_IncomeTaxesTable_label_en-US" xlink:label="lab_brns_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:label id="lab_brns_IncomeTaxesTable_documentation_en-US" xlink:label="lab_brns_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_IncomeTaxesTable" xlink:href="brns-20231231.xsd#brns_IncomeTaxesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_IncomeTaxesTable" xlink:to="lab_brns_IncomeTaxesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_eaadcbaf-1f7d-4396-8b6a-516cf1cdab1c_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_df8d0282-b83b-4c90-b2bf-cf7a3046c92c_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_74931144-b0bb-4709-bdfd-14bbbc3dcb87_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_e12aa2dd-0279-4e53-a639-40d7f073973f_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_ad2de474-7705-4af8-9ada-1ee2835dff28_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_71d2b687-2c67-4820-9425-20d358694b1e_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total minimum lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_1d0ae4ae-c0c7-43b7-9066-4c0804acd12d_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited/expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_25047983-a836-4798-b50f-e0d14e50d84f_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Benefit Plans</link:label>
    <link:label id="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_label_en-US" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation and Employee Benefit Plans [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_f998b8b2-2e37-4035-aa27-4ed993c7eb6f_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ordinary Shares</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_8f92af61-411c-4b33-bb97-338adeb82051_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_72348fbe-82d2-4b33-997b-05438cd61bc3_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net decrease in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_11701587-5252-44c5-9918-560833ac2d41_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_999c95ba-2425-4e39-8861-7b2787657107_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_ConcentrationRiskThresholdPercentage_8a67709c-4575-43df-8180-8ff7a2939bea_terseLabel_en-US" xlink:label="lab_brns_ConcentrationRiskThresholdPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration risk, percentage</link:label>
    <link:label id="lab_brns_ConcentrationRiskThresholdPercentage_label_en-US" xlink:label="lab_brns_ConcentrationRiskThresholdPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Threshold Percentage</link:label>
    <link:label id="lab_brns_ConcentrationRiskThresholdPercentage_documentation_en-US" xlink:label="lab_brns_ConcentrationRiskThresholdPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">For an entity that discloses a concentration risk threshold Percentage in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ConcentrationRiskThresholdPercentage" xlink:href="brns-20231231.xsd#brns_ConcentrationRiskThresholdPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_ConcentrationRiskThresholdPercentage" xlink:to="lab_brns_ConcentrationRiskThresholdPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_3b9da633-f838-47d0-b728-d87f8350f966_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development credit carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_7e6e5889-36c2-4a9a-b087-8936e756726d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_906f4a54-bd4a-4a2a-a360-84407b803ee3_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average ordinary shares outstanding, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_3895366a-1773-41dd-9e83-5b846e39c013_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_46c4dc83-70ba-44fb-be82-e287103adf64_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_17e1aed3-3bae-48fe-b1e4-2236be296bd2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_ec94f795-f48f-4989-a6bb-0e81987792fd_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_49a5a127-87a8-46da-9b10-ce41b686f279_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesDomain" xlink:to="lab_srt_ConsolidatedEntitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent_9f6e19b4-774d-45b3-b5dd-2de99559fdce_terseLabel_en-US" xlink:label="lab_brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent_107f2523-acb1-4875-83a3-698f7063dbde_totalLabel_en-US" xlink:label="lab_brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent_label_en-US" xlink:label="lab_brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities and Other Liabilities, Current</link:label>
    <link:label id="lab_brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent_documentation_en-US" xlink:label="lab_brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:href="brns-20231231.xsd#brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:to="lab_brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_bd7d1f0f-be1e-4f9f-8757-0b56dc29fa66_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issue of shares from the exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_5a26a711-fe91-4de6-9d1a-06e599eccb86_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_deb70a7e-05a9-407a-839e-d08ddace6e5c_verboseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_7c059c46-0adc-450c-9182-ea8f4c9377c5_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_82a42eac-df83-465f-b482-22ca5dd81601_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_cf0a8105-abe9-4fd4-b392-531f73f2b4bd_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_ec62cf5b-d9f9-4f25-9779-b31efcb81cfd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_cd9379d9-cd4b-41af-a5de-03d1caf74630_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Disclosures</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_21da7bb4-33f0-4f15-b6c6-40515deef59e_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_259d9008-adde-4e00-b49c-e3a1e2f0ff1c_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>brns-20231231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:568bf53a-35e8-4830-ae45-40f379b83a88,g:160c7384-88e8-453d-8496-8cc857f3b5f9-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.barinthusbio.com/role/Cover" xlink:type="simple" xlink:href="brns-20231231.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_9235278b-9688-46d1-a66e-64b989c7547a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_789cdf02-1d99-41af-a2dc-dbb0ceac7457" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9235278b-9688-46d1-a66e-64b989c7547a" xlink:to="loc_dei_DocumentInformationTable_789cdf02-1d99-41af-a2dc-dbb0ceac7457" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_cdcb25bf-5b66-45db-a441-538a7cbaa217" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_789cdf02-1d99-41af-a2dc-dbb0ceac7457" xlink:to="loc_us-gaap_StatementClassOfStockAxis_cdcb25bf-5b66-45db-a441-538a7cbaa217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_5dd47c46-baa8-46f0-9a00-0d75534852ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_cdcb25bf-5b66-45db-a441-538a7cbaa217" xlink:to="loc_us-gaap_ClassOfStockDomain_5dd47c46-baa8-46f0-9a00-0d75534852ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_de03bfca-98e2-4b31-bff3-2c580b37e2a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_5dd47c46-baa8-46f0-9a00-0d75534852ec" xlink:to="loc_us-gaap_CommonStockMember_de03bfca-98e2-4b31-bff3-2c580b37e2a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_AmericanDepositarySharesMember_31402981-6e59-4f1e-9128-3c58a8e07f45" xlink:href="brns-20231231.xsd#brns_AmericanDepositarySharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_5dd47c46-baa8-46f0-9a00-0d75534852ec" xlink:to="loc_brns_AmericanDepositarySharesMember_31402981-6e59-4f1e-9128-3c58a8e07f45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_cf15fe6d-ef71-4b43-9c7e-a47bb857b51e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_789cdf02-1d99-41af-a2dc-dbb0ceac7457" xlink:to="loc_dei_DocumentInformationLineItems_cf15fe6d-ef71-4b43-9c7e-a47bb857b51e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_280c48ea-c226-44e2-bc5a-f369cf1a0313" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_cf15fe6d-ef71-4b43-9c7e-a47bb857b51e" xlink:to="loc_dei_DocumentType_280c48ea-c226-44e2-bc5a-f369cf1a0313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_04a091e7-a49c-41d5-aa3a-d48a7ad6c881" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_cf15fe6d-ef71-4b43-9c7e-a47bb857b51e" xlink:to="loc_dei_DocumentAnnualReport_04a091e7-a49c-41d5-aa3a-d48a7ad6c881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_7c4462c3-66bb-4da1-b080-598ffd343506" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_cf15fe6d-ef71-4b43-9c7e-a47bb857b51e" xlink:to="loc_dei_DocumentPeriodEndDate_7c4462c3-66bb-4da1-b080-598ffd343506" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_28397e28-c5e8-47aa-9d00-be45d8654f39" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_cf15fe6d-ef71-4b43-9c7e-a47bb857b51e" xlink:to="loc_dei_CurrentFiscalYearEndDate_28397e28-c5e8-47aa-9d00-be45d8654f39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_1045e961-6002-49d2-b6e7-ec0ce936984b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_cf15fe6d-ef71-4b43-9c7e-a47bb857b51e" xlink:to="loc_dei_DocumentTransitionReport_1045e961-6002-49d2-b6e7-ec0ce936984b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_af7b94f9-748d-4476-ad4b-b70afedc1dc0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_cf15fe6d-ef71-4b43-9c7e-a47bb857b51e" xlink:to="loc_dei_EntityFileNumber_af7b94f9-748d-4476-ad4b-b70afedc1dc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_7a74c40b-6db6-43b8-a8b5-de175b2c4717" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_cf15fe6d-ef71-4b43-9c7e-a47bb857b51e" xlink:to="loc_dei_EntityRegistrantName_7a74c40b-6db6-43b8-a8b5-de175b2c4717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_5b66d3a5-d7a5-4ee8-9f5f-53690f5a684a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_cf15fe6d-ef71-4b43-9c7e-a47bb857b51e" xlink:to="loc_dei_EntityIncorporationStateCountryCode_5b66d3a5-d7a5-4ee8-9f5f-53690f5a684a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_28a3cce2-05b4-4395-ba31-c7fbaef2ec16" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_cf15fe6d-ef71-4b43-9c7e-a47bb857b51e" xlink:to="loc_dei_EntityTaxIdentificationNumber_28a3cce2-05b4-4395-ba31-c7fbaef2ec16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_008328d9-b461-4245-ab3c-9320761babbf" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_cf15fe6d-ef71-4b43-9c7e-a47bb857b51e" xlink:to="loc_dei_EntityAddressAddressLine1_008328d9-b461-4245-ab3c-9320761babbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_dd8861d3-9669-40bb-af31-984ef0cf319d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_cf15fe6d-ef71-4b43-9c7e-a47bb857b51e" xlink:to="loc_dei_EntityAddressAddressLine2_dd8861d3-9669-40bb-af31-984ef0cf319d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_50ecd367-83b1-4774-b7f8-bc3cc77e7f9f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_cf15fe6d-ef71-4b43-9c7e-a47bb857b51e" xlink:to="loc_dei_EntityAddressCityOrTown_50ecd367-83b1-4774-b7f8-bc3cc77e7f9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_5b9c42cc-b3bd-4ee0-b8cf-25cf86cbc954" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_cf15fe6d-ef71-4b43-9c7e-a47bb857b51e" xlink:to="loc_dei_EntityAddressPostalZipCode_5b9c42cc-b3bd-4ee0-b8cf-25cf86cbc954" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry_7f02ac64-3649-4793-b01c-9ac6bf9d7215" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_cf15fe6d-ef71-4b43-9c7e-a47bb857b51e" xlink:to="loc_dei_EntityAddressCountry_7f02ac64-3649-4793-b01c-9ac6bf9d7215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_3d5197e7-3038-49f4-a737-d37f12aa3ab1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_cf15fe6d-ef71-4b43-9c7e-a47bb857b51e" xlink:to="loc_dei_CityAreaCode_3d5197e7-3038-49f4-a737-d37f12aa3ab1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_db93448b-850e-4bfb-a197-8f4c20c46c98" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_cf15fe6d-ef71-4b43-9c7e-a47bb857b51e" xlink:to="loc_dei_LocalPhoneNumber_db93448b-850e-4bfb-a197-8f4c20c46c98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_ea5a0bdf-d481-4c0e-a740-0744028559ec" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_cf15fe6d-ef71-4b43-9c7e-a47bb857b51e" xlink:to="loc_dei_Security12bTitle_ea5a0bdf-d481-4c0e-a740-0744028559ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_fad4b185-1e02-4fb5-9133-c948f0b28f40" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_cf15fe6d-ef71-4b43-9c7e-a47bb857b51e" xlink:to="loc_dei_TradingSymbol_fad4b185-1e02-4fb5-9133-c948f0b28f40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_c9b65939-1566-4321-925f-960a014cce57" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_cf15fe6d-ef71-4b43-9c7e-a47bb857b51e" xlink:to="loc_dei_SecurityExchangeName_c9b65939-1566-4321-925f-960a014cce57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_51cafe5f-2193-46d2-87d0-04b731853818" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_cf15fe6d-ef71-4b43-9c7e-a47bb857b51e" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_51cafe5f-2193-46d2-87d0-04b731853818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_b6c5417d-7a72-4f7f-b01b-7d8c7124e7e6" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_cf15fe6d-ef71-4b43-9c7e-a47bb857b51e" xlink:to="loc_dei_EntityVoluntaryFilers_b6c5417d-7a72-4f7f-b01b-7d8c7124e7e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_f95db436-4ab4-4964-85f8-1e26bec28c23" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_cf15fe6d-ef71-4b43-9c7e-a47bb857b51e" xlink:to="loc_dei_EntityCurrentReportingStatus_f95db436-4ab4-4964-85f8-1e26bec28c23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_f3dd1577-bfee-4478-ba31-69362052b2d2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_cf15fe6d-ef71-4b43-9c7e-a47bb857b51e" xlink:to="loc_dei_EntityInteractiveDataCurrent_f3dd1577-bfee-4478-ba31-69362052b2d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_259e5a26-af80-495d-918b-c4e0dca004d7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_cf15fe6d-ef71-4b43-9c7e-a47bb857b51e" xlink:to="loc_dei_EntityFilerCategory_259e5a26-af80-495d-918b-c4e0dca004d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_2ed61f7d-e57e-4c09-8de1-91bbc5907e18" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_cf15fe6d-ef71-4b43-9c7e-a47bb857b51e" xlink:to="loc_dei_EntitySmallBusiness_2ed61f7d-e57e-4c09-8de1-91bbc5907e18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_df8ac37d-d295-4a8a-80dd-a5db18b183ba" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_cf15fe6d-ef71-4b43-9c7e-a47bb857b51e" xlink:to="loc_dei_EntityEmergingGrowthCompany_df8ac37d-d295-4a8a-80dd-a5db18b183ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_9a57dcf8-4c9c-40ef-8d2a-a988ebf994c9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_cf15fe6d-ef71-4b43-9c7e-a47bb857b51e" xlink:to="loc_dei_EntityExTransitionPeriod_9a57dcf8-4c9c-40ef-8d2a-a988ebf994c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_a00efc24-f6b8-42f9-84e7-d12c113374d3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_cf15fe6d-ef71-4b43-9c7e-a47bb857b51e" xlink:to="loc_dei_IcfrAuditorAttestationFlag_a00efc24-f6b8-42f9-84e7-d12c113374d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_c20fa2f4-2e37-4b92-a419-77e0e1393f4c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_cf15fe6d-ef71-4b43-9c7e-a47bb857b51e" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_c20fa2f4-2e37-4b92-a419-77e0e1393f4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_074eb22c-1fa4-426b-8151-2f69bc8c8d6c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_cf15fe6d-ef71-4b43-9c7e-a47bb857b51e" xlink:to="loc_dei_EntityShellCompany_074eb22c-1fa4-426b-8151-2f69bc8c8d6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_d9fce211-138f-482f-9c45-75feb58e051f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_cf15fe6d-ef71-4b43-9c7e-a47bb857b51e" xlink:to="loc_dei_EntityPublicFloat_d9fce211-138f-482f-9c45-75feb58e051f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_74904a83-67c3-4edc-a2eb-c2b78ec7d024" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_cf15fe6d-ef71-4b43-9c7e-a47bb857b51e" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_74904a83-67c3-4edc-a2eb-c2b78ec7d024" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_fd4c492e-845e-4511-988e-48d72d64481d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_cf15fe6d-ef71-4b43-9c7e-a47bb857b51e" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_fd4c492e-845e-4511-988e-48d72d64481d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_c818d7dd-10b7-46a3-bf21-72e551832537" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_cf15fe6d-ef71-4b43-9c7e-a47bb857b51e" xlink:to="loc_dei_EntityCentralIndexKey_c818d7dd-10b7-46a3-bf21-72e551832537" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_6a674b4a-4404-4af3-a098-ee43c2583426" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_cf15fe6d-ef71-4b43-9c7e-a47bb857b51e" xlink:to="loc_dei_DocumentFiscalYearFocus_6a674b4a-4404-4af3-a098-ee43c2583426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_ef2667fb-dd24-4b8d-ba4c-71951cde4b2e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_cf15fe6d-ef71-4b43-9c7e-a47bb857b51e" xlink:to="loc_dei_DocumentFiscalPeriodFocus_ef2667fb-dd24-4b8d-ba4c-71951cde4b2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_a857f186-9d71-42e3-ad87-e440ce94521a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="37" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_cf15fe6d-ef71-4b43-9c7e-a47bb857b51e" xlink:to="loc_dei_AmendmentFlag_a857f186-9d71-42e3-ad87-e440ce94521a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/AuditInformation" xlink:type="simple" xlink:href="brns-20231231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_brns_AuditInformationAbstract_a4809e78-29ba-4b7a-ad9a-b9d5b46a44a3" xlink:href="brns-20231231.xsd#brns_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_cd2ef2c7-54a4-40fb-aef3-c4419ea65ede" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_brns_AuditInformationAbstract_a4809e78-29ba-4b7a-ad9a-b9d5b46a44a3" xlink:to="loc_dei_AuditorFirmId_cd2ef2c7-54a4-40fb-aef3-c4419ea65ede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_37352260-5525-4218-9b10-76dd67960430" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_brns_AuditInformationAbstract_a4809e78-29ba-4b7a-ad9a-b9d5b46a44a3" xlink:to="loc_dei_AuditorName_37352260-5525-4218-9b10-76dd67960430" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_f9cfe24f-3a5f-4bf6-a0c6-ea7215521301" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_brns_AuditInformationAbstract_a4809e78-29ba-4b7a-ad9a-b9d5b46a44a3" xlink:to="loc_dei_AuditorLocation_f9cfe24f-3a5f-4bf6-a0c6-ea7215521301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="brns-20231231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_b1e51c2c-c636-48ce-8ddf-2e5cced3e3ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_2f71b51b-3403-419a-85c3-d5890df13195" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b1e51c2c-c636-48ce-8ddf-2e5cced3e3ea" xlink:to="loc_us-gaap_StatementTable_2f71b51b-3403-419a-85c3-d5890df13195" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2e43085c-f627-4fd4-8d6f-d528aee52a45" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2f71b51b-3403-419a-85c3-d5890df13195" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2e43085c-f627-4fd4-8d6f-d528aee52a45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_61cacd9e-1acc-48e7-8c35-fa6fcd9867e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2e43085c-f627-4fd4-8d6f-d528aee52a45" xlink:to="loc_us-gaap_RelatedPartyDomain_61cacd9e-1acc-48e7-8c35-fa6fcd9867e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember_45d2b802-5332-4ac9-bfc1-a8f16b365481" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_61cacd9e-1acc-48e7-8c35-fa6fcd9867e5" xlink:to="loc_us-gaap_NonrelatedPartyMember_45d2b802-5332-4ac9-bfc1-a8f16b365481" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_3e17b4a5-7a9d-4879-b744-d1b07738305e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_61cacd9e-1acc-48e7-8c35-fa6fcd9867e5" xlink:to="loc_us-gaap_RelatedPartyMember_3e17b4a5-7a9d-4879-b744-d1b07738305e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_ba2beab3-330c-4b0d-8d92-ef484e2c35f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2f71b51b-3403-419a-85c3-d5890df13195" xlink:to="loc_us-gaap_StatementClassOfStockAxis_ba2beab3-330c-4b0d-8d92-ef484e2c35f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_0cd623b8-6e44-4ed4-bd1c-4bb44d02b3ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ba2beab3-330c-4b0d-8d92-ef484e2c35f2" xlink:to="loc_us-gaap_ClassOfStockDomain_0cd623b8-6e44-4ed4-bd1c-4bb44d02b3ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredShares.Member_345aa8cc-1d14-43ea-a346-b7e4d9889346" xlink:href="brns-20231231.xsd#brns_DeferredShares.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_0cd623b8-6e44-4ed4-bd1c-4bb44d02b3ba" xlink:to="loc_brns_DeferredShares.Member_345aa8cc-1d14-43ea-a346-b7e4d9889346" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredBSharesMember_e9518342-d055-48a9-8ed6-f239ecf0f8b7" xlink:href="brns-20231231.xsd#brns_DeferredBSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_0cd623b8-6e44-4ed4-bd1c-4bb44d02b3ba" xlink:to="loc_brns_DeferredBSharesMember_e9518342-d055-48a9-8ed6-f239ecf0f8b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredCSharesMember_bc477291-c0c1-43c6-a4a2-00502001f048" xlink:href="brns-20231231.xsd#brns_DeferredCSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_0cd623b8-6e44-4ed4-bd1c-4bb44d02b3ba" xlink:to="loc_brns_DeferredCSharesMember_bc477291-c0c1-43c6-a4a2-00502001f048" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_ac1ec670-23e4-495b-9879-f541a800fa5d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2f71b51b-3403-419a-85c3-d5890df13195" xlink:to="loc_us-gaap_StatementLineItems_ac1ec670-23e4-495b-9879-f541a800fa5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_95811e89-826b-4ddb-8321-00d5ec9df4f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ac1ec670-23e4-495b-9879-f541a800fa5d" xlink:to="loc_us-gaap_AssetsAbstract_95811e89-826b-4ddb-8321-00d5ec9df4f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_24dee1b9-4dd8-4c36-8902-ab95333e90ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_95811e89-826b-4ddb-8321-00d5ec9df4f4" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_24dee1b9-4dd8-4c36-8902-ab95333e90ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_c8d67a2a-000e-4889-977f-03b2ddf4a670" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_95811e89-826b-4ddb-8321-00d5ec9df4f4" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_c8d67a2a-000e-4889-977f-03b2ddf4a670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ResearchAndDevelopmentIncentivesReceivable_5c386d21-f710-4827-9a20-64101af16cdd" xlink:href="brns-20231231.xsd#brns_ResearchAndDevelopmentIncentivesReceivable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_95811e89-826b-4ddb-8321-00d5ec9df4f4" xlink:to="loc_brns_ResearchAndDevelopmentIncentivesReceivable_5c386d21-f710-4827-9a20-64101af16cdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8bbb12db-d6f0-489d-9166-ceebacd8daf8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_95811e89-826b-4ddb-8321-00d5ec9df4f4" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8bbb12db-d6f0-489d-9166-ceebacd8daf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_0fe3daee-cc3a-407f-8509-7e79cdc4cb34" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_95811e89-826b-4ddb-8321-00d5ec9df4f4" xlink:to="loc_us-gaap_AssetsCurrent_0fe3daee-cc3a-407f-8509-7e79cdc4cb34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_f7bcd639-6870-4047-bb31-10c18c3fa026" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_95811e89-826b-4ddb-8321-00d5ec9df4f4" xlink:to="loc_us-gaap_Goodwill_f7bcd639-6870-4047-bb31-10c18c3fa026" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_e13bae08-e041-4e95-9c20-8472e58a6369" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_95811e89-826b-4ddb-8321-00d5ec9df4f4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_e13bae08-e041-4e95-9c20-8472e58a6369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_5fb61395-2cac-42cd-9c31-02be0a142f94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_95811e89-826b-4ddb-8321-00d5ec9df4f4" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_5fb61395-2cac-42cd-9c31-02be0a142f94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_176d066f-94a6-4db8-8c42-7b0199adccb6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_95811e89-826b-4ddb-8321-00d5ec9df4f4" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_176d066f-94a6-4db8-8c42-7b0199adccb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssets_b132612f-c64a-4af7-9823-73063f1c4e8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssets"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_95811e89-826b-4ddb-8321-00d5ec9df4f4" xlink:to="loc_us-gaap_OtherAssets_b132612f-c64a-4af7-9823-73063f1c4e8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_b5f38b81-03e5-4f42-904f-3067332334de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_95811e89-826b-4ddb-8321-00d5ec9df4f4" xlink:to="loc_us-gaap_Assets_b5f38b81-03e5-4f42-904f-3067332334de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_99e75fe2-c4b2-4451-abe0-6dab1ef197a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ac1ec670-23e4-495b-9879-f541a800fa5d" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_99e75fe2-c4b2-4451-abe0-6dab1ef197a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_a75a2ebe-5767-47c3-9d3b-d07920fb349c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_99e75fe2-c4b2-4451-abe0-6dab1ef197a2" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_a75a2ebe-5767-47c3-9d3b-d07920fb349c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_58ff531d-25e3-42ca-b96c-0923e0d66506" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a75a2ebe-5767-47c3-9d3b-d07920fb349c" xlink:to="loc_us-gaap_AccountsPayableCurrent_58ff531d-25e3-42ca-b96c-0923e0d66506" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent_900c903b-034a-4e53-a9f6-fbb5876cd661" xlink:href="brns-20231231.xsd#brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a75a2ebe-5767-47c3-9d3b-d07920fb349c" xlink:to="loc_brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent_900c903b-034a-4e53-a9f6-fbb5876cd661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_b5d23ff8-38c0-48cc-b47f-4f27a378eb5d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a75a2ebe-5767-47c3-9d3b-d07920fb349c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_b5d23ff8-38c0-48cc-b47f-4f27a378eb5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_e3d03726-4318-4f27-909d-bdb329a3d73c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a75a2ebe-5767-47c3-9d3b-d07920fb349c" xlink:to="loc_us-gaap_LiabilitiesCurrent_e3d03726-4318-4f27-909d-bdb329a3d73c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_f5359bfd-45f8-4f2f-8d57-16e975b6ea71" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_99e75fe2-c4b2-4451-abe0-6dab1ef197a2" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_f5359bfd-45f8-4f2f-8d57-16e975b6ea71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_8e0e5046-7134-47eb-a15c-fa029aa69c1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_f5359bfd-45f8-4f2f-8d57-16e975b6ea71" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_8e0e5046-7134-47eb-a15c-fa029aa69c1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_fdbe6dc3-6862-4961-8b89-81bb39cd6fe2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_f5359bfd-45f8-4f2f-8d57-16e975b6ea71" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_fdbe6dc3-6862-4961-8b89-81bb39cd6fe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_502d0e84-5f5d-44be-900c-53878ab687c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_f5359bfd-45f8-4f2f-8d57-16e975b6ea71" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_502d0e84-5f5d-44be-900c-53878ab687c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredTaxLiabilityNet_710ca327-3fc0-45ed-871d-ba20af9cae0d" xlink:href="brns-20231231.xsd#brns_DeferredTaxLiabilityNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_f5359bfd-45f8-4f2f-8d57-16e975b6ea71" xlink:to="loc_brns_DeferredTaxLiabilityNet_710ca327-3fc0-45ed-871d-ba20af9cae0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_db368fb6-1a2e-430c-95ea-01a82b5132ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_99e75fe2-c4b2-4451-abe0-6dab1ef197a2" xlink:to="loc_us-gaap_Liabilities_db368fb6-1a2e-430c-95ea-01a82b5132ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_67bd7c12-07df-403d-9a6f-fcf940774cf5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_99e75fe2-c4b2-4451-abe0-6dab1ef197a2" xlink:to="loc_us-gaap_CommitmentsAndContingencies_67bd7c12-07df-403d-9a6f-fcf940774cf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_24be7ee1-28a6-4092-857d-ea5b8477c9d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_99e75fe2-c4b2-4451-abe0-6dab1ef197a2" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_24be7ee1-28a6-4092-857d-ea5b8477c9d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_2779cf99-48f6-4a69-856c-e784fcbc2de0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_24be7ee1-28a6-4092-857d-ea5b8477c9d2" xlink:to="loc_us-gaap_CommonStockValue_2779cf99-48f6-4a69-856c-e784fcbc2de0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredStockValueIssued_4e15935e-d690-42d8-9dce-218dc05541d1" xlink:href="brns-20231231.xsd#brns_DeferredStockValueIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_24be7ee1-28a6-4092-857d-ea5b8477c9d2" xlink:to="loc_brns_DeferredStockValueIssued_4e15935e-d690-42d8-9dce-218dc05541d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_3b6c936b-d7a2-4332-92c9-e8d3d1b82496" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_24be7ee1-28a6-4092-857d-ea5b8477c9d2" xlink:to="loc_us-gaap_AdditionalPaidInCapital_3b6c936b-d7a2-4332-92c9-e8d3d1b82496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5676f05c-0763-4cc3-a42a-dfad6fa53f1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_24be7ee1-28a6-4092-857d-ea5b8477c9d2" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5676f05c-0763-4cc3-a42a-dfad6fa53f1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_2013b70d-fc80-4bfe-9f9a-fba1075dcb93" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_24be7ee1-28a6-4092-857d-ea5b8477c9d2" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_2013b70d-fc80-4bfe-9f9a-fba1075dcb93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_07a26318-d98c-4fca-bb3d-277d105112eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_24be7ee1-28a6-4092-857d-ea5b8477c9d2" xlink:to="loc_us-gaap_StockholdersEquity_07a26318-d98c-4fca-bb3d-277d105112eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_174840f9-8430-42b6-9a8a-029209251ad1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_24be7ee1-28a6-4092-857d-ea5b8477c9d2" xlink:to="loc_us-gaap_MinorityInterest_174840f9-8430-42b6-9a8a-029209251ad1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_becfc47b-5b38-4a35-bda4-d5c89c7fe7d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_24be7ee1-28a6-4092-857d-ea5b8477c9d2" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_becfc47b-5b38-4a35-bda4-d5c89c7fe7d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_233af636-7a7c-454b-88d1-f4ac496162ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_99e75fe2-c4b2-4451-abe0-6dab1ef197a2" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_233af636-7a7c-454b-88d1-f4ac496162ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="brns-20231231.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_1feb98c8-99b5-4e40-b18d-83469acffe06" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_891f302f-4d0d-455f-8e0c-3ca96bd71edf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1feb98c8-99b5-4e40-b18d-83469acffe06" xlink:to="loc_us-gaap_StatementTable_891f302f-4d0d-455f-8e0c-3ca96bd71edf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_9bd5aab0-aafa-470a-8b9e-15c7fc1912ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_891f302f-4d0d-455f-8e0c-3ca96bd71edf" xlink:to="loc_us-gaap_StatementClassOfStockAxis_9bd5aab0-aafa-470a-8b9e-15c7fc1912ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_e94e9556-8904-4e2f-827d-bdcc85caae91" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9bd5aab0-aafa-470a-8b9e-15c7fc1912ff" xlink:to="loc_us-gaap_ClassOfStockDomain_e94e9556-8904-4e2f-827d-bdcc85caae91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredShares.Member_0c8ae606-d8b0-40d6-9fe5-0d49c218b3bb" xlink:href="brns-20231231.xsd#brns_DeferredShares.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_e94e9556-8904-4e2f-827d-bdcc85caae91" xlink:to="loc_brns_DeferredShares.Member_0c8ae606-d8b0-40d6-9fe5-0d49c218b3bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredBSharesMember_dd268da3-abb9-4fe9-b6c6-1f86049330bc" xlink:href="brns-20231231.xsd#brns_DeferredBSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_e94e9556-8904-4e2f-827d-bdcc85caae91" xlink:to="loc_brns_DeferredBSharesMember_dd268da3-abb9-4fe9-b6c6-1f86049330bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredCSharesMember_208b0ee1-30e6-4717-a597-883f35b54ffa" xlink:href="brns-20231231.xsd#brns_DeferredCSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_e94e9556-8904-4e2f-827d-bdcc85caae91" xlink:to="loc_brns_DeferredCSharesMember_208b0ee1-30e6-4717-a597-883f35b54ffa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_c662cd4f-4dc3-4261-b0d6-f4d2f2ffdd64" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_891f302f-4d0d-455f-8e0c-3ca96bd71edf" xlink:to="loc_us-gaap_StatementLineItems_c662cd4f-4dc3-4261-b0d6-f4d2f2ffdd64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_4e3ed841-4b00-4ec2-96d4-97977c7ea1d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c662cd4f-4dc3-4261-b0d6-f4d2f2ffdd64" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_4e3ed841-4b00-4ec2-96d4-97977c7ea1d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_6e689c06-4259-419a-bc38-16265e98d115" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c662cd4f-4dc3-4261-b0d6-f4d2f2ffdd64" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_6e689c06-4259-419a-bc38-16265e98d115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_2a7807bb-9063-49a6-98c0-2bb16d61d308" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c662cd4f-4dc3-4261-b0d6-f4d2f2ffdd64" xlink:to="loc_us-gaap_CommonStockSharesIssued_2a7807bb-9063-49a6-98c0-2bb16d61d308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_05b6c1fe-c04c-44bc-ada2-8f91be9d528c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c662cd4f-4dc3-4261-b0d6-f4d2f2ffdd64" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_05b6c1fe-c04c-44bc-ada2-8f91be9d528c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredStockParOrStatedValuePerShare_81057e77-ea85-4820-879a-41a788dc0e16" xlink:href="brns-20231231.xsd#brns_DeferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c662cd4f-4dc3-4261-b0d6-f4d2f2ffdd64" xlink:to="loc_brns_DeferredStockParOrStatedValuePerShare_81057e77-ea85-4820-879a-41a788dc0e16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredStockSharesAuthorized_8d94748f-06bf-4db5-a952-f484f19f83c8" xlink:href="brns-20231231.xsd#brns_DeferredStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c662cd4f-4dc3-4261-b0d6-f4d2f2ffdd64" xlink:to="loc_brns_DeferredStockSharesAuthorized_8d94748f-06bf-4db5-a952-f484f19f83c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredStockSharesIssued_1a74292a-8cdb-4453-a635-f56a52a30f36" xlink:href="brns-20231231.xsd#brns_DeferredStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c662cd4f-4dc3-4261-b0d6-f4d2f2ffdd64" xlink:to="loc_brns_DeferredStockSharesIssued_1a74292a-8cdb-4453-a635-f56a52a30f36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredStockSharesOutstanding_a38156e5-ca61-4cfb-a8ed-82b134c2882c" xlink:href="brns-20231231.xsd#brns_DeferredStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c662cd4f-4dc3-4261-b0d6-f4d2f2ffdd64" xlink:to="loc_brns_DeferredStockSharesOutstanding_a38156e5-ca61-4cfb-a8ed-82b134c2882c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="brns-20231231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_e78a99b0-6f10-431a-a6da-05f5e30c3bd4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_8b3aec4d-2e13-4f10-a2fc-4664215b63e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e78a99b0-6f10-431a-a6da-05f5e30c3bd4" xlink:to="loc_us-gaap_StatementTable_8b3aec4d-2e13-4f10-a2fc-4664215b63e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_286b9161-0bb3-4d3b-8b33-cf7ee47c92ac" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8b3aec4d-2e13-4f10-a2fc-4664215b63e6" xlink:to="loc_srt_ProductOrServiceAxis_286b9161-0bb3-4d3b-8b33-cf7ee47c92ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6d9fbfa6-a1d3-482c-b9d8-1f112569b72c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_286b9161-0bb3-4d3b-8b33-cf7ee47c92ac" xlink:to="loc_srt_ProductsAndServicesDomain_6d9fbfa6-a1d3-482c-b9d8-1f112569b72c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_940d105b-9f08-4375-909f-1966e56d7124" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_6d9fbfa6-a1d3-482c-b9d8-1f112569b72c" xlink:to="loc_us-gaap_LicenseMember_940d105b-9f08-4375-909f-1966e56d7124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ResearchGrantsAndContractsMember_4149f947-ca82-4017-a564-2e486ced684f" xlink:href="brns-20231231.xsd#brns_ResearchGrantsAndContractsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_6d9fbfa6-a1d3-482c-b9d8-1f112569b72c" xlink:to="loc_brns_ResearchGrantsAndContractsMember_4149f947-ca82-4017-a564-2e486ced684f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_e36caab5-e3b5-4229-8553-44c5bcf32d04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8b3aec4d-2e13-4f10-a2fc-4664215b63e6" xlink:to="loc_us-gaap_StatementLineItems_e36caab5-e3b5-4229-8553-44c5bcf32d04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c0fe8f4b-1990-4651-91e9-d4217ba2aece" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e36caab5-e3b5-4229-8553-44c5bcf32d04" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c0fe8f4b-1990-4651-91e9-d4217ba2aece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_bb3f14ca-0b46-4f27-9c92-01d8c201ef39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e36caab5-e3b5-4229-8553-44c5bcf32d04" xlink:to="loc_us-gaap_OperatingExpensesAbstract_bb3f14ca-0b46-4f27-9c92-01d8c201ef39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_f28ee5b8-47f1-41d9-981e-72b8200bb1fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_bb3f14ca-0b46-4f27-9c92-01d8c201ef39" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_f28ee5b8-47f1-41d9-981e-72b8200bb1fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_ddf94da3-2f9d-421e-a6d2-ab6d280942f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_bb3f14ca-0b46-4f27-9c92-01d8c201ef39" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_ddf94da3-2f9d-421e-a6d2-ab6d280942f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_8a0079ff-421b-4374-a2e5-26c0ef96fee0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_bb3f14ca-0b46-4f27-9c92-01d8c201ef39" xlink:to="loc_us-gaap_OperatingExpenses_8a0079ff-421b-4374-a2e5-26c0ef96fee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_bca0a8dd-9df8-41bb-a804-309d1d151601" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_bb3f14ca-0b46-4f27-9c92-01d8c201ef39" xlink:to="loc_us-gaap_OperatingIncomeLoss_bca0a8dd-9df8-41bb-a804-309d1d151601" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_c504a54a-8f87-40b1-be73-d177c818b8b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e36caab5-e3b5-4229-8553-44c5bcf32d04" xlink:to="loc_us-gaap_OtherIncomeAndExpensesAbstract_c504a54a-8f87-40b1-be73-d177c818b8b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_f6480bcd-a16d-4771-a300-f7d62254b958" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_c504a54a-8f87-40b1-be73-d177c818b8b0" xlink:to="loc_us-gaap_InvestmentIncomeInterest_f6480bcd-a16d-4771-a300-f7d62254b958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_faf146dc-d94b-4c82-b4d3-e7d826365c36" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_c504a54a-8f87-40b1-be73-d177c818b8b0" xlink:to="loc_us-gaap_InterestExpense_faf146dc-d94b-4c82-b4d3-e7d826365c36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ResearchAndDevelopmentIncentiveIncomeExpense_f3faadba-5dfd-466b-b267-ddf6bce63f8c" xlink:href="brns-20231231.xsd#brns_ResearchAndDevelopmentIncentiveIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_c504a54a-8f87-40b1-be73-d177c818b8b0" xlink:to="loc_brns_ResearchAndDevelopmentIncentiveIncomeExpense_f3faadba-5dfd-466b-b267-ddf6bce63f8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_cd7a3c5f-5f19-4838-86e1-bc573948abe7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_c504a54a-8f87-40b1-be73-d177c818b8b0" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_cd7a3c5f-5f19-4838-86e1-bc573948abe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_cf2caf89-92a8-4931-be0d-dc8b853fb3ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_c504a54a-8f87-40b1-be73-d177c818b8b0" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_cf2caf89-92a8-4931-be0d-dc8b853fb3ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8ec294b3-eba9-4e96-925d-3aec3a2fc992" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e36caab5-e3b5-4229-8553-44c5bcf32d04" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8ec294b3-eba9-4e96-925d-3aec3a2fc992" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_58958240-2c82-446f-969d-35e54b84bd42" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e36caab5-e3b5-4229-8553-44c5bcf32d04" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_58958240-2c82-446f-969d-35e54b84bd42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_4916065a-a0e9-49ea-a889-861a4737963b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e36caab5-e3b5-4229-8553-44c5bcf32d04" xlink:to="loc_us-gaap_ProfitLoss_4916065a-a0e9-49ea-a889-861a4737963b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_db865df8-04f0-4db5-93ed-194142d59992" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e36caab5-e3b5-4229-8553-44c5bcf32d04" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_db865df8-04f0-4db5-93ed-194142d59992" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b42b8f81-ee66-43a9-958a-c02685facd33" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e36caab5-e3b5-4229-8553-44c5bcf32d04" xlink:to="loc_us-gaap_NetIncomeLoss_b42b8f81-ee66-43a9-958a-c02685facd33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6a5f6ec4-8b48-4d45-b70b-735b72d53e04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e36caab5-e3b5-4229-8553-44c5bcf32d04" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6a5f6ec4-8b48-4d45-b70b-735b72d53e04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4a6d33f2-57d3-40ab-905f-29ed1575a03c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e36caab5-e3b5-4229-8553-44c5bcf32d04" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4a6d33f2-57d3-40ab-905f-29ed1575a03c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_bee1ff85-3472-4958-84ea-1b612f09f5ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e36caab5-e3b5-4229-8553-44c5bcf32d04" xlink:to="loc_us-gaap_EarningsPerShareBasic_bee1ff85-3472-4958-84ea-1b612f09f5ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_992e9778-d141-4613-8acd-fa2b594cfefe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e36caab5-e3b5-4229-8553-44c5bcf32d04" xlink:to="loc_us-gaap_EarningsPerShareDiluted_992e9778-d141-4613-8acd-fa2b594cfefe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_1011101f-a228-4da2-8773-e736e0600fe9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e36caab5-e3b5-4229-8553-44c5bcf32d04" xlink:to="loc_us-gaap_ProfitLoss_1011101f-a228-4da2-8773-e736e0600fe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_7019d32a-04fc-4a6f-9698-38c1656e2002" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e36caab5-e3b5-4229-8553-44c5bcf32d04" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_7019d32a-04fc-4a6f-9698-38c1656e2002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_a4d2a1c3-3f07-44e4-85a8-b68bad2a99db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e36caab5-e3b5-4229-8553-44c5bcf32d04" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_a4d2a1c3-3f07-44e4-85a8-b68bad2a99db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_c4ce9e4b-fa1d-4854-8182-6ec27ab24b21" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e36caab5-e3b5-4229-8553-44c5bcf32d04" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_c4ce9e4b-fa1d-4854-8182-6ec27ab24b21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_d4fcc948-4070-47b7-a0de-fea753e025dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e36caab5-e3b5-4229-8553-44c5bcf32d04" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_d4fcc948-4070-47b7-a0de-fea753e025dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical" xlink:type="simple" xlink:href="brns-20231231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_4755185b-89ab-4fed-9d18-005e76377a5d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_16227075-fa4e-438a-b4be-cfc065749daa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4755185b-89ab-4fed-9d18-005e76377a5d" xlink:to="loc_us-gaap_StatementTable_16227075-fa4e-438a-b4be-cfc065749daa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_96d8bc05-5db8-4a19-854e-45424d5edfab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_16227075-fa4e-438a-b4be-cfc065749daa" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_96d8bc05-5db8-4a19-854e-45424d5edfab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_e93e78f4-c60b-422a-ad88-baaef5beff27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_96d8bc05-5db8-4a19-854e-45424d5edfab" xlink:to="loc_us-gaap_RelatedPartyDomain_e93e78f4-c60b-422a-ad88-baaef5beff27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_f116b763-2124-4d7c-9eeb-57c92f070797" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_e93e78f4-c60b-422a-ad88-baaef5beff27" xlink:to="loc_us-gaap_RelatedPartyMember_f116b763-2124-4d7c-9eeb-57c92f070797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_672a7392-4f39-42fd-8c56-f7cdf155924b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_16227075-fa4e-438a-b4be-cfc065749daa" xlink:to="loc_us-gaap_StatementLineItems_672a7392-4f39-42fd-8c56-f7cdf155924b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a97e2c95-f386-42a1-a77d-746aed7079d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_672a7392-4f39-42fd-8c56-f7cdf155924b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a97e2c95-f386-42a1-a77d-746aed7079d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_6fda9a0d-5c21-4f9d-8e5c-8e5d7826d3f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_672a7392-4f39-42fd-8c56-f7cdf155924b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_6fda9a0d-5c21-4f9d-8e5c-8e5d7826d3f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="brns-20231231.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_1ffbc371-940b-4034-8fac-deb4e3eaf02a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f59ed825-44f0-4d8e-8287-eac9ac6eafc9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_1ffbc371-940b-4034-8fac-deb4e3eaf02a" xlink:to="loc_us-gaap_StatementTable_f59ed825-44f0-4d8e-8287-eac9ac6eafc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2f4abd6a-c6b6-4c86-84be-e593b490a74d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f59ed825-44f0-4d8e-8287-eac9ac6eafc9" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2f4abd6a-c6b6-4c86-84be-e593b490a74d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c3cb3297-fb57-4947-9c20-36feaf9f73da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2f4abd6a-c6b6-4c86-84be-e593b490a74d" xlink:to="loc_us-gaap_EquityComponentDomain_c3cb3297-fb57-4947-9c20-36feaf9f73da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_549e21f7-5473-49b4-a6c4-0c07fd7a7650" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ParentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c3cb3297-fb57-4947-9c20-36feaf9f73da" xlink:to="loc_us-gaap_ParentMember_549e21f7-5473-49b4-a6c4-0c07fd7a7650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_2314574e-b551-440e-a687-b92451af5f34" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_549e21f7-5473-49b4-a6c4-0c07fd7a7650" xlink:to="loc_us-gaap_CommonStockMember_2314574e-b551-440e-a687-b92451af5f34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredSharesMember_b91da951-f7ba-4876-bd84-b112556ba6de" xlink:href="brns-20231231.xsd#brns_DeferredSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_549e21f7-5473-49b4-a6c4-0c07fd7a7650" xlink:to="loc_brns_DeferredSharesMember_b91da951-f7ba-4876-bd84-b112556ba6de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_12f90fc1-c14b-45ad-9684-a99648aecb1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_549e21f7-5473-49b4-a6c4-0c07fd7a7650" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_12f90fc1-c14b-45ad-9684-a99648aecb1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_874e18d4-a531-41aa-be8a-5ba2ab858bf5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_549e21f7-5473-49b4-a6c4-0c07fd7a7650" xlink:to="loc_us-gaap_RetainedEarningsMember_874e18d4-a531-41aa-be8a-5ba2ab858bf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_96d33fa1-8e32-4450-a565-642ab507a9ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_549e21f7-5473-49b4-a6c4-0c07fd7a7650" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_96d33fa1-8e32-4450-a565-642ab507a9ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_c18bdd42-0d65-40c4-bacf-04ccbd9cf528" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c3cb3297-fb57-4947-9c20-36feaf9f73da" xlink:to="loc_us-gaap_NoncontrollingInterestMember_c18bdd42-0d65-40c4-bacf-04ccbd9cf528" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4c66d9a8-cb8f-44de-8667-5dd572a88ada" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f59ed825-44f0-4d8e-8287-eac9ac6eafc9" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4c66d9a8-cb8f-44de-8667-5dd572a88ada" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_a44b1b2d-e39d-49e0-acf6-8d0a2d028c4f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4c66d9a8-cb8f-44de-8667-5dd572a88ada" xlink:to="loc_us-gaap_ClassOfStockDomain_a44b1b2d-e39d-49e0-acf6-8d0a2d028c4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredShares.Member_a295b0db-d74b-435e-96e3-ae42a38c3404" xlink:href="brns-20231231.xsd#brns_DeferredShares.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_a44b1b2d-e39d-49e0-acf6-8d0a2d028c4f" xlink:to="loc_brns_DeferredShares.Member_a295b0db-d74b-435e-96e3-ae42a38c3404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredBSharesMember_1b62437d-46a4-4fd5-bcbe-1bb2ed631293" xlink:href="brns-20231231.xsd#brns_DeferredBSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_a44b1b2d-e39d-49e0-acf6-8d0a2d028c4f" xlink:to="loc_brns_DeferredBSharesMember_1b62437d-46a4-4fd5-bcbe-1bb2ed631293" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredCSharesMember_ebc244a7-09d7-47e2-8f56-3f0998fec444" xlink:href="brns-20231231.xsd#brns_DeferredCSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_a44b1b2d-e39d-49e0-acf6-8d0a2d028c4f" xlink:to="loc_brns_DeferredCSharesMember_ebc244a7-09d7-47e2-8f56-3f0998fec444" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_672ff6a0-7632-43ee-8216-bf4f621ddb85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f59ed825-44f0-4d8e-8287-eac9ac6eafc9" xlink:to="loc_us-gaap_StatementLineItems_672ff6a0-7632-43ee-8216-bf4f621ddb85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b36c89f3-4d74-41b7-aa80-7d657efdd30a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_672ff6a0-7632-43ee-8216-bf4f621ddb85" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b36c89f3-4d74-41b7-aa80-7d657efdd30a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_d79e4711-0647-44e7-ba76-3ca760bb5bab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b36c89f3-4d74-41b7-aa80-7d657efdd30a" xlink:to="loc_us-gaap_SharesIssued_d79e4711-0647-44e7-ba76-3ca760bb5bab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1d1513f4-3cce-4520-ac50-706b704ee7c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b36c89f3-4d74-41b7-aa80-7d657efdd30a" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1d1513f4-3cce-4520-ac50-706b704ee7c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_48e3fb01-42e2-49f7-a072-0bbd0236d6fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b36c89f3-4d74-41b7-aa80-7d657efdd30a" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_48e3fb01-42e2-49f7-a072-0bbd0236d6fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_81e172d6-38cc-4a68-bb1d-d8d883f6e26a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b36c89f3-4d74-41b7-aa80-7d657efdd30a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesOther_81e172d6-38cc-4a68-bb1d-d8d883f6e26a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther_2f19abbf-312a-47d3-8e9a-7ce311aabd4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b36c89f3-4d74-41b7-aa80-7d657efdd30a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueOther_2f19abbf-312a-47d3-8e9a-7ce311aabd4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_c2478f95-3d7d-450d-a508-7071a59fedc7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b36c89f3-4d74-41b7-aa80-7d657efdd30a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_c2478f95-3d7d-450d-a508-7071a59fedc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_AdjustmentsToAdditionalPaidInCapitalMeasurementPeriodAdjustmentsInBusinessCombination_686c160f-2f38-42dc-9ab8-f26485eceb11" xlink:href="brns-20231231.xsd#brns_AdjustmentsToAdditionalPaidInCapitalMeasurementPeriodAdjustmentsInBusinessCombination"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b36c89f3-4d74-41b7-aa80-7d657efdd30a" xlink:to="loc_brns_AdjustmentsToAdditionalPaidInCapitalMeasurementPeriodAdjustmentsInBusinessCombination_686c160f-2f38-42dc-9ab8-f26485eceb11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_SharesCancelledDuringPeriodSharesDeferredShares_f5aba600-0d10-4a1e-80b4-d406d071b9b9" xlink:href="brns-20231231.xsd#brns_SharesCancelledDuringPeriodSharesDeferredShares"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b36c89f3-4d74-41b7-aa80-7d657efdd30a" xlink:to="loc_brns_SharesCancelledDuringPeriodSharesDeferredShares_f5aba600-0d10-4a1e-80b4-d406d071b9b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_SharesCancelledDuringPeriodValueDeferredShares_514635d6-727e-43bf-b61c-5d523e41e441" xlink:href="brns-20231231.xsd#brns_SharesCancelledDuringPeriodValueDeferredShares"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b36c89f3-4d74-41b7-aa80-7d657efdd30a" xlink:to="loc_brns_SharesCancelledDuringPeriodValueDeferredShares_514635d6-727e-43bf-b61c-5d523e41e441" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_0acd13bf-e29c-4396-80c3-12bdb7ae2250" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b36c89f3-4d74-41b7-aa80-7d657efdd30a" xlink:to="loc_us-gaap_ProfitLoss_0acd13bf-e29c-4396-80c3-12bdb7ae2250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_89522946-e59c-4826-addf-e10cf90af75b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b36c89f3-4d74-41b7-aa80-7d657efdd30a" xlink:to="loc_us-gaap_SharesIssued_89522946-e59c-4826-addf-e10cf90af75b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7ed8fd21-3bc9-43b9-a2bf-9d593e1e12eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b36c89f3-4d74-41b7-aa80-7d657efdd30a" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7ed8fd21-3bc9-43b9-a2bf-9d593e1e12eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="brns-20231231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_b5c61f87-4771-46b5-a223-a73468defa36" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e45eb0f2-257f-4f14-8c55-a6cf0a2dbe54" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b5c61f87-4771-46b5-a223-a73468defa36" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e45eb0f2-257f-4f14-8c55-a6cf0a2dbe54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_11d316d3-9d7f-42e4-8314-a25923edfb74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e45eb0f2-257f-4f14-8c55-a6cf0a2dbe54" xlink:to="loc_us-gaap_ProfitLoss_11d316d3-9d7f-42e4-8314-a25923edfb74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_652ad055-6ff9-4f48-b0d6-4ca94fa51623" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e45eb0f2-257f-4f14-8c55-a6cf0a2dbe54" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_652ad055-6ff9-4f48-b0d6-4ca94fa51623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_ba3e1ca3-3ba3-40d9-b934-0dfed5d0403a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_652ad055-6ff9-4f48-b0d6-4ca94fa51623" xlink:to="loc_us-gaap_ShareBasedCompensation_ba3e1ca3-3ba3-40d9-b934-0dfed5d0403a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_ad24f678-6537-4935-b0e5-21a57322ce20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_652ad055-6ff9-4f48-b0d6-4ca94fa51623" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_ad24f678-6537-4935-b0e5-21a57322ce20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_NonCashLeaseExpenses_eb0319d4-dcb7-407b-aa3e-b8615d83ea6c" xlink:href="brns-20231231.xsd#brns_NonCashLeaseExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_652ad055-6ff9-4f48-b0d6-4ca94fa51623" xlink:to="loc_brns_NonCashLeaseExpenses_eb0319d4-dcb7-407b-aa3e-b8615d83ea6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_65f6cf1f-52b3-433a-a718-a22ca45f8032" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_652ad055-6ff9-4f48-b0d6-4ca94fa51623" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_65f6cf1f-52b3-433a-a718-a22ca45f8032" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_6751ac11-c229-4b71-a720-71fa1f61f564" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_652ad055-6ff9-4f48-b0d6-4ca94fa51623" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_6751ac11-c229-4b71-a720-71fa1f61f564" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_NonCashInterestExpenseOnConvertibleLoanNotes_446f15e5-c973-4ba3-9d27-fe910ecb04fb" xlink:href="brns-20231231.xsd#brns_NonCashInterestExpenseOnConvertibleLoanNotes"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_652ad055-6ff9-4f48-b0d6-4ca94fa51623" xlink:to="loc_brns_NonCashInterestExpenseOnConvertibleLoanNotes_446f15e5-c973-4ba3-9d27-fe910ecb04fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_cf6e5e18-811a-48be-a4bb-90001048700f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_652ad055-6ff9-4f48-b0d6-4ca94fa51623" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_cf6e5e18-811a-48be-a4bb-90001048700f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_c18665c5-0744-41b7-899d-247d89f19698" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_652ad055-6ff9-4f48-b0d6-4ca94fa51623" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_c18665c5-0744-41b7-899d-247d89f19698" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2d90468c-b05f-4ff5-8293-3679614e8546" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_652ad055-6ff9-4f48-b0d6-4ca94fa51623" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2d90468c-b05f-4ff5-8293-3679614e8546" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_c16cd5ff-861a-4de0-9f11-e849a96a969d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2d90468c-b05f-4ff5-8293-3679614e8546" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_c16cd5ff-861a-4de0-9f11-e849a96a969d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_39da40a6-7aee-4b97-9f0e-196f4dd49ec7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2d90468c-b05f-4ff5-8293-3679614e8546" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_39da40a6-7aee-4b97-9f0e-196f4dd49ec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable_d59112d8-4e89-4292-b5dc-0e37b51df322" xlink:href="brns-20231231.xsd#brns_IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2d90468c-b05f-4ff5-8293-3679614e8546" xlink:to="loc_brns_IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable_d59112d8-4e89-4292-b5dc-0e37b51df322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_7f68b3d5-be56-4dca-91c9-48f921a518a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2d90468c-b05f-4ff5-8293-3679614e8546" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_7f68b3d5-be56-4dca-91c9-48f921a518a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_d9019193-0af5-40a2-b313-8f53063ea12a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2d90468c-b05f-4ff5-8293-3679614e8546" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_d9019193-0af5-40a2-b313-8f53063ea12a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_1b698aa4-a271-4702-becc-71e66d3ac5ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2d90468c-b05f-4ff5-8293-3679614e8546" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_1b698aa4-a271-4702-becc-71e66d3ac5ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_7e002a72-7039-4e2b-99e7-ed8ba3ad3600" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2d90468c-b05f-4ff5-8293-3679614e8546" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_7e002a72-7039-4e2b-99e7-ed8ba3ad3600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_8188b41c-86b7-470a-a347-44c3d1a44e62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2d90468c-b05f-4ff5-8293-3679614e8546" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_8188b41c-86b7-470a-a347-44c3d1a44e62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_dacc7924-713e-4671-8aa8-0191c29bf7c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_652ad055-6ff9-4f48-b0d6-4ca94fa51623" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_dacc7924-713e-4671-8aa8-0191c29bf7c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_90c498cf-a767-4028-bbad-bbc76f458751" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b5c61f87-4771-46b5-a223-a73468defa36" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_90c498cf-a767-4028-bbad-bbc76f458751" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_5292b853-0ed1-4d33-be9c-30ca0753e089" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_90c498cf-a767-4028-bbad-bbc76f458751" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_5292b853-0ed1-4d33-be9c-30ca0753e089" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4a8a6e3e-682c-4dbb-950a-4b9fd4943765" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_90c498cf-a767-4028-bbad-bbc76f458751" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4a8a6e3e-682c-4dbb-950a-4b9fd4943765" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5bbd0067-c2c9-489c-aa88-f08def5d81b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_90c498cf-a767-4028-bbad-bbc76f458751" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5bbd0067-c2c9-489c-aa88-f08def5d81b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b47d8316-606a-463a-b2d3-f2a5acb333d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b5c61f87-4771-46b5-a223-a73468defa36" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b47d8316-606a-463a-b2d3-f2a5acb333d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_9d69f00c-3df2-47c4-ba15-373c2b1df8c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b47d8316-606a-463a-b2d3-f2a5acb333d1" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_9d69f00c-3df2-47c4-ba15-373c2b1df8c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_60553178-ca58-4c5e-8e57-8557a4e2b606" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b47d8316-606a-463a-b2d3-f2a5acb333d1" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_60553178-ca58-4c5e-8e57-8557a4e2b606" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_ba7a9e84-cd50-4d61-a05d-446fa4bba1c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b47d8316-606a-463a-b2d3-f2a5acb333d1" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_ba7a9e84-cd50-4d61-a05d-446fa4bba1c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_35ccd17c-c323-4b6c-a2a5-dad2ae7ccaf4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b47d8316-606a-463a-b2d3-f2a5acb333d1" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_35ccd17c-c323-4b6c-a2a5-dad2ae7ccaf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6820c2e2-fd31-409a-9b47-40a98c1b36c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b47d8316-606a-463a-b2d3-f2a5acb333d1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6820c2e2-fd31-409a-9b47-40a98c1b36c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_0090fe45-05d3-4337-852e-f45a0358a1c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b5c61f87-4771-46b5-a223-a73468defa36" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_0090fe45-05d3-4337-852e-f45a0358a1c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0e855edf-fb83-4de4-bf32-b151cac5eaac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b5c61f87-4771-46b5-a223-a73468defa36" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0e855edf-fb83-4de4-bf32-b151cac5eaac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4bfaa307-8d4a-4ad6-9939-b1451ef78930" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b5c61f87-4771-46b5-a223-a73468defa36" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4bfaa307-8d4a-4ad6-9939-b1451ef78930" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b766c034-6cb7-4904-8589-7fe22658c30e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b5c61f87-4771-46b5-a223-a73468defa36" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b766c034-6cb7-4904-8589-7fe22658c30e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_a8ee1665-9617-4786-acd4-a846a1754475" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b5c61f87-4771-46b5-a223-a73468defa36" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_a8ee1665-9617-4786-acd4-a846a1754475" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_07e9fe17-85df-4b2f-83e7-86b01757fd61" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_a8ee1665-9617-4786-acd4-a846a1754475" xlink:to="loc_us-gaap_InterestPaidNet_07e9fe17-85df-4b2f-83e7-86b01757fd61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_8c5dec83-2607-45b2-ab50-b18e33b6a01a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_a8ee1665-9617-4786-acd4-a846a1754475" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_8c5dec83-2607-45b2-ab50-b18e33b6a01a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_6773eaf1-a742-4384-881a-b35cdb977775" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b5c61f87-4771-46b5-a223-a73468defa36" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_6773eaf1-a742-4384-881a-b35cdb977775" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_c97aecc0-9b21-4af4-86d9-1874bc52dc76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_6773eaf1-a742-4384-881a-b35cdb977775" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_c97aecc0-9b21-4af4-86d9-1874bc52dc76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_64809bbb-e848-46b9-a8e8-39bab19eb1da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_6773eaf1-a742-4384-881a-b35cdb977775" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_64809bbb-e848-46b9-a8e8-39bab19eb1da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_AssetRetirementObligations_7b54ca66-445a-4a79-b545-99e0ec43a721" xlink:href="brns-20231231.xsd#brns_AssetRetirementObligations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_6773eaf1-a742-4384-881a-b35cdb977775" xlink:to="loc_brns_AssetRetirementObligations_7b54ca66-445a-4a79-b545-99e0ec43a721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ChangesToRightOfUseAssetResultingFromLeaseReassessmentEvent_b4ed28bd-17c4-4096-a750-2ec63d9374fb" xlink:href="brns-20231231.xsd#brns_ChangesToRightOfUseAssetResultingFromLeaseReassessmentEvent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_6773eaf1-a742-4384-881a-b35cdb977775" xlink:to="loc_brns_ChangesToRightOfUseAssetResultingFromLeaseReassessmentEvent_b4ed28bd-17c4-4096-a750-2ec63d9374fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_NonCashInvestingAndFinancingActivityOfMeasurementPeriodAdjustments_3abd6d0f-df83-4c5e-b57d-d85a273223fc" xlink:href="brns-20231231.xsd#brns_NonCashInvestingAndFinancingActivityOfMeasurementPeriodAdjustments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_6773eaf1-a742-4384-881a-b35cdb977775" xlink:to="loc_brns_NonCashInvestingAndFinancingActivityOfMeasurementPeriodAdjustments_3abd6d0f-df83-4c5e-b57d-d85a273223fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ContingentConsiderationSettledInEquity_2f3a0f11-c3c7-4772-af5e-e29950fcb8b4" xlink:href="brns-20231231.xsd#brns_ContingentConsiderationSettledInEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_6773eaf1-a742-4384-881a-b35cdb977775" xlink:to="loc_brns_ContingentConsiderationSettledInEquity_2f3a0f11-c3c7-4772-af5e-e29950fcb8b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/NatureofBusinessandBasisofPresentation" xlink:type="simple" xlink:href="brns-20231231.xsd#NatureofBusinessandBasisofPresentation"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/NatureofBusinessandBasisofPresentation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_813ee960-fdc0-4985-8952-aef412c0b9bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_252ff8e9-03f4-49c9-a654-1b880a9d8683" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_813ee960-fdc0-4985-8952-aef412c0b9bc" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_252ff8e9-03f4-49c9-a654-1b880a9d8683" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="brns-20231231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_6955404c-3b8b-4b12-a6ba-7fbaed343569" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_06752452-c252-4edf-beac-86e8b5ba0ce5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6955404c-3b8b-4b12-a6ba-7fbaed343569" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_06752452-c252-4edf-beac-86e8b5ba0ce5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/ForeignCurrencyTranslationinGeneralandAdministrativeExpenses" xlink:type="simple" xlink:href="brns-20231231.xsd#ForeignCurrencyTranslationinGeneralandAdministrativeExpenses"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/ForeignCurrencyTranslationinGeneralandAdministrativeExpenses" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyAbstract_8fd314b3-74bc-4dc7-a741-830db8c0d79c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyDisclosureTextBlock_61ce7236-6e18-4db9-b99b-1e3df6ad84e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ForeignCurrencyAbstract_8fd314b3-74bc-4dc7-a741-830db8c0d79c" xlink:to="loc_us-gaap_ForeignCurrencyDisclosureTextBlock_61ce7236-6e18-4db9-b99b-1e3df6ad84e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/NetLossIncomePerShare" xlink:type="simple" xlink:href="brns-20231231.xsd#NetLossIncomePerShare"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/NetLossIncomePerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_7299bc52-3fca-4e7f-81fd-c3e7e87c2536" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_349e6125-d4c5-46b9-91b8-a5cd7487ae38" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_7299bc52-3fca-4e7f-81fd-c3e7e87c2536" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_349e6125-d4c5-46b9-91b8-a5cd7487ae38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/PropertyandEquipmentNet" xlink:type="simple" xlink:href="brns-20231231.xsd#PropertyandEquipmentNet"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/PropertyandEquipmentNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_04a244b3-b457-47fd-a5d5-d7ec9ae738fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_fba5cc0b-6008-4fa2-bb73-4eebb8a7aded" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_04a244b3-b457-47fd-a5d5-d7ec9ae738fd" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_fba5cc0b-6008-4fa2-bb73-4eebb8a7aded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/Intangibleassetsnet" xlink:type="simple" xlink:href="brns-20231231.xsd#Intangibleassetsnet"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/Intangibleassetsnet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_72705faa-c86f-4345-9ad1-480a5ac21ff7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_79af5b6c-0e34-4adf-b759-a2edc8ec6487" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_72705faa-c86f-4345-9ad1-480a5ac21ff7" xlink:to="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_79af5b6c-0e34-4adf-b759-a2edc8ec6487" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/Prepaidandothercurrentassets" xlink:type="simple" xlink:href="brns-20231231.xsd#Prepaidandothercurrentassets"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/Prepaidandothercurrentassets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_601d1d4e-7d72-4cf0-a24d-d9e0d82ea307" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_PrepaidExpenseAndOtherAssetsCurrentTextBlock_5c1deeb7-a406-4c7a-b3fa-c1bcdda170e7" xlink:href="brns-20231231.xsd#brns_PrepaidExpenseAndOtherAssetsCurrentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_601d1d4e-7d72-4cf0-a24d-d9e0d82ea307" xlink:to="loc_brns_PrepaidExpenseAndOtherAssetsCurrentTextBlock_5c1deeb7-a406-4c7a-b3fa-c1bcdda170e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilities" xlink:type="simple" xlink:href="brns-20231231.xsd#AccruedExpensesandOtherCurrentLiabilities"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_c5602c3c-4fc4-486d-943f-4c1e1cf0317e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock_64752325-5ce2-40ea-b405-5d330cb9804f" xlink:href="brns-20231231.xsd#brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_c5602c3c-4fc4-486d-943f-4c1e1cf0317e" xlink:to="loc_brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock_64752325-5ce2-40ea-b405-5d330cb9804f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/OutlicensesandGrants" xlink:type="simple" xlink:href="brns-20231231.xsd#OutlicensesandGrants"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/OutlicensesandGrants" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_5279c8db-5725-4df0-a0bc-f7ee23955ad4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_43628f61-6ada-4241-92a2-e0b8a52c082c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_5279c8db-5725-4df0-a0bc-f7ee23955ad4" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_43628f61-6ada-4241-92a2-e0b8a52c082c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/OrdinaryShares" xlink:type="simple" xlink:href="brns-20231231.xsd#OrdinaryShares"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/OrdinaryShares" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_9ea121f2-f8e5-4612-b136-843a70149a53" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_16e4c46b-24be-4c9b-85b2-c85e7c0d9f78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_9ea121f2-f8e5-4612-b136-843a70149a53" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_16e4c46b-24be-4c9b-85b2-c85e7c0d9f78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/Deferredshares" xlink:type="simple" xlink:href="brns-20231231.xsd#Deferredshares"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/Deferredshares" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_3c8a3666-1652-4336-9c3d-4ff17efe0242" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_StockholdersEquityDeferredSharesDisclosureTextBlock_04965aab-dd70-4106-9c21-bb1cc87a3c18" xlink:href="brns-20231231.xsd#brns_StockholdersEquityDeferredSharesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_3c8a3666-1652-4336-9c3d-4ff17efe0242" xlink:to="loc_brns_StockholdersEquityDeferredSharesDisclosureTextBlock_04965aab-dd70-4106-9c21-bb1cc87a3c18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/FairValue" xlink:type="simple" xlink:href="brns-20231231.xsd#FairValue"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/FairValue" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_c25d8779-9cf4-4f42-ac7c-3a0731c751ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_915f7166-6796-40fb-81e5-d103d9bc0a25" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_c25d8779-9cf4-4f42-ac7c-3a0731c751ed" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_915f7166-6796-40fb-81e5-d103d9bc0a25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/Goodwill" xlink:type="simple" xlink:href="brns-20231231.xsd#Goodwill"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/Goodwill" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_bae0007d-5f86-493b-b255-aa552cea63a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillDisclosureTextBlock_c0e10275-2b07-4bea-8513-6887c98fad20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_bae0007d-5f86-493b-b255-aa552cea63a7" xlink:to="loc_us-gaap_GoodwillDisclosureTextBlock_c0e10275-2b07-4bea-8513-6887c98fad20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/ShareBasedCompensation" xlink:type="simple" xlink:href="brns-20231231.xsd#ShareBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/ShareBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d991c85a-a1fd-4567-8f49-ba37595295d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_f2ff1961-d44e-418a-b88e-b57457e1a4a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d991c85a-a1fd-4567-8f49-ba37595295d6" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_f2ff1961-d44e-418a-b88e-b57457e1a4a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/IncomeTaxes" xlink:type="simple" xlink:href="brns-20231231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_6d060f34-4768-4b99-b07c-ed7d96712bf7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_55fdcf3b-5088-43db-9755-f773914a17a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6d060f34-4768-4b99-b07c-ed7d96712bf7" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_55fdcf3b-5088-43db-9755-f773914a17a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="brns-20231231.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_11750bf7-2ea0-48bc-8b9f-2108f0e064cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_aabd4b33-f070-48fc-bdb3-cb7374e28e0a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_11750bf7-2ea0-48bc-8b9f-2108f0e064cb" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_aabd4b33-f070-48fc-bdb3-cb7374e28e0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/EmployeeBenefitPlans" xlink:type="simple" xlink:href="brns-20231231.xsd#EmployeeBenefitPlans"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/EmployeeBenefitPlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_4744a002-7aac-48f9-a525-d7bd99b78908" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_e358738c-9b6b-48f7-9d44-b58accab6378" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_4744a002-7aac-48f9-a525-d7bd99b78908" xlink:to="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_e358738c-9b6b-48f7-9d44-b58accab6378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="brns-20231231.xsd#RelatedPartyTransactions"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_77772c6e-1049-459d-aac6-5420fe397661" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_51a8dde6-88a7-45a5-842e-1d33ac785c5b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_77772c6e-1049-459d-aac6-5420fe397661" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_51a8dde6-88a7-45a5-842e-1d33ac785c5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/SubsequentEvents" xlink:type="simple" xlink:href="brns-20231231.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_e13adfc5-e249-478a-bebe-a0b0041a6bb8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_d8b0356f-1263-45e0-a290-10d4f9552edc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_e13adfc5-e249-478a-bebe-a0b0041a6bb8" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_d8b0356f-1263-45e0-a290-10d4f9552edc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="brns-20231231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_e9e27561-20eb-4a1e-8a9c-abc35d941879" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies_6b6b823d-45ce-4ecb-b443-a7241c92aca5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e9e27561-20eb-4a1e-8a9c-abc35d941879" xlink:to="loc_us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies_6b6b823d-45ce-4ecb-b443-a7241c92aca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_657bc56a-3710-4d9f-8c3a-ce61434cc574" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e9e27561-20eb-4a1e-8a9c-abc35d941879" xlink:to="loc_us-gaap_UseOfEstimates_657bc56a-3710-4d9f-8c3a-ce61434cc574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_23dcbb64-79ce-4d3f-bb55-5513591de73b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e9e27561-20eb-4a1e-8a9c-abc35d941879" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_23dcbb64-79ce-4d3f-bb55-5513591de73b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_d0c677ce-466c-4236-9d80-f13526186380" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e9e27561-20eb-4a1e-8a9c-abc35d941879" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_d0c677ce-466c-4236-9d80-f13526186380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_97153b61-36b2-4b87-af35-7042e34a881a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e9e27561-20eb-4a1e-8a9c-abc35d941879" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_97153b61-36b2-4b87-af35-7042e34a881a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_dc445cde-b95b-45ad-8201-32d04114cfc0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e9e27561-20eb-4a1e-8a9c-abc35d941879" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_dc445cde-b95b-45ad-8201-32d04114cfc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_MinorityInterestPolicyTextBlock_0fffe149-51a6-4341-afbf-6dc366af04cd" xlink:href="brns-20231231.xsd#brns_MinorityInterestPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e9e27561-20eb-4a1e-8a9c-abc35d941879" xlink:to="loc_brns_MinorityInterestPolicyTextBlock_0fffe149-51a6-4341-afbf-6dc366af04cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_a298de42-d72c-4b23-aba0-eb651cf83b77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e9e27561-20eb-4a1e-8a9c-abc35d941879" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_a298de42-d72c-4b23-aba0-eb651cf83b77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_e7483acd-e7ef-41ce-8f84-9f65c27b2eae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e9e27561-20eb-4a1e-8a9c-abc35d941879" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_e7483acd-e7ef-41ce-8f84-9f65c27b2eae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_0f654dde-f619-4a37-ad1f-a703bb6959ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e9e27561-20eb-4a1e-8a9c-abc35d941879" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_0f654dde-f619-4a37-ad1f-a703bb6959ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ResearchAndDevelopmentServicesPolicyPolicyTextBlock_13fc9618-50c4-4130-9aa1-bcd01eadd3c9" xlink:href="brns-20231231.xsd#brns_ResearchAndDevelopmentServicesPolicyPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e9e27561-20eb-4a1e-8a9c-abc35d941879" xlink:to="loc_brns_ResearchAndDevelopmentServicesPolicyPolicyTextBlock_13fc9618-50c4-4130-9aa1-bcd01eadd3c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_GrantIncomePolicyPolicyTextBlock_c431e86c-cf8b-4328-903c-4f2a21ec7ef2" xlink:href="brns-20231231.xsd#brns_GrantIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e9e27561-20eb-4a1e-8a9c-abc35d941879" xlink:to="loc_brns_GrantIncomePolicyPolicyTextBlock_c431e86c-cf8b-4328-903c-4f2a21ec7ef2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_52666812-cab0-4494-8aa0-920e45614fab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e9e27561-20eb-4a1e-8a9c-abc35d941879" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_52666812-cab0-4494-8aa0-920e45614fab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock_ea5410ca-5257-4462-82f9-419bf4ed8d2e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditLossFinancialInstrumentPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e9e27561-20eb-4a1e-8a9c-abc35d941879" xlink:to="loc_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock_ea5410ca-5257-4462-82f9-419bf4ed8d2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_4047d5f6-7ad1-4173-8d6d-39f52a5fe2a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e9e27561-20eb-4a1e-8a9c-abc35d941879" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_4047d5f6-7ad1-4173-8d6d-39f52a5fe2a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_74ae9ce3-5b0c-46b7-843b-88d54ef838dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e9e27561-20eb-4a1e-8a9c-abc35d941879" xlink:to="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_74ae9ce3-5b0c-46b7-843b-88d54ef838dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_45ec30e3-7e15-4952-904a-73fb7a534c18" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e9e27561-20eb-4a1e-8a9c-abc35d941879" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_45ec30e3-7e15-4952-904a-73fb7a534c18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_0862cf7a-fbfd-4122-9678-ae8941c46921" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e9e27561-20eb-4a1e-8a9c-abc35d941879" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_0862cf7a-fbfd-4122-9678-ae8941c46921" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_d795aaaf-893e-4a4c-b381-04d941cdddc7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e9e27561-20eb-4a1e-8a9c-abc35d941879" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_d795aaaf-893e-4a4c-b381-04d941cdddc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_075ea61e-1254-482c-a52e-881ffe75da69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e9e27561-20eb-4a1e-8a9c-abc35d941879" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_075ea61e-1254-482c-a52e-881ffe75da69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_aadddbcb-5351-4af5-ac94-6fceb9286401" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e9e27561-20eb-4a1e-8a9c-abc35d941879" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_aadddbcb-5351-4af5-ac94-6fceb9286401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_eb8db4d1-683c-4e9a-ac3b-973b34f0ad10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e9e27561-20eb-4a1e-8a9c-abc35d941879" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_eb8db4d1-683c-4e9a-ac3b-973b34f0ad10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ClinicalTrialCostsPolicyTextBlock_c731826f-8b42-43fd-a3f5-25567dfd4070" xlink:href="brns-20231231.xsd#brns_ClinicalTrialCostsPolicyTextBlock"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e9e27561-20eb-4a1e-8a9c-abc35d941879" xlink:to="loc_brns_ClinicalTrialCostsPolicyTextBlock_c731826f-8b42-43fd-a3f5-25567dfd4070" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend_9a5e9bee-9c23-418c-8167-8ec82f93cdc8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e9e27561-20eb-4a1e-8a9c-abc35d941879" xlink:to="loc_us-gaap_IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend_9a5e9bee-9c23-418c-8167-8ec82f93cdc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityPolicyTextBlock_74178116-b468-473f-bdb6-945f23c6d69e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityPolicyTextBlock"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e9e27561-20eb-4a1e-8a9c-abc35d941879" xlink:to="loc_us-gaap_StockholdersEquityPolicyTextBlock_74178116-b468-473f-bdb6-945f23c6d69e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_AdditionalPaidInCapitalPolicyTextBlock_df095f0d-20b4-4fab-b68e-cc2c4a2517fa" xlink:href="brns-20231231.xsd#brns_AdditionalPaidInCapitalPolicyTextBlock"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e9e27561-20eb-4a1e-8a9c-abc35d941879" xlink:to="loc_brns_AdditionalPaidInCapitalPolicyTextBlock_df095f0d-20b4-4fab-b68e-cc2c4a2517fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_a7915e13-657a-41b7-9193-8585a821cd04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e9e27561-20eb-4a1e-8a9c-abc35d941879" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_a7915e13-657a-41b7-9193-8585a821cd04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RegulatoryIncomeTaxesPolicy_00989fd7-8aae-4b3f-8d3f-2c0c1db78b46" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RegulatoryIncomeTaxesPolicy"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e9e27561-20eb-4a1e-8a9c-abc35d941879" xlink:to="loc_us-gaap_RegulatoryIncomeTaxesPolicy_00989fd7-8aae-4b3f-8d3f-2c0c1db78b46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ResearchAndDevelopmentIncentivesPolicyTextBlock_a92f13b6-b4cd-4985-9cba-3bc0c874145e" xlink:href="brns-20231231.xsd#brns_ResearchAndDevelopmentIncentivesPolicyTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e9e27561-20eb-4a1e-8a9c-abc35d941879" xlink:to="loc_brns_ResearchAndDevelopmentIncentivesPolicyTextBlock_a92f13b6-b4cd-4985-9cba-3bc0c874145e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_39b36c06-586b-4322-8981-0ac871149054" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e9e27561-20eb-4a1e-8a9c-abc35d941879" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_39b36c06-586b-4322-8981-0ac871149054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentLiabilityReserveEstimatePolicy_07ac9036-ee18-4d10-8e5b-4dac0a710e51" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentLiabilityReserveEstimatePolicy"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e9e27561-20eb-4a1e-8a9c-abc35d941879" xlink:to="loc_us-gaap_ContingentLiabilityReserveEstimatePolicy_07ac9036-ee18-4d10-8e5b-4dac0a710e51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_fdd2383d-cbf6-4388-b3e1-8908b9163a1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e9e27561-20eb-4a1e-8a9c-abc35d941879" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_fdd2383d-cbf6-4388-b3e1-8908b9163a1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="brns-20231231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_b34eb951-1b56-4099-820a-40eb58324e0a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_68acc013-151c-4524-83d9-44f3d4c6b770" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b34eb951-1b56-4099-820a-40eb58324e0a" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_68acc013-151c-4524-83d9-44f3d4c6b770" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_46f89b90-c304-4f68-abb6-5900065a50f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b34eb951-1b56-4099-820a-40eb58324e0a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_46f89b90-c304-4f68-abb6-5900065a50f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/NetLossIncomePerShareTables" xlink:type="simple" xlink:href="brns-20231231.xsd#NetLossIncomePerShareTables"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/NetLossIncomePerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_b736ef65-5e54-44e9-adae-23ce41b22e27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_368c9a9e-489a-4e5d-8327-781149b3cde5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b736ef65-5e54-44e9-adae-23ce41b22e27" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_368c9a9e-489a-4e5d-8327-781149b3cde5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/PropertyandEquipmentNetTables" xlink:type="simple" xlink:href="brns-20231231.xsd#PropertyandEquipmentNetTables"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/PropertyandEquipmentNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_b84f60c5-8936-472e-8199-94698c1b2406" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_cf7de3e1-3c90-450f-8071-c639caccf715" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_b84f60c5-8936-472e-8199-94698c1b2406" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_cf7de3e1-3c90-450f-8071-c639caccf715" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/PrepaidandothercurrentassetsTables" xlink:type="simple" xlink:href="brns-20231231.xsd#PrepaidandothercurrentassetsTables"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/PrepaidandothercurrentassetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_6f538a78-2084-49ef-af54-cb5ee9d4371c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_bb707b66-4a7b-405d-ab45-0266ae48371c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_6f538a78-2084-49ef-af54-cb5ee9d4371c" xlink:to="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_bb707b66-4a7b-405d-ab45-0266ae48371c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables" xlink:type="simple" xlink:href="brns-20231231.xsd#AccruedExpensesandOtherCurrentLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_dff1a610-d517-4fd8-84ee-b4ffed444bda" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock_b8a73ddf-4174-4f15-af16-e095d36acc0c" xlink:href="brns-20231231.xsd#brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_dff1a610-d517-4fd8-84ee-b4ffed444bda" xlink:to="loc_brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock_b8a73ddf-4174-4f15-af16-e095d36acc0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/OutlicensesandGrantsTables" xlink:type="simple" xlink:href="brns-20231231.xsd#OutlicensesandGrantsTables"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/OutlicensesandGrantsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_16f098b1-1f5a-4545-8881-a95c3ca2c51a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ContractWithCustomerLiabilitiesTableTextBlock_b1561422-19b8-4f29-a332-9c3ac57b0ce0" xlink:href="brns-20231231.xsd#brns_ContractWithCustomerLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_16f098b1-1f5a-4545-8881-a95c3ca2c51a" xlink:to="loc_brns_ContractWithCustomerLiabilitiesTableTextBlock_b1561422-19b8-4f29-a332-9c3ac57b0ce0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/OrdinarySharesTables" xlink:type="simple" xlink:href="brns-20231231.xsd#OrdinarySharesTables"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/OrdinarySharesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_9ec7db8f-66d5-4ebb-826c-fb38d4e0ef1e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ScheduleOfOrdinarySharesReservedForFutureIssuanceTableTextBlock_b0684b7a-8cef-4216-97cb-deb3ed9484dd" xlink:href="brns-20231231.xsd#brns_ScheduleOfOrdinarySharesReservedForFutureIssuanceTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_9ec7db8f-66d5-4ebb-826c-fb38d4e0ef1e" xlink:to="loc_brns_ScheduleOfOrdinarySharesReservedForFutureIssuanceTableTextBlock_b0684b7a-8cef-4216-97cb-deb3ed9484dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/FairValueTables" xlink:type="simple" xlink:href="brns-20231231.xsd#FairValueTables"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/FairValueTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_89477502-7d85-4672-8c98-26d03e58e1b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_62811676-a8f0-42a9-bf9d-0cddf00fcd56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_89477502-7d85-4672-8c98-26d03e58e1b4" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_62811676-a8f0-42a9-bf9d-0cddf00fcd56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/GoodwillTables" xlink:type="simple" xlink:href="brns-20231231.xsd#GoodwillTables"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/GoodwillTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_130183db-9d4c-42cf-8d60-e54af452065e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_0bd41921-ca8b-45bd-836f-655e720cffb0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_130183db-9d4c-42cf-8d60-e54af452065e" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_0bd41921-ca8b-45bd-836f-655e720cffb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/ShareBasedCompensationTables" xlink:type="simple" xlink:href="brns-20231231.xsd#ShareBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/ShareBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ad51752d-bfb3-4c58-a7de-3219e4fd5f87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_8d2859cc-b2ca-435f-970a-6376693c31b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ad51752d-bfb3-4c58-a7de-3219e4fd5f87" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_8d2859cc-b2ca-435f-970a-6376693c31b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_5354ab18-9c68-450a-a068-3ea7e9e33526" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ad51752d-bfb3-4c58-a7de-3219e4fd5f87" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_5354ab18-9c68-450a-a068-3ea7e9e33526" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_78b53ebe-375e-44ab-913a-1703e7534652" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ad51752d-bfb3-4c58-a7de-3219e4fd5f87" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_78b53ebe-375e-44ab-913a-1703e7534652" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="brns-20231231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_e39e0c65-ce8f-4b96-b9d8-79de76b746cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_bf786964-0713-4c12-9da7-a639475f924b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e39e0c65-ce8f-4b96-b9d8-79de76b746cb" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_bf786964-0713-4c12-9da7-a639475f924b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_76486c20-ecf5-4530-aa0a-263f946a57d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e39e0c65-ce8f-4b96-b9d8-79de76b746cb" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_76486c20-ecf5-4530-aa0a-263f946a57d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_72951640-c96d-4c49-942f-a16a98d79106" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e39e0c65-ce8f-4b96-b9d8-79de76b746cb" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_72951640-c96d-4c49-942f-a16a98d79106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_9efdad00-f86d-427e-9612-45ba6a54c579" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e39e0c65-ce8f-4b96-b9d8-79de76b746cb" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_9efdad00-f86d-427e-9612-45ba6a54c579" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfValuationAllowanceTextBlock_01ec54e3-a4d6-4710-b90e-cd7b1b0330e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e39e0c65-ce8f-4b96-b9d8-79de76b746cb" xlink:to="loc_us-gaap_SummaryOfValuationAllowanceTextBlock_01ec54e3-a4d6-4710-b90e-cd7b1b0330e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="brns-20231231.xsd#CommitmentsandContingenciesTables"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/CommitmentsandContingenciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c1fbf7bb-23c5-4490-8e0c-71b13ca31214" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_LesseeOperatingLeaseRightOfUseAssetAndOtherInformationTableTextBlock_83bb91e9-4df7-4de6-aa74-21c65df77a0b" xlink:href="brns-20231231.xsd#brns_LesseeOperatingLeaseRightOfUseAssetAndOtherInformationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c1fbf7bb-23c5-4490-8e0c-71b13ca31214" xlink:to="loc_brns_LesseeOperatingLeaseRightOfUseAssetAndOtherInformationTableTextBlock_83bb91e9-4df7-4de6-aa74-21c65df77a0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_c48d9318-9c19-4438-863a-7ed198c8336b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c1fbf7bb-23c5-4490-8e0c-71b13ca31214" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_c48d9318-9c19-4438-863a-7ed198c8336b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/NatureofBusinessandBasisofPresentationDetails" xlink:type="simple" xlink:href="brns-20231231.xsd#NatureofBusinessandBasisofPresentationDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/NatureofBusinessandBasisofPresentationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_235f6905-c947-4561-88e8-f2c5f9b7fd87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4a63f0d3-bf59-446c-b272-9e14e92ab191" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_235f6905-c947-4561-88e8-f2c5f9b7fd87" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4a63f0d3-bf59-446c-b272-9e14e92ab191" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_0f34746a-baf8-44b1-addf-89c87c98c14b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_235f6905-c947-4561-88e8-f2c5f9b7fd87" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_0f34746a-baf8-44b1-addf-89c87c98c14b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesForeigncurrencytranslationDetails" xlink:type="simple" xlink:href="brns-20231231.xsd#SummaryofSignificantAccountingPoliciesForeigncurrencytranslationDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesForeigncurrencytranslationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_156fce8c-b7a4-42d7-a954-efb37f96ef49" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_69fd961d-49ed-4ce2-9303-fe9c2e31edd2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_156fce8c-b7a4-42d7-a954-efb37f96ef49" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_69fd961d-49ed-4ce2-9303-fe9c2e31edd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesSegmentinformationDetails" xlink:type="simple" xlink:href="brns-20231231.xsd#SummaryofSignificantAccountingPoliciesSegmentinformationDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesSegmentinformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1d0591ce-40f7-49ba-9820-18f198784b89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_dcb78a1f-f4e8-4978-a282-908dc0816f6e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1d0591ce-40f7-49ba-9820-18f198784b89" xlink:to="loc_us-gaap_NumberOfOperatingSegments_dcb78a1f-f4e8-4978-a282-908dc0816f6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesNoncontrollinginterestDetails" xlink:type="simple" xlink:href="brns-20231231.xsd#SummaryofSignificantAccountingPoliciesNoncontrollinginterestDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesNoncontrollinginterestDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_243b5ae8-51b9-45f4-a578-baf65c95e570" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_f1250b03-1721-4c50-81de-3cf66be9a344" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_243b5ae8-51b9-45f4-a578-baf65c95e570" xlink:to="loc_us-gaap_MinorityInterestTable_f1250b03-1721-4c50-81de-3cf66be9a344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_32095641-d6ab-4037-9b86-897b26102807" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_f1250b03-1721-4c50-81de-3cf66be9a344" xlink:to="loc_srt_OwnershipAxis_32095641-d6ab-4037-9b86-897b26102807" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_37e428b5-a139-49c7-8d0c-5708bf559c8f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_32095641-d6ab-4037-9b86-897b26102807" xlink:to="loc_srt_OwnershipDomain_37e428b5-a139-49c7-8d0c-5708bf559c8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_VOLTMember_b3b23d26-9992-454e-8a34-2e00aeb5e144" xlink:href="brns-20231231.xsd#brns_VOLTMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_37e428b5-a139-49c7-8d0c-5708bf559c8f" xlink:to="loc_brns_VOLTMember_b3b23d26-9992-454e-8a34-2e00aeb5e144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_fe47ac28-0f02-4998-8554-877c8f92c8b5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_f1250b03-1721-4c50-81de-3cf66be9a344" xlink:to="loc_srt_ConsolidatedEntitiesAxis_fe47ac28-0f02-4998-8554-877c8f92c8b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_372249da-3930-42fb-8088-bdd30fade9ec" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_fe47ac28-0f02-4998-8554-877c8f92c8b5" xlink:to="loc_srt_ConsolidatedEntitiesDomain_372249da-3930-42fb-8088-bdd30fade9ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_SubsidiariesVOLTMember_6efb0118-1216-4c57-8406-ac3fb28c0d19" xlink:href="brns-20231231.xsd#brns_SubsidiariesVOLTMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_372249da-3930-42fb-8088-bdd30fade9ec" xlink:to="loc_brns_SubsidiariesVOLTMember_6efb0118-1216-4c57-8406-ac3fb28c0d19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_817f1e63-4109-48ed-a23f-7b7945e06931" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_f1250b03-1721-4c50-81de-3cf66be9a344" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_817f1e63-4109-48ed-a23f-7b7945e06931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_c73c52b7-e476-4a86-a476-f4b34dbd451b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_817f1e63-4109-48ed-a23f-7b7945e06931" xlink:to="loc_us-gaap_RelatedPartyDomain_c73c52b7-e476-4a86-a476-f4b34dbd451b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_5127ef74-bc11-4ccf-b258-9fcc21df2ff0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_c73c52b7-e476-4a86-a476-f4b34dbd451b" xlink:to="loc_us-gaap_RelatedPartyMember_5127ef74-bc11-4ccf-b258-9fcc21df2ff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_a7f99af0-24f5-47fc-8437-30d0b4cb2bd0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_f1250b03-1721-4c50-81de-3cf66be9a344" xlink:to="loc_us-gaap_MinorityInterestLineItems_a7f99af0-24f5-47fc-8437-30d0b4cb2bd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_SubsidiaryCumulativeContributionsParent_1ca97047-f381-4d59-8468-2b851983f0ef" xlink:href="brns-20231231.xsd#brns_SubsidiaryCumulativeContributionsParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_a7f99af0-24f5-47fc-8437-30d0b4cb2bd0" xlink:to="loc_brns_SubsidiaryCumulativeContributionsParent_1ca97047-f381-4d59-8468-2b851983f0ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_3d9d64ba-f5cd-4b68-a88f-816f26f49b77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_a7f99af0-24f5-47fc-8437-30d0b4cb2bd0" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_3d9d64ba-f5cd-4b68-a88f-816f26f49b77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_SubsidiaryCumulativeContributionsNoncontrollingOwner_e7798bd5-9ceb-4228-a1f8-252f81656a6f" xlink:href="brns-20231231.xsd#brns_SubsidiaryCumulativeContributionsNoncontrollingOwner"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_a7f99af0-24f5-47fc-8437-30d0b4cb2bd0" xlink:to="loc_brns_SubsidiaryCumulativeContributionsNoncontrollingOwner_e7798bd5-9ceb-4228-a1f8-252f81656a6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_89bcf7b0-85c9-4dfa-b4de-97207ede63b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_a7f99af0-24f5-47fc-8437-30d0b4cb2bd0" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_89bcf7b0-85c9-4dfa-b4de-97207ede63b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_67506fcf-617b-4c12-ae8c-e791b4d2f2da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_a7f99af0-24f5-47fc-8437-30d0b4cb2bd0" xlink:to="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_67506fcf-617b-4c12-ae8c-e791b4d2f2da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesCashandcashequivalentsDetails" xlink:type="simple" xlink:href="brns-20231231.xsd#SummaryofSignificantAccountingPoliciesCashandcashequivalentsDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesCashandcashequivalentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_e7a518d6-a22e-4b5b-89d0-055880ba5222" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_a299b403-d074-4796-9c6e-903ba907ab95" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e7a518d6-a22e-4b5b-89d0-055880ba5222" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_a299b403-d074-4796-9c6e-903ba907ab95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesConcentrationsofcreditriskDetails" xlink:type="simple" xlink:href="brns-20231231.xsd#SummaryofSignificantAccountingPoliciesConcentrationsofcreditriskDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesConcentrationsofcreditriskDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_f63dae3d-a273-4786-9780-7b9e13fd4356" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_238b6b86-38c6-4fe3-8d3c-315af91d4b3e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f63dae3d-a273-4786-9780-7b9e13fd4356" xlink:to="loc_us-gaap_ConcentrationRiskTable_238b6b86-38c6-4fe3-8d3c-315af91d4b3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_ca0437cd-690c-44ea-84db-6274716830ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_238b6b86-38c6-4fe3-8d3c-315af91d4b3e" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_ca0437cd-690c-44ea-84db-6274716830ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_52ff5fee-d240-45df-99ec-8f7a4bcf5ec2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_ca0437cd-690c-44ea-84db-6274716830ce" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_52ff5fee-d240-45df-99ec-8f7a4bcf5ec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_7bfc9d41-a266-4868-ade7-c5b8c478c6b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_52ff5fee-d240-45df-99ec-8f7a4bcf5ec2" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_7bfc9d41-a266-4868-ade7-c5b8c478c6b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_0ef4f734-d62e-4c4d-aef6-70fca19a9110" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_52ff5fee-d240-45df-99ec-8f7a4bcf5ec2" xlink:to="loc_us-gaap_AccountsReceivableMember_0ef4f734-d62e-4c4d-aef6-70fca19a9110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_185151b7-cd2e-4306-8a8f-8157407c3de8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_238b6b86-38c6-4fe3-8d3c-315af91d4b3e" xlink:to="loc_srt_StatementGeographicalAxis_185151b7-cd2e-4306-8a8f-8157407c3de8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_2c948fb9-754e-4ec3-bee9-bfb60ef8a420" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_185151b7-cd2e-4306-8a8f-8157407c3de8" xlink:to="loc_srt_SegmentGeographicalDomain_2c948fb9-754e-4ec3-bee9-bfb60ef8a420" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_GB_cd27c62d-74a4-4c8b-9b01-e89ec92d597a" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_GB"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_2c948fb9-754e-4ec3-bee9-bfb60ef8a420" xlink:to="loc_country_GB_cd27c62d-74a4-4c8b-9b01-e89ec92d597a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_03e4f733-456f-4a8f-8aad-31fa50c43de0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_238b6b86-38c6-4fe3-8d3c-315af91d4b3e" xlink:to="loc_srt_MajorCustomersAxis_03e4f733-456f-4a8f-8aad-31fa50c43de0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_4dcbf0b0-11e7-42e5-820e-7973afd5b837" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_03e4f733-456f-4a8f-8aad-31fa50c43de0" xlink:to="loc_srt_NameOfMajorCustomerDomain_4dcbf0b0-11e7-42e5-820e-7973afd5b837" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_OxfordUniversityInnovationMember_7e0a055c-c768-4d9b-9691-0fc731878640" xlink:href="brns-20231231.xsd#brns_OxfordUniversityInnovationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_4dcbf0b0-11e7-42e5-820e-7973afd5b837" xlink:to="loc_brns_OxfordUniversityInnovationMember_7e0a055c-c768-4d9b-9691-0fc731878640" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_8c0a1396-f896-4c7b-980e-8f69ac824945" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_238b6b86-38c6-4fe3-8d3c-315af91d4b3e" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_8c0a1396-f896-4c7b-980e-8f69ac824945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_AccountsReceivableStandardPaymentTermsPeriod_a7b2b8e6-a96f-4635-b99c-468caad789b4" xlink:href="brns-20231231.xsd#brns_AccountsReceivableStandardPaymentTermsPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_8c0a1396-f896-4c7b-980e-8f69ac824945" xlink:to="loc_brns_AccountsReceivableStandardPaymentTermsPeriod_a7b2b8e6-a96f-4635-b99c-468caad789b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ConcentrationRiskThresholdPercentage_2ad4d581-cfe3-4ddb-8350-6c028b7b5605" xlink:href="brns-20231231.xsd#brns_ConcentrationRiskThresholdPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_8c0a1396-f896-4c7b-980e-8f69ac824945" xlink:to="loc_brns_ConcentrationRiskThresholdPercentage_2ad4d581-cfe3-4ddb-8350-6c028b7b5605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesAllowanceforcreditlossesDetails" xlink:type="simple" xlink:href="brns-20231231.xsd#SummaryofSignificantAccountingPoliciesAllowanceforcreditlossesDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesAllowanceforcreditlossesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0a5d6525-77be-412b-b580-bf694537b5aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_6ab319d8-d441-46a2-964b-09ab55b245cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0a5d6525-77be-412b-b580-bf694537b5aa" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_6ab319d8-d441-46a2-964b-09ab55b245cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPropertyandequipmentDetails" xlink:type="simple" xlink:href="brns-20231231.xsd#SummaryofSignificantAccountingPoliciesPropertyandequipmentDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPropertyandequipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_b8885f98-7985-401a-a261-89006e1655ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7d4d83a6-2764-4afb-8cfb-cfe4b4153218" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b8885f98-7985-401a-a261-89006e1655ba" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7d4d83a6-2764-4afb-8cfb-cfe4b4153218" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c9f5718d-c6d8-46a6-8ac6-9b594b328b34" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7d4d83a6-2764-4afb-8cfb-cfe4b4153218" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c9f5718d-c6d8-46a6-8ac6-9b594b328b34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ddec4c35-144b-4a7a-b759-7263bf77709c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c9f5718d-c6d8-46a6-8ac6-9b594b328b34" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ddec4c35-144b-4a7a-b759-7263bf77709c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_93388294-ea47-41da-923a-ef26dd398c69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ddec4c35-144b-4a7a-b759-7263bf77709c" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_93388294-ea47-41da-923a-ef26dd398c69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_LaboratoryEquipmentMember_fb8e7c03-2ac3-4864-a4b9-290226a48763" xlink:href="brns-20231231.xsd#brns_LaboratoryEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ddec4c35-144b-4a7a-b759-7263bf77709c" xlink:to="loc_brns_LaboratoryEquipmentMember_fb8e7c03-2ac3-4864-a4b9-290226a48763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_51677e04-0dfe-4f56-9619-561d5b3c6c89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7d4d83a6-2764-4afb-8cfb-cfe4b4153218" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_51677e04-0dfe-4f56-9619-561d5b3c6c89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_25dbe837-435d-4045-b732-e06594f6c8cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_51677e04-0dfe-4f56-9619-561d5b3c6c89" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_25dbe837-435d-4045-b732-e06594f6c8cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsDetails" xlink:type="simple" xlink:href="brns-20231231.xsd#SummaryofSignificantAccountingPoliciesIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1a638713-2618-4b53-8b68-56ede8807b89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_160ab386-2032-4278-b568-60db204de83a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1a638713-2618-4b53-8b68-56ede8807b89" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_160ab386-2032-4278-b568-60db204de83a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_87a53409-e4d8-4971-9b47-b568406992d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_160ab386-2032-4278-b568-60db204de83a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_87a53409-e4d8-4971-9b47-b568406992d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b5cfe03f-3350-4e3e-83b9-692d326b36db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_87a53409-e4d8-4971-9b47-b568406992d2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b5cfe03f-3350-4e3e-83b9-692d326b36db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_a561570e-d75a-42dd-9560-3e0e37d9cf4e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b5cfe03f-3350-4e3e-83b9-692d326b36db" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_a561570e-d75a-42dd-9560-3e0e37d9cf4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d5fadd5c-15f2-4215-badd-67614170af74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_160ab386-2032-4278-b568-60db204de83a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d5fadd5c-15f2-4215-badd-67614170af74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_07d61dec-101c-4e8f-b3bd-3508fe270513" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d5fadd5c-15f2-4215-badd-67614170af74" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_07d61dec-101c-4e8f-b3bd-3508fe270513" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesImpairmentoflonglivedassetsandGoodwillDetails" xlink:type="simple" xlink:href="brns-20231231.xsd#SummaryofSignificantAccountingPoliciesImpairmentoflonglivedassetsandGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesImpairmentoflonglivedassetsandGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_c555747b-cd6a-4c1b-99b1-6a4d0d365d73" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_0a4aeebc-a487-4280-a521-4d11f0e5c959" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c555747b-cd6a-4c1b-99b1-6a4d0d365d73" xlink:to="loc_us-gaap_AssetImpairmentCharges_0a4aeebc-a487-4280-a521-4d11f0e5c959" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_cdef7aaa-65b1-40ea-96f7-4ff3dc6983ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c555747b-cd6a-4c1b-99b1-6a4d0d365d73" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_cdef7aaa-65b1-40ea-96f7-4ff3dc6983ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesSharebasedcompensationDetails" xlink:type="simple" xlink:href="brns-20231231.xsd#SummaryofSignificantAccountingPoliciesSharebasedcompensationDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesSharebasedcompensationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_88489adb-bf3b-4728-974a-983a28d594a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_cfeb9663-93e5-41e7-9cd0-14f94335d58b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_88489adb-bf3b-4728-974a-983a28d594a8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_cfeb9663-93e5-41e7-9cd0-14f94335d58b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesResearchandDevelopmentIncentivesDetails" xlink:type="simple" xlink:href="brns-20231231.xsd#SummaryofSignificantAccountingPoliciesResearchandDevelopmentIncentivesDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesResearchandDevelopmentIncentivesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_def01a7b-be28-4410-97ac-fc75198fa91f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ResearchAndDevelopmentIncentiveIncomeExpense_c306d2bb-fc25-47c2-b879-ad32ec9c7b2b" xlink:href="brns-20231231.xsd#brns_ResearchAndDevelopmentIncentiveIncomeExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_def01a7b-be28-4410-97ac-fc75198fa91f" xlink:to="loc_brns_ResearchAndDevelopmentIncentiveIncomeExpense_c306d2bb-fc25-47c2-b879-ad32ec9c7b2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/ForeignCurrencyTranslationinGeneralandAdministrativeExpensesDetails" xlink:type="simple" xlink:href="brns-20231231.xsd#ForeignCurrencyTranslationinGeneralandAdministrativeExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/ForeignCurrencyTranslationinGeneralandAdministrativeExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyAbstract_c61a0080-08fe-43cf-8f84-276206db683d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_b1cd7d43-779e-47a7-ac63-33ff508c2b42" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ForeignCurrencyAbstract_c61a0080-08fe-43cf-8f84-276206db683d" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_b1cd7d43-779e-47a7-ac63-33ff508c2b42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/NetLossIncomePerShareComputationDetails" xlink:type="simple" xlink:href="brns-20231231.xsd#NetLossIncomePerShareComputationDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/NetLossIncomePerShareComputationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_98c65ae4-a0c3-4295-be42-72528d5eca26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract_6c322378-ff2a-490a-b100-c562a70a256e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_98c65ae4-a0c3-4295-be42-72528d5eca26" xlink:to="loc_us-gaap_NetIncomeLossAbstract_6c322378-ff2a-490a-b100-c562a70a256e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_d44a955d-b300-4a6f-9a8d-d3fefd4f5ac5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_6c322378-ff2a-490a-b100-c562a70a256e" xlink:to="loc_us-gaap_ProfitLoss_d44a955d-b300-4a6f-9a8d-d3fefd4f5ac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_23aea6a3-5037-4663-bcf5-d8237c3576c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_6c322378-ff2a-490a-b100-c562a70a256e" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_23aea6a3-5037-4663-bcf5-d8237c3576c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_4dbd8b07-dfb1-4878-a4d4-57c826f63b47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_6c322378-ff2a-490a-b100-c562a70a256e" xlink:to="loc_us-gaap_NetIncomeLoss_4dbd8b07-dfb1-4878-a4d4-57c826f63b47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_35a8a6b1-9735-4ab9-a014-ebfa4f1fcde8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_98c65ae4-a0c3-4295-be42-72528d5eca26" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_35a8a6b1-9735-4ab9-a014-ebfa4f1fcde8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ffc92539-4c77-4c01-9b00-b45f7e9db135" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_35a8a6b1-9735-4ab9-a014-ebfa4f1fcde8" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ffc92539-4c77-4c01-9b00-b45f7e9db135" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_6f069a3d-685e-4571-9002-fce7c8a3f7f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_35a8a6b1-9735-4ab9-a014-ebfa4f1fcde8" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_6f069a3d-685e-4571-9002-fce7c8a3f7f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_de01df30-fad2-44a9-88cd-0ff7067ffdde" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_35a8a6b1-9735-4ab9-a014-ebfa4f1fcde8" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_de01df30-fad2-44a9-88cd-0ff7067ffdde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_1cb2ded3-c9cc-489c-bbc4-185326b732a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_35a8a6b1-9735-4ab9-a014-ebfa4f1fcde8" xlink:to="loc_us-gaap_EarningsPerShareBasic_1cb2ded3-c9cc-489c-bbc4-185326b732a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_ed00c22d-d58e-4b49-beb3-74ac054bdc8e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_35a8a6b1-9735-4ab9-a014-ebfa4f1fcde8" xlink:to="loc_us-gaap_EarningsPerShareDiluted_ed00c22d-d58e-4b49-beb3-74ac054bdc8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/NetLossIncomePerShareAdditionalInformationDetails" xlink:type="simple" xlink:href="brns-20231231.xsd#NetLossIncomePerShareAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/NetLossIncomePerShareAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_7639b63a-6129-48b0-8fcd-ffc68aeb639e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_666b6331-6d7b-4157-8021-4373ba7d8a2e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_7639b63a-6129-48b0-8fcd-ffc68aeb639e" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_666b6331-6d7b-4157-8021-4373ba7d8a2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/PropertyandEquipmentNetComponentsDetails" xlink:type="simple" xlink:href="brns-20231231.xsd#PropertyandEquipmentNetComponentsDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/PropertyandEquipmentNetComponentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_26dd1128-69e6-4075-a25f-e01bae2d07d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_39a0c5f2-2ccc-4d9d-b67f-6871bda81fb5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_26dd1128-69e6-4075-a25f-e01bae2d07d9" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_39a0c5f2-2ccc-4d9d-b67f-6871bda81fb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_25f79467-c701-45ad-91b0-be0c03589d60" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_39a0c5f2-2ccc-4d9d-b67f-6871bda81fb5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_25f79467-c701-45ad-91b0-be0c03589d60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bee3553b-857e-4bdc-b59e-16b8993194cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_25f79467-c701-45ad-91b0-be0c03589d60" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bee3553b-857e-4bdc-b59e-16b8993194cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_016e3761-136f-42dc-baf7-8a91c2ab6db7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bee3553b-857e-4bdc-b59e-16b8993194cd" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_016e3761-136f-42dc-baf7-8a91c2ab6db7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_LaboratoryEquipmentMember_de44db86-6470-4ab6-afff-c3d69f73c2ac" xlink:href="brns-20231231.xsd#brns_LaboratoryEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bee3553b-857e-4bdc-b59e-16b8993194cd" xlink:to="loc_brns_LaboratoryEquipmentMember_de44db86-6470-4ab6-afff-c3d69f73c2ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_6cddb621-0f0e-4be5-af35-8017c135cd6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bee3553b-857e-4bdc-b59e-16b8993194cd" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_6cddb621-0f0e-4be5-af35-8017c135cd6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fe1deb2e-4653-4a6a-9880-933480a323b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_39a0c5f2-2ccc-4d9d-b67f-6871bda81fb5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fe1deb2e-4653-4a6a-9880-933480a323b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_e9107697-89ad-4d10-9190-982eea531cb0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fe1deb2e-4653-4a6a-9880-933480a323b3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_e9107697-89ad-4d10-9190-982eea531cb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_4bc0af35-f771-4912-8c34-adcfb6b030e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fe1deb2e-4653-4a6a-9880-933480a323b3" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_4bc0af35-f771-4912-8c34-adcfb6b030e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_667420e7-8fbd-4dbe-8479-2824b6ebb679" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fe1deb2e-4653-4a6a-9880-933480a323b3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_667420e7-8fbd-4dbe-8479-2824b6ebb679" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/PropertyandEquipmentNetAdditionalInformationDetails" xlink:type="simple" xlink:href="brns-20231231.xsd#PropertyandEquipmentNetAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/PropertyandEquipmentNetAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_dbad8a40-2cf5-43d0-b51a-7e92f62a29f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_3419dcdb-9fe8-435a-820d-f51711f6ca68" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_dbad8a40-2cf5-43d0-b51a-7e92f62a29f1" xlink:to="loc_us-gaap_Depreciation_3419dcdb-9fe8-435a-820d-f51711f6ca68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/IntangibleassetsnetDetails" xlink:type="simple" xlink:href="brns-20231231.xsd#IntangibleassetsnetDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/IntangibleassetsnetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ad2e0084-61b3-44ea-a87a-e4b451d1add3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_6d721e16-720b-4934-ae0d-d8584798797a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ad2e0084-61b3-44ea-a87a-e4b451d1add3" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_6d721e16-720b-4934-ae0d-d8584798797a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_51a45792-0ec3-4556-8db7-a674eb193fd3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_6d721e16-720b-4934-ae0d-d8584798797a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_51a45792-0ec3-4556-8db7-a674eb193fd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_54b7287f-26b3-4371-a889-21f660a81668" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_51a45792-0ec3-4556-8db7-a674eb193fd3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_54b7287f-26b3-4371-a889-21f660a81668" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_9992b619-075c-48d9-897c-4cc208906bf4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_54b7287f-26b3-4371-a889-21f660a81668" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_9992b619-075c-48d9-897c-4cc208906bf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b6b25b6b-a0b6-41a6-9761-7712920e338f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_6d721e16-720b-4934-ae0d-d8584798797a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b6b25b6b-a0b6-41a6-9761-7712920e338f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_64e4c485-227f-4864-99d0-a182d417c62a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b6b25b6b-a0b6-41a6-9761-7712920e338f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_64e4c485-227f-4864-99d0-a182d417c62a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_03b73a78-0e09-4413-9dfd-113fa9da2566" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b6b25b6b-a0b6-41a6-9761-7712920e338f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_03b73a78-0e09-4413-9dfd-113fa9da2566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_a60987c2-070f-4e8c-96f3-2ecafecef037" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b6b25b6b-a0b6-41a6-9761-7712920e338f" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_a60987c2-070f-4e8c-96f3-2ecafecef037" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_05c7ca79-bbff-40b2-b804-8164226ede91" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b6b25b6b-a0b6-41a6-9761-7712920e338f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_05c7ca79-bbff-40b2-b804-8164226ede91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_deaccbfd-5b76-4fb5-83a9-c059e264b38e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b6b25b6b-a0b6-41a6-9761-7712920e338f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_deaccbfd-5b76-4fb5-83a9-c059e264b38e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_d250d81d-5a3c-49c3-8f56-cf57a62dacd4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b6b25b6b-a0b6-41a6-9761-7712920e338f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_d250d81d-5a3c-49c3-8f56-cf57a62dacd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_90f0f813-a2a8-443a-a11a-e56fa6d2e84c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b6b25b6b-a0b6-41a6-9761-7712920e338f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_90f0f813-a2a8-443a-a11a-e56fa6d2e84c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_0c1c46c7-e7a5-4f6d-b25d-f197b22a4e3e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b6b25b6b-a0b6-41a6-9761-7712920e338f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_0c1c46c7-e7a5-4f6d-b25d-f197b22a4e3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSix_93776fab-95ac-415e-a178-3f0b43ee2e38" xlink:href="brns-20231231.xsd#brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSix"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b6b25b6b-a0b6-41a6-9761-7712920e338f" xlink:to="loc_brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSix_93776fab-95ac-415e-a178-3f0b43ee2e38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSeven_322e70a9-1ac9-4207-af31-d0bb04e0ebad" xlink:href="brns-20231231.xsd#brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSeven"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b6b25b6b-a0b6-41a6-9761-7712920e338f" xlink:to="loc_brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSeven_322e70a9-1ac9-4207-af31-d0bb04e0ebad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_FiniteLivedIntangibleAssetExpectedAmortizationYearEight_fdff1557-1c54-48ed-8e06-f7439506dd2a" xlink:href="brns-20231231.xsd#brns_FiniteLivedIntangibleAssetExpectedAmortizationYearEight"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b6b25b6b-a0b6-41a6-9761-7712920e338f" xlink:to="loc_brns_FiniteLivedIntangibleAssetExpectedAmortizationYearEight_fdff1557-1c54-48ed-8e06-f7439506dd2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/PrepaidandothercurrentassetsDetails" xlink:type="simple" xlink:href="brns-20231231.xsd#PrepaidandothercurrentassetsDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/PrepaidandothercurrentassetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_e133bb5a-c573-4496-b606-aa4b60528db8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_30b0056c-b5c7-4562-baa5-2f7e1f51c4b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_e133bb5a-c573-4496-b606-aa4b60528db8" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_30b0056c-b5c7-4562-baa5-2f7e1f51c4b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValueAddedTaxReceivableCurrent_8d0a1b28-6305-453f-9104-8128b282c5bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValueAddedTaxReceivableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_e133bb5a-c573-4496-b606-aa4b60528db8" xlink:to="loc_us-gaap_ValueAddedTaxReceivableCurrent_8d0a1b28-6305-453f-9104-8128b282c5bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_LeaseIncentiveReceivablesCurrent_85a24dc1-b1b1-40d1-be9f-3893204b5a57" xlink:href="brns-20231231.xsd#brns_LeaseIncentiveReceivablesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_e133bb5a-c573-4496-b606-aa4b60528db8" xlink:to="loc_brns_LeaseIncentiveReceivablesCurrent_85a24dc1-b1b1-40d1-be9f-3893204b5a57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_0c20144e-2a29-4705-b1bf-0ae7b3b9dacb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_e133bb5a-c573-4496-b606-aa4b60528db8" xlink:to="loc_us-gaap_OtherAssetsCurrent_0c20144e-2a29-4705-b1bf-0ae7b3b9dacb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9faf8ed8-59be-4ed3-ac53-0df624a4c409" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_e133bb5a-c573-4496-b606-aa4b60528db8" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9faf8ed8-59be-4ed3-ac53-0df624a4c409" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="brns-20231231.xsd#AccruedExpensesandOtherCurrentLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_2794e39d-5f84-45b4-93f0-5c464a7b5912" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_AccruedManufacturingAndClinicalExpensesCurrent_963933ad-4881-41b7-bfad-0278bd4c3ab5" xlink:href="brns-20231231.xsd#brns_AccruedManufacturingAndClinicalExpensesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_2794e39d-5f84-45b4-93f0-5c464a7b5912" xlink:to="loc_brns_AccruedManufacturingAndClinicalExpensesCurrent_963933ad-4881-41b7-bfad-0278bd4c3ab5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedBonusesCurrent_e491ab26-9273-4e95-bbbf-6b0399ca5c45" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedBonusesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_2794e39d-5f84-45b4-93f0-5c464a7b5912" xlink:to="loc_us-gaap_AccruedBonusesCurrent_e491ab26-9273-4e95-bbbf-6b0399ca5c45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_e9b0d674-e141-4bc1-a3a2-a8bcd1239cd6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_2794e39d-5f84-45b4-93f0-5c464a7b5912" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_e9b0d674-e141-4bc1-a3a2-a8bcd1239cd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_d1ac5a82-aad5-459d-9c72-59318d43b5c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_2794e39d-5f84-45b4-93f0-5c464a7b5912" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_d1ac5a82-aad5-459d-9c72-59318d43b5c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_614c6a42-1847-44f2-a43d-a9dbf8c184a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_2794e39d-5f84-45b4-93f0-5c464a7b5912" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_614c6a42-1847-44f2-a43d-a9dbf8c184a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent_91ebb216-c40e-4dbf-855b-e3ec42e1edd4" xlink:href="brns-20231231.xsd#brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_2794e39d-5f84-45b4-93f0-5c464a7b5912" xlink:to="loc_brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent_91ebb216-c40e-4dbf-855b-e3ec42e1edd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/OutlicensesandGrantsAdditionalInformationDetails" xlink:type="simple" xlink:href="brns-20231231.xsd#OutlicensesandGrantsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/OutlicensesandGrantsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_32dd823b-4bd8-4df0-98d1-fdca482b7fb2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_951d5434-b3d5-470e-a630-e7d980ac3980" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_32dd823b-4bd8-4df0-98d1-fdca482b7fb2" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_951d5434-b3d5-470e-a630-e7d980ac3980" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_f572256d-4300-41a4-a594-7941d4b4bd8e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_951d5434-b3d5-470e-a630-e7d980ac3980" xlink:to="loc_us-gaap_TypeOfArrangementAxis_f572256d-4300-41a4-a594-7941d4b4bd8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_88770ec0-564d-48e1-9707-280c70dbaaee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_f572256d-4300-41a4-a594-7941d4b4bd8e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_88770ec0-564d-48e1-9707-280c70dbaaee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_OuiLicenseAgreementAmendmentMember_9a2495f7-18a9-4541-ae63-d55748a425cf" xlink:href="brns-20231231.xsd#brns_OuiLicenseAgreementAmendmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_88770ec0-564d-48e1-9707-280c70dbaaee" xlink:to="loc_brns_OuiLicenseAgreementAmendmentMember_9a2495f7-18a9-4541-ae63-d55748a425cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_AgreementWithOxfordUniversityInnovationMember_4ec58669-497e-4dfe-9fed-1ab66d35267c" xlink:href="brns-20231231.xsd#brns_AgreementWithOxfordUniversityInnovationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_88770ec0-564d-48e1-9707-280c70dbaaee" xlink:to="loc_brns_AgreementWithOxfordUniversityInnovationMember_4ec58669-497e-4dfe-9fed-1ab66d35267c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_AgreementWithScancellToGrantResearchAndDevelopmentLicenseMember_ecccb39c-fc3f-49a7-8c13-503f89ffbe50" xlink:href="brns-20231231.xsd#brns_AgreementWithScancellToGrantResearchAndDevelopmentLicenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_88770ec0-564d-48e1-9707-280c70dbaaee" xlink:to="loc_brns_AgreementWithScancellToGrantResearchAndDevelopmentLicenseMember_ecccb39c-fc3f-49a7-8c13-503f89ffbe50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_CoalitionForEpidemicPreparednessInnovationsFundingAgreementMember_76b7eefc-b97c-4595-8bb8-59794b40accd" xlink:href="brns-20231231.xsd#brns_CoalitionForEpidemicPreparednessInnovationsFundingAgreementMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_88770ec0-564d-48e1-9707-280c70dbaaee" xlink:to="loc_brns_CoalitionForEpidemicPreparednessInnovationsFundingAgreementMember_76b7eefc-b97c-4595-8bb8-59794b40accd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_02197810-107a-4ca0-aabd-03e072dfb45f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_951d5434-b3d5-470e-a630-e7d980ac3980" xlink:to="loc_srt_ProductOrServiceAxis_02197810-107a-4ca0-aabd-03e072dfb45f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_bcd29b67-30b7-4555-bcfe-17e0e7b96787" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_02197810-107a-4ca0-aabd-03e072dfb45f" xlink:to="loc_srt_ProductsAndServicesDomain_bcd29b67-30b7-4555-bcfe-17e0e7b96787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_3db17900-3815-493f-9d8c-09bdbb9f2c38" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_bcd29b67-30b7-4555-bcfe-17e0e7b96787" xlink:to="loc_us-gaap_LicenseMember_3db17900-3815-493f-9d8c-09bdbb9f2c38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dd9b6185-5c42-4052-8cab-f51bb692cf31" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_951d5434-b3d5-470e-a630-e7d980ac3980" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dd9b6185-5c42-4052-8cab-f51bb692cf31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_PercentageOfRoyaltiesOnNetSales_7ab57d09-dc15-4b5c-9313-e47a258ce1bc" xlink:href="brns-20231231.xsd#brns_PercentageOfRoyaltiesOnNetSales"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dd9b6185-5c42-4052-8cab-f51bb692cf31" xlink:to="loc_brns_PercentageOfRoyaltiesOnNetSales_7ab57d09-dc15-4b5c-9313-e47a258ce1bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_040cc8f0-5341-4534-b26d-6e504b33d962" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dd9b6185-5c42-4052-8cab-f51bb692cf31" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_040cc8f0-5341-4534-b26d-6e504b33d962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_f98742b2-4fc2-48d0-b91a-018fafc8c382" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dd9b6185-5c42-4052-8cab-f51bb692cf31" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_f98742b2-4fc2-48d0-b91a-018fafc8c382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ContractWithCustomerLiabilityRevenueRecognized1_8034d038-dcaa-4e57-9293-3d426c629dc9" xlink:href="brns-20231231.xsd#brns_ContractWithCustomerLiabilityRevenueRecognized1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dd9b6185-5c42-4052-8cab-f51bb692cf31" xlink:to="loc_brns_ContractWithCustomerLiabilityRevenueRecognized1_8034d038-dcaa-4e57-9293-3d426c629dc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_FundingAmountMaximum_1b16635a-24f8-42f4-8af2-a0bba587913d" xlink:href="brns-20231231.xsd#brns_FundingAmountMaximum"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dd9b6185-5c42-4052-8cab-f51bb692cf31" xlink:to="loc_brns_FundingAmountMaximum_1b16635a-24f8-42f4-8af2-a0bba587913d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_RoyaltyPaymentTermMaximum_6b8ab09d-d1e9-4e67-a84f-629f821df49a" xlink:href="brns-20231231.xsd#brns_RoyaltyPaymentTermMaximum"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dd9b6185-5c42-4052-8cab-f51bb692cf31" xlink:to="loc_brns_RoyaltyPaymentTermMaximum_6b8ab09d-d1e9-4e67-a84f-629f821df49a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ProceedsFromGrantsReceived_8e758b79-5798-4a46-ae20-299972719745" xlink:href="brns-20231231.xsd#brns_ProceedsFromGrantsReceived"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dd9b6185-5c42-4052-8cab-f51bb692cf31" xlink:to="loc_brns_ProceedsFromGrantsReceived_8e758b79-5798-4a46-ae20-299972719745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_ebf05dfc-a2a6-4481-885a-2f3920436142" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dd9b6185-5c42-4052-8cab-f51bb692cf31" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_ebf05dfc-a2a6-4481-885a-2f3920436142" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/OutlicensesandGrantsChangesinthecontractliabilitiesDetails" xlink:type="simple" xlink:href="brns-20231231.xsd#OutlicensesandGrantsChangesinthecontractliabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/OutlicensesandGrantsChangesinthecontractliabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_78c6c0d3-ff5d-4673-a91c-9fdf58f54e04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ContractWithCustomerLiabilityRollForward_823157b2-d298-4386-8172-ca4c444c87d0" xlink:href="brns-20231231.xsd#brns_ContractWithCustomerLiabilityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_78c6c0d3-ff5d-4673-a91c-9fdf58f54e04" xlink:to="loc_brns_ContractWithCustomerLiabilityRollForward_823157b2-d298-4386-8172-ca4c444c87d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_d3882658-ebd3-4887-b8b6-1c54618432a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_brns_ContractWithCustomerLiabilityRollForward_823157b2-d298-4386-8172-ca4c444c87d0" xlink:to="loc_us-gaap_ContractWithCustomerLiability_d3882658-ebd3-4887-b8b6-1c54618432a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ContractWithCustomerLiabilityRevenueRecognized1_f6c5e804-e172-47f1-b56b-c7a54cc98ef3" xlink:href="brns-20231231.xsd#brns_ContractWithCustomerLiabilityRevenueRecognized1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_brns_ContractWithCustomerLiabilityRollForward_823157b2-d298-4386-8172-ca4c444c87d0" xlink:to="loc_brns_ContractWithCustomerLiabilityRevenueRecognized1_f6c5e804-e172-47f1-b56b-c7a54cc98ef3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ContractWithCustomerLiabilityForeignExchangeTranslation_8ae082f5-7c49-4826-b25b-cddf001bfb00" xlink:href="brns-20231231.xsd#brns_ContractWithCustomerLiabilityForeignExchangeTranslation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_brns_ContractWithCustomerLiabilityRollForward_823157b2-d298-4386-8172-ca4c444c87d0" xlink:to="loc_brns_ContractWithCustomerLiabilityForeignExchangeTranslation_8ae082f5-7c49-4826-b25b-cddf001bfb00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_00017a31-6a8e-4ff8-9bb5-ebdb4d14c3c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_brns_ContractWithCustomerLiabilityRollForward_823157b2-d298-4386-8172-ca4c444c87d0" xlink:to="loc_us-gaap_ContractWithCustomerLiability_00017a31-6a8e-4ff8-9bb5-ebdb4d14c3c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/OrdinarySharesAdditionalInformationDetails" xlink:type="simple" xlink:href="brns-20231231.xsd#OrdinarySharesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/OrdinarySharesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_badd8328-2400-44a9-b29b-d93b810df2f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_eeb58bc8-226a-42ee-9dc3-a57e430fcddc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_badd8328-2400-44a9-b29b-d93b810df2f5" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_eeb58bc8-226a-42ee-9dc3-a57e430fcddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_f67fb9e5-bd67-4a98-b8d1-294160e46b6e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_eeb58bc8-226a-42ee-9dc3-a57e430fcddc" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_f67fb9e5-bd67-4a98-b8d1-294160e46b6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4650cc10-ea65-4e28-9a48-012c6b080677" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_f67fb9e5-bd67-4a98-b8d1-294160e46b6e" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4650cc10-ea65-4e28-9a48-012c6b080677" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_b5e2bb5e-aae7-41a1-8164-03bc0e073a74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4650cc10-ea65-4e28-9a48-012c6b080677" xlink:to="loc_us-gaap_IPOMember_b5e2bb5e-aae7-41a1-8164-03bc0e073a74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_7b97fa67-e718-4685-af32-db4edf8085ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_eeb58bc8-226a-42ee-9dc3-a57e430fcddc" xlink:to="loc_us-gaap_SubsidiarySaleOfStockLineItems_7b97fa67-e718-4685-af32-db4edf8085ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_NumberOfAmericanDepositarySharesAdsIssued_532d2e42-a5e4-46bb-8da0-49e859cc28fc" xlink:href="brns-20231231.xsd#brns_NumberOfAmericanDepositarySharesAdsIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_7b97fa67-e718-4685-af32-db4edf8085ad" xlink:to="loc_brns_NumberOfAmericanDepositarySharesAdsIssued_532d2e42-a5e4-46bb-8da0-49e859cc28fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_5ab107f5-09a8-455f-81d0-a85d1b0c65bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_7b97fa67-e718-4685-af32-db4edf8085ad" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_5ab107f5-09a8-455f-81d0-a85d1b0c65bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_eef91d6c-5c39-4f26-87a6-441d4f79e6a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_7b97fa67-e718-4685-af32-db4edf8085ad" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_eef91d6c-5c39-4f26-87a6-441d4f79e6a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_f7e90877-c216-4a97-ada0-1fbb649281bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_7b97fa67-e718-4685-af32-db4edf8085ad" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_f7e90877-c216-4a97-ada0-1fbb649281bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_5acd90f8-6b1b-466f-9901-d685aac120e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_7b97fa67-e718-4685-af32-db4edf8085ad" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_5acd90f8-6b1b-466f-9901-d685aac120e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_IssuanceOfCommonStockUnderwritingCommissions_4213d5d3-cf02-4a56-af24-e0aa0e22dadb" xlink:href="brns-20231231.xsd#brns_IssuanceOfCommonStockUnderwritingCommissions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_7b97fa67-e718-4685-af32-db4edf8085ad" xlink:to="loc_brns_IssuanceOfCommonStockUnderwritingCommissions_4213d5d3-cf02-4a56-af24-e0aa0e22dadb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_IssuanceOfCommonStockOfferingCosts_e8355dbe-22ad-4a28-b605-c3c7ff49788b" xlink:href="brns-20231231.xsd#brns_IssuanceOfCommonStockOfferingCosts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_7b97fa67-e718-4685-af32-db4edf8085ad" xlink:to="loc_brns_IssuanceOfCommonStockOfferingCosts_e8355dbe-22ad-4a28-b605-c3c7ff49788b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_CommonStockNumberOfVotesPerShare_f9f5cab0-b48d-44f8-a660-ef55699272a1" xlink:href="brns-20231231.xsd#brns_CommonStockNumberOfVotesPerShare"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_7b97fa67-e718-4685-af32-db4edf8085ad" xlink:to="loc_brns_CommonStockNumberOfVotesPerShare_f9f5cab0-b48d-44f8-a660-ef55699272a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_PercentageOfSharesNecessaryToExercisePreemptiveRights_9e8156b2-ef39-421e-9597-7a3c63ff4aa4" xlink:href="brns-20231231.xsd#brns_PercentageOfSharesNecessaryToExercisePreemptiveRights"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_7b97fa67-e718-4685-af32-db4edf8085ad" xlink:to="loc_brns_PercentageOfSharesNecessaryToExercisePreemptiveRights_9e8156b2-ef39-421e-9597-7a3c63ff4aa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_PeriodOfPreemptiveRightsToBeExercised_815eff91-65e0-4226-8abf-b1f93fe82e02" xlink:href="brns-20231231.xsd#brns_PeriodOfPreemptiveRightsToBeExercised"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_7b97fa67-e718-4685-af32-db4edf8085ad" xlink:to="loc_brns_PeriodOfPreemptiveRightsToBeExercised_815eff91-65e0-4226-8abf-b1f93fe82e02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_MaximumAggregateNominalAmountOfSharesAuthorizedToBeAllottedFreeFromStatutoryPreEmptionRights_84c6fa6a-afb3-4d2d-b039-e0d0cf04720d" xlink:href="brns-20231231.xsd#brns_MaximumAggregateNominalAmountOfSharesAuthorizedToBeAllottedFreeFromStatutoryPreEmptionRights"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_7b97fa67-e718-4685-af32-db4edf8085ad" xlink:to="loc_brns_MaximumAggregateNominalAmountOfSharesAuthorizedToBeAllottedFreeFromStatutoryPreEmptionRights_84c6fa6a-afb3-4d2d-b039-e0d0cf04720d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/OrdinarySharesOrdinarysharesforfutureissuanceDetails" xlink:type="simple" xlink:href="brns-20231231.xsd#OrdinarySharesOrdinarysharesforfutureissuanceDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/OrdinarySharesOrdinarysharesforfutureissuanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_500ec51c-c5db-42ae-b01c-f1a38a28b6cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e7711dbd-b331-4008-9d1b-1d00c6dac0bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_500ec51c-c5db-42ae-b01c-f1a38a28b6cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e7711dbd-b331-4008-9d1b-1d00c6dac0bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_4e497ecc-78f6-47ec-8659-fd5be59183b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_500ec51c-c5db-42ae-b01c-f1a38a28b6cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_4e497ecc-78f6-47ec-8659-fd5be59183b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_ca9ceec5-4f1e-46cf-92f6-4ddb27e89b49" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_500ec51c-c5db-42ae-b01c-f1a38a28b6cc" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_ca9ceec5-4f1e-46cf-92f6-4ddb27e89b49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/DeferredsharesDetails" xlink:type="simple" xlink:href="brns-20231231.xsd#DeferredsharesDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/DeferredsharesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_aa2819ca-c4a2-4ac0-9ddd-9d276a61319f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_78bf326e-85c2-489b-af27-99fe7d9c6909" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_aa2819ca-c4a2-4ac0-9ddd-9d276a61319f" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_78bf326e-85c2-489b-af27-99fe7d9c6909" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_31bbf2b4-423e-45b5-88b1-d321d2963d2b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_78bf326e-85c2-489b-af27-99fe7d9c6909" xlink:to="loc_us-gaap_StatementClassOfStockAxis_31bbf2b4-423e-45b5-88b1-d321d2963d2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_a2cbd46d-f5b4-4585-b852-280582110e1f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_31bbf2b4-423e-45b5-88b1-d321d2963d2b" xlink:to="loc_us-gaap_ClassOfStockDomain_a2cbd46d-f5b4-4585-b852-280582110e1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredShares.Member_ecb049a6-7572-499f-96d1-bce792b9d821" xlink:href="brns-20231231.xsd#brns_DeferredShares.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_a2cbd46d-f5b4-4585-b852-280582110e1f" xlink:to="loc_brns_DeferredShares.Member_ecb049a6-7572-499f-96d1-bce792b9d821" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredBSharesMember_fadefac6-59d2-4327-84aa-d17c981ceb2a" xlink:href="brns-20231231.xsd#brns_DeferredBSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_a2cbd46d-f5b4-4585-b852-280582110e1f" xlink:to="loc_brns_DeferredBSharesMember_fadefac6-59d2-4327-84aa-d17c981ceb2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredCSharesMember_8252a54d-8a08-41d0-94d9-37354a9789f3" xlink:href="brns-20231231.xsd#brns_DeferredCSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_a2cbd46d-f5b4-4585-b852-280582110e1f" xlink:to="loc_brns_DeferredCSharesMember_8252a54d-8a08-41d0-94d9-37354a9789f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_5d52d994-6de1-4f7f-ad97-b487e1f7a75e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_78bf326e-85c2-489b-af27-99fe7d9c6909" xlink:to="loc_us-gaap_ClassOfStockLineItems_5d52d994-6de1-4f7f-ad97-b487e1f7a75e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_OrdinarySharesLiquidationPreference_73204195-653b-4f1a-9d8c-fe0bf3d469ec" xlink:href="brns-20231231.xsd#brns_OrdinarySharesLiquidationPreference"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5d52d994-6de1-4f7f-ad97-b487e1f7a75e" xlink:to="loc_brns_OrdinarySharesLiquidationPreference_73204195-653b-4f1a-9d8c-fe0bf3d469ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredStockParOrStatedValuePerShare_c1a896e1-54f1-409e-b026-38e1e7eeeb8b" xlink:href="brns-20231231.xsd#brns_DeferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5d52d994-6de1-4f7f-ad97-b487e1f7a75e" xlink:to="loc_brns_DeferredStockParOrStatedValuePerShare_c1a896e1-54f1-409e-b026-38e1e7eeeb8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/FairValueAdditionalinformationDetails" xlink:type="simple" xlink:href="brns-20231231.xsd#FairValueAdditionalinformationDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/FairValueAdditionalinformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_ff1443d3-1b87-4f42-97d5-2d7f4ca2f3ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_3bba5b1f-a961-4ece-889f-2b6201a85ec0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_ff1443d3-1b87-4f42-97d5-2d7f4ca2f3ba" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_3bba5b1f-a961-4ece-889f-2b6201a85ec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_19924d61-2b9c-4407-9d0f-fa1b5f75a956" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_3bba5b1f-a961-4ece-889f-2b6201a85ec0" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_19924d61-2b9c-4407-9d0f-fa1b5f75a956" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a4f0fe8c-abef-405e-b47d-4fa8d42127c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_19924d61-2b9c-4407-9d0f-fa1b5f75a956" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a4f0fe8c-abef-405e-b47d-4fa8d42127c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_AvideaMember_bd2814df-967a-457a-b4ad-6c2d96fd7f54" xlink:href="brns-20231231.xsd#brns_AvideaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a4f0fe8c-abef-405e-b47d-4fa8d42127c5" xlink:to="loc_brns_AvideaMember_bd2814df-967a-457a-b4ad-6c2d96fd7f54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_6bbba7c2-7b04-4fc7-a959-64c420bf2149" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_3bba5b1f-a961-4ece-889f-2b6201a85ec0" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_6bbba7c2-7b04-4fc7-a959-64c420bf2149" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_c21ed3a2-ee0b-445d-823d-6b85bebf80ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_6bbba7c2-7b04-4fc7-a959-64c420bf2149" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_c21ed3a2-ee0b-445d-823d-6b85bebf80ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/FairValueChangeinfairvalueofcontingentconsiderationDetails" xlink:type="simple" xlink:href="brns-20231231.xsd#FairValueChangeinfairvalueofcontingentconsiderationDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/FairValueChangeinfairvalueofcontingentconsiderationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_db47e50d-2d1b-46e0-8259-9567518c0a1d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_1cb65ea3-052d-4e61-8a28-03259e083918" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_db47e50d-2d1b-46e0-8259-9567518c0a1d" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_1cb65ea3-052d-4e61-8a28-03259e083918" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_d8ad4f18-c57e-4a94-8f16-329920f2b83f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_1cb65ea3-052d-4e61-8a28-03259e083918" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_d8ad4f18-c57e-4a94-8f16-329920f2b83f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_88b3c79d-5c88-48af-91dc-c615b7258f96" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_d8ad4f18-c57e-4a94-8f16-329920f2b83f" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_88b3c79d-5c88-48af-91dc-c615b7258f96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ContingentConsiderationLiabilityMember_9adffb29-c779-423a-89c9-c311e80853dd" xlink:href="brns-20231231.xsd#brns_ContingentConsiderationLiabilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_88b3c79d-5c88-48af-91dc-c615b7258f96" xlink:to="loc_brns_ContingentConsiderationLiabilityMember_9adffb29-c779-423a-89c9-c311e80853dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_24aff454-7238-4a88-96fa-dc069a9f6a25" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_1cb65ea3-052d-4e61-8a28-03259e083918" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_24aff454-7238-4a88-96fa-dc069a9f6a25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_b8f2f6cd-4d37-411d-9e94-5ce038e676ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_24aff454-7238-4a88-96fa-dc069a9f6a25" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_b8f2f6cd-4d37-411d-9e94-5ce038e676ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_21d2a20d-612a-4120-986a-5b950bd9bc50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_b8f2f6cd-4d37-411d-9e94-5ce038e676ee" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_21d2a20d-612a-4120-986a-5b950bd9bc50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_73e41ff0-1542-40c8-86d9-117f6330c2ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_b8f2f6cd-4d37-411d-9e94-5ce038e676ee" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_73e41ff0-1542-40c8-86d9-117f6330c2ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_a83ea3d4-d124-4ec2-9cdc-a0c543d7ee24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_b8f2f6cd-4d37-411d-9e94-5ce038e676ee" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_a83ea3d4-d124-4ec2-9cdc-a0c543d7ee24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeTranslation_36e241ee-929c-4cbe-8f66-531097fc5334" xlink:href="brns-20231231.xsd#brns_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeTranslation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_b8f2f6cd-4d37-411d-9e94-5ce038e676ee" xlink:to="loc_brns_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeTranslation_36e241ee-929c-4cbe-8f66-531097fc5334" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_fea8bf67-ae3a-43b2-bf14-1a35544010db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_b8f2f6cd-4d37-411d-9e94-5ce038e676ee" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_fea8bf67-ae3a-43b2-bf14-1a35544010db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/GoodwillDetails" xlink:type="simple" xlink:href="brns-20231231.xsd#GoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/GoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_73ad8c01-893a-44eb-963e-b9fd323ec5b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_84c8b237-a6ae-44ee-b4ea-5fd8ab126626" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_73ad8c01-893a-44eb-963e-b9fd323ec5b0" xlink:to="loc_us-gaap_GoodwillRollForward_84c8b237-a6ae-44ee-b4ea-5fd8ab126626" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_281bcdfe-a710-4c13-90fd-893c648c27b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_84c8b237-a6ae-44ee-b4ea-5fd8ab126626" xlink:to="loc_us-gaap_Goodwill_281bcdfe-a710-4c13-90fd-893c648c27b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_7d85e88d-5807-43d9-bba9-78050a1c3bc7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_84c8b237-a6ae-44ee-b4ea-5fd8ab126626" xlink:to="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_7d85e88d-5807-43d9-bba9-78050a1c3bc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_4bbbb025-88fb-40f8-b372-d27cbd17a5ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_84c8b237-a6ae-44ee-b4ea-5fd8ab126626" xlink:to="loc_us-gaap_Goodwill_4bbbb025-88fb-40f8-b372-d27cbd17a5ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/ShareBasedCompensationAdditionalInformationDetails" xlink:type="simple" xlink:href="brns-20231231.xsd#ShareBasedCompensationAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/ShareBasedCompensationAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_568a0850-9842-41c8-92f9-42af94cc8ea3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_16dfa84b-5d69-4a03-ad8f-a271307cbe0e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_568a0850-9842-41c8-92f9-42af94cc8ea3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_16dfa84b-5d69-4a03-ad8f-a271307cbe0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_9f2f1fa1-dd7c-450c-9cfb-3a567fccfa52" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_16dfa84b-5d69-4a03-ad8f-a271307cbe0e" xlink:to="loc_us-gaap_PlanNameAxis_9f2f1fa1-dd7c-450c-9cfb-3a567fccfa52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_76379b6c-a5b0-422a-8d31-d91fae538a6c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_9f2f1fa1-dd7c-450c-9cfb-3a567fccfa52" xlink:to="loc_us-gaap_PlanNameDomain_76379b6c-a5b0-422a-8d31-d91fae538a6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_BarinthusBiotherapeuticsPlcShareAwardPlan2021Member_18108dbf-0ecc-45c7-aaf5-db201d91f87a" xlink:href="brns-20231231.xsd#brns_BarinthusBiotherapeuticsPlcShareAwardPlan2021Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_76379b6c-a5b0-422a-8d31-d91fae538a6c" xlink:to="loc_brns_BarinthusBiotherapeuticsPlcShareAwardPlan2021Member_18108dbf-0ecc-45c7-aaf5-db201d91f87a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_EnterpriseManagementIncentiveShareOptionSchemeMember_bfe57e64-2f5b-4f44-a2c9-db31b0812a49" xlink:href="brns-20231231.xsd#brns_EnterpriseManagementIncentiveShareOptionSchemeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_76379b6c-a5b0-422a-8d31-d91fae538a6c" xlink:to="loc_brns_EnterpriseManagementIncentiveShareOptionSchemeMember_bfe57e64-2f5b-4f44-a2c9-db31b0812a49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_3aaba6f8-0e44-4f30-913b-77ab9b8d60aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_16dfa84b-5d69-4a03-ad8f-a271307cbe0e" xlink:to="loc_us-gaap_AwardTypeAxis_3aaba6f8-0e44-4f30-913b-77ab9b8d60aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c4c7dc0e-0c1e-41a7-b49f-6c801cea8b85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_3aaba6f8-0e44-4f30-913b-77ab9b8d60aa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c4c7dc0e-0c1e-41a7-b49f-6c801cea8b85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_RestrictedShareUnitsStockOptionsShareAppreciationRightsAndRestrictedSharesMember_3b35dd35-fc67-462b-b318-894154b74399" xlink:href="brns-20231231.xsd#brns_RestrictedShareUnitsStockOptionsShareAppreciationRightsAndRestrictedSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c4c7dc0e-0c1e-41a7-b49f-6c801cea8b85" xlink:to="loc_brns_RestrictedShareUnitsStockOptionsShareAppreciationRightsAndRestrictedSharesMember_3b35dd35-fc67-462b-b318-894154b74399" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_e0143781-5818-45f8-8c45-34419c5380c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c4c7dc0e-0c1e-41a7-b49f-6c801cea8b85" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_e0143781-5818-45f8-8c45-34419c5380c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_080f6118-c645-4be7-a5a8-2e23206ad56c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_16dfa84b-5d69-4a03-ad8f-a271307cbe0e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_080f6118-c645-4be7-a5a8-2e23206ad56c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_cc82007b-bb62-43f9-9e8f-8cc74487518f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_080f6118-c645-4be7-a5a8-2e23206ad56c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_cc82007b-bb62-43f9-9e8f-8cc74487518f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ShareBasedCompensationPercentageOfSharesAvailableForIssuanceAsPercentageOfIssuedAndOutstandingShares_f9f6cc4f-1b50-4a0c-80c4-8b6473d2928e" xlink:href="brns-20231231.xsd#brns_ShareBasedCompensationPercentageOfSharesAvailableForIssuanceAsPercentageOfIssuedAndOutstandingShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_080f6118-c645-4be7-a5a8-2e23206ad56c" xlink:to="loc_brns_ShareBasedCompensationPercentageOfSharesAvailableForIssuanceAsPercentageOfIssuedAndOutstandingShares_f9f6cc4f-1b50-4a0c-80c4-8b6473d2928e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_754efb26-738e-43f8-9e28-c5e25057eaea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_080f6118-c645-4be7-a5a8-2e23206ad56c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_754efb26-738e-43f8-9e28-c5e25057eaea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ExpirationOfShareBasedCompensationPlanFromDateOfInitialIssuance_80d109fe-bac6-4fbf-a079-7c4a106443cc" xlink:href="brns-20231231.xsd#brns_ExpirationOfShareBasedCompensationPlanFromDateOfInitialIssuance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_080f6118-c645-4be7-a5a8-2e23206ad56c" xlink:to="loc_brns_ExpirationOfShareBasedCompensationPlanFromDateOfInitialIssuance_80d109fe-bac6-4fbf-a079-7c4a106443cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3d0e79a7-b90d-43a8-82b5-78ce869f5508" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_080f6118-c645-4be7-a5a8-2e23206ad56c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3d0e79a7-b90d-43a8-82b5-78ce869f5508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8c9ccda5-d8de-4dfb-af2b-d11f98aabb18" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_080f6118-c645-4be7-a5a8-2e23206ad56c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8c9ccda5-d8de-4dfb-af2b-d11f98aabb18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_c0acb406-ea6d-459a-82e0-e56abe64536f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_080f6118-c645-4be7-a5a8-2e23206ad56c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_c0acb406-ea6d-459a-82e0-e56abe64536f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_312987e2-e485-48dd-80dd-2bda26c0161a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_080f6118-c645-4be7-a5a8-2e23206ad56c" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_312987e2-e485-48dd-80dd-2bda26c0161a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_805b4273-853e-4216-8969-116646e1ea3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_080f6118-c645-4be7-a5a8-2e23206ad56c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_805b4273-853e-4216-8969-116646e1ea3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_572b3a7e-d9cd-467b-a7af-1b9b45316f5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_080f6118-c645-4be7-a5a8-2e23206ad56c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_572b3a7e-d9cd-467b-a7af-1b9b45316f5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_93197e8a-d063-4500-a2a4-a091c411aa4f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_080f6118-c645-4be7-a5a8-2e23206ad56c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_93197e8a-d063-4500-a2a4-a091c411aa4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_68db7182-5ad8-457d-9600-4443c66cdad4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_080f6118-c645-4be7-a5a8-2e23206ad56c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_68db7182-5ad8-457d-9600-4443c66cdad4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/ShareBasedCompensationWeightedaverageassumptionsDetails" xlink:type="simple" xlink:href="brns-20231231.xsd#ShareBasedCompensationWeightedaverageassumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/ShareBasedCompensationWeightedaverageassumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_29194ab0-8cfd-49a4-bf4b-b689a514a811" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_682b6322-f00f-41de-965d-eeba88116c7a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_29194ab0-8cfd-49a4-bf4b-b689a514a811" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_682b6322-f00f-41de-965d-eeba88116c7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_d8f23b34-4b7f-4ef3-9aa7-adb80c8a5b64" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_682b6322-f00f-41de-965d-eeba88116c7a" xlink:to="loc_us-gaap_PlanNameAxis_d8f23b34-4b7f-4ef3-9aa7-adb80c8a5b64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_3e84d2ef-e7df-4b0c-a540-db97af314ff4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_d8f23b34-4b7f-4ef3-9aa7-adb80c8a5b64" xlink:to="loc_us-gaap_PlanNameDomain_3e84d2ef-e7df-4b0c-a540-db97af314ff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_EnterpriseManagementIncentiveShareOptionSchemeMember_f67bc167-38dd-4ff9-afa8-09da126b9b34" xlink:href="brns-20231231.xsd#brns_EnterpriseManagementIncentiveShareOptionSchemeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_3e84d2ef-e7df-4b0c-a540-db97af314ff4" xlink:to="loc_brns_EnterpriseManagementIncentiveShareOptionSchemeMember_f67bc167-38dd-4ff9-afa8-09da126b9b34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_71f94d33-bce6-445e-854c-1d78c695fb34" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_682b6322-f00f-41de-965d-eeba88116c7a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_71f94d33-bce6-445e-854c-1d78c695fb34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_432c6d00-f8ec-41e0-a079-cf575d6a04bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_71f94d33-bce6-445e-854c-1d78c695fb34" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_432c6d00-f8ec-41e0-a079-cf575d6a04bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_b39add07-c542-42ca-85d8-72f4fa150ac3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_71f94d33-bce6-445e-854c-1d78c695fb34" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_b39add07-c542-42ca-85d8-72f4fa150ac3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_41efb29d-e3ee-4d58-89a6-8962b33ecffb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_71f94d33-bce6-445e-854c-1d78c695fb34" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_41efb29d-e3ee-4d58-89a6-8962b33ecffb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_332df4c3-4f4d-448f-ab2b-d0577765deda" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_71f94d33-bce6-445e-854c-1d78c695fb34" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_332df4c3-4f4d-448f-ab2b-d0577765deda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/ShareBasedCompensationSummaryofstockoptionactivityDetails" xlink:type="simple" xlink:href="brns-20231231.xsd#ShareBasedCompensationSummaryofstockoptionactivityDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/ShareBasedCompensationSummaryofstockoptionactivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_67fe4051-ada3-45ac-8bc9-87bbe567ee92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_fac29276-ab1f-4084-b46b-36a6686ec35b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_67fe4051-ada3-45ac-8bc9-87bbe567ee92" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_fac29276-ab1f-4084-b46b-36a6686ec35b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5be4d98f-da75-4a04-9ace-50a10070a863" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_fac29276-ab1f-4084-b46b-36a6686ec35b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5be4d98f-da75-4a04-9ace-50a10070a863" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_b83654f8-1ece-4c1e-b864-93d26acd6f72" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_fac29276-ab1f-4084-b46b-36a6686ec35b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_b83654f8-1ece-4c1e-b864-93d26acd6f72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_60103c08-e915-412d-9e68-40322eb03557" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_fac29276-ab1f-4084-b46b-36a6686ec35b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_60103c08-e915-412d-9e68-40322eb03557" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_29fe489f-8395-4def-9921-2ce7eba64d35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_fac29276-ab1f-4084-b46b-36a6686ec35b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_29fe489f-8395-4def-9921-2ce7eba64d35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_96cc8515-ad6a-4671-b6ce-8ac695f4a5d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_fac29276-ab1f-4084-b46b-36a6686ec35b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_96cc8515-ad6a-4671-b6ce-8ac695f4a5d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c469cb17-b9e4-4e5b-9307-25a909261c05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_67fe4051-ada3-45ac-8bc9-87bbe567ee92" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c469cb17-b9e4-4e5b-9307-25a909261c05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2f6673f8-6fa4-4694-9233-d3d270bd3853" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_67fe4051-ada3-45ac-8bc9-87bbe567ee92" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2f6673f8-6fa4-4694-9233-d3d270bd3853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_55b76a0f-c124-40ee-ba8c-406848ce4858" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2f6673f8-6fa4-4694-9233-d3d270bd3853" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_55b76a0f-c124-40ee-ba8c-406848ce4858" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_3a86c7c7-8707-4424-b650-bfcd39efac19" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2f6673f8-6fa4-4694-9233-d3d270bd3853" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_3a86c7c7-8707-4424-b650-bfcd39efac19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c24e1e7d-97b3-417d-a295-5534df6fb596" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2f6673f8-6fa4-4694-9233-d3d270bd3853" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c24e1e7d-97b3-417d-a295-5534df6fb596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c309beeb-9adf-481c-bb67-802224a3e86b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2f6673f8-6fa4-4694-9233-d3d270bd3853" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c309beeb-9adf-481c-bb67-802224a3e86b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8dabfb4c-a8c6-4375-b029-2b1b0017f1ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2f6673f8-6fa4-4694-9233-d3d270bd3853" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8dabfb4c-a8c6-4375-b029-2b1b0017f1ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_24f00c7d-3818-4993-a38e-cedb965f8b83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_67fe4051-ada3-45ac-8bc9-87bbe567ee92" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_24f00c7d-3818-4993-a38e-cedb965f8b83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_656b4b76-5edc-49fa-b943-c6264effbd4b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_67fe4051-ada3-45ac-8bc9-87bbe567ee92" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_656b4b76-5edc-49fa-b943-c6264effbd4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_54cd8069-50c5-4c9c-9b7f-44a3db722539" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_656b4b76-5edc-49fa-b943-c6264effbd4b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_54cd8069-50c5-4c9c-9b7f-44a3db722539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1a998e83-4d15-4c9c-b6a3-30f990dc2355" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_656b4b76-5edc-49fa-b943-c6264effbd4b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1a998e83-4d15-4c9c-b6a3-30f990dc2355" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_cc043beb-e028-407b-8010-2f37b0df2c72" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_656b4b76-5edc-49fa-b943-c6264effbd4b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_cc043beb-e028-407b-8010-2f37b0df2c72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2954848d-16a6-4172-8c91-b6b4f89c0b26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_656b4b76-5edc-49fa-b943-c6264effbd4b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2954848d-16a6-4172-8c91-b6b4f89c0b26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/ShareBasedCompensationSharebasedcompensationexpenseDetails" xlink:type="simple" xlink:href="brns-20231231.xsd#ShareBasedCompensationSharebasedcompensationexpenseDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/ShareBasedCompensationSharebasedcompensationexpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_dd710dea-6aaf-4a1e-9102-9e77f43a5ef5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a06793ea-335c-4665-b695-17590d0c27ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_dd710dea-6aaf-4a1e-9102-9e77f43a5ef5" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a06793ea-335c-4665-b695-17590d0c27ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_5703ff84-a370-4af4-ab00-4e877882bde7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a06793ea-335c-4665-b695-17590d0c27ef" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_5703ff84-a370-4af4-ab00-4e877882bde7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_7c61f446-5bba-4def-8d32-3ac245f32695" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_5703ff84-a370-4af4-ab00-4e877882bde7" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_7c61f446-5bba-4def-8d32-3ac245f32695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4664e33e-ffdc-4180-885d-77f8ed9f3d29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7c61f446-5bba-4def-8d32-3ac245f32695" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4664e33e-ffdc-4180-885d-77f8ed9f3d29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_c0d7fad7-2f52-4dc5-89a3-1fe829327ad1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7c61f446-5bba-4def-8d32-3ac245f32695" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_c0d7fad7-2f52-4dc5-89a3-1fe829327ad1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_38b21bd9-0850-46d6-a4b1-37f911bce99a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a06793ea-335c-4665-b695-17590d0c27ef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_38b21bd9-0850-46d6-a4b1-37f911bce99a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_0bb4be20-41be-4aa0-855a-4ad2769ff41b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_38b21bd9-0850-46d6-a4b1-37f911bce99a" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_0bb4be20-41be-4aa0-855a-4ad2769ff41b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/IncomeTaxesLossincomebeforeincometaxesDetails" xlink:type="simple" xlink:href="brns-20231231.xsd#IncomeTaxesLossincomebeforeincometaxesDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/IncomeTaxesLossincomebeforeincometaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_a8de0083-cae8-47c7-b23d-629e19544f36" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_IncomeTaxesTable_48b6c035-b5bb-43b1-9bf0-2b34511e623f" xlink:href="brns-20231231.xsd#brns_IncomeTaxesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a8de0083-cae8-47c7-b23d-629e19544f36" xlink:to="loc_brns_IncomeTaxesTable_48b6c035-b5bb-43b1-9bf0-2b34511e623f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_b1b281e8-5808-4d2a-99e7-cdf9c2ddccb2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_brns_IncomeTaxesTable_48b6c035-b5bb-43b1-9bf0-2b34511e623f" xlink:to="loc_srt_StatementGeographicalAxis_b1b281e8-5808-4d2a-99e7-cdf9c2ddccb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_8e3bebe8-c1bc-4dea-9ab7-9f2f73abea2c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_b1b281e8-5808-4d2a-99e7-cdf9c2ddccb2" xlink:to="loc_srt_SegmentGeographicalDomain_8e3bebe8-c1bc-4dea-9ab7-9f2f73abea2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_b06ef201-cca0-4b87-8b16-91c8388085c2" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_8e3bebe8-c1bc-4dea-9ab7-9f2f73abea2c" xlink:to="loc_country_US_b06ef201-cca0-4b87-8b16-91c8388085c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_6cbbecc1-b486-4fa0-8ea6-20157fb6fe4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_8e3bebe8-c1bc-4dea-9ab7-9f2f73abea2c" xlink:to="loc_us-gaap_NonUsMember_6cbbecc1-b486-4fa0-8ea6-20157fb6fe4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_IncomeTaxesLineItems_4ca37c1d-17b0-49c3-9d1d-ea1d0000437a" xlink:href="brns-20231231.xsd#brns_IncomeTaxesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_brns_IncomeTaxesTable_48b6c035-b5bb-43b1-9bf0-2b34511e623f" xlink:to="loc_brns_IncomeTaxesLineItems_4ca37c1d-17b0-49c3-9d1d-ea1d0000437a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_3d581d38-c530-43b1-ac84-587d6fe28d25" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_brns_IncomeTaxesLineItems_4ca37c1d-17b0-49c3-9d1d-ea1d0000437a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_3d581d38-c530-43b1-ac84-587d6fe28d25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_64647bc7-9ed2-448a-b589-814e514f3025" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_brns_IncomeTaxesLineItems_4ca37c1d-17b0-49c3-9d1d-ea1d0000437a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_64647bc7-9ed2-448a-b589-814e514f3025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4b247996-27ca-4c2a-aee6-d6b4f90cc201" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_brns_IncomeTaxesLineItems_4ca37c1d-17b0-49c3-9d1d-ea1d0000437a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4b247996-27ca-4c2a-aee6-d6b4f90cc201" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/IncomeTaxesComponentsofincometaxbenefitexpenseDetails" xlink:type="simple" xlink:href="brns-20231231.xsd#IncomeTaxesComponentsofincometaxbenefitexpenseDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/IncomeTaxesComponentsofincometaxbenefitexpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_6820cce7-b11f-48ee-9847-b0b110fe80a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_IncomeTaxesTable_65794393-54da-4f82-987e-236d919e8e7a" xlink:href="brns-20231231.xsd#brns_IncomeTaxesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6820cce7-b11f-48ee-9847-b0b110fe80a5" xlink:to="loc_brns_IncomeTaxesTable_65794393-54da-4f82-987e-236d919e8e7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_ca749c0f-7815-4063-8085-5f8ffeddb13e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_brns_IncomeTaxesTable_65794393-54da-4f82-987e-236d919e8e7a" xlink:to="loc_srt_StatementGeographicalAxis_ca749c0f-7815-4063-8085-5f8ffeddb13e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_4881bc6b-480a-4875-8c21-b226701c6832" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_ca749c0f-7815-4063-8085-5f8ffeddb13e" xlink:to="loc_srt_SegmentGeographicalDomain_4881bc6b-480a-4875-8c21-b226701c6832" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_100c855d-bba4-4f52-8659-fcee89ca106c" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_4881bc6b-480a-4875-8c21-b226701c6832" xlink:to="loc_country_US_100c855d-bba4-4f52-8659-fcee89ca106c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_7c769795-f11c-4476-bd02-eb4c4c6dfd41" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_4881bc6b-480a-4875-8c21-b226701c6832" xlink:to="loc_us-gaap_NonUsMember_7c769795-f11c-4476-bd02-eb4c4c6dfd41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_IncomeTaxesLineItems_92c8284d-1ca2-4cf2-a4f4-1c8a44308eca" xlink:href="brns-20231231.xsd#brns_IncomeTaxesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_brns_IncomeTaxesTable_65794393-54da-4f82-987e-236d919e8e7a" xlink:to="loc_brns_IncomeTaxesLineItems_92c8284d-1ca2-4cf2-a4f4-1c8a44308eca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_4e1ee0aa-2be5-426c-ba3b-7e15dc7b6638" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_brns_IncomeTaxesLineItems_92c8284d-1ca2-4cf2-a4f4-1c8a44308eca" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_4e1ee0aa-2be5-426c-ba3b-7e15dc7b6638" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_844da483-c75a-449c-b502-4450e21d9ff8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_4e1ee0aa-2be5-426c-ba3b-7e15dc7b6638" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_844da483-c75a-449c-b502-4450e21d9ff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_3addce26-69be-4a25-826a-332c50cd40a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_brns_IncomeTaxesLineItems_92c8284d-1ca2-4cf2-a4f4-1c8a44308eca" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_3addce26-69be-4a25-826a-332c50cd40a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_b2a152c0-5982-40d5-961a-f6f0f8640489" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_3addce26-69be-4a25-826a-332c50cd40a8" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_b2a152c0-5982-40d5-961a-f6f0f8640489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_db567d4f-ffa5-4334-99c1-f605514b43cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_brns_IncomeTaxesLineItems_92c8284d-1ca2-4cf2-a4f4-1c8a44308eca" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_db567d4f-ffa5-4334-99c1-f605514b43cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/IncomeTaxesReconciliationtotheeffectivetaxrateDetails" xlink:type="simple" xlink:href="brns-20231231.xsd#IncomeTaxesReconciliationtotheeffectivetaxrateDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/IncomeTaxesReconciliationtotheeffectivetaxrateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_69cffd52-9268-4a94-a471-fc07382e36cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_48d8bd42-a093-4213-88f8-5f65523ac7d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_69cffd52-9268-4a94-a471-fc07382e36cb" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_48d8bd42-a093-4213-88f8-5f65523ac7d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_EffectiveIncomeTaxRateReconciliationPercentIncreaseDecreaseAbstract_42cb9fb3-b520-4a59-91f8-500964854bbe" xlink:href="brns-20231231.xsd#brns_EffectiveIncomeTaxRateReconciliationPercentIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_69cffd52-9268-4a94-a471-fc07382e36cb" xlink:to="loc_brns_EffectiveIncomeTaxRateReconciliationPercentIncreaseDecreaseAbstract_42cb9fb3-b520-4a59-91f8-500964854bbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_16032393-33d9-4767-b980-9eea28d5d18e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_brns_EffectiveIncomeTaxRateReconciliationPercentIncreaseDecreaseAbstract_42cb9fb3-b520-4a59-91f8-500964854bbe" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_16032393-33d9-4767-b980-9eea28d5d18e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustments_bf660cc8-e4a9-4939-8eef-8a28eced3faf" xlink:href="brns-20231231.xsd#brns_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_brns_EffectiveIncomeTaxRateReconciliationPercentIncreaseDecreaseAbstract_42cb9fb3-b520-4a59-91f8-500964854bbe" xlink:to="loc_brns_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustments_bf660cc8-e4a9-4939-8eef-8a28eced3faf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment_b579eaf8-05c9-452b-a925-9b49fa96aa11" xlink:href="brns-20231231.xsd#brns_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_brns_EffectiveIncomeTaxRateReconciliationPercentIncreaseDecreaseAbstract_42cb9fb3-b520-4a59-91f8-500964854bbe" xlink:to="loc_brns_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment_b579eaf8-05c9-452b-a925-9b49fa96aa11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_5a6b3b66-38b7-4031-b701-b32911dfa126" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_brns_EffectiveIncomeTaxRateReconciliationPercentIncreaseDecreaseAbstract_42cb9fb3-b520-4a59-91f8-500964854bbe" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_5a6b3b66-38b7-4031-b701-b32911dfa126" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_ee1e897b-5ae4-4a9c-8c73-08d30882ffbb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_brns_EffectiveIncomeTaxRateReconciliationPercentIncreaseDecreaseAbstract_42cb9fb3-b520-4a59-91f8-500964854bbe" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_ee1e897b-5ae4-4a9c-8c73-08d30882ffbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_ae75b645-fd8f-4462-bf47-e4d1b36cb53b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_brns_EffectiveIncomeTaxRateReconciliationPercentIncreaseDecreaseAbstract_42cb9fb3-b520-4a59-91f8-500964854bbe" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_ae75b645-fd8f-4462-bf47-e4d1b36cb53b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_3674cd12-1ccd-4abe-b57e-bd4e63b463e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_brns_EffectiveIncomeTaxRateReconciliationPercentIncreaseDecreaseAbstract_42cb9fb3-b520-4a59-91f8-500964854bbe" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_3674cd12-1ccd-4abe-b57e-bd4e63b463e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails" xlink:type="simple" xlink:href="brns-20231231.xsd#IncomeTaxesDeferredtaxassetsandliabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_d74807a6-040c-48a0-94e0-17db4b9db056" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_88f873e3-063d-413a-8fd4-f0763ef68e19" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d74807a6-040c-48a0-94e0-17db4b9db056" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_88f873e3-063d-413a-8fd4-f0763ef68e19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_c7629e41-b6b6-4155-be76-0ac135ad10ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_88f873e3-063d-413a-8fd4-f0763ef68e19" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_c7629e41-b6b6-4155-be76-0ac135ad10ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_74796309-3feb-4a4e-b669-672fe7a91957" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_88f873e3-063d-413a-8fd4-f0763ef68e19" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_74796309-3feb-4a4e-b669-672fe7a91957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_4dff9fcb-88ff-4bee-a589-b0bea401c2b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_88f873e3-063d-413a-8fd4-f0763ef68e19" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_4dff9fcb-88ff-4bee-a589-b0bea401c2b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_ab9952e2-e631-4b51-a226-d39da9cef64b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_88f873e3-063d-413a-8fd4-f0763ef68e19" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_ab9952e2-e631-4b51-a226-d39da9cef64b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredTaxAssetsLeasingArrangements_5c11ef80-0767-4b73-ad0a-747d4547878e" xlink:href="brns-20231231.xsd#brns_DeferredTaxAssetsLeasingArrangements"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_88f873e3-063d-413a-8fd4-f0763ef68e19" xlink:to="loc_brns_DeferredTaxAssetsLeasingArrangements_5c11ef80-0767-4b73-ad0a-747d4547878e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsIntangibles_8c349881-fac3-486f-b3ec-448c83c3e69e" xlink:href="brns-20231231.xsd#brns_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsIntangibles"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_88f873e3-063d-413a-8fd4-f0763ef68e19" xlink:to="loc_brns_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsIntangibles_8c349881-fac3-486f-b3ec-448c83c3e69e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_e4332e54-dcb9-4cb9-ad9c-31bda3040471" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_88f873e3-063d-413a-8fd4-f0763ef68e19" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_e4332e54-dcb9-4cb9-ad9c-31bda3040471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_cb755eb8-4224-43c2-8c43-b3bb049ec569" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_88f873e3-063d-413a-8fd4-f0763ef68e19" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_cb755eb8-4224-43c2-8c43-b3bb049ec569" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_7792e8e0-06ac-4828-b772-838bb00a03a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_88f873e3-063d-413a-8fd4-f0763ef68e19" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_7792e8e0-06ac-4828-b772-838bb00a03a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_f58c823c-31c6-421e-a9a3-575cc26d0d1d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_88f873e3-063d-413a-8fd4-f0763ef68e19" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_f58c823c-31c6-421e-a9a3-575cc26d0d1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_3e454a3f-e11e-4f65-a6d2-8eee488b19e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_88f873e3-063d-413a-8fd4-f0763ef68e19" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_3e454a3f-e11e-4f65-a6d2-8eee488b19e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_768bfbea-df72-4480-b1c5-beb118f98896" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d74807a6-040c-48a0-94e0-17db4b9db056" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_768bfbea-df72-4480-b1c5-beb118f98896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_e7f90093-b3d6-4149-a3af-1bbd4630b92d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_768bfbea-df72-4480-b1c5-beb118f98896" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_e7f90093-b3d6-4149-a3af-1bbd4630b92d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_91beb292-f5ab-4831-80ea-f84237c74221" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_768bfbea-df72-4480-b1c5-beb118f98896" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_91beb292-f5ab-4831-80ea-f84237c74221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities_36cba796-99f3-4a4f-8cde-daf3a6cb7654" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_768bfbea-df72-4480-b1c5-beb118f98896" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities_36cba796-99f3-4a4f-8cde-daf3a6cb7654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_e49f0a81-89f8-4f51-83fb-1208214c90c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_768bfbea-df72-4480-b1c5-beb118f98896" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_e49f0a81-89f8-4f51-83fb-1208214c90c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_004adf68-331f-46cc-b74b-f345eeac7624" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_768bfbea-df72-4480-b1c5-beb118f98896" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_004adf68-331f-46cc-b74b-f345eeac7624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_52a71547-c1ce-4406-94c8-924c4256d065" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d74807a6-040c-48a0-94e0-17db4b9db056" xlink:to="loc_us-gaap_DeferredTaxLiabilities_52a71547-c1ce-4406-94c8-924c4256d065" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="simple" xlink:href="brns-20231231.xsd#IncomeTaxesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_17097e3a-788b-420c-9458-1422781e7616" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_0d06fc61-48f1-49a9-a434-f41bf9a854e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_17097e3a-788b-420c-9458-1422781e7616" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_0d06fc61-48f1-49a9-a434-f41bf9a854e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_57ca848d-68e4-426c-8207-60702787a995" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_0d06fc61-48f1-49a9-a434-f41bf9a854e7" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_57ca848d-68e4-426c-8207-60702787a995" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_6daa6636-c445-4cb6-a525-c52e9789d9a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_57ca848d-68e4-426c-8207-60702787a995" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_6daa6636-c445-4cb6-a525-c52e9789d9a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_f428e4d3-da56-467d-89cb-e88f7ab995db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_6daa6636-c445-4cb6-a525-c52e9789d9a3" xlink:to="loc_us-gaap_DomesticCountryMember_f428e4d3-da56-467d-89cb-e88f7ab995db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_b6178768-e3b0-4616-be36-fd2e5a80f1e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_0d06fc61-48f1-49a9-a434-f41bf9a854e7" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_b6178768-e3b0-4616-be36-fd2e5a80f1e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_c5e30e06-5cac-4106-9219-d71c58963746" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_b6178768-e3b0-4616-be36-fd2e5a80f1e1" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_c5e30e06-5cac-4106-9219-d71c58963746" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_4c432268-c0ad-4476-a7be-8910854ad4e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_b6178768-e3b0-4616-be36-fd2e5a80f1e1" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_4c432268-c0ad-4476-a7be-8910854ad4e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_c97cfdb2-c823-471a-8942-8f21bc9dc976" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_b6178768-e3b0-4616-be36-fd2e5a80f1e1" xlink:to="loc_us-gaap_OperatingLossCarryforwards_c97cfdb2-c823-471a-8942-8f21bc9dc976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_2f58bf56-cfe9-409c-89b4-701b189a157c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_b6178768-e3b0-4616-be36-fd2e5a80f1e1" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_2f58bf56-cfe9-409c-89b4-701b189a157c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxCreditsAndAdjustments_3740506c-33c5-41b6-9c8d-3a67d7eb3cc6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxCreditsAndAdjustments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_b6178768-e3b0-4616-be36-fd2e5a80f1e1" xlink:to="loc_us-gaap_IncomeTaxCreditsAndAdjustments_3740506c-33c5-41b6-9c8d-3a67d7eb3cc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/IncomeTaxesChangesinthevaluationallowancefordeferredtaxassetsDetails" xlink:type="simple" xlink:href="brns-20231231.xsd#IncomeTaxesChangesinthevaluationallowancefordeferredtaxassetsDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/IncomeTaxesChangesinthevaluationallowancefordeferredtaxassetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_6849b416-7fde-4f9c-8e44-8d402ae53370" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ValuationAllowanceRollForward_48453541-73ea-42f6-ad18-c43ca1f914f1" xlink:href="brns-20231231.xsd#brns_ValuationAllowanceRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6849b416-7fde-4f9c-8e44-8d402ae53370" xlink:to="loc_brns_ValuationAllowanceRollForward_48453541-73ea-42f6-ad18-c43ca1f914f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_26d202e8-bd18-43c4-a1fe-b924f9020679" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_brns_ValuationAllowanceRollForward_48453541-73ea-42f6-ad18-c43ca1f914f1" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_26d202e8-bd18-43c4-a1fe-b924f9020679" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ValuationAllowanceDeferredTaxAssetIncreaseResultingFromCurrentPeriodAdditions_a3a95bda-3a38-415e-9a51-22361d77607e" xlink:href="brns-20231231.xsd#brns_ValuationAllowanceDeferredTaxAssetIncreaseResultingFromCurrentPeriodAdditions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_brns_ValuationAllowanceRollForward_48453541-73ea-42f6-ad18-c43ca1f914f1" xlink:to="loc_brns_ValuationAllowanceDeferredTaxAssetIncreaseResultingFromCurrentPeriodAdditions_a3a95bda-3a38-415e-9a51-22361d77607e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ValuationAllowanceDeferredTaxAssetIncreaseResultingFromIncomeTaxProvision_db2beb7f-35de-485f-b800-ea5ec28efd3b" xlink:href="brns-20231231.xsd#brns_ValuationAllowanceDeferredTaxAssetIncreaseResultingFromIncomeTaxProvision"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_brns_ValuationAllowanceRollForward_48453541-73ea-42f6-ad18-c43ca1f914f1" xlink:to="loc_brns_ValuationAllowanceDeferredTaxAssetIncreaseResultingFromIncomeTaxProvision_db2beb7f-35de-485f-b800-ea5ec28efd3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseResultingFromForeignCurrencyTranslation_5d22e190-2928-4382-89c8-af3ade19a6c6" xlink:href="brns-20231231.xsd#brns_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseResultingFromForeignCurrencyTranslation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_brns_ValuationAllowanceRollForward_48453541-73ea-42f6-ad18-c43ca1f914f1" xlink:to="loc_brns_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseResultingFromForeignCurrencyTranslation_5d22e190-2928-4382-89c8-af3ade19a6c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_ec448e65-589a-4132-a890-3599b4c07203" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_brns_ValuationAllowanceRollForward_48453541-73ea-42f6-ad18-c43ca1f914f1" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_ec448e65-589a-4132-a890-3599b4c07203" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/CommitmentsandContingenciesAdditionalinformationDetails" xlink:type="simple" xlink:href="brns-20231231.xsd#CommitmentsandContingenciesAdditionalinformationDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/CommitmentsandContingenciesAdditionalinformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_830243a8-b424-45d6-99b3-c0ce38ffdbe5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_71d323ad-4f8e-4e50-988b-2b400dcde99b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_830243a8-b424-45d6-99b3-c0ce38ffdbe5" xlink:to="loc_us-gaap_OtherCommitmentsTable_71d323ad-4f8e-4e50-988b-2b400dcde99b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_f6e57ca0-8efe-4908-82fc-269f602a17e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_71d323ad-4f8e-4e50-988b-2b400dcde99b" xlink:to="loc_us-gaap_TypeOfArrangementAxis_f6e57ca0-8efe-4908-82fc-269f602a17e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_dd5d91f8-ec32-43ce-9411-de16cf653b5b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_f6e57ca0-8efe-4908-82fc-269f602a17e0" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_dd5d91f8-ec32-43ce-9411-de16cf653b5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_InLicenseAgreementsMember_66349bc0-b9ca-4793-907b-397c09ea413c" xlink:href="brns-20231231.xsd#brns_InLicenseAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_dd5d91f8-ec32-43ce-9411-de16cf653b5b" xlink:to="loc_brns_InLicenseAgreementsMember_66349bc0-b9ca-4793-907b-397c09ea413c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4643d1bf-f9b2-44f7-abd7-e80c14b4480a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_71d323ad-4f8e-4e50-988b-2b400dcde99b" xlink:to="loc_srt_RangeAxis_4643d1bf-f9b2-44f7-abd7-e80c14b4480a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_680391cd-ce6e-43af-81ad-410b11429acf" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_4643d1bf-f9b2-44f7-abd7-e80c14b4480a" xlink:to="loc_srt_RangeMember_680391cd-ce6e-43af-81ad-410b11429acf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7e5edd88-0103-492f-809b-0310a3e6f870" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_680391cd-ce6e-43af-81ad-410b11429acf" xlink:to="loc_srt_MinimumMember_7e5edd88-0103-492f-809b-0310a3e6f870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_3f7fff07-0f42-466a-8765-b381d95d532c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_680391cd-ce6e-43af-81ad-410b11429acf" xlink:to="loc_srt_MaximumMember_3f7fff07-0f42-466a-8765-b381d95d532c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_f2ecc03d-58ac-4062-a7ba-de50c8855ce4" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_71d323ad-4f8e-4e50-988b-2b400dcde99b" xlink:to="loc_srt_StatementGeographicalAxis_f2ecc03d-58ac-4062-a7ba-de50c8855ce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_3728b4e3-2c4c-4165-b2ef-2ff04eb0076d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_f2ecc03d-58ac-4062-a7ba-de50c8855ce4" xlink:to="loc_srt_SegmentGeographicalDomain_3728b4e3-2c4c-4165-b2ef-2ff04eb0076d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_OxfordshireMember_855ce156-1bfc-4e01-bb4e-71970e50fe2c" xlink:href="brns-20231231.xsd#brns_OxfordshireMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_3728b4e3-2c4c-4165-b2ef-2ff04eb0076d" xlink:to="loc_brns_OxfordshireMember_855ce156-1bfc-4e01-bb4e-71970e50fe2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MD_8b77a9ea-de76-4c2e-ac0d-fec5e30e8a9a" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_MD"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_3728b4e3-2c4c-4165-b2ef-2ff04eb0076d" xlink:to="loc_stpr_MD_8b77a9ea-de76-4c2e-ac0d-fec5e30e8a9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_e977c277-3ff1-4fa1-a22c-0b878e8c62ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_71d323ad-4f8e-4e50-988b-2b400dcde99b" xlink:to="loc_us-gaap_OtherCommitmentsLineItems_e977c277-3ff1-4fa1-a22c-0b878e8c62ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_PercentageOfFutureRoyaltiesForDirectSalesOfCoveredProductLicenseAgreement_bec7434c-0134-4f17-9f8c-79f98b2911db" xlink:href="brns-20231231.xsd#brns_PercentageOfFutureRoyaltiesForDirectSalesOfCoveredProductLicenseAgreement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_e977c277-3ff1-4fa1-a22c-0b878e8c62ca" xlink:to="loc_brns_PercentageOfFutureRoyaltiesForDirectSalesOfCoveredProductLicenseAgreement_bec7434c-0134-4f17-9f8c-79f98b2911db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_PercentageOfNetPaymentsReceivedForAllowableSublicensesOfTechnologyDevelopedLicenseAgreement_f07e882d-8939-4f5f-ba24-3306eb7fe9cb" xlink:href="brns-20231231.xsd#brns_PercentageOfNetPaymentsReceivedForAllowableSublicensesOfTechnologyDevelopedLicenseAgreement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_e977c277-3ff1-4fa1-a22c-0b878e8c62ca" xlink:to="loc_brns_PercentageOfNetPaymentsReceivedForAllowableSublicensesOfTechnologyDevelopedLicenseAgreement_f07e882d-8939-4f5f-ba24-3306eb7fe9cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_NumberOfSquareFeetUnderLeaseAgreement_cf90bce5-01fd-43f4-b9c9-3c2c3032864f" xlink:href="brns-20231231.xsd#brns_NumberOfSquareFeetUnderLeaseAgreement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_e977c277-3ff1-4fa1-a22c-0b878e8c62ca" xlink:to="loc_brns_NumberOfSquareFeetUnderLeaseAgreement_cf90bce5-01fd-43f4-b9c9-3c2c3032864f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecurityDeposit_bff1a6ec-f879-4064-8dc1-e0111e8ccb25" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecurityDeposit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_e977c277-3ff1-4fa1-a22c-0b878e8c62ca" xlink:to="loc_us-gaap_SecurityDeposit_bff1a6ec-f879-4064-8dc1-e0111e8ccb25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_LesseeOperatingLeaseExtendedTerm_01ffcdb0-9298-4558-abcb-9d1245487689" xlink:href="brns-20231231.xsd#brns_LesseeOperatingLeaseExtendedTerm"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_e977c277-3ff1-4fa1-a22c-0b878e8c62ca" xlink:to="loc_brns_LesseeOperatingLeaseExtendedTerm_01ffcdb0-9298-4558-abcb-9d1245487689" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsGross_d69aa4ec-1838-4bab-8345-93794e373db8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsGross"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_e977c277-3ff1-4fa1-a22c-0b878e8c62ca" xlink:to="loc_us-gaap_LeaseholdImprovementsGross_d69aa4ec-1838-4bab-8345-93794e373db8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/CommitmentsandContingenciesRightofuseassetsleaseliabilitiesandotherinformationDetails" xlink:type="simple" xlink:href="brns-20231231.xsd#CommitmentsandContingenciesRightofuseassetsleaseliabilitiesandotherinformationDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/CommitmentsandContingenciesRightofuseassetsleaseliabilitiesandotherinformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b07980d9-e0ad-463c-99a1-54c8f01efd4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_f00fd61d-851f-4873-9b3c-67432fe907e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b07980d9-e0ad-463c-99a1-54c8f01efd4d" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_f00fd61d-851f-4873-9b3c-67432fe907e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_feec1ec3-1365-4c83-83b6-616294ac77d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b07980d9-e0ad-463c-99a1-54c8f01efd4d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_feec1ec3-1365-4c83-83b6-616294ac77d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_6fe63d09-bcc0-48ec-a830-00587397c491" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b07980d9-e0ad-463c-99a1-54c8f01efd4d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_6fe63d09-bcc0-48ec-a830-00587397c491" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_OtherInformationLesseeAbstract_32dde26d-b706-41ba-9ad3-cc8b8ac7c35e" xlink:href="brns-20231231.xsd#brns_OtherInformationLesseeAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b07980d9-e0ad-463c-99a1-54c8f01efd4d" xlink:to="loc_brns_OtherInformationLesseeAbstract_32dde26d-b706-41ba-9ad3-cc8b8ac7c35e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_feb70689-5740-4ad7-bad9-d97a183cb13f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_brns_OtherInformationLesseeAbstract_32dde26d-b706-41ba-9ad3-cc8b8ac7c35e" xlink:to="loc_us-gaap_OperatingLeasePayments_feb70689-5740-4ad7-bad9-d97a183cb13f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_b1154e80-77dd-4440-a415-9bbd92f462bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_brns_OtherInformationLesseeAbstract_32dde26d-b706-41ba-9ad3-cc8b8ac7c35e" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_b1154e80-77dd-4440-a415-9bbd92f462bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_9c66ea67-aa4a-49b9-9bfa-326b086b17cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_brns_OtherInformationLesseeAbstract_32dde26d-b706-41ba-9ad3-cc8b8ac7c35e" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_9c66ea67-aa4a-49b9-9bfa-326b086b17cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract_22376505-3513-493a-8b25-7e29a1cd7b28" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b07980d9-e0ad-463c-99a1-54c8f01efd4d" xlink:to="loc_us-gaap_LeaseCostAbstract_22376505-3513-493a-8b25-7e29a1cd7b28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_bd60fa27-46d2-448f-baaa-1b2a47de9ffd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_22376505-3513-493a-8b25-7e29a1cd7b28" xlink:to="loc_us-gaap_ShortTermLeaseCost_bd60fa27-46d2-448f-baaa-1b2a47de9ffd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_8f557080-9de3-42bf-a41f-08cdebd97dec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_22376505-3513-493a-8b25-7e29a1cd7b28" xlink:to="loc_us-gaap_OperatingLeaseCost_8f557080-9de3-42bf-a41f-08cdebd97dec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_4de7f1a6-6e0b-4103-876a-45be90af6974" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_22376505-3513-493a-8b25-7e29a1cd7b28" xlink:to="loc_us-gaap_LeaseCost_4de7f1a6-6e0b-4103-876a-45be90af6974" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails" xlink:type="simple" xlink:href="brns-20231231.xsd#CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_fe063f72-a2af-422b-b4c1-40e228aad535" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_518ea7dd-9eec-45ef-9d90-df24ab747e54" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_fe063f72-a2af-422b-b4c1-40e228aad535" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_518ea7dd-9eec-45ef-9d90-df24ab747e54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_b99c2467-bbd7-4fb7-b420-fd3ccd5ee4c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_fe063f72-a2af-422b-b4c1-40e228aad535" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_b99c2467-bbd7-4fb7-b420-fd3ccd5ee4c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_3e3a48a1-a2fe-4c7b-8702-151fd1a0705c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_fe063f72-a2af-422b-b4c1-40e228aad535" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_3e3a48a1-a2fe-4c7b-8702-151fd1a0705c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_31dce16d-8c71-4faa-9ece-b4b0f0e457ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_fe063f72-a2af-422b-b4c1-40e228aad535" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_31dce16d-8c71-4faa-9ece-b4b0f0e457ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_6f35a18f-8ec9-42ed-bcce-89e80f8092b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_fe063f72-a2af-422b-b4c1-40e228aad535" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_6f35a18f-8ec9-42ed-bcce-89e80f8092b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_bfc6c884-8d88-47ea-840f-c229578a6e66" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_fe063f72-a2af-422b-b4c1-40e228aad535" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_bfc6c884-8d88-47ea-840f-c229578a6e66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_672673c6-ebc5-404e-892b-12a3919d8a90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_fe063f72-a2af-422b-b4c1-40e228aad535" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_672673c6-ebc5-404e-892b-12a3919d8a90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_4b39a879-e0d8-49cc-83dc-66023230cf02" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_fe063f72-a2af-422b-b4c1-40e228aad535" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_4b39a879-e0d8-49cc-83dc-66023230cf02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_bda4c13d-5e48-4c64-9a50-6dd705af36c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_fe063f72-a2af-422b-b4c1-40e228aad535" xlink:to="loc_us-gaap_OperatingLeaseLiability_bda4c13d-5e48-4c64-9a50-6dd705af36c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails_1" xlink:type="simple" xlink:href="brns-20231231.xsd#CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails_1"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/EmployeeBenefitPlansDetails" xlink:type="simple" xlink:href="brns-20231231.xsd#EmployeeBenefitPlansDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/EmployeeBenefitPlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_579649f5-f21d-4f62-91c7-0d7583392ac4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_758c63b9-220d-46d2-9859-3043cf7e5bfb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_579649f5-f21d-4f62-91c7-0d7583392ac4" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_758c63b9-220d-46d2-9859-3043cf7e5bfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="brns-20231231.xsd#RelatedPartyTransactionsDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_6c9867e4-5b2b-4c6e-9080-2a4aa5060672" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b340b48d-458b-461d-883b-5cea10d240bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_6c9867e4-5b2b-4c6e-9080-2a4aa5060672" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b340b48d-458b-461d-883b-5cea10d240bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_f69d0520-1a20-4f86-9fa8-3f55bd3795cf" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b340b48d-458b-461d-883b-5cea10d240bd" xlink:to="loc_srt_CounterpartyNameAxis_f69d0520-1a20-4f86-9fa8-3f55bd3795cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ea1dea92-dafd-4ca3-b4b4-a0b19a99c7ec" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_f69d0520-1a20-4f86-9fa8-3f55bd3795cf" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ea1dea92-dafd-4ca3-b4b4-a0b19a99c7ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ShareholderTheUniversityOfOxfordMember_c87ee020-57ed-4b10-9a4e-1f2ba5d94036" xlink:href="brns-20231231.xsd#brns_ShareholderTheUniversityOfOxfordMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ea1dea92-dafd-4ca3-b4b4-a0b19a99c7ec" xlink:to="loc_brns_ShareholderTheUniversityOfOxfordMember_c87ee020-57ed-4b10-9a4e-1f2ba5d94036" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_OxfordUniversityInnovationLimitedMember_a88390f7-d181-4b1e-a185-79483855fe11" xlink:href="brns-20231231.xsd#brns_OxfordUniversityInnovationLimitedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ea1dea92-dafd-4ca3-b4b4-a0b19a99c7ec" xlink:to="loc_brns_OxfordUniversityInnovationLimitedMember_a88390f7-d181-4b1e-a185-79483855fe11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_ed46f8f6-09d8-4106-896d-9a8110398327" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b340b48d-458b-461d-883b-5cea10d240bd" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_ed46f8f6-09d8-4106-896d-9a8110398327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_06e0e32c-5b11-4506-91f6-3fdecb5efef1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_ed46f8f6-09d8-4106-896d-9a8110398327" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_06e0e32c-5b11-4506-91f6-3fdecb5efef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ExpensesMember_da35e23b-c9e6-4dc2-a9d3-8a0bf6d2ce06" xlink:href="brns-20231231.xsd#brns_ExpensesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_06e0e32c-5b11-4506-91f6-3fdecb5efef1" xlink:to="loc_brns_ExpensesMember_da35e23b-c9e6-4dc2-a9d3-8a0bf6d2ce06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4d8c19a2-fc41-4326-b1d7-b34de2bc966f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b340b48d-458b-461d-883b-5cea10d240bd" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4d8c19a2-fc41-4326-b1d7-b34de2bc966f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_4da0247f-441f-4551-b641-faf4a16cd093" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4d8c19a2-fc41-4326-b1d7-b34de2bc966f" xlink:to="loc_us-gaap_RelatedPartyDomain_4da0247f-441f-4551-b641-faf4a16cd093" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_c1fbd36f-5cc9-48f3-983c-89d4cf2b1ba8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_4da0247f-441f-4551-b641-faf4a16cd093" xlink:to="loc_us-gaap_RelatedPartyMember_c1fbd36f-5cc9-48f3-983c-89d4cf2b1ba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_4386b4b6-91d4-49b4-8f73-d8f52821ab0e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b340b48d-458b-461d-883b-5cea10d240bd" xlink:to="loc_srt_ProductOrServiceAxis_4386b4b6-91d4-49b4-8f73-d8f52821ab0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f877bdbc-9187-4e3e-975a-66b5c4b2b840" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_4386b4b6-91d4-49b4-8f73-d8f52821ab0e" xlink:to="loc_srt_ProductsAndServicesDomain_f877bdbc-9187-4e3e-975a-66b5c4b2b840" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_efc13a14-4191-42d3-ab4e-b1683ed28f3a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f877bdbc-9187-4e3e-975a-66b5c4b2b840" xlink:to="loc_us-gaap_LicenseMember_efc13a14-4191-42d3-ab4e-b1683ed28f3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_2b7ee07a-7d6c-4efd-9e20-291adf67aa1f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b340b48d-458b-461d-883b-5cea10d240bd" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_2b7ee07a-7d6c-4efd-9e20-291adf67aa1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_34537c48-0242-42f5-939a-6aa1a7ce1c02" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2b7ee07a-7d6c-4efd-9e20-291adf67aa1f" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_34537c48-0242-42f5-939a-6aa1a7ce1c02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_6f4d0d82-4732-4089-8ac1-ed534a2b8a43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2b7ee07a-7d6c-4efd-9e20-291adf67aa1f" xlink:to="loc_us-gaap_AccountsPayableCurrent_6f4d0d82-4732-4089-8ac1-ed534a2b8a43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0f358f28-aa9e-4496-b534-d5d63d6309c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2b7ee07a-7d6c-4efd-9e20-291adf67aa1f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0f358f28-aa9e-4496-b534-d5d63d6309c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_d79f0b22-d214-46eb-8a91-a31075feff45" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2b7ee07a-7d6c-4efd-9e20-291adf67aa1f" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_d79f0b22-d214-46eb-8a91-a31075feff45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="brns-20231231.xsd#SubsequentEventsDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_896ba8f7-e358-45eb-bce3-56ad404fd7df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_aa97b2a7-b7e5-4d5c-be53-8500e78ed389" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_896ba8f7-e358-45eb-bce3-56ad404fd7df" xlink:to="loc_us-gaap_SubsequentEventTable_aa97b2a7-b7e5-4d5c-be53-8500e78ed389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_f5f6dbb8-9dde-408b-aec2-0c2b88139f67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_aa97b2a7-b7e5-4d5c-be53-8500e78ed389" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_f5f6dbb8-9dde-408b-aec2-0c2b88139f67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_b92fe56c-23ac-43db-b14a-765b78447f89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_f5f6dbb8-9dde-408b-aec2-0c2b88139f67" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_b92fe56c-23ac-43db-b14a-765b78447f89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_b744b23f-2660-413a-9063-923359d4a374" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_b92fe56c-23ac-43db-b14a-765b78447f89" xlink:to="loc_us-gaap_SubsequentEventMember_b744b23f-2660-413a-9063-923359d4a374" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_fa5d8b47-ea50-4918-bbae-e49afa1d385a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_aa97b2a7-b7e5-4d5c-be53-8500e78ed389" xlink:to="loc_us-gaap_PlanNameAxis_fa5d8b47-ea50-4918-bbae-e49afa1d385a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_1eef5f8d-bb6b-4697-b795-6695f0fd34de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_fa5d8b47-ea50-4918-bbae-e49afa1d385a" xlink:to="loc_us-gaap_PlanNameDomain_1eef5f8d-bb6b-4697-b795-6695f0fd34de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_BarinthusBiotherapeuticsPlcShareAwardPlan2021Member_def9e8f2-6e57-40b9-a2f3-ea291cef83bf" xlink:href="brns-20231231.xsd#brns_BarinthusBiotherapeuticsPlcShareAwardPlan2021Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1eef5f8d-bb6b-4697-b795-6695f0fd34de" xlink:to="loc_brns_BarinthusBiotherapeuticsPlcShareAwardPlan2021Member_def9e8f2-6e57-40b9-a2f3-ea291cef83bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2a956518-2827-429a-844b-d076fab71389" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_aa97b2a7-b7e5-4d5c-be53-8500e78ed389" xlink:to="loc_us-gaap_AwardTypeAxis_2a956518-2827-429a-844b-d076fab71389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9e61b444-410f-494c-8180-916fd49f377c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2a956518-2827-429a-844b-d076fab71389" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9e61b444-410f-494c-8180-916fd49f377c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_f096983d-31f0-4886-8446-4f8c3e6c6911" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9e61b444-410f-494c-8180-916fd49f377c" xlink:to="loc_us-gaap_EmployeeStockOptionMember_f096983d-31f0-4886-8446-4f8c3e6c6911" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_061d444f-cfdb-4112-9809-037c12fb0fd9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_aa97b2a7-b7e5-4d5c-be53-8500e78ed389" xlink:to="loc_us-gaap_SubsequentEventLineItems_061d444f-cfdb-4112-9809-037c12fb0fd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ShareBasedCompensationPercentageOfSharesAvailableForIssuanceAsPercentageOfIssuedAndOutstandingShares_74ea45a1-b616-4d77-b699-e120baee87cf" xlink:href="brns-20231231.xsd#brns_ShareBasedCompensationPercentageOfSharesAvailableForIssuanceAsPercentageOfIssuedAndOutstandingShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_061d444f-cfdb-4112-9809-037c12fb0fd9" xlink:to="loc_brns_ShareBasedCompensationPercentageOfSharesAvailableForIssuanceAsPercentageOfIssuedAndOutstandingShares_74ea45a1-b616-4d77-b699-e120baee87cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ba8a25c9-6ad8-4ab3-8a0d-3645f42213a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_061d444f-cfdb-4112-9809-037c12fb0fd9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ba8a25c9-6ad8-4ab3-8a0d-3645f42213a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_4e6e72c6-74ec-46dd-8b56-67b977126038" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_061d444f-cfdb-4112-9809-037c12fb0fd9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_4e6e72c6-74ec-46dd-8b56-67b977126038" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>annexev6a.jpg
<TEXT>
begin 644 annexev6a.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" )I O,# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0_\ R#1_PTMX1_Z!'Q _\-QXA_\ D&@#U6BO*O\ AI;PC_T"/B!_X;CQ#_\
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M_P#R#1_PTMX1_P"@1\0/_#<>(?\ Y!H ]5HKRK_AI;PC_P! CX@?^&X\0_\
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M!H ]5HKRK_AI;PC_ - CX@?^&X\0_P#R#1_PTMX1_P"@1\0/_#<>(?\ Y!H
M]5HKRK_AI;PC_P! CX@?^&X\0_\ R#1_PTMX1_Z!'Q _\-QXA_\ D&@#U6BO
M*O\ AI;PC_T"/B!_X;CQ#_\ (-'_  TMX1_Z!'Q _P##<>(?_D&@#U6BO*O^
M&EO"/_0(^('_ (;CQ#_\@T?\-+>$?^@1\0/_  W'B'_Y!H ]5HKRK_AI;PC_
M - CX@?^&X\0_P#R#1_PTMX1_P"@1\0/_#<>(?\ Y!H ]5HKRK_AI;PC_P!
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MRK_AI;PC_P! CX@?^&X\0_\ R#1_PTMX1_Z!'Q _\-QXA_\ D&@#U6BO*O\
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M4 %%%% !1110 4444 %>5>(_^3IOAY_V)GB;_P!+M!KU6O*O$?\ R=-\//\
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MM3TO49Y;SR[9I;62VDC5("BM&YFBDE23;M VE@:R_P!GG]MC1?'7P7^'^O\
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M4 %%%% !1110 4444 %>5>(_^3IOAY_V)GB;_P!+M!KU6O*O$?\ R=-\//\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 5Y5XC_Y.F^'G_8F>)O\ TNT&
MO5:\J\1_\G3?#S_L3/$W_I=H- 'JM%%% !1110 4444 ?-7[1WP7T?XZ?'WX
M9:#K<_V>TM_#/B.^5O[+TW4/G6ZT5 /+O[6YB'$A^94#CH& +!O,OC-^Q_\
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M+7U510!\J_\ #NKX??\ 02_\LGPA_P#*6C_AW5\/O^@E_P"63X0_^4M?55%
M'RK_ ,.ZOA]_T$O_ "R?"'_REH_X=U?#[_H)?^63X0_^4M?55% 'RK_P[J^'
MW_02_P#+)\(?_*6N?T3]C+X:^"_VDO"6F:CH6C^,M-U'PEKMRUGK?A70H88Y
M8;S1U20)9V%N&;;/(-T@<J&(7;N?=]E5Y5XC_P"3IOAY_P!B9XF_]+M!H /^
M&3O@A_T1OX?_ /A+V/\ \:H_X9.^"'_1&_A__P"$O8__ !JO5:* /*O^&3O@
MA_T1OX?_ /A+V/\ \:H_X9.^"'_1&_A__P"$O8__ !JO5:* /*O^&3O@A_T1
MOX?_ /A+V/\ \:H_X9.^"'_1&_A__P"$O8__ !JO5:* /*O^&3O@A_T1OX?_
M /A+V/\ \:H_X9.^"'_1&_A__P"$O8__ !JO5:SO$/B/2?".BW>L:[JEEHND
M6B>9<7^H7"000KD#<\CD*HR0,D]Z /._^&3O@A_T1OX?_P#A+V/_ ,:H_P"&
M3O@A_P!$;^'_ /X2]C_\:KM_"7C[PQX_L$OO#'B/2?$=E(I=+G2;Z*ZC90[(
M2&C8@C<CKGU4CJ#6]0!Y5_PR=\$/^B-_#_\ \)>Q_P#C5'_#)WP0_P"B-_#_
M /\ "7L?_C5>JT4 >5?\,G?!#_HC?P__ /"7L?\ XU1_PR=\$/\ HC?P_P#_
M  E['_XU7HVKZS;Z)#;R7$=W(L]S%:H+.SFN6#R.$4L(E8H@)&Z1L(@RS,H!
M-7Z /*O^&3O@A_T1OX?_ /A+V/\ \:H_X9.^"'_1&_A__P"$O8__ !JO5:*
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MP:R=:^)7AGP[XT\.>$=1UB"W\2^(A.=+TW#-+<+#&9)6P =JJJGYFP,X ))
MH Y#_AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_T1OX?_\ A+V/_P :KT;1=:M]
M>LVNK:.[BC6:6 K>V<UK)NC=D8A)55BI*DJV-K+AE)4@F_0!Y5_PR=\$/^B-
M_#__ ,)>Q_\ C5'_  R=\$/^B-_#_P#\)>Q_^-5Z3K&LZ?X=TF\U35;ZVTS3
M+.%KBYO;R9888(U&6=W8A54 $DDX %9_A/QUX;\>:=%J'AGQ!I?B*PEC\V.Z
MTF]BNHG3S)(]P:-B"-\4J9_O1N.JG !PW_#)WP0_Z(W\/_\ PE['_P"-4?\
M#)WP0_Z(W\/_ /PE['_XU7JM% 'E7_#)WP0_Z(W\/_\ PE['_P"-4?\ #)WP
M0_Z(W\/_ /PE['_XU77^+/B3X9\#ZOX;TK7-7@T_4O$E[_9^DVC!FENYPA<J
MJJ"<!1RQPHRH)!89V-+UFWU>2^2".ZC-G<-:R_:K.:W#.%5B8S(JB5,,,2)N
M0D$ Y4@ 'G'_  R=\$/^B-_#_P#\)>Q_^-4?\,G?!#_HC?P__P#"7L?_ (U7
MJM% 'E7_  R=\$/^B-_#_P#\)>Q_^-4?\,G?!#_HC?P__P#"7L?_ (U7JM%
M'E7_  R=\$/^B-_#_P#\)>Q_^-4?\,G?!#_HC?P__P#"7L?_ (U6]\3OC3X/
M^#MG%=>*]3FL8I(I+@_9K"YO&B@CV^;<2+!&[1PH70-,X$:ET!8%AF+PW\<O
M!/B[QQ-X2TG66NM;CAFN$7[%<);W,<,BQ3FWN6C$-QY<CJCB)W*-E6P00 #&
M_P"&3O@A_P!$;^'_ /X2]C_\:H_X9.^"'_1&_A__ .$O8_\ QJO5:* /*O\
MAD[X(?\ 1&_A_P#^$O8__&J/^&3O@A_T1OX?_P#A+V/_ ,:KU6J&BZU;Z]9M
M=6T=W%&LTL!6]LYK63=&[(Q"2JK%25)5L;67#*2I!(!YS_PR=\$/^B-_#_\
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M **** /*O$?_ "=-\//^Q,\3?^EV@UZK7E7B/_DZ;X>?]B9XF_\ 2[0:]5H
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M:R-$^*-T=0UCXPG0;J/7M+L[MQ:&01"2,1I"5W*$!SN7$:",1_-N^B8_A?\
ML\ZIXLU#P7'X1^&5WXGB8:K>^'ETW3GO4; Q<R6^W>#B5?WC+TD'/S<]=KGP
M(^&GB;4KC4=8^'GA35M0N+A;R:ZOM$MII99U7:LK.R$EPHP&)R!QF@#YQT'X
MG?$W1]7LY]0\?W&N:?IGQ2_X09K2XTJRB;4;.7_EK=21Q+^^3S$V& 0+B/YU
MDW$B+PC\5/C;XWU^^\5VGB?POH_AB36->\/?V#>S_;)+2XM?M26ZK9QV$4R3
MI]F2:42WS(Z-*RK"&18_H5OV;?A')OW?"SP4V^Y^V-GP]:'=/S^]/[OE^3\W
M7GK6M??!GX?ZIKFKZU>^!?#5WK.L6S6>I:C/I%N]Q?0,JJT4TA3=(A5$!5B0
M0H&.!0!\@:1\3OBMKGPI\.SZQ\1KV\O?&7PCU3Q2[Z?I=G:FQO+:.Q:)K?$3
M-ND6Y<2EBP+$M$L'RJO??$>WU/3?^";VO#3_ !EJUQJ5GX(:9M4C^R"Y %J'
M:W;RX515"'R\A1($&=^_YZ]GL_@]\'?"OB30(+7P1X'T?Q EM<1:/'#I-G!=
M+ -QN%MP$#!!]H<N$X_?-G[YST-OH?@GPYI5E\/X-/T#2]-OK2YCM?"\<,$,
M-Q;# N%CM0 'C'G+O 4C]Z-WWN0#YK\0?$/QDO\ PL72]%^*EQI-U\-/"]MK
M%N]_9:=*NNMY<\LTE\?LX @5H#;$6WD,A60LQ8J%W?VMM<O/$'[-_@G5-=M9
MM(\-:CKGA^?QI:,#BVTJ2>-KN.;C(C5BBR?[ <'C->Q:?\-_A;XTTWPQJ-EX
M6\(:[I^@_+H%W;Z=:W$6G>6X&+1PI$6UX@/W9&#&.ZUWDL23Q/%*BR1N"K(P
MR&!X(([B@#B]2TOP'>>+/ NH3VFFS^(85G/ANZMH]TR0FW(F\MHQQ 8V4')\
MO<T/\9BKY_\ V9?^$FT/X(_#;5_%/BCPL_P^1U2/2CH$J7WGR7#1V:B=KB59
M9/M#1;1'#$Q8K@\;6]]T'X#?#/PKINKZ=HOP[\)Z/I^L0_9M2M;#1+:"*^BY
M_=S(B 2+\S?*P(^8^M4-'_9G^$'AW5+74]*^%/@G3-2M9!+;WEGX=LXIH7'1
MD=8P5(]0: /G"W^$_C+XX3^,?#=K:>'=+\*V'Q7DUR3Q'/?SR:K;O:RQ2E;:
MU%N$1V*B/S3<<)))\AX%>X_!W_DNOQ]_[#6E_P#IGM*ZWPYX!^&?P1WS:!X<
M\)^ 1J]Q!9-)IMC;:;]MF+%8(245?,<L[!%Y.6.!S5WPO\(O O@CQ!?Z[X=\
M%>'= UR_#K=ZEI>E06US<!W#N))40,X+ ,<DY(!ZT >&V.D_$#4OCU\<O^$/
M\2^'=#M!/I(N8=9T26[ED/\ 9T>2DZW*)$-N1EX90#S@CY:YWXD?'+6+[P_\
M4M:^'7C"/PWH/P[\(V^MZ'I>GZ=;/!K4<EK)/'/+YT3-]DQ&L<?V<Q<K(=[@
MJ%]TU']E_P"#>L:A=7]_\)? M[?74K3SW-QX;LI)9I&)9G=C%EF))))Y)-8O
M[0?[+OA/XY?#2^\-)H7A;3-6.F'2=+US4/#D-_)I%N1M(MEW1M&57.S:ZA&V
MG!Q@@'D'Q4^,GC3P7I7Q]NC\0;G2XO"L&@:GI,]S;:>JVOVL,)("7M\/$[@*
M-^7R,*^:QOCQX[\8^--!^,.GVGCN:+1M*\2>#VT:X\.6ULJFQOKBU#H9'27S
M5(F$F\$!BB\",O&WTII_PT\ >/I+6_\ $6B^"_'7B_0K<:)?:TND6\LD$BQY
MD@ =I9(%(F9O):0D";DG=DZ\WP3^'=Q=:_<R^ O#$EQX@4KK$SZ-;E]24L'(
MN#LS,-P#?/GD9H ^>_%7QB\0>'?BQX:30_B-K?BOP]#XFT_0M:+Z-IT.BV\$
MM@CXFNS&DD]V[-]H,EHWDQ@JCQ1\;^:^"NN^+/!-OI>IZ9XM:?3]:^+6NZ#)
MX0:QMS!+;R:E?/-,)-OG^?&$>;<)/+\N/:8LYD/T_J/[/_POUC7AKE_\-_"-
M[K0\D#4KC0K62Y_=*BQ?O#'N^18XPO/RA% Q@5L6_P ,?!UGXNU#Q5!X3T.'
MQ1J,/V:]UN/385O;F(A1Y<DP7>ZX1!M8D81?04 ?&/@?QYX]T_PGX,\"> [V
MRT:_\4^*O'$QU2ZU"*R<26NKRLEO$\MC>QLSK-*Y0P[BL#$,N#7U?\/O&6J:
M;\%-/U[QQ?Z;J.M6%DZZK>:$LAM;JXA9HW:W$B(S;V3Y0% 8L-N05)FC_9]^
M%T/A67PS'\-O"">&YKH7TFCKH5J+-[@+M$QA\O89 H"[B,XXS6[XC^'/A/QC
MX;A\.Z_X7T;7/#\'E^5I.I:?#<6L>P83;$ZE1M' P..U 'RM\*]2UKX8?M(:
M#JOB;P)KG@./XE:?)I>M76K7>GRVMWX@C>6\M_+>VNIF.8GO(4\T(2D,"*#C
M:.^\#^./&/B>QU7XC/XV=+6PU77-,F^';6%IY+-:27$%O;QR[1<I=,88IF+2
M.K"1@L2JRE?7_%_P?\!_$&STVS\4^"?#OB6TTQ2EC!K&DV]W':*0H(B61"$!
M"*/EQ]T>@JQ%\,/!L'CB;QG'X2T./QA,GER^(%TV$:@Z[!'M:XV^81L55P6^
MZH'04 ?..I_%3QMX%_9\E^*T?Q*L_&,FN:!8ZC;Z/J%G:6MIITLUS D]S;S0
M1^8MK EU\PG%PR;$+2'Y@U=O%'QX\*Z5<Z3J?B&R\1ZI_:UM=V\/AN^L+S6V
MTY[.X<Q*;BQL;.Y;SK;S#''&DOD&3#!@CM]'Z+\(_ OAN[URZTCP7X>TJYUT
M,-6FLM*@A?4 Q8L+AE0&7)9B=^<[CZFJ'_"A/AD?"8\+GX<^$_\ A&1<&\&B
M_P!AVOV,3D &7R?+V;\ #=C/'6@#P=?CAXO?4_ &LCQ+J5UX)O+#0H[[5]/T
M2T9#<W$[).=0L'<7=D9V1(XY(C)''YDF]255QVO[2USKEG\3_@'+X;T[3]5U
MI?$]_P"19ZI?R6-O)_Q(]1#;YDAF9,+N(Q&V2 . =P]$T_X>?#/Q-JFFZ_8^
M&?">K:CX?D;3['5+>PM9IM->W8Q-!%*%)A,3(4**04*D8&,5+XE^&OPZ^(?B
MB&[\0>%?"_B;Q'HZ1&*?4M.MKN\LD+,\95G4O&"RNRXQR"1T- 'SIX0\(^+?
M@GK'A3X<W7BFW\&W?Q)\1Z_XCN[_ ,,0Q2PZ;*$BECTNQ-Y"\>'W/(7>')$4
MP5%+!EA\,^,?$_C3QU\ F\37-O?Z[I7BKQ7H9UJ&W$<.J"TL[VW2\\I2%!<1
M@NJ$+O#[=JX4?5OB[P3X=^(&BOH_BG0-+\2Z2[K(UAJ]G'=0,RG*L8Y%*Y!Z
M''%9.J?!OP!K<VAS:CX&\-W\VA1)!I,EUI%O(VG1IC8EN60^4J[1@)@# ]*
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M\TGB[X:^$?']QIEQXG\*Z+XDGTN0S6$NKZ=#=-:2$J2\1D4E&)1.5P?E'H*
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M\MW?;+F)-RQ3>4NUF5TQ(%/S?6?_  I+X=_\(9_PB'_" ^&/^$3\[[1_8/\
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M2]5>?4M777I;H^(]2^T0WZJ4^T6\WVCS+9RAV$PLFY J'*J  #C/V1HF\$_
M7Q;%#IVGVCZ1XJ\4*FG:5%Y5G&8M4N@(H4 ^6,;=JC'"@#%><>+?AUX:\:?L
MS_ K6_$^@:5XDUG7O$?AK5M2OM4L(KB2>XU&YMGO>74X20$1[.GEQQQ_=10/
MJ/X;_"'P?\(]'U#3/"6A0:1::C>3:A>X=Y9+JXE8M))+)(S.Y.<?,3@  8
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M.H+Y<7V8SW@28?9-X4_:7(]G_P"%R>+O^B$_$#_P.\/?_+6C_A<GB[_HA/Q
M_P# [P]_\M: .2_8KL(]%^ =Y9:/96MO%:>)O$D-G9)B"!%36+P1QC:IV(
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M)^('_@=X>_\ EK0!ZK7E7B/_ ).F^'G_ &)GB;_TNT&C_A<GB[_HA/Q _P#
M[P]_\M:Y32?&6K^+OVIO!7]J^!/$'@K[/X,\1>7_ &[/ITOVG=?:'GR_L=W<
M8V[1G?M^^N-W. #Z HHHH **** "BBB@#RKQ'_R=-\//^Q,\3?\ I=H->JUY
M5XC_ .3IOAY_V)GB;_TNT&O5: "BBB@ HHHH **** "BBB@ HHHH *\J\1_\
MG3?#S_L3/$W_ *7:#7JM>5>(_P#DZ;X>?]B9XF_]+M!H ]5HHHH **** "BO
M,O G[2OPR^)GQ&\1> O#'BZSU?Q;X?W?VCIL22*T>UPCE790DH5B%;RV;:2
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M<213QK9P^:K1(Y2X8[6D* ;4.9\5OC[XG^'9^%FD:]?>%_AEJGBBWN3J>O\
MB2WEU#1[*\@BC;[$KI<6ZJ\I>5HWEE4%;=E"L[   ^BJ*Y[P3J'B*\\+Q7/B
M_3K#1M;\VX^T6NGW1N+:.-9G$165E4N#$$;<50DDY1/NCQ+3/VD(/%/[2&B:
M?H_BJ _#EO".JZM=+=:1+91O);W%F$OEO)PHGM3'-)LEA_=';(V^3Y=@!]'4
M5X1XY_;*\!>#_">JZQ#'KNI7>G7=A:3:3_PC^HV]V/M<WE03&*2W#^0Q#A9@
MI1V41H6D9$;L;_\ :#\"Z5KFEZ3>ZG>VEWJ$EM C3Z/>I!;SW"JT%M=3&'R[
M6X</'B"=HY/WD?R_.N0#T:BO$/\ AM;X++H<FN/XXAB\/)?#3!KLMA=)ILMT
M9C#Y4=V8A#(V59R$<XC4RG]T"]:.G?M9?"W5-2@TZ'Q%<1Z@^H1:7+:W6CWT
M$ME<RLJP)=I)"IM1,741-.$64DA"V#@ ]>HKQF__ &F_A7X-O/$][K?Q0M$L
MK3Q'#X;GCOC&EKINHF*,&UCD6)2P&?,E=WD$1,FYXU0JFM'^TMX F\/+J\6H
M:I*C:J^B#3H_#^HMJ?VY83.T'V 6_P!I#B$&4CRN$^?[O- 'J%%>)#]KCP->
M>,O >BZ8VI:II_B_2+C6K77+?2[LV<-O$T2YE?R<)S(=Y<J(=G[W9O3=?TG]
MH;P%I/P[\/>(/^$NU3Q?INN/=/IM[9Z-/?7MY'%(YE=;:RMM_DQ8"&7R@H'E
M[F+.&< ]>HKR'5/VM_A'I=SI=K_PFEKJ-]JFDG7+"QT>WGU"YNK,,%,L<-O&
M[OC+,5"E@D4SD;(I&7JO$GQB\)>%/A?_ ,+%OM3DD\&?8H]2_M33[*XO5^RR
M*'6?9!&[^7M8,6VX5<DX )H [2BO-9OVB/ ]OJ/B#3Y+K6$OM!TJ'6[^V;PY
MJ7F+92DA)D7[/F4$AP1'N(,<@(!1L<5XQ_:P\$^ [/Q#K%KK.M>,_L_B/3?#
MMSI&GZ5+,NDW5QY*F(&&VW[@LA=D<N_F@PKMDQ$ #W^BOF;X:?M06UG\5/B9
MX:\=>)C*T'BJRT_088="N(5L;6[M+1[6*Z*HQ@9Y9S&)+ID\R02!0NWRT]P\
M??$S0/AI::?/KDU[NU"Y^R6=KIFF76HW5Q*(WD*QV]M')*V$C=B0N %))% '
M4T5Y7K'[4'PUT7P7HWBN37YKW0]7TQM:M9M*TJ\OY?L*J&>ZDA@A>2&)-RAW
MD50C$*Q#<5H:Y^T!X"\.^)+#0[S7&:[O);6!)[2QN;FSBDN2!;1S744;00-+
MN38LKJ6#J1D,,@'HE%><_P##0WP_7Q5/X?EUYK6\BCNI!=75C<PV$_V49NEA
MO7C%O,\(#^8D<C,GER;@/+?;#;_M'> +O19M3BU6^98;J.REL3HU\-0CG>-I
M5B:S,/VA6\I&F(,>5B'FG"?-0!Z917FGQ&^/GAOP'\"]6^*ML9_$?AVTTUM2
MMFTF&2;[8FTE"I16VHQQ^]8;%4[F(49JIK7[3OP_\,:?IMUK6H:GI8O+%-2D
MCFT'4-VGVS.8UGO5\C-G$75P)+D1JWEN02$8@ ]6HKQ7]K#XE:S\-?@F/&'A
MOQ#8:)%;:QHWVO4+F".>-K&?4+>&;:[MLCRDV3(P<! V K%73H=-_:(\!ZMH
MNK:C!J=\K:5=QV-YI=QHU]#JL=Q)&)8XAI[PBZ9GC8.H6([E!9<@$@ ])HKC
M=&^,'@[7OA_>>-[;7(8O#%DMPUY?7L;VIM# S+.L\<JJ\3HR,&1U# C!%<7I
M_P"V)\']2T6YUA/&,=MI,&CG7A?7UA=6L-Q9#:&D@>6)1.5:1(V2(LZR,(V4
M/\M 'LU%>5R?M.?#]?#EAKBWFM36.H2R1V,=OX9U.6YO$2)97N(+=;8RRVP1
MT/VE$,/SJ-^6 -_0_P!H+P)XF\2Z+H6CZO<:K?:UI+ZYI\ECI=W-:W-DFT/*
MMRL1A^4NBE=^X,Z*1N900#T6BO+-!^.G@?Q1XOMTM/&=U9SIX=GUN;0-2L6L
M%CL1,B?;KA;B!)H"I!"AW1621GV. KKQ7@_]HJ+Q)\=O%,3>(Q%\/M/\*6VK
M16VH:)/IDUO(UQ(C3.;A5DE5PH*.JK&PP%#$%B ?1%%>9V/[1W@&_P!#U74U
MU2^@_LN\BT^ZTV\T6^M]36XE17BB6PDA6Y=I$8,@2([P&*YVG&+^S#\2M8^)
M?A3Q?J>M:O'K9LO$^H6%K/;Z:UCLMXRFR(V[9D1TR599"9 P(;!&  >S45\K
M^!/VAI?&'BG7_&EYXQ\0Z!X2T/7+C1)?"5]X*N534%YAMA;.ULMTUX9AN:%&
ME(7Y#"A.^O2[K]K+X56>C:1J,OBD@ZMJ=QHMIIJZ;=MJ;WT )FMC8B(W*2K@
M91HP<R1#K+&& /7:*Y3Q1\4/#_@WPE9>(]6DU"WT^]:".V@CTJ[FOI9)L>7$
MMFD37!DYYC\O<NUMP&TXXN3]K;X31V_AY_\ A+D>X\0)=-I>G1V-T]_<M;NT
M<T8M!$9A*LBLGE% [,K*JD@B@#U^BN1L_BCX5UCX9?\ ">6^OPV_A&2P;4/[
M9F!A2& *2SN)%!0K@Y5U!!!!&017GUO^UA\*?#.CZ%9WGC^?7]1N?#MOX@A*
MZ;-<:E>V#HK+=O;6MN"I9#YC*L2;5#.45%) ![?17SK^U5^TE9> _@GXIO/!
MGBJ&T\7?\(X^MZ9>0Z1-JD$,)1FAEF9 8K<3;62%[A@CN#A9=K(?1M6^._@[
MPKK&F:)K6K30:E=/;6SSIIUS+9P7$X7R8KBZ2,P6\DA=-J2NC-O3 .Y<@'HE
M%>1^&/VLOA1XTUVQTK0_%L>IRWVIS:-;7EO97+6$E]&)"UL+SR_(\TK$[HAD
MS(FUD#*ZDV+S]J+X8Z9/JJ:AXG&F1:=8SZD]YJ%C<VUK<VT)599;6XDC$=VJ
MLZ ^0TG+J.XH ]4HKS#PS^TS\,_%UKJMUIWBJ'[#INEIK=Q?7EM/:6IL6W?Z
M3'-,BI-&"C*S1LP1@5;#<5PGPY_:)_MKXM?%Y]8UZ5/!.@:9H5QI]A>>'[G3
M+VREN9+Z-XI()D%S+/*T,&Q=@+[XA'&2^9 #Z*HKQVZ_:\^$FGV^FO?>+ETR
MZU'49M(MM,U#3[JVU!KR*,2O UG)$LZ/M>+ 9!N,T*KDRQAJMU^UKX+D\0?#
M_3-)AUK6D\7WMW917%MH=_\ Z&UL)4F69/(+I(DT8C>-PAC4M(^U5Y /;*\J
M\1_\G3?#S_L3/$W_ *7:#7JM>5>(_P#DZ;X>?]B9XF_]+M!H ]5HHHH ****
M "BBB@#RKQ'_ ,G3?#S_ +$SQ-_Z7:#7JM>5>(_^3IOAY_V)GB;_ -+M!KU6
M@ HHHH **** "BBB@ HHHH **** "O*O$?\ R=-\//\ L3/$W_I=H->JUY5X
MC_Y.F^'G_8F>)O\ TNT&@#U6BBB@ HHHH \"^$'[$OPV^"/QK\6?%'PXFJ_\
M)%XB$PEAO+L26MH)I!+,($"!AO=0?G9\8PNT9%>^T44 %>$?M%?![7OB]XS^
M'!7PIX.\5^#_  _J4NI:GI_BJ_D479>UN+81BW^QSQML\]9@S,,M&%PO#CW>
MN:\<?$SP?\,K2VNO&'BO0_"EK=.8H)M<U&&S25P,E5:5E#''.!0!YMXY^#NL
M1_$+X+W/@30?#&E^$/!.I75U=6/VI[ QPSVD]H4MH(;9XR56X>3!9 Q0+QN+
MKYGXS_9]^+>M:E\09K'3?!9BU[QYHWBRS^T>(KM&6WL!:CRI -/;:\GV&/H6
M"^<W+>6/,^B=2^,WP_T<:X;_ ,<^&K$:$L#ZL;G5[>/^SUG*B W&7'E"0LNS
M?C=N&,YKBOVCOC]!\(/!HET/4_#%UXMN/)GL]'U?4A'-<VK2JLLT,*?O)]JD
MG VKP26&,$ X%?@3\4+;XD^(_'-K;^$TU*/QFOB;1M/DUFZ:"]MWTI=*GM[E
MQ9@V[^4@G21%F <^65V@NW3^+O#OCZ?XD?#CX@^(X?!>BZ%X1M=4N-=E;7KA
M%M(IXPK,CO:!9%BCB#F20P@Y8;4"[CUOQ%^//A+X-P:]J_C'QGH-KI5I=65C
M'IZ,D5Y;7$X)6.4M.0Q=<RJ-D>V..1CN52PZOQ)XJLX_ <VOZ=XFT/2K&:VC
MN+77]2*W&G*C[?+E8K-&'1@PP1(N=PP: /D']C_POXJ^)7P!^#&OV\?A.XT_
MP9H-T-&^RZS-)+?7TMJ]MY-WBV(LUC620.%,[%MIPFTJ=/P[^QSXFTGP_P##
M*37_  9\,_B#J?AOPLGA2_T?Q--)/9!8I"\-Y:SO8R,LARP>(P@$, )/ERWI
M_B[]H.^UOX[2_##X>^)_ J^(M)MK2]O]-\07#23:CYD\HGM(##*&@FAM[=Y6
M)BF_U\.4098^N:M\3/!_A_Q):>'=4\5Z'IOB"\:);;2;O488KJ<REQ$$B9@S
M%S'(%P.=C8S@T >*Z'\ /&'AGXP:)K&CRZ/H6B6ALX]0U+1=4N;/^UK:#3TM
MO(N-%$+69;>GR3QR1O'$L2 $1X9?VM/@S\3_ (UZ5J_ASPSJFFKX3U30+C3W
ML;K6[C2C%?OO"W,C6]K*]S$%91]G,D<9PV\2 @+[-H/Q2\&>*IM=AT3Q=H.L
M2Z"VS5X[#4H9VTYLN,7 1CY1S')]_'W&]#6?;?'7X;7FDV6J6_Q"\*SZ9?7,
M=G:WD>M6S0W$\AD6.*-P^&=C#* H)),;X'RG !\=_$K6GA^*WB*UUOQ!X)TV
MYSHZ:QX)O/&C:.=9NK2**Y@V02:5/<WBAY(XEFMG@%QY(C:+Y2I]>N?V=?&/
MCO0_C]I/B*/0=%LOB%?0ZAI4D%Y)J#P&*UMX$CNX6@C3!-K&S!)''[QT!.T.
MWM.K?$G0+[2]4.B>./#%K=:9JD&EWMQ=W$=U#:7+3HC6DJ)/&4G?=Y:*S AW
M0[7QL:[_ ,+3\%_\)-<>'/\ A+]!_P"$AMQ(9M)_M.#[7&(XUDDW1;MXVHZ.
M<CA64G@B@#YJUO\ 8]O?$GA*SD7X<?"3PQJFGZSIVJ_\(GI=BLNB:P;>*[AE
M^US?8HI!OCOI?+4PRB%H48%_,=1U&A? CQK\.O%F@>+O!&@^ =%F6SO=-O\
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MH;O[*+<ZL-3\OS/[/W>9O A^YC!\S.?W=1^,OV?_ (N^(/\ A97V73/!2_\
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M>)O_ $NT&@#U6BBB@ HHHH **** /*O$?_)TWP\_[$SQ-_Z7:#7JM>5>(_\
MDZ;X>?\ 8F>)O_2[0:]5H **** "BBB@ HHHH **** "BBB@ KRKQ'_R=-\/
M/^Q,\3?^EV@UZK7A7Q8LO%5]^TE\-X_".LZ/H>I#PEXD:2XUO2)=2A:+[9H>
M4$<=U;D-N*'=O( !&TY! ![K17E7_".?&_\ Z*'\/_\ P@[[_P"7-'_".?&_
M_HH?P_\ _"#OO_ES0!ZK17E7_".?&_\ Z*'\/_\ P@[[_P"7-'_".?&__HH?
MP_\ _"#OO_ES0!ZK17E7_".?&_\ Z*'\/_\ P@[[_P"7-'_".?&__HH?P_\
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M6EDMYR68*0+H-RQ<+[C_ ,(Y\;_^BA_#_P#\(.^_^7-'_".?&_\ Z*'\/_\
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M^_\ ES0!ZK17E7_".?&__HH?P_\ _"#OO_ES1_PCGQO_ .BA_#__ ,(.^_\
MES0!ZK17E7_".?&__HH?P_\ _"#OO_ES1_PCGQO_ .BA_#__ ,(.^_\ ES0!
MZK17E7_".?&__HH?P_\ _"#OO_ES1_PCGQO_ .BA_#__ ,(.^_\ ES0!ZK17
ME7_".?&__HH?P_\ _"#OO_ES1_PCGQO_ .BA_#__ ,(.^_\ ES0!ZK17E7_"
M.?&__HH?P_\ _"#OO_ES1_PCGQO_ .BA_#__ ,(.^_\ ES0!ZK17E7_".?&_
M_HH?P_\ _"#OO_ES1_PCGQO_ .BA_#__ ,(.^_\ ES0!ZK17E7_".?&__HH?
MP_\ _"#OO_ES1_PCGQO_ .BA_#__ ,(.^_\ ES0!ZK17E7_".?&__HH?P_\
M_"#OO_ES1_PCGQO_ .BA_#__ ,(.^_\ ES0!ZK17E7_".?&__HH?P_\ _"#O
MO_ES1_PCGQO_ .BA_#__ ,(.^_\ ES0!ZK17E7_".?&__HH?P_\ _"#OO_ES
M1_PCGQO_ .BA_#__ ,(.^_\ ES0!ZK17E7_".?&__HH?P_\ _"#OO_ES1_PC
MGQO_ .BA_#__ ,(.^_\ ES0!ZK17E7_".?&__HH?P_\ _"#OO_ES1_PCGQO_
M .BA_#__ ,(.^_\ ES0!ZK17E7_".?&__HH?P_\ _"#OO_ES1_PCGQO_ .BA
M_#__ ,(.^_\ ES0!ZK17E7_".?&__HH?P_\ _"#OO_ES1_PCGQO_ .BA_#__
M ,(.^_\ ES0!ZK17E7_".?&__HH?P_\ _"#OO_ES1_PCGQO_ .BA_#__ ,(.
M^_\ ES0!ZK17E7_".?&__HH?P_\ _"#OO_ES1_PCGQO_ .BA_#__ ,(.^_\
MES0!ZK17E7_".?&__HH?P_\ _"#OO_ES1_PCGQO_ .BA_#__ ,(.^_\ ES0!
MZK17E7_".?&__HH?P_\ _"#OO_ES1_PCGQO_ .BA_#__ ,(.^_\ ES0!ZK17
ME7_".?&__HH?P_\ _"#OO_ES1_PCGQO_ .BA_#__ ,(.^_\ ES0!ZK17E7_"
M.?&__HH?P_\ _"#OO_ES1_PCGQO_ .BA_#__ ,(.^_\ ES0!ZK17E7_".?&_
M_HH?P_\ _"#OO_ES1_PCGQO_ .BA_#__ ,(.^_\ ES0!ZK17E7_".?&__HH?
MP_\ _"#OO_ES1_PCGQO_ .BA_#__ ,(.^_\ ES0!ZK17E7_".?&__HH?P_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Y5XC_ .3IOAY_V)GB
M;_TNT&O5:\J\1_\ )TWP\_[$SQ-_Z7:#0!ZK1110 4444 %%%% 'E7B/_DZ;
MX>?]B9XF_P#2[0:]5KRKQ'_R=-\//^Q,\3?^EV@UZK0 4444 %%%% !1110
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MZ(W\/_\ PE['_P"-4 >JUY5XC_Y.F^'G_8F>)O\ TNT&C_AD[X(?]$;^'_\
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M_P#&J /5:*\J_P"&3O@A_P!$;^'_ /X2]C_\:H_X9.^"'_1&_A__ .$O8_\
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M_P#^$O8__&J/^&3O@A_T1OX?_P#A+V/_ ,:H ]5HKRK_ (9.^"'_ $1OX?\
M_A+V/_QJC_AD[X(?]$;^'_\ X2]C_P#&J /5:*\J_P"&3O@A_P!$;^'_ /X2
M]C_\:H_X9.^"'_1&_A__ .$O8_\ QJ@#U6BO*O\ AD[X(?\ 1&_A_P#^$O8_
M_&J/^&3O@A_T1OX?_P#A+V/_ ,:H ]5HKRK_ (9.^"'_ $1OX?\ _A+V/_QJ
MC_AD[X(?]$;^'_\ X2]C_P#&J /5:*\J_P"&3O@A_P!$;^'_ /X2]C_\:H_X
M9.^"'_1&_A__ .$O8_\ QJ@#U6BO*O\ AD[X(?\ 1&_A_P#^$O8__&J/^&3O
M@A_T1OX?_P#A+V/_ ,:H ]5HKRK_ (9.^"'_ $1OX?\ _A+V/_QJC_AD[X(?
M]$;^'_\ X2]C_P#&J /5:*\J_P"&3O@A_P!$;^'_ /X2]C_\:H_X9.^"'_1&
M_A__ .$O8_\ QJ@#U6BO*O\ AD[X(?\ 1&_A_P#^$O8__&J/^&3O@A_T1OX?
M_P#A+V/_ ,:H ]5HKRK_ (9.^"'_ $1OX?\ _A+V/_QJC_AD[X(?]$;^'_\
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M_P"&3O@A_P!$;^'_ /X2]C_\:H_X9.^"'_1&_A__ .$O8_\ QJ@#U6BO*O\
MAD[X(?\ 1&_A_P#^$O8__&J/^&3O@A_T1OX?_P#A+V/_ ,:H ]5HKRK_ (9.
M^"'_ $1OX?\ _A+V/_QJC_AD[X(?]$;^'_\ X2]C_P#&J /5:*\J_P"&3O@A
M_P!$;^'_ /X2]C_\:H_X9.^"'_1&_A__ .$O8_\ QJ@#U6BO*O\ AD[X(?\
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M_P"T5X$\6>,;/PI!J&I:3XDOH9)[+2_$>A7^C3WJ("9#;K>01><5 +,(]Q4
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M1VWP1\%MX9LM?UCQ%9_;[K4$GUO[-YT;W$K3RH#;P1*5,LDLG*D@R$ [0JJ
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M_P"3IOAY_P!B9XF_]+M!KU6O*O$?_)TWP\_[$SQ-_P"EV@T >JT444 %%%%
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M?$#_ ,-QXA_^0:/^&EO"/_0(^('_ (;CQ#_\@UZK10!Y5_PTMX1_Z!'Q _\
M#<>(?_D&C_AI;PC_ - CX@?^&X\0_P#R#7JM% 'E7_#2WA'_ *!'Q _\-QXA
M_P#D&C_AI;PC_P! CX@?^&X\0_\ R#7JM% 'E7_#2WA'_H$?$#_PW'B'_P"0
M:/\ AI;PC_T"/B!_X;CQ#_\ (->JT4 >5?\ #2WA'_H$?$#_ ,-QXA_^0:/^
M&EO"/_0(^('_ (;CQ#_\@UZK10!Y5_PTMX1_Z!'Q _\ #<>(?_D&C_AI;PC_
M - CX@?^&X\0_P#R#7JM% 'E7_#2WA'_ *!'Q _\-QXA_P#D&C_AI;PC_P!
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M&C_AI;PC_P! CX@?^&X\0_\ R#7JM% 'E7_#2WA'_H$?$#_PW'B'_P"0:/\
MAI;PC_T"/B!_X;CQ#_\ (->JT4 >5?\ #2WA'_H$?$#_ ,-QXA_^0:/^&EO"
M/_0(^('_ (;CQ#_\@UZK10!Y5_PTMX1_Z!'Q _\ #<>(?_D&C_AI;PC_ - C
MX@?^&X\0_P#R#7JM% 'E7_#2WA'_ *!'Q _\-QXA_P#D&C_AI;PC_P! CX@?
M^&X\0_\ R#7JM% 'E7_#2WA'_H$?$#_PW'B'_P"0:/\ AI;PC_T"/B!_X;CQ
M#_\ (->JT4 >5?\ #2WA'_H$?$#_ ,-QXA_^0:/^&EO"/_0(^('_ (;CQ#_\
M@UZK10!Y5_PTMX1_Z!'Q _\ #<>(?_D&C_AI;PC_ - CX@?^&X\0_P#R#7JM
M% 'E7_#2WA'_ *!'Q _\-QXA_P#D&C_AI;PC_P! CX@?^&X\0_\ R#7JM% '
ME7_#2WA'_H$?$#_PW'B'_P"0:/\ AI;PC_T"/B!_X;CQ#_\ (->JT4 >5?\
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M3?#S_L3/$W_I=H->JUY5XC_Y.F^'G_8F>)O_ $NT&@#U6BBB@ HHHH ****
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M">58X[.Z:X1H0Y$3EFCC(=DVEDP0I)4,X&XV+VRM]2LY[2[@BNK2XC:*:"9
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M+:WEMX;T#2_#UO>73WUS#I5G';)/<. 'F<(H#2,%4%CR=HR>*VJ** "BBB@
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M/D8 43IC);YMNQ@#Z&_X1SXW_P#10_A__P"$'??_ "YH_P"$<^-__10_A_\
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M4WW[,_@+5+/2+:\M]>NCI>HC5K:YF\4ZJ]S]J4!4EDG-SYDI11M42,P0$A0
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M]EWQ=\,]#\&/H/Q!TA/%/ARSO=(;4+OPS++8WVGW$RS^7+;"^5Q+'*@994F
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MP\_[$SQ-_P"EV@UZK7E7B/\ Y.F^'G_8F>)O_2[0: /5:*** "BBB@ HHHH
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M>(_^3IOAY_V)GB;_ -+M!KU6O*O$?_)TWP\_[$SQ-_Z7:#0!ZK1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 5Y5XC_P"3IOAY_P!B9XF_]+M!KU6O*O$?_)TWP\_[$SQ-_P"EV@T
M>JT444 %%%% !1110!Y5XC_Y.F^'G_8F>)O_ $NT&O5:\*^+'@?3O'_[27PW
MT_4[G6+6WC\)>)+A7T36[W2IBPO-#4 RVDL3LN&/R%BI(!(RH(L>+O@M\._
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M_P#)U 'JM%>5?\,T^$?^@O\ $#_PX_B'_P"3J/\ AFGPC_T%_B!_X<?Q#_\
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M#V/@'XG^.K/XM:-X+\;GP[J\'B+PY-K^F:IX;M)[5;=X)84N+:5)9IO,7%U
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M_P $_"'PG7'AK3[JWVVR64)OM3NK\VMLF-EO ;B63R(1@8BCVI\H^7@5A_\
M"Y/%W_1"?B!_X'>'O_EK1_PN3Q=_T0GX@?\ @=X>_P#EK0!S'B3X!KJ^L:I*
M/ NDW=M=:K+JVZ3QWJUL)+E@5^TF!+<I'*4.WY2=H.T$@4>'/@&-(U;0Y/\
MA!M+LK73-3;4X&A\>ZM/]DN)&?S[B.%[<(TKB6;=DC?YCACAVKI_^%R>+O\
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M:;<Z3!=6_B?5(G%O<%FN-Q6Y&^21V\QYFS(TBHY8NBL#_A<GB[_HA/Q _P#
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M7XO\)>.O$R7_ (CB\;WNAZ:;+1YH[:&()&UO!))&KQPLP\S9Y\FZ0JVTMC
M/HZBO*[?]J#X9SZOJFG2>(VL'TZUO;V6ZU+3KJSLY8+.0174D%U+$L-PL3L
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MU6BO-=!_:*\#^);..YL+O6'C;6W\.NLWAW487@ODB$KI,CVX:)%0[FED"QJ
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M $ &W83N;=@;7_#0W@!?&W_"*2:ZT&J&[DL$GGL+F.PENHT+R6T=\T8MI)D
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M5A\,+S1UT+XJZGXE@T-KW3(1_9MW;WT<3(8KEXT$;7$0=/O ;MBO@ ^M^"/
M.HZ%^T1XNTZWD@?P+')'XOM[97/F6NKWB2V\\87IY;>7/<D?\];HMZ9Z7_A3
M?B[_ *+M\0/_  !\/?\ RJK%\)_LRWG@/39=/\,_%?Q9X=L)9FN9+72=%\,V
ML3RMC=(5CT@ L<#+8R<"@"]\7/"?B2^^,7PG\4:'HTFL6>C2ZE:7_DW,,)M4
MNH(T6=O-8;D4H<A%=N1A3S7E?PI^"OC:&/X+^'_$/A=M%U+X7ZA=3W'C-;NV
MF@UJW>WN8'6W"RFX#W+30S3>?&@!C;ESM)]@_P"%-^+O^B[?$#_P!\/?_*JC
M_A3?B[_HNWQ _P# 'P]_\JJ .%^/G@+5M>^.W@S7[+X877C/1K/PWK>EZQ=6
M[:8!<I=1HL-FRW-S&TBYCERK#RQYXYY?;YQ\#/AKXY^$\?P&#?!S6+8>$?!>
MKZ;K:Z;=Z,N^_N'M&&W_ $U?,:1K*1BYXS<1EB"9/+^@?^%-^+O^B[?$#_P!
M\/?_ "JH_P"%-^+O^B[?$#_P!\/?_*J@#PSX4>!?B=X#T'X):U>?#C5KN7P7
MI.H>'-5\,_VCIANRTZ6[QZC9M]K^SNH:%H2))8Y LKD*1PS/A#^SWXA^%GQL
M^&6I#X?M)I>EZ1XAAGU6RDL/+TE+_4/M=E8+NG69TMH_.BRB%%,_R95G*^[?
M\*;\7?\ 1=OB!_X ^'O_ )54?\*;\7?]%V^('_@#X>_^55 'R]X$^ ?B;0-/
M^&UA_P *(NM-L=)^*&J>*[ZVCDT,10V4@NELI"J7A#/$+BV 5<E!:-M^[%O^
MA/V6?".NZ1\,?$>B>-/!]UX>-YXCUJ]73=5FL[E9K.\O9KA 1;S3)C9-L96(
M^8,,%<,=W_A3?B[_ *+M\0/_  !\/?\ RJJOJ'P+\2:M87-C??&WQU>V5U$T
M,]M<:;X<DCEC8$,C*=)PRD$@@\$&@#YO_9<^&>H^.OAI\%HM/\%'PII7A.;6
M-0?Q%YEHMOJ N8;NU$,"12&;+-/&\AECC'^C8!?*M5KPC\$_BSJ6B?#SPO<^
M!(] MM ^&.L>!K_5M7UJV\IKJ>&S2*:!+9IG>)FMAC>(VVF0L%*HLON7@_\
M9ANOAYHXTCPK\5O%?AG2A(THL='T3PS:0;VQN;9'I 7)P,G'.*W/^%-^+O\
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M'7?%D^M+>;)(V1;$->3".V4I*^)(X7!E0*H'F"OI2O*O^%-^+O\ HNWQ _\
M 'P]_P#*JC_A3?B[_HNWQ _\ ?#W_P JJ /5:*\J_P"%-^+O^B[?$#_P!\/?
M_*JC_A3?B[_HNWQ _P# 'P]_\JJ /5:*\J_X4WXN_P"B[?$#_P  ?#W_ ,JJ
M/^%-^+O^B[?$#_P!\/?_ "JH ]5HKRK_ (4WXN_Z+M\0/_ 'P]_\JJ/^%-^+
MO^B[?$#_ , ?#W_RJH ]5HKRK_A3?B[_ *+M\0/_  !\/?\ RJH_X4WXN_Z+
MM\0/_ 'P]_\ *J@#U6BO*O\ A3?B[_HNWQ _\ ?#W_RJH_X4WXN_Z+M\0/\
MP!\/?_*J@#U6BO*O^%-^+O\ HNWQ _\  'P]_P#*JC_A3?B[_HNWQ _\ ?#W
M_P JJ /5:*\J_P"%-^+O^B[?$#_P!\/?_*JC_A3?B[_HNWQ _P# 'P]_\JJ
M/5:*\J_X4WXN_P"B[?$#_P  ?#W_ ,JJ/^%-^+O^B[?$#_P!\/?_ "JH ]5H
MKRK_ (4WXN_Z+M\0/_ 'P]_\JJ/^%-^+O^B[?$#_ , ?#W_RJH ]5HKRK_A3
M?B[_ *+M\0/_  !\/?\ RJH_X4WXN_Z+M\0/_ 'P]_\ *J@#U6BO*O\ A3?B
M[_HNWQ _\ ?#W_RJH_X4WXN_Z+M\0/\ P!\/?_*J@#U6BO*O^%-^+O\ HNWQ
M _\  'P]_P#*JC_A3?B[_HNWQ _\ ?#W_P JJ /5:*\J_P"%-^+O^B[?$#_P
M!\/?_*JC_A3?B[_HNWQ _P# 'P]_\JJ /5:*\J_X4WXN_P"B[?$#_P  ?#W_
M ,JJ/^%-^+O^B[?$#_P!\/?_ "JH ]5HKRK_ (4WXN_Z+M\0/_ 'P]_\JJ/^
M%-^+O^B[?$#_ , ?#W_RJH ]5HKRK_A3?B[_ *+M\0/_  !\/?\ RJH_X4WX
MN_Z+M\0/_ 'P]_\ *J@#U6O*O$?_ "=-\//^Q,\3?^EV@T?\*;\7?]%V^('_
M ( ^'O\ Y55RFD^#=7\(_M3>"O[5\=^(/&OVCP9XB\O^W8-.B^S;;[0\^7]C
MM+?.[<,[]WW%QMYR ?0%%%% !1110 4444 >5>(_^3IOAY_V)GB;_P!+M!KU
M6O*O$?\ R=-\//\ L3/$W_I=H->JT %%%% !65XI\,V'C+P[J.AZHMPVG:A"
MUO<+:W<MK(T;## 2Q,KID<95@>:U:* ,+P+X)TCX;^$=*\,:#%<6^BZ7"+:S
M@NKR:[>*(?=3S9G=RJCA06.U0%&  !NT44 %%%% &1XJ\+V?C+0[C2;^;4;>
MUG*EI-*U.YTZX&U@PVSVTD<J\@9VL,C(.02*MZ1I-GH.EVFFZ?;I:6-I$L$$
M$8^5$48 'X"KE% !7E7B/_DZ;X>?]B9XF_\ 2[0:]5KRKQ'_ ,G3?#S_ +$S
MQ-_Z7:#0!ZK1110 4444 %%?&W[,O[:'C[XU?M9?$_X7Z_X%M]%\/>&?M!MK
MZ&*=;B#RYUCC6Y9R48S*2Z[53A3C>.1]DT %%%?.7[0*+XV_:&^#?PX\029\
M":Q%JVJ7VENQ6#6KJTBC,%I. 0)8E666=H&RK^2I965"* /HVBOGSQUIO@[]
MEVSN-7\#Z=8Z'K6O2Z;H%EH,<IATBVDN+U((KLVB$+%$DET7D\D)YF3D[V##
MC?'W[2GQ7^&U[X@\+RZ-X1\1>*-(UOPW NI@W6FV-W8:M<O;J?)W7#Q3)+#(
MAS(ZA6$@#[3$P!]:T5\F?\-&?%+0=5UB/68_"%[IOAGQWI?@_4KBQL+J&;5%
MOFL\2PQM<.+0PK>(?F>X\X[AB':"\,G[2/Q?_M*[N!H_@B.P@^(C>!8]/,EX
M\LPD4"*<W/ C,;,I8>2_F D#RL!F /JK5]>TSP_#;RZIJ-IIL5Q<Q6<+WDZQ
M++/*X2*)2Q&7=V"JHY8D  DU?KYAA_:-\>6/A_3EN['P[J&IVWQ.A\":O?PQ
M7%K#);/<1J+BWMS)(RR%)5&UYB%(+?,,+7&:+\:OC/X8AUFY-_X4\6-J/Q4;
MPA$FH6MW8BRBW"+,>V:8%"%3"X780Y)E+_* ?:-%?*F@_M$?$Z#5[%=>B\)7
M.EV?Q!/@/4)-.LKJ*>_+Y\NZA5YV6U";H@T;&XW_ #D/'P*C\/\ [2GQ=\7>
M(+C6M&^'^GR?#N:ZUC3K.ZU2YM;/RYK-KB&&0W*WTLLPEFMB'B%C&T8D.&E$
M6Z0 ^KZ*^+M/_:8^+FO?#/2]4OF\):/?>*?AEJ/C/3GTVQN9CITUJEH2',DX
M$HE6Z+*H5?)8!2UP%W/VWQ#\5?$#PO\ L :KXEB\4V?_  FEKX..H?VW%I\J
MG'V??E5:X9A/L./.+L/,&_9CY* /INBOF36OC)\4;.'QC9Z%=>$M2U#X=Z':
M:IK<=]IES$VMR3127'E6V+H_8U\F+:)9#<;I&;*J$.[O_'_QJN=-^'7@/5]
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M60X /K6BOC_QE^TA\8_",7Q!$]IX&:3PKX/M?',C1VUXX\F3[3G3@#*OF/\
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M<J%!(!.6 /NM>5>(_P#DZ;X>?]B9XF_]+M!H /\ AI;PC_T"/B!_X;CQ#_\
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MX** /ECQ]#\"/BAK.I:EXG\#_$35)-42W34+4^"_%L5G>^0<PM/:I;+#*Z8
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MB@ HHHH *\J\1_\ )TWP\_[$SQ-_Z7:#7JM>5>(_^3IOAY_V)GB;_P!+M!H
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MFD47FA@QD7=O.FTE@V0@;*C# 9!Z#_A3?B[_ *+M\0/_  !\/?\ RJH\1_\
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MM\0/_ 'P]_\ *JC_ (4WXN_Z+M\0/_ 'P]_\JJ]5HH \J_X4WXN_Z+M\0/\
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M_HNWQ _\ ?#W_P JJ]5HH \J_P"%-^+O^B[?$#_P!\/?_*JC_A3?B[_HNWQ
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M"& ;&001Q0!YQ_PIOQ=_T7;X@?\ @#X>_P#E51_PIOQ=_P!%V^('_@#X>_\
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M;\7?]%V^('_@#X>_^55'_"F_%W_1=OB!_P" /A[_ .55>JT4 >5?\*;\7?\
M1=OB!_X ^'O_ )54?\*;\7?]%V^('_@#X>_^55>JT4 >5?\ "F_%W_1=OB!_
MX ^'O_E57*:3X-U?PC^U-X*_M7QWX@\:_:/!GB+R_P"W8-.B^S;;[0\^7]CM
M+?.[<,[]WW%QMYS] 5Y5XC_Y.F^'G_8F>)O_ $NT&@#U6BBB@ HHHH ****
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MZ'T+4OB+X4T?6I]&O_$^C6.KV]J+V;3[G4(H[B.W)($S1E@P3*M\Q&/E//%
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M<7%YX-U2%M#\0>*5N)KW4-,6Z$&ISO+#?2"WE\H*JNN]8ANWAPL00*S?0/\
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M5=-\#>(?#^I:XMUIGV>RU&_CA1+AO)NFD<%K<NSHC-\Z'!;<%^J/^%-^+O\
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MAB?>6U*"-HT\SY5WH[QG) *R,#P37$>/OAIX\U>75O%VF?#/5H[K7/'WAOQ
M_AR+4-,%W!:Z8]NTT\[&Z6#S91"RJL<LF0L19ERP3T_QM^RF?B9I\%AXO^)W
MB;Q78V\OGPVVMZ#X8O(HY,%=ZK+I# -@D9'.":Z%/@QXLC143XZ>/U51@*MA
MX=  ]/\ D$T >#>*/!/Q0U;XR:+K&J?"6?5_"^AZYKI.AZ,NAPZ9?V%W;74(
MG8SW7GSW,YE5IO,$,9WX,9*F5E_9O^$?C3X<R?L\Z?>_"R_T&/PMX>U;3M>O
M8;G2O)AN[IK;]X1%=%Y-YM2S,JL3YD>>=P7WK_A3?B[_ *+M\0/_  !\/?\
MRJH_X4WXN_Z+M\0/_ 'P]_\ *J@#C_B5X;\9^(/V@S/I7A76K?1)_!>H^&E\
M66UU8+#:75U+;RQSB-KI9]L?DL"1%NW;=H8?,/+=4^"'C'QAX&\,66I_"C^S
M-0\%^"M1\+SVL-UITMOK[S6\4$$=H// ^S!XOM!^U>2R%8PJ,S.5^@O^%-^+
MO^B[?$#_ , ?#W_RJH_X4WXN_P"B[?$#_P  ?#W_ ,JJ +?P=M=5\"_L]^$+
M&Z\)7UKK.B:!;6DGARWEL_M!E@A6,QQL)_L_S%,J3*%PPW%3D#S7X :I\2_
MOPO\$^![GX1Z]IFHV;QVU]J^I:CI+Z?;PF<M+(!!?/,Y$9.U1'RV,X&37?\
M_"F_%W_1=OB!_P" /A[_ .55'_"F_%W_ $7;X@?^ /A[_P"55 'D][X#^(^O
MZGH?C;PSX/U#P/XVTO7K^SE77KK3W6[T34I6,Q/V:YF5S;2"VN0CD9:W95#;
MSG*UKP/XUTW3?C[X?T+X1^)#IGB/P]%H7AZ4:CI&R7RK)[-6;=?AU4F02 N
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M>5>(_P#DZ;X>?]B9XF_]+M!H ]5HHHH **** "BOC;]F7]M#Q]\:OVLOB?\
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MJ?ED+, ,W0_VE_B%J>@^+()M'L8O&6E06=S)X;3P_J/]IZ='-=F&:4V;.O\
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MV\,^$/#.G^.]<\.>'M-U?7;XV\%I;7OVIIBD6ZYU6-[/;%;-F?%WO=F)CC"
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M9^T!X5\+^&K>P\,V^NZUI^MW6M_VYI-U)836EEJ+::85LI)$E0W!.YA*S>2
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M-NC&>.WM9XI VSAUFDDD5NJO(S#DDU?_ &7OA'X.^.W[/^F?$#QWI\&O^/\
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MX6TVWN+AH965VF<7#M\C+E8A%\P/G<5:TC]HCXI77B"ZGU'3?"%CH%G\1?\
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M5K97IU/Q/ +;5OM&K7D]O<1*-JJ+>25HHPJDJNQ%V@D# )%<3\1/CYXN\/\
MQ4U7P)X5^&P\27UCX<_X2-;[4-=BT^WN$$K1F%-L<T@<E=JED +9!VKASSGA
M3]L27QQK6I7&F>#/L/@K2O"VF^,;_P 0:SJJPRC3[N&:4M#;0Q3%W00,NUWC
MR5?D (9 #V/0OA'X4\.?#>7P%9Z8[>%9;.2PELKN[GN7E@D0HT;S2NTC#8=@
MRQ*J%48"@#F;C]EWX;7,FC2-HMXDVEV+:7'-#K5_'+<V;2F5K:[=9PUY"9"S
M&.X,BDN^1\[9Y&']I;7K::TM/%7PV^QIXA\.77B#P]!IFLQ7SWR01I)+9W(D
MCACM[CRY8C@/+$?W@$IV?-R$G[94?ASP1X$M_!7PKO\ 6+BX\&Z5XEE\-:#:
M7TJ:=9741^SVML;.PFC+J(9%59OLT>$7#CY@@![E=_ 7P7=^+[WQ+]AU"UU.
M^F6YNX['6KVUM+FX5 BW$MK%,L$DRA$VRLA=3'&P8,BD<U9_LA_#/3M/T6RL
M[3Q):0:+<75WIWV?QEK,;VLUR")W1UNPP+AGSS_RTD(P7;,NG_&KQ3XN\67-
MOX0\!1ZSX8TW4H=(U34K[6!87MO<-"DLC):-"P>*$31*Y:5)-PE"1/L4O#^R
MM\2O&OQ5\!ZOK/C/3])L9X]?U2PM?[+O7N 8[>^G@V,&@BP$\L(K98R ;V"$
M[  6O#W[*/PS\+OX9_L_2-3$'ANSGT[2[2Y\0ZE<6T%K-GSH3!+<-')&XP"K
MJP(1!T10+>C_ +,OP\T'PYJ>A6.EZC%IFH6/]EO&VNZ@[V]GD$VMK(TY>UA.
M%S% R(0J@C &/!O@_P"*M-^''A+3]%N?";^*[+4OC/KFCVU[J-TLYTR8:G=F
M*Z9YR\LDPV'##+$[BSJ>6]=TO]H;6;[3=1\93>"HX_A1:VNI78\1P:PLE\L=
MEOW22V)B4*DIBE\ORYI'QL+I'N(0 UIOV6OAM<6^@Q-HU^O]BZ:=&MI8]=U!
M)9M/+A_L=S(LX>[MP0<0W!D10S * S \3\0O@9XOUCXD:SJNDZ7I]QI%Y%:V
M]I-9?$'7?#$EG%%$$\N2UL$:*Y*N9'5R\9VN(^ @8\[<?MP:]I_@OQ9XBNO@
MYXB:TTFRM=1LIECO+.VNXII_*,;S7]G:A)D#1N5B$ZD2#:[;6(ZC7?VJ=4\)
M:?XS7Q'X0T_P]JF@7NEP ZAKY&G1P7Y(AFO;M+9OLNPJRR;4EC5MF)&5BX .
MZTCX>ZOJWQ(T7Q!XJL-(E'A.RN;'0M1ANWNKVZ-P(5FN)@T$:V[%8-OEHTH;
MS22PVC/4>/\ X;^'OBAI-KIOB2RDO;6UNX[Z#R;J:V>.9 0K"2)U8<,P(S@A
MB"""17A?C;]LJ]T'3](7P_\ #S4/%6O7VC'Q%_9.F27.H V+RRQVQBN--M+R
M%Y9A$2H=XXAG_78&:ZSPO^TLOBSXR)X%M_#\=D^V.26/4]4CL]6@B:R%UY[:
M=*JN\.YXX-\32$2>:'5!'D@&U:_LQ_#RS\.Z_H<>FZH=/US4X=9O!)X@U%Y1
M?12K+'<PRM<&2WD#QH=T+(?D7L!69:_L@?#"SU:RU./3]?:_L]476HKB7Q=J
M\CF]">6)W+71\Q]A9<OGAY!T=\^H^+O%&G^!_"FM>(]6E\C2M'LIM0NY0,[(
M8HVD=OP52:^8M&\3>+KS]J"/Q5>>!9(-8N/AGJ%YIFB6OB+[4+Q!>630P-YJ
MQPVMP2=L@4-'\R'SI<': >HQ?LE?#:WLI+:&U\1VXEN+NYDFA\8:Q'.[W11K
MH&9;L2%)6CC9T+;690Q!;FMB']G7P%#XRO?$XTJ\DU"]T\:3<VLVL7LFG2V(
M1T6U:Q:8VQ@42R;8O*V*9&8 $DUX7XT_:[\;W'AWQ%:>'-!\)+XI\/>,]#\.
M7\ECXH;4-/9+RXA1E2860990[202(\0,7+C>5"'TOQ-^T+KW@;XK^#O"GB+P
MIHMA8>)M472;.>/Q0DFI2O\ 9#*]S%8^0/,M4F @,AE60$AC$ 0" :$G[(_P
MRF\%)X3DTW6Y-"26TD2&3Q3JK21BU)-M$LQNO,6&)OG2$,(U<*X7<H8>B>+?
M NB^.O!][X7URUDO]%O(1;SPM<RI(R@@@^:K"0,"H(<,&R,YSS6OJ%];Z78W
M-[=RK!:V\;32RMT1%!+,?8 &OD'4OBQ-=_'#X<_%7Q-H$OAGPJ/!'B'6;29=
M8DO'?3$2SN \UIL6.WN/+;<RQF3(*J96V   ]XN/V:_AW<:Y%J[:%,EX+>VM
M;D1:G=QPZC';[O(%]"LHCO2FYL-<K(>3S72_$'X9^'_BAIMA9>(+>[D2PO%O
M[.?3]1N;"YMKA4>,21SV\D<B-LED4[6&5=@<@UY!<?M4:WX4:4>-/A\='-]X
M7NO%.@_V3JK:E]LCME1I[6X"VZ&"X1)H7Q&)T(,FUR4 >"^_;"M]+^'^C>*;
MK3O#:V&I:S)I<6J0^+[>31I5BMC-))'J C\M79DEBBCN!!O= ':$L!0!UMK^
MR/\ "VQL;"VMM$U&W>PO+J_MKV+Q#J2WL4ER2;E1="X\[RI6)9X=_ELQ+%2Q
M)I(_V0?A':Z+HFE6'A!='LM'M)K"V71]0N[%WMIF#303R02HUQ%(R@LDQ=6.
M20<FN:US]H[2O!?C'Q-J'B;X?2Z5J&A>!+/Q#<:K;2V]Y=W$4TS@V$!BR719
ME*AF959\D+MP[<]_PV;XKM='=[WX-:S!J3^(M(T&V>5[VPTZX%_*(DE6?4+&
MUF)CD^5T6W;!:,[MK%E /4-!_97^&/A>_P!-NM(\.S:<-.T:3P_;6=OJMXEF
MMA(#YL+6PF\I]Y)=F9"S/B0DN U2:'^R_P##KPYKNAZQ9:5J7VW1=.ETFS^T
MZ_J%Q%]DE_UL,D4D[1S*WRY\U6SY<?\ SS3;?^(WQ:F^$7PE?Q;XJTA!JD;6
MUJ=*T6:>_1[NXG2"&*-U@6613)(F66'?C.V-CA3X=JG[5/Q.UH>!(M(^'$?A
MR]U+QFOAZ\3Q%-J%A!>1&RFNHVM7N=-CE,;"&17D:!61H@JJXD\Q #UZS_97
M^&MCX9U?P_!HVH+I&IV)TN6W.O:@QM[(L&>TM6,^ZU@8JH:& QHX1592% $%
MS^R;\-+YF:ZTW6KHMID&C_Z1XHU60+:PNLD**&N3M9)%5U<?.KC<&#<U9\#_
M !>\3?$#Q-#<:3X)@F^'<]_?:<GB3^VE%W'):O+$\LED8@!"\\+QHR3._*,T
M: MM[_Q=J&L:7X9U*\T#2K?6]9@A:2UTZZO#:1W#CG891'(4SS@[#SCIU !Y
M7<?L;_"V\^U&XT_Q%/-=:A;ZM-<R^,=9:=KR!46&?S3=[PZB.+Y@<DPQ$Y,:
M%>S^)GP7\+_%U](;Q*FL2'29_M-G_9>OW^F".;C$I%K/'N=<?*S9*Y;:1N.?
M'M&_;"U#5+CPZ'\):7#;>(O D_C#39UUR=PUQ%$LAL)!]A!1C^]^<;FVP2'R
M\C:<'XL?M">*?"FF?&2XT;X=Z+X=^(?A?0]!>[UJ?44F6Y2\:Y5?*D6W+2I;
MR+)Y8F5-Q=R40<2 'L,G[,/@.;3KZSD'BB7[=-;3W-W)XRUEKR4V_F&!#<F[
M\[RT::1A'OV;FW;=P!&MK7P$\$>($\0?:],NDN/$%A::7JM]::K=VUW>6UL7
M\F.2XBE64\2.&.[,@.URP %?-S?$OQ)\%?C;\=/%4O@^#4T@T?PYJGB)?^$C
ME>"Q0)=+(EH\D)>9N2R1^5#&0CDM&Q"MZMXV_:@O?"MUXHUFU\(1ZK\//">J
MQ:-KVNKJOEWL$Q$1FD@L_)(EAA,\8=FFC;Y92J,%4N =-IO[,/@+2=6\*ZE;
M1^)!=^%D\K2&E\7ZO*MM'OW&,HUT5=#A597#!D54(**JB6[_ &9_AU=^(-5U
M8:+=6;ZO=->ZII^GZQ>VFFZE.V/,DNK&*9;:X:0 "0RQMY@^_NKCX?VF]<\F
MY>Y\&:?$;'XAP>!+T1:[(^U9C;B.[BS:+O.;E<Q-LQM.'-;/[,/Q+\<?$_1_
M&5YXSTS1]..F^)]3TBT&DZA)<_+;74L#QL&MXOE4QC;)DF3<6*Q<+0!U\WP5
M\)3^/V\926=\^M/<I>NAU>\^PO<) L"3M9>;]G,JQ(BB0Q[AL4@Y4$:\?@/3
M8?!K^&%N=:.FLCQF=M<O6OL,Q8D7IF^T Y)PPDR!@ @ "O'=8_:BUOPM\3[K
MP?K7@>Q%W)I&JZQIUAI?B>WN=6DBLW41&YM6CC2W6Y3>\;B:0#85;:V0,GPE
M^U=XV\:Z'I5SIWPH@35/$'@D^-= TJX\2CS+R*-[19X)&2V=8G;[6K0$;_,7
M;YHMV+(@!VN@_L@_"WPZWAD0:/JU[9^&;B.[T;3-7\2ZIJ-A831HR1216EQ<
MR0JR*[;#LRF<K@X-2ZO^R;\--;UI]5N-.UJ*Z;4;C5E2S\4:K;00WDXD$\\4
M,5RL<3R":7<45=WF-G.35_X6?&#4/BE+X?NK+2-+_L'4/#5GKESJ%MJLLDEO
M/<E]ELD3VR;U C<EV:-P1AHES4$WQ?\ $NL>/-6TCPAX*@\2:'H&KVVBZ[J,
MNLK9W-O/)%#-(UO;M$5G2&&YA=RTL;'+*BN5P0!O_#+'PY7P)X?\&II^LP^'
M?#]ZNHZ9:P^)M4C:VG5MR.)5N1(0C?,JEB$/*@&H3^R=\-S'.GV/Q %GUI?$
M,F/%NKC.H+TN,_:N&Z=./E7CY1C#TW]J"]O-4\/:I+X0C3X;^(]??PWI7B2'
M5?,NVN1*\$4L]F80(H)98G5&$SOAHRZ(6(7@/%G[8WB;Q!\"_'OBCP7H.AVV
MIZ)!""\OB&.>73GFF:'RKJV$!E@O(L9>&6/RMW"RRA30![#=_LK?#:\\00:T
MVDZG!J%OK4OB*)K7Q#J,$:7\C.SS"*.X"<F68[=NT>?/@#S9-S8?V5?AS;:2
MEA#8ZY$L>K3:[#=IXIU47L%[-')'--%=?:?.C,BRR!U5PK[R6!/->GZ+-J-Q
MI%G)J]K:V.J-$IN;:RN6N8(I,?,J2M'&SJ#T8HI/]T5=H \<L_V0_A-I>C1Z
M3IGA:31=,!G,UII&JWME%=K,^^9+E89E%S&YP"DV]=JJF-JA1WGCSX;>'OB5
MH=OI'B"RDN;&WN8KR!;:[FM)(IHSE'22%T=<<C@X()!R"173T4 >>:?^S_X"
MTGQE/XFLM#:TU">\&HRVL-]<II[W@14%T;$2?9O/VHO[[R]_R@[L\UZ'110
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MC_\ ':/^&L?@A_T63X?_ /A46/\ \=KU6B@#RK_AK'X(?]%D^'__ (5%C_\
M':/^&L?@A_T63X?_ /A46/\ \=KU6B@#RK_AK'X(?]%D^'__ (5%C_\ ':\T
MU_\ :;^#TW[27@74X_BOX'?3;;PEXAMI[Q?$=F88I9+S16CC9_,PK.L,I52<
MD1N1]TX^H** /*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%18__
M !VO5:* /*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%18__ !VO
M5:* /*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%18__ !VO5:*
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MJ>D?M0Z=ID-]-#>:GIL/B_1FM]1O(XT3[5(7C:1'?RXRZPO'&Y3YD(9PW,^
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MWK'[/WAVQ2W;]I;3-4FL=+DT;0[V]\9Z2+G0K20IO2UDC5&9B(81YD_FR8B
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M6*+@"-(U^6NA_P"&L?@A_P!%D^'_ /X5%C_\=KU6B@#RK_AK'X(?]%D^'_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
A10 4444 %%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>brns-20231231_g1.jpg
<TEXT>
begin 644 brns-20231231_g1.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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M /$5^,=%'^KN7?\ /I?>_P#,/[4Q7\_Y?Y'[.?\ $95\0?\ HB?@W_P=W/\
M\11_Q&5?$'_HB?@W_P '=S_\17XQT4?ZNY=_SZ7WO_,/[4Q7\_Y?Y'[.?\1E
M7Q!_Z(GX-_\ !W<__$4?\1E7Q!_Z(GX-_P#!W<__ !%?C'11_J[EW_/I?>_\
MP_M3%?S_ )?Y'[.?\1E7Q!_Z(GX-_P#!W<__ !%'_$95\0?^B)^#?_!W<_\
MQ%?C'11_J[EW_/I?>_\ ,/[4Q7\_Y?Y'[.?\1E7Q!_Z(GX-_\'=S_P#$4?\
M$95\0?\ HB?@W_P=W/\ \17XQT4?ZNY=_P ^E][_ ,P_M3%?S_E_D?LY_P 1
ME7Q!_P"B)^#?_!W<_P#Q%'_$95\0?^B)^#?_  =W/_Q%?C'11_J[EW_/I?>_
M\P_M3%?S_E_D?LY_Q&5?$'_HB?@W_P '=S_\11_Q&5?$'_HB?@W_ ,'=S_\
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M8+:XNEFDN6B4NMO$)'8AU3S"AKEOC!_P3B^,_P !?AOJGBKQ5X-_L[3/#_\
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M_P!$3\&_^#NY_P#B*_&.BC_5W+O^?2^]_P"8?VIBOY_R_P C]G/^(RKX@_\
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M\'=S_P#$5^5^N?\ )F_A?_L<]8_](=+KS.LZ?#V7-.]);OJ^_J5+,\2GI/\
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MN=8N-L:VMO8RJX.S.6-VP([;!ZURG_$95\0?^B)^#?\ P=W/_P 17Y8>)/\
MDS;P9_V.>O\ _I#HM>95G3X>RYK6DMWU??U'+,\2G\?;M_D?LY_Q&5?$'_HB
M?@W_ ,'=S_\ $4?\1E7Q!_Z(GX-_\'=S_P#$5^,=%:?ZNY=_SZ7WO_,7]J8K
M^?\ +_(_9S_B,J^(/_1$_!O_ (.[G_XBC_B,J^(/_1$_!O\ X.[G_P"(K\8Z
M*/\ 5W+O^?2^]_YA_:F*_G_+_(_9S_B,J^(/_1$_!O\ X.[G_P"(H_XC*OB#
M_P!$3\&_^#NY_P#B*_&.BC_5W+O^?2^]_P"8?VIBOY_R_P C]G/^(RKX@_\
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M=_X.KG_XBOSQ\5?\$G/C[X,^&%]XPU#P/:KHVF^%[;QK<I!XCTJXOX=$N/\
M5:@;*.Y:Z^SG#9<1838^[;L;#=*_X)1_'K6OA'-XXM_!5F=!M_![^/Y1)XDT
MJ+4(M 5'D&I-8M<BZ6!UB<HQB_>;2$W&J_L?([7M'M\77MN+ZYCN[^[_ (!^
MB'_$9'\0/^B*>#O_  =7/_Q%'_$9'\0/^B*>#O\ P=7/_P 17XS45U?ZLY9_
MSZ7WO_,R_M+$_P WY'[,_P#$9'\0/^B*>#O_  =7/_Q%'_$9'\0/^B*>#O\
MP=7/_P 17XS44?ZLY9_SZ7WO_,/[2Q/\WY'[,_\ $9'\0/\ HBG@[_P=7/\
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MTN^U7X<ZK:1I#)<::TE\GF">-YA]I1K2>'RD\L9E+Q+^U!_P6;^#/[2_BO\
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M*?\ H6O$'_@NF_\ B:.>/<.5G/T5T'_"J/%/_0M>(/\ P73?_$T?\*H\4_\
M0M>(/_!=-_\ $T<\>X<K.?HKH/\ A5'BG_H6O$'_ (+IO_B:/^%4>*?^A:\0
M?^"Z;_XFCGCW#E9UFG?\F;ZQ_P!CG8_^D-Y7US^VO+K _P""8_["Z?"MM?\
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MF_\ B:/^%4>*?^A:\0?^"Z;_ .)HYX]PY6<_170?\*H\4_\ 0M>(/_!=-_\
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M%TW_ ,31SQ[ARLY^BN@_X51XI_Z%KQ!_X+IO_B:/^%4>*?\ H6O$'_@NF_\
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M  73?_$T?\*H\4_]"UX@_P#!=-_\31SQ[ARLY^BN@_X51XI_Z%KQ!_X+IO\
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M)_X3C2?^?Z']?\*/^$XTG_G^A_7_  K6HH R?^$XTG_G^A_7_"C_ (3C2?\
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M^@A;_F::_4?[H_E3: )/^$^T?_H(6_YFC_A/M'_Z"%O^9J.B@"3_ (3[1_\
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M #_0_K_A6M10!D_\)QI/_/\ 0_K_ (4?\)QI/_/]#^O^%:U% &3_ ,)QI/\
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MVX_^U** ";_D>+?_ *\9?_1D=:U9,W_(\6__ %XR_P#HR.M:@ HHHH ****
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M1_!279'G#3H3&K190>7EW<E>6+. X<I0L[?UN$8RZ_UL>7?MX_MJ>)/V4?\
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M/?\ RO?_ '/7Q;11_J!D/_/C_P GG_\ )!_Q%CBO_H*_\IT__D#[2_X>^_\
M5/?_ "O?_<]'_#WW_JGO_E>_^YZ^+:*/]0,A_P"?'_D\_P#Y(/\ B+'%?_05
M_P"4Z?\ \@?:7_#WW_JGO_E>_P#N>C_A[[_U3W_RO?\ W/7Q;11_J!D/_/C_
M ,GG_P#)!_Q%CBO_ *"O_*=/_P"0/M+_ (>^_P#5/?\ RO?_ '/1_P /??\
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M .2#_B+'%?\ T%?^4Z?_ ,@?;W_#Y+_JG/\ Y7__ +FH_P"'R7_5.?\ RO\
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MG*Y]2^(__!,[P'\3_!^DZ)J&K>+H;71OAO>_"^![>ZMUD;3+M+5))F+0$&Y
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M0 4444 ;#0I<VICD19(Y$VLK#*L",$$>E9'PW^'6C_"3P+I?AGP_:R6.AZ+
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M>/\ YYI_WS0!0_X3+1_^@KIO_@2G^-'_  F6C_\ 05TW_P "4_QJ_P#9X_\
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MX3+1_P#H*Z;_ .!*?XU?^SQ_\\T_[YH^SQ_\\T_[YH H?\)EH_\ T%=-_P#
ME/\ &C_A,M'_ .@KIO\ X$I_C5_[/'_SS3_OFC[/'_SS3_OF@"A_PF6C_P#0
M5TW_ ,"4_P :/^$RT?\ Z"NF_P#@2G^-7_L\?_/-/^^:/L\?_/-/^^: *'_"
M9:/_ -!73?\ P)3_ !H_X3+1_P#H*Z;_ .!*?XU?^SQ_\\T_[YH^SQ_\\T_[
MYH H?\)EH_\ T%=-_P# E/\ &C_A,M'_ .@KIO\ X$I_C5_[/'_SS3_OFC[/
M'_SS3_OF@"A_PF6C_P#05TW_ ,"4_P :/^$RT?\ Z"NF_P#@2G^-7_L\?_/-
M/^^:/L\?_/-/^^: *'_"9:/_ -!73?\ P)3_ !H_X3+1_P#H*Z;_ .!*?XU?
M^SQ_\\T_[YH^SQ_\\T_[YH H?\)EH_\ T%=-_P# E/\ &C_A,M'_ .@KIO\
MX$I_C5_[/'_SS3_OFC[/'_SS3_OF@"A_PF6C_P#05TW_ ,"4_P :/^$RT?\
MZ"NF_P#@2G^-7_L\?_/-/^^:/L\?_/-/^^: *'_"9:/_ -!73?\ P)3_ !H_
MX3+1_P#H*Z;_ .!*?XU?^SQ_\\T_[YH^SQ_\\T_[YH H?\)EH_\ T%=-_P#
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M:7?XAS2Z'ZF4445SFP4444 <AXD_Y'>X_P"O&W_]&3U%4OB3_D=[C_KQM_\
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M^3/$[B3-\+Q+B:&%Q52$%R6C&<DE>G!NR325VV_4]I_X>&_&'_H</_*59?\
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MO_!L_P#Y(]I_X>&_&'_H</\ RE67_P 9IT7_  42^,4,BLOC##*<@_V58_\
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M_P",UXA11_J[E7_0+3_\ C_D'^N&??\ 0;6_\&S_ /DCV_\ X>.?&;_H<O\
MRDV/_P 9H_X>.?&;_H<O_*38_P#QFO$**/\ 5W*O^@6G_P" 1_R#_7#/O^@V
MM_X-G_\ )'M__#QSXS?]#E_Y2;'_ .,T?\/'/C-_T.7_ )2;'_XS7B%%'^KN
M5?\ 0+3_ / (_P"0?ZX9]_T&UO\ P;/_ .2/;_\ AXY\9O\ H<O_ "DV/_QF
MC_AXY\9O^AR_\I-C_P#&:\0HH_U=RK_H%I_^ 1_R#_7#/O\ H-K?^#9__)'M
MDW_!1/XQW$A9_&&YCW_LJQ_^,TS_ (>&_&'_ *'#_P I5E_\9KQ:BC_5W*O^
M@6G_ . 1_P @_P!<,^_Z#:W_ (-G_P#)'M/_  \-^,/_ $.'_E*LO_C-'_#P
MWXP_]#A_Y2K+_P",UXM11_J[E7_0+3_\ C_D'^N&??\ 0;6_\&S_ /DCVG_A
MX;\8?^AP_P#*59?_ !FC_AX;\8?^AP_\I5E_\9KQ:BC_ %=RK_H%I_\ @$?\
M@_UPS[_H-K?^#9__ "1[3_P\-^,/_0X?^4JR_P#C-'_#PWXP_P#0X?\ E*LO
M_C->+44?ZNY5_P! M/\ \ C_ )!_KAGW_0;6_P#!L_\ Y(]I_P"'AOQA_P"A
MP_\ *59?_&:_3NOQ;K]I*_*?$[+L)A?JWU6E&%^>_+%*]N2U[)7M=G[UX(YQ
MC\=]=^O5YU>7V=N>4I6O[2]KMVO97MO9!1117Y2?O 4444 %%%% &T_4?[H_
ME3:<_4?[H_E3: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#:C_U:_2G
M5\Y_\%;_ /E&#\=/^Q,U#_T2:^<?$7[.$FGZ;=>+/ _P"'[/_AG0?AEXFA\3
M7(30;$^+C<Z>@MK<P:5<W'G".2-I_,N-AC*X3/F.*TC"ZN2Y6=C]&J*^!_V7
M/VPO'7P#^$OA_P -^-KWX;OHNG_ 2W^(6AWRVU[ID.DK:1P0?9+^;S+EKA2)
MH"9X((V^60+ Q*+4W@;_ (*+?&+Q)H7QATK3O#FG^-O%7@/2/#^N:5+9> -:
M\/275K?W$\5XXT>_N?METULEO)+&B20M=!2B;6*ECV;#G1]Y45\*^(O^"GGB
MC1_AWX7TBSU#PSK7C[Q'XYN_"T]_9?#[Q(_]BVUO92:@TMSX:.-56Z:!%18%
MD9,2"<S",,@^D/V+?C=XH^/GP276/&7AK4/#.O6>IWFF2K<Z+>Z-'JD<$S)%
M?PVEZJW,$,\>R18Y<LFXJ6?;N,R@TKL%),]:HK\X]7\ ZM\-Y/\ @H!INN>,
M/$/CK5#\*].GN-5U<Q*[N^DZTQ2**%$B@@4DA(D7 '+%W+.W2Z3^UK\3?@5\
M%AX'\1-X/U'6M7^#D/B'P7=:#:W%BUCJ#26NF6^G7#RS2K<,US?V(2ZC\C?B
M4_9U^457L^P<Q][T5\&_M*_L<?#OPH_@'X9_#;PU9W_QV(T"33_$BN[:GX)T
M33'MX6OS<L7:QM#%:O!':Q%$N9II@L;_ .DNO=?\%>O#&L>.OA]\)/#]I<>%
M7T7Q'\3M#TS5=.U_0GU>RU)7F+1+-"+B%9(5D0,\39\S"C<FTY.5-H.8^N**
M_.7]E']IOQ]:>&OA[\.?A9I/PO\  NG:S8?$#Q!-]NTG4M4M[1]-\436ZK%'
M]OC?]\9G=PTNU6<E J*L)V/BE_P5=\:_\,L>"_''A?\ X1'3_$6K?"Y_B%J&
M@OX1USQ/-<2^7E(B]F\,&F61DCF7[9=SN/\ IG^[9F/9N]A<ZM<_0*BOE']A
M+QDOQ%_;$_:&\0+;M:KKMMX.U!8"^\PB;1%DVEL#.-V,X&<5X[^T=\>/'G[1
MNI>"]>W>$;'X=Z#^T=I'A&TTDZ=<KK8?3M7%J][)=F<Q$27$4N+;[*C+'(C&
M8LA1SV>MA\VA^B%%?"?AW_@HKX\^(GQZT_PEI>J>#[[1/'5MXJL])U&Q\$Z[
M;VFAW6G1RM:RKJ=W+!!K*,(9!*+.*%4<8$H&QY//?A7^WM\4OA1_P3W^#TZ^
M,/#OB+QOJ'PTN?&$[:AX-\0>*M4U18A&+=+D6DX2UC8L4EU&[N5C+\B%5#E#
MV3%[1'Z745\[_M!?MC:Y\/?^";Q^-GA[2=*DURX\.Z7KEMINHM(]JK7;6V8G
M9"KX F(W#N <'H?)/VBOV^?BY\&?BYJ7P[TBUT7Q5XJ\$^$HO$NJS:7\,O$.
MJP^*KJYGN!:Z?;16$]P=)'E6KJUS=RSJTDJE8@L;BE&FV-R2/N.BOAO]JK_@
MIQXO^#VN->Z%:Z*MKH5IX<O=:\*W7@[6]0U2%=1GC^T0WFJ1F'3M(FCMY"8X
MY_/>1D^X"Z1MR/[?WQU^('Q\^#'Q3-BW@_3?AO\ #_XJ>&?"%Q8W%A<R:Y?3
MP:SHLTEVMR)Q#&GGSQHL+6[%HU:3S02J%QIMASH_1*BOCOP%^WSX]\4>,O!_
MBJXL?!X^%7C_ .(VH_#C3M*2VGC\1:;+:O>01WTUR9S#*)9]/G+6PMXVCCFC
M(DD*,7PM"_;]^(OQ5^"'P3N+6/PEHNM?&+2/%C7MVMA<RQ:9-IUK</;/!&+E
M&QNC4N&D)(SM9#@@]FPYT?<-%?&OP*_:+\9?"C_@ACI?Q4U[6F\4>,M'^%C^
M(H;^:&5Y;F<6+2VYN#++*TL@/EB64MAR'?8@.P9EQ^SWX73]JOX:?!'QQ;V&
MO?#;P3\,KOQ,FE:PJS:;XFUK[;'!>:A>Q2#R[N2,2O.?-#!9;UIB-^UU.0.8
M^W:*^&_A/H?PML/$7[17@;Q#/HDG[./@2?0/%5C8SWY_X1[2OM=D;VYM%57\
MM[ E;>Y%HVZ#_3,+'L9%'J/_  3/^%UY\/OA[XXU.W\.S^!? _C3Q7/KG@SP
MC+;BU/A[2WM[>,?Z, !:?:9HIKHVH \K[3AE60R*$XV!2/I.BOBVQ^!7@F]_
MX*$>#F^#?AVTTS5?AWJ>HZA\3_&-L3)/?B\LY@FBW=W(6EO[B2>:"Y,<CO\
M9H[>)OW9:!3Y-^P7X8MG\5?LXZU':3:?XA^/G@'Q?=?$6^L;M[34-<N!<V,Z
MW$]Q"RS>?!-<S1Q3*ZR0K,51E 4!\@<Q^E=%?!_P?U+X:_LP?$CXF?&CX<^'
M](\$_L]^"_!8T*YET:*+3].\:ZQ;WC-]JMXU"QS" 9M1?2$"62XD4.R1;ZX/
M]BJ;0?VH]:_:^\.WWQ(\*^-O$GBIM(\0#4-#UBWOX]-NQI<,T4MBT3-F'3KP
M110RC)5K2(L3)N)/9]1<W0_2RBO/?V1_BW=?'W]E3X:>.;Z/R;[QEX6TS6[E
M A0)+<6L4S@#TW.<8X(P1QBO0JSVT+,G_F>/^W'_ -J44?\ ,\?]N/\ [4HH
M )O^1XM_^O&7_P!&1UK5DS?\CQ;_ /7C+_Z,CK6H **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH RI?^1W@_P"O&3_T9'6K65+_ ,CO!_UX
MR?\ HR.M6@ HHHH \8^'_P"W;X$\9?%'7O!E]??\(_XAT35+G3%BOV"0WQAE
M:/?%+]W+;0=C;6R< -C->SU^,7[4G_)S7Q&_[&?4_P#TKEKZ7_X)R?&3XX:Q
M?V^FZ;8R>*?!%LZP33:O,8HM/48R(K@@N2!@>6 X Q\JYS7AX7-I2J>RJ1OK
MNOU1^3Y!XAU:V.EE^,I.3YFE*";=D_M17XM?=U/T&HHHKW#]8.3^*GQS\)?!
M+3X;GQ3KEGI*W3;8(WW233GOLC0%VQQR%."1ZBCX5_'+PE\;=/FN?"VN6>K+
M:L%GC3='- 3TWQN ZYP<;E&<'T-> ^&_B0/!'Q'\>?$[7/#EQK0L/%]SX6OM
M21]\WAK2K>.,121P[23&SR%Y"I!VL&PW-<O\1KRX^,WQP^'?Q4BT.UL/#LGB
M[3] T7SK8QWVNPL[.U](<JPC0Q!HE;/ +$ 'GRY8Z2=U:U]K.]N]]OP\KW/C
M:G$E6,^:"35[<EI*7+>W.Y;6\E%Z^[S<Q]I4445ZA]D%%%% &5JG_(UZ3_N3
M_P EKGM/_9S\&Z5^T'J'Q4M]'\OQYJFBQ^'KK5/M<Y\VQCE\Y(?)+^2,2<[@
M@<]"V.*Z'5/^1KTG_<G_ )+7C7Q3_P""@G@OX&_'#QIX9\7ZMH>CZ3X%\'Q>
M,-4ND;4;G4+:V>Y$&]K:.Q,)BW$ -'<R2D\&%5^>JC=["=NIJ_M1?\$^/@U^
MVEXB\-:M\4/ >E^+=0\(R&33)KB:>'RP65S'((G03Q%D!\J4.G+?+\S9^=OC
MW_P1"\!_%3XN? C1['PWX=7X#_#&R\1V^K>&+S5M0-U(VI*)(OLKY9U"7.9#
M^_CV#&P$?+7>G_@MI^SCKWPV^)/B#PO\0K3Q2WPOTEM6U6TM;"\BDD0R+!'Y
M320@2J\[Q1^9'O1#*A8JI!KC/@?_ ,%Z?@WK_P"REX=^*7Q2U[P[\-8?%6IW
M&G:=I=E<ZEKUSN@BB>59%73X9 \;2[7,<<D S'B9B^U=(JHMKD/D>Y[SX)_X
M)U?!?X<:/\-]/T+P-9Z79_"2]GU+PK';WMTO]G7,Z[9IG/FYN'<'DSF0]^M)
M\-?^"=7P;^$&M?#_ %#P[X/_ +/O/A;=:O>>&)/[6OIO[,EU5=M^V))F$OFK
MQB4.$_@"5F?'W_@J9\ /V8O ?A/Q-XT^)FC:;HOCJW%YH,]K!<:DVI0%0WG)
M';1R2"/! WLH4$A<YXKB/''_  6=^#/A']KCX7_":WU=M5N/BC9VUW8:U:QR
MRV"F\98]/B4QQL9&N)&QGY4C'+N.@FU1]Q^ZCL/@Y_P2C_9Y_9^^/]Q\4/!O
MPNT/0_&TS3NE[#-</#9M-_K&M[9Y#;VY(RH,,:%59E&%9@=CP5_P3G^#7P[\
M.?#W2='\&_8]/^%>KW.O>%XO[6OI/[+O;AG::7<TQ,NYI'.V4NHSP!@5PFC?
M\%?O@SX9_9 \$_&#XA^-O"OA;1?'5Q=VVF?V8^I:I'>O;7,L$GD))86][(J&
M,>8[6B*C.!DAD=^A\:?\%8?V>?A[\&_"/Q U;XG:1!X.\=)<OHFIQVEU<1W;
M6\7FS1,L<3/%,J_+Y4JI(7_=A2_RT?O/,/<(?B)_P21_9X^+'P^U'POXA^&]
MKJ6BZKXIN_&MQ&VJWZ3'5KI0MQ<).LXEC60*NZ)'6([%.S*@CH-*_P""<?P4
MT+]GKQ?\)['P'8V?PZ\=:C)JNL:%#>726LMQ(869HL2[K=0T$15(#&B%,JJD
MG/6?LQ?M5_#_ /;*^%4'C;X:^([?Q1X9N+B6T%W';S6[)-$</&\4R)(C#(.'
M495E895@3Z%4N4EHQ\L=T>:ZU^Q_\.?$"?#-;KPVC)\'9(I?!ZI>W$:Z,T<
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MS7D:MX/RK-@C^U;[_P"/4?\ $4LJ_P"?=3[H_P#R8?\ $"\^_P"?U'_P*?\
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M7W_QZC_AW'\&?^A-_P#*M??_ !ZC_B*65?\ /NI]T?\ Y,/^(%Y]_P _J/\
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M5O?_ (]1_P .\O@]_P!"?_Y5;W_X]1_Q%+*O^?=3[H__ "8?\0+S[_G]1_\
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M_"C2O$WA[7? MWXELM/NK9-1U*[N(+RUOBTEJ&$<BA\,6V2; "6<Q]-\%?\
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M_='\J;3GZC_='\J;0 4444 %%%% !1110 4444 %%%% !1110 4444 ;4?\
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M  B:?\_^K?\ @6U:U% &3_PB:?\ /_JW_@6U'_")I_S_ .K?^!;5K44 9/\
MPB:?\_\ JW_@6U'_  B:?\_^K?\ @6U:U% &3_PB:?\ /_JW_@6U'_")I_S_
M .K?^!;5K44 9/\ PB:?\_\ JW_@6U'_  B:?\_^K?\ @6U:U% &3_PB:?\
M/_JW_@6U'_")I_S_ .K?^!;5K44 9/\ PB:?\_\ JW_@6U'_  B:?\_^K?\
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M6G10!F?\(PO_ #^ZG_X%-1_PC"_\_NI_^!35IT4 9G_",+_S^ZG_ .!34?\
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M4V@#,_X1A?\ G]U/_P "FH_X1A?^?W4__ IJTZ* ,S_A&%_Y_=3_ / IJ/\
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M]&1UK4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 94O\
MR.\'_7C)_P"C(ZU:RI?^1W@_Z\9/_1D=:M !1110 4444 %%%% !1110 444
M4 %%%% &5JG_ "->D_[D_P#):U:RM4_Y&O2?]R?^2UJT %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 <AXD_Y'>X_Z\;?_ -&3U%7RG_P5
MD_X*@_\ #MSQOX/_ .*'_P"$S_X3.QG_ .8S_9WV/[+(O_3"7?N^T?[.-G?/
M'R3_ ,107_5#_P#R\O\ [AKTL/E&+KTU5I0NGYKTZL^HR[@S.,?AXXK"T>:$
MKV?-!;-IZ.2>Z?0_6*BOR=_XB@O^J'_^7E_]PT?\107_ %0__P O+_[AK;^P
M,?\ \^_QC_F=O_$.^(?^@?\ \GA_\D?K%17Y._\ $4%_U0__ ,O+_P"X:/\
MB*"_ZH?_ .7E_P#<-']@8_\ Y]_C'_,/^(=\0_\ 0/\ ^3P_^2/UBHK\G?\
MB*"_ZH?_ .7E_P#<-'_$4%_U0_\ \O+_ .X:/[ Q_P#S[_&/^8?\0[XA_P"@
M?_R>'_R1^L5%?D[_ ,107_5#_P#R\O\ [AH_XB@O^J'_ /EY?_<-']@8_P#Y
M]_C'_,/^(=\0_P#0/_Y/#_Y(_6*BOR=_XB@O^J'_ /EY?_<-'_$4%_U0_P#\
MO+_[AH_L#'_\^_QC_F'_ !#OB'_H'_\ )X?_ "1^L5%?D[_Q%!?]4/\ _+R_
M^X:/^(H+_JA__EY?_<-']@8__GW^,?\ ,/\ B'?$/_0/_P"3P_\ DC]8JL:7
M_P A&'_>%?DK_P 107_5#_\ R\O_ +AKZ,_X)A_\%D?^'AO[0FH>"_\ A7/_
M  B']EZ)+K?VS^W_ .T/-\NXMX?*\O[-%C/VC=NW'&S&.<C.MDV,I0=2I"R6
M^J_S.7&\$9UA*$L3B*/+"*NWS0=EZ*39]W4445Y9\H%%%% !1110 4444 %%
M%% !1110 4444 %%%% %'6/^0@_T7_T$55JUK'_(0?Z+_P"@BJM !1110 44
M44 %%%% !1110 4444 %%%% !1110!M/U'^Z/Y4VG/U'^Z/Y4V@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH VH_]6OTIU-C_P!6OTIU !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% &3_ ,SQ_P!N/_M2BC_F>/\ MQ_]J44 $W_(\6__ %XR_P#HR.O-
M_P!M_P#:UL_V+_@+<^+Y='G\3:O<WUMH^A:#;S>3<:]J-S($AM8WV/M8_,Q.
MUL+&V 3@'TB;_D>+?_KQE_\ 1D=?+_Q\_9Q^+G[1O[>OA_Q-9S>&O"/@7X-V
M(N?#,_B#3/[=MO$>KWD3I<7(M;>^MY(_LL6V-&G92)"S(K [UZ<)"G*I>J_=
M6K\_+OJ]--E=]#EQE2I&G:BO>>B\O/731:ZZ-V74]6_9P_;+\-_&_P#94\!_
M%/6KC2/!%CXY@@$-OJ.JQB.*ZE<QK:K,XC$DAD4JH"@L>B]JC_:-_;]^$?[+
M7@'Q-KWBKQOH ;PK*EI>:797\-QJC7<B[HK1;</N$T@(8*^T*F9&*1JSK\;^
M!_V-/C=\./V;_P!GOP?J7@6\\1:7\(?BK?>)=2TW1M1TR&ZNK*"XN;C39X!<
M7:1>49)R?)>?>@" @[1B/4_V'_C!XA^$<.K>(?AFM]XB\9_'Y/'WC#0].UFP
MENHM!@):&VCEEGA@E0^1",&57^<$IG.ST?J6%]HVYKEN]$UM?3?R6_FCR_KV
M+]DDJ;YK+5I[V5]O-[>3/O27]J;X:VGB?0="NOB#X'L_$'BBWM[K2-*FU^T6
M]U.*?_4O!%YFZ99#D*T>X-@[2:Y^7]JZQT+XY>-O#WB ^$?#OA/P7:::9_$5
MYXOL5D^VWQ/E6DUGD26I8;2CS%?.+ (&ZU\??%G]A#XK>-;3XW?#F'P3;S_\
M+F^*%OXG_P"%DRZE9O:Z3HL;P3Q1^49A>_:K;R&@C183'F9CYBKEJ3XB?\$^
M/B9\8/%_C4:]X1CETGXF?'NQUC7EDU*R>.7P?ID(2WD==Y+><PQY.#(HQN09
M.)C@\-UFMNZ\M5KVNK/MYERQN*Z4WOV?]Y6>G?E=UWT>CO\ :%A^VO\ !K5;
MRPM[7XM_#&XN-4OFTRRBB\4V+O>7:F,-;Q@2Y>4&6(%%RP\U./F&;WB#]K+X
M5^$_%/\ 8>J_$OX?Z;K9O&TX:?=^(;2&Z-RHC9H/*:0-Y@$L1*8W 2(<?,,_
M#-W_ ,$ZOB-XN.LM?>![73Y/B+\?[3Q-XA==1LLV7A'3239)\DGS9P0L:[F3
MS3E!S3+'_@G)\1/']SITWBKP%8)-X^^/D_C_ ,<22W]E,T6@V?G?V=:2%9"9
MH3OXC3>R^8VX+N:CZEA=_:?BOZ[^NG</KV,V5/\ !_UV]->Q]WZ'^U'\,_$_
M@C_A)M-^(O@74/#?]H)I7]K6VOVLUC]L?:$MO.60IYS;TQ'G<=ZX'(JWJW[0
M?@'0+[5+6^\<>$+*YT.\MM/U**?6;>.33[FYYMX)E9P8Y)<C8C89_P"$&O@&
MZ_8F^,<%AH_B#4OA[=ZM-K'[05U\3O$VA:9JVG?;O[/@##3D1I[J.WD3**S(
M9@WSKE>& ?;?\$__ (J?&-+3_A.OA_86MO\ $/X\R>//&MC)JUG>0VGA^T@*
M6-G*0^+F-R.51=QW?,J D!?4</NZBMZK^NC]=.X_[0Q.RI._H_\ +NUZ:]C[
MV\.?M(?#OQC\/M5\6Z1X]\%ZIX5T*22+4M:L];MI]/T]XU5W6:=7,<9571B&
M8$!U)X(K6^&_Q3\,?&/PO'KGA'Q'H/BK199&B34-'U"*^M7=3AE$D3,I(/!&
M<BOSR^(W_!.KXK>._ 'Q#UP:'>:=K6M?'JV\:C1+'4-,^U:KX:L5\BT2$3^;
M8_:/F$_E77[MO)"N,X!^G_\ @GQ^SYK7P'\#>/M>\0:5XHL?$GQ \377B*\L
M=8UK3-2OYF*+&DLGV&VMK.":98PS11&5%)'[YB2%QQ&%H0IN<)W=]KKR_P"#
MKMH;X?&5YU5"=.RMO9^?_ TWU^_SSQE_P5/\4Z)\//C'X^TOX7^'M3^'7P9\
M477AG4+^;QG);:EJC6TD*336ML-/>)@#,  URNXJPR#7T;H/[6'PT\07]CI\
M?CSP?;ZSJ (CTF?6;6/4$D6!;B2)H/,WB2.%U=TQE5(8\<U\R_L$?\$MM)TG
M]F/0O^%U>']:O/'.I:Y=^*-?T*Y\6WUUH8OWOI)H2]A%<FPF*QB DM&^Y@<D
M]O-]>_X)9>+/B9^R)^T3J^I^#=%M?CK\4_%NH:QILMY>6\EU%I0O87CTV&[C
M++;K<6L,D1PXSYZB4A5PG3.C@I2<$^6SM?O>ROJW=*S;:MNCEIU\?&*G*/-=
M7MU5KNVB5F[I).^S9]Y_#/\ :(^'_P :=*U&_P#!OCKP=XLL='Q]ON-&UJVO
MXK+(+#S6B=@F55C\Q' )[5F>&?VO?A-XUM99M&^*'P[U:&"TN+^22R\26=PL
M=M;@&XF)20@1Q!E+N?E0,-Q&:^$?VQ_V9?'/Q0\*?&[QU-H>@?!.'Q-X'T;X
M:>$?#&L:WIEC/KIBO([N42S07#V<32J9+*W3S2S(/F$*A=W$?$'X2>-/VK?C
MM^U(WPY^&?\ PBOB3P_\,M#^%^G:#+J6G1S0+>2QO<K)-#,]JICLT==J3,?)
M6-3B1C$I3RZC)<W/IZK3X5J^NLMUM;4*F:5X/EY-?1Z_$]%TTCL]7=6/T?U#
M]LWX/Z3X?FU:Z^*WPUMM*MYX+66]E\3V26\4T\+3P1M(9=H>2%6D12<LBEAD
M FKWBG]J?X8^!M%T_4M;^(W@/1]/U;3TU>QNK[7[2WAO;)VC5+J)WD"O"S2Q
M 2*2I,B 'YAGXY_:*_8=\:? Z]\&^'_@3\-[&'PWX7\(ZF+76O#VF^'!KT_B
M&>".T5KR?5\[+>>!%\^XMTDN7"LA)4@5YSX/_P"";OQ:\&_#]VC\"176M>"_
MV?U\%^$XI]4L':+Q'J7G/J<D3&4K&\(N98?,9E1T!"E@QJ8X+#2BI>T^5U?M
MKVZ=]'Y:W+'XN,G#V6JZV=N^G?KVU2[Z?HIX _:0^'?Q8\43Z'X6\>^"_$NM
M6MHM_-I^E:W;7EU%;,$*S-'&[,(R)8R'(VGS$Y^893X4?M*?#GX\W5Y!X&\?
M>"O&<^FHLEW'H6N6NHM:JQ(4R"%V*@D$ G&<&OB30_\ @GYXW^'GB>^%G\,]
M,\0^&_!OP&@^'NC:2?$<.DCQ)?74ADU4+.@E:"9E,H$DD2H\D@)=0S2)Z1_P
M3<_9?\??!+XM>(;CQ%H^L0^!M#\-Z?X7\%7'C>/0[OQI8VL3-+-:-?:67#V'
MF,"D4LK%3''M10I+Y5<+0C"4X3O:UM5_75=K:ZNQK1QF(E4C"<+7O?1Z?IT?
M>^FBN?6<O_([P?\ 7C)_Z,CK5K*E_P"1W@_Z\9/_ $9'6K7F'JA7D?[<?[3.
MH?L>_LV:[\1;'PFWC*/PVT,M]IZ:A]BD6V:18Y)E?RY-QCW!BN!E0QR,5ZY6
M/\0O VF_%#P#KGAG6(?M&D>(M/GTR^B_YZP31M'(OXJQ%;8>4(U(RJJ\;JZ[
MKJ9UHSE3:INSMH^S/'/%W[==C!^T-\'/A_X5T/\ X2BX^+&F3^();S[=]E70
M])2)9$NW7RW\SS2614!7YD(+#(SXAIW_  5#^/VH?M 3?"\?LF;?&MKHZ>(9
M]/\ ^%H:<?*T]IA )_-\CRC^\.-@??WVXYIO_!(7]@/XB?LT^,?%GB?XL&.3
M6M)L(O ?A)A<0S,=!MI3,LV8V;:LKF/:C%740'<HR*]8T/X ^+K/_@K9K?Q.
MDTG;X'O/AA%X=AU+[5"=]^NHK,8?*W^:/W8+;BFSMNSQ7N2C@*-2=**C448W
M4FY:RO?2TET=K>7K?QXRQE6G"HW*#E+5)+16MK=/JKW\_0\)T;_@MSXV'PG'
MQ1UK]G>ZT[X.VNL?V5J'BBV\<6EU-:@70MF=;$P)-(0Y^[\H/]X#FON3XQ_%
MO1O@3\,]6\6>(&O%TG1XUDF%I:R75Q*S.L:1QQ1@L[N[JH '5AG R1\/?\$[
M/^"+7@#PE\.=-\2?&+X6V;?%*QUV\OM]UK$EW"8Q<LUL6AAN&M'&S:=K(?\
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M6%[:RB6"\MY4#QRQN.&1E8,".""#7Y(_M4_\$W?VJ_B%J7PC^)&M?\)GX_\
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M"GB3Q-_8&H:W;^,]/M['2HUL[JYEF21G*7,L?V=0;>-O,V2-)PL35S_[,O\
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M3)+H5%OJ>MT445F4%%%% !1110 4444 %%%% &3_ ,SQ_P!N/_M2BC_F>/\
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M!"?XT?\ "5:7_P!!*P_\"$_QH OT50_X2K2_^@E8?^!"?XT?\)5I?_02L/\
MP(3_ !H OT50_P"$JTO_ *"5A_X$)_C1_P )5I?_ $$K#_P(3_&@"_15#_A*
MM+_Z"5A_X$)_C1_PE6E_]!*P_P# A/\ &@"_15#_ (2K2_\ H)6'_@0G^-'_
M  E6E_\ 02L/_ A/\: (9?\ D=X/^O&3_P!&1UJUSLOB;3?^$TA;^T+';]BD
M&?/7&=Z>]:?_  E6E_\ 02L/_ A/\: +]%4/^$JTO_H)6'_@0G^-'_"5:7_T
M$K#_ ,"$_P : +]%4/\ A*M+_P"@E8?^!"?XT?\ "5:7_P!!*P_\"$_QH OT
M50_X2K2_^@E8?^!"?XT?\)5I?_02L/\ P(3_ !H OT50_P"$JTO_ *"5A_X$
M)_C1_P )5I?_ $$K#_P(3_&@"_15#_A*M+_Z"5A_X$)_C1_PE6E_]!*P_P#
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MG_\ /]9_]_E_QH N453_ .$AT_\ Y_K/_O\ +_C1_P )#I__ #_6?_?Y?\:
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MTS]1_NC^5-JF_B73LC_B867W1_RW7T^M)_PDFG?\_P#9?]_U_P : +M%4O\
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M8Y V/WG?%% $EW!'/XWMO,17Q8RXW#./WD=:7]GV_P#SPA_[X%9\W_(\6_\
MUXR_^C(ZUJ (?[/M_P#GA#_WP*/[/M_^>$/_ 'P*FHH A_L^W_YX0_\ ? H_
ML^W_ .>$/_? J:B@"'^S[?\ YX0_]\"C^S[?_GA#_P!\"IJ* (?[/M_^>$/_
M 'P*/[/M_P#GA#_WP*FHH A_L^W_ .>$/_? H_L^W_YX0_\ ? J:B@"'^S[?
M_GA#_P!\"C^S[?\ YX0_]\"IJ* (?[/M_P#GA#_WP*/[/M_^>$/_ 'P*FHH
MA_L^W_YX0_\ ? H_L^W_ .>$/_? J:B@"'^S[?\ YX0_]\"C^S[?_GA#_P!\
M"IJ* ,66P@_X3: >3#C[#)QL'_/1*U/[/M_^>$/_ 'P*H2_\CO!_UXR?^C(Z
MU: (?[/M_P#GA#_WP*/[/M_^>$/_ 'P*FHH A_L^W_YX0_\ ? H_L^W_ .>$
M/_? J:B@"'^S[?\ YX0_]\"C^S[?_GA#_P!\"IJ* (?[/M_^>$/_ 'P*/[/M
M_P#GA#_WP*FHH A_L^W_ .>$/_? H_L^W_YX0_\ ? J:B@"'^S[?_GA#_P!\
M"C^S[?\ YX0_]\"IJ* ,74[" >*M*_<P_<G_ (!Z+6I_9]O_ ,\(?^^!5#5/
M^1KTG_<G_DM:M $/]GV__/"'_O@4?V?;_P#/"'_O@5-10!#_ &?;_P#/"'_O
M@4?V?;_\\(?^^!4U% $/]GV__/"'_O@4?V?;_P#/"'_O@5-10!#_ &?;_P#/
M"'_O@4?V?;_\\(?^^!4U% $/]GV__/"'_O@4?V?;_P#/"'_O@5-10!#_ &?;
M_P#/"'_O@4?V?;_\\(?^^!4U% $/]GV__/"'_O@4?V?;_P#/"'_O@5-10!#_
M &?;_P#/"'_O@4?V?;_\\(?^^!4U% $/]GV__/"'_O@4?V?;_P#/"'_O@5-1
M0!Q?B*RA7QM<#R8\?88.-@_YZ3U']CA_YXQ_]\BK/B3_ )'>X_Z\;?\ ]&3U
M%0!']CA_YXQ_]\BC['#_ ,\8_P#OD5)10!']CA_YXQ_]\BC['#_SQC_[Y%24
M4 1_8X?^>,?_ 'R*/L</_/&/_OD5)10!']CA_P">,?\ WR*/L</_ #QC_P"^
M14E% $?V.'_GC'_WR*/L</\ SQC_ .^14E% $?V.'_GC'_WR*/L</_/&/_OD
M5)10!']CA_YXQ_\ ?(J?3+*$ZA#^YC^\/X!3*L:7_P A&'_>% %K[!!_SQA_
M[X%'V"#_ )XP_P#? J:B@"'[!!_SQA_[X%'V"#_GC#_WP*FHH A^P0?\\8?^
M^!1]@@_YXP_]\"IJ* (?L$'_ #QA_P"^!1]@@_YXP_\ ? J:B@"'[!!_SQA_
M[X%'V"#_ )XP_P#? J:B@"'[!!_SQA_[X%'V"#_GC#_WP*FHH A^P0?\\8?^
M^!1]@@_YXP_]\"IJ* (?L$'_ #QA_P"^!1]@@_YXP_\ ? J:B@#+U>RA&H/^
MYBZ+_ /[HJO]CA_YXQ_]\BKVL?\ (0?Z+_Z"*JT 1_8X?^>,?_?(H^QP_P#/
M&/\ [Y%244 1_8X?^>,?_?(H^QP_\\8_^^14E% $?V.'_GC'_P!\BC['#_SQ
MC_[Y%244 1_8X?\ GC'_ -\BC['#_P \8_\ OD5)10!']CA_YXQ_]\BC['#_
M ,\8_P#OD5)10!']CA_YXQ_]\BC['#_SQC_[Y%244 1_8X?^>,?_ 'R*/L</
M_/&/_OD5)10!J/809'[F'[H_@'I3?L$'_/&'_O@58?J/]T?RIM $/V"#_GC#
M_P!\"C[!!_SQA_[X%344 0_8(/\ GC#_ -\"C[!!_P \8?\ O@5-10!#]@@_
MYXP_]\"C[!!_SQA_[X%344 0_8(/^>,/_? H^P0?\\8?^^!4U% $/V"#_GC#
M_P!\"C[!!_SQA_[X%344 0_8(/\ GC#_ -\"C[!!_P \8?\ O@5-10!#]@@_
MYXP_]\"C[!!_SQA_[X%344 :D>GV_EK^XAZ?W!3O[/M_^>$/_? J2/\ U:_2
MG4 0_P!GV_\ SPA_[X%']GV__/"'_O@5-10!#_9]O_SPA_[X%']GV_\ SPA_
M[X%344 0_P!GV_\ SPA_[X%']GV__/"'_O@5-10!#_9]O_SPA_[X%']GV_\
MSPA_[X%344 0_P!GV_\ SPA_[X%']GV__/"'_O@5-10!#_9]O_SPA_[X%']G
MV_\ SPA_[X%344 0_P!GV_\ SPA_[X%']GV__/"'_O@5-10!#_9]O_SPA_[X
M%']GV_\ SPA_[X%344 0_P!GV_\ SPA_[X%']GV__/"'_O@5-10!#_9]O_SP
MA_[X%']GV_\ SPA_[X%344 0_P!GV_\ SPA_[X%']GV__/"'_O@5-10!#_9]
MO_SPA_[X%']GV_\ SPA_[X%344 0_P!GV_\ SPA_[X%']GV__/"'_O@5-10!
M#_9]O_SPA_[X%']GV_\ SPA_[X%344 0_P!GV_\ SPA_[X%']GV__/"'_O@5
M-10!CQ01P>./W<:IFQYVC&?WE%._YGC_ +<?_:E% !-_R/%O_P!>,O\ Z,CK
MYI_:#\9^(?CC_P %$/"OP)M?$&N>&/!MCX*E\?>))-$OY=-U'6 +\6EM9I=P
ME9X(_,5G?R71G4%2X!P?I:;_ )'BW_Z\9?\ T9'7G?QH_9$TOXL_%[0OB!IO
MBCQ=X#\<Z!I\VCQZUX>EM/-N["5@[VD\5W;W$$L7F!9!NCW*Z@@C%=&%J1A-
MN79V?9]'_6VYRXNG.<$H]U==U?5?UOL<?\2O$'_#NKX+W6H6>N:UXTM=<\1V
M]O9+\0_'MO9:?X=2X?\ >&35;Q6N!:Q(KL%;[7.S;412&)7S#P+_ ,%?KWXI
M:)\,[?PQ\,8=>\6?$?Q1KOAB"PM/%,;:<G]E*6DU""]-OBXLRK0L9!$C!6?:
MDK*JR>I^*?\ @G/H/BB#P'=/X_\ BDOBCX>ZI=ZSIOB2[U>WU?4)+FZ@$$S/
M'?V]Q:JA4 K'%!''$PW1K&2<U/@%_P $O? G[.FL^ =0T37O&UY>?#?3-8TW
M2)-1O+:<DZI=/<W-S+B!?,G#/L5CA=BJ&5R-U=L:F$Y+U/>EKW71VO9[7L^^
M_P ^&5/&>T2I>[#331]5>UUO;F7;:WEQ?P[_ ."L$WQ5^'_P_CT/X>K<?$CX
MC>)]7\-:7H3ZZ5TK_B5R'[9?-J(MBYM4AVON6U+EVV!,#?3/CI_P5=O?V>9/
M"_AKQ=X"\/\ A#XEZ[87VL7>D^)?'EGIVC65E;&54>/4UBE\Z6Y=$6&$0*YR
MYD\H(-W7^'_^"6/@CP-\*OA9X;\,>*/'_AC4/@\VI_\ "/>([&]M'U94U(2_
M;HY?.MI+:02F4-GR Z-%&49"#NT_%G_!.7P_KA\.7VE_$#XM>&?%?A[P[<^%
M&\567B$7>N:KI]P_FRQW-Q>Q7&YC-^]61%1XGV^6R*B*KY\#SZ1TU[]W;KM:
MW1N]];;KDS#DUE[VG:VROTWO?JE:VE]O*](_X*]:S\7/$GP]T'X5_!O4/'GB
M#Q]X(B\:-9R>(H=,31(VO!:NEU*\3HL:[9F$@RSE8U$69 5^VJ\J^%O['_AC
MX2?'C7OB)I^H>)[[7->T.P\.LNJZH^H):VEGN*!))0T[N[-N=YI9&9AG(R<^
MJUQXJ=%M*A&R^=_Z6VAW82%>*;KRN_E;3\==]6%%%%<IUA1110 4444 %%%%
M !1110 4444 94O_ ".\'_7C)_Z,CK5K*E_Y'>#_ *\9/_1D=:M 'R/_ ,%2
M?'?B?]FW6/A%\9M)U_7K'PGX)\4PV'C;3;:\E%C>:3?,MN\\]ON\J1H68!"X
MR'F4@@@$<O\ LW67B/\ X*"_$_\ :,\2S?$+XA>&?A_<:M%X'\(/X9U^2Q-H
ME@Z/=W]M]Z-9)I%0"4)DHTJ9.>/K+X]?!/0_VC_@SXD\"^)8YI-#\46$EA=>
M0P6:(,.)(R00)$8*ZD@@,HR".*S_ -F+]G#PW^R3\#/#_P /O"<=TNA^'86B
MADNF1KBX9G9WEE9%56D9F8DA0,GH!Q7L4\?3A@^5+]ZG9.WV;J7WW5O1V/,G
M@YRQ/,W^[>K5_M6Y?NMKZH_+'_A7WCC0/V<OVJ/&R_M ?M$W.J?!+Q7JOAG0
MH+CQS</:W5O%Y<22W*X#-,!,S;HVC 95(48P>Z_8/\5_%"S_ &A?AYX@T.]_
M:VD\$0Z#>WWQ&N_C$S3: ]J+:.2.32\Y9Y/.!*E<RE-O_+,S5]HW?_!-_P #
MWOPE^,G@UM5\5C2_C?KMUXAUV47-O]HM+BX:-G6V/D[4C!C7 D60\G)->V^"
M/"=OX!\%Z/H5F\TEGHME#80/,0TCI%&J*6( !8A1G  SV%>CB,\I2I2@HJ3E
M=:JUDXI=M[W:[/4X:&4U%4C)RLEKH[W?,W^5D^ZT/SE_;W_X*.>%_P!J'P[\
M+X?@W\2OB5J7AV_\53Z;XCT[X;65Y8>,=2"633I]A$\,;/'%C,H!V_O8\@XX
MY/X*_%OXE_M.?"K]EGX6ZE\7?&FC1_$?6?%@UG7='U4VOBJ*VT>/S+>RN;@I
MN6Y&[$F<[E"L=^<G[W_:Z_8D\,_MBV_AF;5M:\9>$]?\'74MWHOB#PKJITW5
M-.,R".98Y=K@+(H4-\N<*,$9.?/+_P#X)#?#%_@3X3\$Z7K'Q \.WG@O5)];
MT[Q7I.N?9_$8O+@8N9VN?+*EIAM#8C'"+C;BGA\RP$,/"G%.+3>Z4FFU))WL
MKV;B]KZ6Z(5; XR5:4VTTTMFTG9QNK7=KI-;]?-GR#\#/CK\4/VQX/@-\%-8
M^*7CKPS'->>*K;6?%.@ZA]@U[7$TD&.RW7&"Q(S^])+&;:2Q+CS#WW[-/[5'
MQ"^/_P"S]^S;HE[XVNM/\2+J_B'4O$&NS7+6_P#:-AH4=S%$UV58;K=YI;)9
MMY(<QLS$G<#]">)?^"1_POU3X&?#_P $:/J7CKP9)\,VN7T;Q'X>UG['KP>[
M0I>M)<;&5C<YS)A . JA$^2NL^#G_!.GX:_ Z705T6UU)[#P[X.N/!-M875P
MLMNUI<W/VFZF;Y WVB>4DNX8+@X"J*K$9I@90?)&VK:7*M+\^OSYHZ;+EMT0
MJ.7XN,ESOHKN[_N:?*TM>M_-GY]_\$R_VIOB-/\ M)^#[S5O&'QJ\01^)O"6
MOZQK-CXQDEET;Q=<VQ,D*>&4$9+8R&(55(574#&U##^RA\:OB]^S9K+:U\8_
M^&A-)\;:_P"!O$OB'PQ;>)/&PU#P[JUQ96<MU(DFE/$)K)HHPA599&8''R@,
M /M+X(_\$=?A;\%?',&L-K'Q#\866EZ;?Z1HFB>)=>-]I?ARUO4:.XBLX@B-
M&KPN\1R[95B3EL,+'[/W_!(CX8?L_P#C;^VEU;Q_XR2TTJZT/1]-\3ZY]OL/
M#MC<AEFM[.,(AC1T<H0Q8[2>Y)/1B,XR^4JCBM))?9LW;FLD[JVZO=/166R,
M:.68V*@F]4^]_P"6]]/)VLUKJ]V?/_\ P3X\:_$'X9_M0?!&WUKXH^./B)IO
MQ^^&LOBK6+/7]2-]:Z1?J%N5:S&!]G15<Q&->,DYSB,1_I-7S=^R7_P2Y^'W
M['OQ.D\6:+K/CKQ)J5OI;:)H\?B36!J%OX:L&E,K6UBOEKY49; ^8L0 0"-\
MF_Z1KY_-\31KU^>CM;>UKZOIY*R^1[.6X>K1I<M7>_>]M%U\W=_,RM4_Y&O2
M?]R?^2UJUE:I_P C7I/^Y/\ R6O@G]NK_@IA\7/@W^WS>_"/P3XF_9A\#Z+8
M^$K3Q$=5^+.HWNFI=2RSR1-!#-#.JL^%5@FP':'.XXQ7FQBY.R.Z4DMS]"Z*
M_/+X/_\ !>[2H_V;_A-KWCSX<^-M<\:_$^^US2+&P^'>EC5[;5+C29(DFEM4
MEF25HIO.0QA?,((D#-A-Y]!^)/\ P7)^%'PL\?ZAH^H>$_B]<:3X9DL[;Q=X
MFL?"S76A>![JX*C[+J5PLA,<T1=%=8TD 9MJEV#**]G+L+VD3[,HKY5\5_\
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MTO\ A[[_ -4]_P#*]_\ <]'_  ]]_P"J>_\ E>_^YZ^+:*^E_P!0,A_Y\?\
MD\__ )(^+_XBQQ7_ -!7_E.G_P#('VE_P]]_ZI[_ .5[_P"YZ/\ A[[_ -4]
M_P#*]_\ <]?%M%'^H&0_\^/_ ">?_P D'_$6.*_^@K_RG3_^0/M+_A[[_P!4
M]_\ *]_]ST?\/??^J>_^5[_[GKXMHH_U R'_ )\?^3S_ /D@_P"(L<5_]!7_
M )3I_P#R!]I?\/??^J>_^5[_ .YZ/^'OO_5/?_*]_P#<]?%M%'^H&0_\^/\
MR>?_ ,D'_$6.*_\ H*_\IT__ ) ^TO\ A[[_ -4]_P#*]_\ <]'_  ]]_P"J
M>_\ E>_^YZ^+:*/]0,A_Y\?^3S_^2#_B+'%?_05_Y3I__('VE_P]]_ZI[_Y7
MO_N>C_A[[_U3W_RO?_<]?%M%'^H&0_\ /C_R>?\ \D'_ !%CBO\ Z"O_ "G3
M_P#D#[2_X>^_]4]_\KW_ -SU):_\%@_LUPDG_"N]VTYQ_;W7_P EJ^*:*/\
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M4X-!S)GJ=%%%24%%%% !1110 4444 %%%% &3_S/'_;C_P"U**/^9X_[<?\
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MH_X=!?\ 50__ "@__=%?2_Z_Y#_S_P#_ "2?_P B?%_\0GXK_P"@7_RI3_\
MDSXMHK[2_P"'07_50_\ R@__ '11_P .@O\ JH?_ )0?_NBC_7_(?^?_ /Y)
M/_Y$/^(3\5_] O\ Y4I__)GQ;17VE_PZ"_ZJ'_Y0?_NBC_AT%_U4/_R@_P#W
M11_K_D/_ #__ /))_P#R(?\ $)^*_P#H%_\ *E/_ .3/BVBOM+_AT%_U4/\
M\H/_ -T4?\.@O^JA_P#E!_\ NBC_ %_R'_G_ /\ DD__ )$/^(3\5_\ 0+_Y
M4I__ "9\6T5]I?\ #H+_ *J'_P"4'_[HH_X=!?\ 50__ "@__=%'^O\ D/\
MS_\ _))__(A_Q"?BO_H%_P#*E/\ ^3/BVBOM+_AT%_U4/_R@_P#W11_PZ"_Z
MJ'_Y0?\ [HH_U_R'_G__ .23_P#D0_XA/Q7_ - O_E2G_P#)GQ;17VE_PZ"_
MZJ'_ .4'_P"Z*DM?^"/GVFX2/_A8FW<<9_L'I_Y,T?Z_Y#_S_P#_ "2?_P B
M'_$)^*_^@7_RI3_^3/BFBOM[_AS;_P!5&_\ +?\ _NFC_AS;_P!5&_\ +?\
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MW_\ [IH_X<V_]5&_\M__ .Z:/]?\A_Y__P#DD_\ Y$/^(3\5_P#0+_Y4I_\
MR9\0T5]O?\.;?^JC?^6__P#=-'_#FW_JHW_EO_\ W31_K_D/_/\ _P#))_\
MR(?\0GXK_P"@7_RI3_\ DSXAHK[>_P"'-O\ U4;_ ,M__P"Z:/\ AS;_ -5&
M_P#+?_\ NFC_ %_R'_G_ /\ DD__ )$/^(3\5_\ 0+_Y4I__ "9\0T5]O?\
M#FW_ *J-_P"6_P#_ '31_P .;?\ JHW_ );_ /\ =-'^O^0_\_\ _P DG_\
M(A_Q"?BO_H%_\J4__DSXAHK[7O/^"/7V2X:/_A8F[;CG^P?49_Y^:B_X=!?]
M5#_\H/\ ]T4?Z_Y#_P __P#R2?\ \B'_ !"?BO\ Z!?_ "I3_P#DSXMHK[2_
MX=!?]5#_ /*#_P#=%'_#H+_JH?\ Y0?_ +HH_P!?\A_Y_P#_ ))/_P"1#_B$
M_%?_ $"_^5*?_P F?%M%?:7_  Z"_P"JA_\ E!_^Z*/^'07_ %4/_P H/_W1
M1_K_ )#_ ,__ /R2?_R(?\0GXK_Z!?\ RI3_ /DSXMHK[2_X=!?]5#_\H/\
M]T4?\.@O^JA_^4'_ .Z*/]?\A_Y__P#DD_\ Y$/^(3\5_P#0+_Y4I_\ R9\6
MU^TE?%O_  Z"_P"JA_\ E!_^Z*^TJ_-O$+B# 9G]7^HU.;EY[Z25K\MMTNSV
M/V?PAX3S7)/K?]ITO9^T]GR^]&5^7GO\,G:UUO;?0****_-3]H"BBB@ HHHH
M VGZC_='\J;3GZC_ '1_*FT %%%% !1110 4444 %%%% !1110 4444 %%%%
M '!_MR? O5OVF_V-_B1\/=!N--L]:\8^'[K2K*:_D>.UBEEC*J9&1'8*">2J
ML?8UBC]A'X?^ ?@;XQT/X>?#[X<^"?$OBKPO=:#+J&D:%;:;]H:6W9%$TL$0
M=H_,(8Y!Z9P37N$?^K7Z4ZJYG:PN5;GQSJW[!'Q.M=-T:7PUXNT/PUX@T7X"
MS?#*UU2WGG,UGK)>S:.ZC_= B ?9W_>9$JDJ1'D<<5X5_P""9?Q$AN?BS>:U
MIGPYUBW^)/AW0=,?0]>\:>(?$GF3:=>7,LHDU6X1+Q'D26.2"ZC&ZTE5 L$@
MA5Y/ONBJ]HQ<B/A'Q#_P3>^*GB[P;X?U+4O$QO-?\'^.9O$>A>&[CXE>()(;
M+3+C36L+BP'B58DU8.6DDN5D\ME7<8"CQL6KZ0_8E_9\O/V;O@O+H^I6>BV.
MK:KK%]K=_%I>JZGJT0FN9BY+WFHRR7-U,1MWS.(Q(^YA%&#MKUZBIE-M6!12
M/F?XC?L@^-O$'C[]HS5M%UC0=/7XR>'=$T#2IFGE6?3Q;Q7<%W+(!$0K>7=%
MHMI?++\VP<UF_'C]GCXL>,/V@M N=-\*_"_Q3\)? =M:2^&/#&I^,+W1$34H
MAQ>WD,6E7:3F#"+;1[PD14RE6D\LP_55%'.PY3QO]MKX">(/VH/V89_".ERZ
M/INN7>KZ#J;FZN)#:1BRU>ROIT$BQEV)CMI%0^6-S%<[ 21X?XE_8-^*DWQ*
MOM/TZX^'\G@6[^-6G_%L:G<ZG=QZMY4;VCSZ?]C6U:(.&BE9)_M)# (AB0L9
M$^U**(S:5@<4SX(U'_@F#\1KO[=I\>H>"8],MM0^)$^G3MJ5TT]Q%XECD-IY
MT?V4+&\,DI64*[C:H922VP6Q_P $TOB-HEI=7UC?>"K[5K/7/A[KNG6L^I7-
MM;W3>'K6&"[BFF6UD:(2%',;+')D;=RKD@?=E%5[1A[-'QI^RO\ "=?$/_!2
MKXO>)M*US3]>^'O@RXN$TF*TD66'2_$>IK:C6K<NA*F6$Z?$S*</$^I3J>78
M#O\ ]HS]FWX@:K^T8_Q$^'DG@Z^N-<\$S^!=5LO$5Y<V:6,1N&N(;Z!H(9C*
MR-)*'MV$0E&S]]&5S7T912YW>X<I^;/Q+_X)-_&SQG^S#I?PQ_X2OPW?:7;?
M"C3?!D,,GC+6],TO1-6M8IQ/<_8+6$0ZG'<%H%#W>UH/+#B*3:(V]=^)W[$W
MQ?N]>^+%YX/U[0-%;XB+X4NA-;^)+_2[QFTOR8KW3S<6]L9;:&XMT=5NX6,J
MEL>4 21]DT4_:,7LT?-__!/']DOQ3^RM)\4I/$LFBE?'OBA/$=E%9:[J&M2V
M:MI]I;R0SW=\@GN)%D@?]^Y)F!#E8BWEKYIX2\$?%>+]G'Q=\&?AK>>'])\6
M>%/'VJQ:]<ZCKT^D7TF@:C?7.J6\]C<16MVT4T\%VD(N#&PC>&ZV$319C^VZ
M*7.[W8^4^5;S]E?QY9>"OA#J7A?P3\*_!?B3X)Z[<2Z/X8M?%%Y=:'J&EW&G
MSV4\;WQTV.>&<FX,H;[-+EX1N+&5BG%ZU^PQ\7]#^!'PW^&>GP_#OQ9X%T\7
MVK^/-)O/$M[X?7Q/J=W>27KVOF1:?=EM,$T\Q:(A'G'EJ^(Q)'+]O44>T8<J
M/FWXX?!SXI^/-#?^QOA_\ _M_BCP7=>$=9_M&_N_/T-92P5(;Q+ G4+$JY8V
MCPV>'CSYA\S]WC_#OX1KX9_:5^!?P_TO4KC7;7]GKP!/;:UJTIVO+-<6UI86
M4<@!($LT=O=SLI/RA(SSO4U]544N;H'*%%%%24%%%% !1110 4444 %%%% &
M3_S/'_;C_P"U**/^9X_[<?\ VI10 3?\CQ;_ /7C+_Z,CK6K!UG5K71O&5I)
M=W$-M')92JK2-M#'?&< FK'_  G6B_\ 04L?^_R_XT :U%9/_"=:+_T%+'_O
M\O\ C1_PG6B_]!2Q_P"_R_XT >4^ ?\ @G7\'_AEXYTWQ!H_A:[AO-%U*ZUG
M3;6XU[4;O3-+O;DL9KBVL9IWM8)&+MAHXE*Y^7'%>V5D_P#"=:+_ -!2Q_[_
M "_XT?\ "=:+_P!!2Q_[_+_C6E2K.;O-M^NIG3HPIJU.*7HK&M163_PG6B_]
M!2Q_[_+_ (T?\)UHO_04L?\ O\O^-9FAK45D_P#"=:+_ -!2Q_[_ "_XT?\
M"=:+_P!!2Q_[_+_C0!K45D_\)UHO_04L?^_R_P"-'_"=:+_T%+'_ +_+_C0!
MK45D_P#"=:+_ -!2Q_[_ "_XT?\ "=:+_P!!2Q_[_+_C0!K45D_\)UHO_04L
M?^_R_P"-'_"=:+_T%+'_ +_+_C0!K45D_P#"=:+_ -!2Q_[_ "_XT?\ "=:+
M_P!!2Q_[_+_C0!K45D_\)UHO_04L?^_R_P"-'_"=:+_T%+'_ +_+_C0 LO\
MR.\'_7C)_P"C(ZU:Y>7QGI)\8PR?VE9^6+.12WFC&=Z'&:TO^$ZT7_H*6/\
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MM163_P )UHO_ $%+'_O\O^-'_"=:+_T%+'_O\O\ C0!K45D_\)UHO_04L?\
MO\O^-'_"=:+_ -!2Q_[_ "_XT :U%9/_  G6B_\ 04L?^_R_XT?\)UHO_04L
M?^_R_P"- &M163_PG6B_]!2Q_P"_R_XT?\)UHO\ T%+'_O\ +_C0!K45D_\
M"=:+_P!!2Q_[_+_C1_PG6B_]!2Q_[_+_ (T 8WB3_D=[C_KQM_\ T9/455->
M\5Z;/XQN)([ZU>/[% NY9 1D/-D?J/SIG_"3Z?\ \_MO_P!]B@"]15'_ (2?
M3_\ G]M_^^Q1_P )/I__ #^V_P#WV* +U%4?^$GT_P#Y_;?_ +[%'_"3Z?\
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M/_OZ*/\ A+]+_P"@A9_]_10!I45F_P#"7Z7_ -!"S_[^BC_A+]+_ .@A9_\
M?T4 :5%9O_"7Z7_T$+/_ +^BC_A+]+_Z"%G_ -_10!UD?^K7Z4ZLE/'.C!%_
MXFECT_Y[+_C1_P )UHO_ $%+'_O\O^- &M163_PG6B_]!2Q_[_+_ (T?\)UH
MO_04L?\ O\O^- &M163_ ,)UHO\ T%+'_O\ +_C1_P )UHO_ $%+'_O\O^-
M&M163_PG6B_]!2Q_[_+_ (T?\)UHO_04L?\ O\O^- &M163_ ,)UHO\ T%+'
M_O\ +_C1_P )UHO_ $%+'_O\O^- &M163_PG6B_]!2Q_[_+_ (T?\)UHO_04
ML?\ O\O^- &M163_ ,)UHO\ T%+'_O\ +_C1_P )UHO_ $%+'_O\O^- &M16
M3_PG6B_]!2Q_[_+_ (T?\)UHO_04L?\ O\O^- &M163_ ,)UHO\ T%+'_O\
M+_C1_P )UHO_ $%+'_O\O^- &M163_PG6B_]!2Q_[_+_ (T?\)UHO_04L?\
MO\O^- &M163_ ,)UHO\ T%+'_O\ +_C1_P )UHO_ $%+'_O\O^- &M163_PG
M6B_]!2Q_[_+_ (T?\)UHO_04L?\ O\O^- &M163_ ,)UHO\ T%+'_O\ +_C1
M_P )UHO_ $%+'_O\O^- &M163_PG6B_]!2Q_[_+_ (T?\)UHO_04L?\ O\O^
M- &M163_ ,)UHO\ T%+'_O\ +_C1_P )UHO_ $%+'_O\O^- &M163_PG6B_]
M!2Q_[_+_ (T?\)UHO_04L?\ O\O^- !_S/'_ &X_^U**KZ9K-KK7C1GL[B&Y
M6.RVLT;!@I+]#BB@#>HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M&_\ H,A][_R/K&BOD[_A\7\,O^@'X[_\ K3_ .2:/^'Q?PR_Z ?CO_P"M/\
MY)H_U/SK_H'E_7S#_B(G#?\ T&0^]_Y'UC17R=_P^+^&7_0#\=_^ 5I_\DT?
M\/B_AE_T _'?_@%:?_)-'^I^=?\ 0/+^OF'_ !$3AO\ Z#(?>_\ (^L:*^3O
M^'Q?PR_Z ?CO_P  K3_Y)H_X?%_#+_H!^.__  "M/_DFC_4_.O\ H'E_7S#_
M (B)PW_T&0^]_P"1]8T5\G?\/B_AE_T _'?_ (!6G_R31_P^+^&7_0#\=_\
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M&_\ H,A][_R/K&BOD[_A\7\,O^@'X[_\ K3_ .2:/^'Q?PR_Z ?CO_P"M/\
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M_DZC^Q\;_P ^V'^I>>?] TOP_P S]':*_.+_ (B?/@'_ -"C\7__  5:=_\
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M /X*M._^3J/['QO_ #[8?ZEYY_T#2_#_ #/T=HK\XO\ B)\^ ?\ T*/Q?_\
M!5IW_P G4?\ $3Y\ _\ H4?B_P#^"K3O_DZC^Q\;_P ^V'^I>>?] TOP_P S
M]':*_.+_ (B?/@'_ -"C\7__  5:=_\ )U'_ !$^? /_ *%'XO\ _@JT[_Y.
MH_L?&_\ /MA_J7GG_0-+\/\ ,_1VBOSB_P"(GSX!_P#0H_%__P %6G?_ "=1
M_P 1/GP#_P"A1^+_ /X*M._^3J/['QO_ #[8?ZEYY_T#2_#_ #/T=HK\XO\
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M^^)E]X:L["[M;NZ*6EW>PQSWD,K1-#)':PF+SI',KAV<ERX'Z645XC_P3?\
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M?^F..OP7K\6K_P#(UQG^/]#_ %8^B_\ \D?3](_DPHHHK4_I **** "BBB@
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MFTNXU"X/B[Q!<^([S[4Z-Y=Q.(PZQ[57$8\M<!MQY.6/;L** "BBB@ HHHH
M**** "BBB@ HHHH YKXI_"+P_P#&?PV-+\0V"WEO%*+BWD5C'-:3+]V6*1<,
MCC/!!]CD$BN!MOV*- O;N/\ X2+Q-X_\:Z;%*LR:7X@UQ[NQW+]TM&%7?@\_
M.6]\Y.?8Z*QJ8>G-\TEJ<.(RO"5Y^TK4TWYK?U[KUN-CC6&-41555&%4#  ]
M!3J**V.X**** "BBB@"CXIT"/Q9X9U+2YKB^LXM2M9;1Y[&Y>UNH%D0J7BE0
MAXY!G*NI#*0"""*X#X-?LQ6GPE\;ZCXGOO%?C#QQXDU#3K?1_P"TO$,]L\MM
M9PLSK#&MM!#& 7=G9F4N[<EC7IM% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 ?A/17W9_PY3_ .JE_P#EO?\ W31_PY3_ .JE_P#EO?\ W37]
M)_Z_Y#_S_P#_ "2?_P B?QA_Q"?BO_H%_P#*E/\ ^3/A.BONS_ARG_U4O_RW
MO_NFC_ARG_U4O_RWO_NFC_7_ "'_ )__ /DD_P#Y$/\ B$_%?_0+_P"5*?\
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M1^%/[=OQ6^".L>/;[POXLDTNY^)RR+XF(L+69-4\QI6;*21,L9S-+@QA2-Y
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M]O8#_GY^$O\ (/\ B(G#W_01_P"23_\ D3\@Z_HZ_P""#'_**#X4_P#<7_\
M3Q?5\@_\0I__ %7G_P LG_[OK]'?V#/V4_\ AB+]D_PI\+_[>_X2?_A&?M?_
M !,_L/V+[3Y]Y/<_ZKS)-NWSMOWSG;GC.!XF?9GAL3AU"C*[YD]FM+/NCX3Q
M"XJRO,\NA0P-7FDIIM<LEHHR5]4ENT>OT445\D?C84444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
61110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>brns-20231231_g10.jpg
<TEXT>
begin 644 brns-20231231_g10.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M$$>U?O\ ?\$4?^"Q"_MW^')? OC^:QL_BKH<'FI+&HAC\26RCYIT0?*LR?\
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M<W%U,0 9)I#(Q Z#)YJO17T$*<8*T5;T/G)U)S=YMOU"BBBJ("BBB@ HHHH
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M86-HTID33+-21!;)VVHF,X W,68C+&OV:_X.</VB_P#A6G[%>A^ K6X\N_\
MB1K*B>,'!>QL]L\O_D=K3VP37X(U]YPK@E&D\3+>6B]%_F_R/SSB['2E66%C
MM'5^K_R7YA1117UA\<%%%% !17V!_P $DO\ @E-=?\%-O%OBZ.Z\17/A'P[X
M2M(6EU&*P%VTUU,Y\N$*SH,;(Y68@DC"#'S US'_  5/_P""<]]_P38^/]CX
M4.L3>)-$UK2X]3TW59+06QG^9HY8V0,P#(Z]B?E=#WKC6.H/$/#*7O[V_K0[
M'E^(6'^MN/N7M?\ #;<^9J***[#C"BI],TRXUK4K>SLX)KJ[NY5A@AB0M),[
M$!54#DDD@ #J37N7[8/_  3H^(W["WP_^'^M?$:UL=(OOB%]N>TTE)_.N[!+
M46Q)N-OR*S?:5PJLQ&T[L'@9RK0C)0D]7LN]M32-&I*$JD5I'=]%?1'@U%?=
MGP._X(ZZ;\7O^"6NN_M%2>/+ZQO-'TW5+\:&NE+)%*;.21 OG>:"-_EYSLXS
MWKX3K.CBJ=9RC3=^5V?J:8C"U:*C*HK*2NO0****Z#G"BBB@ HHJ2TM);^ZC
M@@CDFFF<1QQQJ6:1B<  #DDGC H CHK]5?BW_P &S.I?#;]DG5O&UOX_O-2\
M;:+X=_MBX\.KI"B%[B.$2SVR3"8EB,2*C;?F(7@9X_*JN3"8ZAB4W0E>VC.S
M&9?B,*TJ\;75U_2"BBBNLXPHHHH **** "BBB@ HHKZP_P""7'_!-B']O+6/
M&VL>*->O/!OPY^'ND/J.KZY# LA20 NL2[OEXC261CSM"#CY@:QQ%>%&#J5'
M9(VP^'J5ZBI4U=L^3Z*^SO\ @E-_P2VT3_@IMX[^(E@GC/5/".F^#UMI[*0Z
M:EY-=13R3*HD'F(%8+$"<9!+'TK['D_X-4_#VK6]Q'IGQXNS<V\GE.Q\,QSK
M"P/*LJW:G/7C(Q7#B,ZPE"HZ565FO)]?1'H87(\9B*:JT8W3O;5=/5GXU45]
ME?\ !3+_ ((N^//^"<6BV?B2;6+'QMX&OKG['_;%G:M:RV4QR46X@+/Y8< [
M65W7(()4E0WQK7=A\13KP]I2=T<.)PM7#U'2K*S04445L<X4444 %%?=GQQ_
MX(ZZ;\(?^"6NA?M%1^/+Z^O-8TW2[\Z&VE+'%$;R2-"OG>:2=GF9SLYQVKX3
MKGP^*IUTY4G>S:?JCHQ.%JX=J-56NDUZ/8****Z#G"BN@^$G@E?B9\5?#/AN
M2X:SC\0:M:Z:TZIO,(FF2,N%R,XW9QD9Q7UU_P %3?\ @E/X=_X)E^.OA?:W
M?CC5O%6C^-IKIM2E33$M)[&"WDM@YB'F.'<K.Q&< %1US7/4Q5.%6-&3]Z5[
M+TW.FG@ZM2E*O%>[&UWVOHCXEHKZT_X*K?\ !,:3_@GKXM\*WV@ZY<>,/A[X
MXT\7>D:V\2H6E !DB?:2O*M'(C<!E?C)1J^2ZK#XB%:FJM-W3(Q&'J4*CI55
M9H****V,3TW]CS]J7Q#^QE^T7X9^(?AN:07>A72M<VHE,<>I6I($UM)C^"1,
MCD'!PPY4$?U1?!SXM:'\>/A5X?\ &?AJ\6^T'Q-8Q:A93#J8Y%!PP_A9>59>
MJL"#R*_D0K]XO^#8/]HO_A87[('B7X>75QYE]\.]9,UK&3]RRO=TJ #VN$NB
M<?WQZ\_)\58)2HK$K>.C]'_D_P S[#A''.%=X66TM5ZK_-?D?IE1117P9^B!
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?DK_P=<>*9K3X6?!O
M158^1J&JZG?.O8M!#;HI_*X;\_S_ %JK\G?^#K3P=-??!CX0^(%4_9]+UJ_T
M]VQP&N((I%'XBU;\J]C(;?7Z=_/\F>+Q%?\ LZI;R_-'XFT445^H'Y*%%%%
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M]O+XPW7PG\%_"_4;;5UM;B:RU"0W=BE\L>&=H)1<F4L -P$J#Y5;C&0?!/\
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M&WB[PS\,?!OB71=4\(JD4NJW=W=P:FIF#K'>1[YY(Y5+1M\DBX4CF-<K4WP
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MZT0.%T^W_>W )[;T7RP?[TBUG6J1IP=2>R5S2C2E5J*G#=M)?,_5K]G]I/\
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MDGK6E^Q]^UGXK_8C^/NC_$;P;_9\FM:.DT0M]0CDDL[N.6)HWCE1'1F7#;@
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M?_&:/K-'^9?>@^JUOY']S/':*]B_X=W?M _]$+^,7_A%ZE_\9H_X=W?M _\
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M4 %?//\ P4F_X)V^%O\ @HU\!I/#&L.FE^(--9KKP_KBPB272[@C!!'!:&0
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MZK6_D?W,\=HKV+_AW=^T#_T0OXQ?^$7J7_QFC_AW=^T#_P!$+^,7_A%ZE_\
M&:/K-'^9?>@^JUOY']S/':*]B_X=W?M _P#1"_C%_P"$7J7_ ,9H_P"'=W[0
M/_1"_C%_X1>I?_&:/K-'^9?>@^JUOY']S/':*]B_X=W?M _]$+^,7_A%ZE_\
M9H_X=W?M _\ 1"_C%_X1>I?_ !FCZS1_F7WH/JM;^1_<SQVBO8O^'=W[0/\
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MPW_T-7Q(_P#"CE_PH_X8,\-_]#5\2/\ PHY?\* /<**\/_X8,\-_]#5\2/\
MPHY?\*/^&#/#?_0U?$C_ ,*.7_"@#W"BO#_^&#/#?_0U?$C_ ,*.7_"C_A@S
MPW_T-7Q(_P#"CE_PH ]PHKP__A@SPW_T-7Q(_P#"CE_PH_X8,\-_]#5\2/\
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MPT/2=8\:V>H>#)/#'B;3M=\0/>R?#35)[8J=4TWS"45 QVLJC( ^7&1CC?\
M@F!_P1T^,7P.^(FM0^-OAS+:W&B>"M=\-WNK1ZY!;VWC26[=S&FZ-?,<."&\
MZ4ED)Q0!^P'AO]J[X9>,-'U;4-+\?>$;^QT&40ZC<0ZI"T=DQ.T"1MV%R> 3
MP:O>&?VB? /C/PQJVM:3XS\,:AH^@N8]1O8-2B>"Q8=1*X;"?CC-?ST^/O\
M@GM\:OV2_P!@/X[1^)/A_9^%? -]I&C:5!9Z@ELVJ7-VNH+MMXYK55\Z#Y@#
M-*"_S9S7NNN?\$E/C7\?_"/Q'\7>&OA#HOPC\/WS>%)!\-(-4CCM?'T>F-ON
MA,8P$C68$ ;AEL9.3DT ?LS9?M._#G4? UOXF@\<^%9?#MY/]FAU)=3A^RR2
M_P#/,/NV[N.F<U7OOVL_ACIOPXA\87'C[PC%X7N)C;1:HVJ1?99)0<% ^[!8
M>@YK\B[+_@D%\4OB]XK;Q-=?!O1? /P_\7_%W0->F^&*7\4EKHVFVB%+N\D5
M (@TO0QQ@ CM63^T;_P1K^)T?@SQM8Z%\(VFTFT^+NJ>(O"EOHU]:,FD:?<0
M%$ECT^=&@EC8X!0@%!R* /V;\6?M#> _ G@S3O$6M>,/#>EZ#JY5;'4+G4(H
M[>\+?=\MR<-GVS47B?\ :3^'W@OQ)H^CZMXU\+Z=JGB!5?3;6XU*))+U6^ZT
M8+?,&[$<'M7XV?M&?\$H/VDO'/[,O[,MWXB\$Z-XNN_AWX<U?0==\%Z0]NL-
MH]T6^S7*1S!H?,$95'*CY"/EQ7*?&;_@C'\?O"VL?#1O!OPW_M#Q3I?A?2-,
M.J:KJEKK&FJ\%R9?L]R9D\VV$"G DMR-P0"@#]BOV[_VX?#7[ /P9L_''BJS
MO[W2;S6[+1,6N-T+W4HC61B> BDY)]*[3PG^TI\/_'5MIDNC^-/#&I)K-PUI
M8FVU**3[5.HRT28;YG _A'-?*/\ P6U_90^(W[7/_!._1?!_A7P[I_B[Q=:Z
M[HNHZCIAN!!:WB6\BO<(&?\ @;!'/.#7YX_M1_LPZS^RO^SQ\:?VA/$7@WP_
M^S_X@L_'FA^*/A+X,2Y2;9?V*"&>-4@ 7_2E9OD0#=U- '[:?$G]ISP3\+?A
M%XT\<:AKEG<>'_A_;W%SKDUFXN&LO(0O*C*N?G 'W>M?+O[+_P#P7)\&_M :
MU+'KWP[^(WPWT6\\.S>+-$US7+%3IVMZ9$NYI4EC)6-BO*QN0QJ/]@K]C7QI
M\$?^".\WAFSL=!O/C!\0-&O?$FL1^(HO/L+W6M1W3R1W(ZM%N<)CLHKY!_8B
M_P"":/QJM/B_?P6?PBO/@-\.]0\$:KH_C3PM<^*SK7AWQ5J<\)2&2QM7+?9D
M\SY\DY4'% 'Z!? S_@J[\//VC=2\"W7A2UU2Z\'^.?#]YX@3Q)<>7;V>E1VT
MGEM%<AFW1R$\@'C'6O5!^V;\(V@DE'Q+\#F.&Y2S=O[:M\+,XRB?>ZFOQM^'
M_P#P27^/$OP*\)Z(GPCM/"^I>&/@EXG\"WBI?P;=3U:XNE>"4%>OFJN[<>1W
MKIOBS_P08US5-%\=0Z+\&?"BM??L\Z/X<TH1F&,#Q7&P:YD Q\L_'^OZD9&>
M30!^RFJ?&/PGHEWJD%YXDT6UFT.U2^U!)+Q%:RMW^Y+)D_*C=F/!KR'X??\
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MX_?\6SL?#GC/Q)XJUCQ)X2\*6=^C01I<1(;>$./E0*W&.@V\8&* /<_V<_\
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MX8>^%_\ T3#P7_X#C_"C_AA[X7_]$P\%_P#@./\ "@#M?^&A_A__ -#SX/\
M_!S;?_%T?\-#_#__ *'GP?\ ^#FV_P#BZXK_ (8>^%__ $3#P7_X#C_"C_AA
M[X7_ /1,/!?_ (#C_"@#M?\ AH?X?_\ 0\^#_P#P<VW_ ,71_P -#_#_ /Z'
MGP?_ .#FV_\ BZXK_AA[X7_]$P\%_P#@./\ "C_AA[X7_P#1,/!?_@./\* .
MU_X:'^'_ /T//@__ ,'-M_\ %T?\-#_#_P#Z'GP?_P"#FV_^+KBO^&'OA?\
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MF7PR_P"Q>M/_ $6*ZCX\G/P#\7?]@.Z_]$M7+_L'?\F9?#+_ +%ZT_\ 18H
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M?X?_ /0\^#__  <VW_Q=<5_PP]\+_P#HF'@O_P !Q_A1_P ,/?"__HF'@O\
M\!Q_A0!VO_#0_P /_P#H>?!__@YMO_BZ/^&A_A__ -#SX/\ _!S;?_%UQ7_#
M#WPO_P"B8>"__ <?X4?\,/?"_P#Z)AX+_P# <?X4 =K_ ,-#_#__ *'GP?\
M^#FV_P#BZ/\ AH?X?_\ 0\^#_P#P<VW_ ,77%?\ ##WPO_Z)AX+_ / <?X4?
M\,/?"_\ Z)AX+_\  <?X4 =K_P -#_#_ /Z'GP?_ .#FV_\ BZ/^&A_A_P#]
M#SX/_P#!S;?_ !=<5_PP]\+_ /HF'@O_ ,!Q_A1_PP]\+_\ HF'@O_P''^%
M':_\-#_#_P#Z'GP?_P"#FV_^+H_X:'^'_P#T//@__P '-M_\77%?\,/?"_\
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M/?"__HF'@O\ \!Q_A0!VO_#0_P /_P#H>?!__@YMO_BZ/^&A_A__ -#SX/\
M_!S;?_%UQ7_##WPO_P"B8>"__ <?X4?\,/?"_P#Z)AX+_P# <?X4 =K_ ,-#
M_#__ *'GP?\ ^#FV_P#BZ/\ AH?X?_\ 0\^#_P#P<VW_ ,77%?\ ##WPO_Z)
MAX+_ / <?X4?\,/?"_\ Z)AX+_\  <?X4 =K_P -#_#_ /Z'GP?_ .#FV_\
MBZ/^&A_A_P#]#SX/_P#!S;?_ !=<5_PP]\+_ /HF'@O_ ,!Q_A1_PP]\+_\
MHF'@O_P''^% ':_\-#_#_P#Z'GP?_P"#FV_^+H_X:'^'_P#T//@__P '-M_\
M77%?\,/?"_\ Z)AX+_\  <?X4?\ ##WPO_Z)AX+_ / <?X4 =K_PT/\ #_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>"_\%(/^39Y
M/^PYI7_I9%7O5>"_\%(/^39Y/^PYI7_I9%0!Z1\>/^2!>+O^P'=?^B6KE_V#
MO^3,OAE_V+UI_P"BQ74?'C_D@7B[_L!W7_HEJY?]@[_DS+X9?]B]:?\ HL4
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M-_[]U_Z4RT 0>,_^3]_!?_8KWO\ Z,%>VUXEXS_Y/W\%_P#8KWO_ *,%>VT
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M7$7P%\%A+5I!_8MJ2=PX/ECB@#T"BJ']I77_ #XO_P!]BC^TKK_GQ?\ [[%
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MZ*H?VE=?\^+_ /?8H_M*Z_Y\7_[[% %^BJ']I77_ #XO_P!]BC^TKK_GQ?\
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M?VE=?\^+_P#?8H_M*Z_Y\7_[[% %^BJ']I77_/B__?8H_M*Z_P"?%_\ OL4
M7Z*H?VE=?\^+_P#?8H_M*Z_Y\7_[[% %^BJ']I77_/B__?8H_M*Z_P"?%_\
MOL4 7Z*H?VE=?\^+_P#?8H_M*Z_Y\7_[[% %^BJ']I77_/B__?8H_M*Z_P"?
M%_\ OL4 7Z*H?VE=?\^+_P#?8H_M*Z_Y\7_[[% %^BJ']I77_/B__?8H_M*Z
M_P"?%_\ OL4 7Z*H?VE=?\^+_P#?8H_M*Z_Y\7_[[% %^BJ']I77_/B__?8H
M_M*Z_P"?%_\ OL4 7Z*H?VE=?\^+_P#?8H_M*Z_Y\7_[[% %^BJ']I77_/B_
M_?8H_M*Z_P"?%_\ OL4 7Z*H?VE=?\^+_P#?8H_M*Z_Y\7_[[% %^BJ']I77
M_/B__?8H_M*Z_P"?%_\ OL4 7Z*H?VE=?\^+_P#?8H_M*Z_Y\7_[[% %^BJ'
M]I77_/B__?8H_M*Z_P"?%_\ OL4 7Z\-_P""@/\ R1*'_L)0?S->Q_VE=?\
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MZA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M+%X1:VY=,N#N.[]W_%Q7M7[/6JS0? ;P8JV-Q)_Q);4D@C@^6O% 'H5%9O\
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MYB@#2HK-_MNX_P"@;<_F*/[;N/\ H&W/YB@#2HK-_MNX_P"@;<_F*/[;N/\
MH&W/YB@#2HK-_MNX_P"@;<_F*/[;N/\ H&W/YB@#2HK-_MNX_P"@;<_F*/[;
MN/\ H&W/YB@#2HK-_MNX_P"@;<_F*/[;N/\ H&W/YB@#2HK-_MNX_P"@;<_F
M*/[;N/\ H&W/YB@#2HK-_MNX_P"@;<_F*/[;N/\ H&W/YB@#2HK-_MNX_P"@
M;<_F*/[;N/\ H&W/YB@#2HK-_MNX_P"@;<_F*/[;N/\ H&W/YB@#2HK-_MNX
M_P"@;<_F*/[;N/\ H&W/YB@#2HK-_MNX_P"@;<_F*/[;N/\ H&W/YB@#2HK-
M_MNX_P"@;<_F*/[;N/\ H&W/YB@#2HK-_MNX_P"@;<_F*/[;N/\ H&W/YB@#
M2HK-_MNX_P"@;<_F*/[;N/\ H&W/YB@#2HK-_MNX_P"@;<_F*/[;N/\ H&W/
MYB@#2KPW_@H#_P D2A_["4'\S7L']MW'_0-N?S%>)_MZ:C+=?!6W5[2:$?VE
M#\S8P.:]CA__ )&-+U/)SW_D7U?0^63UKZ0_X)X_\>WB[_KO;_\ H+U\WGK7
MT1_P3_O9+2W\7;+>6;]];_=_W7K[7.O^1=6](_\ I43XW)_]_I>K_P#29'TY
M16;_ &W<?] VY_,4?VW<?] VY_,5^9'Z0:5>'?\ !2K_ ),1^)W_ &!G_P#0
MUKU_^V[C_H&W/YBO%?\ @HYJ4MU^PM\4%DLYH0-$<Y;'/SIQ0!Z9\(_^2!>&
M/^Q?M?\ TF2N)_X)_?\ )J7AO_?NO_2F6NV^$G'P"\,_]B_:_P#I,E<3_P $
M_O\ DU+PW_OW7_I3+0!!XS_Y/W\%_P#8KWO_ *,%>R:S<PV6CW4UQN%O#"[R
ME>NT*2<?A7C?C/\ Y/W\%_\ 8KWO_HP5[!XEF-OX=U"185N&CMI&$1'$N%/R
M_CTH _%+0_A]X,\+^-]9\1_#KX(MH:W<-UXYGUB;XAW NK_2X[PQ2E<8>*Y9
MQ(P3<5"@#'-?L_\ #77+;Q-\.M!U*S\[[)?Z=;W$/G/OD"/&K+N;NV#R>YK\
M2?V6_ W[-UC^T587_P 4-=TO7=-^(%KJ4FJZ%?F[MK7P3>1WK>7:0>7("L<G
MWBCY!.3Q7[@^%+?3[/POIL.DK''I<=K$EFL?W%A" (![;<4 :%<?-\ /!5QX
M,USPZ_AG1VT/Q)+)-JED;<>5?22<N[CNQZYZUV%% 'D5_P#L$_!S4_AOI'A"
MX^'OAR;PWH-R]W86+0'9;RN0SN#G<2Y W9)W8YS6[XN_93^''CSQYH/B?6/!
MF@W^O>&8TATR[DMANM$0YC4 <%4/*@@A3R,5Z!10!Y7^V]_R:/\ $+_L"S_^
M@UT'[./_ "0+P;_V![7_ -%K7/\ [;W_ ":1\0O^P+/_ .@UT'[./_) O!O_
M &![7_T6M ':4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 5X+_ ,%(/^39Y/\ L.:5_P"E
MD5>]5X+_ ,%(/^39Y/\ L.:5_P"ED5 'I'QX_P"2!>+O^P'=?^B6KE_V#O\
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MX/\ A/X5^(%G=*VA:-87$$UI?*9"R7+/G,EP^%9HW^Z<8%?I?$BQ1*L:JJ*
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M_3K<_P#?%']M_P#3K<_]\4 7J*H_VW_TZW/_ 'Q1_;?_ $ZW/_?% %ZBJ/\
M;?\ TZW/_?%']M_].MS_ -\4 7J*H_VW_P!.MS_WQ1_;?_3K<_\ ?% %ZO!?
M^"D'_)L\G_8<TK_TLBKVS^V_^G6Y_P"^*\,_X**7WVO]FB;]U+'MUW2?OKC.
M;V*@#T_X\?\ ) O%W_8#NO\ T2U<O^P=_P F9?#+_L7K3_T6*ZCX\?\ ) O%
MW_8#NO\ T2U<O^P=_P F9?#+_L7K3_T6* ,W]H3_ ).;^#'_ %_7_P#Z35[9
M7B?[0G_)S?P8_P"OZ_\ _2:O;#0!\(?$?_@I?HUUXVU/2/#?P?T?Q!K$.IZE
M#(VJZCI^G^=:V'$\[F4@JQ;[BORPYZ5]@? +XGZ9\:/@QX;\5:/9R:?IFNV$
M=W;VTB!&@5A]S XXZ<<&O@#Q/X5\!_$+_@ICK&F_M%>$_A;X85=\GA<07,,G
M_"2(6VI->/D.LV./*;"D>M?I+HVGVFDZ3;6MA#!;V-O$L<$<*A8T0#"A0.,
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M)M)T^U\/BQT?49+.$S!S(RKW.!C-?4PUK)_X]KG_ +XKX#^++[_CCXZ."/\
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M>HJC_;?_ $ZW/_?%']M_].MS_P!\4 7J*H_VW_TZW/\ WQ1_;?\ TZW/_?%
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M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5X+_P %(/\
MDV>3_L.:5_Z615[U7@O_  4@_P"39Y/^PYI7_I9%0!Z1\>/^2!>+O^P'=?\
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M(_\ D@7AC_L7[7_TF2N)_P""?W_)J7AO_?NO_2F6@"#QG_R?OX+_ .Q7O?\
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M@"]15'_A(+?^[<_]^'_PH_X2"W_NW/\ WX?_  H O451_P"$@M_[MS_WX?\
MPH_X2"W_ +MS_P!^'_PH O5X+_P4@_Y-GD_[#FE?^ED5>V?\)!;_ -VY_P"_
M#_X5X7_P44U..]_9ID"+,-NN:5]Z-EZWL7J* /4/CQ_R0+Q=_P!@.Z_]$M7+
M_L'?\F9?#+_L7K3_ -%BNH^/'_) O%W_ & [K_T2U<O^P=_R9E\,O^Q>M/\
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M1,BL">C$''/2M;]BSQ#;O^RIX%D5;K;-I4;KFW<'!R>1C@^QH ]>KS+]JO\
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M_L#VO_HM: .THHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?_2HGV&:?[I/Y?FCZXHHHK\N/BPHHHH **** "BBB@ K\I?VB_\ DYGXD?\
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M?^^&_P *#K]H!_K#_P!\-_A0!<HJG_;]IG_6'_OAO\*/[>M?^>A_[X;_  H
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M#_WPW^%!U^T'_+0_]\-_A0!<HJG_ &_:?\]#_P!\-_A1_;UK_P ]#_WPW^%
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M6A_[X;_"@Z_:#_EH?^^&_P * +E%4_[>M?\ GH?^^&_PH_MZU_YZ'_OAO\*
M+E%4QK]H?^6A_P"^&_PH&OVA_P"6A_[X;_"@"Y15/^WK7_GH?^^&_P */[?M
M/^>A_P"^&_PH N453_M^T_YZ'_OAO\*/[>M?^>A_[X;_  H N5X;_P % ?\
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MRHV#T'Y4M% ";!Z#\J-@]!^5+10 FP>@_*C8/0?E2T4 )L'H/RHV#T'Y4M%
M";!Z#\J-@]!^5+10 FP>@_*C8/0?E2T4 )L'H/RHV#T'Y4M% ";!Z#\J-@]!
M^5+10 FP>@_*C8/0?E2T4 )L'H/RHV#T'Y4M% ";!Z#\J-@]!^5+10 FP>@_
M*C8/0?E2T4 )L'H/RHV#T'Y4M% ";!Z#\J-@]!^5+10 FP>@_*C8/0?E2T4
M)L'H/RHV#T'Y4M% ";!Z#\J-@]!^5+10 FP>@_*C8/0?E2T4 )L'H/RHV#T'
MY4M% ";!Z#\J-@]!^5+10 FP>@_*O!O^"CXQ^S/)_P!AS2O_ $LBKWJO!?\
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M[3X2Z[&D$.VWTJ:.,% =JB(@#FOG76_^4;?A+_KE:?\ H1KZ2^+O_)+/$?\
MV#;C_P!%M7S;K?\ RC;\)?\ 7*T_]":O6R'_ )&%'_$CR\[_ -PJ_P"%GA]8
MGQ"_Y([XH_["NF?^SUMUB?$+_DCWBG_L*Z9_[/7ZIA-W\O\ TJ)\SPM_R.\+
M_B?_ *1(\W?[Y^M?9_\ P2:&?!WCC_L*1?\ HJOC!_OGZU]G_P#!)G_D3O''
M_84A_P#15>-GW_(MJ^D?_2HG[=FG^Z3^7YH^M]@]!^5&P>@_*EHK\N/BQ-@]
M!^5&P>@_*EHH 38/0?E1L'H/RI:* $V#T'Y4;!Z#\J6B@!-H]!^5?CO\>?\
MDZ;XM_\ 8VWG_H5?L37X[?'G_DZ?XN?]C;>?SK[W@?\ YB/\,?\ TI'CYU_!
M7J<=KO\ J[#_ +"=E_Z41U^W.T>@_*OQ&UW_ %=A_P!A.R_]*(Z_;JM^./\
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M33W>H>3>P#6'"I#;IM(=[=3NDS@'H* /HC]M[_DTCXA?]@6?_P!!KH/V<?\
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M7_!1B^AN_P!F>3RY%?;KNDYP>F;V+% 'IOQX_P"2!>+O^P'=?^B6KE_V#O\
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MUI_Z+% &;^T)_P G-_!C_K^O_P#TFKVRO$_VA/\ DYOX,?\ 7]?_ /I-7ME
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M/_/&+_O@4?88?^>,7_? J6B@"+[##_SQB_[X%'V&'_GC%_WP*EHH B%E"/\
MEC%_WP*_'KX\<?M3?%S_ +&V\_\ 0J_8JOQV^//_ "=-\7/^QMO/YU][P/\
M\Q'^&/\ Z4CQ\Z_@KU..U[_5V'_83LO_ $HCK]MFLX6;)BC)/4E1S7XDZ[_J
M[#_L)V7_ *41U^W5;\<?[OAO\53\J9GD?P2]2+[##_SQB_[X%'V&'_GC%_WP
M*EHK\[/<(OL,/_/&+_O@4?88?^>,7_? J6B@"+[##_SQB_[X%'V&'_GC%_WP
M*EHH B^PP_\ /&+_ +X%'V&'_GC%_P!\"I:* (OL,/\ SQB_[X%'V&'_ )XQ
M?]\"I:* (OL,/_/&+_O@4?88?^>,7_? J6B@"+[##_SQB_[X%'V&'_GC%_WP
M*EHH ^4?^"@4*1?$#POM55_T.?H,?Q"O"3TKWC_@H+_R4#PO_P!><_\ Z$*\
M'/2OU+*O]QH_X?U9^:YG_OU7_%^B/I#]GCX_>$/A!\$_#VG>(+Q8+Z\CFN8X
MQ 9"8]^-QP/4UV3?MJ?#-5+'4&PHR?\ 0V_PKY+\2C-KX.X'_("E[?\ 3<5F
MW2@6DW"_ZMNWL:SQG#^"JUY5:G->3;=FDM6_)E83/<93HQIT^6T4DM&]DO,_
M13POJ^F^,O#=CJVG^3<6&I0)<V\@CQOC<!E/X@U?^PP_\\8O^^!7%?LOC'[.
M/@7_ + 5G_Z)6NZK\ZQE%4L1.E':,FON=C] PE5U:$*DMY)/[U<B^PP_\\8O
M^^!1]AA_YXQ?]\"I:*YCH(OL,/\ SQB_[X%'V&'_ )XQ?]\"I:* (OL,/_/&
M+_O@4?88?^>,7_? J6B@"+[##_SQB_[X%'V&'_GC%_WP*EHH B^PP_\ /&+_
M +X%'V&'_GC%_P!\"I:* (OL,/\ SQB_[X%'V&'_ )XQ?]\"I:* (OL,/_/&
M+_O@5\J?\%?[>.+]F&QVQHO_ !/;7HH'<U]85\H_\%@O^38;'_L.6O\ ,U]!
MPK_R-J'^+]&<^,_@3]&? 3_?/UKTWX"*/^%:Z\V!N_X2K3AG'/\ Q[75>9/]
M\_6O3?@)_P DSU[_ +&K3O\ TFNJ_68_PZGI^J/@Z_\ !GZ+_P!*1W0Z5]2?
M\$\+>.7X/ZUNC1O^*@O.JY[BOEL=*^IO^"=G_)'M:_[&"\_FM?(<0?\ (NGZ
MQ_,K(O\ ?X>DOR/>?L,/_/&+_O@5XA_P4FMHXOV$OB>5CC4_V*XX4#^-*]TK
MP[_@I5_R8C\3O^P,_P#Z&M?FI^A'H/PD_P"2!>&?^Q?M?_29*XG_ ()_?\FI
M>&_]^Z_]*9:[;X1_\D"\,?\ 8OVO_I,E<3_P3^_Y-2\-_P"_=?\ I3+0!!XS
M_P"3]_!?_8KWO_HP5[5<^8;>3RMOF;3LW?=SVS[5XKXS_P"3]_!?_8KWO_HP
M5[;0!^0G[7OP@UCX1_M(>)+37OVLM%\+W/C.2"]OO#VH^,M4AEMXRVT11B*-
MBL3+P <$9(Z5^L7PZLX=/^'^AP6\L<]O#I\"1R1NTBR*(U 8,WS,".<GD]Z_
M+/\ ;C\;_%[X:?MR_&+Q!\(+SP_H=CI-CI4NO6^LWMI%)K,Q&U&MTF1F/RD+
ME>">.M??7[ G[4ES^UK^SY:^(M2T==#US3KJ32=5M(K@7$"74(7>8I0 '0[A
MR.AR.U 'M=%1WD[6UI)(L;2M&A8(O5R!T'UKX1\9?\%6?B-\&?B+J7ACQI\,
M]'M]:U*TCGT.QTW5A=2:?+/<FWM8M18<1&7&\8P0.* /O*BOA#4/^"I/Q)&O
M:MX!L_A[H,WQ4\#P:AJ?BBT;42--CL;5%D1X).K23H3A3]T@YK1\3?\ !6'7
M-0,/B+PGX'M]0\!Z#H/A[7/$]Q=7GEWENNKN%2*!.C- I#/GKG H ^BOVWO^
M32/B%_V!9_\ T&N@_9Q_Y(%X-_[ ]K_Z+6O*_P!O;]HSP'X<_9U\<:#J7B[0
M=-UF\T%Y8;.YNECFD61,QD+U^;MZUZ9^SKJEO#\!/!H::-2=&M2,MU'EK0!W
ME%5?[9M/^?B'_OJ@ZU:#_EXA_P"^J +5%5?[:M/^?B'_ +ZH_MFT_P"?B'_O
MJ@"U157^V;3_ )^(?^^J/[:M/^?B'_OJ@"U157^VK3_GXA_[ZH_MFT_Y^(?^
M^J +5%5?[:M/^?B'_OJC^VK3_GXA_P"^J +5%5?[9M/^?B'_ +ZH.M6@_P"7
MB'_OJ@"U157^VK3_ )^(?^^J/[9M/^?B'_OJ@"U157^VK3_GXA_[ZH_MJT_Y
M^(?^^J +5%5?[:M/^?B'_OJC^V;3_GXA_P"^J +5%5?[:M/^?B'_ +ZH_MJT
M/_+Q#_WU0!:HJK_;-I_S\0_]]4?VU:#_ )>(?^^J +5%5?[:M/\ GXA_[ZH_
MMFT_Y^(?^^J +5%5?[:M/^?B'_OJC^VK3_GXA_[ZH M455_MJT_Y^(?^^J/[
M9M/^?B'_ +ZH M455_MJT_Y^(?\ OJC^VK0_\O$/_?5 %JBJO]LVG_/Q#_WU
M0=:M!_R\0_\ ?5 %JBJO]M6G_/Q#_P!]4?VS:?\ /Q#_ -]4 6J*J_VS:?\
M/Q#_ -]4?VU:?\_$/_?5 %JBJO\ ;5I_S\0_]]4?VS:?\_$/_?5 %JBJO]M6
MG_/Q#_WU1_;5I_S\0_\ ?5 %JBJO]LVG_/Q#_P!]4?VU:?\ /Q#_ -]4 6J*
MJ_VU:?\ /Q#_ -]4?VS:?\_$/_?5 %JBJO\ ;-I_S\0_]]4?VU:?\_$/_?5
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M %JBJO\ ;-I_S\0_]]4?VU:?\_$/_?5 %JBJO]M6G_/Q#_WU1_;-I_S\0_\
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M J>B@"#^S+?_ )]X?^^!1_9EO_S[P_\ ? J>B@"#^S+?_GWA_P"^!1_9EO\
M\^\/_? J>B@"#^S+?_GWA_[X%']F6_\ S[P_]\"IZ* (/[,M_P#GWA_[X%']
MF6__ #[P_P#? J>B@"#^S+?_ )]X?^^!1_9EO_S[P_\ ? J>B@"#^S+?_GWA
M_P"^!1_9EO\ \^\/_? J>B@"#^S+?_GWA_[X%']F6_\ S[P_]\"IZ* (/[,M
M_P#GWA_[X%']F6__ #[P_P#? J>B@"#^S+?_ )]X?^^!1_9EO_S[P_\ ? J>
MB@"#^S+?_GWA_P"^!1_9EO\ \^\/_? J>B@"#^S+?_GWA_[X%']F6_\ S[P_
M]\"IZ* (/[,M_P#GWA_[X%']F6__ #[P_P#? J>B@"#^S+?_ )]X?^^!1_9E
MO_S[P_\ ? J>B@"#^S+?_GWA_P"^!1_9EO\ \^\/_? J>B@"#^S+?_GWA_[X
M%']F6_\ S[P_]\"IZ* (/[,M_P#GWA_[X%']F6__ #[P_P#? J>B@"#^S+?_
M )]X?^^!1_9EO_S[P_\ ? J>B@"#^S+?_GWA_P"^!1_9EO\ \^\/_? J>B@"
M#^S+?_GWA_[X%']F6_\ S[P_]\"IZ* (/[,M_P#GWA_[X%']F6__ #[P_P#?
M J>B@"#^S+?_ )]X?^^!7A'_  4:M8[?]F>3RXXTW:[I6=JXS_ID5>_5X+_P
M4@_Y-GD_[#FE?^ED5 'I'QX_Y(%XN_[ =U_Z):N7_8._Y,R^&7_8O6G_ *+%
M=1\>/^2!>+O^P'=?^B6KE_V#O^3,OAE_V+UI_P"BQ0!F_M"?\G-_!C_K^O\
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MX:T7P]X;\;:]X7\,GPM'X,\36%O#%+_PDNG+)YA#.P)BD),B[TP0LA%?8E%
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M_L!6?_HE:[JOR7-/]\J_XI?FS]3RW_=*7^&/Y(@_LRW_ .?>'_O@4?V9;_\
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M?]]4 /HIGVB/_GHG_?5'VB/_ )Z)_P!]4 /HIGVB/_GHG_?5'VB/_GHG_?5
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M ,DL\1_]@VX_]%M7QS^TK_RB?\(_]=;#_P!#:OK'XM>.-'_X5)K$DNI6-O\
M;M'EN(5FG6-G1HB00">G-?)G[2;K)_P2=\(E65E,NGD$'K\[5[O#/_(UP_\
MB1CB?X4O1GQ\_P!\_6I=$_Y)YX__ .POHG\I:B?[Y^M2Z(?^+>^/NF?[7T3C
M\):^YXK_ .2?QO\ U[7_ *7 GPV_Y*3"?XBY)_K&^M?9G_!'G_D!_$?_ +"U
MM_Z(%?&<G^L;ZU]E?\$>Y%30OB/N95_XFUMU/_3 5_-G#_\ OB]&?TIX@?\
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M/_GWC_*C^P[/_GWC_*K5% %7^P[/_GWC_*C^P[/_ )]X_P JM44 5?[#L_\
MGWC_ "H_L.S_ .?>/\JM44 5?[#L_P#GWC_*C^P[/_GWC_*K5% %7^P[/_GW
MC_*C^P[/_GWC_*K5% %7^P[/_GWC_*C^P[/_ )]X_P JM44 5?[#L_\ GWC_
M "H_L.S_ .?>/\JM44 5?[#L_P#GWC_*C^P[/_GWC_*K5% %7^P[/_GWC_*C
M^P[/_GWC_*K5% %7^P[/_GWC_*C^P[/_ )]X_P JM44 5?[#L_\ GWC_ "H_
ML.S_ .?>/\JM44 5?[#L_P#GWC_*C^P[/_GWC_*K5% %7^P[/_GWC_*C^P[/
M_GWC_*K5% %7^P[/_GWC_*C^P[/_ )]X_P JM44 5?[#L_\ GWC_ "H_L.S_
M .?>/\JM44 5?[#L_P#GWC_*C^P[/_GWC_*K5% %7^P[/_GWC_*C^P[/_GWC
M_*K5% %7^P[/_GWC_*C^P[/_ )]X_P JM44 5?[#L_\ GWC_ "H_L.S_ .?>
M/\JM44 5?[#L_P#GWC_*C^P[/_GWC_*K5% %7^P[/_GWC_*C^P[/_GWC_*K5
M% %7^P[/_GWC_*C^P[/_ )]X_P JM44 5?[#L_\ GWC_ "H_L.S_ .?>/\JM
M44 5?[#L_P#GWC_*C^P[/_GWC_*K5% %7^P[/_GWC_*C^P[/_GWC_*K5% %7
M^P[/_GWC_*C^P[/_ )]X_P JM44 5?[#L_\ GWC_ "H_L.S_ .?>/\JM44 5
M?[#L_P#GWC_*O"?^"B]A#9_LSR^7&J;M=THG ZXO8L5] 5X+_P %(/\ DV>3
M_L.:5_Z614 >D?'C_D@7B[_L!W7_ *):N7_8._Y,R^&7_8O6G_HL5U'QX_Y(
M%XN_[ =U_P"B6KE_V#O^3,OAE_V+UI_Z+% &;^T)_P G-_!C_K^O_P#TFKVR
MO$_VA/\ DYOX,?\ 7]?_ /I-7ME !1110 5\Z_M-_L VO[3?Q*\1:QJ6O7%C
M8>(/!DGA1H((AYD#FX6=+@,>#M9%^4]:^BJ* /B"P_X)A_$;3/B1:_%B'XFZ
M.GQJTZU;0[34_P"R VEQZ3Y(B6 P'DR JLF_NPQ]TT_Q-_P2(NK#P)8^$?!_
MCIM%\-ZQX-B\#>+H[BS$UQJ-FLID,]NW_+*<AY$Y^4!\]0*^W** /(_VA?V9
M_ ?CGX<:E=:YX9TO5KO2="ELK6>XCW/%$D9*J#]1FOFW]HRPAL_^"3/@^.*-
M8TCDTY5 '0!VQ^5?9GQ=_P"26>(_^P;<?^BVKXY_:5_Y1/\ A'_KK8?^AM7N
M\,_\C7#_ .)&.)_A2]&?'C_?/UI^B0J_@'Q\VW+KJ^B@'N.):8_WS]:K2Z?'
MJOPK^(%O,9A%)K.B!O*E:)_^6O1E((_"OTO-,LJ9CEF)P-)I2G!)-[+WX;VN
MSR^#LTI9;F]''UTW&F^9I6O9+I=I7^:-N2-O,;Y6Z^E?8W_!(.PBN=$^(_G1
M*Q_M6V'S#_I@*^")?AGI1D;]YK/4_P#,6N/_ (NONO\ X(J:7#HOA7XDVUNU
MPT*:Q;D>=,TS\P#^)B37XQ0\/<=EJECJM2#C!:I<U]6EU26[[G[%Q!XFY7G&
M GE^%IU%.5G>2BEHT^DV^G8^U?[#L_\ GWC_ "H_L.S_ .?>/\JM5X[^T_\
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MX_RH_L.S_P"?>/\ *K5% %7^P[/_ )]X_P J/[#L_P#GWC_*K5% %7^P[/\
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MUH[N[MY>3/KOX2?\D"\,_P#8OVO_ *3)7$_\$_O^34O#?^_=?^E,M=M\(_\
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MRXA*J)%+_-YHZJ"/QK[*KYW_ ."E/Q=\<_ CX#/XG\#^(M%T74K>=+2"VO\
M3FO/[4NIF6."%0O*Y<Y)[ &@"C;_ /!'[]FPV\?F?"/PX)-HW#S;@X/?_EK3
MO^'/W[-/_1(_#O\ W]N/_CE>Y?"2'Q+;_##04\93:?<>*Q8Q?VM)8IMMFN=H
M\SRQ_=#9 ]A714 ?-?\ PY^_9I_Z)'X=_P"_MQ_\<H_X<_?LT_\ 1(_#O_?V
MX_\ CE?2E9?C:_U33/!^J7&B6<&HZQ#;2/96LTWDQSS!3L5G_A4G&3V% 'QV
MW_!&'X/_ /#5G]I#X7^'S\//^$86U^R_;;C:-2%R[&3R_-Z^447=CMBO1/\
MAS]^S3_T2/P[_P!_;C_XY7DUA^W/\;O^&7?A;XINM*\%C6M<\?\ _".>+98Y
M2;?3[;[3)%LM5ZR2':!N/ P37W;0!\U_\.?OV:?^B1^'?^_MQ_\ '*/^'/W[
M-/\ T2/P[_W]N/\ XY7TI10!\U_\.?OV:?\ HD?AW_O[<?\ QRN#_9R_X(R?
M!G0/AU-;^./A;X?O-;_M?494D-Y<S'[(]Y,]LN[S3]V!HUQV"@=J]2_X*%_'
M?XA?L^?#+0M:\":;H-U!)K=M;:Y=ZE,5^PV;NJDPQCF21B=H'09R:XG5OVB/
MBUHW_!072_ ]K?>$?$7A[5+EY;W0[&W?[7X<TD1#;?75Q]U9GFR%B_B4C'2@
M#H/^'/W[-/\ T2/P[_W]N/\ XY1_PY^_9I_Z)'X=_P"_MQ_\<KZ4HH ^:_\
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M_P".5]*44 ?,.O?\$>OV<Y=#O%L_A+X=6\:!Q ?.N%P^T[>?-XYQ7)_LY?\
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M ..5]*5P'[3&J^+-)^$E^W@F^TG3?$3L@M[B_B,RJH.Z01Q#F25D5E1>[$4
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M-L/08/>O9* /FO\ X<_?LT_]$C\._P#?VX_^.4?\.?OV:?\ HD?AW_O[<?\
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MH5(3]Y,FNH_X*#?M!?$7]GK2/ .H>"=-\/S:3JWB[2](\07FHS'S+6UN;N.
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M#.GW-\WB.$&2,7$36K+;@KYGS[9BIQSC&:]N_80^.'C+X]?LG:;XG\60:/\
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M^;X\^';VS^#'@M?"$&FW<>I0YE7?<,8_);9YGS8 ?G'&37;'_@BM^RJ8]O\
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M0$':?0U5B_;P^'K?$S^P7UFSCT^71;36K36C<(;&^2YF,,443 Y>1F&-HR:
M'_%_]A7P)\:OCAI7Q&U:/68?%VBV7]G6=]9ZC);F&W+AVC 4X 9@,^HXZ5<\
M#_L5?#_X??&:Z\=Z?I<_]NSO++$)KIY;>QDE_P!=)!$Q*QM)_$5'-:%A^V'\
M+=4F\0QV_C[PO(WA2-IM6Q?(!9(IPS,<X*J>"1D \'GBN*^'_P#P42\$?%+X
M;?%7Q9H"W6J:%\*;B:VN[J JR:BT4/FMY)_3G'- 'OM%?+OP8_X*=Z;XW\;Z
M#HOC3P/XD^&:^+- G\2Z-J.LW%LUC=V<"J\K/(CYB94=&^< $,.<\5WFI_\
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M?AW86U]>:G:N)+6Y$T<D@2,]=P6/)SU# C@T =-KG[)?@;7/V;;KX2G26M?
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M"?\ )S?P8_Z_K_\ ])J]LKQ/]H3_ ).;^#'_ %_7_P#Z35[90 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%&: "BH?M\'_/:'_OL4?;X/^>T/_?8H
M FHJ'[?!_P ]H?\ OL4?;X/^>T/_ 'V* )J*A^WP?\]H?^^Q1]O@_P">T/\
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M4_X)W_ ?Q;X7TW58?AQI,<.IVL5VB.TFY5D0, ?FZ@&OD_\ :1/PI^"_QO\
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M<\#:IJ4?PDL_#^J>'=9NO#VLZ9=3&9K"_MBHEC66-RDJC<N'0X.?:O,_VV?
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MQ5=Z+9I^T%I,F@Z7<:;<K;7.DZH/LCVEX+DB&&-U@;S,;2TJ,P[&NKO/V>O
M&O:5<6NH?&K0\:=I=Q8Z!);>'KL-;RG5#J%M)<ALB0(WR.JXW#D8H ]1U7Q/
M^PCH6A6=]>1^$[;[=//;+:NER+N.2!%DE62'.]-D;JYW ?*P/2O>?#7_  3R
M_9]\8^'=/U?2_ WA^_TS5+:.[M+F&21H[B&10Z.IW<JRD$'T-?)7A_X5>"=8
M^/VO_%3QC\9/#>H>-/%FDZKI>IQZ9X<NX-/B%UI]O80&!7W./+2W#.6)+%B
M0.*^I?@#^U;\*/@C\#_"/@UO&T.H-X7TBUTLW2:?<1K<&&)8]X4ID [<X[4
M;O\ P[/^!G_1.]%_[ZD_^*KXD^-7BWX7_#;XN^+O#FF_ 7P7?6GA?49=.%Q<
M7]RDEP8U4EL*V!G=7W;_ ,-__";_ *&J/_P#G_\ B*^0/B_\%?@U\4?BCXH\
M2P_&?4-+'BB^DU"6U71WD6%W50P4F/./E'6OI>&IY9&K/^T[6LN6ZDU>ZO\
M#KM\CEQ:K.*]AN>IZ;^SU\ T_8RM_C!J/PETN.W/A]==GT^WED9QE QC5F?'
M7C)KAO!?A7X,S?!/7OB#XQ_9TA\+^'=(TM-4MQ8:Y;Z_>ZDKIO$4<%I*SK)M
MYPV._H:]#\2?$[X1WW[$EU\&['XA1*C^'3H,.HW>F3R+]S:'DC5!N![@8R,U
MYK^QU/X'_9T^'OB/PSJ&O? ?1[/6M"&DK=>!_ ]_I%U<2^48_.NF=G$G!S@
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MO7CD/P_\#Z'^U3XJ\>6?BKX%:M:>*O$[>(?[0USP+?W'B?2E=45HK:]1@J%
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MQTWP/JO[3.@^,]>^)O@)M'\.:DNN6RZ+X/GT[6'NO(,)@DN57;):C.0K*7P
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MAX7_ /!K!_\ %5R?_##_ ,(?^B=^%?\ P!6C_AA_X0_]$[\*_P#@"M '6?\
M"\?!7_0X>%__  :P?_%4?\+Q\%?]#AX7_P#!K!_\57)_\,/_  A_Z)WX5_\
M %:/^&(/A#_T3OPK_P" *T =9_PO'P5_T.'A?_P:P?\ Q5'_  O'P5_T.'A?
M_P &L'_Q5<G_ ,,/_"'_ *)WX5_\ 5H'[$'PA'_-._"O_@"M '6?\+Q\%?\
M0X>%_P#P:P?_ !5'_"\?!7_0X>%__!K!_P#%5R?_  P_\(?^B=^%?_ %:/\
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M $,?@S_P86W_ ,51_P +3^'O_0Q^#/\ P86W_P 57/?\,/\ PA_Z)WX5_P#
M%:!^Q!\(1_S3OPK_ . *T =#_P +3^'O_0Q^#/\ P86W_P 51_PM/X>_]#'X
M,_\ !A;?_%5SW_#$'PA_Z)WX5_\  %:/^&'_ (0_]$[\*_\ @"M '0_\+3^'
MO_0Q^#/_  86W_Q5'_"T_A[_ -#'X,_\&%M_\57/?\,/_"'_ *)WX5_\ 5H_
MX8@^$/\ T3OPK_X K0!T/_"T_A[_ -#'X,_\&%M_\51_PM/X>_\ 0Q^#/_!A
M;?\ Q5<]_P ,/_"'_HG?A7_P!6C_ (8?^$/_ $3OPK_X K0!T/\ PM/X>_\
M0Q^#/_!A;?\ Q5'_  M/X>_]#'X,_P#!A;?_ !5<]_PQ!\(?^B=^%?\ P!6C
M_AB#X0G_ )IWX5_\ 5H Z'_A:?P]_P"AC\&?^#"V_P#BJ/\ A:?P]_Z&/P9_
MX,+;_P"*KGO^&'_A#_T3OPK_ . *T?\ #$'PA'_-._"O_@"M '0_\+3^'O\
MT,?@S_P86W_Q5'_"T_A[_P!#'X,_\&%M_P#%5SW_  Q!\(?^B=^%?_ %:/\
MAA_X0_\ 1._"O_@"M '0_P#"T_A[_P!#'X,_\&%M_P#%4?\ "T_A[_T,?@S_
M ,&%M_\ %5SW_##_ ,(?^B=^%?\ P!6C_AB#X0_]$[\*_P#@"M '0_\ "T_A
M[_T,?@S_ ,&%M_\ %4?\+3^'O_0Q^#/_  86W_Q5<]_PP_\ "'_HG?A7_P
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M\ 5H Z'_ (6G\/?^AC\&?^#"V_\ BJ/^%I_#W_H8_!G_ (,+;_XJN>_X8?\
MA#_T3OPK_P" *T?\,/\ PA_Z)WX5_P# %: .B3XK?#Z-PR^)/!JLIR"-0MLC
M_P >JU_PO'P5_P!#AX7_ /!K!_\ %5R?_##_ ,(?^B=^%?\ P!6C_AA_X0_]
M$[\*_P#@"M '6?\ "\?!7_0X>%__  :P?_%4?\+Q\%?]#AX7_P#!K!_\57)_
M\,/_  A_Z)WX5_\  %:/^&'_ (0_]$[\*_\ @"M '6?\+Q\%?]#AX7_\&L'_
M ,51_P +Q\%?]#AX7_\ !K!_\57)_P###_PA_P"B=^%?_ %:/^&'_A#_ -$[
M\*_^ *T =9_PO'P5_P!#AX7_ /!K!_\ %4?\+Q\%?]#AX7_\&L'_ ,57)_\
M#$'PA'_-._"O_@"M'_##_P (?^B=^%?_  !6@#K/^%X^"O\ H</"_P#X-8/_
M (JC_A>/@K_H</"__@U@_P#BJY/_ (8?^$/_ $3OPK_X K1_PQ!\(3_S3OPK
M_P" *T +\=?C+X/O_@IXNAA\6^&))9-'NU51JL&6/DMQ]^J_[!;K)^QA\,64
MAE/AVT(([_NQ4[?L/?"%A\WPZ\*,#U!L5P:]*T71;/PYI-O8:?:PV=E9QB*"
M"% D<2#@*H'  ]* /$?VG_$&G^&OVC/@S=:EJ%CIMJM_?@S7=PD$>?L_3<Q
MS[=:]0_X7CX*_P"AP\+_ /@U@_\ BJD^)7P=\*_&/3[>U\5>']+U^WLY?.@C
MO;=91"^,;EST..,BN/\ ^&'_ (0_]$[\*_\ @"M '6?\+Q\%?]#AX7_\&L'_
M ,51_P +Q\%?]#AX7_\ !K!_\57)_P##$'PA_P"B=^%?_ %:/^&'_A#_ -$[
M\*_^ *T =9_PO'P5_P!#AX7_ /!K!_\ %4?\+Q\%?]#AX7_\&L'_ ,57)_\
M##_PA_Z)WX5_\ 5H_P"&'_A#_P!$[\*_^ *T =9_PO'P5_T.'A?_ ,&L'_Q5
M'_"\?!7_ $.'A?\ \&L'_P 57)G]B#X0G_FG?A7_ , 5H_X8?^$/_1._"O\
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MI_#W_H8_!G_@PMO_ (JC_A:?P]_Z&/P9_P"#"V_^*KGO^&'_ (0_]$[\*_\
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,O&(XXE] !P* /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>brns-20231231_g11.jpg
<TEXT>
begin 644 brns-20231231_g11.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X0!F17AI9@  34T *@    @ !@$2  ,
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MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$
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M[CT;\?H#[ @&Y16%_P )/JF,_P#"/7@XSS<P\=?]KVQ^-'_"3ZG_ -"_>?\
M@3#[?[7O^A]L@&[1618^(-0N;R..;1;JWC<X:1IXF"#GD@-GL.GJ/<#7!S0
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MND8^7'_/;\_K^':O(/\ @VB./^"WGP)Z_P#'[J71=W_,)O?\Y[5Z]_P> _\
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M^-"T4]>G_$Y2OQU_X+3;A_P5I_:*W'<?^$^U7_TH:OV*_:?)_P"(+7P?U_Y
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M6O@_Y2V-"T7'^S_Q.4YH _+W_@VOODT[_@MI\"Y)/-V_;M14^7&78YTJ\ X
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MZZW:7-O!!?ZA#?Q_9+.QCCGEDD$-J[+</.L;"3R!M#2%1]@J<CIB@#DOCO\
M!;1_VAOA1K'@_7OM"Z;JZ)F2W?9-;2QR)-#-&<$!XY8XW7((R@R".*I_L_\
MP(T_X >$M2T^SN)KZ\U[6+SQ!J][(H1KZ_NY3+/*$'"*6.%0<*J@9/)/=44
M8WB+X>:#XPQ_:VBZ1JFUMP^V6<<^#C&?F![$BJND_"#PIH%PTUAX9\.V,K+L
M9X--AC8KUP2J@XX''M71T4 <O>?!+P;J%[)<7'A+PO/<3,7>632H&=V/<DKD
MGZU9?X6>&I-'736\.Z"VG* JVIL(C"H!R $V[< \].M;]% ',Z?\%O!^D7L=
MS:^$_#-K<0\I+%I<".G&."%R.":=JGP<\):Y<B:^\+^&[R8*$$D^F0R,%'09
M92<#TKI** ,"S^%?AG3M+>QM_#N@P6<F[?;QZ?$L3[N&RH7!SWR.:IP_ KP3
M;S1R1^#_  K')&P=&72+<,I'((.S@@]ZZNB@#GM8^$OA?Q%,DFH>&_#]])&"
MJ-<:=#*R@\D LIQFGZ-\+O#7AQ)%T_P[H5BLK!G%M811!R. 3M49/UK>HH Y
M.3X#>!Y69F\&^%&9B22=(MSG_P <J]J?PO\ #>MVBV][X>T.\@C(9(Y["*1%
M(& 0"I P.*WJ* .<TKX0^%=!F:2P\,^';&21=C/!IL,;,N<X)51QGG\*BO?@
MCX-U*[DN+CPEX8N+B9MTDDFE0.[GU)*Y)^M=110!@R?"_P -S:.NGOX?T-M/
M4!1;-81&$ '(&S;MX//2J^F_!CPAHUXEQ9^%?#=I<1YVRPZ9!&ZY&#@A01D<
M5TU% '-ZG\&_".MW7VB]\+>&[RXVA#)/ID,CX'0992<#TJ:R^%OAO3M.DL[?
MP]H5O9R!@\$=A$L3[N&RH7!SWXYK>HH Y2#X%>"K69)(O!_A6.2-@RLNDVZL
MI'((.S@@U:UCX3>%_$<R2:CX;\/W\D8(1KG3H964$Y."RGJ>:Z&B@# TCX6>
M&O#Z.NG^'=!L5D(+BWT^*(.>G.U1G\:I?\*%\#D_\B;X3ZY_Y!%O_P#$5UE%
M &#JWPL\,Z]#''?>'="O(XCE%GL(I%3C' 93CCCCM4>D_"'PKH$SR6'AGP]8
MR2+M9K?3H8F89S@E5&1[5T5% '+W?P0\&7]W)<7'A'PO//,Q>2232H&>1CU)
M)7))]35F;X6^&[G2%T^7P]H,FGH JVS:?$85 .0 FW;P>1Q6_10!S.G?!?P?
MH]TL]GX4\-6LZ_=DATN"-U^A"YK^5G_@ZE\1ZAX5_P""S/CRTTN_O=-M5TC1
MV$%K</%&I-E'G"J0!GKT[U_697\D_P#P=B?\IJ/'G_8'T?\ ](8Z /O#_@F9
M/)J7_!HW\=-4N)6N-2BMO$[I=RR,9XV"1$$2'Y@1@$8/IWK\>_\ @ESXVUG5
M_P#@I5^S_:W>L:I<6MQ\1-!CEBDNY&213J$ *L,\@]"#P1UXK]@O^"8&3_P9
M_?'C[W%GXIZ+NXV1]O3^7)K\:O\ @E0,_P#!3C]GG_LH^@?^G&"@#].?^#TO
M5;KP;^V7\((]'NIM*CF\&3/(EG*8-[?;I1E@N,_4U[=_P9TR2>+_ -B[]HRX
MU:1]4FCU:W1)+MC,Z#[!+P"V<?A_A7A7_![@V?VS_@V/^I*F[?\ 3]+WKW/_
M (,Q_P#DR3]I#CG^V+?GU_T"2@#^?M/B1XB:\'_$^UKF3M?2^O\ O5_01_P>
M.3R>$_V,OV=IM)>72Y)M8N%D>T8PF0?8(L;BN"?;.:_G?B'^FJ/]L=O>OZ'?
M^#SWG]BO]G'[O_(8N?7/_'A%0!X5_P &6>MWGBG]NCXK?VI>76H_9O PDA^U
M3-,(F_M"V&Y=Q.#R>1SR?6OZ3A7\T_\ P9*?\GT_%S_L0Q_Z<+:OZ6* "BBB
M@ J.=&D9!T7.3@X/'^>:DK)\:>,-*\ Z!-K&N:I8Z-I-CAKF\O)T@MX5)V@N
M[D!06*C)/4@=Z /A']F'X":#\=_CPNMZM8^)?#=YIIFO(K1YM4C,5M;:M;SQ
MV&;FP@MGMO.MH7W1.\C;5 =D.X_H$C[U!P1D9P:^!?\ @G!\._#47[5VO>,-
M#6W@NM6T/4%GDF\06>H:MJ;R:A$?/N88Y7>$!4CX  W%W8EI-J_?2)L'7=[G
MO0 ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH *_DF_X.Q/^4U/CW_L#Z/\ ^D,=?ULU_)-_P=A_\IJ?
M'O\ V!]'_P#2&.@#[O\ ^"8&6_X,_?CQA=W^A^*>!G^Y'Z>G6OQK_P""4XS_
M ,%.?V>?^RCZ!_Z<8*_9+_@F%@_\&?OQXW;<?8_%/WCQ]R/\J_&W_@E/_P I
M.?V>?^RCZ!_Z<8* /TP_X/<#_P 9H_!S_L2IO3_G^E_&O=/^#,?_ ),C_:0Y
M_P"8Q;\=O^/"2O"_^#W!L_MG_!L9/'@J;C' _P!.E[U[I_P9C_\ )D?[2'_8
M8M^__3A)0!_/%#S>K_OC^=?T._\ !YX<_L5?LX\M_P AFY/7C_CPBK^>*,_Z
M8O\ O_UK^A[_ (//.?V*_P!G'O\ \3FXYQG_ )<(N_\ G- '@'_!DI_R?5\7
M/^Q#'_IPMJ_I8K^:?_@R4_Y/J^+G_8AC_P!.%M7]+% !1110 55U:RAU"T,5
MQ##<1,1F*4 H_H"#P>?7OBK5<?\ 'J\BL?A%X@DG\4W'@>$V,L?_  D%N(FF
MT=G&Q9XUE1XV=68%0Z,I;'RMTH \O^"GP5^(7P^^-\ESXB\9:->>$-/TJ[M-
M+L(6GN-3UN6>\CG:_O99L['AYC2.'*8G/(41HOOBRJJ*V[[V,$\9KXS_ &"_
MA]X1^&G[4OQ!T5?$^G?$KXDZ7;0VFN^+KK6;J^\01#RK5FLIHIPT5NK2,L[P
MVK+'$98U:),I7UG\0_"%UXW\#:IH]GKFJ>&[O4+=H8=5T[R_ME@Y'$L7FH\>
M\'D;T9?4$4 <UXL_:E\#^!?%NI:)JVM+8WVCZ9_;%^7AD,%C;%@JM+,%,<;L
M6&R-F$CY^56XKIOA]\1]'^*7A_\ M30[Q;ZQ\V2W:0*4:*:*1HY871@'22-T
M961@"",$5\L_&W_@G%JWQQ\0ZO=7.H:5I>I0:39Z=!XDBG=M4\9FUDLKFW;6
M8HXHX"T=S:95T#,JR-L\M2R-[C^RA\!+KX!^$/$L>H7D-YJOC#Q5JOBR^6 L
M8+26^N&E^SQE@"RQKL3<0NXJ6VKG  /31<*6VY7<.2,\BG>967J'@^#4KIII
M+B_C9N2L5T\:,1T)4''M^ JNWP_M6'-UJG)W?\?LG^/L..E &YYE'F5B?\*_
MM=H7[5JWR@CF^DY^O//X]^>M(/A]:A3_ *5JOW=O-])_C[]>] &X):!)S6)_
MP@%KC_C[U;J#_P ?TG4<>M(?A]:D-_I>K?-P?]-D],>OI0!N"2CS:Q?^$!M=
MX;[5JOR]/]-D_P :;_PK^U 4?:M5^4Y'^G2>_O[T ;GFT>96)_P@%J&W?:M4
M!SGB^D']:#X M6;<;K53@Y'^FR8[]L^_^<"@#;\R@R5A_P#"O[7_ )^]6X)(
MS?2=^O>E/P_M6'_'WJWWL_\ '])_C0!MB2@25BGP#:LQ/VK5?FZ_Z;)_C_G\
MJ!X!M1M_TK5?E&!_ILG^- &T),T>96(/ %J!_P ?6J]=P_TZ3C]?>E7P#:J>
M+K5.3G_C]D[=.] &T9,4>96'_P *]M-N/M6K8QC_ (_I?7/K3O\ A K4MN^U
M:IG&/^/V3'7/3.* -KS*/,K#'P_M0BJ+K5ODZ?Z=)_CS_CS0?A_:L&_TK5/F
M.3_ILG^/\J -P29H\RL0^ ;4EO\ 2M5^;@_Z;)_C2CP#:C;_ *5JGR\?\?TG
M/UYH VM]'FUACX?6HV_Z5JWRXQ_ITG^-.3P#:QCBZU7KGF]D/]: -HR8H\RL
M,?#^U"J/M6J_*01_ITG;IWI?^%?VN&'VK5<-U_TZ3].>.G:@#;WU_)1_P=B?
M\IJ?'O\ V!]'_P#2&.OZO1X!M5.5N]67G/%](/Z_YR?4U\A_M=_\&^?[,O[<
MWQRU+XC?$CPOXBUKQ9JL%O;7%U'XBO+=62!!''A$< '8H!/?KUR: /SM_P""
M8!)_X,_OCQMW?\>?BGH.VR/-?C7_ ,$IS_QLX_9Z_P"RCZ /_*A!7].7[<?[
M _PY_P""??\ P0I_:$\ _"_3]6TGPO#X2UG4$LY]4FN\331@N=TC$D?*.#T&
M:_F*_P""5T(N/^"F?[/<9:10WQ&T ;D;:R_\3&#D'M0!^F?_  >X?\GH?!OY
ME_Y$J;CN/].E_P _A7NG_!F.?^,)?VD./^8Q;\_]N$M>"_\ ![!IZZ;^V3\'
M422>16\&3M^]F>1@3?R]V)X]AZ5[C_P9JZ8E_P#L3_M&,TETGEZS;D".4HI_
MXE\O7'7KW]!0!_/7&/\ 35_W_P"M?T/?\'GIS^Q9^SC_ -ABY_B_Z<(NW?Z_
MXU_/#'S>K_O]C[U_0K_P>8:9'8?L6_LZLKW$A?6KD_O9VDVC[!%P ?I_G- '
MA/\ P9*?\GU?%S_L0Q_Z<+:OZ6*_FD_X,F[=9_VZ?BT6:16C\"JPVN5!_P")
MA;<$#K7]+= !1110 5Y/^W)XTL_AS^RGXSUV^AFFATNS6=!%=O9M%,)4\F7S
MD21HO+E,<A=8W*A"0C_=/K%-EA64KNYVG</K0!\2_P#!+OQ?\+_$&EZ/I'A_
M5VC\;>'-.U0ZSI-K>WE_8WTUSJ(FO-8:[N[6&6YN+N7RW,DA5L2D! %S7VU&
M^]>F#W'I0Z;]O3Y3D<=*=0 4444 %%%% !1110 4444 %%%% !1110 4444
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MD9!##@@CN* )Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M>2<?\2]>./\ ?^GZTO\ PCVOD_\ (P0[<\XT\9QC_?Z^]=#10!SH\.:_\O\
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M_GO7144 <Z?#NOCIXABQS][3U_#^,?C_ $H/AWQ !\OB*/VSIZ_K\WI7144
M<]_PCNO?]##%V_YAZ\\_[_I_GM2#P[X@Q_R,,.?^P<./_'_\C\ZZ*B@#GO\
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..G@'FOOBBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>brns-20231231_g12.gif
<TEXT>
begin 644 brns-20231231_g12.gif
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MG7K!B+S<PJS6M'O"B8C(E9;/H;+<NJ/5K=SOWP
M
M
M
M
M
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M]>RGK3N@$_:.4/3 FYPD01(8./S3QAN4(,SKN]'Y$I*^K8VM?0A,X(I&ESL
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MQ 'K.+T$X2UKCBP#)$4Y $,.!(P+RN0F.ZF@289RE.A4&!,MY,0!E$P@#QR
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M 53CIE O>5B<=C28%NV@@D"*1Q=*F7"W^L2!U!I U0.QE([!O>V#'EK9@1!
M9>YE;B(=4D""T!&*&50>: ? !)VJ%Y[I8W !RO [ D</ 0?^[K=4Z[]3SBYQ
M WGK 7@* ,Q1=,$-'@!\Y6O)64JX 12U)X1X3+^E_C9E^D3<V_!;39@U]  4
MC>?6F FY_#%XL)AE2(<'\F$3#T#$!2:QF466X@*L^'=X>W&,94QG<_^%=T(-
M 02")&R@$H=T:SG<8-*VZR"*<JX!7[7QZ@2<H/4BZ*D 6-M 9.K.:B):( 1
MT 'N>%KLQH[/ W@H6)V[$,SMC7,438.!6+;; ;"4O!%54 63,)"SUCE:- :?
MC1."@QSR&'-HCB=ZHUK-I)GN9>)[6Q H--1."S-E3Z7=I?V*S,,6LZ#)Q;%
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MRT6]P:O<SQ1@TP31RAY]S'I,UWJ=$!/0S3J<R7/-$%&@PQ<MS 0AQ 1QQAU
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MS20?Z8OEML:9S!:104G!*%BJX@$%J=S# Q*2 N5&= ^7#"1@%7O0 YL9H83
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M%2!5H7PP@=.?KF"1&),/)%@!1!FN4G,:8I@= L076Y!<I/(WD._<L4 (L7
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M-].\<CS'=*2Z$0RK@"(] 'BQQ3LL/ HT;(HKDQ.I/B@UD5B]&*BR^#JPXY)
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M(( #I+!C6J9DVC&-\ZMG>B;=+$BQ$X@K:S "^T1=XH.U M7EC"J$,#G_>ZL
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MIB>7\[UE\&+?)Q@#B!$F]@"(\0( PH0)_YAX@8)%"@ L3.1!.'&%PHL 5IC
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M, XC,1:C,1H/+QZC,BXC,[)B,C8C-$:C-%;B,TZC-5XC-O)A-69CVJ4 #J0
M.(:C.(XC.9:C.9XC.J:C.JXC.[:C.[XC/,:C/,XC/=:C/=XC/N:C/MHC#N#_
M #?^([CAGS?N(T$6I$$>)$(FI$(N)$,VI$.^XS?N5S\.Y#=6)$5>I$5F)$9N
MI$9V)$=^I$>&)$B.I$B6)$F>I$FF)$JNI$JV)$N^I$O&)$S.I$S6)$W>I$N"
MHS\")$\:F_G9)%#BI% &)5$.I5$6)5(>I5(F)5,NI5,VI4S2US<^)55"955>
MI55F)59NI59V)5=^I4KVI%@.F_D-I%E:Y%FFY46FY52VI5JBI5NZY5K&I4[6
MI5S"I5W6Y5SF)5OJ)5[N)6#^I6"^)6'>96'ZY6'VI6+2Y6+R)6,^IF-&9F F
M)F1.IF%>)F)B9F-:9F9VYF8.YEVBET82)FD:9FDB_^9IIJ9IKB9JLJ9JMB9L
MOJ9LNB9MQF9MSJ9MYB9N[N9M]J9N^B9O_J9PXF9%CF4!#@ 0!(&+( $0(.<0
MA$49-"<0 $%"1"<2O-WTC29=XB5W[F5W?F=>@N=';N1X:B=YFB=Z]J5X>N1Y
MMB=X;F=XJF=\PF=Y>J=]PB=]LF=ZKJ=[RF=^]B=^QF=]OJ> ZN=]^N=.GE1G
M!NB 'BB#&NA^^N=\3FB#$FB%2NB%/BB 8BB$.BB%=JB%@BB';JB&1FB)>FB&
M?BB)JBA%)BA/!H$3+,%T+H$3*&>)H$%SVJB,E,%SAH42 ,$2@-X; ($0N(B,
M3N=T7B=7# &23N< V*B,,OB!X*6(A/YGA%XHEHIHEF[HEEZIEGXIEX*IEX8I
MF8ZIF1YHEZ*IF*IIF;+IF?*G-Y+71**HB)YHB*YHBN9IG:JHB?(IG>+IGNHI
MH YJGPIJH08JHA+JGQXJGMI<-!I!DS:IE)((DLY($*P!$$SJ5X3!=#H!Z$VG
MIJH($TRG&P  DP(!$6Q%$"!GJ8["=+X!0D#J&DSIB8RDHMJIG^)JFO+GF\KG
MKOKJFO*JFPZKL!8KL+:IL5HIL1YKKRIKLA;H1I)79&*F9OXG9U8KM%ZK9UHK
M:%)FMG8KMK:GMGXF9Q[KN%:F>9ZK9*8KN&[KMQYFN+(KO+JKN+:K1O^*Y1E$
M:J3J*'1.9Y'*R!%,IQ)\11 ( 9+"JN=Q:G(BA,*60;XB9QD@!!%()\4B9Q@
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M:V@=<[:NDO8;&WBNLFA YS5ACVB!.SA 0WB#R_4@%R=*P:9EG[%?T[5>!^5
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MSSJ%"^5,;G]I0WLV?WU1@C]:+C9@K_TU[[JNO__\/S@?B[VHI_UAZ[_5\C]
MX$@A4.! @P0/IDB8$"%#@PX1%FP8\2%%B1 K.LQX<>+"CA0SAD0(@&1)DR=1
MIE194@H4*%-(1G$)9245EUM.5IFY<V>6E2136.")_[-DEBE0MEP!\&7F$P!;
M7%(Q.;-*2BTNI92TB92D3I=.25J)JO5F2:\T 7B9Z:4D5)<DU;I42A*+2[8
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M,"[N1XOJJA<@%8E;*%+1(&FTC! ,< 4<E$&RI3EH&QXCT<]!,K.9D8!EW@"
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MJ*46&<()5Z=30 3K<%/XT,[(2\,!+($LAY3TDBEEZ 7 -2V?6FHFMQQ5;Y4
MP(GT$F, S806TZ2;Z)IFROQL3DL_2B::9IO[(2:!M\FZ%(X6'D&;U:5/_REF
M"QL!QK#0RVI7M6;L_GSTTU=_??;;=_]]^*UR-BZ@;]Y^YI3\E"TZ5Z4S(2F8
MY \F":O;P>[7&X)!1#TF,1CU< ,  ;(&7ZPYCG*6)Y CX4PAR#/8:E[CF_>
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MU(^,IQ _%F6,(1J10EI2DWZ52I7$3&,D4F"K3P4LF 8Y2XLD$KVPZ&0DW'G
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M%$A=7PBH2DSJG;=[;WSG6]_[YG>_Z=E=M]0OJ']>3!I=)S%S'85<+"!!Z_2
M"'"I+F(D.,L>\OJVB>!$PDG949-7@%9OGH5Q*[C1IC9G\8;#U')T,A)$? @
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MP:Z@2=0CQJ.J%FPIB@?LEYB(L3Z$F+>1G>G )"W:J?G;-!7RB7G9P@RLGCS
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MTA 8B3 .%C"$0*''ZE!A;?]$C)8H@4BX11EF/A<FE2'%74_]0?4@',!E5)=
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MZD/&ZO#MZK]"Y;/^ZK46\:RF<;-SY ?Z(,PPB2E/HIEV;"S'-R-0;"[G<B:
M"\5> K]@@#4 @B^_"C;H<BY7@BP7#+UN;+S0ZRX_ ZD( R X LZ>"Q+\95J&
M:.=UQ1.A./,8IK,@ ?!(8*,=)MUH 8\9L7"J4 ?.";T[D67>2Z-YW(PAN>/^
MRJ/Y6L4QB,,=N[/ J@9^80$(.F[=6_/(.12VM8XA@1?^I:@#.A3.R%EG$C.,
MB*1#.GP=7(]E=%RO$'^&T79+3=V=V#C3QW#ZG1]"%2;Y/!6RV]OZN:!C/5,/
MNA^Z$%Y^W[1?SSR1$7:4)'8ZR0D!P/7,*4-:SXF8B&Z!HS.Y?@K4U<VZ:%W7
MC0^"4JA#7AXACV0V+M[>+62?WG 2VFI\=VL6!QB+>@X/Q^,GC^J)(> 5BM&%
M&JECQ.J>BM'C!:DH]W?D8!GN>Q>R5N6L_O"USJB"QV16+GF'4C*'*2JA_VES
MF+>NQ%;S+A_LKBB#Q?8+-%!L.+>*)5#L,   G+_SF/>+-]CKO#@#H@> +0<"
MJ1@%Q=YL7.[LJ[#RTH5PA1!MOT2K;'E4-#S/Z5#@1QT!#D%O)C$=QD :CBD!
M.X&=V1ZCC!X/-NNR8A9BZR@9Q4.-/T"K-3J>(!R!2RT2+4INEX@>_;H<Y$(/
MC=/ Q*>1$2LM[]B2$;M4"EY2V* Q",;2,#YMY]4-7L+C%PK;#H8;/,JHS3G$
M'U[,.&,C\5B! 1O]0,N#+5MUVP SGF !CQAP)*VPL+ Q+(6Y*/O\E,AH/YM!
MH(GWW'QI^GEW *9-CK?I0V1EZEAX&R]?]_V3*?_9ZHHZ^:-&<9YKEUA^#H%R
M^-B=<25_\N2H*($J(NFO#DX.J$6^?A'_7H#>Y(]J^'_W]U8&Y'M798  D&)@
M"H$##18\F% A@8$-':9HV!!'"HH4*V*\:#'C0(H /H(,*7(DR9(F3Z),J7(E
MRY8N7\*,*7,FS9HV;YX< F2G$"4?R^P$,H3EFYU#<8(,6C*($#1H0*+9B70J
MU:I6:2X!TB8I$"1!!NQ\^C$J6"!E!QP!$&3GFY)(@)RY*G<N51(Q.6[4R!%O
MQ[YY,6)$F/"B08&%"1H.G##QPL6(4[1X89!PX\2'%2[$L?'C0H2)+Z9XL8>Q
M0L^8.U=^C/JPY=6E&SO_)EV:,>W9J&^3OGS9\>K6'E4?G/Q:<&O&%!M^3F$B
M3VS7 C>F3GR%P$<"$C/S%OZ<+V#H?_7^[0YS$?GRYA^-N@N>KU[V?3DB!(WY
M\'K*F.WOWLW[-.#'AZT_-)%B$>&6$"(1/71<7PGN)9Q]S<T'&W"F 5>@0-,1
MN!&&UV&X7W898O?00@\)%EV%V^E&$(C$\?=::B[F5B!VI]7FHHHL"H0<1-=Q
MYUUW&=$5I)!#$EFDD4<B"4901HA$!!!+,/E1$&=D-0 :48)TQDYN-+$&6$X4
M$-*455XITDY+ *#33F7QI))22,(9)UU. A$&2%D%%903'PF19YYHTNE&4$R$
M_Z2FG(<&:1=,>WWGGJ/M;6?C;1'.J.*$-P[$@@DK4#J@I37V)Y]K[Q& @@E_
M7.$?IIT*ADBJD[)HZ8FR>HBCK"7&JII!)*JZ*H6WM?=>;126Z.&M]R%F0@G%
MOA<JC;**J.NSP+[7:'B-_KC92^9Q2UXFZO7H%Z/5ALO:::!MAQ]L^;$JH;D0
MC@C1;R\2\.JN.T9T8+T-2LLOK"\.-^VPJLD'8*H!7G><=>NFMJ^ _J((H[LV
MMG=@0CI*'+# #,\J8XP1VOHN0;SN>VVV/P*&J,HKL]RRRRNKB29*8?@95DA1
MU0Q$$R#17+-8:NTDAA%GUDPH2FH"\;+22Q>Z4QT@'?]AU$=OKI$S$&GU[*>=
M']%9!M-?KZ3H2RBW5]^XCGJZ'WV41ARCN2248((); M;J\2__=I9"7'G@0B
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MWH(_F"02=X^$O@M/I%T"(0F!5@+2")4"OS(3"$;_@[Q (+]AP^*,4'"PMDA
M?.^1L.'<AE^K!Z&&V&UVTR3_&^#_0+*_K8W>*OQ."9)U;C:8RZ>W:-_A(LWN
MNT/.D#]E==9A.J1@C]]Y?")+=*>)>SNAYW/+R5'T9MHUH_A87S@8^QC09XU*
MT!!2H+TF2$GMZ-+ T-S/T^VWS.W(QOOR7,T0,LZ2;]W\+V.'GUS^:;PNX[[Z
MIUGSB<;!I< *@)KRL=U""!X+D-]IY)9%$ _O+9T)<%K'^!#V]1#],5S0A1;&
MW1&4/95[ 9]B/ RQ44]UU=W=J: )$!Y(Y,$*RDT+E 00V9T,QMX-5H6)Y<Q<
M_<\9@ $89) VK1A(#"&?_U#6#P8AN163MN%82>@8NN&@+4&3,[5;8C6A_A0-
M$490%-;%7>">GFE6DNF4!?+?QS5@T855;8@1\#C<UB&$Q/&0F:V=;HE6NS#?
M03E?6.% &:G=&&:?FAE=(@5?*)U.S_%+@RF=^"3?>I7?&CE*G_D9>:!'D8W4
M&K%3K:5=X.3>JNB1J7S:J:3 "-R=BOS!W?W!0!@@K)D "A!&*<I-#!Q$*;JB
MLA#&"]0@B0A #2[/+*[B19@ ";R@W"B$*,K-"H1==@3C"QA@07Q:J0' TQ6$
M,LH-<Y@:WD5$+L8@ )P:@6"C"<A@09C*+'[CN?B!W>U!1?#B*1:&-'X1 .R!
MW?_9!4$$8SLJ!PG$@-S(VD#,(PHD1!Z4P">"(CC>'=8-Q$#2T/C)E"=ID08:
M$>18AWG-G<QM%[+!H I*4SE6Y"J.A')8)!=Z9$U 4\U@B3'Y"1I(4\\<!3+E
MV_Z4I#3I58JQ6Y[ 9$A(6\Y\I"SMSTS:&.JQ!)YP4]-HT$W:Q.RA1,XY%\ 1
MCD39'\!LXIEE#/)(U"AQC*N9DH@HG7Y8C*%!E-N)V?T9U7?%UO^-':54U_69
M$FPY!G1 2%/:8<)ECVDL94*1I43J6>U)DTM$(K>H%/LY(F>ED2$%V/[MGLB]
MAZGD 0 P8"ERVCL*D2P*A $*T2<*A*FP8@I0ID"\H$"@N*(0B>(Y L  AN*F
M1 00 9YR+ MJA.-D:B1'HH! Q "JE6(\OF %*L0+Q(! "-[<%* ),*! @*8M
M AX+X, +'&8TWJ9EFL (-$0>'"=C%H2RJ.8!QF9M )$0 < 7400%4L@]!F<U
M<B8%%D0)%.=UGB-'<LIGQH!'V*9F_F)X:F<*.*>I6"<0#80H%J<!GJ+&V%/W
M+=^7(5*\#([ *8BQQ?\21<J-W@$ &+RCW+1@#>H="\1-K(U$;I; /6JD4&)H
M2Q2 $>#)$IS!3()$"@P!GJ ![ % AX'$ZH6$B)*HB09%MKG>6W"02""-GU16
MALY/5J2D7%3-C>+H2Q#E2;Q/&.:9(>&1?JP9%/%7E?'G1C4/]LB(TF&5N4#E
MG?7G3?4GPHTE]YE6**T=G/V>T7VE3&UB5ZW7J&2@<&D1:! FOUBB49H,).;E
M(JS?2;@?H;$3(Z(E95"9(::(X/%C03 G8CP= )C*JN#G06SC,Y[F<T)=;";$
M'J#::BZ$*')*0<@B@UU!'E#C<Y+ <S;J FICHY+G:\@G0;PC,R;G083=,[[_
MP$7(8D(LHZ'RIJ"^0&A^ZH&48FM2IJ)VJD&((@G ZBHZ:G;89BP2JT *40Q<
M:FE\$:9J9#C**F]JX]P(A"BVY@K(6F*DJJ*>9L7]I52::9(.$4 IB,(LG;8(
MF=T!7DA$Z I\A-TA* #,XD@$(PI\XK+\Z+[R:[\.B4X8UE7LQ.?Y:]AX89[B
MZ9T.6VE)9<@D#UQN55:]5IHR#,9,3YG.3K-L)9,VF4)N+-5)1YL%H'<E'Y@^
M"!Z"J09:7,!I;!U)SC[A0+%UE$SA4Z$-VG/AY9R6AR3$D9U65R7699IZSQDN
M$2!B1FH6Y'D.Q![ (C$JK:HFAGQJRM,R)[U2*M.Z_Z>L[=/5%88)"(!C1(\J
M<MI[TBH#BJ9!Y %M%H2D1NT!&F!OA@:GQ<!X+H0MRHT0G:JIW2;29N<Y(JVI
M%6=?2*MAO.=[/L;<&L2G)8:FM"8-DL;9#D38O2-"[*K>&@3CIH KMB9B@*9
M*.YO\9$?/E_*1EP>B0LA89>!4FM(&."F?(3=QD +VJG=C0 Q)F?!XF[NZFY,
M7*%54%# [JY)!*E)F-60ME\/>4S'U"R76E7W+>79_1S!E1Q$<H?P=!%JG):
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M+ IJ+)$'/'BB?TSHU#A"=^S>*B=6=;I;=M/?/FFSEJT>Z/+V]HL^-,X2).(
M7"E YI@[2+77%%Q-P<<6>1#"""5\4!3%..KIB@(75*VU#I-S+S<$@YMOM]Z
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M7J$42/,1\B90/1[IQ4!T/V)#40=6-WG_\RV S^%$$C@S4H'> N#,U-]"DOB
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MR<&VC3K'YT#H?S]X0G-UI_V9 WED!0BGMDE(?BJ"50[B9@(J*1:'#QJ"/%A
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MK_,N0L0;,4,R<D1H7_1H)2(^17AO>5*+J!%Y?#9?[J=RMJ9 :0,Z;%98UTB
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M,?)PY_I$0ZF >U8Y0HE 1V)CF/0P15E\:.IXW-.DYZE$[3:P5M2V^*IQ"[M
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MG;ICS,;E# ")H"P$*<<>OA3"CA.<U3YT?)%I"B5*@=CTO\X  >"/B1( (ID
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M9\RXE"NS+CLTFM,^C0L_-,O"CYJ6,8LPJ&JPAY(J2RDB2!D*-^.\LFA% F'
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MD<$LU6&G&+6FCBU%E^"\.L'8:X'8R)7<R:7<RK4=B5V*2!PT!W6RI:LLBYQ
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MU_7;WV /<Z]<GKQH[.DY>RZL_CUG\Y_13V:_'O3?WHZY9R<N]HK_:K1YEP*
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M$$@)*'(P$WP/8 *3",$R,B/T":0%ZQ-(*3LIRUGVSW\K*\C%@&"_@I#$8P
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M C36 A=USVBSFU,IQ-V+IN[!#U[S15+_<",8E4!%*SKE0OK%2@#PU2(WJA$
M<HSM=8^()#&KR&0;>S\A9W-DCC5R,9<)I7A[5M^$U:R1%.L_R[*[X  @K6I7
MJTXN . G7O )F#/83@ ( IX F&<]#;ZF-F]$SHW+]!;M:RUF.Q*Y<=SPK7-M
M:*2:7.4G=U:TVX9# '\.7 LNVU:W-6$!K5"3D.)TJKCKT9^'$<\V#]VT@=[;
M2-OIB[\E7&@"1)=X21U5][7;$S634_VJEUK0!2E"=YWK'9+]6<73\X E2AE4
MZUJG]!HC1@>I&D;Z%-'#0I:@?[K51CXHZZ2FEV5\#FQ8:7PAD7BK0%[0@G]5
MQ,5U'?>-7%D1_[["1=V%O[Q-*&:QE\P[?XL=6<D*4EE\W]+>I =ME(&P!,6*
M"/,:OS( O@F%+2#B)T-A.,2#HDYV3EQ,3[&MZX?$<8WPENNL1J_H5(WL$,]<
MJ6DCZT1EW?R9CPW$+B^=G[_Z88LN'U6!/O5TQ!6;JHLE-3)5:9SUF76_B1SI
M;QXZ;U;-SX^G5"TXR%GRC2A68&-.U+J1]>SX3=&=#;5IT;6X'/7ID=OLG;.M
MW/=%&\K9FH=-E,@QU24-3UO(U-])#WEIRMEY6,J974-%WW^!E!M]C;@,4?"M
M( ONF.95A.GY&[U]'O^8#!!$EI)15B\M1"[UFT0 '&/=6PM6&6DA0O^6P-:7
MK18 Y-[!S=Y"D-E"9 (\I=D0 LGP$9^FS<K',=I'D94D.=OV%9K7C>$?79_J
M\!#8A1V?W1 #,A_B-%6O;5KFD%_PO,:)W5QUM=JG]1V>78L'GN!;G-?\'9_C
MX)^F> 9YC5@F_1T8W900/9]1U=35=%W^6=^?O5S+.=]"->#;0%39B2&'Q=#L
M8(@E!9N  $_?3.*FD-^M]9GS,> "/M)3?=< #LN(D=]X5*$N[N((N9M%J,PU
M =P,!I,0%H01U ]B$=8:;!8SK9XQ.2, G(PSG@P0X!))E $OAA;LR1YL/9 3
M(EQK/<$3CHE$C$+3.$4V(L<58D3Z=5W]T5^(&]'.'<V:)DX@'XFA5KW<&NHC
M]BD@HTR:KDF2S6V=S*U:!MK.9>#BZ-#)I_EAUBW:J,#)4XW7"2D=T"F=SA#+
M\O&*LA%;$HT4T7D80>:7MHQ< 7J7/\JC*X9=]1T7'\(0'L6:4*D+X)'<VUW'
M!L(&35W.'7J@?05@"(X@3"Y7KZ5:T"U1@% =8O^D(U,V)<2\8$508Y$,(Y'5
MDO\ D"TI"0#$6Y$H04&P@?]<DU-J$\)E29C('E+ GCB-8]3$5M-<Q5CNQ#IF
M!$I>I $>94D>55"-'03&4:T)V!@:74'67( ))#WNVE%QU41VGP/VRINQG5F0
M7]+!E/N](:;95P?^)+OXEBIZW'GEC;>UEZ0A2'80 -4=V[ \W?OQ7%-1VB$6
MWR4U%U"N'+,,I03BW2;J$*WAYKKL5#Z.YOX%XBW.5RD:CO1M%=O8F24"4<DI
MAA]6E^)4F$:R1EQ6IW6V&Q"(95261)!Y'C%>!#4NP0CD&P X&53>3TEHI>B9
M!&A=IPAMXT\\ 2)@4 ;_D18&88%$0.%",$+3G)E[VL1<7H0[?J8@YHKRJ0YS
MGB&"1F)*2@O-M60(JN1?UE!QU2:A&51PK0X%V@YXW1<&ZA=)PA1!RM\3T5FS
M(>1)(1^!;N']34UX65%O>&3O)%&&IMJI2)]UO*,586@)ZF8"QMSS_2/K&":L
M:2+>_$U,WB2'/@HJ2L?O$(A2/L]82::$@MB!1:C9'%@6)F1PYN)_?BF8AJF8
MKDD19DEJ 4 %L5.65,%0! U;3H0YDN.8?D2 8@07@AR+DB2#Z26!D1U1_>8'
MSJ,:"BDG.A*1$FI@JJ'^O>B0%@I/C2AL>(M2"ITDGE%'01$@X=%S'IB[&"AH
MR:+?@##0DOH?$A$G1>WA'G8H)3FF9](B85(H)/+F2F9B<[4=S&EH'/GF?1QI
MM^"73":24NH.(@EG)[KAV FE&SK4*++1U(D57Q! B\ZIM$XKM5:K32""M4Y)
MG=+E7=IER+W7 "*J[/CCG\)B1.T=&QX:SAVF]J&.R25K+ 8BI$;7WR!D96*8
M*0(2: *B>=E.&9*8!?;F/E&B>LU%MAXLPB:LPBXLPS:LPR;LMCZLQ$XLQ5:L
MQ5XLQF:LQFXLQS)0Q'8LR(:LR(XLR626K,F>+,JF+&!]K,JVK,N^+,S&K,S.
M+,W6K)BRK,WFK,[N+,_VK,_^+- &K4?@K- 6K=$>+=(FK=(N+=/R(M$V+=1&
MK=1.+=56K=5>;4@\+=9N+==VK==^+=B&[<5JK=B6K=F>52W:IJW:KJUHD2W;
MOBW<QJW<SBW=UBU&N*W=YJW>[BW?]JW?\BS>_JW@#B[A%J[A'NZT!B[B+B[C
?-J[C/B[DHI7B1B[E5J[E7B[F9B[5:"[G=N[B!@0 .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>brns-20231231_g2.jpg
<TEXT>
begin 644 brns-20231231_g2.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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MQ_\ (]?A;17O?ZKY;_S[_&7^9Y_]K8K^;\%_D?NE_P 1F</_ $0>3_PIQ_\
M(]'_ !&9P_\ 1!Y/_"G'_P CU^%M%'^J^6_\^_QE_F']K8K^;\%_D?NE_P 1
MF</_ $0>3_PIQ_\ (]'_ !&9P_\ 1!Y/_"G'_P CU^%M%'^J^6_\^_QE_F']
MK8K^;\%_D?NE_P 1F</_ $0>3_PIQ_\ (]'_ !&9P_\ 1!Y/_"G'_P CU^%M
M%'^J^6_\^_QE_F']K8K^;\%_D?NE_P 1F</_ $0>3_PIQ_\ (]'_ !&9P_\
M1!Y/_"G'_P CU^%M%'^J^6_\^_QE_F']K8K^;\%_D?NE_P 1F</_ $0>3_PI
MQ_\ (]'_ !&9P_\ 1!Y/_"G'_P CU^%M%'^J^6_\^_QE_F']K8K^;\%_D?O;
MK/\ P> QZ1X*T76C\#GD769+F,1#Q)@Q>24!.?(YSO\ 08Q6)_Q&9P_]$'D_
M\*<?_(]?C+XT_P"2&^!_^OG4_P#T."N'J*?#.7-7<.KZR[^I4LVQ2>DNW1=O
M0_=+_B,SA_Z(/)_X4X_^1Z/^(S.'_H@\G_A3C_Y'K\+:*O\ U7RW_GW^,O\
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M (4X_P#D>OPMHH_U7RW_ )]_C+_,/[6Q7\WX+_(_=+_B,SA_Z(/)_P"%./\
MY'H_XC,X?^B#R?\ A3C_ .1Z_"VBC_5?+?\ GW^,O\P_M;%?S?@O\C]TO^(S
M.'_H@\G_ (4X_P#D>C_B,SA_Z(/)_P"%./\ Y'K\+:*/]5\M_P"??XR_S#^U
ML5_-^"_R/W2_XC,X?^B#R?\ A3C_ .1Z/^(S.'_H@\G_ (4X_P#D>OPMHH_U
M7RW_ )]_C+_,/[6Q7\WX+_(_=+_B,SA_Z(/)_P"%./\ Y'H_XC,X?^B#R?\
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M!?Y'[-?\1F</_1!Y/_"G'_R/1_Q&9P_]$'D_\*<?_(]?A;16G^J^6_\ /O\
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M3_@_Y,^/Z***](Y0HHHH [C]G'_DKMA_UZWO_I'-7#UW'[./_)7;#_KUO?\
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M1^1%U;265S)#-')#-"Q22-U*LC X((/((/:HZ_2SXT?L;?#GX$_!SX.V^B_
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MO%?>TNZ[]SIITXSJM2VU?W)OS/FCQ'_P3'^.7A+QAXTT+4/ LUOJ'P_\)_\
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M?C=^RE;?M+_\%7O$7PE^!_AE_#MOXF\5R:;HNC:GJ5I,FBG&ZX22>TFN(3#
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M?BM16E3*8SFYM[N^VNK3U?5:$1QLHQ2M_5FOU/V<_:?_ &I/ >LZ9^T->?\
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MZAX!NO@%#X8N/"6J_$NVL;?3O$OVAM]Q#X6CTZ>]EUA+]OM(OFECAE0[VG1
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M[SXL_M2_$[X]Z'INE^.OB-X\\::;HI+:?::]K]WJ4%@2H4F))I&6/Y0!\H'
M K5\3?MP_&KQKXN\.^(-9^,'Q1U;7O"#3/H6I7OBJ_N+S1&F55E-K*\I> NJ
M(&,97<%4'.!7EU%3[&G:W*ON[[_>/VDNYZ%I/[7'Q7T"\T.XL?B=\0K*X\,W
M-[>:/+!XCO(WTF>]W_;);<K(#"]QYC^:R8,F]MQ;)JGX7_:8^)'@<>$QHOQ
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M\"?\D5\>_73O_1[5P]=QX$_Y(KX]^NG?^CVKAZRI_%+U_1%RV7I^K"BBBMB
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MA/XM?!N_\>Z=H7BC6+2]_L?48%_>1NT=I%'>*(W'E[H4",I=EDX5/%OV:/\
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MX7N+W3++Q!<ZOJDS6YB.H+%/";2*2)V$YLD>19 !$AC8O[9>_P#!'7X*^"_
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MVG_Q%>R44?6*O\S^]A[.'9'C?_#NWX"_]$9^&/\ X3=I_P#$4?\ #NWX"_\
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M'=OP%_Z(S\,?_";M/_B*]DHH^L5?YG][#V<.R/&_^'=OP%_Z(S\,?_";M/\
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MGX8_^$W:?_$4?\.[?@+_ -$9^&/_ (3=I_\ $5[)13^L5?YG][#V<.R/&_\
MAW;\!?\ HC/PQ_\ ";M/_B*/^'=OP%_Z(S\,?_";M/\ XBO9**/K%7^9_>P]
MG#LCQO\ X=V_ 7_HC/PQ_P#";M/_ (BC_AW;\!?^B,_#'_PF[3_XBO9**/K%
M7^9_>P]G#LCQO_AW;\!?^B,_#'_PF[3_ .(H_P"'=OP%_P"B,_#'_P )NT_^
M(KV2BCZQ5_F?WL/9P[(\;_X=V_ 7_HC/PQ_\)NT_^(H_X=V_ 7_HC/PQ_P#"
M;M/_ (BO9**/K%7^9_>P]G#LCQ^[_P""?7P+U"?S;CX/_#>>0@*7D\/6K,0
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M$9^&/_A-VG_Q%>R44?6*O\S^]A[.'9'C?_#NWX"_]$9^&/\ X3=I_P#$4?\
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M,?\ PF[3_P"(H_X=V_ 7_HC/PQ_\)NT_^(KV2BCZQ5_F?WL/9P[(\;_X=V_
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MVG_Q%>R44?6*O\S^]A[.'9'C?_#NWX"_]$9^&/\ X3=I_P#$4?\ #NWX"_\
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M_/;5?_!G<_\ QRM6B@#*_P"$.L_^>VJ_^#.Y_P#CE'_"'6?_ #VU7_P9W/\
M\<K5HH RO^$.L_\ GMJO_@SN?_CE'_"'6?\ SVU7_P &=S_\<K5HH RO^$.L
M_P#GMJO_ (,[G_XY1_PAUG_SVU7_ ,&=S_\ '*U:* ,K_A#K/_GMJO\ X,[G
M_P".4?\ "'6?_/;5?_!G<_\ QRM6B@#*_P"$.L_^>VJ_^#.Y_P#CE'_"'6?_
M #VU7_P9W/\ \<K5HH YGPGX:AU#PW9S37&K22R1AF8ZG<\G_ONM'_A#K/\
MY[:K_P"#.Y_^.4G@;_D4=/\ ^N(K6H RO^$.L_\ GMJO_@SN?_CE'_"'6?\
MSVU7_P &=S_\<K5HH RO^$.L_P#GMJO_ (,[G_XY1_PAUG_SVU7_ ,&=S_\
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M (Y1_P (=9_\]M5_\&=S_P#'*U:* ,K_ (0ZS_Y[:K_X,[G_ ..4?\(=9_\
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MYJ__ (,[C_XNK5% %7^RO^GS5_\ P9W'_P 71_97_3YJ_P#X,[C_ .+JU10
MS3]%668AKO5F&W/_ "$[C_XNKG_".P_\_.K?^#.Y_P#BZ-+_ ./AO]W_  J_
M0!0_X1V'_GYU;_P9W/\ \71_PCL/_/SJW_@SN?\ XNK]% %#_A'8?^?G5O\
MP9W/_P 71_PCL/\ S\ZM_P"#.Y_^+J_10!0_X1V'_GYU;_P9W/\ \71_PCL/
M_/SJW_@SN?\ XNK]% %#_A'8?^?G5O\ P9W/_P 71_PCL/\ S\ZM_P"#.Y_^
M+J_10!0_X1V'_GYU;_P9W/\ \74&H:%'%""MUJRG=C_D)W'_ ,76M5;5/^/=
M?][_ !H QO[*_P"GS5__  9W'_Q=']E?]/FK_P#@SN/_ (NK5% %7^RO^GS5
M_P#P9W'_ ,71_97_ $^:O_X,[C_XNK5% %7^RO\ I\U?_P &=Q_\71_97_3Y
MJ_\ X,[C_P"+JU10!5_LK_I\U?\ \&=Q_P#%T?V5_P!/FK_^#.X_^+JU10!5
M_LK_ *?-7_\ !G<?_%T?V5_T^:O_ .#.X_\ BZM44 5?[*_Z?-7_ /!G<?\
MQ=7K/0(Y+96:ZU8DY_YB=SZ_[]1UI6'_ !Z+^/\ .@"K_P (Y#_S]:M_X,[G
M_P".4?\ ".0_\_6K?^#.Y_\ CE:%% &?_P (Y#_S]:M_X,[G_P".4?\ ".0_
M\_6K?^#.Y_\ CE:%% &?_P (Y#_S]:M_X,[G_P".4?\ ".0_\_6K?^#.Y_\
MCE:%% &?_P (Y#_S]:M_X,[G_P".4?\ ".0_\_6K?^#.Y_\ CE:%% &?_P (
MY#_S]:M_X,[G_P".4?\ ".0_\_6K?^#.Y_\ CE:%% &#>:.L=RRK>:N ,?\
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MG<__ !RM6B@#*_X0ZS_Y[:K_ .#.Y_\ CE'_  AUG_SVU7_P9W/_ ,<K5HH
MRO\ A#K/_GMJO_@SN?\ XY1_PAUG_P ]M5_\&=S_ /'*U:* ,K_A#K/_ )[:
MK_X,[G_XY1_PAUG_ ,]M5_\ !G<__'*U:* ,K_A#K/\ Y[:K_P"#.Y_^.4?\
M(=9_\]M5_P#!G<__ !RM6B@#*_X0ZS_Y[:K_ .#.Y_\ CE'_  AUG_SVU7_P
M9W/_ ,<K5HH RO\ A#K/_GMJO_@SN?\ XY1_PAUG_P ]M5_\&=S_ /'*U:*
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MBD)BF20A8R0&3JKJY\C^&W[!W[2?[+OPK_9M^)NFZ=I?Q5^+'PET/4O#VO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M*?B/_D7K[_KWD_\ 033]&_Y ]K_UQ3_T$4SQ'_R+U]_U[R?^@FGZ-_R![7_K
MBG_H(H I>(_^0KH?_7\W_I//6M63XC_Y"NA_]?S?^D\]:U !7SK_ ,%:/"_B
M[QK_ ,$X_BWI/@:WO[SQ'?:(8H[:R#-<75N98_M42*OS.7MO.78,EMVW!SBO
MHJBM*-1TZD:BZ-/[C*O2]K3E3;MS)K[S\_\ ]F/]N/X+_M+1?!WX2?!GX40_
M$[P_X6BMM2U6:^T<V=C\.)((&:&=FN+=D>^:3SE1HW&YS(1-RS5\5_!_XN^$
M?V@O^"DWP8\?>'X8_!_Q USQQJ&H>+("=>DUG0[6RAD\RTOK^\N3:3FXMUD#
M06EI&(HP(B57Y#^ZE%>I2S.%-RY(/WDU\5][WOI9[KHMEKO?RJV4U*JASS7N
MM/X;;6M;6ZV:U;W>BTM^(/PU_9_L?&WPU_9U^*'VSQ#'\5/CE\=;C7=-O#J=
MP%T/3#>S->R1VX8(TDH@@=I"I9UV NJJ%KL_A9IGP[^/_P"W/KUK\5&^-4_[
M4D?Q6FBTE?#/FI)X+T.WE#6LI:8?9%TP(V78>;(R.K(")"S_ +%T5I+.I2O[
MKZVUVN[VVVV376WF90R*,;>\NE[K>RM??XKW:>MKVZ(_$/P#X%NOC?\ \%&9
M+?Q9XF\5Z3^TA9_%*>?R;'PKJ-YJ6@:+ ZO$6NY-4M[!-):W; *6TDI20;?,
M210WUM_P2)_9=\+_ !NU+Q1^TMXAL[S5O$GB;XA^)-9\)//?3&ST:UEF:SD>
M"#<(S)(L)C:1U9ML$0&W;D_H-166(S:=2')%6T2WZ:W2T6CTTZ:[W-<+DL*5
M3GD^;5O;KI9O5ZK772[:VL%%%%>0>T%%%% &3X&_Y%'3_P#KB*UJR? W_(HZ
M?_UQ%:U !17Q;_P5HTE_@=XN^#O[1VGQS+)\)_$D5AXA: '=)H=^?(N-Q&<[
M&90H(QF=CD$<\O\ L0_L[^&?^"B'A_X\?%3XE:.VO>&_C9XB72])M&N)K8/H
M6DS(MF4DA:-UWSP!F"$;F@!);<PKUH9;%X98N<[0V=E=\U[<NZO[OO;KMYGG
M2QTO;O#1C[V^]E:V^S^U[NS[^1]]45^(>E?L-_"W0O\ @G3^U)\0+7POY7B[
MP'XXUOPWH5__ &E=M]AT])K2%(?+,ICDQ'-(-\BLYW9W9 (]L_8&_8Q\<?"G
MX]^ ?B;X=^!-Y\#?"OAOPW?W/B>2S\=_\)1=?$:*6UC-O;16@D/E/YJ^:$.U
M<L.=R(#W5LCH0IRFJWPMK515VDG;XVW>Z2LGKNDM3CI9M6E.,72WL]&W9-M7
M^&VEF]6M-KO0_5"BORY_X*$_M0:O^VCJ_P %?"$7P3^,0\-^(O$&J0ZGX%\5
MD>"Y_%\]K9PS6J?:3*0MNKR.Y).6:'"C<%8<C\.+'P9^U%X8_9*^#.I1^-[7
MX6WOB+Q?IWB+PUKVN>=-#?Z=;)-;:>;VV6#S88Y)F$1(#;<("-H SIY#+V4:
MM25MVTDG9)2?\U[OE=M$O[U[I7/.(^T=.G&^R3NU=MQ7;;WE?5ORV/UTHK\<
M_@)IT?[47@?]E/X.^/M5U77/A3J'BSQIIC02ZE+&NK6VEP*=+@:>)E)5"[H@
M#?=153 "@?:G_!$KQ7J/B+]A'3[.\U*ZU:Q\,ZYJ>A:-=7$_GN^G6]PR6ZA_
MXD1/D7L%10,* !EC\G^K4G-SNT[6MTO**=[[WB[JVFFK-,'FGMZBARV37?K:
M+:M;;WEK?Y'UQ63X;_Y"6M_]?P_]$0UK5BZ1>1Z=+X@N)FV0P79D=L$[5%O$
M2<#GI7B'K&U17Q_X)_;5^*L7[*C?M%>(=/\  %U\*[SP=J/C!?#5C;W=KK^D
MP);M=6"M>M++!=O+&@CE46]N(WF#*TBQD.>,OVP?B_\ L[6C1_$"'X=ZU>>*
M?AYK7BWP])H.F7=G#HVI:7:)<S6%XLUU*UW"Z3Q[+B(V[$P2!HE\Q"E^S9/,
MC[ HKXA\)?M5?M'>*_B+H?A-KSX*V&H^*_AP/B1;71\.ZG-%HT:2I&^FR1C4
M%-VS-<V^+I7MPHCE/D/N4+B?"3]I#XX?M3_'C3?$WPWU'PIX?MO$7P&\,>+Y
MM(\21WNIZ7!J=W>:L1;PP0W-N(VFV;'O"794M8@89-P\M^S>X<R/OFBOC/X>
M_M[?$K]L?P[-K'P=T_P3X<M=!\!:7XNU"V\66ESJ,NJWVHP33P:9"]O/;BVC
MC6W97NW6;<TZ[8 (SO\ IC]G'XU6?[2'[/\ X)^(&G6LUC8^-=#L];AM9FW2
M6JW$*2^4Q'!9-VTD<$C(XJ91:W!23V.THKXL_:W_ ."D7C3]FK6_BIH%KHGA
MO6/$OAK5=%N/#%HT,T9U+1KFRN+Z\:1?-S)<)%I6L*A0HNY(<H<,&O\ Q+_:
MV\4>/?CWX.T_PK-H$?AS4OB++X1T+57>_D2XDC\+7E]-=30V]Y!'=0I=E8?(
MF&W-M*PP_E2QOV;#F1]B45^9O['GQ.^/7C>\_9:L;3XD:7>:KXK^&WB/5-0O
M=<L=0O[-HXKO2A#+=6HOT:]NU+O&)C/%M6X=@ORE)/L/]FS]K:;XI?L*:=\7
M/$6GVUK>6VBWM_J]KIQ8PF:R::.X\C?\P1GMW**Q) 8 LV-Q)4V@C*Y[3?V$
M&JV,UK=0PW-K<QM%-#*@>.5&&&5E/!!!((/!!K/\#> M#^&'A.QT'PSHND^'
M="TU#%9Z=IEG':6EJA);;'%& B#))P .2:^)_P!IGXT_M 7'_!-SX@?$?5-4
M\"Z/I/B#X<7GB#3_ /A%AJ&FZYX0N9(5GM4%VT[K>8C<J\\:6C+(BE8V5CLZ
M3XG?M]?$+]D[5OB!I_Q(T_P?XGU#0_ EEXSTB#PYI][8;;BXU"33_P"S9MTM
MV\X69K;%Q$B,P9\6X( +]F^@<R/LJBOAV'_@I)\1OAMX:\97'B/PK=>+DTCP
MW#JNFZROPX\1^ =,&IR7T%BFF3#5A*9-SW4,JS1/DQI/F$% 6M?MJ?%OXT_L
MX?!'3->^(&N>';_3]/\ '?@^==0^'VG:CIM]=6[:Q;+?Z?)8O<7#S+)'\J^7
M,?/$CHT*8'F'LW>P<R/MBBOBW2?VT_C3\4/"GP3UCPK#\+;.+X]:_<1:9;7M
MC=WK^%]*CTV[N\W;QW<8N+Y/LX,L*+"J.)+?=D?:!=\/?MP?$[QKXSL_A38V
M_@.Q^*$?C36?"^HZ_/I]W/H:6NG65IJ'VV.P%PDQDFM[^S3R#=XCD:4^;(J
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M?HE_P:F_\I#?&7_9.KW_ -.6EU\8_P##N']H;_H@WQG_ /")U/\ ^,U^A_\
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M444 %:5A_P >B_C_ #K-K2L/^/1?Q_G0!-1110 4444 %%%% !1110 4444
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MI<_L]ZA\*Y/ACI;> M2UUO$LFE_;KS]QJ#*B-/!-YWG6^4C5-L+HNS<NW:S
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ML2SLS,Q+,2>BHJ9XFM./).3:O>S;M=[OU\QQH4XRYXQ2=K7LKV[>@5D^&_\
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MV1&.U1[IHXT2.-]0:Z:,*2#N9F;N/B_^Q/X'^._Q"U_Q!XHBU+4O^$E\(?\
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M^/4?\14RG_GW4^Z/_P F'_$'\Y_Y^TO_  *?_P @?EW17ZB?\.ZO@W_T)_\
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M^"O_ $)G_E7OO_CU'_#MOX*_]"9_Y5[[_P"/4?\ $5,I_P"?=3[H_P#R8?\
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M "BBB@ HHHH *TK#_CT7\?YUFUI6'_'HOX_SH FHHHH **** "BBB@ HHHH
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M<16M0 4444 %%%% !1110 4444 %9/AO_D):W_U_#_T1#6M63X;_ .0EK?\
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MHH **** "BBB@"SI?_'PW^[_ (5?JAI?_'PW^[_A5^@ HHHH **** "BBB@
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M_/Q#_P!]BC^TK?\ Y^(?^^Q5;_A%M+_Z!MA_X#I_A1_PBVE_] VP_P# =/\
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M?[2M_P#GXA_[[%']I6__ #\0_P#?8JM_PBVE_P#0-L/_  '3_"C_ (1;2_\
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M_P * +'V^#_GM#_WV*/M\'_/:'_OL57_ .$:TW_H'V/_ 'X7_"C_ (1K3?\
MH'V/_?A?\* *U_?0_:V_?1=OXQZ5#]NA_P">T7_?8I+[P[IXNF_T&S[?\L%]
M/I4/_"/:?_SXV?\ WY7_  H G^W0_P#/:+_OL4?;H?\ GM%_WV*@_P"$>T__
M )\;/_ORO^%'_"/:?_SXV?\ WY7_  H G^W0_P#/:+_OL4?;H?\ GM%_WV*@
M_P"$>T__ )\;/_ORO^%'_"/:?_SXV?\ WY7_  H G^W0_P#/:+_OL4?;H?\
MGM%_WV*@_P"$>T__ )\;/_ORO^%'_"/:?_SXV?\ WY7_  H G^W0_P#/:+_O
ML4?;H?\ GM%_WV*@_P"$>T__ )\;/_ORO^%'_"/:?_SXV?\ WY7_  H G^W0
M_P#/:+_OL4?;H?\ GM%_WV*@_P"$>T__ )\;/_ORO^%'_"/:?_SXV?\ WY7_
M  H [K^TK?\ Y^(?^^Q1_:5O_P _$/\ WV*K?\(MI?\ T#;#_P !T_PH_P"$
M6TO_ *!MA_X#I_A0!9_M*W_Y^(?^^Q1_:5O_ ,_$/_?8JM_PBVE_] VP_P#
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MBVE_] VP_P# =/\ "C_A%M+_ .@;8?\ @.G^% %G^TK?_GXA_P"^Q1_:5O\
M\_$/_?8JM_PBVE_] VP_\!T_PH_X1;2_^@;8?^ Z?X4 6?[2M_\ GXA_[[%'
M]I6__/Q#_P!]BJW_  BVE_\ 0-L/_ =/\*/^$6TO_H&V'_@.G^% %G^TK?\
MY^(?^^Q1_:5O_P _$/\ WV*K?\(MI?\ T#;#_P !T_PH_P"$6TO_ *!MA_X#
MI_A0!9_M*W_Y^(?^^Q1_:5O_ ,_$/_?8JM_PBVE_] VP_P# =/\ "C_A%M+_
M .@;8?\ @.G^% %G^TK?_GXA_P"^Q1_:5O\ \_$/_?8JM_PBVE_] VP_\!T_
MPH_X1;2_^@;8?^ Z?X4 6?[2M_\ GXA_[[%']I6__/Q#_P!]BJW_  BVE_\
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MAKTCZ UJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7_>_QH H4444 %%%% !1110 4444 %%%% !6E8?\>B_C_.LVM*P_X]%_'^=
M$U%%% !1110 4444 %%%% !1110!FW__ !]M^'\JAJ:__P"/MOP_E4- !111
M0 4444 %%%% !1110 4444 =I1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 4_$?_
M "+U]_U[R?\ H)I^C?\ ('M?^N*?^@BF>(_^1>OO^O>3_P!!-/T;_D#VO_7%
M/_010!2\1_\ (5T/_K^;_P!)YZUJR?$?_(5T/_K^;_TGGK6H **** "BBB@
MHHHH **** "BBB@ HHHH R? W_(HZ?\ ]<16M63X&_Y%'3_^N(K6H *X7XW_
M  LOO'D6CZMH-Y;Z;XK\+W+7>EW%PI:!]RE)8)0.?+D7@E?F& 1Z'>\>?$SP
MW\*]+M[[Q1X@T/PW97=TEE!<:I?16<4T[YV0JTC*&D;!PH.3@X%'BGXH>&?
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M9^HE%?EW_P /%?C)_P!#A_Y2;'_XS1_P\5^,G_0X?^4FQ_\ C-'_ !"O-O\
MGY3^^7_R ?\ $8,F_P"?57_P&'_R9^HE%?EW_P /%?C)_P!#A_Y2;'_XS1_P
M\5^,G_0X?^4FQ_\ C-'_ !"O-O\ GY3^^7_R ?\ $8,F_P"?57_P&'_R9^HE
M%?EW_P /%?C)_P!#A_Y2;'_XS1_P\5^,G_0X?^4FQ_\ C-'_ !"O-O\ GY3^
M^7_R ?\ $8,F_P"?57_P&'_R9^HE%?EW_P /%?C)_P!#A_Y2;'_XS1_P\5^,
MG_0X?^4FQ_\ C-'_ !"O-O\ GY3^^7_R ?\ $8,F_P"?57_P&'_R9^INE_\
M'PW^[_A5^OREB_X*-_&:%LKXRP>G_()L?_C-2?\ #R3XU?\ 0Z?^4BQ_^,T?
M\0KS;_GY3^^7_P @'_$8,F_Y]5?_  &'_P F?JM17Y4_\/)/C5_T.G_E(L?_
M (S1_P /)/C5_P!#I_Y2+'_XS1_Q"O-O^?E/[Y?_ " ?\1@R;_GU5_\  8?_
M "9^JU%?E3_P\D^-7_0Z?^4BQ_\ C-'_  \D^-7_ $.G_E(L?_C-'_$*\V_Y
M^4_OE_\ (!_Q&#)O^?57_P !A_\ )GZK45^5/_#R3XU?]#I_Y2+'_P",T?\
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M+XF>&YOB))X/3Q!H;>+(; :K)HBWT1U&.S+^6+DV^[S!"7^3S"NW=QG/%;E
M!1110 45G>+?&&D^ /#5YK6O:IIVBZ/IT9FN[Z_N4MK:U0=6DD<A57W) K1H
M **YV_\ B]X3TK6I]-NO%'AVVU"UO;;3)K674H4FBN[E0UM;LA;<)95(,:$;
MG!RH-:/ASQ?I/C!+QM)U33M473KN73[LV=RDXM;F([9()-I.V1#PR'#*>H%
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M 4444 %%%% !1110 4444 %%%% &3X&_Y%'3_P#KB*UJR? W_(HZ?_UQ%:U
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ME_R)<3_A_5'U7 __ "/L+_B7Y,_0ZBBBOY=/ZZ"BBB@ HHHH **** "BBB@
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MQQQH J*!P%4 "I<T^@U%GP)\>?#UO\/+F\\#^%OB)X^\=>$_B'\%-?\ $'B
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M:?JFS6AP_E=&HJM'#4XR6S4(IKT:5T4****\L]<**** "BBB@ HHHH ****
M"M*P_P"/1?Q_G6;6E8?\>B_C_.@":BBB@ HHHH **** "BBB@ HHHH S;_\
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M6[DMK6$7+RR^7$K.P4>@)Z>M?7/_  E=A_SV;_OT_P#A1_PE=A_SV;_OT_\
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M]F_[]/\ X4?\)78?\]F_[]/_ (4 ;6E_\?#?[O\ A5^N?TWQ;IZSMF9ON_\
M/)_;VJ[_ ,)AI_\ SW;_ +]/_A0!IT5F?\)AI_\ SW;_ +]/_A1_PF&G_P#/
M=O\ OT_^% &G169_PF&G_P#/=O\ OT_^%'_"8:?_ ,]V_P"_3_X4 :=%9G_"
M8:?_ ,]V_P"_3_X4?\)AI_\ SW;_ +]/_A0!IT5F?\)AI_\ SW;_ +]/_A1_
MPF&G_P#/=O\ OT_^% &G5;5/^/=?][_&JO\ PF&G_P#/=O\ OT_^%5]2\7:>
MT"XG;[W_ #R?W]J 'T5G?\)78?\ /9O^_3_X4?\ "5V'_/9O^_3_ .% &C16
M=_PE=A_SV;_OT_\ A1_PE=A_SV;_ +]/_A0!HT5G?\)78?\ /9O^_3_X4?\
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MTS_GX;_OR_\ \30!K45D_P#";:9_S\-_WY?_ .)H_P"$VTS_ )^&_P"_+_\
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M 4444 %%%% !1110!C_#[_D2]._ZXBMBL?X??\B7IW_7$5L4 %%%% !1110
M445\I_%3_@J/H>D++;^$='N=8G'"W=[FWMP?4)]]A['97/B,52H*]5V.#'YI
MAL%%3Q,N6^W=^B1]645\I_"O_@J1HFL&*W\7:+<Z/,WRM>61^T6_U*'#J/8;
MS_3ZLHP^*I5U>D[AE^:8;&Q<\-/FMOW7JF%8_A;_ )"FO?\ 80'_ *3P5L5C
M^%O^0IKW_80'_I/!70=YL4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 <U\1?];HO_ %^M_P"B)JH5?^(O^MT7_K];_P!$350H ***
M* "BBB@ HHHH **** "BBB@#.U;_ )#.E?\ 75__ $4U:-9VK?\ (9TK_KJ_
M_HIJT: "BBB@ HHHH **** "BBB@ HHHH LZ7_Q\-_N_X5?JAI?_ !\-_N_X
M5?H **** "BBB@ HHHH **** "JVJ?\ 'NO^]_C5FJVJ?\>Z_P"]_C0!0HHH
MH **** "BBB@ HHHH **** "M*P_X]%_'^=9M:5A_P >B_C_ #H FHHHH **
M** "BBB@ HHHH **** ,V_\ ^/MOP_E4-37_ /Q]M^'\JAH **** "BBB@ H
MHHH **** "BBB@#M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"GXC_Y%Z^_Z]Y/
M_033]&_Y ]K_ -<4_P#013/$?_(O7W_7O)_Z":?HW_('M?\ KBG_ *"* *7B
M/_D*Z'_U_-_Z3SUK5D^(_P#D*Z'_ -?S?^D\]:U !117Y7?%W_@M%\7+3Q!\
M:-3\*>)OV5]&\+?"_7M1T?3M)\6WU_#XH\0K: ?-;6L5Q^^\QOD1ML:EL@D!
M6(Z\)@JF(;5/I^IQXS'4L,DZO7MY'ZHT5\B^&O\ @L5X)U;X@Q>#[KP3\2(_
M$]A8:/J/B-+'2DO-/\+07UBEY+<7=SO7RK>S61%FDD1&W-B-)"KA-#]G/_@K
M]\-?VDOB_H/A*Q\._$OPU%XR%X?">O\ B+P\;#1?%QM3^\%C/O8N=F7 =$X&
MT[7*H7++\0DY.#LE?Y;_ ):BCF6&DU%35V[?/;\]/4^JJ*^//A1_P6T^%?Q>
M^*GA?PS9>&?BCI]EXNUZ;PQI_B2_T!8M!?4HV=5MOM*S-NDD*IM5%8@31E]G
MS;>(^&'_  6_TH_'/QKX?\9>&?$,GAFS^)$G@30M?T'P[.^F6 5TBCDU*[DF
MV;Y9&<HD*EPD3,4 *DU_9N)U7(]%?]"/[5PNCYU9NWX7/OJBOF_Q5_P5#^'W
MA'X<^-O$%SI7B^2?P3X^;X;'1HK2W;4];U??$L:V<9G"O'(LOF(TCQDI&Y*@
MC!Y'PG_P4MUC_A-/CU>:EX$\3^(_"OPW\36'A/P[I7@[P]<:MXBU*]-J9+])
M525H6$3\AOW2*BX+R,R Q' UFF^7^M/\T:2S"@FES;_Y-_HSZ^HKY1L/^"QG
MPIN/V=;[X@76F^/-+N['Q._@P^#[S10GBB?65VD6*68D(,I5U(RX Y4E7!6O
M.?C[_P %S=%\*_LN7'B[P+\-_B#J?C*;Q'+X+7P[KFD&TN-!U<*A2/4(HW9A
MO5]T<49W3,CQ[HV5V2X9;B92Y5![V^?]=3.>:86,>9S6U_E_73<^]**^/Y_^
M"L?A?P7JWQ.U;Q8VMZ3X=^'-AHL$VD3>%O)U>XUG4;7[3'IT+K?2B:YX,;0F
M")8G!+3LBEQZO^QQ^W1X6_;3L_%$>C:'XR\(Z]X+OH['6_#_ (KTL:;JVG-+
M'YD3R0AW"K(H;;EL_(V0.,YU,'6A'G<=--?6W^:^\UIXZA.2A&6KOIZ7_P G
M]S/4?A]_R)>G?]<16Q6/\/O^1+T[_KB*V*Y3K"BBB@ HHHH *_'O4]+NM$OY
M+6\M[BSNH3MDAFC,<D9]"IY'XU^PE<]\0?A-X:^*NG?9?$6B:?JT>-JM/$#)
M%_N./F0^ZD&O+S/+WBE'E=FK_C;_ "/F>),AEF48<D^5PONM'>WW;>9^3FEZ
M5=:Y?QVME;7%Y=3-MCA@C,DDA] HR2?I7["5SOP_^$?AGX5V/V?P[H>GZ4F-
MK-#$/,D'^TYRS?B371499E[PJES.[=OPO_F'#>0RRV,^>?,YVV6BM?[]_(*Q
M_"W_ "%->_[" _\ 2>"MBL?PM_R%->_[" _])X*]0^F-BBBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#FOB+_K=%_Z_6_]$350J_\
M$7_6Z+_U^M_Z(FJA0 4444 %%%% !1110 4444 %%%% &=JW_(9TK_KJ_P#Z
M*:M&L'QSXFTWP?\ 8-2U;4+'2]/MY6\VZO)U@ABW(57<[$*,L0!D\D@5C_\
M#2WPY_Z*!X)_\'EK_P#%UT4L+7JKFI0<EY)O\CFK8S#T9<M6<8OS:7YG;45Q
M/_#2WPY_Z*!X)_\ !Y:__%T?\-+?#G_HH'@G_P 'EK_\76G]FXO_ )]2_P#
M7_D9?VI@_P#G['_P)?YG;45Q/_#2WPY_Z*!X)_\ !Y:__%T?\-+?#G_HH'@G
M_P 'EK_\71_9N+_Y]2_\!?\ D']J8/\ Y^Q_\"7^9VU%<3_PTM\.?^B@>"?_
M  >6O_Q='_#2WPY_Z*!X)_\ !Y:__%T?V;B_^?4O_ 7_ )!_:F#_ .?L?_ E
M_F=M17$_\-+?#G_HH'@G_P 'EK_\71_PTM\.?^B@>"?_  >6O_Q=']FXO_GU
M+_P%_P"0?VI@_P#G['_P)?YG;45Q/_#2WPY_Z*!X)_\ !Y:__%T?\-+?#G_H
MH'@G_P 'EK_\71_9N+_Y]2_\!?\ D']J8/\ Y^Q_\"7^9W^E_P#'PW^[_A5^
MO.=-_:9^&Z3MN^('@A?E[Z[:_P#Q=7?^&GOAK_T4/P-_X/K7_P"+H_LW%_\
M/J7_ ("_\@_M3!_\_8_^!+_,[FBN&_X:>^&O_10_ W_@^M?_ (NC_AI[X:_]
M%#\#?^#ZU_\ BZ/[-Q?_ #ZE_P" O_(/[4P?_/V/_@2_S.YHKAO^&GOAK_T4
M/P-_X/K7_P"+KN:QK8>K2M[6+C?NFOS-Z.*HUK^QFI6WLT_R"BBBL3<****
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MLX])O9@T;"66U$?E.X:*([F4G,2'^$8]!HHI78!1110 4444 %%%% !1110
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M^(KXO_GQ'[V'_$&\'_T$2^Y'Y#)^S-\2'/R_#[QNWTT*Z_\ B*=_PS#\2O\
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M7_75_P#T4U:-9VK?\AG2O^NK_P#HIJT: "BBB@ HHHH **** "BBB@ HHHH
MLZ7_ ,?#?[O^%7ZH:7_Q\-_N_P"%7Z "BBB@ HHHH **** "BBB@ JMJG_'N
MO^]_C5FJVJ?\>Z_[W^- %"BBB@ HHHH **** "BBB@ HHHH *TK#_CT7\?YU
MFUI6'_'HOX_SH FHHHH **** "BBB@ HHHH **** ,V__P"/MOP_E4-37_\
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MN4]O>KW_  F6C_\ 05TW_P "4_QIVEH/M#<#[OI]*O[!Z#\J ,[_ (3+1_\
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MO^@EI_\ X$)_C5_8/0?E1L'H/RH H?\ "6Z5_P!!+3__  (3_&C_ (2W2O\
MH):?_P"!"?XU?V#T'Y4;!Z#\J *'_"6Z5_T$M/\ _ A/\:T;'QAI(M5_XFFG
M=_\ EY3U^M-V#T'Y5I6"#[(O []O>@"I_P )CI'_ $%--_\  E/\:/\ A,=(
M_P"@IIO_ ($I_C6CL'H/RHV#T'Y4 9W_  F.D?\ 04TW_P "4_QH_P"$QTC_
M *"FF_\ @2G^-:.P>@_*C8/0?E0!G?\ "8Z1_P!!33?_  )3_&C_ (3'2/\
MH*:;_P"!*?XUH[!Z#\J-@]!^5 &=_P )CI'_ $%--_\  E/\:/\ A,=(_P"@
MIIO_ ($I_C6CL'H/RHV#T'Y4 9W_  F.D?\ 04TW_P "4_QH_P"$QTC_ *"F
MF_\ @2G^-:.P>@_*C8/0?E0!SU]XNTDW3?\ $ST_M_R\IZ?6H?\ A+=*_P"@
MEI__ ($)_C6K?H/M;<#MV]JAV#T'Y4 4/^$MTK_H):?_ .!"?XT?\);I7_02
MT_\ \"$_QJ_L'H/RHV#T'Y4 4/\ A+=*_P"@EI__ ($)_C1_PENE?]!+3_\
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MTO\ \"H_\:/^$XT7_H,:7_X%1_XUI>6O]U?RH\M?[J_E0!F_\)QHO_08TO\
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M "*.G_\ 7$5K4 %0ZAJ%OI-C-=74T-M;6Z&26:5PD<2@9+,QX  YR:FKQO\
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MUO\ Z_A_Z(AKV3ZXUJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** .:^(O^MT7_ *_6_P#1$U4*O_$7_6Z+_P!?K?\ HB:J% !1110
M4444 %%%% !1110 4444 9VK?\AG2O\ KJ__ **:M&L[5O\ D,Z5_P!=7_\
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M^R%%7[9D^S1^,WQ!_9WUSXX>%OVH?'7PE_9Q\??!7P#KOPMMO"5KX/O?"O\
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M^('POMH[RUTWQOI[7>@V]W=?:98-2M 9H%,BQHN759$9@B[@%&.@KNO \_\
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MKHU*,Y/WN754X1V;>RDEUWW.E^.7_)I'P-_ZXZY_Z<*/VH%9/A)\%_[0\O\
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M'L5%%%9E!1110 4444 %%%% !1110 4444 4_$?_ "+U]_U[R?\ H)I^C?\
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M'_QJ@#5HK*_X1RY_Z#>J_P#?,'_QJC_A'+G_ *#>J_\ ?,'_ ,:H U:*RO\
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M+_T%=4_\@_\ QN@#-HK2_P"%>+_T%=4_\@__ !NC_A7B_P#05U3_ ,@__&Z
M,VBM+_A7B_\ 05U3_P @_P#QNC_A7B_]!75/_(/_ ,;H S:*TO\ A7B_]!75
M/_(/_P ;H_X5XO\ T%=4_P#(/_QN@#-HK2_X5XO_ $%=4_\ (/\ \;H_X5XO
M_05U3_R#_P#&Z *VE_\ 'PW^[_A5^F1> O(;<NK:H#T_Y8__ !NG_P#"&/\
M]!C5/R@_^-T %%'_  AC_P#08U3\H/\ XW1_PAC_ /08U3\H/_C= !11_P (
M8_\ T&-4_*#_ .-T?\(8_P#T&-4_*#_XW0 44?\ "&/_ -!C5/R@_P#C='_"
M&/\ ]!C5/R@_^-T %%'_  AC_P#08U3\H/\ XW1_PAC_ /08U3\H/_C= !5;
M5/\ CW7_ 'O\:L_\(8__ $&-4_*#_P"-TV7P,9UVMJVJ$9S_ ,L?_C= &316
ME_PKQ?\ H*ZI_P"0?_C='_"O%_Z"NJ?^0?\ XW0!FT5I?\*\7_H*ZI_Y!_\
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MQ?\ H*ZI_P"0?_C= '145E?\(Y<_]!O5?^^8/_C5'_".7/\ T&]5_P"^8/\
MXU0!JT5E?\(Y<_\ 0;U7_OF#_P"-4?\ ".7/_0;U7_OF#_XU0!JT5E?\(Y<_
M]!O5?^^8/_C5'_".7/\ T&]5_P"^8/\ XU0!JT5E?\(Y<_\ 0;U7_OF#_P"-
M4?\ ".7/_0;U7_OF#_XU0!JT5E?\(Y<_]!O5?^^8/_C5'_".7/\ T&]5_P"^
M8/\ XU0!JT5E?\(Y<_\ 0;U7_OF#_P"-4?\ ".7/_0;U7_OF#_XU0!JT5E?\
M(Y<_]!O5?^^8/_C5'_".7/\ T&]5_P"^8/\ XU0!JT5E?\(Y<_\ 0;U7_OF#
M_P"-4?\ ".7/_0;U7_OF#_XU0!JT5E?\(Y<_]!O5?^^8/_C5'_".7/\ T&]5
M_P"^8/\ XU0!JT5E?\(Y<_\ 0;U7_OF#_P"-4?\ ".7/_0;U7_OF#_XU0!JT
M5E?\(Y<_]!O5?^^8/_C5'_".7/\ T&]5_P"^8/\ XU0!JT5E?\(Y<_\ 0;U7
M_OF#_P"-4?\ ".7/_0;U7_OF#_XU0!JT5E?\(Y<_]!O5?^^8/_C5'_".7/\
MT&]5_P"^8/\ XU0!JT5E?\(Y<_\ 0;U7_OF#_P"-4?\ ".7/_0;U7_OF#_XU
M0!JT5E?\(Y<_]!O5?^^8/_C5'_".7/\ T&]5_P"^8/\ XU0!JT5E?\(Y<_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MRTRJ<E@!L.XKD&L/X/?M5#Q?K/BC0?B-=:%:^'?'6FW-OJ&H6OANT@EAO/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
?"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>brns-20231231_g3.jpg
<TEXT>
begin 644 brns-20231231_g3.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X0!F17AI9@  34T *@    @ !@$2  ,
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MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$
M A$#$0 _ /SGHHHK]H/PL**** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M ^Q/^"!'_*6SX3_]Q?\ ],]]7]*'>OYK_P#@@1_REL^$_P#W%_\ TSWU?TH=
MZ_/>+/\ ?%_A7YL_2>#_ /<G_B?Y(****^9/JPHHHH _CKHHHK]H/PL****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M21T<C@^4NR$=>(@>]?0YUFOU2@I4]92T7^9\UD>4_7,0X5-(QU?^1\M>"?\
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MRHTR*&(!!(&2 :/;T^?V=U?M?4GV%3EY^5V[VT.*HHKV ?\ !/7X_$?\D/\
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MC]BL?$OX[ZW\9M:M?,TCP K:=HFXC;)JD\>)'P&S^YMW/#(06N48$-'7MO\
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M_B#XA:;K$FK7>GF'1KVSAM?+BV;3MEM9&W'<<G=CV%>*_P#!:_\ X)H>!?\
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M!RK4GJEH]]7HCIRO!^VQL:%1:-ZK;1:L[;_B$V;_ *+XO_A$?_?"C_B$V?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH ^Q/^"!'_*6SX3_]Q?\ ],]]7]*'>OYK_P#@
M@1_REL^$_P#W%_\ TSWU?TH=Z_/>+/\ ?%_A7YL_2>#_ /<G_B?Y(****^9/
MJPHHHH _CKHHHK]H/PL**** "BBB@ HHHH **** /ZCO^"6/[3?_  UO^P7\
M._%\UW)=:RVFKINLO(J+(U_:_N)W94^5?,9/- &/EE4X7.!^7/\ P=#?LS?\
M(5^T9X-^*5A:[++QQIC:7J<D5IM7[=9XV22RCAGDMY(T56 .VS."P&%Z+_@U
ME_:2DTOXB?$3X37DT[6NL6<?B?2X]J>3#-"RP77S??WR));$#E<6['Y3][[@
M_P""[W[-<?[1?_!-SQJ\<,,FK> U7Q;822R.BQ?9 QN3\N<DVCW("L"I8KG&
M R_GU/\ V#-K?9;_  ?^3_(_2)O^T,GNOB2_%;_>OS/Q,_X)!?LUG]J;_@H7
M\.?#\T+3:/I=^-?U7IM%M9_ORK=]LDBQQ''/[WMU']+_ ,1?'FE_"KP!K/B7
M6KJ.ST?P_8S:A>SN0JQ0Q(7=B20.%4]37Y1_\&LG[-?]F^%/B+\7+ZWVRZE/
M'X8TF1XMK"*/;<714GEE=VMAQQN@8<D?+['_ ,'*O[2W_"H?V&[/P39W'DZK
M\3M52T9%EV.+&U*SW##N1YGV:-@, K,03@X:LWD\;F4<-'967ZM_UV,\EBL#
ME<L3+=W?Z)??^9^%OQT^+FI?'SXT>*_&VL,W]I>*]6N=5G5I/,\III6?RP>/
ME0$*HP  H   Q7*445]Y3@H1Y%L?GTI.4G*6[/L3_@@3_P I:_A/_P!Q?_TS
MWU?T8?%7_DF'B3_L%W7_ **:OYS_ /@@3_REK^$W_<7_ /3/?5_1A\5?^28>
M)/\ L%W7_HIJ^"XG_P!^A_A7YL_0^$_]QGZO\D?R%T445]]'9'YW+<_I,_X(
M#?\ *)7X4?75_P#T\WU? ?\ P=3G/[27PO\ ^Q:G_P#2IJ^_/^" I_XU*?"G
MZZO_ .GB^K[%.T=<?C7YFL=]5S*==1YK2EI>V[?J?JGU'ZWE<*'-RWC'6U]D
MO-'\A7@CX9^)/B9>26_AOP_KGB"XAQOBTVPENW3(8C(C4D9"L?\ @)]#7]"'
M_! W]BKQA^QI^QY?P^.K&;2/$7C#6I-7?2I=OFZ="(XX8UDVL1O81ER,Y4.H
M(# BON">Z@LX&DEDBBC7JSL%4?B:\:_:?_X*%_!W]CWPJ^I^.?'6BV$F&%OI
MUM,+O4;QAGY8[>/=(?F&TN0$4D;F4'-=.89U7Q\/80IVN^FK?X(Y,MR.AE\_
MK%2I>RZZ)?B?%G_!T[XOT^P_8W^'^@27$:ZKJ?C-+^W@,BAWAM[&ZCE<+G<0
MK74() (&\9()7/X5U]&_\%//^"A.L?\ !1C]I&X\67-O<:3X;TN'^SO#NDR2
M[OL5J&+%WQ\OG2L=SD>B)EEC4U+_ ,$]O^"77Q _X*3MXN'@75O"&E_\(9]C
M-]_;MU<P>;]J^T>7Y?DP2YQ]G?=NVXRN,Y./JLMHK+\"GB';J_*[V/DLVK/,
M,>_JRO?1>=EO^;]#YMHK])/^(7+]H -C_A+/A!_X-=1_^0:\A_;=_P""(OQ8
M_8)^"4GC[QAKWP]U'1X[V"P,6C7UY-<^9+NVG;+:QKM&TY.[/L:Z:><82I)0
MA--O8Y*F38RG!U)P:2W/E?P'\4O$_P *]1:\\+^(]>\-W;%6,^EW\MG(2N0I
MW1LIXW-CTW'UKZ"_8D_8(^*'_!6_XI^++JS\9:7-K&CK:W6MZKXIU&[N+NZ2
M4M&&5Q'*TKJL1X=E& HW>GR_7VE_P25_X*GZ)_P3#\/?$:\G\':EXT\0>,GT
MZ*UM4O4T^UMH;;[079YRLK%F,XPHA('E_>^8XK'*I&C*>&5ZFEMNZ[^1&7NE
M*O&&*E:GK??MY>9^SG_!+C_@FKH?_!,KX)ZKHT.M#Q'XB\170O\ 6]::S2S6
M3RU*Q0HN680Q*7(WNV6DE8;0^Q?RV_X.%O\ @I9X?_:V\?>'?AS\/]6M=<\&
M>#)'U&^U.SF66UU74)$"((SMY6",R .CE7-P_'R*3^DG_!.C_@KE\-_^"H%E
MJWA=M#?P[XJMK3SKWPYJCQWL-];'"R/#)M59D5F"L&16P0=N#Q\7?\%X?^"-
M7A7X5_#:]^-OPET>#P]9:5*@\3>'K*+;9B*20(MY;1C_ %.UW17B0>7L(<!-
MC[_C\LER9C?'W]H]KVM=Z?\  70^VS6/M,MY<OM[-;VO>RUZ_>[ZC?\ @U#\
M/1W/C'XW:J8U,UC9Z-:JQ W!9GO7('&<9@7//8<'M]4?\''FN7&D_P#!,;6K
M>'_5ZEKNF6TV<\H)O-'?^]$O7(_'!'S3_P &G'^L^/GT\/?^Y.OHW_@Y1Y_X
M)IW?_8R:=_.2GC-<Z5_YH_D@P>F0MK^5_FS^>JO[ /!^J_V_X1TN^^8_;K2*
M?+  G>@;D#COVK^/^OZ]/A7_ ,DO\.?]@NU_]%+77Q=_RZ^?Z'%P6[NJO3]3
M^;?_ (*#? "UC_X+">.O L<UQ';^*/'D9+N!&T/]IS13L%^4@*IN2%.T_*%.
M#W_IAMX5MX%C156-%"@ 8"@= !7\\W_!0N^74/\ @X'OI%W!5\=^'8_F]4CL
M%/ZJ:_H>/^K_  KS\^E*5+#W_E_1'H\.PC&MB7'^:WW7/Y2_^"@6LW6O_MV?
M&>ZO)I)II/&^LJ2S%MJK?3*JC))VJH"@=@ .U?J9_P &I7C07_PK^,?AW]]N
MTO5M.U$Y5?+_ -)AGCX/WB?]%Y!X VXZFORI_;H_Y/<^,G_8\:U_Z7SU^FG_
M  :;_P"L^/GT\/?^Y.OH,ZBO[*]%'\T?-Y')_P!K^KE^3/5O^#H_P=_:?[%'
M@G6HX))9M(\90P.Z1;A!%-9W6YF;'RKOCB7L"64=<5^$-?T!?\'-'B2#0_\
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M&II!=SI_K(+5 TMPR?*P\P0QR%<C;NV[B!DC^J_0-837_#]C?1?ZJ^@2=/\
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ME[X<U2=1_P 3*P=[\H2R@ RQG,<F OSH2 %92<__ (.E!C]@7P;_ -E L_\
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M_P!?6D_^G.VJLR_Y'$/6)GE/_(EGZ2/YP*_H^_X-\!G_ ()3?#O_ *^M6_\
M3G<U_.#7]'W_  ;X?\HI?AW_ -?6K?\ ISN:];BK_=(_XE^1Y/"'^^2_PO\
M-'PC_P '4_\ R<E\+_\ L6I__2IJ]\_X-7?^33_B/_V-H_\ 2."O _\ @ZG_
M .3DOA?_ -BU/_Z5-7OG_!JY_P FG_$?_L;1_P"D<%>?6_Y$<?E_Z4>AA_\
MD?2_KH?;_P"TIX.^$OPZUV'XZ?%"/1X$^&>F2)9:IJ41FCT5994+RPQ@,3<.
MZPHA13+GY(^9"&\,_9[_ ."^'P!_:0_:(L?ASH]UXGTV_P!8F%II6J:KIR6V
MFZI<L56.WC82M*LDA;"B6- S+MSN9 WC7_!TMXUN-)_9"\!Z'#=20QZUXL$\
MT2[A]H2"UFP&(X*AI5.T]2%/\/'XY?L>S-;_ +6_PMDC9HY(_%^DLK*<%2+V
M'!!KGRW)88G!NO5;OK;LK?\ !-\TSNIAL<J%&*MHY=W?_@']1'[4G[,GA/\
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M5KT7;S/X^-=T2Z\,ZY>:;?1>3>Z?.]M<1[@WER(Q5ER"0<$$9!(K^NGX5?\
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MG*WK^JK5+W^SM,N+C;N^SQ-)MSC=@$XS^%?RJ_\ !/3_ )/\^!O_ &4'0/\
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MCQQ=7<5GK6OVNGW$L+6.GH)%CFD5BA9'4,!@E&&<@U^@G_#Q7]GW_HN'P?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M")IK>2.1XPSNP1F*JSL0 6)/H-C9>#?V:OA*L,":%X+\%^%;(M@>796&FVZ
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MBG[;NL?\% /VHM8^(&I0R:?8M&FG:-ISNKG3+"(L8XBR@;F+/)(Q.?FE;'&
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M_JC]*_E-_P"">O\ R?W\#?\ LH.@?^G*WK^K)F!B;GM7L\6?[Q#T_4\7@_\
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M*&9& _@!=I1CD$H3GD@?@77UE_P2 _X*/O\ \$Y_VCYM3U6*^O? OBR!-/\
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MN?\ ]*FKWS_@U=./V3_B/_V-H_\ 2."NJM_R(X_+_P!*.;#_ /(^E_70Q?\
M@ZR/_%DOA)_V'+[_ -)TK\D?V0O^3L_A?_V-NE?^ED5?K=_P=8G/P2^$G_8<
MOO\ TG2OR1_9"_Y.S^%__8VZ5_Z615Z>0_\ (L_\"_,\S/O^1K_X#^2/ZSC_
M *G\*_DQ_:]_Y.S^*'_8VZK_ .EDM?UFEOW/X5_)E^U[_P G9_%#_L;=5_\
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M6?[XO\*_-GZ3P?\ [D_\3_)!1117S)]6%%%% '\==%%%?M!^%A1110 4444
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MIII]KZ^7YGU6;8RG1P-/ T)*763337>VG=E>BBBOJCY$**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@#[$_X($?\ *6SX3_\ <7_],]]7]*'>OYK_ /@@
M1_REL^$__<7_ /3/?5_2AWK\]XL_WQ?X5^;/TG@__<G_ (G^2"BBBOF3ZL**
M** /XZZ***_:#\+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /L3_@
M@1_REL^$_P#W%_\ TSWU?TH=Z_FO_P""!'_*6SX3_P#<7_\ 3/?5_2AWK\]X
MK_WQ?X5^;/TG@_\ W)_XG^2"BBBOF3ZL**** /QS_P"(3@_]%[_\LD__ "PH
M_P"(3@_]%[_\LD__ "PK]BMU&ZO8_P!8<?\ \_/P7^1X?^K>7_\ /O\ %_YG
MXZ_\0G!_Z+W_ .62?_EA1_Q"<'_HO?\ Y9)_^6%?L5NHW4?ZPX__ )^?@O\
M(/\ 5O+_ /GW^+_S/QU_XA.#_P!%[_\ +)/_ ,L*/^(3@_\ 1>__ "R3_P#+
M"OV*W4;J/]8<?_S\_!?Y!_JWE_\ S[_%_P"9^.O_ !"<'_HO?_EDG_Y84?\
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MX_\ Y^?@O\@_U;R__GW^+_S/QU_XA.#_ -%[_P#+)/\ \L*/^(3@_P#1>_\
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M "#_ %;R_P#Y]_B_\S\=?^(3@_\ 1>__ "R3_P#+"C_B$X/_ $7O_P LD_\
MRPK]BMU&ZC_6''_\_/P7^0?ZMY?_ ,^_Q?\ F?CK_P 0G!_Z+W_Y9)_^6%'_
M !"<'_HO?_EDG_Y85^Q6ZC=1_K#C_P#GY^"_R#_5O+_^??XO_,_'7_B$X/\
MT7O_ ,LD_P#RPH_XA.#_ -%[_P#+)/\ \L*_8K=1NH_UAQ__ #\_!?Y!_JWE
M_P#S[_%_YGXZ_P#$)P?^B]_^62?_ )84?\0G!_Z+W_Y9)_\ EA7[%;J-U'^L
M./\ ^?GX+_(/]6\O_P"??XO_ #/QU_XA.#_T7O\ \LD__+"C_B$X/_1>_P#R
MR3_\L*_8K=1NH_UAQ_\ S\_!?Y!_JWE__/O\7_F?CK_Q"<'_ *+W_P"62?\
MY84?\0G!_P"B]_\ EDG_ .6%?L5NHW4?ZPX__GY^"_R#_5O+_P#GW^+_ ,S\
M=?\ B$X/_1>__+)/_P L*/\ B$X/_1>__+)/_P L*_8K=1NH_P!8<?\ \_/P
M7^0?ZMY?_P ^_P 7_F?CK_Q"<'_HO?\ Y9)_^6%'_$)P?^B]_P#EDG_Y85^Q
M6ZC=1_K#C_\ GY^"_P @_P!6\O\ ^??XO_,_'7_B$X/_ $7O_P LD_\ RPH_
MXA.#_P!%[_\ +)/_ ,L*_8K=1NH_UAQ__/S\%_D'^K>7_P#/O\7_ )GXZ_\
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M)_\ EA1_Q"<'_HO?_EDG_P"6%?L5NHW4?ZPX_P#Y^?@O\@_U;R__ )]_B_\
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M]_\ EDG_ .6%'_$)P?\ HO?_ )9)_P#EA7[%;J-U'^L./_Y^?@O\@_U;R_\
MY]_B_P#,_'7_ (A.#_T7O_RR3_\ +"C_ (A.#_T7O_RR3_\ +"OV*W4;J/\
M6''_ //S\%_D'^K>7_\ /O\ %_YGXZ_\0G!_Z+W_ .62?_EA1_Q"<'_HO?\
MY9)_^6%?L5NHW4?ZPX__ )^?@O\ (/\ 5O+_ /GW^+_S/QU_XA.#_P!%[_\
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MQ_\ S\_!?Y!_JWE__/O\7_F?CK_Q"<'_ *+W_P"62?\ Y84?\0G!_P"B]_\
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MK#C_ /GY^"_R#_5O+_\ GW^+_P S\=?^(3@_]%[_ /+)/_RPH_XA.#_T7O\
M\LD__+"OV*W4;J/]8<?_ ,_/P7^0?ZMY?_S[_%_YGXZ_\0G!_P"B]_\ EDG_
M .6%'_$)P?\ HO?_ )9)_P#EA7[%;J-U'^L./_Y^?@O\@_U;R_\ Y]_B_P#,
M_'7_ (A.#_T7O_RR3_\ +"C_ (A.#_T7O_RR3_\ +"OV*W4;J/\ 6''_ //S
M\%_D'^K>7_\ /O\ %_YGXZ_\0G!_Z+W_ .62?_EA1_Q"<'_HO?\ Y9)_^6%?
ML5NHW4?ZPX__ )^?@O\ (/\ 5O+_ /GW^+_S/QU_XA.#_P!%[_\ +)/_ ,L*
M/^(3@_\ 1>__ "R3_P#+"OV*W4;J/]8<?_S\_!?Y!_JWE_\ S[_%_P"9^.O_
M !"<'_HO?_EDG_Y84?\ $)P?^B]_^62?_EA7[%;J-U'^L./_ .?GX+_(/]6\
MO_Y]_B_\S\=?^(3@_P#1>_\ RR3_ /+"C_B$X/\ T7O_ ,LD_P#RPK]BMU&Z
MC_6''_\ /S\%_D'^K>7_ //O\7_F?CK_ ,0G!_Z+W_Y9)_\ EA1_Q"<'_HO?
M_EDG_P"6%?L5NHW4?ZPX_P#Y^?@O\@_U;R__ )]_B_\ ,_'7_B$X/_1>_P#R
MR3_\L*/^(3@_]%[_ /+)/_RPK]BMU&ZC_6''_P#/S\%_D'^K>7_\^_Q?^9^.
MO_$)P?\ HO?_ )9)_P#EA1_Q"<'_ *+W_P"62?\ Y85^Q6ZC=1_K#C_^?GX+
M_(/]6\O_ .??XO\ S/QU_P"(3@_]%[_\LD__ "PH_P"(3@_]%[_\LD__ "PK
M]BMU&ZC_ %AQ_P#S\_!?Y!_JWE__ #[_ !?^9^.O_$)P?^B]_P#EDG_Y84?\
M0G!_Z+W_ .62?_EA7[%;J-U'^L./_P"?GX+_ "#_ %;R_P#Y]_B_\S\=?^(3
M@_\ 1>__ "R3_P#+"C_B$X/_ $7O_P LD_\ RPK]BMU&ZC_6''_\_/P7^0?Z
MMY?_ ,^_Q?\ F?CK_P 0G!_Z+W_Y9)_^6%'_ !"<'_HO?_EDG_Y85^Q6ZC=1
M_K#C_P#GY^"_R#_5O+_^??XO_,_'7_B$X/\ T7O_ ,LD_P#RPH_XA.#_ -%[
M_P#+)/\ \L*_8K=1NH_UAQ__ #\_!?Y!_JWE_P#S[_%_YGXZ_P#$)P?^B]_^
M62?_ )84?\0G!_Z+W_Y9)_\ EA7[%;J-U'^L./\ ^?GX+_(/]6\O_P"??XO_
M #/QU_XA.#_T7O\ \LD__+"C_B$X/_1>_P#RR3_\L*_8K=1NH_UAQ_\ S\_!
M?Y!_JWE__/O\7_F?CK_Q"<'_ *+W_P"62?\ Y84?\0G!_P"B]_\ EDG_ .6%
M?L5NHW4?ZPX__GY^"_R#_5O+_P#GW^+_ ,S\=?\ B$X/_1>__+)/_P L*/\
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MPX__ )^?@O\ (/\ 5O+_ /GW^+_S/QU_XA.#_P!%[_\ +)/_ ,L*/^(3@_\
M1>__ "R3_P#+"OV*W4;J/]8<?_S\_!?Y!_JWE_\ S[_%_P"9^.O_ !"<'_HO
M?_EDG_Y84?\ $)P?^B]_^62?_EA7[%;J-U'^L./_ .?GX+_(/]6\O_Y]_B_\
MS\=?^(3@_P#1>_\ RR3_ /+"C_B$X/\ T7O_ ,LD_P#RPK]BMU&ZC_6''_\
M/S\%_D'^K>7_ //O\7_F?CK_ ,0G!_Z+W_Y9)_\ EA1_Q"<'_HO?_EDG_P"6
M%?L5NHW4?ZPX_P#Y^?@O\@_U;R__ )]_B_\ ,_'7_B$X/_1>_P#RR3_\L*/^
M(3@_]%[_ /+)/_RPK]BMU&ZC_6''_P#/S\%_D'^K>7_\^_Q?^9^.O_$)P?\
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MY^"_R#_5O+_^??XO_,_'7_B$X/\ T7O_ ,LD_P#RPH_XA.#_ -%[_P#+)/\
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M_+)/_P L*_8K=1NH_P!8<?\ \_/P7^0?ZMY?_P ^_P 7_F?CK_Q"<'_HO?\
MY9)_^6%'_$)P?^B]_P#EDG_Y85^Q6ZC=1_K#C_\ GY^"_P @_P!6\O\ ^??X
MO_,_'7_B$X/_ $7O_P LD_\ RPH_XA.#_P!%[_\ +)/_ ,L*_8K=1NH_UAQ_
M_/S\%_D'^K>7_P#/O\7_ )GXZ_\ $)P?^B]_^62?_EA1_P 0G!_Z+W_Y9)_^
M6%?L5NHW4?ZPX_\ Y^?@O\@_U;R__GW^+_S/QU_XA.#_ -%[_P#+)/\ \L*/
M^(3@_P#1>_\ RR3_ /+"OV*W4;J/]8<?_P _/P7^0?ZMY?\ \^_Q?^9^.O\
MQ"<'_HO?_EDG_P"6%'_$)P?^B]_^62?_ )85^Q6ZC=1_K#C_ /GY^"_R#_5O
M+_\ GW^+_P S\=?^(3@_]%[_ /+)/_RPH_XA.#_T7O\ \LD__+"OV*W4;J/]
M8<?_ ,_/P7^0?ZMY?_S[_%_YGXZ_\0G!_P"B]_\ EDG_ .6%'_$)P?\ HO?_
M )9)_P#EA7[%;J-U'^L./_Y^?@O\@_U;R_\ Y]_B_P#,_'7_ (A.#_T7O_RR
M3_\ +"C_ (A.#_T7O_RR3_\ +"OV*W4;J/\ 6''_ //S\%_D'^K>7_\ /O\
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M_P#EA1_Q"<'_ *+W_P"62?\ Y85^Q6ZC=1_K#C_^?GX+_(/]6\O_ .??XO\
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MW_Y9)_\ EA7[%;J-U'^L./\ ^?GX+_(/]6\O_P"??XO_ #/QU_XA.#_T7O\
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M0G!_Z+W_ .62?_EA1_Q"<'_HO?\ Y9)_^6%?L5NHW4?ZPX__ )^?@O\ (/\
M5O+_ /GW^+_S/QU_XA.#_P!%[_\ +)/_ ,L*/^(3@_\ 1>__ "R3_P#+"OV*
MW4;J/]8<?_S\_!?Y!_JWE_\ S[_%_P"9^.O_ !"<'_HO?_EDG_Y84?\ $)P?
M^B]_^62?_EA7[%;J-U'^L./_ .?GX+_(/]6\O_Y]_B_\S\=?^(3@_P#1>_\
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M #\_!?Y!_JWE_P#S[_%_YGXZ_P#$)P?^B]_^62?_ )84?\0G!_Z+W_Y9)_\
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MO\7_ )GXZ_\ $)P?^B]_^62?_EA1_P 0G!_Z+W_Y9)_^6%?L5NHW4?ZPX_\
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M ,S\=?\ B$X/_1>__+)/_P L*/\ B$X/_1>__+)/_P L*_8K=1NH_P!8<?\
M\_/P7^0?ZMY?_P ^_P 7_F?CK_Q"<'_HO?\ Y9)_^6%'_$)P?^B]_P#EDG_Y
M85^Q6ZC=1_K#C_\ GY^"_P @_P!6\O\ ^??XO_,_'7_B$X/_ $7O_P LD_\
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M?@O\@_U;R_\ Y]_B_P#,_'7_ (A.#_T7O_RR3_\ +"C_ (A.#_T7O_RR3_\
M+"OV*W4;J/\ 6''_ //S\%_D'^K>7_\ /O\ %_YGXZ_\0G!_Z+W_ .62?_EA
M1_Q"<'_HO?\ Y9)_^6%?L5NHW4?ZPX__ )^?@O\ (/\ 5O+_ /GW^+_S/QU_
MXA.#_P!%[_\ +)/_ ,L*/^(3@_\ 1>__ "R3_P#+"OV*W4;J/]8<?_S\_!?Y
M!_JWE_\ S[_%_P"9^.O_ !"<'_HO?_EDG_Y84?\ $)P?^B]_^62?_EA7[%;J
M-U'^L./_ .?GX+_(/]6\O_Y]_B_\S\=?^(3@_P#1>_\ RR3_ /+"C_B$X/\
MT7O_ ,LD_P#RPK]BMU&ZC_6''_\ /S\%_D'^K>7_ //O\7_F?CK_ ,0G!_Z+
MW_Y9)_\ EA1_Q"<'_HO?_EDG_P"6%?L5NHW4?ZPX_P#Y^?@O\@_U;R__ )]_
MB_\ ,_'7_B$X/_1>_P#RR3_\L*/^(3@_]%[_ /+)/_RPK]BMU&ZC_6''_P#/
MS\%_D'^K>7_\^_Q?^9^.O_$)P?\ HO?_ )9)_P#EA1_Q"<'_ *+W_P"62?\
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M[_%_YGXZ_P#$)P?^B]_^62?_ )84?\0G!_Z+W_Y9)_\ EA7[%;J-U'^L./\
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M444 %%%% !1110 4444 %%&:,T %%%% !111F@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M1\/^+KSPU\/XM"L[B\M-*S;3ZLUP/,<7$P.]E&T*$4JI7(8-DFO<O^#.0_\
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MC*JQSSZ5]OGE;%TLOJU,!'FJJ+<5:]WTT/CLGIX:IC:4,8[4W)<S[+J>=_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M[X27G[/_ ,=_&W@/4+A+K4/!.OWV@7,R+M666UN)('8#)P"T9.,GKU-?T_\
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MNBW@95L'!P<8K^J?]EWG]F;X=_\ 8L:;_P"DL5?R;?\ !6C]C3_A@O\ ;_\
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M%?"TLQSGZO!6A!:VTO;?;S:1S4ZLL/@_:/XI;?/;\-3X_P#VK_\ @I#\??\
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M>".K @^I'K7W#^PG^U-J7QUTK4M)\1,DFN:2J2K<)&(Q=Q,2-Q51M5E; .,
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M&<XO!8R"ER)QU5]5*UU?N=)\5OVJ/$WQ%\&:+X>;4[Y=-TVTB6Y=IG,VHS@
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M\1:A9SFY$EO<ZC--$^+64_,C,0<, 1D<$ U]G?M*?\F^^-O^P%>_^B'KX/\
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M @95(EXYVC/4G&3FLNXTGQ9\)+Z*XFM?$7ABYDYBD>.:RD?'=20I./:OIO\
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M!L2[<)D'C&XC.>U?EKIUI)K6KV]ON;S;N98]QY)9FQG]:_7O%SB_%X&E1RW
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M#NJ3+']CUGP-8O;LK9.8[J\C=6'4$$ ^A##G.0,'_@@S_P %M/!'_!*_P/\
M$;P_XZ\*^*M>L_%-U;ZEIUQH*V\DB7$<;1M%,LTL86-@5(=2Q!!^4Y&/IZU"
MIB>'X0H+FE:.GHU<\JG45+'2E-V5V?T6_M1G_C&GXB?]BQJ7_I++7\5%?U_^
M OVJ]/\ VV_^"7^J?%32],FT?3_&'A#5KF&SFE\Z2V"1W,6UFVJ"V8SG QG@
M%AAC_(!6'!=.5-5X35FFD_57-<YDI.$ELT_T/[5OV73_ ,8S_#O_ +%C3?\
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M/\+L72S3*L3P]BGI9M>DM';_  O7U8?$CQC=?%/XE:MK3++)<:Q>R2QQ[<N
MS?(@ ST7:HZ].]?I3^S7\,/^%0?!30=!D2..\M[<27>T[LSN2\G/\7S,0#Z
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MO[)_A?W:[_\ 2N:O!_\ @J5X(GM?'/A[Q$J[K6\LVL&89RCQNS@'MR)#CO\
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M>1_P$UQ__!27]GZZO[BW\<Z3:S7"0Q>1JP0;O+1?N2D=< $AB!P-I]37SM\
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MU<7_ ,$Q/^3@]0_[ <O_ *46]=I_P5A_X^O G^[?_P#MM7%_\$Q/^3@]0_[
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M_P!?L!'_ ,>7_;/^E>;X$?#C_P#MS_VX]+QL^+!>D_\ VP_)/QK_ ,CGJ_\
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M"?\ D3UO^OC_ /245XT?\C:E_P!>U^;'4445^Y'XZ-4Y-? O_!3O_DX33_\
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MU_:?\3?%CQAXJ^*FF^(O%?V7[7;:/J5A#91_9[2&U3RUELI'&8X$)RYRQ8C
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M^4WP=^#/BK]H+XCZ5X1\%:#J7B7Q)K4ZV]G86,1DDE9B%!/95&<L[$*HR6(
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MXIOPZ_X)A^'?#NIQW/B#6;OQ!'&<_9TA^R1.<_Q8=F(]@P_I7U$JT-TKY/\
MXASPZ\3]:>%CS7ON[?\ @-^7\#Z;_7W/UA_JJQ,N6UNE_P#P*W-^)XO\9OV'
M?"'QHUBPO;F74]*;3[06446G-%##Y09F VLC 8+MTQUK<_9\_9DTK]G&+4HM
M'U36KNWU-D>2&]EC=8V7(W+MC4@G.#R<X'I7I@.:!T_^O7M4.&<LHXSZ_1HQ
MC5_F6CVM^6AX]3/LPJ87ZE4JR=/^5NZWO^>IY3^T)^R5H/[1^IZ;=:Q?:Q:2
M:;&\<8LY8T5@Q!.[>C<\=L56^ 7[''A[]GCQ/>:KH^H:U=W%Y;&U9;R6-T5=
MRMD!(U.<J._K7K^"!0#FB7#66/'?VDZ,?;7OS=;VM^6@+/\ ,%A/J'M9>RM;
MEOI:]]O74!SS7G_QM_9M\+_'[35AUVS?[5 "L%[;MY=S!G^ZV"".ORL&7OC/
M->@;L"@G!Z5Z6-P-#%T7A\5!2C+=-71Q87&5L+55?#S<9QV:=FCY U/_ ()2
MPRW;-9^-988/X$FTOSG'U82J#^0KM/A)_P $XO"/@'6(;_5[J[\27-K)OBCG
M016P((*[HQDL1_M,5/\ =]?HMAQ0.!7R.#\-^',-66(I86/,M=6VON;:_ ^G
MQ7'W$&)H^PJXE\KTT44_O23_ !&H@C 5> .F*P?B+\.])^*GA&ZT36K5;S3[
MP .A)5@0<AE(Y# \@BM[J?;ZTO6OM*V'I5:3HU8J49*S35TT]U;L?)T:U2G4
M56FW&47=-:--;-/N?(VL_P#!*FRFU3?I_C&[M[+M%<V GEZ_\]%=!T_V/\*]
M?_9@_95L?V9(-6^RZM>:M/K1A$K2QK&B"+?MV@9.29&R2Q_AX&"3ZV?E[US/
MQ?NK[3_A9XDGTN9K;4(]-N'MIE W12")BK#/&0V#SZ5\?@^"<BRFL\RPF'Y9
MQ3::;?1WLF[+2_0^HQG&&=9G167XJNY4Y-)II+JK7:5W9Z[FWJ>H0:7IUQ<7
M4T=O;P1M)))(VU$4#)))X  &23TK\G?B/JMCKOQ!UV]TN-X=-N[^>:U1OO+&
MSLR@CM\I''..F3UKJ/&_[5/Q!^(WAYM+UCQ-?76GL-LD21QP^:N,8<QJI8'T
M8G-2_LV?L[ZM^T%XY@L[6&2/1[>16U&]8$1P1YR5![R,.%4<]S@ D?@7'/%C
MXOQ6'R[*Z$M&_B6MW9=+I))7;N?MW!G"ZX4P]?,<SK1U2^%NR2OW2;;;LE;R
M5[GV3_P3W^&*^ O@!9W\L:QWWB1VOY"T>'\L_+$,]67: P[?O#CKD^[J/RJG
MH6CV_A[1;6QM(_)M;.%(88QG"(H 4<\\  <U<+9%?TWD.5PRW+Z6"I[0BEZM
M+5_-W9_.^<9C/'XZKC*F\Y-^B;T7R5D>6_M+?LZ^'OCYHUE-XBU*_P!+M=!6
M:826\T<2A6"[B[.K#: F<\8YS7R[_P $W]&AN_VD-4NK/[0UC8:=/Y+/C=AI
M8@@?@9)4L> .1^%?0'[:_P &/&GQFT31K'PGJ,L-O),T&I6S7 AMVC8;A)(0
M-S!2@&T;C\X(7@FN@_97_9HL?V;_  ;+;)+]MU?4662_N\;5<J#M1!V1=S8S
MR2S$XS@?GV9<.U<?Q;2Q=/#\D*/O2J/[;LK)=[6LS[;+\^IX+ABMA9U^:=;W
M8TU]A7?,W_BO^7G;U84445^LGYN1L./3->&?M$?L,^'_ (]>)&UN.]NM#UJ0
M*MQ-$@FCN0%"KN0D?,%  ((X'(/!'NO6@'FO)S?)<%FE#ZKCZ:G"][/NNJ:U
M3\TT>AE>;8O+J_UG!5'"=K77;LT]&O)H^1=#_P""4]E;7P;4_&5U=V^1E+6P
M%NY'?YF>0?\ CM?7*IA OH,4O448_*N/(>%\LR:,XY=2Y.:U]6[VO;5MO2[.
MS.N),RS:49YA4YW&]M$K7M?1)+6R/(?C?^QAX-^.5V]]=VLFEZLP^:]L=L;R
MGC!<%2KD8QDC=CC(XQXW/_P2E4WA,?C=EM]V0C:5N<+Z;O- S[X_"OL+!'2@
M5Y^:>'^09C5=?%8:+D]VKJ[[NS5WYG=EO&V>8"DJ.%Q#45LFE*WIS)V^1X1\
M%?V O!OPFOX-2O/.\1:I;_-')>!?(A?/#)$!@$<8+%B",C!QCW8+A%I1R:"-
MM>YE.28'+*7L,!34(]DM_-O=OU/%S+-L9F%;V^-J.<O/IY);)>2/+_VBOV7-
M#_:4ET<ZS>ZM9_V*)A#]B>--_F>7G=N1\X\M<8QU/7ME_ 7]B_PW^SWXSFUS
M2-0UJ\N9[1K-DO)HFC"LR.2 L:G=E%[XP3Q7LA/)YXH W#GK7//AG+)XW^TI
MT8NM=/FZW2LOP21M#/LPCA/J$:LO9:^[?35W>GF]0*Y7UKPCXV_L"^#_ (O:
MG<:E:_:/#^KW&&DEM IAE88&YHB,9P/X2N3R<G.?=]J_E1LYKHS;)<#F='V&
M/IJ<>S6S[I[I^:9CEF;8S+ZWM\%4<)=UU\FMFO)Z'Q[;_P#!*11>;I/'#-;[
MLE%TK:Y7TW>:1GWQ^%>W? /]DGPI^SVS7.FPSWFJ2IY;W]TP>;:>JJ  JKGT
M&3W)P*]47[M. KQ<IX"R'+*RQ&$PZC);-MMKTNW;Y'L9GQIG684O88NNY1>Z
M244_7E2O\[C6&Y6]#7SMXP_X)P>#O&OB_5-8N-6\31W&K7<UY*D4\"HK2N78
M*#$2%!)QDDX[FOHDGGK0O(KV,VR/ YG35/'4U447=)]&>1EN<8W+YNI@JC@V
MK.VET<K\'_A;8?!;X=Z?X9TV:[N++3S)Y<ERRM*WF2-(<E54?>8@8 XQ]:ZH
M*0*,\\T,<5Z&'P].A2C0HJT8I));))62^1Q5JTZU256J[RDVVWU;U;^;/)?V
MAOV0O#?[0\D=U?--INL0)L2]M@N]ESD*ZD8<#G'0C)P:\<L/^"4EO'?;KKQK
M--:Y_P!7%I@CDQ_O&1A_X[7UZ!0O%?*YIP#D.8XAXO%X=2GU:;5_5)I/YH^E
MRWC;.\!0^K83$.,%LK)V]+IM?(\E@_8T\$Z=\(=0\'VEG-;6NKA#=7BR9O)6
M5T=6+L#T9 =N-O7Y>37)^!_^"=7A7X?>+M/US3=>\51WVF3K/"3<6Y4D=B/)
MY4C(([@FOH8@@4TC=_6NRIPADTITZCP\;TTE%I6LD[JUNSU]3CCQ-FL83@J\
MK5&W+6_,VK._JM#E_B_\+;'XT?#F_P##.I3W=O9:@8_,EMF595\N5)!@LK#[
MR '(/&?K7EOPR_X)[^$OA7X[T[Q!8ZIXAN+K39#)''<30F-SM*_,%B4XY[$5
M[X?RH%=6.X=RW&8F&,Q-&,JD;<K>ZL[JWS9SX//,?A:$L+AZKC"=^:*>CNDG
M?U2L?.?QA_X)P^%OB)K,VH:+>3>%[FX):2.&$36S,>XCRNWOPK <]*Q?A_\
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MCPE;^//!NJ:)=2316NL6DME,\1 D5)$*$J2" P#'&01GL:V.@]*#7+E^18#
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MEI-@20S1B2-P#GE6!!Y //I7-6/[/?@73;CS+?P=X9AD[,FEP*1^(6NS()%
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MKA>*.@ZTH/RU-##TJ*Y:,5%=DDOR*JUIU'S5)-OS=Q:***Z#,**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** &[^:=7G7Q%_:1T/X9_';X<_#W4+75I
MM:^)QU/^RY[>*-K6W^P6ZW$WGLSAEW(P"[%?)SG:.:]%!S0TUN%[A1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!11FB@ HHHH **** "BBB@ HHHH **** "BBB@ HHS1F@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>E>J;<YJY7LN;MIZ7?ZW(C:[MW_1#@<T4#BBH+"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH8X4T -X[\T <U^"W[7?\
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M:?[-%Y^Q5^U7XL^'<NK1ZM-X5N8?(U"!&A\Z*:"*YA<KU201RIN ) 8, S
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MVVCZ<NI2VEK%;PR^2;@FW=)3*9HITPSA0HSL)*L/G+_@LY_P36TG_@G]\6=
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110!X)^T!\ ?$7Q$_;;_9^\=Z
M;';-X?\ AU_PD8UEY)@DJ?;;"."#8G5\NISCH.:]YW8S7E?Q7_:7@^%W[2OP
MG^&\FCS7DWQ3_MCRKY;@(NG?V?:K<'<FTE]X;:,%=N,\]*]4VYS5SO97[:>E
MW^MR(VN[=_T0X'-% XHJ"PHHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH *1_N'Z4M(_P!P_2@&?R[?M]#'[=7QJ_['S7/_ $X3
MU_11_P $]^/V#?@I_P!B)HG_ *;X*_G7_;Z.?VZOC5_V/FN?^G">OI3X/_\
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M;_QIK?ES[F"E@T4KO<JS?+DM&!\N"01BOE;X(?\ ):/"/_8:L_\ T>E?J?\
MM'?\'+&F^*OA3<:/\+O OB*R\6:Q9_91?:O)$L6E32#:SPI"SM.RY^0L8OF(
M8J0-C?E;X!>3P%\8=%;5H+BQDT768#>PSIY4MN8IU\Q75L;67:00V,$<XK[+
M)*V95:-7Z[2C36T8K?K>^K\K;'SF94<'3JP^JS<W]IOY6MHO,_JOUW1+7Q/H
M-WIM]"MS9:A ]M<0MG;+&ZE64^Q4D?C7\PW[6'P<U+]B?]LOQ9X4L;B:WNO
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MOPKP+_@J?_RCJ^,7_8L7?_H-=F6?[Y1_Q1_-')C_ /=JG^%_D?@Y_P $I?\
ME(S\'_\ L8H/_9J_IB'2OYG?^"4O_*1GX/\ _8Q0?^S5_3$I^6ON/$?_ 'ZG
M_@_5GRO!/^ZS_P 7Z(****_.S[4**** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ /2OPM_X.9?^3]?"W_8AV?_
M *<-1K]TC7X6_P#!S+_R?KX6_P"Q#L__ $X:C7V7 7_(WAZ2_(^8XN_Y%[]4
M?7'_  ;*''["WB_/_0^7?_IOTZOT8[5^ /\ P3,_X+.-_P $Z/@7JW@O_A6_
M_"8#5=>FUO[9_P )!_9_E>9;V\/E>7]FESCR-V[<,[\8XR?:OB'_ ,'0WBK5
M-($?A7X2Z#HM]SF;5=<FU.'M_P LXXK<\<_Q\^U=N=<(YKB,PJU:5+W9-M.\
M?RO?\#BRKB/ 4,%"G.?O16JL_P#*QS?_  <U^/K?6_VJO OAV&ZAFDT'PX;B
MXC1PS6\EQ/)A7P/E8I"C8)SAE. ""?:/^#7GP'=:=\)_BSXH>W466L:O8:5%
M+Y@W226L,LKJ5SD!5O(SG'.\CG;Q^6]W<_$7]O7]I=IIC?>+O'WCS48T9]H_
M>2.5C3.,)%#&NQ<_*D<:#[JKQ_1=^P)^R99_L4_LH>%_A_"UG<:AIL#3ZM>6
MT>U;Z^E)>:3. S@$A$9QN\N.,<8 'K<32CEN1TLI<DYRM>W9.[?I?1=S@R.,
ML;FL\Q2M%7M\U9+UMN?&_P#P4]_X+U2_LR_%'5/AW\+='TO6O$.B,UMK&K:H
MCO9V-Q\N8H8T=3(Z98,6(57 &'PPKX2E_;G_ &ROVYI;NST#7/B1X@M9G-M+
M!X2TIK2WME9P=CR6<:[5&Y06E?.TX9B"<_.O[3OA_4O"O[2/C_3=9AFM]5L?
M$>H0W<<C!F65;F0-E@2&YYW D'J"0<U^SWPH_P""^7[,W@C]GC2%M;77/#-Q
MH]G%;1>#['1GDDM L0.R&4!;9HPV45FD1FQDJN:[:V74LKPE*6!PJKSEO)J]
MG9:]='TM9:;G)3QM3'XFHL7B/9QCM&]K^73;SU/Q2^-WPK\6?!3XI:OX;\<Z
M=>Z3XLL7274;:[D$DZO-&LRL[!F#%DD5LY/WN>:_HF_X) \_\$V/A%_V!?\
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M'Q1&UK=0L;G2-7A0-<:1=8($B=-RGH\9(#KW5@KK^?/[!'_!>7XP?M3?M?\
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M#;1@KMQGGI7JFVKG>ROVT]+O];D1M=V[_HAP.:*!Q14%A1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4$9%%% 'RQX]_X(O\
M[-?Q/\=:UXDU[X;F]UOQ%?SZGJ%Q_P )!JD?VBXGD:65]B7(1=SLQPH"C.
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M21IIVVMP#L"-C.&!((_4D@YIN,"O8PO$F9T*/U>E6:CLEH[+R;5U\F>;6R/
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M48HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** #I1110 4444 %%%%
M!1C-%% !1110 FT>@I:*,T %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !111G% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110!X'\?_@%XA^(G[;?[/OCK38[
M9M ^'?\ PD8UAY)PLJ?;;"."#8G5\NISCH.:][/*UY?\4/VEK'X8_M&?"WX=
M3Z;=W=Y\4/[6^RWD<BK%8_V?:K</O4\MO#;1CH1S7J'054^:T;]M/2[_ %N3
M&UW;O^B%HHHJ2@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #2
M.?I1@*M!''/>OR>_X.!?^"MFN?!+5V^!OPTU2;2=?N+2.X\4:S:2&.YT^*8;
MHK2%P=T<KQE9'<8(22,*<LVWJP.#J8JJJ5/_ (9=SBQ^.IX2DZM3;\WV/KO]
MK/\ X+)? /\ 8W\2WF@>)O%TFI>*+!E6XT71+5[ZZ@)(R)&&(8V4')2217QT
M4UX?H7_!SM^SQJVM-:W&D?$[3+==V+VYTBU:!L=,".Y>3YNV4^N*_ .BOMJ?
M"N%C&TVV^][?A_PY\'5XNQ<IW@DEVM?\3^M#]G?]J7X>_M8>"E\1?#OQ;H_B
MO2SM$K6DO[ZT9@2$FA8"6%R.=DJJV.<8KT0G%?R1_L[?M$^+_P!E7XNZ3XX\
M#ZM-H_B#1Y-T<B\QSH?OPRIT>)QPRG@CT(!']-'_  3O_;4T7]O?]EO0O'VE
MB&UOILV6MZ?&Q;^S-0C53-#D\E<.CJ3R4D0GDFOF\XR66#M.+YH/[UZGT^29
M]''7IS7+-?<UW7^1[I10.!17AGT04444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M]WVF';CIC!^M=6!C0=9+$NT=;[_+8X<PEB%1;PJO/2VW?7?R/-O^(I3X!_\
M0F_&#_P6:;_\G4?\12GP#_Z$WXP?^"S3?_DZO'?^(39_^B^+_P"$1_\ =]'_
M !";/_T7Q?\ PB/_ +OKZ#V61_SO\?\ (^<]MGW\B_#_ #/8O^(I3X!_]";\
M8/\ P6:;_P#)U'_$4I\ _P#H3?C!_P""S3?_ ).KQW_B$V?_ *+XO_A$?_=]
M'_$)L_\ T7Q?_"(_^[Z/99'_ #O\?\@]MGW\B_#_ #/8O^(I3X!_]";\8/\
MP6:;_P#)U'_$4I\ _P#H3?C!_P""S3?_ ).KQW_B$V?_ *+XO_A$?_=]'_$)
ML_\ T7Q?_"(_^[Z/99'_ #O\?\@]MGW\B_#_ #/8O^(I3X!_]";\8/\ P6:;
M_P#)U'_$4I\ _P#H3?C!_P""S3?_ ).KQW_B$V?_ *+XO_A$?_=]'_$)L_\
MT7Q?_"(_^[Z/99'_ #O\?\@]MGW\B_#_ #/8O^(I3X!_]";\8/\ P6:;_P#)
MU'_$4I\ _P#H3?C!_P""S3?_ ).KQW_B$V?_ *+XO_A$?_=]'_$)L_\ T7Q?
M_"(_^[Z/99'_ #O\?\@]MGW\B_#_ #/8O^(I3X!_]";\8/\ P6:;_P#)U'_$
M4I\ _P#H3?C!_P""S3?_ ).KQW_B$V?_ *+XO_A$?_=]'_$)L_\ T7Q?_"(_
M^[Z/99'_ #O\?\@]MGW\B_#_ #/8O^(I3X!_]";\8/\ P6:;_P#)U'_$4I\
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M'_$)L_\ T7Q?_"(_^[Z/99'_ #O\?\@]MGW\B_#_ #/8O^(I3X!_]";\8/\
MP6:;_P#)U'_$4I\ _P#H3?C!_P""S3?_ ).KQW_B$V?_ *+XO_A$?_=]'_$)
ML_\ T7Q?_"(_^[Z/99'_ #O\?\@]MGW\B_#_ #/8O^(I3X!_]";\8/\ P6:;
M_P#)U'_$4I\ _P#H3?C!_P""S3?_ ).KQW_B$V?_ *+XO_A$?_=]'_$)L_\
MT7Q?_"(_^[Z/99'_ #O\?\@]MGW\B_#_ #/8O^(I3X!_]";\8/\ P6:;_P#)
MU'_$4I\ _P#H3?C!_P""S3?_ ).KQW_B$V?_ *+XO_A$?_=]'_$)L_\ T7Q?
M_"(_^[Z/99'_ #O\?\@]MGW\B_#_ #/8O^(I3X!_]";\8/\ P6:;_P#)U'_$
M4I\ _P#H3?C!_P""S3?_ ).KQW_B$V?_ *+XO_A$?_=]'_$)L_\ T7Q?_"(_
M^[Z/99'_ #O\?\@]MGW\B_#_ #/8O^(I3X!_]";\8/\ P6:;_P#)U'_$4I\
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M'_$)L_\ T7Q?_"(_^[Z/99'_ #O\?\@]MGW\B_#_ #/8O^(I3X!_]";\8/\
MP6:;_P#)U'_$4I\ _P#H3?C!_P""S3?_ ).KQW_B$V?_ *+XO_A$?_=]'_$)
ML_\ T7Q?_"(_^[Z/99'_ #O\?\@]MGW\B_#_ #/8O^(I3X!_]";\8/\ P6:;
M_P#)U'_$4I\ _P#H3?C!_P""S3?_ ).KQW_B$V?_ *+XO_A$?_=]'_$)L_\
MT7Q?_"(_^[Z/99'_ #O\?\@]MGW\B_#_ #/8O^(I3X!_]";\8/\ P6:;_P#)
MU'_$4I\ _P#H3?C!_P""S3?_ ).KQW_B$V?_ *+XO_A$?_=]'_$)L_\ T7Q?
M_"(_^[Z/99'_ #O\?\@]MGW\B_#_ #/8O^(I3X!_]";\8/\ P6:;_P#)U'_$
M4I\ _P#H3?C!_P""S3?_ ).KQW_B$V?_ *+XO_A$?_=]'_$)L_\ T7Q?_"(_
M^[Z/99'_ #O\?\@]MGW\B_#_ #/8O^(I3X!_]";\8/\ P6:;_P#)U'_$4I\
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M'_$)L_\ T7Q?_"(_^[Z/99'_ #O\?\@]MGW\B_#_ #/8O^(I3X!_]";\8/\
MP6:;_P#)U'_$4I\ _P#H3?C!_P""S3?_ ).KQW_B$V?_ *+XO_A$?_=]'_$)
ML_\ T7Q?_"(_^[Z/99'_ #O\?\@]MGW\B_#_ #/8O^(I3X!_]";\8/\ P6:;
M_P#)U'_$4I\ _P#H3?C!_P""S3?_ ).KQW_B$V?_ *+XO_A$?_=]'_$)L_\
MT7Q?_"(_^[Z/99'_ #O\?\@]MGW\B_#_ #/8O^(I3X!_]";\8/\ P6:;_P#)
MU'_$4I\ _P#H3?C!_P""S3?_ ).KQW_B$V?_ *+XO_A$?_=]'_$)L_\ T7Q?
M_"(_^[Z/99'_ #O\?\@]MGW\B_#_ #/8O^(I3X!_]";\8/\ P6:;_P#)U'_$
M4I\ _P#H3?C!_P""S3?_ ).KQW_B$V?_ *+XO_A$?_=]'_$)L_\ T7Q?_"(_
M^[Z/99'_ #O\?\@]MGW\B_#_ #/8O^(I3X!_]";\8/\ P6:;_P#)U'_$4I\
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M'_$)L_\ T7Q?_"(_^[Z/99'_ #O\?\@]MGW\B_#_ #/8O^(I3X!_]";\8/\
MP6:;_P#)U'_$4I\ _P#H3?C!_P""S3?_ ).KQW_B$V?_ *+XO_A$?_=]'_$)
ML_\ T7Q?_"(_^[Z/99'_ #O\?\@]MGW\B_#_ #/8O^(I3X!_]";\8/\ P6:;
M_P#)U'_$4I\ _P#H3?C!_P""S3?_ ).KQW_B$V?_ *+XO_A$?_=]'_$)L_\
MT7Q?_"(_^[Z/99'_ #O\?\@]MGW\B_#_ #/8O^(I3X!_]";\8/\ P6:;_P#)
MU'_$4I\ _P#H3?C!_P""S3?_ ).KQW_B$V?_ *+XO_A$?_=]'_$)L_\ T7Q?
M_"(_^[Z/99'_ #O\?\@]MGW\B_#_ #/8O^(I3X!_]";\8/\ P6:;_P#)U'_$
M4I\ _P#H3?C!_P""S3?_ ).KQW_B$V?_ *+XO_A$?_=]'_$)L_\ T7Q?_"(_
M^[Z/99'_ #O\?\@]MGW\B_#_ #/8O^(I3X!_]";\8/\ P6:;_P#)U'_$4I\
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M'_$)L_\ T7Q?_"(_^[Z/99'_ #O\?\@]MGW\B_#_ #/8O^(I3X!_]";\8/\
MP6:;_P#)U'_$4I\ _P#H3?C!_P""S3?_ ).KQW_B$V?_ *+XO_A$?_=]'_$)
ML_\ T7Q?_"(_^[Z/99'_ #O\?\@]MGW\B_#_ #/8O^(I3X!_]";\8/\ P6:;
M_P#)U'_$4I\ _P#H3?C!_P""S3?_ ).KQW_B$V?_ *+XO_A$?_=]'_$)L_\
MT7Q?_"(_^[Z/99'_ #O\?\@]MGW\B_#_ #/8O^(I3X!_]";\8/\ P6:;_P#)
MU'_$4I\ _P#H3?C!_P""S3?_ ).KQW_B$V?_ *+XO_A$?_=]'_$)L_\ T7Q?
M_"(_^[Z/99'_ #O\?\@]MGW\B_#_ #/8O^(I3X!_]";\8/\ P6:;_P#)U'_$
M4I\ _P#H3?C!_P""S3?_ ).KQW_B$V?_ *+XO_A$?_=]'_$)L_\ T7Q?_"(_
M^[Z/99'_ #O\?\@]MGW\B_#_ #/8O^(I3X!_]";\8/\ P6:;_P#)U'_$4I\
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M'_$)L_\ T7Q?_"(_^[Z/99'_ #O\?\@]MGW\B_#_ #/8O^(I3X!_]";\8/\
MP6:;_P#)U'_$4I\ _P#H3?C!_P""S3?_ ).KQW_B$V?_ *+XO_A$?_=]'_$)
ML_\ T7Q?_"(_^[Z/99'_ #O\?\@]MGW\B_#_ #/8O^(I3X!_]";\8/\ P6:;
M_P#)U'_$4I\ _P#H3?C!_P""S3?_ ).KQW_B$V?_ *+XO_A$?_=]'_$)L_\
MT7Q?_"(_^[Z/99'_ #O\?\@]MGW\B_#_ #/8O^(I3X!_]";\8/\ P6:;_P#)
MU'_$4I\ _P#H3?C!_P""S3?_ ).KQW_B$V?_ *+XO_A$?_=]'_$)L_\ T7Q?
M_"(_^[Z/99'_ #O\?\@]MGW\B_#_ #/8O^(I3X!_]";\8/\ P6:;_P#)U'_$
M4I\ _P#H3?C!_P""S3?_ ).KQW_B$V?_ *+XO_A$?_=]'_$)L_\ T7Q?_"(_
M^[Z/99'_ #O\?\@]MGW\B_#_ #/8O^(I3X!_]";\8/\ P6:;_P#)U'_$4I\
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MV?\ Z+XO_A$?_=]'LLC_ )W^/^0>VS[^1?A_F>Q?\12GP#_Z$WXP?^"S3?\
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M3?\ Y.H_XBE/@'_T)OQ@_P#!9IO_ ,G5X[_Q";/_ -%\7_PB/_N^C_B$V?\
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MV?\ Z+XO_A$?_=]'LLC_ )W^/^0>VS[^1?A_F>Q?\12GP#_Z$WXP?^"S3?\
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M3?\ Y.H_XBE/@'_T)OQ@_P#!9IO_ ,G5X[_Q";/_ -%\7_PB/_N^C_B$V?\
MZ+XO_A$?_=]'LLC_ )W^/^0>VS[^1?A_F>P/_P '27P#V_+X.^,'_@KTW_Y.
MK\1?CY\6]0^/7QN\7>--4N+FXOO%6KW.IR/<,#(/-D9U4XX 52% 4!0%
M%?JRW_!INX_YKXO_ (1'_P!WU^67[3?P(U+]F']H3QE\/M6:2:\\(ZO<::;A
MH##]LC1R([A4))598]DBC)^5QR:]S(XY?&I+ZG*[MK>^WS2/"SR692IQ>-C9
M7TM;?Y-G"T445]$?,A7W%_P13_X*E^'_ /@FSXP\=+XRT[Q)JWAKQ=9VQ6#1
MK:&>XBO+=WV/B:>)50QS2AL$DD1]A7P[7VA_P2L_X(XZY_P4RT'Q7KC>+/\
MA!?#OARXBL(K]M(.I?VA=LN^2%%\Z(+Y49C9B6/^NC !R2//S/ZO]7DL2[0T
MO]^FWF>CE?UGZS%X57EK;[M=]-C]&O\ B*4^ ?\ T)OQ@_\ !9IO_P G4?\
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M6:;_ /)U'_$4I\ _^A-^,'_@LTW_ .3J\=_XA-G_ .B^+_X1'_W?1_Q";/\
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M6:;_ /)U'_$4I\ _^A-^,'_@LTW_ .3J\=_XA-G_ .B^+_X1'_W?1_Q";/\
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M6:;_ /)U'_$4I\ _^A-^,'_@LTW_ .3J\=_XA-G_ .B^+_X1'_W?1_Q";/\
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M6:;_ /)U'_$4I\ _^A-^,'_@LTW_ .3J\=_XA-G_ .B^+_X1'_W?1_Q";/\
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M7U.5W;6]]OFD>%GDLRE3C]=C97TM;?Y-G%T445]$?,A7W=_P13_X*O\ AO\
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M4^ ?_0F_&#_P6:;_ /)U>._\0FS_ /1?%_\ "(_^[Z/^(39_^B^+_P"$1_\
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M'^9[%_Q%*? /_H3?C!_X+--_^3J/^(I3X!_]";\8/_!9IO\ \G5X[_Q";/\
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M?X_Y![;/OY%^'^9[%_Q%*? /_H3?C!_X+--_^3J/^(I3X!_]";\8/_!9IO\
M\G5X[_Q";/\ ]%\7_P (C_[OH_XA-G_Z+XO_ (1'_P!WT>RR/^=_C_D'ML^_
MD7X?YGL7_$4I\ _^A-^,'_@LTW_Y.H_XBE/@'_T)OQ@_\%FF_P#R=7CO_$)L
M_P#T7Q?_  B/_N^C_B$V?_HOB_\ A$?_ '?1[+(_YW^/^0>VS[^1?A_F>Q?\
M12GP#_Z$WXP?^"S3?_DZC_B*4^ ?_0F_&#_P6:;_ /)U>._\0FS_ /1?%_\
M"(_^[Z/^(39_^B^+_P"$1_\ =]'LLC_G?X_Y![;/OY%^'^9[%_Q%*? /_H3?
MC!_X+--_^3J/^(I3X!_]";\8/_!9IO\ \G5X[_Q";/\ ]%\7_P (C_[OH_XA
M-G_Z+XO_ (1'_P!WT>RR/^=_C_D'ML^_D7X?YGL7_$4I\ _^A-^,'_@LTW_Y
M.H_XBE/@'_T)OQ@_\%FF_P#R=7CO_$)L_P#T7Q?_  B/_N^C_B$V?_HOB_\
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M4^ ?_0F_&#_P6:;_ /)U>._\0FS_ /1?%_\ "(_^[Z/^(39_^B^+_P"$1_\
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MA^$(=8^'_BK3=;C:,236JR!+RS.R-V26$_,K+YT8;@@,V,YKU0<&OFW]A?\
MX)9?"/\ X)^6IN/!FBS7GB:XMS;7?B'4Y?M&H7"$@L@. D2$J"5C50<#.XC-
M?2&[-?F>(5)5&J+;CTON?JF%=9TDZZ2EUML.HHHK$Z HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% #?\:_-[_@N3_P $>[C]LG36
M^*/P[MT_X61HEDL%[IB*J+XDMH]Q7!P/]*0$JI8G>BJF1M2OTB(R:0K71@\7
M4PU55:;U7X^3.7&8.GB:3I5%H_P\S^/_ ,8>#=8^'WB:]T77])U+0]9TV3R;
MNPU"U>UNK5^NV2-P&5N1P0#6;7]87[0W[&/PK_:QAMD^(G@/P[XJDL5*VUQ>
M6W^E6RG.42=<2*IW$[0P&<'&0"/&_#/_  0S_95\):@EU:?"+39I(Y$E O=6
MU&^C)4Y&4FN'4KZJ1AAP017V5/BRBX_O(-/RLU^:/AZW!U=3_=S37G=/\$S\
M#/V'_P!@?XA?M\?%6U\.^"])NFT^.9%U77)H'_LW1HSD[YI ,;BJL5C!W.00
M!P2/Z4_V-_V4/#?[$W[.GA[X<^%S--I^AQNTMW.JB?4+B1S)+/)@?>9V.!SM
M4*HX45W'@'X<>'_A5X7M]%\+Z%H_AS1K7(@L-+LX[2UASR=L<:JJY]A6YU:O
MG<VSJIC6E;EBNGZL^ER?(Z>!3E?FF]WY=D.!S1117CGNA1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MB@ HHHH **,XHH **** "BBB@ HHS10 4444 %%%% !111F@ HHHH **,T4
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %'2BB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M3:/JWA'Q!J.I>"VTV\TQ(1I]E'K:SR:G+(6!7)A3RT4+EG ?&0,9(SR'P/\
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M8P37Q;_P1L^&"^+/VD]0\1S1S-%X2TQY(71?D6XN/W*AFQCF(SX&021GH"*
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%&: "BC-% !1110
M 4449H **** "BBB@ HHS1F@ HHHH **,T4 %%%% !1110 4444 %%%% !11
M1F@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH_X2+4/^?Z\_[_-_C5.B@"Y_PD6H?\_UY_W^;_&C_A(M0_Y_KS_O\W^-4Z*
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MT?VE/CMH7@G_ (0/^Q?[:-Q_IO\ ;?VGR?*MY9O]7]G3=GR]OWAC.><8*_\
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M%_:B_:"TGPO<R7EOI.R2\U.>V3=)#;QKDX)X7>Y2,,<@&0'!^Z?T _X+#_\
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MBJES-*_;3[W^MR8VN[=_T0M%%%24%%%% !1110 4444 %%%% !1110 4444
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M=K]GT'XI6T7BZS*0;(A<3%H[U=PX:0W44LK=& N$R#D,W])_[!0S^PU\&?\
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M<%2<D\]A^@O_  >J<?\ #-7_ '-'_N'K0_X-/_V/?A+^T;^QW\1M4^(7PO\
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MC1?B_HT>I,Z0>5%_:-H%MKI%Q\K,8Q:RL1@EK@DC)W-^ZG_!'[]H7Q#^U/\
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M2_\ !5'XK:]X/^'WAWXC:-J7AW2?[8N9?$-A96\#P^='#M0P74S%]TBG!4#
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M?_@F[^T9<_#'QQX7^*&JZ]:V%OJ#W&A:=83V9CG!9 &FO(GW#'(V8]S7B?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZ>&-2TW3]!M]%\'^&8GUK48K:1Y<(@(0W$Y #8SA$55#,<D':"G._P#!+?\
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MCZX_9;_;=M=+\21MI9U!IO#.I+*F#;O(Z^7G(X7SXXLMP I)SCJ ?J/\</\
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MR#@K)'W%?65 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M'S_^T)\"?$OCW]N7]GGQOI=G#/X=^'Y\2?VU.TZ(UM]LT^."WVH3N?=(I!V@
MXZG KW\KD5YM\3/VDM+^&?[0/PS^'=U8ZA<:I\3_ .U/L%S#L^SVGV"V6XD\
MW+!OF5@%V@\]<"O22V*J7,TK]M/O?ZW)C:[MW_1"T445)04444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 -?K7PG_P<N#_C2=\:O^X'_P"GW3J^[!R:
MY[XF?"WPS\:O U]X:\9>'-#\6>&]2\O[7I.LZ?%?V5UY<BR)YD,JLC[9$1QD
M'#(I'(!K;#U?95HU?Y6G]SN9U(\T7'N?SO?\&=&BR3_\%%?B!J"M'Y-K\.;J
MV=23N+2:GIK*1QC&(FSSW'7G'*_\':GP#_X5C_P4\A\80VOEVGQ+\,66H2S^
M?O\ .N[4-92#83E-L,%KP!M.[();>!_1'\&_V//A)^SEKUUJGP]^%OPZ\!ZE
M?0?9;F[\.^&[/2YYX=P;RW>"-&9-RJ=I)&5![5/\:_V4/A=^TE<Z?<?$3X:^
M ?'LVDJ\=C)XC\/VFJ-9JY!<1F>-R@8JI(7&=HSTKV5G:6.^MJ.C5K'']2?L
M?9WUO<_&C_@S-_9Z_P"2S?%:XAOE_P"//PEITVW;:R=;J[7/\4B_Z$<<;0_?
M>,?G]_P<1:9<:3_P68^.$-Q'Y<DFH6$X&0V4DTNSD0\>JLIQU&><&OZJO@W\
M!? W[._AFXT7X?\ @OPGX%T>ZNFOIK#P_I%OI=K-<,B(TS1P(JF0I'&I8C)"
M*,X KD_B9^P3\#/C3XUO?$_C+X,?"CQ9XCU+R_MFJ:SX1T^_OKKRXUC3S)I8
MF=]L:(@R3A44#@ 4Z.><F,GBI1TDK6[;?Y!+!7I*DGLR3]@S_DQOX,_]B+HG
M_I!!6E^UK^S]I_[5O[,?C[X;:HWEV?C;0KO2#,.ML\L3+',.#\T;E7&01E1P
M>E=SH.@67A30[/2]+L;33=-TZ!+6TM+6%88+6% %2.-% 5450 %     J_TK
MP7-\_/'O<[N7W>5G\,/C+PCJ7P^\7ZMH&LVLECK&AWDVGWULY!:WGB<QR(2"
M1E64C@D<5_0Y_P &?W[)G_"N/V0O&WQ>U"S\O4/B3K(T[3)9(/F.GV&Y"T<A
M_A>ZDN$8+P3:KDD@!?T6\4_\$W_V>?''B?4M:UKX"_!G5]8UBZEO;^_O?!6F
M7%U>W$KEY)I9'A+/([LS,S$EB22237J7@3P%H7PO\(:?X?\ #.C:3X=T'2HA
M!9:;IEG'9V=E&.0D<48"(O)X4 <U]!F?$'UJA[&,6MK_ ->IP8? >RJ<[=RY
MJFK6^@Z7<7U[<06=G9Q-////($CAC4%F=F. J@ DD\ "OXU_VMOC!KW_  4I
M_P""BOBSQ-IEO=:AK'Q6\7?9-"M'9I)O*EF6VT^VSC<2L(@B&%'W1A1P!_9/
MK^@V7BK0KW2]4L;74M-U&![6[M+J%9H+J%P5>.1&!5D9205((()!KR3P;_P3
MI_9]^'7BRPU[P_\  SX.Z#KFDSI=6&HZ?X+TVUN[*93E9(I4A#HZGD,I!!KC
MRK,H8-RGRWDU9&V*P\JMDG9'&_"7_@C_ /LV_#+X4^&/#=U\#O@[XANO#^DV
MNFS:MJ'@C39KS4WAA2-KB9WB9WED*EV9F9BS$DD\UT?_  ZU_9F_Z-U^!7_A
M!:5_\8KW?;0!S7FRQ%1N[;^]F_LX+H?QU_\ !6/]F"Z_8)_X*6_$SP;I:W&C
MV.DZ\=8\.2VT1M?L]E<[;NT\EEX_=+(L>Y,8>%N%(*C^I#_@E;^U>O[;W_!/
MKX6?$B2X2ZU36=$BM]99-PQJ5L3;7?#?, 9XI& .<JRG+ ACV?Q=_8E^#7[0
M/BQ=>\>?"3X9>-M<6!;0:CKWA>QU*[$*DE8_-FB9]@+,0N< L?4UU/PI^"_@
M[X#>$4\/^!_"GAOP9H,<KSIINAZ9!I]FLC\NXBA54#-W.,FO4S#-(XJA"$HO
MFCU[Z:_><^'PKIS<D]'T.H8>E<)^U,O_ !C'\1/^Q8U/_P!)):[VJ>J:5;Z]
MIEQ8WUO!>6=Y$T%Q!/&)(IXV!5D93D,I!((/!!KQXRLTSKDKJQ_'=_P1S_Y2
MJ?L__P#8\Z7_ .E"U_8V#\U>,>#?^"=7[/OP\\6Z?KWA_P"!GP=T'7-)G2ZL
M=1T[P7IMK=V4RG*R12I"'1U/(92"#7M X:O4S;,EC*D9I6LK'-A<.Z,>5NY^
M,7_!YKQ^S+\%_P#L9[S_ -)17!_\&577]I3_ +EC_P!S%?M!\:/V;_A[^T;I
M=C8_$/P'X,\>6>FRM/:0>(M$MM4BM9&&TO&LZ.%8C@D8)%0_!/\ 9;^&/[-9
MU/\ X5S\._ O@'^VA%_:/_"-Z!:Z5]O\K?Y7F^1&GF;/,DV[L[?,;&-QS<<T
MBL!]2Y7?O\[D_57[?VU_ZM8_&;_@]6Z_LU?]S1_[AZ_/G_@FG_P70^+7_!*[
MX5Z]X0^'OA[X<ZQIOB+5O[8N9?$-A>W$Z3>3'#M0P74*A-L:G!4G)//8?U0?
M&S]EKX9?M*/IG_"QOAUX%\??V*)?[/\ ^$CT"UU7[!YNSS?*\^-_+W^7'NVX
MW>6N<[1CA?\ AUO^S+_T;K\"O_""TK_XQ73A<XHPPD<+6I\R5^OG<RK8.<JK
MJ0E;_AC\'->_X/ /VH-7TBXM;?PM\%]+FF7:EW:Z'J#30'U42WSIG_>1A[5\
M3?#3X5?&S_@K[^V5<1V$=_XZ^(_CR_\ M6K:I-$L-K:@C#7-PT:".W@C1<85
M0 %"(I.U#_5];?\ !,#]FNPNHYX/V>O@?#-"XDCDC\":6K1L#D$$09!!YR*]
M5\!_"OPS\*M-:S\+^'="\-V<FW=!I>GQ6<;;1A<K&JC@<#T%;4\\P]"+^JT>
M63ZDRP-2;_>3NCF?V3?V<M(_9&_9H\#_  ST&:XNM+\$:-;Z3%<S_P"MNVC0
M!YF&3M:1]SE1\JE\    =%\7OAAI?QL^%'B;P;KT<DVA^+=)NM%U")" TEO<
MPO#* 2",E';J"/8UT@//M2G@YKYKVDG+G;UW/1Y5:Q_#Y\>?@[J_[/'QM\7^
M ]?C\G6O!NLW>BWJ]C+;S-$Q&"05)7(()!!!!(.:_<7_ (,XOV2?[(\ _%#X
MW:A9[9M:N8O".BRR0;6%O"%N;QD<\M')(]JORX7=:L"6(POZM^.O^">?P"^*
M7B_4/$'B;X'_  A\1:]JLIGO=2U+P=IUY>7DAX+R2R0EW;@<L2>*]!^&GPN\
M,_!;P/8^&?!OAW0O"?AS3?,^QZ3HVGQ6%E:^9(TC^7#$JHFZ1W<X RSL3R2:
M^CQ_$#Q.&]BHV;M=_P!>9Y^'P'LZG.V='1117S9Z04444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 )GG\:_"?\ X/5C\W[-?_<S_P#N'K]V
M._XU^$__  >K?>_9K_[F?_W#UZ_#_P#OU/Y_DSCQ_P# ?R_,_/;PI^SC-\1/
M^""7B;XB0V=IYWP[^,2I+=31D2?9+S3+2&:.)^Y\_P"PED[@*Q(V@-^L7_!L
M!^W!I6@?\$B?B-::Y>1LOP!O-3U6YM_.&Z#2I8'U!7/=0TR7X!QC]V3R<@>,
M?\$1/@$W[3W_  ;8?M0>"8;>.ZOM6\2ZW-8121"027EOH^DW-L,$'!\^&/#
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M-&: "BC-&: "BC-&: "BC-&: "BC-&: "BC-&: "BC-&: "BC-&: "BC-&:
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M[5C@<S6&P\Z48OFEU[:67ZE5L,ZE2,F]%T.0_P"'6_[,H_YMV^!?_A Z5_\
M&*\[_:U_X(T? /XR_LQ>/?"OA?X+?"'PIXHUW0KNTT;6-,\':=:76FWK1-]G
MF26.)&7;+L)PRY&1D9S7U]GFBO/CB*L9*2D]/-G0Z,&K6/XS?^"<_P"U-JW_
M  3\_;X\ ^/)I+_1XO"^O1VOB*V998Y&T]I!%?021KABPB,F$(.'125)7%?V
M46EY%?VL4\,D<T,R!XY$8,L@(R""."".<BO&/$'_  36_9U\5:_>:IJ?P"^"
MNI:EJ4[W5U=W7@C3)I[J9V+/)([0%F=F))8DDDDFO9-*TNUT+2[>QL;>"SL[
M.)8+>"",1Q0QJ JHJC 50   . !7H9MF4,9*,U%II69SX3#NBG%NZ+A&17YK
M_P#!UO\ \HC=7_[&;2O_ $8]?I0"*Y;XK_!CP=\>?"$GA_QQX4\-^,]!DE2=
M]-US3(-1LVD3E',4RLA9>QQD5PX2O[&M&K_*TSHJPYX./<_GW_X,V?\ D^;X
MH?\ 8C'_ -.%K7]&*]*\U^#7['?PE_9RUZZU3X>_"[X=>!-2OH/LMS=^'?#5
MEI<\\.X-Y;O!&C,FY5.TDC*@]J]+K;,L8L57=9*U[&>%HNE3Y&?RZ_\ !UQ_
MRERUC_L6-*_]%O7[.?\ !M(/^-)OP6_[CG_I^U&OICXL_L/?!3X\^,'\0>.?
MA#\+_&FO21) ^I:YX5L-1O'C3[B&6:)G*KV&<"NT^&GPM\,_!;P/8^&O!OAW
M0?"?AS3?,^QZ3HVGQ6%E:^9(TC^7#$JHFZ1W<X RSL3R2:Z<7FBK8.&&4;.-
MM?1-?J9T<-R595;[G\R__!UQ_P I<M8_[%C2?_1;UE_L<_\ !S+\>/V(OV:/
M"OPK\)^$_A+J'A[PA;R6UG<:KI>HS7DBO-),3(T=]&A.Z1@-J+P!WY/])'Q8
M_8>^"OQY\8/X@\<_"'X7^-->DB2!]2USPK8ZC=O&GW$,LT3.57L,X%<Y_P .
MM?V9?^C=?@5_X06E?_&*[8YUAWAX8>O2YN5+KU1C+!U/:.I"5KGX!?%C_@[3
M_:J^)/@NZTG3;;X7^"+BXR#JNA:'<M>Q*58$)]KNKB(=<Y\O<"HP1SGP?_@C
MQ_P2W\8?\%1_VK-)M9=-U*3X;Z-J,5YXUUYR\<*6P</);+-WNIURBA<LN\R$
M;48U_3]HG_!-?]G3PW<M/I_P#^"^GS,OEM);>"-,B8KD'!*P XR <>PKUSPK
MX5TOP5H<.FZ/IMCI.G6V[RK2SMTMX8MS%FVHH"C+$DX'))/>C^W*5*E*&$I<
MK?7^OP#ZG.4DZLKV-(+TKX=_X.)/V36_:S_X)3_$*UL[>2ZUSP&J>,]+5-OW
M[(.;C@\L39R7:@*0Q9EQG[I^XPV3535=+MM>TNXL;ZW@O+.\B:"XMYHQ)%/&
MP*LC*<AE()!!X(-?/X>LZ52-2.Z:9WU(J47%]3^%NOZW/^" '[)?_#('_!+'
MX:Z3=6GV/7O%UL?%VLAH/)E-Q?!9(UD7J)([46T1W?-F'D+]T>N?\.MOV9<_
M\F[? K_P@M*_^,5[L.E>UF^>?7*:IQC97N_T.+!X/V,G)NXZBC-&:\$] **,
MT9H **,T9H **,T9H **,T9H **,T9H **,T9H **,T9H **,T9H **,T9H
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *]DKQNO9*"9!11102%%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 !KR7]I[]E7_AIMM$_XN1\5OA__ &+Y
M_P#R)?B#^R?M_F^7_P ?'[M_,V>7\G3;YC]=W'K(.X4N*<9-.Z%**:LSY/\
M^'5?_5Q_[5?_ (7_ /\ <]'_  ZK_P"KC_VK/_"__P#N>OK"BK]K(CV43Y/_
M .'5?_5Q_P"U9_X7_P#]ST?\.J_^KC_VK/\ PO\ _P"YZ^L**/:R#V43Y/\
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M %<?^U9_X7__ -ST?\.J_P#JX_\ :L_\+_\ ^YZ^L**/:R#V43Y/_P"'5?\
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M -ST?\.J_P#JX_\ :L_\+_\ ^YZ^L**/:R#V43Y/_P"'5?\ U<?^U9_X7_\
M]ST?\.J_^KC_ -JS_P +_P#^YZ^L**/:R#V43Y/_ .'5?_5Q_P"U9_X7_P#]
MST?\.J_^KC_VK/\ PO\ _P"YZ^L**/:R#V43Y/\ ^'5?_5Q_[5G_ (7_ /\
M<]'_  ZK_P"KC_VK/_"__P#N>OK"BCVL@]E$^3_^'5?_ %<?^U9_X7__ -ST
M?\.J_P#JX_\ :L_\+_\ ^YZ^L**/:R#V43Y/_P"'5?\ U<?^U9_X7_\ ]ST?
M\.J_^KC_ -JS_P +_P#^YZ^L**/:R#V43Y/_ .'5?_5Q_P"U9_X7_P#]ST?\
M.J_^KC_VK/\ PO\ _P"YZ^L**/:R#V43Y/\ ^'5?_5Q_[5G_ (7_ /\ <]'_
M  ZK_P"KC_VK/_"__P#N>OK"BCVL@]E$^3_^'5?_ %<?^U9_X7__ -ST?\.J
M_P#JX_\ :L_\+_\ ^YZ^L**/:R#V43Y/_P"'5?\ U<?^U9_X7_\ ]ST?\.J_
M^KC_ -JS_P +_P#^YZ^L**/:R#V43Y/_ .'5?_5Q_P"U9_X7_P#]ST?\.J_^
MKC_VK/\ PO\ _P"YZ^L**/:R#V43Y/\ ^'5?_5Q_[5G_ (7_ /\ <]'_  ZK
M_P"KC_VK/_"__P#N>OK"BCVL@]E$^3_^'5?_ %<?^U9_X7__ -ST?\.J_P#J
MX_\ :L_\+_\ ^YZ^L**/:R#V43Y/_P"'5?\ U<?^U9_X7_\ ]ST?\.J_^KC_
M -JS_P +_P#^YZ^L**/:R#V43Y/_ .'5?_5Q_P"U9_X7_P#]ST?\.J_^KC_V
MK/\ PO\ _P"YZ^L**/:R#V43Y/\ ^'5?_5Q_[5G_ (7_ /\ <]'_  ZK_P"K
MC_VK/_"__P#N>OK"BCVL@]E$_/?XM?\ !)/Q1??M/_"&\TOXL?M :]X;L?[9
M_MWQ%?\ CB)]4\+[[1!;_8G9%=/M$F8Y?+23** VT<UZQ_PZL/\ T<?^U9_X
M7_\ ]SU[-\3/VDM*^&7[0/PS^'=U8ZA<:I\3_P"U/L%S#L^SVGV"V6XD\W+!
MOF5@%V@\]<"O2&ZU4JU2ROV_5DQIPN[?UH?*/_#JO_JX_P#:K_\ "_\ _N>C
M_AU7_P!7'_M6?^%__P#<]?6%%3[617LHGR?_ ,.J_P#JX_\ :L_\+_\ ^YZ/
M^'5?_5Q_[5G_ (7_ /\ <]?6%%'M9![*)\G_ /#JO_JX_P#:L_\ "_\ _N>C
M_AU7_P!7'_M6?^%__P#<]?6%%'M9![*)\G_\.J_^KC_VK/\ PO\ _P"YZ/\
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MSU]844>UD'LHGR?_ ,.J_P#JX_\ :L_\+_\ ^YZ/^'5?_5Q_[5G_ (7_ /\
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M.J_^KC_VK/\ PO\ _P"YZ/\ AU7_ -7'_M6?^%__ /<]?6%%'M9![*)\G_\
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M_:L_\+__ .YZ/^'5?_5Q_P"U9_X7_P#]SU]844>UD'LHGR?_ ,.J_P#JX_\
M:L_\+_\ ^YZ/^'5?_5Q_[5G_ (7_ /\ <]?6%%'M9![*)\G_ /#JO_JX_P#:
ML_\ "_\ _N>C_AU7_P!7'_M6?^%__P#<]?6%%'M9![*)\G_\.J_^KC_VK/\
MPO\ _P"YZ/\ AU7_ -7'_M6?^%__ /<]?6%%'M9![*)\G_\ #JO_ *N/_:L_
M\+__ .YZ/^'5?_5Q_P"U9_X7_P#]SU]844>UD'LHGR?_ ,.J_P#JX_\ :L_\
M+_\ ^YZ/^'5?_5Q_[5G_ (7_ /\ <]?6%%'M9![*)\G_ /#JO_JX_P#:L_\
M"_\ _N>C_AU7_P!7'_M6?^%__P#<]?6%%'M9![*)\G_\.J_^KC_VK/\ PO\
M_P"YZ/\ AU7_ -7'_M6?^%__ /<]?6%%'M9![*)\G_\ #JO_ *N/_:L_\+__
M .YZ/^'5?_5Q_P"U9_X7_P#]SU]844>UD'LHGR?_ ,.J_P#JX_\ :L_\+_\
M^YZ/^'5?_5Q_[5G_ (7_ /\ <]?6%%'M9![*)\G_ /#JO_JX_P#:L_\ "_\
M_N>C_AU7_P!7'_M6?^%__P#<]?6%%'M9![*)\G_\.J_^KC_VK/\ PO\ _P"Y
MZ/\ AU7_ -7'_M6?^%__ /<]?6%%'M9![*)\G_\ #JO_ *N/_:L_\+__ .YZ
M/^'5?_5Q_P"U9_X7_P#]SU]844>UD'LHGR?_ ,.J_P#JX_\ :L_\+_\ ^YZ/
M^'5?_5Q_[5G_ (7_ /\ <]?6%%'M9![*)\G_ /#JO_JX_P#:L_\ "_\ _N>C
M_AU7_P!7'_M6?^%__P#<]?6%%'M9![*)\G_\.J_^KC_VK/\ PO\ _P"YZ/\
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MSU]844>UD'LHGR?_ ,.J_P#JX_\ :L_\+_\ ^YZ/^'5?_5Q_[5G_ (7_ /\
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M.J_^KC_VK/\ PO\ _P"YZ/\ AU7_ -7'_M6?^%__ /<]?6%%'M9![*)\G_\
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M_:L_\+__ .YZ/^'5?_5Q_P"U9_X7_P#]SU]844>UD'LHGR?_ ,.J_P#JX_\
M:L_\+_\ ^YZ/^'5?_5Q_[5G_ (7_ /\ <]?6%%'M9![*)\G_ /#JO_JX_P#:
ML_\ "_\ _N>C_AU7_P!7'_M6?^%__P#<]?6%%'M9![*)\G_\.J_^KC_VK/\
MPO\ _P"YZ/\ AU7_ -7'_M6?^%__ /<]?6%%'M9![*)\G_\ #JO_ *N/_:L_
M\+__ .YZ/^'5?_5Q_P"U9_X7_P#]SU]844>UD'LHGR?_ ,.J_P#JX_\ :L_\
M+_\ ^YZ/^'5?_5Q_[5G_ (7_ /\ <]?6%%'M9![*)\G_ /#JO_JX_P#:L_\
M"_\ _N>C_AU7_P!7'_M6?^%__P#<]?6%%'M9![*)\G_\.J_^KC_VK/\ PO\
M_P"YZ/\ AU7_ -7'_M6?^%__ /<]?6%%'M9![*)\G_\ #JO_ *N/_:L_\+__
M .YZ/^'5?_5Q_P"U9_X7_P#]SU]844>UD'LHGR?_ ,.J_P#JX_\ :L_\+_\
M^YZ/^'5?_5Q_[5G_ (7_ /\ <]?6%%'M9![*)\G_ /#JO_JX_P#:L_\ "_\
M_N>C_AU7_P!7'_M6?^%__P#<]?6%%'M9![*)\G_\.J_^KC_VK/\ PO\ _P"Y
MZ/\ AU7_ -7'_M6?^%__ /<]?6%%'M9![*)\G_\ #JO_ *N/_:L_\+__ .YZ
M/^'5?_5Q_P"U9_X7_P#]SU]844>UD'LHGR?_ ,.J_P#JX_\ :L_\+_\ ^YZ/
M^'5?_5Q_[5G_ (7_ /\ <]?6%%'M9![*)\G_ /#JO_JX_P#:L_\ "_\ _N>C
M_AU7_P!7'_M6?^%__P#<]?6%%'M9![*)\G_\.J_^KC_VK/\ PO\ _P"YZ/\
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MSU]844>UD'LHGR?_ ,.J_P#JX_\ :L_\+_\ ^YZ/^'5?_5Q_[5G_ (7_ /\
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M_@'_ * M8]!H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %>R5XW7LE!,@HHHH)"BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M>"_M-?\ !0SP'^RIXTM?#^O0Z]JFJ7%L+IXM*A@F^RJ3A1)OE3:S8R!SQ@\
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MINR/T@Q@4 ]*\+_X)M?MGM_P4)_8M\&?%_\ X1O_ (1'_A+OMW_$I_M#[?\
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M"P4_4*\5X->A4HS=*JG&2Z,[Z=2,US0=T.HHS16904444 -)Q0S8H7FOC/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
MF@ HHS10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110!YGX]_Y&R\_X!_Z M8];'CW_ )&R\_X!_P"@+6/0:!11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MR.M?'O[9W[$NN?L=>)=/CO+V#6=#UKS#I^H0H8RQ0C='(F3L<!E/4J0>"2&
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MY25^=7P ^,?C#X87>K:7X&:^A\0>+HX=,BFL<F[ \T-LB !.]V"C(P0,XZY
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M6NF0@8V[7+R29[YS''CH.O7C !]P_'#_ )(KXP_[ E[_ .B'K\)Z_=CXX?\
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MFW^WI^WJW[9TFA^'/#FAZE8Z'8WAN(HK@A[O4+E@8X_W<9*C"LP"@L<R'GU
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MU9[4(J,5%#@<T445!04444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M[6GQ"\??8;[4]:\7W^J>)9;6%&E:RLH8Y;IU R2(K:SA;DD[8X,DX&:^[O\
M@U#_ &SX_P!GG_@H+>?#G4FD71?C-IPTV-U'RPZG:"2>T9SN'R-&UU$,*QWS
MQ]%W&O<Q'#<Z5!U5.[2NU;];^O34X:>8*4U"VC>]S^FJBBBOFST@QFFD\4IZ
MU^:__!UN?^-1NK_]C/I7_HQZVPM#VU6-*]N9I7,ZM3D@Y=C])NOH:=VZ5_.=
M_P &;7_)\OQ1_P"Q%/\ Z<+6OZ, <FMLQP7U6NZ-[VMK:VY.'K>UASV!G %
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M00:TO"?C;1?'FG/>:'JVEZU:1R&%Y[&Z2XC5P 2I9"0& 93CK@CUH U****
M"BBB@ HHHH **** "BBB@ HHK'\6_$+0? $,,FO:YH^BQW+%86O[R.V64CDA
M2Y&2,CI0!L45S?AOXS>#_&>JK8Z/XJ\-ZM?2*66WL]3AGE8 9)"JQ. /:NDH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ KV2O&Z]DH)D%%%%!(W/S5R_B/XFVOAGXG>&_#<Z[9?$T
M%Y);OGJ\'E,4_%'=L_['O74#:#7R?_P4@\;7WPX\>_#'7=.?9=Z7->SQ\\-@
MVV5/^RPRI]B:^;XLSG^RLNEC^D90OZ.<4[>=F['O<-Y2\SS".!6\E*WJH-KY
M72OY'U@!TH886L+X>>-K/XC>"=+URQW?9=4MEN$!'S+N&<'W'(/N*W0U>]0K
M0K4XU:;O&233[IZH\6I3E3FZ<U:46TUV:W0X=****V,PHHHH **** "BBB@
MHHHH **** "BBB@ HHHH _%7]N;1+KP]^U_\1+>[B:&636Y[E5(ZQS-YL9_%
M'4_C7Z;?\$W_ !5;^*?V+_ \D,ZW#6-K)8S $;H7BE==C =#M"D9Y(93WKY?
M_P""S'[-UQ8^*-,^)VFV[-8W\2:;K)7_ )8SIQ!*<MD[T^3A0J^2N3EZ\Y_X
M)R?M\Q_LO:I-X8\3*TG@G6+HW+W$<1DFTJX950R@*"SQD(H9 "1C<HSN5P#Z
M8_X+ _#+Q)\3/A5X1M_#?A_6_$%Q;ZL\DT6FV,MV\2F$C<PC4D#/&37YX^*?
MV>_'_@?09]4UKP/XPT?2[7;YUY?:-<V]O#N8*NYW0*,LR@9/)('4U^OEE^VY
M\(K_ ,.QZI'\1O"*VL@R$DU&..Y'S;>8&(E'/JO3GIS7R?\ \%$_^"CG@7XJ
M?!G6OA_X/^V>()-8> 3ZH$:WM;817$<WR!UWRDF/;T5<'<&;&" >!_\ !+?_
M )/K\#?]O_\ Z;[FOK__ (+6?\FL:!_V-=O_ .DEY7R!_P $M_\ D^OP-_V_
M_P#ION:^O_\ @M9_R:QH'_8UV_\ Z27E 'S%_P $A_AW9^.OVMEO+Z%9E\,:
M3<:I KQ[T\[?% A/8$"9F!YP4!'(R/U>K\R_^")O_)Q/BC_L7'_]*;>OTTH
M_"?XV^);KQC\8_%6K7LDDUUJ&KW4\C,=QRTK''88'0       5^VWPJ\"V_P
MP^&GA_P[:QQQ0Z'I\-DBQG*GRT"DYP"<D$DD9).3R:_'/]M+X27'P4_:=\8:
M+):_9;5M1EO=/4,64VDSF2'#$DG"L%)))RISS7Z;_L%_M5:!^T;\&=)MK6X2
MW\1Z#916FIZ=)+NF0QJJ><N>6C? .[L6VDY'(!D?\%5?!5GXL_8N\17%T&\[
M0;BUU*T9?X9?.6$Y]<QS2#\<]J^*/^"1_BB^T/\ ;+TNSM9O+M]:T^\M+M"H
M/F1K$9E'L1)$AR.>".A-?07_  5I_:Z\.R?"-OAUH.J:?K&IZY-%+J?V2=9E
ML((I%E57*Y =I$4[<A@JY(PPSY+_ ,$;?@]J'B?X_7WC%H6CTGPO8R0><5XD
MN9QL6-<^D?F,2.GR@_?% '>_\%T/^:6_]Q;_ -LJN?\ !#7_ ) 'Q(_Z^-/_
M /0;FHO^"Y5BTFF?#2Z^;;#+J41^7C+"U(Y_X >._P"%<Y_P16^+&B^%O$WC
M+PSJ5Y;V.H:X+.XL//F2-;EHVDC:)=Q!:0F5"%4$D;NF.0#ZH_X*6_\ )C_C
MW_KWMO\ TK@K\\_^"6__ "?7X&_[?_\ TWW-?87_  5F_:+\.:%^SGJ7@FUU
MBQO/$?B"Z@@DL;>82SVL44RS.\@5OW8S&J?-RVX@ X8K\>_\$M_^3Z_ W_;_
M /\ ION: /MC_@L/_P F?-_V&[3^4E?*/_!'3PE:>)/VO'O+CS/.\/Z#=7]K
MM(P)6>&V.>.GEW$G3'./<'ZN_P""P_\ R9\W_8;M/Y25\%?L%_'BR_9V_:<T
M'7]6<0Z+*)+#4)=A8P0RJ5\S !/R/L8X!)52!R: /V=K\5?VX?#5KX2_:Y^(
M%C9QQPVZZQ+,L:+M5/,Q(0!V +G@<>@ XK]?M<^-O@_PWX$D\47GB;0X_#T:
M;_[02\22&3Y/, 0J3O8IR%7+,,8!S7XO_'KXAM\;_CMXF\26T-QM\0ZI+/;0
MM\\@1GQ&G Y(7:, 4 ?KY^QAKMQXD_9/^'MY=-NG;0;6-GR27V1B,,2226(7
M)/<DUZA7%_L]> I/A;\"_!_AV:'[/<Z/H]K:W,?F>9MF6)?-^8$@_/NZ<>G&
M*[2@ KS+]J/]J/PY^RG\.)->UV3SKJ;='IVFQ.%N-2F ^ZO7:HR"SD$*".I*
MJW2_&+XI:;\$_A=KGBK6)%CT_1;5KAP6VF5NB1@_WG<J@]V%?C#^T7^T'KO[
M3'Q1OO%&O3,9+@^7:VJN6AT^ $[(8QV SDG W,68\DT =9X@\1_$_P#X*+_'
M.)?)N-:U*8E;>V@C*6.C6Q?J<9$<2D@%V)9CMR68@']./V//V//#_P"R/X 6
MQL5COM?OE5M5U5H\273C^!>ZQ*?NK^)R37RK^RY_P4'^!7[*7PXCT/0_#?Q
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M6^+[JXDNM:@TI=#UAY%"R/>V1-M)(P7C,OEK-Q@8E'"_='\P_P :;6;X ?\
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M\55*6$PBPE#[<G)_?=_BU;R1YN5QE5K>UG]E)'H]% Z45^='T04444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 )GG\:_"?_ (/5C\W[-?\ W,__ +AZ_=CO^-?A
M/_P>K?>_9K_[F?\ ]P]>OP__ +]3^?Y,X\?_  '\OS/R@U+X'+J/_!,C1OB5
M#Y<;:/\ %"_\,W9$)+3BZTJRN8,OG"A/L=QA2,MYI(^Z:_HX_P"#;+]I6#XZ
M_P#!(CP.;N:WANOAU)=^%=0D\PB.(6K"6$L6)VXM9K<G)QU("KA1^7__  3\
M_9VA^.W_  :W?M0?9XY%U30_'$_B%)$C\T^7IMEI-TX*DC:/)-R"RX(#$G<!
MM/DO_!'_ /X*0V_[(G_!/C]L;P7>:U]CU3Q%X3AOO"MLS!2+V=SI=P\/&7E
MO;.3;DX2U=MNU7(^DS&F\91E".\)I??;_/\  \_#R5&:D]G'^OR/-_A')_P\
MP_X+&^*?%C0^;I?B#7=?\<+#>3?ZBRM(;J_MX6.W+[4AAB"[1NX#;06(X/\
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MX/:<]PLTJ*Z/JMXDD%K&%8Y)6+[5-O ;8T,6=I=#6N54?J=&OB:F\;Q7JO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MU+39&MKS4KL%H8)1E72.,8W,C8&YCM#*1M8<UX#=_P#!0_XN7,Q9/%$=NO\
M<CTNT*C_ +ZB)_6@.8_3"BOSS^'G_!3OX@>&]7@;7AIOB/3Q\L\;VZVLS#U5
MXP%5OJI'MWK[B^"_Q>TOXY?#G3_$FCLPMKY2'A<CS+:13AXW Z$$?B""."*"
MCJJ*^?\ ]NG]JWQ%^S%_PBW]@V>BWG]N?:_/_M"&639Y7D;=NR1,9\QLYST'
M3OYW\&?^"G5Q?Z3XAU#QQ9Z1;PZ=%$+"VTF"1;B]F=F&S]Y*PP N2>  .Y(!
M /L2BOSC\:_\%*OB=XCU:2;3+ZP\/VI;Y+>VLHIMH]VF5R3[C'T'2M[X,_\
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MW$9!!7!X)^=O%?\ P4E^*6OZM-/8ZI8:';LPV6UKI\,BQ@#'WIE=B3U)SUZ
M#B@.8_2&BOB']G'_ (*::P?$]GI/Q 6SNM/O)%A_M:&,6\MJQXWRJ,(R9QG:
M%*C)^; 6OMZ@H_/']N?X*>,O%W[4_BC4-)\(^)M4T^X^R>5<VFESS0R[;2!3
MM=5(.&!!P>""*^A_^":/@K6O ?P)U:SUS2-4T6[DUZ:9(+ZU>WD9#;VP#!7
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M/_\ !'/6X?AWX@O/%5[H_P#PE%YI\EOHMB)W:UL9VR/-GD53N('W0@8 G/)
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M4 8/PY\.S>$?A]H6DW+1-<:7I]O:2M$249XXU0E20#C(.,@?2LOXX_!#P_\
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MBJ56HE9-V[7)Y(WO8=BCK114E % [4444 )M'H/RI:** #%!&:**  #%%%%
M 5![4444 )M!["C8/0?E2T4 )M ["EHHH *.M%% ";0.PI:** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MR_U75(97E+&:RMX/LD/R=$ DAN",C<P<-DJ4Q^(W_!'+_E*I^S__ -CSI?\
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MT:_-+^D<.!PLX3<JB]#F_P!I?X[Z5^S!^SWXV^(FN&/^R_!.B7>LSQM*(OM
M@B:01*Q!^>1E"* "2SJ "2 ?Y!?@-\+_ !I_P5:_X*':/H&H:K(WB_XR>*I+
MG5]52R\[[)YTCW%Y=BW4H"D,0FD$89%"Q[<HHR/ZKO\ @J%^Q)K'_!1']C[7
M/A+I?CS_ (5Y!XFN;5M2U(:-_:C3VT,JS&W$?G0E=\D<1+!_NHRD$,:^3?\
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MP.U#X=+>9\*ZEKMKXDDM2#\M[;V]S;I(O..8[J0'(/1<$<Y_H[_X-.OV2_\
MA1G_  3ENO'U_9^3K7Q>UB345=X/*E_LZT+6UJC9^9E,@NI5)P"MP"!@[F^;
MO^(*L_\ 1RO_ )CW_P"^=?M7\#O@[H?[//P;\*^ _#-O):^'O!^DVVC:='(V
M^18+>)8DWM@;G*J"S'EF))Y-?1YYF]"M1]EAG>[N]&MO5+^D>=@L+4A/FJ+9
M:'7T445\F>L%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?LGS?!#PQ+XDUZ%H?$VO6XC$# JVGVQ(;RV&<;V*HS C*[0.#NKR?_@G=^R
MOBN[A\>>)K,MIMJ^=(M9D!2[D!(,[ _PH1\H(Y;G.%Y^Y: B?./[9G[%NO\
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MJWVK[?=?\?7E1R^9L\S9]_G;MV]L8XKA/^"M?_(G>#?^OVY_] 2OH?\ 9O\
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MN:M_\BT?5ZO\K^YA[:'='U91TKY3_P"'W?[,'_13?_+<U;_Y%H_X?=_LP?\
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M_P#EN:M_\BT?5ZO\K^YA[:'='U9CVHQ[5\I_\/N_V8/^BF_^6YJW_P BT?\
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MF#_HIO\ Y;FK?_(M'U>K_*_N8>VAW1]68]J,>U?*?_#[O]F#_HIO_EN:M_\
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M5ZO\K^YA[:'='U9CVHQ[5\I_\/N_V8/^BF_^6YJW_P BT?\ #[O]F#_HIO\
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M>"__  +N?_D>@-3Z6L/V^?@SI=C#:VOBB&WMK>-8HHHM(O$CB11A551#@
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MAJOA6:STB^CN9DM[FX:5E4\A0T(!/U(H#J?:U?G[_P %6?\ DX;1?^Q=@_\
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MY.Z^0^BBBOO#XP**** "BBB@ HHHH **** "BBB@ HHHH ,48HHH ,48HHH
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MBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@
MQ1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BB
MB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q
M1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB
M@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1
MBBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@
M Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1B
MBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@
MQ1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BB
MB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q
M1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB
M@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1
MBBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@
M Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1B
MBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@
MQ1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% 'F?CW_D;+S_@'_H"UCUL>/?^1LO/^ ?^@+6/0:!1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !7LE>-U[)03(****"1O_+.OCG_ (*O_P"O\!_[M_\ SMJ^QO\
MEG7QS_P5?_U_@/\ W;_^=M7YOXM?\DMB?^W/_2XGWGAE_P E+AO^WO\ TB1\
M?T445_%9_8!-I]_-I5_#=6TCPW%K(LL<B'#1NIRK ^H(!K]4_@C\3+;XN_"[
M1_$%J4QJ$ ,B*<^5(/ED3J?NN&'X5^4U?<W_  2]TC5+/X5:Q=W4^[2[R_\
M]!@ZF-D4"5\^C$J,>L9/<5^W>"&;5Z.:SP,4W"I%M^3CL_35KYH_&_&3*Z-7
M+(8Z3M.G*R\U+=>NB?I<^HJ***_JX_F<**** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@#YU_:/^#OB3QE^WS^S;XNTO2IKOP[X+_X2?^V[U945;#[5IT<5
MON!(9M\@*C:#C'.!7T3MS7G7Q&_:/T/X:_'CX<_#V_M=6EUKXG?VG_9<UO%&
MUK;_ &"W6XF\]F<,NY& 78KY.<[1S7HI;%5*4FE?MI][_4F-KOU_1"T445)0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !11G-% !111F@ HHHS0 4444 %%%%
M!11FB@ HHHH **,T4 %%&:* "BBB@ HHHH **** "BBB@ HHHSB@ HHS10 4
M49HS0 4444 %%%&: "BBB@ HHS1F@ HHSFB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@#S/Q[_R-EY_P#_T!:QZV/'O_ "-E
MY_P#_P! 6L>@T"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "O9*\;KV2@F04444$C?^6=?'/\ P5?_
M -?X#_W;_P#G;5]C?\LZ^.?^"K_^O\!_[M__ #MJ_-_%K_DEL3_VY_Z7$^\\
M,O\ DI<-_P!O?^D2/C^BBBOXK/[ -+PAX5O?'/BG3]'TZ+SK[4ITMX5[;F(
M)/91U)[ $U^J'PJ^']K\+?A]I/A^SRUOI=NL*LPPTA'WF(]68ECCC)KXW_X)
MK_!+_A+?B'=>+[R+=8^'LQ6FX?+)=..3Z'9&<X[&12.E?=BG!K^JO!/AOZKE
M\\TK1]^J[1_PK_-_?9'\R^,'$'UG'QRVD_=I+WO\;_R5O1MCJ***_<C\="BB
MB@ HHHH **** "BBB@ HHHH **** "BN:^*GQ5T'X*^!;_Q)XCOH]/TG3TW2
M2-RSG^%$7JSL> HY)K\TOVA_^"MGQ"^)NK7%OX0E_P"$)T$X2-(0DU]* 3\S
MS%?D)X.(\8QC<W)(!^J5%?B+<?M??%>YO6N&^)7CH2,V[":Y<JF?]P.%Q[8Q
M7I'P/_X*C_%3X2ZU;G5-8D\9:,LH:XL=5(:61< '9<8,B-@<9+*#R5.3D _7
M*BN$_9W^/^@_M+?"ZR\5>'Y)OLUP3#/!*,2V<Z@%XG[9&1R.""".M=W0 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !14%S=1V5O)--)'##"I=W
M=MJHH&223P !WK\]/VKO^"P&L1>+[[1?AA#8VNFV,S0G6KF);B2]9206A0Y0
M1D\J6#%A@X7.* /T2HK\C?#_ /P5<^-VCZE#<7'B:QU:&-U=K:[TBU6*4#JK
M&*-'P>^&!]"*^^/V(?VX])_;!\-WD?V2/1?$VCJAO;#SPXE4@ SP_P 1CW<$
M$?*2H).02 >]4444 %%%?GC^V/\ \%&_'5U^THO@OX1ZTMM:V,Z:29(;&"\.
MJ7SN%8)YL3$!7/E@+PQ5B"05H _0ZBN/\6W.K> _@5J4TFJ-J&NZ/H4KOJ1M
MDB-S<Q6Y)G\H HNYUW; -HSCI7Y8V_\ P5,^.D%Q&[>-EF56#&-]&L-K@=CB
M$'!]B#[T ?K]17"?LZ?'K1_VD?A%I/BW1]L<=\FVYM?,#R6%PO$D+GCE3T)
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MC\8/V3/VD[(:3XFCN/".K0PZE9Z=/IEJT>U&VS6KR>6)2"RD[@P8+*H#9&:
M/O>BN3^"OQ9TSXY_"K0_%FCL_P#9^MVPG5&^] X)62)O]I)%9#CC*G&1764
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'SK^T=\
M'/$GC+]OK]FWQ=I>E37?AWP7_P )/_;EZLJ*MC]JTZ.*WW D,V^0%1M!QCG
MKZ)(R*\_^('[0OA_X<_&_P"'_@'4$U!M=^)']H_V2T,(:W7[#;K/-YK%@5^1
MAMP&R?3K7H.[FJG*32OVT^]_K<F*2;MW_1!1114E!1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 4=3U:UT'3+B]O;BWL[.SB:>>>:01Q01J"S.S' 50!DD\ "O@/
M]H+_ (.;?V4_@1XIOM'M?$WB#Q_=::S1S2>%=+^U6K.I<%8[B9XH9A\HP\;M
M&P=2'(W8_.__ (.;?^"NFO?%/XSZQ^SOX%UB2Q\!^%72#Q4]L&CEUO4U;<]M
M(QP3;P'8-@ #2AB=P2/:[_@E#_P:]3?M7?!?2?B1\:O$GB#P;H7B2 7>CZ%H
MJ11ZI/:NK>7<32SQND(?Y'1!&Y:,@DH2 /K,'D>%HX58S,IN*EM%;_E_74\B
MKCJLZKI8=7MNV?>OP0_X.G?V5?B_KZ:?JE]XZ^'IFE$,=QXDT1?L[$X )>SE
MN BY."S[0.I('-?H'\.OB-H/Q<\#Z7XD\+ZQIWB#P_K4"W5AJ-A<+/;7<3=&
M1U)!';V((ZBOPQ_X*/?\&H47P:^"VK>-/@/XM\3>*+KP[ UW=^&O$ MY+R^M
MT7=(]M<0I$AD0 L(FBRXR%?<%63PW_@V@_X*6>(_V9?VR=!^$.K:M)-\-/BE
M>FP%E<W 6+2]6D7%M<0AAP\TBI;LBE0_FHQW-&@-8C)<%7PLL5ETV^7>+_K?
M\&%/&UH552Q"WV:/Z,/CC\</"_[-WPFU[QUXTU3^Q?"WAFV-YJ5[]FEN/L\0
M(!;RX5>1N2.%4GVKPW]E?_@LK^S=^VQ\6X? OPR^(S>)?%5Q;2WD=C_8&J6>
MZ*( R-YEQ;1Q\ ]"V3V!JC_P7&Y_X)+?';_L6I/_ $;'7X;_ /!J_P#\I:M%
M_P"Q:U7_ -%+7'EN44L1@*N+FWS0O:UK:*^NGZFV(QDZ=>%)6M(_IV;FC'M^
MM>6^/?VW/@S\*O%K:!XG^+GPQ\-ZZLOD'3M4\4V-G=B3Y?D,4DJON^9>,9^8
M>HKT30/$&G^*]'M[_3+ZSU*PNEWP7-K,LT,R],JZDAA[@U\_*G):R3.]23T3
M+Z=*X[XY_''PK^S9\)=<\=>.-8AT#PKX:MC=ZE?RQO(MO'D+PD:L[L695"HI
M9BP !) KL0U?D1_P=U?M6_\ "O/V2?!7PET^Z\O4/B/K!U+48XY_F.GV&UPD
MD8_A>ZDMW4MQFV; )!*]66X-XK$PPZ^T]?3K^!EB:WLJ;J=CZ0'_  <E?L6*
M?^2S'_PD==_^0J^P?A-\5O#_ ,<?ACX?\:>%=1CU?PSXITZ#5=+O4C>/[3;S
M()(WV.%="5895U5E.0P!! _C<\0?LK>*O#7[*'AGXR7%O'_PB/B?Q%?^&K9P
M?WD=Q:P6\VYATV2":55(R<VLN<?+N_?'_@T^_;-N/CC^Q-KGPMUB[CGU?X0Z
M@L=@"6\UM*O#)+"&+$[S'.MT@VX"1^2NT8!;Z3.N'*&%PWUG"R<K.SNT[=.B
M770\[!9C4JU?9U4E=:'ZLT&C-5[V]AL+.6XN)8X8(4+R22,%2-0,EB3P !SD
MU\>>P38_[ZKYM_:^_P""MW[/G[!?Q+L?!_Q8^('_  BOB+4M,CUBVM/[#U*^
M\RT>66%9-]M;R(,R02C:6##;G&"">\\+?MR_!7QUX['A70_C#\+=8\3M.;4:
M18^*K"XOS,&V&/R$E,F\-\NW&<\=:_!C_@[Y_P"4E?@G_LFEA_Z=-5KV<ERM
M8O%QP]>\4TWIH_Q1PXW%.E2YZ=F?T _LV?M*>"_VO/@IHWQ$^'NL_P#"1>#_
M !#Y_P!@O_LD]I]H\F>2WE_=3HDB[98I%^91G;D9!!/5>)_%.F>"/#]YJ^M:
ME8Z1I.GQF:ZO+VX6WM[9!U=Y'(55'J2!7Q7_ ,&VQQ_P1;^#/UUO_P!/NHU^
M2G_!R!_P5RU[]JO]HGQ!\%_".L26_P *? &HFQOH[8-'_P )!JD#;9GF;/[R
M&&962-1\A*&3YLQE=,+D<L3CIX2F[1@VFWT2=OO)JXU4Z$:L]VEIYL_4'X]_
M\'/W[*?P0U>\L;'7O%'Q NK&?R)!X7TD3PN>,LDUQ)!#(HR1N1R#M.,C!.+\
M(/\ @ZQ_97^)OB.WT_5)/B'X#CN)&3[;KVA(UM&0 1N-G-<, Q.T';@'EMHY
MKX/_ ."6G_!K=J7[5/P@T7XC?&;Q9JW@G0?$MM'?:5H&C0Q-JMQ:2 -'<2SR
MAX[?>GS+'Y4C;74L4(*'US]L3_@T$T73_ %YJ7P*^(7B.ZUZPMFE31/%K6TR
MZK(H8^7'=01P+"S?*J[XV7/WG4'*^O/ Y#"I]7=27-LY=$_N_P" <L:V/<?:
M**MV_IG[,?"7XQ^%?CW\/]/\5>"_$&E>)_#NK1"6UU#3KA9X9 0#C*GAAGE3
MAE/! /%=+FOY)_\ @DK_ ,%,O&'_  2L_:QM;Z:;58_ ^I7T>G>-_#KQG,UN
MKE'E6%L;;NWR[)RI)#1L0KL*_K.TK5;77=+M[ZRN(+NSO(EG@GAD$D4T; ,K
MJPR&4@@@C@@UXF=9//+ZJC?FC+9_FGYH[,%C%7C?9K=%T'(HH# T9Q7C'<%%
M&X9ZT9H :.!7C/[97_!0+X1_L >&=%UCXM^+/^$4T_Q!<O9V$O\ 9=[?_:)4
M7>R[;6&5EPO.6 'O7LRG-?C;_P 'C?\ R;;\&?\ L9+W_P!)17H91@XXO%PH
M3NE+MOLV<^+K.E2=2.Z/TC_8R_X*)_!W_@H'IFO7GPA\7GQ;;^%Y88=2;^RK
MZP^S/,',8Q=0Q%LB-_NY QSC(KV_.&K\4_\ @S3_ .2;?'K_ +">C?\ HJ\K
M]JSPU5F^#CA,9/#P;:C;??5)_J3@ZTJM%5);L^1/CC_P7=_95_9O^+>N^!?&
MGQ3_ +%\5>&;HV>I67_"-:O<?9I0 2OF16KQMP1RK$>]?3?PP^).B_&;X:^'
M?&'AN]_M+P[XJTRVUC2KOR9(?M5I<1+-#)LD577=&ZG:ZAAG! .17\G'_!;_
M (_X*S?';_L9Y?\ T7'7].G_  2_/_&M3]GO_LFGAS_TUVU>AFV3T<+AJ-:F
MVW-:WM;9/2R.?"8R=6K.$DK1/*?B?_P< ?LC_!WXE>(O"'B3XLG3?$7A34[G
M1]5M/^$7UF;[+=V\K0S1[X[1D;;(C#<C%3C()&#6(?\ @Y+_ &+/^BS'_P )
M'7?_ )"K^</_ (*=_P#*2C]H3_LI?B3_ -.MS7ZC>$_^#.,^*/"VFZI_PT7]
MG_M*TBNA%_P@.[R]Z!MN?[2&<9QG KUJV095AZ-.KBJLH\ZNNO17VB^YRPQV
M*J3E&E%.W]=S]$_ /_!?W]C_ .).K6MGI_QO\/V\]Y.+:-M5T^_TF%6..7DN
MH(T1.?ONP4<\\&OKK0=>L?%&A66J:7>VNHZ;J4*75I=VLRS074+J&22-U)5D
M92"&!((((K^:G_@J)_P;7>-/^"=_[/FH?$_1?B!IOQ(\*Z"T"ZRO]D-I-]8+
M-+Y*RK%YTRRQAWB#$.&'F$[-J,P^@_\ @T(_;$\4WWQ+\>? N_O)[[PM;Z')
MXMTF.:1G&E2QW5O;SQQ9;"I*;I7*@8WH6X+-NXL=D6$>#EC<!5<HQW3_ .&5
MM^QM1QU5551KQLWV_IGZC_M:?\%?_P!GG]A?XJ1^"_BIX]N/"?B2:QBU**TD
M\.:K=+-;2,ZI*DL%M)&REHY%^5CAD8'!!%>F?LH_M@_#G]N#X5?\)M\+?$B>
M*O#)O)=/-XME<696>/:70QW$<<@(#J>5P0P(R*_*_P#X/ ?V5%\1_!GX:?&6
MPMX_M7A?4)/#.K2*6\R2UNE,UNQ'W=D<L4JY&#FZ'4?=\U_X,^?VK_[%^(7Q
M/^"NH76V'6K6/Q;HT3S[4%Q"5M[M40\-))&]LWRX.VU8D$#*X+):,\K^O4F^
M=;K2V_I?SWV+^N3CBO832L]C]Z.?\*\%_;._X*8_!'_@GU=>'[?XO>-D\)S^
M*EN)-+C&EWVH/<+ 8Q*Q%K#*4 ,J %]N[)VYVMCWHG!K^6O_ (.5?VK_ /AI
MG_@J+XITNSNOM&A?"^VB\)682??'Y\):2\;:.%<7,LL3=21;KDC 5>3A_*XX
M[$^RG=12;=M_+>_4UQ^*="GS1WZ']%_[&_[>_P )_P!OSPCJVO?"7Q1+XKTK
M0[M;"]N3I-[8+%.4#A +J&(L=I!.T$#(SC(KV4C!KXU_X(*_LD2?L=_\$Q/A
MWHNH6,FG^(O%$+>*M;BEMOL\RW-[AT25#\PDCMQ;PL&^8&'!"XVC[*/6O.QM
M.E3KSIT6W%-I-[NQTT92E34I[V'4445SFH4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%&:,T %%%% !1110 449HSF@
M HHHH **** "BBC- !11FC- !11FB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH ***,T %%%% !1110 4449Q0 4444 %%%% !11FB@ HHHS0 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M-X=_9EMM)DUZVU:Z.LM*MNEA%'(P\L)N+;W3CYUZ9ZUY?_P]:^'?_0'\:?\
M@);?_)% 'TU17S+_ ,/6OAW_ - ?QI_X"6W_ ,D5Z;^SG^U;X=_:<_MC^P;/
M6K/^P_(\_P#M"&*/?YOF;=NR1\X\MLYQU'7L >FT444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %>R5XW7LE!,@HHHH)&_\LZ^.?^"K_P#K_ ?^[?\
M\[:OL;_EG7QS_P %7_\ 7^ _]V__ )VU?F_BU_R2V)_[<_\ 2XGWGAE_R4N&
M_P"WO_2)'Q_3[>WDN[B.&&-Y996"(B+N9V/  '<GTIE>W?L$?!V3XH_'*UOI
M85;2O#>+ZY+(&5I.1$G((R6!;ITB;H<&OY#R'*:F9YA2P-+><DO1=7Z)7;/Z
MJSS-:>6X"KC:NT(M^KZ+YNR7J?:G[,7PA/P3^"^CZ'(=U\L9N+QMVX&>3YG
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M5+YKBSBM3J>BK--S;E7 GAC!Y(;>) H/R[)#CYF( /J/]J[]M;PK^Q]_8/\
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M"1+D^05(]#YGX$ ]0*_:*@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%D<[IAR/O#^O!?E_"O8X@RNAE]2%&FVY-7=VOPLEYG)E^*J5XN<DDNECS/\
M:I_:Z^'?[$_PEF\<?$_Q+!X5\,0W45D;M[6>Z9YI20D:10(\KL<,<*IP%8G
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MB>UT+X?_ !<\*ZSKVH?\>NESR2:??7AV[RL4%RD<DC!<DJJD@*V0,''Y@_\
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M_P#@G_X:T75_BYXL/A/3O$%R]G82_P!EWM_]HE1=[+MM8967"\Y8 >]?/_\
MQ$E_L6C_ )K-_P"6CKO_ ,A5\J?\'C9_XQN^#?\ V,M[_P"DHK\XO^",?_!&
M/_A[N?B1CXD?\*^_X5[_ &8?^1?_ +6^W_;?MG_3S!Y>S[)_M;O,_AV\_89=
MD>!J9>L=BYRBM;VM;>RTLV>/B,;7C7]C12?KZ7[G[IZ%_P '&/[&?B+5X;*W
M^--K'-<-L1KGPWK%K"#_ +4DMHJ*/=F KZK^#?QV\$_M"^$8]>\!^+O#GC+1
M9<8O-'U"*]A!Y&TM&Q"L"""IP0000"#7X:_&'_@SD\>>'O#EQ<>!?C3X7\5:
ME&@:.TUC09M&CE.3N421S7.#MQMRN"3@E1\U? /['_[7WQ@_X(T_MDWEU;6=
M]I.L>'[YM+\6^$KZ9HK75HXRRO!.%)4LNYFBF&[:2'7<I(:UP[@,53D\MK.4
MET?_  R:)_M"O2DEB(63ZK_AV?U]4$9KD?@A\8-#_:%^#WA?QUX:N)+KP_XP
MTJVUG3I)%V2&">)9$#KD[7 8!EZJP(/(KK!Z5\9*+B^5[H]I.ZNCG_B?\2=%
M^#'PU\0^,/$E\=-\.^%=,N=8U2[\F2;[+:6\3332;(U9VVQHQVHI8XP 3@5\
MQ?!+_@N]^RE^T=\6=!\#^#_BQ#JGBCQ-="RTVSE\/ZM9+=3$$K&)9[5(E9L8
M 9AN) &20#Z1_P %0#G_ ()J_M#?]DT\1_\ IKN:_CJTS5+G1-1M[RSN)[.\
MLY5F@GAD,<D,BD,KJPY5@0"".017U/#V0TLPIU)3DTUHK6MMUT_5'E8_'SP\
MHI)-,_N*(R:\9_;)_P""@/PC_P""?_AG1M8^+?BS_A%-/\073V>GR_V7>W_V
MB5%WLNVUAE9<+SE@![UX[_P1%_X*:0?\%,OV.++7-49(OB%X29-(\6VZJJK+
M<A,QWD:J !'<(-^ JA9!*@!"!F^-?^#QL_\ &-_P;_[&6]_])17G8'*W/,%@
ML1=:M.V^B;T_K8Z:V*M0=:GKIH?I9^QO_P % ?A'_P % /#6M:Q\(_%G_"6:
M?X?N4L[^7^R[VP^SRNN]5VW4,3-E><J"/>L']L;_ (*F? G]@'Q+HVC_ !:\
M<_\ ")ZEX@MGO+"'^Q=0O_/B1]C-NM8)57#<88@^U?GC_P &<O\ R;=\9?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@#S/Q[_R-EY_P#_T!:QZV/'O_(V7G_ /_0%K'H- HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M-NY0VX9/ H _0;_@IG.MM^P[X\9SM7R;1>G<WD 'ZD5^?'_!+?\ Y/K\#?\
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MK73T4 %?A+\:/^2Q>+/^PS>?^CWK]VJ_"7XT?\EB\6?]AF\_]'O0!^V7P/\
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MI7[:?>_U)BDF[=_T04445)04444 %%%% !1110 4444 %%%% !1110 4444
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M7P'C_9>_X)_?L>_#N.-4;P;I]WI5P5(Q+<1V=@)I,CC+R[V..,L<<5PY?1>
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MNJ6V@:5<7U[<06EG9Q-///-((XH(U!9G9C@*H ))/  KQO\ X)Q_LNK^Q?\
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M87$P]EM+=?,_K>HH%%?!'OA1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 >9^/?\ D;+S_@'_ * M8];'
MCW_D;+S_ (!_Z M8]!H%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\SE5&%5CR1T]:^%_^'>_Q?\ ^A1_\JME_P#'J"W<^S_^'A/P@_Z&[_RE7O\
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M&GX#>$_VB/"MOHOC'2?[9TNUO%OHH?M4UOMF5'0-NB=6.%D<8)QSTR!7:44
M>7_!3]CGX<_LZ^(+K5O!OAW^R-0O+8VDTOV^ZN-\197VXED<#YE4Y SQUKU"
MBB@#/\2>&]/\7Z+<:;JVGV>J:?=KLGM;N!9H9ER#AD8%6&0#@CM7S/XW_P""
M07PA\6ZO-=6J^)?#JS/O-OIM^GDKP 0HFCD(!.3C/!.!@8 ^J** /G'X/_\
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M%LEK;1( ,*HQDX RQY)/<DGJ:VJ "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@#YO_:5^%?B+Q?\ \% OV9_%&FZ3=7GA_P (_P#"
M4_VS?1@>7I_VG38XH-YS_&X*C'<5]'GE:\_^('[0OA_X<_&_X?\ @'4$U!M=
M^)']H_V2T,(:W7[#;K/-YK%@5^1AMP&R?3K7H!.*J<FTD^VGW_YDQ23=N_Z(
M6BBBI*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *,444 %%%% !1110 4444 '
M6BBB@ HHHH **** "BBB@ HHHH **** "C&:** "BBB@ HHHH *.M%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !0WW:*#S0!_'#ING3:O_ ,%-K>TMT\RXNOB>
ML,29 W,VJ@ 9/ R3WK]QO^#MOX"M\0?^"?/AOQQ;V]W-=?#WQ/"T[Q1!XX+.
M\C:!VD.-R@SBT4$'&6 ()*E?I+3O^"!_[)ND?%NW\=6_PI,?BJUU===BO?\
MA)]8.V]683B7RS=^6<2#=M*[>V,<5]%?M$_LY>#?VLO@UK7P_P#B%HL?B+P?
MXB6)-0T][B:W$XBE2:/]Y"Z2*5DC1@58'*BOKL;Q%2JXFA7IIVI[WM>SM>VK
M\^QY%'+YQIU*;:][;^K'\F?_  2-^!'_  TI_P %+O@OX1:1H[>Z\2V^H7.(
M?.+6]ENO9EV\CYH[=UR00N<D$ BOU;_X/)[61OA9\")O+D,4>JZNC.%.U6:&
MU(!/3)"M@=]I]*_0O]E;_@C7^S?^Q-\6H?'7PR^')\,^*K>VELX[[^W]4O=L
M4H D7R[BYDCY ')7([$5W7[9'_!/[X1_\% ?#6BZ/\6_"7_"6:?X?NGO+"+^
MU+VP^SRNNQFW6LT3-E>,,2/:KQ7$E&KF5+%*,N2">FE[N]^MNW4FEELXX>5)
MM<TONZ'YV_\ !G@<?L5_%+_L=_\ VPMJ_7CK7CW['G[!WPI_8%\%:IX=^$OA
M5O">CZU??VE>6_\ :=Y?>=<>6L>_=<RRLOR(HPI XSC.37L(.*^<S3&1Q.+G
M7A>TGUWV/1PM%TJ2A+='\D'_  7$_94;]D'_ (*=?$_P[;V[P:+KFHGQ-HY+
M JUK??Z1M3'(6.5IH0#S^YZG[Q['_@WT_8[7]MG_ (*>>$UUV&XU#P]X%W^,
M]9+LK"X-M(AMTD\P$.LEW);AT()>/S1QRR_T7?MD_P#!+SX%_P#!0'7M$U3X
MN>!8_%>H>'8)+;3YAJ]_I[012,&93]EGBWC<H(WYQSC&3F3]C7_@F1\#?^"?
M>J:]??"'P'#X3O/$T4,&HSG4[W4))HX2[(BM=32F-<R,2$VAB%W9V+CZJ7%D
M7E_L$I>TY>6^ENU[WOMY;GEK*Y?6.>ZY;WMU/?":_G,_X.V?VK6^*7[;WAGX
M6V=Q(VF_"W1EGO(B% &HWX29^G+ 6JV9&[H7?  )+?T9GDU\??&?_@@W^RG^
MT-\5M>\;^,?A;)K7BCQ/>/?:G?/XIUF(W,S_ 'FV1W:H@[!44*    .*^?R'
M'T,'BO;UTW9.UDMWZM=+GH8[#U*U/V=.WG<^&/\ @A?_ ,$%_@;^T5_P3U\.
M?$+XU> 3XI\3>-;V[U&PE.NZE8M9Z<KB"&(I;3Q1G<T,DP8AF*SKEN J_88_
MX-M/V+<_\D9X_P"QNUW_ .3:^R/AU\/-%^$WP^T'PKX>L8],\/\ AK3[?2=,
MLT9F6TM8(UBBB!8EB%1%7+$DXY)-;IXK/%9UBZM:52-244VVDI-671:,*6#I
M1@HN*;7DC^8'_@XY_P""9G@W_@G7^TSX-D^&F@_\(]\/O'&AM):69O;J\,-_
M:R[;H"2X>1RI2:U?[YP9&&  ,_J5_P &L_[9%Q^TC_P3\G\$ZQ>1W&O?!_45
MT:-=R>9_9<J>99,P4 @ K<1#.<BW!W$Y ^T/VQ?V!?A+^W[X3TG0_BWX1C\6
M:;H-X;^PB.H7=BUO,4*$A[:6-R"IP5)*G .,@$8?[''_  3 ^!O_  3]US7-
M2^$7@F3PC>>)+>.VU(_VYJ-^MS'&Q9 4N;B505+-@J ?F(S@UZF+SREBLMCA
MJZDZL=I:-;]7>^WEN<]' SI8AU(6Y7T_KS/H':/0?E2A0.U%%?+GJ'\I_P#P
M<D?\II/C1]=$_P#3'IU?T-?\$=QN_P""6GP"_P"Q)TW_ -$K6+^TE_P1'_9C
M_:Z^-.M?$3XB?#,^(/&'B#R/[0U#_A(M5M/M'DP1V\7[J"Z2-=L44:_*HSMR
M<DDGZ&^#OP@\._ 'X6^'_!7A+3_[)\,^%[*/3=,L_/EN/LUO&NU$\R5FD; '
M5F)/<FOH\TSBEB<!1PL$^:"5[VMHK::O\CS<+@YTZ\JCM:5_SN>9_P#!4 ?\
M:U/VA?\ LFGB/_TUW-?S%?\ !$#_ )2S? G_ +&>+_T7)7]9/Q.^&^B_&?X:
M^(O!_B2R_M+P[XJTRYT?5;3SI(?M5I<1-#-'OC977=&[#<C!AG((.#7S'\#_
M /@A%^RK^S?\6]"\=>#/A9_8OBKPS="\TV]_X275[C[-* 0&\N6[>-N">&4C
MVI9/G%+"X6M1J)MS6EK6VMKJ/%X.=6K"I%JT?\R]_P %Q3_QJ6^.W_8M2?\
MHV.OYG/^"8G[=/\ P[B_;#\/_%C_ (1?_A,O[#M;RV_LK^TO[.\_[1;O#GSO
M*EV[=^[&PYQCCK7]<?QP^!_A?]I#X2Z]X%\::7_;7A7Q-;&SU*Q^TRV_VF(D
M$KYD+)(O('*L#[U\D?\ $-K^Q;T_X4R?_"NUW_Y-KHR/.L+A<+4PV)C*2FWM
M;9JW=,SQV#K5:L:E)I6[_P##,^&O^(ST_P#1MO\ YD#_ .]M? ?_  5I_P""
MU7CS_@J]?Z#8ZQH.D^#?!OA>YGN]-T:QN)+EY)90%$MS,VT2R)&-JE8XP-\G
MR_-Q^\(_X-M/V+<_\D9_\N[7?_DVN[^$O_!$?]E/X(>(['5O#_P1\)+J&ELD
MEM-J7GZKY3H"%?%U)*"XSD,03N"MG<H(ZL/G&2X6?ML/0ES+:_\ P9/\C*I@
M\957)4FK?UY(^4_^#5;]@+Q%^S!^RUXJ^)GC"PNM)UCXNSV<FF6%S"$E@TJU
M64P3G(#H;A[B5MIX,<4#C[W'ZK8]:  H% .!7RN/QD\5B)8BIO+\.R/4P]%4
MJ:@NA_)G_P %Z_V4?^&1?^"HOQ(TFUM/LN@^++H>+='"P>3$;>^+22+&O01Q
MW(N81MXQ#T7[HV/^" ?[,]Q^V7_P5?\  K:QYFJV'A*XE\<:W+<N\DDWV1E>
M)G/\9:]DM0V\X8.V=WW6_HM_;%_X)5_ 3]OWQ;I.O?%KP"OBK6-#LSI]G<C6
M;_3VB@+F381:SQ!AN9B-P)&XXQFK?[&W_!,;X&_\$^]4UZ^^$/@.'PG>>)HH
M8-1G.IWNH231PEV1%:ZFE,:YD8D)M#$+NSL7'USXLA_9WU>TO:<O+?2W:][W
MV\MSR?[)E[?VEURWO8]^HHHKX<]P**** /R!_P""WW_! GXQ_P#!2K]M&'XC
M>!?$GPUTG0X_#MGI!@UW4+Z"Z\V&2=F;;#:2IM(E7!WYX/ [_H[^P3\!M8_9
M=_8P^&/PY\07.G7FN>"_#UII%[-I\CR6LLL485FC9T1RI(X+(I]A7L&,TF-V
M:[L1F5>M0AAZC]V.VGR.>GAH0J.I'=[CJ***X3H/AC_@Y+/_ !I:^,WUT/\
M]/NG5_/;_P $F_\ @HQ_PZ]_:EF^)G_"&_\ "<>=HESHW]F_VM_9F/.>)_,\
MWR9ON^5C;LYW=1CG^KO]I;]FSP7^UW\%=9^'?Q#T7_A(?!_B#R?M^G_:Y[7S
M_)GCN(OWL#I(NV6*-OE89VX.02#\JG_@VV_8M_Z(S_Y=VN__ ";7U62YUA,-
M@YX3%1E)2;;M;9I+NGT/)QF#K5*RJTFE9=?7T9\-_P#$9X3_ ,VV_P#F0/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#S/Q[_ ,C9>?\
M /\ T!:QZV/'O_(V7G_ /_0%K'H- HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH *_,K_@H1_R=]XN_P"W/_TBMZ_36O,OB%^QS\-_BKXPO->U[P[]
MOU:^V>?/]ONHM^Q%C7Y4D51A54< =/6@4MCSK_@EK_R;A>?]ARX_]%05]&7]
MA!JEE-:W4,-Q;7$;12Q2H'CE1AAE93P002"#P16#\+/A%X=^"OAM]'\,Z?\
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M!KP76O\ @EQ\-M4OY)H+KQ1IL<CEE@MKV-HXP>B@R1.V!VRQ/J30+E['P_\
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M_#(W[4'_ $=Y_P"8LTG_ ..4>RC_ #+\?\@]H_Y7^'^9]745\H_\,C?M0?\
M1WG_ )BS2?\ XY1_PR-^U!_T=Y_YBS2?_CE'LH_S+\?\@]H_Y7^'^9]745\H
M_P##(W[4'_1WG_F+-)_^.4?\,C?M0?\ 1WG_ )BS2?\ XY1[*/\ ,OQ_R#VC
M_E?X?YGU=17RC_PR-^U!_P!'>?\ F+-)_P#CE'_#(W[4'_1WG_F+-)_^.4>R
MC_,OQ_R#VC_E?X?YGU=17RC_ ,,C?M0?]'>?^8LTG_XY1_PR-^U!_P!'>?\
MF+-)_P#CE'LH_P R_'_(/:/^5_A_F?5U%?*/_#(W[4'_ $=Y_P"8LTG_ ..4
M?\,C?M0?]'>?^8LTG_XY1[*/\R_'_(/:/^5_A_F?5U%?*/\ PR-^U!_T=Y_Y
MBS2?_CE'_#(W[4'_ $=Y_P"8LTG_ ..4>RC_ #+\?\@]H_Y7^'^9]745\H_\
M,C?M0?\ 1WG_ )BS2?\ XY1_PR-^U!_T=Y_YBS2?_CE'LH_S+\?\@]H_Y7^'
M^9]745\H_P##(W[4'_1WG_F+-)_^.4?\,C?M0?\ 1WG_ )BS2?\ XY1[*/\
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M@]H_Y7^'^9]745\H_P##(W[4'_1WG_F+-)_^.4?\,C?M0?\ 1WG_ )BS2?\
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MD_\ QRCV4?YE^/\ D'M'_*_P_P SZNHKY1_X9&_:@_Z.\_\ ,6:3_P#'*/\
MAD;]J#_H[S_S%FD__'*/91_F7X_Y![1_RO\ #_,^KJ*^4?\ AD;]J#_H[S_S
M%FD__'*/^&1OVH/^CO/_ #%FD_\ QRCV4?YE^/\ D'M'_*_P_P SZNHKY1_X
M9&_:@_Z.\_\ ,6:3_P#'*/\ AD;]J#_H[S_S%FD__'*/91_F7X_Y![1_RO\
M#_,^KJ*^4?\ AD;]J#_H[S_S%FD__'*/^&1OVH/^CO/_ #%FD_\ QRCV4?YE
M^/\ D'M'_*_P_P SZNHKY1_X9&_:@_Z.\_\ ,6:3_P#'*/\ AD;]J#_H[S_S
M%FD__'*/91_F7X_Y![1_RO\ #_,^KJ*^4?\ AD;]J#_H[S_S%FD__'*/^&1O
MVH/^CO/_ #%FD_\ QRCV4?YE^/\ D'M'_*_P_P SZNHKY1_X9&_:@_Z.\_\
M,6:3_P#'*/\ AD;]J#_H[S_S%FD__'*/91_F7X_Y![1_RO\ #_,^KJ*^4?\
MAD;]J#_H[S_S%FD__'*/^&1OVH/^CO/_ #%FD_\ QRCV4?YE^/\ D'M'_*_P
M_P SZNHKY1_X9&_:@_Z.\_\ ,6:3_P#'*/\ AD;]J#_H[S_S%FD__'*/91_F
M7X_Y![1_RO\ #_,^KJ*^4?\ AD;]J#_H[S_S%FD__'*/^&1OVH/^CO/_ #%F
MD_\ QRCV4?YE^/\ D'M'_*_P_P SZNHKY1_X9&_:@_Z.\_\ ,6:3_P#'*/\
MAD;]J#_H[S_S%FD__'*/91_F7X_Y![1_RO\ #_,^KJ*^4?\ AD;]J#_H[S_S
M%FD__'*/^&1OVH/^CO/_ #%FD_\ QRCV4?YE^/\ D'M'_*_P_P SZNHKY1_X
M9&_:@_Z.\_\ ,6:3_P#'*/\ AD;]J#_H[S_S%FD__'*/91_F7X_Y![1_RO\
M#_,^KJ*^4?\ AD;]J#_H[S_S%FD__'*/^&1OVH/^CO/_ #%FD_\ QRCV4?YE
M^/\ D'M'_*_P_P SZNHKY1_X9&_:@_Z.\_\ ,6:3_P#'*/\ AD;]J#_H[S_S
M%FD__'*/91_F7X_Y![1_RO\ #_,^KJ*^4?\ AD;]J#_H[S_S%FD__'*/^&1O
MVH/^CO/_ #%FD_\ QRCV4?YE^/\ D'M'_*_P_P SZNHKY1_X9&_:@_Z.\_\
M,6:3_P#'*/\ AD;]J#_H[S_S%FD__'*/91_F7X_Y![1_RO\ #_,^KJ*^4?\
MAD;]J#_H[S_S%FD__'*/^&1OVH/^CO/_ #%FD_\ QRCV4?YE^/\ D'M'_*_P
M_P SZNHKY1_X9&_:@_Z.\_\ ,6:3_P#'*/\ AD;]J#_H[S_S%FD__'*/91_F
M7X_Y![1_RO\ #_,^KJ*^4?\ AD;]J#_H[S_S%FD__'*/^&1OVH/^CO/_ #%F
MD_\ QRCV4?YE^/\ D'M'_*_P_P SZNHKY1_X9&_:@_Z.\_\ ,6:3_P#'*/\
MAD;]J#_H[S_S%FD__'*/91_F7X_Y![1_RO\ #_,^KJ*^4?\ AD;]J#_H[S_S
M%FD__'*/^&1OVH/^CO/_ #%FD_\ QRCV4?YE^/\ D'M'_*_P_P SZNHKY1_X
M9&_:@_Z.\_\ ,6:3_P#'*/\ AD;]J#_H[S_S%FD__'*/91_F7X_Y![1_RO\
M#_,^KJ*^4?\ AD;]J#_H[S_S%FD__'*/^&1OVH/^CO/_ #%FD_\ QRCV4?YE
M^/\ D'M'_*_P_P SZNHKY1_X9&_:@_Z.\_\ ,6:3_P#'*/\ AD;]J#_H[S_S
M%FD__'*/91_F7X_Y![1_RO\ #_,^KJ*^4?\ AD;]J#_H[S_S%FD__'*/^&1O
MVH/^CO/_ #%FD_\ QRCV4?YE^/\ D'M'_*_P_P SZNHKY1_X9&_:@_Z.\_\
M,6:3_P#'*/\ AD;]J#_H[S_S%FD__'*/91_F7X_Y![1_RO\ #_,^KJ*^4?\
MAD;]J#_H[S_S%FD__'*/^&1OVH/^CO/_ #%FD_\ QRCV4?YE^/\ D'M'_*_P
M_P SZNHKY1_X9&_:@_Z.\_\ ,6:3_P#'*/\ AD;]J#_H[S_S%FD__'*/91_F
M7X_Y![1_RO\ #_,^KJ*^4?\ AD;]J#_H[S_S%FD__'*/^&1OVH/^CO/_ #%F
MD_\ QRCV4?YE^/\ D'M'_*_P_P SZNHKY1_X9&_:@_Z.\_\ ,6:3_P#'*/\
MAD;]J#_H[S_S%FD__'*/91_F7X_Y![1_RO\ #_,^KJ*^4?\ AD;]J#_H[S_S
M%FD__'*/^&1OVH/^CO/_ #%FD_\ QRCV4?YE^/\ D'M'_*_P_P SZNHKY1_X
M9&_:@_Z.\_\ ,6:3_P#'*/\ AD;]J#_H[S_S%FD__'*/91_F7X_Y![1_RO\
M#_,^KJ*^4?\ AD;]J#_H[S_S%FD__'*/^&1OVH/^CO/_ #%FD_\ QRCV4?YE
M^/\ D'M'_*_P_P SZNHKY1_X9&_:@_Z.\_\ ,6:3_P#'*/\ AD;]J#_H[S_S
M%FD__'*/91_F7X_Y![1_RO\ #_,^KJ*^4?\ AD;]J#_H[S_S%FD__'*/^&1O
MVH/^CO/_ #%FD_\ QRCV4?YE^/\ D'M'_*_P_P SZNHKY1_X9&_:@_Z.\_\
M,6:3_P#'*/\ AD;]J#_H[S_S%FD__'*/91_F7X_Y![1_RO\ #_,^KJ*^4?\
MAD;]J#_H[S_S%FD__'*/^&1OVH/^CO/_ #%FD_\ QRCV4?YE^/\ D'M'_*_P
M_P SZNHKY1_X9&_:@_Z.\_\ ,6:3_P#'*/\ AD;]J#_H[S_S%FD__'*/91_F
M7X_Y![1_RO\ #_,^KJ*^4?\ AD;]J#_H[S_S%FD__'*/^&1OVH/^CO/_ #%F
MD_\ QRCV4?YE^/\ D'M'_*_P_P SZNHKY1_X9&_:@_Z.\_\ ,6:3_P#'*/\
MAD;]J#_H[S_S%FD__'*/91_F7X_Y![1_RO\ #_,^KJ*^4?\ AD;]J#_H[S_S
M%FD__'*/^&1OVH/^CO/_ #%FD_\ QRCV4?YE^/\ D'M'_*_P_P SZNHKY1_X
M9&_:@_Z.\_\ ,6:3_P#'*/\ AD;]J#_H[S_S%FD__'*/91_F7X_Y![1_RO\
M#_,^KJ*^4?\ AD;]J#_H[S_S%FD__'*/^&1OVH/^CO/_ #%FD_\ QRCV4?YE
M^/\ D'M'_*_P_P SZNHKY1_X9&_:@_Z.\_\ ,6:3_P#'*/\ AD;]J#_H[S_S
M%FD__'*/91_F7X_Y![1_RO\ #_,^KJ*^4?\ AD;]J#_H[S_S%FD__'*/^&1O
MVH/^CO/_ #%FD_\ QRCV4?YE^/\ D'M'_*_P_P SZNHKY1_X9&_:@_Z.\_\
M,6:3_P#'*/\ AD;]J#_H[S_S%FD__'*/91_F7X_Y![1_RO\ #_,^KJ*^4?\
MAD;]J#_H[S_S%FD__'*/^&1OVH/^CO/_ #%FD_\ QRCV4?YE^/\ D'M'_*_P
M_P SZNHKY1_X9&_:@_Z.\_\ ,6:3_P#'*/\ AD;]J#_H[S_S%FD__'*/91_F
M7X_Y![1_RO\ #_,^KJ*^4?\ AD;]J#_H[S_S%FD__'*/^&1OVH/^CO/_ #%F
MD_\ QRCV4?YE^/\ D'M'_*_P_P SZNHKY1_X9&_:@_Z.\_\ ,6:3_P#'*/\
MAD;]J#_H[S_S%FD__'*/91_F7X_Y![1_RO\ #_,^KJ*^4?\ AD;]J#_H[S_S
M%FD__'*/^&1OVH/^CO/_ #%FD_\ QRCV4?YE^/\ D'M'_*_P_P SZNHKY1_X
M9&_:@_Z.\_\ ,6:3_P#'*/\ AD;]J#_H[S_S%FD__'*/91_F7X_Y![1_RO\
M#_,^KJ*^4?\ AD;]J#_H[S_S%FD__'*/^&1OVH/^CO/_ #%FD_\ QRCV4?YE
M^/\ D'M'_*_P_P SZNHKY1_X9&_:@_Z.\_\ ,6:3_P#'*/\ AD;]J#_H[S_S
M%FD__'*/91_F7X_Y![1_RO\ #_,^KJ*^4?\ AD;]J#_H[S_S%FD__'*/^&1O
MVH/^CO/_ #%FD_\ QRCV4?YE^/\ D'M'_*_P_P SZNHKY1_X9&_:@_Z.\_\
M,6:3_P#'*/\ AD;]J#_H[S_S%FD__'*/91_F7X_Y![1_RO\ #_,^KJ*^4?\
MAD;]J#_H[S_S%FD__'*/^&1OVH/^CO/_ #%FD_\ QRCV4?YE^/\ D'M'_*_P
M_P SZNHKY1_X9&_:@_Z.\_\ ,6:3_P#'*/\ AD;]J#_H[S_S%FD__'*/91_F
M7X_Y![1_RO\ #_,^KJ*^4?\ AD;]J#_H[S_S%FD__'*/^&1OVH/^CO/_ #%F
MD_\ QRCV4?YE^/\ D'M'_*_P_P SZNHKY1_X9&_:@_Z.\_\ ,6:3_P#'*/\
MAD;]J#_H[S_S%FD__'*/91_F7X_Y![1_RO\ #_,^KJ*^4?\ AD;]J#_H[S_S
M%FD__'*/^&1OVH/^CO/_ #%FD_\ QRCV4?YE^/\ D'M'_*_P_P SZNHKY1_X
M9&_:@_Z.\_\ ,6:3_P#'*/\ AD;]J#_H[S_S%FD__'*/91_F7X_Y![1_RO\
M#_,^KJ*^4?\ AD;]J#_H[S_S%FD__'*/^&1OVH/^CO/_ #%FD_\ QRCV4?YE
M^/\ D'M'_*_P_P SZNHKY1_X9&_:@_Z.\_\ ,6:3_P#'*/\ AD;]J#_H[S_S
M%FD__'*/91_F7X_Y![1_RO\ #_,^KJ*^4?\ AD;]J#_H[S_S%FD__'*/^&1O
MVH/^CO/_ #%FD_\ QRCV4?YE^/\ D'M'_*_P_P SZNHKY1_X9&_:@_Z.\_\
M,6:3_P#'*/\ AD;]J#_H[S_S%FD__'*/91_F7X_Y![1_RO\ #_,^KJ*^4?\
MAD;]J#_H[S_S%FD__'*/^&1OVH/^CO/_ #%FD_\ QRCV4?YE^/\ D'M'_*_P
M_P SZNHKY1_X9&_:@_Z.\_\ ,6:3_P#'*/\ AD;]J#_H[S_S%FD__'*/91_F
M7X_Y![1_RO\ #_,^KJ*^4?\ AD;]J#_H[S_S%FD__'*/^&1OVH/^CO/_ #%F
MD_\ QRCV4?YE^/\ D'M'_*_P_P SZNHKY1_X9&_:@_Z.\_\ ,6:3_P#'*/\
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M0?\ 1WG_ )BS2?\ XY1[*/\ ,OQ_R#VC_E?X?YGU=17RC_PR-^U!_P!'>?\
MF+-)_P#CE'_#(W[4'_1WG_F+-)_^.4>RC_,OQ_R#VC_E?X?YGU=17RC_ ,,C
M?M0?]'>?^8LTG_XY1_PR-^U!_P!'>?\ F+-)_P#CE'LH_P R_'_(/:/^5_A_
MF?5U%?*/_#(W[4'_ $=Y_P"8LTG_ ..4?\,C?M0?]'>?^8LTG_XY1[*/\R_'
M_(/:/^5_A_F?5U%?*/\ PR-^U!_T=Y_YBS2?_CE'_#(W[4'_ $=Y_P"8LTG_
M ..4>RC_ #+\?\@]H_Y7^'^9]745\H_\,C?M0?\ 1WG_ )BS2?\ XY1_PR-^
MU!_T=Y_YBS2?_CE'LH_S+\?\@]H_Y7^'^9]745\H_P##(W[4'_1WG_F+-)_^
M.4?\,C?M0?\ 1WG_ )BS2?\ XY1[*/\ ,OQ_R#VC_E?X?YGU=17RC_PR-^U!
M_P!'>?\ F+-)_P#CE'_#(W[4'_1WG_F+-)_^.4>RC_,OQ_R#VC_E?X?YGU=1
M7RC_ ,,C?M0?]'>?^8LTG_XY1_PR-^U!_P!'>?\ F+-)_P#CE'LH_P R_'_(
M/:/^5_A_F?5U%?*/_#(W[4'_ $=Y_P"8LTG_ ..4?\,C?M0?]'>?^8LTG_XY
M1[*/\R_'_(/:/^5_A_F?5U%?*/\ PR-^U!_T=Y_YBS2?_CE'_#(W[4'_ $=Y
M_P"8LTG_ ..4>RC_ #+\?\@]H_Y7^'^9]745\H_\,C?M0?\ 1WG_ )BS2?\
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M/_,6:3_\<H]E'^9?C_D'M'_*_P /\SZNHQ[5\H_\,C?M0?\ 1WG_ )BS2?\
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M_P"8LTG_ ..4?\,C?M0?]'>?^8LTG_XY1[*/\R_'_(/:/^5_A_F?5U%?*/\
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M_CE'LH_S+\?\@]H_Y7^'^9]745\H_P##(W[4'_1WG_F+-)_^.4?\,C?M0?\
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M_#(W[4'_ $=Y_P"8LTG_ ..4>RC_ #+\?\@]H_Y7^'^9]745\H_\,C?M0?\
M1WG_ )BS2?\ XY1_PR-^U!_T=Y_YBS2?_CE'LH_S+\?\@]H_Y7^'^9]745\H
M_P##(W[4'_1WG_F+-)_^.4?\,C?M0?\ 1WG_ )BS2?\ XY1[*/\ ,OQ_R#VC
M_E?X?YGU=17RC_PR-^U!_P!'>?\ F+-)_P#CE'_#(W[4'_1WG_F+-)_^.4>R
MC_,OQ_R#VC_E?X?YGU=17RC_ ,,C?M0?]'>?^8LTG_XY1_PR-^U!_P!'>?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KV2O&Z]DH)D%%%%!(4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\
MW_M*_"OQ%XO_ ."@7[,_BC3=)NKSP_X1_P"$I_MF^C \O3_M.FQQ0;SG^-P5
M&.XKZ//*UY_\0/VA?#_PY^-_P_\  .H)J#:[\2/[1_LEH80UNOV&W6>;S6+
MK\C#;@-D^G6O0"=M5.3:2?;3[_\ ,F*2;MW_ $0M%%%24%%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 =**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH \S\>_\ (V7G_ /_ $!:QZV/'O\ R-EY_P  _P#0%K'H- HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ KV2O&Z]DH)D%%%%!(4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110!\W_M*_"OQ%XO_ ."@7[,_BC3=)NKSP_X1_P"$
MI_MF^C \O3_M.FQQ0;SG^-P5&.XKZ/\ O+7#>.?C]X=^'OQD\!^!=2DNU\0?
M$3^T/['2. O&_P!B@6>?>_\ !A&&,]3Q7<;L54Y-I)]M/O\ \R8I)NW?]$.H
MHHJ2@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHSBC-
M!1110 449HS0 4444 %%%% !1110 4444 %%%&: "BC-&: "BBB@ HHHH **
M** "BBB@ HHHS0 4449H ***,T %%%% !111F@ HHS10 4449H **** "BBC
M- !1110 4444 %%%% !111G% !1110 449S10 4449H **** "BC.** "BBB
M@ HHHH **** "BBB@ HHHH **,T4 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'F?CW_ )&R\_X!_P"@
M+6/6QX]_Y&R\_P" ?^@+6/0:!1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !7LE>-U[)03(****"0HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^:_VA?\
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ME_CA_P D5\8?]@2]_P#1#U^$] '[[:7J5OK.FV]Y:7$-U:W4:S0SPN)(YD8
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M^$2=;MB%7>R1HWGIN." 8BS8'WFC3@G% 'M7PL^)6D_&'X?:3XGT.<W&DZS
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M>_5C&6C)4LJD@C(!XK]+AT_"OXX/^"G?_*2C]H3_ +*7XD_].MS7]3_[6/\
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M:5!-<:1?)<BVEW,WERJIW1/M(.QP&PP.,$5\L_\ !G'_ ,G,_&/_ +%FS_\
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M42U:'0?#.O77A?QI,@,?AOQ(L5E>W;?-E;8J[1W! 0MMC8N$^8HN#C@/%?\
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M>,O'VM07UUH_@?0[W7[Z&R17N98+2W>>18E=E4R%8R%#,H)(R0.:^'OV0/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%&:* "BBC- !1110 4444 %%%&: "BBB@ HHS1F@ HHHH **,Y
MHH **** "BC-&: "BBB@ HHHH **** "BBB@ HHHH ***,T %%&:* "BBB@
MHHHH **,T4 %%&:,T %%&:,YH **** "BBB@ HHHH ***,T %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 >9^/?^1LO/\ @'_H"UCUL>/?^1LO/^ ?^@+6/0:!1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !7LE>-U[)03(****"0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH _&+_@H#XPN/&O[8OCZXN))&^R:FVGQAS]Q+<"$  < ?)G\
M23DDFOT7_P""8'P_MO /[&GAF2%7^T:^TVK73,FW?)(Y5>/:..,9/7;G@$ ?
MFW^W-HEUX>_:_P#B);W<30RR:W/<JI'6.9O-C/XHZG\:_3;_ ()O^*K?Q3^Q
M?X'DAG6X:QM9+&8 C="\4KKL8#H=H4C/)#*>] 'NE<C\8/@AX7^/GA:/1/%V
MEKK&EQW*7:P-/)"!*@(5MT;*W 9AC.#GD&OFO_@L#\,O$GQ,^%7A&W\-^'];
M\07%OJSR31:;8RW;Q*82-S"-20,\9-?GCXI_9[\?^!]!GU36O _C#1]+M=OG
M7E]HUS;V\.Y@J[G= HRS*!D\D@=30!^QGPT_94^'7P;UQ-4\,^#]'TG4HXVB
M2ZBB+3*K?> =B2,],YZ<=.*\"_X+6?\ )K&@?]C7;_\ I)>5\@?\$M_^3Z_
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M'XY[5\4?\$C_ !1?:'^V7I=G:S>7;ZUI]Y:7:%0?,C6(S*/8B2)#D<\$=":
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M^3HP_!E;T-?K9I7QRTO]HS]CK5_%FD[8XM2\/WGGVWFB1[*=8'$D+$8Y5NY
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M*4NJ=OP_2YY>;W^KZ=T?J!_P;.>&K70_^"-WPONK==LFLW6LW=P<#YI!JUW
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M>DZQ'KWAG[.[,MG9W 6ZMD1G^8^3O\K+9.Z$\M]X_P!27["/[56F_MM?LA>
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M_%#PK9Z/?^(/"%Q)<V=OJL4DMG*SPR1$2+')&Y&V1C\KKR!]*_=#]@$_&_\
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MB^#]#2&4W"M#9$Q.8B.&26Z-Q*H48/G<;L[C_2U_P3C_ &7E_8O_ &&/A?\
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M]BS=_P#I57] )^Z*_G^_X/'/^3F?@Y_V+-W_ .E5>APE_P C*'S_ ".?-?\
M=G\OS/LC_@TM_P"46^H?]CQJ7_I/9U^GG>OS#_X-+?\ E%OJ'_8\:E_Z3V=?
MIYWKS\\_Y&%;_$SHP/\  AZ!7\I__!R1_P II/C1_P!P3_TQZ=7]6&:_E/\
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MZ:=*-./+#8=1116)H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M=?\ P<Q:M_P4+_; \)_"C2_V?Y-%;Q$\[W>JCQD;Q-*MX8'FDF>/[ @8 )M
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MQ/S]X'SVLA\O56<$X.UOD[_@T2_8TN/%WQS\:?'34K6-M'\(V;^&M&=]X/\
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M  :E?L__ !0\!:LWPI77?AGXM2V)TI3JT^HZ2\X'RK<I<>;/Y;8(+1R J6W
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M?-VIYFSS-N[:N[&=HS@?G%_P4E'_  3#'[:?C3_AH?/_  N+_0?^$@_Y&O\
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MK(SK&&TR? 1Q5=4Y22=U9.^O=76VG4C&8ATH<R7STT^\_97_ ()1?\%"YO\
M@IM^RFOQ/D\%?\(&DFKW6EPZ?_; U3S%@$?[WS?)AQEG9=I3C9G)!%?3.=U?
MRZ_\$R_A3\<OV_\ 0+S]E?3?CQIOP:\.^&6O7O/!UW'<Z?J6N-([_;5>.*)#
M>&/E9+>XG&Q4!$>%=E_IB^#7AC6O _PB\*Z+XDUC_A(O$6CZ/:6.J:L(V3^T
M[J.%$FN-K,S#S)%9\%B1NY)ZUMGF6T\)7<826[LE?1=-7O<C XB5:%Y+Y]WU
MT.J%%%%>*=P4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MI>&[ZWU6Y:UA73;B>1U8*6RPDB08P.Q-4?V4_P!BOQ5^V!_;W_",ZAX?L?\
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M'[GC'/7U%>I?\%-/@U=?&;]DG7(M/C:;4/#LB:Y!$!_K!"&$H'OY+RD 9)(
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M#DDX'- 'XU_M3ZPWCW]JKQY<6>ZX^W>([R.VP,&5?/9(\ @'D <$9YYK]H?
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MUB\T[3W>XT^QFEF^SQ2W=VRJLMV4G*(N$^03%(QF3/T=_P &<O\ R<S\8O\
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M_ GASX:ZMHLVJ3ZNTVO6%[/=":5(D90T-W$NP")<#;G)/)XQ[M_Q%\_M+?\
M0D_ _P#\$VJ?_+&OW('_  3 _9IS_P F\_ W_P (32__ (Q0?^"8'[-6/^3>
M?@=_X0FE_P#QBO<K9YEE6;J5,-=O=W//C@<3&/+&IH?%O_!!#_@M=\5/^"I7
MQ?\ 'OA_XA:#\/\ 1[/PKH\%_:/X?L;RWEDD>?RR)#/=3 KCH  <]Z_)?_@Y
M(.?^"TGQH^NB?^F/3J_IJ^#?[)7PL_9SU.\O?A]\,_ /@6\U*(07=QX?\/6F
MF2W,8.X)(T$:%E!Y .0#63\2OV$O@A\9O&U]XE\7_!OX5^+/$6I;/M>J:QX3
ML+Z]NMD:QIYDTL3.VV-$09)PJJ!P *Y<#G6'PF.EBJ5)J+5E%/;;K\C:M@:E
M6@J4Y7:=[G\[7[*O_!S1\>OV0?V>?"OPU\,^$_A)>Z#X/L1864^I:7J$EW+&
M&9LR-'?(A;+'E44>U<E^V5_P7\_:9_X*">$)_ >H:EI'ASP[XD5;&\T+PAI;
MV_\ ;&YE A:21YKE@Q&#&D@5PY5E8$ ?T<_\.O?V:<_\F\_ [_PA-+_^,5U/
MPR_8U^$/P4NUN?!OPK^'/A.X643B71O#5E8.) ,!\Q1J=P'&>M=BX@RZ-3VT
M,-[][W;Z]S+^S\0X\CJ:'X__ /!MA_P1)\6> OBC!^T!\9/"]YX>;28"?!.B
M:G'Y=W)/*KI)?SP$[HA&A*Q)*NYFD,H"^7$[_N5BEV\4A^[7SN9YE5QU=UZO
MHET2['H8;#QHPY(@!R*_#7_@\\^_^S=]/$__ +B*_<K'(K@_C5^R]\-?VD7T
MW_A8?P\\#^//[%\W^S_^$BT&UU3[#YNSS?*\^-_+W^7'NVXW;%SG Q64XY8/
M%0Q+5^6^GJFOU%BZ+K4G3VN? /\ P:7?\HN-0_['C4O_ $GLZ]6_X+W_ /!-
M)?\ @HM^Q7??V#8QW7Q+^'JSZSX78!O-NOE4W-@N.IN(XU"@C!ECAR57)KZX
M^$GP1\&_ +PL^A^!/"/AGP7H;7#73:?H.E0:;:F9@H:0Q0JJ[R%4%L9(4>@K
MK#WXJJF93^O/&TM'S77^01PJ]@J,]=+'\.-U:2V5S)#-')#-"Q22-U*LC X(
M(/((/&#7]J?[+A_XQG^'?_8L:;_Z2QUQVN?\$W?V>/$^MW>I:E\!_@SJ&I:A
M.]S=7=SX)TV:>YE=BSR.[0EF=F))8DDDDFO8M*TRUT+3+>QL;>"SL[.)8(((
M8Q'%#&H"JBJ,!5    X %>CGV?1S%0M!QY;_ (V.; 8%X=R;=[G\='_!3O\
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MYEXG UH4G*51M+IK_F?*G_!G+_R<O\9/^Q9L_P#TJKZL_P"#O_\ Y1L>!?\
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MQ*Y?:R3UTM_PQ^I@_P"#SUA_S;=_YD#_ .]M?M7\+O&I^)/PT\.^(FMOL?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#S?XBQ>5XKF;_ )Z*C#_O
MD#^E8==S\3M%:ZLH[R,9:W^5Q_LGO^!_G7#4%QV"BBB@84444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $EK U
MU<QQ+]Z1@HX[DXKV"O._AWHG]HZM]H=<PVN&Y[OV_+K^ KT2@F04444$A111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% 'RO_ ,%A_P#DSYO^PW:?RDKY-_X(
M^?\ )X</_8&N_P#V2OU:HH **** "BBB@ HHHH **** "BBB@""ZM8[VWDAF
MCCFAF4HZ.NY74C!!!X(([5^3'QT^'>J?\$ZOVV=-U;2XYH](M[U=6TB0'?\
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M8U:RJM]KKO8BL;*+3[.&W@ACAAA0)'&BA4C4# 4 <  <8%?"O_!=?_@D4?\
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M!AJ!C%?+XC$5*U1U:CO)[L].G34(J$=D.HHHK,L**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!KH'4JV
M&5A@@]ZX7Q9\/Y+-VGL8VDA.6:,'+1_3U'ZUWE% 'CC*R,58$,#@@]J2O5[_
M $&SU0[KBUAD;^\5^;\^M4O^$ TG_GT_\BO_ (T%<QYK17I7_" :3_SZ?^17
M_P :/^$ TG_GT_\ (K_XT!S'FM%>E?\ " :3_P ^G_D5_P#&C_A -)_Y]/\
MR*_^- <QYK17I7_" :3_ ,^G_D5_\:/^$ TG_GT_\BO_ (T!S'FM%>E?\(!I
M/_/I_P"17_QH_P"$ TG_ )]/_(K_ .- <QYK17I7_" :3_SZ?^17_P :/^$
MTG_GT_\ (K_XT!S'FM%>E?\ " :3_P ^G_D5_P#&C_A -)_Y]/\ R*_^- <Q
MYK17I7_" :3_ ,^G_D5_\:/^$ TG_GT_\BO_ (T!S'FM%>E?\(!I/_/I_P"1
M7_QH_P"$ TG_ )]/_(K_ .- <QYK17I7_" :3_SZ?^17_P :/^$ TG_GT_\
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M_(K_ .- <QYK17I7_" :3_SZ?^17_P :/^$ TG_GT_\ (K_XT!S'FM%>E?\
M" :3_P ^G_D5_P#&C_A -)_Y]/\ R*_^- <QYK17I7_" :3_ ,^G_D5_\:/^
M$ TG_GT_\BO_ (T!S'FM%>E?\(!I/_/I_P"17_QH_P"$ TG_ )]/_(K_ .-
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1BBB@ HHHH *.M%% !1C-%% !1110 4444 %%%% !1THHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "C&:** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
K "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>brns-20231231_g4.jpg
<TEXT>
begin 644 brns-20231231_g4.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 'D!U # 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M1_9F)SCV%>\T5]/0X)R.A-5%1NUWDVONO9_,^>K<79Q6@X.K9/LDG]]CR?\
M:!UC7O#_ (=TEO#DMU;2M<%'^QH2=@0X& #@5X7_ ,+"^)G_ #_ZU_WY;_XF
MOLRBL\VX8Q&98N6)IXV=).WNQO965OYE^1>6<0T,OPRH5,)"HU?WG:^K]&<]
M\/;J\OO ^AW&H-(]]):1M,TPPY<CG(]:K>._AMI'Q$CM(]7^T%+4N8U@DV<M
MC)/'/3]:XO\ :,T77;KPW;ZGHMW>1)9%OM5O:S,FZ,X^<@'G:1^1]J\[^$_[
M0D7@_0SI.N6MS>1QLSP7$)#/@G)5@Q'?H<]ZPQN>8'!XE9)FU/\ =\J]^6L9
M6MTMW3UONC?!Y/C,50>;Y9/]YS/W(Z.-[]?1]MF<YXVT?5O@3XX$6BZK<)#(
M@GA?.-ZY(VNO1L$$=/RKTKXV:TWC;X%:)K:($\RZAGE5>BG;(C#_ +Z->3^/
MO%FH?&;QQ"]AI\@9PMM:6JG<^W).6/3J23V'X9KZ2O/AJ9O@W_PB(96N%LPJ
MMV\X'?GZ;Z^&R?#SS#^U,+EMWA7%\BUMS;JU^^OG:USZ_-*T<#_9V(Q]EB%)
M<[TOR];V[:?.]CS']DF4"\\2Q_Q-' P^@+_XBM3]K2X5=%\/0D_.]Q*X^@50
M?_0A7EGPM\=3?"'QE='4K*8QLK6UW;C D0@Y! /4@C]:F^,'Q)_X6QX@T]=.
ML[A+6W4Q6\+@&21W(W' SUPHQ[5P4\ZPM/A*65N7[^_+RV=]9\U_NT]=#NGE
M.(GQ-',5']S:_-=6^#E_/\#I/AK823? +QW(HX:3C_@"HQ_0U0_9?E5/B1(A
MZO92 ?@5->\?#[X>1Z!\,8O#MXNV6Z@?[7C!.^0'/Y @?\!KYBT>ZU+X*?$J
M.2[M]\UC(R2Q]!-$P()4^X.1[XKKQV#J9#4RC&8E6A!)2_NN_,T_E)_<SEP>
M*AG,,TPN'=Y3;<?-6Y5^2^\^A_VD95C^%EZ#U>>%1_WUG^E>=_LF6['6/$$_
M\"P1I^)8G^E87QH^-MO\1M-L]+TNUGMK-)//F:XP&=P"%4 $\#)^IQZ5Z[^S
MOX&G\(^#7N[U#'>ZFXG,;#!2,#" ^YY/XBO:HUZ>>\7T\5@GS4Z4-9=-I?K*
MWR9Y-6C4R;A>>'Q:Y:E66BZ[K]%^*/5:\H^/'Q0UCX;1Z(VDI:N;PS"3[3&7
M^YLQC##^\:]7JI?:38ZIL^VV=O=[,[//B5]N>N,CCH/RK]3S3#8C&82=#"U?
M9S=K2[:IO[UI\S\XR[$4,+BH5L33]I!7O'OHU^>I\8>/OB]KGQ&L;:TU6.S2
M*WD\U/LT3*<XQSECZU<\&?'+Q%X%T*/2=.BL6M8W9P9XF9LL<GD,*]._:BT7
M3],\,Z,]G86UH[7C!F@A5"1L/!P*W_V=] TS4/AG:376FVES,;B8&2:!7;[W
MJ17X92RC-9<15,)'&M5E"[G9ZKW=-_-?<?L=3-,MCD4,4\(G2<[*%]GKKM_5
MS>^"?CW4OB%X8N=0U1;=)X[EH@+="J[0H/0D\\UZ'5>RT^UTV,QVEK#:QDY*
M0QA 3ZX JQ7[QE]"MAL+3HXBISS2UEW\S\8QM:EB,1.K0AR0;T78\,_:P_Y%
M71/^OT_^BS4_[*O_ ")>I_\ 7\?_ $!:@_:P_P"15T3_ *_3_P"BS7EWPP^-
MUQ\,]'N=/ATJ._6:;SC(\Q0C@#& #Z5^/X_,L-E7&,L3BY<L%!*]F]XKL?J6
M"P&(S+A6.'PT;R<GU2VEYGV)7(?%V]FT_P"&?B*:W)$OV1DR.H#84G\B:\<_
MX:TO?^A<M_\ P*;_ .)KT+X>>/#\;?"OB&UO-/33XRAM"(Y"^1(A&>0,$5]O
M'B3+,[C/ 8&M>K.,DO=DOLOJTD?(RR#,,HE#&XRE:G"46]4^JZ)GCG[+]G!=
M?$B5Y@"]O82RQ9_O;T7_ -!9J^K[B".Z@DAE0212*4=6Z$$8(KXHM)=<^"?C
MY99;;9=VC$;)!\D\1XX/H1W'3\*]-\3_ +5 O]!DMM(TB6TU"9"C3S2@K#D<
ME<#YCZ9Q7PW"G$&7Y)EM7!Y@^2I"4FXM.[\MM^FOY'V'$F1X[-\?3Q>"]^G*
M*L[JR_X'70\N\!2/H_Q9T9;!V8)JJ0(RGEHS)L/YJ3^=>K?M7>&V_P")-KT:
M?)\UG,WO]Y/_ &?\JQ?V;_AO=ZGXAB\37MNT>G6>XV[2#'G2XQD>H7.<^N/>
MO;?C-X>/B7X;ZS;(F^:*+[3$ ,G<GS<>^ 1^-89+DM;%<+XOVD;>T;G!?X4F
MFO6UO0VS;-J6'XBPO)*_(N63_P 3M;Y7OZGS_P#$KQN->^$W@>Q$NZ4!S.N>
M0T7[M<_@2?QK#U?09_A;XM\)7A#1R-;VFH-GLQ.74_0@BN<\%Z2WB+Q7H^EG
M+I<72(5[;2PW?H*]^_:MT,3^']&U5$^:UG:!F _A< C]4_4U\S2I5LXP.*SF
M7QT524?^W4E)_P#MQ]!4J4LKQF'RJ/P574;_ .WFW'_(\Y^+=\_Q(^,8TZP?
M>GF1:?"W4 \;C] Q;\J]I^-]UJ_A'X>Z9'X8DNK::&[BMQ]E4LWE"*3@X!XR
M%KQ_]FKPZ^N?$(ZC(I>'3H6F9VY_>-\JCZ\L?^ U]:5^@<+X&KF^!QN/G)TY
MXF3M);I+MMU;7R/B>(L93RS%X3!1BIPP\5=/9M]]^B3^9\9_\+"^)G_/_K7_
M 'Y;_P")KVJ+4-3U7]FR]NM8DFEU*2SN?->X7#G$SA<C']T"O8JY#XN_\DS\
M2?\ 7F]>M1X=KY10Q->KC)U4Z4U:5[;7O\3UTM\SS*V>4<SK8>C3PL:352+O
M&U][6V7?\#Y\_9=_Y*3+_P!@^7_T)*^LJ^&_AGX^D^&_B)]6CLEOF:!H/*:0
MH/F*G.<'^[7I=]^UCJLL++::%:6\I& \LS2 ?@ *^2X1XHRO*,K^KXNHU/F;
MLHM[VZVM^)]-Q/P[F.:9C[?#03CRI7NEW\[_ (%/]JJ^CG\::;;J07M[(;QZ
M;G)'Z5KZ@MSHO[*EI&NY#=2#?VPCSEA^8 _.N(\'_#_Q)\9_%$FJ:CYRV<TN
MZZU"08&/[J9ZG'  X'%?3GC#P1;Z]\/[SPW;*L$36RQ6X[*R8*?JHJ\KP.+S
MJKF6;P@X*M"487W=[?Y)7VN]-B,QQF&RFG@,LE-2=*<93MLK?\.W;R/$_P!D
MRS@DUCQ#=. ;F&&%(_4*S,6_]!6O??&%C;ZGX5U>UNP#;R6DH?/8;3S^'7\*
M^0/!OBK6/@OXRG:>Q83(#!=6<QV;USG@_4 @\BNZ^(G[2G_"3>';C2='TV6R
M^UQF.>XN) 6"D895 ]1QDG\*.'^),MRS(IX+%^[5ASIQ:=Y7;\O.SOM;4,[R
M''YAG$<7AM:<N5J5U:-DO/YJV]SDOV>[N>U^+&CK"3MF$T<BCNOE,>?Q4'\*
M]%^/'P5UC7->F\1:'%]N\Y%\^U4@2!E&-RC^(8 XZTG[,_PWNK.XE\4ZC;M"
MK1&*R6088@_>DQV&.!ZY-9_QB^(OCWP7XTGMEOVM]+9_.M"D"A9(\YVEL9)'
M0\_SK@PF$P^#X57]KTYN%2IS1Y;7C=))Z[)V?K?S.W$XJOBN)'_9<X<T(<KY
MMI:W:TZJZ^[R.'LOB5\0? >RWDO+ZW2/"B'4(2P ';YQ7M?PF_:!A\;:A%H^
ML6T=AJD@Q#)$3Y4S 9Q@\J?;)SC\*IK^TUX3U#10-2TNZDN&CVRVAA21&..0
M"3@CZUXQ\-M)N?%GQ2L9-)LC;0+>BZ*1Y*VT0?=@GT X]^*C#YA6R?&8:GEF
M/>)A4:3@TW9:=[V?I:W56+K8&EFN%KSS'!+#S@FU-6U?X7^=_6YH_M$W,EQ\
M4]260G$4<2)]-@/\R:['0_B]\1-+T:QL[/P;&]K;P)%$WV*<Y0* #PWI4G[3
MOP^NCJ$/BFSC::V:-8;L*,F-APKGV(./8CWJ;P/^TU8:/X4M;#6-/NIKZSB$
M*26^TK*JC"DY(P<8SU]?:GRO+L_QL<7BY8;G;DI)74DW=='_ ,.FMQ<RQV28
M26&PRK\B46F[<K2M_7JGL>:>,M+\7^-?$=SK-SX8N[6YGV[TMK24+E5 SSDY
MX]:^Q?#MQ/=^'],GNHVBN9+6)Y8V&"KE 6!'8YS7S;X7^+WQ!\=^-#;:-*L<
M%Q+N^SM LD=M%W); . /4\GZU]0*"% 8[CCD^M?9<%4<-*IBL9AJDYJ;U<XI
M*3NW=6>N^NVY\KQ;5Q$88?"XB$(N*T46VTK)6=UY>>PZOBN\_P"2W2_]AO\
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M_P SZ'#8NCBN**GL7?DI<K?GS)_A>Q]#0?\ ) 8_^Q8'_I)7@_[,O_)3H_\
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M:S_Y#7A__KWD_P#0A7HG[-^I"^^%]G"#\UK-+"1]6W?^S5YW^UG_ ,AKP_\
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M96Y/E1M\TLLC<9P/P '/>O=?A[\.;[PW\(Y]%$\FGZQ>QR3-+#(5>&9E 7#
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MU]M4</9.3Y>U]/N"BBBMC(SM:\.Z7XDACAU73[;4(HVWHES$'"G&,C/>L?\
MX5;X/_Z%G2O_  $3_"NIHKCJ8/#5I<]6E&3[M)LZJ>+Q%*/)3J22[)M'+?\
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MTT_1CP^(J86M"O2=I1::^1\S_LO^)WTCQ%JGAJ[)B^TCS(T?@K,F0RX]2/\
MT"OH+6O"6B^))(GU72K347B!5&N85<J#U R*YR\^#GAZ[\8)XF07-GJBRK/N
MMI0J%QU)7'?OZY-=S7S'#^58C+\"\NQRC.$9/EZWC>ZNGLTSZ'.\RHXW&+'8
M-N$I)<W2TK6=FNEBKINF6FCV<=I8VT5I:Q\)#"H55YSP!4EY9P:A:RVUU"EQ
M;S*4DBD4,K*>H(/45-17URA%1Y$M-K=+=CYGGDY<[>N]^IS^F_#_ ,-:/>1W
M=CH.GVEU&<I-#;JK+QC@@>E=!116=*A2PZY:,%%>22_(NI6J5GS59.3\W<**
M**W,0KD_$GPI\*>+9S/J>C02W#<F:,M$Y^I0C/XUUE%<V(PM#%P]GB*:G'LT
MFOQ.BAB*V&G[2A-Q?=-I_@<KX9^%_A;P?,)M*T>""<=)G+2R#Z,Y)'X5U5%%
M&'PU#"P]GAX*$>R22^Y"K8BMB9^TKS<I=VVW^)S_ (F\ >'O&0']L:5!>N!@
M2D%9 /0.I#?K63H?P9\&>';I;FST.'SU.5>X=YMI]@Y(%=M17-4RW U:WUBI
M0@Y_S.*O]]KG1#,,93I>QA6DH=E)V^Z]@KY*^,6H3_$[XN+I&DC[1Y#+80G/
MR[@27;Z YY]%KZRFC\Z%X]S)N4KN0X(R.H]ZXOP9\'O#O@;5IM2T^*>6]D4K
MYUU+O*Y/..!@GUKY_B3*<5G4*.#IM1I<UYN^MELDOZUL>YD&98?*9U<543=3
MEM!=+OJ_Z[G2>&="A\,^']/TJW_U5I"L0.,9P.3^)R?QK3HHKZZG3C1A&G!6
M25EZ(^7J3E4FYS=V]6%%%%:$!1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MX7^/7C^^_;BE\'3^)[R3PR-<N;8::0GE^6J.57[N<# []JSOB]^T%\2OC_\
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M>*PCBYMTZ[J-)Z'MM%?)W_!/SXW:O\4?!OB#2?$NKW&KZYI5TLJSWDF^5X)
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M.29@R.HR=H/IP0:]=_;(\;?%;P_X=T[3OAAH.J7<UYO:^U73;;SY+=!@*B*
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MUUML8U\/B*DZJJ0<KWY==$O3O_7F;'A\8_X)GS?]@6X_]*WK._X)@C=X!\=
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MAC&6^:-AZX4],@BO=OVROVN/$G@/4]#\)^ V6QO]4L8KZ34WC5Y%24D1I&K
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MZ,/<$'-.6*PE18JG*I93:L[/R_IF<</B(+#RC"[A>_\ 7GT*/_!4;5]/EO/
M.F(\;ZI"EW/(H^\D3>4%S[$JV/\ =-)^TY9W-A^P3\*H+L,+A9[#<&ZC-K.0
M/R(K4\$_\$\_$6N>.H=>^*7C!->@CD626&"66::Z"]$:60 JO&#CG' QUKZ!
M_:B^ %U\>/AGIOA32-0M=$^QW\5TKSQLT81(I$" +T^^/RK'ZUAL-##8:$^9
M0ES-]-_^";^PKUZE:O*'+>+BEU>G_ /-/@#_ ,H_;O\ [ ^J_P#H<U>:?\$M
M?^0E\1?^N-C_ .A3U]-?#CX$W_@C]FV;X:3ZI;W-])97EJ+Z.-A$#,TA!VGG
M WC\JY7]D7]E?5?V;[KQ/+J6N6>L#5DMU06L3IY?EF0G.[KG>/RK*6,H.GC8
MJ6LW[OG[UQK#5O\ 9/=^!:^6B/D_X4_\I"I_^QBU#^4M;_\ P4H^7XX>#R>!
M_9$?/_;S+7MO@_\ 8OUKPS^TM)\39?$=A-8-J=S?_84A<2[90^%W=,C?^E='
M^UQ^R7+^T5)HNIZ7J\&D:SIL;VY-U&S1S1,=P!(Y!!S_ -]&NJ.88>.,PU7F
MTC&S\G9F4L'6EA\3#EUE*Z\]4?0NGHDVDVR, Z/ H([$%17YE^%_$!_8W_:[
M\2V]XK1Z$T=RFSM+;R)YT&/^!!%_,5]K?LR_!WQ5\%O#>K6GB[Q<?%$]W-&\
M,CR2.+=539L#2'..G P.*^3O^"F8T*Z\?>%)+"YCGU\V<D-W#"0Q6,.#%NQT
M)+/@5R98H1QD\+&7/"HFKKTO?Y:HZ,;S2PD:\H\LH-.S];?CN:G_  3M\)W?
MCKXH>,OB9JR>=-$7BCG8<&YG8O(1[A>/H]?H/7C_ .R?\+7^$?P/T#1[F'R-
M3N$-_?+C#":7!*GW5=J_\!KV"O-S7$1Q&*ER?#'W5Z([,MI.EATY_%+5_/\
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MD:N*J5(.Z;=CW,'"5/#PA-6:1^:/P!_Y2):I_P!AC6O_ $7<57_;Z4-^U-I
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M<^-+_3XKBS\=:P8[N>.U^:XM;<$+M&W^,(78XY&X]Q7V[#8V]NVZ*WBC;U1
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MBOIV?F7U4*H Z#BEHHKP3UPHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MP[0T_P#Z*3K7_@*O_P 77VK11_;&._Y^?@O\@_LW"?R?B_\ ,^*O^':&G_\
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M  [0T_\ Z*3K7_@*O_Q='_#M#3_^BDZU_P" J_\ Q=?:M%']L8[_ )^?@O\
M(/[-PG\GXO\ S/BK_AVAI_\ T4G6O_ 5?_BZ/^':&G_]%)UK_P !5_\ BZ^U
M:*/[8QW_ #\_!?Y!_9N$_D_%_P"9\5?\.T-/_P"BDZU_X"K_ /%T?\.T-/\
M^BDZU_X"K_\ %U]JT4?VQCO^?GX+_(/[-PG\GXO_ #/BK_AVAI__ $4G6O\
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M:?\ ]%)UK_P%7_XNOM6BC^V,=_S\_!?Y!_9N$_D_%_YGQ5_P[0T__HI.M?\
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MX+_(/[-PG\GXO_,^*O\ AVAI_P#T4G6O_ 5?_BZ/^':&G_\ 12=:_P# 5?\
MXNOM6BC^V,=_S\_!?Y!_9N$_D_%_YGQ5_P .T-/_ .BDZU_X"K_\71_P[0T_
M_HI.M?\ @*O_ ,77VK11_;&._P"?GX+_ "#^S<)_)^+_ ,SXJ_X=H:?_ -%)
MUK_P%7_XNC_AVAI__12=:_\  5?_ (NOM6BC^V,=_P _/P7^0?V;A/Y/Q?\
MF?%7_#M#3_\ HI.M?^ J_P#Q='_#M#3_ /HI.M?^ J__ !=?:M%']L8[_GY^
M"_R#^S<)_)^+_P SXJ_X=H:?_P!%)UK_ ,!5_P#BZ/\ AVAI_P#T4G6O_ 5?
M_BZ^U:*/[8QW_/S\%_D']FX3^3\7_F?%7_#M#3_^BDZU_P" J_\ Q='_  [0
MT_\ Z*3K7_@*O_Q=?:M%']L8[_GY^"_R#^S<)_)^+_S/BK_AVAI__12=:_\
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M*G+ECVT?Z'11RG#TX*,US/OK_F?%7_#M#3_^BDZU_P" J_\ Q='_  [0T_\
MZ*3K7_@*O_Q=?:M%<W]L8[_GY^"_R-_[-PG\GXO_ #/BK_AVAI__ $4G6O\
MP%7_ .+H_P"':&G_ /12=:_\!5_^+K[5HH_MC'?\_/P7^0?V;A/Y/Q?^9\5?
M\.T-/_Z*3K7_ ("K_P#%T?\ #M#3_P#HI.M?^ J__%U]JT4?VQCO^?GX+_(/
M[-PG\GXO_,^*O^':&G_]%)UK_P !5_\ BZ/^':&G_P#12=:_\!5_^+K[5HH_
MMC'?\_/P7^0?V;A/Y/Q?^9\5?\.T-/\ ^BDZU_X"K_\ %T?\.T-/_P"BDZU_
MX"K_ /%U]JT4?VQCO^?GX+_(/[-PG\GXO_,^*O\ AVAI_P#T4G6O_ 5?_BZ/
M^':&G_\ 12=:_P# 5?\ XNOM6BC^V,=_S\_!?Y!_9N$_D_%_YGQ5_P .T-/_
M .BDZU_X"K_\71_P[0T__HI.M?\ @*O_ ,77VK11_;&._P"?GX+_ "#^S<)_
M)^+_ ,SXJ_X=H:?_ -%)UK_P%7_XNC_AVAI__12=:_\  5?_ (NOM6BC^V,=
M_P _/P7^0?V;A/Y/Q?\ F?%7_#M#3_\ HI.M?^ J_P#Q='_#M#3_ /HI.M?^
M J__ !=?:M%']L8[_GY^"_R#^S<)_)^+_P SXJ_X=H:?_P!%)UK_ ,!5_P#B
MZ/\ AVAI_P#T4G6O_ 5?_BZ^U:*/[8QW_/S\%_D']FX3^3\7_F?%7_#M#3_^
MBDZU_P" J_\ Q='_  [0T_\ Z*3K7_@*O_Q=?:M%']L8[_GY^"_R#^S<)_)^
M+_S/BK_AVAI__12=:_\  5?_ (NC_AVAI_\ T4G6O_ 5?_BZ^U:*/[8QW_/S
M\%_D']FX3^3\7_F?%7_#M#3_ /HI.M?^ J__ !='_#M#3_\ HI.M?^ J_P#Q
M=?:M%']L8[_GY^"_R#^S<)_)^+_S/BK_ (=H:?\ ]%)UK_P%7_XNC_AVAI__
M $4G6O\ P%7_ .+K[5HH_MC'?\_/P7^0?V;A/Y/Q?^9\5?\ #M#3_P#HI.M?
M^ J__%T?\.T-/_Z*3K7_ ("K_P#%U]JT4?VQCO\ GY^"_P @_LW"?R?B_P#,
M^*O^':&G_P#12=:_\!5_^+H_X=H:?_T4G6O_  %7_P"+K[5HH_MC'?\ /S\%
M_D']FX3^3\7_ )GQ5_P[0T__ **3K7_@*O\ \71_P[0T_P#Z*3K7_@*O_P 7
M7VK11_;&._Y^?@O\@_LW"?R?B_\ ,^*O^':&G_\ 12=:_P# 5?\ XNC_ (=H
M:?\ ]%)UK_P%7_XNOM6BC^V,=_S\_!?Y!_9N$_D_%_YGQ5_P[0T__HI.M?\
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M_P#T4G6O_ 5?_BZ^U:*/[8QW_/S\%_D']FX3^3\7_F?%7_#M#3_^BDZU_P"
MJ_\ Q='_  [0T_\ Z*3K7_@*O_Q=?:M%']L8[_GY^"_R#^S<)_)^+_S/BK_A
MVAI__12=:_\  5?_ (NC_AVAI_\ T4G6O_ 5?_BZ^U:*/[8QW_/S\%_D']FX
M3^3\7_F?%7_#M#3_ /HI.M?^ J__ !='_#M#3_\ HI.M?^ J_P#Q=?:M%']L
M8[_GY^"_R#^S<)_)^+_S/BK_ (=H:?\ ]%)UK_P%7_XNC_AVAI__ $4G6O\
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MV,=_S\_!?Y!_9N$_D_%_YGQ5_P .T-/_ .BDZU_X"K_\71_P[0T__HI.M?\
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M'O[+6]9AT^ZDOVE6.16)*E$&> >X/Y4FB^)-,\6?M8VNI:1=I?6,EOM6:,$
MD0$'J/6M''WE%?UH?/4\ZA4P]&JK<\Y).-]5=VOW/HFZ\9>'["XDM[G7--MY
MXSM>*6[C5E/H03D5<T[6M/UA6:POK:]5>K6\RR ?D:^1+[3_  ?J7[0GC"+Q
MK<+;:4&D9&:5H_WN4P,KSTW4MQ9>'-+^*WA>/X37E[=7+2C[8(W=H@FX9&6
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MO-?2;1[BW%O<QLJH2 V\9D;GY<=.]>JP>$]%M=<EUF'2K.+5I01)>I"HE;(
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M[_C0!NT5A?\ "4+_ ,^D_P#X[_C1_P )0O\ SZ3_ /CO^- &[16%_P )0O\
MSZ3_ /CO^-'_  E"_P#/I/\ ^._XT ;M%87_  E"_P#/I/\ ^._XT?\ "4+_
M ,^D_P#X[_C0!NT5A?\ "4+_ ,^D_P#X[_C1_P )0O\ SZ3_ /CO^- &[16%
M_P )0O\ SZ3_ /CO^-'_  E"_P#/I/\ ^._XT ;M%87_  E"_P#/I/\ ^._X
MT?\ "4+_ ,^D_P#X[_C0!NT5A?\ "4+_ ,^D_P#X[_C1_P )0O\ SZ3_ /CO
M^- &[16%_P )0O\ SZ3_ /CO^-'_  E"_P#/I/\ ^._XT ;M%87_  E"_P#/
MI/\ ^._XT?\ "4+_ ,^D_P#X[_C0!NT5A?\ "4+_ ,^D_P#X[_C1_P )0O\
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M_P#2XG'7_BTO5_\ I,CZ,HHHKSSL"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M -)D?1E%%%>>=@4444 %%%% !1110!F:Q_;&Z+^R_L.W!\S[9OS[8V_C6?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1M-.CD.U&NYUB#'T!8C)K\U=/^(WAOX7_P#!4WQYKGBO6;;0M'2W>%KN[8A
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MO_'M%_NC^5=?J/\ QY3?[I_E7(6O_'M%_NC^5 $M%%% !1110 4444 %%%%
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MN,MN.XDGJW-%+&0IJF[:P4K>K>GW%5*4IN=MI<OW+?[S\O?VB-#_ &A/A/\
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M0R0+';Q)(P8E"#AR!C"FJ_Q-\;6?QLU+1;+P=X4O+:^@GW&Z\A4?!Q@'9D
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MM"T^:_U&[AL;*%=TEQ<.$1!ZDG@5Q.D_M ?#G6]22PL_&.E2W;ML2,S[=Q]
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MG44 %%%% !1110 4444 %%%% #5C5,E5"D\G ZTZBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQ*R[MS'T7. /J?IG%_NDNO-(T?\ $;Z61P'PO^"=I\>/BC=P>&;&\T?P/:2
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M^%6NK+&T;'67.'4@_P"IBKZ>KJJ;_)?D8T]OO_,****S- J"^_X\Y_\ </\
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M4?\ "M="_P">=Y_X,;C_ ..4 =117+_\*UT+_GG>?^#&X_\ CE'_  K70O\
MGG>?^#&X_P#CE '445R__"M="_YYWG_@QN/_ (Y1_P *UT+_ )YWG_@QN/\
MXY0!U%%<O_PK70O^>=Y_X,;C_P".4?\ "M="_P">=Y_X,;C_ ..4 =117+_\
M*UT+_GG>?^#&X_\ CE'_  K70O\ GG>?^#&X_P#CE '445R__"M="_YYWG_@
MQN/_ (Y1_P *UT+_ )YWG_@QN/\ XY0!U%%<O_PK70O^>=Y_X,;C_P".4?\
M"M="_P">=Y_X,;C_ ..4 =117+_\*UT+_GG>?^#&X_\ CE'_  K70O\ GG>?
M^#&X_P#CE '445R__"M="_YYWG_@QN/_ (Y1_P *UT+_ )YWG_@QN/\ XY0!
MU%%<O_PK70O^>=Y_X,;C_P".4?\ "M="_P">=Y_X,;C_ ..4 =117+_\*UT+
M_GG>?^#&X_\ CE'_  K70O\ GG>?^#&X_P#CE '445R__"M="_YYWG_@QN/_
M (Y1_P *UT+_ )YWG_@QN/\ XY0!U%%<O_PK70O^>=Y_X,;C_P".4?\ "M="
M_P">=Y_X,;C_ ..4 =117+_\*UT+_GG>?^#&X_\ CE'_  K70O\ GG>?^#&X
M_P#CE '445R__"M="_YYWG_@QN/_ (Y1_P *UT+_ )YWG_@QN/\ XY0!U%%<
MO_PK70O^>=Y_X,;C_P".4?\ "M="_P">=Y_X,;C_ ..4 =117+_\*UT+_GG>
M?^#&X_\ CE'_  K70O\ GG>?^#&X_P#CE '445R__"M="_YYWG_@QN/_ (Y1
M_P *UT+_ )YWG_@QN/\ XY0!U%%<O_PK70O^>=Y_X,;C_P".4?\ "M="_P">
M=Y_X,;C_ ..4 =117+_\*UT+_GG>?^#&X_\ CE'_  K70O\ GG>?^#&X_P#C
ME '445R__"M="_YYWG_@QN/_ (Y1_P *UT+_ )YWG_@QN/\ XY0!U%%<O_PK
M70O^>=Y_X,;C_P".4?\ "M="_P">=Y_X,;C_ ..4 =117+_\*UT+_GG>?^#&
MX_\ CE'_  K70O\ GG>?^#&X_P#CE '445R__"M="_YYWG_@QN/_ (Y1_P *
MUT+_ )YWG_@QN/\ XY0!U%%<O_PK70O^>=Y_X,;C_P".4?\ "M="_P">=Y_X
M,;C_ ..4 =117+_\*UT+_GG>?^#&X_\ CE'_  K70O\ GG>?^#&X_P#CE '4
M45R__"M="_YYWG_@QN/_ (Y1_P *UT+_ )YWG_@QN/\ XY0!U%%<O_PK70O^
M>=Y_X,;C_P".4?\ "M="_P">=Y_X,;C_ ..4 =117+_\*UT+_GG>?^#&X_\
MCE'_  K70O\ GG>?^#&X_P#CE '445R__"M="_YYWG_@QN/_ (Y1_P *UT+_
M )YWG_@QN/\ XY0!U%%<O_PK70O^>=Y_X,;C_P".4?\ "M="_P">=Y_X,;C_
M ..4 =117+_\*UT+_GG>?^#&X_\ CE'_  K70O\ GG>?^#&X_P#CE '445R_
M_"M="_YYWG_@QN/_ (Y1_P *UT+_ )YWG_@QN/\ XY0!U%%<O_PK70O^>=Y_
MX,;C_P".4?\ "M="_P">=Y_X,;C_ ..4 =117+_\*UT+_GG>?^#&X_\ CE'_
M  K70O\ GG>?^#&X_P#CE '445R__"M="_YYWG_@QN/_ (Y1_P *UT+_ )YW
MG_@QN/\ XY0!U%%<O_PK70O^>=Y_X,;C_P".4?\ "M="_P">=Y_X,;C_ ..4
M =117+_\*UT+_GG>?^#&X_\ CE'_  K70O\ GG>?^#&X_P#CE '445R__"M=
M"_YYWG_@QN/_ (Y1_P *UT+_ )YWG_@QN/\ XY0!U%%<O_PK70O^>=Y_X,;C
M_P".4?\ "M="_P">=Y_X,;C_ ..4 =117+_\*UT+_GG>?^#&X_\ CE'_  K7
M0O\ GG>?^#&X_P#CE '445R__"M="_YYWG_@QN/_ (Y1_P *UT+_ )YWG_@Q
MN/\ XY0!U%%<O_PK70O^>=Y_X,;C_P".4?\ "M="_P">=Y_X,;C_ ..4 =11
M7+_\*UT+_GG>?^#&X_\ CE'_  K70O\ GG>?^#&X_P#CE '445R__"M="_YY
MWG_@QN/_ (Y1_P *UT+_ )YWG_@QN/\ XY0!U%%<O_PK70O^>=Y_X,;C_P".
M4?\ "M="_P">=Y_X,;C_ ..4 =117+_\*UT+_GG>?^#&X_\ CE'_  K70O\
MGG>?^#&X_P#CE '445R__"M="_YYWG_@QN/_ (Y1_P *UT+_ )YWG_@QN/\
MXY0!U%%<O_PK70O^>=Y_X,;C_P".4?\ "M="_P">=Y_X,;C_ ..4 =117+_\
M*UT+_GG>?^#&X_\ CE'_  K70O\ GG>?^#&X_P#CE '445R__"M="_YYWG_@
MQN/_ (Y1_P *UT+_ )YWG_@QN/\ XY0!U%%<O_PK70O^>=Y_X,;C_P".4?\
M"M="_P">=Y_X,;C_ ..4 =117+_\*UT+_GG>?^#&X_\ CE'_  K70O\ GG>?
M^#&X_P#CE '445R__"M="_YYWG_@QN/_ (Y1_P *UT+_ )YWG_@QN/\ XY0!
MU%%<O_PK70O^>=Y_X,;C_P".4?\ "M="_P">=Y_X,;C_ ..4 =117+_\*UT+
M_GG>?^#&X_\ CE'_  K70O\ GG>?^#&X_P#CE '445R__"M="_YYWG_@QN/_
M (Y1_P *UT+_ )YWG_@QN/\ XY0!U%%<O_PK70O^>=Y_X,;C_P".4?\ "M="
M_P">=Y_X,;C_ ..4 =117+_\*UT+_GG>?^#&X_\ CE'_  K70O\ GG>?^#&X
M_P#CE '445R__"M="_YYWG_@QN/_ (Y1_P *UT+_ )YWG_@QN/\ XY0!U%%<
MO_PK70O^>=Y_X,;C_P".4?\ "M="_P">=Y_X,;C_ ..4 =117+_\*UT+_GG>
M?^#&X_\ CE'_  K70O\ GG>?^#&X_P#CE '445R__"M="_YYWG_@QN/_ (Y1
M_P *UT+_ )YWG_@QN/\ XY0!U%%<O_PK70O^>=Y_X,;C_P".4?\ "M="_P">
M=Y_X,;C_ ..4 =117+_\*UT+_GG>?^#&X_\ CE'_  K70O\ GG>?^#&X_P#C
ME '445R__"M="_YYWG_@QN/_ (Y1_P *UT+_ )YWG_@QN/\ XY0!U%%<O_PK
M70O^>=Y_X,;C_P".4?\ "M="_P">=Y_X,;C_ ..4 =117+_\*UT+_GG>?^#&
MX_\ CE'_  K70O\ GG>?^#&X_P#CE '445R__"M="_YYWG_@QN/_ (Y1_P *
MUT+_ )YWG_@QN/\ XY0!U%%<O_PK70O^>=Y_X,;C_P".4?\ "M="_P">=Y_X
M,;C_ ..4 =117+_\*UT+_GG>?^#&X_\ CE'_  K70O\ GG>?^#&X_P#CE '4
M45R__"M="_YYWG_@QN/_ (Y1_P *UT+_ )YWG_@QN/\ XY0!U%%<O_PK70O^
M>=Y_X,;C_P".4?\ "M="_P">=Y_X,;C_ ..4 =117+_\*UT+_GG>?^#&X_\
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MVH_\>4W^Z?Y5R%K_ ,>T7^Z/Y5U^H_\ 'E-_NG^5<A:_\>T7^Z/Y4 2T444
M%%%% !1110 5%<6L-Y&8YXHYH_[LBAA^1J6B@!B0QQQK&D:K&O 55  _"G@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/[HI(Y( &>0/O"O7J)TY4Y<LU9A&2DKQ"BBBLR@HHHH **** "BBB@ HHHH
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MM0JB+N +<DL6QCM7ULW*D X/K2E?ECS;_P!6%IS/EV_JYY?\0-+O?AGX<O\
M4?AKX-L;O7[Z55GCAB" J QWL 5W8)Z9Y)KR3]B5]*CO/%OVB\F'C"XE#WMC
M-%Y?EHKMRO//S,<],<#%/F^+_P 4?@OXTUFT\7Z+?^,M&G/_ !+[NSA$:  G
M:0R)CD$94\C _&?]F/X<^);WXD>(OB5XBTR30EU,3?9K&52CL97#%MIP0H P
M,CG.:=/9OHU_2"IM;K?[_,^@/B+KC^&O /B'58SB6SL)ID/HP0D?K7A7["^D
M)%\/]=UAANN[_42CR'J51!@?F['\:]V^(6AOXF\"^(-)C&9+VQF@0?[3(0/U
MKPC]A?5U;P)X@T23Y+S3]1+O&>"%=0!Q]48?A4P^WZ+\PGM'U_0^>;/X8W?Q
M"UKXF7FEM)_:VAW+7L$<?61?.?>H_P!K !'TQWKI/BU\8D^*WP!\.+>39\0:
M;J(M[U&^\_[IMLOT8#GW!KU[]EOPCKOA_P"*/Q%NM5T74--M;J0FWGO+22))
MAYSGY&8 -P0>/6O*_P!I;]G'6]$\=2ZGX4T.^U71]5)G,&FVKS&VES\ZE4!P
MI)R/J1VJ[JT8O9I?>BMYREV;^X]Z\9?%OQ;\/=(\)VGA[P/<^*;>?2()9+B$
M28C;:!M^5#V&?QKEO^&G/B=_T1^__*?_ .-UU7CKX9_$CQ5I_A=_"?BX^%8+
M;2H8;FUDDEC9I0HR2%4\@<<\\5R7_"B?CI_T55?_  )G_P#B*<K<TK]W^9G'
MX8^B_(]'\2_"FR^/6F>#M7\5Q7>FI:PFXGT6-BH:1PIV.2,@+@CH#SU%>0?L
M96L5C\3_ (DVT""*"%Q'&B]%43R  ?A7U'X1T_4=)\+Z79:M>?VAJ=O;I'<W
M62?-D PS9//)]:^>/V5?"&O>'?B=\1;K5=$U'3+6ZE)MYKRTDB28>=(?D9@
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M,'_ 1ES[LOH:_.>OLLIPOLJ?M9;R_+_@GC8NKS2Y%LCK/A1\2-4^$/Q&\/\
MC'1GVZAI%TMPBYP)%Z/&?9D+*?9C7] 7PP^(ND?%KP!H?B[0I3+IFK6J7,0;
M&^,D?-&V.C*V5(]0:_G1K]$_^"4?[1DFEZ]??"/6;I?L6H%[[1/,."DX7,T(
M/HRKO ]5;^]3S;#>UI>UCO'\@PE7EER/9GZAT445\8>R-D;RXV;&=H)K\U_^
M"=V@6OQ9_:<^,'Q%\2(NI:YIUWFT-R-_DO/-+\ZYZ%5A"+Z G%?I57YO>(?
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M^,/QC^"/[7FA?"KXF^+K7QQI/B:V\RWNH[583#(P<J5PH(^9"I4Y&""*TO\
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MPUNQD#6MU$)!GJA_B4^X.0?I7Q+^T%\2C\1O'EPUN^=)T_-M: 'A@#\S_P#
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MONV_*RTTW./+<!7IUL/^Y<)0YN>>GO7\[WE=ZZ['H-%%%?''WX4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110!6U'_CRF_W3_*N0M?\ CVB_W1_*NOU'_CRF_P!T_P JY"U_X]HO
M]T?RH EHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% 'RMXJ_X)L_!_QMXEU37]:_X2*^U;4KA[JZN)-4.9)'8EC]WCD]
M!P.E97_#K#X%_P#/IKW_ (-#_P#$U]?45V+&8A*RFS'V-/\ E/D'_AUA\"_^
M?37O_!H?_B:T/#O_  30^#?A/7].UK2E\0V>IZ?<1W5M<1ZJ0T<B,&5A\OJ!
M7U=11]<Q#T<W]X>QI_RB#\Z6BBN,V"BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MXT?\)%XC_P"A2D_\&$/^- '445R__"1>(_\ H4I/_!A#_C1_PD7B/_H4I/\
MP80_XT =117+_P#"1>(_^A2D_P#!A#_C1_PD7B/_ *%*3_P80_XT =117+_\
M)%XC_P"A2D_\&$/^-'_"1>(_^A2D_P#!A#_C0!U%%<O_ ,)%XC_Z%*3_ ,&$
M/^-'_"1>(_\ H4I/_!A#_C0!U%%<O_PD7B/_ *%*3_P80_XT?\)%XC_Z%*3_
M ,&$/^- '445R_\ PD7B/_H4I/\ P80_XT?\)%XC_P"A2D_\&$/^- '445R_
M_"1>(_\ H4I/_!A#_C1_PD7B/_H4I/\ P80_XT =117+_P#"1>(_^A2D_P#!
MA#_C1_PD7B/_ *%*3_P80_XT =117+_\)%XC_P"A2D_\&$/^-'_"1>(_^A2D
M_P#!A#_C0!U%%<O_ ,)%XC_Z%*3_ ,&$/^-'_"1>(_\ H4I/_!A#_C0!U%%<
MO_PD7B/_ *%*3_P80_XT?\)%XC_Z%*3_ ,&$/^- '445R_\ PD7B/_H4I/\
MP80_XT?\)%XC_P"A2D_\&$/^- '445R__"1>(_\ H4I/_!A#_C1_PD7B/_H4
MI/\ P80_XT =117+_P#"1>(_^A2D_P#!A#_C1_PD7B/_ *%*3_P80_XT =11
M7+_\)%XC_P"A2D_\&$/^-'_"1>(_^A2D_P#!A#_C0!U%%<O_ ,)%XC_Z%*3_
M ,&$/^-'_"1>(_\ H4I/_!A#_C0!U%%<O_PD7B/_ *%*3_P80_XT?\)%XC_Z
M%*3_ ,&$/^- '445R_\ PD7B/_H4I/\ P80_XT?\)%XC_P"A2D_\&$/^- '4
M45R__"1>(_\ H4I/_!A#_C1_PD7B/_H4I/\ P80_XT =117+_P#"1>(_^A2D
M_P#!A#_C1_PD7B/_ *%*3_P80_XT =117+_\)%XC_P"A2D_\&$/^-'_"1>(_
M^A2D_P#!A#_C0!U%%<O_ ,)%XC_Z%*3_ ,&$/^-'_"1>(_\ H4I/_!A#_C0!
MU%%<O_PD7B/_ *%*3_P80_XT?\)%XC_Z%*3_ ,&$/^- '445R_\ PD7B/_H4
MI/\ P80_XT?\)%XC_P"A2D_\&$/^- '445R__"1>(_\ H4I/_!A#_C1_PD7B
M/_H4I/\ P80_XT =117+_P#"1>(_^A2D_P#!A#_C1_PD7B/_ *%*3_P80_XT
M =117+_\)%XC_P"A2D_\&$/^-'_"1>(_^A2D_P#!A#_C0!U%%<O_ ,)%XC_Z
M%*3_ ,&$/^-'_"1>(_\ H4I/_!A#_C0!U%%<O_PD7B/_ *%*3_P80_XT?\)%
MXC_Z%*3_ ,&$/^- '445R_\ PD7B/_H4I/\ P80_XT?\)%XC_P"A2D_\&$/^
M- '445R__"1>(_\ H4I/_!A#_C1_PD7B/_H4I/\ P80_XT =117+_P#"1>(_
M^A2D_P#!A#_C1_PD7B/_ *%*3_P80_XT =117+_\)%XC_P"A2D_\&$/^-'_"
M1>(_^A2D_P#!A#_C0!U%%<O_ ,)%XC_Z%*3_ ,&$/^-'_"1>(_\ H4I/_!A#
M_C0!U%%<O_PD7B/_ *%*3_P80_XT?\)%XC_Z%*3_ ,&$/^- '445R_\ PD7B
M/_H4I/\ P80_XT?\)%XC_P"A2D_\&$/^- '445R__"1>(_\ H4I/_!A#_C1_
MPD7B/_H4I/\ P80_XT =117+_P#"1>(_^A2D_P#!A#_C1_PD7B/_ *%*3_P8
M0_XT =117+_\)%XC_P"A2D_\&$/^-'_"1>(_^A2D_P#!A#_C0!U%%<O_ ,)%
MXC_Z%*3_ ,&$/^-'_"1>(_\ H4I/_!A#_C0!U%%<O_PD7B/_ *%*3_P80_XT
M?\)%XC_Z%*3_ ,&$/^- '445R_\ PD7B/_H4I/\ P80_XT?\)%XC_P"A2D_\
M&$/^- '445R__"1>(_\ H4I/_!A#_C1_PD7B/_H4I/\ P80_XT =117+_P#"
M1>(_^A2D_P#!A#_C1_PD7B/_ *%*3_P80_XT =117+_\)%XC_P"A2D_\&$/^
M-'_"1>(_^A2D_P#!A#_C0!U%%<O_ ,)%XC_Z%*3_ ,&$/^-'_"1>(_\ H4I/
M_!A#_C0!U%%<O_PD7B/_ *%*3_P80_XT?\)%XC_Z%*3_ ,&$/^- '445R_\
MPD7B/_H4I/\ P80_XT?\)%XC_P"A2D_\&$/^- '445R__"1>(_\ H4I/_!A#
M_C1_PD7B/_H4I/\ P80_XT =117+_P#"1>(_^A2D_P#!A#_C1_PD7B/_ *%*
M3_P80_XT =117+_\)%XC_P"A2D_\&$/^-'_"1>(_^A2D_P#!A#_C0!U%%<O_
M ,)%XC_Z%*3_ ,&$/^-'_"1>(_\ H4I/_!A#_C0!U%%<O_PD7B/_ *%*3_P8
M0_XT?\)%XC_Z%*3_ ,&$/^- '445R_\ PD7B/_H4I/\ P80_XT?\)%XC_P"A
M2D_\&$/^- '445R__"1>(_\ H4I/_!A#_C1_PD7B/_H4I/\ P80_XT =117+
M_P#"1>(_^A2D_P#!A#_C1_PD7B/_ *%*3_P80_XT =117+_\)%XC_P"A2D_\
M&$/^-'_"1>(_^A2D_P#!A#_C0!U%%<O_ ,)%XC_Z%*3_ ,&$/^-'_"1>(_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110!6U'_CRF_W3_*N0M?^/:+_ '1_*NSN
MEWP.O7(Q7%VWR(8C]^([&'T_^M0!-1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 C#<I%<5XIL[BRF-W:C+8^9>S"NVJ&ZM4NHRK#- 'CUS\3K/3LK>6EQ
M&XZ[5R*I-\;-"7@Q77_?NN[USX>VVH$MY8R?:N6F^$%NS'$8_*@#,_X7=H/_
M #RNO^_='_"[M!_YY77_ '[J[_PI^#_GF/RH_P"%/P?\\Q^5 %+_ (7=H/\
MSRNO^_='_"[M!_YY77_?NKO_  I^#_GF/RH_X4_!_P \Q^5 %+_A=V@_\\KK
M_OW1_P +NT'_ )Y77_?NKO\ PI^#_GF/RH_X4_!_SS'Y4 4O^%W:#_SRNO\
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MU?;-VTWLGUVLVSR\9/'1G3]DM==M5TWND?HY\.?BOX3^+&CKJ?A76[75K?\
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MK&'SUU"X=?+D7=M&1_"3R>IX!KD?$W[:&AZ?K5S8^'_#NH^*(;4D37ELVR/
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MW$EO/&LL;CHRL,@_D:^:_P!MRWCL_@SX=MY"#/%J4**>_$$@/]*]H^#/G?\
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MI3J* &^6OI1Y:^E.HH ;Y:^E'EKZ4ZB@!OEKZ4>6OI3J* &^6OI1Y:^E.HH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZ(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
=44 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>brns-20231231_g5.jpg
<TEXT>
begin 644 brns-20231231_g5.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" ' !R0# 2(  A$! Q$!_\0
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M\_\ CM']A5/YT'UZ/\I_0O17\]'_  T_\9/^BM>.?_"DO/\ X[1_PT_\9/\
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M?\-/_&3_ **UXY_\*2\_^.T?V%4_G0?7H_RG]"]%?ST?\-/_ !D_Z*UXY_\
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MV%4_G0?7H_RG]"]%?ST?\-/_ !D_Z*UXY_\ "DO/_CM'_#3_ ,9/^BM>.?\
MPI+S_P".T?V%4_G0?7H_RG]"]%?ST?\ #3_QD_Z*UXY_\*2\_P#CM'_#3_QD
M_P"BM>.?_"DO/_CM']A5/YT'UZ/\I_0O17\]'_#3_P 9/^BM>.?_  I+S_X[
M1_PT_P#&3_HK7CG_ ,*2\_\ CM']A5/YT'UZ/\I_0O17\]'_  T_\9/^BM>.
M?_"DO/\ X[1_PT_\9/\ HK7CG_PI+S_X[1_853^=!]>C_*?T+T5_/1_PT_\
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M3_HK7CG_ ,*2\_\ CM']A5/YT'UZ/\I_0O17\]'_  T_\9/^BM>.?_"DO/\
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MUZ/\I_0O17\]'_#3_P 9/^BM>.?_  I+S_X[1_PT_P#&3_HK7CG_ ,*2\_\
MCM']A5/YT'UZ/\I_0O17\]'_  T_\9/^BM>.?_"DO/\ X[1_PT_\9/\ HK7C
MG_PI+S_X[1_853^=!]>C_*?T+T5_/1_PT_\ &3_HK7CG_P *2\_^.T?\-/\
MQD_Z*UXY_P#"DO/_ ([1_853^=!]>C_*?T+T5_/1_P -/_&3_HK7CG_PI+S_
M ..T?\-/_&3_ **UXY_\*2\_^.T?V%4_G0?7H_RG]"]%?ST?\-/_ !D_Z*UX
MY_\ "DO/_CM'_#3_ ,9/^BM>.?\ PI+S_P".T?V%4_G0?7H_RG]"]%?ST?\
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M\_\ CM']A5/YT'UZ/\I_0O17\]'_  T_\9/^BM>.?_"DO/\ X[1_PT_\9/\
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M?\-/_&3_ **UXY_\*2\_^.T?V%4_G0?7H_RG]"]%?ST?\-/_ !D_Z*UXY_\
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M_7L3[3V7L/>M?XEMMV-?84^7GY]/0_(&BOV9^%OQP_X9T_X)P^#/'O\ 8O\
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M^Z2(H68 C 9P>"HI1S+EC-UH<KBD[7O=/8;P]VE"5TS\ZJ*_9OX2_M)_#/\
MX* 7/COX7:GX-$.GV=J\MC+=.LK7-J'$0N8QL5K>16>,@#)&X?-U%?D#X\\*
M3> _''B+PS<2BXN-&U&XTZ255VAVAE:,MC)QDKG&:Z<-BI5I2IU(<LE;3?<R
MJ4E!*47=,PJ**^N/V]?V1O!_[+=C\.IO"FI:YJ#>(H[U[L:Q/#*$,(MBGE^7
M%'C/GOG.>@Z<YZ9UH0J1IO>5[?(S4'*+DMD?(]%%?IC_ ,$8/^:P_P#<'_\
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M_L.\EDDMX@"6D998H\JN.=N2 <XP"1<L50A/V<IKF[$JE-QYDM#Y5HK]0O\
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M5!(!*[L9R?E!(7US#\W)SJ^P>QJ6YK:'R[17WM\ _P#A=?\ PP)X[_X1O_A
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M#\GJ*]=_99_9[U+]I;XP:5X2M#+;:9G[5JVH1@?Z):*1O89XW'(11@_,PR,
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M9&[W%?E;7N?['_[3G_#*/Q+U/Q;_ ,(W_P )3]MTB72OL?V_['LWS0R^9O\
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M)+!K\VABFC8[)5?RY!]UW4C;SE3GY<'R;XU?%/4/C9\5O$WCC4XA;W6M7C7
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M2]1\B+3+62 1*GE>21(5;>V04!#!0%QD^7_\-H?\85_\,_\ _"'?]S%_:?\
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MG\#_ /"L?[&_MJU^S?;_ .W_ #_)^96W>7]E7=]WIN'6N1_9>_X*6>*_V>_
ML7@_5_#D/C?0K+(TWS+XVEQ:(228O,\N0/&"?E!4%<D9QM"^9]7KJ$)PI6<'
MMS)WON[]SI]I"\E*5TUO;8^@_CI;3^!?^"37AK1=<A?3=4N[?38$M;E3')O:
MZ%P$*GD-Y:,2.HP?2OG;]E?]D;0I_!TGQH^-UX?#GPNT[;-:VDP*RZPP/R@*
M/F,;'@!1ND/3 Y/%_M7_ +:_B']J[5-'@U728] \*:7*9H=%LKHN[NP 9WF9
M<,^W<%.P!0QX.3GZ9TK_ (+%VFAZ7::=8?!:.TL;2%((+>+Q*%2.-0%55 L^
M   *2HXRC0Y:<?>FVW9K2_1-_F'-1G.\GHE9'S'^V)^U[??M.:]IMEIVG-X<
M\!Z$&CTC1E8 XP%$LJK\N_: H49" D G))]%_9I_99\*>!_ L/QS^/TG]E>"
M(&271O#LR9FUJ0Y,9:/JT;8RJ?Q@%FQ&#NT/VBO^"E%E^T1X'L/"VI?"[[!I
MT.KVFI7(_M_SOM$4+[G@Q]F7;O4E=W.,YP:]/B_X+-)!$D47P;6.- %5%\38
M"@<  ?8^!6DEBHT(TJ-'E[^\KV]>[[B7LG-RG._R9\D?M>?M6ZQ^U/X\@U":
MT_L?PSI2-;Z/I"MN\F,D;I)".#(^U<XX 55&<$GP>OKG]L+]OS_AK#X?Z1X8
M_P"$$_X1;^S]474OM7]L?;/,Q%)'LV^1'C_69SD].G-?(U>IA8N-)1<.2W2]
M_P 3EJM.;:E<****ZS$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH *^Y?^"/\ _P G+>)?^Q1N?_2RRKX:K[E_X(__ /)RWB7_ +%&Y_\
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M?W!]3JGY T5^OW_#G_X-_P#0R^.?_ ^S_P#D2C_AS_\ !O\ Z&7QS_X'V?\
M\B4?VQA>[^X/J=4_(&BOU^_X<_\ P;_Z&7QS_P"!]G_\B4?\.?\ X-_]#+XY
M_P# ^S_^1*/[8PO=_<'U.J?D#17Z_?\ #G_X-_\ 0R^.?_ ^S_\ D2C_ (<_
M_!O_ *&7QS_X'V?_ ,B4?VQA>[^X/J=4_(&BOU^_X<__  ;_ .AE\<_^!]G_
M /(E'_#G_P"#?_0R^.?_  /L_P#Y$H_MC"]W]P?4ZI^0-%?K]_PY_P#@W_T,
MOCG_ ,#[/_Y$H_X<_P#P;_Z&7QS_ .!]G_\ (E']L87N_N#ZG5/R!HK]?O\
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M_P"1*/\ AS_\&_\ H9?'/_@?9_\ R)1_;&%[O[@^IU3\@:*_7[_AS_\ !O\
MZ&7QS_X'V?\ \B4?\.?_ (-_]#+XY_\  ^S_ /D2C^V,+W?W!]3JGY T5^OW
M_#G_ .#?_0R^.?\ P/L__D2C_AS_ /!O_H9?'/\ X'V?_P B4?VQA>[^X/J=
M4_(&BOU^_P"'/_P;_P"AE\<_^!]G_P#(E'_#G_X-_P#0R^.?_ ^S_P#D2C^V
M,+W?W!]3JGY T5^OW_#G_P"#?_0R^.?_  /L_P#Y$H_X<_\ P;_Z&7QS_P"!
M]G_\B4?VQA>[^X/J=4_(&N[\$_'+QQ\._!?BCPCH&O267AOQ-$8=5TV2WAGB
MG4J4)'F(QC8JV-\>UN%Y^5<?J'_PY_\ @W_T,OCG_P #[/\ ^1*/^'/_ ,&_
M^AE\<_\ @?9__(E1+-L'-6EK\AK"5EJC\@:*_7[_ (<__!O_ *&7QS_X'V?_
M ,B4?\.?_@W_ -#+XY_\#[/_ .1*O^V,+W?W"^IU3\@:*_7[_AS_ /!O_H9?
M'/\ X'V?_P B4?\ #G_X-_\ 0R^.?_ ^S_\ D2C^V,+W?W!]3JGY)^&?$6H>
M#_$6EZ[I4RV^J:9=1WEK,\22B.6-@Z,4<%6PP!PP(..16Q\3/BCXI^,?C"[\
M4^,=7EUO7;I422ZD1(QM10JJJ(JH@ '10!DD]237ZJ?\.?\ X-_]#+XY_P#
M^S_^1*/^'/\ \&_^AE\<_P#@?9__ ")4?VM@^;FZ^@_JE:UC\@:*_7[_ (<_
M_!O_ *&7QS_X'V?_ ,B4?\.?_@W_ -#+XY_\#[/_ .1*O^V,+W?W"^IU3\@:
M*_7[_AS_ /!O_H9?'/\ X'V?_P B4?\ #G_X-_\ 0R^.?_ ^S_\ D2C^V,+W
M?W!]3JGY T5^OW_#G_X-_P#0R^.?_ ^S_P#D2C_AS_\ !O\ Z&7QS_X'V?\
M\B4?VQA>[^X/J=4_(&BOU^_X<_\ P;_Z&7QS_P"!]G_\B4?\.?\ X-_]#+XY
M_P# ^S_^1*/[8PO=_<'U.J?D#17Z_?\ #G_X-_\ 0R^.?_ ^S_\ D2C_ (<_
M_!O_ *&7QS_X'V?_ ,B4?VQA>[^X/J=4_(&BOU^_X<__  ;_ .AE\<_^!]G_
M /(E'_#G_P"#?_0R^.?_  /L_P#Y$H_MC"]W]P?4ZI^0-%?K]_PY_P#@W_T,
MOCG_ ,#[/_Y$H_X<_P#P;_Z&7QS_ .!]G_\ (E']L87N_N#ZG5/R!HK]?O\
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M9_\ R)1_PY_^#?\ T,OCG_P/L_\ Y$J/[6P;?,]_0?U2M:Q^0-%?K]_PY_\
M@W_T,OCG_P #[/\ ^1*/^'/_ ,&_^AE\<_\ @?9__(E7_;&%[O[A?4ZI^0-%
M?K]_PY_^#?\ T,OCG_P/L_\ Y$H_X<__  ;_ .AE\<_^!]G_ /(E']L87N_N
M#ZG5/R!HK]?O^'/_ ,&_^AE\<_\ @?9__(E'_#G_ .#?_0R^.?\ P/L__D2C
M^V,+W?W!]3JGY T5^OW_  Y_^#?_ $,OCG_P/L__ )$H_P"'/_P;_P"AE\<_
M^!]G_P#(E']L87N_N#ZG5/R!HK]?O^'/_P &_P#H9?'/_@?9_P#R)1_PY_\
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M?W!]3JGY T5^OW_#G_X-_P#0R^.?_ ^S_P#D2C_AS_\ !O\ Z&7QS_X'V?\
M\B4?VQA>[^X/J=4_(&BOU^_X<_\ P;_Z&7QS_P"!]G_\B4?\.?\ X-_]#+XY
M_P# ^S_^1*/[8PO=_<'U.J?D#17Z_?\ #G_X-_\ 0R^.?_ ^S_\ D2C_ (<_
M_!O_ *&7QS_X'V?_ ,B4?VQA>[^X/J=4_(&BOU^_X<__  ;_ .AE\<_^!]G_
M /(E'_#G_P"#?_0R^.?_  /L_P#Y$H_MC"]W]P?4ZI^0-%?K]_PY_P#@W_T,
MOCG_ ,#[/_Y$H_X<_P#P;_Z&7QS_ .!]G_\ (E']L87N_N#ZG5/R!HK]?O\
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M_P"1*/\ AS_\&_\ H9?'/_@?9_\ R)1_;&%[O[@^IU3\@:*_7[_AS_\ !O\
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MX<__  ;_ .AE\<_^!]G_ /(E']L87N_N#ZG5/R!HK]?O^'/_ ,&_^AE\<_\
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M_ ^S_P#D2C_AS_\ !O\ Z&7QS_X'V?\ \B4?VQA>[^X/J=4_(&BOU^_X<_\
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M#?\ T,OCG_P/L_\ Y$H_MC"]W]P?4ZI^0-%?K]_PY_\ @W_T,OCG_P #[/\
M^1*/^'/_ ,&_^AE\<_\ @?9__(E']L87N_N#ZG5/R!HK]?O^'/\ \&_^AE\<
M_P#@?9__ ")1_P .?_@W_P!#+XY_\#[/_P"1*/[8PO=_<'U.J?D#17Z_?\.?
M_@W_ -#+XY_\#[/_ .1*/^'/_P &_P#H9?'/_@?9_P#R)1_;&%[O[@^IU3\@
M:*_7[_AS_P#!O_H9?'/_ ('V?_R)1_PY_P#@W_T,OCG_ ,#[/_Y$H_MC"]W]
MP?4ZI^0-%?K]_P .?_@W_P!#+XY_\#[/_P"1*/\ AS_\&_\ H9?'/_@?9_\
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MY_\ @W_T,OCG_P #[/\ ^1*/[8PO=_<'U.J?D#17Z_?\.?\ X-_]#+XY_P#
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M\#[/_P"1*/\ AS_\&_\ H9?'/_@?9_\ R)1_;&%[O[@^IU3\@:*_7[_AS_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MH\+_  Z\0Z=\#]=\/W&G^7J]U,[16_G1G<#Y>/F#;1]T]3VKH_A'X1U?PO\
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M<=^/2NG^(GP'\.^'?A_=7^FB>#4M.B\XW33,3-@C.Y<X'?&T#M76_%SX3_\
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M/!8B-.;J*7-S)*4>5;/K[UVT4OV6E:/Q!XD5VW.L48+>IWMS7O\ K7_('O\
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M;Y6G9;))M>JN>,?&KX?:+X%^&F-+MMLT^HQF6YE.Z63Y9#@GT]A@5ZE\)?\
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M1110 4444 %%%% !1110 4444 %%%% !1110 4444 >4?';]I'PS^SY_8?\
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MJX(RH4$?@:P5&Z<D]C3VEFDT?6^C_%SPSX@^(VI^"--OC>:]IEL;J]2)#Y<
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MXR:M\'?A/'/H$WV76M6O%L8;K:&,";&=W7/&["A1GINSVKYH_:$^#?Q4\!_
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MK):]W9*[]0HHHKV#R0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** *&NZ+:>(]'N],OH_-M+I#'(H.#CU![$'G\*\@C_9OO+*&:ST_P ;ZA9:
M9,<R6:Q-M?UW;9 IX_V:]NHKR<;E.#S"2GB87:TO=IV[736AZF$S/%X&+AAY
MV3UM9-7[ZIZG,?#_ .'^G?#O13I]@TDS2/YDUQ+C=(V,=N@ Z"NGHHKOH4*>
M&I1HT8\L8Z)'#6K5,14E5JRO)[L****W,0HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M3@KM:Z,GGD[7[H]*^%OQ!\0:]^T7X^\/7WCC3=9T?3XI&M?#]O921W%B1+&
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 445C:%XECUW5/$5DD#Q-HM^E@[L01*S6L%QN7VQ<!?JII@;-%%%( H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M6-^:VH4445!04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M88@>.^SG/4TJV$E0@I3DKNVFM]?D$*JJ-I(],HHHKA-PHHHH **** "BBB@
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MR=6FBD*2 $83RXTPO/?)]ZX*=:,:%2F]W:WR9O*+<XR72YZ]1117$;!1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'Q
M;_P5H_Y-9M?^QBM/_14],3_@FG\$_''P;TY],\.S^'_$M_I$,\6K0:I=2;;A
MH P9HY)'0J7.2 HXX!%/_P""M'_)K-K_ -C%:?\ HJ>N!L?^"K'@ZQ^&>G>'
MO!_@SQ7JWC.WTR*QM(KBU@6W:X6((&S',[LH89P$R1QQ7T%".)EA8?5K_$[V
M^6YY\W3567M.R'?\$[_VCO$5M^RCXY6ZTO5O'%_X'FC32M,T^&2XN[B*9<0V
MRA59BJR*_.#L0]-JUK?$+]LS]H'X%^%?"/C[XB^ /"%MX-\072P?V+9O>0ZS
M9[D,@2;S6V*^Q7.-IP1A@IKSWX9?!SXM?LR_L">.?$&A66H:1X^\07EO>2V]
MK'_IUAIR%5W;>2LF&D8X&Y%?/!4X^:OC7;_#SQ)\!?#&O>&M2\:>-_B"KP2^
M*==U[[0]MII:-E>VW.NS+3,FTAG.$^]DFN^.'HUZ\Y))Q<K?A\K:]>IBZDX4
MTKV:1^EGB+]J?Q/X-_;$\'_#?5].TI/A]XQTU+G1]46WE6\$S1MB.1S*4/[U
M"N @($L?N3/J7[3?BK6/VW;+X+^%+'1KCP]I^F"_\1:A=0RR74!V%]L3+(J#
MB2V7YE;!D/IBO-/V_/!TGB+]FOX>_%GPLZ3:OX'EL-9M+R%=VZUD$7S#!!(#
MBWD]@K'W%W_@FOX=O_&=K\1OCGK\&S6/'>LS"U!8MY5K&[$JA_N^8QCZ=+=:
M\SV5%8?ZQ;9<MO[U]_NU.GFG[3V=_/Y?\.?8GBZUU:]\*:U;Z#<0V>N364T=
MA<7&?+BN#&PB=\ G:'VDX!X'2OS-^)G[#?P__9]_9;\9^)/BWK$>J_$ZZDN'
MTO5K/49R);ILF")(V"^87.6D+JQ +$, ,U^E7CSQIIWPY\$Z]XIU=F33-&LI
MK^Y,8RQCC0L0H[L<8 [DBOQ\L?VM_ /QB^,UUX^_: L/$OB*PT^0CP[X/T6W
MMY=.M(B<_OC)-&9#P,_+\Y&6.T! \MC7:E*G=15F[;OR_P Q8EPT4M_ZU.B^
M-&H>,[7]C+]FC1_'&H:E:^$=5U&Y;5Y]S-(MFLT9LE?^]BW:5T4YX1.ZC%KX
MC7GPG_9Q_:J^#^L_ 'Q##=65Q)!%K=OIFJM?0M$\R(R.Y9OFD1GW(6^4JIVJ
M<5]*_M%?M"'XQ?L?V'CGP)\,;?QMX-O+Y[74=$\36+--:PQ,R"=$MILIM=<;
ME?*AP> #7S#X!\!^"?VHOCM\,+#X+?"[4O!7@/PY=KJ7B'5+]FE:1O,CD>-I
MVDD)&(=D8+YS(QV*,UZE&?-!RJIQ2Y[K2VO?SZ(Y9QM)*+N]+=_D?K]1117Q
MQ[ 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !7Y\?MAZ#IGB?\ X*&_ 72M8TZTU;2[JQCCN+*^@6:&9?/N/E=&!5A[$5^@
M]?GU^W-IWCOP[^UY\*?B'X4^''B+Q]9^'=-666'1[&>2-I!/,?+:6.*0(V&!
MY!."..:]/+_XS2?1_D<V(^#YHU?^"C'[+OPRT']FO7?&?ASP=HWA77M FLY(
M9]#L8[,2I)<QP-&ZQA588FW9()!08.,UT7AOXK?&SQA^R#\(-2^'=I9SZ]JU
MNEMK?BK6+BW$>EP0OY+7+I-(OFNVW=P'^Z^1DK7DGQN^)G[0_P"VCX5C^&>E
M? C6/ASH^HW,+ZEJ&O&=49(Y Z@R2P0A4#*K$*KL=@QZ'1_;"_9I\6^&?!OP
M)\-Z)H&O>/\ X9>$TCMM?T3P]YANKMP\;22F)/F/F*)-K '82W*[@3Z4(^Y3
MHUY)RYF]7>RMMOU>RN<S?O2G!.UO3J;OPR_:<^(O@S]L30/A'K_Q-T'XR^'M
M;MR6UC3;"UM9+*;RI6\O%L2H96BY5BQ*N#\IXKNOV3_V@?&MQ\:/C'\+OBMX
MA35M5\*3&]TZ^FMK>V+6"L0SE88T!&Q[>3)&?WA]*^?/"7PNU2Q_;6^$_C+P
MK\"?$WPY^',.+*..72I&F4[9E-S>A#)Y)+3JN9&^Y'G.!5W_ (*A>'=:^%GQ
M6T#XC^%)3;W'B_1;SPMJ4<0RTV8_+Z#DLT4H (Z&%?QJ5&C5J*BDDYQWTW3\
MM%IO82G.,7-]'^!]!_L'_&;XA_M#7'Q&\;^)-8DE\$MJ[V7AK2C8P0B",,78
MF14#OM1X4RS'D/WZ>[?''X+Z'\?_ (>7O@SQ'=:E::1>21RS-I<ZPRML8,H)
M96!&X X(Z@5G?LS?"2/X'? KP?X-$:)=V-BK7S(!\]U)^\G.>X\QF SV ]*P
M?VPO _Q$\>?!/4+3X7:_?:#XOM9X[N#^S[LVLEW&H97MQ*"-NX/N'(&Y%Y'6
MO'G*,\5>DU%7T?;S.R*<:5I:L_/WXR>%?".B_M1_##P9'X)A^"O@_P *ZN+6
M+QQ<6<RR>(##+$1)YHA17;>FWS&+!2[,7VX6MS]M+X@65U_P4!T>R\4^%;[X
M@Z%X<TV&*Q\(V2&3[?<2PM*BE,'(,DB%OE;*Q 88<5=^(MO^T'^VYH?@/X7^
M(OA/J/@F#1;V.?6?%>K0RQQ3ND;1&9?,1?X7<[$:3>Q7D <>H?M6?!7X@_"W
M]I3P5\??AMX5F\>II-FMEJ.BPAI+IBL,D&_:H+-NADP&56*L@)!%>_&I&,X1
MJ-<W+)6OUZ._2^OH<#BVFXK2ZZ?IY&=^PIK_ ,+M:_:2\;76F^"O$'PC^)$U
MFXN?!EU<(-.2#,1D6*+R(FC8,JOL8<;V*_+POZ#U\$_LT_#_ .)GQG_;"U/X
M^>.? ]Q\-M*MM/-E8Z3J"LMS*YA$(!#HC, I=B[*O)4 '!Q][5X>86]JK/HK
MZWL^USMP]^37N%%%%>:=(4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% 'P)_P31_Y+7^U#_V,-O\ ^E.I5R?[;.I6?Q._;O\
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M[O0_!-NTD^F+?QC,M]+&L3/D94MCSY&VD[6D7D]:_2FLLRFN94HJW5_XGO\
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M$[3-L$\-QYY(@@F>"1"OE[8S&TB[OF. V&KV[]KK_A%-,\2?LO>);X:EXI^
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MTF^K"BBBO(.L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N;\*V^D0Z]XR?3;F:>
M\EU:-]3CD!"PW'V&T543Y1E?)6!NK<NW/8=)7-^%;K2;C7O&2:=:2V]Y#JT<
M>I22'(GN/L-HRNOS' $+0)T7E#QW+741TE%%%(84444 %%%% !1110 4444
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MO=6SAXY$/0@CK5^N'8ZM]4%%%% PHHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "ODV\_8)7Q5^T5'\2_
M&GQ(UKQ?I-CJLFJZ1X6OD=H+!FE\U85>29QY*L%^1$0$*HZ#%?659^O^(--\
M*Z+>:OK%]!INF6<9EN+NY<)'&HZDDUO2K5*3?LW:^AG.,9*\NAH45\KZA_P4
MF^#ECKC6"3:Y>0*Q4ZC;Z>#;\'&1N<.0?9*^B? WC[P]\2O#L&N^&-6MM9TJ
M8E5N+9L@,.JL.JL.ZD C-%2C5IJ\XM(BGB*55M0DFS?HHHK W"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH ***Y_P :^/\ PY\.=&?5?$^M66AZ>IQYUY*$#'T4=6//0 FFDY.R$VHJ
M[.@HKR3P=^UG\(O'VLII6B^.M.N-0D<I'#<+);&1AV4RJH;\"<]J];JI0E!V
MFK$PJ0J*\'?T"BBBH+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?]&O>,?^^[O_ .0:/^&W/BM_T:]XQ_[[N_\ Y!K[%HH]M1_Y]+[W_F'L*_\
MS^?W+_(^.O\ AMSXK?\ 1KWC'_ON[_\ D&C_ (;<^*W_ $:]XQ_[[N__ )!K
M[%HH]M1_Y]+[W_F'L*__ #^?W+_(^.O^&W/BM_T:]XQ_[[N__D&C_AMSXK?]
M&O>,?^^[O_Y!K[%HH]M1_P"?2^]_YA["O_S^?W+_ "/CK_AMSXK?]&O>,?\
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M[[N__D&OL6BCVU'_ )]+[W_F'L*__/Y_<O\ (^.O^&W/BM_T:]XQ_P"^[O\
M^0:/^&W/BM_T:]XQ_P"^[O\ ^0:^Q:*/;4?^?2^]_P"8>PK_ //Y_<O\CXZ_
MX;<^*W_1KWC'_ON[_P#D&C_AMSXK?]&O>,?^^[O_ .0:^Q:*/;4?^?2^]_YA
M["O_ ,_G]R_R/CK_ (;<^*W_ $:]XQ_[[N__ )!H_P"&W/BM_P!&O>,?^^[O
M_P"0:^Q:*/;4?^?2^]_YA["O_P _G]R_R/CK_AMSXK?]&O>,?^^[O_Y!H_X;
M<^*W_1KWC'_ON[_^0:^Q:*/;4?\ GTOO?^8>PK_\_G]R_P CXZ_X;<^*W_1K
MWC'_ +[N_P#Y!H_X;<^*W_1KWC'_ +[N_P#Y!K[%HH]M1_Y]+[W_ )A["O\
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M'L*__/Y_<O\ (^.O^&W/BM_T:]XQ_P"^[O\ ^0:/^&W/BM_T:]XQ_P"^[O\
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M]A7_ .?S^Y?Y'QU_PVY\5O\ HU[QC_WW=_\ R#1_PVY\5O\ HU[QC_WW=_\
MR#7V+11[:C_SZ7WO_,/85_\ G\_N7^1\=?\ #;GQ6_Z->\8_]]W?_P @T?\
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M?Y'QU_PVY\5O^C7O&/\ WW=__(-'_#;GQ6_Z->\8_P#?=W_\@U]BT4>VH_\
M/I?>_P#,/85_^?S^Y?Y'QU_PVY\5O^C7O&/_ 'W=_P#R#1_PVY\5O^C7O&/_
M 'W=_P#R#7V+11[:C_SZ7WO_ ##V%?\ Y_/[E_D?'7_#;GQ6_P"C7O&/_?=W
M_P#(-'_#;GQ6_P"C7O&/_?=W_P#(-?8M%'MJ/_/I?>_\P]A7_P"?S^Y?Y'QU
M_P -N?%;_HU[QC_WW=__ "#1_P -N?%;_HU[QC_WW=__ "#7V+11[:C_ ,^E
M][_S#V%?_G\_N7^1\=?\-N?%;_HU[QC_ -]W?_R#1_PVY\5O^C7O&/\ WW=_
M_(-?8M%'MJ/_ #Z7WO\ S#V%?_G\_N7^1\=?\-N?%;_HU[QC_P!]W?\ \@T?
M\-N?%;_HU[QC_P!]W?\ \@U]BT4>VH_\^E][_P P]A7_ .?S^Y?Y'QU_PVY\
M5O\ HU[QC_WW=_\ R#1_PVY\5O\ HU[QC_WW=_\ R#7V+11[:C_SZ7WO_,/8
M5_\ G\_N7^1^+G[77Q#\4_%#XN/KWBKPAJG@:XDLH8K71M56021PKD;E,D<9
M*L_F'(4#)(YQFO%*_;?X_?LT^#OVBM%M[7Q'!-;ZA9AOL6J6;!9X-PY'(PRD
M@':1VXQ7SIX7_P""5_A33=<6YUWQGJ6MZ:K[A8P6BVK,N/NM)O8GGNH7\*]R
MAF-"-)*6ENG]?J?/XC+,1*JY1?-?KM_7R/.?V3_VEOB3\+/@[9:'I?P4\3>/
MM(6ZGFL]6L1<+#L9OFC7;;2*<.).0W4D8XKV/_AMSXK?]&O>,?\ ON[_ /D&
MOK3P[X=TWPCH-AHNCV<6GZ78PK;VUK",+&BC  _Q/)ZFM&O'J8BC4FY.EOYL
M]NGA:U."@JKT\E_D?'7_  VY\5O^C7O&/_?=W_\ (-'_  VY\5O^C7O&/_?=
MW_\ (-?8M%9^VH_\^E][_P S7V%?_G\_N7^1\=?\-N?%;_HU[QC_ -]W?_R#
M1_PVY\5O^C7O&/\ WW=__(-?8M%'MJ/_ #Z7WO\ S#V%?_G\_N7^1\=?\-N?
M%;_HU[QC_P!]W?\ \@T?\-N?%;_HU[QC_P!]W?\ \@U]BT4>VH_\^E][_P P
M]A7_ .?S^Y?Y'QU_PVY\5O\ HU[QC_WW=_\ R#1_PVY\5O\ HU[QC_WW=_\
MR#7V+11[:C_SZ7WO_,/85_\ G\_N7^1\=?\ #;GQ6_Z->\8_]]W?_P @T?\
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M?Y'QU_PVY\5O^C7O&/\ WW=__(-'_#;GQ6_Z->\8_P#?=W_\@U]BT4>VH_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[&-;&.5&&O(Y-_*VY^D'P$^*D7QI^$?AOQ@BQ13ZA;?Z5!"3MBN$)25 "20
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MASLX&0&^-?VHOV8/!?PK_9B\&^--&BO!XLNKBS-_J<UW)(;IIX'D<E2=JX<
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***\$_;.^/GB#]G7X
M7Z7XD\-V>FWM]=:S%I[QZI%))$(V@GD) 21#NS$O?&">/32G3E5FH1W9E4J1
MI0<Y;(][HK\MO^'I7Q6_Z%_P=_X!7?\ \DT?\/2OBM_T+_@[_P  KO\ ^2:]
M+^S,1V7WGF?VMAN[^X_4FBORV_X>E?%;_H7_  =_X!7?_P DT?\ #TKXK?\
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M_P '=M_\71RR[!S+N=U17"_\+X^&G_11/"G_ (.[;_XNC_A?'PT_Z*)X4_\
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M? 74KO6/@9\.K^_NIKZ^NO#FG3W%U<R&26:1K6-F=V))9B222>237S-9^/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M13YNXK=CY>_9;\=?"7_A(KJVTOQ_'X[^*7B0&XU75I;>9)+DQH6,<09 L4*
M':@/0#KQCZ#\=VOB.^\(ZG!X2OK+3?$<D6VSN]1A:6")\C+,HY/RYQVSC((X
M.]10W=W&EI8^?O@S^R_?? 'QC#>>%?%#7N@ZK#_Q4ECJT :2YNE#%;FW*8$9
M+,04.5"GN0*]:^*'AB7QM\,_%WAV @3ZOI%WI\9)P-TL+QCGMRU=/12NV[A;
MH?*'PC_:Z\"?#CX0^&?"GBY]3T'QKX>TNWTFX\-SZ7<&[EF@C6(>4%0JP?8"
M"#CGG%<+XBT74/AG^QKX'O/&$)T:[D\9VFN7UO*IS:1RZ@\^&'7(0@D8R"2,
M9%?=-%7S+L+E/'_"O[77PA\<>(K#0=#\:VNH:M?RB&VM4MIU,CGL"T8 _$UY
M-\'/A+:?&C]E'4_#\LYL-17Q#JEWI>IQ\26-Y'?2M#,I'(PW!QR5+#O7US14
M\UM@MW/D+]D/Q]JMYXN^/'B7QY:_V)J^G-IB:TH5F"/:63132@*"2&\EG &>
M&&,U]3^$_%6E^./#6FZ_HEU]MTC4H%N;6X\MX_,C895MK@,,CL0#5_4+5KZQ
MN;9;B:T::-HQ<6Y DB)!&Y<@C<.HR",CH:H^$_#-AX+\,Z7H.F(\>GZ;;1VL
M"R.7?8B@ LQY9CC))ZDDT-WU&M#Y-\6?%R75/BMXZT/Q[\2/$GP^BTJ^^SZ'
MX8\,62I=:I;>6I6=)O)D>5I#D;4(V^U<'\)XMWP_^ =O<PS1SP?$R_6:WO7W
MSPR*URVV4GGS <$D\YYK] Z*KF\B>4^:/C'H=SXF_:<T[1[*18KS4/AYK-I#
M(QP%>21$4D]L$BO'?B!\=O"MA^Q#/\-[JUO+'QYI^AV^BWGAN2QD$]O-!Y:R
M3O\ )M$?R&3S,X.1R37WS124A\IE^%O^19TC_KSA_P#0!6I114%!1110 444
M4 %%%% !1110 4444 %7=)_X^&_W/ZBJ57=)_P"/AO\ <_J* -:BBB@ HHHH
M **** "BBB@ HHHH **** "BBJFK:M9Z#I=WJ6H7,=G8VL333W$IPL:*,EB?
M84 6Z*^5;K]N:?7-0NU\"?"_7_&>FVI(>^A+QCCJVU(9,#_>(.,9 Z5WWP)_
M:GT#XV:I>:&=.NO#GB6U1I'TV]8-O52 VQL#)4GE2H(Z\X. #VRBBB@ HHHH
M **** "BBN&^,GQ@T3X)^#)?$.MB::/S%M[>UMP#)/,P)"#) '"DDGH >O (
M!W-%?+7A7]N>&[\3:/IWBWP'JG@W3]8(^Q:G<S-(DBL<*^UHDRF2 64L!FOJ
M6@ HKS'5?C=%#\<M*^&FF:5_:=[+:->ZE>_:/+33XPN5RH1M[-\O&5 WISSQ
MZ=0 4444 %%%>#?$']K#2_!OQJ\/_#FQTG^VKS4+RVL[V\6\$2V3S2*BC;L;
M>P#;B,KV&>N #WFBO&_CY^TGIWP1N-)TJ'1KKQ-XEU3YK;2;1]C%,[0Q;:QY
M;(4!220?2H?@3^TU9?&?5=6T*ZT&Z\*^*=-0RRZ3>R;B4!"D@E%8%25!!4$;
MAUH ]JHKS'X(_&V'XOV^OV]QI3>']?T&^>QU#2I)_.,9!(5PVU202K#E1@J?
MK7IU !1110 5S?A6WTB'7O&3Z;<S3WDNK1OJ<<@(6&X^PVBJB?*,KY*P-U;E
MVY[#I*YOPK=:3<:]XR33K26WO(=6CCU*20Y$]Q]AM&5U^8X A:!.B\H>.Y:Z
MB.DHHHI#"BBB@ HHHH ***\O^)7[3GPO^$6J?V;XK\86>FZB "UG''+<S1@\
MC>D*.RY'/S <5<82F[15V1*<::O-V1ZA17$?#/XV>!OC%:SS^#O$EGK@@ ,T
M419)H@>A:)P'4'U(Q1X*^-/@WXB>*O$GAOP]K/\ :&M>'9VMM4M?LLT7V>19
M&C*[G0*WS(PRI(X]*;IS5[IZ;B52#M:2UV\SMZ**\W^*W[17P\^"%YI]IXU\
M1+HUS?QM+;Q?9)[AG52 6/E1MM&3WQGG&<&IC&4WRQ5V.4XTUS3=D>D45G^'
MO$&G^*]!T[6M)NDO=+U"W2ZM;B,$"2-U#*V" 1D$<$9'>M"EMHRD[ZH**X3P
M7\</!/Q"\9>(?"GA_6OM^O\ A^22'4K3[)/'Y#)(8V&]T"MAP1\I/KTYK*^)
M7[3GPO\ A%JG]F^*_&%GINH@ M9QQRW,T8/(WI"CLN1S\P'%:*E4<N51=_0S
M=6FH\[DK=[GJ%%<)\,?CGX#^,D4[^#?$UGK;P*'E@CW1SQJ>C-$X5P,\9(QG
MBN[J)1E%VDK,N,HS7-%W04445)04444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !117D?@3]K#X5?$SQE#X4\-^*UU#Q!-Y@CLS874);RU+. TD2KD
M*K'KV-7&$I)N*O8B52$6E)V;V/7**\Y^+'[0WP^^!]QIL'C;Q"NBS:BLCVR?
M9)[@NJ%0Q_=1OM&6'7&><9P:S8?VJ/A?/J_A/3%\3D7GBJ.*71E?3[I5NUDE
M:),.8@JDNI7#$$<9ZC-*E4:YE%V]"'6IQ?*Y*_J>L45D^+/%>E>!O#6I>(-<
MO%L-(TZ%KBZN65F$:+U.U06)]@"3T KE]%^._@;Q!\,;SXA6.N;_  =:+*\N
MIR6D\0 C.'(1T#M@\?*IR>!DU*A)JZ6A;G&+LWKN=]17GOPG^/W@'XX?VE_P
MA/B!-:.F^7]J7[+/ T>_=L.)44D':W(STKT*E*,H/EDK,<91FN:+N@HHHJ2@
MHK)\6>*M+\#^&]2U_6[K[%I&G0-<W5QY;R>7&HR6VH"Q^@!-5/ 'C_0?BCX1
ML/$_AB__ +3T.^\S[/=>3)%OV2-&WRR*K##HPY Z>E5RNW-;0GFCS<M]3H:*
MY'XG?%CPK\&_#::]XPU3^R-):X6U%Q]GEGS(P8JNV)&;D*W.,<5Y?9_MY? F
M^NH[>/Q[&KR':#-IE[$@^K-"% ]R:TC1J37-&+:]#.5>E3?+.23]3WZBJFDZ
MM9:]IMKJ.FW<%_8748E@NK:021RH1D,K#@@^HJW6)L%%%<1\0OC3X-^%6K>'
M=,\4ZS_9=[X@G:VTR+[+--]HD5HU*YC1@O,L?+$#YO8XJ,7)VBKLF4HQ5Y.R
M.WHHHJ2@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQ'X@\.^$?'G@:QOKWQGX3U-)((],MVGN&A<@Y"("6VR)&<8(PSYXS6M^R#\
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M_P"U_&O]DQ7.HV_]GSP?O5C03MN,2Q\.QX4XYXXKK_VB/^3?_B;_ -BQJ?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MO_PL-7_^2J/^%,Z!_P!!#Q7_ .%AJ_\ \E4>[W#4[JBN%_X4SH'_ $$/%?\
MX6&K_P#R51_PIG0/^@AXK_\ "PU?_P"2J/=[AJ=U17"_\*9T#_H(>*__  L-
M7_\ DJC_ (4SH'_00\5_^%AJ_P#\E4>[W#4[JBN%_P"%,Z!_T$/%?_A8:O\
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M .%AJ_\ \E4>[W#4[JBN%_X4SH'_ $$/%?\ X6&K_P#R51_PIG0/^@AXK_\
M"PU?_P"2J/=[AJ=U17"_\*9T#_H(>*__  L-7_\ DJC_ (4SH'_00\5_^%AJ
M_P#\E4>[W#4[JBN%_P"%,Z!_T$/%?_A8:O\ _)5'_"F= _Z"'BO_ ,+#5_\
MY*H]WN&IW5%<+_PIG0/^@AXK_P#"PU?_ .2J/^%,Z!_T$/%?_A8:O_\ )5'N
M]PU.ZHKA?^%,Z!_T$/%?_A8:O_\ )5'_  IG0/\ H(>*_P#PL-7_ /DJCW>X
M:G=45PO_  IG0/\ H(>*_P#PL-7_ /DJC_A3.@?]!#Q7_P"%AJ__ ,E4>[W#
M4[JBN%_X4SH'_00\5_\ A8:O_P#)5'_"F= _Z"'BO_PL-7_^2J/=[AJ=U17"
M_P#"F= _Z"'BO_PL-7_^2J/^%,Z!_P!!#Q7_ .%AJ_\ \E4>[W#4[JBN%_X4
MSH'_ $$/%?\ X6&K_P#R51_PIG0/^@AXK_\ "PU?_P"2J/=[AJ=U17"_\*9T
M#_H(>*__  L-7_\ DJC_ (4SH'_00\5_^%AJ_P#\E4>[W#4[JBN%_P"%,Z!_
MT$/%?_A8:O\ _)5'_"F= _Z"'BO_ ,+#5_\ Y*H]WN&IW5%<+_PIG0/^@AXK
M_P#"PU?_ .2J/^%,Z!_T$/%?_A8:O_\ )5'N]PU.ZHKA?^%,Z!_T$/%?_A8:
MO_\ )5'_  IG0/\ H(>*_P#PL-7_ /DJCW>X:G=45PO_  IG0/\ H(>*_P#P
ML-7_ /DJC_A3.@?]!#Q7_P"%AJ__ ,E4>[W#4[JBN%_X4SH'_00\5_\ A8:O
M_P#)5'_"F= _Z"'BO_PL-7_^2J/=[AJ=U17"_P#"F= _Z"'BO_PL-7_^2J/^
M%,Z!_P!!#Q7_ .%AJ_\ \E4>[W#4[JBN%_X4SH'_ $$/%?\ X6&K_P#R51_P
MIG0/^@AXK_\ "PU?_P"2J/=[AJ=U17"_\*9T#_H(>*__  L-7_\ DJC_ (4S
MH'_00\5_^%AJ_P#\E4>[W#4[JBN%_P"%,Z!_T$/%?_A8:O\ _)5'_"F= _Z"
M'BO_ ,+#5_\ Y*H]WN&IW5%<+_PIG0/^@AXK_P#"PU?_ .2J/^%,Z!_T$/%?
M_A8:O_\ )5'N]PU.ZHKA?^%,Z!_T$/%?_A8:O_\ )5'_  IG0/\ H(>*_P#P
ML-7_ /DJCW>X:G=45PO_  IG0/\ H(>*_P#PL-7_ /DJC_A3.@?]!#Q7_P"%
MAJ__ ,E4>[W#4[JBN%_X4SH'_00\5_\ A8:O_P#)5'_"F= _Z"'BO_PL-7_^
M2J/=[AJ=U17"_P#"F= _Z"'BO_PL-7_^2J/^%,Z!_P!!#Q7_ .%AJ_\ \E4>
M[W#4[JBN%_X4SH'_ $$/%?\ X6&K_P#R51_PIG0/^@AXK_\ "PU?_P"2J/=[
MAJ=U17"_\*9T#_H(>*__  L-7_\ DJC_ (4SH'_00\5_^%AJ_P#\E4>[W#4[
MJBN%_P"%,Z!_T$/%?_A8:O\ _)5'_"F= _Z"'BO_ ,+#5_\ Y*H]WN&IW5%<
M+_PIG0/^@AXK_P#"PU?_ .2J/^%,Z!_T$/%?_A8:O_\ )5'N]PU.ZHKA?^%,
MZ!_T$/%?_A8:O_\ )5'_  IG0/\ H(>*_P#PL-7_ /DJCW>X:G=45PO_  IG
M0/\ H(>*_P#PL-7_ /DJC_A3.@?]!#Q7_P"%AJ__ ,E4>[W#4[JBN%_X4SH'
M_00\5_\ A8:O_P#)5'_"F= _Z"'BO_PL-7_^2J/=[AJ=U17"_P#"F= _Z"'B
MO_PL-7_^2J/^%,Z!_P!!#Q7_ .%AJ_\ \E4>[W#4[JBN%_X4SH'_ $$/%?\
MX6&K_P#R51_PIG0/^@AXK_\ "PU?_P"2J/=[AJ=U17"_\*9T#_H(>*__  L-
M7_\ DJC_ (4SH'_00\5_^%AJ_P#\E4>[W#4[JBN%_P"%,Z!_T$/%?_A8:O\
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M .%AJ_\ \E4>[W#4[JBN%_X4SH'_ $$/%?\ X6&K_P#R51_PIG0/^@AXK_\
M"PU?_P"2J/=[AJ=U17"_\*9T#_H(>*__  L-7_\ DJC_ (4SH'_00\5_^%AJ
M_P#\E4>[W#4[JBN%_P"%,Z!_T$/%?_A8:O\ _)5'_"F= _Z"'BO_ ,+#5_\
MY*H]WN&IW5%<+_PIG0/^@AXK_P#"PU?_ .2J/^%,Z!_T$/%?_A8:O_\ )5'N
M]PU.ZHKA?^%,Z!_T$/%?_A8:O_\ )5'_  IG0/\ H(>*_P#PL-7_ /DJCW>X
M:G=45PO_  IG0/\ H(>*_P#PL-7_ /DJC_A3.@?]!#Q7_P"%AJ__ ,E4>[W#
M4[JBN%_X4SH'_00\5_\ A8:O_P#)5'_"F= _Z"'BO_PL-7_^2J/=[AJ=U17"
M_P#"F= _Z"'BO_PL-7_^2J/^%,Z!_P!!#Q7_ .%AJ_\ \E4>[W#4[JBN%_X4
MSH'_ $$/%?\ X6&K_P#R51_PIG0/^@AXK_\ "PU?_P"2J/=[AJ=U17"_\*9T
M#_H(>*__  L-7_\ DJC_ (4SH'_00\5_^%AJ_P#\E4>[W#4[JBN%_P"%,Z!_
MT$/%?_A8:O\ _)5'_"F= _Z"'BO_ ,+#5_\ Y*H]WN&IW5%<+_PIG0/^@AXK
M_P#"PU?_ .2J/^%,Z!_T$/%?_A8:O_\ )5'N]PU.ZKXZ_P""I7_)O_A__L9[
M?_TDNZ^B_P#A3.@?]!#Q7_X6&K__ "57RA_P4F^'^F>%?@;H=W976MSROXC@
MB*ZEKU]?1[3:W1R(YYG4-\H^8#.,C."<]N#M]8AZG#CK_5I^A\/_  /U[Q=8
M>)=5\/\ @NUM;[5_%^D7/AM[>Z9%\R&<*75&=U57/EC:2>O&"2*^\&?]J_X6
M^$_!7A[PKH&B^(M/M?#UE')NMH8GL95CV&U<M=?O&0(N9% 5MW K\T+.\GT^
M[@NK6>2VNH'66*:%RCQNIRK*PY!! ((]*_2;PWX9^-GQ*^'_ (-\5>(OCII_
MPXAOM(MQ:VMNAWW46W<EQ.7E4-,ZL"Q7C 7CK7T&-BDXR?+;S3?Y'S> DY*4
M5S7\FEI\SPO]NJ;XF7_A7X5ZA\3Y=/MM9NEU,KH]G9K$]B5>W5M\BS2+*'41
ML"-N.0>>GR/7TA^V7\/=7\&ZEX9O]:^+:_%6[U);E!(KY^PK%Y.  )7"A_,S
M@!>4)Y)KPOP+X9_X37QMX>\/?:X]/_M;4;>P^URC*0>;*J;V&1D+NR>1TKKP
MUHT$^FNRMU./%<TJ[36NF[N]EU/MO]FCX=_'O]G_ .'UQKNC^&(?$5KJFK1I
M+X.NVC):(0"1-0BG63:OS;4Z'. << BW^U%JWQB^(OP!\7ZEXM\-6OPQ\.:/
M<V5P^CQJL\NL22SB,EIUDX",R.5V<G!R<<:OP%TCXK:Q\-?$'@O1_C+I'AVS
M\(^*KO1;;4+BT\V[EAMT1 B,TNT6YW[E7:6!7 ?;\M<O^U7\)_B7I_P8UC6/
M%/QU@\9Z7IKP2'1((5A^T,\\<8)"-\VTON^8'&WC'6O)4E+$)R<;W71W_P C
MV'%QPS45+EL^JM_F?"%?KA^PG_R:KX(_[?O_ $NN*_(^OUP_83_Y-5\$?]OW
M_I=<5OFW\!>OZ,Y\G_WB7I^J/>Z***^4/L HHHH **** ,[Q)H__  D'AW5-
M*\W[/]NM9;;SMN[9O0KNQD9QG.,BN=^#?PZ_X5)\+_#G@_\ M#^U?['M1;?;
M?(\GS<$G=LW-MZ]-QKLZ*?D!X-KW[+LFL?"7XB^"HO%/V67Q=XFF\1IJ/]G;
M_L9>\BN1%Y?FCS,>5MW;ESNSCC!H^(/V=/B5\0=*FT'QK\;)M5\+W>%O]/TK
MPU;Z?-<QYR8_.$CE5/?"\_3@_0]%/F9/*CQOQ-\ =2M_&4'B?X>^,&\"ZC_9
M4.C7%M+IJZC9SV\))A_=,Z%70' 8-TXQUSB:/^R;!INI>$;BY\4W&IQ:7XCN
MO%VK+<6:A]6U650(YLJP6%8R 0@1NG4=:]_HHYF.R.%^-_PIM/C9\,=:\(7=
MT=.-\B-!?I%YCVLR.KQRJ,C)#*. 1D$C(S7SKXZUC3OA/\5M6ED^*M[\-/$M
MYIMC'K-]J?AM;K3O$;QPA1=VB[SLE7YD*DDY&-K@;C]B44*5A-'@'[$_A>^\
M-_"?5KB\&H&'6?$6H:K92ZNA2\GMI) L<LRD AW";SP/O9Q@UZ%IOPM_L_XV
M:U\0?[3\S^TM&M])_L[[/CR_*D=_,\S=SG?C;M&,=37>T4-W=QV/$=0_9<TK
M7M)^(VGZMK%Q-'XLUQ=>M[BTB\B?2[A$C$;1ON;<RM&#NP,@D8I^@_ /Q)?>
M./#WB+Q_\1)O&J>'2\NE:?#I,>G0K<,I3SYMCMYKA2<?= /('4'VNBCF861\
M#^*O$F@>$](\?^$M!^)?B#P=8WMS? _#>X\.B756N)-V^*RG4MMAF8Y4J& #
M9!7DUZ_X-_9I\2V?A/X5Z[I'BH^"/'6@>&(M$O?/TU-0@DA8+(T+Q,Z89),_
M,K=O2OIFBGS"Y3POPI^S)<:+X@\?ZMK'C6^\1W7C71ETO4IKBT2*5) )$\R(
MJVQ$"2!5CV<; =QR:7P5^SEJ_AVZ^%$VK^-(];_X5[]K@LQ'I MC/:RV2VL4
M3$3-AHP-Q?G=G&!UKW.BES,?*CQ_Q-^SCIOB3X_Z#\37U-X5TZ%/M&B^1NBO
M+F))DM[AGW##1K<2 ?*?X>1CF;QY\#]2U;XA+XZ\%>+I/!/BB:R73K^1]/2_
MM;^!6W()(69/G4DX=6!QQR.*]:HHYF%D>#7'PI\1?"'X,^.KCPUXDU36OB5K
M,C:C+KPTZ*XGNKS*JB);']VD>T! "2J!BQ.!Q[CIRW"Z?:K=L'NQ$HF9<8+X
M&XC'OFK%%*]PL?.FF?LI^(-#\.ZOX,TSXH7NG_#K4)KF3^QH-)B^V11SNSR0
MB\+D["6;)V;L$C<*Z'P%^SB_@O6/AA?R>(UOF\$Z'<Z($6P\H7@EV 29\UO+
M*A!Q\V<]17M5%/F8<J/)M:_9ZTOQ1XT^(6K:U>F^TKQEHUMH]QIBP;&@6(./
M,67<<L2X(^4;2H/-<'K7[*/C'Q59^%M+UWXOWFJ:'X:U&TO["S?1(D>7R'!4
M7$JR9E;9E0WR@$[BK&OI6BCF8604445(PHHHH **** "BBB@ HHHH *NZ3_Q
M\-_N?U%4JK7WAFS\50BTO9M0@B1O-#:;J5S8R;@",&2"1&*_,?E)QG!QD# !
MUE%<+_PIG0/^@AXK_P#"PU?_ .2J/^%,Z!_T$/%?_A8:O_\ )55[O<G4[JBN
M%_X4SH'_ $$/%?\ X6&K_P#R51_PIG0/^@AXK_\ "PU?_P"2J/=[AJ=U17"_
M\*9T#_H(>*__  L-7_\ DJC_ (4SH'_00\5_^%AJ_P#\E4>[W#4[JBN%_P"%
M,Z!_T$/%?_A8:O\ _)5'_"F= _Z"'BO_ ,+#5_\ Y*H]WN&IW5%4=%T>#0=,
M@L+:2ZE@A!"O>W<MU*<DGYI969VY/\3' P.@%7JDH**** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KF_"
MMUI-QKWC)-.M);>\AU:./4I)#D3W'V&T977YC@"%H$Z+RAX[GI*YOPKK%OJ>
MN^,;:'3HK&33M5CM9IX\;KQS8VDHE? '(658^2>(EYZ -=1'24444AA1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MJI"* K<L0/E/H:Z6ODS]GV\?XH?M8?%/QA<_Z1#H:_V38LW B0R-&A4'D$K
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MF1W" 4G@K1K+X7_M[7V@^';6/3-%U;3"7L;?Y8D_T<2G"]!\\9( Z;B!@<4
M?4G@/XC>'?B;H\FJ>&M274K*.9K:1O*DB>.1<;D9)%5E/(ZCN*Z2ODSX-WC_
M  X_;,^(_@J+Y-(UN/\ M2&&/[B3%4FX ^Z,2RK_ ,!7VKZSH **** "L+P[
MJFIZAK'BB"_M/LUK8ZBEOI\GE,GVB VEM(7R3AL2R3)E<#Y,=0:W:PO#JZT-
M8\4?VJ<V)U%#I/W/^/7[);;ON\_Z_P"T?>Y_X#MIKJ(W:***0PHHHH ****
M"N?\5?$+PMX%$1\2>)='\/B7F/\ M6_BMM_TWL,T[Q[XH7P3X%\1>(G02II&
MFW.H,AZ,(HFDQ_X[7P?^R'^SSH?[5&G^)?BC\6);OQ5J%YJ<EI%:M=RP1KM1
M&+$QLK8&\*JA@JA>AR,==&C&4)5*CM%?><=:M*$XTJ:O)]]C[[\/^*-&\6V
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M;-M &_;NXZUSVG_LB_"72X4C@\)@F)XI(9IM1NY9;<QR+(@AD>4M$H9%.U"
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MH_!'X<ZH_P"T1\:WU_P_J5OX>UK[3 EQ=6TL,-W').01')@;LJ3RIZ<BN_\
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M'/"M&LQ]5,+K(1_L"OV2HHACG&I.IR_%^#">7J=.%/F^'\5U1^?_ .VQ9?\
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MME_Z/6O*OA3_ ,%(/AIX&^%_@_PW?Z'XKFOM'T:ST^XDM[2V:)I(H$C8H3<
ME25.,@''85]W45VTZ]-4O95(7UOO;]#AJ8>HZOM:<[:6VO\ J?G=^W)\7-'^
M(O@7X%>/]-MKZ#1KG4;N[2"ZC1;@)')"K JKE<Y0X^;TK9^+_P#P4$T7XO?#
MO7/!/P\\'>)M0U_Q!:2:9B\M8L1QRKL<JL4DC.Q5F &!@D'/&*^^**TCB::C
M%.G?EO;7SOV,I86JY2DJEN:U].RMW/$OV.?@_J'P3^!.C:%K""+6KB234+Z$
M$'RI)",1Y'4JBH#[@UXC_P %(N=:^"H/(_MN;_T*VK[;HK&&(<:WMI*[U_$W
MJ892H>PB[+3\#XE_X*1?\ASX*_\ 8;F_]"MJ3XY_\I)O@]_V!(__ $9?U]MT
M5<,5RPC'EV37WF<\)SSE/FW<7]W^9^?G_!0C2M7^$'Q+T?XI>&C]F?Q!I5WX
M>U&11_&T#1JQ/]XQOE?0VXKUKPI^S/>P?L*S_#JS18/$FL:9]OF60[=UZ[+.
M(V)Z8VI$3VVYKZIHH>+E[.$$M8]>]MON!8./M)S;TET[7W^\_-SP-^V!<?"7
MX"3?![6O &N1^/;2TN=*M+?R D4GF&3:[J2'!7?T56W;<[AGCZ<_83^$.M_!
MSX"V^G^(8'LM6U2^EU26RE^_;!TC148=FVQ*Q'8M@\@U]#T45L2JD7&$;7=W
MK<*.%=.2E.?-RJRTM_PX4445PGH!1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %?)/\ P4X_Y-RM/^P]:_\ HJ:OK:BMJ-3V
M-2-2U[&%>G[:G*G>US\JOVP/"=_X;TWX/ZOH226Z^*?!%CHD\<''G&%83L_$
M/"N/1/K7HOQ$\#VWPZ_;F^ F@VIREGH6EVYV_=S$]Q%D<#J(P>><DFOT0HKN
M^O/E4>79-??_ )'G_P!GKF<N;=I[=O\ ,^'/^"BGA^^\"^*/AM\9M$B4WVAW
MT=G<$CAMKF> -_LY693_ +X'>J'['UP_PE_9M^)GQRUX+/JVMR7%Y$\JX,WE
MLZH,]O,N9'4_1>M?>5%9K%_N51<?^&O>QL\'^_==2^79VM<_-#]E7]DOQW\3
M_ $WQ!TSXN:U\/KC7KJ;S(],@EWWBQNP\UW2XBS^\,N!@XP3GG%;?P"T?5/V
M1?VTI_ .N:S)K6G>+K-%359H6A^UROEXI2I9OF\U9HOO-DL3WX_12BKECIU'
M-37NRZ::=M;=#..7PIJ#@[2CUUU[Z7ZA1117F'JA1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %?'7_!4K_DW_P__P!C/;_^DEW7V+7QU_P5*_Y-
M_P##_P#V,]O_ .DEW7;@O]XAZG!CO]VGZ'Y;5]X?"W]E'P+K/B#X,6ESIMQ/
M OA5_&OBF]N2Q@NTG$?V6WW9 4(RR94 94'.=V1\??#KX7ZO\3O^$G_LF6UB
M_P"$>T.Z\07?VJ1DW6\&W>$PIR_SC .!UY%?>GP\\"_M+^(OV:]$\,:3J/@9
M/#>KZ%$EIJ%Q)<IJ45E/$&2(LJ[ 5C?9G:2!W)YKZ;&5'%)1G;Y]T?+8&FI-
MN4+_ "OLSYR_:^\/^!=0\-_#3XD> _#C>$].\86U\)M)V+&B/:RI'O"+\J[M
MY^[P0%.,DD_--?3G[9_@?XE>!-+^&.F>.Y]#_LS3](.D:-;:)+)(%6VC@666
M4NBG?(6C/''RXP,9/S'71A?X2L[[^?4Y<7I6=U;;RZ(****ZCD"OUP_83_Y-
M5\$?]OW_ *77%?D?7ZX?L)_\FJ^"/^W[_P!+KBO%S;^ O7]&>[D_^\2]/U1[
MW1117RA]@<)\3OCIX$^#+:6OC/Q';:$^IR&.T69'=I",;CA%8JHR,LV%&1DU
MW,4J3Q))&ZR1N RNIR&!Y!![BO(/CU^RMX'_ &C+K1+KQ4NH17.DEA%-IUP(
MFDC8@M$^5;*DC/&&'.",FO6K&Q@TVQM[.UC6&VMXUBBC7HB*  !] !3TMH+6
MY/1112&8/C^YFL_ ?B2XMY7@GBTVYDCEC8JR,(F(8$<@@]Z\._9I_:,\$_\
M"A_!?_"6?$_0/^$C^P#[=_;/B"#[7YFYO];YDF_=C'WN:]L^)'_)._%/_8*N
MO_1+5XI^R3\*O!6M?LW^ +[4/!^@W][/IJO+<W6F0222-O;EF922?K5JW+J2
M[W/,O$7Q.UC4OV4?C=XAT_QEJ+>3X^N(--UNRU1]T%D=3M506\ZM\L7E.0-I
MV[6..#4'Q$OM"\ Z-;:M\*?V@/$?C;QX+VVATWPU-XL37(M29YD5HGMQG V%
MCOXQ@\UE^*[:QT?]D+]H"WC@AM=-M?B3<QK!'&%BCB75[0!0H& H48P!T%:7
MQP^(W[/?Q"^&FKZ'\/-,TO6O'ETBKH</AK07COH[O</+D21(E*!3@D[AQQSG
M%:HS/ICX@?'C2_ WBR/PQ:^'O$7B_P 0&T%_-I_ANR2X>VMRQ59)2[HJ[F#
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MP:K86U[:R":UN8EFBD (#(P!4\^H(JQ6184444 %%%% !1110 4444 %%%%
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M+_Z&WPI_X2US_P#+&NZHJN9D\J.%_L?XE_\ 0V^%/_"6N?\ Y8T?V/\ $O\
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ME_\ 0V^%/_"6N?\ Y8T?V/\ $O\ Z&WPI_X2US_\L:[JBCF8<J.%_L?XE_\
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MM<__ "QKNJ*.9ARHX7^Q_B7_ -#;X4_\):Y_^6-']C_$O_H;?"G_ (2US_\
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M?"G_ (2US_\ +&NZHHYF'*CA?['^)?\ T-OA3_PEKG_Y8T?V/\2_^AM\*?\
MA+7/_P L:[JBCF8<J.%_L?XE_P#0V^%/_"6N?_EC1_8_Q+_Z&WPI_P"$M<__
M "QKNJ*.9ARHX7^Q_B7_ -#;X4_\):Y_^6-']C_$O_H;?"G_ (2US_\ +&NZ
MHHYF'*CA?['^)?\ T-OA3_PEKG_Y8T?V/\2_^AM\*?\ A+7/_P L:[JBCF8<
MJ.%_L?XE_P#0V^%/_"6N?_EC1_8_Q+_Z&WPI_P"$M<__ "QKNJ*.9ARHX7^Q
M_B7_ -#;X4_\):Y_^6-']C_$O_H;?"G_ (2US_\ +&NZHHYF'*CA?['^)?\
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MM<__ "QKNJ*.9ARHX7^Q_B7_ -#;X4_\):Y_^6-']C_$O_H;?"G_ (2US_\
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M?"G_ (2US_\ +&NZHHYF'*CA?['^)?\ T-OA3_PEKG_Y8T?V/\2_^AM\*?\
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M_P#'A_C0!6HJS_9]Q_SS_P#'A_C1_9]Q_P \_P#QX?XT 5J*L_V?<?\ //\
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M2?N?\>OV2VW?=Y_U_P!H^]S_ ,!VUNT4P"BBBD 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
;%%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>brns-20231231_g6.jpg
<TEXT>
begin 644 brns-20231231_g6.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /W4TKXQ
M:'KEA'=6/]L7EK+G9-!HUY)&^"0<,(B#@@CZBK'_  LO3?\ GV\0?^"&^_\
MC-<_^RW_ ,D)T+_MX_\ 2B6O0* .?_X67IO_ #[>(/\ P0WW_P 9H_X67IO_
M #[>(/\ P0WW_P 9KH** .?_ .%EZ;_S[>(/_!#??_&:/^%EZ;_S[>(/_!#?
M?_&:Z"B@#G_^%EZ;_P ^WB#_ ,$-]_\ &:/^%EZ;_P ^WB#_ ,$-]_\ &:Z"
MB@#G_P#A9>F_\^WB#_P0WW_QFC_A9>F_\^WB#_P0WW_QFN@HH Y__A9>F_\
M/MX@_P#!#??_ !FC_A9>F_\ /MX@_P#!#??_ !FN@HH Y_\ X67IO_/MX@_\
M$-]_\9H_X67IO_/MX@_\$-]_\9KH** .?_X67IO_ #[>(/\ P0WW_P 9H_X6
M7IO_ #[>(/\ P0WW_P 9KH** .?_ .%EZ;_S[>(/_!#??_&:/^%EZ;_S[>(/
M_!#??_&:Z"B@#G_^%EZ;_P ^WB#_ ,$-]_\ &:/^%EZ;_P ^WB#_ ,$-]_\
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MH Y__A9>F_\ /MX@_P#!#??_ !FC_A9>F_\ /MX@_P#!#??_ !FN@HH Y_\
MX67IO_/MX@_\$-]_\9H_X67IO_/MX@_\$-]_\9KH** .?_X67IO_ #[>(/\
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M^1:Z"B@#G_[2\5?] ;P__P"#F;_Y%H_M+Q5_T!O#_P#X.9O_ )%KH** .?\
M[2\5?] ;P_\ ^#F;_P"1:/[2\5?] ;P__P"#F;_Y%KH** .?_M+Q5_T!O#__
M (.9O_D6C^TO%7_0&\/_ /@YF_\ D6N@HH Y_P#M+Q5_T!O#_P#X.9O_ )%H
M_M+Q5_T!O#__ (.9O_D6N@HH Y_^TO%7_0&\/_\ @YF_^1:/[2\5?] ;P_\
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M\5?] ;P__P"#F;_Y%H_M+Q5_T!O#_P#X.9O_ )%KH** .?\ [2\5?] ;P_\
M^#F;_P"1:/[2\5?] ;P__P"#F;_Y%KH** .?_M+Q5_T!O#__ (.9O_D6C^TO
M%7_0&\/_ /@YF_\ D6N@HH Y_P#M+Q5_T!O#_P#X.9O_ )%H_M+Q5_T!O#__
M (.9O_D6N@HH Y_^TO%7_0&\/_\ @YF_^1:T/">N_P#"4>%=,U/RO(_M&TBN
MO+W;O+WH&VYP,XSC.!6A7/\ PF_Y)7X9_P"P5:_^B4H Z"BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH \_\ V6_^2$Z%_P!O'_I1+7H%>?\
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M_&_]G/7?#OBS]J27P[XU\4Z5IFIZG\1=66/3?$27,L2N+6PWRDP/#(765Y9
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MZ1G;9YLLD\J*,'+I&S.OF&6(X/FM:6][;]-RY8BU[K:WXGZ@45^5/PM_:O\
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M??N?JEXX\::9\-_!6L>(M:NEL=&T&RFU&_N2C.+>WAC:21RJ@L=J*QPH)..
M37FG[&/[;?@O]NOX;ZAXG\%KJT%GI>HMIES;ZG#'#<QR"..3=L1W&QED&&SR
M58=C7QY_P5>_;5L1_P $U?ASH>A^.(M>N/C-%;65QXF:TEM/M=E;+$;^Z:.
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M50C!WALVU]S-*%64M)=E^)XQ^QC^V-_PUW^R9:_%'_A'/^$>^T_;?^)9]O\
MM>W[/)(G^M\M/O;,_<XSWKPSQ=_P65_X1;_@GMX7^/'_  KCS_\ A)/$3Z!_
M8?\ PD&W[-M^U?O?M'V8[L_9ON^6/O\ 7CGYQ_X)Q_L??%[XJ?L$V/B3PM^T
M1KO@/PW(-2V>';?0%NH8_+FE$G[TW"']X02?EXW=Z\N^+?\ RKV_"_\ [*'-
M_P"Y.NN.%H^T:W]Y+KHM=#GEB*G)?;2_378^S!_P6C\2?"W7]'D^,W[//COX
M5>#]6O5L&\0SW$M[#:RL"1NC-K$6 568JC-(41RJ.5VG[=\5^/-#\!VT,VN:
MSI.BPW$GE1/?7<=NLK_W5+D GV'-?D#^W!I\OPZ\ :#XSU;]JWX>_M,1^$=<
MM[V/P'JKQM::@Q#()6@M+R0S&/<"5D"IL,H+$,8I?1/VUOV<?$/Q]_;^U#Q3
MX=TGP'\:]0N_#6GQZC\+_$.M2:=K7A&U:*%I&3]]$D6"ZL',A99-08^2V!)4
M3PM.5FM%KWZ6[V[[O0J->:NGKMV_3_AS]3T=9$#*0RL,@@\$5\F?L0?\%9O#
M?[:_[1_C;X?Z=H3:6GA]9[K0]5%^;B+Q'9PW)A,X1HHVA8JT+B/+G#ODC8<_
M,_A']NGPU\,_^"&6KR_#W3?$7A^^&J7'P_T^UU743J4T5[=?Z1+)#<Q"+.+6
M:66-A'&%E7;L8#+_ #[IWC[Q5^RGJW[/OCR'X!_%/P##\$8C8>*=>U72+AH]
M:M+NX)N$!FACBA+/=WR1[CD&[C7?E%-%+ W4E+>]E\O\]%U"IBM8N.V[_K\3
M]OO$/BO2_"-O!-JVI:?I<-U.EK"]W<)"LLKYVQJ6(!=L'"CDXK0K\V_B)H/A
M+]K?_@LSJ7AWXO'2M;^&]C\/8]3\ PW6IM;Z?J0E%I+)=6Y215N&;-]EESE+
M8'D0JRG_  0?TCP_X>_:(_:JT_PC<077A/3_ !#8VNB2P7)NHI+%+C54MRDI
M+>8OE!,/D[A@Y.:YY85*FYWU23VTU?<V6(;GRVZM?<?I)1117&= 4444 %%%
M% !1110 4444 %%%% !7/_";_DE?AG_L%6O_ *)2N@KG_A-_R2OPS_V"K7_T
M2E '04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'G_[+?_)"
M="_[>/\ THEKT"O/_P!EO_DA.A?]O'_I1+7H% !1110!Y#^UI^Q9X6_;0@\(
MV?C*_P!>_L/PGJZ:U_9%G+ EGJTR<*MT'B=V0(94Q&\9*S29).TKT'[3O[.7
MA[]K3X':Y\/_ !2VH1Z+KZQ":6QE6*YA:*5)D>-F5E#!XU/*D$9!!!-=]15^
MTDK6>VQ/)'7S/GSPK_P3>\&>%?CU\+_B,NN^,K[Q!\)_#$?A/25NKJV:WNK1
M(;F%7N L"L\H2Z?YE9 2J$@_-NZ']B;]B;PK^P9\*M0\'^#]0\0:EINI:M)K
M$LNL3PS3K,\,,)53%%&NS; A *DY+<] /8J*<JTY*S?]?TQ1IQ3ND>8C]E#P
MZ/VN#\9_MFM?\)0?#O\ PC/V7SHOL'V;SO.W[/+\SS-W&?,VX_A[UUWQ6^%^
MB_&OX:ZYX2\16:WVA^(K.2QO82=I:-UP2IZJPZJPY5@".0*Z"BIYY-I]A\JV
M/C_P]_P1?\ :%-X/GF^('QEUF[^'NIVFI>&9=4\117:Z"+<AA;V\+6_DI"[)
M 741[O\ 1H@K*NX-[5\"OV0/#7[/GQB^)GC;1;[7+K5?BK?07^K17LT3V]O)
M"9RH@5(U95/GOG>SGA>1SGU:BM)8BI)6DR8T81U2/F'5?^"4O@.Z^+OQ%\6Z
M=XJ^)'A]?BI:WUMXDT33=8BCTC4#=VD]M)*\+0LSR*US-.F]V5)7) "_)5BZ
M_P""57PSN_V5_!_PI:\\61VOP_OY-3\.^(X+Z.#Q!I%R]T]RTD5PD2H,M(5Q
MY9&%1L;T1U^EJ*/K%3N'L8=CYN^&/_!+SP#\./#WQ(AN-<\=>+/$7Q3T:?P_
MK7BGQ'JJ:AK@L9;<0&&*=H@JJ%"D;D;)2/=N5$5?G/\ ;4_X)[-I7C7]D/X;
M^%=-\?ZQX(\'ZEJMMJ&M6:2/=Z-%+-92)<2W5O&J0.&#LCD*,Q=]IK]':*J&
M*J1ES-W_ .&L3*A!JUOZO<^<?@I_P2^^'?PAO?'E]J.I>-OB'K7Q(TE]!US5
M_%NLF]U"YT]XUB>V$\:Q,JLB(-V=X\M,, H \[M/^"'/PZMO#.AZ6WQ&^-EU
M#X4OHK_P^;CQ'!*F@.A9F%K"UMY$8D<H['RRVZ%,%07#_:5%+ZU53OS#]C3V
ML>4^!OV/O#/@#]K'QM\8K.^UV3Q-X\L;;3]0M9IHFL(8X(X(T,2",2*Q$"9+
M2,,EL < >7^%O^"1/PS\*?L<>(_@C#JOC.X\*^)M877)[R>[MCJ5M<+]GQY3
MBW$87%L@PT;'#OSR,?4U%2JU1;/M^&WW#]G%]._X[GRSXQ_X).^$?&8\(ZA-
M\1OC5:^-/!MC-IEOXRMO%97Q!>VDD\\_D3W!B*LJ-<2JI5%;80I+!0*]/_9.
M_8W\(_L=^%]7L?#<FL:MJGB2_DU36]>UNZ%YJVMW#LS;[B<*N[;N; "@99F(
M+N[-ZO11*M4DN5O0(TH)W2/G?]IO_@FEX)_:G^/&F?$C6/$'CW0?%.B:,NC:
M=<^']673VL0LLTJW$;B,R"8&>09W[,8!0]37^%W[.'A#_@F#\(O'7BCP[I/Q
M0^)FL:_?PZCK4D2KKGB;7)7F$:X51$)-C3RRL3AL-*Q+5](44_;SY>1O3L'L
MHWYDM3X/_P""*_[(6I?"FX^*'Q2U[P5>?#ZX^(6M2QZ#X;U"U,=YH6EI-)($
M+,1(%=Y%38\<9(LT?E9%Q]F?%WX1>&_CS\-]6\(^+M)M]<\.ZY$(;VRF9E65
M0P=2&4AE96565E(964$$$ UTE%%6M*<_:=0ITU&/(?&>D?\ !#WX8HGAZQU[
MQM\8O&?A?PQ,);#PUKOB1)M'BP& 40QP(44;CQ&RYY!R"0?4/VF?^">'A']I
M?XJ:7XZ;Q)\0/ 7C32[$Z8-;\':U_9EY<VI+,(9&*."H+-RH5B&P2P"@>^44
M/$56[MA[&"5K'RCXF_X(Y_"?Q)^R?IGP?6]\86'A_3_$'_"437]M?0'4M2OS
M#) 9)Y)(6C.8Y ,)&O\ JTZ8.?6OVL?V//"'[8W@W3=+\3-JVFWV@W\>IZ-K
MFC77V/5=%N48'S+>;:P7( !#*PX5L!T1E]4HH]O4;3OM^H>RA:UCP'X$?\$W
MOA]\$H?'$UY=>*?B%K?Q&LSI>O:[XPU+^TM5O; PB$V?GJB%82BC('S-M3+$
M1QA.)^$G_!&[X:_"?Q_X/UMO%7Q0\367P_O'U#PYH.N:\ESI&C3EQ('AA6%"
MA60*^ V&9 6W5]:44?6*FNNX>QAV/,?@W^RCX=^"'QJ^)7CO2;S6KC5_BE<V
M=UJT-W-$]M;M;+*L8@58U901*V=[/G QCG/DNK_\$A_AKK/[)/AOX,RZYXX7
MPOX7\0'Q':W27EK]ODN")QM=_L_EF/\ TA^!&#POS=<_5%%)5JB=T^WX:('2
M@U9K^F>0>"_V*_"O@7]L?Q?\;[/4/$$GBSQII<6DWUI-/"VGQ11I:H&C01"0
M-BTCR6D899^.1CY]^//_  3LTK]F[_@GKXV\"> ?!^K?%S3M8UUO$FHZ/JNI
MB'523%&C2:?+;P+B>(P0NJ,C;U$R8DWB)ON&BG'$3BT[]OPV"5&+5O7\3\G/
MV6/V5+SXF?MF? W5-'^&?[0'AW3?AY%->^)/$'Q.9_,58X%^Q:?:%O+1K>&5
M"B"*-7Q<,S1A4X_23]J']G/0_P!K3X$Z]\/?$=UJMEHOB$0+<S:;)''=)Y4\
M<Z[&D1U&6B4'*G@GH>1W]%56Q,IR4MK;?F33HJ,7'N>._$S]B;PK\5?V,K;X
M&ZAJ'B"'PG:Z3INCI=V\\*ZB8;%H&A8NT31[V-NFX^7@Y; 7(QP_Q[_X)6>
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MX;X:_P#!(_\ 9T^$OBRUUO1?AAI/]HV;"2%M0O;O4HXV'1A%<S21[AU!VY!
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MHI-OU_.C;]?SH 6BDV_7\Z6@ KA_@K_Q\^,_^QENO_1<5=Q7#_!7_CY\9_\
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M\"UCX1^.UW;ZUIG_  3/6Q87EPLND?-;GS-BQ#15G!V]-I4AO38V<8-?6?\
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MH)8@FNBG@<7I*+MJ^MNZ;_!J_P#FCDJ9A@]8R5[)?9OV:7XIV_R9]L6/[/\
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M_A$?!NE1VFLVVN:O'HVKVZ::EFMPFGK.UBRO# L@C59"C2"3 =Q(_O1I9/\
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ME,:?H-15RS2NU).WO73T[W_S9G'*:$7&U_=::UZJUO\ TE!1117G'J!1110
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M@#N*Y7XX?\DA\1_]>$O\JZJN5^.'_)(?$?\ UX2_RH ZA/O/]?Z"G4U/O/\
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MD+7N7[3W[3'AW]D[]GSQ%\2O$:WUYX>\-P1W%PFG"*2XF#RI$BQB1T1F+R*
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ML\,X8RQD,DADV\7:>&/$OP0_:?\ A8UU\,[WQQJUN?BQK$-A8WFFB^L+6_\
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M7$:W(V;[.&.3RSDI7U6AHG/=I;KJM_*VVO\ PT_6Z^K4-DWL^CM;6R=]]/\
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M_ ****Q-@HHHH **** //_V6_P#DA.A?]O'_ *42UZ!7G_[+?_)"="_[>/\
MTHEKT"@ HHHH **** .#_:=_Y(#XJ_Z\6_F*[RN#_:=_Y(#XJ_Z\6_F*[R@"
MOI1/V!-V,Y/2%HNY_A8DC^O6K%5]+#"Q3=MSD_=B,0ZG^%B2/Z]:L4 %%%%
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MRS:*=N">&<@]P:YR+]F+XM?"F",?#[XY:IJEG:QS;-(^(ND1>((9&8LR#[9
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MOE^+_P @C'*8KWI5)/TC'_VZ9R=__P %&O@#IL#R2?&KX72+&,D0>)K.9C]
MDA)_ 5S>G_\ !63X!:Y?-;Z7XWN]<F4[<:1X;U7458^Q@MG!_ FOH:SL(-.M
MUAMX8;>%?NI&@51] *FHY:O1K[G_ )A&OE*3YJ-1]OWL5_[A?YGAZ?\ !0/P
M-?0-)I^A_%[5E SFT^&'B)@?Q:R _6L-/^"B7]HZM]DTOX%_M&:I_P!-CX+_
M +/A_P"^KR:"OHRBCEJ/[7X?\%A'&9;"]L/*7^*I?_TF$3Q*7]JGQS=1!K#]
MG7XN3,PSBYU'PY:C]=4)_2L+4/VE_C[<WBQZ5^S-<+&Q_P!;J_Q!TNT"CW$
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M:OU1\,1M%X;T]6\G<MM&#Y5JUI'G:/NPL2T2^B,25'!)(H O4444 >)_M?\
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M^"=&UW7=+O/&'A:UU+POIYU;6;2;5H(Y](LPNXW-PA?=#"%^;S' 7'.<5C?
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M$?\ ]3?7:]PMIV;Q7>Q^9(8UM+=@AMI5527F!(E)\IR<#*( Z8!<D/&!X?\
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M*PZ:NO'XJ6*Q-3$R5G.3E;U;9%/EMRI[:?A_D%%%%<A84444 %<?^SW\)U^
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MWU+4)KF*;0_$?@.XDDT#Q9I<]E:W,-_;+++)+&OF330_.W[S[/YJ@)*@'MU
M!1110!P?[3O_ "0'Q5_UXM_,5WE<'^T[_P D!\5?]>+?S%=Y0!7TH%;! VW/
M/W83$.I_A))'Y\]:L57TI&CL55O+R"WW(3"O4_PDDC\^>M6* "BBB@ HHHH
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MO:G5DK/1\M*<H2C).THWBFFFT[6U5T*52\;Q[K\T?2U%%%?-&H4444 %%%%
M'S=_P4I_Y%SX,_\ 98/"O_I<*^D:^;/^"EDJQ^'?@ON95W_&'PHJY/WC]MZ#
M\J^DZ^AS#_D4X3UJ_G$SC\;^04445\\:!1110 4444 %%5;S7K'3L_:+RUM\
M<'S)E7'YFLB]^+GA/3,_:?$_AZWV]?,U&%,?FU:PH5)_#%OT072.AHKB+O\
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M\3#PQ-'J#ZW8)I\IU0_\>,4=ZUM))<\^5'&[X;&" 9'_  3"^(?Q*\>CQO\
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M3^=:]OX/TBTQY6EZ;'CILMD7'Z4OW?9_U\C2,<=]J4/_  &7_P D>:_\-_\
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MA=,\11_M/?L^^(O!L-U=>+? >G^*/%VG6<$SQMJHT\:7<3V.(U9V-S;K/;@
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M^",O[+EF^Y?@IX-D;^]-%),3]2[G/XU].45K_KCG]K?7JW_@V?\ \D+V-/\
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M*UNMK 4C^RR*R.7FW-YQ;RWR @V*H9-I+%A(@7PW_@FG_P FZ^(_^RJ_$?\
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M[>J2.JQL ?GQ_P $7/VK_$EC^U'I/@/X7ZAX$^(GP!\;7UU<_P!O>$O@3/\
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M7XX\>?V'XFTE8FN[/^Q-1N?*$L22I^\AMW0Y1U/#'&<'!R*X_P#X?J_LK?\
M14O_ "VM7_\ D6OR:_X+R?\ *4CXB_\ 7'2O_39:U\?U\[B,WK0J2@DK)M=?
M\S^H^'?!+(\?E6&QU:K54JE.$VE*%KRBF[7IMVN]+M^I_6+X \=Z5\4? >B>
M)M!NOMVA^(K"#5-.N?*>+[1;SQK+$^QP'7<C*<, 1G! /%:]>1_L _\ )B'P
M3_[$+0O_ $WP5ZY7T%.7-%-G\T9AAXT,54H0VC*25][)M!17Y?\ [(W[/?@W
M]J_]@/P?\?\ X@?!_P 2?M _&SXH7LNI:KJOA[4[>S\0>";E-0O)DM]*NM4U
M.U?2(=-F06JQV5S'*LD88HY\UQZ+\//V_/&^J>'+'Q%X3US3G^"/P\^ _A;X
ML:W?^,O#\VK>.O$=O>?VNTL)-G>06D=U)::0S-*L<JI<2DB*5&"I1QGWW17Q
M%X#_ &R?CQX8TCX$^+/&\WPCUSPK\>=(N6BT[0]%OM-U#PIJ1\/7>O6P-Q)?
MW,6HVXAL+JWD98K5B[0RKA2T0K6G_!37QY<?#[]DG5FTGPC]H^/7PNU7QMX@
M46MQLL[VU\/VFIQQVH\_*0F:=U99#(Q0* P;+$ ^YJ*^)_V8OVS/C9J/BG]F
MB]^)5W\+=8\,_M*>'I[NWL_#'AZ]TR_\+ZE_9*ZQ CS3ZC<I>6OV:*\A>188
M&$HMR!MD*KTO_!1[X9?!?5-:TS6/BUX=NOB_K6NZ9-X;\#?"^Y2&^AUC43OF
MEN+"S9?DO3'L62_D<)9V\)??;HT[R 'UG17F?[%_PX\:?![]D?X:^%?B-XB;
MQ9X\\.^&K#3]?U@SO<&_O8X$65_.D DF^8$>;( \F-[ ,QKTR@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MXG6OAR/7TM$&GOH+730>1:Q0?ZP7";MWE;ONC&<<XS7C?_$+?J7_ $6JQ_\
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M@[L Y&WD L5\R_L[?\I1OVF/^Q<\$_\ H&L5]-5\R_L[?\I1OVF/^Q<\$_\
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MN6,]5(88=48._9?_ &D(_CSH&I6&K:>WAGXA>$94L/%GAN9]TVD7++N1U/\
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MG[9WBSX=>%_#WP[OM$T&.R:WGU2PO);IS-9PSMO:.ZC4X:1@,*. .IY/@_\
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M=MHVE6?G23?9;2WB6&&/?(S.^V-%&YV9CC)).36]110 4444 %%%% !1110
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M9)'MCCVD_*D?EJ.2>F3_ #YJQ5?28/LU@D?EQQ[2WRQQ>6HY/\.3_/GK5B@
MHHHH **** "J>F6?V6]U&3RX(_M%P)-T<'EM)^ZC7+MD^8WRXW8&%55Q\N3<
MJCI-E]EO]4D\FWC^TW2R;H[<1M+B&)=SMN/F-\NW<0N%55Q\NY@"]5'PS9?V
M;X;T^W\FWM_L]M''Y4$ MXHL*!M6,,P11C 4,<#C)QFKU4/"MA_97A?3;7R+
M>U^S6L47DP6XMXHMJ ;4C#,$48P%#,% QDXS0!?HHHH **** "BBB@ HHHH
M**** "J\EONU6&7RXSLBD3>8\NN2AP&SP#MY&#G .1MYL57EM]VKP3>7&?+A
MD3>8LNN2AP'SP#MY&#G .1MY +%%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %</\%?^/GQG_V,MU_Z+BKN*X?X*_\
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M"Q^*[VZ^PPQO-:6\1O!"@DG"/.1&7#;V5-Y(4J%4RL06+,% -"BBB@ HHHH
M**** (8X%749I/)56:-%,NT;G +D*3G) R3@C W'&<G$U01PJNI32>0JLT2*
M9MHS( 7PN<Y.W).",#><$Y.)Z (-.@%O;%5A2$>8[;50*.7)S@$C)SDGN3DX
M)Q4]0Z?"L%MM6%8!O=MBJ%&2Q). 2.<YSU.<G!XJ:@ HHHH **** "BBB@ H
MHHH **** /(?V=9VF^.?Q\4S/((O&5BH5G+"(?\ ".:,=H!' Y+8&1EB<Y)
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MPKG_ (3?\DK\,_\ 8*M?_1*5T%<_\)O^25^&?^P5:_\ HE* .@HHHH ****
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M#!#)6,<IK.G*?\MNCUVZ]-T]?/L;2SF@JD*?\U^JTWZ==4UIUMW/UFHKX1^
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MLD?\E1_:$_[*0/\ U'M$KVRO$_V2/^2H_M"?]E('_J/:)653XH^OZ,];+_\
M=L3_ ((_^G('ME%%%:GDA1110 4444 %%%% !1110 4444 %>%_L _\ )-_'
MG_93O&'_ *?;RO=*\+_8!_Y)OX\_[*=XP_\ 3[>5E+^(O1_H>QAO^1;7_P 5
M/\IGNE%%%:GCA7/_  F_Y)7X9_[!5K_Z)2N@KG_A-_R2OPS_ -@JU_\ 1*4
M=!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@#S_P#9;_Y(3H7_ &\?^E$M>@5Y_P#LM_\
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MD_X1^/FB^/OB%;_$;1/!&B>+YKC7O&^M:QI>N7+VUO+<6EQ8W-XUNR71DDB
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M\1_]>$O\JZJN5^.'_)(?$?\ UX2_RH ZA/O/]?Z"G4U/O/\ 7^@IU !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_!/^V^'5K<2^(KSPSX<%D&LK-H4G9!N,=K;!G,4*\I#;JSF.-8XP7V@GK_\
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MJ_\ \CT >C45YS_PT_H?_0!^(W_A$:O_ /(]'_#3^A_] 'XC?^$1J_\ \CT
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MH?\ T ?B-_X1&K__ "/1_P -/Z'_ - 'XC?^$1J__P CT_:SO>_6_P ^_P"
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M !\^,_\ L9;K_P!%Q4 =Q7*_'#_DD/B/_KPE_E755ROQP_Y)#XC_ .O"7^5
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MJ>%?A]H6EZYKL_BC6M-T^WM=0UF>UBM9=7N$C59;IH80L4;2N&<I&H12V%
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MFD62:=]IN)+C:  #CO\ @G;^U9J7Q>_:)^-GP]D\8^*/B3X=\$VWA[Q!X?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >?\ [+?_ "0G0O\
MMX_]*):] KQ[]G?XL>&_#7P=T>QU#6K"TNX?.\R*23:R9GD89'N"#^-=K_PO
M7P?_ -#%I?\ W^H ZRBN3_X7KX/_ .ABTO\ [_4?\+U\'_\ 0Q:7_P!_J .L
MHKD_^%Z^#_\ H8M+_P"_U'_"]?!__0Q:7_W^H ZRBN3_ .%Z^#_^ABTO_O\
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M_0Q:7_W^H ZRBN3_ .%Z^#_^ABTO_O\ 4?\ "]?!_P#T,6E_]_J .LHKD_\
MA>O@_P#Z&+2_^_U'_"]?!_\ T,6E_P#?Z@#K**Y/_A>O@_\ Z&+2_P#O]1_P
MO7P?_P!#%I?_ '^H ZRBN3_X7KX/_P"ABTO_ +_4?\+U\'_]#%I?_?Z@#K**
MY/\ X7KX/_Z&+2_^_P!1_P +U\'_ /0Q:7_W^H ZRBN3_P"%Z^#_ /H8M+_[
M_4?\+U\'_P#0Q:7_ -_J .LHKD_^%Z^#_P#H8M+_ ._U'_"]?!__ $,6E_\
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M_J .LHKD_P#A>O@__H8M+_[_ %'_  O7P?\ ]#%I?_?Z@#K**Y/_ (7KX/\
M^ABTO_O]1_PO7P?_ -#%I?\ W^H ZRBN3_X7KX/_ .ABTO\ [_4?\+U\'_\
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G 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>brns-20231231_g7.jpg
<TEXT>
begin 644 brns-20231231_g7.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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MAOCE_P"%YJG_ ,?KPRBCZG0_D7W(/;5.[^\]S_X>??M+?]'#?'+_ ,+S5/\
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M/J=#^1?<@]M4[O[SW/\ X>??M+?]'#?'+_PO-4_^/T?\//OVEO\ HX;XY?\
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MG_Q^O#**/J=#^1?<@]M4[O[SW/\ X>??M+?]'#?'+_PO-4_^/T?\//OVEO\
MHX;XY?\ A>:I_P#'Z\,HH^IT/Y%]R#VU3N_O/<_^'GW[2W_1PWQR_P#"\U3_
M ./T?\//OVEO^CAOCE_X7FJ?_'Z\,HH^IT/Y%]R#VU3N_O/<_P#AY]^TM_T<
M-\<O_"\U3_X_1_P\^_:6_P"CAOCE_P"%YJG_ ,?KPRBCZG0_D7W(/;5.[^\]
MS_X>??M+?]'#?'+_ ,+S5/\ X_1_P\^_:6_Z.&^.7_A>:I_\?KPRBCZG0_D7
MW(/;5.[^\]S_ .'GW[2W_1PWQR_\+S5/_C]'_#S[]I;_ *.&^.7_ (7FJ?\
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M<O\ PO-4_P#C]'_#S[]I;_HX;XY?^%YJG_Q^O#**/J=#^1?<@]M4[O[SW/\
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M]I;_ *.&^.7_ (7FJ?\ Q^O#**/J=#^1?<@]M4[O[SW/_AY]^TM_T<-\<O\
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MAOCE_P"%YJG_ ,?KPRBCZG0_D7W(/;5.[^\]S_X>??M+?]'#?'+_ ,+S5/\
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M/J=#^1?<@]M4[O[SW/\ X>??M+?]'#?'+_PO-4_^/T?\//OVEO\ HX;XY?\
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MG_Q^O#**/J=#^1?<@]M4[O[SW/\ X>??M+?]'#?'+_PO-4_^/T?\//OVEO\
MHX;XY?\ A>:I_P#'Z\,HH^IT/Y%]R#VU3N_O/<_^'GW[2W_1PWQR_P#"\U3_
M ./T?\//OVEO^CAOCE_X7FJ?_'Z\,HH^IT/Y%]R#VU3N_O/<_P#AY]^TM_T<
M-\<O_"\U3_X_1_P\^_:6_P"CAOCE_P"%YJG_ ,?KPRBCZG0_D7W(/;5.[^\]
MS_X>??M+?]'#?'+_ ,+S5/\ X_1_P\^_:6_Z.&^.7_A>:I_\?KPRBCZG0_D7
MW(/;5.[^\]S_ .'GW[2W_1PWQR_\+S5/_C]'_#S[]I;_ *.&^.7_ (7FJ?\
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M<O\ PO-4_P#C]'_#S[]I;_HX;XY?^%YJG_Q^O#**/J=#^1?<@]M4[O[SW/\
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M]I;_ *.&^.7_ (7FJ?\ Q^O#**/J=#^1?<@]M4[O[SW/_AY]^TM_T<-\<O\
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MAOCE_P"%YJG_ ,?KPRBCZG0_D7W(/;5.[^\]S_X>??M+?]'#?'+_ ,+S5/\
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M/J=#^1?<@]M4[O[SW/\ X>??M+?]'#?'+_PO-4_^/T?\//OVEO\ HX;XY?\
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MG_Q^O#**/J=#^1?<@]M4[O[SW/\ X>??M+?]'#?'+_PO-4_^/T?\//OVEO\
MHX;XY?\ A>:I_P#'Z\,HH^IT/Y%]R#VU3N_O/<_^'GW[2W_1PWQR_P#"\U3_
M ./T?\//OVEO^CAOCE_X7FJ?_'Z\,HH^IT/Y%]R#VU3N_O/<_P#AY]^TM_T<
M-\<O_"\U3_X_1_P\^_:6_P"CAOCE_P"%YJG_ ,?KPRBCZG0_D7W(/;5.[^\]
MS_X>??M+?]'#?'+_ ,+S5/\ X_1_P\^_:6_Z.&^.7_A>:I_\?KPRBCZG0_D7
MW(/;5.[^\]S_ .'GW[2W_1PWQR_\+S5/_C]'_#S[]I;_ *.&^.7_ (7FJ?\
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M<O\ PO-4_P#C]'_#S[]I;_HX;XY?^%YJG_Q^O#**/J=#^1?<@]M4[O[SW/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M1F6+P-.BJ$]7>[LM;6UU5E\B\KPU*O*?/'3IJ]-S\6/^(,'_ *N2_P#,??\
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M^; 1[D;69EQ_-[7T&1YHL=A55^TM)+S_ .#NC@QV%="JX=.GH?IO_P $IO\
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M$2#D#Y?@LFSO&_VD\%C9\VZV2U771+=+\3WL9@J/U95J*ML]WL?B)7>_LM_
M'5/VJ?VD/ WPWT?[0FH>-M;M='2:&U:Y-FLTJK)<-&I!*1(6D;D +&Q)4 D<
M%7ZK_P#!I1^RI'\7OV\/$?Q,OK>WGT_X2Z)FU+2.LD6I:AYEO"X4?*RBVCO@
M=QX8H0I(W+]AFF,^JX2I7_E6GKLOQL>1A:/M:L:?=_\ #GN?_$&#_P!7)?\
MF/O_ +Y5\K_L"?\ ! 32_P!OG]I#]H+P+HWQHN-%T_X%ZW;:(FKS>#UG/B!I
M);Z&2585O@(45[)MO[R0NLBDA""M?O1_P5A_; E_83_X)]_$KXDV6[^V]*TX
M6>C 1B3&H74BVUNY4LH*QR2K(PSG9&V 3@'^=K_@C!_P6?\ ^'0__"R?^+;?
M\+"_X6%_9G_,P?V3]@^Q?;/^G:?S-_VO_9V^7_%NX^.RG'9QC,'6K0G>2LHZ
M16MTY;I+;OW[GKXJC@Z-:$)*RU;U?R_$^Y?^(,'_ *N2_P#,??\ WRH_X@P?
M^KDO_,??_?*C_B,^_P"K;?\ S(/_ -[:_8#]C?\ :(_X:U_96\ _$S^Q_P#A
M'_\ A.-%M]8_LW[7]K^Q>:@;R_-V)OQG&[8N?05YV.S+B#!Q4\3+E3T6D'^2
M9T4,/E]9\M-7_P# C\?_ /B#!_ZN2_\ ,??_ 'RH_P"(,'_JY+_S'W_WRKZL
M_P""O_\ P<#_ /#J3]I;0_AW_P *D_X3W^VO#,'B/^T/^$I_LOR?-NKNW\GR
MOLDV['V7=NW#._&T8R?E/_B,^_ZMM_\ ,@__ 'MKHP^(XEKTU6I.\7L_W?ZD
M5*>6PDX2W7^(_/?]@G_@D_\ \-O_ /!1#QE\ _\ A/O^$8_X1'^UO^)[_8?V
MW[7]ANEM_P#CW^T1[/,W;O\ 6-MQCYNM?H1_Q!@_]7)?^8^_^^5>(_\ !M+\
M2/\ A<G_  6Y\;>+_L?]F_\ "5:+K^L?9/.\[[+]HO()O+W[5W;=^-VT9QG
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M^R2[L]C+\!"I!UJWPH_'_5/^#,:[AM&:R_:+M[BX[)/X%,*'@_Q#4'/7';_
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M5F52P&1R/45E&O3D^6,DWZE.$DKM'+T445J2%%=O\)?V9_B1\?8II/ OP_\
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MW+_@F#_RDK_9Y_[*9X;_ /3K;48B3C2E*.Z3_(*:3FD^Y^K'_$&#_P!7)?\
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MPAEY':?VI]A^P_;-\$<N[R?,DV8\S&-[=,]\#QZOL+_@OS_RF!^.'_87M_\
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M=>C/-E%Q?*]PHHHJR0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P#P555XXXXVG\&Z8\K*H!D;S+E<GU.U5&3V ':OT+_X- /^4:GCC_LIE_\
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M%>=E'#O]H8)5J]1]5%+96?\ G?:WJ=&,S'ZO6<(17GY_TC^RC]N#]A/X<_\
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MRG$.M@Z566[BK^MM3S<534*THKN%>I?"_P#8=^-7QO\ !\'B+P7\'_BEXO\
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M&QL59/YT_!'@S4OB/XTT?P[HMM]LUC7KV'3K&W\Q8_/GFD6.--SD*N68#+$
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M_9\/^Z^V6SQ;\GY/F^PXX^;]WSQMK\8O^"B'_*0#XY_]E!U__P!.5Q7ZT?\
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MXR?#F7X/?%[Q5X1GNH[Z;PMK%WI$EPB%%N&MYGB+A3R Q3.#TS7]N%?QD_\
M!0.\CU#]O3XW7$+;X9_'VNR(V"-RG49R#@\]*\7@63]I6CTLOU_S.S/%[L'Z
MGD-%%%?HQ\Z>Y?\ #L+]I;_HWGXY?^$'JO\ \8K]O/\ @U!_9R^(?[.GP.^+
MUI\0O ?C/P)=:EKMC-9P^(=$N=+DND6W<,T:SHA=02 2,@$U]Z?\//OV:?\
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M^G6YK^R*OXW?^"GW_*2O]H;_ +*9XD_].MS7YKP+_'J^B_,^DSSX(^I]U_\
M!O#_ ,$+]*_;@,GQC^+EK-<?#+2;HV^B:,DH1?$UW&Q$K3LK;UMH2 I0 &5V
MQN"HRR?O/\1_BY\(/V /@O83>(M7\$?"CP+IK"QTZW;R-,LD8AG$%M @4,Q
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M3WK^G[_@CI_P0;^'O_!/OX;Z'XH\9:)I?B_XU74,5[?:I?P1W,7AN<@-]GL
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M;_9K\>?#JXOI-+@\<:#>:')=QH'>V6XA:(N >"0&SS^M?RU_\$!O^4P/P/\
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M!N5Q"J9  &XL<#.*X^'X/,,VJ8Z>T=5\](KY+\C?'R6'PD:"W?\ 3_$^D_\
M@@Q_P1J;_@I[\7[[7_&$EYI_PB\$RJNK26DJQW&LW9"LEA&V=T:E3ODE )"
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MR/[4_P!DO_DU7X9_]BII?_I'%7\P'_!Q)_RF5^-G_7WIO_IILJ_I_P#V2_\
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MAT7PKHVJVYFL;^Y10UU>302)Y<\2!TBCR70R?:-RAHD(XG_@[_\ ^4E?@?\
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MEQ,?FCI/^#Q#]F/^POB]\*?C!9PW31^(M-G\+:H^5\B&6U?[1;'&-WF2)<7
M)R1MMEX4\M^+M?TN?\'9/PO/CK_@EQ;:TEQ' W@OQEIVJ.K*6-PDL=Q9F,<X
M!W72/DYXC([U_-'4<)XAU<NBG]EM?JOP96;4^7$NW6S"BBBOI3S0HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@#[E_X-M/^4T_P8_[CG_IBU&OZKZ_E0_X-M/\
ME-/\&/\ N.?^F+4:_JOK\MXX_P!^A_@7_I4CZC)/X#]?T04445\:>P%%%% '
M\-9ZT4'K17]"'Y^%%%% !1110 4444 %>H?L1?\ )Z'PA_['71O_ $NAKR^O
M4/V(O^3T/A#_ -CKHW_I=#6.(_A2]'^1=/XUZG]HE?QN_P#!3[_E)7^T-_V4
MSQ)_Z=;FO[(J_C=_X*??\I*_VAO^RF>)/_3K<U^=\"_QZOHOS/H<\^"/J?U8
M?\$P?^4:G[//_9,_#?\ Z:K:OYL?^#B3_E,K\;/^OO3?_3395_2=_P $P?\
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M[4_\7Z'M9'_%EZ?J?BS_ ,'?_P#RDK\#_P#9,[#_ -.NK5^4]?JQ_P '?_\
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M07&NQ:/J-K9>'9+6+2HY8I6CN'F,\GREXUC^9% >5!N)8 ^:?\$+?^"DUO\
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M(8YR&.>XKQL_P-7%X*5"C\3MOY-,[,!6C2K*<]M3[\_X/-?^1K_9Z_Z]-?\
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M+^S;\2-7CTF'4-1:?P)?W"I':^?.Y:;39).-KR2MYD)?(=Y)(]P8Q(WZK_\
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MXNI>'=>A^U:=>*,)>0%B$E7OL< ,N<':PR >!_+'_P '$G_*97XV?]?>F_\
MIILJY."[_P!H5.;?E?\ Z5$USFWU>-NZ_)G[M_\ !MI_RA8^#'_<<_\ 3[J-
M?DO_ ,'<O_*3WP]_V3[3O_2W4*_6C_@VT_Y0L?!C_N.?^GW4:_)?_@[E_P"4
MGOA[_LGVG?\ I;J%;9)_R/ZWK/\ ,G&_[A#TC^1X[_P;:?\ *:?X,?\ <<_]
M,6HU_1[_ ,%/O^4:G[0W_9,_$G_IJN:_G"_X-M/^4T_P8_[CG_IBU&OZ/?\
M@I]_RC4_:&_[)GXD_P#35<TN+/\ D;4?2/\ Z4PRK_=9^K_)'\;M?U/?\&S7
M_*&KX7_]?>M?^G:[K^6&OZGO^#9K_E#5\+_^OO6O_3M=U[7&W^X1_P :_*1Q
MY+_'?I^J/RY_X.__ /E)7X'_ .R9V'_IUU:OTV_X-Q?V O#W[)O_  3Y\'^-
MI='T\?$+XK:9'KVJZJF9)GL9V,UC;JS %$%NT+LB@ R,QRP"FOS)_P"#O_\
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MGQ>\,_M&_"'P_P"-/">HV^N>%?%VGQZAI]TBD+<02KD!D8!E89*LC ,K!E8
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M#;SC(S^3=?N=_P &;'PBE2V^.7CR98_)D;2] M&V'=N43SSC<1@##6_ )SW
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^Y?\ @VT_Y33_  8_
M[CG_ *8M1K^J^OY4/^#;3_E-/\&/^XY_Z8M1K^J^ORWCC_?H?X%_Z5(^HR3^
M _7]$%%%%?&GL!1110!_#6>M%!ZT5_0A^?A1110 4444 %%%% !6IX(\9ZE\
M./&FC^(=%N?L>L:#>PZC8W'EK)Y$\,BR1OM<%6PR@X8$''((K+HH:35F!]R_
M\1)?[:G_ $6?_P M'0O_ )"KXV^)_P 2M:^,WQ+\1>,/$E[_ &EXB\5ZG<ZQ
MJMWY,</VJ[N)6FFDV1JJ+ND=CM10HS@ # K#HKEH8+#T&W1IQBWV27Y&E2M4
MGI.3?JS[(^&'_!P%^US\&?AIX=\'^&_BU_9OAWPIIEMH^E6G_"+Z--]EM+>)
M888]\EHSMMC11N=BQQDDG)KYL_:)_:(\8_M8?&76_B#\0-8_M_Q?XB>*34;_
M .R06OVAHXDA0^7"B1KB.-%^51G&3DDD\513HX/#TINI2IQBWNTDG]Z"5:I)
M<LI-KU/5OV/_ -MSXH?L$_$N^\8?"?Q-_P (IXBU+3)-'N;O^SK2^\RT>6*9
MH]ES%(@S)!$=P4,-N,X)!]6_:3_X+<?M/?M>?!76OAW\1/B=_P )#X.\0^1_
M:&G_ /".Z3:?:/)GCN(OWL%JDJ[98HV^5AG;@Y!(/RG12G@L/.HJTZ<7)=6E
M?3;7?0(UJBCR*3MVOH%?8GPF_P""^_[6WP-^&'A_P9X6^+']E^&_"NGP:5I=
MG_PC&C3_ &6VA01QQ[Y+1G;:J@;G8L<<DFOCNBKKX6C75JT%)+ND_P PIU9P
MU@VO0[K]I/\ :3\:_M>?&K6OB)\1-:_X2'QCXA\C^T-0^QP6GVCR8([>+]U
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M3TR^B17:VGB8,C;7!1UR,%'5E8$JP*D@\Y12E%27++8$VG='W+_Q$E_MJ?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** /N7_@VT_Y33_!C_N.?^F+4:_JO
MK^5#_@VT_P"4T_P8_P"XY_Z8M1K^J^ORWCC_ 'Z'^!?^E2/J,D_@/U_1!111
M7QI[ 4444 ?PUGK10>M%?T(?GX4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M'W_WRK]RJ*/]:LT_Y^_^2Q_R#^R\+_+^+_S/PU_X@P?^KDO_ #'W_P!\J/\
MB#!_ZN2_\Q]_]\J_<JBC_6K-/^?O_DL?\@_LO"_R_B_\S\-?^(,'_JY+_P Q
M]_\ ?*C_ (@P?^KDO_,??_?*OW*HH_UJS3_G[_Y+'_(/[+PO\OXO_,_#7_B#
M!_ZN2_\ ,??_ 'RH_P"(,'_JY+_S'W_WRK]RJ*/]:LT_Y^_^2Q_R#^R\+_+^
M+_S/PU_X@P?^KDO_ #'W_P!\J/\ B#!_ZN2_\Q]_]\J_<JBC_6K-/^?O_DL?
M\@_LO"_R_B_\S\-?^(,'_JY+_P Q]_\ ?*C_ (@P?^KDO_,??_?*OW*HH_UJ
MS3_G[_Y+'_(/[+PO\OXO_,_#7_B#!_ZN2_\ ,??_ 'RH_P"(,'_JY+_S'W_W
MRK]RJ*/]:LT_Y^_^2Q_R#^R\+_+^+_S/PU_X@P?^KDO_ #'W_P!\J/\ B#!_
MZN2_\Q]_]\J_<JBC_6K-/^?O_DL?\@_LO"_R_B_\S\-?^(,'_JY+_P Q]_\
M?*C_ (@P?^KDO_,??_?*OW*HH_UJS3_G[_Y+'_(/[+PO\OXO_,_#7_B#!_ZN
M2_\ ,??_ 'RH_P"(,'_JY+_S'W_WRK]RJ*/]:LT_Y^_^2Q_R#^R\+_+^+_S/
MPU_X@P?^KDO_ #'W_P!\J/\ B#!_ZN2_\Q]_]\J_<JBC_6K-/^?O_DL?\@_L
MO"_R_B_\S\-?^(,'_JY+_P Q]_\ ?*C_ (@P?^KDO_,??_?*OW*HH_UJS3_G
M[_Y+'_(/[+PO\OXO_,_#7_B#!_ZN2_\ ,??_ 'RH_P"(,'_JY+_S'W_WRK]R
MJ*/]:LT_Y^_^2Q_R#^R\+_+^+_S/PU_X@P?^KDO_ #'W_P!\J/\ B#!_ZN2_
M\Q]_]\J_<JBC_6K-/^?O_DL?\@_LO"_R_B_\S\-?^(,'_JY+_P Q]_\ ?*C_
M (@P?^KDO_,??_?*OW*HH_UJS3_G[_Y+'_(/[+PO\OXO_,_#7_B#!_ZN2_\
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M'W_WRK]RJ*/]:LT_Y^_^2Q_R#^R\+_+^+_S/PU_X@P?^KDO_ #'W_P!\J/\
MB#!_ZN2_\Q]_]\J_<JBC_6K-/^?O_DL?\@_LO"_R_B_\S\-?^(,'_JY+_P Q
M]_\ ?*C_ (@P?^KDO_,??_?*OW*HH_UJS3_G[_Y+'_(/[+PO\OXO_,_#7_B#
M!_ZN2_\ ,??_ 'RH_P"(,'_JY+_S'W_WRK]RJ*/]:LT_Y^_^2Q_R#^R\+_+^
M+_S/PU_X@P?^KDO_ #'W_P!\J/\ B#!_ZN2_\Q]_]\J_<JBC_6K-/^?O_DL?
M\@_LO"_R_B_\S\-?^(,'_JY+_P Q]_\ ?*C_ (@P?^KDO_,??_?*OW*HH_UJ
MS3_G[_Y+'_(/[+PO\OXO_,_#7_B#!_ZN2_\ ,??_ 'RH_P"(,'_JY+_S'W_W
MRK]RJ*/]:LT_Y^_^2Q_R#^R\+_+^+_S/PU_X@P?^KDO_ #'W_P!\J/\ B#!_
MZN2_\Q]_]\J_<JBC_6K-/^?O_DL?\@_LO"_R_B_\S\-?^(,'_JY+_P Q]_\
M?*C_ (@P?^KDO_,??_?*OW*HH_UJS3_G[_Y+'_(/[+PO\OXO_,_#7_B#!_ZN
M2_\ ,??_ 'RH_P"(,'_JY+_S'W_WRK]RJ*/]:LT_Y^_^2Q_R#^R\+_+^+_S/
MPU_X@P?^KDO_ #'W_P!\J/\ B#!_ZN2_\Q]_]\J_<JBC_6K-/^?O_DL?\@_L
MO"_R_B_\S\-?^(,'_JY+_P Q]_\ ?*C_ (@P?^KDO_,??_?*OW*HH_UJS3_G
M[_Y+'_(/[+PO\OXO_,_#7_B#!_ZN2_\ ,??_ 'RH_P"(,'_JY+_S'W_WRK]R
MJ*/]:LT_Y^_^2Q_R#^R\+_+^+_S/PU_X@P?^KDO_ #'W_P!\J/\ B#!_ZN2_
M\Q]_]\J_<JBC_6K-/^?O_DL?\@_LO"_R_B_\S\-?^(,'_JY+_P Q]_\ ?*C_
M (@P?^KDO_,??_?*OW*HH_UJS3_G[_Y+'_(/[+PO\OXO_,_#7_B#!_ZN2_\
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M'W_WRK]RJ*/]:LT_Y^_^2Q_R#^R\+_+^+_S/PU_X@P?^KDO_ #'W_P!\J/\
MB#!_ZN2_\Q]_]\J_<JBC_6K-/^?O_DL?\@_LO"_R_B_\S\-?^(,'_JY+_P Q
M]_\ ?*C_ (@P?^KDO_,??_?*OW*HH_UJS3_G[_Y+'_(/[+PO\OXO_,_#7_B#
M!_ZN2_\ ,??_ 'RH_P"(,'_JY+_S'W_WRK]RJ*/]:LT_Y^_^2Q_R#^R\+_+^
M+_S/PU_X@P?^KDO_ #'W_P!\J/\ B#!_ZN2_\Q]_]\J_<JBC_6K-/^?O_DL?
M\@_LO"_R_B_\S\-?^(,'_JY+_P Q]_\ ?*C_ (@P?^KDO_,??_?*OW*HH_UJ
MS3_G[_Y+'_(/[+PO\OXO_,_#7_B#!_ZN2_\ ,??_ 'RH_P"(,'_JY+_S'W_W
MRK]RJ*/]:LT_Y^_^2Q_R#^R\+_+^+_S/PU_X@P?^KDO_ #'W_P!\J/\ B#!_
MZN2_\Q]_]\J_<JBC_6K-/^?O_DL?\@_LO"_R_B_\S\-?^(,'_JY+_P Q]_\
M?*C_ (@P?^KDO_,??_?*OW*HH_UJS3_G[_Y+'_(/[+PO\OXO_,_#7_B#!_ZN
M2_\ ,??_ 'RH_P"(,'_JY+_S'W_WRK]RJ*/]:LT_Y^_^2Q_R#^R\+_+^+_S/
MPU_X@P?^KDO_ #'W_P!\J/\ B#!_ZN2_\Q]_]\J_<JBC_6K-/^?O_DL?\@_L
MO"_R_B_\S\-?^(,'_JY+_P Q]_\ ?*C_ (@P?^KDO_,??_?*OW*HH_UJS3_G
M[_Y+'_(/[+PO\OXO_,_#7_B#!_ZN2_\ ,??_ 'RH_P"(,'_JY+_S'W_WRK]R
MJ*/]:LT_Y^_^2Q_R#^R\+_+^+_S/PU_X@P?^KDO_ #'W_P!\J/\ B#!_ZN2_
M\Q]_]\J_<JBC_6K-/^?O_DL?\@_LO"_R_B_\S\-?^(,'_JY+_P Q]_\ ?*C_
M (@P?^KDO_,??_?*OW*HH_UJS3_G[_Y+'_(/[+PO\OXO_,_#7_B#!_ZN2_\
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M'W_WRK]RJ*/]:LT_Y^_^2Q_R#^R\+_+^+_S/PU_X@P?^KDO_ #'W_P!\J/\
MB#!_ZN2_\Q]_]\J_<JBC_6K-/^?O_DL?\@_LO"_R_B_\S\-?^(,'_JY+_P Q
M]_\ ?*C_ (@P?^KDO_,??_?*OW*HH_UJS3_G[_Y+'_(/[+PO\OXO_,_#7_B#
M!_ZN2_\ ,??_ 'RH_P"(,'_JY+_S'W_WRK]RJ*/]:LT_Y^_^2Q_R#^R\+_+^
M+_S/PU_X@P?^KDO_ #'W_P!\J/\ B#!_ZN2_\Q]_]\J_<JBC_6K-/^?O_DL?
M\@_LO"_R_B_\S\-?^(,'_JY+_P Q]_\ ?*C_ (@P?^KDO_,??_?*OW*HH_UJ
MS3_G[_Y+'_(/[+PO\OXO_,_#7_B#!_ZN2_\ ,??_ 'RH_P"(,'_JY+_S'W_W
MRK]RJ*/]:LT_Y^_^2Q_R#^R\+_+^+_S/PU_X@P?^KDO_ #'W_P!\J/\ B#!_
MZN2_\Q]_]\J_<JBC_6K-/^?O_DL?\@_LO"_R_B_\S\-?^(,'_JY+_P Q]_\
M?*C_ (@P?^KDO_,??_?*OW*HH_UJS3_G[_Y+'_(/[+PO\OXO_,_#7_B#!_ZN
M2_\ ,??_ 'RH_P"(,'_JY+_S'W_WRK]RJ*/]:LT_Y^_^2Q_R#^R\+_+^+_S/
MPU_X@P?^KDO_ #'W_P!\J/\ B#!_ZN2_\Q]_]\J_<JBC_6K-/^?O_DL?\@_L
MO"_R_B_\S\-?^(,'_JY+_P Q]_\ ?*C_ (@P?^KDO_,??_?*OW*HH_UJS3_G
M[_Y+'_(/[+PO\OXO_,_#7_B#!_ZN2_\ ,??_ 'RH_P"(,'_JY+_S'W_WRK]R
MJ*/]:LT_Y^_^2Q_R#^R\+_+^+_S/PU_X@P?^KDO_ #'W_P!\J/\ B#!_ZN2_
M\Q]_]\J_<JBC_6K-/^?O_DL?\@_LO"_R_B_\S\-?^(,'_JY+_P Q]_\ ?*C_
M (@P?^KDO_,??_?*OW*HH_UJS3_G[_Y+'_(/[+PO\OXO_,_#7_B#!_ZN2_\
M,??_ 'RH_P"(,'_JY+_S'W_WRK]RJ*/]:LT_Y^_^2Q_R#^R\+_+^+_S/PU_X
M@P?^KDO_ #'W_P!\J/\ B#!_ZN2_\Q]_]\J_<JBC_6K-/^?O_DL?\@_LO"_R
M_B_\S\-?^(,'_JY+_P Q]_\ ?*C_ (@P?^KDO_,??_?*OW*HH_UJS3_G[_Y+
M'_(/[+PO\OXO_,_#7_B#!_ZN2_\ ,??_ 'RH_P"(,'_JY+_S'W_WRK]RJ*/]
M:LT_Y^_^2Q_R#^R\+_+^+_S/PU_X@P?^KDO_ #'W_P!\J/\ B#!_ZN2_\Q]_
M]\J_<JBC_6K-/^?O_DL?\@_LO"_R_B_\S\-?^(,'_JY+_P Q]_\ ?*C_ (@P
M?^KDO_,??_?*OW*HH_UJS3_G[_Y+'_(/[+PO\OXO_,_#7_B#!_ZN2_\ ,??_
M 'RH_P"(,'_JY+_S'W_WRK]RJ*/]:LT_Y^_^2Q_R#^R\+_+^+_S/PU_X@P?^
MKDO_ #'W_P!\J/\ B#!_ZN2_\Q]_]\J_<JBC_6K-/^?O_DL?\@_LO"_R_B_\
MS\-?^(,'_JY+_P Q]_\ ?*C_ (@P?^KDO_,??_?*OW*HH_UJS3_G[_Y+'_(/
M[+PO\OXO_,_#7_B#!_ZN2_\ ,??_ 'RH_P"(,'_JY+_S'W_WRK]RJ*/]:LT_
MY^_^2Q_R#^R\+_+^+_S/PU_X@P?^KDO_ #'W_P!\J/\ B#!_ZN2_\Q]_]\J_
M<JBC_6K-/^?O_DL?\@_LO"_R_B_\S\-?^(,'_JY+_P Q]_\ ?*C_ (@P?^KD
MO_,??_?*OW*HH_UJS3_G[_Y+'_(/[+PO\OXO_,_#7_B#!_ZN2_\ ,??_ 'RH
M_P"(,'_JY+_S'W_WRK]RJ*/]:LT_Y^_^2Q_R#^R\+_+^+_S/PU_X@P?^KDO_
M #'W_P!\J/\ B#!_ZN2_\Q]_]\J_<JBC_6K-/^?O_DL?\@_LO"_R_B_\S\-?
M^(,'_JY+_P Q]_\ ?*C_ (@P?^KDO_,??_?*OW*HH_UJS3_G[_Y+'_(/[+PO
M\OXO_,_#7_B#!_ZN2_\ ,??_ 'RH_P"(,'_JY+_S'W_WRK]RJ*/]:LT_Y^_^
M2Q_R#^R\+_+^+_S/PU_X@P?^KDO_ #'W_P!\J/\ B#!_ZN2_\Q]_]\J_<JBC
M_6K-/^?O_DL?\@_LO"_R_B_\S\-?^(,'_JY+_P Q]_\ ?*C_ (@P?^KDO_,?
M?_?*OW*HH_UJS3_G[_Y+'_(/[+PO\OXO_,_#7_B#!_ZN2_\ ,??_ 'RH_P"(
M,'_JY+_S'W_WRK]RJ*/]:LT_Y^_^2Q_R#^R\+_+^+_S/PU_X@P?^KDO_ #'W
M_P!\J/\ B#!_ZN2_\Q]_]\J_<JBC_6K-/^?O_DL?\@_LO"_R_B_\S\-?^(,'
M_JY+_P Q]_\ ?*C_ (@P?^KDO_,??_?*OW*HH_UJS3_G[_Y+'_(/[+PO\OXO
M_,_#7_B#!_ZN2_\ ,??_ 'RH_P"(,'_JY+_S'W_WRK]RJ*/]:LT_Y^_^2Q_R
M#^R\+_+^+_S/PU_X@P?^KDO_ #'W_P!\J/\ B#!_ZN2_\Q]_]\J_<JBC_6K-
M/^?O_DL?\@_LO"_R_B_\S\-?^(,'_JY+_P Q]_\ ?*C_ (@P?^KDO_,??_?*
MOW*HH_UJS3_G[_Y+'_(/[+PO\OXO_,_#7_B#!_ZN2_\ ,??_ 'RH_P"(,'_J
MY+_S'W_WRK]RJ*/]:LT_Y^_^2Q_R#^R\+_+^+_S/PU_X@P?^KDO_ #'W_P!\
MJ/\ B#!_ZN2_\Q]_]\J_<JBC_6K-/^?O_DL?\@_LO"_R_B_\S\-?^(,'_JY+
M_P Q]_\ ?*C_ (@P?^KDO_,??_?*OW*HH_UJS3_G[_Y+'_(/[+PO\OXO_,_#
M7_B#!_ZN2_\ ,??_ 'RH_P"(,'_JY+_S'W_WRK]RJ*/]:LT_Y^_^2Q_R#^R\
M+_+^+_S/PU_X@P?^KDO_ #'W_P!\J/\ B#!_ZN2_\Q]_]\J_<JBC_6K-/^?O
M_DL?\@_LO"_R_B_\S\-?^(,'_JY+_P Q]_\ ?*C_ (@P?^KDO_,??_?*OW*H
MH_UJS3_G[_Y+'_(/[+PO\OXO_,_#7_B#!_ZN2_\ ,??_ 'RH_P"(,'_JY+_S
M'W_WRK]RJ*/]:LT_Y^_^2Q_R#^R\+_+^+_S/PU_X@P?^KDO_ #'W_P!\J/\
MB#!_ZN2_\Q]_]\J_<JBC_6K-/^?O_DL?\@_LO"_R_B_\S\-?^(,'_JY+_P Q
M]_\ ?*C_ (@P?^KDO_,??_?*OW*HH_UJS3_G[_Y+'_(/[+PO\OXO_,_#7_B#
M!_ZN2_\ ,??_ 'RH_P"(,'_JY+_S'W_WRK]RJ*/]:LT_Y^_^2Q_R#^R\+_+^
M+_S/PU_X@P?^KDO_ #'W_P!\J/\ B#!_ZN2_\Q]_]\J_<JBC_6K-/^?O_DL?
M\@_LO"_R_B_\S\-?^(,'_JY+_P Q]_\ ?*C_ (@P?^KDO_,??_?*OW*HH_UJ
MS3_G[_Y+'_(/[+PO\OXO_,_#7_B#!_ZN2_\ ,??_ 'RH_P"(,'_JY+_S'W_W
MRK]RJ*/]:LT_Y^_^2Q_R#^R\+_+^+_S/PU_X@P?^KDO_ #'W_P!\J/\ B#!_
MZN2_\Q]_]\J_<JBC_6K-/^?O_DL?\@_LO"_R_B_\S\-?^(,'_JY+_P Q]_\
M?*C_ (@P?^KDO_,??_?*OW*HH_UJS3_G[_Y+'_(/[+PO\OXO_,_#7_B#!_ZN
M2_\ ,??_ 'RH_P"(,'_JY+_S'W_WRK]RJ*/]:LT_Y^_^2Q_R#^R\+_+^+_S/
MPU_X@P?^KDO_ #'W_P!\J/\ B#!_ZN2_\Q]_]\J_<JBC_6K-/^?O_DL?\@_L
MO"_R_B_\S\-?^(,'_JY+_P Q]_\ ?*C_ (@P?^KDO_,??_?*OW*HH_UJS3_G
M[_Y+'_(/[+PO\OXO_,_#7_B#!_ZN2_\ ,??_ 'RH_P"(,'_JY+_S'W_WRK]R
MJ*/]:LT_Y^_^2Q_R#^R\+_+^+_S/PU_X@P?^KDO_ #'W_P!\J/\ B#!_ZN2_
M\Q]_]\J_<JBC_6K-/^?O_DL?\@_LO"_R_B_\S\-?^(,'_JY+_P Q]_\ ?*C_
M (@P?^KDO_,??_?*OW*HH_UJS3_G[_Y+'_(/[+PO\OXO_,_#7_B#!_ZN2_\
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M'W_WRK]RJ*/]:LT_Y^_^2Q_R#^R\+_+^+_S/PU_X@P?^KDO_ #'W_P!\J/\
MB#!_ZN2_\Q]_]\J_<JBC_6K-/^?O_DL?\@_LO"_R_B_\S\-?^(,'_JY+_P Q
M]_\ ?*C_ (@P?^KDO_,??_?*OW*HH_UJS3_G[_Y+'_(/[+PO\OXO_,_#7_B#
M!_ZN2_\ ,??_ 'RH_P"(,'_JY+_S'W_WRK]RJ*/]:LT_Y^_^2Q_R#^R\+_+^
M+_S/PU_X@P?^KDO_ #'W_P!\J/\ B#!_ZN2_\Q]_]\J_<JBC_6K-/^?O_DL?
M\@_LO"_R_B_\S\-?^(,'_JY+_P Q]_\ ?*C_ (@P?^KDO_,??_?*OW*HH_UJ
MS3_G[_Y+'_(/[+PO\OXO_,_#7_B#!_ZN2_\ ,??_ 'RH_P"(,'_JY+_S'W_W
MRK]RJ*/]:LT_Y^_^2Q_R#^R\+_+^+_S/PU_X@P?^KDO_ #'W_P!\J/\ B#!_
MZN2_\Q]_]\J_<JBC_6K-/^?O_DL?\@_LO"_R_B_\S\-?^(,'_JY+_P Q]_\
M?*C_ (@P?^KDO_,??_?*OW*HH_UJS3_G[_Y+'_(/[+PO\OXO_,_#7_B#!_ZN
M2_\ ,??_ 'RH_P"(,'_JY+_S'W_WRK]RJ*/]:LT_Y^_^2Q_R#^R\+_+^+_S/
MPU_X@P?^KDO_ #'W_P!\J/\ B#!_ZN2_\Q]_]\J_<JBC_6K-/^?O_DL?\@_L
MO"_R_B_\S\-?^(,'_JY+_P Q]_\ ?*C_ (@P?^KDO_,??_?*OW*HH_UJS3_G
M[_Y+'_(/[+PO\OXO_,_#7_B#!_ZN2_\ ,??_ 'RH_P"(,'_JY+_S'W_WRK]R
MJ*/]:LT_Y^_^2Q_R#^R\+_+^+_S/PU_X@P?^KDO_ #'W_P!\J/\ B#!_ZN2_
M\Q]_]\J_<JBC_6K-/^?O_DL?\@_LO"_R_B_\S\-?^(,'_JY+_P Q]_\ ?*C_
M (@P?^KDO_,??_?*OW*HH_UJS3_G[_Y+'_(/[+PO\OXO_,_#7_B#!_ZN2_\
M,??_ 'RH_P"(,'_JY+_S'W_WRK]RJ*/]:LT_Y^_^2Q_R#^R\+_+^+_S/PU_X
M@P?^KDO_ #'W_P!\J/\ B#!_ZN2_\Q]_]\J_<JBC_6K-/^?O_DL?\@_LO"_R
M_B_\S\-?^(,'_JY+_P Q]_\ ?*C_ (@P?^KDO_,??_?*OW*HH_UJS3_G[_Y+
M'_(/[+PO\OXO_,_#7_B#!_ZN2_\ ,??_ 'RH_P"(,'_JY+_S'W_WRK]RJ*/]
M:LT_Y^_^2Q_R#^R\+_+^+_S/PU_X@P?^KDO_ #'W_P!\J/\ B#!_ZN2_\Q]_
M]\J_<JBC_6K-/^?O_DL?\@_LO"_R_B_\S\-?^(,'_JY+_P Q]_\ ?*C_ (@P
M?^KDO_,??_?*OW*HH_UJS3_G[_Y+'_(/[+PO\OXO_,_#7_B#!_ZN2_\ ,??_
M 'RH_P"(,'_JY+_S'W_WRK]RJ*/]:LT_Y^_^2Q_R#^R\+_+^+_S/PU_X@P?^
MKDO_ #'W_P!\J/\ B#!_ZN2_\Q]_]\J_<JBC_6K-/^?O_DL?\@_LO"_R_B_\
MS\-?^(,'_JY+_P Q]_\ ?*C_ (@P?^KDO_,??_?*OW*HH_UJS3_G[_Y+'_(/
M[+PO\OXO_,_#7_B#!_ZN2_\ ,??_ 'RH_P"(,'_JY+_S'W_WRK]RJ*/]:LT_
MY^_^2Q_R#^R\+_+^+_S/RH_X)M?\&R/_  [U_;3\%_&#_A=O_"7?\(C]N_XE
M/_"'_P!G_:_M-A<6G^N^W2[-OVC?]QL[,<9R/U7HHKRL=F&(QE15<1+F:5MD
MM-^B7<ZJ.'IT8\M-604445QFP4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 445YKX__;-^#_PG\77?A_Q3\5_AKX:U[3]GVK3=5\3V5G>6V]%D
M3?%)*KKN1E89 RK C@BJC3E-VBKDSJ1@KS=O4]*HKQW_ (>(_L__ /1=/@[_
M .%IIO\ \>H_X>(_L_\ _1=/@[_X6FF__'JT^K5OY7]S,OK5'^=?>CV*BO'?
M^'B/[/\ _P!%T^#O_A::;_\ 'JTO"'[<'P5^(/B:RT70/B_\+]<UG4I1#:6&
MG^*K&YNKJ0]$CC24LS'T )H>'JK5Q?W,:Q5%NRDOO1ZA1116)L%%%<G\5OCU
MX&^ ]C9W7CCQIX3\&VNH2-%:S:[J]OIT=RZC)5&F=0Q Y(&2!51BY.T5J3*2
MBKR=D=917G?PW_:^^$OQD\41Z'X0^*'P[\5:U+&TJ:?H_B2SOKIT499A'%(S
M$ <DXP*]$HE"47:2L$*D9J\7?T"BBBI*"BBB@ HKS7Q_^V;\'_A/XNN_#_BG
MXK_#7PUKVG[/M6FZKXGLK.\MMZ+(F^*2577<C*PR!E6!'!%=+\+?C/X/^.7A
M^;5O!/BSPUXPTJWN&M);W1-3@U"WBF55<Q-)"S*'"NC%2<@.IQ@BM)4IJ/,T
M[=[&<:T'+E35^USI:***S- HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **XKXK_M*?#GX#75G!XY\?>"O!D^
MI(TEI'KNN6NG-=*I 8QB9U+ $@$C.,BHOA7^U'\,_CKK-QIW@CXB^!?&6H6<
M/VF>UT/7[74)H8MP7S&2&1BJ[F4;B,9('>M/93Y>>SMWMH9^VI\W)S*_:^IW
M5%%%9F@4444 %%%% !1163XX\>Z'\,?"MYKWB76M)\/:'IZA[K4=3NX[2UME
M+!07ED(1068 $D<D#O32;=D)M)79K45Y+I'[?7P)\0:M:V%A\:OA+?7U],EO
M;6UOXOT^2:XD<A51%68EF9B  !DD@5ZU53ISA\::]2(5(3^!I^@4445!H%%>
M4^(OV[_@?X0\07VDZM\9OA3I>JZ7<26E[97?BVP@N+2:-BDD4D;2AD=6!4JP
M!!!!&:[[P!\1/#_Q8\(VGB#PMKNC^)=!U#?]EU+2KV.\L[G8[1OLEC9D;:ZL
MIP3AE(/(-:2I3BN:2:7H9QK0D^6+3?J;%%%%9F@4444 %%%% !1110 45G^*
MO%NE>!/#]SJVN:GI^C:59*&N+V^N$M[> $A07D<A5!) Y/4BOF?QQ_P6U_99
M^'NHS6M_\8-"N)(93"S:997FIQE@6!*O;0R*R_*<,"5(P02""=J6'JU?X47+
MT3?Y&%;%4:7\6:CZM+\SZHHKY=^'_P#P6H_9;^)=ZMOIOQB\.VTCRB('5;>Z
MTE,GG)>ZBB4+_M$[1ZU]+Z'KUCXGTF#4--O+34+&Z7?#<VTRS0RCIE64D$<=
MC15P]6EI5BX^J:_,='$TJNM*2EZ-/\BW1116)L%%%% !1110 4444 %%%<-\
M1?VG_AK\(+^:U\6_$/P-X7NK?'FPZOKUK8R1Y"D;EE=2,AT(SU#+ZBJC&4G:
M*N3*<8J\G8[FBN&^&/[3_P -?C9?M:^#?B'X&\774>=T.BZ]:W\BX&3E8I&/
M Y^E=S1*,HNTE8(SC)7B[H***S?%/C'2/ VE?;M;U33='L0XC-Q?7*6\6X]!
MN<@9/IFI5WHBF[:LTJ*\K\/?MU_!'Q;J(L])^,GPKU.[92X@M/%EA-(5'4[5
ME)P/6O5*N5.4-))HB%2$]8-/T"BBBH+"BO.?''[8/PE^&6HS6?B3XI?#GP]=
MV\I@E@U/Q)9VDD<@+ HRR2 A@58$'D%3Z&MGX8?'WP+\;H))?!?C3PEXNCA!
M,CZ+J]OJ"H <')B=L<\<]ZT=*:7,T[>AFJU-RY5)7[7.MHHHK,T"BL3QO\2_
M#?PSL8[KQ)X@T3P_:R;MDVI7T5I&^T9;#2, <#D^@K@]$_;R^!OB6^6UTWXS
M?"C4+IND-MXNT^60\@?=64GJ0/J16D:4Y*\4W\C.5:G%VE))^IZO11169H%%
M%% !1110 4444 %%%% !1110 4444 %%>17_ /P4"^ NE7TUK=?&[X16UU;2
M-%-#+XQTY)(G4X964S9!!!!!Y!%>E>#?&NC?$;PO9ZYX>U;3->T74H_-M-0T
MZZ2ZM;I,D;HY$)5AD$9!(XK25*<5>2:^1G"M";M%I^C-.BBBLS0**** "BBB
M@ HHHH ***Y/XK?'KP-\![&SNO''C3PGX-M=0D:*UFUW5[?3H[EU&2J-,ZAB
M!R0,D"JC%R=HK4F4E%7D[(ZRBO._AO\ M??"7XR>*(]#\(?%#X=^*M:EC:5-
M/T?Q)9WUTZ*,LPCBD9B .2<8%>B42A*+M)6"%2,U>+OZ!1114E!1110 4444
M %%%<+\5/VH_AG\"M9M].\;_ !%\"^#=0O(?M,%KKFOVNGS31;BOF*DTBEEW
M*PW 8R".U5&,I.T5<F4XQ5Y.R.ZHKBOA1^TI\.?CS=7D'@;Q]X*\9SZ:BR7<
M>A:Y:ZBUJK$A3((78J"00"<9P:[6B491=I*S",XR7-%W04445)04444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%0:GJ=MHNFW%Y>7$%I9VD333SS2
M"..&-02SLQX50 22> !7DG_#Q']G_P#Z+I\'?_"TTW_X]6D*4Y_ F_1&<ZT(
M?&TO5GL5%0:9J=MK6FV]Y9W$%W9W<2S03PR"2.:-@"KJPX92"""."#4]9F@4
M45F>,O&NC?#GPO>:YXAU;3-!T738_-N]0U&Z2UM;5,@;I)'(51D@9) YH2;=
MD#:2NS3HKR*P_P""@7P%U6^AM;7XW?"*YNKF18H88O&.G/)*['"JJB;)))
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BN3^*WQZ\#?
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "OY^O\ @MU^QE\8/BQ_P4_^)WB#PM\*/B5XET'4/[*^RZEI7AB]
MO+.YV:391OLECB9&VNK*<$X92#R#7] M%>CEF8RP55U8J]U;\4_T/,S7+(XZ
MBJ,VU9WT]&OU/Y1]3_8!^/&BZ;<7EY\$_BY:6=I$TT\\W@_4(XX8U!+.S&'"
MJ "23P *\CK^M[]I?_DW'X@?]BWJ/_I+)7\D-?>9+FL\;&3G%+EMMYGYYGN3
MPP$H1A)RYK[^5CU;P[^PA\</%_A^QU;2?@S\5M4TK5+>.[LKVT\)7\]O=PR*
M'CECD6(JZ,I#!E)!!!!Q7T3_ ,$M?V'_ (U?#[_@H7\)=:U_X0?%#0]&TWQ!
M#-=W^H>%;ZVM;6,!LO)(\055'J2!7[I_\$[O^4?WP+_[)[H'_IMMZ]BKY_%<
M357ST>1=5N_0^DP?"E)<E?VCOH]EZA17YE_\%G/^"SGQ0_X)U_M0Z#X)\$Z#
MX!U32M4\+6^MRRZW97<]PLTEW>0E5,-S$NS;;H0"I.2W., >4^#?^#F7Q)8?
ML>ZYXD\3^&_!MU\4+W6Y-+\-:7I=M<PZ?'!'!#))=7@>XDDVJTP551T,AX!
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MNO'W[7/AWX:V\UTND?#_ $A+JXA8!8Y+^\Q(SC'WP+=;< M]TM( !DEO3RC
M_6\2J4MMWZ+_ #V/*SK,'@\+*K'XMEZO_+<^._VV_P#@H5\3OV^O'C:OX\UR
M233K>=Y=-T.U)CTW20P Q%%DY;  +N6=N[=JM?LY_P#!,#X^_M8^'X]8\!_#
M'Q!JVC3Q--!J5RT.FV5VJOL)AGNGBCEPV1A&8Y5O[IQ[Q_P00_X)SZ+^W)^T
M3JVN^-+-M0\#?#F."ZNK%P/)U6\F9_L]O)R"8P(I)' !!V*K8#\_T/6EI%86
ML<$$4<,$*"...-0JQJ!@  <  <8%?5YIG4< UA<-!77W+Y+J?'93D,\PB\7B
MINSV[OSN[Z=#^5O]I7_@G'\</V0=,.H?$+X;^(-!TI2H?4D$=]I\18J%5[FW
M:2%&8L  S@DY !(.-C]@W_@IC\4/^"??CB&\\(ZQ-=^&YYT?5?#=X_F:?J<8
M/S  @F&0@G$L>&!QG<N5/]0VM:+9^)-&N].U&TM=0T_4(7MKJUN8EEAN8G4J
M\;HP(964D%2"""0:_F[_ ."V_P#P3_T_]@C]KQ[/PO;M;^ _&=I_;&A0M*9#
M8'=LN+3<WS$1R#<N<XCEC!9F#&JRO.(9A?#8F"NU\G]^S%FV25,MMBL+-V3^
M:^[=/8_H(_9+_:?\.?MD?L^>&_B+X5:9=)\10&3R)BOGV4JL4E@D"D@.CJP.
M#@X!'!%>C5^)_P#P:S?M,76B_%?Q_P#"2\N+A]-URP7Q+IL1!,-O=0,D-QC'
M1I8I(<DC!%JHR#@-^V%?'YI@OJN)E16VZ]'_ %8^URC'?6\+&L]]GZK^KA7X
M'_\ !PE_P4VA_:@^+B_"7P;?077@/P'>>9?7MNQ*:QJBJR.5;.&A@#-&IQ\S
M^:P++L-?<G_!>_\ X*B1_LA_!=_AOX,U-8_B9XXMRDLD.UFT+36W+).<YQ++
M@QQC&0#(^5*)N_")O@KXDB^"G_"PI=/DA\*2:RN@P7D@*K=7?DO,Z1_WMB*"
MQ[&1!SDX^BX;RQ*V,K>D5^O^7S9\SQ1FS=\%0]9-?E_G\EW/MW_@V>_Y222?
M]BGJ'_HRWK^@ROY\_P#@V>_Y222?]BGJ'_HRWK^@RO/XH_WWY+]3TN$_]Q_[
M>?Z!1117SI],?D?_ ,%^_P#@K_XN^"OQ#F^!_P +M3N_#.IV=M!=>)=?LYC%
M?PF:,2Q6ENXP8?W;1R-*IWGS%52H#;_R!\"_#/QE\>_%TUGX9\/^)O&FO73/
M<2P:98SZE>3,=SN[+&K.QX9B3Z$^M?H5^V#_ ,$)OVI/CK^T7XZ\?#1?"FI/
MXNUJZU:.&#7XE:".:=FCA_>[!^[C*CJ1A>I-?J%_P1Z_8UN/V)/V'/#?AG7-
M AT'QMJ$D^I>)D6YCNI);MY7";I(V9#L@6% $.T;>[%F/W4,PPF78./U>TIN
MU[/K;5OK8_/IY;C,RQTOK/-""O:Z=K7T2Z79_-;XO\#>*O@GXR6QU_1_$'A'
MQ!I[K,MOJ%I-87ELRL=KA7"NI#*<' P5]J_:;_@W\_X*V>)OVE=3F^"_Q*O+
MK7/$FDZ=)J&B>(KF8R7.I01,@>VN6;+23*K[EE.2Z(V\[E#/TW_!SY\.?#&J
M_L/:!XHU"UM8_%&C^)[:RTJ]"*)W2:&<S6V[!)C98_,*@CYH5/8@_F/_ ,$,
M=.U#4?\ @JG\)?[-6=I8+N\FF:)MNR!;"Y\TDY'RE-P([YQSG!Z*M2GF66RK
M5(V<4_DUKH^S.:C2JY7FD*%.5U)I/S3=M5W1_19^T3\=-$_9F^!OBGQ]XBE\
MO1_"NGRW\X!PTQ4?)$O^W(Y5%_VG%?S'_MV_M_\ C[]O_P"+]]XF\7:A-;Z;
MYFW2]!MYF^P:1"N[8B+P&DPS;I2-S%CT&%'ZY?\ !T1\8)?"'[&7A'PA;G:W
MC+Q*LMP=X^:WM(6<KMZG,LD#9Z#9[BOS;_X(5_ ?3OC[_P %+O =GK%JMYI7
MAW[1XAG@=-RR/;1%H-W; N#"QSP0N.]<?#^'IT,)/'U%=ZV]%V]6=W$F(JXC
M&0R^F[+2_J^_HCYP\:_L^^/?AKX7L=<\1^"/%_A_1=4S]CU#4M&N+6UN\$ ^
M7)(@5\$@':3U%??'_!#+_@KSXH^!?QIT+X4_$#7[K5_AKXFF^P:=)?SIN\.7
MLKKY<@FD^;[.S95XRVU2X=<$.LG[;_M(_ K2/VF_@-XL\ :ZJ-I?BO39;"1V
M3?\ 9V8?NY@,C+1R!''(Y0<BOY*;B"Y\/ZO)&V^WO+&8J2C_ #12(<<$'J".
MH-=V"QE/-Z$Z5:-FOGOLUYGGX[!5<FQ%.K1FVG\KVM=/R=_ZL?V&5^&/_!<W
M_@L?XU\8_'#Q)\&_AOK6H>$_"?@^[ETG6[[3KEH+W7;M/DN(FD7#);QMOB\M
M3^\(<L6!55_7S]G'XMZQ\9OV,/!'C>S^RZKXB\2>#K+5U5RL45Q?2V:2%'V?
M*@,Q*L!]WD=J_#'Q_P#\&[_[50U*^U!M"\-^)+RZE>>5[3Q#;J]S(^79OWQC
M&2Q(YQR?3FOG\AIX:%>4L4TG'1)OKWU[?J?2<15L54P\(8.+:EJVETZ+3O\
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M_AW1^R^?$.FV=KJ7C#Q%=?V5H%M<9\E)BC,]Q(!]Y(E&=N1N9E7(!)'Y4_\
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M&I.G*5G"][KL[:=]3]9:*_G#\0_\'#'[5FM>(#>6WC[2])M]P/V"T\-Z<UN
M#G&987EP>GW\^X/-?;'_  2@_P"#A/5/CI\5="^&/QHL["/5_$4T>GZ-XDT^
MW,2W=[))MB@N8%^5?,+*BR1@*&"AEPQ==L1PWC*--U'9VZ)Z_DCGPO%&"K55
M25XWV;2M^#?XGZR445\?_P#!4C_@L#X-_P"";FBV>FK8Q^,?B%JR"6TT"*\^
MSBU@.1]IN9 KF-,@A5V[I""!@!G7Q\/AZE>HJ=)7;/;Q.)I8>FZM9VBC[ HK
M^<WX@?\ !Q/^U-XRUQKO3?&&A>$[=B2++2O#MG) N>P-U'/)Q[O]<UU'P/\
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M12?NH(G!&$9'D^4$NNXHLX'+:^+DU16V[>R*S#-</@HJ59ZO9+=G[A5^%/\
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M?$3Q1/#\*=/TSX>^'X]Z6\UW:0ZEJ4X(3#R&4-"I!5B%5" 'P2V :\Q^'_\
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MW<_??_@WF\<ZW\2O^">XUSQ'K&J>(-;U'Q/J,EWJ&I7<EU=73#RE!>60EF.
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M[X;J"5 \<B-W5E8$'N"*Y,PRNO@Y)5EH]FMCLRW-L/C8MT7JMT]T:%%?)_\
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M9+56.R'%86'M)V:ZM/;\A8#B'"8NI[*#:D]DUO\ <VBQ_P %^?\ E$G\6/\
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M%OX'L]1&B:38V;ZMK>I^7YC6=HCHA\M20&D=Y$11GC<6.0I%?4?_  =*?\I
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M#I4-K?V,J@!))'0*UR/E =968N"WS*Q#C^<75[#Q)^S/\<[JU6XFT?QA\/\
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M1G6- ""7=0"#@U\GA<3+!X]^QU7,U9=5>UO\C['%86..RY>WT?*I7?1VO?\
MS\C^<#]@O_@IQ\0O^"?&C>/-/\'FUN+/QUIAM6BN2<:;>*K+#?18Y$D8=QMX
M5\KNSL7'F7[.WP#\7?MC_'_1?!7AF&?5O$WBJ\;=++)NVCF2:XE=C]U%#NQ)
MR<'&20#Q6OS6=QKM[)IL,UOI\EQ(UK%*^^2*(L=BL>Y"X!/<U^G/_!K_ /&K
MX?\ @/\ :)\8>%]<M;6S\>>,+".'0-5GD_U\,3&2>PC&/E9R$E^]\_D 8RHS
M]]CI+#4:F*I0]ZVORTU]#\ZP$7BJ]+"5IVA?3YZM+U/V#_8^_97\.?L7_L\>
M'/AWX73=8:%!MFNVB6.;4;AOFEN)-O\ &[9/? VJ#A17Y@_\'97_ #0'_N8O
M_<77[%5^.O\ P=E?\T!_[F+_ -Q=?"Y#4E/,H3D[M\W_ *2S] XAIQAE<X05
MDN5+_P "1^=/_!.']BRZ_;Z_:R\/?#N*_;2=/NA)?:K>JNZ2VLH0&E*#!'F-
MD(NX;0SJ3QFOZ$-!_P""0O[-.@?"IO!Z_!WP7=:;) ;>2\NK(3:JX(P6%\?]
M)1SU#)(I4_=Q7Y/_ /!KE=Q6W_!0;Q4DDD<;W'@"]CB5F ,C?VAIS87U.U6.
M!V4GM7[X5Z'$V-KQQ2I0DTDD]';7N>?PK@:$L(ZLXIMMK57T70_F!_X*P_L&
MI_P3P_:]U#P38ZA)J?AS4[&+7=!FG8&Y%E,\D8CFP /,26&9,CAU17PN[:OZ
M=?\ !KU^T[J/Q(_9R\:_#75KR2Z_X5YJ$%WI7FLN8K*]$I,*<[BJ30RN<C@W
M &<8 \#_ .#JS_DX[X6_]BW<?^E1J7_@U0^T?\- ?%?;YWV7_A'K3S,9\O?]
MI.W/;.-^,\XW>]>CC)O$Y*JM7XK)W\T[7^9Y>!@L+GKHTM(W:MY-7M\G^1],
M_P#!6?\ X(E>//\ @HE^T/'XZTKXE:!IMI8Z1!I6G:/J.FRHMFB&1W_?1LV_
M?+(S;B@(#[>0BYWO^";G_! WX=?LP> &NOBUX?\ !_Q.\?7%Y.YFN+=[W2K*
MVY2**."=0DC%?WC.\65=]JY$:NWGO_!;/_@N!XD_9(^(]Q\(_A.EK9>,K*&&
M?6]?O+9+G^RO-1)HH;>)\QM*T;*S-*K*JR !2QW)^44-_P#M#?\ !13Q=-!'
M-\4/BSJ&U?-C5[K4(;5%;(W#F.% SY&=J@OZMSS8/"8^O@U&I55.G;3O;Y6T
M?KJ=>.QF74,;*5.DZE2^NNE_G?5>2T/T'_X+Q_"3]D?0_P!GF/4OAK-\+]%^
M*5KJ4!MK'P?<0*;NVSY4\<UM;'R4 W!P[HKEH2%8YD!^*?\ @BSXIN/!_P#P
M5&^#MW;_ .LFUB2Q/3[EQ:S6[]0?X96]_0@\B'X[?\$@_CI^S%\ -0^)'Q \
M-:?X7\/Z>;=6CGU6">[E>>58D01PL^UOF#$.5P 1][Y:H_\ !(;_ )28_!?_
M +&2#^35[%&G3A@*E.%3VBM+6]^FQX5>M4GF-.I.E[-WCI:W7<_HD_X*(_\
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MC^)OV$?VC/&'B34-6U#X'_&";4-4N9+RYD3P/?Q*\LC%W(1( J@L2<* !T
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M_!-_QG<_$']@+X,ZM>;FO+GP=IBSNS;FE=+:.-I"<#EBI;';=CGK7M5?/O\
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MS7 ZK"1B(X+$R?+']9@\+1RFE]9Q3O4>R_1?J]OU^/QN,KYS6^JX16IK=O\
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MD\\9KYW!9IB5BXU'-N[5U?>[VM^78^HQV4X5X.5)02LG9VU32WOOZ]S\&?\
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M]HZ_ZO<-WW>?NYZ<UCPI2BE5J=;I?(VXPK2;I4^EF_GH?T)?\$U?^"(_P?\
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M7+3Q/H=GJ6GSI=6.H0)<VTR?=EC=0RL/8J0?QK^5RX_X)Z_M!7-Q)(WP+^,
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M6H1>,K*G%=%I]^R/S_Z_E]#$26"H.I)]7K]V[/7_ /@N7\._V?? G[16AM\
M]0\,R6UUI[IXAL/#UY]KTZTNT<%'1@S1JSQOM9(FVJ8>5#E\_1?_  :D>*;B
MT^+GQBT5?^/74-(TZ^DZ??@FF1>V>EP_0@>QXQ\#?ME?\$^/B3^P5)X;A^)-
MCI>EWWBE+B6TM+:_2[D2.%HU9G:/* ,9!@!B?E.0.,_<W_!JG_R<=\4O^Q;M
M_P#TJ%=F81@LIE&,^=66N]]3ARV4WG,92AR-OX;6M>+/IC_@Z4_Y1_>#_P#L
MH5E_Z;=3K\6?V1?V=K[]K/\ :6\&_#G3[J&QN/%>HI:&YE/RV\8!>5^AR5C5
MR!W( [U^TW_!TI_RC^\'_P#90K+_ --NIU^:G_!!"TBO?^"M'PE2:*.9%?59
M KJ& 9=(O64\]PP!![$ UADM5T\JE4CNN9_<CHSVE&KG$*4MI.*?S=C]O?A9
M_P $?/V;?A/\.5\-V_PD\(:U"UM]GGU#7+%-2U*X.TAI?M$H+QNV2V8B@4D;
M0H50/P'_ ."J'[*&C_L5?MT^-_A_X=GFG\/:?)!>::)V+2V\%S!'.(68\MY9
MD*!B265 3R2!_4=7\[G_  <??\I/-<_[ 6F?^B:\SAG&5IXN4:DFTTWJ[ZW1
MZG%6#H4\'&5.*332T5M+/0^]/^#7#QG<ZS^P]XQT:?<\>B^,9FMV+<(DUI:L
M8P,< .KMG)R9#TQS^E]?EO\ \&K7_)J/Q)_[&Q?_ $CAK]2*\C.U;'5+=_T/
M;R%MY?2OV_5A7S7_ ,%4_P!AOQ%_P4'_ &9!\/\ 0/&5GX._XF<.I737.GM=
M1ZDL2OLMV974Q+O99"P5SF)1@ FOI2OFG_@J7_P46TO_ ()O?LZ_\)/)IW]M
M^)M<G;3?#^G,2L,USL+&6=@01#&!E@OS,2JC;N+KR8+VOMX^P^*^GK\SLQWL
M?J\_K'P6U]/D?$?[$_\ P;+?\*S^.T>M_&;6_"OCCP?I\$C6VCZ<]W$;VXR!
M&TYQ'B-1EB@9@S!0<KD'ZD_:U_9/_8@\!_#BZT#XB>'O@KX!C$("2VR6>CZS
M&=A57C:(+<2, V[!#AB S*V*_$?XU_\ !2+]HS]MKQFMGJ7CCQAJ4E]<,]GH
M'A\R6EL#]Y4CMK;'F;%&%+[W !)8DL3UGP<_X(6?M/?&7[/+%\-KKPW8W$:R
M?:?$-W#IOE!NFZ%V\\'@Y7R\CN!D9^RK8"NY*KCL3ROLM/NU7Y'P^'S"@HNC
M@,*YKNU?[]'^9\EZA#%;7\\=O-]H@CD98Y=A3S5!X;:>1D<X/2OZO/V'/$4O
MC#]BGX/ZM,NV;5/!.BW<@R.&DL(7/0 =3V ^E?RBZQIDFB:O=6<K(TMG,\+E
M#E2RD@X]N*_JJ_X)W?\ */[X%_\ 9/= _P#3;;U/%O\ !IOS?Y%\&W]M47DO
MS/YK_P#@HC_RD!^.G_90M?\ _3E<5]/?\$:O^"+MK_P45\/ZYXU\;:[K'A_P
M'I%XVDVZ:08DO]2NQ&LC[7E1TCCC$D>28VWEBHVE2:^8?^"B/_*0'XZ?]E"U
M_P#].5Q7[Q?\&^NAVFD_\$G_ (:W%O D,VJ3ZM<W3#K-(-4NX@Q]_+BC7Z**
M[,WQE3#9?"5)V;LK]M+_ *'#DN!I8K,9PK*Z7,[=];?J._X)Q?\ !&;PI_P3
M?^/?C3QAX?\ $VL>(K;Q!I4.E:9%J442W6G0F;S;A9)(PJR[VBMBK*D>-C@J
M<@C\?O\ @OS_ ,I;/BQ_W!__ $S6-?TGU_-A_P %^?\ E+9\6/\ N#_^F:QK
MQ^&\34KXZ52J[OE_)Q/;XHPM+#Y?"G15ES_FI'N/_!OE_P $N?!'[8L?BWXB
M_$K2F\0>'/#EVNC:;I4C/':W5V8UEEED9&4MY:/$ GW3YV3G %?3G_!?;_@F
MU\)/"G[".K?$;P9X#\)^!_$7@6]LI#-H.G1Z:E];7%S':O#)%"JQR'?/&X=E
MWKY6 P#,K=9_P;#6$5G_ ,$Z]8DC7:]UXVOY93DG<PM;),^WRJHX]*]1_P""
M_/\ RB3^+'_<'_\ 3S8UGB,=7>;J/,[*25KZ6ND_O-,-E]!9*Y<JNX-WMK>S
M:U\C^<#PCX7O/''BS2]%TZ/SM0UB[BL;6/\ ORRN$0?BS 5_2M^S-_P1=_9^
M_9X^$%IX;O?A[X5\=ZHULL>I:[XBTJ&]O+^7YMTB>8&%N,N0JQ$$*$RS,N\_
MS[_\$^;2*_\ V]_@A!/%'-!-X_T&.2.10RR*=1@!!!X((XP:_JVKLXJQ56#A
M2@VEJW;J<7"&#I5(U*M2*;T2OK;N?RS_ /!3[]E[3?V-OVZOB!\/=#%Q_8.C
MW<-QI@F=I&2VN;>*YC3>P!?8)?+W'))0Y).2?V!_X-AO%-YX@_X)V:S:74GF
M0Z'XWO[&T7_GG$UK97!'_?R>0_C7YO?\'#O_ "E3\<_]>&E?^D$%?HA_P:U_
M\H_O&'_90KW_ --NF5MG%1U,HA.>K?*_G8QR6FJ><U*<-$G)?*Y^E%%%%?!G
MZ$?C/_P=1?LU+9Z[\-_B]96ZJM[')X5U60 C,B;[FTSV)*F[!)P<1J.0/EI_
M\&JWQ[BTOQ[\4?AG>7C!]8L[7Q%IENQ 4- S0717CEF6:V.,](B0.&(_0#_@
MM!\!)_VB?^":_P 3M'L;?[3JVDV":_8@1F23?92I<2!%!&7>&.:,#DYDX!.!
M7X3_ /!'O]H4_LU?\%&/AEKDF[^S]3U,:!?J(P_[F]!MMWK\CR))\O/[O&#D
MJ?ML _K>43H/>-[?+5?Y'P>8KZGG5.NMIVO\_=?^9]6?\'27QT_X2W]J3P-X
M!M[N:2U\&Z$U_<P[-L<5U>2<\X!9O)@A.<E0'P,'>*_,?3[Z\\+ZS:WENTUG
M?6<D=U;R8VM&PPZ.,_\  6![\5[A_P %-?CE)^U!_P % OBAXHM;R36+.^U^
M6PTJ5(MOG6EN1;6VQ,9P8XD(X#,3DC<37N7_  72_86M?V*_''P=AT^W@2WU
M/P)9Z5?W,*GR[_4].58+F8,0"=R/;'D9&1T! 'MX!PPU*CA9;R3^_=_F>#F*
MGBJU?&1VBU]ST7Y'[:^)_P!LNQT7_@G?<?':+[&T/_"$#Q3;PG+1/.]H)8[<
MX.>9F6,C(()P2""1_,1\-/ FN?M'?&_0_#=B7OO$7C?6H;&)WQF6XN9@N]B<
M #<^220 ,DD"ON;QU^W=)<?\&\_A'X<6^I1MK5YXPG\+WT:_ZTZ=;/\ VD-V
M1D8::S0%."JE2<AU-7_@VR_9RA^,7[?;>++Z*.73_AII$VJ(LD(D5[R;_1H!
MSP"JR32JW)#0K@9^9?,R^BLOP]>M+HW;T6B^]L]3,L0\RQ.'H1ZI7]7J_N2/
MVY^)'P\TWX1?L3:]X3T=9(](\+^"+C2;%9""RP6]@T48)  SM0= !["OY/J_
MK>_:7_Y-Q^('_8MZC_Z2R5_)#6/"4FXU6^Z_4WXRBE.DEV?Z']3T?[+W@7]K
MW]B3P%X.^(FA_P#"0^')-$TF\:T^VW%IF6.V38V^"1'XR>-V#W!K^<S_ (*-
M_"3P]\!OVY?B=X.\)Z?_ &5X<\/:W+9Z?:>?)/\ 9X@%PN^1F=NO5F)]Z_IS
M_9H_Y-Q^'_\ V+>G?^DL=?S7_P#!7G_E)C\:/^QDG_DM8\,5)_6:E.[M9NW2
M]UK8Z.+*4/JM*I9<UTKVUM9Z7/T$_P""(G_!*?X!_M>_L-6OC'XB> _^$A\1
MR:W>V;7?]MZC:9BC*;%V07")QD\[<GN37VY_P5L\.6?@_P#X)/\ Q5TC38?L
M^GZ7X9CL[6+>S^5%&\*(NYB6.% &223W->4_\&V'_*,ZR_[&34OYQU['_P %
MD?\ E&'\9?\ L!'_ -'1UYN,KU)YGR3DVE/1-Z+7IV/4P6'I0RKGA%)N&K25
MWH]^Y_,/;V\EW<1Q11O)+(P1$1=S.QX  [D^E?TA_L0?\$0/@G^S#\(])L_%
M7@?PK\0O&TEFHUK5=<LEU.WEN&VLZV\,ZF..-6&U&$:N5'S'+-7\\OP%_P"2
MY^"_^P[8_P#I0E?UT5[/%6*JTU3ITVTG=NW6UCPN$,'2J.I5J13:LE?I>Y_/
M3_P<'_L)>"?V,_VE?#.H> +"/0]!\>:9+=R:/#GR+"Z@D"2-#G[L;J\9V<[6
M#XPI55]4_P"#53Q;=6?[2/Q2T)))!8ZEX:@OY4#?*TD%TJ(2.Y N9,'/&X^O
M'<?\'97_ #0'_N8O_<77F?\ P:O_ /)XOQ"_[$UO_2ZUK3VLJN1\]1W=ORE9
M?D9^RC1S]0IJRNMO.-W^9^ZU%%%?!'Z(>._\%$?^4?WQT_[)[K__ *;;BOY3
M:_JR_P""B/\ RC^^.G_9/=?_ /3;<5_*;7W7"/\ !J>J_(_/N,OXU/T?YG]A
M.O:Y:>&-#O-2U"=+6QT^![FYF?[L4:*69C[!03^%?RE_MK_M5:U^VA^TQXI^
M(6M37#'6;MOL%M+(S+I]FI(@@0,S;0J\D*<;F<]Z_IK_ &Z8[F;]B/XQI9R)
M#>-X'UI8'<?*DAL)]I/!X!QV/TK^3^L>$:,?WE5[Z(WXRKR_=T5MJ_T_#]3]
MX/\ @D%_P0]^&?@_]G?PU\0/BKX7L?&WC3QA90:O%8:S;F2QT.VE4210?9F.
MR24J5:1I5)4G8%7#%^G_ ."H?_!"WX8_'/X':]KWPL\'Z/X'^(NBV[7UE#H=
MI]FL]8$2<VC6L0\L,ZKA&C0-YFW)(9L_H+I/V7^RK7[#]G^P^4GV?R,>5Y>!
MMV;>-N,8QQBK%?/RS?%/$?6.=WOM?2W:W8^DCDN$6&^K<BM;>VM^]^Y_)5^R
MW^T;X@_9+^/_ (6^(7AF9X]4\,W\=UY(D:..^A!Q+;2$<^7+&6C;'\+G'.*_
MH<_X*D_";3_V]/\ @E1XFO='MWDEGT"#QMX?^T QS(T,0NU7:N1YDEN98L'(
MS+U'##^<+XJW%C=_%#Q)+ILB2:;)JET]HZ$LKQ&5BA!/)!7')K^GS_@EK]J_
MX=R?!+[9]H\[_A#=-V^=G=Y?D+Y>,\[=FW;VVXQQBOI^)/W;HXN/Q)_\'^O4
M^3X6O55;!R^%K_@7_KL?SP_\$O/CY'^S1^W[\+?%MS?/IVFVVMQ66I3A=RQV
MER#;3EEP<J(Y68X!8;<KA@"/V^_X.$/CA_PIG_@F1XLM(9IK>_\ '5]9^&K6
M2,9_UDAGG4\$8:VMKA.<?>X.<9_!G]N#X"W/[,'[7?Q$\!W$)A7P[KEQ#:CR
M3")+5F\RVD"$DJKP/$X&2,,,$CD_7O\ P6T_;];]K[]G_P#9KM([]FNKSPLW
MB;Q!:^0J?\3!V^QECM^4 26UV44!?DE#$890.K'8-8G%X?$1VZ^B]Y?J<>7X
MYX;!8G#3TET]7[K^[0_/%;>1K=I1&YB1@C.%^56.2 3ZG:<#V/I7[Y_\&QWQ
MQ_X6!^PGK'@Z>9WNOA_XAFBAC)R([2[ N(\>F9C=<=.,]SC\^/A/^PK%XG_X
M(._$;XK?9;>77+?QG::G:NL1\X6%IFS=0Y'3=>W#LH.W$*G)88&K_P &_?[8
MMI^RC\3OC(VJ7D-OIUSX O=>A@F9MM]>Z8#/%$ /XC#)=$9(/&!RP!K.+8S"
M5(T]7"5OFK7_  ;%DO-@L;2G5T4XW^3O;\4CSG_@NK^T)-^T%_P4L\?-YBMI
M_@J1/"=BH8MY:VFX3 G_ *^GN3@8QNQR02?UD_X-UOV:S\"_^">6F^(+R!HM
M7^)5_-K\NX@LML,06R\<;3'&91U/[\Y/\(_!3X:>#-<_:I_:,T/0?M3W/B+X
MA>(8;-[IT#%KB[N K2L!@8W2%CT &>@K^L;X?^!]-^&/@/1/#6CP+:Z1X>L(
M-,L80 !#!#&L<:C  X50. !Q7F<136'PE+!Q^?HO\WK\CU>&:;Q.,JXZ?G;U
M;_1:?,UZ*_ET^-?_  4"^/6E?&7Q=:VOQN^+MM:VVM7D4,,7C'44CB19W"JJ
MB;     '  KF/^'B/[0/_1=/C%_X6FI?_'JYX\)UFK^T7W,Z)<944[>S?WH_
MH*_X+1_M(7G[,7_!.7X@ZUI<UU;ZUK5NGA_3Y[=S');R7;>4\H<<HR0F5U8<
M[E7!!.1_.7^S3\!M7_:A^/WA'X>Z&T<>I^+M3AT^.:09CM59OGF<=2L:!G('
M)"'&3@5^F'[=7COQ!\3_ /@V_P#@QKWB+7-3\0:UJ'B>)[[4-4N9+R\N\2:H
MB[I9&+%@ @RQ;Y5QZ$?*G_!!G[+_ ,/8_A)]L^S^3YNI[?.QM\S^R;WR\9XW
M;]NWONQCG%>ID]/ZI@:TH_%%R_\ )5H>5G57ZYCZ$):1DH:?XGK^?X'[;? _
M_@C?^SK\%OA';^%9/ACX3\52?9/L]YK&O:9#?:E>N00\OG.I:%B6)'DE O&W
M&T8_(C_@O+_P3"\/_L%_%CP[XD\!0M9^ _'BS)%IKS/,VCWL.PR1JSY)A=9%
M9,LS K*#A0F?Z&*_+7_@ZGMXV_99^&<IC0RIXJD17*_,H-I*2 ?0[1GZ#TKP
M<CS#$/'14I-J5[W?D?0\09;AU@).$$G&UK+S1\(_\&\7_*5/P-_UX:K_ .D$
M]?JW_P %]?VQM0_9,_85O+70+V:Q\4?$"]'A^RG@=XYK2%HWDN)T=64J0BA
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M!_X-B_VR-2\&?'W7/@OJ$MU=:!XRM9-6TE-Q9=/O[="TN!G"K- &W'D[K>(
M<L:^OO\ @YDN+&'_ ()N0K=2(MQ-XMT]+,,2"\OEW!('J?+$IP>P/M7Y0_\
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MX[.VMXY6B-U,@8><TC(VQ7&P)AL.74I]??ML?\$/O@?^U!\*M3L_#7@GPO\
M#GQE':D:/J^@V":=##,N603P0!8Y8V)VN2A?:?E8%5Q[%_P3;^R_\.]?@;]C
M^S^3_P ('HF[R<;?,^PP^9G'&[?NW=]V<\YKVJO%QF:8EXJ513:LW97T23VM
M^?<][ Y3A5@XTG!.Z5W;5MK>^_IV/Y%3)XH_9M^-$@AN+[P[XR\#:PT8EB)B
MN-.O;:8J<9 (9)$/!';!':OZF/V)_P!I&+]KS]E'P)\2([/^SY/%6EI<W5L
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M4GFN?]@+3/\ T37VW_P:M?\ )J/Q)_[&Q?\ TCAKXD_X./O^4GFN?]@+3/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M'4M!OXO[-\1:6NK:CF_L6=6;9FQPLR,H=&R.05)VNX/._P#!V5_S0'_N8O\
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MX:>%I5.CU?5M;ABL#F=;%4\96I]5HNB3V_K_ (!^LW_!1'_E']\=/^R>Z_\
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M3NK\0?@1\&M:_:'^,_A?P-X>@>XUGQ5J4&FVP"%Q&9'"F1L<A$7+LW155B<
M$U]6>'O^#>?]JS6O$ L[GP#I>DV^XC[?=^)-.:W !QG$4SRX/7[F?8'BOU(_
MX).?\$0-#_X)\ZXOCCQ1K4/B[XES69MDEMD:/3]$#@B9;?=AI68';YKJIVY
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M[8X(QS_SX99B269F)9F8LQ)))\\_XA:_V@?^AP^#O_@UU+_Y H_XA:_V@?\
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MZ5J\I_8Y_8Q\!_L+?!RU\$^ =-DM=/C<S7=Y<LLE]JLYX,]Q(JJ'<@ <*JJ
M JJ !7JU?/9SF7UROSQTBM%_G\SZ3(\K^HX?DEK)ZO\ R^04445Y)[)_(O\
M'K_DN?C3_L.WW_I0]?TG_P#!&[_E&'\&O^P$/_1TE?F/\3/^#9#X]>,_B1X@
MUBU\7?"*.UU;4KF\A675-1$BI)*SJ& L2,X(S@D9[FOUQ_8$_9_UG]E?]CGP
M!\/?$-UIEYK7A73?L=W-ITCR6LC^8[9C9T1B,,.J@^U?8<08[#U\-"%*2;3_
M $9\3PWE^)H8J<ZT'%-/?U1^"'_!?G_E+9\6/^X/_P"F:QK])_\ @UK_ .4?
MWC#_ +*%>_\ IMTRO-?^"GG_  00^,'[:?[<GCCXF>%O$GPUT_0?$OV#[+!J
MNH7L5Y'Y&GVUL^]8[21!EX6(PY^4C.#D#ZZ_X(Q_L$>,/^"=?[+VO>"?&VI>
M&M4U75/%-QK<4NB7$\]NL,EI9PA6,T43;]UNY("D8*\YR 9ACL//*X4823DE
M'3T6H\MR_$T\WJ5YP:BW*S]7H?07[2__ ";C\0/^Q;U'_P!)9*_DAK^O+XO>
M$KGQ_P#";Q1H-G)!'>:WI%W80/,2L:22PO&I8@$A06&< G'8U^&O_$+7^T#_
M -#A\'?_  :ZE_\ (%1PSCJ&'A45:2C=K?YE\59?B,1.FZ$'*R=[?(_;71O!
M5G\2?V;[7P[J/F?V?K_AI--NO+V[_*FM1&^-P(SM8XR"/4'I7\JO[0_P(\0?
MLQ_&[Q-X!\4VDEGKGA>^>SN$9"HE PT<J9ZQR1LDB-T9'4C@U_6;X(T2;PUX
M+T?39VC:?3[*&VD:,DJS)&JDC(!QD=P*^4_^"I/_  2!\&_\%'] M]42ZC\*
M?$72(6BL==B@$BW<8#%;:Z48+Q!B"&'S1Y.,@E3QY'FT,)6E&I\,NO9]SMX@
MR>>,HQE2^./3NNJ]>QQ'_!+_ /X+2?"'XU_LU>&](\=>._#O@?Q[X8TR&PU:
M#Q#>IIL%Z856-;F">9A%)Y@ 8H'\Q6WY7:%9OGK_ (+I?\%F])E\)^'? GP"
M^)EQ)K<.J?VAKNO>%]0DCCABB0B*U2ZC(659'?>WELRXA4$X8BOE/XH?\&YG
M[3_@3Q!/:Z/X;\/>-;.-@([W2M?M8(Y5(SG;=O X(Z$%>O0L.:Z#X ?\&U'[
M07Q+U^W7QI_PC?PUTCS,74]WJ$6IW:)G!,4-J[I(W<*\T8Q_$#Q7KT\'E-.M
M]:]JFM^6Z?X;_(\:ICLXJT/JGL6GMS6:_';U9Z]_P05_:X_:3_:S_:[33==^
M)OB/7/A[X5T^6^\00WZV]T;@.ACMH?,E0RJ6E"MN0[ML3C(W$UZ9_P '67_)
M#/A)_P!AV]_])TK[Z_89_89\$?\ !/[X(P^"?!,-W)#).U[J.HWKA[S5+E@%
M,LA4!1A55550%55'4EF;PG_@M?\ \$VO'/\ P4A^&_@?1_ ^K>$]*NO#.I7%
MY=-KMS<01R))$J (88923D<Y &.]>73S"A/-(UXI0@M-K='J[=SUJF6XB&4S
MP\FYU'KO?JM%?LOU/RV_X-P?^4GFA_\ 8"U/_P!$U^T?_!57P/??$7_@G-\9
M-*TV&:YOI/#-U<QPQ)ODE\D"8JJYY)6,@ 9))X!. ?BG_@DQ_P $-?BU^P?^
MV-IOQ"\7^(OAWJ6BV>FWEF\.CW]Y-=%YH]JD++:QK@'K\V?8U^J5W:17]K)!
M/%'-!,ACDCD4,LBD8((/!!'&#4YYC:<\=&O1?,DE^#;*R# U88"="NG%R;^Y
MI(_C_P#"/B6X\&>*]+UBU6&2ZTF[BO(5E!,;/&X=0P!!QD#."#CN*_IF^&W_
M  6/_9O^(7P@M_%TGQ7\(:&ILDNKO2]1OA;ZE:.<AX?LS 32NK*P_=HP8 ,N
M592?SQ_X*!?\&TWBNW^(FJ^)/@'-H^H>&;XM<IX7U"^^S7NGR'),-O+)^ZDB
MS]TRR(R@JI+X+UX+\*/^#<O]ISQ[XGM;/7O#N@^!]/DD(GO]3UVUNE@0#)(2
MT>9V)Y"C R>I4?-7NXZ679A3C4G5Y;>:OKNK/]#Y_+X9GEM2=*G1YN;R;6FS
MNOU_ Y/_ (+5_P#!0/0?^"@W[5=IK7A&*\7PCX7TI-)TV:ZB:&:].]Y99C&2
M=@+/M4$!BJ*2 3@>^?\ !J__ ,GB_$+_ +$UO_2ZUKW?]IC_ (-O9#^RWX/\
M#?!_6?#7_"16>KRZIXFU_P 333VLNLDQ%(518(9MJ1[G"Q\!=['+,S$]S_P1
M;_X([?$W_@G+\>_%7BKQOKG@75-/US0#I4$>AWMW/,DIN(9<L)K:(!=L;#()
M.2..XPQ&8X)Y;*A0ETLD]W9[_/<WPV68]9I'$5X[N[:V5UM\MB'_ (.<?V9K
MOXL?LB>&?'VFVL]U>?#359#=+&KMY5A>*B3287(^66&UR2,!2QR.A_*7_@E3
M^W)'_P $^_VQ=&\=7]I=W_AVZMIM'UVWM3B=[*;:2T8) 9HY8XI=IX;R]N5)
M#+_3QXE\.6/C'PYJ&CZI:PWVF:K;26=W;2C,=Q#(I1T8>C*2#[&OQ7_;A_X-
MD?%_AWQ'>:U\"]6L/$6AW#RS+X=U:Z%IJ%EDDI##._[J9<?+NE>-AA<E\EAR
MY'F6'>'>"Q3LG>SZ6>ZOT[G7GV58E8E8_!J[5KI;W6SMUTTL?I5#_P %=?V9
MY_AI-XL7XT>!QI<,7G- UX5U,KQPM@1]K9OF'RB(MUXX./Y_?^"HG[:[?M\_
MMC>(O'EM'>6_A]4CTO0;:ZXEM["'.S<NY@K.[22LJG :5NO4^Z?!3_@V_P#V
MD?B+XGAMO%&DZ#\/=+\S$][J&KVU\RIC)*16DDI8]@&9!GJ0.:^M/VQO^#;V
MZ\1?!'X4^$?@OJ'@ZRO?"?\ :4_BC6O$LT]M>>(+FY%F(Y!Y$$V$3R)0L1(6
M-6&-[,[GJP7]F8"O>%3F<M+Z-);[KO:QRX[^U<QP]ITN51L[6:<GML]=+W/.
M_P#@U'_Y*I\9/^P5IO\ Z.N*Y_\ X.AOV8[[PG^T9X4^*UM'(^B>+M,31KMR
MP(AOK8N5'7.'@9<#&,Q.<\X'V!_P1,_X)-?$;_@FWXT\?:EXYUKP5JL'BJRL
M[:T70KRZG:-H9)68R>=;Q  AQC!/?I7VC^TC^SEX1_:Q^#6M> _'&F_VIX=U
MR-5FC60QRQ.K!XY8W'*NCJK ].,$$$@^?B,UA2S5XFF^:.B=NUE?[CTL/D]2
MME"PM1<L]6K][NWW_J?B9_P0!_X*J^$?V*[WQ+\.OB5>S:/X1\5WJ:II^KB-
MY8-,OO+$4BSH@9@DJ)"!(HPAB&[Y6+1_HO\ M\?\%J/A#^SW^S'K&L^!?B'X
M1\:>.-6LI+?P[8:+J,&I/#=.F$GN$C+"*.(L'99=I?84')X_.[]J3_@V2^,'
MP[\2WD_POU30_B'X=9F>T@N;I-,U:,=1'(LI$#$ @;UE&X@DI'D"O+?!7_!O
M#^U5XJUR&TOO ^C^&K>:58VO=2\1V$D$(/5V%M+-)M7J=J%N> :]*OA\JQ5;
MZVZJ75JZ5_D]?4\O#XK-\)1^IJBWT3LW:_FM/0[W]E__ (+T?M:?$SXP>%?!
MNGZEX4\8:QXDU.VTRVBU'P_$@E>21$R_V8P84<ECE0JECE0 1^^FF1W,6FVZ
MWDT%Q>+$HGEAB,,<DF!N94+,54G)"EF('&3UKXF_X)/?\$7/#/\ P3NBF\4:
M_>V/C+XG7T9A&II;E+71867#Q6H;YMS<AIB%9E.T*BEP_P!P5\[G6(PM6K;"
M12BNJ5K_ / /I<CPN+I47+&3;D^C=[+_ #"O-?VS--U76OV/_BM9Z$S+KEWX
M.U>'3ROWA<-93"+'7G>5KTJBO)IRY9*78]FI'FBX]S^.NOZ:OV=?^"NW[-/Q
M$^!6EZU8_$3P3X%L[#3D#^'M5OH-,O-)6-,?9DMB1OV!-JB ," NW.0*^&?^
M"D__  ;?Z_XH^*6I>,O@+)I#:;K4IN;KPO?W?V9[.=BS.;:5OD,3'!".RE"2
M 2N OS!\-_\ @W7_ &HO&GB.&SU;PCHO@^S=U$E_J?B"RGBC4GD[;62:0X'.
M-O-??8ZIE^8THSG5Y;=+I/7=6?Z'YW@*69996G"G1YN;K9M:;.ZVWZE3_@N1
M_P %&/#'_!07]HK19/ \=Y)X1\$V,NGV=_=0F%]5DDEW23K&P#I&0L84/AL*
M254G:/>O^#5/_DX[XI?]BW;_ /I4*]8^+'_!LAI]G^QYIOAWP'X@T>]^+G]L
M6]_JGB+7FGM;*XMECN$>U@CB64PINEB;)5V<P#)4$!=;_@DK_P $8/CI_P $
M[/VN(/'&L:]\*]5\.ZCI5SHFL6]AJ5\]X;>1HY5:$26:*6$T$)(++E0PSS7/
MB,=@99=/#4)VLK)/=V=_Q-L/E^81S.&*Q$+W=VULKJWX'5?\'2G_ "C^\'_]
ME"LO_3;J=?FQ_P $!O\ E+9\)_\ N,?^F:^K]E_^"SG[!'C#_@HI^R]H/@GP
M3J7AK2]5TOQ3;ZW++K=Q/!;M#':7D)53#%*V_=<(0"H& W.< _(O_!,/_@@A
M\8/V+/VY/ _Q,\4^)/AKJ&@^&OM_VJ#2M0O9;R3S]/N;9-BR6D:'#S*3EQ\H
M.,G //E^.P\,KG1G)*34M/5:'7F67XFIF].O"#<4XZ^CU/URK^=S_@X^_P"4
MGFN?]@+3/_1-?T1U^5/_  5G_P""&OQ:_;P_;&U+XA>$/$7P[TW1;S3;.S2'
M6+^\AN@\,>UB5BM9%P3T^;/L*\WAW$TJ&*<ZKLK/]#U>)<+5Q&$4*,>9\RV^
M9>_X-6O^34?B3_V-B_\ I'#7ZD5\9_\ !%C_ ()V^-O^"<?P2\7>&_'&J>%M
M4OM>UP:G;R:'<SSPI&((X\.9H8B&W(> ",8Y[5]F5QYO6A5QDZE-W3>_R.S)
M:,Z6"ITZBLTM5\V%?BW_ ,'7.DZTOQ#^#5]*TC>'FT[4X+8;LI'="6W:;CL6
M0P<GKL/]TU^TE>*_MZ_L+>#_ /@H+\ [SP/XL$UK(LGVS2-5MQFXT>\565)E
M&0'7#%7C)PZL1E6VNIE.,CAL5&M/9;_-6#.,'/%82=&GN[6^3O8_$'_@@+^V
M)\-?V//VKM;O_B5-#I%KXBT5M.L-;EMO.CTN42+(P=@"\:2*NW<H(W!0V%RR
M_K-^V1_P6Y^!'[+WPNOM2T;QQX;^(OBB6VD_LG1_#6HQ:D+B?!">?-"S1P1!
ML%RS;]N2J.<*?R;^*_\ P;E_M.> O$]U9Z#X=T'QQI\<@$%_IFNVMJLZ$9!*
M7;PNI' 88.#T+#YJ]D_8H_X-D?'7BWQ39ZM\<-6L/"?AVV=))=#TJZ6\U._X
M#&)IDS# N3@NK2L2C * 5DKZC,:65UZGUNI5]4FG>WENOZV/D\LJYMAZ7U.E
M1ZNS::M?SV?];GY9ZA?S:I?SW5PWF3W$C2R-@#<S').!QU/:OZK/^"=W_*/[
MX%_]D]T#_P!-MO7Y;_M6?\&R/Q#\9?M">*-4^%VM_"_0_ -]<K+HVG:A?7\-
MS91&-,Q,JVTP^5]X#>8Q8 ,=I)4?IA_P3/\ V?O'7[*G['/A?X=_$&X\+7NL
M^$_.L[>YT&XGFMY[4R%XBQFBB82#>RD!2"$4YR2!R<0X[#XG#P=&2NGMUU7Z
M'7PWE^)PF)J*M!I-6OT=G^I_./\ \%$?^4@/QT_[*%K_ /Z<KBOWM_X(#?\
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M8&L?%T;RK<_#_7[>Z<!"R/;W7^BN#C[I\R2 ACQP5ZL,9/\ P1F_X(J>./\
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MLJ?LV>(OVO/V@O"_P[\+P[M4\37JV_G,NZ.RA'S37,G^Q%&'=L<D+@9) /\
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MX=\L<;L59[ASE0!YN!T)/V57EY[C8XG%N4'>*T7]>IZO#^!EA<&H35I-MO\
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M?\D,^$G_ &';W_TG2OCK_@W!_P"4GFA_]@+4_P#T37ZD_P#!:_\ X)M>.?\
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M;0Q4E2H_!'\7_DCU^'<FGA(NM7^.73LO\WU/Y3?^"B/_ "D!^.G_ &4+7_\
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M /!4C_@F#X8_X*3_  BM[&ZN5T'QMX=$DGA_7 A=;=GV[X)T!^>&3:N<?,A
M9?XE?\;_ !M_P;L?M3>%/%9TZQ\'Z%XFLP0/[4TWQ%9QVAR2,[;F2&;@#/\
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M_4L*J4OBW?J_\M$%%%%>8>L%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MN$J205RT@(P4KZZK:IAZM.,9SBTI;7ZF%/$TJDI0IR3<=[=+_P##!17YS_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@MHQU9F;@=A[D@#DU^4?_!J%_P B'\;/^O\ TC_T7=UX)_P<<_M[:O\ &?\
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MD\-3J-S77H^]N_\ EU.K%9MFU"*Q52FE3?3JD]KZW3_7IT/Z?:_G<_X./O\
ME)YKG_8"TS_T37Z<_P#!OQ^V?J?[67[$QTOQ+J;ZIXJ^'5__ &+<S3,[W%S9
MF-7M9I78G>Q'FQYSD^1DC)RWYC?\''W_ "D\US_L!:9_Z)J,@P\J&93HSW2?
MYHTXBQ4<1E<*\-I-/\&?I]_P;J?\HMO"?_85U3_TKDKZL_:"_:7\!_LJ_#^X
M\4?$+Q1IGA?1+?CSKIBTDS<?)%$@:25^1\L:LV.<8KY3_P"#=3_E%MX3_P"P
MKJG_ *5R5^-G_!3[]MWQ!_P4<_;'U#4X9);CP_I]V^A^#]-CX5+3SBL;[02/
M.G)#NV3R57)5$ QIY6\;F-:+=HQDVW\WH;5,V6!RRC)*\I122^2U^1^KVI_\
M'/W[.]AJRV\6A_%2]A9L&ZAT>S$*C)&</=J^,<_=S@^O%?5W['W_  4-^$?[
M=.DS3?#KQ9:ZGJ%G%YUYI-PAMM2LTW!=[P/ABF2HWKN3+ ;LG%?G_P#!K_@U
MF\):A\!K)_'7CWQ98?$B\MA+/_97V5])TR5@#Y)C:,R3[#D%UF0.>0%'7\U?
M'GA_XA?\$E_V\[RRTW56M_%WPYU59+6^B22*WU2W8!T+)D%H9X6 =,D%79<G
MK71'*LNQ:E3P<WSQ[[/\-O0Y9YQF>#Y:N-@N27;=?COZG]2U%<3^S9\<]-_:
M9^ /@_X@:1&UOI_B_2;?4XX';>]JTB O"Q  +1ON0D<$J<<5VU?)RBXR<9;H
M^RA)2BI1V84445)04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MA1\5-)\=>"?&/@O[1JUC>6*:]I5SI_VO=#*DAC29%W;=B;BN?O*#CC/YT?\
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M_+<[:O@S_@Y!GN8O^"8NLK '\J37],6XPFX"/S21D]AO"<\<X'?%?>=>'_\
M!27]FJ\_:^_89^)'P]TSG5]<TOS=-C+*@GO+:6.ZMXBS,JJ'F@C0L3A0Q)R!
M@_-9?5C3Q-.<ME)7^\^JS*C*KA*E.&[B[?<?B[_P;3?9_P#AY5'YWD^9_P (
MMJ/D;\;M^8<[<]]N[ISC/;-?T)5_*G^Q)^U+KW_!/G]KS0?'4>EW$EYX8NY;
M/5M(N ;>6XA8-%<6S;E)CD )QE<JZC(XQ7[8>-?^#D7]FW0O@[<>(-'U/Q)K
MOB3RB;?PO_8\]K>-+DA5DG=?LR)G!9EE<A3D*[#97TG$678BMB8U*47)-):?
MKV]=CY;AG,\-1PLJ5::BTV]=---N_IN?D/\ \%H+&+3O^"H?QCCA78C:RDI&
M2?F>VA=CSZLQ/XU^[?\ P1N_Y1A_!K_L!#_T=)7\V?Q\^)NO?&[XR>)/&_B1
M)DU?QEJ$^M3;PP7]_(S@1[O^6:YVKC@*H X%?TF?\$;O^48?P:_[ 0_]'25O
MQ'3=/ 4H/=-+[HG/PQ453,*U2.S3?WR1^"7_  5Y_P"4F/QH_P"QDG_DM?OQ
M_P $P-#M/$__  2_^$.FZA EU8ZAX+M;:YA?[LL;P[64^Q4D?C7X#_\ !7G_
M )28_&C_ +&2?^2U^XG[)FJ?$#0_^"*/@.^^%EOH]Y\0+'P#:W&BVVIP--;W
M<R1AC#M5T_>.@=(R6"B1D+94,"L\BY8'#I.VWY%</RY<?B9-7^+_ -*/RU_X
M*"?\&^?Q8_9W\>:EJ7PMT74OB3\/IG>>S^PE9M8TZ/&X0SVXP\S#D*\"N'"Y
M*HS!*^/_  O\2OBU^QYXOACTO6/'GPVUF%A>+;I-<Z7(V[ WM$=NY6" '<"&
M"X.1Q7V=\*/^#D;X\^'?CWH6I>/)M-U3P;8WC+K7A_3M)M[.2XA99$(61U:1
M7C9U=1O7<T*JQ 9L_H'\2?\ @NQ^QI\1OAA-)XBU/_A+%D@97\.7_@ZXNIY5
M<A7BQ-#]F.0 2#+M(7J3@5V/%9A04:6(I>T3ZQN_OTM^2.%8/+<0Y5<-6=)K
MI*R^[6_YL^%?^"?G_!QK\2OA+XUTO0?C->1^.O!%U<+%<ZO);!-8TA&*CS T
M0 N(T^9F1T:1L_+(,!3]B_\ !SOJ[3_\$Y_#<EEY=U:7WC>PWS1_O%$1LK]U
M<,.,%@@SR#N]Q7XC>,K-?VAOVEM9B^'OA:>SA\:>)+@^'?#MH@>2UCN+EC;6
MB!>/D5T08P/E["OZ'?\ @H)^PCK'[0G_  2FF^%=C<-?>+_"N@6$VFF-_,_M
M&^T^%/W0+;-QG"21JS;<-*K$<$5RYE1PV%QE"O%*-WJONU^5SLRNOBL7@L1A
MY-RLM']^GSMIV/S@_P"#6+[/_P -J>/MWD_:O^$)E\O./,V?;[/?COC.S..,
M[?:OW;K^7'_@FW^VWJ?_  3=_:YL_&DNCW%_9QPS:)K^EDF"XDM)'0RJN< 2
MI)$CA7X+1X.W.X?L%\=_^#D/X!^$_@1J&L>!-5U/Q3XXF@>/3=!GT6ZMQ!<%
M'\M[J1U2+R58+N$4K.0P"CJ5Y>(,MQ-7%J=*+DI):K]>QU<-YIA:."=.M-1<
M6W9]?3O\C]#*_$3_ (.K[^:3]H#X46K-^XA\/7<J+@<,UR QSUY"+^7UKY,_
MX);Z%\3/VD_VY?!?A;P]XL\::=:W^LKJ^OS:1K$MBT-DDRS7<VY6559@, X.
M79."< _JM_P<B_L8:Q^T=^REH?CGP[;7FHZO\*;BYNI[*WC,C2Z?<B(7,@4<
MDQ&"%SQQ&LI[5.&P<,MS&E&<T[WZ6M=67WLK%8Z>:995E3@X\MNM[V:;[;(Y
M;_@U=ATM?V0?B))#,K:TWC$K=18&4MQ96WD-TSRYN!U/W3P.<_J#7\W?_!&K
M_@JG)_P3C^+&HV/B"TN-3^''C!HQK$5LBM=:?,F1'=Q XW;0S*\>1N4Y'S*
M?TL_:R_X.1?@=\/?A=JG_"K]2U3Q]XPNK5X],6/2;BQLK.=@0LEP]U'&Q5/O
M;41RQVK\H)9<LXRG%3QLI4XMJ6SZ?-]/F;9'G&$IX",:DU%QT:Z_)=?D?C;_
M ,%(;33[#_@H'\;(-+BCALX?&^KQK'&I58V%Y*' '8!]PP./3C%?T7>$_/\
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M (-C_P#E'+J'_8Y7_P#Z3VE?$?\ P=*?\I ?!_\ V3VR_P#3EJ=?;G_!L?\
M\HY=0_['*_\ _2>TI8[_ )$E/Y?J/+_^1]5^?Z!_P<X?\HY=/_['*P_])[NO
MB/\ X-:_^4@/C#_LGM[_ .G+3*^W/^#G#_E'+I__ &.5A_Z3W=?$?_!K7_RD
M!\8?]D]O?_3EIE&!_P"1)4^?Z"S#_D?4OE^I]'?\'67_ "0SX2?]AV]_])TK
MS/\ X-1_^2J?&3_L%:;_ .CKBO=O^#HSX97WBC]C+P=XDM+836_A;Q.JWKA\
M-;PW$$D8;'0J9%B4]P77 P6(_/?_ ((<_P#!1?PS_P $]_VA_$5SXX6^7P?X
MPTE;*YN;.U^T365S%('AD*@[C'M,RL%!;+H<8!K3!TY5LDE3I*[UT_[>O^1G
MCJD:&?1JU7:.FO\ V[;\S]MO^"L=Q';?\$V/C4TCI&I\*WB L< EDP!]22 /
M4FOY_P#_ ()#?\I,?@O_ -C)!_)J^_O^"OG_  7+^'/[1G[..N?"3X-IK'BZ
M\\7&*WO]7?3I[2VAM5*S.(4DV3O(60(=T84*'/S<9^ ?^"0W_*3'X+_]C)!_
M)JVR?"U:&7U?:JS:;L][6,<ZQE+$9E1]C)22:5UM?F/T(_X.Q+Z\CT+X%VT;
M3?V?-<:Y+.H'[LRJNGB,D^H5Y<>Q:O@/_@GM\<_VH/@M8>*C^SGIOC*[@U.2
MU_MZ30?!L>O8:,2_9Q(S6TQCX>8J,KG+'G%?K]_P<5?LA:E^TG^P_'XET"UD
MO=<^%]\=9:WBC,DMQ8.GEW80 =4'E3$]-EN_4D5^8?\ P1+_ ."H.E_\$YOB
M_P"([?Q?:ZI=^!?&UM$E^UBJR36%S!YA@G6,X+C$DB,JLIPX;YB@6C*:G/E/
M+3@IN-[Q?76_Y;>@LXI\F<<U6;A&5K2732WYK7R9V?Q$_:I_X*0?%CX?Z[X6
M\0>&?C%J&@^)=/N-*U*U_P"%4QQ?:;:>-HI8]Z:>KKN1F&Y2&&<@@\UQ7_!,
M']C/XX?"?_@H+\(_$&K?!WXK:/I6G^([;[;?7?A:_M+>TA<F.2225H@JH%<D
MEB!C() K[T_X*)_\'&7P_P##?P5:Q_9\\2R>(O'6I31JFI3Z%/#9Z3"&S(Q6
M[CC\R1@ J@(R@.22"H!S?^")'_!3/]I7]O+]H>\TWQ7_ ,(]JWP]\/Z>TNMZ
MDNBK;RPS,K"WCCDC=%$LD@W$%'&R.3"J2&$_6,3#!SJ>PC3C9W6L7VVM]QI]
M7PL\;3I^WG4DFK/22WOO?[['ZL4445\*?H!^4/\ P=9?\D,^$G_8=O?_ $G2
MN3_X--?^:_?]R[_[E*ZS_@ZR_P"2&?"3_L.WO_I.E<G_ ,&FO_-?O^Y=_P#<
MI7V,?^1 _7_V]'Q$O^2C7I_[8SYW_P"#@;_@GA_PR7^TU_PGOANQ2'P#\2Y7
MNHTAB6.+2]2Y:XM@J]$<8F0X ^>10,1Y/SS\5OVWM4^-?["?@'X2^(/.N;SX
M9ZW/-I%Z2,/ILT "V[<9S#(K88DY255  CY_I!_;9_9#\.?MR_LW>(?ASXF_
MT>WU>-9+._2%9)M*NXSNAN8P>ZMPP!4NC.F0'-?RV?&[X->(/V>/BWX@\$>*
MK/\ L_Q!X9O7L;V$-N4.O\2L.&1@0RL."K ]Z]+(<;#%T53J_'3_ "V3^[1_
M\$\SB+ SP=>52E\%3\]VOOU7_ /UW_X-0O\ D0_C9_U_Z1_Z+NZSO^#L>PFD
ML/@-=*O[B&37XG;(X9AII48Z\A&_+Z5H_P#!J%_R(?QL_P"O_2/_ $7=U[K_
M ,'%_P"RAK'[1G[#L&O>';.[U#5_AMJ7]M2VT"[VDL&B=+DA<@DH/+D)&2%C
M?CG(\JI6C3SWFEM=+[XV_4]>G1E5X>Y([V;^Z5_T/F__ (--[N)+KX]0-)&L
M\B>'Y$C+#<RJ=3#$#J0"R@GMN'J*_8ZOY9?^"=7_  4 \4_\$Y_V@(_&OAZU
M@UBQO+<Z?K6C7$IBBU6T+*Y0. WE2*RJR2!6*G((96=&_5W_ (BH/@W_ ,(G
MYW_"OOB;_;OEY^Q^78_9-^>GG_:-^,<Y\G.>,=Z,]R?%5<6ZU*/,I6VZ627Z
M!P_G6$I8-4:TN5QOOUNV]/O/G3_@ZHU*.7]J/X9V85O,@\*R3,<?*0]W(!CW
M^0_F*^@O^#5K3&B_9.^)%Y]G*K<>+5A$_EX$A2S@)3=WV^8#CMO]Z_)__@H/
M^W#KW_!0?]I74OB'KEA#HZ2P1V&FZ7%</<1Z99Q;C'$';&X[G=V8*@9Y'(5<
MX'[N?\$'OV4]8_9/_P"">>@V?B&UN-/U[QI?3^*KVQG7;)9"X2*.!&&20QMX
M('92%9&=E90RFNG-*;PV4PP]3XM-/Q?W'+E-18K.9XFG\.NORLOO/R[_ .#E
M;X57W@?_ (*,R>()@K6/C3P_8WUJZMG!A4VKH>!A@85; R,2*<Y) ^X/^#7S
MXRZ?XO\ V+/%7@M65=7\&>)'N)XP#S;7D2M#(3ZF2&Y7 [1@]Z]K_P""T'_!
M-F7_ (**?LW6L'A_[+#\0O!,TM_X?>XD,<=VLB@7%DS$[4\X)$0[#AX8P652
MYK\$OV;_ -I;XH?\$V?VD9-;\/&Z\.^*]!FDT[5]'U.!Q#=*K8EM+N#*EEW+
MTRK*RAE96 8/"J.999]6B[3C;\-ODU^).*<LKS9XJ:O"=_QW^:>MNQ_5A7RC
M_P %.O\ @JWX:_X)EV_@T:QX>O/%5]XPEN?+L[.\6"6VA@5-TIW*P(+R(H!*
MY^8C.TBO@BQ_X.N_$D?@E;>Y^"^B3>)/+(:^B\1RQV)?=P1;&!G VX&//)SS
MGM7YS_M+?M-?$C_@H'\?#XH\63W7B3Q5JB1Z?8V=A:L5@B4L8[:V@3)"AF=M
MHR2SLQ)9B3PY=PU6=6^+5H+SW^[8[\RXIHJC;!.\WY;?>M>Q_1M^P3_P4Y^&
M?_!1FQUV3P OB2WNO#26[ZE:ZMIWV>2V$_F>7ET9XB3Y4G <GY2>@S7PO_P6
ME_X(4>*OCC\5]5^+WP:ACUC5M>(G\0>&IKE()I9U54-Q:.Y5&W*-SQNP.Y24
M+EPB_7/_  1C_8$N/V!/V0;72]<6'_A-/%D_]M:]Y98K;.R!8K;D#F*, -QC
MS&DP2,&OS5_;B_X+7?M??LW_ +0WB[X>:QJGA'PMJGAZ]D@632_#T317$+9:
M&XB^TF8^7)&\;KN)(&T-\P8'/+Z-18Z?]FR5H_S/===EM?\ 0US*M3>7P_M2
M+O+^5;/IN]';]3X3\8?";XM?LA^)7FUK0/'GPYU**8V8NIK:YTQG<8?8DN%#
M@[5<;6(( 89&#7T1^R[_ ,%Z_P!HG]G/Q+:R:EXLF^(V@JJ17&E>)R;II47:
M"R7(Q.DNT$!B[*2VYT<BOU ^"/\ P<0_LV_&'X364GQ&U2?P3KDT,8U+1K[0
M[S4[?S@<MY4D$,JO&&4,I<*V"O (./R&_P""KW[1OPH_:A_:L?Q)\'?!\/@_
MPM'I<-I<)'IT.G_VK>"6:26\,,7RJ6$B)D_,WE;CR<#Z+#UIXR;HXS#VMU>W
MR=OR;/FL31IX*"KX'$WOT6_S2?YI']&/['G[4_A[]M+]G+PS\2/#(FATWQ%
MS/:S']]8SQNT<T#^Z2(PSC# !APP->F5\3_\&_7P0\0?!'_@FQX;3Q%;W%C=
M>*-0NO$%M:SEA)!:S%%A)4@;1(D8E &?EE!R"2H^V*^!QM.%/$3IT]DVD?HN
M!K3JX:%2HK2:3?W!7\IO_!1'_E(#\=/^RA:__P"G*XK^K*OY3?\ @HC_ ,I
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M !?^9AG5*7U'"5>BBD_*Z7^3^X^NO^&Z/^"FW_0$^,7_ (:2#_Y75\[?M(?
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M"^ 'AOX<>&KK5K[0_"\,D-K/J<L<EU(KS/*=[1HB$[I"!A!P!]:\U_X*#_\
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MO_;V\92>+TOK_P !^.+D1I>:GIL"30:DJ\;I[=BH>3;A1(KJV%7=N  KP_\
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MGAW1_'&K>+-*M?#-W+>6K:%<V\$DCR($(<S0R@C XP <]ZSO^">?_!+7X?\
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MKQ4DNYA_##P!9_"?X:^'?"NG274VG^&M,MM*M9+EE::2*")8D+E0H+%5!)
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M2Q++(\FW^Z7"D]01Q7Z5T5T1SC&JE[%5';\?OW_$YI9)@75]LZ:YM^MONV_
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MING5BXM=&K/[F:4ZD*D>>FTUW6J"BBBLRPHHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MIKHU_75+?#YI]:HUJ<X\E2":E%Z]'9I]4_ZZ'P;_ ,&MG_(E_&;_ *_=)_\
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M:\K_ .#93_DPWQ;_ -C]>?\ INTVOT#,<RHXSAVH\/35.$:BC%+M9.[\W?\
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M_P %N?V?_P!J3Q!:Z+9^([[PAKU^_EVNG^)[9;%KALD!5F5WM]S'&U#+N8L
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M:^B*^%S:6!]ORY>GR+2[=W+S\EV7_#+ZW+8XKV/-C&N=]$M%Y>?]>H5^;?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M'A'_  4Z^$'_  O3]@#XK^'5E\F630)M0A/E>;OEM"MW&F/]IX%7(R1NR 2
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_#CPEJ6O:]J-GI&BZ1;O=7M[=2".&VB499F8\  5^9OA+_@M7\:/VS?VQ)?
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MN\%R#^BO_!,7_@H=I/\ P41^ C:_'9+H_BG094L?$&F(VZ."<KN6:$DEO)E
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\4?^
M"O>ES?L9_P#!9+P)\6H88+'2=:FTO7Y9TA,B2-;2+;W:M'U+&*-2=N,^:"#O
M)->@?\'.?QN;4[_X6_">Q:9[J9Y?$MY#N"QL6+6MH1S][/VL9(  Q@G)QW__
M  <T? R+Q5^S'X,\?V]J9-0\(ZX=.N)4 &RSNXVR7.1D":"!0,'!E.,9;/QY
M^SAXR?\ X*;?\%9?@Q-?1W%]I?AW1]%6\AOUWPI_9>G)/=1A"6_<R7J3!58G
M=YP+8W,!^NY/R8C"X7-:G_,/"HI?]NI<J^YW/SC,^:C7Q&7P_P"7TH-?]O?%
M^.A^VO[+7P4A_9Q_9P\#^!(3"Q\*Z+:Z=-)"28YYTC432C(!^>3>_0?>Z#I7
MY%?\%Q-$N/V2?^"K'@7XP:5/<0OK4>FZ](T08R?:+"1()$ 8A65H(H!MR VY
M@P .6_;*OSG_ .#E3X&S>/?V./#_ (TM;>&2;P#KB_:9#&3)#:7@$+8;L#.M
MJ"#P>.<@ _'\(XZV;Q=;:K>,O/F_S=CZ7B/"7RU^RWIVDO+E_P"!<\A_X.6?
MCO#XXTSX-^!=#N)KRWUA)?%&5EVP7*R!8+1@I/+$-<?,RC:&X/S,!^G/[+7P
M4A_9Q_9P\#^!(3"Q\*Z+:Z=-)"28YYTC432C(!^>3>_0?>Z#I7X=?LG:_>?\
M%$_^"F_P#L=0$>L:;X'T'0[*X^V;VCD@TFR6XG$@<,6WW*RJ0<K(TF3A7)']
M 5=7%5/ZEA,+E?6*E)^LF[?=J<_#]3ZUB:^/[M17HEK^A_.?\9?B5XTT;_@L
MOXZ\3>!_"K>-/&>@?$'59M*T8:?/J'VM[.>95/D6Y65]B1>9\I!&S)) )/U]
M_P /:_V\O^C9?_,=>(?_ )(KQO\ X*6^&O$O_!-?_@KW8_%^WTY=0T?Q!JO_
M  E.EO)#M@O,@)>VV0<>8I=L\Y FB8CYN?V._9H_:Y^'G[7?@.T\0> O$VFZ
MU;W$7FRVBS*M]8'@-'<09WQ,"0,,,'(()5E)]_/L=2AA<-BOJT:M-P2YG?1K
M=:;?/K?L>/E&#J2Q%?#^WE3FI-V5M4^NO];'Y%_M<?MB_MG?MG_ /6OAWXK_
M &:]3M=&UM[>22YTWX>ZY'>6[0SQS*T3222*I)CVDE3E68<9S7TY_P $0-$^
M(W[-G_!/;XK6OC#PKXH\)WF@:C?:SI-OKFF7%C,P_L^)CY:SJ 8_,BSPI&YG
MSG.*VO\ @LW_ ,%>+;]E'P.O@GX5^*M-D^*UY>(+V:UC@OQX;MHV)D$JN'C%
MQ(RK&(G4L$9W(0^66]\_X)B>.?B=\</V,-%\3_&9K.ZU[Q89;N"W_L]+7;IS
M )")8E4*3(JM+T(*3+T^Z/+S#%U?[%4GAX4J4YII)OF;75)K9I6O?]+^A@L/
M3_M1I5I5*D8M-V5DGTNGNF[VL?AG_P $S/CG\6OV<_C5JWB?X._#=?B-XD_L
MA["X@;0;[5_[/MY)8V:4):NC(Q:-5WL<89AWK[D_X>U_MY?]&R_^8Z\0_P#R
M17SS^QS\4[S_ ((J_P#!4'7/#_CRWD_X1J8R>'M5OC;2,PT^66.6WU&%5&YE
M'EQNRJ&)0RJ%+A<?NI\/_C#X4^*W@E?$GAGQ)HFO>'V0N=0L;V.:W0!0YW.I
M(4A2"0V" ><5ZW%F84J6(C7GA8U83BG&;OKY::?\.>=P[@ZE2BZ,<1*G*+=X
MJVGF?AG^WK\3_P!KC_@HCX?\.Z=XV_9W\3Z9'X8N)KFTET3P%K,,K&555U<S
M-+\OR*< #D=Z_1'X5Z3XG\/?\$!-<TWQCINLZ/X@TOX6:_8SV6JV\MO=VJ16
MMY'"CQR@.N(5CP"  NW  P*^??\ @JG_ ,%O?$?A?XX^'_ O[.?B2UU"XTYW
MBUF_LK"WU6'5KJ4HL-I;[T</L.26C^\\BJ#\C _;'[1-OXMM?^"4OQ$7QY<V
MMUXU/POU9]<>VC2.%;QM+F:5$"?+M5R5!'4*#WKS<TK5_JF#IU*,*4)34HQ3
M?,M=;IK1.]]^J.W+Z5'ZQB9PJRJ24;-M*VVEFGJU:VW<_ S]E'X7_%K]J>TU
M3X0?#*QO=3MM<GCUO5K6&;[/;R"U1Q$]S*S"-8U:0[0Y ,CIC+;:^[O^#<']
MK[0_AEXX\3?!+Q%IMCHNN>)+MM0TK4'M?)NKRXA3;)I\[XR2BJ\D08#:?/7.
M713UW_!K5 B^$?C1($42->:0K/CYF 2\(!/H,G\S7$?\%^_V'-4^ WQJTS]H
MKX?QW&EVNI7T$NLW%C(L+Z1J\;*8+Q N&4RE Q<9_?(68[I!GZ+-,PHX['U\
MAKI14DN677GLFK^NB7I;JK>+@,'5PF#I9O2;DU?FC_=NUI^+?K?IK^R]%?.W
M_!,C]O#3/V^_V9]/\2JUK:^*M+Q8>(M-CF5WM;E1@2[1@K', 73(P/F4%BA-
M?1-?C^*PM7#5I4*RM*+LT?I6'Q$*]*-:D[QDKH****YS8^6O^"U?_*+_ .+/
M_7E:?^E]M7AW_!LI_P F&^+?^Q^O/_3=IM>X_P#!:O\ Y1?_ !9_Z\K3_P!+
M[:O#O^#93_DPWQ;_ -C]>?\ INTVOM,-_P DO6_Z^K\HGS%?_D?4_P#KV_S9
M^BU%%%?%GTX4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'Q3_P '
M 'P:7XL?\$WO$%\LS1W'@;4[/Q%"@0L)RK-:NIQT BNI&S@C*#IG</D;PM^V
MC-X=_P"#;R[L[5H8=6_M.?X<^8;DY=9Y3<R#:<'<;*5TV GCYONY4?K;\7OA
MY;_%[X3>*/"=VZQVOBC2+O29G:/S%1+B%XF)7(W !SQD9Z9'6OY@6\2^+)O!
MJ?!:&+[5'_PES7D=JDA;?J)1;,+'DA5W8 )Q\V$R<**_3>#:,,?@_JM3_ES5
MC4U[6>GWI_>?"<35)83$^WA_R\@X?.Z_S_ _;#_@W=^!L?PN_8 M_$4UK<0:
MCX_U>YU.1YAM9X(F^S0A1UV?NG<$C)\TGE2M=?\ \%V/@A_PNK_@FWXRDAM;
MB\U+P9-;>);-8AG9Y#[+AV&"=JVDMRQQC&,DX!S])?L__"FW^!7P+\&^"[7R
M?)\*Z+::4&B&%D,,*QL_0$EBI8D\DDD\FM?XB^!K+XG_  ^UWPUJ1F73O$6G
MW&F71A;;((IHVC?:2" VUC@X.#7R%7.)/-WF*_GYODGHONT/I:>6I9;]2?\
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M_!NK^QKXTTF_UKXU>,I-8M=*UFR:T\.6EW.__$R,LF^>_9">G&U&8'?YTK=
MK-C6Q6:QRNM7QO+1C)<JCR)2G?1K=-6[V?5]#2GA\O>84J6%YJK3YF^=M1M]
MZ?WKHNI\O_\ !8_PKKWBS_@M#K6DV-^NAZAK5]X?M=&U&5Y(4LVDL[.-)]\2
MM(JI-O)9%9QM. 2 *^BO^'2G[>7_ $<U_P"9$\0__(];G_!PO_P3^\1>+M4T
M?X[> M/U"_U#1[=;+Q'!IR2275O%#NDAU!0F2%B 99&&"@$38VAV7I/V&/\
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MJ_VB_P!F#XA?\$+?VMOA_P",]#U-_$6G/;Q74&I"%[>TU"4+MO=/E 8D*>2
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M]F%](^OG_3\ONZOYJ?"G_!0-M=_;RD^.GQ2\(Q_$F\6\>_M=#;4S8V=G(O\
MQZHI,4O[FW&-B%3DJI9B=V[]R?V-/^"IGPI_;N\=:IX=\!W&O2:GH]A_:4ZW
M^G&V3R?,2,D-N.3N=>/>O6/^&;/AU_T(/@K_ ,$=M_\ $5\[D^8+)9UJ..H-
MRFDM^5I:WUWUTVML>SF6#>:1IU,)62C%M[<R;TMY::[]S\PO^(I[_JA/_EZ?
M_<%?$7P#_P""AW_"CO\ @HSK7Q__ .$/_M3^V-8UG5O[!_M7R?)_M SGR_M/
MDMGR_.^]Y0W;>BYX_H:_X9L^'7_0@^"O_!';?_$5^,?[#7@'0M;_ .#@OQAH
MEYHNDWFBV_B[Q='%83V<<EK&J&]"*L9&T!0!@ <8&*^HR''Y1.ABGA\*X)4V
MY+GD^9:Z:O3U1X.<8/,85L.JU=2;FE%\J5GIKY^A^FW_  3 _P""C/\ P\A^
M&/B3Q)_PAO\ PAO_  C^J+IOV?\ M;^T?/S$LF_=Y,6W[V,8/3.>U?3=8_A#
MX>Z!\/H)H]!T/1]#CN6#3)I]E';+*1P"P0#)'O6Q7YGCJE"I7E/#0Y(/97;M
M\WN?=86G5A24:\N:75VM?Y!1117*= 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZ?\ W!7S3_P4\_X+#VG_  4@^$6@>&W^%Z^#[[P_K U.'4_^$A.H,8S#+')
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M\OY6;>V[)<1'ELJSGK&?L,IR7#4<.LTS5VI_9BOBF_\ +^KI;_-YCFE>I6>
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %5]7TJWUW2KJQNH_-M;R)X)D
MW%=Z,"K#(P1D$\CFK%%%[:H#\)?^"/<TG['7_!9?5/A_??;+=;R36/!K&>$-
M(XC?SH2V.@=K2(ATR#N'\))'[M5^'O\ P6)TJ;]C;_@LEX3^*EMN6SU:;1_%
MA6+*(6M9%M[B'Y<$[UM0SC)W>>>>2!^UWB#QII?A;P7?>(KZ^AAT33;*34;B
M\4^9&ENB&1I!MSN4("W&<CIFOM^,?]I^JYA'_E[!7_Q+?\['RO#/[CV^#E_R
M[F_N>WY7/QO_ ."CT+?M[_\ !=7P?\*9-MUX?\-SZ?H=PMFP<R0*G]H7[9^8
M"14>6-LC"^0 5RISG_\ !%K5_P#AC/\ X*Y>/?A%J5Y.MKJG]J>&+<S#8MU<
MV=QYMO,25'WX89MOW0WGC&25%;O_  ;^^%M0_:6_;_\ BM\:=>MFU":Q@N+D
M7LA$?DZAJ5PS95%.,^2ERN!E4# 8Y0U@?\%C[2\_8F_X*_>#?C!86,:V.JG3
M?$9$* B[EM7$%U$58X#M'$F2-H_? YW;B/K+J527#JV5%+_N(O>O\[W/G;-0
MCG3ZU6_^W'I^EC]MJ_"G]IW3I/\ @H%_P7\3PG"S/IECXEM]#D59$W1VFF1[
M[[:7^7=F"[8 @\D##'@_MKXN^)VE^#?A3JGC*X::;1-*TF76I&ACS));QPF8
ME5;'S%!P#CG@XK\>/^#=#X>:A\<_VU_B-\6O$$,FJ76CV$LKZA-,=RZGJ,Y9
MI,$[G9HDN@2<@;^>64U\EPHWA<-C,Q>CA#E7^*3T^YI?>?1<0_[17PV"6TI7
M?I'?\&S]J*YCXF_&SP;\%-/M[OQEXN\,>$;6Z8K#-K6J06$<Q&,A6E90Q&Y<
MX]1ZU\T?\%CO^"CEW_P3Y^ FGMX=M[>X\=>-I9[+17N%W0Z>D2J9KLH1B0Q^
M9$%0_*6D4ME5*M\,?L%?\$2O$G[?'AB/XN?'?QEXLL[/Q8HO-.BCG$NLZK P
M8K<R37"R"*-LHT8V.70D_("I/GY=D-*>$_M#'U?9TKV5E>4GULOU\GZG;C<W
MJ1Q'U/"4^>I:[ULHKS9^N_PP^/W@3XVK<-X+\;>$?%RVIQ.=%UBWU#R>GWO*
M=MOWEZ^H]:ZZOQR_;;_X(&ZA^R;X&NOB?\"?''BZ>^\&1-J4ME=2[=7C5-NZ
M6TN+5(_G0;V*[5.T<,2,'ZQ_X(B_\%&]2_;I^!>J:/XPFBF\?> WA@O;E5"?
MVM:2J?)NB.GF;HY%D"C&51N/,V@S#(:*PCQ^7U?:4T[235I1;VNNJ\Q8/-JK
MQ/U/&4^2;5U9W4O3S/MRN&^)7[3WPU^#.K1V'C#XA^!O"=],NY+;6=>M;&9Q
MP<A974D88=NX]:^!/^"['_!43Q5\"-;LO@O\,+F\TWQ5KEI%<ZKJ]B[K?64<
MK%8K:V*C*S28R74[E5E"X9LKQ?[*/_!MGI_C;X=6OB#XV^,/%%KXHUR,7LVF
M:%/"CV#2!7V7$\\4OF3#+!PJA0V0&<#<VF%X?P]/"1QN9U?9QG\*2O*2[^2_
MKJB<1G%:>(EA<#3YY1^)MV2\O-GZF_#_ .)GAOXL>'EU?PKX@T3Q-I+.8UO=
M*OHKRW+  E1)&S+G# XST(]:VZ_#_P#;?_X)I?$/_@CQJUA\9/@SXZUZ[\,6
M-]'%=3,NR\TO?(?*6[$8\FXMG.R-F955G=5*?.*_5#_@G9^V3:_MV_LI^'_'
MT=K#I^J3F2QUFQA+&.SO83B15+<[&!211EB%E4$E@:Y\UR.%##QQV#J>THR=
MKVLXOLU^O^:OME^;2JUI83$PY*B5[7NFNZ?]?F?EK^P-_P K&7C;_L</&/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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ME_94_P"B6?\ ERZQ_P#)5'_#B7]E3_HEG_ERZQ_\E5]<T5W_ -O9G_T$5/\
MP.7^9R_V1@?^?,/_  &/^1XC^S#_ ,$X_@S^QKXOO]>^&W@W_A&]6U2S.GW,
M_P#:U]>>; 7639MN)I%'S(IR #QUQFO;J**\_$8FM7G[2O)REW;;?WLZZ-"G
M2CR4HJ*[)67X!7B/@'_@G'\&?A?^T9??%K0O!OV'X@ZC>7FH7&J_VM?2^9/=
M^9]H?R7F,(W^:_ 0!=WR@8&/;J**.)K4E*-*3BI*SLVKKL[;KR85*%.HTZD4
MW%W5U>S[KLPHHHK$U"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH *\=^#'[-%]\+_P!K3XU?$:XU.TNK+XI?V']ELXXV66Q_L^S>W?>3
MPV\MN&.@'->Q5X[\&/VE[[XH?M:?&KX<W&F6EK9?"W^P_LMY'(S2WW]H6;W#
M[P>%V%<#'4'FM(<UI<O;7TNOUL3*UU?OI]S_ $/8J***S*"BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KS']L[]GW_AJK]E;QW\/
M5N(K2Y\4:3+;6D\IQ%#<C#P,_P K'8)DC+84MM!Q@X(].HK2C6E2J1JPWBTU
MZK5&=6G&I!TY[-6?HS\P_P#@E+_P1$^('[%'[6EO\0O'FL^ =5L=+TJZ@L(]
M(N;JXN8KN8+$'Q+;Q*J^2TX+!B?FQMPQ(_3RBBN[-<VQ&8U_K&):<K):*VB_
MX<Y<ORZC@J7L:"TO?OJ<%^U+\%(?VCOV</''@28PJ?%6BW6G0R3$B."=XV$,
MIP"?DDV/T/W>AZ5^?W_!*G_@B!\0OV*_VMK/XA^.M=\!ZE8Z1IEW#8Q:-<7-
MS<"ZF41!CYUM$$7RGFRRL6R0N,,Q'Z?45I@\ZQ6%PM3"4G[E3?3RMIVNB,5E
M>'KUX8FHO>AM^85YQ^U1^RCX(_;,^$=UX*\?:4VIZ/-(+F!XY6AN+"Y575+B
M%Q]V1 [8R"I#%65E9E/H]%>;1K3I352FVI+5-;H[JE.-2+A-73W3/R!U/_@W
ME^-GP*\<7>H?!+XWV>D6]PY"3S7]_H-\D7S;4=[191(5#%<_*#DG:N=M:'@+
M_@W6^(WQ?^)T/B'X^_& >(OE5;I]/O;O5-0NT1E"Q?:KQ%*+LWC.UMIQA2,X
M_6ZBOJ'QIFK7Q+FM;FY5S??8\!<+Y>G\+MO;F=ONN8/PP^&/A_X+_#_2?"OA
M72;/0_#^AVXMK&RMEVQP(.?JS$DLS,2S,Q8DDDGP'_@HE_P2M^'W_!1'1(+K
M6GN?#WC;2[;[)IGB.S7S)((@780S0E@LT(=V;:2K@D[73<V[Z<HKY[#8[$8>
MO]9HS:GO?KYW[WZWWZGM5\)1K4O858IQ[?UMY6/QZ\-_\$+OVLO@BDVE_#GX
M_:9H>@,VY8[/Q/K.C"0Y)RT$$3H#R3]X\L:]6_8?_P"#>+2?A%\3[;QM\8/$
MEG\0-3L;DW<&D00NVGSS?*RRW+R_//ARYV%0K$*6+ LA_2^BO=Q'&&9U:<H<
MRCS;N,4F_FM?N/(H\,X"G-3Y6^79-MI?(*_.O_@CK_P2-^)'_!/?X[>)O%'C
M36_ ^IZ?K6@MI<$>BWEU-,LIN(9<L);>(!=L;#().2..X_12BO'PN9U\/0JX
M:G;EJ64M.U[6[;GIXC TJU:G7G\5.]OG:_Y&/\0_A]HOQ7\"ZOX9\1:?#JNA
M:]:26-_:2YV7$,BE64D$$<'@@@@X(((!K\S_ -B/_@C5\=_V ?VQ5\:>#O%_
MPXUCP:UQ)I]Y::A?7T%YJ6DO("0\<=LT:W"JJNN'9!(@Y*Y!_4BBM,!G&)PE
M*I0IV<*BM)-77_ ?G_DC/%Y;0Q%2%:=^:&J:T84445Y9Z!^17[=/_!"'X[_M
M:?M:>./B!#XO^&O]G^(=2:33H[_4[];BWM% 2"-U6T=5*QJH(5B,@X-<;_PX
M!_:L_P"BN>"O_"IUC_Y$K]IZ*^NI<;9E3IQI1Y;122]U;+0^;J<*X&<Y5'S7
MD[OWGU/Q8_X< _M6?]%<\%?^%3K'_P B5]\?\$E/V,/B9^Q+\'_$V@?$OQ3I
M?BB^U;6!J%E)8:E=7T<$?D1QL";B*,JQ9,X4$$ <U]7T5R9EQ1C<=0>'K\O*
M[;12>GF=6!R#"X6JJU*]UW=]SP3]O7_@G5\/_P#@H1\/K?2?%L-SI^L:66?2
M=<L BWNGL1RN6!#PL<;HVX.,@JP##\^D_P""#W[4/P;2\T+X9?M 6-EX2N%(
M:(:]JVA"XR6R'M;=)H\$,2?G/+,/<_L!1667\28[!TO84Y)P_EDE)+TOL:8W
M(\)BJGM:B:EW3:?SMN?G5_P3]_X-_?#?[-WCZQ\=?$W7X?B!XJT^07-EI\5L
M4TJQN S'SG,F7N7'RLI81JK9)5R%9?T5HHKAS+-,5CZOML5+F?3LEV26B.K
MY?0PE/V>'C9?B_5A1117GG8%%%% !1110 4444 %%%% !1110 4444 %%%%
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MTUAZ?L?8->[:UO*UC\(_ +_M2?\ !!SXDZQ:KX87Q)X%UR2-IY$M9;[0=2D
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MLORB281PSE48Y 41@@LQ/ZB?L7?\$S?AG^P5X@US4O ":]%/XBMX[:\6_O\
M[2C+&Q9"/E!!!9N_.?I7Y/?M03ZQ_P $N/\ @M[<_$;4M,O+K0]0\1W/B>UF
M.-NH66HK*+L1-MQNC-S/'@C(,8[$,?+X8IX/Z_B'EUW)4VZ?/:_-;7LM_P /
MF>AGT\3]4HK&V2<US\M[<M_OV_$_53X2?\$B_P!G3X/>#6T>T^%?A?6O.@2&
MXO=>M5U6\N&52ID\R<-Y3MDL?)$:Y(P %4#X'_X+6_\ !*+PW^RYX&@^-_P=
MCNO!\>CWT2:WIMG<2+#:&618X+JU(^: B5@C+NV_O(]@3:0_ZJ_!?]HCP/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M<<<:A4C4# 4 <  <8%245EF.;8S'S4\7-R:V[+T2LE]QI@LNPV$BXX>"C?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M7WL/]3:/_/Q_<C^4W_AW=^T#_P!$+^,7_A%ZE_\ &:/^'=W[0/\ T0OXQ?\
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MC_6ZM_S[7WL/]3:/_/Q_<C^4W_AW=^T#_P!$+^,7_A%ZE_\ &:/^'=W[0/\
MT0OXQ?\ A%ZE_P#&:_JRHH_UNK?\^U][#_4VC_S\?W(_E-_X=W?M _\ 1"_C
M%_X1>I?_ !FLKQQ^Q5\9/ACX5O-=\2?"7XF^'M#T]0]UJ.I^%[ZTM;92P4%Y
M9(@B@LP&21R0.]?UCUC_ !#^'^C?%CP'K'ACQ%I\.JZ#X@LY=/U"SER$N8)5
M*.A(((RI/(((Z@@@&G'BZI=<U-6]29<&TK/EJ._HC^0.BOIK_@IM_P $R?%_
M_!.'XO'3M1$VL>"]8D=O#_B!8ML=X@Y\F7'$=P@^\O0CYER#Q\RU]I1K0K05
M2F[IGPM>A4HU'2JJS0445]U?\$7O^"3&N?MR_%?3?&GB2Q^Q_";POJ$<U]+=
M1$KXBEB<,;&(<;D;&V5QPJD@?,1B,5BJ>'INK5=DBL)A:F)JJC25V_ZN?..G
M?\$__CQK&GV]W:?!/XN75K=1K-#-#X/U%XYD895E80X*D$$$<$&IO^'=W[0/
M_1"_C%_X1>I?_&:_JRHKXW_6ZM_S[7WL^Y_U-H_\_']R/Y3?^'=W[0/_ $0O
MXQ?^$7J7_P 9H_X=W?M _P#1"_C%_P"$7J7_ ,9K^K*BC_6ZM_S[7WL?^IM'
M_GX_N1_*;_P[N_:!_P"B%_&+_P (O4O_ (S1_P .[OV@?^B%_&+_ ,(O4O\
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M8O\ PB]2_P#C-?U944?ZW5O^?:^]A_J;1_Y^/[D?RF_\.[OV@?\ HA?QB_\
M"+U+_P",T?\ #N[]H'_HA?QB_P#"+U+_ .,U_5E11_K=6_Y]K[V'^IM'_GX_
MN1_*;_P[N_:!_P"B%_&+_P (O4O_ (S1_P .[OV@?^B%_&+_ ,(O4O\ XS7]
M65%'^MU;_GVOO8?ZFT?^?C^Y'\IO_#N[]H'_ *(7\8O_  B]2_\ C-'_  [N
M_:!_Z(7\8O\ PB]2_P#C-?U944?ZW5O^?:^]A_J;1_Y^/[D?RF_\.[OV@?\
MHA?QB_\ "+U+_P",T?\ #N[]H'_HA?QB_P#"+U+_ .,U_5E11_K=6_Y]K[V'
M^IM'_GX_N1_*;_P[N_:!_P"B%_&+_P (O4O_ (S1_P .[OV@?^B%_&+_ ,(O
M4O\ XS7]65%'^MU;_GVOO8?ZFT?^?C^Y'\IO_#N[]H'_ *(7\8O_  B]2_\
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M>]FO=UW?I^H+A&C!./M'[VFR]?T/YK_^'=W[0/\ T0OXQ?\ A%ZE_P#&:/\
MAW=^T#_T0OXQ?^$7J7_QFOZLJ*/];JW_ #[7WL/]3:/_ #\?W(_E-_X=W?M
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M&+_PB]2_^,U_5E11_K=6_P"?:^]A_J;1_P"?C^Y'\IO_  [N_:!_Z(7\8O\
MPB]2_P#C-'_#N[]H'_HA?QB_\(O4O_C-?U944?ZW5O\ GVOO8?ZFT?\ GX_N
M1_*;_P .[OV@?^B%_&+_ ,(O4O\ XS1_P[N_:!_Z(7\8O_"+U+_XS7]65%'^
MMU;_ )]K[V'^IM'_ )^/[D?RF_\ #N[]H'_HA?QB_P#"+U+_ .,T?\.[OV@?
M^B%_&+_PB]2_^,U_5E11_K=6_P"?:^]A_J;1_P"?C^Y'\IO_  [N_:!_Z(7\
M8O\ PB]2_P#C-'_#N[]H'_HA?QB_\(O4O_C-?U944?ZW5O\ GVOO8?ZFT?\
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M  [N_:!_Z(7\8O\ PB]2_P#C-'_#N[]H'_HA?QB_\(O4O_C-?U944?ZW5O\
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MO_C-?U944?ZW5O\ GVOO8?ZFT?\ GX_N1_*;_P .[OV@?^B%_&+_ ,(O4O\
MXS1_P[N_:!_Z(7\8O_"+U+_XS7]65%'^MU;_ )]K[V'^IM'_ )^/[D?RF_\
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M&+_PB]2_^,U_5E11_K=6_P"?:^]A_J;1_P"?C^Y'\IO_  [N_:!_Z(7\8O\
MPB]2_P#C-'_#N[]H'_HA?QB_\(O4O_C-?U944?ZW5O\ GVOO8?ZFT?\ GX_N
M1_*;_P .[OV@?^B%_&+_ ,(O4O\ XS1_P[N_:!_Z(7\8O_"+U+_XS7]65%'^
MMU;_ )]K[V'^IM'_ )^/[D?RF_\ #N[]H'_HA?QB_P#"+U+_ .,T?\.[OV@?
M^B%_&+_PB]2_^,U_5E11_K=6_P"?:^]A_J;1_P"?C^Y'\IO_  [N_:!_Z(7\
M8O\ PB]2_P#C-'_#N[]H'_HA?QB_\(O4O_C-?U944?ZW5O\ GVOO8?ZFT?\
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M  [N_:!_Z(7\8O\ PB]2_P#C-'_#N[]H'_HA?QB_\(O4O_C-?U944?ZW5O\
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M8O\ PB]2_P#C-'_#N[]H'_HA?QB_\(O4O_C-?U944?ZW5O\ GVOO8?ZFT?\
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M  [N_:!_Z(7\8O\ PB]2_P#C-'_#N[]H'_HA?QB_\(O4O_C-?U944?ZW5O\
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MO_C-?U944?ZW5O\ GVOO8?ZFT?\ GX_N1_*;_P .[OV@?^B%_&+_ ,(O4O\
MXS1_P[N_:!_Z(7\8O_"+U+_XS7]65%'^MU;_ )]K[V'^IM'_ )^/[D?RF_\
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M&+_PB]2_^,U_5E11_K=6_P"?:^]A_J;1_P"?C^Y'\IO_  [N_:!_Z(7\8O\
MPB]2_P#C-'_#N[]H'_HA?QB_\(O4O_C-?U944?ZW5O\ GVOO8?ZFT?\ GX_N
M1_*;_P .[OV@?^B%_&+_ ,(O4O\ XS1_P[N_:!_Z(7\8O_"+U+_XS7]65%'^
MMU;_ )]K[V'^IM'_ )^/[D?R1_%;]F;XD? C3[2[\<?#[QQX-M;^0PVTVNZ%
M=:='<N!DJC3(H9@.2!DXKAZ_;[_@ZFMY+SX#_"6&&-Y99?$=RB(B[F=C;@
M#J3Z5\;_ +#_ /P;X?&;]J7['K'BZ'_A5?A&;#_:-7MRVIW*'_GE9Y5ESZS&
M,<Y&ZOHL'G%.>$6)Q#4;W_!].K/F<9DM6&,>%PR<[6_%=>B/@RWMY+RXCAAC
M>665@B(B[F=CP  .I/I7[&_\$1_V6OVS/ &H:3J-YKDW@/X4M)'+-H_BV)[J
M>]AS#N%M9DB2!C%"L:N[1A58E5;-?=O[$_\ P25^"O["EO;W7A?PVFK>*8EP
M_B/6MMWJ);N8R0$@!](E7(ZENM?2]?-YIQ'&M%TJ,%;O)7^Y'T^4<,2H25:O
M-W[1=OO?7^M0HHHKY,^Q"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH ^$O\ @I7_ ,$(OA_^W;K]YXRT#4'^'_Q&N5+7%]!;
MB?3]8< 8-S!E2). /-C8'!)992% _,+XA_\ !N9^U%X*NS'IOAGPUXN02%/-
MTGQ#;1(0!G?_ *6T#;3TZ9]J_HJHKVL'G^+P\.2+4DMKZV_)GA8[AW!8F?M)
M)Q;W:TO^:_ _ /X!_P#!LU\>/B-JENWC:^\+_#G3&8"=IKM=4O8U^0DI%;L8
MV/S,,&9>4/(!!/Z]?L"_\$UOAK_P3N\$3Z?X+L9KK7-4CC75M>OR)+[42HZ9
M'$<6[)$:  =3N/S5]!45ECLZQ6*7)4=H]EHC7+\CPF#ESTU>7=ZO_)?<%%%%
M>4>P%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 9OC'P9H_Q$\,7NB>(-)T
MW7-%U*/R;NPU"U2ZM;I.NV2-P59>!P017PO\6_\ @VX_9L^)VOW%_I]MXT\$
M_:)C,]OH.KH+<$CE52YBGVKG+;5P 3@84!1]]45TX?&5Z'\&3CZ'+B<%0Q'\
M:"EZH^&_@I_P;O\ [,_P?UN/4+OP_K_CBX@\MH4\2:H9H$=>K&*!88Y-W=9%
M9..%%?;>BZ-9^&]'M-.TZTMK#3["%+:VMK:)8H;:)%"I&B* %55  4    "K
M-%+$8JM7=ZTG+U8\/@Z%!6HP4?1!1117.=(4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^+?^"@'_!#3X0_MU:OJ
M7B:,7G@/XA:A\\NNZ6OF0WL@ 4-=6C$)+@<EHS%(QQN<@8K\]]<_X-8?C3;Z
MVL>F^/OA?=Z;\NZ>YGOK><?WL1+;.IQV^<9]J_=JBO6PN>8RA'DA*Z\];'C8
MO(,%B)^TG"S\M+GY)_LI?\&MNA^%_$%CJWQA\=?\)1;V\F^7P_H,$EI:W&&X
M62[9A*49?O+''$PSQ)WK]5/A[\/=#^$_@C2_#?AO2[/1=!T6W6TL;&TC$<-M
M$HP%4?J2>222<DDUL45S8S,,1BG>M*_ET^XZ\%EN&PBM0C;N]V_F%%%%<1W!
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% &;K/@S1_$>KZ;J&H:3IM_?Z+(TVGW-Q:I+-8.
MPVLT3L"8V*\$J02.*TJ**+L+(**** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH ***Q_&GB5O#>G*T:[IIB53/1?4F@#8H
MKRF7Q/J4K[C?763_ '92H_(4W_A(]0_Y_KS_ +_-_C05RGK%%>3_ /"1ZA_S
M_7G_ '^;_&C_ (2/4/\ G^O/^_S?XT!RGK%%>3_\)'J'_/\ 7G_?YO\ &C_A
M(]0_Y_KS_O\ -_C0'*>L45Y/_P )'J'_ #_7G_?YO\:/^$CU#_G^O/\ O\W^
M- <IZQ17D_\ PD>H?\_UY_W^;_&C_A(]0_Y_KS_O\W^- <IZQ17D_P#PD>H?
M\_UY_P!_F_QH_P"$CU#_ )_KS_O\W^- <IZQ17D__"1ZA_S_ %Y_W^;_ !H_
MX2/4/^?Z\_[_ #?XT!RGK%%>3_\ "1ZA_P _UY_W^;_&C_A(]0_Y_KS_ +_-
M_C0'*>L45Y/_ ,)'J'_/]>?]_F_QH_X2/4/^?Z\_[_-_C0'*>L45Y/\ \)'J
M'_/]>?\ ?YO\:/\ A(]0_P"?Z\_[_-_C0'*>L45Y/_PD>H?\_P!>?]_F_P :
M/^$CU#_G^O/^_P W^- <IZQ17D__  D>H?\ /]>?]_F_QH_X2/4/^?Z\_P"_
MS?XT!RGK%%>3_P#"1ZA_S_7G_?YO\:/^$CU#_G^O/^_S?XT!RGK%%>3_ /"1
MZA_S_7G_ '^;_&C_ (2/4/\ G^O/^_S?XT!RGK%%>3_\)'J'_/\ 7G_?YO\
M&C_A(]0_Y_KS_O\ -_C0'*>L45Y/_P )'J'_ #_7G_?YO\:/^$CU#_G^O/\
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M445YITA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MT4 ==_:5O_S\0_\ ?8H_M*W_ .?B'_OL5R-% '7?VE;_ //Q#_WV*/[2M_\
MGXA_[[%<C10!UW]I6_\ S\0_]]BC^TK?_GXA_P"^Q7(T4 ==_:5O_P _$/\
MWV*/[2M_^?B'_OL5R-% '7?VE;_\_$/_ 'V*/[2M_P#GXA_[[%<C10!UW]I6
M_P#S\0_]]BC^TK?_ )^(?^^Q7(T4 ==_:5O_ ,_$/_?8H_M*W_Y^(?\ OL5R
M-% '7?VE;_\ /Q#_ -]BC^TK?_GXA_[[%<C10!UW]I6__/Q#_P!]BC^TK?\
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M )?_ /;O_MQ\[GOV/G^@4445^A'SX4444 %%%=E_PSM\0?\ H1?&7_@EN?\
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MH**** "BBB@ HHHH ***R/'OC_0_A;X/O_$'B35M/T/0]+C\V[OKV=88(%R
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MP=R;0$V%=HP3G.>.E:0YK2Y>VOI=?K8F5KJ_?3[G^AZY1116904444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P!-^GT3P?+05>^_2P1Q%ZKI6/T$J.[NXK"UDGGDCAAA0R222,%6-0,DDG@
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MA[P;H/PW\8& C3-8T"T^Q06THQM\VUB*PRHVT!LIOP6*LI.:_!G]G?2OBI\
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MGQ\\)_LQ_"?6/&WC;6+?1/#NB0^;<7$IRS'HL<:CEY';"JBY+$@"OQM_:O\
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M\13A"HXTY<T>C[GUN%J5)THSJQY9/==@HHHK$W"BBB@ HHHH **** "BBB@
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M[B>UEM5B2WE E("SLY<J$^3&XD@'HC3@Z?,WJ8RG+GLEH?NE1117.;!1110
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M:,D-A"UQH\3M,D8^U>7).DC;IBL,2$E78DQB12V=)7EM<TJ.RWL>=ZO\(O\
M@J'%I,WB&'XI?"62;;YJ^&+>TL_.!/R^6KR6 3(^]EKG''WC]VO7?^"+O_!3
MOQ!_P4!\#>,-#\?:1INC_$3X;W4-IJGV(&*&_CD,JK*(F+%)%>"19 I*[MI&
MT.$7RBS_ &J?^"CWQRU6.U\/? KX>_#G39L*VH:Y,#):G:XW,'NMS*2. ENQ
M!VY^4\^*_P#!MM;:]9?MZ?M$0^*;B&\\30P.FKSPA1'/>#47$[J%55VF3<1A
M0,'@#I6THW@V[?(Q4K25K_,WO'7_  5[_:(\$_\ !4+XK?!WP;8VOQ(OKS5#
MHG@;P]>6%O#9:7*&CEDN)Y85BGDC2!)L[Y@J@EV8!,%W[3?[1/\ P4._X)T>
M#K/XI?$+Q1\-?&W@WS;:#4-)M+&W:+3WE( 64QV]O-NW#86CED0-)QD8(M?L
M ^&+77_^#E3]H*ZN!)YVB:5JE[;;6P!(UQI\!SZC9._'K@]J^J?^#@/_ )1&
M?%K_ +@__IZL*=XJ48V6M@U<7*_<\6TK]M?]JC_@JM:?VS^R[#X=^$/P]TB"
M*&X\0>,8XYKC5]1*H\]O OV>Y7RX2VS<(L-AB7!(C2O_ ,$[/^"E/QX\&_M_
MWO[,_P"TXNDWGBB[AD?2-:MX(+<SR+$]RF#;HL,L4T )1ML;*T>Q@9"RK]#_
M /!"^WCM?^"4?P?6*-(U-A>.0J[06;4+IF/U)))/<DU\C?M8V\</_!S[\&62
M-%:;1;9W(7!<_9M0&3ZG  ^@%)<K<H6VO^ ];*5SV/\ X+>_MQ_%+]D'XO\
M[.NE_#OQ1_PCMCX[UB^M=<B_LVTN_MT<<VFJBYGB<QX6XF&8RI._G.!CTO\
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MH^BV=CI+G4[<[[2*!$A.1K(ZQJO8?05XO^WI^R_^W]_P4+UGP3JGB[X$^"=
MU7P#-/-I=[X>US3[>;,K0L1(9M3E#!6@1EP!@EO4T<L6[.UA<S2NKW/KG_@O
M[^W3\3/V%?AA\-=8^&WB'^P9]9UR>WU(?8+6Z^V0)$KB/_2(I G.?F4 \UQW
MP1\2?\%#OVGM3\,_%2QU[X<^!/AUXKOX+FW\(7MI!/=6FDS,"MPY-OYCXA</
MC[3'(Q4?NT!VUR/_  =??\D ^$O_ &,%W_Z3"OU8T/1+7PUHEGIMC"EM8Z?
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M[>'_  5+O-2\7?!:?P7\'?AHMV\.F76L6\%S]I";E9#));7#RL&7YF2%%#,
M.AKK_@=_P5'^.7[%/[6^C_!?]KZST">Q\5RK#H?C[3HEMK.9V(17=D1(F@,A
M16)CA> OND&Q@5XC]D'XT?\ !0SX=?LL?#O1OA]^S_\ "'4O ]GX>LO[#OI]
M3@\[4+1H5>.X?_B<)\\JL)&^1/F<_*O0<#_P4'_9Q_;^_P""D_A#P[H_COX
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MV/P7I,L9@1%69I+.*1Y3L 5FD=FD9@/F9V8\DU*:C"]M;E:REOI8^,?V./\
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MFB,K&%55;>W&5CV@_NAR.IZUZM117&W=W.H****0!1110 5VE<77:4 %%%%
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MD/,70;X&\A_Y^;20&*XCZ'!:%Y #@[6VL 2!7Z&?\0QG_5;O_+._^[J^&O\
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M6?\ X*F^!KKXB_\ !/7XL:;9QM+<1Z&]^$4X9EMG2Y;'J=L)XZGH.37Y%_\
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MJ$2JU54X\S./_P""N7_!:*XU34=0^&'P9UGR=/A\RUU[Q-:,"UX2"KVUH_\
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M6D.:TN7MKZ77ZV(E:ZOWT^Y_H>N4445F6%%%% !1110 4444 %%%% !1110
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M_8^_8'\;:^D[V^M:];/X<T1DVEQ>W4<BJX#$ F-!)+W_ -5T(R*?_P $;O\
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M^S=)#HMM8Q_$CPIOO/#MW*1&;CC,MDSD@*DP P6X5U0D@;C7XA_\$:?AO?\
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M>E&C26B_K\0HHHK Z HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0+D9!*-C&"H_,G_@Y/\ VF/^%R_MX0^#;.Z\[2/A?I<>GE4N/-B-]<!;BY<
M<*P4V\3 9(:W()R-JZG_  ;F_MM:=^S)\7?B9X>\2W<L/AK6?"]SXC"B121/
MI<4EQ((T8@;FM#<L2",^0N<@97XG_P"*H_;>_:S_ .?OQ=\5/%'L%-U>W/\
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MXK,ZGJ\R37]]L4*)9W1$5Y&QEF"C<<D\DUM445P-MN[/1BDE9!1112&%%%%
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M5I;<S+:H9!:S)I@TZ6%\*?*E\M?.B9OE9AP?E8+^RE%%.IRNXY1YD?F7JO\
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MP<,IP,U[W_P;^?\ *(SX2_\ <8_]/5_7V316<JETUYW+C&SOY6/R&_X.D_\
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MH;J3RY)HF5#P#+)&@8C=NQL?]-:*OVJ=KK5$^S:V9^.__!L-I?\ PI']H/\
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M_P"(K[X?_P#1)?&'_@SMO\*^HO\ @F/_ ,%>O#__  4W\3^+--T/P;K'A?\
MX1&UM[F>2_O(YO/\YW50H0=O+8DD^GX?8%%9RE!K2/XE1C*^K"OQI_X-RO\
ME(/^TA_NS?\ IRDK]EJ*(SM%KN5*-VGV"OFW_@KS\<[?]GS_ ()O_%K7))H(
MKJ^T*;0[)9"-TEQ>_P"BIL4_>9?-+XYXC8D8!KZ2K\UO^"F\%Q_P4_\ VY/
M?[*_ANZF/@[P3<Q^+OB;J5L"!9J%VPV:R;2%F,,CX'S+ONHB1F%P"G&\M=@J
M/0]3_P"#?CX!7'P(_P""9/@^2^@^SW_CBYN/%4L9A,;;+@JENQ)/S;[:&!PV
M ,. ,XW'[6JKHNBV?AO1K33M.M+73]/T^%+:UM;:)8H;:)%"I&B* %55  4
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MW46N@C4)[>SUX1;C'%Y;JJ7323,6FG$6!&AA#@A2/U.HI^TC]E!R/JS\G?\
M@M+_ ,IC_P!C+_L8-)_]/=O7ZQ445,IW278J,;-L*_)W_@Z^_P"2 ?"7_L8+
MO_TF%?K%12ISY9<P3CS*Q^<O_!P'_P H=]/_ .O_ $/_ -!->H_\Z^7_ ';S
M_P"ZW7V313]IHEYW%RZW/@+_ (-JO^48FF_]C'J7_H:5\^_\%]_^4H/[*O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MHQ)C;D<'(KX:K4C2E.GB*M/FN[OV3E;YK32ZTUMW/<C%S2E3C*VGVDC\W?\
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M&-:C&HK2/Q/_ .(;SXX_]#5\*?\ P9ZA_P#(5'_$-Y\<?^AJ^%/_ (,]0_\
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M_P!#URBBBLRPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH _GQ_P""Z7_!*G6?V2/C1K'Q,\*:;)=?"OQ=??:2\.Z1O#]Y+@R039Y$
M<DI9HGZ#<(SA@I?%_P""??\ P7Q^*'[#OP_L?!6H:1IGQ#\%Z8Q^Q6NH7,MM
MJ&GQ\8@AN1O A'S85XGV[@%(4!:_H:\2>&M-\8Z%=:7J^GV.JZ9?1F*YM+R!
M9X+A#U5T8%6'L017Q3\<_P#@W@_9I^-.JR7UGH.O^ [J8@R'PSJ7D1,1Z0SI
M-$F1QA$4=\9)-?687/,/5H+#YA#FMU_K6_FCX_%</XFCB'B<MGRWW7^6C5O)
M['YV_MN?\'(7Q%_:?^%M_P"#_!OA.S^&&FZU;FUU*[BU1M2U&>)@RR1QR^5$
ML2NK $A"XP<.,\>'_P#!(O\ X)SZU^W]^TQID-QI\R_#WPS<1WWB;4'1U@>%
M'4_8T<*5,TV<!<@A-[?P\_K-\+_^#:K]FWX>^((+[4E\>>,XX6+?8];UE%MY
M"1@;A:PP,0IY W8)X.1Q7W!\+?A1X9^"7@>Q\->$=#TSP[H.FQB.WLK"!88D
M  &<#[S' RQRS'DDGFJK9YA,/1='+X--]?ZNVS.CD&,Q-=5\RFFET_31))=[
M&3^TO_R;C\0/^Q;U'_TEDK^6/]D?_DZ[X8_]C9I7_I9%7]7WCGPE;>/_  5K
M&@WDD\=GK=C-83O"0LB1RQM&Q4D$!@&.,@C/8U\"_#K_ (-H_@3\,OB#H/B2
MP\6?%J:^\/ZC;ZG;1W&J:>T+R0R+(H<+9 E2RC(!!QGD=:Y,CS.AA:52%6]Y
M;:>3.W/LJKXNK2G1M:.]WYH_0ZOYD/\ @M=_RE)^,7_85A_])(*_IOKX5_:A
M_P"#?7X,_M:?'SQ)\1?$?B;XG66M^*;A;F[@TW4;&.UC98TC 19+-V P@ZL>
M<_2L,AQ]+"5Y5*VS5M/5&_$675L90C3HVNG?73HSM/\ @E]\2M'^#?\ P1[^
M&_BSQ!=I8Z'X;\)RZC?3L?\ 5PQ/,[8]3@8 [D@=Z_G=^+'Q"\2?M=_M):UX
MBN8[C4/$WQ UUYX[<S>8QFN)L16Z,V!M7<D:C@*JJ    /Z5O$'_  3C\'Z]
M^P5;_L[KXB\;6'@JWLX;!KZTO+9-6G@CG$^QI3 8\,P ;$0W+E>A.?#?V>/^
M#=CX&_LW?&_POX]TO7?B1K&J>$K^/4[*UU:_L9K-IXSNC9U2S1CL?:XPP(95
M/:N[+<TPN&G6K2OS2;MITW7WL\_-,GQ>*A0H1MRQ2OKUT3^Y;>IL?#__ (-\
M?V7M"\!Z)8Z[\.6UO6[.P@@U#43XCU:(W]PL:K+,4CN41=[AFPJ*HW8"@8 U
M_P#AP-^R3_T2?_RY]9_^2Z^Q:*\-YGC&[^UE_P"!/_,^@658)*WL8_\ @*_R
M/Y@_^"NO['=C^P_^W3XJ\&Z'9S6/A.Z2'5_#\<AD;;93IG8KR,S.L<RS0[RS
M%O)))SD#]DO^"'7[1T/[;?\ P3/M_"OB*^2[UCP?!-X+U98YD6Y>R\G;:RE0
M 5!MG6(.0=[V\C9+;@/4O^"@W_!*?X:_\%);KPO=>.+SQ1I%]X32XBM;K0;B
MVMYIXYC&3'*TT$NY5,>5 QM+O_>-4_\ @GY_P26\ ?\ !-WQ5XBU3P+XG^(6
MI+XHM(K6^LM;O[6:U<Q.6CE"0VT1\Q-TB@DD!97&.<U[.-S:ABL!&G-OVL;?
M>M-_-:^IX>!R>OA,PE4II>RE?2_1Z[>3T]#^>'XL?#/QK^P'^UE<:/?1W&D^
M,/AUKD5W97#Q;=[PRK-;72#)!1P(Y%P2,,.:_;SX+?\ !R-^SYXP^#D.L>,=
M0UCP?XMM[+S+O0%TFYO3/<*IS';31H8F#,N%,K1??7=MPQ'NW_!0C_@EU\,_
M^"C?ABSC\76]YI/B31XWCTOQ#I91+VU4Y/E/N4K-#O.[RV&1EMC(68GXE\!_
M\&I7A?2O%T-QXD^,6M:UHD<X=[*P\/QZ?<21C/R>>UQ, 3\OS"/L>.1CIK9E
MEV/HQ>,;C./;KZ:-6?GL<M'+,SR^M)8%*4)=^GKJG=>5[GYK?\%+OVT-3_X*
M ?M1ZM\2Y],OM)T&X5=(T*UN',GV6TMP"(]WW?,+2F5U3A6N#UR&/ZU_\&M?
M_*/[QA_V4*]_]-NF5ZQ^T3_P0>^!O[0_@;P%X;9O%O@_1/AU8SV.F6OAV[MH
M1.)F1Y)9VFMY6DE9D#%\@DDDY[>P_L$?L$>#_P#@G7\'M2\$^"=2\2ZII6J:
MS+K<LNMW$$]PLTD$$)53#%$NS;;H0"I.2W., 8YCFV%K8%8>BFFFK+R7GZ'1
MEF38NAF#Q-=IIIW?F_+U/SM_X.3O^";VJ>)+^']H/PA9S7T=K:1:=XNLH(V>
M2&.,-Y6H]_D5-L4F,;0L38(\QE^%O^"9'_!6'QO_ ,$UO%-]#I=C8^)/!?B"
MXBFUC1+LF-F9<#SK>4<Q3;/ER0Z,,;D)"LO]-5?!/[6O_!NW\"?VD-8U+7/#
M\>K?#/Q%J#&5WT1EDTUY2V6=K.0;5!!QMA>)00#C[VXRW.J'U?ZICHWCT?EY
M]=.C09ID-?ZS]=P$K2W:VU\NFO5,\TF_X.HOA OA>&:/X=_$EM:8?O;5A9+:
MH<'[L_GEFYV]8AU/I@_EU_P49_X*:^//^"DGQ TW4O%$-AHVAZ DD>CZ)8;C
M;V?F$;Y&=OFDE8*@+' P@VJO.?T"_P"(3BW^W[O^%\S?9?,SY?\ PA@\S9GI
MO^W8W8XSMQGG':OJ3]CW_@@'\"?V4?$6G^(;JUU;X@>*--E6YM[W7I5:VM9E
M965XK:-53*E01YGF$$D@],=5'&9/@W[7#WE+IOI]]K''6P.=XU>QQ+48]=5K
M]U[_ )'A_P#P;@_\$VM6^"'A?4?CAXTL9M/UCQAIXL/#=C/&4EMM.=UDDNG5
MN0TY2+R^ 1&I/(E&/J3_ (*\_P#!1BT_X)V?LQ3:K8M;W'C[Q2SZ=X7LY0&7
MS@%\VZ=3UB@5E8C!#.\2' <L/JROC7]M;_@B1\.?V^/C-)XW\>^.?BJU^MLE
ME9V5AJ&GPV6FVZDL(H4:R9@"S.Q+,S$L<G& /#CC*>)QOUC&_#V6NVR_S/H)
M8&KA<#]6P/Q=WION_P#+_@'X<_\ !/\ _8V\3?\ !2[]L&S\,?:[O[/J$\FL
M^*M:8[I+.TWAIYB2#F:1G"(""#)*I.%#$;W_  5E_P""=.H?\$Z/VF;C0[==
M0O/ GB!6OO"VJ70!:YA 3S8'9?E,L#N$;H2IC?:HD '[[?L!_P#!.'X=_P#!
M.+P-K>B^ _[:OI/$5XEWJ&I:Q-#-?7.Q=L41>**)?+CW2%5V\&60Y.ZM;]N/
M]@_P#_P4%^$"^#_'EO?QPVMTEY8:GILD<.H:9*I&XPR.CJ Z91E9&4JV<!E1
ME]I\36QB:_A6M;KZ_P!=/,\&/"E\$U+^->]^GI_P>_D?-?\ P0=_X*<3_MN?
M Z?P9XPOY[SXE^ ;>,75U./FUJQ)V17);)+2J<)*2!DLC9)<X^^J^%/V9/\
M@W[^$_[(_P =/#OQ"\&^.OB[;Z]X;N?/B6?4]/>WND(*R03*+)2T4B%D8!E;
M#':RL P^ZZ^=S.6&E7<\+\+UM:UG_D?395'%0PZIXOXEI>][KI\_^'"BBBO/
M/2"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MFC15*W-!6>ODO^"=)_P;I_!J;X3_ /!,W0]0N%:.;QUK%]XB:,DY12R6D?\
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M1O[0/AG]E;X(>)/B%XPNY++P[X7M?M5V\:;Y)"65(XHUR TDDCI&H) +.H)
MYHWT [:BOS?_ &6/^"^GB;]J_P"-'A?0=#_9L\9Q^$?%&KPZ9'XH_M9I+6T1
MYECDFE_T01 1@NQ43$DH%'+"OT@JI0<=&3&2EL%%%%24%%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MM7N/AIING>#O&^KQ:M'92>'X=(O8 JRQS3*S*$>];$*,SH0"&#Q*?$/V'_\
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MW7__ $VW%?RFU]UPC_!J>J_(_/N,OXU/T?YA70?"CX;ZE\9/BEX:\(:/Y/\
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M.L4JN87'56 /RL/0\U\GBN*H4ZKA3I\R6E[V_1GV.$X1G5I1J5*G*VKVM?\
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MEVIF8 L3$R*VU21N ./G/_@X]_:U\:V_PB\4?"-?@YXHD\$W']EW[_$,-/\
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M'^#/^"CWP9N/%GA.WU#2[C2[LV.JZ5?*//T^;&Y067Y75TPRLI[D'!! ]F\
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M\6E_\%,_V6[J=O+@M[FTED;!.U5U6(DX'/0=JWIRO5;]3.2M3MZ'["5\^_\
M!5S_ )1L?&[_ +%"_P#_ $4:^@J^>O\ @K'<1VW_  35^-S2.D:GPE?("QP"
M6C( ^I) 'J37/3^)&DMF>#_\&U7_ "C$TW_L8]2_]#2OFK_@CK_RL&_M3_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ KM*XNNTH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *XWXM_\P_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O$_@9^S=KGP
MR_;(^.WQ#O[K29M%^)W]@?V7#;RR-=6_V"Q>WF\]60*NYV!78SY&<[3Q7ME>
M4_"/]IW_ (6G^U!\7OAO_8?V'_A57]C?\3'[9YO]J?VA:/<_ZK8OE>7MV_??
M=G/R]*TAS6ER]M?2Z_6Q$K75^^GW/]#U:BBBLRPHHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\BQC /S%(I#]%-?N77R?\1O^"'G[+OQ9^(6O>*O$'PP_M#7O$VHW&JZE=?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "NTKBZ[2@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KC?BW_P P
M_P#[:?\ LE=E7&_%O_F'_P#;3_V2@<=SC:***"PHHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "O9*\;KV2@F05_#77]RE?PUU^A<!_\ +_\ [=_]N/G<]^Q\_P!
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M/^'5G_5R'[5O_AP/_N>OJVBCZS4[A[&'8^4O^'5G_5R'[5O_ (<#_P"YZ/\
MAU9_U<A^U;_X<#_[GKZMHH^LU.X>QAV/E+_AU9_U<A^U;_X<#_[GH_X=6?\
M5R'[5O\ X<#_ .YZ^K:*/K-3N'L8=CY2_P"'5G_5R'[5O_AP/_N>C_AU9_U<
MA^U;_P"' _\ N>OJVBCZS4[A[&'8^4O^'5G_ %<A^U;_ .' _P#N>C_AU9_U
M<A^U;_X<#_[GKZMHH^LU.X>QAV/E+_AU9_U<A^U;_P"' _\ N>C_ (=6?]7(
M?M6_^' _^YZ^K:*/K-3N'L8=CY2_X=6?]7(?M6_^' _^YZ/^'5G_ %<A^U;_
M .' _P#N>OJVBCZS4[A[&'8^4O\ AU9_U<A^U;_X<#_[GH_X=6?]7(?M6_\
MAP/_ +GKZMHH^LU.X>QAV/E+_AU9_P!7(?M6_P#AP/\ [GH_X=6?]7(?M6_^
M' _^YZ^K:*/K-3N'L8=CY2_X=6?]7(?M6_\ AP/_ +GH_P"'5G_5R'[5O_AP
M/_N>OJVBCZS4[A[&'8^4O^'5G_5R'[5O_AP/_N>C_AU9_P!7(?M6_P#AP/\
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M^' _^YZ/^'5G_5R'[5O_ (<#_P"YZ^K:*/K-3N'L8=CY2_X=6?\ 5R'[5O\
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M .YZ^K:*/K-3N'L8=CY2_P"'5G_5R'[5O_AP/_N>C_AU9_U<A^U;_P"' _\
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M^' _^YZ/^'5G_5R'[5O_ (<#_P"YZ^K:*/K-3N'L8=CY2_X=6?\ 5R'[5O\
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M .YZ^K:*/K-3N'L8=CY2_P"'5G_5R'[5O_AP/_N>C_AU9_U<A^U;_P"' _\
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M^' _^YZ/^'5G_5R'[5O_ (<#_P"YZ^K:*/K-3N'L8=CY2_X=6?\ 5R'[5O\
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M .YZ^K:*/K-3N'L8=CY2_P"'5G_5R'[5O_AP/_N>C_AU9_U<A^U;_P"' _\
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M("JJ@DDD  $UP=%?42CS1<>Y\A"7+)2[']67_#Q']G__ *+I\'?_  M--_\
MCU'_  \1_9__ .BZ?!W_ ,+33?\ X]7\IM%?)_ZHT?\ GX_N1]C_ *Y5O^?:
M^]G]>G@#XL^%?BOIRWGA;Q-X?\2V;(L@GTK48;R,JP!4[HV88(((/<$5^4__
M  <]_M!^"?&WPA\)^!]*\2Z7>^,/#?BDS:IHZ2_Z98(;.3#R1GE5;>A!Z,'4
MC((-?F__ ,$P/BSXR^#W[>7PQOO!-UJD6I:CK]GIEY;62F3^T[&:XC6YMY$
M.^-HP2<@[2JN,,BL/U)_X.>OV/\ 2_%WP$\/_&BQACM_$?A&\BT74Y 0OVW3
MKAF\O=QEGBN"NT#'RW$N<X7''1RV& S*E&<KJ6WKMJ=M;-:F8975E"-G'?KI
MO='X=4445]T?GYM?#KX<Z]\7/&^F^&O"^D:AKVOZQ,+>RL+*$S3W#G)PJCT
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MOR3,O][J_P"*7YL_9LK_ -RH_P"&/Y(****XCN"BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "O9*\;KV2@F05_#77]RE?PUU^A<!_\O_\
MMW_VX^=SW['S_0****_0CY\**** /TZ_X(A_\%'/C)\+? UU\(/@E^S+X'^*
M>O7SR7.K:NFGM!>7=MN>2)=2NLB,QQL\BQM,ZJ-ZHHW'YOLSXY?M'?M=_ [P
M3J?B[Q9_P3Q^#<FF6(:YOKC3_L&M7"+GYY7BM)9IBHSN9]N% 9F( )'Q[\'/
MBQXP_9(_X-O)O%GP4U+5M-USQQ\3I]+^(.OZ6?\ 3?#\"V^VWMUEC >VC<+:
MD2$Y#794,#.JUXQ_P2=_X*$_M(:'^WW\,M+\,>/OB%XO;Q)K]IIVH:#?ZE=Z
MM9ZA9O(!<-);N[#]U"99/-X,01GW* QKXW$8%5ZE7$TX0M%N]W*[:WU327EH
M]-3V*=?DC"G*3U2VM97VZ:_>?,O[5_QWM_VG/VA_%/CZU\*:#X(C\472W9T7
M18A%8V3^6BOY:@# =U9SQG<YR2>3YY7TM_P6-\#>%OAM_P %0OC=HO@P6::!
M9^)YS'%:S"6&WG<*]S"I!(7R[AID*?P%2F!MP/FFOJL)*,J$)05DTK+LK'EU
M4U-I[W84445T&9^K'_!H!_RDK\<?]DSO_P#TZZ37]'E?SA_\&@'_ "DK\<?]
MDSO_ /TZZ37]'E?DG&'_ ",7Z(^LR?\ W?YL****^6/4"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KPWX#?L[^(/AO^
MVE\?/'^H/I[:%\2O^$>_LA89BUPOV&Q>";S5*@+\[#;@G(YXZ5[E7E/PC_:=
M_P"%I_M0?%[X;_V']A_X55_8W_$Q^V>;_:G]H6CW/^JV+Y7E[=OWWW9S\O2M
M(<UI<O;7TNOUL1*UU?OI]S_0]6HHHK,L**** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^%'_  ZF_9M_Z(G\._\ P41_X5_/S_P]U_:8_P"BT>./_ P?X4?\/=?VF/\
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M37,2ZB3L?K%17Y;_  /_ ."_WCCX5?&[1OA[^U1\(9OA?>ZY(J1:Y;136-G
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M7%UVE !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !7&_%O_F'_ /;3_P!DKLJXWXM_\P__ +:?^R4#CN<;11106%%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 5[)7C=>R4$R"OX:Z_N4K^&NOT+@/_E__
M -N_^W'SN>_8^?Z!1117Z$?/A7H'[-/[*_Q _;#^)'_"(?#7PS>>+/$@M)+X
MV-M)'&X@C*AWS(RK@%E[]Z\_KIOA-\:_&7P$\5'7? OB[Q-X+UQH&MCJ.@ZI
M/IMT8F(+1^;"ROM)525S@X'I6=7GY'[.W-TOM\RH\M_>V/TY_P""<_[,W_!0
MS_@FS?:]9^&/@/)XI\%>+0JZ[X3\1R6=UI=_CY3*JBY4QS>7E-P)5@5WI($0
M+],:Q\3_ -LOX;^ ]9L?@/\ \$__ (;_  '\2:\@@NO$&A0:4URD020*42/R
M4,J,^4:42(N7'EG=D?.EM^VG\>_ '_!OE'\1_"OQ>^)'BKQ3XN^(<FC^,=>N
MO$5UJFI>#;)(V6VMXI6E9[!976)C)\K,;J-=PWQY\0_X(_?\% _VJ]?_ ."@
MGPZT7POX^^)7Q"CUG5K>VUK0]6UBYU:RGTSS4-W)(EP[)%Y<6]A,-K)V;#%6
M^.JX6M757$SC3O%M._,D^7O[UO2Z>GD>Q"I"FXTXN6OII?MI^1\:?M"_#'QM
M\'/C7XD\._$:SU*P\=6%XS:U#J$XN+K[1(!*S2R!FWNV\,6W$DMDG-<;7TI_
MP6)TC0]!_P""H?QQM?#NL76N:5'XKNBMS<7?VITE)#30"3J5AF,D*@Y*K$JD
ML02?FNOKL+4=2C"H^J3^]'DU8\LW'LPHHHK<S/U8_P"#0#_E)7XX_P"R9W__
M *==)K^CROYP_P#@T _Y25^./^R9W_\ Z==)K^CROR3C#_D8OT1]9D_^[_-A
M1117RQZ@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P!.][7UQ7R/_P $)_\ E%7\+/\ N+?^G>]KZXK\DS+_ 'NK_BE^;/V;*_\
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MO^"\OP)^#=JL-YH'PE\OQ'K=O=1AK?SRJW\H<#)=6MX;)%#\;IB" I8MY_\
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MB/WC#(K@J6 .1(OS;"Q^D:_)G_@UHT^'2=/_ &@K6W3R[>UUW3HHER3M51>
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MYK=KX:T2\U*^F2VL=/@>YN)G^[%&BEF8^P )_"K5?)'_  79\67O@S_@D_\
M&"\T^3RIYK.QL&;UBN=2M+>4?C'*X_&N6,>:21M)V5SYP;_@MO\ '3]L[XFZ
MWHO[)/P0T_QAHOAN;9=:YXEE,<%PAWA&VF>V2 R;=R*\K.54Y0'(7D?VH_\
M@X7^+G[-/P[F\+>)_A'HO@/X\:/K-O'>:9K,=Q?Z-J>E20W):[M7AFCPRS)
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M2_M0:M\&_P!F/X5?\+=\4^&Y/*UC5KFX:+3;.5)?*FC"C8-B2,B&XDF1 VX
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M6&W&2XBQM$N"<@GJ/MK_ ((!W,EU_P $C_A&TLCR,%U9 68L0JZQ?*H^@
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ME1QS2#8S-<WEQ-&,>NR-B?[N5SU%)_P:]+-\(_VA?VB/AOJUM-;ZY9BQ$Z3
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MR:7UYW<]A]^5A4CRR:-(.\4PHHHJ"@HHHH **** "BBB@ KM*XNNTH ****
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MP\LB6WB33-5>T30+^4QN420W4T*^<JG=F&19 "@8['VM^FGQ.T3_ (*D>,_
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M3T9'4E6'N#4FL:Q:>'M)NM0U"ZM[&QL87N+FYN)!%#;QH"SN[L0%55!))(
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M]O-L****\,]X**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >._\
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M&W]D^9]A_M[1;;4OL7F;/,\KSD;9O\M-VW&=BYS@5QO_  [H_9\_Z(3\&_\
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ML4?]G_8O+\K[+Y&WR_)\OY/+V[=ORXQQ1[31+SN3RZW/AO\ X-JO^48FF_\
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MC);(3DJC3(Q52><# S6W,H5.;I_F9<KE"W4^.O\ B)5_9A_Z"7C3_P $#_\
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M &%_#F@_"KQEHOCJW.[4M=U6R)CEN]0GXD>6!PLL.!&L2)*BOY<"9!.27?\
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MYO#O@^SN--\-ZOHUMK%G:2W+7'V8.\L+JKNS.5WP.1O);D\XQ7V5_P $R?\
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M_297\V?_  3E_P"3]O@__P!C=IW_ *4)7])E3G'QQ]"LN^!^I_-G_P %&O\
MD_;XP?\ 8W:C_P"E#U^^W[!__)COP9_[$71/_3?!7X$_\%&O^3]OC!_V-VH_
M^E#U^^W[!_\ R8[\&?\ L1=$_P#3?!5YE_ I_P!=#/ _Q9_UU/YV/&?B'_A$
M?VC]6U;R?M']E^)9KORM^SS?+NB^W.#C.,9P<>E?5?A/]A[]I+_@L%JUU\4]
M5O\ 3;72[QYHM,O/$5Y+;VHB64GR+2***1O*5G8!@@0E'RQ8&OD'XR_\E?\
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MI<K4'='G_P"SQ^RSX!_90\,ZAH_P^\.6_AO3M4O/M]U%%/--YLWEI'NW2NS
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M"RQ>3)G[-,-@7S(U5U* '<NY#_27^S?\>M#_ &H?@5X7^('AN1Y-&\56"7L
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %? ?_!R?_RC.O?^QDTW^<E?
M?E? ?_!R?_RC.O?^QDTW^<E>AE/^^TO\2/-SG_<:O^%GYL?\&X/_ "D\T/\
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MA NX ,Z9S7[\?L?_ +*7A?\ 8I_9\T#X=>$8YO[+T2-C)<SX-QJ$\C%Y9Y6
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MP].T[:/E1\LT445]4?(!14UA;I>7T,,EQ#:QRR*C32AC'""<%F"AFP.IV@G
MX!/%??FF?\&U_P"T1K>FV]Y9WWPTO+.\B6:">'7WDCFC8!E=6$.&4@@@C@@U
MSXC&4:%O;24;[7.K#X*OB+^QBY6WL?)G[)_[8OQ"_8G^)T?BSX=Z]-H^H,%B
MNX&42VNI0APQAGB/#H2/9ADE64\U^EWPM_X.M=0M;*QM_&GP=M;R9856[O\
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MVBWMM=TF#488)=I7>B3(P5MI(R!G!(KJJ* ([6UCL;6.&&..&&%0D<:*%5%
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M$71/_3?!7\V?@W_D;]*_Z_(?_0Q7]3UI:16%K'!!''##"@CCCC4*L:@8  '
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MZ+X+D:*/2;._U&]%U#$D*(?-VVK@NS*S$[CDMDG)K]1/V:?AO??!O]G+X?\
M@_5);2XU+PKX;T[1[N6U9F@DFM[6.%VC+*K%"R$@E02,9 Z5AF.(IU*<539K
M@Z,X3DYH_FE^,O\ R5_Q7_V&+O\ ]'O7] G_  36_;7\*?M9_LT>$Y+36]+_
M .$NTO3H-/UO21,L=U;74<6UF$1.[RY-C.C#*XR,DHX'\_?QE_Y*_P"*_P#L
M,7?_ */>ON;]I+_@@+\0+"/3_$'PB>U\7:'K5I#>#2KJ[BLK_37D"DQ!YF6.
M6,;LARZM@$%20&?NQU.E4C&-27*^C.3"SG"3E!7[FY_P<)_MB^%OC+XK\'?#
M[PGK%KKB>%6GU#5KFRG$UJMQ*J+%$&4;6=$#DE6('F[3\P8#U#_@VH^$%UI/
MP^^)7CJZLY([;6KRTTBPN&? E%NLDD^U>XS-$-QR,J0#D,*\'_9H_P"#>SXN
M?$3Q3;O\1I=,^'OA^&4&Z5;R'4=2G3DXA2%GB!. "SR#;O#!7P5K]D/@W\(=
M ^ ?POT7P=X7L1I^@^'[86MG!O+E5R22S'EF9BS$GDEB:X<56I4Z'U>D[]W^
M)UX>G.=7VTU8Z:BBBO'/1/P=_P""^O\ RD8UO_L#Z=_Z)KZ._P""/'_!2WX)
M_LL?L<0^%?'GC3^P=>76;N[-K_8]_=8B?9L;?# Z<X/&[(KIO^"G/_!&OXG_
M +:7[5^H^.O"VO> ]/TB\L+6U2'5;V[BN0T4>UB5CMI%P3T^;\J^??\ B&\^
M./\ T-7PI_\ !GJ'_P A5] JF'J8>-.I*VQY+A6A6<X1[GWYJG_!<?\ 9CT^
MQDFA^(=Q?2+C$$'A[4UD?) X+VZKQUY8<#UXK\E_^"K/[<FG_MX_M,IXBT/3
M[K3_  [H.FIHVF_:<">[1)99&G=1]PLTI 7)PJKG!)%>V?\ $-Y\<?\ H:OA
M3_X,]0_^0J]8_9^_X-LGL/$5O??$SQ]9WFGVTR.^EZ#;2#[8H8$JUQ)M9 5&
M#MCS\V0PQS-'ZG0?/&5W_7D%3ZS57*XV1Z9_P;D_"?5/!_[)_B;Q1?6[6]GX
MPUPG32S _:(;9/*:4 =!YQE3DYS$> ,$_H96;X-\&Z5\//"FGZ'H>GVFDZ/I
M,"VUG9VT8CAMXU&%55'0"M*O'Q%7VE1S[GI4:?)!1"OYCOB1H-S\"_VK-<TV
M_3R;KPEXJFAF$GS@&WNR"3MQN'RYRO4<CK7].-?A+_P7J_9RO/@W^W%?>*([
M7RM!^(]M'JEG*@/EFYB1(;J/)_C#A)2!D 7"<\X'H9142J.#ZK\CCS"+<%)=
M#]VJ_*7_ (.<_P#FB/\ W'?_ '&U]W_\$Y/BU_PO#]ACX7^(F6-9I]"ALY_+
M;<IFM<VLA' QEX6.W^'.,G&3XE_P6(_X)N^./^"@_P#PKK_A#-5\*:9_PB/]
MI?;/[:N;B'S/M/V39Y?E0RYQY#YW;<97&><<^#:I8E<[M:_Y,VQ"=2B^7K8\
M/_X-EO\ D4/C!_U^:5_Z!=U]6_\ !9'_ )1I_%/_ *\[3_TNMJXW_@C[_P $
M[?&W_!/W0O'EKXRU3PMJ<GBBXLI;4Z+<SS+&(5G#;_-ABP3YBXQGH>G?VS]O
MO]GW6OVJ/V0_&G@#P]=:79ZQXB@@BMIM1D>.U0I<Q2G>R([#Y8R!A3R1]:JO
M5@\7SIZ76OW!2A)8?E>]F?BS_P $1/\ E*!\,?\ N*_^FF]K]<_VX?\ @EI\
M/_V^_&.BZYXQUCQEIMUH-FUC;IHUW;0QNC.7)<2P2DMD]B!CM7R?_P $ZO\
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MZ$#]WO/..F,@D5]/Z/H]IX>TFUT_3[6WL;&QA2WMK:WB$4-O&@"HB(H 554
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MO&%O'9WDUJEXUYK<EO=)&S*L\92^9_+DP&7<JOAAN53D#],/VI_AYX=^$O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M7![9K[N_X(O_ +-GC7]DW]@CP]X*^(&B_P!@>)K'4+^>>S^UP76Q);AW0^9
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M!.W&-P!XS_@DC_P;\^+-#^*6A?$SXYV-GH^FZ'(FH:7X4>2.YNKRX4AHWO
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MM?A1X!\4:3\1M,E_MG1C?SZTRQ36ZF8L3]JE@&P(3^]PC'"@L6537_X.LO\
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ME\1O%MCKFHZ)I=Q;VTL&D0Q373--(L:E5EDC7 9AG+CCUZ5\6_\ $4I^S_\
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M^'IY)&K%PDV[Z7YM^G0\_%5,_E2DIQ25G>W+MUZGY@T445]F?#']%'_!"?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M12)':20EF<.WWVQNP#@"O/J**]>G'EBHKIWU?S9R2E=W"BBBJ$?JQ_P: ?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M<CT<#4SAUXK$+W.OP_IJ>7F%/)%AY/#/W^GQ?KH? =%%%?5'R)ZI^Q-^TO\
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M&8T_U:+C;CIFO5JFI)2E=#IQ<59A1116984444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M!NH6L(/^U)+$J(/=F H^N8=:\Z^]![&I_*_N/MO_ (- /^4E?CC_ +)G?_\
MIUTFOZ/*_-/_ (-U_P#@CGKW_!.3X;Z_XZ^(RP0_$KX@6L%LVF1N)/\ A';%
M&9_(:16*O+*Y1I,9"^5&H.=V?TLK\CXFQE+$X^4Z+NE97[V['UN6T94Z"C/?
M<****^?.\**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "O"/@#^S_XB^'?[;G[07CO4H[5?#_Q&_X1S^QGCG#RO]BL)()]
MZ=4P[#&>HYKW>O+OA3^TU!\4OVEOBQ\.(]'FLYOA7_8_FWS7 ==1_M"U:X&U
M-H*; NTY+;LYXZ5I!RM*W;7TNOUL1*UU?OI]S/4:***S+"BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?^"]WP<A^)7[ .J:T(8&OO ^IVFK0R, )!&\@MI45O0K.&*YP?*7J0M>#?\
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M?G_DLO\ (_8JBOQU_P"(LK_J@/\ Y?'_ -[Z/^(LK_J@/_E\?_>^C_5W,/\
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M_P# H_YA[:/G]S_R/JVBOE+_ (:X_:@_Z-#_ /,J:3_\;H_X:X_:@_Z-#_\
M,J:3_P#&Z/J\^Z_\"C_F'MH^?W/_ "/JVBOE+_AKC]J#_HT/_P RII/_ ,;H
M_P"&N/VH/^C0_P#S*FD__&Z/J\^Z_P# H_YA[:/G]S_R/JVBOE+_ (:X_:@_
MZ-#_ /,J:3_\;H_X:X_:@_Z-#_\ ,J:3_P#&Z/J\^Z_\"C_F'MH^?W/_ "/J
MVBOE+_AKC]J#_HT/_P RII/_ ,;H_P"&N/VH/^C0_P#S*FD__&Z/J\^Z_P#
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MMH^?W/\ R/JVBOE+_AKC]J#_ *-#_P#,J:3_ /&Z/^&N/VH/^C0__,J:3_\
M&Z/J\^Z_\"C_ )A[:/G]S_R/JVBOE+_AKC]J#_HT/_S*FD__ !NC_AKC]J#_
M *-#_P#,J:3_ /&Z/J\^Z_\  H_YA[:/G]S_ ,CZMHKY2_X:X_:@_P"C0_\
MS*FD_P#QNC_AKC]J#_HT/_S*FD__ !NCZO/NO_ H_P"8>VCY_<_\CZMHKY2_
MX:X_:@_Z-#_\RII/_P ;H_X:X_:@_P"C0_\ S*FD_P#QNCZO/NO_  */^8>V
MCY_<_P#(^K:*^4O^&N/VH/\ HT/_ ,RII/\ \;H_X:X_:@_Z-#_\RII/_P ;
MH^KS[K_P*/\ F'MH^?W/_(^K:*^4O^&N/VH/^C0__,J:3_\ &Z/^&N/VH/\
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MO_ H_P"8>VCY_<_\CZMHKY2_X:X_:@_Z-#_\RII/_P ;H_X:X_:@_P"C0_\
MS*FD_P#QNCZO/NO_  */^8>VCY_<_P#(^K:*^4O^&N/VH/\ HT/_ ,RII/\
M\;H_X:X_:@_Z-#_\RII/_P ;H^KS[K_P*/\ F'MH^?W/_(^K:*^4O^&N/VH/
M^C0__,J:3_\ &Z/^&N/VH/\ HT/_ ,RII/\ \;H^KS[K_P "C_F'MH^?W/\
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M^4O^&N/VH/\ HT/_ ,RII/\ \;H_X:X_:@_Z-#_\RII/_P ;H^KS[K_P*/\
MF'MH^?W/_(^K:*^4O^&N/VH/^C0__,J:3_\ &Z/^&N/VH/\ HT/_ ,RII/\
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M-#_\RII/_P ;H^KS[K_P*/\ F'MH^?W/_(^K:*^4O^&N/VH/^C0__,J:3_\
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MJVBOE+_AKC]J#_HT/_S*FD__ !NC_AKC]J#_ *-#_P#,J:3_ /&Z/J\^Z_\
M H_YA[:/G]S_ ,CZMHKY2_X:X_:@_P"C0_\ S*FD_P#QNC_AKC]J#_HT/_S*
MFD__ !NCZO/NO_ H_P"8>VCY_<_\CZMHKY2_X:X_:@_Z-#_\RII/_P ;H_X:
MX_:@_P"C0_\ S*FD_P#QNCZO/NO_  */^8>VCY_<_P#(^K:*^4O^&N/VH/\
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MMH^?W/\ R/JVBOE+_AKC]J#_ *-#_P#,J:3_ /&Z/^&N/VH/^C0__,J:3_\
M&Z/J\^Z_\"C_ )A[:/G]S_R/JVBOE+_AKC]J#_HT/_S*FD__ !NC_AKC]J#_
M *-#_P#,J:3_ /&Z/J\^Z_\  H_YA[:/G]S_ ,CZMHKY2_X:X_:@_P"C0_\
MS*FD_P#QNC_AKC]J#_HT/_S*FD__ !NCZO/NO_ H_P"8>VCY_<_\CZMHKY2_
MX:X_:@_Z-#_\RII/_P ;H_X:X_:@_P"C0_\ S*FD_P#QNCZO/NO_  */^8>V
MCY_<_P#(^K:*^4O^&N/VH/\ HT/_ ,RII/\ \;H_X:X_:@_Z-#_\RII/_P ;
MH^KS[K_P*/\ F'MH^?W/_(^K:*^4O^&N/VH/^C0__,J:3_\ &Z/^&N/VH/\
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M$,_.UC'#OD1L%\Q! <-Q_/W86$^J7T-K:PS7%S<2+%%%$A>25V.%55')))
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M1A1110 4444 %%%% !1110 4444 %%%% !117R?_ ,//_P#C:Q_PS'_P@_\
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MOYT_^"BO[&]Y^P_^T]K7A%O.FT*X)U'0+J0[FN+"1F\L,V &D3!C<@ %D)
M(K^CROG?_@HU_P $\=#_ ."A?PPTO1[[5?\ A&]<T&[-SIFLK9_;&M4?:)XC
M%YD>Y9 B9^88:-#V(.61YI]4K6J/W);^79FW$.4O&T+TU[\=O/NOZZGY4_\
M! K_ )2*:/\ ]@74/_15?J[^W5_P3?\  _\ P4%_X1;_ (3/5?%>F?\ "(_:
M_L?]BW-O#YGVGR-_F>;#+G'D)C;MQELYXQXE^P)_P1._X8<_:*L_'W_"S/\
MA*/LEE<6?V#_ (1W[%O\U-N[S/M4F,=<;>?45]W5IG&91GC%B,)+96OJN_?U
M,LCRJ=/ RPV,AO*]KIZ:6V?='Y^_\0W_ ,#_ /H:OBM_X,[#_P"0J/\ B&_^
M!_\ T-7Q6_\ !G8?_(5?H%17'_;6._Y^,[_[!R__ )](^7OV)_\ @DO\.?V#
MOBIJ'B_PAK7C;4M2U+2I-'EBUB\M9H%A>:&8L!%;QMOW0( 2Q&"W'0C\U/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M4G]FN24P:1<ZNUD+#QAX3OHDF6VD=-LBM#)N$MI+\VQSE64E6PZNB^<^,?\
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MB3="]G]G?R1(<$+_ *9]E(.0<C&<$@]$:%Z?/<QE5M/EL?T54445SFP4444
M%%%% !1110!\S_\ !9'_ )1@?&C_ +%]_P#T9'7C7_!M5_RC$TW_ +&/4O\
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M21J#)$D,).]6 5B&Z8^C]-_X.C_V<]&TZWL[/P/\7K6TM8UA@@AT;3(XX44
M*JJ+["J   !P *(T;13Y;W'*I[UKV/L7]A'_ (* _#W_ (*%_"AO%'@6\NEF
ML2L6K:3>QB.]TB5MVU)0"5(8(S*R,0P]""H\._:K_P""W?A/]C?]MV^^%/C;
MPR]GX>TW0/[;F\2Q:GOFD<V[RQVL5EY/SR2.JQJ3,!E]QVJ"1\#_ /!+G]J'
MPAXO_P""^<M_\'=+UKPO\-_BM;WT<NB7L,5G]G9--DNY/W,$DD6T75N[( ?E
M67  Q@^F_M>?LW^'_P!JK_@Y8\)^$_%EJNH>&_[%M=3O[-B-MZMK8SW"0L"I
M#1O+'&KJ<;HRXR"0:/8Q4[2VM<7M&XW6]['I>I?\'&VO:)H5KXROOV6?BE9_
M">Z8%/%TTTB0/&[LD3)NM1;L7;:,?:0,D@%L#/WO^R?^UGX'_;5^#&G^//A_
MJDFIZ'?,T#B:!H+BRN% ,EO*C?=D3< <$J<@JS*0Q[S4/#>G:MX=GT>ZT^RN
MM)NK9K.:RE@5[>6!EV-$T9&TH5)4J1@@XQBOR2_X(*"3]FO_ (*=?M,? C3Y
MIIO#>FO=WUDID9DB6PU$6L9^8DAVBO$#'G/EC).U36=HRBW%6:-+RBTF]S[
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ML2/S.&Q*OR=":_\ P<I?\E__ &1O^Q@U/_TIT:O9?^#E7_E&)J7_ &,>F_\
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MD7TEIN\GR$\G=Y>_&]\9QDXS1_P0W_Y13_!W_L'77_I?<U\F_P#!%K_E,?\
MMF_]C!JW_I[N*F23<G;;_,<6THH^M/\ @H]_P5Y^'?\ P3G_ +-T?4[74/&'
MCO6E$ECX;TIT$ZQDX$MP[9\F-CE5PK.[#A2 S+XO\,/^#@6/2?&.A6'QV^!/
MQ%^ VC^*)##I6O:M'/<:=,P"G<[2VUNP0!AEHUDV[D+ *2R^-?\ !(ZRT_\
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M6N^I^PE%%%<IN%%%% !1110 4444 %%%% !1110 4444 %%%% !7:5Q==I0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *\(^ /[/_B+X=_MN?M!>.]2CM5\/_$;_A'/
M[&>.</*_V*PD@GWIU3#L,9ZCFO=Z\S^%_P"TO8_%#]HSXI?#FWTR[M;WX6_V
M3]JO))%:*^_M"U:X38HY78%VG/4GBM(.5I6[:^EU^MB96NK]_P!&>F4445F4
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MVMAK\,(,?V62&5UQ)(OW%N()S$CL&57BPV0R(WVYX)_X+ _LV>-?A';^,O\
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M=6TZ%)K-57$,#J22KQP^6C ]"A&!T'N5%%82=W<V6BL?B/\ &+XR>%_V?_\
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M@?\ IYU&NX_X./\ ]F?Q9=:3\,_C_P"";*35+[X0WQ?5;80M,(+<2QW$-VR
MC]U%+$RR8YQ,K<*C,/N/XJ?L'?"CXV?M%>%_BQXG\*_VG\0/!<=O%HVJ_P!I
MWD/V-8)I)XAY,<JPOMDED;YT;.[!R  /6KJUCOK62&:..:&92DD;J&5U(P00
M>"".,&M/;6<6N@O9WO?J?*_PF_X+5_LV_$[X)V_C2Y^)WAOPQ_HZ2WFC:O=K
M#JUE(3M:+[,,R3%6R,PJZD?,#@YK\]?V+OVO[7]N;_@XRL/B%I-C=6/AN\TR
M_L=$6X3;+/9V^G30K,W YD=)'V\[-VS)*DG]#->_X(B_LK>(_&[>(+CX.:!'
M?O(93%:WEY:V.22<"TBF6W"\_=$>.G' KTCP[_P3_P#@]X._:!TGXHZ/X'T_
M1_&F@Z:-'TZZL+B>VMK*T$30B&.T206RJ(V91B+C/K@T*=.*=KZDN,W:Y[%1
M117.;!1110 4444 %%%% !1110 4444 %%%% !1110 5VE<77:4 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<;\
M6_\ F'_]M/\ V2NRKC?BW_S#_P#MI_[)0..YQM%%%!84444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !7LE>-U[)03(*_CKK^Q2OXZZ^TX0_Y>_P#;O_MQ\'QI_P N
M?^WO_;0HHHK[0^%"BBB@ HHHH **^QO^"=G[%GPQ\6_ ?QQ\?/CQJVKVOPI\
M!WJZ/!I.CC_B8>)-3>-7%NC9!7"RPX *[C)EI(TC<GU#P]XR_P""=?[1FO6?
M@M?A[\3O@S/K,RVMKXODUMKBWL9"?E>Y$UU/''&Q 5F\HJHD)+1J#(OGU,PC
M&;C&$I<N[2T7XZ_),]*GELI0C.4XQYMDW9OIV:7S:/SIHKTS]L;]F35OV-?V
MFO&'PSUJZAO[[PK>B!;N-/+6\@>-)H)MF3LWPR1N5R=I;&3C)\SKNIU(SBIQ
MV>J."I3E"3A-6:=GZH_2C_@UK_Y2 ^,/^R>WO_IRTROWLK\$_P#@UK_Y2 ^,
M/^R>WO\ Z<M,K][*_.>)O]^?HC]-X4_W!>K"BBBOGSZ0**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O"/@#^S_XB^'?[
M;G[07CO4H[5?#_Q&_P"$<_L9XYP\K_8K"2"?>G5,.PQGJ.:]WKS/X7_M+V/Q
M0_:,^*7PYM],N[6]^%O]D_:KR216BOO[0M6N$V*.5V!=ISU)XK2#E:5NVOI=
M?K8F5KJ_?]&>F4445F4%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >._\
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M=E\=:A_:NLPP7MR]I/=?-F6.W>1H8"=Y!\E$# (""$7'HU%%V 4444 %%%%
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MU!QE3R,'FOIBBBG*3>XDDM@HHHJ1A1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !7:5Q==I0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 5QOQ;_ .8?_P!M/_9*[*N-^+?_ ##_ /MI_P"R4#CN
M<;11106%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQ2^%GB+X)?$+5O"?BW1[[P_XBT.<V]]87D?ERP/@$>Q5E(96&5965E)!!/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M&_=_U^A$/K%2/M$[=C2_8"_X*3>!O^"@'A:\DT)9]#\3:0H?4M!O95:XA0X
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M._B0DC;EMTTN.,8^ZO\ 9=HV/S8GGUKJHU(U<:Y1Z+_)&-2,H891?5GZ ?\
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MT3+\4OV1M6\%7UQ-<:A\.=3\F'?@A+&Z#2PKN^\<2I=#!Z*$ .!A?OROP_\
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MEPJLK$/N(W*_XE_L)^)/B?\ L]?M(^%?B/X'\'^+-<N/"NH>9<PZ?I=Q,MU
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M$5J5^./_  ;#_MS7UQJ'B#X!Z]=S7%E#;R:_X5+G<MIA_P#3+4$GA6,BS*H
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MZK/:_P!C:?>>9<O>WT32;[B"1QE(8QM!"_+G&22?URK\$_\ @Z4_Y2 ^#_\
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MZ;[';7MREI B(J^7/'(BI)),3N*AB8,*<!P?S&_X?\_M;?\ 16/_ "V-&_\
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MK,!U^62*-74^ZL#7Y*_\%XO^"/'A/]CKPQIOQ6^%L3:3X1U"_BTG5/#[S2W
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MU3P]J@1+VU4X'FIM8K-#O.WS%.1E=ZH64'T3]LGXE^#?@[^S#XR\3_$+P_\
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M:5M4NX4445D;!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% 'CO_  41_P"4?WQT_P"R>Z__
M .FVXK^4VOZLO^"B/_*/[XZ?]D]U_P#]-MQ7\IM?=<(_P:GJOR/S[C+^-3]'
M^85]+?\ !';Q9I_@S_@IS\&;S4KC[-;S>($L$?8SYFN8Y+>%<*"?FEEC7/0;
MLD@ D?--:?@KQCJ7P[\9:3X@T6Z:QUC0KV'4+&Y558V\\+B2-P&!4[64'!!!
MQR#7U&(I^TI2I]TU]Z/DL-6]E5C5_E:?W.Y^\7_!S%\&_%'Q:_9#\#MX7\/Z
MYXCN-,\7(UQ;:7827DL4;V=R/,98P65 RJNXC&749!(!^L?^"<'[-[?LE_L.
M_#;P'-#Y.HZ1I"3:FG/RWUPS7%R,GD@32R*,XX X'0>!_L._\%]/@C^TKX"L
MH?&GB2P^&?C:VM_^)C9:[(+:QG=%3?+;W1_=%&9OE1V27Y6^0JN\\#_P5*_X
M+Q?"_P"'GP#U_P *?";Q-:^-/'7B:Q>Q@O-+)>RT6.9&1KAIBI1Y%&=L:Y.X
M@M@#!_.WA\;4IPRYTVK-N_37K?:RU/TQ8K 4ZD\R51/FBE:ZOITMO=Z:'Y[^
M$=+\4?\ !2C_ (+@77B/PS#=:UI<WQ"BU!]5AMWDMK'1K*Y4032L"57_ $2V
M0+E@'?:H(W"OTU_X.3O&5KX7_P""9M]8W'^N\1^)--TZVZ\R*TER>@/\%N_7
M ]\X!^5?^#9K]JCPK\$?AS\;+'QSXJ\.^%-!L;C2M4M[C5=0CM(VDD6YBE ,
MC@,3Y4  4;B3CG*BOG[_ (+A_P#!5*R_X* _%'2?#O@BXG?X8^$?WUG+/:-;
MS:K?.I62X*M\ZQJA"(K!3RY(^8!?=J8>K6S*%.,;0HVU^2?^6A\_3Q-&AE52
MK*5ZE:^GS:?ZNY\(T445]:?&A1110!^OG_!!W_@C'X;^)O@"U^-/Q@T&/7++
M4F)\+^'=1@/V22)6YOKB)AB97((CC8&,IER'WH4_4CXL_MB_!_\ 9KU.'0_&
M7Q%\"^#[^.W22+3+[5K>VN$A/RHP@+!PAP0#MQ\IQT..'^*6O77[(W_!++5+
M_P #6WEW/P^^'&_1T=3-Y'V:P CD?NVP+O8GKM))ZFOY@_%7BS5/'7B&[U?6
M]2U#6-6OW\VYO;ZX>XN+E_[SR.2S'CJ237PN'P<\WK3K5IM1B[)?UM^I^@8C
M'0R:A3H48)RDKM_UOY=D?U=?"3]K+X3_ +2_VC3_  9\0/!/C*785N+&PU6"
MZFV$$'?"&+[2 W5<$ ^]?E+_ ,%X_P#@C+X=^$/@J^^-GPETF'1=)M)@?$_A
MZTC"6EHCM'''<VD2)B) Y/F)G: RLH4*PK\G_"OBS5/ OB&TU?1-2U#1]6L'
M\VVO;&X>WN+9_P"\DB$,IYZ@@U_3QX \0W'[9_\ P2ML=1\96T#WGQ#^')?5
ME\K;')+/8$22JHV[0S$NH4C;D8/ -%?!SRBM"M2G>,G9K^M_T##XVGG5"I0K
M02G%73_K;S[H_EWHHHK[H_/S^BC_ ((3_P#**OX6?]Q;_P!.][7UQ7R/_P $
M)_\ E%7\+/\ N+?^G>]KZXK\DS+_ 'NK_BE^;/V;*_\ <J/^&/Y(****XCN"
MBBB@ HHHH X_XY?'_P %_LT?#ZX\5>/?$ND^%?#]JPC:\OYO+5Y""1&B\M)(
M0K$(@+':< X-<5^RG_P4'^#?[;AU*/X7^.M-\376D_-=V?D3V5Y$GR_O/(N(
MXY6BRZKY@4IN.W.>*^%O^#I/X#>.OB;\!_ASXH\-Z=>:KX7\$WFHR>(HK2)Y
MI+0310&&Z=54XAC6&X5Y"0%,J9X;(^.?^#;GX ^/O$W_  4!T'QYI>FZY:^!
M_#=CJ*ZSJ:QO%8W8EM9(8[4R<)(WG212>7\Q'DAL#;D=$:,73YVS&51J?+8_
MH4HHHKG-@HHHH **** "BBB@#YG_ ."R/_*,#XT?]B^__HR.OE7_ (-]?VO_
M (2_!C_@G7I^A^,/BC\.O">M)KVH3-8:SXDL["Z5&==K&.616VGL<8-?57_!
M9'_E&!\:/^Q??_T9'7YV_P#!&;_@C-\$_P!M[]B>R\=>.K+Q)-K\VL7MDS66
MJM;Q&.)E"?( >>3S733Y?9/F[F,K\^G8_4;_ (>+_L^?]%V^#?\ X6NF_P#Q
MZOS/_8V\>:'\3?\ @YH\?Z]X;UG2?$.AZC87CVFHZ9=QW=K=*-/ME)CEC)1@
M&!&03R".U?2__$-5^S#_ - WQI_X/W_^)KY&_P"";W[/WA[]E?\ X.)O%GP_
M\*+>)X>\-Z;?062W<WG3*C64$A#/@9^9SVZ8IT^2TN6^Q,N:ZOW.D_X.V?\
MFW__ +F+_P!Q5?LE7XV_\';/_-O_ /W,7_N*KL/^(4'X?_\ 16O&'_@LMO\
M&AQBZ<>9VW&FU-V78SO^#GSXJ>#?B?X1^&7PR\/WVG^(/BC'XF,B:;82I<75
MC#)"T)AD506C>:9[?:A92WED[6P"OZ/W?Q&MOV0/V,[?Q)\0+R::/X?^%8)=
M<N($$DUS+;VR+)L&0&=Y%(49 +,.0.:_(G]J'_@EA\0?^"'AA_:&^$OC?2?%
MVE^'9X;2^M]<T")[BPCN'2(.<EU96FV)YD9BE3S5 )&YJ_0_6;VP_P""U?\
MP2/NAH=Q:Z!=?$O1%4K<J9H=+U2UN%9X7XW&-;JWVA]NXH5<+D@43BN6*6W<
M<6^9WW/FOX??\%6_VU/VRM/D\5? ?]G'PG-X!GN+B*POO$=R5>]6*386262\
MM$?!RK>6'7>KJ&)C;'JO_!/W_@L?XD^.W[4LWP+^,_PSN?AC\4'ADN+**,N+
M>Z$=N)VC:.0ET8QK)*K!F5D7&00"WR3\&?VZ/VNO^"-WPWTWX=?$?X'MXP\!
M^&YS:Z;J<22JJQ.2ZP)J%N)8"IRS(LD?FC+ _=V)]6?L'_\ !7K]FO\ ;O\
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M4G]N;P;\/KGXJ6_[,WAG2/A-!'_:3+J+2W6LV^GABQDFCBNTFBQ$-S.UJ%C
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M:UN/!>F:FZ*  9[NW2ZG?@#EIII&/?+<Y/-9+EC#F:N[FFKE:Y\W_P#!/_\
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MUCW-\JB9B< ;E_>GQ!HL7B30;[3IVD6'4+>2VD:,@,%=2I(R",X/<&OY]_\
M@HS_ ,$PO&G["?C6[OC9SZQ\.KZZ*Z5KL*[DC#<K!< $F*4 X!;"R8)4DAE7
M8_9K_P""VGQU_9I\'6/AVVU+0_%FAZ7:BSL+7Q#8M<&RC!&T++"\4S!0-JB1
MV"K\H  4#VL7A/K-JU%_U_F>;A\1[&].JC[X_P"(;SX'?]#5\5O_  9Z?_\
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M(A3BXS/C/_@H!K5OXA_;D^+UW:R++;R>,-4"2*0RR!;J1=P()!4XR#W!%?T
M?L'_ /)COP9_[$71/_3?!7\YGQP^'/B;X3_%36-"\9+-'XIM9%EU-9IO.F6>
M5%F82/D[I/WGS')^;/)ZU_1G^P?_ ,F._!G_ +$71/\ TWP5EFB2HP2_K0O
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M^*?_ %YVG_I=;5\I?\&RW_(H?&#_ *_-*_\ 0+NOJW_@LC_RC3^*?_7G:?\
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MW_9]0TV[DM+JWWHR-LDC(9=R,RG!Y#$=":] _P"&\/CC_P!%F^*W_A6ZA_\
M':]:MA)NFJ5%\L3SZ>(BI^TJ*[/Z7J_!?_@O;X,F\+_\%'O$5])#)&GB32M.
MU&)F4@2JMNMKN7GD;K9EXQRI^I]2_P""%_[4/Q,^+G[<8TGQ9\1/'7B?2O\
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M[/L?GE_P05TA]2_X*0>&IEW;=/TO4KA\)N&#;/'R>PS(.?7 [U^]5?C_ /\
M!M9\'/[7^+GQ$\>30H8]#TN#1;5G&?WES)YLA7T*K;*">#B7'0FOV J\TE>O
M;LD3@(VI7[A1117FG8%%%% !1110 4444 %%%% !1110 4444 %>!_L]_ CQ
M+X _;F_:'\;ZI9PP^'?B#_PC?]B3K<([7/V/3Y(+C<@.Y-LC #<!GJ,BO?*\
MS^%_[2]C\4/VC/BE\.;?3+NUO?A;_9/VJ\DD5HK[^T+5KA-BCE=@7:<]2>*T
M@Y6E;MK]Z_6Q$K75^_Z,],HHHK,L**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *^6_^"U6M3Z#_P $M_C%/;MMDDTF*W)R1\DMU!$XX(ZJ
M[#T]<CBOJ2OGO_@J[\*K[XT_\$YOB]X?TT*U])X?EOH4+;?--JRW6P<'YF$)
M4#H20"5'(ZL#)+$TW+;F7YG)CXMX6HH[\K_)GX _\$?_  K;^,?^"FGP8L[I
M4:.'Q%%?*&7<-]NCW"'J.0\2D'L<'GI7]05?RC_L$?&73_V>_P!M/X7^--69
M4TCP_P")+.XU"0@GR;8RA9I !U*QLS =RH%?U<5]%Q;&7MX2Z6_77\T?,\&R
MC]7J1Z\WZ:?DPHJ.[NXK"UDGGDCA@A0R222,%6-0,DDG@ #G)K\U_AM_P= ?
M!7Q#XKO]/\3>&?&7ANQAG:.SU.WC34+>YC#L!(ZC9+'E0C!1&Y^9@<;1N^=P
M^"KUTW1BY6WMYGTV*QV'P[BJ\E'FVOY'V5_P41_Y1_?'3_LGNO\ _IMN*_EG
M^&_AO6?&?Q!T31?#JW4FO:W?0Z=I\=L6$LL\SB)$7;\V69PN!R<XK^I3_@H-
M=+>_\$\_C?,@D5)OAWKSJ)(VC8 Z;.>58!E/L0".]?SE_P#!+C_E(U\$?^QR
MTW_TH2OK.&9N&%K3[:_@?'<5TU/%T8/KI][/T_\  O\ P:L^ 1\)HX?$WQ*\
M7MXZE@4O=:9';KI-K,47*B"2(RS(K[\-YL98;?E0Y%?CU\1/!OB#]EC]H76=
M!FN/L?B?X>Z_+:?:(AD1W5I<%1*F1@C?&&4G((P>17]<%?RR_P#!4?\ Y2-?
M&[_L<M2_]*'K3AW,<1B:LX5Y<RM<SXFRS#86E3GAX\KO;\#^FG]GCX@R?%K]
MG_P+XJFD2:7Q-X>L-6>1  KM/;1RD@*2,'?G@D5\9?\ !QA^UC#\ _V$KCP;
M:SO%X@^*T_\ 95OLVDK9PM'+>-@G.TH4B) .//['!'TY_P $[O\ E']\"_\
MLGN@?^FVWK\,_P#@X-_:RE_:/_X* ZUX?M986\/_  NC_P"$<LQ&P;S+E3OO
M)&ZX<3DQ$9QBW7@$M7BY-@55S"WV8-O[GI^-CW,\Q[HY;>_O327WK7\+FK_P
M;D?LUGXV_P#!06U\37<#2:1\,].FUEV)&QKN0?9[9#WSF2248P,V_)[,_P#X
M.,/V2E_9Z_;LD\7:=%(N@_%>U.M)^Z98X;^,B.\C5B3O);RISTP;K;M "D^7
M_L!?\%@/B-_P3C^'>M>&_ WAKX?ZE#K^H_VE=W>MV5Y/=,PB2-8P8;F)?+4*
M2!M)S(^21@"'_@H!_P %<OB!_P %(/!.@:+XZ\,?#_3?^$;OGO;&]T2SO(+I
M-\922(F6ZE0QOA&/R;LQ)A@-P;ZSZOB_[2^L67L[<N_3?;U_ ^.^L8+^R_J]
MW[2_-MUVM?T_$_5O_@VR_:O_ .%X?L1W/@*\7&K_  GO19"0'/GV-TTL]LS<
M\,K"XCP !MA0Y)+8^T?VK/CQ:?LO_LV^./B%>QB>+PCH]QJ*0$,1<S(A\J+Y
M02-\A1,]!NR2 "1_/C_P0L_:UC_90_X*#>&&U347T_POXX5O#.K,2/)!G(^S
M2/NX4+<K#F3(V(TAS@L#^R7_  7EGN;?_@DY\6VM0YE,.F*VU-Q\LZK9B3C'
M386R>PR>,9KYC-LO4,SC#[-1I_>[/\?S/K,GS)SRJ4U\5--?<KK\/R/Y]+"#
MQW^W[^UA##->?VYX^^)VNJC7%R_EQM<3R8R<#$<* \*HPB( HPH%?K7_ ,0J
M_@/_ (4Y%;_\+-\7?\+ 6W8R7_V>W_L9YOF*@6NSS@@R@),Y)VL<#(5?AW_@
MWK^S_P##UGX?^=Y/F?9-6\C?C=O_ +-N<[<_Q;=_3G&[MFOZ/J]'B#,Z^&K0
MHX=\J2OI\U]RL>9PWE.'Q5"=?$+F;;6M^R=_5W/Y'_VA_@_XH_9[^,NO> _&
M(V^(/"-R=,N$6<S1*$Y0QM_SS92&7@<,. <BOZ&_^" W_*)/X3_]QC_T\WU?
MD-_P<*6$5G_P59^($D:[7NK32993DG<PTVV3/M\JJ./2OUY_X(#?\HD_A/\
M]QC_ -/-]5<05G5RRE5>\G%_?%D\.451S6M2CM%27W21_.E\7=:G\1_%CQ1J
M%TV^ZO\ 5KNXF;).YWF=F.22>I/4DU_5S^S#X3C\ _LU_#S0H@@CT7PSIM@@
M3[H$5K&@QP./E]!]!7\KW[3_ ,-[_P"#W[1_CSPKJ=O-;7WA_7[VQE23K\D[
MJ&S@!@P 8,!A@01P17].7_!._P".6G_M%_L1_#'Q5874-TUYX>LX+X)*)3!>
M0Q+%<1L<DY65''S<XP2!FIXI3="E*/P_YI6*X1:CB*T)?%I^#=_T/:*^*?\
M@X5\+6OB#_@E-\0+NX\SSM#O-)OK7:V )&U&WMSN]1LGDX]<'M7VM7P'_P '
M(OQJT_X<_P#!-S4_#,T]I_:7Q"UBQTVUMVD'G-';SI>R2HF<E5^SQJS8(!F0
M'!9:^9RJ,GC*2C_,OSU_ ^KS>45@:KE_*_RT_$_)W_@A9XJO/"G_  50^%+V
M<C(+ZZO+&X3<P6:*6QN%8, 1G!PP!R R*<'%?KQ_P7-_X)F_\-V?L]KXC\*Z
M?'-\4/ <3SZ8(TQ+K5H3NFL2PZMP9(LYQ(&4;1,[#\G_ /@@%\,;SXD?\%2?
MA_-;P7$EGX7AO]:OY(A_Q[Q):2Q(S'! 4SS0(<X^_@$$BOZ1J][B'%2H9A"K
M2^*,5^;T?R/G.&L)'$9;4HU5[LI/\EJO1G\Q?_!*;]OW4O\ @G3^U;9ZW=_:
M/^$1UEETKQ78B'?(UKO_ -:J'!\Z%OF'<C>O\1K)_P""AO[9/B/_ (*5_MBW
MGB*.TF>WNITT/PMI4(8M%:"5EMTVDG,TC/N?& 7D.   !W'_  72LOA?I_\
MP46\80_#!3"L)6/Q+##'&EC%K*EA<BWV'I]P2!@")Q/U! &W_P &_NO?"_0?
M^"AWA\_$6-6U*ZB-MX0DN%1[.+5W91%Y@8'$A&Y86!XE*8^8J1]$W25/^TE!
M\_+MU[_T^Q\RE5=196ZBY.??IV_I=S]A?^"/O_!.2T_X)X?LQPV.H1(_Q"\7
M+#J'BJY60.J3*&\JT0J2IC@61EW G<[2N#M957ZRHHK\UQ%>=:HZM1W;/U3#
MX>%"E&C35D@HHHK$V"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M-XF_X*7>+/%&F^'?$6@^&U\*6D-S<RZBDKF4S.RHJ+&I_N.221CY< Y.-_\
M;E_X)%>*_P!A_P",/PT\$ZAXK\/Z]JOQ.N3:V,MO%-#;VC>?#"IE+ M@M,"=
MJG 7N>*W?^",_P#P4Y\+_P#!-3QAX[U'Q/X=U_Q!#XLL[2V@72VB#0M"\K$M
MYC*,$2#&/2NH_P""E?\ P5S\(?MM?M+_  6\;Z#X7\2:38_#&^%W>V]^T/G7
M@%U;SXCV,P^["1\Q')%>I.IC_KSC%?NK>6]OOW/*IT\O^H*4G^]OY[<WW;'J
MW_$*I\2O^BI>!_\ P#NO\*/^(53XE?\ 14O _P#X!W7^%>^?\14OPF_Z)O\
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MT6'XA>$M1>(76O\ @9-0MPH4X5K=8))()E)<'$>UA("" 2!P'_!0+]I/P?\
M\%65^'_[,?[*7@7S/#FG>(DUN\U2RT/^R-+L=D,T(=(=J>7"J3S.[2I&2R(J
MAB<'HC'W^9KY]#%OW;)_YGZW_L7?\F=?";_L3='_ /2&&O3*R? /@NS^&_@3
M1?#NG>9_9^@V$&G6N_;N\J&-8TSM &=JCH /0#I6M7"]SJ6P5X3^V%_P38^#
M?[=&FR+\0/!MA=:P81!#KUDHM=7ME7.T+<*-S*I)(23>F6/R\U[M134FG= T
MGHSXI_X)A_\ !*#5O^":'Q?\<-I7Q"OO$_PY\36D1L=*NR\4]E=JR;IGC7]R
M[,H*^8H5MJJ,$=/M:BBG*3D[LF,4E9'Y+_M:_P#*SU\%?^P';?\ HC4:_6BN
M2U?X!>!-?^)]CXWO_!7A*^\:::@BL]?N-'MY-4M4 8!8[ED,J !W& P&';U-
M=;53GS6\D$8VN?B[\%/C'<?\&_W_  45^)7A'QUHVM/\#OB=>+J&C:Q9VQ:&
MR0&62!XXU 1FC65K>9$"-^Z1U4J$5M[_ (*K_P#!7OP_^WY\,$_9^_9PTW7?
MB%K'CZ[@M[_4(],EMX_(22*18H8YT63+2!0\KK&L:QL<D-N7];O''@#0?B=X
M;N-&\2:)I/B'1[M2L]CJ=G'=VTP(((:.0%6&"1R.A-<_\*?V:OAS\"+FXF\#
M^ /!/@V:\79.^A:':Z<TZY!PQA12PRJ\'T'I6GM8WYFM3/V<K<J>AP?[+O[%
M6D_ S]@'P_\  W4FAOK"'PS+HNM/" \5U-=)(;YXPZ8*/+/,5#H?E8;@><_F
MA_P3:_;@/_!$_P"*'CK]G?\ :"M=:TGPS'K4VHZ#XECLIKBV((2,R)$JL[6T
M\:)*IBW&-RZLFYF*_M#7-_$WX.^$?C5H/]E^,O"OAOQ;I88.+/6M,AO[?(((
M.R567.5!Z=0/2HC4W4MF5*&S70_'S_@I/^W+)_P6T^(O@K]GK]GO2]4UCP^V
MM1ZCK'B.\L9(+9"OF1K,59?,BMHHV>5G<*[DJ@3< '_8OX8?#S3?A%\-?#OA
M/1DDCT?POIEMI-BCD%E@MXEBC!( &0J#H /852^%GP-\$_ S3)['P3X/\+>#
M[.Z8/-;Z'I,&GQ2L,X++"B@D;FY/J?6NII3FFE&.PXQ:=WN%?C;_ ,%BO^5@
MW]EC_N4O_4DNZ_9*N-\8_LZ?#WXB?$+2O%WB#P)X-UWQ7H7D_P!FZUJ&BVUU
MJ&G^3(98O)G=#)'LD9G7:PVLQ88)S13J<KN.<>96,?\ ;$_9WMOVL_V7?'7P
MXNKE+$>+M(FL8;IX_,6TG(W03%>-P254<@$$A<9'6OR&_P""</\ P5#UK_@C
M2^L? #]H3P+XHL-/T_5)+W3;RS@1Y[!)6VR$*S*MQ:-(C2)+$Q.6EQYF55?W
M#KG_ (B_";PK\8-%_LWQ=X9\/^*-.Y_T75].AOH>>OR2JR\X':G"HDN62NB9
M1;=UN?G;\<_^#GGX-Z'X#U!/AQH?C#Q=XRGA\O2;>[TT6M@;AB0OG-YGF%5Z
ME8U)?A05R65W_!O5^PQXU^%%CX\^-WQ,T_4M$\7?$^=TM-.O81#.+1I?/DN)
M(V'F1F68_*K$';&&((92/NCP'^QM\(/A7K*ZCX7^%/PW\-Z@C(ZW6E^&;*SF
M5D;<A#QQJ<JP!!SP1FO2*<JD5'E@MP4&W>1^:_[)-[#^V;_P7P^-GQ"N,3Z9
M\ ])3P5HJ- VZWN6>6"9][<*?,34P  -RS<$@,6^D/\ @LC_ ,HP/C1_V+[_
M /HR.O=/ 'P=\(_">?5I?"WA7PWX:EUZZ-]J;Z5ID-FVHW!R3-,8U7S)#DY9
MLGD\UH^,O!6C?$;PO>Z'XATG3->T74H_)N]/U&U2ZM;I.NV2-P59>!P01Q4N
MI[R?:PU'2Q\D_P#!OY_RB,^$O_<8_P#3U?U\G_\ !4__ )6*/V7_ /L':!_Z
M>=1K]8/A_P##GP_\)O"-GX?\*Z#HWAG0=/W_ &73=*LH[*SMM[M(^R*-51=S
MNS' &68D\DUD^*OV?/ /CKXBZ7XPUSP/X0UCQ;H:QIIVMWVC6]QJ.GK&[21B
M&X=#)&%=W8!6&&9B.2:J-2TW+O<3A>*B:/Q2_P"29>(O^P7<_P#HIJ_-+_@U
M._Y-%^)'_8WC_P!(H*_4>ZM8[ZUDAFCCFAF4I)&ZAE=2,$$'@@CC!KF?A3\#
M/!/P'TBYT_P/X/\ "O@VPO)OM%Q;:%I,&G0SR[0N]TA10S;0!DC. !4QG:+C
MW*<;R3/Q%LOVN?!W[$G_  <*_%GQYXZFU"#0+:\U*S=K*U-Q+YDL,83" CC(
MZU]S_P#$2K^S#_T$O&G_ (('_P#BJ^J_&/[#GP4^(GB>]USQ!\'_ (6Z[K6I
M2&:[O]0\*6%U=73GJTDCQ%G;CJ236;_P[H_9\_Z(3\&__"*TW_XS6DJE.5N9
M,SC&:V,O]AW_ (*-_#;_ (*%:?XDNOAS-K5Q;^%I+>*^;4+$VOS3"0H%!)+<
M1-GIU'7MS_P3_P""JGP]^//[;?BSX"Z/HWC.V\8>#3>B]O+RTMDTV7[+*D<G
MENMPTARS@KNC7(SG'2O:?A-^SYX!^ =O?0^!? _A#P7#J;(]XF@Z-;Z:MVR9
M"&00HN\KN;!;.-QQUKY/_9R_9@USQ5_P5]^)WQHF^','PU\(^&]$?P?ITBVT
M-O-XYOI+DW%QJ[*@!9=I">8X)D!BPY,<B+FN5W*][0^WZ^;O^"O/P:\5?M ?
M\$X/BGX3\%6]Y>>)-0T^":UM;0GS[Q8+N"XE@0 @LTD44B;!RV_;@YP?I&BI
MC*SN6U=6/QU_X(K_ /!73]GG]CW]B2#P+X_O;KP/XTT&^O'OV_L6ZNFU]GGE
MEC<-!$^UD1EAVRE<>6"#@G'BO_!<'_@H9<?\%'/AQI-]\/?".OQ_!KP#JZQW
M'BG4H#:KJFIW$<JQQQ1EON+'%(>A<;OF$8P'_:SQ?^QM\(?B#XD;6=?^%/PW
MUS6))C<M?:AX9LKFY:4D$R&1XRVXD ELY) K>\8? OP3\0O <?A7Q!X.\*ZY
MX7A97CT?4-)@NK!&4DJ1 Z&,$$D@A>,FMU6@I<]M3+V<G'EN?GE_P6TOX=5_
MX(6^#;JW;S(+F/PU+&V"-RM I!P>>A[U]I_\$Z/^4?'P)_[)YX?_ /3;;UV6
ML?LY_#WQ%\,+7P1J'@/P;?>"[#9]FT"XT2VETNWV$E=ELR&)=I)(PHP2:Z;P
MYX<T_P '^'K#2-(L+/2])TNWCL[*RLX%@M[."-0D<4<:@*B*H"JJ@    8K)
MR]WE\RU'WKGY)?\ !4__ )6*/V7_ /L':!_Z>=1KV7_@X*_85\8?'SX;^#?B
MU\,K>ZN_'GPANI+MK6T0/<W-D2DWFQ*0?,E@EA5UC ^99)?O,%4_<OBK]GSP
M#XZ^(NE^,-<\#^$-8\6Z&L::=K=]HUO<:CIZQNTD8AN'0R1A7=V 5AAF8CDF
MNOJO;6<6N@O9WO?J?G?\)O\ @Y;_ &>_$OP3M]<\677B#PSXOBMT-YX;ATJ>
M\DDGSAQ;SJODLG\0,KQG:1D;N*^2?V _VE?$G[87_!P;H7Q*\0:#>>&;?Q7H
M]]<Z'IUPC*T6EKILT5J_S?>\Q$\PL/E9G9E^4K7[ :]^Q]\)/%/C=O$VJ?"W
MX<ZEXDDD,S:M=>&[.:^9R22QF:,ONR2<YSR:W9?@;X)F^*<?CI_!_A9O&T,/
MV>/Q VDP'54BVE/+%SL\T+M)7&[&"1TIJI!)\JW$X2=KL^ O#5[;_MG_ /!Q
M-JTUP8YM _9N\)FWLHVMF:.?49=JNQ#<!D>\EPWK:1E0?OU]=?\ !1;]E+_A
MMG]C'QU\-XIH;74-<LUDTZ>5-RQ7<$J3P9.1M#21JA(/"NW49!]*\'?!_P )
M?#OQ)KVL^'_"_AW0]8\53+<ZU?:?IL-K<ZO*I<K)<R(H:9@9)"&<DC>WJ<]%
M42J:IKH6HZ-/J?D#_P $M/\ @L3H/["/PO3]G_\ :2TS7/A[K?P[GFLK'4Y=
M.GNDDMS)+)Y<\<*N^48[(Y(E>.1"AXVEWQ_^"F7_  4#D_X+'WGAW]G7]FG2
MM9\36>I:M'?:[KUS9265DT40)CSY@WQVZL3*[R(C%H8U0,25;]9OBE^SWX!^
M.2PKXV\#^#_& MU*1#6]&MM0\I20Q"^<C8&0#@=P#5SX9?!WPC\%=!_LOP;X
M5\-^$M++%S9Z+ID-A;Y)))V1*JYRQ/3J3ZUI[2%^=+7\#/V<K<M]#XC_ ."M
MOP7M?V<O^" _B3P%9RM<6_@_1/#FDB9FW-.8=4TY&D)P.68%N !SP .*]H_X
M(W?\HP/@O_V+Z?\ HR2O?_B!\.?#_P 6?"-YX?\ %6@Z-XFT'4-GVK3=5LH[
MVSN=CK(F^*161MKHK#(.&4$<@5-X-\%:-\.?"]EH?A[2=,T'1=-C\FTT_3K5
M+6UM4Z[8XT 55Y/  '-9\]X<OG<OE]Z_D:=%%%9EA1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !7:5Q==I0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 5QOQ;_ .8?_P!M/_9*[*N-^+?_ ##_ /MI_P"R4#CN
M<;11106%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?+?I^FS37J?G!^WU_P '#'Q(_;&^&6H>"?#?AVS^&OA?7+=[35TM[\ZA?:A
MX4/";@QQ!(V&X,JH"RN5)*DAN7_X(=_\$Y=6_;+_ &I='\3:K830_#KP%=Q:
MKJ=U-%(L6I31MNALXF VLS2*I<9&V-6[E0?T^^$7_!MS^S7\,-=COM1M/&GC
MCR9!(EOK^L+Y (Z96UB@W#/.UB0>A!'%?</@+P#HGPL\&Z;X=\-Z38:'H>D0
MBWLK"RA6&"VC'155>!W/N22>33Q&>86C0=#+X6OU_J[;]0P^08NOB%B,RG>W
M3]-DDO3<\T_X*(_\H_OCI_V3W7__ $VW%?SC_P#!+C_E(U\$?^QRTW_TH2OZ
M=?C-\+=/^.7P>\6>"=6FO+?2O&&C7FB7LMHZI<10W,#PR-&65E#A7)!96 .,
M@CBOBKX"?\&Z/P2_9V^-7A;QWHOBCXJ76K^$=3@U6SAOM2L'MI)8G#J)%2S5
MBI(Y"LIQW%<N3YE0P^&JTJM[RVT\K'9G65U\3BJ56E:T=]?.Y]]5_++_ ,%1
M_P#E(U\;O^QRU+_TH>OZFJ^!?CW_ ,&Z/P2_:)^-7BGQWK7BCXJ6NK^+M3GU
M6\AL=2L$MHY97+L(U>S9@H)X#,QQW-99!F%'"593K7LU;3U-.(LMKXRE"%"U
MT[ZNW0[[PO\ M,V7['__  1)\"_$*[FACGT'X4Z*VG1R$#[3?/ID"6L0R#]Z
M9D!X.!DX(!K^?#]FGX/:O^U_^U3X1\&M=7EYJ?CK7H;>]O9)O,GVRR[KBY=W
MR694\R0DY)VG@G@_T<_M%?\ !+[P1^TQ^R%X&^">M>)/'>F^#O <-A!:OI=[
M:PWFH+96IMH?M+O;NC_*=Q"H@+@-@8 ' _L6?\$*O@[^PO\ 'JQ^(OA?5_'F
MM:]IEM/;6B:Y>6<]O;F9#&\BB*UB82>6SH#NQB1A@YKLR[-L-A:562OSR;MI
M]QQYED^*Q=6C!V]G!)/7TO\ @6_^' W[)/\ T2?_ ,N?6?\ Y+H_X<#?LD_]
M$G_\N?6?_DNOL6BO"_M+%_\ /V7_ ($_\SZ#^R\%_P ^8_\ @*_R/Y//VR?@
M%>?LC?M:>.O +M=1/X1UN:"RF=&AEEMMWF6LV"<C?"T4@Y/WA@GJ?W\^#?C<
M_P#!7'_@CG-'-?V\GB;QGX5N-%U-X9(\P:U IC+R(NT1AYXXYO+PH\N5<':0
MQM_MW?\ !%3X2?\ !0?XP6GCCQ=J7C30]<MM-CTN0^'[JTMH[N.-Y'1Y1+;2
MEI!YA7=D?*J#^$5WO_!/_P#X)T^$/^"<7@G7_#O@GQ#XUUC2/$%\FHR6^O7M
MO<+:SB,1L\0A@B"EU6,,2"3Y2=,5[>8YO0Q.&IR5_:PL]NO7_,\#*\EKX7%5
M(NSI336_3II]Z/YQ/@%\6O%__!/?]L'1?%!TN>Q\6?#G6'2^TN[S"[%=T-S:
MN<$KOC:6,D X#Y&:_<#_ (B1/V:_^%.2^(O[4\2_\)%';K(OA;^QI_MTDIVY
MC$^W[+@%CEC,.$8@$[5/>?\ !1C_ ((Q?"__ (*(:K'XBU":_P#!_CN&%;<:
M[I<:-]M1<!5NH6&)MJY"L&1P-HWE5"U\R_!7_@U<\#^$_%UO>>.OBAKGC+2H
M&+/IUAI"Z.+CIM5Y?/F;;USMVDY&&7&3TXG'Y9CH1JXJ\9KHNOE>S5ON9S87
M+LUP$Y4L):4)/=]/.UT[]]T?D7^UO\?->_:I_:'\4?$OQ%:S6=YXVO7U&&)G
M>1(K<$PQ11NP!=(DB$08<?NB,#&!_0/_ ,$!O^42?PG_ .XQ_P"GF^K+_:N_
MX((_!+]K;Q_I>O:E?>-O"J:+HUMH5CIGANYLK33[:UM]_EA8Y+61@?G.?FP>
M..N?H_\ 9"_9:\/_ +%G[.WA[X9^%KS6-0T'PU]I^RSZK+'+>2>?<RW+[VCC
MC0X>9@,(/E SDY)YLWS;#XG!PHTDTTUIV236_P!QU9+DV)PN-G6K----7[MM
M/;[S\E_^#D/_ ()M:MX=^)LW[07A.QFO/#^O1P6_BN*&,LVF7:*(8[L@?=AE
M18D8XPLJY))E 'S#_P $O/\ @L7XU_X)OS7.@KIUKXK^'NKWRWE[I$[F.>TD
M(59)K64<*[(J@JX96V+]TY8_TF7=I%?VLD$\4<T$R&.2.10RR*1@@@\$$<8-
M?GS^T]_P;;_ KXWZG<:IX2N-<^&.IW#EVBTMENM,)(&?]&EY7D9 CD11D\=,
M7E^=8>6'^J8]7BM$_+I?KIT:,\QR'$1Q/US+Y6D]6MM>MNFO5,X77/\ @ZC^
M$=OX5\[3?AS\1KO7,G_1+DV5O:XYQ^_6:1_3_EEW/IS^4O[?W_!0KQU_P45^
M+D'BCQI_9]C;Z7 ;/2=)T^-DM=-A)W$#<2SR.<%W8Y)  "J%5?T:L/\ @TXM
MX[M6NOCS--!SN2+P8(W/'&&-\P'..Q_K7UY^Q5_P0S^!G[%GBC3?$UGIVI^,
MO&6E[);;5]?G6864X',L%NBK$AW<JS*[IM7:^<D]-''91@KU,,G*7S_6UOS.
M6ME^=8ZU+%-1CUV_)7O^1Y3_ ,&\7_!-[5/V4O@WJ7Q-\:6<VG^,?B-;116F
MFSQM'/H^FH[,HD4XQ).VR0J02JI$/E8NH])_X+8_\%,E_8"_9X_LSP[/"WQ*
M\<Q36>B@.I;28MNV2_9,YRF[$>1M,F"0RHRG[5KXC_:Y_P""#_PP_;9^.6J?
M$#QSXZ^+,^M:D%B2&TU#3H;6Q@3B."%#9$K&H)QN9F))+,S$D^'2QE*OC/K.
M-VWLE?T7I_74^@K8*MA\#]5P'Q;7;MZOU_+Y'XR?\$KO^"?VJ?\ !1S]J:WT
M&Y>[B\)Z1C4_%6HI*%FBMBV-B,P;,TK?*N0<?.QR%-8W_!1C]A_Q#_P3A_:N
MU#PG)/J$FEQR+J7AC6\>4U_:DAHY RXQ-$V8WQC#QD@!64G^B;]A7]@GP'_P
M3U^$EQX0\"KJ=Q;WUZ]_>ZCJCQ2ZA?2' 7S)(XXU*HH"JH4 #/<L3G_M\?\
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M!7H99G5.EAYX?%IR4NVNZL]W]QYN:Y%5JXFGB<&XQ<=[W2T=ULG\S["HK/\
M"7A:Q\#>%=,T32X6M]-T>TBL;2)I7F:.&) B*7<EV(50-S$D]22>:T*^;]#Z
MA7MJ%?+?_!5/_@FM_P /,_A1X;\+_P#":?\ "$_\(]JQU3[3_9']I?:,PO%L
MV>?#M^_G.3TQCO7U)16U"O.C456F[-;&.(P].O3=*JKQ>_\ 2/E#_@E-_P $
MPO\ AV-X&\7:+_PG'_";_P#"4W\-[YW]C?V;]E\N,IMV^?-NSG.<C'H:^KZ*
M*,1B*E:HZM5W;W_I!A\/3H4U2I*T5LO^'"BBBL38_'7_ (.RO^: _P#<Q?\
MN+KX)_X)Y_\ !4KX@?\ !-3_ (2__A!='\':M_PFGV+[=_;UI<S^5]E^T>7Y
M?DSQ8S]H?=NW9PN,8.?Z'OVL_P!@/X2?MR_\(_\ \+2\)_\ "4?\(O\ :/[,
M_P")I>6/V;[1Y7G?\>\T>[=Y$7WLXV\8R<^.?\.!OV2?^B3_ /ESZS_\EU]9
M@<ZP=/!1PF(@Y;WT5MVUU1\=F&0XVICY8S#3C':VKO\ "D^C/S8_XBE/V@?^
MA/\ @[_X*M2_^3ZO>%_^#H#X^ZWXFTZSE\(_!]8KRZBA<II6HA@K. <?Z=UY
MK]&?^' W[)/_ $2?_P N?6?_ )+J;3_^""O[)^EW\%U;_"GRY[>198V_X2;6
M#M93D'!N\=1WIO,LFMI1?W+_ .2$LKSR_P#'7WO_ .1."_X.3_\ E&=>_P#8
MR:;_ #DK\0?V*/VRO%'[!_QWM?B%X0L=!U+6K.TGLTAUB"6:U*3+M8E8I(VR
M!T^;'L:_I[_:4_9>\"_M>_#.3P=\1-#_ .$A\.27,=XUI]MN+3,L>=C;X)$?
MC)XW8/<&OGG_ (<#?LD_]$G_ /+GUG_Y+K+*<YPN'PKP]>+=V]DK6?S1MG&1
MXO$XM8G#R4;)6NW>ZOY,_-#5?^#H?]H74+"2&'PU\);&1\8G@TB^:1,$'@/>
M,O/3E3P>QYKX[_:;_:]^*O[?WQ3T_5/'6M7_ (LUO(L-)L;:U6.*W$DGRP6]
MO"H&YF*KD N^%W%B!7[Y_P##@;]DG_HD_P#Y<^L__)=>T_L^?L%?!O\ 94U:
M34?A_P##GPSX:U22+[.VH06WF7OE\903R%I K8!(#88@$Y(KIAGF74/?PU%\
MWHE^-VSEJ</YGB/<Q5=<OJW^%DCY@_X(.?\ !,75/V%_@WJGBSQM#]F^('C^
M*$SZ>1\VB6:%FCMV()!E8L'?@;2%7JI)^^Z**^6Q6*GB*KK5-V?6X/"T\-1C
M0I;+^KA7Y0_\'67_ "0SX2?]AV]_])TK]7J\G_:L_8?^%W[;NA:3IOQ0\+_\
M)/8Z%.]S8Q_VE=V7D2.H5FS;RQEL@ 88D5MEN*CA\3"M.]EVWV,,UPD\3A9T
M*=KRMOMNGYGY6_\ !J/_ ,E4^,G_ &"M-_\ 1UQ7Z4?\%7?^4;?QK_[%.]_]
M%FMC]E'_ ()W?!W]B#5=9OOA?X/_ .$8NO$$44%^_P#:M]>_:$C+,@Q<32!<
M%FY7!.><UZ5\5_A7H/QP^&VM>$/%%C_:GAWQ%:/8ZA:>?)#]HA<89=\;*ZY'
M=6!]ZZ<=F%.MCOK,$^6ZWWTMY^7<Y<ORZK0R_P"J3:YK26E[:W\O/L?S,_\
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M5O\ @M-^TQ\;_AMK?A'Q1\2O[4\.^(K22PU&T_X1[2H?M$+C#+OCME=<CNK
M^]*CE.:QJ1E.M=)J_O2V^X*V<Y/*G*,*%FT[>['?[SY:HHHKZ\^+/Z*/^"$_
M_**OX6?]Q;_T[WM?7%?(_P#P0G_Y15_"S_N+?^G>]KZXK\DS+_>ZO^*7YL_9
MLK_W*C_AC^2"BBBN([@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** .%^*'[,'PT^-]['<^-/AWX%\7W$
M>-DNMZ#:Z@Z8&!@RQL1QQ]*U/AI\%O!OP6T^:T\&^$_#/A.UN-GFPZ-I<%A'
M+L!";EB50=H) ST!XKIJ*=WL 4444@"BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *[2
MN+KM* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%Q?*Q1E=704445)04444 %%%% !1110 4444 %%?)_\ P4I_X:D_X3_X1_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MY^B/U#A5-8!7[L****^?/I HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *\#_ &>_@1XE\ ?MS?M#^-]4LX8?#OQ!_P"$
M;_L2=;A':Y^QZ?)!<;D!W)MD8 ;@,]1D5[Y151FTFEUT_%/]"913:?8****D
MH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH \=_X*(_\H_OCI_V3W7_ /TV
MW%?RFU_6;^V+X!U#XK?LC?%3POI,+W&J>)/"&K:59Q( 6DFGLIHD4 D#)9@.
M2![BOY,J^ZX1DO95%YK\C\_XS3]K3?D_S"BBBOKCXL**** "BBB@ HHHH **
M** "BBB@ HHHH **** /Z*/^"$__ "BK^%G_ '%O_3O>U]<5\C_\$)_^45?P
ML_[BW_IWO:^N*_),R_WNK_BE^;/V;*_]RH_X8_D@HHHKB.X**** "BBB@ HH
MHH **** "BBB@ HHHH **** /F?_ (+(_P#*,#XT?]B^_P#Z,CKQK_@VJ_Y1
MB:;_ -C'J7_H:5]^T5I[3W.0GE][F"OR _9M_P"5I+XF?]>5W_Z;K6OU_HHA
M/EOYA*-['XV_\';/_-O_ /W,7_N*KL/^(K[X?_\ 1)?&'_@SMO\ "OUBHJE4
MCRJ,EMYD^S?,VF?A[^V3_P %._BM_P %JO 5K\%?@K\&?$5EHFO7<%QK%_-,
M;G[1'%*K1K)(J+!:P),BLTCNVYD0#800_P!^Q?L%>/\ X"?\$B++X,_"WQA>
MZ3\2O#.CM-8:KI]Z;1;K4'N'N[F%)67*Q2R2S1H6VX#(25P2/L6BB571**L@
MC3ZMZGY'?LS_ /!?S7/V.?AK8_#W]J#X8_%2W\8>$X4TXZS%:K+=:NJ@B-[A
M;J2$F0Q@$S+))YV"_P#$36%X9M/B!_P6]_X*7_"WXL:?\-]<^'/PE^%+6.HQ
M:YJT<D%QK*0W(NUCBE4!9'>0 *(21$A9R^70']CJ*/;):Q6H>S>S>A^,'_!7
M2ZNO^"BW_!9[X6?L]Z=))>>&_"+6T6M1Q-+MB:?;=ZA(2O&5LEA4$8PX8%@2
M0O[-VMK'8VL<,,<<,,*A(XT4*J*!@  <  <8%245,JETEV*C&S;[GAO_  4B
M_9/7]MC]BWQU\/(UA75-4LQ<:3+)&K&*^@=9H,%BNS<R",MD861LY!(/YY_\
M$$_VLCXT_P""?/QF^#FM7=TVO^ ]+U/4M.@N&<LFG36[*\:AAA1%<;R1D?\
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M-.US7M4ABMQIMJ[ 31'R9)88XY4(1YII5 21U"%G5A]>? W_ ()Q>)/V5O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M 'PH_P"(37_JOW_EC_\ WPK]BJ*]+_6+,/\ GY^$?\CRO]6LM_Y]_P#DTO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\:_
M^"N'_!OSXF\2?$K7OB=\#;2VU:WUR9K_ %/PDK1VT]M.VYI9;,MMC:-C\WDY
M#AB0F\$(O[*45W8',*V$J>TI?-=&<&89;1QM/V=9>C6Z/Y5]8_X)L?M#:%J<
MUG-\#?BU)+;MM9K?PI?7$1/^S)'&R,/=2157_AW=^T#_ -$+^,7_ (1>I?\
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M']FV_P#S[P_]\"@#D:*Z[^S;?_GWA_[X%']FV_\ S[P_]\"@#D:*Z[^S;?\
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M .?>'_O@4?V;;_\ /O#_ -\"@#D:*Z[^S;?_ )]X?^^!1_9MO_S[P_\ ? H
MY&BNN_LVW_Y]X?\ O@4?V;;_ //O#_WP* .1HKKO[-M_^?>'_O@4?V;;_P#/
MO#_WP* .1HKKO[-M_P#GWA_[X%']FV__ #[P_P#? H Y&BNN_LVW_P"?>'_O
M@4?V;;_\^\/_ 'P* .1HKKO[-M_^?>'_ +X%']FV_P#S[P_]\"@#D:*Z[^S;
M?_GWA_[X%']FV_\ S[P_]\"@#D:*Z[^S;?\ Y]X?^^!1_9MO_P ^\/\ WP*
M.1HKKO[-M_\ GWA_[X%']FV__/O#_P!\"@#D:*Z[^S;?_GWA_P"^!1_9MO\
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FBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>brns-20231231_g8.gif
<TEXT>
begin 644 brns-20231231_g8.gif
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MW !MGB\"[,$  X@@ R=(N7XA$  )Y+<!$!CYH^][ ';$8_+W)0 Y#H#Y^V)
M 9Q', %V$0T<0P #DN^\ZE=?Y7MD(,, \/A_$\"  #@ OT+(@(/U\($,.![
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M(T<.A,F@!QA@E7F9M;</"RI?!&  -S9?[F /+'I?Z@>$^36'UZ</Y."!CT8
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MJ[Y*@SQX E&8 ;YJQ"=0BPQ #P00M1= >#S<JR<0?B&0ALU6 0QP8PU KR+
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MLPJLA$=S=N8N&  #:#)@KQ<J^. $ %YH;5)#.VB]S=9:FSS\R"](\*GZ#7K
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ME@D0!/"'D4*B!"B!_VPH$:@9<F0(=@H,)SN!6IR7 )"-,O*L!- '%8F'!"B
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MBHP(AA*-+>!3C01$.L* JF.R!#@'UO*DIX@*J'"MY:D-! BN>@F3"CF7!/B
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MB5E1  G@67-U .5&:'&.8$N6;$QN8_4=XJ06DZ3-WCI&6M%&WM(NB!5H A1
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M0^HWAZS'_J"9O5^T_/>AO4)\?ESP Q&P >^OP<:W'Q;VO*!(&V!B>]:N!)Q
M/O-_6E_9.I@%JY0^/5U<-P@0P=Q&K91+A.,+RHF9?H9<WJ*T!4!@. " 8$&#
M!Q$F5+B084.'#R%&E#B18D6+%S%F-'B/ 8*"_T"&%#F29$F3)C6F-*@@@(2%
M$""HU)A&!8IP38CT&C%A! R+">X1D#DT)0$%"8@FQ4A/@3Z*&,YM43J5:E6K
M5[%FU8I000:/!$^&%3L6Y-:'$ ((6=@@IEF%>K0D0J'"!I$6.S? $#H1@8*O
M;J\28(<4_S!6# H&3DS08"_6!H0+1Y8,F)\>/0 J7\Z,&<#ER5@5=/Q(-FP
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M9#\EE!R,0HUI"6>(9OIB8!4BV";F0_?47S_C/\-LT;+C:W26("R #7HV)2R
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MP9&?"E<9LD-QC&) @,%EO2#D?,[%O5BZX@2\K+Q$0 $4X 740;LEO:KO7%.
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MF]J>8KH%Z&!L(UR]G:L06((W!  A6,(W5_(I.4L2)O0]DTC 3+JK0CNT#I$
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M*>=^[MX0[BL@[^!^[G"1[OCN[G#A(.Z^[^*Q*?K>?BN@ ?*P!C! J7WLCG8
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M<$ (C3F5]+&A!I12.^DM/5C28B0]IFE"!29"@^]$%#O:I93?4G11HP(R* X
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MZ@-],HU<"*UV*[# "O*0""+,E78\L8 -CJ70W\VD8;T803\!T$FE,D9^*"&
M!>1 IDJ@8#8B2P0P$K2!,]X/TR]:-=5$/^=5CN2OFF)5SC)/M+11F79UE[0H
M/*CDU02P527>6(*PA 4#.W!B6%%-!!L2T801#>2W0*T!^G;R2D$^+Q=Q$-0/
M*FFQ4K[Q,@0-)CJ\IP</'( 6-0!!WH!1D+]2A (XZ(\),AN[K.[KB*!-28R6
M2-KD8!-$JI-F;$D:.P(H@(%(C*T^;H*. P6X"S"0QH'L<(I3W$(+ JO$@K5
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M@3',3$ERC*3[XY&Y;*!EBSV;I"*V ,"<B ?C#(X5*(!S*!77K(LML 'QD::
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M59[0 UJC'5NCB7B(!P] M=%84:)X*MN"@7V22F&)/]!Y46A*4_QL2Y6T487
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MYG:D"W/5J]28-=JIJTL>9$^&8[_=XU_.96">9FFNYICM96N.YFNFYCYV9MB
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M#O6XHR2-,.V$-=D"/2JYQT\ZY(#@\^-=EI8!!R"DD$H[P/E2F0& ,:T!#?B
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M"%;@]BU?\_U>!XX@""I? .R>"*H@"+K>"?"?]ZV?$*A*JGW&91R*+NG!LP%
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M1W>%!&BT/<"4"*C$AL6%R3I K]W&L&HTKZ:A:&X!/ZL&/XS.2M60%M'E!S!
M0/+O7VR8=;PJ&O_'KYKG;"0KR79O1Y+O4,]&'2=S:2!Q")R%M@E$.>62'C2S
M= R9NX[Q"2S& ;AS3Y"%0]\$)4X<DXF 7WAF4_,&]^J&>7VU9QY'J$J ]A!
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MI$(J/42L521 WTV$I Q93=&E]H)SLYW .[2NO0)WG >[L%M%-""6-YRS 2"
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M0,+ $QD0*#P10$%#=P$$_LS@H(*("@8@5GS80**^# 8 D MP8AX /08RZ$/
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*/Q540U52 P( .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>brns-20231231_g9.gif
<TEXT>
begin 644 brns-20231231_g9.gif
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MI00$! P,#/O[^_6R;_BN9?/EV/WIU?6=1_/*H_O2JP
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MF&#"*7T T,?49)=M]MD?5WWN0'@F,% VY;DM$-SS9:-0 @NLXET( X4@KBD
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M#12QR^;G!)+:"U5V0G-LK83"*DPB-5>Y !!$/3=KUO:Z5TW[% AZLD'*MTZ
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MY!P&!/%$D'8*G8,"L1..] -F\+R[))H^HE;/LY:ROLB1>S80WDK7>\O$USL
MNU6D*+!;)NB\N#2= 5(";)MU<!S1J,V2Z:80<..)8=AQ3;L $["4!)< >.C:
M2&F&))2&09E !>RS#0RTW2&TY$&TBAR*M:TWN,V347D*^,O;6+N>0J8W#+
MKM -'W"5Q/\-'E<[RK\MW011M.JACVG$>Q@7U$)-$:6H.:=XI00!5>ZS1Z;
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M@,V_N2";$*GF.PHG@VK&X"TMJ.8,IGE-=J[@'>ML9PM<L)TXR( -U,0!#&9
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M @[+8M4?)A&KJ8O9 0!7=$TQA9#69@1$FVB[GX"(;M6%-QP(T'(WA<!#T@2
M!IV0<IR)@7C_P^.8U[Q+3B1+3N\D"4633U\,V$\$6(I( [IR7H$]V.NDIJ*3
MSC'-8HJ8N,M0Q0-[1%?$6(@HXE;<CIYC P1V8BNNJU.43P!H@_C<,)-M+9)0
MV3*DB%.3T#QVQBL0"$50B%.;#85X!5 (D4%>X1].4 X1B%*1S6KS68KPUG/E
M#S\=P$H+O(O\O+S;LAH+6P^EIBHFB=M+7^#5X'Y\T;E]LDJKRV*K49RL)AIX
M SI 8,N8VY#CM4V]14D,VYZ[5QN("Z1RW[EMTS2HM"H.Y5*V2LW@Y3&6/@V>
MM6JZ4)_B6L(K!/2C"%/V7M5U@368A0YET_EUWY$P/P^D"..%"]F-_\PR)HE<
MAMQO@N6&J[WD;>?=^CZ(>%KTI0AETV#W55SQ/=4F?5S*[&>[RT>1<[E\A#UV
M_N1NAHAO#F>%>&A^;CA)O#V U QBI@ACEN:.+JZI7 ,7<,J1>.9'S4A>N\KN
MLE, F,HZ4 /5A0C='<!;_":5MH&X_&>"MBD,[+U8)M2H%6%C;:NUBT.;B%=%
M'@!:8&$3/DV04*8^' !N_ X@%C&(&)5O7==%UL^/(#'-..,R]JF!.D5=5(AW
M@($6B*R"H[-_=4Z 30-O,K2Z MDKQD1X:L1 @R<EQKC+P#AV<.,X?CEWOM@*
M,UAK$FPU]DY_/>PZ(]E\M=>2A1,Q ^*4/?\F$5M:FQ!D SUAD A7RYAD1B8M
M;^T3R@X4! 4)N7-F&K5:E>JY6R:T6:B#A1Q1Y1VN958!.;A;5*[H5-9?YWRR
M:A)FB,C'6);;Q2I+B+@!-<@#M%Q;+TO5@@QE379IRHT+:QZ)9"X]&Y #M,1G
M7WM*W9X][P!@R/MHY9WF@A1N+17O:L*MI+0,@CPIUTONP9;I?8:(&)"#0J!M
M[WUGYD9+XXX+K.WKAJMB?RYNY:V]A*9H5+Y*4/8UGW+>[CWH\^W X?9>Z:K5
MBLS'6V;P!Q??<AX)?P9QQ\VIVMT.[";HFX[3D1"R)!34ZS7?D)(ND$RJ!%?>
MD,*M&+_EO5NI%1W_XX:SL%"6<(603B?DVY#*O:&&'Z6%BPB-6:%MZM<$ &6=
M<I#X =ATQJJF4"U'5K1CA*Q&X0D%B=W<CM]<Q$,# +J:S.JL)OET/;F"N.;L
MI[FVIBIN8RPN8[U6Q */"XE=SY2KV%?$L!R0 24>14O+;TP3NN5< <&ZM)1S
M3XK@U];1+!%CQI$XU@FU[/<RL?^LQA5#V61=9 0E+6UD:F\UPQ4#"2D_#FK6
MC$6E 1>\9AOHU-K68( 4L@/7<5SW;94$;F!'/%B'BYQ>+(N+@>_31P/WWI#"
MO%VO\,E"*HUV<?#./_X+*65^4>R]IF&+B^AFMF@6Y7CLP. N2+APU/=V_W"2
MN,4;(%]BS3Y%_' ZN/79+>-D#ZFUQ=T5<%X?_\3=0O!-C>8/)_$2'_?;]K%E
M]O';C4$-?RWRBT&*('C@+7B2(/'>CLP",_8EMXQESK_;'7?<BH%.-2=P_]23
M--\15/:4=.E.?3+=K7;Q^O"Z/?CHTS5'U3%AM5@F?Q_[4NVG&XB.0L0J%XA,
MF'()/368A8MQ75J2N.-QI8@^? 4\E"\1\\PA07-V+Z=JNF6,8P,9<(%*GT3F
MA+B><["):P<9<(>/;6NWOEB*X/,]&]F=5[G VNNX&$^Z+T5K*KCSK '8KM>"
MAN+JACF?PK/5 4;^$$97IXVODU 1JSJ!<-!/%_^(5]@,@<AT4G<UT<:(K_N3
M 5 $;AP(^]04D(<+(;/U<]?(.G !?^_M4,:U8L.!0K !T 4 C _;VU7'$"9N
MTY=B-9A)$)T].<#Q#GS2=.IX7Y-U *@TF28)VLON46[(WDO]>0Q;V:=]V]>,
M&(1WFQ?\D'?."^7]M\#^VH]:^,;0[&+%+!V)?-15*;7W &S]O/MP\KTMXO?]
M <_=&<S@!@>(%6L  %"QXJ *@@#6'!Q(T.!!A7(:*@10AR)!ABOD5-3((N/!
M.A4!L#B(@^#!%6HJ0ESACJ3)D2-;LDRI$ ;&B2M.RKR)$8!.APIQ'(Q1Z*"+
MGDI!KA!9D>B*CP!2SAI)J;%011M'4X8LF'+&4IU<O2+L>##/4H5TMG)U*M9J
MUY8Q1J9,NO @1X4>*]Y@ 97KW*MI!Q,N;/@PXL2*%S-N[/@QY,B2)U.N;/_Y
M\M(!F@=<&UGLU>81!"EL[DRPV&8*!%%H1D%PF^9;:3<OJO@*%"6%FTTH#+%Y
MY"W-)33'4FB*-N1W-@<# B#C8(Z#,BJRD>YS10N%%U? 4)CRA<(7*=\!B/-=
M8?2HV@]V]WZ0/ #E$17*7T%P1MV*+9:GQ7EP_PHYI%6?3 0R%D-UW '07$4N
M\!=#2FF4E])<!"5H%V89*H5-9*QI5MM(F2 '@ FI5>2A:P"0IAE!E(2VE(>@
M5)0)"K&8LIIFJNFF&6\*B3@ : /(J%"00SZ6TDN$V7!0.S&MMY.$9-E'4%!/
M.@7 .BE)!=65)0DDT4]WK8 62F6YMT)" #395$7_8J5)F IB#:0&A6>^J>5]
M*:VTE$9Y*;2FESR%95*44G)TPWE,227FHEPJY&4[AZ6A9UK;1?JD4%.9N296
M"A52AQI@.4J0EPZU=(-",>"01X4 +!G@=G0,AN>?R[U!Z$/\T400G479B=A>
M0/&GZ49@?BGEF]L)M2M,.SWU4Y]FJ2?L084",.JH5*:4T*LKH*H4LU(::VI*
MWP(00SN%5%BEML<JE,=!7JX %F(ZX5!H2WFMF2FB!X$G4PRS_ 4 ?@?M>5A+
M;U(K*&$!#]SL"K(2-"E>91:K4*\K5!BM7A7+E(96*7$$K[,:FGPRRBFKO#++
M+;O\LF6=;(8+!:*9LDAP_YH)HM"*/ (PPB>;+4!0'ZT15*)FF8CFVX<$#:=9
M" "8 LIFQ0&P62< 3$'B;Q7UK%DQ)VJF2-13=WV8@835]UY%*=E0*W;H'=3&
MF>W$ 8 +":Y 7GUI-$>Q@@2E5\.Y%L.7=GS\Z9U4',\-JQ2$7*V 84^($V2Y
MI"FU)Y-Y!Q621AQ0"9J@W6D N(*U,$O&(613;"8D*01=X2&0"B&M&2-2]YRU
MBEVCIMDKL8\09(H]+W*CS)H-B:+6!.U6T>T^\XQUV,D/L#5BVQ96L,C2D@D
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M 41=Z).TAX.*U>/.Z(7,$^(N10S  #P-T)J\WOSE!<&>D_LI1;:JZ4C,P#O
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MM#QR!WG)E5PLHC[Q\,IK.&WK88FTY$1)* ]6+%.K#(<;&'MKF=58,<OQO\V
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M:4Q#^M*5IK2G+7T*4!=:T74HKI>7">8QLR3,9=Z$-.KZ5S*+]!HH&,"M<3T
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MD:S)2A0 <4Z,A929,0TDV4^'#W*A8;FA:Q2A]TNA=_2B"WIG#SJ6-=IZ'1C
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MO%VQ$%4#F;!00LR%1&*55M84TY4 E($--LZ-Y PV1_AD1)=;:%2&,%T>\>5
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MV:BI0CI[8*"3#)7/<YJH4=;+ 1!+'PO1\CM!)O!0[110'A1TM1A!0=%!KU"
M-T14MUO5(BD.,#W>2#4S;N+BW]2M>5O 2[=(6V!#@!$[%7$$ ="L.X9#6:SK
MC%1I$P G $5 @XTJ5(<1!!N!(%[AKP'T(1.Y(LBS $:2'21P *8HR;->D1$#
M(E!ZH"B>2T8 "C](3Q<5Y$G?(.@0(HF0>XMP2$6.M+P&CF^&-'1)WW;EP1J"
M331_DIAAN,(PL"AF0A?_REE[6A8Q0X&.8H92V'Y.41_([.=E9KD=?IR(H2C:
M96828ECK*H=%P^B%4&M!S& "XR'<27&,;(D0PJRHJF+H3H< 6-X P.8U.NJ1
M)6,K#_L(T(KXB4LDZ$/70)S0)304@QCWPH81G$ 01'9IDI3$!AH.N:[]$0!N
M R&&N?KGA/8)HU[F&J5TC#&PHAD+A0!(T=]$8L>#'(TD*<H-T8QU&N^EY(86
M>44);[*;@[R215E;R&QBQ+16#J"%>VQF008P01D"P#<3G"8T!X ]A]#B(-K(
M $&V><W#D>17=_0).342@NV!0IH$&02T7C*"[=WBE\[TCFC\\J?&T"R)JH+5
M_WS &$?6>:R(K-./Q%9FT-%9;(J8JDRD0+09A68*,Z)J*!4!2B&+D25VHWN5
MY_K94;[D;C3C*]+?L':06X -?/5LJ4C*5YY2=H$+Y@H?1HH!2&PDJUP$$(::
MYG:N@91K?N&*7U$)P 6AFLL(.#57_0B"/F=X9'^&A$YV]D4M7 J3(*XD2587
M8JV1U-(A7\7E/%LR JV&M28A(*>1,*+*75$"F0/(57*&Z5(:QO*M#BGF'4FQ
M$%82A)S'K(I;!U!8KW+3)UG51D9X:3V,0.TE+;*(0/+:'1Y""CT,LQEE_.E/
MO6"(/[@3W18_-L6W4(Y2[.&H8^A2%4)M+D.J%2@</?\TF)'UYT&%8L]5>MO;
MMD2T=923(H-"VYXY"@YJN,2KP/)H,#,LXY(:D2XX""*-,U 7(U6HQADND=<^
MDN<(AN0"-J!Q-HX4X;S]^PA0@6I*GJ[KCVYSWT>, +<_<A( ?RP#,8X@IOQA
MQ!GF*H=TKIJO(MW"-B,HT@"<)#R^BH2<VV/G1B)L2T8L1!&4V   3!&+( U
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M5G(+D7K:V!W%0@'4LG)82 D):2.2.!!9M7+B-X< ,)(=T0GKY)(OV1%V1 &
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M]GA@^^*%OKF=K^20:C5PJ6<K13**Y%F>4S82I$!.KZ")DQAD)H&2*4*10#8
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MTWD\13<G.OB;R7'&49(BR;@(BQ>RVB %['OIOD(?VY<2]7,/%.1.,,50!6;
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M$/XJPPD=;1=]QNLJAA .&R7A[/?:.S\#PI<AZY/0>!N]#)ZE>EP);0_Y- ,
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M"8=8R(@  )'$L&61B)C8+,I[L=%@E5/8+%9)@\%*")D\#).DNJH[EL@HO80
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M4%>N3%&>7_ZUSVW<3Z0H5J,=S2$MUB,X5ID@!OKM#0$%D6"&W)W(8&)&5)J
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M"Y>/YR ^<]1&Z!6NB8M.YQ).^+5UUXM^\4$@BS\?)%2U[PH]RZ7_KV^,;!"
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MC)IH28XL\43O/2)?!,6NY-;PS0ZND-KQZ0X#1(;R&4^R,!P ?,,J(D0W:$,
MH$%"+-= 1-M ),#Q1%<MEMM T&( L-M'?$,M7DPM%B.#D1/!K5 Z<82)O 9"
MY!]"U-_]#*!": 3XT-<X043".<@WF@00>$C#N<;>A<3!44 Z$5@ )DVZA97&
M*6$S;%3?%(%U6,P<[DTQQ/]"DMP"+=07C:6(B[D10D@(C8Q W-T"!;@8$0X$
M)=#"SBD""G2"$64=UB $DRT=0KQ+V8'$1<I=0G#A1H($%E($#SR$(H "^"!'
M.DG<H5' U:@D$NIC3>8=P"4)1QQ@0MR07%$CETR=HMV=GX$$UK6@(DP#'2$-
MU9TA2Q@A:-A;T'#/:\BA3;X4)<V6;=UA'MK6[%G>Y9 *Y:1%)]V%:(%>IWR*
M6I@25GQ6Z4E*L&7*$:S>5Z1:;+4:66J27;A6L*$6J T%4WABLME2*3*6)AT%
M*O;-!]2BVV1#[QS+*SY? "1$9FC#]P% \EWFL6"?N5$;]QE+, ) +[VB0O32
M=/7_SIE5"?,4A$(]8W]X&6B(2S4"S?T=W #,FS5Z5T>RY$<(655R9$3L)DC\
MAU!=H]<554J<!@J<QO[D9D/<)F(]8 9RP<3P34G1Y+]PE%5JIW;NY'9Z9TBD
MF4'1S>$-Q+E(44*X"0\JQ,YAG$*89(DHVH#(X$A@X0]R27":H95PX'&R84*8
M @HJ0MSYYG=F$:3%Q.!,FJ1]@3(DPSJ8 :=5 P&L0Z_ A*X9P1E Z 0X2A8<
MP29PFC)4 S0DP%DTPSA\Z#-P@:)LP3B8 Z=) S&P$EO6!#8XXAA( X1Z$.-\
MP3@LPX=*PZYE!:=E03)PFEQ^*(.>@NNIDA%4 Z<M S:X0<)2Z!I,/ /M$4.3
M*L./Y@4@&$$RG .$CH,J4,6")D,68 .62L,8X$0Q'*DR;()C<0,T]"B(AL,Z
M%,XB(>AD61)B__(-+2*C0EQ#+;[B,4HF0@1J *0+0FQ;H2XJ-/7B]H'?L;B-
MGRXC0J!!LF"J\+ 8#K(AOFP+- [$?EI$;8 JOHE+#[G-CN%F1-@@0I"+.N73
MJ!Z14!W<.Q7G27C9ALB;:[3G2\FC$E90/C)-,:38WE 3@2(K!'9GLA*HX0'
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M<LF&1184 <'L*RB[7OHF@Q%L05L K+YNPLAZ:*>-$BT[8E[DK#+ :%AL01%
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M2;/W0$8HLPE.9V9^TNE^#J5I00>E:1/B7VQ-Z]9?%UG[[47:?>O5O/?N^^_
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M8'5'0'$&8>A3)K$.9W 0U?^0##*F#,Y@*$182 >11C*V#%M0$IL@D<E0)]5
M5I(#>X14#"29#')">B@!D0?Q#(#DD5]H8EY44VD$2%&B#(8Q>7P8)OD8B#88
M)H8HCT9YE-%'?7O%6#RB+4CYE(JX=E YE4IF451Y2ET1)(-G@Z)D-P @5$_R
ME0=QAMPV<$F521@91W9SA&]C22LA+#L% ,0 2.<@#45 >K'WA%]R!"2)#0F
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M,\*^GL++>''>YF/R9H$MO)NR90 TSST_5^S9MVO7MET_5FZ:KH"VWH000%N
MA&BT[9?@OH.RV:^;A(CY#P(!D1J!H(XV&LB$@P::Z*,&!W!I@#YD8JB@@W@@
M2,*#8B%H&YPZ=&A"#8/J R(>$+H0E(-"&B 6 #(9X!J5!@AA01\3(O_@1R&'
M%-(8(H]$,DDEEV2R22>?A#)**:GJJJ[XDE@+2[/>@H_+-)*P+#S7KBNBKV(
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MB@Z&*?Y! (A?1IGB[U@A^_$?B/XHLH,!E. : WD1A$0$,)8IA"$P44B&(,A
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M:"D\"'8^)M4^"$$HT SI/HL]B(^$8T;0.>B.;HJ8:/!VSN"/8.]?XEJ1UDT
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M,8+]\8J&Q(SS.-2]^"G$7-39$$'"@)P5*22+TWH(^"!2#'^A8&$#X)7#R@>
M+/9GC)2L2+5>D2 31&MCU.N5(OJS@%9NZY \1(Q8:E@R @[*%6EP24S6LL&;
M3# F/S&+!^-4$ZH\;6I?>EJ=I-+,/74):G&Q&0,Y>+-IU@QF4@LFF:@R)V8>
MT((DDTK)6-(U174-@"HQ6?\Q;JA#!02  9*!0 #R606%Y/.2MOPG0 _)MH 6
MQ!E3'$.0BD";P)W-& 25(\%T(;^.A6L!R$$?0^R'.BY.)UK> X#U",:#$5E(
M$7W:E[$6 CLU2HPA-5*$!3B:4HAXL2#0"A']%E.BCRHR<2G2T$.#RI@'2:Q:
MT'FE0EJ)D!'U47H+L>@>&Y+)AUARD]DA*29%:3_J!*]]W!,/4@$PQF$)=8>(
M&<I;5/;.E2P)@(A:B9&6*34O*2TNQ'2F L,$*!%JDRIE\>LW18@T8M8):,(<
MK&!Y=J<Q)64G>6$L41#XD;3^Q0/J- F3/A)  J8!ESS4AC8@Z9@LY%,; 3!M
M!PK_TH%ZEK6UKBV;#Q_:C-%TBD&^.0+ATJ8%UXX %*WLI#\CQ\6!>-*?Z7/?
M=?SUB6O@AZ<CT$4J0=%2@HSQCVWLZD(>1$@Q(L>Z*<(NMZ):# H 3[2+\9=Y
MEQ6>$:CO%:=\+7RE"K]1>HN1"H$CQ0B2(AXXQ%]^")\H&5(BZ#@ROQ!YV$*2
MQZR9HA(AMS =[^!%KF/]-#L\B&I\T0:(LTY6E[S<RT><-,[!F@E*!TQAE[CY
MIFHVA9LFUJ $<<:TLTPPQ4%+9M/DVDR;W5@M*W0FG,@4XV'*!,1@\TL2++O6
MK7TMQ(Q*S X5 -K(K *TMV& E6-DVMMDN,M>#M) @_JV_[LUB+9MV^V7T[S#
M/*HYS42-9+S"RKCI@!( #ZKS0N!82/E.N"&F\!=X0_I) /?90.I31":X[%44
M% ,4Z;G%>N3<VT=GHG$8;C.]SEKD$.]%R>X<H*+BFK-1^XR"#PR:8.]$9#;U
MC+%_C:R/O]0S$O8L:B..FM-^W%?"EGJO>R+:6D3<$O^99(9*$LR'.2)/''Y#
M&_:$#&BS09 )F%8"!4$MIML,"FT@;'W9OE1KMS!%*"XH;[E-VW"^K>ZTL7G=
M[GYW1"P&[X=J.B4@3L)F/;Q9$^+IKGOM9@;+HDV8Z4364Y$:T'1R<)>5>$I!
M:V&58)(T**$:R$+AH-,<J\R%$[K%PZ!.DLEHN%9?+F46L]AA-T[[@8(P()]9
M6&T^(;F ?-*\Y@%H"!I.FVX 8!D"ZNYV3@FR &X/0!L4, &WVY5=;M].Z$3G
M;T5XH(T=4$;J5%^(=+B]K1T(4C%$#VV:PQS43=6V.&]CZ+S3KO:(M'OM;O]V
MC7CZ]AQR>--(RNRG/_PS(#\\U@J7*V OOD %.MROI!XAJ_>:I[_R&Z]F02L$
M^VU7+LG:G,4\;&"#]K.5'1G$(@F,DCY>0)C_\! -INT&RVU.<]1GP;2N/RW-
M&Q+[@I@^ (IN,]<=+*[YY'[/?32O@LDW *5'YD#$-Q]UH%X0[-1R(A">;H9C
M._?I4[_Z%6F[];-?5GEK'W\;7H&37 @VCX^<T^9'_,V2&4Y<EW#BM:;2WO>4
M3/:S4*]3(TMD9PRT9QJ<@8HO)XD)7M40DUJ%A*=E5I*%7+X!DTWP$ 9D&4%@
MV90!0,YI0VJ1UFF!E@9.8$%\0&G=G@3$W+=!V+3T$4)8$7ZLAR@-PG08#$38
MS]5!!@Q*V+T@Q'0-WV+LSB!@FMAUWR&5G0\&(61@GQ 6X0[%G1$6CJ;9W9(=
M6UNU5?GYDBMD7&,-_]:(.1PVU5KAU9B85(V=O!K!P01<\!C$T5K$H07C[<SA
M$5GD'1XX'45:+)9:#=M:N9.GP=638%7^--O-L1QH05+K.=M%9(,&IE9!=(-I
MH<&WY5Z^B ?7Y=Y &)]"'(CW[$X?G1%$.,[Q-88F]@L.GH?Q%(2,-)]$[([<
M15\2&M(JI"(KMJ(KQA=S8.(K@LSWV=W_>("] 88N>ACA?5"_"1F--9Z+.=P%
MD1#0+$TP(=/04 G%+1P)Z4FP.6/EF9A=L2%?E9"+^5@-%5LO"0J^'4D:^ ]2
M\! $:(//^:$V<!D&@D-&3(#*'>)I25NV^0MW*$NPW (D(E_7\1%"N"!^F/\
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M!"Z;7$'VU[^6]8$1IN#((E#@OP&@0&6HN87+#F("'FB0!Y@;B!\L=XV!M$R
M*!@ #[(70T"!0H,*D"&>; 8]M6W(8INY21*D0S9.$<]5[ +58H#7*5A!:%1&
MRDZLF-8=[>CN84>\DNZ6:):>S*=J1JFB#MOF'&6-\731\= +;IA&-8J(;BPJ
M7_S@"+^]*408\;,>:8BAOB.P3R"!\U[\NH>-^P% ?'=<8T&N\<&6*<)R WB%
M"@5"P)8]I ^-W,%#)#D $Q DD99C9"/#D!'_4V# DY:+Q6EX8#F#(+"1+9O"
M"0=0R0=*4B"4^-\A<?DB4+1R@;E\D>>D\[.6F*M"IZB8<HZYNIO%;EZCTA'$
MK$:@+?;'=]EY6JCFL[!K/M%6VAR8PY"DNJ+-9WE3:EBJ>G(I'B;K,F#4(6A6
MX$MYSE,VVUO1%[PW1X=L(9^F*4(=[0:_,1!$*78K!TC ][V!%($ @J0G *;0
M2HD.P(( N(8J&S("B7:0(0ULV28%$M&)-E* %\G$2!\H&E/0HI$%T>A$7S&0
M6YSRHP*)Q2T!X-&'[JF!&GQ904[J4P"<U&60+$@J7591 -"P@!Q]" H-F!JH
MAI 6&J2%"0'0L@7N__(6&1D!"B2(@03L=#4V2\*D1G(AFEA(>I1)0DO>NAFY
M6@=US_358VQW*B;URTSFA-*O1%7-IXE3B]C,YE%F%TX&E5-WW*'=%*&8+U@]
M!G5FFUB/J,>VS/R,,*%)#<) &UK1CI:TI37M:5&;6M6NEK6M=>UK81M;V<Z6
MMK6U[6UQ:UK2M'%%1FAH_ASB1^".X6Y&N ,Q[*8W]A$W;\W5FT"(ZSUAR(^/
MQ( ?%P9"7"/HLZ#CZPTC_F0*%+9,$!N(I"P'T$N/#L AC&C9+5[1,E X9+T@
M%:_E: ')*1"U95B5B"DLAP*8W;1EF5 I*UM*$*(J0H4(#B5!:@J FW8UIX&3
M)"N>,MFR3A0DOBT5Z0# :Q#+@6 @IE#$)P<P7X@@E;VH8?$J)_I*@=34EA2V
M"( 7.0!%7%@U.0IFSX)$1@I=[%S%_%F$;F>F<@+6++ZCII)\=UC('$VQ4N07
M.$FEQ"S2*[!)VA(64R69MHRJ)\])0\76N1P/],A2TP/23%:"$\__HB:W=;;S
MG?&<9SWOF<]]]K.?26-/%1W!;D:P&^(,69!BJ,]Z_"0 H1O:O=\*A)_AL_3W
M% J +13Z%'#DX_N@X8R%<&'2O\$6GSIAN0T7! 4\B,7&UIO35_B/@P?IL"!8
MJ0BE$D2$_GO%(NHKD%3+UR $3K% )*>-DIIB!_[SPZX'8LN668^H?4!(LI?=
M[ $\^]J6ZW"+!]+AD@* I0,P,(0U:5.<ZO0@4!WWC%TF0$;X;Q0CV&7+: %M
M'M-FO2T;!$%>FF!%7K(@8; <):+=R!/K&R$K37!I'([1@02\E3$5R >W>NR+
M&+QEI!C/OD_C$7:F5287>ZO)V]HVYHC+_SI 1*PTH0:EAS7,+*\+%L1DQ<4H
M55'*4C33D^63)2A+38E]#=.2&[O$H:3YK$?.S%S7ZH%)'1DD<P;YU;&N$-Z>
M:-%Z5!\7$KU0^ F#(%L ) $D_75*QY'M<J2T$0;G/0+P$8Y?0*[?#EH0WT)C
MD+TA&9\Z;&.%K!?!EG.J12U'BF(<',85MQQ( X\0%^I8IBW;@04KY_&#Q*(/
MK["X0*J=D/%>'@"93XCD*'!1"Z\PPJ5O&0H*$N$)"X3=!B$J[!-.>=?_;[R6
MNT78LZZ:]9Z8H@,IO(4%83G_WGO' YD\BQ&^$%,<']P'EBA0%]E@RSTXJ[[/
M2.6";YIVM. [[/^\PRDR!-><&8M"R23Y^7>4Y,^P27=1ME6\3I$E,!^IR4,/
M6(/Z958 9DINIXG>I78"<&KXJNA6I2W(Q4+4C$-2CN0H4*X@Q2/<(_PT$.L$
MS42(Z]#4Q^T0XN[T2=/T*"JR@-3@QR(\C2"@H7L"ZH^.( L(PKJP ;M^X^_V
MQ')Z:2'Z3:)HH2!TX;T$8O*L#>!0*L)X$"&,#:36BP(^K <=0I%"["!4+[VB
M4"$6 11H,-8&8KU,R-AB+]T0K\5NR@\0(N!,B*C.K7(FJ@0VL#76Z]ZBC]S^
M)\%(P7*J4" ^Z=RDPG(0 :G@<"$JY]L(L8"6[8.T@=LBQ]LD3B#$;2#_RNW<
MC*WU#*($7(8"3*"J_L>&5N81,\C<"&(0_,</XW AQ,PRT*Q<G*Z'0*<Y/$,^
MJ$D^CH>)O(P_^HIJ ! !CVZ*%H06MR0[9/$7684!GZ3_DH=-'H9-AD*=) 6M
MIF-M-BM2QJA.V,3J3C$;Z6GK3*0( L<(N@  LB!P[(8&#\)P^*[LY@>XTL=[
M+(*Z""*.7C!^1)#2 @DX)H!/KE *$V+X5&@$#)$@%$D7:DGY%(P'V2,64&R3
M]A$AULNHDD_'.NSS'(+Y@$\@(E(1)I*!'C&3>.T1NP^DNN^4*LD4.4S#! +'
M!D#S*H?!   @+4?&M-$TGI"1_- F Q( %(DB_Z5M &32O2CO"@Q2(5#O"AEB
M]#!O*!LQO8P2W<AP]V#OI3:)P!)B\KXMP")IHC9I\J20*V=2(89B7#0K_3+K
M8H FB#"ER3YC+$K"R91(&/'/YF2' '>GF;[,=1IFK_Y*7I)(=IB&%[4,>-($
M=5ZQS>*L1XQI8EC"_>1L!3+P*R%3C3K013K-;H!+[[RG[\S.;AI-?=9N?KSN
MN@ZB!0<"!,^G&/+(;MC'[%Y0GIZP(=;KE+)R]<K0)P5B\;2*(#I,Q0JRIAHR
MA!YO($X!Q3H.(OCKW0YB.%M)\V#S$9N2]D"R]=SP<A)"VBR.P&RL<D2R&,:+
M("-S-)Z0JT*J92AA\O_ +2*I$_2(,-P*C ]S4R$8(1-@Q@L58A^S,"'B<SX?
M$0P'0@S9[:7\R_F2<(%^L*:\4D#3ZSL-8CN:KH?:3%TLL&PL,!8E R=P@D%
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MZ&5P<J>F9>=Y<"&<?<WR@H<=!  JJ H(-T&HH*I8Y2(HK;IJ" 8]-\ %#HW
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MME(K9^/*F8291%#1JGC%+&ZQBU_L)99*:*."1%/'WD;1\^VT/,J-$Z+@PZ]
M#;!/AE*4_?97,$0ED' $E,]<$C72^J&+D)E*;D;?9:;2;JQ2\'*47C3(''"4
MUR#98&I!E(E"J8YNNZ-[I9@#@*HLK+D@5TVJ55<X7H1T8X7S]5)]&9+A_'(3
M )E "3/;>K66&7:;!69P0OQK6"$B3R'4-*Q")(V]B8@5 (5-;*8!\)S;8?/
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MW=$%40Q?_,JW@<P43=,U?4=I  ,N   ;M$$"W<TP  A!'=3O4,\^ 0,['=0
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M/<XJ N:<WR+OPH'%&>W8Q> ,K=X,%F'2QKSE6O\06*SU K'2&WW[98 000$
M8(\-!N_[IHX06R[PJ&$,"HA_K*+=BC#W_\=![C(1AD]N]\&1"3F2(XJPG@=1
M_0-0 CL1!F@?=M,O_B*!]Q4_9NV%7E3IX@O12T7H\5HY-GIU#4/"-#5!"88_
M-&+%K^O75GX $  $#B28B8+  0-N$60(@$+"3"42FF@HT"!"A0.O)3PH$$5"
MAP,HQAK0D>%'D !(9@0P(B&*@2A'"'0YH$]%G#EU[N39T^=. C^%#B6*\P@V
M D<('H&&C=A/;$VW$"36E O!+U8%EH'6U>M7:$]QED-:CF$1;$>-%&O(-6U1
MN#O#Q*5;U^Y=O#T?)N3;-Z$I@7MAYO5I@F\(PHD5+V;<V/%CR)$K,O);.=9
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M_)+<3SY)&\XIP$NW2 N;<HHIQIFHH.GBIZ..<%"@%:FB4*@L, 21MC)N3A$
MF[L:NJ*B4WM79BAU98BOP;3FTR]%("5H$2)?.1( LA-2)&P_U>.K1K]N'"@+
M#/IB.Q.L\]:;-*\%,J57>)4$8(%AC4V27H&ZX:%8A2@X._&/M%$$!9;=GF@1
M#,+MCB%&^C <!<3W%GUTTDL_%XW?NA7HR@0"OLVG"7[;S38("/K@-VA-W^GA
MY_@Z*),Z 0"91Y4W%KO0/'$:<H!JD1^H)KP%PA/E^^"--$< *&T96-(SO=2(
M C%4&AM;>3+BJ 4M;*K_U =/'8J8H)&Z&56F"MQ0?IH%,M$IU8S1W<6^M6P
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3C$$9#9Q!&JQ!&[Q!' 2T@   .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>image_0a.jpg
<TEXT>
begin 644 image_0a.jpg
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MTL/28>"@6[];X!+HT@/38>"@6[LEP4&W;K?!I="E!Z<@..A4#@XZE8.#3D>
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MTG=%!MS!\.*S3=_ "J61K(X,N ,@IF<#W $0T^<&KF$GH/KQ_.D;T%D!I]*
A4VEO'RY7X06<J_3Z!Q!1>?WZA/<C     $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>image_1a.jpg
<TEXT>
begin 644 image_1a.jpg
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MWBR5>:C $YRMJ4"NAFW.R;7%-;-\:8.AP[(#B)>5Y+0EI1@4QKC^)%DM.:E
M"1&^IW'^Z6;L3+N:+!'%Y\JV4L97@3$.U&.+&I#<L8E_TQ&D/SFFHB8S?N%S
MC']^#O%WV]"S:CFZ&L(8JI/=<XIB2)"A-4]!><=T'J>SNJ:7=\6EO=6SXB2E
M<8W*,1UFV 93E"#W4,A]$U;05=XNDDKD>UBNRG++\U;9U21I,L_7C;%EQAL\
MB*]>B.%]N_@W?8:Q+\^JJ,F,?O<M1F_=1,^Q8VC?O!EW6UL0::Q')NPKQVG9
M!I)/OINB7%.1=;Z,O&<:152P]95;EP2* MM:0:1R/2LP=)1D4)8KP'Z)]3.8
M$*<P1$RGH$I[;;*XSLDZEJ7,(8X'W0L;T;-U/:+'W\?PK6L8^>ZFBIK,\*-'
M&&QOQY//SN#VKK?PW8J5Z&IM0JK65QYVY43+90K?=.0\4Y!QO8BL^R7*>IGK
MT!1;8-')F,YT9[D=Y58GLU-01,E%0[9+SU0^YR4>IU%09?G*,%NCW R3#OO1
M/V\N'K^Z%(_;=J+WW&G$[]]#_&&[BII,O*O+OD6LZ_+?</_(!VC?NA6198L9
MTYG\I#V)*"[TI:!L^[ %!EA9_FEL65,I:JI=;279"7?7V*+D:F\Y)8K@&1/P
M.11FR4:N7#'F>TH59AU5]GH87SH?/6]L1/<'!Q#YVT7$'CU$?V>'BII,M+?7
MONFR]YMOT<VJZMV_'X/K5MOS5(XQ6EJ;7(8'X[-5QTJHESN1Y!(]A8DH;V59
MC.SSB2@7?W95V;-2R3VU+"K,$%$OMY?5V!N](C''-2M9-1VC3);QE4L0:WL3
MT5,G$+UY'='NKO(][RKJ'V3)[5GW[B%RG2?IKW^U[RL?9SO*</W(AF1+QV$/
MI85:@=$[))<L9!NHPK[A4F(\_(SS7@ZZ+KG<P0C/"%YB6RSQ>19?:S7\/7A(
MV$BR[8UZN#[-;<3@&Z]AX,11]'_U):)W?M"[D/X9<E]?Y,D3]-V[B^BU:QAZ
M_S"2Z]8BU3(7Z<9:)$,>)!DLDERS4I+NB*2\@CU/R4Y$@.M1B,)\E",WK<@]
M$S7VMI,]<\EF;-B%3,#)^.[ $*MOJ#:,P:86Q->LQ<"A@^B_<AG1GWY ]/$C
MO:_OOY/5%^E#],$##)T]B^1;NY%<]0H2+2T8"OCMDSOLJL:(8R:2/&;E,@:K
MJ!0*<J:J(_44$F8K]'/=XN-R72K@L44667$%!@S[2J[3B5ZW#]&F>8BM6HO^
MW7L1.WO>_KT1^2K.[_S-#O-%129.3L<3Q&]\C=%3IY%X;S_&MFY!8ND2C#7/
M08()+<$!.$U)>;GFQ*&X%.30&PB2$-M@P!95\OGLZK(8%$J4):+R%)4,!Y!H
M9*N;OQ#QS5L0?^\0!DZ?0>S&3;NB(_HE@=].E(MXOWQI[?OO,7+I$L8^.(+T
M]FU(KUZ)=.M<MCZN6U(ALG/!EE>DD#PK*._V,LE1'&59?L(J1$A$EC=X\SXG
M<DV-R"Q;AN3FUS%Z^,\8O'@)_=__B-B#A_;OC3R#[TD]-Z)L61-)</#G>TA<
MOH3TAT>1V?,6TG(_PX)F9.<UH3"O&27.6X6&!N1843EI>:PJ*U3+=%@/JW$V
M+%9AB>M<OF4.<GQ-;LUJ9+=O1_K0820^_P*#=^^A_^D7 _3[4?\B$U\)%5G]
M3QYC4&Z&E/OLSIU!XO@QML.]2.W9C>R;.U!@6RRL7HT\6UF^L0G%N937U(K2
M@D4HKEJ%PL8-R/UI*[*[=R&U[QV,'_L B4]/8^3R90S>OHU^SF\Q^_<]FP_@
M\R5J<F7)2>SI1JRK$P,/'V#PSH\8OG438_:7K3]%]NA1Y'>_C?S:]2@M78[B
MDN4\KD!QS3KDM^]$=O\!I$]\C.07GV/LZQL8^?$'Q!_<1XS#;+1[TA?7GN%W
M>9]+49/IYQ Z2%E#/]U!XL9UGOPOD/GX8^3:]J*P83.*RU;^0F$=*^G-MY Y
M_#Y2IT]C_*NOD*"D(4H:X/M$H_*>S_Z+UO\O1#TOJ"A#4%&&H*(,0449@HHR
M!!5E""K*$%24(:@H0U!1AJ"B#$%%&8**,@0590@JRA!4E"&H*$-048:@H@Q!
M11F"BC($%64(*LH05)0AJ"A#4%&&H*(,0449@HHR!!5E""K*$%24(:@H0U!1
MAJ"B#$%%&8**,@0590@JRA!4E"&H*$-048:@H@Q!11F"BC($%64(*LH05)0A
MJ"A#4%&&H*(,X9F(4O[WJ"A#4%&&H*(,0449@HHR!!5E""K*$%24(:@H0U!1
MAJ"B#$%%&8**,@0590@JRA!4E"&H*$-048:@H@Q!11F"BC($6]0??2N4\AMO
M%_NC_PA%13TWJ"A#L$5!_QGQ3T49\N^_ !0S9RG^,S7,     $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>image_2a.jpg
<TEXT>
begin 644 image_2a.jpg
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M8,"  0,>%>!X9]W%@ $#!@P8,&# HP(<#W \P/$ QSMK9\ Q7, +!#@>X'B
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MX'B XP&.!S@>X'B XP&.!S@>X'B XP&.!SC>%V"U AP/<#S \0#' QP/<#S
>\=Z!7YST 1P_KSR:MKHGP^LO     $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>image_3a.jpg
<TEXT>
begin 644 image_3a.jpg
MB5!.1PT*&@H    -24A$4@   !@   "W" 8    (/9[#    "7!(67,  $SE
M  !,Y0%USO"5    ;$E$051XG.W-L0T (0P L<S"0K__'J#O$D3!""F0?-+5
MCAA?=3S77Z<
M                             &\!F5D=WZ*:V]9(JIHM!7.V     $E%
&3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140564693687456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 14, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">BARINTHUS BIOTHERAPEUTICS PLC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">X0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">00-0000000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Unit 6-10, Zeus Building<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Rutherford Avenue<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Harwell,Didcot<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">OX11 0DF<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">GB<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">+44 (0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">1865 818 808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 79.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,921,212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Portions of the registrant&#8217;s definitive proxy statement to be filed with the Securities and Exchange Commission relative to the registrant&#8217;s 2024 Annual Meeting of Shareholders are incorporated by reference into Items 10, 11, 12, 13 and 14 of Part III of this Annual Report on Form 10-K.</span></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001828185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Ordinary shares, nominal value &#163;0.000025 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=brns_AmericanDepositarySharesMember', window );">American Depositary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">American Depositary Shares<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BRNS<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=brns_AmericanDepositarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=brns_AmericanDepositarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140564694483872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">876<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">PricewaterhouseCoopers LLP<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">United Kingdom<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Audit Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140564687236672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 142,090<span></span>
</td>
<td class="nump">$ 194,385<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_ResearchAndDevelopmentIncentivesReceivable', window );">Research and development incentives receivable</a></td>
<td class="nump">4,908<span></span>
</td>
<td class="nump">4,541<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">9,907<span></span>
</td>
<td class="nump">8,268<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">156,905<span></span>
</td>
<td class="nump">213,041<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">12,209<span></span>
</td>
<td class="nump">12,209<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">11,821<span></span>
</td>
<td class="nump">7,957<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">25,108<span></span>
</td>
<td class="nump">28,269<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use assets, net</a></td>
<td class="nump">7,581<span></span>
</td>
<td class="nump">7,753<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssets', window );">Other assets</a></td>
<td class="nump">882<span></span>
</td>
<td class="nump">976<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">214,506<span></span>
</td>
<td class="nump">270,205<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,601<span></span>
</td>
<td class="nump">3,748<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">9,212<span></span>
</td>
<td class="nump">8,061<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability - current</a></td>
<td class="nump">1,785<span></span>
</td>
<td class="nump">433<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">12,598<span></span>
</td>
<td class="nump">12,242<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability - non-current</a></td>
<td class="nump">11,191<span></span>
</td>
<td class="nump">8,340<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration</a></td>
<td class="nump">1,823<span></span>
</td>
<td class="nump">1,711<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">1,325<span></span>
</td>
<td class="nump">965<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_DeferredTaxLiabilityNet', window );">Deferred tax liability, net</a></td>
<td class="nump">574<span></span>
</td>
<td class="nump">3,746<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">27,511<span></span>
</td>
<td class="nump">27,004<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 16)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Ordinary shares, &#163;0.000025 nominal value; 38,643,540 shares authorized, issued and outstanding (December&#160;31, 2022: authorized, issued and outstanding: 37,683,531)</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">386,602<span></span>
</td>
<td class="nump">379,504<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(176,590)<span></span>
</td>
<td class="num">(103,243)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax', window );">Accumulated other comprehensive loss &#8211; foreign currency translation adjustments</a></td>
<td class="num">(23,315)<span></span>
</td>
<td class="num">(33,460)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity attributable to Barinthus Biotherapeutics plc shareholders</a></td>
<td class="nump">186,784<span></span>
</td>
<td class="nump">242,896<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interest</a></td>
<td class="nump">211<span></span>
</td>
<td class="nump">305<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">186,995<span></span>
</td>
<td class="nump">243,201<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">214,506<span></span>
</td>
<td class="nump">270,205<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=brns_DeferredShares.Member', window );">Deferred A shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_DeferredStockValueIssued', window );">Deferred shares</a></td>
<td class="nump">86<span></span>
</td>
<td class="nump">86<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=brns_DeferredBSharesMember', window );">Deferred B shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_DeferredStockValueIssued', window );">Deferred shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=brns_DeferredCSharesMember', window );">Deferred C shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_DeferredStockValueIssued', window );">Deferred shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember', window );">Nonrelated parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">323<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 5,524<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:5.75pt">Indicates amount less than one thousand</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_DeferredStockValueIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued deferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_DeferredStockValueIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_DeferredTaxLiabilityNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of classified as non-current liabilities, net value of deferred tax liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_DeferredTaxLiabilityNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_ResearchAndDevelopmentIncentivesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of research and development incentives receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_ResearchAndDevelopmentIncentivesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated adjustment, net of tax, that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency translation gains or losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482736/825-10-45-5A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479668/805-30-25-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479613/805-30-35-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 41: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-15<br><br>Reference 42: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-16<br><br>Reference 43: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=brns_DeferredShares.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=brns_DeferredShares.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=brns_DeferredBSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=brns_DeferredBSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=brns_DeferredCSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=brns_DeferredCSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140564693337616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - &#163; / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares, nominal value (in gbp per share)</a></td>
<td class="nump">&#163; 0.000025<span></span>
</td>
<td class="nump">&#163; 0.000025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, authorized (in shares)</a></td>
<td class="nump">38,643,540<span></span>
</td>
<td class="nump">37,683,531<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares, issued (in shares)</a></td>
<td class="nump">38,643,540<span></span>
</td>
<td class="nump">37,683,531<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ordinary shares, outstanding (in shares)</a></td>
<td class="nump">38,643,540<span></span>
</td>
<td class="nump">37,683,531<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=brns_DeferredShares.Member', window );">Deferred A shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_DeferredStockParOrStatedValuePerShare', window );">Deferred shares, nominal value (in gbp per share)</a></td>
<td class="nump">&#163; 1<span></span>
</td>
<td class="nump">&#163; 1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_DeferredStockSharesAuthorized', window );">Deferred shares, authorized (in shares)</a></td>
<td class="nump">63,443<span></span>
</td>
<td class="nump">63,443<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_DeferredStockSharesIssued', window );">Deferred shares, issued (in shares)</a></td>
<td class="nump">63,443<span></span>
</td>
<td class="nump">63,443<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_DeferredStockSharesOutstanding', window );">Deferred shares, outstanding (in shares)</a></td>
<td class="nump">63,443<span></span>
</td>
<td class="nump">63,443<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=brns_DeferredBSharesMember', window );">Deferred B shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_DeferredStockParOrStatedValuePerShare', window );">Deferred shares, nominal value (in gbp per share)</a></td>
<td class="nump">&#163; 0.01<span></span>
</td>
<td class="nump">&#163; 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_DeferredStockSharesAuthorized', window );">Deferred shares, authorized (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">570,987<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_DeferredStockSharesIssued', window );">Deferred shares, issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">570,987<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_DeferredStockSharesOutstanding', window );">Deferred shares, outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">570,987<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=brns_DeferredCSharesMember', window );">Deferred C shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_DeferredStockParOrStatedValuePerShare', window );">Deferred shares, nominal value (in gbp per share)</a></td>
<td class="nump">&#163; 0.000007<span></span>
</td>
<td class="nump">&#163; 0.000007<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_DeferredStockSharesAuthorized', window );">Deferred shares, authorized (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">27,828,231<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_DeferredStockSharesIssued', window );">Deferred shares, issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">27,828,231<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_DeferredStockSharesOutstanding', window );">Deferred shares, outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">27,828,231<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_DeferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of deferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_DeferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_DeferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of deferred shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_DeferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_DeferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of deferred shares of an entity that have been sold or granted to shareholders</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_DeferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_DeferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of deferred stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_DeferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=brns_DeferredShares.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=brns_DeferredShares.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=brns_DeferredBSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=brns_DeferredBSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=brns_DeferredCSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=brns_DeferredCSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140564693281696">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 802<span></span>
</td>
<td class="nump">$ 44,703<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">44,874<span></span>
</td>
<td class="nump">42,350<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">39,842<span></span>
</td>
<td class="nump">6,394<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">84,716<span></span>
</td>
<td class="nump">48,744<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(83,914)<span></span>
</td>
<td class="num">(4,041)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other income /(expense):</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,877<span></span>
</td>
<td class="nump">3,103<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(28)<span></span>
</td>
<td class="num">(19)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_ResearchAndDevelopmentIncentiveIncomeExpense', window );">Research and development incentives</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,461<span></span>
</td>
<td class="nump">1,240<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,082<span></span>
</td>
<td class="nump">567<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,392<span></span>
</td>
<td class="nump">4,891<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">(Loss)/profit before income tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(76,522)<span></span>
</td>
<td class="nump">850<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Tax benefit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,075<span></span>
</td>
<td class="nump">4,471<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net (loss)/income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(73,447)<span></span>
</td>
<td class="nump">5,321<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to noncontrolling interest</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">100<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss)/income attributable to Barinthus Biotherapeutics plc shareholders</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (73,347)<span></span>
</td>
<td class="nump">$ 5,342<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average ordinary shares outstanding, basic (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">38,386,491<span></span>
</td>
<td class="nump">37,248,126<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average ordinary shares outstanding, diluted (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">38,386,491<span></span>
</td>
<td class="nump">38,169,307<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net (loss)/income per share attributable to ordinary shareholders, basic (in usd per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (1.91)<span></span>
</td>
<td class="nump">$ 0.14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net (loss)/income per share attributable to ordinary shareholders, diluted (in usd per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (1.91)<span></span>
</td>
<td class="nump">$ 0.14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net (loss)/income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (73,447)<span></span>
</td>
<td class="nump">$ 5,321<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Other comprehensive gain/(loss) &#8211; foreign currency translation adjustments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10,151<span></span>
</td>
<td class="num">(25,083)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(63,296)<span></span>
</td>
<td class="num">(19,762)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Comprehensive loss attributable to noncontrolling interest</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">94<span></span>
</td>
<td class="nump">132<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss attributable to Barinthus Biotherapeutics plc shareholders</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(63,202)<span></span>
</td>
<td class="num">(19,630)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">802<span></span>
</td>
<td class="nump">44,694<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=brns_ResearchGrantsAndContractsMember', window );">Research grants and contracts</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:5.75pt">Includes <span style="-sec-ix-hidden:f-192"><span style="-sec-ix-hidden:f-193">license revenue</span></span> from related parties for the year ended December&#160;31, 2023 totaling $0.8&#160;million (December&#160;31, 2022: $43.7&#160;million). License revenue is generated in the United Kingdom. </span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_ResearchAndDevelopmentIncentiveIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the research and development incentives (expenses) for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_ResearchAndDevelopmentIncentiveIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=brns_ResearchGrantsAndContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=brns_ResearchGrantsAndContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140564687897152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized</a></td>
<td class="nump">$ 802<span></span>
</td>
<td class="nump">$ 44,703<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized</a></td>
<td class="nump">$ 800<span></span>
</td>
<td class="nump">$ 43,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList', window );">Revenue from Contract with Customer, Product and Service [Extensible Enumeration]</a></td>
<td class="text">License revenue<span></span>
</td>
<td class="text">License revenue<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates product and service for revenue from satisfaction of performance obligation by transferring promised product and service to customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140564792809424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Total stockholders&#8217; equity attributable to Barinthus Biotherapeutics plc stockholders</div></th>
<th class="th" colspan="2"><div>Ordinary Shares</div></th>
<th class="th">
<div>Deferred Shares </div>
<div>Deferred A Shares</div>
</th>
<th class="th">
<div>Deferred Shares </div>
<div>Deferred B Shares</div>
</th>
<th class="th" colspan="2">
<div>Deferred Shares </div>
<div>Deferred C Shares</div>
</th>
<th class="th"><div>Additional Paid-in-capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Noncontrolling Interest</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,188,730<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">63,443<span></span>
</td>
<td class="nump">570,987<span></span>
</td>
<td class="nump">27,828,231<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 252,562<span></span>
</td>
<td class="nump">$ 252,125<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 86<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 369,103<span></span>
</td>
<td class="num">$ (108,585)<span></span>
</td>
<td class="num">$ (8,488)<span></span>
</td>
<td class="nump">$ 437<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share based compensation</a></td>
<td class="nump">9,877<span></span>
</td>
<td class="nump">9,877<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">9,877<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Issue of ordinary shares, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">494,801<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Issue of ordinary shares, net of issuance costs</a></td>
<td class="nump">484<span></span>
</td>
<td class="nump">484<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="num">(25,083)<span></span>
</td>
<td class="num">(24,972)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24,972)<span></span>
</td>
<td class="num">(111)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_AdjustmentsToAdditionalPaidInCapitalMeasurementPeriodAdjustmentsInBusinessCombination', window );">Measurement period and contingent consideration adjustments</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net (loss)/income</a></td>
<td class="nump">5,321<span></span>
</td>
<td class="nump">5,342<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,342<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,683,531<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">63,443<span></span>
</td>
<td class="nump">570,987<span></span>
</td>
<td class="nump">27,828,231<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2022</a></td>
<td class="nump">243,201<span></span>
</td>
<td class="nump">242,896<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 86<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">379,504<span></span>
</td>
<td class="num">(103,243)<span></span>
</td>
<td class="num">(33,460)<span></span>
</td>
<td class="nump">305<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share based compensation</a></td>
<td class="nump">5,055<span></span>
</td>
<td class="nump">5,055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5,055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Issue of ordinary shares, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">960,009<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Issue of ordinary shares, net of issuance costs</a></td>
<td class="nump">2,035<span></span>
</td>
<td class="nump">2,035<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="nump">10,151<span></span>
</td>
<td class="nump">10,145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,145<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_SharesCancelledDuringPeriodSharesDeferredShares', window );">Cancellation of deferred shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(570,987)<span></span>
</td>
<td class="num">(27,828,231)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_SharesCancelledDuringPeriodValueDeferredShares', window );">Cancellation of deferred shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net (loss)/income</a></td>
<td class="num">(73,447)<span></span>
</td>
<td class="num">(73,347)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(73,347)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(100)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,643,540<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">63,443<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2023</a></td>
<td class="nump">$ 186,995<span></span>
</td>
<td class="nump">$ 186,784<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 86<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 386,602<span></span>
</td>
<td class="num">$ (176,590)<span></span>
</td>
<td class="num">$ (23,315)<span></span>
</td>
<td class="nump">$ 211<span></span>
</td>
</tr>
<tr><td colspan="13"></td></tr>
<tr><td colspan="13"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:5.75pt">Indicates amount less than one thousand</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_AdjustmentsToAdditionalPaidInCapitalMeasurementPeriodAdjustmentsInBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) to additional paid in capital (APIC) resulting from measurement period adjustment in business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_AdjustmentsToAdditionalPaidInCapitalMeasurementPeriodAdjustmentsInBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_SharesCancelledDuringPeriodSharesDeferredShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares Cancelled During Period, Shares, Deferred Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_SharesCancelledDuringPeriodSharesDeferredShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_SharesCancelledDuringPeriodValueDeferredShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares Cancelled During Period, Value, Deferred Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_SharesCancelledDuringPeriodValueDeferredShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 41: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-15<br><br>Reference 42: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-16<br><br>Reference 43: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140564808264736">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net (loss)/income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (73,447)<span></span>
</td>
<td class="nump">$ 5,321<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net (loss)/income to net cash used in operating activities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,055<span></span>
</td>
<td class="nump">9,877<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,429<span></span>
</td>
<td class="nump">4,323<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_NonCashLeaseExpenses', window );">Non-cash lease expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,328<span></span>
</td>
<td class="nump">1,216<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized', window );">Unrealized foreign exchange loss/(gain)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,531<span></span>
</td>
<td class="num">(24,905)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in contingent consideration</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">55<span></span>
</td>
<td class="num">(73)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_NonCashInterestExpenseOnConvertibleLoanNotes', window );">Non cash interest expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">28<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred tax expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(3,075)<span></span>
</td>
<td class="num">(4,337)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Profit on sale of property and equipment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(348)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable (including related parties)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,800<span></span>
</td>
<td class="num">(5,833)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,200<span></span>
</td>
<td class="num">(2,170)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable', window );">Research and development incentives receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(127)<span></span>
</td>
<td class="nump">1,158<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(3,378)<span></span>
</td>
<td class="nump">1,140<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,993<span></span>
</td>
<td class="nump">751<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(183)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(445)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">128<span></span>
</td>
<td class="num">(387)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(50,925)<span></span>
</td>
<td class="num">(14,431)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of property and equipment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">388<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(5,413)<span></span>
</td>
<td class="num">(6,138)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(5,413)<span></span>
</td>
<td class="num">(5,750)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Issue of shares from the exercise of stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issue of ordinary shares, net of issuance costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,035<span></span>
</td>
<td class="nump">484<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Payment of contingent consideration</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(163)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfShortTermDebt', window );">Repayment of debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(159)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,872<span></span>
</td>
<td class="nump">325<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Effect of exchange rates on cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,171<span></span>
</td>
<td class="nump">187<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(52,295)<span></span>
</td>
<td class="num">(19,669)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of the year</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">194,385<span></span>
</td>
<td class="nump">214,054<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of the year</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">142,090<span></span>
</td>
<td class="nump">194,385<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental cash flow disclosures:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for income taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-Cash investing and financing activities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchases of property and equipment included in accounts payable and accrued liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">87<span></span>
</td>
<td class="nump">559<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">ROU assets obtained in exchange for operating lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,400<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_AssetRetirementObligations', window );">Asset retirement obligation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">287<span></span>
</td>
<td class="nump">999<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_ChangesToRightOfUseAssetResultingFromLeaseReassessmentEvent', window );">Changes to right-of-use asset resulting from lease reassessment event</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">88<span></span>
</td>
<td class="num">(207)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_NonCashInvestingAndFinancingActivityOfMeasurementPeriodAdjustments', window );">Measurement period adjustments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(38)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_ContingentConsiderationSettledInEquity', window );">Contingent Consideration settled in equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 78<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:5.75pt">Indicates amount less than one thousand</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_AssetRetirementObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset retirement obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_AssetRetirementObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_ChangesToRightOfUseAssetResultingFromLeaseReassessmentEvent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of changes to right-of-use asset resulting from lease reassessment event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_ChangesToRightOfUseAssetResultingFromLeaseReassessmentEvent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_ContingentConsiderationSettledInEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contingent consideration settled in equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_ContingentConsiderationSettledInEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in research and development incentives receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_NonCashInterestExpenseOnConvertibleLoanNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of non-cash interest expense on convertible loan notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_NonCashInterestExpenseOnConvertibleLoanNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_NonCashInvestingAndFinancingActivityOfMeasurementPeriodAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of on cash investing and financing activity of measurement period adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_NonCashInvestingAndFinancingActivityOfMeasurementPeriodAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_NonCashLeaseExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-cash lease expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_NonCashLeaseExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-6<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481956/830-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481926/830-20-50-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossUnrealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482312/912-310-45-11<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (f)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140564689998128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Nature of Business and Basis of Presentation</a></td>
<td class="text">Nature of Business and Basis of Presentation<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Nature of business</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Barinthus Biotherapeutics plc (formerly Vaccitech plc) is a public limited company incorporated pursuant to the laws of England and Wales in March 2021. Barinthus Biotherapeutics plc and its direct and indirect subsidiaries, Barinthus Biotherapeutics (UK) Limited (formerly Vaccitech (UK) Limited), Barinthus Biotherapeutics Australia Pty Limited (formerly Vaccitech Australia Pty Limited), Vaccitech Oncology Limited (&#8220;VOLT&#8221;), Barinthus Biotherapeutics North America, Inc. (formerly Vaccitech North America, Inc.), Barinthus Biotherapeutics Switzerland GmbH (formerly Vaccitech Switzerland GmbH) and Barinthus Biotherapeutics S.R.L. (formerly Vaccitech Italia S.R.L.), are collectively referred to as the &#8220;Company&#8221; or &#8220;Barinthus Bio&#8221;. The Company is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity and cancer. The Company is headquartered in Harwell, Oxfordshire, United Kingdom. On November 6, 2023, the Company announced its renaming as Barinthus Bio to represent the evolution and expansion of its focus beyond vaccines.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In connection with the initial public offering of American Depositary Shares (&#8220;ADSs&#8221;), in March 2021, the Company completed a corporate reorganization wherein the shareholders of Barinthus Biotherapeutics (UK) Limited exchanged each of their ordinary shares, series A shares and series B shares of Barinthus Biotherapeutics (UK) Limited for the same quantity of ordinary shares, series A shares and series B shares in Barinthus Biotherapeutics plc (resulting in the shareholders of the Company holding the same percentage and class of shares in Barinthus Biotherapeutics plc as they had in Barinthus Biotherapeutics (UK) Limited). The group reorganization under common control constituted a change in reporting entity and has been given retrospective effect reflecting the net assets of Barinthus Biotherapeutics (UK) Limited and its subsidiaries and Barinthus Biotherapeutics plc at their historical carrying amounts. On April 4, 2022, a merger was effected between subsidiaries Vaccitech USA, Inc. and Barinthus Biotherapeutics North America, Inc., with Barinthus Biotherapeutics North America, Inc. being the surviving entity.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company operates in an environment of rapid technological change and substantial competition from pharmaceutical and biotechnology companies. The Company is subject to risks common to companies in the biopharmaceutical industry in a similar stage of its life cycle including, but not limited to, the need to obtain adequate additional funding, possible failure of preclinical testing or clinical trials, the need to obtain marketing approval for its vaccine product candidates, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of any of its products that are approved, and protection of proprietary technology. There can be no assurance that the Company&#8217;s research and development will be successfully completed, that adequate protection for the Company&#8217;s intellectual property will be obtained, that any products developed will obtain required regulatory approval or that any approved products will be commercially viable. Even if the Company&#8217;s development efforts are successful, it is uncertain when, if ever, the Company will generate significant product sales. If the Company does not successfully commercialize any of its products or mitigate any of these other risks, it will be unable to generate revenue or achieve profitability.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Basis of presentation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and pursuant to the rules and regulations of the Securities and Exchange Commission for annual financial reporting. The Company&#8217;s reporting currency is the U.S. dollar. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2023, the Company had cash and cash equivalents of $142.1 million and an accumulated deficit of $176.6 million and the Company expects to incur losses for the foreseeable future. The Company expects that its cash and cash equivalents will be sufficient to fund current operations into the fourth quarter of 2025, without additional financing. The Company expects to seek additional funding through equity financing, government or private-party grants, debt financings or other capital sources, including collaborations with other companies or other strategic transactions. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into collaborations or other arrangements. The terms of any financing may adversely affect the holdings or rights of the Company&#8217;s stockholders. If the Company is unable to obtain sufficient capital, the Company will be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or future commercialization efforts, which could adversely affect its business prospects, or the Company may be unable to continue operations. Although management continues to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations, if at all.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates, among other things, the realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Guarantees and indemnifications</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As permitted under the laws of England and Wales, the Company indemnifies its officers, directors, consultants and employees for certain events or occurrences that happen by reason of the relationship with, or position held at, the Company. Through the years ended December&#160;31, 2023 and 2022, the Company had not experienced any losses related to these indemnification obligations, and no claims were outstanding. The Company does not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and no related reserves were established.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Use of estimates</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue, income and expenses during the reporting period. The Company bases estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions on an ongoing basis, including those related to fair value of contingent consideration and impairment of goodwill and intangible assets. The Company&#8217;s actual results may differ from these estimates under different assumptions or conditions.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of the date of issuance of these consolidated financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update its estimates, assumptions and judgments or revise the carrying value of its assets or liabilities. These estimates may change as new events occur and additional information is obtained and are recognized in the consolidated financial statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to the Company&#8217;s financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140564694407680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Principles of consolidation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The accompanying consolidated financial statements include the accounts of Barinthus Biotherapeutics plc and those entities in which it has a controlling interest. Intercompany amounts are eliminated on consolidation. Amounts attributable to the noncontrolling interest are presented as a separate element of equity in the accompanying consolidated financial statements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Comprehensive loss</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Comprehensive loss for all periods presented is comprised primarily of net (loss)/income and other comprehensive loss, which solely relates to foreign currency translation adjustments.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Foreign currency translation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company&#8217;s reporting currency is the United States dollar. The functional currency of the parent and each subsidiary is the currency of the country and economic environment in which it is located. Assets and liabilities of each legal entity denominated or measured in a currency other than British Pounds are first translated into British pounds and consolidated. The consolidated balances are then converted into United States dollars at period-end exchange rates. Revenues and expenses are translated into British pounds, then into U.S. dollars at average exchange rates for each reporting period. Translation adjustments are reflected as accumulated other comprehensive loss within stockholders&#8217; equity. Gains and losses on foreign currency transactions are included in the consolidated statements of operations and comprehensive loss in the general and administrative expenses. The aggregate net foreign exchange gain or loss included in determining net loss was a loss of $7.6 million and gain of $26.4 million for the years ended December&#160;31, 2023 and 2022, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Segment information</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, the Company&#8217;s Chief Executive Officer, in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one operating segment, the research and development of immunotherapies and vaccines.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Noncontrolling interest</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In 2018, Barinthus Biotherapeutics plc established VOLT with a related party. As of December&#160;31, 2021, Barinthus Biotherapeutics plc had contributed cash and intellectual property with an aggregate value of $11.9 million for a 76% controlling interest. The related party had contributed cash and intellectual property with an aggregate value of $3.8 million for a 24% noncontrolling interest. There were no further contributions in the years ended December&#160;31, 2023 and 2022. The contributed intellectual properties were initially recorded at investment date fair value by VOLT and immediately expensed as research and development costs. The Company accounts for the noncontrolling interest in the accompanying consolidated financial statements initially at fair value with the subsequent carrying value adjusted for the noncontrolling share of VOLT&#8217;s comprehensive loss.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Business Combinations</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company accounts for business combinations using the acquisition method of accounting, which requires the recognition of tangible and identifiable intangible assets acquired and liabilities assumed at their estimated fair values as of the business combination date. The Company allocates any excess purchase price over the estimated fair value assigned to the net tangible and identifiable intangible assets acquired and liabilities assumed to goodwill. Contingent consideration is included within the acquisition cost and is recognized at its fair value on the acquisition date. A liability resulting from contingent consideration is remeasured to fair value at each reporting date until the contingency is resolved and changes in fair value are recognized in general and administrative expenses in the consolidated statements of operations and comprehensive loss. Transaction costs are expensed as incurred in general and administrative expenses. Results of operations and cash flows of acquired companies are included in the Company&#8217;s operating results from the date of acquisition.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Cash and cash equivalents</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company considers all highly liquid investments purchased with remaining maturities of three months or less on the purchase date to be cash and cash equivalents. Cash and cash equivalents include bank demand deposits and money market funds that are actively traded (a Level 1 input). As of December&#160;31, 2023, and 2022 there were no cash equivalents.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Revenue</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has entered into collaboration and license agreements, which are within the scope of Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, to discover, develop, manufacture and commercialize product candidates. The terms of these agreements typically contain multiple promises or obligations, which may include licenses, or options to obtain licenses, to product candidates or future product candidates. The Company also derives revenue from government grants.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Amounts received prior to revenue recognition are recorded as deferred revenue. Amounts expected to be recognized as revenue within the 12 months following the balance sheet date are classified as current portion of deferred revenue in the accompanying consolidated balance sheets. Amounts recognized as revenue, but not yet received or invoiced are generally recognized as accounts receivable.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">License revenue</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company&#8217;s arrangements may provide the collaboration partner with the right to select a target for licensing either at the inception of the arrangement or in the future. Under these arrangements, fees may be due to the Company (i) at the inception of the arrangement as an upfront fee or payment, (ii) upon the exercise of an option to acquire a license or (iii) </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">upon extending the selection period as an extension fee or payment. If an arrangement is determined to contain customer options that allow the customer to acquire additional goods or services, the goods and services underlying the customer options are not considered to be performance obligations at the outset of the arrangement, as they are contingent upon option exercise. The Company evaluates the customer options for material rights, or options to acquire additional goods or services for fee or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the inception of the arrangement. The Company allocates the transaction price to material rights based on the relative standalone selling price, which is determined based on the identified discount and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised or expires.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For arrangements that include sales-based milestones and royalties, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). This could require management to estimate the amount of revenue to recognize in the period if the actual data for the period has not been provided.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Research and development services</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The promises under the Company&#8217;s collaboration and license agreements generally include research and development services to be performed by the Company on behalf of the collaboration partner. For performance obligations that include research and development services, the Company recognizes revenue allocated to such performance obligations based on an appropriate measure of progress. The Company utilizes judgment to determine the appropriate method of measuring progress for the purposes of recognizing revenue, which may include an input measure such as costs incurred during the reporting period or ratably over the service period. Reimbursements from the partner are evaluated as to whether the Company acts as a principal or an agent in such relationships. The Company evaluates whether control over the underlying goods or services were obtained prior to transferring these goods or services to the collaboration partner. Where the Company does not control the goods or services prior to transferring these goods or services to the collaboration partner, such reimbursements are presented net of costs. At the inception of each arrangement that includes development milestone payments in respect of development efforts, the Company evaluates whether the development milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated development milestone value is included in the transaction price. Development milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular development milestone in making this assessment. There is judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each reporting period, the Company reevaluates the probability of achievement of all development milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. If a milestone or other variable consideration relates specifically to the Company&#8217;s efforts to satisfy a single performance obligation or to a specific outcome from satisfying the performance obligation, the Company generally allocates the milestone amount entirely to that performance obligation once it is probable that a significant revenue reversal would not occur. To date, the Company has not recognized any development milestone revenue resulting from any of its arrangements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Grant income</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company receives certain grant income which support its research efforts in defined projects and include contributions towards the research and development costs. When there is reasonable assurance that the Company will comply with the conditions attached to a received grant, and when there is reasonable assurance that the grant will be received, grant income is recognized as other operating income on a gross basis in the consolidated statements of operations and comprehensive loss on a systematic basis over the periods in which the Company recognizes expenses for the related costs for which the grants are intended to compensate. Grant income may be subject to review by the grantor in periods subsequent to its recognition and may result in the reversal of grant income previously recognized. Payments received in advance of incurring reimbursable expenses are recorded as deferred income.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Concentrations of credit risk</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash and cash equivalents and accounts receivable. Periodically, the Company maintains deposits in financial institutions in excess of government insured limits. Management believes that the Company is not exposed to significant credit risk as the Company&#8217;s deposits are held at financial institutions that management believes to be of high credit quality and the Company has not experienced any losses in these deposits. The Company&#8217;s standard payment terms are 30 days&#8217;.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company recognizes revenue earned in connection with the license and services provided to customers and grantors. The Company provides credit to the grantors in the normal course of providing such services based on evaluations of their financial condition and generally does not require collateral. To manage accounts receivable credit risk, the Company monitors the creditworthiness of its grantors. Historically, the Company has not experienced any credit losses related to accounts receivable and does not maintain allowances for uncollectible amounts.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Licensees and grantors that represented 10% of more of the Company&#8217;s revenue and accounted for 10% or more of accounts receivable are presented below:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.606%"><tr><td style="width:1.0%"></td><td style="width:53.767%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.820%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.507%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.298%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.507%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.301%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Revenue</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Country</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year ended<br/>December 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year ended<br/>December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Oxford University Innovation</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">U.K.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">100&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">98&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.000%"><tr><td style="width:1.0%"></td><td style="width:53.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.912%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.513%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.408%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.513%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.409%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Accounts Receivable</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Country</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">As of<br/>December 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">As of<br/>December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Oxford University Innovation</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">U.K.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">94&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Allowance for credit losses</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company evaluates its cash equivalents and accounts receivable for expected credit losses. Expected credit losses represent the portion of the amortized cost basis of a financial asset that an entity does not expect to collect. An allowance for expected credit losses is meant to reflect a risk of loss even if remote, irrespective of the expectation of collection from a particular issuer or debt security. The Company has not historically experienced any credit losses on any of its financial assets. With respect to cash equivalents and accounts receivable, given consideration of their short maturity, historical losses and the current market environment, the Company concluded there are no expected credit losses for these financial assets.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Property and equipment</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Property and equipment are stated at cost, net of accumulated depreciation. Expenditures for maintenance and repairs are charged to operating expenses as incurred, whereas major betterments are capitalized as additions to property and equipment. Depreciation is recorded using the straight-line method over the estimated useful lives of the assets as follows:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.787%"><tr><td style="width:1.0%"></td><td style="width:73.323%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.477%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Asset Category</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Estimated Useful Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Office furniture and equipment</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Laboratory equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Lesser of lease term or estimated useful lives</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Intangible assets acquired through business combinations</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Intangible assets consist of acquired developed technology. Intangible assets are stated at cost less accumulated amortization and impairment losses. Amortization is computed using the straight-line method over the estimated useful lives of the respective assets, which is 10 years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Impairment of long-lived assets</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company reviews long-lived assets to be held and used, including property and equipment, intangible assets and operating lease right-of-use assets, for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets or asset group may not be recoverable. Evaluation of recoverability is first based on an estimate of undiscounted future cash flows resulting from the use of the asset or asset group and its eventual disposition. In the event such cash flows are not expected to be sufficient to recover the carrying amount of the asset or asset group, the assets are written down to their estimated fair values. No such impairments were recorded during the years ended December&#160;31, 2023 and 2022.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Goodwill</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Goodwill represents the excess of cost over the fair value of the net tangible and intangible assets of businesses acquired in a business combination. Goodwill is not amortized but rather is tested for impairment at least annually, or more frequently if events or changes in circumstances indicate that the carrying amount of goodwill may not be recoverable. The Company has elected to first assess the qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount as a basis of determining whether it is necessary to perform the quantitative goodwill impairment test. If the Company determines that it is more likely than not that its fair value is less than its carrying amount, then the quantitative goodwill impairment test will be performed. The quantitative goodwill impairment test identifies goodwill impairment and measures the amount of goodwill impairment loss to be recognized by comparing the fair value of a reporting unit with its carrying amount. If the fair value exceeds the carrying amount, no further analysis is required; otherwise, any excess of the goodwill carrying amount over the implied fair value is recognized as an impairment loss, and the carrying value of goodwill is written down to fair value. For the years ended December&#160;31, 2023 and 2022, goodwill has been tested, and no impairments have been recorded.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Financial instruments</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company&#8217;s financial instruments consist of cash and cash equivalents, accounts receivable, accounts payable, certain accrued expenses, contingent consideration and short-term debt. The carrying amounts of cash, cash equivalents, accounts receivable, security deposits, accounts payable, accrued expenses and short-term debt approximate their fair value due to the short-term nature of those financial instruments.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Fair value measurements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company follows the guidance in ASC 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Fair Value Measurements and Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, which defines fair value and establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are described below:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.67pt">Level 1 &#8211; Inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.67pt">Level 2 &#8211; Valuations based on quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.67pt">Level 3 &#8211; Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Fair value is a market-based measure considered from the perspective of a market participant rather than an entity-specific measure. Therefore, even when market assumptions are not readily available, the Company&#8217;s own assumptions are set to reflect those that market participants would use in pricing the asset or liability at the measurement date. The Company uses prices and inputs that are current as of the measurement date, including during periods of market dislocation. In periods of market dislocation, the observability of prices and inputs may change for many instruments. This condition could cause an </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">instrument to be reclassified within levels in the fair value hierarchy. There were no transfers within the fair value hierarchy during the years ended December&#160;31, 2023 and 2022.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company recognizes a contingent consideration liability related to the acquisition of Avidea Technologies, Inc. The liability is remeasured to fair value at each reporting date until the contingency is resolved. The fair value of the contingent consideration is a Level 3 valuation determined using significant unobservable inputs being the probability of success of achievement of the milestones and the expected date of the milestone achievement. Changes in fair value are recognized in general and administrative expenses in the consolidated statements of operations and comprehensive loss.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Leases</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Leases are accounted for under ASC 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(&#8220;ASC 842&#8221;) resulting in the recognition of lease liabilities and right-of-use assets. The Company only has operating leases. The Company has elected the practical expedient allowed under ASC 842 to account for each lease component (e.g., the right to use office space) and the associated non-lease components (e.g., maintenance services) as a single lease component. The Company also elected the short-term lease accounting policy for all asset classes; therefore, the Company is not recognizing a lease liability or right-of-use asset for any lease that, at the commencement date, has a lease term of 12 months or less and does not include an option to purchase the underlying asset that the Company is reasonably certain to exercise.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Variable lease payments such as the Company&#8217;s share of real estate taxes, utilities, and common area maintenance, are reported as non-lease operating expenses.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Right-of-use assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Right-of-use assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. As the Company&#8217;s leases typically do not provide an implicit rate, the Company uses an estimate of its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Right-of-use assets also include the effect of any lease payments made and exclude lease incentives. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized as part of total operating expenses on a straight-line basis over the lease term. The difference between the value of the right of use asset and lease liability is due to the reclassification of prepaid rent and unamortized lease incentives.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Research and development</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Research and development costs are expensed as incurred on an accruals basis. Research and development costs include payroll and personnel expense (including share-based compensation), consulting costs, external contract research and development expenses, raw materials, drug product manufacturing costs, and allocated overheads including depreciation and amortization, facility costs, and utilities. Research and development costs that are paid in advance of performance are capitalized as a prepaid expense and amortized over the service period as the services are provided.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Clinical trial costs</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Clinical trial costs are a component of research and development expenses. The Company accrues and expenses clinical trial activities performed by third parties based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activation, and other information provided to the Company by its vendors.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Patent and licensing costs</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Patent and licensing costs are expensed as incurred because their realization is uncertain.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Ordinary shares</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Ordinary shares are classified in stockholders&#8217; equity and represent issued share capital.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Additional paid-in capital</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additional paid-in capital is classified in stockholders&#8217; equity and represents the share premium account, where the difference between the price paid per share and the nominal value is recognized. The equity element of share based compensation is also recognized in additional paid in capital.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Share based compensation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company grants options over ordinary shares and restricted shares units to employees or Non-Executive Directors and accounts for share based compensation using the grant date fair value. Share based compensation awards are classified in the accompanying statements of operations based on the function to which the related services are provided. For service-based awards, compensation expense is generally recognized over the requisite service period of the awards, usually the vesting period. The Company applies the &#8220;multiple option&#8221; method of allocating expense. In applying this method, each vesting tranche of an award is treated as a separate grant and recognized on a straight-line basis over that tranche&#8217;s vesting period. For performance-based awards where the vesting of the awards may be accelerated upon the achievement of certain milestones, vesting and the related share-based compensation is recognized as an expense when it is probable the milestone will be met. Assumptions used in the option pricing model include the following:</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Expected volatility.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Previously there was insufficient trading history for the Company&#8217;s ordinary shares, therefore the expected price volatility for our ordinary shares was estimated using the average historical volatility of industry peers&#8217; shares as of the grant date of our options over a period of history commensurate with the expected life of the options. When selecting industry peers used in measuring implied volatility, the Company considered the similarity of their products and business lines, as well as their stage of development, size and financial leverage. The Company applied this process consistently using the same or similar public companies until 2023. During 2023, the Company determined that there is sufficient historical information on volatility of its share price available and the expected volatility used in the fair value calculation of new option grants is calculated based on a blended volatility of both historical volatility of the Company's share price and the expected volatility of the average historical volatility of industry peers&#8217; shares.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Expected term</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. The expected term of the Company&#8217;s share options has been determined utilizing the &#8220;simplified&#8221; method for awards that qualify as &#8220;plain-vanilla&#8221; options. The &#8220;simplified&#8221; method was determined to be appropriate as the Company does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term due to the limited period of time its equity shares have been publicly traded.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Risk-free interest rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods that are approximately equal to the expected term of the award.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Expected dividend.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Expected dividend yield of zero is based on the fact that the Company has never paid cash dividends on ordinary shares and does not expect to pay any cash dividends in the foreseeable future.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has elected to recognize the effect of forfeitures on share-based compensation when they occur. Any differences in compensation recognized at the time of forfeiture are recorded as a cumulative adjustment in the period where the forfeiture occurs.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">When awards are modified, the Company compares the fair value of the affected award measured immediately prior to modification to its value after modification. To the extent that the fair value of the modified award exceeds the original award, the incremental fair value of the modified award is recognized as compensation on the date of modification for vested awards, and over the remaining vesting period for unvested awards.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Income taxes</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The financial statements reflect provisions for income taxes in the United Kingdom and foreign jurisdictions. Deferred tax assets and liabilities represent future tax consequences of temporary differences between the financial statement carrying amounts and the tax basis of assets and liabilities and for loss carryforwards using enacted tax rates expected to be in effect in the years in which the differences reverse. A valuation allowance is recorded when it is more likely than not that some or all of the deferred tax assets will not be realized.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company determines whether it is more likely than not that a tax position will be sustained upon examination. If it is not more likely than not that a position will be sustained, none of the benefit attributable to the position is recognized. The </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">tax benefit to be recognized for any tax position that meets the more-likely-than-not recognition threshold is calculated as the largest amount that is more than 50% likely of being realized upon resolution of the contingency. The Company accounts for interest and penalties related to uncertain tax positions as part of its provision for income taxes. To date, the Company has not incurred interest and penalties related to uncertain tax positions nor has it recorded any unrecognized tax benefits.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Research and development incentives</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the United Kingdom, the Company had previously been entitled to a research and development tax credit regime, being the Small and Medium-sized Enterprises R&amp;D tax relief program, or SME Program, and, to the extent that our projects are grant funded or relate to work subcontracted to us by third parties, the Research and Development Expenditure Credit program, or RDEC Program. Until March 2023, under the SME program, the Company was able to surrender some of its trading losses that arise from qualifying research and development activities for a cash rebate of up to 33.35% of such qualifying research and development expenditure. Qualifying expenditures largely comprise employment costs for research staff, consumables, outsourced contract research organization costs and utilities costs incurred as part of research projects. Certain staff, consumables (including utilities), subcontractors and externally provided workers qualifying research and development expenditures are eligible for a cash rebate of up to 21.67%. A large portion of costs relating to research and development, clinical trials and manufacturing activities are eligible for inclusion within these tax credit cash rebate claims. From April 2023, under the SME program the additional deduction has decreased from 130% to 86%, the SME credit rate has reduced from 14.5% to 10% and the SME cash rebate for the Company has reduced from 33.35% to 18.6% and from 21.67% to 12.1% for subcontractors. Furthermore, the SME credit rate will decrease to 10% for expenditure incurred on or after April 1, 2023 unless the SME qualifies as an R&amp;D intensive business i.e., R&amp;D expenditure constitutes at least 40% (from April 1, 2023) or 30% (from accounting periods starting on or after April 1, 2024) of total expenditure. If the Company incurs tax losses, the Company is entitled to surrender the lesser of unrelieved tax loss sustained and the tax relief. As the realization of the tax relief does not depend on our generation of future taxable income or the Company&#8217;s ongoing tax status or tax position, the Company does not consider the tax relief as an element of income tax accounting under ASC 740, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Income taxes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">and records the tax relief as a form of government grant or assistance. For the years ended December&#160;31, 2023 and 2022, the Company recognized research and development incentives of $3.5 million and $1.2 million respectively. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Net (loss)/income per share</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Basic net (loss)/income per share is computed by dividing the net (loss)/income attributable to ordinary shareholders by the weighted-average number of ordinary shares outstanding for the reporting period without consideration for potentially dilutive securities. Net (loss)/income attributable to ordinary shareholders is computed as if all net (loss)/income for the period had been distributed. During periods in which the Company incurred a net loss, the Company allocates no net loss to participating securities because they do not have a contractual obligation to share in the net loss of the Company.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company computes diluted net (loss)/income per ordinary share after giving consideration to all potentially dilutive ordinary equivalents, including stock options outstanding during the period, except where the effect of such non-participating securities would be antidilutive.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Diluted net (loss)/income per share is computed by dividing the net (loss)/income attributable to ordinary shareholders by the weighted-average number of ordinary shares and dilutive ordinary share equivalents outstanding for the period, determined using the treasury-stock and if-converted methods.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Contingent liabilities</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A provision for contingent liabilities is recorded when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. With respect to legal matters, provisions are reviewed and adjusted to reflect the impact of negotiations, estimated settlements, legal rulings, advice of legal counsel and other information and events pertaining to a particular matter. The Company is a party to certain litigation and disputes arising in the normal course of business. As of December&#160;31, 2023, the Company does not expect that such matters will have a material adverse effect on the Company&#8217;s business, financial position, results of operations, or cash flows.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Recent Accounting Pronouncements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">From time to time, new accounting pronouncements are issued by FASB or other standard setting bodies that the Company adopts as of the specified effective date. The Company qualifies as an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups Act of 2012 and has elected not to &#8220;opt out&#8221; of the extended transition related to complying with new or revised accounting standards, which means that when a standard is issued or revised and it has different applications dates for public and nonpublic companies, the Company can adopt the new or revised standard at the time nonpublic companies adopt the new or revised standard and can do so until such time the Company either (i) irrevocably elects to &#8220;opt out&#8221; of such extended transition period or (ii) no longer qualifies as an emerging growth company.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Recently Issued Accounting Pronouncements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have reviewed all recently issued standards and have determined that such standards will not have a material impact on our consolidated financial statements or do not otherwise apply to our current operations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140564694549472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Foreign Currency Translation in General and Administrative Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyAbstract', window );"><strong>Foreign Currency [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyDisclosureTextBlock', window );">Foreign Currency Translation in General and Administrative Expenses</a></td>
<td class="text">Foreign Currency Translation in General and Administrative Expenses<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The aggregate, net foreign exchange gain or loss included in determining net (loss)/income recognized in general and administrative expenses for the year ended December&#160;31, 2023, and 2022, was a loss of $7.6&#160;million and a gain of $26.4&#160;million, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for foreign currency transactions and translation. This may include description of foreign currency transactions, foreign currency gains and losses, explanation of change in cumulative translation adjustment, description of effect of subsequent foreign currency exchange rate change, cumulative translation adjustment movement, foreign currency translation adjustment by component movement, translation adjustment for net investment hedge movement, adjustment for long-term intercompany transactions, schedule of long-term intercompany balances and any other foreign currency transactions and translation related items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-13<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-16<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479424/830-30-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//830/tableOfContent<br><br>Reference 7: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481926/830-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140564694817472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net (Loss)/Income Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net (Loss)/Income Per Share</a></td>
<td class="text">Net (Loss)/Income Per Share<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table sets forth the computation of basic and diluted net (loss)/income per share for the years ended December&#160;31, 2023 and 2022 (in thousands, except number of shares and per share amounts):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Numerator:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net (loss)/income </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(73,447)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,321&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net loss attributable to noncontrolling interest</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">100&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">21&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net (loss)/income attributable to Barinthus Biotherapeutics plc shareholders</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(73,347)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,342&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Denominator:</span></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Weighted-average ordinary shares outstanding, basic</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">38,386,491</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">37,248,126</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Effect of dilutive stock options</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">921,181</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Weighted-average ordinary shares outstanding, diluted</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">38,386,491</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">38,169,307</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net (loss)/income per share attributable to ordinary shareholders, basic</span></td><td style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1.91)</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.14&#160;</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net (loss)/income per share attributable to ordinary shareholders, diluted</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1.91)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.14&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Since the Company was in a loss position for 2023, basic net loss per share is the same as diluted net loss per share, as the inclusion of all potential ordinary share equivalents outstanding would have been anti-dilutive. For the year ended December&#160;31, 2023, 6,207,664 potential ordinary shares issuable for stock options were excluded from the computation of diluted weighted-average shares outstanding because including them would have had an anti-dilutive effect. For the year ended December 31, 2022, 2,912,756 potential ordinary shares issuable for stock options, respectively, were excluded from the computation of diluted weighted-average shares outstanding because including them would have had an anti-dilutive effect.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140564694637568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text">Property and Equipment, Net<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Property and equipment, net consists of the following (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Office furniture and equipment</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,108&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,041&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Laboratory equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,728&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,312&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,673&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,926&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Property and equipment, at cost</span></td><td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">15,509&#160;</span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,279&#160;</span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(3,688)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1,322)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Property and equipment, net</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">11,821&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,957&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Depreciation expense for the year ended December&#160;31, 2023 was $2.3 million (December&#160;31, 2022: $1.1 million).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140564694517680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible assets, net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible assets, net</a></td>
<td class="text">Intangible assets, net<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The gross amount of amortizable intangible assets, consisting of acquired developed technology, was $31.6 million at both December&#160;31, 2023 and 2022 and accumulated amortization was $6.5 million and $3.3 million as of December&#160;31, 2023 and 2022, respectively. The amortization expense for the year ended December&#160;31, 2023 was $3.2 million (December&#160;31, 2022: $3.2 million). The estimated annual amortization expense is $3.2 million for the years 2024 through to 2031.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//350-30/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140564694613664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid and other current assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_PrepaidExpenseAndOtherAssetsCurrentTextBlock', window );">Prepaid and other current assets</a></td>
<td class="text">Prepaid and other current assets<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Prepaid and other current assets consist of the following (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Prepayments and accrued income</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,402&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,887&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Value Added Tax receivable</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,031&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Lease incentives receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,770&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,474&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">611&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,907&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,268&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_PrepaidExpenseAndOtherAssetsCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure on prepaid expense and other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_PrepaidExpenseAndOtherAssetsCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140564694485456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock', window );">Accrued Expenses and Other Current Liabilities</a></td>
<td class="text">Accrued Expenses and Other Current Liabilities<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Accrued expenses and other current liabilities consist of the following (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued manufacturing and clinical expenses</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,003&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,997&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued bonus</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,412&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,925&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued payroll and employee benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">789&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">928&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued professional fees</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">942&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,270&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,066&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">941&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,212&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,061&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of the components of accrued liabilities and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140564693979680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Out-licenses and Grants<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Out-licenses and Grants</a></td>
<td class="text">Out-licenses and Grants<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">OUI license</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In April 2020, the Company entered into an Amendment, Assignment and Revenue Sharing Agreement (&#8220;License Agreement Amendment&#8221;) with Oxford University Innovation, or OUI, which vested and assigned all intellectual property rights in relation to any ChAdOx1 or ChAdOx2 vector-based vaccine jointly owned by the Company and OUI in order to facilitate the license of vaccines based on the ChAdOx1 by OUI to AstraZeneca plc (&#8220;AstraZeneca&#8221;). Under this agreement, the Company is entitled to receive from OUI a share of all payments received by OUI from AstraZeneca in respect of the vaccine based on the ChAdOx1. On December 30, 2020, AstraZeneca announced that vaccine based on the ChAdOx1 which we refer to as Vaxzevria had been approved for emergency supply in the United Kingdom by the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA).</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company determined that the intellectual property vested and assigned under the License Agreement Amendment is a functional intellectual property (that is, it has significant standalone functionality in the form of its ability to treat a disease or condition) and there is no expectation under the License Agreement Amendment that the Company will undertake activities to change the functionality. Consequently, the Company concluded that the nature of the Company&#8217;s promise in transferring the intellectual property is to provide a right to use the Company&#8217;s functional intellectual property. Accordingly, the Company recognizes revenue in manner that depicts the Company&#8217;s progress toward satisfying its performance obligation of providing access to its intellectual property throughout the license period based on the terms of OUI&#8217;s agreement with AstraZeneca.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On March&#160;28, 2022, pursuant to the OUI License Agreement Amendment, we were notified of the commencement of payments, arising from AstraZeneca&#8217;s commercial sales of Vaxzevria. Under the terms of an exclusive worldwide license agreement between OUI and AstraZeneca, OUI is entitled to milestone payments and royalties on commercial sales of Vaxzevria that began after the pandemic period. As part of the assignment from us to OUI, we are entitled to receive approximately 24% of payments received by OUI from AstraZeneca. For the year ended December&#160;31, 2023, the Company recognized approximately $0.8 million as revenue (year ended December&#160;31, 2022: $43.7 million) and had an outstanding receivable of nil as of December&#160;31, 2023 (2022: $5.5 million). There is no guarantee that further payments will be received pursuant to the agreement in the future and, if such payments are made, that we will be notified of such payments in a timely manner.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Scancell contract</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On November 2, 2022, the Company entered into an agreement with Scancell to grant a research and development license, consisting of upfront and development milestone and royalty payments, for the development and commercialization of the SNAPvax functional intellectual property. The Company recognized non-refundable upfront revenue, amounting to nil for the year ended December 31, 2023 (December 31, 2022: $0.7 million). As of December&#160;31, 2023, nil was recorded as a receivable (December 31, 2022: $0.3&#160;million). </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Coalition for Epidemic Preparedness Innovations (&#8220;CEPI&#8221;) Funding Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 20, 2023, Barinthus Biotherapeutics (UK) Limited (the &#8220;Company&#8221;), the Chancellors, Masters and Scholars of the University of Oxford (&#8220;Oxford,&#8221; together with the Company, the &#8220;Partners&#8221;) and the Coalition for Epidemic Preparedness Innovations (&#8220;CEPI&#8221;) entered into a Funding Agreement (the &#8220;Funding Agreement&#8221;) pursuant to which CEPI will provide funding of up to $34.8 million to the Company to advance the development of VTP-500, the Company&#8217;s vaccine candidate against Middle East Respiratory Syndrome (&#8220;MERS,&#8221; and such development activities, the &#8220;Project&#8221;). In December 2023, VTP-500 received PRIME (PRIority MEdicines) designation by the European Medicines Agency. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Funding Agreement, the Company has agreed to pay CEPI on a country-by-country basis increasing mid-single digit percentage royalties of net sales and net income with respect to future cash sales of VTP-500, less certain deductions, for a period starting on December 20, 2023 (&#8220;Effective Date&#8221;) and ending the later of: (i) the expiration of the last valid patent claim included in intellectual property developed under the Project covering VTP-500 in such country, (ii) the expiration of Regulatory Exclusivity (as defined in the Funding Agreement) for VTP-500 in such country, and (iii) the tenth (10th) anniversary of the first commercial sale of VTP-500 (the &#8220;Royalty Term&#8221;). The Company shall also pay CEPI a mid-double digit percentage of net revenue earned on VTP-500 until CEPI has received payments from the Company under the Funding Agreement equaling the total amount of funding paid by CEPI to the Company and a low double-digit percentage of such net revenue thereafter. Sales for the benefit of end users in specified low and middle income countries </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;LMICs&#8221;) and upper and middle income countries (&#8220;UMICs&#8221;) are excluded from the calculations of net sales and net revenue. Sales of product for the benefit of end users in LMICs and UMICs are subject to tiered discounted pricing requirements under the Funding Agreement. The Company is further required to pay a mid-double digit percentage of any proceeds earned on any priority review voucher related to VTP-500 during the Royalty Period.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For the year ended December&#160;31, 2023, no proceeds have been received and no income has been recognized in relation to this contract as no activities eligible for the funding were undertaken during the period. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Contract assets and liabilities</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company discloses accounts receivable separately in the consolidated balance sheets at the net amount expected to be collected. Contract assets primarily relate to the Company&#8217;s conditional right to consideration for work completed but not billed at the reporting date. As of December&#160;31, 2023 and 2022 the Company did not have any contract assets.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Contract liabilities primarily relate to payments received from customers in advance of performance under the contract and are disclosed as deferred revenue separately in the consolidated balance sheets. The Company&#8217;s contract liabilities arise when payment is received upfront for various multi-period extended license and service arrangements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Changes in the contract liabilities during the years ended December&#160;31, 2023 and 2022, are as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.112%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.620%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">182&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Revenue recognized related to contract liability balance</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(158)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Foreign exchange translation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(24)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Ending balance</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-15<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140564694545424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Ordinary Shares<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Ordinary Shares</a></td>
<td class="text">Ordinary Shares<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On May&#160;4, 2021, the Company closed its initial public offering (&#8220;IPO&#8221;) of 6,500,000 ADS representing 6,500,000 ordinary shares having a nominal value of &#163;0.000025 per share, at a public offering price of $17.00 per share, for aggregate net proceeds of $102.8 million after deducting underwriting commissions of $7.7 million and incurred offering costs of $2.2 million.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">All ordinary shares rank pari passu as a single class. The following is a summary of the rights and privileges of the holders of ordinary shares as of December&#160;31, 2023:</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Liquidation preference:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> In the event of the liquidation, dissolution or winding up of the Company, the assets of the Company available for distribution to holders of the ordinary shares shall be distributed amongst all holders of the ordinary shares in proportion to the number of shares held irrespective of the amount paid or credited as paid on any share.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Dividends:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Holders of the ordinary shares are entitled to dividends, as may be recommended from time to time by the Board and declared by the ordinary shareholders out of legally available funds.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Voting Rights:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Each holder of ordinary shares is entitled to one vote for each share on all matters to be voted on by ordinary shareholders.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Preemption rights:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Pursuant to section 561 of the Companies Act 2006, shareholders are granted preemptive rights when new shares are issued for cash. However, it is possible for our Articles, or shareholders at a general meeting representing at least 75% of our ordinary shares present (in person or by proxy) and eligible to vote at that general meeting, to disapply these preemptive rights. Such a disapplication of preemption rights may be for a maximum period of up to five years from the date of the shareholder special resolution. In either case, this disapplication would need to be renewed by our shareholders upon its expiration (i.e., at least every five years) to remain effective.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On April&#160;21, 2021, our shareholders approved the disapplication of preemptive rights for a period of five years from the date of approval by way of a special resolution of our shareholders. This included the disapplication of preemption rights in relation to the allotment of our ordinary shares in connection with the IPO. This disapplication will need to be renewed upon expiration (i.e., at least every five years) to remain effective, but may be sought more frequently for additional five-year terms (or any shorter period).</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On November 6, 2023, we held a general meeting where our shareholders approved resolutions granting our board of directors or any duly authorized committee of the board of directors the authority to allot shares in the Company or grant rights to subscribe for or to convert any security into shares in the Company free from preemption rights. Pursuant to such approval, our board of directors was authorized to allot shares up to an aggregate nominal amount of &#163;1,928 free from statutory preemption rights.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2023, the Company has reserved the following ordinary shares for future issuance:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Exercise of stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,207,664</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Shares available for future stock incentive plan awards</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,623,840</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,831,504</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140564694603632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Deferred shares<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_StockholdersEquityDeferredSharesDisclosureTextBlock', window );">Deferred shares</a></td>
<td class="text">Deferred shares<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">All deferred shares rank pari passu as a single class. The deferred shares do not have rights to dividends or to participate in profits on a return of assets on liquidation, the deferred shares confer on the holders thereof an entitlement to receive out of the assets of the Company available for distribution amongst the shareholders (subject to the rights of any new class of shares with preferred rights) the amount credited as paid up on the deferred shares held by them respectively after (but only after) payment shall have been made to the holders of the ordinary shares of the amounts paid up or credited as paid up on such shares and the sum of &#163;1.0 million ($1.4 million) in respect of each ordinary share held by them respectively. The deferred shares shall confer on the holders thereof no further right to participate in the assets of the Company.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On March 29, 2023, all deferred B shares (nominal value of &#163;0.01 each) and deferred C shares (nominal value of &#163;0.00000736245954692556 each) previously in issue were transferred back to the Company and subsequently cancelled. These deferred shares had previously been issued to certain pre-IPO shareholders in connection with the implementation of certain stages of the Company&#8217;s pre-IPO share capital reorganization. The Company received shareholder pre-approval on April 21, 2021 (pursuant to the shareholder resolutions passed on that date) in order to effect the transfer back and cancellation of the deferred shares for nil consideration in accordance with sections 659 and 662 of the Companies Act 2006.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s deferred A shares with a nominal value of &#163;1.00 each remain in issue for the purposes of satisfying the minimum share capital requirements for a public limited company as prescribed by the Companies Act 2006.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_StockholdersEquityDeferredSharesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for Deferred Shares as disclosed by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_StockholdersEquityDeferredSharesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140564784123680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value</a></td>
<td class="text">Fair Value<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company&#8217;s financial instruments consist of cash and cash equivalents, accounts receivable, accounts payable, certain accrued expenses, contingent consideration and short-term debt. The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable, certain accrued expenses, contingent consideration and short-term debt approximated their respective fair value due to the short-term nature and maturity of these instruments.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2023, the Company had a contingent consideration liability of $1.8 million related to the acquisition of Avidea Technologies, Inc. The fair value of the contingent consideration is a Level 3 valuation with the significant </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">unobservable inputs being the probability of success of achievement of the milestones and the expected date of the milestone achievement. Significant judgment is employed in determining the appropriateness of certain of these inputs.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes changes in the fair value of Contingent Consideration (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year ended December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year ended December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,711&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,371&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Change in fair value recognized in net loss</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">55&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(73)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Settlement of contingency</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(163)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(325)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Foreign exchange translation recognized in other comprehensive loss</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">219&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(262)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,823&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,711&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140564784102256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillDisclosureTextBlock', window );">Goodwill</a></td>
<td class="text">Goodwill<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes changes in goodwill (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year ended<br/>December 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year ended<br/>December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12,209&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12,630&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Measurement period adjustments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(421)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12,209&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12,209&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//350-20/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140564784130928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Compensation</a></td>
<td class="text">Share-Based Compensation<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On April&#160;8, 2021, the Board of the Company adopted the Barinthus Biotherapeutics plc Share Award Plan 2021 (&#8220;the Plan&#8221;) and the Barinthus Biotherapeutics plc Non-Employee Sub-Plan which is a sub-plan of the Plan. Under the terms of the Plan, the Board is permitted to grant awards to employees as restricted share units, options, share appreciation rights and restricted shares. The aggregate number of shares initially available for issuance under the Plan and the Barinthus Biotherapeutics plc Non-Employee Sub-Plan cannot exceed 3,675,680 ordinary shares (the &#8220;Initial Limit&#8221;). Beginning calendar year 2023, the total number of ordinary shares available for issuance under the Plan shall be increased on January 1 of each year in an amount equal to the lesser of (i) 4% of the Company&#8217;s issued and outstanding ordinary shares (which 4% limit shall be measured as of January 1 of such year) and (ii) such number of ordinary shares as determined by the Compensation Committee of the Board in its discretion (the &#8220;Annual Increase&#8221;). In accordance with the terms of the Annual Increase, the total number of ordinary shares available for issuance under the Plan increased by 1,507,341 of January 1, 2023. The awards generally vest based on the grantee&#8217;s continued service with the Company during a specified period following grant as determined by the Board and generally expire ten years from the grant date. Option awards generally vest over three years, but vesting conditions can vary at the discretion of the Company&#8217;s Board. As of December&#160;31, 2023 and 2022, 1,623,840 and 1,670,268 ordinary shares are available for future grants, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In 2018, the Company&#8217;s board of directors adopted the Enterprise Management Incentive Share Option Scheme (the &#8220;EMI Plan&#8221;) which provided for the grant of incentive stock options and nonqualified stock options to non-director employees of the Company. The Company also has a nonqualified stock option plan for officers and directors. The awards generally vest based on the grantee&#8217;s continued service with the Company during a specified period following grant as determined by the board of directors and generally expire ten years from the grant date. Option awards generally vest over three years, but vesting conditions can vary at the discretion of the Company&#8217;s board of directors. A total of 3,530,634 ordinary shares were reserved for issuance in accordance with the provisions of the EMI Plan and restricted stock unit (&#8220;RSUs&#8221;) plan. Upon adoption of the Plan, no further awards are to be made under the EMI Plan.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The fair value of each stock option issued to employees was estimated at the date of grant using Black-Scholes with the following weighted-average assumptions:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.454%"><tr><td style="width:1.0%"></td><td style="width:65.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.284%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.285%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year Ended, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">97.1&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">94.7&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Expected term (years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Expected dividend yield</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Prior to the IPO, the Company applied a discount for lack of marketability calculated using the Finnerty model</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Expected volatility: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Previously there was insufficient trading history for the Company&#8217;s ordinary shares, therefore the expected price volatility for our ordinary shares was estimated using the average historical volatility of industry peers&#8217; shares as of the grant date of our options over a period of history commensurate with the expected life of the options. When selecting industry peers used in measuring implied volatility, the Company considered the similarity of their products and business lines, as well as their stage of development, size and financial leverage. The Company applied this process consistently using the same or similar public companies until 2023. During 2023, the Company determined that there is sufficient historical information on volatility of its share price available and the expected volatility used in the fair value calculation of new option grants is calculated based on a blended volatility of both historical volatility of the Company's share price and the expected volatility of the average historical volatility of industry peers&#8217; shares. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Expected term (years): </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expected term represents the period that the Company&#8217;s option grants are expected to be outstanding. There is not sufficient historical share exercise data to calculate the expected term of the stock options. Therefore, the Company elected to utilize the simplified method to value option grants. Under this approach, the weighted-average expected life is presumed to be the average of the vesting term and the contractual term of the option.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Risk-free interest rate: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company determined the risk-free interest rate by using a weighted-average equivalent to the expected term based on the daily U.S. Treasury yield curve rate in effect as of the date of grant.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Expected dividend yield:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> The Company does not anticipate paying any dividends in the foreseeable future.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A summary of stock option activity is presented below:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Number of<br/>Stock Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Weighted-<br/>average<br/>Exercise<br/>Price Per<br/>Option</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Weighted-<br/>average <br/>Remaining <br/>Contractual <br/>Term (Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Aggregate <br/>Intrinsic Value <br/>(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Outstanding, January 1, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,884,720</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9.04&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7.36</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,619&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Granted</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,288,236</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.51&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(72,386)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.00026&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Forfeited/expired</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(892,906)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7.30&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Outstanding, December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,207,664</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6.91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7.95</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,044&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Exercisable, December 31, 2023</span></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,839,791</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8.91&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7.33</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,883&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The weighted-average grant date per-share fair value of stock options granted during the year ended December&#160;31, 2023 was $1.99 per share (December&#160;31, 2022: $3.51 per share). The aggregate intrinsic value of stock options exercised during the year ended December&#160;31, 2023 was $0.2 million (December&#160;31, 2022: $0.8 million). As of December&#160;31, 2023, there was $3.0 million (2022: $7.1 million) of unrecognized compensation cost related to stock options, which is expected to be recognized over a weighted-average period of 1.60 years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Share based compensation expense is classified in the consolidated statements of operations and comprehensive loss as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year ended December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year ended December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Research and development</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,011&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,668&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,044&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,209&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,055&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,877&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140564693289120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Loss) income before income taxes are as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.778%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year ended<br/>December 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year ended<br/>December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">United Kingdom</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(50,534)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,511&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(24,507)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(14,648)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1,481)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(Loss)/income before income taxes</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(76,522)</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">850&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The components of income tax benefit are as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year ended<br/>December 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year ended<br/>December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Current income tax benefit/(expense):</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">United States</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(28)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">133&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(45)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Deferred income tax benefit:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">United States</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,338&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total income tax benefit</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,075&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,471&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A reconciliation of the UK statutory income tax rate to the Company's effective tax rate as reflected in the consolidated financial statements is as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year ended<br/>December 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year ended<br/>December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Statutory tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">23.52&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">19.00&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Increase (decreases) resulting from:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Permanent differences</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.03&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(103.46)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Provision to return adjustments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(4.09)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(105.66)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Research and development credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(4.94)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(307.09)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Foreign rate differential</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.23&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(149.82)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(11.84)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">146.55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Share based compensation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.84)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(10.21)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Effective tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4.07&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(510.69)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income and for tax carryforwards. Significant components of the Company&#8217;s deferred tax assets and liabilities are as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net operating loss carryforwards</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">23,589&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,940&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Research and development credit carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,146&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Deferred revenue</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">54&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Share based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,226&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,956&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Lease liability</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,404&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,257&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accruals and intangibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">745&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">765&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Capitalized Research and Development expenditure</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,228&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,522&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Gross deferred tax asset</span></td><td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">36,233&#160;</span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">22,641&#160;</span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(25,057)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(13,707)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net deferred tax assets</span></td><td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">11,176&#160;</span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,934&#160;</span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Depreciation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1,652)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1,704)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Right-of-use lease asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1,922)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1,993)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Unrealized gain on investment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1,267)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1,204)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(6,909)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(7,779)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net deferred tax liabilities</span></td><td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(11,750)</span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(12,680)</span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total deferred tax, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(574)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(3,746)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Specified research and experimentation costs under Section 174 of the Internal Revenue Code are required to be capitalized and amortized ratably over five years for domestic expenditures and over 15 years for foreign expenditures. This provision of Section 174 became effective for tax years beginning after December 31, 2021. As a result of the capitalization of these costs in the current year, the Company has recorded a $4.2 million deferred tax asset (2022: $2.5 million). </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2023, the Company had a valuation allowance of $25.1 million (2022: $13.7 million) against its deferred tax assets, which consisted principally of net operating loss and research and development credit carryforwards. The Company considered the positive and negative evidence bearing upon its ability to realize the deferred tax assets. In addition to the Company&#8217;s history of cumulative losses, the Company cannot be certain that future taxable income will be sufficient to realize its deferred tax assets. Accordingly, a valuation allowance has been provided against its deferred tax assets. When the Company changes its determination as to the amount of its deferred tax assets that can be realized, the valuation allowance is adjusted with a corresponding impact to the provision for income taxes in the period in which such determination is made.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Changes in the valuation allowance for deferred tax assets during the years ended December 31, 2023 and 2022 related primarily to the increase in net operating loss and credit carryforwards, and were as follows:</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.901%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year ended<br/>December 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year ended<br/>December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Valuations allowance at beginning of year</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,707&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,500&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Changes in valuation allowance arising from in-year additions</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,052&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Increases recorded to income tax provision</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,605&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Foreign exchange translation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">693&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1,293)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Valuation allowance at end of year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">25,057&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">13,707&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2023, the Company had net operating loss ("NOL") carryforwards totaling approximately $92.7 million which have an unlimited carryforward period, of which $74.2 million originate in the United Kingdom. As of December&#160;31, 2023, the Company had $0.04 million of research and development tax credit carryforwards which also have an unlimited carryforward period.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2022, the Company had NOL carryforwards totaling approximately $39.6 million which have an unlimited carryforward period, of which $35.1 million originate in the United Kingdom. As of December&#160;31, 2022, the Company had $3.1 million of research and development tax credit carryforwards which also have an unlimited carryforward period.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2023 and 2022, the Company does not have any material unrecognized tax benefit liabilities. The Company files corporation/income tax returns in the United Kingdom, Australia, and the United States. The associated tax filings remain subject to examination by applicable tax authorities for a certain length of time following the tax year to which those filings relate. In the United Kingdom, tax years from 2020 remain subject to examination by HMRC. In all other jurisdictions, the tax years since inception remain subject to examination by the applicable taxing authorities as of December&#160;31, 2023 and 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140564783785472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">In-License Agreements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company is party to a number of licensing agreements, these agreements serve to provide the Company with the right to develop and exploit the counterparties&#8217; intellectual property for certain medical indications. As part of execution of these arrangements, the Company paid certain upfront fees, which have been expensed as incurred because the developing technology has not yet reached technical feasibility, the lack of alternative use, and the lack of proof of potential value. The agreements cover a variety of fields, including influenza, cancer, HPV, HBV and MERS. The Company&#8217;s obligations for future payments under these arrangements are dependent on its ability to develop promising drug candidates, the potential market for these candidates and potential competing products, and the payment mechanisms in place in countries where the Company retains the right to sell. Each agreement provides for specific milestone payments, typically triggered by achievement of certain testing phases in human candidates, and future royalties ranging from 1 to 5% for direct sales of a covered product to 3 to 7% of net payments received for allowable sublicenses of technology developed by the Company. The obligation to make these payments is contingent upon the Company&#8217;s ability to develop candidates for submission for phased testing and approvals, and for the development of markets for the products developed by the Company. The Company has not made any material payments under these license agreements during the years ended December&#160;31, 2023, and 2022.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Leases</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company leases certain laboratory and office space under operating leases, which are described below.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">The Oxford Science Park, Oxford</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company leased an office and laboratory space from a related party in Oxford, England under an operating lease with a contractual term expiring in 2028. The lease was terminated on July 31, 2022, and the Company relocated its corporate headquarters to The Harwell Science and Innovation Campus, Oxfordshire, in the third quarter of 2022.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">The Harwell Science and Innovation Campus, Oxfordshire</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On September&#160;3, 2021, the Company entered into a lease agreement for the lease of approximately 31,000 square feet in Harwell, Oxfordshire which expires in September 2031. The property is the Company&#8217;s corporate headquarters. As the Company&#8217;s leases typically do not provide an implicit rate, the Company uses an estimate of its incremental borrowing rate based on the information available at the lease commencement date, being the rate incurred to borrow on a collateralized basis over a similar term at an amount equal to the lease payments in a similar economic environment. The Company has provided the lessor with a refundable security deposit of $0.7 million which is included in Other assets.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Germantown, Maryland</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On June&#160;14, 2022, the Company entered into a lease agreement for the lease of approximately 19,700 square feet in Germantown, Maryland. The site will house the Company&#8217;s state-of-the-art wet laboratory in the United States of America. The lease expires on February 28, 2034, with the Company having a single right to extend for an additional five years on the same terms and conditions other than for the base rent. The Company has a rent-free period up to February 29, 2024 and is entitled to up to $3.5 million for leasehold improvements to the premises desired by the Company. The Company has provided the lessor with a refundable security deposit of $0.2 million which is included in Other assets.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company recorded a right-of-use asset and a lease liability on the effective date of the lease term. The Company&#8217;s right-of-use assets and lease liabilities are as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Right-of-use asset</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,581&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,753&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Lease liability, current</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,785&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">433&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Lease liability, noncurrent</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">11,191&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,340&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 13pt 0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 13pt 0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Other information</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating cash flows from operating leases</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">639&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,081&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Weighted average remaining lease term (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8.93</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9.44</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Weighted average discount rate</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Lease Costs</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Short-term lease costs</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">189&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">529&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Fixed Lease Costs</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">883&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,216&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease cost</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,072&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,745&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Maturities of the Company&#8217;s minimum lease liabilities as of December&#160;31, 2023 were as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Maturity of lease liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2024</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,785&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,936&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,960&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2027</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,985&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,010&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,999&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total minimum lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">17,675&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: imputed interest</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(4,699)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total lease liability</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12,976&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Non-lease and other costs paid to the lessors are primarily related to services provided by the lessors in operating the premises that includes fees, operating costs, taxes, and insurance related to the leased premises.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Other contingencies</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company is a party in various contractual disputes, litigation, and potential claims arising in the ordinary course of business. The Company does not believe that the resolution of these matters will have a material adverse effect on its financial position or results of operations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140564688960896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">Employee Benefit Plans</a></td>
<td class="text">Employee Benefit Plans<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the United Kingdom, the Company has adopted a defined contribution plan (the U.K. Plan) which qualifies under the rules established by HM Revenue &amp; Customs. Contributions to the U.K. Plan are charged to the consolidated statements of operations and comprehensive loss in the year to which they relate.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has 401(k) defined contribution retirement plans in which all its employees located in the United States are eligible to participate. Eligible employees may elect to contribute up to the maximum limits, as set by the Internal Revenue Service, of their eligible compensation. Contributions to the plans are charged to the consolidated statements of operations and comprehensive loss in the year to which they relate.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the year ended December&#160;31, 2023, the Company provided a total of $0.7 million (December&#160;31, 2022: $0.5 million) in contributions under both the U.K. Plan and the 401(k) plans.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 710<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//710/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 712<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//712/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//715/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140564694289056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text">Related Party Transactions<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the year ended December&#160;31, 2023, the Company incurred expenses of $0.4 million (December&#160;31, 2022: $0.4 million) from its shareholder, the University of Oxford, related to clinical study costs. As of December&#160;31, 2023, the Company owed nil (2022: $nil).</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the year ended December&#160;31, 2023, the Company incurred expenses of $0.6 million (December&#160;31, 2022: $0.4 million) from Oxford University Innovation Limited which is a wholly owned subsidiary of the Company&#8217;s shareholder, the University of Oxford. As of December&#160;31, 2023, the Company owed $2&#160;thousand (December 31, 2022: nil) to Oxford University Innovation Limited.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the year ended December&#160;31, 2023, the Company recognized license revenue of $0.8 million (December&#160;31, 2022: $43.7 million) from Oxford University Innovation Limited which is a wholly owned subsidiary of the Company&#8217;s shareholder, the University of Oxford. As of December&#160;31, 2023, the Company was owed nil (2022: $5.5 million) from Oxford University Innovation Limited.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140564689889552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent Events  <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In accordance with the terms of the Annual Increase of the Barinthus Biotherapeutics plc Share Award Plan 2021, the total number of ordinary shares available for issuance under the Plan increased by 4% of the Company&#8217;s issued and outstanding ordinary shares as of January&#160;1, 2024.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2024, the Company granted a total of 1,592,423 share options to employees and directors with a weighted average exercise price of $3.70.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140564693385744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies', window );">Guarantees and indemnifications</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Guarantees and indemnifications</span></div>As permitted under the laws of England and Wales, the Company indemnifies its officers, directors, consultants and employees for certain events or occurrences that happen by reason of the relationship with, or position held at, the Company.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Use of estimates</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue, income and expenses during the reporting period. The Company bases estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions on an ongoing basis, including those related to fair value of contingent consideration and impairment of goodwill and intangible assets. The Company&#8217;s actual results may differ from these estimates under different assumptions or conditions.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of the date of issuance of these consolidated financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update its estimates, assumptions and judgments or revise the carrying value of its assets or liabilities. These estimates may change as new events occur and additional information is obtained and are recognized in the consolidated financial statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to the Company&#8217;s financial statements.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of consolidation</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Principles of consolidation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The accompanying consolidated financial statements include the accounts of Barinthus Biotherapeutics plc and those entities in which it has a controlling interest. Intercompany amounts are eliminated on consolidation. Amounts attributable to the noncontrolling interest are presented as a separate element of equity in the accompanying consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive loss</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Comprehensive loss</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Comprehensive loss for all periods presented is comprised primarily of net (loss)/income and other comprehensive loss, which solely relates to foreign currency translation adjustments.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign currency translation</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Foreign currency translation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company&#8217;s reporting currency is the United States dollar. The functional currency of the parent and each subsidiary is the currency of the country and economic environment in which it is located. Assets and liabilities of each legal entity denominated or measured in a currency other than British Pounds are first translated into British pounds and consolidated. The consolidated balances are then converted into United States dollars at period-end exchange rates. Revenues and expenses are translated into British pounds, then into U.S. dollars at average exchange rates for each reporting period. Translation adjustments are reflected as accumulated other comprehensive loss within stockholders&#8217; equity. Gains and losses on foreign currency transactions are included in the consolidated statements of operations and comprehensive loss in the general and administrative expenses. The aggregate net foreign exchange gain or loss included in determining net loss was a loss of $7.6 million and gain of $26.4 million for the years ended December&#160;31, 2023 and 2022, respectively.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment information</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Segment information</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, the Company&#8217;s Chief Executive Officer, in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one operating segment, the research and development of immunotherapies and vaccines.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_MinorityInterestPolicyTextBlock', window );">Noncontrolling interest</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Noncontrolling interest</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In 2018, Barinthus Biotherapeutics plc established VOLT with a related party. As of December&#160;31, 2021, Barinthus Biotherapeutics plc had contributed cash and intellectual property with an aggregate value of $11.9 million for a 76% controlling interest. The related party had contributed cash and intellectual property with an aggregate value of $3.8 million for a 24% noncontrolling interest. There were no further contributions in the years ended December&#160;31, 2023 and 2022. The contributed intellectual properties were initially recorded at investment date fair value by VOLT and immediately expensed as research and development costs. The Company accounts for the noncontrolling interest in the accompanying consolidated financial statements initially at fair value with the subsequent carrying value adjusted for the noncontrolling share of VOLT&#8217;s comprehensive loss.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Business combinations</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Business Combinations</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company accounts for business combinations using the acquisition method of accounting, which requires the recognition of tangible and identifiable intangible assets acquired and liabilities assumed at their estimated fair values as of the business combination date. The Company allocates any excess purchase price over the estimated fair value assigned to the net tangible and identifiable intangible assets acquired and liabilities assumed to goodwill. Contingent consideration is included within the acquisition cost and is recognized at its fair value on the acquisition date. A liability resulting from contingent consideration is remeasured to fair value at each reporting date until the contingency is resolved and changes in fair value are recognized in general and administrative expenses in the consolidated statements of operations and comprehensive loss. Transaction costs are expensed as incurred in general and administrative expenses. Results of operations and cash flows of acquired companies are included in the Company&#8217;s operating results from the date of acquisition.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and cash equivalents</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Cash and cash equivalents</span></div>The Company considers all highly liquid investments purchased with remaining maturities of three months or less on the purchase date to be cash and cash equivalents. Cash and cash equivalents include bank demand deposits and money market funds that are actively traded (a Level 1 input).<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Revenue</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has entered into collaboration and license agreements, which are within the scope of Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, to discover, develop, manufacture and commercialize product candidates. The terms of these agreements typically contain multiple promises or obligations, which may include licenses, or options to obtain licenses, to product candidates or future product candidates. The Company also derives revenue from government grants.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Amounts received prior to revenue recognition are recorded as deferred revenue. Amounts expected to be recognized as revenue within the 12 months following the balance sheet date are classified as current portion of deferred revenue in the accompanying consolidated balance sheets. Amounts recognized as revenue, but not yet received or invoiced are generally recognized as accounts receivable.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">License revenue</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company&#8217;s arrangements may provide the collaboration partner with the right to select a target for licensing either at the inception of the arrangement or in the future. Under these arrangements, fees may be due to the Company (i) at the inception of the arrangement as an upfront fee or payment, (ii) upon the exercise of an option to acquire a license or (iii) </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">upon extending the selection period as an extension fee or payment. If an arrangement is determined to contain customer options that allow the customer to acquire additional goods or services, the goods and services underlying the customer options are not considered to be performance obligations at the outset of the arrangement, as they are contingent upon option exercise. The Company evaluates the customer options for material rights, or options to acquire additional goods or services for fee or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the inception of the arrangement. The Company allocates the transaction price to material rights based on the relative standalone selling price, which is determined based on the identified discount and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised or expires.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For arrangements that include sales-based milestones and royalties, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). This could require management to estimate the amount of revenue to recognize in the period if the actual data for the period has not been provided.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_ResearchAndDevelopmentServicesPolicyPolicyTextBlock', window );">Research and development services</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Research and development services</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The promises under the Company&#8217;s collaboration and license agreements generally include research and development services to be performed by the Company on behalf of the collaboration partner. For performance obligations that include research and development services, the Company recognizes revenue allocated to such performance obligations based on an appropriate measure of progress. The Company utilizes judgment to determine the appropriate method of measuring progress for the purposes of recognizing revenue, which may include an input measure such as costs incurred during the reporting period or ratably over the service period. Reimbursements from the partner are evaluated as to whether the Company acts as a principal or an agent in such relationships. The Company evaluates whether control over the underlying goods or services were obtained prior to transferring these goods or services to the collaboration partner. Where the Company does not control the goods or services prior to transferring these goods or services to the collaboration partner, such reimbursements are presented net of costs. At the inception of each arrangement that includes development milestone payments in respect of development efforts, the Company evaluates whether the development milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated development milestone value is included in the transaction price. Development milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular development milestone in making this assessment. There is judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each reporting period, the Company reevaluates the probability of achievement of all development milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. If a milestone or other variable consideration relates specifically to the Company&#8217;s efforts to satisfy a single performance obligation or to a specific outcome from satisfying the performance obligation, the Company generally allocates the milestone amount entirely to that performance obligation once it is probable that a significant revenue reversal would not occur. To date, the Company has not recognized any development milestone revenue resulting from any of its arrangements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_GrantIncomePolicyPolicyTextBlock', window );">Grant Income</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Grant income</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company receives certain grant income which support its research efforts in defined projects and include contributions towards the research and development costs. When there is reasonable assurance that the Company will comply with the conditions attached to a received grant, and when there is reasonable assurance that the grant will be received, grant income is recognized as other operating income on a gross basis in the consolidated statements of operations and comprehensive loss on a systematic basis over the periods in which the Company recognizes expenses for the related costs for which the grants are intended to compensate. Grant income may be subject to review by the grantor in periods subsequent to its recognition and may result in the reversal of grant income previously recognized. Payments received in advance of incurring reimbursable expenses are recorded as deferred income.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of credit risk</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Concentrations of credit risk</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash and cash equivalents and accounts receivable. Periodically, the Company maintains deposits in financial institutions in excess of government insured limits. Management believes that the Company is not exposed to significant credit risk as the Company&#8217;s deposits are held at financial institutions that management believes to be of high credit quality and the Company has not experienced any losses in these deposits. The Company&#8217;s standard payment terms are 30 days&#8217;.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company recognizes revenue earned in connection with the license and services provided to customers and grantors. The Company provides credit to the grantors in the normal course of providing such services based on evaluations of their financial condition and generally does not require collateral. To manage accounts receivable credit risk, the Company monitors the creditworthiness of its grantors. Historically, the Company has not experienced any credit losses related to accounts receivable and does not maintain allowances for uncollectible amounts.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock', window );">Allowance for credit losses</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Allowance for credit losses</span></div>The Company evaluates its cash equivalents and accounts receivable for expected credit losses. Expected credit losses represent the portion of the amortized cost basis of a financial asset that an entity does not expect to collect. An allowance for expected credit losses is meant to reflect a risk of loss even if remote, irrespective of the expectation of collection from a particular issuer or debt security. The Company has not historically experienced any credit losses on any of its financial assets.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and equipment</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Property and equipment</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Property and equipment are stated at cost, net of accumulated depreciation. Expenditures for maintenance and repairs are charged to operating expenses as incurred, whereas major betterments are capitalized as additions to property and equipment. Depreciation is recorded using the straight-line method over the estimated useful lives of the assets as follows:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.787%"><tr><td style="width:1.0%"></td><td style="width:73.323%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.477%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Asset Category</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Estimated Useful Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Office furniture and equipment</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Laboratory equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Lesser of lease term or estimated useful lives</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible assets acquired through business combinations</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Intangible assets acquired through business combinations</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Intangible assets consist of acquired developed technology. Intangible assets are stated at cost less accumulated amortization and impairment losses. Amortization is computed using the straight-line method over the estimated useful lives of the respective assets, which is 10 years.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of long-lived assets</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Impairment of long-lived assets</span></div>The Company reviews long-lived assets to be held and used, including property and equipment, intangible assets and operating lease right-of-use assets, for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets or asset group may not be recoverable. Evaluation of recoverability is first based on an estimate of undiscounted future cash flows resulting from the use of the asset or asset group and its eventual disposition. In the event such cash flows are not expected to be sufficient to recover the carrying amount of the asset or asset group, the assets are written down to their estimated fair values.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Goodwill</span></div>Goodwill represents the excess of cost over the fair value of the net tangible and intangible assets of businesses acquired in a business combination. Goodwill is not amortized but rather is tested for impairment at least annually, or more frequently if events or changes in circumstances indicate that the carrying amount of goodwill may not be recoverable. The Company has elected to first assess the qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount as a basis of determining whether it is necessary to perform the quantitative goodwill impairment test. If the Company determines that it is more likely than not that its fair value is less than its carrying amount, then the quantitative goodwill impairment test will be performed. The quantitative goodwill impairment test identifies goodwill impairment and measures the amount of goodwill impairment loss to be recognized by comparing the fair value of a reporting unit with its carrying amount. If the fair value exceeds the carrying amount, no further analysis is required; otherwise, any excess of the goodwill carrying amount over the implied fair value is recognized as an impairment loss, and the carrying value of goodwill is written down to fair value.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Financial instruments</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Financial instruments</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company&#8217;s financial instruments consist of cash and cash equivalents, accounts receivable, accounts payable, certain accrued expenses, contingent consideration and short-term debt. The carrying amounts of cash, cash equivalents, accounts receivable, security deposits, accounts payable, accrued expenses and short-term debt approximate their fair value due to the short-term nature of those financial instruments.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair value measurements</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Fair value measurements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company follows the guidance in ASC 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Fair Value Measurements and Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, which defines fair value and establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are described below:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.67pt">Level 1 &#8211; Inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.67pt">Level 2 &#8211; Valuations based on quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.67pt">Level 3 &#8211; Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Fair value is a market-based measure considered from the perspective of a market participant rather than an entity-specific measure. Therefore, even when market assumptions are not readily available, the Company&#8217;s own assumptions are set to reflect those that market participants would use in pricing the asset or liability at the measurement date. The Company uses prices and inputs that are current as of the measurement date, including during periods of market dislocation. In periods of market dislocation, the observability of prices and inputs may change for many instruments. This condition could cause an </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">instrument to be reclassified within levels in the fair value hierarchy. There were no transfers within the fair value hierarchy during the years ended December&#160;31, 2023 and 2022.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company recognizes a contingent consideration liability related to the acquisition of Avidea Technologies, Inc. The liability is remeasured to fair value at each reporting date until the contingency is resolved. The fair value of the contingent consideration is a Level 3 valuation determined using significant unobservable inputs being the probability of success of achievement of the milestones and the expected date of the milestone achievement. Changes in fair value are recognized in general and administrative expenses in the consolidated statements of operations and comprehensive loss.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Leases</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Leases are accounted for under ASC 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(&#8220;ASC 842&#8221;) resulting in the recognition of lease liabilities and right-of-use assets. The Company only has operating leases. The Company has elected the practical expedient allowed under ASC 842 to account for each lease component (e.g., the right to use office space) and the associated non-lease components (e.g., maintenance services) as a single lease component. The Company also elected the short-term lease accounting policy for all asset classes; therefore, the Company is not recognizing a lease liability or right-of-use asset for any lease that, at the commencement date, has a lease term of 12 months or less and does not include an option to purchase the underlying asset that the Company is reasonably certain to exercise.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Variable lease payments such as the Company&#8217;s share of real estate taxes, utilities, and common area maintenance, are reported as non-lease operating expenses.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Right-of-use assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Right-of-use assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. As the Company&#8217;s leases typically do not provide an implicit rate, the Company uses an estimate of its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Right-of-use assets also include the effect of any lease payments made and exclude lease incentives. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized as part of total operating expenses on a straight-line basis over the lease term. The difference between the value of the right of use asset and lease liability is due to the reclassification of prepaid rent and unamortized lease incentives.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and development</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Research and development</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Research and development costs are expensed as incurred on an accruals basis. Research and development costs include payroll and personnel expense (including share-based compensation), consulting costs, external contract research and development expenses, raw materials, drug product manufacturing costs, and allocated overheads including depreciation and amortization, facility costs, and utilities. Research and development costs that are paid in advance of performance are capitalized as a prepaid expense and amortized over the service period as the services are provided.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_ClinicalTrialCostsPolicyTextBlock', window );">Clinical trial costs</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Clinical trial costs</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Clinical trial costs are a component of research and development expenses. The Company accrues and expenses clinical trial activities performed by third parties based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activation, and other information provided to the Company by its vendors.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend', window );">Patent and licensing costs</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Patent and licensing costs</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Patent and licensing costs are expensed as incurred because their realization is uncertain.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityPolicyTextBlock', window );">Ordinary shares</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Ordinary shares</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Ordinary shares are classified in stockholders&#8217; equity and represent issued share capital.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_AdditionalPaidInCapitalPolicyTextBlock', window );">Additional paid-in capital</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Additional paid-in capital</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additional paid-in capital is classified in stockholders&#8217; equity and represents the share premium account, where the difference between the price paid per share and the nominal value is recognized. The equity element of share based compensation is also recognized in additional paid in capital.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share based compensation</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Share based compensation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company grants options over ordinary shares and restricted shares units to employees or Non-Executive Directors and accounts for share based compensation using the grant date fair value. Share based compensation awards are classified in the accompanying statements of operations based on the function to which the related services are provided. For service-based awards, compensation expense is generally recognized over the requisite service period of the awards, usually the vesting period. The Company applies the &#8220;multiple option&#8221; method of allocating expense. In applying this method, each vesting tranche of an award is treated as a separate grant and recognized on a straight-line basis over that tranche&#8217;s vesting period. For performance-based awards where the vesting of the awards may be accelerated upon the achievement of certain milestones, vesting and the related share-based compensation is recognized as an expense when it is probable the milestone will be met. Assumptions used in the option pricing model include the following:</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Expected volatility.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Previously there was insufficient trading history for the Company&#8217;s ordinary shares, therefore the expected price volatility for our ordinary shares was estimated using the average historical volatility of industry peers&#8217; shares as of the grant date of our options over a period of history commensurate with the expected life of the options. When selecting industry peers used in measuring implied volatility, the Company considered the similarity of their products and business lines, as well as their stage of development, size and financial leverage. The Company applied this process consistently using the same or similar public companies until 2023. During 2023, the Company determined that there is sufficient historical information on volatility of its share price available and the expected volatility used in the fair value calculation of new option grants is calculated based on a blended volatility of both historical volatility of the Company's share price and the expected volatility of the average historical volatility of industry peers&#8217; shares.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Expected term</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. The expected term of the Company&#8217;s share options has been determined utilizing the &#8220;simplified&#8221; method for awards that qualify as &#8220;plain-vanilla&#8221; options. The &#8220;simplified&#8221; method was determined to be appropriate as the Company does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term due to the limited period of time its equity shares have been publicly traded.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Risk-free interest rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods that are approximately equal to the expected term of the award.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Expected dividend.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Expected dividend yield of zero is based on the fact that the Company has never paid cash dividends on ordinary shares and does not expect to pay any cash dividends in the foreseeable future.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has elected to recognize the effect of forfeitures on share-based compensation when they occur. Any differences in compensation recognized at the time of forfeiture are recorded as a cumulative adjustment in the period where the forfeiture occurs.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">When awards are modified, the Company compares the fair value of the affected award measured immediately prior to modification to its value after modification. To the extent that the fair value of the modified award exceeds the original award, the incremental fair value of the modified award is recognized as compensation on the date of modification for vested awards, and over the remaining vesting period for unvested awards.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RegulatoryIncomeTaxesPolicy', window );">Income taxes</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Income taxes</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The financial statements reflect provisions for income taxes in the United Kingdom and foreign jurisdictions. Deferred tax assets and liabilities represent future tax consequences of temporary differences between the financial statement carrying amounts and the tax basis of assets and liabilities and for loss carryforwards using enacted tax rates expected to be in effect in the years in which the differences reverse. A valuation allowance is recorded when it is more likely than not that some or all of the deferred tax assets will not be realized.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company determines whether it is more likely than not that a tax position will be sustained upon examination. If it is not more likely than not that a position will be sustained, none of the benefit attributable to the position is recognized. The </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">tax benefit to be recognized for any tax position that meets the more-likely-than-not recognition threshold is calculated as the largest amount that is more than 50% likely of being realized upon resolution of the contingency. The Company accounts for interest and penalties related to uncertain tax positions as part of its provision for income taxes. To date, the Company has not incurred interest and penalties related to uncertain tax positions nor has it recorded any unrecognized tax benefits.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_ResearchAndDevelopmentIncentivesPolicyTextBlock', window );">Research and development incentives</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Research and development incentives</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the United Kingdom, the Company had previously been entitled to a research and development tax credit regime, being the Small and Medium-sized Enterprises R&amp;D tax relief program, or SME Program, and, to the extent that our projects are grant funded or relate to work subcontracted to us by third parties, the Research and Development Expenditure Credit program, or RDEC Program. Until March 2023, under the SME program, the Company was able to surrender some of its trading losses that arise from qualifying research and development activities for a cash rebate of up to 33.35% of such qualifying research and development expenditure. Qualifying expenditures largely comprise employment costs for research staff, consumables, outsourced contract research organization costs and utilities costs incurred as part of research projects. Certain staff, consumables (including utilities), subcontractors and externally provided workers qualifying research and development expenditures are eligible for a cash rebate of up to 21.67%. A large portion of costs relating to research and development, clinical trials and manufacturing activities are eligible for inclusion within these tax credit cash rebate claims. From April 2023, under the SME program the additional deduction has decreased from 130% to 86%, the SME credit rate has reduced from 14.5% to 10% and the SME cash rebate for the Company has reduced from 33.35% to 18.6% and from 21.67% to 12.1% for subcontractors. Furthermore, the SME credit rate will decrease to 10% for expenditure incurred on or after April 1, 2023 unless the SME qualifies as an R&amp;D intensive business i.e., R&amp;D expenditure constitutes at least 40% (from April 1, 2023) or 30% (from accounting periods starting on or after April 1, 2024) of total expenditure. If the Company incurs tax losses, the Company is entitled to surrender the lesser of unrelieved tax loss sustained and the tax relief. As the realization of the tax relief does not depend on our generation of future taxable income or the Company&#8217;s ongoing tax status or tax position, the Company does not consider the tax relief as an element of income tax accounting under ASC 740, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Income taxes </span>and records the tax relief as a form of government grant or assistance. For the years ended December&#160;31, 2023 and 2022, the Company recognized research and development incentives of $3.5 million and $1.2 million respectively.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net (loss)/income per share</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Net (loss)/income per share</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Basic net (loss)/income per share is computed by dividing the net (loss)/income attributable to ordinary shareholders by the weighted-average number of ordinary shares outstanding for the reporting period without consideration for potentially dilutive securities. Net (loss)/income attributable to ordinary shareholders is computed as if all net (loss)/income for the period had been distributed. During periods in which the Company incurred a net loss, the Company allocates no net loss to participating securities because they do not have a contractual obligation to share in the net loss of the Company.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company computes diluted net (loss)/income per ordinary share after giving consideration to all potentially dilutive ordinary equivalents, including stock options outstanding during the period, except where the effect of such non-participating securities would be antidilutive.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Diluted net (loss)/income per share is computed by dividing the net (loss)/income attributable to ordinary shareholders by the weighted-average number of ordinary shares and dilutive ordinary share equivalents outstanding for the period, determined using the treasury-stock and if-converted methods.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContingentLiabilityReserveEstimatePolicy', window );">Contingent liabilities</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Contingent liabilities</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A provision for contingent liabilities is recorded when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. With respect to legal matters, provisions are reviewed and adjusted to reflect the impact of negotiations, estimated settlements, legal rulings, advice of legal counsel and other information and events pertaining to a particular matter. The Company is a party to certain litigation and disputes arising in the normal course of business. As of December&#160;31, 2023, the Company does not expect that such matters will have a material adverse effect on the Company&#8217;s business, financial position, results of operations, or cash flows.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Recent Accounting Pronouncements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">From time to time, new accounting pronouncements are issued by FASB or other standard setting bodies that the Company adopts as of the specified effective date. The Company qualifies as an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups Act of 2012 and has elected not to &#8220;opt out&#8221; of the extended transition related to complying with new or revised accounting standards, which means that when a standard is issued or revised and it has different applications dates for public and nonpublic companies, the Company can adopt the new or revised standard at the time nonpublic companies adopt the new or revised standard and can do so until such time the Company either (i) irrevocably elects to &#8220;opt out&#8221; of such extended transition period or (ii) no longer qualifies as an emerging growth company.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Recently Issued Accounting Pronouncements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have reviewed all recently issued standards and have determined that such standards will not have a material impact on our consolidated financial statements or do not otherwise apply to our current operations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_AdditionalPaidInCapitalPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for Additional paid in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_AdditionalPaidInCapitalPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_ClinicalTrialCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for Clinical Trial costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_ClinicalTrialCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_GrantIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Grant Income, Policy</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_GrantIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_MinorityInterestPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for Minority (Non Controlling) interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_MinorityInterestPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_ResearchAndDevelopmentIncentivesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for Incentives received o to be received from Research and Development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_ResearchAndDevelopmentIncentivesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_ResearchAndDevelopmentServicesPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for research and development services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_ResearchAndDevelopmentServicesPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479515/805-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480981/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentLiabilityReserveEstimatePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the claims loss reserve for insurance contracts with a life contingency (permanent life, some term life, accident and health, some annuities), describing the loss exposures and bases and methodologies for making the relevant accounting estimates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(13)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentLiabilityReserveEstimatePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit loss on financial instrument measured at amortized cost basis, net investment in lease, off-balance sheet credit exposure, and available-for-sale debt security. Includes, but is not limited to, methodology used to estimate allowance for credit loss, how writeoff of uncollectible amount is recognized, and determination of past due status and nonaccrual status.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479391/326-20-30-5A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-3C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479366/326-20-35-8A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-3D<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479344/326-20-45-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479175/326-30-30-1B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-3C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-3A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-3D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 13A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479148/326-30-35-13A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 4A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479391/326-20-30-4A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 7A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479148/326-30-35-7A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-21<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-7<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-17<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.M.Q4)<br> -SubTopic 20<br> -Topic 326<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483530/326-20-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditLossFinancialInstrumentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 60<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482053/820-10-60-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for guarantees, indemnifications and product warranties, and methodologies used in determining the amount of such liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//460/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483256/920-350-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483256/920-350-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483256/920-350-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the treatment of costs incurred to renew or extend the term of a recognized intangible asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RegulatoryIncomeTaxesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, including investment tax credits, and the related regulatory treatment (for example, whether deferred income tax accounting - normalization - is allowed in rate making).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 980<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481974/980-740-25-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 980<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481974/980-740-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RegulatoryIncomeTaxesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140564807035344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedule of concentration of credit risk</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Licensees and grantors that represented 10% of more of the Company&#8217;s revenue and accounted for 10% or more of accounts receivable are presented below:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.606%"><tr><td style="width:1.0%"></td><td style="width:53.767%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.820%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.507%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.298%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.507%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.301%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Revenue</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Country</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year ended<br/>December 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year ended<br/>December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Oxford University Innovation</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">U.K.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">100&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">98&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.000%"><tr><td style="width:1.0%"></td><td style="width:53.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.912%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.513%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.408%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.513%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.409%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Accounts Receivable</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Country</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">As of<br/>December 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">As of<br/>December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Oxford University Innovation</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">U.K.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">94&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property and equipment</a></td>
<td class="text">Depreciation is recorded using the straight-line method over the estimated useful lives of the assets as follows:<div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.787%"><tr><td style="width:1.0%"></td><td style="width:73.323%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.477%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Asset Category</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Estimated Useful Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Office furniture and equipment</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Laboratory equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Lesser of lease term or estimated useful lives</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Property and equipment, net consists of the following (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Office furniture and equipment</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,108&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,041&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Laboratory equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,728&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,312&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,673&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,926&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Property and equipment, at cost</span></td><td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">15,509&#160;</span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,279&#160;</span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(3,688)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1,322)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Property and equipment, net</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">11,821&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,957&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-16<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140564688739104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net (Loss)/Income Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of computation of basic and diluted net (loss)/income per share</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table sets forth the computation of basic and diluted net (loss)/income per share for the years ended December&#160;31, 2023 and 2022 (in thousands, except number of shares and per share amounts):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Numerator:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net (loss)/income </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(73,447)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,321&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net loss attributable to noncontrolling interest</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">100&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">21&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net (loss)/income attributable to Barinthus Biotherapeutics plc shareholders</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(73,347)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,342&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Denominator:</span></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Weighted-average ordinary shares outstanding, basic</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">38,386,491</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">37,248,126</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Effect of dilutive stock options</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">921,181</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Weighted-average ordinary shares outstanding, diluted</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">38,386,491</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">38,169,307</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net (loss)/income per share attributable to ordinary shareholders, basic</span></td><td style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1.91)</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.14&#160;</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net (loss)/income per share attributable to ordinary shareholders, diluted</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1.91)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.14&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140564693782608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property and equipment, net</a></td>
<td class="text">Depreciation is recorded using the straight-line method over the estimated useful lives of the assets as follows:<div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.787%"><tr><td style="width:1.0%"></td><td style="width:73.323%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.477%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Asset Category</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Estimated Useful Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Office furniture and equipment</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Laboratory equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Lesser of lease term or estimated useful lives</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Property and equipment, net consists of the following (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Office furniture and equipment</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,108&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,041&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Laboratory equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,728&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,312&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,673&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,926&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Property and equipment, at cost</span></td><td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">15,509&#160;</span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,279&#160;</span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(3,688)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1,322)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Property and equipment, net</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">11,821&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,957&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140564689893152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid and other current assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Schedule of prepaid and other current assets</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Prepaid and other current assets consist of the following (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Prepayments and accrued income</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,402&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,887&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Value Added Tax receivable</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,031&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Lease incentives receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,770&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,474&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">611&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,907&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,268&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140564693900496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock', window );">Schedule of accrued expenses and other current liabilities</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Accrued expenses and other current liabilities consist of the following (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued manufacturing and clinical expenses</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,003&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,997&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued bonus</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,412&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,925&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued payroll and employee benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">789&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">928&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued professional fees</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">942&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,270&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,066&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">941&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,212&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,061&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140564688965600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Out-licenses and Grants (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_ContractWithCustomerLiabilitiesTableTextBlock', window );">Schedule of changes in contract liabilities</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Changes in the contract liabilities during the years ended December&#160;31, 2023 and 2022, are as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.112%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.620%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">182&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Revenue recognized related to contract liability balance</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(158)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Foreign exchange translation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(24)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Ending balance</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_ContractWithCustomerLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure of contract with customer liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_ContractWithCustomerLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140564688723472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Ordinary Shares (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_ScheduleOfOrdinarySharesReservedForFutureIssuanceTableTextBlock', window );">Summary of ordinary shares reserved for future issuance</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2023, the Company has reserved the following ordinary shares for future issuance:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Exercise of stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,207,664</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Shares available for future stock incentive plan awards</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,623,840</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,831,504</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_ScheduleOfOrdinarySharesReservedForFutureIssuanceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure of ordinary shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_ScheduleOfOrdinarySharesReservedForFutureIssuanceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140564694452016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of financial instruments carried at fair value and classified within Level 3</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes changes in the fair value of Contingent Consideration (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year ended December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year ended December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,711&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,371&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Change in fair value recognized in net loss</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">55&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(73)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Settlement of contingency</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(163)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(325)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Foreign exchange translation recognized in other comprehensive loss</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">219&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(262)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,823&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,711&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140564688723472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of goodwill</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes changes in goodwill (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year ended<br/>December 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year ended<br/>December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12,209&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12,630&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Measurement period adjustments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(421)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12,209&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12,209&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140564694846704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of weighted-average assumptions of fair value stock option issued to employees</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The fair value of each stock option issued to employees was estimated at the date of grant using Black-Scholes with the following weighted-average assumptions:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.454%"><tr><td style="width:1.0%"></td><td style="width:65.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.284%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.285%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year Ended, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">97.1&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">94.7&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Expected term (years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Expected dividend yield</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of stock option activity</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A summary of stock option activity is presented below:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Number of<br/>Stock Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Weighted-<br/>average<br/>Exercise<br/>Price Per<br/>Option</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Weighted-<br/>average <br/>Remaining <br/>Contractual <br/>Term (Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Aggregate <br/>Intrinsic Value <br/>(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Outstanding, January 1, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,884,720</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9.04&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7.36</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,619&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Granted</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,288,236</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.51&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(72,386)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.00026&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Forfeited/expired</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(892,906)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7.30&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Outstanding, December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,207,664</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6.91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7.95</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,044&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Exercisable, December 31, 2023</span></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,839,791</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8.91&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7.33</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,883&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of share based compensation expense</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Share based compensation expense is classified in the consolidated statements of operations and comprehensive loss as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year ended December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year ended December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Research and development</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,011&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,668&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,044&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,209&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,055&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,877&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140564694380192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of (loss) income before income taxes</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Loss) income before income taxes are as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.778%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year ended<br/>December 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year ended<br/>December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">United Kingdom</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(50,534)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,511&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(24,507)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(14,648)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1,481)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(Loss)/income before income taxes</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(76,522)</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">850&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Summary of components of income tax benefit (expense)</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The components of income tax benefit are as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year ended<br/>December 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year ended<br/>December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Current income tax benefit/(expense):</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">United States</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(28)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">133&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(45)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Deferred income tax benefit:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">United States</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,338&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total income tax benefit</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,075&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,471&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation to the effective tax rate</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A reconciliation of the UK statutory income tax rate to the Company's effective tax rate as reflected in the consolidated financial statements is as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year ended<br/>December 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year ended<br/>December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Statutory tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">23.52&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">19.00&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Increase (decreases) resulting from:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Permanent differences</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.03&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(103.46)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Provision to return adjustments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(4.09)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(105.66)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Research and development credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(4.94)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(307.09)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Foreign rate differential</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.23&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(149.82)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(11.84)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">146.55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Share based compensation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.84)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(10.21)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Effective tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4.07&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(510.69)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Summary of significant components of deferred tax assets and liabilities</a></td>
<td class="text">Significant components of the Company&#8217;s deferred tax assets and liabilities are as follows (in thousands):<div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net operating loss carryforwards</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">23,589&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,940&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Research and development credit carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,146&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Deferred revenue</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">54&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Share based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,226&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,956&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Lease liability</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,404&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,257&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accruals and intangibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">745&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">765&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Capitalized Research and Development expenditure</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,228&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,522&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Gross deferred tax asset</span></td><td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">36,233&#160;</span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">22,641&#160;</span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(25,057)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(13,707)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net deferred tax assets</span></td><td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">11,176&#160;</span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,934&#160;</span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Depreciation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1,652)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1,704)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Right-of-use lease asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1,922)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1,993)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Unrealized gain on investment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1,267)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1,204)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(6,909)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(7,779)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net deferred tax liabilities</span></td><td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(11,750)</span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(12,680)</span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total deferred tax, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(574)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(3,746)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfValuationAllowanceTextBlock', window );">Summary of changes in the valuation allowance for deferred tax assets</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Changes in the valuation allowance for deferred tax assets during the years ended December 31, 2023 and 2022 related primarily to the increase in net operating loss and credit carryforwards, and were as follows:</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.901%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year ended<br/>December 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year ended<br/>December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Valuations allowance at beginning of year</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,707&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,500&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Changes in valuation allowance arising from in-year additions</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,052&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Increases recorded to income tax provision</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,605&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Foreign exchange translation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">693&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1,293)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Valuation allowance at end of year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">25,057&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">13,707&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 9<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfValuationAllowanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfValuationAllowanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140564694521040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_LesseeOperatingLeaseRightOfUseAssetAndOtherInformationTableTextBlock', window );">Schedule of right-of-use, lease liabilities and other information</a></td>
<td class="text">The Company&#8217;s right-of-use assets and lease liabilities are as follows (in thousands):<div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Right-of-use asset</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,581&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,753&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Lease liability, current</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,785&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">433&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Lease liability, noncurrent</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">11,191&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,340&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 13pt 0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 13pt 0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Other information</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating cash flows from operating leases</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">639&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,081&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Weighted average remaining lease term (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8.93</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9.44</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Weighted average discount rate</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Lease Costs</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Short-term lease costs</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">189&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">529&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Fixed Lease Costs</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">883&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,216&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease cost</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,072&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,745&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of maturities of minimum lease liabilities</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Maturities of the Company&#8217;s minimum lease liabilities as of December&#160;31, 2023 were as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Maturity of lease liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2024</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,785&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,936&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,960&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2027</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,985&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,010&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,999&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total minimum lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">17,675&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: imputed interest</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(4,699)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total lease liability</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12,976&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_LesseeOperatingLeaseRightOfUseAssetAndOtherInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for Company's right-of-use asset and lease liability and other information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_LesseeOperatingLeaseRightOfUseAssetAndOtherInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140564783838848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Nature of Business and Basis of Presentation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 142,090<span></span>
</td>
<td class="nump">$ 194,385<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 176,590<span></span>
</td>
<td class="nump">$ 103,243<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140564694613664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Foreign currency translation (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Net foreign exchange gain (loss)</a></td>
<td class="num">$ (7.6)<span></span>
</td>
<td class="nump">$ 26.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482014/830-20-35-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481956/830-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481926/830-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481839/830-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140564688953120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Segment information (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140564693735392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Noncontrolling interest (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_SubsidiaryCumulativeContributionsNoncontrollingOwner', window );">Cumulative contributions from noncontrolling interest owner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=brns_SubsidiariesVOLTMember', window );">VOLT</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_SubsidiaryCumulativeContributionsParent', window );">Cumulative contributions from controlling interest owner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries', window );">Contributions to acquire additional interest in subsidiaries</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=brns_VOLTMember', window );">VOLT</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Controlling interest (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=brns_VOLTMember', window );">VOLT | Related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Noncontrolling interest (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_SubsidiaryCumulativeContributionsNoncontrollingOwner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Subsidiary, Cumulative Contributions, Noncontrolling Owner</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_SubsidiaryCumulativeContributionsNoncontrollingOwner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_SubsidiaryCumulativeContributionsParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Subsidiary, Cumulative Contributions, Parent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_SubsidiaryCumulativeContributionsParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of noncontrolling interest during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=brns_SubsidiariesVOLTMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=brns_SubsidiariesVOLTMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=brns_VOLTMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=brns_VOLTMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140564789424336">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Cash and cash equivalents (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140564806620672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Concentrations of credit risk (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_AccountsReceivableStandardPaymentTermsPeriod', window );">Standard payment terms</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember', window );">Revenue | U.K. | Oxford University Innovation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_ConcentrationRiskThresholdPercentage', window );">Concentration risk, percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">98.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable | U.K. | Oxford University Innovation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_ConcentrationRiskThresholdPercentage', window );">Concentration risk, percentage</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">94.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_AccountsReceivableStandardPaymentTermsPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, Standard Payment Terms, Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_AccountsReceivableStandardPaymentTermsPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_ConcentrationRiskThresholdPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk threshold Percentage in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_ConcentrationRiskThresholdPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481027/954-310-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_GB">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_GB</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=brns_OxfordUniversityInnovationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=brns_OxfordUniversityInnovationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140564783841888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Allowance for credit losses (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Expected credit losses for financial assets</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140564694565632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Property and equipment (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Office furniture and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=brns_LaboratoryEquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=brns_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=brns_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140564790017104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Intangible Assets (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful life of intangible assets</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140564783991728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Impairment of long-lived assets and Goodwill (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment of long-lived assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment of goodwill</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140564784090000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Share based compensation (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140564688891424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Research and Development Incentives (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_ResearchAndDevelopmentIncentiveIncomeExpense', window );">Research and development incentives</a></td>
<td class="nump">$ 3,461<span></span>
</td>
<td class="nump">$ 1,240<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_ResearchAndDevelopmentIncentiveIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the research and development incentives (expenses) for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_ResearchAndDevelopmentIncentiveIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140564694734144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Foreign Currency Translation in General and Administrative Expenses (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyAbstract', window );"><strong>Foreign Currency [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Net foreign exchange gain (loss)</a></td>
<td class="num">$ (7.6)<span></span>
</td>
<td class="nump">$ 26.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482014/830-20-35-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481956/830-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481926/830-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481839/830-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140564786756048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net (Loss)/Income Per Share - Computation (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net (loss)/income</a></td>
<td class="num">$ (73,447)<span></span>
</td>
<td class="nump">$ 5,321<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to noncontrolling interest</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss)/income attributable to Barinthus Biotherapeutics plc shareholders</a></td>
<td class="num">$ (73,347)<span></span>
</td>
<td class="nump">$ 5,342<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average ordinary shares outstanding, basic (in shares)</a></td>
<td class="nump">38,386,491<span></span>
</td>
<td class="nump">37,248,126<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Effect of dilutive stock options (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">921,181<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average ordinary shares outstanding, diluted (in shares)</a></td>
<td class="nump">38,386,491<span></span>
</td>
<td class="nump">38,169,307<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net (loss)/income per share attributable to ordinary shareholders, basic (in usd per share)</a></td>
<td class="num">$ (1.91)<span></span>
</td>
<td class="nump">$ 0.14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net (loss)/income per share attributable to ordinary shareholders, diluted (in usd per share)</a></td>
<td class="num">$ (1.91)<span></span>
</td>
<td class="nump">$ 0.14<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480454/718-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-22<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-28A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140564693289120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net (Loss)/Income Per Share - Additional Information (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Shares issuable for stock options that were excluded from the computation of diluted weighted-average shares outstanding (in shares)</a></td>
<td class="nump">6,207,664<span></span>
</td>
<td class="nump">2,912,756<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140564694149568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment, Net - Components (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, at cost</a></td>
<td class="nump">$ 15,509<span></span>
</td>
<td class="nump">$ 9,279<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(3,688)<span></span>
</td>
<td class="num">(1,322)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">11,821<span></span>
</td>
<td class="nump">7,957<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Office furniture and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, at cost</a></td>
<td class="nump">1,108<span></span>
</td>
<td class="nump">1,041<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=brns_LaboratoryEquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, at cost</a></td>
<td class="nump">5,728<span></span>
</td>
<td class="nump">4,312<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, at cost</a></td>
<td class="nump">$ 8,673<span></span>
</td>
<td class="nump">$ 3,926<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=brns_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=brns_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140564783804800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 2.3<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140564687244960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible assets, net (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense for intangible assets</a></td>
<td class="nump">$ 3.2<span></span>
</td>
<td class="nump">$ 3.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Estimated annual amortization expense for 2024</a></td>
<td class="nump">3.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">Estimated annual amortization expense for 2025</a></td>
<td class="nump">3.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">Estimated annual amortization expense for 2026</a></td>
<td class="nump">3.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">Estimated annual amortization expense for 2027</a></td>
<td class="nump">3.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">Estimated annual amortization expense for 2028</a></td>
<td class="nump">3.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSix', window );">Estimated annual amortization expense for 2029</a></td>
<td class="nump">3.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSeven', window );">Estimated annual amortization expense for 2030</a></td>
<td class="nump">3.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_FiniteLivedIntangibleAssetExpectedAmortizationYearEight', window );">Estimated annual amortization expense for 2031</a></td>
<td class="nump">3.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross amount of amortizable intangible assets</a></td>
<td class="nump">31.6<span></span>
</td>
<td class="nump">31.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization for amortizable intangible assets</a></td>
<td class="nump">$ 6.5<span></span>
</td>
<td class="nump">$ 3.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_FiniteLivedIntangibleAssetExpectedAmortizationYearEight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived Intangible Asset, Expected Amortization, Year Eight</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_FiniteLivedIntangibleAssetExpectedAmortizationYearEight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSeven">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived Intangible Asset, Expected Amortization, Year Seven</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSeven</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSix">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived Intangible Asset, Expected Amortization, Year Six</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSix</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483147/928-340-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140564694571856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid and other current assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepayments and accrued income</a></td>
<td class="nump">$ 5,402<span></span>
</td>
<td class="nump">$ 5,887<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValueAddedTaxReceivableCurrent', window );">Value Added Tax receivable</a></td>
<td class="nump">3,031<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_LeaseIncentiveReceivablesCurrent', window );">Lease incentives receivable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,770<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other</a></td>
<td class="nump">1,474<span></span>
</td>
<td class="nump">611<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total</a></td>
<td class="nump">$ 9,907<span></span>
</td>
<td class="nump">$ 8,268<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_LeaseIncentiveReceivablesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the current receivable for an incentive or inducement contractually stipulated between parties to a lease whereby the lessor has committed to provide the entity (lessee) with a cash payment as inducement to enter the lease. The receivable is due within one year. For classified balance sheets, this element represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_LeaseIncentiveReceivablesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValueAddedTaxReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValueAddedTaxReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140564687905712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_AccruedManufacturingAndClinicalExpensesCurrent', window );">Accrued manufacturing and clinical expenses</a></td>
<td class="nump">$ 4,003<span></span>
</td>
<td class="nump">$ 2,997<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedBonusesCurrent', window );">Accrued bonus</a></td>
<td class="nump">2,412<span></span>
</td>
<td class="nump">1,925<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Accrued payroll and employee benefits</a></td>
<td class="nump">789<span></span>
</td>
<td class="nump">928<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="nump">942<span></span>
</td>
<td class="nump">1,270<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued other</a></td>
<td class="nump">1,066<span></span>
</td>
<td class="nump">941<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 9,212<span></span>
</td>
<td class="nump">$ 8,061<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_AccruedManufacturingAndClinicalExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for manufacturing and clinical expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_AccruedManufacturingAndClinicalExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedBonusesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedBonusesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140564684868144">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Out-licenses and Grants - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 20, 2023</div></th>
<th class="th"><div>Mar. 28, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 802<span></span>
</td>
<td class="nump">$ 44,703<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_ContractWithCustomerLiabilityRevenueRecognized1', window );">Non-refundable upfront revenue recognized</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">158<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">802<span></span>
</td>
<td class="nump">44,694<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=brns_OuiLicenseAgreementAmendmentMember', window );">OUI</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_PercentageOfRoyaltiesOnNetSales', window );">Percentage of royalties on commercial sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=brns_AgreementWithOxfordUniversityInnovationMember', window );">Agreement with OUI</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=brns_AgreementWithOxfordUniversityInnovationMember', window );">Agreement with OUI | License revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="nump">43,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=brns_AgreementWithScancellToGrantResearchAndDevelopmentLicenseMember', window );">Agreement with Scancell</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_ContractWithCustomerLiabilityRevenueRecognized1', window );">Non-refundable upfront revenue recognized</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=brns_CoalitionForEpidemicPreparednessInnovationsFundingAgreementMember', window );">CEPI Funding Agreement</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_FundingAmountMaximum', window );">Maximum funding amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 34,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_RoyaltyPaymentTermMaximum', window );">Maximum royalty payment period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_ProceedsFromGrantsReceived', window );">Proceeds from grants received</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Income recognized</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:5.75pt">Includes <span style="-sec-ix-hidden:f-192"><span style="-sec-ix-hidden:f-193">license revenue</span></span> from related parties for the year ended December&#160;31, 2023 totaling $0.8&#160;million (December&#160;31, 2022: $43.7&#160;million). License revenue is generated in the United Kingdom. </span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_ContractWithCustomerLiabilityRevenueRecognized1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract with Customer, Liability, Revenue Recognized1</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_ContractWithCustomerLiabilityRevenueRecognized1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_FundingAmountMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Funding Amount, Maximum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_FundingAmountMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_PercentageOfRoyaltiesOnNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of royalties on the net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_PercentageOfRoyaltiesOnNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_ProceedsFromGrantsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Grants Received</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_ProceedsFromGrantsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_RoyaltyPaymentTermMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Payment, Term, Maximum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_RoyaltyPaymentTermMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479428/808-10-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=brns_OuiLicenseAgreementAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=brns_OuiLicenseAgreementAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=brns_AgreementWithOxfordUniversityInnovationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=brns_AgreementWithOxfordUniversityInnovationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=brns_AgreementWithScancellToGrantResearchAndDevelopmentLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=brns_AgreementWithScancellToGrantResearchAndDevelopmentLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=brns_CoalitionForEpidemicPreparednessInnovationsFundingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=brns_CoalitionForEpidemicPreparednessInnovationsFundingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140564689529984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Out-licenses and Grants - Changes in the contract liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_ContractWithCustomerLiabilityRollForward', window );"><strong>Contract with Customer, Liability [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Beginning balance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 182<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_ContractWithCustomerLiabilityRevenueRecognized1', window );">Revenue recognized related to contract liability balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(158)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_ContractWithCustomerLiabilityForeignExchangeTranslation', window );">Foreign exchange translation</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(24)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Ending balance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_ContractWithCustomerLiabilityForeignExchangeTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in contract liabilities due to foreign exchange translations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_ContractWithCustomerLiabilityForeignExchangeTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_ContractWithCustomerLiabilityRevenueRecognized1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract with Customer, Liability, Revenue Recognized1</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_ContractWithCustomerLiabilityRevenueRecognized1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_ContractWithCustomerLiabilityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract with Customer, Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_ContractWithCustomerLiabilityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140564693526032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Ordinary Shares - Additional Information (Details)<br> &#163; / shares in Units, $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th">
<div>May 04, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th"><div>Apr. 21, 2021</div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>vote </div>
<div>&#163; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 06, 2023 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>&#163; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 04, 2021 </div>
<div>&#163; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 04, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Ordinary Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, authorized (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,643,540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,683,531<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares, nominal value (in gbp per share) | &#163; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 0.000025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 0.000025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issue of ordinary shares, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,035<span></span>
</td>
<td class="nump">$ 484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_CommonStockNumberOfVotesPerShare', window );">Number of votes per common share (in votes) | vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_PercentageOfSharesNecessaryToExercisePreemptiveRights', window );">Percentage of ordinary shares present to exercise preemptive rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_PeriodOfPreemptiveRightsToBeExercised', window );">Maximum period to exercise preemptive rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_MaximumAggregateNominalAmountOfSharesAuthorizedToBeAllottedFreeFromStatutoryPreEmptionRights', window );">Maximum aggregate nominal amount of shares authorized to be allotted free from pre-emption rights | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 1,928<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Ordinary Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_NumberOfAmericanDepositarySharesAdsIssued', window );">Number of ADS shares closed (in shares) | shares</a></td>
<td class="nump">6,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, authorized (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,500,000<span></span>
</td>
<td class="nump">6,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares, nominal value (in gbp per share) | &#163; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 0.000025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Ordinary shares, public offering price (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issue of ordinary shares, net of issuance costs</a></td>
<td class="nump">$ 102,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_IssuanceOfCommonStockUnderwritingCommissions', window );">Underwriting commissions</a></td>
<td class="nump">7,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_IssuanceOfCommonStockOfferingCosts', window );">Offering costs</a></td>
<td class="nump">$ 2,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_PeriodOfPreemptiveRightsToBeExercised', window );">Maximum period to exercise preemptive rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_CommonStockNumberOfVotesPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of votes that each common share is entitled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_CommonStockNumberOfVotesPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_IssuanceOfCommonStockOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Offering costs related to the issuance of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_IssuanceOfCommonStockOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_IssuanceOfCommonStockUnderwritingCommissions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Underwriting commissions for issuance of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_IssuanceOfCommonStockUnderwritingCommissions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_MaximumAggregateNominalAmountOfSharesAuthorizedToBeAllottedFreeFromStatutoryPreEmptionRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of maximum aggregate nominal amount of shares that the board of directors are authorized to allot free from statutory Pre-emption rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_MaximumAggregateNominalAmountOfSharesAuthorizedToBeAllottedFreeFromStatutoryPreEmptionRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_NumberOfAmericanDepositarySharesAdsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of ADS shares issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_NumberOfAmericanDepositarySharesAdsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_PercentageOfSharesNecessaryToExercisePreemptiveRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum percentage of shares required to exercise preemptive rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_PercentageOfSharesNecessaryToExercisePreemptiveRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_PeriodOfPreemptiveRightsToBeExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The period allowed to exercise preemptive rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_PeriodOfPreemptiveRightsToBeExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140564693816368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Ordinary Shares - Ordinary shares for future issuance (Details) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Exercise of stock options</a></td>
<td class="nump">6,207,664<span></span>
</td>
<td class="nump">4,884,720<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future stock incentive plan awards</a></td>
<td class="nump">1,623,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total</a></td>
<td class="nump">7,831,504<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140564693406080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Deferred shares (Details)<br> &#163; / shares in Units, &#163; in Millions, $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>GBP (&#163;) </div>
<div>&#163; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 29, 2023 </div>
<div>&#163; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>&#163; / shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=brns_DeferredShares.Member', window );">Deferred A shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_OrdinarySharesLiquidationPreference', window );">Ordinary shares, liquidation preference</a></td>
<td class="nump">&#163; 1.0<span></span>
</td>
<td class="nump">$ 1.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_DeferredStockParOrStatedValuePerShare', window );">Deferred shares, nominal value (in gbp per share)</a></td>
<td class="nump">&#163; 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=brns_DeferredBSharesMember', window );">Deferred B shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_DeferredStockParOrStatedValuePerShare', window );">Deferred shares, nominal value (in gbp per share)</a></td>
<td class="nump">0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 0.01<span></span>
</td>
<td class="nump">0.01<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=brns_DeferredCSharesMember', window );">Deferred C shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_DeferredStockParOrStatedValuePerShare', window );">Deferred shares, nominal value (in gbp per share)</a></td>
<td class="nump">&#163; 0.000007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 0.00000736245954692556<span></span>
</td>
<td class="nump">&#163; 0.000007<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_DeferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of deferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_DeferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_OrdinarySharesLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liquidation preference on ordinary shares to be paid after which the deferred shares have the entitlement to receive out of the assets of the Company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_OrdinarySharesLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=brns_DeferredShares.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=brns_DeferredShares.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=brns_DeferredBSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=brns_DeferredBSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=brns_DeferredCSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=brns_DeferredCSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140564783917408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value - Additional information (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=brns_AvideaMember', window );">Avidea</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Contingent consideration liability</a></td>
<td class="nump">$ 1.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=brns_AvideaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=brns_AvideaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140564786671024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value - Change in fair value of contingent consideration (Details) - Contingent consideration liability - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">$ 1,711<span></span>
</td>
<td class="nump">$ 2,371<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value recognized in net loss</a></td>
<td class="nump">55<span></span>
</td>
<td class="num">(73)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Settlement of contingency</a></td>
<td class="num">(163)<span></span>
</td>
<td class="num">(325)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeTranslation', window );">Foreign exchange translation recognized in other comprehensive loss</a></td>
<td class="nump">219<span></span>
</td>
<td class="num">(262)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">$ 1,823<span></span>
</td>
<td class="nump">$ 1,711<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign exchange translation of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=brns_ContingentConsiderationLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=brns_ContingentConsiderationLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140564807470352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="nump">$ 12,209<span></span>
</td>
<td class="nump">$ 12,630<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillPurchaseAccountingAdjustments', window );">Measurement period adjustments</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(421)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">$ 12,209<span></span>
</td>
<td class="nump">$ 12,209<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillPurchaseAccountingAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 16<br> -SubTopic 10<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479405/805-10-25-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillPurchaseAccountingAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140564684852352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Apr. 08, 2021</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares available for future grants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,207,664<span></span>
</td>
<td class="nump">4,884,720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,831,504<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.99<span></span>
</td>
<td class="nump">$ 3.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value of stock options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost related to options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.0<span></span>
</td>
<td class="nump">$ 7.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period over which unrecognized compensation cost is expected to be recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=brns_BarinthusBiotherapeuticsPlcShareAwardPlan2021Member', window );">Barinthus Biotherapeutics plc Share Award Plan 2021 | Restricted share units, options, share appreciation rights and restricted shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Shares available for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,675,680<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_ShareBasedCompensationPercentageOfSharesAvailableForIssuanceAsPercentageOfIssuedAndOutstandingShares', window );">Percentage of issued and outstanding ordinary shares available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional number of shares available for issuance (in shares)</a></td>
<td class="nump">1,507,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_ExpirationOfShareBasedCompensationPlanFromDateOfInitialIssuance', window );">Expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares available for future grants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,623,840<span></span>
</td>
<td class="nump">1,670,268<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=brns_EnterpriseManagementIncentiveShareOptionSchemeMember', window );">Enterprise Management Incentive Share Option Scheme</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=brns_EnterpriseManagementIncentiveShareOptionSchemeMember', window );">Enterprise Management Incentive Share Option Scheme | RSU's</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,530,634<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_ExpirationOfShareBasedCompensationPlanFromDateOfInitialIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The duration of grants awarded under a share-based compensation plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_ExpirationOfShareBasedCompensationPlanFromDateOfInitialIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_ShareBasedCompensationPercentageOfSharesAvailableForIssuanceAsPercentageOfIssuedAndOutstandingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares available for issuance under the Plan as a percentage of the Company's issued and outstanding shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_ShareBasedCompensationPercentageOfSharesAvailableForIssuanceAsPercentageOfIssuedAndOutstandingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=brns_BarinthusBiotherapeuticsPlcShareAwardPlan2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=brns_BarinthusBiotherapeuticsPlcShareAwardPlan2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=brns_RestrictedShareUnitsStockOptionsShareAppreciationRightsAndRestrictedSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=brns_RestrictedShareUnitsStockOptionsShareAppreciationRightsAndRestrictedSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=brns_EnterpriseManagementIncentiveShareOptionSchemeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=brns_EnterpriseManagementIncentiveShareOptionSchemeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140564784175728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Weighted-average assumptions (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=brns_EnterpriseManagementIncentiveShareOptionSchemeMember', window );">Enterprise Management Incentive Share Option Scheme</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">97.10%<span></span>
</td>
<td class="nump">94.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.70%<span></span>
</td>
<td class="nump">2.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=brns_EnterpriseManagementIncentiveShareOptionSchemeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=brns_EnterpriseManagementIncentiveShareOptionSchemeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140564684872288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Summary of stock option activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Stock Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at the beginning of the period (in shares)</a></td>
<td class="nump">4,884,720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">2,288,236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(72,386)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Forfeited/expired (in shares)</a></td>
<td class="num">(892,906)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at the end of the period (in shares)</a></td>
<td class="nump">6,207,664<span></span>
</td>
<td class="nump">4,884,720<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at the end of the period (in shares)</a></td>
<td class="nump">2,839,791<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted- average Exercise Price Per Option</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at the beginning of the period (in usd per share)</a></td>
<td class="nump">$ 9.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in usd per share)</a></td>
<td class="nump">2.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in usd per share)</a></td>
<td class="nump">0.00026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Forfeited/expired (in usd per share)</a></td>
<td class="nump">7.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at the end of the period (in usd per share)</a></td>
<td class="nump">6.91<span></span>
</td>
<td class="nump">$ 9.04<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at the end of the period (in usd per share)</a></td>
<td class="nump">$ 8.91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Additional Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding, Weighted-average remaining contractual term (Years)</a></td>
<td class="text">7 years 11 months 12 days<span></span>
</td>
<td class="text">7 years 4 months 9 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable, Weighted-average remaining contractual term (Years) (in years)</a></td>
<td class="text">7 years 3 months 29 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 6,044<span></span>
</td>
<td class="nump">$ 2,619<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 2,883<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140564790030032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Share based compensation expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share based compensation expense</a></td>
<td class="nump">$ 5,055<span></span>
</td>
<td class="nump">$ 9,877<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share based compensation expense</a></td>
<td class="nump">2,011<span></span>
</td>
<td class="nump">2,668<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share based compensation expense</a></td>
<td class="nump">$ 3,044<span></span>
</td>
<td class="nump">$ 7,209<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140564786587504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - (Loss) income before income taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">United Kingdom</a></td>
<td class="num">$ (50,534)<span></span>
</td>
<td class="nump">$ 15,511<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">(Loss)/profit before income tax</a></td>
<td class="num">(76,522)<span></span>
</td>
<td class="nump">850<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="num">(24,507)<span></span>
</td>
<td class="num">(14,648)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Other foreign</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="num">$ (1,481)<span></span>
</td>
<td class="num">$ (13)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_IncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Taxes [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_IncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140564693914272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Components of income tax benefit (expense) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred income tax benefit:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income tax benefit</a></td>
<td class="nump">$ 3,075<span></span>
</td>
<td class="nump">$ 4,471<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current income tax benefit/(expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="num">(28)<span></span>
</td>
<td class="nump">133<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred income tax benefit:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">3,148<span></span>
</td>
<td class="nump">4,338<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Other foreign</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current income tax benefit/(expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="num">$ (45)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140564693969824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation to the effective tax rate (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory tax rate</a></td>
<td class="nump">23.52%<span></span>
</td>
<td class="nump">19.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_EffectiveIncomeTaxRateReconciliationPercentIncreaseDecreaseAbstract', window );"><strong>Increase (decreases) resulting from:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Permanent differences</a></td>
<td class="nump">1.03%<span></span>
</td>
<td class="num">(103.46%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustments', window );">Provision to return adjustments</a></td>
<td class="num">(4.09%)<span></span>
</td>
<td class="num">(105.66%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment', window );">Research and development credits</a></td>
<td class="num">(4.94%)<span></span>
</td>
<td class="num">(307.09%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Foreign rate differential</a></td>
<td class="nump">1.23%<span></span>
</td>
<td class="num">(149.82%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(11.84%)<span></span>
</td>
<td class="nump">146.55%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent', window );">Share based compensation</a></td>
<td class="num">(0.84%)<span></span>
</td>
<td class="num">(10.21%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">4.07%<span></span>
</td>
<td class="num">(510.69%)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_EffectiveIncomeTaxRateReconciliationPercentIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Percent, Increase (Decrease)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_EffectiveIncomeTaxRateReconciliationPercentIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to provision to return adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -SubTopic 740<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480887/718-740-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140564684128256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Deferred tax assets and liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 23,589<span></span>
</td>
<td class="nump">$ 9,940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credit carryforwards</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">3,146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Share based compensation</a></td>
<td class="nump">4,226<span></span>
</td>
<td class="nump">3,956<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_DeferredTaxAssetsLeasingArrangements', window );">Lease liability</a></td>
<td class="nump">3,404<span></span>
</td>
<td class="nump">2,257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsIntangibles', window );">Accruals and intangibles</a></td>
<td class="nump">745<span></span>
</td>
<td class="nump">765<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Capitalized Research and Development expenditure</a></td>
<td class="nump">4,228<span></span>
</td>
<td class="nump">2,522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax asset</a></td>
<td class="nump">36,233<span></span>
</td>
<td class="nump">22,641<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(25,057)<span></span>
</td>
<td class="num">(13,707)<span></span>
</td>
<td class="num">$ (13,500)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="nump">11,176<span></span>
</td>
<td class="nump">8,934<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Depreciation</a></td>
<td class="num">(1,652)<span></span>
</td>
<td class="num">(1,704)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Right-of-use lease asset</a></td>
<td class="num">(1,922)<span></span>
</td>
<td class="num">(1,993)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities', window );">Unrealized gain on investment</a></td>
<td class="num">(1,267)<span></span>
</td>
<td class="num">(1,204)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Intangible assets</a></td>
<td class="num">(6,909)<span></span>
</td>
<td class="num">(7,779)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Net deferred tax liabilities</a></td>
<td class="num">(11,750)<span></span>
</td>
<td class="num">(12,680)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Total deferred tax, net</a></td>
<td class="num">$ (574)<span></span>
</td>
<td class="num">$ (3,746)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_DeferredTaxAssetsLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_DeferredTaxAssetsLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals and intangibles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from unrealized gains on trading securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140564687618112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Deferred tax assets for capitalized research and development expenditure</a></td>
<td class="nump">$ 2,522<span></span>
</td>
<td class="nump">$ 4,228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">13,707<span></span>
</td>
<td class="nump">25,057<span></span>
</td>
<td class="nump">$ 13,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">39,600<span></span>
</td>
<td class="nump">92,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Research and development tax credit carryforwards</a></td>
<td class="nump">3,100<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxCreditsAndAdjustments', window );">Unlimited carryforward amount</a></td>
<td class="nump">$ 35,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 74,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxCreditsAndAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A credit or adjustment for government or taxing authority authorized decrease in taxes owed as a result of meeting certain tax policy conditions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxCreditsAndAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140564792822192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Changes in the valuation allowance for deferred tax assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_ValuationAllowanceRollForward', window );"><strong>Valuation Allowance [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuations allowance at beginning of year</a></td>
<td class="nump">$ 13,707<span></span>
</td>
<td class="nump">$ 13,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_ValuationAllowanceDeferredTaxAssetIncreaseResultingFromCurrentPeriodAdditions', window );">Changes in valuation allowance arising from in-year additions</a></td>
<td class="nump">1,052<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_ValuationAllowanceDeferredTaxAssetIncreaseResultingFromIncomeTaxProvision', window );">Increases recorded to income tax provision</a></td>
<td class="nump">9,605<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseResultingFromForeignCurrencyTranslation', window );">Foreign exchange translation</a></td>
<td class="nump">693<span></span>
</td>
<td class="num">(1,293)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance at end of year</a></td>
<td class="nump">$ 25,057<span></span>
</td>
<td class="nump">$ 13,707<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseResultingFromForeignCurrencyTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Valuation Allowance, Deferred Tax Asset, Increase (Decrease) Resulting From Foreign Currency Translation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseResultingFromForeignCurrencyTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_ValuationAllowanceDeferredTaxAssetIncreaseResultingFromCurrentPeriodAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Valuation Allowance, Deferred Tax Asset, Increase Resulting From Current Period Additions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_ValuationAllowanceDeferredTaxAssetIncreaseResultingFromCurrentPeriodAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_ValuationAllowanceDeferredTaxAssetIncreaseResultingFromIncomeTaxProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Valuation Allowance, Deferred Tax Asset, Increase Resulting From Income Tax Provision</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_ValuationAllowanceDeferredTaxAssetIncreaseResultingFromIncomeTaxProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_ValuationAllowanceRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Valuation Allowance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_ValuationAllowanceRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140564684943248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional information (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 14, 2022 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Sep. 03, 2021 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=brns_OxfordshireMember', window );">Oxfordshire</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_NumberOfSquareFeetUnderLeaseAgreement', window );">Size of space under lease agreement (in square feet) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Refundable security deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_MD', window );">Maryland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_NumberOfSquareFeetUnderLeaseAgreement', window );">Size of space under lease agreement (in square feet) | ft&#178;</a></td>
<td class="nump">19,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Refundable security deposit</a></td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_LesseeOperatingLeaseExtendedTerm', window );">Additional lease term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseholdImprovementsGross', window );">Leasehold improvement expense</a></td>
<td class="nump">$ 3.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=brns_InLicenseAgreementsMember', window );">In-License Agreements | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_PercentageOfFutureRoyaltiesForDirectSalesOfCoveredProductLicenseAgreement', window );">Percentage of future royalties for direct sales of a covered product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_PercentageOfNetPaymentsReceivedForAllowableSublicensesOfTechnologyDevelopedLicenseAgreement', window );">Net payments received for allowable sublicenses of technology developed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=brns_InLicenseAgreementsMember', window );">In-License Agreements | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_PercentageOfFutureRoyaltiesForDirectSalesOfCoveredProductLicenseAgreement', window );">Percentage of future royalties for direct sales of a covered product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_PercentageOfNetPaymentsReceivedForAllowableSublicensesOfTechnologyDevelopedLicenseAgreement', window );">Net payments received for allowable sublicenses of technology developed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_LesseeOperatingLeaseExtendedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease extended, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_LesseeOperatingLeaseExtendedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_NumberOfSquareFeetUnderLeaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the information pertaining to number of Square Feet Under Lease Agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_NumberOfSquareFeetUnderLeaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_PercentageOfFutureRoyaltiesForDirectSalesOfCoveredProductLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of future royalties for direct sales of a covered product under the In-License Agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_PercentageOfFutureRoyaltiesForDirectSalesOfCoveredProductLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_PercentageOfNetPaymentsReceivedForAllowableSublicensesOfTechnologyDevelopedLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of net payments received for allowable sublicenses of technology developed under the In-License Agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_PercentageOfNetPaymentsReceivedForAllowableSublicensesOfTechnologyDevelopedLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseholdImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseholdImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=brns_OxfordshireMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=brns_OxfordshireMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_MD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_MD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=brns_InLicenseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=brns_InLicenseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140564693272240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Right-of-use assets, lease liabilities and other information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use asset</a></td>
<td class="nump">$ 7,581<span></span>
</td>
<td class="nump">$ 7,753<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liability, current</a></td>
<td class="nump">1,785<span></span>
</td>
<td class="nump">433<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liability, noncurrent</a></td>
<td class="nump">11,191<span></span>
</td>
<td class="nump">8,340<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_OtherInformationLesseeAbstract', window );"><strong>Other information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">$ 639<span></span>
</td>
<td class="nump">$ 1,081<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term (years)</a></td>
<td class="text">8 years 11 months 4 days<span></span>
</td>
<td class="text">9 years 5 months 8 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">7.50%<span></span>
</td>
<td class="nump">7.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease Costs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease costs</a></td>
<td class="nump">$ 189<span></span>
</td>
<td class="nump">$ 529<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Fixed Lease Costs</a></td>
<td class="nump">883<span></span>
</td>
<td class="nump">1,216<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">$ 1,072<span></span>
</td>
<td class="nump">$ 1,745<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_OtherInformationLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Information, Lessee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_OtherInformationLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140564784074448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Maturities of minimum lease liabilities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 1,785<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">1,936<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">1,960<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2027</a></td>
<td class="nump">1,985<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2028</a></td>
<td class="nump">2,010<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">7,999<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">17,675<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(4,699)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liability</a></td>
<td class="nump">$ 12,976<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140564694124128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Employer contribution</a></td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140564684065792">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Amounts owed to other party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,601<span></span>
</td>
<td class="nump">$ 3,748<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">802<span></span>
</td>
<td class="nump">44,703<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">802<span></span>
</td>
<td class="nump">44,694<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related parties</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">800<span></span>
</td>
<td class="nump">43,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Amounts owned from other party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,524<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=brns_ShareholderTheUniversityOfOxfordMember', window );">Shareholder, The University of Oxford | Related parties</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Amounts owed to other party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=brns_ShareholderTheUniversityOfOxfordMember', window );">Shareholder, The University of Oxford | Expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Amounts of related party transactions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">400<span></span>
</td>
<td class="nump">400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=brns_OxfordUniversityInnovationLimitedMember', window );">Oxford University Innovation Limited | Related parties</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Amounts owed to other party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Amounts owned from other party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=brns_OxfordUniversityInnovationLimitedMember', window );">Oxford University Innovation Limited | Related parties | License revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">800<span></span>
</td>
<td class="nump">43,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=brns_OxfordUniversityInnovationLimitedMember', window );">Oxford University Innovation Limited | Expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Amounts of related party transactions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 600<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:5.75pt">Includes <span style="-sec-ix-hidden:f-192"><span style="-sec-ix-hidden:f-193">license revenue</span></span> from related parties for the year ended December&#160;31, 2023 totaling $0.8&#160;million (December&#160;31, 2022: $43.7&#160;million). License revenue is generated in the United Kingdom. </span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=brns_ShareholderTheUniversityOfOxfordMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=brns_ShareholderTheUniversityOfOxfordMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=brns_ExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=brns_ExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=brns_OxfordUniversityInnovationLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=brns_OxfordUniversityInnovationLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140564693734368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2024</div></th>
<th class="th"><div>Jan. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,288,236<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price of options granted (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.51<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,592,423<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price of options granted (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Barinthus Biotherapeutics plc Share Award Plan 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_ShareBasedCompensationPercentageOfSharesAvailableForIssuanceAsPercentageOfIssuedAndOutstandingShares', window );">Percentage of issued and outstanding ordinary shares available for issuance</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_ShareBasedCompensationPercentageOfSharesAvailableForIssuanceAsPercentageOfIssuedAndOutstandingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares available for issuance under the Plan as a percentage of the Company's issued and outstanding shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_ShareBasedCompensationPercentageOfSharesAvailableForIssuanceAsPercentageOfIssuedAndOutstandingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=brns_BarinthusBiotherapeuticsPlcShareAwardPlan2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=brns_BarinthusBiotherapeuticsPlcShareAwardPlan2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>115
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
M*8-T6*1'<8C*"   Z#D  !@   !X;"]W;W)K<VAE971S+W-H965T,2YX;6RU
MF_]SVC@:QO\5#;NST\Z%X&]):)MD!DRRY;9).""[V]VY'Q1;!$]MBY/ED/SW
M]TH&C'.RL&]$.FG ^'TL?9#D]Y'DRS5E/[(E(1R])G&:7766G*\^]WI9L"0)
MSD[IBJ3PR8*R!'-XRYY[V8H1',J@).XYEG7>2W"4=JXOY;$)N[ZD.8^CE$P8
MRO(DP>QM2&*ZONK8G>V!:?2\Y.) [_IRA9_)C/#'U83!N]Y.)8P2DF8131$C
MBZO.P/X\\LY$@#SC]XBLL[W72%3EB=(?XLTXO.I8HD0D)@$7$AC^O!"?Q+%0
M@G+\9R/:V5U3!.Z_WJK?RLI#99YP1GP:_Q&%?'G5Z7=02!8XC_F4KK^2385D
M 0,:9_)_M"[./7,[*,@S3I--,)0@B=+B+W[=@-@+Z%LU <XFP'D78'LU >XF
MP&T:X&T"/$FFJ(KD,,(<7U\RND9,G UJXH6$*:.A^E$JOO<99_!I!''\VJ<O
MA*$N>IR-T(>?/Z*?492BNRB.X4O)+GL<+B%.[ 4;N6$AY]3(V0ZZHRE?9N@F
M#4E8%>A!V78%=+8%'#I:Q1$)3I%KGR#'<EQ%@7Q]^!UFI\CV9+BG"!_IP_^9
MIW!U2W7U2FW<'6Y7ZKEUM:%!#KV&HW%:]%G1]O_^!F>A,2=)]F\5\D+24TN*
M@>%SML(!N>I S\\(>R&=ZU]^LL^M+RI<)L5&AL0J*+T=2D^G7J*<OZV("IL^
MW+:ZOZGX:*/:\C$D5N%SMN-SUHS/($US'*,I65'&5:#T.ISE*KR^-JHM*$-B
M%5#G.U#GS4!-"(MH*$8N!&.ILDT=4-J.5;6#E3:^+31#8A5H%SMH%]JJ^CEC
M@MEME 70N+X3S+3@]&K=KNUT75M%3!O8EI@AL0JQ_HY8O^%XQ3"D37+DK^^3
M>JT%CC-EI]2&M:5E2*Q"Z]..UB=M#6]2'O$W:%XQ0?=Y\D28BI)>P[+LKF>Y
MYQ<J4MK0MJ0,B55(V5:9PEE-6$W)<Y1Q:%P<W>-$V0L/" T'T_']_.OC# W'
M#_.O-]/!Y.9Q/O9G:/+-5T'4Z[6E:$JMBG$O$[:;8!RG 670+65N=H)F'$8T
M1!GR:9YR]@9_0S5;O?J?EA*@-J@U0$-J58!."=!I G".7]$XA)$N6D1!D>'6
M]^ #DI;5M8H?)3UM<&MZAM2J]$IG8&NSY2V]01B">G:R?8&D.7A(U6U.+_F8
M1AR==VWP+W^1/$/#/(K#*'U6LC1J#$RI55F6UL#6)_=:EO,U5;+42TYSOB0,
M3%N(!B\D5>?$>HW6$(]A'^S2/]CZQ/\]1%^\@X%P3M>I$J!>[BMF:Q+')Z,H
M#*@JY_'U JWI'<-3V*6IL/5>X#V]"<TX),I_1:OZ.XA>\>%/VT;6Z%:)SJBQ
M,*5615=:"UOO!OZGX15W7B4RO=*O0R4LHY["E%H55NDJ;+T5D+URP BN;U9Z
M@7]X'OI@?52",FHG3*E5096&PM:[@6]4&-7)DJ8Z1W% Q.Z?GZ&^W4=]JZ\D
M9M16F%*K3KR6OL)IY"O^@%&[^R.%41_-",Z 7XC&69:K 1[0O%?=>WU]4%ML
MIM2JV$H?X33R$;_3&(8MS H3RY23Z0>4:F 9]0RFU*JP2L_@-/(,V^FD8D($
M4E3INW(U-+WB=Z**\O51K:D=PRLXI5=P&GF%<<H)*U;.Q,0;WF)44M,KUE$S
MZ@I,J56IE:[ :>0*9'=$/MCZ9ZK.*@[HW-.TBX. @ R(A(6@DIY1.V!*K4JO
MM -.(SLP2W <@Y/,X.-,W3__O_4$?5AK6,?(_ITR^W<:9?\W"6'/8C3[%13X
M$E*T9(53=9O3"]92,YKXFU*K4BL3?Z=1XG_SNC]'7JS**)'IU6HGR?5QK9D=
M(_]WROS?T:?O8_]VB@9Y&'&PY@/."=A,R>TVQJJ)GN$!O7IJ1LV *;4JM=(,
M./H\?K<8<QNE. TB< 9RHE<>NV%,SO?"O;38G/*W8*E<FC]PF7J81GV"*;7J
MEH;2)[B-?,)L"49!-\0=D*F%I8]KO6?A&.[ +=V!V\@=3/*G. J@DU*L3-?T
M*JTW?1BU#!NU,ZDF-I:]7%]\.O6LO1_[LO>BPE3Z K>9+Z!) AUPQFGPXP1:
M&(;BH8><PR"7ULQD#_7*K=$5:N=[E77[GQP;_NWJN,%R#$_@[NTLTF?PVR$M
MVUO!@N3T22P,+@C8@D Y.W1 =2+L&$TS1!>(+PEBNT7&7W[J._;%ETSLLHO2
M2)J0%:.O;RC;C:2<HB>"%I ?AV@=00(D)&8DR!F<#]\D?(EPMP^6.'TF\KN.
MLLV&PAA+01"HN:K8S[7=VG)'B/2,4$;91)8T#L%Q(WB)HG<PV!8&? +J<M<5
M$BLDM@V_#ORZLEBV)^0FF'$T'H^+ZD=9=3,-$K=9RA(D-A.=*EN/V>U6Q_!/
M;NF?W$;^R8=OE@&#<1J25_0;48_U>BDQ1/2=OMT_4U(SZIM,J56IE;[);;@/
M:W^KS"T<5)JG V)U^XKT8:V)'<,\N:5Y<AMNR-H0V^S+JF>FE[O]KB1FU#B9
M4JL2*XV3J[<Z \ 5%LAJLOX# O6YEU&O9$JMBJGT2J[>VSPPR!G$C&PF$PDE
M)Y,NQS>J-C*E5J57>B:WL!%F]RZ;-#J^4;61*;7J]N72-GEZOS./>$Q$8F$[
M'YX^;M,BY=WT@-*[=GV"4IK @1B]X#@G2)39_6*=BL3<.4,KPHH3583U5VJ]
M__D87LLKO9:G]UHP++(HP"D:0;J617(Q9E;;]?5B;9NJ4;61*;4JR-*->8[Y
MKN\9]6%&U4:FU*H\2Z_FZ5U5FZZO5VK5Q'V]6&N(1WG\8^_Y#[V'F#,<RI7"
MM^2)QDIV>H'A]'ZFI&34?IA2JU(J[8>G=PS;ME7Z[+K-P0>$[@>ST>!?2EY&
MS8<IM8)7;^_1.+$8(Q\QS% @MA053\GMCNX>8QS(A_=ZY>G%,Y!W6*SE9"@F
M"PBU3B^@H*QXK+!XP^E*/FCW1#FGB7RY)#@D3)P GR\HY=LWX@*[ASNO_PM0
M2P,$%     @ *8-T6,O6O-4Y @  O 4  !@   !X;"]W;W)K<VAE971S+W-H
M965T,BYX;6R-E%UOFS 4AO^*Y4F[F@(A'^TR0$J:58N63E&K;A?3+APX :O8
M9K8IW;^?/PC+I 3E!OQQWM?/,9P3MT*^J!) HS=6<97@4NMZ$00J*X$1-1(U
M<+-S$)(1;::R"%0M@>1.Q*H@"L-YP CE.(W=VDZFL6AT13GL)%(-8T3^64$E
MV@2/\7'AD1:EM@M!&M>D@"?0S_5.FEG0N^24 5=4<"3AD.#E>+&:VW@7\)U"
MJT[&R&:R%^+%3C9Y@D,+!!5DVCH0\WJ%.Z@J:V0P?G>>N#_2"D_'1_=[E[O)
M94\4W(GJ!\UUF>!;C'(XD*;2CZ+] ET^,^N7B4JY)VI];/01HZQ16K!.; @8
MY?Y-WKI[.!7<7!!$G2!RW/X@1[DFFJ2Q%"V2-MJXV8%+U:D-'.7VHSQI:7:I
MT>ETV>14HPWWG]?<4QQH8VLW@ZRS6'F+Z(+%.$(/@NM2H<\\A_Q_@\#P]%#1
M$6H5#3JN(1NAR?@#BL)H,N WZ9.<.+_)M4FBG\N]TM+\$K_.Y>O=IN?=;)DL
M5$TR2+"I P7R%7#Z_MUX'GX:8)WVK-,A=\\J)+JGDJ'-^AS>L,'MS7P 8]9C
MS*["^$88G&,85N\DS: E&F0I&ELRIHE(A;;;W0#:O$>;7X6V%=G%/W;8X9E3
M#3GZ2GF1"W8.*3BI* :R<'U#H4PT7/OBZE?[UK3T%?DOW/>U!R(+RA6JX&"D
MX>C&7)WTO<)/M*A=?>Z%-M7NAJ5IKR!M@-D_"*&/$WM W[#3OU!+ P04
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M*-VR5$&PJN+V20\,0(N%%PU0FT8Q"6,[ZK!#'3I1?Q6294< #(UKXR!<>,$
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MF J0Q[>4BJ>!>L<OONG,_@=02P,$%     @ *8-T6'["K*QU!@  IQL  !@
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M;"]W;W)K<VAE971S+W-H965T-BYX;6RM56UOVC 0_BNGK)I:J6M">*LZ0*)
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MRM!!P$C/<;#+32J8VB'J!D*X,?"@K:M*XX7U/I*,S-MBJYL-/VDH@HU8:SV
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M",SEX$CZ=?8=_DM S/(#+YAW,%-= 8<1I+"59&/K[%)?[/NNV@Q]OJD!YI;
M;MIF;BF:E.B@P3D)).^.>0=+P&*T?]RI^WVH^A/"W__#Z%MG5_!VY_8H)Z]=
M5K?>S_T$XCO+ZSH[NJYJ2V_ JGR&"W:5AS_@?X ,JIH(H0&=\ A'/WX"A]0>
M'&&=SH*')$NL!/L KX/QG:L!1H\H@K5!. )&AZYS37'*@+T:7S/%Y.5O(.5D
M+]_>]B;2UA6CYD__\O+B_,M7'E8YMAV19Q@"^T$T_M)4N+L//4%1PM'DW9KF
MV X-:03 8Q@$N\5!<#9X)KA-E^->AHVOR@H90Z8=CR!ZA<<T!$ZK/50%D.1U
MU;4-G:^E2IBC;@L\2Z G[QV2$XRKJWQ3U4S$2 ZX<NUV !_1]@FT#,XKE-EE
M!Y?[H<.C:Y#( T1T,/T^;[*W'<SF]\"S0U,R<6^K#BA2\4F#X6CTQ:.\"-!8
MDF.$)42XR6L@0L>3PHK$*->N"U/.(1[91DCOS"&F/A4 YLYER IP[C^Y:]<,
MC@%PG\#B\+K"K0"O& )>=_UA;9?+ 2@P*T9K$2,0AB/I,&"PUWFR)#C 5D!#
M0MBX*(;#P% ML0/H\7X/!P0:O/BX;^O2=5[(5AA^G?T9C"8A 1B!I]\L,$M.
M%,N@B, L56 DQV,$*Y 2V&Y=+B/I:"=0RAP[U\";-;V5ET!K%>I -)C"<3 M
MY+M=!Z0) @RE@P(;<+R#'2&)RMP1T-*!3,1Y =\XDE%$(I'^"<#^ZY?K%V#B
M@ Q%_ ,@/!D\N'BQ?AZ>X $BR">'!^W0LLC +G"'#9R#V@8T'OYQL8*3\T='
MME\-*/_@=L*6;-#BC#\RE@ RST\%SR6RW[;B,T?<M8TB%G@,I6='8C/+-V#N
MJOA3 5]6ONA@UT9LVT5!%N37>563'B&BO,[K@9]M3GRP^\J%,P3H2E=49 P?
M\H^N(]J?",0K&O/-)U<,='H_;D&3X\L5#;/3H/3<Y5V)OP&2VJ$K'.H(E%!Z
M!#F2I1<F(>"!]]=6%&?7:"B#=/-C:H-W@?_XT6: 21S3&V#1;$I0SKM!I91W
M@$4<7X)0J-NC:LGJ<!@:,00J$177P(DX[SK[ZX(*_JX!,CA_N;K#G(!7X2!
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MYD^2S'6:=Z!M2>J+FFIQ_0!L>EZY22H,C73Z\KJYU$./-D>)X&#_+F<_0IZ
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M$RX0)70+/XSOL-"*57\G(_V!0,)"1C5?MA)M;WQ(W!')F$9ZS#1AGC3/?M;
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M^B>6"[H.7X#GVQ;X0/[ !="D)_#>_"]02P,$%     @ *8-T6%)$M\>< @
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M*DLCDE^6-).B=@)TOU(4]&[C#&RGW/D_4$L#!!0    ( "F#=%B_+RM/YP(
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M<R]S:&5E=#$W+GAM;*U:;6_C-A+^*T2Z5R2 XSA.M@WV)4"2IFW02S=(=GO
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MQC _N7NK<AT"2''_5<G2%QEY#AOD30:7W:M% Y@9NP'H>9O]VU_O+Q"FC[V
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M.LE$)F'K1JF2=">GID(Z[)W4UN)YHQ)9N^"":"CYSZLD*TUN=@<(<*(T7AS
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MXNP-\X4 E[=E[Z.#)ORRW-NN;=I!*E;2=^VO3<G&% 6GT(E"OAH,XX<Z=CR
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M>?\B -T.H%:PJO9-OU"61HC?KFAFHW8*=%\J9;>"<[#["V3_ %!+ P04
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MN"UWZ!]][I1+R@PNE?C)<UO-@TD .1:L$?9>K3_C)I]SAY<I8?POK%O;\64
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M9B5JYT#GN5+V:+@$P_1-_@!02P,$%     @ *8-T6+LURF[V @  =08  !D
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MORWINX#:.9"]4,KN#NZ![DN3_@902P,$%     @ *8-T6 JJ3]6# @  B 4
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M]5KCVAW@'XTUEE<Y)36$WWC5.$O[8H=AF*;#<,PBN(!)+QK"N!<G-&9A,IC
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M.,DQ4IOV,MZ^.+WV%^ K[7"=]LNE%)4T= #?YUJ[[H48]+^(G/P/4$L#!!0
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MEI-!X*:SF-[3Z(A9*]H]R\ -,H,Y<Z.I#]_^747XUJ%D1CR0,U5!:?,HI6A
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M*BB- 7TOA="O$Q-@_/59_@U02P,$%     @ *8-T6)A#Q2YZ @  ]@4  !D
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MK9'+Y"#EDS.^5#F.G2!@4!K'0.SO"/? F".R,GZ/G'@*Z8#GZQ/[)Y^[S>5
M--Q+]H-6ILWQ>XPJJ$G/S*,</L.8SYWC*R73_HN&X/ON#J.RUT;R$6P5<"K"
MGSR/=3@#I.D50#H"4J\[!/(JM\20(E-R0,IY6S:W\*EZM!5'A;N4O5'VE%J<
M*?;A,I"LT9XV@M:T),*@=5G*7A@J&K23C)84-'J+]M#8^S"(BM -KJROMF (
M9?IU%AFKQ[%&Y1A[$V*G5V(G*7J0PK0:?1055/\31#:1*9OTE,TFO<FXA7*&
MYLD;E,;I'.D@]P;O?*K2W//.K_!>*L?/]4$;9;OJUZ7, ]_B,I^;M)7N2 DY
MMJ.D01T!%R]?),OXPPVUBTGMXA9[\;7G!U#N2NWL*N)EC[70E[0&MJ5G<T-\
M+)(L.IX+B,X:C(-J_!AIY(L2>FW:G29U'1KTGWL8\P>B&BHT8E!;:#QS@Z'"
MZ 3#R,ZWZT$:V_Q^V=K7!I1SL.>UE.9DN #3^U7\!5!+ P04    "  I@W18
MD/.*4L\#  "I%   &0   'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6RUF%%O
MVS80Q[\*H15# VR6*#NVD]D&$FO# C1;$*_=P[ '6CK;1"52):FX _KA2U*R
M;+FR$G?,BRU1O#^//_$HWDVV7'R4&P"%/F<IDU-OHU1^[?LRWD!&9(_GP/23
M%1<94?I6K'V9"R")-<I2/PR"H9\1RKS9Q+8]B-F$%RJE#!X$DD66$?'?+:1\
M._6PMVMXI.N-,@W^;)*3-2Q O<\?A+[S:Y6$9L DY0P)6$V]&WP=X4MC8'M\
MH+"5!]?(3&7)^4=S<Y=,O<!X!"G$RD@0_?<$<TA3HZ3]^%2)>O68QO#P>J?^
MFYV\GLR22)CS]&^:J,W4&WLH@14I4O7(M[]#-2'K8,Q3:7_1MNH;>"@NI.)9
M9:P]R"@K_\GG"L2! 1Z>, @K@_#88'#"H%\9]%]J,*@,!I9,.17+(2**S":"
M;Y$PO;6:N; PK;6>/F7FO2^4T$^IME.S1?F^$5^A!5TSNJ(Q80K=Q#$OF*)L
MC1YX2F,*$OV,_N LYDP)GJ;F"64*!$B%WD:@"$WEA>[S?A&AMV\NT!O]&-U3
MW9,S.?&5]M6,Z,>57[>E7^$)OW"([O50&XE^90DD30%?3[*>:;B;Z6W8J1A!
MW$-]_!,*@[#?XM#\Y>9ABWGT<G/<,9M^_=[Z5F]P0N\14J(@03D12K^<-L"=
M F8_N98YB6'JZ0U#@G@";_;C#W@8_-(&QZ58Y$BL 6Y0@QM8]?X)<$=K^&ZW
MAO]YISNB.P69_+>-YL E39=BD2.Q!LW+FN9EYS*<%UFA%Z+>NI&E2I>%V<XE
M6@F>(79BO^!;!J(-<N=@YT)V*1:58I=6S'Q+GV;]WGCB/[6P&];LAIWL/OSY
M[J\V")U6YT)P*18Y$FO0&M6T1J\2MR.7-%V*18[$&C3'-<WQ_XC;\X*V<Z1S
M";L4B\;?!"W&O:OVJ+VJR5UUDVO@4ER?7#\55  B24)-(TGWS/012!9+21-*
MQ(FO=#G:Z,#'H':P1/)LCZC3X^]<23C8GR"#[]K'NLW.71A.U2)7:DUD!X=N
M_"J;627K"JE+M<B56A-IN$<:/A^7WR0F1"*"<A Q,'712K13]6RB+M6B2@V'
MAZ'?&PW;-S"\3QUP=^Y@ A9]02]((;J%SJ;C-(EPI=:$N$\C\.OD$=AI(N%4
M+7*EUD2ZSR5P=S)QLKSP?!0[31R<JD65VE$4AX.C*/8/:C@9B+6MA4EDRS!E
MD:-NK>MM-[;*=-1^BZ_G9=5L+U,6\>Z)6%-]:$EAI27U3J(]$V5=K+Q1/+>5
MHB57BF?V<@,D 6$ZZ.<KSM7NQ@Q05R=G7P%02P,$%     @ *8-T6+*+!2@M
M @  )P4  !D   !X;"]W;W)K<VAE971S+W-H965T-#4N>&ULK51-;]LP#/TK
MA%8,+;!%CMV/(;,-I F&[5 @:-#M,.R@.+0M5)9<28G;?S])=H)T2(H>=K%)
MB>^)CQ*9=DH_FAK1PG,CI,E(;6T[H=04-3;,C%2+TNV42C?,.E=7U+0:V3J
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M%\ZV-VS;(5.'6VUIB._(T%SSHX36&_!\:0SM.OZB[)ZY["]02P,$%     @
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ME63-*\E+GC.)9);GJI/(94562O"<@R$W9"F1R8IO!)"9,8"&O%L ,B[,^R1
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MO:@_8^O'"4P$4^X)=5L;>)!LE!9E"S8*2LJ;-WEJUV$/,+@\  A;0/@2,#H
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M;&^QUW-E^7+!E/O"MO<-/,C72HNF!YL(&LJ[E3SW[[ '"$<G %$/B%X"DA.
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M2911[YPDZ29+FHU5M1_'A;(TW'Y94ORB=@7T?JF4W6W<!5V@IW\ 4$L#!!0
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M"51'P8O33S&0+,T/$#,FU7$DOURJ$R-P':#N+QB3CP-])JG.H.-_4$L#!!0
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MC#H?49'RO<-/C*Q=^2VDP6)VPQ+;+2@;@/M+*<U^8@]H&WCV"U!+ P04
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MM?2]D,T$BM9!0,7[+?/Y=M@P&[L=C]YB*>,=S=%@11?LB<GGU4RHK69.<;V
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MB;B!.C[G7.XVX@[R5;^C_P!02P,$%     @ *8-T6,IC0P#@ @  U0<  !D
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M_\;>7%H-:"!Y4Q;GQ6_R5IVK=<ATE7.65,&B@B1*R[_!>_6/V DPQD<"C"K
MV O0^T<">E5 ;S^#<22@7P7T3PT85 &#O8#>Z$C L H8GIIA5 6,]C,<"QA7
M >/] /U(P&45<'EJ@*ZMW[E"DMWR+2_T8@8\F%QG[(UD\GS!DQN%Z(IX(9,H
ME?YXXIEX-1)Q?/(U"Z-4&(,\+8*,YN03N0W#2$HWB(F7E@:40CXW*0^B./]
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M@\@)0H&%=0R,?CN\1R$<$<GXW7$&?4D'/!R_LS]X[^0E9P;OE?C!2[M-@YL
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M/MY3537>:F+DPO6NJ338"=TPQV\54-8 ]V=2FI>)/:#Y^DG^ E!+ P04
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M:6VL/$AI5GWCQ_I!'!C8TQ<,G-K >:N!6QNX'0/'?<%@6AM,W]K#K#:8O=7
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M_7VY.Y$L+[<*WS,I65H>K@F."=<-U.\/C,G=B>Y@OP%^^1]02P,$%     @
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MZ;7[>$O)HH4J!EKDM@M9"(T]C?U,L.T$:0QP?2F$W@^,@ZJ1#?\"4$L#!!0
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M0E<<DY@/3"&%*7HS*D6,"A'.$1&V@VXI$0E'GTD,<9W E(XJ6\[6ULAI99Q
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M:*KV<D7PG# %D.\732.>;M2!8W\B/?T/4$L#!!0    ( "F#=%A"RA/MI ,
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M"J$50PJLUH>_DLPQD%@KEB'9@@3=+H9=,-*Q390259*RDV$_?H>2(EN>3-0
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M1)K:J&8N*IA5- Z?Y>:Y/VF)WS*,T_.%R#*F\4%J16B>DH7(-<M7D"<,%/E
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M=CIP\3[@NX#:'JV9<[+6^M%MON7CH.<$@80,'0.GUQZF(*4C(AF_6\Z@2^F
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M*])'??JHC_&R(6/]P>+8?2)UV6<:14$0AMB*CL=6!6-LW<(0_NQLF#;PP.)
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M<F]P<R]A<' N>&UL4$L! A0#%     @ *8-T6#!1ZN_M    *P(  !$
M         ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ *8-T
M6)E<G",0!@  G"<  !,              ( !RP$  'AL+W1H96UE+W1H96UE
M,2YX;6Q02P$"% ,4    "  I@W18I$=QB,H(  #H.0  &
M@($,"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ *8-T
M6,O6O-4Y @  O 4  !@              ("!#!$  'AL+W=O<FMS:&5E=',O
M<VAE970R+GAM;%!+ 0(4 Q0    ( "F#=%CL_QOK*@@  $(I   8
M      " @7L3  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4
M"  I@W18#RBJ?:0#  #?$0  &               @(';&P  >&PO=V]R:W-H
M965T<R]S:&5E=#0N>&UL4$L! A0#%     @ *8-T6'["K*QU!@  IQL  !@
M             ("!M1\  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4
M Q0    ( "F#=%A/DA^JV@(  '<'   8              " @6 F  !X;"]W
M;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    "  I@W18*L &LLH(  #A
M10  &               @(%P*0  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL
M4$L! A0#%     @ *8-T6)Q5U5?L"   #"@  !@              ("!<#(
M 'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( "F#=%A% ##8
M&@T  .<C   8              " @9([  !X;"]W;W)K<VAE971S+W-H965T
M.2YX;6Q02P$"% ,4    "  I@W18P)_Y!M@G  #:A0  &0
M@('B2   >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( "F#
M=%A21+?'G (  #8&   9              " @?%P  !X;"]W;W)K<VAE971S
M+W-H965T,3$N>&UL4$L! A0#%     @ *8-T6#WE')HL!   \0H  !D
M         ("!Q',  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4
M    "  I@W18OR\K3^<"  "2!@  &0              @($G>   >&PO=V]R
M:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( "F#=%B;/\ WSP(  )D&
M   9              " @45[  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL
M4$L! A0#%     @ *8-T6!JL+)R[ @  '08  !D              ("!2WX
M 'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    "  I@W18+LH<
MG[\"  !7!@  &0              @($]@0  >&PO=V]R:W-H965T<R]S:&5E
M=#$V+GAM;%!+ 0(4 Q0    ( "F#=%@E4=92[@L  !L@   9
M  " @3.$  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @
M*8-T6"'4% KW!@  $A$  !D              ("!6)   'AL+W=O<FMS:&5E
M=',O<VAE970Q."YX;6Q02P$"% ,4    "  I@W18_%'CQ]\$  "O"P  &0
M            @(&&EP  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4
M Q0    ( "F#=%A>'E7C)@0  - )   9              " @9R<  !X;"]W
M;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ *8-T6++EQL=U @
M? 4  !D              ("!^:   'AL+W=O<FMS:&5E=',O<VAE970R,2YX
M;6Q02P$"% ,4    "  I@W18HGA/\*0*   )'0  &0              @(&E
MHP  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( "F#=%C$
M/KOQCPD  'P9   9              " @8"N  !X;"]W;W)K<VAE971S+W-H
M965T,C,N>&UL4$L! A0#%     @ *8-T6/3UHP#K"0  GA@  !D
M     ("!1K@  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( "F#=%CJH)<3[@,  #D)   9              "
M@3GV  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ *8-T
M6+82E(!^ P  1P@  !D              ("!7OH  'AL+W=O<FMS:&5E=',O
M<VAE970S,"YX;6Q02P$"% ,4    "  I@W18@KEN^# #  !4!P  &0
M        @($3_@  >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0
M   ( "F#=%@(=_=5R0(  !$&   9              " @7H! 0!X;"]W;W)K
M<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ *8-T6()NCL/2 @  /08
M !D              ("!>@0! 'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q0
M2P$"% ,4    "  I@W18GB =);D"   C!@  &0              @(&#!P$
M>&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( "F#=%B%@PGM
MA@(  (D%   9              " @7,* 0!X;"]W;W)K<VAE971S+W-H965T
M,S4N>&UL4$L! A0#%     @ *8-T6+LURF[V @  =08  !D
M ("!, T! 'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    "  I
M@W18"JI/U8,"  "(!0  &0              @(%=$ $ >&PO=V]R:W-H965T
M<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( "F#=%C?_SLB4@0  "@*   9
M          " @1<3 0!X;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#
M%     @ *8-T6$?3GT1\!@  '1$  !D              ("!H!<! 'AL+W=O
M<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    "  I@W18;4PH:KX#   &
M"0  &0              @(%3'@$ >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM
M;%!+ 0(4 Q0    ( "F#=%B80\4N>@(  /8%   9              " @4@B
M 0!X;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @ *8-T6%33
MT^AY @  Y04  !D              ("!^20! 'AL+W=O<FMS:&5E=',O<VAE
M970T,BYX;6Q02P$"% ,4    "  I@W18XS=]5S("  #+!   &0
M    @(&I)P$ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    (
M "F#=%B0\XI2SP,  *D4   9              " @1(J 0!X;"]W;W)K<VAE
M971S+W-H965T-#0N>&UL4$L! A0#%     @ *8-T6+*+!2@M @  )P4  !D
M             ("!&"X! 'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"
M% ,4    "  I@W18TS4])18#  " "P  &0              @(%\, $ >&PO
M=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( "F#=%A0T6&.<P(
M .D%   9              " @<DS 0!X;"]W;W)K<VAE971S+W-H965T-#<N
M>&UL4$L! A0#%     @ *8-T6+TS(/U= @  \@8  !D              ("!
M<S8! 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"% ,4    "  I@W18
MN.1VVS("   +!0  &0              @($'.0$ >&PO=V]R:W-H965T<R]S
M:&5E=#0Y+GAM;%!+ 0(4 Q0    ( "F#=%B3M,3W@ (  (P&   9
M      " @7 [ 0!X;"]W;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%
M  @ *8-T6,41A==8 @  O 4  !D              ("!)SX! 'AL+W=O<FMS
M:&5E=',O<VAE970U,2YX;6Q02P$"% ,4    "  I@W18Z;:T?W0"  #P!0
M&0              @(&V0 $ >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+
M 0(4 Q0    ( "F#=%@+L5]O=0(  -P%   9              " @6%# 0!X
M;"]W;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @ *8-T6*^B\M6Z
M P  ?PP  !D              ("!#48! 'AL+W=O<FMS:&5E=',O<VAE970U
M-"YX;6Q02P$"% ,4    "  I@W18XP7:5:@"   J!@  &0
M@('^20$ >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    ( "F#
M=%@UJ;8M6 ,  (\.   9              " @=U, 0!X;"]W;W)K<VAE971S
M+W-H965T-38N>&UL4$L! A0#%     @ *8-T6.<W8"9J @  S 4  !D
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M=#8Q+GAM;%!+ 0(4 Q0    ( "F#=%C*8T, X (  -4'   9
M  " @?AB 0!X;"]W;W)K<VAE971S+W-H965T-C(N>&UL4$L! A0#%     @
M*8-T6(W'S3W5!@  8CX  !D              ("!#V8! 'AL+W=O<FMS:&5E
M=',O<VAE970V,RYX;6Q02P$"% ,4    "  I@W18D%V0>'P"  "[!@  &0
M            @($;;0$ >&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;%!+ 0(4
M Q0    ( "F#=%@&="#RA ,  !03   9              " @<YO 0!X;"]W
M;W)K<VAE971S+W-H965T-C4N>&UL4$L! A0#%     @ *8-T6,&&075, @
M$@4  !D              ("!B7,! 'AL+W=O<FMS:&5E=',O<VAE970V-BYX
M;6Q02P$"% ,4    "  I@W18P++49TD#   )"0  &0              @($,
M=@$ >&PO=V]R:W-H965T<R]S:&5E=#8W+GAM;%!+ 0(4 Q0    ( "F#=%AH
MKY58B@(  -8&   9              " @8QY 0!X;"]W;W)K<VAE971S+W-H
M965T-C@N>&UL4$L! A0#%     @ *8-T6)XKJ;:Q!@  #"\  !D
M     ("!37P! 'AL+W=O<FMS:&5E=',O<VAE970V.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( "F#=%A;6("E'@,  & ,   9              "
M@0.2 0!X;"]W;W)K<VAE971S+W-H965T-S0N>&UL4$L! A0#%     @ *8-T
M6*Z7GAVI P  , P  !D              ("!6)4! 'AL+W=O<FMS:&5E=',O
M<VAE970W-2YX;6Q02P$"% ,4    "  I@W186?OE4,T$  "=%@  &0
M        @($XF0$ >&PO=V]R:W-H965T<R]S:&5E=#<V+GAM;%!+ 0(4 Q0
M   ( "F#=%A"RA/MI ,  )4.   9              " @3R> 0!X;"]W;W)K
M<VAE971S+W-H965T-S<N>&UL4$L! A0#%     @ *8-T6-$AD0TE P  S0@
M !D              ("!%Z(! 'AL+W=O<FMS:&5E=',O<VAE970W."YX;6Q0
M2P$"% ,4    "  I@W189_S7L\4$   A&P  &0              @(%SI0$
M>&PO=V]R:W-H965T<R]S:&5E=#<Y+GAM;%!+ 0(4 Q0    ( "F#=%@A]7'0
MV@,  'L-   9              " @6^J 0!X;"]W;W)K<VAE971S+W-H965T
M.# N>&UL4$L! A0#%     @ *8-T6 "3>^_& @  _P<  !D
M ("!@*X! 'AL+W=O<FMS:&5E=',O<VAE970X,2YX;6Q02P$"% ,4    "  I
M@W18\"HTUE<"  "E!0  &0              @(%]L0$ >&PO=V]R:W-H965T
M<R]S:&5E=#@R+GAM;%!+ 0(4 Q0    ( "F#=%@(" >UM 0  '8;   9
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M 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    "  I@W18DS&\_8 "  "3,0
M&@              @ '1QP$ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-0
M2P$"% ,4    "  I@W18]S F!B<"   R,   $P              @ &)R@$
I6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     7 !< #L9  #AS $    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>144</ContextCount>
  <ElementCount>366</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>52</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="brns-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="brns-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="brns-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="brns-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="brns-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="brns-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="brns-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="brns-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="brns-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Nature of Business and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/NatureofBusinessandBasisofPresentation</Role>
      <ShortName>Nature of Business and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="brns-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="brns-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Foreign Currency Translation in General and Administrative Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/ForeignCurrencyTranslationinGeneralandAdministrativeExpenses</Role>
      <ShortName>Foreign Currency Translation in General and Administrative Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="brns-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Net (Loss)/Income Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/NetLossIncomePerShare</Role>
      <ShortName>Net (Loss)/Income Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="brns-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/PropertyandEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="brns-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Intangible assets, net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/Intangibleassetsnet</Role>
      <ShortName>Intangible assets, net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="brns-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Prepaid and other current assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/Prepaidandothercurrentassets</Role>
      <ShortName>Prepaid and other current assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="brns-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Accrued Expenses and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilities</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="brns-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Out-licenses and Grants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/OutlicensesandGrants</Role>
      <ShortName>Out-licenses and Grants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="brns-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Ordinary Shares</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/OrdinaryShares</Role>
      <ShortName>Ordinary Shares</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="brns-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Deferred shares</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/Deferredshares</Role>
      <ShortName>Deferred shares</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="brns-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Fair Value</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/FairValue</Role>
      <ShortName>Fair Value</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="brns-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Goodwill</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/Goodwill</Role>
      <ShortName>Goodwill</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="brns-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Share-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/ShareBasedCompensation</Role>
      <ShortName>Share-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="brns-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="brns-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="brns-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Employee Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/EmployeeBenefitPlans</Role>
      <ShortName>Employee Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="brns-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="brns-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="brns-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.barinthusbio.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="brns-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9954472 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.barinthusbio.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="brns-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9954473 - Disclosure - Net (Loss)/Income Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/NetLossIncomePerShareTables</Role>
      <ShortName>Net (Loss)/Income Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.barinthusbio.com/role/NetLossIncomePerShare</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="brns-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9954474 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/PropertyandEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.barinthusbio.com/role/PropertyandEquipmentNet</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="brns-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9954475 - Disclosure - Prepaid and other current assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/PrepaidandothercurrentassetsTables</Role>
      <ShortName>Prepaid and other current assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.barinthusbio.com/role/Prepaidandothercurrentassets</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="brns-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9954476 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilities</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="brns-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9954477 - Disclosure - Out-licenses and Grants (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/OutlicensesandGrantsTables</Role>
      <ShortName>Out-licenses and Grants (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.barinthusbio.com/role/OutlicensesandGrants</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="brns-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9954478 - Disclosure - Ordinary Shares (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/OrdinarySharesTables</Role>
      <ShortName>Ordinary Shares (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.barinthusbio.com/role/OrdinaryShares</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="brns-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9954479 - Disclosure - Fair Value (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/FairValueTables</Role>
      <ShortName>Fair Value (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.barinthusbio.com/role/FairValue</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="brns-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9954480 - Disclosure - Goodwill (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/GoodwillTables</Role>
      <ShortName>Goodwill (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.barinthusbio.com/role/Goodwill</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="brns-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9954481 - Disclosure - Share-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/ShareBasedCompensationTables</Role>
      <ShortName>Share-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.barinthusbio.com/role/ShareBasedCompensation</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="brns-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9954482 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.barinthusbio.com/role/IncomeTaxes</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="brns-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9954483 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.barinthusbio.com/role/CommitmentsandContingencies</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="brns-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9954484 - Disclosure - Nature of Business and Basis of Presentation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/NatureofBusinessandBasisofPresentationDetails</Role>
      <ShortName>Nature of Business and Basis of Presentation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.barinthusbio.com/role/NatureofBusinessandBasisofPresentation</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="brns-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9954485 - Disclosure - Summary of Significant Accounting Policies - Foreign currency translation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesForeigncurrencytranslationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Foreign currency translation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="brns-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9954486 - Disclosure - Summary of Significant Accounting Policies - Segment information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesSegmentinformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Segment information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="brns-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9954487 - Disclosure - Summary of Significant Accounting Policies - Noncontrolling interest (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesNoncontrollinginterestDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Noncontrolling interest (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="brns-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9954488 - Disclosure - Summary of Significant Accounting Policies - Cash and cash equivalents (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesCashandcashequivalentsDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Cash and cash equivalents (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="brns-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9954489 - Disclosure - Summary of Significant Accounting Policies - Concentrations of credit risk (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesConcentrationsofcreditriskDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Concentrations of credit risk (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="brns-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9954490 - Disclosure - Summary of Significant Accounting Policies - Allowance for credit losses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesAllowanceforcreditlossesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Allowance for credit losses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="brns-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9954491 - Disclosure - Summary of Significant Accounting Policies - Property and equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPropertyandequipmentDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Property and equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="brns-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9954492 - Disclosure - Summary of Significant Accounting Policies - Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="brns-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9954493 - Disclosure - Summary of Significant Accounting Policies - Impairment of long-lived assets and Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesImpairmentoflonglivedassetsandGoodwillDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Impairment of long-lived assets and Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="brns-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9954494 - Disclosure - Summary of Significant Accounting Policies - Share based compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesSharebasedcompensationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Share based compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="brns-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9954495 - Disclosure - Summary of Significant Accounting Policies - Research and Development Incentives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesResearchandDevelopmentIncentivesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Research and Development Incentives (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="brns-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9954496 - Disclosure - Foreign Currency Translation in General and Administrative Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/ForeignCurrencyTranslationinGeneralandAdministrativeExpensesDetails</Role>
      <ShortName>Foreign Currency Translation in General and Administrative Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.barinthusbio.com/role/ForeignCurrencyTranslationinGeneralandAdministrativeExpenses</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="brns-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9954497 - Disclosure - Net (Loss)/Income Per Share - Computation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/NetLossIncomePerShareComputationDetails</Role>
      <ShortName>Net (Loss)/Income Per Share - Computation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.barinthusbio.com/role/NetLossIncomePerShareTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="brns-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9954498 - Disclosure - Net (Loss)/Income Per Share - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/NetLossIncomePerShareAdditionalInformationDetails</Role>
      <ShortName>Net (Loss)/Income Per Share - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.barinthusbio.com/role/NetLossIncomePerShareTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="brns-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9954499 - Disclosure - Property and Equipment, Net - Components (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/PropertyandEquipmentNetComponentsDetails</Role>
      <ShortName>Property and Equipment, Net - Components (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="brns-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>9954500 - Disclosure - Property and Equipment, Net - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/PropertyandEquipmentNetAdditionalInformationDetails</Role>
      <ShortName>Property and Equipment, Net - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="brns-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>9954501 - Disclosure - Intangible assets, net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/IntangibleassetsnetDetails</Role>
      <ShortName>Intangible assets, net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.barinthusbio.com/role/Intangibleassetsnet</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="brns-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>9954502 - Disclosure - Prepaid and other current assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/PrepaidandothercurrentassetsDetails</Role>
      <ShortName>Prepaid and other current assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.barinthusbio.com/role/PrepaidandothercurrentassetsTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="brns-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>9954503 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="brns-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>9954504 - Disclosure - Out-licenses and Grants - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/OutlicensesandGrantsAdditionalInformationDetails</Role>
      <ShortName>Out-licenses and Grants - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="brns-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>9954505 - Disclosure - Out-licenses and Grants - Changes in the contract liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/OutlicensesandGrantsChangesinthecontractliabilitiesDetails</Role>
      <ShortName>Out-licenses and Grants - Changes in the contract liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="brns-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>9954506 - Disclosure - Ordinary Shares - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/OrdinarySharesAdditionalInformationDetails</Role>
      <ShortName>Ordinary Shares - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="brns-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>9954507 - Disclosure - Ordinary Shares - Ordinary shares for future issuance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/OrdinarySharesOrdinarysharesforfutureissuanceDetails</Role>
      <ShortName>Ordinary Shares - Ordinary shares for future issuance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="brns-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>9954508 - Disclosure - Deferred shares (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/DeferredsharesDetails</Role>
      <ShortName>Deferred shares (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.barinthusbio.com/role/Deferredshares</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="brns-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>9954509 - Disclosure - Fair Value - Additional information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/FairValueAdditionalinformationDetails</Role>
      <ShortName>Fair Value - Additional information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="brns-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>9954510 - Disclosure - Fair Value - Change in fair value of contingent consideration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/FairValueChangeinfairvalueofcontingentconsiderationDetails</Role>
      <ShortName>Fair Value - Change in fair value of contingent consideration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="brns-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>9954511 - Disclosure - Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/GoodwillDetails</Role>
      <ShortName>Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.barinthusbio.com/role/GoodwillTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="brns-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>9954512 - Disclosure - Share-Based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/ShareBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Share-Based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="brns-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>9954513 - Disclosure - Share-Based Compensation - Weighted-average assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/ShareBasedCompensationWeightedaverageassumptionsDetails</Role>
      <ShortName>Share-Based Compensation - Weighted-average assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="brns-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>9954514 - Disclosure - Share-Based Compensation - Summary of stock option activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/ShareBasedCompensationSummaryofstockoptionactivityDetails</Role>
      <ShortName>Share-Based Compensation - Summary of stock option activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="brns-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>9954515 - Disclosure - Share-Based Compensation - Share based compensation expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/ShareBasedCompensationSharebasedcompensationexpenseDetails</Role>
      <ShortName>Share-Based Compensation - Share based compensation expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="brns-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>9954516 - Disclosure - Income Taxes - (Loss) income before income taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/IncomeTaxesLossincomebeforeincometaxesDetails</Role>
      <ShortName>Income Taxes - (Loss) income before income taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.barinthusbio.com/role/IncomeTaxesTables</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="brns-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>9954517 - Disclosure - Income Taxes - Components of income tax benefit (expense) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/IncomeTaxesComponentsofincometaxbenefitexpenseDetails</Role>
      <ShortName>Income Taxes - Components of income tax benefit (expense) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="brns-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>9954518 - Disclosure - Income Taxes - Reconciliation to the effective tax rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/IncomeTaxesReconciliationtotheeffectivetaxrateDetails</Role>
      <ShortName>Income Taxes - Reconciliation to the effective tax rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="brns-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>9954519 - Disclosure - Income Taxes - Deferred tax assets and liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails</Role>
      <ShortName>Income Taxes - Deferred tax assets and liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="brns-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>9954520 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/IncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="brns-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>9954521 - Disclosure - Income Taxes - Changes in the valuation allowance for deferred tax assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/IncomeTaxesChangesinthevaluationallowancefordeferredtaxassetsDetails</Role>
      <ShortName>Income Taxes - Changes in the valuation allowance for deferred tax assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="brns-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>9954522 - Disclosure - Commitments and Contingencies - Additional information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/CommitmentsandContingenciesAdditionalinformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="brns-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>9954523 - Disclosure - Commitments and Contingencies - Right-of-use assets, lease liabilities and other information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/CommitmentsandContingenciesRightofuseassetsleaseliabilitiesandotherinformationDetails</Role>
      <ShortName>Commitments and Contingencies - Right-of-use assets, lease liabilities and other information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="brns-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>9954524 - Disclosure - Commitments and Contingencies - Maturities of minimum lease liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails</Role>
      <ShortName>Commitments and Contingencies - Maturities of minimum lease liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="brns-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>9954525 - Disclosure - Employee Benefit Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/EmployeeBenefitPlansDetails</Role>
      <ShortName>Employee Benefit Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.barinthusbio.com/role/EmployeeBenefitPlans</ParentRole>
      <Position>82</Position>
    </Report>
    <Report instance="brns-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>9954526 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.barinthusbio.com/role/RelatedPartyTransactions</ParentRole>
      <Position>83</Position>
    </Report>
    <Report instance="brns-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>9954527 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.barinthusbio.com/role/SubsequentEvents</ParentRole>
      <Position>84</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[EFM.6.05.45.coverPageFactNotVisible] Submission type 10-K has 1 cover page fact(s) in ix:hidden that should be visible or referenced by an -sec-ix-hidden style property: EntityTaxIdentificationNumber - brns-20231231.htm 4 - brns-20231231.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="brns-20231231.htm">brns-20231231.htm</File>
    <File>brns-20231231.xsd</File>
    <File>brns-20231231_cal.xml</File>
    <File>brns-20231231_def.xml</File>
    <File>brns-20231231_lab.xml</File>
    <File>brns-20231231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>brns-20231231_g1.jpg</File>
    <File>brns-20231231_g10.jpg</File>
    <File>brns-20231231_g11.jpg</File>
    <File>brns-20231231_g12.gif</File>
    <File>brns-20231231_g2.jpg</File>
    <File>brns-20231231_g3.jpg</File>
    <File>brns-20231231_g4.jpg</File>
    <File>brns-20231231_g5.jpg</File>
    <File>brns-20231231_g6.jpg</File>
    <File>brns-20231231_g7.jpg</File>
    <File>brns-20231231_g8.gif</File>
    <File>brns-20231231_g9.gif</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="604">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="41">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>122
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "brns-20231231.htm": {
   "nsprefix": "brns",
   "nsuri": "http://www.barinthusbio.com/20231231",
   "dts": {
    "inline": {
     "local": [
      "brns-20231231.htm"
     ]
    },
    "schema": {
     "local": [
      "brns-20231231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "brns-20231231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "brns-20231231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "brns-20231231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "brns-20231231_pre.xml"
     ]
    }
   },
   "keyStandard": 297,
   "keyCustom": 69,
   "axisStandard": 23,
   "axisCustom": 0,
   "memberStandard": 27,
   "memberCustom": 24,
   "hidden": {
    "total": 7,
    "http://xbrl.sec.gov/dei/2023": 5,
    "http://fasb.org/us-gaap/2023": 2
   },
   "contextCount": 144,
   "entityCount": 1,
   "segmentCount": 52,
   "elementCount": 549,
   "unitCount": 9,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 604,
    "http://xbrl.sec.gov/dei/2023": 41
   },
   "report": {
    "R1": {
     "role": "http://www.barinthusbio.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.barinthusbio.com/role/AuditInformation",
     "longName": "0000002 - Document - Audit Information",
     "shortName": "Audit Information",
     "isDefault": "false",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorFirmId",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorFirmId",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS",
     "longName": "0000003 - Statement - CONSOLIDATED BALANCE SHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "brns:ResearchAndDevelopmentIncentivesReceivable",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
     "longName": "0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "gbpPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
     "longName": "0000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical",
     "longName": "0000006 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Parenthetical)",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R7": {
     "role": "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
     "longName": "0000007 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS\u2019 EQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS\u2019 EQUITY",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-51",
      "name": "us-gaap:SharesIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-51",
      "name": "us-gaap:SharesIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "longName": "0000008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.barinthusbio.com/role/NatureofBusinessandBasisofPresentation",
     "longName": "0000009 - Disclosure - Nature of Business and Basis of Presentation",
     "shortName": "Nature of Business and Basis of Presentation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPolicies",
     "longName": "0000010 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.barinthusbio.com/role/ForeignCurrencyTranslationinGeneralandAdministrativeExpenses",
     "longName": "0000011 - Disclosure - Foreign Currency Translation in General and Administrative Expenses",
     "shortName": "Foreign Currency Translation in General and Administrative Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ForeignCurrencyDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ForeignCurrencyDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.barinthusbio.com/role/NetLossIncomePerShare",
     "longName": "0000012 - Disclosure - Net (Loss)/Income Per Share",
     "shortName": "Net (Loss)/Income Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.barinthusbio.com/role/PropertyandEquipmentNet",
     "longName": "0000013 - Disclosure - Property and Equipment, Net",
     "shortName": "Property and Equipment, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.barinthusbio.com/role/Intangibleassetsnet",
     "longName": "0000014 - Disclosure - Intangible assets, net",
     "shortName": "Intangible assets, net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.barinthusbio.com/role/Prepaidandothercurrentassets",
     "longName": "0000015 - Disclosure - Prepaid and other current assets",
     "shortName": "Prepaid and other current assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "brns:PrepaidExpenseAndOtherAssetsCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "brns:PrepaidExpenseAndOtherAssetsCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilities",
     "longName": "0000016 - Disclosure - Accrued Expenses and Other Current Liabilities",
     "shortName": "Accrued Expenses and Other Current Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "brns:AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "brns:AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.barinthusbio.com/role/OutlicensesandGrants",
     "longName": "0000017 - Disclosure - Out-licenses and Grants",
     "shortName": "Out-licenses and Grants",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.barinthusbio.com/role/OrdinaryShares",
     "longName": "0000018 - Disclosure - Ordinary Shares",
     "shortName": "Ordinary Shares",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.barinthusbio.com/role/Deferredshares",
     "longName": "0000019 - Disclosure - Deferred shares",
     "shortName": "Deferred shares",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "brns:StockholdersEquityDeferredSharesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "brns:StockholdersEquityDeferredSharesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.barinthusbio.com/role/FairValue",
     "longName": "0000020 - Disclosure - Fair Value",
     "shortName": "Fair Value",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.barinthusbio.com/role/Goodwill",
     "longName": "0000021 - Disclosure - Goodwill",
     "shortName": "Goodwill",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GoodwillDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GoodwillDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.barinthusbio.com/role/ShareBasedCompensation",
     "longName": "0000022 - Disclosure - Share-Based Compensation",
     "shortName": "Share-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.barinthusbio.com/role/IncomeTaxes",
     "longName": "0000023 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.barinthusbio.com/role/CommitmentsandContingencies",
     "longName": "0000024 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.barinthusbio.com/role/EmployeeBenefitPlans",
     "longName": "0000025 - Disclosure - Employee Benefit Plans",
     "shortName": "Employee Benefit Plans",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.barinthusbio.com/role/RelatedPartyTransactions",
     "longName": "0000026 - Disclosure - Related Party Transactions",
     "shortName": "Related Party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.barinthusbio.com/role/SubsequentEvents",
     "longName": "0000027 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "longName": "9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GuaranteesIndemnificationsAndWarrantiesPolicies",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GuaranteesIndemnificationsAndWarrantiesPolicies",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesTables",
     "longName": "9954472 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.barinthusbio.com/role/NetLossIncomePerShareTables",
     "longName": "9954473 - Disclosure - Net (Loss)/Income Per Share (Tables)",
     "shortName": "Net (Loss)/Income Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.barinthusbio.com/role/PropertyandEquipmentNetTables",
     "longName": "9954474 - Disclosure - Property and Equipment, Net (Tables)",
     "shortName": "Property and Equipment, Net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R32": {
     "role": "http://www.barinthusbio.com/role/PrepaidandothercurrentassetsTables",
     "longName": "9954475 - Disclosure - Prepaid and other current assets (Tables)",
     "shortName": "Prepaid and other current assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables",
     "longName": "9954476 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)",
     "shortName": "Accrued Expenses and Other Current Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "brns:AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "brns:AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.barinthusbio.com/role/OutlicensesandGrantsTables",
     "longName": "9954477 - Disclosure - Out-licenses and Grants (Tables)",
     "shortName": "Out-licenses and Grants (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "brns:ContractWithCustomerLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "brns:ContractWithCustomerLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.barinthusbio.com/role/OrdinarySharesTables",
     "longName": "9954478 - Disclosure - Ordinary Shares (Tables)",
     "shortName": "Ordinary Shares (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "brns:ScheduleOfOrdinarySharesReservedForFutureIssuanceTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "brns:ScheduleOfOrdinarySharesReservedForFutureIssuanceTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.barinthusbio.com/role/FairValueTables",
     "longName": "9954479 - Disclosure - Fair Value (Tables)",
     "shortName": "Fair Value (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.barinthusbio.com/role/GoodwillTables",
     "longName": "9954480 - Disclosure - Goodwill (Tables)",
     "shortName": "Goodwill (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.barinthusbio.com/role/ShareBasedCompensationTables",
     "longName": "9954481 - Disclosure - Share-Based Compensation (Tables)",
     "shortName": "Share-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.barinthusbio.com/role/IncomeTaxesTables",
     "longName": "9954482 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.barinthusbio.com/role/CommitmentsandContingenciesTables",
     "longName": "9954483 - Disclosure - Commitments and Contingencies (Tables)",
     "shortName": "Commitments and Contingencies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "brns:LesseeOperatingLeaseRightOfUseAssetAndOtherInformationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "brns:LesseeOperatingLeaseRightOfUseAssetAndOtherInformationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.barinthusbio.com/role/NatureofBusinessandBasisofPresentationDetails",
     "longName": "9954484 - Disclosure - Nature of Business and Basis of Presentation (Details)",
     "shortName": "Nature of Business and Basis of Presentation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R42": {
     "role": "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesForeigncurrencytranslationDetails",
     "longName": "9954485 - Disclosure - Summary of Significant Accounting Policies - Foreign currency translation (Details)",
     "shortName": "Summary of Significant Accounting Policies - Foreign currency translation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ForeignCurrencyTransactionGainLossBeforeTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R43": {
     "role": "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesSegmentinformationDetails",
     "longName": "9954486 - Disclosure - Summary of Significant Accounting Policies - Segment information (Details)",
     "shortName": "Summary of Significant Accounting Policies - Segment information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesNoncontrollinginterestDetails",
     "longName": "9954487 - Disclosure - Summary of Significant Accounting Policies - Noncontrolling interest (Details)",
     "shortName": "Summary of Significant Accounting Policies - Noncontrolling interest (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-69",
      "name": "brns:SubsidiaryCumulativeContributionsNoncontrollingOwner",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "brns:MinorityInterestPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-69",
      "name": "brns:SubsidiaryCumulativeContributionsNoncontrollingOwner",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "brns:MinorityInterestPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesCashandcashequivalentsDetails",
     "longName": "9954488 - Disclosure - Summary of Significant Accounting Policies - Cash and cash equivalents (Details)",
     "shortName": "Summary of Significant Accounting Policies - Cash and cash equivalents (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "us-gaap:CashEquivalentsAtCarryingValue",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "us-gaap:CashEquivalentsAtCarryingValue",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesConcentrationsofcreditriskDetails",
     "longName": "9954489 - Disclosure - Summary of Significant Accounting Policies - Concentrations of credit risk (Details)",
     "shortName": "Summary of Significant Accounting Policies - Concentrations of credit risk (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "brns:AccountsReceivableStandardPaymentTermsPeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "us-gaap:ConcentrationRiskCreditRisk",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "brns:AccountsReceivableStandardPaymentTermsPeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "us-gaap:ConcentrationRiskCreditRisk",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesAllowanceforcreditlossesDetails",
     "longName": "9954490 - Disclosure - Summary of Significant Accounting Policies - Allowance for credit losses (Details)",
     "shortName": "Summary of Significant Accounting Policies - Allowance for credit losses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ProvisionForDoubtfulAccounts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "us-gaap:ProvisionForDoubtfulAccounts",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ProvisionForDoubtfulAccounts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "us-gaap:ProvisionForDoubtfulAccounts",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPropertyandequipmentDetails",
     "longName": "9954491 - Disclosure - Summary of Significant Accounting Policies - Property and equipment (Details)",
     "shortName": "Summary of Significant Accounting Policies - Property and equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-77",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-77",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsDetails",
     "longName": "9954492 - Disclosure - Summary of Significant Accounting Policies - Intangible Assets (Details)",
     "shortName": "Summary of Significant Accounting Policies - Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-79",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "us-gaap:IntangibleAssetsFiniteLivedPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-79",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "us-gaap:IntangibleAssetsFiniteLivedPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesImpairmentoflonglivedassetsandGoodwillDetails",
     "longName": "9954493 - Disclosure - Summary of Significant Accounting Policies - Impairment of long-lived assets and Goodwill (Details)",
     "shortName": "Summary of Significant Accounting Policies - Impairment of long-lived assets and Goodwill (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AssetImpairmentCharges",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "us-gaap:AssetImpairmentCharges",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AssetImpairmentCharges",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "us-gaap:AssetImpairmentCharges",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesSharebasedcompensationDetails",
     "longName": "9954494 - Disclosure - Summary of Significant Accounting Policies - Share based compensation (Details)",
     "shortName": "Summary of Significant Accounting Policies - Share based compensation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
       "span",
       "div",
       "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R52": {
     "role": "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesResearchandDevelopmentIncentivesDetails",
     "longName": "9954495 - Disclosure - Summary of Significant Accounting Policies - Research and Development Incentives (Details)",
     "shortName": "Summary of Significant Accounting Policies - Research and Development Incentives (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "brns:ResearchAndDevelopmentIncentiveIncomeExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R53": {
     "role": "http://www.barinthusbio.com/role/ForeignCurrencyTranslationinGeneralandAdministrativeExpensesDetails",
     "longName": "9954496 - Disclosure - Foreign Currency Translation in General and Administrative Expenses (Details)",
     "shortName": "Foreign Currency Translation in General and Administrative Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ForeignCurrencyTransactionGainLossBeforeTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R54": {
     "role": "http://www.barinthusbio.com/role/NetLossIncomePerShareComputationDetails",
     "longName": "9954497 - Disclosure - Net (Loss)/Income Per Share - Computation (Details)",
     "shortName": "Net (Loss)/Income Per Share - Computation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.barinthusbio.com/role/NetLossIncomePerShareAdditionalInformationDetails",
     "longName": "9954498 - Disclosure - Net (Loss)/Income Per Share - Additional Information (Details)",
     "shortName": "Net (Loss)/Income Per Share - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.barinthusbio.com/role/PropertyandEquipmentNetComponentsDetails",
     "longName": "9954499 - Disclosure - Property and Equipment, Net - Components (Details)",
     "shortName": "Property and Equipment, Net - Components (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.barinthusbio.com/role/PropertyandEquipmentNetAdditionalInformationDetails",
     "longName": "9954500 - Disclosure - Property and Equipment, Net - Additional Information (Details)",
     "shortName": "Property and Equipment, Net - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:Depreciation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:Depreciation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.barinthusbio.com/role/IntangibleassetsnetDetails",
     "longName": "9954501 - Disclosure - Intangible assets, net (Details)",
     "shortName": "Intangible assets, net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.barinthusbio.com/role/PrepaidandothercurrentassetsDetails",
     "longName": "9954502 - Disclosure - Prepaid and other current assets (Details)",
     "shortName": "Prepaid and other current assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:PrepaidExpenseCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:PrepaidExpenseCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails",
     "longName": "9954503 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)",
     "shortName": "Accrued Expenses and Other Current Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "brns:AccruedManufacturingAndClinicalExpensesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "brns:AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "brns:AccruedManufacturingAndClinicalExpensesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "brns:AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.barinthusbio.com/role/OutlicensesandGrantsAdditionalInformationDetails",
     "longName": "9954504 - Disclosure - Out-licenses and Grants - Additional Information (Details)",
     "shortName": "Out-licenses and Grants - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-85",
      "name": "brns:PercentageOfRoyaltiesOnNetSales",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.barinthusbio.com/role/OutlicensesandGrantsChangesinthecontractliabilitiesDetails",
     "longName": "9954505 - Disclosure - Out-licenses and Grants - Changes in the contract liabilities (Details)",
     "shortName": "Out-licenses and Grants - Changes in the contract liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:ContractWithCustomerLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "brns:ContractWithCustomerLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-60",
      "name": "us-gaap:ContractWithCustomerLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "brns:ContractWithCustomerLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.barinthusbio.com/role/OrdinarySharesAdditionalInformationDetails",
     "longName": "9954506 - Disclosure - Ordinary Shares - Additional Information (Details)",
     "shortName": "Ordinary Shares - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockSharesOutstanding",
       "us-gaap:CommonStockSharesIssued",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "brns:CommonStockNumberOfVotesPerShare",
      "unitRef": "vote",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.barinthusbio.com/role/OrdinarySharesOrdinarysharesforfutureissuanceDetails",
     "longName": "9954507 - Disclosure - Ordinary Shares - Ordinary shares for future issuance (Details)",
     "shortName": "Ordinary Shares - Ordinary shares for future issuance (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "brns:ScheduleOfOrdinarySharesReservedForFutureIssuanceTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.barinthusbio.com/role/DeferredsharesDetails",
     "longName": "9954508 - Disclosure - Deferred shares (Details)",
     "shortName": "Deferred shares (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c-13",
      "name": "brns:OrdinarySharesLiquidationPreference",
      "unitRef": "gbp",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-13",
      "name": "brns:OrdinarySharesLiquidationPreference",
      "unitRef": "gbp",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.barinthusbio.com/role/FairValueAdditionalinformationDetails",
     "longName": "9954509 - Disclosure - Fair Value - Additional information (Details)",
     "shortName": "Fair Value - Additional information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c-104",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-104",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.barinthusbio.com/role/FairValueChangeinfairvalueofcontingentconsiderationDetails",
     "longName": "9954510 - Disclosure - Fair Value - Change in fair value of contingent consideration (Details)",
     "shortName": "Fair Value - Change in fair value of contingent consideration (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c-105",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-106",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.barinthusbio.com/role/GoodwillDetails",
     "longName": "9954511 - Disclosure - Goodwill (Details)",
     "shortName": "Goodwill (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:Goodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-60",
      "name": "us-gaap:Goodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "unique": true
     }
    },
    "R69": {
     "role": "http://www.barinthusbio.com/role/ShareBasedCompensationAdditionalInformationDetails",
     "longName": "9954512 - Disclosure - Share-Based Compensation - Additional Information (Details)",
     "shortName": "Share-Based Compensation - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "unique": true
     }
    },
    "R70": {
     "role": "http://www.barinthusbio.com/role/ShareBasedCompensationWeightedaverageassumptionsDetails",
     "longName": "9954513 - Disclosure - Share-Based Compensation - Weighted-average assumptions (Details)",
     "shortName": "Share-Based Compensation - Weighted-average assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
       "span",
       "div",
       "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-116",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "unique": true
     }
    },
    "R71": {
     "role": "http://www.barinthusbio.com/role/ShareBasedCompensationSummaryofstockoptionactivityDetails",
     "longName": "9954514 - Disclosure - Share-Based Compensation - Summary of stock option activity (Details)",
     "shortName": "Share-Based Compensation - Summary of stock option activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "unique": true
     }
    },
    "R72": {
     "role": "http://www.barinthusbio.com/role/ShareBasedCompensationSharebasedcompensationexpenseDetails",
     "longName": "9954515 - Disclosure - Share-Based Compensation - Share based compensation expense (Details)",
     "shortName": "Share-Based Compensation - Share based compensation expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R73": {
     "role": "http://www.barinthusbio.com/role/IncomeTaxesLossincomebeforeincometaxesDetails",
     "longName": "9954516 - Disclosure - Income Taxes - (Loss) income before income taxes (Details)",
     "shortName": "Income Taxes - (Loss) income before income taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R74": {
     "role": "http://www.barinthusbio.com/role/IncomeTaxesComponentsofincometaxbenefitexpenseDetails",
     "longName": "9954517 - Disclosure - Income Taxes - Components of income tax benefit (expense) (Details)",
     "shortName": "Income Taxes - Components of income tax benefit (expense) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-122",
      "name": "us-gaap:CurrentForeignTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "unique": true
     }
    },
    "R75": {
     "role": "http://www.barinthusbio.com/role/IncomeTaxesReconciliationtotheeffectivetaxrateDetails",
     "longName": "9954518 - Disclosure - Income Taxes - Reconciliation to the effective tax rate (Details)",
     "shortName": "Income Taxes - Reconciliation to the effective tax rate (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R76": {
     "role": "http://www.barinthusbio.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails",
     "longName": "9954519 - Disclosure - Income Taxes - Deferred tax assets and liabilities (Details)",
     "shortName": "Income Taxes - Deferred tax assets and liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R77": {
     "role": "http://www.barinthusbio.com/role/IncomeTaxesAdditionalInformationDetails",
     "longName": "9954520 - Disclosure - Income Taxes - Additional Information (Details)",
     "shortName": "Income Taxes - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:OperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "unique": true
     }
    },
    "R78": {
     "role": "http://www.barinthusbio.com/role/IncomeTaxesChangesinthevaluationallowancefordeferredtaxassetsDetails",
     "longName": "9954521 - Disclosure - Income Taxes - Changes in the valuation allowance for deferred tax assets (Details)",
     "shortName": "Income Taxes - Changes in the valuation allowance for deferred tax assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "brns:ValuationAllowanceDeferredTaxAssetIncreaseResultingFromCurrentPeriodAdditions",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfValuationAllowanceTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "unique": true
     }
    },
    "R79": {
     "role": "http://www.barinthusbio.com/role/CommitmentsandContingenciesAdditionalinformationDetails",
     "longName": "9954522 - Disclosure - Commitments and Contingencies - Additional information (Details)",
     "shortName": "Commitments and Contingencies - Additional information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "c-129",
      "name": "brns:NumberOfSquareFeetUnderLeaseAgreement",
      "unitRef": "sqft",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-129",
      "name": "brns:NumberOfSquareFeetUnderLeaseAgreement",
      "unitRef": "sqft",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R80": {
     "role": "http://www.barinthusbio.com/role/CommitmentsandContingenciesRightofuseassetsleaseliabilitiesandotherinformationDetails",
     "longName": "9954523 - Disclosure - Commitments and Contingencies - Right-of-use assets, lease liabilities and other information (Details)",
     "shortName": "Commitments and Contingencies - Right-of-use assets, lease liabilities and other information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "unique": true
     }
    },
    "R81": {
     "role": "http://www.barinthusbio.com/role/CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails",
     "longName": "9954524 - Disclosure - Commitments and Contingencies - Maturities of minimum lease liabilities (Details)",
     "shortName": "Commitments and Contingencies - Maturities of minimum lease liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R82": {
     "role": "http://www.barinthusbio.com/role/EmployeeBenefitPlansDetails",
     "longName": "9954525 - Disclosure - Employee Benefit Plans (Details)",
     "shortName": "Employee Benefit Plans (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "82",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R83": {
     "role": "http://www.barinthusbio.com/role/RelatedPartyTransactionsDetails",
     "longName": "9954526 - Disclosure - Related Party Transactions (Details)",
     "shortName": "Related Party Transactions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "83",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:AccountsPayableCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-135",
      "name": "us-gaap:AccountsPayableCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "unique": true
     }
    },
    "R84": {
     "role": "http://www.barinthusbio.com/role/SubsequentEventsDetails",
     "longName": "9954527 - Disclosure - Subsequent Events (Details)",
     "shortName": "Subsequent Events (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "84",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-144",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20231231.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Policies [Abstract]",
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.barinthusbio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "verboseLabel": "Amounts owed to other party",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r722"
     ]
    },
    "us-gaap_AccountsReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableMember",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesConcentrationsofcreditriskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Receivable",
        "label": "Accounts Receivable [Member]",
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold."
       }
      }
     },
     "auth_ref": [
      "r679"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.barinthusbio.com/role/OutlicensesandGrantsAdditionalInformationDetails",
      "http://www.barinthusbio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable",
        "verboseLabel": "Amounts owned from other party",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r283",
      "r284"
     ]
    },
    "brns_AccountsReceivableStandardPaymentTermsPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.barinthusbio.com/20231231",
     "localname": "AccountsReceivableStandardPaymentTermsPeriod",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesConcentrationsofcreditriskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Standard payment terms",
        "label": "Accounts Receivable, Standard Payment Terms, Period",
        "documentation": "Accounts Receivable, Standard Payment Terms, Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedBonusesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedBonusesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "parentTag": "brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued bonus",
        "label": "Accrued Bonuses, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_AccruedEmployeeBenefitsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedEmployeeBenefitsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "parentTag": "brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued payroll and employee benefits",
        "label": "Accrued Employee Benefits, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.barinthusbio.com/20231231",
     "localname": "AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of accrued expenses and other current liabilities",
        "label": "Accrued Liabilities And Other Current Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accrued liabilities and other current liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.barinthusbio.com/20231231",
     "localname": "AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued Expenses and Other Current Liabilities",
        "label": "Accrued Liabilities And Other Current Liabilities [Text Block]",
        "documentation": "The entire disclosure of the components of accrued liabilities and other current liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.barinthusbio.com/20231231",
     "localname": "AccruedLiabilitiesAndOtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails",
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other current liabilities",
        "totalLabel": "Total",
        "label": "Accrued Liabilities and Other Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": []
    },
    "brns_AccruedManufacturingAndClinicalExpensesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.barinthusbio.com/20231231",
     "localname": "AccruedManufacturingAndClinicalExpensesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "parentTag": "brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued manufacturing and clinical expenses",
        "label": "Accrued Manufacturing and Clinical Expenses, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for manufacturing and clinical expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "parentTag": "brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued professional fees",
        "label": "Accrued Professional Fees, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/PropertyandEquipmentNetComponentsDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/PropertyandEquipmentNetComponentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: accumulated depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r182",
      "r544"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive loss \u2013 foreign currency translation adjustments",
        "label": "Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax",
        "documentation": "Accumulated adjustment, net of tax, that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency translation gains or losses."
       }
      }
     },
     "auth_ref": [
      "r193",
      "r194",
      "r195",
      "r196",
      "r466"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Loss",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r16",
      "r32",
      "r455",
      "r458",
      "r494",
      "r562",
      "r563",
      "r763",
      "r764",
      "r765",
      "r772",
      "r773",
      "r774"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r722",
      "r855"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-in-capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r413",
      "r414",
      "r415",
      "r582",
      "r772",
      "r773",
      "r774",
      "r835",
      "r858"
     ]
    },
    "brns_AdditionalPaidInCapitalPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.barinthusbio.com/20231231",
     "localname": "AdditionalPaidInCapitalPolicyTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid In Capital [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for Additional paid in capital."
       }
      }
     },
     "auth_ref": []
    },
    "brns_AdjustmentsToAdditionalPaidInCapitalMeasurementPeriodAdjustmentsInBusinessCombination": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.barinthusbio.com/20231231",
     "localname": "AdjustmentsToAdditionalPaidInCapitalMeasurementPeriodAdjustmentsInBusinessCombination",
     "crdr": "credit",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement period and contingent consideration adjustments",
        "label": "Adjustments to Additional Paid in Capital, Measurement Period Adjustments in Business Combination,",
        "documentation": "Amount of increase (decrease) to additional paid in capital (APIC) resulting from measurement period adjustment in business combination."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r72",
      "r375"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net (loss)/income to net cash used in operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "brns_AgreementWithOxfordUniversityInnovationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.barinthusbio.com/20231231",
     "localname": "AgreementWithOxfordUniversityInnovationMember",
     "presentation": [
      "http://www.barinthusbio.com/role/OutlicensesandGrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Agreement with OUI",
        "label": "Agreement With Oxford University Innovation [Member]",
        "documentation": "This member stands for Oxford University Innovation Agreement."
       }
      }
     },
     "auth_ref": []
    },
    "brns_AgreementWithScancellToGrantResearchAndDevelopmentLicenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.barinthusbio.com/20231231",
     "localname": "AgreementWithScancellToGrantResearchAndDevelopmentLicenseMember",
     "presentation": [
      "http://www.barinthusbio.com/role/OutlicensesandGrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Agreement with Scancell",
        "label": "Agreement with Scancell to Grant Research and Development License [Member]",
        "documentation": "This member stands for the information pertaining to Scancell contract."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationSharebasedcompensationexpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r408",
      "r420"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "brns_AmericanDepositarySharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.barinthusbio.com/20231231",
     "localname": "AmericanDepositarySharesMember",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "American Depositary Shares",
        "label": "American Depositary Shares [Member]",
        "documentation": "Represents the information pertaining to american depositary shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.barinthusbio.com/role/IntangibleassetsnetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization expense for intangible assets",
        "label": "Amortization of Intangible Assets",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r52",
      "r56"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.barinthusbio.com/role/NetLossIncomePerShareAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issuable for stock options that were excluded from the computation of diluted weighted-average shares outstanding (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r251"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesAdditionalinformationDetails",
      "http://www.barinthusbio.com/role/OutlicensesandGrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r446"
     ]
    },
    "us-gaap_AssetImpairmentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetImpairmentCharges",
     "crdr": "debit",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesImpairmentoflonglivedassetsandGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of long-lived assets",
        "label": "Asset Impairment Charges",
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r58"
     ]
    },
    "brns_AssetRetirementObligations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.barinthusbio.com/20231231",
     "localname": "AssetRetirementObligations",
     "crdr": "credit",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset retirement obligation",
        "label": "Asset Retirement Obligations",
        "documentation": "Amount of asset retirement obligations."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r186",
      "r218",
      "r258",
      "r273",
      "r277",
      "r285",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r448",
      "r452",
      "r467",
      "r536",
      "r619",
      "r722",
      "r735",
      "r795",
      "r796",
      "r842"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASSETS",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r192",
      "r218",
      "r285",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r448",
      "r452",
      "r467",
      "r722",
      "r795",
      "r796",
      "r842"
     ]
    },
    "brns_AuditInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.barinthusbio.com/20231231",
     "localname": "AuditInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Audit Information [Abstract]",
        "documentation": "Audit Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.barinthusbio.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Firm ID",
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r744",
      "r745",
      "r746"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.barinthusbio.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Location",
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r744",
      "r745",
      "r746"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorName",
     "presentation": [
      "http://www.barinthusbio.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Name",
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r744",
      "r745",
      "r746"
     ]
    },
    "brns_AvideaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.barinthusbio.com/20231231",
     "localname": "AvideaMember",
     "presentation": [
      "http://www.barinthusbio.com/role/FairValueAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Avidea",
        "label": "Avidea [Member]",
        "documentation": "This member stands for Avidea."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://www.barinthusbio.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Axis]",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r379",
      "r380",
      "r381",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407"
     ]
    },
    "brns_BarinthusBiotherapeuticsPlcShareAwardPlan2021Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.barinthusbio.com/20231231",
     "localname": "BarinthusBiotherapeuticsPlcShareAwardPlan2021Member",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://www.barinthusbio.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Barinthus Biotherapeutics plc Share Award Plan 2021",
        "label": "Barinthus Biotherapeutics plc Share Award Plan 2021 [Member]",
        "documentation": "Barinthus Biotherapeutics plc Share Award Plan 2021"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://www.barinthusbio.com/role/FairValueAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition, Acquiree [Domain]",
        "label": "Business Acquisition, Acquiree [Domain]",
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "auth_ref": [
      "r444",
      "r714",
      "r715"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://www.barinthusbio.com/role/FairValueAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition [Axis]",
        "label": "Business Acquisition [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r80",
      "r444",
      "r714",
      "r715"
     ]
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in contingent consideration",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement."
       }
      }
     },
     "auth_ref": [
      "r445",
      "r766"
     ]
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent consideration",
        "label": "Business Combination, Contingent Consideration, Liability, Noncurrent",
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r81"
     ]
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationsPolicy",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business combinations",
        "label": "Business Combinations Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchases of property and equipment included in accounts payable and accrued liabilities",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r40",
      "r41"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.barinthusbio.com/role/NatureofBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r180",
      "r696"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents, beginning of the year",
        "periodEndLabel": "Cash and cash equivalents, end of the year",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r118",
      "r215"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net decrease in cash and cash equivalents",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r118"
     ]
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesCashandcashequivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash equivalents",
        "label": "Cash Equivalents, at Carrying Value",
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r759",
      "r851"
     ]
    },
    "brns_ChangesToRightOfUseAssetResultingFromLeaseReassessmentEvent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.barinthusbio.com/20231231",
     "localname": "ChangesToRightOfUseAssetResultingFromLeaseReassessmentEvent",
     "crdr": "debit",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes to right-of-use asset resulting from lease reassessment event",
        "label": "Changes to right-of-use asset resulting from lease reassessment event",
        "documentation": "Amount of changes to right-of-use asset resulting from lease reassessment event."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.barinthusbio.com/role/Cover",
      "http://www.barinthusbio.com/role/DeferredsharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Domain]",
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r187",
      "r188",
      "r189",
      "r218",
      "r242",
      "r246",
      "r248",
      "r250",
      "r256",
      "r257",
      "r285",
      "r329",
      "r331",
      "r332",
      "r333",
      "r336",
      "r337",
      "r340",
      "r341",
      "r344",
      "r347",
      "r354",
      "r467",
      "r571",
      "r572",
      "r573",
      "r574",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r607",
      "r629",
      "r653",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r752",
      "r767",
      "r775"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.barinthusbio.com/role/DeferredsharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Line Items]",
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r187",
      "r188",
      "r189",
      "r256",
      "r340",
      "r341",
      "r342",
      "r344",
      "r347",
      "r352",
      "r354",
      "r571",
      "r572",
      "r573",
      "r574",
      "r710",
      "r752",
      "r767"
     ]
    },
    "brns_ClinicalTrialCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.barinthusbio.com/20231231",
     "localname": "ClinicalTrialCostsPolicyTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Clinical trial costs",
        "label": "Clinical Trial Costs [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for Clinical Trial costs."
       }
      }
     },
     "auth_ref": []
    },
    "brns_CoalitionForEpidemicPreparednessInnovationsFundingAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.barinthusbio.com/20231231",
     "localname": "CoalitionForEpidemicPreparednessInnovationsFundingAgreementMember",
     "presentation": [
      "http://www.barinthusbio.com/role/OutlicensesandGrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CEPI Funding Agreement",
        "label": "Coalition for Epidemic Preparedness Innovations Funding Agreement [Member]",
        "documentation": "Coalition for Epidemic Preparedness Innovations Funding Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://www.barinthusbio.com/role/OutlicensesandGrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r446"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies (Note 16)",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r97",
      "r538",
      "r606"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]",
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r322",
      "r323",
      "r680",
      "r791"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "calculation": {
      "http://www.barinthusbio.com/role/OrdinarySharesOrdinarysharesforfutureissuanceDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/OrdinarySharesOrdinarysharesforfutureissuanceDetails",
      "http://www.barinthusbio.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "terseLabel": "Number of shares reserved for issuance (in shares)",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares",
        "verboseLabel": "Ordinary Shares",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r725",
      "r726",
      "r727",
      "r729",
      "r730",
      "r731",
      "r732",
      "r772",
      "r773",
      "r835",
      "r854",
      "r858"
     ]
    },
    "brns_CommonStockNumberOfVotesPerShare": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.barinthusbio.com/20231231",
     "localname": "CommonStockNumberOfVotesPerShare",
     "presentation": [
      "http://www.barinthusbio.com/role/OrdinarySharesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of votes per common share (in votes)",
        "label": "Common Stock Number of Votes Per Share",
        "documentation": "The number of votes that each common share is entitled."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.barinthusbio.com/role/OrdinarySharesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares, nominal value (in gbp per share)",
        "verboseLabel": "Ordinary shares, nominal value (in gbp per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.barinthusbio.com/role/OrdinarySharesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares, authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r607"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares, issued (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares, outstanding (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r102",
      "r607",
      "r625",
      "r858",
      "r859"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares, \u00a30.000025 nominal value; 38,643,540 shares authorized, issued and outstanding (December\u00a031, 2022: authorized, issued and outstanding: 37,683,531)",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r539",
      "r722"
     ]
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/EmployeeBenefitPlans"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Benefit Plans",
        "label": "Compensation and Employee Benefit Plans [Text Block]",
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r134",
      "r135",
      "r136"
     ]
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retirement Benefits [Abstract]",
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets:",
        "label": "Components of Deferred Tax Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract",
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liabilities:",
        "label": "Components of Deferred Tax Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive loss attributable to Barinthus Biotherapeutics plc shareholders",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r198",
      "r200",
      "r207",
      "r531",
      "r552"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Comprehensive loss attributable to noncontrolling interest",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r84",
      "r89",
      "r198",
      "r200",
      "r206",
      "r530",
      "r551"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r145",
      "r198",
      "r200",
      "r205",
      "r529",
      "r550"
     ]
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comprehensive loss",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesConcentrationsofcreditriskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark [Domain]",
        "label": "Concentration Risk Benchmark [Domain]",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r46",
      "r92",
      "r93",
      "r282",
      "r679"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesConcentrationsofcreditriskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark [Axis]",
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r46",
      "r92",
      "r93",
      "r282",
      "r567",
      "r679"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentrations of credit risk",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r164"
     ]
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskLineItems",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesConcentrationsofcreditriskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk [Line Items]",
        "label": "Concentration Risk [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r679"
     ]
    },
    "us-gaap_ConcentrationRiskTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskTable",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesConcentrationsofcreditriskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk [Table]",
        "label": "Concentration Risk [Table]",
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r45",
      "r46",
      "r47",
      "r92",
      "r148",
      "r679"
     ]
    },
    "brns_ConcentrationRiskThresholdPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.barinthusbio.com/20231231",
     "localname": "ConcentrationRiskThresholdPercentage",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesConcentrationsofcreditriskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration risk, percentage",
        "label": "Concentration Risk Threshold Percentage",
        "documentation": "For an entity that discloses a concentration risk threshold Percentage in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ConsolidatedEntitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ConsolidatedEntitiesAxis",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesNoncontrollinginterestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidated Entities [Axis]",
        "label": "Consolidated Entities [Axis]"
       }
      }
     },
     "auth_ref": [
      "r225",
      "r448",
      "r449",
      "r452",
      "r453",
      "r503",
      "r690",
      "r794",
      "r797",
      "r798"
     ]
    },
    "srt_ConsolidatedEntitiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ConsolidatedEntitiesDomain",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesNoncontrollinginterestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidated Entities [Domain]",
        "label": "Consolidated Entities [Domain]"
       }
      }
     },
     "auth_ref": [
      "r225",
      "r448",
      "r449",
      "r452",
      "r453",
      "r503",
      "r690",
      "r794",
      "r797",
      "r798"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principles of consolidation",
        "label": "Consolidation, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r701"
     ]
    },
    "brns_ContingentConsiderationLiabilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.barinthusbio.com/20231231",
     "localname": "ContingentConsiderationLiabilityMember",
     "presentation": [
      "http://www.barinthusbio.com/role/FairValueChangeinfairvalueofcontingentconsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent consideration liability",
        "label": "Contingent Consideration Liability [Member]",
        "documentation": "Represents the information pertaining to contingent consideration liability."
       }
      }
     },
     "auth_ref": []
    },
    "brns_ContingentConsiderationSettledInEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.barinthusbio.com/20231231",
     "localname": "ContingentConsiderationSettledInEquity",
     "crdr": "debit",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent Consideration settled in equity",
        "label": "Contingent Consideration Settled in Equity",
        "documentation": "Amount of contingent consideration settled in equity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContingentLiabilityReserveEstimatePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContingentLiabilityReserveEstimatePolicy",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent liabilities",
        "label": "Contingent Liability Reserve Estimate, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the claims loss reserve for insurance contracts with a life contingency (permanent life, some term life, accident and health, some annuities), describing the loss exposures and bases and methodologies for making the relevant accounting estimates."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r150"
     ]
    },
    "brns_ContractWithCustomerLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.barinthusbio.com/20231231",
     "localname": "ContractWithCustomerLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/OutlicensesandGrantsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of changes in contract liabilities",
        "label": "Contract With Customer Liabilities [Table Text Block]",
        "documentation": "The tabular disclosure of contract with customer liability."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.barinthusbio.com/role/OutlicensesandGrantsChangesinthecontractliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Contract with Customer, Liability",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r356",
      "r357",
      "r368"
     ]
    },
    "brns_ContractWithCustomerLiabilityForeignExchangeTranslation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.barinthusbio.com/20231231",
     "localname": "ContractWithCustomerLiabilityForeignExchangeTranslation",
     "crdr": "credit",
     "presentation": [
      "http://www.barinthusbio.com/role/OutlicensesandGrantsChangesinthecontractliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign exchange translation",
        "label": "Contract With Customer Liability, Foreign Exchange Translation",
        "documentation": "Amount of increase (decrease) in contract liabilities due to foreign exchange translations."
       }
      }
     },
     "auth_ref": []
    },
    "brns_ContractWithCustomerLiabilityRevenueRecognized1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.barinthusbio.com/20231231",
     "localname": "ContractWithCustomerLiabilityRevenueRecognized1",
     "crdr": "credit",
     "presentation": [
      "http://www.barinthusbio.com/role/OutlicensesandGrantsAdditionalInformationDetails",
      "http://www.barinthusbio.com/role/OutlicensesandGrantsChangesinthecontractliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-refundable upfront revenue recognized",
        "negatedTerseLabel": "Revenue recognized related to contract liability balance",
        "label": "Contract with Customer, Liability, Revenue Recognized1",
        "documentation": "Contract with Customer, Liability, Revenue Recognized1"
       }
      }
     },
     "auth_ref": []
    },
    "brns_ContractWithCustomerLiabilityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.barinthusbio.com/20231231",
     "localname": "ContractWithCustomerLiabilityRollForward",
     "presentation": [
      "http://www.barinthusbio.com/role/OutlicensesandGrantsChangesinthecontractliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract with Customer, Liability [Roll Forward]",
        "label": "Contract with Customer, Liability [Roll Forward]",
        "documentation": "Contract with Customer, Liability"
       }
      }
     },
     "auth_ref": []
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.barinthusbio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Axis]",
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r223",
      "r224",
      "r338",
      "r342",
      "r501",
      "r698",
      "r700"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditLossFinancialInstrumentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CreditLossFinancialInstrumentPolicyTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Allowance for credit losses",
        "label": "Credit Loss, Financial Instrument [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit loss on financial instrument measured at amortized cost basis, net investment in lease, off-balance sheet credit exposure, and available-for-sale debt security. Includes, but is not limited to, methodology used to estimate allowance for credit loss, how writeoff of uncollectible amount is recognized, and determination of past due status and nonaccrual status."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentForeignTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/IncomeTaxesComponentsofincometaxbenefitexpenseDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesComponentsofincometaxbenefitexpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Foreign",
        "label": "Current Foreign Tax Expense (Benefit)",
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r758",
      "r769"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesComponentsofincometaxbenefitexpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current income tax benefit/(expense):",
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "brns_DeferredBSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.barinthusbio.com/20231231",
     "localname": "DeferredBSharesMember",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.barinthusbio.com/role/DeferredsharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred B shares",
        "verboseLabel": "Deferred B Shares",
        "label": "Deferred B Shares [Member]",
        "documentation": "Represents information pertaining to deferred B shares."
       }
      }
     },
     "auth_ref": []
    },
    "brns_DeferredCSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.barinthusbio.com/20231231",
     "localname": "DeferredCSharesMember",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.barinthusbio.com/role/DeferredsharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred C shares",
        "verboseLabel": "Deferred C Shares",
        "label": "Deferred C Shares [Member]",
        "documentation": "Represents information pertaining to deferred C shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/PrepaidandothercurrentassetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of prepaid and other current assets",
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/IncomeTaxesComponentsofincometaxbenefitexpenseDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesComponentsofincometaxbenefitexpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Foreign",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r769",
      "r832"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deferred tax expense",
        "label": "Deferred Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r142",
      "r170",
      "r437",
      "r438",
      "r769"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesComponentsofincometaxbenefitexpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred income tax benefit:",
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Net deferred tax liabilities",
        "label": "Deferred Income Tax Liabilities, Net",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r424",
      "r425",
      "r537"
     ]
    },
    "brns_DeferredShares.Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.barinthusbio.com/20231231",
     "localname": "DeferredShares.Member",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.barinthusbio.com/role/DeferredsharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred A shares",
        "verboseLabel": "Deferred A Shares",
        "label": "Deferred A Shares. [Member]",
        "documentation": "This member stands for deferred A shares"
       }
      }
     },
     "auth_ref": []
    },
    "brns_DeferredSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.barinthusbio.com/20231231",
     "localname": "DeferredSharesMember",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deferred Shares",
        "label": "Deferred Shares [Member]",
        "documentation": "Represents information pertaining to deferred shares."
       }
      }
     },
     "auth_ref": []
    },
    "brns_DeferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.barinthusbio.com/20231231",
     "localname": "DeferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.barinthusbio.com/role/DeferredsharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred shares, nominal value (in gbp per share)",
        "label": "Deferred Stock, Par Or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of deferred stock."
       }
      }
     },
     "auth_ref": []
    },
    "brns_DeferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.barinthusbio.com/20231231",
     "localname": "DeferredStockSharesAuthorized",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred shares, authorized (in shares)",
        "label": "Deferred Stock, Shares Authorized",
        "documentation": "The maximum number of deferred shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": []
    },
    "brns_DeferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.barinthusbio.com/20231231",
     "localname": "DeferredStockSharesIssued",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred shares, issued (in shares)",
        "label": "Deferred Stock, Shares Issued",
        "documentation": "Total number of deferred shares of an entity that have been sold or granted to shareholders"
       }
      }
     },
     "auth_ref": []
    },
    "brns_DeferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.barinthusbio.com/20231231",
     "localname": "DeferredStockSharesOutstanding",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred shares, outstanding (in shares)",
        "label": "Deferred Stock, Shares Outstanding",
        "documentation": "Number of shares of deferred stock outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "brns_DeferredStockValueIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.barinthusbio.com/20231231",
     "localname": "DeferredStockValueIssued",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred shares",
        "label": "Deferred Stock, Value Issued",
        "documentation": "Aggregate par or stated value of issued deferred stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsDeferredIncome",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "label": "Deferred Tax Assets, Deferred Income",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r831"
     ]
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross deferred tax asset",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r430"
     ]
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.barinthusbio.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalized Research and Development expenditure",
        "verboseLabel": "Deferred tax assets for capitalized research and development expenditure",
        "label": "Deferred Tax Assets, in Process Research and Development",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r831"
     ]
    },
    "brns_DeferredTaxAssetsLeasingArrangements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.barinthusbio.com/20231231",
     "localname": "DeferredTaxAssetsLeasingArrangements",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liability",
        "label": "Deferred Tax Assets, Leasing Arrangements",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to lease liability."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred tax assets",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r831"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Deferred Tax Assets, Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r831"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development credit carryforwards",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r77",
      "r831"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share based compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r831"
     ]
    },
    "brns_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsIntangibles": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.barinthusbio.com/20231231",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsIntangibles",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accruals and intangibles",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Intangibles",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals and intangibles."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.barinthusbio.com/role/IncomeTaxesChangesinthevaluationallowancefordeferredtaxassetsDetails",
      "http://www.barinthusbio.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Valuation allowance",
        "terseLabel": "Valuation allowance",
        "periodStartLabel": "Valuations allowance at beginning of year",
        "periodEndLabel": "Valuation allowance at end of year",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r431"
     ]
    },
    "us-gaap_DeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total deferred tax, net",
        "label": "Deferred Tax Liabilities, Net",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r830"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilitiesNet",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Intangible assets",
        "label": "Deferred Tax Liabilities, Intangible Assets",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r831"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilitiesNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Right-of-use lease asset",
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r831"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilitiesNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Depreciation",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r831"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilitiesNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Unrealized gain on investment",
        "label": "Deferred Tax Liabilities, Unrealized Gains on Trading Securities",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from unrealized gains on trading securities."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r831"
     ]
    },
    "brns_DeferredTaxLiabilityNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.barinthusbio.com/20231231",
     "localname": "DeferredTaxLiabilityNet",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liability, net",
        "label": "Deferred Tax Liability, Net",
        "documentation": "Amount of classified as non-current liabilities, net value of deferred tax liability."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.barinthusbio.com/role/EmployeeBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employer contribution",
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://www.barinthusbio.com/role/PropertyandEquipmentNetAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation expense",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r59"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "label": "Depreciation, Depletion and Amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r263"
     ]
    },
    "us-gaap_DevelopedTechnologyRightsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DevelopedTechnologyRightsMember",
     "presentation": [
      "http://www.barinthusbio.com/role/IntangibleassetsnetDetails",
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Developed technology",
        "label": "Developed Technology Rights [Member]",
        "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property."
       }
      }
     },
     "auth_ref": [
      "r143"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Compensation",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r373",
      "r378",
      "r409",
      "r410",
      "r412",
      "r717"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement [Abstract]",
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Annual Report",
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r744",
      "r745",
      "r746"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Financial Statement Error Correction [Flag]",
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r744",
      "r745",
      "r746",
      "r748"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Information [Line Items]",
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Information [Table]",
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Documents Incorporated by Reference",
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r742"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Domestic Tax Authority",
        "label": "Domestic Tax Authority [Member]",
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings Per Share [Abstract]",
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.barinthusbio.com/role/NetLossIncomePerShareComputationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net (loss)/income per share attributable to ordinary shareholders, basic (in usd per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r208",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r240",
      "r242",
      "r248",
      "r249",
      "r250",
      "r254",
      "r462",
      "r463",
      "r532",
      "r553",
      "r704"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.barinthusbio.com/role/NetLossIncomePerShareComputationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net (loss)/income per share attributable to ordinary shareholders, diluted (in usd per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r208",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r242",
      "r248",
      "r249",
      "r250",
      "r254",
      "r462",
      "r463",
      "r532",
      "r553",
      "r704"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net (loss)/income per share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r43"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/NetLossIncomePerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net (Loss)/Income Per Share",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r239",
      "r251",
      "r252",
      "r253"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of exchange rates on cash and cash equivalents",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r839"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://www.barinthusbio.com/role/IncomeTaxesReconciliationtotheeffectivetaxrateDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesReconciliationtotheeffectivetaxrateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Effective tax rate",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://www.barinthusbio.com/role/IncomeTaxesReconciliationtotheeffectivetaxrateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesReconciliationtotheeffectivetaxrateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statutory tax rate",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r220",
      "r427",
      "r440"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://www.barinthusbio.com/role/IncomeTaxesReconciliationtotheeffectivetaxrateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesReconciliationtotheeffectivetaxrateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r829",
      "r833"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "calculation": {
      "http://www.barinthusbio.com/role/IncomeTaxesReconciliationtotheeffectivetaxrateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesReconciliationtotheeffectivetaxrateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign rate differential",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile."
       }
      }
     },
     "auth_ref": [
      "r829",
      "r833"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense",
     "calculation": {
      "http://www.barinthusbio.com/role/IncomeTaxesReconciliationtotheeffectivetaxrateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesReconciliationtotheeffectivetaxrateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Permanent differences",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r829",
      "r833"
     ]
    },
    "brns_EffectiveIncomeTaxRateReconciliationPercentIncreaseDecreaseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.barinthusbio.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationPercentIncreaseDecreaseAbstract",
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesReconciliationtotheeffectivetaxrateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (decreases) resulting from:",
        "label": "Effective Income Tax Rate Reconciliation, Percent, Increase (Decrease) [Abstract]",
        "documentation": "Effective Income Tax Rate Reconciliation, Percent, Increase (Decrease)"
       }
      }
     },
     "auth_ref": []
    },
    "brns_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.barinthusbio.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustments",
     "calculation": {
      "http://www.barinthusbio.com/role/IncomeTaxesReconciliationtotheeffectivetaxrateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesReconciliationtotheeffectivetaxrateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provision to return adjustments",
        "label": "Effective Income Tax Rate Reconciliation, Provision to Return Adjustments",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to provision to return adjustments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent",
     "calculation": {
      "http://www.barinthusbio.com/role/IncomeTaxesReconciliationtotheeffectivetaxrateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesReconciliationtotheeffectivetaxrateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share based compensation",
        "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent",
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r754",
      "r829"
     ]
    },
    "brns_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.barinthusbio.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment",
     "calculation": {
      "http://www.barinthusbio.com/role/IncomeTaxesReconciliationtotheeffectivetaxrateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesReconciliationtotheeffectivetaxrateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Research and development credits",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credits, Research And Development",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development tax credit."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted-average period over which unrecognized compensation cost is expected to be recognized",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r411"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation cost related to options",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r828"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.barinthusbio.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options",
        "label": "Employee Stock Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "brns_EnterpriseManagementIncentiveShareOptionSchemeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.barinthusbio.com/20231231",
     "localname": "EnterpriseManagementIncentiveShareOptionSchemeMember",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://www.barinthusbio.com/role/ShareBasedCompensationWeightedaverageassumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Enterprise Management Incentive Share Option Scheme",
        "label": "Enterprise Management Incentive Share Option Scheme [Member]",
        "documentation": "Information pertaining to the Enterprise Management Incentive Share Option Scheme."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Country",
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r741"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r741"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Ex Transition Period",
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r751"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r741"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r749"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Public Float",
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r741"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r741"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r741"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r741"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Voluntary Filers",
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r750"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity [Abstract]",
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r175",
      "r201",
      "r202",
      "r203",
      "r226",
      "r227",
      "r228",
      "r230",
      "r236",
      "r238",
      "r255",
      "r286",
      "r287",
      "r355",
      "r413",
      "r414",
      "r415",
      "r433",
      "r434",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r461",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r494",
      "r562",
      "r563",
      "r564",
      "r582",
      "r653"
     ]
    },
    "brns_ExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.barinthusbio.com/20231231",
     "localname": "ExpensesMember",
     "presentation": [
      "http://www.barinthusbio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expenses",
        "label": "Expenses [Member]",
        "documentation": "Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "brns_ExpirationOfShareBasedCompensationPlanFromDateOfInitialIssuance": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.barinthusbio.com/20231231",
     "localname": "ExpirationOfShareBasedCompensationPlanFromDateOfInitialIssuance",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration period",
        "label": "Expiration Of Share Based Compensation Plan From Date Of Initial Issuance",
        "documentation": "The duration of grants awarded under a share-based compensation plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByLiabilityClassAxis",
     "presentation": [
      "http://www.barinthusbio.com/role/FairValueChangeinfairvalueofcontingentconsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liability Class [Axis]",
        "label": "Liability Class [Axis]",
        "documentation": "Information by class of liability."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r147"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Disclosures [Abstract]",
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/FairValue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r464"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "presentation": [
      "http://www.barinthusbio.com/role/FairValueChangeinfairvalueofcontingentconsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value by Liability Class [Domain]",
        "label": "Fair Value by Liability Class [Domain]",
        "documentation": "Represents classes of liabilities measured and disclosed at fair value."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "presentation": [
      "http://www.barinthusbio.com/role/FairValueChangeinfairvalueofcontingentconsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "presentation": [
      "http://www.barinthusbio.com/role/FairValueAdditionalinformationDetails",
      "http://www.barinthusbio.com/role/FairValueChangeinfairvalueofcontingentconsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "presentation": [
      "http://www.barinthusbio.com/role/FairValueAdditionalinformationDetails",
      "http://www.barinthusbio.com/role/FairValueChangeinfairvalueofcontingentconsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r91"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/FairValueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of financial instruments carried at fair value and classified within Level 3",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r91"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value measurements",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "brns_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeTranslation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.barinthusbio.com/20231231",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeTranslation",
     "crdr": "credit",
     "presentation": [
      "http://www.barinthusbio.com/role/FairValueChangeinfairvalueofcontingentconsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Foreign exchange translation recognized in other comprehensive loss",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Foreign Exchange Translation",
        "documentation": "Amount of foreign exchange translation of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "crdr": "credit",
     "presentation": [
      "http://www.barinthusbio.com/role/FairValueChangeinfairvalueofcontingentconsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Change in fair value recognized in net loss",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r465"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
     "crdr": "debit",
     "presentation": [
      "http://www.barinthusbio.com/role/FairValueChangeinfairvalueofcontingentconsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Settlement of contingency",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements",
        "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "crdr": "credit",
     "presentation": [
      "http://www.barinthusbio.com/role/FairValueAdditionalinformationDetails",
      "http://www.barinthusbio.com/role/FairValueChangeinfairvalueofcontingentconsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent consideration liability",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial instruments",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r22"
     ]
    },
    "brns_FiniteLivedIntangibleAssetExpectedAmortizationYearEight": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.barinthusbio.com/20231231",
     "localname": "FiniteLivedIntangibleAssetExpectedAmortizationYearEight",
     "crdr": "debit",
     "presentation": [
      "http://www.barinthusbio.com/role/IntangibleassetsnetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated annual amortization expense for 2031",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Eight",
        "documentation": "Finite-Lived Intangible Asset, Expected Amortization, Year Eight"
       }
      }
     },
     "auth_ref": []
    },
    "brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSeven": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.barinthusbio.com/20231231",
     "localname": "FiniteLivedIntangibleAssetExpectedAmortizationYearSeven",
     "crdr": "debit",
     "presentation": [
      "http://www.barinthusbio.com/role/IntangibleassetsnetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated annual amortization expense for 2030",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Seven",
        "documentation": "Finite-Lived Intangible Asset, Expected Amortization, Year Seven"
       }
      }
     },
     "auth_ref": []
    },
    "brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSix": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.barinthusbio.com/20231231",
     "localname": "FiniteLivedIntangibleAssetExpectedAmortizationYearSix",
     "crdr": "debit",
     "presentation": [
      "http://www.barinthusbio.com/role/IntangibleassetsnetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated annual amortization expense for 2029",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Six",
        "documentation": "Finite-Lived Intangible Asset, Expected Amortization, Year Six"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Estimated useful life of intangible assets",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "presentation": [
      "http://www.barinthusbio.com/role/IntangibleassetsnetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated amortization for amortizable intangible assets",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r184",
      "r318"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "presentation": [
      "http://www.barinthusbio.com/role/IntangibleassetsnetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated annual amortization expense for 2024",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r124"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "crdr": "debit",
     "presentation": [
      "http://www.barinthusbio.com/role/IntangibleassetsnetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated annual amortization expense for 2028",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r124"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "crdr": "debit",
     "presentation": [
      "http://www.barinthusbio.com/role/IntangibleassetsnetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated annual amortization expense for 2027",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r124"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "presentation": [
      "http://www.barinthusbio.com/role/IntangibleassetsnetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated annual amortization expense for 2026",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r124"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "presentation": [
      "http://www.barinthusbio.com/role/IntangibleassetsnetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated annual amortization expense for 2025",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r124"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.barinthusbio.com/role/IntangibleassetsnetDetails",
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r316",
      "r317",
      "r318",
      "r319",
      "r514",
      "r515"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "presentation": [
      "http://www.barinthusbio.com/role/IntangibleassetsnetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross amount of amortizable intangible assets",
        "label": "Finite-Lived Intangible Assets, Gross",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r515"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://www.barinthusbio.com/role/IntangibleassetsnetDetails",
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r514"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.barinthusbio.com/role/IntangibleassetsnetDetails",
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r55"
     ]
    },
    "us-gaap_ForeignCurrencyAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCurrencyAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign Currency [Abstract]",
        "label": "Foreign Currency [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCurrencyDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCurrencyDisclosureTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/ForeignCurrencyTranslationinGeneralandAdministrativeExpenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign Currency Translation in General and Administrative Expenses",
        "label": "Foreign Currency Disclosure [Text Block]",
        "documentation": "The entire disclosure for foreign currency transactions and translation. This may include description of foreign currency transactions, foreign currency gains and losses, explanation of change in cumulative translation adjustment, description of effect of subsequent foreign currency exchange rate change, cumulative translation adjustment movement, foreign currency translation adjustment by component movement, translation adjustment for net investment hedge movement, adjustment for long-term intercompany transactions, schedule of long-term intercompany balances and any other foreign currency transactions and translation related items."
       }
      }
     },
     "auth_ref": [
      "r468",
      "r480",
      "r736",
      "r737",
      "r738",
      "r739",
      "r753"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "crdr": "credit",
     "presentation": [
      "http://www.barinthusbio.com/role/ForeignCurrencyTranslationinGeneralandAdministrativeExpensesDetails",
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesForeigncurrencytranslationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net foreign exchange gain (loss)",
        "label": "Gain (Loss), Foreign Currency Transaction, before Tax",
        "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r469",
      "r470",
      "r471",
      "r472",
      "r650"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCurrencyTransactionGainLossUnrealized",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Unrealized foreign exchange loss/(gain)",
        "label": "Unrealized Gain (Loss), Foreign Currency Transaction, before Tax",
        "documentation": "Amount, before tax, of unrealized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r627",
      "r733",
      "r837",
      "r838",
      "r857"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency translation",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r468"
     ]
    },
    "brns_FundingAmountMaximum": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.barinthusbio.com/20231231",
     "localname": "FundingAmountMaximum",
     "crdr": "debit",
     "presentation": [
      "http://www.barinthusbio.com/role/OutlicensesandGrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum funding amount",
        "label": "Funding Amount, Maximum",
        "documentation": "Funding Amount, Maximum"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.barinthusbio.com/role/PropertyandEquipmentNetComponentsDetails",
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPropertyandequipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office furniture and equipment",
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "country_GB": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "GB",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesConcentrationsofcreditriskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.K.",
        "label": "UNITED KINGDOM"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Profit on sale of property and equipment",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r631"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationSharebasedcompensationexpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Goodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.barinthusbio.com/role/GoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Goodwill",
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r309",
      "r528",
      "r709",
      "r722",
      "r780",
      "r787"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined."
       }
      }
     },
     "auth_ref": [
      "r308",
      "r314",
      "r709"
     ]
    },
    "us-gaap_GoodwillDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillDisclosureTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/Goodwill"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "label": "Goodwill Disclosure [Text Block]",
        "documentation": "The entire disclosure for goodwill."
       }
      }
     },
     "auth_ref": [
      "r308",
      "r311",
      "r313",
      "r709"
     ]
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillImpairmentLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesImpairmentoflonglivedassetsandGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of goodwill",
        "label": "Goodwill, Impairment Loss",
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r310",
      "r312",
      "r314",
      "r709"
     ]
    },
    "us-gaap_GoodwillPurchaseAccountingAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillPurchaseAccountingAdjustments",
     "crdr": "debit",
     "presentation": [
      "http://www.barinthusbio.com/role/GoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement period adjustments",
        "label": "Goodwill, Purchase Accounting Adjustments",
        "documentation": "Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r786"
     ]
    },
    "us-gaap_GoodwillRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillRollForward",
     "presentation": [
      "http://www.barinthusbio.com/role/GoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill [Roll Forward]",
        "label": "Goodwill [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "brns_GrantIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.barinthusbio.com/20231231",
     "localname": "GrantIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grant Income",
        "label": "Grant Income, Policy [Policy Text Block]",
        "documentation": "Grant Income, Policy"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GuaranteesIndemnificationsAndWarrantiesPolicies",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Guarantees and indemnifications",
        "label": "Guarantees, Indemnifications and Warranties Policies [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for guarantees, indemnifications and product warranties, and methodologies used in determining the amount of such liabilities."
       }
      }
     },
     "auth_ref": [
      "r328"
     ]
    },
    "us-gaap_IPOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IPOMember",
     "presentation": [
      "http://www.barinthusbio.com/role/OrdinarySharesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "IPO",
        "label": "IPO [Member]",
        "documentation": "First sale of stock by a private company to the public."
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ICFR Auditor Attestation Flag",
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r744",
      "r745",
      "r746"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of long-lived assets",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r127"
     ]
    },
    "brns_InLicenseAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.barinthusbio.com/20231231",
     "localname": "InLicenseAgreementsMember",
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "In-License Agreements",
        "label": "In-License Agreements [Member]",
        "documentation": "Represents the information pertaining to In-License Agreements."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/IncomeTaxesLossincomebeforeincometaxesDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesLossincomebeforeincometaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "United Kingdom",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations."
       }
      }
     },
     "auth_ref": [
      "r219",
      "r439"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.barinthusbio.com/role/IncomeTaxesLossincomebeforeincometaxesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.barinthusbio.com/role/IncomeTaxesLossincomebeforeincometaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "(Loss)/profit before income tax",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r108",
      "r155",
      "r258",
      "r272",
      "r276",
      "r278",
      "r533",
      "r546",
      "r706"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/IncomeTaxesLossincomebeforeincometaxesDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesLossincomebeforeincometaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": [
      "r219",
      "r439"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement [Abstract]",
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationSharebasedcompensationexpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Axis]",
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r320",
      "r321",
      "r636"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationSharebasedcompensationexpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Domain]",
        "label": "Income Statement Location [Domain]",
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r321",
      "r636"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority [Axis]",
        "label": "Income Tax Authority [Axis]",
        "documentation": "Information by tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority [Domain]",
        "label": "Income Tax Authority [Domain]",
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxCreditsAndAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxCreditsAndAdjustments",
     "crdr": "debit",
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unlimited carryforward amount",
        "label": "Income Tax Credits and Adjustments",
        "documentation": "A credit or adjustment for government or taxing authority authorized decrease in taxes owed as a result of meeting certain tax policy conditions."
       }
      }
     },
     "auth_ref": [
      "r120"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Disclosure [Abstract]",
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r220",
      "r423",
      "r428",
      "r429",
      "r432",
      "r435",
      "r441",
      "r442",
      "r443",
      "r576"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0,
       "order": 1.0
      },
      "http://www.barinthusbio.com/role/IncomeTaxesComponentsofincometaxbenefitexpenseDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.barinthusbio.com/role/IncomeTaxesComponentsofincometaxbenefitexpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Tax benefit",
        "negatedTotalLabel": "Total income tax benefit",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r172",
      "r237",
      "r238",
      "r264",
      "r426",
      "r436",
      "r554"
     ]
    },
    "brns_IncomeTaxesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.barinthusbio.com/20231231",
     "localname": "IncomeTaxesLineItems",
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesComponentsofincometaxbenefitexpenseDetails",
      "http://www.barinthusbio.com/role/IncomeTaxesLossincomebeforeincometaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes [Line Items]",
        "label": "Income Taxes [Line Items]",
        "documentation": "Income Taxes [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for income taxes",
        "label": "Income Taxes Paid, Net",
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "brns_IncomeTaxesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.barinthusbio.com/20231231",
     "localname": "IncomeTaxesTable",
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesComponentsofincometaxbenefitexpenseDetails",
      "http://www.barinthusbio.com/role/IncomeTaxesLossincomebeforeincometaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes [Table]",
        "label": "Income Taxes [Table]",
        "documentation": "Income Taxes [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts receivable (including related parties)",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other current liabilities",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other."
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r509",
      "r766"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r756",
      "r766"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other assets",
        "label": "Increase (Decrease) in Other Operating Assets",
        "documentation": "Amount of increase (decrease) in operating assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other current assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "brns_IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.barinthusbio.com/20231231",
     "localname": "IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Research and development incentives receivable",
        "label": "Increase (Decrease) in Research and Development Incentives Receivable",
        "documentation": "Amount of increase (decrease) in research and development incentives receivable."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "calculation": {
      "http://www.barinthusbio.com/role/NetLossIncomePerShareComputationDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/NetLossIncomePerShareComputationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Effect of dilutive stock options (in shares)",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements",
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method."
       }
      }
     },
     "auth_ref": [
      "r243",
      "r244",
      "r245",
      "r250",
      "r377"
     ]
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/Intangibleassetsnet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets, net",
        "label": "Intangible Assets Disclosure [Text Block]",
        "documentation": "The entire disclosure for all or part of the information related to intangible assets."
       }
      }
     },
     "auth_ref": [
      "r315"
     ]
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets acquired through business combinations",
        "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r510",
      "r511",
      "r512",
      "r514",
      "r702"
     ]
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Patent and licensing costs",
        "label": "Intangible Assets, Costs Incurred to Renew or Extend, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the treatment of costs incurred to renew or extend the term of a recognized intangible asset."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets, net",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r54"
     ]
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Interest expense",
        "label": "Interest Expense",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r157",
      "r204",
      "r262",
      "r481",
      "r637",
      "r733",
      "r856"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for interest",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r213",
      "r214"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income",
        "label": "Investment Income, Interest",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r261"
     ]
    },
    "brns_IssuanceOfCommonStockOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.barinthusbio.com/20231231",
     "localname": "IssuanceOfCommonStockOfferingCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.barinthusbio.com/role/OrdinarySharesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offering costs",
        "label": "Issuance Of Common Stock, Offering Costs",
        "documentation": "Offering costs related to the issuance of common stock."
       }
      }
     },
     "auth_ref": []
    },
    "brns_IssuanceOfCommonStockUnderwritingCommissions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.barinthusbio.com/20231231",
     "localname": "IssuanceOfCommonStockUnderwritingCommissions",
     "crdr": "debit",
     "presentation": [
      "http://www.barinthusbio.com/role/OrdinarySharesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underwriting commissions",
        "label": "Issuance Of Common Stock, Underwriting Commissions",
        "documentation": "Underwriting commissions for issuance of common stock."
       }
      }
     },
     "auth_ref": []
    },
    "brns_LaboratoryEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.barinthusbio.com/20231231",
     "localname": "LaboratoryEquipmentMember",
     "presentation": [
      "http://www.barinthusbio.com/role/PropertyandEquipmentNetComponentsDetails",
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPropertyandequipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Laboratory equipment",
        "label": "Laboratory Equipment [Member]",
        "documentation": "This member stands for laboratory equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesRightofuseassetsleaseliabilitiesandotherinformationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesRightofuseassetsleaseliabilitiesandotherinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease cost",
        "label": "Lease, Cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r486",
      "r721"
     ]
    },
    "us-gaap_LeaseCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCostAbstract",
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesRightofuseassetsleaseliabilitiesandotherinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease Costs",
        "label": "Lease, Cost [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "brns_LeaseIncentiveReceivablesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.barinthusbio.com/20231231",
     "localname": "LeaseIncentiveReceivablesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/PrepaidandothercurrentassetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/PrepaidandothercurrentassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease incentives receivable",
        "label": "Lease Incentive Receivables, Current",
        "documentation": "This item represents the current receivable for an incentive or inducement contractually stipulated between parties to a lease whereby the lessor has committed to provide the entity (lessee) with a cash payment as inducement to enter the lease. The receivable is due within one year. For classified balance sheets, this element represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseholdImprovementsGross",
     "crdr": "debit",
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold improvement expense",
        "label": "Leasehold Improvements, Gross",
        "documentation": "Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r126"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.barinthusbio.com/role/PropertyandEquipmentNetComponentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold improvements",
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r126"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r485"
     ]
    },
    "brns_LesseeOperatingLeaseExtendedTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.barinthusbio.com/20231231",
     "localname": "LesseeOperatingLeaseExtendedTerm",
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional lease term",
        "label": "Lessee Operating Lease, Extended Term",
        "documentation": "Term of lessee's operating lease extended, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of maturities of minimum lease liabilities",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r840"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total minimum lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r493"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r493"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r493"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r493"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r493"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r493"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r493"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r493"
     ]
    },
    "brns_LesseeOperatingLeaseRightOfUseAssetAndOtherInformationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.barinthusbio.com/20231231",
     "localname": "LesseeOperatingLeaseRightOfUseAssetAndOtherInformationTableTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of right-of-use, lease liabilities and other information",
        "label": "Lessee Operating Lease Right of Use asset and Other Information [Table Text Block]",
        "documentation": "Tabular disclosure for Company's right-of-use asset and lease liability and other information."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r218",
      "r285",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r449",
      "r452",
      "r453",
      "r467",
      "r605",
      "r705",
      "r735",
      "r795",
      "r842",
      "r843"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders\u2019 equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r154",
      "r542",
      "r722",
      "r768",
      "r778",
      "r836"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r179",
      "r218",
      "r285",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r449",
      "r452",
      "r453",
      "r467",
      "r722",
      "r795",
      "r842",
      "r843"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Current liabilities:",
        "label": "Liabilities, Noncurrent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LicenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LicenseMember",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.barinthusbio.com/role/OutlicensesandGrantsAdditionalInformationDetails",
      "http://www.barinthusbio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License revenue",
        "label": "License [Member]",
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark."
       }
      }
     },
     "auth_ref": [
      "r801"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "stpr_MD": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2023",
     "localname": "MD",
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maryland",
        "label": "MARYLAND"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesConcentrationsofcreditriskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Axis]",
        "label": "Customer [Axis]"
       }
      }
     },
     "auth_ref": [
      "r282",
      "r713",
      "r800",
      "r852",
      "r853"
     ]
    },
    "brns_MaximumAggregateNominalAmountOfSharesAuthorizedToBeAllottedFreeFromStatutoryPreEmptionRights": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.barinthusbio.com/20231231",
     "localname": "MaximumAggregateNominalAmountOfSharesAuthorizedToBeAllottedFreeFromStatutoryPreEmptionRights",
     "crdr": "credit",
     "presentation": [
      "http://www.barinthusbio.com/role/OrdinarySharesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum aggregate nominal amount of shares authorized to be allotted free from pre-emption rights",
        "label": "Maximum Aggregate Nominal Amount Of Shares Authorized To Be Allotted Free From Statutory Pre-emption Rights",
        "documentation": "Amount of maximum aggregate nominal amount of shares that the board of directors are authorized to allot free from statutory Pre-emption rights."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r324",
      "r325",
      "r326",
      "r327",
      "r372",
      "r508",
      "r561",
      "r597",
      "r598",
      "r662",
      "r664",
      "r666",
      "r667",
      "r669",
      "r691",
      "r692",
      "r708",
      "r710",
      "r716",
      "r724",
      "r799",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r324",
      "r325",
      "r326",
      "r327",
      "r372",
      "r508",
      "r561",
      "r597",
      "r598",
      "r662",
      "r664",
      "r666",
      "r667",
      "r669",
      "r691",
      "r692",
      "r708",
      "r710",
      "r716",
      "r724",
      "r799",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849"
     ]
    },
    "us-gaap_MinorityInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MinorityInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling interest",
        "label": "Equity, Attributable to Noncontrolling Interest",
        "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r153",
      "r218",
      "r285",
      "r329",
      "r331",
      "r332",
      "r333",
      "r336",
      "r337",
      "r467",
      "r541",
      "r609"
     ]
    },
    "us-gaap_MinorityInterestLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MinorityInterestLineItems",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesNoncontrollinginterestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling Interest [Line Items]",
        "label": "Noncontrolling Interest [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesNoncontrollinginterestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling interest (as a percent)",
        "label": "Subsidiary, Ownership Percentage, Noncontrolling Owner",
        "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesNoncontrollinginterestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Controlling interest (as a percent)",
        "label": "Subsidiary, Ownership Percentage, Parent",
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage."
       }
      }
     },
     "auth_ref": []
    },
    "brns_MinorityInterestPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.barinthusbio.com/20231231",
     "localname": "MinorityInterestPolicyTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling interest",
        "label": "Minority Interest [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for Minority (Non Controlling) interest."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MinorityInterestTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MinorityInterestTable",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesNoncontrollinginterestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling Interest [Table]",
        "label": "Noncontrolling Interest [Table]",
        "documentation": "Schedule of noncontrolling interest disclosure which includes the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r83",
      "r86",
      "r111"
     ]
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesConcentrationsofcreditriskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Domain]",
        "label": "Customer [Domain]"
       }
      }
     },
     "auth_ref": [
      "r282",
      "r713",
      "r800",
      "r852",
      "r853"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r212"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r212"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r119",
      "r120"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.barinthusbio.com/role/NetLossIncomePerShareComputationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net (loss)/income attributable to Barinthus Biotherapeutics plc shareholders",
        "label": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r120",
      "r156",
      "r177",
      "r197",
      "r199",
      "r203",
      "r218",
      "r229",
      "r231",
      "r232",
      "r233",
      "r234",
      "r237",
      "r238",
      "r247",
      "r258",
      "r272",
      "r276",
      "r278",
      "r285",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r463",
      "r467",
      "r549",
      "r628",
      "r651",
      "r652",
      "r706",
      "r733",
      "r795"
     ]
    },
    "us-gaap_NetIncomeLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAbstract",
     "presentation": [
      "http://www.barinthusbio.com/role/NetLossIncomePerShareComputationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Numerator:",
        "label": "Net Income (Loss) Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.barinthusbio.com/role/NetLossIncomePerShareComputationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Net loss attributable to noncontrolling interest",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r146",
      "r197",
      "r199",
      "r237",
      "r238",
      "r548",
      "r765"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recent Accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "brns_NonCashInterestExpenseOnConvertibleLoanNotes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.barinthusbio.com/20231231",
     "localname": "NonCashInterestExpenseOnConvertibleLoanNotes",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Non cash interest expense",
        "label": "Non-Cash Interest Expense On Convertible Loan Notes",
        "documentation": "Amount of non-cash interest expense on convertible loan notes."
       }
      }
     },
     "auth_ref": []
    },
    "brns_NonCashInvestingAndFinancingActivityOfMeasurementPeriodAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.barinthusbio.com/20231231",
     "localname": "NonCashInvestingAndFinancingActivityOfMeasurementPeriodAdjustments",
     "crdr": "debit",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement period adjustments",
        "label": "Non Cash Investing And Financing Activity Of Measurement Period Adjustments",
        "documentation": "Amount of on cash investing and financing activity of measurement period adjustments."
       }
      }
     },
     "auth_ref": []
    },
    "brns_NonCashLeaseExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.barinthusbio.com/20231231",
     "localname": "NonCashLeaseExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash lease expenses",
        "label": "Non-Cash Lease Expenses",
        "documentation": "The amount of non-cash lease expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonUsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonUsMember",
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesComponentsofincometaxbenefitexpenseDetails",
      "http://www.barinthusbio.com/role/IncomeTaxesLossincomebeforeincometaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other foreign",
        "label": "Non-US [Member]",
        "documentation": "Countries excluding the United States of America (US)."
       }
      }
     },
     "auth_ref": [
      "r860",
      "r861",
      "r862",
      "r863"
     ]
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Cash investing and financing activities",
        "label": "Noncash Investing and Financing Items [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncontrollingInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncontrollingInterestMember",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling Interest",
        "label": "Noncontrolling Interest [Member]",
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r355",
      "r772",
      "r773",
      "r774",
      "r858"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other income, net",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r114"
     ]
    },
    "us-gaap_NonrelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonrelatedPartyMember",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nonrelated parties",
        "label": "Nonrelated Party [Member]",
        "documentation": "Party not related to reporting entity."
       }
      }
     },
     "auth_ref": [
      "r770",
      "r771"
     ]
    },
    "brns_NumberOfAmericanDepositarySharesAdsIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.barinthusbio.com/20231231",
     "localname": "NumberOfAmericanDepositarySharesAdsIssued",
     "presentation": [
      "http://www.barinthusbio.com/role/OrdinarySharesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of ADS shares closed (in shares)",
        "label": "Number Of American Depositary Shares (ADS) Issued",
        "documentation": "Represents the number of ADS shares issued during the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesSegmentinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of operating segments",
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r777"
     ]
    },
    "brns_NumberOfSquareFeetUnderLeaseAgreement": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.barinthusbio.com/20231231",
     "localname": "NumberOfSquareFeetUnderLeaseAgreement",
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Size of space under lease agreement (in square feet)",
        "label": "Number Of Square Feet Under Lease Agreement",
        "documentation": "Represents the information pertaining to number of Square Feet Under Lease Agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r258",
      "r272",
      "r276",
      "r278",
      "r706"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesRightofuseassetsleaseliabilitiesandotherinformationDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesRightofuseassetsleaseliabilitiesandotherinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fixed Lease Costs",
        "label": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r487",
      "r721"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total lease liability",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r483"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesRightofuseassetsleaseliabilitiesandotherinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liability - current",
        "verboseLabel": "Lease liability, current",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r483"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesRightofuseassetsleaseliabilitiesandotherinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liability - non-current",
        "verboseLabel": "Lease liability, noncurrent",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r483"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesRightofuseassetsleaseliabilitiesandotherinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating cash flows from operating leases",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r484",
      "r489"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesRightofuseassetsleaseliabilitiesandotherinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right of use assets, net",
        "verboseLabel": "Right-of-use asset",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r482"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesRightofuseassetsleaseliabilitiesandotherinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average discount rate",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r492",
      "r721"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesRightofuseassetsleaseliabilitiesandotherinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining lease term (years)",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r491",
      "r721"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards",
        "label": "Operating Loss Carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsLineItems",
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Loss Carryforwards [Line Items]",
        "label": "Operating Loss Carryforwards [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsTable",
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Loss Carryforwards [Table]",
        "label": "Operating Loss Carryforwards [Table]",
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "brns_OrdinarySharesLiquidationPreference": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.barinthusbio.com/20231231",
     "localname": "OrdinarySharesLiquidationPreference",
     "crdr": "credit",
     "presentation": [
      "http://www.barinthusbio.com/role/DeferredsharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares, liquidation preference",
        "label": "Ordinary Shares, Liquidation Preference",
        "documentation": "The amount of liquidation preference on ordinary shares to be paid after which the deferred shares have the entitlement to receive out of the assets of the Company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/NatureofBusinessandBasisofPresentation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nature of Business and Basis of Presentation",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r144",
      "r568",
      "r569"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "parentTag": "brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued other",
        "label": "Other Accrued Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_OtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets",
        "label": "Other Assets",
        "documentation": "Amount of assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r185",
      "r535",
      "r735"
     ]
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/PrepaidandothercurrentassetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/PrepaidandothercurrentassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Assets, Current",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r191",
      "r722"
     ]
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCommitmentsLineItems",
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Commitments [Line Items]",
        "label": "Other Commitments [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCommitmentsTable",
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Commitments [Table]",
        "label": "Other Commitments [Table]",
        "documentation": "Disclosure of information about obligations resulting from other commitments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive gain/(loss) \u2013 foreign currency translation adjustments",
        "verboseLabel": "Foreign currency translation adjustments",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherIncomeAndExpensesAbstract",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income /(expense):",
        "label": "Other Income and Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "brns_OtherInformationLesseeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.barinthusbio.com/20231231",
     "localname": "OtherInformationLesseeAbstract",
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesRightofuseassetsleaseliabilitiesandotherinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other information",
        "label": "Other Information, Lessee [Abstract]",
        "documentation": "Other Information, Lessee"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-current liabilities",
        "label": "Other Liabilities, Noncurrent",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other income, net",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r115"
     ]
    },
    "brns_OuiLicenseAgreementAmendmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.barinthusbio.com/20231231",
     "localname": "OuiLicenseAgreementAmendmentMember",
     "presentation": [
      "http://www.barinthusbio.com/role/OutlicensesandGrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OUI",
        "label": "OUI License Agreement Amendment [Member]",
        "documentation": "The member stands for OUI license agreement amendment."
       }
      }
     },
     "auth_ref": []
    },
    "srt_OwnershipAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "OwnershipAxis",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesNoncontrollinginterestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership [Axis]",
        "label": "Ownership [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_OwnershipDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "OwnershipDomain",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesNoncontrollinginterestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership [Domain]",
        "label": "Ownership [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "brns_OxfordUniversityInnovationLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.barinthusbio.com/20231231",
     "localname": "OxfordUniversityInnovationLimitedMember",
     "presentation": [
      "http://www.barinthusbio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Oxford University Innovation Limited",
        "label": "Oxford University Innovation Limited [Member]",
        "documentation": "Represents the information pertaining to Oxford University Innovation Limited."
       }
      }
     },
     "auth_ref": []
    },
    "brns_OxfordUniversityInnovationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.barinthusbio.com/20231231",
     "localname": "OxfordUniversityInnovationMember",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesConcentrationsofcreditriskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Oxford University Innovation",
        "label": "Oxford University Innovation [Member]",
        "documentation": "Represent information related to Oxford University Innovation."
       }
      }
     },
     "auth_ref": []
    },
    "brns_OxfordshireMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.barinthusbio.com/20231231",
     "localname": "OxfordshireMember",
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Oxfordshire",
        "label": "Oxfordshire [Member]",
        "documentation": "Oxfordshire"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ParentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ParentMember",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total stockholders\u2019 equity attributable to Barinthus Biotherapeutics plc stockholders",
        "label": "Parent [Member]",
        "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payment of contingent consideration",
        "label": "Payment for Contingent Consideration Liability, Financing Activities",
        "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireAdditionalInterestInSubsidiaries",
     "crdr": "credit",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesNoncontrollinginterestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contributions to acquire additional interest in subsidiaries",
        "label": "Payments to Acquire Additional Interest in Subsidiaries",
        "documentation": "The cash outflow associated with the purchase of noncontrolling interest during the period."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r117"
     ]
    },
    "brns_PercentageOfFutureRoyaltiesForDirectSalesOfCoveredProductLicenseAgreement": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.barinthusbio.com/20231231",
     "localname": "PercentageOfFutureRoyaltiesForDirectSalesOfCoveredProductLicenseAgreement",
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of future royalties for direct sales of a covered product",
        "label": "Percentage of Future Royalties for Direct Sales of Covered Product , License Agreement",
        "documentation": "Percentage of future royalties for direct sales of a covered product under the In-License Agreements."
       }
      }
     },
     "auth_ref": []
    },
    "brns_PercentageOfNetPaymentsReceivedForAllowableSublicensesOfTechnologyDevelopedLicenseAgreement": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.barinthusbio.com/20231231",
     "localname": "PercentageOfNetPaymentsReceivedForAllowableSublicensesOfTechnologyDevelopedLicenseAgreement",
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net payments received for allowable sublicenses of technology developed",
        "label": "Percentage Of Net Payments Received For Allowable Sublicenses Of Technology Developed License Agreement",
        "documentation": "Percentage of net payments received for allowable sublicenses of technology developed under the In-License Agreements."
       }
      }
     },
     "auth_ref": []
    },
    "brns_PercentageOfRoyaltiesOnNetSales": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.barinthusbio.com/20231231",
     "localname": "PercentageOfRoyaltiesOnNetSales",
     "presentation": [
      "http://www.barinthusbio.com/role/OutlicensesandGrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of royalties on commercial sales",
        "label": "Percentage Of Royalties On Net Sales",
        "documentation": "The percentage of royalties on the net sales."
       }
      }
     },
     "auth_ref": []
    },
    "brns_PercentageOfSharesNecessaryToExercisePreemptiveRights": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.barinthusbio.com/20231231",
     "localname": "PercentageOfSharesNecessaryToExercisePreemptiveRights",
     "presentation": [
      "http://www.barinthusbio.com/role/OrdinarySharesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of ordinary shares present to exercise preemptive rights",
        "label": "Percentage Of Shares Necessary To Exercise Preemptive Rights",
        "documentation": "The minimum percentage of shares required to exercise preemptive rights."
       }
      }
     },
     "auth_ref": []
    },
    "brns_PeriodOfPreemptiveRightsToBeExercised": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.barinthusbio.com/20231231",
     "localname": "PeriodOfPreemptiveRightsToBeExercised",
     "presentation": [
      "http://www.barinthusbio.com/role/OrdinarySharesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum period to exercise preemptive rights",
        "label": "Period Of Preemptive Rights To Be Exercised",
        "documentation": "The period allowed to exercise preemptive rights."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://www.barinthusbio.com/role/ShareBasedCompensationWeightedaverageassumptionsDetails",
      "http://www.barinthusbio.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Axis]",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://www.barinthusbio.com/role/ShareBasedCompensationWeightedaverageassumptionsDetails",
      "http://www.barinthusbio.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Domain]",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.barinthusbio.com/role/PrepaidandothercurrentassetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.barinthusbio.com/role/PrepaidandothercurrentassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Total",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r762"
     ]
    },
    "brns_PrepaidExpenseAndOtherAssetsCurrentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.barinthusbio.com/20231231",
     "localname": "PrepaidExpenseAndOtherAssetsCurrentTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/Prepaidandothercurrentassets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid and other current assets",
        "label": "Prepaid Expense and Other Assets, Current [Text Block]",
        "documentation": "The entire disclosure on prepaid expense and other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/PrepaidandothercurrentassetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/PrepaidandothercurrentassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepayments and accrued income",
        "label": "Prepaid Expense, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r306",
      "r307",
      "r697"
     ]
    },
    "brns_ProceedsFromGrantsReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.barinthusbio.com/20231231",
     "localname": "ProceedsFromGrantsReceived",
     "crdr": "debit",
     "presentation": [
      "http://www.barinthusbio.com/role/OutlicensesandGrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from grants received",
        "label": "Proceeds From Grants Received",
        "documentation": "Proceeds From Grants Received"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.barinthusbio.com/role/OrdinarySharesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issue of ordinary shares, net of issuance costs",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issue of shares from the exercise of stock options",
        "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised",
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r21"
     ]
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Proceeds from sale of property and equipment",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r116"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.barinthusbio.com/role/OutlicensesandGrantsAdditionalInformationDetails",
      "http://www.barinthusbio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Axis]",
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r279",
      "r513",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r694",
      "r711",
      "r723",
      "r757",
      "r792",
      "r793",
      "r800",
      "r852"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.barinthusbio.com/role/OutlicensesandGrantsAdditionalInformationDetails",
      "http://www.barinthusbio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Domain]",
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r279",
      "r513",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r694",
      "r711",
      "r723",
      "r757",
      "r792",
      "r793",
      "r800",
      "r852"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.barinthusbio.com/role/NetLossIncomePerShareComputationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net (loss)/income",
        "verboseLabel": "Net (loss)/income",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r177",
      "r197",
      "r199",
      "r211",
      "r218",
      "r229",
      "r237",
      "r238",
      "r258",
      "r272",
      "r276",
      "r278",
      "r285",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r447",
      "r450",
      "r451",
      "r463",
      "r467",
      "r533",
      "r547",
      "r581",
      "r628",
      "r651",
      "r652",
      "r706",
      "r719",
      "r720",
      "r734",
      "r765",
      "r795"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Abstract]",
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.barinthusbio.com/role/PropertyandEquipmentNetComponentsDetails",
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPropertyandequipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset [Axis]",
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/PropertyandEquipmentNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment, Net",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r165",
      "r168",
      "r169"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/PropertyandEquipmentNetComponentsDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/PropertyandEquipmentNetComponentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, at cost",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r181",
      "r545"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.barinthusbio.com/role/PropertyandEquipmentNetComponentsDetails",
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPropertyandequipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Line Items]",
        "verboseLabel": "Property, Plant and Equipment [Line Items]",
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.barinthusbio.com/role/PropertyandEquipmentNetComponentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.barinthusbio.com/role/PropertyandEquipmentNetComponentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r534",
      "r545",
      "r722"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r165",
      "r168",
      "r543"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/PropertyandEquipmentNetTables",
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of property and equipment",
        "terseLabel": "Schedule of property and equipment, net",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.barinthusbio.com/role/PropertyandEquipmentNetComponentsDetails",
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPropertyandequipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset [Domain]",
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r126"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPropertyandequipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated Useful Life",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProvisionForDoubtfulAccounts",
     "crdr": "debit",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesAllowanceforcreditlossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected credit losses for financial assets",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r293"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r324",
      "r325",
      "r326",
      "r327",
      "r370",
      "r372",
      "r404",
      "r405",
      "r406",
      "r507",
      "r508",
      "r561",
      "r597",
      "r598",
      "r662",
      "r664",
      "r666",
      "r667",
      "r669",
      "r691",
      "r692",
      "r708",
      "r710",
      "r716",
      "r724",
      "r727",
      "r790",
      "r799",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Domain]",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r324",
      "r325",
      "r326",
      "r327",
      "r370",
      "r372",
      "r404",
      "r405",
      "r406",
      "r507",
      "r508",
      "r561",
      "r597",
      "r598",
      "r662",
      "r664",
      "r666",
      "r667",
      "r669",
      "r691",
      "r692",
      "r708",
      "r710",
      "r716",
      "r724",
      "r727",
      "r790",
      "r799",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849"
     ]
    },
    "us-gaap_RegulatoryIncomeTaxesPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RegulatoryIncomeTaxesPolicy",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income taxes",
        "label": "Regulatory Income Taxes, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, including investment tax credits, and the related regulatory treatment (for example, whether deferred income tax accounting - normalization - is allowed in rate making)."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r159"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical",
      "http://www.barinthusbio.com/role/RelatedPartyTransactionsDetails",
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesNoncontrollinginterestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party, Type [Domain]",
        "label": "Related Party, Type [Domain]",
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r371",
      "r498",
      "r499",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r624",
      "r626",
      "r661"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical",
      "http://www.barinthusbio.com/role/RelatedPartyTransactionsDetails",
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesNoncontrollinginterestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related parties",
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r221",
      "r222",
      "r498",
      "r499",
      "r500",
      "r501",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r624",
      "r626",
      "r661"
     ]
    },
    "us-gaap_RelatedPartyTransactionAmountsOfTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionAmountsOfTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.barinthusbio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amounts of related party transactions",
        "label": "Related Party Transaction, Amounts of Transaction",
        "documentation": "Amount of transactions with related party during the financial reporting period."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r498"
     ]
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://www.barinthusbio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Axis]",
        "label": "Related Party Transaction [Axis]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r498",
      "r499",
      "r841"
     ]
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://www.barinthusbio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Domain]",
        "label": "Related Party Transaction [Domain]",
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://www.barinthusbio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transactions",
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r632",
      "r633",
      "r636"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transactions [Abstract]",
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical",
      "http://www.barinthusbio.com/role/RelatedPartyTransactionsDetails",
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesNoncontrollinginterestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party, Type [Axis]",
        "label": "Related Party, Type [Axis]",
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r371",
      "r498",
      "r499",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r624",
      "r626",
      "r661",
      "r841"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/RelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Related Party Transactions",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r495",
      "r496",
      "r497",
      "r499",
      "r502",
      "r577",
      "r578",
      "r579",
      "r634",
      "r635",
      "r636",
      "r658",
      "r660"
     ]
    },
    "us-gaap_RepaymentsOfShortTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfShortTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repayment of debt",
        "label": "Repayments of Short-Term Debt",
        "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.barinthusbio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Domain]",
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r223",
      "r224",
      "r338",
      "r342",
      "r501",
      "r699",
      "r700"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r422",
      "r850"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationSharebasedcompensationexpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r421"
     ]
    },
    "brns_ResearchAndDevelopmentIncentiveIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.barinthusbio.com/20231231",
     "localname": "ResearchAndDevelopmentIncentiveIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesResearchandDevelopmentIncentivesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development incentives",
        "label": "Research And Development Incentive Income (Expense)",
        "documentation": "Represents the research and development incentives (expenses) for the period."
       }
      }
     },
     "auth_ref": []
    },
    "brns_ResearchAndDevelopmentIncentivesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.barinthusbio.com/20231231",
     "localname": "ResearchAndDevelopmentIncentivesPolicyTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development incentives",
        "label": "Research And Development, Incentives [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for Incentives received o to be received from Research and Development."
       }
      }
     },
     "auth_ref": []
    },
    "brns_ResearchAndDevelopmentIncentivesReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.barinthusbio.com/20231231",
     "localname": "ResearchAndDevelopmentIncentivesReceivable",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development incentives receivable",
        "label": "Research and Development Incentives Receivable",
        "documentation": "Amount of research and development incentives receivable."
       }
      }
     },
     "auth_ref": []
    },
    "brns_ResearchAndDevelopmentServicesPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.barinthusbio.com/20231231",
     "localname": "ResearchAndDevelopmentServicesPolicyPolicyTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development services",
        "label": "Research And Development Services, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for research and development services."
       }
      }
     },
     "auth_ref": []
    },
    "brns_ResearchGrantsAndContractsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.barinthusbio.com/20231231",
     "localname": "ResearchGrantsAndContractsMember",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research grants and contracts",
        "label": "Research Grants And Contracts [Member]",
        "documentation": "Information pertaining to research grants and contracts."
       }
      }
     },
     "auth_ref": []
    },
    "brns_RestrictedShareUnitsStockOptionsShareAppreciationRightsAndRestrictedSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.barinthusbio.com/20231231",
     "localname": "RestrictedShareUnitsStockOptionsShareAppreciationRightsAndRestrictedSharesMember",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted share units, options, share appreciation rights and restricted shares",
        "label": "Restricted Share Units, Stock Options, Share Appreciation Rights And Restricted Shares [Member]",
        "documentation": "Information pertaining to aggregate awards under a specific share-based compensation plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RSU's",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.barinthusbio.com/role/NatureofBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "negatedLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r132",
      "r540",
      "r565",
      "r566",
      "r575",
      "r608",
      "r722"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r226",
      "r227",
      "r228",
      "r230",
      "r236",
      "r238",
      "r286",
      "r287",
      "r413",
      "r414",
      "r415",
      "r433",
      "r434",
      "r454",
      "r456",
      "r457",
      "r459",
      "r461",
      "r562",
      "r564",
      "r582",
      "r858"
     ]
    },
    "us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer",
     "crdr": "credit",
     "presentation": [
      "http://www.barinthusbio.com/role/OutlicensesandGrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income recognized",
        "label": "Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer",
        "documentation": "Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606."
       }
      }
     },
     "auth_ref": [
      "r161",
      "r834"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from Contract with Customer [Abstract]",
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical",
      "http://www.barinthusbio.com/role/OutlicensesandGrantsAdditionalInformationDetails",
      "http://www.barinthusbio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total revenue",
        "verboseLabel": "Revenue recognized",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r259",
      "r260",
      "r271",
      "r274",
      "r275",
      "r279",
      "r280",
      "r282",
      "r366",
      "r367",
      "r513"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerMember",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesConcentrationsofcreditriskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue",
        "label": "Revenue from Contract with Customer Benchmark [Member]",
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r282",
      "r755"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerProductAndServiceExtensibleList",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from Contract with Customer, Product and Service [Extensible Enumeration]",
        "label": "Revenue from Contract with Customer, Product and Service [Extensible Enumeration]",
        "documentation": "Indicates product and service for revenue from satisfaction of performance obligation by transferring promised product and service to customer."
       }
      }
     },
     "auth_ref": [
      "r711"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/OutlicensesandGrants"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Out-licenses and Grants",
        "label": "Revenue from Contract with Customer [Text Block]",
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts."
       }
      }
     },
     "auth_ref": [
      "r173",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r369"
     ]
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue",
        "label": "Revenue [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r630",
      "r693",
      "r703"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ROU assets obtained in exchange for operating lease liabilities",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r490",
      "r721"
     ]
    },
    "brns_RoyaltyPaymentTermMaximum": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.barinthusbio.com/20231231",
     "localname": "RoyaltyPaymentTermMaximum",
     "presentation": [
      "http://www.barinthusbio.com/role/OutlicensesandGrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum royalty payment period",
        "label": "Royalty Payment, Term, Maximum",
        "documentation": "Royalty Payment, Term, Maximum"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.barinthusbio.com/role/OrdinarySharesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Domain]",
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://www.barinthusbio.com/role/OrdinarySharesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares, public offering price (in usd per share)",
        "label": "Sale of Stock, Price Per Share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://www.barinthusbio.com/role/OutlicensesandGrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r446"
     ]
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of share based compensation expense",
        "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]",
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of components of income tax benefit (expense)",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r141"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of significant components of deferred tax assets and liabilities",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r140"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/NetLossIncomePerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of computation of basic and diluted net (loss)/income per share",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation to the effective tax rate",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://www.barinthusbio.com/role/IntangibleassetsnetDetails",
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r55",
      "r514"
     ]
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfGoodwillTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/GoodwillTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of goodwill",
        "label": "Schedule of Goodwill [Table Text Block]",
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule."
       }
      }
     },
     "auth_ref": [
      "r709",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789"
     ]
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of (loss) income before income taxes",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions."
       }
      }
     },
     "auth_ref": [
      "r769"
     ]
    },
    "brns_ScheduleOfOrdinarySharesReservedForFutureIssuanceTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.barinthusbio.com/20231231",
     "localname": "ScheduleOfOrdinarySharesReservedForFutureIssuanceTableTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/OrdinarySharesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of ordinary shares reserved for future issuance",
        "label": "Schedule Of Ordinary Shares Reserved For Future Issuance [Table Text Block]",
        "documentation": "The tabular disclosure of ordinary shares reserved for future issuance."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.barinthusbio.com/role/PropertyandEquipmentNetComponentsDetails",
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPropertyandequipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Table]",
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://www.barinthusbio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r96",
      "r632",
      "r633",
      "r636"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://www.barinthusbio.com/role/ShareBasedCompensationSharebasedcompensationexpenseDetails",
      "http://www.barinthusbio.com/role/ShareBasedCompensationWeightedaverageassumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r374",
      "r376",
      "r379",
      "r380",
      "r381",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of stock option activity",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r20",
      "r69"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of weighted-average assumptions of fair value stock option issued to employees",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.barinthusbio.com/role/DeferredsharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock by Class [Table]",
        "label": "Schedule of Stock by Class [Table]",
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r62",
      "r63",
      "r64",
      "r65",
      "r66",
      "r67",
      "r130",
      "r131",
      "r132",
      "r187",
      "r188",
      "r189",
      "r256",
      "r340",
      "r341",
      "r342",
      "r344",
      "r347",
      "r352",
      "r354",
      "r571",
      "r572",
      "r573",
      "r574",
      "r710",
      "r752",
      "r767"
     ]
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of concentration of credit risk",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r45",
      "r46",
      "r47",
      "r92",
      "r148"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "us-gaap_SecurityDeposit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SecurityDeposit",
     "crdr": "debit",
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Refundable security deposit",
        "label": "Security Deposit",
        "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease."
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r743"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesAdditionalinformationDetails",
      "http://www.barinthusbio.com/role/IncomeTaxesComponentsofincometaxbenefitexpenseDetails",
      "http://www.barinthusbio.com/role/IncomeTaxesLossincomebeforeincometaxesDetails",
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesConcentrationsofcreditriskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Domain]",
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": [
      "r280",
      "r281",
      "r594",
      "r595",
      "r596",
      "r663",
      "r665",
      "r668",
      "r670",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r695",
      "r712",
      "r727",
      "r800",
      "r852"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment information",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r280",
      "r707"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r717"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationWeightedaverageassumptionsDetails",
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesSharebasedcompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected dividend yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r405"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationWeightedaverageassumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r404"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationWeightedaverageassumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r406"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://www.barinthusbio.com/role/ShareBasedCompensationSharebasedcompensationexpenseDetails",
      "http://www.barinthusbio.com/role/ShareBasedCompensationWeightedaverageassumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r374",
      "r376",
      "r379",
      "r380",
      "r381",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional number of shares available for issuance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "calculation": {
      "http://www.barinthusbio.com/role/OrdinarySharesOrdinarysharesforfutureissuanceDetails": {
       "parentTag": "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/OrdinarySharesOrdinarysharesforfutureissuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares available for future stock incentive plan awards",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationSummaryofstockoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Disclosures",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationSummaryofstockoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable at the end of the period (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r385"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationSummaryofstockoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Exercisable at the end of the period (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r385"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value of stock options exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r398"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationSummaryofstockoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeited/expired (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired."
       }
      }
     },
     "auth_ref": [
      "r808"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationSummaryofstockoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited/expired (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price of options that were either forfeited or expired."
       }
      }
     },
     "auth_ref": [
      "r808"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares available for issuance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "documentation": "Net number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r809"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationSummaryofstockoptionactivityDetails",
      "http://www.barinthusbio.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Granted (in shares)",
        "terseLabel": "Number of options granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r387"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average grant date fair value (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r397"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationSummaryofstockoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding, Aggregate Intrinsic Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "calculation": {
      "http://www.barinthusbio.com/role/OrdinarySharesOrdinarysharesforfutureissuanceDetails": {
       "parentTag": "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/OrdinarySharesOrdinarysharesforfutureissuanceDetails",
      "http://www.barinthusbio.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://www.barinthusbio.com/role/ShareBasedCompensationSummaryofstockoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of stock options",
        "verboseLabel": "Shares available for future grants (in shares)",
        "periodStartLabel": "Outstanding at the beginning of the period (in shares)",
        "periodEndLabel": "Outstanding at the end of the period (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r383",
      "r384"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationSummaryofstockoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Stock Options",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationSummaryofstockoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding at the beginning of the period (in usd per share)",
        "periodEndLabel": "Outstanding at the end of the period (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r383",
      "r384"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationSummaryofstockoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted- average Exercise Price Per Option",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://www.barinthusbio.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Domain]",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r379",
      "r380",
      "r381",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationSummaryofstockoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised (in usd per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r388"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationSummaryofstockoptionactivityDetails",
      "http://www.barinthusbio.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Granted (in usd per share)",
        "terseLabel": "Weighted average exercise price of options granted (in usd per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r387"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share based compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r373",
      "r382",
      "r401",
      "r402",
      "r403",
      "r404",
      "r407",
      "r416",
      "r417",
      "r418",
      "r419"
     ]
    },
    "brns_ShareBasedCompensationPercentageOfSharesAvailableForIssuanceAsPercentageOfIssuedAndOutstandingShares": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.barinthusbio.com/20231231",
     "localname": "ShareBasedCompensationPercentageOfSharesAvailableForIssuanceAsPercentageOfIssuedAndOutstandingShares",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://www.barinthusbio.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of issued and outstanding ordinary shares available for issuance",
        "label": "Share-Based Compensation, Percentage Of Shares Available For Issuance As A Percentage Of Issued And Outstanding Shares",
        "documentation": "Total number of shares available for issuance under the Plan as a percentage of the Company's issued and outstanding shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r718"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationWeightedaverageassumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term (years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r403"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationSummaryofstockoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable, Aggregate Intrinsic Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationSummaryofstockoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable, Weighted-average remaining contractual term (Years) (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationSummaryofstockoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding, Weighted-average remaining contractual term (Years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "brns_ShareholderTheUniversityOfOxfordMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.barinthusbio.com/20231231",
     "localname": "ShareholderTheUniversityOfOxfordMember",
     "presentation": [
      "http://www.barinthusbio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shareholder, The University of Oxford",
        "label": "Shareholder, The University Of Oxford [Member]",
        "documentation": "Represents the information pertaining to Shareholder, the University of Oxford."
       }
      }
     },
     "auth_ref": []
    },
    "brns_SharesCancelledDuringPeriodSharesDeferredShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.barinthusbio.com/20231231",
     "localname": "SharesCancelledDuringPeriodSharesDeferredShares",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Cancellation of deferred shares (in shares)",
        "label": "Shares Cancelled During Period, Shares, Deferred Shares",
        "documentation": "Shares Cancelled During Period, Shares, Deferred Shares"
       }
      }
     },
     "auth_ref": []
    },
    "brns_SharesCancelledDuringPeriodValueDeferredShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.barinthusbio.com/20231231",
     "localname": "SharesCancelledDuringPeriodValueDeferredShares",
     "crdr": "debit",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Cancellation of deferred shares",
        "label": "Shares Cancelled During Period, Value, Deferred Shares",
        "documentation": "Shares Cancelled During Period, Value, Deferred Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesIssued",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Shares, Issued",
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_ShortTermLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesRightofuseassetsleaseliabilitiesandotherinformationDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesRightofuseassetsleaseliabilitiesandotherinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term lease costs",
        "label": "Short-Term Lease, Cost",
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less."
       }
      }
     },
     "auth_ref": [
      "r488",
      "r721"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Significant Accounting Policies",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r216"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.barinthusbio.com/role/Cover",
      "http://www.barinthusbio.com/role/DeferredsharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Axis]",
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r187",
      "r188",
      "r189",
      "r218",
      "r242",
      "r246",
      "r248",
      "r250",
      "r256",
      "r257",
      "r285",
      "r329",
      "r331",
      "r332",
      "r333",
      "r336",
      "r337",
      "r340",
      "r341",
      "r344",
      "r347",
      "r354",
      "r467",
      "r571",
      "r572",
      "r573",
      "r574",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r607",
      "r629",
      "r653",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r752",
      "r767",
      "r775"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r30",
      "r175",
      "r201",
      "r202",
      "r203",
      "r226",
      "r227",
      "r228",
      "r230",
      "r236",
      "r238",
      "r255",
      "r286",
      "r287",
      "r355",
      "r413",
      "r414",
      "r415",
      "r433",
      "r434",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r461",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r494",
      "r562",
      "r563",
      "r564",
      "r582",
      "r653"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesAdditionalinformationDetails",
      "http://www.barinthusbio.com/role/IncomeTaxesComponentsofincometaxbenefitexpenseDetails",
      "http://www.barinthusbio.com/role/IncomeTaxesLossincomebeforeincometaxesDetails",
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesConcentrationsofcreditriskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Axis]",
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r280",
      "r281",
      "r594",
      "r595",
      "r596",
      "r663",
      "r665",
      "r668",
      "r670",
      "r678",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r695",
      "r712",
      "r727",
      "r800",
      "r852"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical",
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r226",
      "r227",
      "r228",
      "r255",
      "r513",
      "r570",
      "r593",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r607",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r626",
      "r630",
      "r631",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r653",
      "r728"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Cash Flows [Abstract]",
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position [Abstract]",
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Stockholders' Equity [Abstract]",
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical",
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r226",
      "r227",
      "r228",
      "r255",
      "r513",
      "r570",
      "r593",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r607",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r626",
      "r630",
      "r631",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r653",
      "r728"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesOther",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issue of ordinary shares, net of issuance costs (in shares)",
        "label": "Stock Issued During Period, Shares, Other",
        "documentation": "Number of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationSummaryofstockoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Exercised (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r101",
      "r102",
      "r132",
      "r388"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueOther",
     "crdr": "credit",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issue of ordinary shares, net of issuance costs",
        "label": "Stock Issued During Period, Value, Other",
        "documentation": "Value of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity attributable to Barinthus Biotherapeutics plc shareholders",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r105",
      "r106",
      "r122",
      "r609",
      "r625",
      "r654",
      "r655",
      "r722",
      "r735",
      "r768",
      "r778",
      "r836",
      "r858"
     ]
    },
    "brns_StockholdersEquityDeferredSharesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.barinthusbio.com/20231231",
     "localname": "StockholdersEquityDeferredSharesDisclosureTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/Deferredshares"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred shares",
        "label": "Stockholders Equity Deferred Shares Disclosure [Text Block]",
        "documentation": "The entire disclosure for Deferred Shares as disclosed by the entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r83",
      "r87",
      "r175",
      "r176",
      "r202",
      "r226",
      "r227",
      "r228",
      "r230",
      "r236",
      "r286",
      "r287",
      "r355",
      "r413",
      "r414",
      "r415",
      "r433",
      "r434",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r461",
      "r473",
      "r474",
      "r478",
      "r494",
      "r563",
      "r564",
      "r580",
      "r609",
      "r625",
      "r654",
      "r655",
      "r676",
      "r734",
      "r768",
      "r778",
      "r836",
      "r858"
     ]
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders\u2019 equity:",
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/OrdinaryShares"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary Shares",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r217",
      "r339",
      "r341",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r353",
      "r355",
      "r460",
      "r656",
      "r659",
      "r677"
     ]
    },
    "us-gaap_StockholdersEquityPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityPolicyTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares",
        "label": "Stockholders' Equity, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r657"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://www.barinthusbio.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event",
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r479",
      "r505"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.barinthusbio.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r479",
      "r505"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://www.barinthusbio.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Table]",
        "label": "Subsequent Event [Table]",
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued."
       }
      }
     },
     "auth_ref": [
      "r479",
      "r505"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.barinthusbio.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Axis]",
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r479",
      "r505"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.barinthusbio.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Domain]",
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r479",
      "r505"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events [Abstract]",
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r504",
      "r506"
     ]
    },
    "brns_SubsidiariesVOLTMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.barinthusbio.com/20231231",
     "localname": "SubsidiariesVOLTMember",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesNoncontrollinginterestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "VOLT",
        "label": "Subsidiaries, VOLT [Member]",
        "documentation": "Subsidiaries, VOLT"
       }
      }
     },
     "auth_ref": []
    },
    "brns_SubsidiaryCumulativeContributionsNoncontrollingOwner": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.barinthusbio.com/20231231",
     "localname": "SubsidiaryCumulativeContributionsNoncontrollingOwner",
     "crdr": "credit",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesNoncontrollinginterestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cumulative contributions from noncontrolling interest owner",
        "label": "Subsidiary, Cumulative Contributions, Noncontrolling Owner",
        "documentation": "Subsidiary, Cumulative Contributions, Noncontrolling Owner"
       }
      }
     },
     "auth_ref": []
    },
    "brns_SubsidiaryCumulativeContributionsParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.barinthusbio.com/20231231",
     "localname": "SubsidiaryCumulativeContributionsParent",
     "crdr": "credit",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesNoncontrollinginterestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cumulative contributions from controlling interest owner",
        "label": "Subsidiary, Cumulative Contributions, Parent",
        "documentation": "Subsidiary, Cumulative Contributions, Parent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "presentation": [
      "http://www.barinthusbio.com/role/OrdinarySharesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]",
        "documentation": "Different names of stock transactions and the different attributes of each transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.barinthusbio.com/role/OrdinarySharesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Axis]",
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockLineItems",
     "presentation": [
      "http://www.barinthusbio.com/role/OrdinarySharesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary Shares",
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SummaryOfValuationAllowanceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SummaryOfValuationAllowanceTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of changes in the valuation allowance for deferred tax assets",
        "label": "Summary of Valuation Allowance [Table Text Block]",
        "documentation": "Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental cash flow disclosures:",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development tax credit carryforwards",
        "label": "Tax Credit Carryforward, Amount",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesAdditionalinformationDetails",
      "http://www.barinthusbio.com/role/OutlicensesandGrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r446"
     ]
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "US",
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesComponentsofincometaxbenefitexpenseDetails",
      "http://www.barinthusbio.com/role/IncomeTaxesLossincomebeforeincometaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "United States",
        "label": "UNITED STATES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r49",
      "r50",
      "r162",
      "r163",
      "r166",
      "r167"
     ]
    },
    "brns_VOLTMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.barinthusbio.com/20231231",
     "localname": "VOLTMember",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesNoncontrollinginterestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "VOLT",
        "label": "VOLT [Member]",
        "documentation": "Represent of VOLT Member"
       }
      }
     },
     "auth_ref": []
    },
    "brns_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseResultingFromForeignCurrencyTranslation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.barinthusbio.com/20231231",
     "localname": "ValuationAllowanceDeferredTaxAssetIncreaseDecreaseResultingFromForeignCurrencyTranslation",
     "crdr": "credit",
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesChangesinthevaluationallowancefordeferredtaxassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign exchange translation",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease) Resulting From Foreign Currency Translation",
        "documentation": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease) Resulting From Foreign Currency Translation"
       }
      }
     },
     "auth_ref": []
    },
    "brns_ValuationAllowanceDeferredTaxAssetIncreaseResultingFromCurrentPeriodAdditions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.barinthusbio.com/20231231",
     "localname": "ValuationAllowanceDeferredTaxAssetIncreaseResultingFromCurrentPeriodAdditions",
     "crdr": "credit",
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesChangesinthevaluationallowancefordeferredtaxassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in valuation allowance arising from in-year additions",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase Resulting From Current Period Additions",
        "documentation": "Valuation Allowance, Deferred Tax Asset, Increase Resulting From Current Period Additions"
       }
      }
     },
     "auth_ref": []
    },
    "brns_ValuationAllowanceDeferredTaxAssetIncreaseResultingFromIncomeTaxProvision": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.barinthusbio.com/20231231",
     "localname": "ValuationAllowanceDeferredTaxAssetIncreaseResultingFromIncomeTaxProvision",
     "crdr": "credit",
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesChangesinthevaluationallowancefordeferredtaxassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increases recorded to income tax provision",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase Resulting From Income Tax Provision",
        "documentation": "Valuation Allowance, Deferred Tax Asset, Increase Resulting From Income Tax Provision"
       }
      }
     },
     "auth_ref": []
    },
    "brns_ValuationAllowanceRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.barinthusbio.com/20231231",
     "localname": "ValuationAllowanceRollForward",
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesChangesinthevaluationallowancefordeferredtaxassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation Allowance [Roll Forward]",
        "label": "Valuation Allowance [Roll Forward]",
        "documentation": "Valuation Allowance"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ValueAddedTaxReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValueAddedTaxReceivableCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/PrepaidandothercurrentassetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/PrepaidandothercurrentassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Value Added Tax receivable",
        "label": "Value Added Tax Receivable, Current",
        "documentation": "Carrying amount as of the balance sheet date of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r761"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "calculation": {
      "http://www.barinthusbio.com/role/NetLossIncomePerShareComputationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.barinthusbio.com/role/NetLossIncomePerShareComputationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average ordinary shares outstanding, diluted (in shares)",
        "totalLabel": "Weighted-average ordinary shares outstanding, diluted (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r241",
      "r250"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "calculation": {
      "http://www.barinthusbio.com/role/NetLossIncomePerShareComputationDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.barinthusbio.com/role/NetLossIncomePerShareComputationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average ordinary shares outstanding, basic (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r240",
      "r250"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "presentation": [
      "http://www.barinthusbio.com/role/NetLossIncomePerShareComputationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Denominator:",
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "940",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "16",
   "SubTopic": "10",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479405/805-10-25-16"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Subparagraph": "b",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479613/805-30-35-1"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(f)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c),(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "60",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.24)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-16"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-21"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "((a)(1),(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-4"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(CFRR 211.02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "05",
   "Paragraph": "4",
   "Subparagraph": "(a)-(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479515/805-10-05-4"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "30",
   "Section": "25",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479668/805-30-25-6"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-15"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-16"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-21"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4I"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205/tableOfContent"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.19)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//360/tableOfContent"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480091/360-10-S99-2"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "710",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//710/tableOfContent"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "712",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//712/tableOfContent"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//715/tableOfContent"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r137": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r138": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r139": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r140": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r141": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r142": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r143": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-38"
  },
  "r144": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//810/tableOfContent"
  },
  "r145": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r146": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r147": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r148": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21"
  },
  "r149": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(13)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r150": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r151": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r152": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r153": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r154": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r155": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r156": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r157": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r158": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "980",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481974/980-740-25-1"
  },
  "r159": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "980",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481974/980-740-25-2"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479428/808-10-45-3"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.M.Q4)",
   "SubTopic": "20",
   "Topic": "326",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483530/326-20-S99-1"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//606/tableOfContent"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(210.5-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//260/tableOfContent"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-22"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-23"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-28A"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479391/326-20-30-4A"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479391/326-20-30-5A"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479366/326-20-35-8A"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-5"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-17"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-21"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-3C"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-3D"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479175/326-30-30-1B"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "13A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479148/326-30-35-13A"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479148/326-30-35-7A"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-3A"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-3C"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-3D"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//350-20/tableOfContent"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-2"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//350-30/tableOfContent"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//460/tableOfContent"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-15"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-9"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480454/718-10-45-1"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-4"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-4"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482736/825-10-45-5A"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//830/tableOfContent"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481839/830-10-45-17"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482014/830-20-35-1"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481956/830-20-45-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481926/830-20-50-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479424/830-30-S99-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//850/tableOfContent"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481435/852-10-45-14"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//855/tableOfContent"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482312/912-310-45-11"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-4"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-6"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-3"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-13"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-14"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-15"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-16"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481926/830-20-50-3"
  },
  "r754": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "SubTopic": "740",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480887/718-740-35-2"
  },
  "r755": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r756": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r757": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4H",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H"
  },
  "r758": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r759": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r760": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r761": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r762": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r763": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r764": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r765": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r766": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r767": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r768": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r769": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r770": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r771": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r772": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r773": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r774": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r775": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55"
  },
  "r776": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r777": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18"
  },
  "r778": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r779": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r780": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r781": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r782": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r783": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r784": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r785": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r786": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r787": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r788": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1A"
  },
  "r789": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2"
  },
  "r790": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r791": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r792": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r793": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r794": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r795": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r796": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r797": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r798": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r799": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r800": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r801": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r802": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r803": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r804": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r805": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r806": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r807": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r808": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r809": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r810": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r811": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r812": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r813": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r814": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r815": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r816": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r817": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r818": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r819": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r820": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r821": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r822": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r823": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r824": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r825": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r826": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r827": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r828": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r829": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r830": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r831": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6"
  },
  "r832": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481956/830-20-45-1"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481926/830-20-50-1"
  },
  "r839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>123
<FILENAME>0001828185-24-000011-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001828185-24-000011-xbrl.zip
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M=+?>-V&/]]O[K?V=G]X61EWB(9I??@P2SPW_*=SX(WR2F,?L;+W'UW^J!US
MY=(O/F)WZ_W'?W[[ WHPND]/"-WAEL/\Z^<MX'F'@^!>^/6!&R)/4D_;VWI/
M'WS[ WE?KMW[4]C/-!@$'O%+N+,O8O.<?=R?>I/_M]3#D/[Y:>J,'5Z*6Q%E
MXF,LQTB]L>NE?X!8.\J25,((%['T,R_M1?Z5B&\#3YS< TTG03\4GX(DU5-J
M';2WWC]TC/_R">Z-$O%9X)LL-^?N<\VY\UUS?EL\>+$8B!C4!Y&4\ N41X<)
M\4MX*X?DTV$*7.+GK2083T)DGO39*,:7+K"&QGWB ^.@Y^4/4<],9!;3;R0
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M(,J<3Q:^G;%N]H'7@I9UYB:^^Z?S2RC[;NA@ZI1('_3)/D=(>,V(NO,H_G(
M%FP,:X%,)2&F4G,B.88/0N<66XXZ?_M+:[?SCC3)9GO'F6 U#%XXQWR>C?L\
MTV5+.0T+3O9N8T<331"A:_*P3A^M)G?$K/N+/[NX*KBL#P@K9^Q.G3Y8]MB+
M/O+ N.I/G;+++X4G@DF:-)P35"L6C@CJQ03&Q91S!RWI[=8;+(ZP:+FQT#(K
M3/Q@=C,/5K:55=G+-JX !FH&F&7&$K'F]+,45CJ<8@08F$VD#.*[(!V1,1R"
MMH=J,6B$#] !W+&(IR_>L%?@-!@6G ;.&=#LXST'*R#&T\C'@(O <^J-A'<#
M)SB^<0)^!RLY($@<UT$?<OTFDG<P3>$F\'(^?)%DZ-MR$\<7@R#BW('+#*S(
M;G-'KX:UB+ P#>>?\,.2Q^#[T[ H"6]EA^\;,E+^@/7^#9?[2JWV*2VVR0AN
MXOF==_NM8EWO7PV91\ 18_%G%N QA]--*54Q9> EY<>^@S%=SCC+#_^&QA]'
MX[_+,(M0=&#V69P8VFYM:/N[:/MN)"@9H4C@AZ1!C8!9(UG[CAN&AK9MHN\+
M=0$,^@"=6VQ=FWU(^_@U9E8Z/GP+N@)>BHV$!3G46FV'TKX39QO&0^4CR4 '
M3$824\T<KN*&>]QT]G3>N<G\T:2;U3N\J5$^SW:;W[$/9B9\W_\7O %>3Y?"
M33@+-0ZAZ+,&A)-TD]0Y:#J^.P75=%E25GGOG*V+[H743;.<HMM;[_\Y[\]9
M,4FO@D6<R17SQ?4_QT3>0-GC(,6PL B!PF,9H3\#5'=Q*T 5/T6=&5%J;H5S
M[*:N\Y$E6>&4YV/8HLU6WR[%,..2>>>J?NULHZ]@[UV[TVX8_2Z@1-$))HH^
M]Y'G^9J3+)(WRY]3:V%P7=2Q->>TLSFGFW/Z5.>4[*80IBT<U_/@G,:("$6D
MBT935/HIZ*!1O?2+9 P'')X2:QD#U#Z&-9C64#;#<"#0<(F&SC"6=V"RJZ\;
M(*H%S8V,-*HJH6P,S%9HPVLNF"%]W7JG+_OJ!8OGIR]$^:PN7C!7?:4V(UOM
M?KVM-0Y;S7B4)Z'57I^H?&NWT=IK/TD O-W8:>\]20!\,ZG-I,RD.@^/]-29
M$"^0G5P>=?E4S@^_KYKN"=[Q:6H1Y<K?XRGWJK?9I378I6\I1HR/8%.'LBQ1
MEN'E:+L]=5$>4L:.LV=E*M335L=6AE+N5_X>3TDI5XMT2&?EK_G2I>!\%&A!
M/F0)#)0D7X4)V7ERG)"*T<=)N=FP\G=<#7'HU?B%%N.(U^*K1++[-2)9)G%B
M17;XX %[%W/M'QGR04\:^<] 2&#L)Y5.EK"M# O/:"NI@6+0OBKT8>&SPBD^
MG*+CR*$B>#6)K.LV2$CH1&[D!6Z(JB26=N#%"!#ON[&?.%B;&OB+HLF=;?=-
MJ=F[&J_,TH1YGP-8,/;,5P$LL!_S8@2+2A+ATDY;%7=1T@T3):@*.4T%T 5M
M/-  EM[#U%QN 6PJ2MPD 0F 'VFZ$(.!($=FI*IK\,X 61DF=^$>Q3)T)+ U
MBQ9SP4HHD(;BNLVN5?5PY<9]%X:MG]^'8DIAG>W6CO.E<84P='OM72R1>(,O
MGK^E2HWHAT @%L4/@GC,WMT)/-O%B^"04.: 3S-V,S](U;PJ3]ZGWB#NX81E
MW,NW[6/H#K].X/MK1^ #)\F#?)R1M53ES$).;)^1G#83W3<TT6/8SE2JG^(,
M$[Y-A?(&(47XX"-/QK$PE=<H(.(8@WL22>\VD%F"J4U,>65/K3SU:72@CT%T
ME8[3$WR](_/2CZ/"@[6CPH=)""4O48L$P<T;GM.!IEJ+LH@5F:@2\F)/4L@,
M6&XX38)$5>VCD7DKZGT793E*>Q$ES*,QL@5?47S</-VF5<.S9XL<X\0.D<6@
M>=PB:9LI*/W"/EHJXM9M-EK-XWH+SM>*J/35!6:2D0A#8UYNE^2P%8(/P,[>
M_*AY/:L*!BYM+..6/F &%3@A=HM?; =5D<A[1BZ&F*O25UX!S%AY@ F-94(L
M!A@:B#^R6P3:.R#:9>1K>,D_,P)[JM$H[G ( ^%Q&E/:KJH46/P,^6TE!C4C
MS&&K'LXJKCFPM\1R*3XZ0/$/$TPH2<"=@#5U'\!N"WC%_Z7(YF/,;7I TPV8
M:++$WYJAHNX6''L/;@V3G[?J._,T=4$:[<=0NC,@?%$VKON2@-7Q]BT'UQ%N
MW34$UMIZOW?0Z&H:T_-Y[P!IA/##8[.A5T-MF,/-Q>NX,XG*[<Y2,F%5%OA3
MDX-+%/[9C;T17M1\U^H2WF?7E,K/;RH_8W9?=^Q]/3W[6)*Q)<=C1)*2W@V3
MV'G^;H_;Z:;9Z?;6^\Y^[:#=JK5;[?G]YBFN6_+[\?G1E\\G9]=7SNG9T?GE
MQ?EE#]'?/_S3N3SY>')Y<G9T4GRCI?78) ?U$CXVTQJ :0&JUS7<]R&$C3$+
MW-ER!*SZ!&NST)=5N=-R@5:URJM8<"IT]L4M9D?)^VEN>12R+DVUA95@B6X"
MXP:R(!^YH0D," ,L>"J>'H>QIIW/0NCZ#:OC,BO)@;45R&9CO1GH4I#.*<PT
M<1!^J-6"/^T:IH3BM%I=' [;G#FGIZ<F)TP]\=)X.CXBBT<8]YEC,"N UQY>
MH?K-)>R.+R1FL2F()J6Y'C#Y%.C9S?P6MY_(,$OG;^$3^/ZG?ORVM%/(LKUK
M]DSOFI%9M(D[!.LL%NX-: / (P_=\,Z=)OCVFP8WFP8WS]3@9D&2V?.+[+F%
M*)?97X&K?5S*7&7>IM@7X/S,H68BW MDS5X%9DYXU!]/KX[@E?YYTKMT3LZ.
M09\Z/CDZ^?SAY-+IM#2V_9J]VW7OPZ<31-0^.C^[1H7QM>5F'C0.=I^F%<K>
M?F.ONQSVTL*A&@<'SY61]R!(PG/+S#DB6Z',7'(NCQ<W"/QRT0.N=EHB;9X>
M6:%<XVSM/*!RO@0ZP_H1YP^AT"%J"!I\3JOQ3=3Y#7!"FWU[HGW3N6(OM7%Z
M".L6 B5_=EVD;!47[-LS/G%NWR*Y]);M+]BK#8NL[E'#BEYFD;T-CUS]7);;
MN,L@N7$^NEXJXPV?7 \^B=NVT]TPRHK,98F-V]&,\L.&4:Y^+LMMW)<(N\^'
MF.QTE;J# <6>%KA(-URS@EP3,=Q;K0W;K,A<'K]SNSM[FF\>;?CFZN>RY,X=
M3?LB5LG3TPVS7 MF21O7POR=#;>LQ%R6D'/[BEFN;?@9WZ"]UK/?2*G5SV6Y
M';M8:WJ+Y01I1&QLD?40K[AG&^FZCJ<-$]E)NG8V/'[U<UENWSZ)H1LZ%['T
M!,$Q;KCE>G!+W+L-MUS+4]=5W+*[X9:KG\MR^_89;G&NW(%(I\YQD'BA3+)X
MHV&N"\_L/H)G;E+@-OF9CZ&E/9V?N4G07"OJ_"%D5;>I=(R=C8ZQ^KDLMV_<
M"8M Q$H:AW-5LG/R9Q:DTQI<$5)!)I4I<[FF\QD!HV(N"N6F0,Y%%GLC-Q%4
M?LKW6N6C&_5E+=07)(Y6J[,Q^2HRER5VKJ/8\>Z&':]^+LOMV_][*6 "M\+_
M_S9L<CW89 ?9Y.Z&359D+DOLW*YBDWL;-KGZN2RW;Y_G$4G1098Q#@FJHCT+
M/^^C05<\DI'/X+EX#?#:+&1XQ_.)X"EMU-,UX;N[&[Z[GN=W7]<J[6UJE2HP
ME^4V[O\@$FB0,LP3\E#X(-2_6S$*I]>76:KZ;#M8X;3AJVO!5W&36^U-#6A5
MYK+$SNG2IOT-6UW]7);;MUQ#O<JQH9&]7F6324B_(X E]@C=\-'UX*-8Z]0^
MV/#1BLQEB9W3V?L'&SZZ^KDLMV]'A$F*?4>(>X)"Z@YCH?CIVN:7XYO=K?7L
M$42VQUU87&JH$>E?$0 6MRJ7@+D5L1%UZR'J,)6^T]R(NHK,Y?$[=Z!3Z0\V
MKI@*S&6YC4-\V!BVAM@GI=3[F^S0M6&:N(,;IKF69T]GU!]L(&0J,)?E-NZ<
M&C"=1MQ0 T;:L,OU8)>83-_9%"!592Y+[)Q&CCG8(,=48"[+;5QNBV-VL!M3
MIZ6/,H9'1<X_LCA(_$"U-J1.AA>QN,4.,J=1,E$]#S<,=CT8[-XC&.RF'F13
MK?08%.%FTY0K;>J5UHH^?PC)UFKJ#/E6<Z.3K'XN2^[<<8#]E&6<U)P3T]+X
M7+<T1F_8D>X=Y_R"K8PQLK ))JR''D([W.ILZHZJ,I=EMDYGU+<VG3HJ,)<E
M=R[GI4=6?_D-VUP3MKF[89OK>OA,?Z/VAFVN?BY+[IPJ;)\ZYW<1Z)^C8(+U
M1$>P]&X0.1]$)$ QQ;P6_I[TT[Q\2=4A+2RKW[#?-6&_!QOVNZ:'N&5Z)VT
M)2LPER5W3C-:XJ$8;P &G!2XZG4,TW0Y&%%3::'L0'!.X:F@Z?IBXQ]8&TZ+
MF[[AM.MY7DWSI0T8907FLN3.7<1!Y 43T&2MU.V/0JA")1'?!MXF_7!MV.C.
M(]CH)IZVB?<^BICV=;SW]TVX=YW(\\>07FU=YM#: %168"Y+[MS)_2CH!RG8
M;B55TLZ5-Q)^%FX4CW51/-I4^+#IG5N5N2RS=;KRH;5!EJS 7);<N8\RQH2G
M^F_.538>N_&F$>2Z<$RJ?=A;;U-M=\/#J\$)]K;>7YW^<M:[_G)Y<K5A 6O"
M B@[_T%4KK>IVP^%_MQ:<S6/+G"$=Q.9$/SE84SADEOQ[B[PTQ&\!2V+=1?O
MWF$SO\7M)S+,TL6W6)OK@6HNXA7M;GMFB:R_1W%.S$-1[\?"O:F[ YCKH1O>
MN=,$^9?U2N,@JMOK-_OJ&Y[T!#P):/L::1?S)M86Y62/"_(1:*;DE,Z>2>NH
M_"M+TF P??FSTFH#$?^A)VH_O.]Z-\-8PC+4U3P&]+]W+S4KX91-ZZ6>+N\B
M)QT))Z9^&"(6OI/&KB] 9[YQ/O0N3\^N?_URA1A#>-67*, H\V\@&7TYY@#S
M7?D+K'Q=1^ZM< 9!"/-U)Y,0A#77[KDIO\IOSBF0<!@*+\VX3R,VM9VJY/J5
M;@HNJZ3B[<">XL3TW:WFBJ?2D%%.1 FU6S&4M,IEK3E79[V+^O6I^N'HM)++
M2*?*=7R18.%I*(=RE8OF#$/9=\-P6LFU:JQT:2JY)'\(QPT3Z2!GOW7C0&:)
MQ=)CU?=(\<*HR!R9HV=1F32 +X/("S,JBUXH,G[O'1V=7I\<_<I#66R M7"\
M5]+MJ?!&$:S)$/F9Z_V9!3B2FS@3-TY1/9)9S)^S3HX?]6X#7[C.M75K#=BX
MUT !=2P\,>X#[VDWVZU'S#5QKB][%\?,#'[O_1>']O\);.K\TS^O3X]625JE
M=+URTG)Z8:@$$ZVB$[ECW %K27$-$TZ/</@3W$FZQ9-C>!G:[<E$ &7"WI!>
M$21.+XI0PEV*B<3-CYS<@;>]5?ARZXWCQH(V=:)%-CP"?@]BV&8NQ0?)SZG%
M2<.YDJ$(IR2%/!G="IA!Y(D:TV!QXM9++9C9V)TZ?22G@8B)F*1S%Z0CA/_&
M\?[VE]9>]QV-];>_['?WV^^<9#KNRQ 6J0_7))DWXIMQ#HF3P)VA[T0RQ5%A
M>G T,SX%;C2%.?AX,F'F!#@P]XZ2LZSO M@6',--8.G3FCYA@PQ4AR1U0/_&
MZ!%I^OJXHPD2NG<U/2CN,N(:P,Q2V7" B?B2QD0-)*(7S1)X8NSX03()81EF
M-E7UIGAH26&,8#R!O7 5,^ ,1EK!&@X-#Y)QPK$N^#69P 72I)D#'^M/:[0P
M,\]N.$43Y#'&Q_N?^O';]\O?5YG#^#&68R>%$6F[X=\:JN)(H+11P#SO1!]8
M)WR.O_R7LXTX0&#K39V;"(4#$-DU+#UP13A2G.6$RO'_\P&/9CK*DGX@:0_Q
M]D]!="/\T\B^,J3/@J@!&_&6-V/ZMJ_OKN/M,#4?Y4T U(^3@X=A2#/(,8D:
MSCD,/S#1SESW+;O:@1,)BPYR!,_T1"8I'T(29!X<J20@XYK-E5,X[@D6SP)+
M\K0,*:R,>^L&(1T&>)^[N[M&WWIY?*^&-0CR'3BW,( [Y,?&XC: W7S,L^"
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M7 %7ELR5=&6Q^8A"]\I_P:A(1MU1\K4P$PXU":!V#YA^Z.G:'H%!:(P#3^
MZCKWNY&$LUA') V?*@0#/Z 5)S&7)=;^XBFTL#OZ H.4SAD(%4*=V:LA\$P'
MI[,=O/G*E)*1&0UO^!VD3X#1-?RR!O<_.,#VE]_>.)]4Y<S"D>RK:,@'QSR#
M31XY/5 &0; I3)WMK<+USAGFMR]\7LD(^-C;AYYZ!;STWV ^DQTS[O^Z>/39
M*V'HAT=N7#8^-1:/=PHF6.#JRW#4[=L'%^@"#ME7U[R'AA8-;%T.E(-.(Z6
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M9U%)=U&]?(1..J=XX1FL=^CN6\Q'1YKGDXAU#RR9KS^O3HW>>M]PKLF58BB
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MRS!B#4BH)M[8,W28CHRA-6>XZBI58JPDFXS&F7$RO4.<QZ@UNJ0:E6N,O8[
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MNDOU'WXVF104.C"M&QHEDE]W'C&:'.=>LCJ#4?,0=";V8]:TYT&Y-57$)O=
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M5^4=@E9]0T]")ZRQV3"XQ%Y=U2_:&8:RCZA;*/N#?J9?6"<KX-D*J(V-1N/
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M;'85?+-R0O7NOHLH);&YWD'!BPGAQ9G^HP+'":9.!(+B"(-.F<><E:/+"D?
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M COXUX&%$@G?/&Q;NUL[VB3X:\:=N@:6,*ZU:X\*^15<I]Q5L'->[!FQY\;
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M+1&/KM(*18O?N?7D_/@EV#+71?E9"AZ+@/S+6REAK@+8LA+M.ZQ<#Y18CRW
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M)X>L[&Y4[[!LU^ZLZ %'^1<7/;1=\26%#SC:6RA\L)];,*#5%C_\;7\O7/=
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M(LJ:%T[H$S_E:O,V+,:XFR-1IAUU2R*\FE.;S#,Z,-JRC.%I[E:E%E+79>,
M\/%M$P$;.53C)/!.^Q<0@+,I=I[8__N!S2O5W*+%A6W8<0Q,R$]$4<S6MB#1
M 3/SP%EO6;'D&M-E<DG:H?W,;5MZ1FC2-,>9R"[)"N-&KBD+*0)3J5DEE=9P
MY$63L@$)?L2,01UD[5??+<NNEK;,?[U>5DLD;(' AQ)R&V!.R%!/V(5A6@Z;
M656CX%-XF94W?6>4L!/&VK9,!-@21[Q("6J"'!=$1]>1=CX4(#=@>\Y!>TZ+
M)L.\152#XY1S178R1\>-<QSP9GS@"Z5W)6"$MD<R'6%,&#QOR' FZM=*<G1)
M,<\2X7^%D9 .H!6FG#=V"Z!"_TE2P&K-I]P& !]K,Z^C9 @?P?,M^728,#7K
M(C@7 BAW==%3PH#9HF[> 5:_:XN$LUW]4M&#\PI O(([X0D5*)EKVE#Y+8UL
MT((@()@F8=>V9%F)^1NQ]5KCL2PS[! X_ 7R)NBVX:=YW2@33Y@2>-"DD$0C
M9B$Z7W<68 1^O$'F82(#T^>8[YH8RK-* A3%)*<L:%Z (BC*'9C(.$639!+G
MDMCG>,49;^<Y/!C^=8Q[2<K;/1W3))N;(]*2 )I)6E5-LAO]5ES#?I2#5HJ/
M$T=B9[0 .207\ I:S/E<SC7^'V,R4/E;A !\ C8$VV^4Q@O@>'I5[S@?<RXA
M6O@*838= = P2$S'+KP0E,S4SAW# O,&(*+:HP.A&!5FLE%R^CXT2V(!C-"?
M8.NLL"JC J$9%O0U[)].S@I^<G_O)SQ-0W+%\DAP=56M,@5S"_A8:' I19XW
M1_P#MHK*4LHUFV8<?9.7&SPM<>6Q"CUQJ*=1#[O:%^[0)*.+'O,=\Y3!,*+-
M1CG*#G[5UQ\NC/$17YOK>FL4O;&6)JK%&O4UWD:,CFB<7D-]1!&]_I:$!#'#
M[)4H2=#.\)EI-)#LQSP7I6/JG\.C?UCI3-J6]R[+E-8B^;09,+%RL9PF8^OC
M[]NP' RZLK$W#58I/4@+(DZ:;ZM%F; ], Z+!O+6?&\K0N;&BIW<W=R10S9K
MEKA0R&=B:W=<5>)*GA2B8[7W<%@VA!YQ@K%>T+IDTI+D"_4#RA8$325R;/+S
MB7O![7BDP3$7#$XA.?O^1U9/$78838N?!W7$.I0+>^%J"IT<1H\J&+%A3R W
MK(&;9HI:JQWL7;%4&O4ED$K!;UFA(&\2S)76!9VB^!:#CU^VP1BHN+]A>ZN.
MWP/Y<ZZ;+46\R$^FQZ/W7[@# O]\8-J.7=%%;BYPMW2#@-)S9/C"I+_#@Z3O
MYL(#LC <8(T]E)L,O<G0_[S)T-^#L6PR] \Q0W]^_.%\YZ3X=*!(X)2=)-92
MF.C-.=:)ZNGD_:?35]'^+YR'6J'YF8C-O65L%BD67/-2HA]4BK%YIU&JPV+'
M\NQ82I6^=*$IDOIG B9TZ9 L<M H3R9%G<8F)(-!*K 3<)1SN/!F\9#L/ *)
ME34\X6$9V"W6M15[U@HF:K# "(G%];TQ.&2Z+S$H[=#TZZ7(%^# 7HSLV:Z\
M#[%26]\9X!$@^\2B=0M++496MS*U,>O.Q]W?=T/5E^Y%SF&!F=Y]'!VH<21.
M_C=N34LX>EA*O0FVNX\6FMFUTLS&T['.1%BECNWXD+C'*4WR 2DK:LGLD,&9
M[!MT<,B!TW:5E!86LF3 G+N@>C6GV-,:+':'2+]@D8/89EZJ$9\R*T;84=NX
M-C""8CPP!0G)E[3B"!-E]^!)!.0.(\M72#Q)%Y8Z@6/CPUUEO ;3OJ#R&3<T
MP*!FU#\8$/N28CP8Q.[@*:'G%=[LK8$!JM,T#09YH&@FD\'J\?F#=4$WWF7=
MW';VWYYS9]NQ5BBMAEE1V6SR$C%8ANU=K7WT"C*$652*N!;N5[N6W2FMP^-R
M<T]G\WA82QVZ;97M1TB.J[J,_Y. *,8/[^9CJ$^UA&#0Y#S]%"WQYYFN-GU(
M)V=M^@%/SH?X<-C0%L>=YJ[:2<V>+'TX/UJ*9:AZTEZ":Q\X/$RL$22;1Q/'
MHU#*&/BP+QN'R<W(#:$UE9J8=4#__[)Q3R]]N^H5A$_ABAR-<&$8FZ[D83$7
M7*'[+OS;%4K,0HI%A@W,:&$RU3+#EFF!=6/KCPK%BB)BE-)61$*I<[3902IP
M9\WICU'3>C@Q 2,8#>M*!L4D(^&"P3QE/$(S%S=,I(5"I#"80@M?G=+Z];:Q
M0QK[MH!+5]-(6#,7YV0N%T1VS%W##0QC^;.1F1*D"K/_8"F2_6]CH>891G#P
M=1@8Y2J5V5Q8"B0%$@JW>\OJ "]0V[N?;QTJ#;G;DB3,VOD]12HQ,K<E$B.#
M=5:V[^7ZH%*3/ HFUGVB9VSS/)EQ2PR?[F'2B[I!H^HA\CY?K#[DJ!.K]OY0
MI#P)(Z;[[2%CX'3+0 ,=6^$;QNQ%5)L0;+B9W99;T[&K*@G3I5A77:97%&NK
M=KW9Q'E>-/G09+%)?+2Z;Y_;#4G?>1V^(995(S2V+!U8PV93K0W8.Z59@M("
M C2L2-.@K,$O>ZA%\KHDXO13J25$;?;:?.ECA9GZRA)2X*C^A==A]!MG#-\[
M*6RUVTSJ45!PR"USS36*HK+37'!.^T^?VE' A\NBF;"%"UMQ_/]';^)ABCF&
M!^ALMX/7Z[C<QOK_V\&N;?U#C58R*OW<(WE!VG$*PHL\NJV^J+P3U(9G;<B-
M2SN,TEYG;#7+^S#8H<]3![-5,LF%WPY''F4$C!O3KD3_%'_Y,[F":\_GU0";
MNW2]E5 UL=2>=N;POCWK-=Y.5X[GE.WO/OWI*ZWW^R!9G">%E: KS^2A4TM1
M0BD]O$:"^^P5@A>EO=WH=%MV'D(6Z($/*E>[QEPX:KUN6!$!&\#TBI%JA6L'
MC,RR0'^6@9,]@SFA0H1]GYL;1%N*N^*J5%+>UU/0A8YP$#YF4L##QC%8" ,?
M&"97->GV'=#M9GSH7X)EL^U 98JE2ZO@L-#2>H>2UMD>H$"MLX.2;JW7(\9=
M7$QM&3JYU'@+]YQ<$CJZ)F%OB1^17#&W9'G <""^/Q8[EXL=^5&10(&29J)#
MTM 0%7W9Q+L)A[@ 4X=TJ\-(@T,3$!"]5_!-?LFT(P?J;6)@6@T0)P;C/LHB
MBK!(K55,S90[#@I7X;=+'OC(0A9<+=3;6XDQ'7%^GL).ODR)WG]8@9LW?("6
MQ%I%6#->D%;THA6GT!7IQ";"2Q5MZ3>XS"&).@]0OQ\5NL5>LT-FB@*'L0S%
M?]D6BBCBT? LPG/HG)DA5W)0$=*?56V,I=_>2;YLT7!K=7Y04V>30C<I].>;
M%/H]&,LFA?X04^C*@<.E-K8JB/GUC(JR45DO+-?5K)H=M4Q( 25)R/"F=#^D
M6'6OR5O@!0/OUQ<&X6XJV$ZF:1Z[H:R+.+V.P<W_#8,POQ>"EGX;#^-B&PMX
M,] "Z/)=3$%EPY_@=XLXAPT;P'4R0K<1__I'7, :?4J3.H]GMB[I; J>_GS.
MW+/7Q/^%$[/(>[["_+Y'9M14+NA6WB65"5Q3_/X'*D9=NN=$0</A;8HFF4RL
MPT>#%11LIN^,X8M]%4)2%I=RKID++B[CX>=)"2;G:'ER>@LVTGSR].P#[)\M
M491:-PG0L<A+Z-,9I4E4.;4==3'AW+!@.$P]G^/::OZ/T[<[Y 3 GZF0-29<
M@KR?^A<J[>%8\ J=+O<>C\\;^M0B;)YXBX_.)X:D$Z?O8Q+<"XR=.#1=DDZH
M/ IA]E$[ZD&!&:8:K+O12[>6' CGC;VU7N[K6]F4-05NI8CY\B(4L6'Z"VI]
M 6<I+(%8HU7;# L2>6K)A*G:% G@"#SWL.1=4[P(-]&*S9)CC0S.YSKUBJ2Z
M6GWK"9YREGA9"$HYUPX7*E75NQ533#M-K<U:%GZ;>&WI^=B-SMDC;!O#AKD/
MXQ=^"?&6YM"ULB5TI+:E;,:XRAS76!@ZZ!Z\ P:"JJ2F:U(F8#1)1YAWS6JV
MB]K\Q>+M,M2E>68J%KMWG;1'HU;/3E!GV0/E63WWT&[T$K; )&SPP2P-'DB?
MI=J^)<-PD7!Q)PA3*$H^)[/X2SJC,70X/DW:L)Y::G#T:ESY>,3!I%==G@$I
M]V_I0-]1IF0M^-)S!D=)@BUL?;&BLWQIG),DGP?NQ,1E?FN+)+V47XFHF::J
M&./D[0X3Z\(&8\$GV(O8JM82, <(BI$2L213C&%IE<?2*]F7TEX2F?![8I6^
M'#44K:D*<7>QBK)-=:*?45+AEK@%'X.A-VHZXZA.AVS^,LF0M%'^C,$!.W>>
M.K-,F+DO)/8JZ=%14G.+8,RJ%V&UP0O#P[)/;S$)R"@%R&45.!61!F8UENM=
M\XDVPN'>]Y9/=F $:RK\"/:^$HVYX^A:HUK;];-2D(BF@,1Y&"U9)5+C9$@
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MF<Z!>]KWM.8M_%-7GD"U86RKJ4&6J;0J<[<G7<D;5QB*A9][/F&>QLW.J$8
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M,\#Z[6(AV ,Q?[5%=T>6F&80Q-)-,O%3Q^#%NL 1XVH)MT6E#!K4)[.:]KS
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M&'(L99%#EM.3P6_;:EZHSE!TM)MV/&QYO#&MYL%A=/+Z[#1Z(]11CSN4M7^
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MXRT.O-'=T3M9&1+-<PXZDMG1Z816B-5"DE../PZK?CW:_U&YPW3SDPE:KB+
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MYOX!04&M^T5Y+?8F??T:!0G0W0O7Q'6Q7"]4@3D=0;=QRW6\L^!ZAT'4CLH
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M,)<KG_A\!:!2Y[GO\%HDPWQ$$S(;'>SM/Q07\<5O9(#JA<8KG T[MOEX+^O
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M-T@1J#P!/),R.F_A%5N)BO7E> 9$N[WA1I&ZXS#PL<#=J?TERR?-0$]R)-)
M#J.=T_SL!.K)U9R- ZL'0ORM!+,M3A1N))G*ZZ$#:09PKI""<I?!LKLTN#X\
MH_@V8/<XC*#US>TRTDA:U=5.F$0[1?(86,SK23$+OB5NNXYS+<NW,Y_RN@3#
M2=<26OH0^ C3"4UG08^S+$2,QG-]HMR$W@T%[=5^=XD_J7Q]-?:3% !WR3Y6
MZUBMIMW6K HY4Y5&?=CT\1DIDY: 4!P[F);9N->9C5BFLZ#[6T%3KJY%UF=6
MGZV*)(9$>[CJ4I+#.UZU2@'?9>S7<7@E;K^/Z8;D2LX!GW4,$-ZZ8+=Z"X/W
ME <P=Y_-D];H''%<#CN><81E;#3@N6#$E^HJT7O )PLHW5CRC1O%Z=6E'!M'
MRK$#>Z5G!2MZ+]BAP]KF*50CG*S:<'1),Q[K -,7V/!P^_F @ /9%1^FQ[$(
M_<GH:/2A''_8J:=3QH/(E?F\%!*%ME#E8'HEY^5"W:ZH(;XL<@8MLR(R7E])
M1H[M#Y28P2GKF$%<*':V*L4M5PR7H:6[EMG3E;&I.F-$+S<Q)LACG)Y#]C$:
MKR',E<0 4BHW[$L6XO=HTI/WH#ZL<3#2V?//]R>8XKVGSQX!I-,_9*(?'\_<
MZ>CUB[?O1APMAGA3?E4W9!,OR@88$D#U<_C$]*'>?L0Z>5Z,!3%PL'=PZ-C5
M[J#W"CI!(V0TV;+;KJ+T,H"OK-0OOI4!]7VSP6!J*/3T==E*R2I5 O-.*5TC
MBZF>C1T)I' O/HY%GDA3.K.BXQ.X1+*JQ'EQY  LVUQ^_[.HA5M3;3CX]M6&
M@PW5AO?),MN<@.'L6Z@:BCL&%"ECBX,[<D&F5#J#A5C2X"N<J% $KJCJJ;]6
M2G=%JWF.WG6$=F> 3JKF!@KTP/!B!&4]WW%W]&NQ=KF_-BQ&'$:3<IFPL#-(
MC3ODF5);^K)-#(_.5D?XEDH324<(.5V:XEPMN.5*KMPB[?WNM[?MO0>;#?!V
M\?[UQ7L$.4.Z/'EUFA^VEYUSOSJL&D6;XAL"JG[_WEOPEFG+[JDY#MW/ZN(-
M,$WKQN$H:[%BSYV[$$1D3BFDN&73LNCLY_!!SVU4Y%#-Z6'#W;BUOAZ7[$D&
M3]B;T4WTN"RJ"&!_.6>ARI 7\VN>^QI<J>/* V1W2RX3@5&/M\"H&S"6+3#J
M"F#4=4Z.;W1.O$/%@YE"U.*I\Q!JBXWP@7>5-9SI@GT+5CQV+.DY"Q44,HGB
MHZ+0$?(&Z?G,QR\7N0P7KO(,[I(#(H@\N'1L>F-M>!S1^2'^ -^!X_:F7I%1
M+9*R WO593,1"KRB-=8Z204!Q)OYXH;E3\B%5Y]CZSC\IQV'KAAKB'-  R#9
M.N-J\-D4I[#1@IV<8>S+D#66QN-W\Y- C=)(14Y*[=,=EI)U057)0()S<D8X
MW23D*#O+>@<W(+^B20;*B3K'-Q*SVF4;*"?T8IN:^8]F:&$Y.S=BAP&BE4U3
MPVF>#:T2#E$HR8].]6!BM"]:.)@4%#RHT*S7$^M( (MHU16$4,K&3-=G:4CI
MP:E,KE2IV#E7>(=Q\]Q7@74VE]02\I._C9K53'.+D<,C523C]?$EB>AO2I[H
MYZ;X6$;!^[?1F7X)NM#+NOG0Z<7[E5;[I)[?\E32JVKT/R LC\50[H>HN<0S
M^,"CBUJ-Q32_J#D-,"OR"XN-.EOO/GAH&5;"=!N:<Z)X0_LF9=ZU2_)![%#J
MW+-F(!$O2,FATM.'K'FW[-C3C=U+J?@ES=3,R20Y49R\X=R7)KRDC]F+PG9&
M9 ,=8G3N?!3IV$3 7 5L&2<G5!&"G II61LW!:#OXV=/^+.@T4[:Y;MJ';R)
M305Q$@J1NZ-?ZDO03&2;.LD&ALXE0E"PP;^:R- G:D-KU0&JM>V;0V$:\/$1
MABACPZ,O3*.W:T]:],6%=R6/O"\D6%98D=<T]+77>?B*Q+]TWUAE\!H))A#L
MF.12#HNH<>?RD -<@;32_\[,R,*1J*+#22;4"BZ!M6G@\*/GPV6B6* 0P4H3
M6H!4P3BWZ <\K^E](HLZ/**!9=EYM1W"#G=>TMG.FG(MUSW^CG+^Z.>FY"0=
M7D$  !:]BWJIR(19X8H<\,!D>-I"X8Q_'3R4M^Y@)_-T,+J/-,6<X0\/1O=C
MI>4?-</XJM$KI!K@:S?ULB8+.KC279YD&DP[9VILS\3:/<U#]^(/>MD6^K%D
MXHG.#$9?CLO&6,0S+D9Z^ID-HQ/LR+ELV$V\TIQS/./3@,<_ <*5.P='4UHK
M##E4J85D9(XEO"/L(PB3R/VRR<2:M<">"RO6ZG3386V</[-6W2H3Z8S 93!H
MJ](5RV@3FH"&'H=6X.1ZJN-]CD&_1N/J[*@<=*[]H+-Z]QXFJU?6D((=Z'Z>
M=\M)EV]22NV>+WCY\[)IZJB;>X52>U@4Y\Q!,E=>18$#&#X..A\?Z)-57(7\
M_+^\/=+O&622$X? !09CD)L>JB"><7NI/\II1.\(44_0B:W.EN?#9VSW\?UR
MN+N^>6I%$C)W9OAV>EC)YG%D=8E6+#X9-),\T&@3:7E\Y9P7%M2G)86O,+:]
M/QEO66?8?@QI\B0RW5N4YK[-@SGF;&^4'LGUL_*/DD+IHKDH0;!S_][QZW?W
M'KB*?,J+^PD%+QR.037U"IRQ:AB)H3\MDM*J@EG1?][VS@<$UD,B>5:)%26/
M:[PO[_":$W7)$/P$X\I-YHVX[C2V=)5MY*^_KPT45Q64K1ZX8(*=5>1RR/6F
M\+\>J/918!+BLV4_C!S#'C+K_<,J$RLD>@KT8&QQHK1&_H&11INEO^K VN&4
M\1B6>#6QX@;&Y!) 1UYBM:08Z?V//]"XK,D"E[[6;"NPF?['EA<+GI_A&(&!
M/-W;0O'()Q$D^-[LLO W(:N!G:*2%1Z^!/0X[(TD;8  )+-CE,I],MM\]-NO
M7;>0?MW;YE>R-]@PPKW-7PA6)G-5.(T*65H#"".CSS$B1.UY64O# K/2P'E&
MTJ*4K@>N'0>$PPB*LD())=CX )S8I"GDT)SR$)RCUKNTYT8UH@C&J,N2CQ[+
M@\I0*9*UM%F N@<U".M?&-)8N<,'V[NA>"]C=T'-K ET;> 48=[YA="#]<WI
M^PAEOL29"4G1C2:S?_'[LMV:PLF#I0?L@[Z/WY%%OHH0):K*@*C#P;=XZW9(
MX@5XV)47[V5%FNL;ED^2A7'>+S2:Y!OF ,3K%S$$66N@U#M0..6C/78RJY8(
M_ZLL05:@D?-Z'$3,N^^&.7W HZPM=T//8J\OI8I*[^#&'8FB'O58HGKWOP++
M<5N3I,<,N3P3C^NM%R*_Y5G0=PZ"OJJ4^'VY-F*KO+4%-/8SD$JQ"X&72)2M
MNX&L$ H[Q<U.&Z=*?[=%\6%(O9=.H7Q6Q(L;&60Y#36D;"1A>Q#2RLS1Z8:9
M[)H%[JPA%[UL)CNX!-TI7]>-8Z^?%M!<(U^_%?$.[81@77,IRO!<B*X7.^>*
ML6ZYTWA>-$J(A?INHX!K0=),_+?JYBROS G=#?X/>X%Y,Y'DIRBT,821@Y6*
MNP_J5<+8K.#TSERY>4%0I&]5\=]S5(($ ^E?<$?[#L/D_CSI@R9/:.=TO<.P
MH2T^)N!CGFSQ,3=@+%M\S&T07V)26M>53A['BHZENIE35$,G]%J%43<>07I<
M#7&&9EJSV?A=5Q)W#5GH7T.<SN< @Q3QPQV.45[3859S4#K0X(0C6CE#37^T
MF%B/&DU552!Z07##[ZE=[H2>?6230HZ"#MF\?\P:ZVX\S89ZK,11T$8198\7
MTF'R.=8MJJ35B+R.60AUINF)[RXF[4P&0I'"&S,KFMA,P#9K<AB7H^,5!1U:
M4:ZW/I0"6VM8,^[+X$AS=J/C6%AW+-(X3"@2<GIAI>K*9UA)ON:ERNBGB/AH
MBZ6I/944V%Q6G97=R/I'=8TS).<2P-B')?YH!YD3Z1<T6MD"86@FOQEJ:#%)
MFJ5.8O))KSXMCYUSO+<C^?/ %X)U(VS,8TF\Y8'X4E(:J]9W13GYA(1QWQJ2
M+ .LNN+#WA%W$P,X(PO1XG&TL'$VLD+)GEPV3CWQB!)+$OH/TXDWW])"]@B!
MFO$."6(%:K"LRU$HTB5?&,NF$T $VR5ON9C39>HPJ?!*X!PV0:;7%Z;@3X_6
MV.*#!BWHADO@#I#]-HH.#0^1."LP.DXUZ^OL(+1YUW'NE]9(@!%B3D.^(QU!
M%SI6+MMB-C50H@N"FU18>I#:@SO$G,$*6,/,9='*^0+MB!L-AP>9WUV;_RIR
MW6?]D]/'-5*RPINS4A1760PEH8B+4(24I4?'@#+]^Z;3UO?%\CKB*Z [C2TK
MF"V6H:MUX[F=Z:\ZB#SN>"^7*WN1)FSC:7Q[QIA%::5'E :%DL$YK=>B.C-L
MCRYW^G5SIMS0UJ"=P!M:K<$\XWJM;,'0 ,;=W#!MVBU^G4B9KB1IL]BZZ0_7
M"H:R<\ZU0E-M"N1!;69 -K#[36S7.NBS(7V?OI]@II/W:J!E1A'G[@*<-0IO
M]$*/M%*X(OZU:LIV8J^:[4;@QDGN%R\O9_Y4O$25C6X'T@,CE>]CNN36Y1+4
MP<2X+#DG5<:.C<\'L@0#7@_6"UDV! T8:'2"E"3'H#B1%B.3ZY>#%TY?[::$
MA RPBL:<FY/[07N03G)PTT*U?<*N A8VFD>VMY:0[=U:ZU&=VX17RO=C@AGQ
MG(#Z$-^)T\2!8MO!AE"N07-],7/;*(@QK#G[P7W;ZMG'$?6/#__Z>?8'?,Z1
M?#GU-IV6R;!'V9KY43X(<$$8#X;?/7?[G&!I^XX,+-MK_R+8D789,'5;!6+3
M0L]UW8FQ3M<&/PX9,?M-:><+_")8=*X^LCDJF 2*#PB/=XMV>!GUK'K@F2[P
M)BH/Q@+@(+6\63*!JUB[\$ =.V%((6<[3)O,C20!7?-G&WS:_G2*<CVLH3^(
M-M]7>#+(!T+<E<"_N1]NH0@4/V^84O/ !G1W>#JTVX1&FT_$QN,: IWB D93
MR,:#K>.?@PVO W4:[^M@!WR_('H$D[,R(5],8':[HY/TW R/CR%.\[')^"H#
M'"*867U9-#O\I)/X^;(*&=RXXA0?=!'4DSHG8!^JE2R\T'2H4L)RL)5,C5'$
MC'$X<.]<I>0-G\V_1"/PO]"[Q=0<1TZQM\YKN^4%E,YBC*2B0@,9L<^QG<I9
M2 =Z8\>LH@4RELVO15*M.W1]\=.TUU7CR%;%J%UM(G6S?,RT#MU>8J5.5RWP
M?:T6_E6GF/$)65!SB1F(GP8"!AOL$44 .[^6XP^G^?@#_W'%PE1'O[Z[]^"9
M[/SRHIR-7M)>*4;'L[PD(W@T!HKZ)5#4SY)GE]4T>A7,Y@F(9M22X&&/QKR!
M[5='TL&V__3I8[K@+Z].COB2[* K=[=.3Q;K.C'"F3;Y2I)".<T)3@T69LXA
MF:G'%!F%"SC0F*0[?.ZC>$[O++1*(<<UK]%=)06H<YS"65 +DB6\5! X#"_@
M/!)1&2INNF+><_8:!3(=9'PS@?#(3PV\!QP)9"96E<'M :+$FA5GM:Q,XV<*
M<)2J( F8--*[)FP*H=-QL6K&( G+T,/1\O4F\=[2$F%ZM/0_(.7F<]5!V?!]
M?PF)1TH^'AL+"YUC8*Z1YEZXG*9TF?0]6_C]:J+)L37S=&)"WT I;%],^WK:
MU/E$, H!:%2M^:UAA- <Y:2(E!//$$_J22YI*CO+D;D!*63>GNNT?Z _R5"P
M/ 9O'J#D^,%WF%AK2><83<,"1JL5=.5JHAM.-48E!.J'14;6ED7&J^!ZR&K%
MM0PKP^#)4;5B]PA1,)NHFIF83,>]1ZD$VED:\RDR!L9RRCS#<W8YYC#BKAV2
MJP=-W1;CE81^IRM#CB"7"C(D\@R;IKZ<!:N"[X_-"RFKBWK&G&#Q1<>"M&*/
M.7EJ32@6'AIQZ&Q6G,FK8![=2* HFRC,JK0NR(JV+9"L>+V@9QD=-VCF72O/
MX7HTJ3FP\NQRN4-Y\3:(,TA^.86=2.,QXR#T7B/#<I+4D1WLNV#Z[TK&._2F
M(DA_GG\H L!%>+6Q,4<E)HG67\RLTI(&XQ[[NA(R\"><V^K6<XRS1<)7%689
MTH:R.)/#BNABU)\=C5?SE=2^3;X(CRDS@-@#&T&S+65#'U;MS-W1&\YBVS*Q
M+"?P6#.%T?5F,T$_#;#S?M9\(JI0V$_=B+%?QSEF?LVE%AJPEVE><03,BLE9
MR""WZ@Y@0<0,B2$U+LIZQAUXRP1?JHG&N2IJY?HYKJXD6<P<P,=R[M2WN/%L
MLT6UO:;]4R7'8]%FMUK@X+, 6]K=VIX(-A#;4:)4%$6F[-= V R^Q&K&=48>
M5]B?"BZ'7657B%QC=5_B2B1?Z,M[%]\?%./'+13C!HQE"\6X#5",8S9&?/(T
MS(X[4V,VEB -$8]"*OB3Y/44HD9<T&>7:_U K/"H'<N"?@&WMFBD.PD]9G(U
M^DR[G!6GG+"!_21'8+0D(ZUD'UD(188CD>CHM^%\&@A&(D,RNSHH</)0%>?&
M?P183I]Y*M&(8>&&PW+_S)M/FY# !R-+_Y 82%?2W,7X2]+<W?/W3SY=[M_L
M]1X2UXLWFG/'239:M</W$I!@(Q59NQO\RH:;D#C:UBA(41=R5F\^/#>-"VZ)
M?"0<Y-I0@0E32AE<4G+W7C\="WBME660L*[C%-G]-E5%=T?O"J9B[<8R,0O$
M?@O'1A8*^")^6TB:1;M2X*P+ (+6L#@<12QM(Q-,IH&BC::-3"H@ZQMK!V*D
M88N?D[8-^*A7+,IN 9[?I553:2A_2%&.EH=M!@NVXIJ/P6+<TS0KJJMMM9.\
M!1""DSAQ1X@"L\0DH:#CV;>E.&_8E2^?/+UQ5IAS5J,QJT%/?.[07N*X;Z:C
M \G9D"'SN"D=4WSD()7)Z(WU&YSGE@E;^T5C<B;Z_K((:,F0EIP7N= ##&UC
MS@U4K6"H=)\YG15A 1?,7B14[VW0^E(8<#+1@PE4\ECU$X6@2<D$<K&?&KX
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MB5(T #_?S& EW#D:1F,@Q6E11+1JGT.<CRX.:OWP[K [B%+M;[OO=L,LG@2
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M<(0_3'26-Y%:E>.7)DWT^JQ"(S,7-3NCV<?N<05"(3QT@EM^I1O8$:9I(3+
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MP!5BLCX*;1A24Z UJM.EGE[&RH^=,,"2$J;XQL'0?^U) H/\80397EU1N,.
M;KS(QV,NS0<MA)BID"TQ46C$L3+3%S"UK^;S565:HB<)_]'1\:L3R0[1S"B
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MK_@3!.[+\=7+7AZ0MW?)LH_B-<SITCB4GA<,(@$ARCLH$;>C^_>.GK]K[SV
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M'<D]%NX)[R?6<'MBU=44UC4G=@9>0B\OO$EBWPF1/T3PO>1$%7*QR-7OA^$
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MM117TD30>R6C;B&B:9$ P@#DEEW[B&VB)'5D\O57,6OS>SO^Y[A)73_OD+&
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M_%>=QH4+C;LXM(0>,[7^QH/HDQ-F[H58L=T;5P"\/\_P+G74+;Z%MTA,\6
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M1Y;M!+*@#4'--VJH+F#^P%V!*>9V>J3J%XHR.=8;HF&N^9K<$@<IOZ5Q4=C
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MD.#\T5L@3TN]L#F2JE>Y^$;VA8AHDJ:"D^5,*1E2X)B,@:K"VF&?LP^W(#]
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MEWKD'UE3R/4Y^_VD+!QSK<P,2R,Q<N/I8G&V5)IXF60-,0KU?@U27>JB Y2
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M?:X'FF^]%8M;D=5,09\M$QH=B.$3CW[=2F(M*/92FN6\UP]&2,O7: ((Y[:
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M$C(7NU,>F6OY*C]_"#(* 7/K;^6&3E0)'+[D[JI_2/Y7ROA2!)(7T1<B!IB
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M8[^NQ8;I.5#@&O=S*V$P&O*+78?3YM#0%L'<&"W :.+!_Y?_/;HL6<$R)=R
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MT4"Z!-3KF.9FMD,;8!@9ZP8(-!&Q5%"!?0!<G:M8E@$+5?V=.PZ!2@3::SA
M]'%.6W& &/(<PA<?]'QCV4OO5/AY'@V8*@YMC/0A HKX=2M+*=8GT2NM]T-E
ML&^3-@HVKZC<//4MMI'1*!N@GF<,/T-A4IA2M/)@V:O*O_E 7.BS"/H4EUP2
M^1MZ)C!&?OM(>NFL[12J??[L<$+*PAPE&[63DLXBVM;;2=J.IU\M(+:2P\#9
M!)-%P&@;+O_ 1(;!8+G9(1^8\.$2#$!BQP!X."73&C&^:X$J8JL?4-6,[OGL
MS76Y99E'IJS^6_!E)A]N1#Q=4PUYL0QF88-&VAOU:)@7M-S["#&C7!4W8R\4
M?@3Q!B>%]6:-]LG%SON#?%D&8RP2$@\@V(DQRW)L\I0RIBN8M!5C05-27A18
MK'O_D\19>$.7!WC:MZ[U<5OC)]KJ;@25/ )S+]";69*Z0&[7+WQZ\/;*"$$-
MLM<88PS#'4S:"VJK2'R*+RL:\'*5A[I@^^#6?<3.#9QWD+:,Q36L:< 20-O2
M3<%*D-J69UW2.9331\FD_(#5ISW*"BY5^&()1Z&VE7N=EF81F$OXO $M+DA%
M$5R"3;!M:$6<))<>NBK(<'();2X\N<T<ZAKF?-L@"AX7E$!9 8'!>U.RB<D6
MK0?6M Z,.$8U%I/-(925 &7>$'E26$EN2#PV =_%0F/R3@Q:$+ 7G-<@!!1N
MJZ1S)4=*BI,^]8@E0T<KT"CG\:Y)"32HUOB1*AZ1>I)'/VYHOVQIN_LYTG,P
M7YM8/Q6\I\;=UD.CV!Q.,N.=:QHQJ#<B:9F1BG-"8N\6=G A/H4!'YZ""1DA
MM-PE3XVG$<8?9F-BTO!;,->%F9KHU;I^-DM ^8]'V*B>M^^G=!Y:DI@W?$'W
MG(XRMR( GKN6]H2D%)T3U5O2">@7;,F,%SM6N%UNJ"<]U3[EH"7#!T\6CN9$
M\P=4 I_I]4Q1*34H9]M=3.ZLHHYP?ZM.2%6LJK+))90C!47K9@V@62T-Z_C)
M ?F'=]01\C;Z3_&Y!H'' 5"M0(?3M03/T/W.6UD=>+[JX<E4J6=+&Y?=?\DU
M"LX[;JSDE2"00RC/R9M[77<':-PK-VX:N>F^\MNC/^9OO%N(=?S0P]$/B'$B
MH46# 6D9Z F::0G$UMU4W>*.1F4G#Q"$U(%C?83 Y3=L>O\*K?K%>O9% PKK
M8=C^ D_*12^2_%J.ORX#%?!X\+$Q/P;ZQO>C*,9!9QA3XU-"6#_9'--;*(1U
MOQ6:W:^];_&__]='?WGY,6^T =7V;F&/W8$:VZ Y%!$.,'(VI-.Q(+&#%U[P
MP\O5H3YH[]5"9!: SX>I'RP-?M)!<GHI,+O"$CS@X*A6@*[T@AL'P 7X]2,:
MI87.BNR8J.H=,CIP^I*8GQQ+\-RF@6&[ ?@I9,6$3/3VYTI5_(&)@/+^"I!@
M[K%Y*Z@G1+HMY89@P!V)YJ)6]\G=>:7T^L +:TEMC+NZ@N:^OD4W0=G@H+9,
MM^"L)\BZQ("V<*38@<CJ<ARA" :8C>OJ?MC5/;E0!L6L&5YO<W'-L&GDSJF&
MB1%[5S+]<B1UL%Z;1E"T^0YLMA_6]2Q?U&K[)2X@&! ] )1B+]#]VT$+Q=B)
M!$N_!T_0-O 5MG<UM)+&+<=D)3BE'Y0(CRR^T]3O("ZBLHW&.91F(P:M62>3
M5I[AUN>DA$#X-05[W647MLO$2:"]@[WS;>CE)!2Y8DBTW O9M>/^X%?JA-WX
MUP,$_O4*"+R L5P!@8\#!%[-[*_#M<N7'8/&E^VNA6(,72C]2#ZY2C,$ B=+
M'D/H+0"%8QD(@G38S-<K]@.O_<.+S7?LICR(M:%65OJTMCU+Q?M_)J@Y$_7(
MB(660$L""5#"D:*>\<?^/Z_K_>'/NLE\^\AJ=U\>SSCW_L "B1 E8T'>F)*0
M*OP(Y<GR#OAR79R[!;H6;QVZ/>3JGFN7\V>:;"W.Q1XEY3W\U*E\E,0FE,:R
MO%3F:UM_R4H"N :*&.AJB>@0 +5<ULV$*&D RB)/A-:ZY7>-E;:B@1 &031V
M["8L,9;#,/4E$2832D$8%R4Q%ZUU6=V5I-MH^NE/O_6XZU$",BV/<MKX8K?+
M^Y5! #G(S7>"[8NRF)QNC\"F\[.(A27MYL:2,"?,O97&(0$Y6YM-F=FO&LIT
MOZ*(K#\$^?D.=6,Y::^8ZU++<!AFU[NNJUB<\Z+7ZR$2@YB_8-MMIB&J3_%$
M>Q-&DKYQ\OFDZ:1>^]!/S[T?E)^(.T (-NZWE&L'PK3ZWT#=OI*MC0OU$'RN
M-NSOG2,@1T N$$Y5B*9RJ(#\OKFK^;JV7*S:I&VV2*X%MJ"&5I8EQKGT%TY'
M^ 4HB^(>KXF +.J=-:PP^9U+_Z:!?.#[Q_VHD&),+LDNS1%^%@2(\?O CW+8
MK;#K&]Z'LHELUG:GS)7?F4VYYM"GX!7CJC$-L^^.)6BKEWT/WG* "^#8_7_0
MP?(388 IS%'HK>CH(VVHP5/S!R'1";C;->< 2>A52& 92=QP<*V24*#5H"*]
M5!9M63'">C _8+8*!W@8Q(U;LR)^(]7OD 78$)W(_@K%]"\STMG:BS\FM,"6
MMI4!Q7'T<L)T%N]39(;=:@><$-AXHT@KR) B(!U@S6*#* H57>F^#N=4LD67
M4>#_M=K^WY;8-O8F.$G^Q3_E(I#_\J7>%(^_V9&SQ'ILF_"6"-L!VO^[VCMK
M$A43D6AH4D,8(D;50JD6 W\8.BN53?1#JT?YI*%#K9_YI0&:1,HXPJH3'0_L
M?$">3SO$L.<-A#N#G<LQ<T>/#TQ)\3G\Y5"8RW$SOB70DRX[ TZS&"BX$(4Q
M&'>+NM>8VS;MC>278*=G0E6 ,([!V>T([?9UXV+%=6Z<,TU []KNOG$5;$>%
MD27#MA<%LL./-3448@ Q#3%D&ENHY%ZC+C@\-09M:\X,Z87 O0$!)@4QF:ZE
M??DC^"/1_ &<#JXDO'N3?Z+&Q6@!$!C7HMM2;DH21P==L7J< IS38$W]Z%&Z
M,4*J"U@?;\GZCMU#NE/E88'_O&46>FF)BGC/8QJ;[-7^PIM4(W27BJV;QAZ_
M9<0-"D<R.*ZEJ$^.3!&[Y @DPRJ(B306D2Z6+$_L/80/!7N28*+W4?1HWP]%
M;;30 SVC:+VP.@R_,#)8'\F7U"-+'3"PT:352WA;<.4<@5W)9Q,>%X:SF]T2
M*HTQJHK<K!3@P%*?=!"F@688F5-E;<FE@_\5%(C,*20H,3"5DCOF+2UT)#32
M!.B=$N^^SHF365:HC 7:$3N-7HCD*&9,6&9/PT0AI&9F;BC_@_#+'NQX0:!K
M,.7P!_]@A>@34CB./-)-BU 0OM?T,!0V!HHOA$=>5L_SIOAZN4TD>D_%T"2&
M@O,TT0Z<\T2&;OF8/H\2 AL0I H:4E&CS(O56_;[J?/1=,0OMV''8Q(!1P/_
MT;6,A)1*IHZ*;3^<8FQX@K\"-AD2&!7E-0>B&!AH _GE[-IIT[AN]#<3W _U
M-__]NEA]^LV7;[_^9N6JFNR7CX&'NC*DJ@4#*_U(^F/T=PWR9B0)^.3/X/]X
M>]O1Z6O\+?K]?WWMS28T:U3$_C"ZN@5'RG_UYEV-?,EWY69#W#SR^(C%X%EN
MY"^7.P#[I*T^Y1$-R2>.#0.KG^U/0*![VV;HXPLRU;CK&!,2'0@.+*6E2PW+
MGK8>@&77W1W!W^>YB2% X)?H!E^L_M,%C.O685>UG&0*&8/3;!QCQ3.D([;T
MR^C4#,JP092)*3T>.&X&'L^_4;"]"'KV,WA[[C[C+I_Y?:O[%1Q.O$PGRAF!
M;W'4K J\]N/ZC9;:F<&1CN09$>E;[]>3CT4(!PP>I/7;E#\9$68W<#*A_'$D
MH6ZX\Z#9(':>>'6(&:W>&(],?-IVWMRY,'GX^#F39NPI*6\L4$:&3%*>4Y'/
M3&UWKHI4F#O0+%W:9##$NKDQVZU]@\C9 *!!WVFL&>@2^$;FXZJ)'$"UK$*1
M^:II%T W_WX%W5S 6*Z@F_?1M+O@U",8F\]B' K89/&J/]6KY%)]JO<2< LQ
M.2!NQ;_/:>I(V:=R>W_M8&):*1R;8^1+8((&7(G#U*OK( [&@SP/JER+]XN(
MNFDI*,DQ+&0N\TD0IHK9HW*K\"R >Y*9AWFL:Z$MXG3>.?(CJ*NW;O.2K'KQ
M$D.UWM*_E23E)QQ6GX5R2&HS0]FDOF0J++3W+Q?MNVBS37W4AK_1K17DF"DH
M7->4-Q\L.YHKH5)-)2%3()>:7>/:VW%W+"($"U;DL97@S /TPIN1\,'X ]PY
M6@_FL<PNY<?USF%NB_K\CJ[L(U4<.EGUB'(4&'LCWP)!.$ PN65>8;_U&> !
MCR46"X1:'5%6;551[I#Y?*-7.F9>2) 6F--LJT#=<R)NXYH&4L0.D-%%S69[
MF U> +7'L+?.8%,PIK)\/WB""4UF.AMI[\75PF=YJKY5PA/2EUO8:S2EN8[R
M!SDO_",KIDM@JACS>U@AOZ&EFFOM-4"J=)NM=U.C5CBM_B/[>J#6:K63CWH;
MCLIEY)8(+,+Q#TI9.!_Q%P J^PE5%(O0KPV;LM[CA,&A&%!]KS<E!*U&L7J?
MGE=5 F=NFIX%P9-9I,?K*\HK"/\U0CMP$>AQ1C070U8Z$./Q0%DS/$(_C="=
M[O\'G1)$]VRQC\U40C#OQ@<GW[2+9]AQ>VO/BWF>.7N6QRF3'_6+2#@0W.6&
MG2[O^D K$H/.!D2J@(6Z$:H^Q+@@SF(XU",V47.A]!9HSY"2]/0TJ[AFNG?_
MJW[G@/RDH.-14 X13N<&;L\3?DI\PM&5FO#213G#K@_GIV5?"*4C^<&'^JX;
M<P,"6B<_J_:8@Q/MAR39E<#_<.M:)&J22X;RGU\C0NFCN0+JY*_ZNL+Q6R-B
M>GC#10H#-T\V[N@!F/?\F.AG7JUGO^.7\QZK/.,I'#KA)>-MXXV?:1;78N 9
M#!54:YO0M%01F][@QG6Y>6=VY&&742+T+XIV3U1"U.'I3?ZN;LU<^9DQ^:[,
MYTFH<ZYT21H8D,X>(8V(*DZ\G>?&7*A-K5K273F,5&V5'U^H3Z O" G%TU="
M?D*0383(_PQ-Z_.^]U\C3\]9$8GE 9,JL9S^18<YCL[BX"S4Y((.R3R7^+,R
M@0D$8R'I^N7,J[#2K9V1;SHO$"5'TK^I]/*FXCZ/"D,7]8!%G%8QDABSR%A<
M6Z&6'L,5D#9Y&&>N/0!47 GA$#6LRFG?.)&F(8<7V2SIT,&+N1Y\BF'H-C5:
MU9.4KT$]1@7F-5(FQ_B\F.Q!C4*LMP\88;0#=K8.XK!#1+&., 1('"MF!]RR
MI06Q=DCVR-J-]\A%JR[8N9N#75@,L>>(6C:=WG*['D&21-IAZX.$IB)+'L*<
M"@LP V$%QQTYK]W8>7, FDX\S$VX 0:B/:O ;0N*W7,UE,+^( )RJAT]2G;R
M/.JBGPU\B.S\5<#O!/H8^VY>V8^TB@.6)Q(\(]<#I9HSF8LS-+2%CXH]@Y>%
M0HSJ*.K+.EEG_@832])__)O\QROYCS_+?_S[OP7RR;_@4)!)$&>T5#U$%&"#
M6JWEW.(*62G4F#=$C;EZB!JS %"N_PWI(V?01Z_G,U*<38\WE6106^6?(\T]
MSE1OZ4#CHK7D%Q;S'UP+763E8D'G2G<@5YW.E_5:$EV6SO]4;[IGZ>28$7![
MAJSJ65+*WSY34>/7%O 4E"D')HKO]P]S$PK(BND)HSKF,_6<(FIMO*[8_*86
M!^7*@[_D-WKGM_D-DL %^P]QWFVK](QK_1(< % CDH8<$P_H385X*ICES*>$
M-!S6<85M?R\_#@/ /WST<6K'ZP'U*^_1K"@QOEPL%$!*QM/O)\!C*FNJ_60]
M,)V%I/S21&FV>TAT&]L "E*7&S0Y&%6Q<>L.V#B]\Z]9B\).[LR%=4">V'()
MX>&A( 9?1:0PU]1!6S'TM:C+4$%/3@.6!$KKRS]>]I%",/@MX!O@@J7M3NZG
M\O;64=VC/5I$A; H0N0A;/!@F4[_;GD/__<>M+24B,2LB]BED^.7RR6\0BG;
M259[79>#;"C:.CI&Y(*M[T0\41@NM!^FWO/Z>I<);C5VH>C3.'S!,H1Q:PJ+
MN1;->T2(S1.3DWDI/231#I^_&O&T ?'7, 3 Y%WM[C6]O3L.M>+G.6T^+)F)
ML$[^ U26TMG#*6)>F,J0ZHNU &!+[Z_AD3<V^ E6!(>^XK]ZZ_W1 ^$PMN5=
M![?H<74+*1G*0"BPF@)K<91)I"':9F0G%M,_V=J4/L^J1)^X40,A'Z.(RA,[
MG;8W.>T5L9%"MH7O1=O@0+\N%@3O;!HW?_YB+Z1'EEWGJ@JGXK)3$M@!P</K
M?1N>9DG@*2; ?>_O_S8(;Z#(W8!-?!"+L*:A[F-"N1@9>0UP9B38%[LX#]97
M&*^]% C$D,REL""7V>JDJ*@G78T#A^IL"3+J,H44 #>.FL+]QN@8L*J=C#4!
MI#=XW26M?<$"8%'P"IY2\-3?KN"I"QC+%3SU3"4,UWU78E>9$4OXY]XLJ^_9
M)Q>2703>JJ:$!CBG$.,R6/D1O")-XN_*U_L$C#+J*.;Q^R?6D]M\JBOQTX?F
M5C0G_=SSK>$2ZB14V(>\N+@HL"AJD0'9H4^^KO@3'-20C<3UY)Q!95IS3RF0
M8&G6M&L%2?E4K+RL.A4"HTRT.LVLT0@UZ+*O2"^HOQ*_?>C=,&O!B0O,YV\(
M0K]J[UJ(=DB!*M%<-*HB72^->P0V 0] _@U]!WC>=5\\A94(]2;,T$HMBM'>
MMJAR79_+7A_*/,WDB$QI-"O>N/2-ZW(_F^5^5,G[H9WPJ(==-\D'WB3?OO<F
ML1E1E@Q]C(%XX.O7??"!8SI!&(C\6>AJ!ZB7Z\=8$(UK5V<T&U^/] =>2ENU
MACQ*V0/N#R-O*#2%!)C6[671KTOU!%?TZ)<+SMM6:G8U%#J1H^*DJ*<AW+%,
M65(.O*[E4R0S.U( #3D+Q$TWBI/.IT"N:_4$:Y62@$C7"$E*E<!?%_.",$<;
M<GF(W%1,!I(2OETOP2==82@1^7\0<)*FH($L&XA-IO&FV]X<N@U97<9M#@*6
ME7UP7>Q+7VR!*D2\1-0R1+B.LO)WK!+815Q@L<!QWCZGU#V!].QC^*?K<G_X
MLQWW*XKR+= &,_)%P%1,POX\H4FG*="D (K-DM*<NBA!]XL!8!+G+5?I"U5Y
M2"18;_TR4?NFZ0Y"^-/DGNG*6!!K*5WP"XM%@&1D<.=N!< 1$7)S(5VZV'IB
M& UAZ% 582)E:M\8J%6B''>#LC_/\*RD#(W]Z^?^< Y^Z!C$"*MM1 JP!=WO
M25E].RM='LB8DH@%>71SQ5J]]JD5C*S+9)E"[JG6AK.SE=L-(?^)/J?3>O%$
M<-(-.>+W0/XG!YB;I/R06/(=F2SV\$=I7ED0%7B>AT? KY;Z;MEP:7MC8E3V
M_B#A86)H?FKOL,2(M":P1?W(K1)%S(*-[6FCJ%+I^B18[ #R!@8(._@B?!Q#
MP(!9P(:>($FL(V#YX8M=O\<SV0<F2^XHM(AF2"OCY=SUMV5KZ9GDPX'P8A6!
MH1]0>A!RP>R/H? 8!'C<-DUT@GZE_35YVSL^J]QZ9\2#34<S)<2;YE23L.31
MEC:JWG[R_6=]\V67>B#!AK (I*5.]P L=;04CUOW'QRQT5>6[[.$.^+&W[J#
MBWXUV5VT#[P1W:@Z0JR59?P1%K)AH:4:"5<+2Z(=TY^#9<'!X0/Q=;BG+^%<
M36@@RF4B>9)JP5Y"[Y+52"/3E]P5S!HNN7VN[-["%8,]1,AL1S>]-)ABMUA$
MR(E]^/<M/^B*$!>$^%]?7A'B%S"6*T+\F2+$XR!\9OWQ:!-_%ES&5F8A?QU[
M$T=*(M3![OH[[SNG=%Z)1 +:3F8=#O? G&(/+/D-X%*G?>!IAGB$F";+-A!Q
M-^74;G;/\^*>^4\8*&Z@N@\.2^1-8=-BR[2,T<5>HG3GPLT>$@"B1IA?6<ZD
MI@\O,D]7L33(N?KPK>P5*9I+]R2$VI%_]F+UC^[>H59$1%GBO9"'Q2K#W(#2
M@(0>Q)Q@7Q(Z]C0R!:*$@5E>2+A6.%\2HFOL72Z4+P*4!,T\);/8-*J5$P(-
ML\,'&N)9*T8, NR0PJ@XR*&?J1QJ3DZ'CJ)D533<TIM'Q]1J.[$'' 0GT%,B
M3H(["'S'D39@VTEG)\=K.Y=U<4[^,G603+V^!V96Y,S2 [B;N %", K@:!5V
M92)_42U"5J$2Y'TI<DF1"P)UB!+%+DQ$DA8.90$22^:WFE\,53E:VLCFA7]C
M.E://'CB\:N['V9K.<* 6R%[8*48Z[W?0\8BQ>:&_'FK[&>N DX<?=<BI\/;
M494F,1E77N[Z/#*T_[*5%3ITD%#C?$E\A;*B ^QJY'#  XC$&RIBB/&(V(C&
ME:!C.N%5W U4?+'!V-0"?QU4983SY-GJF/R@'&(;;\B/2,Q'$[IE2AI0A;WM
M4+<-2!2 [U:U<'3^D'NB]8X)7,TO5F\-JXDNS+V-S77/2X<^Y2&:P")3K)QW
MG+HC*W9"ISW<'N;?18BC6$U['^?XPR%W=(_)8>1=^.BO'Y,%!@XO%_ZF+_H\
MURUL?*T$UP/U4I/GBLE:_Y_-,3D-D=[10]G+>OXSR"D##^]:5M,=1I)?MOR7
MY1[V GG'X?B)-E+3 ?N%,D7*DN+=%6U'56%=&SZ,WM^+/WM7"\H+]^4PNLPP
M"[UVPR[9E,-$TK50'4_WFWF(;MG!B$'Y::2=JC,!)Z0J]]A,@NEP:A3IB7H2
MK<SI8:-YF7H6 _,SCL15R +_>N-CM0K7KY E8Y+Y;?Q9FOL?IYXJ7$J*M0.)
MVJ86NBL=*11-_"NZEAT*O&9HZ$1_34L'K\O,N^2\J$ZA3.R,VB[RZV(!F#E5
MU_,\=N);1:)@!TB@<KV^E((/Y<U8I6D/'.GU2$EX*+B!CB_3('31?15DD9EY
M0XR9-6*Y35M8ZO%$J9KJ#OY/5$+ [7TD B&!#_"6QKT$Q.M&]95)G%%S>ACM
MV*Q8P."?!M+$\JA$':^.Y=C#'(07ALH<J N;?&)0#SRX[D"V"<)K5//&"ZCC
M7CNU^87Y._A'WIEWM.M+N,_=9F*F&;H.K,D!#ANH-G,81BYXZO&I:52&J6 W
MB!]&H%I$[63!.A3/G/8DCJR02RG@20%!5H:7C6LL0I%5K/4F;Q=TC&AF W<?
M;5R@F/M-"32#:HC_GS45VMK5MQCE?$U1SJ6:G<?7M(#NJE"M!R*A$IIH2M8C
MJUD[C_*$56Y&3WBF4,276YL'T"?S,:(+M\DID>.=#AR@1,^%P75)JFK5)+$1
MDMG2*R'==5G!ZP]+!:P'M<<Z[MBTP5*Q"%WARTT]6W-S11:Q[/?/^!(3!69T
MES&/<FHGY3Z-:1> @>%UCF#BP'HFMXJ)5P/[JB!SK!QQH7LAB/7:>MFP^OWO
M/OWFJ^%W?S"?C#6%9Q]_0Q_'74@:]8##\'NU=7UT#&B?'@Y=_[Y'@A49TKKM
ME.: .;$6)HVO,5"P)2I!&EX!4DYOZ[9;?2)Z,$4TX@5J>A@VL\SBQ>HO[8,?
M\<_^WD8E'^%T>K;[-NS/4-,,^[3U@2HR!/OC6]TZ=6YHO_"BP#8J9GK"L%NL
M!Y48&:)OG*=/\ZKVC-YA=)$EOH)L?J/]Y %(A)Y5*-@BD^'.E7=^$LF"SZVM
M9B0WF/M[Y(Y5=U$3G) 9D=U?,MTJA?!U+RH&E).U?MV]+3$W8##)$YLG3GGO
M%M)3(K#5QAF^P>$1-.M,[FMJX. 'EF,9]*L?*QK"VI)B\I6,F5U!U].MBRE0
MO^UPF= 0:J5Z],[7"[_A_5O[;S=(:\NG'AC@@5]$ C('GA\KAH^D\?1(JU,/
MANL5A:TA:#2NZ.'@O0E1&4):[L(OTBT7^@W>+,*'H3T,:MU":6%"O]YX5ZD/
MX/\/'![X"""F)LT21S_'4Z&)_A^<+.ALH]/<A6@&-\V1WO#OGWXM1Y ^)B \
MAL!/=<7GS;58?J@(,$_-@;(%SR.%WF;A@0B<E'6Q&KG/TL1^DW]UGCR8[G"D
M .!9(04&6@MJZ=N*987UQ6O_X/<X\$HW&0_!6&&&4*&K5EK>Z'@S")+8;@*S
MS6& 9A,4,6$J&@<!/%6J!YNG=JW@*@?V<MSLZT8WZ./IQ#,1'5>,!:8[UZ\1
MT5FJ#TH:YLV;UW18_ 9$B:8!\T?';D(KHFZ9K A[70OCXC(:,:9SD<.0JZ8C
MLG,.\Y!,=DJ>FYM:$,F+&*KQ80D(20[903"/Y%UM_O[FZ]D)CP!3)0D#&0YK
M)&Z.M04@.E31*=IK\C_)-,SV7++=Z"-V(%!)4W 4%/1#'M32:1N"]?F.Z+U/
M6,XDP>(0GTK^214RXF-ES;L75[!4 $M]= 5+7<!8KF"I9PJ6>N-OH0X3HK.*
MWQKIU^'NQ>MT>^KBYAL/Q=48(*5-.R ;AR$&J1WB[[A=V6Q7=S[\)59O5V&Y
MID,=O!%0%.5$"A_E>B+6K:TWF([%)_Q-<#]8+U<,M8^JFG$'U&S@F=R!J@_!
MJ#>D- 7?>YZ^V^OVF,PY7[/B/&1UR;HQW*,<],)GJ?;J*/ HL!ATH&0]1 D4
MD5"/,@7(D^1 D'\MR8-DX3CJPTBDJ"RI/4&^0&_ .]1=+*R'/1.<R&; ,\?9
MHM@5:=C:4"JG&/5M9JO"UL8J#[/GST 9W+<4]($A5*+7"LV;...,OD%'F'A#
M2?;R&'XDN$/1X$-1+99ACFBT-2H7/X&E8*@ 0*$['SP)U\+A>BB/^QZIVV[=
ML"S&Z4PNZ8J!DAN%=%BO0EK]*LB.4?6'%"!)BG0CUB5QZ?%9G >NR4]%!4#X
M496#4"\/2DT5*3%T\;D(VE5=OQ@=@Z$QK#)0!Q\6O%TRD=X^8,6S4,FSN4I1
M/NND&CRQWE!Q!BL_QE'Q"IZ3_TZR._"A(,HCI2.)@\P!" H]RXH (:]"R7.>
M-*PITKZ5?)CF&0R1H_:I"(Q.$_,\J\_3:+_U!F6SXZ84ZB=>KM<\*C=$O15#
M5#A$K 893]S1 VU.K#R;/)K:V&VWF=*X;@P*V'[_3CW^I)\!*C%25H D-4IL
M; MO<U093=@+_;MDLW'6%'6BU)Z5L,L!CHU5%^]ME#P/9FN@F:%,*TG>YO(Q
M(?5ZL1OE\25 %/Z%/ (<=N?>1?D$K;Z(.0Y5$#^9F+^;-9Z%KX=&TPC@&Z&'
MBM1V^=.+A2+X"$L.!U1L/* B'D3^YRYVJ1ZJ4YQ:F,PR%*L-ZNRL?@3-SA4J
M(/<T,>FL/7;!<AT+#&9=<XH6?3^Z:T0EKIQNZ3^3^@5G3/4BH?M&X,"IT.F)
M&BNF7417-=^$S/N*?SY1DXN]LGDZA5 L;=?>].#9]U)Q8-=M!WDB<M?HQH&A
MMJXDF$WC7<D;N*&3=CO4&Y9006>RJB$/0EZS8$(&_P-NUS45<Q-4]=!/!YI/
M8VBQW8XCJN>YUZ.KX=X1Z#QJ7(P!Z' 85);-!V#(NS"OSHJ+(14]D]M"E<Q<
M4PSLWY] UDWBU=BI"LZ0)'YEVT8-%&5F.'Z/!4?<LK!$)^V$Y[-VFW)"/YL]
M_Y!?)N\7.BNZCC5(@1-FA4*D6-$RQV\;&X0[:7K@^4J#&'AST!4[P=+& O#C
MCFLLD(LWE 0)@_9YJL5XSF8>*N:QR\O5R#JYS;\@X<\BO54#5\4)*A0C$J?*
MOA'@G)38"%V*MZO_D>[^*OKQX=E[XA8+C/^M,?-FW-\78LND<B('2.Q)DIW@
MMBF&@D*QZD@BB-%>NO)R/>E2B[GDUL"'?9X3Z@$]M4,T<.:Y>5%1*D2YX=\J
M"NG[1_T <=YT[8)(8B39S:J9>J5A1&>S(N6&K+XH%F?8.HL9'>%V:BN.6>E2
MA# 26S)5L5S07J6%TNW7 EIGSPE@$H,Y+# 3Z DK;RBR+=17\KI+.214@YR5
M*:7G$^#,FJN5;8*M1,EW@*4(J#)F?R[7?J>C)/%LZQ=2):5^"?Q'.$N9I&DH
M"<,'(!3C(@!Y5W/)7G2M]#E$N'3=;A]XNU4.F-Z<*2!8CRML06JZ7#"/T",@
MD"7NT !L&V:)R!PVW2:FVYK!GS#)A?B+.-/,)8NU(] )@4@$.VH>Z%V^O8\6
MV4=D(_FC=Y8'E+KU?[[NK2<U98;N#KL6^Q2GDV1BL/-#X,:2<HW:;Y4^2V]=
M?R7V4/LY)GX^91PP\6TR$)A&8"9FFSXHI/,'^=PV[TC O201A%;3X80G'5T#
M;L=$*7GL>\.'78W94V\XJ7 H]KM10U80V049M7F^K@A;"ZV9L#@1T+8Y4M.6
M_B^J4&9-XW4+?. M4$:W%RW-">Z+'AY']>P60P7LE9MI:%-;FRV*1[5P,C[+
M/W/=!4_N1$=M4MI1B%9@Z[CVF3?FO$4XQIPX<YW_+.&5??3DQA);^Q$'(-F+
M$GA>R:+<UE H[ &%@]VB^!BD!\%8K,7VQ)$K^V*$P)S]Z$ FIX+K#XW0G=\7
MZ$V_UZ"P4P8(%P0DJVE(;8Y<WKO_>KC&5U=<XP6,Y8IK?!RN\7JA_ IA<CT<
MIE&0:FBWUVZ\=ZY%D@VD:XX<#S+94H+B'(Y!(84&+&V_+'Y!AK)8R6^&GC@(
M=YJCO4<@*=2O:]8]B#."MD8ZCM2T&.?5KU[,DWDQLA:W?6F2? ;TR17.&.-&
MJ#_]4Y'T3)8$!MPR#$I +$Q["]X 9>:W5(D[:W>RCICI@4L#HJM"QB6XP] Y
MB6MX _^5]QN10R,IM [6R(ADP125R/T7I&EG7PC_$<&1RD$X(=&7!9^<FHJA
ME =</PB+0X=[3K:&C\B.]'D6N&.R%FQWS<.,$C,0#GV^SQ[A.8KO<HL71AX
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M<T[C0MCSK,&8$F;;[*!#>X(%-IO!]:%)68JBD_;!:,;N?Z:2>T9.(PGD441
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M1:=GCQ6*R"YA6OIX1LHB2!X[H=R M!3E1B1XL>2+VFL?L:R8- #<3IR):T_
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M(U;C8>+$%@T6>ZC06JJB*6N+L+.HR8PS/;CMF2*26Q8CH*6@R[%W2+"--+#
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M(IZ>49GI ^:,50AT*1@G[U1R 9F6V_I .42]D)3P,W,[^5W>_?!QAKMZ-U7
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M-12&?"<VFI4;G7@'6LS"_+UM+ICVTHLD67QQ[13D>#8FLTF!8],S-I']=&=
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MGK_VE@_<K>6$1EOD/A=__?K;UQR2?/7M6PX$.<3(GXNO;@E43I%L*.?H! I
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M5'6LI?F!&QOQ^-)]4TG7[Q-65[&ZO__D":O[ )[E":O[2*D)3;1EKN(_Z_,
M3[NDCH:=\1DB5T4:]>UEUZTJ(WKHM6$Y76W2]GE#56CM%2!7AJ<9G>"UL!-)
MW]24,@F^A4ZK2-8R;#J0WC@DK5[5USL1TM##S3GD"C  Y]>Z:QTDP@R7GW&^
M*N8YESNC)U#N&=C1[4SQ?*QU26^Z@?GH)R3"HK(4<Q2"?%W01$'%6SGS.4X)
M $\Y 1^L#W1?ED%5VSQQ8',;78-V0V[[Y5SK!,52&J?+]KS=!3>$Z\'8'^OU
M"V1HD7Q]L*-X2ISNA(9D'S1K9&'1[];=?NO]5\D!1X_NYB!#1#V<V?"XQ%AP
MU!2L4PK61:"/-2X[[./D!'.F<V.J0$T^>=J_.V3]G-"EK<^)28*:WU+XP)O<
MGS<3C?AJ&RA'517+7%=$D^P))R]U:)19&\/0IT<E4BMZ#R*57%PE0]?4JU%Y
M'@]3ARR_Z5?467W8MKH,?E K6G/Z-["%26LR7S"D1A33>WSK0(IPTT1NVI%C
MK1?7\D4TO_FZL<7"=\Y6S(>MCW6S F]].&X(/;HA6!D]$2DE(4!D/('$B MD
M\XSFP9D+@578I*.H6=DB/V(%A'MM2);EGQULL?+HATO2&==L+[31/5S!+NQK
M'=!7A2\U0X@/]'IPPYG$ ,J,Z8V3F],W#0H]2LA$/2P7C+$A0DH_JXR_+\;5
M'%)R("4<ZKSZ? -)!EO[AA6]VD$[@^!-C1V[XBTXG=OF($07$T9U#F<1A=@!
M$F$P\9V61AX3GM*O,)6&&5#XPP!@W_UP!"3['9I-E=\2P)?Z0EMOH^8.!_/B
MVFP.+TK;,PB@7P#Y9XL_>SP_H3!H>M1';FD*MG><_N6\D*044/*31MH[(AN@
M?T-)Q[2YY>>&/S^L\__=98[2@FUAVSGA<Q(X4#A9IV>1O&%.-MU!V QGZ,AK
MKPCDOD][F(C111D$O35'EX]--1SW01!-N8+6H6-"[FK,-Q%C#:B^NQ79'&);
MO'G?I2H2Y15BYF9"H=%5YY@%1V =F>*3C?39XBWD_X*,I,!7]0FD_@<E*I8&
MM$3;6';0TUNJ?&A7=G%!CG>"^&/Z9EJY@W"497 DW:2L39T%)L1>AA:%E<L8
MYIIR6$?1Q2(%I7K9['<HE_FSD!D9<BECY/OHKW["LW$FD7N [^1Q65AE,_U<
MF:R\]44<UV-VIZHDG)<%S3S[Z#DJ .A]B8;$2A$Y/U#AT=?:/HJ9;>ID9"^+
M,B_1[@]#>[[A)BQE4:5F(N^HA%\I0JJ;C/1"&_@*=@NS@880&P*[7GAK7>"\
M?5\)XE'GRZ$IG-.\;+>JRYYI<"U)E,C5VD7/):/MG3H#&NE7F-%G$V]1VOCF
MYS+MK(:HWYAS 8R65,N3_K@_R>'/#%#P:5]^OOB+>Y/?VBSF'WD=#=2WT4"=
M2:?=HSP@OLDG+_/A<K7GF0!2SW;&(JN9UN0%+_Q#-G-P=Z.$?,NAEL(BE02O
M$Z]N?!HPWUEV_)M"E/*9."K;VT*Q_&/DT-0;,/IZZHG",H^'<![>T,Z1C\+%
M:GK9A/S275"C2G8]K*4LLK+/CT\M+ZW,W([C#OX=7*^&Z<ZR6U?D U&U1P!#
MC<._, ?<@ET?Q!];!4WD?(@W-%$B1B:#QPL$7[*,7Z&$>\@M-KBSY6WD;$X&
MFB#-3(FSABF@&A6W(YC(I&;MUND3<3[3ODY&:SB2RXAK*EEG4I#<M5Q#2WN/
M6+^NB+=Z:<ILG#VLYA8><YP-NY/W)&T7$.4?)B:IDEB(W((>#1\X#+W/&[A/
MYO.1K],'(U5@,<U1A7B5#_P'+&GSO++%-K=4D1Z.&LTF?<.5QC0J=1I\ZO%I
M93 O$"= R]F1_8'-?][U0X"9+[-6N-><<))RL$/6^TVSZ])CO)JKF#'-R"GO
M:?"*-)$VV?DH#CH6PG!D 5;^(D(/%QZ)6#'2>44J'-@ U+-/^!/J)K&=&F,O
M/9?SX58-S&P:1#G5M"[T7'Z<6<UWRD@<LP$6LNY<UDX*W'<*C#4B'F7CAKE
M1OSJ+76 ;&!\&=W+>;WIZ E6F9-1%%,?KL4<(3N9MO)K0GQ22O""VD<"P>?B
MKW]]B[:=] DQ],"&8Y_6G'-C[2BV8G5V.[-3& !)]08CP@FAKW%D$/79F]QR
MJQ3YNL.BI$< EV6PLNF9*/&4Q@J;U#2Y1[I8]&6QU'Q:%>9@/&Y$>5OSL4(2
M".D--G[XZ\F9UG6:J#=ZF-Q>=BS8('M1CL--(#Q;!Z_<".Z<EUGUFB>"S/B4
M"R$S90]F'0Z-4B*;[V7W)__Z#KF3W&5)+Q"."&4GUMXI#2TT%J;&<K+Z2\9
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MI-5;*^F;@FA=;4WPS2LB4!:,F#4@AQYDB2'2!:1 N(FBC5H<>-+$#6"R3Y_
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MPAFW4I>_5 D0"DG] -"MO-N;F5!0O=N3$DJ: HQ*'H!Q!C#$RP\U4/Z HD#
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MP8J%HY-WQD#Q.1P]OE%!0DP91NE7BD8.0HE26B@-XX9A=4,6&%I<W/;+_=4
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M/.*ROF8W7+'I0;9MET^4S$[&HS(T%Q3O29.9:6N1TQY@\V_3A?^5+!/]GA@
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M^I =1KK'#:XKICM-VSE= &XMKK>[TW3[Y/#$G*&YF0(<=F?&CVB(L<OZ6@1
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MP5ZLRSTS<Y9;DZG;' JD\Y$N4<A29!TS[2(VQFN#4)FC&R6O<6"PPZBL#PQ
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M)@P\WD(WPH05@O)?2>BO6#'!A&T92$U'"?UX27FV2DU4.D.H*1$7E*+'GM5
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MFJ_Y+-+Y(XVAZ6+ILZM^#SIIEO62KGL4]W:,HHI_R527@TJ5WCF4FV\S;@=
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MK=G-1""'9_]A9]*YVYK^-R'Z :K+0J:\NBR:FLSKIYF\XYD4TQCY24%YL]A
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MFJL_*6\B)Z,HATL&./#7QZKE^MY7[BA.1'CC*Z+NIJR0L;R5O!8$VR'LN:<
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MXW_O.X!ZHY2(6;Z,87OT+,(BEYF+;U?9SA;5VJV<K(Q>ZE&FGT[>VGUN31!
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ME?"RAR0V3(ZHT_N5,!S+:,HXEJEW<K1UI%N6:[^/%93",:0O"Z!D-UWW8X1
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M=U9.^AI=HYU@B5Y&FG(RV>WLD1I(_1.V@-;&.XA+2<HQX&T?[UL>XIC$O44
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M*3S?!)\]QRY!J*7T\,DK2B,F .]PMW1]$_VPV.VQ?9Z>4WP/^2C>\:L:119
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M+I!Q9NSQ/:"V[WW9O%Y+"X(_POPJ)V"[: =[,M(==F=")!%\X2Z*O(7\9-T
M:"$@6SX<!Y.5F9Q2S3#<P,@(E8KI<L<:5[B3T4<\?_IGF6QS2SR_[2=_89)"
M26X_Q4^?/1:@U#\Q%+@-U&^6\A@$IUS[QMQ#]LK7O)<UV#^[W8O-9RTE5X3Z
MPWKX*7'$4#U^JBM0TV;GYXBW8*H]$M*/A+<?DB* A<83ZE 0%<HKJ<D/SH(^
M)Q2X<R68[:N>3DP8-'QJX2ZBD@R N66M4N>,QX]?B9 <8<#\RQ+[ZD?NMDOB
M#VH.(JQOV 'B1 K09;B7QV8WV<F/QB[$XVNW-W52^ QZ!J0WN1L_8'J,9D=Y
M_LLJE_CB4;0KNMG_8^]-F-M&LJS1OX)P5T](,Q#-35OYFXZ09;M*72Y;;=E5
M,]^+%R] ,DFB#0)L+)+9O_[=+1> ($5YD4@)$3-=ED0"N=R\>==SNN !C1.W
M/I6;#M)D''+%*]6'-F4+MFRAU_");,%8F@J$-14(VW^74'"%\U+=PS85\H(6
MZIRNU488R6 ; 9T7_K9\F;ME/':YJ3<5/1%6>5)#J9\R4/D-XM"5OH^W>VDX
ME#BFI".;&=HT6&$06)/A29H&R+9=]>+P:B_[</ML@ NK1T0AHV$0#:7QNAJ.
M%^@ &RTEI.CP6E(@58^ VFHPSA#IKE_[=D2&-E"QQF[!<-<0LPN4V$1S^TXA
MJ=MCL@^^+V"R+9+"E#8O15U^HY7D<(KUK/>P)5<^,@PRH<5SO!^?GI:#0P\Z
M+85A$V6=?CJX%?A2"8?B)V.-;CM0VCQTWHNN>,F AVLSHDQ70G0G:6$[#1AC
M56<AU\>+3>"IB(U(K/H(KM!41:,ZZ(X%M>90R<@P2-.01V.7T/2$>P,D!9W2
ML$'(AXOZE71L: Z\(#3TG'H(<&\, @"6$^^;CK%U(Z>>9DV:AXZ3SY.A]9/T
M65W\A&2>9Z9#Z]4I?$_<C0<_#F<E%]Y64ZQ:6W3MA\3\*CBC&QX@!ED58&MX
MOH@?YA,P\L6N)2%13!,18DF'K$I;,-PRN;WR6,H88#.+/5.D(?."49^MMD-%
M7,SQE,%4Y$\T%TR<<M.ZF9>F(70F5Q4:# T8WWV4%.3LZ6@L$>HN]O6J+#OF
M(Y7!K_@%B"-MT#W=G=&PB?4K'A@L3^5@G=(]L+FT;DT^X2H/9G/O52%@.,Z/
M'Q2A"E#6\!$=0I[A2":,&+"9_4TJ<Z9 KL3UKUY]^&@BV$1//9L3DU1][B"Q
M"33JKAA+%LHI6=FS+9]RT$CM&Z,3FT"D?1/[UI@2VZD?J'WQ/D$]F+A$NV62
MBQ4KANIQ+ ,U#['EG=<.FH='Y*)2,!:R7B#H9,($I3H0#5""8V5+#!&=)/"J
MQ]2!,;6\C^X+".1% ]W(VX0"*W"+U A6N?PR+A^C#&GIHQS37_XPC,R:?IP.
MX&]G)8GP<+]_/,#D]A\4+NW1,5^Y8P@9.Z;8&JX36QC4,MF$O:JC4KHMG#*/
M-RFVVJ,%D.5IP3Q_L(I6^/:UR5IR4.;!0L+8!C58S&$L]:2<AIRGVI(%JVG@
M*T5LVL01NQEIOV8"FVL?4C$!JJ>)(;O(0',/72H%J((7YF@X>@ 5A"JE[;K<
MFB@98<MCS80%?A(%(_02=#GS9,<UK\QT7L>P3U /7'7$Z/U1,:NK]?!5QJ8N
M\JJ]006I ?<\(CR^F!.^:]$O+PW"M<R"$:<<,%:,:I7AM%0DACW7?F?RT^GQ
MF<%%_LU[0TW]BM@ .Z<G1SXOMOMA_1R-54Z/RW)$VB![YM??/YR+@95I4T<C
M1"-6Q<=SQK=>'KRL0.;87 )9IITX AG3AEC=H- 7P!4C;X 6 N0?7HEUS0M7
MV<*K2(=H$<?*Y'72S**T6NC*=X05U,K1L:^HNV@V>*;/<00XQB$!10V49L6D
M:4CQ=>U0UKR(BD03G:4,4WUF?)W()@>.*UV8O81&@7V> NU551RA*037,T9
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M(L<!2Y$H#,_E<!8?PY70;VVAW9X>\K,5K53+[8E3SD5.E4Z:%%&0EO,.OA!
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MG"S!)=!^[RJQB!$NQ0"\6@J2]!=7SA5[1BE C5FDI?<Q4:7;%^&^AJ:JBZ_
M\-36KD#L"MTT>?4N285^'..*8";I($J2SP1>8!>'0H]",LI4S5BA+S%,P],!
M_D8A@4EBG ED>RA.AI[&F)F;W2DPH+K\P9F^F-L2QG!YGS5YDBZUJN50X*X3
M^$)!T3,6$F:N'H7DY3MLW<;HUQ]TK7X*588ST&!44N:+W*Y<JLIV;R#C+<\Y
M&L, ;)8"1V4.B:S!>5!05B==@-^9(S.IIJ9XPZ/QWLIHKLQH]%IQ//"VI<SJ
MUQ*EB3"W@EBW(@=20B'2CDA-2&%O]M$A"A\&Z&M5=H+83FNW@0[[=UW=K[YR
M3K?WRGDOY =;>2]L0H6,S>EAC/TO<(W K>D-PF0^#4"9#8DJBQ0]]_:,,/6<
MS*E+/\$L]$=OB(&9<#8K8I=>"SMN1J3BZ03#7#F1CQ6&2@05OJ(Q0TA)PCI*
M>4.:P'!0H])9*$A+$SB3[\'!2^BKH6"(##&ID;:\7U5$XYJ#"G8OD1!D&!<O
MY*80?#4.0F*GR'T>*5US.E5(!E-E#>-XI"8'I@.'EQ%^U!2[8/ _34!)S,.Y
MPI7&OO$0U&U I6AP-(AK'=M%%'5TP'60$U-=KH;3&#9\ @-\X>4WB7<=IDCH
M19$H\SF8^OGT;/3^"\WK]S_.6)'@Y[,%#%7AHE^].[MTOX$_'WQ,(L7MYA?.
M+BV\O6?\YXMG##U&/YW3:M9_\AP^V?K(B 7Z'5)7@.E/C.<)?@T)">6=)BH^
M, 08&TM) A?7# 19,GRT]P=CE%Q\RQ#6?N#4*+,,\H8;^9K96@S<UBB?(OU:
MA--K$4O>VL$$U'YC!W2#E&X#*F1(!5I+#\O,[OS5R7_I\X H =<HH946O#6B
M[0@S\Y_ ZT;8VD:QQ?-7_?^B3SAOR7RIG3)C2M4$$1:1O5XO"EX5SI%9UL"[
ME5_^-4C14J(+K\ B#8PGPL*Z1ZMT?LC@,@>D]M3Y&G,C&%VC+8K)97..\>'Z
M\&+8NB0EPQ3Y"JCN22$INQF.*U8![HYC9OWL_?'Q\J"'><# NZ0007>=-%I!
M)""1>8*AD5"4<A(+$WG@C<$(E%*3(9*E4;I3Y.W7EW\8F8M?T "ZY0$@K&-6
MP$4UY)!J>:[,>PYSQ-P*5FC!EAR@[>G]>OD'F[LQEH6!_3 SMPE930?84<QO
M[%#NDST([*.;I\I\U,BHJILXG$!8DTAK!-%;SFXF7$!GE3\-"4Y & SU"6.%
MB0,Y.:2I@Z4%_LL!0WDPD=I==L.\-%6FG![D(2<\>KZ4'F^=QQG68.A.\4R5
MK[8TF:3!C,\5H54Z-36DD6#CN$"-3QP^A"K+;+$4/F^ZB AM1=_D9C-JCB+2
M;[W^<.5[_S?![!]]Y1V(]!6BD7KGJ)/?%JA'^7[;>_;NZOSM.=QGI;N=4!:'
MR0&6HQ+75."=O__CXM5!Y]2[#H9#U >6#2&F4R]E;N^_@"2.=$[09#_4%SCU
M6.H!-C76<\:(9@>W232B$A%8@C-T!_\OR. P$/Y-_7[C4*GE48S4+(G9D>3D
MLZZX@R?&P75(Z;J $R[D,<>@%1,NKZ09P+6EN+1-89XKI))@HJO0KLY-L- ]
M1$FL\:5 0U"1KAK1L8TQ45/*SW&O$.M0&%]"9E:2C _@_^"X8?&PJ7@0@T8?
MXT=\7/Y$Q%8P03$[S'<);+"7X;+G9#Q@QC+-0RQ+TI<)^G'@484)@^\EX%!A
M:GE9-XN]17L+E_R_"A0VG6[*Q"@S0J'-HA&,YYK3I:3&V*<C/5]2HNNM<#+/
M0/!U(;<8,.QTTMD',8#UQTFB4PKN*38H<PD0F.98 HQV#IZ.ZP?!\MB:\A',
M<KK92M8D-THS#9,EDX 7[Q2.5/B)T?"[L@QZS*/!A265FI05A2:^1 6DI+^4
MCJ4/?X]\/OU<D\&_3$-.A,MJT!J-&:>", =L4!&&/V.L$0I4P(_71$6+]PH+
M<I6,#M\Y)]!Q+ W1F'WU7XR2():8(ZBL:SR8C N(8ZO"_CFZC\8R20,]9U;X
MI MU/UE&*ZR(*)D(]F T(=HM"_FK[820YZ%AAI&6-(DBWA:&\63C/T"&Y;[>
M$:^8PW=B\SQ^POM/%[B9?R]@N4#VVG7(UU14 U\9,5KB68:'EA[!<7!05X5B
MV?+.]&1\C0>(;WC+MYO]J_L\'<B5^FF[,"ON-]_[(_CR;W6=A@'U=PJY(<H*
M1U3%:,,P(0^-P4EM*4=R4Z,J87WI0J;[R;P!PZ=@7:*T-<E_F_P_:I+_6S"6
M)OG_+>PG]W6Y)P,J('?B+X&P>+-C29F>6+EE851Q7:>AD-H\QV)'WUR<*L4,
M&;J_3B2"[_@;:NM1@A(-SO9!W:VCE7R8CKB[<B<KR\"$.BLF6)G/A95=MA"H
MZ"O '(RMX[RJJ>/LT64=X*T$7]C#>^?9U51%XV?[OE,T5N:[?_U%BM;.C0'#
M7E$D->Z)9*N<EY.M8<(TPET?:A[W]=C!U=;?&N9C;)P=Y$[]((P^2(W9\9RP
MX*0DGHH/D]D GLG#Q2PFM8YQ#;XI[;35^ P)]E.WW6ZU;0$Q>J:T6/ N=!Z&
M48"&5+GJE3>G<\R[P\@,Z%)G(0*+!;$"+P(1P6.-P44%N!F1E]N6>]J*2EDR
M-HW*Q\B@L&ZF=B:U0>G;E3;%PX139^=6J:3V?CH^M%-=LAS74%!SLA*!*E ,
M\+]AK'-[07X PSI@C 2=W-.#S-SZ0UQ5RM%B1[P".W2 #(N=H_:+7H=6LD=R
M3K9_Q^_T3OU^O[_1^.Q+*FOLRWZ+5S^A.&;)TN^U.G;S=T]5_"F1)X;!Q1("
M<&60F0A>0:T7U,4*6G)(G^&69HN#DIB-\&0/.DP-BFO)#):D1*J?8HVDC5-^
MJS0_XJ(>MGK6>;(^3%!.SXM)BUD(!L3F[E4;)Y+=A(\:&Y9]*HP#E8\16.9K
M!UXC9W5+1H>D9QV-]>*J&UBZ$@$D0&XP[(N9\#^-%(:<<O$_CUI'YO#A-\'+
M[+6Z=J&DD(*":+[&R!:/P%(<BF]@VH%2"8%<4_9EZHVCY$9.K.-(FLPUGAUN
M3V)]3<K+^ANT*+0B\F78%ED;ZLW(,6Z6Y5+$_ 6U\S4"1&L&F(QR#!+M7)%.
MT-)G@N).8,=GDGG7P,!*^VN$2(=S/P\DX&]_*S",U&H_I 23G&^<CFM4&#2.
M^F&5/%QT1$-TMRCYHAU9?)4;A +5G:2YV]F/[S1=DLQ-+^_'8I0"2Q68]T;0
MAQ9\53,*9 EI;P?-EK.<"SGP@N"X3Q!S%VR K= #%%X8'U9?D$GW.4YN6) "
ME$0?O\BX-"/SP9&#X6W;8O3"4_1-=]Z!QE!9)G0=.N3$F55GS\166"D&\DSS
M)2.M\G&*^!LL)KKUBUCWZ\XQR@&/P\TD Y<[_TU? )XK.J1AS,>4QDY"@N>%
MJ4.TSJL9FQV68SX+NB@!C!J6N;@ N<-8)A5.T9)6:J=TBX?T$3@5#W6+DI@3
MMV2L2^.G6UZEG)?A6O^\L3#/,3<23PXB-<Y_[AW5BC?_*B3(C9\/.B?W4!&S
MAH3^Z,6/04;:9 CEY>KT6X>X%N!QX4D8%Y$^!J+XW$1DEL-FZ6R\_F6.4IJ]
M:';K7G?+YJ66"D_)VJ&J4KB$X$]#/HLE[6;U7K._6[B_8 ^"U:T]XHMWKS)3
M#ZL;PRK[@W>C.-/-SFV''J7,/+R/G'K,4)B405G#-OOU@/L%IDI@"WK-5HC1
MYF7%'%/-9&&R+8-66]F:02>5SRO^#6VGYP-P1<>A.%R1<DYO;74&5^+G['W.
MDWG!\;-&%.Y5%#2UD$%G5;'6P/:Z=)U,^AQ&L!SQB,2-=J#YEP/?')>4C8\(
M"\!0.AC?SZU*R:=4+L,%9HU4W.M5[$)V"4*OUO 8-( ;5_N(:7!CW+:L!+)J
M_?AREH+K$,OZW_<R^$$=%'-MVI6C !2IR'11+-8&B;I8XY_B:S"Z1"2C$W85
M70>WK-#T$[ <LI&U>Y0U$P6BVH^0T1PD7U\6@G*9=RJP1M34LJA/;1U@:FOA
M2F):$3^\ZZ+%766E-*Y&7.Y57.)<TU_ ,$!))3IR:^AA# <'?&9<I"11-=&M
M>K71[.9][B:GR74L4\/#ZZJF"$''"BG^5:G<10S EZEARL5HN6XU3%VK0]?9
M:ASQ517[-I0M<'&20O3=T?A@F,#OAGJ@(S46G&)*VM>/E?".=%PA"&>-:#V0
M4XJ5UD$1#Z="?AEDV+5  %$ZQ\]_)\?4:GD38%YI8.CN1FT'-SO\< $C2N+*
M+EF 7?9)):XO#'6ZG)F[A77E.FZ\;2)TS8=YL$C2NVWW$ZP./&ZJ [=@+$UU
MX!V@@1HE_.U*&%7H/%6@#96IL,)DK@/V'8RX?P6K6$ 54V<+IG%T1G5UC-"Q
MV)NK]<&<\JII'IBJCY$;!,Z"L<H7.OPKP3V<7[OSHK&>MFZ+5[M>W!T_))(/
MQ&! ! AJ+1DI\)&HQ8+9XY5M*:FQET(WA$R$]EF8HJ10WVVSU_=YG'51;D3%
MOW-EO9]$AT?28+Z;1>!G#HHHU?T6N:ZOE (F[DC&( !-]CI(0Y3#; F6:7T-
ME&[JIA TIYUK]!H#ZS@MCKCF/$!.=F0:BD2*N"KU135CH$JKI5<Q:C@'3!FG
MENHPWW#$:T8D(4Z7'$;1"7$*F6[+*R:386U,Y"I2QR=+F=FU2R@UB'X2I7.D
M]A(?&5/[L&W8QCX]JL&8*5LD27^A'F%I#F5(:4D;"-9794$8LC[B"O'*9%K>
M)R9RX+HM:=K"!DC3#Q8@ECYBM%#MO:UJ+_6)K:IT# 7 ^!JQ\V_<^D\N/>',
MAJY!P((UGIRNA=-=EJEI+!2L7U/W+;7[4LE"ORC'-7VW:S E0 GI2]1[(O4N
M5"I8+>^7%!N6LTX2>$3+>QE@QWD2KZ_8I-4M39DXE1&L^(L$3VBZO(OP#YP7
M&8$BW3PT6Z!CRG*$'5YQ+2#W(J.L5&35(#:[<D*_! DK4E66&8H'\T11_#&6
ME^9,-8*0^=2M@!:H%$LRGLM KX0#C<;S1'FF71<^@QML6S?2SB><0(JQOIIS
M99%RI%E7(%%K#PQS^!F1I9&'P"SH+M;07XQQ_&F Q _+)UT7*U>D5\#M$+4!
M$>.9MFV$O3'(?B*!VQ4BOMRDY&MU0\7\I*M@G+#$(()()B_E"!1YE<;A,K*+
MG%5]^C-L=9]Q=?BR+H??4O>N1FJ@?GN$-''D1$A,QL%UDNKRUH().@1%QI:]
MKE@Z*FE&Q2%:YJ:.LW*D(F2 (D8H7_-?)8RP@J>]7$5>ND&LAEJJ\M8%PF:F
M=NTL:I-.^:^K N8Q6V(0;JU>\9P$C<>HOKU_,_RWP^[F^&^K  $V?-/A]B+-
M70AXPMB[R-) <?G5+\&_ X0M'8/0YCNH9$HLQ;I**(VU]3"4F:'Q4IFUQ9>)
M$[>G@^ALL#8%T[^L]>V7X8_\70;)-(TWU'"@.<^D+ZP.RO+&(GD(W*+@692!
M/)WAD/U8 YFJZ_/A.,,M%7W]V3C9!8DEQ)S/*>)%>N?8U[2=.+K?)*L9F"J&
M@%,F:X4TP(*63(TJ<E-05E(+@??G'43:O.(E7!9IP2;A!\3=%/G.-?DL0N["
MY<*=4G%2HJ5#%*\$>YLFE*XH0[3<#M;[U7)[U-D%N?TE2@8PW]>P#LD,4?XL
M Q>N\ 5HIT!#P5Z"=&1P\>ZD:&,(D"O 0+(F/&NE9STLSWJBDGF"E3E#JH[)
M<\(L=)+KUPFNBGZ:%1LV",CI0?M! (),'Y )'3/9I?5::G"E5ZA5;?N'[L;,
M]<8P3C5W56H@%2(8L\R#X.N"I%/_N*0,Y5>_P9=&!#(R<@"A:0J3$.&<4C2$
MN%=0 S(2XE6J_0QZ6.NJY</__M9R_"999W%4L/U+L([1XLP2--QPL+[=D)1"
M;33?*Q <#<-;-V=?#X@[KITY$\W[\B,]XDG3(5_BR\G17$=*.33ETV)>:IX4
M85G:9=EDV50L(99MM3ZT\8-MM1<3Q%LTLX#R^H*BR1Z7/+_EG1DUAIVAXBIP
MJZ;NNI>ITV"MN\EA&>D+<Y1A:07-=[]>Q?4W4'';0UEQK@$E&?$>5O&]63&!
MPM]*S;82_+Y^FH)FM)536<^LE'@<";1V;^XTFV,PJ!3FXC"A<>,$ P!#/U4X
M)?A%ENCS3$B>?'Y*[92_)YFII-/OR7E(%O!P!%,S=)T;8$.9-G6!U."0I$5_
M:FHN;,W%25-SL05C:6HNMIN.::7O9OC?V[Z!3=(H-'?25&')#R1U:,)H&">V
MV*8=&XXD2[B*<\?A<,8\"*1O58*/[&(B(8<\?+"@EU<A8S\)QDM8@G>16*1F
M?.?0*?$Y6DS @*%CJ /:P1_4[>IIL@@B@X,TPQZO'*P#0C 49D@9TA(^25AQ
ME&%L,N&61SB8F(/HGFC(%!?U<B,X00Q *F8[9JO4;2V*AZ9;Q4YK%92**1VL
M*P1U, @_&20=C@=3JM"B^SJ0OGK[+!"+9@6F-4?F(?MZG^4I*VV466HS?G9;
MS'X0D<V:X;*W,5#(^,H0G52V P]1:.AC/4XR(@B7N? =$!:4Q7S47-LP&!C?
M6FDJ$WYV^W]UU_U626$H?F.T5'!J<,-6(,P@"-5/;8M%ZNW=!F[3]7[J]UK'
M^@O[OD5,TN ,G"W,C'DE_)56Q@+V&>Q))-N'&4Y,MHD0XW7:@=KMR-\EM.90
M X<3<7?.?6](YY.C$,!*#CAW,"705A<X%]<HA:UV<YDWAE8]&8+/LXLY)L3V
M5)S3T*SJ3E!7MW. Q!*Y$F5@!Q$"&3.T\?*IW$Q_$+0N4;&'.B('NQ-G8TXB
MKJWP3^)H 8=G."0$KHEXGIA!E7.1P*[]6P.CLW LM$1H$0LRNXO4^(B\!B-!
M[?DZ8<!PLB,+'R7VYWO3Y(;Q5F+D7PDP[Z,HE\3VOP:&@[<P)J$^O +"(H@_
MY>(!&"?Y!O"K!7@/ODT,:=09Y]B4'XN,%+II?(:-_FMP\G?(J[2N\FO)96_E
MK-8#+-;GY*LP:70\4:-AL^Z(A7!%88&M?V$_%6-\&.MFK,1K*9#9,0&H7[P/
M[AJ\<M9@)^6A?0Q3N@IUS8O9?!M\($1Z-:HH)ET+<5O%B3#DA&7TRZ5"5"11
M8EQ,?EXP4G%R':9@G&C: -]<$RJ>2C21AWQ@&!?$&M<<2EU-HB0L,5268YFM
M8/$(P\UA!M'O-<0RH*J'F*W77W#L?$N.9"=&S$Q[FKC$TBU=[)-MH '4:Y!J
M2D/#6C9$KUK1+BU934-C4X<DYW0X$6:7,TA-?U+%74&[3 A<? M+CW56)J=$
M8.\Z9%Q^6RDQ$&(I66 LKE5O(G(:0Y.#_SAJMUW^%K:(53!:4+\>_O;0^012
MS=0UGK>\#[<+)(:<J6R, /6\"$XGLS&XZ*!+6M+4"TE4;34ZGE:K-E50N5W7
MC%+T::KT8T:\J@S9J),?_"DADVQ QNZU#S$ >:%C6VI&TV!5D<7N<_4>.>('
MG-BEBMTX$_@X3;R$>/U81C<))IS\72E?F@>J:4"]WZ)K?:P-?NH*FH7-=/&&
MF&7K<#O9.UH+ NY+N2U7"!!&LWBK8)_)S1@, XX;A.#"AGEATZ][S\X_O,^>
M[;_8W/%L).W[]& -)1=3-@1&:6%@*ODR+?AN<:5I">BBBLUBA?"N$D1"4QE3
MDDZ"6.H/)1 B<B8P&T;4&GUUGU(D5;L(GD#74=.F<^\[P#49&O)86P58!,RG
M<X0!2NR-T,C84BUB+$ZVQ<7.T^E><@&B*!F2J6'HE;;2^[RCB_V+CB%@%+T<
M1]A))]L$72;.Q"H!$F-72,#%P8W'2+LV#0^T;6FE8Q/S,HRERT,-"WR=KSM=
M?%/,NG1AL!16AFFLSI;WGOZ^R92TY,JE0 D:)88.-I9R/1):0$BQC4C02@.N
M%R-B&?.)18O(MM3$?I"25*ZOY1!0D?N&V++L6]LC1L8V[ SE=;AC"JG6A<M+
M@/!YO:@'1NB$L>R29HS5 3AC9.PRUKD-@/$C*?XY#L*4^A>8%)@<YPF[=S&2
M:G+0H>5=.:&5?Q:C"6U!B)1^NDE 0N><X*&(L=10C36(&^4MAE.L6+8-9LJ-
M5Y2, )OGTQ6D3CFT=FZ5DP_DP8C_2CT9I*YFR4A%-B^W:H869#_9\!@0$I3$
MI%=ZT *X#U_2O C687<<??C.(+%TGM4JOU(M8)G5)5J48/?+)H^0L*P$V=^H
ML[#LRU-8W<P52]7A.5,5C#A2@6D,1B/'+FL/47 TKJ>!0W)K)S-+"2C4[JZZ
ML/6"=>>'#IJO@R1T!BN(D7 DC3K2!W*IS\]M02:P6&H6TCV:3K.7R%!3"&0+
M@4Z;0J M&$M3"+2+A4#O@FP4_$O7]?_.'6KZJKN=_,L7,QO\5:D=89N(# K[
M.]!FIIH^*U)2;7!AS,)BYO*B)*EA$LN<BVEC8WU[LI]D 5T0U=%S;T^L\?VM
MM,;OZ'1<Z)IYGMU63FFS"0@3E>ZGJ)#HFGXF_"C7(VAS-YN"(7& MB9;OB.F
M&];=VHXM##9)1-4^+^')<3XM,N]EF#CD[9FW]^FW?>\M]K5*%U/)RAIA/W&J
MK2WJET5"=Z2^?10NK-D,.2);.:?-9B#&X3IYPIXW3(7EH8:0-M4[3.%'_2::
M*1H%[EH*>B(53_*I-OXB;>)7ZB[1 I;F_\<1X5A91 #*!SV/ZUV,<*S,9H9F
M4N33(85JI720&=FT.%5\M E*"U<L.OX)&#ESL7,H.("0 6J,JFPU_$6:_%,-
M\VH3F+R'6:V<G#!%O.6QIL(1?3*Z!%G+;J<TKF\OF9*A@]Z@35ZN6ON5:^FP
MFB,I*E*>#93.]U_-D*V,BB_@$\6,Q@=V%JJ4.3NQ'_XCF,U?O'*W3C-5[#V[
M^OVU=\D_(6DK5:'5E%-*1HSW%'UT!CO07/(Z$8M?O4G2SUC*H/,0+$,%E5M7
M$AWXEO5%/H)5<BZD[F;8'UZ]/K?CWBW1H$*@3X2U(W7;1!3I\)?:/;&5V1H"
M(Z-0QXA@:QBD"84*,9U#RZ#(%8[4/DGBYD S;U _)&4:9(:D:B#!JCTI? X^
M2Z]G8HXP20N5"L%FI_+YD1(Z@'TAB>WU6KW#OYKRQ4W&Y.#5M+Q_V"\XO\^X
MG$2 N6C*:C:/DH53W3%.G+JI+ _&8TF;S0C&"F&><BZSLNDS!\3)R;<YT<<B
MUU#ZICB$L]2!K0(WS]!GI^6=,UM=S3"\/2=/J!^^[[MG*1$[#H]F&DO0#'E[
M,08$YPZ;V>^XKE+[ D<BI)NA;NMY_[J=UM'Q7UO>V7(!#Z^ VV^VZM7^4KZ=
M84U*T3ZG<*@Z-EJB3*?_^7;!!A&K(]VQ,VYX31GW>F"3Y?#4P]TC75 6;ZC(
M7S?;K-(5MQQ#ZB@<*1V()+W0[;7_BKO5.3GZJV^>IR\;W8:(K0&P]*8CD;%S
MY!&8>^-GP*/VU!>L:J2=TM>.]#I?T[--BDT77.G[09,?89D?"J S!)@$O63?
MMU$%'*6SSYR87S_0(':XM?6#12?1$K2.8 +P]>Y1Z_3XKVOFL,]Q9EI .A/T
M_6ZK\U<Q9MSS6@&4JUMC"D7KG=%+.99R<GT%&O7"[>2LC%DF= M'P5!N^A6L
M")B"$V>_/!F+KA*V5,LWGW#?2WT66*2"S]&DO'W<Z[&52AG!/HZL9_YF ]K2
M(8.>9\#$6*MFT=\G#R6IH)7MU@V_9/PY.%?Z'G=3+J2F-C$ L\K)UP91.54S
M4,. RE0TP!:8!?$$OB97 V<K,K(<,=7B&HZ2O&B!>V3:^%EJ7W_BB()W%A*@
M'"-IL;CQ?@6A,#70',N^92"0#G(1XJS_XR\GO:/^B^/6H>DY8MU F ."%U*4
MH MXH5R#5J\+Y@"EU%/.FT!-("[$&\$:/..Q(/DXG@+*$.&%3=-)R%5B(#JY
M2>CV6*%L0TIJ2CH0^Z)Z+[IM'ZMD*>$B@!OCDN;NH U,N%Z$]9PG8,FG23#"
MCI=\FBI%71SNDE["4IQEWO\FA?<Z2&.P?"_/_O>U6.K>.XV3<V%"HAA0UL!P
M8%$\>W=QGN'';?C4=O9QE@K4E=X1;L"3G@3>BWDJJ-,"%V&)RA:$AO@1+4W[
M)<DS9>XK! ,0U9M.,),)F>5JSME'_(MB=(XXF*QD+RG5/4^#:_S@':V=BE1*
M-:%RX?%HVJ,$YL =_<3PW6'#U6X,R0;6!U^(.5M:._-U6BB?&S89O ,#/6DX
MS)W^.&GP<T5/-__0:];RS7NZ&T_<J9JS0?Z#+NG7[^<60AJ$ 6#$+XD'H?WV
MWTP/H6YRY#8HO&I!L>AOF,=280WA*IFVO!7'M?+X-5/K[6(?WJ?8>&HP)9BH
M+"PJ-SP-09KB&L'T;X(4P[8CL'\P(A#I Y.,QQCK"ZAD(M?*'5:1]HI@PO.L
M='X-%S>Y#]IC24," Y("?[--G _7(D@"A[BO]L5$"$+; L(;27B9]#8JN\-6
MVZCM>520A4%I;CQR<$ .VW1B8.*5$3< %#;OW&VOSCO? 13G^%F3K-[N/.\3
M3U8_%/Q2*HAJ9]83N4PB)$'GN,,G1H5XK6&-=^^:^8B6!:9["D8:X^[H(%ID
M(5FF=3B9<A'40,"%F05UIKJJV[ *M;UDN_NEB(L2D0&U=-LJ)-<A3.&R".<8
M]I(:-<.(;(O?RHG,O6>_G)U=/MOG>XO?8ZK Z@9GK5&R*SE?1L2JGTM0UK <
MNA90AT[9>L<QI 13BEZ"-)H3:D&F) JH[6HM4;@5<--38*U<B;CJ2S4@J:I^
M.CKZ43<D:5KW=4J:HX12:S;BN)K]KG7)"3X$Q!8<1(0WQ^W'#G=GP127(*)-
MB.0S>MG<\C9!5;$9H\W*,;EL WR$,-6%E),D&5$XA"LZ\B#FT!\O7LO[W8YK
MP"!T[IA0;.$\Y$E*I]X2Y7!%26RZ/3FO)&#*Z U@3:B<BP@FS-M5Q32WKV:\
MVDP,-8S;) +';GS%89@.BUE&]&H(K,>NC#YV[ N,0D2QUQFAQ 58W\& QY\N
MD*^ ,SHD-<[9-RH8XTM:1XNW(*VWW(K#?F)-S:Z$P<W&B\*H* 7"15QUDFBK
M<']&NC5:)%VW.YMC5@+AQ^W;O6JB7]QS=5F ETQJ_L*>L#,Z8;L;**>LVI\:
M%/@61<*I!*MY3& S(&QJ=-DQ&H'L ^/4M&2'8TW!A;7(MOB\=-31DPN'##TE
MAP!]/8I0:'WMA ,1W00I@F!L%JI8128N7IU.9>#@PH_#%'L8&-"%Z:4H*))S
MF3<_0%]]MK[]9JHXN4[U[S35*/RL-,\"#L^>XI(Z#YQ+!(E,R#WDP#/Z@*C=
MRA/F>"/=+)R1X#$0A4YI%);N"(8J,Z(!_ O!K/2,S%HXZP Z(+?KAT7TY3%6
MX&4$<#$$J7,O'>>!LHO$PY3IL>"5J[.=,)S% >-38:@)C9+0L3@8ZTEVCU-<
M8'18]96J29"RYJ%;27%D;JQ[1.WE:ML,@UQCJV=.,XDPC> "@4'%EIK#IS(&
M_9LY.+<2@#4MIZ6K$%_1\EY*_)C!K@.*FN$_85D*1-_%_*54^U\GT;6QUS#;
MK,?O*FV^YA2=#@W=E5?Y1-!NK;LC^2<;WW4W"<Y@.M%MO/1I#7P<E2+(96Q<
M1X^3)6FV'];_ITZWU35Q#6UP5?4'?;)[V.J83QJ0(H; SU>B;$T3')NMEJ
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MAK5;QV Y>12%\?34W!5K>W==MX=8LI]*DO*]E\"=.K%R;-7<3]I=]D]^Y!J
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MI2:;)%Y=(?XX[^2NWSEN^"6^J_8\^;'\)T^&7P*O9X-7%VYR,DO!T U]E@:
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MZ=YA;TY6Z]---T=O017'[M<@1;P2OPH]M;NG_=+)RKPQ69DG=N)O2TW)5>U
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M131-NE36P'* 1)3.U"H$]#<(?$"D#'J>LE[\#%*\>DRP('D"RD<J:= WSP2
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M"LJL4I$^:-E37Z,W<>1;V;H)(C%*I%C4HN!1Q/>NY8^;7D9;3#K,EU&GY=Q
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M%YEJE@ 65%ZF>%Q3!-*8!.ZE0U[":?OT$?0D4.D9;]Q.-3S8,*JR]/?:%UI
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MKT3GDX M-L18I0]Q 2?0$5X^\_B0?PHN*E5 &9/,E0580'D7FP.Y=G11MTN
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M 2J$XCUWA,BE;JTNEZN=JNL!<9?:96Z'!"?@TDOBDTC5B4[@;A%PMW4"W%4
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M;G>R2I7.._Z=H_J/;7_A(LO4=0RI@U@@%K%%T]@=[/N'9I@6$$V?PRN*/NI
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MLPU)G?YSQ<90')0"?N8IMDFZAMX%#R+0Y81!_XX#?X2P9V_L&=.1?Q(][R!
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M0K#:EUEG2JTL@9*A@/;MJ-2!\Q^I.*>RQCD;FPSSF2W5G:.!C_Q#<^9W@+O
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MH3S"G#,IN0A,ZKQ;HD4C':WSQ,F])A_^([&RT;)D$#KW6H,+L&D: ,!V]NO
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M,5%H'VE<1(Y\3Y8@@S5ZYI)J3#%\"HO[=U*V?-ZTLX/[!H$'O^N$9J(8TUX
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MF.*QTB>++%5MZB7N4M7%=.;$DB8T3<3A.LUE^>@^AKMRX+NN%NYAZ1G3 1Y
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MJ]UW^^@-$?H#!OPH<=DH=7/5U"VMTC?57MU'+%3K13.NV%?P("=K; #Z:R1
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M%L*_KDAH!=RYR(N(/0$ZH38?Z/0O1!IKYG*N6@MU0E>-O?7XU5,"*S&7S'*
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MJ3F(.+(P*98ZEJE3+PB <<61AM6$P>N RD&PX(8( S/N8:XB+1-#>@'6C=?
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M?:(3WO8 SKT,5HN#/DY/9W?,,J<VIH^P2D])G1)@DR "T#6,^X5WSH -T&>
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MW=9?#CY>G0)\;72XJLQ0Q_=SIP5])LUWVG1K>/P9#.K)G]SU$5*(J,*U 8P
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MS=\'"2+U]E']-NKOFD*R +W!_=T$G0#Z'V$4"($,C036N(:>4"ATU'!'NIJ
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ML^Z2^8\\'R_RS>Y#$R,20K">G(0>-;Q'&H(<KSL1:XJT?8I5NW(90W*C@ O
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MH NWTFK0VNDY/_A?L (_O/NW]!G!R<1[JF7[M'0"&\#+!2:J_@YM3[!%76)
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MQ'T",NU0)0E.EO5"YFI2ACZYC#1_DY4I_ -9'Q0 ?JB6-^-#^R7<1?@WRO#
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M7&*49:"QRAYWZCE]23OE#2TDHH:=F!;>O^?<R'KT^=#UQ.$Z].#6YXL1PT4
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M9#?YBZ6:M@0UTFL@3%EM,.C4^JTLOLJVBUM>O/9[[X2J&HB2C_,+)IT8>ZG
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M#_YJ8(O%G<FQ,)L=!7RTN%RFIXA@)V:(8&A%'".8&H00&%-!B!VUA\*(]/F
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M@7:L<@(6]#7,5B3/^CF2^$O387_F07V;N$0TB?&T*1Z/,=_U.#[@66X)NX$
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M2$DTIW>#/G)-=6^2I9VT_9V\:)^Q[KJ>M,[7-:Q@9""Q$+2UAJ2,"8)0H?Y
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MUF?,OH^H3P>)NC$;#37R8(=*GIZ\^_N+5Z?_;'I^Y.)+NSXJ<@?\1J="ZJV
M8?:1HO3/0_JV)]_^F&%^.5Y%#+7"*)%M6!U,D@PC+SJ X*H&"Z3Q$(,'3Q[$
M>1VX4*W7#[9'UV"=)"'F97;Q+HSPM-QYJ\* DA:58D&0Q:?:HSF#Y\Y2,NQT
M4HZ -F__LP.\7H6SW;#KED6V3I37;A4N?%MVP7H_.4F$9(IWXPM):^.YJH<J
M0KV* 2%(EL%$LN-6BNAX\ZM2MD;7KT#Y2.3J1G<M"_%N&X87PW$8IZO#4(0N
M)0L$'VK98:T6]$4SR#PJ$716Z%H?N=@>74L+7ON*U[O43\N[CX'2GC_(4T[/
M(]W:;JR^_200EKI90+',DG!5H[/S+8)EWYG33\O%I4&2SA=C.3@1R&S4"S:C
MKMWK-'.ZI!RD[=+F-Q?H!_ 2AS+X>U[B80G2<G?G%I$N]<\>%"E"4*:>I$"Q
M7-<!5^T20V6M]*EXWGI_Y%Y0?5J>?E#N[:NHUG')B\GTOD8AMPV(E9Q)3!QL
MJ/=BUA9&T61.V9_DED7-F&F]4'T0X!W7=QXD>FE.O*-IN.&)[4_KD*M:Y\ET
M_AZG9\\PSNNB991AN8%4KRRJ"]<^F032:V&U19Y+ZPJ'.\'LN/;S4Y"IC6:Z
MCGS/#\A<DCH7782@B%^G9(C(A?QT85B/KVLN=>(BM][?W1Y=PQJ/9%Q.V3-@
M05*BHWB&2%Z%]*P89UH@O?6@-4 /'%,>RHWOE/?L,O3M6IC>&J8.>"!;'2F$
MX*D&$XFR44>3$%CFRF<?'=K6BPBW(_D!0KW6E&B@DF;T>(:?IIB&2P3T^PC7
MA8PG9[7\[=\K9*+PK*,1$)15)*Q;7F\N*9&1*11R$$*W+B3>!E>O=N..0YWF
MZFJS<_MZ,J[2+]M5GA\Z5:@"PV()0?)D[LC9!T=Q1!'>H9(!L[MVSO>.'=K;
MOKU7&VO=ZK[-"+<LLIM6%,]P]=]+@EYM5SI0'J5)LH#07(,RWH+GBD$@.;VJ
MGC"V+]O8$ER?>OL=R79TH[AFO+J[KOZW,!S7 .J/,>$>#?^->2"]TXXAY2AD
MZNJ!SE3W: 2X(# GQH-N7@&W"[X=+Y!]D-2O-;TZT]\#]"\^F1+Z#[A,9)]^
MK+^^').+78SG=4GN^ZLD?%"DEE;4/KFRUCP$0V)F5L 4C89Q561LW>K@2*)M
MPVO[<UG-/I*F:=!VK>[OM(KW&2F:C"-\-0GCUY,Y#6'"[!-7$2S63?&PK(6.
M##2GM$7SI,3U^[&^'\QM]=1MZ.9^#KIUJY&&Z>*JC_1=QSXXRR85$T%[RT Y
MY\&9+*#>[J&"-B8V;PQU#Z1M..1_#@YUH:1FS-D$ :?C6^IO+@HD;"TWUQS!
M+$L1+26PL99E)!-19&4-AM:!W7;(MEJZ9#]93->!TCK,0T]2JMYV]A83#C_7
M YL#652)ABE(PM3[7=$2LMJ+,-H298Z1-6_1MPVNK<ATS+Y+#Y-_'JBP#JGT
M9HJ?PC!O+.G:@)Z,5S?]UJ9Z\]D@6I&C$0:BH%Q9B2#!2>&!QZ0-30G/30<G
M2_= NA7='KHJKWNZ-5=JFSC\)M![SF%<GB]!1!&=S<!8JK,D>@C&!0A.,!1U
M(9!M%Y<?@F(K?CUTW4332/UH.CN"NWP3OBUA69^LE,%!5+5)9!()'"=8@CDG
M=+TUK[BC^<HUJ*V8]9.L\W>CJ6X)-%U@OGI-[]*67BPL7[JVQGMA!/T?L%C'
MQ'!.^(T Y4,2CM(0'5OO(AZ*>2OZ_?3;!!WJN4-VWM86^6*+@T6RLF@*:!&6
MK58*>%XB!(H_E30Z4CK3.1F_"W$K[IF?G7OMM-CE!NB5N; .)(UADB:"!NWJ
M=5KU:K40BX(2'0HL(4K6O3N]#=E6Q+(_2;36H=+:]?TC^>O_UP65SV&$RXQX
M-I\.TQQS_0.9VZMO7/KD&YP.)_FF>.L3",^_IN56Q-LPQ^>E8)H/N-+H"A>0
MC9.UMZ$!%U" *(R;7 J-9O/NJD>5\)A5HYYEBQB!0B[*%ITMX&AX@7LL.05,
M+G70XWNOJM$'[N[77X[?TCR\"_5W7=1\VZE&9XW.3KC:C:[VI<N49";F@2OE
M,T/I+#]24?.]![(?N"'@#T_/0]7_$*=-)8N9HQ;@D](T#,I!X%& E)3)%J>\
MR:U#I'U/FSYL=>F/3\]#U=^,GBL13\MEL4_'!PWP^5 ^&\X^369A]-MTLOA4
M%P*'L[3J0X?YH@W= "F,I*#24O2ZK-T4B1)D82%HC<(8+,JWSCT?7NH^%>S^
M0-/IX16W$UT[;^%#YJ5N2*]*&T@5R[,4]1C%8KXNBI^'X6AV%<]VC7RV_>I6
M[7SV$J514Y]_+J<9YI//I.8/^'IQ%BD9+L^&HP6]NSKQ?KJ8S^9A7)DR<%D&
MS8T 5A I+V8)O%<%;$F!.6F,B:W+,G:$>*A?N.-Q-Y[S),R&:> M-T%P"\RQ
M #6: I<X@RPTBXD+%YOG?3L![%/JUR77KIO+[K38=OFP[@V&T?IT_Q+<U3[C
M%T?$UL>S+Q>7#J3.ID1R*-+I6I_O$@23-8T01N=LLLZW[K-U..H^I7O'I.21
M]=VY!][4@(5+?8UJT$^.:S*N< ]PP5M_=RL?O)\PC9SPG6VB",$ 2[8IUD(H
M*SFHY?D]CA%L\-K[@*AS!^>T[\33X 3Z[=]-P>=L-N F62N$!%XBQ9BLWAOO
M-8,0O,O68?WSL:1=(NJ3 VW&DUO.IK=22C/W>)+2XJR.->9M#KO>W6I-R^K+
M&8.B4NU/JVN5C46HS2U,-MP+;#V!6F'O51.]SMCW()H^@GM<%AF20YG4#<:T
M/ XW#\OMQ8,\X_U?V\XI[BA",W^X?.ZM=9FK8X6DZYA<-%I \G'9;RB J^=3
M!4O,AQQM%*T;%&X!ZW#O>/D1&UE=21Q5D/5"1%T;D7J(D5[J$'01Z%),[9WB
M+4#ZY0O;<N2F2SQ4$\T\X3_":($G.2\O;[\H']U@\DFD[*4"Q)QK.S@+CG$)
M+),M)F VE=;E=-]'U*<$KVN:--1-FR+R5^M%Z%6U\06B<VF]REER;H%^(2>)
M/D)TQH'EQ1H;(D<4]SFAK9[4IWVSKFC0?LC;WI!P54*E4V(4FP']=*"*-$ &
M34&0#JT/R;3WF?>YR(?=_^G:.ARH@\YCU'5![Z:/3%@/P!KKI5K> P+6G9_1
M*GH]3+@#0]FE8;B[7OK26QMB"&L=D4.#CJ[>>EUYYJP!J:362N2DA-O*+N_R
MU(-<S?I!OX?QHH0T7TSKKOXX/Z4/#TESFX'?")A-4<XI\H724HK(F2%[:!.%
M4I26&<=C\F87 ;=\;A^"UF[9<,49=:B4EDL[%>.3R7AQ"0J%T%I9GX$9YBN4
M#($7>NDHB(H",;C6=_;<"J0/X>MQ"--.'ZVI\9P\R^0;;CH5G&-R,<1(#P?D
MR\Z9A"ZZZ("3C_843$7I6Q>*?1]1'X+<!R%+"PVU9DUML8JS&8U4&+W "W$I
M!;.I7ELH-<%1D7X$4R(4Y:-ES//2O/OX]Q'U(09^$-:TT%#C#.G&"&PP22XC
MST9!MCR",E&#ST%#E"5+E8S,S2^Q^CZB/K0J/"YK&FJH\USJ='U]\+IH8/UJ
MMGQ5)M.RH%@,A^L+'0[(I_9Z3JN<ZG A&VT17+H/XVGX-)R'T0I2/7T__8SY
MQ63Z8@EF<X7&@/NL6;$># I3KY1&\)K(:#CGB659T+;N2+4SR&YZ?%\J(7GR
M[6:!R9<PS>NK:2Z5NJQ*80:<G#FS9)B=S:)N_4J((6=*%S @TB3SX3CMP0\0
MH@\9X'%XNUV#\6/QH>/6]5N(<;7L[^0SF:.Z,$N#_!O]VSE)HX(4O)!ODA1V
M<$EC:S2'@@6SXTG$YC:A*UGZD+7^8"1OR8[.PXOS'GXXJ\7BP^7+B*4VVUW^
M/J]_.B"NV.T!K0** \1J%$FL$-2'UQNW5OU9%V3P+@X^/%G"N83T^=?Y-$S6
MP<]+F@JSUY-Q/3%!(HV6-Q^O^G8. F,VU/N4T<92:1UK-RD/EDRF4L)+;-Z=
MND-Q&A0\[PKM&?TRFP]3;0>7H[8:N$;*(EABY'=\!.%X-,JA+JGUXN !</L4
M<?2%W[>40Q^%#2WK]7<%O&Z%/C 80@F<$E5M:I=SI@BO]E!$\5JZP)UO??QZ
M?[1]BB1^(O+NPX5C1A47I>Z3<NYZXVIU%U>[1FVBBQT>U$&4L:^83:.-FZV8
M!7-9)VLI *:42D4AP*'ED')!K[55YGI;]486XIX^V7NLS*P6Y]9TORFI4BX9
M5A!8#B2I=!Y"IEF8T3-DT18I6E^/? ^D_GGKP_AQW5BUU$CS!O)K5'?)S5)!
MO>Q<D2-Y>L4L!)<$J))#UHA9->\,L1VR_GG)MJ3I0#_']&9OD5Q^&HY61PGF
MM7X=ER?HAY^KP2<GW<B;[?"@#KS9OF(V\F;/-\\ZAU3;$MP6#@W(Q$0MG 2S
MO+F:N $A:@?29!Y<3-&)UKMIVZ-KTTOD^I.N*N=D_@+K=2^C=_,P7]#W?;OR
M80I'8T&)&IBN35!2YE#O;:.)I3U//'/E6D< #6#WR7=VQ,;;.W$<3]F-.]Y\
M'SCE2F06%FEYQ\S:U@^"0)9$,2#$\G"7IP"!;&'MM\B<9%YGU_KRA'VQ]LDM
M]XB/!ZNUS>&$;: N&T;5"I'WD[<X7TS')_F_%[/Y^@!\2590H@S%6%DOQPI
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M: 4Z03DZ>R"^70':I_.'O2+=_NK<<JUE_7[]$0G#W_[T_P%02P,$%     @
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MZ1,!&:>+B$"_Q6%5\888[WOZ[I@OGP492[@83!LBOOOLIGA'YZ'?4L!W'MT
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MN0 A._+U0L"B(Y8B6N>N[DL='FD2<CAMV$3F'6O!HK!#X=S$VAM;<*% 99O
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M&4HF+U&VN#>]9\X?V(;W0ODF4FV=T//F:Z'G_#[L?Z'YS8Y_AZ,OLQ5M&1)
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M.COR<B 5RAF32N09<%4;< 8;(%KMP0HC8['6,M^ZH\;!5.>1;)ICT)Q-Z.A
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M!)F5,,D(GY-?:]O;<.#O4'<ZYZ=A?&2>>+<(V9Q75?\M?.V?7YSW>.3&2!U
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M009M:"=.)>C672ZOCW\$A7'VJ0&W*TUORT0'0:<EEL7YRSIH.LHPN(GD,.D
MVS.S@N(=Q-H]V=9(ZZ,A?U3'68G* "Y+ ND)*VKI0O,=?Q\D/W((WA7'FTBS
M]0'U\Z5M^KP_FG["<?B,%]-^FKP=I-DB-ENX*EXBA"^.0KGCS.58@&&J4Z\Y
MX:%HR%$P7D$[NUZ%E2T&W[\#O@M9HSU*NG61AQ=D2XP_C_L3_"T,PWQK>S6L
M]8S[7W"&^,VL(&C=&<]Q>26EH+9H%(BB:U4*I6A?2YX 2QZ9XR+<OG.^0C6V
M&?WIZD;GLNY@2YB;-/3A>6FP$&(PQ9&FJGI/1#+P7$:P-D0?738LA,8[P@T
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M/[,HBC>;P>,T;M+:2])D3ET=_SN8SW%,BA8T63\@O!8==W'$[&)N#C0+4I9
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MN%Y 4>L<5?+RW4Y!*25M\A[:=]5^T^SG% O\W]+L=\7^KM<@(,QUS UBO&(
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M=9ZVEH@>3-SZ8?6>W_.#TO-WC)9*<D1:L\>>7%FL4'7%K6*3TM8+!1+U=E;
MOW& !ZC$GS&-$@AC;Q[ (:&L*/1UC#S3N;C78/^8:/ ]XZ!74\DZ:;793F;;
M9K:I@RN.IA_ZI7!T_]VQ"BESBW)?R0]V(4C1A-%$M+SASF%P?8O;6X)K$CDD
MR)T"WZ9![\,JTV]AO04"T7%>$PN"*-.*-\0#!]S'_;6'3A_J'*+<FRKOAX4C
MAR,2->0DBDC#L^-?.SIQ8%0^190E!MW$ 4:_37*!S_C1]DMU2VR!([1)4VI[
M47$N0I]H5OQT^AK5!<3\&K+P2^2YQR97[[P:3,&4?79\UX1:G]G7:6PN9L<!
MJ%:6GZWMN33H@^K63VH\Y@7[9&#FGSWH<&8UV?FKN/J:YUC<*<0YD\0M<4?S
M(H-CS,3.P=1LC"1OOU_T[QAHV%_KZSGOL;)TJDTN.LH_Q7<9-OX5]>3GW-_6
M\O?(T?I/#]DQA 9;9)(V&8&2 ]L<T4%I8B&60D,.'3O-"YPDG[=[[>3;5AK%
MWR&?T/IC#D#9,G=S@#@!F@>[?AW.?GX1IU5 ;ASPNGLFCE0]5T-4[=AV=>%?
MX 4;[!^4@PT^Q4TR">]8SW\FXK9/9;"<VPB370S26B@]6V6- V@L0MU^F(CY
MP:=P+?K[.(#MW86UY;I5]B56;@0;W<;$#'3\C/?18B*@O5^JV0$:M1S@*?K&
M90)VD0,HTKU^F+KO1RV8KNF8%3]U#H U7T!/0/Z[ZDOD3@^JK/'GKQ>"2J$;
MGE/#DV>=L*:Z'&!(6O:":T7(V;6!Y_'[M].+K/\)]3=P /:O0V8<H/CC*@<P
M]53YD*^//):DO6!V:YVP=, ^;4\ X5]1K_MW6./_\Z'Y;^<*8#N7'[P02V2_
MZ,M=+\$C9-FR>+.N%47%66G!D\[3]-6;;P0Z'2Z_6!7<<O?'^@B6",%W,!.%
MX Q))I<2LX\*+AWXB!&]^E&@ROQJ+W>7X\\HYY.M_P5D"_^@(N%_ZL'_R'IP
M,)0IUS'6!@W4MXSDK^_87#:86'D_$U_9IZZ;/C0T>'JGW+/W>DJNK-A9)]P/
M.(RCN(ZW%TY&,W:N8%B[NV8_S/[."G7L+'.MIIS,?R5,5"S_[JV6_[5C[+\@
MIZQ"SO\E1>0PMWYBVA'X#12Z;PQ.9&3J?/>&EO)RNF9^4.D15]^W,4/\A?^4
M&.25N!V"+M6-%7./FS >3^$G+J0:RK<E]\4-KP2P3%0[Q+'$H8J?CC+)G-^=
M7?H_'9[_=NZ@0B$RY1K'"*'ZV1BX:#U)P%D]]^7T>K5TG[ITFT?*E:<OUO3W
M(WE)DFWHIBOHK="I",11+O_8?N<I.W8/9%$38<EN:A?B !;4_GXT]2P:W)/3
M2/B<1"Z*O*:]$&6[/AGI72@RUH#=2BC3?E;#2W$<*B/Y\$6]%W*?BMB1X:Z>
M?>V">FOQP]U$ANS^P!R9)[73GOG3W': Y?OKU/J$NNV=Q,AN)H9+,11-:!AD
MV<A CHM0_E\0PE#X66*6_.C1F=\ BH*Z8T$%Z6;< [2LX]OU"Y./D%=]LL$S
MHI(>54_D%;NUYX^>"$^$ZLUK.3OO"MSC?\$U<>P]X[APYTO!SX6C7-&<YFCS
M>M).'5$I)]#R;7)2O9"0;.2\B@U-)&5G_^*(M@5@[S!^,6;XA:]/I;NNZ4RQ
MT<21.]M+/@0W6^P;&)HW+-R3M5!]<OVC/KV:P27>FS]@QN5L2)/HND*:"#<D
M>G^+I^<.J\QMHF-)(3IR=_L8;]E&Q% #88*XCR1[H'MH;IW7S?.;S5W9P] J
MIS9VLW(3!-RK080$8_EN&>Z>31-PA I_GDY&X>_9.G1/]F@/J2S:?)R8:#@R
M^&UDO]U!FT3)'>=$-NM4T-5-YYZX%HTLS2XISCX=6?BMC\7\S/8,OO<E@2;(
M0WT<P%-Q%+T#S&EQ@5"AC9!'B2Y0L#@WHT%=N_87C\VW7+JZC"OVY6T9+^_U
MCGT7<R<.-1G)].0*6S*-NM"CZ00)0QZD7N<$+21WU%[=1^5"_-GRBF3/G:I>
M];<7M$[*FGH6J0TDZ)?*O8CQ2$MSC#OM5->NX9=BTU51R.Q>OMYE]_R&[<3L
MK106<9CTPSZYS&)"XV6'Y001J#Z_,4L+I!3.%..G++3@!N&-:)$:$^40IA!_
M.%-/(W+.Y[U.]18;XKENQ7>: V8>MS\-5QY>4TP:MQ$9WQIRQ(' W*;2)'\
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M(6P@D,\C<MC!N*WHT2HX>V_=4'!FHK/0*CK%T$_/<O;<&LH$:N0-H>896'.
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M]#^"__&"&]6TFFST/W3(%?98FVT7;LV9 %:;)1W9;A@&ES0'GYSET6-BI#C
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M=L$$>O0WG[YD@[JQC%0,XR7F;X9>!% )S!LX!IX-6E<#4S>4-[,@&S .B&Y
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M>)!G<,2@V[&WYF$S@6J,"&6=I?9K7LGRH_B''T"+&U&S;E6_X)WVN.5X6D$
MXK9S1$7JCL['B,F@).4'X^Z.[35G.,"'AUL"OC0[\]@&%O\ ONZ ]535JV(
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MHHJ,C@D;<5>%I%[&+E:UY&66!T5VSB@L3]<ISL83!%1).UE?P2*HVZ-,97W
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M/YB71,H10JQ?)L9<B_QXRT J2C7+N&LIS5E-Y%& JQY*BVK%V@/7:.0'^8U
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M?.<5\S=AJ$+W!490DI7.%!#*<448$\?:[VK;M?Z\[I!NI@V :?;5V=TOGVQ
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M7/FT[_8!A99GU;O6#MF<Y 1Q#T^B!QN/@N_?(!>:82*-^\&>5K01A>XT:?2
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MRBXVY E0*K'&W#G,B?/*.=% /.(/&,?_2A*?UC]C?A+0=)IUY*OY9<:U]_'
M8A%GR7/_Y;LXYU>1IGK_*06M?I58#@5_E6@7M?^ A%Y_0!A[?H'JA_526<X2
M?K=X4'P>;Y>[%Y[)*#M+FZY<3";?1?^<BO./[P@)7!B:<T@=&\^T2<:0-7RJ
M?<9<QL<XT1[\:5;]WTH,K0:!6EBR[HN_OI7SIQ&8-^RGSVJ^PQ> 8L^AC*E
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M>:\],0O1Z7S1HI028G1KN'E2-^Y8SH$S/$=0:KPT)AA-=9B*:-*/OL10R%Z
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M;$;J]2G#4%'O0,F[&;EC5^8=?W[Y=B!RYK)H 'A#0,JB\K-_)^0S\GDTV?E
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MX(A:J\6B="5&D9>>ZH/<T1>^3VNK[?F",!9_0=(?N@WKH;$3W8T#'I>@Q'.
MZ^-@N4L=U:@0ZY-)(CO&#@\8K"=_S2-'+Q\<W$LPT[$@81<S*"NTM&$#F0+D
M0HMNX_XZRLXRV8:7G=H#9C2IUGW%SV('S=_;'3RV3<Y7PO:!2Z2)ND=P7)=K
M4Z,V^E-M3WO/>"I!/+Z2M^$@;#M#?N"G4Y>%2:(M$%(\J7KWVY<Z5-EV>Z(I
M']0_@6(+.;R6IO2JZ@.#]4].*#>^TT^R>HP$P)^D8 "TT ;(B,5T$;K&QD5*
MD,N-1 0;8K_P8M'E??O1=LO?\)0EC5#\JB(;,F._QH;$.RR@CG2,H9U2;)H<
M'GW-Z0Y6&K^LESN=V5/&H'?(BLRN?PETTFP>S'MEY'3HF.)K.?'@DR4#"V7K
MD2;H# ZEZQL%@-XL-B39"<\R-&/H=TVM,;DY$;I= QM"&EH"6FT^8><FK&IA
MC.?+6.K6E:5UIADGTN*,4($=4<(,8,' U*:E#6$V9+DHF WIV'ST(P@ERX:\
M@K$ARM58QKUX,.JR X/^9HTS+DD ?!"TQF!Q7,4'5IQ%LYX]=?B._]VJ@\#O
MH3)1+6*%#-(YHSHC&"?JZ2R X_)\R&=#/O5\/JNRNL22F:$$LQZQ(8S"23:$
M.@\C3,*YL-\X*WPJ66)#9'-8!U+LV!"C^9 ^-F2ZA;7/)80-@7% G>*8OQF/
M6071C4 V9/<R:,B&G )8=@@ _ G]'9TY*PI:*+,A67>,.'*S?(T-V:-AQ/EU
M$*!L=A(J7Q&*8NK_$^3_0)['N<E 3VU6 +!^F/.+>!;0,P\#13C(7_ZG/+$9
M!9KTT;N[@R2K0Y>+1^7H]O1_ YIE5A33D@.-/T." XT>!YH1_%^@@39E;0@#
MRR4A_R$P;B;H/ XP-2P^-J0WG0.-S])?=DC\5 ^3&[MNW_@75OU]?SP#6GE[
ML',_H0P>@%',>)>-M04(7X&=P#<.()\JU_["!YD.B@?K$9Y1! <X;"(><H.O
M_,B?@++.P8@[YO K&_&L'3"6/?JR-?P-EO(#%@I;/<AA@.-?4=Y- K4X'$*P
M[#!8#H>H(N\PZVNV/^+9D(/0W^U-U0+,(/X/Z/Z!'G^R-5,N.LPC?H_N'\CQ
M)UNS2UGEI][O,/X#0?YT8\XDBVZD_P'M/]+ES[?"IRCFJ4'L5$86E]J2A&T3
M_>*6#EK)VDLV)&^(ZP^B]R_YV9J-/<^&_$&P?B]Y_Y*EUZWA^< ?9>IW0O=G
M+/W_0MTDT\^XJ/U^U6!+%%3:_[SP,1K,+B9546<]T6D9-XPHA]E3.A[X,X[]
MS,*<%Z+5ITS? @0,EY =Z\DEZ%<F(@X?LHK^;\Y"MV+;LAY-0L$E2O45"B)J
ME1.WP?G!M'9+F$WYRG0H^;!YG;->^Z>%A(E+@J-#2X)(J 75XP&F7J_ D9EC
M,EA\8T#=M[X#KCEI_MDO_6FXQ"G3D]OO? DJ,6=#AC#]&2=D[8K1K5F\]2=S
MVUQ#"$<U5 D45X;A)??Z]P&LEML2/J?X7JSP>73#&G8@_;_\IHJ=2H?O7'PY
ML@WI<;&QEBJ3FYR9 P!$7_NU"S5BMO6T6\Q2GY0,C^J$GN3C-6D*%^WN7.IS
MF% JG UI^Q0OE4K;#CK 6KZC]-0CBKH1NN^AD4XVJ:VUK].6:"_\'^?42[ZI
MT2.Z/=IE'-DDZ'Z$_N[B&GPGBP?TF.)Z\(HR]ZBB+/>[=8_.@,H5BSN&GU?,
M;Z0%Y3_/O)R7,/;\=?+8Z(M$G\+L5*W@L(0F'WPY] '#"J#RS-.-5^; -Z_;
M7H&O&L=^P^)2_(T-N,5$/T0+?CU7ESW:@3XCO_68QA:@R=!(D*&3,K&*Y9LL
MO]28=K.;A2V85[2*/O_BZZ5Q)V8VT>K ,'?<:E7TS?W)YWN2_<D7;6>OW4 .
ME]&W,XX/&QT"0]NCT/N\T >H=I_U[E5LF+5J[/'RAW?R^8B83%4UQ D):5_D
M+?>TCKG>L(WHT"RPFP&WY$:9Y .>&N%WTA%[O')Z4J#E<">A:ZEK-^NJ4F J
M;N>#=M8Z'KI]^)U!]0=866 ++&QC.+G $RU)YY^-]"CRHMD GLX6TTV%+LQ:
MYN'E)Y.^/4N:'Y[2"^S0CC,_ ? @O,GP=LMQV6B]1PCQ,QRG,\*AV7[X-V2$
M;74XZ8R]NY-*;AS!9/KLY\]%MV=]W>6O)OI,%N1_ID<H'\WBR&DY)K21:QY7
MN1:NG3JPI-/E:_1EPZ&AYKW/XV+?L)("(Y\JGE.O OG$YMO2TZ8-C-F0[6P(
M:$',BE(A\>+Y)HS>9NZKIEYODWU?8)R75\:5.C-_JDU1[.&2H'(%4>/(8&V=
M9ETXS5%IDXK8EAY0L:,9'@8(:0-BGFBI0;5*[.Z)R4G/)8W'.BI%(3(8,;=:
M"Z<@/TE>I-O*M!J?>9F88%5W7[N#/"=J.]S(G<7_[1Z,<6#CW7<T=$"Q3\W7
MH>UX;=O!=.WLR]KK@\[79WONQ58-K#]Y^:E0.5$ :VVF71>=+"V+I6N"BFVP
M\@EL<X.Q:>+"A[NUOJ5)LFEK:_IAE9C4Z?U9GU=&,<G0SU?*?=<C.[]8=0"C
M6$(/61'348BL,\&^QSIK^@H1?6%.V/[S^?EGFUZ7U8LEG=90L[BQ+BY[P_5S
M$H]!Q\3\19M9M\NR<E1C%G<7Y39)MJ[ 6W+MT0]Y7T=<?S^MO^?*8 #3Z+NO
MN&].0VX]=?SYU2N[<H^L)X0Y%]<Y"*,XRO0A"B4'MI#&EX20H<UK#HXI;P(]
M"B9?2\Z^\G +"?2\,.[<[<7W':'0BG94>D[2O'DA/8I121:QG4WUOY73%8 8
MK2:4/J 66CT6:Y1-@PE6KFX4JGA7Q^?A\%;BR8:+QX//WB34)NMQ91ZU=UA1
M4&W]./.N?AN'H^O@&4H742TB*@#!-]%4Z+EV/&PR51KW(^?.M1P=-B0-8?_E
MRV4<;OC0YR\N2G+FHX_T;TOZ<CS[V6N?XO5Z@1OX;: MS;4>A.5]7QMF;:GO
M^U$!?6OYY@K>0-=!L![!8W%KV7R/?$Q!751VF-V6$]NVG64^]64IH80IZO'4
MZTJ5B+U(60WE\5;)G9B07+R9<OMP^_SD\MC+VFJ?9X?=H_3&G\MJ]F>'(SPX
MCKV867>CV%]>EQ:@.+3$VC;A7"*(13 >;UQ;_N/< 3EJ5559VYMQ_4Z919L0
MS)>XZXLQ;3>VI.VZ%-M7)' #-*'8FH$*N<YCWT8RU1O"EZVU8S%@T47J]L(/
MKMP*S-8E21)X(4SQA4?:0L&KSH;16[EE)-@N[%4@ K959R'$N!E+R?("/!JS
M;,1@E+?U)XW2%5J7#9+,:38NE15ATPD3H>TGW55-@W+[8%,<(\7-T&6IZLI*
MU5?");U&:DU?2=_[D5WF-#9Y;F#":2P_JZKY6-YMN9*7C[0(\<JO@]5$;AL1
M/L5K@J)T.:0>#?$^K%Y%+\ZUNGJ@/17A6@C..0T7J_D.Y@U&#=-^>!Y0EK.S
M/\U7E+Q=Y;!VHSKKBZ]>:*/2%91A7(LQ=:3-LX1\Q_+ZCQ^W$LCA^AJ5RM=-
MA)H\)7)B[<0NRYG<O="][V>ATFQ@S>6;K@P#RL%T2O4'26AX !+=DP,&6E7W
M+UY7-+JXQ[3,]#W-;FN54O9K=ZN_E2SF_.VH\<*67PX4BP[^4LOXAZXJ_^SS
M[S3B61$(PTX]8XDW@EU$0 +YA<02$A^N3&\X.W+N1!_N0^*798UGMVM-<2UR
M85QRL](C_1M^SWVSOU-PE\>;O'S\'AY]%7Y$VE_I6V'.?:Z7;[X5>Q*^]X.B
M\7IJG13D#H6PO.SI'WC[M:$?;(C"9@G<Z&K\?BK^0X\($B"JYQ*7(AP;X]V"
M,:8)"Y+JE7R)7O>B"W#ELUJ-Q^XR7M\WYA/2W.T\%?^ I4S5:,W0;X<*Z<1R
MO+$+O7T#YGVKGC<LM:P2VH=K#MJX7(YBO'R[)6C?#>K"4P?8T+7N;DPPW&*M
MFK10.I?*C(^@O=C ,;Y6H^I'&LA5&^,^"S[S(M8F ;(O-VGPC\^#,VB;%V30
M38"8T7%T'[SB8 ,!S@-X>QD=!35\"(9" %G_J-'XF[R\I,K&,07[<Z:\B-_>
MC-]%8GHS_G[:-UQR\0;Q1^13/_1=<('&#28KDOG2VJ.GP*N]/8OO;U.&IA]N
M?!$]WN<Z<^GIBK$H1%V^(_&PD7\4!1^'IUA XX>S^&#NV#U(CY/4(?QC%"]E
MPD"8J,;;E"6XB)(K_C[P0U-<?+G#L+YJ3DWZ\7/5TS>$7B;0N4T\B\X(?<]#
M.X%P&A?80^=>@'$QW"@=A!T1;0FO&#J#!CL*D?I7J)61=;V32S:I-BN-$PJ5
ME0W-F#3?43.>Q.<G:Z#::SA@L8[:0H@G7Z8K,TY4@%93O-_J880N/"\X8$%Q
M_HF-6(7O- L.%*Z@T5;JM#OY;,S;]JNZ(>4[4ANT-D1--+Q;QG*6'6@NS/M8
MSZS1EJFE12R)K$BPCR?UR#"4^NLM">3 #]5HA7<#/TJ2K =+?^RKKVQ44RBX
M)AT%Y7.ZD0Y1>-$Q@!+EL,&5X42ICC&"@.DNE)0(_H]@ Q$:.:G6M[HP[EY&
M.7WOD6"06(*?_UR0AA ;4K!;M+PB^0)Y(])$S_&<89K1%<X,+N@OLNK,])LL
MF!.(.>V\&]\.E6"8$;,$3J<>/I<J:3(RUMBM^=CYT<DJV ^\3^DQZX2L@F_9
MY4]+?SC:VV\V0+GV/[UY$2<P*(+G'D^';E1NV/Y;68O_9&O%K57E>>KY)"<[
MK])7XVZ'/FL^ZV1.A_C; P1AJW6.'XVEJ!7\DDD9W.Q.M"L-Z&&5<(()7S/&
M 2].I+91S=I1Z6-]0@)&B<QGL"'S>%!L$&@^F+7"00"8<K*O%/D?,4ZZOE',
M"CSW"E[MG46=V=^#2X>%J%BP!+4Y<2;3B1.@X5)^21K]OX-88R[A!ESXNP^-
M;#M[YKV>94+S:HD&>'J !?Q$,'B]G?]1?4)NL"%_G]KZ'Z=U'+RPT^H?IH;^
M'9RA$I/_,0.YLL"(%N],S1IXE;<9DV=;TJTQ^@H0Q@D3=N'8D)Y9CBU_H.;(
M^KWV<>?,J8M=67\#3%E8__K=BQ=V(AAR/AQ@TE)9VSG Q&(8+&\X*#24:_)?
M.LXN5J_E[ @GOLKSAB,#WGM7_DT_[@2:#V-7Z&\V3VDV9V_FS/XCGS.[I6/
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M='0OYZ<UL(/1PMJ/W\/1U3"6E0#+G'D]&ZL(_/)-JH@X\P(;PJC'TL/C%_D
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M.:0]%UA24KO0H6IZ]:EO,,<2:SB=)7_/L33MLL![#(QV,$1GK7A08F!" 7*
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MVI%PE*Y6T3Q-]D!Y35E_N-;SV3,\)AVP8](.G<?C%SVH%BU&$GV<L$2<@HB
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MN8G8*/U'IQ+.8G@;A(XTZI64DR$OY![\43B%Y+$55)NQ+0$E3Q3GI4(>GX?
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M9$JA3WQV5QDZX=JL":_NRGN%>S)6%F9I=^#5V3-WMG%\S2FBJH8AKL)#F!M
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MA_CEW-W/Y=^"'61U?;#;+E.UO9T9F^?DE9@O8_8Z_D-U=X;DINQO'QHV/'G
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M,#=8 0L&\#^FI_V]6;"3"\RZJ^N7E05#P^<AN"\+)CDC]G\B,V89<0QB]2Z
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MC4Q_UK:G=C5X>$HV%V?'/I5WT?A(?!BM!S6>[4)DF49$./Y""$W!Q0>[M>X
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MO[==(*FAT&2K'@=67O%>J\:&VA1GS*CX:V_%E.=7Y4E]YG$3[T\MSV3,E1%
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M:_I>N<.HN]C;92Q&P#\-1'+#PGX<Z>I.;4K@_FC:R0/I"'!?4>L]N_[R1B=
MWP]Z#OZ(!(FJUI&A7/*)^<4/I;OD!8*0O OI*)YOWS3EI3+P;+%E\O+TFIF
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M/&\0X++#]35]U5SPLZ $*$MGM4&QN\GW!C,AUR"&^B!,QGWFRY6-T]8 Q/V
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MJTOUT!^6+8S?0V7_6JNGTW?\BW[Q'*[.Y3B20I\_2M37B0ZX,+ +[D#79U.
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M@]H)L^/+TZ_6:0/EB>_1/;<>0L<J#?)K-_Z0(:70+ZL7)J+:[E?-.VQ6H]9
MB_JNY_]7V_XWXDF&<+6(.F+.*U]$M%S'":_X(8,7&WF]&+;"R) 4=_6".)K7
M\M_YM2XSZZ(DR)#:PAWX$LL,')^$D^O08]6ZD6I>;V/K.)S&\;#*X 'WSQGG
M:[?>R-VT%Y1$X!$DYI?$7#)DT0+9Z0=]4^ZJV$B&1%[LB5RF.;_] C\H3=)
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M+,$[$6'W7 N6^ :K50LS5N/[$8Z$M-%_O@=]$J\TH%?,7VOY^WSE)[+50H_
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MGI_GX8@;SMS'[@55ZECUH6O#ZL"'=]U\+S5DLZPL.4N&DSR<$=9.:O.Z2^A
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MB+*S)M_@;HJR+QZ6].#6M>"Z=2>OMCV74@2RQ,.X;^<Y>=S9J3CS4T#,K4]
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M 3!%ML,Y$%E<0,%BYNOY;>\MI55\1LF\Y2,AA*GOS]BTVMM/NVP-OKM((DU
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M@446)Q>?*5I8)]FPA;7K:-RUN<C>9_Y%3J'J+OVGC^)O][(K)PB7>'&-^$>
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M!,QW,/8 L"0*\MZ"5C5C@JL5^OG,*D=?P$T3-XT;8MT$-.QIE9^@/_QSU!F
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M:3JS!%PNKM^_&#N[,C0KW%309P;AFF5>I?7WU=J LP[IL(46F L;6P]LC=X
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M=^;5^I>&9^89^(H7_* Z>/MD#5V$0CC7F5JK-:.G"WP#,EY-<5I&*NC[BPY
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M'[>R44D W'UC:4(?GDY>L.3LGT.])<^S6 7L>RR%"!R*@X+">SHRX7%(:>C
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MJ(U]ZMD[-"2/4>L:[=!:I)[U;WHHIU&: ^L5 +%P\,QO026!"P-IE !LE^V
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M(31?N"X KJ*H^3UT?BJ8P;1K^SVOY,&7[KP(5CP?TVN(><SPN*H)3WOH 9]
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M-"6N!BMI8A4M!CTYQM(,N4[SJ/719QL_\--:<;ET&(4^SK5D17.E928MVP5
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MRB#P9&!"-- /"X!-P *!\8POK/;3=[H X*J.$EBW")1C7.$KGTTW"P#(L%(
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M/7P[6C.!K3TA?&.SVZC;CK^$]/^)V7.V>,@K1&ZA*[BZZNX7I/,B(<WZEV5
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MQ#<:8KO:T< EED(B]RK3%=8^L04R]6.BUG5(<"MO>AN1J8^1GRZ=7C]6</W
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M<,OJ:,65>QD'6_<KT#1J@CAFGY?DE]&WD>8P+\3J5FX*ZN*MG[),<3A4B2R
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M 8QG0\G>UZD\%-P#6F)?C1_C;&)';>JGF/&;[FYS35LTKQM[_[+FP*>:%64
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M;&@[:'#?-NL89\$,L5[O7>BQ?^' 3JZE4V-M_N7S.AUB]';M.)]<<./*H?:
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MO0YMK_$?+#59P"\A6(L5*?N"GN5EULM;>6?1)Q=$]3XBY\VF,F1OWRF$<5?
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MREJSSHVZ%Q10[?>(=X0<N#G2]4C/]5.<PPB,WEG ^)T,7!MJ^811E=)N3]G
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M9,6'N=73.14$HYDE;_UQ"6=]-XLG;J6;4T%V0W@5>5H0Y"I#-=H9B/Q0E/^
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M:'-F;%'Q\HO#G6_*+VX4?4$///,[+DT_C:RE.#-Y@W(!?-NF0#S9@@-()68
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MR (=6VHC.Z;'-^R9-=*E)D=K+IWK]-6TX.E6WG1IC:'K=V3N(S?8Q,T=>B$
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MSVB(?G,B?\RIRR.*I,NVY956ZOM[LQ<.PWF8'YD<%(56]M"2LPW"??Y8H?G
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M..B2S%;T[G!A8(!4%6O@$@Z9"XE.]G>$FI254 K!4L^K1E6^1']ZJ.&9=H-
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M.#R[>RN#*'[273+J1%/AZM>8RWM:D2%X>&^A]\MY; $#.N)7N_6,L8-NR!R
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MKZ>ME^#G*-Q7IMJ<T?)M#JZD6]V?)>B05G3E>C-4!+"_U/^%>BO*\-RPV96
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M'HXJ'!ZP<>*F+->3\)%&D'X&A*S#L)9/):"XI^9"G%X].D72<1+G8TPYK]Q
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MV\8O#"SVFNRHJ+NA0X(=Y]I^%\H:_3]02P,$%     @ +(-T6&E5/=21-
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MBH5F&^7G#8H$4.TO ?2:%E]2^=F\OXZZ^F9CTJ3?6GNI=\_.GLD3[HM-BNW
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M>%IS(SRO;;ZAV7%\$7]F^<)P[;>NV9HL %:G^1F%+,^N/26?U2\-K3_0=,.
MUVB!;4"Q$I2'.@/ME\,B\B1ZX:$!RM A3*I2 -W1COI"Y:JT\=RP4Z6JE0<Z
MI._"C(^??>F+H!(=L?<>,^<PL @2AZ9V?0VJ+M&X)MS90&"?*/\^B$G,\:Q:
MU%B%_2YCY_:2J[;6#M0,@32T' B,)_@5U#$KF*]70HD#]%;A3F ?Q7>I[R!P
MCO?-"*#0_6(SH(N$3R(<IG0LGFU-C#;)2PP>E98<WEXC]_98B:3=YY)'UCDI
MA[=]6;+DZ*G %DJ6F3(O E5 2"S32.5Z6,YL)4OWS&A(2MYP^@OGM$/C2J;K
MDM(N2#F(X=+1&'[Q'D!X^A%"Y 4< HC0,)EJ"#-^E'UW1'33:@L_%+ZUWU-D
M:\5_#,K9:4UM4#4?MK)5RUMWNU0GS\$&GDPX"_ [J-OI2$JPYL]H;67',J5!
M? _E=SLF58T4L$AB8#^Y51WPS$9N-ZSV>8J$V_I+%N5L,UCB<V6]]DM<1JCJ
MY5%B-IWMXSZN$<ZVPL0E.6*LJ!+^,U:YV<I")/YX:E_X=\_)%5U?^X@;SD9V
MA_BL49%9MC(!XI_!RV^[U*2&3#016C4FVQ%-O%QQ3/8$M9^"[AN<;9XCT%SO
M(OUL B:]@TUNHB5A4NP+!*$(NSP::]SKH[7+/8[9%MV"$U]N379S_<NT+OJG
M/ J6GTU#%99AR[J9?HAZ9X.C:&A(0Q_$44S*YN22_?-KS1]$2E9T;SIXG;OY
M5H"#Y?OA20N\+SYAM06F,[$4SV$2?!?=]>AXNC(K^=;-DO1Y1X<+&OT"2&6!
MKP.,.J).017<ZZGLHZ2ER*@3NS,FF"9:S_#^N,^X\U!5 K/H9MT>YJVF'=V_
M92PQ]F ^I3@?]Q@O%Y3Z86M^Q,]FD)< 8BWF&6#[.7+:#3^T,IG*EIXR+DI(
M@ 8=&U77:)F62 EI8!OF5-PPH87]=+F9(-VTFOE \LQ2'OQN9_-@<DG; 0N5
M25174F/'ER>=BR&+*37W9!/DMETTYSYIQ<^+]8 M%1WUV/]S4-!^,5,!M,QV
M#ZVO9C2)'Q,!#^'3*%Z.R/'5QH0P7B:!P_3O8<!@B9]7F&CB'@N@:SG9<!B/
MBM9/F,+O0*!!,73@0G(#^61S4ZG*G<WMU+"A_$PI/TSA[4W2;%HOD'9J*Q?<
M>1GD3V$)EY$GV216S02AOR[J!XT=+H >.5M90Z=_1EBU!R_[4<@RRCC[^975
ML4]9YK^*Q!QFR_]QC,ZFG$/,HD1._+M.;!5'/CNM2^T-/N6R[^V/ON<=RJ;7
MG0M6PMT]/=R:/O3<F/[10P!55HIQ&%%EF=) %3 RMF^/DN$751UBNA#%/!;.
M#=S.(CH^'WGE%;)%MS&[*U55=Q/CWA2#AG/9]-3EYJN!/8>C<VTLY^X$+%4,
MF%%?5R,$-K^O>0YA_$K_D^494'G;.*,CKR:Q?O^-#>WZZ1-=/]>451A-%T]M
M<KJYXMH-MX0=6?C*36W2U#7&-Z/F+#LI_18K0!+_F%0!U)*$J@,3,DR=B6'5
MK ,8H0O_UOS;?$9L)0%"*N$.HFKMS6.&;!+6? _(I&4)R&UL>;$2B",+Z2;-
MYZ;-]V=B7]L)"QU_7.I]-TRBC6<=44MEU7PKEZS$7/'548U1'3AL1PD;_EB)
MK3^N[TOF&.]%@\ MVMTP-3#:YPN!:?XMC+00&@9$<?YV$A#IM?2015&\!?3$
MA;R]$%H'HO,$PAA8S1#@ZDCC^_)I:!W%>Y%IA!:MZ2#_1I=-J  JH@\F3!&0
M[8ED1'?P';D:".B*-)MN(* ?TJ>39T?I[%!%-%=A%&OH55<10)WPAVCS#A"+
M_BFX-I]0; N0G00KNN/(\V*-W_]X4B KHP HAM)0YR[%55]@UFG@3 '2*-;B
MV5YBX]*=V$[T9#*8^E;$$>0*& G4]VT$ 7K0#8OM)DS+QD03G*A_+"<A)@*8
M-/&;=#P7\>Z&&<V8N3C6JJ$.E+$CJ&E>>#H'C^S\(8":CJ/ 0KZRF0224S+<
M#UVU8($ #<V?G)<<QCLB<^69TH.#+"IZ5W\E_"]O2F8'_P1J'S '?9$Y!@F<
M#6631!KQ#R]M%$ O"SNQY##L&H$QVK@X#OM2_L7Y1!N?.K#,OXN\WYSX_V )
M*SS[*'  %#2YM->1MZOFU^(X^#=P__\>1V54$*;N@U%8L\LD7_P@;I;&;;T
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MP3Z$DF94;I!!'=-AC];5;$)R6#3$)DA:F9"6=5)9.9%<0M:TGSMC<X[_4VP
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MI7\00P]4V/C3^2%$K#IT#E4^L 4@A$@YLN)+M_-XUW6-2_3Y:ZZ=%+B6;F0
M**#V%$5-23T%9DI^-3];J[IQPH3O@1LG(>O8W7\_N521!O;CDD./.[:A+622
M>)W =O0G=],7GT<N*&*/3E&Z28BZ6I8?'EU-XNVV:=^5&DENI&O=\@4T$722
MNAJU 3T?\9+8W<E('CB"9Y,]CJUG2"/W+2WP!80_CS$I?QZ."*"9EYV KFM)
M#=(QA&+I/AJW+X6,BI53EH.LNWU95?P7F$3Q0=MUE*M%'7=._2#XF/F[@@Q$
MK5R[NR)D^9D1+5DW'KI\-:@&4/>QFO9L 3LLA&+HT7Y6VHUJ0HDO=2:P<T8#
M-,;)5)B10'Y3U)L#3$W$+7ADF?]7:@8MH3FD$;\"?_(?EK$$+%.3Y1T,P->%
M_UA>3SW5<;P:#^W0%4!K]L6^EQ.:)J!*]@!]Q9&[ N@, /KAX,(((U#L]C/T
M/VYC/1XI]+/%3TKP8K'E135QS9C$,HY6;OH.9TS&V#A$@M"_T/F]!CBOF,&]
M;T#F1*I'G(W3(6!G9 +)]_>+C>:-/Q% VJZA8M@[3!4PY(%_J 6XIA^HRK^9
M)27JYQS;"%6ZP5@5,91$_:FFJFP$&D>!5,J U8D/B>P+USHND=G')V-]-MU8
M_<!PC5*R*/P&L$WU/VS3I_V';8#N.4T,@VME<$;HZD*>Y7+\;)1^4Q]U2C*N
M!NC1V)*)+.#D8SZ'YCQ)-7;&9#\K#]CT$/H[\",$$]Y'3/QF?C=H-M%"K/5
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M?R)XE-ZZ7VRZ$_2"/7%. !7"5G3VY6':V#'>#E#6,X,(=;A.KQ>C]A-IRR,
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M*'UF<R-8B5$:87(!SNB(K:]9TXPF;1[$:NM)*(R2OOR)$^B90%<:FB2[6&/
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M?+&#CH&!!( I _\!8B9 Z*['^'/-=B!E"R<R4+NOY%'<Z4YY;?7<4B?SV16
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M%KZ4 C2^>;^X@OW\ASJD4WSS&"4-[45BZ $V?&)9HZ3 ES==J 3VI5QS[F8
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MW)UL>NU^?U6[2.4UH]FL!]7ZDOUYLNI0X# -?QJ;6<2J6%6);NY+2N7;5UG
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M!"0!0$"(>"@0 MV'(%6>B'%" (IP94[R[O6K1 [K+?: ,Z> <!>;R'TUKYU
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MU=Y:I8J)VWVB[(X^XO+7=4F9&"/3+B,/58'@ 5,'*_=]W5^Q( <S%'M97)Y
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MV7];#=SS(!_@"*QXY8VB1NRF&O7J:TV'J^45,3CZ2@,;X/Z^9ITNFKK^92,
M1EEP>M[=>L[(/4ZG,FKA)=)U?L!2D1C'M\VB[,<Y[,<ZO!4WT#MU\8I>A5[;
M!>*]0?H^@"3@CQEV/^38HYP#N8\%>-TF!+ 5 -!6'^<=!03DGI0V*,S^L=T2
MF"+A?^'ARNC76IMZ34\?6-OH"MM_9O?>%2$C"5,*C)K\ Z7AU!PH=<IO>+'8
M8H.["XN2%(^_>??#$95]@RH.C%W=B6T*C.OSMG\1Z(*A?J\BTPC/O/+INEX>
M?,,SV9KTZXWZ^U/MMBM-5B]6(Z"*VBL.UF'WM]'47]I9M8#J_TXIM2.X*,X
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M56111@E#W+#%&CT$S\05]]/001<-=/ ^"U5Z8BT LG!)KY2.XLJDLWARZ0)
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MC.",*FW-A$>D-B4"_X_PC+#&Y*Y +9WR)SL+#;'M]1 +V\A0/+Y1Q<9'*;S
M?B8S,S5S,SFSK\)Q):81J';RM1ZS#<&0Y2*-:B+."+9.TN Q*G%@ BV#%[^+
M'KDKC0K -B,N""Q.TLHK^&X1WA G-Q7E ,@N"D5H.L:M(,2+..?P=@3".3'.
M#A5ESHP/;)@1 ,+- -)(-A\#+2<RWWAK"]GN'+M--'GKX(QL/"&3"WFPAPRD
M$26#T(1//.^PY3*C-=J XXR'NMJKY>X0 $H%#KP+$3YK"=RK%^M0(0H@A0Z
M#1!!(2*T(+XR0B7-C-:C%@N" /3O,>S %[4P,T@0"' #*G5',DJENR+T0/\)
M0"V!H+R\*S\-HA5)BO>* PD[-  !@+IVIT!QD0@=+K1>SS%A,OH8JS/S:M9(
MAFF0M$F=]$FA5/6^PSU;#\?64YZT3&%ZTQ$'PNNB!A!;"NM<\K/$X':V"PA$
M]"-_S.I^AP"H*P%&8+H>(P$4XD+'3Z3V+46N((6.@ $ P$LO T^=8TW_4"!"
M@R+?-$Y-<BRI2PS\]"%%]*2LK#!)"FJ   T$ FOZ] KL0#1J2@M_L/EZT*'2
MCLZ(U.WRZ25?\CTWC0UECUR(S"#V#- VD#HCZKW88%.F8W?V%#)>ZK/T[.*
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M9'%RSRN$%$5^Z_ *\K""+(-8IT-I^R,S2.IQ%73-T,@9)71Y'G?\Q.LQ!H!
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MJTP%/$S7$ 4,;/#!(PP1WQ(:ZWEFI&*"J.>:.<D4QL#:,> 1AVLHL3!=:>"
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M[ !@>IRL);.>%2WQ80$ KMD"^9ZU+=VDRS7M"]<35 ,:T0" -NVS92;U]Q4
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M @#.Q1D U*^9ANT=-+TBMB1"5*R6_^P?$DE:R*/DD$A;L^H@#U4?ON7090Q
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MXX>-A)20QX$ZAN-[7[ASO@9^[81K:_9&1U& PR5LH$A(>Z=2;A9\U%<F\GB
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M2H&C%)*'QO7Q?]&9B&X8<!Q'9>I34''!' E5QSS@<4B; 1*&5F6V__\9Y#P
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M(O,8ET*D&_ P!P?_'VH!02*!7$6X-P4"$P\X&Z'%Y$P85S?R+T?&@]R<>!,
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MAL/4<G0R$D1\" !;Q8#D@1(G\CB9DQ6 [Y1,^=*-7D "\JAD(B,H60M6L()
MU;1&. =?.:]0@)+E(>=A43$!B'XB_.+H?^K1;)&FWCP-JXT$*VA=NU,PDQB^
MYBS63,&.=)KAWY2L13,A';M@(K)"D& /I1'3V/_%7I&267P/(:NT"=0F=9$#
M0B*;:X$?HL<"OHKLYY8"T43H]',_[,B5+<E[R@FQ4G3.VXA/S',4\U+%>H>^
M>E)SX,-:LIG3(=IX%W%M"F*$E*+@ "=^^-QF91L6D*SUM$_:4,+N)OP4"*!Y
M MD= 9"/B+@*$H,-C*1 -I+;M<G'L!E=_4C>VOW;UD1K&07=1032DI$,5GJM
MT>RGC": K %.(,@WB&YTD@<^5)4@>!U)C$PHZJ'HG=_CG8*HOHBH+!AY-L/1
M/X*8B9K@FM]+"ZPAK*1P0'TYP%^*"-W0D;1JP,.IEPE:C3G[LR_Q-Q,\011,
M015<01;D"H!K"Z+2)Z3_PHYX$XL?HK 3.B$["HTTDA!AJK_=R#%<B0E"6+ZD
M(#JL J88.HM<:@A;$:?@Z"G;&Z24B).;4S% >8&-Z*:+Z"1.*PW""8JD80S=
M> %180&P0)J?6XBSJ G+21V5* XF(1T<,  3. %.TQ\9<1%SXIR):"38XXX8
M* !W$YF%RL/78 $9&8&"0*Z168%$(*B<*L1D>RC1HI$T*0% ^)(V-+ W0@',
M")^+8)(0J2&A<S <<0C=B '%$P^1P8S@. [RJ(DTB0%&])]S.:HF2B<%(;U%
M:*K3"SVIBI6+J365\@D!DR:"\*.!*!F"^+2[BQ.<$ #T@C9G"B9309KLHPAF
M_T2V4KDT/5*D11,)0%K&_]F(UX <<]RCMHH-S'J1QBG'+MR,0%.E2]K B\@#
M3QJMG\@1;$*FMS$E.<$VF.*2TLA&N,$J'""8]=H,=2R=&E&Z<].76M*PLBC'
M@7@V%1JW==3&NU&DB&@FCL0K#)20"0Q"DN!(DP*E60ND!F$8X>$68806.VM!
MF[Q)G,Q)G=S)]'G!KJ!)U"/&HZH6;"F*!^R7F(BQ/H28MY&=Z< D+=JI^=LT
M%?*)>=G"#*R>/, 7'"".B%&=,&$^F.I$!^JHE&@P[7 ,C-$C<V04]4">LS0(
M>\$@'#F*]3(!,.B63(J(L."^6F2(;CH[A'B7@>+#,O^1C!<8MFLR$1QY0,.!
MMI*IB26+B;YD"AVSB93XO+C4#@!P"$.,"$ P 470O;HDB;,0$K3CB!@C@)DP
MA(MBGD5J+R02RM0#R@)YBSS+39_!"Z"DS5VLC\9B"-"9&ZB1&KHSG$P"BX0@
M@-HJQ."*!"!AO1C@@X= O@"L&";9FAWQ)N0C@,#<*;C9#.C+OMJ;3/,XO\TB
M+)^ '3BTDY10)2;QIL:J+%*!R):8J?B<-/0D$2\:COU+KGH\J74#"Z,0G'"I
MSK>)28-K1H30/PN!0THQ0,W2 X(*M$ *RX@(/-0(E,P)+<'<$I&1BLT)KDYI
M*Z2PJWC10/D23&OJJ-C0RXP&:)@4XD7X_^!)&[U1',U1'=W1K/!)KGBN89S-
M_&% 8#J7'/S!''Q#I=0P]PN4@2#)C7K22" !M)(04_2FSO&($?B#%2 $CHF,
M,CJ(1K@O$\"R4 J+$MB#'_K"@>"81E@!,?L--JTV(/L#%!  #F&40'E$!O"(
ME/@Y ?"#0#T+MJC/?,RD&)4=X-@-'U(@'G21C,$6HQ,5UH(@LJ,ZA9 [<C-&
M%S'4V1D[DM,->E2$&CL!.+4)4DF8T!@O'R$3E[B"1N4,$WB(KQ"9/7 V6=T#
M4!V[5+5-J/I-!/'%TL.+HD*JT;NB8-(U1..VM0&G6UT;#2D/,;J)CJE&^&(S
MD<C&-'(_9+J4RO^T(U-I#7!*NVMU)&:L* M)+G:,3384%%TRKD!K,%O;N73-
MOC02BX+HD[6(C:L*B2L8*[&8IGJ-A$0JMZ.1"&%BCW=%"QN)"(9)V'",K2?%
M(JX#,<4,CJH"IR;4,"Q-$Q;II#0"CXJL"'4<B2^3C$R5I)&P%0DAC@ZJS7KC
M49F=69JM69N]+A_=BI^:S8%#"G]"%QPLS,)DSJ:$J8@13!H1F)EXCZ"(!"(I
M@1[Z'53Q4!H+'V=,(]Y[B#5K$47(D9B(!(X)"Q?P0"WZ'B+) V]""JA\+9@J
MKA4I6_#Q#D:LP7WU4(4XVH5XPPU:F[,YB:/E#1AJ/=:Z0"9!-%NY%5?_RJ@3
M:8JPE8RG09/!NY!;7-P-I9IY*1BD103E&[9  ; 3B! HN:+'I;?P@BY]$M9%
MN 0PN(NH$K@Z2U$&+#*UA5W5 ("=:3T,&ERI2-&#>8W2,B',?5@?ZUV, ,$V
M*8Z$*5YV"ZG;X$.)25ZS8P@O8C?9Z*DE<]"04EZ(D"BXX\/]:=[K8-Z8($R,
M4BG:;=[L/1B_J<H_,:GNY;[U!2*>/:"=N5G[O5_\S5_]'9:<U8I?[=G7C:6.
M25^HC V4>DH>'"\D!0",S<AC>X$&HPZ<> $4$)7Q,D5]2<4K8!+T$!#VRA^1
M"),T,82# 02"!8O2$!B), X6,(1 H<?J4&%M_T2,EBB!2+A%&68^%R:5(<5=
M3_U!]2 <P&54ET#'!;Z8F> EB8%($\*1B2C<4!V[0 $/A0HTI3OB]=7AI.L<
MU5C5 3Z)X""  C+%@((@$E";$.%"P<4;?9K)T<.SW,S-/;,+:?FNYS*AZ5GB
M5ID8_E&7"V1>\>W>970EYT#?X5UBDE*RU]1C1/[C03-DKIN8E=VF)18HC6C?
M1CY$AV67]#5?L?EC@G*-@EDRY\7>Z4F4P2UE=8'?5+Y Y$@4I'A9/_O?^MU?
M6[YE7,YE7;Z*_LV*WO15F&T*V4D4'XJ.RA3:L_BL@UU2A!*('9FMBCFRO8W0
M#M3*>S&/Y @+;5S.AO_P.NE1&AC.E(3H* -]B)+ANN,T"":QIL L0-S*RG-^
M-]PH@1=;NNDYYH7 B1)XBDZTN:6LCK4\.(QHB0A.Q")QQ4"2C==;(*T<B72V
MK(3P%(E"G>HQK80DS7U^E$ IGK9Z"![THXV@$Z.80\S\FO< 5F#VS=MTBSB.
M8].C"]!#O8&C72+5J!<=WM2 7NX#9)9A7F>6OTP>".:2W]Z]7IM@F"-ACLO8
MB)3JY#7>Z9W&Z7>DB*$.01#$9*S.+'_Q' N*7DE^WA=5#W0$H5=NY/+MY.5E
MZ*+AW=BMZ85Z"JM6Z9G99;HVP2 X@R,8 "!8 B=@@+@X B 8 +_VBS(8@JS_
M" (G  +%%@(VJ&O#2 ,@$ .]0(+ !@(CF HA&( RT.5>QHJ@E&D_Z^&W?D*#
M$),_0E2E5-*M8U**L!7V0F>3'M$3^B1*$AD1BQ[+DC YRH."!IL'U##P$!A;
M:;"'N(,7 ".%6D5O0L.R(=1KW(V4V)J!.&YS3#M;P:KAWM2]3 X;^I+7^T+M
M>,HA]L$E/HB.N<6;"!1K(NU3#AE*I>W7>+?,&8% >8F4. &#^0HG 9(&-4<J
MMJ%KQ) &]I^)0#N'N(+WA!LP(@CZ=HF**58@-=T2A(N6SDU@A.G_#6:V!NN?
M^F3G52%T$63H>!A0%N3B:([IL\1!,]D?*0[W"%Z9__QP](5JXN5=\Z6(L7Y9
MEP4U[^7#RS@3%V_J0\;J\.WJOT+EL_[JM1;QK*9QLW/D!_H@S#")*4^BF79L
M+,<W(U!L+N=R)H +Q5X"OV" -0""+[\*-NAR+E>"+!<,O6YLO-#K+C\#J0@#
M(#@"SIX+$OQE6H9HYW7%$Z$X\QBFLR !\$A@HQTFW6@!CQFQ<*I0!\X)O3N1
M9=Y+HWG<C"&YX_[*H_E:Q3&(PQV[L\"J!GYA 0@Z;MU;\\@Y%+:UCB&!%_ZE
MJ ,Z%,[(66<2,XR(I$,Z?!U<CV5T7*\0?X;1=DM-W9W8.-/'</J='T(5)OD\
M%;+;V_JYH&,]4P^Z'[H07G[?M%_//)$1=I0D=CK)"0' ]<PI0UK/B9B(;H&C
M,[E^"M35S;IH7=>-#X)2J$->'B&/9#8NWMXM9)_><!+::GQW:Q8'&(MZ#@_'
MXR>/ZHDAX!6*T84:J6/$ZIZ*T>,%J2CW=^1@&>Y[%[)6Y:S^\+7.J(+'9%8N
M>8=2,H<I*J'_:7.8MZ[$5O,N'^RN*(/%]@LT4&PXMXHE4.PP    $T#LOYR_
M\YCWBS?8Z[PX Z('@"T' JD8!<7>;%SN[*NP\M*%<(40;;]$JVQY5#0\S^E0
MX$<= 0Y!;R8Q'<9 &HXI 3N!G=D>HXP>#S;KLF(68NLH&<5#C3] JS4ZGB <
M@4LM$BU*;I>('OVZ'.1"#XW3P,2GD1$K+>_8DA&[5 I>4MB@,0C&TC ^;>?5
M#5["XQ<*VPZ&&SS*J,TYQ!]>S#AC(_%8@0$;_4#+@RU;==L ,YY@ 8\8<"2M
ML+"P,2R%N2C[_)3(:#^;0:")]]Q\:?IY=P"F38ZWZ4-D9>I8>!LO7_?]DRG_
MV>J*.OFC1G&>:Y=8?@Z!<OC8G7$E?_+DJ"B!*B+IKPY.#JA%OGX1_UZ WN2/
M:OA_]_=6!N1[5V6  )!B8 J! PT6/)A0(8&!#1VF:-@01PJ*%"MBO&@QXT"*
M #Z"#"ER),F2)D^B3*ER)<N6+E_"C"ES)LV:-F^>' )DIQ E'\OL!#*$Y9N=
M0W&"#%HRB! T:$"BV8ET*M6J5FDN =(F*1 D00;L?/HQ*E@@90<< 1!DYYN2
M2("<N2IW+E42,3ENU,@1;\>^>3%B1)CPHD&!A0D:#IPP\<+%B%.T>&&0<./$
MAQ4NQ+'QXT*$B2^F>+&'L4+/F#M7?HSZL.75I1L[_R9=FC'MV:AOD[Y\V?'J
MUAY5'YS\6G!KQA0;?DYA(D]LUP(WIDY\A<!' A(S\Q;^G"]@Z'_U_NT.<Q'Y
M\N8?C;H+GJ]>]GTY(@2-^?!ZRICM[][-^S3@QX>M/S218A'AEA B$3UT7%\)
M[B6<?<W-!QMPI@%7H$#3$;@1AM=AN%]V&6+WT$(/"19=A=OI1A"(Q/'W6FHN
MYE8@=J?5YJ**+ J$'$37<>===QG1%:200Q)9I)%'(@E&4$:(1 002S#Y41!G
M9#4 &E&"=,9.;C2Q!EA.%!#2E%5>*=).2P"@TTYE\:224DC"&2==3@(1!DA9
M!164$Q\)D6>>:-+I1E!,A/^DIIR'!FD73'M]YYZC[6UGXVT1SJCBA#<.Q(()
M*U ZH*4U]B>?:^\1@(()?USA'Z:="H9(JI.R:.F)LGJ(HZPEQJJ:022JNBJ%
MM[7W7FT4ENCAK?<A9D()Q;X7*HVRBJCKL\"^UVAXC?ZXV4OF<4M>)NKUZ!>C
MU8;+VFF@;8<?;/FQ*J&Y$(X(T6\O$O#JKCM&=&"]#4K++ZPO#C?ML*K)!V"J
M 5YWG'7KIK:O@/ZB"*.[-K9W8$(Z2ARPP S/*F.,$=KZ+D&\[GMMMC\"AJC*
M*[/<LLLKJXDF2F'X&59(4=4,1!,@T5RS6&KM)(819]9,*$IJ O&RTDL7NE,=
M(!W_8=1';ZZ1,Q!I]>RGG1_160;37Z^DZ$LHMU??N(YZNA]]E$8<H[DDE&""
M"6P+6ZO$O_W:60EQYX$(@"!O_-K"V+U;W*6M062:XB8^6V.D.:J:8N"%5SBO
MN8LCSJ!CRQF>HN1X$Y@YW73[:'+9)Z>\;;?<<K)HZ>-:2S;*OZXM>Z\IJ\9K
MY-.N*N./_^F^W74 7E?[999W^B&QO"^NT&\2+7RO[@2J3;W?Q8M+?7]Y(]Y\
MNO]>VN^DU=LH'.Y]L2LINS7^+6#L[N$ MOSSTU^_RF)LB=):.]F)2)]"<>5)
M1 ! S]8@I:#T[W]'$100< ; -NS$:REAPI+L9\$B:2EI_W>2RD<RJ!*D!0$
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MJ!3[.2)GI9$A!=C^[9[(O8>IY $ ,& I<MH["I$L"H0!"M$G"H2IL&(*4*9
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M0NRJWAH$XZ: *[8F8H"F0"CN;_&1'SY?RD9<'HD+(6&7@5)K2!C@IGR$W<9
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M[%&^%/VZGT%UK\&-Y<<.\%<6;?)>#*4M8E-=;!,UW<:%('P1H,(ME/X)E[2
MU7XF99BFG?^VZ1I:7\:2(&8@_]%J!7"17I?YR:G.UBE)%#)=TB7+)J @6JE9
MJ@K23FUS',8[VH4])D8S3FUB<*K5;BY\YB-[O@ BK'#W# 0B$&=B%"ZGS3#9
MID )J*T['J!J#L35)01H(FY%_.VG,6#>5FTX!I5H_NTR/\;@/J<5:[-"G#-\
MAK/R:,H!KJ9 4" .3"Y!Q&K5%@3FED;<\",W4[,$*AH BV!L"7 A"RB0Q$D=
ME'$9QX&0R"M(L  1MVLWPV ,M&M(T*"BP)ID!/)*LW1+N_14#&])V&4CWFP\
M97*7(A+T=F7H'F0JMT=]44\)5A&4*MF4YJ$E8[+S->]&49IU=!%\*2^9+ME4
MWS1VP/_4F?'IRY5=<%G2F&V=7Q)RDJ7?G!Y"41JO9J61__Y>5@]P0CZ< 3,J
M0FSCIX0=9$)PO<1 ":@(>$HP"A^& >+ $V?*+[(&!3Y$*4)=J0HD#LWU<Y9G
MV^KP0 N>,X+G9W:J70OJJBX@#0?KPCPQ7',J;U@J0:\F$*\C-=)J?F8NL18P
MM7JC0>PJ#M"S#"]J"C!N;A!V8P, ?4H4 %[<4RG:OE1*3@GWD,:)'61T&3\-
M761D'8>H,<)@"G'DZMKNO+[T=6-W=FMW3-NR(=ME.PV5>NT:;U0?%2F:]?VE
M?BJBL#T:5_O:5+,IR"4R11$85\D6DSID4.>607R4V%$+)..T#L;B7X(QJ<M2
M-2MC[R?OEL+F&2S-\IPZ0E'"'"YCBQA*]'[Z%O_]K6*J*N!-\V5^&JI]VA_X
MC:G :S6R9R1$ZFT&\W,RAT"#(GKNABT2;C8;Q*EVID#$30461MQ$YT%7]HZ[
MYGAZHN<>*'*6FD&39D5P#G*69C<'[@^="D"CMN$N1#X#0-Q89Y,;;@SP04&6
M=G$.IW22L$%+\6Y;:PJ,.&(V^67^FD!!I<^%'"8%J!LNB*7!_XZ<('=RIYY5
M-/?JB@0+K, \RDU)P]IM@D2$CH9V,WJC.WKP<O=&HO6>!>U$_R?_(<Z!?^^"
M;S5]^Y-\T=?(I J& Q0<SB$":MSVIKK&^-&O8 ]R9264^1[[^AIPNZ6>*I+X
M96^<K1?2C?I]_9N1U;2PC'4DZB_QPNFPUU1;F^Y_,Q7\X69 7NM &D8&!ZH!
M6C #1,\L4C S#S$#]_,T+H0%-VHF47&A#RH('P0Y/Z?<[$':X@81'^I S"(*
M'*,+$X0%Y\$3?R9TICL 6/!C@S9J=X8%?R- )W9GY'5G$'$(G[N$UK,YWL@^
M&D9M8RXXLVNR9/QCLJ!.;S4>HJ%K\/^AY@!5?X@E2,6)$B3W'' T#.;!\*9
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M2(+02)YM+^<WB]+_ GI[V/54=W4#2/D6]M["%+ $"R35 @^!8"+/,(#J@"V
M#PY]&$U$]B4OKIB(%Q*M+'D18<P><<PTCCNAEU'?HGH'&)S0N![WQH. ]H3A
M\80]9K=.372[$$!&UT))@E4Z#TGI,2"["B%&X 7(DL)N:F(F["YG\'[AR&RY
M%Y(Z=XML$%T?-^9<#>]X^*4DA(P2^#X#<SWUCM7$MOV"5D<11O\"-Z2@J,-
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M\%BSI]&[7]&'Q90;QW/_7,=W7%&8FRT"DWI)5%I)FUH)$JL<;QX32421$2/
M0O6ZJY/:VY=AN$C+U35[HX], [AL^MKX-^P(EVR;9VBS&IA#VB6:$?TL&<@1
M6S$B)*+[>PO#N:(CU>?R;,G!MHTZQ^= Z'\_>$)S=:?]F0-Y9 4(I[9)2'XJ
M@E4.XF8"*BD6AP\:@CQ80&BK')'K\E[Q4G-7^&PX,)=YV[\\D'0N)W($EL=/
M'=537=4MP\?70FPO^68%V&!J;J1D&\)/_#+?51T#6JAX-6)\D&"HDNDZV])_
M]"JNDJC.S:L;R==+M!V7!;8SFK(Q&EQ#K]@^.<C3V-0/&$)2M#)J*MG!N9*]
M31I&<UV%:7JM=,+<$.FM_5$T)_MV0D:W$XW$ 2 I!@K#)2?3 &,D!IDH_)T\
M$"W@S6*0Q6JSAPW;*)>8J6UQ![>70SVL QI[51J521 M_U8=XS->XS=^+5I=
M+3Q96JFWD4'JPY 02JG<PTQ\0OEZ;B#&7<9BQMV1R24YO!UOYYXR0ENC0/K<
MP!-W WM5DX!>HX$.1]LZJQF8HNV;S>L"0C:Y,H0.F=-\/?.Z/GM-_8PMK"$/
M;D 4<O6U8AR773FI2=A/)PC#:NED(/AI(.3',(0E)@"C:4E\AO+)[,/B9GZ%
M(32BSN/R\=A1Y6'9TLL;XJ%J%!D/I\66,JL%C^V#XQO?\1_?N#W>;IW[;EW+
M+N/1T]%)7]T8WE5:@]/*"'?XW+B[D,79R&_=\T:LDDCX6J@J?[O:52 9&6F4
MY<-6'+V\M^G7YAQZZE^+=0H3,_\B[XR,$E@G13'QO 5#<XX^F*I(YW':G7EJ
M_78N1O0EE$;V@']ZZ%0)HQ>GV]$V8IZAY"'$P\,;XCD*#0<"'MP2OI"6[==>
M7+W7>'*!UOM!G?UQ]:--)7Y-%_+['R  "!Q(L*#!@P@3*ES(L*'#AQ C2IQ(
ML:+%BQ@S:MS(L6-&$A1QI! I<J1)DR13H%Q9,J7+% !6GBP94R5,E35OJJ2)
M4V?/GSEUQAQJ4ZA/HSYK*K69\F1-D012$(A*]8I4J5:=VB2 J&=41%:7_KR9
M4RQ1LC;/GDU:U*S/IE"O3J6*56O9MFR-\M2Y=Z_8DUKSEASK5O!,H&D))][)
M>'!+QBS_9<)M+'/BHD6<.D8M23?JS<F/7T8^#/EI:<6G^8Y%B[BHYZDFO\J%
M/7CIW[4Q'>/5?9) 5M--[[(&D*>$3A-[;D8RP>(O8@![3-@<86)%VCQY4JQ@
M7I,Z"IL/3'P?WM-VZ_+GA:_&G5AXT*.%U1;-2_2]>;SDD=9>O#<V;+HI>1:9
M1P06:."!"":HX((,-NC@@Q!&*.&$%%9HX4 @3009:)0]=EAH@#T6WV+RY97?
M<_B=R!I\1^DWFFF=2=4974O1=1-5-@;7'HDIMAC4?3\J)ER B>%X%5)KL6BB
M7ZT%69B+*YJV7F BY98:4OD!]U)*P'T8&8>6:>(18X5M2=EH_Z(!V1J3)DDY
M8I HWBC72CE%E21JZ+69IYYTRJB29Z;=AM<+>2B%G$TH,!>G3]$190)(-Y50
M:*(LX,2""9'<U$=U@P6V&I)*NJ6F>O;A)Y]Z/N99XHZ"HBJEAR6*5>6?M(IT
M!:!^PGIA@R;TZFNO+[307$'+^1K)027\^FL>Q^[J[+/01BOMM-16:^VU$68H
MD9G<=O@E:4NQ"2I3/\V*&GL[XIGD7>RR"&)@LL5(XU:U F:CE4;!"6>4])F*
M99 >\B3@O>>I>I2.4/:W;FKN^<LO:4U]%MA]5$)L,8@<OENE1(L0*!FM'XN6
M\9E#,KPA8%+B>2*<GL7E6[V=UL=C3O\1W\7A:U?AZRJ)V/5D0@M#40J=LKU"
MBE-T1<60'$Y*I_"'"7_4]/0?6&$B7D_FDB>HPXMU'6J^>^X+ML%8LK7UUPW_
MVUI57NDTE[T#8LL1T<HV.U +OP)M4!YT^ZJMW( '+OC@A!=N^.'0_@W1R2$W
M'C"XY)[LW%G[D6WBPD]:_FFX9';NHLLI=(6KE7'-.J_*F&]N=GHI4DQZ97+:
MZ>_"9#O7UYE91NYFOYZ_'JCNJ)=[)L9>%D\\EQ(YXO& L0V/IO'%R]JDYSRE
M?*>HM,KWMFKHDGI8E][B&CKPJR.U1PPY(5=3HB.@=VH*>!-U?DV7HA#3HS>1
M8$),4<D ]=D?76M8ZER7+B6Q:%3SH=VX5@0JBH5M>E.ZD8#4([M7C?\$<1/I
MVZ]@(I 4$(V#!.&;!O^'P1*:\(0H3*$*5S@AQ3U$9,_[V//,Q26U/5!B:%O4
MP\PCP+&])406@QV?WL.VEIU,80><F0%MV+VB3$:&GE+@PWZ(LNF)R(DFD]A^
M/"3$'U9N<CS2B[<X]*TRZLI",C'BMQYG)AQ*KV+\J6*_G%0PV2UF@@7#7@3=
M*$/.G4U?.!$:3'ZF'.[,QVM#TPEU6@"3&)2@)MNAVM/&(Q4_[ \R8-N:]]Z3
MPQN^#Y$)3&($4^>UU0&2<;P[G=OD1*[@L# AOAH6 $80G5[9+5$F*$$,;+FW
M7JU@("G I?I>*;CQ+:4KQS0*,GNRS)LT,R;_SS0F,Y5)S61"TYG8O*8VI;G,
M;F933[,*I\2L1$YN?O.<VT2G--49S796<YK6A*<\V?E.>L;3GO-,ISZE"1M$
M]/.?7P%HZ 3JSX .=)W[=.<]$UI/ABX4H1!])H)<Z!!O>:E;W8+CE6@'JSVJ
M36S[VEGYNO2[FUS!G\*;F$GGLIF<"0^,(54B V?:Q"Z!Z%;BRQI[VC6V,@7P
M-+Y+*9;,!3ZB4N:-L0IC&X]W,8NZ9%=:P:D,F5J\(4+P+R!Z$D_/53XYB0ZH
M88P3OJ@H%IPA3$5BP=\@][ ^1<GL/DA3I*\*U9/M],I^LGO!'F1GU*O^E%4W
MG!(8 RNS/:T,+W2<_V*<V)34GXQN+!7T%C$1XJNH$219U;G;7?5G O051(2_
M) AG"S59N45B!:A-K6I7R]K6NO:UL(VM;&=+V]K:]K:XS:UN=\O;WOKVM\ -
MKG"'2US8CN! %&V(XZ 7P]N)T8'CZB'K"H@N'PYV3;CCC!U?0D'8T.ME4:1N
M3U570+3$-(XXY IB*F?84Y+/I[=C;]I**D8<!K&CG3(,])9ZT1G2Z4*.I<T8
MS0@[FF612>"KV,[^TI6Z[*NE9;M>V70SHC+Z\,(Q64$,/MJZ0R;U38QY&@/
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MY;1*VOADW'<0BH"%!B%,' 1:";JHC-JHCHHA5&9E$:>3"==7,29X<7B6,=6
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MX-5'< ;4%Q'A/0""4"!E, 0)40!#  1>+01E[=T/\=5LH!%?#=_P?08"$09
M< 1F':GFRF@$7M*_?<*$Q:9;Y9WK-KR]DE:] A/&ZRCV?!/* C0I,+V&JA)X
M'<_L?-0QX;YTQ3[+T3[]O!;J>\PB(>(9MKPEWM IH#]/@;\XY<B',)O_2\';
M&3D6'(#!6'3BU"<1Q%X/K++G.MO[6LH1EY-E:&"\(U\=5CI3>Z&\\\U$UY1
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ML7?."JUV(@K;R@DI79GB^O9)GMNM"$3T53WN&7L:J+NRB /JZM2RN+*NN+N
M6,U*6I0PC9'V'J$]#]DE&%9JEN]% 7TD@MN-L)H+7U>2U O^C&6.\W+W9L_-
MZ3^XGO"*'@CF(CBBT:_(\:BO$>\-WV)0\0"@\? =U@[AWT# WAZAWPDQ!$(
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MR@LD<P2S/,C$60:?U+8)A8GX)8^LC:!(!G>XQ:V:XM7G*/)!P_N&N=9PS1@
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MRPQI) FY.9$:U$"1&#6^5,&\Z;3,3 %Q3$$+"36)N)!C#3\B5$< :(&.<D>
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M!-EGUO;=[MB>4:W?JJVHB>!OL0.WOW?SP),1V(.YUS0,OWN!-^F)!P@3 ED
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M?=< #LN(D=]X5*$N[N((N9M%J,PU =P,!I,0%H01U ]B$=8:;!8SK9XQ.2,
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M):5EY1657[Y6-1 ;FYI;OK5^[^[YU=O7/S X1*9,_)Z<FIZ9G:.MK*ZMTS?
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MFT3O'BD?K;/V;G2[&K'R1?6[% >HS)TG%1]O/Y[49?Z'U2O^'?3^@XK@1S&
ML$5)>TA<+GM0BF<(-7)+NUMI6GOEEX&FH&90-K$XY=2^'3*+AMK,;=S)<YR,
MWCZ'I:8S8307IO+647?87>I4,7V^<'L0L^H!?S&JTU^_);6E$+;NI6:A8<&<
M9-]F?8S]Y]6G0__(LE4@G)_@0I)!^A?3C/N?,@U""^U S0O81IG%1B,;>8UF
M276E[NH].4\>?QV9?K8;D7U3*]78Z0I7LHIS@.-J_5*C+_[(K$6^ORNSRN?1
M)1L+;A3,4 ^1(%X.$X:[GK3A /S, T$3%HX!1R;CEQXNQD0F\,AYRCA_N7TS
M.\NW(>:U;DH#M.=9&IC+=DYPBTTN21LG?&,%_4,6#_?_C &9$:0CN:Q383LQ
MW8+E1<C P@IS6R?4 ]O.FS?3I%]7Y$WY/S6]^DTV;+GCA%;<7=N%7O1>+I=>
MQFV:\G$K-0/B#V-IAA%*8\ QY;;/H-[G!(63%N[YH<A.OR--UPKY]1+H+I.=
M3/E*#G"XM1N]X%O,18NN)',(]"-N9*G1A!)2WA/IL:S+%'USUTK>U4.)8=F3
M4=O5SK3N%UYG'4+7#Z-7XC)5V"VJ$):X#[R#M##+%7=\XY:,O?X<@'4D 9_S
M=/)A+4%W4[&U0Y)FLV*"0_Y96#9C(L%#V>#0AB,U(FZ1.C:FWREY8]9)LRL@
MWI)(-:M\V&]C$^0[TJ2P]WA@W-&\F\_?)*Z&HCZCZV^A/34%V-\AU"O<4CQL
M3,421^][14,DRG90#7$4#]LF?I^\H=E^FT!U7W7_@86)NXD3"3HBZK^J[71Y
MPJYL33>APTD[^]D";ZEMY/NX<<VG]K!(-/G: "*?J+>7VO$JMXF"VULFIIY2
M.]IM(M=_O%.9;U IXUO6^7A[79<#C,-3O2FG?N%$8J#?1Y,L9H-Z9RLSXU3"
MPS/B3S]<Q.6O.&(:]53ID?2[K%2\&-A&B5R(0L$0(@T*>\!-RCD*?!&R8Q3Q
MH)\HA3]HJO25W:27E[S[6#U_\*\6J9G;#/OL_. ZX!'V":D$CRD$B6S^5;YF
MD3"T4(W^Q+*\^]AQA6-=N53E5SEXG%!MJ:Q1R&T)_KV#^YXT>H@]=1$JMXO6
MN0I]ZO@U9'UL9#C(::*_'?G"=].PEB#K-<@8#M:B]L6PLKG)]T3N[4$9SAN>
MI#5_I.:0,?%J9+#MWKA#/)\1Z/Y6":_0?2"YW;WMJTJ$@X.CNOK8;W.U0+C'
MEZ3#S\>:)4X\<FE8'O0BX^K;T?5ZN]&[4'M'C'#L7I0259U$WPC79EE3O$0^
MUH2$&"?-20?$J5V!>KX[=EWVANH7MX]99\6\)WN#-^%;2Z)M(TDI:RBG0-@.
M5UR/"'C4LH&P<PY&M11<WC?+YJ5J1D"-QKEC+-V(%BF;QPG/2 WI5\1*B$%/
M]K RQ1<M((E[[8J@K5_NW#WT6W,3ZY0G(I%/S%1]T#_BVY>[,/E=PLHX8.\S
M":LS\BWQL-\1((2-#X"QA 4RZ/=9:4P_QAVD4S$50LR41!I1"B_N6U)?2-\:
M^@;U;NS^WNP0K1@=F'U\\Z6+W%W:%;"';>K%M7KSTU<YP,]Q' XV/M3 =2N\
M+M2@EP5<2KL]7QU6T6U"=^SP]O99KR^2,PZV:OB5+T]YQY[/E)C]V!>GT-&V
M8G@/G&:(("^R,E$R,RAMFC(F9P2AVQA4ZE8A0W]",=!JM+]9Z7/8I=(]TY""
MR$ES&U%,3'FIFK)#T;G5?2V<S3_)N(HT ,FT6/HCUBNF+C5SC4O/&W#)_F:G
M ^'->K\5CGZE\<[;99SJJBLIKS05$QMO^5VQ<B5)('.T'1->AHVVMUU\\A&I
M#WI1&4U8"%L!_ X3 DT:9+R(F<J;_EA!D_QO2:/VKFVN/TF7][[3<FSC;:2=
M/]CV)MG/EP.X_LK;5#5QA);Y3MKV#E?WTW[VSQ4G387W,%-(7HF;%DY/&.:H
M-I0^"\-6QO(AC7\2R/*T@X,.<SM[%BLVT%\RMS<RQA-[IJZ^]ORVQ(/K)<60
M2D@-%MM;(.7SJ$XV#]4V :6/"#I';:S [XX\6T$SQD5X3E<;TP1F']WMZMR1
MMP^:XOU1<U#&]ADT]T? '+?Z6=:%\M&?LCYQ@(=>(MSB+_Z&.^-T"/5<=D?
M+&(O8:[W[D\_-7@_V6)ODF/;U-G<MX<29IHO7PCFQHJGEX4.NX>N_RY=VZB<
M=UGM9QBLU 8P#?LGWH+2MF4XH0?VBPFY <[O24[V,Q4-JU?2=\F8+NS7,@%2
M;8"HG^W:QR,>;EO)GE;C8=6RLM'.V$B4*.L-2NT&*$Z.)&8LQSE!0%'RJ&T=
M7MQ2Z,:<5%7*:JNWCODW_T[U-_@:4ZM]029'E"*X9OH4Z$F0JM%G0%"C"GMJ
M0$TJL0'"K6S%-:+YA+ :"-E R]81AZZ8"BZ0&(T:]4AQ<?>55+]1-BM476TZ
M9*(7-]&^BP-H+)'$8PC94Z0JU[0G/H')RR4+V(F\EDEL'62PI1E;Q@'BELH@
M.V9(0_U#GAE^!7-B[4&\\:DISIX9T]7555\0BXMOC![?2S]OT1&;V?%F!O43
M6P+#<(![WZ"Z?A/J4GW]YK1G[]*&I KSYOH>=207&,M%'+&H77Q1ZG"QZPLQ
M^YN=KO*XK@;J!9==[GF![QD"['X8'U/K0!7XD<9G2EUZ3\X4$R)YTB0K4CZ8
M!WP8&OJP+]UGNUK8J)92K/BBS:Z!?FZD%[K^&#/T+;K>R%!J!B91HTF&"]Y$
MA)OU0DUNDW%R ^<^.3U(M!_^D2^7OJ\J#*TS:?VS)?"V&30:(FXBWCRJ<WRL
M(^#TT$5YO?*VD$*4@P&V;2]Y,T?AVG":4ZP#VG[=<'<VX8V'*ET9M/S [N,
MP'J\Y;A7Y-JY"<UP0Q5"'Q)&@0BY?2YULBL3$AP='!H:MC<.W9L9_K*0XJ]T
MI-X(<QP499SF6LE6F@K]- T;@Y)C'C<\!J90\QO3?&;WS)Q,MXFF$/;8G0A]
M:NF\[5"./K^*4O!%N4_;OZBYGNI#6^2O&&"O]V1P)<*C+7G(8$GM5T(AK!W"
M%6""L/'7\'UL'5A# +4S'%V6,1%)KV0>@-%.%D<RW!EJ7_ <P.[$IH)5/ ?H
MWPRAK7A^*]*D/V2]@OHPG)@W2JDP8JT(6PPB0:HW^"$%?UA91I(3U>ZN?*7_
MSOFA:POODU-UK76X(<Q3+%\1_A"2ZX7"[H"6$RY$$0&WC?0XB.BP(S5T^EFA
M6MEXO8)K7-6M.*/=\5'O79^ZBMG E.YZ.'J!2AOUPS"^>5B)TU<J@=P2OL3<
M7H0\T:^)=)]PU3;5T#E58_+[8K)#^\<3P=2JX\=S/R<[*R6+RNXZU_+L$MW[
M_1$[IX[1L@"QOJU1(]?"(-!-#J]AYCALOM%KTF89NS4/"MK;X\+70P7/=J^;
M+VI:E_8$-"8YGEP*<4D0,E)\WJ)X]C?O<Z68;TUFQ"-\.^X0/#G >#KAL\H3
MIA=#""%M25,APG:"# OP";6SL6H>D6-&S4S$7,+;;6MR\_OTO5*Z9*ZXV#MQ
MJ.WN\X(3&&7?>*50S? :'3)AB&#-BOP-AI.QN]VSA*K <][^05Z[9MMSYPS5
MP_:)D<S'%&-4R!IR;GF(MTFFMK[;5!^\6G,^^<(_-JB_)"28@?,[-=GM=G*C
M<L)K%;;=%<>54N-EA@"U\W$>>"*5)!S@%8F'UE#SS2GH2H3S!6KL?'@[Y&Y-
MJ(A%[5<9Y(^L.]]*"@Y]WR8>)DT1H'OW]CYXD#W/#CSE?M4[357@<':E%O?I
M\7^TZV-$.4#K%_ <NUG(A0.8K7TG<JF]K1&[E^GF3";L D-NTFRCR@]2.LV[
M%@[A:ZL.QRMN>C<6+)>+OAR7.YJ$V%D)_<L-I#DO4%>$?=68:LNN?L !MNX1
MBH[V9LKI7&Q;^ BK6IAY9OBH.'S^WL; 9L@$;"&?=H[N7=$S!49222WX[9$V
M+N;[H,9D1JVZU[YM::*O)LY,GM,X.RT;\2AF/'_M'-V!UD\D)9!VH110+9#=
M:R1)Y!7('D-UXPEU>T:S305;.*)O[T/GIT/#LNZ9%CEN!Q/&V_P- ^)VF-YU
M^<XRY<K:B[#!]Q25)O1@K'474I .%P&7*;!HZ#Z*Q8F^:?N2XE[GXH0%#6)0
MB,[ ROWRN^*JPZ\^__AYUO+%ZP M1->&>Q/)P<[?K'JP.G]PB!6?\R1 )Z_?
MDF")[S>A.$IN?4ZO)#J*L/EO,WP=0*_Q3B)!Q()LN6\6M;?"5:5/0R.KMWR[
M4,W*B"5R1;L8:NB;?>),=][=)SW\CBZ+HQQ@QR#(1]848O?;\X4;2@^"MM?
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MWMBW'6ZQ/CELVV<9VN^)?_K9/^.%6V4 !^!K]3<9OR[)2*,QZ#NH][DIVS$
M$G+-J,3ZM$H%$? V&2L*NE"$P\GN0JKF?2JI%U+M'FKZZ*R/#9R'/_B:Q9I
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MY1@DD^DZC_AG!N:Y[8I?VEO-#I9F?X-:7U=+2#)4FZX3*K18O'"H@JU.5'.
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MQNYP'._!"Q7['-NX4F[$C.OE=83^;NBIY'P-G5(0HL/4Z=9%4N-;Q)'/0H3
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M:B($-<Q4]$%]2B<_R9":/3=R.R4UI7QX;D/4?RBQS<O+T<;IDF!VFIA@1EN
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M!?D2@@+D$W7'Z$,>/TN_0S60B.7%D*^"0Y\PU&A(:\C3#EA^&&3J.[-R SC
M =ZV":T4A%KGNLQ8CZ%_RY<<),#E,S_"'^E!SN#O,BN-;BOKFS3U0&V(K$T9
M["E,-#D-[$TTL\O.N#0@5WQ&:\AZB# 9&:M@9/.FQK-[O6OD.MT"#&(@P/UP
M/K01M1,;68'R$EDX.)UB<[0Z^:'N@Z8VV=LQ3RO#)HW/[(CZKFO[EQL]24PA
M'XFK-+),R1-)*H^9.EHCOHN[9S\\,;4-')?^$&?PJO;[JO-A%:9!X5A!\;$I
MQ<;C)]--=-ZD6P4/N<Y<IE:XC.7O&+4*,+4<WI12F>( H'Q  R:2 P!H'2K!
MCLJ?[#.)X5G2-LP0ZANMC%:0+NN2*!K%^HC>FG[CXO*@*<DIEII*U@IC[V!J
M]M0=)DL>&;I )84OIPPVMHQ)/G_]_7OIB94.4[72$TL='::GY+.S\U!I??&R
MWT?JET8K)U:'.KRSKJC.QESSKUS">4T\MM63X #/4ZHY (+( 2[J0YV,3-CD
M\8 Z&?S'18W(MU-2?!  4:!KHYTBR@4A@CXWP!8CYI'F1?2X:OI_BS[WOJ(N
MEI(B,'9>>*##=&]9ZZ& @ -OSC=8"APR/R2NQ3R )>:8]6?1Y&/U#J,6W.N.
M!DS&'EETJBU/1.Z=#["(6-G?3?387]%[_((49=KU96C=S3<R**^"D#'L'E_D
MMCFV-,THODY@,BCXP9C#J$$)F&\:F:8FFQ"VW\A'5I6KYP/?H3C5(K5D:0.:
M#'T)1%"1E&1<F"Z"TGF@L90T=PI\,FH_J*%C*BE%$9-SNR;[(<5R7,W3=<^V
MG4+/44<J-B(W3!\*+$62"0)HDV[F=3[ZAY&PIY/^U)UU2'5#T??NO[WX/&G(
M@_6KX?OTK &9E"7E_@;3<*).9W).78-*:,)%2PDF&5)%L-3QW-[5'ZRA+8/T
ML1J>BU4/CH^I.>!=(XR.>$I=-Z@Q8T=#!*N=BOMD=L"AOU(!J6$JR4WL1J48
M]:XLN:;,#'I@R_.3MSN<:!)I6-^SVWC2V$%(] T+QY9<(/!IK JC7)LGA&E5
MJ>3"B&4_T6ZF0=Z7E'*=[-W?TTPC)B/9]_W;CASHOA-QS>E\5C.JD,W3-LDH
M\%QFPB@"XFB5OM%&*DKE>AFU>+KNZN+#BWO:/)%G/CX),#ELXGKQ8[6;UX6O
MPR^68_*+00%R,):H&*QVI7NEY =4X.<>:E1%YH$/%2;%@Y]9;=I,J$UO,ICU
M">3<8U5'&W>-=<YR@+UP)"D4)HQDR^N[3JD(?&NE1EL&JS19BXY4OKHZNC/L
M&-\@6<VS:EQ1?\:D?*-J/4_U668>?*20C";Q4FB-:&/J 91RH-/NGS0*KWYN
MVQ%NY2>S'6O1"K%MV\HT-1^*IW:6[VSO;@1C&:*@&B5_68.,C1II7+B.>MJX
MI303NO-=QY/&!=[D!+&\F"R7A/T>SRY(GK.//,\=<)#$AYG$AO" EI,"SZ0D
M>G\*'#@;W^#I-&7?,_VQ+LY]=<5+NC[,I=8'MJH57!.@HRG)N')_#]:9FA^M
M3I $78AVW3^5X+8]/VWV+WQAMY"5E9"'[XO)QET\ZGAPG_XQZ:<))F1ST7D]
MW>ZL ?6SUZ\,^K:'^4:MM$PK2R<DC&CMF;N46%+T9COQ&/=SMYF;=SY.(0#"
M;P*\["X]&:I53AX8W;Q5"@;EW V1ZI[LSZUP*[ZGDE_Y<E+/K.X>^[J=H4S
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M^^\ZPUM_&/6*^5.UR_HH+1FH83VOW.  4H48ZC+A">&''&;:Z7].*WC]& ?
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M8:BW8A0ICIF!4ZZBG=Y\.3H9J9.NZJ>ENPR<[B6<-A0O>I?@(BBZF^LE%];
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M=-DBNFU%@L>.&<O%>$9NOM_#?IR",JQUMU^ITXEA7@7EMJ-'OT0?PIG0Q-E
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MHN1/_#ZC7F$&3B$3%EF ,$BA&(0.5:=AB>;3?U,.H!"?3P] T@CC9JZ5!2R
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MIWGF3V?(O.]5BG&+[9BX(*76]3PQ9F_4 EV6C10.<Q#5KZ)XXVI_1?J$LGO
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M[/,!*(Z1BWL*X]6Q1KIVHPJ\=0+>3EBP!:+K']=>K'[ X>ITZUS-;G/_ZO;
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MJ,MEOUQ/>/=6B9)>O23X3^<J\F_N<X ! 8&M_5S+]A?.6/!\?U-G0U&9)FN
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MAD_\8'H5.)5(_,L'?7U?4CX8Z;T-8WLLZ";#<LW^?*6B(&F81 -H9FTP08%
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MS6<2<:3DDQ1;$N_S,-$!PI&$"0)Z1L];9FA1^E[SMN@IT>NL+R]&O+]BR?=
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M'C[D/!\/8G]M9;"6B>.6]>/D7)^F<@.]A.](".[$IO*U#JW*1?B"1L!VM=V
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M+QMW1KR1P-9IR-:Z%95'-$PQ%M%CJ\G::!,S^9 [%RNZ#V]43?XU(D<NG&S
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M/-PFRN<DC)/AMN<[@KV=K=X"T@U80-;SD[I30,/>*+96Z/:(K4[4<X?5B5(
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M[P8Q.!:I(117!J<,5<>&LM95%_3,I%N3N\CCP'X@!%DP\U&FY:I)B5Q\6>R
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MX>+W*5-SB:W%P0+Z$Z?<:S9.3TR;%NNXNB>&',NXG_3BT8GB1Q=1;_D<0-[
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M7D]4#RG<8(N,3+*K0(*)%&-9.[I#M7V]MK:2/(/#S<B<P_)K<7Z*^Y#F\@@
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M/I2?_SR\:*+LA*E 7L,?G/W8EK]__O\#][W]N_^[_Y_V_W?NF81^VJ3((3=
M_.#VH1ZA:9/"L'[VGDJ%%5EE+7&O96 XQER0LUEJ6*^9^B%DVKU+=GBX'4@C
M?LQ6:]).P6I<(^'R]VW6JTB][W .1;*6658;$\&3LE6)H@OUR>KW'O!,J46T
M/WRF0M%()R>G&%->D00(&@NCM165KI!7.PWDHI1C/ZHZ K?#Z5NR:=T\5D+K
M<(N]-M" B$WXH"]C&$$T&1)K>=)UNARO 1/Z:70N\;7P)(MXRM:R+$[W"V=[
M\:/&7A:599"&_%3S#$]C FP,LRWHC2S&C_X_;;(80<P,1HVDQN X0M5 X;+
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MZK:=:OY*KF;4:GZ_%%'(CQDG#AL98)NV6IMLKQUT4P:(%@3LQA05:O1Q;>+
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MH$#!\*#4B-@0FOCJP5*U2N0[>(&EE9Y+(%.'XZL>X:EHI9)O?-J=PO3B&^F
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MAN-#31AI!^\604R:/U\ADD02;/8N<,R=65.S=PQW35J,>1K]PBW6NT"WI3P
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M:A6^L8W_[7G'"@4GR-VXD*)OI:K+<3):/=/B25/!Z9\M'1U%H=+H.K!8"QH
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M6&QB>YN>Q\%? )/?C 7H;S94N"N-;#?QSXL&\@NH.&CP"Y]>>8[H:M^LSC;
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M;OHCLC%F).+4QZFU\+JZ>OB6<JRFY$*AP%@0B[%.1ZZVP[6]=WJJ+">.OE&
M,\W!XUB8^3QC%/F\<Y4Z?; 0;:?9)?][ARGON@M]3A82?F(%/.EMZ*!\B@N<
M(*P/[?K<V!&Z Q[E6T[>G!=6%BQLT:'/VRR]77G?RA;K'C42A/X.?PUB]4&]
M0K$0;R^ &&:"XJRPW5D7\NR$.9/L(CH^VY$%%#J$,>_?P:ZAGH.A(+RHPWH!
M(3"X_<K!*Z(F[J3.>7QHUPL9S]*\_O ]S;#!&H7]OLM_^&IM[30&[[-X<LC3
M$SN-O]N4U[@?1DMZ9__F<!*]MC'8K%RSI])X(CHOHM<AM%200]UD)B^X$+I<
MD(5WPVQ=7.5A&E_W<1$YVGD\*M/X=G,=*7;-45SL6DQHSPU/8?K8$IHS^F=Y
M+WI9Y0D164 +BQ75;KB.^1W1DR4%W681](RZZAE6]U6#Q![)+&]I"*W&);]Q
MKB;]DFMF_ZO#X_]-AU__5QV.^*O#J:J_K\#)ZEIS577M[ ;_>J2B(9M7E60K
MA[W MM:S0$/\P0(J=ES."[_0W2*&>S_I+&6F4>9\<"74K/BBB9J]K\@YX)UD
M.N.C1:H0#\_-ZV,O/JBH+A[U6/PW(7[QWV39G[C78*P)<M)\SNV-RRZ$,=!T
M/$6K)EJ5WBRIIJSHZ=T#/:M-85-#-4#7'0"L/4PI #=JK@1=;;PA-#<5QXAO
MG,]L]L^>#=,L5F)WV:W;XK=UG!16S?7PCY>J."/_G2>7Z00R8Z4,\ADS4D]*
M=YO]OFR\'R;8$3^2U&@YM5E'G8(1S\PW!"4RU?TR@6W[6;Z5$!5QR?48I:D8
ME),Y-4\9W+H7?E;H515+6V"/B(#1>9/XT+Z 4321+6Z_HGEX<K1%S.+&\X]T
M0N'5'Q9[JDH_6P>U]06&JWJ.M&)6-:E!.&CR\6I!;*=!G."M!,U*EV!U=9S!
M_$$D-0B-K74&W\1=0,Z[O-CA<=G/\SU@EHIKR/J0?G77D-V0"Z!E_:EG5"VF
MP@TQKZJN:ZD9VM@L>&C;W&!J1J=J#_3R1O#<B[PP?XFC_ )K[(E92=V8G(KH
M_&717J\#9C+#"U)Z/E9HO7<!'&%<,7U?(J[&MJ*"X6JUOIE).$3VB2>=A99[
MN$?_)AM DXRGBHX+8%)Y*=P1/"72W_I".7G<3*+]H>!P;EW$V%VY/(_?S?-A
M1OR7#MWO/7G9>T.:)E-R/SP*/%<+KD*L9Q#HU3'@$+(\HIM'&.L6[K*KPS Q
MZWCKM9B/C..[W -&L29)[J;O<U*;DVUW!,X3A<=DHU 75\?-PK)\/(*"@J2G
M+::G']JES:L+ILY\2/CQ@QHM- 3&?]B9/*JIJ)&L&8Y[F)\6A$2F+ 49N407
MJ-/HT-Q[9&D[K.7W)6/"*O(ZLDCE 36% H[MV/Y7M;]U!/^32S32_I8._&\J
M5A(/HL!HMK_% H=@8!(U$D:0'U(?<IBXVAYY_1/C0AEU3TPRMO]MG#RV8SNV
M_^.,L0+\G]6T/43^YW?X],.0)!S\3?!SDE H]0<(/&(QA.I$4E5*_CHGHA<%
M>*O-2&)#$2NI[NG&]7]NBNZ+^G 6_Z( )AX48&<'"UF$P5=GJ0]7H0!L9(<%
M)/&>.WREF0+\3H ?/E7_IQ:DPOSSC/I11QP%0"!"*  O!3#:I@"'!WC4#I@;
M/L],[8[J%O5-$BE [WGP?VB3(F?45L%C7' BD<AV2'M4FT(!^E%41YF*7Z,
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MB771O;2"TZEGZK>RI"J&7!^7E .=W!]N# Z*GW]6)4S0L0DW#J( 7TG/1BC
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M49>:#?'9H^YYNEZEK\DPH;"[ @;=K5(-Y5_M>$/.SH5"A#)L1Z6.9G]JXP+
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M>RN)0<QPJYS'G* :/)(&6A\YNK=V^47- O2JF]"Z!N?K;6+S5&W#@HIUM_3
M[E8JEFU_ (O>8%@PK;;DUQDKV739N+*7N7U]3*KHZ^N3E9(S*5:_6I7'8^%M
M)F?$ VG)U,"]\Z5,@GSNK33A[BIH_^1'"O"(%]F)2_=)'5I0C>])^34K,C;V
M\UQSD.G1&%NHYR$VZB=:OJ:ZX4_NH5%F./J]7KJ!F:I.TW>5?-3SYEJP(+>J
M](8DXE]BB3)7Y(>?$O:7GZIRY*>R4 ..C_'?""R;:VB1K'M;(\O>&"PJ?'0E
MTR[ 0I9;E:/KYK0:. 9\2U"@]JF]2NC0!W%J<C0(OA5T*2'@Q#>B-3['!FN,
M&3V(\+DNOGEC=P>4REU9_*A;PTCRY8^<XI.>ZAQ'QN_P8/)Y\!SZ"JQ1<W!C
M%\&L[E%LV>7 W'N*[DIUV27-2\)\=Y^FG_3X-:Y.@%. ;P5X!&E-AR0:UG(>
M3]?? SI- 7[]+5;[B!_9A=^*K5(N '?8_3(&.>BI-A8WULOL[3XD.80J2$O\
MV%;6?AJQM)R_F)21])XE.;,441PYE:)2_00JTG-ET\Z*UD#;=)"\1AT?*5.6
MOV8/+%3%(@=]A2?@*( &*8,H[%("E6MX,],\.CF1;=H=P^NK;OW00:_V;,"R
M@(?EH0*2@U1%/KD&J1;JB %K#-H/;VRZ^ @T^3;'QY^_X9D%%%7\*\OX3M:*
M]YZK-9Y[?882/FZ^+_S%;H@]]KD%&^_50/GOJ[FU@Z;&VU$<*E?_M' .>Z,N
MFL^NJNF(:[Y]:I)BZ\8W;:1V^^*KE_X]8\T!/5;BM5A0J(^6ZZIB?LV0F&!S
M*A_P]=L5-KZ[O)?YM*7N]'M 1,D_X.6(:!5&HOM DT81!!9LSBWSPTXS(,+,
MIN4</^=]M9RMFT("'HB\H$L$C3A\#YH3_NO" 05X<#L016>?^OMQ9HN08KB@
M8[UGL=A[ ^W>G\O-G:G!.CHR>>'?EI8?/9)W._SH5-IH@MO"OP"_H@ K=/-(
M(FTM!5@8W45];+A-GF#%'T#*]1CVG6_KPD6P@6(+RKTJ)DBD)\JAM]?.Y1 )
MK^<YB.#B?_5UEG/5C[0LN[E5*X:2"UPHI"IFK2;67&=CN4I'\G4G,3O'#R47
M700U:$$M?[H"PMNWWB:C6)M.%\#"NCG?/M][V/1KH<[0E,53Q3HO#+:N%6@W
M+X&_UA\G"[\(L50OA)G:--0E&#+XR,UQ1'"0^JV@:XB) \S>5CLJ] 5/Z.?F
MZI0&.U22Z)2D8\0WL+#U!<7-TR^4V=(\Y(1 1IE>FLD).DD3SINE16YY_> H
MJ4VNK) \Y>SB)*-Q*9>5DJU!GXH=>#LJ%O7%MY0"G!89;Q*=WPI!,<K )R(Y
MD/Q#1#LH4O4:\H8&LVQU*=MDZD3>NZO5:F.2[/8J-L]/DXL&5/@<6T3'][BE
MM49*W9#500B7,+8=A@K/U:).=T[)EB?;DE\Y. ZI^T4>A^XD7\;]1KRI;M:V
M!&O4#3.M>KAM:T@K_8CFZ%'R_72H=F(K4U*>R/3J91WN%P6P[Z#F5U (_JUW
MD<<-A> W\HWZB4%/S"LU?Q<3(BB 7E%'>!["*#-SZX9Q^GM7]$K+SGJD<+XA
MJ!.5(=)0>X]Q"*6QI-X:I<H2C7GQ3J6ZU4R8)FSE;E[V'(N>FB.0G38L DI]
M'Z0E-&G3?]1) 5J*@G*-UGUM5K),;BX@\EB-+^II[1B#_>&W/*S/>'6)VY[X
MZW.62<_@Z"?8"9:<Z\T?3-^P4-VJ5\_8Y[/HV-?!AIU$/_Q:'KD_\T*<V9C8
M%E)LL<[<4%/&*#'@C+7[CQR0\-8?RT]U6K]VV,!FAVCR>5<O[)E^%%%K;IE\
M0BP0S;*4Y&ZJ&FC/4093K0DR'(_?P&Y"=#A3!]J-\0X"&=6^]N'M5 ET7?XU
M602VHX4EQ2;.7W>35:37:^Z\^'9D0VR'-2E689TA8'5;=(=S7YH")'[$AI."
M:LE1+T@*VDG;LVPX(Z7;O:O//,:6HDM*2O,2B5,JB$Y7CK;%#ZNP0.Y#.\[&
MQC5?U)VG%CH]H)@TMU;(J2_-Q>;H&?-S"0S);TNO+?V\P/'>)LYL([P"*4I"
MMM"MHGE4F+D9U=.Z.3O\N B;&<FWB].CBRKZ59+V#W\_M[S14OKXE'_1YUI6
MZ,SN 'X],_-*OMQ[R=B1Z13I]89,/PK ^!"K E^DFT?]8_N-,.)%U%]1W1<O
MA)4 S_D7Q8H;I "GVO$A\"5^#(1(AZ  T>,)1 \\J)@(X )OB=?(OND:&2N&
ME3KPRSSER+@C&*^]GN/;?78)E;FC+;?0U! ^YE']Y*EWV7RI7ZW!P0UD*%[H
M)G+O.;?_(]_F]S65Z'6$%;QCD,A( >Y 6*GYX&T4!>#Y!&_3(S(B#D_BJ_Y-
M? :F8(7V \?!CB[..SH#FS*_KE6\UN%KBE\PTK\WYZ*N^(VZ]^*(2HSS%Z8I
M@"/,F *<7*:.2<:N"=J3^N9T9-N@?FAS6N27-)7L'W7@$'?V\+"N\??VI=Z+
M6V7%ZPA'(@B?]Q17@)D)IVHT";'_6Z/E*UZ1?E?2L27,?PH7E^?#NV/E3Y @
MBH\$TQ,9!IN4BKY!9?<S':1JJJ0?^/4+A#K9T6[6T?)Z(4I?L"^7PA_8R4JR
MWI1QMF$M4NCZYN(D4U:ZV-]>=<N;+ZJ87K195OAZ"TYK@C0&HD9'#N3#^?/"
M8?,W@X^"O8NE)#'O20PZU3$;'A.QV=&#:5FG_Z%LD2,#XOPV'<AE_555)3DE
MR9$)4*^:VV;T<)7>#+RG&K&)^/W@M^.7D%N-(!D*\.^G5O;OU"(_*=/-K\%Y
M8/*:XV(V::*69D.BOQ)T3T4F\+JSG[QCS>YP*OI ]I ?4HBN\@PEW,8+O%@Q
M@ASQB>+@]+ %Z7Y)6*3",N==2U/STK@Q9;6Y:91@QT!AZ%+35//,OD:F&XZ9
M?)YOCIHLS<J-['+V"74FSCAYL0LFG.5SG C7S_U^0>63<7X@ WXBGQB(U1WW
M_ABP9FZ4.C?A&UGI:F&+,0U3W$/^W)JL)6LK=8/VF1*/C'^!L5JZC.LKJ/U+
M=62H7MNT7^J2A29$M'.;H. U^;U?+6%\H$5DKJE1''/$D0SZ.*F3?.!GM>NZ
MNZ<2EATINC^\?3,[$OJX\"#5>-7ID89SJP]+FQ<'!4BF>K(@@] SF\)J'@$W
MJRY'7A=BO<-BP-!I30%*='XFV1NM? \.*YA4;;RF=),V[5P?R(\(;4>YQ44=
M+;>#0O=KS1@F)ZR<;X68?+NIVW]%1K]"F#3VG5Y>[Z?BHG_J3Q=UL;8G/49:
MW><WQ,C&2MLE#65@-AU:U3SAQFO[AYE5A<2[@]Y(5J<CUNX")YZ*(E>"6";6
M_KU(8S+=N.,3MP\Q]>P_']*ZL?/L'7806*!^5KRD"F59^&=+'7]_+['IA'[I
M9'_V2:T$C<4T$O=IK<!E&IS7_ WNQPY"5Z.GGR'];!,;=T8.ZGK?H,H]WK75
M[]2>OK9AYSM9N3V !;U%8/5 9XFRN);"3[-.*OR9:YH?VD0[3HEQWEQ]4OUI
M8?7T"X?6_I@&MQ[TJ1B_1[4M-35.F0PICH77?G?#C)[&!D&7P+$0K$X_9Z J
MOAX)3;X5'K90/2H^"4N&IB:K&@S<-'G;/Y!V@)R@F^LNQ@IAKJR\Z!R3GHFJ
M=T [KN/>/+>V2]*&[2)!83O:0J49AED?AO0ZQ%U-344G_I0>Y0SU5Y*Y\]X/
ME::,>G:J6-GYY8TUWY(>NYX?P0:B!@5?Z.Z>P#X8?/YZG\SW''S*3H%W+4T&
M/@=W81RC\[(&=''UXK260[[JTC<N@(/=EO&]I%YF0+P5*.]?T@/FXE6C_8J5
MV>NFXGDF[ZLONIQ^2P-N^=/W8GGC-/:(,(]L:_:Z.VS[)7;'(/1[3!E[R9U%
MT(?/0ER^9UK4L5M$9IN>-!64C<^U/(Q][-B\HHG8R-1;HU,+![=AR!\*_3+S
MSU54DI334F2OI4A7^OJ-&Q% G]PS(1U)6$.ACZ/N11]_:S0;)GW1*>UOY%<:
M5\F1A>B-N.Q&"9>YYL?.SIYR$DA0/U_Q>3%!!P"D-/X8Q,VT*Q**(1]!-04]
M;BR!#_"(>3&0WLB2"^C1J%!U;674@?OI2.,']GH'"%"G9W#HR>9@N85'%DJA
M,2_*/=]7:S@BH:M'$HG*LXP8D8E]2<P?+35)8Y>UO(WL5;(CB07K%[6+YE[1
M6WUQ>_%6&$+Z&Y??Q?3<,,4K<I,O;M*72"DH?!6X"#6)&5T E;-$@NT8Z<K\
M9ZB1(\_+N&I+]U9<Y_C 8FI4]^]=R<1*'SX.F2]:N9/*7%,GRV&KOQY^&55\
M)-P\&>6\M<FED/UR(KO9J_^\<+ZJ0>]UHE-;[07%O!\OKV='6O^/^2#ZV(Y-
M%9")OC('=Z( 47$$,+D/<DG9G\M=2R@D4+H0VLN%B=;G-#=U.!%"G-))":U-
M]UYJIOF,3('/U8">4X!P/>(+ N/1%OZ!ZT$0>L^$QVUV@61% >#:'N9/G7;&
M7_/TY1U4W1KR"$U8225&K:7]1D?L]?9IZM8EK!)T,S9=[>'-,K%=J7'USW06
M(&,%Q$OW]V4'X<_0>"%P1P:;3DV,#Y+9R8@L@#N-">U-VS[:%DQ-PI]Z:SAT
MZBNMK<A#>C-4PA7R=# S"%\33(U/Y5I(<L0C$DU,T7<9)_W8OB]DH]JE0+(F
MR[)P\RB*.<M5TJ*@NS]4A9N41;Z$3VR=%1T>?X)%1\D<5C>K3408"$AE&4UV
MO/?(^+X69G2^->1$677TT(EJXV7)Q"A]\YR522U31.=XS];K% 0UR^J!<\(8
M=>LT2^^WW2+MO_*2$A]--C>/X/6E$0*J;1>$D :080I Y,PCW+<D#Z"P&EOA
M4LY:G*L\=,QX;77UKXXE:+M:#L&'-5 ?WCW1=P OXW(/F4[' ^I#U39F>.Q8
ML,EKV)<-SF?/>9Z]$UB@0=R4T_%*_.D%J09C'=T;J#%>@HV4L\%C3+P!I0!5
M_JE3ORF @U/J! *#1A5PUOKU!2=U,4[^?K*F _<AK1DL2Z&\6*^+U4"\P->I
MN<UBW*&64'=<&36FY]^^50>>R"&?K\%%[3N28F1!+RG >?$"[(],"=R3R=&E
M^MQJU%1B]?Z8[^#$9 -76Z)+79/U]ZY1PW=GF/P06$\P,3]N 4QJI0"[/07&
MLPBLH\.Z9?8,#-2#X)%U41G;L8@S5&$=$$P3&W+ZQG6IST]&->6W5-2'^=G2
M='41+/MRY9>K,?3)26:XI4>2E9OK)4^O>&5*N8?63(U_7UY =Z-?P3E;SCK[
M6@G@X^;0D9F,+=#W<FG(".^/)!4#%:L'VTMUJDK;"0IM/_7>KF@%]5$S<"\*
M$/JVY6KP-SB3#.0TT1IWN6H!^;HA5# %\;EO/T.]_9#/"%8 G]5P#3V1Y<>G
MY\4SE"= CB+?#.3!]O?TA[T8#PVTRS;!1W7P7*V!WKZOTZ@U:*'F?U1\DD94
MF+ZDZ/M]0!U73X $GJHC)8.=X]XB+HA?<0)CSN,8-N-9AA:"?D@^[F4I !AG
MU2X=7>#\],?$SC\,=*M 6>5JFCXDQ6=4!AJ994 KJ,]$U0MFB$G!I&FS-^E^
ME[?599N^"L0^L/YV-?Y=:^Q9WN6KJ&0P7B3\;T6XY0XT_OI!]P;C'3P&!W\P
MZ(U@7Y7[8A84'EW#:6[^T,B7CDM/H$V/Q9WU#F"\64#DW,+EKRVX$9GD,0Q[
M!QG[I>?;X1>8>MP=UUT%OX0Z[5Y4O[C,SAO[DIFX!&^#4(#?PF 0>!TV"M[-
M6ON*L6#ACRN^5ZF3)%NTONYCGY2[HN8Q1 $6X?=16%=$%Y(UT(4"A!C#Y#NM
MI'$2;Y4MY^E*=?X>GX#J?=1M2M7?-U1ULK/WI/:%N14XWT;]W75XFY,+?"Z%
M ERHI@#T>/W9'A-\_0*=<=TP;SW?1K72G6[I( ]VOH]>X0\3W_C&WM/FOT[5
M,J%/+X#GXH)/4W=X604UE.X8S\41+[OMOVXAY8/G"M <@:H^ @GFO_ )RW>&
M1[[^B'"R1MN\_L3[_$+YX1OWFT-?/#6$N%#"!9$_1;JATZ&N,WN#+ZX\D]3/
M>QT5NR'Q%4/TQR4N]!!9(/.!\:N3!9T245;71[C%U3*@K-W9AZJ71%6=SB?=
MR=HGO@5F RKZXDX%VI$^H>;24)=+A[5&502)()Q59L4TM]21:(9L[EO4AY
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MQ\@?+U:Z$Y2@ZM,V_?(Q)[L RVGWMH>D<BI@)%6!%O>_AF.U14%G_NQHT%,
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MK0OGR#@(%U4LY0CZ914;R94@B7?1]7G:2JWY8_F.R=\YA:K83Z*_XU*-/U(
M5945JTR:E8H[9;D7#ISE5*VEBY/NL./O;JZG\'@P\@)"J&DSGJQ81XC'J=N@
MRM_8&C5,5AH-S&8PFF1G""==D4X-'PZG1@6ZN=Q*H,ME1^^OCG]EV/W4&*-(
M_?F=8!2[QB!+FL1(0([SP'&U6T%!6K"547WM/WYQYQ!7YVDPVMQ<HE3OJ]M/
MM_IL@Y%A$:C#9D>[*-5<5ZWSTZPGCXT<'C]@J5N?'1F+^GO'SX>Y3KG+06Z2
MQ!4L?':OM-3-;*"%VU ]\]V,_+7Q9Y&Z]U7P[$>;)'9=D?A>?C;TSZ:ZQG]
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MF2R&Y(45^&*1L9R,7FJJBMB4#U<6Y&:.QO1MT*=O%NV1UN>?@.Z7*0!7&/U
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M'5I=EI:T2=NN5R:_% C7),P2[X78KIY9-\16['/;:]QMR.#)3.@6X.E5:-A
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MK-!=M<+.[VZ]V0KHM2Z/\K0(6<Q$JYRJ<M*[TFT@'N09C2K(GOA)XO!7T.B
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M"#\@'W>Q:/M%JJ7F4K&WTXUZ&6EC*  ])"A<S(; 0;X:3 WL5XJI8'--X%Q
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M:SQ9_T#,G^#GAO)1><>G'?DD9T+,*C.;]?0LH:]']FWIO/#UDDD7"_G'R^:
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M #OH7/QL09$"2!6XN$4-OOI:UN=UY86_SDLT;*J%A)2Z_62)!B\3(K6:X"7
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M2PH[F:'K!_VO3F8;3-O@,P!OWR+P=!]$::_M_B\;L ^BCT1!N!@HY:YPB3/
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MQQ@FUS54]VV)#BX9LL,^O :)3@713HYUG9X!H@IB_>9?- 67OMDQB+F2=*F
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M1' ;R(E$YQY!9?$N ;G^#EKCVR)USTWGE]9V;:+]_UH?O?-]U,UX(6[6A_T
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M3^MQ&;(1UO2<$'UT@864U")"/EP@)P]9YBXA::;Q@UW&*(L#00^GHJ=8+3:
MBB -9POL<&MI8;KY"#\*O0JY78>=6XLH6@ [P?D1CA9&_"D:V2J-7W=>27-&
M3;=O3+;-C^W:CGOC71^XC.A\^+/,0O7&9ZUM_X-76;-X?[%5D<&K9#GWF&6'
M@A2G.9/-]#- A))$K'@F%)QAV&,<&I6E,7![=]=R<UX;II&3Q"F"G5OO0K*]
M937'<!LW*<Y^9@)_V8G]2:/4\//>,;7D+JP^%7,7R0"]3015(9+6QUVNE!8]
M2*A]WO@1H*X@]UNL'>V1'7U>B MOU'8'7UR(CYH$"B]TOZ07,SR!CC!>X/M3
M+>ZS:1BOL+RVEO#UH;W-76ME16I+D,3)U/Y-#S.FKH9,J+KN8M'HB<5CLM/T
M:<Z(B2&[]"UK+,N<;E36S&&--B2OHI6N$(3^"J-%(J#<;^=YTR7%_OEVSE_4
MH-(2]E2W_?CJ)JQ-1E%]CFK%^ NY%WB3:;%P^_ ;JM;:3>0'^4^CK$(+4F:X
MJ=AP.3X5J;\Y0=)8G%<E)2?H?1>)TDJWK)X<'C&!Q*_?E/N-K-TO^?N)R+_7
M-RH'7MLAVQ;]B"*$KER,>OCM_Q[_]_@_=5R?JG^Y@-)P\[CKI2S^)9'OY>"#
MA) \SJN*HL[[6^>&P*&.('LD"F$Q+CG$IS$!9?)/>IDZG+[>.?;(2$(CAF/R
ME>#3$G_N)P\&:;M7ZG?__-K]%EO0)/IW !_@]2<I>H\4E#:>>SUJS!A$MP-#
M_VKFFR#^A#E&%QV0!EZ(H,.<HG - 2%$FFQW7X^$CCZE#8+P&:"C$%RSVS&#
M/Z3[)(>,:A,$JPJ*SUAHDY(*&/H&:*0PZQ*7^GF#R]]?M[V/U+\PHSU<%VCH
M'RU6RJEAZ+M737SU8C7.(CRZ*7[3BBB&MUY<""%3C2F(+ K1:6$7(A[[MT0+
M26O7:SF;&?3;T-\%B'=7*6K8Z&CP-C%N/7%]N"D+9WSE,K?C]PX:#)T!8UV!
M'<"9J:,<G'1//+-_Z5)!QI(( RD5XXM2RK>F_0)SJ V?4*A+&5!GB:/B$_;L
M^=3>SE$73[R5@>9>J)R,QU*;C1T.W_4'=R&,_5!J\.+9+E)C_K 7?XIZ^!JS
MK<$@.\-T74B1#^0Z089L<&%8$T,>Z]GKY1Q!2=4WFZFZ)0P?OC7V7#4.RHEB
M/0,06<H79^",M2C=OG+7895UQE0H0]3FMD^O@UG1V!CY]9%22_ QA29,4U2"
M%)'M_#\W&VX^:)+4ECDN?^7*C5T&Y\L\X[QJ*,N'(25YMU)>/KW7#W#SXY(\
MK)!XWHOH7O^ZK0JR,\WUP/P@;">3WXQUO"P4=NS3D[8RQBU3D-5FJNR\ OIE
M2?QA0.&LNH\S7UR=CX:MK+J@SP-VSF7/;'7JHI\=<"0(_0\^<[Q$'09#?V.$
M K B\42/10Y@E]*MD.'7-:.205ER;%L9?8D!*I_>7'1$S97?W>$P#+_*<**-
M]4,/1R$=13Z=&G^$,'S;M.3!\=;)S4S_?=W])M'(YNZ=:0.'1]M/B_IM +QM
M,Q_W$&&%AZCJ4;V9ZGE,MK!3Y%'UD9B9Q"F%Q(4ZU(ILY^"YP)V$>.E?Y/'F
MR0I?3%]RK.F.4.,P:+,F6^E(_@TI%9>*1E(RL:-;^"DBE.CR;:.-!SM?=T/9
MSSJ8+HT]JKU">3-.7+/I\X"[0<@%N.+Y'F7HX!2X*F);$3NU&/?=AW8M?U'Q
M_KW6= 9!MMF?F,<=GD/)MY^CV?>NN#>B%)M](#?EZ8>CBXWH J1RAE5FO^NF
MQ%@+]T.IEQ<PE\X 5R!$$1P\DK<%[X53[[&\4-,P>(-62SO>,GPNVH$>D>9V
M+T8$(-_LD+B>_Q)_GW*]#U$!B_S$U8 /Q87V6(I7A^O=JQDY\/<6$X_AB-L5
M&F3@"]&WM<(:$"<(O'0G0_>5<GXW(R<5!I.F"<9NR60"&"=&'NY:R$C=EX%/
M'Q_Y8]VVR[&YZEB1K@6ZUWAP9]-=>WGY&RZ_BA.U).13 KCM>=+5[7VY4[@S
MIUSE_Z@"NRP?Y?-K#.AL8V)>&:GWY6#U=/$/^-H7\/QJ%9*[S$ZFJ1'$=Y4W
M?'!\$6M:9AN&OMMWPM7CW+\_#7V0<BW9R%(,RYE+>0P'IU'_#RNUI.\BY0<U
M#_G=I$-2G,/B8XJ_@ 52MO8#K.A4P(AVU^-<-\ZZ36NO65]6SM^Q:JDN'*W"
M67&F7UDE@8]SBT]V"1<H:($  \X -B &IS:!\1_C;0_]9[0\).O. )\2N6QM
M1?G>U1]I-C-,K0J,UI;%?1_Y\B'^3\Q2#/KT54J%@I%X/2]TM"4S)ZU53K2@
MT:HL/NV\0M4"5LLM'(DUR GS50+BEMZ:0HN_*8PYLNZD/=0:XM5X&O#^RF7N
M*%T!T7]=:U>EOEA5@*2%D.@A6EX0?=^CA5K&?-XX9J9ZW2L_S*N7/_-*YRL/
MR^[]IF96=#[:@K=27:YHX?2+[1P[,N =#S(!-6W,K-B:75;+:\SGT*4A)8.L
M%FY ^X&5.QE8IF<3"LI%>+#NV"&M/&9JM'-J3VA[;%C"]?FDJ,IL?^4[F9??
M=NXE88>)3ZD)DCDGV5 9&'I9ZWQ3/;3<.X\KJC/%+BJ?7S,3Y>D'?==H[:3!
M\W!^AIE\$1L,[X)3.<X#JQ*7G!6O=](JS:U;C;9XJ%45VP N?])+!+!L"[[]
M,!JUW.RZ/4O<(I7#T-/QE.'22?K>HHT3-)ULX\7[F>!<IF;@&&\AG0%YWH9[
MUW@,LT<=C!(^^++A&N, [,:C.5B=,P">3[IK <^KWKZ5<Y$H[^*YU_=R?'4"
M#C_,^+HC G?E>*70K,[NR& ;RV!(_^2ZS@T)B2"<S.,+]4TE]LSI7R98AAI*
MG3:J8MP/<H7]>\S=2P(KDEW@3GZ,TI-82Y/Y9W]TJ7"1#[*E+INPZ*CP4X70
M4;$VJGIF ).1=;M$5AA6>KDOJHXV:''WDX(R-NX,\-*6ZZ_ID_24Z+L?$TWE
MG5AX8F[K_JSY-&[UX!LS'(B'4<:FL[^;#HZ&;@D>;[I65?"HR!XQVL+/F.;!
M;2L_89>XN6@8SVS+=B%T#^$V<[$WKFY[;.E1[ZTCCQ+,6A(LR)BHPV*'#U!R
MN-,-LL[!\R$ZA_%\X,Z-%GXL\HF<1>M!J5(^S(N_85S2R="W=%ALM5*B[JX
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MG/SF?X)R1G)TI;F*?Q3]6Z+Y,J(S:[NLO'!0)9XZVQ:;7/BIR] CD\R+"%P
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M_A-E62X$'IK+^7W2:ZL E:L0+]A/@D:V,O6;<)H1M*"_VSCQ)[DFVDM"FF<
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MC2MSM9YX."\0AJ?'J'4ML+7A*WC4-C9PL@EY 1[G=V[\F'W^"5#+S7#OE\S
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MN%L-,5<X4@FF^@CN6Z]@]END"&H8M;3/;7X!"(:/--4Z)9,6#@:'&JPFU%0
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M;24 X9"DL"?O,7,+Q;XD,M5$Z><M@W.B8S(A?*_AE]:4) X54TPFA$?1VV2
M^%+X#'8 N[]M53M!LUH3V5IL8=PX*3?2@!";QRB4E0@TZ[?<2?VYJ^E21 9\
M[Y*G!!M9_/$\A%C0< ']P^-SLAYU6^CBHHQG'TRH?<\&2K7R^%W6HU3T^X73
MM+@8O.S/9C\+OU9$A-JU0)_+%IU(FQQ-R0_R.D)%TM\WP(JG3/=NI3YMB/;%
M'L'\GF+9<+^(.5/.48<1#<%+?5HRCE/  (&$J%N1@OJ=]6Q 46U.QKK"K@.K
MD]/P[D1$*6CK,QH1AJE,Z_R<VSRR,9$XM W97-<)R.ZG4CCS2LNKOB=:JA/
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MR#6".^/Q"$&1/K*$><5<I Y\&_18L^$##R[C/O'+0C(>1*)A/>'<X"MGW$H
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M-D'S.H:1]&H^D@\O/H(X4FKP(UV10QQ+4HSV2IL,\*,H]F(*D,C600F% F1
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M)W2A"90L>P1?0(A>J3CI2%FL7YY D+.&'AH6,QQPTJ*,RRF$<@,Y,K>,V?:
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MT"U=7[B_*_#=@M3YI:Z;^_4C%,\]F O=;6BV976DOPY)>= /IYP?CT:N<7&
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M4/+ B6LI@+VK:J*/@B)G$OV#6Q1\$Z\.&$<.^^XBQ<DA\@N4[*J'6-C<1OA
M.,(-0:N@>TDNC)2O%E:J+@C4XSH1I\O[R?;_J36:: [ .(?>157#@N[(P9FF
M#9LW&G1?TCI5D=9#UI&W#BQ Q/ &?C2;&=W_W"<D)G-K%?.+@7]) V'(U)3N
MR#C#A*[VMOMXZSX.(BY%>K5>?(2"H<#@07>%Y0>UU?:WQ9QT5VMR350BL[R.
MYPXCJM@E!T]4_'=\@W-<%BY)MV3SV7" EP>9D&V4PMBXPM^,CWS_X?]_MW&
M,<C,(N%)QQI 'MLH)L0B@X^P.X0P?4@!MK:?Z%A7W^^YZW3M7!-G6FF;=;VO
M<-_5H6\S]*TC&=O@IZR=:^6X5F:8DMP,8P/*.(U"Q=8GMY62R9B#?DYMSD+&
MPJ/(V06'Z*VX2H/"DIPFXYU^3<;9'&"'#]AZ2=<;"LI-?Z8/S,HOH0=S_-HN
M0P\_#7$IC]5H.T1>"0->-_Y4+$SIS)Y*7\GSB_O]7::REBK;>(-W]-Y^W]Q*
M=(-[1J($KE<+Y1YQZ6?+-C\S'8DZL@[Y/-)_'$)QU?7. FO/P8F5.C/!*Q41
M:NG8AG+'^M.":H7;]^H^:'91/CL\=0;UOMS=4+BLPU^Q$;+PHFJ!$@H_4^34
MY(EG]BX'HL,2<U2*WO#=C/)0J=R_+^' *]?A8!.%VS]G-,DP"DJQ/F!Q&')A
M&Q(H[-)V,.U@M%[F9-7-KH.W'2V\I)\L[>5M>\IG'47R*@OUAZ*>M#P'.!Q+
MAP+@'6L$2VNH;\#_B-\K4N) YD;NTL',JDN]@?? *\BO$/6*DJ)#T?RN:@0'
MR-AKN7R' W ?9[> E.](RK5%D?M]/GC''YC#U@83<^K/79_>NFAUJG?DI/.>
MGJNMH^*\3[YI[Q[O N>%-1A[T%#FRQ.#_+5KI])R)IMOF?4B<0(W?YH$1O9=
MIU:_I^1:6P<,8FX;)G\4?KSAT6"C\FI+.3=ZK\F>I=>J2@.3JT.7<I>8"%,)
M1&HHXW[@GSFZ+:P<D)3[Y[-$^!YOEVQ\T=R80+&>0)_I+?^E9\_VYC5U:9DK
M)'P8,J^8_CZ2P&A>AYAX\#J[UQPS.$ZQP#T="DLYGI2 )04T4-R?/&]U%TG+
M/ZAX3*!>H<1PVH+G*'I!R]&3!M+E$$P1)%N<G\A-/IV.M#41 NODQI0H^86>
MA28YY]OLI$$M\^.)/D^"Q=V*7'<S<Z?A%)38O"N^A)LI JM##O\8N6\K2SG(
M 23G# 9OW)*ZN7<X(^R,_N?$..OP<[O\F)W-RM5C4MS2,H_H6;G>;LO]["W-
M.AU%)\VMJZ TM0&EHV!W=MLQ=B/L:V+=>)@L,MZ?9,,COGJ [S-?FJJ[VDZE
M6G,OY8;;J3NGRG&ZT-4C[,$UY-=<IA!R0BNJ,%"?H=7HFY"5YN=CS_T]9H-:
M^3Y!XX?);H>;/242(>F!W:NOQ47HD%;BCF+W4^GA$VKU\,=#-LP'S:0!!:IM
MU38MV;OO>XBU#G%R)(48 0\ZZM7[H;W ;>OI!T-J(E&1"26^8#*#8"J@>>%%
MR3L]*"J'V(#W>EGIT,!\+%=[BLJ9Q.G3$9F$B8B&)Z$!:<\"-,5G'K4??;7U
M# <PU":,HC[!B53<P,+X>2I_/3RFW.:-1W%^EY\1\I7&],W8W31%Z2\7G?TR
M*)Z2@8LDYAK40(@3U#KJ'0!K#Q7"Q6] 6J>Y/N=FI=OISQO1_4]=U505&_-;
M\PS#>#^>.3MSP>.LMA?A_HK:,('-ITKO_+/.CI7DC0VMUJ&@ZJQ/\]XH+2[7
M2C)\_5$_T%E92.%3IVY)OIRBL^%(],O8FMIZ_MR<4,@AG9H%I!ZH:,WV(RSI
MLM?N7Z7Q)8_.+</-X,0?B\,'89&PO/&(ZMV_A<"&25+8QXVP%-F=EEV+*>^)
M/X-;?&EQ S4-G=0W+S96>UW6U: >\L6[;&?%03WT":)%[KFJ\D4_F'Z+Q*HK
MXSXG;%^*,F.$>1L*[]X0X<EY$SC%#@>)I3E4#;:,%U6?+;S(5,11\O 3%BQ(
M_._T'>( Q5"25;&?8>'F\9 ,NC*#&N0 RFLS4^WH!=_'/YL?Y @/]1>X$ZBG
M=^]QZ:SX%>BP8Z&HEMTSON2*%\#/W^CA "MQ5FPH)$\Z(%<#D>O>EK]QS+V+
M;$DIMLP,PP2L/P?63;,'&)H$&H*IC"3#BP)Q#'4;MM%P-4H-M'GCF*L9C\X<
M,!H*,&ZS>(>Q-V\,,&IK[62R,.V@["IVT&5R+82MX(<9OU39KROR:7A.].C]
M8Y4)<>V\X1;Q5SI;!;5Y?GN.6,Y"!A'2@'=.XP#J\!H\4Q"J15[N4SCQY1AO
M)UL>K#5A<SOIR74]'/75[ZVT_S T[KP1^LG&RO9<]T>GJ8A:(T-ID=MG15A6
M'* ^AP,X7.$ )^8H2E GJ4"'*,L?CGZ5*CJQ%K->%<YK;\1UO.U%24JP[R!3
MN(W-ZTFU9O/D$%&[Z> $+)PM^XN&$<(G7BX$^0;&K-L4XHRF8O>E_KYM*0,
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M]$-JY#D2C'YP9G[6FWJJ6=(WPMMM1Q]['.%T7,E/L5+=K/%R:-*-%T[-BIC
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M&PD ^08X]=X"EV'Y\5F+BN0'S<J(^I.>7GR"/_H_BXQCOD1,N3:]$&']5;V
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MGWW#JQY@ON/AT/@T?X):H[B59D>1<C428GFNTN&VZ;=?-*<,V6&,?DA!1M5
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M_ZP)U,8S8^0IA5@W(SHJ!()AU^@I[&CE1"AK:ZWCL> #V[;7QW[@9F-#!KK
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MRWC#4H0NP7Q82F10Q$/1@2_Y:JWSQ)YLH-P<TQ_7Q4S,7VA3XU6,/V$R6E?
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MO)&FE=S<2ZNNSK#_$MN2)Y7-,>?I5R57J6:S[@[>:#&\%7W.Z#LR#A& F$E
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MMBRW1V#$(5R9L,/@&+RDXA4HXZ>[K!XMV&P=8!DI]%$FL<7"=&&\^T?"O<S
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M+IR/,:*)'M^DORVJV)M")"T -^$5OO0/3%@+@G9L&\^03,=_ *B2@O2OO#,
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MYM/F"KZ_5'+:D<::]^JME3V5$D]QZZ]M@(684DP/$R81H$2[3><CX9O@APB
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M>^F5-L.: QU-8@]XWT"3,]\[7C(#7ZNCW:(J$"WK%<2 AGO^_IE:L41]W7=
M3J1S>9)W:>N:!1GMRN=K\O;'@;&G@I(5 P]1END/36_QQAFVEZ[E9*3C_1?O
M1@EP5)9UE1'P6[%+83/P%EM92@15:I97PD71?UPAJA1E[-9<\Z;PY+V[8D':
ML%')H.L'CW*<JCFDBFU'4"_;4&J!2$(1;X36"3=+G$\!*<=J\[R#_422$6[J
M_#6/-G4/J1JX E>!D.2C$SL0PKN I)_(A_P=/+8122W'DXH0L_: &]#5R(AG
M9% 4BIBP@5+0B0DK8\)**CK!"Y,!KQ_COC=K7%#V]44;[^U*Y%\Z1C'\4JZU
MM@(J[T*GL]LP81U29;$TX2TL0VA[PW_?>>.7Q_5 ,0608ID'_987$^8F17,#
MZJMQHM1<1A@D30+]]%YZ[#<FS"FP8BW#OFM#OE>],Q:86BEZOE4X><7F32/1
MU;#V<6K<%*+]PU#3G5Q#PR-[\+3]B@"5M152!LA)HYE3-YLR!&O-H=O%1!;X
MW5Y*M$2,)26!WJWC:_-CY<-G[V%N.B3"/*,6#^!=V>EB%;3C"O3A#'JI-P&\
M@5U<!SFF(*W)1I L\#%:9TA6Y$6Z))P4[:)G37.FR%(JQH'^4V$=8Y0W$.(N
MF*KQI%6VJL&SX&0V"\3"[S!0E #NCI2EF'8ZAJ./J>E:6"M0G7=3_:P_O+XU
M2$P&:WN#@9D98'QGEK!6!\%*_L$ ?U)C$YSTWL]B[L; :A:.QM:=N&2ORZ>0
MY"GV](G^?"&O/6HG ^3)@@"H;, )*/ M@AEE(B T?3-Y2)*) S3:9D8A>K^L
MJL&6">/$CUVN,3:BW:')T52 ].QR?ZUGHQ,Q-;M; @PA:-I+@8U7A!#\CA@D
M4TJ6:;INZM-EP_A:CWQZ/H.5M8O,YS7=NZDWQTL71S-A9SV'$:M6_?@MFY$_
M[/1CK2!W 4T.[,"3C!&O 5YZ(-F(QMX\+5I4%6;Z R+7:,MJFE+=[Z;O&FWN
M=E<ZKJ;F'>NY.F^Y"&%L\2? G(=U*R-2Q 2,?+Z%I<IBZ2(]@ <4$ @_F3!!
MQ.QSH %R&9S9^2-2AM"]E-8(#AM_95ZBTRC4G<6.J;3(Z-&U^#HW/]??I1;R
MMR[U#Z^C=?]Q-+>761V:QF>TT7HI$%-^F8YWG)*EN)"],QKQ_,L9QS1L"EPM
MG_NDY4Q0?2C]'(N)@OKSE2]&'YI(*QVH5RF"1><H[P9#?K@5;)"09V0A9C(Q
M@M0DB20 3:+-&@\FA^;D!4F%&A%**B'@_D%\0_"9K_G!_ ?SF<]DIW%7@?H4
M^-$ ^$ST#29L%J*@"D>H!*O2"J7KV<O/N?^$;K<8A,L("G(47F,Q6C-K/=Q6
M]7S7&>2\! D^FIH-">X+X],S_$%JWNTA#]SQ,93B$NX,*9OJ>B0,]R3)\DI>
MIY[&^<(%F5UI+?NWPO3F*$T1;G:+=%MYIQT<Q(QVV0SN4GXEGKPGW[HU0;/%
M=%O#UZ)I2M2Y6>#-N/ZS#)$E)==B$Z$IF90?798<BBQ^V9RG7M:?86EKP\[?
MH1A0&[% O?)^9CSN./E*+MH[9P7.%6!+,?;YQ:VGDL#?[?[-QEDTV.4?LE@N
MK?6</SM-OK0V!AP7GHU3R_S(VGKJHN.[_[)_;&H$>!^8^8,=4P:<>:GGY,N(
MHJ)^,WV@W!+)+YU%6,;LS\(T^9;_], -)TD^1+_NI1W+WMGJ]AZ_>VM0H&9A
MK&Q<5>)0U\WWU=L^GKT\/$[YB YT\.3YG39OI%E+:I..<!D]9&DA?/C+T>MB
M1U&[$-((R<+T52?1^=$@5SR9M4E"8E,YFZP2;MDX+1 B]^[4_?&&3L='I]0X
M/C^(/,TR4>VDIG8>>(!A >JMYG\!,R.V=UHSQH]#]N(YDR:!##W:(2!R<Q#P
M=74\-3^;K*X>Z3I:V7X)IYU1MPN!HT-MF.8=9)D"G;^S$3Q371PSUX#GL 3Y
MW*_/WW6D61TIYV 5"Q44=3K(&EL"K]9_^.O]0_!;'E&6@A9@^/_1/9=3_B1'
MHCJCWW<5"OQ_"$6MJV4SR% )>"C',P+;'Y+K!#'ZMFV/X+.=\_RP1\E.<9:J
MHNFZJL+86]JI T7-,'N<KMG3^/BI]%('QT?\ICJL_QG[B/[_X=#H;<5O7+$#
M?B*VV/*?C_ZWFTV_O/8??5^W*0=R04A<-I"X3H,\:K_<\TTT)_T"626VX%'&
M#=)"78&V!TTFKM$D\;?#8^>#G]\>4:O'0I0^Y!703O"K 2>9L*V(:=Q^"98Q
MT'Z1;,EX#>F5#A?G5(8TT*@:<),)R^1MR:!*5S%A1+G$D5JU;WZ69B\TS1HV
MC6MCU^N]6;5/^?RV.G 5WH%_)+= H)Z3"8U'K.ZZ:RZ.A>:B<W48Z5W7/B0>
MU,^;S+73%W.\FW[MDYK)?B%V #BRUYP1LZ9QC.AN.&?:O_U8^VNO[]DXH[-!
M#3>%YM\'L''=XE]K85&C?<:?PG!U>[J38QO,[H6BOFVG7 DZYV%/?#81W'/+
MLT4-.^)VX*1.0 H-0NGU>M)43V*:7@/(4U1>/5@Z)C*^:5;#EAEBFO LYE)T
M5W1P54Q?A^ZPV$@0%";KM4'Y^UWW-$S%JYFPIYKR?5#HQGV6W?ZD%CO );?9
M.[M(YU\GLH=N^XG:B:#?;)$W>D4G"O*[-,WG6,QQW_4JGM,B9_#-:PIS28UI
MB*9D]8OE.#,)0:FN\G>W)%18,P]B)$-43X7$?(_89<(H2XR\ !W:):#A N.E
M\^=IP",0VPOVA=Z[XF^G.U4C_8]SU^-%3?9;H"_)&>3R]@2^4,-NDYO3WZ&/
MI/'?:)@P"-&IK/LX%MH[;=@(DS>8@:G'L<!H?!'T.3*6SI]']'VS[7IZ0"%?
M ^%F,U]17ASAGC7UU5*:%A7(;CA-5=I? R(#80':AS&*)\"3_:??G? _51$S
MO3SESQ;_X*Y#F[J55]2!JNZ#FW# ]"Y=$SONEW>M:.CR[NOFF&RT^%!IIF&X
MO??AZ! 68;,C'(?V.U8<I[SN8\*<$:P&^2@^_Y'C3NK<'*.<V&S6O]C/42$]
MNOP2\]_?9M5^QJO6[F\<?8Z:2=0T,RB=TC8A,8KL'4*&6\Z68Q]8.SXUR15J
M7V47&*!# 3XDDYIU;<A]C>Z*1F%=W677"PMFK!3L[P2_%7S\F-VVYFYJ1LK7
M _ZQ:> YH-V$+,MX+0]LH2R7V%<%F;#3"3/K>W,(\'TG,@5QU%O(&X"CDGSZ
M.=W_EG$NA/^<_?7%GI?(@XG'U ,;KG9'F+!":%Z6_BD]:&+WN1*(19:R0S#.
M&6 '4*B2BH^7SCH[GSB\4\R2]DV37=BA8=Y7$AZ!D03J;X$G_9+N?BQ5'@A0
ML6]\;*IW8,KPY5#Z-6V57_P.%<^Y$-K?L-UI[" 7@HS4K37P4,[CL5!^_,&C
M=%1 [#G\K&G1EN0FTAK3 2\'HVEZ;>/&4\4N&-E036)?-TY]B'7!SRKHZ44#
M[3:QD)^78(6Q3S]'T!E,6%C^OCE^4@F!\"(?A$GBS@COL>D$N-*,]_> R!GP
M]M]"AKUKC'1R*51^\<WW[Q/"1CUGR[36YLO4U#,_'>:M9>G\+X@M"=\+FENJ
M''(;<DX/+QH'VWMXA3C<!3Q$ZR#)9_-;=NU9TOD'&I[N0[57(1L]^G0#,8*C
M^Q&U8'\D;#>"2N13F]2]SO;$3W81#4&V>@/,6=1>Z<#H<J*(>,W%,7=43N.I
M%ECK]$?;<$V#7KN@(V>..&R%1E##*)[[Q:0H]B;*<Y,FMI+J@75I*Z L,\JF
MTZTU>N-;@Z*S\#C_M_;='R=PTY^R-ELIB]2S<PJ"F$'PS.#E# YJRMV!OUKM
MO^^/NWIU'ZYQE[Q3-J2O^N!Z_4R(W!^ >CHVI S+0N<<RM_NEKK[RV-^Y.M'
M25S9"W]AGKH?AP5^RAA8""^]#90+9>0",Y\PBE0I,L&6A(O_ZN<T9](/]OXV
M\$6K=TT[UIJE-3N9[J0&!ZFV#M>]I,@R/GECQ[5G[3(+48G5M@53A7DR$3)1
M:#''$T+W^<0G_W9%$X188V^GY_PP10J!?7B2*5(TX#3U%Y'WB&LU\K534;]'
MP >[A7&?A- AQ*5[[YW3?UI"FLIK10UGPJZA]^N19'J9,.G;ZEE;7/]S.<N-
M O; A$,SLC2LV5A;>^0R=/GXN/62&5)JM/[R4\%[F=<X_>^[-T5/J+%FW):/
M_>:"U61\8<)<ZF0I;B2^%9'WBLC[MO]<6%W]_"3N/HY3(W7-G%7FA^?;JV]Y
MF\"+D%@2Z;?(AS(O)P<NI'R:J'$Z4Y#O\*&E+MA5^Z]6#FMZT+-/\K&_OLMM
MZC:"7++DI_VV_7YQW)F,L6>=MQ'DT4$F;"]O&3[&3:%64)DPK-YLW8M;809D
MZ7>UB>N/N]S1Y;\_FELE1H<<GDD\*"<6<R*H6BL:V\.$Q1+V%U0$ VXI65$=
MLTF),=V-$^U@VL5=_:DSO]4.$C5SV _^6-D*6QN@65 C*?:00MK0#O7JU(*3
M-&0&(_-P\>.-VN@:'_T/O1_&>IX?@8B4ZA_^V&'L6/>XR=CZSZBF$I6P9QL&
M&O$4EY5&8"8'SUNV#J?>:?#\<U6BJ,  [?MDX,+KU*0+1\\$G> XPE*_8H>D
MJ4(Z?5T#\E><@D%T7D;*;,9J1NG2GF *Q1_\->\1PS-1NU9#V4RK['WL:<>$
MT3S!@>J=U=Y/?IB5ZR6__LX/><A$/ 3XX\Z],I?R:+WEK^EU[9F6#S3'0( H
M.0R2J:O[%9H5"1M^.45H3=Z\4.%R^Z=P@Z@@;L7@N,"5]>5=.8H>HY;^D+P^
M9YX1NAVMTN@SK')BT[#7&:UHR'7R84C_CY; O!7K_9!73_L'&JU^*?[U>-EP
MV*RHNCM@5>;%O^-511/("ZFZS1_ZGC'SI(,_N/.IW"+W_JO?C.;.*E\]HOX%
MO1W[@0OZ3%AK%D3 5C[YZBUY"Y 4&GJIYTPB2WF,!9LMKEP%TW_*E=7:#_^^
M2O\9^W;[S]UGRVK8"IQX@,XO4,Y/J]>V#RN%&\ F/;W*F-?\%6;^P$]R@X=5
MY0Q6CE&$47,CE!#JYX@\)PBWJFMISZY,*#CX1J)"VQNNII+41R"5/PA)1&0Q
M'"?9B)[C1AY>2H?;O C_ZUQ:GGI+HS)MZ,ZS?$ZGVY=>IE)6KL'=3)$93)@0
M?B8'=XFL\,8)R5Z #WOF]_$5SX527T$O[+5^]&2$7YNYF#-;2H$]%0YR69*5
M&I-KO=R2AK5.E;83T)[. KC9J">_SKWKU5@(\=_7YWBJ+#G6@$HF;?0V6:LE
MN/]]&J=SCFCD;RDZY]$4M2UV[*6MXW^L4O6%C-_4"YF#;6<^1W"*9L3AU"!Y
M8Z');0UBPJ;PH,\0185>@HT!9O*@R::S@VM,V&8YMIMN#5FW#02X/( E3ZW-
M1H7=LT\(E!WPG102Y(PE?W #A2"J.@!\<57'/@Z<]6$0F;"?ML$[FYIYRW/=
M&(L %FJ.0CT0F:SPYKA_2(][Q:5<&JGRK&2K5VD<"RC)Z\8P[-_6]RZ0G]X8
MUTF>7E9.E-5.>/;P[?4MJ>2- '&BR=KAE&5OV^7; ;@ ["R0O"N1$S&)V#X\
ML7)YI,IFF@FKP/7O_@$=ZW7X+5=:?\_^.Y5%AX"( (4<ZDCC3O*M F?T-]?J
M5\9LW:7M.+5WH1RG<)R,S_B9*,L[*-_DI$9C^QYU8=^.9/EO?PO0+3<]33;1
M!^=Y+YX5\_!I?[C'HP/#W$ "]>>UU*PG!6+K?TPIT+<B[Q69(W8&?X)I*V74
M_26#Q]0$8MXZ-5>9A[>A'%7A)8R9>N(UXJ9[0\QK6&=1J&T>DV5Z34*=I@ V
M:;$Q$LY_W%(75N;Q<)S0*L*<,&H1_\4!NYG*&&25Y&E^<Z@(F,E$%#-A;Q H
MA9!Q9)B&NN^7>\A[*$^W6WOOB_6.13^HC IRB.Y9[:AU$&)/#Z+]YF<A$^C'
M.T%.QIS"F"RQL*30+]Z,U+W]-?-+693KUTD3Z8@%EPQI RZ>2NV^^%1/I+VI
M#LPO9RV,QN?G3/E)^EV-;!M'O+D\6]YJ%7),^MU)M4OZ'Y&*&G$W_K+9O-6U
M4OF)48%TR(#N1.HIN'S5XUTV-6X,>6QRS.W)C6)Y%O;':Z)'*J7$K[?H<C*<
M/P<ASH-'@7HX3H9:<_^57PD-T7 5R:.4\@$KSS')8F[U,<GS_ELCAQR,W);7
M#+8>R8OI)?">#U":31$H&7B\ZX1.1N7JBWY-^*&B/RJL"8/!^&'J7&=8.YDP
M%#!68L+X#G(C_2PVT$53_I'^.;8S%:-_WUZT/,<QF7VO[R5=7K\>%ML#YP/J
M9;647:KGR\LQ\('MR$=O/]O9N)7_:CY%#IV0RPI>M=20N.J\71T!HZ]1$?NE
MR,.S5%\B=Z^ W1\HTKVW<]VP^5-^RA=E(SPAU9VN<Z<R>.?&(5CJQK76Z_O;
M&M8K@)*87GAI3BC=H0 E<;2Z?\O+>U''P?OI#L_">#?7&N^!W$;]+[_#8-L:
MEM-W;[-W[*>  KM*"TS8CZF<C3@<&R,"<#:"CR<1MT=>8;%?^[M;$C2;Z^9-
M=T.G'YTQCWB$MM.7>_?63W)FA(#\MY="$"M$"VB?;63"'J#PC+@@1?K^XFPJ
M=2AS9>/>&/6%R;"[^8^*\NJ"TB>5[<(3<E]>QF#6 >L]!XH8=*GE?C>!46IK
MZ\CP\]"JG.+>'-?$Q[UL[RO9'..THS?.MG%E/9!+ZVW1&OY7;B@(<K'1KOHU
M4CY3KSO, IS+(A+I^/&SOICQ]W$MIZ./E9_Z, ?,/6B5#/S5>QL#N9NPL_2[
M$%=[.<N$@8<@:K.AC/ED>@V^O]O(;T1$QM;% &C*?T[@0=T"=!B!I(<.GSY.
MIH1]OX]*/QA',!Z4K/GH4%<C;Z$F\.:V>U /N_ IO.&W_]('*7U_XZ2,0X4X
M)4S[U7GK /<KF;-CQ^^'2"*&.;0YK^ULV)G!VJ5A5T<ZD"0==#C[->H<$7VX
M7=JSD7CAK,<=Q'.#M2^[=R'TI['PL3IX8X>(-RPL<*BKB!/.BG%Q,HN)J4D8
MC#IZ?29$W7*^M=4D['D._7@>Y7]A[[WCFOJVM/&#H(@H09H@)2HH2A$+O05$
MNH"@B((0$6DB3;I HB@@O0DH"%%! 2D1Z37214"JE" E!*1#0@F!M-_A.W-G
M[GOOG7?NE-^4]^,?.W^<3YYS]MYG[?6LM<_::XWT^[B>5<KJDUZUN-$GQHK$
M2KV*-'0S!L9*V[DY. 998>=DF7;>$@6;2OQK<*2:[%%90\^/SEM\";+9SRP2
MY35N/C:^H.,!Z:MG(1\'WU0D.9DPA#=YIJH=7.0OX@*%+/I:)C=J!GCWU7I\
M3SRG,3C)=]R8Z9ACY2+\3?UAHEQ.#%7R_:)E4)@1[$9I)&F$O#V5P/P6+YIL
MVS/X'N %I[G";RD&NNQ#"/4>O>7Z@&J8_?VL=U1^JGV8_,G+Q5_-;Y4K<S0=
M3X9H:&Z!2VF]9)*5RF4QI=N(BA7A(IY]6T ^Y2+,>J.\OC(6NS;_P3M6VV'_
MT3'-!QP7-+9X=\3_K.:2Q2]T,Y0L6M&\RN=/N?U#>K-[CZY[WGWNL<;/-F/A
M[&+17\[Q-3NRON:&O[]^=1^D"<71A8.&8_F2'O;*M:;FC&(->KE,,Q5_L)EI
M*'Y5_ HUZ"#C"5J@()?"FM*[V4&]4B1+:2P247OGXLPS<R_BI7"1DD";CFU/
M@G4R#].V'=&"OG^3J 72-HH04Y\T-;K/;RW:3]+1(U=]/N&4Q.-/2T7#QV:9
M66;(K'0V*#&JQ;+YZ@+6(167+N]QLJIVP!9U?TLB7C8T[HTBR^8Q+W@!N#33
M$!VH$M9PC+U,6*\_4NM&965\1)FPCGDS-IK<X+M8IJNMX9$UD.(PA9G\@.%"
MXJSH;2(23M.)*H7^NEF:I7B_U\,OH'8'.C;G>X9Z>+=+0._2ASP:0+3"ZSPE
M8)J6Y=^D23WOQUKM6?;+,PF-/<>D\NIP2"[ V:\X^VDOA"P*;=BN-2&VW22^
MZ 4M;;)-0R$N^ NT['905NSDY<^S/9^'Y@L#=)><*<I:%!GJGC[5BVOM>4(3
M]TM.,P!KOV."E(1G5Q-"E ON;)ZJL_F[=WS4 VCOZMG(66VPBKBE6;R:I"$%
M'D9E TW-<T/NZOT\2%N*#4I(G@&(G@M0^/H>Z5M8(?" PV7.N@JM3 8=Q3GD
M(81JD!(Y$.F2;U@89$SOIW>DC9_&#DXL\2UZ*F1VXE(?GF,OAHLK8970VM)/
MS,_HOT=@@U<W3\G7;-(X2_^5NHQ_=],4>!<)['F"W2V4]OB-[V[F1_:G?9&G
M 0G(?>7=X\J'TTZ_ <ZJF()_8,&J[3USFP3^YWP+/_@[23^+Z()R(-1U\O'H
M</H!XKN/!??EQCB&S Y\[/P&"XKYXG"7]6[SEEPR 4.2(BL1#"U<M1J0;(BC
M9(/M##&7C".-)'EN/J-1P2#3,]]6'@@1*_%Y:!/F$V&-D>]OO+MA-%K6/AVS
M:CN<5<AS_063QC+8X3VN(D_7WN]VX8^> RV@R<9T-7!W<:5K+IT>5F.=,=0&
M3O6H'+ $1Q1;:JK!5LK1F/(?C$3_+VI,.;F\Y-W2.Q\SD0X82AIL"P*OQJ>@
MGV$FRU $[6O@T@B!'4).S2 ;:QE J!\MCP%<V")A2.&CB#8&8'(N(%"]G3ZX
M>I'LNSYGKQCI?=XCWQPKP0"2K#F"K)6,DZ+]U!\R@*<&M8=SJ 8@EQD$72>L
M%$*PLG7(MIWR], CU,TP5T'#6&VJ^7/T;,F418B<^U/DX5H3G+#!S2$S CW+
MZ]W"":Q93\?)VADAYM;I==&O7Y<XF-"+.70V05 UC\((AI 1&SPN@9A#%;=!
MU'@5(IV1]Y#VR^M9H:IHR>_I*]M*8YB,L7V@Z)- J_2I\0.D"P8[U#;!7<H
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ML4(?Z854/-B("*3?GL5CHI"L99@0D3-QVD26JU8+1FZITCQF$4'O[VKL#1?
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M "=Z06&HH;V$S7U@ #-5^<@U:9?-1YAO]%^ZY>'>P;?B[I]?AI]A $TKH(:
M[)S!;+O=GZ!&Z5+55TEW&,"[= :0\@NDVJ^EP3;H-4Q5^&_4;]1OU&_4;]1O
MU/]B%.S M@D=ZD<YA^P%_;D.KQL,8-H2AMM"EK#2>":H%7+N=.VLA4UD,JU3
MK50EZQTM6_T0.;457H%9&IT:DS%(6VRJW_VBAZ*X;=IK6T'*G'M;W"NY!"J^
M'HAY@Q>:M.BU7L376=#92RCR\_6G>S?(0;;Y]_FJ4S-(,083&G56UN(=&AVS
M!0D%7;^XRX)>SC2P(EJ:;F"HZHLDN#C=X$_T_>-;C$.BYZ.SW77M,0;.%3[H
M5YO.62(_UE!_/4#D7\R!Z3_PO,7_FG?R&_4;]1OU&_7_&HIL&G?_W\0V"YV!
MOR&_(;\AOR&_(;\AOR&_(;\AOR%_ _)-^1]W_)_^WW;\H1;Y5/2*[?+;,>@-
MT[[Z:PP@?(S>"=VXAES[^0.SS1='#IY8:F  V@H,0+K+B@$D..W4P6>07A!7
MCKF=SY'_?_?)#OM/7R[^;HQW%@']@@'\13?^JI_J:(MM^,^F4:UJ]8*L]T$Y
M?WW/OWSJ/^R:B&"%>S<=G*B2,["_GIR_FK_\'W2+K7.DGI6X?&73?[N#H/UO
M[)<]-/3?.A*UW+:R?R/&T>#?Y^S\>S#D_PJ1^8WYC?F-^8WYC?F-^8WYC?F-
M^8WYC?GOQL0U_DV'=/9?=DA+$I8UE%;_<#-6D0[0G3.H;;<%T,NPZ:8HT'_8
M,-&*J$?\IB#AC[:H8D=U4$%8[RWHW<JR$>5W>M<>$+.@*9>5@+CT(LUF@Q=3
M1?V&/9YY BJG'JGQF)K=_+^=J/J%4 ,[\GF=SL0 WDC;#;;]>;G[C:-_[^DN
MZ"LXX6K<MLKJ$>0HBIY@-=2#(>BCMT^)2#" 3^^0<V]O393)4+E76^&"=)7%
M^M-]/K"#H_,[.2/4W)45<?W4CHI(T4HI*?4UKG,F_#L6>?1F:(E##46.K&+9
MOSE:>&K%U6#3[80+V[T$\TM[&\:?>R4,'V5;"#0?RU8.S2[?.JPKRWT\5F_Z
M:ON)A)!LD?VBT4>IG;1RI$,Y+5-= C9LQP BW6_+>'TX=_(9,TRM2OSU6U&A
MU_G'Q5[C-\8KD5C1R3 413-(<D!5)>CRA:^J%,'H>]C;N>JW4<8&GQ;,7^YA
M^WI@M]YI"!+1UT$PG'(DJ>?+3W"07_6QW7IE+K5R@<4K\9',2:MXX'C<SP8*
M,VDU9&&1=(68B'5;O\Q98T</*&PV$J<K'JV_!4K%->INHL&AW42#9V?!V5]<
MBGNJSD;<ETZP'&I"J 3+F->'C6Q0(EQ/!IRHJVC],5;%&3;L6\&JXN<HI<$6
ML>U"6+<I(53$;:A=NUIBK672[\,>F)]N]K'QEUC"+?SQ2I47AY^VJ0[-EZ&6
M4PFMJXW043CAE5//J 2KDUCZD:C7GB3D9H$.,M1$:\YE!A6+)%R!<\_1Q:JJ
M"+"1LA@11YE#V4.2AWY\PD]+'S_PY2'3V&N.@.DU^@%P_/>IQD210B'EC)CP
M\&7#H*TC"L5&I8%24M,HN[C<18W[L5#2)_*8.T6#>G] 5<O>7:XHL[?-]7Z2
M7>?Y-ZV_VH!B,;RX0*NQY/Q?G)):P+1@R">_HAK514H(1G242):#@W+AKWRI
MA++U"\T\N3%"$GFZC?C'#, _T\2.<ACQ342>]I)ZK5 >'8A+[X):5<386ZE$
MI'FGG&B59\*95D".B8KFJDX]'IQE_8NS5#)_''80/U2('*Z!T5]@AWK@%;I+
M.5,R6"_Z8?<EP2Z^;@ID&8$D/>MKPW2MR2^/",Z*6#DJ+BB39C%WD<-9+? 2
MOQ8CK=M#<A#(F*6UL]G-=S>[91-9G=]ZZ/G'NS:[3BB)QFDHHZX.S9@L!X"/
MNHB/H[ ;41<W+>O/D!<9  N.V-;, *+53Q#WH3Z2;PBJV>P8OC2;^H6S-[?[
M<N=3/*0G;8]N(;)!#C;]8X,![-"K&4!O\MHJE<</=WT"@G1*KS-3%)"=X+U<
M0=!3X+GPF,O^)_+Y.0X-\3WF\_&L6.AGF8;@:Y-'&@+A'"Y'C@9W;1RY>*7;
M887(N9P0\BT'%NH2A"2SOD/TVNQ)TAJ\H9>FL%ZP,L4 K!Q/L^P3?GXL_CI!
M<TGCF'"INNYNRF#$L#*T@<9%:41(H"@PX\HJEU&5M>AYP<\?2XUYN)BP^X_Y
M2&>^JW],>P-S@[-0SQ/DEM)DGLO6!=ID[K-B#U;VKC:/#^&=OG>2]_J:IM(Q
M#PY0ZIY#"5<80(3ZD<%,89'QIN;!DQ&14^,+*@ZCB?LV7J6ZW-ES*949YK]N
M;?&EFWQR];E<\%WV;N';5LY''YPM(/'U1:P4/>(*'5B*,=;[*1#'"MR3VS.P
MK1,P_LLQ4<=9+"'JXOF.\ZJ))H6(S+](.ENVOMJ"(I]2B%*]1A2].2#+WLTZ
MCY7^T> B:5&9*1]R=D^>^;,GCU6X-]%Y& =DV-'P!M03+"3,1[]@1::T<D;_
M7IF#T\W2[WAG^VN]X5>5NIBXURM(S61M3X(7GE1WEU!P0SFT:4$YX,J2_%K-
MA<<F6\97*>AK@W44TEY:V0:4G7QVHD'D;%V<OOQ9G5>YQIYN<\LH"9U640G]
MX\/+$AX&RX+UR60*1=T?28HD.)*,J]BEXHL3OY.$V*/$\2?U69\^%C!AL:LT
M4Y<B[Y8T;20_P:63Z VN,LWE#U9G7J[P87U,M_P*WE_G@E4O?U53%#M4KHXB
MCU#\R1"<7VC1A[[-0H5F[%?K\G)?[HA$W6-W:B.2S058UC/?[/&*^RXI*&S8
M1I>*'1]7*CMD=;-Z__,W[I5I.M3/-VE*Z+L]L,G7,#ZYJ,TPO%9QG]U=ILQ%
MLR=9\(<G'-W47@P-,H#/J4M:[Q#?#]$*?3RJ9R-/Q=G6.I6W..S?3N&=CI[=
MV][._/C-YW@YQZR@0V1':$/W,P24T.DJ%).-E?)2M9M)M$M)#F<.2W@9O=ZM
M.C3M@_AN,;M*549-B=/VU1YA $_\8-0X#3V*W:0N-0&RCP$,<W0P /V^>I!,
M0VJ072"55:;2L1:#J$-!*K"G]<+^2+UJIWM5?:6C@4J6)ZX\(#;GMN@#^&/X
M8T*^O'C8W[ON6:7C4,C)%Q-K'M@A6E0)*$9&A8@G%AT3Q; ETRGT2,W4A[=%
M+FGAX2N%9TOSI$RE'-/TF4M[*L54]>2GY%=?)[3E#,@>$,<[@-#C+NB=)7!-
M'T;_8  C&+H1_@N2='8>O&(D'.2>BVR0K#]N#>^26!0YQ"X6C5?P4VI08@"9
MO*391O<#M_TA.'B8MTI;F&'=$8.RX@S<R2S'2!X="3V6/ G/> Z5 WO$9RVH
M/*)T8TK+! DDE^P;FQL35*YTNM&L)0,HCD323I45V9'>@Q,63.[ (]N"_5J.
M&N?@TH-AURFP9.&QYOD+V[[$RWY[0\/'+^FPX:$&).@PBH08Q#@P@-!'8>%%
MULY^%GZ6!:E?21=4$YXYV6JP>6O5G*]X<"<V&%@(RJ<@$: D$"JIA@Q@?_U3
MV7Q<G8B9>-(ODV7VQQ[Z K]DVSH27J_ QMH2J,P]M=!"JF:%N]#BQ# "6M;<
M_Z \+4!FO^AAF928"K5ATG<EU<#PY\C)E E..5?$SH*:74.'\(_FQ%R7FHPO
M%[DN4F)K?\#(/K!FDYU#_C(,8,\*<EOD\<".91-IFWSQ_7"3B\O4<]?E0OS-
M=Y'2)XBB$3RVYM>U'@, H+BGO):7<C_H(CEB*E^:6Y<H,RIG=,E$8ARZM)A+
M;6U0_-F[5XAY('(;1A<V(7+3G^ZF.OE2@Z+K%O63'H&SY^,_BE-HC8.0X\Q^
MJ$K*Q29YS5Y)&;I86B#_:5OK4I;JUHG' P3D:$C?3C?I(S%QX6"7;*JSF'VZ
MKZU3?,O3.5'L^5'^99MM< E/TMX%02;AX4<R!0?+)"&0Q4-!6S"G6DD6A>=7
M[;9RF"5+HY6@ ;ZS8I!KM&+DW7P85@<K;&%86=%'O>40PI/I.N%8^YSKDF$I
MUX'I^$GN 4X=>6J".)6[9&K*1DJKR4/UP1>!L!R78AW/I%<*=AAF6!S/OD[2
MZBB>U$G(>8XXLB!R@-"U83E#RA-S\?%Q7<>.7DYDXQA15BG69G:SV!L[J<$Z
M@P0EU1@*2NIY9U!2KPD'&Q% 'O7C0'TP"<3'7!K'7ZTL]RXO+OO9<^MK>VBB
M[K=7 OK?6QIG$.O,M\^BP$&6DN,^P!N\^,HFBZ5KHR2X?1[JS"A!UU:7->X'
M;\-CJCMA#H-GLT9GMKV4EUOE<<];)4F2^H$?^@J-UD;?$R/4>SZ==TJY<JB!
M'3"8511CCFVL/TG+P4R^%A&K)8?FNMCLBYVXUN^C?W2FP+[JIF-9<JRUEMZE
MZA2QD)N'7Q]N_;5'MQK1A2IM>V(UB7KL74X\FRY2,.A[]-BG"[\6ER_)/I=)
MN=!@R"$44QN=8+.;--T%-,M4&C";NR<DWYP,D&F2(8NGMEPGEJ=Z^60/.Q7?
M&CO9D+EX-4S;.EHP6T='#,\<6^>AA,Z%N<%&XFQH'V0A$.R<0II:=IIY\^=.
M]YE$N3L+;UR'X[I9BTYSA'^#$XS0V\J%,O3:(LR&*1J-<8<\JX ?P3BJF8TW
MGC_[-NM;6F%M\,S:4U93^E#*VAT_1>%U&VN**+TA\QR9C?BQNSFM]3VN)ETP
M,.#=O9+*5S,G>W*_.+VP4]_<+&3JH8:2]8D2E$D&T)P!;:[V'_/)_LD6PH<]
M=>E [3W2P= 7%#E$ E655E8O2&8 C?H?%2)E,T3,H^5:4K(>EF]QRE^X+GGX
MEYWP-0]5/T6T/.T#<C*]VKU%^#[^-B%TIOYIOHW>O:JRU]!/G<W!,]CW67=_
MOM['JO1%J?N[<NJNV(W%C.H>"9NLU9Z74L[(U=EQ3[!:Y]F7NP2;?(,I^Y5$
M+'6F'R'4]EG/53]@ "Y5=5C3L[-8\TO[F,K?.$Y/GG=C.E!PGP$T7$2PF^#=
MH[NF\I^;EZ+812^4O+%/G!\HN,^T\O'6EE?I1V^QPUF$<#J;UQ2:\WY\%YZ]
M0XW92-]3EJ]?NF7ZX_DMO7URW1K-Q?SMUR:6,>%PC@UDJ#JDI*=44G')>Y$7
M^QP3T.UG]^-EIKYJDD9 IO@_E&M,NN=.8;="BJ.CD?=@VTHH9I!E+*&S\#?P
M<IDORU:D9V35(-B[G\Z#%2BWL-G@I=@$5XT1@<MVF;KWM[<F+:C<X6W0@^KG
MR'[-1\/R<;<*-J+F5AP, ]/#DI--CFM=8H*9G>;(P?[8IH"/ YV!I+!>Y)+U
M4P9@X):_<:#>AE8.NQO'B^B#\<K2O+0&5&$NSB[O=>_.!ZOV?K5V>-7.=,*S
M@DLF:%I$3;/#+OV/C%1?H6WPS7&0"#4SZUO0++0PF#V:$]%9+B(695/;NS)Z
M,W$,1V'YK,>C(W:H)L@YKOY\]-:\S99&XVXBP7^MU276NM4EANR6$&&)80 I
M/L1N*B^2AOSW9EC&[YQ^AXDZ@?73)3%;W'"<#U\*((; HI',I>DYJ9T#I7,M
M,723KE]OF$'#.=@7D],5^V.A PX@&Y3J92!,5-OT2]6O[/JI)OP1?MY'SD^W
M=;M^NVU7=68>CCR]#U-!59HZ^?K>BWRC\6RUD4>%J*Y;J-:?@?&J.8IY.I(_
M4^N@NOW3*_5:<^\B*4WX?VG,S#QW(T\#?Z1-/*]S^MWC@Z;_.RZJ>].RZ@^1
MDUKA%=U_Q//KIZW^*9[_X>8];2OH7\?S']\;,-'LCH5ID5V(>%QWTRC%VM+:
M9<J/A"+='B3J#)8S@#L55A&U),>#-0F/K2.WE;[W=CTZ\\#<P,P97HX*I.E%
M6OBN[ASW!#N0_>E_RDS\OOC[XO_ B_]%69+^QS:+SQ8Q0Y^O7@D!IR0!L_;]
M3_GZT00HI8(!?,?6M_X-AMG&1,'7#.\BE[MI9\7'_4'K[.190?HX ^@3"T)J
M\U@0;]$>&^5,=+V'-_FXBC9YNISH$'KNT5O].I]Y8?\^S'7Z?NJ5<G(-H4:7
MN#?ORGU.YA-GNI./;=\SSEFIM"5;S,@%=X'V:5V?G"$LU+)E;(!26@-RZ0:_
M\LL1'C:X>K1!]*-6$T]XA?_Q=(NLM&YFGI\2VA73^)*-'^@TF" Q23++0BI,
MV;@_1U)&3GJH*&+G]DYDY&GT G[[]=]S+/R_NVT/D>+(*E,F H@)6(E[5&F=
MA N&@RQ#YT(NU_Q(YGV@_B-'E[=^4L]AXIB$_--HKR?PR\M= 4/_(=+0CRFB
M(2]+\YB:7?U/D2T=+VV QU3'"7@7>?'/EI/#/XXR2_8JD[; WTH.G:4(,O[%
M77#:/P'3_@1R /_PW>E?-Y%^M_]G&N3BG]>#*U<-9 "B]K-4T ?0L&Q[T_/?
MO5;_H^T_/P7%NTA)<@']BVSM<9S5A! YQZ1W8ZYV<=G NR(TT.TN($8R'<C\
MP@W_"#U0#\52I<G!V61$M[3[^]$"B<YS?8>W7L;=N'L3'YU&GJ"SH0F&=*Z)
MYWXV,K51/G'A);P?<&OMWOBD.5\=K]A6;='WP<,Y^S ?:[EQF(\SZUV2NA,?
MEZ$$]#HR.(':@6?E#':$"I4G;3G+!%+=J<EU@G:Y[R)I7ZG>_^*,%+E,Y;18
MLTZBG[A3]:=4YC9HXB9&?7H_2U"XRS8%2_X'E$YA9#%.2+*D8[-,1'59"^;9
M2=":%M=4U.OC3((;,,$N=EI,BS]]3HRV\WJHQ[J0S$N.\J3 @RRJZES"R,GX
MMZ+R2Z>J'N:AMIA#V\K/VR008/0#<<1KN+-E;CY&=TT$G#I.NT0)7P]+T?["
M:M]Z\/FPT+W/3]NO)<5#AB0DG]$RZ+ Y6&E%XZ(,KS]"O[[+X\K%AM/-Y5ZY
M>Z<0(P)"L?N/Q9:-]?SKR>,UO7R$DVN3C,0\F@ZD^OEB<]_<2S0!F,8Q:K#[
MJV2I?<5'HE9+X6&<P]CY\HNRXI95$6YB=?9B?*$<5W5,)&Z>MWT:^OTT\X9!
M)#6&P "HO%YXW[@\+4_/*1=A2_XQZ\*BC2CSR*O*^?Q9N@VK8:P]D10\Z3BM
M<@,URMKDET!+5#O2C%5^6_=IO2GB^N.#X"T.Q_FQ'%Y+?),4K\=:]P]J'.%/
M'V8 !%.,L#6B+VH2\^Q1WZCE\/<T_41!?AF.O* 5WI" XO-,M[?OR!PT?R[&
M^P;2LR 91W3]7C@)>V+YHN]^3*Y+M7JH9'VV:Z*HEQ=OU2GDZ3U154.^7^2C
M\>\1-T'Y;KBFKJSI*5@1DV)_XZ!=\-$FER?#4YP>P<_5-YAV:-H>J)*<MD(H
M*8&LG4VNT!T5\FLO_S74"3D9VD@4.^L_8W))X^?[FP?/%:(BJW\,A:OSDY-,
M2Y+::_LW:M)?BF$%.Q)..%P+V:]X3(A3&_"^;C&#7@(MB[U\Y'8B*RF,8!Q:
MX-^VG'8#76B)M6Z@)=E!T[F_?>RHLCUX@6V:,WAQ4^*?B4E2IJ5>JC^(#3?:
M97>SOKQ?MDX=)C^U@&OV;,ZJ$B< ?F),70AKZGW0?OI$-29"6@[=76S(/):D
M2:@QJ3 N23(L2;D<H<&4D1TSZF7G*?A\[R=%'J:=8FTOS(&R?/1AZGG">%:
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M:6URHDBY8*'ZID^@V\@6N@%"5O8CF9,QZ ^HCW#_1=Q\FNE!/Q&QWB-+2\;
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M,+RX'^JW.=M8C]3N6*X$AFJRW>=N[1QK46K4"21^_\]^NL_EUQ!O0+ X&>Z
M$$:VTFD+![]PW&>.+0K.NG?6$K1+T@_'5[L4E3XT*VI_Q+PWF>'!;6.V)<CN
M% 4\*DY.#BT;_GS%6]IPPD?8PGW-J)_T\5W_ZI5GXHZ-(FE^[_?A(]T4UONM
M5>&WP+D\$4S?/KFO[ZW:7!B<99)L>:K 6!7]18_WQ= )+P)\"+[U805&<L',
M!>&*7]5LPL4 +AHDV;]9W[0NVT2ZGRQ$,;N=..U=OS?-$95<KS*6!I]S_*XM
MC1FRH-PA8$X+;#L?0V=JDMZK<C^9F^L45+CQ0BR)4THOS^$2701DY629>9A
MC^]6?GU=FGK>NU.IO0)G##D38TX]T1%<-8^GS* ,:F$94-+50YPLJLV7)#W5
M@2N>TW=W7KY5,96IO+$V;]7A \V4E']2I3ZD_@S2I41VID%.[9 >X79)4BQ@
M+W%U+Q&B>K.36<LL#!_.6^5(:S4U! S4OKZ;>!*E*%F3] (67#Q@J\1-^7=8
M?0)"Y2'%&QR4[^$F.7?JD_]TM\N[XZI3K1Z&3&:.=#_#R/M_W_\9:7B:^>FA
M_NX4A346UX%B0&)3D73^O?EI"U^KSTR>K!?):/F>?6"3%NQ<SZCU"NL/#<L=
MNM?WY%NH\;.9 Q(2ET)')^QE?HL80!E>Y^G69B;5@$W6 N^:U,TR*SY&>80_
M-#5J%)C6,8*QNN^Q9$Q]#@M[922&EC!,91;B96F&81N1>+@Q/;&&^KJ) [^+
MT^H@5E!NCHE,:3J*+@ TB-'U'<STWDM>.6?C/<$(4U%L63%4'PRG.12#-N<2
MT(/@)_B^DLL?TY9^Z.'NC-,]7>&9Y#/?D--H9<OX2C1IUF'@R3=OTX%N6!3L
M&S7V18WOK-(/(H;CJXJT2>P4_T09XD)V.]0M>:#GHUE!:K7WG_8,V]?G(%!'
M^23&OFC-MFJMXZ"-1KO&S9*MG>0[NKG"G_+I=_KQ0 /J*PKOB:*P7PXW+9D%
MQJ"LU;6>0JJ6)B>L;$NJ@Y2^!!>.OWMFLO-64;?^.7Z4V4P5O2@768'@_QW*
M$J,-==/PC788\PY7*G:?),YJ:B"6*MM=4J5^5&P?A5?RWFL,GCUS%=VU1+JZ
M"YR?(]] M*) (Q/=!,5_6J:GB+8(C3>QN)?9SB(?;4PM.L\M_6&MSMGQ7GWZ
M%OO*FY'3>TC1$,9R?VZ==^WCJ _1Q"G+6)X&80Y[LMIVKW&JN:&*V,28.+42
M1!%6]B.KA0O0()69_U'Q@'@*8J\AM!9%Y?8#77PFB-\]YH=(BI#NLM$N'[(5
MAG1Y[FB6LVV=6?Y$7FYM^LM:_\4<CD;O>YS.<5<A)W(A:+A\KS1628JYRN1=
MHU5+W)%8.EM2=+CF^/W1N6,4"[*5'X23VB7\!@M3,-D$[)$CJ/[I (Z$4FF4
M$L NOX6J?/[AHJWC5M7NPMJZNJWW;J[V) WR:FB8*N +.+$ Q*E49&LU#'\'
M%0G#WS.AH]@TDAJQ*)*1CZ;\\Z+V(D-J)?(1T2G[6KI(9QGA3&^2-M&@F[<7
M/0XEQ4P196#[>LB][2GDD6ICU7L+8T:GE?A/ETV,JA=J+<A&Q:DQS+E71NR'
M#/6+EWX/KQ43EZA%&-PWC*>\$,44  7/2U^ P]NT1GYKN/9YU99-AMZPFE,8
ML&N7,%6(M(+BC4#]PS].S:5!MK*#P0$T#IR@5"!;[P/G@N'$)V!.Q(1;X>4C
M_RYMP<^37.W2AHV_D>_405U>B;*V.)7MJ8GO#9@T(^_3('@C (;-1E4-4]--
MF)$;);-5RS,Z6/Q.6G6HO+0TSYM]J0G.NLU#5!^*PKD/F-TGWT#.&!$D@0\^
MG@<\;7!\\$JP3=NLSSL:A'%SG09QM>[T7*-!VI[7#4R_"'(D*Z]<'5+TW-L$
MS@?^>U]SF9H/VRHDI=,@=^M4J*SAFB!X/,,XV@7A@+CG 7C_WH"01[Z:PS3(
M.9?ZQH5/%HXO0B&]DB\Z0_EJO%IR65@._OA8N_MD2Q_8ZVNSJ_PR0UJF66\B
M4>DP,7"RORSAGRXEP; %\"IJ=QL5]H/?I'WXG,>4J>V?%;*UL=D>Y3JAG_$&
M7(K3H*-W36&O]W%EQ -I7^I9L!$VX.^S?R*&X/0JODD-M<VX!;\.&H3-2W1L
MJ]P_X;-\UHT*QJKJ^R8<"AP#B[I-UX&M6[Q>WZ7>@8K*A*2JC[V8058@K70A
MS^5-@J23WGJL,E3CZW5<V%589%=>+2OSNJ>.2;S/SC0B(/W78^9).F^$#[*U
M 5/;G0"*2=*EI<AP^6)[.V/0H<:')MH+32FGJ+$.[>T8>;XN%C%D+"MOY+OR
M[KX80E_+I'1YK^1U'[6GV^IBS7/OL):%8W[=6=-.O8>HD&8.6 %R+HSH,H;Q
M0LU(+M.W,YE)6UT@Q"1H)37.K_?7-':1;:(B[CZJ-R@4%'84%(X]N@V&BA<P
M<KA4 :5PPG%+B0=*3XOT<7#6!!96_;W=^#ZSR:P>\Q:S?L:TU^=XG<W.BB@
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M%*4).5C]CG(C'$^7/!,IX79]VN*FT?B%K%474T7?$\O>!>S)C1E98A=>H8L
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MX!NJ,DDFFCVUN?TJIQX]^JF%FE 8:SF:(61O$95)3_MUG4PVH&A9VG>9_F1
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M!&*I+P=:!RA"/K#MHJ:7>DTF"CO +Y-AY5UAY97WVQO40_:D@&&8)YRL0>G
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MNB#Q]R8EB(V7HB).$-5?Z:# 5M(GA:%5R53^38!Y13CEFR>6]:?@8)[#IP7
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M R)L6XX!;6)[\1 Y;ZXO82?1&.Q>/(3<EB[VF$_CO+/WEP!_D<5?C;1\M.L
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M)H007+(->Z$C.4@S^-XF1]W@^QGL%-\_,-R+X"N'*E[+<F5+RH&ITP3 .EA
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MJ7[X.RTY&+@7/G*[,J'_^(2%7Z4:9W91GL;?#P$"#0FI<XLV?RHV8^;G7P;
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M$APW[LHXQD'DH+%]\;#5C]+6FKEI)_:3LTW4;H()\?)Q.2R8K)\Q'W$R0M1
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M:7+HJA\8]6_Z05FA;09KG1W?K1:.BH?73<(X4829C=%UQ.@BXQABQMC.$,/
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M+0J/9&Y>T7%$.CJF-=5N.ACG1^3MW/'T],27K/FUP@A_-H!SW=$P-^BKG'.
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M11X56?X^*'DL%VJ2L/81T@#WPYFO%N7CU N<.3_/O:FIL96.FWYF#DU"37Y
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MGCC'%/]KR(J]*/C17]$Q=$U[LR# 8=^1#+BG?Q.*XD">\)<[MZH(8@Y:5KB
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MI,\PYD*L5\9YR<%U>%0>2&.1S<5F(_VM1%CCD1]H='%JP6H;NG(%5T$&*-7
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M^#1B&7+"WYFXF_"/VX>WBH&0?-EYX#/ )-2&//A<S)D,"",#7#_A>?A(S_'
M53)@+C]P/YBO?'N_-/C9A$MBJ/)0L<B]C)^BCSB(S@<[."C)Z1@Z_8$,V,+#
M&.^6:%'3N&R@UE6HDC]7&,;O")\J,T-Z\4,!*)&G9$"YNS5;.- ^1AGX*GK3
M<A)8?3_VX$*$<4\+^TY 'LMR* T:'UG.C/\\J:&Y[Y?L?- "&SC?F;?.- T+
M*[6[X(<MO>TE ]YSO[5!DP&1WJGH]3K3L9I6K0O.V[Z4\NR 95 X&=#6AOM!
M!@#Q*.*Y.^DA8B"W:K#^+>./-_^B"N.R^/</NK"FIB3[<[94#WHZ)%V1<9M:
M'N@L"UYZXJ",QNX<7?S%<W?]'%,^24VL'GS<GL:7F6!1MH:,F-7J>+[/-TD:
M,9QHB'N=[" :F]RM#+2X7)_W@VS6C>@%1&'NPN*S5 W$I+NSU,.M(15/BDU'
MWD0L_ E._T)-8YE(MZWXKVQPW:-*B>W6U^%03Y,PQJ6<X<!VKNS7'_Q3DMY-
MD %^?2WGSAP6"Z(+RNZ-<JWKN $3ZHQ_R<1-J3.^O+A#U"AV)G,SKCK$<ED_
MGM)"K/3#UYY0?[#\8@.?,URSE=*;4#J&D'5^N>;^R>)A[1>F@<:( )/ 1W/W
M'U^VK[@ 8$*S>5'P.TR'N&UA#T?;G(5%\?R%IY[9R8ZV<N1*.E[G>*4X8WF)
M</]>2CGK@%"=NSSW.=X='M&+/AX UCQN<%UDZ3P2=1ULK+G8W72VPA/&JC\
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MNY;)F.V-"0<H35Q(ORB4[U9XNPM2XL#T=]A0C>2->6_]MIB2<[CF_R-#Q#.
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M@=FXV]3P<,._O>I E<9F&6^_M #5HI =IV-+4@-EV08#N[9;XVU=R2;W#[G
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ML[MDP.@CL%1,*ZH5'2[N5C9L^4-@IK/@;)8,D-KZ,-TH7RY8O&=]_LBS;G,
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M^& :7.V>CFBO\HJF51AYA0*%\,.K;VA4>'!19G8A$6 B):K/%'ED8TL&5*1
M3TH0<-PEW>2_))K@TS4YTD?GL,_W$04_FGS2UH<6!9/QB];;O(.\3R#]8EH=
MPC74$>/K FAON"FN%#.LC59><WQD2ZPH*J+G?_$T6NGHZAV>P#L4-OH7HF1
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MY=7<%R_'7C$MN_+HP>#86$U6^O:;\HQ?%N^Q'K-F<QJ.SKPT=$(LH$PTE7:
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M=$9RYC"WVC2FXIJA;*_X5T#?&Y^$78L5C'C7\< /=;'%JE>F K*>QI,+F8E
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M*W?>8_=XYEA_!FQ>-0E\BZ 2+BT<<MZT&BY6-U3AIJ7.[KAQ\J1.D9-@2E3
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MF0U29UV-6./LI*XSMUJ%^RE.&YT[X&GR5H'6P69%IK54[)8IXOY!UAZ0V9/
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M8+DGXY6RYGX)$+,]^PGKMIR*)^C+=#%BZ3^G4!BG784O%=5YDXWYK<5Q;O\
M>$WJ7A/C/G/V=KP3G"%Y[;X0:O: [^5H'ROZG5?<B]Z;'#XC9<'8P><G6'.W
MC&F#6$1*!$*(W76T\\]<OYEM\,(![.D.+@58=19YN)%).TZFZ9O1MEI7*.NU
MYO1]P6EY?H-,>34F'R._<)X>7FU:MHZ-Q@>X/9S#9G9^&_A0^<E((<1P$+:K
M4M68N?JU\)R^SD[@1AQ@Z[G85 LG[C]2\FG\;,]KK'!W49F%VT!QSUWUVH3&
MO1GKC(/3Q0LS46G&^V&=!F&VKMI3HV=$0KH5C6T-93]"(/;P#&83_QU&^U\2
MO%T=^:G0KI5K\KOSA(;R_5#.2\ MMM?+5;6:_]QPG3!]$^(C AM8F9Y4< ![
MIK/&RKS'.^'EI9[UM?Z;T"X753TV88.ZOT45A\ +AF /5R,Q+>%Y7GG6H;6"
MR&KK'/E5&4<[OZ0T$^P[I\@_>N)C=V6.JB;>>9\ZZ--F^"<E-Q]4*^N.EA[Z
M@_!\IK]2NM+WIH<$K^AEA+?%U*O-&1@6+$-\)-%Y8=+SIPS^(LY\VJ)FTO;
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M*;M;$-T(:%=KR*%?KM1;J;O*]07U4:&861P'_(@Y%4(#G#"D <(RJ=SIN33
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M@#\9*O,(C-2IIK#*?:H.Y)M0X@4:DZVPN3?OVA<4L.B]NA,.4!0:MMRV)]$
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MT%7P;&*1UIT<WOA.<!P-()6*F.C+3K4T>'-#7T6#Z3T]4F]("@DRCI@?0FU
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MOO]6+9AXDP:(AQY<S%W9TAL@PD#)_5?,787KK2825C'=BSXLS#HO? DZRK<
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M W3O?V[P>.9+L<EE\3 ?2LZE<&867HGM:N (8)%7/]>['V80<Y"";MNZHD3
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MUJ\YK- S)ENDA D[\A5RT/)>0+VAW"'+$\!_M8;FC0F96RF#=%CS(EG1=2M
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M_+R-[+?EJR$H,M/ EW0C0NH-00[39?,MC""VE[=WE@'HK*X:L00]3P5L$FQ
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ME6_S4DZ8KT[M'\[.;[-/!ARWU<57^Z<$?Y1YEXR4H+N4LR(-<23#\.!HRHT
M^+@6?J_*C^@%^A@P)BLC.[_UN3E+MO/H$EZ*]$R*FPKH"SDESV<A5$#<"/^,
M8G26 H>)G+"I.^,H<9(*^$$%R+:*#2.<D&\-\0<=#_-ZQN7B#%@/-!*ZWB"3
MP#\H;T8/R#)L\8AES+M3"B9%!;2?,N2(>X0^\L$@"'\*&TB3YI'=3[Z3^^BM
MY0L'4N:VRXDA+%UDZ2'?3;:F('CFG$*HG?X #*D\I7GS9]A6DBZ=XLR)6%%)
MWQ^1WN$WST=0 WN7]*V%Y=15\*!(<+0J/R%I@ TVT%4M'7^<$XBD63L#C#,F
MV7SM+2!+DU+FQ*I<\H_/6N;&C0'.ZBP4@"X=ZT<KRR^DK<!*O-@+[QGEM_0.
MP9_CUHF!2-2[Q>F*DHN^>%.M"+-)[G<]L?DU,K=O8EY4X^%%T]>QLY;UWP;;
MT<14R-%SNFDJ (LH#>G4LE# ]IWX*TMSJ'JR!\EQ;VYLH* C):-'D&6''I"S
M%*O.#")<897F0GZ#\9,7Q1U3[(I'?*X[5  -I>>H=SGL11X5\*;]0#?AX2NP
M))(9^LW#N(FKW4@Z2VSU2-3"9E_9D\-1W,S7O*+!Y+MUL;\_> &&PGMH1+AM
M<\#X"?P]?+L-I'36W[WE$7X+W.Y<7*OI>_52KS'<)(<OI R3 =Q^V:U!=XGQ
M35DZNSS_EV?CO;(;_:(% [4GH4]?UIIQJYHDF7AZI*!+3/T-?HU-'%(!1(WR
MJCJ2?Z'<*$&_Q>0EY_W+B)&.=:N$RWY40!6S"+,;)_V3\+L *N"AVZJRZ 1*
M4&K=C:-#Q+AYH,7[%&/J38W_F1I' JL3Y)"1H$J=6'DUU^8YRJ"F #U/@Q[_
M><$+BE[G;W\M)AL2T,CV7@.M[WC_<"D)U&>D9]T."Y".G>[Y7<!NDMM&M.C3
MC6RD9NI7 W//0H-Q:Z;D9-NBH_IM1/^<NFB &MD1WV(V>.DP#>FX>^,@Y?PB
M^6?'/$3]]*6&',13^&Q<ZW(X'N-'0L<U:GQ>I&CL VK)YT*\M1AAI=CU,8(*
MP>J9M&6TV41I9QW%3055NSY\NOUT*O\K\]G,_X,C=>O[0-).QLD0N3@1304D
M.&,G@5VO!/\;&< \/FE0-2X)@#11V--T1J3D:AVQ[YX%*Z7?;.G^==%$1BP,
MO[VQ3$"UJ@.'T#&@MZ&*V]#!)>'%X:T60!<[S1O5W8=YP:O5A[9?2SUD-^O$
MYOO^I,W3Q>]-Q_IC+Y.A!9W%#7 ?-_$M@221IR8=UWT='>E0U49N:TB6@"$-
MO%KHU/H1^NL[UP[73E]APX[^J[DGHGO?T[2-JMV*[A24,;1@>=6! 2CCZ!8#
M@GN&;Z 8-!ZHX*:TQU6>O"'VA6 15PFDM6[Q1JV-UADV]"UV" Z_IKDC^WH[
M6O7'>'8-BA'F@E=X0^D\*9V+4_XY>;^B&75;G/"M"W/>Z((2[9A9[AK1FICA
M4> R]G#:<D*25,;W<F5][<)G>A\+M3FIJ"PV?-RP'VXLRF=2=$DC)6)KE=]+
M[:61YS;D%GP(>$T^!H1C:OKFC.&KC]&M-Q#:V2C[K2%3N< 4KOA89_E^R*JV
M6/&WO*VV[N^UQ#P64[.1DDH)=;<3[2TN+F$+GS2VJXS7@I("6%I7095T+9D>
M)@;T(/95D\GZ%[H]Q_[ NT9GR"OK3PZSPK1,1M'U#%=7_3E3\_U9XL+KME/G
MGN.B9&.326,2(82*'T%^D>?+/><:9=3N^#O/U>PV79<YF?GLY3G-?&;<V!:-
M:@-=L"?9@QE;YM24]A0S'*9#OMQWG9X4V'/7X0G,PWNT4@&78/=V.R+EUR7L
M9I8L-Q>Z/^^+!G8T\FHL^3);_ )RD8$%ZT N584"&YC6D*H"]+)?TYY-J<9L
MZC*3M* #]YT9O]A]?I8-BB I9Q9X?NULBRV!%9EG+_?4^-SP+/<7@?--FXD(
M4;U)NP.'X-]KPF5T%+;E%N01CYP'F=YZ=1_%YHSA&=!&%;E6I7(ZG'.LJWE_
M\S8_/^W^S[W\)2E^^^C=1BEB! E:"A',S(^MK)44@!:4WNEMW0-\.YL0/\V:
M-C/=LHZ\EI>^9D%_4Y.EWN ;J_>KUOT?Q%Q<=#VGA9].MK$M6Q."VXZL3;+(
M7L>%V7043-_=Z4I\6;C[C9U#  ! "9^DP7@* SS:< L'6,8]+*= U1?SP0[C
MX-17VW2>YBLJS[,:)DHRCAM^'IE$+\.>$)A:U,]$*,&TRJQ<Z(6.T+7OQ=25
M-^WS\2R0IFEF,C_AK!X_?CM*W-<EARN+7?#\736_+,_M:(7?P>Z^CRQ <PE1
MZEQX6V+B>MU(5HK$*.Q-W?L;R;0T"?8YNR4)UV#N>&"XK\=&KTU;$/04"P*:
M!%J\EK]NA$RWI_3S-++PH(<54@E@#U$P;1&/0%R8F @'+>/PH_<__O*KB])O
MDW:1)RWDHJ#08XKJ,A7PD@H0!1"F_\$7#[D#$Z("$L.H@#%-\OJJ"I!T8 VH
M^+>CVI [E%_8'6]0I=,)?!5T)#J'24)E()P@ATI(G.R_Y"BR>-K'<Y%.$6TS
M=J_FDQD5$*-SRO]7Q8_THX51BIO_PQ-.KNUODXJ*P+:7?/_[66'3!ZZ6T@\M
M?127,O_1NLD[/.HTNP06HBE5_J^)I/S_^?J?CQ(!;R&:-+$+>GCDR9MG5,"
MV5(:DANC2E;$LR;(MW]DS9REGJH*RRFX^&VBM4-\]>:;P%EM=3P*3 6$OK'I
M]IQ!7;J0$WAA6."GEA#%:JR&I-/"JBY)XL]V#D)CD0Z!.1JT ]^6SPLN_P[[
M>< 2:XK6KD?]K+7&@RO(?5=.WL&OV4'<DLD68[[K=M[&PTE@H8TRVQSL47MB
MXFW2O#/W\TJ$2U^D_=EALD<N*;EC2B5$IGF2A4V#,<W%@4Z<_X)_7$<Q%&1L
M[X)G:.7,WY@E#)GA66MV,6$AWD1/:=/%DLB3!RW?+E^@6Y,=+(8/$"5FMG'1
MTZV4V_UE\ML7'CQ)$@[=BM<=O9UW'FYBUO3TS6Y6T$AG_L:$'SG*PG9U^S +
M0A@R)SD%!N?UX?L,AGW0;[[5U""#.O@OLXC4OJ7U7L4U;A-[AH5&,&?(2HVU
MWH*]W1IR94$5\E5ZY-[ _$UI@@CF]DH=SW:D*G](;H#.@Y32P2TWQU@]E3(_
M8=M79_,=#CWMJ(!-0\^3ZF-YLF0-.F[1W !65"C " UEZ \5A>!SL0T1V"AD
MLCQ,Z%B2Y-0*J4"1!93K;.U)9<>ZT'MJ^GH3'W2C*H79%'',PDW (8Y3]M-J
M@V4@\Y+"EF3!K!%Q""A3TKW4N+?&*_1\H+>HSZHT7%(;0]DW3( 4QH#V0:6^
M/W46OR#?#L+[HAHD"/S:]7H2<\,2.57B7=H*XF&J1\_+_(DI#KS3Q;=8?5:[
M3J=[WQM;P="T+H63;86+$*3BW=W1\J'W+Q=+:Z>[*%RWBN03-GXE/>S'7N8V
MAVW^#;]&Z<=P]V^X;TE6)OL[>3ZKEJJ=U?[@*+LQC@59CY,T"5PV)XDPMSD>
MFC9U8'U]1;U8C0W>X,;CI';PU1+V YY&:<OIZPU6*+(A:7$6S+RF?.57C$.P
MM\L)$GI;$/.K L#]B:'!G_?#<FR\Z^K.L;X1EQT"$BB+%30*V5=C(-80SN<0
MQ.:K(RF<&G[$]&=>-ATWPW8J!V<^7MA&LY\A'8U9$(J)\GA()(5I+1T9,5]7
M.2H7;%ZOP#0AAW1Y9/>+!PQ(O,AU=QE7 7K!$(X1&,#<6$4PJTHY2JQ474/_
M?GTY[G(Y,%7;^%?SY[/!#EGH/O*]DV]H; S\0EH3!8@/&2FK*.9#UP9\ZDMQ
MYW%X6'M8]VR/]L0MP\*P#6:!P%^93+D_W>)(!= VSJ"BK-/B04_[N*U=TZ[;
M3:S,6 OL?*JX;\5Q1HWP\^C,0_A/+  F13"=72HN)GW%0?7FZX.Y%'NV8MR_
ML/QY?U9)G K(\WU(YL&2#(ZY S M)AHGU04ZQ/H/#H<-W^W.?M4Q8?;>,O3!
M?K.5T< _/W&,R_'8#(QGOX88:;-C-4DQ($*^1!3=WG?ZA?B.;0Z1G=-I[87<
M&[,/+F4PC-L2*+>RNA[(0JZ4J(S/>$L%K#^OFQ1J\4.<HP*@O0I:^.V/T#Q;
M ^Y[Y[W&'=*O6<D$\BGPJX=68I\<6WTA=<^;)W'PFT)OT8L *&2SA*C1"H7-
MQ<_Z-Q-;)<6_SQJ!1J[N,X_#VPXFZM["]_W&\:+P4>".+_P\%5!V!WAD)AB\
MW$X%O#IE!F077^]Y(*>AKZOXBU:O/IZQ%,[V\ ^>\4:6)UYB352 :[=5WDF1
MZM75R_&A7-S?"_D0>7I3%0AW\%M>OE'5%S"VRR9:GW\+F'YO+C%L+:FOEMZS
MG6$H/')B.\ZMV]4=^*N07:K.&3QV)C._(R%:X67 \_9=';Q:[JM>7T^ACS?;
M&6@\V7>!2><5>6N6UQAP8;/^8?O%P"L3 <4=$K-V3'JQFBQA0AG$5](U!72>
M(9\OO_)<M1?"CQ/K/<+A3)7]<J"(3I9*?BE^B%)@+BAPXM V^<B'16A3'Y=5
M,0\&G'Z;!]RE8"*!^=:=@N]?M/%#VQ;?5"D**)C&4EAR2]X_K<)0 ?"OGB.=
MC9O5$R^1/&BIL#&<VB?(E<I,;1QQZH5A"%^BAD" *FS#:&-FCV=] *X<<$>*
M&=YC?X:P?[(YG-X8CX0^+E]\X,4OS941F_J#9UV!^(J$=B&XS3:6(6<2:.U7
M[=D'G>)MZMLK=7/BHD2X79GX20D((Y6QX+DX]?5VY#=X5+I=9;7L;YV+Z>S]
M:9!;YA;S*![X>R1^X?@4)M"ZD=[M.5D<G^+)(561&2X$Y[B]77>!&RY0;W-1
M;%&;5;M]0A+QQO=60P:1OI85KDK(:[E<8OTD,>')+;=AK ,BIGL.?'Z<Q+TR
M9E[-R8L42(+H(GPE'14?2C>UQ.>7H^1.0O<.N3HHM^/G.*XK^6Q&>KU+=.0H
M!2VN+VYLDA*QX2A?;[:9CC#$;#%&/B#!BI R?* ,3?^8CE.Z=+UD\6FX[N)#
M0)!W!\:U8U,!']]!]"3HA),M9JRVY,KE2EA9/W0NZK_B+N;5_Z;(ESP]QF)A
MD-R&*$]HVS3:6KZ?889?^H(13%(M\;^V/1$.H16/F007[I_/)XQ%-Y@=NP2,
M:PU62EWMRW.V#KZ^VV508A,U+9[PZO/,8^&%8^(OY?9+6>M'P]6Y^7WE'L11
MP@U"1#(^W_ZM:L1P9:?DR)GC\%:)A!_I&W!12C>&$3^]L1M<UD:[&Y ]^DME
M=5_/R2\P3_#!1]IY.L_-U=Y3HEPM%#&D006$.^6N]NN.!H6\KRH_9])Z,U"T
MMN,;*EM=57L'WHOAUS)W4K[WZO.S/>LT#R<%WNU=!PMBHLD&5C/E)%+5S'=.
M*M3%S9=?'V>X5V5<P8V4<M7-P>]>.#H#N6?1 \*#20+5)+.RDO+*%[YIBKY\
M5$!A-":KK"B#G+;@ /; _E7NO$+NTM_ T*R_R<QZI>H_"R*_ 5+J@,L0O=^G
M8*1NK!=YD0I8.'W0?O]?N8!&?^4"OA(?^+?"&;W8TX_<I[Y-CG^M7!!=@\HM
M7IK^,T8Q<B+&_M\E#K1L+7(B*%<0>-2)I! +8FY@'W%DH)Z4'2WV2^7>W[FY
MND8;I)_,G7^+,O>3/LO669LD6?/+[W:?T?['4T8T=H\*R/)'DJ1KJ(#Y]V>&
MC6VQ9#$[>DK@%&*F?9X*B#?^I] _A?XI]$^A?PK]4^B?0O\4^J?0/X7^*?1_
MM)#Q^(_4;SJ7 R]ROK'KL9RY?!5\*_?OX^JX!'*@(6658O;3^I3P5$*V$A;M
MX/_HG'U(6_DWOF\6EK82A7<?EJ.5<B@;T>QP[;SL5^R)'=QNG-K%G'B61P#0
MI0# R_/G_M5S3ZO :GZ0 1^@-=U4@DC3.*RF)W>;QA;,YS.O"0.*\*O$JL'*
MQ'%-YKB#3'X LI#EZ;_K7I.LR=,*Y2XO*:\V>WD!%*X>#8CGLH3.,FI=U[JV
M$O59:A%L=NGV>3JT!#/@]YSNZPO1KSYEYIP^^_-Y0UI_Z0]+<8YQ=<4%?)3S
M25,X+MW6E_<3.TY^#PN3P_7^WJ//<NZ '-A'F:68J3TG91B$V>&7BK].GK]3
MG?I]O(NQ*C,^W(:NO$EN!%60A>,U_H?D@MWM']CRZ5>J6GX#DU6EE=+ ^GKC
MZ9,NH@J$)*30;/7E<B_*"7>"($T&V7><HP) 2,H9*F"<6WV(A0I03Z.<WL(A
MS8PA$HB6&C@C%1 ,H0)^[)^NH\\_W CF9B-3$"0Z*N %R"6:"D :4 %GJ8!-
M<*$S*A4[.P&Z0 4THJB F:"_>LN!_OT-M7AZ"@)$IJ$"JAC^?KC;/W)7<R>R
M2N0L\ !-!9 9(!2%1R 'T-E5Y&6*+"P WYZPS"-K6#N8';;)@#'\JI*Z,..4
M%&SQ0&1V/K)L]9&7GTW[M*OZB^7WZ_IH*1?:E&F;D[2%A-+35<7W6?[O;A/R
M?]I5^H_AE?_)XDH/TI]5AR^^"]6.MOJP![B<#"ZA A@1/[&%5,!8"?;H3(DT
M"P^G;$&U'K:6TS1!=1ABKI5-*M8E,"?=RB@8GVIP\"X!)YW9-O>U>]JM6:%@
M<2"-LRF\]"QQYMD>RPXD#*;G.W/B-6Y6?=DACJB?DQL=5$@&I02GM1N:C%N3
M+(CK>K150YWT.0SW$)EPSU1"3(_,)R.))M%A4UC=G[*$QCH02?AXHSL\E>YV
MR^QP1IY9'KQPVFR\%_%#C<E@!"I?+%=?7F-0[/33RD')-"SL:*1HAG(!T:DP
MA)A.HP*TY?U3#O[XW;+L8>%^,/)IG@.4_H TT7*%FU>FC%-R[;K;EM^EEF&R
MYV?GZ@27D&(;ZXFO"EK\LQ':.BMN7AB')$.V-@@3NI:L&32:[O%1Y+K8D_A!
M1L ,$9@'.V!<]OT>?B^+1^M72?K!9':2==61CUILC$A^NE%QV<(7(X4#LW'_
M <&#+"K@*VF]Y:AMP2_5&EW:V_/Q#[-'JB('Z'.Q\EBT'/)JI:8I-O1G;S+[
MQ_)Z]E\@:5N%ENVS)&EY732"88W)OL\-F?*5SGU1K&N3[HM\&\RU+LR<]/&K
MRX'IX9W;'<S>ND9WSC^UPVXG@41WRP.)H#,IXHX!0[Y"\NP[G35R1]4'61%
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M58N@5L^VP@F;W(J.2RF/GG/@S@@0D-:X(K>4/YGOEXHT#%^,-$<+YSHS6R3
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M[ O'@H@H* I2!!10I(F ]!(;!$2*((0>%1 0 1&! "%1D2(M @*" M([$4D
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M+9V "JJC/X73AIH2D(O.P..%.QT:+@0[0=1W#T"<.^#,5EO@HHX<[(E)) $
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M@():5%/UR@O;B[L+Y'I2ZJ>/+PJ&=D64?C#=:1/#)I5UQ!M/V"?/H/<NH ?
M>TRO31U7*C<+('F&<G;9EP7(E8$8@GOBZ6S4D!SH.H3"'59GF.=F5#A^?\^C
MBVG;7B=U3%%I(#_7S^$P&=$B)]F\,Z)SF>*;5)Q=5)TT?*Y)0?KV]*[A[ZGM
M50?FXQ-J><6WT:\B!VPGY"JK2+ RL/F9D+E,<V[YP)?^_<->P>O4"^=7HE@
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M4ZL;S7'2]>]FDN8+'^CR'CEQM0Q,4FTV4B66A8OD%WHZQ4.G]'_3NZS#]%D
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M9 &<WYQ:\5D&USF>Q\; LVDOXS=-UH"Z=)E"ZS]4T$W;SP5RHVCJ<6LG"XD
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M<GM(XRMS$51>N%>$E(D"5[GL9YO T_1U.Y; M'[<./Q=N\_)!\5U!1$3 I\
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M_R&(A8[T%A6I$1"$1T$@(@\H(%4@5%% $ )$F@HA1-"H= $!I2I-D1(ZTI4
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M*NV$' _73^J:D&ET<P^2Q\3MHLL.4:+'E#JU58XQ];UU#FN?^UO%?&PN5+O
MTDYY*5*MX(4VPO*B]3,C7YA$O#+N'FBB#4^B=[5[X6YK4Z(K/YC=SYR^2;*(
M"98'"YXS_7/U5K[([MEV__C%HKBR:YC&!'K# CYTI/O.$ND!&W#,KM>>L<R&
M;>ECR;BO5*HKMKHR!PNO=&Y<]2OM<[Q%3WW)]21R9P6< H\Q/ OA@'[M"']!
MJV[?-V4#.FUYK77TQM\0-.) ](>%5K=MB91F])J'UBX;D#\4";K;,?.LQ?QK
M-_>6#WM_<M&8F)Z%KAG42?][/"@?A==#DOW/A="SS;(O^_:@!2P\&^#4@3S7
M*RTK@Z5/S\Y;"L_,2/M)TGKY775MDQ-P#0CDH?G^(%N5G-O)/SQ%/H5,XF^[
M)&<UO_N=B_0FXRYF*"6TQ\6WVXP)6P3O.VE491TH?E]%AUSE2XP]?OG8,1EZ
M6=11"J*;, ])Z>TP&%?;: "'S\!\8?VF$4 ^ '@O\FZ%9M/VP/!U/=; U#(B
M9'Y^M]7M=X2AY 2M928G)Y.U>0GQZ!"#VM)G_PN(M)B6)&GK$XQH-@#M"):M
MS+4$IP7GAG'.YG+L8KZS <G'G[9[Y__]/$V;"WZD@FQ/1:&O5TN T-%)*U*!
MI97^$X2)ZGG7&BYLL$0JO]X#4S"8)0CB10TW%Q^B):\'TU)[+6HB.&-B2-=+
M*E[376V<N5#8>0-"Y*#@#GBRK5E SR'^C!Q.>H'GD"6W4=1_!GWYFS^877,,
MD^41_.O?<[0;P[C9)J&-^$9?:;GJE+R];2;P-SS*RV]/P&6[<WJ5Y#&C4<D$
MW36\V]1-WQ=P/MY_9D\@1ZXX$CKF D?O!$J%&A843TX.0OW2IJ?D/0VTW@7;
MN#&4L$U-PM;![Y;3\?)B$=YU26_C5LS :;"1@1K[ZL?HV\41E;7;&TA%);4>
MDM;/&%J906[%KGLGGG7B3YU)]*M#K.,@HO;$=E*8' EL(*Z()2C PP:&FXI1
M_^D;F;(W9L%"0MH8F[NJ34PVX!'*!BZ24IY A'.(^!2UXGSW;$NJ&"%^(4P%
M F8#7ZQU=Q0[=AUYWSU]96HD^O2_PT_3V;C32?))8I>'C]K;/GD7!CP4W6JN
MTLN\Z^#X3/<V'E]#>ZOHZ@$N4A5553&ENP3.+K9=I%@;4=J;XM87\_=^@02?
MNS8TITK?O[)==UR3CG?;$77%%G!$72&BCJU&R]0WC\OAH2227W'B(/>%(Z^>
M"'3+-2QK0^-^;ADXQ&!-)V)':6R@J6E_4(.+83CPY;9DW?#.']_LT?$+UYOO
M^?$[U7RS.79KV:T-=23J$JC[*=D!AE^_J%% 0R[34!>J+@5.M1JPZ"X[+BIS
M"SEE(5TVK\]8V5AI-F3! D(ZA3IDG:*LAM-OC&,T*M7$[KU%)Q2*GY;AGJW$
MZ>[%N+:HIP82#\[B+>OL,AM?56BJK#:8<B-7UD4:APF38PZR,,20"\L]6?HJ
MP[CHL2^N)2OAO#K\??LX9P2MPQ.9NW$ZO<EGHPB"*-,AK&1'17:\?>1U40L;
MSM.U+LD16WTZ-960W6"BGMM^)$\J[);]CZJ9:$QH*@-&P5LP7 OQ)<NWYF9=
MAW0_^[2%^\XZ0(%/'WM%'G[:I&3=2"?9,69G%U#^GR(\99?_\?+YGG,IC WX
MM_JK5FV&*CQ[5]:;%OLSH<4]6Q_5XU&[B=:_2P(?^-#VH<DK-./S"5Q4+JX]
M3LG+3+\.T$%&E,"[E0OSHN,Z2G%/*Q[5E=U,?H9VP)-[$*(B2@,U ^<Q1U5:
MTHIS@MB %D_K97C%K_KL"[1MTQ%][P?VB4)_H (4_&)5#*5TA46^D4DCP7KL
M'[:ERGR*M1+W5^=&A@Y#428*12U7/ES+,.LM)C^2+8"A;0G:;Z*,"E>DW+$W
M,NF-6ZXW1@1EP&5V1J<3%^G<&%MS6SLK#9\P4RLUG>9_.NL@:V/$E"DH<8W%
M3\EC57[T2_<P^ZC=,CAB<>G-2OQ539S4>I< $7\;-O&QL/+;@*.Y^14Y-9+
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M97]D]>":_W6( 5&! N@S/Y5T4J4 NC(.*8#4,5+LO9.?$<] 0W"=/^##,0J
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M!6=6A<)4(7??@;-N-\>NO;GMO'SYJ<!ZPM<^!GW5U:Q^G"&VLX!@;(K1%V]
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M <S6>5, )=S6:01)\L \)_G"JS6#OIUNU&CL?/!<M<^ULV[3/,#79X$W4](
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MR1]=&2BZV$';;0CEF:;I[P^-'ZS@0,FYBU,,QQIV.'-/A_2>(GIVF'&7@*Z
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M7>354II7V]PJ38(2V(OTJ/Q&V[<EN&+Z..Y/)B.5Z0*?EY ]QUM?NEFOK!^
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M2N2Q;<E<>R?6U,<Z(@7&.2 [[I'"L8GAA]G*NF>J>25(REGDFFJ[J<GU'"V
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M<3\1NX/A/G$J4T=>G'<K%X&J&&PRL6T)G*AZF8 J\S:1'30:_L<TKGQ L#O
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MNBG@X<%;Q&58N[5G6:=_GII20*"(9L1X5.J%S9<$>%A= F A?[@N 1>-&I>
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M(0BRI#L3T#5_"[\7>I1Y1O,> F95X6CV-T<^ #U'R7 YBH>6T,/GA/]=*'6
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M0WS[@P425.,"5??OB+5DG/?LM9C?4]3,+UD?_=E7EP ?_D0WL(:>BGGR=X,
M^OQD:--^WXX&7J&72XS4M-C!X1N")%I)C]7]T*>"TRY8]%%J-!B[=_]Y\;7S
MMV+PXA_KGO>^S(M[W17@F=P7I/ *$E!GU/.N<&&8EB(7<2[Y]<N;WQX_ZT_[
ML/->3QU)&',)^J+B6*&AECK_*D J()=; Y^V1(?LF GO#A;#1\07;S;313D8
M-K8T-L;Y2>_Q0A].H8 4['=NWN8>\\'Z_%:F-[_BA&,!.,LG,) P;JIJQZ4J
M=9590D42EB58;:? DON#\C0IAM-)ZAW1D139N4!S"7""?FK6*5K,O6VZ?EK\
M27C@KQ-,BY=]Y_A^VJND_U3=DBH3KO&S;EE].GL5R$E*OM(DTQVO\)A9T?A
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M$H+)6Y&/:;5 GZRHI10XPIS;T2,5K>_K@* /:L-#UVN^#2G0!7.<=R^J]OG
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MM4 3;85W5KTW(AM>5>FZ/L6\>*6GEXJ>+8$C(NA2ET)Y%DZ8"9M#UZ-.8_D
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M)E1B@RJ,W!6<[+879:OR+(NZ7=07N*83C"(\74'IU;M>1>KQA6(J[.&T WU
M:A'1&ZSTZ;:\9\^4//0:ZBPAB.&&IIEQ&T&\$70J57WO9]XV_4B^,S<_QNP3
MNZ.,.(/AQUKK$9XD5FF =_$]Q ]FY<:GHRIP(N4X_KXO'AN(7HX](/B7%)PO
M997E,_] .-%0.T>%1&D./3$GZW]1O592&1)2O-5, MA!567XYQ$93W<"8%J,
M9K>*_^$T,L\4Q\##(&0%T4:]9\3DU1&9@5LLJ?7KWM]2K@G</F6]WDO6[]%5
M:=J#C<7IERYI.MEA=+I\DCWDYE;@F"MY YOCS_3BH8G.Z>N521^;!/,<<L=U
MR]DTA:_H#O#G%!3?^>_=K?$<M"84")&OD@@K\UWK>6]3UWMG$NP%\G734P5$
MI\O!J I8Q&\R.+EY,SXWT#2MF9#9KJ?>'?(7O?9T.&D'^3Q& '@@S1"H.O(:
MIXYT^*AVBSIX%<BTE7F;F6!P'EO<X[/A4'@@'J/.KFA=Y7IYU[8@-T)$^Q_;
ML[+1PT1B*W%F:(H7->,$/V36GKCVX0+JK>9YEI=[N_AP&ER3X<.1* U#ILBJ
MH1>/&--RW+WXB!9O5;<(=.QEXB+/Y78!WZ#EAS^@M\R'2GXI(<CE&^!R#\QL
M0[2<UK3LA0*SU^-%%R^T_K;RLTBCL?M1>>*O]R_^VOZB7#CL$GDG541SEW;.
M1L[;DPLL'DZ^6+(>X(]@Y++XBKZB^N>^H[&-./K@@@E+88!]<3A0-U&E9DKV
MNWF^7+R&:G5*H,"G>?/I-PKDJWK;UE5]1E%+E#BA;$0Y;JW7%,K]+8[0F+I2
MJS)\]1&"_?+^_?40"J:R/)-[3]Q] L1+.#'.VUO>7\RR(+=PYVC\VDR:C_^*
M.L,\+DA4F]J=TTE 6C,=)<D849F]LI+8U870M FV&+P7O!%?*RPKZ'F!0+<[
MXD[VY7^U$7[@/##2V)KS7.@=R/,)E4L8'<WQNH-KNY*.KV;J%I[W&JEV=Q>;
M#)HLF"Y^$-/8GA7B6N[FF<];$^HVFI?6P2GC[]_.*!E"7F+??H_-XG3?C]>V
M^T1$&5MS32&B([JJY]OT[([Y/?/3'F&-K,!SO\T_M3BB?N$G(@[!D5GUX.[8
M#TKE2@XQ*G:@/&</;4$K@2!021#G:LHM'3L*BBN!H\(<%VE@3 )05>XB56SN
MPIO1=N7;KAXEEE9&BO"X.9'R. '[AP(UYQL\ON\C5K&REB9/O/V=FN J8%!F
MO9;[+ G TGJK$"+.0U_I5;R&!LXQ/&4OCM!^ZK;#!GQI?7HK; CN;2B5*7+2
M,_;)DJ(/3.&T)()NV]U1HLTNQ\*-7,4[4DO[*"E%RBXE*@AX3+D_615H2IT$
MI[P8Q#:-CP/9H',D0)U#'Q?%6O('*#6$/T!=#R,?+C9S6I^A+1-G:QK_YOFE
MZ<0'D7YLX=H"KE327<%8HPM?B\%1+,B##UFLA9->8S<<L4"W,,M)/MTIPK=&
M<K[<&A6//+)J\QN:M%";L9)G6)N97=!"14-3;$.LO.0 WB2",(Z!HZ0PM4@A
M%!M&O8=X!3>RLAQ*9$(OY38'U."^_;3J$8C\FL*7I.]DH^/$E_C-"'KWKNB^
MY,\U?5QL/D&F/A*9'%Y7Q8PKU%M/QC_5?F[E)+YPE;?EU2=NY;U-50.1.;TG
M05_6*U&%\-GU&Z6E<O&J]R+N5#*\_?>O_.54@9)LV'X<<]F:I.W->V>Y"BX.
M+[ 1&O-,]A>>W7R;G0XP*KB88L#<=GL2("P!.@K\8PP[#"N!':KZ^_3 (C+I
M<7\[(!_5<147A.A5NOB2>&%M@GLTFA;Q-%2[BP($>*OEJL144C9Z75)F(%I7
M7[<EPYK1V)SYGPJ+F3*&#,D2!F6ZT' 8]8AC<T]7JB[-7];#;$'K@8#G5U+"
M>:\\T1/Z8(+C0+ +]69=VX8*H3<.L#%A)3V;\]9^1BQ?/\9E5);V?'X?Z-QD
M-S3B>L7+GZ/.+-09!J?K;./IU^F>A=V4::SW2ML[^)A2$?]XI>S%Q[N5=!02
M4DMM=$BSOH.K!&[T("ZXW^96[0_/4'=.'Q8:JY'7]YAEGUB,7E)X8GA)-B_/
M5%R(I7+>S4C%>MZ?*X3I=P<%">!$%]K!/7- O*'.; F:F+\^N2#V3D,%E.XF
M]:@8[]&/:MRL>/_\88X(.,EYN$#PGVK!_7^L%OQOL&\0Y?P=)>]J9%KDPEB]
M%7!'S\.6Y>L8UE<KHTY;A3YDN/H1SD;=+S-_YM@#RC0A[KGHWV_&?!9E5NO,
M7N<C?U<GZN> F"L?O1SE>KZ>$"_G(X5^2E!Q3'S$G?R[_^OJ\0IX#D$T&L(F
MDP!53; _%64))$!0AG,2C%Y-$4*-E@P#VTZI&+G"E'Y9SC?ZP.49+,6LT-"G
M^&0%!5[ >W:L43@/6K\C!,8("4#2L3A?-.\H\6-Q9ZS5[J?R U=FIGAML0=7
M&UZS"$7%!^S"<63X*P3A\PS(@W;>'R['UX&]]&4"[)E-;Q.&W%A?M=8_?&BB
MP?_VQ4I<.H,-"3#S%EU:+6+P7=1RT=5U_ZV_4HS:2(5DQ^AF!&X7&>\,:R@*
MER$!@K.N54"L,"#];\QG61%>Y_:.>ZA7S\)U8R[C&87?F'RO#Y<,?#<,.2%2
M[JXLXQZW"T(GEVYB'K+[LA>>JS^%3TAC><=4?[VCAF0=OZQU4;W?%V"-X<=R
MHH5ZU2/,U&]4'%<QX:1[X=5^\B?<#--:G]JL<W03UNU/$Y_)3;14)R2,R*^.
M[?6L\,P1UQ"P&P1)H?#;]<FZ\:!%.I34B_[O;J$ONKF>#Q>!/K2_8.!WX+S1
M7J\SI_2V0UK/:U'M9*'^\WGZZ51!_<]3%$\?RK^SHV8YB@2P]SGB05"O"?X0
M=\V[8HT23,PT"#PVS>1K]6+AG\V:X0F&74>IW2"(HN'!8A%U2A)93#EQL(WR
M#QX"&11B&VE%&+/-V;VC_.V.^HL)CBHF.(Q#A&%YOBS:,<ICRB;A9BBS;:H>
MY@=)&K</EEQ-%0X_"(D'GX&?ICPSBY8I7VZ3Q,B>!ZSUZ/A!DG,,UW2^-4]5
MR++MN19.B<T\;&B)%W1Z:2%W^H$SJMBU[#.=LO9[LVX@6@]VRDP4)P'F>CO.
MR,R69=?5:Q%[B%7PS\*A7M-VUH[I@[592:WC[].%$0_B =H,0]%W6T^^GU12
M>>6Q,PFW+58<VA]&>D0EZV>V75 ^^F__(.6[A $3F/*(!O:SQ'Y1HW,F52GU
ME508.<$=#38,D.ZIQ<%ZX6</I?O*-$JM]1I6LVG8\N)U'A2,ZE(IK- ;7>1\
M'>Q[^?S%Y?<YD0"Y1957$42JZI5=GM#W/F&M/"MC3#M+TO!)ONJZ".3,%3@H
MY!.O"T*ZY<ZK=/+OG.Y C0<**:]>'8,(AMA3-[\CSVD+?\,!'P)#!S8&PP3?
MRUM+;)XX!G,"<=R.DX\F97!O&EL:(^QZY0:9+"+*(P@K>YJ3SC/P7LD%:>P'
M',LJ\!H.CY0,5+GENK)\PUJ,9ZX![$=;Z]!$\^'VD=7K]CZ/Z"+R5T&I1\NA
M0 HU<>APQS>A&(A&CH4SNTYLJX8?V$^\K1RV/</^CLEZP4_T-KNV D<<4(5)
MX;1LS;JC9^PFY JZOVVU0K\_4QX75$7>+CSK=5"GVI!J*6?6\&NW5ESZ]@3;
M*,/!F]2#&.[H]T?Q>GV#RV&#\\<[KW<,&2?:4G6V'3YU.,,8</+87C2L)P!H
M.)&P>A+E.=4T?JP%3P23CW"\5N0<?$(\IEKAY=7G:9+> =8M1]3'+G@/K72$
MB'F"8NF<SEYV8)ASO&AJK.][LRPPB$4$AXLG_S;M^GSVNG422T![9O*=IQ*Y
M"1;HVOSYC@\;WV9<)6]9+U2\H8?TD-\DB_13#:H^88&MI!*Y.C 95;W@F/<$
M#ME8KEUIZB?F\$001[5(&+[=EO7,$VYYI)K(%';6U_"B@7A\@J]7\BM"J680
MB$#TYERF1/UT%42XPFI+_L;/W00+ ZZ0OGY(8R6-"Y]/IY!C0/X*-\4CP@@N
M!7^=H'Z>!;/K8,,E()>JN<LP2COZ81/'(%7M=X+-+E_Y=.<DO[[8R)<HOR^F
M"9 &%MBH8 HST)M=2B<17MYO)F5 PE7[CVW%;*.I;^2U<+ZD78\@0*K/*PAD
MF,@UV=G8#D=JNINXB!ZCS[&T.'4M.#S9L.Y3.A'W7<9>LW-LZ"@N2?G^_<.Y
M66>3(B\F>U3+(0D@]?J%C,GRV=16NXPSMW3]>52'?30/@CVT +3*96;<Y&H3
M,#PAGCK"5F-&Q(K/FVDIKC(T1UGBHOW065CW\])VNEUU $3S^G1B[V>MBH7M
MU#+@@W&5@:B8C;3?<6PGM\!?2C-*W8&/B./ NENX/CS/G.]F9Q:-*\%U96%H
MLW[*TXC!O-8 1/-X0.AA0YIP_2Q'XF%.UPH9\"Z.HA-*>5[<K@RY^PTGCFXQ
M09L%$A2]FY,_>>ECG2RUC_CCUISF]2A9P]Z\;/?@YXJ0MBE@.](8+'77S]S5
M!RV/Y2HZ<.C=:6D37UZ'=AAK,6$0W_ZA@TQ/,?A76TH.X7][F*#CDF>%K6'=
M=%U+&>M:8TW[!_M0NZ-]-3/M*^;^],#LX]-CO(?3DC+Z .6'+D+RA*AQ^D8B
M9J!<DZ86K\;W'.+E/AM)'<Z;(S_SO_JPSA"D\+M-I0,W(C1.U)'C7SG-,R-2
M2>$E"/=^P.S;?/JAG&COZ%5K__NIH[H./_9L:V_F)TMUCC?W,YF_=OW)^_G)
MRS79<5\P$MX_Q@H=4+\F*QGFG>2Q.U_?; 6"BLQ(B/>^?W&C(WY6(D&W'=2P
M^(L"7Q477[^>Q=%^&_J#!&B(#;'%.11 KLVH<6Z=10]+ECBS8S*,XQ7)BN_I
MD]]Z<J_L1NF>-\U[+IX%:JP3!AP*X4 +];R__:'*EP183?XXH>P*>X@^^>I6
M^4O%5:!0X#3V:ZY!^:4Y_7<M']2^\.\_S;/1&TIIL]ZK:#BW&=R4AOXI(D>!
M#0L/>B3G/9"2P>HN!F2KW!T8>0W<T"K*[5?2C,P"M96%6.%A 5B2N;?8SK')
M5.Q1H[HPLJ7JISKV Z8"T1\;!?O;.D.(K*M9=P+'HM(9".3_>H:J5SHQ5(;<
MQ=_OGC;,-T!T<XP2(C$M!G,%?R3>0U=U9C% %'$>M&)Y,=8BVBF&/[_\6OIX
MST^@;J<IKGW=;_2*]47-SO'UL<198*SNXV)7]0S:$)%_K,:HG8U[[TW:JTMF
MK]=JW0'$A#(1G)\Y3A<7YR>D^TQZ$NHLP:^$1Z4\ GA6 BCP% 1[7!A>\P5$
M&],1+ALNB-9W/K!;K;@SUW4MZ&[?7 H36?N4[U,QQ.?S,W\X@B?HC =Q0::3
MVVDP7#,%3ODV>IRU<LE*/:(N+P<I[5YJK]!>V[GB !U>IN3'<:%%NXC7Z7.M
MY^;*@/<N'2WJX;^/^L=*?:7!DDU\@[E(DA$>8C:[5!],KGIW!&3CVF=\]U>(
M8RUR-=;].8FHWNSHEN!]S@]-+'$SK7Z#TGTV"<9FX]@C9;YT)TO+VJ.3-:$0
M"'\N<0I&H\+&$_0*)[IR(>YVD#.2G"\LAFM\ WO$'NK]_F1L#2]<EHJ\(C$,
M=&.&J[M*?F(V Z*?<'$/]:DQM>."<WP]#$)%>:[]O)6 .KG9/9'[I6O@GFY(
MN^E@[U56=S,HWP+Q!ZSA=]B*>@B1#V=4C+M]G1FK>)S%M/-CB/-IL_8X6_*P
M%I'%HYK=8,_L,P5W#MX4PH0+1L.Q7]!FB.70):8T1$G^SXJDO-QN=OU"49K/
MX/GL6K?0QU>?ORX/_*SECREA':4OGI472ZR:S>O0W]UZJ]"0%C&Q6[2][@#M
M3B4!NE$@;#RF?B9MI>H&A!\7)YL6F775^@7O9#Q-[QOSW$,^Q[E[97NO^K&B
MA^B.[&.TT=XDF@1 .O3#%JB?XD[7LLA^0>0F*NJ.[&SS=ZB&/$2_/N2]L175
M*>PM,=B:".#D#$#9<+\".Y>?B>[ZJ\TJOSU9GVV\*#F_,V[](P]!=6:A#7A.
MQ6'U=.=1<B3 V=,2,R&\RXXIC*'#C03X &5%C_RQ3*HN6+1,VZA_2P+8D0#Z
M-QL.E>XA.!2Y[G<=V%0@JW""+-U&K+YYYK-5*EIKNE6R^M^K"G4E*\B=#YN\
MJ:Z7\-K%W--#>-A4X%6AO1TTZO85CURM>ICED\_VJOUXYN>'=U5[':&'A=//
M'I^(9&>F()C^W.Q[M69J_O5[DRS(:G#AU\JS'8525R?8S.;8.X)A5F]6?5AO
M"SB0!*"H&_%'S"C_(0'H?7OZ+'O[E]=?4?,MU'U]=IU[6%OC9=@&P(R2!"#?
MP[E?B/L0]3J?#\=&-6*6=1B+!$<]>*BI56"-%G&PT11H9WF6UZ_^#=A# C!!
M#&=4/!PJ<"W=2H5UK,XS1+9I8A^XV(UW0/ 2]:N!*T'?R(^BCHS01IW+ &@W
ME 67L)9%)Q_N]D?TDW9>0$[YCU_EPI3>E^?NY4'*^.DR-3]?U>-E-V+2&_?<
M!J8<+OA?,&A\@\;>YMB(:CW!:*P1*@DBWCM/A$CBI;5^ZZR50.SGK_25O:FQ
M0-R)>QCH$=+XF?:]>-.?M>/E3N*-;SC8R@AUCY*)WWNW6+OKT<TK9#4RUR@1
M'E%9[T!'0U@9='01BA[OY+N\-A(6LO]'G7RA+F$[$L8Z#)_HKY9>M].W'8MK
M2*C/MS&R/!<NKQ6NM'LDL@C$99( [N:.+8KJ6ENQHT8+D>H<'2[@T(O)*=-2
M1D<&2GI+/4#PD!Y(=I<6B\^_F^@Y,&SK./HX^K#FJ/E"1"S! M7A0M%$UEWY
M!AB][+G-2&%R/W[=]3Y3M(.C_3)_R&)LRCM#],=J5K)=R7E1K"(.C#>4S1B+
M=*E$U4<J$#[)1M]VOS[1%P^IL;"PUA (''RKUW_/ XCU.(\D<A"'Y9.;PT)<
MJP[JRP;:QVY7E!O6OK@&=Y.J[-5ZHOL"]<1P/-[=['@0^!QKB0)951SX$X.P
MTMC6)7]BDMHCG!&:!?L$=YX-,<'0L*C=B2!VZ[EY45\$&EA0WY\^6C#2Z_YP
ML$#^@ 1X03?,^MZL#-9U&V)0!5JNM3LOK!"8W#ZS@<L6)HOU9GS[FNL=K4=D
M\GFG*D^_$%.$3"8PZ*PL]X&YK7&5^^(@S;;V]%]+EEMP]QY7]UN*]F]\TTML
MX[V9O@L<*U;EJG$2%-$'W>"KV^U,Z,HT[H2<[>T::M_OJGIBPX@D>X'XWO5X
M9RF%9J\[C=J&9@T7@FJQ3<?P2Y[,_*/%Y@QQ1F,;X?E_]V'I/1!O$B">!T-'
M[%O4(0'T\BM_-RY',\LK%74M<_VTL!KR\_/(7NZYTM;,$F_!OMB=6[SQ-1Y
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M0#WK5\? O^9?\Q:,28 L_0/8;^[N#@(1]HX$X%^KPKF.12S_ 2U)D0#M^R3
MZ=78OQMI[\N-_><+_NI/10(<G9X/$6)C.E;A:J*P\2I?!!'?0@*LLZO_RP$\
M<X1J/<_IG_83XJN_@/Y?"+3$#N]">*B?=F2+OXM+J4Q]"^ZK?0&V(-0!#"(Y
M#PX_"KAMOHIM$$51=:/W2TIVV!$1O!UU>-F*F-RD,TCF4Z%Y7KFD"9;O"B[Z
M M\3.T^EIMC_IYM %VZ:_9N;S/ZO=]-_0CX0&''A:P9 )$]T?=:-W1J]VR6P
M=X?# J.VFQ_)OAF'D,TW;=A'!PN+#+YCY;P!^B./S2$!@KR=B2*8F!QD1^B1
M.6I*0/K7EH_1.F-BC342UA+D-^\>9'2[=6@5?*'BD?*?9(>\,6D6.#-MG>L*
M5E^:FN(T:4JO?7^B.R;8^$=5=$=X[2UQ1#]%DG^]]*6[VC@BL4,=)U1.$#BO
MAXI:0F31J,8+A5?%_LGUYBTDM6GCX4$0(5>C81RA$1RJ$FSM0Y#;[ .?R1ZP
MD@#+/C!",- <!^Q1\@F&*!9N66HUSSNE0BA=P51_GAD'BIJTVS_?4I3?2UXB
M 8;/BE=W^X7]'?XA!XH$_#_>M\/_-8W_ OH7T/]$H(<ZV)GS[%97#'2WI]DG
M7(6B'*)071>CMS9QK"GAEI[NUP.1N@G@>,]=E'H*[7A# H# /^W'L%_0%:E6
M2UKYN+3']B".[<]U+A71&+T8[W2RN!\QH>UTDR3 2AH)P+9?WU?3.%G7(JK:
M*5=P.X_CP265SZ6/P\@:QH$:P7VKY_%FQG#-W]6-*D8-[VH3SRYHO(OG<G45
M2AE#MAH;>&Q IHD#5D$>3R!;CUXG/'9JF$L"IDIO+ R=?%K\SK6[1?=W,6GK
MP;KBKA1"1Y=I>=$;7T@ <'OBR&A.L<M/;/@G,E[O)X GE%NJN].@_JI/.4KQ
M\44PY=K%GM7J&P6LS15^%M+_VL!_^^<09/P73)J_@/X%]#\&*&AS;$$>FX3[
M@#'J;-8.JR1(S!+9MF^?C,8;&!3^A.P4N<!46S4WOKN\P2H@.TQ$@W _T7_;
M!^-6N>*S"J87B"2/N@UO#KYL99&L_.:!MO1W<N[LN*6&O/ <PWR[/118SF.V
M>[;DT1,LO"/^ C:ZN3W]/)RH@IM=(>8@K< T.&IS7*R=/Z.)4:&3/?"/$^/G
MV\JWDMG(JS32:7V9MN;#"#>K^JDK9;S59'ZLCY]PP5GH'R=?\NBWI7J6#H,#
M': CR[7 L [[9<I?VZF/)W8L$_]$BA-+WN:\R?CRZMFE$^-W;YM4JA45JVR9
M8GH&$R).JB:?]G>M2$F5YI\O>/W _+W3_S_#T,KS/S3I'[7_XX+X7R9;_P+Z
M_S>@H%6Z>8\UH_!V.8C)E*SD37-K1W'[_HGE^TWV0@;4@>.?!XO\7NK?S-[\
MULF$=P(R$&>7OQDL]V4Q6?LN=,*]DYH7YX-A!4L,G#[W:"2_QMQCBHC18!5P
MX$VPQHD9<C-)K.1M>I, TJ.(5^[2!7;RDJ*"ISPILF>7\"K$^2S&.A(@Y+UI
M&D_7P4W(8P.5^E)<4-^F*%_)8'^?>/Z5.-T7^Z. @>/#*@H2H$NN71(TWVVU
M:SKO$^IYOJ[G[^[/U36O7/IPV#" $@@QVX9U'80HJ7<!PYK-/GK>'7%X'08Y
M##C=L&U:!WN_]MV[JVQFK\P4]N692R$)4%F,'$)__3HRN$\]^<=A9!F]D,74
ML37;:DL"!"R2 (?7>?YN)"!2RS=S/I9P!O2_ +2$92(!-H_PR:<\7+ >-X@I
M"9!G@XD]/_$A 09D_FY$%BO.Z.^L?K0=<$#HF3.[2(>Q?> ZQ(L$N-Z$L2)&
M^_>KGRPNDP"\XW\W,CM79XPJO@AAP4G'$=TK(!&FW@2+P\S^2\FJ\W<:]O6X
M3D,>":#V3T)5-01V2B!N$'40P'\=6.Y_QGKW+ZA_0?T+ZG\=J% )Z"SP!N$I
M1A.YMKLD@@XM60&%B^5$S&I/FVH(O*W4WKBGPR8R]ILSA$P@QCT5\^@<CCO'
MR^"4L1'CKBB(#OG,6<A7<+5SD@NSKSRM#C]-?J!WW$*4V6@F"PD09(9[:C#+
MO&F-R2RHV"[%AT0Q1SH/-^(K;F.%,G=8T%7O0FT?R,0G)6V?0XO&D/>&'Y8V
M:1T!*Y=G!XZR?JI?4.4$=.T**BFL@,"(D8^M"VG.!*E:]KX04V9K=YQUK8MX
MBS34]!*PC<"J_WT_K4,?A'DN7]N28Y>(=6#.*ICK;L#.?(L2<\P#T&%4,@OK
M0(B23WDF;H9)1!?L]BKH:5!0Z9_#?WWP3:'_HT$ _V^-_G^A1/\+ZO^Y4-.R
MZG506A@*I% W1QN/.4X0"018I+4X];= 3BXK6 O0Y(F#6,D_ Y0_C'@LUTJB
MQC'O$);5Z+ZE.#^,Z<P#)MX>KD>RQPR!/A_2$^[8=G),F6T!^XT^*LDCZ,B_
MK[I"K8KKFMQ>-2;ON=W4.9R[:]W+>5E']5S*#,I)$$8G=ULS.D%O_G#Y8_7B
M^F_R\_5\GWC-)(_]WEF3OE?3W$8.5<>S'M$K&(F.NN>>#20 6DZ)2^300,>@
MOCEU<,T@R7%&N[;YCMW'N(S8ZA0?VC 0_;[S(J/99W^-?^M+$<QMN*P=0=QW
MB-.*U4H17$+[,$353W%XP!)L]CSOP(,$N+1@51^\NBAD/%D?R_C+9BF@=)X$
M,-%/8VWMA]5VBZ%RI5:B).PBS+HQ^.'CVZD[_.__7;O3?]E_B%6"D#JQ,A<R
M38UB1L6X]"I(7(Y'*D[M3Y3N,XW]X<&.:,_Z5?4&1!BX50NO"NKNLM2I3N+X
M:7M?SS&NGTAA1^&.?7J?VW85QD2<6.:2F43&TBQO0:E^2,C+)K8-&U>G:/1K
M^!;8#JA+S=,I=/:]U]G#KX&C6#*%IEOE,9(]8K=J37[@0J_%W\E_J3/41<W[
M\AW;5>V[.@5&(42I-EPX7MP1RW,=HE6XK28U6=>BS"^X;2(N\+&_ENU&WLH]
MT94O_)L4O_S&NF!1,$:!\T*Q5C)D!Z<35/B;>2$H='P5#O)YY38!$- UKJD(
MU.$,ND.V4-4!@GUL=IG_*&\C&<-6+J$VY,YA_FO?XEYGH$KYMRL<8DUD49G:
M[]59"9YHGD"9:/FGLP0=UR++G2<5?=EOXC92Y0!A]"+)_=<VP1"S[[ :<,\R
MK>_:&KR/K54SSV+W=?]O,!\'CMDQ,?/W?2O;RY3=40R3M^L\52GN8XI0X\@V
M9006>T)ON7#Z7BT-&B&^+E)][<FM4W._QWLLK (),X%JWW#^&(]N'J8*^T9T
M80NX+)_UR)CLOQ]:=2E0+=]X53W2AA$S%NYU0+>56K7@%4!E&FP,QZM4G])6
M#FAOWJ\X$J7[DIEXF!12N&U#?=XNYCD&T *#"\8<OY?\G(.?J5A\F-?J7+TO
MRN'*>;5SK<"%.'B66!"+DL+\E)!X_2'-I/D+):?$<\G;$K^P;&Q_1@ !;#D$
M)S0X7!;(L-WL78N-7*9)N5K!\M,>6.OG,DBH >#N++_-3#<3( $:6+IP?[;
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MP]A^"^(^W<Y%N-/Z;7Q6$WX$]J*>RW/=D]MG\WP+<'@&D- CW^12@Z##^DD
M<IP#-GVB%9BWS5Z0]='5)6\2M?=0BCJQKSCP9KO]9-)I^&)"_/M9.(2L%8X^
M0*5@O'N,4SFLTL;4?%4VJ=L>?[]]]7U&# ?9-Z'L;%K$"ET_D(U@A8;%JHB6
M&3$G8#AZVNU*ES497[(9'FL[#GX9_,YFVME%_I)J%V8'BTJ&L;9S^)T-21($
MYI_WF.^\Y'TPJF@A%WAYG^+S57E16R[1[QUO4O@Q="@.3%DONY]%77)K'']C
MU(; L@<_O_#^M0<P>A,HXG02J@;QG!3O\"I"E.DUT ]8)YM1M6;ZDL?"N@/5
MFO^ITX"[F[4JTZI\!Y'+QA%85TW3F-^_KV'2%*]$YS^XW:7R)5Q@G2Q<A[5+
M5= #R@2?N#7;^N;,=7AR2;],^RS]W65FCMAO\R*YD#S1]?+KTTW>F]_^Q5D
MEVIT/_<?Z@YQ.E)+2W4"O 1F^\VR&GQZJR)MI*;KL@*7Z<15C JVP36NMN;O
MJO5G::3%'@6NH&@V/K%U;JEEX$9<_?W0,(3IF1NLSNX'.*\! 919:#0B^#,=
M 0DW+_2<8=J*(=S)#0-S[*H</#&N.NNLH+&QDJ^>[^3!&A7XC$?Q/_(JX*A_
MXS>]H6@:PCJ4J-QR/)DS QWCJ6>)5O'",), JR>]P+ 3;A:,>+DVN-Y"ZU;=
MJH]K0%^#G9_ITN"BTIHHVA9;VH$)ZX-%L;-$V:%)@#""_,K( WU]:ZV4BII(
M#YG[(P(U7T;Y;3[X"6T#-1%(5V[K=]9,LE8L,WP: JGO?]UJU.*_%>7WZQ+G
M)M/I*EIR13U430DZG<6%@@"O]^?D.35O_.DQC-C1Y4]R:,LP_M6OH7R5\$[M
MQ#W.<C):I#2_@/M9_-'NY%1_?IFQYRJ;A]S2F>?N%C3,UZ?W3#VR;FK*4]P2
M83GY*]&J36E#*/S3#ED.;U9_N\EY98=+%A.!&1?]:I7G\M:98;T?]]>SS$(O
MUMM?N[.E 2I-3]WFUAQ<-D-M,D[5YYAG>,(Z6-O5?$V7]G4)RKG.USE!;U="
MS"4D^&D1LZ\/_=<R@UHE5P]0&BNZ,$>Z\.4;*K""7<LV^"?4YF0=WE6-M5!J
M?N#A&_44OI>?3&18QZXT,M5S\D5;; _GMN/W;*U8-[39#Q7E#QLVMRDZC2+B
M($XXG=4.5KX^QK,0^-FS&PD-HA\%!>]3"@!VYL84^. 7<B6<^R:ZL A<N L5
M'O<,T%[C-BC,*=8DKW'X4,_U03VPZA,)L/)5G1'5_G.-)^PUTJS.@K:Z(*"(
M^E8LGZ(&X#,'M_Y+!@+,<K/##AP$93XO;?7'V/8NWYS8M9C.G0H2S)I?#_Y^
M1-,A-:=QZBU2NNEX38,BRNXI)>NSDE$4*[&%?;+?L$ )$G&8#!,?RR4"B)-J
M?+@"S#*R*-@KS8![]B&Z8&38U,?4?2"^6<=S_&IBJO;3PV*!$.,L-]$/4^JN
MX(OK8VIU+77,ND3DL<3E&4URO&EN*!_F2XXGHUMZ6!T<#/>(OS]*H;$.K%7_
M"%OEP(RAE%>SKB^V9\^\9RYZ5?1B?^F0R<^$3Q<_DOXFIK MBTCI4[J= *&;
M]<3[O29.PV?64W?H/]Q&A-[BR'KB?9=G/W6I0N29W\Z=I5\--F4>F='.TTW"
MBI:$V0!/?WZSE0-4&E(Y-J)A^3KTKJ^B"A/2'UEBZPYNM!KA?UO\/*7QW7]C
M[[VCFNJ^M=$@4@0%"T4Z2I4JO2<J @("@O06$>F]MT!$I4H1$! 1$!!IAHCT
M&NG2>PM2 D@O"24$TC[><^YWQ[V_\3OE.W?<<\<=W_O'^B?CV=E[KS777,^S
M]IISTIJ9/;.BWP=KSQ'.7VXQW@$]P"TXNH;AMSB4#=Y?=NMLWU-Z(X^)6B_6
M=UO.PPGK#5:48N:6,M*^,*IT8N8S4E7\\$L_K*W>^K3]4DDU C:4\Z -PT7Z
M4?!XU2L8JXZ/U:%"R04->.G.UY)!U^_<MK:G<0R4CSCH*_S.G#FY.>6/M*YP
MV5Q#:+I7R@F+Q!MDW8>%SI)*\"IZN#B4GGUGIBWW=XQ\<C@<N8?73/> ,F4^
MV>65Q[UFL;Y.\6M%;F2Z-P^M#Z7&A4ZCN*838 ',4P2S9?H&ALH0P<??E1MN
M7S!0([1#8^M57XIN*Y]/*N,R1:W\3;LM'9B<D<XTG7#!=^4+_UX"E58ZW TR
M@(H2DY?<JKC)??W\63Y;;K">#!>'P_5K<P2U/RB^=%AS.,VYIQJDN D.G5X)
MBB3(!"]>BA )'C>X)\=(%YRM.?$YRV @VZ%)<V7<?Y0'QQ!F5OZJ2/^+TU"3
MP.$(!G-<9I0#<L37K7L85",\>.84.J%5PPG5(,9@ X/1&HZL'<LSPM:[?LD,
MF."O5Z>^7Q?K3X="X?JX7%YB;7/0$A&T5!=;$R[4L=(>(1/)89*K8M&9,53'
M(73P8<B8@H-/^%G(E2%ER"'&J?,*9EL7A\$X<@2RVS2,R;Z]TF>0>2U7[3=V
MC8D_]R#9VNP'[A %)X@QX@3A;^!VL=HEP;Z]<L'Z2@>3\XYL1P>SV22 :*5A
MH3[3BN)V&.@C N47MRPZD:/]P-)R>W47-W.&P";CFB.H"1P8FK<%29?V=_G,
M=SXW7.P1[TRX1DG%FWYQC_>J=W&*[;/%ZL5X52D\9_);X)W*411&_ CHF%.,
M[!"QJLS0RT"E?W%TA^\SW(0T7[:7.UCL3(Z?!E>3 2^A3HBH*86L23G6^]]^
MI#[VNI%MG-)3T?GQZ3$-\Q2T38L04KCY<;@C+ZI_O0,U+_!\0DY8+-;)'#K1
M&?LELN6Y16PO3WAHP#<7U'7O(H%R#X0&R?%8*K%T\O6)D78HXD#M+19$A*OJ
M83JZ+?>C5/V^;(8*UGC9,Q39<>==_G[Z_;O17(8V9UJMN;D]I]1*_%DWXDZS
M'?YIL* 7LO G&7 #<JUX"RD7]>F)N2NV,>&:1BLS-8LP7\HA/IJ2YJ84+*)<
M7=KZ86KG-K]^?OK(ZEW55XP^UO5(X)!A:K)(ZES55L"2&]Z\C\%Z2#)B.S][
M&<SBG'MYG*%H^8J3P4CUTK),4*F-0//]9(V%U<MYCZ>B8!,*M:/65OV<V$/>
M5*7GSWYM::I?4.1-\A4]1&!W,. >-?5V[MOC$).EP1MZ.#>6ACJ#*7%'S<:/
M<NE=5=)O,WE_/,N;3PJ3U#ECQ!K_!7?4I9>,C;@\*BM)I9[?C?0L+!Y(5AUC
MY']8037PACKV5\^JK;&O,EL&:T9\^4#K,=&Z_OEIN;(U? \ZF6R%FUMQVX]>
MI"58+>=(BX8<7Q'2S]BCW9O\*!C 1O'J1RKPC:G03@=&UQ0WB5;HL)69VMW9
M#=#3W07Z*X<JWVNU&:B4&-D9 )JW*=GW@G3>8BO(@#0/7#(9\$PWF4C=(#G#
M2-(3^IF')0/(@*(39L[*LZJ<FK6Z);!J:W5^N)(7KE 7VX'[ X\81EQ:PH!B
M/&2WYTXF4#^DME)Z^:VX^)][)\4HW5^<CL=P["-5L##T?C0?QA:&SNX(XF8W
M9SG0=F?[DOGK#B)BHCGEO<=J:@S7]CGS??4)VMM@"9T)G28#-/3 ZL$26WT]
M*);7/J6JAILC&T^T?0\C_\1&-6:*YZ'F/N%-T=[%#Z2]]6I/3CD/GY;'?F+Z
M;:3KE?4:KT((&@,Y>\7(DX3'EMS8,DQK6L=7O7<]O#^SV,QPO(\VO1+Y3@NP
MRK#82;H[ KGQ-5&]TW(AY[.Y[*M; 64V/1[7?"_1M_QBX^66F9GN J%UK,**
MT.#D=>_%Y^$/9F^#.M;$/,'<.&<R0&?W?)$LYCGP-,W#<M>0 :-/C2<Z>K8C
MVM0D3%2-2<6[JS651VX08[31]NB&4]<9[5113^;7''W&ZM;0YVIS21'IZ]!J
MH:X\-H@"QJFC!=0^@K.T$O?%/I*36>;2Y+#(D.*G P[\L.Y\X:XM^.!;C(HB
M&T6K'+$$X<A(11 E?FCF6-%C%VU;[B]_*P,M'0SBC]XLCESU-<XICP&\^LP9
M( 0+6JPU63V+;L"+V%CWC?\>]A;(,%-R<O10S!":2'5S#7:%H'V"#+)<F_CH
M/I1]2C,R=4O?P"/4=^<E>X <TW)SQ!MZ&.K,$C?EB(C98LN%'O&N6@;&+/;*
M%ZN1OSC/Y<REZ>CA^.1HK5A_.$[[0DB,%MX=[#Y7%[@O%$CP6%?<'(1$8CYH
MX55(OVTOXV*':FUO8C[1/)YT!(FY"--SR%S[24ED?V!@4Q&^+81]VC@!L2F'
M^!/SO];*V YR_687>?P&Q9<\.)N$,ZY-3M[[_BVBK$&M(-0B?!=Y+B6L(L9G
MY6#SQ.LMPS^:M3"Z;;F,$WS?IYMM\ITSQP!&TT83^77I5>-T.Y<&_0-/KMG<
MYQSYE:9^.T:;[UE?G^;]BP$7S=:3=T+P4L%"V#2<SU\U).]_) ,Z;04G K27
M4C? VIP9 \P< Z?Z[ ^L\SY)KWAQN8V EK)((I,2S0HKYUKN-QA85(#S,XKS
MGXM6XG"0CC%1 DGNI;_DI+QU7%#!<C6AP2&( ZQ/?)4D$2! I3BKCYVN\]L5
M$2YH7AG_[RXE];_6X!>)5>=\]34V  <NPJ5U!(9Z[!Y/5;'D8K92M/D?R+\*
MN43!K]XD)0EYEJLF6ZQOXIC/-9NNDU)$H^2>'%: $$>@-L',B TP.HA$84,&
M'.CQH(_@\8M'DC@5,@!P[F].!5LD=P:T'$YRG;"U'$WXY(F/H@=S).YTC!4I
MB@R@@2XQGZMY_G,;8]3YZU#% S+@-0)-MT\&I#J3!CH#P<%0-[LF1#U1^S]W
MM^1_N5G,OW>OZ=^+5>!N-;<5UC8P0S#"LN9[S<0Q3_5II;GF)MUID'1GD[K*
MM8/N2[VJ:4<5H3CE^N##8?MBQJ3"N$P!M1.UI/A>TE0VOO24!U.(M_3:*UZ%
M=M?K'UK^DY]?RI5\R]MU033FI9 ![*":KZ2M""V",^7?V/^OL97VX0(#7>;"
M%'X_/]-/_%O9!'KSDY99XXTMGJ?H-"I2F5][1:NF 8P'G/9W@;^#V\_9B>LX
M^%YC;>1:[5KM6(6AW<5CY ]-O-9W7H:?#*((G %>$<>Z- #S0Q'%LY\&""/3
MCW(#NL<G[_^D \U3JAW:YF@ 0I+;%V=/.A"T!,-EO3"MEHD]+[EU:>NBH\IF
MYZ J0J2]D9+?1*Z42804:2""%K<80(5M\@AP*7N0:SXA.VMZ)XM&PZ.O[V=@
MWVJ@W#;3$YI," <QF\"&EJMP1!-;!KL+O7.M/T;G"Z?Z9M$\$RDKDZ98NKSD
M5.2[>!7T'!$#O=;L%+!LM5)N8;N@O6ZC;N<;=WG/)^-62JQ0ZYB28,M6/ "]
MRX/U1\/;P(R$!Y.J"H*?8TS'BK6J&]*Y;YK8^Y9S7U6 +CO*'0;M%.'OXA16
MX.U6\[JVRHFY12ZP0<\Z2_>M! RM^ P?C9GUA0%? $AJ#7&OY#.#/6JX(Y$&
M91;ET:R&FC/XX8).7:V<YZ_P:=3R6K:/'/Y.":"P43M_GT\XIR73URCPV[]<
MMI5NBXZ>EV6=F]O;D**$.9&,V-3XJW>5HD(KMZ",F@7G(^/4AM3&J>"=@U\-
MH2 M?#VUJ;8S []%K:,/^1^?[1T&;Q\6P\)H(ENIG$&,I-O!A=V6 0M%\J7+
M0DZ-T5OF2"9QP<,_4?<Z\DQ5S0H-[W'[+7E%6C)VD &QN<*8C)R@4KVRX+C9
MO?S&#/DH>NWF4[LG=]<GDYDW)OZU3@&W"QE ]Q<<W01".8=7&9$6#YKSJD(J
MB9G<!FDGD);9N>'%[5-34+?DK,'/10ZY#\?A#I)'1!/[:VIKF=*:!R7X_(["
M.S]7%(<4AR^T),4##J&T.-8V,J#*K,/FR:9W346Z/5/F2:;"=9I<W_)4B_J+
M2P  ()3!;1!AMTBYL$&BF(+8ESVTFX" 0[W:K[U>O>,E1A([N(M]%C8])ONO
M'\'^DP'>_[)C-25^K!;4+3^R.6K>6^Q:B1Q4#9X/7NL>,Q1=8GC05WE@<$U2
M#?"/Z2OA:<T^>(I9ZV#D22<9<(4 _480:VX5J+ ;,TFP$!+_LY,AJ"&4TQ3+
MMD31%6ZOX:%?O='4-M,.8P](-6'>@6SB0:2N1IHV$*O>RA4M\(2JRPH;\VB
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MH %]BH#L]K8J5A1CN+#3HS.[[GBSD9)>T!NY\. ^:[W7<Z%&N(1;U]\XM!.
MEKMO*W99 ISW9 UK<7M)\XEN;:NM!WT@/FP0+NVLD-$,Z]PI5\[8D45;V> M
M_(C0]P7B-/!^P>*$$]8Z:59K_2*#K!WI>19[0?BV%U$4[;*?I\IRQXG&G\W*
ML_+I[AM(S=WJOYS@F:#3;M%-;04X&5_V;,'.XN3&/-K")L\!-T5 ?E93"680
MWYYTUC'34FF=AFC[&>5JR1[1KSS?_.6;<(QX<K1(T,(=+$/=RA539UI\R>Z#
M/:&)XH<J'P:NS7YW&^M38Q,C-YO\]&E<;\TF83QYMO7X'!!H&Y)D:"#EYFP!
MW6DR)5TZ7*/3L>#?^U>UB?\/!C"J[89=^G<25RL^\X8B5AU?]T(CQ&QCYR!]
M1 K#>;L-(WL$GTW7!4>> QA:.1R2CU7\N;XW6F1;7HF+L_99SZ1X-Q> L\Q:
M%YTVU/Q/,8=?X*NP2]A@8"5YM_&1XLWM;]Y39I-">4$:*=K9NV.J5%UWX8).
M.+1IT+'K>^WQ;1X#]BD46&_L1 [>KB#YR,$/:.?(['92>@[XSHD?73)>/PLG
MW80]&;\4]0I3K^?S$]9/]RVS/!MGJX;-WD\[')DU7*G'+NYT+U%041RG(;JD
MZCZBOFMYJE;FA5/KR$3(8WRG*F'W\=KOT.> Z5)US*TV:]<\,-A>U[C?&4[Q
M3+BZ.Z/G1[34Y?+*KZH.)WS_N9#N]L0E:4.**".UE;48,2NM%_+E*E&M6Y&W
M'/[]$#E+,]]*&S"L2*5PS=N[#%51)]R2%]_3*7Y]QKB?C.1KUA?,CG?NY/M'
MPKF)(@WI*G2QQFLWOM0$7ZJ*?1"$.7[Z%:KAJ"/,/,/W!TLJ,+86K83D>_:1
MWV_VC0:B^$@W5@J)XGA?D :FPYG>.ZC+0.IKDU'?Z%S?*(V2?<)=G<'2CT[B
M(92N/<J% @ZBN3)0[OTM(C%$E]YLS23C493!8>RI3W9.S1_@+H0 ]8:W!]S&
MW@I:4F3R1Z!5TOW92DW/ ;;]?,D&+WG-QY]82@,.$G?!:D1^K&3^"C"4Q#KI
M42ZVKS+Y8"?7;Y9EV[,NF>E[U_N>[_0L'[BXXI3V+30)+P,&?%5[J,-.NPM#
M0'++YGP]7L<Z9FQN6_WWDBHY(!3:K)KWA,2W,PXLM( S'27ZM=IK!W_D,[1K
M,AE^.TV-K*U#2!=!M$;U0X"HL;W)U;"(BP]$Z%DB_7"N\UDV"-AB]%-K-EH#
M>*LW1'HC5A!YEJ.XNDCBO3"#RN)SP"9W]4APVQ68,*;W\<\89$BSO"7ZPNVQ
MR T9OAA'QQKGW2GZ>/*%?EK\@<_J$9>$\TI/IE<9C!H?86D)E=@]F@KSN"N\
MZ[@BIO$HQI&SA/-#LI4:X):ZA/ XKG\<=?8\LGB'N;BET9==Z1QP9?."1IC^
MA&_C+ER!:LW+"W_P$=Y?-7>Q$I/QDQIOY,XF=AQ=]QT84LM.=<'6/+&Q33CC
M@O3=UF?SK?NB@RMV,\"[PPK'$BC2SP4^[,;N/0+W5J(ZIK3+@FEJ&4MW6_6S
M1/6QE&Y'.!+W/NN)Y(^^P<P\6VKYL)S-Y])M#KN#0_->H&X3FG8"3X"3Q4C=
MEVT+RK-/K0SX@R5PR.X1\/)O4;,M9JKTP:*93:R2U[I$(RU'*IW"3N8,7^*4
MQ"H0HX&D6>Q?'@D/H*FO]XMBNT5:@#KV!A\TK[GD@BZ_ID(8\#64-/+M:F*;
MU/%>>7AMI;,LF*9MJ3'DZ^9/AZF?9M5*N>$<'WLF^\CGARE6ZB2VP5\7=PY*
MB>1XGV)MM&,Q&G';3/C7ZLUE8O#CIZY5MRA@P[VLMI6S$O0RQ:/%S$C/\O+3
M%(WD?%^WO%JMO<E-TIO"W1:L<M=%C JX-H(&WG" S\@V;C%@*!!5W5)]W754
MWP1%I-E*UT?8B>_.BF 4F(W.108)X5=/:C %>8[$ECO"5@GF";R_%][VW/5Y
M;[<:=]MT#ZFTOXAY*7)C.T#\+,OIT2+U;U1H4U&FUJ02I #5TI6O]+:VZ\J2
M+[I!$77A5KFQU#NJR_(4SS&DXN)ME_:\&^ZS<OP\#=%Y'-+VOS2H"H/B>WT?
M#J<%T^5DKMD%H*[QZWD(2/>7/I-P.OVT6*O:S7(\&G 9:F!@8L1\UF$VR)"?
MAP)_"HYZBX\IC/AAXZPHYLA'EG75,PW1X\Q,E#^KW8%1H>7M=@,N8S41J;E*
M/&7\.$@DIM6*PU/!1NN3E7?2N^FIC( )\"V8,9H:0!J:/ 6'2F0^7U'7<"UZ
M9E<X)#B#%GP,6RIYX2W0N=X[KY"T":_+[ICWZVXEQVQ$@UBLO?Q61*X[Q%L8
M]Q9^'S=[]':[R>J^4+>Y%0S@;?!H9><$TCYK8;M9$9TJV_Q+0'!SX,S]%QV)
ME>B)M>O*1C6AJ3);&VNS;S;3.W)[&: G&8SMGOT99/)D$FUYXUH3=H?Z5;8T
MIJT'@5+&Y39CJ<-;Z>=_D^Y@ E+=)B>_+G;3]GL.D/G8YD6^Z*_YF%V?Z\*T
M;U%%H"-2-6# .^< /_+(MQ5E1^< 1@W7=R7/W&/H?]@O]80OA^K7KITP75.V
M &(ZS@$K83NFC.'-%':86@*:-^J=[[&O17$!-Y*Y2:  )YI+S.-<EYQ6(E]O
M']+3E^+O2=,LY?&#SI\F\ND_H2E9S16L@\Z#;5<1G]NLLU&*>OC=Y7F_%UC-
MCR;P:**$6VUCM$M%5YSD$K*.#^H4\^O]TFUJ)H#_';!P0*?B):(F9D0+ZQP-
M<G:JM;B/=1R;4[<23??NE"-^=RD;$:1I"43"(D^3FW=T \MYM*TG.F1CH\W-
MSP&E%Z':K-#H[_ND#'O!&#WDB=3?&CFF1YS/ 7DI'CCAOV[EN_K\PIG ,>>
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M_PO8(/J>)<QZS6^<P5$*QXH8MIHF(P6V,0\V.2.L9O?N!JH<><3=4!GUPXX
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MO^/B\#E Y%5=,DU>8EC+P&+W[,"BHO)WP;\7]0M0G=H.V^$[!_"6+B$( >>
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M3UUB/F TNVJHKK,MQ#<[A@N?N")L<-SIR%X*L4;OVA&TM>O3I*Y:)]PPA#*
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MNX&H0DD^'>6\LQ'\$8&G=K]IY/2"K_GOP9?D_NK,L?\?.W,VB/I8BHZ%JW>
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MF:IJ8[!G>5MIM1D_4FH9#$<UY4L%Z2V%'+KC0J^JO7ZHPI\E@ ]9=KX<CH@
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M@W\O'36B]TU)CG*6?^"#> BKWF6S;4NN532YR +(.DB@V'5M2GRB&I;.L]O
M:\PYI_$.P_#/'DDY]?8>?RIV'GS0LO/5>6-3[Z"N1I405YA:39AN6^3\WG6.
M.W<]KWXU5F7:DH>BX>_!6 2\#A$; &P[50A#U_A%716ND7H]]YV\XA<$S79P
M.CV9>^% (B^L-A)E=."ZO!_V52B!TI;R:]S&K*)]/-UI>$LI8TAD^M3\VGK;
MT;I398*+B=_<7"VI&5$%,L9R=5A<]K/!2D4^ M]J^6E]>0L5+%GPLG[NU0_+
M)B:FWA>1<]]:ZB;*EIJJLP1+-<(GC>Q".GLY'PY\^[IT0;AB&Y##R!B+.RUG
ME7"H" L^H,/X6NI2^37TY$S*7LVJP^-7>TXV',>"]'Y31-I.=!!^>TF(F7XE
M>]?YYC#*INB$>C6CFCMV6K?_'/"VQ,%27U8@QW?3 T6@UV#8,G!'C9LJX.9.
M(R/O(T&'@?\[1_T?%/A50E>0> %#8OHY(.P<L&-7=PX8TVC<;8<W*T\L]<*;
MM'\2:Y&U"O2DGV!Z$AEIV)>W#HT@WPS@P<.%MZ;MM<O4O^TXJ9N]!4A:7N9K
MMR6/KT[J4>!#-EEB#(/@T/W@;"K'U_@FZ%*+<@>*FUGS8A^.Q$(HOQ9I5^<Y
M"L&^*L*<KHA%_[?VOC.JR6Y;-TA50$3I+2H@2%60CD1%F@@11(J4H#0A1D2Z
M!"*]@Z# )R!(KP&1$FD)'40Z2.@M%*4FU$!"<OGN'F>?>_;>9]R]S[ACW'O&
M]<?\\68\66N-=ZVYUGSF.]><173 XO;M"8GL ]>R(__.KKG#+3&#"=-A6,!.
M)^@%<WS4.[)I"-RPNKK2H:;C'==[?>>%6?5#*5\Q[YGIL#YEYBJSONK=_HW8
MA7YF*L"6+$?TF\=PH>)%\)Y)0S;$"%V1N 6]&46F.-Y $_:W ,<S>69N%[$]
M/\KXB49#L^%[_CUND(YD%!E1\MPO<WV+9&Q-9AWR+#^[&L SW. V-VW=AE45
M*J@22P?P-]N[=1<'\>JJF?$T]W5VRD[24KB\6_?P2B'DTSED)7PNBMG3SR[O
MN6NUZMONT[HYCVC>V(5^DVB8LR7_TE(*SUW9X,,>'9Y^ZE(<T*L/7BN;_R>J
MCJ?]Y;;WGMQ_J#K^;Z$3IVKR"B97CSQ_A$X%P) C!G2#FY*U/)Q/WKZ2._W+
M@L**]TK 4P$M1][A'LS@S\\F/&P,D*C4;5_G1+?:;W8C>U=JGGTZR_B0R#8'
MLVN>$<4C9\*7?VH(C^3^V-,'UQABGM7Y)CJ^\WGY[8.P]D2(+$^'G&3B$,).
M-CA5(P_FSQULNNKG3%<ADU-D8W.7Q^/*U7P/L=7\QK(H>/_7TCBV!;$F#"W9
M%%.%(2B&R2KPF_=<F[6<!CN_K$C4B^\-'>RV?U>5;I^ADCN$IB4R:];BJXX0
MX=+KDRT;ZJGW-$6B!>M[ZAW>YF^4K8-B6Z^M,BG,#&J-6?!0KN'C$G!;+"XV
M0MCU%*/!:I[[W*9E/=EW;Z*NLK#=.:$Y- QH3R(2_V(5USYPB2COC#L^U6J(
MJAATW<6P:WQ N)[1YD26VUB,3%V9?_MJ2D"NXEMY86%^[H""^S>$(RCD ,,4
M(##E?/2Q,2DLK]@%];J](S,_?=*"-U/2E;VI.UM"]I:R,BYUFAB+%VN:Y5+@
M%]1L.SH_NZHH_A35&+8,M1@\^RK#7B;&[-UVHHY8'+0Q.VEZDVNH,W6<TDL%
ML/YY=7N5C[4@[%+58/G6W,A*)>IKJG)OFYIZP8,R1?KMX26KJYT7%[$6"VRG
M?@9<':UBA9A4D$RS/DW='/VHE';9][PJAV/+9]8DD2>!G(U:W+:^3M$@A]G0
M&24"_3*JE'AO9I5R&#R]_C5#O,S\K)!YPJ@*#\+W??I.^FA&!9ZMZ60?"/1P
M95P5$@Q;N37XB-L@M.!$J3X_N>\>OF."(P8O'F$_&>G(,PM'XB'-KO3PFWA*
M2?8S53JN5*]2JU5FR6]NHLM+$C//$RO5\+J'?^QI5+]C6Y_$+\@"$"T<,_R6
M\2S(KH:HOM7-!7>Z)GI6COA+B5( P%@33;JGRFZW>#VS<!31$V_7G'GFP@,A
M[L'S+=:W@ZVG>M51\E.VMHS)CMZV<B^9;4T9HDDR<&G\5B1L;QK4HCAZ,%J9
M5O*,?)@Z.F/LCI9T=&>!9=PVX=FP*=+B?F+_DIL*H('3%_OD6!%8L>'9:0^Q
MT@;)^8]]&]*^1H5>UE4Z?#YYBW]_$X=TGT"L1^-3]$.%@UML_\BX>BD5IKUI
M >MY)15Q*6%)^GR8EMJ#-VY!3.6VV7%.4U+Q5PE*Z]7XU@Z^_2*D"YIG9P]F
M#%'=WY8D%=JGKYM,=*B8+4H4G_$?CDG(@!:FS<N&.%;CD9\'YH(F6PZ8/7.:
M7?I9O!+I[%DXF5A;E5B85I3[%;!&)^M8R %7/EXRCVJ+#?!WA>![O!_GM4$Y
M>]L;I]N+:K7FI%IXS]V['K@3W$2;I]:9R5"JKHMAD[[Q75)0M;4EM1>=<ZK(
MA]++(3ZF:P=^GZSV<&7NZE,-6\FAG]GK4E%'R1^AI<X'IMRCA.EQZ[L#8%>Y
M,#UAVT=)@:M,(NQ;-IILZY[X %:-A2Z?F_8U'Q0E>@NMNVRMFPDTSGK!2<#5
MJ-W.>_LNXO66-,$Y1&[- ?BC<I_$CJY6)#02)I3CX9A WD.9ZFJ//BVIM@[O
M9G#O@PJBSQ"O0%B)T:T[/@$S:]H$ABR-DJ+Q:;6>=]/WYQ=35IZ:) -BOY[1
MZ:;W&C'RDN^J0HPKS=L$%_JC.ULVN++V_=(T7T\D3?8]S9"]8B)W(R]BO&61
M_$%4,='@-6MGX"YS/T/\Z:E?IE@; :YHN^,T5=\$WS-9CYB>KP!8A!IH1U'B
MV>NF.FE$QGU/HC>^TY*O,QRNG%R7W68;M;F\ZE=[,69/-V8(E(S^%A@<M=K
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M^D/_3%9!0Y!L&56RT6@<]/CJT6OTB+?LQ6(<5^2R WWZ8<1*0D,)2SKA,0@
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M\\E)S"&0]^24O2X%VP./=[9S>;M)[:.$A.O"S-,=K/GZ1N0RGYXNCW-5YU]
MRBYPY9"4;U^WUMCI.-<%%, C^7K\35K6+@'7SQPG9D?8I;L8%LBV$Z]EV!08
M<ARB@>V>.BLGAT^% Q7 ++: ;7$=IP):'TJ'?JR[.RR7]=:2 2)]^I;V_0<Z
MPCCA2YV7"\D^QZ%DWSRRZ ESVXJI6XG;((.>NR)WI>],V'$)6UTWP!K320J1
MG_C9Q6!_>G*R=QJFAMB6IO2=</+0[S2&.>G%:JA5Y&1901BE?983-/\\H#^
M'YWAJF8R+$SYAOZVTA-";ZJQP1L;7\]W("%>)I'X,"W1]/Y6 3>3^+?I3]E1
MDO*W_H68?]IEU[]Q]G:C.4[>I:X&GP__/"*8K(3((I9!-X#:E<.;(JBJFF>I
MNI]TQ[*4 $FBAG(TG4\@WD;656O#)HU)NA#++=>!^:+PPE728_>:Y DJH.AP
MFO0*;C5(N4SDGC.+WYV$_KP!_:B]N7&Q+I9K3N35G=(S)4E]#W#+N\C,:"H
M_\" >^&@M=&]&<2F+K@ TX00Z'-3'66EG[:Y==<+%+>+Q*P_^H,F,.AV/T\Y
M6API')F?P_%K-GD?VW<<DQ=:O'15(GFY>G<=.460'5N9HV3AP7.&L5E0ILNC
M92+O'J!#SL&+1(39%STEHMZ0@FV$J0#ZRRN/B1)LPJ07KL=G)M"3V15AESI0
M-8GU6()249AQUOKE]2HR6R1B+A>R+4"4I *>U&)V)5W <8CM1-?@V7VZ>"I
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M)8.H +N;&$JB-7:LFH E<TI2#$XV.2I@7WZ2"O@E.NTUAYFYM/K2#C-=\#/
MTFP&R(QP )Y:T[A(O.[LGC\%/D5\1(8NI$TF=C!7I>OL6_J/T]R1^Y8$<+C=
MYVT/]\>OS0>4$]0HYQ'K'V!/J8 0/\TZ OWL1*[]M"O#]/RU MF=&-I ; +D
M-5P=+[LANR [7GX7W_&ND,BKKE3RTT@T/\M-M-O%R )\SC[B2UF3J=+XQ]S
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M\);7,KD3ZMY<0WJ%LU>5HP9@;$ETKM_$Z]V#S)UH1?P-/.=!X\'-WN^(JE0
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MR/D;/8ZJ/,YTHP).7@EAGG(#\5<<P/0_^]LMSL(2T+\_ZNS[=Y)WJ(#.<.(
MO8M$_[\_#OZO+=/\[NG_I9Z0_K RZSL76H_B,O-M&+[W%IGK^?+&,TJP7PD)
MZQNN=^.ALTN/E5TGQ1^NG*Q>-D*)JG_IY_L]:U6P3J-5<=KD?XI^ESF")?X9
MKTO.A_#_XSCQGY]7'SB_U2F9?CSK(L&6YN;P?'00),9OYRPBV<$HXTM'2&<>
M,3)^\%]-2&G*'6[VF*\S"E1M^-PP.UR/E$E8V]>'S7IG[E$!STA35$"3U^@&
MQY_>MEO_*-3ZM_S?$P1U_'\ 4$L#!!0    ( "R#=%@L^_>$YVL! -B8 0 4
M    8G)N<RTR,#(S,3(S,5]G-BYJ<&?LNW=84U_W)QH$1)H(TA&B5*5*%XU$
M19H("-(1(@+2B8A D) H2 =1JH(2%9 F("5TB'0!$>D0A) @HM(2D' @(;GY
MOC-SY_G]9N8^=^YS_[CW>=Z=K)R=<\Y>6>OL53YKGQ/F#',1=.R:B;D)B(V-
M#81@O4!,(LC%&.%W%P2RM 0I@T"@(R!.=C80)ZO'QJ)K[.S_VOY#()MC_Z7_
MSX>-((CCO^P_-6DC]-_[_YP'8HM_ P+5I#/G0$:@0VQL_[S_:V/G9/^G'>;@
M8.?D.LS%]0\=X>;E/G*$YP@7%P\_#P\O'ZMQ<1\5X.<[^D__'R;_#/]G%.O-
M=X3K"-__=F-^ @D>87O$T<W.)@LZ),C&+LC&[ &!69)RLOVK@?YK8SO$SL%Y
MF"42#R_K!.PQEOCL[(=8PG)RL%1DBV8=!W$(<@J=TKQ\^+B-!Y=LB+#6X^=O
MC\A=J>D4L1TERVO?N1_#S2,J)BXAJ:"H=/J,LHZNGOXY@_-&5XU-3,W,K]VT
MLW=P=')V\?3RONOCZ^<?^B L/ (1^3#V25Q\0F)2<D9F5G9.[HN7>>\*BXK?
MEY26E=?6U6,;&IN:6[JZ>WK[^C\/#(Z-3TQ.3<_,XHFDI1_+/U=^_?Y#V=K^
MNT/=!?;V_]&+#<3.]M_:_U0O099>AUASP,'UCUYLAR+^.4&0@_.4YF&ARS9<
M'B''9;4>'Q&^\OQM32>WG+8M6>3._5$>47D=H@+E']7^I=G_/<5B_A]I]G\J
M]M_UPH/X6(9Y2)!=$ 0%'4R,=6CZ/EQ^$N$ G1/+J5WQ^N8[G6$"R)\XFQ@;
M<V0_N88)XM6P9((P\&/HQ7@:$Y0Z#:6I,4$#W-]PZTM,T#6%ZDMOCJ(9HN[Y
M3)#APDDFJ)-_EPF2*/P?]E3%)(-6F""B]V_<]CI)@'Z,@*;D0?_CUU^G_\WK
MW[S^S>O_V[PJ.L0H\9@EE8"D^CWOYT%* <Y/&K8N4<S>"!5[V=^^Y#'7[C<M
M0'9D&")]F"!/M6E&2O*C"\F#E/XD')&/'%]<$0GU8XP\+MEJ7-L^JYVZN+0:
MZX(=I-]C@C*,2-!]<N[>#<[J=0T1]#>I;B8(,&#]^G-?QAC%\8"M#<H$Q;[$
M[8FV\)QFQ_RG?>G_:4S FW>/#)B@?W/Z-Z=_<_K_!:=ZB%(5$]1E0W33OKG5
MEKXN95;5UC[7UOY+*OB>=NK2.9&WMUB'X7L** DFZ*-]-2/I&NC7Z7?)H/\W
M:9L)FH4SS*SBF" X>-]&[2%G)!.TUL@$R2M=88(:TP].Y[0?>L1S^MTC'C)N
M=IS!<XJ\0L4 E"5T@J$4QAXFA! UG_H=7#D:M%D8OS@WI-N6N"&C^ZQ_*$C^
MVA/V[:!\!H\*C06INN48_>XZE.SVKLY*H[N!#]QO1N(PNS>T*L@,5_V\H=BL
M)*#Z<_4C0KU&%WQFJ1]7Y_,4R4]*"M,0],O9]F."CB^>#YK_<'=AX\K:E2#>
M$(666Y;B'G(JV-<5')]D6S_.6 =8#L$TW';H'3YJ@:;R&;21&;0X"N\N1#9=
MCR/"8O1S\$N([C[)FW^HVL9P*:>BTXW7KV9(L,?WOFKCD,M>R8RE:A[4MRG0
MPI#J.$I$;!!VR$W#:M)K3,'28>&<HK;\C4$S;KFT5A^KT%>Q_:%;N'6^.=PB
M2>#1C_L"CX/-Y' ;87CHXMS(GB9!!#VS$\$$O3\P3'Z!4(:L1FGTXK:.3&66
M#8UMDAOW"OII=]"=KBAQ1@]4]!09GJK#!(F[^8_[4?RO[7NG:ALMFVW)IHUH
M2<^FU6H^?34-ITFS<M&E#@G&]Q;COPL<DU5%$SHOQBR-+'#U 0%#(N%A5SXM
MGY!^\E/IGM;;1'F>/0OJ:PJAQSH!0W8QQ@&>BZZP1'=9>+QFMV*N8>71%V7!
M<*>VCL /PMFW8X/O1ZS45()GF2 J$B@D;Y,B^C'X@*6[Q6_HX&F(,=&@OA7Q
M]V-+^:^0?CX03,=_JRA=O+[QC'B$5JL9SWM[2PL!Z]F2NMK5UFBU9N7Z/?QO
M%*%LG]\8I4^_"%0LC;#1X0>O=@A'@3IJ46YWAR[%*ON]_T-,CYNSYSCR:JY6
M3Y5:H/[@=0&^N"G'G$OZZN/-]B.-C!$"/R2(YLY2VH@)\I7B=UU2ZE43ZV2"
M^.F67M3]H]DDW@K?X+:!GX96.\]TSD;>N!YW:L;B^E/QR$LZ(UQ#%3DYN*4[
MA4D=20%,T*$5_/GJ]4PR==P:>*L6WWZT/80<:AUMVJN7=^=ET4=>X2WQV!-7
MQ^_@O343!K6"HN/K<7?!>.W+!Q\8AW^ACT&TCQ;#WP*Q(S2=AT\L1+KV](5<
M.Y8=O,&0ZR;BE*>O5;;&J1<!BV@RK0_:Z-#\'L$$D8P[BLD-(RXQ8][3$F"7
M%]T?WKD1:DO]-CQ]K]8,\H@\GT]P/P_F8XPQ04*&)U']L)K-QUY $JE2&99F
MJ# 92#<G^6*=3=K5VAMJ9<WNM-W_FCIT]@;+*1TEP9GW]3([37T[*F"T\+5$
M4L&6&Q-T 5P&%4').2%E #>2M9A_6:AB+C%(>=6QS>*!@+81_/@U(MM)4>4$
MT#/N?KE*;]17)DBZ'H8/6.R(7:H6,"XU>@<DBQ9,:MQQVA!Q,$G=M+\+6A8P
M@=SIN#W%. )D4J\"^C0C?GUJ+"7BJ5H0G;,4]GM?#U<J-7(,N//G K?DA?IV
MYUC9.OAMT2-[FL=FK\!^5GHN6?? )9 G#^(?-#'.(%8O84AA7VN*$ EV#=,*
MKL-7S@2O!VV-F3E!5D^,J:H34^]KU7H\TLTZ6VXQ'QTQ71<EIKRA8;^U5X2J
MMX$5H#BFD#8T =0\X5C'"0+2BP6L(%R1Y(:E/DU_E')ST,/-KKI+7]\3<\%M
M,W(OOX24<XN:9<<*.T#U %?2RE.Z7 52G)(;3W>CV?UQL6I="M*X/A'&!)WP
M[^J_/"T:^;HM)0ABKGTM74C(2[M%0*WO>^UZ2*=!X,$AIZ)&T[6=^RSG[- !
M'*DH(!I-JI98S3$$?].9G+\X/W3"YY7L:<ZBYS5Q5_F^($ %*L0THZZ"LP?E
MN,5*Z(D.23>Z"U"VR 2Q_SIOE5WA.@MXP@(D9)MH(AEQ:2_E!7L(OJ]_F'4E
MG>@;SHCI,*94IT+<:!8LJQ<IHD2D0D*6W.XP09\,+^2;Q$A@]7+XK1:(JN\/
M[][3N$=NQ65\W4LU&]1JO52.$%&L5I_>6SM#RK,:PBVB?HS"6 FHL?&3=1J,
M$XM)H**DIG&^FXD$[K]JB@&NO]LT2/,%JIFV>53GO*@2"Y^HTBG1Y',3_5@.
MIWE1\\SON,5,L,0'E!Q2B1(>*_"TXR301>LRE&UJS!GI?_@0#V1V?VO5S_4+
M)SE#J Y/;YF9&1S-ESM24Z75C<?46_V:TJTV-/GPL#&9"0K$\""@U [R2.>%
MBFB_-C=2Y:F="H/"1J,['T\WRT/BNA.8(./,1T_NMVV%K(KL5=/"D<KP-!SY
M%N9)AQA,&,COQ.$+0,_TRHAS1,_RJX+8))Y.O:D9U[M3B\N\3W?RWR)"29,E
M25#_S=G-*P"&8M03L< ]M@:Q9EWS8];EU_=[/S"N.\)F&??/7Y#*>A![<#M5
M?,$X4<R[4D947=-O[BJ!$/"2%JDX[A;8L8HIL1^AVP,51$(,^.@.7!11YX#]
M1K_P]E,P'![,/2?D!0*!ZK0U>4K?U-4IEZI>@F)PW.A C>,, E@:Z@T]"OCT
M+)P=]QRC&VBD&LI9OI\O?A6QY6JFAJQ()"'KK:-\_WC*'58!YN!0C4D,V98@
M@)#J@]:8IM7#$Q?DF\CHN#"SV_%!=Z4,U)F@NA77Q!\-X4]U55=7BBY5#S5)
MO\WZZ)'UD9Z9JC0=!6]/$PGV;38MV9/Q),\Q>./( ?T,R+>_KG-@&<!DI&<\
M4M*DL?K74%"QO\9/54^O,I5GQ2\.K94G3<ZJK%VCEQR\_5N=QHHZ:ZO$)I2V
M'YH'ZHMYU'+TK6^.>BH5GQU7?B7HP[S$53/GPLPR,=.<[\"IU4F&(A#;@VG4
MIXNXP@!65.;E)9EVC[ #7)TAJWH$<J)__[6FR0T?/2V)(K1JCENC_^-;9V^R
MS=6WO5QX+RK@%%0YOXEME]Z9Z1/Y49^S'QF,>C0*>X$FV[@YDDS73)D@CK5O
M)T<9AHC\?LF?^12#(%D*GY@B?A__W7E!VZ_15GY,MS\7$OA%T7/RQANGB2,L
MK'*FXR2J4^8H<)-<VT]*Z!.0<J';46[EYDW5>$>H]:?@\0L7M<ZHZOR6F//)
M5\T<3#Y[_[>4=O4+[\3%O4H_>!1\_/YR(G:CH9&$>F,#RX;RHOV9H%1"+1,4
MWW'1S?47NIY_NONU?A<4OR ZT7'FMU #]KU_GX7%]<@-/HTC 4D^FK?3<F;9
MK/-&/C.^$H089WT73@)JI!'> 9H7HM!V8D>%N^T.Q++8.I*H9F'5C/?)&&XT
M?W)DQ2OC#*>3&9_QE=P="?\-7#'Z64=]O0/40V6 Y2_0.;DN3(U8]VN-7IFS
MC5-5]>NNCBG&<0^&'N390)Y;*N<<_74H*&[KLI)\R.\M\*..XX@YZI>#5B;(
M#\:W0 \ L"S#YT6HV(RCZ]8@%ZO:&W,AWX;K_((6;BG+/:O7?"*D77C\Q52;
M)REB/8 BN\LX\I8<T2N(6.J=0BEGDMA&-W4K@NX@X#N\89+/[7*\;F^T.IPT
M.HXY8SY08GWX548PS>UAQ9,:R0LL$XVMV=\U1H7X[W.EX/QA@&I"'SIN&B;:
MH8J =CZ$)GP(BXJ"\B'BUMK*'*:O2WGR5=44ZGZIZA2QT.3(_(K4Z(8VHGMQ
MO*Q@)Z-K\9XR51E"4AE)MEY$T$VC(^3^G/>.=2I>TKJU\H7PD\M&+L?KJ0./
M8Z"W\#UUA[IIZQZ9,RKS$72!64F6OGX8//C*01:*:Q5S#&)YM#CD+8"\,JTY
M<[7VNWX^Y)[ZY-T;J$A' X\^5#:YI!\<;ZA^D(*&"\PV=K=H] ND&BJ3"6D[
ML_%OBQ'I/;5N#7>B;L\-!@H9R0Z"TK[%^?XX^7J-"\<2,P"W+(X3AJX6L&)K
MB<6U88^Q5R(;Q8SP,U/(VO ZV'+HN*'\/V@3<*7)S-&#)RJQ Q!P6+$?OL6(
MLRT(>:K#5_28IQ;'=_ZN8"GRV1DE=HC N@@3Q.D.^-$TZ>J #VE3T G1$J1!
M:L@*BY90#7R;X?M6T-4B*?;Z6]>@">09CV??R=Q "?4ERT*?,D$)VGXX\C-6
M>9#)!,6QX/61DGAZ]=KF.A0PZQCX.1.=&?&2D?YS8POY'=FTK<>"3KZH233Y
M.6N !LO;EIB@)T8T,890^EH ;*UZ/5V?!EV'>HTB<=#!@Y7<5JD&Y,QO-SMR
MUD8S=G)GK<I3]>I^."RE9F=WC:4_)PK0IGG0C1*ZW&4ZIA^D"RV(TOCCZTKV
MU$HYTHK0:DM^<H/E0D:U-6L"Y_:3<=HH52"6U-@-!LXDK*U6HT9O "I.V,GJ
MX+_6W',('N<[C>,:&_SMS04_W'H47^I;<Y]68 MI1ZT:ZXO17(THF$_@>HU>
M?D?2Q9%U>T]B9+6NM$5W@2P KTQZ<%'J>IJ32R15\YU)C(ZQG\6M3VOLFGM)
MV>^<S@U:/)_5C=Z<P@?:A0@E(P?W]Z-IF'+W<Y3W+\F$3I?^1&Q%<<UHO=09
MK!0M(Y6TL"".-S]1'M/OKW+BM/S2(\O(DC5/6A"@05T%X*4(3&= Q66?XC]J
M[V_-_;G7S__E_I&ES/">""D)+_' +?L$3Y@,NM,1%^0JR+JZDT#HVU^H<RGN
M3<"P"#:[/REOS-4:.^NJ:L+X7?@(M8SWY#$_/-5E"?'@=C\'!I24UN7(N8OI
M=.'M&^2(KNC(Z@Y1^LUOJH&5HJYGU"2''.H>?;ASM^G(QMA:<]#GLULP$\WL
M<S:=C<;#)=%!<ZRYKSXU=-P_606^/;>_#74Z7?T5_&0?F@8-'L'#J<\FL0)/
MP<<,90;(N3WW?W6<&*=?J#C(O3Z^U!A5]/0G=;+3?"DT^,-B%J'!6ZW1UYH%
M.6).TBTHX-[T&:C5%,2>Q _OP=?G#?^UC"HG6$3>^UQUJ"S#Y.ZG->W'3A-=
M6\:#-!<F2#?4R>%G=B6!?#&6!=,;<I^TP6D>B(K%M-<-31UGR:BLO/:_8W-]
M#1J\E15L)V*N+-=$BG&"B,V+/M,J6]-]!&&L1@R,[%B-W^[%GZ_P7Y &S!4.
MDKRV190LU([U?2F)MP_4E/ZDN\P$<75H([W([S/)U22Q..)!/22,!%U7"6+A
M>7Q![L65)SO#>I>&=<)/2F@W2]CJA\G]W!8;]+ZDCY#Q>N56#XMRU-R?S+<,
M0X>-S):K;#N2-M<+ES0 I83^:GQHM[LB12Q1=\@-=ME:@GX.8S\AUTP3;KR9
M8@.'"Z=^N?/TY\J!@\E,_:RX:8(\&5>OU -/AAU^ )O%+5;A2-;IN_B<]D)K
M%D1<0%@YPY'.Y=:G<XS'UV>7?:!>,[\6S>ONSO)YE;HD+GJM5Z73JQCK[1:(
MK!:T8\U^*&5H232;9D@_11%("_N\>7<,HGMW=]K/3W+@@DG[%16MF.@DD5"B
M8T^ 0"J4MTV?M'Y&G84T;A:[_*'ZW7NLZ!0LZWSC',>CSEM>ARX9_-BI_I+.
M W23G [2</XC_$#YR-*3!8[&;[8L[]=G5=(/FH-VO!P=7!/ELW>YC\A"..Z_
M.76[]%;I >@@E@GZT8_B8X)F4MZA?W?P?&V0OAFW3_C;;+=J,+2\7U!I+.QX
MILGQ/ZUWMB83&3Q,4/](*A.TYMW"!(V&W. *N57=+[ G;RC',E!N=':8_7]<
M\^2R-Q:^P?:_(*XO3!#91@ X;?66QO<')O#@0(FXT]^C=I,D\G<_^O7KCM+
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M[V88:"C43GBW>M\)Q6[(OXP_Q_9(',2SB/;:G%WJ=.<@6Z]3(HM^JP1$+Z9
MCP.>IO &ZU.UXWR.GXRPKQ)&9@OWOFLSUNC?&Q[L8R_ !I";BJV9ZR51#QF.
M:Z@TU  &&YY+LT8*D7V2[Z9;DS>JEU2X=8_H*$UDD);ES-WU5+8*S0KO6G"
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M$VU36:H603@0;E(B8I;C@\ W72M2(BM3;W*3^&2?.]B;7[Y=>_B&<]->OA8
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MW1^CJCGU!L9L0*X-]ET6-[GSIN4CVW.):!7J;R8H)@F) C2CJQ&%W>YJ\6#
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MABMYHX[Y2'S6RAZ=>-N^8S)<\<FO?V+M+W5D])*1ZV6$1N EN!ZY.XRF\L6
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MU..%,65TU];M.:T_1NVOG8P2P1FWZ &^Q]+;]UQ>?_^=/[#1)P&5#J37':#
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M=X\2VXDN&CA1G)O?V%I%5NG>,E<'P7F48I W'%1C%I]MUC!2M ED ;T$!I\
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MX*P;%12L4Z4Z8X!:%1)7OMW:,3>=YH:7;4YH5^&#4FIO/?NLAHL>_/Y<DV=
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MX-E[9P5_I1P:: 8D]I=T(8:5#8,:&B%K.?1,U73[/_Y&%,]&2^E#R<D EQ-
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MDVNP'I<,-T5:J8\1\=?XY4)MW*P">C27WQ97$:4PSR9!/S^*96HZ0X0@0T\
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M^/F(OH$PPU$. 1%4KLO>5UM#E,<*_V0< FS"Q,?Y'.HMHATG7MM\4$QFFX&
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M*Q2>E&S3G7(P@[-5?\5JRWA"_"1%*<N)B_ZO)_V2VD;F#W[^N8'@8"2CW83
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MZ3=JR.;AR,DRJ52K=0&7_&-'3TIMU;+7SS&0U8^G2^ZTKFF/SM/:VIH_%<M
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M(M1O@:%+T$$? DY^(N7"H^O5O*R'GU)Y6+P,I^U:'#AA;JCP.1-KG*Y'I[N
MD;@GHUQY5N1"4<'6-)5V])WODQH@J :9-[HL;.00  010DMGK"[A:/I1WSX:
M8[EL<%8V?W_F+JEK_E1U]FWC[()UR**?SX9TP&O.=,YJZ5'WR?%ZR5W"O#43
MZ#HO6$VU HVCH0OI<D.D;>P//\_C;K^VM*1OD4#33+S<CULV4B;=]_U%S.$M
M>#-M:T4!:)_]/NI3XYC-3+])3FY5,1PL\E.#>VV.Y\C8@$G6=DC,/+\E5&4<
M<6MI#*I< K$^!#P.O3_X6O)8D%!D>2]KQ\ICUP=FVPEU?W^\JY.WL/JG8Q])
M$J*%=XV10>,O1WS;(.2&&;P L>#6N-P;\WBUW#V/3W6E:E]XGW(F5RKE2FSU
MK5M*F2="S,@.FU7DX.5IIBBH_A#0Q:ZQH*0YWB:!;UV-V944>L>^-A+-?Q#1
MB3X-<^?@T!*8@P92 ZOK84%;*-[OB>+8[Q,%P/<\27(HX4;>8L6$TJ"FN3^M
MX RQJM7MV2F51_3!ZMCZ.R6Y?QWP3->?W!9#*)41D*?=33P,+T!6WMQ :"7!
MZNGRE6M2'(PZ=(OP/*+!#:+;#:IG?BR6HT9\0Q_;J^A>4\I93+0P2&R'!5Y/
M4^$_!%1G+.A?]<XNT^5\9&^[+O,G^VUI_>0@:./G?KGD"H@K[">P/BM*+#&-
MXD="Q%P9W@+5H&X\&#O&[)^UM"G3Z.Z=;*"KT$R@ABUUB0W@J5)":&+'$R=]
MT 7JBS6>]A-*9?PB,V]WBV\)=?=<_O.ZZI\2:N3^S2SZ"9P,J/D0D/*GWF)P
M3O)H@<:L"Y^8"!NH##LRR?I$%'! WI+J,FP5?V=X[FL[/#GLXZ(* ;EK1+W!
M$;$G+5LMHRY.;M65'- .(A5V)?3+INK%]6&!I%OC1E%^VJ?NC/@:N;(:P)82
MHQNBL'?[X_YF/3WZ#0QS6$-XDK?7G%R"^#PCV\'$DL*0I;I VM;=@IL< 5<L
MG(_ X2DA!ERF:C%%0P4J8I:B=4P\OE+D&8=ZQ:.S&EW';U1T_AT4+39E,9<@
M!OM9[/Z\6R\\&+I2;VSOB@=/&RW,)WFKY_(1L)B[+VR)4XZ$>,&H(?D$T5*D
MXFJV>8U[]93T8.)$^^]6QM2S]P\3=Z^DV+N(G(C!M%J4WC@H0<NEI_W:@4\[
M]K248L"_Q@@K,?5J?0I$SWLD^YHR]WV?-_:3!$'^HKA[9T5NKA<Y<7;[P\\V
MA.3"\+I1,@@QS_B!V>N30;^]:]4Z$WZ$%:79AQR-ABOEQ='(P^A^4OV%3!YF
MFYRABNKKA3"75O 4<UM(:T$YW%OZ=U)(T"XKBTBJ$ENJ!#(AZN0KS<OADN.Y
M1RS+\7Y5 Z76HK%Q*:*!R6!!;TDO^8\?(?SK;_^+L-[J?ZFVO"?T#Y"_5$66
MQ%20CT&O^S.X(665244MLJAXFF:5UJ;R<?8YU_3+D?-(;T/Y[#+Q'M@9#)X!
M- ?S0MQ?(R[8M,]E!?O?.84J/G</RRYZT7OZIM39[<S[]Q+Y4:O743Y4,$G+
MFH1-4A0"=@&/$Z':7_3(]_>[,_-451OA0N73!J%BL^V+>FC:/=MIZX>-]SGJ
MTF%77^QHMV8YW$ZF@*D=!. ;AY-AP#[2P),Q)ZHI/M3FP82_9!7X\6T//AE\
M!4-NMG)2+3HP2B]7;NRLW<F?] 2V$N#].]8&=,\M.S@\=2S42,FROPS*\2=T
ME#B%#*W7^ YLX,/(NQV98HTZ*^5U2KX["%D5(%DQK?/=Z&-BQ];+\:3\Z@4A
M9X/I XNN8?8-E.(X7=&1P'YQIRM8RF?PR]H3!VTQXCM?/\&!LR_(%1PMEH 0
M%Q2$*D+C+XUH,Z:I-N8OM L+<D3-L_O?O4D+GAY@Y%0.M;#=T/WQ.+5-"?G=
MQ0YS[AMZJ+7-B*++B$)=I6N0X9V6;<\+Z,8MV+8S!"]=TW&ZME(=WFC3JCA3
M<B*/J193E80,0/8\_W K0/E 4Z[OPX6Z@ZHSO..4+:_ 0X!,-W1E Q)YHTPK
MQ"M4Z1"@? AX@\Z:VI]O,,*$&)WU/%@*4R7E4G+^B6*!IJD#YL@FI4P3S(J6
MVDF_F-_)[(+"HB=Y1#EM>SNVIK%X1,^7^N;ZV>#^H6'KD5T#ZYX_%,JD6DB9
MHDT\S3/DI']&A'WE@?\/HW-+T<>>UGFS[GAGT8Y!!C"'  Z82RC??5) \N<^
M/#I*=2NJS?M9ZM"E!73["#%=:L[&)?0@7*VN2_14QWMXCL\X";&9MBCM0/$E
MBY54%" Q[=;#>+YW"H/"&T_&*T<4T)RK?-F#."/1S-$?\6R![(ZO'$05?!?H
MG0\,A/G8"HM:]NV(R )TX=^/O7QQOI.\([O!J*?[>P%[1C]I^D;DI)0*2);)
MB)>_@=**Y<ABE"?M;+7QGY<F7DQ]_4MJ*4[;2SA+P+0@?T>YM6LWC'7#X8(B
M!\L4->U>*]D\Y?BL@]O/]0M]7ZP>_)H6_7IZA_/\;XS<FT".(R]".V,U2XU8
M&,1V&1BJY$^@Y#Q2(3A+T><MHY.$&\_'GCWC/I4J+3?7J7)&9$C/<'G(<\4H
M_!!0B^[R CUBP.F@+U#Y9M)\ NH29"C4L1MV(<=X#/$9BZ?=I0=F<1K>2LJ7
M7 <K/":$^(O\\+MR6D$\[XZ;_2,3I$P))7#/PGS,SGA,RDS_OG'BWX:-AHEV
MH=R],=UUU"A)N0=\AF[4GC>-L9<DS<=42WMY(4KB'X\OM$*\_CA>G/[1J22J
M*^6D*HL?_ZUW&7N,K$4A43V/7/,A@+->D!@PN=,%9X/>@#ZO6&T,5-KZHN=V
MM2FW,.IZBO[C&IMH)Z]\\^6I6-:;V62CJ46*(MFB(YF+^5W>G7EAC [R6@ >
M\P@&);/'3V&6[&<LUXBUFH(N^*+VJ$#7Y!^G,"K@')]5M*?#6XU;Y-YX)DCK
M,_7ZAJ5#+/IT(6DHI1SC]YQ-HOQ^"TEI]&]=4?]H/.U>M8@;56WVN'D\A^93
MI.)$:S&E"C'@H),P)W)A;<=W:KX.YG( G47,RJ\2SQ#@4>JFI1M\P0XQNT*/
ML!BDO-5ZG?4ZIX'P1W6MUS6&_5T/5L]*(<(_;Y\R6C"*$>#HECF'VT#Q3^XF
M<[H%=B0V%A;/Z09YON*)2_UG?^G2A5>&9T4:H.ZTYV$=>:)D9#+=F>,M5-FS
MB,IG3)H/)_X>>^WI=5-Q,BD-86]G:]4-]F<FB.GKONGQ=MP&>G3V#LB=VI/Y
MI;60'*LA0-TGA+4CW,-41O/)VD-YC8M=!TGA6-6(Z8YK??Z4N[PX-7W?N1?:
MRPJU@W+3NFT/:G0$;CY?NVE8Y%J=[;_&!/^A5>?=K*LLZS^/VZAJ.02DTIB'
M -=QE I57 ?K/WMKIT>8MV&\3:8TU\:J/L<\7&4W_G9KXF GWRS;U3"P[#=;
MOT_FRM^ N-)OL/K><*A*%42WJT4C_Q# HO.^9;8J?/[>/MGF-Z^1''? S1&]
M:]U7EG3%OQM"$#EA/,SA/%42C.A:,F]SA,P^DZJ&$^AZ7SQ&J7$<;.OF E"^
MTB=9--W';4BWO:>9:TN1 H(Q15-"XRF\+!?KGC!R4-Q00P9\"\5"C0-',*^C
MLCKA9X'?5%%ICN5N\?[N99I*GP@NKBA+^SE8W0^S4=WWS\")+-WN4M+"YND9
M!QYMNW0^^Q*?'G-?@XYIF]5#0"N"<.#I$@HBNU*J2!P=Z'>8'NO2V/JC40]>
M7[0:Y9TV1KI#M=F4JEYKQ[CS>//GVPW4?-4\<^7R9%8X$P31[SD$L):0WZDN
M9[D66$[IPLKU X/88+_<)E/L>=JN]G_K ROXW@X B%2XNI^DWP2] ,<(<U+/
M(%9;YCL]AV.ML7&HDQ"_;RW6VCX%ITA)Q<Z.@>S=.8-^@8)G41,*?-?<U'_4
MUO#+:K=^F0"Y$(-[%^<[#P%1<FO!GA!70E;4:P,_ L^GM"*$LWBD=I/O"Q>W
M$INI:@5/":4_PMJ?(MB T&!U(58KPZV)EZE@(S&8>?W,T)U-[:T;5N[%><3Z
M!J0%^,'>+]IH7!^I- :AKL4HI@R>,?\9A@F5+@)YITX=(;(7C[U:XK]GVS[X
MJ_8 95OH/BM SO78SFZ,KLZ=Z(R[473[?^.DS8GA0X S^N]553Y&&VSM0<,J
MSW]1UOM7_ORO;B^H;J7'(1HD2%<CGS":O$J=^N)^ (RE*[*75%!D.#326^IQ
M4I0?3E%""'>V;'V6',^9ETTSL?(ZUUX> BZ%]?JZH^M<.XVB@K$=1X$#^HJ$
M[KBAT'[KCKIFH-?RQL#YZ.MP1C[XY##%\::>A&[<YI?MI<R'O_HNZXECQY^<
M>;/FP$[7(T4P6:8]\7 ^C_A*2)HVB6 ]/R,]@_Q2+1MC3G"VJN85Z[H?E*Y_
M(T'ORGFB/<,62%0[ C]GNAWV"/,_+(+N\>Q^'GB1T[@B_J=KY+^7J6@$3\0A
MBJ\F=7,3%^"MG#'^H$X]D9V5*LO_E%__LO9H(+3,>YN$O5(][1*SV)>\)2OZ
MR ^>>P_P7#9==*[<^JF7$*7(9@ S$R7HE7U--^W2WP^I8NK _^>"-W;E&KR)
M>-)0=FJ0CG9#C'*&QV3-RK.A7U8?"X5C?CQ*^J=^Q0S(VCDY)S!6Z!QIK68Y
M'E-E/7G[?G(KU\411,'%HTON# +L_YFRDL%SMITCWRM$?8]75LI5<CS15HT#
MT(>I5TE9E'<,.&BAY!# JWZ*5#W<H03G\*++%AL4VD/:YP[8.?1"*M:JO*H*
M&U(E9GG_A-HKQ-D&^7R+7SYI"1VN*&1D,Y6HK?9-361=(D]HR=K.E:=C=,Z%
M=C4]RR30RA%)H+PKS8,XTR5=.W!WET"D)ULQV1'6,]*)O9AA-IMNWQ?7^)T,
M=+O85A$)O,:B3F]\3Y3=U0XQ"-VZZ&-^K?H:U],UOY";CTPHK]*+&)_ $BIE
M&B[['KB_,RO%VF+80.P/>L41)'8YXD;S),/H(Q0XH +5)(O@3T"U)]65"9[^
M.[?\A]D. 2ZS>FS!A/M%581'R?'=28J?I)Y\#S=+?!\&IXKTJBIWH5G<#_:C
M_>U MB.*;MK=N8R$C;OMXZZ%(F57HT?;))DL?0NYGM^8@M0.X88BCVSU;'CW
M,(^'N6>HIUAS:T/VWVS!&,Q;E 3?LH5MQ7G-:V74+4H8V6BSC,Q+(_!UW%51
ME&:U_E@-=27-/+[2./%I&Y>7;AE#]!<>??"HXS4Z9""=Q089+YLN7XE#-J8F
MAA25%D3JBZ;FX.0:XX*UIR2FK=)T;GWB::0G%W^IEED $D_A'7 V^ -(6F?P
MV[8ZFU@IA/1R[.>V4?"U*P;N_B>>+S0EO!=0/A:EN73!R-TAEW![S\TL0V#$
M)]TNVV-08U#HIE[%Y_+M"B'[TW\#8IS.W$Z=ZG?D^'1C8_N]_BM-0<.79D%/
M<JUY&7.\_*<?BR+%5#5>%28]34">Y*Q?X<S\MTTR!/P0L/!Y[O9$F]!GJ%BH
MR-/Q^M)QC9M43Z,63[6L-[,V^A!>2Z"[8*$__OUORU>:B,^2+:C33[_6UQBL
M&??9(*71:JG% 3^-M7DZ_Q>M&B%P.E=@UT%6(NR9440+JNZ+@P>NL1@OI$HX
M IP!34TM&9_O#XLFZ<MS]8FF&@28=C0_=XU#I:0[@LD2K?1FX)R1<GM_B#.W
ML:WSJ?];Q\0A0#K/"?Q\O(9D6-><Q$\H5_XT-=JA'3WRP5J_T#T;4U49W)Z.
M3,.XEQT"\HW\3I4;*4@HGW8KZ!UL;"=K[#!@GQ&Q1\^M$G92$9XTS\MD6SO
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MU!38((BE&/2+IR R('*(#* [@P620M-;043>?3* )&U\DCI/,714^&NXU!M
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M6J<I?F0 LXO<7(_B>EY7PB?O&=UK*0(75[T'<]_JG=G\:!1)ZJ,X&$10>I5
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MO7<M_;_%L10\L><HIPO_$<;JL"N]-^,A_8_:FEI\<-A!(2M$.[+-.OS^6=J
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M5P<C&U%KQ+X\>$R)%O,VX_[:<M0PPG[2TB\J+:H.EW0N\KIROT\"!E&F04P
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MB\1+8,7-/H[<>.-MGV.R\?T19!A58/'S*Y6"EY<"H5RAUA>Y!5OR*;W>,T"
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M\69&1Y=)7)#" !D"Z"!JB^<33[+0V]00]QYIN3?^:4;C5FUAUY:XJDMIWF!
M<K .0:"]^'G2R"F 5I%/_.V>YUC/:K<XO>,.CZ+&AUGC=6_I^GC7^(^1?9<
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M[')2"=8_V[!^ZDRU,&*5>FY<XDV%[7'00T!<3:2H$0;@NQCF;PE/X+<2>AD
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M^8@EH577",NJ:D?I1S\+'W3':W2) T_;TKSWLG64:&>H7$0@QR1*GRP0#B1
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M8/E4J2E=H"R,:1(<!QF ]2T@J0$%9 #T^-.8.+CP0'%V+8CJT,C! &3%FC
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M2%<']#\L>A+,!_.RVD3L;<^K#8IHC5BQG3 _=$;T66?2X60ZC,D$LM,#GWA
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M!$\YX((H15!Y1YJ??*CUJ0\Y"V#N><X$A_PMKJ\K3FJ7JBRW;_&W/.8CPG7
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MWKDGA2\PYC%8%?W*9V*=R&?A24PE.P,))/+)#T2E%CI,!!A2^,!]?9PSW*>
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MC!TD<)G1$/]7T^*BPQR56^@P(^O*H"EYT,!Q&4Z3%H]%[ A0,?.]"YRX<D\
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MR9SP*V,7]&@U8O8-$D)WK)J>1"8MCY;0_=W+=GG/LC][_,W[PSZJ.RU,"UZ
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M^?;,9M.8 LQ/0<E19K]UJKF3;./_JV^\H^:[Z[$SF6\R1<L9^T"C/?+0.'(
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M\S^:S%T7,<XXJC16FI&HBVCW Q[!B0:8/3V!-2J(8*DWF9 !F:*!6=3?((
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M-._76_IMZ-G@P<J9!G)VB2RMYY=3_B_VWCNHJ:]K&XZ*(B"]URA=JB*(2HF
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MWE/M@NIRR895JV9*+F'2 JP^WL]+XQ-&N.3#EMW.[[C3>!V.&HMC@"_*LUV
M3RP$&1).17GO[L-B_08D4A *D?((?^Y[=V?+&TC98Y.;,^*,KR!*=M'TWL_N
MQEQH^7&ZS=C?*NAXWYLLE&-WJ3ENOP62LD__C%K,A9U24YZ9W>6FZ"T^<PN
M.PF2$K-=2HIIV\T.?K]?N9Z(>%43__SQ*7WD)>K1YF<Y#@ALKKBX:Y $)()
M-"9,5;X;4%*H4*HKJ3LX:RH8:RS5_C?+!'W.RN/RIOG->[I5WR D*Q1%#AR&
M6<Q UU9.Q]0/QX4<@@3@G"8(/(3]U+QV=1!_I!L#;T-\C6K-CY/F/ \,$X2]
MQ4?N9UD61W3**(;8;PWMKU9NFL(B@FR'*I^QK^S1V2PI.6YD>3KS(8@LK@49
M3F%GG5UMD;^=XLUMS/M:45E ^):11)^A9H]I<,?!$P"];"!P" 6&)IG@%[.I
MHW5PW.D=#[\ (T3HV&,L\L<<]N90Z,.EDRN-":8V7KD\BUZPGZ, !=I)BJ5#
MIC4M"/*K:E".H(P[3=_\-09YK38WBY,+T\UY3I[,R8P&L04=Q]R"+$[@L$ZP
MEVB2V?KHL3F8ZC5HK\EQPHA7VT=K./6"]^*3[T-I$<H\3W@R'^MH^/P)_@FL
MB=/T7L_5]T#DYZW"^W[I(&!FKQZ",C']+GL:>/"&?A%2&?#81*0390;N.?4;
M>9,T%57<JC!;D/5S_H/Y\A"?E&TWW]L+O#;+SBR7VG&?MRA7^NG,HNH;LT<2
M9P>9UGU+ME29SKVXWOU/GTH<&WWFYRO,N\IZ]0:F&FJ*;)^?_,+[.D.-BH -
MV-#X?'?C#D&1P&#"<FC.Y-OJXVM"C^S_9&EG2OB 9QX]KXOO:SXK<=HX,3LN
M_>PE3IAB5U,@\*NI;P9\M*OFU ]/,POU#9(4U+T/00F'H$O[3X\.,=,'C*DH
M>I<8A.* >+8K7\5CVZV4$RC6Q^2+\.&=9%1,KGX?P?M11W;CA%(@.Y1L@'E'
M_P(^X2]JCL^;:+NXJ,5L7&I\X2;QT09Q6"3WN8+/SB]0%>!_88JA8QY4,U2G
M<B@K)>=#O?R\+NYZG-YDT:3D;Z6BMH_27SQ$:XP%A4Z<?:"1Z6K^W?DZ*8ER
MC7VW$E*+H7$+6Y'F$[KU*FG6D^](<QJ@A?1P=7[$J/!MG]-0"WK*!4AT4-WC
M>D]GE_3V5/BVR<$ ,<W6(+OG XZ$RZ2-(2TIJ64T-TH> 2H 3U7L:R1\,E^W
MG92ZXR/5VU.I6J%BM#R?)(E^2H]&+6:A2$Z8&8U=U,'S=@Z*3"^.%U.#A.)1
M+#.KV)P,FL2UWOZ9XL0+HIH#E4*7.S<K=#;@?SOR,;8C*D\%UGP*K>KR-RO=
MEK]=^D%J&OR:^O;1[";*"G!X+M@&X#OZZ$.0HFC@(>A5^2*&%]5YO9T[= I-
M\D5O;)%/X$?C\Z;:9,0BVX6>&1@;YUP,G5>UKS-"-*Q=>9L!;^*XQ_'S3GES
MNSWM1B4"1%FQIMQ?JN3OP;(N>>RO1"$6)_^L%^H'-#1'ZJ></_Y1[E9+:?=Q
MMJL,-AE1>$TE49.QUU6R0]?JO:Q:)/TM1\HF:[*L3;24)WZB'N :(%UQHTE
M MX+/>&Q72$4E: )+O]E/5Z#X!SV=U,]W?OD4N1CG^0LNL(Z]>B<NQ]]GLY[
MU&H[="A4F)*&SU0D_IP4YX#;WYJ+*?KJSW-BM.[5<_:A_B>7Y#(2EIZ]N\)+
MAM)XA.FL[A08]3[RWK>VX$6TD">:66V+<R&;:#^E):=E<RO7X(Q;BJSF@-AY
MR5=1SE+G<[[KM$K\#$)<+DZ?+(WL<[JV^REK; &;F^L6D2Y]L=00M@VY<B0V
M#HG"5L5B%DOC*NRP=5F(")I\R;PG]RM=W9J_ >0/3[W=7]]_^NK#T_-5"^!_
ME^M<07^4V1 E0>BG6_&*\ITMVLUJ_?&A"I[5WUD-K9/9"@D:;_)3=,Z8G3UV
M-D)SI8-!UK=Y)M/W%XID#?UKP$\\>53XXG (&C\/CU/]+)'P&6^?A6R,M5E+
MQ6TUM_.S_<(7,B$JZ4ND5#JK*OD@*1P8YYZ]__R/@&DQ!9)I<:&=P?>1N6&U
M0GR"[YP^7)[\14*K%E8/(SG"PK#%0()-D6SL&V5[."R9%?N+M$;N%U%43:V,
M6/Y$[2MK2_=K<!/8[ X?QZ3#9B1V,\GL&UY4(XH&(3#"7FV*!BZIW# ;.&;\
M9N"\*NNKQS4]VP8W!8\-"ISE/ @,[<$T3'?C*+*(C9TBVG4*JE0IKV --(NS
MG3OI,"+^2U9E9EX_M<9J[LJ@C;6-^<!:_S3AL]9=[<NY]T_Z5>[UXF"PWU>V
MLY)+=6T#VS&^D/@6Z@2=M81RL13I"#A&*U*[K1;V1YD!NR8F/CGGG\C0$.+7
M+[JIY#6Y(G)UY0KCGZ5=(."'W]+F1?I3YM5CV\&4+4N*Q7O/::_ LJ  42&M
M6WTJO<:*25OW+Y?XG/N^\*3T,8>X;&)[#W!W%U2G9#O_D9ZYYHEGQ105C1%X
M3\M/'#&)RS-.L/T32]@YDS*&._)/).YN/_G\X[A&K:E"YV3G+1X'WQ3/*>R^
MQJ?V]3?WGV2-5;S=-:47'RE+\@&!B03?9:2,$+STAB]X:)_YYFJ[ %6X>\M+
M\F;^?'C=H(3XB?"P[EBZWB'(79&=X(LTJ"7S=^4H]]GDRI+>DSTYG(*\^T*R
M*R]?QTF^[*JPD>0<94P>&*B:!C!,@LYR,@]I,"9]D!4J[#FV]FIF[;QZDK^P
M5]4CM\;'I-5H6M3#GU;ISN\>I0BD^MQ744105-?IS- \VK46,O\&>8GUEM8%
M^%Y-4%178T;&K?3MNZ]C->).SN\Y3JFE\8A66'O'=VA?513Z&V!EP;/Z^ZK&
M]B>M!>K3UH#)-M=2PD6SPA'7EK^'(%B,'EZ9)O*)>B>T3T]W'.,!"6O$-J!+
M^NDQ)9[V^J,1_B&4I7-2:;>3A8-W4]Z_C+W8],K6^V3H-PK@Y8S04( %"8@M
MX&"32!AI83]X"N?]J:"NX:]$U&\O(3?;WQ%S^ O!9V4587JH3BAF,0W"AEDL
M@S#_J63LF_#,TJ["9Q8U?:T?4<L@7H,/<=R*N,N3<EZSJ3$/A%9\/&0 7P1'
MH$CN_"\T(60)XL(%RA@!RAUDKZXLEEK\\**'#93:*U?CJ/H[TO%%6L.->.-3
M)R^&+QLTZ,<6$B]R^A5_2/[45ED 2Y[$)Q9JVR.RM%'?1J<1T1BV-F7R'CZR
M&(_A\LA"Q+3)$."7$,'NC_/A\%\B[MN_AH:>G&;@N*Y&^QPZ"CE3ET21X:>)
MO,"C3G8I??@#9J49)>E.#-?$2#1.0GP\O_1&:]L[]MC%#)[N!^44[-^AC)*+
M.PY!U5L="<:]"RI3"C3EQ2K&[Z6Y:\LSZ0)?&1+51-I2+F*CXYKG,RV/]YR@
M/0^=QM2GUU.A=*R8.J53=&0WM2PHJ<=\_1J\A\"2HZ26>L#)2^B3C)2,T$MZ
M\V:/RS8E<)&F95_6IK;[)*$-H/4.B.U+(VL&;%Q4(]P/E!MVY\^^4U2P+]QS
M>OHR2;/:0=Y+G:WLUKLK5^:N"W;VP<DGZ!( JR[W.@1]#C\$+6 /+@ +"'JD
M":)YI.@B>_"*IKYD;-PJ0'-$P$4S8O^4Q/;MAQ8*E7VV5KXXX_7CT2#G \F^
M-:8Y ?;7J,5W.!(<TG4(FF59.E6Y-,I F;"DF%4%)?[!>4Y5KYJMM5AN7W!1
M2-;Y>9UL)/E2@_/\[<TNUADQ4QOH,=VV7P^^/GUT0!3"N4\7 &2CEE?N]TOW
M"%0Z)O@GF FUN,X>C0([3[J29#9<EB!"_05OT@_JP-QWUW0'AC%#7&_\BF8P
M0ZG>&][;.$&LSV]^&B^5SL9(YB>BJ4IP- /-C*JY#F/V-W$F]-^AFI82!-V:
M(L[EN,'^>"B<=:[Z^'SVN6APG_QN/YWI2%D*3S*D<;/L!L! 04K/]"SAPRO?
MU)[![D@0[2MGR_*>\"\G\$K<N#D=P9+:/#./X88L_AJER(E%4>UI#TA;7>"H
M_?%U,5:*E^;TTQ%BQ6S%CI9;+=_D$KRR0N>;F[D.O+0#KZ=>GWJ@Q_EF&W^!
MON$XV5Q8V.#E6.DT3&?JC=_]0]HKM[ 9'Z#E'36O"5]A_XA9?([;?@-^<0C:
MY6\ZZN&=12^G \8:E"1##\*4#D%_C*>W\X"1GP*2I(ZCW>R/G_KIK^:F=V#D
M*+J13"QJ@Q/@%?E.F(M+T+TU%!ZV;Z&=+45G^(2Z@>+\]F_M"6AJ57-5E$N,
M=&]C^G+2P6>;*;(-+78-L"UFWUSS;=7!&@0RF-M[5'.%&H+010]!,SJ !YDT
M[I @-"'$(>B\&9K>4PFXD@%V&@<F!1G2 *OB<0>O!2!_9E&P$X"/%1V"MM,$
M#T$;MR:!\7M5!MDA:*GU6I*!SJ@?]\')_R<%/0XD=6HEE!P:'?^;DOP'4@2F
MJ(7O#L"P_'0F'$#)V8I+C/P)L)="<:OZ2LI"!/R?P<'<+] W;A*W1[RC64X:
MZX->1, <R8TTKK7^'A3I+OMI^CC*K98^/$'C]F6=]'C$B[L;DS[.]..>SSFX
M<+&5@@K:.8F!O$P7174V8AK0-!49&@^FV]X[SU]26Y!2$=ZY'R8HN6U.".:8
MN6VF<[)WZ+W.]_M</RV:=5Q@D_/(+8ZQTN?]DVF*O#?HJTCCK0-V0^77\*^Q
MZ614>O_*%DVDG/I GWK^2)<#:92''92A2:+X<'1.X9.FR;-#A57O0W5F=MU2
ME%0"YPQ?V01 TK$'*D# !&;TT2#F81)%UH8FOWY5(K4;=PH@R.?<&/<:IXW.
M["5,)KVNN"C&>$'=+!R66;]+4WZQWW!<<0L23-NE*01E%J(\'&?=BO_297:!
MQ);!#Z D/6B*5%2'J"&T+7%_ ==YS?OUMO2%6KNN!E_#?K]T1CV<K.](*)"R
M=8Y#3M9#(S$D:S0W)9'LZJ5!D$XJ7-OE"E:HCHC\(L\DP3KV1BO/)3',:N 7
M= )%@J-IO"LZ%/<BY8U9LH1-DE'4G4E[U''8G)PA?.7+<M&$:VI"E63E3UW8
MN04CB3F!GH3]*L AS@( !?LGAWJ'E*XGX7I8-(9-] Q?SSULH:>[Q%F,BU9_
M<@FTMHZ]_LZ(N]3ZV$WLKT3,N5NU@[4Q0RW(E';,O/=JE;$\;=3)S/:S^)VG
MY<]^T;76]]N!V0O6/N-YU.LL&<+T:,=M>\N?ZH#F9-CXZ#0W[(.(?[%7N<"W
M7]TI<:K=X2 =8)9?<9$0)KJX1\M*#R+&?KIG6$OIU]T$,59!5;C\?.NM?A_J
MZH^@;>''AB8=+UX=F]\_3W6ESQSI!V2C:JVF$]J\_!'YE$#]& 6_3TI]J@X)
M!O=>ZKFXGY83'+A[4N"&_@/GZ/CN4,DOI0\X([E/!L.?Y5:YINVLN:<O%D=Y
M5WJI'MUI"QTSY21]T*[)@L^&*1D!\67@?5NRZV"B0W9K%"=O/X-!<ON3)](B
M9WRI1]TP$?\LIN-'B\D46$RZF->86<;=?#*86$HUH8P2,F*Q$")&T%,Q6!)8
M;.6UT7+])VM$CIL+F,N^1K^IN)=B:D2O_)]2"59D:4[\DS8M)@1_567.(8CK
M"79AFM<\?YWNCJ^BB28?04$X  67 "B8MYG#D=P1M$Q4+Y0J"B0\-[W6\6B*
MA@3=O(#Q(,;>G9[04N4#F.+Z(0A^P-^)X@B51 I.[<C+"V_Q/T,[D38L/KO
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M" :?_G9C@P!LV2E@7D12X$LM<NOXA]/6E2<E6]\?@BX46S^>8JW2:SD ?O"
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MMT/REG "S3Q_@\K2GDKDKZ;@8AZ+?JU*5[DJ;JX[$*YG?=KP"P/7;8&R_6]
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M7TB([[YSZ/7.X7=)O%:WW=Q8/B:=H)H<E"/Q\WV14THDO[F$E@\JV)8LP=K
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M-JNGVR+V3.@\O^17-.JMO<N,[ 6MI'.QA'P^W^W;.KR]5 BE_".5F0(F< K
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M2L=SK0ML%H6G""\<AHMEGWZIMY\9:S/(9GA>6&:IE^> 7D'- W?A3SC6@M-
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M2LC/CFS?W_LNW!$+ %F0S8>)=R(W^4^[BY>K$3&3[D0(5W*CZW&ZA?(&IJS
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M'-G0SW]Z^?S'.8-)<1US;%YGF%6EUK+,VM/4<M_XE&K+_K])U//"  532:L
MF!Y  8YT:4?>J*28(D_6L\!8 <A&)D#]1RXUZ"6YAEDV*K.>X:$@^G]VBO_Z
M4\\5 @_5)$'P=XD(_&S^0O\9DEOGK-IH47;3B-3^)_I<>]?!O*5@QFN"SQX9
M=>R$393IV%BCFU%XCP0RQ^Y/9)E]F]L9TM <,=5QKA'2B74.>3;@O+!3M%DB
M24YA_QFR%&?Y^DI'EN&3E]\.XR%^+I)"/RKC&87B+U^]S^_1D64D2P<"*8!8
M;HGOI%)9RFB@1!Y\$K6U&G/T-'EQ\3#L;6VLG:)\GW_A:CDYP5ZYQWVOK$OC
MHD[*J,^8]UCO83Z5^1TAXW?8<2 I1,NRS[Z$I+1IISME:"6>9LK^X'872&DA
M83^4V!XP\J]5ED%N%#WF90U"/*_/VRV (&Z<H)-I8M%9U7W%/MV5G[SQ0</X
M79=PR(=D" J#=SX@YR3J'7/NLU)XW* ZR.:Q>3W2@R;&]UU+ =4F%W(#K6<M
M,QD5<2QO;GE^^-6IEGGGHWW&D%X9\HU+H&92<+&8+=<UP4U$FA;5?AE%YD@C
MWFZ@-&)@4&:$<OB6KOS3QCM63@>$=_UV=N>WDS_RQVWN='P^P_!!B^\^^J^!
M!A!DZM2^M]*M7/A/@ 2-*59Y]$%UIB.SS"G196J7#TLB7? )UOYU-VG\/?(Z
M$C=V\HY7:TN##C&A'+#@0=B U-Z.[;N;DX$^]AE3*K_3-V>F9(]7+=)UXXKY
MG^>>DTG4TY7=\G7_#Q!SHS+QG&BB2N#Q?M311 =>SB$+^-VV49UB!S6O<*UB
M(7OX8M6'2+XOBA=Q.T_<>$1*G0,$_OO@CSH426EV5I94C??1YST'?3RLGR[=
M^U/W' AUOV9A+0"6 BA 8QIHD1!X%3G^!7MD";.J?/)HW;8D9]\5DE2Z8-#:
M$O[VNX&1MAD"F#F#(0">5E&3:/VA7#QK<X;<#@S&M_Z:8%3+[@JMDOZ$-\U2
M.1U-L+S]X+&$D/4I=='E!-(5P/GYMF*KW3H3+L(R%2L3 90#L[ZJ_A*@HA@G
M:]XU0?YD*WRFK9"S9.ZQ2&3SH4F(*)D_5;47@S=0O6_/NJ0YUR?KLI-V/P&6
M%#+M)MVOLNC3[@<PT2XQB%*HQ@PW: -\8'EC1-RV3-IZ3<XH2QCNU_[?4?=0
MS<;)43>)S=^<7+]6Z-%,$>EO/K6$?K2[YE_M,EMW4!79SQ,96AZE]V]=![7+
MRT 70IPPSC0020C:+#UICE/%1B"D<<AS"&6"^D>)(ZG*KXX>)@T&8:>,5KJ?
MN0HY@YH/;ITI>S\]MEN/GYIGC8*\QL2]A43)^/'I$/2"*QVV<+-W%Z>GNC+B
M:UNEEFYVPU\^5N$]WJ7R95//N]! ]_1BH23'*X#\]D8DS+N-:Q)C"1%1LLSF
MSTA@0K#+PQ>UB3O+C_"J9.V=7^W3H8]/?Y/0:GG'< ^4_U'_>T3H]_F"#GU_
M&-)R,_N2MUG*=??"T%RQ+K>MJ2'86L(JP.?$ST/.$)NHICL!J;\'7^%MX/T;
M [KUB-.=FVF7=!N6X,S56#<GZ@N$QX*N_?Q*FX"!U:B4:Z6E?YOQH)7EDXW!
M'D^5$M-X+0DMFRW8P9 ^'A/9 (0D_>(:+R2R8N;A@[$*3/C!I3$?I8RD*8O)
MT-FO\E'!9?(I(+YPOS,A6+P-+O\##<24V@)QVFGJHU3:+Q_6[!#]5NM]X!UW
MTPG1RW-UM_(*M94FC0Z%"Z/%?Q=F\3C"L<O]?Z6IYP ".W.?I'4L@S@_,-8Y
MRX#O3VBZZF04HU;KC39Y^-U\HE\H6[6XX0U]I":'U, 5ONEMYS#WF!TPF;N?
M>NX4#A($H;<AM>/S[X>T$.L,AXV:K@T6Y[R?J/!4:F?NU<]HN<Y^1Z,[]UG$
M<TZY>2!X1G9\R=PW9Y51I&MZ[4N),A_4DY/>];SG\69ZSCI\D5$UDFNW-M ^
M"C[^U"!P+]'IR+3>Y1"L^VE)P?!=AD*SE$E51F6=,79W"ZF,_7]UM,H:P9=P
MXPCR9T?A+LD[P'B-4U\=X4?,WTD#2)4-H)UW9*\3.P:D\FKW/,8?B7N'W8F"
MA-) !Y<!7NG;#SR'_'_>)/%N@^Y(Y:Z#*==0F?_;[L=R)UG@QLDJ*!Y)29J2
MIB@Z>2\"_/D(0A)]"MB*LV<I>6YSA!"5)@:\X5<GWLJ/\M)N<GF#MTU<6O-[
M2\O%N>WL7 K#;IK<VD\@*1E0G]/A:*!CT2KHT9OA]3$,;LC_<>;ZPO FIXN*
MXQQI\$'VFT*!)S\8OITI2%3>% RN.FK[NUB0*V_?C>%V&^Y<PZ-12MY<8W>'
M!J![:FND"6#>72B9@5+D"\,JW/;X_A8UCA0''F?O1F'M:&8#O30&6XS#LVL?
MQ?D_?IBPN, V!.YM*LW3^NIT8/2F3*;*4T7JV9+.C2L+4]'45O%#;M(^#72M
MOP-%%&BB@08C2@*YVEZ@*F(7)P?6=Y5J6IFT4649"CG[9N(N,/#0 9D#V>$+
MN8A\*1VB5+F\W%"+]_E47B^WG#PXJ3#YP%W1.K=TRD=QW6H$J@9 F!AFB0]Y
M%K)A ,#]@'53,#JA7:2P3VI[5VV*?JJUN:EGYSSU%097-KG?'PF 9CZ61THJ
MYXZ.8"W14"0I<BY8S(8_:8!-\Y_.RY>Y*"ICNV[ V!^3/.1;^TDWC=MX3#\7
MD]6YPDN=33*F;"NBP! Q?AW^?VQ43B6E+_Q5>*IEG8/:H7X[;+H5 W]<2<9F
MJY$ (#?T2H,C7R.CN7O.%R]U1LT%FR*C!I5?V!IL7(A'XC0P+\0)*U1F?1+V
MM015'"'_.5GV-+'I6KGE^N>OG1,E+-/VBV[EGHD0?S*D_>BP&&84R#=0LB^@
ML36F-[1'LEI>6ULVC.9S^*"C$K]QS]#P3(H(Z-3U!O+1'9.CU!WRA[_XC?F=
M-1<OO5V[ G((T!QTA;G!7'_PVX2)A>,WT^N79MTOV_"8RTWJN3/^ZG^2;B,*
MR8.6)VR&X3N)M?CC-2B+"NPKO&"6BUG&I^QC7=69TRKC_!*E*\+;_ZS$_S.V
MB"8+Z!(&^]L@EZG<9.4*^&(=ONFS;['3V6O&DV,)_!X:K3P:AI6^S2I%?]WI
MSTU=S7ZN&"LTI&M% WG>GK\YO)3R5-\Q'V9NOI8 Y!D.J^MZLN<4_ ,A%WQI
M2C"7OMA%H>OPO:/OF_B(XP&T1;RJN^:VWF;SL37)GLA!2:_$1&:*FDJY[.&O
ME/Z(JNHIL%)#I'DY"]1'BE2QC!@Y"]1 HJ!X%^-6/@P?LOGQU=$YA\&QYB8!
MS+ 4D]H@U<%<W?"RHF+-S#@H(GW.Y-]%>=+L"#V@"<%.F:"F&A/R7?SOP4%F
MJ4&),#_7C<VME1K$_H?8[V#^,V&W3DF83_7^N-WQNC2'J*]+V28/X.S\0G\H
M/BJ47+J>O6Z'[N[%2X<'GB%E &'TCE)'[5===Q(4)S3N6JWY[K"/'LDF_M@5
M.=_?=E'C0<[]L@=?I;2XC@"]RL <V$_EH:1 <.FH,U0P26U4!\)"LFG3=7%*
M5#NTO3XZMYBB\9->2\3W0R3HDL]/NJ =;C)[/_7\W%P_Z;IQB#?)A<J*;+&;
M3V#_7>Q7HC5O6&I7??^X'KYPS!_VC+T7JSC=QDX_<AI+YM*C,CVD@5CODO3G
M,$PT4 N@;$)%J6R;)FLH1^#/B&.=39ZP^8GRC3^;QX>_]9[8-/H:9<=D*J$D
M)+7YG.K-B(WDE C40[:0\--HF6VSO".U@\I--WGTHA?T/Q3B'SND) !I3[:G
M,%2!L6,M><#PJR/G;LWD3#LB7U*'3GZ Q6P@@VJ?+*TGG3?K.6R-04)P*1C\
MLWZ2'W2#4@1?I[*QD@ -589X*!="!&]"-Z7E>ZJJ4'V[*I]*414N4Q4+K]]X
M!LU[:+!45QWU-?9<"Y ?RUOYXYXIE_#CJ))R7 U3K5BOG@^XH<YIW(5ZR96Z
M@.3[2P,Q-US]#@]IXTW.3/CZE[A]<AB[6#2?R7N[C$]X$)?!/.JD((N=Y%=(
M*F__TI@9,C=#/U."1I>@G-TU%([*V1\4?)/H;7[!?@_RFP8B<R50F;CF^TEB
MD)AM%>6L/K\Y;*B/_/E17@B3W+>!I*HU0FJ*]=.YB]<5\!B_X5\!3] W"^,R
MLG.,MLD-_<)ROV^\=)PUZ]K &"_*4YD4@<#1<R.)5;<?"T!:?^C:X*>:$[6_
MW.D7G(I[:OPS<>=^[#\O"]CO=G_K:KU[BMA/YE,'P/J@ 2\85$!^2S",':W.
M%*I0,@YSV;HZV?.Z%ZVZQ>-Y//@AQS4'$>Q:*/1E9YLDC"9??+ PW_96NMTM
MKLK !&[[N-I,,]35I5NW6&Q)M+Z+7OF-NY%0?2Y_1BE.ZQCFZ,@55N1^G].]
M^3SC0KSL^=)OET&G?H(\@JQ&/3[K9S\\AC"4#6"&^IHP'G.+M99O20F;$J[;
M+S"BBZGJN_MD!)!E95(BYLAW'\[Q/]J<9[!E6'H-GGC'KJJQ$+(5 %M!D^3\
MJ<^U1"G1;R.HL=7H'  7-L L/9YSD*"C,M3T^,RZ4?PM1<?$]K&FM_=FZO?Y
M[9<A)#FT07PK];RY&T=A2B.^(_O\2W?&G9R5*48DO[$/AT745 5&SH_4IQ $
M/<P^%#[B0B\:+Z2S39*=":'Z0IW\;Y?6OHI-%IS9 M']X*)X&^^P$N3;].&8
M>;U(69A'I*SNT^6MV_U,(D4+WQBRMA@&:^&:\P44B $Z3HU7APS-HMQ -G/L
MWY"%DJ[E-Z_:&AI9WH1K#'2P[WB!XSGM9YORT.D0W/LFWK06)/X)-IA8_J!J
M6SI\KN'\Q1(C'\>1'_>.>ZXX'_Q^XYFTBJUDV'R(ZQ_?Q?TN7, (K'W/_?O6
M;//4/5C,:J2R).Y)PAW[YA8\Z.RG@L);A^D6%@3/6*ZII.K9 ",6[4R6]+R-
MCX;410<$@G0X!YE(F%,K77#C@UTZ$HWP>HR8BHEZ:IJ@'B_+WQ _;JC>97V/
MBSR";-;#X++,,&1.&/$#JKU:SB4'[JL3<:S<>F3#Y2@I27=I1IR%U_1RJNL_
MMF(B8M=7R)R:P$@3.*CGH01KN>&X]M0P%[?'>&P8(-/]!#XCA%(FZ?3<6X,W
M6*6:3]^8@F9#\8!A(UW)03*YRH!CD+P;@PMMT87^V7"-^0N=V1AF@?99O3YW
MI2(1:^'@MJZ=SOU/*I+\>:FC'D_W!7OVH(53^R2RZYTF3_.U&G4GF \-)'\D
M.4O-!,"*_F2G6'4;8HN<*#CN%+Q9^J6_ \N!2 N!>;"FRB7G:UQN9A(7\TK4
M\/W0X7X_]"+O7=0?)S% %LSG1Q;?')I!.8:TM#)KR-S8P.117T$_8O!0"$GB
M4A+.[0P\"0=N+?SE+<V^[JZ6-M]G=(F5)<&5!I(8%?-C]1!RC7\Z('R'!BH2
M[>X!Z&(0V>PK%<B_-AG1@@SZ,JA98GYWDA33;E1O>TSW!NWXNHUMA>5AKV)L
M[%46)M$50-:84\^Y+6!(-_3:5E-&=>+HFJLNV(TB]+Q=AS1BM=J>!1O_SHA4
MH3^E81IY^##@NL''!Q\#&^,&Q5^@<-B_=53D[?05@V+(MY>JJZI\T&AHX>JA
M [*9'TB53%\:J+I_TSQO"FLZS1I!Y?@@"V&?/33_ZF7PJ:C93LS*]Y1V)J)4
M_,)F,S5UO1]C1P--()M1I2O-&>(_,\\,)NG\V:N<UKDXQCUT47[Z*4G0MC\H
M!0<Z_<W04/^O[.(*3UK'Z+*9ND/J^JYJ;-(-$UY^M*FJ.47UHA&D30_D"+FD
M!EYOXB*<S2>&A\Q;JBUH#Q<CQF(VY88Z!G0$]VZNU_*$+UT-?\.H,MK.M71]
MJ$XU/,G(?C<) +IMROLF 6H[JHHUG"R.[V_%X.,<E")"BKU--P.QGG[+%HV;
M>[K7CZ-$/#Z&WZZXB)'R2-3:0Y/D440ZP)6\ =AKE@8*RYV#D+0A<]S4#FHO
M#125NY0PT30 1(DR574YP6=;2+HQW66!1Q&"6]4[?,P****-S GD:H\!&C!G
M(;K(90QRNIX&JM4^/AJ/+KQ&+-#[TF->3]8I65GAO#6<Z;]A82PYFV)$@NHF
M_)&.X^T/0>*2H/BG_1Q8N/##"!T\MK51:MF%0^?+O']-TX2G>P>G;XJ!N/"L
M1<GVK*WX^T9.XUU9UTQ1RM>F6U/MUSJRYO4NPZ>,'C\JK^_W_C8[W<WIJE*N
M_&MA.!%V0 -1613BE_5(UVB@R OL0H^^S'YR/<7?!<X$T<77=PM.T_7;D#H!
MO$_:@<PM(<\V#2SY(?$?S6UZ.V8.E94.9JH%=F,]3?#;M:&%T6^[JI&)F.6^
MFC1LQV"+Y)7$,DNIS4.1P+G DZ-/'F*#D&7;K0)JG6V"3/BQMH1+JDTSQJ8$
MEO14PK1VVUT_N5VW:,[GM^J- V>+M)S)GL!T ;8@^!8)/"?_<PH=BV*L4"#?
MI8$8-TI9V1U\PB8'_1WY-:1P#\R[X3/9+#&1O7:H\_JQJ-*1.0C>8"I.;HIZ
M;HA06VG_>!,PY2\>M+VSASF>H8M_\_IVT'A2/P\ZH_GUI^28.$VYK9&1@_I)
M;*K-VNV)IURX):W[XJ+V+@8Z_MOKTV3 ^@:+4B?,(C8"CN$D_8;U"'Q_?(DU
M_G>M0V@R?$OD17A 0]R?7OV=4RZ93A?\PC&YW=3[U,N'0)?+&E2)4.5-R*3/
MK'$RZB[R2[W/0OK*Y4Y%]/I\HY5$]N61,/6&)$PW=AE.YC-[GOT\:5)2=A=S
M>)93'RH2\($<0WY+ R6N+.@=LV"1JP_']E# 3 #P\/'5R9;"CXN  1DTWGU%
M6*?JH.(@&\H!-% N*W0026:KI^I'X&'4GX#PTM2"^K:#MSY2C!?[^^$Z%&)^
M-GF E/0_93)5B'^7R7PN@HT"F?T.@M=!,E(GJ4($Z00UX8F2RCDPX_2UL+Q8
M*:MKF"8[=E?4Z\OMO%Q7'X(V?LJ]N%.=B/S/K47ADZU%%R&]<>$.SR+]HATX
M=4O^O=AT=YU/^@N.X7>FD0+58 /S!0^.[*26%S,H"4/JXU:Z\'RHTG?>@E5M
MU]FXS#"@;< \!VL@V @K&\8+XFAF$D-+X%D".'A/IQ&F-;PG*27.8Z;CP N]
MB6LK7-$4ZOSQ69YKV@0Q@\R8$3:J_2,+,U]7_#*[TVV;><YX6V/MH3BK^SU9
M"BQPD ;:<85<A&R8#R/W4K2ICV%J@#7\KNWQ;:K<?+T6S?UJ=;#XJ=>@;KZ_
M8RD%;H5X6CJ@=E%G05+7K%^W?.!WI0^=VZT'/P[[^WE:0OIY.IVHSY .T+BZ
MSDUA0F>[E<I8CJ,LE,O)P(F#/F#VF<\U&P:Z)?7)F)]SFJ<Q>=*3+;,Z&-*U
MA+::KW&+*7IA9E^%A+;L;7*T072U:LGD>A)R S,U"@$<80*X0I,8CUD[8,;Z
MHNHSTT=5;FC?,/P^NHJ(JVFI2,O5RTT[_(M\ ,7K0DE"D&8:* A5OA*^#Q&$
MB[8&JA&(E78"Q.^^13]EQ95]DN4E+MX7VPD6JI+_*-67:,['A5"F,IT"0HE5
M+[*Z28"@M[& LY3K-*EO\+=$/BQOJAXJ,KH^O>K'Z7E'4W"T^XY&:WB",U+\
M"\7^:Y-KID=T&++(TY+H6YU;#]8W$&G18]VWYTSUAAUA,9X[_51&(+3.-%"R
M,#@4IN)Z82&\Q(UQDL3=SFLPN:Z$4"J<MI 9D%LWU6>3XV'[<C\%P;B<2OHA
M+O^?2\]'C="/$+QW*OE]?RC@XQL!'^]5LE'/HV+D^+12!]HSD!EH'Y0?VNVD
MG^OOMSX"%D VUT!VDOI8J3_-4-0H]#B:))% SF9=D*:\2Z#&QV,$D/]Y),B&
M,?F2)I HA%3J3TT@430M/Z^0XQR14YC/K>^1O[ZB*<!3<[(/.T[>)5Q<;[I,
M XU/Y"(!Z45Q--XQ/A:UT'0\-D#(I!@_GD]H-S.OKYW\=G;Z4:+_*>AHKC$W
MDAV533G;C&HM7,,8$(RI+#5 ![_CW:C-9JG4^.H2/2HSE 9*:B<!\6X-0ZYZ
M%WMA\=[%Y.<(:Q+$J?B8Y.7RP-A"D"L_\D;_4VWYI;T2^_^ZPGN(!OK W44#
MK6IRZ1V*!<)H("W-(0S>"[S)YX?'$@WQ;JV;:N:%CFI":[MZ?B+/RR2J?&[P
MJ4@PS#++MI>_\3@NB5 $IT+QVN#Q&X!"PU;^3L--]<04LC*MII3!U*[65]V\
M'O_[3N%2AWG"'2W;Z%M^DP(HV)F;@0- FA>WH?!55);$KB6DK=/5%]*]K!DL
M6HJ+@K=NW0[IZK^,Q3M5 R/'K$A0]DTFHDCJ\SN["7?M)X=\E!>4[TXI!WS'
MY>$GQ MUYLN1<ILD(0^\2=&^?B%^1MSOFC]BXLCOI#C@ ^6+-S@B9LY/C0G.
MYC7R(-BAZ(Q9/,O&\O[C.M%EA>L6\;?_V!R>_'Q5<!ZUM1BX@D+Y(8NF,[?0
M\YL[_B0\LL>SXC*D]>JNTC_O-Y_]3N#_D)A]IC/S;A!%W7@.0A: N/%2)S"L
M2VS_)),O1?[F7K;C'K,]'4"_$ 08A;ZY!A?[:*)GDF-^?5-COWFTN\PEULF6
M&PJ5954).@*^_WDLR LD[B]JLO[9&%4&KHDCH@)DWHI&5.R/><.\6*(\_)7O
MM(CTLRX]2/L8%$1,[1)YY89L_@8@DJ':'>2XN"X YV-<NV R/_/)(K@1)"I&
M 7E3P2NL>CKM?L+QS3_I_&_D4U<RWRA;-VI[V:CLN$)?RY/9*7I"N8X/KP0G
M3";I#6Y2([XAFS%@_!/4N<!)J[L$XW@UH54::,J*#0_3M('EJL3Q*\5M?.M]
M4N]N*J1;7'&K1\G^YOGJOZED3D\J8S8^@1A+R93%D.ZK,,VA3I$.U,M3=A_5
MX;>2F4-]RS5B>V JSPJ*HFZT;$U:GC,Z\TX?<Q5(IX1)36(+217O_WP(8C^C
MW#F6R8PR35G;W].C4R\QC[O7?/H7[^N*3X6'6O0&[B N!;ZR@-;_PV+X4PA3
M7*;TE$'QY=RR-TZS!3-ODU,7;MUJ/C[_\=KU Z<;V('9(R\U#DHJ#>1@Z4G4
MI_S3<(W T5H<9][R-M@JQZY;<AA1-+JE>?5:5$Y4Z>\)7DS1#(-%!4$MPOZ[
MXV[N2'S6:8NI)R@?DQF #ZQSP!V8Y)X$DBAZ\ZRGAT@<7GH!Y'BY]!PNXSXG
M1S_H'DCPYTOCO<;CBXY?JJ*.+Y&OEH\5;<M0WO0W*\DHQ17/U%;75-6:7S8R
M68Q[)[8V%_3\U'/&G^UO",9E7_*?,\L7#!U12[SQR,J0[]J.N=G&EH"ED*[9
M/R_VM4GF.(201/P")) #58+\DE0_W\]C1C;!6]46P+,-ZT;R [1;5IYB10:[
MKLY?O:6?HA_VZ]ECNO-W#Z2;I4DB*QL#QP+DB]41;58,)#\@X%]/_*SKCVJ
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M'B6++R0PK.(?CTZJI1]X\$W%!O$]]1 4UD\1XPFY]>Q-+<.:WN0848\2J<*
MGU^_1XJ:VPYN.A7[X+2.<\I;M7*><4,KN4C)ME@ZUV:6R^]ZBZ/)FJ0Q0/,*
M4;(A+FB>XLS<A83+3L^A%G<G_@J"[YB9TQTD"U=5=7XNU>!L.@"QFR2V[:,8
M(+@P5,5!![2\A[L5AF8>G]8H"\AODW=?;7KFFI;EL]N,6T(TQ.-L[3<*7XK7
MWJS9T!/?J#BNA'[ DQ MP3'9[UIJ2S:AVP-4^ZZWH;?-H?T"#5B'8$4>F]17
M>K+WYZHR-3055,6/&B@1*NK2L1!K5,A114^5BT&SDN1TB'!X8@NW*DA [R6@
M6[^N\]I^N8[VMA<7UK&_V[+$\J(LD46U!KU6^*^Z>S'J2=V][<%)W;U+H]XE
M(*W3=I$?$'Q(%WT_Z5XJH%EP7R$[[\'Q*.*S2AJ(HFAA/(3%:Z!)0IMH,J=Q
MZ]%*',*E9%T0C!?\ )_4K7.D%\$,E[3!A#?]] <5%M@U$VU<EJ+C<K70GY#_
M=:=M;C+?>M:D(P2O10.%5U_"B]QU2EH;DW^BU'=E1&K^0@"Y)AOZ-7JCCY!\
M:P)Q36NB7IP(N(2LUD2<HW4Y3TM9G<7OF?WJ-67J.<#%GGF-SR=S(!>P<2JO
MYF@@#IB@4!6!/IDE.4_]NSK[C..?SPU388F/6XKJ)\6MB[X+RBG<?,-(#@3"
MD$P#=9NK22"GP330DU%9BNC8[JO_]F"=<PVZVJ35%P5;ATA1CJGY6$D)->AY
M+\-4R'*.?P*9;PEH0BU><S,&'!,H1-8>3&L3Y,<O3?Z==$T65O&I-GXMFV)J
M:VLGN93==CI@:,5V!60\A,)#W4C7QUKTS@>V*%6WN='#65L"&0C<06[..7<=
ME+S>.D'-+2PZG?!=G#=+?_GV\T78S389T8%ZBT>1S3]&V0#(:5;:CQ*V1'LO
MP [M%$4]F<Q%^JN["Q3VT/K_TS,1ZK][IB<GFRDL8+F\IO*[6\OLR&P5TC#$
MG/K'5#SU9GV(;U5U.0PJ?/@3GQ"VK>(QWR>M/I2]6\ELO27.!XP 1J*$C6&^
M]RQ2&ULN3V;S)092,M4NFL%=#^:VPQ"^!;)EG=]A34*#68T-F-3E&2&_H+":
MGO>%;&?$GI3?V8;T8\@<RX/B@-;!XD(YVOG_Z"Y0Z!6%/SR4B/:^?.J,(*-P
M+"^UN+ \NM3PY9PV<VZASYJ'>SA+\N/APN<W&MF;JK:0$B<OO&]/^.M2XC"N
MZ$@PJ]=M#TI(]DRK1]ZYC!S;JMKJZ&69V9_<X]=V#O@3GRTF)2)?(G'C;IRS
M\!#JN8FB24NMY8=9I%EJQP!R)5T79N>N22%G/B2-+1^0^95/WB0G]%/@CM"C
M^V<#(Y'_65AK;L\E\.0K1V;Q#B8C]HV94Z;G\W09K2Y$R;\+;.W_:BX >E7]
M6%8RLQZ/G=]/KBN8[10-\S8%"=^Y?ISVA"CRO?Y,.K]&]GLU,R0@O3MK*C""
M9'V2O1^\>3]&&<KFF+)Q[]F?N_>]C.--4V VL7N1[Q6L(?<@N KP*5'*5^1)
M63)'A3\?LF)M4C<81KRB89L4\/&[QQ7U,W:SEY=C69[:XCB"H*' *&EB)CFI
M?5"\?D*XV6(:IGQ?]8D#]YHPZW':'Y?JM^0$(:V=W>.&EXO?CYWICF;UE5CA
MLUA)XT,PPR?T]Y47Z\7Y,#)EC&H_@L)[I7;JD7203GIT</K9+4=)!%^6+*57
M6:Z3:V0Q??>=:<.GJXI=S\!T#'!T;X#:T6[+45_Q4KVN?8"]B*_1C@U,HY4E
M_BX-=.JE/\$*R,BSLJ0ET4V +<Z>)F7-QYAWR<8H;P::,]]\$>.6X>BJ7EG5
MUN%N$\6(N\N1*,]A!>33V4%*6#'2&L./$(C0JPZ2W(><-ETU/KCU?6=[7U71
MB.ESR,5STPG.?CP\ J= _G"&"[(W%4S=1*@4[#)<,3KS9B7"UB<&ZCD0J+F)
MCJ*!G.L%N*GGL!Z$2>G2"@@^E)5SJN7-@,JVP[7X:=S*Y\\VPE>"W1]?^4!N
M0\C@K]<>:R+<_I#EK:V.VZSD1[-*H[ \*?/++^O'TT'R:EHB_XN]]PQJ\FO7
M1Z."*,50I)>@@$B7)B!(1$1 1!2DERA%0)JH%"4D"M)+! 0$A/P4Z272I8;>
MBX" A!(20*5$$I 02.$?WO_^LO?[SIP]Y^LY'S+/3";E6<^ZRW6MM>[K!JB9
M'F_[29HA+,CTT43'<* 8@8-W?A4NH9UP#NQ-],:=7-]# ,8P^.9-$1\-5FWY
M M/^($WXTIS*[" H$=(P%UI]<'%UDB'BS?<XMOJZM&U+#EWDV!B@=$"C=/[M
MM\J3,(\=M0,%E:Z9"N6DN7&O-O*8E5JWWA!?S$>)$LC4.F,%,8>, P$UL&\@
M59=;<5?%W1$F1'2$LD8._]N((=;62",A:8!Z'=LUMB^HE0-TQ18&PC#OP[/1
M$UXB&*D#D $NMTY+?TW'/V@KF%J\U>=,SP/0][_PZKW7<!_LC[1VES.4N(^'
M@$Y#W("&^052A?Y<H'>66[UY4MMI'LK <C#PB<_^,#/&)#&1SEY[P%PF/B2R
M1;;H$. 1^JP+,U__,KP(*7T(\(QE[=Q*R9I#V;B&;QP\HV>#5^:/%!%_-!3!
MUQ2#:,SLVN$"7[T %@%ONB/WE=RZ^&5WL]_](3PB3.PY_/B-'[Q[4"&?X31S
MBSP]_=*)SL+\R_/P#CG&,<8,^LL4*A%V/A3(X 7Q#%0LSM9AR8OYWN_SY:J"
M#9[$]5KH/@U+@_C#.QSU=#R7F$B7>3\]SE+F,9L'L$S<^TV"Z^+8JI%H9VSS
M^PSMNR=-I?<T5\%$OQA:_I4A1J^YV7Z?2Q_3"E/^M:SG<0CXPL/D@>,S.8DH
MRQ=(Z16,U;C6IYDBM^\=#]<,Y7^]L?07J4U?1,!^[0 # F06N@.-1 <4$WEX
M!)_I2OQK&8E^CM$-(MX 1L!K@)U7+XSUN+ 14=TJHJ:/\AVF@H9DOA-6O_J5
M;P1PKKLE:SZL$[I9>1_:ISA%VZ:Q'BTV+J&I9WX< M:NV^Z.NXSQNY9.WE^;
M]),-)DQ/ZRES=TP4KUN7G,54VZZ%(<<L:&(@ZNE06;(ZO0"J7AQZO/,JT(#T
M,TMI/EM/9UM1^9^WTDEG8)O^*.'9T6E@HIPUY/[1804]QR!/J@G-\ENJ*6MR
M :Y89?4:5L&4=>(3K^Y;9?>.,5$$2KSOOYU8SF+.7QF3*(>BN=&;Y@%TY;J*
MJ^6E*]!=\06TG#WL)FQ0X]DN^^/!C0#M!8;GG[JS]R LL-C0K:-=I'MTTB1C
MX _ZJ/0HGF'E<U#]G[5]PF=.,9%)42D-,?9UB/*=#OH)?WB%W.B-2SJS8_E=
MULQ17)^ML3&+L7GO4\8C_0X#<!1<#EZ/)EA7P#"@VKYXV#D?*R?5:?^Y38&)
M_N&F\.Q4R=<GU/W86]X6B6:-O60P@ZO_^S^/Z+$,U8(/<5S+H2 '._&^P531
MT^2TCB6Q8/ MAL6&!$\^:-$Z['<29; %'6+D5T8' [_3F58580#O ,*$*6!R
M"'&F&QC?)EA%:F""$(^3*/[H&G_WJF^$@GO2=\.SD@=DY*T_>]]/EWU@W26X
M=M2\!$Z\CHT&BS'8?#![G6-LOQELE(1/<W6[[ZZ(%\V6[[[F?>8U70545"_%
MB6AP_?0;.)<#_J?)8A9>70'K(L._[)N2X5(2MIFO&QXM7EX6ZA,JX]_9'B%9
M\.PFAX01PI4P"XC/R69O[ +*GBHXAOG ]O[ 92#56((H'CBKLGP(B&H[%_K(
M$W&?.$(+<3%)R4\^X Y4JGWS;'5(V&L.U/E+#(_^.$:1M^CT Y/_,D=Z/S1[
MS[CAA0SR6F3O(HAZ374XB?,ZP?;QRHM4QRS7CO[A5F-.\ >5^ 8!+?A9/5/E
MG/.FA0.ESE?S/RJB>-+CN2VD^?LNH(O&*#(H#!HWCV1IFR4C=!G<"UH!N;F+
MD+=M+NJC"SG!Y+G$P/@#F#1]+C^!R41HH(WO^_H"K=:.;"I1*(H@HQDT!J3Q
M[BROP&N,"51B0T^#UEB1=SUFWL;A'2Y$,3A3<NZ._9.GGW3LDX\];%"(!B#F
MMBC:ALLQ-#DDY8)Q@M*Y;)^P0X XQ)[R>-JD%SYMXIEKP?*PHJ*2[T/XGS.!
MR [D7.22TMAF!]69=H,HWGV!G_BG,9"K>/OV>3.; #7,M3>II42].R=-NCAY
M=< N3!?P P=,TU%H3R:=K)S0)?N4C7%HQ;48^*S(P[L[YC8]DK'OCLG4S1H=
M@YD:\D3?O5+U0S.N!T?BF4-]VLM<#URE_(KN<'TR.>%\%=+$( #'^!M2*C#W
M1-^G1*A'[5LGF[ <Y!:=^'%@NX6DB8J3^A@";)NRY:%77N3^:0-1HKT^)GZ(
M)2BW?T5(9+U?")Q,W-.F42@65/8>/)PBN=4=$(_U:,AT:B#E%A8]WN#9B8HJ
M]%TP3)D,(G151S9PEPP\?'TDF4MG_*A'5B.ZMQ*32ET, XJ<*,?W7*)/9]5C
M7=9>C9V]!L1?&GA^TT3OP=-VD5&EQ,[[25>=9 *RCS9B>U)W'E35%MD::6-7
MM@)ZI$;A2TWH6FELK2#M;$W?R$\%;P9[BIZLZ\>$%S[>7V^?/@2@BAJUA7HW
MGQK([J8QN*;IV6/M:(IL1@Z>HU]$"8*WIF%HS;&*]5W<CBIB?JJ]'N(66Z,6
M1$2'170>YPSX,1*C;O@-]GU/_SPE"B_DN[CV3=4GH?E5A<*QUTD3 E<!PK\5
M#GHI\*5P+1SBU5\++B^B4F4*;N.4QI#0-8 ABVIY8''[B:B[VH! %T\>\X?$
M=U\"]P]4=I@ R3;:N^6.6N456/!NP%\'Z,A+A?WG_R*!QRF[!5 /4E %JG<K
MH7ZZ'C.U<K=+,#'H;+*T_;Q\:=P7  # !F#_"<;AP;5 NN#1\IG#8PCM9>-R
M9U VNA;R[(I,[WVKAAKX2_ _*(H2B'#N!545WJ$#D]QP<)JQ.9BN\\\#3?YJ
M>":6L>W<\&X[1BQ?^H*MC=@?ZPZ6%;@.O,:BW0]"_DBA,\%&DZBQ1!&><$=<
M7^>S</*4?=N+#T$*(B>?LDF?Z[W#"GL/6W#1);%U,Y/>96:@Z6W%*SVS(IVL
M*P[-DVW[KFF6I:*B3+I0G-!D+U3UX#AG54!ZX&_C0231 'ET5/H'@S>\9I-A
MD5-"V*EJ&&8,M&Z3\K0"YAK:-MT^V):D31X4GJS-)QD-'0)D'"1L@FPWWA]P
M9Z2D1B/Q+QGPUU0_(IAQ"DN]0A.@& ?@[/6%*!8]EN%IFWO9O:V%AN$E+HTL
M>FW/2KSL,J1?R!PG-8C>!)\'+[6@B;=5@(P.N(">+M[BV/5IV D2?CC%&Z4^
MC+FZJ<N94J9O&C5MY#ZD?KPZ,NHT\K<K6@F^M!X6.D>VIWC*)7&6X$MXG%##
M_V!NF;!](P@? &\1G^IU<9/&+=,>V[9B4_[J&63@IH_?X3;MG:[>,>X$$P,$
M:046[=A=7"DSK[+L'AQ)F^S2J^J L^ID_I:Z;RJ/JDC&W1SC.*K<4DBRCXF#
M5BK^>9"'_/6+U]I313R6$E/VF=SU) D^>)_&=0AP$4$QWEI 7. =/^[-(SEI
M7$$IK-D+/C[R/#L:48J7>?JNL63]HL2P-52]OY?D]/.=;%T:M1'Y.[31[\6]
M_HT[H@LH=#JLZ*?*I@Q5YC&D 4BPPH&CF_PFUY9=<C';-,-?7/K3%S'VA0IO
M3Y]Z<U'Z9+#1V+#"@>3_BZ6GB__[4_%ZYLGE5>R)TA.F5S6F<N<5,K]E",]\
ML$KS>XQR1_S",C@ZF/^>/PY_"!;ZW:9#@;-,H\_0'CZ9-B_2-;TTKC+%L6\F
MY?Y^U2C8Z)$BYU-$T\FK; RN!'JUILI):/B,/L<Z[X*SEX1:79K-A%6@Q^06
MX5OM5^'.\F\GYU_H5N !3WO;VIC0)$M9\:@AJO_U!LOS\^;XA:N*7;P<0ZOS
MO&PEV]U%;%_T_U6IRP*FVM*NFC&S\@_&^"^XE[/_]K/F(2KK6-:'9PV/" OU
MO_0>M8IIFKJIQ5'#'2P@YE9Z\];:2S7%X1 C67'!O5JO P3C3.E,$ <"XX:#
M94FGY2J/=?$Y.WY\M#WM[9_K(:_>$&CW<."$-.OH-:<70!J/11^\VC.R#LT#
M[[KA_1*Z*/4"YW=RQ[DFFWK3[MH^WNNNANOU'ZZ3'YW_ 0R&L-'?''4JAG>H
MZS$Y)ZL"1=7[\R+D<@S^$,!9.R,A-D6<,/:1_JCWXU$B*$\86MS%LR-G].".
M,(@X1GY_5%G#&$=6_\)4!ED (*%I1G4[=NN+PF!,?:\VXV]Y"D)?>F['/T-Z
M&;S@>],JOLOUD@*;W+:I=W[-X@%8O[A\F2V^ZQ%05 1*>KE>65]?5M $-B2+
M+N\=-65TI+?!6"BI,[C@!&+>3/?T01@7R(GH-#U-7-M+3)P>>:+X%,&GQ2DN
M]&ZA@9,_<P4]6\3@^D2I((;A9][H>8![4"=_-S5$[>HZ.UR>K-U(NF:DH2[]
MZIALJC0D,Q\ O'[)'&;2H5^P-!(H$[=5FWMK)%*JQ$OV3<I; ]R[)<;--C)S
M="_A'7"&/&RD36_R.38.\Q-%DL+M=L]I @G"7--5KN7\T-_*8EMO"^?WGZK:
ML+Z2'VGQLU(:OO37Z<G4B\Q'=7]MFVB)WC^S@B_4>B3D]U-[UM8)GOO(1G1=
M45\8?#:![$'"=G-$)5M0;OQUS+TN]/EF4%Y0XKXJ=PMN]6)6_XE@4P O.-V,
MF0AY&-_@@M"-C:&*9STPM:EK&3]7A\S"0@(OBKX_J$$'.##BP$L-#(68'C#1
M&!GW<O3UTP;RE;KHE""?0, .+Q[C?*=_/Z%O05559_-,*.J7S])H,Q[.07M(
MS"M:>K\E3<K(+9]=\)+S]E)1!MTU':]X\R3]H4+6]8?L7]Q>1WZPT5,P,@9:
MEE)0?M!4> E:T.9I]^1GABC$XO+,;[@QNAI+XX$O@3;WB(X6Q)\EQ(U.?:WI
MQ1&IJ;J*,/.$NXTM2$YGO%K)MJ!RQPT#$^O;&1X+$ 28Z(2ER$HD,5WD$$#_
M7-O8(J%\GJB"(!1^UQBRCW,K&#O[RLE!ZD-F$LO;:@'=B$'^FH:P T^:EC'M
M[!SC%5((39Q@4O?!=1*3U/;VD1?I7PE_+S+DH%J4#GP4<>@.QAO,Y5[M8P7.
MD.EHJ$G\$B"O%RT-C2A3ZL(7NX97/!Y_Y_RG,>=OW50#[=2(JMT5"L3M^IM\
M&1_]^ZW^DVW8N+TBFL@"]>ZZOB9%?1D=)5(P81ZPE/ ^R(_+^4=_QIZ?"N;\
MO6\WT\X/K#L0J&Z@,GY*!3/P+C"&X?QM+ R,BW(+J:@+"0K5-6PCF@\K!%50
M7FY8-&2O0.RJ;U:;BT10]2;.BKTM?Q),HEI!=+MY(GH')F=GUQ8QR'M=:26*
M+/PW_E36$<+!7,?;3ARINA\"5H5GT&0U;_3H+>KVO[^W.@C'>L/CQ.W'J$D0
M8@W1=@G4,6)&CJ8LX%2.>^TXS*W#+DT1:A.\*^W*+^EME[L:2_+5A?AKLRP=
ME>8?7*<P*1V+%SU7_P1-(Z;K$$ LARK@AS+J30*" GB\28]M9ZI9SQ5P77QX
MVK4;S_TJD#Z.Z$!3I-UYYIEHTZR-HSRV^B))LQG0)<GS-7*7Y?C54ZCU\VUI
M\55!#RW/?KR0CBK,M7B/$Q,7GLRU[]$*\T$9[F<R?6P4UK<H1H]C$IZ%L,XV
MH+T23:7$?F[C95!:8TKMRH=+H2?R[&UNI'GKG&,_;A?1]U>6P65.\IOZU;Z5
MD,TW<*YJ,FA.@?*V8;#:PO_WRIGN!*_M9Z/C:V.CD'\3A&AAWF<Q9/L<S9>)
M]8Z.GA@MS-R\\KET)?[9% :<;7P!<D>CYM>=O/CMR979LG\36:!L,+B8O_8N
MSPM./OZ=R03-PQ/^%Q]2!-+B9-941M+?P_L/]+_04@Y0S$"[2$]UIY<>=5IU
MD4XSFUQN(X%?Y4+-"Q_"H0.GSJ]K2*4US18\B-1=U.Y5KT5T!E!D!0GWF#'Y
M(=6; L3S=V>:??;68MS\\M:]-H.O)'IYA:%6U7RE9+V_)3("7"K:;((BN$>$
MYF>??MLG_?2B1XI)QW\M:MJ@ESY!JLN159Z$E&5$#++-#VS2RN?]M(E_I[S(
M*/OX::7F4[C3 _LIKSM8.+4]>41J2Q^4^J$'?A\"+%I^XUOTBJ>+D@M:-^DV
M9;M4Q#K$@03+Q&%/+6S,-$S7'R@EY:SS+6:>%"*,<R8IXWJ_O:HW?LRP/ 3X
M@3 BO\B5]#)H.(D75SB'SWT45G8_VU"JP^O,D%>"&-]J>XKDTI-(P!FVM88>
M)$4.3MZBB69][&U*"1#V&49R^E>]R(ER#,S*K=K13K,PZ?HEMJB,GQ5EB#)-
M2(<QR W[ 6\X6E_6*L&8AN!&9%9FZNKN!T.JY[@ZG$I8;4P3>03Z^W+FE\2K
M]<YW7*\_WS#;M*_$V-L7(IU472Z]VW67:@/7\8,;[2-;0<1;H%DYN"LS95NT
M,WB^QIOL;C3?J_!I\S4_&\'X?5HZZ5U:)/N[R/H;Q^(C3%"=%A3%/D)2,>P'
MN,$VH3)J<S(4TBE8$PHW>*6[K\#)*[08=+W[A'K)TW8YA1I)_G9&U@9EGW0C
MY!(EYY[9 *]/3U.ZYW.00K_8'ZG7'3J;^NEC7>"V[JGN[Q3TZ!XM.5F!WBN0
M+(!D>F1_0< P'<H<Y9&XHR"-C019LD;T6B0XR%,^MMS<1@!_V[Y>KJEO2+:)
M7;C].N;#A-KEGL O%T3/.-\*#Z?ZPCN ;6R,[R#V.ETP5ZALYR'@#-1#O$1$
M'_7/CPNYG.K*]BS$:P(Z;J[!C1<AWOMV_$YA@C2^@$TT<0OR&NU&!3/#S2F)
MN.:!7JSZYJ7]K#[1AC\+V.!GHSZ8LI[>1^\SX].-+I<OI/\UO5JQOW=U\XQ5
ME)WVQ),[:\YS-IA%ZD$P.,5*-A[\")O$>\I?I45W6>6$#Y=0QGG7KY,HOT+Y
MP+>GW%. +,$=XF4'[X\"@K<0VF=LUK@=R2M5PQA+ZW%P<%IP! 3/S9>HCL:E
MFAJHF9S-NQ4ERX)'YVQ1Y$=ZDL9H9Q'+;M[;TAG+/0W]/::2MZIY+O[Z^E9;
MJNHDV@^]M BL@W>508%D1.T+,$8$-0L=)FPSL)>#/9.:::,?_!>PFG_%S/BM
MV"RX9UJ+\*@#D&9G=;JBGY,:C(!<(L"[:?+_M1QT#78%/GO]:#EH-1#2BB9>
M"]B_@>R$4Q/A:S\/T"SH?]]9"J!QBS+NR1*1C&70P8NV4KS*OJ#E+H*1VH]#
M[ M/_<UDO$,,@BC:5(;EBTKX#X[;AX!Q33*6)L+\@0OY)%E&;\\A8$+;!V_Q
M/S\S1A.I"A2%#8'YSI^)OD^Z[]\/9!*.&\>DOA&T#T"W5 \!V](QGV\-H5?"
MP?:PHC7;'N2^#.S"(>"+]0PC[B7C^L;!'\HX7""3&-*3:=60R=J6]$(Q*2*X
MM'WEPYF79Z9HL=-0*>+4/JSP@S>)Z<H-:,.#?GH">F6TC0_^(R>?R5,X-6G#
M_T&2;RV'K'P(2+M",3\$N/HC#@&?+\WLJ/^G\K4:''*O%#MC22FC3\3L?J,?
M/>=C\ X9AACT 1V9N2S8C>7"4-J6[;][Q!A,UEU,^.%HX'<NZ:=73?73'86/
M]OQO3U5%?IT.H8FE,),8C>)-5#E:!X-="&7K= $1K5<P2\2?!=Z?,!7I%=MF
M?AI$].SR<1DOQHBD8FGY8L!(\V,"-9-Q"O)0()?Y_4**H9A"E<C$@:6:Q?!!
M^F35KZGWR-X6%<:9=\P;AX>"&8/\F8R<H"N_\I-1>OC1._,C#@>.U@V[)5..
MQZX+RWRWWK=JK6NN:=T[!+S^2*FB2C'&]D!U%@3-)7A,\(R*ZZ+RM.3D:I-)
MRW1M5([Z;3ZI0).NMOE$0J^Q R.QA3EC+ 'T'*@JT=+B!*H3Q8%UF+?/L:\+
MF[OX:WK%3>CF!Y?T';>WA(7W\?)5,M8&Y]&\\*4(@92C51\'?=[/X\9J"NO5
MK$&<)Y137@Z^^"-T'.AZ#+5VIQZ?Z.%E&W71M,!GK; !OO*PTTY>O6NTPJ1P
MR\_Z;S6\A/:6,8$\-;<$)/ LHT]H5#O!.T%X#H+PH[</BQS#8N+<?^MO%_LN
MN8OAT9]0E',!\0%Z1RUJ"BB&(>&R.1J7,Z?E%U,<UVV#2<!.[;<P?LK17!LS
M'UD2U/\04#5D>51?AUJ _/<:1&<G4UF]M@^KS3ZD!&V*B[QPNIVQ>P'%5(*)
M1UB-F+-XAF9(;T8_O@K!WTPC:75=ZBEV=,0X>#ODY6HVK;WMC(^0R5 _]U9@
M1UK1&N9]JEVHKQC> 88O11T"3L/=MR+'ATB&7?KLE(3EZ!>5FDJV5G5:V7XM
M3IO)%_W!S_GYTLXEJKJ::EOWO89W>,.7FACR%'$2Q)IB2'SL]3?<T> \D#LT
MP\<]SZO(P_8R.1:7$ER"V;Z2]O7M:W:V@.$1CBYPK1;MK$_/9'@&* [)OU7X
M%:LQ8?HLW,=/TBII6V?[ 3LJBJ7X+N[FL>/5G4ND76**=6GI\\V*Q045'^^=
M7:T>-[5UH5EF'+,L6#@HVZW;0GWZJW]DO#2H$OU=BPX1:_J]C6<!JCNI?\&P
MO(>5G(X3C;W-.RLD _PY-Y?&J8P0DQ93$">\G>N08#LJ0 B-=^9CL-<1R=.:
M@QL"V76?/R2?]6Y0?PE_R;^&0+G] M?":;SP9=O-!"(O*!;)TP(NHG@:-Z)C
M[L1/F]\139A.O9\R*7<ZZ%[]Y=&?+$]4/[S&, WK&'I5"7GZ$/!']>CD[OIN
M^(=S&=_?R(?=R%<*@.5 $:*8^WD^MYX5;<Z]>U[75 'SW+2E"?YB1CR2&X,Y
MFH,75:A??.V+G-_;I$/GC(E_$'XR/U$HB$&1W5QO0?:+GREN20! JMDE(4">
MSX'NO^\4'[7V8AG.PV 9[%+$JY410HADC2CG@:\OHO^< PEMM%0"W2)[U9WT
MU+4X64TKD]"T=(D8?BNK8>^.W7@(-(LZ1U6 =PCH'X.-8D_ZTJZ60G6)J&3-
MH83[(KUUJ#72NJU@B*A)R)OAHLVUC',VW.^/F?D_<6(\@G>THXEFP-.PWFQ4
M#$P&JE7E)]H)4T&GF7]_'J0XC7$F=RD^FD^]U2<OW3<HR_,^>2PEPI@Z"4$R
M\?-3-#,8G?F>,[K=,D:YI;$E"],*Z)Z=VVH(N1.8-XMBNS@<"'))>)?S,S@D
MG)G<#Q0W%+L46;Y+9LHW>?L4[2.18*(?@J!:#)6EMPBVIS[F L4P9+PG,4,^
MYXY?:*U/JI1\)S'*(YOX+'JG*B)X^> DZJ<5XU2*M^86C5]WZ<#P;-J5]1!>
M?B/%ZQ7I7:K+7^Z:7GUU 5W8]!M?&IBL9!H4CUX<'^O4E%'D2UB[D#F/_-D9
M?Q&5I5]\\5,\X/]__7_[A8=[P_>U0+$@LM(Z^,!,!BZM27\!=2&FCR$8?*'Y
M!C6II[8T6\__Z61[GYXDG2&89,9]FIV#<XDON1?-!<<+H#%LC!A@))JB^1V]
M?[RM(3KP^R5B<9GI34+ CKY6?#7MYOGG"Z=T['7G5HY:!^NB5T'8XT>U+[]!
M!WX-*-=*-O)]BF,QE(N>V29*D;7)'EVV)L*C:D=XR8[&G@T9/CXF'U/R%4M[
M.,Y)5I=("0-(SKO0WO.WK-UG0O:1]C$)21=[MCS^HRY@%;RC$+T#0?]Q/@3,
M%[QLH D\8YSJ(QDRV.6H=W_K7R;>:5T25[DU05,*^&0FT! 6PMIE+KZPTO/.
MT$]^<^[)*][V%2VACJM[-!XVQFD?T@G&Z9)# (<N@Z_"K0/30+N G(4\9'0T
M-R('J2IST#'UT0A%3\+I!O]-7$TB)]W:-UA\A=%A^FS6>P9_>Y]=!R;C";=[
M LU\^9?BH$]&,3'@E2&&B6>G!?7,(A,;7;%=WX6:,3,A$RA%^(7^8K ;$K'M
M!^#7NP&GUVQ=A+]7JBCG.#=^C=#A-4D'&'*JI3[5Z3\AOM$QL'$]0XU?7E<F
M'';[@/-/XL:#QU:%E0NU^_G;<_]&9#V81-;%NZD<#6QC7[P^0H\)*%[_MH#
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M,: JFQ3B3'?;12*V"RL8&DPF^^P'->(F_791^GC[5)R_6*FNXDUMD^ S>ND
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M5L^W4%.KU8E1<\V@G74:^L2V"MF8&1LJ*4Q:Z/8H_1!0D&*[6P")09X +V'
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MG\^0FQ[MT0K/YEY#OH_Q%O/75BZ]YJ[9S\ BB0%@FI8*P0\_%@\A-J!Q@H>
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MG3))%J#G0Z6H%Z'PR98@/#;&C*3Z7%/=.]L)\V62L-3,XOLU[9+Y3]^5TB4
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MFPAUU*#^O#$[@^HF .ODS:#!"C\:].8:@4:9MA8']-=<GYDWTY5@BUED=3K
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MU8T(<B$+-@-)!0=HB0YO@RB@/9,PP8*UMZ_5 KU&Z4.X="Q-JA?,:9_68<1
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M4Y#9)(X,L '5Q<"4&^ 2@/N+@&#=9<,7LX7V71EI0Z^IM+GN^C%2<,1\S'[
M#1'!E\E+<YJ.I^GYK"",@LP"D<MNUWN[JO3.1^80/ \\>;:AK11L/==SB1W>
MM0:>QU'L@(>,;":2V3S_E 7+2U=VZYV.82HR]D,&*@,0(Q#D%2,\FP5E&)1>
MHQDB*NLUE4*H<)H.HAR%E9_# \J03OW6/DI=P5_!J?(W;JFD90KT1Q>*YR3-
MVE().CO9'5-6[W*M]&/NA;B^W[+&X[%:,4/_*N/0S \TM9.QH,(V&(,8+0/L
M@9]^3$W4 (X)L04)0B]AY[M*R0:3W9(%.]K'@AW);L&0?P'K4BR8*^<*L /!
M2OM\(J0@WH2O(0:7Z1BYZ31P&L*:0L3,= ,O"S92[<F"Y6I_GV8>LV+!DHQI
M$&^P?\2"+9Q6G!YJ'+L8BPX PIBKC'BO.+6=EJ_,'LV@I< QOV]4CQ7(T0YJ
M_*\D_G)R=4OO:>!?.?PO7+Y"=[)W^5<2O[2!.-U?]%IJV+6*-P19SV#VZ%:
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M9,'"7D%L&")NZUI TPV !6.7 &,QZUSTVQ@7%NP>';LUZ;2+2Z+7/\*92>U
M'AL<P8)U7D6K :/7AUFPS5E/Y+7F&B,/$]=,XS*Z+"%@ V48L_O]@D'BE3J
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M-XYVD7,9VK;#+6GQ5(G("M4Q$S+STX^*2^/+DH\RKHHV"ZL\PLF_*5)VNT"
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M]I5M/6=XL[6FR?T?A$)"TH@'>^]IHE]KT+S=7EJ@&",-BW!=&W$BZ31/7,E
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M$/9R;/Z)_2.&'E,>W%\F:U"*]<HG]/B?>DLZ6+S=/CB\_V $N W!]&EHEK?
M*Q!0;C.RP%O/IT,;D&RT9CUKJ?1T=62%H>/S4Z^FWGQ6CPF\W=EX[6GMZ0>"
M VQW3,OT[N64; TP)W$S3G$%@@*;+H.^<6DLV%@5V#OF09,ZT^)+(!O&QQJ*
MY+B@I/Q?EOX02X(%Z0ESFKA"^O_?$SGI=.81Z.V#7;3G=&UTC]I\DU&(<Y%_
M[49KFU0@PW9S844FJ]*D7"54=%3]I^4_9_I"CYP&QYV(<)JH,IC33L0Q8MX
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M9T,C#[_M/AGX,2J]K<UF;NC2*: V,;%;?]'=CQ?Q_%MYL?*D8HKR=8.YY5.
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MVO57 8?%[__$J1ZG^28)CW8E79X0=/\2U/5L>\E'5GQ&3!R]\1M>5<;./E,
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MK0C!X.S\?45;9O[/D9 %)K_T)V%ZDW606_6^^[QRF>;W+B!\4FEHS>07T*<
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MQCN<;\0SV<^4\4L?!,U.HOKW"]?Y9*J(9IN=?36'?W?W=**_Q<C^TKY,9PW
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M3BPL&"B\Q$0UK 2GXE@(_66<!N(Q>9^)26:K5E'\ V%T-)RY/:PC!AM X$W
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M'%:P:9V?4PA]4!IR*5K4Z,52ZL(%VQ)H^0*T_U>[[X6HUR'D]G_%6F^9_2N
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M_8ZN/I>(1[7?G$>$T[@-RNX4W DL,GZ.&G-UO^\9]FHK^\>U6RDA%W)#H9B
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M'Y*?K\P3K*KT]]6N>=(!;&5=^%'15/_8-G-_%Z$OR89]\OGA\$8]\+UU,/&
MFJ%D<JS;QS/?XT4E^F<9?PY[>>!S]I_MQ])4F')?+7HX_G:=>2N7Z$NM0;OV
MDB[LEF&:T:!0U=JA6EZG1T[EI8.4D0ME\O.(-15"]+-6$<5+ +V<FWIC;=>Q
MU7<MU*"GPVPX9'G$DPOU:[;*!TRJ/;Q7>PZ<^<$51<5WI:_Z<Y7UUV&<J^D
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MM8Q@M8\T4!*2_MQ]C!LR"<5K;Y)$VZK(OA3(0*@;SA!43!''U[\7Q/1/_FY
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MP ;_)!I9@^Q9K$_<I_)NTT_ZE%(? CI+#!#7.HI7WX>DXL/1V_*]\KW6SI]
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MBJ>VE]1C3'Y=)CBP'MT/VJ##+@I<><DZ7>0A#Z]_/9AA*3+RUTIWFD.?:77
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MU&6C?]\Z/+6!S,:"SSR,.4':#OKC&KJ1FK7B"LU6)6;''K?)2(<UR&WA'B(
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M)I(YI]-&?>ZXA=TZ'68V\E?SJM"KY1>^)F.015_]!WJ#''2KL"3T-PXUZ,A
MRECNN'C;[&>->KS9Z*YP/I/4<'M-6FW\QU-W.V(6G>2:@^5]CO+'EJ!;;Z )
M,7IP6IVN$1%_FXBJ="+.KK76_5S14/1U:4:LO[RSS\XFBYQM:Q$_VOM%[#<U
MCG.VQOK[<+_*A7TM*>)=Q<:MM1V]D@^WHXH'!D1W:F9IZKO[0K@3X7#I]JTC
M[@=\V3]JYZ4'U^>KM7.QJB;HB,HKL6X!UZQ3*S/OO??[IIMN?\?<@:-N<\!
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M1,<^.HQ9#C(?%35EBM NGL:QMC4I8ZG8]UN:'?^=A .D#:GO%PAFM/0!SD.
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MC/V'H*I*;;[O0DF+2_;:3[_+1G[X*\*L%_T<1_2_0CU-/)D<A7/G?$&'\5[
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M5FED5*L>*_FW,G<,P52=ZUR?'NX"*>Z0_\M/MX?T.+0A&A<O;,"/ PU,KI<
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M_C*35G5?Y)0"3O=MULLBU5V_+WW!G_WN->CY?NU:,90>[M-,_3-BF\WLPM7
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MI5XVX\VUMRBV+%+TIM;L0^Z@I&IF0^2H;D ,19S K"#V\S<C949T% DT8_]
MK@?:;,?0/@(H1/7OXYOGD;?;D[E9FC$K4":_$Y3F2M.F.=QB_IRM6L5ZFVL'
M%_8MZDU@,@]*K8%2.?@YDPO9C#NAHTWTY_/:,VL@I? X3WBJ\_GY))GY?OYH
M$,_V0_7,78+M(YGG%H;Q"M;%8K<+2GQ >LEQ>N51KM:E>9L"W]-H$Y]AAZK=
M#Z##61E,@'U( 4[!Z!\P! ]&._;O1AC<T?8@QNX::E<?WC)(2T MS5&;OF*Z
M+ZKLU&.)60N#DY78'048(>5W1+Q\N?37_UI8=2^E+JDZ)9K).U+#0%E6_?KK
M)#6[OH$IG^>]ZL/'6=4@!8'8+NJ!8\;*;TJ1Z] 8@QV"><#C<&+5WY7C9Y?5
MC76_F.7<U><JZXUZ^#8TSPZ/:"2CFG^A1 )YCB!;YB3(95$CF;\ 7!NY_=.'
M?_1'"ZHMS><EBDEKAZ9N17"[''YI&IY*@R#[]:",=)B;^6% HW4LB$J9]GKD
MB!N4N ^W^)XIX[4N<_)07__,IJ#%,_G#GAT74BYEK#^8?CQO>!"M  .'O@[-
M@_+%Q?&'<-SY%>@?C>(5_$A3CROM$H%_AK2[9'D_N,?!SW^Z=E3&#T):A &7
M=Z@UE#)LBPJHPN"1>?+IS1K0R> -"N<E4)H$F"PJH3VD5^=LUGKX&2&:]SM"
M0$]/?H)K28!'314U[T.2G84GWP$;IF/8*K15C;B?G.<=)[N>,*'GA'0?U\LO
M#[_\+#P'PW_74P'!Y"!9NN<(2(&J&"FT@&KEZUU;.H-R_5\C3'.^:+@&77S^
M]JG@1U=!^6[EOM\XQ80_CZ'@O$['$(63D,)T-<#T$^(()3,*_UVN=9.10^1J
M=01UZK*4W0/3YV5"*F\K+.*F,W2?V2Z%(P;_]T25]Q#"^Y"*<-A?MXR_[:[6
M17*N]BAVO:N,)BR^+%ME]2CM%D*-K!';J,'5$4GZE#3PGG@V\,G#;$X.C<Q-
MD2-\HK7E#IZ!<N*&,K:QP""36WC,W[><?IV\2(4#-21T-/5<B[]@O\28^GMA
M+R_6+!^=^X\FQ>>O1WR,DCO<C<7C4=$V4#$LOA!>B8L,-"694'S["Q-";K^<
M,QTH$5").*XYM?B>=<9V92[APR3@;U ]7+UBX@0S'R:8^#@X>&;*^W[09T_]
M(,]B?0<B (% V']],CA;$Y:ZH3[D 0YEL_9!H>PC!_72$/*-%)X7R-'"Y6=*
M*_ZE?[(*3.<R-[ ]#Q0WJQ\K7#!TYAZ74/TB ,._1Y/O8*)A9%-PC4WVDS@2
M^JW:LMM\SV01UI1DLL9OJNJ,SS2[Q 3WN+FF1T^46[]"R()#J5>5T PEV\&F
M>ENU;GD5_5$/GNI[--&BWLHWO1)]^8IDA'1ER@,U-$T>X#!G-*#PQ)1$L9TD
MG:1@<\!8>8?JE-NG0&$K]7/Y4F>9<T617U3VR._=V!CE7BMJ@&5XVM<P V)#
MWIL2\(O:G2\ _AZ^Y2$[5!/@/1Z$>&<(V2=8V.K%&Q%,9M>9RN@S,Z)&;1.[
MT6Q=:GNL-%7F\!P; \/D66K2)'/7<->\6[8S_?$P>\B] SB32/_5\TW4:J*$
MLT11JJ&]B6]8)Y20LR9L7U$S\C?73*BNON9KHHY51^O1NV+T@R@53MG!U7'P
MG3<9!7I'O<;Y30BZE^#.4QT/E%(9D9;)4_PUSWW7N.9$HA=[(1LM&0D&%KZ*
ME[2_5N?,4/V38620\\:@/ [2=Q&#6TU]"+5E@<4A9P**_GB8C?3W=\:KB!FE
MWN<-?\L14&O@TF$(.R-H]YI]VWQBD<D>0S*?@MT"DN<N,/+H >0\&F$]?F^X
MO6S&J,(Y*?'7-3$?3QE;U#FK5''Y.P./KV!2]B$N*M%B_FTJ@&8,Z<'[3X82
M0R'J.*NQU<@.";;>R:G#@]?XEKITKQY>@7^&5\?0<[ IJ%7'$=C?[)O%GQ1E
M&M@E!FT&!P\Z3'Y<%\4\C9 9+G\*REJFTKB>W(I]8FVF%!MY;7+4?=/B/8?.
M<"QO>M^6S/$XSD3[<T$Q7$YR!^/$RAH2W F34F)*T%T 5Z+Y/TTG1SY><##!
M./M5Q^)7:==-N1I?;@2Z'>GH_<KYI7L:I"QD;X_F7/5.*A+(H'"5*:'OCNI<
M:Y(T^?#F:S1'F*>?V/G.]?R:H31A\42?!FTK"31=TH+ (>E A*ZN2+?/SWAO
M^HB%]_T)D+Y6N=0@_#;E5?\IB< G8]6_"Y?#M/G[]<S"\KHI*":WP,A3S-I:
M&"%F=9'"#TX&E*=7QRJ$8+]H/N1^ F^L4#_95R*BJ9GZ\WF$]9/GVQYT_E8F
M.Q0_",CO-.>D"(68X6X/K5]JJ'+]O&3;H\/0>^AWVPYI:WM+M3+OM\2)*U1_
M",!C"#C@<^5:D9+#OD^3>*[7)/>T],RJM_MR>@OR&KX[C)4K7L#*H_"SDF+0
MH\RI?4A-4&0A9K(Z5_M.\AR'YP^CT5-8;#(L]0H\P_@P!,)V&#)F\^+=E(-P
MZ%F9N<5Q./FV/Z 4W(J=4&RG(KE\51R!YQ1QBQ>F/#%/3R3)?GHH0+OU(ITW
M4*GG<YHFA.]S:2DRG&)+E[A PD0.E;^GR%&O V5X<_8W["AOG&D +^V'2F^
M*V>H=HR4OR6K9G_@/D0<<9UV"EQS%[ @4@HA/"G!2=MAF(0\A1JWG*NJJ(?&
M1:$+IX>O\[4YCR;>%!!]8/$[\XZ(;U'/P9X@</DZ ;VF1M-#7"$+_X,4H-^F
M5,^=)&]3<X-EJ">FIR;UU:J*ID3:989<=#)E/KCV=MT?<?0J\C%@AO&?56N
M&6,?^$^9MZ!J!ILE68FL$?XYM\F@,#ZE>LTMI3=[=C3>F+.8KBI=HLB9FOK2
MSLAU-_2@+LH^I'L!.0+?I@DSLYS'09K07);=/E8$ M0Z14:#7Z?"BZG;5%=K
ML\3YH-/\U2<J3KIN-"E4CBX>M@^1>T.S0(VOPO><P@Q5%-Z&'\Y>5V*@,"H,
MD*AX<< G^:F6E,6VA(^U;QKE/IH$^QQM78U?7B5J>][]?4(FEVBFN0MT_\#<
MQ@R@ <V-#ELID8/KSE[4\^5_Z(8D79C9VPW%&J&Y]=\2W%BU>DXIS<';BNP!
M"VD&51D?)E%,KA% ]),GJM+L&R6X7<]])ZE)S6?GV>Q<?B#$H23!/2/5I%:#
M5X9(?$@^_L9(I!4*DML(VD%Y!Y0[?(]1N0\9KE;; WW[D3URM1X;XP62<REH
M'W(IJ(GM5[,?*F2AYTQ0LYSXZXJ.1Q>?MR,/ K%^C%.\4&0KV*3?<M FONY;
M=:9!L[9UX-VXRQ)_)4N>/?YNP[CUN\QL+F95%@&^Z2CH2E\]1("64'%M'[(/
MT1?;8V\Z*+Y0,6/H^Z\:$C-#6@9%+;9='!*'[%4A>VE7I#Z.Z\+BQ$P>A,#H
MXM;[$/FV8=2JZPCV[R5,-A:?C-W\XK]FO@]YXL_\F)GQ%_/?_I^AG3<I1M#*
M.Q;ZCR59-PDT)68[\S0P29.F&P U^ <C*8EZ'"M:?OF_)]&YI4YR:78_ [>4
MYX[_%D=%]G?)G(.%@]SG%99\.^DBD_TL3=&K26[6PX>D+.Z70\Q5%^J<]+<V
MW$CE.2TZOA,WPMD8]N:#*_P@7K!HK *'N 00.']U7KH(]S*6\7N?,=(>=/PD
M^:K$O7$>BFMK/98NO@2.D4DUI3#&)Q3V Y; )[+A2S(X?]>A6V^WS,(V4O=-
MVY??[N]12NKV-I*CWW<O!SI(5#-&"H:+P:7?''Y0P -6B6$@)U%+4V*@W77"
M@'-9L:N(^^!CH8S40-]SR^)K&G?2S1JKO\6N)Q-%U8PD)<T?]5QE_3F^ZG[?
M%A]7K7<&:0L^2X]NZ@5.R/)!L@?$748.,$QGHRB8 T:-I_RBQ,1-,O]QC#44
M3]5!Z_%^752OX%0G=VY?PQY$L5:(Q=#/^@/G6%>K2"6B4MHY6X5>X\4"KBJ'
MEM/TSTHD#9!GZQ\_4Z!BQF]:UYO4LX??MCC(^; Y2!> ,MFGR3@FVUJQYQYW
MA6]I2$.GWLGF"O+<B]3>(-[DD33?/IWJH%TKEMSI]?<L\?1!(ARX;$Y4:?65
MHSWI@%?@VLW9@1M?)DN='6?:.101/4_.H25"Y44K%H*6#:5_PGSN[D/<<!/:
MU(UTZC] !LG7BBE46."58,XCVE%Z_]AQO#&QYFZV VJVC2 3RJ?3^/[)#[@.
MT WZ('&$(M")WQ ,T?@!X] [2]=O'*D.Z_4ZY:0GK[P019P8F);)=$_@#KX0
M*TB*S--R/3)4[>=Z5GMY-9Q$@R+'FS@87YG'O+ G=-@" ]63/FDWRP@_BO5;
M/<<OY<9_4DE(OXM6VG/]4&G/59@D#M7<-L=*UNCP3YCCH@1'J/FJTPB#L0OD
M@;ACZ2A&,8I(>[U>#JZ68/_?;2>A7VUDNO"BUH^-G>:"0?3*]]&P8O9#!:IW
M\@PJ:R@ZPKS7S'LETNP_-_ $\1KPT"*^H@$9T#MR=()NTLE_*J9MJN:MQO@<
M.X4G]LS0BXIH!X>X[3>N%S'YI2XW6(=L=*]<"KM<;*SW?/!,OE]1L0^.')!<
M0\ZR'_;3DT/VX@3TI$)@=QM/3/IHO:C,=VP=Z4HU]6+7CNVIRTRKL]IZ*O<W
MDH!N^\Y*DFM=@[8["X\J!V)X5JC%8??#_(R3B7*B1SR.2+7?/69Y_.0)?<0:
M:*:EY+64.!@^"RXBC:V)6/-]&MCPPJBAL3@_3\X0;F #B8"EJN'AY)LJ"7N#
MK5A0NMA03&O:TI9!(K$1CWDZU%_=YCNU&3(>[,CZ)_3'#PF(@J.K_):^@X-
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M? )'N4#SR&$4,]Y[[L"6:U4RYM>F=W!!3S;_EIWJ]WI,'1]:V:[@JQFE+>W
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MD^I:+QF'TS3R<$MB$A&>QY+#DAN]HG B(Z=/QE\YA#*^T^_Y/RP"^W_.2Y"
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MN$Z_Y#XZA=Y[J.\G&%(<0J\> UWPW&V5U-.4@,T+"TC*ACH>."U,.]+4C:Z
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M4'SAB_I.*"P:<T3KS%Z[4NPA31VRX>>S-"6RR@\*7VMVNUK:\<J-1;,@I^D
M#1<=3:7>+(,8IZ75W^D^AIOG%VJ*?X?LG50<" /U)!O(9K#5S:^'/EP20X=[
M-VO,?]+>T=33^NCJX^/CZNXE_=2UCK=? MK7D$3KW3G]YMC5337P8QC&)*S:
M.X(GMN40ZNL3&Z1JHFIC;0-99QGD(X^Q]N1$D991;]2]TBNQ,EP-JBGS 1@0
MZ4"F> TYM1,]Z:C78N%YV<)\3.'W?M4QY1[55['/)PB9GEM%1L->?[PNS7[[
M-BMN8V@Y)G(\C-6G+0IR]^[1TT\AD(>08OI$VQG<LGFI$?P:Z#5)==,$,Z&
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M6$L3>#T7$$Z31N0"FYUK\AZ[U0$!7-+KZ;U#IW1??2@Z)YE\E]WJFN/#?J0
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MGUET@!64Z#9O@&K%1"-DB8@BKIE#G^B XA*G344+RP_&7OC0;&?.WH+>')
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MZ*' 5]7L5AN<6=),]WM2MP;I:& H!S MOUG2-J2XY7 OXU65Z"?WL66LWYO
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MXQ@/6D05FHEZF]!<6;QU'P4+G?JUB?L'MIF3;;[4I:4:PY2P<*ZI'I."G.(
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M;+U\?497!Z)W9!)<4KX$YAE:/#9\#U"#RW&#>;<M7*LL?DV3*FD8!"^B'4Y
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MCBH4_=R?>1?I:N^-("1A["'=L'IY-X]T[/IVU>=\O-L=EWM=^KO,IW172*S
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MU']K1U!6@)R7@4_&TB,=U($)8F* B!8D>"=F<AB_U;VU#NA@F.Y)'%84Z7*
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M.B'C'(0)RJ0B[HPB6]./5S8+"M\B>IXY6>>D]LUF/,#V^EW^=8%-%Q6+P67
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M'$G21G64V*RUZ%V*Y*I/2I5(#HOP\56+RJA)%UJ4L,6=JJBH2)\R/=:XC:R
M4/DQ"VY4_G$ZNY$H]3P%&8UT [.WQ9?4%.;:WAJ?9M*:/<^R4/<]Z,'8Y>6V
M&\V/AEI?4!:ZH>5;;;#7<TKT.2*D#1NK=V[<#TQ**L07*S8T"WVCK2=GX%]?
M>9;B64.H?;F+.4Y&C)L,JO=#C8;6WQ0T92?6VTZWY*=<-WRND)#RE/6N^W(D
M^8Y?7S%4$?E?2X00Y59R\]#GS2Q$5$?BQ2X;3"15[DL(QB#1<;BZK__<7,3-
MUM/9:4[?7=0,<_+_>?X5I-)=5UKQR7_9)$A!M=(1#A#._]3E9TQAD:X4SD*
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M^>TX)4_<U>V\P_D@%=7*)]3GM&CDTB-($G1O"8CY/Y:!5G2.O/G3M/=07!F
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M$]"(O3T.48\/W5-DM@RRB,/_TR,2DW+]^#=0@\1RT9C=S-@L;U&#'_H]AN
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MQY+/T S):13Y<&7RP%>]G 5P3#.(^"A'=G9?>P"@Z9^\BJO]MKLZ\"%BA,O
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M7BSALDBO91!3U E)L)RU\#XS8\\P@EX&\OKMM'$(TFN"FV!/:S(74N6 T'\
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M82 )OT"1+V]@4E.5OV&LD.4?YU7SMX]JV()[6_"AQ-OA=RE\2H3..D&"[J*
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MZK)X3EP!W$HU[9VU;?>),WH<W/\D7Y^_7R+\\@7H'(A9D'_%-:-P=%5G)"K
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M?_+=F0&;VV4H0':9RN_9!>:E>A.X7D!.C\$$J<<!WTA([',LAUN"%Z9Z'AW
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M*XM^_V9X9P'ZFM[!'#03#^.G/_(H(8UJ#)*3R&& :WN?*1N1]3W?UYNMJ6M
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MW7Z-<\]\-MTO5)]05==TX[],ET_K<0*<,5SA=XU[^@)!$F6]8]F$7Y1/$.,
M%PR8@>R%FYHOE*S;LV&+>N#G%F=UC+3&;?SI\R.%%PT7! 6N&+U4M+HHCN5Q
M%(O"D_987+@^VTGKCE<;QG=#@=Y8NUUY*LL>/6PT#"-GX&BQ.K49\+%E*C]>
M*[6"S7_VKO=EC_K.KLM)S_HSO(WM!.*^<)+5M1>6I\XWPU#\K6B<F3Q1@J/5
M]=YV X'*/ZR4K&(XL./OHC8NKU5ZO4[FK([0<Y/P*W,=+.8]RV-;ES@6Y=?I
M,>JX#"4-Y!(54HSVZ[P]3#Z2AK9F309;XF_5^6Y]%"DKB-^"4LVCNJ O\LS(
M/8K@/L;U79QP,ZR4L=& C<C8I.S0V3S-7VJI:_1<4&*^M//,@V,Z$N%;:@ 5
MM>*&[E?[X2_,[KU<Z2O+.Y?DTFE#V/>YKE[BM^YJ$7>9/^+"N<_@E&1CPMHD
MU1)F6U4/G((.3Q^I(.8Z)" YW,M#7)5:_*MEQ2.9#1(6ZXIKKFD+*_QJ-1/-
M>;T#JJ<3:$SO& U DL&B<06RU.:%5W\I+?2AU&RKKLX-78O],A'I]<TND=A,
M9:$[K1,$OU(;8F$A1(O(Y>A8X$0]717[8(@L/7H9-3EN]:MUWO\6R?:9CF1=
M^NHO_2'V3&G(8Y@#?$)7'Q?8WER.B\(*U/-&:W0K?^2M*'AI_@#@\QF\XV E
M?1#UF;T*X<+U2'57J.JY=NF@L3^4WX+J^#XH^V*-849HL[_>2Q_DG&,&60UH
MUHH7IS*#:0!FMMUP-'O=$W?1Y/F17+_1Q,GX/1UAA0+\YWK'K?D&^\D\XI-J
MHWF.00X4'+,4##V\LB9%E2*Z-UV#'!@$O70/1 U7?+57@2]:6D;(!81,OU(\
M<>R=Q'[CS#;X&Q*G@R2J(%LY(;H#&F<AKP>P+P. =Q)EL(I-GMVBK6U9"M@8
ME3KC*:$;[(K,MAL=)IJ:QT&KH]BD&3;P;/MZ ![<5 \LH_:-UNG.8,'W!ETA
M0V%8%<5Q/9Z'FYXYM<F?W6QY'"7>=ON99SG+<.DG2Y<DZEE76T.0ALN>B4K3
M0EGWAC(8)08>1J1,P>[ Y&B $G";&=(1AGJ/V8PLDJT?=\$ .<>=*SF?YB9*
M96M['S_VSDB9G9U=]3K'KN\,4&P9S4,^E4F,;:Z)*$*DK<473X_93%0L%SWQ
M/EF4/2D6'-TW,SJCLEY]^$HAOGA@>P"C 3$#1]ULIAZK<\(,>ZN!N9R\]!X7
M'G]W]:%XE:]MR;[C,Q-& 7'! E D&G<_:N(806A$"<[DIPF5),8VOO[*+E?'
MZ!6@%%3(Z9[06_YF0X<'>>$L)_M6P:H*W%$YXT/[4/@3\PN24U=&T37J%Q/K
M%>6R+AAEG.<C71FT,1G?VU(&S<S!45Y:1 K)VV)Y6JR^?*@,'7QP\?6=[09?
M\>FZ$KU+'.&7C/UBP]_\FMP]M@$FGHU:+\QU@>'N1 G[O5Y4"[$G=M201T*Z
MSGJ(=B>NY-Q\?"M(>>'])?&3PG%GZYDH'^CT\RU0$.2T*=0H'UFF9XEQ?^]J
M<=5=KCS,I'+([5-E-^_/VHA9O53R0%X>3G]N"[X,:M XVE_/YW=>!X<.?CEA
M+7Z[#VM7\J.DTKK8\E8H[T/M'Z(&YW-_%XG,"6H%":6P<L@Y\B5!X8N[UT]&
M,8"Y0G.C6MKC=*XD();C4QRWX"0ELEX-)1KI@F8@YIN4#IV!TSUKJ*S;KJ[
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M*([5HWJ:HN.V@&2^38(-?A3K3V*S]E/#3 ?3729'R/S(.H)O$%M!^!JJ0)J
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MEE5)J Q)[8,V4_(I20NOXD<-]^L=8Y4]"*ZU/N&;/5J78&?IYH/&/6BE5-(
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M_[T-C_[/1/;N88Y/KL.\T)"7-$")/X(&6*F817Y&D8JXJ&P&QOM N$<"/O<
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M-HW?>?8V95@RZJRK^)7,?V ]N*M=S"])=[=+OEYL.V&<,GVCI=/<R]$/X82
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M;L-E4<N9YGOJTB'51 RHQ+<\-HM\X<]49\'"ZXGU<C_LS7Q5,C]ZFMG_H1;
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MZEMJO5P.:<+22;;WQQ5=7AMVV7/>D7WT241'4'02I\-PG K2<;(3:1MT!FI
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M9$-:YYPB:8J0T^$HC$?%[#[81%6OJADKG@^[T3<BD_IGI3_?1H3),NXF4M5
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MRSF*,AZU(2[93/L]#)/'V _)W;+3.F\IR;Z\XGDCS23,WSBL^.2O^:MPPQ8
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M^$0]K,=E'C;\:;/,J:4F5;@@V<W%,M5P3=C!N(U%G$TR\>S;OI';)?*EP+=
M_$W,-#?Q-LF$S!%LOGB'(-..8:=<&Z6L(TZ#XKS++NW%-//VON+Y>'[)XM)Y
M1)_4<3EET:^H%- \5HETT2:*#O!&\ ;KF)$\&C,:YM&QFH+/P<%O[4S$D7!X
M8,69B O^K/ONGN<YC7F]?=]]9H6,X?QH;)YD65)LYV#I0ZCX\&+CLV6%&GFR
MO2,=L+TENLZV3AVRN.Z Z=PB78"TPA,PS+N0F,/)#@=V*!^6C"WYY1[J.5@D
MI2EQ(:[/<7PQT,7(J^OMEI;+[U:>X;-?K5;&ND;3$(JQ/Y!X7X>Q( S>M'3U
M?:KV^YS.L_8]$LK. 9>63ANQ\/PP"--FQ+"_#"4/A3(48&7(456FQLQ$<3?B
MUR3#$'GP9WNPR"1_$>3I8"4S^_LQ?8O6W_B 51<?V&Y:/_:1!&B[IF3],!60
MRL;11"F@$3T^Z-6?4'DL&;1!9>VX$M"2_G'Z *4T5?8NZ4G\U4W;&0^)I(&N
M9!43W0E%T[3,@='T'3\@ [+Q]^B @P<%1# =\#4PG XHSC-L0I"TZ "B*\%Y
M(@T_M,AXU<\*QY5:3F,$Q[VB%)0C?IN*=6H^>XF8-;ATN](I]W99>X$R&;%0
MO"&&+UATQ?%CX0GB,G@4$=G)?;P'(I#TF0YPG],GJD>XR\2%7.[[VC(EG=+B
M_VRS[3N VZZQ)OEPPM@E6?M]UBT3D4_. 9(LIX//)2M[6GBY"C1R3,WMKT%1
M^!P:APU9@V).DH$LFB)?S8G@>PZOF(84>.Q[<I4YG]>Q4ZKB[+UL_7U ;LUH
M@(O+<V>2J$A%X>#>$))67\>"0)I3@!.V:5"%UG/3/FKF$C'PT/_GE\'6/T8F
M0(B.YK->.1,JYR1Z/@Y=61='\9X[5T_2?F<$VQ:^;5V7F5&K+97+8?S1_GDS
M=5C\BD\KRAB_=93%-[\?B783DUE(1LR'@8P('R,_)@'-&[_6YT]/]_V\^3/.
MJ=KD>.6GI"Q#B46]>C79T?C EL+ZP>F5BG_5V.S_?O%/VP@Z%/V'\Z_XNRGV
M=,!;^%&/OBGYRG+-!0R%H4QPQ;3>:XL-W<,&9P3^,]*\^#?2%P,VWO"=0RV6
MHRMNT:ZLX[3T:0SWF4&3??!0=SI $8[;HE9?_!!/UL?>^"_=*,DB-/8IL@#T
M,H'A5Z)0*(E0ZD%$GX2RAC;JGC5/!BT\7C S6[01^#MU_'EEQ\N3FRK.A4F2
MOF'Z'7,J#",,H UG[R$C)K%;G5N1JNNJ"F6HA*6)Z86Y[ALPFP8^!PM1GPHF
MV^8/GZ6DJCTX$U;&!B2%Z[MY,Q5Q"@P(Z%4=*<[HNY.XK-63\W0V9W6J:,>-
MLOKAFRJQFYJE#ODU2<PFQ'9<]5@3(6^=G(L3V%3;GMAF3;H0X96EH]DAY6TC
MX_[LZ:+,P'ICGO$/.9^IM>23;Y;9M<QLBUW7$ R!K8ZB63(O<I-EZM"'OJ/R
M^Y5H%H:%_!OIGRNOT!CD!Y 9UF+_^%I[_$444N_UOSMUY7_A)=^N!Z -T21(
M061OV$]'G;&"&C WQ9 .B/(C"R_FZJ*(\NSGD*$!MW4X73_]^3;7/,3@&TI.
M!'UB(JD(_P=SNZGF&\F>FD8L[96RCB>3;XR7\SU)MGGD4'S59*$Z,KW(>_K0
M 59[P;H1#1_.SS(X8^U\_,S=:__G^O_.):[SSPJ>-W"H_U'Z,HIAV+4+Z#?3
MM"\,K@;:1FPE(XD6 4=@]MMF.P<<T YJ*UE#2^YLJM#4048'T6$,YL2"(. 0
M'6"2K%';H)5EAM8E.@![/KZW,"7^LWK?MTK>Y\^9;S7GL_J>,#[X\?$K&FG:
M$K,VX5ZVZ;5D^R1#1E;*O%BNK^/U=4"$]HF6SS4@=_-[F'N3<] ,\:HB:W6;
M*7?JCY5=:3J E9_6#U.C%J&?Y%V L*P&9>]-1JKO3BCMSMQ4>6CF20Q9"'&Z
M/I D<B7O,_OT#Z/9<W3 U;I_?];4+N/16>J/3E<I(.HG&G"U1824A_K;<H*4
M\R0!(CMV@:R(1#EY?/DY>$'2]N%KSDMM";QWE+^#&XOP\)CF1YAIBZ*_H04.
M (R'IUOQSDLA5AC7)D#LA4T'5M7NX*&CP#>=J2:=F=T@O7WAM)^#A17!H;6-
M-M;HM2]#?V)I[/ID*1*9F$FMI $=2!9&8SFW\.BXC1H'&_L'2\E#IO'33^N]
M1J/E*M-O&Z)#LC)KC:DOCUKN-'L5D\ T=N2GU?TT%8?@M,XK ='QQV?_W$J>
M5$!>DXS03^M^?B4%; OUIQ:W"-.^.Q[+N4^HB]<%8<4NM#'H7U^)5*S3=XF8
MXP=+@?=\/\7;UN8R@X<P% $@[61!&,,>1$@-GIX%^@%%4$U\;FIY@JM\9?\G
MXU^G0JZXN@4RL]4/N'4^S7BV%5L"5NT>1?7VL\$[ML96NBS?IS^2>WQP4&QE
M,>J=';;2O7O7(*P$'WY4#+!+92ST.RJB&OP+13R']T[CRCD5&U=3IHBQ(UP=
MR[>WN+H[_.JIB=3M4BF1 9.(>U*/EC)<-"A'A]\^U&RH[&?UO,ENQ+%^%<Z,
MJA;R,W#4ZUC]T0J4&DF)\-&")(NB\" ?UN!=WKMJ)JF#61Z2;*SJ'G;6'GZM
MX.EG/J9W/^WYN<27:5SFI^!7].3P^27SX-.SJV?G<CZY'=9$'MAHV$QL07R>
MT0&SP;]/6 W=8$*%MRYSB-A]J5#Q,%G+H ,0YCU_&V+\\6<N]G"PS"\6O AU
MGVR@JL,[EN$NW(>7\OGI@.]T ,6[V8)V\NK1H"MJOIX,K!W,WZS-((+Q,.#X
MWF!01YV&@(#U\(_MWX,2&P;,_9O&2_-,J<: ;!K4#?4DDP.+55?7=AM='5T*
M3J]OXK/DRHD*, M8WSDJ'7A[8'5X\6C;GP[HDZ,)P'\SF('Y?LU>%Q3!6%@9
MA@/?IS#<KKZ.EK?EN1Y/26- [(M2FBSL&35'G@[P+: )T8P9F+"@$_'_M-UT
M,]+JZ/1K'5CCG4=H7&FGN7:=NO![>GH=/&WCN6SX*/4WZK7T-O=F48JOD\R?
MH3ML>_&R'R=:&93BW/^;3NBZ0\14:E*+(&UR6N$CDB#39J<4CQU=VO'*7Q66
MJ=/%IQE:&UBEI9^J)KQ^+M_[C[F!_'#GK4B]2W63:DI1H2!B>FZ)&J^'YG[C
MAYM_@^0O!5D9OXR,S/L6'69B8*.;6OETN[CT^G\9L?,O)&@%= S^="@64Z78
MM(#3;SWJ4!@5"!;S $XW#B@[_OY6N _6<$Z>77)[)!/"VGN3\]@Q-H.>@KL&
MO_Z'T=6/#C@#.T/R7'0-WVI67\!QWR8(1)9T/VFH0(>[Q%R[+MSVMT-7N4-V
MZ71(>40\X$  0V.[3KXPO4Y8,\7'6FCR?'V$*/. >!L+_>'S=9+\5<Z^4A9F
M,@]B<D-R0,4^DH(Z0LV1[_^&WI2'.#]V/M8!\1+Z^SD>P(QND-HK\Y KDKTZ
M)2?[+ 051P<\58IU5*(6JD$2LE$QHW=)X=@9OF+WT+Q!7&="<7O0DH'WTVT>
M=# =H(6 #\ \=C]?+&EZ\=^OSQ*F>FM# 8\@]M?6(!9<P_WA_":/^?2]_#2S
MCL]67NZ7L^"3^ERX\[+5-7LOFV$'GS1_'R#G&7XY272G(G6=71>X.:"RPUY[
M27KZ"C5=>\MS'Q_Y7FZP7G,_PS,FZFQQE/OR)%ZVSVQ3*O47PU!3HO^S4"XP
MO6O2_3_^,1^T !WPAV$&7B#BK8W2)%(=':!,!Y 9?+CRCM:F3_5=@^/_*??X
M0CIX]H4TR_>C@J0-2W1R(]G\-!V0B29NT7Y#@6?A_4CR"\9='$6!GR2KW:IY
M5YSJ!X;5*\/G,\#L,(E@&2PFDF)!T%_X@RKK"5LX%60J^*I0WS6P@@-R64SZ
M1J]8\RN!^<)74N=>,_NA";RH'LCAF18N!D:#&";:>[^$$4!6&:$E$:J&5]I
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MY(0F*<1V;4TM=D_(+PR=]D"?IDA*?6^,SB_3;FAY\/*1'4>L3D?2S->ETC.
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MD;7UJA,YF%3Z,'MDQ.P&A]O2J/]ZSM=3U7S*:8-<Y/=+AG=O$BH>-<53<N@
M5@-8'U%<BL2/Y4Z8AB&3@CJN9/^U*QJX%>_\M=[&;=HJ:4 BC]^*-=*?(KKL
MV^_7?*^T/4-1PXKD4+:Z33'SNQW+?I:O-#)]%O3*D=:2%-:S<(I!L>R@;O\8
M.J\,;Q-!NR)8*&K4HSR T@Z:R*@_Y#2IM)VHNJXY$?<D[7[:X_/%;9U1@KX<
MS$D]0KVH0ET;O%^[GDX+V;H!"SZUKBE9.#G]5)/7GWGK2MKPO3# +FH9>(U:
MK"<=;&50.^J/CG/48CR?5J<UL;81-Z;<&OGA@WSTG:N KM"@CA*X)W>B.##6
M&I\&^SEW<:1<\\"F\?J$4MGRKRZ19RG>5C7A5I%M0NM@X7AL7VJ)W,B7= RX
M;U]OA:-SM^"6FN3U)NF:%O(#6CH:FZ4G A^^B@?1V,K@I'@\DB2[U:IT+-B)
MQKY"2+LS"N7'*N@=3K9G#IT:K$5 .'_6O0FQN<<"?.Z)ARPX%I/O401'0-6Z
M3C[DZ\'F'>?"BFW#'-M%T\)W^JM]@]<GFB?!_W@DE$'#:( %XY'&JM>_#]@(
MU-GAQG[^B/W<J)K^*(RM2Q?$==\JR<!N51U3//"@_$(A5LX[TNQC8\"!Z%7&
MLC^%:E//P-O8Z8!E?C@':%.!#BA^,7VXT&+T;VT3P4RRX-_&Z8 S: W88#H=
MT,#@U9QP*8:T]Q%K^Q]T\/CG%4P'X/;)USQ!E>@-'P+K@F!LF7__H&=[J#W8
M3O]3][;==^RXCT1! ?\!PI!UKAY(DK+!E2R@9M:)5ZI(T8NG0!V'WC4^I8X/
MU*ZH\>E[\ K<*;Q4V3>3'')0L2'7 %:ZK-M'U,O_$$\"864H_*P]<T>C9@9)
M:&(  W:!P @H"*);N_]U^G?YIV6%\V\AKW\\D?1/Y)(09<*D&BK,S1ZS-/7;
M.BD_;T%2!%'XC18$&5J.Q@^GG L%109 2&;H&M@L]9N[G\]R6.:&(SA]:8A+
ME9@YVQ3XO+Z;"^I$$[_,H+KGZ8 "9SR<Q@:A PZ<;,ZJ>+[-O"OCM!<?3ZDC
M 1E_0"/TM*.2IC4[,-,%6$X,QU9 +[_$I,*'[.X?@)T0=]4V_\&<QS\.%O/:
MW\XLZT93C4OR-,7Z$M_4,NCW.P9&4HZJU2(&&++=CN)%/D8BM[9PDAXSL)F#
ME-.5+_&U>2) /NP)^R:LWUF0I]*(<UCC88^OKXG0RY?L,OQL#3H2SM+\@;"7
M=QV/VII.4JN]T!#X%',['7 Z*C"P<7#,I=^ANMI60.2JX27V%.;E" UK@^,Y
M'!(1 ]=EYF1-U#;ZS-?^,N#ZVG]W^&?3*GZ.<5<3]J11VLFJ>?A+^"DLGO8-
MZUE:LLN@[IYI1E)?)DU84@\"+8TNFE6\)38U*KM<.@-XG[-U6&+0X^LD13PI
MOT,'$/&,;^DA(;$].!-//#<1CC^%ZMQ*X%61'G4P;3*O2$G);6_7/KUI,+VM
MTWOVIFK]DEB++QIO#T]&5B Z9_D,J&4M;.XT[F&HB4:_@U^'9=:YNNM?=;SX
M?A?^N3J39WG_^1?EJ'GUSRIN2'>^O;/QL?^S/M&H03H  <;;*;W"\,,]!IWF
MMS8*\&@34CHJV.&/@\V#\7*F4?L^.:G+Z?DL#\;W#:52'XGU15NE-$JR*L2_
M2?U-O?"!X2>,4-OFU2(!53SJ"1L%K+%ISP''.$H2U CVOSSMGO:0E:LKU7Q4
MY4U4WIKB]-7\&DN??KW/@EI5YXU,Q@K+?+UK &4GOX"WW8.=A_6#\?<0$8QW
M!P45D#1VVI$\Z*]T0'7Y'H=IECJ;WDSID+-2ZNH5P_ID:?E&C0Y><^QVQ&7?
MP.NRTJ5ZY _-K+23T>1[P;%$&6HTQ8>@TUX;JO$>%>RZ 72N&W^2:J^M2[TQ
M/;7_Q==PA5V5)Q:H+/S]^Q4@WEQIVLJ!BJ(#GB"8H,8$]8]I3N7!'R;<-^='
M)5+EC:<47>*>V8K]/E41V9]O<GBW[R D,@O\AKAV$17%^ R&)+N"0!\UT!OJ
MM@@/_9."Y0"S0W5KQE9&RS>\O"7'7#V];HQ,@[3G@I+"37[G590_4%1681>J
M"VQD3K5'!MZ].^M@Y.0I-6HBJMQ>M)3R2^Y#>*J)+H!56WT;0>&%$/\0ZBAG
MF%LQIYN=4:LPX%=\#'(A:Q?.;E'\Z_?TX*?IFYK"'_END=]^2>'\\(ZSDO/I
M8P.!\9[!,L273_^R0<B/YVX%D>2*.Y7BX?@'0\*TH= 8Q/POJ"!V%*: \L(I
MVMR#2TCY8R3-AT4SM#OUD]^BT)^+!,5Z$]..=AE3__5NN/P"B!0"2D9C]S!X
MAAE-Z3%B:120+(_#>),5>HBU=, &IF9Q8(=2UN(*7*NJ2US)_M3U[17#:LB^
M\?)+:-*%.MSL(O<,<B&S1SXAAYNK!S_4VB(#X0XVM?I:41^S:,,VDB7NFNIB
M**%4I<P6YZ,EI70L^I_/5?:?NO'Y_^--4L]6<#4X#CV?S1"IQDK1+8HD4U?/
MPN#%Q9BFTKP77>BINPZ#Q1V/?7_J/Y5ZHR*;8A,J+RM$UK]X:F?R"]2,U+"@
M% /$^]'0Q7]#H5>Z$(B/([HR"Z<TW#X$;_F7YDF::XHT=T(RE!1<SS]_>,U*
MQR'\H(K&'D#V#$99X&/>XR4M23)*.&'\CET#C0&Z41Y:'[/W#=(&7IU=8^60
MZ&)3R#A^!_):,T=\!4.$X";)?L&11'U";)R>DANP@J'7H)($UJZ)#W/["\!X
M826GD=_7^7//0R/5+J>F=+[G?!U[T1?1D 3]*)%;$)>NR;*LKOZB+"3W(20(
M'B#OM=I % K]FG^6_\QO)U963U/S^]+RMO9SWN3##=@MVB20NQH=A:X)ZMPZ
M^=>SZB9^*$'=0<8"K-Q;.\?1^R3.^XDI-*XYU61/?:7&Z<&$(D6_U,'C;/1X
MU][>[I"/GY_/^0S/5Z(9KH%/3%4O2Z6:2*7=7U]S[_I4N.?Z?2SU3<ZM[X<=
M1#YJ&MP5B0"R[8DY+4SV($CW:9)U$])5M2,M[3)D@P\=S&7=&_ S"#DG6M:+
MR28W^%?DAB">;!EK2Y#!&7T.SC$:73)Q'=E0Z^7U_"D&#WK[(=6L;-^\5>B8
M^7*W4<X_:NVX*>=(1F3IX!UB.FD86TL@(K$X;Q ;R:K=Z_GYNO$:FW!OD1^Z
M2Y>\BQG*)$$UQ/?KM9;(>00CEFWT$](Z)UJ$23ED"<IE/#(JX"-9FMB 30A^
MAQ[A8="IQCB%@O2(VA%H W_[IIPH)6E^P=GQONM&[F^KB=\)X_*EZ!V]! Y1
M75G]&3D/,P<_OR:B]X\^.B!E.XAR)I*(K*16HKVVXL \NTWN7O[(TQYLV:']
MM J<UWS\!+OH(R_79!;?9MPE0WMA/4G'HXDXQZD93M1X]#.$&$4E@N9E.=2A
M64&-__,L9,1NB"5(.23GVHGK9[X+O61ZU G00HF@7#EZ-QYOM(C(A]I;M.()
MCJ,S0],4FZ"]%O2K_^!^*=)'D[RS:[0J*DN;__;@K@'_SLK(/_P->I0V/D@M
M0H%<AWX%W1G=+2FL&V\."VP!)C]HF^5O*OC6X?V]VTD?Z$>>8V5!5'INK]"X
MW/(FV\!L3ISM&BWCPID@60F=A[Q7#2W^>)8R'Y<CW%[I,NE.<R-9T=BCR>?L
M:3.@FKE8K-C=<L&.C.?]I>LNQZSUW;F&O_+L0WO%+_8_Y>?EU08 _]IC5SH@
MW!0I?%%Y-#9,T!1/0[AH=+@^?O;U1BY3WF> U&)JR-5>5"^8I)&JXT?H6'!2
M_=KH</*7(;+]NS?7=O :FSEUR!%3WB(_"<(*X6N+2D(<X<2P+W5ZCK@6ETZ%
M.BVM'Y=SSZX-RMVZWW!%4I2%MWCP]P+< S$%;\?43+8EN;:U7/Q:DR]F.&&\
ML>7()'5HU@9L:HC"WQ^.J&5BBL ]*SE'TZ%H,"C06=JHN!"A*[^FV'V:*_*3
MV]F(.??]H+-+MVA/>6/B[V_?CO:]I]S+XI1[=M^"]&J(]@E!<P11.XPH-U?H
M@'L,WJX$I&'+GN_Z5#]9%/I+KJ&Y!'Q^_%EMB0X ;8/NJZTJ2H_BIK<O/FIT
M&QL45<ER2B+LR#7<O_1NZ81<8?+S*S9_6,/A\\NF$'[2C-'(EA[/]8*I-9N?
M=D-PS42C3&>1[Y]'-9Z->5TS%?TJ)&9D1SU+XB: :(*0UJT3P4,;H"DD/M/-
M^LKD+\J6S@;2O<ZD^1O9!C9+#O)ZN*@E)G\0^*G_:_5:P^<$3UB1TV6^6/E(
M#(WI,(EL"&_KH4F-TF0=;!GN!(]QP=<B5:\IJ6.O=G5_XJ_X\Z'CDN?)E%SY
MD%@AJ<1TX#MX!3?.%80S()__BS[3;%(P15(4^>OM4F^K%#ECQ-^,$,V4_J64
M*7Q9YS%M+=DV=@#&>]37<WX6PDUB4$V?X0"40/!D9[914@WU"@?A5*[RU8PW
MSL<LY(RG@@;Z$L^DIP">^]0[::#G:_0TP+_ZB>=(MF00R?IPV6N/XSI7@>]G
MIQ?]INJ)&A11;KT0W>Z[*=L\K><$+?/%"Y+.BF!LEL?.6U;SE=AXBH!K7"FB
MK@R.?IP4LVA,,L,Z$SQF4LO*/4:NEN4F@E823[)4READ34N^?EYX>GR!QH@=
MD6DM\E.>RKVH8$'L9E'QEWB7B#:E2R[^-&E;\9"(BHTN(6[]AW *CQ&-O>T]
M;6I.=Z+9=O%IQDI;"T<V6TRNWKT)[T+..?NO.E$^GTM5$KUW3KN*A%-5J.^/
M\M+1S"TZ4/D&/!49WJPY_\U$82 TL.J]>X6=@ZWI-BYHNSTA/)TIP]+D.+YO
ML-[=:LW?>:-(9!\^^?>F7H6EWK!.H!KZD1))5C,</?].7* Y[8;M+HC/_230
M\B?$V;H^F@N0?4'4E&NQ+AA0^DBE?'EV'2VN=U1ODDH26P0)4V/)%C0>L9-D
M.S(P;XF*VIC8TLQ$>SZ;K?+&E26NL!;!M>!L+9*D4B*0^MF?Z@+4L2#(O SH
MKD/7<!J]??RFR\^#)'EQ32HIQE!?W,B.]A+^#,[WZV@N&(Y@93NR*;!S>[Q%
M;&V_-NW3>=<8,PU7(\#+:W*MVTQ_&BK>:HV4B(-C#$E0_5RQ?:,>.J JDR(J
M2P><8B)LM=%8Z8!H?6H:'<#N@O(J"JNC\:*JPS)_O);)6J8F!2UJS]2[CMFL
MJL,UX'AS\ $($LFP(TUWS.&==.J%NUF/5T>R[XU7<_*[CR7XN?X9PHG0 :PG
MX1T@R@M"[%%_E3M'<P#:94I_KX(943&J=(,.\-A^*OLG!.[DE=4=N*FUI[Z/
M:86_8G"-)AAKL&HW_#&-H?2BFFY43+3TK(1@GI+-&LV6MZ:;B%LS31XKPJVK
MX!_[E#.>-(N9159JTC2"]N8JC QKHP.VG= GX!L&PZ!=S'%K'6[SO(NW.&QH
M-[&>Y@'2PE<1L73 @B20U,3XI7AX>QX=\+:':#&-QEZB S[2;+*J-N#)LW-3
M6^;4:O@\=A"$125"H-IX1$<H_-7R:*&;ZV1 ;,HSN_NN-L;O$DN_Y\KR"I\6
MOV:I/'Y@1,BDW:(#XAGD]G(00PO/H1E">#[_B#TAHM'']9B"85O=+>S#%/!B
M$L0B?L<FK3/T69#IXTN?DB<JVBX^3;QI.-@55#%GPE2K9"W)'?WNS3(P9<BP
M)K2L"Y2UH[G!<")624\;/96Z*E+9_+<35P76G)/VE+C8L2]8I V)$;;2*M$'
MKT[V^?SD589;ZXHL*L@O */5J'[Z8PKJ7D#K<.]G6PJ%O/H^(IRE\ESO)A?@
M%$$9&CL!BYSB7M",H=C,FZJ/0.47[^I:K;J?=]M=_U5;)53'VRYK?>T&9Y3;
M[V/\*8)KW"1&D%[$32;"F(.'L+B]_@%=_D\&\(]?DD%!7B%_!.,OY^)LWZ<,
MB:KW6.5R0:W%WWSZ8B F>)\D\GC]WOVK2?J[\?$745*[W.U(DA(")Z+9;3$3
MN-A.W+<T_4#1KC)3%*HBOP^Z:%M>R$SN?/O!J1OVXZH*[&@&&!.M0QR(Q[1^
MAZEX9CN7%RQ ^(;40B]E*L=<N?]%I=I@D>6U5*KQKZW61Y_?B:IZ4XZZT[PV
MWP?6]72?2,GZ%5QUY\Z#I9<RCUA_ EA_VFS:4'@[&$:(WP)&H9WI@/O4<(%-
M]+JF!@V-VR3N+O)O.4FM8L^S!=0M^_5UO""]NF6$GEPR.C(XMNA%A"AM?#*[
MIPUQTEV9I-DIX![FBX1$],V8M5Q:>)"JF0:;:/^N<<Y A9_I1CPUZ$-SKMX%
M?^=!YI8:H3'KE!T@A?<%T9>43KX(Z]^:A[_B6[7A6PW]LNWVIWNOW%I$FQ_8
MKVW0?4%5>8E*BV0&F=\U<+8LR,W%6!D;&,I=E,>OT#@8\L#<C!!)[ "S3!\,
M_V4XL9?U$&>/5]?&6IK%14?E8V\+5G,[>Z24>S;5X2H@X;WU(00=4 -_A2IN
M=E>D."PD1"A>Z/?:V7RK) 24BP$ 3@  3(DVQ6]&S0MR_J)58Y5S[MQUL)A#
MD*2-6O^V,,%:,5S^[T7^+][>,ZK)J L7C(H"(KTW@X""4J5*,1&1)B*"TDM0
M0)H0BC0-1$% NH" @A %$9$2Z5(C74!$>B<0BM(3P/!""O?EFYFU9N:N6V;-
M7?='\@?.6_;9^]G/DW/.WEU/OZS$EN%#XRQ-8<2P]\7'3PGR#FH[)RO4=6MW
M47G6Z*<##R%L"V#<2M"EDX%;N'DE"IK:":]L[B(C*M%#S,&;% /*E0F\=IAQ
M@8>O^Q.'ZO22<(O2=\8,%[_5M-_AU3>5@K"9JN[;@;ZN<0CI ]/!MRWZ@A>&
MA=>.J^G3KT-(VL.1Q16SO2?6_^"L((EM"6?.)",P74_V7OA4]7.:E$V[U[M%
MK5>[-F61[M?6OBW[^#8O09?/Y[A_@A'BM7I?Y;(6!M!06#CAQ=G-'M$L;% 8
M<W+^Z=/1MYG!8H;RUQB1@N.^H2TK]F-4CC'R*2)VXSD)WN$H1AJ)6Z4+$>]Q
MZ&=YW1XHV!CI>OOU!_^R^\"#H,ZE7@$Z\8S,&A*04Z!R=\T[)E/XO7*UB)@(
M%'SN$,(5(F]L0TB[_C7>-&F;V<<YPOI3DF+YM^,(Q<OF<^T0,>43,]TO"NW&
MO\W@6BDBC>.Q0^387##6&:9!!_X0XD8_S?[!DR_%HR($V6DK8JQ*3]W>[Y:4
M\J3E":HE#FQI&8HII2J_TM'&4WDJZ:?[0?MO 9'S38QT#G;@%GQ>; A$H'[Z
M-+V? ILX\U2-ENLPT1F0LHO]N06<LWJYJ6(*7 Q^OG'_H?6_>)/;OWR%C[VR
M-E5D'/:)NGUED?V6U1ITXVBYL@I 4\* +KTQ;>>2D%Z3^M^/)CMG5+P:W)T?
MN\D;QSJ]SNA>O];E^0=[/5'$I) XN3S\9:18GP24H0(.(9S@5(Z 4]D+)IUO
M[J V>W<(67T)J@304Z955_$DUC_?MPZ$FF70<_VFAY#%2W""</]S_*XJRA*<
MXES,(>2'1:$:@HHE'4*48?8(="\UR6H.3A4Q/H2PU"XD1VH+'AWFI"C3N3:"
MNO0H;M3SX<$3L"'?5_O9L$XP8\S4^O\1^+'FD$SEZR)S '641ZOA)TPA4ROU
MT?'SO4\GY+VEAE-'$G]&RZJ-';.3?G/WV\+R?$#&) #>@($!T" B"=AHU/T"
M()/@VEDP[V [9ET5MW:GW%TR:];E+=^UFK@.%C&&4PP)<TG5>Z(!P]B;.7K:
M2E--??,W/\XMV&".DH"^ G ^MY1RJ8^ YJ/>(]9DLR<ZKFJ9L/_\%D%95^MY
M/AN2\*@G63*QTD_K^[,%SSH% SK;!4!BG@4S@30F#7G4.V0FR%)UO=WX\E)*
M@JU(QF<^S 4)*-U_8"!<R\N1\^UDY=Y8.S;6EKUEZ]AJKA0)5N21]U=3]M0R
MF;Q4TW6:#5;2_NK+%Q9ECO=<U^ OX$>'7 #IH *0F;$"^/OYP -173J']ZFY
M20!M:FVW(530_N)<74BGS<> J$2VFUC(J>!?XW O!.<&QH3R1/#!U9Q+L+ZS
MX/!34_%8X!%6X'62+HBC3/9TKQ<]LAB?BG$6YPB#M\]S?9\L)("WNI)-H(TE
MPA_1I%J;'V$F9EE^?[!XT5MWLJ];V5C,,<X67EFTB?KZQ!EZ5*=2$#>'"<:7
M&WPOWKC;89DR!>QU]O-V?N!(^ZD96.6TS]>^R\;RH[]6K/)8VE<A:B<8*/..
M1J"CG=0"7J6J+=6:R%_IA*T>0EPGU>!J4AC;U7QS5;\RL[^X;H'AA _19F$V
M!\? )R?1^R?AD6@7+RRT.44(2.L4*O@I4]0-W<IM/66=(3!5%?[8O[Q377&_
MLOPRR93*7TQ&#H2?")^H.<B,*9%[/*/>)71S=<=NJC!3R)'9)<F?QU?=V^ *
MA"]HH0A>@";>,-W7.X2T02D@)5B9)#<K'W6WPRU^IH*DZZO%(82>%%W>-IS6
M93R"_398Q3]B]>/ E,Y*!OH"2#)D+DW1]3Y)^LG1S<>?U;GZR!Z\\L[=$I4F
MEXZE124\%N!=1!#]"[\#6RAVXA;A:A/V0!\3JAZ#+30W"EG2O?I-0OND>YG&
MB9)O4ILC>$ MDF[$V*% .6-S"/D;@_T GZNE<]22$%3NNUV#)D)-G<D7,)]M
M*[447J^%';^\4'39Z-+<HFME"R3A75.NUNU#"(:JX1$P'[BQ?]8+M-LV?4")
M:DY+J4:>1-B;^'U&:0Q3WP3/O2BO9Y65:=@2N9FIRYCW C)W/YR*!<$#4$=V
M#88XDU>&5<(JC) $Y)F9*5[+UH\I1F?6SHD2RW_DT^NM-D_>?WMWL6QC[*Z]
MZ&U/X]YK>7$R+U;_FYMQB/")K3F#6-0Q2D#X;[KZB.Q\3!N. STO3&_/\>&<
M_+/^!/7*WN=:\(4)@6/?SOP3Y-U*7SXJ*^3Q%!H'K7+K4(A1.W"=*=UJQ:]C
MJAV-Q*NL\)-\I;[9//X-QS<T5DUY/XJ4R@2-;2%*7Z:78?&[;I] 8?_V_G]W
ME>?_^O"FD$YT:2+;H,?6PL^/2MDY2+2-<J\&#W%!HIF</22=4QE/?]R^1L@R
M:3BGEMH "SLB*J#3FQ_MEVU11[&R=C;A$*3H4FZC?.#AX'W1CK^,R&R9^1<<
M/@L_725?M?#V?(6^@O*#Y'(1/6G<=3"RVRPZC%*><X!Y!'@A"_\29XV0 E*>
M59G7[ZSKGU ;84B(TOF^;TI^ > )AY"I!O*G46V;+Q+X$$R7;467AZOPDA-;
MJXR786Q7M]"^7Y'VJ_?EDJGH(+@3#A##M^ F&N8MW\QJ$VN22<)=5J_:8,6!
MI7:E(SE5;;+W:Y]7"B0:3=I$"JHMSHE&;CARG\@P2R@W^_.N'KF_XHH/0HEW
M/A2L#C5@EK_IMU9;,#FZ5=.[0VT#$&""%Z0/T1E(#/RV7;':5Q?LKHR_E:UV
M.#[*M&1^.7$T]D2$9H0P]DY;W-&&_0@W=(MUX]$V+VEBP?03AQ*Z *DSF1-C
M09QI+_4=_;TUGM;AMY1G(M@3<<W2\HHK)!^>0\?CB-<5(N%5R-:P)VO?PUD'
MJ,=(;,(!?A]GW._$:VF]=3;-F+2S<*EEEC^>>;JD1'=3PA]'0*Q+$4Q!&5(Y
MMB$QCWA)9R2BXU5[DT^OGG7]J1F>Z:<T<XT],\!GB6=.Y=&/@-]?-T^RLS_[
M^74[]ZQV6G+>;E-5Y=8W64OG=(+SF5M-'\^OTKS#?!H>H6\AJA$=5W7GD.M-
M)(G.R5MJP4+82*I<T5J0F4/^U<9*.UMC%2\Q2TMI&\@Y&R/!%L8L:@XM 3='
MV$K$59ENW"=N?<\:BZ+S3JZ<E1_;4"GN+GD\M5N7=-'UGK/PU05I)_:3Z=%/
MA6A''60B'>2VJ-S]"Z@?DO>RYV<;0;F8[\26K;%D?>KN^C6))K0&FFB<O&\X
MU@*EB%3A:=(W"3^(CSU!?51RUPLIQP:R8E'')/F$BT8%<M1_!O]4]5!Z%"-T
M2PN\$KN^L&"7R$BQ<R2-_,NCTTU/V[8]]>+>O.2\\S%+>B):*4A96L1-V^H^
M11C=XD9GH$_ERM<0\=&!,\8W2!9_^\H2L9,L6MD5/.76$S:$H&-&ERKXNL0X
MLXA+&81\T\EZ9&93\OLDCQ?IIBY?Y'W&8*5Y<?D$!)<UH-66%8W]XJ#K_,G#
M<M#18;K'3[3Q<E%P$"SN?=JZ3'P8Y\Q3S_Y?[( LELJWTX'_RM^UP0)RJ+92
M]E;-SO<J*45K:6LU>_S,++<6=<Y<%YR_U"+A]F#J.;=!8H$=*/PBKAP51VXT
MHX124:,P*.KF($HTSS-3$SV%TC[@+1T^OD*8'N,T/)_E9)JA6W02PGEE/YX5
MEW0(J9+J,.4)Q^-KDIH(TG*;U:9<J)LDKJD5RQOB-V]4R#6EO__C/B$0+69$
MY\S03F/_CHW+E:8]QSVZ*M'N-]7M1D!''^R^FIWX(<KLGC-77^-[ND90>WS<
MQ;?][+\#?C(;=#6WLW?2?VL4Y$IA5]G[T*.RIF-AM<ID^ZG'M?M3B+L'S7F5
MVKP+<@H$]<C'&(Z_P:]6;>6;7-GR"V<Z,/*KLRXV$BD!OP0%#?N=;0/WUTRT
ME'<_#EGIZ*%  0&&E&GX&7I+D2@NN?%>RMK8Y5#R)%LV<^/P\JWGWSH;;Q1*
M%M\:*'[D5!"7XLA.=*.SW:!E-\L"%7(7Z N=N2<I-V)YK'+%!_/L#-PDSS15
M#>T[B;@NGGXOD@'ATKJX!'QY17[U:7(+N?J'U;Z7^79A19'9Q2#<GZGED$(J
MKS&=I8X43!:E56L;$1=:PT4!O\_N3ZZ6OO[=7SSNV/>X3[7*OV8Y;E5%3/F5
M8F1"X!KB,;I%\1#BB> (GT1_Q3^G7PCYU&\P]&^+BX;;N.-A9L3[+ES_0\"C
M;#XC2;_744:]F#?OG)S8VY*!*^RVE20I4)UT3";E!!]59(Y.RY^>G+&[6=$6
MP+WR6\DPZ6.TI3F3DZ%8A,R_/3H3J"NDTP"0B/HET[3Q5DU93I^'>J5'7IBG
M+34<0FH=^C$]?B.KR]6??WEW!-@\'C12^'X );^E%6KS4\ZAQ(8;_19F'H@*
MZPSY9K_$JT[WY;S2%5@VLF,\K77*.<KR/M!+N8UNZ<?P:GL36(K14<UG?VMS
MOR^IJZD?]L95J1KQ/\1C D)9,L[7O!Q/D)Z^YCWK#8+E"?JT.KYJ:^/#EQ#Y
MSF478G)K0VR5W5-D?24B_U%#SK,'@B_BG.^VL$"O&;M-P>=BH41=W)GP 3R+
M=[@"RJ6B>5A%U-R#,:91LY;5FY<J;:L<[#OP-?/^*_5,@8L8A0"DP9TGBJ%!
MW(Q1UHV>RTC7M8I:J]D_\LK*G<[ER8S/4%^T<"938;SDFC^_^.!$7\3&?8^2
MTF$,E[?\>QN6; V4:L%+:_3C]%H;Q:L8[4!L*>X^*+,(A 7[JM_AL)#P7\+"
ML6KLO.X<FK17HN^%L^%OZA/*W5Y$0"#7_US Z3::@#R[D);=:#/WX;T#BAL(
MYGT9Y;3SJ"JD!!L4-<D^.<_LUR!J]W/:5#*M+UP6W>*%FTOU1;=H:WM]!+);
M_#TS\6=0-EIVWY'61A?BGT:CRZLB3XZD..0_%*[)+^:3=JAJL^PA;1_@*A:1
M7I(XWK'A7MZ8ONV_-.?)G0YD$'[NX(DG^GHX$ZDYF235*H1\J0TOLOE/5>+,
M(*N:U-C[];&=%B,Q#)RVZ0"H64ZUT:?'QH1B7L*.K8T%V-OH(B_@YLW_^$_>
M/X0,R>E(13F+__P"@<1'W+8_3:&0(T" J3G:R%M1V[[6?XIZC=3Q)QIE\"!6
M-B,-<+-\I7FEIULD9;+*_]SB*7W7'Q(:#.S9G:Z!GPFN,1'^-5]Z#H*'#NK^
M79&=C'HDZZ><&O=$J\&&/$;<AKW*:\21+6E5,,'P*1C'44]8V,7(#B&?E% R
M2Q=?)I^_75^Y_:DXPI7%28MHJ,^@+L3(\CANPX;B2Y6CO:R2DS('/A"^H10\
ML+?)HPSCT[-&_G\_8)B1(LE1#*XO3[-(_S)D3%[]%U98L82:*=G:\PD.>Y!9
M29[NS6P:::8E6^<UGB [@R^7AV*E582+&<^CHYN5ZDGZM4C/O4I=:$RU5LA<
ME.')69O2015!UQ,!9U(AW5>PZ*)B_8*+_L/Q\>LC<?FV.=8[@ZFIFSEC<SQF
M>@_=_W<VY^#=%_X_"[/FHOQI\?!'4%; ;AZ3!)\7^AW(SFB[6CEY"''VV,MU
M[9W%WQA$?HLP$#1T%M9AV?XC*(D9N_2?OC4%\"4Q&/O1N4_7H[8UMYM^B>:?
M?M,AE&)B\W>D'T/P'+GH]&[%J&/&,P<S%]K?>J2%I,CO!F$70H+6VC%<F1;$
MC;)";_EB%Y1Z@;Z"')^%LEZ]ED5*L+Z@?X* 6P0;*UIO--,/,=FES66@PBV6
MJB'AU"N>\DI'A,- @Y>:"&#F7<=BFKE"K#H6C6@8@E<QA:F7/;._4E$0 NL.
M.-9UQ_3;B8-[1WWL4"&(H](T;<1BNX<Y6)4-H:NG=G_:? Q=#W ?5.8*%F2X
M;C*AL:/1\N-L(;>3>^L[F3MQ-S>T)'$*^J':,LFEYA__6J6E57ANX/I'H# P
M8WX'9:TY.Y3>%LX-!'Q$*9#DDF-01H2G#0V]*\U=WD_],UZ)BV,SM?W%/Z;>
MNDWX$!MYVE<$^A,)H/LW0$S3 WU'+A&<@A29(M"0+V%7U+O8@8OAV+R)8W[>
M<U>5^MLLZ88/=Y;:['NW%ZD$NT\OY\[LWU3T2R-U=6*C#F):%!)@EXA!I2>F
M5AWY1LJJBM],1*:'N+KW_[QR?WM1<2[)X%130KY<FZR<JB6GO^?!QUG<TN.0
MNE&/N)">I$0CZ4)O86,3S>!*>,@AQ <W&;.0&8&>2\2SA*L"C)W**^&*R;I$
M>CFAH6"PBO)B^%Q39>S#UVTJ9SZWKKI;AU[Z8(%9FCR&2$+/92*(]LE)4"[P
M*AA(R%U"8=)4NR,[R75EP*7&@=NDVK4^1TC+DOT,)XZ*$GB=."- -(30/X;W
MX)BJX,DXXDW3*#HS20X[I0+EH<H-5$V-=YX(]5_QO>@B*5I6-UV:4'PIY0<O
M=00HU"&IKZ=0#/ >&Y)9R/AF82 VSR;?N_3D4DY7KWA%;K^ 4T^H@-BNZK++
MKB*0%?AU.V+99&+"L=\[>( >4YSSX/(5V]>7+[^KL[6R"JJOWIVR.,",+OD?
M0H1A,BN8X^'L(?F=64,O=[&G/:PTJT?M3J8*9%W/CPA6FX8<DWP%D8K#4N H
MUR&T>_+S9D[2:-I2(KQC4J^FF,=#,?/'CK.5>SQ$Z4=[OB^3J]@S'5X2EBKR
ME')-EYA,9Q[Z'.*IX6)REZ!?[)7?*OZ@[)6>6$/.-M/^S>_EBG_$4<X,*=O?
M[&6*8Q,91R;HA6,+E_T*HC+./4H?FRF<#7=<@1(=MJ88NV:5JH<>HV-/(ZN+
MAVLJRFN)OY)K?Z:W=G'QUT@)OY&6;=_MONIU<!Y %WC6\S_;-18-ONN-M*O\
M&L&J:W994I\^[VR1\:#\B_B6;U^4GEG#L6O?H?TQ5.%>BE0;Q2 <SZ=)+SC1
MG4=5J#DK\7 _2'7U1['["X[;NAFOG04H\#N^[+LFCGCNITP6B:<5S2H:*HS#
M:NC5VF=Y#SIN*F$=?:R"K+PWFNGHE/\Y_8?+P0@<_8)Y"*G6QQ%HEI1;0,RI
MR$^SLR97/[UECZDJ6ACZ$"S[2C;5MBKI\T=IMP?M\D92%W!&H.Y;8I]L"6>A
M=P3AV'=G=$JI.B1-FK=KDF!CG97)LU@?@86<,@+3RSG-;K'N8Z_IYZFJM->-
M#J2[Y"= +$G+N-J*B&M3^VIBJ2^II;HX:Q[JG/^B$\'P^LR+A,L2#3'^![ 6
MPN7+IF\_EJ5MK\TTH)+AL967#B'6UH]DL_Q,&M3J$79!-P\AR@?R(*C<")\<
M0]2BUX^:?/-[<8?E=]C>PWX(B;Y__'HM_V]QY9N<;",[$JD7F8Y=<W/Z\@6"
M+90A6M%9,30L]SS[QOUBE-*H*GO%7PQ72>S7Q!%4Y9<I*BFB*QW/F)O/N.S'
M-9=ZF3+BR!88>5 C?R=NS[%XX!"2T37@8KU5ZK2@ 0]UIUGMEUX_6E(@'X^3
MV8FALYD!2PO(YXA*>!OE$'(":.N L38WDK3LINW_/BDY>#S41;:Q<ZZ2+\CT
M9618$!-:;9EW%*]R[YBHS!2-L_;DPIX/Y-Y]$D?M Q')G7XUY,]"5PLVCM_Q
M"JDP7MLUL'#-,L6VKVQU3R@AX\?ORY<2E<OOF$J>.>ZUVY/@PSM?W/,B9Y*/
MD:_\GH3CI1X'6-!IZ;RZVY4["#J;  T7+D=O0Q _H^<M@4HZ)QJX":]!5QU"
M"%9N861,)2VR^Q"2_-)EJK8_<W-!J^[7*79 '4.F ;44,$1;9P\A406$?G#0
M/#^]\VAQ+-8A)WFB>8!\"-&B7YU/#MJZH-#TSGM!4(.$![1DZ.[LM)\(2GP^
MG57U$))%.X3X;]&79-::2PTH[%/^93YD*V"CF>*.0HX6HY&4L\'=DYOXD^2I
ML##3\2_2><TW*!*+<$ .OZ&[@)U@(0O5DY+;F@+HG%N<7:43-J7X\=)-$D_4
M7EGWPN,_)W+J1%]B._O_:V#_9TIG YGT:S?'0\AX]Z=#B(;,]AJ=B9M8"29"
M0?A<7CTLAG (8?T+NS3@.A#(C# =50&PI0ZCLL4"2Y;F.HLB+E:3BU5?2;U+
M+TM-C-.;!I$W&C#,&,OV7J7HLXD&O)(9B07%3R9XY<"PP.&K/ZIS-J#N&:5;
M7S8@=B97?U_W\V1C+V><;>HE.X SFD._!/ [U%0#1>__AFO^=GSHE=W <K_0
ML_R<P#$USA,GKYR[Y6GZDV7[-+W&"T,T,9WXTZYYBVP%/=',W<7:NO&PAEB:
M7O(]<-\E3C40MOI];!%+Y8^G,Y'FX>-K;4+(#F14N5K:O.AUNIS4/2*E3^[[
M4)FH:"I!4/(A\B*UHB2A/;]BHZ=F?)9?,'U!:OV\GEY3E3')-I[_>=_7.P?M
M7G726\7HR'IW6AXM!^V.9J:/(!A5$** U%T'J[;)=9B+DO.C%$4MQXO<7PP3
M3E?DO@@6D*K!MO8#:A+DBN%&5LHM+PP34KYLF;B5)'MA1-8[ID^TIN!17)^8
M8"NS7$J;8K?S&3&B$OSQVG+E+9;6!Z+RV5C]L-NF;V1]!"TGUFE6_WSSXO9W
MZ*<905YTGJA.Y7[:FBLZJNWW$:BTJ":I3M<$%7^PG>J71 HQGF\?N@%I66!X
M1RZ[I.)FZ9FC&G0@.E)\_;7HS:3N0%AD7K,"<!>\S!+ 0E*8@\8V2S@ZA&2W
M'+!'(PF#/S677HOOW:U/54L1KXZ>]4AX$:4AY>Y88J%S?[O_)7INC<8WU7[J
MJM1<4M'3 A^(O0/P0<[G<J[IZYH*>;^IGW^& \L.;-34\OT2U3]1%'[N%+N]
M$?*X&<C7X',(D>P?\R3B@8O(3@6N\'[\U\SV?L$0 S-Z-TDJ9C<MH' V+%<F
MN;)[67QSXE*%.@.QQT U$I0?>T=$EJH,?B<"#[813/VA'X$T@T3)$>VK7QB,
MIRRNG/7T?E"IV[BQP[/H&OR%[TX8-[D;R)S#1^(JV1,:34DL;2 =2@]1,/BZ
M\\];:ET1$58ONJH6JES1(?53I^W5E;*0@1S9&QXC246E6FNU/U=SG@1^'2RZ
M^41EX_R0"=U@H8O*M4=G@5(,PP<0M;@VY,F07H(ZN2LZD';=4&']$/)5I0%]
M]61C&>-;WHH?.*6BGJ_:5ILYX<[T#BCQKL)X_X+IAO'<(82%JD'#H.>Y237E
M020/6QQ5K%XT9MR%XT='(R#E<5>Z1.E9KM_OK#W3J6PZRWUB&YUYCU2NS;B
M9J$:-HY<&/HPXE0W^)BBX2TOEIYS3#]C5>U*R.+=[>?IVEG_ FYIKQ$D3O-H
MB-946(VL?5A8NI(5@I(M=,1I+@-E,U6VGF&Q>B%[ZUH4'T"=?OH8\5K(7@NG
M)[G>%M_WR=3KBQY/<$9E.V_<CW(C\83\SH5ER>*B!=55F!S)$C.'.+WZ9+G4
MO\;6,M%#[M]&V_%>ALOG0D6>,8M=2OLN%4=<-7]W8:7;LZI\EV?MNJ^%V!9_
M:=]IF9VI>3>J2 H1L0!OQ[$#!FW-)X&.,&Q(]IU(XZ$Y^L\A#F/M05EW%E7@
MM+IB+Q=$4/(9:]@AI-3+,EQXH.R?J/[FF.G0+N"XO+JZ;!$G[)YBK)VT?LW"
M@B%#$G+L0G6[T]H=#\MXDW7GZ*X[[5*7E,R-_4=X]QLHYNB6GVC&\#,A&3OZ
M1/G(,M2=AO*'B5NEGQRTC-*[3CKGC"SZ,DD\:?N:P.O&J/H'SP+BTYH"XYJC
M6 14@"I.8H]Y/"%0DFEK6<M7*JD+O;B]&(>7"+97N[;H Y<+ZI+HNBFRFEW;
M<P@)W/3MA_<NP PL$,MCL^DX[G])C6#.<-NP(B[,];?WLP):';DJQ$-(C+81
MX6]!IF'EL'Q471-GH]\KT:_/WR[IW7C(>FZ:0ZUK2FI]AG(K1(I<"Y@Z+R A
M7AD'>S%;$_E<>57^=CW?\&?*O[*+Q*>D.[&=_MI3D492I_+AZ,R)Q#URE#I.
M*/P<]<$H[.P*G>?WD(E>VNWH@U^\-I*/K?-.791,-3I_O_*I5J4T X0G8%YQ
M=PDQ\4 XV20[^&_I:J#S956)&/*X2\'8X_3ZAHWR+I0RK1FF 8#>M_(9Q=E(
MJDN;3T\J"N_[V%'@L58Q>57)^,V=7TX[_5O:[PW#9O3]^L*?HY1HI3!AE#N0
M@PU1;W54^DTU(BB<:1']5>A5:$*.JDZZ=?*"WBDU#3&.DINY3*=P&31A_3$7
M+P0W8A6F\A5 %WO*S&OA> Q<)?%_![K8*-ZYGA^310M?MP[_Y/F2%WU:G7TZ
M&9#8HG+)?,=58&(?'T(29EF EB*4?B7I0C0Y*,UFO,NY<';JYT ETF30*#U5
M+(C/TN"68D\*0B?']9NGRO!TR;"YD8'!^09D Z4_Z\?.+0O/I*S$H33O.L\\
MLM'51PVE[/DPI?#)<!X2LH4]R1)]!A4VOY8<"V5587UDY"%2WAV:[\F7T1][
M=E;O_$*2?QS"N=V:IY>C%Z$(<D107L[ET=6!?8H&]39IJPO[TC:L,WV^U%S8
MV$'W3LW7P8WU >])#X--\7@_L:+]6FCF$EV6:@"B[W,0SSRH</#[:;]4/$@V
M$F<O##=+AN2;AQD8_RY3 9(^:!II"99]JHLV;+]T0I&+"1<JGGX/4A?_!S[!
M3C:I!(9(6\: +LFY:W*KY>4_';;\_+:BO_U72T?Z?OJI.'U,:_VJ3=Q_>OY<
MY#S/3I7HU_W;7"$:-Y4&)F:Z9BUG9VQW%=O_7/GA["QXO<_!O^AI:1.V-&W;
M;;<!#%A$%,X].;H>G:#-7V('1+9I5MZJ"2;*E 2?$LQE5MN$S!D)E_E%UDI(
MG*K/(F(!J<QUN8*CWF_TX\9SHM#VK/[8$I>1\R-\"V:& _,>SK%G5>Y!&&8$
M?=ENN_B8\FY6;_,NF-SS3&M$YF_#AM@O);US</6PN]<0Q6-F(_R_<V/X___Z
M4""Y80@B/<3,]0,7^UNR^VXNK(_NA#R7Y20K+WN]6:R-\GV/R;)QMM\5KC"$
MI.R8>  RG9J9;3A!#YC8@$]6E_5O[/UA61\+B\1&XK=4]6//[U:_%N'0Z1(;
M&WYPD7+3O'!&=2]_\>M(4[KU"-T2,[T93@+A#7&*:D;R(NL2M4(0;0=_7FZJ
M]/-+V-MY!'$Y&O,@W?RU.ZU;7*_U%']+<!UVX3IVT$5G;J&HUZYG4MBH:D21
MW_N:22D?)2>S K;Q]LKV]@FYAMS&X@D+SZZ(,CZGM^&("-,(>!7V6<D'4F&L
M+$P0F)S$TR^HV:Y'3'8&ZYEL3\U 9W@>(M-%4Q'IS=>+&XEPXKVC4N(@<8S!
M0/X=0DZC+I!4L8G:@00O_O*('>/SZU76R_KZWSSB7H?RN#WR2OL6,7Z"<:<V
MIG.X\$S=D&=?P^Y8*<B3:)<??.59-56RX%Z.LZQOSI%KFLV"YM(Y!ZEF1PM,
M8*S,.80DMRG.>-G:XSGRAJ$6T3.+->4#)67W=%1*F"T.(3=JKM4YB9(_2_AB
MAQ" AE:G93,_..PAWGH:74:"QJK,:$YAE62,_)^<H/)MC9W 7V%<0@!J7N3/
M1&P+- 8N+(L*(&#9@+LZY=\&JXV?)EK=21I42]6KB[MS)ND$]](UB-FWM"3_
MO.;PHZ5MT.?O@9[R'L[S&,,&B!." >=Y*-ZF]VJ^7=\7O&9ZZEPQ:DWH U-<
MBZF\X?XS1-"GLZ6/>G@6A*\G5N]+T6VA<%-N_6@+\Y*")^G8PK["@P8,TX >
M[[_"SJ-C!5 LAJB#!R2@T?0+P/&Q!=-.UE-7_7O-'Z 4YF?T3Y"-Q"V7#P@7
M!-[:1T@D/D_X9!\S&P4WA\G2QW$@2WS8=%N4O1/!B6*9HP ;@X95O1NVLY/S
MY^"7%)]]]8UA.%$+O=BEFP0E9#0%4B30+;+5QJ JLPL-AK,WBR '!H;[%L.R
MOC,MAF]\E2=+E0T:K7KM1Y*LXE5-14.BMZQ&_\GI6H]@\7UU3<W?GL;'9])W
M?BQ6GM5,-4')0QFU9ZO6++/-XBL0H_BB@U,2HF>RHC1YG-Y]+,/_PV6ZH*T0
MS' OA1>'D"K<I,HAY!3J&M$TH6#<DM#99A&QZOV"([A5H'GP1* ]!WM3N#EH
MYA 09Q.:10'=N>*M1 SSXS>/'2X,.J%,Y]<,6VUM):K\N@(\N"Z(7UO<C\UY
MKU01=;H5)T65(?3=_=Y\KFIDU\3XSL _+\8=;^PCG[.SA(E#2&/JN3.%N>\C
M$4-=S[1U_2ANX$UD'@5"!>VN[6$XZ"*9(YD]4R*I_4XW4K\D-NA>EO]@.)42
M^5W%JJ5?NO3T<&%(]P1V#?U;$9@,'3G]6D;G8H<#? T)^TMW^)L71\G?V?E?
M7-"*#;Z0V75T5*\/REZF;;& YUJ!\1)IQ4R3VW2DG.-U9LZ\[4'#Z^5,S\HG
M?=E8_1 5&"H/= Z_\2U0FLX/K)F05$?3=APF]KDG'&]@%+:TXU\NI.?U?ME_
M?M-'*R!79AX):)K.J2<U7Z R @&$9-:5L2QL%)4[]',W0;I4//1C%;?>L>B5
MD7L$@5'AJ%#F8[>*<H4E%C" VI\Y]N2C98*3QWZC0@M6ZI>PSZGJSI_+*HM*
MD+R)XQFCAL[52KZIZCF2YJ'HRV<-'['6B7+F\YOF5 K>\T35P#_<!)5XW__]
MJ!+[6W"V*^#;">R)4+("CIZ0U R&=F08VNL0\@)W"CZ7\R0\9H$]#L[6*%5Z
MH>GSK5&A_EC9=?ETP3$O@:44.X]UOTB$!?K_V2PE/.C_V+Z2@&<XA'AOC>?V
M=CEJ5I D)ZF3'1MIJAE?1DD"!%?F;4CHXHZ#RGY8VO*FL\S.RCA-'T2U>'H_
M9M>AF?40,N\%2F72*K6?EM@8^H$*OG=DEC8:&X*T&43I?EA5XT_V^+R2Z3<S
M.2,]M/'ZS5+":R<!SE>F8DDCNSBJK@4%) V_U3LQ !Q-O] ,7CH"&=X_>Y:6
M#KXQ <F'@A/S9J5B&M4_X75<:@-"ARZION;BZ'^.>=OO\Z;0-'5PJ;F]-VN5
M]BN-S@8Z<3;Z$.0#AQ _"\IY1"*.&-1/G0*3U4\$):ZLC7Y.!P#_KN?5"05D
M:PXA0B(/5KK>3OE]&I[)=-:BLZ& HCE\+)T3<"7VMNU-HE_"I+L(SN(>-5P%
M'2,)2M=_OW&Q.)D?^NEIV&<;XU"7C4?'<?E[:,Y2G O[^"]\.X9#X4(6/(;.
M&^'@3V#@,@F0:ZJ0S3YUS2V4)TH04LEV;1DGCO:$ N=CVJ' N?D8<C1@O! F
MU3&)B'&+'CS V_\6?QK/M"DJSN;O8&/K';NL_R!=>P224E>\"[=I^@I:9@2<
M,(G-Z!@_K_<.*.,!WIO315FB"O>JOUF&(!([5>MK)Z$^A"A[>4.>VS(9%[VG
M_9!O\0'+N!@\T0(W=9?<,[1(LOJ.GNAJ#0@Y]33^98E"HX&_Q9;E134^(Y?&
M*H.6GMH,T>#BSP^<'SW!4KF/%![!- E?+8L_3E>F*M<!SB2=^51"CW1O_-,/
MHM]R\MT7SP\D>$E^:7EKPR_(<!PO216DU<.]L(!$<%N8^OQ8._KYQ@+[,< G
MP.O3JI_DEV+NU+7CGGP$Z]/O*L6[H5E*WVDSL?_<UH].W#ZA91U"0$F<+.39
M/=< 9: ^',FW>QKZ+_'"I%T\^:6RI**G=$&V9X2%RW:2D07#@KSOP*1F\(U.
MV]+ ';B.#&F+SCRCA&XQ!=VF!L\'4USCG%C+90(\W/P*_GI<*AG=.M-IIZ5X
MCS4IU2Y^(FECW$U@YEG;1C\ @LZ&LQ_EJ WL5:H'@55IXQ'5H+0D_.R ?44T
MO_J-8J5H!CY#OM!K+?WIXR[)/Q4 "3<JG]0<FLH=3'8=;E0EF+*AC$>T'0BL
M#QWNFM</5E$$2Z\S&+Z/4TM=53]GQB)2.)N^+\&K\D'>X/Q?"R-YE[>;..(-
M*!^"WHXFFJ$3\16?ROTDG\"G-JO1["PO4EQR#5$5"5^,3KM]=2^0C$PY3NU*
MH%=[VJ8W)Q;:.SK:ZWIY> F;:.]<2;IBIB/[LROJSC')7 @O]0\=#R?>/81
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M1;1"+R)5ZI#+\ [)H>D^F?*K](=B;N\ACX\7G!=P*&X8EU^2D?I] )W;;"!
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M^AG=@O_"VWL'-15]_Z)10*2)=)$2I$L1I M(;'0111&I$1$1D X"$HC208J
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M#Y@0/168-HI[^$)GFE]$6_*%/?W)ELDO3R^D<+FY/:@!V>R%7$C#XF=1%5-
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M9O@283JXU_%>3Z%L7SUT^:;S[M.=TXYLT<<0'TLU7I%%#V6QF/9:7?_K,-'
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MZ)*U#?$9U"ALFS%I?> 8$C?^?C_FX!!Y-GMGM 9YB.45!!]VO@AA< S)R5M
MDFGJ0!IY.$YE!&$(K2O!F,SAC'L=LH@\[]=Y@\"I3BVFI#)?#&P8K'19T;_\
M6BY._M//?>+:'A]5. \P F'=_*($9=_A&-+IO 2.209TQ*K-2+R)7(@@%WX@
M'"&]&'MF[<987*'25.X-NP3-*.&I)LOR?K@FX9WUDXN3]6BNR/C:\3L>+S@5
MGN"6\4,'1TX# Q<E<YH*#L_G1$O2')W$S<D$3=A *1CDT^OT-T;$*QH($L'>
M-0W2B]8*CIJ38M%J#9]<!9ZD>->\NWG%3X'A8V K7#IH"'2FW"BTWQS)!# C
M\'JS<!-ZO_^IVTJ:#8R0S8KRCJ_-A7SXLG3E=(&#IZ'9"OWF.,D(F"9J Q6V
M2VZ0C51U[L9GS/9+ASGU89%RM(.H%+T,I\22L]W%S J%T +8&=C"^D8/E'7:
M L3J.)DWX;G,$*/"E^F='U(56')A+Q+%)UA[]=DSW4\?0*&1/5<G+':+4[&O
M+:KRE_?VU@/+^%1Z"!]%=!4>?_0VAO<Y-1P)R&UN@7#[^\LY04)8=AY!8_%1
MMO!0J<4UL<%*Z^LE*5LA(@K7>_3ZA874ST?&W3XM<+8]$(35=#F4,DT8B?V$
MS>Q3V/N=+:'G_88-,EJ:>(>%/DWWLBV>[U.Z^2C9\.5SEFR('?OV8Y^!=B@O
M=F%#P/G^D)ML$!0A-NQ=WS$E6R6 - L8>;";.NO,[.%U\)-R"/6)U"PD#U+R
MCR'.L$AH-:RM)YX;<8<@=A"IK*_P732V>MPX/D;;[>SAI?BW[F]=K[V8:2N7
M/[2!<5DH>]%O=UHZ'CENC/C%3,NUW$_FKPH8&FQ$JJ+S;_>_S(DFT2P:_\FE
MG@4_0;(8,#^&>+A1-.;&Q[EV8>3S*.H#,WP%=7'^R+<172:]>[>'LHT&\@XK
MB*_0E.YXP.Y0*"=:.G+[?]I&!+RT0)T,_G4,Z9;74D).-($F1D&=@ 94BJD/
MHKX=0R8Z"Y%_'.$^?CW-%JIM;DQS?X(N#7GW!6B/Y.ZZ[E%T1J^4NB:538JX
MFZ:^:Z;U>-1T$2&!QS3',U^)6#@)FT>VO)'2&Y8-C\V_;>M4-N\?ZB%5MC2S
M)%ZY=G -T;5R4!L7C!6"O9@_M#!<=*#X6X,0OFX,"]^('T8ZH"%_YCG+&KP<
M%I#T4\#4OL&,7[# Q:GK)NZ/+K%Z<O0]-36]9_F9YG-.YJ';:O"#QOBN>4##
M@0I"E?^P,K,A+($=O=EZ#+DI=Q&Y /I9H(@DMSB_^1=_L'1 1)(ELFGQ;K'8
M'XB![\<0MY?54ZD3#7W9#LEK(J_F5[YMU?2W][M+QQY#(KR#!E![MX)."I-P
MG10F2<<ZTG/QRD:N)"8Y%QX&@-IULE\^X>=+9:3!:P?1DAGP S'DF\5^N\0I
MINFH5YJ%XG'73)YCJL-X\Q+F],;]G[Y[H'?8FHA]AE"BI#<I!(% 0'M6L07*
M/#=.Y>$)4RI4=JB.Z^8[AE19]7F)C?85%6K8)[";Q5YPG?G]^=0[",467T_T
M @+P6N:B>+.W9+Z%0_&85I&7Z6+5V=9,KE)W)6NM9Y:^^9=U?RR2EFQ_J=8\
MM[4>].*DZI1'?LL6?&$;E4M^,UKE1DO6PY.%.Y_49MRJ29\VS58L__:H,JK7
M1$55GT_W8G$*4P?D<,>&$ >R3[H31>DCRQ%T-T$Y:&S)@8(])_?*)YX+*'_%
MWKKUGFMMRL:1$SW_]*+H/\_=E%??VL2QUE2QH&XH4Y#B!FN!7RL._5;3O$ ?
M$]A?@=LP_)OAM&754%ZN9D.O>4ZZ$ ][JP0-U^+###:HYCAJ"0YN<<IPJ]MG
MOD[Y_19RRBZ&[L%;>IK/G)2OC\LMWB<:ZPQT@A-ZI?.]C]QT )71#A] M/N]
MO4KM*Z^I3#)[(G[C:6V#RY!>]\WFX#8&'4\/15M_/JSE'CRXB16_'>N8/^D'
M;R427\OG-;#)ACZ)5KI?E"L] 9'*BM]<P1_<!8I5XV4;Z!=ZD/Q6K@I M"S[
MI+*YJD3*=%FP?_[EW4R,=.<]Z8J"9,,\KM\%'7W5B I00.:4L+WYJ7HB.V$\
MC*R!HXC+<;:^2B^+QEM$+JL^[A=C0Z=\K3"\D"CT]?S=W"_-4'!^05!EYPS>
MR@O*UA!A0,G<WW*ZH+S%.!>H:.3_@+?T5?X#V4S2*5;AUM?H^L$[=NXS*E2,
M6=1)%],'@U0NA"AA_^ GZ@Q C]MIE[6\51^A/[J'/3=AH2\V:8(OZ5MQ>>Z8
MK+AZYG[0LW-732]F[TCO?,X3\(_OAP)B*#(7*\@!@ZW\-)Y0,HXACK(P&[Q6
MZ4*@B;]WW\U77QNKN _8&2S$G]RN!>%PFEBLQ361#WM230X@G?6!+12F.VP=
MXHN-\#LM68IM;R):0%R^X6'E'"2>W;Y5*J?,(%)CJ,=E?KOHT%DSI%?**OO^
MA6:M'M)_DM&#N,BZO_=93U-GYI@';8$PG*SV(H_%,>1=TGT,(R?.8O9IHIZX
MB16_;E7HV^!30NX@6I:;,FX&089I,H D7:5VV]#]T[R6[Q>E7-]GTG.;^FMH
M\_5MI4M# H4K+86:_5M2.H;"4N$2]#E7#P[3#_>NNLW^0*X&8:CM\[L.< ;L
MIM'@,60O_.)>=Q>>-7B3R@=P:..WLU:1#G]4SCN.U1.W=[_$VMW=@C@XQ;UE
MO:'^N,J]L3_ONUDH=0*.-XH/06)T,H3)-_ N86/?;<_?1IM+5HUN)7M5RK;$
M]A;I7Q*=2[/;_6>SI:TLGO5;*3L&R*<R1("HX?,H=B$=RD-VGS)KD][A(%\C
M*'_5Z32HE^,DFCEUU3G$(CTWNQD/H[FJBV+8AK><)/,O7]/X8<>9G' H]U\K
M1;PL,S0#Z!:,D(N!\;$[9"Z<],Y%QP+ABO%MI0!_9<-'I]X^V39G+H#X7F ^
M(]!HY%/U$*7<\$%'I1:HQS]<$N@D\U% Q>,"DG%0@9=3P^1S0)9?77ALB?DT
M=WC7J10]0;41VA>Q]L[^":=5MQ-&#4(?SX':4@S.GPT91@I"R!M/DHCNPS[S
MD1:=\64+&.R(R+ 8)OZ7OG#"L_!K@\][]#@UR\I+G/GX/TRG[M=W"D)^!TGX
MN2[I$,2CO@(1NO4F%1/KKSUFI^^>%0J/NV$:SL ?%SH.P^<3G0 OO/#JHAL-
M0-.LQ9).>'WOB#O".5]IXX-[!Z=)JU0#].9?BX G\VFE=RF9I=W9$?2D*]1V
M"^.? Q/TH%&B\1$//P)M:4_.AO%95JZ1<?U+37ZMWQ@U*WH?J4.3PQ?\!U8C
M0/A&7(#A[QQ#H@75*5D@DY2V=M;'][X9F8H+67RR^:VF6B@TYE>"5$55)2''
MX)MLA^J5DHRT:.KO<56"ZL).:)#R2]ADD (>'4ZVS L_)[-?JL!'0@2?U1![
M;+5R\^\(JT'DR*SABT=?*JQ9.P> R["M'@DR]_"B7##6 3VY8SBJ',]:7268
M6^(7M]NA)_L!G7:QUS2U-WI*<G+%P;ULN8AV!H*<P(9#697F0^$L" W<=5[1
M>%U\4YK+UXG<#^9/,5'/8M@AO(PAGVDF3.7"4#0(#KSBW>S.9BU6/"9D<_N3
MYMB18-(9%&>)8G /HZ2HJZMQX7[9MX^KZ0_B6F,L? /"_FMEB VB0<W\!6H_
MBC5(&'%KJ,%ZD?6TGZHUP29L^1CR8L,B_+V+3X$C]6[XDX:T6>:$S82T<6>6
MDO9PAC[.=<_Z.(_5QU>/(:^,)^>FB1645(0/?G%]14;W?654B6V='[F],C/V
M]UVSV&:Q1YZG:,,Z="W(X2?9'N H[N^C 1'##2@$]M+X-)#3:CR\KR_G/=VC
MQK;V7=_R5:BT0FE[KEZLL"$'1TJJX M3LX-SM<>02"Q#@S0A1)O:1_ -1\ 6
M8S50>];P>^%'@F_(B<5R:@*%+3F&*09_TK0Q/K6'TX0!ZCE_0/4+P'K?..(B
M-$;3>NDR;G<O(Z!1R6*"+UQ4+G/.X9/IF^18_2!.KBY[7S+?*(G9;QRG'1^O
MI8JX.[POR]$^S['F73F,MCW?+WL1KF48)6*[JF/_B5S4)E >+A1NHO4'#]UT
MP8?@;'[4Q8=1.<FJ^+G/,7$8"WCXJY+5QSHSH9H>A=W?:?GQ.LY#E[N_/O)_
MBJ$[,[L<Y$SM4OU.G<3BX:RQJ/-E5[72\*SZQG0O"WZK; 2D^#]-.\ P(MI&
M?D)8>E1IW[8W??BOJ.W &((0P,>W^.\[(F1Q<!; R?K-GWDGMSS'#Y/5N>Z>
M=X<OC"*ZSMTS_^&O.18?T\"5B]#!-VY'+ I(W!VOM#: B>\8C[B8K(_]5=]*
M5*4S]^,_K\MU);\!Y<RB:P@].0? HG8C!T*Q_PD6&:4@4*#] '%I<C3,_AA"
MHG\)/?(?<=X/.6D\A6(EB^-C41%DZ<]_YGA_>X.FQG[8NUARLV0+4Z]'$HXU
MY?&JO_J3]X7HKM%SH)B(P+/&-0G_#9(?UV3%L=BUUUWL2'^-"<RUG'%2?].Q
M)?J,+^*VJ*WU[-O'%UX\NR9>I"RK>N6 (VPQYR49A%Z)]HMR)+J98\B?;^@^
M.4!9@VK$LZA+B069EMYG]$A \9.=TN?A+Y?2>3]^3:@+-S.1OTD??';I3"TJ
M#$:CR8&'ZM4.DUE!O,H(J+3LNE5:6;ZTN'O16[&G\LJ!WH/;*K_/Z/5#N*YF
MY2S-Y/-U*1*X>XBU>-]-_9,FSV1SPEK<MQ&AW[)H96E59^F''G)I,E=#6TZK
M_=J >QU#V@RP%:P4V@9'<,) 1KE8O(Z]0&U%T6D)^V4?6!'H0:\65K==5:CW
MHAX[HGG9UL?'>ZU87Z3-?#KN:Y(Y%K\=/_F/&FG<C"4+5\Y3%2T,\JY9IBFJ
M=3C;R1$%3JIU_Z=M?)@C5;0.\%*I\G##.<HN-KG<:ILB#S,PTM$FSMR9_#OB
MLS5PTJTEN AQ'?A'<@$J%J[$Y_KU3W<(LJCF$'=WAR:5)H-ZI'0E4C;<A_@K
M@NMSK6+6!*2G@CB"!K)/ ?1N@:SO$*PX5KK6PA_7%U^J*S>E8UZEG7U^/F='
MNO:[I=J,QUB3,243^X+%JQV.-YN/FK\H#GC1M\+/ FYWD/1_AV0K5?[YK1X9
M)GEX%/_X3)?JR+"J)G[C66L2?V1MF9EGXQ8K9F-U!Y >:$9S!?V&XN^Q1@=Q
MX$T;5]:BE%FT&$I=7!C^[7 SU5P1>P<1JM#G-!%O[G&;#LF$?GU9&%.R;6GV
M&": 7(@&(8*9\>0:\3HE2@@O%[_CVL"Z9'3FB+ S3>)>_UM%]%])466A-:Y*
MX+6=OFSE_S0DV&,1B[>" I+VG61.+UQ'4B#^H$6=C#S30%-<XBMX>>2S2G&1
MDR];=WDGIWW38B=GQ!>/^E6V&'I*"0$)KO2(1=8H/O/QDY4^KAPEKBH;6.#W
MHGMU)4^4XU+"DFS-!X97RQ^D SJ@I\D<!*:?'H!9F^ Y?%DMSL_<YCKT_M#3
MNN\Z)@8)-%]BSNL+A2V)8TP_YPVXW&W,S/1W#?)'-KO(X4:1"V%-+'48-P6F
M3V1E&9=@5>D;7_D%WPCN$U%DCESJ P)>@MJU!B*,O6DWZY1RTC7R=0)/*Q.<
MUDF0!N]R$+RI$IAQHV90-F]HB\AN9E]Q*>IUHEY+#+OS-_Q:A!*HQ,";5KTA
M&9F]1@E#3%Q_=W<_7?!<_]D140_=BV\+HC]+%;V%0$Y%=_7,KOR3U9VK/13[
M?UOXD\B%!?2$60<4JL4'J"Z.MTH'%&,%$9?J$K=*7<Y?[^M+N*R:P?X!T?4T
MA<LGAC7M>>J.O"G,\W]_\=<=H5T<N.N8)N<.UH-\R>+'D)"48X@#EIW,@1G7
M-/=99&4&FJ2]5;/Y(@RR=_4E^ODM^XN7?R#/*S0X./+RU: 3D4]A( 1#5?.0
M^?F^( P(9T+\<1E(KC\'X^J"6>XQI=PI=:\&+;!]!PUMQO+?#\VSTH),JDBG
MT$&=\PR:#Y=>$U0*\1A<?]ZBOJBB2JD/KOX:.JU+M#PM5ZY>-'--,WTV=<$M
M^ 60#XU#-5.YW?ANLTXN$6@<Y05,A:<>]O!H:/ZNU[=R[6 0N%ST07^WM TG
MX5RQ(,=B,TV=!!780Z54N3G.A8;HBD_#_(@M3<M%/4AUJC\_<T:W(95EPY'W
M?A ET >< F[*1RRN&FD'%4"H1K]T\6'Q['L^G)^L*F/F;I#4G)10J910Q,[*
MN#7R'&J ]P4-#0-"@R#>6 *2<JK [_UXKKL8]5$BZENKLU=Q=UYWEY>PI.,G
M7M%+F8FJF,(![0=2Z=_JN'-SC0L/:4Y:((/FH^T/['M\RQX%=4(7%*V @%*R
M1K:SM, ]:_6 KXDS73+95H26LD,=#9%$,;_E6Q&Q>?-0*B.H)'0T250FJ#]N
M?G*<Z#A4A>(P7[>H])W:;O2R%TM.TCXOKGD8@GB]WM:](RS"':Y\HRW9;<PM
M&EXQ_S;HFHST$@@%81VG9PWN*#=>G+Z_^_%#FUQF[+L/Y^C=6:P >[QO"XS.
M&[J)/0.8M0:Q#_7PJ+RYDL82UJ0OFI4@5>;9MK=N7.JX=2G(NXK,#"+&GD#6
MR&/(0BF6;@OI( <(P:(TZ1RDK2P!V!W\:J+XBYGA3SY&UR[><K_V@JX&XO63
M)IH8#XCXDG-I%K"4]W^/(;FB:"3P#K\&@DUNA(@_Z/"X7JJK1E4*W':8JIQ]
MW*TQK9$5]T,<^/I89^I/B<(YWIO\[Q[ZJ39;J+:BF"9?!@D.>??1:P_;[;HH
M4=1'95U<'I9-+-W@,DOZ"?$R_S?'W^0KESJ'3<C7YGQL'_;_8Z5NNM?)[>..
M__NW>6"YCR&KT).8?*+!9G$L@#F&R(.6 ?1Y/^ZK;7M4/M"F^S_R'0%B?K,!
M8K2_I($-]*8)-JZ.=._\,2052]RASB"@%Y$]*%( . K&HV,(]6S> HIQGCH:
M)$S8B?$FQ=KI M"%TH>+:L-?IC,F06V6[K%2I2TV7)7LCB5\NS<3LDOWGT+C
MF93OE<836&)CQ;BFM1L1=1K(O5N+QT9SV?IG*9%*\[),]41%RUMZ(2\DR[@,
MN3I'EI:NV:Y=<'/-.!)9]OQ[2^V3P;=QR\V&^<1KR*G;5$9E0BZQ@+"_VKB(
MAOI%!N:\2&11-6Y*&;@W/%+!%7>!K;K@_O1ME34AEMY.4<HI< !1)R&5?OT]
MQ'C\,:0%&GF1^F4)'@JJVA76,.5 #HL4PQ66-\%3W&$3J>\/PD6?GNN+.3P5
M7.>*> 5:0K^@RU9.JH)" +0(@"\>M,8^HA2W'A#35RI54[E[?])]^&5RQOOP
MG=_R5#-#R]7=\09**G8AK0Y)9H\W+Z=\ACGNL/DY&+F=_5F'"M?DR+?1#2QR
MFBH;7NE80*=8\$@]:NDO%F)7*O]Z!YL:V?Y4(MR[<+*Z) >#-5*]=PSQV+#%
MU\9<-2BU_)HUDW'@,K;S(ITTT#\PI8JS(#-2OB#\%\)JG-OQ;I%5+"P.UQVX
MQQ5N-N#5-P=NCG\NAE7P;!Z4!8VBH W2^'^M3A%F!-/=J3O;-PR]F_U?O$I(
MCA/S%>+_$,J<2&=+-@,2"A'/@;Q%.,^&H#$1$UUE6?KLH,ND_/" 0VG(A3:1
MQROSM'ZGUUA3#"A-(6#8$,]#YM)=H!#+9=RGC MF'0<KELXLKG>LCLWZ;SND
M"VDLQWC9E+Y)OHS+@U7FS/?)_=/,O*[NX_$@9$@A$0[ZF%\#X(.R$$( +TD#
MH3](A9(%QC1O+P9:MER=>0*T6F+MG5UN >H+-RO#3BNN=C3?EYP*0936;NS$
M3_$0 RDA06>"IM^8_13P6L!$>\^ZM<4ZV--'EB(,"Y3S0C&YK\[=28W8KA<2
M2_CH(,I%:[;"NB6&CVB#0J@PO];F)BG+5C3@^[BFHB%E747_RL2U]LZ^Q!ZI
MY 1+485?)0RT''^I(D ^097*6$7R]W/=/GKRL--&:41&*</1^[U$G*RRR$2P
M>Z1A:)3I-U^9UV&ONXL(K69,UUI8IYI,>55%I^I?._ZMLS@2#.-_?ND:VE[0
M03*/AW/(X&_I:S?CQ_Z=6T8D+2?L#]06QQ)KQ)N1\ADX8/@PY>>,#L2RIKGW
MX5O>ZB@129*^F._"0K#T.W0);*&F26FX(?!D8Q2H+7#T3<&,)<R9/TES667O
M7)UV'*O>+<-UK"1*/!9(TUN77C[:DT\6,PF5,GZ=%%0J:*.0Z;@H<8]/?&CO
M[O]N,0W@_RZF$?=?BFF UUD? ?7Y)\/;,CNRN+JJNM@OZ;P?]/E_M3*7Y(>;
M,- *GE7^M],& T1W-C<(MTUK&D>UN/S>:+Q/8;DT;!,HJ]\2$U:=J$R[1;O
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M]MJN@VVP^1=JL!!Z-RSF]1@"?I!I)14/-9\F,07=[&FF6U$7(\%\IF;K1)\
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MOG0_]E*->%MC&G]]QTJ,6T\#5=SU9NT3DS='$GK&;#VSTV=N@[?-O%@(2Z-
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MJ:?MK]S<T^3,OW#%#ZW6O:X3H7EJ\&Y\H=Q"%S8VC^Q-:8F0Q7_4^1?1'HI
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M+=G=Q7K"PO>YOW[>WI*1J/&%./K33%_1X=4BCF* XT&",A8,0:4IH:6Y/%O
M"31L'N =!3U$B <+CP][W]:@KFJ_*'JJ9,5C<5-+:<&9#+/+(\M3)+J0&C?S
M2#P!1P)E2>1BZHXI#;+;.)+(#O&C(W7VW1EC=Y.-_O96)H5DFD:<*3JH))7T
M7'&)3V0O\KZLA)  /0OXXPH.U$V;98F?$)KF%UFS1Z>04R$#+?FMV/F$( +S
MI2ES[W:12P?WZY[J]KMZR\#0,I.:#.VNI9_!]J3,?1ZU'^]:(KUU44^&UV*"
M_J0)CW^K#9'V\%AM<VUA#8_[S<^";OKAVT\Z^'QK.F!3'B1-W0-Q[J'#%*W^
MB(ZTOX<)\9+_^4E"8RR_;=#+Q8=2]XBUI8ELF>$9E8_"):\X#!VKDQ9+=! ^
M@KH ^P&;,@F=1HAC8]*0[AA2SG6^9< M0);3X8!MULM+;3M.FUE^,)?992ZY
M;($'Z@',,?M)-"C-W;2A=/E$6]8;]<U^*]3,BXZ<8=E6R5D?ORA@P/CI9-Y]
M8[S\A1:EA)2Y?HB3FI1,%:NO,GFF>GK0YYB074F8:>^O"9F.JLI7@I>F8;/8
M(WGT0$O9X@P 'K;#>\-,J%Y!AZO31Z5+SE5Y.%_#5-S"NU64*<!S/9!S,^.3
M0P%1([+J$SA%Q4%[Y.GG,%LYS[&,FZ#)A#P:M$RNM(ZEL3]69>\]EB2A/%YS
MV3EN\D+:S6*.BU+)-T=K!^7V!Z*BQD[#;>*QS74[4B>SPQEG*0.3>B&_ [T"
M"D$_XP^/<?H59MP*/4L5E2_RV&Z2]_:$L.'$A.Z70ARDB3=*EK#28%SAZD;_
MXNZA=DS2J#;9A#=#Q:9T9+!5JGC:PWQWBW:[7H?*T8G\M6LWNH]A##/L7"N_
M9W7&I.\8OG&.A?"U'#4HP=WF0$8_,/:*CC=T<!2N]/.&H10.5\%"A!'&WQ)*
M=1*H?(TTF.V4W#"@61<E.=//_UPO#E&V*4N]AA68NC=\<3INWZY[.N(@;"-L
M:)!*#X3ZK+L:3(:X];M_UR(;[ZL^Q,6HY9LJ>)&=HKKHS?X3CU\?USUAJ)JJ
MP79%@AU^@7I.C&&^OSU-E%FN\#N)[IOXUJ5DS(54>W[NQAO4U;U^0:17-RLV
M(LB;,>S=2(J;$JP@I4&]9F+S:WEF<0[8,SE@^KI(O$#=-WJOU>?VG%<O?>H3
M-Y8XKD6=3*,-)LK(2SX%"70;: Q),33LU&@FB3I3T"U*H=&^SQ?\K+5K!$E.
MW.5F.^.&;6HN6]69^]L:'F7/P7\O5*'-4)#/6(C;-K&Q#VU7;?T/2&R?0ILG
MW%7AV5Y'O\UQT%@Z.IW(P1PG[O%*WKKUG''(?JIKT&9J7V*N[ISU#7\-L]O;
MZBT,]27$@;*BO,:3(J;]=;#K>H*M$Y0APR!@YP,PD;+<E"STW"7M(%6P^&VC
MZN[B#G=/'9R388M7J&.*E:7@B 97]D'WW)XKLW?Z'=U$[K\D;8,)N0DH*\3@
MGVNL1//H""WB]D'<&!W"1__?#WZ0TU_;%ESNOB09<$S1,8%7?I?OI1\EQV_<
M+/3%E7@R^)UIST$1>J#+UD87^5BZ2U5?:\0Q]V$C&%QQ7CRLK)#/OSPC&SV5
M8BD5%1RG?*IXA\NPG<PX:<B;M@D;ZD57OX?(AD^JA @<%V,C._@;<?=RO%!0
M]E?!$OZJ\-19Z8-^L;Z3]RWYR.CB=8;XH1S_Y*FT)Q3\U'K#&_L)($J-GAIT
MBDC3E D>'+T,7>4@*Y[K].337PDCR>Z<J,@KC986(R4>J:D\HCA<\:H?5JDG
MX(&*0)=PPY!@:, 0])N,!?7N8OP*T-:+<8 3T999I3G;:R:DTC2K=:RI\42B
M#'#R<PL[0SQNG!25DKR46."F(T9U#OL-*_VA>V*&/^'<QQ";*WT>8M<J!/%[
MQ'P=K[]HZ R?^G*^\8$6C!VS6 AI%H)VD84H?G*-A>AY(UKW"FZZ!=IY<(*$
M7_#D9>=SOARZCUJ\GX57ABJT#"&N==";?M&5Q%:S9Y*;QY_>X,="(#S*3O_X
MSE!CJU+,=481!^6_3'9:/EH\.3L#^DR5K!$H%Y2&8R>3R4%4@!;1 QWVSX1X
MY9';W035J\310Q5)N%LQ^N72/E]Y#B7(>^[^&O)LJ$79>W'KSI -750]B<YN
M"\P'=6)2_Z$401O + *6;O:B?F=;95BO$A:]](S-F'<?LC/X\#00+$.-YR&%
M4<Y % 1C]J<),!'F!:\&1HL.F+R*Y]A9_.C89*Q.T(L.C64-Q"$Q2X=ENA"-
MRLPI8R$&NV@7J0--;O,\CM]56Z%OT:'8/D#F5^'M%FZNTRT<]9S5+Z..XKN6
M045LI,S2+;H_MHM0KACM0CWKG/L^?-*B_%F#QU5E2_DO;W_%!YY4.M2QW?=,
MYJQIN3L\LXT$WB*""UX LY/YFB&6<ZQSKHE\A\MIUD;_0AO-&2BU-FC/7G_.
M)_WU71('%"4F(V*V]"-+L )X/S7K9>2CO0QQF-+-_.E;!]MW1AD>S'2,B\_N
M7]-U_8>J/O6ZJ_9]Z!EG]LA>DHPZK2]UM2I)Q$OAEG^]9ZJ."#2*JL S!-R:
M-\?*Z=J-$YXP?=K[H".[M[#<]N$81U31I^<B!RYYB,S*7E%NY+DP]C8>^Y"&
M A5;0^!A.W.#DM)SP1@1CTV_T-\#W1BM8D4'EX+;*=KIN"+#\\+.,L<^SDG'
M8!_ PPK$W&;6846Q+3J(;HB/P0&:%&&TPDQ<?]N>6S5][*%DGV)UQ-4!2>S>
M3Y:*N70B?>?SZZ)>$:Z=-MAW;64_;+OT*+$,_E9:Q%8A36SWF 2%FQS '88Y
M/\Y""'T(,Z&.Q7E4T"@G7^R*2Y'-C,Z,MIF+:A3/RT(^QWK^B/S7-F0)(BA/
M_!,8RWF"LET-VJ?KZTXQ<5CQ>=HI\_P#>'>_C$7UXW9Z<LT*-GZ&>>W5(HYW
MB\8N74MCPQ9!7R A*O=C%L)1*?244F2&OY9%)FAB4-*?&7#5*88FKQGOHR0B
MVW2I2..0W,/@BURZ+OE'"H'#\Y6!#[0Y(V0+N/YZE^KO3JH-)A?+_N/-/I(B
M@578,U3@Z-*^9JT,Z^@H<Z781,-<G3E/4)1=XIOB?^'1N42$BFI>Y/K+1_*#
M.4?.HEMM@=N)#"S8U6 QMHT:6IA^QRO@5%)D@%K("+#ZS?)U)GZ\73<H>[?V
M'3P%RJZG9OAFL!"P,ZUX56:J&Y1.2?_K:RGF]1BB RS$T6W4,&;",(EYTC61
M/H0.05+NP&98#G/[89E)[F>3E;X]JOA=.JG>FNQWO4=(UFV<?+T*%0EQ713D
M^=C1APQ2>(K_W,_8'YIF:H\L?C7\?["K:&HF4I9B^X!QC<GQXIHK;:LTS]N_
M@WVO/^7_>H^PWY,<.2YQ?K)R*9IZK6'SLI)7GG]"@VA%HC,OPEH_NR1%Z@K'
M#NF7^RX=F"0DR-&+>.)I9D(IC-@NL!/E9K2!^@K;U.;49,._X2.X_PXN>L!V
M6P>:>#]/0P>^E%_908.#6>*[NB/ 0"()2BUT6X,B#NG8;#S-#$1&$RB^78QA
M6#]?T?2(HD;H<!T(L! 7DEN0H I,"SB9MS-RK\?*126-.= UOA*=)Y;)6P>'
MIT&8,+'E403P]>A@PBZ,KF.&V\"]&VY"JY<]L-WB5_,OEES*^6#].>%PZ:5?
MPZ_V<SW=ST)@F^EL_BS$N R#]W#'>%<#2=AN'L5;HY)9UB]:A'OH+KAX)3"L
M^E.(M&-[LT)\IZC@\*,O^C=X=9HSPLVZ9?,/1NL4+F#UL%]A>HKN]*:=!-WL
M*>NTMZ ]]2JIY0!?B.I40?.=DM$["V^?C4UXO'OZ:N]-/N4VF3?!+$23T2U_
MI]Y)=H;@.L2)IE1.MN HI!N@-R5YPM!RX81;2MG]LUX%[S0.D^TCS+8Y^#U'
M9/!>N&35,?,=.;@@2VMS$\@)U"A]B(Q"4BP,\_%;6S&"@1/.2^O9^M)SH8S#
M_=UNIDT]Y/#L8;^<2P;4Q!++ZSQ1FC<M><]!G41BJ[V;^/%6\>,-Z9+1_'(9
MCQ\AQ!'LP@+2 LJY#Y)O9XJIT]/$8'4>9B8,T :9D1@?RHI:B(_1U:\W7)7;
M1(LC-MFMWM;?KM90WMWA<,OA[C0O]QR.L=^$5J*C"EL#AN$$GBRT'54GC&LK
M7?M1]E-1I./(&[5J^9;T4'Y=KYJX.!8"N6-&6 HBF%ZX8ZU58*RSKHS:#HQ'
MD2J5FM"@C,SG0L-FZ]9&%H+'?XX&4.V*O6C#H[M.J V$JLF[V*^^=]2T+6FX
MN=/@Y[L+(N+"TWIK2EM'X80_+@+\7?L=XF6P@T&3T>P3 76AJW;4 P2/@\^^
MO"(J2H6_"]7,/#UR$2\57W+4C$T=1S20U[/R]AZ^*J#A8?/S/K"M;I\KJK2K
MWH337^B\497)TP?Y07*#2YP]!2?R J+8Q4:"EQXFW3;6+RJ)D'\]R!#X47><
M8<9,(XQ7$PYH^5&R&_SL3G^DY(_9^2<T]C>%E[N+9)6&.ACE]7A8954^%^Z+
M>/E$P,'BVN_D5FY0\_1UYCLMGES,:>8;B)MQO0[,+3JKGBR57*$O!GJ87XT^
M)5W=WB7E_/5@QW2!XXZ*<R6B!(HQL&&UAY8"DP3@*DP2F$<(EOEY[R93JGY&
M'1)<=OZQP?</=[C.>@ZZT0YYLH%5))-JJE[4^]2KU OW/L2KJ5PL/I;]4F>S
ME3-$4]JO)DN?ZR-#FI)J"\*D;-=/3  U)K;07\8.#*%K^6=0\<?4WN@<7/8X
M<UA$]&:&YB^M#[R6CH/(#I((\9,G,4)>L]\/0QRI--'U")L6(MO ^G]*=68(
MF$QX9%'0M-N@*95S 1 [ITKVMNL[%#'B6E'TV8AGQ2%)>"IQMUZ*Z_6=<3\.
M.9LC[3!<L.%X^2?0MC#UM07<+LR>R7E5?+B%J./H"AAKE+C4E/(U>NZ(^$R\
MPCOSF8;0$T?(Z>$"-"[^K&N&NE;;0RN=IY%+K7#_G=2N)9YQ64@"ZB/LA62-
M)H_MF[STEBIZ(<'V3ERU_D$K['=JJ_P1,W/+F9O4J4=7REXO-S$]6TB4>QKD
M! KN&B6LT60_R#V!;+3)]?BE95-XYGM;$)^)IU1$R7M[Y1>A/.(G3K]PM1VB
M2730M74M*O17=>\H.9&=?J-D@/$9I0TE%J)$@QDEBH->_.RC^3$$=XS;U=+U
M@7H-[%%_5*.H3W\A'FTY/#HT9&/_K2K0YHOB5Q=4^+-'CS*3-$W;!'YG"1SH
MO;0AT$9XM7$+GD>8< >G^0-V% T8_3II7VL\14N>\MP[=,? TX&G\%V=65/O
MRW:5</.S8L\;73<R[3^C%)T98C;_P"4_;7')RUM<THE@F9.7>'W9\6.F4;[M
M$F89UM1U9@+LB.^2!FU:L3R"\79NOC3E.YO;6PIZ )=A2?WM>;D[7^FX5%./
M:DIM0[]"43S7']48T3T@8BXUK"5!C99*036D *&J3BFHY&^"T:[;<Q'L1SE'
M+C57'@_(E(DO1%?^N!IM(?SQ:>[8C=8$[ BI)":9[@ZUIRF#SGF7%0::?/U+
M:X:KEX3B2CK<U7=Q7'^UOR1XSY&9+Z/HE\CB 9A_3"HQ>,(:DE%L+(2K4NB8
M6@VE,M3C705EX)EJH%JBG;IS0GN$58ILT5NII.BGCZ?$GN/;>5%#$4<O9B7+
M6YQ_X?&K$B6!507JS^J@@/K;D)R_23VJ%!V&E63(4XQ3<UN#\OSK?TE]N!_U
MT?Q3TBZ>=W+1DI&W%$+O\S\RV(NM]3<YZ\D)6ACUP,[E2I^845G$CS'2%ZFJ
M&MG'F"%+-BY)>^_]"*F$QSUELAG>)A<*-)L+;>"06"K[/XTQ_T\2WXXL&VU%
MKK_D7)(7:MATW>LA$7A+93.%^!_G'_D+#QU.U:;:C!P!2:OL/\Q@H!.;,"&7
MM*'TRN)[(V[A*(&2BUHXQ$(\1]'EEG+>^CG#@84S <I ;E5_+LF$!&28%U K
M[#"SLTWD9QMJ82$:WK$0.6'0&19B*8>%"-%G(4RY&;#Q#UDXZF[S]?K+!Z(F
MK@(_SK,0!P&:V9#I&=O7G@PYD\UGP#0W!,.7Z[@U.,A_03(3?:]?$?JSX[^7
MCI],="%L?FKH!%X:4%$:D?;-"YSJK\S)>,R&.?$/V93!7 Q59C7#QVOJM(3]
M%3!@RJUO3V#@+5>)OJ1WGY%C77<-!)-_1<\?=N!^>:(>Z=UM*WS7[(86,TO$
MZC58("U^6?N-_ZHD=0 ZI,9"Y#%9B"04"X&1_>>YB\R(C%JEM<CC?V0L E]6
M"'T%E5 0"S'=PT*H_)_;QO[OIJB_MY9RW^ 6N]Y8U><V$,-:W5+SU>YV"A">
M)''8!@D0UQIP]PM_XP=%X>=;>G-O;(!ZC#"HT)&PNDQ-WDA#T?F@I@,[F<'8
MO<.@QN=^Q3C!U36NBW-NZ#OKPO5)S@@'FAE"+@8A/C<HFU$3D2A]U=C;SS-W
MZ5HVY[TK[PN2OL#^Y<F9OP.^]:?\/RSX%@(H'\806YWTY,48#-3)8+C**OH*
MU]I@W'N-$E_FVSML/)QB=;?#/3K3?C7@Y#[AYZGUNPDE+RQ\V8\7/LTE'\4,
M7+SG).(N[HYRMGJH5H5*#+*'.(KIYUVL7_=[8[C <JD*<GD*J2%Y@(</^AK7
M\J5Q5%_  I(8I</.L'L/V,Q"/+7+8B%:W#9+,FI9B+6J2@8=':CCS31*9R%0
MR)'8&8V_\=\N+$28'_8[ZO<YZ 0P(90+4%.@@IQLJ!*&M3BWY5O0^V[XE]A?
M>BNI+,2^7\RWP,\0QFW8$2O!8'Y*-1ZHUX)0YZI3QSU;!-#7QCLO &11J.!G
M)M,#IK<Z V.-3*/,?^P>"0GOF&IE\J B<:#> I+A% O>Y(Y%_KX *0(3R)P_
M>AYK$>'NW&NT=E:?F>H)/X ">Y+ML?_X+MQKZK$,!G ?]8+TURU1$X]TM(!N
MOJV2J$^QZ?^@!JBS$AZ[/[#\6(_F3F#087J&X43U+Y!6R4%+J!]$U"J5^06Z
M!OR+MK!20A$@%6;Q)I-S$,]F& LA@E_HH*N3H* )%J*.#3D$,_O596XF!79*
M-OE 5_GZ!WBBX79=K>N2&T9_HWWF7[\](5]I:1C86 ^#0'[ :1AN6H-:__RW
M%*?Q[U <H11&QG-C2/JXZ;^AN:WBX<$G,*B!.L&M.VKKQ'[J'.E6 _8M)J&(
M@&MON>%)A5^%ZPO),:F3S]EMO[0W'G2T//#4XH?:P%^,\'^K 5-WN#3?W Q-
M=&?^FNN_E9.G:J_KUAY/3XRY&+'XMT=4K'Y25+[H;\X,8MJEJ/IOZGA'7$;5
M\M]0UMM]_VH_C_[LYL]N_NSFSV[^[.;/;OZU;J:BLX+R"CI_[C)R<\6*.-^2
M;FTGC/S"EI>+&^YNR,NA"6=?0>27W]N%&-]&_)\^;OU3_I0_Y>]>N%E#_PM0
M2P,$%     @ +(-T6&3DU^U1I   OZ0  !0   !B<FYS+3(P,C,Q,C,Q7V<X
M+F=I9A17!U!331=]"8&$4!) .@(!I"-5.AAZ$1 1$) 2.@(B1>DEH7=";T$C
MO?<JY0N]*(B(@(@TI8@H2!=+?O^=?3-W=N?=LW?/V=U[]0QT%94<Q\#N8%\
M0/V$4 ( &1 '_K7_CR60R>1_YOGY^?;V]L'!045%A;*FYL+"PNKJZLS,*(%
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M:E8JKK4NYB_(*?U2N$HL[A/)Z?U2W!^2/?BS>(B:,&9-F# @3'TIU.I)OP1
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MO]O;0_A5>VH!L)MVT=FXXHI;>SZ$3'EVXZB2\+T>)\W=L#R CM@##JW-+G:
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MAHMM/#SK&),.CWA7IG.24YX9\_#;T">791T*@6QCT2OVFM?F!,BFB18L3QA
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MX@?5N8;\BV>/*BBO^Q\$_VRS,%0TFVCPG4\-X;U50(()KG\O6+QGE^^SF'1
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M:=RY]1\J?2'OZM_QL+WLA\T'Y_?"=A<^#Z5>W.,-?/D<?0;\K#VJ_P;G6W+
M-ZL-'DB#OW@S59E/T8SZ?<68)IJ!-JSJ;D%3F"C0AYE,2=Q\$&P^3B"I+86=
M:R%-\*A/76P 9<,@UOO^FE^S"H.?85(Z+BXM. &A)$O @A0:9_59I_/'Q[A1
MTWG8M=)O7[%5%66-\=$'(_1 .#=ZSFCY])@B+^;@DU R4],Y_4Q$I.!#4"?3
M(%B.G#_AOSMP6C"_0<<^;+66JJA$\4= @6GU]Y#''\GEEZ9W/;HU%&GRV#59
M=)CAJ.B<2+Q4JP"M'(?,7I!\*PDF9"ZK%=K64%4@\_,%^@HVV-)*F\(WNG&R
MV+0'^HXU!@DULY0D)Z_DM7+%G/OO(,AKV6R&9IPU_U4*" N09QZS0.R76QX/
MA"Z;#9Y?G,S[3HDS23UG\V P^\_'/1'!UN,(3F%6X:KF#&:L:4W9JYV")H3W
M$CEUB&N](A->4%-3@:@)U0CQ&P^1D>*:>$,=8II24<D'"YUP*:SU3T$!9G;;
MQG@.+B71[N10^@R#/CKLGVKR+K[2P>;1D=T/V4V,-OXS!6/XBW9?9$Z03Z*P
MU@DK,^1<ZMQ$EO@R $WW65_Y:9IV*^$:2,K09&I"#!#?(&53PA_MRV'IG4*>
M$0=ZA#-%"X#P)/N )[K[RS=3,@6_*G9QQ9IGKI#ZP;!*W/%NU=1IZ79W3_S?
M<&\!,>?IS\^8'TXGXJ3-8NI\WEWCJ94SJQEPIBTQ*V(#.6LO6G%L2Q@/5RYW
MO+);STFY4]L%S,!6;JQSF.@_SBJR%/"!-2<F\%AW/7:@2]$ OCZSW)\=DG5G
MK\:WH<&*1C+Z7:YI/?Q3$./]H?US__(!D'8)\%KGG'3R1?K>X8=OH==(R=RB
MYI[EPDHT,?TJJ7EMOW>I4Q_"T^D__GA\K== /4&1*;K"NO3M*&<-6O% :F0J
M;WRS "XE9!:'4['\7-&@=D'-$I-)A+OT1;!#2J7)2RO7?@S0O?AJ9:YQ89G]
M'$2L#"  2 #Y8K,Y(DCKZZC=]]]CTM[V,KN7]F3Y8N"4#A#J%OYQ$JB3[6?H
M3TWVE(GD%]%8TL<?LJR(U[=N-<5_NM@$)_J@\0ST::E[+^1T"586 @A92_OU
MH5I<&=7XH\D:FX6-WHD4.H5)!_Y?16?R]T919D5J0N8T%'QU" _^9U-"I'^G
M)JBV*?N6QUB#3]% 9'4F!+;PZ6A4]RH,IXMB8O2<M<3'ZZ*!<9'[PZK'M?%H
MF/3= J$\[DP! S/<$^/Y-L'-VD9MS8RFF&;5A]H[A!%#HRPS\0GW/_I$.L><
M1PR\T>_?D7X)57D^DT40EZ7#]643O60RAB5?^S:>J4O"+%0#C/COQ<FVEW_$
MPK?6@1#YKO@MS8X2.E:.)4P!&37 6@%]-4$_^6/*_/XMH3MLS(Q>I7FW1*]8
M[P.!])9$VT3G@^WB$.ZAJ_'ABN\OF^(_ATUX^#6R16J,57G,@S<.2KN(\F&E
M)1+;-SO2\E Q>"<XDHY'22[!K&*8MT*4T]#BO44\>[L I,Y8K'=Y3@1;5)C>
M?_%(E:"+X_+PO[6S*_9;? C!MKG.@^DAB!DV2F*]D?XQ3D7V733;)O%F:\CH
M ]-D(],"RR0 W/!][A\_H_=M\YCZHB*^I?%Z%3Q%*<30GP93Z'&W2I)*L$OG
M0Q,[>ND#H.E<-X'QB!>699XEKHEDH#D% ,93KB-) + Y$;#T(+D-&K_R;-T=
MG)6 X0C  Q4V 11#]\+$N+5F+SL/35Q0A%,4/I]^]9'3Z)W0^@4_=[7GYV@(
M?(C_5R,9;9X7'RTD!&2$$Z#B% "L4:X!%C^N&GDNB7)5X#WJ$Z7WPS[R0AP1
M4X$[S/G-!2_E;SO=\0'I#XJZM;N%NV\R/-2Y,"BP7BNF ,^! )#E;S.L+*9@
M:\M/)V?9SH#OQXN0,W*P%34C]^AV8I<"B_]S;3(SZY+EG\9X,]&4!&T8E^,6
M1/A+FT1!F@(>3MRGQR.(9'JN6M"OO'WBW\@\5 "S8YI78?]2%<CGH!8ZO,5R
M%QI1,:Q('#-NOV;K^Z="_$V=V9A-VPQ7%J4E84\ &IE*QTP":5G?PVJ7KQ5"
MGWNC*\X:> X16H)&<Q/&25+7S"?I%PA;"G3G%-6@AU"U=(>6#)E^]B8*@JT6
M!1,E"G^1%7/P,T'#*S:("J_U),7=&'- <DT^,VB>U#](!*L7YV)Y9ZTDQH+=
ME%$YN-ZIXMO>17^J?1(?XYDL@2D/:,VY";[4<\_R%) [E726BQ:5:DO#=/ K
M5%/[F1_5O__09W-EE.0T"S:Y&]CXW_O:^Z*-0T^@VS?*KB[5[U5, ,V/ 6IZ
MY9>3WP#P6/(U;,S/_E]IU7Q97BUW='EQS+GCTNL$<N;-F WN\9YQU7]?<W)=
M-X51OUX3*D,+;FJL2RG;:]2DD/F7(-R\Y'S$M:#0XOV8+76#.V_C9[[E\C!H
M<7$) @?RO^;*N.V:B0#F'QZ%-5JX[=GEGK]KR@F_<1D'E+)  [=GOZ:C/FT1
M+GJI;RN_WI%][<C_\&QEB.]VSUNWH_"&WY\.*V\/?''[$OO?[\]_^2(I%ZAK
MQZ$O58!,>2F_NWRE?UPEOYH]NO6Z//8DOT&#ZC*3*^E)3OK-Q_""-<$]^@\G
M@(Y(B60 Q:OSZX+VP@>CKN25L$^//'W^T. IUC(:0JW\\?58XLO=E]&0LVMG
MG3+_CA.#8VBL_&?C-U\<YZ)B/ZW\ SB?I4PMW8-;%/F#3U2N'@]=Q'Y-??AG
M0_GNK_(O#ETK5\]&;[^\_CDWYM?XPW_'W1=_OER_^\OD+I_$<7.;;-53D/]Y
MELQ9A+M<V)=?119G;+*_-I_^FK0XKP\&B;6!I(Y!<K)@11)8M0VL>0R6(O&=
MT&I>0"&/;VC'T;Z&H?[./(4Z'4/=9&$C,FULQ.]7C2YFSEH__T$*R&*ZS*7>
M_C&\[)F!49#F*Y#>A6,8/-**3@$OYJ" ML1@66'Z*\(VC7G65<>(]F-ZN>0X
M+E!BTC"(29)7Q5TD 6-9*XN\HH=<)B$_M2'7CI%;>5:6^@SJ.BN/T6;4T2NG
M:!N5#=2O/,P/2S1"#L4@A_Y[C )27C*NWSG#W8_R=.G:E.^ATA^VT4.IONN!
MA*XJEZ!''K*UQMPB2>MM;/\=LYG)L5O-(@\3K1:&^#GVQNU%)[(V(;Q$?SX*
M=^DT0#)SA6GX :0^CHT2)H3CK1JB]M':DY)Z7%L<(TT%PWQ9@9X,"[5SJR-@
M[T?$'CJ0-D.NH^%RD-\%%DX#FU>!)'U','7 56P-=\T@H\<D'P(6!801JZ#.
M>*87!.XH=SZ):I:EJNT([> 7IDV@^MH<$PF:.[32BAL(UK,D(_ A)HU[]V9V
M8*T,#T[@PQ%Y6&XR$$0#BN,AXA2@.$60J0H$!P,7IH#7,H&X77=K)"#(Q*8&
M".O#P!-HN)L 4%^52"* IX\&8P%RB1M:EEK-UCP&3KMC9;3'N.0]\#07#8F@
M4PKL:F;$4C6/WG[?N90 &P9BCI%\)<^O(0 \ ,JSX"'#'2"6-]B/<M^%WEC6
MN$O_)\\W.<&S(\]]A&$>QC)G^8$2\)<NZ:KHBT_C,F4,@XDU7YG%,F] Y_#2
M\N(H%@\!J[1O3!>&,W-&@@0+]$/IO0AW3CA>G!8/6$6D"PQS(D%Y(%BX> ?&
M)\%LDL1+!% K1Z(^=&!^&@B\"!2G#95S75&MW,<2*$O;4T]XQV=.DZOE;01E
MM.E3UZ7LI*2; [B7"(3WTURJ9/#,L=$>R?N?[[32-V64-R1D&B9D@PVJ?UR?
M"91LZ=,(?HK9TQB>-Z)I S\\PPC!'G4%7RVUEI\SF[U6@)6E\9P7/J69:0B/
MU' ]A<D>2L%$ZS$;FHJARYY@M<\2+Q)F@WT.,=XY'N+NRB5$9?]"7A96Q]&#
M5YTU,B7^K-_)W"X+\JX*^O\]$^#]=LL2^MF\D:Q@%MK8F)P4T#QSD?2DBPR0
MO@%MD>%K3,%HD&/C_%@C04V/4S$/]?SAGEU//!AP.7+S%+6>!35N6S'>#C,_
M,EQWP;<SOZ*3Y8K!OL&BV.2JE5IOH5O+!L^FK=JVEY&(]V\<YE*L4-328]W4
ML4]_]L005>98(6:\M]J+,-%30#%)$#FY@&G,4+J9TA<9-I,0H/\4)/5QH0M#
MME:U,NM1\.L[-=D 0H:QO.1JUZBAV0+P-.D*GC.!G[Y(X,Q=SLG6N%87Q2B)
MZO!T2$_@'@_L3L,+C"(RYDX%7L[6E[)&JMF]<S2S.=MV^(X!3KASACWW8Q1
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M(:9.XKM?8-#%\,?T0V>!LZ'\A_0.ESIT0K(\\.0AKT',9LS,JT''OG7(0,N
M+A[(1H,N$/J%!Q]_<;4A@^X6:IN%'< FD\%*[N 9X93G2D3C<PRT>-C7X.[]
M*K.40.G2V#7^]94&W@Y.$% (\P,OY;*ZMGQ9>_B+8Q*T<C[U#77S$</I)P'[
MR*KXP6[W./WU!Q3I\J]+F]LA+RZ+J,:-USJ*8Z1X,?R3+?SFQ#T'[:7O#7M
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MV+3TZ-=-H2:[GH:\BS8H0>+/L8";*!FO>XC<)9@@,0OD&"0T[Y;&R?]0N-_
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MXYMBDOT0W8@>B9W6%9I:04%*3XQ\[9<0JS\O2@)*>NG2Q61&FCABH\21Z6U
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MRI)0)Q(OY1TJ%$U8RCVD@0O="<5$YMJG+Z>>VN,ZA7\!M3$:< Q$=XW)KG%
M);(Q(S/C*AL21T:.%#V7(J'F\*9.ZKF"!'W[_D$I60>A#W6[O94F5<!-$Y;
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MU=)^E5?WJK9W\Z\!P</DSG*Z>ND]-_A>$V[O<8G?XQF_YO=^>3E[#W+VW'P
MMRB \IS=_)Q46O+>TQG?I_;[S^/VGWC[UG&4HRJ1AHD* FFIS1&[[)3=.\?[
M396I%(Z]SBO^(U<#1E_XED;X]W@'C ?Y3WC[O];?98\L/=D@^/QAOR,:4&'>
MWZ4/>/MCEPK;FSW:G3L*@)P=S,,.%S@.W_/YC=7[A.>]T[^PZWF@0F8%$(M&
M1W]XD$\# (@=.BPE)RX/P"Q:H'_-9>N:RS/'S:VXH)V<H-W*H+TG0?LI1TME
MJ?NK04='05_L@^(P9+?2S"VF+U^N!I]6!GV#?1&1ZRR[MG*GZ^AX*?E[RM%Y
MW-%OZ2];YD?WZWU &)"SSSHNH@T@0[JXYO)O^\N?E*/(JJ--IB]TMX/@UU<0
M(F3ZER3$VV/X9Q*]P?%I_;&/XQ&:+H29[@OS]176_U+9^+\>/V&$^/1% H;J
MHT."\XZ@+[_NC(7\G@GA^_R5[_H*IXK[[O<5>BYB]DXJ*[E*AR\7U+9J<>>&
M16=CS/*:U+F]M:1',3SXC$P^K?.0N:!KY;CZZ>_'=-@$6>+/"H,L"DSDCFP$
M1'.MYF!2>6!DWG^KG[Y? LG2)4(?.-Y9SB:Y0 :_R?"'-0XUNNXO/<#\K]"
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M$?RY7IVC!/P[QQUKUPVH$;L&-"(%>,+!])DKF6_0?9J2 E\XR^3#4[2MCO[
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MEE;FPP,]T_+#G)M %7+"E<>L<+-F2HU^=RI9'5N%*A74$O:<3G/"5H\H">J
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M@_2M+/E8=/=[R(RY:S**+!!A35$.I%NF_-W?7KQX7?K++XCM^S*M[*MA']\
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M8[9Y8RY&$UYS$X%<$^%Y$W%&4VES4]E<4\5Y4U5&,PUS$P@84/P?4$L#!!0
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M\Y>H%[JR\<,TFW+C:SG) IBS%:E:U')^!$4%WV,^4TSFWCPDX0ZXY97E0E(
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MF9.!"\5J"$C#SI&&?R40+4:2#/WE::SLR$/O'_CH.H!-IYMJ'(SV!C5"X6?
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MNH4 ?_ MM,51J7$B/)==KQ)[K$)]T7=SB%:S@&%U-KEK+:5R^1!1(^+&;&&
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ME"PZH#-WZK2&Z;>?>$=4^]%Y>4<KDLW#EH/+ML< A9:*&V\^FUF]:HBJIT(
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M13+KXC4]8P ^8%T$&ZEZZK"S6 -?;9[C-+[F8[6P)ZW6^LJN1UYK03*9&6O
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MKDZL!02A@"?]TR]^Y3T*16*L63\V\9.B/K898(QI*%?R?QJS<0N(7]S*7 ?
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M^F*B$Q3A#>$P#N5P#NFP#F_A#O$P#_5P#_FP#V_A%0 Q$ 5Q$ FQ$ VQ#U
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M1,<8P%-/P'?9]PJ\_@X\CZ<Y_GY,.?U;D1%\]4*;F$44/ /Y:--C*9/8(D)
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ML))3$:3 R"FR]AH8^X$@C$@@M9UUD$P0),HY_/!"QCV03IB;(QL.TC##\!L
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M_M%<,=S_)-X4/3TPH):W&3'49[!K0.IMK&P,%)Q7%IPG\ (-UH$^&(X4JU!
MH) U*" (TN3=;P78&Y&1OT0!FW<-0+.'@G"@H"!.-_0[0KR(&+%7P-)N_=J\
M@-[A4OB@Q4 !%S3@*2&> "Y,(X \W-.\4#X4"CUR[:+@(MYCY/2E+G2?(B'0
M,%N[S<?&&%'J3P,LBH#?8I52*S3>4FR>.+QAX)39F$X8#8+B21Z^1G?2"R)S
M'.J+Q<Y9/^Y1K.VB_I=TQDBLO(UUP!ZBRXJ+J5U1_R%;B&RA0D>UBF*U<F3
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MY-ICH)%*DSWD%-Y;!FZ*03@"2.A+">!DS,9ECFX0)!D-Y5DWWE.,+:S,H48
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MUAH GTF)T) #;+-2N*[59AF.#?$ 94.@#!1+0ZFA:-RT^YI$ +^;B2??249
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M]E6[;UVE0T'[E\BH4JBD_4YC:#B>7!AP_[PL *"# ?@@ ";@P>Y1#Q3:&,
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MW,-*%KT^#!<@&\1$7,1&+$%960P!K(^!.!42Q[]1^D6RRU6X&VX6+*!C>JO
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M_@'0 :KD^>HS"*&?%@ Q:,#  8L '$28\""%@900$H1(\)9"BA4!A!B(8N%
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M 1:M9R=$YU"*D$YVMM.=[X1G/.5)I"JIYX6(5(L*D16>1MIQ3(%23*NDP35
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M<N29 #.!?!W  C.B(OE9I$,PT24%$T*_HYUS:%N 1IB-(),Q8 ,:ZTS*:0D
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M+.US+*3AK)_I@I5K+=+RB'((LSC;@L_2-&)HK=1:K8.(1]321]0BK9+;/X0
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M==9NI&=@A&F^%=7H@[9)8DU""0Q>FQAU4R^L^3\[%;Y7#"2('(YU, :( 10
M$ 2 8H# @@H7,FSH\"'$B!(G4JQH\2+&A\5.;70%R..I.X"2 +KCP63(CRH]
MLE19["7'8H V%DOS\F;,F#>+ 7C9D^=&FR^%<BQ*$R;2F3*'[JRY%!#'-%%S
M(K7_&55FN63*E"V35J0ITYE7Q09%NC2G5)I"CRHE>\JJTXU;S"F3EL6LTJ(M
M1;HZN5(E29%\T[3T2'/%BHR*%S-N[/@QY,B2)U.N;/DRYLR,L6GN3(P :&Q'
M1).&9L2A$='$%&XA()HU:8M9H(D^D@7 EM%'CB@D)OIT9\L3@A.W& +A@$43
M#R8LR'P@P5?(IU,?09 "0D4+,R'L0_ X0N@+32 7#V"$HNGF'RY"#HKG1/3J
M+?8)KQ#[ !0*D9O(R#R$'PA=LY]]!9&'T!3%*;@@@\2!-T 8!B'4R802(J30
M%,C% @!RRA&4(74APA?1@0-09$IZ"$5848D*/6@=0;$@_X=1??DM5-YU,SI7
M($$UKM<@D$%V1M-,A/U5V$@EG>072T8:MI131HD%UU-@-<416466565:3"'U
MEE$[45D47$:E%=-,/?5DE55A=AEE53HI19-1I^1UDU)=UNG3*6M>A>9+1Y8T
MDF!^"78*24@V^1)B0CKZ**212CHII94R1H"ECAE!&W .$<,I;*.Q-AHT%QDQ
M6BNDD5:$0J=BLUJFL3I:#'*WF++0-;=D0LF.S?58X @A"@M=B0D21"M"^A&$
MG"(#*E2,= C!2!!STSG[$"DI_@A1M<A=*]%S"LEX(4'7('<K1I0@%.TM-ZY[
MGXZRRCNO8R7VA]\M"%IHHD+Y#O] RXL%"2(L=1Z2B) V% W,++H3/>CN /WE
M:.-%S"E;4(<3\TLMCP!H2R_(DC)U"I)\?61HDDT6)M1:;%VYI4\Q%V.!4W/B
M=-1;8(%)Y%%0SD3667C1Z;*55/TY-*!ASID6TSK9I"7.:@6J,]$UE1R8!QXD
M"I@'@P[FT1U&-1HRV66;?3;::4?$F=H.<2$:%Q!M41MKM/%6T-S08&I1,:22
M-AJL!9&Z1=N%*X;? *^$0- (B \ 8[B]0L<=0@T7Q.ZQR+TRX C57MQ>=A18
M9\HB_@Z0B4(4(D1)BB5 9 J.%3&"'.L(N4Z1CPH%BU FIHP0[2N*H3@?@0B!
M8MVX_QJ.OGRF]@)0X@#: 8#X0KH@1\N[!05(,'(70]2B1- GRV*\!/G;24'8
M#R (C><:R)_&"C$'2D&[^\H\_HK%@8=:21AILLGZ C9!L>044N)9S+"$DY;=
MY"=R6DJ9Z'0FH<')2S<;&94B.*>V\"QG0].2FX8V-:.-<"='*U*8XJ) *)WI
M?RIA4J$&>(>M*4HI8__+'PYSJ,,=XG!O^=L4-N(&D=%@8T1S$Q7>8H.1(KB*
M $9@U;.P 8U2I8T1/)0(Y;C'/H[=+W< \!<M&J*ZB&E,6-XI""BXMZX1R6<
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ML#ECY9F87;$A7Y60B_E8#15;+PD*OAU)&O@/4O 0!&B#S_FA-G 9!H)#1DR
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M[%]8#0<-W-(8'!P6PR@O0SED 98 PL](K.!)[$^@K$T00%WHVC)MA30HM$P
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MZTRD" +'"+H  +(@<.R&!@_"</BN[.8'N-+'>RR"N@@BCEXP?D20T@().":
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M! ],G;(.7S(X[],@@FT@,FQ+%>+>1)$AUA0BZ!, /-)+:3,D/[&_%$(E8>9
M=Z_Z $"6@K!'-4)+ATT# & (+\<\!R(/41+>> ; .\N4/-43IYKS3A$B(S>2
MOCIR/U7)HZ923P\"O5[!O$S@DYKO3PG"3P/U/0D506(T,Y)%)="%)B8P)=QI
M8LQ&8*X,/Q0$:8C(0:#DL10$8IJD)Y0'5AV$%O-EBYJ5_PY+6%_N0]$24N!O
MY$H.;:8G0JVQ2(H!&_\)-5SC9C))I!RX '$(8KH<ZB! 33,]<R VDUJ2% 1!
M$!IPL"!(4R#.]08)PH^L%)"  PW^Q'($X5*K;TZ)<Z(X*CB=$J0LQR0'8MB>
M4BI0C/L8PDW9]""*H6(AHDZA4U0E#"0OXMX8 3?34U57=8+$%2.>T%$W++YV
MC%$KSY$$@N,&P*B&+577Z_#Z4623,V%ELJ.<TU,MS#Q;!H8D;Y&4Z@HA"?P0
MM"M=M4<+)+,RJU)BXJVP-6MC\2Q-0LL*ZZZ(1D-#!1CKC^CDLHF$56FF)FE4
M])G:%HL4Z\G$\BB&IC-&8E+,C#,T(YDPA'HR1C[ =64%MV2P=$3J"!KT:='_
MO&>@SC%^-'-^U%%)*R)*!:(<_&9\Y >XKA0X=%!/(D]H:9,^;1:E_%#5D##"
MOBWLT O[/.DB2^S;>#8A^$O'7+<@YK3[GE)R<$\C/.H5I&UW478@!'5P*^(U
M7P\W@U!F,=(@[XTB%<D4GY=3,14A>C)!.9(V/;;"5L]-(98@9 EX<3<*D T4
MHU:6,O8KXP /*G3D2@<"XXRS9%5"TXQJHP.(.F0N525@IN94UA8OF0?_ %A#
MKV8NU78OT<EM>Q$P-T4LNU9B(-1:T>;-B*QM'M2, I=X,=A;R'5$BN"/RD$<
MP:=[$J)=R^Y=U\YN6!!^^*A\IA0D\DB%X15R?\-Q__BD<E9M55& $3!G3NG3
M39.PHKXW3\E08GFS/RVGB L4? ^"J%YA :ZWD90X(;)7)Q_5#M]T(W:R961S
M?"GU-C_I?#.X9UM&929OV#9,>2=U $[ID\;-47_X4J.*(;AS^SJ6:$]6#"-B
M\L!W"8,7 %B5514TAXJ%G=X*&IUQ;:115W45+;,HZ&K11+&I,;#(Z+QV0\%I
M=@!+LIPIS+1,Z< C4SKC4:XC:R_K:D\B1BVD.N#J%=?R6W<TC&&Y6PI71,1$
M?1H*?J#A,@OBA4MP7B/7NR*"<OM(?9KTN0;"NA"7<__$9-,+<\KSB#_V8#%*
M)0NVX$R)B]/+@A9A(5-2D?]BZ0H$XAI\V(1,09%00%$' )Q/;Y$LX"'*^?70
M69U!%U#=5(4D-G8M8CKOJ"55YJLLQXECV2$R:9,D1Y%@9G4)8KQH(9/6, FU
MV& =8G85H78_\DX9%BHE(HB=<M6<M@BCEH][U',4F4=R)OT6LV=JHEHE%(P^
M-$H&D+$ \'7>1; 6D!>3Z$SJA<H@)CST#TF$+LS*KWG.3*4KRX=60B42\_S4
MKX*[]B<N.*"A6E$V>$2:P6ZZ1WZ>M" V37)/N(WB-8771]'\" 3!CB#* 7Z$
M=#?R\4]&H/<F2A%VN%,MS-B"=B ^"?<V-@E%<@025J+(%)U'X!2\F>'2^ T3
M CW_ WNP&V***:Z1*%(C**Z(_W2BCC"J?3 X?Q";"Z)RK%(@'3J6('J>L5*@
M05*1;KC<JADBS%.I'E*S$=0/LP"D>=3'U*DFM)4Q><@LRV:0=SLDJ&<_ZJ^;
M1J6;KN-$AUNRFJ1L$VOFP@.)JJQME<ZEG\:!HP-G*HNWW^0E$/F45W&=Y.I,
MGMJRQ7M09GE$LN#N$)=Q%>(%":#19'A)N7HBA/F8#8?0OL"0#BT<Z:F3)NH6
M3(B',6KR4K4@W!1S,JQEODTD(<J;-ZJBK7>]!M7VDK"R!XB/(3RT":(2%RE
M,\(\C0J;C=:1*-JR!QI2-\BU!^(*&6\V!\!B*_5DQ1A09 _BG3<(/5T\(9Y3
M(-QTD^XYH[W-XTR@PU*UHUNU951H"KX-C+71<\9%S9Y#_6S4=*"G%>TV=1AX
MF6)%:;@H:AHFB>XO;D7TB29+NJ/)IXM&_]BEBH(Q5\'H6 ZS9T!GS<IH+</_
M>[SM7$^F&D_.&AMTN3=J&9A]J1ABP3QO@1:V.)H)PB--MGO3N ='H-QN@0),
M5L%KB1;&2Q%0H!/NB,8I$CW)5'@G7&-WDB#0^=,/8HIICW]T#!0X/".PTR#
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M.WK\"#*DR)$D05(8@+*DRI4L6[I\"3.F3)$H4**8B3.GSIT*5ZPX5:S8*5>
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M":B74>2Q-QF$EFU5VH1:.66>>!06M?_8=!Y^F%$) V@S(BT(B:C- A/=0N(
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MP7 Y9J?!  ;XGH,.IPNA9'>P&^E1X%%5)G9.H<<9AFWY)%TWIHX\[&T0C!R
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M,FOK8_LP59G%?&XY(M/&Z1#R@0!DP8R@$EG*#*( 4^&P(*LX54$6 "HYYC(
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MEFX' 'X.@!+50\G.A.@[A.2, DR,G@UGZ) AU68AQ\G$71>2";K&\VI"%"P
MHOBJ 13):M43Z#@56Q!LRD9V@E5K#Z'TQH9Z*0R:[:QG/PO:T+:F,8*4F&?8
MYIVVH3:CI3S?6NSF(,+8Q15@.9  %V/2_NBID95L"[X8U-O$)&IQDG2D)Q=U
MTY[R-$V C% %S32I= 4%J,E9Q0H3,!%E>A4 '1B=UP"@0FU(((4KC"HPNUH0
M-(AN"U)-F2P3$H*49>-+8&W(EMAZSO\7 H"> '#A  R+M$$8Q+\[RYGT#C)7
M@^C5K12!539QQZJX-@0E^MPO2@Q[UGH6Z20)2)(1V7GAME(K9^/*F8291%#1
MJGC%+&ZQBU_L)99*:*."1%/'WD;1\^VT/,J-$Z+@PZ] #;!/AE*4_?97,$0E
MD' $E,]<$C72^J&+D)E*;D;?9:;2;JQ2\'*47C3(''"4UR#98&I!E(E"J8YN
MNZ-[I9@#@*HLK+D@5TVJ55<X7H1T8X7S]5)]&9+A_'(3 )E "3/;>K66&7:;
M!69P0OQK6"$B3R'4-*Q")(V]B8@5 (5-;*8!\)S;8?/ "*F)L7+VX00;9--/
MRBQ'JJ"%51C_(]:SEC6M;VWK7-=ZU[CFM:Y[#>Q?"]O7Q YVL8=M[&0C>]G'
M;K:RG8WL6&L!VM1^MK69?>UJ8WO;VNYVMK_-;7![.]SD'K>YI5WK:8M[W>5F
M][G;#>]WR]O=](YWO>=M[WSC6]VQ9L4J^OWO5?@;X 3/];0#CN^$WWOA^NYU
MFE6CELJ4\DTW=DIGMH(>/UK.01F_RG:F;&73&&4Q0Q%42RG9MX,Q4F^#P2V^
M($DPEQ-PY?M3.0.OW%%UB86U;$)E6-@7EK-0MS@J?&]!RJRZ/BLSJ@!HI9W!
M.SKR:B.J7*WJ-E*6YE;V^2!:_U*A!V!-A=BP2$@;E\^<5A!("R]Z_P#8IC@-
M<IP/%T2O)U8(-LF:5T=KNI\6_F\]/\T1_UX#F[$+\:KY_J04PW@ZR%R\XQ\/
M^<B+;SY3EHIWI.(NT'0Y4QG2<D8E!R$&0F9A+-7MH1+8\@1%V8#Y>TS!H#Q)
MV$<4MY!3;>1JKW'MP*VY1FG;1&]Z"C OYP-X)K/J M!GHW[0(*'[;@JA"O4
M8%?-Z+US +(^NJ8B1,[5SY)_'8M&)?V=[$7SY]F'J/:"(,UW>I6[^I$(=U:Y
M/R%W'Q=#:E9$BFQZBPI&?$<NK'<F=A"LQB2N)GG*T3T'J( +R( -Z"5WDSG=
M@12;D2E1 2&7PE%5AG.!X5JUM63"U1;WXNPX?$-R+_=DN(4XD?1;^O)DMQ4X
MLY4YD,(HF7$*4&&#&J=QG -(/C>!7 9TM 440T<<K;1\!W$-\G5F*\1UH/)T
MX25U404%*0,.Z04JP%$079<0:(80#/!*4K(J H4K>!=H91=9YX<]9)AV; <
M,12 JS(NV\0J# $\X*<0PR,T>U=AUQ,M_ <2#O9@!9$S5V-@4J)X#N@;"6B(
MB:B(B\B(NV$'>!""%96!.*8N%9<Q.'9C-*9S(P=RDD$P9/%R>L*!\@,?NZ5
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M9B*!3:$4$E<9Z'$*%>=1\&,:]XD5I[!ZBS)EG<2EBI(W0M$O#6(=#Y*90R9
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M3=,U?4=I  ,N   ;M$$"W<TP  A!'=3O4,\^ 0,['=0 X-/<#-0\#0A$7=1
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M3PO!I,AED$(FD0[C$@*25.<MX2@*.1>,R-A;P&9'\X\?MMEC9WI0\XJ(XWW
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MO AI&A"!@R 1S"H'WICRQ+IF+T/ (7O+"#Y#HVT*4"P]7WU)C$EBX:SE\YG
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M/KJ:&ZHQ47.P'CJL5M]*92VU#1&ZWNR/I#I3>=$>-S-%Z@L+.^6Y^6*V9&\
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MS-YS1L9.CVE0.CK@)TWIM/:VMKB.2N#)6-H=>U8[YZA8^R;*\8=\M9Q=1''
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M5,)%<K.J U/A]U6!\7N.;D=]+NB<"J_655%^Z>R1SMG0_K&/QQ_RR_B"9C3
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MCO<-6&[9M-!B5\R"P<8P#[9VVT//$Q@W=%5<@3Y1KD=S_%>+>V.O %ML%O,
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M_M@9>]YSQ3&Q#LX+1Q]RN)MY):30E1+;5MT?2/6^^M3HV,._D^5:#!UEU*%
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MV%+OK_(L%,D%M S4KS\,[#3M:?%=%.H%'"QTIS\\W-3DQZT-JXMW%:<[+@T
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M6)<@$Q#'$,6Q2$HL,A<CYT![8H.F!Y^I>Y?:B:FZR:%O2!T1[<)H7AP[Q[O
M:F?')@++/311\8ILGF^B/0/1@8.;X+GK'F('LDTNE&>U0QZ0O+0Y/DN$;,#:
M^\Z]?3[?@;EMOMP;[O-B"-#[OQ2O52W,5.2O2GGE>J-O7.1EEI=%CD&><@&@
MKKY!M&" IV6:0&7$)'>:8#R_"!-;NWV1=-1527>,]&9\-\R'Z @[Z<.V#.#^
MU(_0WV_L2W/D/-+GH>[Y^[[Y/;ENHI/A;"_>BBGFK[W>@YFT/>ZD OP$W77G
M>$!VS7EGX<3OT]=%*6[9_^RJVD0Y;O^JZD6IZ[RD^C1)IE/B.<L!Q0*"!!)9
MHJ)$4CKU%[] 9^*/R#Y@VR.K3(0B['@N=PDF.\L>0'@W\^LCM[-9O")5(-MU
MB<JL!N:*J"^MP+7+/0[K_N/^T[>NR1;/4L*@!%0@Y3H2D@&B=KP@8P(J1[(L
MRIA9G[ =UIU8%34AAZ.2GKP6AU)^4KCIE*;AT]ZO)XG#28V?1"/;]ND3%B-F
M0SG0<<>I*(-G%+W+YSM8..7QZ#3@S*_]/K<?2+4QU9R?VLS?2O?D,\<(_'[U
M5<\6V:AOOW(/JOKWU9K68O-#G_-_7#WMML>CAIO<$$'4ASJ5&4@E*0#$+ $H
MEP40G.,<YDE>Y$[E,Z$9G-BJ:':;JN6;J,=Q=Y;+(_7=VS,=&:YOHC[?D6'\
M9(JS3^Y.\&=KYUR\YA-SLZ"O]+"<'9NI$ WD$05G;U97:BIP7_I@D]$)DO;8
M.@0QCTN<Y"7(\T19;XIR@-*D! F1<5SD-'4\K#A+9>;$QU$)CTYECZ.E=3]7
M.$YY#%[P."C1-$F/KU'P."CFE;3'(&[88:K'NJY-EXTVFE(O,@I3E"$*=$TC
M@(ENTBXS!+)4Q@7-4$:Q4R^ RZ0FUDO3O.DPHD;WPF)]\FYZ.H"8G;*&P<%-
M8WN3C+3X=U;B.ROM=<D":>X H5G5][K +W78X@[/E*B7Y7W=#YK>6(N2",FS
M+ 4%5_^!@F9Z^$("&,0B+02!L=O,^"OT)E;I?=7N1BA3.-"IR0LK.ST.B(";
M,I\M6=[_L*$>, 7)3LQ0*497J,V;0F0G^DF*D.5M'L'/CVW6[[LVY_>C\M]K
MH=;X?KOB[Y0N+-=/.NRUGWU8*P=>5,:?7Q1IC-*4")"C/ <P58XV864*!,JY
MC#,<LY0O5N)!YS%9!$S'\&*E'+A1CCY'#I&\AA53<< /S.B\Z98;W2F\9<<A
MB#GJ"5@$<"='U<OD?-QGF[_;9YM7.D;10[G'7'3@+OHZ.\H.P>6YT)XBVU_A
MOW%ZRT-E[8< ;3#P/8K ?*'R$#@<!=>#+.CG/C:?IM_4"VH.Y[O<D45",L'S
MDH$\R=4FD!0)()A ('B2IHADNH3<Q6V\0&=B=['MYKLG:Y,<XP23G<<80'AG
ML^TLM[.#>$6J0([A)2JS.H171'WI"%Z[W,\!5$LJSU*8&O2/:N5Z :D@ B$(
M8AKKX*GNL,)D"6)!RDPWC\MD;'T.?H["/.II:$9_:*J1(>MRN'P6&#M_:Y2X
M7@H97E(WGV>4Q'Z^C+ODSD[)1:FN.1NG-\[J1%SD^Z5S</E"OX^^Z?VF>_Q_
M?'S:K'\T/:#^L5G7]:+ .4F01$ F&050X@3@&,9 ,IJPM"R2HK1JVG2=U,2V
M94\XJ@Z4S<RH5>T8-AJ R^[['P8$-XMSD+]/]"8R9,,Y ==%"^0'#!":U16X
M+O!+;\#B#C\U-H>[MYR;B--A1W"WVYB")>4;<$(I @(5A1Y8D ,B4PSB#%,L
M:4J%7:,G.W(3J[,A'AGJ)OSI&L.QQ,Q.G\,AX:;3+T$XD+Z)6N+A--M.R$#:
M?878K!IN)_A++;>\:T1[6C,4TY#Y6-<[P1=QP3BD,@,)U;-FI7+_25G&(*4,
MI52I.2-6&>J#5.8ZT*E=AV=?A,7"^0\AK.?9C2%YTR2!10W5$$)[=)4=([QG
M7//A86."^M$3V2@%B&J]1>:FBZPPX4[#R*%[;*U9#-T9]I+<5MU@3VZ>OP/L
M)?[/=GV]>+%[2\G?=,98M7U.4OJMVB[%(LYXC(7R+=("(P#C# *<Y$27<<J<
MQ#'*8ZNCY7.+3VQV# W]QB7I&_I+U%&W[QMY L:PU1DKHINQ<97.J3GD)3&\
M>D*>+#9;*\A+8O0[0%Z\QN,KWHXRW)O S^O':D66S5'/O6R&T[>C!/ZO<B+6
M;\7M<KG>*OOX82/$!\6\#BCNU(-Y_K(1[Q]-N=Q772&G=NTY3BBC)9 QY$H3
M*06H2&) 1"DS+!*,F'W+N2DYG5BMNVF;9/^A637,1V1_I-8X&A'9"]#.CR:M
M#)%40C0]LIXV HB&_6AC^'?X5$_ZP"U\G)_E,;J9KNX)'ER%EN^H/12]ETW)
M=!T=>(^^K:.W:F/4/4'-?Z0%B/821%]ZS_+K3_4L'5RWG^69CCW6?K37T^UW
MLE7_$1%=DPTWLP4JM?E7$B@=UO,(CO38*'%/@^NSS[_1Y5!^Y1P/9= WG92!
M^?S;.7 \\I%G(>@7VFN[2GTAF^WSN_4CJ5:+DHJ8"]VH72840,+U !J8@1*K
MW\@,4BJMOO&724S\<6X)1H;BC9G\%_W14'8\C3^#CEW@;IS,;E\R+W&=HW27
M)0H4F3M#8-9HW&4!7T;@!J[TK%C2>^=V%+:>2KI]_K)>5NSYT-N0\[1(4DB!
MQ+G2219KESO!(&.)( Q+4A+B5+UTC>+$*GJ_X<H"JJ^E2S3.'BX[)0T*@IO.
M]DG_6]00OXD:\M$?[9^3-'RT%CI4#=15>O/60]F*?U(;97VCQY[]\TY76MW+
MVT>QJ1A9O1-/Z[K:*@5I?0->M^'7+$O+C,D$I#!C -),SW T)@'EC!:$B\+J
MK,V-[,36H.%#N]RW[W[K_''=!%-]U=Y4J_8GEBT7'0&UV.!. I.;O6@14GO2
MCHGHP$6W3WVCT/O%/=1OCY7#!G(2S$;VW*C-]FYU[F7KS@-VIAY>7]:T*@^U
M=7.&8W ?9K_:?)LJ9PF/=DCN=WM8V?M=]:EB.BWG5FW$FHQ)]1_^>*B&3C.2
M9$6. .&4 R@X!XC&$*0%8DF6)T41VR<Z7J<WM9?U^T<'.V !CX6Q#"NTFY54
M\D8M\6A//=J3]VDI9 &*@U4,"XZ?.?RFC-NCH169_G=U)-?JRZ*@6[;0D3UT
MI&,NE!VT!V#0 %HL,Y_ELY?IR.0YW#9A*^_/2L!#L^OFD@4JDR2-<0+B/(4
M)D@H>UBD@$F:42+R!,9.'0F].9G:[SPB.6.G[[.HVVU:9\'2<3-[M0OX"Z#-
M13/W!!^"9,X.X6?Y^/GZA0_!Y=4]?'!!/P/W66R;G'7=ZF!?*97%+"5)' .4
M*I,%8ZA'IR?:A2N0%#*+X\3*A1ND,OV&6'=Q6&_^EYOQ.8^(G6$9+:?CCE9L
MVTX"T1M-\9?H]L7<[J;?_"0598.R!K(&YVG,JNF#8K[4XN&+/9O_J)WTIFE1
MT"4^YP**HDA+0%*$ %3;+4!03H#2V;(0DDJ6.JGG*8FI-U6:H&-'GU,8['1R
MG'".FR=-:]_M(WB6]V510K7L.24P;ZN>BP*>M.BY?*5'5,/,JE&J^I_5]OO=
MKMXJ#=YTC?B>OZK/[8=V- (MDSB'RJ$72:8T#\54)U 6@,*2%5E,1)9:G2$Y
M49U8&3LVHC\5'U''R*'GY7/TAV8F:KEQV?E;XVH1%)D"+3?M_AF <@B43 &8
M7[CD*G"!(B.N$@_&1ZP7FR]*XBK?4:S$^68_=^5N2>KZ7IJCOD_[RN=,BE*P
M@@ L8@D@SB@@I=Y?T!1E(BYQC)S:%)ZE,K6=U#3UF8>AZE$8/@R1G3<S6G!'
MD^<AL[-;,RA3(,_F/(U9G9M!,5_Z-\,7CVD?\XW\=1B/V-OQ4UF@D@*9D 3
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M,:802(EU-BS4<]50 :1(RBQE.>3"*J'G*J5Y/!Y-'/RWIAYUY)O=K/.I]R7
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MZS_K9G#L>O\;,U'*\13G F9VQFD\$FY&YP!".W&J(QDP#610I% Y(.>)S)L
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M]GD!B[)(D4R!*"@#D/(8X"Q- 2F%3%!1,IE+Q^RC4RK39QIIFA'51)U3BLZ
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M0]WG[YPOSCW(^5&0>_A*SR->\: ?M7IXZXTNB/ZBW#WVW/SWT.2/0,G+!&=
M2#TQ@4((""HI0"G)$L(S+*B547:B.O7A;\.#^VA7-^CL'*_@@+@9K@Z+/?V;
MJ*$=_='^.4D?6R>I0QT;6]&<]PS9!8:3 V6GFSVW8Z;FKMM*B**,E4%(0,[T
MN(,D1@!1F8*""0II(83R1UPF'1RM[J3TGE,,1@UP.L;"<EOE*Z'C+JJM?PV_
M93K'?Z@=TM':\VZ(SHEULO\Y>]&X-@3-H))OY*\V8/U6K(2LMCIINUKME!*W
M,WC7JUX\F7/"9$$!8QSJ_,@8$)@S(% AU"_2#%/ATY' @Y>Y-E"58<U4S-.&
M*\=^HV/PMM/LF5#TW(8T7)G:^&[6VIN6LU],7+AE+CIP-^GLR1$H!2Z7]^'D
M52KG1T!VJ8A^S)(CPCQWQS$-7F9I*@E F"ASAA*H_H83@%"JMF<P844<.X=Y
M[EXCS'/G'^9Y 0GB3"29 +*("8!QH< IH;+PF$M:9CS/&/$(\WB#,B[,<^<?
MYKGS#?-XB^II7^\"A'GNQH9YO(6>(\QS-U&8YZS05F&>NU<.\YSE_&R8Y_R5
M(W9P'Q^?2+71C_Q.K?P@ZD6**45$[=U(46( "ZQ;O"8)R+*4Y2*E-&-6?5Z'
MR4QLB0_T]%GV4I>=+4W9F??V[A0HAWW>*/$]-GQ13_Z68N"=WT6)0FX!3XG,
MOQ>\*.C93>'EJSU#L>R[X+NEJ._EG69ZM=VT!^U?J_J_WS[K_WY0SMAZ<X@N
MIB(3<2%+P#E4/D/*E,\@"GU:EC*L=H3JQ]@I,.O.P]1AVI8CK=NLSY+Y@3*3
MU3;:**X<8[<>6%M&<J=%T#&NVS&CP;I[B9YFY49/LM%_B1JFHC^^F:&XT\1[
M_;$)%?WUX&#>6+ _1">1X1%+^;9^^B%6.Z&;ZIYK0+"/K>09SY(\P8 6C .8
M%3' *"[TP%S":,FX%$ZYD99T)[94+1>1?JC1OJ/)GT<=37R3&VV1M;-1$^#E
M9I<"0>71.LI)\&!-I.RHSMQ.R@F*T\92;K?[%B _/2U-9B%9WI'Z^X?E^L]S
M-7^Q2$J*DU1Y0(0"B#($D*0Q*!(!29H4/(%.!L62[M2N3X^+B"DV(JGXZ(VI
M<YV_90NGI:<3'B1'[Z:/C^8@TBQ,5E7I*7>P<F<[JC-7/SM!<5H,[7:[9SW'
M]KO8?%ZOUDU8>_70!,"[2B29)64IDP(P"3-]G T!(5("!G,HA2@HA+E;\^EA
M@I.'8 WY]O#L)EJY#FV^ I>=;0@'@9M):&3O$^X.P=ZTM"_7E;I7,U@)&:I,
M89C8O/4'5H*?%!;8W>6FY%Q4B_=F".N':BDV=V0K'M:;YP6.A6 <02"Q+ &D
M$@.<9!(0$7.BB[4QHS8>P87U)_[R-Q0C0S+J:-JI\25 AO4V@)ANBNHFH;5J
M7I'CC"[6@OWM8?WC[^K.1@W57P[:=VF]6=3MBC"=?EV[S-/U[FIZ3#QHP3-!
M*<PE*%C" (RI "B#!,@\A801P86P.J\]O_S4CG1'K(UN.6Z^7T!AZ1U["^CH
M!%O+YN[HGA4AE#][O/B\;NM9P4Z\T_-7^:G3VUU=K41=WZT?:;7JBNOT5U"?
M'ZQ7=<7;I(M]F\[#/-L%PHQ@3@N N2#J:Y:JKUG&&$ADD2",<2S=>@R,XF9B
M93TPHN/]!T[<='8<WG8J/AN*;A:A8ROJ\=5E>QE8CUB[Z7=9/K 7SHH$02F0
MT1G'RZPV*@AL+TU:F$7=/?0V??9#53.R_#^";-ZO^#ME71<H%W$IL7(F,%=N
MNH@S0+$R<3CC,A4PQZ2PFJ4]1&1J>]4FDS=T(TTX>J^G#2G2]B[[182N^^TA
MY':S,%XB._GPUV3R<N0O+CJ;-W]-K+Y+?_7:,*UX7]8KL9B4*:($%#Q/ 90\
M5GMF*@%*J?H_9EF2.'4XNT)O8N7\++;1F^6ZKG_Y>YM-_J3VFR8G;5Q;7K\R
MKX!@.&ZW3YKTSE/A92GP1,U[7[6JRU+T:ZU\PU9R=3D!]_*]E(+IIDG[=/"O
MRKA\%5HZ]>$W3H#9^!S>\221,!89 X)S#"!6&Q J]=]BR(HD0SFT*\T/P<SD
M9_E]TCJE=?M=1*)CT]2D;*P_\$'0MPP[S(2I8Y"BE\2UYZM?GJ)9BUZ /D<F
MTAB8 J<D>;'R*KE)8T"[E*0T:DT_6[BG<]LT)MT^FTF'K"APRF,(:(F4 X13
M"2@C$@B&U?Y$))QF5EN283(3VZ^>:NW)>@V!O "2G3$:+[J;F?&1VMET# L5
MR"A<(#*KN@\+^E*1KUSMIZ(?2+4Q/5Q_%40GO.AHK$XS^GVUIK78_-#FX./J
M:;>MC^V$_J?:/BD_ZBVIJWH?S&A: V-$*!5IH51:;W$RM=DA>4D!(2S)"\E0
M3IVRA2;A\I6BK/O97Y;'C=,^*3T/4$*LXT&$ 0AQH?:A9:+<3@QC5)(LC^5"
M[>BJ-?]M2S;;?Y+G]9)C^]"N>*A6ILB*$O4+YNA_3O.0(&4%BX4>Z:K[0<0E
M!"C7T]O+6,2(E9*PK'U([U?\G^H1=?PZ'&OSG^SIV'VI7QUOMP^]9K?KH=[C
MN,D@[O,<-4R_V%K<1'NV(\-W[Q"D63:<NS ILH&\C6EXG-59F13FE[[.M,0\
M1U4TX6*?5A><HS(1$@'() <P+90KA-7>!\%8H#)+<"&M<J7&LS+34<UI8Y&_
MOQ%M>J!C2O4(V.TL\SQ@^IW__"S]1<9C%&I AC\C\X[2& W8R="-\2MZ]!;1
M\U.THZ4KW/9#/WY?J;O_5#M014[_N#)M:^L%BF&<E5B A,D<0$QCW5D6 DK3
M,BZ3O,2)U= Z9\H36[4^5;69VY-U:$;AA..PW9H4'<=P4,M%=*^+7_OC=XX@
MNYL>,H>V'E-!Y]?MX]*[I>>!FR%.!E]3FFWPK36WH9I]^$ QV /$:<'Y6H/X
MR'G4,<1K <^(7+6JML*,=?ZH7J9FKG/3(^_V47>@; 8'M.9?IRU\4-<N6)H4
M.$EB0',D ,R1!"2G%&"6%B7&>0*A4U#=CXV)#?'[>EL]DJV9:[;:Z>E!/5:B
MUL$TFJ->3>08'/##W7+W/SF:CMM[PT\[//S 43,^_,;XFDS#W&?NIDE#^C T
MJ<I]\SX*F%"[<S\FYMU^CP+J9'\];K6QJ1'_6*_YG]5R>3A[CV.D'@M/ <XS
MM4TNLQQ0@2@09493)K(TD]PO\^&$UL0VJG\2_]#2]DUB.,7)-4=AE/3^*0@=
MV9E2#"Y*&3R#X)32*R4(7!3Y\OG_Y5O&-=N]6]?;^HX\55NRU,-'OVS$$ZGX
M[8J;@L3&K+S;U]3W>BM!6;"D3$%)F.ZMI!N4P *"K!!$.3"QP(F3SS*6H1DM
MPU/#4C.?U934CFF9/?I)V)F5.?%ULSV'AI&:M9NHQ]Q-U+)W8\!NZI<;%J,#
MCY,:JE"X!6[1Z\W.J_3I'0O>I6:]H]<=9SQU/H<AH?[2_:QUN]2>4O_9C89K
M(WVU25I]2VK-^N$"+<8"\Y)+B90MS5BB#QMBM0DLU-\*(8B4:4*15POSD$Q.
M;60UX8AJRCIDLB?M9U"#/ATW(_M:F'L:7I,2UHY'T'_?_Z+E69]6')@RIKCC
M^Z;)EP>&]>/+-//A[? 4T :VS4%9?!5[/07(EVSX)+3\[/IGL=6-=KYLUC\J
M+OC;Y]]KO<>^[UIRW.H,W&I;B7K!A4AH(4J=S)/K@1-(CWN"@,6%:=\'*4Q=
MQKS8DW:RP>XS8'1-D.FFM:O-D(GHT"N&['EP,\@.L-J9V6G <C.>&B?35:OC
M0K<*??-[ ]HOT9Z7Z/8Z:L[&T!V 0";.@?"LALL=D)?FR&,%STB:ME[TI?6Z
MW6S4VV5R9=X^'R[Y0I[UCV[_)!M^_V1.AM__)3:LJILLFNVF6M45,RDRR4(0
M"!-<%""!.A!']1%"F96 D 31A)0Y8VZ-_B9C=>JSA@/AF^CVX6$C'G0)S9Z)
M*VEL<S\WR\#@3_$T'..*EYS#'MO:</:O:UF/#.\W4<N]/MCH/53;1^D>F)P<
MY5!QS>D8G3<L.CG@)U'5Z2F.["IUMR1U?2_-2;6I*,HDIDP/H""P+ #D:0%H
MQCF0&.4<HBR#I5LG^TN4ILXQU.1T#-40]*JYN@R2I1D-(;J;%723VK\3U26)
M0C>E.J'S.OVI+HE[L575Q1M&#.YJQM#\K9M0)%%>(B& Y 0#* L]GYT3$.NC
MDI*6&4%6R<*724RLH/O0SZW_X*YC2.(TSP0M&(A+I';*D'& H<Q CA.4I)A"
M$4./P5W>H(P;W'7K/[CK&)9A8Q5&5,]P8"?CW\9,[GJA%^Z3N[RE]LOE^_:]
MJJ-'0RRJMV3%FRP^;JT/?J.ZSDII-:KK^,[Y1W6=Y?SLJ*[S5XYH5WW+V&8G
M>%<AHO;DW<1A?82225& M-2GTCDO 944@U)25.9)6:2ETR'*,+F);7%+MSEC
M]FA3?1DF.T\IG/!NAJ@]YFVE[U&>8'BSG8PANU1?)C9_E^JK@I_M4GW]+C_=
M;K=:];?U+?N?7;41MYQ7VHB3I=IG"?7&;#^N?MO1NN(5V>APL:2$ITG.@<@X
M!3"+,X SG ":PX(61.V:4B=U=^9@ZNV2'AY2T5U3'+1=1Z1A*R)[OJ*J94S'
MZNL>:VX&PQU[.QLR*:)N9J5C1>/8,A,=N(D^]G#\S09'9UOCC44@\^-.?U:+
MY W/2R/EOY!O.LC31K"FB%7]?2G:\\I^-NX"BD0P*A @I1["0Z7.\4\IR G-
MA,2YVA@Z17!LB$Z^5SRP8)("^AG]KCD;%A#:69S0P+ANH@[4;Z(]?0//K0T\
M'HD1]O(&2W2P(#ESXH(]"*>)" [W>M8%[3:K:KM3EFC%/U1_Z;_MYYKG7!*<
M"P )1 !BD@*D>P<F!4L*7$",J5OMST52$UN#>RDK)B+9T3>OO%#V]^EQR&-W
MQ<O."(1!P4WU/QQ)WE&]'D-QK[NY*ERHVIK+A.:MG[DJ\$F-S/4[1A[1W,L/
MU8JLE-U8?EG7QKW8]RXH85+F)8S59@1IG68)0&G& "-)(I-"J3MV*XBQ(#IU
M:N9^D,9:1GLFHHX+[]&=5G@Z'NP$0LE-^P, Y'_P8R%QZ#.@(9*O<QQD <+%
MDR&;>WT-QIK]]_?U4MU1OU=?P^WS(J:2)CCF0"94I^EP#@B7NGE;07@1RYA2
MXI([>$IBXAS!;_J6IIJ])?NO_X+2I/QW\[W?/D=DVX0M3%F&VFZ_5=NLU?;[
MKH[>5B::29[$;ENQ.GI:LB:PWB[D:CU.P+6U%6,@<[,,S?HWT>T+4+Z0L*',
MRS(%T_T3 C-K^B4!3_7ZXI5CRU\'JF^; 5B9.0+.".!,[?%AS/4@;\) F7 J
M$6$%3-QF@5F3GMH%Z)7 #=:@UYZ#Q.PQME3R29!S= O"@3:BQM96_N EMU<)
MOU(%KBT@EPMRK5?PR"UI#UA^):N=5![(3O?$4QN9.W5]Q<BRK8[8G^81Q@0L
MRQ@DLN3*GT@R0-)8 $IAF@F2\\0NA.!!>Z83T,<^-V9[S5I^NL8A+@D9CO .
M&YN)07.S-AU>OY[@U;'2E719G*6.!LXAZ6,Z /VR0>[(9O.LL?NA\SHC8K+W
M])"+MG>M\EF%V$9<9Y6KWZSILGIH6_A5S40PKB[?K'</W]6?I+U2/X@G\FP<
M0)U<8O%:_RTR)27*752F>2G8UG#1U9L_Z0BEVERVS"T/)[+1&Z[XUAU?=0G/
M2D3/NO^+HMG^2%^^TJ/$E[T"'_;,%&>5C);KU8/8_!*J597?TQW,@G%<<K[T
M&#]9C_)F/)?P\VR[QA(?'Y](M=&:\FE=UPN!85[@& $!,P$@S@G0C:A 6:98
MYF5&H72:J7F>S,2?CP,Q_X8N%_"Q\T#'2^UF_SMZ-U%/=$TRG%,Y+%(@!_("
MD5F=Q6%!7SJ&5ZX.U&= 5QDTQ0K+Y?I/_2%:Y#'G*.,,R#PN <PI E0D!8"%
M+&B,4:'^LEB9^B?+[O(65*W>8-R\P7W:UB_RGF1$.IHCFP"<@0Z7!4?*S@$9
M%QHPQ@!!&08\2Y,X2;*8"3:JXX(G</X&;Q;84@%QF:E/ Z8ZH3M/.<!%C('$
M)"\+FL $INYC)P*#YSU$8D^V/F 8*0>.[H=+J$^)=J;" ZN#OSAF",1IP0#D
M#.H.( APAE(HN/H00^XZ*F(26)T'/YQY+S6F0C=0F@I-NR]T8'S</M=G&W <
ML+J]JL/CNVA<%G>JIAAG*+YNCXO+$%QM63%PJT?8YXM0KXG:J3Z(>_EU_4R6
M>B-WO_HLMK^1I5 ^>9JHCWR< ,)+"2#D"!!!,"!%69(BE67)[5MT7R$V\8?J
M0%T;@$U'7^U43:]D75^I3Y@T)P[QB6L 6D1R L+B9@MZB-S+:$\ZNE]%NM7$
M;X&A<(C-!(3$MS3'#":^],*84(:"R+PMH4(6ED(/QBBNK3%?4,)2FJ,HA.T]
M8P_4SG?SZ55CUVTY]MN7Y=C-61!+4BXP@B"11&V 4HH!A; $!1*95"8SYM3*
M*@;G;,;CN*9] AULLU ?^BS0TSX+8X_LQCY%UQ.]&9^-_X&?3?>+>K#]Q92'
M@H$@#'YF.):O5SI2# 3GY1/'4 3&%+OKO(JFG%-/51!\4=(BRS.D=O\L30",
MBQ)@R91WFB>X2.,$B\*J FN8S,2F=+\/:TI\;\SL#O7/-[JDROSH%Y\*Z!.P
M+/S/(!!X[D+;\2\-U:@A&T1NG^KO,?)[NIDFJVVU,R7@RGKSX[="_XBL(K6L
MSG SAWK?R0\142'46[)><GVZ]J"4<=N<UUEEM7D6C5\"QZYP_.3N5R@>OR3!
M^0+RBU=[V++[OZ2ZMOY>;417@L%B*DB:@51YCVI?G3! 68I @>,LDR6D),ZL
M;=C)\A/;KAX]!UT]!<'"-HT2S<TF]4CY-*$X%<_!!(T2T\_TV#Q$-U-Q48A!
M$W%ZUWRFX2+'1R;A\E4>IN"W@XG^]EW\OJI^*/U3UOU>-F3:=R<794D)ST&>
MP0(H<P !SF$")(E9@9,R)8F]CV-'<^J]XX&)FTB'5PY\Z,]<PXF#OED":6%C
MPL/CN'T;0.:^0\;')%E"Y&"GPD/E9[R^ZOK)NJFL5X!5*ZGSBLP^]TELMJ0R
MIV;*(SK"=GOAK0L5P'-#9] J6BXUGZETD^W(?CK>&GP,WJ_DO]8;TX?M,WD4
M[]:/ZO58L+PH8U10D".J#"S+$X R@8"4&<$%30I!4*#Y=^?H3VQLA].^;R+#
M4M3T"-1,17\T;#G&XEQ!MXNX30BEFV$.CV+(>7=#6$P_Z.XL]9]EPMT0- ZC
M[0:7&=%+3,?2E$44JUI1;08TZ\RM#^N-J!Y638XE>_ZF]O6U[G]O.@.8?RV;
M\!O_KUV]U1_-SV)[+[^1OQ:DQ(BF20EH)I0U0U0 S!+=$C(KB>0<9Z53]>\T
M;$Z]+6WF8O6YCA[4(_O[FZ5B^Y?(% PF_Z[3H+4 ;48S>XZV!Z8CLN?:L2YP
MHB=;T#1E<2Y!+'7#!DY20+%(@2QR"#,D<ZQXL&IE^?,\6Z]VF!_^F9Z:W8?N
M]9^$8X3$*-@1PU'#<?1&\_S+3=0]I8[OJ,>XJ3;HL1X=>+\Q"0?*(5?\!VZT
M-QF^(1OTA6=R_L9^DP%]MB'@=-1&)Q?HR/';9^,W- ?-*<QI2E,"<IGI= '!
M *(\!82HGY>IU(,R/-,%7M*:,P' -!:GSZT#//8P_P0U.QL:" O'B(T_#&,.
MSR\)&/XX_(32:QUP7Q)YX,CZXBT>T=K39,N7^9C*]&P$J<574>^6NJ+M@Q*G
ML4?J$C/:I]9AM31AK"QI#E+3>"O-4X"@'EB-BY@G92K2PKY+>S"V)C87'1=U
MM!%,@VY.*:O&9=B2OZ*GCA&'J&:X9V(1&WX5I-V,T9GD[9OH-,U;SZ]I.(WV
MK$::U\Z%TU=^>=7GX1"(?I7GXA>KGO?YN$6L@\,X&-0.1VV^N'=PA(Y"X^%7
M]_->]PO>*=+5MM:M* ];ZH40F" 8$UT;%.LR/PE03C,@F/I!2F2>%$X-(X?)
M3?Q1^GVUK!XKG3'#=,6]7&],UB-Y7.]<>T9>@<W.@PT'AMMWHV=66LI-QUB+
M4(JS$VLG8R _]@JQ65U9.\%?>K.6=\T\#/(#J39FYI@R3+O';B[9DV!*E[Z)
MS6.RB*DH40)+92<@ 9 (" A.,<@*B6DFL'*!G7KC3\?JQ#:FHQ6I>Q^C-[K:
MT#:?<X;'9+FS_BG ]TBE&#?[47/?#'B,>OS?1/M'JD7X"68_6J/\VK,?KS/Z
MSS'[T1KP8+,?[2EZ?@EVM!;_LU/DWO_0'Y9]\UM.<<EB1$ B,00PU_/3>)X"
MGC"6)K0H$KOLU&N$IHY6[LE&#5W_EL&7D+(TI0'D=S2$/J*[&Z\K<H4R/9?(
MS&LXK@A[HO;7KA^S53-G'8I%/:VG6NW4OK"=&JY,Q%NA3[CW/J10-D,15C2J
M%=D\?]R*Q_JS$EG/^5DO%:6';D+) F:20\)*/3=1 LB5\F.H&[LPQ#DA<4YD
MXM(E>$)>G4R'>[OAYCSS[T^;M:QT(P[-92]PZ;--G.:1N>PQ7_U!>&U0FT<1
M:86,#IQ'!]:[QW/8T.IZJF-N]Z.60N]I)\4TZ(9X&DY?83<]*>3GM^+3DO0X
MF/HJ:K6G9-]O5_R=^"&6:S/Q1#&A:\6Z _&V:]\B)05B,(6 <:S/GM($4,(1
M2&6*.<$4R=S^[,F%\L3^7<>*B5OQ S/:4#?<N+2O<(+4XNAH*J#<C.@>(\5&
MU.,CVC.R3^%I>7&I.W7"S.%X9RKL@E0;;*Z_=M&;KIGJ+Z;KZK9I)U*M@]4:
M^" T>#CCM.!\YR\^<AX=L7@MX&&1E8V_(_7WSKBW*]ZOU"?CA]AL=5;QIS59
M?5YO1;U %'*:$0&RK,#*T<X8P#'+ 4\9BDN*<E0*AP'E+K0G3]3\K!LJ*6X.
M4T);77"P*TY@6MCBJ0!RL\6*"Z#9.,S];!G1'9=ZK$2:E\@P,Q5F#K9X*NS\
M;/&M.:;3B5<KA>;9]ZSIZ'5 <ZG17&GV0AE?'T@&C:_3@O,97Q\YCXROUP*>
M!6!=L/170>K=Q@16OZR7%7MN_OM-_+5]JR3[[T5!L,0(Y8 *HF<@\@*01&0
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M]U6AO(ZX+Z\ZVP'W5<'ZQ]O7+_;S&SX)M0,3;>79ZN&3-@"?*D*KI=+ZMG%
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M1)TX42M/U D4&8D"=Z^>[Q&$;&4] ]?S][6>[U&<;7(](_F0#LJBP#F,\ZP
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MJJYW>ORH"1$VYG#FV."+1S1/"- ?^->+]#4\Z^R#ANNF!XSNG;#>2%'IHNN
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MB-F6&;.!P!0QSFQB#S-G@%PD$E-0!C.,_LBZO.>F=F^K(Y: Z<I :-T4?D3
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MA)BQO$QE7&"DI8Z-B2LQ8KR@" LJ>5*4E$@%<5U[:X_M;-877S[7IGWYW9Q
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ML#2'<RYHAF3!$YGE-$]SV G]$J61-;FA:R\8EKM1DNN6-/#X?A$KQ\-\" 2
M1_N=\/LYFI^O"0\_YU\3+-2I_R*=:6, U\0]B0A<?< S/E WYMJU#TSC)"^I
MCE&18(XPBREB"4M169(TMQ,N&04U4SM<?F0U;8BY= QT@<+Q=.XM(/#,[2P;
M_/!\5H101^+#Q:<]Z)X5[.3X>OY3?NJT4\_W=H[M48';)V7]Y^Z/=BY),E,Z
MY0R+$F58FL-J75V2)ASE!6&Y)B0K$M!A%<K R"JY*U!E;8'JJF,AFM?SFNVL
MINC%LV*K-;!&&0RUFT*/"2!,Y??;;4WM3+7OCIWF$_4@HG!VP1>)0)8#3'Y2
MV^(+SK'U\5YGE XO;WZ(^5:V$[?-_]EDZIG6<9(IAE%1V!3#-":(Z#PQKKS*
M<L9E*F!>O </(UNIYH)\-4(/F+. EBDCDN,4Q:RH 2T19]*6,&F=LT1I(0I8
M<XN1(?5J5-&UE%DIL?RZJ/Y#.8Z7NP59-Q,_,EHP*^_0><<F=;8L11U/-C8Z
M6?N=(42F:<9SEH-?J37/$$3 1CV#2WET[#7'1&F/BF_G[.M,82%TS(R_J0J*
M<*X3Q&SW7DVSN"P+7E#BY&^>K#RRB=[1BBPQ0-_> ^F'[<--,L&TWE$<6/?>
M<ZS[]>\]6&FZ#K[G!#CHX7OV [[7AX?YEOO Z#[6KKC($J$E$F69F8V:V?BE
MS9@4&J>4X:PH@#>)5VF.?JEXE!1]%RT4.!'P.G)N&W%@/& J>)(2W;NR&.G&
M B!OL*O'ZQ0GOH5TAN#T0M+]49]9VE+6I7AL_I%5\MWB%7NJS+'@XW)>B>?]
M-YMH&:M"&>==<V,)%,&(XRQ#<5PRS6@F6>[><,"-YMA;ZXZ)Z,EP@>R@PX8/
MR#QH-_2&[<)(F "WYCT<EH'HW2)J68C^;)B(7(R#-T208=G!H?(KYN\93EN$
MTTQDMJ>5IP8OO5Q%1]^R:/\M"U5H#T-C>%BVVU(3CLD&R78X(!OVJ)\W98XH
MKU;*$'K%5JMG\[YMQ[>FQ\.,)G&<VR(SI7F*<"R*ID6+IK8.7J<TX4YC0AQH
MC6PI;?\  \U#7= NS2ENOJQ+?>NB"E'S9+[4>Z: E\-#(+HY5(&@@1E,FZ75
M4(WZ9._:7F;AW"<'Z0*Y34.4)G67'$0^=I-<'O%3\O-SO?Y8K!2;V_B>K8M?
M?UA\63%97U"+[:K^Q"PII8@SDB)29'8^2JX0875:B,!2T@PKGNV*JMP-@2\_
M3JIP5'4%-Q9[/J*OMN_#<F'VO&]JO8$WP? &WLUJC(KC[5V:>CS=13U4:[8L
MK"UCT9ZS<#;G5FP"&21O-B:U5K>"=6S*;E[/<W(I6S_<+Z3]CTT.^,;F-M'F
MOC&HAE"=2#>+<1F;XYYQ9M)4(LR40ER6 J5*"YP34?($5"#C1'5D!\<2KYT;
M87]0>S: \TJ= '0S3L%A@5FB'2+U#ST.[FSW]8Z)*VF^\ &E$*%#S29UHCGM
M6%((#"<324$/^P2,OJY4W73%7MY\^&$\+?G'HOIFM*X>M;A8?JM/T6VQIK$)
M298+B91([9C2(C;F(B6(E#FE&%-*$J?,.CCIL<-''2_-I>6'/]Y!8B(@#%VB
M1V,A PPB[4#Y1PU*S4BTYR3:LW*]:/96V" 1I;'@\PLL?7FHUM%C32Q:;XP9
M7M>QI$$X=R($BROY8#(<7@*M.&&4R4?2PV"3UPHCY%K:D*0]\MI2Q+;<=$8R
MK3DK2I1S5B*<9L9W2YA BN29RDJ-C8D.EFMYAH&1#?%)KJ5L68A6SK,\O;%U
M<^;&1 QFH*\G5W;LU)7-(]0L^V(Q17KE.?*_3GKE #B@],JA=7S&CEQLYF0+
MGH6EVYOA]^^*K3Y7/V8RCW6N2HR(,4C&+Y2I<0D502(NC&,8)P073K.#_5D8
MV2R]66^JQWI()ELLMFR^:]+6[^A8;^OF.THA@SZ\\';P(4='$6:J!ANY-0T?
M16VX#N:,6K8BP]?H@$)&JXP-K.?LE7$ !HYHN06;X1DN7BM/..3E%LD/I\#<
MM))W'IDRWZV-O5S]76UF0I.4ETPAD>$<X4)GB+$D1D2G,E,EC66N@3EC_?6G
M" #6]_/6(%<M;7!^V $B;J[A#7+"S&E'J,[NZ*=6MQ?C]=U"]Z&[7M'KO6UR
M$OAZX8+4X;*_#E:?.M/KG&AGLKK.?LPS=+]\?%JI!^-2[/K1F$4_Z"_LA_E7
M\Z(_6A.P7-SW1D=\6?YNA+*YV,NY6?UKQ]1,T3PN55F@I"AM!7LL;;=^A:0Y
M2!*<QUE6%+.->Q_(P/R!K &\<>0!M]%\J%_L)&_#\<;@YV$,O%LX@+?M>=.,
M![B+#,LVF<HP;4?.=#:JY3NZ/YI[<LCZSGP%O)$8!]10=Q>!N9OVEF,<:$_N
M0T8BXW%2KOM?OEL8%^.Q]L3>VS(7M:N\+UF><<9SI'*=(HQYC#A-2U00;$>D
M4'OAZGPD'J8ULCO5-/JL]M0!I[$K(#F<8\.)#HRMU5+W"-]%#6EP:P87( #G
MSW" ^!TT+P(3Z SI)M_@8?'*$M.="MUD.3C^.3[B8;!<6ARV$43SB96--;Y6
MS7]WW]-<ZIQG&4%$2&D.AL1V%F<2"84%+G)9YL1I4DLHAD8V?1W9Z(5L":]_
MLX/7MO/Z,&7?]E\!1B#$&W PF1/C"K.K[GU76Q9KS[%]"QV;O_D9X1#X RSU
MQ._!SYR'>1^!;'] Q 8WB!!TIMM% J)RL-6$7#=,_6HO]MF4=LQREI6Y2G*4
ME[1 .,,9XBE62.(X45+'2:&=;I:<*8Z^HQS5KD9,_&M;U0-!'U;+[=>'B&_7
MU<+L^G9J&*\6]6L QBRNX^H<SPR'%CC">3SLIW_%8<Q14Y8%*6>[N=;UHOPC
M5;J>TONI=:X7Q;]6Y7KY03^[\;)5D5<]#6F_V"47-,TRB5*AF?%0LQQQ66C$
M<J9XK!6E&%2H=9G4R);BY>UF8  F-_T/(SQ,\7=R]XE.HNW7I0VDY@.$)M7O
MZP(?*[;#$WX:?3!^]'XA=Q-(_U@KO9V_K[2:%3G.-64I*F*9V[8O.2)QK%"9
M9#3-22X2V)A0!YJ3I94T)"-+$Z;C+L"Y*7M@.&!:WQ&_:P<'VVJ%'0-W3O"
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M1JSC#9#"'/9U#1NOG_L28";N;+C]-"[?2U[>L1N]K:=6-0Q'#<>[3N\_[]T
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M&;B,L$]A9-/9?$$M09^*P0,HW(X9-PD(LW?M&#%+;)2;C(NBA"P%/%A_^@+
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MF&F"*),,)4JE),NEUBD!5<U<)#6R0C3C%!?+!6KI1?,]%\ *FLMPN3D+84"
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M2$C,$4Z81N;HI%"<R40P7>(BBT'QBS&Y'3L!<$<[ZA&?=@;?\-MRC*K\*N\
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M/!ZC].0JT@YN#+V3"!Z,\6L,R\?3X@ @>SMPN<:)9B(S= ITT21(12Y)#6=
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MQ=J4+%-07% #R\HGP5V4,3[DT#RAN1H'*>SAN1J'2&\H^K\Y&2)G85P.DB*
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ME/5RT_O6PW(Z9&=P[[I."1:'HO;![ !B<;.#G^,42VTH[RB8$8J!J,ZK4J:
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M@^3+'7(W)^-%X3+64S]E4-YI<BYC !F).4<^@=(/=D(Y9N']4/14\OB=BWX
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M_"XG.9O"O(L<>-&!H@DZYIQS'(+72:8@DF[>!']/TDY['K7EPSMV!:\=O(0
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MB(K.[E+L1<[C^N%A\F9:9O.+3J['GERDVXNRW?GK^LK,&NFCD0$,%Q2XN,C
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MVKV7XG=OVKV/%H;;M#NC4KF.G33*UIJS:""44B#);'RQDCA)S[GXY]ZT^Q"
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M)9T-M]9$BU@2Q%5?/^TUN!AKH0OY)U&1&WQ_8.86<!Y-2K^W%R>#YVE5UB-
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M%F\6BTO,(RU%%J@$20@5<14CN!S(N_7HM$])N++;6XB=EQS@^7:@DF>=2WP
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MWS<&)P7/X3+N&S*WF+B*7_]KML3%S8'MBTXA,HC*Y3I$PD$PA@$6K8WWPHK
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MH7#[!LNUG_3DFXO$@_.&)*6)&U#,UXRB," =<K2(&'<LUMQIN>%X(0T TU[
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M#]7'@+"T*9.U1EH?38) L78=P1; 94G,>.()M73!M!XM=)>"?O%TN":W0.(
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M<GDYQVN_C_QO[RP*0.5(S"YGBNOIBX@Y"),8-[QU,+LWD3MAV?VB6.Y6I0/
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M[BK>;B#U\VJZ]B+G<?W(,'DS+;/YQ>KSV[S@>/*CNWBWL3LO)WBMP2WS%F4
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MVR\NJB,Z$D6[6,CW3 4]*%8;JOFHP#(>N?.!4[#4&%!/D-/O#6+7B&JEAP%
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MP%D6]*_-"S$/(;1?<]<43P]*-SM77,^]B%^NPM/YMTK\NW"!FTDO/C,M&/!
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M6+,QCU@2EX&3)+BG0UE01!#J-,'(C9.8!=G+UO/9[A#0.SJ.5>C]2MJ#I3L
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MH'A-W2Q\T/J8B1S3EZ0<?L /7V3[_.D/4$L#!!0    ( "R#=%B<K(O-*^$
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M2?(<7F67G4J]#SH*R2KVP8U*[@*/8@V(1.R0K>ZBSDQ\H0^CF+WK:98WC+3
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MQ;WU(#,:I*&KI<J3-)/20VX&1I85_/8@DM.M6EQ<7U)4)?H+1I,A869^?$:
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MK)S,0Z)&I39F^KMX^?/:<=M;O!LZ>PI*:<%>1SEE:'A7U_]$U>0IM;(.UC7
M>7>*J'GD+F1/!'7^>]"T43;)4^=]$#=SG%-+0]PCS)W._HDNB84;W@4PX+L8
MCA65<+1!L@$U5!)MY75=V]SN=10)Q/99"4OXB:GINV"EO="HOVZ8V;8?>ELE
MO0X:NJ.@(AK>M7+].1[J*KE3=I:T6VG@GZ%(>8!YL>TE-LG+(O'9ZS(XPF9,
M1I+%NPX!(GJ$7(\L#IDWP_F;XC=RYX5J&3_1K,M#-PV0Z",,F3CRC@(!TJ5%
M\EC,#OT_!1%-I?%S'9-TQ3]G4NCDB\ITRLK83LZLW*  KK;B:YJ8<R08=P1]
M88,TI_)JI<_DY8B!AKL26&&Y(L@@K\$O7=/0NO:]Q-Q37V<NL9UP!8"/3HTA
M86$JF:$*:=A2AJF'6_+J"[:A&N&R,H%#1*JH*3>XC3TO3Q;;@4>+<Z)7&?Z+
MW6^_XR+# $+W?I0C.QDO-*^RPF>V7^+*7'&D!OZD7X1HT(8*/,%XF('7AQD$
M? ZR+-&RF$(.<@SMEW*(=D:"KK5OP]-=3+5;NR@!1HP(XH<@ZF=Z[\IDZ]=E
M:'<A.;__=FF5O'R&5_RD@4X8 U/_SD&W&TD,4IN$M_9M*&@=9'BI(7%'64):
M6S- '_/.P3#7*V*QMF\$*MTD%PEK;U3:+H_R@@H>]+G597A3G;!WYN"B;6L7
M7*7Y+''-'TJD%&[1I\!H\07]CM+YX>2(?S@]EQ_.?[L^TAZ]%&DEQ;28&Q,*
M,)H730ET 1@'OHGEF#Y3"9XWVJDWG&]6Y1?<B5C$D#V9V9>=21SZ;+62=..W
MQTFU%X/6,W+BM=$@52UI1MUJ-^[T=UJVO'C%NK]BW=<6ZW[03:S[>K6S.>@\
M9\->E]&5EIX__0H'6$I;J3-G\6*Y<N4LG.9A%AC?\8\\"5(P3IFE"OP/E!8Y
MM\46AA,J4W*!9H]R-=EGZ5,Z"!\TSZNG'.>6D*$3JQ7AB"Z%[WLUG4E+_4>I
MS9$L@AS(/=WF-)LD<3X6!*@J5HI!2O1FUE^IWG+1^*_I=U0]I9OGDV[$;SA+
MD.4CXQ'760KBDMX2+]<5\7(UFPU%JPN0#?"@M".<NE/N QN E($/[3+56.5&
M@>D>B&:7W()C;O1NU7?>4/UQOP=^XGTQ *0HRN;E"<0+/$2XXD.:+D"7+BYY
M_@N7(+I+.E.5/XR3&0J>G^3CQ6^!.-(KS>)9[9=G\,HNN$!>]9XT[Y;?1O)B
M9(2ZEQ1?:$=[MKZ-+?8Z"B05S8L^K$>T_FY'N+<UI<4,]%?A89!A]5@NE,'.
MSIH>VR#W3>(3(OVSSP'.N7/C1AX'J3#V00WK8$Z4G!W%IP8H:I$L#^=$O$WZ
M<"Z-?(CP63$LB' T4@KFA6Y*@3!>GG23&)\?A;!K6)7NHF>*16E,6X6Q)RAZ
MULD>:-B8 6$E/FU#?&T=>V#E)@&=8=JKQHMY&9EUF^/4I6O?W&-C6[.^S+\=
M)\^Y(&NQ31HS)'Z0P-'+D&@\(_5O]Q&CJTO 4SZ]N*&5P;GU$'Z#2\%?9JLM
M,0'*H8K4*,B(YM1HK42!^25A0Y %#&5; +D-"9 0.7A6M/IB$3&+N<D!W&%\
M]]P8UG8'YTJ7] $0]L[N:@_->.Z&8(EUI1N4E>FJ6IJ8TZH:GY64EU/)>4E!
M0!!CX :31[P5*&PX&@G5[@FV42/J?^'9C42Q9=0BK?5A7:>"RE'PQ6.A,\'M
M@^:SF3<W@0%+R:\4ER$,?$S%!U-)]+'79Q^S-B*JOE2$?:!C# .G]3[&@E\U
MHN1BZ^.:>HRW.[#W%I=FE9B2@^;CF=:$YJ(^YE!DVY:93MP)CP6L#7:V:T3;
M;O"^$LEN/$[))(%!3IR-P58VP6,M"E *79X4RC,$29I14T:54!@4"1:_0Q^*
M=<B =;D0PQ@:G3G%JI&##0FVD7.Z289SK]1F&^L1,!62<O%<$NE296IKTW,4
M_#D6,L!1$,$+!U2>I-TA;$(Z'8( QJI=(4"-6EQO >UH*4!90+N8H45-=Q$G
M]VH<N)%SDQ&R'__X.0K0W[O0?7[(=,KQY(;KX$-I7N"<*^HH2]\TV)*Z"^6&
M_P7"Y<?3TM^*+Q^!LH5=TW..W<CUX=^C'%L6A8';,W7W14*WZN-H=Y1',96&
M]^7^"B%V0>*4)O8U4EXN/V+%N,?L>9:34Y-(#CC@/(Q]:BG(8Z"ZGRABSXI#
M[6;=V\8&UQ4'OM_1"H7*[L.04F<VWO>(!+[MB EKQ.)AUP)#?[3IBR72X3S=
M)D_O0@X?I<[4#716@OI;VS%!HUR--2O??LXH4O>FN-%+*)JZU,YO$5QU) 9K
MUS[Z\<PD[&JFN/>40,Z*9@L#OZ$T/&=@$>AZ'T&&U-6&-#\'TQ(U"UWLH<[%
M0# (P@+!O]^S#5U7;*G]+E?UW"@NG[5X<E32&:6.>7)LMO,&NV*6R.42W2X)
M6>+P.X.#=REM/,I"F$"K_974RA,'J4Y?;P2;ND5PT<)8T_H6T7F[>?/#PKJ]
MUQ)%LAR:Y157]HHK6WM<V=N?$U?66B5TZ'C'A%0 NM&TP-5:<JBR>RPJ('Y.
MU*B$T=7)*E&=&T]J7%<3^7R[TB.\HP6)^@@/T6.^ D>_DP6Y*2:J\VP=:@T?
M*,?=ZP^6ZHGZF)!U9TS6+E<6WF1P/C@?W:P3PJYQ2=,<4W'A7&M)F:AQ3"Y@
M%#OX$W\%9(LZ?#LS:O@,KI"T  <5ZXS!A(M*1%7D6.(UTRGW5B^Z7U !!OND
MCZ!'KHF/=4_S=KE6J)!$YT2Y?K@Z7IJ7KW^WERKT7@NCHLO@>TNTKYFC!1.W
M09:I3HKX6A$:/"3D^TM8&"TI/]:E+'2_RY#H@KBN"^*OC0Z[N[A&AQ)RT?5,
MM-FFS!3^II1]-VR]( 1-#&Z1*\'8$.Y7V]9@,C'LSF#X !<H_"HD?,6DI1K(
ME&K#"#Y[<RQ#C9-4WJQM8X>US>QUF42VLB1=$/07:<KL]+>?YD>NB:QW&>1T
MJ]RI<SP!C=>E= ?#Z&!D'H_,EG=N1__^\0;PFDA-EY%'58K?C72S"\+S8JWA
MO?9=;^I84M9#X@^ZC/;I2C7#"Q5Q\,W:=W9:JKU?R_*LU;I\!UV&1M@EXL>Q
MWPG';_4=5+AK43>FP^Z=@N1=<4A,VE2BE#'R-!Z5$2)W;I@+BYM :V?P+28A
MFB5$DRT?SQ)P60,BF7\IRD9BJ S\S3+7F\ K86-L+D=D"_/L)V4E.^ARCK>J
MBYP3A5$6!AY^4EGGO!C?&E](XW-X:PX.LXGS00V3'$N#MK>V!\\ACH^$"'99
M'+N<@KU-X,LS-R%F1>FI-PIPX@*84NP(BDJU8U49S8<"?!+Y;N(CK^,8_B6:
M%_L5#3!P1J0XO3K.'3I"2K<=47Q4#AM,TJ:$DJU(.OQ))+U'D5QG]X5WMSWH
M<DJ7N;MO,J6HMTVGDE[=L/UN;[K0L?*E.H0'_;V?(SI\T.7L]VV24P7',0*=
MAS$U[^FFT(\TH]CZBOPNMK=^_DX7K3F#5MOKXJ"C66\:WN?SL^-.M"%:^=''
MTS&;J>0-V7/<X^O-6>3%4P5Z ND?P +LPES9,1$9EL.V^2A@78%^I#.@\F"R
M/#^T;9_QTGRL+F?C+4:8+AP]&G+B&8H:TR0 ]T,>$8F*\C5Q#9=9X8&%+1FH
M7(AJ :D?0:+NXB_4CF (7XZ%<VNB0KH1%XY3 1*Q<]W13!"8!<D:P@) 2TPY
M(.4)4=N5Z,\U.?J;,BDZ-P,@VK3I3-%(R\RL>>3"+G=#_7C]NY2'"0T/U3 2
M\3]6-6*!)UW4LRK,]*O3"_M!2A.'[PRR'_ +NSXY%T0'-E3F3>FI]BQHAM5$
MT8PCUX7Z"HM=%)Z:^R>FDSN6;/RLH;PN(P]LH'9'\L=Z;Z,4); I&'90=+:R
M4&"Z!FANZB3QKRWJ>I<LFGIK.2?+E$RU=7Y^D(36B\!VOTD^KZXO_W%Z?.M<
M7G\\NCB[.;H]N[QPCBY.G/.CBZ./I^>G%[?/GBGLM)4L\]68)WS%$/WR][YS
M:S'#F<8\<%]0,0M[M0!M$DT<WD>GPN02"6#:7+")FB4JQ3,T(_RH6TF*X;?M
MZ7@0L+2D*MBQ8?JO%=6O%=7V1OKI*ZH/?\Z*ZF?NU-'J"%SA^=>8F^Z*);M2
MM'C?.76M^@4^ >F<R]POBGI;Q$-86>%!6BA;L/L<YBG^E]G.26,CIXU[!SYF
M2CT^O$F@[I3DN$/DN,2KTIX#[Z72#'Q93OBA%8PC)4(FZFU5JNFD2XK;T056
MS97NK\C6MB_%A<X&7>=V(0W4S=K'3>QD(@SUG'W-XMCGVAA7\!.>&Z%?[H(K
MG6#%+1_>N*8&W1OG&<7UL/)6UI&]_&A>+K0M65X!%LF,W2A(R2C"YI.1XI:7
M\*#2;F&6Y 6IP)@!MH9)T]@+F(0_]Y%1"OYN0<%1--[3!_62GU)LHEF(9_!O
MSC*H"WWJ]\CB"+'BV// >G&Q%-GDQ?5HJ*[H/H"'S]PY?UV/[<%O<O/1>TR)
ME_K3Y;,XHE!-J#(3\+%$;X,,43A>II0'H1=SN:9Z?1,BV]SX>[/O'!4]@BIA
M [#NYVCDBX: R;U'# *(?<7<I_.^AJ>[QV$JF6+A;43BQSG)CGR]5[@3+IKS
MTO$R0A80VB'<2I8=")#_(QP.QMKZ%7F7X7+S5XY^$<V];],N<0T]O0E\1) ^
M@6M80ZH3I#5>Z\$2)9_KVNYFNYDX>I5'F&G<'A/[ N&60C=:J27SS R6'>^:
MLHVIWR;1N!76-5%!4D J+40Q]"XTL>1*DUKR_42EJ6;3D ;4-FN^G)W4(DSS
MOQ'S;#8I.-]8L^$1R,%WBYX#3TDK&*H-25OQD7*<PCRC>:C&>$AY:(>2UC+?
M)"7*Q!ULE!"S;E',NX'#[("5U\$MHBV]IQ&^[A_6;9=6U-S,U[\BP,!&L-FT
M7Y"3&3M8#X-08O4@B2'(.C>]\[#[N&[)H0]M%D'/@KFD5+;]QK$*@:4W2)3&
M< #G4V=*#-4IM<,&BY@Z^FE!N59I'F;I$OTDVJY-*U6VXK5I7AP.QFKTZ1<U
M-S-VCMU1 C=,39H/%R?P@IF+?0PK?3\,EI0;_U&T]MFGNEWMT*KFFK0 S'7S
M9!-?IR >/+=P'&9)#,X>VK"6JD6_SG94>OR7KRXZ'=B[J5P6+]VIT<?I6;C@
M)( O:</5M9I-HD?40].WS,M0(ER@I'' 9K;GSCCU/-*^&=6]6Y<;?/%4)(?Z
M5:'UCZYKF1W*"B*4[7'X;*SB<>+.)OBU<.[XU*]#.=2KC"GJ2\<EO79IV,&C
MSTC,6"N/PR,ER'2B_IVKE/RW(G[CUGM!Z5)=5NJRW$WBWV7I'QR0]-\U"C^*
MN0H#1 <D\YIM8,<D:ME_4^YAAL$0;$(Z9RC\B%WX0AX8 G*99Q17QEN>11Z&
M'.!VYJ]7B9KI,I +<537S7F#&6]$+B[#2;6(GBIU^7E8V%;2^&>P)S9Z8_CY
MQFZ*5#$2K=!!F3C4#D\(IN;/?SH<O/O+7_X"_^Z\,TTO%AJ+83LS3]_/BDV4
M.BI2Y$U3-G/K2A!>I,YKNU"+J?,G0&%6Z%PU%EJLTJ7X!Y$>GL<1-JKDOCR^
M<^3?!2E6TWP$$VBVVEP"B/-TALT@"R^S+GQ6EF*00SBWX# ,4@S0_T$O.2V_
MI*M?<HPOZ6QTP+_[Q_G1QRXX<V)=T'Z>*I5)FY@$^313!WO-&/ JF31%+Z@2
MZ@!;B_.<HZTWIF@ G5,T^73DE-BJ,,2 4R!/]N(8B[]0V= Y-X*#D#MJE+B.
M=:1@L0-\.39A64'&R"P%TS>"H@V\_OJ"%U>)^S>\>GMWN*9PC,ZA+L&F&A5:
M<[0(K!><,8JWQ--I'HG)D]8=.TOX3(M *M.,LJO'MIFLQF-;;Q+IZHE>!FT.
MDG"3!4.37BR]F@3FV VBE#K@MIE([@>Y?,I^O[P ?/CN+YR]2Z!]7C%"KQBA
MGPPC--AZ!0FUUCBHWI<!RJY(OU?A)M26#RD64BY"T $ALJ!2-(3$NL#P+'6%
MCN"_;\8QY8RQR3,U)>=PP5Q,)LZG(.KA'L0"GI4R$:@/6F\N].-E1$3KD[4V
M'M,X]1WVM2@@@Z=M8XZ3PX%L4PK@1P>"K57<&.;<3]XR2!&G,G'EJS09E#F2
M^W$QC/:^;90$]:\?!<FT@ITHD!.IY/\+'SK-AW]89BQQO:;<#76TQC$:#:98
MPN2K;3_^%.S\2HW QB" 9O-UT3O)I^2C8 5(GE)ME4L*X7ZB*-O LFO\&2]/
M$GBYHMT!BF6"0D2GHF((3@H+D8(R*85XIP'=O[VB6$)+='\U&JO>S38ONK%:
M6YVP,KP;X:\E0[P &N8SVKS@ZFP,MC;1L/=$S1#:'Z8)%0:L&5B/$<*E\*NC
MQ$48SX*?:1KZV _K:0IH@=216T Y 3- S K )Q%F!#B0;WQG/U9<$A=,9ZZ7
MF1H$=KV-GL)#K)*X7Z8]_:-.E0ZTJ$?I:*P%?U@Z3( >9HU)O;7/2VL CK :
MQXD5;G4%=M?3VIZ63W(\>*1S4_N)&Q%6,5%\HTCEV#OX21G'9E7:M<5H+ Y.
MN"$"F4BR B:S:.8,:V)G9(\Y=CC: (U[#I[W5!L;3 ,N NV54KV5</KWF?6:
MUD,KG?3&RDUKTN60PCS7&TPB<MX3;5[]2T9I45B4+$:?T\9W'Y\?@_EZI\)X
M1D98FN7^W+Y4=\4&>PAYH9#12J_J,DNPC.1W8PW,&=7(P%PC^'Q4&#(L["T.
MRH:SZO@96HT5$-8_7<]#0+75D$"'>\V6B2/[KJ, &YSQIH)E$0NB_7(\QJ#K
MR%H,&LF!93&$^Y*@!;GL@QB.?E<RYLAZE@N$!Z$%.JP,BU+'<K.1MK>4ZSI(
ME8.CG8F$#AKCQG5ZA4C>.'J\3*3X);@-QIL=- :/]339H!ECW6,F#%XUHH!#
MC-XE(OJC>14@QJF3HJ4V&XG2+*3']@=^&56V58FNOXWG)M97>."(T*UB<9[=
M F-2JFE%8H>0TD'5=I9D#CTJA+&4I[@&OLF@,8)A;1+6T)P1_3<8)Q2Q/F)P
M(67]-W(X,\/Z"RB[2[V7=:YT/2$A#W#L[O9WB&,7*S(HP(+]T1G_)! OJ9L
M0]W3<9GFR5I"&[^,:)HV! >-<0NCID':I/$\&B.S)*"\O+8\;"./,-D&XB0Z
MI<DFX5!J"G:D>@/22D8'_0(ZYCNY/FNP'(V!"]L2K/;'8+NCJKRG+D:=[MR
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M(UU/H [N$DRR4N$!$SJD#%F55<@N"WGVAE-KT(MQNQF9U*6&NQP_D@#Y(NU
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MZARXG$I71E@U-5RK,V3@-8T$OM$5*K<%4>U4<\O-LN%6;R<O5.DS6*C1KD8
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M7$PS\ Q4$[\;VD7DF#)]&2ZIW(6"K18_\B;+ G*-1'1L4[$A&"02G$&W#B'
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M)"*6Y92J;G7CYS[RNWSB4_<)./&[UL:1QO6!9!>,,&H-7%'.,,>K"KV];3(
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MFYX8VU^E[;[?S?#^Z5<OF*$PK%AEU/BLME9 :;LK@$;37.K"E!F^(2_*I8(
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MWO'N+VAK-#HS9VU#CSTG1SBNL$>8ZIO"4Y63FVHLRK  ;'^*#!R:G]^-"I.
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MX[_.X+B["+9$(ABWU9G&(Q!@*H]2#CD0O7 U$WC!?*XFE(EP=F/*&=OT@;M
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M*>B%2<G5-1N02-=V%*C &M)7)'.PW+%.12M+,W&UW<!#QE#_3 0UY:,9)[U
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M#R!:K.7=SH-<RG#C4SZC3]FL 5J7LM/."J"5$D)0Q7O/RJ&74\JQUUUN*AP
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M>'M+L(F1HU<9W'*C;%K!J2TO4/?1LG64N91_Q%F>$^6\27LPLS#F3M[#3QY
M%'3X8B1JCY;1R\D^3]U;X3&9W4K)ASV_:GD_+K.IYJJ_,O!SXJ76HK\[ VLU
M4\ODR<C(4#_@R!.\1%(R9KL(9NJ*? J="B/<(.9#8R4'."4@F_EYBGFB]F8(
M=\;\;!OV7NXDIYTM+>44FTD<Q6*-878/6U<XD =;EHT5^5@/%-^AM:?UIQ T
MDN5749K\C]9N8,'5I&(24TY2%7"0SZ(<;45:OE?@MN6(1^%CG0R B)>S6P-;
M:RC\D$_K+"_\(F>Z[Q6BX@DAI?TU+4*A)2;^5:6\88 UEZBITT!E"%GUTWI/
M[I<D>7VTC'G+I,*-(EX="$8Y?=B_8:(7.#.N=$X\#"9)SINU'E-R('B?%_^"
MQX^P3I0@P/V)PHK*6.%29E</IQHZI^??D08[8,;ZZ.;ND@- XR$\*@P#04/,
M2XR%X41EG)0R)'E=3-K!KGE:U@TLX01=L0>LGA>U>#KI8(CZ3*I&:YTK;-<P
M$']E^7<PDN+OR+6@/4$$R&!)*>Q@\Z2 '3//%GE";E(>W"09+I"&]O4I'.JS
MF>*!A1%"^"ALUJ0O$!//]8+T3VB-T5;[4_:[P8X8*S4?+6-&X=,43VV3P/'.
M=Y,A0E02=&794,7.:;]*2@V9PT'2C&^16RU=@)6KE41I-EA=^$SB*KSY1K3J
M[LSAYPZ_XR(+K,-NP/KI<58A;,/;:<?9A"9$-,'27P+^XA$)4Q#.=QV?^5>5
M)\4D85<=?UV7#&Z9.P^,4^^37;[)<6UR7)L<UU-R7(>;'-=3<UQ#QW<<+>.=
M206^YV[02$?!AP0S15Q48XP%3Q3:Z0F=#:&YAG6!* F@P+[/[I2C)Z\Y4JUW
MJ\913G)"N>\Z\C=TK+&%L[?;9RA?/Q6&LZ)!^;9SL7.R$^SO'VY%V^8@-YZO
M52<%%SL*SOEHSO*[X-@$8Q N*8 6.7UA.&X)="O1<1)5^8V<'#O=.ZO4T.>T
M' C6HW=AY?5L15L)%#/V.J"QNFXEEU'-3+JD9@YBDB>O5,A.L2J5IB_D.BY!
MO!O765K3W^QNY2-<!XYX'+U.93HV:\&*[AV^W=W;V6]TQ-%N/V'7=[\DJ]+>
M$5O)=N<<1D!8F2=$(/356/B/]L:@.XYZ=<<*.Z.[-V"IH&7"^B8742I>,P'K
M(N<#LW%J=^@I_?7F\2&'=Y2]6I$/"QW9W9/.84PH_QN,VC+C$SF#L%%%";J@
M,?QW'I(:&)@'A(*<,H&59B6#'\,4U=EBC&#0+LLA#3K36*90GVIH/#CAY\@]
MY&S\Z(Y*3"1JBW?H/=S]QOI%)1YV7W>:?%EJ330BT=5D]>THD"U=&'*31 AL
MK<;@>:8E(@?,T"(KP3:EX*K"SAEP$B24.[OC.67^Y<0(I7P50\!%5L$<H&!(
M5!2J%'[?^GX7.O3ZU]FMND&=:$T@Q%@-#+4@N-O9'&JO165B2&)J\%AUY'!#
M:^">QG 3R J0.\-3#=B+Q8+GBU(FJQ^$,3/W@5+FO:-K@V<7H$G;F9[L(]''
M^0;*7M)>P@DR2A1QK^)-2++48JSONZ<=6['SDF*YS:9--?KR.BID)F(0;X[T
MJ3!E;^"9I#B1.]*+=ID1.BJ;*:FUPIUOF]N?9K(/7KM\L9'F!C3SBG=;OK10
MZKOF = /Z_/F9A[6+F0#3,!!$B@T=JJ[V.[O6SD'W-9"*Y&X*V7W4%>#//I9
M=:;.EUU;=33,VBKM$9VK!2P.34ZP8F;9]S4)S<;Y$+)HGFX\G2I/DY=:5W=Z
M29&86P]FBL2<O&%3^9I#1AR>,& C#3+$TN87P*U^)(SAMUDUF^"F/<O2*WBE
M<0M Z581TX0BOC[!N3JDX=:BT!/1 ":Q)R=),:[RPH VM,7"9ET+$F1]>W6?
M658>9!YU%.GYGSYP):X(/F@78^<>W[X8ITU(KUF(.L6,'SJ@8*0[9A,=9VST
M79$+=QUAGF\&UTWNV*#AKP2";;.$3OH0O(0[B_;VYK& ,RPBP+(#<P/GR%XY
M07.-=#_(C*OE$2W#D($BZ%+^5G[INI R4P6 .XN.8L@W=]Y#=P^VA*$EY.B"
M&1^A >B0/V!]7\%*JV!A<;YW'A%/4E#@#6$44XU2HH1H*P[BT9(XB(EMC7D/
MW^@?9)4(K:&5@V'%5&&*\2> 8,FH]DBGOJ?9[4Q-KI1H[R"^C<HRBBR81NA\
MZS-IYM3NRIP-GP-5V^:WKD=\>DDUS?-C:/MTYL'._@8*L8%";* 03X1"'/V>
M4(B]1VT>[,T.)I_^R%*#%T3F@@=3IVLP+#"VIQ2K2P<UE@&_1U6V1Z"T^VOP
MK<-@+D/6+P-JZSK,5.7%  #;+T;X&L>D$SQO[6:!WJ*C'0;WXKAK.:FAHKB/
MZ)185WM]"<S^H7B2=D! GVXX.-HY^"W0)&O0&8-"D[Q[]&Z(O;C!DOQJ+$G_
MW'Q;Y?">/P?6 $2L2\?VNXM?Q"+!@^L*HU0PTA+KI!#'G=?O/K]\G>-LBT>7
MN+<[F*:E7J:>L.M'G-DV*IV, OT&9<49@4Z;9)4!U+.,U4H&$T0=_=?)Z.ME
M<'P!?R$IQ<6G_PXN1I?!AR_GEW\&IV?!Y9^G%\'QQ_/1Z//H[#(,SKX$7X_/
M+_\[^'S\C]%%2-P5H^.3/^53>Y?WIQ<GGXY//],U_TW7'7_ZY/!<!%\^T#?_
M.#U['^H?!E_.@]//7S^=CN"ST[.33]_>GYY]A%:,:K]\/[HX_7@6!I]'YR=_
MPL?'?YQ^.KW\[S#X<'IYAC>"-PB.J56G)]\^'9\'7[^=?_UR,0J#?QY_.GT/
MU^)MOAY?PFM=X'N=O3H]^W .3Z,WQ2_QJ:=GEZ-/GT8GE]^./P5?S[]\'>%K
MGI]^_//R@J\Y/7_/C\'NP(>>GUY@FS^<?_D,+3CY\NW\8L1-A@>??0R#;Q?'
M'T=XZ>7Y\?L1W/7X!!HYNNA+C_*Z;VCBGHJ WO"-7[26.XA4WG02J9R>77R#
M.7$"@_KI5&8 S3284J//9Z<?3D^(8N6Y\T?M,9XAG$JZQX9&IT+M.DV+*L=#
M:\5[7@/ $F!2DKB-$MU$P4UZZ2%*'L%80R/RN]9Z")NL#>&H+[X+0_TB*YEO
M/\C ;V7U!\N%5<LBV;QL#*W'^'504FQJED3CA"C[;2MCC#!%5ZI5O%<((HS\
M ,N5PPM ZWW9WJC!1J8E> T2""_#+*^OYT5L]A3Q;>W7%CG@(,:H/%$;BQ8"
MHN^NM(R!?C&1=R90QP[X\'7 #'49^>W!GTB!?LW@MD*9I+ZDG\W(41MT3KH0
MS0(RQT*7H==,!;3&HYQ^;IL%+U2R;O'C-*[6 S'W9IB(N5/HG'EJ:+%I.KJ1
MGA-TFE9K4/TVM?]FHG0?-2W[02(CZ#!-M\A[)0(3AC6>Y'J+Q62Z%%6:X#O1
M6NOR2OT;SY5%[PGQ :'63N:KCDEY!/^EV4E=^2?B.=1TB$V$_!9^CRB;O0&@
M,61-E&JUG@1UQ^[?MT.-MH8SY2I"4@:.M>._D?N05B@,7S2'7I?349]KI+\!
M Y,3VD]^3=OT L8<S\SQ72T*O^4>EGAK&K]47<%R0:3S=HW1B2G-B: 3FXF4
M3&W0*<*@>Q/3@*K@"UOWVR+AWD&?R0Q+U!1LA(KR^!H^G<")-LL6<HU#J@O_
MXEJ)\+G3E1L(PP;"\+M!&-[\GA"&%\E83OT<&_$(,/"9,@]WA:Q %RO'8CL\
M*YB >:S ])C:!#MO]9R$=*V%&?L/>"HYS XM-HKKHM&A1BZA$M-"P?^'Y^<%
M^T9$D-NJ%QJ:#UHSE($02=0BP2YE'YPHE#; D\]Z114C;ELAP>U/:M3DMVF;
M<N*547R)>YN%OHW&\4[KL>T.>D56H^-$!QL$^%Z.EUNPI" 99S;]1#>GVA2'
M&JK%3!O?<2D9/- :!)QV(6\\0RU/<,<M H,IM^MFU;.*&1\-/9W_9AF4_A>Z
MX90P"2C;P2-Q5P-Q;!7;M9P)H^D[6A0[FGLZ&2/":X2KX>Q)I.>W?N8+DL*#
MD<5*D5!7'5 W1U2/JXLX?[('07?\CZ2$J1_WF(OS"DOBB@#_"\N\YT)LK6WI
M2B^N@W\]S$H "UN#@VD!SIFBK.; PC$D#:"##HG21SW/?5*KI=)D*SD ET8W
M6973RS#[C;LC3!V1 5-+I.MZDCRNYAA7C76M#I8=V*HA4BC-$]94C?Q(!1WA
MO#"QK&8LD5T)3*SUIB-5?V5VQ77<% :.LX60$7M:95JGNPBY2@-G%FM ,,22
M!+Z7CRIFVTFUVJN*CHP^@G-@U%/P[BA0/?O+&@&M4R*PT\)AM/:FM]ALCI&;
MTD%8SI1;Q\8J'_7N"P=VB!BB@E7N0UIWN1 Z!IRC5>J4%AH[%OD/C&H*V*H3
ML,OOU,2?\G:49,Y3#:(A_!9Q)2R>(4*2;$9"OVIJQ524S'4KG_Q=J84W%>RZ
M<MK).R*:3GP7Z%VPMXOF0F[,BT+6%6Z)+VUAV5Z4B+,%Y31[4XS.-,(PGUY+
M>G"XMC2:W. APK@P_KMKS\/#@D8?752L+"W4C*.C<;(0^HVM,2QZX=C%V;!-
M#7#F0Z27KACTC<?8Z.=MBI*,:. _JULT>)0S#O8@$46C'[!+%ZLGCCC+/$VH
ML2)'GB7<+)N)(SD%G\TRWCE@%T'YS]!\X*BVVP]=<J4Q3#',T6ZAZ'9D%+,T
M50QGAUQJ)9UQV#;Q$_T-'70H- 4G2LB;]+\KSM:'K(& ?RRP,92"RIFN:(80
M@!DIV-,^K1,:#EN-;G"HJU21'M1$(K!,&MF=&&1LPQZA]3Y#OD4RKCR,)Y)*
MP5H%2Y(*0RHZD3/]R)33TWH+<D,B3ZJC;O6?!L^>]&:8[M,G$^0ZB1:K7;@7
M%I*\UH?Q04AGL:></(]^)/-J[B%G@N@*UL,558IX2RAL7T-A/:YHW0R,:L(1
MZ4N<P4Y8XN\L^[POC)RPNC-%HW08;-(=1^-630W)EH?$%TM^2ML7!L/1OG"*
M:>#B-1[3MP\?T3*K 0ZZAZDY[VD249\VGX(4%BZ<H>54^^E3JY? =7]PZ":E
MNTGIKF]*]^TFI=OS5RT$KMU:D0-"@W=:= /WPQA:-" +[QZ#!(Z;:T-*UW(<
MH7XLQP6\XY!RT\W*):MUQZ"M:$:2<5R -E$10H!]SX4BY5^],$.??"T[<@2K
MFN911=$R^J.:8=OAPMPC5NR^4^CDTOUV- N3V51X=,'%PRJJ5E3!.%A;$5IW
M3W(S0 'BK>1F^6"R@/UW$HWFPO^F.1>Z(APU4F);Q&>EGDT$-^28K>>MDTFW
M0.*V0C26RPY6Z7XE0+N$(WB$1/)Z%/R\[2SX.?ER]N'T_>CL\O08:WT>27^Q
M'B#\M\,LXCEQ_,W@U.J#K 'L_L60VKQ=IE@\!&3Z .>((-2#N8HH,F*%;2QC
M#&(&4V4%[Z/4=?#KF' ._*H"IHCRL.A,AVGX,_'TZ'Y>#:,8F1 #VE :F+.H
M\J*28K'UC>CL,_Z(;#8Y574AQ@MYPUV;$'SDJ&MK@ZM5O&ZIU?6+_= G\&_3
M$HL\04QD%@9HJ6 >!OWB%LY*YH"-;K*$"PHQ@YQ5XS+TX*&:G@!?>#F:U:2%
M)M@D#GAV;1,&,*O[!#V$:9(7I9;99OH+!O'E4N>(__ HM'3CLGQYVYZ *VL]
M/@[6X?CHQ'B:JJT[GF"(I2EJ*B($%G #SS0!T,C5L]S?.HT-WCGB,NW99PPL
MV85U)PDS):;YEG;7S%YL%Q$M+@-^OG,+=_S=6[ZQ]6.A4U^&TG&,0N(<'E6:
M.?5D7+B$PO-:[0)9G0DL,[E)"KK'[74F[-#@T#+C&Q+,<N.6]D1\G2A!=%@5
M=BY(:R?(PO/&(9/NO/FM1Y"VA2[S WYI71?&*6C->Z&ZUH.7:ZH[O=29,!OA
M*? NB\3!'2'T=IM[,%>NQV7+K.OY#0+JA@X"WFW7FB<\=O9WZ/Q K(<;>^#L
MM]L-&+9)7Q&"D59>^DJ&%4$ESA19Z][@P]2<'%TB-HU2]68M %Z,ZW-6*U_G
MTP_W!?5CD7"02LO!8(UW2^&Y<,23#($]ML'+OV8$K-D!77'X[M4N+ ,N,93/
M0.@#1:W,>60+'51YB[!VCT?>R)"V%=CZ]]PBBZ"-C+[S)M!B&]R0MF^']H!H
M M)LI08]P9FM\)&7XHM<*2JBQ!*N!7KK"=^%B!MKB<_<K EO[=SR%E2'*VXE
MJMBF :9O:(1#V:4$Q-9()9K"9:L_T;UADLK%V-O5Z!</?H70UDT0TLP=(6X:
M]F95R-AB]QE[[YXV)F*3N;:I>_^V!< %'#,2<X)W$KVEY4\*;?.7]/!MEG^W
M..$:(WA3])TPJ3J07.O:3=9SD_5\@5G/=\/*>JZV)+4C3+>RDE1_+]=V6?T\
M,@3.#F&.=H^I;L'6ML[NW-J4!>RT4>4R$Y=$%"U$"54JE(ZXC=-#<_\S]\B=
M/M _JRG"U#UL*5FQQPC96V!N)85U#[X*9P/AGC S5\R:]74/2X2\&'@Q>N2=
M0,5Z_G:];7J3J.M=R&N9TL$5SUL"JK 4)E7,,\TRN[RHB&)5Z$*<94&SJ&90
MV7#;LE]Y!M^+5H)\.TQ>JY/:T?$)$1=#4(/LG#46J,A)CX=('/7.P@U^SU["
M?>5N3UH<#H-_AF"!W29;38HGIJD\Q(YUW$8X+%_!F9D4[.TL#0P]@+N^=T![
MN"3,=B2Z-3Y:HBW8Z(6BEL_N- F3M53J8Z,+)R-2QQ/R;H=J \\R\]7##*O^
MP]4R5AV"C6\&A/!H1QC1B'4+>;2,&-;\"*$$1F],_2%#YK6JH.7('M]U&K_C
MN\8 =\:YY N=Y+4TZQ+K-F&SMFGCJY$(OZ4_\OU)T_N:NNNP5CL!G#6C#CH9
MR^O'2,?9O3J%E[[(JMRA;25Y\:Q*Z6?1DBH)O2'+2)G[/I+?\XF54BN%UKX=
M9K'45Y/>>6]6\<JK'5^22\9U-FUK"QU[D]!8[GG4UT]OB_ !AL@:^/%+9#"]
M3.683;X7I44-KW\D<XGWU&\[%SO!A8JK7-@]X8U'/V(XH*]P.LV%#%L?LYQT
M@\E5V)\H?;EHI)C4P;_@BF*2,.9EBXJS(LW*ZOS>**!H_->4436&W'6]NQM[
M>_MIRD0=?']KL-*6V/Q!+JQ$G$*]@;= J! !IHCP *R%DMVG^4(1'9TWH8RA
MYTGXN:(Y5,F9I+)MFBAMMDA2!\)4VU"-/\#0$2%L"!LY42^_ZC*S.RAT)&EW
M96'H1=MFOM2\&R84)F[SJ/BH.;,[WI]@35+A?JLGA/EW0F(1FY'.R;$H49<I
M1>N>KF__UN\_4_J/MT/DS[^KJ+BVE#,TBD[U!]N'<!?-S4Y5^@*-\T!*)>)5
MYLP#C%W*H $AO;@W14]X%7'*==3,/*<^+L?;&'PC%A=&Y]&]8^48L8*$P;[9
M^H,N)Z[#+)W=-5FH+4P'/^;'(B0'!JMB$%R-PM]OD'$V!#2#QG5&4VNB=?AT
M>GJII\IJ!C*1PF *B^@:N309&;$L.NG),GJ+TQO7EK[426JJ0]+"F5'I18!-
MY,1T09:[O#4>$LE<P__L:!GF:<KL9VRMPW?1EJALDC=E.%2%+[&V382\%YU;
M\3$C%1;R/#4#XXX73/]I-6M#L^(<09\<H=6P!!VS 9-E5:H% =HD.6I,IC\C
M/K869FFGTRW]I)>7G A6_J1CL8A;K4]/P4*ZJG+-15F_AYNBB;3:AX&OJ>!#
MKM0D0T!7GQ';IR4X!,'W#<?Z!IKRFT%3#EX/"YHRM(+\]0.TN/;5,1R@>_"X
ML+8M>R;>UD6<E3.P$+?U]7MA,$IODCS3#I1[^;D54\=K#_#(Z+[:N7G]ARWN
M#16\H!]%9]@4$9$(S043-PM;'1LAG4;?07P9;>([7EFG>U/ ?3'1YYDV"ZP;
M8#OV0;'^WJ"6-3 Z.B6FT:\3YQFIVR@0,_IZNL1R9/!HYF.%IV0KU#1]0NWH
M-!YA\1%=ANO6KBE-$WUX#!<9^38Z'\<8AJ'G+$1/7JOQTH?2IA"=ESOZ8QRE
MW[FJ!&M#Z*(M,&.W'<4!^K=3;.+KS!3M)5[*UX]QY&.T:2P:"?_CEU75=0BP
MEF)OVXDX^,$!>"IT;,3H>#'2IVZ1C=2M:38K2J)I,0!*E1&-,G[:"H1K7;\N
ML5^PM95LFT'=#DT5FW4>[2H-^7?:R%3&?S39(!VTZ%-AX2Y_%]&79F#Q%KC>
MF;^/@QL13S?WQ@AP@]<OKU\"A?Q;##?>'PCHC!SEBO*TXF13E$ES04ZC9";9
MV?J@\N9-P9M[\.QN#.2E%,%@ES_67UWS;.0@B7YL-A*,\DT:\KFKO304@^/:
M]Z-#PX<"(K6@#!6D:!2J4PUE(!UT@=Z""KLK=3YORZOZU]%:>V?G*#&MF4<3
M]>*2@%3GOPTV\4R4#\!BF"8SWW1S#TFJY=/6@W>5F!&MDO<>2+C#0#*JNI:C
MFY A;A1*[ AWJ+!TEY4A"VU#DDH,6CT)]&24!V.$Y(()X!+E.^88^0^UGS!.
MF8H-20XIDF*WB6-ZU<#R\' T5^#FST_>VS-LN>)#H-.%6.4A<&9\Q#^(C'4@
M@M9W5G:9I4FD9I&,4H-*U,(;J575<DI%_L='R]5#Z@^LZS>R3$EI 'SHU/2C
MCW^()OOPW>&C(<YD!YWQ@3(LHC#WOEY.?FRS<I^BVYV5ZFDX$SZ*$58]4Y,K
MY=2_"F$%3VZ'PJ>K.IF22F6S\(1\8SBZ5/TK3=^K6C/NY/<B3+@)(=!2MIHE
M@:3BD^F2W"V?78GEM^#&%DM:V_B.F\LZ+LWF-F"MEL)A:58YK 4*G(@7G=@4
M3TNI5!['4"O-UQGPZC>UY!U=JAK^7M:6]5OD"L7;V2NDHFF;-9S6\* U7 "F
MH#C_[M6C]>#U-@.DU/?"D Q&7@RAUI_/.AX4B'Q1\08&.!D^)7<I2_"AX#A7
MNL1(7.\.L.!,.[EH^LGT:M IY*X6C$G14QR-ZS1#'8QQY8>*9*+I G2'-I9W
M?=VF$_YE4>H]IC8A^[%9[I%]^@@V2X-1<XS5W=715K[KI*V\')U_#H[/W@?X
MQ^G9\>7IE[-5:7&LU)Q_-TQ.2V2-6;5.80OS,B_$6&G-*)^A+>#SBU2:Q$>U
M-[BHYL2>!&LTA.5*L6H5Y;-$68*;&@!CW??*=\PN:$P&<)HK0QK49[7M/9)5
M]_GQ(QLDR 8)LKY(D-T-$N0!-LR#E!A6=&XW&->82XT\H&0*9M_6X4\Y/J5S
M[CT1FALDCLFK?=Z#ZZL:+&&\P]_^;[G2N!UFM%-H:\ZI]6G;$;\U #+G4U2^
M@YUGU4:2%/!L(Q?-;);=HA.D6?NX\]R6AEX8'1T?)D8CG +X*Y,V"LT(?9PD
M(WG3:D%&T2U\AWC\"C$2!]O!'-IY76B3BB348]JH\3$.FPU^\Q?RF7V-XN\L
M#>@+ZCHT<+7K*#Q%0O7$?J?04-O"MQG 9!C,)'CVE/@Z9$/>#9._Y-(R9F)0
M:I28, UF7G%AO5?3""-X\.=I"@;I#;@U=ZOUN(XMT?J UA9UHX!FH&U#6&HV
M64TQR!FS;U.0"3.\%'O*%;,\XHZIO4NZ(DEO<+1UBK:VY\)DN6*04*V0##=T
M9U))'"KSYI6#!PS%+L%S,P&?>8+L#;,[#LKZ<<,'$-7T+N@9>NKIW3*FFCET
M5<YD<YP-;&0/-)B6@H.2,4SP3.4?^OI/AH6W-I/K&?TV&FO.="C>/A 05C 5
MM'ZV>:(T B..E&>@2^S1W<;Q*Q.+R"(ZFFB(PV=9>H6-0XI?G$&<H[>I>)'D
MY"PKM=DI8"Q*M;BGW9%.JB'?'Q:O*0[?V+Y%C((;GXT67!PYY;M2J+7VEIH9
M=I*0=%:)2R++D:D\Q\!OD@J+!IONL529"M7X)+3XR_I7NIO;>I64S#''K"NP
MH(7\%C^ESFH-UEGG ;T5;5/ 'K.4050@H8RQ.VGP5:JF2:E):&!+)04(Q :/
MMR6K1T6-='S2#*/$)-6S2^4K# "O*T0<Y]6BC$E.6A^X(?PZRZ^B-"F$E9?@
MJQ5"AF5::U0+?A-7%,0GZ)/ Z7F>WF;Y#$Q20;'4:E4)^$(/A*4QCV97T=P\
MS'VXO(Q]_#:\:;R-&80L21DZ7%2PK>><P)#/-;8FTL3#6(4X@:6<P*W(]W.^
M&,,>DDR)H F> RM3,>(KFF57657X][RA_,<8\WLE[X=X[,EP+$0K MHX,>6S
M+"J )CHGH**@@.USSE!S5/R^DFT-[7@\A^ LA.5'<5G[M<WV669C*4P7MY9O
M +M-4H@ >8GQ(5YNV+J)&F.Z9DO5FH9-,J@V(C)*"@H'2O_/DG]7R<0,1PP[
M#B74*';J\ -V=(J%0&U-MVLLYK9DD[$F.C.DGX6N5IDX4Y;@*.LY;>$CY'HR
M",':JYH7Q?4Z,82M26FA[N:GK&,O)P!:5M>P4^+V+)LP.J(ENH9;N^",3J*[
M0I^YTME4MTPRC"QSOW6U3>NC=+%D8III-4?63YDQ5F^N5-G ZG,2$5':R#9>
MF2Z57Q*=0J'T0W^S>NEWR\C,;I)L)KS[7KK^(DICP^Y>)J_&>3)63&X*_XJS
M'->!X4:!CZ36-J$M3N;W1&,&$H&48,8H*?EAR8QK<LW:$'B&*E;F/*]RC 9)
M;57SG ER/%!_F=KV6%=0>2$!XPLL]0[#H '"T0_#I\-S8+4\VH,DW-42K]&V
MM;^_V-S/]OQ=;HTLV24\5O=[C,_DQR$B&_5)]E]O!W_H7>P]GGE-GT[#^7LY
M< \YJ%KT0]?VG%I"F;1Q3Y[DGFSP!1M\P09?\&OP!7L;?,&3F2:&A"[81'8V
MD9V!GOB;R,[#(SLO2%C@W3(FO/6-[+P03 1+";P;'$T M>L+[?LM\9T517&H
M42N)XMP7PI$:?!<$17$=3D@^-K233!\0N7DIE$NP%KK#-C3TG*S%3<M75Z?#
M15+%$IPIHBF-CRE+@[^+..&:@S@ DP5I&:J8S!P%HQPC%@#Y:/%4*;(XH1(#
MRE6+X:'+YFQ5OL>8-5$\K@Y!@U8,U8VM!Y40R(>[HXDM40-L1*D_*.#A :3G
M)/,:[DEH=MGNV!$.T$4)ZS;XB-O$N;I)X+'$[UZB96[&5<IR(_=J9#%&D\AB
M'84"P;GFO8HF5$&Z3IINT'$=I2I[4M;H3<D', V_@$GU5D^J3O/*U=8NKZ^S
MV:0(+1$,V403-4,SF<L=T\+1"C2;&(L'%/KSDVSBB/@X1MLB@[_NUFM^O>TL
MA=ICD<4'3*G>L@##3_0==!N$M,>W'3AF8])S+D&$&LT,D70G;ZWA/;6CV*;D
MR4>XG^'I\5W=22%WJF:L,!]?I] A5W<4+T?=HD)H,O $!HM>"M.U)PMG$E+P
M(?&>;).ZD!WL.#E,"^'7P';?P/&H&V^YNN&HU*\WR50#9 ;W@HT;MUN/@0=6
M5JSRM.B)MFL[02.C$"L':2?)S5/IUCL4T8;MQ]B)V\EUPUQ4O-VY?%@<!KK3
MAO7+89':UX7O%%#2TQ9C,6CZ,6D3AFT*8;?1G2#D"!RU<\HQUKDG#KFPE4@0
M+*I>6\"2<;.!IF2^4).$>P#%(Z5GL",G$Y1=[EC?=6Y5%]0J?<U:$6&@]P)H
M#^\&>CMX[OT ?_XX*^G%2$/COM#)'.0OC5@L[@EX-%'%JB#!!_"34TKMG.;L
MRB$_'0MZNSI(]4-L  41[4T?0$V$5KV5V!\N3#B(O\-T$299'>,+^TS5=SO[
M/5,[F[SM)F^[OGG;_4W>]J7D;2DH9.M938HC58L,#(4Y4Y9)FN(*[)F*"F0Y
MC31/"O"\\VP!'KIV9.*HN&86]91HW_6>RHZZV5DC<(W*PC)0SR/B0J+CKIH1
M7LF<&9JNV_FH*,&],9816SL/@2SW-2J&*YYG R]ONFR*:I&94+N;6&2&?M=C
M'*L95@C5G6=+\9K[>LKFBS+Z$413,&%S<"NS:C;AFN?(QFVB"1;&(RYS$6&$
M.:W1PJI%5=+DZ<DC>=@?RSS<J)DV" =)B=J:\)I7I*%@X ^K)EDRB03.L=*$
M1E?$YKB:%:KR#CH)9=[EN7.MZQ"B&"2%Z5?V<'&CP:3."=95PL;E3,45T[2?
MUKTK8GY&DNF9$I2[\K*HPLYK0G>H/FE)NUP)OK6*6"\C[\(292T=O*XO0+SG
MP58-WNX"G@C1))S+R \N2)'MD&=$KHCG5' _EIS9O<'4L5O\2>&&4%[,M#B4
M/N5-V,G[;QL@5&-UT+;>T@.<'U_?&7:@9YADV1>YTA9X'=GG9=FM_F(3CD+[
M#YK)48S@.8H=P^^7)="VB5LG=;$DN4KF8P2*>:) 6\4VT^KX;*/@-U0Y:7Y6
MY:ML^FJ1Q=]5B5P^J(:$UF2>55?77FLU RRV-,9&SCC!T7$+#H@P2ZJ6.W)X
M>LA>O64 (05R#(.B,Y%<0 J^"33A?_^O@S=_QQ=BJO3"9P4P/<J@!32)<U)3
MZGH?4T+O?C.!AX>.=H)#P$I /<P08>;&2@;$"'!U9CX*4&%[3$6_D4LBR2BT
M<FH0&FS-3SXBZ8[_D91@W<0]#DW3]E6>W!QZ<#6-1'M>'[X5"8.XLQLQ51,5
MW2!JDC"729H0N)>\59@G5]C])E:O)^Q/$'=8!W.RTP==I3EY;(FYF(V-(@^.
M-;EB8S(7LA72.>>=_BI';3-6"7?7M7QM[<ZMI&&*^J>G:YB6FI=D:OC6>+='
MW 0#S^LD9VZ2N3#$]4N?2'KG#94) K<G,8;\77H6[W,?,7A/:^V&2@O/:8!S
M>_>.V[WQ@R\HU?3F'OB@IZ#CRCHSTSU6!K 2G$X[&L.AV>&U,[7)(M1]%H=:
M'^J:BA4#_)E#A/P">(R?/\^Y!G.O$V!(?E#+DM7&9UGE7&EA[!_?!/2LX2SO
MFEE%%UM^"_^1(9)JLZ?$^$,L#DQ-S*8R$5DH-A\8-E5,C3.&LTAX=.Y./>SH
MH&X%FPL\ [!N;#[%MG;E1.^UKTEDZ^GV==V\'BM4X:#3P1C4+8,2;BS<Y1:N
M)^?Z;);M[PC8>-.-:E5UJ2[9O C-6I1Y=A=LD:X&9IP%VS21HC2VZ+9#+0(#
M'TLTT*<X#,53[Y;DHA&26UB)UOK"=M:JTH60+4 1J;K#.<0Y:13K-9%U>+](
M?&N]49Q3E,NK*<2O9S"=2EWPE.(,U"5OUI-M4DAB9RT7\GT9,+#=MZ&1PB%I
M:V<F83]_5VH!W:9(P3K.%G=FG#LG AXI\RQ%&@<.(<T7LZ1+8'$'WLZ6_]S9
M&B+7"IPH1/#CXT5CKO/9J)5-QC_N]1E^&.,DBV$%I/#G&(Z%:A$4=S#%Y\6#
MY-/W,/NZ(5G8@'4V8)V''ETN6.=@ ]9Y*EAG#6HEWG372E#<1@D5+%@-Z2L2
MN@MBN!&5^I64'Q!U3S()QZ[-8&2'^DO<FLH<NLS5N<.R^J2L)"R7<X'9.(MR
M+ JBVD.+?N64JHG5VO)%[5;04]ND!^%>3XARV)QL6U5(6YGK[Q'%V/A=S4:0
MPR5FL;KAW(XD&?0DPF 8BNN-A42+223\Q4<64P'V8&OU]C9IF<-&\VJ2W?*S
M:K^O)9V]V .YS)Y/R,MBDL%SV)T/R-R8(7E$<4W7D^&(+!*PZF!Q,OL7W(LT
MS:B>V%3T"@^X0!TXK)LLV $1SZ 8\OP)]2;PTP,+]\\DSA%*? 8EEQ/. -*X
M(U6(GT=<HB#:/EX\5MNF^(R&J#D='9] HEHV*>DX>^N\JTGE+G336K_%&W$F
M"V?\G\0*NYXAY[=#S#^>*U.R-0T^F+S>\(IAFI+(O":*-5T45FMX/=LOBYJ9
ML=PH/UB2>"8+=U?[1 K;$0XZ2+F([C1DGMGXYUG%,]3)MDA9)IX,[0_1.8*[
M]IR*Y/W::5X,7O=^Z]RURCT+IHD)V\S5%<U5:K_V$%,M2R*!:;T!8E%C%DL2
M2Y1<?U.HS+LA'E4757Z3W$1$&WC.]CR.Y:D5)I95MF+<?QT2TZ*U/.:H-^8)
M%KGZ5S7!+4C,YMR^VJ0J$V68^70((XKCO/+RK.X3\YI,H1-3O_3P*GI+JDD8
M<V1%I:3"299Z2N=N8,[=UL=QS'$=MP>N=U_#EN_O'*QQVW?WV8!8S\8?K'/C
M#]>V\0<[NVO<]O6=\0<[ZSOAC]:VY6_7MN6[K]>WZ7MK/-?7^%Q:XU-I]VB=
MI\R;]6WZ&F^0[W;6]URRT;_U;/Q:3YMW:]OXO=?K'$;<V]W!YO="]NP]!M?S
MSO"X.&' W5\0!6R/MNV]WND* IZ/+KY\^N?IV<?@_>F'#Z/ST=G)Z*)?H/1M
M_T!I3T#3JN0 WG(?=58PK4H.X"TE]8PZB\"?_A/U:8(O2'.#UUFZ[%4)!+Q=
MPI&B(Y(HE8,P_R0-KK)L@BR4B!3.@@A:CF+H#B'E)$%U-)7&4A:(&-2*]#(8
ML/"?GX\_]F7O:4[1-4PXP]SLK'!:911_5,31S&@I7*@4@]B?HS2Z,FPD3K![
MM:'\8Y(ZTA.+RB9X6C& *HY2DQBD66B(,7"VV5!_48V%*5,7,?'+"<%4X)38
MGEPG:AJ,?JBXHG\3B!<7!Y=LP$13BC/TN5GC0OEB$P2YFF,5A*64UHN$$E[Z
M%5J3HEL:^Q79NF3#HDJL&,C=7!<HV'8*8@W0,L_53193[1AW *W<?)R4N:T(
M0""9?9. V,# ,%!YSGD>K\6&BF:]J-.7640[^[VMBE8PS%&7Y&NOPY,3EZO;
MH :IDGQLI^CJ=Q],R^7(N%'<A7H=$.(XGD7)G&H2"<I<T<;)2&2GK*I%X=@P
M_4BY4VCW*5\192RP/G?);ED61H0^<$D7+5D$8&I%,/4C*4K<,</@!J;?!"$8
M=:Z .F)YF^OW:2_%Y<^;)7Z$A(JXZY@]5@.>57!>S6QZ]%.63I"Y#Y7-\+-3
M!.SSXV O<48U%!@Y_SKBNM$L7^#:Y%>G)M"6#U93MN[H:+/+D+F55O,Q\@],
MS<!F>6'G0 EOIX*M_6TVS@H5\<1A<LW%+,)1=7Y,Y57ZQSP$83!*KV8P='P+
M^.NJ0OPY9Y:KPO+?R$UF6'(7PY$"$\AI"MXE*:Z;P"_F78 YAR4"H2$OX]*T
M0JGO&MP>(U,XE8'19$QP1L"J@=>A204?_*M*8Q%[G.')*[AYALKKS^ 82F"P
MHCR Z51Q]2^+>>M"XUA/.A970SOF7Q6LS4D2\PE]Z4PA\X)7N+!3754Y(5F1
MDE+[+>SZ5+2(F-FI[E[ZS5\13F(-)A!U<FF<0+#BZTP03H*YQ9+%6<+4!_@1
M@8P+E[GN'F'AGN[MII)M4\GVNU6R'?Z>E6Q[C](:?_=F9=8GFDIT_C-[!-$"
MQY&4@?O*JU.]]YKZ$3X>O!W^)\8%Q<8?2BBL(URXVQDN_'QZ<3+Z].GX;/3E
MVU/"A!UJ.P/JF@Y'9W=P44*!_HOBZW6R&%38!>R]:_(E&OP+24%&7#HA]X ,
M4\=[@6OX8_!*X#0 V]%4>V& D5X3EBV%0K$,#DVYL2IOE1^Z"-D0PPI0Y1B7
MM"]<.82Y'@F&RR/C_DB XF@QXK;+#@6;C!B!9>0X1D+P_Z70''B=*3_!N3_V
M29T*X5K!EC5+(EVR1ZQ6<9739RS(W&2YBHA@#F-)TXAH,9KO\EBFZ76D3X&E
M.<@@Z7&:9N"9:#UXL/._L;3X631?_>KT9B)+H-(ZRUDY?:9(?'Q1P1*, Z."
M0-5^_%GDO%Z#C:^VY+5K0[I;A'C6W.A:A5&FMB?)NQ-<O(@2P+<:)I#ZO:X-
ME13F P53\FBB8'U^+QI[1T,8H=!>:^\!D\(>ZO)4,3=0"VN+-U;8,B84NS-"
M"CQ^Z@<_N#:..\*HSO3D2<FJ&G:B\!Y;>/6D8)2%@<<4@R$ +$J>9;@/8\P\
MSI-%*U&Q;B5UF4-P0SR2T&&:0>B3BB::9M>M12+>(Y<"MSE5ET[1?D'?O;:8
M;\_@[BKWU6'&=@M,H?364V@S1-=:]Q''I=L8]7?V\)%;K]3QZTLP0R:1O]2A
M$R297;1@M+(NUKA'-#R<%.(J&+1K[E% U6$N^#2?D+%WY]&$678P)A.@R^'&
M5U&:%,;%PTWE)B)1'U1?33@^-(?339<#DHXJU9_'T8(MK-ZKN"?;W-'PS:7]
M;H/I@E1U"H=498$1?TI\MDO7IL[6;>L_>1:$8,?&R#' MG/,86MG:M1XWC#<
M/T.&"F3NAP_AV3@1ZC1P$N!MO5JR+;,9'RYN,2<&C_F,(++..E-Z)'3I7)A:
MYZK\9Q3'T)=AX&1/X#U'N!+P'US,YJ\W9X4QS?OC%U4J1,M&QQ5O*I%B[ZX.
MC1X=L0Y38V0V3LX&R- DJ*TY475R/<STM++W63)-& ,>U)Q"W(DEZ,-KX.\,
M\TG2F;X:$P]_VXS:@7%U6$[0$A)) 6'JP]'EC\VXRH1PI)CM_(UB-C4DO=W"
M3P*]4.F.,FR4\K/<=$]TBUDFAVBXI7/XO:4 FO+W8Z39UKF!?CU,EAW=@<SI
M);M3RW8T@%UF=T_O,IWF0ULR*$?.2@[$K1/_(KQM-]@0-EJV_&E5TFRG=Y:(
MY1]P1J7E=54$?R093C1<Q E<A'WB83IV:M?R'",&1[[U8D)Y3_'#,)%;Z#-U
M,8,W@TV7=@523=.W7L-.Y=Z@/CUMD"'Y?42*Y3XR)D'WAJD D"J5NLXA$_,O
M-E V_*.M^]%%J8HB]+%MH0X^BURA7N<NVH5SUV:KOL+D)9Z*>A-?*]:!>U;
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M??TVDJKED$?Z;.5OT0NLYCW(7U!+ P04    "  L@W18\T&.I>X#  "E#0
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M+08^H]CJ=C8(I3M\=U-@NM\X"JP?SDEC*X%HN:3V<2C5;+X->:G7[V(3WX@
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M/+!O,/\&4$L! A0#%     @ +(-T6$^OYQ16/ 0 :4 A !$
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M<RTR,#(S,3(S,5]G,2YJ<&=02P$"% ,4    "  L@W18Y-AH0)1$ 0 $NP$
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M,#(S,3(S,5]G,BYJ<&=02P$"% ,4    "  L@W18W]FF^".F P  4P4 %
M            @ %4M@D 8G)N<RTR,#(S,3(S,5]G,RYJ<&=02P$"% ,4
M"  L@W18O88W4?57 0"?N $ %               @ &I7 T 8G)N<RTR,#(S
M,3(S,5]G-"YJ<&=02P$"% ,4    "  L@W18UB&4SGEH 0 F\P$ %
M        @ '0M X 8G)N<RTR,#(S,3(S,5]G-2YJ<&=02P$"% ,4    "  L
M@W18+/OWA.=K 0#8F $ %               @ %['1  8G)N<RTR,#(S,3(S
M,5]G-BYJ<&=02P$"% ,4    "  L@W18\/&O\'[L!0#GH < %
M    @ &4B1$ 8G)N<RTR,#(S,3(S,5]G-RYJ<&=02P$"% ,4    "  L@W18
M9.37[5&D  "_I   %               @ %$=A< 8G)N<RTR,#(S,3(S,5]G
M."YG:6902P$"% ,4    "  L@W18@/_VU% @ 0!;( $ %
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M."YH=&U02P$"% ,4    "  L@W18*0_YIQ8#  "*%   %P
M@ 'OR!L 8G)N<RTR,#(S,3(S,7AE>#(Q,2YH=&U02P$"% ,4    "  L@W18
M\T&.I>X#  "E#0  %P              @ $ZS!L 8G)N<RTR,#(S,3(S,7AE
M>#(S,2YH=&U02P$"% ,4    "  L@W18*E^;J3$(  !9+   %P
M    @ %=T!L 8G)N<RTR,#(S,3(S,7AE>#,Q,2YH=&U02P$"% ,4    "  L
M@W18< J71#P(  !$+0  %P              @ '#V!L 8G)N<RTR,#(S,3(S
M,7AE>#,Q,BYH=&U02P$"% ,4    "  L@W18R")V6?4$  #('   %P
M        @ $TX1L 8G)N<RTR,#(S,3(S,7AE>#,R,2YH=&U02P4&     !@
,& !$!@  7N8;

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>brns-20231231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:brns="http://www.barinthusbio.com/20231231"
  xmlns:country="http://xbrl.sec.gov/country/2023"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="brns-20231231.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">brns:AmericanDepositarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
        </entity>
        <period>
            <instant>2024-03-14</instant>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">brns:DeferredShares.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">brns:DeferredShares.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">brns:DeferredBSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">brns:DeferredBSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">brns:DeferredCSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">brns:DeferredCSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">brns:ResearchGrantsAndContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">brns:ResearchGrantsAndContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">brns:DeferredShares.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">brns:DeferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">brns:DeferredBSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">brns:DeferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">brns:DeferredCSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">brns:DeferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">brns:DeferredBSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">brns:DeferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">brns:DeferredCSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">brns:DeferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">brns:DeferredShares.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">brns:DeferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">brns:DeferredBSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">brns:DeferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">brns:DeferredCSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">brns:DeferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">brns:DeferredShares.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">brns:DeferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">brns:DeferredBSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">brns:DeferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">brns:DeferredCSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">brns:DeferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">brns:SubsidiariesVOLTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">brns:VOLTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">brns:VOLTMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">brns:SubsidiariesVOLTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">brns:SubsidiariesVOLTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">brns:OxfordUniversityInnovationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">brns:OxfordUniversityInnovationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">brns:OxfordUniversityInnovationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">brns:OxfordUniversityInnovationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">brns:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">brns:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">brns:OuiLicenseAgreementAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-28</startDate>
            <endDate>2022-03-28</endDate>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">brns:AgreementWithOxfordUniversityInnovationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">brns:AgreementWithOxfordUniversityInnovationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">brns:AgreementWithOxfordUniversityInnovationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">brns:AgreementWithOxfordUniversityInnovationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">brns:AgreementWithScancellToGrantResearchAndDevelopmentLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">brns:AgreementWithScancellToGrantResearchAndDevelopmentLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">brns:AgreementWithScancellToGrantResearchAndDevelopmentLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">brns:AgreementWithScancellToGrantResearchAndDevelopmentLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">brns:CoalitionForEpidemicPreparednessInnovationsFundingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-20</instant>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">brns:CoalitionForEpidemicPreparednessInnovationsFundingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-20</startDate>
            <endDate>2023-12-20</endDate>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">brns:CoalitionForEpidemicPreparednessInnovationsFundingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-04</startDate>
            <endDate>2021-05-04</endDate>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-04</instant>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-21</startDate>
            <endDate>2021-04-21</endDate>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
        </entity>
        <period>
            <instant>2023-11-06</instant>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">brns:DeferredBSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-29</instant>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">brns:DeferredCSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-29</instant>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">brns:AvideaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">brns:ContingentConsiderationLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">brns:ContingentConsiderationLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">brns:ContingentConsiderationLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">brns:ContingentConsiderationLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">brns:ContingentConsiderationLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">brns:RestrictedShareUnitsStockOptionsShareAppreciationRightsAndRestrictedSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">brns:BarinthusBiotherapeuticsPlcShareAwardPlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-08</startDate>
            <endDate>2021-04-08</endDate>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">brns:RestrictedShareUnitsStockOptionsShareAppreciationRightsAndRestrictedSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">brns:BarinthusBiotherapeuticsPlcShareAwardPlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">brns:RestrictedShareUnitsStockOptionsShareAppreciationRightsAndRestrictedSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">brns:BarinthusBiotherapeuticsPlcShareAwardPlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">brns:RestrictedShareUnitsStockOptionsShareAppreciationRightsAndRestrictedSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">brns:BarinthusBiotherapeuticsPlcShareAwardPlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">brns:EnterpriseManagementIncentiveShareOptionSchemeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">brns:EnterpriseManagementIncentiveShareOptionSchemeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">brns:EnterpriseManagementIncentiveShareOptionSchemeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">brns:EnterpriseManagementIncentiveShareOptionSchemeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">brns:InLicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">brns:InLicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">brns:OxfordshireMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-03</startDate>
            <endDate>2021-09-03</endDate>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">brns:OxfordshireMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-03</instant>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-14</startDate>
            <endDate>2022-06-14</endDate>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-14</instant>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">brns:ShareholderTheUniversityOfOxfordMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">brns:ExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">brns:ShareholderTheUniversityOfOxfordMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">brns:ExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">brns:ShareholderTheUniversityOfOxfordMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">brns:ShareholderTheUniversityOfOxfordMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">brns:OxfordUniversityInnovationLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">brns:ExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">brns:OxfordUniversityInnovationLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">brns:ExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">brns:OxfordUniversityInnovationLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">brns:OxfordUniversityInnovationLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">brns:OxfordUniversityInnovationLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">brns:OxfordUniversityInnovationLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">brns:BarinthusBiotherapeuticsPlcShareAwardPlan2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-01</endDate>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="gbpPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:GBP</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>brns:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="vote">
        <measure>brns:vote</measure>
    </unit>
    <unit id="gbp">
        <measure>iso4217:GBP</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-34">0001828185</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-35">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-36">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag contextRef="c-1" id="f-37">false</dei:AmendmentFlag>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-38">00-0000000</dei:EntityTaxIdentificationNumber>
    <us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList contextRef="c-23" id="f-192">http://fasb.org/us-gaap/2023#LicenseMember</us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList>
    <us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList contextRef="c-24" id="f-193">http://fasb.org/us-gaap/2023#LicenseMember</us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList>
    <dei:DocumentType contextRef="c-1" id="f-1">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="c-1" id="f-2">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-4">2023-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-3">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-5">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-6">001-40367</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-7">BARINTHUS BIOTHERAPEUTICS PLC</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-8">X0</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-9">Unit 6-10, Zeus Building</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c-1" id="f-10">Rutherford Avenue</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-11">Harwell,Didcot</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-12">OX11 0DF</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry contextRef="c-1" id="f-13">GB</dei:EntityAddressCountry>
    <dei:CityAreaCode contextRef="c-1" id="f-14">+44 (0)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-15">1865 818 808</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-2" id="f-16">American Depositary Shares</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-2" id="f-17">BRNS</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-2" id="f-18">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c-3" id="f-19">Ordinary shares, nominal value &#xa3;0.000025 per share</dei:Security12bTitle>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c-1" id="f-20">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c-1" id="f-21">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-22">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-23">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-24">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-25">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-26">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="c-1" id="f-27">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag contextRef="c-1" id="f-28">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="c-1" id="f-29">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="c-1" id="f-30">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="c-4" decimals="-5" id="f-31" unitRef="usd">79400000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-5" decimals="INF" id="f-32" unitRef="shares">38921212</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="c-1" id="f-33">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%"&gt;Portions of the registrant&#x2019;s definitive proxy statement to be filed with the Securities and Exchange Commission relative to the registrant&#x2019;s 2024 Annual Meeting of Shareholders are incorporated by reference into Items 10, 11, 12, 13 and 14 of Part III of this Annual Report on Form 10-K.&lt;/span&gt;&lt;/div&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId contextRef="c-1" id="f-39">876</dei:AuditorFirmId>
    <dei:AuditorName contextRef="c-1" id="f-40">PricewaterhouseCoopers LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="c-1" id="f-41">United Kingdom</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-6" decimals="-3" id="f-42" unitRef="usd">142090000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-7" decimals="-3" id="f-43" unitRef="usd">194385000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-8" decimals="-3" id="f-44" unitRef="usd">0</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-9" decimals="-3" id="f-45" unitRef="usd">323000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-10" decimals="-3" id="f-46" unitRef="usd">0</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-11" decimals="-3" id="f-47" unitRef="usd">5524000</us-gaap:AccountsReceivableNetCurrent>
    <brns:ResearchAndDevelopmentIncentivesReceivable contextRef="c-6" decimals="-3" id="f-48" unitRef="usd">4908000</brns:ResearchAndDevelopmentIncentivesReceivable>
    <brns:ResearchAndDevelopmentIncentivesReceivable contextRef="c-7" decimals="-3" id="f-49" unitRef="usd">4541000</brns:ResearchAndDevelopmentIncentivesReceivable>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-6" decimals="-3" id="f-50" unitRef="usd">9907000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-7" decimals="-3" id="f-51" unitRef="usd">8268000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-6" decimals="-3" id="f-52" unitRef="usd">156905000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-7" decimals="-3" id="f-53" unitRef="usd">213041000</us-gaap:AssetsCurrent>
    <us-gaap:Goodwill contextRef="c-6" decimals="-3" id="f-54" unitRef="usd">12209000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-7" decimals="-3" id="f-55" unitRef="usd">12209000</us-gaap:Goodwill>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-6" decimals="-3" id="f-56" unitRef="usd">11821000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-7" decimals="-3" id="f-57" unitRef="usd">7957000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-6" decimals="-3" id="f-58" unitRef="usd">25108000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-7" decimals="-3" id="f-59" unitRef="usd">28269000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-6" decimals="-3" id="f-60" unitRef="usd">7581000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-7" decimals="-3" id="f-61" unitRef="usd">7753000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssets contextRef="c-6" decimals="-3" id="f-62" unitRef="usd">882000</us-gaap:OtherAssets>
    <us-gaap:OtherAssets contextRef="c-7" decimals="-3" id="f-63" unitRef="usd">976000</us-gaap:OtherAssets>
    <us-gaap:Assets contextRef="c-6" decimals="-3" id="f-64" unitRef="usd">214506000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-7" decimals="-3" id="f-65" unitRef="usd">270205000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c-6" decimals="-3" id="f-66" unitRef="usd">1601000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-7" decimals="-3" id="f-67" unitRef="usd">3748000</us-gaap:AccountsPayableCurrent>
    <brns:AccruedLiabilitiesAndOtherLiabilitiesCurrent contextRef="c-6" decimals="-3" id="f-68" unitRef="usd">9212000</brns:AccruedLiabilitiesAndOtherLiabilitiesCurrent>
    <brns:AccruedLiabilitiesAndOtherLiabilitiesCurrent contextRef="c-7" decimals="-3" id="f-69" unitRef="usd">8061000</brns:AccruedLiabilitiesAndOtherLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-6" decimals="-3" id="f-70" unitRef="usd">1785000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-7" decimals="-3" id="f-71" unitRef="usd">433000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-6" decimals="-3" id="f-72" unitRef="usd">12598000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-7" decimals="-3" id="f-73" unitRef="usd">12242000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-6" decimals="-3" id="f-74" unitRef="usd">11191000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-7" decimals="-3" id="f-75" unitRef="usd">8340000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="c-6" decimals="-3" id="f-76" unitRef="usd">1823000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="c-7" decimals="-3" id="f-77" unitRef="usd">1711000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-6" decimals="-3" id="f-78" unitRef="usd">1325000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-7" decimals="-3" id="f-79" unitRef="usd">965000</us-gaap:OtherLiabilitiesNoncurrent>
    <brns:DeferredTaxLiabilityNet contextRef="c-6" decimals="-3" id="f-80" unitRef="usd">574000</brns:DeferredTaxLiabilityNet>
    <brns:DeferredTaxLiabilityNet contextRef="c-7" decimals="-3" id="f-81" unitRef="usd">3746000</brns:DeferredTaxLiabilityNet>
    <us-gaap:Liabilities contextRef="c-6" decimals="-3" id="f-82" unitRef="usd">27511000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-7" decimals="-3" id="f-83" unitRef="usd">27004000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-6" id="f-84" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-7" id="f-85" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-7"
      decimals="INF"
      id="f-86"
      unitRef="gbpPerShare">0.000025</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-6"
      decimals="INF"
      id="f-87"
      unitRef="gbpPerShare">0.000025</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued contextRef="c-6" decimals="INF" id="f-88" unitRef="shares">38643540</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-6" decimals="INF" id="f-89" unitRef="shares">38643540</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-6" decimals="INF" id="f-90" unitRef="shares">38643540</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-7" decimals="INF" id="f-91" unitRef="shares">37683531</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c-7" decimals="INF" id="f-92" unitRef="shares">37683531</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-7" decimals="INF" id="f-93" unitRef="shares">37683531</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c-6" decimals="-3" id="f-94" unitRef="usd">1000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-7" decimals="-3" id="f-95" unitRef="usd">1000</us-gaap:CommonStockValue>
    <brns:DeferredStockParOrStatedValuePerShare
      contextRef="c-12"
      decimals="INF"
      id="f-96"
      unitRef="gbpPerShare">1</brns:DeferredStockParOrStatedValuePerShare>
    <brns:DeferredStockParOrStatedValuePerShare
      contextRef="c-13"
      decimals="INF"
      id="f-97"
      unitRef="gbpPerShare">1</brns:DeferredStockParOrStatedValuePerShare>
    <brns:DeferredStockSharesAuthorized contextRef="c-13" decimals="INF" id="f-98" unitRef="shares">63443</brns:DeferredStockSharesAuthorized>
    <brns:DeferredStockSharesOutstanding contextRef="c-13" decimals="INF" id="f-99" unitRef="shares">63443</brns:DeferredStockSharesOutstanding>
    <brns:DeferredStockSharesIssued
      contextRef="c-13"
      decimals="INF"
      id="f-100"
      unitRef="shares">63443</brns:DeferredStockSharesIssued>
    <brns:DeferredStockSharesOutstanding
      contextRef="c-12"
      decimals="INF"
      id="f-101"
      unitRef="shares">63443</brns:DeferredStockSharesOutstanding>
    <brns:DeferredStockSharesAuthorized
      contextRef="c-12"
      decimals="INF"
      id="f-102"
      unitRef="shares">63443</brns:DeferredStockSharesAuthorized>
    <brns:DeferredStockSharesIssued
      contextRef="c-12"
      decimals="INF"
      id="f-103"
      unitRef="shares">63443</brns:DeferredStockSharesIssued>
    <brns:DeferredStockValueIssued contextRef="c-13" decimals="-3" id="f-104" unitRef="usd">86000</brns:DeferredStockValueIssued>
    <brns:DeferredStockValueIssued contextRef="c-12" decimals="-3" id="f-105" unitRef="usd">86000</brns:DeferredStockValueIssued>
    <brns:DeferredStockParOrStatedValuePerShare
      contextRef="c-14"
      decimals="INF"
      id="f-106"
      unitRef="gbpPerShare">0.01</brns:DeferredStockParOrStatedValuePerShare>
    <brns:DeferredStockParOrStatedValuePerShare
      contextRef="c-15"
      decimals="INF"
      id="f-107"
      unitRef="gbpPerShare">0.01</brns:DeferredStockParOrStatedValuePerShare>
    <brns:DeferredStockSharesOutstanding
      contextRef="c-15"
      decimals="INF"
      id="f-108"
      unitRef="shares">0</brns:DeferredStockSharesOutstanding>
    <brns:DeferredStockSharesAuthorized
      contextRef="c-15"
      decimals="INF"
      id="f-109"
      unitRef="shares">0</brns:DeferredStockSharesAuthorized>
    <brns:DeferredStockSharesIssued
      contextRef="c-15"
      decimals="INF"
      id="f-110"
      unitRef="shares">0</brns:DeferredStockSharesIssued>
    <brns:DeferredStockSharesIssued
      contextRef="c-14"
      decimals="INF"
      id="f-111"
      unitRef="shares">570987</brns:DeferredStockSharesIssued>
    <brns:DeferredStockSharesAuthorized
      contextRef="c-14"
      decimals="INF"
      id="f-112"
      unitRef="shares">570987</brns:DeferredStockSharesAuthorized>
    <brns:DeferredStockSharesOutstanding
      contextRef="c-14"
      decimals="INF"
      id="f-113"
      unitRef="shares">570987</brns:DeferredStockSharesOutstanding>
    <brns:DeferredStockValueIssued contextRef="c-15" decimals="-3" id="f-114" unitRef="usd">0</brns:DeferredStockValueIssued>
    <brns:DeferredStockValueIssued contextRef="c-14" decimals="-3" id="f-115" unitRef="usd">8000</brns:DeferredStockValueIssued>
    <brns:DeferredStockParOrStatedValuePerShare
      contextRef="c-16"
      decimals="INF"
      id="f-116"
      unitRef="gbpPerShare">0.000007</brns:DeferredStockParOrStatedValuePerShare>
    <brns:DeferredStockParOrStatedValuePerShare
      contextRef="c-17"
      decimals="INF"
      id="f-117"
      unitRef="gbpPerShare">0.000007</brns:DeferredStockParOrStatedValuePerShare>
    <brns:DeferredStockSharesAuthorized
      contextRef="c-17"
      decimals="INF"
      id="f-118"
      unitRef="shares">0</brns:DeferredStockSharesAuthorized>
    <brns:DeferredStockSharesIssued
      contextRef="c-17"
      decimals="INF"
      id="f-119"
      unitRef="shares">0</brns:DeferredStockSharesIssued>
    <brns:DeferredStockSharesOutstanding
      contextRef="c-17"
      decimals="INF"
      id="f-120"
      unitRef="shares">0</brns:DeferredStockSharesOutstanding>
    <brns:DeferredStockSharesIssued
      contextRef="c-16"
      decimals="INF"
      id="f-121"
      unitRef="shares">27828231</brns:DeferredStockSharesIssued>
    <brns:DeferredStockSharesOutstanding
      contextRef="c-16"
      decimals="INF"
      id="f-122"
      unitRef="shares">27828231</brns:DeferredStockSharesOutstanding>
    <brns:DeferredStockSharesAuthorized
      contextRef="c-16"
      decimals="INF"
      id="f-123"
      unitRef="shares">27828231</brns:DeferredStockSharesAuthorized>
    <brns:DeferredStockValueIssued contextRef="c-17" decimals="-3" id="f-124" unitRef="usd">0</brns:DeferredStockValueIssued>
    <brns:DeferredStockValueIssued contextRef="c-16" decimals="-3" id="f-125" unitRef="usd">0</brns:DeferredStockValueIssued>
    <us-gaap:AdditionalPaidInCapital contextRef="c-6" decimals="-3" id="f-126" unitRef="usd">386602000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c-7" decimals="-3" id="f-127" unitRef="usd">379504000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-6" decimals="-3" id="f-128" unitRef="usd">-176590000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-7" decimals="-3" id="f-129" unitRef="usd">-103243000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax contextRef="c-6" decimals="-3" id="f-130" unitRef="usd">-23315000</us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax contextRef="c-7" decimals="-3" id="f-131" unitRef="usd">-33460000</us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax>
    <us-gaap:StockholdersEquity contextRef="c-6" decimals="-3" id="f-132" unitRef="usd">186784000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-7" decimals="-3" id="f-133" unitRef="usd">242896000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest contextRef="c-6" decimals="-3" id="f-134" unitRef="usd">211000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest contextRef="c-7" decimals="-3" id="f-135" unitRef="usd">305000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-6" decimals="-3" id="f-136" unitRef="usd">186995000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-7" decimals="-3" id="f-137" unitRef="usd">243201000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-6" decimals="-3" id="f-138" unitRef="usd">214506000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-7" decimals="-3" id="f-139" unitRef="usd">270205000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-18" decimals="-3" id="f-140" unitRef="usd">802000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-19" decimals="-3" id="f-141" unitRef="usd">44694000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-20" decimals="-3" id="f-142" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-21" decimals="-3" id="f-143" unitRef="usd">9000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-3" id="f-144" unitRef="usd">802000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-22" decimals="-3" id="f-145" unitRef="usd">44703000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-3" id="f-146" unitRef="usd">44874000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-22" decimals="-3" id="f-147" unitRef="usd">42350000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-148" unitRef="usd">39842000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-22" decimals="-3" id="f-149" unitRef="usd">6394000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="c-1" decimals="-3" id="f-150" unitRef="usd">84716000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-22" decimals="-3" id="f-151" unitRef="usd">48744000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-152" unitRef="usd">-83914000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-22" decimals="-3" id="f-153" unitRef="usd">-4041000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest contextRef="c-1" decimals="-3" id="f-154" unitRef="usd">2877000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c-22" decimals="-3" id="f-155" unitRef="usd">3103000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense contextRef="c-1" decimals="-3" id="f-156" unitRef="usd">28000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-22" decimals="-3" id="f-157" unitRef="usd">19000</us-gaap:InterestExpense>
    <brns:ResearchAndDevelopmentIncentiveIncomeExpense contextRef="c-1" decimals="-3" id="f-158" unitRef="usd">3461000</brns:ResearchAndDevelopmentIncentiveIncomeExpense>
    <brns:ResearchAndDevelopmentIncentiveIncomeExpense contextRef="c-22" decimals="-3" id="f-159" unitRef="usd">1240000</brns:ResearchAndDevelopmentIncentiveIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-160" unitRef="usd">1082000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-22" decimals="-3" id="f-161" unitRef="usd">567000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-162" unitRef="usd">7392000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-22" decimals="-3" id="f-163" unitRef="usd">4891000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-164" unitRef="usd">-76522000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-22" decimals="-3" id="f-165" unitRef="usd">850000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-166" unitRef="usd">-3075000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-22" decimals="-3" id="f-167" unitRef="usd">-4471000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-3" id="f-168" unitRef="usd">-73447000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-22" decimals="-3" id="f-169" unitRef="usd">5321000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-170" unitRef="usd">-100000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-22" decimals="-3" id="f-171" unitRef="usd">-21000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-172" unitRef="usd">-73347000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-22" decimals="-3" id="f-173" unitRef="usd">5342000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="0" id="f-174" unitRef="shares">38386491</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-22" decimals="0" id="f-175" unitRef="shares">37248126</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="0" id="f-176" unitRef="shares">38386491</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-22" decimals="0" id="f-177" unitRef="shares">38169307</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-178"
      unitRef="usdPerShare">-1.91</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-22"
      decimals="2"
      id="f-179"
      unitRef="usdPerShare">0.14</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-180"
      unitRef="usdPerShare">-1.91</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-22"
      decimals="2"
      id="f-181"
      unitRef="usdPerShare">0.14</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-3" id="f-182" unitRef="usd">-73447000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-22" decimals="-3" id="f-183" unitRef="usd">5321000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-1" decimals="-3" id="f-184" unitRef="usd">10151000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-22" decimals="-3" id="f-185" unitRef="usd">-25083000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-186" unitRef="usd">-63296000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c-22" decimals="-3" id="f-187" unitRef="usd">-19762000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-188" unitRef="usd">-94000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest contextRef="c-22" decimals="-3" id="f-189" unitRef="usd">-132000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-1" decimals="-3" id="f-190" unitRef="usd">-63202000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-22" decimals="-3" id="f-191" unitRef="usd">-19630000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-23" decimals="-5" id="f-194" unitRef="usd">800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-24" decimals="-5" id="f-195" unitRef="usd">43700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:SharesIssued
      contextRef="c-25"
      decimals="INF"
      id="f-196"
      unitRef="shares">37683531</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-25" decimals="-3" id="f-197" unitRef="usd">1000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="c-26"
      decimals="INF"
      id="f-198"
      unitRef="shares">63443</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-26" decimals="-3" id="f-199" unitRef="usd">86000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="c-27"
      decimals="INF"
      id="f-200"
      unitRef="shares">570987</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-27" decimals="-3" id="f-201" unitRef="usd">8000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="c-28"
      decimals="INF"
      id="f-202"
      unitRef="shares">27828231</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-28" decimals="-3" id="f-203" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-29" decimals="-3" id="f-204" unitRef="usd">379504000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-30" decimals="-3" id="f-205" unitRef="usd">-103243000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-31" decimals="-3" id="f-206" unitRef="usd">-33460000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-32" decimals="-3" id="f-207" unitRef="usd">242896000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-33" decimals="-3" id="f-208" unitRef="usd">305000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-7" decimals="-3" id="f-209" unitRef="usd">243201000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-34" decimals="-3" id="f-210" unitRef="usd">5055000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-35" decimals="-3" id="f-211" unitRef="usd">5055000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-1" decimals="-3" id="f-212" unitRef="usd">5055000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="c-36"
      decimals="INF"
      id="f-213"
      unitRef="shares">960009</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c-36" decimals="-3" id="f-214" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c-34" decimals="-3" id="f-215" unitRef="usd">2035000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c-35" decimals="-3" id="f-216" unitRef="usd">2035000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c-1" decimals="-3" id="f-217" unitRef="usd">2035000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-37" decimals="-3" id="f-218" unitRef="usd">10145000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-35" decimals="-3" id="f-219" unitRef="usd">10145000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-38" decimals="-3" id="f-220" unitRef="usd">6000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-1" decimals="-3" id="f-221" unitRef="usd">10151000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <brns:SharesCancelledDuringPeriodSharesDeferredShares
      contextRef="c-39"
      decimals="INF"
      id="f-222"
      unitRef="shares">570987</brns:SharesCancelledDuringPeriodSharesDeferredShares>
    <brns:SharesCancelledDuringPeriodValueDeferredShares contextRef="c-39" decimals="-3" id="f-223" unitRef="usd">8000</brns:SharesCancelledDuringPeriodValueDeferredShares>
    <brns:SharesCancelledDuringPeriodSharesDeferredShares
      contextRef="c-40"
      decimals="INF"
      id="f-224"
      unitRef="shares">27828231</brns:SharesCancelledDuringPeriodSharesDeferredShares>
    <brns:SharesCancelledDuringPeriodValueDeferredShares contextRef="c-34" decimals="-3" id="f-225" unitRef="usd">-8000</brns:SharesCancelledDuringPeriodValueDeferredShares>
    <brns:SharesCancelledDuringPeriodValueDeferredShares contextRef="c-35" decimals="-3" id="f-226" unitRef="usd">0</brns:SharesCancelledDuringPeriodValueDeferredShares>
    <brns:SharesCancelledDuringPeriodValueDeferredShares contextRef="c-1" decimals="-3" id="f-227" unitRef="usd">0</brns:SharesCancelledDuringPeriodValueDeferredShares>
    <us-gaap:ProfitLoss contextRef="c-41" decimals="-3" id="f-228" unitRef="usd">-73347000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-35" decimals="-3" id="f-229" unitRef="usd">-73347000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-38" decimals="-3" id="f-230" unitRef="usd">-100000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-3" id="f-231" unitRef="usd">-73447000</us-gaap:ProfitLoss>
    <us-gaap:SharesIssued
      contextRef="c-42"
      decimals="INF"
      id="f-232"
      unitRef="shares">38643540</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-42" decimals="-3" id="f-233" unitRef="usd">1000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="c-43"
      decimals="INF"
      id="f-234"
      unitRef="shares">63443</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-43" decimals="-3" id="f-235" unitRef="usd">86000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="c-44"
      decimals="INF"
      id="f-236"
      unitRef="shares">0</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-44" decimals="-3" id="f-237" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="c-45"
      decimals="INF"
      id="f-238"
      unitRef="shares">0</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-45" decimals="-3" id="f-239" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-46" decimals="-3" id="f-240" unitRef="usd">386602000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-47" decimals="-3" id="f-241" unitRef="usd">-176590000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-48" decimals="-3" id="f-242" unitRef="usd">-23315000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-49" decimals="-3" id="f-243" unitRef="usd">186784000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-50" decimals="-3" id="f-244" unitRef="usd">211000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-6" decimals="-3" id="f-245" unitRef="usd">186995000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="c-51"
      decimals="INF"
      id="f-246"
      unitRef="shares">37188730</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-51" decimals="-3" id="f-247" unitRef="usd">1000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="c-52"
      decimals="INF"
      id="f-248"
      unitRef="shares">63443</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-52" decimals="-3" id="f-249" unitRef="usd">86000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="c-53"
      decimals="INF"
      id="f-250"
      unitRef="shares">570987</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-53" decimals="-3" id="f-251" unitRef="usd">8000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="c-54"
      decimals="INF"
      id="f-252"
      unitRef="shares">27828231</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-54" decimals="-3" id="f-253" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-55" decimals="-3" id="f-254" unitRef="usd">369103000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-56" decimals="-3" id="f-255" unitRef="usd">-108585000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-57" decimals="-3" id="f-256" unitRef="usd">-8488000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-58" decimals="-3" id="f-257" unitRef="usd">252125000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-59" decimals="-3" id="f-258" unitRef="usd">437000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-60" decimals="-3" id="f-259" unitRef="usd">252562000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-61" decimals="-3" id="f-260" unitRef="usd">9877000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-62" decimals="-3" id="f-261" unitRef="usd">9877000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-22" decimals="-3" id="f-262" unitRef="usd">9877000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="c-63"
      decimals="INF"
      id="f-263"
      unitRef="shares">494801</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c-63" decimals="-3" id="f-264" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c-61" decimals="-3" id="f-265" unitRef="usd">484000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c-62" decimals="-3" id="f-266" unitRef="usd">484000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c-22" decimals="-3" id="f-267" unitRef="usd">484000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-64" decimals="-3" id="f-268" unitRef="usd">-24972000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-62" decimals="-3" id="f-269" unitRef="usd">-24972000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-65" decimals="-3" id="f-270" unitRef="usd">-111000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-22" decimals="-3" id="f-271" unitRef="usd">-25083000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <brns:AdjustmentsToAdditionalPaidInCapitalMeasurementPeriodAdjustmentsInBusinessCombination contextRef="c-61" decimals="-3" id="f-272" unitRef="usd">40000</brns:AdjustmentsToAdditionalPaidInCapitalMeasurementPeriodAdjustmentsInBusinessCombination>
    <brns:AdjustmentsToAdditionalPaidInCapitalMeasurementPeriodAdjustmentsInBusinessCombination contextRef="c-62" decimals="-3" id="f-273" unitRef="usd">40000</brns:AdjustmentsToAdditionalPaidInCapitalMeasurementPeriodAdjustmentsInBusinessCombination>
    <brns:AdjustmentsToAdditionalPaidInCapitalMeasurementPeriodAdjustmentsInBusinessCombination contextRef="c-22" decimals="-3" id="f-274" unitRef="usd">40000</brns:AdjustmentsToAdditionalPaidInCapitalMeasurementPeriodAdjustmentsInBusinessCombination>
    <us-gaap:ProfitLoss contextRef="c-66" decimals="-3" id="f-275" unitRef="usd">5342000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-62" decimals="-3" id="f-276" unitRef="usd">5342000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-65" decimals="-3" id="f-277" unitRef="usd">-21000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-22" decimals="-3" id="f-278" unitRef="usd">5321000</us-gaap:ProfitLoss>
    <us-gaap:SharesIssued
      contextRef="c-25"
      decimals="INF"
      id="f-279"
      unitRef="shares">37683531</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-25" decimals="-3" id="f-280" unitRef="usd">1000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="c-26"
      decimals="INF"
      id="f-281"
      unitRef="shares">63443</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-26" decimals="-3" id="f-282" unitRef="usd">86000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="c-27"
      decimals="INF"
      id="f-283"
      unitRef="shares">570987</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-27" decimals="-3" id="f-284" unitRef="usd">8000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="c-28"
      decimals="INF"
      id="f-285"
      unitRef="shares">27828231</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-28" decimals="-3" id="f-286" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-29" decimals="-3" id="f-287" unitRef="usd">379504000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-30" decimals="-3" id="f-288" unitRef="usd">-103243000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-31" decimals="-3" id="f-289" unitRef="usd">-33460000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-32" decimals="-3" id="f-290" unitRef="usd">242896000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-33" decimals="-3" id="f-291" unitRef="usd">305000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-7" decimals="-3" id="f-292" unitRef="usd">243201000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-3" id="f-293" unitRef="usd">-73447000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-22" decimals="-3" id="f-294" unitRef="usd">5321000</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-3" id="f-295" unitRef="usd">5055000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-22" decimals="-3" id="f-296" unitRef="usd">9877000</us-gaap:ShareBasedCompensation>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-1" decimals="-3" id="f-297" unitRef="usd">5429000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-22" decimals="-3" id="f-298" unitRef="usd">4323000</us-gaap:DepreciationDepletionAndAmortization>
    <brns:NonCashLeaseExpenses contextRef="c-1" decimals="-3" id="f-299" unitRef="usd">1328000</brns:NonCashLeaseExpenses>
    <brns:NonCashLeaseExpenses contextRef="c-22" decimals="-3" id="f-300" unitRef="usd">1216000</brns:NonCashLeaseExpenses>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized contextRef="c-1" decimals="-3" id="f-301" unitRef="usd">-7531000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized contextRef="c-22" decimals="-3" id="f-302" unitRef="usd">24905000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-1" decimals="-3" id="f-303" unitRef="usd">55000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-22" decimals="-3" id="f-304" unitRef="usd">-73000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <brns:NonCashInterestExpenseOnConvertibleLoanNotes contextRef="c-1" decimals="-3" id="f-305" unitRef="usd">28000</brns:NonCashInterestExpenseOnConvertibleLoanNotes>
    <brns:NonCashInterestExpenseOnConvertibleLoanNotes contextRef="c-22" decimals="-3" id="f-306" unitRef="usd">19000</brns:NonCashInterestExpenseOnConvertibleLoanNotes>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-307" unitRef="usd">-3075000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-22" decimals="-3" id="f-308" unitRef="usd">-4337000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c-1" decimals="-3" id="f-309" unitRef="usd">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c-22" decimals="-3" id="f-310" unitRef="usd">348000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-1" decimals="-3" id="f-311" unitRef="usd">-5800000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-22" decimals="-3" id="f-312" unitRef="usd">5833000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-1" decimals="-3" id="f-313" unitRef="usd">-2200000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-22" decimals="-3" id="f-314" unitRef="usd">2170000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <brns:IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable contextRef="c-1" decimals="-3" id="f-315" unitRef="usd">127000</brns:IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable>
    <brns:IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable contextRef="c-22" decimals="-3" id="f-316" unitRef="usd">-1158000</brns:IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-1" decimals="-3" id="f-317" unitRef="usd">-3378000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-22" decimals="-3" id="f-318" unitRef="usd">1140000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="c-1" decimals="-3" id="f-319" unitRef="usd">1993000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="c-22" decimals="-3" id="f-320" unitRef="usd">751000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-1" decimals="-3" id="f-321" unitRef="usd">0</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-22" decimals="-3" id="f-322" unitRef="usd">-183000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-1" decimals="-3" id="f-323" unitRef="usd">-445000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-22" decimals="-3" id="f-324" unitRef="usd">0</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="c-1" decimals="-3" id="f-325" unitRef="usd">-128000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="c-22" decimals="-3" id="f-326" unitRef="usd">387000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-327" unitRef="usd">-50925000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-22" decimals="-3" id="f-328" unitRef="usd">-14431000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-329" unitRef="usd">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="c-22" decimals="-3" id="f-330" unitRef="usd">388000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-331" unitRef="usd">5413000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-22" decimals="-3" id="f-332" unitRef="usd">6138000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-3" id="f-333" unitRef="usd">-5413000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-22" decimals="-3" id="f-334" unitRef="usd">-5750000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="c-1" decimals="-3" id="f-335" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="c-22" decimals="-3" id="f-336" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-1" decimals="-3" id="f-337" unitRef="usd">2035000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-22" decimals="-3" id="f-338" unitRef="usd">484000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities contextRef="c-1" decimals="-3" id="f-339" unitRef="usd">163000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities contextRef="c-22" decimals="-3" id="f-340" unitRef="usd">0</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:RepaymentsOfShortTermDebt contextRef="c-1" decimals="-3" id="f-341" unitRef="usd">0</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt contextRef="c-22" decimals="-3" id="f-342" unitRef="usd">159000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-343" unitRef="usd">1872000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-22" decimals="-3" id="f-344" unitRef="usd">325000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c-1" decimals="-3" id="f-345" unitRef="usd">2171000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c-22" decimals="-3" id="f-346" unitRef="usd">187000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-3" id="f-347" unitRef="usd">-52295000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-22" decimals="-3" id="f-348" unitRef="usd">-19669000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-7" decimals="-3" id="f-349" unitRef="usd">194385000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-60" decimals="-3" id="f-350" unitRef="usd">214054000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-6" decimals="-3" id="f-351" unitRef="usd">142090000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-7" decimals="-3" id="f-352" unitRef="usd">194385000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet contextRef="c-1" decimals="-3" id="f-353" unitRef="usd">0</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-22" decimals="-3" id="f-354" unitRef="usd">0</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-1" decimals="-3" id="f-355" unitRef="usd">0</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-22" decimals="-3" id="f-356" unitRef="usd">0</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-1" decimals="-3" id="f-357" unitRef="usd">87000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-22" decimals="-3" id="f-358" unitRef="usd">559000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-1" decimals="-3" id="f-359" unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-22" decimals="-3" id="f-360" unitRef="usd">2400000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <brns:AssetRetirementObligations contextRef="c-1" decimals="-3" id="f-361" unitRef="usd">287000</brns:AssetRetirementObligations>
    <brns:AssetRetirementObligations contextRef="c-22" decimals="-3" id="f-362" unitRef="usd">999000</brns:AssetRetirementObligations>
    <brns:ChangesToRightOfUseAssetResultingFromLeaseReassessmentEvent contextRef="c-1" decimals="-3" id="f-363" unitRef="usd">88000</brns:ChangesToRightOfUseAssetResultingFromLeaseReassessmentEvent>
    <brns:ChangesToRightOfUseAssetResultingFromLeaseReassessmentEvent contextRef="c-22" decimals="-3" id="f-364" unitRef="usd">-207000</brns:ChangesToRightOfUseAssetResultingFromLeaseReassessmentEvent>
    <brns:NonCashInvestingAndFinancingActivityOfMeasurementPeriodAdjustments contextRef="c-1" decimals="-3" id="f-365" unitRef="usd">0</brns:NonCashInvestingAndFinancingActivityOfMeasurementPeriodAdjustments>
    <brns:NonCashInvestingAndFinancingActivityOfMeasurementPeriodAdjustments contextRef="c-22" decimals="-3" id="f-366" unitRef="usd">-38000</brns:NonCashInvestingAndFinancingActivityOfMeasurementPeriodAdjustments>
    <brns:ContingentConsiderationSettledInEquity contextRef="c-1" decimals="-3" id="f-367" unitRef="usd">0</brns:ContingentConsiderationSettledInEquity>
    <brns:ContingentConsiderationSettledInEquity contextRef="c-22" decimals="-3" id="f-368" unitRef="usd">78000</brns:ContingentConsiderationSettledInEquity>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="c-1" id="f-369">Nature of Business and Basis of Presentation&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Nature of business&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Barinthus Biotherapeutics plc (formerly Vaccitech plc) is a public limited company incorporated pursuant to the laws of England and Wales in March 2021. Barinthus Biotherapeutics plc and its direct and indirect subsidiaries, Barinthus Biotherapeutics (UK) Limited (formerly Vaccitech (UK) Limited), Barinthus Biotherapeutics Australia Pty Limited (formerly Vaccitech Australia Pty Limited), Vaccitech Oncology Limited (&#x201c;VOLT&#x201d;), Barinthus Biotherapeutics North America, Inc. (formerly Vaccitech North America, Inc.), Barinthus Biotherapeutics Switzerland GmbH (formerly Vaccitech Switzerland GmbH) and Barinthus Biotherapeutics S.R.L. (formerly Vaccitech Italia S.R.L.), are collectively referred to as the &#x201c;Company&#x201d; or &#x201c;Barinthus Bio&#x201d;. The Company is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity and cancer. The Company is headquartered in Harwell, Oxfordshire, United Kingdom. On November 6, 2023, the Company announced its renaming as Barinthus Bio to represent the evolution and expansion of its focus beyond vaccines.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In connection with the initial public offering of American Depositary Shares (&#x201c;ADSs&#x201d;), in March 2021, the Company completed a corporate reorganization wherein the shareholders of Barinthus Biotherapeutics (UK) Limited exchanged each of their ordinary shares, series A shares and series B shares of Barinthus Biotherapeutics (UK) Limited for the same quantity of ordinary shares, series A shares and series B shares in Barinthus Biotherapeutics plc (resulting in the shareholders of the Company holding the same percentage and class of shares in Barinthus Biotherapeutics plc as they had in Barinthus Biotherapeutics (UK) Limited). The group reorganization under common control constituted a change in reporting entity and has been given retrospective effect reflecting the net assets of Barinthus Biotherapeutics (UK) Limited and its subsidiaries and Barinthus Biotherapeutics plc at their historical carrying amounts. On April 4, 2022, a merger was effected between subsidiaries Vaccitech USA, Inc. and Barinthus Biotherapeutics North America, Inc., with Barinthus Biotherapeutics North America, Inc. being the surviving entity.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company operates in an environment of rapid technological change and substantial competition from pharmaceutical and biotechnology companies. The Company is subject to risks common to companies in the biopharmaceutical industry in a similar stage of its life cycle including, but not limited to, the need to obtain adequate additional funding, possible failure of preclinical testing or clinical trials, the need to obtain marketing approval for its vaccine product candidates, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of any of its products that are approved, and protection of proprietary technology. There can be no assurance that the Company&#x2019;s research and development will be successfully completed, that adequate protection for the Company&#x2019;s intellectual property will be obtained, that any products developed will obtain required regulatory approval or that any approved products will be commercially viable. Even if the Company&#x2019;s development efforts are successful, it is uncertain when, if ever, the Company will generate significant product sales. If the Company does not successfully commercialize any of its products or mitigate any of these other risks, it will be unable to generate revenue or achieve profitability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Basis of presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) and pursuant to the rules and regulations of the Securities and Exchange Commission for annual financial reporting. The Company&#x2019;s reporting currency is the U.S. dollar. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of December&#160;31, 2023, the Company had cash and cash equivalents of $142.1 million and an accumulated deficit of $176.6 million and the Company expects to incur losses for the foreseeable future. The Company expects that its cash and cash equivalents will be sufficient to fund current operations into the fourth quarter of 2025, without additional financing. The Company expects to seek additional funding through equity financing, government or private-party grants, debt financings or other capital sources, including collaborations with other companies or other strategic transactions. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into collaborations or other arrangements. The terms of any financing may adversely affect the holdings or rights of the Company&#x2019;s stockholders. If the Company is unable to obtain sufficient capital, the Company will be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or future commercialization efforts, which could adversely affect its business prospects, or the Company may be unable to continue operations. Although management continues to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations, if at all.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates, among other things, the realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Guarantees and indemnifications&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As permitted under the laws of England and Wales, the Company indemnifies its officers, directors, consultants and employees for certain events or occurrences that happen by reason of the relationship with, or position held at, the Company. Through the years ended December&#160;31, 2023 and 2022, the Company had not experienced any losses related to these indemnification obligations, and no claims were outstanding. The Company does not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and no related reserves were established.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Use of estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue, income and expenses during the reporting period. The Company bases estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions on an ongoing basis, including those related to fair value of contingent consideration and impairment of goodwill and intangible assets. The Company&#x2019;s actual results may differ from these estimates under different assumptions or conditions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of the date of issuance of these consolidated financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update its estimates, assumptions and judgments or revise the carrying value of its assets or liabilities. These estimates may change as new events occur and additional information is obtained and are recognized in the consolidated financial statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to the Company&#x2019;s financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-6" decimals="-5" id="f-370" unitRef="usd">142100000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-6" decimals="-5" id="f-371" unitRef="usd">-176600000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:GuaranteesIndemnificationsAndWarrantiesPolicies contextRef="c-1" id="f-372">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Guarantees and indemnifications&lt;/span&gt;&lt;/div&gt;As permitted under the laws of England and Wales, the Company indemnifies its officers, directors, consultants and employees for certain events or occurrences that happen by reason of the relationship with, or position held at, the Company.</us-gaap:GuaranteesIndemnificationsAndWarrantiesPolicies>
    <us-gaap:UseOfEstimates contextRef="c-1" id="f-373">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Use of estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue, income and expenses during the reporting period. The Company bases estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions on an ongoing basis, including those related to fair value of contingent consideration and impairment of goodwill and intangible assets. The Company&#x2019;s actual results may differ from these estimates under different assumptions or conditions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of the date of issuance of these consolidated financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update its estimates, assumptions and judgments or revise the carrying value of its assets or liabilities. These estimates may change as new events occur and additional information is obtained and are recognized in the consolidated financial statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to the Company&#x2019;s financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-374">Summary of Significant Accounting Policies&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Principles of consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The accompanying consolidated financial statements include the accounts of Barinthus Biotherapeutics plc and those entities in which it has a controlling interest. Intercompany amounts are eliminated on consolidation. Amounts attributable to the noncontrolling interest are presented as a separate element of equity in the accompanying consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Comprehensive loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Comprehensive loss for all periods presented is comprised primarily of net (loss)/income and other comprehensive loss, which solely relates to foreign currency translation adjustments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Foreign currency translation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company&#x2019;s reporting currency is the United States dollar. The functional currency of the parent and each subsidiary is the currency of the country and economic environment in which it is located. Assets and liabilities of each legal entity denominated or measured in a currency other than British Pounds are first translated into British pounds and consolidated. The consolidated balances are then converted into United States dollars at period-end exchange rates. Revenues and expenses are translated into British pounds, then into U.S. dollars at average exchange rates for each reporting period. Translation adjustments are reflected as accumulated other comprehensive loss within stockholders&#x2019; equity. Gains and losses on foreign currency transactions are included in the consolidated statements of operations and comprehensive loss in the general and administrative expenses. The aggregate net foreign exchange gain or loss included in determining net loss was a loss of $7.6 million and gain of $26.4 million for the years ended December&#160;31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Segment information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, the Company&#x2019;s Chief Executive Officer, in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one operating segment, the research and development of immunotherapies and vaccines.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Noncontrolling interest&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In 2018, Barinthus Biotherapeutics plc established VOLT with a related party. As of December&#160;31, 2021, Barinthus Biotherapeutics plc had contributed cash and intellectual property with an aggregate value of $11.9 million for a 76% controlling interest. The related party had contributed cash and intellectual property with an aggregate value of $3.8 million for a 24% noncontrolling interest. There were no further contributions in the years ended December&#160;31, 2023 and 2022. The contributed intellectual properties were initially recorded at investment date fair value by VOLT and immediately expensed as research and development costs. The Company accounts for the noncontrolling interest in the accompanying consolidated financial statements initially at fair value with the subsequent carrying value adjusted for the noncontrolling share of VOLT&#x2019;s comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company accounts for business combinations using the acquisition method of accounting, which requires the recognition of tangible and identifiable intangible assets acquired and liabilities assumed at their estimated fair values as of the business combination date. The Company allocates any excess purchase price over the estimated fair value assigned to the net tangible and identifiable intangible assets acquired and liabilities assumed to goodwill. Contingent consideration is included within the acquisition cost and is recognized at its fair value on the acquisition date. A liability resulting from contingent consideration is remeasured to fair value at each reporting date until the contingency is resolved and changes in fair value are recognized in general and administrative expenses in the consolidated statements of operations and comprehensive loss. Transaction costs are expensed as incurred in general and administrative expenses. Results of operations and cash flows of acquired companies are included in the Company&#x2019;s operating results from the date of acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company considers all highly liquid investments purchased with remaining maturities of three months or less on the purchase date to be cash and cash equivalents. Cash and cash equivalents include bank demand deposits and money market funds that are actively traded (a Level 1 input). As of December&#160;31, 2023, and 2022 there were no cash equivalents.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company has entered into collaboration and license agreements, which are within the scope of Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, to discover, develop, manufacture and commercialize product candidates. The terms of these agreements typically contain multiple promises or obligations, which may include licenses, or options to obtain licenses, to product candidates or future product candidates. The Company also derives revenue from government grants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Amounts received prior to revenue recognition are recorded as deferred revenue. Amounts expected to be recognized as revenue within the 12 months following the balance sheet date are classified as current portion of deferred revenue in the accompanying consolidated balance sheets. Amounts recognized as revenue, but not yet received or invoiced are generally recognized as accounts receivable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;License revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company&#x2019;s arrangements may provide the collaboration partner with the right to select a target for licensing either at the inception of the arrangement or in the future. Under these arrangements, fees may be due to the Company (i) at the inception of the arrangement as an upfront fee or payment, (ii) upon the exercise of an option to acquire a license or (iii) &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;upon extending the selection period as an extension fee or payment. If an arrangement is determined to contain customer options that allow the customer to acquire additional goods or services, the goods and services underlying the customer options are not considered to be performance obligations at the outset of the arrangement, as they are contingent upon option exercise. The Company evaluates the customer options for material rights, or options to acquire additional goods or services for fee or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the inception of the arrangement. The Company allocates the transaction price to material rights based on the relative standalone selling price, which is determined based on the identified discount and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised or expires.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;For arrangements that include sales-based milestones and royalties, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). This could require management to estimate the amount of revenue to recognize in the period if the actual data for the period has not been provided.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Research and development services&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The promises under the Company&#x2019;s collaboration and license agreements generally include research and development services to be performed by the Company on behalf of the collaboration partner. For performance obligations that include research and development services, the Company recognizes revenue allocated to such performance obligations based on an appropriate measure of progress. The Company utilizes judgment to determine the appropriate method of measuring progress for the purposes of recognizing revenue, which may include an input measure such as costs incurred during the reporting period or ratably over the service period. Reimbursements from the partner are evaluated as to whether the Company acts as a principal or an agent in such relationships. The Company evaluates whether control over the underlying goods or services were obtained prior to transferring these goods or services to the collaboration partner. Where the Company does not control the goods or services prior to transferring these goods or services to the collaboration partner, such reimbursements are presented net of costs. At the inception of each arrangement that includes development milestone payments in respect of development efforts, the Company evaluates whether the development milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated development milestone value is included in the transaction price. Development milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular development milestone in making this assessment. There is judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each reporting period, the Company reevaluates the probability of achievement of all development milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. If a milestone or other variable consideration relates specifically to the Company&#x2019;s efforts to satisfy a single performance obligation or to a specific outcome from satisfying the performance obligation, the Company generally allocates the milestone amount entirely to that performance obligation once it is probable that a significant revenue reversal would not occur. To date, the Company has not recognized any development milestone revenue resulting from any of its arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Grant income&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company receives certain grant income which support its research efforts in defined projects and include contributions towards the research and development costs. When there is reasonable assurance that the Company will comply with the conditions attached to a received grant, and when there is reasonable assurance that the grant will be received, grant income is recognized as other operating income on a gross basis in the consolidated statements of operations and comprehensive loss on a systematic basis over the periods in which the Company recognizes expenses for the related costs for which the grants are intended to compensate. Grant income may be subject to review by the grantor in periods subsequent to its recognition and may result in the reversal of grant income previously recognized. Payments received in advance of incurring reimbursable expenses are recorded as deferred income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Concentrations of credit risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash and cash equivalents and accounts receivable. Periodically, the Company maintains deposits in financial institutions in excess of government insured limits. Management believes that the Company is not exposed to significant credit risk as the Company&#x2019;s deposits are held at financial institutions that management believes to be of high credit quality and the Company has not experienced any losses in these deposits. The Company&#x2019;s standard payment terms are 30 days&#x2019;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company recognizes revenue earned in connection with the license and services provided to customers and grantors. The Company provides credit to the grantors in the normal course of providing such services based on evaluations of their financial condition and generally does not require collateral. To manage accounts receivable credit risk, the Company monitors the creditworthiness of its grantors. Historically, the Company has not experienced any credit losses related to accounts receivable and does not maintain allowances for uncollectible amounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Licensees and grantors that represented 10% of more of the Company&#x2019;s revenue and accounted for 10% or more of accounts receivable are presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.606%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.767%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.820%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.507%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.298%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.507%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.301%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Country&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Year ended&lt;br/&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Year ended&lt;br/&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Oxford University Innovation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;U.K.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.912%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.513%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.513%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.409%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Accounts Receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Country&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;As of&lt;br/&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;As of&lt;br/&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Oxford University Innovation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;U.K.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Allowance for credit losses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company evaluates its cash equivalents and accounts receivable for expected credit losses. Expected credit losses represent the portion of the amortized cost basis of a financial asset that an entity does not expect to collect. An allowance for expected credit losses is meant to reflect a risk of loss even if remote, irrespective of the expectation of collection from a particular issuer or debt security. The Company has not historically experienced any credit losses on any of its financial assets. With respect to cash equivalents and accounts receivable, given consideration of their short maturity, historical losses and the current market environment, the Company concluded there are no expected credit losses for these financial assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Property and equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Property and equipment are stated at cost, net of accumulated depreciation. Expenditures for maintenance and repairs are charged to operating expenses as incurred, whereas major betterments are capitalized as additions to property and equipment. Depreciation is recorded using the straight-line method over the estimated useful lives of the assets as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.787%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.323%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.477%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Asset Category&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Estimated Useful Life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Office furniture and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Lesser of lease term or estimated useful lives&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Intangible assets acquired through business combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Intangible assets consist of acquired developed technology. Intangible assets are stated at cost less accumulated amortization and impairment losses. Amortization is computed using the straight-line method over the estimated useful lives of the respective assets, which is 10 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Impairment of long-lived assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company reviews long-lived assets to be held and used, including property and equipment, intangible assets and operating lease right-of-use assets, for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets or asset group may not be recoverable. Evaluation of recoverability is first based on an estimate of undiscounted future cash flows resulting from the use of the asset or asset group and its eventual disposition. In the event such cash flows are not expected to be sufficient to recover the carrying amount of the asset or asset group, the assets are written down to their estimated fair values. No such impairments were recorded during the years ended December&#160;31, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Goodwill represents the excess of cost over the fair value of the net tangible and intangible assets of businesses acquired in a business combination. Goodwill is not amortized but rather is tested for impairment at least annually, or more frequently if events or changes in circumstances indicate that the carrying amount of goodwill may not be recoverable. The Company has elected to first assess the qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount as a basis of determining whether it is necessary to perform the quantitative goodwill impairment test. If the Company determines that it is more likely than not that its fair value is less than its carrying amount, then the quantitative goodwill impairment test will be performed. The quantitative goodwill impairment test identifies goodwill impairment and measures the amount of goodwill impairment loss to be recognized by comparing the fair value of a reporting unit with its carrying amount. If the fair value exceeds the carrying amount, no further analysis is required; otherwise, any excess of the goodwill carrying amount over the implied fair value is recognized as an impairment loss, and the carrying value of goodwill is written down to fair value. For the years ended December&#160;31, 2023 and 2022, goodwill has been tested, and no impairments have been recorded.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Financial instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company&#x2019;s financial instruments consist of cash and cash equivalents, accounts receivable, accounts payable, certain accrued expenses, contingent consideration and short-term debt. The carrying amounts of cash, cash equivalents, accounts receivable, security deposits, accounts payable, accrued expenses and short-term debt approximate their fair value due to the short-term nature of those financial instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Fair value measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company follows the guidance in ASC 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Fair Value Measurements and Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, which defines fair value and establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are described below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;-&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.67pt"&gt;Level 1 &#x2013; Inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.67pt"&gt;Level 2 &#x2013; Valuations based on quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.67pt"&gt;Level 3 &#x2013; Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Fair value is a market-based measure considered from the perspective of a market participant rather than an entity-specific measure. Therefore, even when market assumptions are not readily available, the Company&#x2019;s own assumptions are set to reflect those that market participants would use in pricing the asset or liability at the measurement date. The Company uses prices and inputs that are current as of the measurement date, including during periods of market dislocation. In periods of market dislocation, the observability of prices and inputs may change for many instruments. This condition could cause an &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;instrument to be reclassified within levels in the fair value hierarchy. There were no transfers within the fair value hierarchy during the years ended December&#160;31, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company recognizes a contingent consideration liability related to the acquisition of Avidea Technologies, Inc. The liability is remeasured to fair value at each reporting date until the contingency is resolved. The fair value of the contingent consideration is a Level 3 valuation determined using significant unobservable inputs being the probability of success of achievement of the milestones and the expected date of the milestone achievement. Changes in fair value are recognized in general and administrative expenses in the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Leases are accounted for under ASC 842, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Leases &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(&#x201c;ASC 842&#x201d;) resulting in the recognition of lease liabilities and right-of-use assets. The Company only has operating leases. The Company has elected the practical expedient allowed under ASC 842 to account for each lease component (e.g., the right to use office space) and the associated non-lease components (e.g., maintenance services) as a single lease component. The Company also elected the short-term lease accounting policy for all asset classes; therefore, the Company is not recognizing a lease liability or right-of-use asset for any lease that, at the commencement date, has a lease term of 12 months or less and does not include an option to purchase the underlying asset that the Company is reasonably certain to exercise.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Variable lease payments such as the Company&#x2019;s share of real estate taxes, utilities, and common area maintenance, are reported as non-lease operating expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Right-of-use assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. Right-of-use assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. As the Company&#x2019;s leases typically do not provide an implicit rate, the Company uses an estimate of its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Right-of-use assets also include the effect of any lease payments made and exclude lease incentives. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized as part of total operating expenses on a straight-line basis over the lease term. The difference between the value of the right of use asset and lease liability is due to the reclassification of prepaid rent and unamortized lease incentives.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Research and development costs are expensed as incurred on an accruals basis. Research and development costs include payroll and personnel expense (including share-based compensation), consulting costs, external contract research and development expenses, raw materials, drug product manufacturing costs, and allocated overheads including depreciation and amortization, facility costs, and utilities. Research and development costs that are paid in advance of performance are capitalized as a prepaid expense and amortized over the service period as the services are provided.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Clinical trial costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Clinical trial costs are a component of research and development expenses. The Company accrues and expenses clinical trial activities performed by third parties based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activation, and other information provided to the Company by its vendors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Patent and licensing costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Patent and licensing costs are expensed as incurred because their realization is uncertain.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Ordinary shares&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Ordinary shares are classified in stockholders&#x2019; equity and represent issued share capital.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Additional paid-in capital&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Additional paid-in capital is classified in stockholders&#x2019; equity and represents the share premium account, where the difference between the price paid per share and the nominal value is recognized. The equity element of share based compensation is also recognized in additional paid in capital.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Share based compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company grants options over ordinary shares and restricted shares units to employees or Non-Executive Directors and accounts for share based compensation using the grant date fair value. Share based compensation awards are classified in the accompanying statements of operations based on the function to which the related services are provided. For service-based awards, compensation expense is generally recognized over the requisite service period of the awards, usually the vesting period. The Company applies the &#x201c;multiple option&#x201d; method of allocating expense. In applying this method, each vesting tranche of an award is treated as a separate grant and recognized on a straight-line basis over that tranche&#x2019;s vesting period. For performance-based awards where the vesting of the awards may be accelerated upon the achievement of certain milestones, vesting and the related share-based compensation is recognized as an expense when it is probable the milestone will be met. Assumptions used in the option pricing model include the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Expected volatility.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; Previously there was insufficient trading history for the Company&#x2019;s ordinary shares, therefore the expected price volatility for our ordinary shares was estimated using the average historical volatility of industry peers&#x2019; shares as of the grant date of our options over a period of history commensurate with the expected life of the options. When selecting industry peers used in measuring implied volatility, the Company considered the similarity of their products and business lines, as well as their stage of development, size and financial leverage. The Company applied this process consistently using the same or similar public companies until 2023. During 2023, the Company determined that there is sufficient historical information on volatility of its share price available and the expected volatility used in the fair value calculation of new option grants is calculated based on a blended volatility of both historical volatility of the Company's share price and the expected volatility of the average historical volatility of industry peers&#x2019; shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Expected term&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;. The expected term of the Company&#x2019;s share options has been determined utilizing the &#x201c;simplified&#x201d; method for awards that qualify as &#x201c;plain-vanilla&#x201d; options. The &#x201c;simplified&#x201d; method was determined to be appropriate as the Company does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term due to the limited period of time its equity shares have been publicly traded.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Risk-free interest rate&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods that are approximately equal to the expected term of the award.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Expected dividend.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; Expected dividend yield of zero is based on the fact that the Company has never paid cash dividends on ordinary shares and does not expect to pay any cash dividends in the foreseeable future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company has elected to recognize the effect of forfeitures on share-based compensation when they occur. Any differences in compensation recognized at the time of forfeiture are recorded as a cumulative adjustment in the period where the forfeiture occurs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;When awards are modified, the Company compares the fair value of the affected award measured immediately prior to modification to its value after modification. To the extent that the fair value of the modified award exceeds the original award, the incremental fair value of the modified award is recognized as compensation on the date of modification for vested awards, and over the remaining vesting period for unvested awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Income taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The financial statements reflect provisions for income taxes in the United Kingdom and foreign jurisdictions. Deferred tax assets and liabilities represent future tax consequences of temporary differences between the financial statement carrying amounts and the tax basis of assets and liabilities and for loss carryforwards using enacted tax rates expected to be in effect in the years in which the differences reverse. A valuation allowance is recorded when it is more likely than not that some or all of the deferred tax assets will not be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company determines whether it is more likely than not that a tax position will be sustained upon examination. If it is not more likely than not that a position will be sustained, none of the benefit attributable to the position is recognized. The &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;tax benefit to be recognized for any tax position that meets the more-likely-than-not recognition threshold is calculated as the largest amount that is more than 50% likely of being realized upon resolution of the contingency. The Company accounts for interest and penalties related to uncertain tax positions as part of its provision for income taxes. To date, the Company has not incurred interest and penalties related to uncertain tax positions nor has it recorded any unrecognized tax benefits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Research and development incentives&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In the United Kingdom, the Company had previously been entitled to a research and development tax credit regime, being the Small and Medium-sized Enterprises R&amp;amp;D tax relief program, or SME Program, and, to the extent that our projects are grant funded or relate to work subcontracted to us by third parties, the Research and Development Expenditure Credit program, or RDEC Program. Until March 2023, under the SME program, the Company was able to surrender some of its trading losses that arise from qualifying research and development activities for a cash rebate of up to 33.35% of such qualifying research and development expenditure. Qualifying expenditures largely comprise employment costs for research staff, consumables, outsourced contract research organization costs and utilities costs incurred as part of research projects. Certain staff, consumables (including utilities), subcontractors and externally provided workers qualifying research and development expenditures are eligible for a cash rebate of up to 21.67%. A large portion of costs relating to research and development, clinical trials and manufacturing activities are eligible for inclusion within these tax credit cash rebate claims. From April 2023, under the SME program the additional deduction has decreased from 130% to 86%, the SME credit rate has reduced from 14.5% to 10% and the SME cash rebate for the Company has reduced from 33.35% to 18.6% and from 21.67% to 12.1% for subcontractors. Furthermore, the SME credit rate will decrease to 10% for expenditure incurred on or after April 1, 2023 unless the SME qualifies as an R&amp;amp;D intensive business i.e., R&amp;amp;D expenditure constitutes at least 40% (from April 1, 2023) or 30% (from accounting periods starting on or after April 1, 2024) of total expenditure. If the Company incurs tax losses, the Company is entitled to surrender the lesser of unrelieved tax loss sustained and the tax relief. As the realization of the tax relief does not depend on our generation of future taxable income or the Company&#x2019;s ongoing tax status or tax position, the Company does not consider the tax relief as an element of income tax accounting under ASC 740, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Income taxes &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;and records the tax relief as a form of government grant or assistance. For the years ended December&#160;31, 2023 and 2022, the Company recognized research and development incentives of $3.5 million and $1.2 million respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Net (loss)/income per share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Basic net (loss)/income per share is computed by dividing the net (loss)/income attributable to ordinary shareholders by the weighted-average number of ordinary shares outstanding for the reporting period without consideration for potentially dilutive securities. Net (loss)/income attributable to ordinary shareholders is computed as if all net (loss)/income for the period had been distributed. During periods in which the Company incurred a net loss, the Company allocates no net loss to participating securities because they do not have a contractual obligation to share in the net loss of the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company computes diluted net (loss)/income per ordinary share after giving consideration to all potentially dilutive ordinary equivalents, including stock options outstanding during the period, except where the effect of such non-participating securities would be antidilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Diluted net (loss)/income per share is computed by dividing the net (loss)/income attributable to ordinary shareholders by the weighted-average number of ordinary shares and dilutive ordinary share equivalents outstanding for the period, determined using the treasury-stock and if-converted methods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Contingent liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;A provision for contingent liabilities is recorded when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. With respect to legal matters, provisions are reviewed and adjusted to reflect the impact of negotiations, estimated settlements, legal rulings, advice of legal counsel and other information and events pertaining to a particular matter. The Company is a party to certain litigation and disputes arising in the normal course of business. As of December&#160;31, 2023, the Company does not expect that such matters will have a material adverse effect on the Company&#x2019;s business, financial position, results of operations, or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;From time to time, new accounting pronouncements are issued by FASB or other standard setting bodies that the Company adopts as of the specified effective date. The Company qualifies as an &#x201c;emerging growth company&#x201d; as defined in the Jumpstart Our Business Startups Act of 2012 and has elected not to &#x201c;opt out&#x201d; of the extended transition related to complying with new or revised accounting standards, which means that when a standard is issued or revised and it has different applications dates for public and nonpublic companies, the Company can adopt the new or revised standard at the time nonpublic companies adopt the new or revised standard and can do so until such time the Company either (i) irrevocably elects to &#x201c;opt out&#x201d; of such extended transition period or (ii) no longer qualifies as an emerging growth company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;We have reviewed all recently issued standards and have determined that such standards will not have a material impact on our consolidated financial statements or do not otherwise apply to our current operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="c-1" id="f-375">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Principles of consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The accompanying consolidated financial statements include the accounts of Barinthus Biotherapeutics plc and those entities in which it has a controlling interest. Intercompany amounts are eliminated on consolidation. Amounts attributable to the noncontrolling interest are presented as a separate element of equity in the accompanying consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="c-1" id="f-376">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Comprehensive loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Comprehensive loss for all periods presented is comprised primarily of net (loss)/income and other comprehensive loss, which solely relates to foreign currency translation adjustments.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="c-1" id="f-377">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Foreign currency translation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company&#x2019;s reporting currency is the United States dollar. The functional currency of the parent and each subsidiary is the currency of the country and economic environment in which it is located. Assets and liabilities of each legal entity denominated or measured in a currency other than British Pounds are first translated into British pounds and consolidated. The consolidated balances are then converted into United States dollars at period-end exchange rates. Revenues and expenses are translated into British pounds, then into U.S. dollars at average exchange rates for each reporting period. Translation adjustments are reflected as accumulated other comprehensive loss within stockholders&#x2019; equity. Gains and losses on foreign currency transactions are included in the consolidated statements of operations and comprehensive loss in the general and administrative expenses. The aggregate net foreign exchange gain or loss included in determining net loss was a loss of $7.6 million and gain of $26.4 million for the years ended December&#160;31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="c-1" decimals="-5" id="f-378" unitRef="usd">-7600000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="c-22" decimals="-5" id="f-379" unitRef="usd">26400000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="c-1" id="f-380">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Segment information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, the Company&#x2019;s Chief Executive Officer, in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one operating segment, the research and development of immunotherapies and vaccines.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c-1"
      decimals="INF"
      id="f-381"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <brns:MinorityInterestPolicyTextBlock contextRef="c-1" id="f-382">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Noncontrolling interest&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In 2018, Barinthus Biotherapeutics plc established VOLT with a related party. As of December&#160;31, 2021, Barinthus Biotherapeutics plc had contributed cash and intellectual property with an aggregate value of $11.9 million for a 76% controlling interest. The related party had contributed cash and intellectual property with an aggregate value of $3.8 million for a 24% noncontrolling interest. There were no further contributions in the years ended December&#160;31, 2023 and 2022. The contributed intellectual properties were initially recorded at investment date fair value by VOLT and immediately expensed as research and development costs. The Company accounts for the noncontrolling interest in the accompanying consolidated financial statements initially at fair value with the subsequent carrying value adjusted for the noncontrolling share of VOLT&#x2019;s comprehensive loss.&lt;/span&gt;&lt;/div&gt;</brns:MinorityInterestPolicyTextBlock>
    <brns:SubsidiaryCumulativeContributionsParent contextRef="c-67" decimals="-5" id="f-383" unitRef="usd">11900000</brns:SubsidiaryCumulativeContributionsParent>
    <us-gaap:MinorityInterestOwnershipPercentageByParent contextRef="c-68" decimals="2" id="f-384" unitRef="number">0.76</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <brns:SubsidiaryCumulativeContributionsNoncontrollingOwner contextRef="c-69" decimals="-5" id="f-385" unitRef="usd">3800000</brns:SubsidiaryCumulativeContributionsNoncontrollingOwner>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners contextRef="c-70" decimals="2" id="f-386" unitRef="number">0.24</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries contextRef="c-71" decimals="-5" id="f-387" unitRef="usd">0</us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries>
    <us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries contextRef="c-72" decimals="-5" id="f-388" unitRef="usd">0</us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries>
    <us-gaap:BusinessCombinationsPolicy contextRef="c-1" id="f-389">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company accounts for business combinations using the acquisition method of accounting, which requires the recognition of tangible and identifiable intangible assets acquired and liabilities assumed at their estimated fair values as of the business combination date. The Company allocates any excess purchase price over the estimated fair value assigned to the net tangible and identifiable intangible assets acquired and liabilities assumed to goodwill. Contingent consideration is included within the acquisition cost and is recognized at its fair value on the acquisition date. A liability resulting from contingent consideration is remeasured to fair value at each reporting date until the contingency is resolved and changes in fair value are recognized in general and administrative expenses in the consolidated statements of operations and comprehensive loss. Transaction costs are expensed as incurred in general and administrative expenses. Results of operations and cash flows of acquired companies are included in the Company&#x2019;s operating results from the date of acquisition.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c-1" id="f-390">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;The Company considers all highly liquid investments purchased with remaining maturities of three months or less on the purchase date to be cash and cash equivalents. Cash and cash equivalents include bank demand deposits and money market funds that are actively traded (a Level 1 input).</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c-7" decimals="-5" id="f-391" unitRef="usd">0</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c-6" decimals="-5" id="f-392" unitRef="usd">0</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="c-1" id="f-393">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company has entered into collaboration and license agreements, which are within the scope of Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, to discover, develop, manufacture and commercialize product candidates. The terms of these agreements typically contain multiple promises or obligations, which may include licenses, or options to obtain licenses, to product candidates or future product candidates. The Company also derives revenue from government grants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Amounts received prior to revenue recognition are recorded as deferred revenue. Amounts expected to be recognized as revenue within the 12 months following the balance sheet date are classified as current portion of deferred revenue in the accompanying consolidated balance sheets. Amounts recognized as revenue, but not yet received or invoiced are generally recognized as accounts receivable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;License revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company&#x2019;s arrangements may provide the collaboration partner with the right to select a target for licensing either at the inception of the arrangement or in the future. Under these arrangements, fees may be due to the Company (i) at the inception of the arrangement as an upfront fee or payment, (ii) upon the exercise of an option to acquire a license or (iii) &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;upon extending the selection period as an extension fee or payment. If an arrangement is determined to contain customer options that allow the customer to acquire additional goods or services, the goods and services underlying the customer options are not considered to be performance obligations at the outset of the arrangement, as they are contingent upon option exercise. The Company evaluates the customer options for material rights, or options to acquire additional goods or services for fee or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the inception of the arrangement. The Company allocates the transaction price to material rights based on the relative standalone selling price, which is determined based on the identified discount and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised or expires.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;For arrangements that include sales-based milestones and royalties, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). This could require management to estimate the amount of revenue to recognize in the period if the actual data for the period has not been provided.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <brns:ResearchAndDevelopmentServicesPolicyPolicyTextBlock contextRef="c-1" id="f-394">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Research and development services&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The promises under the Company&#x2019;s collaboration and license agreements generally include research and development services to be performed by the Company on behalf of the collaboration partner. For performance obligations that include research and development services, the Company recognizes revenue allocated to such performance obligations based on an appropriate measure of progress. The Company utilizes judgment to determine the appropriate method of measuring progress for the purposes of recognizing revenue, which may include an input measure such as costs incurred during the reporting period or ratably over the service period. Reimbursements from the partner are evaluated as to whether the Company acts as a principal or an agent in such relationships. The Company evaluates whether control over the underlying goods or services were obtained prior to transferring these goods or services to the collaboration partner. Where the Company does not control the goods or services prior to transferring these goods or services to the collaboration partner, such reimbursements are presented net of costs. At the inception of each arrangement that includes development milestone payments in respect of development efforts, the Company evaluates whether the development milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated development milestone value is included in the transaction price. Development milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular development milestone in making this assessment. There is judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each reporting period, the Company reevaluates the probability of achievement of all development milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. If a milestone or other variable consideration relates specifically to the Company&#x2019;s efforts to satisfy a single performance obligation or to a specific outcome from satisfying the performance obligation, the Company generally allocates the milestone amount entirely to that performance obligation once it is probable that a significant revenue reversal would not occur. To date, the Company has not recognized any development milestone revenue resulting from any of its arrangements.&lt;/span&gt;&lt;/div&gt;</brns:ResearchAndDevelopmentServicesPolicyPolicyTextBlock>
    <brns:GrantIncomePolicyPolicyTextBlock contextRef="c-1" id="f-395">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Grant income&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company receives certain grant income which support its research efforts in defined projects and include contributions towards the research and development costs. When there is reasonable assurance that the Company will comply with the conditions attached to a received grant, and when there is reasonable assurance that the grant will be received, grant income is recognized as other operating income on a gross basis in the consolidated statements of operations and comprehensive loss on a systematic basis over the periods in which the Company recognizes expenses for the related costs for which the grants are intended to compensate. Grant income may be subject to review by the grantor in periods subsequent to its recognition and may result in the reversal of grant income previously recognized. Payments received in advance of incurring reimbursable expenses are recorded as deferred income.&lt;/span&gt;&lt;/div&gt;</brns:GrantIncomePolicyPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c-1" id="f-396">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Concentrations of credit risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash and cash equivalents and accounts receivable. Periodically, the Company maintains deposits in financial institutions in excess of government insured limits. Management believes that the Company is not exposed to significant credit risk as the Company&#x2019;s deposits are held at financial institutions that management believes to be of high credit quality and the Company has not experienced any losses in these deposits. The Company&#x2019;s standard payment terms are 30 days&#x2019;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company recognizes revenue earned in connection with the license and services provided to customers and grantors. The Company provides credit to the grantors in the normal course of providing such services based on evaluations of their financial condition and generally does not require collateral. To manage accounts receivable credit risk, the Company monitors the creditworthiness of its grantors. Historically, the Company has not experienced any credit losses related to accounts receivable and does not maintain allowances for uncollectible amounts.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <brns:AccountsReceivableStandardPaymentTermsPeriod contextRef="c-1" id="f-397">P30D</brns:AccountsReceivableStandardPaymentTermsPeriod>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock contextRef="c-1" id="f-398">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Licensees and grantors that represented 10% of more of the Company&#x2019;s revenue and accounted for 10% or more of accounts receivable are presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.606%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.767%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.820%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.507%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.298%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.507%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.301%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Country&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Year ended&lt;br/&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Year ended&lt;br/&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Oxford University Innovation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;U.K.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.912%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.513%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.513%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.409%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Accounts Receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Country&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;As of&lt;br/&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;As of&lt;br/&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Oxford University Innovation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;U.K.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <brns:ConcentrationRiskThresholdPercentage contextRef="c-73" decimals="2" id="f-399" unitRef="number">1</brns:ConcentrationRiskThresholdPercentage>
    <brns:ConcentrationRiskThresholdPercentage contextRef="c-74" decimals="2" id="f-400" unitRef="number">0.98</brns:ConcentrationRiskThresholdPercentage>
    <brns:ConcentrationRiskThresholdPercentage contextRef="c-75" decimals="2" id="f-401" unitRef="number">0</brns:ConcentrationRiskThresholdPercentage>
    <brns:ConcentrationRiskThresholdPercentage contextRef="c-76" decimals="2" id="f-402" unitRef="number">0.94</brns:ConcentrationRiskThresholdPercentage>
    <us-gaap:CreditLossFinancialInstrumentPolicyTextBlock contextRef="c-1" id="f-403">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Allowance for credit losses&lt;/span&gt;&lt;/div&gt;The Company evaluates its cash equivalents and accounts receivable for expected credit losses. Expected credit losses represent the portion of the amortized cost basis of a financial asset that an entity does not expect to collect. An allowance for expected credit losses is meant to reflect a risk of loss even if remote, irrespective of the expectation of collection from a particular issuer or debt security. The Company has not historically experienced any credit losses on any of its financial assets.</us-gaap:CreditLossFinancialInstrumentPolicyTextBlock>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="c-22" decimals="-5" id="f-404" unitRef="usd">0</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="c-1" decimals="-5" id="f-405" unitRef="usd">0</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c-1" id="f-406">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Property and equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Property and equipment are stated at cost, net of accumulated depreciation. Expenditures for maintenance and repairs are charged to operating expenses as incurred, whereas major betterments are capitalized as additions to property and equipment. Depreciation is recorded using the straight-line method over the estimated useful lives of the assets as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.787%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.323%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.477%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Asset Category&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Estimated Useful Life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Office furniture and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Lesser of lease term or estimated useful lives&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c-1" id="f-407">Depreciation is recorded using the straight-line method over the estimated useful lives of the assets as follows:&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.787%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.323%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.477%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Asset Category&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Estimated Useful Life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Office furniture and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Lesser of lease term or estimated useful lives&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Property and equipment, net consists of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Office furniture and equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Property and equipment, at cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;15,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(3,688)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1,322)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;11,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-77" id="f-408">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-78" id="f-409">P4Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="c-1" id="f-410">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Intangible assets acquired through business combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Intangible assets consist of acquired developed technology. Intangible assets are stated at cost less accumulated amortization and impairment losses. Amortization is computed using the straight-line method over the estimated useful lives of the respective assets, which is 10 years.&lt;/span&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-79" id="f-411">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="c-1" id="f-412">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Impairment of long-lived assets&lt;/span&gt;&lt;/div&gt;The Company reviews long-lived assets to be held and used, including property and equipment, intangible assets and operating lease right-of-use assets, for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets or asset group may not be recoverable. Evaluation of recoverability is first based on an estimate of undiscounted future cash flows resulting from the use of the asset or asset group and its eventual disposition. In the event such cash flows are not expected to be sufficient to recover the carrying amount of the asset or asset group, the assets are written down to their estimated fair values.</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:AssetImpairmentCharges contextRef="c-22" decimals="-3" id="f-413" unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges contextRef="c-1" decimals="-3" id="f-414" unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy contextRef="c-1" id="f-415">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;Goodwill represents the excess of cost over the fair value of the net tangible and intangible assets of businesses acquired in a business combination. Goodwill is not amortized but rather is tested for impairment at least annually, or more frequently if events or changes in circumstances indicate that the carrying amount of goodwill may not be recoverable. The Company has elected to first assess the qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount as a basis of determining whether it is necessary to perform the quantitative goodwill impairment test. If the Company determines that it is more likely than not that its fair value is less than its carrying amount, then the quantitative goodwill impairment test will be performed. The quantitative goodwill impairment test identifies goodwill impairment and measures the amount of goodwill impairment loss to be recognized by comparing the fair value of a reporting unit with its carrying amount. If the fair value exceeds the carrying amount, no further analysis is required; otherwise, any excess of the goodwill carrying amount over the implied fair value is recognized as an impairment loss, and the carrying value of goodwill is written down to fair value.</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-1" decimals="-3" id="f-416" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-22" decimals="-3" id="f-417" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="c-1" id="f-418">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Financial instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company&#x2019;s financial instruments consist of cash and cash equivalents, accounts receivable, accounts payable, certain accrued expenses, contingent consideration and short-term debt. The carrying amounts of cash, cash equivalents, accounts receivable, security deposits, accounts payable, accrued expenses and short-term debt approximate their fair value due to the short-term nature of those financial instruments.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="c-1" id="f-419">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Fair value measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company follows the guidance in ASC 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Fair Value Measurements and Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, which defines fair value and establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are described below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;-&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.67pt"&gt;Level 1 &#x2013; Inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.67pt"&gt;Level 2 &#x2013; Valuations based on quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.67pt"&gt;Level 3 &#x2013; Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Fair value is a market-based measure considered from the perspective of a market participant rather than an entity-specific measure. Therefore, even when market assumptions are not readily available, the Company&#x2019;s own assumptions are set to reflect those that market participants would use in pricing the asset or liability at the measurement date. The Company uses prices and inputs that are current as of the measurement date, including during periods of market dislocation. In periods of market dislocation, the observability of prices and inputs may change for many instruments. This condition could cause an &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;instrument to be reclassified within levels in the fair value hierarchy. There were no transfers within the fair value hierarchy during the years ended December&#160;31, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company recognizes a contingent consideration liability related to the acquisition of Avidea Technologies, Inc. The liability is remeasured to fair value at each reporting date until the contingency is resolved. The fair value of the contingent consideration is a Level 3 valuation determined using significant unobservable inputs being the probability of success of achievement of the milestones and the expected date of the milestone achievement. Changes in fair value are recognized in general and administrative expenses in the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c-1" id="f-420">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Leases are accounted for under ASC 842, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Leases &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(&#x201c;ASC 842&#x201d;) resulting in the recognition of lease liabilities and right-of-use assets. The Company only has operating leases. The Company has elected the practical expedient allowed under ASC 842 to account for each lease component (e.g., the right to use office space) and the associated non-lease components (e.g., maintenance services) as a single lease component. The Company also elected the short-term lease accounting policy for all asset classes; therefore, the Company is not recognizing a lease liability or right-of-use asset for any lease that, at the commencement date, has a lease term of 12 months or less and does not include an option to purchase the underlying asset that the Company is reasonably certain to exercise.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Variable lease payments such as the Company&#x2019;s share of real estate taxes, utilities, and common area maintenance, are reported as non-lease operating expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Right-of-use assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. Right-of-use assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. As the Company&#x2019;s leases typically do not provide an implicit rate, the Company uses an estimate of its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Right-of-use assets also include the effect of any lease payments made and exclude lease incentives. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized as part of total operating expenses on a straight-line basis over the lease term. The difference between the value of the right of use asset and lease liability is due to the reclassification of prepaid rent and unamortized lease incentives.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c-1" id="f-421">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Research and development costs are expensed as incurred on an accruals basis. Research and development costs include payroll and personnel expense (including share-based compensation), consulting costs, external contract research and development expenses, raw materials, drug product manufacturing costs, and allocated overheads including depreciation and amortization, facility costs, and utilities. Research and development costs that are paid in advance of performance are capitalized as a prepaid expense and amortized over the service period as the services are provided.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <brns:ClinicalTrialCostsPolicyTextBlock contextRef="c-1" id="f-422">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Clinical trial costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Clinical trial costs are a component of research and development expenses. The Company accrues and expenses clinical trial activities performed by third parties based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activation, and other information provided to the Company by its vendors.&lt;/span&gt;&lt;/div&gt;</brns:ClinicalTrialCostsPolicyTextBlock>
    <us-gaap:IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend contextRef="c-1" id="f-423">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Patent and licensing costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Patent and licensing costs are expensed as incurred because their realization is uncertain.&lt;/span&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend>
    <us-gaap:StockholdersEquityPolicyTextBlock contextRef="c-1" id="f-424">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Ordinary shares&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Ordinary shares are classified in stockholders&#x2019; equity and represent issued share capital.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityPolicyTextBlock>
    <brns:AdditionalPaidInCapitalPolicyTextBlock contextRef="c-1" id="f-425">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Additional paid-in capital&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Additional paid-in capital is classified in stockholders&#x2019; equity and represents the share premium account, where the difference between the price paid per share and the nominal value is recognized. The equity element of share based compensation is also recognized in additional paid in capital.&lt;/span&gt;&lt;/div&gt;</brns:AdditionalPaidInCapitalPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c-1" id="f-426">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Share based compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company grants options over ordinary shares and restricted shares units to employees or Non-Executive Directors and accounts for share based compensation using the grant date fair value. Share based compensation awards are classified in the accompanying statements of operations based on the function to which the related services are provided. For service-based awards, compensation expense is generally recognized over the requisite service period of the awards, usually the vesting period. The Company applies the &#x201c;multiple option&#x201d; method of allocating expense. In applying this method, each vesting tranche of an award is treated as a separate grant and recognized on a straight-line basis over that tranche&#x2019;s vesting period. For performance-based awards where the vesting of the awards may be accelerated upon the achievement of certain milestones, vesting and the related share-based compensation is recognized as an expense when it is probable the milestone will be met. Assumptions used in the option pricing model include the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Expected volatility.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; Previously there was insufficient trading history for the Company&#x2019;s ordinary shares, therefore the expected price volatility for our ordinary shares was estimated using the average historical volatility of industry peers&#x2019; shares as of the grant date of our options over a period of history commensurate with the expected life of the options. When selecting industry peers used in measuring implied volatility, the Company considered the similarity of their products and business lines, as well as their stage of development, size and financial leverage. The Company applied this process consistently using the same or similar public companies until 2023. During 2023, the Company determined that there is sufficient historical information on volatility of its share price available and the expected volatility used in the fair value calculation of new option grants is calculated based on a blended volatility of both historical volatility of the Company's share price and the expected volatility of the average historical volatility of industry peers&#x2019; shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Expected term&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;. The expected term of the Company&#x2019;s share options has been determined utilizing the &#x201c;simplified&#x201d; method for awards that qualify as &#x201c;plain-vanilla&#x201d; options. The &#x201c;simplified&#x201d; method was determined to be appropriate as the Company does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term due to the limited period of time its equity shares have been publicly traded.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Risk-free interest rate&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods that are approximately equal to the expected term of the award.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Expected dividend.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; Expected dividend yield of zero is based on the fact that the Company has never paid cash dividends on ordinary shares and does not expect to pay any cash dividends in the foreseeable future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company has elected to recognize the effect of forfeitures on share-based compensation when they occur. Any differences in compensation recognized at the time of forfeiture are recorded as a cumulative adjustment in the period where the forfeiture occurs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;When awards are modified, the Company compares the fair value of the affected award measured immediately prior to modification to its value after modification. To the extent that the fair value of the modified award exceeds the original award, the incremental fair value of the modified award is recognized as compensation on the date of modification for vested awards, and over the remaining vesting period for unvested awards.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-22"
      decimals="INF"
      id="f-427"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-1" decimals="INF" id="f-428" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:RegulatoryIncomeTaxesPolicy contextRef="c-1" id="f-429">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Income taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The financial statements reflect provisions for income taxes in the United Kingdom and foreign jurisdictions. Deferred tax assets and liabilities represent future tax consequences of temporary differences between the financial statement carrying amounts and the tax basis of assets and liabilities and for loss carryforwards using enacted tax rates expected to be in effect in the years in which the differences reverse. A valuation allowance is recorded when it is more likely than not that some or all of the deferred tax assets will not be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company determines whether it is more likely than not that a tax position will be sustained upon examination. If it is not more likely than not that a position will be sustained, none of the benefit attributable to the position is recognized. The &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;tax benefit to be recognized for any tax position that meets the more-likely-than-not recognition threshold is calculated as the largest amount that is more than 50% likely of being realized upon resolution of the contingency. The Company accounts for interest and penalties related to uncertain tax positions as part of its provision for income taxes. To date, the Company has not incurred interest and penalties related to uncertain tax positions nor has it recorded any unrecognized tax benefits.&lt;/span&gt;&lt;/div&gt;</us-gaap:RegulatoryIncomeTaxesPolicy>
    <brns:ResearchAndDevelopmentIncentivesPolicyTextBlock contextRef="c-1" id="f-430">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Research and development incentives&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In the United Kingdom, the Company had previously been entitled to a research and development tax credit regime, being the Small and Medium-sized Enterprises R&amp;amp;D tax relief program, or SME Program, and, to the extent that our projects are grant funded or relate to work subcontracted to us by third parties, the Research and Development Expenditure Credit program, or RDEC Program. Until March 2023, under the SME program, the Company was able to surrender some of its trading losses that arise from qualifying research and development activities for a cash rebate of up to 33.35% of such qualifying research and development expenditure. Qualifying expenditures largely comprise employment costs for research staff, consumables, outsourced contract research organization costs and utilities costs incurred as part of research projects. Certain staff, consumables (including utilities), subcontractors and externally provided workers qualifying research and development expenditures are eligible for a cash rebate of up to 21.67%. A large portion of costs relating to research and development, clinical trials and manufacturing activities are eligible for inclusion within these tax credit cash rebate claims. From April 2023, under the SME program the additional deduction has decreased from 130% to 86%, the SME credit rate has reduced from 14.5% to 10% and the SME cash rebate for the Company has reduced from 33.35% to 18.6% and from 21.67% to 12.1% for subcontractors. Furthermore, the SME credit rate will decrease to 10% for expenditure incurred on or after April 1, 2023 unless the SME qualifies as an R&amp;amp;D intensive business i.e., R&amp;amp;D expenditure constitutes at least 40% (from April 1, 2023) or 30% (from accounting periods starting on or after April 1, 2024) of total expenditure. If the Company incurs tax losses, the Company is entitled to surrender the lesser of unrelieved tax loss sustained and the tax relief. As the realization of the tax relief does not depend on our generation of future taxable income or the Company&#x2019;s ongoing tax status or tax position, the Company does not consider the tax relief as an element of income tax accounting under ASC 740, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Income taxes &lt;/span&gt;and records the tax relief as a form of government grant or assistance. For the years ended December&#160;31, 2023 and 2022, the Company recognized research and development incentives of $3.5 million and $1.2 million respectively.</brns:ResearchAndDevelopmentIncentivesPolicyTextBlock>
    <brns:ResearchAndDevelopmentIncentiveIncomeExpense contextRef="c-1" decimals="-5" id="f-431" unitRef="usd">3500000</brns:ResearchAndDevelopmentIncentiveIncomeExpense>
    <brns:ResearchAndDevelopmentIncentiveIncomeExpense contextRef="c-22" decimals="-5" id="f-432" unitRef="usd">1200000</brns:ResearchAndDevelopmentIncentiveIncomeExpense>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c-1" id="f-433">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Net (loss)/income per share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Basic net (loss)/income per share is computed by dividing the net (loss)/income attributable to ordinary shareholders by the weighted-average number of ordinary shares outstanding for the reporting period without consideration for potentially dilutive securities. Net (loss)/income attributable to ordinary shareholders is computed as if all net (loss)/income for the period had been distributed. During periods in which the Company incurred a net loss, the Company allocates no net loss to participating securities because they do not have a contractual obligation to share in the net loss of the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company computes diluted net (loss)/income per ordinary share after giving consideration to all potentially dilutive ordinary equivalents, including stock options outstanding during the period, except where the effect of such non-participating securities would be antidilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Diluted net (loss)/income per share is computed by dividing the net (loss)/income attributable to ordinary shareholders by the weighted-average number of ordinary shares and dilutive ordinary share equivalents outstanding for the period, determined using the treasury-stock and if-converted methods.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ContingentLiabilityReserveEstimatePolicy contextRef="c-1" id="f-434">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Contingent liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;A provision for contingent liabilities is recorded when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. With respect to legal matters, provisions are reviewed and adjusted to reflect the impact of negotiations, estimated settlements, legal rulings, advice of legal counsel and other information and events pertaining to a particular matter. The Company is a party to certain litigation and disputes arising in the normal course of business. As of December&#160;31, 2023, the Company does not expect that such matters will have a material adverse effect on the Company&#x2019;s business, financial position, results of operations, or cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:ContingentLiabilityReserveEstimatePolicy>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-435">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;From time to time, new accounting pronouncements are issued by FASB or other standard setting bodies that the Company adopts as of the specified effective date. The Company qualifies as an &#x201c;emerging growth company&#x201d; as defined in the Jumpstart Our Business Startups Act of 2012 and has elected not to &#x201c;opt out&#x201d; of the extended transition related to complying with new or revised accounting standards, which means that when a standard is issued or revised and it has different applications dates for public and nonpublic companies, the Company can adopt the new or revised standard at the time nonpublic companies adopt the new or revised standard and can do so until such time the Company either (i) irrevocably elects to &#x201c;opt out&#x201d; of such extended transition period or (ii) no longer qualifies as an emerging growth company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;We have reviewed all recently issued standards and have determined that such standards will not have a material impact on our consolidated financial statements or do not otherwise apply to our current operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:ForeignCurrencyDisclosureTextBlock contextRef="c-1" id="f-436">Foreign Currency Translation in General and Administrative Expenses&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The aggregate, net foreign exchange gain or loss included in determining net (loss)/income recognized in general and administrative expenses for the year ended December&#160;31, 2023, and 2022, was a loss of $7.6&#160;million and a gain of $26.4&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyDisclosureTextBlock>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="c-1" decimals="-5" id="f-437" unitRef="usd">-7600000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="c-22" decimals="-5" id="f-438" unitRef="usd">26400000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:EarningsPerShareTextBlock contextRef="c-1" id="f-439">Net (Loss)/Income Per Share&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table sets forth the computation of basic and diluted net (loss)/income per share for the years ended December&#160;31, 2023 and 2022 (in thousands, except number of shares and per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Net (loss)/income &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(73,447)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Net loss attributable to noncontrolling interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Net (loss)/income attributable to Barinthus Biotherapeutics plc shareholders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(73,347)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Weighted-average ordinary shares outstanding, basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;38,386,491&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;37,248,126&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Effect of dilutive stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;921,181&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Weighted-average ordinary shares outstanding, diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;38,386,491&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;38,169,307&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Net (loss)/income per share attributable to ordinary shareholders, basic&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1.91)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Net (loss)/income per share attributable to ordinary shareholders, diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1.91)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Since the Company was in a loss position for 2023, basic net loss per share is the same as diluted net loss per share, as the inclusion of all potential ordinary share equivalents outstanding would have been anti-dilutive. For the year ended December&#160;31, 2023, 6,207,664 potential ordinary shares issuable for stock options were excluded from the computation of diluted weighted-average shares outstanding because including them would have had an anti-dilutive effect. For the year ended December 31, 2022, 2,912,756 potential ordinary shares issuable for stock options, respectively, were excluded from the computation of diluted weighted-average shares outstanding because including them would have had an anti-dilutive effect.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c-1" id="f-440">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table sets forth the computation of basic and diluted net (loss)/income per share for the years ended December&#160;31, 2023 and 2022 (in thousands, except number of shares and per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Net (loss)/income &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(73,447)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Net loss attributable to noncontrolling interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Net (loss)/income attributable to Barinthus Biotherapeutics plc shareholders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(73,347)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Weighted-average ordinary shares outstanding, basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;38,386,491&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;37,248,126&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Effect of dilutive stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;921,181&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Weighted-average ordinary shares outstanding, diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;38,386,491&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;38,169,307&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Net (loss)/income per share attributable to ordinary shareholders, basic&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1.91)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Net (loss)/income per share attributable to ordinary shareholders, diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1.91)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-3" id="f-441" unitRef="usd">-73447000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-22" decimals="-3" id="f-442" unitRef="usd">5321000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-443" unitRef="usd">-100000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-22" decimals="-3" id="f-444" unitRef="usd">-21000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-445" unitRef="usd">-73347000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-22" decimals="-3" id="f-446" unitRef="usd">5342000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="0" id="f-447" unitRef="shares">38386491</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-22" decimals="0" id="f-448" unitRef="shares">37248126</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c-1" decimals="0" id="f-449" unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c-22" decimals="0" id="f-450" unitRef="shares">921181</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="0" id="f-451" unitRef="shares">38386491</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-22" decimals="0" id="f-452" unitRef="shares">38169307</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-453"
      unitRef="usdPerShare">-1.91</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-22"
      decimals="2"
      id="f-454"
      unitRef="usdPerShare">0.14</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-455"
      unitRef="usdPerShare">-1.91</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-22"
      decimals="2"
      id="f-456"
      unitRef="usdPerShare">0.14</us-gaap:EarningsPerShareDiluted>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-1" decimals="0" id="f-457" unitRef="shares">6207664</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-22" decimals="0" id="f-458" unitRef="shares">2912756</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c-1" id="f-459">Property and Equipment, Net&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Property and equipment, net consists of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Office furniture and equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Property and equipment, at cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;15,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(3,688)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1,322)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;11,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Depreciation expense for the year ended December&#160;31, 2023 was $2.3 million (December&#160;31, 2022: $1.1 million).&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-77" decimals="-3" id="f-460" unitRef="usd">1108000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-80" decimals="-3" id="f-461" unitRef="usd">1041000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-78" decimals="-3" id="f-462" unitRef="usd">5728000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-81" decimals="-3" id="f-463" unitRef="usd">4312000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-82" decimals="-3" id="f-464" unitRef="usd">8673000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-83" decimals="-3" id="f-465" unitRef="usd">3926000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-6" decimals="-3" id="f-466" unitRef="usd">15509000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-7" decimals="-3" id="f-467" unitRef="usd">9279000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-6" decimals="-3" id="f-468" unitRef="usd">3688000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-7" decimals="-3" id="f-469" unitRef="usd">1322000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-6" decimals="-3" id="f-470" unitRef="usd">11821000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-7" decimals="-3" id="f-471" unitRef="usd">7957000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation contextRef="c-1" decimals="-5" id="f-472" unitRef="usd">2300000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-22" decimals="-5" id="f-473" unitRef="usd">1100000</us-gaap:Depreciation>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="c-1" id="f-474">Intangible assets, net&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The gross amount of amortizable intangible assets, consisting of acquired developed technology, was $31.6 million at both December&#160;31, 2023 and 2022 and accumulated amortization was $6.5 million and $3.3 million as of December&#160;31, 2023 and 2022, respectively. The amortization expense for the year ended December&#160;31, 2023 was $3.2 million (December&#160;31, 2022: $3.2 million). The estimated annual amortization expense is $3.2 million for the years 2024 through to 2031.&lt;/span&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-79" decimals="-5" id="f-475" unitRef="usd">31600000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-84" decimals="-5" id="f-476" unitRef="usd">31600000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-79" decimals="-5" id="f-477" unitRef="usd">6500000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-84" decimals="-5" id="f-478" unitRef="usd">3300000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-1" decimals="-5" id="f-479" unitRef="usd">3200000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-22" decimals="-5" id="f-480" unitRef="usd">3200000</us-gaap:AmortizationOfIntangibleAssets>
    <brns:FiniteLivedIntangibleAssetExpectedAmortizationYearEight contextRef="c-6" decimals="-5" id="f-481" unitRef="usd">3200000</brns:FiniteLivedIntangibleAssetExpectedAmortizationYearEight>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="c-6" decimals="-5" id="f-482" unitRef="usd">3200000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="c-6" decimals="-5" id="f-483" unitRef="usd">3200000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="c-6" decimals="-5" id="f-484" unitRef="usd">3200000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="c-6" decimals="-5" id="f-485" unitRef="usd">3200000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <brns:FiniteLivedIntangibleAssetExpectedAmortizationYearSeven contextRef="c-6" decimals="-5" id="f-486" unitRef="usd">3200000</brns:FiniteLivedIntangibleAssetExpectedAmortizationYearSeven>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="c-6" decimals="-5" id="f-487" unitRef="usd">3200000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <brns:FiniteLivedIntangibleAssetExpectedAmortizationYearSix contextRef="c-6" decimals="-5" id="f-488" unitRef="usd">3200000</brns:FiniteLivedIntangibleAssetExpectedAmortizationYearSix>
    <brns:PrepaidExpenseAndOtherAssetsCurrentTextBlock contextRef="c-1" id="f-489">Prepaid and other current assets&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Prepaid and other current assets consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Prepayments and accrued income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Value Added Tax receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Lease incentives receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</brns:PrepaidExpenseAndOtherAssetsCurrentTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock contextRef="c-1" id="f-490">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Prepaid and other current assets consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Prepayments and accrued income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Value Added Tax receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Lease incentives receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <us-gaap:PrepaidExpenseCurrent contextRef="c-6" decimals="-3" id="f-491" unitRef="usd">5402000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="c-7" decimals="-3" id="f-492" unitRef="usd">5887000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:ValueAddedTaxReceivableCurrent contextRef="c-6" decimals="-3" id="f-493" unitRef="usd">3031000</us-gaap:ValueAddedTaxReceivableCurrent>
    <us-gaap:ValueAddedTaxReceivableCurrent contextRef="c-7" decimals="-3" id="f-494" unitRef="usd">0</us-gaap:ValueAddedTaxReceivableCurrent>
    <brns:LeaseIncentiveReceivablesCurrent contextRef="c-6" decimals="-3" id="f-495" unitRef="usd">0</brns:LeaseIncentiveReceivablesCurrent>
    <brns:LeaseIncentiveReceivablesCurrent contextRef="c-7" decimals="-3" id="f-496" unitRef="usd">1770000</brns:LeaseIncentiveReceivablesCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c-6" decimals="-3" id="f-497" unitRef="usd">1474000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c-7" decimals="-3" id="f-498" unitRef="usd">611000</us-gaap:OtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-6" decimals="-3" id="f-499" unitRef="usd">9907000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-7" decimals="-3" id="f-500" unitRef="usd">8268000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <brns:AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock contextRef="c-1" id="f-501">Accrued Expenses and Other Current Liabilities&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Accrued expenses and other current liabilities consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Accrued manufacturing and clinical expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Accrued bonus&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Accrued payroll and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Accrued professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Accrued other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</brns:AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock>
    <brns:AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock contextRef="c-1" id="f-502">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Accrued expenses and other current liabilities consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Accrued manufacturing and clinical expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Accrued bonus&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Accrued payroll and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Accrued professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Accrued other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</brns:AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock>
    <brns:AccruedManufacturingAndClinicalExpensesCurrent contextRef="c-6" decimals="-3" id="f-503" unitRef="usd">4003000</brns:AccruedManufacturingAndClinicalExpensesCurrent>
    <brns:AccruedManufacturingAndClinicalExpensesCurrent contextRef="c-7" decimals="-3" id="f-504" unitRef="usd">2997000</brns:AccruedManufacturingAndClinicalExpensesCurrent>
    <us-gaap:AccruedBonusesCurrent contextRef="c-6" decimals="-3" id="f-505" unitRef="usd">2412000</us-gaap:AccruedBonusesCurrent>
    <us-gaap:AccruedBonusesCurrent contextRef="c-7" decimals="-3" id="f-506" unitRef="usd">1925000</us-gaap:AccruedBonusesCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent contextRef="c-6" decimals="-3" id="f-507" unitRef="usd">789000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent contextRef="c-7" decimals="-3" id="f-508" unitRef="usd">928000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="c-6" decimals="-3" id="f-509" unitRef="usd">942000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="c-7" decimals="-3" id="f-510" unitRef="usd">1270000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-6" decimals="-3" id="f-511" unitRef="usd">1066000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-7" decimals="-3" id="f-512" unitRef="usd">941000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <brns:AccruedLiabilitiesAndOtherLiabilitiesCurrent contextRef="c-6" decimals="-3" id="f-513" unitRef="usd">9212000</brns:AccruedLiabilitiesAndOtherLiabilitiesCurrent>
    <brns:AccruedLiabilitiesAndOtherLiabilitiesCurrent contextRef="c-7" decimals="-3" id="f-514" unitRef="usd">8061000</brns:AccruedLiabilitiesAndOtherLiabilitiesCurrent>
    <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="c-1" id="f-515">Out-licenses and Grants&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;OUI license&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In April 2020, the Company entered into an Amendment, Assignment and Revenue Sharing Agreement (&#x201c;License Agreement Amendment&#x201d;) with Oxford University Innovation, or OUI, which vested and assigned all intellectual property rights in relation to any ChAdOx1 or ChAdOx2 vector-based vaccine jointly owned by the Company and OUI in order to facilitate the license of vaccines based on the ChAdOx1 by OUI to AstraZeneca plc (&#x201c;AstraZeneca&#x201d;). Under this agreement, the Company is entitled to receive from OUI a share of all payments received by OUI from AstraZeneca in respect of the vaccine based on the ChAdOx1. On December 30, 2020, AstraZeneca announced that vaccine based on the ChAdOx1 which we refer to as Vaxzevria had been approved for emergency supply in the United Kingdom by the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company determined that the intellectual property vested and assigned under the License Agreement Amendment is a functional intellectual property (that is, it has significant standalone functionality in the form of its ability to treat a disease or condition) and there is no expectation under the License Agreement Amendment that the Company will undertake activities to change the functionality. Consequently, the Company concluded that the nature of the Company&#x2019;s promise in transferring the intellectual property is to provide a right to use the Company&#x2019;s functional intellectual property. Accordingly, the Company recognizes revenue in manner that depicts the Company&#x2019;s progress toward satisfying its performance obligation of providing access to its intellectual property throughout the license period based on the terms of OUI&#x2019;s agreement with AstraZeneca.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On March&#160;28, 2022, pursuant to the OUI License Agreement Amendment, we were notified of the commencement of payments, arising from AstraZeneca&#x2019;s commercial sales of Vaxzevria. Under the terms of an exclusive worldwide license agreement between OUI and AstraZeneca, OUI is entitled to milestone payments and royalties on commercial sales of Vaxzevria that began after the pandemic period. As part of the assignment from us to OUI, we are entitled to receive approximately 24% of payments received by OUI from AstraZeneca. For the year ended December&#160;31, 2023, the Company recognized approximately $0.8 million as revenue (year ended December&#160;31, 2022: $43.7 million) and had an outstanding receivable of nil as of December&#160;31, 2023 (2022: $5.5 million). There is no guarantee that further payments will be received pursuant to the agreement in the future and, if such payments are made, that we will be notified of such payments in a timely manner.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Scancell contract&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On November 2, 2022, the Company entered into an agreement with Scancell to grant a research and development license, consisting of upfront and development milestone and royalty payments, for the development and commercialization of the SNAPvax functional intellectual property. The Company recognized non-refundable upfront revenue, amounting to nil for the year ended December 31, 2023 (December 31, 2022: $0.7 million). As of December&#160;31, 2023, nil was recorded as a receivable (December 31, 2022: $0.3&#160;million). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Coalition for Epidemic Preparedness Innovations (&#x201c;CEPI&#x201d;) Funding Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 20, 2023, Barinthus Biotherapeutics (UK) Limited (the &#x201c;Company&#x201d;), the Chancellors, Masters and Scholars of the University of Oxford (&#x201c;Oxford,&#x201d; together with the Company, the &#x201c;Partners&#x201d;) and the Coalition for Epidemic Preparedness Innovations (&#x201c;CEPI&#x201d;) entered into a Funding Agreement (the &#x201c;Funding Agreement&#x201d;) pursuant to which CEPI will provide funding of up to $34.8 million to the Company to advance the development of VTP-500, the Company&#x2019;s vaccine candidate against Middle East Respiratory Syndrome (&#x201c;MERS,&#x201d; and such development activities, the &#x201c;Project&#x201d;). In December 2023, VTP-500 received PRIME (PRIority MEdicines) designation by the European Medicines Agency. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the Funding Agreement, the Company has agreed to pay CEPI on a country-by-country basis increasing mid-single digit percentage royalties of net sales and net income with respect to future cash sales of VTP-500, less certain deductions, for a period starting on December 20, 2023 (&#x201c;Effective Date&#x201d;) and ending the later of: (i) the expiration of the last valid patent claim included in intellectual property developed under the Project covering VTP-500 in such country, (ii) the expiration of Regulatory Exclusivity (as defined in the Funding Agreement) for VTP-500 in such country, and (iii) the tenth (10th) anniversary of the first commercial sale of VTP-500 (the &#x201c;Royalty Term&#x201d;). The Company shall also pay CEPI a mid-double digit percentage of net revenue earned on VTP-500 until CEPI has received payments from the Company under the Funding Agreement equaling the total amount of funding paid by CEPI to the Company and a low double-digit percentage of such net revenue thereafter. Sales for the benefit of end users in specified low and middle income countries &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(&#x201c;LMICs&#x201d;) and upper and middle income countries (&#x201c;UMICs&#x201d;) are excluded from the calculations of net sales and net revenue. Sales of product for the benefit of end users in LMICs and UMICs are subject to tiered discounted pricing requirements under the Funding Agreement. The Company is further required to pay a mid-double digit percentage of any proceeds earned on any priority review voucher related to VTP-500 during the Royalty Period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;For the year ended December&#160;31, 2023, no proceeds have been received and no income has been recognized in relation to this contract as no activities eligible for the funding were undertaken during the period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Contract assets and liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company discloses accounts receivable separately in the consolidated balance sheets at the net amount expected to be collected. Contract assets primarily relate to the Company&#x2019;s conditional right to consideration for work completed but not billed at the reporting date. As of December&#160;31, 2023 and 2022 the Company did not have any contract assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Contract liabilities primarily relate to payments received from customers in advance of performance under the contract and are disclosed as deferred revenue separately in the consolidated balance sheets. The Company&#x2019;s contract liabilities arise when payment is received upfront for various multi-period extended license and service arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Changes in the contract liabilities during the years ended December&#160;31, 2023 and 2022, are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.112%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.620%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Revenue recognized related to contract liability balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(158)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Foreign exchange translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <brns:PercentageOfRoyaltiesOnNetSales contextRef="c-85" decimals="2" id="f-516" unitRef="number">0.24</brns:PercentageOfRoyaltiesOnNetSales>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-86" decimals="-5" id="f-517" unitRef="usd">800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-87" decimals="-5" id="f-518" unitRef="usd">43700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-88" decimals="-5" id="f-519" unitRef="usd">0</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-89" decimals="-5" id="f-520" unitRef="usd">5500000</us-gaap:AccountsReceivableNetCurrent>
    <brns:ContractWithCustomerLiabilityRevenueRecognized1 contextRef="c-90" decimals="-5" id="f-521" unitRef="usd">0</brns:ContractWithCustomerLiabilityRevenueRecognized1>
    <brns:ContractWithCustomerLiabilityRevenueRecognized1 contextRef="c-91" decimals="-5" id="f-522" unitRef="usd">700000</brns:ContractWithCustomerLiabilityRevenueRecognized1>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-92" decimals="-5" id="f-523" unitRef="usd">0</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-93" decimals="-5" id="f-524" unitRef="usd">300000</us-gaap:AccountsReceivableNetCurrent>
    <brns:FundingAmountMaximum contextRef="c-94" decimals="-5" id="f-525" unitRef="usd">34800000</brns:FundingAmountMaximum>
    <brns:RoyaltyPaymentTermMaximum contextRef="c-95" id="f-526">P10Y</brns:RoyaltyPaymentTermMaximum>
    <brns:ProceedsFromGrantsReceived contextRef="c-96" decimals="-5" id="f-527" unitRef="usd">0</brns:ProceedsFromGrantsReceived>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-96" decimals="-5" id="f-528" unitRef="usd">0</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <brns:ContractWithCustomerLiabilitiesTableTextBlock contextRef="c-1" id="f-529">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Changes in the contract liabilities during the years ended December&#160;31, 2023 and 2022, are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.112%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.620%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Revenue recognized related to contract liability balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(158)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Foreign exchange translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</brns:ContractWithCustomerLiabilitiesTableTextBlock>
    <us-gaap:ContractWithCustomerLiability contextRef="c-7" decimals="-3" id="f-530" unitRef="usd">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability contextRef="c-60" decimals="-3" id="f-531" unitRef="usd">182000</us-gaap:ContractWithCustomerLiability>
    <brns:ContractWithCustomerLiabilityRevenueRecognized1 contextRef="c-1" decimals="-3" id="f-532" unitRef="usd">0</brns:ContractWithCustomerLiabilityRevenueRecognized1>
    <brns:ContractWithCustomerLiabilityRevenueRecognized1 contextRef="c-22" decimals="-3" id="f-533" unitRef="usd">158000</brns:ContractWithCustomerLiabilityRevenueRecognized1>
    <brns:ContractWithCustomerLiabilityForeignExchangeTranslation contextRef="c-1" decimals="-3" id="f-534" unitRef="usd">0</brns:ContractWithCustomerLiabilityForeignExchangeTranslation>
    <brns:ContractWithCustomerLiabilityForeignExchangeTranslation contextRef="c-22" decimals="-3" id="f-535" unitRef="usd">-24000</brns:ContractWithCustomerLiabilityForeignExchangeTranslation>
    <us-gaap:ContractWithCustomerLiability contextRef="c-6" decimals="-3" id="f-536" unitRef="usd">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability contextRef="c-7" decimals="-3" id="f-537" unitRef="usd">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-538">Ordinary Shares&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On May&#160;4, 2021, the Company closed its initial public offering (&#x201c;IPO&#x201d;) of 6,500,000 ADS representing 6,500,000 ordinary shares having a nominal value of &#xa3;0.000025 per share, at a public offering price of $17.00 per share, for aggregate net proceeds of $102.8 million after deducting underwriting commissions of $7.7 million and incurred offering costs of $2.2 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;All ordinary shares rank pari passu as a single class. The following is a summary of the rights and privileges of the holders of ordinary shares as of December&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Liquidation preference:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; In the event of the liquidation, dissolution or winding up of the Company, the assets of the Company available for distribution to holders of the ordinary shares shall be distributed amongst all holders of the ordinary shares in proportion to the number of shares held irrespective of the amount paid or credited as paid on any share.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Dividends:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; Holders of the ordinary shares are entitled to dividends, as may be recommended from time to time by the Board and declared by the ordinary shareholders out of legally available funds.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Voting Rights:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; Each holder of ordinary shares is entitled to one vote for each share on all matters to be voted on by ordinary shareholders.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Preemption rights:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; Pursuant to section 561 of the Companies Act 2006, shareholders are granted preemptive rights when new shares are issued for cash. However, it is possible for our Articles, or shareholders at a general meeting representing at least 75% of our ordinary shares present (in person or by proxy) and eligible to vote at that general meeting, to disapply these preemptive rights. Such a disapplication of preemption rights may be for a maximum period of up to five years from the date of the shareholder special resolution. In either case, this disapplication would need to be renewed by our shareholders upon its expiration (i.e., at least every five years) to remain effective.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On April&#160;21, 2021, our shareholders approved the disapplication of preemptive rights for a period of five years from the date of approval by way of a special resolution of our shareholders. This included the disapplication of preemption rights in relation to the allotment of our ordinary shares in connection with the IPO. This disapplication will need to be renewed upon expiration (i.e., at least every five years) to remain effective, but may be sought more frequently for additional five-year terms (or any shorter period).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On November 6, 2023, we held a general meeting where our shareholders approved resolutions granting our board of directors or any duly authorized committee of the board of directors the authority to allot shares in the Company or grant rights to subscribe for or to convert any security into shares in the Company free from preemption rights. Pursuant to such approval, our board of directors was authorized to allot shares up to an aggregate nominal amount of &#xa3;1,928 free from statutory preemption rights.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of December&#160;31, 2023, the Company has reserved the following ordinary shares for future issuance:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Exercise of stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,207,664&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Shares available for future stock incentive plan awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,623,840&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,831,504&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <brns:NumberOfAmericanDepositarySharesAdsIssued
      contextRef="c-97"
      decimals="INF"
      id="f-539"
      unitRef="shares">6500000</brns:NumberOfAmericanDepositarySharesAdsIssued>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-98"
      decimals="INF"
      id="f-540"
      unitRef="shares">6500000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-98"
      decimals="INF"
      id="f-541"
      unitRef="gbpPerShare">0.000025</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-98"
      decimals="2"
      id="f-542"
      unitRef="usdPerShare">17.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-97" decimals="-5" id="f-543" unitRef="usd">102800000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <brns:IssuanceOfCommonStockUnderwritingCommissions contextRef="c-97" decimals="-5" id="f-544" unitRef="usd">7700000</brns:IssuanceOfCommonStockUnderwritingCommissions>
    <brns:IssuanceOfCommonStockOfferingCosts contextRef="c-97" decimals="-5" id="f-545" unitRef="usd">2200000</brns:IssuanceOfCommonStockOfferingCosts>
    <brns:CommonStockNumberOfVotesPerShare contextRef="c-6" decimals="INF" id="f-546" unitRef="vote">1</brns:CommonStockNumberOfVotesPerShare>
    <brns:PercentageOfSharesNecessaryToExercisePreemptiveRights contextRef="c-6" decimals="2" id="f-547" unitRef="number">0.75</brns:PercentageOfSharesNecessaryToExercisePreemptiveRights>
    <brns:PeriodOfPreemptiveRightsToBeExercised contextRef="c-1" id="f-548">P5Y</brns:PeriodOfPreemptiveRightsToBeExercised>
    <brns:PeriodOfPreemptiveRightsToBeExercised contextRef="c-99" id="f-549">P5Y</brns:PeriodOfPreemptiveRightsToBeExercised>
    <brns:PeriodOfPreemptiveRightsToBeExercised contextRef="c-100" id="f-550">P5Y</brns:PeriodOfPreemptiveRightsToBeExercised>
    <brns:PeriodOfPreemptiveRightsToBeExercised contextRef="c-100" id="f-551">P5Y</brns:PeriodOfPreemptiveRightsToBeExercised>
    <brns:PeriodOfPreemptiveRightsToBeExercised contextRef="c-100" id="f-552">P5Y</brns:PeriodOfPreemptiveRightsToBeExercised>
    <brns:MaximumAggregateNominalAmountOfSharesAuthorizedToBeAllottedFreeFromStatutoryPreEmptionRights contextRef="c-101" decimals="0" id="f-553" unitRef="gbp">1928</brns:MaximumAggregateNominalAmountOfSharesAuthorizedToBeAllottedFreeFromStatutoryPreEmptionRights>
    <brns:ScheduleOfOrdinarySharesReservedForFutureIssuanceTableTextBlock contextRef="c-1" id="f-554">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of December&#160;31, 2023, the Company has reserved the following ordinary shares for future issuance:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Exercise of stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,207,664&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Shares available for future stock incentive plan awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,623,840&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,831,504&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</brns:ScheduleOfOrdinarySharesReservedForFutureIssuanceTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-6" decimals="INF" id="f-555" unitRef="shares">6207664</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="c-6" decimals="INF" id="f-556" unitRef="shares">1623840</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="c-6" decimals="INF" id="f-557" unitRef="shares">7831504</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <brns:StockholdersEquityDeferredSharesDisclosureTextBlock contextRef="c-1" id="f-558">Deferred shares&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;All deferred shares rank pari passu as a single class. The deferred shares do not have rights to dividends or to participate in profits on a return of assets on liquidation, the deferred shares confer on the holders thereof an entitlement to receive out of the assets of the Company available for distribution amongst the shareholders (subject to the rights of any new class of shares with preferred rights) the amount credited as paid up on the deferred shares held by them respectively after (but only after) payment shall have been made to the holders of the ordinary shares of the amounts paid up or credited as paid up on such shares and the sum of &#xa3;1.0 million ($1.4 million) in respect of each ordinary share held by them respectively. The deferred shares shall confer on the holders thereof no further right to participate in the assets of the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On March 29, 2023, all deferred B shares (nominal value of &#xa3;0.01 each) and deferred C shares (nominal value of &#xa3;0.00000736245954692556 each) previously in issue were transferred back to the Company and subsequently cancelled. These deferred shares had previously been issued to certain pre-IPO shareholders in connection with the implementation of certain stages of the Company&#x2019;s pre-IPO share capital reorganization. The Company received shareholder pre-approval on April 21, 2021 (pursuant to the shareholder resolutions passed on that date) in order to effect the transfer back and cancellation of the deferred shares for nil consideration in accordance with sections 659 and 662 of the Companies Act 2006.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s deferred A shares with a nominal value of &#xa3;1.00 each remain in issue for the purposes of satisfying the minimum share capital requirements for a public limited company as prescribed by the Companies Act 2006.&lt;/span&gt;&lt;/div&gt;</brns:StockholdersEquityDeferredSharesDisclosureTextBlock>
    <brns:OrdinarySharesLiquidationPreference contextRef="c-13" decimals="-5" id="f-559" unitRef="gbp">1000000</brns:OrdinarySharesLiquidationPreference>
    <brns:OrdinarySharesLiquidationPreference contextRef="c-13" decimals="-5" id="f-560" unitRef="usd">1400000</brns:OrdinarySharesLiquidationPreference>
    <brns:DeferredStockParOrStatedValuePerShare
      contextRef="c-102"
      decimals="INF"
      id="f-561"
      unitRef="gbpPerShare">0.01</brns:DeferredStockParOrStatedValuePerShare>
    <brns:DeferredStockParOrStatedValuePerShare
      contextRef="c-103"
      decimals="INF"
      id="f-562"
      unitRef="gbpPerShare">0.00000736245954692556</brns:DeferredStockParOrStatedValuePerShare>
    <brns:DeferredStockParOrStatedValuePerShare
      contextRef="c-13"
      decimals="INF"
      id="f-563"
      unitRef="gbpPerShare">1.00</brns:DeferredStockParOrStatedValuePerShare>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c-1" id="f-564">Fair Value&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company&#x2019;s financial instruments consist of cash and cash equivalents, accounts receivable, accounts payable, certain accrued expenses, contingent consideration and short-term debt. The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable, certain accrued expenses, contingent consideration and short-term debt approximated their respective fair value due to the short-term nature and maturity of these instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of December&#160;31, 2023, the Company had a contingent consideration liability of $1.8 million related to the acquisition of Avidea Technologies, Inc. The fair value of the contingent consideration is a Level 3 valuation with the significant &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;unobservable inputs being the probability of success of achievement of the milestones and the expected date of the milestone achievement. Significant judgment is employed in determining the appropriateness of certain of these inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table summarizes changes in the fair value of Contingent Consideration (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Year ended December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Year ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Change in fair value recognized in net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(73)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Settlement of contingency&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(163)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(325)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Foreign exchange translation recognized in other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(262)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-104" decimals="-5" id="f-565" unitRef="usd">1800000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="c-1" id="f-566">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table summarizes changes in the fair value of Contingent Consideration (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Year ended December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Year ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Change in fair value recognized in net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(73)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Settlement of contingency&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(163)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(325)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Foreign exchange translation recognized in other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(262)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-105" decimals="-3" id="f-567" unitRef="usd">1711000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-106" decimals="-3" id="f-568" unitRef="usd">2371000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="c-107" decimals="-3" id="f-569" unitRef="usd">-55000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="c-108" decimals="-3" id="f-570" unitRef="usd">73000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements contextRef="c-107" decimals="-3" id="f-571" unitRef="usd">163000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements contextRef="c-108" decimals="-3" id="f-572" unitRef="usd">325000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <brns:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeTranslation contextRef="c-107" decimals="-3" id="f-573" unitRef="usd">219000</brns:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeTranslation>
    <brns:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeTranslation contextRef="c-108" decimals="-3" id="f-574" unitRef="usd">-262000</brns:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeTranslation>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-109" decimals="-3" id="f-575" unitRef="usd">1823000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-105" decimals="-3" id="f-576" unitRef="usd">1711000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:GoodwillDisclosureTextBlock contextRef="c-1" id="f-577">Goodwill&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table summarizes changes in goodwill (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Year ended&lt;br/&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Year ended&lt;br/&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;12,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;12,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Measurement period adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(421)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;12,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;12,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:GoodwillDisclosureTextBlock>
    <us-gaap:ScheduleOfGoodwillTextBlock contextRef="c-1" id="f-578">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table summarizes changes in goodwill (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Year ended&lt;br/&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Year ended&lt;br/&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;12,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;12,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Measurement period adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(421)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;12,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;12,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill contextRef="c-7" decimals="-3" id="f-579" unitRef="usd">12209000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-60" decimals="-3" id="f-580" unitRef="usd">12630000</us-gaap:Goodwill>
    <us-gaap:GoodwillPurchaseAccountingAdjustments contextRef="c-1" decimals="-3" id="f-581" unitRef="usd">0</us-gaap:GoodwillPurchaseAccountingAdjustments>
    <us-gaap:GoodwillPurchaseAccountingAdjustments contextRef="c-22" decimals="-3" id="f-582" unitRef="usd">-421000</us-gaap:GoodwillPurchaseAccountingAdjustments>
    <us-gaap:Goodwill contextRef="c-6" decimals="-3" id="f-583" unitRef="usd">12209000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-7" decimals="-3" id="f-584" unitRef="usd">12209000</us-gaap:Goodwill>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c-1" id="f-585">Share-Based Compensation&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On April&#160;8, 2021, the Board of the Company adopted the Barinthus Biotherapeutics plc Share Award Plan 2021 (&#x201c;the Plan&#x201d;) and the Barinthus Biotherapeutics plc Non-Employee Sub-Plan which is a sub-plan of the Plan. Under the terms of the Plan, the Board is permitted to grant awards to employees as restricted share units, options, share appreciation rights and restricted shares. The aggregate number of shares initially available for issuance under the Plan and the Barinthus Biotherapeutics plc Non-Employee Sub-Plan cannot exceed 3,675,680 ordinary shares (the &#x201c;Initial Limit&#x201d;). Beginning calendar year 2023, the total number of ordinary shares available for issuance under the Plan shall be increased on January 1 of each year in an amount equal to the lesser of (i) 4% of the Company&#x2019;s issued and outstanding ordinary shares (which 4% limit shall be measured as of January 1 of such year) and (ii) such number of ordinary shares as determined by the Compensation Committee of the Board in its discretion (the &#x201c;Annual Increase&#x201d;). In accordance with the terms of the Annual Increase, the total number of ordinary shares available for issuance under the Plan increased by 1,507,341 of January 1, 2023. The awards generally vest based on the grantee&#x2019;s continued service with the Company during a specified period following grant as determined by the Board and generally expire ten years from the grant date. Option awards generally vest over three years, but vesting conditions can vary at the discretion of the Company&#x2019;s Board. As of December&#160;31, 2023 and 2022, 1,623,840 and 1,670,268 ordinary shares are available for future grants, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In 2018, the Company&#x2019;s board of directors adopted the Enterprise Management Incentive Share Option Scheme (the &#x201c;EMI Plan&#x201d;) which provided for the grant of incentive stock options and nonqualified stock options to non-director employees of the Company. The Company also has a nonqualified stock option plan for officers and directors. The awards generally vest based on the grantee&#x2019;s continued service with the Company during a specified period following grant as determined by the board of directors and generally expire ten years from the grant date. Option awards generally vest over three years, but vesting conditions can vary at the discretion of the Company&#x2019;s board of directors. A total of 3,530,634 ordinary shares were reserved for issuance in accordance with the provisions of the EMI Plan and restricted stock unit (&#x201c;RSUs&#x201d;) plan. Upon adoption of the Plan, no further awards are to be made under the EMI Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The fair value of each stock option issued to employees was estimated at the date of grant using Black-Scholes with the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.454%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.378%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.284%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.553%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.285%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Year Ended, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;97.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;94.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Expected term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Prior to the IPO, the Company applied a discount for lack of marketability calculated using the Finnerty model&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Expected volatility: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Previously there was insufficient trading history for the Company&#x2019;s ordinary shares, therefore the expected price volatility for our ordinary shares was estimated using the average historical volatility of industry peers&#x2019; shares as of the grant date of our options over a period of history commensurate with the expected life of the options. When selecting industry peers used in measuring implied volatility, the Company considered the similarity of their products and business lines, as well as their stage of development, size and financial leverage. The Company applied this process consistently using the same or similar public companies until 2023. During 2023, the Company determined that there is sufficient historical information on volatility of its share price available and the expected volatility used in the fair value calculation of new option grants is calculated based on a blended volatility of both historical volatility of the Company's share price and the expected volatility of the average historical volatility of industry peers&#x2019; shares. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Expected term (years): &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Expected term represents the period that the Company&#x2019;s option grants are expected to be outstanding. There is not sufficient historical share exercise data to calculate the expected term of the stock options. Therefore, the Company elected to utilize the simplified method to value option grants. Under this approach, the weighted-average expected life is presumed to be the average of the vesting term and the contractual term of the option.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Risk-free interest rate: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company determined the risk-free interest rate by using a weighted-average equivalent to the expected term based on the daily U.S. Treasury yield curve rate in effect as of the date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Expected dividend yield:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; The Company does not anticipate paying any dividends in the foreseeable future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;A summary of stock option activity is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Number of&lt;br/&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Weighted-&lt;br/&gt;average&lt;br/&gt;Exercise&lt;br/&gt;Price Per&lt;br/&gt;Option&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Weighted-&lt;br/&gt;average &lt;br/&gt;Remaining &lt;br/&gt;Contractual &lt;br/&gt;Term (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Aggregate &lt;br/&gt;Intrinsic Value &lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Outstanding, January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,884,720&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7.36&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,288,236&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(72,386)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.00026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Forfeited/expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(892,906)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Outstanding, December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,207,664&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7.95&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Exercisable, December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,839,791&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7.33&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The weighted-average grant date per-share fair value of stock options granted during the year ended December&#160;31, 2023 was $1.99 per share (December&#160;31, 2022: $3.51 per share). The aggregate intrinsic value of stock options exercised during the year ended December&#160;31, 2023 was $0.2 million (December&#160;31, 2022: $0.8 million). As of December&#160;31, 2023, there was $3.0 million (2022: $7.1 million) of unrecognized compensation cost related to stock options, which is expected to be recognized over a weighted-average period of 1.60 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Share based compensation expense is classified in the consolidated statements of operations and comprehensive loss as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Year ended December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Year ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="c-110"
      decimals="INF"
      id="f-586"
      unitRef="shares">3675680</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <brns:ShareBasedCompensationPercentageOfSharesAvailableForIssuanceAsPercentageOfIssuedAndOutstandingShares contextRef="c-110" decimals="2" id="f-587" unitRef="number">0.04</brns:ShareBasedCompensationPercentageOfSharesAvailableForIssuanceAsPercentageOfIssuedAndOutstandingShares>
    <brns:ShareBasedCompensationPercentageOfSharesAvailableForIssuanceAsPercentageOfIssuedAndOutstandingShares contextRef="c-110" decimals="2" id="f-588" unitRef="number">0.04</brns:ShareBasedCompensationPercentageOfSharesAvailableForIssuanceAsPercentageOfIssuedAndOutstandingShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="c-111"
      decimals="INF"
      id="f-589"
      unitRef="shares">1507341</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <brns:ExpirationOfShareBasedCompensationPlanFromDateOfInitialIssuance contextRef="c-110" id="f-590">P10Y</brns:ExpirationOfShareBasedCompensationPlanFromDateOfInitialIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-110" id="f-591">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-112"
      decimals="INF"
      id="f-592"
      unitRef="shares">1623840</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-113"
      decimals="INF"
      id="f-593"
      unitRef="shares">1670268</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c-114" id="f-594">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-114" id="f-595">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-115"
      decimals="INF"
      id="f-596"
      unitRef="shares">3530634</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c-1" id="f-597">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The fair value of each stock option issued to employees was estimated at the date of grant using Black-Scholes with the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.454%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.378%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.284%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.553%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.285%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Year Ended, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;97.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;94.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Expected term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-116" decimals="3" id="f-598" unitRef="number">0.971</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-117" decimals="3" id="f-599" unitRef="number">0.947</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-116" id="f-600">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-117" id="f-601">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-116" decimals="3" id="f-602" unitRef="number">0.037</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-117" decimals="3" id="f-603" unitRef="number">0.024</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-116"
      decimals="INF"
      id="f-604"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-117"
      decimals="INF"
      id="f-605"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c-1" id="f-606">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;A summary of stock option activity is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Number of&lt;br/&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Weighted-&lt;br/&gt;average&lt;br/&gt;Exercise&lt;br/&gt;Price Per&lt;br/&gt;Option&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Weighted-&lt;br/&gt;average &lt;br/&gt;Remaining &lt;br/&gt;Contractual &lt;br/&gt;Term (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Aggregate &lt;br/&gt;Intrinsic Value &lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Outstanding, January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,884,720&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7.36&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,288,236&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(72,386)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.00026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Forfeited/expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(892,906)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Outstanding, December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,207,664&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7.95&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Exercisable, December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,839,791&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7.33&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-7" decimals="INF" id="f-607" unitRef="shares">4884720</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-7"
      decimals="2"
      id="f-608"
      unitRef="usdPerShare">9.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-22" id="f-609">P7Y4M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-7" decimals="-3" id="f-610" unitRef="usd">2619000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c-1" decimals="INF" id="f-611" unitRef="shares">2288236</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-612"
      unitRef="usdPerShare">2.51</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-1" decimals="INF" id="f-613" unitRef="shares">72386</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="5"
      id="f-614"
      unitRef="usdPerShare">0.00026</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="c-1" decimals="INF" id="f-615" unitRef="shares">892906</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-616"
      unitRef="usdPerShare">7.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-6" decimals="INF" id="f-617" unitRef="shares">6207664</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-6"
      decimals="2"
      id="f-618"
      unitRef="usdPerShare">6.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-1" id="f-619">P7Y11M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-6" decimals="-3" id="f-620" unitRef="usd">6044000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="c-6" decimals="INF" id="f-621" unitRef="shares">2839791</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c-6"
      decimals="2"
      id="f-622"
      unitRef="usdPerShare">8.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-1" id="f-623">P7Y3M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c-6" decimals="-3" id="f-624" unitRef="usd">2883000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-1"
      decimals="2"
      id="f-625"
      unitRef="usdPerShare">1.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-22"
      decimals="2"
      id="f-626"
      unitRef="usdPerShare">3.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-1" decimals="-5" id="f-627" unitRef="usd">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-22" decimals="-5" id="f-628" unitRef="usd">800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="c-6" decimals="-5" id="f-629" unitRef="usd">3000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="c-7" decimals="-5" id="f-630" unitRef="usd">7100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-1" id="f-631">P1Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock contextRef="c-1" id="f-632">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Share based compensation expense is classified in the consolidated statements of operations and comprehensive loss as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Year ended December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Year ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-118" decimals="-3" id="f-633" unitRef="usd">2011000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-119" decimals="-3" id="f-634" unitRef="usd">2668000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-120" decimals="-3" id="f-635" unitRef="usd">3044000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-121" decimals="-3" id="f-636" unitRef="usd">7209000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-3" id="f-637" unitRef="usd">5055000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-22" decimals="-3" id="f-638" unitRef="usd">9877000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c-1" id="f-639">Income Taxes&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(Loss) income before income taxes are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.778%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.557%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Year ended&lt;br/&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Year ended&lt;br/&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;United Kingdom&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(50,534)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(24,507)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(14,648)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1,481)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(Loss)/income before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(76,522)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The components of income tax benefit are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Year ended&lt;br/&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Year ended&lt;br/&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Current income tax benefit/(expense):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Deferred income tax benefit:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total income tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;A reconciliation of the UK statutory income tax rate to the Company's effective tax rate as reflected in the consolidated financial statements is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Year ended&lt;br/&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Year ended&lt;br/&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Statutory tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;23.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;19.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Increase (decreases) resulting from:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Permanent differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(103.46)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Provision to return adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(4.09)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(105.66)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Research and development credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(4.94)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(307.09)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Foreign rate differential&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(149.82)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(11.84)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;146.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Share based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.84)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(10.21)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(510.69)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income and for tax carryforwards. Significant components of the Company&#x2019;s deferred tax assets and liabilities are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;23,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Research and development credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Share based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Accruals and intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Capitalized Research and Development expenditure&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Gross deferred tax asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;36,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;22,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(25,057)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(13,707)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;11,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1,652)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1,704)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Right-of-use lease asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1,922)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1,993)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Unrealized gain on investment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1,267)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1,204)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(6,909)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(7,779)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Net deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(11,750)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(12,680)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total deferred tax, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(574)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(3,746)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Specified research and experimentation costs under Section 174 of the Internal Revenue Code are required to be capitalized and amortized ratably over five years for domestic expenditures and over 15 years for foreign expenditures. This provision of Section 174 became effective for tax years beginning after December 31, 2021. As a result of the capitalization of these costs in the current year, the Company has recorded a $4.2 million deferred tax asset (2022: $2.5 million). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of December&#160;31, 2023, the Company had a valuation allowance of $25.1 million (2022: $13.7 million) against its deferred tax assets, which consisted principally of net operating loss and research and development credit carryforwards. The Company considered the positive and negative evidence bearing upon its ability to realize the deferred tax assets. In addition to the Company&#x2019;s history of cumulative losses, the Company cannot be certain that future taxable income will be sufficient to realize its deferred tax assets. Accordingly, a valuation allowance has been provided against its deferred tax assets. When the Company changes its determination as to the amount of its deferred tax assets that can be realized, the valuation allowance is adjusted with a corresponding impact to the provision for income taxes in the period in which such determination is made.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Changes in the valuation allowance for deferred tax assets during the years ended December 31, 2023 and 2022 related primarily to the increase in net operating loss and credit carryforwards, and were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.557%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.901%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Year ended&lt;br/&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Year ended&lt;br/&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Valuations allowance at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Changes in valuation allowance arising from in-year additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Increases recorded to income tax provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Foreign exchange translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1,293)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Valuation allowance at end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;25,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;13,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of December&#160;31, 2023, the Company had net operating loss ("NOL") carryforwards totaling approximately $92.7 million which have an unlimited carryforward period, of which $74.2 million originate in the United Kingdom. As of December&#160;31, 2023, the Company had $0.04 million of research and development tax credit carryforwards which also have an unlimited carryforward period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of December&#160;31, 2022, the Company had NOL carryforwards totaling approximately $39.6 million which have an unlimited carryforward period, of which $35.1 million originate in the United Kingdom. As of December&#160;31, 2022, the Company had $3.1 million of research and development tax credit carryforwards which also have an unlimited carryforward period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of December&#160;31, 2023 and 2022, the Company does not have any material unrecognized tax benefit liabilities. The Company files corporation/income tax returns in the United Kingdom, Australia, and the United States. The associated tax filings remain subject to examination by applicable tax authorities for a certain length of time following the tax year to which those filings relate. In the United Kingdom, tax years from 2020 remain subject to examination by HMRC. In all other jurisdictions, the tax years since inception remain subject to examination by the applicable taxing authorities as of December&#160;31, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="c-1" id="f-640">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(Loss) income before income taxes are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.778%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.557%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Year ended&lt;br/&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Year ended&lt;br/&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;United Kingdom&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(50,534)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(24,507)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(14,648)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1,481)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(Loss)/income before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(76,522)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-1" decimals="-3" id="f-641" unitRef="usd">-50534000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-22" decimals="-3" id="f-642" unitRef="usd">15511000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-122" decimals="-3" id="f-643" unitRef="usd">-24507000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-123" decimals="-3" id="f-644" unitRef="usd">-14648000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-124" decimals="-3" id="f-645" unitRef="usd">-1481000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-125" decimals="-3" id="f-646" unitRef="usd">-13000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-647" unitRef="usd">-76522000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-22" decimals="-3" id="f-648" unitRef="usd">850000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="c-1" id="f-649">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The components of income tax benefit are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Year ended&lt;br/&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Year ended&lt;br/&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Current income tax benefit/(expense):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Deferred income tax benefit:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total income tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="c-122" decimals="-3" id="f-650" unitRef="usd">28000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="c-123" decimals="-3" id="f-651" unitRef="usd">-133000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="c-124" decimals="-3" id="f-652" unitRef="usd">45000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="c-125" decimals="-3" id="f-653" unitRef="usd">0</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="c-122" decimals="-3" id="f-654" unitRef="usd">-3148000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="c-123" decimals="-3" id="f-655" unitRef="usd">-4338000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-656" unitRef="usd">-3075000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-22" decimals="-3" id="f-657" unitRef="usd">-4471000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c-1" id="f-658">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;A reconciliation of the UK statutory income tax rate to the Company's effective tax rate as reflected in the consolidated financial statements is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Year ended&lt;br/&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Year ended&lt;br/&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Statutory tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;23.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;19.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Increase (decreases) resulting from:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Permanent differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(103.46)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Provision to return adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(4.09)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(105.66)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Research and development credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(4.94)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(307.09)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Foreign rate differential&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(149.82)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(11.84)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;146.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Share based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.84)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(10.21)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(510.69)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-1" decimals="4" id="f-659" unitRef="number">0.2352</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-22" decimals="4" id="f-660" unitRef="number">0.1900</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense contextRef="c-1" decimals="4" id="f-661" unitRef="number">0.0103</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense contextRef="c-22" decimals="4" id="f-662" unitRef="number">-1.0346</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <brns:EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustments contextRef="c-1" decimals="4" id="f-663" unitRef="number">-0.0409</brns:EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustments>
    <brns:EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustments contextRef="c-22" decimals="4" id="f-664" unitRef="number">-1.0566</brns:EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustments>
    <brns:EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment contextRef="c-1" decimals="4" id="f-665" unitRef="number">0.0494</brns:EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment>
    <brns:EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment contextRef="c-22" decimals="4" id="f-666" unitRef="number">3.0709</brns:EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="c-1" decimals="4" id="f-667" unitRef="number">0.0123</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="c-22" decimals="4" id="f-668" unitRef="number">-1.4982</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-1" decimals="4" id="f-669" unitRef="number">-0.1184</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-22" decimals="4" id="f-670" unitRef="number">1.4655</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent contextRef="c-1" decimals="4" id="f-671" unitRef="number">-0.0084</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent contextRef="c-22" decimals="4" id="f-672" unitRef="number">-0.1021</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-1" decimals="4" id="f-673" unitRef="number">0.0407</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-22" decimals="4" id="f-674" unitRef="number">-5.1069</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c-1" id="f-675">Significant components of the Company&#x2019;s deferred tax assets and liabilities are as follows (in thousands):&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;23,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Research and development credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Share based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Accruals and intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Capitalized Research and Development expenditure&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Gross deferred tax asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;36,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;22,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(25,057)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(13,707)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;11,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1,652)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1,704)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Right-of-use lease asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1,922)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1,993)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Unrealized gain on investment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1,267)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1,204)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(6,909)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(7,779)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Net deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(11,750)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(12,680)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total deferred tax, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(574)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(3,746)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-6" decimals="-3" id="f-676" unitRef="usd">23589000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-7" decimals="-3" id="f-677" unitRef="usd">9940000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="c-6" decimals="-3" id="f-678" unitRef="usd">40000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="c-7" decimals="-3" id="f-679" unitRef="usd">3146000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsDeferredIncome contextRef="c-6" decimals="-3" id="f-680" unitRef="usd">0</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome contextRef="c-7" decimals="-3" id="f-681" unitRef="usd">54000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c-6" decimals="-3" id="f-682" unitRef="usd">4226000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c-7" decimals="-3" id="f-683" unitRef="usd">3956000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <brns:DeferredTaxAssetsLeasingArrangements contextRef="c-6" decimals="-3" id="f-684" unitRef="usd">3404000</brns:DeferredTaxAssetsLeasingArrangements>
    <brns:DeferredTaxAssetsLeasingArrangements contextRef="c-7" decimals="-3" id="f-685" unitRef="usd">2257000</brns:DeferredTaxAssetsLeasingArrangements>
    <brns:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsIntangibles contextRef="c-6" decimals="-3" id="f-686" unitRef="usd">745000</brns:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsIntangibles>
    <brns:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsIntangibles contextRef="c-7" decimals="-3" id="f-687" unitRef="usd">765000</brns:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsIntangibles>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="c-6" decimals="-3" id="f-688" unitRef="usd">4228000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="c-7" decimals="-3" id="f-689" unitRef="usd">2522000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsOther contextRef="c-6" decimals="-3" id="f-690" unitRef="usd">1000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther contextRef="c-7" decimals="-3" id="f-691" unitRef="usd">1000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-6" decimals="-3" id="f-692" unitRef="usd">36233000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-7" decimals="-3" id="f-693" unitRef="usd">22641000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-6" decimals="-3" id="f-694" unitRef="usd">25057000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-7" decimals="-3" id="f-695" unitRef="usd">13707000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet contextRef="c-6" decimals="-3" id="f-696" unitRef="usd">11176000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet contextRef="c-7" decimals="-3" id="f-697" unitRef="usd">8934000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="c-6" decimals="-3" id="f-698" unitRef="usd">1652000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="c-7" decimals="-3" id="f-699" unitRef="usd">1704000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements contextRef="c-6" decimals="-3" id="f-700" unitRef="usd">1922000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements contextRef="c-7" decimals="-3" id="f-701" unitRef="usd">1993000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities contextRef="c-6" decimals="-3" id="f-702" unitRef="usd">1267000</us-gaap:DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities>
    <us-gaap:DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities contextRef="c-7" decimals="-3" id="f-703" unitRef="usd">1204000</us-gaap:DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets contextRef="c-6" decimals="-3" id="f-704" unitRef="usd">6909000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets contextRef="c-7" decimals="-3" id="f-705" unitRef="usd">7779000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="c-6" decimals="-3" id="f-706" unitRef="usd">11750000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="c-7" decimals="-3" id="f-707" unitRef="usd">12680000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredTaxLiabilities contextRef="c-6" decimals="-3" id="f-708" unitRef="usd">574000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities contextRef="c-7" decimals="-3" id="f-709" unitRef="usd">3746000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="c-6" decimals="-5" id="f-710" unitRef="usd">4200000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="c-7" decimals="-5" id="f-711" unitRef="usd">2500000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-6" decimals="-5" id="f-712" unitRef="usd">25100000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-7" decimals="-5" id="f-713" unitRef="usd">13700000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:SummaryOfValuationAllowanceTextBlock contextRef="c-1" id="f-714">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Changes in the valuation allowance for deferred tax assets during the years ended December 31, 2023 and 2022 related primarily to the increase in net operating loss and credit carryforwards, and were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.557%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.901%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Year ended&lt;br/&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Year ended&lt;br/&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Valuations allowance at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Changes in valuation allowance arising from in-year additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Increases recorded to income tax provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Foreign exchange translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1,293)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Valuation allowance at end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;25,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;13,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SummaryOfValuationAllowanceTextBlock>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-7" decimals="-3" id="f-715" unitRef="usd">13707000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-60" decimals="-3" id="f-716" unitRef="usd">13500000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <brns:ValuationAllowanceDeferredTaxAssetIncreaseResultingFromCurrentPeriodAdditions contextRef="c-1" decimals="-3" id="f-717" unitRef="usd">1052000</brns:ValuationAllowanceDeferredTaxAssetIncreaseResultingFromCurrentPeriodAdditions>
    <brns:ValuationAllowanceDeferredTaxAssetIncreaseResultingFromCurrentPeriodAdditions contextRef="c-22" decimals="-3" id="f-718" unitRef="usd">0</brns:ValuationAllowanceDeferredTaxAssetIncreaseResultingFromCurrentPeriodAdditions>
    <brns:ValuationAllowanceDeferredTaxAssetIncreaseResultingFromIncomeTaxProvision contextRef="c-1" decimals="-3" id="f-719" unitRef="usd">9605000</brns:ValuationAllowanceDeferredTaxAssetIncreaseResultingFromIncomeTaxProvision>
    <brns:ValuationAllowanceDeferredTaxAssetIncreaseResultingFromIncomeTaxProvision contextRef="c-22" decimals="-3" id="f-720" unitRef="usd">1500000</brns:ValuationAllowanceDeferredTaxAssetIncreaseResultingFromIncomeTaxProvision>
    <brns:ValuationAllowanceDeferredTaxAssetIncreaseDecreaseResultingFromForeignCurrencyTranslation contextRef="c-1" decimals="-3" id="f-721" unitRef="usd">693000</brns:ValuationAllowanceDeferredTaxAssetIncreaseDecreaseResultingFromForeignCurrencyTranslation>
    <brns:ValuationAllowanceDeferredTaxAssetIncreaseDecreaseResultingFromForeignCurrencyTranslation contextRef="c-22" decimals="-3" id="f-722" unitRef="usd">-1293000</brns:ValuationAllowanceDeferredTaxAssetIncreaseDecreaseResultingFromForeignCurrencyTranslation>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-6" decimals="-3" id="f-723" unitRef="usd">25057000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-7" decimals="-3" id="f-724" unitRef="usd">13707000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:OperatingLossCarryforwards contextRef="c-6" decimals="-5" id="f-725" unitRef="usd">92700000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-126" decimals="-5" id="f-726" unitRef="usd">74200000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="c-6" decimals="-4" id="f-727" unitRef="usd">40000.00</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:OperatingLossCarryforwards contextRef="c-7" decimals="-5" id="f-728" unitRef="usd">39600000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:IncomeTaxCreditsAndAdjustments contextRef="c-22" decimals="-5" id="f-729" unitRef="usd">35100000</us-gaap:IncomeTaxCreditsAndAdjustments>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="c-7" decimals="-5" id="f-730" unitRef="usd">3100000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-731">Commitments and Contingencies&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;In-License Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company is party to a number of licensing agreements, these agreements serve to provide the Company with the right to develop and exploit the counterparties&#x2019; intellectual property for certain medical indications. As part of execution of these arrangements, the Company paid certain upfront fees, which have been expensed as incurred because the developing technology has not yet reached technical feasibility, the lack of alternative use, and the lack of proof of potential value. The agreements cover a variety of fields, including influenza, cancer, HPV, HBV and MERS. The Company&#x2019;s obligations for future payments under these arrangements are dependent on its ability to develop promising drug candidates, the potential market for these candidates and potential competing products, and the payment mechanisms in place in countries where the Company retains the right to sell. Each agreement provides for specific milestone payments, typically triggered by achievement of certain testing phases in human candidates, and future royalties ranging from 1 to 5% for direct sales of a covered product to 3 to 7% of net payments received for allowable sublicenses of technology developed by the Company. The obligation to make these payments is contingent upon the Company&#x2019;s ability to develop candidates for submission for phased testing and approvals, and for the development of markets for the products developed by the Company. The Company has not made any material payments under these license agreements during the years ended December&#160;31, 2023, and 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company leases certain laboratory and office space under operating leases, which are described below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;The Oxford Science Park, Oxford&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company leased an office and laboratory space from a related party in Oxford, England under an operating lease with a contractual term expiring in 2028. The lease was terminated on July 31, 2022, and the Company relocated its corporate headquarters to The Harwell Science and Innovation Campus, Oxfordshire, in the third quarter of 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;The Harwell Science and Innovation Campus, Oxfordshire&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On September&#160;3, 2021, the Company entered into a lease agreement for the lease of approximately 31,000 square feet in Harwell, Oxfordshire which expires in September 2031. The property is the Company&#x2019;s corporate headquarters. As the Company&#x2019;s leases typically do not provide an implicit rate, the Company uses an estimate of its incremental borrowing rate based on the information available at the lease commencement date, being the rate incurred to borrow on a collateralized basis over a similar term at an amount equal to the lease payments in a similar economic environment. The Company has provided the lessor with a refundable security deposit of $0.7 million which is included in Other assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Germantown, Maryland&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On June&#160;14, 2022, the Company entered into a lease agreement for the lease of approximately 19,700 square feet in Germantown, Maryland. The site will house the Company&#x2019;s state-of-the-art wet laboratory in the United States of America. The lease expires on February 28, 2034, with the Company having a single right to extend for an additional five years on the same terms and conditions other than for the base rent. The Company has a rent-free period up to February 29, 2024 and is entitled to up to $3.5 million for leasehold improvements to the premises desired by the Company. The Company has provided the lessor with a refundable security deposit of $0.2 million which is included in Other assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company recorded a right-of-use asset and a lease liability on the effective date of the lease term. The Company&#x2019;s right-of-use assets and lease liabilities are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Right-of-use asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Lease liability, current&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Lease liability, noncurrent&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;11,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 13pt 0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 13pt 0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Other information&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Weighted average remaining lease term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8.93&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9.44&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Lease Costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Short-term lease costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Fixed Lease Costs&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Maturities of the Company&#x2019;s minimum lease liabilities as of December&#160;31, 2023 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Maturity of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;17,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(4,699)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;12,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Non-lease and other costs paid to the lessors are primarily related to services provided by the lessors in operating the premises that includes fees, operating costs, taxes, and insurance related to the leased premises.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Other contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company is a party in various contractual disputes, litigation, and potential claims arising in the ordinary course of business. The Company does not believe that the resolution of these matters will have a material adverse effect on its financial position or results of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <brns:PercentageOfFutureRoyaltiesForDirectSalesOfCoveredProductLicenseAgreement contextRef="c-127" decimals="2" id="f-732" unitRef="number">0.01</brns:PercentageOfFutureRoyaltiesForDirectSalesOfCoveredProductLicenseAgreement>
    <brns:PercentageOfFutureRoyaltiesForDirectSalesOfCoveredProductLicenseAgreement contextRef="c-128" decimals="2" id="f-733" unitRef="number">0.05</brns:PercentageOfFutureRoyaltiesForDirectSalesOfCoveredProductLicenseAgreement>
    <brns:PercentageOfNetPaymentsReceivedForAllowableSublicensesOfTechnologyDevelopedLicenseAgreement contextRef="c-127" decimals="2" id="f-734" unitRef="number">0.03</brns:PercentageOfNetPaymentsReceivedForAllowableSublicensesOfTechnologyDevelopedLicenseAgreement>
    <brns:PercentageOfNetPaymentsReceivedForAllowableSublicensesOfTechnologyDevelopedLicenseAgreement contextRef="c-128" decimals="2" id="f-735" unitRef="number">0.07</brns:PercentageOfNetPaymentsReceivedForAllowableSublicensesOfTechnologyDevelopedLicenseAgreement>
    <brns:NumberOfSquareFeetUnderLeaseAgreement contextRef="c-129" decimals="-3" id="f-736" unitRef="sqft">31000</brns:NumberOfSquareFeetUnderLeaseAgreement>
    <us-gaap:SecurityDeposit contextRef="c-130" decimals="-5" id="f-737" unitRef="usd">700000</us-gaap:SecurityDeposit>
    <brns:NumberOfSquareFeetUnderLeaseAgreement contextRef="c-131" decimals="-2" id="f-738" unitRef="sqft">19700</brns:NumberOfSquareFeetUnderLeaseAgreement>
    <brns:LesseeOperatingLeaseExtendedTerm contextRef="c-131" id="f-739">P5Y</brns:LesseeOperatingLeaseExtendedTerm>
    <us-gaap:LeaseholdImprovementsGross contextRef="c-132" decimals="-5" id="f-740" unitRef="usd">3500000</us-gaap:LeaseholdImprovementsGross>
    <us-gaap:SecurityDeposit contextRef="c-132" decimals="-5" id="f-741" unitRef="usd">200000</us-gaap:SecurityDeposit>
    <brns:LesseeOperatingLeaseRightOfUseAssetAndOtherInformationTableTextBlock contextRef="c-1" id="f-742">The Company&#x2019;s right-of-use assets and lease liabilities are as follows (in thousands):&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Right-of-use asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Lease liability, current&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Lease liability, noncurrent&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;11,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 13pt 0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 13pt 0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Other information&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Weighted average remaining lease term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8.93&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9.44&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Lease Costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Short-term lease costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Fixed Lease Costs&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</brns:LesseeOperatingLeaseRightOfUseAssetAndOtherInformationTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-6" decimals="-3" id="f-743" unitRef="usd">7581000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-7" decimals="-3" id="f-744" unitRef="usd">7753000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-6" decimals="-3" id="f-745" unitRef="usd">1785000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-7" decimals="-3" id="f-746" unitRef="usd">433000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-6" decimals="-3" id="f-747" unitRef="usd">11191000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-7" decimals="-3" id="f-748" unitRef="usd">8340000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeasePayments contextRef="c-1" decimals="-3" id="f-749" unitRef="usd">639000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c-22" decimals="-3" id="f-750" unitRef="usd">1081000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-6" id="f-751">P8Y11M4D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-7" id="f-752">P9Y5M8D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-6" decimals="3" id="f-753" unitRef="number">0.075</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-7" decimals="3" id="f-754" unitRef="number">0.076</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:ShortTermLeaseCost contextRef="c-1" decimals="-3" id="f-755" unitRef="usd">189000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost contextRef="c-22" decimals="-3" id="f-756" unitRef="usd">529000</us-gaap:ShortTermLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-1" decimals="-3" id="f-757" unitRef="usd">883000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-22" decimals="-3" id="f-758" unitRef="usd">1216000</us-gaap:OperatingLeaseCost>
    <us-gaap:LeaseCost contextRef="c-1" decimals="-3" id="f-759" unitRef="usd">1072000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c-22" decimals="-3" id="f-760" unitRef="usd">1745000</us-gaap:LeaseCost>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c-1" id="f-761">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Maturities of the Company&#x2019;s minimum lease liabilities as of December&#160;31, 2023 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Maturity of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;17,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(4,699)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;12,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c-6" decimals="-3" id="f-762" unitRef="usd">1785000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c-6" decimals="-3" id="f-763" unitRef="usd">1936000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c-6" decimals="-3" id="f-764" unitRef="usd">1960000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="c-6" decimals="-3" id="f-765" unitRef="usd">1985000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive contextRef="c-6" decimals="-3" id="f-766" unitRef="usd">2010000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive contextRef="c-6" decimals="-3" id="f-767" unitRef="usd">7999000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c-6" decimals="-3" id="f-768" unitRef="usd">17675000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c-6" decimals="-3" id="f-769" unitRef="usd">4699000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c-6" decimals="-3" id="f-770" unitRef="usd">12976000</us-gaap:OperatingLeaseLiability>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock contextRef="c-1" id="f-771">Employee Benefit Plans&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In the United Kingdom, the Company has adopted a defined contribution plan (the U.K. Plan) which qualifies under the rules established by HM Revenue &amp;amp; Customs. Contributions to the U.K. Plan are charged to the consolidated statements of operations and comprehensive loss in the year to which they relate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company has 401(k) defined contribution retirement plans in which all its employees located in the United States are eligible to participate. Eligible employees may elect to contribute up to the maximum limits, as set by the Internal Revenue Service, of their eligible compensation. Contributions to the plans are charged to the consolidated statements of operations and comprehensive loss in the year to which they relate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;During the year ended December&#160;31, 2023, the Company provided a total of $0.7 million (December&#160;31, 2022: $0.5 million) in contributions under both the U.K. Plan and the 401(k) plans.&lt;/span&gt;&lt;/div&gt;</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount contextRef="c-1" decimals="-5" id="f-772" unitRef="usd">700000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount contextRef="c-22" decimals="-5" id="f-773" unitRef="usd">500000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c-1" id="f-774">Related Party Transactions&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;During the year ended December&#160;31, 2023, the Company incurred expenses of $0.4 million (December&#160;31, 2022: $0.4 million) from its shareholder, the University of Oxford, related to clinical study costs. As of December&#160;31, 2023, the Company owed nil (2022: $nil).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;During the year ended December&#160;31, 2023, the Company incurred expenses of $0.6 million (December&#160;31, 2022: $0.4 million) from Oxford University Innovation Limited which is a wholly owned subsidiary of the Company&#x2019;s shareholder, the University of Oxford. As of December&#160;31, 2023, the Company owed $2&#160;thousand (December 31, 2022: nil) to Oxford University Innovation Limited.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;During the year ended December&#160;31, 2023, the Company recognized license revenue of $0.8 million (December&#160;31, 2022: $43.7 million) from Oxford University Innovation Limited which is a wholly owned subsidiary of the Company&#x2019;s shareholder, the University of Oxford. As of December&#160;31, 2023, the Company was owed nil (2022: $5.5 million) from Oxford University Innovation Limited.&lt;/span&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="c-133" decimals="-5" id="f-775" unitRef="usd">400000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="c-134" decimals="-5" id="f-776" unitRef="usd">400000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:AccountsPayableCurrent contextRef="c-135" decimals="-5" id="f-777" unitRef="usd">0</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-136" decimals="-5" id="f-778" unitRef="usd">0</us-gaap:AccountsPayableCurrent>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="c-137" decimals="-5" id="f-779" unitRef="usd">600000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="c-138" decimals="-5" id="f-780" unitRef="usd">400000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:AccountsPayableCurrent contextRef="c-139" decimals="-3" id="f-781" unitRef="usd">2000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-140" decimals="-3" id="f-782" unitRef="usd">0</us-gaap:AccountsPayableCurrent>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-141" decimals="-5" id="f-783" unitRef="usd">800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-142" decimals="-5" id="f-784" unitRef="usd">43700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-139" decimals="-5" id="f-785" unitRef="usd">0</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-140" decimals="-5" id="f-786" unitRef="usd">5500000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:SubsequentEventsTextBlock contextRef="c-1" id="f-787">Subsequent Events  &lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In accordance with the terms of the Annual Increase of the Barinthus Biotherapeutics plc Share Award Plan 2021, the total number of ordinary shares available for issuance under the Plan increased by 4% of the Company&#x2019;s issued and outstanding ordinary shares as of January&#160;1, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In January 2024, the Company granted a total of 1,592,423 share options to employees and directors with a weighted average exercise price of $3.70.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <brns:ShareBasedCompensationPercentageOfSharesAvailableForIssuanceAsPercentageOfIssuedAndOutstandingShares contextRef="c-143" decimals="2" id="f-788" unitRef="number">0.04</brns:ShareBasedCompensationPercentageOfSharesAvailableForIssuanceAsPercentageOfIssuedAndOutstandingShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c-144" decimals="0" id="f-789" unitRef="shares">1592423</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-144"
      decimals="2"
      id="f-790"
      unitRef="usdPerShare">3.70</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#f-125"
          xlink:label="f-125"
          xlink:type="locator"/>
        <link:footnote id="fn-1" xlink:label="fn-1" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:5.75pt">Indicates amount less than one thousand</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-125"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-141"
          xlink:label="f-141"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-140"
          xlink:label="f-140"
          xlink:type="locator"/>
        <link:footnote id="fn-2" xlink:label="fn-2" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:5.75pt">Includes <xhtml:span style="-sec-ix-hidden:f-192"><xhtml:span style="-sec-ix-hidden:f-193">license revenue</xhtml:span></xhtml:span> from related parties for the year ended December&#160;31, 2023 totaling $0.8&#160;million (December&#160;31, 2022: $43.7&#160;million). License revenue is generated in the United Kingdom. </xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-141"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-140"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-253"
          xlink:label="f-253"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-214"
          xlink:label="f-214"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-264"
          xlink:label="f-264"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-286"
          xlink:label="f-286"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-203"
          xlink:label="f-203"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-239"
          xlink:label="f-239"
          xlink:type="locator"/>
        <link:footnote id="fn-3" xlink:label="fn-3" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:5.75pt">Indicates amount less than one thousand</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-253"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-214"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-264"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-286"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-203"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-239"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-354"
          xlink:label="f-354"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-336"
          xlink:label="f-336"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-356"
          xlink:label="f-356"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-335"
          xlink:label="f-335"
          xlink:type="locator"/>
        <link:footnote id="fn-4" xlink:label="fn-4" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:5.75pt">Indicates amount less than one thousand</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-354"
          xlink:to="fn-4"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-336"
          xlink:to="fn-4"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-356"
          xlink:to="fn-4"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-335"
          xlink:to="fn-4"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
